FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Brunet, MC
   Chen, SH
   Khandelwal, P
   Hare, JM
   Starke, RM
   Peterson, EC
   Yavagal, DR
AF Brunet, Marie-Christine
   Chen, Stephanie H.
   Khandelwal, Priyank
   Hare, Joshua M.
   Starke, Robert M.
   Peterson, Eric C.
   Yavagal, Dileep R.
TI Intravenous Stem Cell Therapy for High-Grade Aneurysmal Subarachnoid
   Hemorrhage: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; Stem cells; Stroke; Subarachnoid hemorrhage
ID STROKE; TRANSPLANTATION
AB BACKGROUND: Aneurysmal subarachnoid hemorrhage (SAH) is associated with high mortality (30%-40%) and morbidity with long-term physical, neurologic, and psychological impairments; most patients present with high initial Hunt and Hess grade. In view of the great need for efficacious therapies for high-grade SAH, recent animal studies have demonstrated improved outcomes with administration of mesenchymal stem cells (MSCs) as a potential neuro-regenerative strategy. We present the first case of human intravenous administration of MSCs after aneurysmal SAH.
   CLINICAL PRESENTATION: An 80-year-old man presented with sudden severe headache with nausea and vomiting. Computed tomography demonstrated SAH with hydrocephalus from a ruptured basilar tip aneurysm. Initial examination of the patient showed Hunt and Hess grade 5 and World Federation of Neurosurgical Societies grade 5. The patient was treated with external ventricular drain placement and coiling of aneurysm. The patient received an infusion of intravenous bone marrow-derived allogeneic MSCs on day 3 post-bleed. The patient made a better recovery than anticipated with a modified Rankin Scale score of 3 at 6 months.
   CONCLUSIONS: Several studies using models of ischemic brain injury have found that administration of MSCs may improve functional neurologic recovery and decrease brain lesion volume. Although there have been limited human studies in patients with stroke, the role of stem cell therapy for aneurysmal SAH remains unclear. This is the first case of use of MSCs in a patient for treatment of aneurysmal SAH. In conjunction with the promising results in animal studies, this encouraging preliminary case report supports the need for additional dinical trials.
C1 [Brunet, Marie-Christine; Chen, Stephanie H.; Hare, Joshua M.; Starke, Robert M.; Peterson, Eric C.; Yavagal, Dileep R.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
   [Starke, Robert M.] Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA.
   [Yavagal, Dileep R.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Khandelwal, Priyank] Univ Med & Dent New Jersey, Dept Neurol Surg, Newark, NJ USA.
RP Yavagal, DR (reprint author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.; Yavagal, DR (reprint author), Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
EM DYavagal@med.miami.edu
CR Detante O, 2017, INT J STROKE, V12, P748, DOI 10.1177/1747493017696098
   Donega V, 2013, J CEREBR BLOOD F MET, V33, P625, DOI 10.1038/jcbfm.2013.3
   Donega V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051253
   Ghonim Hesham T, 2016, J Vasc Interv Neurol, V8, P30
   Hao L, 2014, BIOMED RES INT, DOI 10.1155/2014/468748
   Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660
   Khalili MA, 2012, J STROKE CEREBROVASC, V21, P445, DOI 10.1016/j.jstrokecerebrovasdis.2010.10.005
   Kocsis JD, 2012, PROG BRAIN RES, V201, P79, DOI 10.1016/B978-0-444-59544-7.00005-6
   Lee JS, 2010, STEM CELLS, V28, P1099, DOI 10.1002/stem.430
   Lovelock CE, 2010, NEUROLOGY, V74, P1494, DOI 10.1212/WNL.0b013e3181dd42b3
   Nagpal A, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0643-x
   Nijboer CH, 2018, STEM CELLS DEV, V27, P313, DOI 10.1089/scd.2017.0148
   Onda T, 2008, J CEREBR BLOOD F MET, V28, P329, DOI 10.1038/sj.jcbfm.9600527
   Prasad K, 2014, STROKE, V45, P3618, DOI 10.1161/STROKEAHA.114.007028
   Savitz SI, 2014, STROKE, V45, P634, DOI 10.1161/STROKEAHA.113.003379
   Scheibe F, 2012, J CEREBR BLOOD F MET, V32, P1578, DOI 10.1038/jcbfm.2012.55
   Tewari M, 2015, ANN NEUROSCI, V22, P78, DOI 10.5214/ans.0972.7531.220205
   van Velthoven CTJ, 2010, J NEUROSCI, V30, P9603, DOI 10.1523/JNEUROSCI.1835-10.2010
   Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4
NR 19
TC 4
Z9 4
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 573
EP 575
DI 10.1016/j.wneu.2019.04.055
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100234
PM 30981798
DA 2020-05-12
ER

PT J
AU Chen, R
   Xiang, Z
   Gong, M
AF Chen, Ran
   Xiang, Zhou
   Gong, Min
TI The Efficacy and Safety of Epsilon-Aminocaproic Acid for Blood Loss and
   Transfusions in Spinal Deformity Surgery: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Blood loss; Blood transfusion; Epsilon-aminocaproic acid; Meta-analysis;
   Spinal deformity surgery
ID TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENTS; TOTAL HIP; REQUIREMENTS;
   QUALITY; TRIALS; AMICAR
AB OBJECTIVE: To assess the efficacy and safety of epsilon-aminocaproic acid (EACA) in reducing the blood loss and transfusion volume during open spinal deformity surgery.
   METHODS: A systematic search was conducted for all studies written in English published on or before October 2018 in PubMed, EMBASE, and the Cochrane Library that compared antifibrinolytic agents with placebos for open spinal deformity surgeries. The primary outcomes included the total blood loss, intraoperative, and postoperative blood loss, transfusions volume and complication rate.
   RESULTS: Seven studies that included 525 patients who were diagnosed with spinal deformity. Compared with placebo, the patients who received EACA showed a reduction in the postoperative blood loss (mean difference [MD] -249.80; 95% confidence interval [CI] -375.65 to -123.95; P = 0.0001) and total blood loss (MD -670.30; 95% CI -1142.63 to -197.98; P = 0.005). Furthermore, the patients treated with EACA received approximately 1.67 fewer units of blood (MD -1.67; 95% CI -3.10 to -0.24; P = 0.02). However, in this cohort, no statistically significant differences were observed in the intraoperative blood loss (MD -45219; 95% CI -108221 to 177.83; P = 0.16) and complication rate (odds ratio 0.73; 95% CI 0.16-3.24; P = 0.68).
   CONCLUSIONS: This meta-analysis demonstrated that EACA could he safe and potentially efficacious for reducing blood loss and transfusions volume in patients with spinal deformity surgeries when compared with placebo. In light of the significant heterogeneity, the findings of this meta-analysis should be confirmed in methodologically rigorous and adequately powered clinical trials.
C1 [Chen, Ran; Xiang, Zhou; Gong, Min] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Sichuan, Peoples R China.
RP Xiang, Z (reprint author), Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Sichuan, Peoples R China.
EM xiangzhou@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31870961]; Foundation of sino-german center for
   Research promotion [GZ1219]
FX This work was supported by National Natural Science Foundation of China
   (No. 31870961) and Foundation of sino-german center for Research
   promotion (GZ1219).
CR Alshryda S, 2014, BONE JOINT J, V96B, P1005, DOI 10.1302/0301-620X.96B8.33745
   Berenholtz SM, 2009, SPINE, V34, P2096, DOI 10.1097/BRS.0b013e3181b1fab2
   Boese CK, 2017, J BONE JOINT SURG AM, V99, DOI 10.2106/JBJS.16.00738
   Cardone D, 2009, EUR J ANAESTH, V26, P722, DOI 10.1097/EJA.0b013e32832c5280
   Cheriyan T, 2015, SPINE J, V15, P752, DOI 10.1016/j.spinee.2015.01.013
   Chiem J, 2017, PEDIATR ANESTH, V27, P774, DOI 10.1111/pan.13141
   Dhawale AA, 2012, SPINE, V37, pE549, DOI 10.1097/BRS.0b013e31823d009b
   Erstad BL, 2001, ANN PHARMACOTHER, V35, P1075
   Florentino-Pineda I, 2004, SPINE, V29, P233, DOI 10.1097/01.BRS.0000109883.18015.B9
   Gill JB, 2008, J BONE JOINT SURG AM, V90A, P2399, DOI 10.2106/JBJS.G.01179
   Goodnough LT, 1999, NEW ENGL J MED, V340, P438, DOI 10.1056/NEJM199902113400606
   Hu SS, 2004, EUR SPINE J, V13, pS3, DOI 10.1007/s00586-004-0753-x
   Imbesi S, 2010, PHARM WORLD SCI, V32, P416, DOI 10.1007/s11096-010-9415-8
   Iorio Justin, 2013, Surg Technol Int, V23, P291
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Ker K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3054
   Li G, 2017, EUR SPINE J, V26, P140, DOI 10.1007/s00586-016-4792-x
   Lucas-Polomeni MM, 2004, ANN FR ANESTH, V23, P607, DOI 10.1016/j.annfar.2004.04.012
   Mannucci PM, 2007, NEW ENGL J MED, V356, P2301, DOI 10.1056/NEJMra067742
   Mannucci PM, 1998, NEW ENGL J MED, V339, P245, DOI 10.1056/NEJM199807233390407
   McCormack PL, 2012, DRUGS, V72, P585, DOI 10.2165/11209070-000000000-00000
   McNicol ED, 2016, COCHRANE DB SYST REV, V9
   Moher D, 2000, ONKOLOGIE, V23, P597, DOI 10.1159/000055014
   Murkin JM, 2010, ANESTH ANALG, V110, P350, DOI 10.1213/ANE.0b013e3181c92b23
   Sukeik M, 2011, J BONE JOINT SURG BR, V93B, P39, DOI 10.1302/0301-620X.93B1.24984
   Theusinger OM, 2016, BEST PRACT RES-CLIN, V30, P41, DOI 10.1016/j.bpa.2015.11.007
   Thompson GH, 2008, SPINE, V33, P2623, DOI 10.1097/BRS.0b013e318187c046
   Urban MK, 2001, SPINE, V26, P1152, DOI 10.1097/00007632-200105150-00012
   Verma Kushagra, 2014, J Bone Joint Surg Am, V96, pe80, DOI 10.2106/JBJS.L.00008
   Wang M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137886
   Yuan CQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082063
   Zufferey P, 2006, ANESTHESIOLOGY, V105, P1034, DOI 10.1097/00000542-200611000-00026
NR 32
TC 1
Z9 1
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 579
EP +
DI 10.1016/j.wneu.2019.03.186
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100236
PM 30926553
DA 2020-05-12
ER

PT J
AU Marek, T
   Spinner, RJ
   Syal, A
   Wahood, W
   Mahan, MA
AF Marek, Tomas
   Spinner, Robert J.
   Syal, Akshay
   Wahood, Waseem
   Mahan, Mark A.
TI Surgical Treatment of Lipomatosis of Nerve: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Fibrolipomatous hamartoma; Lipofibromatous hamartoma; Lipomatosis of
   nerve; Macrodactyly; Overgrowth
ID MEDIAN NERVE; LIPOFIBROMATOUS HAMARTOMA
AB BACKGROUND: Lipomatosis of nerve (LN) is one part of the spectrum of adipose lesions of nerve. Nerve-territory overgrowth is present in approximately 62% of cases. Given the wide variability in published reports, there is substantial need to understand the results of surgical treatment and outcomes in this disorder.
   METHODS: Raw data from the published systematic review of LN were used for this analysis. PubMed and Google Scholar databases were also screened for any additional papers. The cases were sorted into 2 groups: (1) definite LN cases and (2) probable LN cases (lacked definite proof of LN diagnosis). For statistical analysis, P-value <0.05 was considered statistically significant.
   RESULTS: The total number of 486 definite and 160 probable LN cases (646 cases combined) was included for analysis. The most commonly performed procedure was nerve decompression in both definite (n = 104; 21.4%) and combined definite and probable LN groups (n = 107; 16.6%). Improvement of symptoms was most often reported after nerve decompression (n = 52). A soft-tissue debulking procedure had the highest association with improvement (odds ratio 144.6, 95% confidence interval: 13.8-1516.2, P <0.001) in the definite LN group.
   CONCLUSIONS: Treatment options for IN ranges widely, although notable consistencies exist. The most conservative procedure involving nerve decompression was the most commonly performed procedure, with reported good outcomes. In contrast, worsening of symptoms was most commonly reported when nerve resection was performed. All treatment modalities were associated with improvement compared with no treatment. Diagnostic biopsy should be avoided.
C1 [Marek, Tomas; Spinner, Robert J.; Wahood, Waseem] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Marek, Tomas] Charles Univ Prague, Fac Med 1, Prague, Czech Republic.
   [Syal, Akshay] New York Med Coll, Sch Med, Valhalla, NY 10595 USA.
   [Mahan, Mark A.] Univ Utah, Dept Neurol Surg, Salt Lake City, UT USA.
RP Spinner, RJ (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM spinner.robert@mayo.edu
RI Marek, Tomas/T-4236-2018
OI Marek, Tomas/0000-0003-3588-9236; Wahood, Waseem/0000-0002-2963-4096
CR Abdel-Daim M.M., 2018, ENVIRON SCI POLLUT R, V25, P1
   Abu Jamra F N, 1979, J Hand Surg Am, V4, P160
   AlArifi M, 2019, CASE REP ONCOL, V12, P63, DOI 10.1159/000496685
   AMADIO PC, 1988, J HAND SURG-AM, V13A, P67, DOI 10.1016/0363-5023(88)90203-1
   Cerrato F, 2013, J HAND SURG-AM, V38A, P2112, DOI 10.1016/j.jhsa.2013.08.095
   Cherqui A, 2009, NEUROSURGERY, V65, pA229, DOI 10.1227/01.NEU.0000345353.21320.1F
   Clavijo-Alvarez JA, 2010, PLAST RECONSTR SURG, V125, p120E, DOI 10.1097/PRS.0b013e3181cb66b7
   Frykman G K, 1978, J Hand Surg Am, V3, P307
   Ho CA, 2007, J BONE JOINT SURG AM, V89A, P1097, DOI 10.2106/JBJS.F.01378
   HOUPT P, 1989, J HAND SURG-AM, V14A, P706, DOI 10.1016/0363-5023(89)90195-0
   Hsu Chung-Chen, 2005, Chang Gung Med J, V28, P111
   Kavecan I, 2019, BALK MED J, V36, P60, DOI 10.4274/balkanmedj.2018.1322
   Kitridis Dimitrios, 2018, J Orthop Case Rep, V8, P57, DOI 10.13107/jocr.2250-0685.1160
   Mahan MA, 2014, WORLD NEUROSURG, V82, P492, DOI 10.1016/j.wneu.2013.09.005
   Mahan MA, 2013, J NEUROSURG, V119, P934, DOI 10.3171/2013.7.JNS13537
   Mahan MA, 2013, ACTA NEUROCHIR, V155, P1131, DOI 10.1007/s00701-013-1707-z
   Marek T, 2020, J NEUROSURG, V132, P1286, DOI 10.3171/2018.12.JNS183050
   Marek T, 2018, ACTA NEUROCHIR, V160, P2209, DOI 10.1007/s00701-018-3677-7
   Marek T, 2019, CLIN ANAT, V32, P166, DOI 10.1002/ca.23279
   Marek T, 2018, CLIN ANAT, V31, P1210, DOI 10.1002/ca.23190
   Marom EM, 1999, SKELETAL RADIOL, V28, P260, DOI 10.1007/s002560050512
   Porrino JA, 2019, PM&R, V11, P900, DOI 10.1002/pmrj.12153
   SCHOBER R, 1985, ACTA NEUROPATHOL, V66, P18, DOI 10.1007/BF00698290
   Spinner RJ, 2012, J NEUROSURG, V116, P418, DOI 10.3171/2011.8.JNS101292
   WARHOLD LG, 1993, J HAND SURG-AM, V18A, P1032, DOI 10.1016/0363-5023(93)90398-M
NR 25
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 587
EP +
DI 10.1016/j.wneu.2019.04.110
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100237
PM 31009789
DA 2020-05-12
ER

PT J
AU Giannopoulos, S
   Texakalidis, P
   Alkhataybeh, RAM
   Charisis, N
   Rangel-Castilla, L
   Jabbour, P
   Grossberg, JA
   Machinis, T
AF Giannopoulos, Stefanos
   Texakalidis, Pavlos
   Alkhataybeh, Redab Ahmad Mohammad
   Charisis, Nektarios
   Rangel-Castilla, Leonardo
   Jabbour, Pascal
   Grossberg, Jonathan A.
   Machinis, Theofilos
TI Treatment of Ethmoidal Dural Arteriovenous Fistulas: A Meta-analysis
   Comparing Endovascular versus Surgical Treatment
SO WORLD NEUROSURGERY
LA English
DT Review
DE eDAVF; Endovascular therapy; Ethmoidal dural arteriovenous fistula;
   Surgical disconnection
ID ANTERIOR CRANIAL FOSSA; STEREOTACTIC RADIOSURGERY; TRANSVENOUS
   EMBOLIZATION; MANAGEMENT; MALFORMATIONS; HEMORRHAGE; DRAINAGE; ANEURYSM;
   SERIES
AB BACKGROUND: Dural arteriovenous fistulas (DAVFs) in the anterior cranial fossa constitute approximately 1%-1.5% of intracranial vascular malformations. Depending on the drainage patterns, the diagnosis of ethmoidal DAVFs should prompt treatment because of the high risk of bleeding. Available treatments strategies are surgical treatment and the endovascular approach.
   OBJECTIVE: To compare the surgical treatment with the endovascular therapy in terms of complete obliteration and perioperative adverse events.
   METHODS: This study was performed according to the PRISMA guidelines. Eligible studies were identified through a search of PubMed and Cochrane until February 2019. A random effects model meta-analysis of odds ratios (OR) was conducted and the I-square was used to assess heterogeneity. Good outcome was defined as no neurologic deterioration within 30 days after the procedure.
   RESULTS: Five studies comprising 81 patients were included in the metaanalysis. Surgical disconnection was superior to endovascular therapy in terms of postprocedural complete obliteration rate (surgery group, 100% [n = 65/65]; endovascular therapy, 47% [n = 15/32]; OR, 32.19; 95% confidence interval, 5.46-189.72; I-2 = 9.9%) and 30-day good outcome (surgery group, 98% [n = 63/64]; endovascular therapy, 47% [n = 15/32]; OR, 21.90; 95% confidence interval, 1.94-247.27; I-2 = 53.6%). No significant differences in terms of 30-day stroke, transient ischemic attack; visual deficit, new-onset seizure, and intracranial hemorrhage were identified.
   CONCLUSIONS: Surgical treatment was superior to endovascular therapy in terms of complete obliteration and overall good outcome. Adverse event rates were similar between the 2 groups. Future studies should be conducted to validate our results.
C1 [Giannopoulos, Stefanos] 251 HAF & VA Hosp, Dept Surg, Athens, Greece.
   [Texakalidis, Pavlos; Grossberg, Jonathan A.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA.
   [Alkhataybeh, Redab Ahmad Mohammad] King Abdullah Univ Hosp, Dept Neurosurg, Ar Ramtha, Jordan.
   [Charisis, Nektarios] Stony Brook Univ Hosp, Dept Surg, Div Surg Oncol, Stony Brook, NY USA.
   [Rangel-Castilla, Leonardo] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Jabbour, Pascal] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA.
   [Machinis, Theofilos] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA.
RP Giannopoulos, S (reprint author), 251 HAF & VA Hosp, Dept Surg, Athens, Greece.
EM stefanosgiannopoulosmed@gmail.com
RI Giannopoulos, Stefanos/W-9294-2019
OI Giannopoulos, Stefanos/0000-0002-1942-911X
CR Abrahams JM, 2002, SURG NEUROL, V58, P410, DOI 10.1016/S0090-3019(02)00871-6
   Agid R, 2009, J NEUROSURG, V110, P79, DOI 10.3171/2008.6.17601
   AWAD IA, 1990, J NEUROSURG, V72, P839, DOI 10.3171/jns.1990.72.6.0839
   BARNWELL SL, 1989, J NEUROSURG, V71, P352, DOI 10.3171/jns.1989.71.3.0352
   Brown RD, 2005, MAYO CLIN PROC, V80, P269, DOI 10.4065/80.2.269
   BROWN RD, 1994, J NEUROSURG, V81, P531, DOI 10.3171/jns.1994.81.4.0531
   Cannizzaro D, 2018, NEUROSURG REV, V41, P391, DOI 10.1007/s10143-016-0764-1
   Chaichana KL, 2012, NEUROSURG CLIN N AM, V23, P7, DOI 10.1016/j.nec.2011.09.001
   Chen CJ, 2015, J NEUROSURG, V122, P353, DOI 10.3171/2014.10.JNS14871
   Chen Z, 2008, SURG NEUROL, V69, P318, DOI 10.1016/j.surneu.2006.12.057
   Chung SJ, 2002, CEREBROVASC DIS, V13, P79, DOI 10.1159/000047755
   Cognard C, 2008, AM J NEURORADIOL, V29, P235, DOI 10.3174/ajnr.A0817
   Collice M, 2000, NEUROSURGERY, V47, P56
   Defreyne L, 2000, AM J NEURORADIOL, V21, P761
   Deng JP, 2014, CLIN NEUROL NEUROSUR, V117, P1, DOI 10.1016/j.clineuro.2013.11.013
   Geibprasert S, 2008, STROKE, V39, P2783, DOI 10.1161/STROKEAHA.108.516757
   Grady C, 2017, HAND CLINIC, V143, P125, DOI 10.1016/B978-0-444-63640-9.00012-6
   Gross BA, 2016, WORLD NEUROSURG, V93, P94, DOI 10.1016/j.wneu.2016.05.052
   HALBACH VV, 1990, NEUROSURGERY, V26, P816, DOI 10.1227/00006123-199005000-00014
   Hashiguchi A, 2007, NEUROL MED-CHIR, V47, P70, DOI 10.2176/nmc.47.70
   Hellstern V, 2019, CLIN NEURORADIOL, V29, P341, DOI 10.1007/s00062-018-0669-1
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Inoue A, 2015, J NEUROINTERV SURG, V7, pE15, DOI 10.1136/neurintsurg-2013-011098.rep
   Jamous MA, 2004, NEUROL MED-CHIR, V44, P516, DOI 10.2176/nmc.44.516
   Katsaridis V, 2007, J NEURO-OPHTHALMOL, V27, P281, DOI 10.1097/WNO.0b013e31815b99ee
   Kim MS, 2002, J CLIN NEUROSCI, V9, P147, DOI 10.1054/jocn.2001.1029
   Kortman HG, 2017, INTERV NEURORADIOL, V23, DOI 10.1177/1591019917728399
   LASJAUNIAS P, 1986, J NEUROSURG, V64, P724, DOI 10.3171/jns.1986.64.5.0724
   Latini F, 2014, ACTA NEUROCHIR, V156, P93, DOI 10.1007/s00701-013-1937-0
   Lawton MT, 1999, NEUROSURGERY, V45, P805, DOI 10.1097/00006123-199910000-00014
   Lefkowitz M, 1998, NEUROSURGERY, V43, P1298
   Li Q, 2013, J CLIN NEUROSCI, V20, P281, DOI 10.1016/j.jocn.2012.03.031
   Limbucci N, 2018, WORLD NEUROSURG, V110, pE786, DOI 10.1016/j.wneu.2017.11.095
   Mack WJ, 2011, INTERV NEURORADIOL, V17, P93, DOI 10.1177/159101991101700115
   Magro Elsa, 2014, Surg Neurol Int, V5, P172, DOI 10.4103/2152-7806.146345
   Malek AM, 2000, NEUROSURG CLIN N AM, V11, P147, DOI 10.1016/S1042-3680(18)30151-7
   MARTIN NA, 1990, J NEUROSURG, V72, P692, DOI 10.3171/jns.1990.72.5.0692
   Mayfrank L, 1996, MINIM INVAS NEUROSUR, V39, P74, DOI 10.1055/s-2008-1052221
   Meneghelli P, 2017, ACTA NEUROCHIR, V159, P823, DOI 10.1007/s00701-017-3107-2
   Nelson PK, 2003, J NEUROSURG, V98, P498, DOI 10.3171/jns.2003.98.3.0498
   NEWTON TH, 1969, RADIOLOGY, V93, P1071, DOI 10.1148/93.5.1071
   Pabaney AH, 2016, WORLD NEUROSURG, V89, DOI 10.1016/j.wneu.2016.01.058
   Park SH, 2017, ACTA NEUROCHIR, V159, P1093, DOI 10.1007/s00701-017-3177-1
   Pradilla G, 2012, NEUROSURG CLIN N AM, V23, P105, DOI 10.1016/j.nec.2011.10.002
   Reinard Kevin, 2014, Surg Neurol Int, V5, pS512, DOI 10.4103/2152-7806.145669
   Robert T, 2016, J NEUROINTERV SURG, V8, P954, DOI 10.1136/neurintsurg-2015-011956
   Spiotta AM, 2014, J NEUROINTERV SURG, V6, P195, DOI 10.1136/neurintsurg-2012-010642
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Tahon F, 2008, NEURORADIOLOGY, V50, P429, DOI 10.1007/s00234-007-0344-8
   Tanei T, 2008, NEUROL MED-CHIR, V48, P560, DOI 10.2176/nmc.48.560
   VINUELA F, 1986, J NEUROSURG, V64, P554, DOI 10.3171/jns.1986.64.4.0554
   Woo HH, 2005, NEUROSURG CLIN N AM, V16, P381, DOI 10.1016/j.nec.2004.08.012
   Xu K, 2019, INT J MED SCI, V16, P203, DOI 10.7150/ijms.29637
   Yang HC, 2013, PROG NEUROL SURG, V27, P195, DOI 10.1159/000341796
NR 54
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 593
EP +
DI 10.1016/j.wneu.2019.04.227
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100238
PM 31059849
DA 2020-05-12
ER

PT J
AU Zanaty, M
   Banu, M
   Flouty, O
   Grady, S
   Holland, MT
   Isaacs, A
   Kung, D
   Limbrick, DD
   McKhann, G
   Nagahama, Y
   Zipfel, GJ
   Howard, MA
AF Zanaty, Mario
   Banu, Matei
   Flouty, Oliver
   Grady, Sean
   Holland, Marshall T.
   Isaacs, Albert
   Kung, David
   Limbrick, David D., Jr.
   McKhann, Guy, II
   Nagahama, Yasunori
   Zipfel, Gregory J.
   Howard, Matthew A., III
TI The Wishbone: A Cranial Midline Localizing Device
SO WORLD NEUROSURGERY
LA English
DT Article
DE Midline localizing device; Parietal shunt; Posterior shunt; Posterior
   ventriculoperitoneal shunt
ID PLACEMENT
AB OBJECTIVE: The Wishbone device is designed to enable surgeons to quickly and accurately localize the cranial midline. It is intended to be of particular use when localizing the burr hole site during posterior ventriculoperitoneal shunt (VPS) surgery.
   METHODS: The Wishbone is a simple mechanical device with 2 adjustable caliper arms that reversibly attach to a patient's left and right external auditory canals. The Wishbone's laser localizer illuminates the midline scalp. The Wishbone was used to localize the posterior midline in a pilot series of patients undergoing VPS surgery. Midline localization and ventricular catheter placement accuracy were determined using findings from postoperative computed tomography scans.
   RESULTS: The Wishbone is a mechanically robust device and proved easy for surgeons to use. Forty patients underwent VPS surgery using the Wishbone to localize the posterior midline. The localization procedure took less than 3 minutes. The average distance separating the Wishbone-localized midline scalp location and the computed tomography-defined anatomical midline was 2.9 mm (95% confidence interval 1.6-4.1 mm). In all cases, the ventricular catheter entered the ipsilateral lateral ventricle. The catheter tips were placed in the ipsilateral (n = 34) or contralateral (n = 5) frontal horn in all but 1 patient. In 1 patient, the catheter tip entered the parenchyma due to a burr hole localization error in the rostrocaudal dimension, unrelated to the Wishbone.
   CONCLUSIONS: We describe a simple, efficient, and cost-effective system for accurately localizing the posterior cranial midline. A larger patient series is required to definitively compare its clinical utility relative to frameless stereotaxis-based midline localization methods.
C1 [Zanaty, Mario; Flouty, Oliver; Holland, Marshall T.; Nagahama, Yasunori; Howard, Matthew A., III] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
   [Banu, Matei; McKhann, Guy, II] Columbia Univ, Dept Neurosurg, New York, NY USA.
   [Grady, Sean; Kung, David] Univ Penn, Dept Neurosurg, Philadelphia, PA USA.
   [Isaacs, Albert; Limbrick, David D., Jr.; Zipfel, Gregory J.] Washington Univ, Dept Neurosurg, St Louis, MO 63110 USA.
RP Howard, MA (reprint author), Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
EM matthew-howard@uiowa.edu
OI Holland, Marshall/0000-0002-4936-4193; Howard,
   Matthew/0000-0003-3935-8889; Zanaty, Mario/0000-0002-6605-690X
CR Bhattathiri PS, 2003, NEUROSURG FOCUS, V15, P15
   Garell PC, 1998, J NEUROSURG, V89, P157, DOI 10.3171/jns.1998.89.1.0157
   HOWARD MA, 1995, J NEUROSURG, V82, P300, DOI 10.3171/jns.1995.82.2.0300
   Jung N, 2013, J KOREAN NEUROSURG S, V53, P150, DOI 10.3340/jkns.2013.53.3.150
   Lind CRP, 2008, J NEUROSURG, V108, P930, DOI 10.3171/JNS/2008/108/5/0930
   Nesvick CL, 2015, NEUROSURGERY, V77, P321, DOI 10.1227/NEU.0000000000000849
   Quinones-Hinojosa A, 2006, J NEURO-ONCOL, V76, P65, DOI 10.1007/s11060-005-2915-z
   Zrinzo Ludvic, 2012, Surg Neurol Int, V3, pS53, DOI 10.4103/2152-7806.91612
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 600
EP +
DI 10.1016/j.wneu.2019.05.046
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100239
PM 31100521
DA 2020-05-12
ER

PT J
AU Piergallini, L
   Dargazanli, C
   Derraz, I
   Costalat, V
AF Piergallini, Lorenzo
   Dargazanli, Cyril
   Derraz, Imad
   Costalat, Vincent
TI Immediate Development of Dural Arteriovenous Fistula After Middle
   Meningeal Artery Embolization: First Angiographic Demonstration
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural arteriovenous fistula; Embolization; Endovascular therapy;
   Pathophysiology; Pathogenesis
ID MALFORMATION
AB BACKGROUND: Cerebral dural arteriovenous fistulas (DAVFs) are vascular lesions consisting of a pathologic high-flow connection between dural arteries and veins or dural sinuses. Small DAVFs shunts have been demonstrated to exist physiologically, but as their estimated diameter is around 8-12 mu m, they are not visible even on high-quality angiography studies.
   CASE DESCRIPTION: We report 2 cases of immediate development of a DAVF after embolization with microparticles of the middle meningeal artery for treatment of chronic subdural hematoma.
   CONCLUSIONS: This report represents the first description of sudden development of a DAVF after endovascular embolization of an intracranial artery and may shed light on the pathophysiology and development of DAVFs.
C1 [Piergallini, Lorenzo] Univ Milan, Postgrad Sch Radiodiagnost, Milan, Italy.
   [Piergallini, Lorenzo; Dargazanli, Cyril; Derraz, Imad; Costalat, Vincent] Univ Hosp Gui Chauliac, Dept Diagnost & Intervent Neuroradiol, CHU Montpellier, Montpellier, France.
RP Piergallini, L (reprint author), Univ Milan, Postgrad Sch Radiodiagnost, Milan, Italy.; Piergallini, L (reprint author), Univ Hosp Gui Chauliac, Dept Diagnost & Intervent Neuroradiol, CHU Montpellier, Montpellier, France.
EM lorenzo.piergallini@gmail.com
CR AMINOFF MJ, 1973, BRAIN, V96, P601, DOI 10.1093/brain/96.3.601
   AWAD IA, 1990, J NEUROSURG, V72, P839, DOI 10.3171/jns.1990.72.6.0839
   Ban SP, 2018, RADIOLOGY, V286, P909, DOI 10.1148/radiol.2017170053
   BRAININ M, 1983, NEURORADIOLOGY, V25, P161, DOI 10.1007/BF00455736
   Byrne JV, 2017, TUTORIALS ENDOVASCUL, P229
   CHAUDHARY MY, 1982, AM J NEURORADIOL, V3, P13
   Djindjian R, 1978, SUPER SELECTIVE ARTE
   HERMAN JM, 1995, J NEUROSURG, V83, P539, DOI 10.3171/jns.1995.83.3.0539
   KERBER CW, 1973, NEURORADIOLOGY, V6, P175, DOI 10.1007/BF00335317
   Lawton MT, 1997, J NEUROSURG, V87, P267, DOI 10.3171/jns.1997.87.2.0267
   ROWBOTHAM GF, 1965, BRIT J SURG, V52, P8, DOI 10.1002/bjs.1800520104
   WATANABE A, 1984, NEURORADIOLOGY, V26, P375, DOI 10.1007/BF00327490
NR 12
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 606
EP +
DI 10.1016/j.wneu.2019.04.246
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100240
PM 31077902
DA 2020-05-12
ER

PT J
AU Dibble, CF
   Khalifeh, JM
   VanVoorhis, A
   Rich, JT
   Ray, WZ
AF Dibble, Christopher F.
   Khalifeh, Jawad M.
   VanVoorhis, Anna
   Rich, Jason T.
   Ray, Wilson Z.
TI Novel Nerve Transfers for Motor and Sensory Restoration it High Cervical
   Spinal Cord Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spinal cord; Nerve transfer; Neurotization; Spinal cord injury;
   Tetraplegia
ID GREAT AURICULAR NERVE; RECONSTRUCTION
AB BACKGROUND: Tetraplegia caused by cervical spinal cord injury is devastating for patients and represents a significant public health problem in both developed and developing countries. Improved functional outcomes after nerve transfers are increasingly reported in the literature, but thus far, no options exist for injuries above the C5 level.
   CASE DESCRIPTION: We report the cases of 2 patients with C4 spinal cord injury American Spinal Injury Association A, who underwent successful bilateral spinal accessory nerve transfers, on 1 side to the triceps nerve with long intervening sural graft and on the other side direct transfer to the motor fascicles of the middle trunk. Patients improved from Medical Research Council 0 to 4 on the side of the nerve graft and 0 to 2 or 3 on the side of the direct transfer. Both patients also underwent transfer of the greater auricular nerve to sensory fascicles of the middle trunk, and they experienced sensory recovery in the C6 distribution. Notably, both patients were far removed from the traditional window of nerve transfer surgery at 4 years and almost 11 years out from injury.
   CONCLUSIONS: We describe 2 successful cases of the first and to date only option for motor and sensory reinnervation in high cervical spinal cord injuries. These procedures provide a robust nerve transfer option capable of improving quality of life in tetraplegic patients. There may be a significant undertreated population of patients with cervical spinal cord injury patients in the United States who were previously considered outside the window for benefiting from nerve transfers but who would benefit from these techniques.
C1 [Dibble, Christopher F.; Khalifeh, Jawad M.; VanVoorhis, Anna; Ray, Wilson Z.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA.
   [Rich, Jason T.] Washington Univ, Sch Med, Otolaryngol, St Louis, MO 63110 USA.
RP Ray, WZ (reprint author), Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA.
EM rayz@wustl.edu
FU Department of Defense Spinal Cord Injury Research Program
   [W8IXWH-15-1-0456]
FX This project is the recipient of support from the Department of Defense
   Spinal Cord Injury Research Program, Award No. W8IXWH-15-1-0456.
CR Ahuja CS, 2017, NEUROSURGERY, V80, pS9, DOI 10.1093/neuros/nyw080
   Benassy J, 1966, Med Serv J Can, V22, P695
   Bertelli JA, 2015, J NEUROSURG, V122, P121, DOI 10.3171/2014.8.JNS14277
   Bertelli JA, 2013, J HAND SURG-AM, V38A, P1366, DOI 10.1016/j.jhsa.2013.03.056
   Brown Justin M, 2011, Surg Neurol Int, V2, P121, DOI 10.4103/2152-7806.84392
   Bulstra LF, 2018, J NEUROSURG, V129, P1041, DOI 10.3171/2017.6.JNS17290
   Cain SA, 2015, J BRACHIAL PLEX PERI, V10, pE34, DOI 10.1055/s-0035-1558427
   *CTR NSCIS, 2009, SPIN CORD INJ FACTS
   Emamhadi M, 2017, CLIN NEUROL NEUROSUR, V163, P67, DOI 10.1016/j.clineuro.2017.10.009
   Fox Ida K, 2018, Spinal Cord Ser Cases, V4, P37, DOI 10.1038/s41394-018-0067-6
   Fox IK, 2015, PLAST RECONSTR SURG, V136, P780, DOI 10.1097/PRS.0000000000001641
   Ginsberg LE, 2000, AM J NEURORADIOL, V21, P568
   Gordon T, 2016, EUR J NEUROSCI, V43, P336, DOI 10.1111/ejn.13005
   Jowett N, 2019, BRIT J OPHTHALMOL, V103, P1235, DOI 10.1136/bjophthalmol-2018-312563
   Khalifeh JM, 2019, NEUROSURGERY, V84, P362, DOI 10.1093/neuros/nyy015
   Krueger E, 2019, NEUROSCI LETT, V696, P38, DOI 10.1016/j.neulet.2018.12.004
   Lefkowitz T, 2013, AESTHET SURG J, V33, P19, DOI 10.1177/1090820X12469625
   Li YQ, 2018, J MOL NEUROSCI, V65, P400, DOI 10.1007/s12031-018-1098-y
   Murphy R, 2012, J OTOLARYNGOL-HEAD N, V41, pS75, DOI 10.2310/7070.2011.110090
   Oppenheim JS, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.2.E6
   Pet MA, 2011, J HAND SURG-AM, V36A, P398, DOI 10.1016/j.jhsa.2010.11.024
   Ray WZ, 2016, NEUROSURGERY, V78, P1, DOI 10.1227/NEU.0000000000001029
   Ray Wilson Z, 2010, Hand (N Y), V5, P313, DOI 10.1007/s11552-009-9242-3
   Sananpanich K, 2018, J HAND SURG-AM, V43, P920, DOI 10.1016/j.jhsa.2018.07.013
   Singh A, 2014, CLIN EPIDEMIOL, V6, P309, DOI 10.2147/CLEP.S68889
   Vathana T, 2007, CLIN ANAT, V20, P899, DOI 10.1002/ca.20545
   World Health Organization International Spinal Cord Society, 2013, INT PERSP SPIN CORD
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP 611
EP +
DI 10.1016/j.wneu.2019.04.264
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100241
PM 31078807
DA 2020-05-12
ER

PT J
AU Abraham, ME
   Potdar, A
   Ward, M
   Herschman, Y
   Mammis, A
AF Abraham, Mickey E.
   Potdar, Anushka
   Ward, Max
   Herschman, Yehuda
   Mammis, Antonios
TI Risk Factors Associated with Lead Migration Requiring Revision in Dorsal
   Root Ganglion Stimulation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic pain; Complex regional pain syndrome; Dorsal root ganglion
   stimulation; Lead migration; Neuromodulation; Spinal cord stimulation
ID SPINAL-CORD STIMULATION; REGIONAL PAIN SYNDROME; NEUROMODULATION;
   PREVALENCE; MANAGEMENT; COUNTRIES; TARGET
AB BACKGROUND: Neuromodulation is an evolving therapy for chronic pain. Aiming to meet the limitations of traditional spinal cord stimulation, dorsal root ganglion (DRG) stimulation targets pain in a dermatomal distribution at the site of pain transmission. Despite these advantages, lead migration is a significant complication that hinders the long-term efficacy of DRG stimulation. This study aims to identify risk factors for lead migration requiring revision in DRG stimulation.
   METHODS: We performed a retrospective review of all subjects who had DRG stimulators implanted at T10-S2 by a single physician over a 2-year period. Their history was reviewed for the following: age, sex, diagnosis, lead placement, reported symptom relief, complications, and postoperative activity.
   RESULTS: In total, 19 cases of DRG stimulator implantation were identified. All patients reported pain relief, with 84.2% (16/19) describing >50% relief. In total, 31.6% of patients (6/19) developed lead migration and 15.8% of total implanted leads (9/57) migrated. Of the migrated leads, 4% (4/9) occurred at S1 and 33.3% (3/9) occurred at L4. The underlying etiology of lead migration was clear and preventable in 66.7% of patients (4/6). All patients who developed lead migration were women.
   CONCLUSIONS: Premature activity, hardware manipulation, and female sex appear to be associated with an increased risk for lead migration. Leads on the S1 and L4 locations may he more likely to migrate. Large trials are necessary to gain a more conclusive understanding of these risk factors for lead migration.
C1 [Abraham, Mickey E.; Potdar, Anushka; Ward, Max; Herschman, Yehuda; Mammis, Antonios] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
RP Abraham, ME (reprint author), Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
EM mea177@njms.rutgers.edu
CR [Anonymous], ENCY PAIN, P436
   Bendersky D, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.06.012
   Billet B, 2017, CASE REPORTS MED, V2017, P1
   Cameron T, 2004, J NEUROSURG, V100, P254, DOI 10.3171/spi.2004.100.3.0254
   Deer Timothy R, 2019, Neuromodulation, V22, P930, DOI 10.1111/ner.12920
   Deer TR, 2017, PAIN, V158, P669, DOI 10.1097/j.pain.0000000000000814
   Deer TR, 2012, NEUROMODULATION, V15, P467, DOI 10.1111/j.1525-1403.2012.00486.x
   Elzahaf RA, 2012, CURR MED RES OPIN, V28, P1221, DOI 10.1185/03007995.2012.703132
   Hunter CW, 2019, NEUROMODULATION, V22, P61, DOI 10.1111/ner.12796
   Jeon YH, 2012, KOREAN J PAIN, V25, P143, DOI 10.3344/kjp.2012.25.3.143
   KIRKPATRICK AF, 1991, NEUROSURGERY, V28, P932
   Kramer J, 2015, NEUROMODULATION, V18, P50, DOI 10.1111/ner.12217
   Krames ES, 2015, NEUROMODULATION, V18, P24, DOI 10.1111/ner.12247
   Langley PC, 2011, CURR MED RES OPIN, V27, P463, DOI 10.1185/03007995.2010.542136
   Levy RM, 2017, NEUROMODULATION, V20, P519, DOI 10.1111/ner.12646
   Liem L, 2016, PROG NEUROL SURG, V29, P213, DOI 10.1159/000434673
   Liem L, 2016, REGION ANESTH PAIN M, V41, P511, DOI 10.1097/AAP.0000000000000408
   Liem L, 2015, NEUROMODULATION, V18, P41, DOI 10.1111/ner.12228
   McBeth J, 2007, BEST PRACT RES CL RH, V21, P403, DOI 10.1016/j.berh.2007.03.003
   Mekhail NA, 2010, PAIN PRACT, V10, P103, DOI 10.1111/j.1533-2500.2009.00341.x
   Pergolizzi J, 2013, CURR MED RES OPIN, V29, P1127, DOI 10.1185/03007995.2013.810615
   SHEALY CN, 1967, ANESTH ANAL CURR RES, V46, P489
   Tsang A, 2008, J PAIN, V9, P883, DOI 10.1016/j.jpain.2008.05.005
   Turner JA, 2010, PAIN, V148, P14, DOI 10.1016/j.pain.2009.08.014
   Van Buyten JP, 2015, PAIN PRACT, V15, P208, DOI 10.1111/papr.12170
   Velsen VV, 2017, PAIN PRACT, V18, P539
   Wilkinson HA, 2008, NEUROSURGERY, V63, P376
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E649
EP E652
DI 10.1016/j.wneu.2019.04.225
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100075
PM 31054337
DA 2020-05-12
ER

PT J
AU Adib, SD
   Ebner, FH
   Bornemann, A
   Hempel, JM
   Tatagiba, M
AF Adib, Sasan Darius
   Ebner, Florian H.
   Bornemann, Antje
   Hempel, Johann-Martin
   Tatagiba, Marcos
TI Surgical Management of Primary Cerebellopontine Angle Melanocytoma:
   Outcome, Recurrence and Additional Therapeutic Options
SO WORLD NEUROSURGERY
LA English
DT Article
DE Black tumor; BRAF; Cerebellopontine angle; Melanocytoma of intermediate
   grade; Meningeal melanocytoma; Pigmented tumor; V600E mutation status
ID CENTRAL-NERVOUS-SYSTEM; MENINGEAL MELANOCYTOMA;
   MALIGNANT-TRANSFORMATION; MELANOTIC MENINGIOMA; TUMORS; CNS
AB OBJECTIVE: Meningeal melanocytomas of the central nervous system are extremely rare, with an incidence of 1 per 10 million individuals. Cases of primary cerebellopontine angle melanocytoma (PCPAM) have only been described in single case reports. The goal of the present study was to analyze the surgical management of PCPAM, with a particular focus on early and late treatment outcomes and recurrence rates.
   METHODS: The patients who had undergone surgery for PCPAM from January 2004 to May 2018 were identified by a local database query. The patients were evaluated for initial symptoms, pre- and postoperative facial and cochlear nerve function, complications, and recurrence rate by reviewing the patient's medical records.
   RESULTS: We identified 4 patients with PCPAM of >1500 cerebellopontine angle lesions ( - 0.2%) that had been surgically treated at our department in the past 14 years. Of the 4 patients, 2 were men and 2 were women, with a mean age of 47 years. Anatomical facial and cochlear nerve preservation was achieved in all 4 patients. One patient experienced a new moderate facial palsy immediately after surgery (House-Brackmann grade III). Of the 4 patients, 3 had undergone radiotherapy and 1 had undergone ion beam therapy for tumor recurrence (6 years after surgery). Of the 4 patients, 3 had presented with tumor recurrence at 2, 3, and 6 years of follow-up respectively. The long-term follow-up examination had not yet been conducted for 1 patient.
   CONCLUSIONS: At long-term follow-up, 3 patients had developed recurrence. Because of the high recurrence rate of PCPAM, we believe that radiotherapy in addition to surgery should be considered in the future to avoid early recurrence.
C1 [Adib, Sasan Darius; Ebner, Florian H.; Tatagiba, Marcos] Univ Tubingen, Dept Neurosurg, Tubingen, Germany.
   [Bornemann, Antje] Univ Tubingen, Dept Neuropathol, Tubingen, Germany.
   [Hempel, Johann-Martin] Univ Tubingen, Dept Neuroradiol, Tubingen, Germany.
RP Adib, SD (reprint author), Univ Tubingen, Dept Neurosurg, Tubingen, Germany.
EM sasan_adib2002@yahoo.de
OI Adib, Sasan Darius/0000-0002-1879-8490
CR Bar H, 1997, CLIN NEUROPATHOL, V16, P337
   Behling F, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0506-2
   Brackmann DE, 2007, OTOL NEUROTOL, V28, P529, DOI 10.1097/mao.0b013e3180383694
   Brat DJ, 1999, AM J SURG PATHOL, V23, P745, DOI 10.1097/00000478-199907000-00001
   Broman KK, 2019, EXPERT OPIN DRUG SAF, V18, P381, DOI 10.1080/14740338.2019.1607289
   Cordoba A, 1989, Arch Neurobiol (Madr), V52, P93
   Doglietto F, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-220
   Freudenstein D, 2004, ZBL NEUROCHIR, V65, P146, DOI 10.1055/s-2004-816266
   Gempt J, 2011, J NEURO-ONCOL, V102, P323, DOI 10.1007/s11060-010-0311-9
   Hamasaki O, 2002, NEUROL MED-CHIR, V42, P504, DOI 10.2176/nmc.42.504
   Ibanez J, 1997, HISTOPATHOLOGY, V30, P576, DOI 10.1046/j.1365-2559.1997.5660798.x
   Jaiswal S, 2011, NEUROL INDIA, V59, P413, DOI 10.4103/0028-3886.82758
   Jellinger K, 2000, WHO CLASSIFICATION T
   Koelsche C, 2015, BRAIN PATHOL, V25, P202, DOI 10.1111/bpa.12228
   Kolliker A., 1850, MIKROSKOPISCHE ANATO
   Kurita H, 2000, J NEURO-ONCOL, V46, P57, DOI 10.1023/A:1006335616839
   LIMAS C, 1972, CANCER, V30, P1286, DOI 10.1002/1097-0142(197211)30:5<1286::AID-CNCR2820300522>3.0.CO;2-V
   Liubinas SV, 2010, J CLIN NEUROSCI, V17, P1227, DOI 10.1016/j.jocn.2010.01.017
   Meyer D, 1999, AM J OPHTHALMOL, V127, P710, DOI 10.1016/S0002-9394(99)00065-3
   Navas M, 2009, J NEURO-ONCOL, V95, P105, DOI 10.1007/s11060-009-9907-3
   OBRIEN TF, 1995, ARCH PATHOL LAB MED, V119, P542
   Oruckaptan HH, 2000, PEDIATR NEUROSURG, V32, P240, DOI 10.1159/000028945
   Pasquali S, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011123.pub2
   Perrini P, 2010, NEUROSURGERY, V67, pE867, DOI 10.1227/01.NEU.0000372919.96651.34
   Phang I, 2012, J NEUROL SURG REP, V73, P25, DOI 10.1055/s-0032-1311756
   PORTUGAL JR, 1984, SURG NEUROL, V21, P275, DOI 10.1016/0090-3019(84)90202-7
   Quatresooz P, 2008, ONCOL REP, V19, P1367
   Rades D, 2006, J NEURO-ONCOL, V77, P311, DOI 10.1007/s11060-005-9048-2
   Rades D, 2002, STRAHLENTHER ONKOL, V178, P336, DOI 10.1007/s00066-002-0930-y
   Roser F, 2004, J NEUROSURG, V101, P528, DOI 10.3171/jns.2004.101.3.0528
   Sharma PM, 2002, OPHTHALMOLOGICA, V216, P292, DOI 10.1159/000063845
   Uozumi Yoichi, 2003, Brain Tumor Pathol, V20, P21, DOI 10.1007/BF02478943
   VERMA DS, 1979, JAMA-J AM MED ASSOC, V242, P2435, DOI 10.1001/jama.242.22.2435
   Wang FL, 2011, NEUROPATHOLOGY, V31, P414, DOI 10.1111/j.1440-1789.2010.01160.x
NR 34
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E835
EP E840
DI 10.1016/j.wneu.2019.05.004
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100098
PM 31082560
OA Bronze
DA 2020-05-12
ER

PT J
AU Alawieh, A
   Kellogg, RT
   Chatterjee, AR
   Korson, C
   Lajthia, O
   Anadani, M
   Lena, J
   Spiotta, AM
AF Alawieh, Ali
   Kellogg, Ryan T.
   Chatterjee, A. Rano
   Korson, Clayton
   Lajthia, Orgest
   Anadani, Mohammad
   Lena, Jonathan
   Spiotta, Alejandro M.
TI Technical and Clinical Outcomes After Thrombectomy for the Various
   Segments of the Middle Cerebral Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Direct aspiration; M2 segments; Stroke; Thrombectomy
ID ACUTE ISCHEMIC-STROKE; 1ST PASS TECHNIQUE; LARGE VESSEL OCCLUSION;
   MECHANICAL THROMBECTOMY; ENDOVASCULAR TREATMENT; STENT-RETRIEVER; ADAPT
   TECHNIQUE; M2 OCCLUSIONS; ASPIRATION; EXPERIENCE
AB BACKGROUND: After showing the success of mechanical thrombectomy (MT) in treating large-vessel occlusion stroke, the target population has been expanded to include patients with smaller and more distal vessels including the M2 segment of the middle cerebral artery. We compared the procedural and clinical outcomes of patients undergoing MT using direct aspiration (ADAPT [A Direct Aspiration at first Pass Technique]) between superior or inferior divisions of M2 and M1.
   METHODS: We retrospectively reviewed a database of patients undergoing MT between June 2013 and July 2018 at our center for clinical and procedural variables. Patients with isolated M1 or M2 occlusions were included. M2 occlusions were classified into superior and inferior divisions. Functional outcomes were collected at 90 days.
   RESULTS: A total of 205 patients with M1, 65 with M2 superior division (middle cerebral artery M2 superior segment [M2S]), and 57 with inferior division (middle cerebral artery M2 inferior segment [M2I]) stroke were included. M1 and M2S patients had comparable National Institutes of Health Stroke Scale score at presentation, but higher than M2I (P < 0.01). Compared with M1, M2 occlusions had longer procedure times and required more aspiration attempts (P < 0.05). M2S thrombectomy had a significantly lower rate of successful recanatization (P < 0.05). Rates of good outcome (modified Rankin Scale score 0-2) were 46% in M1, 34% in M2S, and 44% in M2I, and postprocedural hemorrhage rates were comparable between groups. On multivariate analysis, M2S occlusion was associated with longer procedure times, lower odds of good outcomes, and lower TICI recanalization scores (P < 0.05) compared with M1.
   CONCLUSIONS: ADAPT is safe and effective in M2 stroke. The procedural success and efficacy of ADAPT in M2 stroke are influenced by the anatomic division with less favorable clinical and technical outcomes in the M2S division.
C1 [Alawieh, Ali] Med Univ South Carolina, Med Scientist Training Program, Charleston, SC 29425 USA.
   [Alawieh, Ali; Kellogg, Ryan T.; Korson, Clayton; Lajthia, Orgest; Anadani, Mohammad; Lena, Jonathan; Spiotta, Alejandro M.] Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
   [Chatterjee, A. Rano] Med Univ South Carolina, Dept Radiol & Radiol Sci, Charleston, SC 29425 USA.
RP Spiotta, AM (reprint author), Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
EM spiotta@musc.edu
RI Alawieh, Ali/AAM-1898-2020; Alawieh, Ali/AAM-1420-2020; Anadani,
   Mohammad/J-6012-2019
OI Alawieh, Ali/0000-0003-2601-8850; Anadani, Mohammad/0000-0002-7813-2949;
   Chatterjee, Arindam/0000-0002-6172-2010
CR Alawieh Ali, 2020, Neurosurgery, V86, P61, DOI 10.1093/neuros/nyy444
   Alawieh A, 2018, J NEUROINTERV SURG, V10, P213, DOI 10.1136/neurintsurg-2017-013040
   Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Altenbernd J, 2018, J NEUROINTERV SURG, V10, P434, DOI 10.1136/neurintsurg-2017-013233
   Bhogal P, 2017, INTERV NEUROL, V6, P191, DOI 10.1159/000475535
   Coutinho JM, 2016, AM J NEURORADIOL, V37, P667, DOI 10.3174/ajnr.A4591
   Flores A, 2015, J NEUROINTERV SURG, V7, P234, DOI 10.1136/neurintsurg-2014-011100
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Grossberg JA, 2018, STROKE, V49, P1662, DOI 10.1161/STROKEAHA.118.020567
   Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Lapergue B, 2017, JAMA-J AM MED ASSOC, V318, P443, DOI 10.1001/jama.2017.9644
   Mocco J., 2018, INT STROK C 2018 JAN
   Mokin M, 2017, NEUROSURGERY, V81, P795, DOI 10.1093/neuros/nyx060
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Pexman JHW, 2001, AM J NEURORADIOL, V22, P1534
   Saber H, 2018, J NEUROINTERV SURG, V10, P620, DOI 10.1136/neurintsurg-2017-013515
   Salahuddin H, 2018, J NEUROINTERV SURG, V10, P330, DOI 10.1136/neurintsurg-2017-013159
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Saver JL, 2015, INT J STROKE, V10, P439, DOI 10.1111/ijs.12459
   Spiotta AM, 2014, J NEUROINTERV SURG, V6, P511, DOI 10.1136/neurintsurg-2013-010726
   Turk AS, 2014, J NEUROINTERV SURG, V6, P260, DOI 10.1136/neurintsurg-2014-011125
   Turk AS, 2014, J NEUROINTERV SURG, V6, P231, DOI 10.1136/neurintsurg-2013-010713
   Vargas J, 2017, J NEUROINTERV SURG, V9, P437, DOI 10.1136/neurintsurg-2015-012211
   Vargas J, 2017, WORLD NEUROSURG, V99, P31, DOI 10.1016/j.wneu.2016.11.035
NR 25
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E445
EP E453
DI 10.1016/j.wneu.2019.04.175
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100051
PM 31042600
DA 2020-05-12
ER

PT J
AU Arocho-Quinones, EV
   Huang, CC
   Ward, BD
   Pahapill, PA
AF Arocho-Quinones, Elsa V.
   Huang, Chiang-Ching
   Ward, Barney D.
   Pahapill, Peter A.
TI Care Bundle Approach to Minimizing Infection Rates after Neurosurgical
   Implants for Neuromodulation: A Single-Surgeon Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bundle; Checklists; Deep brain stimulation; Intrathecal pumps; Spinal
   cord stimulation; Surgical implant; Surgical site infection
ID SURGICAL-SITE INFECTIONS; BRAIN-STIMULATION SURGERY; INTRATHECAL
   BACLOFEN PUMP; RISK-FACTORS; GENERATOR REPLACEMENT; SILK; COMPLICATIONS;
   PREVENTION; SYSTEMS; REDUCE
AB INTRODUCTION: Implant-related infections carry a high morbidity. Infectious rates for neuromodulation implants range from 1% to 9% for deep brain stimulation (DBS), 0% to 10% for spinal cord stimulation (SCS) systems, and 3% to 15% for intrathecal (IT) pump systems. Meanwhile, studies of care bundles report infection rate reduction to 1.0% for SCS and 0.3% for cardiac implants. Herein, we evaluate the effectiveness of an infection prevention bundle (IPB) in minimizing infections after surgeries for neuromodulation implants.
   METHODS: An IPB focused on preoperative checklists, screening questionnaires, methicillin-resistant and methicillin-sensitive Staphylococcus aureus decolonization, weight-based antibiotic prophylaxis, strict draping and surgical techniques, and wound care education was implemented in our functional neurosurgery division in April 2015. We retrospectively reviewed all surgeries for implantation or replacement of SCS, DBS, and IT pump system components from March 2013 to October 2017. The patients were divided into pre-IPB and post-IPB groups. All procedures were performed by a single surgeon. Each surgical site was considered a unique surgical case. Infection rates were calculated for pre-IPB and post-IPB groups.
   RESULTS: A total of 688 patients underwent 1161 unique surgical procedures (222 DBS electrodes, 419 IPG, 203 SCS, 317 IT pumps) during the study period. There were 546 pre-IPB and 615 post-IPB surgical procedures. The pre-IPB infection rates were 0%, 1.3%, and 8.7% for SCS, DBS, and IT pumps, respectively. The post-IPB infection rates were 0%, 0.3%, and 1.8% for SCS, DBS, and IT pumps, respectively.
   CONCLUSIONS: Implementation of a standardized IPB approach reduced the number of infections for all neuromodulation implants studied. This approach can be adopted within any specialty to potentially decrease the incidence of implant-related infections.
C1 [Arocho-Quinones, Elsa V.; Pahapill, Peter A.] US Dept Vet Affairs, Dept Neurosurg, Med Ctr, Milwaukee, WI 53223 USA.
   [Arocho-Quinones, Elsa V.; Pahapill, Peter A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
   [Ward, Barney D.] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA.
   [Huang, Chiang-Ching] Univ Wisconsin, Joseph J Zilber Sch Publ Hlth, Milwaukee, WI 53201 USA.
RP Arocho-Quinones, EV (reprint author), US Dept Vet Affairs, Dept Neurosurg, Med Ctr, Milwaukee, WI 53223 USA.; Arocho-Quinones, EV (reprint author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
EM earocho@mcw.edu
OI Arocho-Quinones, Elsa/0000-0002-6000-5503
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR001436]
CR Abode-Iyamah KO, 2019, J NEUROSURG, V130, P629, DOI 10.3171/2017.9.JNS1780
   Bjerknes S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105288
   Calkins M, 2007, PEDIATR SURG INT, V23, P349, DOI 10.1007/s00383-007-1894-x
   Centers for Disease Control and Prevention, NAT HEALTHC SAF NETW
   Deer TR, 2017, NEUROMODULATION, V20, P31, DOI 10.1111/ner.12565
   Fay MP, 2010, R J, V2, P53
   Fenoy AJ, 2012, J NEUROSURG, V116, P1324, DOI 10.3171/2012.1.JNS111798
   Frizon LA, 2017, NEUROMODULATION, V20, P444, DOI 10.1111/ner.12605
   Ghobrial GM, 2014, J CLIN NEUROSCI, V21, P1786, DOI 10.1016/j.jocn.2014.04.007
   Harrop JS, 2012, J AM ACAD ORTHOP SUR, V20, P94, DOI 10.5435/JAAOS-20-02-094
   HORAN TC, 1992, AM J INFECT CONTROL, V20, P271, DOI 10.1016/S0196-6553(05)80201-9
   Korol E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083743
   Malheiro L, 2015, NEUROMODULATION, V18, P421, DOI 10.1111/ner.12265
   Manolis AS, 2017, PACE, V40, P26, DOI 10.1111/pace.12996
   Meinel L, 2005, BIOMATERIALS, V26, P147, DOI 10.1016/j.biomaterials.2004.02.047
   Olsen MA, 2008, J BONE JOINT SURG AM, V90A, P62, DOI 10.2106/JBJS.F.01515
   Pahapill PA, 2015, NEUROMODULATION, V18, P367, DOI 10.1111/ner.12239
   Pepper J, 2013, STEREOT FUNCT NEUROS, V91, P56, DOI 10.1159/000343202
   Piacentino M, 2011, ACTA NEUROCHIR, V153, P2337, DOI 10.1007/s00701-011-1130-2
   Polyzos KA, 2015, EUROPACE, V17, P767, DOI 10.1093/europace/euv053
   Rasouli JJ, 2016, WORLD NEUROSURG, V95, P9, DOI 10.1016/j.wneu.2016.07.063
   Schuster JM, 2010, SPINE, V35, pS125, DOI 10.1097/BRS.0b013e3181d8342c
   Schweizer ML, 2015, JAMA-J AM MED ASSOC, V313, P2162, DOI 10.1001/jama.2015.5387
   Spelzini F, 2007, GYNECOL OBSTET INVES, V63, P155, DOI 10.1159/000096893
   Taira T, 2013, NEUROMODULATION, V16, P266, DOI 10.1111/ner.12010
   Thrane JF, 2014, STEREOT FUNCT NEUROS, V92, P360, DOI 10.1159/000365576
   Yusuf E, 2017, NEUROMODULATION, V20, P563, DOI 10.1111/ner.12555
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E87
EP E97
DI 10.1016/j.wneu.2019.04.003
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100012
PM 30986582
DA 2020-05-12
ER

PT J
AU Baharvahdat, H
   Ahmadi, S
   Ganjeifar, B
   Etemadrezaie, H
   Zabyhian, S
   Sasannejad, P
   Bahadorkhan, G
   Mowla, A
AF Baharvahdat, Humain
   Ahmadi, Sina
   Ganjeifar, Babak
   Etemadrezaie, Hamid
   Zabyhian, Samira
   Sasannejad, Payam
   Bahadorkhan, Gholamreza
   Mowla, Ashkan
TI Malignant Cerebral Venous Infarction: Decompressive Craniectomy versus
   Medical Treatment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral venous infarction; Decompressive craniectomy; Medical treatment
ID WEIGHTED MAGNETIC-RESONANCE; SINUS THROMBOSIS; CONTROLLED-TRIAL;
   SURGERY; HEPARIN; EDEMA; RISK
AB BACKGROUND: Cerebral venous thrombosis (CVT) is a common type of stroke in young adults and associated with 8% mortality. High intracranial pressure (ICP) and brain herniation are the most common causes of death in these patients. In contrast with malignant arterial middle cerebral infarction, there are few studies reporting the efficacy of decompressive craniectomy (DC) for treatment of high ICP in patients with CVT. In this study, we assess the clinical outcome of patients with CVT with impending brain herniation treated with DC versus medical management.
   METHODS: In this retrospective study, medical records of all patients with CVT admitted to our hospital were reviewed. Patients with the following inclusion criteria were entered into the study: 1) CVT proven by contrast-enhanced magnetic resonance venogram and/or computed tomography venogram, 2) malignant CVT (impending brain herniation according to imaging and clinical finding), and 3) age between 16 and 80 years. Patients with deep venous system thrombosis, Glasgow Coma Scale (GCS) score of 3, and bilateral nonreactive midposition pupils or mydriasis on admission were excluded. Patients were classified into 2 groups: surgical group (DC group) including patients who received medical treatment and DC and medical group (MG) including patients who received only medical treatment. Outcomes and complications were assessed and compared between the 2 groups.
   RESULTS: Of 357 patients with CVT hospitalized in our center, 48 patients entered into the study. Twenty-three patients were managed medically, and 25 patients were managed surgically. There was no significant difference between the groups concerning age, sex, presenting symptoms, transient and permanent risk factors of CVT, GCS score on admission, and pupils' reactivity on admission. All patients in the MG died during hospitalization in comparison with 8 patients in the DC group (100% vs. 32%, P < 0.001). Favorable outcome (modified Rankin scale score 0-2) was achieved in 52% of the DC group and 0% of the MG group (P < 0.001).
   CONCLUSIONS: The results of our study confirmed that in contrast with DC, medical treatment could not prevent transtentorial herniation. DC is not only lifesaving for patients with CVT with impending brain herniation but also results in favorable outcome in most patients.
C1 [Baharvahdat, Humain; Ahmadi, Sina; Ganjeifar, Babak; Etemadrezaie, Hamid; Zabyhian, Samira; Bahadorkhan, Gholamreza] Mashhad Univ Med Sci, Dept Neurosurg, Mashhad, Razavi Khorasan, Iran.
   [Baharvahdat, Humain; Sasannejad, Payam] Mashhad Univ Med Sci, Dept Neurol, Mashhad, Razavi Khorasan, Iran.
   [Mowla, Ashkan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA.
RP Mowla, A (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA.
EM Mowla_a@yahoo.com
OI Zabihyan, Samira/0000-0003-0742-6664; Ganjeifar,
   Babak/0000-0002-5212-5791
CR Aaron S, 2013, J NEUROL NEUROSUR PS, V84, P995, DOI 10.1136/jnnp-2012-303356
   Breteau G, 2003, J NEUROL, V250, P29, DOI 10.1007/s00415-003-0932-4
   Canhao PC, 2005, STROKE, V36, P1720, DOI 10.1161/01.STR.0000173152.84438.1c
   CANTU C, 1993, STROKE, V24, P1880, DOI 10.1161/01.STR.24.12.1880
   Chu K, 2001, ARCH NEUROL-CHICAGO, V58, P1569, DOI 10.1001/archneur.58.10.1569
   de Bruijn SFTM, 1999, STROKE, V30, P484, DOI 10.1161/01.STR.30.3.484
   Ducreux D, 2001, AM J NEURORADIOL, V22, P261
   Ebke M, 2011, NEUROCRIT CARE, V15, P166, DOI 10.1007/s12028-010-9389-3
   Ferro JM, 2011, STROKE, V42, P2825, DOI 10.1161/STROKEAHA.111.615393
   Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649
   Keller E, 1999, STROKE, V30, P1144, DOI 10.1161/01.STR.30.5.1144
   Mehraein S, 2003, CEREBROVASC DIS, V15, P17, DOI 10.1159/000067117
   Mohindra S, 2011, BRIT J NEUROSURG, V25, P422, DOI 10.3109/02688697.2011.578775
   Namazi Mohammad Reza, 2004, BMC Pulm Med, V4, P1, DOI 10.1186/1471-2466-4-1
   Raza E, 2014, J STROKE CEREBROVASC, V23, pE13, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.045
   Shakibajahromi Banafsheh, 2018, Acta Neurol Belg, DOI 10.1007/s13760-018-1009-6
   Stam J, 2008, STROKE, V39, P1487, DOI 10.1161/STROKEAHA.107.502658
   Theaudin M, 2010, STROKE, V41, P727, DOI 10.1161/STROKEAHA.109.572909
   Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235
   Vivakaran TTR, 2012, J NEUROSURG, V117, P738, DOI 10.3171/2012.6.JNS11102
   Weber J, 2013, ACTA NEUROCHIR, V155, P651, DOI 10.1007/s00701-013-1627-y
   Zhang S, 2017, J NEUROSURG, V127, P709, DOI 10.3171/2016.8.JNS161112
   Zuurbier SM, 2012, J NEUROL, V259, P1099, DOI 10.1007/s00415-011-6307-3
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E918
EP E922
DI 10.1016/j.wneu.2019.05.028
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100108
PM 31096029
DA 2020-05-12
ER

PT J
AU Baran, O
   Baydin, S
   Gungor, A
   Balak, N
   Middlebrooks, E
   Saygr, T
   Aydin, I
   Tanriover, N
AF Baran, Oguz
   Baydin, Serhat
   Gungor, Abuzer
   Balak, Naci
   Middlebrooks, Erik
   Saygr, Tahsin
   Aydin, Ilhan
   Tanriover, Necmettin
TI Surgical Approaches to the Thalamus in Relation to the White Matter
   Tracts of the Cerebrum
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrum; Endoscope; Microneurosurgery; Surgical anatomy; Surgical
   approaches; Thalamus; Tumors; White matter tracts
ID CAVERNOUS MALFORMATIONS; MICROSURGICAL ANATOMY; BRAIN; SEGMENTATION;
   EXPERIENCE; FASCICLE
AB BACKGROUND: Approaching the thalamus from any angle remains a challenge because of its deep-seated location and intimate relations with adjacent important neurovascular structures and functions such as relaying sensory and motor signals and cognition. Our aim was to explore the relationship of the white matter tracts of the cerebrum to the thalamus using a fiber dissection technique, to delineate anatomic principles of approaches to the thalamus, and to discuss the tracts at risk in relation to each approach.
   METHODS: The thalamus was subdivided into 6 different regions and 13 approaches were examined in an attempt to describe a surgical road map.
   RESULTS: To reach the anteroinferior, medial, and lateral parts of the thalamus, the anterior and middle group approaches were used, and to reach the posterosuperior and posteroinferior thalamus, posterior and middle group approaches were used. The anteroinferior zone was the most difficult site to be accessed and the posterosuperior thalamus had the maximum number of alternative approaches. The distal transsylvian approach to the posterosuperior thalamus and the supracarotid infrafrontal approach to the anteroinferior thalamus had the highest number of neural structures severed within the surgical corridor. The infratentorial approaches and the suboccipital transtentorial approach preserve most of the white matter tracts en route to the posterosuperior and medial posteroinferior parts of the thalamus.
   CONCLUSIONS: When the surgical approaches for thalamic lesions are defined, white matter tracts along the surgical route should be taken into consideration.
C1 [Baran, Oguz; Balak, Naci; Saygr, Tahsin; Aydin, Ilhan] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Neurosurg, Microsurg Neuroanat Lab, Istanbul, Turkey.
   [Tanriover, Necmettin] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.
   [Middlebrooks, Erik] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL USA.
   [Baydin, Serhat] Ondokuz Mayis Univ, Med Fac, Dept Neurosurg, Samsun, Turkey.
   [Gungor, Abuzer] Acibadem Univ, Med Fac, Dept Neurosurg, Istanbul, Turkey.
RP Tanriover, N (reprint author), Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.
EM nctan27@yahoo.com
RI Tanriover, Necmettin/AAD-3212-2020; Middlebrooks, Erik/Q-9389-2019;
   BARAN, Oguz/AAG-3278-2019; Balak, Naci/D-5846-2019
OI Tanriover, Necmettin/0000-0001-7628-9443; Middlebrooks,
   Erik/0000-0002-4418-9605; Balak, Naci/0000-0002-2395-0004; gungor,
   abuzer/0000-0002-2792-7610
CR Apuzzo MLJ, 1998, SURG 3 VENTRICLE
   AUSMAN JI, 1988, SURG NEUROL, V29, P298, DOI 10.1016/0090-3019(88)90161-9
   Balak N, 2018, WORLD NEUROSURG, V110, P133, DOI 10.1016/j.wneu.2017.10.168
   Baydin S, 2016, OPER NEUROSURG, V12, P269, DOI 10.1227/NEU.0000000000001133
   Burdach KF, 1826, BAUE LEBEN GEHIRNS, V3
   Byrne JH, 2017, LEARNING MEMORY COMP
   Campero A, 2006, NEUROSURGERY, V59, P279, DOI 10.1227/NEU.0000223509.21474.2E
   Chechlacz M, 2013, CORTEX, V49, P487, DOI 10.1016/j.cortex.2011.11.008
   Chi JH, 2006, NEUROSURGERY, V59, P41, DOI 10.1227/01.NEU.0000219880.66309.85
   de Oliveira E, 1994, Clin Neurosurg, V41, P364
   de Oliveira JG, 2010, NEUROSURGERY, V66, P389, DOI 10.1227/01.NEU.0000363702.67016.5D
   de Ribet RM, 1957, SYSTEMATISATION CENT
   Fernandez-Miranda JC, 2008, NEUROSURGERY, V62, P989, DOI [10.1227/01.NEU.0000297076.98175.67, 10.1227/01.neu.0000333767.05328.49]
   Fernandez-Miranda J, 2015, BRAIN STRUCT FUNCT, V220, P1665, DOI 10.1007/s00429-014-0751-7
   FORNARI M, 1981, J NEUROSURG, V54, P64, DOI 10.3171/jns.1981.54.1.0064
   Gungor A, 2017, J NEUROSURG, V126, P945, DOI 10.3171/2016.1.JNS152082
   Heimer L, 2008, ANATOMY OF NEUROPSYCHIATRY: THE NEW ANATOMY OF THE BASAL FOREBRAIN AND ITS IMPLICATIONS FOR NEUROPSYCHIATRIC ILLNESS, P1, DOI 10.1016/B978-012374239-1.50004-X
   Hendelman W., 2015, ATLAS FUNCTIONAL NEU
   Horsley V., 1910, P ROY SOC MED, V3, P77
   Klingler J, 1935, SCHWEIZ ARCH NEUROL, V36, P247
   Kubicki M, 2002, AM J PSYCHIAT, V159, P813, DOI 10.1176/appi.ajp.159.5.813
   Kucukyuruk B, 2014, OPER NEUROSURG, V10, P305, DOI 10.1227/NEU.0000000000000288
   Kucukyuruk Baris, 2012, Epilepsy Res Treat, V2012, P769825, DOI 10.1155/2012/769825
   Lawton MT, 1996, NEUROSURGERY, V39, P729, DOI 10.1097/00006123-199610000-00016
   Makris N, 2005, CEREB CORTEX, V15, P854, DOI 10.1093/cercor/bhh186
   Nieuwenhuys R., 2007, HUMAN CENTRAL NERVOU
   Oppenheim H, 1913, BERL KLIN WOCHENSCHR, V50, P2316
   Peltier J, 2012, J NEUROL, V259, P1860, DOI 10.1007/s00415-012-6421-x
   Rangel-Castilla L, 2015, J NEUROSURG, V123, P676, DOI 10.3171/2014.11.JNS14381
   Reil J, 1809, ARCH PHYSL
   Rhoton A., 2003, CRANIAL ANATOMY SURG
   Richard Winn H., 2016, YOUMANS WINN NEUROLO
   Schapira AHV, NEUROLOGY CLIN NEURO
   Schmahmann J.D., 2009, FIBER PATHWAYS BRAIN
   Shimizu Satoru, 2006, Neurosurgery, V58, pE1000, DOI 10.1227/01.NEU.0000210247.37628.43
   Shin HJ, 1998, CHILD NERV SYST, V14, P174, DOI 10.1007/s003810050206
   Tanriover N, 2004, J NEUROSURG, V100, P891, DOI 10.3171/jns.2004.100.5.0891
   Ture U, 2000, NEUROSURGERY, V47, P417, DOI 10.1097/00006123-200008000-00028
   Ture U, 2012, J NEUROSURG, V116, P773, DOI 10.3171/2011.12.JNS11791
   Ulm AJ, 2004, NEUROSURGERY, V54, P1313, DOI 10.1227/01.NEU.0000126129.68707.E7
   Ulm AJ, 2009, J NEUROSURG, V111, P600, DOI 10.3171/2008.7.JNS08124
   VOIGT K, 1976, NEUROCHIRURGIA, V19, P59
   Waldron JS, 2009, NEUROSURGERY, V64, pS86, DOI 10.1227/01.NEU.0000335647.71014.07
   Wilde EA, 2006, J CHILD NEUROL, V21, P769, DOI 10.1177/08830738060210090201
   Yagmurlu K, 2016, J NEUROSURG, V124, P1396, DOI 10.3171/2015.5.JNS15455
   Yagmurlu K, 2015, OPER NEUROSURG, V11, P274, DOI 10.1227/NEU.0000000000000704
   Yasargil MG, 1996, MICRONEUROSURGERY CN, V4B
NR 47
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1048
EP E1086
DI 10.1016/j.wneu.2019.05.068
PG 39
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100123
PM 31103757
DA 2020-05-12
ER

PT J
AU Basaran, R
   Efendioglu, M
   Kaksi, M
   Celik, T
   Mutlu, I
   Ucar, M
AF Basaran, Recep
   Efendioglu, Mustafa
   Kaksi, Mustafa
   Celik, Talip
   Mutlu, Ibrahim
   Ucar, Mehmet
TI Finite Element Analysis of Short- Versus Long-Segment Posterior Fixation
   for Thoracolumbar Burst Fracture
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent-segment disease; Long segment; Posterior screw fixation; Short
   segment
ID PEDICLE SCREW FIXATION; UNSTABLE THORACOLUMBAR; JUNCTIONAL KYPHOSIS;
   ADJACENT SEGMENT; INTERBODY FUSION; SPINE INJURY; LUMBAR; LEVEL;
   MANAGEMENT; INSTRUMENTATION
AB OBJECTIVE: The thoracolumbar (TL) area marks the transition of the rigid thoracic spine into the mobile lumbar spine, and it is considered to be the weakest part of the spine. This study was designed to develop a finite element (FE) model of the TL junction (T9-L3) to provide data that could help the clinician and researcher to answer the question of whether short-segment posterior fixation is sufficient for biomechanical performance. In addition, the aim was to examine whether long-segment posterior fixation carries a greater risk of the development of adjacent segment disease.
   METHODS: This was a biomechanical finite element model analysis. FE analysis of the spine was conducted with posterior instrumentation under multidirectional loading conditions in order to evaluate the kinematics of the instrumented lumbar spine, as well as stresses in the posterior spinal instrumentation. We analyzed the following: 1) the range of motion of the T9-L3 region; and 2) the von Mises stress nephograms of the pedicle screws, rods, vertebrae, endplates, and intervertebral discs of 2 fixation FE models.
   RESULTS: Long-segment stabilization was found to be beneficial in terms of reducing total stress on the spine. However, it is possible to reduce the stress on the system by incorporating the spinal fracture into the stabilization system. Therefore, short-segment stabilization is sufficient to create a safe and robust stabilization system and to maintain neighboring intact vertebrae.
   CONCLUSIONS: Short-segment posterior fixation is sufficient to stabilize fractures at the TL junction, where the spinal fracture is included in the stabilization system.
C1 [Basaran, Recep] Med Sci Univ Sancaktepe Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Efendioglu, Mustafa] Med Sci Univ Haydarpasa Numune Training & Res Hos, Dept Neurosurg, Istanbul, Turkey.
   [Kaksi, Mustafa] Eyup State Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Celik, Talip; Mutlu, Ibrahim; Ucar, Mehmet] Kocaeli Univ, Fac Engn, Dept Biomed Engn, Kocaeli, Turkey.
RP Basaran, R (reprint author), Med Sci Univ Sancaktepe Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
EM drrecepbasaran@gmail.com
RI Basaran, Recep/D-4013-2019
OI Basaran, Recep/0000-0001-5186-1116
CR Baaj AA, 2011, J NEUROSURG-SPINE, V14, P192, DOI 10.3171/2010.10.SPINE10222
   Bono CM, 2004, SPINE, V29, P455, DOI 10.1097/01.BRS.0000090825.94611.28
   Cahueque M, 2016, J ORTHOP, V13, P278, DOI 10.1016/j.jor.2016.06.007
   Chen CS, 2005, MED ENG PHYS, V27, P487, DOI 10.1016/j.medengphy.2004.12.007
   Chen CS, 2001, MED ENG PHYS, V23, P483
   Chen SH, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-72
   Dai LY, 2007, SURG NEUROL, V67, P221, DOI 10.1016/j.surneu.2006.08.081
   DENIS F, 1983, SPINE, V8, P817, DOI 10.1097/00007632-198311000-00003
   Dobran M, 2016, ACTA NEUROCHIR, V158, P1883, DOI 10.1007/s00701-016-2907-0
   Elmasry S, 2017, COMPUT METHOD BIOMEC, V20, P1412, DOI 10.1080/10255842.2017.1366995
   Farrokhi MR, 2010, EUR SPINE J, V19, P1651, DOI 10.1007/s00586-010-1449-z
   Goto Keisuke, 2003, J Orthop Sci, V8, P577, DOI 10.1007/s00776-003-0675-1
   Guven O, 2009, J SPINAL DISORD TECH, V22, P417, DOI 10.1097/BSD.0b013e3181870385
   Han S, 2017, SPINE J, V17, P962, DOI 10.1016/j.spinee.2017.02.005
   Holm S., 1985, ORTHOP T, V9, P451
   Holmes JF, 2001, ACAD EMERG MED, V8, P866, DOI 10.1111/j.1553-2712.2001.tb01146.x
   Ito M, 1997, SPINE, V22, P382, DOI 10.1097/00007632-199702150-00005
   Jutte PC, 2002, EUR SPINE J, V11, P594, DOI 10.1007/s00586-002-0469-8
   Kim HY, 2012, J KOREAN NEUROSURG S, V51, P203, DOI 10.3340/jkns.2012.51.4.203
   Kim HJ, 2012, SPINE, V37, P1637, DOI 10.1097/BRS.0b013e31823f2115
   Kim Y, 2010, SPINE, V35, P599, DOI 10.1097/BRS.0b013e3181b6258a
   Kwon BK, 2006, SPINE, V31, P1943, DOI 10.1097/01.brs.0000229258.83071.db
   Li CQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099156
   Magerl F, 1994, Eur Spine J, V3, P184, DOI 10.1007/BF02221591
   Mahar A, 2007, SPINE, V32, P1503, DOI 10.1097/BRS.0b013e318067dd24
   MILLER DI, 1979, MED SCI SPORT EXER, V11, P115
   Morgan EF, 2003, J BIOMECH, V36, P897, DOI 10.1016/S0021-9290(03)00071-X
   Natarajan RN, 2018, J BIOMECH ENG-T ASME, V140, DOI 10.1115/1.4039989
   Park P, 2004, SPINE, V29, P1938, DOI 10.1097/01.brs.0000137069.88904.03
   Park W, 2009, J ORTHOP SCI, V14, P443, DOI 10.1007/s00776-009-1341-z
   Parker JW, 2000, SPINE, V25, P1157, DOI 10.1097/00007632-200005010-00018
   Pellise F, 2015, SPINE J, V15, P1796, DOI 10.1016/j.spinee.2014.03.012
   Pflugmacher R, 2004, SPINE, V29, P1413, DOI 10.1097/01.BRS.0000129895.90939.1E
   Renner SM, 2007, J BIOMECH, V40, P1326, DOI 10.1016/j.jbiomech.2006.05.019
   Sapkas George, 2010, Open Orthop J, V4, P7, DOI 10.2174/1874325001004010007
   Scholl BM, 2006, ORTHOPEDICS, V29, P703, DOI 10.3928/01477447-20060801-14
   Su YS, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012046
   Tian JW, 2011, ORTHOPEDICS, V34, P594, DOI 10.3928/01477447-20110627-08
   Vaccaro AR, 2013, SPINE, V38, P2028, DOI 10.1097/BRS.0b013e3182a8a381
   Wood KB, 2014, SPINE J, V14, P145, DOI 10.1016/j.spinee.2012.10.041
   Xu GJ, 2014, P I MECH ENG H, V228, P1005, DOI 10.1177/0954411914552308
   YAMAMOTO I, 1989, SPINE, V14, P1256, DOI 10.1097/00007632-198911000-00020
   Yang P, 2016, J HUAZHONG U SCI-MED, V36, P887, DOI 10.1007/s11596-016-1680-x
NR 43
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1109
EP E1117
DI 10.1016/j.wneu.2019.05.077
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100127
PM 31103754
DA 2020-05-12
ER

PT J
AU Bobeff, EJ
   Fortuniak, J
   Bryszewski, B
   Wisniewski, K
   Bryl, M
   Kwiecien, K
   Stawiski, K
   Jaskolski, DJ
AF Bobeff, Ernest J.
   Fortuniak, Jan
   Bryszewski, Bartosz
   Wisniewski, Karol
   Bryl, Maciej
   Kwiecien, Katarzyna
   Stawiski, Konrad
   Jaskolski, Dariusz J.
TI Mortality After Traumatic Brain Injury in Elderly Patients: A New
   Scoring System
SO WORLD NEUROSURGERY
LA English
DT Article
DE Decision-making; Older adults; Prognosis; Scoring system; Traumatic
   brain injury
ID CELL DISTRIBUTION WIDTH; SELF-FULFILLING PROPHECY; DECOMPRESSIVE
   CRANIECTOMY; INTRACRANIAL-PRESSURE; PROGNOSTIC MODELS; 28-DAY MORTALITY;
   IMPACT; ANTIPLATELET; PREDICTION; OUTCOMES
AB BACKGROUND: Traumatic brain injury (TBI) remains a life-threatening condition characterized by growing incidence worldwide, particularly in the aging population, in which the primary goal of treatment appears to be avoidance of chronic institutionalization.
   METHODS: To identify independent predictors of 30-day mortality or vegetative state in a geriatric population and calculate an intuitive scoring system, we screened 480 patients after TBI treated at a single department of neurosurgery over a 2-year period. We analyzed data of 214 consecutive patients aged >= 65 years, including demographics, medical history, cause and time of injury, neurologic state, radiologic reports, and laboratory results. A predictive model was developed using logistic regression modeling with a backward stepwise feature selection.
   RESULTS: The median Glasgow Coma Scale (GCS) score on admission was 14 (interquartile range, 12-15), whereas the 30-day mortality or vegetative state rate amounted to 23.4%. Starting with 20 predefined features, the final prediction model highlighted the importance of GCS motor score (odds ratio [OR], 0.17; 95% confidence interval [CI], 0.09-0.32); presence of comorbid cardiac, pulmonary, or renal dysfunction or malignancy (OR, 2.86; 9 5% CI, 1.08-7.61); platelets <= 100 x 10(9) cella (OR, 13.60; 95% CI, 3.33-55.49); and red blood cell distribution width coefficient of variation .14.5% (OR, 2.91; 95% CI, 1.09-7.78). The discovered coefficients were used for nomogram development. It was further simplified to facilitate clinical use. The proposed scoring system, Elderly Traumatic Brain Injury Score (eTBI Score), yielded similar performance metrics.
   CONCLUSIONS: The eTBI Score is the first scoring system designed specifically for older adults. It could constitute a framework for clinical decision-making and serve as an outcome predictor. Its capability to stratify risk provides reliable criteria for assessing efficacy of TBI management.
C1 [Bobeff, Ernest J.; Fortuniak, Jan; Bryszewski, Bartosz; Wisniewski, Karol; Bryl, Maciej; Kwiecien, Katarzyna; Jaskolski, Dariusz J.] Med Univ Lodz, Barlicki Univ Hosp, Dept Neurosurg & Neurooncol, Lodz, Poland.
   [Stawiski, Konrad] Med Univ Lodz, Dept Biostat & Translat Med, Lodz, Poland.
RP Fortuniak, J (reprint author), Med Univ Lodz, Barlicki Univ Hosp, Dept Neurosurg & Neurooncol, Lodz, Poland.
EM jfort@tlen.pl
RI Jaskolski, Dariusz J/H-8051-2013; Stawiski, Konrad/AAH-8817-2020;
   Stawiski, Konrad/O-6006-2019; Stawiski, Konrad/B-7211-2017
OI Bobeff, Ernest/0000-0003-1891-3791; Stawiski, Konrad/0000-0002-6550-3384
CR Barthelemy EJ, 2016, WORLD NEUROSURG, V88, P411, DOI 10.1016/j.wneu.2015.12.044
   Cap AP, 2011, J TRAUMA, V71, pS78, DOI 10.1097/TA.0b013e3182218cd8
   Citerio G, 2007, INTENS CARE MED, V33, P45, DOI 10.1007/s00134-006-0381-5
   Creutzfeldt CJ, 2011, CRIT CARE MED, V39, P158, DOI 10.1097/CCM.0b013e3181fb7b49
   Cruise CM, 2006, CLIN GERIATR MED, V22, P257, DOI 10.1016/j.cger.2005.12.015
   Dang Q, 2015, J SURG RES, V198, P482, DOI 10.1016/j.jss.2015.03.092
   DAVIS CS, 1988, J AM GERIATR SOC, V36, P225, DOI 10.1111/j.1532-5415.1988.tb01805.x
   De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889
   de Guise E, 2015, BRAIN INJURY, V29, P558, DOI 10.3109/02699052.2014.976593
   Downey DM, 2009, AM SURGEON, V75, P1100
   Dukhinova M, 2018, BRAIN BEHAV IMMUN, V74, P7, DOI 10.1016/j.bbi.2018.09.009
   East JM, 2018, CURR OPIN ANESTHESIO, V31, P219, DOI 10.1097/ACO.0000000000000566
   Erdogan A, 2016, EUR J TRAUMA EMERG S, V42, P513, DOI 10.1007/s00068-015-0572-2
   Estcourt LJ, 2017, BRIT J HAEMATOL, V176, P365, DOI 10.1111/bjh.14423
   Evans LR, 2019, J NEUROTRAUM, V36, P517, DOI 10.1089/neu.2018.5829
   Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009
   Fu WW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175868
   Furay E, 2018, J TRAUMA ACUTE CARE, V85, P881, DOI 10.1097/TA.0000000000002047
   Garbharran U, 2013, AGE AGEING, V42, P258, DOI 10.1093/ageing/afs176
   Gardner RC, 2018, J NEUROTRAUM, V35, P889, DOI 10.1089/neu.2017.5371
   Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542
   Havens J M, 2018, TRAUMA SURG ACUTE CA, V3, pe000147
   Hemphill JC, 2019, WORLD NEUROSURG, V123, P157, DOI 10.1016/j.wneu.2018.12.060
   HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175
   Herou E, 2015, WORLD NEUROSURG, V83, P996, DOI 10.1016/j.wneu.2015.02.023
   Jacobs BS, 2017, NEUROLOGY, V89, P417, DOI 10.1212/WNL.0000000000004195
   Julien J, 2017, J CLIN NEUROSCI, V38, P122, DOI 10.1016/j.jocn.2016.12.032
   Kaufman RM, 2015, ANN INTERN MED, V162, P205, DOI 10.7326/M14-1589
   Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003
   Kim SH, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0274-8
   Kinoshita T, 2016, WORLD NEUROSURG, V89, P187, DOI 10.1016/j.wneu.2016.01.071
   Kirkman MA, 2013, J NEUROTRAUM, V30, P1385, DOI 10.1089/neu.2013.2881
   Kong T, 2017, AM J EMERG MED, V35, P1819, DOI 10.1016/j.ajem.2017.06.008
   Kowalski RG, 2013, NEUROCRIT CARE, V19, P269, DOI 10.1007/s12028-013-9929-8
   Lawrence T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012197
   Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835
   Lenell S, 2015, ACTA NEUROCHIR, V157, P417, DOI 10.1007/s00701-014-2329-9
   Li N, 2017, DIS MARKERS, DOI 10.1155/2017/7089493
   Lippi G, 2017, ARCH MED SCI, V13, P606, DOI 10.5114/aoms.2017.67282
   Liu ZH, 2018, AM J EMERG MED, V36, P1112, DOI 10.1016/j.ajem.2017.10.028
   Majercik S, 2013, J TRAUMA ACUTE CARE, V74, P1021, DOI 10.1097/TA.0b013e3182826f02
   McCracken DJ, 2019, NEUROSURGERY, V84, P741, DOI 10.1093/neuros/nyy193
   McGuire C, 2017, CAN GERIATR J, V20, P2, DOI 10.5770/cgj.20.228
   Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33
   Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290
   Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E
   Orlando Alessandro, 2013, J Clin Med Res, V5, P168, DOI 10.4021/jocmr1333w
   Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x
   Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7
   Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25
   Perlstein TS, 2009, ARCH INTERN MED, V169, P588, DOI 10.1001/archinternmed.2009.55
   Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197
   Richmond R, 2011, J TRAUMA, V71, pE8, DOI 10.1097/TA.0b013e3181fbaa46
   Robertsen A, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0385-x
   Roe C, 2015, BEHAV NEUROL, DOI 10.1155/2015/845491
   Rossaint R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1265-x
   Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58
   Shimoda K, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.014
   Staples JA, 2016, BRAIN INJURY, V30, P899, DOI 10.3109/02699052.2016.1146964
   Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165
   Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004
   Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y
   Wan XY, 2017, WORLD NEUROSURG, V103, P584, DOI 10.1016/j.wneu.2017.04.069
   Wan XY, 2016, WORLD NEUROSURG, V89, P147, DOI 10.1016/j.wneu.2016.01.084
   Weimer JM, 2016, CRIT CARE MED, V44, P1161, DOI 10.1097/CCM.0000000000001570
   Won SY, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.7.FOCUS17417
   Yin P, 2016, OSTEOPOROSIS INT, V27, P2077, DOI 10.1007/s00198-015-3357-x
   Yuan Q, 2015, J NEUROSURG, V122, P574, DOI 10.3171/2014.10.JNS1460
NR 68
TC 1
Z9 1
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E129
EP E147
DI 10.1016/j.wneu.2019.04.060
PG 19
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100016
PM 30981800
DA 2020-05-12
ER

PT J
AU Bozkurt, G
   Leone, F
   Arosio, AD
   Mobaraki, PD
   Elhassan, HA
   Seyhun, N
   Turri-Zanoni, M
   Castelnuovo, P
   Battaglia, P
AF Bozkurt, Gulpembe
   Leone, Federico
   Arosio, Alberto Daniele
   Mobaraki, Puya Dehgani
   Elhassan, Hassan Ahmed
   Seyhun, Nurullah
   Turri-Zanoni, Mario
   Castelnuovo, Paolo
   Battaglia, Paolo
TI Septal Flip Flap for Anterior Skull Base Reconstruction After Endoscopic
   Transnasal Craniectomy: Long-Term Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid leak; Craniectomy; Septal flip flap; Skull base
   reconstruction; Vascularized mucosal flap
ID INFERIOR TURBINATE FLAP; RESECTION; ESTHESIONEUROBLASTOMA;
   ADENOCARCINOMA; ARTERIES; TRACT
AB BACKGROUND: Endoscopic endonasal anterior skull base malignant sinonasal tumor resection and reconstruction remains a challenge. We describe our septal flip flap (SFF) reconstruction, a new surgical technique for repairing anterior skull base defects and report our outcomes.
   METHODS: We retrospectively reviewed the clinical data of 24 patients who underwent skull base reconstruction using a SFF following endoscopic resection with transnasal craniectomy. We raise the SFF from the contralateral nasal septum based on the septal branches of the anterior and posterior ethmoidal arteries; the SFF is then rotated laterally for anterior skull base reconstruction after transnasal resection with craniectomy.
   RESULTS: The SFF was used for multiple tumor types including, most commonly, intestinal-type adenocarcinoma, followed by olfactory neuroblastoma, squamous cell carcinoma, sinonasal undifferentiated carcinoma, and other types. All of the cases had either preoperative or postoperative radiation therapy. All flaps remained viable postoperatively. Postoperatively, nasal crusting was significantly reduced with faster healing of the surgical cavity.
   CONCLUSIONS: The SFF adds to the clinical armamen-tarium the opportunity to provide vascularized mucosal coverage extending from the frontal recess hack to the planum sphenoidalis. The use of SFF requires careful consideration when dealing with paranasal sinus cancers so as not to infringe oncologic principles.
C1 [Bozkurt, Gulpembe; Leone, Federico; Arosio, Alberto Daniele; Turri-Zanoni, Mario; Castelnuovo, Paolo; Battaglia, Paolo] Univ Insubria, Div Otorhinolaryngol, Dept Biotechnol & Life Sci, Varese, Italy.
   [Mobaraki, Puya Dehgani] USL Umbria 1, Gubbio Gualdo Tadino Hosp, Div Otorhinolaryngol, Perugia, Italy.
   [Elhassan, Hassan Ahmed] Homerton Univ Hosp, DOHNS, London, England.
   [Seyhun, Nurullah] Sisli Hamidiye Etfal Training & Res Hosp, Div Otorhinolaryngol, Istanbul, Turkey.
   [Turri-Zanoni, Mario; Castelnuovo, Paolo; Battaglia, Paolo] Univ Insubria, Dept Biotechnol & Life Sci, HNS & FDRC, Varese, Italy.
RP Bozkurt, G (reprint author), Univ Insubria, Div Otorhinolaryngol, Dept Biotechnol & Life Sci, Varese, Italy.
EM gptalayhan@gmail.com
RI Turri-Zanoni, Mario/H-9837-2019; Seyhun, Nurullah/AAA-4876-2020
OI Turri-Zanoni, Mario/0000-0002-3678-9088; Seyhun,
   Nurullah/0000-0002-6236-7479; Dehgani Mobaraki,
   Puya/0000-0001-8339-1868; Elhassan, Hassan/0000-0001-5378-8709; Bozkurt,
   Gulpembe/0000-0003-2100-023X
CR Amin MB, 2017, AJCC CANC STAGING MA
   Battaglia P, 2016, ACTA OTORHINOLARYNGO, V36, P194, DOI 10.14639/0392-100X-748
   Castelnuovo P, 2006, OPER TECH OTOLARYNGO, V17, P152
   Chiu T, 2006, OTOLARYNG HEAD NECK, V134, P33, DOI 10.1016/j.otohns.2005.09.005
   Eviatar E, 2013, J NEUROL SURG PART B, V74, P126, DOI 10.1055/s-0033-1338257
   Fortes FSG, 2007, LARYNGOSCOPE, V117, P1329, DOI 10.1097/mlg.0b013e318062111f
   Gil Z, 2012, OTOLARYNG HEAD NECK, V146, P842, DOI 10.1177/0194599811434516
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Hadad G, 2011, LARYNGOSCOPE, V121, P1606, DOI 10.1002/lary.21889
   Kassam Amin, 2005, Neurosurg Focus, V19, pE8
   Kassam AB, 2008, NEUROSURGERY, V63, P44, DOI 10.1227/01.NEU.0000297074.13423.F5
   Lund V, 2011, RHINOLOGY, P1
   Mattavelli D, 2017, WORLD NEUROSURG, V101, P486, DOI 10.1016/j.wneu.2017.02.066
   Monjas-Canovas I, 2011, ACTA OTORRINOLAR ESP, V62, P367, DOI 10.1016/j.otorri.2011.04.006
   MORITA A, 1993, NEUROSURGERY, V32, P706, DOI 10.1227/00006123-199305000-00002
   Nicolai P, 2008, AM J RHINOL, V22, P308, DOI 10.2500/ajr.2008.22.3170
   Patel MR, 2014, LARYNGOSCOPE, V124, P846, DOI 10.1002/lary.24319
   Prevedello DM, 2009, LARYNGOSCOPE, V119, P2094, DOI 10.1002/lary.20226
   Schreiber A, 2018, ORAL ONCOL, V87, P89, DOI 10.1016/j.oraloncology.2018.10.027
   Shetty SR, 2017, ACTA NEUROCHIR, V159, P1875, DOI 10.1007/s00701-017-3303-0
   Tajudeen BA, 2016, INT FORUM ALLERGY RH, V6, P1047, DOI 10.1002/alr.21794
   Turri-Zanoni M, 2018, WORLD NEUROSURG, V116, pE436, DOI 10.1016/j.wneu.2018.04.225
   Van Gerven L, 2011, HEAD NECK-J SCI SPEC, V33, P898, DOI 10.1002/hed.21556
NR 23
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E409
EP E416
DI 10.1016/j.wneu.2019.04.166
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100047
PM 31042605
DA 2020-05-12
ER

PT J
AU Cabrera, LY
   Sarva, H
   Sidiropoulos, C
AF Cabrera, Laura Y.
   Sarva, Harini
   Sidiropoulos, Christos
TI Perspectives on the Earlier Use of Deep Brain Stimulation for Parkinson
   Disease from a Qualitative Study of US Clinicians
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Parkinson disease; Perspectives
ID SUBTHALAMIC NUCLEUS; STAGE; NEUROSTIMULATION
AB BACKGROUND: In November 2015, the U.S. Food and Drug Administration (FDA) approved the use of deep brain stimulation (DBS) therapy in people with Parkinson's disease (PD) "of at least four years duration and with a recent onset of motor complications, or motor complications of longer-standing duration that are not adequately controlled with medication." Although the full implications of this more recent approval are yet to be determined, to date, there are no strict criteria defining appropriate earlier use of DBS. As such, confusion remains regarding the actual meaning of early DBS initiation. To better inform responsive policy, we sought the perspectives of movement disorder neurologists and neurosurgeons regarding the earlier use of DBS. Insights from these clinicians are key to developing appropriate clinical guidelines and determining how early is too early. The objective of this study is to explore attitudes among clinicians toward the earlier use of DBS for PD.
   METHODS: Twelve Michigan-based clinicians were interviewed both about DBS referral/use processes and their perspectives regarding the earlier use of DBS in PD. We used a structured interview with closed- and open-ended questions. All interviews were transcribed verbatim and analyzed using a mixed-method approach.
   RESULTS: We found that most clinicians considered earlier use not solely to be time dependent but instead determined by patient symptoms. Only 16.8% were aware of the FDA's recent indication of early use of DBS, with 25% of our respondents being unsure as to whether it should be seen as an early treatment modality. On average, neurologists suggested DBS as the next treatment option, after medications have been exhausted, typically 6 years after diagnosis.
   CONCLUSIONS: There remain wide variations in terms of clinician's parameters for referrals and timing of DBS. Larger studies are needed to support or refute our findings.
C1 [Cabrera, Laura Y.] Michigan State Univ, Ctr Eth & Humanities Life Sci, E Lansing, MI 48824 USA.
   [Cabrera, Laura Y.] Michigan State Univ, Dept Translat Sci & Mol Med, E Lansing, MI 48824 USA.
   [Sidiropoulos, Christos] Michigan State Univ, Dept Neurol & Ophthalmol, E Lansing, MI 48824 USA.
   [Sarva, Harini] Weill Cornell Med, Parkinsons Dis & Movement Disorders Inst, New York, NY USA.
   [Sarva, Harini] NY Presbyterian Hosp Ctr, New York, NY USA.
RP Cabrera, LY (reprint author), Michigan State Univ, Ctr Eth & Humanities Life Sci, E Lansing, MI 48824 USA.; Cabrera, LY (reprint author), Michigan State Univ, Dept Translat Sci & Mol Med, E Lansing, MI 48824 USA.
EM cabrer22@msu.edu
CR AAN, AM AC NEUR SUMM EV B
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Bronstein JM, 2011, ARCH NEUROL-CHICAGO, V68, P165, DOI 10.1001/archneurol.2010.260
   Butala AA, 2016, MULTISITE SURVEY PAR
   Charles D, 2014, PARKINSONISM RELAT D, V20, P731, DOI 10.1016/j.parkreldis.2014.03.019
   Charles PD, 2008, NAT CLIN PRACT NEURO, V4, P424, DOI 10.1038/ncpneuro0848
   Christen M., 2014, AJOB NEUROSCI, V5, P65, DOI [10.1080/21507740.2014.939380, DOI 10.1080/21507740.2014.939380]
   Coleman R, 2015, DEEP BRAIN STIMULATI, P5
   deSouza RM, 2013, ANN NEUROL, V73, P565, DOI 10.1002/ana.23890
   Deuschl G, 2013, LANCET NEUROL, V12, P1025, DOI 10.1016/S1474-4422(13)70151-0
   Deuschl G, 2013, PARKINSONISM RELAT D, V19, P56, DOI 10.1016/j.parkreldis.2012.07.004
   Eijkholt M, 2017, NEUROMODULATION, V20, P411, DOI 10.1111/ner.12608
   Heusinkveld L, 2017, J PARKINSON DIS, V7, P89, DOI 10.3233/JPD-161031
   Katz M, 2011, ARCH NEUROL-CHICAGO, V68, P1027, DOI 10.1001/archneurol.2011.151
   Mack N, 2005, QUALITATIVE RES METH
   Mestre TA, 2014, MOVEMENT DISORD, V29, P1751, DOI 10.1002/mds.26024
   Moldovan AS, 2015, NEURAL REGEN RES, V10, P1018, DOI 10.4103/1673-5374.160094
   Ostergaard K, 2006, MOVEMENT DISORD, V21, P624, DOI 10.1002/mds.20776
   Schuepbach WMM, 2013, NEW ENGL J MED, V368, P610, DOI 10.1056/NEJMoa1205158
   Siddiqui J, 2018, EXPERT REV NEUROTHER, V18, P811, DOI 10.1080/14737175.2018.1535902
   Suarez-Cedeno G, 2017, PARKINSONS DIS, V2017, P1
   Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI 10.1111/nhs.12048
   Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929
NR 23
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E16
EP E20
DI 10.1016/j.wneu.2019.03.051
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100004
PM 30880198
DA 2020-05-12
ER

PT J
AU Cao, J
   Liu, YL
   Wang, YQ
   Zhao, L
   Wang, WD
   Zhang, M
   Wang, LM
AF Cao, Jing
   Liu, Yilin
   Wang, Yuqiang
   Zhao, Liang
   Wang, Weidong
   Zhang, Min
   Wang, Limin
TI A Clinical Correlation Research of the Hoffmann Sign and Neurological
   Imaging Findings in Cervical Spinal Cord Compression
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical; Clinical correlation; Hoffmann sign; Magnetic resonance
   imaging
ID MYELOPATHY
AB BACKGROUND: The Hoffmann sign is usually used as an indicator of upper motor neuron lesion, but its clinical effect remains controversial in previous reports.
   METHODS: A retrospective case control study including 107 patients with cervical complaints was carried out. According to the presence of Hoffmann sign, patients were divided into 2 groups. The radiographic results were assessed and the sensitivity, specificity, positive and negative predictive values, and false positive and false negative values of Hoffmann sign for cervical pathology, segment, cervical spine canal ratio, and S-index were calculated.
   RESULTS: There were 56 patients in the positive Hoffmann group and 51 patients in negative group. The sensitivity, specificity, positive and negative predictive values, and false positive and false negative values of Hoffmann sign for cervical pathology were found to be 61.6%, 85.7%, 94.6%, 35.3%, 14.3%, 38.4% and 60.5%, 81.0%, 92.9%, 33.3%, 19.0%, 39.5%, respectively. The ratio of cervical spine canal was lower in the positive Hoffmann group than in control group.
   CONCLUSIONS: Although the Hoffmann sign is not foolproof in the diagnosis of cervical spinal cord compression, it can be used to assess symptomatic patients. The narrower the cervical spine canal or the higher the cervical segment compression, the higher of the incidence of positive Hoffmann sign.
C1 [Cao, Jing] Huazhong Univ Sci & Technol, Dept Nucl Med, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Liu, Yilin; Wang, Yuqiang; Zhao, Liang; Wang, Weidong; Zhang, Min; Wang, Limin] Zhengzhou Univ, Dept Orthoped, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
RP Liu, YL (reprint author), Zhengzhou Univ, Dept Orthoped, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
EM liu212381@126.com
CR Annaswamy TM, 2012, PM&R, V4, P498, DOI 10.1016/j.pmrj.2012.02.019
   Bendheim OL, 1937, B I HIST MED, V5, P684
   DENNO JJ, 1991, SPINE, V16, P1353, DOI 10.1097/00007632-199112000-00001
   Glaser J A, 2001, Iowa Orthop J, V21, P49
   Grijalva RA, 2015, SPINE, V40, P475, DOI 10.1097/BRS.0000000000000794
   Houten JK, 2008, J NEUROSURG-SPINE, V9, P237, DOI 10.3171/SPI/2008/9/9/237
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   MADONICK MJ, 1952, AMA ARCH NEUROL PSY, V68, P109, DOI 10.1001/archneurpsyc.1952.02320190115011
   Malanga Gerard A, 2003, Pain Physician, V6, P199
   Rhee JM, 2009, SPINE, V34, P890, DOI 10.1097/BRS.0b013e31819c944b
   Sung RD, 2001, SPINE, V26, P67, DOI 10.1097/00007632-200101010-00013
   THELANDER U, 1994, SPINE, V19, P1979, DOI 10.1097/00007632-199409000-00020
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E782
EP E786
DI 10.1016/j.wneu.2019.04.254
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100092
PM 31078802
DA 2020-05-12
ER

PT J
AU Carl, B
   Bopp, M
   Sass, B
   Nimsky, C
AF Carl, Barbara
   Bopp, Miriam
   Sass, Benjamin
   Nimsky, Christopher
TI Microscope-Rased Augmented Reality in Degenerative Spine Surgery:
   Initial Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Augmented reality; Head-up display; Low-dose intraoperative computed
   tomography; Microscope-based navigation; Registration
ID DOSE-LENGTH PRODUCT; SURGICAL NAVIGATION; SYSTEM; CT; REGISTRATION;
   INTEGRATION; GUIDANCE
AB OBJECTIVE: To establish microscope-based augmented reality (AR) support for degenerative spine surgery.
   METHODS: Head-up displays of operating microscopes were used to establish AR in a series of 10 patients. Segmentation of the vertebra and additional target structures, which were visualized by AR, was based on preoperative magnetic resonance and computed tomography (CT) images, that were nonrigidly fused to low-dose intraoperative CT (iCT) data. AR registration was achieved by automatic registration applying iCT and microscope calibration.
   RESULTS: AR support could be smoothly implemented in the surgical workflow. AR allowed to visualize the target structures reliably in the surgical field, facilitating surgical orientation. Flexible placement of the reference array enabled AR implementation for anterior, lateral, posterior median, and posterior paramedian approaches. Identification of bony and artificial landmarks allowed validating registration accuracy; the measured target registration error was 1.11 +/- 0.42 mm (mean +/- standard deviation). The effective dose for registration scanning ranged from 0.52 to 8.71 mSv, which is on average about one-third of a standard diagnostic spine scan. This depended mainly on the scan length (mean scan length cervical/thoracic/lumbar: 99/218/118 mm). Longest scan ranges were in the mid-thoracic region to ensure unambiguous vertebra assignment as prerequisite for reliable nonlinear registration (mean cervical/thoracic/lumbar effective dose: 0.52/614/2.99 mSv).
   CONCLUSIONS: Reliable microscope-based AR support is possible because of automatic registration based on intraoperative imaging. Application of AR in degenerative spine surgery has a big potential; it might be especially helpful in complex anatomical situations and resident education.
C1 [Carl, Barbara; Bopp, Miriam; Sass, Benjamin; Nimsky, Christopher] Univ Marburg, Dept Neurosurg, Marburg, Germany.
   [Bopp, Miriam; Nimsky, Christopher] Marburg Ctr Mind Brain & Behav, Marburg, Germany.
RP Carl, B (reprint author), Univ Marburg, Dept Neurosurg, Marburg, Germany.
EM carlb@med.uni-marburg.de
RI Nimsky, Christopher/E-3702-2014
OI Nimsky, Christopher/0000-0002-8216-9410; Bopp, Miriam H.
   A./0000-0003-1574-7572; Sass, Benjamin/0000-0003-2855-3443; Carl,
   Barbara/0000-0003-3661-9908
CR Abe Y, 2013, J NEUROSURG-SPINE, V19, P492, DOI 10.3171/2013.7.SPINE12917
   Agten CA, 2018, INVEST RADIOL, V53, P495, DOI 10.1097/RLI.0000000000000478
   Carl B, 2019, WORLD NEUROSURG, V125, pE873, DOI 10.1016/j.wneu.2019.01.202
   Carl B, 2019, INT J COMPUT ASS RAD, V14, P169, DOI 10.1007/s11548-018-1853-0
   Carl B, 2018, ACTA NEUROCHIR, V160, P1681, DOI 10.1007/s00701-018-3641-6
   Coelho G, 2018, SPINE, V43, P1609, DOI 10.1097/BRS.0000000000002856
   Deib G, 2018, J NEUROINTERV SURG, V10, P1187, DOI 10.1136/neurintsurg-2017-013649
   Elbakri IA, 2013, CAN ASSOC RADIOL J, V64, P15, DOI 10.1016/j.carj.2011.12.013
   Elmi-Terander A, 2016, SPINE, V41, pE1303, DOI 10.1097/BRS.0000000000001830
   Fahlbusch R, 1998, INT CONGR SER, V1165, P583
   Greffier J, 2017, PHYS MEDICA, V35, P88, DOI 10.1016/j.ejmp.2017.02.016
   Huda W, 2008, RADIOLOGY, V248, P995, DOI 10.1148/radiol.2483071964
   KELLY PJ, 1982, NEUROSURGERY, V10, P324, DOI 10.1227/00006123-198203000-00005
   King AP, 1999, STEREOT FUNCT NEUROS, V72, P107, DOI 10.1159/000029708
   Kiya N, 1997, MINIM INVAS NEUROSUR, V40, P110, DOI 10.1055/s-2008-1053429
   Kosterhon M, 2017, OPER NEUROSURG, V13, P297, DOI 10.1093/ons/opw017
   Ma LF, 2017, INT J COMPUT ASS RAD, V12, P2205, DOI 10.1007/s11548-017-1652-z
   Meola A, 2018, OPER NEUROSURG, V14, pE71, DOI 10.1093/ons/opy048
   Nagpal S, 2015, INT J COMPUT ASS RAD, V10, P1371, DOI 10.1007/s11548-015-1247-5
   Nakamura M, 2000, J CLIN NEUROSCI, V7, P10
   Nimsky C, 1999, NEUROSURGERY, V44, P1249, DOI 10.1097/00006123-199906000-00044
   ROBERTS DW, 1986, J NEUROSURG, V65, P545, DOI 10.3171/jns.1986.65.4.0545
   Sarwahi V, 2017, SPINE, V42, pE1311, DOI 10.1097/BRS.0000000000002154
   Umebayashi D, 2018, JAAOS GLOB RES REV, V2, DOI 10.5435/JAAOSGlobal-D-17-00008
   Yoon JW, 2018, INT J MED ROBOT COMP, V14, DOI 10.1002/rcs.1914
   Yoon JW, 2017, INT J MED ROBOT, V13
NR 26
TC 3
Z9 3
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E541
EP E551
DI 10.1016/j.wneu.2019.04.192
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100063
PM 31051306
DA 2020-05-12
ER

PT J
AU Carlson, JD
   Palmer, M
   Hoefer, A
   Cox, E
   McLeod, P
   Mark, J
   Aldred, J
AF Carlson, Jonathan Dennis
   Palmer, Meghan
   Hoefer, Aiden
   Cox, Emily
   McLeod, Pam
   Mark, Jamie
   Aldred, Jason
TI Deep Brain Stimulation Generator Replacement in End-Stage Parkinson
   Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Battery life; DBS; Ethics; Generator replacement; Parkinson's disease
ID HARDWARE-RELATED COMPLICATIONS; SURGERY; MULTICENTER; PROGRESSION;
   INFECTIONS
AB BACKGROUND: The decision to replace deep brain stimulation (DBS) generators in end-stage Parkinson disease (PD) is based on the patients' clinical status and the risks of this surgery. The infection rates of initial DBS implantation surgery and generator replacement surgery are well established. But the risks of DBS generator replacement for the severely disabled end-stage PD patient have not been described.
   METHODS: A retrospective analysis of all DBS procedures (n = 446) for PD spanning 20 years in a single institution was performed. The focus was on generator replacement procedure performed in end-stage PD. Infections related to DBS surgery were evaluated.
   RESULTS: Perioperative infections (<90 days) after generator replacements occurred in 0.6% of 172 cases and 2.5% of 232 primary lead implantation. Delayed infections (>90 days) occurred in 2.7% of all cases. Generator replacement was performed in 11 end-stage PD patients. None of these patients developed perioperative or delayed infections, and none were readmitted for medical or surgical complications.
   CONCLUSIONS: DBS generator replacement surgery is low risk, even in patients who have end-stage PD.
C1 [Carlson, Jonathan Dennis; Palmer, Meghan; Hoefer, Aiden; McLeod, Pam] Inland Neurosurg & Spine Associates, Spokane, WA 99204 USA.
   [Cox, Emily] Providence Hlth & Serv, Spokane, WA USA.
   [Mark, Jamie; Aldred, Jason] Selkirk Neurol, Spokane, WA USA.
RP Carlson, JD (reprint author), Inland Neurosurg & Spine Associates, Spokane, WA 99204 USA.
EM jonathan.carlson@providence.org
CR Bell E, 2009, SURG NEUROL, V72, P577, DOI 10.1016/j.surneu.2009.03.029
   Bhatia S, 2010, STEREOT FUNCT NEUROS, V88, P147, DOI 10.1159/000303528
   Bjerknes S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105288
   Boviatsis EJ, 2010, ACTA NEUROCHIR, V152, P2053, DOI 10.1007/s00701-010-0749-8
   Bronstein JM, 2011, ARCH NEUROL-CHICAGO, V68, P165, DOI 10.1001/archneurol.2010.260
   Carlson JD, 2017, OPER NEUROSURG, V13, P96, DOI 10.1227/NEU.0000000000001326
   Carvallo JFB, 2012, STEREOT FUNCT NEUROS, V90, P300, DOI 10.1159/000338222
   Coelho M, 2010, J NEUROL, V257, P1524, DOI 10.1007/s00415-010-5566-8
   Doshi PK, 2011, STEREOT FUNCT NEUROS, V89, P89, DOI 10.1159/000323372
   Falowski SM, 2015, NEUROMODULATION, V18, P670, DOI 10.1111/ner.12335
   Fenoy AJ, 2012, J NEUROSURG, V116, P1324, DOI 10.3171/2012.1.JNS111798
   Hardaway FA, 2018, NEUROSURGERY, V83, P540, DOI 10.1093/neuros/nyx505
   Helmers AK, 2018, NEUROMODULATION, V21, P593, DOI 10.1111/ner.12720
   Henriksen MB, 2016, EUR J NEUROL, V23, P53, DOI 10.1111/ene.12614
   HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427
   Joint C, 2002, MOVEMENT DISORD, V17, pS175, DOI 10.1002/mds.10161
   Kochanski RB, 2018, OPER NEUROSURG, V15, P584, DOI 10.1093/ons/opx293
   Lilleeng B, 2014, ACTA NEUROL SCAND, V130, P292, DOI 10.1111/ane.12224
   Lyons KE, 2004, NEUROLOGY, V63, P612, DOI 10.1212/01.WNL.0000134650.91974.1A
   Moro E, 2010, MOVEMENT DISORD, V25, P578, DOI 10.1002/mds.22735
   Odekerken VJJ, 2016, NEUROLOGY, V86, P755, DOI 10.1212/WNL.0000000000002401
   Oh MY, 2002, NEUROSURGERY, V50, P1268
   Rizzone MG, 2014, PARKINSONISM RELAT D, V20, P376, DOI 10.1016/j.parkreldis.2014.01.012
   Rodriguez-Oroz MC, 2005, BRAIN, V128, P2240, DOI 10.1093/brain/awh571
   Rolston JD, 2016, PARKINSONISM RELAT D, V33, P72, DOI 10.1016/j.parkreldis.2016.09.014
   Sillay KA, 2008, NEUROSURGERY, V62, P360, DOI 10.1227/01.neu.0000316002.03765.33
   van Riesen C, 2016, J NEURAL TRANSM, V123, P621, DOI 10.1007/s00702-016-1562-1
   Vesper J, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-7
   Voges J, 2007, MOVEMENT DISORD, V22, P1486, DOI 10.1002/mds.21481
   Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929
NR 30
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E683
EP E687
DI 10.1016/j.wneu.2019.04.233
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100080
PM 31059853
DA 2020-05-12
ER

PT J
AU Chang, BW
   Zhu, WC
   Li, ST
AF Chang, Bowen
   Zhu, Wanchun
   Li, Shiting
TI Effects of Depression and Anxiety on Microvascular Decompression Outcome
   for Trigeminal Neuralgia Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anxiety; Depression; Microvascular decompression; Psychology; Trigeminal
   neuralgia
ID PAIN; QUALITY
AB OBJECTIVE: Trigeminal neuralgia (TN) is a common cranial nerve disease. Meanwhile, it is suggested in some studies that orofacial pain can also lead to some psychological diseases. Therefore, the current study was carried out aiming to explore the relationship between depression as well as anxiety and TN; at the same time, the effect on the postoperative outcome of microvascular decompression (MVD) would also be explored.
   METHODS: The Hamilton Depression Rating Scale (HDRS) scores, as well as the Hamilton Anxiety Rating Scale (HARS) scores in TN cases were compared with those among patients without TN. Multiple logistic regression models were also used to assess the associations of HDRS and HARS scores with TN. Patients were divided into 2 groups according to the MVD outcome in TN patients, and the HDRS and HARS scores were between pain-free patients and those who still suffered from pain.
   RESULTS: The HDRS and HARS scores in TN patients were evidently increased relative to those observed in normal individuals. HDRS and HARS scores were found to be positively associated with the Visual Analog Scale pain score and onset duration in TN patients. Additionally, remarkably higher HDRS and HARS scores were observed in the persistent pain group than in pain-free group.
   CONCLUSIONS: The findings of this study reveal that depression and anxiety are closely associated with the incidence of TN, which may also affect the outcome of patients undergoing MVD.
C1 [Chang, Bowen; Zhu, Wanchun; Li, Shiting] Shanghai Jiao Tong Univ, Sch Med, XinHua Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Li, ST (reprint author), Shanghai Jiao Tong Univ, Sch Med, XinHua Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM lishiting@xinhuamed.com.cn
CR Al-Quliti KW, 2015, NEUROSCIENCES, V20, P107, DOI 10.17712/nsj.2015.2.20140501
   Apkarian AV, 2008, CURR OPIN NEUROBIOL, V18, P464, DOI 10.1016/j.conb.2008.09.012
   Barker FG, 1996, NEW ENGL J MED, V334, P1077, DOI 10.1056/NEJM199604253341701
   BEDERSON JB, 1989, J NEUROSURG, V71, P359, DOI 10.3171/jns.1989.71.3.0359
   Carlson Charles R, 2007, Dent Clin North Am, V51, P145, DOI 10.1016/j.cden.2006.09.001
   Case LK, 2016, J NEUROSCI, V36, P5850, DOI 10.1523/JNEUROSCI.1130-15.2016
   Cheng J, 2017, CLIN NEUROL NEUROSUR, V161, P59, DOI 10.1016/j.clineuro.2017.08.011
   Dai CJ, 2019, NEUROPSYCH DIS TREAT, V15, P435, DOI 10.2147/NDT.S190689
   das Nair R, 2018, CLIN REHABIL, V32, P777, DOI 10.1177/0269215518755426
   de Castro AR, 2008, ARQ NEURO-PSIQUIAT, V66, P716, DOI 10.1590/S0004-282X2008000500021
   Doll KM, 2016, GYNECOL ONCOL, V141, P329, DOI 10.1016/j.ygyno.2016.03.003
   Feinmann C, 1984, BMJ-BRIT MED J, V11, P436
   Gambeta E, 2018, PHYSIOL BEHAV, V191, P131, DOI 10.1016/j.physbeh.2018.04.025
   Hals EKB, 2011, SCAND J PAIN, V2, P153, DOI 10.1016/j.sjpain.2011.08.003
   Hayes DJ, 2017, FRONT NEUROANAT, V11, DOI 10.3389/fnana.2017.00073
   Jiang C, 2019, PSYCHOL HEALTH MED, V24, P493, DOI 10.1080/13548506.2018.1530365
   Lai Hung-Chun, 2020, Aging Ment Health, V24, P717, DOI 10.1080/13607863.2019.1582006
   Li XL, 2017, PATIENT PREFER ADHER, V11, P1723, DOI 10.2147/PPA.S147205
   Maarbjerg S, 2017, CEPHALALGIA, V37, P648, DOI 10.1177/0333102416687280
   Mousavi Seyed H, 2016, Surg Neurol Int, V7, P98, DOI 10.4103/2152-7806.194145
   Nelson K, 2017, PAIN MANAG NURS, V18, P16, DOI 10.1016/j.pmn.2016.10.005
   Obermueller K, 2018, ACTA NEUROCHIR, V160, P2521, DOI 10.1007/s00701-018-3695-5
   Oh S, 2007, GEN THORAC CARDIOVAS, V55, P119, DOI 10.1007/s11748-006-0084-4
   Palapattu GS, 2004, J UROLOGY, V172, P1814, DOI 10.1097/01.ju.0000141245.08456.1a
   Ploner M, 2017, TRENDS COGN SCI, V21, P100, DOI 10.1016/j.tics.2016.12.001
   Puskar KR, 2015, J GERONTOL NURS, V41, P8, DOI 10.3928/00989134-20150213-03
   Resnick DK, 1998, NEUROSURGERY, V43, P804, DOI 10.1097/00006123-199810000-00047
   Vachon-Presseau E, 2013, BRAIN, V136, P815, DOI 10.1093/brain/aws371
   Wang P, 2018, IRAN J PUBLIC HEALTH, V47, P1822
   Wu TH, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0548-y
   Yu R, 2019, J CRANIOFAC SURG, V1, P77
   Zakrzewska JM, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-37
   Zhang X, 2017, WORLD NEUROSURG, V108, P711, DOI 10.1016/j.wneu.2017.09.081
   Zhang YY, 2018, FRONT HUM NEUROSCI, V12, DOI 10.3389/fnhum.2018.00107
NR 34
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E556
EP E561
DI 10.1016/j.wneu.2019.04.194
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100065
PM 31071444
DA 2020-05-12
ER

PT J
AU Chen, MJW
   Niu, CC
   Hsieh, MK
   Luo, AJ
   Fu, TS
   Lai, PL
   Tsai, TT
AF Chen, Michael Jian-Wen
   Niu, Chi-Chien
   Hsieh, Ming-Kai
   Luo, An-Jhih
   Fu, Tsai-Sheng
   Lai, Po-Liang
   Tsai, Tsung-Ting
TI Minimally Invasive Transforaminal Lumbar Interbody Debridement and
   Fusion with Percutaneous Pedicle Screw Instrumentation for
   Spondylodiscitis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Minimally invasive surgery; Percutaneous pedicle screw instrumentation;
   Septic spondylodiscitis; Transforaminal lumbar interbody debridement and
   fusion
ID PYOGENIC SPONDYLODISCITIS; POSTERIOR INSTRUMENTATION; VERTEBRAL
   OSTEOMYELITIS; ANTERIOR DEBRIDEMENT; SURGERY; SPINE
AB BACKGROUND: Minimally invasive transforaminal lumbar interbody debridement and fusion (MiTLIDF) with percutaneous pedicle screw instrumentation (PSI) is a less invasive treatment for lumbar spondylodiscitis.
   METHODS: Patients with single-level lumbar spondylodiscitis were surgically treated by interbody debridement and fusion through an anterior or transforaminal approach combined with open or percutaneous PSI (group A: anterior debridement and interbody fusion with open posterior PSI; group B: transforaminal lumbar interbody debridement and fusion [TLIDF] with open posterior PSI; group C: anterior debridement and interbody fusion with percutaneous PSI; group D: MiTLIDF with percutaneous PSI). Perioperative data, fusion status, infection-free survival, and clinical outcome measurements were compared among the 4 surgical groups.
   RESULTS: A total of 82 patients were included in this study. TLIDF was associated with shorter operative time when compared with the anterior approach (group A: 302.8 +/- 59.9 minutes; group B: 209.2 +/- 31.0 minutes; group C: 260.6 +/- 62.5 minutes; group D: 207.1 +/- 33.6 minutes; P < 0.001). Percutaneous PSI resulted in less intraoperative blood loss (group A: 907.5 +/- 253.7 mL; group B: 859.4 +/- 201.2 mL; group C: 532.9 +/- 193.7 mL; group D: 399.1 +/- 84.3 mL) and reduced immediate postoperative pain (group A: 5.5 +/- 0.9; group B: 4.9 +/- 0.9; group C: 3.9 +/- 0.7; group D: 3.2 +/- 0.7) than open PSI (P< 0.001). There were no significant differences in terms of overall infection-free survival (P = 0.936).
   CONCLUSIONS: This study demonstrated MiTLIDF with percutaneous PSI is a safe and effective treatment for lumbar spondylodiscitis while incurring no adverse effects in terms of fusion rate, functional recovery, and infection eradication.
C1 [Chen, Michael Jian-Wen; Niu, Chi-Chien; Hsieh, Ming-Kai; Luo, An-Jhih; Lai, Po-Liang; Tsai, Tsung-Ting] Chang Gung Mem Hosp, Bone & Joint Res Ctr, Spine Sect, Dept Orthopaed Surg, Taoyuan, Taiwan.
   [Chen, Michael Jian-Wen; Niu, Chi-Chien; Hsieh, Ming-Kai; Luo, An-Jhih; Lai, Po-Liang; Tsai, Tsung-Ting] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Fu, Tsai-Sheng] Keelung Chang Gung Mem Hosp, Dept Orthopaed Surg, Keelung, Taiwan.
RP Tsai, TT (reprint author), Chang Gung Mem Hosp, Bone & Joint Res Ctr, Spine Sect, Dept Orthopaed Surg, Taoyuan, Taiwan.; Tsai, TT (reprint author), Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
EM tsai1129@gmail.com
OI Tsai, Tsung-Ting/0000-0002-7776-7627
CR Aagaard T, 2016, INFECT DIS-NOR, V48, P201, DOI 10.3109/23744235.2015.1103897
   Akiyama T, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002412
   Bateman DK, 2015, SPINE J, V15, P1118, DOI 10.1016/j.spinee.2015.02.040
   Berbari EF, 2015, CLIN INFECT DIS, V61, pE26, DOI 10.1093/cid/civ482
   Chen WJ, 2002, CLIN ORTHOP RELAT R, P50
   Dietz N, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2018.10.FOCUS18460
   Fu Tsai-Sheng, 2013, Biomed J, V36, P168, DOI 10.4103/2319-4170.112742
   Fukuta S, 2003, SPINE, V28, pE302, DOI 10.1097/00007632-200308010-00025
   Grammatico L, 2008, EPIDEMIOL INFECT, V136, P653, DOI 10.1017/S0950268807008850
   Kehrer M, 2014, J INFECTION, V68, P313, DOI 10.1016/j.jinf.2013.11.011
   Kim DY, 2005, SPINE, V30, P123, DOI 10.1097/01.brs.0000148999.21492.53
   Klockner C, 2003, SPINE, V28, P1036, DOI 10.1097/00007632-200305150-00016
   Lee JS, 2006, J BONE JOINT SURG BR, V88B, P765, DOI 10.1302/0301-620X.88B6
   Leong G, 2006, J HOSP INFECT, V63, P255, DOI 10.1016/j.jhin.2006.02.007
   Lin TY, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-443
   Liu JM, 2015, WORLD NEUROSURG, V83, P1157, DOI 10.1016/j.wneu.2015.01.041
   Lu ML, 2015, EUR SPINE J, V24, P555, DOI 10.1007/s00586-014-3585-3
   Ozalay M, 2010, ACTA ORTHOP BELG, V76, P100
   Tschugg A, 2017, EUR SPINE J, V26, P3141, DOI 10.1007/s00586-017-5180-x
   Viezens L, 2017, WORLD NEUROSURG, V102, P18, DOI 10.1016/j.wneu.2017.02.129
   Yang SC, 2008, CLIN ORTHOP RELAT R, V466, P3086, DOI 10.1007/s11999-008-0441-y
   Zarghooni K, 2012, INT ORTHOP, V36, P405, DOI 10.1007/s00264-011-1425-1
NR 22
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E744
EP E751
DI 10.1016/j.wneu.2019.04.249
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100087
PM 31077901
DA 2020-05-12
ER

PT J
AU Chen, W
   Wang, XY
   Liu, FJ
   Chen, J
AF Chen, Wei
   Wang, Xiaoyu
   Liu, Fujun
   Chen, Jing
TI Gamma Knife Radiosurgery for Patients with Multiple Intracranial
   Meningiomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gamma Knife radiosurgery; Multiple intracranial meningiomas;
   Stereotactic radiosurgery
ID STEREOTACTIC RADIOSURGERY; NATURAL-HISTORY; OUTCOMES; BRAIN; EDEMA
AB OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of Gamma Knife radiosurgery (GKRS) in patients with multiple intracranial meningiomas (MIMs).
   METHODS: The authors performed a retrospective analysis of 42 consecutive patients (7 men and 35 women) with MIMs who underwent GKRS. The median age of the patients at the time of GKRS was 57.5 years (range, 27-77 years). A total of 115 tumors among 42 patients were identified through imaging or postoperative histopathologic examination, of which 90 were treated with GKRS.
   RESULTS: Follow-up imaging studies were available for 75 tumors in 36 patients (83.3%), with a mean follow-up period of 45.0 months (range, 6.6-90.4 months); 41 patients (97.6`)/0) received clinical follow-up for 16.7 to 106.7 months (average, 57.1 months). Local tumor control was achieved in 68 tumors (90.7%) at the last follow-up. On univariate analysis, surgical resection before GKRS more than once (P = 0.048) and high World Health Organization (WHO) classification (grades II and III) (P = 0.001) were associated with tumor progression. Patients with worsening clinical manifestation showed correlation with peritumor edema (P < 0.001) and had >2 lesions treated by GKRS (P < 0.001) on univariate analysis.
   CONCLUSIONS: GKRS is a safe and effective treatment for MIMs. Variables including surgical resection before GKRS more than once, high grade WHO classification, peritumor edema, and >2 tumors treated by GKRS are predictors of unfavorable outcome after GKRS.
C1 [Chen, Wei; Wang, Xiaoyu; Liu, Fujun; Chen, Jing] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
RP Chen, J (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM wchscu@163.com
CR Pereira BJA, 2019, WORLD NEUROSURG, V122, pE1536, DOI 10.1016/j.wneu.2018.11.097
   Birckhead B, 2016, J NEURO-ONCOL, V130, P553, DOI 10.1007/s11060-016-2257-z
   Bledsoe JM, 2010, J NEUROSURG, V112, P951, DOI 10.3171/2009.8.JNS09703
   DOMENICUCCI M, 1989, J NEUROSURG, V70, P41, DOI 10.3171/jns.1989.70.1.0041
   Jang Chang Ki, 2015, Brain Tumor Res Treat, V3, P103, DOI 10.14791/btrt.2015.3.2.103
   Jo KI, 2012, J NEUROSURG, V117, P102, DOI 10.3171/2012.7.GKS12780
   Kan P, 2007, J NEURO-ONCOL, V83, P33, DOI 10.1007/s11060-006-9294-y
   Koga T, 2010, NEUROL MED-CHIR, V50, P737, DOI 10.2176/nmc.50.737
   Kondziolka D, 2016, AM J CLIN ONCOL-CANC, V39, P453, DOI 10.1097/COC.0000000000000080
   Linsler S, 2016, CLIN NEUROL NEUROSUR, V149, P98, DOI 10.1016/j.clineuro.2016.08.007
   Liu A, 2015, J NEUROSURG, V122, P536, DOI 10.3171/2014.10.JNS132593
   LUSINS JO, 1981, NEUROSURGERY, V9, P137, DOI 10.1227/00006123-198108000-00004
   NAHSER HC, 1981, NEURORADIOLOGY, V21, P259, DOI 10.1007/BF02100156
   Nakamura M, 2003, NEUROSURGERY, V53, P62, DOI 10.1227/01.NEU.0000068730.76856.58
   OLIVERO WC, 1995, J NEUROSURG, V83, P222, DOI 10.3171/jns.1995.83.2.0222
   Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189
   Patibandla MR, 2019, J NEUROSURG, V130, P579, DOI 10.3171/2017.8.JNS171336
   Rogers L, 2015, J NEUROSURG, V122, P4, DOI 10.3171/2014.7.JNS131644
   Samblas J, 2014, J BUON, V19, P250
   Santacroce A, 2012, NEUROSURGERY, V70, P32, DOI 10.1227/NEU.0b013e31822d408a
   Sheehan JP, 2015, J NEUROSURG, V123, P1287, DOI 10.3171/2014.12.JNS142159
   Sheehan JP, 2010, J NEURO-ONCOL, V99, P407, DOI 10.1007/s11060-010-0363-x
   SHEEHY JP, 1983, J NEUROSURG, V59, P1, DOI 10.3171/jns.1983.59.1.0001
   Tsermoulas G, 2018, J NEUROSURG, V128, P1403, DOI 10.3171/2017.2.JNS162608
   Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972
   Wong Ricky H, 2013, Surg Neurol Int, V4, P71, DOI 10.4103/2152-7806.112617
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E495
EP E500
DI 10.1016/j.wneu.2019.04.184
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100057
PM 31048056
DA 2020-05-12
ER

PT J
AU Chen, XQ
   Chen, JX
   Zhang, F
AF Chen, Xiaoqing
   Chen, Jiaxin
   Zhang, Feng
TI Imaging Anatomic Research of Oblique Lumbar Interbody Fusion in a
   Chinese Population Based on Magnetic Resonance
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chinese; Imaging anatomical research; Interbody fusion; Magnetic
   resonance; OLIF; Operative window; Surgical corridors
ID ILIAC VEIN; TOMOGRAPHY; SURGERY
AB OBJECTIVE: To provide anatomic evidence of preoperative assessment of oblique lumbar interbody fusion (OLIF) for Chinese patients.
   METHODS: From the hospital picture archiving and communication system, 400 lumbar magnetic resonance imaging studies of adults performed between November 2016 and January 2017 were selected. L2-3, L3-4, L4-5, and L5-S1 transverse and sagittal images were studied, and anatomic parameters associated with OLIF surgery, including bare window and psoas window, were measured and recorded. SPSS software was used for data summarization, sorting, and analysis to explore the significance of various anatomic parameters.
   RESULTS: OLIF surgical corridors to the L2-S1 discs were found in most magnetic resonance imaging scans studied. The size of the psoas affects the difficulty of psoas muscle traction. It is relatively easy to perform OLIF surgery in older women. Most of the human iliac arteries were bifurcated and aggregated in front of the L4-5 intervertebral disc. The lower the aggregate level of the common iliac vein, the less likely it was to have the OLIF surgical corridor in the L5-S1 segment. The most frequently used lengths for a lumbar interbody cage for OLIF for Chinese patients are 50 mm and 55 mm.
   CONCLUSIONS: OLIF can be a good choice for lumbar intervertebral fusion, including L5-S1 segment, in most Chinese patients. Older women are likely to have more scope of OLIF surgery. As a routine preoperative examination, lumbar magnetic resonance imaging is of great importance to OLIF surgery preoperative assessment.
C1 [Chen, Xiaoqing; Zhang, Feng] Nantong Univ, Affiliated Hosp, Dept Orthoped, Nantong, Jiangsu, Peoples R China.
   [Chen, Xiaoqing; Zhang, Feng] Northern Jiangsu Peoples Hosp, Jiangsu Clin Med Ctr Tissue Engn & Nerve Injury R, Yangzhou, Jiangsu, Peoples R China.
   [Chen, Jiaxin] Northern Jiangsu Peoples Hosp, Dept Orthoped, Yangzhou, Jiangsu, Peoples R China.
RP Zhang, F (reprint author), Nantong Univ, Affiliated Hosp, Dept Orthoped, Nantong, Jiangsu, Peoples R China.; Zhang, F (reprint author), Northern Jiangsu Peoples Hosp, Jiangsu Clin Med Ctr Tissue Engn & Nerve Injury R, Yangzhou, Jiangsu, Peoples R China.
EM zhangfengspine@sina.com
CR Bendersky M, 2015, EUR SPINE J, V24, P1051, DOI 10.1007/s00586-015-3801-9
   Capellades J, 2000, SPINE, V25, P1695, DOI 10.1097/00007632-200007010-00013
   Chung NS, 2017, EUR SPINE J, V26, P2797, DOI 10.1007/s00586-017-5176-6
   Dangelmajer S, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS144
   Davis TT, 2014, J NEUROSURG-SPINE, V21, P785, DOI 10.3171/2014.7.SPINE13564
   Fujibayashi S, 2017, J ORTHOP SCI, V22, P420, DOI 10.1016/j.jos.2017.01.009
   Joseph JR, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15278
   Liu LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163452
   Liu LH, 2014, ACTA ORTHOP BELG, V80, P537
   Lykissas MG, 2013, SPINE, V38, P1656, DOI 10.1097/BRS.0b013e31829cf269
   Mayer HM, 1997, SPINE, V22, P691, DOI 10.1097/00007632-199703150-00023
   Mehren C, 2016, EUR SPINE J, V25, pS471, DOI 10.1007/s00586-016-4465-9
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Molinares DM, 2016, J NEUROSURG-SPINE, V24, P248, DOI 10.3171/2015.3.SPINE13976
   Ohtori S, 2017, ASIAN SPINE J, V11, P105, DOI 10.4184/asj.2017.11.1.105
   Ohtori S, 2015, ASIAN SPINE J, V9, P565, DOI 10.4184/asj.2015.9.4.565
   Ohtori S, 2015, YONSEI MED J, V56, P1051, DOI 10.3349/ymj.2015.56.4.1051
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Phan K, 2015, ORTHOP SURG, V7, P364, DOI 10.1111/os.12204
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Woods KRM, 2017, SPINE J, V17, P545, DOI 10.1016/j.spinee.2016.10.026
   Zairi F, 2017, ORTHOP TRAUMATOL-SUR, V103, P295, DOI 10.1016/j.otsr.2016.11.016
NR 22
TC 0
Z9 0
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E51
EP E58
DI 10.1016/j.wneu.2019.03.244
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100008
PM 31035020
DA 2020-05-12
ER

PT J
AU Cheng, JY
   Song, K
   Liang, Y
   Tang, XY
   Wu, B
   Zhang, GY
   Zhao, YF
   Wang, Z
AF Cheng, Junyao
   Song, Kai
   Liang, Yan
   Tang, Xiangyu
   Wu, Bing
   Zhang, Guoying
   Zhao, Yongfei
   Wang, Zheng
TI Spontaneous Remodeling of Spinal Canal After Sagittal Translation in
   Pedicle Subtraction Osteotomy for Correction of Thoracolumbar Kyphosis
   in Ankylosing Spondylitis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ankylosing spondylitis; Sagittal translation
ID MANAGEMENT
AB BACKGROUND: Sagittal translations (STs) secondary to osteotomy for the correction of ankylosing spondylitis (AS) kyphosis have drawn great attention, which is considered closely related to neurologic deficits and terrible fusion. Despite being discussed in several cases, there were no relevant reports about the transformation of ST and the spinal canal remodeling in AS patients.
   METHODS: Retrospective analysis was conducted on 16 patients with ST for the treatment of AS kyphosis through pedicle subtraction osteotomy during January 2011 to December 2014 in our hospital. Full-length free-standing spinal radiographs were available for all patients before and after surgery and also at the final follow-up. Radiologic parameters including global kyphosis (GK), thoracolumbar kyphosis (ILK), lumbar lordosis (LL), sagittal vertical axis (SVA), and ST were measured. Rates of ST transformation after the surgery and at 1-year follow-up were compared.
   RESULTS: The average follow-up was 22 months, ranging from 12-36 months. There was no internal fixation failure during this period. The preoperative GK was 59.9 +/- 21.0 degrees, TLK was 38.0 +/- 13.0 degrees, LL was 7.4 +/- 26.5 degrees, and SVA was 27.2 +/- 8.6 mm. The postoperative GK was 15.7 +/- 2.1 degrees, TLK was 5.6 +/- 2.6 degrees, LL was -36.1 +/- 2.9 degrees, and SVA was 6.1 +/- 4.3 mm. ST was 7.1 +/- 2.7 mm after surgery and 1.2 +/- 1.0 mm at 1-year follow-up. The difference was statistically significant (P < 0.05).
   The rate of ST transformation was 84.9% +/- 9.7%. According to Scoliosis Research Society surveys, the preoperative and the final follow-up satisfaction score was 1.6 +/- 0.3 and 4.7 +/- 0.4 respectively (P < 0.05). Remodeling of the spinal canal happened to all the patients with different degrees.
   CONCLUSIONS: All patients with ST after pedicle subtraction osteotomy for AS kyphosis occurred with spontaneous remodeling of the spinal canal at 1-year follow-up, by which ST can decrease in different degrees or even disappear, and favorable fusion can be achieved even without bone grafting into the osteotomy vertebra.
C1 [Cheng, Junyao; Song, Kai; Tang, Xiangyu; Wu, Bing; Zhang, Guoying; Zhao, Yongfei; Wang, Zheng] Chinese Peoples Liberat Army Gen Hosp 301 Hosp, Dept Orthopaed, Beijing, Peoples R China.
   [Liang, Yan] Chinese Peking Univ Peoples Hosp, Dept Spinal Surg, Beijing, Peoples R China.
RP Wang, Z (reprint author), Chinese Peoples Liberat Army Gen Hosp 301 Hosp, Dept Orthopaed, Beijing, Peoples R China.
EM wzspine@163.com
CR Braun J, 2007, LANCET, V369, P1379, DOI 10.1016/S0140-6736(07)60635-7
   Chang KW, 2006, SPINE, V31, P1137, DOI 10.1097/01.brs.0000216479.09250.96
   Chen I H, 2001, Spine (Phila Pa 1976), V26, pE354, DOI 10.1097/00007632-200108150-00010
   Cho KJ, 2005, SPINE, V30, P2030, DOI 10.1097/01.brs.0000179085.92998.ee
   Dai LY, 2007, SURG NEUROL, V67, P221, DOI 10.1016/j.surneu.2006.08.081
   de Klerk LWL, 1998, SPINE, V23, P1057, DOI 10.1097/00007632-199805010-00018
   Song K, 2014, EUR SPINE J, V23, P2743, DOI 10.1007/s00586-013-3134-5
   Song K, 2013, SPINE, V38, pE616, DOI 10.1097/BRS.0b013e31828b3299
   Stafford L, 2002, INTERN MED J, V32, P40, DOI 10.1046/j.1445-5994.2002.d01-4.x
   Yazici M, 1996, J SPINAL DISORD, V9, P409
   Zheng GQ, 2014, SPINE, V39, P1055, DOI 10.1097/BRS.0000000000000346
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E245
EP E251
DI 10.1016/j.wneu.2019.04.128
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100028
PM 31026652
DA 2020-05-12
ER

PT J
AU Ciappetta, P
   Tropeano, MP
   Gitto, L
   Pescatori, L
AF Ciappetta, Pasqualino
   Tropeano, Maria Pia
   Gitto, Lorenzo
   Pescatori, Lorenzo
TI Schwalbe's Triangular Fossa: Normal and Pathologic Anatomy on Frozen
   Cadavers. Anatomo-Magnetic Resonance Imaging Comparison and Surgical
   Implications in Colloid Cyst Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Colloid cyst; Fornix; Surgery; Third ventricle; Triangular recess
ID FORNIX; BRAIN
AB BACKGROUND: The fornix is a region of greatest neurosurgical interest in regards to its complex anatomy and surgical approaches to this area. The objective of this study was to evaluate the morphology of the triangular recess (TR) and its role in the growth pattern of the colloid cysts (CC) within the third ventricle and in the choice of the surgical approach for their removal. Furthermore, to compare the results of the dissections with measurements performed on a magnetic resonance imaging scan.
   METHODS: In the anatomic study, 20 cadaveric specimens were dissected and analyzed. In the radiologic study, a magnetic resonance imaging scan was performed in 20 healthy volunteers. In the clinical study, a retrospective analysis of all the patients affected with CCs micro-surgically removed at our institute between 2010 and 2018 was conducted.
   RESULTS: In the anatomic study, the width, height, and the area of the TR were respectively 0.31 cm, 0.33cm, and 0.051 cm(2). In the radiologic study, 3 different typologies of TR were identified: open recess in ventriculomegaly (7 patients); open recess in physiologic ventricular system (3 patients); closed or blind recess (10 patients). Three different growth patterns of CCs were identified: type 1) CCs localized at the foramen of Monro growing behind the fornix and below the third ventricular roof; type 2) CCs growing rostrally between the column of fornix; and type 3) CCs growing above the plane of the third ventricular roof.
   CONCLUSIONS: The anatomy of the TR influences the growth pattern of CC within the ventricular cavity and determines the surgical strategy for their removal.
C1 [Ciappetta, Pasqualino] Univ Bari, Sch Med, Sect Neurosurg, Dept Neurosci, Bari, Italy.
   [Tropeano, Maria Pia] Humanitas Univ, Dept Neurosurg, Rozzano, Italy.
   [Gitto, Lorenzo] SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA.
   [Pescatori, Lorenzo] Ca Foncello Hosp, Dept Neurosurg, Treviso, Italy.
RP Tropeano, MP (reprint author), Humanitas Univ, Dept Neurosurg, Rozzano, Italy.
EM mariapia.tropeano@libero.it
RI Gitto, Lorenzo/W-2080-2019
OI Gitto, Lorenzo/0000-0002-1435-1819
CR Andahazi F., 1997, ANATOMIST
   Apuzzo M L, 1991, Acta Neurochir Suppl (Wien), V53, P77
   Azab Waleed A, 2014, Surg Neurol Int, V5, P124, DOI 10.4103/2152-7806.138364
   Bartholin T., 1677, ANATOME QUARTUM RENO
   Beaunis H, 1894, NEW ELEMENTS DESCRIP
   Belykh E, 2018, J NEUROSURG, V128, P1492, DOI 10.3171/2017.1.JNS161338
   Boyern A., COMPLETE TREATISE AN, V4
   Brix MK, 2017, EUR J RADIOL, V95, P28, DOI 10.1016/j.ejrad.2017.07.013
   Broc PP, COMPLETE TREATISE DE, V3
   Chaddad Neto F, 2017, J NEUROSURG, P1
   Cloquet H., 1816, TREATISE DESCRIPTIVE, V2
   Cloquet J., 1825, MANUAL DESCRIPTIVE A, V1
   Colombo MR, 1559, RE ANATOMICA LIBRI 1, P243
   Cruveilhier J., 1871, TRAITE ANATOMIE DESC, V3, P423
   de Terra P., 1913, VADEMECUM ANATOMICUM, P598
   Debierre C., 1890, TREATISE ELEMENTARY, V2
   Debierre C., 1907, BRAIN SPINAL CORD
   Dehdashti Amir R, 2005, Neurosurgery, V56, P418, DOI 10.1227/01.NEU.0000157027.80293.C7
   Dejerine J., 1895, ANATOMIE CTR NERVEUX, V2, P332
   Dulaurens A., 1605, HIST ANATOMICA HUMAN, P775
   Fere C., 1886, ELEMENTARY TREATISE
   Fernandez-Miranda JC, 2008, NEUROSURGERY, V62, P989, DOI [10.1227/01.NEU.0000297076.98175.67, 10.1227/01.neu.0000333767.05328.49]
   Fort JA, 1902, DESCRIPTIVE ANATOMY, V1
   Heister L., 1719, COMPENDIUM ANATOMICU
   Jamain A., 1853, NOUVEAU TRAITE ELEME, P679
   Kier EL, 1997, AM J NEURORADIOL, V18, P715
   Laqueur T., 1992, FRAGMENTOS HIST CUER, P90
   Lauth T., 1815, HIST ANATOMIE, V1, P512
   Lovblad KO, 2014, SEMIN ULTRASOUND CT, V35, P459, DOI 10.1053/j.sult.2014.06.005
   Longatti P, 2003, NEUROSURGERY, V52, P1491, DOI 10.1227/01.NEU.0000065184.29846.E0
   Maira G, 2000, NEUROSURGERY, V47, P857, DOI 10.1097/00006123-200010000-00014
   Mandressi R., 2003, ANATOMIST, P7
   Marjolin JN, 1815, MANUEL ANATOMIE, V2, P137
   MARK LP, 1993, AM J NEURORADIOL, V14, P1355
   Morel C, 1883, MANUAL ANATOMIST DES
   Olry R., 1995, DICT ANATOMICAL EPON, P138
   Olry R, 1997, J HIST NEUROSCI, V6, P338
   Olry R, 2008, J HIST NEUROSCI, V17, P461, DOI 10.1080/09647040701374825
   Peltier J, 2011, NEUROSURGERY S
   Peltier J, 2011, NEUROSURGERY S
   Poirier P, 1901, TREATISE HUMAN ANATO, V3
   Postans M, 2014, J NEUROSCI, V34, P12121, DOI 10.1523/JNEUROSCI.0026-14.2014
   Rhoton AL, 2002, NEUROSURGERY, V51, pS207, DOI 10.1227/01.NEU.0000028161.91504.4F
   Riolan J., 1672, MANUAL ANATOMY PATHO
   Roth J, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f7427e
   Sabatier RB, 1792, COMPLETE TREATISE AN, V4, P415
   Santucci B., 1739, ANATOMY HUMAN BODY
   Sappey PC, 1872, TRAITE ANATOMIE DESC, V3
   Sboto-Frankenstein UN, 2014, J MAGN RESON IMAGING, V40, P929, DOI 10.1002/jmri.24424
   Spina A, 2016, WORLD NEUROSURG, V95, P457, DOI 10.1016/j.wneu.2016.08.073
   Symss Nigel P, 2014, Asian J Neurosurg, V9, P51, DOI 10.4103/1793-5482.136708
   Tauvry D., 1698, NOUVELLE ANATOMIE RA
   Testut L., 1905, TREATISE HUMAN ANATO, V2
   Thomas AG, 2011, RADIOGRAPHICS, V31, P1107, DOI 10.1148/rg.314105729
   van Diemerbroeck I., 1695, ANATOMY HUMAN BODY, V2
   Verdier C., 1752, ABREGE ANATOMIE CORP, V2
   Verheyen P., 2000, CORPORIS HUMANI ANAT, V1
   Verheyen P., 1708, ANATOMIE ODER ZERLEG, P371
   Vieussens R., 1684, NEVROGRAPHIA UNIVERS
   Vinas FC, 1998, MINIM INVAS NEUROSUR, V41, P20, DOI 10.1055/s-2008-1052009
   Winslow JB, 1752, EXPOSITION ANATOMIQU, V4
   Yeo SS, 2013, YONSEI MED J, V54, P315, DOI 10.3349/ymj.2013.54.2.315
NR 62
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E116
EP E128
DI 10.1016/j.wneu.2019.04.058
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100015
PM 30981795
DA 2020-05-12
ER

PT J
AU Cote, DJ
   Dasenbrock, HH
   Gormley, WB
   Smith, TR
   Dunn, IF
AF Cote, David J.
   Dasenbrock, Hormuzdiyar H.
   Gormley, William B.
   Smith, Timothy R.
   Dunn, Ian F.
TI Adverse Events After Microvascular Decompression: A National Surgical
   Quality Improvement Program Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adverse events; Microvascular decompression; National surgical quality
   improvement program; Outcomes; Readmission; Trigeminal neuralgia
ID PARTIAL SENSORY RHIZOTOMY; LONG-TERM EFFECTIVENESS; PRIMARY
   TRIGEMINAL-NEURALGIA; FOLLOW-UP; AMERICAN-COLLEGE; CONSECUTIVE SERIES;
   HEMIFACIAL SPASM; GLOSSOPHARYNGEAL NEURALGIA; NEUROVASCULAR CONFLICTS;
   VASCULAR DECOMPRESSION
AB BACKGROUND: Although microvascular decompression (MVD) is a durable treatment for medically refractory trigeminal neuralgia, hemifacial spasm, or glossopharyngeal neuralgia attributable to neurovascular conflict, few national studies have analyzed predictors of postoperative complications.
   OBJECTIVE: To determine the incidence and risk factors for adverse events after MVD.
   METHODS: Patients who underwent MVD were extracted from the prospectively collected National Surgical Quality Improvement Program registry (2006-2017). Multivariable logistic regression identified predictors of 30-day adverse events and unplanned readmission; multivariable linear regression analyzed predictors of a longer hospital stay.
   RESULTS: Among the 1005 patients evaluated, the mortality was 0.3%, major neurologic complication rate 0.4%, and 2.8% had a nonroutine hospital discharge. Patient age was not a predictor of any adverse events. Statistically significant independent predictors both of any adverse event (9.2%) and of a longer hospitalization were American Society of Anesthesiologists (ASA) classification III-IV designation and longer operative duration (P <= 0.03) The 30-day readmission rate was 6.8%, and the most common reasons were surgical site infections (22.4%) and cerebrospinal fluid leakage (14.3%). Higher ASA classification, diabetes mellitus, and operative time were predictors of readmission (P< 0.04).
   CONCLUSIONS: In this National Surgical Quality Improvement Program analysis, postoperative morbidity and mortality after MVD was low. Patient age was not a predictor of postoperative complications, whereas higher ASA classification, diabetes mellitus, and longer operative duration were predictive of any adverse event and readmission. ASA classification provided superior risk stratification compared with the total number of patient comorbidities or laboratory values. These data can assist with preoperative patient counseling and risk stratification.
C1 [Cote, David J.; Dasenbrock, Hormuzdiyar H.; Gormley, William B.; Smith, Timothy R.; Dunn, Ian F.] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.
   [Dasenbrock, Hormuzdiyar H.] Rush Univ, Dept Neurosurg, Chicago, IL 60612 USA.
   [Dunn, Ian F.] Univ Oklahoma, Dept Neurosurg, Oklahoma City, OK USA.
RP Dasenbrock, HH (reprint author), Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.; Dasenbrock, HH (reprint author), Rush Univ, Dept Neurosurg, Chicago, IL 60612 USA.
EM Hormuzdiyar_H_Dasenbrock@rush.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [T32 CA001009]
FX D.J.C., NIH training grant T32 CA001009. The American College of
   Surgeons National Surgical Quality Improvement Program and the hospitals
   participating in the ACS NSQIP are the source of the data used herein;
   they have not verified and are not responsible for the statistical
   validity of the data analysis or the conclusions derived by the authors.
CR Acevedo JC, 1997, STEREOT FUNCT NEUROS, V68, P260, DOI 10.1159/000099936
   Arnone Gregory D, 2017, Surg Neurol Int, V8, P268, DOI 10.4103/sni.sni_325_17
   Ashkan K, 2004, NEUROSURGERY, V55, P840, DOI 10.1227/01.NEU.0000137660.06337.C5
   Bakker NA, 2014, J NEUROSURG, V121, P936, DOI 10.3171/2014.7.JNS132667
   BARBA D, 1984, J NEUROSURG, V60, P104, DOI 10.3171/jns.1984.60.1.0104
   BARKER FG, 1995, J NEUROSURG, V82, P201, DOI 10.3171/jns.1995.82.2.0201
   Barker FG, 1996, NEW ENGL J MED, V334, P1077, DOI 10.1056/NEJM199604253341701
   Bartek J, 2016, ACTA NEUROCHIR, V158, P1775, DOI 10.1007/s00701-016-2856-7
   BEDERSON JB, 1989, J NEUROSURG, V71, P359, DOI 10.3171/jns.1989.71.3.0359
   Bick SK, 2019, NEUROSURGERY, V84, P116, DOI 10.1093/neuros/nyy011
   Broggi G, 2000, J NEUROL NEUROSUR PS, V68, P59, DOI 10.1136/jnnp.68.1.59
   CUTBUSH K, 1994, AUST NZ J SURG, V64, P173, DOI 10.1111/j.1445-2197.1994.tb02171.x
   DAHLE L, 1989, ACTA NEUROCHIR, V99, P109, DOI 10.1007/BF01402317
   Dannenbaum M, 2008, J NEUROSURG, V109, P410, DOI 10.3171/JNS/2008/109/9/0410
   Dasenbrock HH, 2016, CANCER-AM CANCER SOC, V122, P1708, DOI 10.1002/cncr.29984
   Dasenbrock HH, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.10.FOCUS15386
   De la Garza-Ramos R, 2016, NEUROL RES, V38, P117, DOI 10.1080/01616412.2016.1138669
   Dumot C, 2017, ACTA NEUROCHIR, V159, P237, DOI 10.1007/s00701-016-2994-y
   Fields HL, 1996, NEW ENGL J MED, V334, P1125, DOI 10.1056/NEJM199604253341709
   GERBER AM, 1987, NEW ENGL J MED, V316, P692
   Gunther T, 2009, NEUROSURGERY, V65, P477, DOI 10.1227/01.NEU.0000350859.27751.90
   Hackett NJ, 2015, INT J SURG, V18, P184, DOI 10.1016/j.ijsu.2015.04.079
   HUANG CI, 1992, NEUROSURGERY, V30, P53, DOI 10.1227/00006123-199201000-00010
   Hyun SJ, 2010, NEUROSURG REV, V33, P325, DOI 10.1007/s10143-010-0254-9
   Jani RH, 2018, J NEUROIMAGING, V28, P477, DOI 10.1111/jon.12554
   Jannetta P J, 1997, Clin Neurosurg, V44, P331
   Kabil MS, 2005, MINIM INVAS NEUROSUR, V48, P207, DOI 10.1055/s-2005-870928
   Kandan SR, 2010, BRIT J NEUROSURG, V24, P441, DOI 10.3109/02688697.2010.487131
   Kim BD, 2014, J NEUROSURG-SPINE, V20, P606, DOI 10.3171/2014.3.SPINE13699
   Kimmell KT, 2015, J NEUROSURG, V122, P1004, DOI 10.3171/2014.10.JNS14632
   Kimmell KT, 2014, J NEURO-ONCOL, V120, P567, DOI 10.1007/s11060-014-1587-y
   KLUN B, 1992, NEUROSURGERY, V30, P49, DOI 10.1227/00006123-199201000-00009
   Kondo A, 1997, NEUROSURGERY, V40, P46, DOI 10.1097/00006123-199701000-00009
   Kondo A, 1998, J NEUROSURG, V88, P221, DOI 10.3171/jns.1998.88.2.0221
   Kundu B, 2018, HEADACHE, V58, P1675, DOI 10.1111/head.13425
   Lee JK, 2012, J KOREAN NEUROSURG S, V51, P276, DOI 10.3340/jkns.2012.51.5.276
   Li DJ, 2010, ACTA OTO-LARYNGOL, V130, P247, DOI 10.3109/00016480903092340
   Lieber BA, 2016, J NEUROSURG, V125, P187, DOI 10.3171/2015.4.JNS142719
   Lieber BA, 2016, J NEUROSURG, V125, P213, DOI 10.3171/2015.4.JNS142149
   Lieber BA, 2016, WORLD NEUROSURG, V89, P126, DOI 10.1016/j.wneu.2016.01.033
   Lim S, 2015, J NEUROSURG, V122, P962, DOI 10.3171/2014.11.JNS1494
   LINSKEY ME, 1994, J NEUROSURG, V81, P1, DOI 10.3171/jns.1994.81.1.0001
   Lovely TJ, 1997, NEUROSURG CLIN N AM, V8, P11
   Lu VM, 2018, WORLD NEUROSURG, V120, P572, DOI 10.1016/j.wneu.2018.09.042
   Lukasiewicz AM, 2016, J NEUROSURG, V124, P760, DOI 10.3171/2015.2.JNS142721
   McCutcheon BA, 2015, SPINE, V40, P1122, DOI 10.1097/BRS.0000000000000599
   McGirt MJ, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.9.FOCUS15335
   McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001
   MENDOZA N, 1995, BRIT J NEUROSURG, V9, P13, DOI 10.1080/02688699550041692
   MENESES MS, 1995, NEUROCHIRURGIE, V41, P349
   Miller JP, 2009, J NEUROSURG, V111, P1231, DOI 10.3171/2008.6.17604
   Oesman C, 2011, SKULL BASE-INTERD AP, V21, P313, DOI 10.1055/s-0031-1284213
   PAMIR MN, 1995, NEUROSURG REV, V18, P163
   Patel A, 2002, NEUROSURGERY, V50, P705, DOI 10.1097/00006123-200204000-00004
   POLLACK IF, 1988, J NEUROSURG, V68, P559, DOI 10.3171/jns.1988.68.4.0559
   Puffer RC, 2016, GLOB SPINE J, V6, P447, DOI 10.1055/s-0035-1564808
   RESNICK DK, 1995, NEUROSURGERY, V36, P64, DOI 10.1227/00006123-199501000-00008
   Resnick DK, 1998, NEUROSURGERY, V43, P804, DOI 10.1097/00006123-199810000-00047
   Resnick DK, 1996, SURG NEUROL, V46, P358, DOI 10.1016/S0090-3019(96)00187-5
   Rughani AI, 2011, J NEUROSURG, V115, P202, DOI 10.3171/2011.4.JNS101924
   Sampson JH, 2004, NEUROSURGERY, V54, P884, DOI 10.1227/01.NEU.0000114142.98655.CC
   Sarsam Z, 2010, BRIT J NEUROSURG, V24, P18, DOI 10.3109/02688690903370289
   Sekula RF, 2008, J NEUROSURG, V108, P689, DOI 10.3171/JNS/2008/108/4/0689
   Sekula RF, 2011, J NEUROSURG, V114, P172, DOI 10.3171/2010.6.JNS10142
   Sellers MM, 2013, J AM COLL SURGEONS, V216, P420, DOI 10.1016/j.jamcollsurg.2012.11.013
   Sherrod BA, 2016, J NEUROSURG-PEDIATR, V18, P350, DOI 10.3171/2016.2.PEDS15604
   Sindou M, 2006, ACTA NEUROCHIR, V148, P1235, DOI 10.1007/s00701-006-0809-2
   Sindou M, 2018, NEUROCHIRURGIE, V64, P106, DOI 10.1016/j.neuchi.2018.01.001
   SINDOU M, 1990, NEUROCHIRURGIE, V36, P225
   SINDOU M, 1990, NEUROCHIRURGIE, V36, P16
   Sindou M, 2008, NEUROSURGERY, V63, P341, DOI 10.1227/01.NEU.0000327022.79171.D6
   Sindou M, 2007, J NEUROSURG, V107, P1144, DOI 10.3171/JNS-07/12/1144
   Sivakanthan S, 2014, NEUROSURGERY, V75, P220, DOI 10.1227/NEU.0000000000000430
   SUN T, 1994, ACTA NEUROCHIR, V126, P144, DOI 10.1007/BF01476425
   SZAPIRO J, 1985, NEUROSURGERY, V17, P920, DOI 10.1227/00006123-198512000-00009
   TAARNHOJ P, 1982, J NEUROSURG, V57, P14, DOI 10.3171/jns.1982.57.1.0014
   TAHA JM, 1995, NEUROSURGERY, V36, P926, DOI 10.1227/00006123-199505000-00006
   Teton ZE, 2020, J NEUROSURG, V132, P232, DOI 10.3171/2018.8.JNS18239
   Verlaan JJ, 2016, J CLIN ONCOL, V34, P3054, DOI 10.1200/JCO.2015.65.1497
   Wang DD, 2013, J CLIN NEUROSCI, V20, P1538, DOI 10.1016/j.jocn.2012.12.026
   ZORMAN G, 1984, NEUROLOGY, V34, P1362, DOI 10.1212/WNL.34.10.1362
NR 81
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E884
EP E894
DI 10.1016/j.wneu.2019.05.022
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100104
PM 31082546
DA 2020-05-12
ER

PT J
AU Davis, M
   Jenkins, S
   Bordes, S
   Iwanaga, J
   Loukas, M
   Uribe, J
   Hynes, RA
   Tubbs, RS
AF Davis, Michele
   Jenkins, Skyler
   Bordes, Stephen
   Iwanaga, Joe
   Loukas, Marios
   Uribe, Juan
   Hynes, Richard A.
   Tubbs, R. Shane
TI Iliolumbar Vein: Anatomy and Surgical Importance During Lateral
   Transpsoas and Oblique Approaches to Lumbar Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ascending lumbar vein; Iliolumbar vein; Lateral approach to spinal
   surgery; Vascular injury
ID INTERBODY FUSION; ASCENDING LUMBAR; ANTERIOR; COMPLICATIONS; SURGERY
AB OBJECTIVE: Safe surgical approaches to the anterolateral lumbar spine require a good working knowledge of the anatomy and anatomic variations of this region. As the iliolumbar vein is in the vicinity of both oblique and lateral transpsoas approaches to the lower lumbar spine, the following study was performed to better elucidate its anatomy, variations, and position during such surgical procedures.
   METHODS: Fifteen (30 sides) fresh frozen adult cadavers underwent dissection of the iliolumbar vein (ILV). The origin, course, variants, relations, and morphometrics of each vein were documented. Fluoroscopy of the vessels was performed. Lastly, anterior oblique and lateral transpsoas approaches to the lumbar spine were carried out in order to evaluate for potential ILV injury.
   RESULTS: An ILV was found on all but 2 sides (93.3%). It arose as a common trunk from the common iliac vein on 14 sides. Left ILVs tended to have a more distal origin than right ILVs. ILVs had a mean length of 3.7 cm and a mean width of 0.9 cm and were significantly larger on right versus left sides (P < 0.05). Left-sided ILVs tended to have more branches than right-sided veins. The majority of vertical branches of the ILV traveled anterior to the ventral rami of the lumbar spinal nerves, most commonly L4. The ILV and, in particular, its vertical branches coursed next to the L4 and L5 vertebrae.
   CONCLUSIONS: The ILV should be considered during both oblique and lateral transpsoas approaches to the lumbar spine.
C1 [Davis, Michele; Iwanaga, Joe; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [Jenkins, Skyler; Bordes, Stephen; Loukas, Marios] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
   [Uribe, Juan] Barrow Neurol Inst, Phoenix, AZ 85013 USA.
   [Hynes, Richard A.] BACK Ctr, Melbourne, FL USA.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.
EM joei@seattlesciencefoundation.org
RI Bordes, Stephen/AAF-8704-2019
OI Bordes, Stephen/0000-0002-7507-0674; Jenkins, Skyler/0000-0001-9594-3869
CR BAKER JK, 1993, SPINE, V18, P2227, DOI 10.1097/00007632-199311000-00014
   Blain M, 2019, CLIN ANAT, V32, P73, DOI 10.1002/ca.23266
   Bohl MA, 2019, CLIN ANAT, V32, P348, DOI 10.1002/ca.23317
   Creze M, 2018, CLIN ANAT, V31, P514, DOI 10.1002/ca.23065
   Davis TT, 2014, J NEUROSURG-SPINE, V21, P785, DOI 10.3171/2014.7.SPINE13564
   Fan CL, 2018, CLIN ANAT, V31, P1092, DOI 10.1002/ca.23248
   Garg J, 2010, J VASC SURG, V51, P946, DOI 10.1016/j.jvs.2009.11.039
   Ghannam M, 2017, CLIN ANAT, V30, P251, DOI 10.1002/ca.22822
   Hamid M, 2007, CLIN ANAT, V20, P545, DOI 10.1002/ca.20489
   Harmon P H, 1964, Clin Orthop Relat Res, V37, P130
   INOUE S, 1984, CLIN ORTHOP RELAT R, P22
   Lolis E, 2011, ANN ANAT, V193, P516, DOI 10.1016/j.aanat.2011.09.004
   Lu S, 2008, CHIN J TRAUMATOL, V11, P110, DOI 10.1016/S1008-1275(08)60023-1
   Mahan MA, 2017, CLIN ANAT, V30, P479, DOI 10.1002/ca.22879
   Nalbandian MM, 2013, SPINE, V38, pE445, DOI 10.1097/BRS.0b013e31828972ac
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Pawar A, 2015, ASIAN SPINE J, V9, P978, DOI 10.4184/asj.2015.9.6.978
   Pumberger M, 2012, EUR SPINE J, V21, P1192, DOI 10.1007/s00586-011-2087-9
   Samudrala S, 1999, Neurosurg Focus, V7, pe9
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Sivakumar G, 2007, CLIN ANAT, V20, P553, DOI 10.1002/ca.20457
   Unruh KP, 2008, CLIN ANAT, V21, P666, DOI 10.1002/ca.20711
   Wang MY, 2017, LATERAL ACCESS MINIM
   Watkins III RG, 2015, SURG APPROACHES SPIN
   Youssef JA, 2010, SPINE, V35, pS302, DOI 10.1097/BRS.0b013e3182023438
   Zairi F, 2017, ORTHOP TRAUMATOL-SUR, V103, P295, DOI 10.1016/j.otsr.2016.11.016
NR 26
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E768
EP E772
DI 10.1016/j.wneu.2019.04.252
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100090
PM 31077904
DA 2020-05-12
ER

PT J
AU Deng, WC
   Yan, JL
   Chuang, CC
   Wei, KC
   Chang, CN
   Wu, CT
   Chen, HC
   Wang, CC
   Tseng, CK
   Hsu, PW
AF Deng, Wen-Chun
   Yan, Jun-Lin
   Chuang, Chi-Cheng
   Wei, Kuo-Chen
   Chang, Chen-Nen
   Wu, Chieh-Tsai
   Chen, Hsien-Chih
   Wang, Chun-Chieh
   Tseng, Chen-Kan
   Hsu, Peng-Wei
TI Adjuvant Radiation Therapy Compared with Observation Alone for
   Postoperative Residual Nonfunctional Pituitary Adenomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Hypopituitarism; Nonfunctional; Pituitary adenoma;
   Postoperative; Radiosurgery; Residual
ID CEREBROVASCULAR MORTALITY; GROWTH-PATTERN; FOLLOW-UP; MACROADENOMAS;
   RADIOTHERAPY; SURGERY; TUMOR; RADIOSURGERY
AB OBJECTIVE: The management of residual nonfunctional pituitary tumors after surgical resection remains controversial. In this study, we compared the prognosis of postoperative radiation therapy and observation only in patients with residual nonfunctional pituitary adenoma and reviewed the long-term complications after radiation therapy.
   METHODS: We retrospectively analyzed 90 patients who underwent surgery for nonfunctional pituitary adenomas from January 2008 to April 2012. Residual tumors were classified by size, location, and pathologic staining. Tumor progression was defined as volume progression >= 15% with or without clinical symptoms. Postoperative radiation therapy was performed <1 year after the last surgery. We compared the progression and 3-year and 5-year progression-free survival between the observation group and postoperative radiation therapy group. Postradiation complications including hypopituitarism, diabetes insipidus, deterioration in visual field or acuity, cranial nerve palsy, and hydrocephalus were also analyzed.
   RESULTS: More of the patients who received postoperative radiation therapy had a tumor progression-free survival of >= 3 years than did those who did not receive postoperative radiation therapy. Postoperative radiation therapy was significantly beneficial for the patients with a tumor size >= 3 cm or with tumors in the cavernous sinus. The most frequent complication after radiation therapy was hypopituitarism and a few cases had third cranial nerve palsy; however, there were no significant relationships with radiation therapy.
   CONCLUSIONS: In this study, immediate radiation therapy after tumor resection was an effective and relatively safe treatment for residual or progressive nonfunctional pituitary adenomas. Moreover, the long-term complications of radiation therapy were mild.
C1 [Deng, Wen-Chun; Chuang, Chi-Cheng; Wei, Kuo-Chen; Chang, Chen-Nen; Wu, Chieh-Tsai; Hsu, Peng-Wei] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Dept Neurosurg, Taoyuan, Taiwan.
   [Wang, Chun-Chieh; Tseng, Chen-Kan] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Dept Radiat Oncol, Taoyuan, Taiwan.
   [Yan, Jun-Lin; Chen, Hsien-Chih] Chang Gung Univ, Keelung Chang Gung Mem Hosp Keelung, Dept Neurosurg, Taoyuan, Taiwan.
RP Hsu, PW (reprint author), Chang Gung Univ, Chang Gung Mem Hosp Linkou, Dept Neurosurg, Taoyuan, Taiwan.
EM leon3096@gmail.com
FU Chang Gung Memorial HospitalChang Gung Memorial Hospital [CIRPG3D0011,
   CIRPG3D0012, CIRPG3D0013]
FX Chang Gung Memorial Hospital provided financial support (grant
   CIRPG3D0011, CIRPG3D0012, CIRPG3D0013). The sponsor had no role in the
   design or conduct of this research.
CR Becker G, 2002, STRAHLENTHER ONKOL, V178, P173, DOI 10.1007/s00066-002-0826-x
   BLACK PM, 1987, J NEUROSURG, V66, P244, DOI 10.3171/jns.1987.66.2.0244
   Boelaert K, 2001, EUR J ENDOCRINOL, V144, P569, DOI 10.1530/eje.0.1440569
   Brada M, 2002, CLIN ENDOCRINOL, V57, P713, DOI 10.1046/j.1365-2265.2002.01570.x
   Bulow B, 1997, CLIN ENDOCRINOL, V46, P75, DOI 10.1046/j.1365-2265.1997.d01-1749.x
   Cawich S, 2009, INT J FAM PRACT, V7, P1
   Chang EF, 2008, J NEUROSURG, V108, P736, DOI 10.3171/JNS/2008/108/4/0736
   De Witte O, 2011, Rev Med Brux, V32, P509
   Dekkers OM, 2008, J CLIN ENDOCR METAB, V93, P3717, DOI 10.1210/jc.2008-0643
   Drummond J.B., 2018, NONFUNCTIONING PITUI
   Erridge SC, 2009, RADIOTHER ONCOL, V93, P597, DOI 10.1016/j.radonc.2009.09.011
   Fernandez A, 2009, ENDOCR-RELAT CANCER, V16, P733, DOI 10.1677/ERC-08-0231
   Hwang JM, 2013, J KOREAN NEUROSURG S, V54, P317, DOI 10.3340/jkns.2013.54.4.317
   Hwang K, 2019, J KOREAN NEUROSURG S, V62, P256, DOI 10.3340/jkns.2018.0153
   Karavitaki N, 2007, CLIN ENDOCRINOL, V67, P938, DOI 10.1111/j.1365-2265.2007.02990.x
   KLINE LB, 1985, OPHTHALMOLOGY, V92, P1118
   Lee CC, 2019, J NEURO-ONCOL, V142, P291, DOI 10.1007/s11060-019-03095-1
   Minniti G, 2005, J CLIN ENDOCR METAB, V90, P800, DOI 10.1210/jc.2004-1152
   Molitch ME, 2014, HAND CLINIC, V124, P167, DOI 10.1016/B978-0-444-59602-4.00012-5
   Monsalves E, 2014, J CLIN ENDOCR METAB, V99, P1330, DOI 10.1210/jc.2013-3054
   Nganga HK, 2013, PAN AFR MED J, V15
   Park KJ, 2011, NEUROSURGERY, V69, P1188, DOI 10.1227/NEU.0b013e318222afed
   Pomeraniec IJ, 2018, J NEUROSURG, V129, P648, DOI 10.3171/2017.5.JNS163069
   Pomeraniec IJ, 2016, J NEUROSURG, V125, P202, DOI 10.3171/2015.5.JNS15581
   Starke RM, 2012, J NEUROSURG, V117, P129, DOI 10.3171/2012.4.JNS112250
   Tanaka Y, 2003, J NEUROSURG, V98, P359, DOI 10.3171/jns.2003.98.2.0359
   Tomlinson JW, 2001, LANCET, V357, P425, DOI 10.1016/S0140-6736(00)04006-X
   Yan JL, 2013, J FORMOS MED ASSOC, V112, P416, DOI 10.1016/j.jfma.2012.01.020
   Yoon SC, 1998, INT J RADIAT ONCOL, V41, P849, DOI 10.1016/S0360-3016(98)00124-2
   Yu YL, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000004662
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1024
EP E1033
DI 10.1016/j.wneu.2019.05.066
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100121
PM 31103758
DA 2020-05-12
ER

PT J
AU Donoho, DA
   Buchanan, IA
   Patel, A
   Ding, L
   Cen, S
   Wen, T
   Giannotta, SL
   Attenello, F
   Mack, WJ
AF Donoho, Daniel A.
   Buchanan, Ian A.
   Patel, Arati
   Ding, Li
   Cen, Steven
   Wen, Timothy
   Giannotta, Steven L.
   Attenello, Frank
   Mack, William J.
TI Early Readmission After Ventricular Shunting Nationwide Readmission
   Database Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult cohort; Hydrocephalus; Nationwide database; Readmission; Shunt
   failure; Shunt revision; Ventricular shunt
ID RETROSPECTIVE ANALYSIS; RISK-FACTORS; HYDROCEPHALUS; ADULT;
   COMPLICATIONS; HEMORRHAGE; MORTALITY; SURVIVAL; FAILURES; OUTCOMES
AB BACKGROUND: Ventricular shunting is one of the Primary modalities for addressing hydrocephalus in both children and adults. Despite advances in shunt technology and surgical practices, shunt failure is a persistent challenge for neurosurgeons, and shunt revisions account for a substantial proportion of all shunt-related procedures. There are a wealth of studies elucidating failure patterns and patient demographics in pediatric cohorts; however, data in adults are less uniform. We sought to determine the rates of all-cause and shunt failure readmission in adults who underwent the insertion of a ventricular shunt.
   METHODS: We queried the Nationwide Readmissions Database from 2010 to 2014 to evaluate new ventricular shunts placed in adults with hydrocephalus. We sought to determine the rates of all-cause and shunt revision-related readmissions and to characterize factors associated with readmissions. We analyzed predictors including patient demographics, hospital characteristics, shunt type, and hydrocephalus cause.
   RESULTS: Analysis included 24,492 initial admissions for shunt placement in patients with hydrocephalus. Of patients, 9.17% required a shunt revision within the first 6 months; half of all revisions occurred within the first 41 days. There were 4044 (16.50%) 30-day and 5758 (28.8%) 90day all-cause readmissions. In multivariable analysis, patients with a ventriculopleural shunt, Medicare insurance, and younger age had increased likelihood for shunt revision. Notable predictors for all-cause readmission were insurance type, length of hospitalization, age, comorbidities, and hydrocephalus cause.
   CONCLUSIONS: Most shunt revisions occurred during the first 2 months. Readmissions occurred frequently. We identified patient factors that were associated with all-cause and shunt failure readmissions.
C1 [Donoho, Daniel A.; Buchanan, Ian A.; Patel, Arati] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA.
   [Ding, Li; Cen, Steven] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA.
   [Donoho, Daniel A.; Buchanan, Ian A.; Giannotta, Steven L.; Attenello, Frank; Mack, William J.] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90007 USA.
   [Wen, Timothy] Columbia Univ, Med Ctr, Dept Obstet & Gynecol, New York, NY USA.
RP Donoho, DA (reprint author), Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA.; Donoho, DA (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90007 USA.
EM Daniel.Donoho@med.usc.edu
CR Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337
   Bondurant CP, 1995, PEDIATR NEUROSURG, V23, P254, DOI 10.1159/000120968
   Cochrane DD, 2003, PEDIATR NEUROSURG, V38, P295, DOI 10.1159/000070413
   Craven C, 2017, J NEUROSURG, V126, P2010, DOI 10.3171/2016.4.JNS16641
   Dharmarajan K, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6571
   Donoho DA, 2018, J NEURO-ONCOL, V136, P87, DOI 10.1007/s11060-017-2625-3
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Farahmand D, 2009, J NEUROL NEUROSUR PS, V80, P1248, DOI 10.1136/jnnp.2007.141416
   Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012
   Hoh BL, 2008, NEUROSURGERY, V63, P70, DOI 10.1227/01.NEU.0000335072.32105.38
   Kestle J, 2000, PEDIATR NEUROSURG, V33, P230, DOI 10.1159/000055960
   Korinek AM, 2011, NEUROSURGERY, V68, P985, DOI 10.1227/NEU.0b013e318208f360
   Lam CH, 1997, BRIT J NEUROSURG, V11, P43
   Lazareff JA, 1998, CHILD NERV SYST, V14, P271, DOI 10.1007/s003810050223
   LUNDJOHANSEN M, 1994, NEUROSURGERY, V35, P839, DOI 10.1227/00006123-199411000-00006
   McGirt MJ, 2002, PEDIATR NEUROSURG, V36, P248, DOI 10.1159/000058428
   Merkler AE, 2017, WORLD NEUROSURG, V98, P654, DOI 10.1016/j.wneu.2016.10.136
   Moore BJ, 2017, MED CARE, V55, P698, DOI 10.1097/MLR.0000000000000735
   O'Kelly CJ, 2009, J NEUROSURG, V111, P1029, DOI 10.3171/2008.9.JNS08881
   PIATT JH, 1993, PEDIATR NEUROSURG, V19, P233, DOI 10.1159/000120738
   PUCA A, 1991, NEUROSURGERY, V29, P822, DOI 10.1227/00006123-199112000-00003
   Reddy GK, 2014, WORLD NEUROSURG, V81, P404, DOI 10.1016/j.wneu.2013.01.096
   Reddy GK, 2012, CLIN NEUROL NEUROSUR, V114, P1211, DOI 10.1016/j.clineuro.2012.02.050
   Reddy GK, 2011, NEUROSURGERY, V69, P774, DOI 10.1227/NEU.0b013e31821ffa9e
   Rekate HL, 2009, SEMIN PEDIATR NEUROL, V16, P9, DOI 10.1016/j.spen.2009.01.002
   Ringel F, 2005, SURG NEUROL, V63, P36, DOI 10.1016/j.surneu.2004.03.015
   Rumalla K, 2018, WORLD NEUROSURG, V110, pE100, DOI 10.1016/j.wneu.2017.10.089
   Rumalla K, 2017, NEUROSURGERY, V81, P740, DOI 10.1093/neuros/nyx063
   SAINTEROSE C, 1992, PEDIATR NEUROSURG, V17, P2, DOI 10.1159/000120557
   Simon TD, 2008, J NEUROS-PEDIATR, V1, P131, DOI 10.3171/PED/2008/1/2/131
   Spencer CS, 2013, HEALTH AFFAIR, V32, P1731, DOI 10.1377/hlthaff.2012.1400
   Tsai TC, 2013, NEW ENGL J MED, V369, P1134, DOI 10.1056/NEJMsa1303118
   Vahidy FS, 2017, STROKE, V48, P1386, DOI 10.1161/STROKEAHA.116.016085
   Walcott BP, 2015, NEUROCRIT CARE, V23, P54, DOI 10.1007/s12028-014-0072-y
   Weygandt PL, 2012, J SURG RES, V177, P288, DOI 10.1016/j.jss.2012.07.003
   Wu Y, 2007, NEUROSURGERY, V61, P562
   Wu Y, 2007, NEUROSURGERY, V61, P557, DOI 10.1227/01.NEU.0000290903.07943.AF
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E38
EP E50
DI 10.1016/j.wneu.2019.03.217
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100007
PM 30930319
DA 2020-05-12
ER

PT J
AU Ellingson, BM
   Woodworth, DC
   Leu, K
   Salamon, N
   Holly, LT
AF Ellingson, Benjamin M.
   Woodworth, Davis C.
   Leu, Kevin
   Salamon, Noriko
   Holly, Langston T.
TI Spinal Cord Perfusion MR Imaging Implicates Both Ischemia and Hypoxia in
   the Pathogenesis of Cervical Spondylosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spondylosis; DSC; Hypoxia; Ischemia; Spinal cord
ID CEREBRAL BLOOD-VOLUME; OXYGEN EXTRACTION; INTRASPINAL PRESSURE; INJURY;
   MYELOPATHY; COMPRESSION; FLOW; MECHANISM
AB OBJECTIVES: Although a number of studies have implicated ischemia and hypoxia in the pathogenesis of cervical spondylosis, quantification remains difficult and the role of ischemia and hypoxia on disease progression and disease severity in human cervical spondylosis remains largely unknown. Therefore, the objective of this study was to assess spinal cord perfusion and oxygenation in human cervical spondylosis and examine the relationship between perfusion, degree of spinal cord compression, and neurological status.
   METHODS: Twenty-two patients with cervical spondylosis with or without myelopathy received a dynamic susceptibility contrast perfusion MRI exam consisting of a novel spin-andgradient echo echoplanar acquisition before, during, and following gadolinium-based contrast injection. Estimation of relative spinal cord blood volume (rSCBV), the reversible relaxation rate (R-2(sic)), and relative oxygen extraction fraction (rOEF = R-2(sic)/rSCBV) was performed at the site of compression and compared with anterior-posterior spinal cord diameter and modified Japanese Orthopedic Association (mJOA) score, a measure of neurological impairment.
   RESULTS: rSCBV was linearly correlated with both anterior-posterior cord diameter (R-2 = 0.4667, P = 0.0005) and mJOA (R-2 = 0.2274, P = 0.0248). R-2(sic) was linearly correlated with mJOA (R-2 = 0.3998, P = 0.0016) but not cord diameter (R-2 = 0.055; P = 0.2950). Also, rOEF was correlated with both cord diameter (R-2 = 0.3440, P = 0.0041) and mJOA (R-2 = 0.4699, P = 0.0004).
   CONCLUSIONS: Results support the hypothesis that spinal cord compression results in ischemia and hypoxia, and the degree of ischemia and hypoxia is proportional to the degree of neurological impairment.
C1 [Ellingson, Benjamin M.; Woodworth, Davis C.; Leu, Kevin; Salamon, Noriko] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA.
   [Ellingson, Benjamin M.; Woodworth, Davis C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Phys & Biol Med, Los Angeles, CA 90095 USA.
   [Ellingson, Benjamin M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
   [Holly, Langston T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA.
RP Ellingson, BM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90095 USA.; Ellingson, BM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Phys & Biol Med, Los Angeles, CA 90095 USA.; Ellingson, BM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
EM bellingson@mednet.ucla.edu
RI Woodworth, Davis/L-9364-2019
FU NIH/NINDSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [2R01NS078494-06]
FX Funding was received through the following NIH/NINDS grants: no.
   2R01NS078494-06 (to LTH, NS, and BME).
CR Ackerman LL, 2002, NEUROSURGERY, V51, P1414, DOI 10.1097/00006123-200212000-00011
   An HY, 2000, J CEREBR BLOOD F MET, V20, P1225, DOI 10.1097/00004647-200008000-00008
   Baptiste Darryl C, 2006, Spine J, V6, p190S, DOI 10.1016/j.spinee.2006.04.024
   Bilgen M, 2001, MAGNET RESON MED, V46, P1099, DOI 10.1002/mrm.1305
   BRAIN WR, 1948, P ROY SOC MED, V41, P509
   BREIG A, 1966, J NEUROSURG, V25, P45, DOI 10.3171/jns.1966.25.1.0045
   DAVENPORT R, 1983, J NUCL MED, V24, P945
   Derdeyn CP, 2002, BRAIN, V125, P595, DOI 10.1093/brain/awf047
   Domsch S, 2014, Z MED PHYS, V24, P231, DOI 10.1016/j.zemedi.2014.03.009
   DOPPMAN JL, 1975, INVEST RADIOL, V10, P543, DOI 10.1097/00004424-197511000-00001
   Geisler BS, 2006, STROKE, V37, P1778, DOI 10.1161/01.STR.0000226738.97426.6f
   Gooding M R, 1976, Surg Neurol, V5, P233
   GOODING MR, 1975, J NEUROSURG, V43, P9, DOI 10.3171/jns.1975.43.1.0009
   GRUBB RL, 1977, J NEUROSURG, V46, P446, DOI 10.3171/jns.1977.46.4.0446
   Harris RJ, 2018, MAGN RESON MED, V80, P1962, DOI 10.1002/mrm.27204
   He X, 2008, MAGN RESON MED, V60, P882, DOI 10.1002/mrm.21719
   Henderson FC, 2005, NEUROSURGERY, V56, P1101, DOI 10.1227/01.NEU.0000157929.85251.7C
   Holly LT, 2009, J NEUROSURG-SPINE, V10, P194, DOI 10.3171/2008.12.SPINE08367
   Jensen-Kondering U, 2012, STROKE, V43, P2264, DOI 10.1161/STROKEAHA.111.632455
   Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633
   Khan NR, 2016, J NEUROSURG-SPINE, V25, P383, DOI 10.3171/2016.1.SPINE151199
   Kurokawa R, 2011, SPINE, V36, P1006, DOI 10.1097/BRS.0b013e3181eaf33d
   Kwon BK, 2009, J NEUROSURG-SPINE, V10, P181, DOI 10.3171/2008.10.SPINE08217
   MAIR WGP, 1953, BRAIN, V76, P70, DOI 10.1093/brain/76.1.70
   MONTGOMERY DM, 1992, ORTHOP CLIN N AM, V23, P487
   OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868
   Phang I, 2015, J NEUROTRAUM, V32, P865, DOI 10.1089/neu.2014.3668
   Squair JW, 2017, NEUROLOGY, V89, P1660, DOI 10.1212/WNL.0000000000004519
   Strek P, 1998, EUR ARCH OTO-RHINO-L, V255, P437, DOI 10.1007/s004050050094
   Tatar Ilkan, 2009, BMC Med Imaging, V9, P10, DOI 10.1186/1471-2342-9-10
   TAYLOR AR, 1953, LANCET, V264, P717
   THOMPSON HK, 1964, CIRC RES, V14, P502, DOI 10.1161/01.RES.14.6.502
   Toth V, 2013, J NEURO-ONCOL, V115, P197, DOI 10.1007/s11060-013-1210-7
   Varsos GV, 2015, J NEUROSURG-SPINE, V23, P763, DOI 10.3171/2015.3.SPINE14870
   Walters BC, 2013, NEUROSURGERY, V60, P82, DOI 10.1227/01.neu.0000430319.32247.7f
   Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028
   WILKINSON M, 1960, BRAIN, V83, P589, DOI 10.1093/brain/83.4.589
   Yablonskiy DA, 2013, NMR BIOMED, V26, P963, DOI 10.1002/nbm.2839
   Yonenobu K, 2001, SPINE, V26, P1890, DOI 10.1097/00007632-200109010-00014
   Young WF, 2000, AM FAM PHYSICIAN, V62, P1064
NR 40
TC 3
Z9 3
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E773
EP E781
DI 10.1016/j.wneu.2019.04.253
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100091
PM 31077900
DA 2020-05-12
ER

PT J
AU Elsamadicy, AA
   Drysdale, N
   Adil, SM
   Charalambous, L
   Lee, M
   Koo, A
   Freedman, IG
   Kundishora, AJ
   Camara-Quintana, J
   Qureshi, T
   Kolb, L
   Laurans, M
   Abbed, K
   Karikari, IO
AF Elsamadicy, Aladine A.
   Drysdale, Nicolas
   Adil, Syed M.
   Charalambous, Lefko
   Lee, Megan
   Koo, Andrew
   Freedman, Isaac G.
   Kundishora, Adam J.
   Camara-Quintana, Joaquin
   Qureshi, Tariq
   Kolb, Luis
   Laurans, Maxwell
   Abbed, Khalid
   Karikari, Isaac O.
TI Association Between Preoperative Narcotic Use with Perioperative
   Complication Rates, Patient Reported Pain Scores, and Ambulatory Status
   After Complex Spinal Fusion (>= 5 Levels) for Adult Deformity Correction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complex deformity; Pain scores; Preoperative narcotic use; Spinal fusion
ID POSTOPERATIVE PAIN; HOSPITAL STAY; BACK-PAIN; SURGERY; MANAGEMENT;
   OUTCOMES; CARE
AB OBJECTIVE: The widespread over-use of narcotics has been increasing. However, whether narcotic use impacts surgical outcomes after complex spinal fusion remains understudied. The aim of this study was to evaluate whether there is an association between preoperative narcotic use with perioperative complication rates, patient-reported pain scores, and ambulatory status after complex spinal fusions.
   METHODS: The medical records of 134 adult (age >= 18 years) patients with spinal deformity undergoing elective, primary complex spinal fusion (>= 5 levels) for deformity correction in a major academic institution from 2005-2015 were reviewed. Patient demographics, comorbidities, intra-operative and postoperative complication rates, pain scores, and ambulatory status were collected for each patient.
   RESULTS: Patient demographics and comorbidities were similar between both cohorts, except that the Narcotic-User cohort had a greater mean age (57.5 years vs. 50.7 years; P = 0.045) and prevalence of depression (39.4% vs. 16.2%; P = 0.003). Complication rates were similar between both cohorts. The Narcotic-User cohort had significantly higher pain scores at baseline (6.7 +/- 2.4 vs. 4.0 +/- 3.4; P < 0.001) and at the first postoperative pain score reported (6.7 +/- 2.8 vs. 5.3 +/- 2.9; P = 0.013), but had a significantly greater improvement from baseline to last pain score (Narcotic-User: -2.5 +/- 3.9 vs. Non-User: -0.5 +/- 4.7; P = 0.031). The Narcotic-User cohort had significantly greater ambulation on the first postoperative ambulatory day compared with the Non-User cohort (103.8 +/- 144.4 vs. 56.4 +/- 84.0; P = 0.031).
   CONCLUSIONS: Our study suggests that the preoperative use of narcotics may impact patient perception of pain and improvement after complex spinal fusions (>= 5 levels). Consideration of patients' narcotic status preoperatively may facilitate tailored pain management and physical therapy regimens.
C1 [Elsamadicy, Aladine A.; Lee, Megan; Koo, Andrew; Freedman, Isaac G.; Kundishora, Adam J.; Camara-Quintana, Joaquin; Qureshi, Tariq; Kolb, Luis; Laurans, Maxwell; Abbed, Khalid] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA.
   [Drysdale, Nicolas; Adil, Syed M.; Charalambous, Lefko; Karikari, Isaac O.] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC USA.
RP Elsamadicy, AA (reprint author), Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA.
EM aladine.elsamadicy@yale.edu
CR Ahn J, 2016, J NEUROSURG-SPINE, V24, P206, DOI 10.3171/2015.3.SPINE141300
   [Anonymous], 2018, US OP PRESCR RAT MAP
   Armaghani SJ, 2016, CLIN SPINE SURG, V29, pE93, DOI 10.1097/BSD.0000000000000109
   Asher MA, 2006, SCOLIOSIS SPINAL DIS, V1, DOI 10.1186/1748-7161-1-2
   Bible JE, 2014, SPINE J S, V14, pS89
   Black N, 2013, BMJ-BRIT MED J, V346, pf167, DOI [DOI 10.1136/BMJ.F167, 10.1136/bmj.f167]
   Devin CJ, 2015, J CLIN NEUROSCI, V22, P930, DOI 10.1016/j.jocn.2015.01.003
   Deyo RA, 2018, PAIN, V159, P1147, DOI 10.1097/j.pain.0000000000001202
   Dunn LK, 2018, ANESTH ANALG, V127, P247, DOI 10.1213/ANE.0000000000003338
   Gottschalk A, 2011, ANESTH ANALG, V112, P218, DOI 10.1213/ANE.0b013e3181d8a095
   Haws BE, 2019, CLIN SPINE SURG, V32, pE37, DOI 10.1097/BSD.0000000000000713
   JACKSON RP, 1983, SPINE, V8, P749, DOI 10.1097/00007632-198310000-00011
   Jain N, 2018, SPINE, V43, P1331, DOI 10.1097/BRS.0000000000002609
   Kalakoti P, 2018, SPINE J S, V18, pS37
   Kla KM, 2016, CURR ANESTHESIOL REP, V6, P244
   Lee Dennis, 2014, J Bone Joint Surg Am, V96, pe89
   Levin JM, 2017, SPINE J, V17, P1586, DOI 10.1016/j.spinee.2017.05.002
   McGirt MJ, 2014, SPINE, V39, pS117, DOI 10.1097/BRS.0000000000000552
   Mesfin A, 2014, SPINE J, V14, P2819, DOI 10.1016/j.spinee.2014.03.049
   Mino David E, 2017, J Spine Surg, V3, P141, DOI 10.21037/jss.2017.04.02
   Nielsen RV, 2017, PAIN, V158, P463, DOI 10.1097/j.pain.0000000000000782
   Qureshi R, 2017, SPINE J, V17, pS259
   Raad M, 2017, SPINE J S, V17, pS91
   Raad M, 2018, SPINE, V43, P1340, DOI 10.1097/BRS.0000000000002631
   Scheer JK, 2015, J NEUROSURG-SPINE, V22, P540, DOI 10.3171/2014.10.SPINE14475
   Siemionow K, 2012, SPINE, V37, P2046, DOI 10.1097/BRS.0b013e31825c6688
   Smith JS, 2009, NEUROSURGERY, V65, P93, DOI DOI 10.1227/01.NEU.0000347005.35282.6C
   Smith JS, 2009, NEUROSURGERY, V65, P86, DOI 10.1227/01.NEU.0000347005.35282.6C
   Teles AR, 2017, GLOB SPINE J, V7, P170, DOI 10.1177/2192568217699182
   Villavicencio AT, 2017, SPINE J, V17, pS197, DOI DOI 10.1016/J.SPINEE.2017.07.282
   Walid Mohammad Sami, 2007, J Opioid Manag, V3, P127
   Walid MS, 2007, J OPIOID MANAG, V3, P130
   Yamashita K, 2006, SPINE, V31, P2602, DOI 10.1097/01.brs.0000240717.25787.7d
   Yen D, 2015, PAIN RES MANAG, V20, P129, DOI 10.1155/2015/761390
   Yu L, 2013, SPINE, V38, P1947, DOI 10.1097/BRS.0b013e3182a69b90
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E231
EP E237
DI 10.1016/j.wneu.2019.04.107
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100026
PM 31009775
DA 2020-05-12
ER

PT J
AU Fanous, AA
   Jowdy, PK
   Morr, S
   Vakharia, K
   Shallwani, H
   Lorincz, K
   Hopkins, LN
   Davies, JM
   Snyder, KV
   Siddiqui, AH
   Levy, EI
AF Fanous, Andrew A.
   Jowdy, Patrick K.
   Morr, Simon
   Vakharia, Kunal
   Shallwani, Hussain
   Lorincz, Katalin
   Hopkins, L. Nelson
   Davies, Jason M.
   Snyder, Kenneth V.
   Siddiqui, Adnan H.
   Levy, Elad I.
TI Vascular Anatomy and Not Age is Responsible for Increased Risk of
   Complications in Symptomatic Elderly Patients Undergoing Carotid Artery
   Stenting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Age; Carotid artery stenting; Elderly; Octogenarian; Perioperative
   complications; Risk factors
ID CEREBRAL PROTECTION; ENDARTERECTOMY; OCTOGENARIANS; ANGIOPLASTY; STROKE;
   REVASCULARIZATION; OUTCOMES; DISEASE; EVENTS; SYSTEM
AB BACKGROUND: Various studies have suggested that age >= 80 years is associated with a higher rate of complications after carotid artery stenting (CAS). The Buffalo Risk Assessment Scale (BRASS) predicts complications in symptomatic patients undergoing CAS. Application of the BRASS has shown the ability to improve patient selection. We used the BRASS system to evaluate whether the higher rate of complications associated with CAS in the elderly is related to vascular anatomy.
   METHODS: A retrospective review of CAS was performed at our institution over 7 years. Demographic information, anatomic characteristics, BRASS categorization, and outcome measures were compared between elderly (>= 80 years) and younger patients (<80 years).
   RESULTS: The study included 447 patients: 335 patients (75%) <80 years and 112 patients (25%) >= 80 years. There were significantly more elderly patients in the high-risk BRASS category (P < 0.01), and more young patients in the low-risk BRASS category (P = 0.04). The complication rates in the 2 groups were similar. Older patients were more likely to harbor complex vascular anatomy: they had significantly higher rates of types II and III aortic arches (P = 0.01 and P < 0.01, respectively), higher percentage of tortuous carotid vessels (P < 0.01), and higher rates of hostile anatomy for deployment of distal embolic protection devices (P = 0.02).
   CONCLUSIONS: Complex vascular anatomy, rather than age, is the key factor behind the higher CAS-associated complication rate in the elderly. Complications can be avoided through proper patient selection and stratifying patients based on anatomic characteristics, which can be achieved through the BRASS scoring system.
C1 [Fanous, Andrew A.; Jowdy, Patrick K.; Morr, Simon; Vakharia, Kunal; Shallwani, Hussain; Hopkins, L. Nelson; Davies, Jason M.; Snyder, Kenneth V.; Siddiqui, Adnan H.; Levy, Elad I.] SUNY Buffalo, Dept Neurosurg, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14260 USA.
   [Hopkins, L. Nelson; Siddiqui, Adnan H.; Levy, Elad I.] SUNY Buffalo, Dept Radiol, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14260 USA.
   [Davies, Jason M.] SUNY Buffalo, Dept Bioinformat, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA.
   [Snyder, Kenneth V.] SUNY Buffalo, Dept Neurol, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA.
   [Hopkins, L. Nelson; Davies, Jason M.; Snyder, Kenneth V.; Siddiqui, Adnan H.; Levy, Elad I.] SUNY Buffalo, Toshiba Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.
   [Fanous, Andrew A.; Jowdy, Patrick K.; Morr, Simon; Vakharia, Kunal; Shallwani, Hussain; Hopkins, L. Nelson; Davies, Jason M.; Snyder, Kenneth V.; Siddiqui, Adnan H.; Levy, Elad I.] Kaleida Hlth, Gates Vasc Inst, Dept Neurosurg, Buffalo, NY 14210 USA.
   [Lorincz, Katalin] Univ Pecs, Sch Med, Doctoral Sch Clin Neurosci, Pecs, Hungary.
   [Hopkins, L. Nelson; Davies, Jason M.; Siddiqui, Adnan H.] Jacobs Inst, Buffalo, NY USA.
RP Levy, EI (reprint author), SUNY Buffalo, Dept Neurosurg, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14260 USA.; Levy, EI (reprint author), SUNY Buffalo, Dept Radiol, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14260 USA.; Levy, EI (reprint author), SUNY Buffalo, Toshiba Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.; Levy, EI (reprint author), Kaleida Hlth, Gates Vasc Inst, Dept Neurosurg, Buffalo, NY 14210 USA.
EM elevy@ubns.com
RI Siddiqui, Adnan H./AAG-9781-2019
CR Alozairi O, 2003, EUR J VASC ENDOVASC, V26, P245, DOI 10.1053/ejvs.2002.1939
   Bazan HA, 2007, J VASC SURG, V46, P841, DOI 10.1016/j.jvs.2007.06.048
   Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558
   Chaturvedi S, 2010, STROKE, V41, P757, DOI 10.1161/STROKEAHA.109.569426
   Chiam PTL, 2008, CATHETER CARDIO INTE, V72, P318, DOI 10.1002/ccd.21620
   Chong PL, 2005, EUR J VASC ENDOVASC, V29, P597, DOI 10.1016/j.ejvs.2005.01.016
   Cilingiroglu M, 2013, FUTUR CARDIOL, V9, P193, DOI [10.2217/FCA.12.84, 10.2217/fca.12.84]
   Duan JH, 2018, BRAIN BEHAV, V8, DOI 10.1002/brb3.873
   Dzierwa K, 2013, CATHETER CARDIO INTE, V82, P681, DOI 10.1002/ccd.25025
   Faggioli GL, 2007, EUR J VASC ENDOVASC, V33, P436, DOI 10.1016/j.ejvs.2006.11.026
   Faggioli G, 2007, J VASC SURG, V46, P1119, DOI 10.1016/j.jvs.2007.08.027
   Faggioli G, 2009, J VASC SURG, V49, P80, DOI 10.1016/j.jvs.2008.08.014
   Fanous AA, 2015, NEUROSURGERY, V77, P531, DOI 10.1227/NEU.0000000000000871
   Fantozzi C, 2016, ANN VASC SURG, V33, P132, DOI 10.1016/j.avsg.2015.10.039
   Gribar JJ, 2011, J INTERV CARDIOL, V24, P247, DOI 10.1111/j.1540-8183.2011.00635.x
   Hobson RW, 2004, J VASC SURG, V40, P1106, DOI 10.1016/j.jvs.2004.10.022
   Hopkins LN, 2010, EUROINTERVENTION, V5, P917, DOI 10.4244/
   Hsia DC, 1998, STROKE, V29, P346, DOI 10.1161/01.STR.29.2.346
   Illig KA, 2003, J VASC SURG, V37, P575, DOI 10.1067/mva.2003.79
   Kastrup A, 2004, J VASC SURG, V40, P945, DOI 10.1016/j.jvs.2004.08.022
   Kwon BJ, 2006, J ENDOVASC THER, V13, P711, DOI 10.1583/06-1900.1
   Lam RC, 2007, J VASC SURG, V45, P875, DOI 10.1016/j.jvs.2006.12.059
   Lin SC, 2005, ANN VASC SURG, V19, P798, DOI 10.1007/s10016-005-8045-4
   Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261
   Mammo DF, 2017, CARDIOVASC REVASCULA, V18, pS18, DOI 10.1016/j.carrev.2017.03.023
   Mantese VA, 2010, STROKE, V41, pS31, DOI 10.1161/STROKEAHA.110.595330
   Maxwell JG, 2000, ANN SURG, V231, P781, DOI 10.1097/00000658-200006000-00001
   Micari A, 2010, CATHETER CARDIO INTE, V76, P9, DOI 10.1002/ccd.22503
   Muller MD, 2017, STROKE, V48, P1285, DOI 10.1161/STROKEAHA.116.014612
   Myla S, 2010, CATHETER CARDIO INTE, V75, P817, DOI 10.1002/ccd.22386
   Myouchin K, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-468
   Naggara O, 2011, STROKE, V42, P380, DOI 10.1161/STROKEAHA.110.588772
   Nikas D, 2012, CATHETER CARDIO INTE, V80, P1060, DOI 10.1002/ccd.24402
   Reimers B, 2004, AM J MED, V116, P217, DOI 10.1016/j.amjmed.2003.09.043
   Rockman CB, 2003, ANN VASC SURG, V17, P9, DOI 10.1007/s10016-001-0330-2
   Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74
   Safian RD, 2006, J AM COLL CARDIOL, V47, P2384, DOI 10.1016/j.jacc.2005.12.076
   Sayeed S, 2008, J VASC SURG, V47, P81, DOI 10.1016/j.jvs.2007.09.047
   Schneider JR, 2000, J VASC SURG, V31, P927, DOI 10.1067/mva.2000.106417
   Setacci C, 2006, J ENDOVASC THER, V13, P302, DOI 10.1583/06-1836.1
   Setacci C, 2010, STROKE, V41, P1259, DOI 10.1161/STROKEAHA.110.578583
   Shawl F, 2000, J AM COLL CARDIOL, V35, P1721, DOI 10.1016/S0735-1097(00)00618-5
   Spanos Vassilis, 2003, Int J Cardiovasc Intervent, V5, P77, DOI 10.1080/14628840304605
   TAYLOR DW, 1991, NEW ENGL J MED, V325, P445
   Theiss W, 2008, STROKE, V39, P2325, DOI 10.1161/STROKEAHA.108.514356
   Touze E, 2009, STROKE, V40, pE683, DOI 10.1161/STROKEAHA.109.562041
   Voeks JH, 2011, STROKE, V42, P3484, DOI 10.1161/STROKEAHA.111.624155
   WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035
   Werner M, 2012, CATHETER CARDIO INTE, V80, P321, DOI 10.1002/ccd.23483
   Wholey MH, 2008, SEMIN VASC SURG, V21, P95, DOI 10.1053/j.semvascsurg.2008.03.005
   Zahn R, 2007, EUR HEART J, V28, P370, DOI 10.1093/eurheartj/ehl421
NR 51
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E513
EP E521
DI 10.1016/j.wneu.2019.04.187
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100060
PM 31048049
DA 2020-05-12
ER

PT J
AU Feghali, J
   Xu, RS
   Yang, WY
   Liew, J
   Tamargo, RJ
   Marsh, EB
   Huang, J
AF Feghali, James
   Xu, Risheng
   Yang, Wuyang
   Liew, Jason
   Tamargo, Rafael J.
   Marsh, Elisabeth B.
   Huang, Judy
TI Differing Surgical Outcomes in a Multiethnic Cohort Suggest Racial
   Phenotypes in Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ethnic groups; Moyamoya disease; Stroke
ID CLINICAL-FEATURES; PREVALENCE; BYPASS; STROKE; WHITE; JAPAN; STATE
AB BACKGROUND: Variable Moyamoya disease (MMD) genotypes and phenotypes between different races have been suggested previously. This study investigates differences in surgical complications and response to revascularization among Asian patients with MMD compared with other ethnicities in North America .
   METHODS: From a database of 185 patients with moyamoya presenting to our institution between 1994 and 2015, 85 patients with MMD underwent surgery and constituted the study cohort. Baseline characteristics before surgery, procedure-related complications, length of hospital stay, and outcome variables including stroke and functional outcome were compared between Asian and non-Asian patients. Kaplan -Meier survival analyses were used to compare time to ipsilateral stroke and any cerebrovascular event after bypass.
   RESULTS: Our surgical cohort consisted of 27% (23/85) Asian and 73% (62/85) non-Asian patients with MMD with a bimodal age distribution. Among the subset of patients who presented with stroke (n = 55), hemorrhage was significantly more common among Asian patients (P = 0.007). In 120 revascularization procedures, per-operative complication rates were greater among Asian patients while controlling for age, type of surgery, and stroke history (odds ratio 2.94; 95% confidence interval 1.16-7.48; P = 0.02). The mean follow-up time after surgery was 4.57 years. Ipsilateral cerebrovascular event rates were 4.77 per 100 person-years in non-Asian patients and 6.51 per 100 person-years in Asians (P = 0.66). Unfavorable modified Rankin Scale scores (>2) were found in 22% of Asian patients and 8% of non-Asian patients on last follow-up (P = 0.13).
   CONCLUSIONS: Asian patients with MMD may be more susceptible to surgical complications and may differ from other races in their response to revascularization. Further long-term prospective studies are needed to investigate these findings.
C1 [Feghali, James; Xu, Risheng; Yang, Wuyang; Liew, Jason; Tamargo, Rafael J.; Huang, Judy] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Marsh, Elisabeth B.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
RP Huang, J (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM jhuang24@jhmi.edu
OI Huang, Judy/0000-0002-0675-1935
CR Bower RS, 2013, STROKE, V44, P1997, DOI 10.1161/STROKEAHA.111.000307
   Chen XX, 2019, J NEUROSURG, V130, P1906, DOI 10.3171/2017.12.JNS172178
   Chiu D, 1998, STROKE, V29, P1347, DOI 10.1161/01.STR.29.7.1347
   Cloft HJ, 1999, NEURORADIOLOGY, V41, P772, DOI 10.1007/s002340050840
   Deng XF, 2018, J NEUROSURG, V128, P1327, DOI 10.3171/2016.12.JNS162626
   Fukui M, 1997, SURG NEUROL, V47, P138, DOI 10.1016/S0090-3019(96)00358-8
   Fukui M, 1997, CLIN NEUROL NEUROSUR, V99, pS238
   Funaki T, 2015, J NEUROSURG, V122, P400, DOI 10.3171/2014.10.JNS14231
   Goto Yasunobu, 1992, Neurologia Medico-Chirurgica, V32, P883, DOI 10.2176/nmc.32.883
   Guzman R, 2009, J NEUROSURG, V111, P927, DOI 10.3171/2009.4.JNS081649
   Hallemeier CL, 2006, STROKE, V37, P1490, DOI 10.1161/01.STR.0000221787.70503.ca
   Hori S, 2019, NEUROSURGERY, V85, P134, DOI 10.1093/neuros/nyy236
   Houkin K, 1996, STROKE, V27, P1342, DOI 10.1161/01.STR.27.8.1342
   Jeon JP, 2018, J NEUROSURG, V128, P793, DOI 10.3171/2016.11.JNS161688
   Kainth D, 2013, NEUROEPIDEMIOLOGY, V40, P282, DOI 10.1159/000345957
   Kawaguchi S, 2000, J NEUROSURG, V93, P397, DOI 10.3171/jns.2000.93.3.0397
   Kim T, 2016, J NEUROSURG, V124, P1788, DOI 10.3171/2015.6.JNS151105
   Kraemer M, 2008, STROKE, V39, P3193, DOI 10.1161/STROKEAHA.107.513408
   Kuriyama S, 2008, STROKE, V39, P42, DOI 10.1161/STROKEAHA.107.490714
   Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0
   Liu XJ, 2015, J NEUROSURG, V122, P392, DOI 10.3171/2014.10.JNS132369
   Mallory GW, 2013, NEUROSURGERY, V73, P984, DOI 10.1227/NEU.0000000000000162
   Meschia JF, 2008, NEUROLOGY, V70, P2353, DOI 10.1212/01.wnl.0000314695.96436.19
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   Numaguchi Y, 1997, CLIN NEUROL NEUROSUR, V99, pS26, DOI 10.1016/S0303-8467(97)00060-7
   Oshima H, 2012, CHILD NERV SYST, V28, P497, DOI 10.1007/s00381-012-1708-x
   Peerless SJ, 1997, CLIN NEUROL NEUROSUR, V99, pS45, DOI 10.1016/S0303-8467(97)00039-5
   Shoemaker LD, 2016, G3-GENES GENOM GENET, V6, P41, DOI 10.1534/g3.115.020321
   Starke RM, 2012, NEUROSURGERY, V71, P93, DOI 10.1227/NEU.0b013e318253ab8e
   Starke RM, 2009, J NEUROSURG, V111, P936, DOI 10.3171/2009.3.JNS08837
   Sun H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186758
   SUZUKI J, 1983, STROKE, V14, P104, DOI 10.1161/01.STR.14.1.104
   Takeuchi K, 1957, BRAIN NERVE, V9, P37
   Uchino K, 2005, NEUROLOGY, V65, P956, DOI 10.1212/01.wnl.0000176066.33797.82
   Yilmaz EY, 2001, ARCH NEUROL-CHICAGO, V58, P1274, DOI 10.1001/archneur.58.8.1274
   Zhai XL, 2018, WORLD NEUROSURG, V118, pE92, DOI 10.1016/j.wneu.2018.06.125
   Zhao M, 2019, J NEUROSURG, V130, P531, DOI 10.3171/2017.10.JNS171749
NR 37
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E865
EP E872
DI 10.1016/j.wneu.2019.05.019
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100102
PM 31082553
DA 2020-05-12
ER

PT J
AU Garcia-Pallero, MA
   Hodaie, M
   Zhong, JD
   Manzanares-Soler, R
   Navas, M
   Pastor, J
   Vega-Zelaya, L
   Delgado-Fernandez, J
   Sola, RG
   Torres, CV
AF Garcia-Pallero, Maria A.
   Hodaie, Mojgan
   Zhong, Jidan
   Manzanares-Soler, Rafael
   Navas, Marta
   Pastor, Jesus
   Vega-Zelaya, Lorena
   Delgado-Fernandez, Juan
   Sola, Rafael G.
   Torres, Cristina V.
TI Prediction of Laterality in Temporal Lobe Epilepsy Using White Matter
   Diffusion Metrics
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diffusion tensor imaging; Fractional anisotropy; Mean diffusivity;
   Mesial temporal sclerosis; Tractography
ID WATER DIFFUSION; ABNORMALITIES; TRACTOGRAPHY; SCLEROSIS; SURGERY;
   TRACTS; MEMORY; BRAIN; MRI
AB BACKGROUND: Diagnostic methods of the epileptogenic area continue to be a challenge in epilepsy surgery research. We hypothesized that temporal lobe epilepsy (TLE) will result in white matter changes that can be detected using diffusion tensor imaging. Measurement of white matter diffusivity will therefore be useful for presurgical assessment.
   METHODS: Twelve patients with TLE who had undergone temporal lobectomy and amygdalohippocampectomy were included. In 6 patients, magnetic resonance imaging (MRI) showed evidence of mesial temporal sclerosis (m-TLE), whereas the 6 remaining MRI studies were informed without any abnormality (nl-TLE). All had excellent outcomes from surgery. Patients were compared with 12 age and sex-matched controls. Five pairs of white matter fiber tracts were traced, and fiber tract fractional anisotropy and mean diffusivity were calculated.
   RESULTS: There were several alterations in diffusion parameters in white matter tracts, both ipsilateral and on the contralateral side, these alterations were more pronounced in the hemisphere ipsilateral to the epileptogenic focus. m-TLE patients had more alterations on ipsilateral side than nl-TLE patients, but similar alterations on contralateral side and bilateral fornix. The discriminant function analysis successfully lateralized all the patients with left TLE, 83.3% of the patients with right TLE, and all nl-TLE.
   CONCLUSIONS: Our results suggest that there are alterations in diffusion parameters in white matter tracts both in m-TLE and nl-TLE patients. Diffusion tensor imaging could be a useful presurgical tool to help establish the laterality of TLE, including patients with "normal" MRI. Further studies with a larger number of patients would be necessary to confirm these results.
C1 [Garcia-Pallero, Maria A.] Hosp Univ Cent Asturias, Dept Neurosurg, Asturias, Spain.
   [Hodaie, Mojgan] Toronto Western Hosp, Toronto, ON, Canada.
   [Hodaie, Mojgan; Zhong, Jidan] Univ Hlth Network, Krembil Brain Inst, Toronto, ON, Canada.
   [Hodaie, Mojgan] Univ Toronto, Dept Surg, Toronto, ON, Canada.
   [Manzanares-Soler, Rafael] La Princesa Hosp, Dept Radiol, Madrid, Spain.
   [Navas, Marta; Delgado-Fernandez, Juan; Torres, Cristina V.] La Princesa Hosp, Dept Neurosurg, Madrid, Spain.
   [Pastor, Jesus; Vega-Zelaya, Lorena] La Princesa Hosp, Dept Neurophysiol, Madrid, Spain.
   [Sola, Rafael G.] Univ Autonoma Madrid, Madrid, Spain.
RP Garcia-Pallero, MA (reprint author), Hosp Univ Cent Asturias, Dept Neurosurg, Asturias, Spain.
EM magpallero@gmail.com
RI Delgado-Fernandez, Juan/AAH-8667-2019; Pastor, Jesus/AAH-9238-2020
OI Delgado-Fernandez, Juan/0000-0002-4251-8356; Pastor,
   Jesus/0000-0001-6870-8409; Torres, Cristina/0000-0002-3420-0786
CR Ahmadi ME, 2009, AM J NEURORADIOL, V30, P1740, DOI 10.3174/ajnr.A1650
   Arfanakis K, 2002, MAGN RESON IMAGING, V20, P511, DOI 10.1016/S0730-725X(02)00509-X
   Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0
   Buchel C, 2004, CEREB CORTEX, V14, P945, DOI 10.1093/cercor/bhh055
   Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004
   Chen DQ, 2015, STEREOT FUNCT NEUROS, V93, P151, DOI 10.1159/000368442
   Cloppenborg T, 2016, J NEUROL NEUROSUR PS, V87, P1322, DOI 10.1136/jnnp-2016-313831
   Concha L, 2005, ANN NEUROL, V57, P188, DOI 10.1002/ana.20334
   Concha L, 2009, J NEUROL NEUROSUR PS, V80, P312, DOI 10.1136/jnnp.2007.139287
   Concha L, 2007, EPILEPSIA, V48, P931, DOI 10.1111/j.1528-1167.2007.01006.x
   Concha L, 2012, NEUROLOGY, V79, P455, DOI 10.1212/WNL.0b013e31826170b6
   Diehl B, 2008, EPILEPSIA, V49, P1409, DOI 10.1111/j.1528-1167.2008.01596.x
   Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008
   Engel J, 2001, NEUROSCIENTIST, V7, P340, DOI 10.1177/107385840100700410
   Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001
   Focke NK, 2008, NEUROIMAGE, V40, P728, DOI 10.1016/j.neuroimage.2007.12.031
   Govindan RM, 2008, EPILEPSY RES, V80, P30, DOI 10.1016/j.eplepsyres.2008.03.011
   Gross DW, 2011, EPILEPSIA, V52, P32, DOI 10.1111/j.1528-1167.2011.03149.x
   Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015
   Keller SS, 2013, J NEUROIMAGING, V23, P352, DOI 10.1111/j.1552-6569.2011.00673.x
   Lin JJ, 2008, EPILEPSY RES, V82, P162, DOI 10.1016/j.eplepsyres.2008.07.020
   Liu M, 2012, NEUROIMAGE-CLIN, V1, P99, DOI 10.1016/j.nicl.2012.09.010
   LIU Z, 1995, PEDIATR NEUROL, V12, P5, DOI 10.1016/0887-8994(94)00122-I
   Otte WM, 2012, EPILEPSIA, V53, P659, DOI 10.1111/j.1528-1167.2012.03426.x
   Pail M, 2010, EPILEPSIA, V51, P511, DOI 10.1111/j.1528-1167.2009.02324.x
   Pustina D, 2015, NEUROIMAGE-CLIN, V9, P20, DOI 10.1016/j.nicl.2015.07.010
   Rodrigo S, 2007, EUR RADIOL, V17, P1663, DOI 10.1007/s00330-006-0558-x
   Rodriguez-Cruces R, 2015, QUANT IMAGING MED SU, V5, P264, DOI 10.3978/j.issn.2223-4292.2015.02.06
   Scanlon C, 2013, J NEUROL, V260, P2320, DOI 10.1007/s00415-013-6974-3
   Spencer SS, 2005, NEUROLOGY, V65, P912, DOI 10.1212/01.wnl.0000176055.45774.71
   Tae WS, 2005, NEUROIMAGE, V24, P101, DOI 10.1016/j.neuroimage.2004.08.005
   Tellez-Zenteno Jose F, 2012, Epilepsy Res Treat, V2012, P630853, DOI 10.1155/2012/630853
   Thivard L, 2005, NEUROIMAGE, V28, P682, DOI 10.1016/j.neuroimage.2005.06.045
   Torres CV, 2015, REV NEUROLOGIA, V61, P241, DOI 10.33588/rn.6106.2015144
   Yamada K, 2009, MAGN RESON MED SCI, V8, P165, DOI 10.2463/mrms.8.165
   Yogarajah M, 2008, NEUROIMAGE, V40, P1755, DOI 10.1016/j.neuroimage.2007.12.046
NR 36
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E700
EP E708
DI 10.1016/j.wneu.2019.04.238
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100083
PM 31059852
DA 2020-05-12
ER

PT J
AU Ghabach, MB
   Mhanna, NE
   Abou Al Ezz, MR
   Mezher, GN
   Chammas, MJ
   Ghabach, MM
AF Ghabach, Maroun B.
   Mhanna, Nakhle E.
   Abou Al Ezz, Morad R.
   Mezher, Georges N.
   Chammas, Monique J.
   Ghabach, Marc M.
TI Comparison of Effects of Hemostatic Gelatin Sponge Impregnated with
   Ropivacaine versus Normal Saline Applied on the Transverse Process of
   the Operated Vertebrae on Postoperative Pain in Patients Undergoing
   Spinal Instrumentation Surgery: A Randomized Clinical Trial
SO WORLD NEUROSURGERY
LA English
DT Article
DE Posterior rami spinal nerve; Postoperative pain; Ropivacaine; Spinal
   instrumentation
ID ANALGESIA; MANAGEMENT; MORPHINE
AB BACKGROUND: Protocols for effective postoperative pain control in patients undergoing spinal surgery are not standardized. In our study, we compared the effects of hemostatic absorbable gelatin sponge impregnated with ropivacaine versus normal saline when applied to the transverse process of the operated vertebrae on the postoperative pain following instrumentation spine surgery.
   METHODS: A prospective double-blind randomized study was conducted on 30 patients undergoing spine surgery. At the end of surgery, the hemostatic gelatin sponge was applied by the surgeon on the transverse process of the operated vertebra containing either ropivacaine 0.5% or normal saline NaCl 0.9. Pain was assessed using the visual analog scale (VAS) every 4 hours for 48 hours postoperatively in the 2 groups (ropivacaine vs. normal saline). The total amount of postoperative opioid use was also recorded.
   RESULTS: The VAS score was significantly lower in patients receiving hemostatic gelatin sponge impregnated with local anesthetics as compared with patients receiving gelatin sponge impregnated with normal saline 48 hours postoperatively; the mean total dose of meperidine given in the first 48 hours postoperatively was significantly lower (53.5 +/- 51.0 mg) in patients receiving gelatin sponge impregnated with local anesthetics as compared with patients receiving hemostatic gelatin sponge impregnated with normal saline (140.5 +/- 102 mg).
   CONCLUSIONS: Use of intraoperative hemostatic gelatin sponge impregnated with ropivacaine applied on the transverse process of the operated vertebrae intraoperatively resulted in decreasing the postoperative pain in patients undergoing lumbar instrumentation surgery as manifested by the decrease in the VAS score and the total dose of opioids.
C1 [Ghabach, Maroun B.; Mezher, Georges N.; Chammas, Monique J.] Rosary Sisters Hosp, Dept Anesthesiol, Beirut, Lebanon.
   [Mhanna, Nakhle E.; Abou Al Ezz, Morad R.] Rosary Sisters Hosp, Dept Orthoped Surg & Traumatol, Beirut, Lebanon.
   [Ghabach, Marc M.] Amer Univ Beirut, Fac Med, Beirut, Lebanon.
RP Ghabach, MB (reprint author), Rosary Sisters Hosp, Dept Anesthesiol, Beirut, Lebanon.
EM maroun_ghabash@yahoo.com
CR Altun I, 2016, NEURAL REGEN RES, V11, P842, DOI 10.4103/1673-5374.177150
   Axelsson K, 2005, ACTA ANAESTH SCAND, V49, P1191, DOI 10.1111/j.1399-6576.2005.00715.x
   Bajwa SJS, 2015, J CRANIOVERTEBRAL JU, V6, P105, DOI 10.4103/0974-8237.161589
   Barletta JF, 2011, ANN PHARMACOTHER, V45, P916, DOI 10.1345/aph.1Q041
   Bianconi M, 2004, ANESTH ANALG, V98, P166, DOI 10.1213/01.ANE.0000093310.47375.44
   BOGDUK N, 1979, J NEUROSURG, V51, P172, DOI 10.3171/jns.1979.51.2.0172
   Du JP, 2018, WORLD NEUROSURG, V114, pE1168, DOI 10.1016/j.wneu.2018.03.170
   Garimella V, 2013, CLIN COLON RECT SURG, V26, P191, DOI 10.1055/s-0033-1351138
   Goettsch WG, 2007, PHARMACOEPIDEM DR S, V16, P668, DOI 10.1002/pds.1338
   Hesselgard K, 2006, PEDIATR ANESTH, V16, P436, DOI 10.1111/j.1460-9592.2005.01804.x
   Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62
   MAIGNE JY, 1989, SURG RADIOL ANAT, V11, P289, DOI 10.1007/BF02098698
   MAIGNE R, 1980, ARCH PHYS MED REHAB, V61, P389
   Mann C, 2000, ANESTHESIOLOGY, V92, P433, DOI 10.1097/00000542-200002000-00025
   Marret E, 2007, BRIT J SURG, V94, P665, DOI 10.1002/bjs.5825
   Mathiesen O, 2013, EUR SPINE J, V22, P2089, DOI 10.1007/s00586-013-2826-1
   Murata Y, 2009, SPINE, V34, P2008, DOI 10.1097/BRS.0b013e3181b1fb96
   Porreca F, 2009, PAIN MED, V10, P654, DOI 10.1111/j.1526-4637.2009.00583.x
   Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493
   Steinke H, 2009, ANN ANAT, V191, P408, DOI 10.1016/j.aanat.2009.04.002
   Tan MJ, 2015, CAN J ANESTH, V62, P203, DOI 10.1007/s12630-014-0275-x
   Wick EC, 2017, JAMA SURG, V152, P691, DOI 10.1001/jamasurg.2017.0898
NR 22
TC 0
Z9 0
U1 5
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1126
EP E1130
DI 10.1016/j.wneu.2019.05.101
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100129
PM 31121375
DA 2020-05-12
ER

PT J
AU Girardo, M
   Zenga, F
   Bruno, LL
   Rava, A
   Masse, A
   Maule, M
   Fusini, F
AF Girardo, Massimo
   Zenga, Francesco
   Bruno, Laura Lorien
   Rava, Alessandro
   Masse, Alessandro
   Maule, Milena
   Fusini, Federico
TI Treatment of Aggressive Vertebral Hemangiomas with Poly Vinyl Alcohol
   (PVA) Microparticles Embolization, PMMA, and Short Segment
   Stabilization: Preliminary Results with at Least 5 Years of Follow-up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Decompression; Hemangioma; Pedicle screw; Poly-methyl-methacrylate;
   Poly-vinyl alcohol
ID PERCUTANEOUS VERTEBROPLASTY; CEMENT AUGMENTATION; ETHANOL EMBOLIZATION;
   SURGICAL-TREATMENT; PEDICLE SCREW; KYPHOPLASTY; MANAGEMENT;
   INSTRUMENTATION; DECOMPRESSION; FRACTURES
AB OBJECTIVE: Vertebral hemangiomas (VHs) are the most common incidental lesions of vertebral body, but they are very challenging to treat if they become symptomatic. Several treatments have been proposed hut none was superior to others. The aim of this study is to analyze blood loss and long-term clinical and neurological results of aggressive VHs treated with arterial embolization the day before operation, followed by vertebroplasty, posterior decompression, and short segment stabilization.
   METHODS: Ten patients (4 males and 6 females) were treated for aggressive VHs with polyvinyl alcohol microparticles embolization, posterior short segment stabilization, and poly methyl methacrylate. Clinical and neurological outcomes were assessed with visual analog, Nurick, and American Spinal Injury Association (ASIA) scales.
   RESULTS: At last follow-up mean, visual analog scale was 1.8 +/- 1.3, with a significant difference with preoperative values (P = 0.00018). Neurological deficits persisted in 4 patients (ASIA scale: C in 1 patient [10%], D in 3 patients [30%]), but they improved from baseline in all cases. Also, Nurick scale rating improved in all patients (0 in 3 patients [30%], 1 in 4 patients [40%], 2 in 2 patients [20%], and 3 in the last one [10%]). A statistically significant difference between pre- and postoperative values was observed for both scores (ASIA, P = 0.0102; Nurick, P = 0.026). Relapse of pathology was recorded in 2 patients.
   CONCLUSIONS: Polyvinyl alcohol microparticles embolization, short segment fixation, and vertebroplasty is an effective treatment option for aggressive VHs, with a fast surgical time, poor blood loss, and improvement of preoperative clinical and neurological outcomes.
C1 [Girardo, Massimo; Bruno, Laura Lorien] Univ Turin, Spine Surg Unit, Orthopaed & Trauma Ctr, Citta Salute & Sci Torino, Turin, Italy.
   [Zenga, Francesco] Molinette Mauriziano Hosp, Citta Salute & Sci Torino, Dept Neurosurg, Turin, Italy.
   [Rava, Alessandro; Masse, Alessandro; Fusini, Federico] Univ Turin, Citta Salute & Sci Torino, Dept Orthopaed & Traumatol, Orthopaed & Trauma Ctr, Turin, Italy.
   [Maule, Milena] Univ Turin, Dept Med Sci, Canc Epidemiol Unit, Turin, Italy.
RP Rava, A (reprint author), Univ Turin, Citta Salute & Sci Torino, Dept Orthopaed & Traumatol, Orthopaed & Trauma Ctr, Turin, Italy.
EM dralessandrorava@gmail.com
RI Massimo, Girardo/AAI-5052-2020; Fusini, Federico/AAE-8693-2019
OI Rava, Alessandro/0000-0001-6985-1442; Girardo,
   Massimo/0000-0002-6538-9294; Fusini, Federico/0000-0002-4223-8485
CR Adeolu AA, 2015, WORLD NEUROSURG, V84, P1090, DOI 10.1016/j.wneu.2015.05.081
   Amoretti N, 2018, EUR J RADIOL, V104, P38, DOI 10.1016/j.ejrad.2018.04.010
   Asthana A K, 1990, Clin Oncol (R Coll Radiol), V2, P159, DOI 10.1016/S0936-6555(05)80151-7
   Bandiera S, 2002, Chir Organi Mov, V87, P1
   Bas T, 2001, SPINE, V26, P1577, DOI 10.1097/00007632-200107150-00015
   Chandra SP, 2019, SPINE J, V19, P131, DOI 10.1016/j.spinee.2018.05.015
   Cianfoni A, 2014, J NEURORADIOLOGY, V41, P269, DOI 10.1016/j.neurad.2012.10.003
   Clark AJ, 2010, WORLD NEUROSURG, V74, P200, DOI 10.1016/j.wneu.2010.03.016
   Doppman JL, 2000, RADIOLOGY, V214, P341, DOI 10.1148/radiology.214.2.r00fe46341
   Gargiulo G, 2019, Eur J Orthop Surg Traumatol, V29, P975, DOI 10.1007/s00590-019-02395-6
   Girardo M, 2018, EUR SPINE J, V27, P198, DOI 10.1007/s00586-018-5624-y
   Girardo M, 2017, EUR SPINE J, V26, P546, DOI 10.1007/s00586-017-5037-3
   Girardo Rava A, 2019, J CRANIOVERTEBR JUNC, V9, P254
   Goel SA, 2018, INDIAN J ORTHOP, V52, P578, DOI 10.4103/ortho.IJOrtho_380_17
   Hu W, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012775
   Jankowski R, 2011, NEUROL NEUROCHIR POL, V45, P577, DOI 10.1016/S0028-3843(14)60125-0
   Jayakumar PN, 1997, SPINAL CORD, V35, P624, DOI 10.1038/sj.sc.3100438
   Lamy O, 2014, OSTEOPOROSIS INT, V25, P807, DOI 10.1007/s00198-013-2574-4
   Lavelle William F, 2006, Spine J, V6, P488, DOI 10.1016/j.spinee.2005.10.013
   Li H, 2017, MED SCI MONITOR, V23, P5271, DOI 10.12659/MSM.907364
   Liu XW, 2013, EUR RADIOL, V23, P2575, DOI 10.1007/s00330-013-2843-9
   Moore JM, 2012, J CLIN NEUROSCI, V19, P1291, DOI 10.1016/j.jocn.2011.12.012
   Moussazadeh N, 2015, SPINE J, V15, P1609, DOI 10.1016/j.spinee.2015.03.037
   Omidi-Kashani F, 2013, INDIAN J ORTHOP, V47, P234, DOI 10.4103/0019-5413.111498
   Polikeit A, 2003, SPINE, V28, P991, DOI 10.1097/00007632-200305150-00006
   Prabhakar H, 2011, NEUROSURGERY, V69, pE502, DOI 10.1227/NEU.0b013e3182198512
   Premat K, 2017, EUR RADIOL, V27, P2860, DOI 10.1007/s00330-016-4664-0
   QUISLING RG, 1984, AM J NEURORADIOL, V5, P101
   Rimon U, 2006, AM J ROENTGENOL, V187, P762, DOI 10.2214/AJR.05.0629
   Saliou G, 2017, NEUROCHIRURGIE, V63, P372, DOI 10.1016/j.neuchi.2016.01.004
   Singh P, 2011, NEUROSURGERY, V68, P78, DOI 10.1227/NEU.0b013e3181fc60e9
   Thakur NA, 2012, J AM ACAD ORTHOP SUR, V20, P715, DOI 10.5435/JAAOS-20-11-715
   Vaidya Sandeep, 2008, Semin Intervent Radiol, V25, P204, DOI 10.1055/s-0028-1085930
   Vasudeva VS, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16169
   Villarraga ML, 2005, J SPINAL DISORD TECH, V18, P84, DOI 10.1097/01.bsd.0000138694.56012.ce
   Wang B, 2018, SPINE J, V18, P1128, DOI 10.1016/j.spinee.2017.11.003
   Yadav N, 2010, J CLIN NEUROSCI, V17, P810, DOI 10.1016/j.jocn.2009.10.027
   Yaltirik K, 2016, J CRANIOVERTEBRAL JU, V7, P153, DOI 10.4103/0974-8237.188413
   Yim KL, 2012, ANTICANCER RES, V32, P4597
NR 39
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E283
EP E288
DI 10.1016/j.wneu.2019.04.138
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100032
PM 31028979
DA 2020-05-12
ER

PT J
AU Greif, DN
   Ghasem, A
   Butler, A
   Rivera, S
   Al Maaieh, M
   Conway, SA
AF Greif, Dylan N.
   Ghasem, Alexander
   Butler, Alexander
   Rivera, Sebastian
   Al Maaieh, Motasem
   Conway, Sheila Ann
TI Multidisciplinary Management of Spinal Metastasis and Vertebral
   Instability: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Combination therapy; Kyphoplasty; Radiation; Radiofrequency ablation;
   Radiosurgery; Spinal metastasis; Vertebroplasty
ID PERCUTANEOUS VERTEBROPLASTY; RADIOFREQUENCY ABLATION; BONE METASTASES;
   KYPHOPLASTY; RADIOTHERAPY; COMBINATION; EFFICACY; TUMORS; CEMENTOPLASTY;
   AUGMENTATION
AB OBJECTIVE: The aim of this systematic literature review is to evaluate recent attempts in creating a standardized multidisciplinary approach combining tumor treatment with current vertebral stabilization techniques for palliative treatment of vertebral metastasis in patients who do not fall into the NOMS (neurologic, oncologic, mechanical, systemic) framework.
   METHODS: We performed a systematic literature search for studies using a tumor modality in conjunction with kyphoplasty or vertebroplasty. In addition, the bibliographies of selected articles were examined for additional studies not viewed in database searches, which led to the use of additional search terms.
   RESULTS: A total of 563 articles were found after our database search. Eighteen studies fulfilled our inclusion criteria. Articles were then divided into categories based on combinations of tumor modality. Multiple studies reported significant decreases in visual analog scale scores after combined procedures with very low rates of symptomatic complications. Studies that compared their combination with control treatment groups showed greater clinical efficacy.
   CONCLUSIONS: Although multidisciplinary management of spinal metastasis using a combination of tumor ablation techniques with vertebral stabilization has been recommended in the previous literature, this review shows that no combination of treatment carried demonstrably different results in pain score reduction, reduced analgesic intake, or improved quality of life. In addition, there is no consensus of standardized variables to evaluate efficacy of treatment, limiting the efficacy of treatment results for the analyzed studies. Although not explicitly included in the initial NOMS framework, our results support the consideration of concomitant percutaneous kyphoplasty or vertebroplasty in these patients on a case-by-case basis.
C1 [Greif, Dylan N.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Ghasem, Alexander; Butler, Alexander; Rivera, Sebastian; Al Maaieh, Motasem] Univ Miami, Dept Orthopaed Surg, Miami, FL USA.
   [Conway, Sheila Ann] Univ Miami, Miller Sch Med, Div Orthopaed Oncol, Orthopaed Surg Residency Program, Univ Miami Hosp Operating Room, Miami, FL 33136 USA.
   [Conway, Sheila Ann] Univ Miami, Miller Sch Med, Musculoskeletal Oncol Fellowship Program, Univ Miami Hosp Operating Room, Miami, FL 33136 USA.
RP Greif, DN (reprint author), Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
EM d.greif@med.miami.edu
OI Butler, Alexander/0000-0003-4135-7391
CR Ashamalla H, 2009, INT J RADIAT ONCOL, V75, P836, DOI 10.1016/j.ijrobp.2008.11.060
   Barzilai O, 2018, J NEUROSURG-SPINE, V28, P72, DOI 10.3171/2017.5.SPINE1746
   Burgard CA, 2018, DIAGN INTERV RADIOL, V24, P158, DOI 10.5152/dir.2018.17265
   Cardoso ER, 2009, J NEUROSURG-SPINE, V10, P336, DOI 10.3171/2008.11.SPINE0856
   Chen F, 2016, ONCOL LETT, V11, P1799, DOI 10.3892/ol.2016.4121
   Cheung G, 2006, CAN ASSOC RADIOL J, V57, P13
   Coleman R E, 2000, Oncologist, V5, P463, DOI 10.1634/theoncologist.5-6-463
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931
   Feng Shi, 2015, Medicine (Baltimore), V94, pe1253, DOI 10.1097/MD.0000000000001253
   Gerszten PC, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.9.FOCUS09184
   Hoffmann RT, 2008, J VASC INTERV RADIOL, V19, P419, DOI 10.1016/j.jvir.2007.09.016
   Huang M, 2016, ASIA-PAC J CLIN ONCO, V12, pE201, DOI 10.1111/ajco.12162
   Jang JS, 2005, J NEUROSURG-SPINE, V2, P243, DOI 10.3171/spi.2005.2.3.0243
   Jawad MS, 2016, J NEUROSURG-SPINE, V24, P928, DOI 10.3171/2015.10.SPINE141261
   Klimo P, 2004, NEUROSURG CLIN N AM, V15, P549, DOI 10.1016/j.nec.2004.04.016
   Lane MD, 2011, SKELETAL RADIOL, V40, P25, DOI 10.1007/s00256-010-1010-5
   Laufer I, 2013, ONCOLOGIST, V18, P744, DOI 10.1634/theoncologist.2012-0293
   Laufer I, 2012, CANCER CONTROL, V19, P122, DOI 10.1177/107327481201900206
   Li Y, 2015, ONCOTARGETS THER, V8, P2139, DOI 10.2147/OTT.S86270
   Madaelil TP, 2016, SKELETAL RADIOL, V45, P1213, DOI 10.1007/s00256-016-2404-9
   Mannion RJ, 2000, CLIN J PAIN, V16, pS144
   Munk PL, 2009, J VASC INTERV RADIOL, V20, P903, DOI 10.1016/j.jvir.2009.03.035
   Rogers CL, 2002, INT J RADIAT ONCOL, V54, P505, DOI 10.1016/S0360-3016(02)02961-9
   Rose PS, 2009, J CLIN ONCOL, V27, P5075, DOI 10.1200/JCO.2008.19.3508
   Ryu S, 2015, RADIAT ONCOL J, V33, P1, DOI 10.3857/roj.2015.33.1.1
   Ryu S, 2010, CANCER-AM CANCER SOC, V116, P2250, DOI 10.1002/cncr.24993
   Schmidt R, 2012, INT ORTHOP, V36, P1255, DOI 10.1007/s00264-011-1470-9
   Stephenson MB, 2016, CURR TREAT OPTION ON, V17, DOI 10.1007/s11864-016-0433-1
   Sung Sang-Hyun, 2014, Korean J Spine, V11, P103, DOI 10.14245/kjs.2014.11.3.103
   Tharmalingam Sukirtha, 2008, J Pain Res, V1, P49
   Toyota N, 2005, CARDIOVASC INTER RAD, V28, P578, DOI 10.1007/s00270-004-0208-0
   Wallace AN, 2015, J NEURO-ONCOL, V124, P111, DOI 10.1007/s11060-015-1813-2
   Wang XS, 2012, LANCET ONCOL, V13, P395, DOI 10.1016/S1470-2045(11)70384-9
   Wang Z, 2015, ONCOTARGETS THER, V9, P7
   Yaltirik K, 2016, J CRANIOVERTEBRAL JU, V7, P153, DOI 10.4103/0974-8237.188413
   Yang ZZ, 2013, CANCER BIOTHER RADIO, V28, P58, DOI 10.1089/cbr.2012.1204
   Yang ZZ, 2009, ACTA RADIOL, V50, P1142, DOI 10.3109/02841850903229133
   Zheng LP, 2014, MED SCI MONITOR, V20, P556, DOI 10.12659/MSM.889742
NR 38
TC 3
Z9 3
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E944
EP E955
DI 10.1016/j.wneu.2019.05.042
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100112
PM 31100530
DA 2020-05-12
ER

PT J
AU Gritti, P
   Zangari, R
   Carobbio, A
   Zucchi, A
   Lorini, FL
   Ferri, F
   Agostinis, C
   Lanterna, LA
   Brembilla, C
   Foresti, C
   Barbui, T
   Biroli, F
AF Gritti, Paolo
   Zangari, Rosalia
   Carobbio, Alessandra
   Zucchi, Alberto
   Lorini, Ferdinando Luca
   Ferri, Francesco
   Agostinis, Cristina
   Lanterna, Luigi Andrea
   Brembilla, Carlo
   Foresti, Camillo
   Barbui, Tiziano
   Biroli, Francesco
TI Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic
   Brain Injury: A Retrospective Monocentric Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Increasing age; Moderate and severe TBI; Outcome predictive factors
   (acute and subacute); Oxford Handicap Scale (OHS)
ID POSTTRAUMATIC CEREBRAL INFARCTION; COMA DATA-BANK; HEAD-INJURY;
   DECOMPRESSIVE CRANIECTOMY; EXTERNAL VALIDATION; PROGNOSTIC MODELS;
   IMPACT; CLASSIFICATION; CARE; GUIDELINES
AB BACKGROUND: Prognostic factors affecting outcome of traumatic brain injury (TBI), despite their importance, are still under discussion. The purpose of this study was to describe risk factors of in-hospital mortality and outcome at 1 year in a homogeneously treated population of patients with moderate/severe TBI.
   METHODS: A total of 193 consecutive patients with moderate or severe TBI (Glasgow Coma Scale [GCS] score 13-3, including patients with initial GCS score of 13 at high risk for subsequent neurologic deterioration), admitted to the intensive care unit, were retrospectively analyzed. Inhospital mortality and unfavorable outcome at 1 year, based on a Glasgow Outcome Scale-Extended score <= 4, were considered as primary and secondary outcomes.
   RESULTS: At 1 year, unfavorable outcome occurred in 47.2%, including an in-hospital mortality of 19.7%. Increasing age, GCS motor score <3, coagulation disorders, and intracranial hypertension were acute risk factors of inhospital mortality. In the 155 remaining survivors, Oxford Handicap Scale (OHS), posttraumatic cerebral infarction, cerebrospinal fluid disturbances, and length of intensive care unit stay were associated with unfavorable outcome at 1 year, in univariate analysis. A cutoff OHS score >= 3 discriminated the probability of an unfavorable outcome (area under the curve, 0.87; P < 0.001; specificity, 74%; sensitivity, 84%). Combining the effect of acute and subacute variables in a multivariate analysis, increasing age and OHS score were independent predictors of outcome.
   CONCLUSIONS: The results of this retrospective study confirmed age as the main acute risk factor and identified OHS as new potential subacute predictor of unfavorable outcome in moderate and severe TBI.
C1 [Gritti, Paolo; Lorini, Ferdinando Luca; Ferri, Francesco] Papa Giovanni XXIII Hosp, Dept Anesthesia & Crit Care Med, Bergamo, Italy.
   [Zangari, Rosalia; Carobbio, Alessandra; Barbui, Tiziano; Biroli, Francesco] Papa Giovanni XXIII Hosp, FROM Res Fdn, Bergamo, Italy.
   [Zucchi, Alberto] Epidemiol Unit, Local Hlth Author ASL, Bergamo, Italy.
   [Agostinis, Cristina] Papa Giovanni XXIII Hosp, Dept Neuroradiol, Bergamo, Italy.
   [Lanterna, Luigi Andrea; Brembilla, Carlo] Papa Giovanni XXIII Hosp, Dept Neurosurg, Bergamo, Italy.
   [Foresti, Camillo] Papa Giovanni XXIII Hosp, Dept Neuropathophysiol, Bergamo, Italy.
RP Biroli, F (reprint author), Papa Giovanni XXIII Hosp, FROM Res Fdn, Bergamo, Italy.
EM fbiroli@fondazionefrom.it
RI Carobbio, Alessandra/G-8407-2016
OI Carobbio, Alessandra/0000-0001-9664-7084; lorini, luca
   ferdinando/0000-0002-2711-3377
FU "Associazione Amici Traumatizzati Cranici" di Bergamo; Fondazione per la
   Comunita Bergamasca Onlus
FX We are most grateful to the collaborators: Drs. M. Marchesi and E.
   Bonanomi, Department of Anaesthesia and Critical Care Medicine; Dr. O.
   Valoti, Emergency Department; Dr. G. Molinero, Department of
   Rehabilitation; Dr. G. Bonaldi, Department of Neuroradiology; Dr. C.
   Bernucci, Department of Neurosurgery; and Dr. S. Magnone and F.
   Martorana, Department of General Surgery. We would like to thank Dr. A.
   Biroli (Neurosurgical Department, ASST Spedali Civili, Brescia, Italy)
   and Dr. P.L Carriero (FROM Research Foundation, Papa Giovanni XXIII
   Hospital) for carefully editing the manuscript. We would like to thank
   Dr. E. Capitoni and Dr. E. Sfreddo (FROM Research Foundation, Papa
   Giovanni XXIII Hospital) for excellent advice and suggestions. We also
   thank "Associazione Amici Traumatizzati Cranici" di Bergamo and
   "Fondazione per la Comunita Bergamasca Onlus" for the generous support.
CR Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034
   Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052
   BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16
   BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828
   Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f
   Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37
   Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55
   Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998
   Caterino JM, 2010, AM J EMERG MED, V28, P151, DOI 10.1016/j.ajem.2008.10.027
   Chambers IR, 2006, ACTA NEUROCHIR SUPPL, V96, P7
   Citerio G, 2007, INTENS CARE MED, V33, P45, DOI 10.1007/s00134-006-0381-5
   Duff D, 2001, Axone, V23, P18
   Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029
   Franschman G, 2012, J NEUROTRAUM, V29, P128, DOI 10.1089/neu.2011.2044
   Gardner RC, 2018, J NEUROTRAUM, V35, P889, DOI 10.1089/neu.2017.5371
   GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Kaen A, 2010, J NEUROSURG, V113, P1287, DOI 10.3171/2010.4.JNS10132
   Karibe H, 2014, NEUROL MED-CHIR, V54, P887, DOI 10.2176/nmc.cr.2014-0204
   Kirkham FJ, 2008, DEV MED CHILD NEUROL, V50, P267, DOI 10.1111/j.1469-8749.2008.02042.x
   Latronico N, 2009, J TRAUMA, V66, P1745, DOI 10.1097/TA.0b013e3181a56c8b
   Le TH, 2006, SEMIN ROENTGENOL, V41, P177, DOI 10.1053/j.ro.2006.04.003
   LeGrand SA, 2007, J NEUROTRAUM, V24, P1437, DOI 10.1089/neu.2007.0293
   Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e
   Liu SW, 2015, ACTA NEUROCHIR, V157, P1697, DOI 10.1007/s00701-015-2559-5
   Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823
   Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024
   Majdan M, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/s13049-014-0068-9
   Marino R, 2006, NEUROLOGY, V67, P1165, DOI 10.1212/01.wnl.0000238081.35281.b5
   MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287
   MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276
   MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285
   MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14
   McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026
   McIntyre A, 2013, BRAIN INJURY, V27, P31, DOI 10.3109/02699052.2012.700086
   MIRVIS SE, 1990, AM J NEURORADIOL, V11, P355
   Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011
   Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028
   Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X
   Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25
   Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38
   Perel P, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-72
   Piper I, 2003, ACTA NEUROCHIR, V145, P615, DOI 10.1007/s00701-003-0066-6
   Rau CS, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14111378
   Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586
   Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609
   Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738
   Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7
   Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165
   Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9
   Suarez JI, 2004, CRIT CARE MED, V32, P2311, DOI 10.1097/01.CCM.0000146132.29042.4c
   Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519
   Tawil I, 2008, J TRAUMA, V64, P849, DOI 10.1097/TA.0b013e318160c08a
   Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713
   Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573
   Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910
NR 56
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E531
EP E540
DI 10.1016/j.wneu.2019.04.190
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100062
PM 31048051
DA 2020-05-12
ER

PT J
AU Gu, Y
   Zhou, Q
   Zhu, W
   Wu, Q
   Xie, T
   Wu, SL
   Hu, F
   Yu, Y
   Sun, CJ
   Li, C
   Zhang, B
   Zhan, LP
   Zhang, XB
AF Gu, Ye
   Zhou, Quan
   Zhu, Wei
   Wu, Qi
   Xie, Tao
   Wu, Silin
   Hu, Fan
   Yu, Yong
   Sun, Chongjing
   Li, Chen
   Zhang, Bo
   Zhan, Liping
   Zhang, Xiaobiao
TI The Purely Endoscopic Supracerebellar Infratentorial Approach for
   Resecting Pineal Region Tumors with Preservation of
   Cerebellomesencephalic Vein: Technical Note and Preliminary Clinical
   Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebellomesencephalic vein; Endoscopy; Pineal region; Supracerebellar
   infratentorial approach
ID MICROSURGICAL ANATOMY; GALEN
AB BACKGROUND: The cerebellomesencephalic vein (CMV) was frequently sacrificed in surgery approached via the supracerebellar infratentorial (SCIT) route for resecting pineal region tumors, which resulted in potential risk of neurologic deficit. Preserving the CMV in the SCIT approach could enhance the safety and effectiveness of this natural corridor surgery. The aim of this article was to identify the probability and safety of preserving the CMV through the application of neuroendoscopy in the SCIT approach.
   METHODS: Clinical data of patients who underwent pineal region tumor resection through a purely endoscopic SCIT approach were retrospectively analyzed, focusing on surgical techniques and clinical outcomes.
   RESULTS: The study included 8 patients with pineal region tumors. The CMV was preserved intact in all patients. Total tumor removal was achieved in 7 of 8 patients. In 1 patient with 2 tumors in the pineal region and roof of the third ventricle, the tumor in the pineal region was resected completely, followed by subsequent chemotherapy combined with radiotherapy, after which the other tumor disappeared totally. All patients recovered normally with uneventful postoperative outcomes.
   CONCLUSIONS: The advantage of close observation and panoramic view provided by neuroendoscopy combined with meticulous manipulation improved the ability to preserve the CMV in resecting pineal region tumors via the SCIT approach. The neuroendoscopic technique enhances the safety and efficacy of the SCIT approach.
C1 [Gu, Ye; Zhu, Wei; Xie, Tao; Wu, Silin; Hu, Fan; Yu, Yong; Sun, Chongjing; Li, Chen; Zhang, Xiaobiao] Fudan Univ, Zhongshan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Gu, Ye; Hu, Fan; Zhang, Xiaobiao] Fudan Univ, Shanghai Med Coll, Shanghai Key Lab Med Image Comp & Comp Assisted I, Shanghai, Peoples R China.
   [Wu, Qi; Zhan, Liping] Zhenjiang First Peoples Hosp, Dept Neurosurg, Zhenjiang, Jiangsu, Peoples R China.
   [Zhang, Bo] Guiyang Coll Tradit Chinese Med, Affiliated Hosp 1, Guiyang, Guizhou, Peoples R China.
   [Zhou, Quan] Guangxi Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanning, Peoples R China.
RP Zhang, XB (reprint author), Fudan Univ, Zhongshan Hosp, Dept Neurosurg, Shanghai, Peoples R China.; Zhang, XB (reprint author), Fudan Univ, Shanghai Med Coll, Shanghai Key Lab Med Image Comp & Comp Assisted I, Shanghai, Peoples R China.
EM xiaobiao_zhang@163.com
FU Foundation of China Ministry of Science and Technology [2016YFC0106103];
   Foundation of Science and Technology Commission of Shanghai
   MunicipalityScience & Technology Commission of Shanghai Municipality
   (STCSM) [16DZ0500302]
FX This work was supported by Foundation of China Ministry of Science and
   Technology (Grant No. 2016YFC0106103) and Foundation of Science and
   Technology Commission of Shanghai Municipality (16DZ0500302).
CR BRUCE JN, 1995, ACTA NEUROCHIR, V134, P130, DOI 10.1007/BF01417679
   Chaussemy D, 2015, NEUROCHIRURGIE, V61, P160, DOI 10.1016/j.neuchi.2015.03.001
   Chaynes P, 2003, J NEUROSURG, V99, P1028, DOI 10.3171/jns.2003.99.6.1028
   Giordano M, 2009, NEUROSURGERY, V64, P247, DOI 10.1227/01.NEU.0000340782.46602.64
   Gore Pankaj A, 2008, Neurosurgery, V62, P108, DOI 10.1227/01.neu.0000317380.60938.79
   Gu Y, 2016, ACTA NEUROCHIR, V158, P2155, DOI 10.1007/s00701-016-2895-0
   Gu Y, 2015, J NEUROSURG, V122, P1166, DOI 10.3171/2015.1.JNS132842
   Hart MG, 2013, ACTA NEUROCHIR, V155, P463, DOI 10.1007/s00701-012-1589-5
   HOPKINS LN, 1975, J NEUROL NEUROSUR PS, V38, P816, DOI 10.1136/jnnp.38.8.816
   HUANG YP, 1965, AMER J ROENTGENOL RA, V95, P808, DOI 10.2214/ajr.95.4.808
   Jakola AS, 2013, ACTA NEUROCHIR, V155, P477, DOI 10.1007/s00701-012-1614-8
   Kanno T, 1995, MINIM INVAS NEUROSUR, V38, P153, DOI 10.1055/s-2008-1053476
   Kilic T, 2005, EUR J RADIOL, V56, P212, DOI 10.1016/j.ejrad.2005.05.003
   Kodera T, 2011, J CLIN NEUROSCI, V18, P1481, DOI 10.1016/j.jocn.2011.02.035
   Krause F, 1926, ZENTRALBLATT CHIRURG, V53, P2812
   Mamelak AN, 2012, J CLIN NEUROSCI, V19, P306, DOI 10.1016/j.jocn.2011.07.014
   Matsuo S, 2017, J NEUROSURG, V126, P1984, DOI 10.3171/2016.7.JNS16277
   Matsushima K, 2016, J NEUROSURG, V124, P248, DOI 10.3171/2015.2.JNS142707
   Mizukami M, 1970, Keio J Med, V19, P195
   Mottolese C, 2015, NEUROCHIRURGIE, V61, P176, DOI 10.1016/j.neuchi.2014.02.004
   Nayar VV, 2010, J NEUROSURG, V113, P1000, DOI 10.3171/2010.3.JNS09987
   Page L K, 1977, Neurosurgery, V1, P36
   Sonabend AM, 2016, J NEURO-ONCOL, V130, P351, DOI 10.1007/s11060-016-2138-5
   Song JP, 2019, OPER NEUROSURG, V16, P389, DOI 10.1093/ons/opy150
   STEIN BM, 1971, J NEUROSURG, V35, P197, DOI 10.3171/jns.1971.35.2.0197
   STEIN BM, 1979, SURG NEUROL, V11, P331
   YAMAMOTO I, 1980, J NEUROSURG, V53, P205, DOI 10.3171/jns.1980.53.2.0205
NR 27
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E334
EP E339
DI 10.1016/j.wneu.2019.04.146
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100038
PM 31028986
DA 2020-05-12
ER

PT J
AU Guo, CA
   Zhu, DW
   Kong, QQ
   Zhang, LF
   Wang, Y
   Yang, J
   Yan, YQ
   Wu, H
   Peng, ZY
AF Guo, Chuan
   Zhu, Daiwen
   Kong, Qingquan
   Zhang, Lifeng
   Wang, Yu
   Yang, Jin
   Yan, Yuqing
   Wu, Hao
   Peng, Zhiyu
TI Transforaminal Percutaneous Endoscopic Decompression for Lower Thoracic
   Spinal Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lower thoracic spinal stenosis; Percutaneous endoscopic technique;
   Sympathetic; Transforaminal
ID DISC HERNIATION; SURGICAL-TREATMENT; INTERVERTEBRAL-DISK; POSTERIOR
   APPROACH; SYMPATHETIC CHAIN; ARTERY SYNDROME; ANTERIOR; MYELOPATHY;
   SURGERY; OSSIFICATION
AB OBJECTIVE: To explore the effect and safety of transforaminal percutaneous endoscopic decompression for lower thoracic spinal stenosis.
   METHODS: We reviewed 6 patients receiving transforaminal percutaneous endoscopic thoracic decompression for sympathetic symptoms in the lower extremities. Pre- and postoperative Frankel grade and Japanese Orthopaedic Association scale (JOA) score, Oswestry Disability Index (ODI) score, and visual analog scale (VAS) scores of back and lower extremities were also evaluated and recorded. Wilcoxon signed-rank test was performed for statistical analysis.
   RESULTS: All 6 patients completed the follow-up. Mean follow-up was 12.6 months. Frankel grade in all patients improved to normal at the third month after operation. JOA scores significantly increased from 4.4 (range, 3.5-5.0) preoperatively to 5.5 (range, 5.0-6.5) postoperatively, to 6.5 (range, 6.0-7.0) at 3 months, to 6.6 (range, 6.2-7.0) at 6 months, and to 6.6 (range, 6.2-7.1) at 12 months (P < 0.05). ODI scores significantly decreased from 71.2 (range, 6578) preoperatively to 50.2 (range, 45-60) postoperatively, to 30.3 (range, 25-40) at 3 months, to 12.2 (range, 0-20) at 6 months, and to 10.2 (range, 0-15) at 12 months (P < 0.05). VAS back scores decreased from 7.8 (range, 7.0-9.0) preoperatively to 6.9 (range, 6.0-7.5) postoperatively, to 3.3 (range, 3.0-4.0) at 3 months, to 2.3 (range, 2.0-3.0) at 6 months, and to 1.9 (range, 1.5-3.0) at 12 months (P < 0.05). VAS lower extremity scores decreased from 8.7 (range, 8.0-9.0) preoperatively to 3.0 (range, 2.5-3.6) postoperatively, to 1.1 (range, 0.5-1.3) at 3 months, to 0.9 (range, 0.2-1.2) at 6 months, and to 0.3 (range, 0.1-1.0) at 12 months (P < 0.05). Four patients reported excellent results and 2 reported good results at the last follow-up.
   CONCLUSIONS: Percutaneous endoscopic transforaminal thoracic decompression is effective and safe in settling lower thoracic spinal stenosis.
C1 [Guo, Chuan; Zhu, Daiwen; Kong, Qingquan; Zhang, Lifeng; Wang, Yu; Yang, Jin; Yan, Yuqing; Wu, Hao; Peng, Zhiyu] Sichuan Univ, West China Hosp Med, West China Hosp, Dept Orthopaed, Chengdu, Sichuan, Peoples R China.
RP Kong, QQ (reprint author), Sichuan Univ, West China Hosp Med, West China Hosp, Dept Orthopaed, Chengdu, Sichuan, Peoples R China.
EM kqqspine@126.com
OI Wang, Yu/0000-0002-0939-5606
CR ABBOTT KH, 1956, NEUROLOGY, V6, P1
   Abramov R, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0403-x
   Almond LM, 2007, BRIT J NEUROSURG, V21, P32, DOI 10.1080/02688690601170650
   Anand N, 2002, SPINE, V27, P871, DOI 10.1097/00007632-200204150-00018
   ARCE CA, 1985, NEUROL CLIN, V3, P383, DOI 10.1016/S0733-8619(18)31043-0
   Arts MP, 2014, SPINE J, V14, P1654, DOI 10.1016/j.spinee.2013.09.053
   Bagley JH, 2014, J CLIN NEUROSCI, V21, P386, DOI 10.1016/j.jocn.2013.07.020
   BALAGUE F, 1989, CLIN RHEUMATOL, V8, P269, DOI 10.1007/BF02030085
   Benjamin V, 1983, Clin Neurosurg, V30, P577
   Bhandutia Amit K, 2017, JBJS Case Connect, V7, pe4, DOI 10.2106/JBJS.CC.16.00106
   BLUMENKOPF B, 1988, NEUROSURGERY, V23, P36, DOI 10.1227/00006123-198807000-00008
   Boschenstein F K, 1989, Clin Podiatr Med Surg, V6, P831
   Brauge D, 2017, WORLD NEUROSURG, V107, P744, DOI 10.1016/j.wneu.2017.08.100
   Choi KY, 2010, MINIM INVAS NEUROSUR, V53, P25, DOI 10.1055/s-0029-1246159
   COSCIA MF, 1993, ACTA ORTHOP SCAND, V64, P489, DOI 10.3109/17453679308993676
   Dimar John R 2nd, 2008, Am J Orthop (Belle Mead NJ), V37, P564
   Ding Wen-yuan, 2009, Orthop Surg, V1, P280, DOI 10.1111/j.1757-7861.2009.00048.x
   EPSTEIN NE, 1994, J SPINAL DISORD, V7, P259, DOI 10.1097/00002517-199407030-00011
   Gokcen HB, 2017, INT J SPINE SURG, V11, DOI 10.14444/4030
   Guest JD, 2000, INTERV NEURORADIOL, V6, P327, DOI 10.1177/159101990000600408
   HAMILTON MG, 1990, NEUROSURGERY, V27, P482, DOI 10.1227/00006123-199009000-00027
   Han S, 2018, WORLD NEUROSURG, V120, pE517, DOI 10.1016/j.wneu.2018.08.118
   Heckmann JG, 2016, NEUROHOSPITALIST, V6, P42, DOI 10.1177/1941874415588748
   Hrabalek L, 2010, ACTA CHIR ORTHOP TR, V77, P312
   Hubbe U, 2015, SPINE, V40, pE999, DOI 10.1097/BRS.0000000000001029
   HULME A, 1960, J NEUROL NEUROSUR PS, V23, P133, DOI 10.1136/jnnp.23.2.133
   Hwang JJ, 2013, SURG TODAY, V43, P397, DOI 10.1007/s00595-012-0246-1
   Jia ZQ, 2018, EUR SPINE J, V27, pS465, DOI 10.1007/s00586-018-5479-2
   Kerezoudis P, 2018, CLIN NEUROL NEUROSUR, V167, P17, DOI 10.1016/j.clineuro.2018.02.009
   KOJIMA T, 1994, NEUROSURGERY, V34, P854, DOI 10.1227/00006123-199405000-00010
   Kommuru H, 2014, J CLIN DIAGN RES, V8, pAC9, DOI 10.7860/JCDR/2014/9274.5246
   Krassioukov A, 2017, TOP SPINAL CORD INJ, V23, P1, DOI 10.1310/sci2301-1
   LaBan MM, 2007, AM J PHYS MED REHAB, V86, P601, DOI 10.1097/PHM.0b013e31806dd497
   Li Ka-Kin, 2002, Spine (Phila Pa 1976), V27, pE308, DOI 10.1097/00007632-200206150-00026
   Lim A, 2009, J CLIN NEUROSCI, V16, P1363, DOI 10.1016/j.jocn.2008.10.023
   Lyu RK, 1999, SPINE, V24, P416, DOI 10.1097/00007632-199902150-00025
   Maiman D J, 1988, J Spinal Disord, V1, P134
   MCAFEE PC, 1995, SPINE, V20, P1624, DOI 10.1097/00007632-199507150-00012
   McCormick WE, 2000, NEUROSURG FOCUS, V9, P1
   Moran C, 2012, SPINE, V37, pE1079, DOI 10.1097/BRS.0b013e3182574657
   NAYLOR A, 1954, BRIT MED J, V2, P570, DOI 10.1136/bmj.2.4887.570
   Nie HF, 2013, MINIM INVASIVE SURG, V2013, P1
   OKADA K, 1991, SPINE, V16, P280, DOI 10.1097/00007632-199103000-00005
   Onishi E, 2016, SPINE, V41, pE1356, DOI 10.1097/BRS.0000000000001622
   Oskouian RJ, 2002, NEUROSURGERY, V50, P103, DOI 10.1097/00006123-200201000-00018
   Ozturk Cagatay, 2006, Spine J, V6, P201, DOI 10.1016/j.spinee.2005.08.004
   Paholpak P, 2018, SPINE J, V18, P1122, DOI 10.1016/j.spinee.2017.11.004
   Palumbo MA, 2001, SPINE, V26, P558, DOI 10.1097/00007632-200103010-00021
   Papapostolou A, 2007, EUR J NEUROL, V14, pE5, DOI 10.1111/j.1468-1331.2007.01539.x
   Power K, 2016, PM&R, V8, pS305
   Reynolds JM, 2014, SPINE J, V14, pE17, DOI 10.1016/j.spinee.2013.10.050
   Roger EP, 2013, BRAIN BEHAV, V3, P207, DOI 10.1002/brb3.127
   Sheikh H, 2007, ORTHOP CLIN N AM, V38, P351, DOI 10.1016/j.ocl.2007.04.004
   Shirzadi A, 2013, COMMUN NUMER ANAL, V2013, P1
   Soliman HM, 2013, J SPINAL CORD MED, V36, P247, DOI 10.1179/2045772313Y.0000000111
   STONE JL, 1994, SPINE, V19, P1281, DOI 10.1097/00007632-199405310-00016
   Street E, 2016, ANN VASC SURG, V34, P243, DOI 10.1016/j.avsg.2016.04.001
   Tang RF, 2017, EUR SPINE J, V26, pS202, DOI 10.1007/s00586-017-5030-x
   Wagner R, 2016, WORLD NEUROSURG, V90, P194, DOI 10.1016/j.wneu.2016.02.086
   Wang Y, 2019, INT ORTHOP, V43, P939, DOI 10.1007/s00264-018-4210-6
   WELCH E, 1984, J VASC SURG, V1, P202, DOI 10.1067/mva.1984.avs0010202
   Yu LJ, 2018, ORTHOPADE, V47, P986, DOI 10.1007/s00132-018-3588-6
   Yuce I, 2018, J CLIN NEUROSCI, V58, P94, DOI 10.1016/j.jocn.2018.09.033
NR 63
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E504
EP E512
DI 10.1016/j.wneu.2019.04.186
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100059
PM 31051300
DA 2020-05-12
ER

PT J
AU Guo, X
   Qi, X
   Li, H
   Duan, ZX
   Wei, Y
   Zhang, F
   Tian, M
   Ma, L
   You, C
AF Guo, Xi
   Qi, Xin
   Li, Hao
   Duan, Zhongxin
   Wei, Yang
   Zhang, Fan
   Tian, Meng
   Ma, Lu
   You, Chao
TI Deferoxamine Alleviates Iron Overload and Brain Injury in a Rat Model of
   Brainstem Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain injury; Brainstem hemorrhage; Deferoxamine; Iron overload;
   Neurological deficit
ID INTRACEREBRAL HEMORRHAGE; PONTINE HEMORRHAGE; CLINICAL-FEATURES;
   HEMATOMA; ACTIVATION; DEATH; HEMOGLOBIN; PREDICTORS; MECHANISMS;
   MORTALITY
AB BACKGROUND: Brainstem hemorrhage (BSH) is the most dangerous and devastating subtype of intracerebral hemorrhage and is associated with high morbidity and mortality. However, to date, no effective prevention methods or specific therapies have been available to improve its clinical outcomes. We preliminarily explored the efficacy of deferoxamine (DFO), a clinical chelator known for its iron-scavenging activities, in a rat model of BSH induced with collagenase infusion.
   METHODS: DFO or saline was administrated 6 hours after BSH induction and then every 12 hours for <= 7 days. The survival curve of the rats was created, and the neurological scores were examined on days 1, 3, and 7 after BSH. The rats were sacrificed after 1, 3, and 7 days of DFO treatment for histological examination and immunohistochemistry.
   RESULTS: The results showed that administration of DFO delayed erythrocytes lysis, reduced iron deposition, reduced reactive oxygen species generation, reduced heme oxygenase-1 expression, and alleviated brain injury such as neuron degeneration and myelin sheath injury. However, DFO did not improve the survival rate and neurobehavioral outcomes in this model.
   CONCLUSIONS: Administration of DFO had limited therapeutic effects on collagenase-induced brainstem hemorrhage in rats. Some potential explanations were proposed, and more preclinical work is required to clarify the controversial curative effect of DFO in ICH.
C1 [Guo, Xi; Li, Hao; Duan, Zhongxin; Zhang, Fan; Tian, Meng; Ma, Lu; You, Chao] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
   [Guo, Xi; Qi, Xin; Duan, Zhongxin; Wei, Yang; Zhang, Fan; Tian, Meng; You, Chao] Sichuan Univ, West China Hosp, Neurosurg Res Lab, Chengdu, Sichuan, Peoples R China.
   [Tian, Meng; You, Chao] Sichuan Univ, West China Hosp, West China Brain Res Ctr, Chengdu, Sichuan, Peoples R China.
RP Tian, M (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.; Tian, M (reprint author), Sichuan Univ, West China Hosp, Neurosurg Res Lab, Chengdu, Sichuan, Peoples R China.; Tian, M (reprint author), Sichuan Univ, West China Hosp, West China Brain Res Ctr, Chengdu, Sichuan, Peoples R China.
EM tianmong007@gmail.com
FU National Key R&D Program of China [2018YFA010860003, 2018YFA010860004];
   Sichuan Province Science and Technology Key RD Project [2018SZ0029,
   2018SZ0100, 2019YFS0120]; 1.3.5 Project for Disciplines of Excellence,
   West China Hospital, Sichuan University [ZY2016102, ZY2016203]
FX The present study was supported by the National Key R&D Program of China
   (grants 2018YFA010860003 and 2018YFA010860004), Sichuan Province Science
   and Technology Key R&D Project (grants 2018SZ0029, 2018SZ0100 and
   2019YFS0120), and the 1.3.5 Project for Disciplines of Excellence, West
   China Hospital, Sichuan University (grants ZY2016102 and ZY2016203).
CR Adeoye O, 2010, NAT REV NEUROL, V6, P593, DOI 10.1038/nrneurol.2010.146
   AISEN P, 1978, J BIOL CHEM, V253, P1930
   Altermann CD, 2017, BRAIN RES BULL, V131, P78, DOI 10.1016/j.brainresbull.2017.03.007
   Auriat AM, 2012, EXP NEUROL, V234, P136, DOI 10.1016/j.expneurol.2011.12.030
   Balci K, 2005, CLIN NEUROL NEUROSUR, V108, P36, DOI 10.1016/j.clineuro.2005.02.007
   Broderick JP, 2007, STROKE, V38, P1072, DOI 10.1161/01.STR.0000258078.35316.30
   Cao SL, 2016, STROKE, V47, P1626, DOI 10.1161/STROKEAHA.116.013146
   Chen ZB, 2016, SCI REP-UK, V6, DOI 10.1038/srep20004
   Crack PJ, 2005, FREE RADICAL BIO MED, V38, P1433, DOI 10.1016/j.freeradbiomed.2005.01.019
   Cui HJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127256
   Dang G, 2017, TRANSL STROKE RES, V8, P174, DOI 10.1007/s12975-016-0505-3
   Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445
   Flores KP, 2018, J NEUROSCI RES, V96, P1586, DOI 10.1002/jnr.24243
   Gaasch JA, 2007, NEUROCHEM RES, V32, P1196, DOI 10.1007/s11064-007-9290-4
   Garton T, 2016, STROKE VASC NEUROL, V1, P172, DOI 10.1136/svn-2016-000042
   Garton TP, 2016, BRAIN RES, V1635, P86, DOI 10.1016/j.brainres.2015.12.060
   Guan QH, 2006, BRAIN RES, V1092, P36, DOI 10.1016/j.brainres.2006.03.086
   Haines S J, 1993, Neurosurg Clin N Am, V4, P481
   Hatakeyama T, 2013, TRANSL STROKE RES, V4, P546, DOI 10.1007/s12975-013-0270-5
   Hatakeyama T, 2011, ACTA NEUROCHIR SUPPL, V111, P185, DOI 10.1007/978-3-7091-0693-8_31
   He XF, 2016, J NEUROCHEM, V138, P436, DOI 10.1111/jnc.13657
   Higgins GC, 2012, FREE RADICAL BIO MED, V53, P1960, DOI 10.1016/j.freeradbiomed.2012.08.586
   Higgins GC, 2009, CELL MOL LIFE SCI, V66, P2773, DOI 10.1007/s00018-009-0079-2
   Ke Y, 2007, PROG NEUROBIOL, V83, P149, DOI 10.1016/j.pneurobio.2007.07.009
   Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7
   LeBlanc RH, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0709-1
   Lee JY, 2010, J CEREBR BLOOD F MET, V30, P1793, DOI 10.1038/jcbfm.2010.137
   Lekic T, 2013, J NEUROSURG, V118, P465, DOI 10.3171/2012.10.JNS111836
   Lekic T, 2011, TRANSL STROKE RES, V2, P144, DOI 10.1007/s12975-011-0068-2
   MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548
   Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517
   Matsukawa H, 2015, ACTA NEUROL SCAND, V131, P240, DOI 10.1111/ane.12312
   Meguro T, 2015, J STROKE CEREBROVASC, V24, P860, DOI 10.1016/j.jstrokecerebrovasdis.2014.12.006
   Ni W, 2015, EXP NEUROL, V272, P128, DOI 10.1016/j.expneurol.2015.02.035
   Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004
   Park HR, 2018, MOL NEUROBIOL, V55, P4650, DOI 10.1007/s12035-017-0652-x
   Qing WG, 2009, J NEUROSURG, V110, P462, DOI 10.3171/2008.4.JNS17512
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Shrestha BK, 2018, WORLD NEUROSURG, V117, pE106, DOI 10.1016/j.wneu.2018.05.195
   Tao CY, 2016, TURK NEUROSURG, V26, P77, DOI 10.5137/1019-5149.JTN.12634-14.1
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Wang GQ, 2018, J CELL MOL MED, V22, P768, DOI 10.1111/jcmm.13441
   Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095
   Warkentin LM, 2010, BRAIN RES, V1309, P95, DOI 10.1016/j.brainres.2009.10.058
   Welch KD, 2002, FREE RADICAL BIO MED, V32, P577, DOI 10.1016/S0891-5849(02)00760-8
   Wessels T, 2004, AM J NEURORADIOL, V25, P257
   Wijdicks EFM, 1997, NEUROLOGY, V49, P1342, DOI 10.1212/WNL.49.5.1342
   Wilkinson DA, 2018, J CEREBR BLOOD F MET, V38, P741, DOI 10.1177/0271678X17753590
   Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0
   Xie Q, 2014, STROKE, V45, P290, DOI 10.1161/STROKEAHA.113.003033
   Xiong XY, 2014, TRANSL STROKE RES, V5, P429, DOI 10.1007/s12975-013-0317-7
   Yang G, 2016, SCI REP-UK, V6, DOI 10.1038/srep21970
NR 52
TC 1
Z9 2
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E895
EP E904
DI 10.1016/j.wneu.2019.05.024
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100105
PM 31082547
OA Bronze
DA 2020-05-12
ER

PT J
AU Hao, YF
   Li, XL
   Chen, HC
   Huo, HZ
   Liu, ZB
   Tian, F
   Chai, EQ
AF Hao, Yunfei
   Li, Xiaoli
   Chen, Hecheng
   Huo, Hongzhi
   Liu, Zongbao
   Tian, Fei
   Chai, Erqing
TI A Cumulative Score Based on Preoperative Neutrophil-Lymphocyte Ratio and
   Fibrinogen in Predicting Overall Survival of Patients with Glioblastoma
   Multiforme
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fibrinogen; F-NLR; Glioblastoma multiforme; Neutrophil-lymphocyte ratio;
   Overall survival
ID PROGNOSTIC-SIGNIFICANCE; PLASMA-FIBRINOGEN; TO-LYMPHOCYTE; CANCER
AB OBJECTIVE: We conducted a retrospective analysis to explore the prognostic effect of the cumulative score based on neutrophil-lymphocyte ratio (NLR) and fibrinogen in patients with glioblastoma multiforme (GBM).
   METHODS: The clinical data of patients with GBM from January 2014 to December 2017 in our hospital were retrospectively analyzed. X-tile software was used to identify the optimal cutoff points of NLR and fibrinogen in predicting prognosis of GBM. Fibrinogen-NLR (F-NLR) score was calculated as following: fibrinogen >3.4 g/dL and NLR >4.1 was identified as F-NLR score of 2, only 1 abnormal index was defined as F-NLR score of 1, and no abnormal indices were classified as F-NLR score of 0.
   RESULTS: A total of 187 patients with primary GBM were enrolled in this study. Of these patients, 116 patients were men and 71 were women, and the mean age was 55 +/- 13.55 years. The cutoffs of lymphocyte, NLR, fibrinogen, and platelet-lymphocyte ratio (PLR) identified by X-tile were 1.8 x 10(9)/L, 4.1 x 10(9)/L, 3.4 mg/dL, and 228.6. There were 87 patients with F-NLR score of 0, 50 patients with F-NLR score of 1, and 50 patients with F-NLR score of 2. In the univariate survival analysis, age, lymphocyte count, fibrinogen, NLR, PLR, F-NLR score of 2, chemotherapy, and radiotherapy were significant predictors of overall survival (OS) in patients with GBM (all P < 0.05). After excluding related parameters, F-NLR score of 2 (hazard ratio [HR], 2.103; 95% confidence interval [CI], 1.401-3.155; P < 0.001) and chemotherapy (HR, 0.650; 95% CI, 0.432-0.977; P = 0.038) were predictive factors of OS for patients with GBM. When stratified by extent of resection, age, and adjuvant chemotherapy and radiotherapy, F-NLR score maintained the prognostic value in patients with GBM (all P < 0.05).
   CONCLUSIONS: F-NLR score of 2 was a risk predictor of prognosis for patients with GBM.
C1 [Hao, Yunfei; Chen, Hecheng; Huo, Hongzhi; Liu, Zongbao; Tian, Fei; Chai, Erqing] Gansu Prov Hosp, Dept Cerebrovasc Dis Ctr, Lanzhou, Gansu, Peoples R China.
   [Li, Xiaoli] Gansu Prov Hosp, Dept Nephrol, Lanzhou, Gansu, Peoples R China.
RP Chai, EQ (reprint author), Gansu Prov Hosp, Dept Cerebrovasc Dis Ctr, Lanzhou, Gansu, Peoples R China.
EM 3549652245@qq.com
CR Arigami T, 2016, ONCOLOGY-BASEL, V90, P186, DOI 10.1159/000444494
   Bao YF, 2018, WORLD NEUROSURG, V119, pE710, DOI 10.1016/j.wneu.2018.07.252
   Han S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1629-7
   He ZQ, 2017, ONCOTARGET, V8, P49605, DOI 10.18632/oncotarget.17849
   Kijima T, 2017, CANCER SCI, V108, P193, DOI 10.1111/cas.13127
   Kitano Y, 2017, ANTICANCER RES, V37, P3229, DOI 10.21873/anticanres.11685
   Kusumanto Yoka H., 2003, Angiogenesis, V6, P283, DOI 10.1023/B:AGEN.0000029415.62384.ba
   Lopes M, 2018, J NEURO-ONCOL, V136, P173, DOI 10.1007/s11060-017-2641-3
   Lu K, 2011, HEPATO-GASTROENTEROL, V58, P1507, DOI 10.5754/hge11133
   Luo P, 2018, CANCER MANAG RES, V10, P4727, DOI 10.2147/CMAR.S171602
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Marchetti C, 2018, INT J GYNECOL CANCER, V28, P939, DOI 10.1097/IGC.0000000000001233
   Massara M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01349
   Perisanidis C, 2015, CANCER TREAT REV, V41, P960, DOI 10.1016/j.ctrv.2015.10.002
   Ridker PM, 2012, CIRCULATION, V126, P2739, DOI 10.1161/CIRCULATIONAHA.112.122556
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Suchorska B, 2016, NEURO-ONCOLOGY, V18, P549, DOI 10.1093/neuonc/nov326
   Wang HY, 2018, J CELL PHYSIOL, V233, P4216, DOI 10.1002/jcp.26239
   Wang PF, 2017, ONCOTARGET, V8, P50117, DOI 10.18632/oncotarget.15235
   Yersal O, 2018, MOL CLIN ONCOL, V9, P453, DOI 10.3892/mco.2018.1695
   Yodying H, 2016, ANN SURG ONCOL, V23, P646, DOI 10.1245/s10434-015-4869-5
NR 21
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E427
EP E433
DI 10.1016/j.wneu.2019.04.169
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100049
PM 31042598
DA 2020-05-12
ER

PT J
AU Hatiboglu, MA
   Kocyigit, A
   Guler, EM
   Akdur, K
   Khan, I
   Nalli, A
   Karatas, E
   Tuzgen, S
AF Hatiboglu, Mustafa Aziz
   Kocyigit, Abdurrahim
   Guler, Eray Metin
   Akdur, Kerime
   Khan, Imran
   Nalli, Arife
   Karatas, Ersin
   Tuzgen, Saffet
TI Thymoquinone Enhances the Effect of Gamma Knife in B16-F10 Melanoma
   Through Inhibition of Phosphorylated STAT3
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoptosis; Brain metastasis; Gamma Knife; Melanoma; Radiation; STAT3
ID METASTATIC MELANOMA; INDUCED APOPTOSIS; BRAIN METASTASES;
   NIGELLA-SATIVA; MALIGNANT-MELANOMA; ANTITUMOR-ACTIVITY; SIGNAL
   TRANSDUCER; TUMOR-FORMATION; CANCER CELLS; EXPRESSION
AB BACKGROUND: Patients with brain metastasis from melanoma have a dismal prognosis with poor survival time. Gamma Knife (GK) is an effective treatment to control brain metastasis from melanoma. Thymoquinone (TQ) has emerged as a potential therapeutic option due to its antiproliferative effects on various cancers. The purpose of the study was to assess the effect of GK on B16-F10 melanoma cells in vitro and intracerebral melanoma in vivo, and its synergistic effect in combination with TQ.
   METHODS: The effects of GK and combination treatment of GK and TO were studied on B16-F10 melanoma cells by evaluating cytotoxicity with an adenosine triphosphate assay, apoptosis by acridine orange staining, and genotoxicity by comet assay. Western blot analysis was performed to investigate the expression of STAT3, p-STAT3 (Tyr705), JAK2, p-JAK2, caspase-3, Bax, Bcl-2, survivin, and beta-actin. Expression of inflammatory cytokines was assessed by enzyme-linked immunosorbent assay. GK alone and in combination with TQ was assessed in an established intracerebral melanoma tumor in mice.
   RESULTS: The effects of GK on cytotoxicity, genotoxicity, and apoptosis were enhanced by TQ in B16-F10 melanoma cells. GK induced apoptosis through inhibition of p-STAT3 expression, which in turn regulated pro- and antiapoptotic proteins such as caspase-3, Bax, Bcl-2, and survivin. Adding TQ to GK irradiation further enhanced this apoptotic effect of GK irradiation. GK was shown to reduce the levels of tumor-related inflammatory cytokines in B16-F10 melanoma cells. This effect was more pronounced when TQ was added to GK irradiation. GK with 15 Gy increased the survival of mice with intracerebral melanoma compared with untreated mice. However, despite the additive effect of TQ in addition to GK irradiation on B16-F10 melanoma cells in vitro, TQ did not add any significant survival benefit to GK treatment in mice with intracerebral melanoma.
   CONCLUSIONS: Our findings suggest that TQ would be a potential therapeutic agent in addition to GK to enhance the antitumor effect of irradiation. Further studies are required to support our findings.
C1 [Hatiboglu, Mustafa Aziz; Nalli, Arife; Tuzgen, Saffet] Vakif Univ, Med Sch, Dept Neurosurg, Istanbul, Turkey.
   [Kocyigit, Abdurrahim; Guler, Eray Metin; Akdur, Kerime; Karatas, Ersin] Vakif Univ, Med Sch, Dept Biochem, Istanbul, Turkey.
   [Hatiboglu, Mustafa Aziz; Khan, Imran; Nalli, Arife] Bezmialem Vakif Univ, Beykoz Inst Life Sci & Biotechnol, Dept Mol Biol, Istanbul, Turkey.
RP Hatiboglu, MA (reprint author), Vakif Univ, Med Sch, Dept Neurosurg, Istanbul, Turkey.; Hatiboglu, MA (reprint author), Bezmialem Vakif Univ, Beykoz Inst Life Sci & Biotechnol, Dept Mol Biol, Istanbul, Turkey.
EM mhatiboglu@bezmialem.edu.tr
RI Guler, Eray Metin/AAC-6551-2020; KARATAS, Ersin/G-1852-2016; Kocyigit,
   Abdurrahim/P-8685-2019
OI Guler, Eray Metin/0000-0003-4351-1719; KARATAS,
   Ersin/0000-0001-6848-7618; Kocyigit, Abdurrahim/0000-0003-2335-412X;
   Tuzgen, Saffet/0000-0002-0490-1506
FU Bezmialem Vakif University FundBezmialem Vakif University [6.2015/22]
FX This work was supported by Bezmialem Vakif University Fund (project
   number 6.2015/22).
CR Acoma IO, 2013, PLOS ONE, V8
   Ahmad I, 2013, TOXICOL APPL PHARM, V270, P70, DOI 10.1016/j.taap.2013.03.027
   ALBINO AP, 1991, CANCER RES, V51, P4815
   Anderson ES, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0282-x
   Antunes Alessandra Armstrong, 2010, Asian J Neurosurg, V5, P68
   Apte RN, 2002, SEMIN CANCER BIOL, V12, P277, DOI 10.1016/S1044-579X(02)00014-7
   Argiles JM, 2003, CURR OPIN CLIN NUTR, V6, P401, DOI 10.1097/01.mco.0000078983.18774.cc
   Attoub S, 2013, FUND CLIN PHARMACOL, V27, P557, DOI 10.1111/j.1472-8206.2012.01056.x
   Badr G, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-236
   Baker-Kubiczek E. K., 2012, Experimental Oncology, V34, P277
   Banerjee S, 2009, CANCER RES, V69, P5575, DOI 10.1158/0008-5472.CAN-08-4235
   Baskar Rajamanickam, 2014, Front Mol Biosci, V1, P24, DOI 10.3389/fmolb.2014.00024
   BEREK JS, 1991, AM J OBSTET GYNECOL, V164, P1038, DOI 10.1016/0002-9378(91)90582-C
   Boasberg PD, 2003, ONCOLOGY-BASEL, V64, P328, DOI 10.1159/000070289
   Brantley EC, 2008, MOL CANCER RES, V6, P675, DOI 10.1158/1541-7786.MCR-07-2180
   BULLARD DE, 1981, NEUROSURGERY, V8, P26, DOI 10.1227/00006123-198101000-00006
   Burke F, 1996, CYTOKINE, V8, P578, DOI 10.1006/cyto.1996.0077
   Byrne T N, 1983, J Neurooncol, V1, P313, DOI 10.1007/BF00165714
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Christ Sebastian M, 2015, Surg Neurol Int, V6, pS355, DOI 10.4103/2152-7806.163315
   DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455
   Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252
   Effenberger-Neidnicht K, 2011, CANCER CHEMOTH PHARM, V67, P867, DOI 10.1007/s00280-010-1386-x
   Gali-Muhtasib H, 2004, INT J ONCOL, V25, P857
   Gaudy-Marqueste C, 2014, ANN ONCOL, V25, P2086, DOI 10.1093/annonc/mdu266
   Gaudy-Marqueste C, 2006, INT J RADIAT ONCOL, V65, P809, DOI 10.1016/j.ijrobp.2006.01.024
   Gholamnezhad Z, 2015, FOOD CHEM TOXICOL, V86, P72, DOI 10.1016/j.fct.2015.08.028
   Guida MS, 2016, CELL PHYSIOL BIOCHEM, V38, P786, DOI 10.1159/000443034
   Hartmann A, 2003, MUTAGENESIS, V18, P45, DOI 10.1093/mutage/18.1.45
   Hatiboglu MA, 2018, WORLD NEUROSURG, V114, pE182, DOI 10.1016/j.wneu.2018.02.136
   Hatiboglu MA, 2012, INT J CANCER, V131, P8, DOI 10.1002/ijc.26307
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   Jing N, 2005, ANTI-CANCER DRUG, V16, P601, DOI 10.1097/00001813-200507000-00002
   Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4
   Kaseb AO, 2007, CANCER RES, V67, P7782, DOI 10.1158/0008-5472.CAN-07-1483
   Khan MA, 2015, ONCOTARGET, V6, P19580, DOI 10.18632/oncotarget.3973
   Knisely JPS, 2012, J NEUROSURG, V117, P227, DOI 10.3171/2012.5.JNS111929
   Koga M, 2008, BIOCHEM BIOPH RES CO, V365, P279, DOI 10.1016/j.bbrc.2007.10.182
   Kong LY, 2010, CLIN CANCER RES, V16, P2550, DOI 10.1158/1078-0432.CCR-10-0279
   Kong LY, 2009, CANCER IMMUNOL IMMUN, V58, P1023, DOI 10.1007/s00262-008-0618-y
   KRASAGAKIS K, 1994, ANTICANCER RES, V14, P2565
   Lathers DMR, 2004, CYTOKINE, V25, P220, DOI 10.1016/j.cyto.2003.11.005
   Lazzari C, 2018, THER ADV MED ONCOL, V10, P1, DOI 10.1177/1758835918762094
   Li F, 2010, BRIT J PHARMACOL, V161, P541, DOI 10.1111/j.1476-5381.2010.00874.x
   Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87
   Majdalawieh AF, 2015, INT IMMUNOPHARMACOL, V28, P295, DOI 10.1016/j.intimp.2015.06.023
   MATTEI S, 1994, INT J CANCER, V56, P853, DOI 10.1002/ijc.2910560617
   MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153
   MORADI MM, 1993, CANCER, V72, P2433, DOI 10.1002/1097-0142(19931015)72:8<2433::AID-CNCR2820720822>3.0.CO;2-L
   Mostofa AGM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00295
   Mrowietz U, 1999, BRIT J CANCER, V79, P1025, DOI 10.1038/sj.bjc.6690164
   Nesbit M, 2001, J IMMUNOL, V166, P6483, DOI 10.4049/jimmunol.166.11.6483
   Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260
   Peng L, 2013, ONCOL REP, V29, P571, DOI 10.3892/or.2012.2165
   Penson RT, 2000, INT J GYNECOL CANCER, V10, P33, DOI 10.1046/j.1525-1438.2000.00003.x
   Purohit A, 2002, BREAST CANCER RES, V4, P65, DOI 10.1186/bcr425
   Rajput S, 2015, J CELL PHYSIOL, V230, P620, DOI 10.1002/jcp.24780
   RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822
   Roepke M, 2007, CANCER BIOL THER, V6, P160, DOI 10.4161/cbt.6.2.3575
   Samlowski WE, 2007, CANCER, V109, P1855, DOI 10.1002/cncr.22605
   SCHEIBENBOGEN C, 1995, MELANOMA RES, V5, P179, DOI 10.1097/00008390-199506000-00006
   Senft C, 2011, J NEURO-ONCOL, V101, P393, DOI 10.1007/s11060-010-0273-y
   Shoieb AM, 2003, INT J ONCOL, V22, P107
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6
   Szostak MJ, 2000, ONCOL REP, V7, P699
   Velho-Pereira R, 2011, CELL BIOL INT, V35, P1025, DOI 10.1042/CBI20100701
   Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455
   Worthen DR, 1998, ANTICANCER RES, V18, P1527
   Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157
   Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383
   Yu C, 2002, INT J RADIAT ONCOL, V52, P1277, DOI 10.1016/S0360-3016(01)02772-9
   Zhang LD, 2016, ONCOL LETT, V12, P2840, DOI 10.3892/ol.2016.4971
NR 73
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E570
EP E581
DI 10.1016/j.wneu.2019.04.205
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100067
PM 31054338
DA 2020-05-12
ER

PT J
AU Hersh, EH
   Yaeger, KA
   Neifert, SN
   Kim, J
   Dangayach, NS
   Weiss, N
AF Hersh, Eliza H.
   Yaeger, Kurt A.
   Neifert, Sean N.
   Kim, Julie
   Dangayach, Neha S.
   Weiss, Nirit
TI Patterns of Health Care Costs Due to External Ventricular Drain
   Infections
SO WORLD NEUROSURGERY
LA English
DT Article
DE Central nervous system infection; External ventricular drain infection;
   Health care cost; Health care disparity; Health care quality assessment;
   Ventriculostomy
ID ANTIBIOTIC-IMPREGNATED CATHETERS; SHUNT INFECTIONS; HYDROCEPHALUS;
   PREVENTION; HOSPITALS; CSF
AB BACKGROUND: External ventricular drain (EVD) infections are a significant cause of morbidity among neurosurgical patients and have been correlated with increased length of hospital stay and longer requirements for intensive care. To date, no studies have examined the financial impact of EVD infections.
   METHODS: Patients who underwent EVD placement between December 2010 and January 2016 were included in the study. Clinical records were retrospectively reviewed and health care cost data were obtained from the hospital's finance department. Clinical information included patient demographics, details from the hospital course, and outcomes. Total costs, direct/indirect, and fixed/variable costs were analyzed for every patient.
   RESULTS: Over the 5-year study period, 246 EVDs were placed in 243 patients with an overall infection rate of 9.9% (N = 24). The median EVD duration for infected versus noninfected patients was 19 and 9 days, respectively (P< 0.0001). Median length of intensive care unit stay also was increased for patients with EVD infection (30 days vs. 13 days, P < 0.0001). Total health care costs were significantly greater for infected patients (US$ 168,692 vs. US$ 83,919, P< 0.0001). This trend was comparable for all other cost subtypes, including fixed-direct costs, fixed-indirect costs, variable direct costs, and variable-indirect costs.
   CONCLUSIONS: EVD infection has a substantial effect on clinical morbidity and healthcare costs. These results demonstrate the imperative need to improve EVD infection prevention, particularly in the setting of a value-based health care system.
C1 [Hersh, Eliza H.; Yaeger, Kurt A.; Neifert, Sean N.; Kim, Julie; Dangayach, Neha S.; Weiss, Nirit] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
RP Weiss, N (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM nirit.weiss@mountsinai.org
CR Alleyne CH, 2000, NEUROSURGERY, V47, P1124, DOI 10.1097/00006123-200011000-00020
   Attenello FJ, 2010, NEUROSURGERY, V66, P284, DOI 10.1227/01.NEU.0000363405.12584.4D
   Baum GR, 2017, J NEUROSURG, V127, P1190, DOI 10.3171/2016.9.JNS16367
   Camacho EF, 2011, INFECTION, V39, P47, DOI 10.1007/s15010-010-0073-5
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   dos Santos SC, 2017, WORLD NEUROSURG, V99, P580, DOI 10.1016/j.wneu.2016.12.071
   Edwards NC, 2015, J NEUROSURG, V122, P139, DOI 10.3171/2014.9.JNS131277
   Epstein AJ, 2010, ARCH SURG-CHICAGO, V145, P179, DOI 10.1001/archsurg.2009.268
   Farber SH, 2010, WORLD NEUROSURG, V74, P528, DOI 10.1016/j.wneu.2010.07.014
   Flint AC, 2017, WORLD NEUROSURG, V99, P518, DOI 10.1016/j.wneu.2016.12.042
   Hoefnagel D, 2008, ACTA NEUROCHIR, V150, P209, DOI 10.1007/s00701-007-1458-9
   Lee GM, 2012, NEW ENGL J MED, V367, P1428, DOI 10.1056/NEJMsa1202419
   Lyke KE, 2001, CLIN INFECT DIS, V33, P2028, DOI 10.1086/324492
   Mukherjee D, 2010, ARCH SURG-CHICAGO, V145, P247, DOI 10.1001/archsurg.2009.288
   Murphy RKJ, 2015, J NEUROSURG, V122, P1120, DOI 10.3171/2014.9.JNS132882
   Nuno M, 2015, J NEUROSURG, V123, P1247, DOI 10.3171/2014.10.JNS141516
   Parker Scott L, 2011, Clin Neurosurg, V58, P122
   Patwardhan RV, 2005, NEUROSURGERY, V56, P139, DOI 10.1227/01.NEU.0000146206.40375.41
   Pople I, 2012, NEUROSURGERY, V71, P6, DOI 10.1227/NEU.0b013e3182544e31
   Roberts RR, 1999, JAMA-J AM MED ASSOC, V281, P644, DOI 10.1001/jama.281.7.644
   Root BK, 2016, WORLD NEUROSURG, V86, P306, DOI [10.1016/J.WNEU.2015.09.032, 10.1016/j.wneu.2015.09.032]
   Sciubba DM, 2005, J NEUROSURG, V103, P131, DOI 10.3171/ped.2005.103.2.0131
   Simon TD, 2009, J NEUROS-PEDIATR, V4, P156, DOI 10.3171/2009.3.PEDS08215
   Sonabend AM, 2011, NEUROSURGERY, V68, P996, DOI 10.1227/NEU.0b013e3182096d84
   STENAGER E, 1986, ACTA NEUROCHIR, V83, P20, DOI 10.1007/BF01420503
   Talibi S, 2016, BRIT J NEUROSURG, V30, P560, DOI 10.1080/02688697.2016.1181150
   Thomas R, 2012, BRIT J NEUROSURG, V26, P175, DOI 10.3109/02688697.2011.603856
   Tunkel AR, 2017, CLIN INFECT DIS
   Upadhyaya P, 1982, Prog Pediatr Surg, V15, P209
   Vaz LE, 2015, INFECT CONT HOSP EP, V36, P649, DOI 10.1017/ice.2015.38
   Wong GKC, 2010, J NEUROL NEUROSUR PS, V81, P1064, DOI 10.1136/jnnp.2009.198523
   Zusman EE, 2017, NEUROSURGERY, V80, pS34, DOI 10.1093/neuros/nyw151
NR 32
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E31
EP E37
DI 10.1016/j.wneu.2019.03.197
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100006
PM 30928594
DA 2020-05-12
ER

PT J
AU Higashida, RT
   Bruder, N
   Gupta, R
   Guzman, R
   Hmissi, A
   Marr, A
   Mayer, SA
   Roux, S
   Weidauer, S
   Aldrich, EF
AF Higashida, Randall T.
   Bruder, Nicolas
   Gupta, Rajiv
   Guzman, Raphael
   Hmissi, Abdel
   Marr, Angelina
   Mayer, Stephan A.
   Roux, Sebastien
   Weidauer, Stefan
   Aldrich, E. Francois
TI Reversal of Vasospasm with Clazosentan After Aneurysmal Subarachnoid
   Hemorrhage: A Pilot Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Cerebral vasospasm; Endothelin-1 receptor antagonist;
   Subarachnoid hemorrhage
ID CEREBRAL VASOSPASM; DOUBLE-BLIND; RECEPTOR ANTAGONIST; ENDOTHELIN;
   NIMODIPINE; MANAGEMENT; SURGERY; TRIAL; TIME
AB BACKGROUND: Clazosentan, an endothelin-1 receptor antagonist, has been shown to prevent the development of large vessel angiographic vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). It has been hypothesized that clazosentan can also reverse established angiographic vasospasm.
   METHODS: The REVERSE (resynchronization reverses remodeling in systolic left ventricular dysfunction) study was a prospective, multicenter, open-label, 2-stage pilot study of adult patients with aSAH who had received intravenous clazosentan (15 mg/hour) after developing moderate-to-severe angiographic vasospasm. The primary efficacy endpoint was the reversal of global cerebral vasospasm in large cerebral artery segments 3 hours after clazosentan initiation. The secondary endpoints included large artery vasospasm reversal at 24 hours and the maximum change in the angiographic cerebral circulation time. The change in vasospasm severity in the proximal and distal segments was investigated in an exploratory analysis.
   RESULTS: The primary efficacy endpoint was met in 3 of 11 evaluable patients (27.3%; 95% confidence interval, 6.0-61.0). However, recruitment was stopped after stage 1 in accordance with the predefined interim analysis criteria. In the exploratory analysis, 50.0% and 77.8% of the patients showed a significant reversal of vasospasm or improvement to the admission :date in >= 2 distal segments at 3 and 24 hours and 28.6% and 77.8% in >= 2 proximal segments, respectively.
   CONCLUSIONS: Although the main analysis showed a reversal of large vessel vasospasm 3 hours after clazosentan initiation in a few patients, the exploratory analysis indicated a clear pharmacodynamic dilating effect on vasospastic cerebral vessels at 24 hours in most patients, in particular, in the distal arterial beds. This observation supported the inclusion of patients with established vasospasm in the ongoing REACT (prevention and treatment of vasospasm with clazosentan) trial.
C1 [Higashida, Randall T.] Univ Calif San Francisco, Med Ctr, Dept Neuro Intervent Radiol, San Francisco, CA 94143 USA.
   [Bruder, Nicolas] Aix Marseille Univ, CHU Timone, AP HM, Dept Anesthesia & Crit Care, Marseille, France.
   [Gupta, Rajiv] Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA USA.
   [Guzman, Raphael] Univ Hosp, Dept Neurosurg, Basel, Switzerland.
   [Hmissi, Abdel; Marr, Angelina; Roux, Sebastien] Idorsia Pharmaceut Ltd, Global Clin Dev, Allschwil, Switzerland.
   [Mayer, Stephan A.] Henry Ford Neurosci Inst, Dept Neurol, Detroit, MI USA.
   [Weidauer, Stefan] Sankt Katharinen Hosp, Dept Neurol, Frankfurt, Germany.
   [Aldrich, E. Francois] Univ Maryland, Dept Neurosurg, Baltimore, MD 21201 USA.
RP Higashida, RT (reprint author), Univ Calif San Francisco, Med Ctr, Dept Neuro Intervent Radiol, San Francisco, CA 94143 USA.
EM Randall.Higashida@ucsf.edu
OI Guzman, Raphael/0000-0001-9620-0581
FU Actelion Pharmaceuticals Ltd.
FX The REVERSE study was sponsored by Actelion Pharmaceuticals Ltd.
   Sponsorship was transferred to Idorsia Pharmaceuticals Ltd. on July 1,
   2018. The study sponsor contributed to study design, collection,
   analysis and interpretation of the data, writing of the report, and
   decision to submit the report for publication. RT Higashida reports
   personal fees from University of California San Francisco and from
   Idorsia Pharmaceuticals Ltd. during the conduct of the study; personal
   fees from Idorsia Pharmaceuticals Ltd. outside the submitted work. N
   Bruder reports grants from Idorsia Pharmaceuticals Ltd. during the
   conduct of the study; personal fees from Actelion Pharmaceuticals Ltd.
   outside the submitted work. R Gupta reports grants from Massachusetts
   General Hospital during the conduct of the study; and was a member of
   the study central Image Review Committee for Idorsia Pharmaceuticals
   Ltd. R Guzman reports personal fees from Actelion Pharmaceuticals Ltd.
   and Idorsia Pharmaceuticals Ltd. during the conduct of the study. A.
   Hmissi, A. Marr, and S. Roux report they are employees of the study
   sponsor Idorsia Pharmaceuticals, Ltd. S. Mayer reports personal fees
   from Idorsia Pharmaceuticals, Ltd. outside the submitted work. S.
   Weidauer reports having been a consultant/scientific advisor for
   Actelion Pharmaceuticals, Ltd. and Idorsia Pharmaceuticals, Ltd. during
   the conduct of the study and having received consulting fees. E. F.
   Aldrich reports personal fees from Idorsia Pharmaceuticals, Ltd. during
   the conduct of the study and outside of the submitted work.
CR ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103
   Appelboom G, 2010, NEUROCRIT CARE, V13, P385, DOI 10.1007/s12028-010-9442-2
   Bauer AM, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00072
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9
   Etminan N, 2017, HAND CLINIC, V140, P195, DOI 10.1016/B978-0-444-63600-3.00012-X
   Feng L, 2002, AM J NEURORADIOL, V23, P1284
   Findlay JM, 2016, CAN J NEUROL SCI, V43, P15, DOI 10.1017/cjn.2015.288
   Fujimura M, 2017, CEREBROVASC DIS, V44, P59, DOI 10.1159/000475824
   Hanggi D, 2008, AM J NEURORADIOL, V29, P1053, DOI 10.3174/ajnr.A1005
   Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942
   Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490
   Macdonald RL, 2012, STROKE, V43, P1463, DOI 10.1161/STROKEAHA.111.648980
   Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9
   Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7
   Pennings FA, 2004, STROKE, V35, P1284, DOI 10.1161/01.STR.0000126039.91400.cb
   PETRUK KC, 1988, J NEUROSURG, V68, P505, DOI 10.3171/jns.1988.68.4.0505
   SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9
   Turowski B, 2005, NEURORADIOLOGY, V47, P134, DOI 10.1007/s00234-004-1281-4
   Uhlmann D, 2006, CURR OPIN INVEST DR, V7, P272
   Vajkoczy P, 2005, J NEUROSURG, V103, P9, DOI 10.3171/jns.2005.103.1.0009
   WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173
   Zimmermann M, 2004, CLIN AUTON RES, V14, P143, DOI 10.1007/s10286-004-0186-y
NR 23
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E639
EP E648
DI 10.1016/j.wneu.2019.04.222
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100074
PM 31054336
DA 2020-05-12
ER

PT J
AU Hoffman, H
   Protas, M
   Chin, LS
AF Hoffman, Haydn
   Protas, Matthew
   Chin, Lawrence S.
TI A Nationwide Analysis of 30-Day and 90-Day Readmissions After Elective
   Cerebral Aneurysm Clipping in the United States: Causes, Predictors, and
   Trends
SO WORLD NEUROSURGERY
LA English
DT Article
DE 30-Day and 90-day readmission; Cerebral aneurysm clipping; Nationwide
   readmissions database; Unruptured cerebral aneurysms
ID UNRUPTURED INTRACRANIAL ANEURYSMS; NATURAL-HISTORY; RISK-FACTORS;
   COMORBIDITY; CRANIOTOMY; COILING; TUMOR; CARE
AB BACKGROUND: Thirty-day readmissions (30dRAs) and 90-day readmissions (90dRAs) are being increasingly scrutinized as quality metrics for hospital and provider performances. Little information regarding risk factors for 30dRA and 90dRA after elective cerebral aneurysm clipping (CAC) of unruptured cerebral aneurysms is available. We sought to characterize risk factors with a nationally representative administrative database.
   METHODS: The Nationwide Readmissions Database was used to identify patients who underwent elective CAC between 2010 and 2014. The outcomes of interest were unplanned readmissions occurring within 30 or 90 days of discharge. Binary logistic regression was used to identify variables related to patients' demographics, comorbidities, and index hospital admission that were associated with readmission. A Cochran-Mantel-Haenszel test was used to evaluate for changes in annual readmission rates.
   RESULTS: A total of 1123 patients met the inclusion criteria for 30dRA analysis and 946 patients were eligible for 90dRA analysis. The 5-year 30dRA and 90dRA readmission rates were 9.1% and 14.9%, respectively. The annual rate of readmission between 2010 and 2014 did not change. Greater Charlson Comorbidity Index (odds ratio [OR], 2.68; 95% confidence interval [CI], 1.14-6.28) and nonroutine discharge after the index admission (OR, 1.81; 95% CI, 1.04-3.14) were associated with greater odds of 30dRA. Charlson Comorbidity Index (OR, 3.45; 95% CI, 1.57-7.56) and treatment at a metropolitan teaching hospital (OR, 2.21; 95% CI, 1.06-4.60) were associated with increased odds of 90dRA. Wound infection was the most common reason for readmission.
   CONCLUSIONS: Readmission rates after elective CAC remained unchanged between 2010 and 2014, suggesting that improved methods for reducing unplanned readmissions after CAC are needed.
C1 [Hoffman, Haydn; Protas, Matthew; Chin, Lawrence S.] SUNY Upstate Med Univ, Dept Neurosurg, Syracuse, NY 13210 USA.
RP Hoffman, H (reprint author), SUNY Upstate Med Univ, Dept Neurosurg, Syracuse, NY 13210 USA.
EM hoffmanh@upstate.edu
CR Alg VS, 2013, NEUROLOGY, V80, P2154, DOI 10.1212/WNL.0b013e318295d751
   Bekelis K, 2017, J NEUROSURG, V126, P811, DOI 10.3171/2016.1.JNS152028
   Bekelis K, 2016, J NEUROINTERV SURG, V8, P1203, DOI 10.1136/neurintsurg-2015-012162
   Bekelis K, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002190
   Birmingham LE, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2840-4
   Dasenbrock HH, 2018, J NEUROSURG, V128, P756, DOI 10.3171/2016.10.JNS161810
   Dasenbrock HH, 2017, NEUROSURGERY, V80, P551, DOI 10.1093/neuros/nyw062
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   Hsu CE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151805
   Jalbert JJ, 2015, STROKE, V46, P2452, DOI 10.1161/STROKEAHA.115.009777
   Juvela S, 2008, J NEUROSURG, V108, P1052, DOI 10.3171/JNS/2008/108/5/1052
   Kocher RP, 2011, JAMA-J AM MED ASSOC, V306, P1794, DOI 10.1001/jama.2011.1561
   Lakomkin N, 2018, J NEURO-ONCOL, V136, P595, DOI 10.1007/s11060-017-2689-0
   Raghavan ML, 2005, J NEUROSURG, V102, P355, DOI 10.3171/jns.2005.102.2.0355
   Ramos CL, 2020, J NEUROSURG, V132, P788, DOI 10.3171/2018.10.JNS18103
   SARTI C, 1991, STROKE, V22, P848, DOI 10.1161/01.STR.22.7.848
   Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E873
EP E883
DI 10.1016/j.wneu.2019.05.021
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100103
PM 31082558
DA 2020-05-12
ER

PT J
AU Hopkins, BS
   Mazmudar, AS
   Bomdica, PR
   Koski, TR
   Patel, AA
   Dahdaleh, NS
AF Hopkins, Benjamin S.
   Mazmudar, Aditya S.
   Bomdica, Prithvi R.
   Koski, Tyler R.
   Patel, Alpesh A.
   Dahdaleh, Nader S.
TI A Financial Analysis of Procedural Revenue in Outpatient Spine Clinic:
   An Analysis of 36,312 Patient Appointments and Subsequent Surgeries at a
   Single Major Academic Institution
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cost effectiveness; Health economics; Hospital costs; Outpatient spine
   clinic
ID MULTIDISCIPLINARY CARE PATHWAY; REFERRALS; TRENDS; TRIAGE
AB OBJECTIVE: The economic pressures widely discussed in health care have a large impact on spine practices. This current study is the first to look at characteristics associated with revenues from an outpatient spine clinic.
   METHODS: All clinic visits to spine providers were identified at a single academic institution spanning the dates June 1, 2014, to June 1, 2018. All payment information was calculated using Medicare reimbursement values for Current Procedural Terminology codes. Relevant clinical, surgical, and cost structure data was collected for each patient.
   RESULTS: On average, providers had 21.9 average appointments over the course of 7.6 hours per clinic day. The average ratio of new to follow-up patients was 39.3%, with an average new patient to surgery conversion rate of 15.0%. The adjusted average total procedural revenue per new patient, controlled for scheduled appointment length and actual appointment length, was $686.02. The adjusted average procedural revenue per surgery was $3444.64 and average procedural revenue per hour in spine clinic was $552.40. With a 1% and 5% increase in new patient visits, total procedural revenue increases 2.7% and 13.5%, respectively. With a 1% and 5% increase in conversion rate, total procedural revenue increases 6.7% and 33.3%, respectively. With a decrease in new patient appointment length from 30 minutes to 25 minutes, the opportunity for 1.7 new patient appointments per day was created resulting in a net increase in procedural revenue per clinic day of $837.57.
   CONCLUSIONS: Incremental changes in practice structure can significantly affect procedural revenue. Significant heterogeneity also exists among spine providers.
C1 [Hopkins, Benjamin S.; Bomdica, Prithvi R.; Koski, Tyler R.; Dahdaleh, Nader S.] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA.
   [Mazmudar, Aditya S.; Patel, Alpesh A.] Northwestern Univ, Feinberg Sch Med, Dept Orthopaed Surg, Chicago, IL 60611 USA.
RP Hopkins, BS (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA.
EM benjamin.hopkins@northwestern.edu
CR Al-Khouja LT, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.4.FOCUS1449
   Alvin MD, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.3.FOCUS1447
   Belatti DA, 2013, ORTHOPEDICS, V36, pE366, DOI 10.3928/01477447-20130222-28
   Birkmeyer JD, 2010, HEALTH SERV RES, V45, P1783, DOI 10.1111/j.1475-6773.2010.01150.x
   CMS, 2018, MED FEE SERV PAYM
   Cutler DM, 2012, NEW ENGL J MED, V366, P1075, DOI 10.1056/NEJMp1113361
   Debono B, 2017, NEUROCHIRURGIE, V63, P267, DOI 10.1016/j.neuchi.2017.05.003
   Deyo RA, 2006, CLIN ORTHOP RELAT R, P139, DOI 10.1097/01.blo.0000198726.62514.75
   Drymalski Mark, 2017, Mo Med, V114, P44
   Fourney DR, 2011, SPINE, V36, pS164, DOI 10.1097/BRS.0b013e31822ef58f
   Kazberouk A, 2016, SPINE, V41, P344, DOI 10.1097/BRS.0000000000001212
   Kindrachuk DR, 2014, J NEUROSURG-SPINE, V20, P87, DOI 10.3171/2013.10.SPINE13434
   Rossi VJ, 2015, WORLD J ORTHOP, V6, P409, DOI 10.5312/wjo.v6.i5.409
   Scalise J, 2018, CLIN SPINE SURG, V31, P261, DOI 10.1097/BSD.0000000000000568
   Wilgenbusch CS, 2014, SPINE, V39, pS129, DOI 10.1097/BRS.0000000000000574
   Zarrabian M, 2017, CAN J SURG, V60, P342, DOI 10.1503/cjs.016116
NR 16
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E938
EP E943
DI 10.1016/j.wneu.2019.05.040
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100111
PM 31096025
DA 2020-05-12
ER

PT J
AU Huang, JF
   Chen, D
   Sang, CM
   Zheng, XQ
   Lin, JL
   Lin, Y
   Ni, WF
   Wang, XY
   Li, YM
   Wu, AM
AF Huang, Jin-Feng
   Chen, Dong
   Sang, Chang-Min
   Zheng, Xuan-Qi
   Lin, Jia-Liang
   Lin, Yan
   Ni, Wen-Fei
   Wang, Xiang-Yang
   Li, Yan Michael
   Wu, Ai-Min
TI Nomogram for Individualized Prediction and Prognostic Factors for
   Survival in Patients with Primary Spinal Chordoma: A Population-Based
   Longitudinal Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chordoma; Nomogram; Prognostic factors; Prognostic model; Survival
ID RADIATION-THERAPY; SACRAL CHORDOMA; MOBILE SPINE; OPERATIVE MANAGEMENT;
   SURGICAL-MANAGEMENT; UNITED-STATES; EPIDEMIOLOGY; SURVEILLANCE;
   RECURRENCE; RISK
AB BACKGROUND: Chordoma is a type of rare bone tumor and is a relatively slow-growing, low-grade malignancy that is locally invasive and aggressive. The nomogram is widely used in the field of cancer because it can provide a clear picture for clinicians to predict the survival rate, which can lead more accurate decisions in clinical treatment.
   METHODS: Overall, 875 patients with a primary spinal chordoma were identified and collected from the Surveillance, Epidemiology, and End Results registry databases (1973-2015). The nomogram was established based on 425 patients with complete data. The predictive accuracy and discriminative ability of the nomogram were determined by the concordance index (C-index) and calibration curve.
   RESULTS: The statistical nomogram was built on 10 independent prognostic factors: age, sex, race, disease stage, surgery, year of diagnosis, marital status, primary site, radiation, and tumor size, with C-indices of 0.76. The calibration curve to determine the probability of survival showed good agreement between the predictions by the nomogram and actual observation. Tumor diameter >10 cm (hazard ratio [HR] 2.95, 95% confidence interval [CI] 1.77-4.90, P < 0.001), regional invasive (HR 1.71, 95% CI 1.16-2.53, P< 0.01), and distant metastasis (HR 3.44, 95% CI 1.98-5.96, P< 0.001) were independent risk factors for poor survival. Undergoing subtotal resection or gross total resection (HR 0.37, 95% CI 0.25-0.56, P< 0.001; HR 0.26, 95% CI 0.17-0.41, respectively) and a primary site located in the sacrum/pelvis (HR 0.51, 95% CI 0.34-0.78, P < 0.01) were prognostic factors for better survival.
   CONCLUSIONS: The nomogram provided more accurate prognostic predictions for patients with spinal chordoma. Moreover, our study suggests that tumor diameter >5 cm, distant metastasis, and not performing resection are major risk factors that can dramatically decrease the survival time of patients with spinal chordoma.
C1 [Huang, Jin-Feng; Chen, Dong; Zheng, Xuan-Qi; Lin, Jia-Liang; Lin, Yan; Ni, Wen-Fei; Wang, Xiang-Yang; Wu, Ai-Min] Wenzhou Med Univ, Affiliated Hosp 2, Orthopaed Hosp, Dept Spine Surg,Zhejiang Spine Surg Ctr, Wenzhou, Zhejiang, Peoples R China.
   [Huang, Jin-Feng; Chen, Dong; Zheng, Xuan-Qi; Lin, Jia-Liang; Lin, Yan; Ni, Wen-Fei; Wang, Xiang-Yang; Wu, Ai-Min] Wenzhou Med Univ, Sch Med 2, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China.
   [Li, Yan Michael] Univ Rochester, Med Ctr, Sch Med & Dent, Dept Neurosurg & Oncol, Rochester, NY 14642 USA.
   [Sang, Chang-Min] Jiujiang Med Coll, Affiliated Hosp, Dept Orthopaed, Jiujiang, Jiangxi, Peoples R China.
RP Wu, AM (reprint author), Wenzhou Med Univ, Affiliated Hosp 2, Orthopaed Hosp, Dept Spine Surg,Zhejiang Spine Surg Ctr, Wenzhou, Zhejiang, Peoples R China.; Wu, AM (reprint author), Wenzhou Med Univ, Sch Med 2, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China.; Li, YM (reprint author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Neurosurg & Oncol, Rochester, NY 14642 USA.
EM aiminwu@wmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81501933, 81572214]; Zhejiang Provincial Natural
   Science Foundation of ChinaNatural Science Foundation of Zhejiang
   Province [LY14H060008]; Zhejiang Provincial Medical and Health
   Technology Foundation of China [2018KY129]; Wenzhou leading talent
   innovative project [RX2016004]; Wenzhou Municipal Science and Technology
   Bureau [Y20170389]
FX This work was funded by the National Natural Science Foundation of China
   (81501933, 81572214), Zhejiang Provincial Natural Science Foundation of
   China (LY14H060008), Zhejiang Provincial Medical and Health Technology
   Foundation of China (2018KY129), Wenzhou leading talent innovative
   project (RX2016004), and Wenzhou Municipal Science and Technology Bureau
   (Y20170389). The funders had no role in the design, execution, or
   writing of the study.
CR Ahmed AT, 2018, SPINE, V43, pE1157, DOI 10.1097/BRS.0000000000002638
   Ailon T, 2016, SPINE, V41, pS193, DOI 10.1097/BRS.0000000000001812
   Amichetti M, 2009, NEUROSURG REV, V32, P403, DOI 10.1007/s10143-009-0194-4
   Angelini A, 2015, J SURG ONCOL, V112, P344, DOI 10.1002/jso.23987
   Bergh P, 2000, CANCER-AM CANCER SOC, V88, P2122, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2122::AID-CNCR19>3.0.CO;2-1
   Bochner BH, 2006, J CLIN ONCOL, V24, P3967, DOI 10.1200/JCO.2005.05.3884
   Chen KW, 2010, SPINAL CORD, V48, P166, DOI 10.1038/sc.2009.95
   Cheng EY, 1999, SPINE, V24, P1639, DOI 10.1097/00007632-199908150-00004
   Chugh R, 2007, ONCOLOGIST, V12, P1344, DOI 10.1634/theoncologist.12-11-1344
   Fuchs B, 2005, J BONE JOINT SURG AM, V87A, P2211, DOI 10.2106/JBJS.D.02693
   Hu H, 2018, EUR RADIOL, V28, P877, DOI 10.1007/s00330-017-4900-2
   Imai R, 2016, INT J RADIAT ONCOL, V95, P322, DOI 10.1016/j.ijrobp.2016.02.012
   Kabolizadeh P, 2017, INT J RADIAT ONCOL, V97, P254, DOI 10.1016/j.ijrobp.2016.10.006
   Kayani B, 2014, EJSO-EUR J SURG ONC, V40, P1412, DOI 10.1016/j.ejso.2014.04.008
   Kayani B, 2015, WORLD NEUROSURG, V84, P1354, DOI 10.1016/j.wneu.2015.06.030
   Kim SP, 2013, J UROLOGY, V189, P2092, DOI 10.1016/j.juro.2012.11.174
   Kishimoto R, 2012, JPN J RADIOL, V30, P509, DOI 10.1007/s11604-012-0086-3
   Lau CSM, 2016, PEDIATR NEUROSURG, V51, P127, DOI 10.1159/000442990
   Lee IJ, 2017, WORLD NEUROSURG, V104, P346, DOI 10.1016/j.wneu.2017.04.118
   McDonald MW, 2013, INT J RADIAT ONCOL, V87, P1107, DOI 10.1016/j.ijrobp.2013.09.038
   McGirt MJ, 2011, SPINE J, V11, P190, DOI 10.1016/j.spinee.2011.01.013
   McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735
   Meng T, 2015, NEURO-ONCOLOGY, V17, P725, DOI 10.1093/neuonc/nou331
   Mukherjee D, 2011, WORLD NEUROSURG, V76, P580, DOI 10.1016/j.wneu.2011.05.016
   Mukherjee D, 2011, J NEUROSURG-SPINE, V14, P143, DOI 10.3171/2010.10.SPINE10189
   Pan Y, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0784-3
   Pennicooke B, 2016, SPINE, V41, pS186, DOI 10.1097/BRS.0000000000001831
   Rombi B, 2013, INT J RADIAT ONCOL, V86, P578, DOI 10.1016/j.ijrobp.2013.02.026
   Rotondo RL, 2015, J NEUROSURG-SPINE, V23, P788, DOI 10.3171/2015.3.SPINE14716
   Ruosi C, 2015, EUR SPINE J, V24, pS912, DOI 10.1007/s00586-015-4276-4
   Siddiqui MM, 2015, J UROLOGY, V193, P1943, DOI 10.1016/j.juro.2015.01.088
   Stacchiotti S, 2010, ANN SURG ONCOL, V17, P211, DOI 10.1245/s10434-009-0740-x
   SUNDARESAN N, 1979, J NEUROSURG, V50, P312, DOI 10.3171/jns.1979.50.3.0312
   Uhl M, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-100
   VandenBerghe H, 1996, EUR J CANCER, V32A, P1849, DOI 10.1016/0959-8049(96)00253-5
   Varga PP, 2015, EUR SPINE J, V24, P1092, DOI 10.1007/s00586-014-3728-6
   Walcott BP, 2012, LANCET ONCOL, V13, pE69, DOI 10.1016/S1470-2045(11)70337-0
   Yonemoto T, 1999, CANCER, V85, P878, DOI 10.1002/(SICI)1097-0142(19990215)85:4<878::AID-CNCR15>3.0.CO;2-7
   Zhong NZ, 2017, SPINE, V42, pE609, DOI 10.1097/BRS.0000000000001911
   Zhou H, 2010, J SURG ONCOL, V102, P720, DOI 10.1002/jso.21674
   Zuckerman SL, 2018, WORLD NEUROSURG, V113, pE618, DOI 10.1016/j.wneu.2018.02.109
NR 41
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E603
EP E614
DI 10.1016/j.wneu.2019.04.217
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100070
PM 31054340
DA 2020-05-12
ER

PT J
AU Hulsbergen, AFC
   Lamba, N
   Claes, A
   Kavouridis, VK
   Lin, NU
   Smith, TR
   Verhoeff, JJC
   Broekman, MLD
AF Hulsbergen, Alexander F. C.
   Lamba, Nayan
   Claes, An
   Kavouridis, Vasileios K.
   Lin, Nancy U.
   Smith, Timothy R.
   Verhoeff, Joost J. C.
   Broekman, Marike L. D.
TI Prognostic Value of Brain Metastasis-Free Interval in Patients with
   Breast Cancer Brain Metastases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastases; Brain metastasis-free interval; Breast cancer;
   Prognostic factors; Survival
ID NERVOUS-SYSTEM METASTASES; STEREOTACTIC RADIOSURGERY; RADIATION-THERAPY;
   SURVIVAL; WOMEN; RADIOTHERAPY; DIAGNOSIS; OUTCOMES; SUBTYPE
AB BACKGROUND: In patients with breast cancer brain metastases (BCBM), time between primary tumor diagnosis and appearance of brain metastases varies widely. Despite being a readily available clinical parameter, it remains unclear whether brain metastasis-free interval (BMFI) carries prognostic value among breast cancer patients. The aim of this study was to compare characteristics and overall survival among patients with varying BMFIs and to assess the prognostic role, if any, for BMFI.
   METHODS: We retrospectively reviewed 3 institutional databases of adult female patients who were treated for BCBM between 1996 and 2017. Cox proportional hazards model and Kaplan-Meier survival curves were used to determine prognostic value of BMFI for survival.
   RESULTS: A total of 503 patients were included. Median age at first brain metastasis was 52 (interquartile range [IQR]: 45-58) years. Median BMFI was 38 months (IQR: 18-66), and median overall survival was 17 months (IQR: 8-31). In univariate Cox proportional hazards model, younger age at BCBM, estrogen receptor (ER)+ /human epidermal growth factor receptor 2 (HER2)+ tumor subtype, and the absence of liver or lung metastases were associated with longer survival. BMFI >3 years was not associated with longer survival (hazard ratio [HR] = 1.13; P = 021). In multivariate analysis, only subtype (ER +/HER2 + vs. ER-/HER2-; HR = 0.77; P = 0.02) and liver metastases (HR = 1.36; P = 0.01) were prognostic for survival. There was no significant association between BMFI and overall survival (HR = 0.99; P = 0.91).
   CONCLUSIONS: In this large, retrospective cohort of breast cancer patients, BMFI was not prognostic for overall survival.
C1 [Hulsbergen, Alexander F. C.; Lamba, Nayan; Kavouridis, Vasileios K.; Smith, Timothy R.; Broekman, Marike L. D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Computat Neurosci Outcomes Ctr, Boston, MA 02115 USA.
   [Hulsbergen, Alexander F. C.] Univ Utrecht, Fac Med, Utrecht, Netherlands.
   [Claes, An; Verhoeff, Joost J. C.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands.
   [Lin, Nancy U.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Broekman, Marike L. D.] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Zuid Holland, Netherlands.
   [Broekman, Marike L. D.] Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands.
   [Broekman, Marike L. D.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Broekman, MLD (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Computat Neurosci Outcomes Ctr, Boston, MA 02115 USA.; Broekman, MLD (reprint author), Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Zuid Holland, Netherlands.; Broekman, MLD (reprint author), Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands.; Broekman, MLD (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
EM m.broekman@haaglandenmc.nl
CR Altundag K, 2007, CANCER-AM CANCER SOC, V110, P2640, DOI 10.1002/cncr.23088
   Andrews DW, 2004, LANCET, V363, P1665, DOI 10.1016/S0140-6736(04)16250-8
   Bartsch R, 2006, RADIOTHER ONCOL, V80, P313, DOI 10.1016/j.radonc.2006.08.001
   Bendell JC, 2003, CANCER, V97, P2972, DOI 10.1002/cncr.11436
   Claude L, 2005, RADIOTHER ONCOL, V76, P334, DOI 10.1016/j.radonc.2005.06.004
   Eichler AF, 2008, CANCER, V112, P2359, DOI 10.1002/cncr.23468
   Gerdan L, 2013, CLIN NEUROL NEUROSUR, V115, P2108, DOI 10.1016/j.clineuro.2013.07.030
   Harputluoglu H, 2008, J NATL MED ASSOC, V100, P521, DOI 10.1016/S0027-9684(15)31298-0
   Huang Z, 2018, ONCOL LETT, V15, P7090, DOI 10.3892/ol.2018.8259
   KIRICUTA IC, 1992, J CANCER RES CLIN, V118, P542, DOI 10.1007/BF01225270
   Largillier R, 2008, ANN ONCOL, V19, P2012, DOI 10.1093/annonc/mdn424
   Le Scodan R, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-395
   Lee SS, 2008, BREAST CANCER RES TR, V111, P523, DOI 10.1007/s10549-007-9806-2
   Lentzsch S, 1999, EUR J CANCER, V35, P580, DOI 10.1016/S0959-8049(98)00421-3
   Lin NU, 2008, CANCER-AM CANCER SOC, V113, P2638, DOI 10.1002/cncr.23930
   Lin NU, 2004, J CLIN ONCOL, V22, P3608, DOI 10.1200/JCO.2004.01.175
   Lobbezoo DJA, 2015, BRIT J CANCER, V112, P1445, DOI 10.1038/bjc.2015.127
   Marko NF, 2012, CANCER-AM CANCER SOC, V118, P3749, DOI 10.1002/cncr.26716
   Melisko ME, 2008, J NEURO-ONCOL, V88, P359, DOI 10.1007/s11060-008-9578-5
   Nam BH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1870
   Nieder C, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-105
   Niikura N, 2014, JPN J CLIN ONCOL, V44, P1133, DOI 10.1093/jjco/hyu156
   Niikura N, 2014, BREAST CANCER RES TR, V147, P103, DOI 10.1007/s10549-014-3090-8
   Park IH, 2009, ANN ONCOL, V20, P56, DOI 10.1093/annonc/mdn539
   Rades D, 2008, STRAHLENTHER ONKOL, V184, P251, DOI 10.1007/s00066-008-1831-5
   Regierer AC, 2014, ANN ONCOL, V25, P633, DOI 10.1093/annonc/mdt539
   Rostami R, 2016, J NEURO-ONCOL, V127, P407, DOI 10.1007/s11060-016-2075-3
   Saip P, 2008, BREAST, V17, P451, DOI 10.1016/j.breast.2008.03.004
   Shen Q, 2015, ONCOLOGIST, V20, P466, DOI 10.1634/theoncologist.2014-0107
   Sperduto PW, 2013, J NEURO-ONCOL, V112, P467, DOI 10.1007/s11060-013-1083-9
   Sperduto PW, 2013, INT J RADIAT ONCOL, V85, P1312, DOI 10.1016/j.ijrobp.2012.11.042
   Sperduto PW, 2012, J CLIN ONCOL, V30, P419, DOI 10.1200/JCO.2011.38.0527
   Sperduto PW, 2010, INT J RADIAT ONCOL, V77, P655, DOI 10.1016/j.ijrobp.2009.08.025
   Yue G, 2017, SCI REP-UK, V7, DOI 10.1038/srep45411
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E157
EP E164
DI 10.1016/j.wneu.2019.04.072
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100018
PM 31035019
DA 2020-05-12
ER

PT J
AU Iordanou, JC
   Camara, D
   Ghatan, S
   Panov, F
AF Iordanou, Jordan C.
   Camara, Divaldo
   Ghatan, Saadi
   Panov, Fedor
TI Approach Angle Affects Accuracy in Robotic Stereoelectroencephalography
   Lead Placement
SO WORLD NEUROSURGERY
LA English
DT Article
DE Accuracy; ROSA; SEEG
ID IN-VIVO ACCURACY; DEPTH ELECTRODES; EPILEPSY; REGISTRATION;
   IMPLANTATION; METHODOLOGY; SAFETY; SEEG
AB BACKGROUND: One third of patients with epilepsy fail to gain optimal control using antiepileptic drugs. New advances in epilepsy surgery have reshaped some diagnostic and therapeutic modalities into less invasive approaches. To understand the cortical epileptogenic net works, stereoelectroencephalography uses depth electrodes as a tool for invasive intracranial monitoring. These electrodes are now being placed using a robot instead of the traditional Talairach stereotactic grid and frame with comparable accuracy and the advantage of shortened surgical time. Whereas accuracy is important for correct cortical sampling and surgical morbidity, the factors that play a role in the deviation of the electrode's trajectory are not yet understood. The aim of this study was to determine if the angle the planned trajectory makes with the skull impacts the final accuracy of placement.
   METHODS: Twenty-five patients with 319 stereotactic trajectories were examined. Skew angle and accuracy measurements were computed based on preoperative and postoperative computed tomography scans fused with trajectories planned using ROSA robot software.
   RESULTS: Trajectories with a planned angle of >30 degrees (oblique group) had significantly higher radial error (2.05 mm vs. 1.45 mm, P < 0.001) than trajectories with planned angles <30 degrees (orthogonal group).
   CONCLUSIONS: The ROSA robotic system is a powerful tool that increases the speed and efficiency of stereotactic neurosurgery. Care should be taken when planning trajectories to avoid high skew angles. If a high skew angle is unavoidable, care should be taken to ensure a larger margin of safety.
C1 [Iordanou, Jordan C.; Camara, Divaldo; Ghatan, Saadi; Panov, Fedor] Mt Sinai West, Dept Neurosurg, New York, NY 10019 USA.
RP Iordanou, JC (reprint author), Mt Sinai West, Dept Neurosurg, New York, NY 10019 USA.
EM joiordanou@gmail.com
CR Balanescu B, 2014, STEREOT FUNCT NEUROS, V92, P117, DOI 10.1159/000360226
   Bourdillon P, 2017, EPILEPSIA, V58, P85, DOI 10.1111/epi.13616
   Brandmeir NJ, 2018, J ROBOT SURG, V12, P157, DOI 10.1007/s11701-017-0712-2
   Brodie MJ, 2012, NEUROLOGY, V78, P1548, DOI 10.1212/WNL.0b013e3182563b19
   Cardinale F, 2016, J CLIN NEUROPHYSIOL, V33, P490, DOI 10.1097/WNP.0000000000000249
   Cardinale F, 2016, WORLD NEUROSURG, V94, P570, DOI 10.1016/j.wneu.2016.07.070
   Cardinale F, 2016, WORLD NEUROSURG, V85, P1, DOI 10.1016/j.wneu.2015.11.029
   Cardinale F, 2013, NEUROSURGERY, V72, P353, DOI 10.1227/NEU.0b013e31827d1161
   Chen ZB, 2018, JAMA NEUROL, V75, P279, DOI 10.1001/jamaneurol.2017.3949
   Fitzpatrick JM, 2010, P I MECH ENG H, V224, P607, DOI 10.1243/09544119JEIM589
   Gonzalez-Martinez J, 2016, NEUROSURGERY, V78, P169, DOI 10.1227/NEU.0000000000001034
   Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503
   Lefranc M, 2014, STEREOT FUNCT NEUROS, V92, P242, DOI 10.1159/000362936
   Mascott CR, 2006, J NEUROSURG, V105, P561, DOI 10.3171/jns.2006.105.4.561
   Mehta AD, 2005, J NEUROSURG, V102, P1040, DOI 10.3171/jns.2005.102.6.1040
   Ortler M, 2011, NEUROSURGERY, V68, P881, DOI 10.1227/NEU.0b013e3182098e31
   Picot MC, 2008, EPILEPSIA, V49, P1230, DOI 10.1111/j.1528-1167.2008.01579.x
   Spyrantis A, 2018, INT J MED ROBOT COMP, V14, DOI 10.1002/rcs.1888
   Vakharia VN, 2017, EPILEPSIA, V58, P921, DOI 10.1111/epi.13713
   van der Loo LE, 2017, ACTA NEUROCHIR, V159, P1733, DOI 10.1007/s00701-017-3242-9
   Verburg N, 2016, WORLD NEUROSURG, V87, P392, DOI 10.1016/j.wneu.2015.11.041
   von Langsdorff D, 2015, J NEUROSURG, V122, P191, DOI 10.3171/2014.9.JNS14256
NR 22
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E322
EP E328
DI 10.1016/j.wneu.2019.04.143
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100036
PM 31028981
DA 2020-05-12
ER

PT J
AU Ishak, B
   Bajwa, AA
   Schneider, T
   Tubbs, RS
   Iwanaga, J
   Ramey, WL
   Unterberg, AW
   Kiening, KL
AF Ishak, Basem
   Bajwa, Awais Akbar
   Schneider, Till
   Tubbs, R. Shane
   Iwanaga, Joe
   Ramey, Wyatt L.
   Unterberg, Andreas W.
   Kiening, Karl L.
TI Early Complications and Cement Leakage in Elderly Patients Who Have
   Undergone Intraoperative Computed Tomography (CT)-Guided Cement
   Augmented Pedicle Screw Placement: Eight-Year Single-Center Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cement leakage; Complications; Elderly; Spinal instrumentation; Spinal
   navigation
ID PERCUTANEOUS VERTEBROPLASTY; PULMONARY-EMBOLISM; POLYMETHYLMETHACRYLATE
   AUGMENTATION; NAVIGATION IMPROVE; EXPERIMENTAL-MODEL; SPINAL NAVIGATION;
   FREE-HAND; FIXATION; ACCURACY; OSTEOPOROSIS
AB OBJECTIVE: To assess early complications, mortality rate, and cement leakage in elderly patients who had undergone navigation-based pedicle screw placement of the thoracic and lumbar spine.
   METHODS: Eighty-six patients older than 65 years of age who had received cement-augmented pedicle screws for various conditions were retrospectively included between May 2008 and December 2016. Complications, mortality, and cement leakage were determined. All patients had a radiograph as a control. In patients with cement leakage seen on radiographs, a computed tomography scan of the surgical area was also obtained.
   RESULTS: Average age was 73.4 years (range 65-86 years). A total of 319 vertebral bodies with 637 screws were inserted, of which 458 screws were cement-augmented; 348 (76%) of the augmented screws were placed in the lumbar spine and 110 (24%) in the thoracic spine. Cement leakage occurred in 55 of 86 patients, of whom 52 (60%) were asymptomatic. In all cases with cement leakage (asymptomatic or symptomatic), cement could be found in the perivertebral veins: in the inferior vena cava in 25%, in the epidural space in 7%, in the azygos vein in 5%, and in pulmonary arteries in 7%.
   CONCLUSIONS: Our study confirms that the use of cement correlates with a high risk of cement leakage in elderly patients. Using computed tomography navigation for screw placement did not reduce the risk of venous cement leakage, but leakage into the epidural space or through a cortical defect seems to be low.
C1 [Ishak, Basem; Bajwa, Awais Akbar; Unterberg, Andreas W.; Kiening, Karl L.] Heidelberg Univ Hosp, Dept Neurosurg, Heidelberg, Germany.
   [Schneider, Till] Heidelberg Univ Hosp, Dept Neuroradiol, Heidelberg, Germany.
   [Tubbs, R. Shane; Iwanaga, Joe] Seattle Sci Fdn, Washington, DC USA.
   [Ramey, Wyatt L.] Swedish Neurosci Inst, Seattle, WA USA.
RP Ishak, B (reprint author), Heidelberg Univ Hosp, Dept Neurosurg, Heidelberg, Germany.
EM basem.ishak@hotmail.com
CR Baroud G, 2006, SPINE, V31, P2562, DOI 10.1097/01.brs.0000240695.58651.62
   Bohner M, 2003, BIOMATERIALS, V24, P2721, DOI 10.1016/S0142-9612(03)00086-3
   CAMERON HU, 1975, J BONE JOINT SURG AM, V57, P655, DOI 10.2106/00004623-197557050-00013
   Chang MC, 2008, SPINE, V33, pE317, DOI 10.1097/BRS.0b013e31816f6c73
   Chen LH, 2009, CLIN BIOMECH, V24, P613, DOI 10.1016/j.clinbiomech.2009.05.002
   Choe DH, 2004, AM J ROENTGENOL, V183, P1097, DOI 10.2214/ajr.183.4.1831097
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9
   Deramond H, 1998, RADIOL CLIN N AM, V36, P533, DOI 10.1016/S0033-8389(05)70042-7
   Ignacio JMF, 2018, ASIAN SPINE J, V12, P380, DOI 10.4184/asj.2018.12.2.380
   Frankel BA, 2007, NEUROSURGERY, V61, P531, DOI 10.1227/01.NEU.0000290899.15567.68
   Gelalis ID, 2012, EUR SPINE J, V21, P247, DOI 10.1007/s00586-011-2011-3
   Groen RJM, 1997, ANAT REC, V249, P285, DOI 10.1002/(SICI)1097-0185(199710)249:2<285::AID-AR16>3.0.CO;2-K
   Hecht N, 2018, SPINE, V43, P370, DOI 10.1097/BRS.0000000000002173
   Hirano T, 1997, SPINE, V22, P2504, DOI 10.1097/00007632-199711010-00007
   Hoppe S, 2017, EUR J TRAUMA EMERG S, V43, P3, DOI 10.1007/s00068-016-0750-x
   Huisman MV, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.28
   Hulme PA, 2006, SPINE, V31, P1983, DOI 10.1097/01.brs.0000229254.89952.6b
   Innocenzi G, 2017, ACTA NEUROCHIR SUPPL, V124, P289, DOI 10.1007/978-3-319-39546-3_42
   Ishak B, 2017, J NEUROTRAUM, V34, P3326, DOI 10.1089/neu.2017.4968
   Ishak B, 2017, WORLD NEUROSURG, V107, P194, DOI [10.1016/J.WNEU.2017.07.159, 10.1016/j.wneu.2017.07.159]
   Janssen I, 2017, SPINE J, V17, P837, DOI 10.1016/j.spinee.2017.01.009
   Jin MR, 2016, EUR SPINE J, V25, P1729, DOI 10.1007/s00586-015-4012-0
   Kerry G, 2013, ORTHOP REV, V5, P107, DOI 10.4081/or.2013.e24
   Kim YJ, 2009, RADIOLOGY, V251, P250, DOI 10.1148/radiol.2511080854
   Kosmopoulos V, 2007, SPINE, V32, pE111, DOI 10.1097/01.brs.0000254048.79024.8b
   Krueger A, 2009, EUR SPINE J, V18, P1257, DOI 10.1007/s00586-009-1073-y
   Lehman RA, 2015, J AM ACAD ORTHOP SUR, V23, P253, DOI 10.5435/JAAOS-D-14-00042
   Liu Z, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003581
   Martin-Fernandez M, 2017, SPINE J, V17, P1192, DOI 10.1016/j.spinee.2017.04.029
   Mehta H, 2012, CLIN BIOMECH, V27, P234, DOI 10.1016/j.clinbiomech.2011.10.004
   Mueller JU, 2016, J NEUROSURG-SPINE, V25, P103, DOI 10.3171/2015.10.SPINE15511
   Muijs SPJ, 2009, SPINE, V34, P2395, DOI 10.1097/BRS.0b013e3181b8707e
   Pare PE, 2011, SPINE, V36, pE1210, DOI 10.1097/BRS.0b013e318205e3af
   Puth MT, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2060-4
   Rasch A, 2010, THORAC CARDIOV SURG, V58, P437, DOI 10.1055/s-0029-1240847
   Rollinghoff M, 2010, ACTA ORTHOP BELG, V76, P269
   Sawakami K, 2012, J SPINAL DISORD TECH, V25, pE28, DOI 10.1097/BSD.0b013e318228bbed
   Schmidt R, 2005, EUR SPINE J, V14, P466, DOI 10.1007/s00586-004-0839-5
   Shea TM, 2014, BIOMED RES INT, DOI 10.1155/2014/748393
   Shi L, 2012, J SPINAL DISORD TECH, V25, P123, DOI 10.1097/BSD.0b013e31820ef9f7
   Shin BJ, 2012, J NEUROSURG-SPINE, V17, P113, DOI 10.3171/2012.5.SPINE11399
   Tormenti MJ, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09275
   Tozzi P, 2002, ANN THORAC SURG, V74, P1706, DOI 10.1016/S0003-4975(02)03962-0
   WEINSTEIN JN, 1992, CLIN ORTHOP RELAT R, P34
   WILKES RA, 1994, J BONE JOINT SURG BR, V76B, P155
   WITTENBERG RH, 1993, CLIN ORTHOP RELAT R, P278
   Yeom JS, 2003, J BONE JOINT SURG BR, V85B, P83, DOI 10.1302/0301-620X.85B1.13026
   Yuan Q, 2015, EUR SPINE J, V24, P1043, DOI 10.1007/s00586-013-3131-8
   ZINDRICK MR, 1986, CLIN ORTHOP RELAT R, P99
NR 49
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E975
EP E981
DI 10.1016/j.wneu.2019.05.047
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100116
PM 31100522
DA 2020-05-12
ER

PT J
AU Iwanaga, J
   Puffer, RC
   Watanabe, K
   Spinner, RJ
   Tubbs, RS
AF Iwanaga, Joe
   Puffer, Ross C.
   Watanabe, Koichi
   Spinner, Robert J.
   Tubbs, R. Shane
TI Division of Sacrospinous and Sacrotuberous Ligaments Expands Access
   Through Greater Sciatic Foramen: Anatomic Study with Application to
   Resection of Greater Sciatic Foramen Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dumbbell tumor; Greater sciatic foramen; Sacrospinous ligament;
   Sacrotuberous ligament; Sciatic nerve
ID DEEP PELVIC ABSCESSES; TRANSGLUTEAL APPROACH; DRAINAGE
AB OBJECTIVE: Tumors of the greater sciatic foramen remain difficult to treat. They often have both intrapelvic and extrapelvic components that may limit visualization and make safe resection of the tumor difficult. Therefore the goal of the present anatomic study was to quantitate how much additional surgical working space could be gained by transection of the sacrospinous and sacrotuberous ligaments.
   METHODS: Sixteen sides from 9 fresh-frozen Caucasian cadaveric torsos underwent transgluteal dissection and exposure of the greater sciatic foramen and associated liagments. With the piriformis in place, the vertical and horizontal diameters of the greater sciatic foramen were measured. Next, the sacrotuberous and sacrospinous ligaments were cut at their ischial attachments. The vertical diameter of the now confluent greater and lesser sciatic foramina (V-2) was measured.
   RESULTS: The mean vertical diameter of the greater sciatic foramen (V-1) was 54.8 +/- 9.7 mm. The horizontal diameter of the greater sciatic foramen had a mean of 44.3 +/- 6.1 mm with a range of 30-52 mm. After transection of the sacrotuberous and sacrospinous ligaments, the vertical distance of the greater and lesser sciatic foramina (V-2) had a mean of 74.8 +/- 6.8 mm with a range of 60.1-90 mm. The mean ratio of V-2 to V-1 was 1.40.
   CONCLUSIONS: The vertical length of the greater sciatic foramen increased, on average, 40% after resection of the sacrotuberous and sacrospinous ligaments. The results of this study support an alternative technique for resecting large intrapelvic tumors via a transgluteal approach.
C1 [Iwanaga, Joe; Tubbs, R. Shane] Seattle Sci Fdn, Washington, DC 98122 USA.
   [Iwanaga, Joe; Watanabe, Koichi] Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
   [Puffer, Ross C.; Spinner, Robert J.] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Washington, DC 98122 USA.; Iwanaga, J (reprint author), Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
EM joei@seattlesciencefoundation.org
CR Aguilera-Bohorquez B, 2019, POSTERIOR HIP DISORD
   Aldabe D, 2019, CLIN ANAT, V32, P396, DOI 10.1002/ca.23328
   Augustine AS, 2018, CLIN ANAT, V31, P981, DOI 10.1002/ca.23273
   Gibbs CM, 2018, CLIN ANAT, V31, P357, DOI 10.1002/ca.23061
   Hammer N, 2009, ANN ANAT, V191, P417, DOI 10.1016/j.aanat.2009.03.001
   Hammer N, 2019, CLIN ANAT, V32, P231, DOI 10.1002/ca.23291
   Harisinghani MG, 2003, RADIOLOGY, V228, P701, DOI 10.1148/radiol.2283020924
   Iwanaga J, 2019, CLIN ANAT, V32, P282, DOI 10.1002/ca.23311
   Konschake M, 2017, NEUROUROL URODYNAM, V36, P1069, DOI 10.1002/nau.23090
   Li JQ, 2018, PAK J MED SCI, V34, P1200, DOI 10.12669/pjms.345.14830
   Li M, 2017, J SURG ONCOL, V115, P384, DOI 10.1002/jso.24552
   Matejcik V, 2012, ANZ J SURG, V82, P935, DOI 10.1111/j.1445-2197.2012.06272.x
   Matsumoto Y, 2016, WORLD J CLIN ONCOL, V7, P414, DOI 10.5306/wjco.v7.i5.414
   Montano N, 2013, J NEUROSURG, V119, P751, DOI 10.3171/2013.3.JNS121161
   Morris H, 1921, MORRISS HUMAN ANATOM
   Reddy CG, 2012, CLIN ANAT, V25, P914, DOI 10.1002/ca.22144
   Robert B, 2013, ABDOM IMAGING, V38, P285, DOI 10.1007/s00261-012-9917-z
   Shafik A, 2007, INT SURG, V92, P54
   Spinner RJ, 2006, J NEUROSURG, V105, P873, DOI 10.3171/jns.2006.105.6.873
   Standring S, 2015, GRAYS ANATOMY ANATOM
NR 20
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E970
EP E974
DI 10.1016/j.wneu.2019.05.045
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100115
PM 31100516
DA 2020-05-12
ER

PT J
AU Iwanaga, J
   Simonds, E
   Schumacher, M
   Oskouian, RJ
   Tubbs, RS
AF Iwanaga, Joe
   Simonds, Emily
   Schumacher, Maia
   Oskouian, Rod J.
   Tubbs, R. Shane
TI Anatomic Study of Superior Cluneal Nerves? Revisiting the Contribution
   of Lumbar Spinal Nerves
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Low back pain; Lumbar vertebrae; Nerve compression syndrome;
   Pseudosciatica
ID LOW-BACK-PAIN; ENTRAPMENT NEUROPATHY
AB OBJECTIVE: Superior cluneal nerve (SCN) entrapment neuroapathy can result in low back pain and thus be confused with other pathologies (e.g., lumbar disk disease). Therefore we performed cadaveric dissection of the SCN to better understand its anatomy and segmental origin.
   METHODS: Twenty sides from 10 Caucasian fresh frozen cadavers (6 females and 4 males) were used in this study. The diameter of the SCN, distance between the exit point of the SCN from the thoracolumbar fascia and midline, and distance between the exit point of the SCN from the thoracolumbar fascia and the posterior superior iliac spine to the medial and lateral SCN were measured. The segmental origins of the SCNs were verified.
   RESULTS: Seventy-five percent of the dorsal rami of L1, 90% of L2, 95% of L3, 45% of L4, and 10% of L5 contributed to the SCN. The SCN was formed by 3 vertebral levels in 55% and by 4 vertebral levels in 30%. Three SCNs pierced the thoracolumbar fascia in 45%.
   CONCLUSIONS: The origin of the SCN, which has been described in the textbook and literature for a long time, should be reconsidered on the basis of our study results.
C1 [Iwanaga, Joe; Simonds, Emily; Schumacher, Maia; Oskouian, Rod J.; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [Iwanaga, Joe] Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
   [Oskouian, Rod J.] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA USA.
   [Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.; Iwanaga, J (reprint author), Kurume Univ, Sch Med, Dept Anat, Div Gross & Clin Anat, Kurume, Fukuoka, Japan.
EM joei@seattlesciencefoundation.org
CR Akbas Mert, 2005, Pain Pract, V5, P364, DOI 10.1111/j.1533-2500.2005.00040.x
   Aota Y, 2016, WORLD J ORTHOP, V7, P167, DOI 10.5312/wjo.v7.i3.167
   Blain M, 2019, CLIN ANAT, V32, P73, DOI 10.1002/ca.23266
   Challoumas D, 2018, CLIN ANAT, V31, P293, DOI 10.1002/ca.23031
   Chang KV, 2017, AM J PHYS MED REHAB, V96, pE117, DOI 10.1097/PHM.0000000000000642
   Creze M, 2018, CLIN ANAT, V31, P514, DOI 10.1002/ca.23065
   Creze M, 2017, CLIN ANAT, V30, P774, DOI 10.1002/ca.22903
   Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508
   Gibbs CM, 2018, CLIN ANAT, V31, P357, DOI 10.1002/ca.23061
   Herring A, 2010, J EMERG MED, V39, P83, DOI 10.1016/j.jemermed.2009.08.033
   Iwamoto N, 2016, WORLD NEUROSURG, V87, P250, DOI 10.1016/j.wneu.2015.11.043
   Iwanaga J, 2019, WORLD NEUROSURG, V125, pE925, DOI 10.1016/j.wneu.2019.01.210
   Iwanaga J, 2018, CLIN ANAT, V31, P937, DOI 10.1002/ca.23232
   Iwanaga J, 2018, WORLD NEUROSURG, V116, pE766, DOI 10.1016/j.wneu.2018.05.087
   Kim Kyongsong, 2015, Surg Neurol Int, V6, pS619, DOI 10.4103/2152-7806.170455
   Kim K, 2013, J NEUROSURG-SPINE, V19, P624, DOI 10.3171/2013.7.SPINE1374
   Konno T, 2017, J PAIN RES, V10, P2539, DOI 10.2147/JPR.S142115
   Kuniya H, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018-014-0139-7
   Kuniya H, 2013, J NEUROSURG-SPINE, V19, P76, DOI 10.3171/2013.4.SPINE12683
   Lu J, 1998, CLIN ORTHOP RELAT R, P224
   Maigne JY, 1997, SPINE, V22, P1156, DOI 10.1097/00007632-199705150-00017
   MAIGNE JY, 1989, SURG RADIOL ANAT, V11, P289, DOI 10.1007/BF02098698
   Morimoto D, 2013, J NEUROSURG-SPINE, V19, P71, DOI 10.3171/2013.3.SPINE12420
   Netter FH, 2018, ATLAS HUMAN ANATOMY
   Tubbs RS, 2010, J NEUROSURG-SPINE, V13, P356, DOI 10.3171/2010.3.SPINE09747
NR 25
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E12
EP E15
DI 10.1016/j.wneu.2019.02.159
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100003
PM 30862587
DA 2020-05-12
ER

PT J
AU Jin, MC
   Wu, A
   Xiang, M
   Azad, TD
   Soltys, SG
   Li, G
   Pollom, EL
AF Jin, Michael C.
   Wu, Adela
   Xiang, Michael
   Azad, Tej D.
   Soltys, Scott G.
   Li, Gordon
   Pollom, Erqi L.
TI Prognostic Factors and Treatment Patterns in the Management of Giant
   Cell Glioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjuvant; Chemotherapy; Giant cell glioblastoma; Glioblastoma;
   Neuro-oncology
ID RESECTION; SURVIVAL; OUTCOMES; SUBTYPE; EXTENT; CARE
AB BACKGROUND: There is a lack of literature guiding treatment of giant cell glioblastoma (gcGBM), a rare subtype of glioblastoma (GBM). We used a national hospital-based registry to explore treatment patterns and outcomes associated with gcGBM.
   METHODS: Adult patients (age >= 18 years) diagnosed with gcGBM or GBM between 2004 and 2014 were identified from the National Cancer Database. chi(2) analysis and Wilcoxon rank sum testing were used to compare characteristics between the gcGBM and GBM cohorts. Kaplan-Meier statistics, univariable and multivariable Cox regression, and propensity score matching were used to evaluate association between patient, tumor and treatment factors, and survival outcomes. Correlation analysis was used to evaluate historical trends in the treatment of gcGBM. Landmark analysis allowed for accounting of immortal time.
   RESULTS: In total, 683 patients with gcGBM were identified. Patients with gcGBM had improved survival compared with patients with GBM (15.5 months from landmark vs. 11.7; P < 0.001). Increased age (P < 0.001) was associated with worse survival whereas being of female sex (P = 0.023) and having a median income >$63,000 (P = 0.004) predisposed patients to improved outcomes. Patients receiving trimodal therapy (biopsy and/or surgery, radiotherapy, and chemotherapy) experienced better outcomes compared with those receiving either biopsy and/or surgery only or biopsy and/or surgery and radiotherapy without systemic therapy (median survival, 17.55 months vs. 6.68 months; P < 0.001).
   CONCLUSIONS: gcGBM has favorable prognosis compared with GBM and should be aggressively managed with trimodal therapy. Prospective studies of gcGBM are warranted to better characterize gcGBM treatment outcomes.
C1 [Jin, Michael C.; Wu, Adela; Xiang, Michael; Soltys, Scott G.; Pollom, Erqi L.] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA.
   [Jin, Michael C.; Wu, Adela; Azad, Tej D.; Li, Gordon] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
   [Pollom, Erqi L.] Palo Alto Vet Affairs Hlth Care Syst, Palo Alto, CA 94304 USA.
RP Pollom, EL (reprint author), Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA.; Pollom, EL (reprint author), Palo Alto Vet Affairs Hlth Care Syst, Palo Alto, CA 94304 USA.
EM erqiliu@stanford.edu
OI Xiang, Michael/0000-0003-0170-9321
CR AKSLEN LA, 1989, ACTA NEUROL SCAND, V79, P194, DOI 10.1111/j.1600-0404.1989.tb03738.x
   Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Belsuzarri TAB, 2015, RARE TUMORS, V7, P26, DOI 10.4081/rt.2015.5634
   Bilimoria KY, 2008, ANN SURG ONCOL, V15, P683, DOI 10.1245/s10434-007-9747-3
   Boffa DJ, 2017, JAMA ONCOL, V3, P1722, DOI 10.1001/jamaoncol.2016.6905
   BURGER PC, 1980, CANCER, V46, P1179, DOI 10.1002/1097-0142(19800901)46:5<1179::AID-CNCR2820460517>3.0.CO;2-0
   Frandsen J, 2018, J NEUROSURG, V128, P1133, DOI 10.3171/2016.12.JNS162291
   Huang M C, 1996, Noshuyo Byori, V13, P11
   Karremann M, 2009, NEURO-ONCOLOGY, V11, P323, DOI 10.1215/15228517-2008-099
   KATOH M, 1995, PATHOL INT, V45, P275, DOI 10.1111/j.1440-1827.1995.tb03456.x
   KAWANO H, 1995, CLIN NEUROPATHOL, V14, P118
   Kozak KR, 2009, NEURO-ONCOLOGY, V11, P833, DOI 10.1215/15228517-2008-123
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Ortega A, 2014, J CLIN NEUROSCI, V21, P1709, DOI 10.1016/j.jocn.2014.05.003
   Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151
   Patel SH, 2014, LANCET ONCOL, V15, P1027, DOI 10.1016/S1470-2045(14)70268-2
   Sanai N, 2008, NEUROSURGERY, V62, P753, DOI 10.1227/01.neu.0000318159.21731.cf
   Shinojima N, 2004, J NEUROSURG, V101, P219, DOI 10.3171/jns.2004.101.2.0219
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324
   Valle-Folgueral JM, 2008, NEUROCIRUGIA, V19, P343
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E217
EP E224
DI 10.1016/j.wneu.2019.04.103
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100024
PM 31009783
DA 2020-05-12
ER

PT J
AU Jin, SJ
   Park, YS
   Kim, SH
   Kim, D
   Shim, WH
   Jang, DM
   Shaffrey, CI
   Naik, BI
AF Jin, Seok-Joon
   Park, Yong-Seok
   Kim, Sung-Hoon
   Kim, Dongseop
   Shim, Woo-Hyun
   Jang, Dong-Min
   Shaffrey, Christopher I.
   Naik, Bhiken I.
TI Effect of Prone Positional Apparatus on the Occurrence of Acute Kidney
   Injury After Spine Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute kidney injury; Intra-abdominal pressure; Jackson spinal table;
   Prone position; Propensity score-matching; Wilson frame
ID INTRAABDOMINAL PRESSURE; BLOOD-LOSS; COMPLICATIONS; RISK; MORTALITY
AB BACKGROUND AND OBJECTIVE: Increased intra abdominal pressure with prone positioning for spinal surgery is associated with intraoperative hemodynamic alterations and the potential for postoperative complications. This study investigated the incidence of postoperative acute kidney injury (AKI) in patients undergoing spine surgery on a Jackson spinal table or a Wilson frame.
   METHODS: A total of 1374 patients who underwent spine surgery were divided into 2 groups: Jackson spinal table (n= 598) and Wilson frame group (n = 776). After 1:1 propensity score matching, a final analysis was performed on 970 patients. The primary endpoint was a comparison of the incidence of AKI in the 2 groups.
   RESULTS: After propensity score matching analysis, the mean +/- standard deviations of spine surgery invasiveness index were 4.7 +/- 3.5 and 2.1 +/- 1.4 in patients with the Jackson spinal table and the Wilson frame, respectively (P < 0.001). Considering the differences in surgical invasiveness, operative time, estimated blood loss, and administration of packed red blood cells were higher in the Jackson spinal table group than in the Wilson frame group (P < 0.001). However, the incidence of AKI was less with the Jackson spinal table than with the Wilson frame (1.7% vs. 3.7%, 2.25 [0.978-5.175), P = 0.056), not reaching statistical significance.
   CONCLUSION: This analysis showed that postoperative AKI in patients undergoing spine surgery in the prone position was not different with the Wilson frame than in the Jackson spinal table despite higher surgical severity, longer operative times, and more blood loss in the latter group. In spine surgery, the appropriate selection of prone positioning apparatus can potentially be an important consideration in reducing the risk of AKI.
C1 [Jin, Seok-Joon] Catholic Univ Korea, St Pauls Hosp, Dept Anesthesiol, Coll Med, Seoul, South Korea.
   [Park, Yong-Seok; Kim, Sung-Hoon; Jang, Dong-Min] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea.
   [Kim, Sung-Hoon; Kim, Dongseop; Shim, Woo-Hyun] Asan Inst Lifesci, Hlth Innovat Bigdata Ctr, Seoul, South Korea.
   [Shaffrey, Christopher I.] Duke Univ, Sch Med, Dept Neurosurg & Orthopaed Surg, Durham, NC USA.
   [Naik, Bhiken I.] Univ Virginia Hlth Syst, Dept Anesthesiol, Charlottesville, VA USA.
   [Naik, Bhiken I.] Univ Virginia Hlth Syst, Dept Neurosurg, Charlottesville, VA USA.
RP Kim, SH (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea.; Kim, SH (reprint author), Asan Inst Lifesci, Hlth Innovat Bigdata Ctr, Seoul, South Korea.
EM shkimans@amc.seoul.kr
RI Naik, Bhiken/AAH-3831-2019
OI Park, Yong-Seok/0000-0002-3752-2211
FU Asan Institute for Life Sciences, Seoul, Korea [2018-788]; 
   [2016R1C1B1012164];  [2019R1A2C4069504]
FX This work was supported by a grant (2018-788) from Asan Institute for
   Life Sciences, Seoul, Korea, and by the Basic Science Research Program
   through the National Research Foundation of Korea funded by the Ministry
   of Science, ICT & Future Planning (Grant Number 2016R1C1B1012164 and
   2019R1A2C4069504).
CR Bihorac A, 2009, ANN SURG, V249, P851, DOI 10.1097/SLA.0b013e3181a40a0b
   DePasse JM, 2015, WORLD J ORTHOP, V6, P351, DOI 10.5312/wjo.v6.i3.351
   Deyo RA, 2010, JAMA-J AM MED ASSOC, V303, P1259, DOI 10.1001/jama.2010.338
   Dharmavaram S, 2006, SPINE, V31, P1388, DOI 10.1097/01.brs.0000218485.96713.44
   Demarchi ACD, 2014, RENAL FAILURE, V36, P557, DOI 10.3109/0886022X.2013.876353
   Hedenstierna G, 2012, CURR OPIN CRIT CARE, V18, P80, DOI 10.1097/MCC.0b013e32834e7c3a
   Hobson CE, 2009, CIRCULATION, V119, P2444, DOI 10.1161/CIRCULATIONAHA.108.800011
   Ishikawa S, 2017, KOREAN J ANESTHESIOL, V70, P527, DOI 10.4097/kjae.2017.70.5.527
   Jo YY, 2017, KOREAN J ANESTHESIOL, V70, P596, DOI 10.4097/kjae.2017.70.6.596
   Kang WS, 2016, ANESTHESIOLOGY, V125, P115, DOI 10.1097/ALN.0000000000001131
   Kellum JA, 2008, NEPHRON CLIN PRACT, V109, pC182, DOI 10.1159/000142926
   Kellum JA, 2008, CRIT CARE MED, V36, pS141, DOI 10.1097/CCM.0b013e318168c4a4
   Kim E, 2017, J NEUROSURG ANESTH, V29, P14, DOI 10.1097/ANA.0000000000000257
   Kirkpatrick AW, 2010, CRIT CARE, V14, DOI 10.1186/cc9099
   Kwee MM, 2015, INT SURG, V100, P292, DOI 10.9738/INTSURG-D-13-00256.1
   Kwon MA, 2018, KOREAN J ANESTHESIOL, V71, P175, DOI 10.4097/kja.d.18.27182
   Lambert DM, 2005, OBES SURG, V15, P1225, DOI 10.1381/096089205774512546
   Malhotra A, 2016, ASIAN SPINE J, V10, P199, DOI 10.4184/asj.2016.10.2.199
   Martin CT, 2015, SPINE, V40, P909, DOI 10.1097/BRS.0000000000000890
   Mirza SK, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-53
   Mohmand H, 2011, J AM SOC NEPHROL, V22, P615, DOI 10.1681/ASN.2010121222
   Mullens W, 2008, J AM COLL CARDIOL, V51, P300, DOI 10.1016/j.jacc.2007.09.043
   Naik BI, 2014, J NEUROSURG-SPINE, V20, P505, DOI 10.3171/2014.2.SPINE13596
   Nam Y, 2010, KOREAN J ANESTHESIOL, V59, P323, DOI 10.4097/kjae.2010.59.5.323
   Palmon SC, 1998, ANESTH ANALG, V87, P1175, DOI 10.1097/00000539-199811000-00037
   Park CK, 2000, ANESTH ANALG, V91, P552, DOI 10.1213/00000539-200009000-00009
   Park JT, 2017, KOREAN J ANESTHESIOL, V70, P258, DOI 10.4097/kjae.2017.70.3.258
   Schonauer C, 2004, EUR SPINE J, V13, pS50, DOI 10.1007/s00586-004-0728-y
   Smit M, 2013, CRIT CARE, V17, DOI 10.1186/cc12568
   Sui F, 2016, EUR REV MED PHARMACO, V20, P452
   Tabara Y, 2005, HYPERTENS RES, V28, P741, DOI 10.1291/hypres.28.741
   Yi M, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.08.010
NR 32
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E597
EP E602
DI 10.1016/j.wneu.2019.04.216
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100069
PM 31054343
DA 2020-05-12
ER

PT J
AU Kan, WW
   Wang, R
   Yang, K
   Liu, HY
   Zou, YJ
   Liu, Y
   Zhao, JB
   Luo, ZX
   Chen, J
AF Kan, Wenwu
   Wang, Ran
   Yang, Kun
   Liu, Hongyi
   Zou, Yuanjie
   Liu, Yong
   Zhao, Jinbing
   Luo, Zhengxiang
   Chen, Jiu
TI Effect of Hormone Levels and Aging on Cognitive Function of Patients
   with Pituitary Adenomas Prior to Medical Treatment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cognitive function; Hormone levels; Pituitary adenomas; Tumor volume
ID AGE-DIFFERENCES; WORKING-MEMORY; GRAPH-THEORY; BRAIN; TUMORS;
   CLASSIFICATION; EPIDEMIOLOGY; RADIOTHERAPY; INSIGHTS; DECLINE
AB BACKGROUND: Cognitive impairments have been reported in patients with pituitary adenomas (PAs). The aim of this research was to demonstrate the effects of hormones and age on cognitive decline in patients with PAs.
   METHODS: A total of 64 patients with PA and 69 healthy control subjects (HCs) were recruited for this study. Both PAs and HCs were divided into a younger group (<50 years of age) and an older group (>= 50 years of age). Neurocognitive domains were assessed using the Wechsler Adult Intelligence Scale-Chinese Revision (WAIS-RC) and Wechsler Memory Scale-Chinese Revision (WMS-RC) tests. Furthermore, we also investigated the relationship between cognitive domains and tumor volume, and the hormone levels and age of patients with PA.
   RESULTS: Several of the cognitive impairments found on the WAIS-RC and WMS-RC tests were more frequently observed in untreated patients with PA. Importantly, no significant correlations were found between cognitive domains and tumor volume after controlling age, sex, and educational levels. Furthermore, several significant correlations were found between cognitive domains and hormone levels, such as free thyroxine and adrenocorticotropic hormone, after controlling age, sex, and educational levels. Finally, the age of the patients was found to correlate with a decrease in memory after controlling sex and educational levels.
   CONCLUSIONS: Our findings demonstrate a significant decline in the cognitive performance of patients with PA prior to medical treatment, especially in older patients, which suggests that hormones and age have the ability to interact and aggravate cognitive decline in patients with PA.
C1 [Kan, Wenwu; Wang, Ran; Yang, Kun; Liu, Hongyi; Zou, Yuanjie; Liu, Yong; Zhao, Jinbing; Luo, Zhengxiang] Nanjing Med Univ, Affiliated Brain Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.
   [Yang, Kun; Chen, Jiu] Nanjing Med Univ, Inst Brain Funct Imaging, Nanjing, Jiangsu, Peoples R China.
   [Chen, Jiu] Nanjing Med Univ, Clin Coll 4, Inst Neuropsychiat, Affiliated Brain Hosp, Nanjing, Jiangsu, Peoples R China.
RP Yang, K (reprint author), Nanjing Med Univ, Affiliated Brain Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.; Yang, K (reprint author), Nanjing Med Univ, Inst Brain Funct Imaging, Nanjing, Jiangsu, Peoples R China.
EM yk_nj@hotmail.com
OI wenwu, kan/0000-0002-7228-1476
FU National Health and Family Planning Commission of the People's Republic
   of China [w201308]; Nanjing Commission of Health and Family Planning
   [H201540]; medical scientific and technologic development project of
   Nanjing [YKK12137, ZKX15035, ZKX14044]; Jiangsu Provincial Health and
   Family Planning Commission [CXTDA2017050]; Jiangsu Government
   [JS-2014-294]
FX This study was supported by a grant from the clinical medical scientific
   and technologic project of the National Health and Family Planning
   Commission of the People's Republic of China (w201308), the Nanjing
   Commission of Health and Family Planning (H201540), a grant from the
   medical scientific and technologic development project of Nanjing
   (YKK12137, ZKX15035, and ZKX14044), the Innovation Team Project of 13th
   Five Year Plan of the Jiangsu Provincial Health and Family Planning
   Commission (CXTDA2017050), and a Jiangsu Government Scholarship for
   Overseas Studies (JS-2014-294).
CR Aflorei ED, 2014, J NEURO-ONCOL, V117, P379, DOI 10.1007/s11060-013-1354-5
   Agosta F, 2013, NEUROLOGY, V81, P134, DOI 10.1212/WNL.0b013e31829a33f8
   Agustsson TT, 2015, EUR J ENDOCRINOL, V173, P655, DOI 10.1530/EJE-15-0189
   BALTES PB, 1995, PSYCHOL AGING, V10, P155, DOI 10.1037/0882-7974.10.2.155
   Bojar I, 2015, MED SCI MONITOR, V21, P1625, DOI 10.12659/MSM.892880
   Brummelman P, 2012, EUR J CLIN INVEST, V42, P1317, DOI 10.1111/j.1365-2362.2012.02721.x
   Brummelman P, 2011, CLIN ENDOCRINOL, V74, P481, DOI 10.1111/j.1365-2265.2010.03947.x
   Cabeza R, 2004, CEREB CORTEX, V14, P364, DOI 10.1093/cercor/bhg133
   Casadesus G, 2006, BBA-MOL BASIS DIS, V1762, P447, DOI 10.1016/j.bbadis.2006.01.008
   Catchlove SJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197055
   Davies BM, 2016, ACTA NEUROCHIR, V158, P677, DOI 10.1007/s00701-015-2699-7
   Ferreira D, 2015, PSICOTHEMA, V27, P216, DOI 10.7334/psicothema2014.192
   Fonda SJ, 2005, J GERONTOL A-BIOL, V60, P385, DOI 10.1093/gerona/60.3.385
   Gao L, 2015, J CLIN NEUROSCI, V22, P488, DOI 10.1016/j.jocn.2014.08.032
   GRATTANSMITH PJ, 1992, ACTA NEUROL SCAND, V86, P626, DOI 10.1111/j.1600-0404.1992.tb05500.x
   Guinan EM, 1998, J NEUROL NEUROSUR PS, V65, P870, DOI 10.1136/jnnp.65.6.870
   Hedden T, 2004, NAT REV NEUROSCI, V5, P87, DOI 10.1038/nrn1323
   Husain MO, 2018, INT J PSYCHIAT CLIN, V22, P13, DOI 10.1080/13651501.2017.1341987
   Kovacs K, 2001, J NEURO-ONCOL, V54, P121, DOI 10.1023/A:1012945129981
   Li S, 2008, LIFE SCI, V82, P934, DOI 10.1016/j.lfs.2008.02.010
   Lopes MBS, 2017, ACTA NEUROPATHOL, V134, P521, DOI 10.1007/s00401-017-1769-8
   Milham MP, 2002, BRAIN COGNITION, V49, P277, DOI 10.1006/brcg.2001.1501
   Noad R, 2004, CLIN ONCOL-UK, V16, P233, DOI 10.1016/j.clon.2004.01.012
   Park DC, 2003, J COGNITIVE NEUROSCI, V15, P1122, DOI 10.1162/089892903322598094
   Park DC, 2002, PSYCHOL AGING, V17, P299, DOI 10.1037//0882-7974.17.2.299
   Peace KA, 1997, J CLIN EXP NEUROPSYC, V19, P1, DOI 10.1080/01688639708403831
   Pereira AM, 2012, NETH J MED, V70, P255
   Psaras T, 2011, J CLIN NEUROSCI, V18, P1340, DOI 10.1016/j.jocn.2011.01.027
   SALTHOUSE TA, 1993, MEM COGNITION, V21, P699, DOI 10.3758/BF03197200
   Shen X, 2010, NEUROIMAGE, V50, P1027, DOI 10.1016/j.neuroimage.2009.12.119
   Souchay C, 2004, BRAIN COGNITION, V56, P89, DOI 10.1016/j.bandc.2004.06.002
   STARKMAN MN, 1981, ARCH INTERN MED, V141, P215, DOI 10.1001/archinte.141.2.215
   Tooze A, 2009, CLIN ENDOCRINOL, V70, P503, DOI 10.1111/j.1365-2265.2008.03464.x
   Wang XX, 2017, NEUROL SCI, V38, P1315, DOI 10.1007/s10072-017-2980-z
   Xu HZ, 2013, NEUROSCI LETT, V543, P27, DOI 10.1016/j.neulet.2013.02.062
   Zhou AH, 2009, INT J GERIATR PSYCH, V24, P1352, DOI 10.1002/gps.2265
NR 36
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E252
EP E260
DI 10.1016/j.wneu.2019.04.131
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100029
PM 31026659
DA 2020-05-12
ER

PT J
AU Karaaslan, B
   Borcek, AO
   Ucar, M
   Aykol, S
AF Karaaslan, Burak
   Borcek, Alp Ozgun
   Ucar, Murat
   Aykol, Sukru
TI Can the Etiopathogenesis of Chiari Malformation Be Craniocervical
   Junction Stabilization Difference? Morphometric Analysis of
   Craniocervical Junction Ligaments
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chian malformation; Craniocervical ligaments; Foramen magnum
   decompression
ID CRANIOVERTEBRAL JUNCTION; ALAR; DECOMPRESSION; BIOMECHANICS; MOVEMENTS;
   ANATOMY
AB OBJECTIVE: The craniocervical junction permits a certain amount of mobility for the cervical spine. The biomechanical properties of occipital bone-atlas joint mainly depend on the bony structure, and atlas-axis joint biomechanical properties mainly depend on ligamentous structure. The underlying etiologic factor of Chiari malformation (CM) is debatable. Nowadays, some researchers argue that stabilization difference is one of the suspicious factors for etiopathogenesis. We aim to analyze the ligamentous morphometric differences of CM.
   METHODS: Magnetic resonance images of 93 adult healthy subjects (n = 93) without any craniocervical junction development abnormalities and 25 (n = 25) adult patients with craniocervical junction development abnormalities (Arnold CM) were evaluated. Length, width, and length-width ratios of ligaments were evaluated.
   RESULTS: Length of transverse ligament (mean: 23 +/- 3.6 [range: 12.1-31.4]) in the normal population was significantly longer than transverse ligament length in CM patients (mean: 21.3 +/- 2.5 [range: 17.2-24.9]). Length of alar ligament (mean: 10.7 +/- 2 [range: 5.1-15.4]) in the normal population was significantly longer than alar ligament length in CM patients (mean: 8.8 +/- 3.8 [range: 1.1-16.6]) (P = 0.007).
   CONCLUSIONS: Craniocervical ligaments play an important role in maintaining stability and motion capacity of this region. This study promoted better understanding of craniocervical junction anomalies and provided data that facilitate performing more precise surgical treatment.
C1 [Karaaslan, Burak] Cubuk Halil Sivgin State Hosp, Ankara, Turkey.
   [Borcek, Alp Ozgun; Aykol, Sukru] Gazi Univ, Fac Med, Dept Neurosurg, Ankara, Turkey.
   [Ucar, Murat] Gazi Univ, Fac Med, Dept Radiol, Ankara, Turkey.
RP Karaaslan, B (reprint author), Cubuk Halil Sivgin State Hosp, Ankara, Turkey.
EM burakkaraaslan08@hotmail.com
RI Borcek, Alp Ozgun/O-6840-2017
OI Borcek, Alp Ozgun/0000-0002-6222-382X; Karaaslan,
   Burak/0000-0003-1015-396X
CR Aydin S, 2005, SURG NEUROL, V64, P237, DOI 10.1016/j.surneu.2005.02.021
   BADIE B, 1995, NEUROSURGERY, V37, P214, DOI 10.1227/00006123-199508000-00004
   Du Boulay G, 1972, Acta Radiol Diagn (Stockh), V13, P496
   DUBOULAY GH, 1966, BRIT J RADIOL, V39, P255, DOI 10.1259/0007-1285-39-460-255
   DVORAK J, 1988, J ORTHOP RES, V6, P452, DOI 10.1002/jor.1100060317
   DVORAK J, 1987, SPINE, V12, P183, DOI 10.1097/00007632-198703000-00016
   FIELDING JW, 1974, J BONE JOINT SURG AM, VA 56, P1683, DOI 10.2106/00004623-197456080-00019
   Finn MA, 2008, J NEUROSURG-SPINE, V9, P296, DOI 10.3171/SPI/2008/9/9/296
   Goel A, 2015, J NEUROSURG-SPINE, V22, P116, DOI 10.3171/2014.10.SPINE14176
   GOEL VK, 1988, J BIOMECH, V21, P673, DOI 10.1016/0021-9290(88)90204-7
   Iai Hiroshi, 1993, Spine, V18, P2388, DOI 10.1097/00007632-199312000-00004
   Klekamp J, 2012, J NEUROSURG-PEDIATR, V10, P538, DOI 10.3171/2012.9.PEDS12110
   Menezes AH, 2008, CHILD NERV SYST, V24, P1091, DOI 10.1007/s00381-008-0606-8
   Naftel RP, 2013, J NEUROSURG-PEDIATR, V12, P351, DOI 10.3171/2013.7.PEDS12522
   Oldfield EH, 2017, NEUROSURGERY, V64, P66, DOI 10.1093/neuros/nyx377
   PANJABI M, 1988, SPINE, V13, P726, DOI 10.1097/00007632-198807000-00003
   PANJABI M, 1991, J ORTHOPAED RES, V9, P584, DOI 10.1002/jor.1100090415
   Steinmetz MP, 2010, NEUROSURGERY, V66, pA7, DOI 10.1227/01.NEU.0000366109.85796.42
   Tubbs RS, 2007, CLIN ANAT, V20, P382, DOI 10.1002/ca.20334
   Wolfla Christopher E, 2006, Spine J, V6, p225S, DOI 10.1016/j.spinee.2006.09.001
NR 20
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1096
EP E1101
DI 10.1016/j.wneu.2019.05.072
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100125
PM 31103770
DA 2020-05-12
ER

PT J
AU Kashkoush, A
   Mehta, A
   Agarwal, N
   Nwachuku, EL
   Fields, DP
   Alan, N
   Kanter, AS
   Okonkwo, DO
   Hamilton, DK
   Thirumala, PD
AF Kashkoush, Ahmed
   Mehta, Amol
   Agarwal, Nitin
   Nwachuku, Enyinna L.
   Fields, Daryl P.
   Alan, Nima
   Kanter, Adam S.
   Okonkwo, David O.
   Hamilton, David K.
   Thirumala, Parthasarathy D.
TI Perioperative Neurological Complications Following Anterior Cervical
   Discectomy and Fusion: Clinical Impact on 317,789 Patients from the
   National Inpatient Sample
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical discectomy and fusion; In-hospital outcomes;
   Intraoperative neuromonitoring; Mortality; Perioperative neurologic
   complications
ID SPINE SURGERY; DECOMPRESSION; DEFICITS; STROKES
AB BACKGROUND: Perioperative neurologic complication after an anterior cervical discectomy and fusion (ACDF) is uncommon but may have significant clinical consequences.
   OBJECTIVE: We aim to estimate the incidence of perioperative neurologic complications, identify their risk factors, and evaluate their impact on morbidity and mortality after ACDF.
   METHODS: ACDF cases (n = 317,789 patients) were extracted from the National Inpatient Sample between 1999 and 2011. Based on their Elixhauser-van Walraven score (VWR), patients were classified as low (VWR < 5), moderate (5-14), or high risk (>14) for surgery. The primary outcome was perioperative neurologic complications. Secondary outcomes included morbidity (hospital length of stay >14 days or discharge disposition to a location other than home) and in-hospital mortality.
   RESULTS: The rate of perioperative neurologic complications, morbidity, and mortality after ACDF was 0.4%, 8.4%, and 0.1%, respectively. Perioperative neurologic complications were highly associated with in-house morbidity (odds ratio [OR], 3.7 [3.1-4.4]) and mortality (OR, 8.0 [4.1-15.5]). The strongest predictors for perioperative neurologic complications were moderate- (OR, 3.1 [2.6-3.7]) and high-risk VWR (OR, 5.4 [3.3-8.9]), postoperative hematoma/seroma formation (OR, 5.4 [3.9-7.4]), and obesity (OR, 1.9 [1.6-2.3]). The rate of perioperative neurologic complications increased from 0.2% to 0.7% from 1999 to 2011, which was temporally associated with the rise in moderate- (P = 0.002) and high-risk patients (P = 0.001) undergoing ACDF.
   CONCLUSIONS: Perioperative neurologic complications are independent predictors of in-hospital morbidity and mortality after ACDF. Both morbidity and perioperative neurologic complications have increased between 1999 and 2011, which may be due, in part, to increasing numbers of moderate- and high-risk patients undergoing ACDF.
C1 [Kashkoush, Ahmed; Mehta, Amol; Agarwal, Nitin; Nwachuku, Enyinna L.; Fields, Daryl P.; Alan, Nima; Kanter, Adam S.; Okonkwo, David O.; Hamilton, David K.; Thirumala, Parthasarathy D.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA.
RP Thirumala, PD (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA.
EM thirumalapd@upmc.edu
RI /AAA-4616-2020
OI Agarwal, Nitin/0000-0003-0256-3897
CR Angevine PD, 2003, SPINE, V28, P931, DOI 10.1097/00007632-200305010-00016
   Barnes Bryan, 2002, Neurosurg Focus, V12, pE13
   BERTALANFFY H, 1989, ACTA NEUROCHIR, V99, P41, DOI 10.1007/BF01407775
   Cabilan C J, 2015, JBI Database System Rev Implement Rep, V13, P146, DOI 10.11124/jbisrir-2015-1885
   Daniels AH, 2008, J AM ACAD ORTHOP SUR, V16, P729, DOI 10.5435/00124635-200812000-00005
   Dayananda S, 2018, WORLD NEUROSURG, V119, pE250, DOI 10.1016/j.wneu.2018.07.126
   Dietrich WD, 2011, NEUROTHERAPEUTICS, V8, P229, DOI 10.1007/s13311-011-0035-3
   Emery SE, 1998, J BONE JOINT SURG AM, V80A, P941, DOI 10.2106/00004623-199807000-00002
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   GINSBURG HH, 1985, J NEUROSURG, V63, P296, DOI 10.3171/jns.1985.63.2.0296
   Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80
   Hilibrand AS, 2004, J BONE JOINT SURG AM, V86A, P1248, DOI 10.2106/00004623-200406000-00018
   Ikenaga M, 2005, J NEUROSURG-SPINE, V3, P210, DOI 10.3171/spi.2005.3.3.0210
   Kamerlink JR, 2010, SPINE, V35, P240, DOI 10.1097/BRS.0b013e3181c7c8f6
   Kelleher MO, 2008, J NEUROSURG-SPINE, V8, P215, DOI 10.3171/SPI/2008/8/3/215
   LESSER RP, 1986, ANN NEUROL, V19, P22, DOI 10.1002/ana.410190105
   Mehta A, 2018, WORLD NEUROSURG, V112, pE385, DOI 10.1016/j.wneu.2018.01.052
   Mehta A, 2017, J CLIN NEUROSCI, V44, P175, DOI 10.1016/j.jocn.2017.06.035
   Netterville JL, 1996, ANN OTO RHINOL LARYN, V105, P85, DOI 10.1177/000348949610500201
   Papadopoulos EC, 2006, SPINE, V31, P897, DOI 10.1097/01.brs.0000209348.17377.be
   Roh MS, 2007, ASIAN SPINE J, V1, P43, DOI 10.4184/asj.2007.1.1.43
   Schwartz DM, 2007, J BONE JOINT SURG AM, V89A, P2440, DOI 10.2106/Jl3JS.F01476
   Shen Francis H, 2004, Spine J, V4, P629, DOI 10.1016/j.spinee.2004.04.009
   Taunt CJ, 2005, SPINE, V30, P1970, DOI 10.1097/01.brs.0000176321.02963.72
   Tew Jr JM, 1967, CLIN NEUROSURG, V23, P424
   Thirumala P, 2017, SPINE J, V17, P1611, DOI 10.1016/j.spinee.2017.05.020
   Udesh R, 2018, NEUROL INDIA, V66, P57, DOI 10.4103/0028-3886.222849
   Udesh R, 2017, J CLIN NEUROSCI, V42, P91, DOI 10.1016/j.jocn.2017.04.006
   Udesh R, 2017, J CARDIOTHOR VASC AN, V31, P529, DOI 10.1053/j.jvca.2016.12.006
   van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5
   Xu Risheng, 2011, Surg Neurol Int, V2, P133, DOI 10.4103/2152-7806.85606
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E107
EP E115
DI 10.1016/j.wneu.2019.04.037
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100014
PM 30980979
DA 2020-05-12
ER

PT J
AU Kim, CH
   Choi, JH
   Park, HS
AF Kim, Chang-Ho
   Choi, Jae-Hyung
   Park, Hyun-Seok
TI Safety and Efficacy of Minimally Invasive Stereotactic Aspiration with
   Multicatheter Insertion Compared with Conventional Craniotomy for Large
   Spontaneous Intracerebral Hemorrhage (>= 50 mL)
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral hemorrhage; Craniotomy; Minimally invasive surgical procedures;
   Mortality; Neuronavigation; Stereotaxic techniques
ID ENDOSCOPIC SURGERY; SPOT SIGN; EVACUATION; VOLUME; TRIAL
AB BACKGROUND: Conventional craniotomy (CC) is generally favored for treating large intracerebral hemorrhage (ICH), but the feasibility of minimally invasive stereotactic aspiration for large ICH is controversial. We investigated the efficacy and safety of stereotactic aspiration with multicatheter insertion (SAMCI) for large ICH (>= 50 mL).
   METHODS: In January 2014, we implemented SAMCI for large ICH. The inclusion criteria for SAMCI were as follows: 1) spontaneous supratentorial ICH, 2) ICH volume >= 50 mL, 3) Glasgow Coma Scale score >= 5, and 4) no bilateral fixed dilated pupils. Forty-seven patients who underwent SAMCI from January 2014 to July 2018 composed the SAMCI group, and 34 patients who underwent CC between January 2010 and December 2013 and retrospectively met the inclusion criteria for SAMCI composed the control group (CC group).
   RESULTS: The mean preoperative ICH volume in the SAMCI and CC groups was 73.1 +/- 22.8 and 72.4 +/- 21.5 mL, respectively. There were no significant differences between the groups in baseline characteristics except for ICH location. The deep portion of the ICH was higher in the SAMCI group than in the CC group. Postoperative mortality and rebleeding rates were significantly lower in the SAMCI group than in the CC group (4.3% vs. 26.5% and 0% vs. 14.7%, respectively; P < 0.05). Logistic regression analysis showed that SAMCI contributed to a decrease in the mortality rate (odds ratio, 0.04; P = 0.008).
   CONCLUSIONS: SAMCI is a feasible therapeutic option for large ICH and has low complication rates.
C1 [Kim, Chang-Ho; Choi, Jae-Hyung; Park, Hyun-Seok] Dong A Univ, Coll Med, Med Sci Res Ctr, Busan Reg Cardiocerebrovasc Ctr,Dept Neurosurg, Busan, South Korea.
RP Park, HS (reprint author), Dong A Univ, Coll Med, Med Sci Res Ctr, Busan Reg Cardiocerebrovasc Ctr,Dept Neurosurg, Busan, South Korea.
EM nsparkhs@dau.ac.kr
OI Park, Hyun-Seok/0000-0002-9936-671X
FU Dong-A University Research Fund
FX This work was supported by the Dong-A University Research Fund.
CR Angileri FF, 2016, WORLD NEUROSURG, V94, P268, DOI 10.1016/j.wneu.2016.07.015
   BATJER HH, 1990, ARCH NEUROL-CHICAGO, V47, P1103, DOI 10.1001/archneur.1990.00530100071015
   BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987
   Chi FL, 2014, WORLD J EMERG MED, V5, P203, DOI [10.5847/wjem.j.issn.1920-8642.2014.03.008, 10.5847/wjem.j.1920-8642.2014.03.008]
   Delcourt C, 2012, NEUROLOGY, V79, P314, DOI 10.1212/WNL.0b013e318260cbba
   Demchuk AM, 2012, LANCET NEUROL, V11, P307, DOI 10.1016/S1474-4422(12)70038-8
   Ge CY, 2018, CLIN NEUROL NEUROSUR, V169, P41, DOI 10.1016/j.clineuro.2018.04.002
   Hanley DF, 2019, LANCET, V393, P1021, DOI 10.1016/S0140-6736(19)30195-3
   Hanley DF, 2016, LANCET NEUROL, V15, P1226, DOI 10.1016/S1474-4422(16)30234-4
   Hong KS, 2013, J STROKE, V15, P2, DOI 10.5853/jos.2013.15.1.2
   Jiang B, 2006, STROKE, V37, P63, DOI 10.1161/01.STR.0000194955.34820.78
   JUVELA S, 1989, J NEUROSURG, V70, P755, DOI 10.3171/jns.1989.70.5.0755
   Dong DB, 2018, J CLIN NEUROSCI, V50, P208, DOI 10.1016/j.jocn.2018.01.066
   Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304
   Kuo LT, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS10313
   Li YQ, 2017, WORLD NEUROSURG, V105, P332, DOI 10.1016/j.wneu.2017.05.134
   Li ZH, 2017, NEUROPSYCH DIS TREAT, V13, P213, DOI 10.2147/NDT.S120368
   Mendelow AD, 2005, LANCET, V365, P387
   Morgenstern LB, 2001, NEUROLOGY, V56, P1294, DOI 10.1212/WNL.56.10.1294
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3
   Wang WH, 2015, J CHIN MED ASSOC, V78, P101, DOI 10.1016/j.jcma.2014.08.013
   Wang WJ, 2017, WORLD NEUROSURG, V105, P348, DOI 10.1016/j.wneu.2017.05.158
   Xia ZW, 2018, WORLD NEUROSURG, V115, P266, DOI 10.1016/j.wneu.2018.04.181
   Xu XH, 2018, J NEUROSURG, V128, P553, DOI 10.3171/2016.10.JNS161589
   Zhao Yi-Ning, 2016, Chronic Dis Transl Med, V2, P140, DOI 10.1016/j.cdtm.2016.11.002
   Zhou HG, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-76
   Zhou HG, 2011, J NEUROL, V258, P661, DOI 10.1007/s00415-011-5902-7
   Zuccarello M, 1999, STROKE, V30, P1833, DOI 10.1161/01.STR.30.9.1833
NR 29
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E787
EP E795
DI 10.1016/j.wneu.2019.04.258
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100093
PM 31078808
DA 2020-05-12
ER

PT J
AU Kim, HJ
   Lee, SJ
   Jung, KO
AF Kim, Hyung Jun
   Lee, Seung-Jae
   Jung, Kyu-On
TI Association of Concomitant Intracranial Atherosclerotic Stenosis with
   Collateral Status in Patients with Emergent Large Vessel Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atherosclerosis; Collateral; Intracranial; Stroke
ID ACUTE ISCHEMIC-STROKE; LEPTOMENINGEAL COLLATERALS; CT ANGIOGRAPHY;
   BLOOD-PRESSURE; THROMBOLYSIS; CIRCULATION; FLOW
AB BACKGROUND: Concomitant atherosclerotic stenoses are commonly encountered in emergent large vessel occlusion. This study attempted to prove whether or not the pattern of atherosclerotic stenosis other than symptomatic occlusion is associated with pretreatment collateral status among patients with emergent large vessel occlusion.
   METHODS: The study included 115 patients with middle cerebral artery territory infarct within 6 hours of stroke onset who were considered for endovascular revascularization therapy. All patients underwent pretreatment conventional computed tomography angiography using a 128-detector high-definition computed tomography scanner. Based on maximum intensity projection images, <= 50% filling of the occluded territory was considered to indicate poor collaterals, whereas >50% filling was considered to indicate good collaterals. Finding of >50% stenosis on computed tomography angiography was considered significant, and the stenosis patterns were classified into intracranial atherosclerotic stenosis and extracranial atherosclerotic stenosis according to the location of the stenosis.
   RESULTS: All patients had symptomatic M1 (47.8%), M2 (20.0%), or internal carotid artery (32.2%) occlusion. There were 44 patients with poor collaterals (38.3%) and 71 patients with good collaterals (61.7%). Univariate analysis revealed that poor collateral status was associated with advanced age (>= 65 years), hypertension, high National Institutes of Health Stroke Scale score, symptomatic internal carotid artery occlusion, and concomitant atherosclerotic stenosis. Multivariate analysis showed that poor collateral circulation was associated with concomitant intracranial atherosclerotic stenosis and symptomatic internal carotid artery occlusion (vs. a more distal occlusion).
   CONCLUSIONS: Concomitant intracranial atherosclerotic stenosis other than symptomatic occlusion might be a crucial factor associated with pretreatment collateral status among patients with emergent large vessel occlusion.
C1 [Kim, Hyung Jun; Lee, Seung-Jae; Jung, Kyu-On] Soonchunhyang Univ, Dept Neurol, Bucheon Hosp, Bucheon, Gyeonggi Do, South Korea.
RP Lee, SJ (reprint author), Soonchunhyang Univ, Dept Neurol, Bucheon Hosp, Bucheon, Gyeonggi Do, South Korea.
EM neurosj@catholic.ac.kr
OI Lee, Seung-Jae/0000-0003-2299-4870
FU Soonchunhyang University Research Fund
FX This study was supported by the Soonchunhyang University Research Fund.
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Arsava EM, 2014, J STROKE CEREBROVASC, V23, P421, DOI 10.1016/j.jstrokecerebrovasdis.2013.03.014
   Bang OY, 2011, STROKE, V42, P693, DOI 10.1161/STROKEAHA.110.595256
   Caplan LR, 1998, ARCH NEUROL-CHICAGO, V55, P1475, DOI 10.1001/archneur.55.11.1475
   Dankbaar JW, 2018, CLIN NEURORADIOL, V28, P339, DOI 10.1007/s00062-017-0568-x
   Frolich AMJ, 2014, EUR RADIOL, V24, P390, DOI 10.1007/s00330-013-3024-6
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Hao YG, 2017, STROKE, V48, P1203, DOI 10.1161/STROKEAHA.116.016368
   Higashida RT, 2003, STROKE, V34, pE109, DOI 10.1161/01.STR.0000082721.62796.09
   Jiang BS, 2017, J STROKE, V19, P222, DOI 10.5853/jos.2016.01739
   Kitagawa K, 2005, STROKE, V36, P2270, DOI 10.1161/01.STR.0000181075.77897.0e
   Lee SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185314
   Lee SU, 2016, J STROKE, V18, P179, DOI 10.5853/jos.2015.01529
   Leng XY, 2016, CEREBROVASC DIS, V41, P27, DOI 10.1159/000441803
   Liebeskind DS, 2008, STROKE, V39, P538
   Liebeskind DS, 2011, J CEREBR BLOOD F MET, V31, P1293, DOI 10.1038/jcbfm.2010.224
   Liebeskind DS, 2003, STROKE, V34, P2279, DOI 10.1161/01.STR.0000086465.41263.06
   Lima FO, 2010, STROKE, V41, P2316, DOI 10.1161/STROKEAHA.110.592303
   Menon BK, 2013, ANN NEUROL, V74, P241, DOI 10.1002/ana.23906
   Millesi K, 2019, J NEUROL SCI, V396, P69, DOI 10.1016/j.jns.2018.11.002
   Ogasawara K, 2002, STROKE, V33, P1857, DOI 10.1161/01.STR.0000019511.81583.A8
   Ovbiagele B, 2007, NEUROLOGY, V68, P2129, DOI 10.1212/01.wnl.0000264931.34941.f0
   Park BJ, 2018, WORLD NEUROSURG, V115, pE585, DOI 10.1016/j.wneu.2018.04.104
   Saarinen JT, 2014, AM J NEURORADIOL, V35, P1892, DOI 10.3174/ajnr.A3983
   Shuaib A, 2011, LANCET NEUROL, V10, P909, DOI 10.1016/S1474-4422(11)70195-8
   Smit EJ, 2013, STROKE, V44, P2194, DOI 10.1161/STROKEAHA.111.000675
   Song D, 2018, YONSEI MED J, V59, P310, DOI 10.3349/ymj.2018.59.2.310
   van Seeters T, 2016, NEURORADIOLOGY, V58, P969, DOI 10.1007/s00234-016-1727-5
   Wufuer A, 2019, HERZ, V44, P455, DOI 10.1007/s00059-018-4691-5
   Zhang H, 2010, J CEREBR BLOOD F MET, V30, P923, DOI 10.1038/jcbfm.2010.10
NR 30
TC 0
Z9 0
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1102
EP E1108
DI 10.1016/j.wneu.2019.05.073
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100126
PM 31103756
DA 2020-05-12
ER

PT J
AU Kim, JY
   Cho, YH
   Kim, YS
   Kim, TS
   Joo, SP
AF Kim, Jae-Young
   Cho, Yong-Hwan
   Kim, You-Sub
   Kim, Tae-Sun
   Joo, Sung-Pil
TI Contralateral Brain Atrophy in Conservatively Treated Primary
   Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain atrophy; Intracerebral hematoma; Neurodegeneration
ID SECONDARY THALAMIC LESIONS; GLOBAL CEREBRAL ATROPHY; SUBARACHNOID
   HEMORRHAGE; INJURY; MECHANISMS; CONNECTIVITY; NETWORKS; THROMBIN;
   IMPACT; EDEMA
AB BACKGROUND: In patients with intracerebral hemorrhage (ICH), brain volume loss can occur in the hemisphere ipsilateral to the hematoma. However, contralateral hemispheric volume change after ICH is not well known. The present study aimed to investigate contralateral brain volume changes in patients with ICH who had not undergone surgery.
   METHODS: Of the 2213 patients with ICH admitted to our hospital between January 2010 and December 2017, 46 patients without surgical intervention were included in the present study. We measured contralateral hemispheric brain volume in the axial images of brain computed tomography at the time of ICH onset and after 12 months. We analyzed the relationship between various factors and volume changes in the contralateral hemisphere.
   RESULTS: The mean change percentage between the initial and follow-up contralateral parenchyma volume was 96.84%. The average volume decreased by 3.16% (P = 0.001). Univariate and multivariate logistic regression models revealed no significant factors associated with contralateral brain volume loss. Kruskal-Wallis test and Mann-Whitney U test showed no statistical significance (P = 0.824, P = 0.122) between ICH volume groups.
   CONCLUSIONS: Contralateral parenchymal volumes were significantly decreased at follow-up brain computed tomography scanning; these changes may provide important clinical information on the remote effect of focal lesion and symptoms in the course of ICH treatment. However, further investigation is required to determine the mechanisms underlying these volume changes.
C1 [Kim, Jae-Young; Cho, Yong-Hwan; Kim, You-Sub; Kim, Tae-Sun; Joo, Sung-Pil] Chonnam Natl Univ Hosp & Med Sch, Dept Neurosurg, Gwangju, South Korea.
RP Joo, SP (reprint author), Chonnam Natl Univ Hosp & Med Sch, Dept Neurosurg, Gwangju, South Korea.
EM nsjsp@jnu.ac.kr
OI Joo, Sung-Pil/0000-0002-4983-0174
FU Chonnam National University Hospital Biomedical Research Institute
   [CRI18036-1]
FX This study was supported by a grant (CRI18036-1) from Chonnam National
   University Hospital Biomedical Research Institute.
CR ANDREWS RJ, 1991, STROKE, V22, P943, DOI 10.1161/01.STR.22.7.943
   Aoi MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046794
   Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225
   Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718
   Babu R, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11366
   Bivard A, 2018, STROKE, V49, P384, DOI 10.1161/STROKEAHA.117.019276
   Chen YJ, 2014, J ALZHEIMERS DIS, V42, P841, DOI 10.3233/JAD-140948
   Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367
   Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019
   Elliott J, 2010, ANESTH ANALG, V110, P1419, DOI 10.1213/ANE.0b013e3181d568c8
   Felberg RA, 2002, ANN NEUROL, V51, P517, DOI 10.1002/ana.10160
   Flower O, 2011, CURR OPIN CRIT CARE, V17, P106, DOI 10.1097/MCC.0b013e328342f823
   Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668
   Gauthier LV, 2012, STROKE, V43, P453, DOI 10.1161/STROKEAHA.111.633255
   Grefkes C, 2011, BRAIN, V134, P1264, DOI 10.1093/brain/awr033
   Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287
   Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7
   Kim HJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97105
   Kim JH, 2017, WORLD NEUROSURG, V102, P56, DOI 10.1016/j.wneu.2017.02.105
   Lee EY, 2013, PARKINSONISM RELAT D, V19, P1088, DOI 10.1016/j.parkreldis.2013.07.018
   Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272
   Lutkenhoff ES, 2013, NEUROIMAGE-CLIN, V3, P396, DOI 10.1016/j.nicl.2013.09.010
   Mayer SA, 2005, LANCET NEUROL, V4, P662, DOI 10.1016/S1474-4422(05)70195-2
   MYERS R, 1991, NEUROSCI LETT, V133, P20, DOI 10.1016/0304-3940(91)90047-W
   Nakamura T, 2005, BRAIN RES, V28, P1
   Narberhaus A, 2003, REV NEUROLOGIA, V36, P925, DOI 10.33588/rn.3610.2002517
   Nordborg C, 1996, ACTA NEUROPATHOL, V91, P61
   ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z
   Scahill RI, 2003, ARCH NEUROL-CHICAGO, V60, P989, DOI 10.1001/archneur.60.7.989
   Sharp F, 2008, ACTA NEUROCHIR SUPPL, V105, P43
   Tam AKH, 2013, J NEUROSURG, V119, P198, DOI 10.3171/2013.3.JNS121950
   Tam AKH, 2013, ACTA NEUROCHIR SUPPL, V115, P17, DOI 10.1007/978-3-7091-1192-5_5
   Wagner KR, 2002, DEV NEUROSCI-BASEL, V24, P154, DOI 10.1159/000065703
   Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0
   Yassi N, 2015, CEREBROVASC DIS, V39, P232, DOI 10.1159/000381105
NR 35
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E391
EP E396
DI 10.1016/j.wneu.2019.04.160
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100045
PM 31029818
DA 2020-05-12
ER

PT J
AU Kim, YS
   Joo, SP
   Kim, TS
AF Kim, You-Sub
   Joo, Sung-Pil
   Kim, Tae-Sun
TI Microsurgical Management of Ruptured Blood Blister Aneurysms of the
   Internal Carotid Artery without Bypass: A Retrospective Single-Center
   Study of 36 Patients over 20 Years
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blood-blister aneurysm; Clipping; Internal carotid artery; Suturing;
   Wrapping
ID TERM-FOLLOW-UP; ISCHEMIC COMPLICATIONS; NONBRANCHING SITES; WALL;
   OCCLUSION
AB BACKGROUND: Microsurgical management of blood blister aneurysms of the internal carotid artery is challenging because of the special characteristics of these aneurysms. We reviewed our diverse surgical methods with long-term clinical and radiologic follow-up.
   METHODS: We retrospectively reviewed all patients with blood blister aneurysms presenting with subarach-noid hemorrhage that were treated with microsurgical obliteration between 1993 and 2017. Baseline characteristics of patients and aneurysms, surgical methods, and clinical and radiologic outcomes were analyzed.
   RESULTS: This study included 36 patients. The patients were treated using microsurgery with direct clipping (2 patients; 5.6%), cotton-assisted clipping (24 patients; 66.7%), wrapping-clipping (5 patients; 13.9%), or wrapping-clipping with suturing (5 patients; 13.9%). Complete occlusion of aneurysm was achieved in 34 of 36 patients (94.4%). Severe vasospasm developed in 18 of 36 patients (50%). Ischemic events occurred in 8 patients (22.2%), 2 of whom remained with severe disability. Regrowth or recurrence occurred in 1 patient (0.28%), which required additional stent-assisted coil embolization. Mean modified Rankin Scale score was 2.0 (median, 1.0; range, 0-4) at discharge and 1.3 (median, 1.0; range, 0-4) at the last follow-up.
   CONCLUSIONS: Direct clipping is ideal if possible; however, direct clipping is challenging in most blood blister aneurysms. Assisted clipping with cotton is mainly used and could be an effective technique for reinforcement of the friable wall, with good clinical outcomes in our series. Moreover, suturing followed by wrapping-clipping is also useful for managing intraoperative rupture.
C1 [Kim, You-Sub; Joo, Sung-Pil; Kim, Tae-Sun] Chonnam Natl Univ Hosp & Med Sch, Dept Neurosurg, Gwangju, South Korea.
RP Joo, SP (reprint author), Chonnam Natl Univ Hosp & Med Sch, Dept Neurosurg, Gwangju, South Korea.
EM nsjsp@jnu.ac.kr
FU National Research Foundation of Korea Basic Science Research Program -
   Ministry of Education [2018R1D1A1B07048483]
FX This research was supported by the National Research Foundation of Korea
   Basic Science Research Program funded by the Ministry of Education
   (Grant No. 2018R1D1A1B07048483)
CR Brown MA, 2017, J CLIN NEUROSCI, V39, P72, DOI 10.1016/j.jocn.2016.12.021
   Consoli A, 2012, J NEUROINTERV SURG, V4, DOI 10.1136/jnis.2010.004572
   EBINA K, 1984, ACTA NEUROCHIR, V72, P61, DOI 10.1007/BF01406814
   Fang YB, 2013, CLIN NEUROL NEUROSUR, V115, P920, DOI 10.1016/j.clineuro.2012.09.022
   Guo YB, 2018, WORLD NEUROSURG, V109, P165, DOI 10.1016/j.wneu.2017.09.186
   Hetzel A, 2000, CEREBROVASC DIS, V10, P194, DOI 10.1159/000016056
   Ishikawa T, 1997, NEUROSURGERY, V40, P403, DOI 10.1097/00006123-199702000-00038
   Joo SP, 2006, SURG NEUROL, V66, P424, DOI 10.1016/j.surneu.2006.01.024
   Kalani MYS, 2013, NEUROSURGERY, V73, P1026, DOI 10.1227/NEU.0000000000000147
   Kazumata K, 2014, OPER NEUROSURG, V10, P66, DOI 10.1227/NEU.0000000000000076
   Kikkawa Y, 2017, WORLD NEUROSURG, V105, P470, DOI 10.1016/j.wneu.2017.06.033
   Kim JH, 2006, SURG NEUROL, V66, P441, DOI 10.1016/j.surneu.2005.12.030
   Lee BH, 2009, J NEUROSURG, V110, P431, DOI 10.3171/2008.7.JNS08257
   Lee JW, 2009, ACTA NEUROCHIR, V151, P125, DOI 10.1007/s00701-008-0165-5
   Liu YT, 2012, BRIT J NEUROSURG, V26, P378, DOI 10.3109/02688697.2011.631617
   Lozupone E, 2018, J NEUROSURG, V128, P1037, DOI 10.3171/2016.11.JNS161937
   McLaughlin N, 2010, WORLD NEUROSURG, V74, P483, DOI 10.1016/j.wneu.2010.06.039
   Meling TR, 2008, J NEUROSURG, V108, P662, DOI 10.3171/JNS/2008/108/4/0662
   Mokin M, 2018, J NEUROINTERV SURG, V10, P1074, DOI 10.1136/neurintsurg-2017-013701
   Murai Y, 2012, WORLD NEUROSURG, V77, P166, DOI 10.1016/j.wneu.2011.05.020
   Murakami K, 2009, SURG NEUROL, V71, P434, DOI 10.1016/j.surneu.2008.03.036
   Ogawa A, 2000, NEUROSURGERY, V47, P578, DOI 10.1097/00006123-200009000-00008
   Owen CM, 2017, NEUROSURGERY, V80, P235, DOI 10.1227/NEU.0000000000001259
   Park JH, 2007, J NEUROSURG, V106, P812, DOI 10.3171/jns.2007.106.5.812
   SACHS E, 1972, ACTA NEUROCHIR, V26, P121, DOI 10.1007/BF01406549
   Shah SS, 2017, J NEUROSURG, V127, P1361, DOI 10.3171/2016.9.JNS161526
   SHIGETA H, 1992, ACTA NEUROCHIR, V119, P42, DOI 10.1007/BF01541780
   Sim SY, 2006, J NEUROSURG, V105, P400, DOI 10.3171/jns.2006.105.3.400
   Zhu DY, 2018, WORLD NEUROSURG, V118, pE79, DOI 10.1016/j.wneu.2018.06.123
NR 29
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E956
EP E965
DI 10.1016/j.wneu.2019.05.043
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100113
PM 31100528
DA 2020-05-12
ER

PT J
AU La Barbera, L
   Cianfoni, A
   Ferrari, A
   Distefano, D
   Bonaldi, G
   Villa, T
AF La Barbera, Luigi
   Cianfoni, Alessandro
   Ferrari, Andrea
   Distefano, Daniela
   Bonaldi, Giuseppe
   Villa, Tomaso
TI Stent Screw-Assisted Internal Fixation (SAIF) of Severe Lytic Spinal
   Metastases: A Comparative Finite Element Analysis of the SAIF Technique
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extreme osteolysis (EO); Finite element model (FEM); Screw
   stent-assisted internal fixation (SAIF); Spinal metastases; Spine
   biomechanics
ID BURST FRACTURE RISK; ISO 12189 STANDARD; PRECLINICAL EVALUATION;
   STABILIZATION DEVICES; VERTEBRAL AUGMENTATION; VERTEBROPLASTY;
   VALIDATION; MANAGEMENT; LOCATION; VOLUME
AB OBJECTIVE: A new stent-screw - assisted internal fixation (SAIF) minimally invasive cement-augmentation technique has been introduced to treat patients with extreme osteolytic lesions of the vertebral body. The aim of the current finite element study, employing a spine model with an extreme osteolytic defect, was to assess the effect of the SAIF technique in reducing strains in the vertebral body in comparison with a standard surgical short posterior fixation.
   METHODS: Different finite element models of a L1-S1 spine were developed, representing an intact condition (reference configuration), an extreme osteolysis condition, and its treatment, respectively with stand-alone SAIF, SAIF and posterior fixation, and with stand-alone posterior fixation. Each model was loaded to reproduce standing and upper body bending. Principal strains were calculated on the superior endplate, anterior and posterior cortical walls. A paired Wilcoxon test with a 0.05 significance level was performed to statistically analyze the results.
   RESULTS: Median strains on the bony structures increased in the osteolysis model compared with the intact model, and the SAIF technique was effective in reducing such strains under both standing and flexion conditions. Additional posterior fixation, combined with the SAIF technique, produced minimal further reduction of the median strains on the bony structures. Stand-alone posterior fixation only shielded the osteolytic vertebra avoiding excessive displacements but failed in restoring the axial stiffness to values typical of the intact vertebra.
   CONCLUSIONS: The new SAIF technique resulted effective in restoring the load-bearing capacity of the extensively osteolytic vertebra; additional posterior fixation provided only further minor advantages.
C1 [La Barbera, Luigi; Ferrari, Andrea; Villa, Tomaso] Politecn Milan, Lab Biol Struct Mech, Dept Chem Mat & Chem Engn G Natta, Milan, Italy.
   [La Barbera, Luigi] Polytech Montreal, Dept Mech Engn, Montreal, PQ, Canada.
   [La Barbera, Luigi] St Justine Univ Hosp Ctr, Montreal, PQ, Canada.
   [Cianfoni, Alessandro; Distefano, Daniela] Neuroctr Southern Switzerland, Dept Neuroradiol, Lugano, Switzerland.
   [Cianfoni, Alessandro] UniBern, Inselspital, Dept Neuroradiol, Bern, Switzerland.
   [Bonaldi, Giuseppe] Pope John XXIII Hosp, Neuroradiol, Bergamo, Italy.
RP Villa, T (reprint author), Politecn Milan, Lab Biol Struct Mech, Dept Chem Mat & Chem Engn G Natta, Milan, Italy.
EM tomaso.villa@polimi.it
RI La Barbera, Luigi/E-6663-2018
OI La Barbera, Luigi/0000-0002-9822-2116
FU Fondazione per la Ricerca Ospedale Maggiore di Bergamo - FROM (Bergamo,
   Italy)
FX The study was supported by Fondazione per la Ricerca Ospedale Maggiore
   di Bergamo - FROM (Bergamo, Italy).
CR Chae SW, 2010, P I MECH ENG H, V224, P87, DOI 10.1243/09544119JEIM654
   Chevalier Y, 2008, SPINE, V33, P1722, DOI 10.1097/BRS.0b013e31817c750b
   Cianfoni A, 2019, J NEUROINTERV SURG, V11, P603, DOI 10.1136/neurintsurg-2018-014481
   Cianfoni A, 2019, J NEUROINTERV SURG, V11, P313, DOI 10.1136/neurintsurg-2018-014231
   Diel P, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-233
   Gonschorek O, 2017, EUR J TRAUMA EMERG S, V43, P9, DOI 10.1007/s00068-016-0753-7
   Groenen KHJ, 2018, MED ENG PHYS, V51, P104, DOI 10.1016/j.medengphy.2017.11.007
   Imai K, 2015, AGING DIS, V6, P180, DOI 10.14336/AD.2014.0621
   La Barbera L, 2017, EUR SPINE J, V26, P200, DOI 10.1007/s00586-016-4766-z
   La Barbera L, 2016, EUR SPINE J, V25, P2909, DOI 10.1007/s00586-016-4622-1
   La Barbera L, 2016, P I MECH ENG H, V230, P122, DOI 10.1177/0954411915621587
   La Barbera L, 2016, P I MECH ENG H, V230, P134, DOI 10.1177/0954411915621588
   La Barbera L, 2015, SPINE J, V15, P2290, DOI 10.1016/j.spinee.2015.07.461
   Lador R, 2017, CLIN SPINE SURG, V30, pE1074, DOI 10.1097/BSD.0000000000000482
   Laufer I, 2012, CANCER CONTROL, V19, P122, DOI 10.1177/107327481201900206
   Ottardi C, 2016, J APPL BIOMATER FUNC, V14, pE197, DOI 10.5301/jabfm.5000287
   Ottardi C, 2016, MED ENG PHYS, V38, P506, DOI 10.1016/j.medengphy.2016.02.002
   Palanca M, 2018, J BIOMECH ENG, P25
   Rohlmann A, 2010, EUR SPINE J, V19, P1585, DOI 10.1007/s00586-010-1386-x
   Rotter R, 2010, EUR SPINE J, V19, P916, DOI 10.1007/s00586-010-1341-x
   Sciubba DM, 2010, J NEUROSURG-SPINE, V13, P94, DOI 10.3171/2010.3.SPINE09202
   Tschirhart CE, 2006, ANN BIOMED ENG, V34, P494, DOI 10.1007/s10439-005-9063-7
   Tschirhart CE, 2004, J BIOMECH, V37, P653, DOI 10.1016/j.jbiomech.2003.09.027
   Whyne CM, 2003, SPINE, V28, P652, DOI 10.1097/00007632-200304010-00007
   Whyne CM, 2001, J BIOMECH, V34, P1317, DOI 10.1016/S0021-9290(01)00086-0
   Yang Z, 2015, J MOL MODEL, V21, DOI 10.1007/s00894-015-2681-6
   Zaryanov AV, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.5.FOCUS1495
NR 27
TC 2
Z9 2
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E370
EP E377
DI 10.1016/j.wneu.2019.04.154
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100043
PM 31029814
DA 2020-05-12
ER

PT J
AU Laeke, T
   Biluts, H
   Sahlu, A
AF Laeke, Tsegazeab
   Biluts, Hagos
   Sahlu, Abat
TI Clinical Outcome of Operated Intracranial Meningiomas: An Ethiopian
   Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial meningioma; Karnofsky score; Resource-limited setup; Tumor
   size; WHO grading
ID SURGERY; TUMORS
AB BACKGROUND: Intracranial meningioma is the most common brain tumor operated in the 2 teaching hospitals in Ethiopia. This study reviews the clinical outcome of intracranial meningiomas in a resource-limited setup.
   METHODS: This is a retrospective study undertaken at 2 neurosurgical teaching hospitals: Black Lion Specialized Hospital and Myungsung Christian Medical Center. It includes all operated patients with intracranial meningioma during the time period January 2009 to December 2013. Patient data regarding sociodemographics, presenting complaint, focal neurologic deficit, preoperative imaging, postoperative neurologic findings, intra-operative findings, and histopathologic results were collected and analyzed.
   RESULTS: A total of 91 patients were enrolled in the study. Tumor size was estimated in 79 cases (86.8%). Fifty-one tumors (64.6%) were >5 cm in diameter, whereas 28 (35.4%) were <= 5 cm. Only 4 patients had tumors <3 cm (5.1%). Tumor size was shown to be related to postoperative functional outcome (P = 0.032). The surgical mortality rate, which was defined as death within 1 month, was 14.3%. Among 88 patients with a postoperative Karnofsky Performance Status Scale score, 43% achieved a postoperative score >= 70.
   CONCLUSIONS: Meningioma size determines the outcome of the patients. It was shown that the functional outcome of patients is encouraging even though further improvement on neurosurgical care is needed.
C1 [Laeke, Tsegazeab; Biluts, Hagos; Sahlu, Abat] Addis Ababa Univ, Coll Hlth Sci, Surg Dept, Neurosurg Unit, Addis Ababa, Ethiopia.
   [Laeke, Tsegazeab] Univ Bergen, Fac Med, Dept Clin Med, Bergen, Norway.
   [Laeke, Tsegazeab; Biluts, Hagos] Univ Cambridge, Grp Neurotrauma, NIHR Global Hlth Res, Cambridge, England.
RP Laeke, T (reprint author), Addis Ababa Univ, Coll Hlth Sci, Surg Dept, Neurosurg Unit, Addis Ababa, Ethiopia.; Laeke, T (reprint author), Univ Bergen, Fac Med, Dept Clin Med, Bergen, Norway.; Laeke, T (reprint author), Univ Cambridge, Grp Neurotrauma, NIHR Global Hlth Res, Cambridge, England.
EM tselaeke@gmail.com
CR Al-Mefty OA, 2011, YOUMANS NEUROLOGICAL
   Arie P, 2010, PRACTICAL SURG NEURO
   Bondy M, 1996, J NEURO-ONCOL, V29, P197, DOI 10.1007/BF00165649
   Central Brain Tumour Registry of the United States, 2009, 2009 2010 CBTRUS STA
   CHAN RC, 1984, J NEUROSURG, V60, P52, DOI 10.3171/jns.1984.60.1.0052
   FINE M, 1980, SURG NEUROL, V13, P385
   Karnofsky DA, 1949, EVALUATION CHEMOTHER, P196
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   MACCARTY C S, 1979, Neurologia Medico-Chirurgica, V19, P569
   Marosi C, 2008, CRIT REV ONCOL HEMAT, V67, P153, DOI 10.1016/j.critrevonc.2008.01.010
   MAURICEWILLIAMS RS, 1992, BRIT J NEUROSURG, V6, P131, DOI 10.3109/02688699209002915
   Mezue Wilfred C, 2012, Surg Neurol Int, V3, P110, DOI 10.4103/2152-7806.101788
   Moiyadi AV, 2012, J NEUROSCI RURAL PRA, V3, P28, DOI 10.4103/0976-3147.91927
   PALMER JD, 1994, NEUROSURGERY, V35, P1061, DOI 10.1227/00006123-199412000-00007
   ROHRINGER M, 1989, J NEUROSURG, V71, P665, DOI 10.3171/jns.1989.71.5.0665
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   TSUJI M, 1993, JPN J PSYCHIAT NEUR, V47, P331
   WARA WM, 1975, AM J ROENTGENOL, V123, P453, DOI 10.2214/ajr.123.3.453
   Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E81
EP E86
DI 10.1016/j.wneu.2019.04.002
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100011
PM 30974276
DA 2020-05-12
ER

PT J
AU Lau, R
   Rubio, RR
   Martino, J
   Sanmillan, JL
   Benet, A
   Meybodi, AT
   Gandhi, S
   Kournoutas, I
   Gabarros, A
AF Lau, Ruth
   Rubio, Roberto Rodriguez
   Martino, Juan
   Sanmillan, Jose L.
   Benet, Arnau
   Meybodi, Ali Tayebi
   Gandhi, Sirin
   Kournoutas, Ioannis
   Gabarros, Andreu
TI Endoscopic Transanterior Middle Temporal Approach to the Atrium-An
   Anatomical Feasibility Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior middle temporal; Atrium; Choroidal arteries; Endoscope; Meyer's
   loop; Optic radiations; Perisylvian network; Surgical approach
ID SUPRACEREBELLAR-TRANSTENTORIAL APPROACH; LATERAL VENTRICLE;
   MICROSURGICAL ANATOMY; DISSECTION; TUMORS; BRAIN; MENINGIOMAS;
   SIMULATION; FASCICULUS; LESIONS
AB OBJECTIVE: The atrium is the taus common location for masses in the lateral ventricle. However, access to this area is limited owing to its deep location and adjacent eloquent neurovascular structures, such as the choroidal arteries, perisylvian white matter (WM) tracts, and optic radiations. We investigated the feasibility and safety of an endoscopic approach to the atrium via the anterior middle temporal gyrus (MTG).
   METHODS: Radiological assessment of a minimally invasive surgical trajectory to the atrium was achieved in 10 patients. Surgical simulation to assess the feasibility of our endoscopic approach was performed on 24 cadaveric specimens using a transzygomatic corridor and temporal craniotomy. Preoperative computed tomography was performed to confirm the surgical trajectory using neuro-navigation. Using Klinger's method, 5 hemispheres were dissected to assess the relationship of our approach to the WM tracts.
   RESULTS: The optimal entry angle to reach the atrium through the anterior MTG was related to the temporal horn in the axial plane and to the Sylvian fissure in the sagittal plane. Our entry point in the anterior MTG was 19 +/- 1.92 mm from the temporal pole. The transparenchymal distance to atrium was 24.55 +/- 4.3 mm. The WM dissections confirmed that our approach did not violate the optic radiations, uncinate fasciculus, inferior fronto-occipital fasciculus, inferior longitudinal fasciculus, or superior longitudinal fasciculus.
   CONCLUSION: Our findings have confirmed the feasibility of an anterior endoscopic approach to the atrium through the anterior MTG, with preservation of the functional integrity of the eloquent cortex and WM tracts.
C1 [Lau, Ruth; Rubio, Roberto Rodriguez; Benet, Arnau; Meybodi, Ali Tayebi; Gandhi, Sirin; Kournoutas, Ioannis] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
   [Rubio, Roberto Rodriguez; Benet, Arnau; Meybodi, Ali Tayebi; Gandhi, Sirin] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
   [Lau, Ruth; Sanmillan, Jose L.; Gabarros, Andreu] Bellvitge Univ Hosp, Dept Neurol Surg, Barcelona, Spain.
   [Martino, Juan] Hosp Univ Marques de Valdecilla, Dept Neurol Surg, Santander, Spain.
   [Martino, Juan] Fdn Inst Invest Marques de Valdecilla, Santander, Spain.
   [Benet, Arnau; Meybodi, Ali Tayebi; Gandhi, Sirin] Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.
RP Lau, R (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.; Lau, R (reprint author), Bellvitge Univ Hosp, Dept Neurol Surg, Barcelona, Spain.
EM ruth_lau_rodriguez@hotmail.com
OI Rodriguez-Rubio, Roberto/0000-0002-7206-309X
CR Benet A, 2014, J NEUROSURG, V120, P1229, DOI 10.3171/2014.1.JNS131857
   Catani M, 2002, NEUROIMAGE, V17, P77, DOI 10.1006/nimg.2002.1136
   Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004
   Cecchi PC, 2008, CLIN NEUROL NEUROSUR, V110, P75, DOI 10.1016/j.clineuro.2007.08.019
   Choi CY, 2006, NEUROSURGERY, V59, P228, DOI 10.1227/01.NEU.0000223374.69144.81
   Doricchi F, 2003, NEUROREPORT, V14, P2239, DOI 10.1097/00001756-200312020-00021
   Duffau H, 2005, BRAIN, V128, P797, DOI 10.1093/brain/awh423
   Duffau H, 2017, CORTEX, V86, P303, DOI 10.1016/j.cortex.2015.12.009
   Fernandez-Miranda JC, 2008, NEUROSURGERY, V62, P989, DOI [10.1227/01.NEU.0000297076.98175.67, 10.1227/01.neu.0000333767.05328.49]
   Goga C, 2015, J NEUROSURG, V122, P1253, DOI 10.3171/2014.12.JNS14281
   Gokalp HZ, 1998, NEUROSURG REV, V21, P126, DOI 10.1007/BF02389318
   Sanchez JJG, 2014, J NEUROSURG, V121, P751, DOI 10.3171/2014.5.JNS132309
   Gungor A, 2017, J NEUROSURG, V126, P945, DOI 10.3171/2016.1.JNS152082
   Ihori N, 2002, EUR NEUROL, V48, P87, DOI 10.1159/000062993
   Jeelani Y, 2017, J NEUROSURG, V126, P1246, DOI 10.3171/2016.3.JNS151289
   Juretschke FR, 2010, NEUROSURG REV, V33, P457, DOI 10.1007/s10143-010-0271-8
   Kawashima M, 2002, NEUROSURGERY, V51, P1208, DOI 10.1097/00006123-200211000-00017
   Kawashima M, 2006, SURG NEUROL, V65, P436, DOI 10.1016/j.surneu.2005.09.033
   Koutsarnakis C, 2015, WORLD NEUROSURG, V84, P483, DOI 10.1016/j.wneu.2015.04.018
   Krolak-Salmon P, 2000, BRIT J OPHTHALMOL, V84, P884, DOI 10.1136/bjo.84.8.884
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Martino J, 2014, CLIN ANAT, V27, P563, DOI 10.1002/ca.22321
   Martino J, 2013, NEUROSURGERY, V72, P87, DOI 10.1227/NEU.0b013e318274294b
   Martino J, 2013, BRAIN STRUCT FUNCT, V218, P105, DOI 10.1007/s00429-012-0386-5
   Martino J, 2010, CORTEX, V46, P691, DOI 10.1016/j.cortex.2009.07.015
   Meybodi AT, 2017, WORLD NEUROSURG, V105, P359, DOI 10.1016/j.wneu.2017.05.124
   Moftakhar R, 2008, NEUROSURGERY, V63, P1, DOI [10.1227/01.NEU.0000297030.82996.6E, 10.1227/01.neu.0000317367.61899.65]
   Nagib MG, 2000, SURG NEUROL, V54, P366, DOI 10.1016/S0090-3019(00)00316-5
   Nakamura M, 2003, SURG NEUROL, V59, P491, DOI 10.1016/S0090-3019(03)00082-X
   Nayar VV, 2010, CLIN NEUROL NEUROSUR, V112, P400, DOI 10.1016/j.clineuro.2010.02.005
   Ojemann G, 2008, J NEUROSURG, V108, P411, DOI 10.3171/JNS/2008/108/2/0411
   Poblete T, 2015, J NEUROSURG, V122, P1274, DOI 10.3171/2014.10.JNS142061
   Sakurai Y, 2010, J NEUROL SCI, V288, P25, DOI 10.1016/j.jns.2009.10.015
   SILVER AJ, 1982, RADIOLOGY, V145, P71, DOI 10.1148/radiology.145.1.7122900
   Smith AB, 2013, RADIOGRAPHICS, V33, P21, DOI 10.1148/rg.331125192
   Stavrinou LC, 2009, ACTA NEUROCHIR, V151, P1517, DOI 10.1007/s00701-009-0252-2
   Wang S, 2010, J NEUROSURG, V113, P949, DOI 10.3171/2010.1.JNS091169
   Wang XD, 2015, J NEUROL SURG PART A, V76, P261, DOI 10.1055/s-0034-1393928
   Weil AG, 2015, J NEUROSURG-PEDIATR, V15, P45, DOI 10.3171/2014.10.PEDS14162
   Wu WT, 2012, NEUROSURGERY, V70, DOI 10.1227/NEU.0b013e31822efcae
   Zhu W, 2013, WORLD NEUROSURG, V80, P167, DOI 10.1016/j.wneu.2012.08.010
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E98
EP E106
DI 10.1016/j.wneu.2019.04.034
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100013
PM 30980970
DA 2020-05-12
ER

PT J
AU Lemee, JM
   Corniola, MV
   Da Broi, M
   Schaller, K
   Meling, TR
AF Lemee, Jean-Michel
   Corniola, Marco, V
   Da Broi, Michele
   Schaller, Karl
   Meling, Torstein R.
TI Early Postoperative Complications in Meningioma: Predictive Factors and
   Impact on Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Meningioma; Outcome; Predictive factors; Recursive
   partitioning analysis
ID INTRACRANIAL MENINGIOMAS; SURGERY; RESECTION; MORTALITY; SURVIVAL;
   READMISSION; RECURRENCE; MORBIDITY; BRAIN; RISK
AB BACKGROUND: Craniotomies carry inherent risks of postoperative complications that may have a negative impact on patients' status. Recognizing and preventing surgical complications is of paramount importance, especially in meningioma surgery, where most of these tumors are benign and current management protocols are effective in terms of disease control and maintenance of higher quality of life.
   The objective of this study was to describe the early complications after surgery and their predictive factors in patients undergoing resection of intracranial meningiomas.
   METHODS: A partly retrospective, partly prospective review was conducted in a Norwegian population-based cohort of 1469 consecutive cases of meningioma surgery treated at the university hospitals of Oslo, totaling 11,414 patient-years of follow-up.
   RESULTS: 2.6% of patients had a postoperative hematoma, 2.7% a postoperative infection, 3.9% a postoperative worsening of neurologic status; 5.4% of patients died during a 30-day period after surgery. Predictive factors of increased risk of postoperative complications were patient's age for the hematoma, a non-skull base meningioma for infection, and postoperative hematoma for the risk of neurologic worsening or 30-day mortality.
   CONCLUSIONS: Early postoperative complications in meningioma surgery have a negative impact on patient survival and postoperative neurologic status, in a disease where survival is usually not limited by the meningioma itself. In this study, we identified risk factors for early postoperative complications, the identification of at-risk populations may help to prevent the occurrence of these risk factors.
C1 [Lemee, Jean-Michel; Corniola, Marco, V; Schaller, Karl; Meling, Torstein R.] Geneva Univ Hosp, Dept Clin Neurosci, Div Neurosurg, Geneva, Switzerland.
   [Da Broi, Michele; Meling, Torstein R.] Univ Oslo, Fac Med, Oslo, Norway.
   [Corniola, Marco, V; Schaller, Karl; Meling, Torstein R.] Univ Geneva, Fac Med, Geneva, Switzerland.
   [Meling, Torstein R.] Oslo Univ Hosp, Dept Neurosurg, Oslo, Norway.
RP Lemee, JM (reprint author), Geneva Univ Hosp, Dept Clin Neurosci, Div Neurosurg, Geneva, Switzerland.
EM Jean-Michel.Lemee@hcuge.ch
OI Da Broi, Michele/0000-0003-1527-1594
CR Abu Hamdeh S, 2014, BRIT J NEUROSURG, V28, P270, DOI 10.3109/02688697.2013.835376
   ADEGBITE AB, 1983, J NEUROSURG, V58, P51, DOI 10.3171/jns.1983.58.1.0051
   Aizer AA, 2015, CANCER-AM CANCER SOC, V121, P4376, DOI 10.1002/cncr.29639
   Asklund T, 2015, ACTA ONCOL, V54, P377, DOI 10.3109/0284186X.2014.975369
   Bartek J, 2015, WORLD NEUROSURG, V83, P673, DOI 10.1016/j.wneu.2015.01.022
   Beniwal M, 2015, BRIT J NEUROSURG, V29, P559, DOI 10.3109/02688697.2015.1019422
   Brooke BS, 2015, LANCET, V386, P884, DOI 10.1016/S0140-6736(15)60087-3
   CHAN RC, 1984, J NEUROSURG, V60, P52, DOI 10.3171/jns.1984.60.1.0052
   Connolly ID, 2015, WORLD NEUROSURG, V84, P1864, DOI 10.1016/j.wneu.2015.08.018
   Corniola MV, 2019, ACTA NEUROCHIR, V161, P1003, DOI 10.1007/s00701-019-03862-z
   DeMonte F, 2011, AL MEFTYS MENINGIOMA
   Dickinson H, 2015, J NEUROSURG, V122, P61, DOI 10.3171/2014.8.JNS1498
   Mesa JAE, 2018, WORLD NEUROSURG, V110, pE112, DOI 10.1016/j.wneu.2017.10.087
   Gerlach R, 2004, NEUROL RES, V26, P61, DOI 10.1179/016164104773026543
   Goldbrunner R, 2016, LANCET ONCOL, V17, pE383, DOI 10.1016/S1470-2045(16)30321-7
   Gupta MK, 2013, MOL BIOSYST, V9, P1390, DOI 10.1039/c3mb25383j
   Han S, 2014, JAMA SURG, V149, P1162, DOI 10.1001/jamasurg.2014.1706
   Hasseleid BF, 2012, J NEUROSURG, V117, P999, DOI 10.3171/2012.9.JNS12294
   Ildan F, 2007, SKULL BASE-INTERD AP, V17, P157, DOI 10.1055/s-2007-970554
   Karhade AV, 2017, J NEURO-ONCOL, V131, P59, DOI 10.1007/s11060-016-2262-2
   Konglund A, 2013, ACTA NEUROL SCAND, V127, P161, DOI 10.1111/j.1600-0404.2012.01692.x
   Konglund A, 2013, ACTA NEUROCHIR, V155, P2263, DOI 10.1007/s00701-013-1872-0
   Ibanez FAL, 2011, WORLD NEUROSURG, V75, P709, DOI 10.1016/j.wneu.2010.11.010
   Lassen B, 2011, NEUROSURGERY, V68, P1259, DOI 10.1227/NEU.0b013e31820c0441
   Lemee JM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42451-z
   Magill ST, 2019, J NEUROSURG, V131, P1179, DOI 10.3171/2018.6.JNS18118
   Maldaner N, 2018, WORLD NEUROSURG, V110, pE287, DOI 10.1016/j.wneu.2017.10.154
   Fors MM, 2017, REV RECENT CLIN TRIA, V12, P3, DOI 10.2174/1574887111666160916144658
   Meling TR, 2019, NEUROSURG REV, V42, P961, DOI 10.1007/s10143-018-1005-6
   Meling TR, 2019, WORLD NEUROSURG, V161, P1003
   Nittby HR, 2016, ACTA NEUROCHIR, V158, P837, DOI 10.1007/s00701-016-2778-4
   Omrani O, 2018, CHILD NERV SYST, V34, P2407, DOI 10.1007/s00381-018-3953-0
   Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI 10.1093/neuonc/now207
   Ourian AJ, 2019, AESTHET SURG J, V39, P572, DOI 10.1093/asj/sjy329
   Pettersson-Segerlind J, 2011, WORLD NEUROSURG, V76, P564, DOI 10.1016/j.wneu.2011.05.015
   Shakir SI, 2018, J NEUROSURG, V129, P1240, DOI 10.3171/2017.6.JNS17120
   Sicking J, 2018, ACTA NEUROCHIR, V160, P1801, DOI 10.1007/s00701-018-3617-6
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Slot K, 2018, EUR GERIATR MED, V9, P95, DOI 10.1007/s41999-017-0015-1
   Steinberger J, 2018, WORLD NEUROSURG, V109, pE16, DOI 10.1016/j.wneu.2017.09.021
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Taylor BES, 2016, NEUROSURGERY, V79, P356, DOI 10.1227/NEU.0000000000001110
   Teramoto S, 2018, SURG J-NY, V4, pe91, DOI 10.1055/s-0038-1660511
   Voss KM, 2017, J NEURO-ONCOL, V133, P641, DOI 10.1007/s11060-017-2481-1
   Wang JJ, 2018, WORLD NEUROSURG, V118, pE766, DOI 10.1016/j.wneu.2018.07.047
NR 45
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E851
EP E858
DI 10.1016/j.wneu.2019.05.010
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100100
PM 31082552
OA Bronze
DA 2020-05-12
ER

PT J
AU Leone, G
   Renieri, L
   Enriquez-Marulanda, A
   Dmytriw, AA
   Nappini, S
   Laiso, A
   Buono, G
   Marseglia, M
   Iuliano, A
   Muto, M
   Briganti, F
   Mangiafico, S
   Limbucci, N
AF Leone, Giuseppe
   Renieri, Leonardo
   Enriquez-Marulanda, Alejandro
   Dmytriw, Adam A.
   Nappini, Sergio
   Laiso, Antonio
   Buono, Giuseppe
   Marseglia, Mariano
   Iuliano, Adriana
   Muto, Mario
   Briganti, Francesco
   Mangiafico, Salvatore
   Limbucci, Nicola
TI Carotid Cavernous Fistulas and Dural Arteriovenous Fistulas of the
   Cavernous Sinus: Validation of a New Classification According to Venous
   Drainage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid cavernous fistula; Classification; Venous drainage
ID ENDOVASCULAR MANAGEMENT; MALFORMATIONS; PROPOSAL; SYSTEM
AB BACKGROUND: Multiple carotid cavernous fistula (CCF) classifications have been proposed. However, they lacked predictive factors for the clinical presentation, natural history, and hemorrhagic risk. Our aim was to externally validate a new classification according to venous drainage (i.e., the Thomas classification [TC]) to assess its relationship with symptoms, endovascular treatment, and outcomes.
   METHODS: We performed a multicenter retrospective review of CCFs at 2 major academic institutions. The CCFs were classified using the Barrow classification (BC) and TC systems.
   RESULTS: The data from 94 patients with a diagnosis of CCF were collected during a study period 23 years, 4 months. Of these 94 patients, 89 had undergone CCF treatment and 5 had experienced spontaneous occlusion. Complete occlusion was achieved in 89.9% of the treated patients. Complications occurred in 5.3% of the patients, including permanent deficits in 2.1%. TC type 4 was associated with cortical symptoms compared with type 2 (P = 0.003) and type 3 (P < 0.001). The BC was not able to detect significant differences among the symptom types. Significant differences were found using the TC for the transarterial-only, transvenous anterior-only, and transvenous posterior-only approaches (P < 0.001, P = 0.03, and P = 0.001, respectively). The transvenous posterior and transvenous anterior approach were significantly associated with type 2 and 3 TC, respectively. Excluding direct CCFs, the BC was not related to the treatment approach. No significant differences in the outcomes were found. However, a trend toward a lower occlusion rate for TC type 4 compared with type 3 was observed.
   CONCLUSION: The TC provided useful information regarding the fistula anatomy and venous hemodynamics, which correlated with the clinical symptoms and treatment strategy.
C1 [Leone, Giuseppe; Muto, Mario] Antonio Cardarelli Azienda Osped Rilievo Nazl, Dept Neuroradiol, Naples, Italy.
   [Leone, Giuseppe; Renieri, Leonardo; Nappini, Sergio; Laiso, Antonio; Mangiafico, Salvatore; Limbucci, Nicola] Careggi Univ Hosp, Neurovasc Intervent Unit, Florence, Italy.
   [Enriquez-Marulanda, Alejandro] Boston Med Ctr, Dept Neurosurg, Boston, MA USA.
   [Dmytriw, Adam A.] Univ Hlth Network, Toronto Western Hosp, Div Diagnost & Therapeut Neuroradiol, Toronto, ON, Canada.
   [Buono, Giuseppe; Marseglia, Mariano; Briganti, Francesco] Federico II Univ Naples, Dept Adv Biomed Sci, Unit Intervent Neuroradiol, Naples, Italy.
   [Iuliano, Adriana] Federico II Univ Naples, Dept Neurosci & Reprod & Odontostomatol Sci, Ophthalmol Unit, Naples, Italy.
RP Leone, G (reprint author), Antonio Cardarelli Azienda Osped Rilievo Nazl, Dept Neuroradiol, Naples, Italy.; Leone, G (reprint author), Careggi Univ Hosp, Neurovasc Intervent Unit, Florence, Italy.
EM g.leonemd@gmail.com
RI Dmytriw, Adam A/U-7239-2017; Limbucci, Nicola/AAE-4861-2019; renieri,
   leonardo/AAC-3202-2019
OI Dmytriw, Adam A/0000-0003-0131-5699; Enriquez-Marulanda,
   Alejandro/0000-0001-6091-390X; Leone, Giuseppe/0000-0002-8727-6303
CR BARROW DL, 1985, J NEUROSURG, V62, P248, DOI 10.3171/jns.1985.62.2.0248
   BORDEN JA, 1995, J NEUROSURG, V82, P166, DOI 10.3171/jns.1995.82.2.0166
   Briganti F, 2013, NEURORADIOL J, V26, P565, DOI 10.1177/197140091302600510
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   De Renzis A, 2013, INTERV NEURORADIOL, V19, P344, DOI 10.1177/159101991301900312
   Ducruet AF, 2013, WORLD NEUROSURG, V80, P538, DOI 10.1016/j.wneu.2013.02.033
   Ellis JA, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS1223
   GRUMANN AJ, 2012, [No title captured], V32, P153, DOI DOI 10.1007/S10792-012-9550-4
   Henderson AD, 2018, EYE, V32, P164, DOI 10.1038/eye.2017.240
   Jia ZY, 2018, AM J NEURORADIOL, V39, P2301, DOI 10.3174/ajnr.A5868
   Jung KH, 2011, NEURORADIOLOGY, V53, P983, DOI 10.1007/s00234-010-0805-3
   Kirsch M, 2006, NEURORADIOLOGY, V48, P486, DOI 10.1007/s00234-006-0089-9
   Luciani A, 2001, AM J NEURORADIOL, V22, P992
   Meyers PM, 2002, AM J OPHTHALMOL, V134, P85, DOI 10.1016/S0002-9394(02)01515-5
   SASAKI H, 1988, ACTA NEUROCHIR, V90, P117, DOI 10.1007/BF01560564
   Satomi J, 2005, NEUROSURGERY, V56, P494, DOI 10.1227/01.NEU.0000153750.95524.62
   SEEGER JF, 1980, AM J NEURORADIOL, V1, P141
   SHIELDS CB, 1981, SOUTHERN MED J, V74, P617
   Stiebel-Kalish H, 2002, OPHTHALMOLOGY, V109, P1685, DOI 10.1016/S0161-6420(02)01166-1
   Suh DC, 2005, STROKE, V36, P1134, DOI 10.1161/01.STR.0000166194.82027.63
   Thomas AJ, 2015, NEUROSURGERY, V77, P380, DOI 10.1227/NEU.0000000000000829
   Wenderoth J, 2017, J NEUROINTERV SURG, V9, P220, DOI 10.1136/neurintsurg-2016-012743
NR 22
TC 1
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E621
EP E631
DI 10.1016/j.wneu.2019.04.220
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100072
PM 31075494
DA 2020-05-12
ER

PT J
AU Li, FH
   Qiao, HH
   Yang, YC
   Du, JP
   Jin, XS
   Wang, B
AF Li, Fei Hu
   Qiao, Huan Huan
   Yang, Ying Cai
   Du, Jin Peng
   Jin, Xia Sheng
   Wang, Bo
TI Incidence and Outcomes of C5 Palsy and Axial Pain After Open-Door
   Laminoplasty or Laminectomy and Fusion: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Axial pain; C5 palsy; Laminectomy; Laminoplasty; Meta-analysis
ID POSTERIOR LONGITUDINAL LIGAMENT; CERVICAL LAMINOPLASTY;
   MULTIVARIATE-ANALYSIS; OSSIFICATION; SPINE; SYMPTOMS
AB OBJECTIVE: C5 palsy and axial pain are significant factors affecting the quality of life after posterior cervical surgery; however, there has been no clear and supportive conclusion on which method is more suitable in a certain case. As a result, we compare the clinical outcomes, complication rates, and anatomical changes between open-door laminoplasty (ODL) and laminectomy and fusion (LF) for cervical spondylotic myelopathy. This is a systematic literature review and meta-analysis.
   METHODS: A comprehensive literature search was conducted using PubMed, Embase, and the Cochrane library. The following outcomes were extracted and analyzed: the cases of C5 palsy and axial pain patients, Japanese Orthopaedic Association, range of motion (ROM), and cervical curvature. Data analysis was conducted with RevMan 5.3. The I-2 statistics were used to evaluate heterogeneity.
   RESULTS: A total of 9 studies were included in the final analysis, all of which were prospective or retrospective cohort studies. The pooled data showed that the incidences of C5 palsy and axial pain in IF were higher than those in ODL. The study indicated that there was no significant difference in pre- and postoperative Japanese Orthopaedic Association scores, preoperative cervical ROM, pre- and postoperative cervical curvature between the 2 groups, but there was significant difference in ROM after operation. These results indicate that ODL was superior to IF in maintaining cervical ROM.
   CONCLUSIONS: Our results demonstrate that the lower incidence of C5 palsy and axial pain can be achieved by using ODL compared with IF. However, current data only provide weak support, if any, favoring ODL over for clinical improvement in reduce these 2 complications.
C1 [Li, Fei Hu; Yang, Ying Cai; Jin, Xia Sheng; Wang, Bo] Yun Cheng Cent Hosp, Dept Orthopaed, Yun Cheng, Peoples R China.
   [Qiao, Huan Huan] Air Force Med Univ, Dept Orthopaed, Tangdu Hosp, Xian, Shaanxi, Peoples R China.
   [Du, Jin Peng] Xi An Jiao Tong Univ, Dept Spine Surg, Affiliated Hong Hui Hosp, Xian, Shaanxi, Peoples R China.
RP Wang, B (reprint author), Yun Cheng Cent Hosp, Dept Orthopaed, Yun Cheng, Peoples R China.
EM 490656547@qq.com
OI Hao, Dingjun/0000-0002-0946-6080
CR An HS, 2014, J AM ACAD ORTHOP SUR, V22, P420, DOI 10.5435/JAAOS-22-07-420
   Blizzard DJ, 2017, EUR SPINE J, V26, P85, DOI 10.1007/s00586-016-4746-3
   Chen Y, 2011, J SPINAL DISORD TECH, V24, P24, DOI 10.1097/BSD.0b013e3181c7e91e
   Epstein Nancy, 2002, Spine J, V2, P436, DOI 10.1016/S1529-9430(02)00394-7
   Geck MJ, 2002, ORTHOP CLIN N AM, V33, P329, DOI 10.1016/S0030-5898(02)00002-0
   Gu YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101933
   Guzman JZ, 2014, BONE JOINT J, V96B, P950, DOI 10.1302/0301-620X.96B7.33665
   Hosono N, 2006, EUR SPINE J, V15, P1375, DOI 10.1007/s00586-006-0089-9
   Iizuka H, 2001, SPINE, V26, P2220, DOI 10.1097/00007632-200110150-00013
   Kaneyama S, 2010, SPINE, V35, pE1553, DOI 10.1097/BRS.0b013e3181ce873d
   Katsumi K, 2013, J SPINAL DISORD TECH, V26, P177, DOI 10.1097/BSD.0b013e31823db346
   Kawaguchi Y, 1999, J SPINAL DISORD, V12, P392
   Komagata Masashi, 2004, Spine J, V4, P650, DOI 10.1016/j.spinee.2004.03.022
   Lee CH, 2017, SPINE, V42, P887, DOI 10.1097/BRS.0000000000001933
   Li H, 2011, SPINE J, V11, P1049, DOI 10.1016/j.spinee.2011.09.008
   Liu JY, 2007, SPINE J, V7, P159, DOI 10.1016/j.spinee.2006.07.007
   [苗洁 Miao Jie], 2012, [中国矫形外科杂志, Orthopedic Journal of China], V20, P978
   Nakamae T, 2012, J SPINAL DISORD TECH, V25, P92, DOI 10.1097/BSD.0b013e318211fc4e
   Nakashima H, 2012, J NEUROSURG-SPINE, V17, P103, DOI 10.3171/2012.4.SPINE11255
   Nassr A, 2010, SPINE J, V10, pS9
   Nurboja B, 2012, NEUROSURGERY, V70, P965, DOI 10.1227/NEU.0b013e31823cf16b
   Radcliff KE, 2014, J SPINAL DISORD TECH, V27, P86, DOI 10.1097/BSD.0b013e31824e53af
   Rao PJ, 2016, J CLIN NEUROSCI, V26, P14, DOI 10.1016/j.jocn.2015.05.064
   Shen C.W, 2013, THESIS
   Singhatanadgige W, 2016, GLOB SPINE J, V6, P702, DOI 10.1055/s-0036-1578805
   Takeuchi K, 2005, SPINE, V30, P2544, DOI 10.1097/01.brs.0000186332.66490.ba
   Thompson SE, 2017, GLOB SPINE J, V7, P645, DOI 10.1177/2192568216688189
   Wang Hui, 2012, Zhonghua Wai Ke Za Zhi, V50, P601
   Wang SJ, 2011, EUR SPINE J, V20, P185, DOI 10.1007/s00586-010-1600-x
   Wang Xin-wei, 2012, Zhonghua Wai Ke Za Zhi, V50, P596
   Yang LL, 2013, ORTHOPEDICS, V36, pE79, DOI 10.3928/01477447-20121217-23
   Yoon ST, 2013, SPINE, V38, pS183, DOI 10.1097/BRS.0b013e3182a7eb7c
   Yuan W, 2015, CLIN NEUROL NEUROSUR, V134, P17, DOI 10.1016/j.clineuro.2015.04.004
NR 33
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1002
EP E1009
DI 10.1016/j.wneu.2019.05.060
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100119
PM 31108254
DA 2020-05-12
ER

PT J
AU Li, JM
   Niu, XD
   Gan, YJ
   Yang, Y
   Wang, TW
   Zhang, HDF
   Liu, YH
   Mao, Q
AF Li, Jiaoming
   Niu, Xiaodong
   Gan, Youjun
   Yang, Yuan
   Wang, Tianwei
   Zhang, Haodongfang
   Liu, Yanhui
   Mao, Qing
TI Clinical and Pathologic Features and Prognostic Factors for Recurrent
   Gliomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glioma; Ki-67; Prognostic factors; Recurrent time
ID CENTRAL-NERVOUS-SYSTEM; LOW-GRADE GLIOMA; GLIOBLASTOMA-MULTIFORME;
   SURVIVAL; TEMOZOLOMIDE; RESECTION; EXTENT; CHEMOTHERAPY; RADIOTHERAPY;
   METHYLATION
AB OBJECTIVE: To explore related factors that influence time to recurrence and prognosis of gliomas.
   METHODS: A retrospective analysis of pathologic and clinical data of patients with glioma who underwent surgery for the first time and had a recurrence between 2009 and 2018 in West China Hospital was performed. Clinical characteristics of patients were reviewed, and survival analysis was performed to identify prognostic factors for the recurrent time. Molecules with differential changes in the paired samples were included in the survival analysis.
   RESULTS: A total of 84 patients met our inclusion requirements and were included in the study; other related factors were also considered in detail in the integrated analysis. Significant differences among O-6-methylguanine-DNA methyltransferase (positive/negative), isocitrate dehydrogenase 1 (positive/negative), and Ki-67 were determined by statistical analysis of paired samples (P = 0.013, P = 0.014, P = 0.017). Univariate analysis demonstrated that Ki-67 (low expression, medium expression, high expression), initial World Health Organization grade (low or high), tumor side (left, right, middle), age (>= 50 years, <50 years), and extent of resection were significantly correlated with time to recurrence (log-rank P = 0.008, P < 0.001, P = 0.015, P < 0.001, P = 0.001). Multivariate analysis results showed that Ki-67 lower expression (hazard ratio [HR] = 0.585, 95% confidence interval [CI] = 0.146-2.336, P = 0.448), medium expression (HR = 0.256, 95% CI = 0.084-0.784, P = 0.017), and high expression (HR = 1 as a reference) together with the initial World Health Organization grade (HR = 0.148, 95% CI = 0.029-0.749, P = 0.021) were independent predictive factors for glioma recurrence.
   CONCLUSIONS: This comprehensive analysis revealed that initial World Health Organization grade and Ki-67 proliferative index were independent prognostic factors that predict the time to recurrence of glioma in patients after first surgery.
C1 [Li, Jiaoming; Niu, Xiaodong; Gan, Youjun; Yang, Yuan; Wang, Tianwei; Zhang, Haodongfang; Liu, Yanhui; Mao, Qing] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
RP Mao, Q (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM maoqing20000@163.com
CR Brandes AA, 2010, NEURO-ONCOLOGY, V12, P283, DOI 10.1093/neuonc/nop050
   D'Amico RS, 2017, WORLD NEUROSURG, V103, P538, DOI 10.1016/j.wneu.2017.04.041
   De Fazio S, 2012, CURR MED CHEM, V19, P972, DOI 10.2174/092986712799320646
   Ducray F, 2011, EXPERT REV ANTICANC, V11, P781, DOI [10.1586/ERA.10.202, 10.1586/era.10.202]
   Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452
   Ganau L, 2015, BEHAV NEUROL, DOI 10.1155/2015/862634
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Horowitz PM, 2013, NEUROSURGERY, V72, pN19, DOI 10.1227/01.neu.0000426216.20454.22
   Jaeckle KA, 2011, J NEURO-ONCOL, V104, P253, DOI 10.1007/s11060-010-0476-2
   Labussiere M, 2010, FUTURE ONCOL, V6, P733, DOI [10.2217/fon.10.25, 10.2217/FON.10.25]
   Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190
   Law M, 2006, NEUROSURGERY, V58, P1099, DOI 10.1227/01.NEU.0000215944.81730.18
   Lee KJ, 2018, WORLD NEUROSURG, V112, pE881, DOI 10.1016/j.wneu.2018.01.208
   Leighton C, 1997, J CLIN ONCOL, V15, P1294, DOI 10.1200/JCO.1997.15.4.1294
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Murphy ES, 2018, INT J RADIAT ONCOL, V100, P965, DOI 10.1016/j.ijrobp.2017.12.258
   Nuno M, 2013, NEUROSURGERY, V73, P458, DOI 10.1227/01.neu.0000431477.02408.5e
   Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189
   Pace A, 2003, ANN ONCOL, V14, P1722, DOI 10.1093/annonc/mdg502
   Pignatti F, 2002, J CLIN ONCOL, V20, P2076, DOI 10.1200/JCO.2002.08.121
   Reavey-Cantwell JF, 2001, J NEURO-ONCOL, V55, P195, DOI 10.1023/A:1013845004294
   Rivera AL, 2010, NEURO-ONCOLOGY, V12, P116, DOI 10.1093/neuonc/nop020
   Sanson M, 2009, J CLIN ONCOL, V27, P4150, DOI 10.1200/JCO.2009.21.9832
   Skjulsvik AJ, 2014, INT J CLIN EXP PATHO, V7, P8905
   Smith JS, 2008, J CLIN ONCOL, V26, P1338, DOI 10.1200/JCO.2007.13.9337
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2010, J CLIN ONCOL, V28, P2712, DOI 10.1200/JCO.2009.26.6650
   Tugcu B, 2010, TURK NEUROSURG, V20, P117, DOI 10.5137/1019-5149.JTN.2461-09.4
   Tully PA, 2016, NEUROSURGERY, V79, P678, DOI 10.1227/NEU.0000000000001338
   Westphal M, 1999, FRONT RADIAT THER ON, V33, P214
   Yang P, 2013, J NEURO-ONCOL, V113, P259, DOI 10.1007/s11060-013-1103-9
   Yang Y, 2013, SEIZURE-EUR J EPILEP, V22, P877, DOI 10.1016/j.seizure.2013.08.004
   Yeh SA, 2005, BRIT J RADIOL, V78, P230, DOI 10.1259/bjr/28534346
NR 33
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E21
EP E30
DI 10.1016/j.wneu.2019.02.210
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100005
PM 30880199
DA 2020-05-12
ER

PT J
AU Li, YW
   Wang, B
   Wang, S
   Li, PZ
   Jiang, B
AF Li, Yawei
   Wang, Bing
   Wang, Shuai
   Li, Pengzhi
   Jiang, Bin
TI Full-Endoscopic Decompression for Lumbar Lateral Recess Stenosis via an
   Interlaminar Approach versus a Transforaminal Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Full-endoscopic; Interlaminar decompression; Lateral recess stenosis;
   Transforaminal decompression
ID SURGICAL TECHNIQUE; LEARNING-CURVE; DISKECTOMY; SURGERY
AB OBJECTIVE: To compare the results of full-endoscopic decompression (FED) in lumbar lateral recess stenosis via an interlaminar or transforaminal approach.
   METHODS: A total of 102 patients with lumbar lateral recess stenosis who underwent FED from February 2015 to June 2016 in our hospital were enrolled. A total of 58 patients underwent interlaminar FED (IL-FED) and 44 patients underwent transforaminal FED (TF-FED). The intraoperative radiation and operation time, length of hospital stay, time to return to work, and complications were compared between both groups. The surgical effectiveness was assessed according to the visual analog scale, Oswestry Disability Index, and modified MacNab criteria.
   RESULTS: In the IL-FED group, the mean operation time was 59.4 +/- 8.5 minutes, and the intraoperative radiation time was 0.50 +/- 0.16 seconds. In the TF-FED group, the mean operation time was 64.1 +/- 10.2 minutes, and the intraoperative radiation time was 7.50 +/- 1.25 seconds. There were significant differences in the operation and radiation time between the 2 groups (P < 0.01). There was no significant difference in the visual analog scale and Oswestry Disability Index scoring between both groups either in the pre- or postoperation (P> 0.05). Based on the modified MacNab scores at the final follow-up, the satisfactory rate in the IL-FED group was 91.4% and that in the TF-FED group was 88.6%, no significant difference was observed between the 2 groups (P> 0.05).
   CONCLUSIONS: FED could provide satisfactory clinical outcomes for lumbar lateral recess stenosis. However, the IL-FED procedure demonstrated shorter operation time and lesser radiation exposure, but higher risk for anesthetic when compared with the TF-FED procedure.
C1 [Li, Yawei; Wang, Bing; Li, Pengzhi; Jiang, Bin] Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.
   [Wang, Shuai] Cent S Univ, Xiangya Hosp 2, Dept Operating Room, Changsha, Hunan, Peoples R China.
RP Wang, B (reprint author), Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.
EM xywb801@csu.edu.cn
CR Ahn Y, 2014, SPINE, V29, pE326
   Ahn Y, 2014, EXPERT REV MED DEVIC, V11, P605, DOI 10.1586/17434440.2014.940314
   Ahn Y, 2012, EXPERT REV MED DEVIC, V9, P361, DOI [10.1586/erd.12.23, 10.1586/ERD.12.23]
   Birjandian Zeinab, 2017, J Spine Surg, V3, P123, DOI 10.21037/jss.2017.06.08
   Choi KC, 2015, NEUROSURGERY, V76, P372, DOI 10.1227/NEU.0000000000000628
   Cong L, 2016, EUR SPINE J, V25, P134, DOI 10.1007/s00586-015-3776-6
   Englund Jon, 2007, Curr Sports Med Rep, V6, P50, DOI 10.1007/s11932-007-0012-0
   Eum JH, 2016, J NEUROSURG-SPINE, V24, P602, DOI 10.3171/2015.7.SPINE15304
   Hong SW, 2011, SPINE, V36, pE172, DOI 10.1097/BRS.0b013e3181db998c
   Hoogland T, 2006, SPINE, V31, pE890, DOI 10.1097/01.brs.0000245955.22358.3a
   Hsu HT, 2013, EUR SPINE J, V22, P727, DOI 10.1007/s00586-012-2540-4
   Kambin P, 1996, J NEUROSURG, V84, P462, DOI 10.3171/jns.1996.84.3.0462
   Kambin P, 1998, CLIN ORTHOP RELAT R, P150
   Komp M, 2015, PAIN PHYSICIAN, V18, P61
   Lee CH, 2018, SPINE, V43, P1756, DOI 10.1097/BRS.0000000000002708
   LEE CK, 1988, SPINE, V13, P313, DOI 10.1097/00007632-198803000-00015
   Li ZZ, 2016, CLIN NEUROL NEUROSUR, V143, P90, DOI 10.1016/j.clineuro.2016.02.008
   Nellensteijn J, 2010, EUR SPINE J, V19, P879, DOI 10.1007/s00586-009-1272-6
   Pan ZM, 2016, MED SCI MONITOR, V22, P530, DOI 10.12659/MSM.894870
   Ruetten S, 2013, OPER ORTHOP TRAUMATO, V25, P31, DOI 10.1007/s00064-012-0195-2
   Ruetten S, 2008, SPINE, V33, P931, DOI 10.1097/BRS.0b013e31816c8af7
   Ruetten S, 2009, J NEUROSURG-SPINE, V10, P476, DOI 10.3171/2008.7.17634
   Sairyo K, 2017, J MED INVESTIG, V64, P1, DOI 10.2152/jmi.64.1
   Shin SH, 2018, WORLD NEUROSURG, V114, pE873, DOI 10.1016/j.wneu.2018.03.107
   Steurer J, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-175
   Tsou Paul M, 2004, Spine J, V4, P564
   Tsou Paul Moody, 2002, Spine J, V2, P41, DOI 10.1016/S1529-9430(01)00153-X
   Wang B, 2011, SPINE J, V11, P122, DOI 10.1016/j.spinee.2010.12.006
   Wang YP, 2016, MED SCI MONITOR, V22, P4604, DOI 10.12659/MSM.901686
   Yeung AT, 2007, ORTHOP CLIN N AM, V38, P363, DOI 10.1016/j.ocl.2007.04.005
   Yeung Anthony T, 2003, Surg Technol Int, V11, P255
   Yeung AT, 2002, SPINE, V27, P722, DOI 10.1097/00007632-200204010-00009
NR 32
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E632
EP E638
DI 10.1016/j.wneu.2019.04.221
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100073
PM 31054348
DA 2020-05-12
ER

PT J
AU Li, ZC
   Wu, WC
   Chen, RM
   Huang, YP
   Chen, XW
   Lin, JH
AF Li, Zhechen
   Wu, Wence
   Chen, Ruomiao
   Huang, Yunpeng
   Chen, Xuanwei
   Lin, Jianhua
TI Could Allograft Bones Combined with Poly-Ether-Ether-Ketone Cages or
   Titanium Mesh Cages be an Alternative Grafting Method in the Management
   of Cervical Spinal Tuberculosis?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Allograft bone; Cervical spinal tuberculosis; Fusion; PEEK cage;
   Titanium mesh cage
ID STAPHYLOCOCCUS-EPIDERMIDIS; ANTERIOR DEBRIDEMENT; BIOFILM FORMATION;
   FUSION; AUTOGRAFT; SPONDYLODISCITIS; INSTRUMENTATION; SUBSTITUTE;
   SECONDARY; REVISION
AB OBJECTIVE: To investigate the effectiveness of allograft bones combined with poly-ether-ether-ketone (PEEK) cages or titanium mesh cages (TMCs) in the management of cervical spinal tuberculosis.
   METHODS: A total of 16 patients with cervical spinal tuberculosis who underwent anterior debridement, reconstruction with allograft bones combined with PEEK cages or TMCs, and anterior plate fixation between 2013 and 2016 were retrospectively studied. Neck pain, neurologic status, operating time, intraoperative blood loss, cervical spine alignment, bony fusion, and self-reported clinical outcomes were reviewed.
   RESULTS: Six patients underwent 1 level reconstruction using PEEK cages and 10 patients received TMCs reconstruction. Patients received a mean follow-up time of 45.9 +/- 13.1 months. Neck pain was greatly relieved, as visual analog scale scores decreased from 4.6 +/- 1.3 preoperatively to 0.7 +/- 0.5 at the final follow-up (P < 0.05). Neurologic status was improved in all patients with neurologic deficits, with 9 patients improving by 1 grade and 1 patient by 2 grades. Kyphosis angle was corrected from 1.3 +/- 12.0 degrees preoperatively to -5.4 +/- 10.2 degrees post-operatively (P < 0.05) and remained at -3.6 +/- 9.6 degrees at the final follow-up (P < 0.05). Bony fusion was achieved in all patients, with a mean time to the fusion of 3.8 +/- 1.3 months. There was no implant failure or signs of cervical spinal tuberculosis recurrence. Excellent results, good results, and fair results were reported in 37.5%, 56.25%, and 6.25% of patients, respectively.
   CONCLUSIONS: Allograft bone combined with PEEK cages and TMCs could bring about favorable clinical results in patients with cervical spinal tuberculosis. This method could be an alternative to autologous bone grafting method in the management of certain cases.
C1 [Li, Zhechen; Huang, Yunpeng; Chen, Xuanwei; Lin, Jianhua] Fujian Med Univ, Dept Spine Surg, Fuzhou, Fujian, Peoples R China.
   [Wu, Wence] Fujian Med Univ, Clin Med Sch 1, Fuzhou, Fujian, Peoples R China.
   [Chen, Ruomiao] Fujian Med Univ, Dept Plast Surg, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China.
RP Chen, XW (reprint author), Fujian Med Univ, Dept Spine Surg, Fuzhou, Fujian, Peoples R China.
EM spine2018@sina.com
FU Key Clinical Specialty Discipline Construction Program of Fujian,
   People's Republic of China
FX The authors thank the colleagues in their department for support. The
   authors also appreciate the grant from the Key Clinical Specialty
   Discipline Construction Program of Fujian, People's Republic of China.
CR Alam Md Shah, 2015, J Spine Surg, V1, P65, DOI 10.3978/j.issn.2414-469X.2015.07.03
   AN HS, 1995, J SPINAL DISORD, V8, P131
   AN HS, 1995, SPINE, V20, P2211, DOI 10.1097/00007632-199510001-00006
   BARTH E, 1989, BIOMATERIALS, V10, P325, DOI 10.1016/0142-9612(89)90073-2
   Bhandari A, 2014, SPINAL CORD, V52, P489, DOI 10.1038/sc.2014.49
   Blanco JS, 1997, SPINE, V22, P1338, DOI 10.1097/00007632-199706150-00011
   Buttermann GR, 1997, SPINE, V22, P2748, DOI 10.1097/00007632-199712010-00009
   COOK SD, 1995, SPINE, V20, P877, DOI 10.1097/00007632-199504150-00002
   Elsawaf A, 2013, NEUROSURG REV, V36, P621, DOI 10.1007/s10143-013-0475-9
   Fisahn C, 2017, GLOB SPINE J, V7, P821, DOI 10.1177/2192568217735827
   Garg RK, 2011, J SPINAL CORD MED, V34, P440, DOI 10.1179/2045772311Y.0000000023
   Ha KY, 2005, SPINE, V30, P38, DOI 10.1097/01.brs.0000147801.63304.8a
   Hahnel S, 2015, CLIN ORAL IMPLAN RES, V26, P1297, DOI 10.1111/clr.12454
   Koptan W, 2011, EUR SPINE J, V20, P308, DOI 10.1007/s00586-010-1537-0
   Kurtz SM, 2007, BIOMATERIALS, V28, P4845, DOI 10.1016/j.biomaterials.2007.07.013
   Ling TX, 2015, EUR SPINE J, V24, P577, DOI 10.1007/s00586-014-3742-8
   Mao NF, 2013, BRIT J NEUROSURG, V27, P160, DOI 10.3109/02688697.2012.722706
   ODOM GL, 1958, JAMA-J AM MED ASSOC, V166, P23, DOI 10.1001/jama.1958.02990010025006
   Pan ZM, 2017, CLIN ORTHOP RELAT R, V475, P2084, DOI 10.1007/s11999-017-5306-9
   Pee YH, 2008, J NEUROSURG-SPINE, V8, P405, DOI 10.3171/SPI/2008/8/5/405
   Samartzis D, 2005, SPINE, V30, P1756, DOI 10.1097/01.brs.0000172148.86756.ce
   Sasso RC, 2005, J SPINAL DISORD TECH, V18, pS7, DOI 10.1097/01.bsd.0000137157.82806.68
   Shibuya N, 2015, CLIN PODIATR MED SUR, V32, P21, DOI 10.1016/j.cpm.2014.09.011
   Tschoke SK, 2015, PATIENT SAF SURG, V9, DOI 10.1186/s13037-015-0083-4
   Walter J, 2010, EUR SPINE J, V19, P1004, DOI 10.1007/s00586-009-1265-5
   Wang L, 2014, SPINE J, V14, pE13, DOI 10.1016/j.spinee.2013.10.055
   Weiss LE, 1997, J SPINAL DISORD, V10, P482
   Yin X, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009627
NR 28
TC 0
Z9 0
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E653
EP E659
DI 10.1016/j.wneu.2019.04.226
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100076
PM 31054342
DA 2020-05-12
ER

PT J
AU Lin, TC
   Chang, TW
   Wu, YM
   Chen, CC
   Chen, CT
   Wu, TWE
   Wu, CT
   Hsieh, PC
AF Lin, Tzu-Chin
   Chang, Ting-Wei
   Wu, Yi-Ming
   Chen, Ching-Chang
   Chen, Chun-Ting
   Wu, Tai-Wei Erich
   Wu, Chieh-Tsai
   Hsieh, Po-Chuan
TI De Novo Formation of Pial Arteriovenous Fistulas: Systematic Review of
   Acquired Lesions and Their Clinical Differences Compared with Primary
   Lesions
SO WORLD NEUROSURGERY
LA English
DT Review
DE Acquired pial arteriovenous fistula; Cortical venous injury; Craniotomy;
   Primary pial arteriovenous fistula; Recanalization; Venous varix
ID CLASSIFICATION; MALFORMATIONS
AB OBJECTIVE: Acquired pial arteriovenous fistula (pAVF) is an extremely rare intracranial vascular malformation, with few case reports in the English literature. This study presents a thorough review and analysis of all acquired pAVF cases from the literature in addition to an illustrated case.
   METHODS: We report a case with de novo development of intracranial pAVF after craniotomy. A medical literature database search between 1975 and 2018, including the Medline, Ovid, and PubMed databases, was performed to identify all reports with possible acquired lesions. Differences between these acquired lesions and previously reported primary lesions were evaluated.
   RESULTS: A total of 8 patients with de novo formation of acquired pAVF were included in this series. Most of these pAVFs were fed and drained via a similar arteriovenous pattern, from distal/cortical branches of the middle cerebral artery (6/8, 75%) to the superficial middle cerebral vein (6/8, 75%). Compared with a previously reported primary pAVF series, acquired pAVF tended to be asymptomatic (P < 0.0001) and found essentially in adults (P = 0.0061). Fewer venous varices (P = 0.0049) and associated intracranial mass effect (P = 0.0189) were found in the cases of acquired pAVF. All 4 reported acquired pAVFs that were treated microsurgically resulted in complete angiographic obliteration (4/4, 100%). The overall outcome was good or stable even with observation only (7/8, 87.5%).
   CONCLUSIONS: Acquired pAVF is highly correlated with sentinel neurosurgical procedures or venous occlusion events. These lesions should be regarded as a different disease entity from primary pAVF because of the relatively low-flow shunting and benign clinical course.
C1 [Lin, Tzu-Chin; Chang, Ting-Wei; Chen, Ching-Chang; Chen, Chun-Ting; Wu, Tai-Wei Erich; Wu, Chieh-Tsai; Hsieh, Po-Chuan] Chang Gung Univ & Med Coll, Dept Neurosurg, Chang Gung Mem Hosp, Linkou, Taiwan.
   [Wu, Yi-Ming] Chang Gung Univ & Med Coll, Dept Med Imaging & Intervent, Chang Gung Mem Hosp, Linkou, Taiwan.
RP Hsieh, PC (reprint author), Chang Gung Univ & Med Coll, Dept Neurosurg, Chang Gung Mem Hosp, Linkou, Taiwan.
EM pochuan.hsieh@gmail.com
CR BORDEN JA, 1995, J NEUROSURG, V82, P166, DOI 10.3171/jns.1995.82.2.0166
   CHAUDHARY MY, 1982, AM J NEURORADIOL, V3, P13
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   Feroze AH, 2015, OPER NEUROSURG, V11, pE202, DOI 10.1227/NEU.0000000000000558
   Hoh BL, 2001, NEUROSURGERY, V49, P1351, DOI 10.1097/00006123-200112000-00011
   Kubo Y, 2010, NEUROSURG QUART, V20, P277, DOI 10.1097/WNQ.0b013e3182012907
   LASJAUNIAS P, 1986, NEUROSURG REV, V9, P253, DOI 10.1007/BF01743632
   Lee JY, 2008, J KOREAN NEUROSURG S, V44, P101, DOI 10.3340/jkns.2008.44.2.101
   Lyons MK, 2017, NEURORADIOL J, V30, DOI 10.1177/1971400916689576
   NEWTON TH, 1969, RADIOLOGY, V93, P1071, DOI 10.1148/93.5.1071
   Nishiyama Y, 2014, NEUROL MED-CHIR, V54, P242, DOI 10.2176/nmc.cr2012-0239
   Nomura S, 2015, NEUROL MED-CHIR, V55, P856, DOI 10.2176/nmc.cr.2015-0072
   Phatouros CC, 1999, STROKE, V30, P2487, DOI 10.1161/01.STR.30.11.2487
   Preter M, 1996, STROKE, V27, P243, DOI 10.1161/01.STR.27.2.243
   Schuette AJ, 2012, WORLD NEUROSURG, V77, DOI 10.1016/j.wneu.2011.09.015
   Yang WH, 2011, BRIT J NEUROSURG, V25, P580, DOI 10.3109/02688697.2011.566382
NR 16
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E276
EP E282
DI 10.1016/j.wneu.2019.04.135
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100031
PM 31026655
DA 2020-05-12
ER

PT J
AU Liu, DM
   Hu, XH
   Liu, Y
   Yang, K
   Xiao, CY
   Hu, J
   Li, ZH
   Zou, YJ
   Chen, J
   Liu, HY
AF Liu, Dongming
   Hu, Xinhua
   Liu, Yong
   Yang, Kun
   Xiao, Chaoyong
   Hu, Jun
   Li, Zonghong
   Zou, Yuanjie
   Chen, Jiu
   Liu, Hongyi
TI Potential Intra- or Cross-Network Functional Reorganization of the
   Triple Unifying Networks in Patients with Frontal Glioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cognitive function; Frontal glioma; Functional reorganization; Network
   interactions; Resting-state networks
ID POSTERIOR CINGULATE CORTEX; EXECUTIVE CONTROL NETWORK; RESTING-STATE
   NETWORKS; DEFAULT MODE NETWORK; BLIND SEPARATION; BRAIN-TUMORS;
   CONNECTIVITY; PATTERNS; FMRI; HUBS
AB BACKGROUND: Patients with frontal glioma might experience cognition alterations together with potential dysfunction of resting-state networks (RSNs). To understand the altered patterns of the intrinsic activity and underlying network interactions between the cognitive-related RSNs is of great importance.
   OBJECTIVE: This study aimed to investigate the characteristics of the altered RSNs, including default mode network, executive control network, and salience network and further elucidate the possible functional reorganization of RSNs in patients with frontal glioma.
   METHODS: Thirteen patients with frontal glioma and 10 healthy controls (HCs) were enrolled in this study. Independent component analysis was performed to identify the characteristics of the selected RSNs activity. Further, functional connectivity analysis was applied to investigate the relationship between the altered regions. Subsequently, partial correlation analysis was performed to examine associations between the neural activity of RSNs and neurocognitive characteristics.
   RESULTS: Compared with the HCs group, the patient group exhibited significant differences in functional connectivity among default mode network, executive control network, and salience network. In addition, the number of the significant functional connectivities between the paired seeds observed in the patients was greater than that in HCs and significantly increased functional connectivity was detected between left posterior cingulate cortex and right angular gyrus. Furthermore, altered neural activities in the RSNs of patients with frontal glioma were positively associated with certain aspects of cognitive function.
   CONCLUSIONS: Our results suggested underlying network functional reorganization of the triple unifying RSNs in patients with frontal glioma, providing novel insights for improving understanding of brain function.
C1 [Liu, Dongming; Hu, Xinhua; Liu, Yong; Yang, Kun; Zou, Yuanjie; Liu, Hongyi] Nanjing Med Univ, Dept Neurosurg, Affiliated Brain Hosp, Nanjing, Jiangsu, Peoples R China.
   [Xiao, Chaoyong; Hu, Jun; Li, Zonghong] Nanjing Med Univ, Dept Radiol, Affiliated Brain Hosp, Nanjing, Jiangsu, Peoples R China.
   [Chen, Jiu] Nanjing Med Univ, Clin Coll 4, Affiliated Brain Hosp, Inst Neuropsychiat, Nanjing, Jiangsu, Peoples R China.
   [Hu, Xinhua; Xiao, Chaoyong; Hu, Jun; Li, Zonghong; Zou, Yuanjie; Chen, Jiu; Liu, Hongyi] Nanjing Med Univ, Inst Brain Funct Imaging, Nanjing, Jiangsu, Peoples R China.
RP Liu, HY (reprint author), Nanjing Med Univ, Dept Neurosurg, Affiliated Brain Hosp, Nanjing, Jiangsu, Peoples R China.; Liu, HY (reprint author), Nanjing Med Univ, Inst Brain Funct Imaging, Nanjing, Jiangsu, Peoples R China.
EM hyliu18@126.com
FU National Health and Family Planning Commission of the People's Republic
   of China [w201308]; project of Jiangsu Provincial Medical Youth Talent
   [QNRC2016047]; Nanjing Commission of Health and Family Planning
   [H201540]; medical scientific and technologic development project of
   Nanjing [YKK12137, ZKX15035]; project of Jiangsu Provincial Medical
   Innovation Team [CXTDA2017050]
FX This study was supported by a grant from the clinical medical scientific
   and technologic project of National Health and Family Planning
   Commission of the People's Republic of China (No. w201308), a grant from
   the project of Jiangsu Provincial Medical Youth Talent (No.
   QNRC2016047), the Nanjing Commission of Health and Family Planning (No.
   H201540), a grant from the medical scientific and technologic
   development project of Nanjing (No. YKK12137 and ZKX15035), and a grant
   from the project of Jiangsu Provincial Medical Innovation Team (No.
   CXTDA2017050).
CR Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x
   Bai F, 2009, BRAIN RES, V1302, P167, DOI 10.1016/j.brainres.2009.09.028
   Bartolomei F, 2006, ANN NEUROL, V59, P128, DOI 10.1002/ana.20710
   BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129
   Biswal BB, 2012, NEUROIMAGE, V62, P938, DOI 10.1016/j.neuroimage.2012.01.090
   Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011
   Buckner RL, 2009, J NEUROSCI, V29, P1860, DOI 10.1523/JNEUROSCI.5062-08.2009
   Chen HB, 2016, NEUROIMAGE-CLIN, V11, P339, DOI 10.1016/j.nicl.2016.02.010
   Cunningham SI, 2017, HUM BRAIN MAPP, V38, P938, DOI 10.1002/hbm.23429
   Darlix A, 2017, J NEURO-ONCOL, V133, P37, DOI 10.1007/s11060-017-2421-0
   Dehcordi SR, 2013, J NEUROSURG SCI, V57, P259
   Derks J, 2017, NEUROIMAGE-CLIN, V14, P87, DOI 10.1016/j.nicl.2017.01.007
   Duffau H, 2014, WORLD NEUROSURG, V82, pE405, DOI 10.1016/j.wneu.2013.02.051
   Erhardt EB, 2011, HUM BRAIN MAPP, V32, P2075, DOI 10.1002/hbm.21170
   Esposito R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040231
   Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106
   Geiger MJ, 2016, WORLD J BIOL PSYCHIA, V17, P47, DOI 10.3109/15622975.2015.1083613
   Ghumman S, 2016, J NEURO-ONCOL, V128, P437, DOI 10.1007/s11060-016-2129-6
   Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100
   Harris RJ, 2014, J NEURO-ONCOL, V116, P373, DOI 10.1007/s11060-013-1304-2
   Herbet G, 2016, BRAIN, V139, P829, DOI 10.1093/brain/awv394
   Kinno R, 2014, BRAIN, V137, P1193, DOI 10.1093/brain/awu013
   Klingberg T, 2006, NEUROPSYCHOLOGIA, V44, P2171, DOI 10.1016/j.neuropsychologia.2005.11.019
   Koechlin E, 2007, SCIENCE, V318, P594, DOI 10.1126/science.1142995
   Krmpotich TD, 2013, DRUG ALCOHOL DEPEN, V129, P1, DOI 10.1016/j.drugalcdep.2013.01.021
   Lee MH, 2013, AM J NEURORADIOL, V34, P1866, DOI 10.3174/ajnr.A3263
   Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162
   Leech R, 2012, J NEUROSCI, V32, P215, DOI 10.1523/JNEUROSCI.3689-11.2012
   Li YO, 2007, HUM BRAIN MAPP, V28, P1251, DOI 10.1002/hbm.20359
   Maesawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118072
   Martin S, 2009, BMC VET RES, V5, DOI 10.1186/1746-6148-5-26
   McKeown MJ, 1998, HUM BRAIN MAPP, V6, P160, DOI 10.1002/(SICI)1097-0193(1998)6:3<160::AID-HBM5>3.3.CO;2-R
   Medford N, 2010, BRAIN STRUCT FUNCT, V214, P535, DOI 10.1007/s00429-010-0265-x
   Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087
   Picart T, 2019, NEUROSURGERY, V85, P105, DOI 10.1093/neuros/nyy218
   Raichle ME, 2015, ANNU REV NEUROSCI, V38, P433, DOI 10.1146/annurev-neuro-071013-014030
   Rigon A, 2016, J NEUROTRAUM, V33, P977, DOI 10.1089/neu.2014.3847
   Soravia LM, 2018, DEPRESS ANXIETY, V35, P925, DOI 10.1002/da.22806
   Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105
   Stevens MC, 2009, HUM BRAIN MAPP, V30, P24, DOI 10.1002/hbm.20478
   van den Heuvel MP, 2013, TRENDS COGN SCI, V17, P683, DOI 10.1016/j.tics.2013.09.012
   Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044
   Wang CH, 2014, J CEREBR BLOOD F MET, V34, P597, DOI 10.1038/jcbfm.2013.238
   Yan CG, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00013
   Yuan ML, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0904-8
   Zhang HS, 2016, SCI REP-UK, V6, DOI 10.1038/srep26972
   Zhang M, 2014, PLOS ONE, V9
   Zhang N, 2018, HUM BRAIN MAPP, V39, P4802, DOI 10.1002/hbm.24324
   Zheng HN, 2015, BIOMED RES INT, DOI 10.1155/2015/386326
NR 50
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E732
EP E743
DI 10.1016/j.wneu.2019.04.248
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100086
PM 31077892
DA 2020-05-12
ER

PT J
AU Liu, J
   Chen, Z
   Feng, T
   Jiang, BW
   Yuan, Y
   Yu, YB
AF Liu, Jiang
   Chen, Ze
   Feng, Tao
   Jiang, Bowen
   Yuan, Yue
   Yu, Yanbing
TI Biomedical Glue Sling Technique in Microvascular Decompression for
   Trigeminal Neuralgia Caused by Atherosclerotic Vertebrobasilar Artery: A
   Description of Operative Technique and Clinical Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atherosclerotic vertebrobasilar artery; Biomedical glue sling;
   Microvascular decompression; Trigeminal neuralgia
ID FACIAL-PAIN; ECTASIA; SERIES; NERVE
AB BACKGROUND: Microvascular decompression (MVD) is the most definitive surgical treatment for trigeminal neuralgia (TN). In the case in which an atherosclerotic vertebrobasilar artery (aVBA) offends the trigeminal nerve, the postoperative outcomes have been reported to be less satisfactory in terms of symptom recurrence and complications. In this study, the authors present their experience using a biomedical sling for MVD in patients with aVBA-associated TN.
   METHODS: A retrospective study of 22 consecutive patients who underwent the biomedical glue sling technique in MVD for TN with aVBA was conducted between September 2016 and June 2017.
   RESULTS: Intraoperatively, aVBA was regarded as the direct or indirect offending vessel in 22 patients. In addition to aVBA, other vessels involved in neurovascular conflict included superior cerebellar artery in 12 patients, veins in 1, and anterior inferior cerebellar artery in 6. All 22 patients underwent the biomedical glue sling technique. Postoperatively, TN was completely resolved in 20 (91%) patients and partially relieved in 2 (9%) patients. During the follow-up period of 18-27 months, pain developed severely in those 2 patients but could be relieved with carbamaze-pine. As for complications, postoperative hypoacusia occurred immediately in 1 case, with complete resolution in 2 months.
   CONCLUSIONS: The biggest advantage of the biomedical glue sling technique is its simplicity in achieving complete decompression, requiring relatively less space and time. Because the outcome of traditional MVD regarding aVBA-associated TN remains controversial, the biomedical glue sling technique in MVD provides an alternative decompressive method for patients with TN associated with aVBA. However, further studies with a larger series and control group are required to prove the high effectiveness of this method.
C1 [Liu, Jiang; Yuan, Yue; Yu, Yanbing] China Japan Friendship Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Chen, Ze] Peking Univ, China Japan Friendship Sch Clin Med, Beijing, Peoples R China.
   [Feng, Tao] Dongying Second Peoples Hosp, Dept Neurosurg, Dongying, Shandong, Peoples R China.
   [Jiang, Bowen] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
RP Yu, YB (reprint author), China Japan Friendship Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM yuyanbing123@126.com
OI chen, ze/0000-0002-9293-354X
CR Bowsher D, 2000, PAIN CLINIC, V12, P93, DOI 10.1163/156856900750229843
   Capelle HH, 2010, J HEADACHE PAIN, V11, P339, DOI 10.1007/s10194-010-0213-4
   Chen JF, 2000, SURG NEUROL, V53, P281, DOI 10.1016/S0090-3019(00)00169-5
   Cruccu G, 2008, EUR J NEUROL, V15, P1013, DOI 10.1111/j.1468-1331.2008.02185.x
   El-Ghandour NMF, 2010, NEUROSURGERY, V67, P330, DOI 10.1227/01.NEU.0000371978.86528.60
   HANAKITA J, 1988, NEUROSURGERY, V22, P348, DOI 10.1227/00006123-198802000-00012
   HARSH GR, 1991, J NEUROSURG, V74, P999, DOI 10.3171/jns.1991.74.6.0999
   Herrera O, 1999, NEUROL MED-CHIR, V39, P134, DOI 10.2176/nmc.39.134
   Kurokawa Y, 2004, SURG NEUROL, V61, P398, DOI 10.1016/S0090-3019(03)00425-7
   LINSKEY ME, 1994, J NEUROSURG, V81, P1, DOI 10.3171/jns.1994.81.1.0001
   Ma XY, 2013, NEUROSURG REV, V36, P573, DOI 10.1007/s10143-013-0468-8
   Maarbjerg S, 2014, HEADACHE, V54, P1574, DOI 10.1111/head.12441
   Mueller D, 2011, CEPHALALGIA, V31, P1542, DOI 10.1177/0333102411424619
   Park KJ, 2012, J NEUROSURG, V116, P73, DOI 10.3171/2011.8.JNS11920
   RASMUSSEN P, 1990, ACTA NEUROCHIR, V107, P112, DOI 10.1007/BF01405789
   Rogers CL, 2000, INT J RADIAT ONCOL, V47, P1013, DOI 10.1016/S0360-3016(00)00513-7
   Sindou M, 2002, ACTA NEUROCHIR, V144, P1, DOI 10.1007/s701-002-8269-4
   Sindou M, 2007, J NEUROSURG, V107, P1144, DOI 10.3171/JNS-07/12/1144
   Sun SJ, 2017, INT J SURG, V41, P183, DOI 10.1016/j.ijsu.2017.04.015
   TAKAMIYA Y, 1985, SURG NEUROL, V24, P559, DOI 10.1016/0090-3019(85)90274-5
   WAGA S, 1979, SURG NEUROL, V11, P13
   Yadav Yad Ram, 2017, Asian J Neurosurg, V12, P585, DOI 10.4103/ajns.AJNS_67_14
   Yang XS, 2012, ACTA NEUROCHIR, V154, P793, DOI 10.1007/s00701-012-1320-6
   YOSHIMOTO Y, 1995, SURG NEUROL, V43, P151, DOI 10.1016/0090-3019(95)80126-2
   Yuan YJ, 2014, INT J MED SCI, V11, P1039, DOI 10.7150/ijms.8566
   Zhang X, 2017, WORLD NEUROSURG, V104, P186, DOI 10.1016/j.wneu.2017.04.048
NR 26
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E74
EP E80
DI 10.1016/j.wneu.2019.03.289
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100010
PM 30954750
DA 2020-05-12
ER

PT J
AU Liu, K
   Zhang, ZF
AF Liu, Ke
   Zhang, Zhengfeng
TI A Novel Anterior-Only Surgical Approach for Reduction and Fixation of
   Cervical Facet Dislocation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior pedicle screw; Anterior reduction; Cervical facet dislocation;
   Facetectomy
ID PEDICLE SCREW FIXATION; CLOSED REDUCTION; FRACTURE-DISLOCATIONS; PLATE
   FIXATION; SPINAL-CORD; DISC; COMPRESSION; SUBLUXATION
AB BACKGROUND: The anterior-only surgical procedure, including discectomy, open reduction, fusion, and fixation, is a recommended approach in the treatment of cervical facet dislocations. This approach has a reduction failure rate of up to 40%. When it fails, a posterior approach is usually required.
   OBJECTIVE: To report a novel anterior-only surgical approach for reduction and fixation in patients with cervical facet dislocation, even for severe vertebral fracture, articular process fracture, and delayed surgical management.
   METHODS: Sixty-three consecutive patients with unilateral/bilateral facet dislocation of the subaxial cervical spine were treated with this anterior-only procedure. After discectomy, kyphotic paramedian distraction reduction with Caspar pins plus vertebral screw plate fixation was performed. If the reduction failed, anterior facetectomy reduction plus anterior cervical pedicle screw plate fixation was introduced.
   RESULTS: Among the 63 patients treated, 52 patients achieved successful reduction with the technique of kyphotic paramedian distraction with Caspar pins; the remaining 11 patients with failure of the former technique experienced successful reduction with the anterior facetectomy technique. No supplemental posterior approach surgery was performed. The American Spinal Injury Association grade was improved by at least 1 grade in 23 patients after this procedure, and no neurologic deterioration occurred in any of the patients. After at least 12 months of follow-up, all patients achieved satisfactory fusion, and there was no implant failure.
   CONCLUSIONS: An anterior-only surgical procedure including kyphotic paramedian distraction with Caspar pins, anterior facetectomy, and anterior pedicle screw plate fixation is safe and effective for subaxial cervical facet dislocations.
C1 [Liu, Ke; Zhang, Zhengfeng] Third Mil Med Univ, Xinqiao Hosp, Dept Orthoped, Chongqing, Peoples R China.
RP Zhang, ZF (reprint author), Third Mil Med Univ, Xinqiao Hosp, Dept Orthoped, Chongqing, Peoples R China.
EM zhangz3@foxmail.com
CR Aramomi M, 2008, ACTA NEUROCHIR, V150, P575, DOI 10.1007/s00701-008-1574-1
   COE JD, 1989, SPINE, V14, P1122, DOI 10.1097/00007632-198910000-00016
   DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13
   DORAN SE, 1993, J NEUROSURG, V79, P341, DOI 10.3171/jns.1993.79.3.0341
   Du W, 2013, SPINE, V39, P48
   Feng GJ, 2012, SPINE, V37, P2082, DOI 10.1097/BRS.0b013e31825ee846
   Gallego-Goyanes A, 2013, Rev Esp Cir Ortop Traumatol, V57, P446, DOI 10.1016/j.recot.2013.08.004
   Glaser JA, 1998, SPINE, V23, P975, DOI 10.1097/00007632-199805010-00002
   Grant GA, 1999, J NEUROSURG, V90, P13, DOI 10.3171/spi.1999.90.1.0013
   Hart RA, 2002, SPINE, V27, P116, DOI 10.1097/00007632-200201010-00030
   Keynan O, 2002, TECH ORTHOP, V17, P336
   Kocis J, 2004, Acta Chir Orthop Traumatol Cech, V71, P366
   Koh YD, 2001, SPINE, V26, P15, DOI 10.1097/00007632-200101010-00005
   Nakashima H, 2011, EUR SPINE J, V20, P387, DOI 10.1007/s00586-010-1589-1
   Nassr A, 2008, SPINE, V33, pE188, DOI 10.1097/BRS.0b013e3181696118
   Ngo LM, 2012, EUR SPINE J, V21, P282, DOI 10.1007/s00586-011-1956-6
   OLERUD C, 1991, ACTA ORTHOP SCAND, V62, P599, DOI 10.3109/17453679108994506
   Ordonez BJ, 2000, J NEUROSURG, V92, P18, DOI 10.3171/spi.2000.92.1.0018
   Panjabi MM, 2007, EUR SPINE J, V16, P1680, DOI 10.1007/s00586-007-0410-2
   Park JH, 2015, J NEUROSURG-SPINE, V23, P35, DOI 10.3171/2014.11.SPINE14805
   Reindl R, 2006, SPINE, V31, P648, DOI 10.1097/01.brs.0000202811.03476.a0
   Rishi MK, 2018, EUR SPINE J, V27, P1447
   RIZZOLO SJ, 1991, SPINE, V16, pS187, DOI 10.1097/00007632-199106001-00002
   ROBERTSON PA, 1992, J BONE JOINT SURG BR, V74, P224
   SABISTON CP, 1988, J TRAUMA, V28, P832, DOI 10.1097/00005373-198806000-00020
   STAR AM, 1990, SPINE, V15, P1068, DOI 10.1097/00007632-199015100-00016
   STAUFFER ES, 1977, J BONE JOINT SURG AM, V59, P45, DOI 10.2106/00004623-197759010-00006
   Vaccaro AR, 1999, SPINE, V24, P1210, DOI 10.1097/00007632-199906150-00007
   Vital JM, 1998, SPINE, V23, P949, DOI 10.1097/00007632-199804150-00021
   Wang B, 2014, J SPINAL DISORD TECH, V27, pE104, DOI 10.1097/BSD.0b013e318291c9f9
   Wimberley DW, 2005, SPINE, V30, pE433, DOI 10.1097/01.brs.0000172233.05024.8f
   Yukawa Y, 2009, EUR SPINE J, V18, P911, DOI 10.1007/s00586-009-0949-1
   Zhang ZF, 2016, SPINE, V41, pE403, DOI 10.1097/BRS.0000000000001260
   Zhang ZF, 2016, SPINE J, V16, P123, DOI 10.1016/j.spinee.2015.09.040
   Zhao LJ, 2014, EUR SPINE J, V23, P2175, DOI 10.1007/s00586-014-3473-x
NR 35
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E362
EP E369
DI 10.1016/j.wneu.2019.04.153
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100042
PM 31029820
DA 2020-05-12
ER

PT J
AU Liu, Y
   Liu, YZ
   Hai, Y
   Liu, T
   Guan, L
   Chen, XL
AF Liu, Yang
   Liu, Yuzeng
   Hai, Yong
   Liu, Tie
   Guan, Li
   Chen, Xiaolong
TI Fat Infiltration in the Multifidus Muscle as a Predictor of Prognosis
   After Decompression and Fusion in Patients with Single-Segment
   Degenerative Lumbar Spinal Stenosis: An Ambispective Cohort Study Based
   on Propensity Score Matching
SO WORLD NEUROSURGERY
LA English
DT Article
DE Degenerative lumbar spinal stenosis; Fat infiltration; Multifidus
   muscle; Prognosis; Propensity scores matching; Surgery
ID LOW-BACK-PAIN; PARASPINAL MUSCLES; INTERBODY FUSION; SURGERY;
   MORPHOLOGY; REGENERATION; DISABILITY
AB OBJECTIVE: To determine whether fat infiltration in the multifidus muscle would predict surgical prognosis in patients with degenerative lumbar spinal stenosis (DLSS).
   METHODS: This ambispective cohort study enrolled 118 consecutive patients undergoing surgery for 14-5 single-segment DLSS. Fat infiltration rate (FIR) on magnetic resonance images of the multifidus muscle at L5-S1 were measured using ImageJ software. The enrolled patients were divided into FIR <25% and FIR >= 25% groups according to their FIR of the multifidus muscle at L5-S1. The 2 groups of patients who finished follow-up were further matched for the baseline covariates based on propensity scores. Patients' reported outcomes including the visual analog scale score for back pain and leg pain, and the Oswestry Disability Index (ODI) score were compared between groups at follow-up and further adjusted using generalized linear models.
   RESULTS: Patients in the FIR <25% group showed statistically significantly greater reduction in ODI at 6 and 18 months after surgery than did patients in the FIR >= 25% group in either cohort regardless of adjustment; however, the 2-point between-group difference was smaller than the predefined minimum clinically important difference. In addition, more patients in the FIR <25% group achieved clinically significant improvement in ODI than those in the FIR 25% group in either complete cohort or matching cohort (63.8% vs. 21.1%, P < 0.001; 70.3% vs. 24.1%, P < 0.001, respectively) before and after adjustment (63.3% vs. 27.8%, P < 0.001; 69.1% vs. 31.0%, P < 0.001, respectively).
   CONCLUSIONS: Fat infiltration in multifidus muscle at L5-S1 could be a potential predictor of functional improvement after surgery in patients with 14-5 single-segment DLSS.
C1 [Liu, Yang; Liu, Yuzeng; Hai, Yong; Liu, Tie; Guan, Li; Chen, Xiaolong] Capital Med Univ, Beijing Chaoyang Hosp, Clin Med Coll 3, Dept Orthoped, Beijing, Peoples R China.
   [Liu, Yang] Capital Med Univ, Beijing Elect Power Hosp State Grade, Teaching Hosp, Dept Orthoped, Beijing, Peoples R China.
RP Hai, Y (reprint author), Capital Med Univ, Beijing Chaoyang Hosp, Clin Med Coll 3, Dept Orthoped, Beijing, Peoples R China.
EM spinesurgeron@163.com
RI Hai, Yong/L-6987-2019
OI Hai, Yong/0000-0002-7206-325X
CR Ahn Y, 2010, ACTA NEUROCHIR, V152, P1695, DOI 10.1007/s00701-010-0726-2
   Altinkaya N, 2016, SKELETAL RADIOL, V45, P73, DOI 10.1007/s00256-015-2252-z
   Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580
   Backstrom KM, 2011, MANUAL THER, V16, P308, DOI 10.1016/j.math.2011.01.010
   Cheng XF, 2018, WORLD NEUROSURG, V109, pE244, DOI 10.1016/j.wneu.2017.09.154
   Fan SW, 2010, EUR SPINE J, V19, P316, DOI 10.1007/s00586-009-1191-6
   Forsth P, 2016, NEW ENGL J MED, V374, P1413, DOI 10.1056/NEJMoa1513721
   Fortin M, 2014, MED SCI SPORT EXER, V46, P893, DOI 10.1249/MSS.0000000000000179
   Fortin M, 2012, PHYS THER, V92, P853, DOI 10.2522/ptj.20110380
   Gerling MC, 2016, SPINE, V41, P901, DOI 10.1097/BRS.0000000000001361
   Ghiasi MS, 2016, EUR SPINE J, V25, P774, DOI 10.1007/s00586-015-4014-y
   Hebert JJ, 2014, SPINE, V39, P1417, DOI 10.1097/BRS.0000000000000424
   Hyun JK, 2007, SPINE, V32, pE598, DOI 10.1097/BRS.0b013e318155837b
   Joanisse S, 2017, GERONTOLOGY, V63, P91, DOI 10.1159/000450922
   Jones ADR, 2014, EUR SPINE J, V23, P135, DOI 10.1007/s00586-013-2964-5
   Jun HS, 2016, NEUROSURGERY, V79, P847, DOI 10.1227/NEU.0000000000001269
   Kader DF, 2000, CLIN RADIOL, V55, P145, DOI 10.1053/crad.1999.0340
   Kjaer P, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-2
   MACINTOSH JE, 1986, CLIN BIOMECH, V1, P196, DOI 10.1016/0268-0033(86)90146-4
   McGill SM, 2009, ARCH PHYS MED REHAB, V90, P118, DOI 10.1016/j.apmr.2008.06.026
   McGregor AH, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-17
   McGregor AH, 2014, SPINE, V39, P1044, DOI 10.1097/BRS.0000000000000355
   Merrick MA, 1999, MED SCI SPORT EXER, V31, P1516, DOI 10.1097/00005768-199911000-00004
   Paalanne N, 2011, SPINE, V36, P1961, DOI 10.1097/BRS.0b013e3181fef890
   Parker SL, 2011, J NEUROSURG-SPINE, V14, P598, DOI 10.3171/2010.12.SPINE10472
   Paulsen RT, 2018, NEUROSURGERY, V82, P645, DOI 10.1093/neuros/nyx298
   Sigmundsson FG, 2012, ACTA ORTHOP, V83, P536, DOI 10.3109/17453674.2012.733915
   Sions JM, 2017, J ORTHOP SPORT PHYS, V47, P173, DOI 10.2519/jospt.2017.7002
   Storheim K, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1505-5
   Sun X, 2006, CALCIFIED TISSUE INT, V79, P43, DOI 10.1007/s00223-006-0041-3
   Teichtahl AJ, 2015, SPINE J, V15, P1593, DOI 10.1016/j.spinee.2015.03.039
   Turner NJ, 2012, CELL TISSUE RES, V347, P759, DOI 10.1007/s00441-011-1185-7
   Zotti MGT, 2017, EUR SPINE J, V26, P2589, DOI 10.1007/s00586-017-4986-x
NR 33
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E989
EP E1001
DI 10.1016/j.wneu.2019.05.055
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100118
PM 31100519
DA 2020-05-12
ER

PT J
AU Liu, Z
   Jiang, XB
   Gao, L
   Liu, X
   Li, JL
   Huang, X
   Zeng, T
AF Liu, Zhen
   Jiang, Xiaobing
   Gao, Liang
   Liu, Xuan
   Li, Jiali
   Huang, Xing
   Zeng, Tao
TI Synergistic Suppression of Glioblastoma Cell Growth by Combined
   Application of Temozolomide and Dopamine D2 Receptor Antagonists
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dopamine D2 receptor; Glioblastoma; Synergy; Temozolomide
ID CANCER STEM-CELLS; ANTITUMOR IMIDAZOTETRAZINES; ADJUVANT TEMOZOLOMIDE;
   HUMAN BRAIN; AUTOPHAGY; DRUGS; DNA; PHARMACOKINETICS; IDENTIFICATION;
   PROLIFERATION
AB OBJECTIVE: The current standard treatment of malignant glioma is maximal resection followed by chemotherapy and radiotherapy. Temozolomide (TMZ) has been the first-line chemotherapeutic agent used, although to achieve a satisfactory clinical effect. TMZ chemoresistance could result from glioblastoma stem cells, which are critical for tumor initiation, recurrence, and therapeutic resistance and are potential targets. Moreover, signals mediated by the dopamine D2 receptor (DRD2) can positively regulate proliferation and tumorigenesis of glioma cells.
   RESULTS: To enhance TMZ's antitumor effect, we treated glioma cells with combinations of TMZ and DRD2 antagonists (DDRAs). The combined application of TMZ and DDRAs (haloperidol or risperidone) had synergistic effects and inhibited proliferation of glioma cells more significantly than did monotherapy. The combined treatment increased the levels of gamma H2AX (a marker of DNA damage) more significantly than did TMZ alone, although DDRAs alone had no effect on gamma H2AX levels. Moreover, the expression of DRD2 transcripts in U251 glioma cells and glioblastoma stem cells were significantly elevated after TMZ treatment, suggesting crosstalk between TMZ- and DRD2-mediated signaling. To explore the underlying mechanisms, we measured the expression of prosurvival proteins after treatment with either TMZ or DDRAs alone or combined. The results showed that DDRAs could inhibit the extracellular signal-related kinase signaling pathway and block TMZ-induced protective autophagy, which could explain why DDRAs increased the cytotoxicity of TMZ.
   CONCLUSIONS: We have provided evidence showing the synergistic effects of TMZ and DDRAs on suppressing glioma cell growth. Our study has provided novel insights on enhancing the effectiveness of chemotherapy against malignant glioma and eventually improving the clinical outcomes of patients with glioblastoma multiforme.
C1 [Liu, Zhen; Jiang, Xiaobing; Huang, Xing] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan, Hubei, Peoples R China.
   [Gao, Liang; Zeng, Tao] Tongji Univ, Affiliated Hosp 10, Dept Neurosurg, Shanghai, Peoples R China.
   [Liu, Xuan; Li, Jiali] Wuhan Univ, Coll Life Sci, Wuhan, Hubei, Peoples R China.
RP Zeng, T (reprint author), Tongji Univ, Affiliated Hosp 10, Dept Neurosurg, Shanghai, Peoples R China.
EM ztbox73@163.com
OI Zeng, Tao/0000-0002-6700-5370
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81272778]; National Health and Family Planning
   Commission of the People's Republic of China [03.02.16.001]
FX The present study was supported by grants from the National Natural
   Science Foundation of China (grant 81272778) and National Health and
   Family Planning Commission of the People's Republic of China (grant
   03.02.16.001).
CR Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Beier D, 2008, CANCER RES, V68, P5706, DOI 10.1158/0008-5472.CAN-07-6878
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Carmo A, 2011, ONCOL LETT, V2, P1165, DOI 10.3892/ol.2011.406
   Chakroborty D, 2004, CLIN CANCER RES, V10, P4349, DOI 10.1158/1078-0432.CCR-04-0059
   Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287
   Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Chou TC, 2008, LEUKEMIA LYMPHOMA, V49, P2059, DOI 10.1080/10428190802353591
   Dalton SO, 2006, BRIT J CANCER, V95, P934, DOI 10.1038/sj.bjc.6603259
   Diamandis P, 2009, MED HYPOTHESES, V72, P683, DOI 10.1016/j.mehy.2008.10.034
   Dolma S, 2016, CANCER CELL, V29, P859, DOI 10.1016/j.ccell.2016.05.002
   Drablos F, 2004, DNA REPAIR, V3, P1389, DOI 10.1016/j.dnarep.2004.05.004
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   Girault JA, 2004, ARCH NEUROL-CHICAGO, V61, P641, DOI 10.1001/archneur.61.5.641
   Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kim SY, 2006, J NEUROSCI, V26, P4567, DOI 10.1523/JNEUROSCI.5236-05.2006
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   Lan Y-L, 2016, ACTA NEUROL BELG, V117, P513
   Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115
   Li J, 2014, ONCOTARGET, V5, P882, DOI 10.18632/oncotarget.1801
   Li YM, 2017, J MOL CELL BIOL, V9, P302, DOI 10.1093/jmcb/mjx017
   Lin CJ, 2012, FREE RADICAL BIO MED, V52, P377, DOI 10.1016/j.freeradbiomed.2011.10.487
   Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67
   Loryan I, 2016, MOL PSYCHIATR, V21, P1527, DOI 10.1038/mp.2015.229
   Luo YQ, 1998, J NEUROCHEM, V71, P980
   Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6
   Marosi C, 2006, WIEN MED WOCHENSCHR, V156, P346, DOI 10.1007/s10354-006-0307-4
   Mizushima N, 2007, AUTOPHAGY, V3, P542
   NEWLANDS ES, 1992, BRIT J CANCER, V65, P287, DOI 10.1038/bjc.1992.57
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Ortensi B, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt166
   Ostermann S, 2004, CLIN CANCER RES, V10, P3728, DOI 10.1158/1078-0432.CCR-03-0807
   Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189
   Palmer AC, 2017, CELL, V171, P1678, DOI 10.1016/j.cell.2017.11.009
   Roos WP, 2007, ONCOGENE, V26, P186, DOI 10.1038/sj.onc.1209785
   Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049
   Sarkar C, 2008, CLIN CANCER RES, V14, P2502, DOI 10.1158/1078-0432.CCR-07-1778
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   STEVENS MFG, 1987, CANCER RES, V47, P5846
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Varghese M, 2008, NEUROSURGERY, V63, P1022, DOI 10.1227/01.NEU.0000335792.85142.B0
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Yeh CT, 2012, AM J RESP CRIT CARE, V186, P1180, DOI 10.1164/rccm.201207-1180OC
   Yoon S, 2013, J BIOL CHEM, V288, P28435, DOI 10.1074/jbc.M113.461202
   Yung WKA, 2000, BRIT J CANCER, V83, P588, DOI 10.1054/bjoc.2000.1316
   Zanotto-Filho A, 2015, CANCER LETT, V358, P220, DOI 10.1016/j.canlet.2014.12.044
   Zhong XL, 2016, ONCOTARGET, V7, P44365, DOI 10.18632/oncotarget.9744
NR 51
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E468
EP E477
DI 10.1016/j.wneu.2019.04.180
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100054
PM 31048057
DA 2020-05-12
ER

PT J
AU Liu, ZH
   Chen, NY
   Tu, PH
   Yip, PK
   Wang, YC
   Chen, CC
   Chuang, CC
   Liu, CH
   Hsu, PW
   Lin, YS
AF Liu, Zhuo-Hao
   Chen, Nan-Yu
   Tu, Po-Hsun
   Yip, Ping K.
   Wang, Yu-Chi
   Chen, Ching-Chang
   Chuang, Chi-Cheng
   Liu, Chi-Hung
   Hsu, Peng-Wei
   Lin, Yu-Sheng
TI Previous Antithrombotic Therapy, Particularly Anticoagulant, Is
   Associated with Unfavorable Outcomes in Patients with Primary
   Spontaneous Intracerebral Hemorrhage Receiving Craniotomy: A Nationwide
   Population-Based Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anticoagulant; Antiplatelet; Antithrombotic agents; Cohort study;
   Craniotomy; ICD-9; Intracerebral hemorrhage
ID IN-HOSPITAL MORTALITY; INTRACRANIAL HEMORRHAGE; ANTIPLATELET THERAPY;
   HEMATOMA EXPANSION; RISK; CLOPIDOGREL; ASPIRIN; STROKE; VALIDATION;
   MANAGEMENT
AB OBJECTIVE: The impact of antithrombotic agents on patients with primary intracerebral hemorrhage (ICH) remains controversial, especially patients who require emergent craniotomy. This study was undertaken to evaluate clinical outcomes in operated patients with ICH with and without previous antithrombotic agents.
   METHODS: This is a retrospective cohort study. Between January 2001 and December 2013, all patients with ICH who received emergent craniotomy and who were present in Taiwan's National Health Insurance Research Database were screened and divided into those with previous antiplatelet therapy, anticoagulant therapy, and nonantithrombotic therapy according to their health care claims data within 3 months of index admission. The primary end points included in-hospital mortality and complications and short-term outcome.
   RESULTS: Of 18,872 eligible patients, 16,251 (87.1%) did not receive any antithrombotic therapy, 2267 patients had antiplatelet therapy, and 354 patients had anticoagulation therapy. After propensity score matching, significantly more blood transfusions and craniectomies were identified in the patients with previous antithrombotic treatment compared with those undergoing nonantithrombotic therapy. Compared with the nonantithrombotic treatment cohort, patients under previous anticoagulant treatment had significantly higher in-hospital mortality (odds ratio, 2.12; 95% confidence interval, 1.45-3.10). Furthermore, during the 6-month follow-ttp period, previous anticoagulant therapy was independently associated with a greater risk of all-cause mortality (P = 0.001). The in-hospital and 6-month all-cause mortality of patients with previous antiplatelet treatment was not significantly different from patients with nonantithrombotic treatment.
   CONCLUSIONS: These findings suggested an increased risk of in-hospital mortality and poor short-term outcome among operated patients with ICH with previous antithrombotic therapy, particularly anticoagulant therapy, but not with antiplatelet therapy.
C1 [Liu, Zhuo-Hao; Tu, Po-Hsun; Wang, Yu-Chi; Chen, Ching-Chang; Chuang, Chi-Cheng; Hsu, Peng-Wei] Chang Gung Med Coll & Univ, Chang Gung Mem Hosp Linkou, Dept Neurosurg, Taoyuan, Taiwan.
   [Chen, Nan-Yu] Chang Gung Med Coll & Univ, Chang Gung Mem Hosp Linkou, Dept Internal Med, Taoyuan, Taiwan.
   [Liu, Chi-Hung] Chang Gung Med Coll & Univ, Chang Gung Mem Hosp Linkou, Dept Neurol, Taoyuan, Taiwan.
   [Yip, Ping K.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England.
   [Lin, Yu-Sheng] Chang Gung Mem Hosp, Dept Cardiol, Chiayi, Taiwan.
RP Lin, YS (reprint author), Chang Gung Mem Hosp, Dept Cardiol, Chiayi, Taiwan.
EM dissertlin@gmail.com
FU Chang Gung Memorial Hospital, TaiwanChang Gung Memorial Hospital
   [CMRPG3G1001-2]
FX We acknowledge the generous support of Chang Gung Memorial Hospital,
   Taiwan (CMRPG3G1001-2). Contributors: Z.-H.L., Y.-S.L., and N.-Y.C.
   designed the research; P.-H.T.,C.-C.C., Y.-C.W., and P.-W.H. analyzed
   and interpreted the data; C.-H.L. validated the data; Z.-H.L. and
   Y.-S.L. wrote the manuscript; and P.K.Y. critically revised the
   manuscript.
CR Alharbi H, 2017, CASE REP HEMATOL, DOI 10.1155/2017/3649397
   Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433
   Chang CH, 2015, CIRCULATION, V131, P2070, DOI 10.1161/CIRCULATIONAHA.114.013046
   Chatterjee S, 2013, JAMA NEUROL, V70, P1486, DOI 10.1001/jamaneurol.2013.4021
   Cheng CL, 2015, INT J CARDIOL, V201, P96, DOI 10.1016/j.ijcard.2015.07.075
   Dewilde WJM, 2013, LANCET, V381, P1107, DOI 10.1016/S0140-6736(12)62177-1
   Fewel Matthew E, 2003, Neurosurg Focus, V15, pE1
   Flibotte JJ, 2004, NEUROLOGY, V63, P1059, DOI 10.1212/01.WNL.0000138428.40673.83
   FOGELHOLM R, 1992, J NEUROL NEUROSUR PS, V55, P1121, DOI 10.1136/jnnp.55.12.1121
   FRANKE CL, 1990, STROKE, V21, P726, DOI 10.1161/01.STR.21.5.726
   Gomez-Outes Antonio, 2013, Thrombosis, V2013, P640723, DOI 10.1155/2013/640723
   Hanger HC, 2008, J NEUROL, V255, P347, DOI 10.1007/s00415-008-0650-z
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Huang Yung-Chuan, 2008, Acta Neurol Taiwan, V17, P258
   Hung LC, 2017, J EPIDEMIOL, V27, P24, DOI 10.1016/j.je.2016.08.003
   Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P817, DOI 10.1097/TA.0b013e3182aafcf0
   Khan NI, 2017, STROKE, V48, P1810, DOI 10.1161/STROKEAHA.117.016290
   Lee VH, 2008, ARCH NEUROL-CHICAGO, V65, P205, DOI 10.1001/archneurol.2007.46
   Li XW, 2013, J NEUROSURG, V118, P94, DOI 10.3171/2012.9.JNS112286
   Maxwell MJ, 2013, NEPHROL DIAL TRANSPL, V28, P225, DOI 10.1093/bjaceaccp/mkl053
   Moussouttas M, 2010, NEUROCRIT CARE, V12, P24, DOI 10.1007/s12028-009-9290-0
   Patil CG, 2012, WORLD NEUROSURG, V78, P640, DOI 10.1016/j.wneu.2011.10.042
   Saloheimo P, 2006, STROKE, V37, P129, DOI 10.1161/01.STR.0000196991.03618.31
   Sansing LH, 2009, NEUROLOGY, V72, P1397, DOI 10.1212/01.wnl.0000342709.31341.88
   Shen AYJ, 2007, J AM COLL CARDIOL, V50, P309, DOI 10.1016/j.jacc.2007.01.098
   Sprugel MI, 2018, STROKE, V49, P2621, DOI 10.1161/STROKEAHA.118.021614
   Stead LG, 2010, CLIN NEUROL NEUROSUR, V112, P275, DOI 10.1016/j.clineuro.2009.12.002
   Stein M, 2016, J CLIN NEUROSCI, V26, P42, DOI 10.1016/j.jocn.2015.05.069
   Steinhubl SR, 2009, ANN INTERN MED, V150, P379, DOI 10.7326/0003-4819-150-6-200903170-00006
   Sung SF, 2016, INT J CARDIOL, V215, P277, DOI 10.1016/j.ijcard.2016.04.069
   Tseng HP, 2015, J STROKE CEREBROVASC, V24, P1179, DOI 10.1016/j.jstrokecerebrovasdis.2015.01.010
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Wang KL, 2013, CIRC J, V77, P2242, DOI 10.1253/circj.CJ-13-0885
   Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234
   Wu CD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108548
   Wu CY, 2012, JAMA-J AM MED ASSOC, V308, P1906, DOI 10.1001/2012.jama.11975
NR 36
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E59
EP E73
DI 10.1016/j.wneu.2019.03.269
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100009
PM 30954751
DA 2020-05-12
ER

PT J
AU Lo Presti, A
   Rogers, JM
   Stoodley, MA
   Assaad, NNA
   Simons, M
   Sen, I
   Morgan, MK
AF Lo Presti, Anna
   Rogers, Jeffrey M.
   Stoodley, Marcus A.
   Assaad, Nazih N. A.
   Simons, Mary
   Sen, Itsu
   Morgan, Michael Kerin
TI Laminar Wall Shear Stress in Brain Arteriovenous Malformations:
   Systematic Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain arteriovenous malformation; Cerebral arteries; Hemodynamics; Shear
   stress
ID ENDOTHELIAL-CELLS; CEREBRAL-ARTERIES; FLOW
AB BACKGROUND: Laminar wall sheer stress (LWSS) modulates inflammatory activity of the endothelium and may be a contributing factor in many cerebrovascular pathologies. There is a lack of consensus whether significant differences in LWSS exist between feeding vessels in brain arteriovenous malformation (bAVM) and healthy vessels. A systematic review of LWSS research in bAVM was undertaken, including the methods used and the assumptions made in determining LWSS.
   METHODS: Ovid MEDLINE, EMBASE, and Scopus electronic databases were systematically searched from inception for articles calculating LWSS in bAVM cases. LWSS values were extracted for comparison between ipsilateral bAVM feeding arteries and healthy contralateral vessels or healthy normative data.
   RESULTS: Three retrospective cohort studies were identified, reporting on 42 adult and pediatric bAVM cases. Mean LWSS (mLWSS) in healthy vessels (contralateral vessels or normative controls) typically ranged from 1.2-2.7 Pa, while mLWSS values in untreated bAVM feeding arteries typically ranged from 1.6-3.6 Pa. All studies had mixed cohorts of ruptured and unruptured cases, obscuring the relationship between LWSS and bAVM history.
   CONCLUSIONS: mLWSS values in healthy arteries and bAVM feeding vessels tend to be low and overlapping. Further research of high scientific and methodologic quality is necessary to improve understanding of how LWSS hemodynamics relate to bAVM formation, rupture, and treatment.
C1 [Lo Presti, Anna; Rogers, Jeffrey M.; Stoodley, Marcus A.; Assaad, Nazih N. A.; Simons, Mary; Morgan, Michael Kerin] Fac Hlth Sci, Dept Clin Med, Sydney, NSW, Australia.
   [Rogers, Jeffrey M.] Univ Sydney, Fac Hlth Sci, Sydney, NSW, Australia.
   [Sen, Itsu] Macquarie Univ, Dept Biomed Engn, Fac Hlth Sci, Sydney, NSW, Australia.
RP Lo Presti, A (reprint author), Fac Hlth Sci, Dept Clin Med, Sydney, NSW, Australia.
EM annaloprestivega@gmail.com
OI Morgan, Michael/0000-0002-9841-9461; Rogers, Jeffrey
   M/0000-0002-0320-969X; Stoodley, Marcus/0000-0002-4207-8493; Simons,
   Mary/0000-0001-9627-7861
CR Alaraj A, 2015, STROKE, V46, P1216, DOI 10.1161/STROKEAHA.115.008836
   Bervini D, 2017, J NEUROSURG, V127, P51, DOI 10.3171/2016.5.JNS16730
   Chang W, 2012, AM J NEURORADIOL, V33, P1565, DOI 10.3174/ajnr.A3010
   Chiu JJ, 2011, PHYSIOL REV, V91, P327, DOI 10.1152/physrev.00047.2009
   Cumming G, 2005, AM PSYCHOL, V60, P170, DOI 10.1037/0003-066X.60.2.170
   DAVIES PF, 1995, PHYSIOL REV, V75, P519
   Fitts Michelle K, 2014, Open Urol Nephrol J, V7, P33
   Guo Yi, 2014, Neuroimmunol Neuroinflamm, V1, P147
   Hasan DM, 2012, TRANSL STROKE RES, V3, pS166, DOI 10.1007/s12975-012-0172-y
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Howick J, 2011, EXPLANATION 2011 OXF
   Hunter W., 1764, MED OBS SOC PHYS LON, V2, P390
   Jia L, 2015, NEPHROLOGY, V20, P335, DOI 10.1111/nep.12394
   Katritsis D, 2007, PROG CARDIOVASC DIS, V49, P307, DOI 10.1016/j.pcad.2006.11.001
   Li J, 2014, NATURE, V515, P279, DOI 10.1038/nature13701
   Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035
   Mcgah PM, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4023133
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Morgan MK, 2019, NEUROSURGERY, V84, P84, DOI 10.1093/neuros/nyy007
   MORGAN MK, 1989, BRAIN RES, V496, P241, DOI 10.1016/0006-8993(89)91071-8
   Murray CD, 1926, P NATL ACAD SCI USA, V12, P207, DOI 10.1073/pnas.12.3.207
   Nichols WW, 2011, MCDONALD'S BLOOD FLOW IN ARTERIES: THEORETICAL, EXPERIMENTAL AND CLINICAL PRINCIPLES, 6TH EDITION, P1
   NORIS M, 1995, CIRC RES, V76, P536, DOI 10.1161/01.RES.76.4.536
   Reneman RS, 2008, MED BIOL ENG COMPUT, V46, P499, DOI 10.1007/s11517-008-0330-2
   Rossitti S, 1995, ACTA NEUROCHIR, V137, P138, DOI 10.1007/BF02187185
   Shakur SF, 2015, STROKE, V46, P1997, DOI 10.1161/STROKEAHA.115.009545
   Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677
   Zakkar M, 2016, CURR VASC PHARMACOL, V14, P181, DOI 10.2174/1570161114666151202205139
   ZAMIR M, 1992, J BIOMECH, V25, P1303, DOI 10.1016/0021-9290(92)90285-9
   Zhao XX, 2015, J NEUROIMAGING, V25, P403, DOI 10.1111/jon.12133
   Zhou G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05886-w
   Zhou J, 2014, ARTERIOSCL THROM VAS, V34, P2191, DOI 10.1161/ATVBAHA.114.303422
NR 33
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E760
EP E767
DI 10.1016/j.wneu.2019.04.251
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100089
PM 31077894
DA 2020-05-12
ER

PT J
AU Loewenstern, J
   Shuman, W
   Rutland, JW
   Kessler, RA
   Kohli, KM
   Umphlett, M
   Pain, M
   Bederson, J
   Fowkes, M
   Shrivastava, RK
AF Loewenstern, Joshua
   Shuman, William
   Rutland, John W.
   Kessler, Remi A.
   Kohli, Karan M.
   Umphlett, Melissa
   Pain, Margaret
   Bederson, Joshua
   Fowkes, Mary
   Shrivastava, Raj K.
TI Preoperative and Histological Predictors of Recurrence and Survival in
   Atypical Meningioma After Initial Gross Total Resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atypical meningioma; Meningioma; Recurrenc; Survival; Tumor pathology
ID PROGRESSION-FREE SURVIVAL; CENTRAL-NERVOUS-SYSTEM; RADIOTHERAPY
   FOLLOWING GROSS; GRADE II MENINGIOMA; PROGNOSTIC-FACTORS; ADJUVANT
   RADIOTHERAPY; MALIGNANT MENINGIOMA; CLASSIFICATION; RADIOSURGERY;
   RADIATION
AB OBJECTIVE: Atypical (World Health Organization grade II) meningiomas (AMs) have been associated with a substantial risk of recurrence even after complete, gross total resection (GTR). The present study evaluated the clinical and AM tumor histopathological features that might predict for the risk of recurrence and survival within this patient population.
   METHODS: The data from 72 consecutive patients who had undergone primary GTR for AM from 2007 to 2016 and corresponding tumor specimens at a single institution were reviewed. The preoperative patient and tumor characteristics were correlated with the post-resection outcomes, including recurrence and 1-year survival. Cox regression models on recurrence-free survival (RFS) and Kaplan-Meier survival estimates were performed.
   RESULTS: The overall 1-, 3-, and 5-year RFS estimates for the AM cohort were 100.0%, 82.4%, and 78.1% after resection, respectively. A high mitotic index was an independent predictor of RFS on Cox regression analysis (hazard ratio, 1.26; P = 0.008), and the tumor volume showed a trend toward a significant association (hazard ratio, 0.93; P = 0.079). Patient age and the mitotic index were significantly associated with 1-year mortality (odds ratio, 1.11 and 1.36, respectively; P = 0.028 and P = 0.045, respectively).
   CONCLUSIONS: AM tumors with a high proliferative index showed an increased likelihood of recurrence and short-term survival even after complete GTR. A smaller tumor volume might also have contributed to an increased risk of recurrence for patients with AM. Although other histopathological features were not linked to recurrence or mortality for patients with AM, the biopsy findings can indicate key predictive information, and further molecular analysis might reveal additional prognostic markers.
C1 [Loewenstern, Joshua; Shuman, William; Rutland, John W.; Kessler, Remi A.; Kohli, Karan M.; Pain, Margaret; Bederson, Joshua; Shrivastava, Raj K.] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
   [Umphlett, Melissa; Fowkes, Mary] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA.
   [Shrivastava, Raj K.] Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA.
RP Shrivastava, RK (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.; Shrivastava, RK (reprint author), Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA.
EM raj.shrivastava@mountsinai.org
OI Kohli, Karan/0000-0001-6248-1880
CR Aghi MK, 2009, NEUROSURGERY, V64, P56, DOI 10.1227/01.NEU.0000330399.55586.63
   Attia A, 2012, J NEURO-ONCOL, V108, P179, DOI 10.1007/s11060-012-0828-1
   Backer-Grondahl T, 2012, INT J CLIN EXP PATHO, V5, P231
   Bagshaw HP, 2017, J NEUROSURG, V126, P1822, DOI 10.3171/2016.5.JNS152809
   Budohoski KP, 2018, ACTA NEUROCHIR, V160, P1813, DOI 10.1007/s00701-018-3593-x
   Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17
   Champeaux C, 2017, NEUROCHIRURGIE, V63, P273, DOI 10.1016/j.neuchi.2017.03.004
   Champeaux C, 2016, J NEURO-ONCOL, V129, P337, DOI 10.1007/s11060-016-2181-2
   Choy W, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1116
   Detti B, 2013, J NEURO-ONCOL, V115, P421, DOI 10.1007/s11060-013-1239-7
   Dohm A, 2017, J CLIN NEUROSCI, V46, P90, DOI 10.1016/j.jocn.2017.08.023
   Durand A, 2009, J NEURO-ONCOL, V95, P367, DOI 10.1007/s11060-009-9934-0
   Fernandez Christian, 2016, Adv Radiat Oncol, V1, P89, DOI 10.1016/j.adro.2016.03.001
   Gabeau-Lacet D, 2009, J NEUROPATH EXP NEUR, V68, P1155, DOI 10.1097/NEN.0b013e3181ba3952
   Graffeo CS, 2017, WORLD NEUROSURG, V103, P655, DOI 10.1016/j.wneu.2017.04.095
   Hammouche S, 2014, ACTA NEUROCHIR, V156, P1475, DOI 10.1007/s00701-014-2156-z
   Hardesty DA, 2013, J NEUROSURG, V119, P475, DOI 10.3171/2012.12.JNS12414
   Hasan S, 2015, WORLD NEUROSURG, V83, P808, DOI 10.1016/j.wneu.2014.12.037
   Jenkinson MD, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1040-3
   Jo K, 2010, J CLIN NEUROSCI, V17, P1362, DOI 10.1016/j.jocn.2010.03.036
   Kano H, 2007, J NEURO-ONCOL, V84, P41, DOI 10.1007/s11060-007-9338-y
   Kirshblum S, 2001, CANCER, V92, P1029, DOI 10.1002/1097-0142(20010815)92:4+<1029::AID-CNCR1416>3.0.CO;2-P
   Klinger DR, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.033
   Komotar RJ, 2012, J NEUROSURG, V117, P679, DOI 10.3171/2012.7.JNS112113
   Lee JH, 2017, J KOREAN NEUROSURG S, V60, P661, DOI 10.3340/jkns.2017.0303.008
   Lee KD, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.9.FOCUS13325
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Mair R, 2011, J NEUROSURG, V115, P811, DOI 10.3171/2011.5.JNS11112
   Masalha W, 2018, J NEURO-ONCOL, V136, P147, DOI 10.1007/s11060-017-2634-2
   Mawrin C, 2010, J NEURO-ONCOL, V99, P379, DOI 10.1007/s11060-010-0342-2
   MOR V, 1984, CANCER, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W
   Nanda A, 2016, J CLIN NEUROSCI, V31, P112, DOI 10.1016/j.jocn.2016.02.021
   Nowak A, 2015, NEUROL NEUROCHIR POL, V49, P1, DOI 10.1016/j.pjnns.2014.11.003
   Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158
   Park HJ, 2013, J NEURO-ONCOL, V115, P241, DOI 10.1007/s11060-013-1219-y
   Pasquier D, 2008, INT J RADIAT ONCOL, V71, P1388, DOI 10.1016/j.ijrobp.2007.12.020
   Pham MH, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS1117
   Phonwijit L, 2017, WORLD NEUROSURG, V107, P698, DOI 10.1016/j.wneu.2017.08.057
   Preusser M, 2018, NAT REV NEUROL, V14, P106, DOI 10.1038/nrneurol.2017.168
   Rogers CL, 2016, NEURO-ONCOLOGY, V18, P565, DOI 10.1093/neuonc/nov247
   Rogers L, 2018, J NEUROSURG, V129, P35, DOI 10.3171/2016.11.JNS161170
   Rydzewski NR, 2018, CANCER-AM CANCER SOC, V124, P734, DOI 10.1002/cncr.31088
   Sahm F, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv377
   Shakir SI, 2018, J NEUROSURG, V129, P1240, DOI 10.3171/2017.6.JNS17120
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Spiegl-Kreinecker S, 2018, NEURO-ONCOLOGY, V20, P1584, DOI 10.1093/neuonc/noy104
   Sun SQ, 2014, NEUROSURGERY, V75, P347, DOI 10.1227/NEU.0000000000000461
   Valery CA, 2016, J NEUROSURG, V125, P89, DOI 10.3171/2016.7.GKS161521
   Vranic A, 2010, NEUROSURGERY, V67, P1124, DOI 10.1227/NEU.0b013e3181eb95b7
   Wang YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep35743
   Wiemels J, 2010, J NEURO-ONCOL, V99, P307, DOI 10.1007/s11060-010-0386-3
   Yang SY, 2008, J NEUROL NEUROSUR PS, V79, P574, DOI 10.1136/jnnp.2007.121582
   Zaher A, 2013, WORLD NEUROSURG, V80, P549, DOI 10.1016/j.wneu.2013.07.001
NR 53
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E148
EP E156
DI 10.1016/j.wneu.2019.04.069
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100017
PM 30995555
DA 2020-05-12
ER

PT J
AU Lvov, I
   Grin, A
   Kordonskiy, A
   Sytnik, A
   Smirnov, V
   Khushnazarov, U
   Krylov, V
AF Lvov, Ivan
   Grin, Andrey
   Kordonskiy, Anton
   Sytnik, Aleksey
   Smirnov, Vladimir
   Khushnazarov, Ulugbek
   Krylov, Vladimir
TI Minimally Invasive Posterior Transarticular Stand-Alone Screw
   Instrumentation of C1-C2 Using a Transmuscular Approach: Description of
   Technique, Results and Comparison with Posterior Midline Exposure
SO WORLD NEUROSURGERY
LA English
DT Article
DE C1-C2 stand-alone screw fixation; C1-C2 fracture; Endoscopic fixation of
   C1-C2; Minimally invasive fixation of C1-C2; Posterior transmuscular
   approach
ID FIXATION
AB PURPOSE: The aim of this study was to compare the feasibility, safety, and fusion results of posterior transarticular stand-alone screw (SAS) instrumentation of C1-C2 with a minimally invasive technique to those of a posterior midline exposure.
   METHODS: Between 2008 and 2016, 164 patients underwent surgical treatment for traumatic injuries to the upper cervical vertebrae at our institution. We included 38 patients (27 men and 11 women; age range, 17-81 years) in the study. The posterior midline approach (PMA) group (23 patients) included patients who underwent surgery by means of a conventional midline incision after percutaneous screw insertion. The transmuscular approach (TMA) group (15 patients) included patients who underwent SAS fixation by use of a minimally invasive technique. The mean follow-up period was 58 months (range, 12-118 months).
   RESULTS: Statistical analysis revealed that the operative time, blood loss volume, and severity of postoperative pain were lower in the TMA group. No significant excess of radiation exposure to the surgical team and the patients occurred in TMA group compared with the PMA group. C1- C2 fusion was observed in 37 patients. Stable fibrous fusion between the C1 and C2 vertebrae was found in 1 patient.
   CONCLUSIONS: A minimally invasive technique by use of a paravertebral transmuscular approach provides an alternative to routine posterior transarticular SAS fixation of C1 and C2 through a posterior midline approach. The minimally invasive technique reduces the duration of surgery and the volume of blood loss, decreases the severity of postoperative pain, and does not increase the amount of radiation exposure for the surgical team and the patient.
C1 [Lvov, Ivan; Grin, Andrey; Kordonskiy, Anton; Smirnov, Vladimir; Khushnazarov, Ulugbek; Krylov, Vladimir] Sklifosovsky Res Inst Emergency Care, Moscow, Russia.
   [Grin, Andrey; Krylov, Vladimir] AI Evdokimov Moscow State Univ Med & Dent, Moscow, Russia.
   [Sytnik, Aleksey] Moscow City Hosp 13, Moscow, Russia.
RP Lvov, I (reprint author), Sklifosovsky Res Inst Emergency Care, Moscow, Russia.
EM dr.speleolog@gmail.com
OI Lvov, Ivan/0000-0003-1718-0792
CR Alhashash M, 2018, SPINE, V43, P761, DOI 10.1097/BRS.0000000000002417
   Blauth M, 1999, ORTHOPADE, V28, P651, DOI 10.1007/PL00003654
   Borm W, 2004, MINIM INVAS NEUROSUR, V47, P111, DOI 10.1055/s-2004-818449
   Elliott RE, 2013, WORLD NEUROSURG, V80, P627, DOI 10.1016/j.wneu.2012.03.012
   Finn MA, 2010, NEUROSURGERY, V66, pA184, DOI 10.1227/01.NEU.0000365798.53288.A3
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Holly LT, 2006, SPINE, V31, P536, DOI 10.1097/01.brs.0000201297.83920.a1
   Lakshmanan P, 2005, EUR SPINE J, V14, P78, DOI 10.1007/s00586-004-0743-z
   Lang Zhao, 2013, Zhonghua Yi Xue Za Zhi, V93, P2296
   Lvov I, 2019, WORLD NEUROSURG, V125, pE1138, DOI 10.1016/j.wneu.2019.01.263
   Magerl F, 1987, CERVICAL SPINE, P322, DOI DOI 10.1007/978-3-7091-8882-8_59
   Schmidt R, 2006, ARCH ORTHOP TRAUM SU, V126, P150, DOI 10.1007/s00402-005-0046-9
   Vergara P, 2012, NEUROSURGERY, V71, P86, DOI 10.1227/NEU.0b013e318243180a
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E796
EP E805
DI 10.1016/j.wneu.2019.04.259
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100094
PM 31078803
DA 2020-05-12
ER

PT J
AU Ma, SC
   Liu, S
   Agazzi, S
   Jia, W
AF Ma, Shun-Chang
   Liu, Shih
   Agazzi, Siviero
   Jia, Wang
TI Rectus Capitis Lateralis Muscle: A Cadaveric Study of a Key Surgical
   Landmark in the Posterior and Lateral Approaches to the Jugular Foramen
SO WORLD NEUROSURGERY
LA English
DT Article
DE Boundary; Far-lateral; Jugular bulb; Jugular process; Rectus capitis
   lateralis; Surgical landmark; Transmastoid
ID JUXTACONDYLAR APPROACH; MICROSURGICAL ANATOMY; ENDONASAL APPROACH;
   TRANSCONDYLAR; TUMORS; SUPRACONDYLAR; LESIONS; BONE
AB OBJECTIVE: The rectus capitis lateralis (RCL) is a small cervical muscle that arises from the transverse process of Cl and is intimately related to the jugular process and jugular foramen. We describe its morphology, neurovascular relationships, and its utility as one of the key surgical landmarks in approaches to the jugular foramen.
   METHODS: Eight cadaveric heads were used to perform far-lateral and transmastoid approaches to the jugular foramen. The neurovascular relationships of the RCL were studied.
   RESULTS: The RCL originates from the transverse process of C1 and inserts onto the jugular process. It can be found in the muscular interval between the posterior belly of the digastric muscle and the superior oblique muscle with the occipital artery coursing between it and the posterior belly of the digastric muscle. It lies directly posterior to the internal jugular vein and cranial nerves (CNs) IX-XI as they exit the jugular foramen. The vertebral artery courses medially to the RCL as it exits foramen transversarium of C1. As the facial nerve exits the stylomastoid foramen, it is anterolateral to the RCL before turning to enter the parotid gland. The CN XII is seen between the RCL and the occipital condyle from a posterior view.
   CONCLUSIONS: The RCL usually is preserved unless jugular process needs to be removed to expose the jugular foramen. The RCL is an important surgical landmark for the early identification of the vertebral artery, internal jugular vein, facial nerve, and CNs IX-XII in approaches to the jugular foramen.
C1 [Ma, Shun-Chang; Jia, Wang] Capital Med Univ, Beijing Tiantan Hosp, Beijing Neurosurg Inst, Dept Neurot, Beijing, Peoples R China.
   [Ma, Shun-Chang; Jia, Wang] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Liu, Shih; Agazzi, Siviero] Univ S Florida, Tampa Gen Hosp, Dept Neurosurg, Tampa, FL USA.
RP Jia, W (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Beijing Neurosurg Inst, Dept Neurot, Beijing, Peoples R China.; Jia, W (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM jwttyy@126.com
CR AlMefty O, 1996, J NEUROSURG, V84, P1, DOI 10.3171/jns.1996.84.1.0001
   Anderson S, 2013, OPER TECH OTOLARYNGO, V24, P163
   Anichini G, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.05.031
   Benet A, 2019, J NEUROSURG, V130, P207, DOI 10.3171/2017.6.JNS17518
   Bruneau M, 2008, NEUROSURGERY, V63, P75, DOI [10.1227/01.NEU.0000297103.19261.79, 10.1227/01.neu.0000317375.38067.55]
   Cohen MA, 2017, J NEUROSURG, V127, P1398, DOI 10.3171/2016.9.JNS16723
   FISCH U, 1978, J LARYNGOL OTOL, V92, P949, DOI 10.1017/S0022215100086382
   George B, 1995, SURG NEUROL, V44, P279, DOI 10.1016/0090-3019(95)00174-3
   Guinto G, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.07.013
   Jhawar SS, 2016, J CRANIOVERTEBRAL JU, V7, P204, DOI 10.4103/0974-8237.193270
   Katsuta T, 1997, NEUROSURGERY, V41, P149, DOI 10.1097/00006123-199707000-00030
   Komune N, 2019, OPER NEUROSURG, V16, P486, DOI 10.1093/ons/opy198
   Komune N, 2016, HEAD NECK-J SCI SPEC, V38, pE1041, DOI 10.1002/hed.24156
   Liu JK, 2006, NEUROSURGERY, V59, P115, DOI 10.1227/01.NEU.0000220025.81500.8D
   MANN WJ, 1991, SKULL BASE SURG, V1, P137, DOI 10.1055/s-2008-1056995
   Matsushima K, 2019, ACTA NEUROCHIR, V161, P739, DOI 10.1007/s00701-019-03860-1
   Matsushima K, 2019, WORLD NEUROSURG, V125, pE984, DOI 10.1016/j.wneu.2019.01.223
   Meybodi AT, 2018, J NEUROSURG-SPINE, V29, P18, DOI 10.3171/2017.11.SPINE171068
   Oghalai JS, 2004, OTOL NEUROTOL, V25, P570, DOI 10.1097/00129492-200407000-00026
   PIFFER CR, 1981, ANAT ANZEIGER, V149, P333
   Rhoton AL, 2000, NEUROSURGERY, V47, pS267, DOI 10.1097/00006123-200009001-00026
   Rhoton AL, 2000, NEUROSURGERY, V47, pS195, DOI 10.1097/00006123-200009001-00020
   Sato A, 2018, J NEUROL SURG PART B, V79, pS356, DOI 10.1055/s-0038-1668518
   SEN CN, 1990, NEUROSURGERY, V27, P197, DOI 10.1227/00006123-199008000-00004
   Shiban E, 2016, J NEUROSURG, V125, P196, DOI 10.3171/2015.5.JNS15176
   Vaz-Guimaraes F, 2017, OPER NEUROSURG, V13, P482, DOI 10.1093/ons/opx014
   Wen HT, 1997, J NEUROSURG, V87, P555, DOI 10.3171/jns.1997.87.4.0555
   Zhang X, 2016, WORLD NEUROSURG, V95, P62, DOI 10.1016/j.wneu.2016.07.073
NR 28
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E859
EP E864
DI 10.1016/j.wneu.2019.05.018
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100101
PM 31082563
OA Bronze
DA 2020-05-12
ER

PT J
AU Mahan, MY
   Thorpe, M
   Ahmadi, A
   Abdallah, T
   Casey, H
   Sturtevant, D
   Judge-Yoakam, S
   Hoover, C
   Rafter, D
   Miner, J
   Richardson, C
   Samadani, U
AF Mahan, Margaret Y.
   Thorpe, Maxwell
   Ahmadi, Aliya
   Abdallah, Tessneem
   Casey, Hannah
   Sturtevant, Dylan
   Judge-Yoakam, Senait
   Hoover, Caleb
   Rafter, Daniel
   Miner, James
   Richardson, Chad
   Samadani, Uzma
TI Glial Fibrillary Acidic Protein (GFAP) Outperforms S100 Calcium-Binding
   Protein B (S100B) and Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) as
   Predictor for Positive Computed Tomography of the Head in Trauma
   Subjects
SO WORLD NEUROSURGERY
LA English
DT Article
DE Calcium-binding protein B (S100 beta); Computed tomography (CT); Glial
   fibrillary acidic protein (GFAP); S100 ubiquitin carboxy-terminal
   hydrolase isozyme L1 (UCHL1); Traumatic brain injury (TBI)
ID GLASGOW COMA SCALE; BRAIN-INJURY; SERUM S100B; OUTCOME PREDICTION;
   DIAGNOSTIC MARKER; BLOOD BIOMARKERS; MILD; MODERATE; MANAGEMENT;
   CRITERIA
AB OBJECTIVE: Traumatic brain injuries (TBIs) are largely underdiagnosed and may have persistent refractory consequences. Current assessments for acute TBI are limited to physical examination and imaging. Biomarkers such as glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCH-L1), and S100 calcium-binding protein B (S100B) have shown predictive value as indicators of TBI and potential screening tools.
   METHODS: In total, 37 controls and 118 unique trauma subjects who received a clinically ordered head computed tomography (CT) in the emergency department of a level 1 trauma center were evaluated. Blood samples collected at 0-8 hours (initial) and 12-32 hours (delayed) postinjury were analyzed for GFAP, UCH-L1, and S100B concentrations. These were then compared in CT-negative and CT-positive subjects.
   RESULTS: Median GFAP, UCH-L1, and S100B concentrations were greater in CT-positive subjects at both timepoints compared with CT-negative subjects. In addition, median UCH-L1 and S100B concentrations were lower at the delayed timepoint, whereas median GFAP concentrations were increased. As predictors of a positive CT of the head, GFAP outperformed UCH-L1 and S100B at both timepoints (initial: 0.89 sensitivity, 0.62 specificity; delayed: 0.94 sensitivity, 0.67 specificity). GFAP alone also outperformed all possible combinations of biomarkers.
   CONCLUSIONS: GFAP, UCH-L1, and S100B demonstrated utility for rapid prediction of a CT-positive TBI within 0-8 hours of injury. GFAP exhibited the greatest predictive power at 12-32 hours. Furthermore, these results suggest that GFAP alone has greater utility for predicting a positive CT of the head than UCH-L1, S100B, or any combination of the 3.
C1 [Mahan, Margaret Y.; Thorpe, Maxwell; Ahmadi, Aliya; Abdallah, Tessneem; Casey, Hannah; Sturtevant, Dylan; Judge-Yoakam, Senait; Hoover, Caleb; Rafter, Daniel; Samadani, Uzma] Hennepin Healthcare, Dept Neurosurg, Minneapolis, MN 55415 USA.
   [Miner, James] Hennepin Healthcare, Dept Emergency Med, Minneapolis, MN USA.
   [Richardson, Chad] Hennepin Healthcare, Dept Gen Surg, Minneapolis, MN USA.
   [Mahan, Margaret Y.; Samadani, Uzma] Univ Minnesota, Dept Biomed Informat & Computat Biol, Minneapolis, MN 55455 USA.
   [Samadani, Uzma] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
RP Samadani, U (reprint author), Hennepin Healthcare, Dept Neurosurg, Minneapolis, MN 55415 USA.; Samadani, U (reprint author), Univ Minnesota, Dept Biomed Informat & Computat Biol, Minneapolis, MN 55455 USA.; Samadani, U (reprint author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
EM uzma@samadani.com
OI Casey, Hannah/0000-0002-6562-4020; Mahan, Margaret/0000-0002-7332-9523
FU Minnesota Spinal Cord and Traumatic Brain Injury Research Fund;
   Rockswold Kaplan Endowed Chair; Abbott LaboratoriesAbbott Laboratories
FX This research was supported by funding from the Minnesota Spinal Cord
   and Traumatic Brain Injury Research Fund, Rockswold Kaplan Endowed
   Chair, and Abbott Laboratories. Dr. Uzma Samadani reports grant money to
   Hennepin Healthcare Research Institute to conduct research conceived and
   sponsored by Abbott Laboratories.
CR Abbasi Mohsen, 2014, Turk J Emerg Med, V14, P147, DOI 10.5505/1304.7361.2014.74317
   Bishop P, 2016, BIOCHEM J, V473, P2453, DOI 10.1042/BCJ20160082
   Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564
   Calcagnile O, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0723-z
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   DAGOSTIN.R, 1973, BIOMETRIKA, V60, P613, DOI 10.1093/biomet/60.3.613
   DAGOSTINO RB, 1971, BIOMETRIKA, V58, P341, DOI 10.1093/biomet/58.2.341
   Dams-O'Connor K, 2017, J HEAD TRAUMA REHAB, V32, P147, DOI 10.1097/HTR.0000000000000263
   Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110
   Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040
   Dutton RP, 2011, J TRAUMA, V70, P554, DOI 10.1097/TA.0b013e31820d1062
   Easter JS, 2013, ACAD EMERG MED, V20, P753, DOI 10.1111/acem.12184
   Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3
   Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963
   Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X
   Gilquin B, 2010, MOL CELL BIOL, V30, P2724, DOI 10.1128/MCB.01468-09
   Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579
   Heidari K, 2015, BRAIN INJURY, V29, P33, DOI 10.3109/02699052.2014.948068
   Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485
   Hughes EG, 2004, MOL BRAIN RES, V124, P114, DOI 10.1016/j.molbrainres.2004.02.021
   Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8
   Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55
   Jung CS, 2007, BRAIN, V130, P3336, DOI 10.1093/brain/awm263
   Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009
   Kellermann I, 2016, CLIN NEUROL NEUROSUR, V145, P79, DOI 10.1016/j.clineuro.2016.04.005
   Kim DS, 2013, J KOREAN NEUROSURG S, V54, P100, DOI 10.3340/jkns.2013.54.2.100
   Kohavi R., 1995, IJCAI-95. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence, P1137
   Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975
   Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296
   Kreitzer N, 2017, AM J EMERG MED, V35, P875, DOI 10.1016/j.ajem.2017.01.051
   KRUSKAL WH, 1953, J AM STAT ASSOC, V48, P907, DOI 10.2307/2281082
   Lagerstedt L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175572
   Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8
   Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2
   Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d
   MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509
   MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491
   MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287
   Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358
   Mata-Mbemba D, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-1781-9
   McKinney W, 2010, P 9 PYTH SCI C, V9, P51, DOI DOI 10.1016/S0168-0102(02)00204-3
   McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635
   Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7
   Mondello S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28203
   Moschnegootz S, 2010, NEURORADIOL J, V23, P296, DOI 10.1177/197140091002300306
   Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa
   Nayebaghayee Hossein, 2016, Asian J Neurosurg, V11, P46, DOI 10.4103/1793-5482.165780
   Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883
   Oliphant TE, 2007, COMPUT SCI ENG, V9, P10, DOI 10.1109/MCSE.2007.58
   Owlia M, 2014, AM J MED, V127, P406, DOI 10.1016/j.amjmed.2014.01.023
   Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018
   Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039
   Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab
   Peacock WF, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00641
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226
   Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296
   Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009
   Shan RZ, 2016, J NEUROTRAUM, V33, P49, DOI 10.1089/neu.2014.3811
   Sharma R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173798
   Sieber M, 2018, J FORENSIC LEG MED, V55, P65, DOI 10.1016/j.jflm.2018.02.016
   Steiner Emanuel, 2016, J Trauma Manag Outcomes, V10, P5, DOI 10.1186/s13032-016-0035-8
   Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511
   Studer M, 2015, BRAIN INJURY, V29, P1667, DOI 10.3109/02699052.2015.1075250
   Sultan HY, 2004, EMERG MED J, V21, P420, DOI 10.1136/emj.2003.011353
   Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066
   van der Walt S, 2011, COMPUT SCI ENG, V13, P22, DOI 10.1109/MCSE.2011.37
   Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2
   WEINSTEIN DE, 1991, J CELL BIOL, V112, P1205, DOI 10.1083/jcb.112.6.1205
   Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149
   Zhou JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040403
NR 71
TC 1
Z9 1
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E434
EP E444
DI 10.1016/j.wneu.2019.04.170
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100050
PM 31051301
DA 2020-05-12
ER

PT J
AU McMains, MC
   Jain, N
   Malik, AT
   Cerier, E
   Litsky, AS
   Yu, E
AF McMains, M. Craig
   Jain, Nikhil
   Malik, Azeem Tariq
   Cerier, Emily
   Litsky, Alan S.
   Yu, Elizabeth
TI A Biomechanical Analysis of Lateral Interbody Construct and Supplemental
   Fixation in Adjacent-Segment Disease of the Lumbar Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent segment disease; ASD; Lateral lumbar interbody fusion; Lumbar
   spine
ID FUSION; OUTCOMES; EXTENSION; LIFE
AB OBJECTIVE: To analyze the stability of lateral lumbar interbody fusion (LLIF) and compare various methods of supplemental fixation in adjacent-segment disease.
   METHODS: Four fresh-frozen human cadaveric lumbar spines (L1 to sacrum) were used for motion analysis in extension, flexion, and lateral bending. The L4 - L5 level was secured with a lateral interbody cage and pedicle screws to simulate a fused segment. The adjacent segment (L3- L4) was evaluated with flexibility testing sequentially under the following conditions: native disc (control), LLIF cage, cage with lateral plate, pedicle screws with z-rod, and single-rod construct. The difference in mean displacement (millimeters) between groups was studied by the analysis of variance and post-hoc Tukey test.
   RESULTS: Mean displacement (millimeters) on averaging motion in all planes was 0.741 for native disc, 0.273 for cage, 0.183 for cage with plate, 0.086 for pedicle screws and z-rod, and 0.106 for the single-rod construct. All 4 constructs led to a significant reduction (P < 0.001) in displacement in extension and flexion, as compared with native disc. There was no demonstrable superiority between the 4 constructs as the mean displacements were not significantly different from each other.
   CONCLUSIONS: LLIF with and without supplemental fixation reduced motion significantly at the adjacent segment as compared with intact disc. There was a trend toward increasing rigidity with supplemental fixation (plate and pedicle screw constructs). Further biomechanical studies with larger sample sizes are needed to confirm these initial findings.
C1 [McMains, M. Craig; Jain, Nikhil; Malik, Azeem Tariq; Cerier, Emily; Litsky, Alan S.; Yu, Elizabeth] Ohio State Univ, Dept Orthopaed, Wexner Med Ctr, Columbus, OH 43210 USA.
RP Yu, E (reprint author), Ohio State Univ, Dept Orthopaed, Wexner Med Ctr, Columbus, OH 43210 USA.
EM Elizabeth.Yu@osumc.edu
RI Jain, Nikhil/R-5904-2019
OI Jain, Nikhil/0000-0002-8699-9630
FU NuVasive Inc., San Diego, California, USA
FX received $ 10,000 from NuVasive Inc., San Diego, California, USA, to
   fund the study.
CR Adogwa O, 2012, J NEUROSURG-SPINE, V16, P141, DOI 10.3171/2011.9.SPINE11419
   Bess RS, 2008, EXTREME LATERAL INTE, P31
   CAPPUCCINO A, 2010, SPINE PHILA PA 197 S, V35, pS36
   Elowitz EH, 2011, MINIM INVAS NEUROSUR, V54, P201, DOI 10.1055/s-0031-1286334
   Fogel GR, 2014, SPINE, V39, pE1138, DOI 10.1097/BRS.0000000000000485
   Isaacs RE, 2010, SPINE, V35, pS322, DOI 10.1097/BRS.0b013e3182022e04
   Khajavi K, 2015, EUR SPINE J, V24, pS322, DOI 10.1007/s00586-015-3840-2
   Lawrence BD, 2012, SPINE, V37, pS123, DOI 10.1097/BRS.0b013e31826d60d8
   Laws CJ, 2012, SPINE, V37, P819, DOI 10.1097/BRS.0b013e31823551aa
   Marchi L, 2012, ADV ORTHOP, V2012, DOI 10.1155/2012/282068
   Marchi Luis, 2012, ScientificWorldJournal, V2012, P456346, DOI 10.1100/2012/456346
   Metzger MF, 2017, SPINE J, V17, P1004, DOI 10.1016/j.spinee.2017.03.005
   Oliveira L, 2010, SPINE, V35, pS331, DOI 10.1097/BRS.0b013e3182022db0
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Palejwala SK, 2014, CLIN NEUROL NEUROSUR, V124, P90, DOI 10.1016/j.clineuro.2014.06.031
   Park P, 2004, SPINE, V29, P1938, DOI 10.1097/01.brs.0000137069.88904.03
   Parker SL, 2012, J NEUROSURG-SPINE, V16, P61, DOI 10.3171/2011.8.SPINE1194
   Pimenta L, 2012, SCI WORLD J, DOI 10.1100/2012/381814
   Radcliff KE, 2013, SPINE J, V13, P1339, DOI 10.1016/j.spinee.2013.03.020
   Reis MT, 2016, J NEUROSURG-SPINE, V25, P720, DOI 10.3171/2016.4.SPINE151386
   Rodgers WB, 2010, SPINE, V35, pS355, DOI 10.1097/BRS.0b013e3182023796
   Saavedra-Pozo FM, 2014, OCHSNER J, V14, P78
   Schlegel JD, 1996, SPINE, V21, P970, DOI 10.1097/00007632-199604150-00013
   Sharma AK, 2011, J SPINAL DISORD TECH, V24, P242, DOI 10.1097/BSD.0b013e3181ecf995
   Wang MY, 2014, J NEUROSURG-SPINE, V21, P861, DOI 10.3171/2014.8.SPINE13841
   WHITECLOUD TS, 1994, SPINE, V19, P531, DOI 10.1097/00007632-199403000-00007
   YOUSSEF JA, 2010, SPINE PHILA PA 197 S, V35, pS30
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E694
EP E699
DI 10.1016/j.wneu.2019.04.237
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100082
PM 31059851
DA 2020-05-12
ER

PT J
AU Mendenhall, SK
   Sahlein, DH
   Wilson, CD
   Filley, AC
   Ordaz, J
   Ahluwalia, RK
   Bakare, WA
   Huh, A
   Dancour, E
   Zaazoue, MA
   Shapiro, SA
   Cohen-Gadol, AA
AF Mendenhall, Stephen K.
   Sahlein, Daniel H.
   Wilson, Christopher D.
   Filley, Anna C.
   Ordaz, Josue
   Ahluwalia, Rahul K.
   Bakare, Wale A.
   Huh, Andrew
   Dancour, Elie
   Zaazoue, Mohamed A.
   Shapiro, Scott A.
   Cohen-Gadol, Aaron A.
TI The Natural History of Coiled Cerebral Aneurysms Stratified by Modified
   Raymond-Roy Occlusion Classification
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Coil embolization; Durability; Natural history;
   Raymond-Roy Classification
ID UNRUPTURED INTRACRANIAL ANEURYSMS; ANGIOGRAPHIC FOLLOW-UP; ENDOVASCULAR
   TREATMENT; SUBARACHNOID HEMORRHAGE; SACCULAR ANEURYSMS; DETACHABLE
   COILS; NECK REMNANT; TRIAL; EMBOLIZATION; MULTICENTER
AB OBJECTIVE: The natural history and long-term durability of Guglielmi detachable coil (GDC) embolization is still unknown. We hypothesize a stepwise decrease in durability of embolized cerebral aneurysms as stratified by the Modified Raymond-Roy Classification (MRRC).
   METHODS: First-time GDC-embolized cerebral aneurysms were retrospectively reviewed from 2004 to 2015. Loss of durability (LOD) was defined by change in aneurysm size or patency seen on serial radiographic follow-up. Kaplan-Meier survival analysis was performed to evaluate embolization durability. Multivariate Cox regression modeling was used to assess baseline aneurysm and patient characteristics for their effect on LOD.
   RESULTS: A total of 427 patients with 443 aneurysms met the inclusion criteria. Overall, 89 (21%) aneurysms met LOD criteria. Grade 1 aneurysms had statistically significantly greater durability than did all other MRRC grades. Grade 3b aneurysms had significantly worse durability than did all other aneurysm grades. There was no difference in durability between grade 2 and 3a aneurysms. Of aneurysms with LOD, 26 (29%) experienced worsening of MRRC grade. Thirty-five (24%) initial MRRC grade 2, 72 (45%) initial MRRC grade 3a, and 6 (22%) initial MRRC grade 3b aneurysms progressed to MRRC grade 1 without retreatment. In our multivariate analysis, only initial MRRC grade was statistically significantly associated with treatment durability (P < 0.001).
   CONCLUSIONS: MRRC grade is independently associated with first-time GDC-embolized cerebral aneurysm durability. Achieving MRRC grade 1 occlusion outcome is significantly associated with greater long-term GDC durability. Although few aneurysms experience further growth and/or recanalization, most incompletely obliterated aneurysms tend to remain stable over time or even progress to occlusion. Grading scales such as the MRRC are useful for characterizing aneurysm occlusion but may lack sensitivity and specificity for characterizing changes in aneurysm morphology over time.
C1 [Mendenhall, Stephen K.; Sahlein, Daniel H.; Wilson, Christopher D.; Filley, Anna C.; Ordaz, Josue; Ahluwalia, Rahul K.; Bakare, Wale A.; Huh, Andrew; Dancour, Elie; Zaazoue, Mohamed A.; Shapiro, Scott A.; Cohen-Gadol, Aaron A.] Indiana Univ Sch Med, Goodman Campbell Brain & Spine, Dept Neurol Surg, Indianapolis, IN 46202 USA.
RP Cohen-Gadol, AA (reprint author), Indiana Univ Sch Med, Goodman Campbell Brain & Spine, Dept Neurol Surg, Indianapolis, IN 46202 USA.
EM acohenmd@gmail.com
CR Batista LL, 2002, INTERV NEURORADIOL, V8, P349, DOI 10.1177/159101990200800405
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Campi A, 2007, STROKE, V38, P1538, DOI 10.1161/STROKEAHA.106.466987
   Chalouhi N, 2012, NEUROSURGERY, V71, P381, DOI 10.1227/NEU.0b013e31825c36dd
   Corns R, 2013, BRIT J NEUROSURG, V27, P30, DOI 10.3109/02688697.2012.701676
   Cronqvist M, 2005, NEURORADIOLOGY, V47, P855, DOI 10.1007/s00234-005-1408-2
   Derdeyn CP, 2002, J NEUROSURG, V96, P837, DOI 10.3171/jns.2002.96.5.0837
   Ferns SP, 2009, STROKE, V40, pE523, DOI 10.1161/STROKEAHA.109.553099
   Gallas S, 2005, AM J NEURORADIOL, V26, P1723
   Gallas S, 2009, AM J NEURORADIOL, V30, P1986, DOI 10.3174/ajnr.A1744
   Groden C, 2003, NEURORADIOLOGY, V45, P435, DOI 10.1007/s00234-003-1007-z
   Grunwald IQ, 2013, CNS NEUROL DISORD-DR, V12, P228
   GUGLIELMI G, 1991, J NEUROSURG, V75, P1, DOI 10.3171/jns.1991.75.1.0001
   GUGLIELMI G, 1991, J NEUROSURG, V75, P8, DOI 10.3171/jns.1991.75.1.0008
   Hayakawa M, 2000, J NEUROSURG, V93, P561, DOI 10.3171/jns.2000.93.4.0561
   Henkes H, 2005, J NEUROSURG, V103, P990, DOI 10.3171/jns.2005.103.6.0990
   Jalbert JJ, 2015, STROKE, V46, P2452, DOI 10.1161/STROKEAHA.115.009777
   KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562
   Koivisto T, 2000, STROKE, V31, P2369, DOI 10.1161/01.STR.31.10.2369
   Kole MK, 2005, J NEUROSURG, V102, P607, DOI 10.3171/jns.2005.102.4.0607
   Leng B, 2014, J NEUROINTERV SURG, V6, P595, DOI 10.1136/neurintsurg-2013-010920
   Levy E, 2001, NEUROSURGERY, V49, P807, DOI 10.1097/00006123-200110000-00005
   Mascitelli JR, 2015, J NEUROINTERV SURG, V7, P496, DOI 10.1136/neurintsurg-2014-011258
   Mascitelli JR, 2015, J NEUROINTERV SURG, V7, P484, DOI 10.1136/neurintsurg-2014-011226
   McDougall CG, 2012, J NEUROSURG, V116, P135, DOI 10.3171/2011.8.JNS101767
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Murayama Y, 2003, J NEUROSURG, V98, P959, DOI 10.3171/jns.2003.98.5.0959
   Quintana EM, 2015, J NEUROINTERV SURG, V7, P892, DOI 10.1136/neurintsurg-2014-011300
   Ng P, 2002, STROKE, V33, P210, DOI 10.1161/hs0102.100486
   Park HK, 2005, AM J NEURORADIOL, V26, P506
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Ries T, 2007, AM J NEURORADIOL, V28, P1755, DOI 10.3174/ajnr.A0649
   Roy D, 2001, STROKE, V32, P1998, DOI 10.1161/hs0901.095600
   SARTI C, 1991, STROKE, V22, P848, DOI 10.1161/01.STR.22.7.848
   SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Spetzler RF, 2013, J NEUROSURG, V119, P146, DOI 10.3171/2013.3.JNS12683
   Stapleton CJ, 2016, J NEUROINTERV SURG, V8, P927, DOI 10.1136/neurintsurg-2015-012035
   Tan IYL, 2011, INTERV NEURORADIOL, V17, P27, DOI 10.1177/159101991101700106
   van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249
   Vanzin JR, 2012, INTERV NEURORADIOL, V18, P391, DOI 10.1177/159101991201800405
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Willinsky RA, 2009, AM J NEURORADIOL, V30, P1035, DOI 10.3174/ajnr.A1488
   Yamazaki T, 2006, NEUROL MED-CHIR, V46, P1, DOI 10.2176/nmc.46.1
NR 46
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E417
EP E426
DI 10.1016/j.wneu.2019.04.167
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100048
PM 31042602
DA 2020-05-12
ER

PT J
AU Metwali, H
   Samii, A
   Gerganov, V
   Giordano, M
   Fahlbusch, R
   Samii, M
AF Metwali, Hussam
   Samii, Amir
   Gerganov, Venelin
   Giordano, Mario
   Fahlbusch, Rudolf
   Samii, Madjid
TI The Significance of Intraoperative Magnetic Resonance Imaging in
   Resection of Skull Base Chordomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chordoma; Intraoperative magnetic resonance imaging; Outcome; Skull base
ID CRANIAL BASE; TRANSSPHENOIDAL SURGERY; COST-EFFECTIVENESS; FOLLOW-UP;
   PITUITARY SURGERY; SURVIVAL PATTERNS; MANAGEMENT; CHONDROSARCOMAS;
   RADIOSURGERY; RADIOTHERAPY
AB BACKGROUND: Skull base chordoma can be a challenging surgical entity because of its invasive nature.
   OBJECTIVE: In this study, the role of intraoperative magnetic resonance imaging (iMRI) to optimize the resection of skull base chordomas is evaluated.
   METHODS: We performed a retrospective analysis of operated patients with skull base chordomas in the setting of iMRI. The clinical records, operative notes, radiologic images, tumor volumetry, location of the residual tumor, and surgical outcome were evaluated.
   RESULTS: Fifteen patients were operated on for resection of skull base chordomas between 2010 and 2017 in our institution. Gross total resection was planned and achieved in 8 patients and partial resection in 7 patients. In 8 patients (53.3%), the preoperatively planned volume of resection was achieved and confirmed in the first iMRI control. In 7 patients, repeated iMRI controls were required to achieve the surgical target. In 3 patients, the tumor residual requiring further resection was located in the clivus and in 4 patients in the intradural space. The improvement of the preoperative deficits showed a significant statistical association with the resection of the intradural component and decompression of the brainstem.
   CONCLUSIONS: This study shows that iMRI is a safe method for intraoperative assessment of the degree of resection and the volume and location of residual tumor when resecting skull base chordomas. When gross total resection of the tumor is not feasible, iMRI can be a useful tool for targeted tumor resection.
C1 [Metwali, Hussam; Samii, Amir; Gerganov, Venelin; Giordano, Mario; Fahlbusch, Rudolf; Samii, Madjid] Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.
   [Metwali, Hussam; Samii, Amir] LIN, Magdeburg, Germany.
RP Metwali, H (reprint author), Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.; Metwali, H (reprint author), LIN, Magdeburg, Germany.
EM drhussamm@yahoo.com
CR Abraham P, 2019, RADIOLOGY
   Almefty K, 2007, CANCER-AM CANCER SOC, V110, P2457, DOI 10.1002/cncr.23073
   AlMefty O, 1997, J NEUROSURG, V86, P182, DOI 10.3171/jns.1997.86.2.0182
   Anand VK, 2006, AM J RHINOL, V20, P401, DOI 10.2500/ajr.2006.20.2877
   Arnautovic K I, 2001, Neurosurg Focus, V10, pE7
   Arnautovic KI, 2001, J NEUROSURG, V95, P798, DOI 10.3171/jns.2001.95.5.0798
   ARNOLD H, 1986, ACTA NEUROCHIR, V83, P31, DOI 10.1007/BF01420505
   Ashour R, 2016, WORLD NEUROSURG, V93, P183, DOI 10.1016/j.wneu.2016.06.045
   Berkmann S, 2014, ACTA NEUROCHIR, V156, P2233, DOI 10.1007/s00701-014-2210-x
   Berkmann S, 2014, J NEUROSURG, V121, P1166, DOI 10.3171/2014.6.JNS131994
   Buchfelder M, 2012, ENDOCRINE, V42, P483, DOI 10.1007/s12020-012-9752-6
   Chambers KJ, 2014, LARYNGOSCOPE, V124, P1097, DOI 10.1002/lary.24420
   Debus J, 2000, INT J RADIAT ONCOL, V47, P591, DOI 10.1016/S0360-3016(00)00464-8
   Di Maio S, 2012, NEUROSURGERY, V70, P1355, DOI 10.1227/NEU.0b013e3182446783
   Di Maio S, 2011, J NEUROSURG, V115, P1094, DOI 10.3171/2011.7.JNS11355
   Dort JC, 2001, LARYNGOSCOPE, V111, P1570, DOI 10.1097/00005537-200109000-00014
   Eljamel MS, 2016, PHOTODIAGN PHOTODYN, V16, P35, DOI 10.1016/j.pdpdt.2016.07.012
   ERIKSSON B, 1981, ACTA ORTHOP SCAND, V52, P49, DOI 10.3109/17453678108991758
   GAY E, 1995, NEUROSURGERY, V36, P887, DOI 10.1227/00006123-199505000-00001
   Gui SB, 2016, NEUROSURG REV, V39, P321, DOI 10.1007/s10143-015-0696-1
   Hsu W, 2010, J NEUROSURG-SPINE, V12, P431, DOI 10.3171/2009.10.SPINE09393
   Hug EB, 1999, J NEUROSURG, V91, P432, DOI 10.3171/jns.1999.91.3.0432
   Iloreta AMC, 2014, J NEUROL SURG REP, V75, pE246, DOI 10.1055/s-0034-1387184
   Jawad MU, 2010, SPINE, V35, P117, DOI 10.1097/BRS.0b013e3181b44387
   Jho H D, 1996, Neurosurg Focus, V1, pe3
   Jho HD, 1997, ACTA NEUROCHIR, V139, P343, DOI 10.1007/BF01808831
   Koga T, 2010, J NEURO-ONCOL, V98, P233, DOI 10.1007/s11060-010-0184-y
   Krishnan S, 2005, NEUROSURGERY, V56, P777, DOI 10.1227/01.NEU.0000156789.10394.F5
   Martin JJ, 2007, J NEUROSURG, V107, P758, DOI 10.3171/JNS-07/10/0758
   McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735
   Nimsky C, 2006, NEUROSURGERY, V59, P105, DOI 10.1227/01.NEU.0000219198.38423.1E
   Noel G, 2005, ACTA ONCOL, V44, P700, DOI 10.1080/02841860500326257
   Pamir MN, 2006, ACTA NEUROCHIR SUPPL, V98, P97
   Pamir MN, 2008, ADV TECH STAND NEURO, V33, P35, DOI 10.1007/978-3-211-72283-1_2
   Paterno' V, 2014, ACTA NEUROCHIR, V156, P463, DOI 10.1007/s00701-013-1978-4
   Rohatgi S, 2015, EURASIAN J MED, V47, P151, DOI 10.5152/eurasianjmed.2015.52
   Sacino MF, 2018, CHILD NERV SYST, V34, P495, DOI 10.1007/s00381-017-3658-9
   Sagit M, 2011, J CRANIOFAC SURG, V22, P1720, DOI 10.1097/SCS.0b013e31822e6434
   Samii A, 2007, J NEUROSURG, V107, P319, DOI 10.3171/JNS-07/08/0319
   Schulz-Ertner D, 2007, INT J RADIAT ONCOL, V68, P449, DOI 10.1016/j.ijrobp.2006.12.059
   Schwartz TH, 2006, NEUROSURGERY, V58, P44, DOI 10.1227/01.NEU.0000193927.49862.B6
   Schwartz TH, 2014, J NEUROSURG, V120, P342, DOI 10.3171/2013.7.JNS13956
   Sen C, 2010, J NEUROSURG, V113, P1059, DOI 10.3171/2009.9.JNS08596
   Shidoh S, 2014, NEUROL MED-CHIR, V54, P991, DOI 10.2176/nmc.st.2014-0135
   Stuer C, 2006, NEUROL MED-CHIR, V46, P118, DOI 10.2176/nmc.46.118
   Takahashi S, 2009, ACTA NEUROCHIR, V151, P759, DOI 10.1007/s00701-009-0383-5
   Tamaki N, 2001, Neurosurg Focus, V10, pE9
   Taniguchi M, 2012, ACTA NEUROCHIR, V154, P627, DOI 10.1007/s00701-011-1225-9
   Theodosopoulos PV, 2010, J NEUROSURG, V112, P736, DOI 10.3171/2009.6.JNS08916
   Tzortzidis F, 2006, NEUROSURGERY, V59, P230, DOI 10.1227/01.NEU.0000223441.51012.9D
   Yu E, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00203
   Zhang HK, 2016, J CRANIOFAC SURG, V27, pE709, DOI 10.1097/SCS.0000000000003031
NR 52
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E185
EP E194
DI 10.1016/j.wneu.2019.04.086
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100021
PM 31003024
DA 2020-05-12
ER

PT J
AU Metwali, H
   Samii, A
AF Metwali, Hussam
   Samii, Amir
TI Seed-Based Connectivity Analysis of Resting-State fMRI in Patients with
   Brain Tumors: A Feasibility Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain mapping; Functional connectivity; Preoperative planning;
   Resting-state fMRI; Resting-state networks
ID FUNCTIONAL CONNECTIVITY; SPONTANEOUS FLUCTUATIONS; NETWORK
AB OBJECTIVE: In this study, we present our experience using resting-state functional magnetic resonance imaging (rs-fMRI) in preoperative planning. We performed group analysis to demonstrate the effects of brain tumor on resting-state networks (RSNs).
   METHODS: Thirty patients with supratentorial gliomas were included in the study. Preoperative rs-fMRI and structural magnetic resonance imaging were performed in all cases. The rs-fMRI was preprocessed (realignment, slice time correction, coregistration to structural images, normalization, and smoothing). The structural images were segmented and normalized. Band filtering and denoising were applied to the functional images. Connectivity analysis was performed using seed-based connectivity analysis (SCA) at single subject level and group level. Correlation algorism has been used with r > 0.5.
   RESULTS: RSNs could be detected in all patients. They showed similarity to the results of the task-based fMRI, when task-based fMRI was feasible. Detection of the networks was also possible in patients with neurologic deficits, in whom task-based fMRI was not possible. We could use SCA in patients under anesthesia. High-level networks (default mode, salience, and dorsal attention networks) were detectable but showed a wide spectrum of spatial alterations and component disconnections.
   CONCLUSIONS: rs-fMRI is a feasible method for extended brain mapping. Diverse RSNs could be detected in patients with brain tumors and could be applied in preoperative planning. SCA was a robust and direct approach for data analysis and could answer specific clinically relevant questions. However, further studies are needed to validate the technique and its clinical impact.
C1 [Metwali, Hussam; Samii, Amir] Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.
   [Metwali, Hussam; Samii, Amir] Leibniz Inst Neurobiol, Magdeburg, Germany.
RP Metwali, H (reprint author), Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.; Metwali, H (reprint author), Leibniz Inst Neurobiol, Magdeburg, Germany.
EM drhussamm@yahoo.com
CR Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002
   Beckmann CF, 2005, PHILOS T ROY SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634
   BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409
   Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107
   Calhoun VD, 2008, HUM BRAIN MAPP, V29, P828, DOI 10.1002/hbm.20581
   Cole DM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00008
   Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103
   Duffau H, 2007, NEUROPHYSIOL CLIN, V37, P373, DOI 10.1016/j.neucli.2007.09.003
   Esposito R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040231
   Harris RJ, 2014, J NEURO-ONCOL, V116, P373, DOI 10.1007/s11060-013-1304-2
   Hart MG, 2017, J NEUROSURG, V126, P1941, DOI 10.3171/2016.6.JNS1662
   Javadi SA, 2017, NEUROSURGERY, V80, P287, DOI 10.1227/NEU.0000000000001347
   Kokkonen SM, 2009, MAGN RESON IMAGING, V27, P733, DOI 10.1016/j.mri.2008.11.002
   Liu HS, 2009, J NEUROSURG, V111, P746, DOI 10.3171/2008.10.JNS08846
   Martino J, 2011, ANN NEUROL, V69, P521, DOI 10.1002/ana.22167
   Otten ML, 2012, BRAIN, V135, P1017, DOI 10.1093/brain/aws041
   Park JE, 2016, NEURORADIOLOGY, V58, P311, DOI 10.1007/s00234-015-1621-6
   Picht T, 2009, NEUROSURGERY, V65, P93, DOI 10.1227/01.NEU.0000348009.22750.59
   Quigley M, 2001, AM J NEURORADIOL, V22, P294
   Raichle ME, 2011, BRAIN CONNECT, V1, P3, DOI 10.1089/brain.2011.0019
   Roland JL, 2017, J NEUROSURG-PEDIATR, V20, P583, DOI 10.3171/2017.6.PEDS1711
   Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719
   Rosazza C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098860
   Sair HI, 2016, HUM BRAIN MAPP, V37, P913, DOI 10.1002/hbm.23075
   Shehzad Z, 2009, CEREB CORTEX, V19, P2209, DOI 10.1093/cercor/bhn256
   Shimony JS, 2009, ACAD RADIOL, V16, P578, DOI 10.1016/j.acra.2009.02.001
   Tie YM, 2014, HUM BRAIN MAPP, V35, P1018, DOI 10.1002/hbm.22231
   Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978
   Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073
   Zhang DY, 2009, NEUROSURGERY, V65, P226, DOI 10.1227/01.NEU.0000350868.95634.CA
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E165
EP E176
DI 10.1016/j.wneu.2019.04.073
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100019
PM 30995557
DA 2020-05-12
ER

PT J
AU Morinaga, Y
   Nii, K
   Sakamoto, K
   Inoue, R
   Mitsutake, T
   Hanada, H
AF Morinaga, Yusuke
   Nii, Kouhei
   Sakamoto, Kimiya
   Inoue, Ritsurou
   Mitsutake, Takafumi
   Hanada, Hayatsura
TI Presence of an Anterior Communicating Artery as a Prognostic Factor in
   Revascularization for Anterior Circulation Acute Ischemic Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Anterior communicating artery; Revascularization
AB BACKGROUND: No reports have evaluated collateral circulation using simpler measures involving magnetic resonance imaging. Because an anterior communicating artery (A-com) is important in collateral circulation, we investigated whether the presence of an A-com affected the clinical revascularization outcomes in acute ischemic stroke (AIS) in the anterior circulation.
   METHODS: The present retrospective study included 73 patients who had undergone continuous administration of recombinant tissue plasminogen activator and revascularization for AIS in the anterior circulation from April 2014 to September 2018. The presence of an A-com was evaluated using preoperative time-of-flight magnetic resonance angiography. The patient characteristics and clinical outcomes were compared, and we investigated the influence of the presence or absence of an A-com on these clinical outcomes. The clinical outcomes were analyzed using multiple logistic regression.
   RESULTS: The clinical outcomes did not significantly correlate with age, sex, or occlusion location but did significantly correlate with the preoperative National Institute of Health stroke scale score, diffusion-weighted Alberta Stroke Program early computed tomography score, reperfusion >50% (thrombolysis in cerebral infarction grade >2b), and onset to recanalization time. The presence of an A-corn correlated significantly with good clinical outcomes (modified Rankin scale score 0-3; P = 0.0081) and reduced mortality (P = 0.03). Multiple logistic regression predicted for significantly good clinical outcomes with the presence of an A-com (odds ratio, 17.03; 95% confidence interval, 1.85-157.10; P = 0.012).
   CONCLUSIONS: The presence of an A-com on preoperative time-of-flight magnetic resonance angiography is a good prognostic factor for revascularization in patients with anterior circulation AIS, confirms collateral circulation, and allows for faster and safer endovascular treatment.
C1 [Morinaga, Yusuke; Nii, Kouhei; Sakamoto, Kimiya; Inoue, Ritsurou; Mitsutake, Takafumi; Hanada, Hayatsura] Fukuoka Univ, Dept Neurosurg, Chikushi Hosp, Chikushino City, Japan.
RP Nii, K (reprint author), Fukuoka Univ, Dept Neurosurg, Chikushi Hosp, Chikushino City, Japan.
EM k.nii@cis.fukuoka-u.ac.jp
OI Nii, Kouhei/0000-0003-0640-6821
CR Abou-Chebl A, 2010, STROKE, V41, P1175, DOI 10.1161/STROKEAHA.109.574129
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Alves HCBR, 2016, ARQ NEURO-PSIQUIAT, V74, P662, DOI 10.1590/0004-282X20160050
   Khatri P, 2009, NEUROLOGY, V73, P1066, DOI 10.1212/WNL.0b013e3181b9c847
   Kohno N, 2016, J STROKE CEREBROVASC, V25, P1807, DOI 10.1016/j.jstrokecerebrovasdis.2016.03.035
   Mayank G, 2016, LANCET, V387, P1723
   Noser EA, 2005, STROKE, V36, P292, DOI 10.1161/01.STR.0000152331.93770.18
   Rangaraju S, 2017, INTERV NEUROL, V6, P36, DOI 10.1159/000452634
   Seyman E, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0722-0
   Tang BQ, 2019, J COMPUT ASSIST TOMO, V43, P22, DOI 10.1097/RCT.0000000000000783
   Zhang S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160502
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E660
EP E663
DI 10.1016/j.wneu.2019.04.229
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100077
PM 31055085
DA 2020-05-12
ER

PT J
AU Nagel, SJ
   Frizon, L
   Maiti, T
   Machado, AG
   Gillies, GT
   Helland, L
   Woodroffe, RW
   Howard, MA
   Wilson, S
AF Nagel, Sean J.
   Frizon, Leonardo
   Maiti, Tanmoy
   Machado, Andre G.
   Gillies, George T.
   Helland, Logan
   Woodroffe, Royce W.
   Howard, Matthew A., III
   Wilson, Saul
TI Contemporary Approaches to Preventing and Treating Infections of Novel
   Intrathecal Neurostimulation Devices
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biofilm; Deep brain stimulation; Intradural device; Spinal cord
   stimulation; Surgical site infections
ID SPINAL-CORD STIMULATION; SURGICAL SITE INFECTION; ELECTRONIC DURA-MATER;
   RISK-FACTORS; TECHNICAL COMPLICATIONS; GENERATOR REPLACEMENT; HARDWARE
   INFECTION; PULSE-GENERATOR; SURGERY; MANAGEMENT
AB INTRODUCTION: Contemporary approaches it . o surgical site infections have evolved significantly over the last several decades in response to the economic pressures of soaring health care costs and increasing patient expectations of safety. Neurosurgeons face multiple unique challenges when striving to avoid as well as manage surgical implant infections. The tissue compartment, organ system, or joint is characterized by biological factors and physical forces that may not be universally relevant. Such implants, once rare, are now routine. Although the prevention, diagnosis, and treatment of surgical site infections involving neural implants has advanced, guidelines are ever changing, and the incidence still exceeds acceptable levels. We assess the impact of these factors on a new class of implantable neuromodulation devices.
   METHODS: The available evidence along with practice patterns were examined and organized to establish relevant groupings for continuing evaluation and to propose justifiable recommendations for the treatment of infections that might arise in the case of intradural spinal cord stimulators.
   RESULTS: Few studies in the modern era have systematically evaluated preventive behaviors that were applied to intradural neural implants alone. We anticipate that future efforts will focus even more on the investigation of modifiable factors along a continuum from bacterially repellant implants to weight management. Early diagnosis could offer the best hope for device salvage but to date has been largely understudied.
   CONCLUSIONS: Historically, prevention is the cornerstone to infection mitigation. However, immediate diagnosis and hardware salvage have not received the attention deserved, and that approach may be especially important for intradural devices.
C1 [Nagel, Sean J.; Frizon, Leonardo; Maiti, Tanmoy; Machado, Andre G.] Cleveland Clin, Ctr Neurol Restorat, Cleveland, OH 44106 USA.
   [Gillies, George T.] Univ Virginia, Dept Mech & Aerosp Engn, Charlottesville, VA USA.
   [Helland, Logan; Woodroffe, Royce W.; Howard, Matthew A., III; Wilson, Saul] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
RP Wilson, S (reprint author), Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
EM saul-wilson@uiowa.edu
OI Howard, Matthew/0000-0003-3935-8889
CR Abdul-Jabbar A, 2012, SPINE, V37, P1340, DOI 10.1097/BRS.0b013e318246a53a
   Abode-Iyamah KO, 2019, J NEUROSURG, V130, P629, DOI 10.3171/2017.9.JNS1780
   Ahmed S, 2018, EXPERT REV MED DEVIC, V15, P61, DOI 10.1080/17434440.2018.1418662
   Alexander S., CONSIDERATIONS COST
   Allegranzi Benedetta, 2016, Lancet Infect Dis, V16, pe276, DOI 10.1016/S1473-3099(16)30398-X
   Allegranzi Benedetta, 2016, Lancet Infect Dis, V16, pe288, DOI 10.1016/S1473-3099(16)30402-9
   Amrani J, 2015, NEUROMODULATION, V18, P177, DOI 10.1111/ner.12216
   Anderson DJ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00253
   Arciola CR, 2018, NAT REV MICROBIOL, V16, P397, DOI 10.1038/s41579-018-0019-y
   Atkinson RA, 2016, J HOSP INFECT, V92, P263, DOI 10.1016/j.jhin.2015.09.014
   Babu R, 2013, NEUROMODULATION, V16, P418, DOI 10.1111/ner.12065
   Bartek J, 2018, STEREOT FUNCT NEUROS, V96, P100, DOI 10.1159/000486684
   Bellusse GC, 2015, ACTA PAUL ENFERM, V28, P66, DOI 10.1590/1982-0194201500012
   Bendel MA, 2017, NEUROMODULATION, V20, P553, DOI 10.1111/ner.12636
   Bhatia R, 2011, BRIT J NEUROSURG, V25, P625, DOI 10.3109/02688697.2011.566384
   Bjerknes S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105288
   Bloch J, 2017, JAMA NEUROL, V74, P470, DOI 10.1001/jamaneurol.2016.5767
   Bosacco SJ, 2001, CLIN ORTHOP RELAT R, P238
   Capogrosso M, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aaa87a
   Chen T, 2017, STEREOT FUNCT NEUROS, V95, P117, DOI 10.1159/000457964
   Collinger JL, 2013, J SPINAL CORD MED, V36, P258, DOI 10.1179/2045772313Y.0000000128
   Critsinelis AC, 2018, J CARDIAC SURG, V33, P469, DOI 10.1111/jocs.13745
   CRUL BJP, 1991, REGION ANESTH, V16, P209
   Dahm P, 1998, CLIN J PAIN, V14, P4, DOI 10.1097/00002508-199803000-00003
   Daley BJ, 2015, J AM COLL SURGEONS, V220, P550, DOI 10.1016/j.jamcollsurg.2014.12.040
   Dalm B. D., 2014, NEUROSURGERY, V2, P13
   Dalrymple AN, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aad872
   de Jong L, 2017, BONE JOINT J, V99B, P1088, DOI [10.1302/0301-620X.99B8.BJJ-2016-1119.R1, 10.1302/0301-620x.99b8.bjj-2016-1119.r1]
   Deer TR, 2017, NEUROMODULATION, V20, P31, DOI 10.1111/ner.12565
   Deer TR, 2014, NEUROMODULATION, V17, P571, DOI 10.1111/ner.12206
   Elsamadicy AA, 2018, NEUROMODULATION, V21, P87, DOI 10.1111/ner.12689
   Engle MP, 2013, PAIN PHYSICIAN, V16, P251
   Ereifej ES, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201704420
   Falowski SM, 2019, NEUROMODULATION, V22, P179, DOI 10.1111/ner.12843
   Fenoy AJ, 2012, J NEUROSURG, V116, P1324, DOI 10.3171/2012.1.JNS111798
   Flesher SN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8083
   Flouty O, 2012, PHYSIOL MEAS, V33, P2003, DOI 10.1088/0967-3334/33/12/2003
   Frizon LA, 2017, NEUROMODULATION, V20, P444, DOI 10.1111/ner.12605
   Fu RZ, 2017, BRIT J NEUROSURG, V31, P16, DOI 10.1080/02688697.2016.1229741
   Ghobrial GM, 2018, J NEUROSURG-SPINE, V28, P209, DOI 10.3171/2017.5.SPINE17158
   Gocmen S, 2014, STEREOT FUNCT NEUROS, V92, P140, DOI 10.1159/000360585
   Gorgulho A, 2009, J NEUROSURG, V110, P239, DOI 10.3171/2008.6.17603
   Graves N, 2018, J HOSP INFECT, V100, P123, DOI 10.1016/j.jhin.2018.07.008
   Helby J, 2017, HAEMATOLOGICA, V102, P1457, DOI 10.3324/haematol.2016.161943
   Hoelzer BC, 2017, NEUROMODULATION, V20, P558, DOI 10.1111/ner.12609
   Howard MA, 2011, J APPL PHYS, V110, DOI 10.1063/1.3626469
   Huang QJ, 2014, MED BIOL ENG COMPUT, V52, P531, DOI 10.1007/s11517-014-1157-7
   Kamath AF, 2017, J KNEE SURG, V30, P269, DOI 10.1055/s-0036-1584575
   Kelley KE, 2018, ANN SURG, V268, P650, DOI 10.1097/SLA.0000000000002932
   Korol E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083743
   Kozlow JH, 2014, J SURG RES, V192, P670, DOI 10.1016/j.jss.2014.05.041
   Kumar K, 2006, J NEUROSURG-SPINE, V5, P191, DOI 10.3171/spi.2006.5.3.191
   Lalkhen AG, 2017, PAIN PRACT, V17, P886, DOI 10.1111/papr.12537
   LaVito A., 2018, THESE MED DEVICE OFF
   Lefebvre J, 2017, J HOSP INFECT, V95, P144, DOI 10.1016/j.jhin.2016.11.019
   Levy RM, 2013, NEUROMODULATION, V16, P285, DOI 10.1111/ner.12103
   Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801
   Mehta AI, 2012, SPINE, V37, P1652, DOI 10.1097/BRS.0b013e318241b186
   Mekhail NA, 2011, PAIN PRACT, V11, P148, DOI 10.1111/j.1533-2500.2010.00407.x
   Miller JP, 2016, NEUROMODULATION, V19, P373, DOI 10.1111/ner.12438
   Minev IR, 2015, SCIENCE, V347, P159, DOI 10.1126/science.1260318
   Nagel Sean J, 2019, Neuromodulation, V22, P916, DOI 10.1111/ner.12913
   Nagel SJ, 2017, NEUROMODULATION, V20, P307, DOI 10.1111/ner.12591
   Oh MY, 2002, NEUROSURGERY, V50, P1268
   Oya H, 2013, J APPL PHYS, V114, DOI 10.1063/1.4827195
   Pepper J, 2013, STEREOT FUNCT NEUROS, V91, P56, DOI 10.1159/000343202
   Pera A, 2015, MATURITAS, V82, P50, DOI 10.1016/j.maturitas.2015.05.004
   Pesenti S, 2018, EUR SPINE J, V27, P2469, DOI 10.1007/s00586-018-5733-7
   Phang I, 2016, J NEUROSURG-SPINE, V25, P398, DOI 10.3171/2016.1.SPINE151317
   Provenzano DA, 2016, NEUROMODULATION, V19, P71, DOI 10.1111/ner.12356
   Puhl R, 2001, OBES RES, V9, P788, DOI 10.1038/oby.2001.108
   Rasouli JJ, 2016, WORLD NEUROSURG, V95, P9, DOI 10.1016/j.wneu.2016.07.063
   Rouhani E, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aac4b8
   Rudiger J, 2011, NEUROMODULATION, V14, P136, DOI 10.1111/j.1525-1403.2010.00317.x
   Scanlon MM, 2017, PAIN MED, V18, P520, DOI 10.1093/pm/pnw203
   Schaller Robert D, 2017, HeartRhythm Case Rep, V3, P431, DOI 10.1016/j.hrcr.2017.06.011
   Schweizer ML, 2014, JAMA SURG, V149, P575, DOI 10.1001/jamasurg.2013.4663
   Shahdoost S, 2018, ANALOG INTEGR CIRC S, V95, P1, DOI 10.1007/s10470-017-1093-1
   Sillay KA, 2008, NEUROSURGERY, V62, P360, DOI 10.1227/01.neu.0000316002.03765.33
   Simopoulos T, 2018, NEUROMODULATION, V21, P508, DOI 10.1111/ner.12687
   Snyderman CH, 1999, LARYNGOSCOPE, V109, P915, DOI 10.1097/00005537-199906000-00014
   Temel Y, 2004, ACTA NEUROCHIR, V146, P355, DOI 10.1007/s00701-004-0219-2
   Tolleson C, 2014, STEREOT FUNCT NEUROS, V92, P227, DOI 10.1159/000362934
   Torrens JK, 1997, LANCET, V349, P729, DOI 10.1016/S0140-6736(05)60168-7
   Tsujinaka S, 2008, DIS COLON RECTUM, V51, P1757, DOI 10.1007/s10350-008-9395-0
   U. S. National Institutes of Health Office of Strategic Coordination, SPARC PROGR STIM PER
   van Walraven C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067167
   Vesper J, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-7
   Viljoen S, 2013, REV SCI INSTRUM, V84, DOI 10.1063/1.4831801
   Wathen C, 2016, NEUROSURGERY, V79, P889, DOI 10.1227/NEU.0000000000001357
   Wetzelaer P, 2018, TURK NEUROSURG, V28, P929, DOI 10.5137/1019-5149.JTN.21511-17.1
   Woodroffe RW, 2018, CLIN NEUROL NEUROSUR, V170, P61, DOI 10.1016/j.clineuro.2018.04.017
   Yamada K, 2018, SPINE, V43, P1765, DOI 10.1097/BRS.0000000000002709
   Yamamoto Y, 2018, SPINE SURG RELAT RES, V2, P127, DOI 10.22603/ssrr.2017-0052
NR 94
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E397
EP E408
DI 10.1016/j.wneu.2019.04.165
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100046
PM 31042596
DA 2020-05-12
ER

PT J
AU Ogiwara, T
   Nagm, A
   Nakamura, T
   Mbadugha, T
   Horiuchi, T
   Hongo, K
AF Ogiwara, Toshihiro
   Nagm, Alhusain
   Nakamura, Takuya
   Mbadugha, Tobechi
   Horiuchi, Tetsuyoshi
   Hongo, Kazuhiro
TI Significance and Indications of Surgery for Asymptomatic Nonfunctioning
   Pituitary Adenomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic endonasal approach; Pituitary incidentaloma; Surgical
   indication; Treatment strategy
ID MANAGEMENT; INCIDENTALOMAS; APOPLEXY
AB BACKGROUND: The availability of magnetic resonance imaging (MRI) has led to an increase in the detection of pituitary incidentaloma (PI). However, there are no robust data on surgical treatment of PI on which to base therapeutic recommendations. This study was performed to investigate the significance of surgery for asymptomatic nonfunctioning pituitary adenoma (NFPA) among PIs.
   METHODS: A total of 180 patients that underwent tumor resection of pituitary adenoma via the transsphenoidal approach between 2005 and 2017 were reviewed. Thirty-three consecutive patients with subjectively asymptomatic NFPA were included in this study. Our surgical indications for asymptomatic NFPAs were categorized as follows: macroadenoma with optic chiasma compression (group A, n = 14), solid tumor >= 2 cm in size (group B, n = 7), and tumor growth on follow-up MRI (group C, n = 12). The clinical outcomes were analyzed accordingly.
   RESULTS: Seven patients (50%) in group A showed subjective improvement of visual function after tumor resection even though they had no complaints preoperatively. On the other hand, no changes occurred in any cases in group B or group C. Although there were no critical complications in this series, the incidence of nonnegligible nasal complications was relatively high (24.2%) and may decrease the patient's quality of life.
   CONCLUSIONS: Surgery should be recommended for asymptomatic NFPA with optic chiasma compression to improve visual outcome. On the other hand, immediate intervention for other asymptomatic NFPA to reduce the likelihood of the appearance of tumor-related symptoms remains questionable considering its invasiveness to the nose.
C1 [Ogiwara, Toshihiro; Nagm, Alhusain; Nakamura, Takuya; Mbadugha, Tobechi; Horiuchi, Tetsuyoshi; Hongo, Kazuhiro] Shinshu Univ, Sch Med, Dept Neurosurg, Matsumoto, Nagano, Japan.
   [Nagm, Alhusain] Al Azhar Univ, Fac Med Nasr City, Dept Neurosurg, Cairo, Egypt.
   [Mbadugha, Tobechi] Memfys Hosp Neurosurg, Unit Neurosurg, Enugu, Nigeria.
RP Ogiwara, T (reprint author), Shinshu Univ, Sch Med, Dept Neurosurg, Matsumoto, Nagano, Japan.
EM togiwara@shinshu-u.ac.jp
RI Nagm, Alhusain/AAF-5478-2020
OI Nagm, Alhusain/0000-0003-0469-4970
CR Arita K, 2006, J NEUROSURG, V104, P884, DOI 10.3171/jns.2006.104.6.884
   Awad AJ, 2015, CLIN NEUROL NEUROSUR, V130, P162, DOI 10.1016/j.clineuro.2015.01.004
   Freda PU, 2011, J CLIN ENDOCR METAB, V96, P894, DOI 10.1210/jc.2010-1048
   Gallagher MJ, 2014, BRIT J NEUROSURG, V28, P622, DOI 10.3109/02688697.2014.887656
   Huang WY, 2018, PITUITARY, V21, P162, DOI 10.1007/s11102-017-0856-0
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Lake MG, 2013, AM FAM PHYSICIAN, V88, P319
   Levy MJ, 2018, CLIN ENDOCRINOL, V89, P354, DOI 10.1111/cen.13791
   Losa M, 2013, EUR J ENDOCRINOL, V169, P735, DOI 10.1530/EJE-13-0515
   Fernandez-Balsells MM, 2011, J CLIN ENDOCR METAB, V96, P905, DOI 10.1210/jc.2010-1054
   Messerer M, 2013, CLIN NEUROL NEUROSUR, V115, P2514, DOI 10.1016/j.clineuro.2013.10.007
   Molitch ME, 2012, NEUROSURG CLIN N AM, V23, P543, DOI 10.1016/j.nec.2012.06.003
   Narayan V, 2018, WORLD NEUROSURG, V114, pE824, DOI 10.1016/j.wneu.2018.03.094
   Ogiwara T, 2018, J NEUROSURG, V129, P562, DOI 10.3171/2018.3.JNS18614
   Ogiwara T, 2019, NEUROSURG REV, V42, P683, DOI 10.1007/s10143-018-1006-5
   Oyama K, 2005, SEMIN ULTRASOUND CT, V26, P47, DOI 10.1053/j.sult.2004.10.001
   Paluzzi A, 2014, PITUITARY, V17, P307, DOI 10.1007/s11102-013-0502-4
   Tanaka Y, 2003, J NEUROSURG, V98, P359, DOI 10.3171/jns.2003.98.2.0359
   Wildemberg LE, 2018, PITUITARY, V21, P138, DOI 10.1007/s11102-018-0870-x
NR 19
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E752
EP E759
DI 10.1016/j.wneu.2019.04.250
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100088
PM 31077893
DA 2020-05-12
ER

PT J
AU Olldashi, F
   Latifi, R
   Parsikia, A
   Boci, A
   Qesteri, O
   Dasho, E
   Bakiu, E
AF Olldashi, Fatos
   Latifi, Rifat
   Parsikia, Afshin
   Boci, Arian
   Qesteri, Orland
   Dasho, Erion
   Bakiu, Elvis
TI Telemedicine for Neurotrauma Prevents Unnecessary Transfers: An Update
   from a Nationwide Program in Albania and Analysis of 590 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Albania; Low- and middle-income countries; Neurotrauma; Spinal cord
   injuries; Telemedicine; Traumatic brain injury
ID TRAUMATIC BRAIN-INJURY; DIGITAL OBSERVATION CAMERA;
   DEVELOPING-COUNTRIES; MEDICAL SYSTEMS; MANAGEMENT; ARIZONA
AB BACKGROUND: The telemedicine program in Albania includes a specialized teleneurotrauma program. There is only 1 national trauma center with neurosurgery capability in the capital city of Tirana. Patients with isolated head or spine injury who require consultation with neurosurgeons located at the National Trauma Center receive telemedicine consultation. The aim of this follow-up study was to evaluate the effectiveness of a nationwide teleneurotrauma network in preventing unnecessary transfers for neurotrauma.
   METHODS: Retrospective analysis was performed of prospectively collected data on all telemedicine consultations for isolated neurotrauma from March 2014 to February 2018. All teleconsultations were coded using the International Classification of Diseases, Tenth Revision coding system (codes S00, S01-S010).
   RESULTS: Of 590 teleconsultations for neurotrauma, most patients (76%) were male (median age 46.5 years; range, 1-93 years); 403 (68.31%; mean age 45.12 years) did not require a transfer to the tertiary center, and 187 (mean age 42.47 years) were transferred. An average 12.5 (monthly average range, 8.5-16) patients were seen monthly with a steady increase to a mature telemedicine program at the present time. Most teleconsultations (70.67%) occurred during business hours (8:00 AM 4:30 PM); 173 (29.32%) occurred at night and on weekends. Analysis by diagnosis indicated that most cases of low severity were not transferred, whereas higher severity cases were twice as likely to be transferred (P < 0.05).
   CONCLUSIONS: Structured and coordinated telemedicine for neurotrauma increases access to care for neurosurgery patients in countries that do not have widespread neurosurgery services. Nearly 70% of patients may be treated locally by nonneurosurgeons.
C1 [Olldashi, Fatos] Univ Hosp Trauma, Dept Neurosurg, Tirana, Albania.
   [Latifi, Rifat] New York Med Coll, Dept Surg, Sch Med, Valhalla, NY 10595 USA.
   [Latifi, Rifat] Westchester Med Ctr Hlth Network, Valhalla, NY 10595 USA.
   [Latifi, Rifat; Parsikia, Afshin; Boci, Arian; Dasho, Erion] Int Virtual E Hosp Fdn, Hope, ID 83836 USA.
   [Boci, Arian; Qesteri, Orland; Bakiu, Elvis] Integrated Telemed & E Hlth Program Albania, Tirana, Albania.
RP Latifi, R (reprint author), New York Med Coll, Dept Surg, Sch Med, Valhalla, NY 10595 USA.; Latifi, R (reprint author), Westchester Med Ctr Hlth Network, Valhalla, NY 10595 USA.; Latifi, R (reprint author), Int Virtual E Hosp Fdn, Hope, ID 83836 USA.
EM Rifat.Latifi@wmchealth.org
CR Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034
   Boer C, 2012, CURR OPIN ANESTHESIO, V25, P556, DOI 10.1097/ACO.0b013e328357225c
   Demaerschalk BM, 2012, TELEMED E-HEALTH, V18, P230, DOI 10.1089/tmj.2011.0116
   Demaerschalk BM, 2010, STROKE, V41, P1251, DOI 10.1161/STROKEAHA.109.574509
   El Khamlichi Abdeslam, 2005, Clin Neurosurg, V52, P214
   Hyder AA, 2007, NEUROREHABILITATION, V22, P341
   Joseph B, 2014, J TRAUMA ACUTE CARE, V77, P984, DOI 10.1097/TA.0000000000000428
   Kahn EN, 2016, WORLD NEUROSURG, V89, P133, DOI 10.1016/j.wneu.2016.01.075
   Latifi R., 2012, TELEMEDICINE TRAUMA
   Latifi R, 2006, TELEMED J E-HEALTH, V12, P332, DOI 10.1089/tmj.2006.12.332
   Latifi R, 2018, WORLD NEUROSURG, V112, pE747, DOI 10.1016/j.wneu.2018.01.146
   Latifi R, 2016, TELEMED E-HEALTH, V22, P1024, DOI 10.1089/tmj.2016.0050
   Latifi R, 2016, INT J EMERG MED, V9, DOI 10.1186/s12245-016-0124-5
   Latifi R, 2015, TELEMED E-HEALTH, V21, P503, DOI 10.1089/tmj.2014.0138
   Latifi R, 2014, TELEMED E-HEALTH, V20, P1027, DOI 10.1089/tmj.2014.0026
   Latifi R, 2014, WORLD J SURG, V38, P1898, DOI 10.1007/s00268-014-2538-7
   Latifi Rifat, 2014, Am J Disaster Med, V9, P25, DOI 10.5055/ajdm.2014.0139
   Latifi Rifat, 2009, Am J Surg, V198, P905, DOI 10.1016/j.amjsurg.2009.08.011
   Lewis ER, 2012, TELEMED E-HEALTH, V18, P434, DOI 10.1089/tmj.2011.0199
   McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287
   Migliaretti G, 2013, J TELEMED TELECARE, V19, P33, DOI 10.1177/1357633X12474738
   Puvanachandra P., 2009, PAK J NEUROL SCI, V4, P27
   Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206
NR 23
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E340
EP E346
DI 10.1016/j.wneu.2019.04.150
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100039
PM 31029813
DA 2020-05-12
ER

PT J
AU Osman, H
   Elsahy, D
   Slivova, V
   Thompson, C
   Georges, J
   Yocom, S
   Cohen-Gadol, AA
AF Osman, Hany
   Elsahy, Deena
   Slivova, Veronika
   Thompson, Corey
   Georges, Joseph
   Yocom, Steven
   Cohen-Gadol, Aaron A.
TI Neurosurgical Flexible Probe Microscopy with Enhanced Architectural and
   Cytological Detail
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ex vivo; Glioma; In vivo; Microscopy; Neurosurgery; Oncology
ID CONFOCAL LASER ENDOMICROSCOPY; RESECTION; SURGERY; FEASIBILITY; GLIOMA;
   EXTENT
AB BACKGROUND: Microscopic delineation and clearance of tumor cells at neurosurgical excision margins potentially reduce tumor recurrence and increase patient survival. Probe-based in vivo fluorescence microscopy technologies are promising for neurosurgical in vivo microscopy.
   OBJECTIVE: We sought to demonstrate a flexible fiberoptic epifluorescence microscope capable of enhanced architectural and cytological imaging for in vivo microscopy during neurosurgical procedures.
   METHODS: Eighteen specimens were procured from neurosurgical procedures. These specimens were stained with acridine orange and imaged with a 3-dimensional (3D)-printed epifluorescent microscope that incorporates a flexible fiberoptic probe. Still images and video sequence frames were processed using frame alignment, signal projection, and pseudo-coloring, resulting in resolution enhancement and an increased field of view.
   RESULTS: Images produced displayed good nuclear contrast and architectural detail. Grade 1 meningiomas demonstrated 3D chords and whorls. Low-grade meningothelial nuclei showed streaming and displayed regularity in size, shape, and distribution. Oligodendrogliomas showed regular round nuclei and a variably staining background. Glioblastomas showed high degrees of nuclear pleomorphism and disarray. Mitoses, vascular proliferation, and necrosis were evident.
   CONCLUSIONS: We demonstrate the utility of a 3D-printed, flexible probe microscope for high-resolution microscopic imaging with increased architectural detail. Enhanced in vivo imaging using this device may improve our ability to detect and decrease microscopic tumor burden at excision margins during neurosurgical procedures.
C1 [Osman, Hany] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
   [Osman, Hany] Harvard Med Sch, Boston, MA 02115 USA.
   [Elsahy, Deena] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA.
   [Slivova, Veronika; Thompson, Corey] Indiana Univ Hlth, Enterprise Clin Res Operat Biorepository, Indiana, PA USA.
   [Georges, Joseph; Yocom, Steven] Philadelphia Coll Osteopath Med, Dept Neurosurg, Philadelphia, PA USA.
   [Cohen-Gadol, Aaron A.] Goodman Campbell Brain & Spine, Indianapolis, IN 46202 USA.
   [Cohen-Gadol, Aaron A.] Indiana Univ, Dept Neurol Surg, Indianapolis, IN 46204 USA.
RP Cohen-Gadol, AA (reprint author), Goodman Campbell Brain & Spine, Indianapolis, IN 46202 USA.; Cohen-Gadol, AA (reprint author), Indiana Univ, Dept Neurol Surg, Indianapolis, IN 46204 USA.
EM acohenmd@gmail.com
CR Akcakaya MO, 2017, WORLD NEUROSURG, V107, P966, DOI 10.1016/j.wneu.2017.07.103
   Babu Ranjith, 2012, Curr Drug Discov Technol, V9, P256
   Bazinet WP, 1961, FIBER OPTICAL DEVICE
   Bedard N, 2012, BIOMED OPT EXPRESS, V3, P2428, DOI 10.1364/BOE.3.002428
   Charalampaki Patra, 2015, Neurosurgery, V62 Suppl 1, P171, DOI 10.1227/NEU.0000000000000805
   Foersch S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041760
   Gareau DS, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3149853
   Han JH, 2010, OPT EXPRESS, V18, P7427, DOI 10.1364/OE.18.007427
   Hansell CW, 1930, US Patent, Patent No. [1,751,584, 1751584]
   Hardesty Douglas A, 2012, Front Neurol, V3, P140, DOI 10.3389/fneur.2012.00140
   Kiesslich R, 2004, GASTROENTEROLOGY, V127, P706, DOI 10.1053/j.gastro.2004.06.050
   Lang TA, 2012, CHEST, V141, P1626, DOI 10.1378/chest.11-1800
   Lee CY, 2013, OPT LETT, V38, P2023, DOI 10.1364/OL.38.002023
   Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94
   Martirosyan NL, 2018, CLIN NEUROL NEUROSUR, V169, P21, DOI 10.1016/j.clineuro.2018.03.015
   Martirosyan NL, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15559
   Martirosyan NL, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.11.FOCUS13486
   McGirt MJ, 2009, J NEUROSURG, V110, P156, DOI 10.3171/2008.4.17536
   Nakai Y, 2014, DIGEST ENDOSC, V26, P86, DOI 10.1111/den.12152
   Nanda A, 2017, J NEUROSURG, V126, P201, DOI 10.3171/2016.1.JNS151842
   Osman H., 2015, MICROSC MICROANAL, V21, P623
   Osman H, 2018, WORLD NEUROSURG, V115, P110, DOI 10.1016/j.wneu.2018.03.218
   Osman H, 2018, WORLD NEUROSURG, V114, pE1310, DOI [10.1016/J.WNEU.2018.03.207, 10.1016/j.wneu.2018.03.207]
   Pavlov V, 2016, NEUROSURGERY, V79, P604, DOI 10.1227/NEU.0000000000001365
   Pierce M, 2011, JOVE-J VIS EXP, DOI 10.3791/2306
   Pierce MC, 2012, CANCER PREV RES, V5, P1273, DOI 10.1158/1940-6207.CAPR-12-0221
   Pierce MC, 2012, CANCER PREV RES, V5, P801, DOI 10.1158/1940-6207.CAPR-11-0555
   PIZER SM, 1987, COMPUT VISION GRAPH, V39, P355, DOI 10.1016/S0734-189X(87)80186-X
   Polglase AL, 2005, GASTROINTEST ENDOSC, V62, P686, DOI 10.1016/j.gie.2005.05.021
   Salcman M, 1994, Clin Neurosurg, V41, P464
   Sanai N, 2008, NEUROSURGERY, V62, P753, DOI 10.1227/01.neu.0000318159.21731.cf
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Sanai N, 2011, NEUROSURGERY, V68, P282, DOI 10.1227/NEU.0b013e318212464e
   Satonaka H, 2010, ONCOL LETT, V1, P69, DOI 10.3892/ol_00000012
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Scott JN, 1998, CAN J NEUROL SCI, V25, P197, DOI 10.1017/S0317167100034016
   Shin D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011218
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Tanbakuchi AA, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.07.027
   Thiberville Luc, 2009, Proc Am Thorac Soc, V6, P444, DOI 10.1513/pats.200902-009AW
   Wallace M, 2011, ENDOSCOPY, V43, P882, DOI 10.1055/s-0030-1256632
   Wang KK, 2015, UNITED EUR GASTROENT, V3, P230, DOI 10.1177/2050640614566066
   Zhao SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071975
NR 43
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E929
EP E937
DI 10.1016/j.wneu.2019.05.039
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100110
PM 31100529
DA 2020-05-12
ER

PT J
AU Ozdol, C
   Kulaksizoglu, S
   Uyar, R
   Gediz, T
   Aghayev, K
AF Ozdol, Cagatay
   Kulaksizoglu, Sibel
   Uyar, Ramazan
   Gediz, Tolga
   Aghayev, Kamran
TI Initial Results of Using Blood Beta 2 Transferrin as a Marker of the
   Functional Status of a Shunt
SO WORLD NEUROSURGERY
LA English
DT Article
DE Beta 2 transferrin; Diagnosis; Malfunction; Ventriculoperitoneal shunt
ID CEREBROSPINAL-FLUID; DIAGNOSIS
AB OBJECTIVE: Ventriculoperitoneal shunt is the most common cerebrospinal fluid diversion procedure to treat hydrocephalus. With the change of physiologic cerebrospinal fluid absorption site from arachnoid granulations to the peritoneum, beta 2 transferrin enters the systemic circulation. Therefore, the detection of beta 2 transferrin in the blood can possibly be used as a noninvasive method to assess the functional status of the shunt. The objective of this study was to study the presence of beta 2 transferrin in patients with functional shunts and in shunts suspected of being malfunctional.
   METHODS: Blood samples were obtained from a group of 20 patients with functional ventriculoperitoneal shunts, from a control group of 10 age-matched healthy volunteers, and from 8 patients with suspected shunt malfunction (6 ventriculoperitoneal, 2 lumboperitoneal). Blood serum beta 2 transferrin levels were measured by enzyme-linked immunosorbent assay with specific anti-beta 2 transferrin antibodies.
   RESULTS: The mean age in the ventriculoperitoneal shunt group was 36.5 years (range, 24-50 years). The mean age in the control group was 39.5 years (range, 32-48). There was no statistical difference in age between the groups. Beta 2 transferrin levels were 1.99 +/- 1.02 ng/mL in the ventriculoperitoneal shunt group and 0.05 +/- 0.02 ng/mL in the control group; the statistical difference was strongly significant (P < 0.001). Patients presenting with suspected shunt malfunction had preoperative low beta 2 transferrin levels (0.10 +/- 0.12). Postoperatively, their beta 2 transferrin levels increased to 1.75 +/- 0.46 ng/ml, and the difference was statistically significant (P = 0.012).
   CONCLUSION: Blood beta 2 transferrin can be used as a noninvasive test to assess the functional status of a shunt.
C1 [Ozdol, Cagatay; Uyar, Ramazan; Gediz, Tolga] Antalya Training & Res Hosp, Dept Neurosurg, Antalya, Turkey.
   [Kulaksizoglu, Sibel] Antalya Training & Res Hosp, Dept Biochem, Antalya, Turkey.
   [Aghayev, Kamran] Biruni Univ, Dept Neurosurg, Istanbul, Turkey.
RP Ozdol, C (reprint author), Antalya Training & Res Hosp, Dept Neurosurg, Antalya, Turkey.
EM drcagatayozdol@gmail.com
OI Ozdol, Cagatay/0000-0001-9817-6722
CR Bachmann-Harildstad G, 2008, RHINOLOGY, V46, P82
   Chiewvit Sunanta, 2014, World J Nucl Med, V13, P75, DOI 10.4103/1450-1147.139135
   CHUNG MCM, 1984, BIOCHEM EDUC, V12, P146, DOI 10.1016/0307-4412(84)90118-3
   Hameed MQ, 2019, NEUROSURGERY, V85, P240, DOI 10.1093/neuros/nyy246
   Hoshi K, 2017, BBA-GEN SUBJECTS, V1861, P2473, DOI 10.1016/j.bbagen.2017.07.005
   Iskandar BJ, 1998, PEDIATRICS, V101, P1031, DOI 10.1542/peds.101.6.1031
   Maller VV, 2016, SEMIN ULTRASOUND CT, V37, P159, DOI 10.1053/j.sult.2016.01.003
   Oakley GM, 2016, INT FORUM ALLERGY RH, V6, P8, DOI 10.1002/alr.21637
   Patwardhan RV, 2005, NEUROSURGERY, V56, P139, DOI 10.1227/01.NEU.0000146206.40375.41
   Piatt JH, 1996, PEDIATR NEUROSURG, V25, P73, DOI 10.1159/000121100
   von Eckardstein KL, 2017, ACTA NEUROCHIR, V159, P63, DOI 10.1007/s00701-016-3007-x
   Winston KR, 2006, PEDIATR NEUROSURG, V42, P151, DOI 10.1159/000091857
NR 12
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E501
EP E503
DI 10.1016/j.wneu.2019.04.185
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100058
PM 31048048
DA 2020-05-12
ER

PT J
AU Ozoner, B
   Aydin, S
   Akgun, MY
   Durmaz, ES
   Sahin, S
   Gazioglu, N
   Kizilkilic, O
   Kadioglu, P
   Tanriover, N
AF Ozoner, Baris
   Aydin, Seckin
   Akgun, Mehmet Yigit
   Durmaz, Emine Sebnem
   Sahin, Serdar
   Gazioglu, Nurperi
   Kizilkilic, Osman
   Kadioglu, Pinar
   Tanriover, Necmettin
TI Predictive Factors for Rathke's Cleft Cyst Consistency
SO WORLD NEUROSURGERY
LA English
DT Article
DE Classification; Consistency; Predictive factor; Rathke's cleft cyst
ID CLINICAL-FEATURES; MR; MANAGEMENT; MANIFESTATIONS; HEADACHE
AB Objective: Rathke's cleft cysts (RCCs) may have various anatomic, clinical, and radiologic characteristics, which may be related to their differences in texture or consistency. The purpose of the study was to investigate RCCs based on consistency.
   Methods: We retrospectively reviewed 25 cases of patients with RCCs who underwent endoscopic endonasal transsphenoidal surgery between 2008 and 2018. Cases were divided into 3 types based on cyst consistency: fluid (serous) or type A (n = 4); semi-fluid (mucoid) or type B (n = 17); and non-fluid (caseous) or type C (n = 4). Demographic, clinical, radiologic, and surgical characteristics for each group were analyzed.
   Results: All type A RCCs (100%) had visual impairment. The mean age (42.8 +/- 13 years) and cyst volume (2442.5 +/- 533.6 mm(3)) were higher in these patients. T1-weighted images were hypointense and T2-weighted images were hyperintense on magnetic resonance imaging. Type B RCCs were more frequently encountered (68%). Although headache was the most common (82.3%) symptom, endocrine disorders were also prevalent (52.9%). T1-weighted images were typically isointense or hyperintense on magnetic resonance imaging. Type C RCCs had the youngest patient population (30.3 +/- 10.2 years) and T2-weighted images were predominantly hypointense in this group.
   Conclusions: The proposed novel consistency classification of RCCs will provide a practical tool for more accurately estimating the nature of the pathology, because each type has its own specific characteristics. Furthermore, the new classification of RCCs may aid in planning a consistency-specific surgery.
C1 [Akgun, Mehmet Yigit; Tanriover, Necmettin] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.
   [Durmaz, Emine Sebnem; Kizilkilic, Osman] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Radiol, Istanbul, Turkey.
   [Sahin, Serdar; Kadioglu, Pinar] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Endocrinol & Metab, Istanbul, Turkey.
   [Ozoner, Baris] Erzincan Binali Yildirim Univ, Sch Med, Dept Neurosurg, Erzincan, Turkey.
   [Aydin, Seckin] Univ Hlth Sci, Okmeydani Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
   [Gazioglu, Nurperi] Demiroglu Bilim Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey.
RP Tanriover, N (reprint author), Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.
EM nctan27@yahoo.com
RI Kadioglu, Pinar/AAM-9935-2020; Sahin, Serdar/AAN-1047-2020; Tanriover,
   Necmettin/AAD-3212-2020; Akgun, Mehmet Yigit/AAA-2136-2020; aydin,
   seckin/F-8538-2015
OI Tanriover, Necmettin/0000-0001-7628-9443; Akgun, Mehmet
   Yigit/0000-0003-1342-7663; Ozoner, Baris/0000-0003-0534-2766
FU Turkish Neurosurgical Society
FX Preparation for publication of this article is partly supported by the
   Turkish Neurosurgical Society.
CR Altuwaijri N, 2018, WORLD NEUROSURG, V111, pE764, DOI 10.1016/j.wneu.2017.12.170
   ASARI S, 1990, J COMPUT ASSIST TOMO, V14, P532, DOI 10.1097/00004728-199007000-00006
   BERRY R G, 1959, Arch Neurol, V1, P48
   Billeci Domenico, 2004, Pituitary, V7, P131, DOI 10.1007/s11102-005-1755-3
   Brassier G, 1999, J NEURORADIOLOGY, V26, P162
   Byun WM, 2000, AM J NEURORADIOL, V21, P485
   FAGER CA, 1966, J NEUROSURG, V24, P77, DOI 10.3171/jns.1966.24.1.0077
   Hama S, 2002, J NEUROSURG, V96, P209, DOI 10.3171/jns.2002.96.2.0209
   Hayashi Y, 1999, J COMPUT ASSIST TOMO, V23, P34, DOI 10.1097/00004728-199901000-00008
   Isono M, 2001, CLIN NEUROL NEUROSUR, V103, P96, DOI 10.1016/S0303-8467(01)00121-4
   Kim E, 2012, WORLD NEUROSURG, V78, P527, DOI 10.1016/j.wneu.2011.12.091
   Kim JE, 2004, J NEUROSURG, V100, P33, DOI 10.3171/jns.2004.100.1.0033
   Koutourousiou M, 2009, J CLIN NEUROSCI, V16, P900, DOI 10.1016/j.jocn.2008.10.007
   KUCHARCZYK W, 1987, RADIOLOGY, V165, P491, DOI 10.1148/radiology.165.2.3659372
   Manzoni Gian Camillo, 2010, Handb Clin Neurol, V97, P3, DOI 10.1016/S0072-9752(10)97001-2
   Nishioka H, 2006, CLIN ENDOCRINOL, V64, P184, DOI 10.1111/j.1365-2265.2006.02446.x
   Nishioka H, 2006, HEADACHE, V46, P1580, DOI 10.1111/j.1526-4610.2006.00539.x
   Potts MB, 2011, NEUROSURGERY, V69, P1058, DOI 10.1227/NEU.0b013e318228bcea
   RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2
   ROSS DA, 1992, NEUROSURGERY, V30, P173, DOI 10.1227/00006123-199202000-00004
   Sade B, 2005, SURG NEUROL, V63, P459, DOI 10.1016/j.surneu.2004.06.014
   Saeki N, 1999, ACTA NEUROCHIR, V141, P1055, DOI 10.1007/s007010050482
   Solari D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139609
   Wenger M, 2001, J CLIN NEUROSCI, V8, P564, DOI 10.1054/jocn.2000.0925
   Zada G, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.5.FOCUS1183
   Zhong WY, 2012, J CLIN NEUROSCI, V19, P501, DOI 10.1016/j.jocn.2011.07.022
NR 26
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E522
EP E530
DI 10.1016/j.wneu.2019.04.188
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100061
PM 31048050
DA 2020-05-12
ER

PT J
AU Ozturk, K
   Soylu, E
   Tolunay, S
   Narter, S
   Hakyemez, B
AF Ozturk, Kerem
   Soylu, Esra
   Tolunay, Sahsine
   Narter, Selin
   Hakyemez, Bahattin
TI Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance
   Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via
   Tumoral and Peritumoral Approach: A Pilot Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dynamic contrast-enhanced T1-weighted perfusion MR imaging (DCE-pMRI);
   Epidermal growth factor receptor (EGFR); Glioblastoma (GB); Isocitrate
   dehydrogenase 1 (IDH1); Oligodendrocyte transcription factor 2 (OLIG2)
ID MICROVASCULAR PERMEABILITY; GENOMIC BIOMARKERS; HISTOGRAM ANALYSIS;
   MUTATION STATUS; MR; GLIOMA; PARAMETERS; DIFFERENTIATION; LYMPHOMA;
   SURVIVAL
AB OBJECTIVE: We aimed to evaluate the usefulness of dynamic contrast-enhanced T1-weighted perfusion magnetic resonance imaging (DCE-pMRI) to predict certain immunohistochemical (IHC) biomarkers of glioblastoma (GB) in this pilot study.
   METHODS: We retrospectively reviewed 36 patients (male/female, 25:11; mean age, 53 years; age range, 29-85 years) who had pretreatment DCE-pMRI with IHC analysis of their excised GBs. Regions of interest of the enhancing tumor (ER) and nonenhancing peritumoral region (NER) were used to calculate DCE-pMRI parameters of volume transfer constant, back flux constant, volume of the extravascular extracellular space, initial area under enhancement curve, and maximum slope. IHC biomarkers including Ki-67 labeling index, epidermal growth factor receptor (EGFR), oligodendrocyte transcription factor 2 (OLIG2), isocitrate dehydrogenase 1 (IDH1), and p53 mutation status were determined. The imaging metrics of GB with IHC markers were compared using the Kruskal-Wallis test and Spearman correlation analysis.
   RESULTS: Among 30 patients with available IDH1 status, 14 patients (46.6%) had IDH1 mutation. EGFR amplification was present in 24/36 (66.6%) patients. Mean Ki-67 labeling index was 29% (range, 1.5%-80%). p53 mutation was present in 20/36 GBs (55%), whereas OLIG2 expression was positive in 29/36 GBs (80.5%). Various DCE-pMRI parameters gathered from the ER and NER were significantly correlated with IDH1 mutation, EGFR amplification, and OLIG2 expression (P < 0.05). Ki-67 labeling index showed a strong positive correlation with initial area under enhancement curve (r = 0.619; P < 0.001).
   CONCLUSIONS: DCE-pMRI could determine surrogate IHC biomarkers in GB via tumoral and peritumoral approach, potential targets for individualized treatment protocols.
C1 [Ozturk, Kerem; Soylu, Esra; Hakyemez, Bahattin] Uludag Univ, Fac Med, Dept Radiol, Bursa, Turkey.
   [Tolunay, Sahsine; Narter, Selin] Uludag Univ, Fac Med, Dept Pathol, Bursa, Turkey.
RP Hakyemez, B (reprint author), Uludag Univ, Fac Med, Dept Radiol, Bursa, Turkey.
EM bhakyemez@uludag.edu.tr
RI Ozturk, Kerem/E-1228-2018
OI Ozturk, Kerem/0000-0001-9664-2347
CR Akbari H, 2016, NEUROSURGERY, V78, P572, DOI 10.1227/NEU.0000000000001202
   Alton G, 2016, FUTURE ONCOL, V12, P1001, DOI 10.2217/fon-2015-0078
   Arevalo-Perez J, 2015, AM J NEURORADIOL, V36, P2256, DOI 10.3174/ajnr.A4484
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Choi YS, 2017, EUR RADIOL, V27, P1344, DOI 10.1007/s00330-016-4484-2
   Cui Y, 2017, EUR RADIOL, V27, P3583, DOI 10.1007/s00330-017-4751-x
   Felsberg J, 2017, CLIN CANCER RES, V23, P6846, DOI 10.1158/1078-0432.CCR-17-0890
   Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707
   Hong EK, 2018, EUR RADIOL, V28, P4350, DOI 10.1007/s00330-018-5400-8
   Jain R, 2014, RADIOLOGY, V272, P484, DOI 10.1148/radiol.14131691
   Jung SC, 2014, AM J NEURORADIOL, V35, P1103, DOI 10.3174/ajnr.A3825
   Kickingereder P, 2014, AM J NEURORADIOL, V35, P1503, DOI 10.3174/ajnr.A3915
   Kickingereder P, 2018, NEURO-ONCOLOGY, V20, P848, DOI 10.1093/neuonc/nox188
   Kickingereder P, 2015, SCI REP-UK, V5, DOI 10.1038/srep16238
   Kickingereder P, 2015, J NEURO-ONCOL, V121, P373, DOI 10.1007/s11060-014-1644-6
   Liu X, 2017, J NEURO-ONCOL, V135, P553, DOI 10.1007/s11060-017-2602-x
   Masui K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122609
   Mills SJ, 2016, AM J NEURORADIOL, V37, P811, DOI 10.3174/ajnr.A4623
   Naeini KM, 2013, NEURO-ONCOLOGY, V15, P626, DOI 10.1093/neuonc/not008
   Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011
   Padfield E, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00005
   Ryoo I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071704
   Santarosa C, 2016, EUR J RADIOL, V85, P1147, DOI 10.1016/j.ejrad.2016.03.020
   Taoka T, 2016, MAGN RESON IMAGING, V34, P896, DOI 10.1016/j.mri.2016.04.020
   Thakkar JP, 2014, CANCER EPIDEM BIOMAR, V23, P1985, DOI 10.1158/1055-9965.EPI-14-0275
   Tietze A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123044
   TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208
   Trepant AL, 2015, TUMOR BIOL, V36, P1943, DOI 10.1007/s13277-014-2800-5
   Tykocinski ES, 2012, NEURO-ONCOLOGY, V14, P613, DOI 10.1093/neuonc/nos073
   von Achenbach C, 2018, J NEUROCHEM, V147, P99, DOI 10.1111/jnc.14538
   Wang PF, 2017, ONCOTARGET, V8, P50117, DOI 10.18632/oncotarget.15235
   Xie T, 2018, J MAGN RESON IMAGING, V47, P1099, DOI 10.1002/jmri.25835
   Xu H, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00352
   Zeng AL, 2015, ONCOTARGET, V6, P30232, DOI 10.18632/oncotarget.4920
   Zhang GB, 2013, J NEURO-ONCOL, V113, P251, DOI 10.1007/s11060-013-1102-x
NR 35
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E195
EP E208
DI 10.1016/j.wneu.2019.04.089
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100022
PM 31003026
DA 2020-05-12
ER

PT J
AU Park, JH
   Lee, KE
   Yu, YM
   Park, YH
   Choi, SA
AF Park, Ji Hyun
   Lee, Kyung Eun
   Yu, Yun Mi
   Park, Youngja Hwang
   Choi, Soo An
TI Incidence and Risk Factors for Venous Thromboembolism After Spine
   Surgery in Korean Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE HIRA-NIS-2014; Incidence; Risk factors; Spine surgery; Venous
   thromboembolism
ID DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; CONSECUTIVE PATIENTS; EUROPEAN
   GUIDELINES; ELECTIVE HIP; PROPHYLAXIS; PREVENTION; DISEASE; POPULATION;
   TRAUMA
AB BACKGROUND: Data regarding the incidence of venous thromboembolism (VTE) after spine surgery are scarce. Identifying ideal candidates for pharmacologic thromboprophylaxis and balancing the risk of thromboembolic complications against the risk of permanent neurologic deficits from a spinal epidural hematoma (SEH) are difficult. Even guidelines cannot suggest the standard of thromboprophylaxis.
   OBJECTIVES: This study aimed to identify the incidence of and risk factors for VTE after spine surgery in the Korean population. In addition, the rate of pharmacoprophylaxis and the incidence of SEH after spine surgery were analyzed.
   METHODS: The study cohort was generated by extracting patients with disease codes of spine surgery and VTE from the Health Insurance Review & Assessment Service National Inpatient Sample in 2014.
   After analyzing the incidence of VTE after spine surgery, a univariate comparison was performed to examine the possible relationship between the incidence of VTE and the independent variable. Variables found to be significant were included in a multivariable analysis model for further analysis.
   RESULTS: The incidence of VTE was 2.09% among all 21,261 patients who had spine surgery, and prophylaxis was applied to 7.89% of all patients who had spine surgery. Comorbidities and surgery-related risk factors were venous disease, cancer, respiratory disease, prolonged surgery hours, and increased total blood loss. Hospital-related risk factors were the location and hospital size.
   CONCLUSIONS: On the basis of the incidence of VTE and the risk factors, more active prophylaxis is suggested for patients in the Korean population who undergo spine surgery.
C1 [Park, Ji Hyun; Park, Youngja Hwang; Choi, Soo An] Korea Univ, Coll Pharm, Sejong Si, South Korea.
   [Lee, Kyung Eun] Chungbuk Natl Univ, Coll Pharm, Cheongju, South Korea.
   [Yu, Yun Mi] Yonsei Univ, Coll Pharm, Incheon, South Korea.
RP Choi, SA (reprint author), Korea Univ, Coll Pharm, Sejong Si, South Korea.
EM sachoi@korea.ac.kr
OI Yu, Yun Mi/0000-0002-8267-9453; Park, Ji Hyun/0000-0002-8233-886X
FU Basic Science Research Program of the National Research Foundation of
   Korea - Korea government [NRF-2016R1D1A1B03935819]
FX This study is supported by Basic Science Research Program (grant number
   NRF-2016R1D1A1B03935819) of the National Research Foundation of Korea
   funded by the Korea government.
CR Afshari A, 2018, EUR J ANAESTH, V35, P77, DOI 10.1097/EJA.0000000000000729
   Agnelli G, 2004, CIRCULATION, V110, P4, DOI 10.1161/01.CIR.0000150639.98514.6c
   Ahn H., 2014, J KYUNG HEE U MED CE, V29, P18
   Ahn Jh, 2012, COMPUTING AUTHENTICA, P1
   Ahn Jh, 2012, COMP STUDY ANTITHROM, V2012, P1
   Akeda K, 2014, SPINE, V39, P791, DOI 10.1097/BRS.0000000000000295
   Al-Dujaili TM, 2012, INT SURG, V97, P150, DOI 10.9738/CC71.1
   Audibert G, 2005, ANN FR ANESTH, V24, P928, DOI 10.1016/j.annfar.2005.05.010
   Awad JN, 2005, J BONE JOINT SURG BR, V87B, P1248, DOI 10.1302/0301-620X.87B9.16518
   Bang SM, 2010, J KOREAN MED SCI, V25, P1553, DOI 10.3346/jkms.2010.25.11.1553
   Bono CM, 2009, SPINE J, V9, P1046, DOI 10.1016/j.spinee.2009.09.005
   Bono CM, 2009, SPINE J, V9, P599, DOI 10.1016/j.spinee.2009.04.009
   Cheng JS, 2010, SPINE, V35, pS117, DOI 10.1097/BRS.0b013e3181d833d4
   Cho GJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0447-x
   Chun B., 1999, J KOREAN NEUROSURG S, V28, P1817
   Cunningham JE, 2011, J SPINAL DISORD TECH, V24, pE31, DOI 10.1097/BSD.0b013e3181f605ea
   Epstein NE, 2005, SURG NEUROL, V64, P295, DOI 10.1016/j.surneu.2005.04.039
   Eskildsen SM, 2015, J SPINAL DISORD TECH, V28, P275, DOI 10.1097/BSD.0000000000000321
   FERREE BA, 1993, SPINE, V18, P1079, DOI 10.1097/00007632-199306150-00019
   Fineberg SJ, 2013, SPINE, V38, P1154, DOI 10.1097/BRS.0b013e318286b7c0
   Flinn WR, 1996, ARCH SURG-CHICAGO, V131, P472
   Freedman KB, 2000, J BONE JOINT SURG AM, V82A, P929, DOI 10.2106/00004623-200007000-00004
   Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S
   Gephart MGH, 2012, WORLD NEUROSURG, V78, P545, DOI 10.1016/j.wneu.2011.12.089
   Gerlach R, 2004, EUR SPINE J, V13, P9, DOI 10.1007/s00586-003-0642-8
   Glotzbecker MP, 2010, SPINE, V35, pE413, DOI 10.1097/BRS.0b013e3181d9bb77
   Glotzbecker MP, 2008, SPINE, V33, P2915, DOI 10.1097/BRS.0b013e318190702a
   Glotzbecker MP, 2009, SPINE, V34, P291, DOI 10.1097/BRS.0b013e318195601d
   Health Insurance Review and Assessment Service medicine reference information, 2015, HLTH INS REV ASS SER
   Heck CA, 2008, J AM ACAD ORTHOP SUR, V16, P656, DOI 10.5435/00124635-200811000-00006
   Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809
   Heit JA, 2002, ARCH INTERN MED, V162, P1245, DOI 10.1001/archinte.162.11.1245
   Hill J, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c95
   Hohl JB, 2015, J SPINAL DISORD TECH, V28, pE310, DOI 10.1097/BSD.0b013e31828b7d82
   International Classification of Diseases Ninth Revision Clinical Modification, 2013, ADD CONV TABL GUID
   Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124
   Jang MJ, 2011, J THROMB HAEMOST, V9, P85, DOI 10.1111/j.1538-7836.2010.04108.x
   Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026
   Kim L, 2011, GUIDE USE NATL PATIE, DOI [10.4178/epih/e2014008, DOI 10.4178/EPIH/E2014008]
   Kim L, 2014, EPIDEMIOL HEALTH, V36, DOI 10.4178/epih/e2014008
   Kim SR, 2017, TUBERC RESPIR DIS, V80, P221, DOI 10.4046/trd.2017.80.3.221
   Korean Information Center for Disease, 2018, DIS COD STAT ADM OUT
   Kozek-Langenecker S, 2018, EUR J ANAESTH, V35, P116, DOI 10.1097/EJA.0000000000000705
   Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6
   Lee CH, 2010, J THROMB HAEMOST, V8, P1515, DOI 10.1111/j.1538-7836.2010.03873.x
   Lee JS, 2005, J KOREAN ORTHOP ASS, V40, P1013
   Lee S, 2016, J KOREAN MED SCI, V31, P80, DOI 10.3346/jkms.2016.31.1.80
   Lee SJ, 2015, ASIAN ONCOL NURS, V15, P171, DOI 10.5388/aon.2015.15.3.171
   Lee YH, 1996, KOREAN J PEDIAT, V39, P436
   Leizorovicz A, 2007, HAEMATOLOGICA, V92, P1194, DOI 10.3324/haematol.10819
   MaCauley Michael J, 2012, Hosp Pract (1995), V40, P7, DOI 10.3810/hp.2012.08.984
   McLynn RP, 2018, SPINE J, V18, P970, DOI 10.1016/j.spinee.2017.10.013
   Mont MA, 2011, J AM ACAD ORTHOP SUR, V19, P777, DOI 10.5435/00124635-201112000-00008
   Mont MA, 2011, J AM ACAD ORTHOP SUR, V19, P768, DOI 10.5435/00124635-201112000-00007
   Mosenthal WP, 2018, SPINE, V43, pE474, DOI 10.1097/BRS.0000000000002379
   National Clinical Guideline CentreeAcute and Chronic Conditions (UK), 2010, VEN THROMB RED RISK
   National Institute for Health and Care Excellence, 2018, VEN THROMB OV 16S RE
   Nicolaides AN, 2006, INT ANGIOL, V25, P101
   North American Spine Society, 2009, EV BAS CLIN GUID MUL
   Oh H, 2016, BURNS, V42, P675, DOI 10.1016/j.burns.2015.10.005
   OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203
   Otero-Fernandez R, 2008, CLIN APPL THROMB-HEM, V14, P75, DOI 10.1177/1076029607303962
   Park SC, 2014, J KOREAN MED SCI, V29, P719, DOI 10.3346/jkms.2014.29.5.719
   Piovella F, 2005, J THROMB HAEMOST, V3, P2664, DOI 10.1111/j.1538-7836.2005.01621.x
   Piper K, 2017, J NEUROSURG-SPINE, V26, P90, DOI 10.3171/2016.6.SPINE1656
   Piran S, 2016, THROMB RES, V147, P97, DOI 10.1016/j.thromres.2016.09.030
   Platzer P, 2006, ACTA ORTHOP, V77, P755, DOI 10.1080/17453670610012944
   Ploumis A, 2010, SPINE, V35, P323, DOI 10.1097/BRS.0b013e3181ca652e
   Prandoni P, 1997, ARCH INTERN MED, V157, P57, DOI 10.1001/archinte.157.1.57
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134
   SALZMAN EW, 1980, ANN SURG, V191, P207, DOI 10.1097/00000658-198002000-00013
   Samama MM, 2000, ARCH INTERN MED, V160, P3415, DOI 10.1001/archinte.160.22.3415
   Sansone JM, 2010, J BONE JOINT SURG AM, V92A, P304, DOI 10.2106/JBJS.H.01815
   Schoenfeld AJ, 2013, SPINE, V38, P1892, DOI 10.1097/BRS.0b013e31829fc3a0
   Schulte Leah M, 2013, Am J Orthop (Belle Mead NJ), V42, P267
   Schunemann HJ, 2018, BLOOD ADV, V2, P3198, DOI 10.1182/bloodadvances.2018022954
   Schuster James M, 2010, Evid Based Spine Care J, V1, P40, DOI 10.1055/s-0028-1100913
   Sen RK, 2011, INDIAN J ORTHOP, V45, P197, DOI 10.4103/0019-5413.80037
   Shin CM, 2017, DIS COLON RECTUM, V60, P1192, DOI 10.1097/DCR.0000000000000876
   Sung SC, MAIN SURG STAT YB 20, V522
   Takahashi H, 2012, J ORTHOP SCI, V17, P114, DOI 10.1007/s00776-011-0188-2
   The Korean Society for Vascular Surgery, 2013, PREV TREATM VEN THRO, P1
   Vu DH, 2015, APPL ENERG, V140, P385, DOI 10.1016/j.apenergy.2014.12.011
   Wang TY, 2015, WORLD NEUROSURG, V84, P1605, DOI 10.1016/j.wneu.2015.07.008
   Yang SD, 2015, SCI REP-UK, V5, DOI 10.1038/srep11834
   Zacharia BE, 2017, J NEUROSURG-SPINE, V27, P189, DOI 10.3171/2017.2.SPINE16861
   Zeng XJ, 2017, WORLD NEUROSURG, V104, P856, DOI 10.1016/j.wneu.2017.05.050
NR 88
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E289
EP E307
DI 10.1016/j.wneu.2019.04.140
PG 19
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100033
PM 31028984
DA 2020-05-12
ER

PT J
AU Park, SM
   Kim, GU
   Kim, HJ
   Choi, JH
   Chang, BS
   Lee, CK
   Yeom, JS
AF Park, Sang-Min
   Kim, Gang-Un
   Kim, Ho-Joong
   Choi, Jae Heouk
   Chang, Bong-Soon
   Lee, Choon-Ki
   Yeom, Jin S.
TI Is the Use of a Unilateral Biportal Endoscopic Approach Associated with
   Rapid Recovery After Lumbar Decompressive Laminectomy? A Preliminary
   Analysis of a Prospective Randomized Controlled Trial
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biportal endoscopic spine surgery; Degenerative spine; Lumbar spinal
   stenosis; Unilateral laminectomy and bilateral decompression; Visual
   analog scale
ID SERUM CREATINE-PHOSPHOKINASE; SPINAL-CANAL STENOSIS;
   BILATERAL-DECOMPRESSION; RADIOLOGICAL OUTCOMES; INVASIVE DECOMPRESSION;
   INTERBODY FUSION; TECHNICAL NOTE; MUSCLE INJURY; SURGERY; LAMINOTOMY
AB OBJECTIVE: The purpose of this study was to assess the immediate postoperative clinical outcomes and perform a preliminary analysis of the effectiveness of biportal endoscopic approaches to lumbar decompressive laminectomy in the treatment of lumbar spinal stenosis.
   METHODS: All participants (64 patients) were randomly assigned in a 1:1 ratio to either the biportal endoscopic lumbar decompressive laminectomy (BE-D) group or the mini-open microscopic lumbar decompressive laminectomy (MI-D) group. Early postoperative outcomes were evaluated using clinical and surgical technique-related outcomes. The visual analog scale (VAS) pain score was measured at 6 time points after surgery (at 4, 8, 16, 24, and 48 hours and 2 weeks). Surgical technique-related outcomes were also analyzed.
   RESULTS: There were no significant differences in the preoperative demographics between the 2 groups. The VAS pain score from 8 to 48 hours (P < 0.05) was significantly lower in the BE-D group than in the MI-D group. Moreover, the total amount of fentanyl usage was higher in the MI-D group than in the BE-D group after surgery (P = 0.026). The length of hospital stay was lower in the BE-D group than in the MI-D group (P = 0.048). The operative time and creatinine phosphokinase level were not significantly different between the groups (P >0.05). Postoperative drainage was significantly higher in the BE-D group than in the MI-D group.
   CONCLUSIONS: BE-D was associated with rapid pain recovery, low fentanyl usage, and early discharge after surgery, but its other benefits have not yet been shown.
C1 [Park, Sang-Min; Kim, Ho-Joong; Yeom, Jin S.] Seoul Natl Univ, Coll Med, Spine Ctr, Seongnam, South Korea.
   [Park, Sang-Min; Kim, Ho-Joong; Yeom, Jin S.] Seoul Natl Univ, Coll Med, Dept Orthopaed Surg, Seongnam, South Korea.
   [Park, Sang-Min; Kim, Ho-Joong; Yeom, Jin S.] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea.
   [Choi, Jae Heouk; Chang, Bong-Soon; Lee, Choon-Ki] Seoul Natl Univ, Dept Orthopaed Surg, Coll Med, Seoul, South Korea.
   [Choi, Jae Heouk; Chang, Bong-Soon; Lee, Choon-Ki] Seoul Natl Univ Hosp, Seoul, South Korea.
   [Kim, Gang-Un] Inje Univ, Coll Med, Sanggye Paik Hosp, Dept Orthopaed Surg, Seoul, South Korea.
RP Yeom, JS (reprint author), Seoul Natl Univ, Coll Med, Spine Ctr, Seongnam, South Korea.; Yeom, JS (reprint author), Seoul Natl Univ, Coll Med, Dept Orthopaed Surg, Seongnam, South Korea.; Yeom, JS (reprint author), Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea.
EM highcervical@gmail.com
OI Yeom, Jin S/0000-0002-8241-5335
CR Akcakaya MO, 2016, CLIN NEUROL NEUROSUR, V145, P74, DOI 10.1016/j.clineuro.2016.04.004
   Arai Y, 2014, SPINE, V39, P332, DOI 10.1097/BRS.0000000000000136
   Arts MP, 2007, J NEUROSURG-SPINE, V7, P282, DOI 10.3171/SPI-07/09/282
   Birkenmaier C, 2013, PAIN PHYSICIAN, V16, P335
   Cavusoglu H, 2007, EUR SPINE J, V16, P2133, DOI 10.1007/s00586-007-0471-2
   Choi CM, 2016, ACTA NEUROCHIR, V158, P459, DOI 10.1007/s00701-015-2670-7
   Choi DJ, 2019, CLIN ORTHOP SURG, V11, P82, DOI 10.4055/cios.2019.11.1.82
   Choi DJ, 2018, ASIAN SPINE J, V12, P569, DOI 10.4184/asj.2018.12.3.569
   Choi DJ, 2016, ASIAN SPINE J, V10, P624, DOI 10.4184/asj.2016.10.4.624
   Choi KC, 2018, WORLD NEUROSURG, V116, pE750, DOI 10.1016/j.wneu.2018.05.085
   Copay AG, 2008, SPINE J, V8, P968, DOI 10.1016/j.spinee.2007.11.006
   Costa F, 2007, J NEUROSURG-SPINE, V7, P579, DOI 10.3171/SPI-07/12/579
   Demirayak M, 2015, ASIAN SPINE J, V9, P713, DOI 10.4184/asj.2015.9.5.713
   Dohzono S, 2017, ASIAN SPINE J, V11, P285, DOI 10.4184/asj.2017.11.2.285
   Eum JH, 2016, J NEUROSURG-SPINE, V24, P602, DOI 10.3171/2015.7.SPINE15304
   Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017
   Forsth P, 2016, NEW ENGL J MED, V374, P1413, DOI 10.1056/NEJMoa1513721
   Fujimoto T, 2015, CLIN NEUROL NEUROSUR, V131, P21, DOI 10.1016/j.clineuro.2015.01.014
   Heo DH, 2018, WORLD NEUROSURG, V120, pE684, DOI 10.1016/j.wneu.2018.08.144
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Katz JN, 2008, NEW ENGL J MED, V358, P818, DOI 10.1056/NEJMcp0708097
   Kim JE, 2019, ASIAN SPINE J, V13, P334, DOI 10.31616/asj.2018.0210
   Kim JE, 2019, WORLD NEUROSURG, V126, pE786, DOI 10.1016/j.wneu.2019.02.150
   Kim JE, 2018, CLIN ORTHOP SURG, V10, P508, DOI 10.4055/cios.2018.10.4.508
   Kim JE, 2018, CLIN ORTHOP SURG, V10, P439, DOI 10.4055/cios.2018.10.4.439
   Kim JE, 2018, CLIN ORTHOP SURG, V10, P328, DOI 10.4055/cios.2018.10.3.328
   Kim JE, 2018, J ORTHOP, V15, P366, DOI 10.1016/j.jor.2018.01.039
   Kim JE, 2018, CLIN ORTHOP SURG, V10, P248, DOI 10.4055/cios.2018.10.2.248
   Kim SK, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0725-1
   Komp M, 2015, PAIN PHYSICIAN, V18, P61
   Liu JM, 2017, INT ORTHOP, V41, P2297, DOI 10.1007/s00264-017-3619-7
   Mobbs RJ, 2014, J NEUROSURG-SPINE, V21, P179, DOI 10.3171/2014.4.SPINE13420
   Park SM, 2019, WORLD NEUROSURG, V122, pE1007, DOI 10.1016/j.wneu.2018.10.197
   Polikandriotis JA, 2013, J ORTHOP, V10, P13, DOI 10.1016/j.jor.2013.01.006
   Sairyo K, 2010, MINIM INVAS NEUROSUR, V53, P175, DOI 10.1055/s-0030-1262814
   Schizas C, 2010, SPINE, V35, P1919, DOI 10.1097/BRS.0b013e3181d359bd
   Soliman HM, 2015, SPINE J, V15, P2282, DOI 10.1016/j.spinee.2015.07.009
   Thome C, 2005, J NEUROSURG-SPINE, V3, P129, DOI 10.3171/spi.2005.3.2.0129
   Torudom Y, 2016, ASIAN SPINE J, V10, P335, DOI 10.4184/asj.2016.10.2.335
   Uehara M, 2014, ASIAN SPINE J, V8, P768, DOI 10.4184/asj.2014.8.6.768
   Wong AP, 2012, MINIM INVASIVE SURG, V2012, DOI 10.1155/2012/325095
NR 41
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E709
EP E718
DI 10.1016/j.wneu.2019.04.240
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100084
PM 31077891
DA 2020-05-12
ER

PT J
AU Pennington, Z
   Ahmed, AK
   Westbroek, EM
   Cottrill, E
   Lubelski, D
   Goodwin, ML
   Sciubba, DM
AF Pennington, Zach
   Ahmed, A. Karim
   Westbroek, Erick M.
   Cottrill, Ethan
   Lubelski, Dan
   Goodwin, Matthew L.
   Sciubba, Daniel M.
TI SINS Score and Stability: Evaluating the Need for Stabilization Within
   the Uncertain Category
SO WORLD NEUROSURGERY
LA English
DT Article
DE Mechanical instability; Pathological fracture; Spinal Instability
   Neoplastic Score; Spinal metastasis; Spine tumor
ID INSTABILITY NEOPLASTIC SCORE; VERTEBRAL COMPRESSION FRACTURE; SPINAL
   INSTABILITY; RADIOTHERAPY; RELIABILITY; METASTASES; OUTCOMES; PATIENT;
   CANCER; SYSTEM
AB OBJECTIVE: The Spinal Instability Neoplastic Score (SINS) is widely used to assess mechanical instability in metastatic spine disease. We sought to identify a cutoff within the "potentially unstable" category, above which lesions were more likely than not to be stabilized.
   METHODS: We retrospectively reviewed all patients consulted for metastatic spine disease over a 1-year period. Patients were included if they were neurologically intact and had complete medical records, including preoperative imaging of every tumor-involved level. Examined variables included epidural spinal cord compression, SINS, revised Tokuhashi grade, age at consultation, and Karnofsky Performance Status. The primary endpoint was whether or not the lesions were stabilized.
   RESULTS: The study cohort comprised 51 patients (average age, 61 +/- 2 years) with a total of 436 lesions; 50.5% were lytic, and 31.4% were blastic. The most common primaries were lung (n = 12), breast (n = 10) and prostate (n = 8). The median SINS across all lesions was 5. In both lesion- and patient-based analysis, a SINS >= 10 portended a >50% probability of undergoing stabilization; only 11% of all patients with a SINS <= 9 underwent instrumented fusion. Multivariable analysis demonstrated that SINS (odds ratio [OR], 2.44; P < 0.01) and Karnofsky Performance Status (OR, 1.10; P < 0.01) were independent predictors of stabilization.
   CONCLUSIONS: For vertebrae affected by metastatic disease, the decision to stabilize remains dependent on both the radiographic lesion properties and the patient's clinical picture. However, our results suggest that lesions with a SINS of <= 9 might not require stabilization.
C1 [Pennington, Zach; Ahmed, A. Karim; Westbroek, Erick M.; Cottrill, Ethan; Lubelski, Dan; Goodwin, Matthew L.; Sciubba, Daniel M.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
RP Sciubba, DM (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM dsciubb1@jhmi.edu
OI Cottrill, Ethan/0000-0001-5991-7962; Pennington,
   Zachary/0000-0001-8012-860X
CR Aiba H, 2016, SUPPORT CARE CANCER, V24, P3361, DOI 10.1007/s00520-016-3167-5
   Arana E, 2016, SPINE J, V16, P591, DOI 10.1016/j.spinee.2015.10.006
   Bakar D, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.6.FOCUS16166
   Barzilai O, 2017, J CLIN ONCOL, V35, P2419, DOI 10.1200/JCO.2017.72.7362
   Bilsky MH, 2010, J NEUROSURG-SPINE, V13, P324, DOI 10.3171/2010.3.SPINE09459
   Bollen L, 2017, SPINE, V42, pE956, DOI 10.1097/BRS.0000000000002058
   Campos M, 2014, SPINE J, V14, P1466, DOI 10.1016/j.spinee.2013.08.044
   Chang SY, 2018, ASIAN SPINE J, V12, P919, DOI 10.31616/asj.2018.12.5.919
   Dosani M, 2018, CURR ONCOL, V25, P53, DOI 10.3747/co.25.3835
   Fisher CG, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-69
   Fisher CG, 2010, SPINE, V35, pE1221, DOI 10.1097/BRS.0b013e3181e16ae2
   FORNASIER VL, 1975, CANCER, V36, P590, DOI 10.1002/1097-0142(197508)36:2<590::AID-CNCR2820360240>3.0.CO;2-F
   Fourney DR, 2011, J CLIN ONCOL, V29, P3072, DOI 10.1200/JCO.2010.34.3897
   Fox S, 2017, GLOB SPINE J, V7, P744, DOI 10.1177/2192568217697691
   Germano IM, 2016, CLIN EXP METASTAS, V33, P143, DOI 10.1007/s10585-015-9764-8
   Hussain I, 2018, SPINE J, V18, P261, DOI 10.1016/j.spinee.2017.07.008
   Lam TC, 2015, INT J RADIAT ONCOL, V93, P373, DOI 10.1016/j.ijrobp.2015.06.006
   Laufer I, 2013, ONCOLOGIST, V18, P744, DOI 10.1634/theoncologist.2012-0293
   Lee J, 2018, J NEUROSURG-SPINE, V28, P333, DOI 10.3171/2017.6.SPINE17282
   Luksanapruksa P, 2017, SPINE J, V17, P689, DOI 10.1016/j.spinee.2016.12.003
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Sahgal A, 2013, J CLIN ONCOL, V31, P3426, DOI 10.1200/JCO.2013.50.1411
   Sciubba DM, 2008, J NEUROSURG-SPINE, V8, P413, DOI 10.3171/SPI/2008/8/5/413
   Shi DD, 2018, PRACT RADIAT ONCOL, V8, pE285, DOI 10.1016/j.prro.2018.02.001
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Versteeg AL, 2016, SPINE, V41, pS231, DOI 10.1097/BRS.0000000000001822
   Versteeg AL, 2016, ONCOLOGIST, V21, P95, DOI 10.1634/theoncologist.2015-0266
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1034
EP E1047
DI 10.1016/j.wneu.2019.05.067
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100122
PM 31103761
DA 2020-05-12
ER

PT J
AU Pop, R
   Aloraini, Z
   Mihoc, D
   Burta, H
   Manisor, M
   Richter, JS
   Simu, M
   Chibbaro, S
   Proust, F
   Wolff, V
   Beaujeux, R
AF Pop, Raoul
   Aloraini, Ziad
   Mihoc, Dan
   Burta, Horatiu
   Manisor, Monica
   Richter, Johann Sebastian
   Simu, Mihaela
   Chibbaro, Salvatore
   Proust, Francois
   Wolff, Valerie
   Beaujeux, Remy
TI Embolization of very small (<= 3 mm) unruptured intracranial aneurysms:
   A large single-center experience on treatment of unruptured versus
   ruptured cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Balloon; Coil; Embolization; Very small aneurysms
ID ENDOVASCULAR TREATMENT; CONSECUTIVE SERIES; SIZE; MANAGEMENT; COILING
AB OBJECTIVE: In selected cases, embolization can be indicated for very small unruptured intracranial aneurysms. Previous studies reported high intraprocedural rupture rates. Recent improvements of endovascular devices and availability of small, soft platinum coils may lead to improved safety and efficacy profiles.
   METHODS: Retrospective review of embolizations for unruptured and ruptured intracranial aneurysms with maximal diameter <= 3 mm between January 1, 2009, and January 15, 2018. Infectious aneurysms were excluded. Patient files were used to extract aneurysm characteristics, complications, and immediate and long-term results.
   RESULTS: We identified 99 embolizations for 97 patients with 100 aneurysms, of which 70 aneurysms were unruptured. Initial success rate was 92.9%. We observed 1 asymptomatic intraprocedural perforation of an unruptured aneurysm, accounting for 1.4% of unruptured cases (1% of all embolizations). Neurological morbidity was 2.8% for unruptured aneurysms and 3.3% for ruptured aneurysms (P = 0.89). There was no procedural mortality. Follow-up was available for 85 (93.4%) patients. After 28.2 months (2-77), there was no aneurysmal bleeding; 2 (2.2%) aneurysms needed retreatment. Long-term results (30.5 months [3-77]) were available for all unruptured aneurysms. Among 64 successfully embolized unruptured aneurysms, 5 (7.8%) had residual neck filling and 1 (1.5%) needed retreatment. There were no significant differences in patient characteristics or complications between ruptured and unruptured aneurysms.
   CONCLUSIONS: In the context of technical evolution of endovascular devices, we observed a procedural perforation rate lower than previously reported, low morbidity and no mortality. Further prospective studies are warranted to update our knowledge about safety of embolization for very small intracranial aneurysms.
C1 [Pop, Raoul; Aloraini, Ziad; Mihoc, Dan; Burta, Horatiu; Manisor, Monica; Richter, Johann Sebastian; Beaujeux, Remy] Strasbourg Univ Hosp, Intervent Neuroradiol Dept, Strasbourg, France.
   [Pop, Raoul; Beaujeux, Remy] iHU Strasbourg, Strasbourg, France.
   [Simu, Mihaela] Victor Babes Univ Med, Neurol Dept, Timisoara, Romania.
   [Chibbaro, Salvatore; Proust, Francois] Strasbourg Univ Hosp, Neurosurg Dept, Strasbourg, France.
   [Wolff, Valerie] Strasbourg Univ Hosp, Vasc Neurol Dept, Strasbourg, France.
RP Pop, R (reprint author), Strasbourg Univ Hosp, Intervent Neuroradiol Dept, Strasbourg, France.; Pop, R (reprint author), iHU Strasbourg, Strasbourg, France.
EM pop.raoul@gmail.com
RI Pop, Raoul/S-9431-2019; Chibbaro, Salvatore/AAI-6368-2020
OI Pop, Raoul/0000-0003-4417-1496; 
CR Aishima K, 2016, WORLD NEUROSURG, V95, P434, DOI 10.1016/j.wneu.2016.08.060
   Bender MT, 2018, NEUROSURGERY, V83, P692, DOI 10.1093/neuros/nyx484
   Brinjikji W, 2010, STROKE, V41, P116, DOI 10.1161/STROKEAHA.109.566356
   Bruneau M, 2016, NEUROSURGERY, V78, P47, DOI 10.1227/NEU.0000000000000991
   Chang HS, 2016, WORLD NEUROSURG, V96, P302, DOI 10.1016/j.wneu.2016.09.017
   Fargen KM, 2018, J NEUROINTERV SURG, V10, P44, DOI 10.1136/neurintsurg-2016-012808
   Feng X, 2017, WORLD NEUROSURG, V103, P576, DOI 10.1016/j.wneu.2017.04.017
   Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1
   Hepokosi M, 2017, ANN INTERN MED, V166, pW20, DOI 10.7326/M17-0138
   Ikawa F, 2020, J NEUROSURG, V132, P69, DOI 10.3171/2018.9.JNS181736
   Ishibashi T, 2009, STROKE, V40, P313, DOI 10.1161/STROKEAHA.108.521674
   Iskandar A, 2011, INTERV NEURORADIOL, V17, P299, DOI 10.1177/159101991101700304
   Kim BJ, 2017, CEREBROVASC DIS, V43, P139, DOI 10.1159/000452347
   Kiran NAS, 2015, OPER NEUROSURG, V11, P3, DOI 10.1227/NEU.0000000000000557
   Korja M, 2018, STROKE, V49, P746, DOI 10.1161/STROKEAHA.117.019235
   Korja M, 2017, J NEUROSURG, V127, P748, DOI 10.3171/2016.9.JNS161085
   Li J, 2017, WORLD NEUROSURG, V99, P763, DOI 10.1016/j.wneu.2015.11.079
   Liu JG, 2019, WORLD NEUROSURG, V127, pE242, DOI 10.1016/j.wneu.2019.02.227
   Maeda Kazushi, 2018, No Shinkei Geka, V46, P303, DOI 10.11477/mf.1436203721
   Mocco J, 2018, NEUROSURGERY, V82, P491, DOI 10.1093/neuros/nyx226
   Narata AP, 2019, NEUROSURGERY, V84, P77, DOI 10.1093/neuros/nyy002
   Pierot L, 2010, STROKE, V41, P2855, DOI 10.1161/STROKEAHA.110.588830
   Rahman M, 2011, NEUROSURGERY, V68, P155, DOI 10.1227/NEU.0b013e3181ff357c
   Rahmanian A, 2018, WORLD NEUROSURG, V110, pE605, DOI 10.1016/j.wneu.2017.11.060
   Rahmanian A, 2017, WORLD NEUROSURG, V98, P470, DOI 10.1016/j.wneu.2016.11.086
   Sonobe M, 2010, STROKE, V41, P1969, DOI 10.1161/STROKEAHA.110.585059
   Spetzler RF, 2020, J NEUROSURG, V132, P771, DOI 10.3171/2018.8.JNS181846
   Starke RM, 2013, J NEUROINTERV SURG, V5, pIII66, DOI 10.1136/neurintsurg-2012-010537
   van Rooij WJ, 2009, AM J NEURORADIOL, V30, P835, DOI 10.3174/ajnr.A1429
   Varble N, 2018, STROKE, V49, P856, DOI 10.1161/STROKEAHA.117.019929
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Xu T, 2017, J NEUROINTERV SURG, V9, P278, DOI 10.1136/neurintsurg-2016-012294
   Yamaki VN, 2016, AM J NEURORADIOL, V37, P862, DOI 10.3174/ajnr.A4651
   Zhang YS, 2017, WORLD NEUROSURG, V100, P22, DOI 10.1016/j.wneu.2016.12.107
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1087
EP E1095
DI 10.1016/j.wneu.2019.05.070
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100124
PM 31103760
DA 2020-05-12
ER

PT J
AU Pujari, A
   Howard, BM
   Skukalek, SL
   Cherian, J
   Al-Bayati, A
   Tong, F
   Dion, JE
   Cawley, CM
   Grossberg, JA
AF Pujari, Amit
   Howard, Brian M.
   Skukalek, Susana L.
   Cherian, Jacob
   Al-Bayati, Alhamza
   Tong, Frank
   Dion, Jacque E.
   Cawley, C. Michael
   Grossberg, Jonathan A.
TI Hemodynamic Fate of the Precommunicating Anterior Cerebral Artery Is
   Predicted by Vessel Dominance After Pipeline Embolization Device
   Deployment Across the Internal Carotid Artery Terminus
SO WORLD NEUROSURGERY
LA English
DT Article
DE A1 segment; Pipeline; Vessel patency
ID FLOW-DIVERSION TREATMENT; ENDOVASCULAR TREATMENT; COMMUNICATING ARTERY;
   OPHTHALMIC ARTERY; CHOROIDAL ARTERY; MODIFYING FLOW; ANEURYSMS; PATENCY
AB BACKGROUND: The Pipeline embolization device (PED) is commonly used for the treatment of distal internal carotid artery (ICA) aneurysms, which often require placing the stent across the origin of the precommunicating segment of the anterior cerebral artery (ACA-A1). We sought to characterize the clinical and angiographic consequences of this maneuver.
   METHODS: We performed a retrospective review of a prospectively collected database of patients treated with the PED at a single academic center from 2011 to 2017 to find patients for whom the PED was extended across the origin of the ACA-A1. The patient demographic data, pretreatment angiographic imaging findings, sizing of the bilateral A1 and ipsilateral M1 segment of the middle cerebral artery (MCA-M1), and follow-up angiographic and clinical imaging findings were recorded.
   RESULTS: A total of 27 patients were included in the present study (8 men and 19 women; age, 52 + 14.9 years). Follow-up angiography was conducted at a median of 9.2 months (interquartile range, 6; range, 5-84). The covered A1 segment was patent in 17 patients (63%). The covered ACA-A1/ipsilateral MCA-M1 ratio was 1.43 times greater for the patent ACA-A1 segments than those that were occluded (P = 0.0006). Similarly, the covered ACA-A1/contralateral ACA-A1 ratio was significantly larger statistically (1.64; P < 0.0001) for the patent ACA-A1 segments than that for those that were occluded. None of the patients developed clinical or radiographic signs of ACA stroke. The modified Rankin scale worsened for 1 patient during follow-up owing to a further decline of presenting vision loss.
   CONCLUSIONS: The PED can be used to treat aneurysms with deployment from the MCA-M1 to the ICA without resulting in ACA stroke. Ipsilateral A1 segment dominance might be predictive of continued blood flow into the ACA after deployment at this location.
C1 [Pujari, Amit; Howard, Brian M.; Skukalek, Susana L.; Cherian, Jacob; Cawley, C. Michael; Grossberg, Jonathan A.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.
   [Tong, Frank] Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA.
   [Al-Bayati, Alhamza] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
   [Dion, Jacque E.] Microvention Inc, Aliso Viejo, CA USA.
RP Grossberg, JA (reprint author), Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.
EM Jonathan.A.Grossberg@Emory.edu
CR [Anonymous], 2019, PROSPECTIVE STUDY EM
   Brinjikji W, 2015, AM J NEURORADIOL, V36, P537, DOI 10.3174/ajnr.A4139
   Brinjikji W, 2014, CLIN NEUROL NEUROSUR, V120, P84, DOI 10.1016/j.clineuro.2014.02.018
   Chalouhi N, 2015, NEUROSURGERY, V77, P581, DOI 10.1227/NEU.0000000000000887
   Colby GP, 2017, J NEUROINTERV SURG, V9, P679, DOI 10.1136/neurintsurg-2016-012946
   Dabus G, 2017, J NEUROINTERV SURG, V9, P147, DOI 10.1136/neurintsurg-2016-012519
   Durst CR, 2016, J NEUROINTERV SURG, V8, P919, DOI 10.1136/neurintsurg-2015-011887
   Gascou G, 2015, AM J NEURORADIOL, V36, P725, DOI 10.3174/ajnr.A4191
   Heit JJ, 2017, INTERV NEURORADIOL, V23, DOI 10.1177/1591019917722514
   Jabbour P, 2013, NEUROSURGERY, V73, P113, DOI 10.1227/01.neu.0000429844.06955.39
   Mascitelli JR, 2015, J NEUROINTERV SURG, V7, P496, DOI 10.1136/neurintsurg-2014-011258
   McTaggart RA, 2013, NEUROSURGERY, V72, P237, DOI 10.1227/NEU.0b013e31827fc9be
   Nelson PK, 2011, AM J NEURORADIOL, V32, P34, DOI 10.3174/ajnr.A2421
   Nossek E, 2014, AM J NEURORADIOL, V35, P2125, DOI 10.3174/ajnr.A4013
   Nossek E, 2015, J NEUROINTERV SURG, V7, P351, DOI 10.1136/neurintsurg-2014-011183
   Puffer RC, 2012, J NEUROSURG, V116, P892, DOI 10.3171/2011.11.JNS111612
   Quinn TJ, 2009, INT J STROKE, V4, P200, DOI 10.1111/j.1747-4949.2009.00271.x
   Rangel-Castilla L, 2017, J NEUROSURG, V126, P1064, DOI 10.3171/2016.4.JNS16147
   Raz E, 2015, AM J NEURORADIOL, V36, P937, DOI 10.3174/ajnr.A4217
   Roy AK, 2018, NEUROSURGERY, V82, P695, DOI 10.1093/neuros/nyx293
   Roy D, 2001, STROKE, V32, P1998, DOI 10.1161/hs0901.095600
   Shapiro M, 2012, AM J NEURORADIOL, V33, P159, DOI 10.3174/ajnr.A2719
   Vedantam A, 2015, NEUROSURGERY, V76, P173, DOI 10.1227/NEU.0000000000000595
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E688
EP E693
DI 10.1016/j.wneu.2019.04.234
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100081
PM 31075493
DA 2020-05-12
ER

PT J
AU Raffa, G
   Scibilia, A
   Conti, A
   Cardali, SM
   Rizzo, V
   Terranova, C
   Quattropani, MC
   Marzano, G
   Ricciardo, G
   Vinci, SL
   Germano, A
AF Raffa, Giovanni
   Scibilia, Antonino
   Conti, Alfredo
   Cardali, Salvatore Massimiliano
   Rizzo, Vincenzo
   Terranova, Carmen
   Quattropani, Maria Catena
   Marzano, Giuseppina
   Ricciardo, Giuseppe
   Vinci, Sergio Lucio
   Germano, Antonino
TI Multimodal Surgical Treatment of High-Grade Gliomas in the Motor Area:
   The Impact of the Combination of Navigated Transcranial Magnetic
   Stimulation and Fluorescein-Guided Resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumors; Corticospinal tract; DTI tractography; High-grade gliomas;
   Motor cortex; Navigated transcranial magnetic stimulation;
   Sodium-fluorescein
ID DTI FIBER TRACKING; EVOKED-POTENTIALS; CORTICOSPINAL TRACT; LANGUAGE
   PATHWAYS; BRAIN-TUMORS; GLIOBLASTOMA-MULTIFORME; SURGERY; TRACTOGRAPHY;
   EXTENT; NEURONAVIGATION
AB BACKGROUND: Fluorescein-guided surgery of high-grade gliomas (HGGs) increases the extent of tumor resection but its efficacy has been questioned, especially for tumors located close to functional networks. In these cases, navigated transcranial magnetic stimulation (nTMS) may be used to plan and guide a safe resection. The aim of this study was to assess the impact of these techniques combined with intraoperative neurophysiologic mapping (IONM) to achieve the maximal safe resection of tumors located in the motor area.
   METHODS: We collected data of patients operated using a multimodal combination of sodium fluorescein-guided resection, nTMS motor planning, and IONM for HGGs in the motor area. The nTMS planning accuracy, extent of resection, and postoperative motor and functional status were compared with a matched control group of patients with HGG operated on only by IONM-guided resection.
   RESULTS: Forty-one patients treated by multimodal approach (group A) and 41 controls (group B) were included. The nTMS-based planning reliably identified the tumor/motor pathway spatial relationship (accuracy, 92.68%). We obtained in group A versus controls a higher gross total resection rate (73.17% vs. 51.22%; P = 0.04), and a reduction of cases with new permanent motor deficits (9.75% vs. 29.27%; P = 0.04) or Karnofsky Performance Status worsening (12.19% vs. 31.71%; P = 0.03).
   CONCLUSIONS: This study supports the role of the combination of sodium fluorescein-guided resection and nTMS-based planning for surgery of HGGs close to the motor pathway. This multimodal approach in combination with IONM may lead to customized preoperative planning, increased extent of resection, and improved functional outcome, compared with standard IONM-guided surgery.
C1 [Raffa, Giovanni; Scibilia, Antonino; Conti, Alfredo; Cardali, Salvatore Massimiliano; Ricciardo, Giuseppe; Germano, Antonino] Univ Messina, BIOMORF Dept, Div Neurosurg, Messina, Italy.
   [Rizzo, Vincenzo; Terranova, Carmen] Univ Messina, Dept Clin & Expt Med, Div Neurol, Messina, Italy.
   [Quattropani, Maria Catena; Marzano, Giuseppina] Univ Messina, Dept Clin & Expt Med, Messina, Italy.
   [Vinci, Sergio Lucio] Univ Messina, BIOMORF Dept, Div Neuroradiol, Messina, Italy.
   [Scibilia, Antonino] Univ Strasbourg, Div Neurosurg, Strasbourg, France.
RP Raffa, G (reprint author), Univ Messina, BIOMORF Dept, Div Neurosurg, Messina, Italy.
EM giovanni.raffa@unime.it
RI Cardali, Salvatore/AAC-1381-2019; Quattropani, Maria C./G-3504-2015;
   Raffa, Giovanni/K-7972-2016
OI Quattropani, Maria C./0000-0003-0711-6412; Raffa,
   Giovanni/0000-0001-8623-4964
CR Acerbi F, 2018, CLIN CANCER RES, V24, P52, DOI 10.1158/1078-0432.CCR-17-1184
   Acerbi F, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.11.FOCUS13487
   Acerbi F, 2013, ACTA NEUROCHIR, V155, P1277, DOI 10.1007/s00701-013-1734-9
   Azabou E, 2014, SPINE J, V14, P1214, DOI 10.1016/j.spinee.2013.08.017
   Bello L, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09240
   BERGER MS, 1994, CANCER, V74, P1784, DOI 10.1002/1097-0142(19940915)74:6<1784::AID-CNCR2820740622>3.0.CO;2-D
   BERGER MS, 1992, STEREOT FUNCT NEUROS, V58, P153, DOI 10.1159/000098989
   Bette S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05767-2
   Bette S, 2016, ONCOTARGET, V7, P61945, DOI 10.18632/oncotarget.11482
   Bloch O, 2012, J NEUROSURG, V117, P1032, DOI 10.3171/2012.9.JNS12504
   Bongetta D, 2016, WORLD NEUROSURG, V88, P54, DOI 10.1016/j.wneu.2016.01.017
   Bozzao A, 2010, EUR RADIOL, V20, P2475, DOI 10.1007/s00330-010-1806-7
   Butenschon VM, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.3.FOCUS1830
   Compston A, 2010, BRAIN, V133, P2835, DOI 10.1093/brain/awq274
   Conti A, 2014, OPER NEUROSURG, V10, P542, DOI 10.1227/NEU.0000000000000502
   D'Amico RS, 2017, WORLD NEUROSURG, V103, P538, DOI 10.1016/j.wneu.2017.04.041
   Folaron M, 2019, J NEUROSURG, V131, P724, DOI 10.3171/2018.4.JNS172644
   Frey D, 2012, NEUROIMAGE, V62, P1600, DOI 10.1016/j.neuroimage.2012.05.059
   Frey D, 2014, NEURO-ONCOLOGY, V16, P1365, DOI 10.1093/neuonc/nou110
   Gempt J, 2013, J NEUROSURG, V118, P801, DOI 10.3171/2012.12.JNS12125
   Germano A, 2013, NEUROSURG REV, P36
   Gessler F, 2015, NEUROSURGERY, V77, P16, DOI 10.1227/NEU.0000000000000729
   Grasso G, 2019, WORLD NEUROSURG, V123, P256, DOI 10.1016/j.wneu.2018.12.037
   Henker C, 2017, J NEURO-ONCOL, V135, P391, DOI 10.1007/s11060-017-2587-5
   Hervey-Jumper SL, 2016, J NEURO-ONCOL, V130, P269, DOI 10.1007/s11060-016-2110-4
   Hervey-Jumper SL, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0284-7
   Holton T, 2019, NEUROSURG CLIN N AM, V30, P65, DOI 10.1016/j.nec.2018.08.012
   Hong J, 2019, CURR PROB CANCER, V43, P236, DOI 10.1016/j.currproblcancer.2018.07.007
   Ille S, 2016, ACTA NEUROCHIR, V158, P2265, DOI 10.1007/s00701-016-2968-0
   Jakola AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101805
   Kamiya-Matsuoka C, 2015, J NEURO-ONCOL, V125, P143, DOI 10.1007/s11060-015-1880-4
   Keles GE, 2004, J NEUROSURG, V100, P369, DOI 10.3171/jns.2004.100.3.0369
   Kim SM, 2013, J KOREAN MED SCI, V28, P1261, DOI 10.3346/jkms.2013.28.9.1261
   Kim SM, 2012, CLIN NEUROPHYSIOL, V123, P1465, DOI 10.1016/j.clinph.2011.11.035
   Korn A, 2015, ACTA NEUROCHIR, V157, P819, DOI 10.1007/s00701-014-2307-2
   Krieg SM, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00261
   Krieg SM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1258-1
   Krieg SM, 2014, NEURO-ONCOLOGY, V16, P1274, DOI 10.1093/neuonc/nou007
   Krieg SM, 2013, J NEUROSURG, V118, P1269, DOI 10.3171/2013.2.JNS121752
   Krieg SM, 2012, NEUROSURGERY, V70, P1060, DOI 10.1227/NEU.0b013e31823f5ade
   Krivosheya D, 2016, J NEURO-ONCOL, V130, P243, DOI 10.1007/s11060-016-2171-4
   Kubben PL, 2010, NEUROSURGERY, V67, P1329, DOI 10.1227/NEU.0b013e3181efbb08
   Lovato RM, 2017, WORLD NEUROSURG, V104, P61, DOI 10.1016/j.wneu.2017.04.169
   Lu S, 2003, AM J NEURORADIOL, V24, P937
   Maesawa S, 2010, WORLD NEUROSURG, V74, P153, DOI 10.1016/j.wneu.2010.03.022
   Mahboob S, 2016, WORLD NEUROSURG, V92, P255, DOI 10.1016/j.wneu.2016.05.007
   Matthies C, 2011, CLIN NEUROL NEUROSUR, V113, P872, DOI 10.1016/j.clineuro.2011.06.011
   Maugeri R, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8020031
   Merlo L, 2011, J NEUROTRAUM, V28, P2493, DOI 10.1089/neu.2010.1624
   MOORE GE, 1948, J NEUROSURG, V5, P392, DOI 10.3171/jns.1948.5.4.0392
   Nimsky C, 2005, RADIOLOGY, V234, P218, DOI 10.1148/radiol.2341031984
   Orringer DA, 2012, EXPERT REV MED DEVIC, V9, P491, DOI [10.1586/ERD.12.42, 10.1586/erd.12.42]
   Ottenhausen M, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.10.FOCUS14611
   Picht T, 2014, J NEUROONCOL, V120, P1015
   Picht T, 2013, ACTA NEUROCHIR, V155, P1813, DOI 10.1007/s00701-013-1839-1
   Raabe A, 2014, J NEUROSURG, V120, P1015, DOI 10.3171/2014.1.JNS13909
   Raffa G, 2017, NAVIGATED TRANSCRANI, P97
   Raffa G, 2019, CLIN NEUROL NEUROSUR, V180, P7, DOI 10.1016/j.clineuro.2019.03.003
   Raffa G, 2018, CLIN NEUROL NEUROSUR, V168, P127, DOI 10.1016/j.clineuro.2018.03.009
   Raffa G, 2018, NEUROSURGERY, V83, P768, DOI 10.1093/neuros/nyx554
   Raffa G, 2017, ACTA NEUROCHIR SUPPL, V124, P251, DOI 10.1007/978-3-319-39546-3_37
   Raffa G, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00552
   Rizzo V, 2014, NEUROSCI LETT, V583, P136, DOI 10.1016/j.neulet.2014.09.017
   Romano A, 2011, NEUROSURGERY, V69, P696, DOI 10.1227/NEU.0b013e31821a8555
   Romstock J, 2000, J NEUROSURG, V93, P586, DOI 10.3171/jns.2000.93.4.0586
   Rosenstock T, 2016, J NEUROSURG, P1
   Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6
   Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998
   Sanai N, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09266
   Schucht P, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.10.FOCUS14524
   Scibilia A, 2018, NEUROL RES, V40, P241, DOI 10.1080/01616412.2018.1429203
   Scibilia A, 2017, ACTA NEUROCHIR SUPPL, V124, P263, DOI 10.1007/978-3-319-39546-3_38
   Scibilia A, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16141
   Seidel K, 2013, J NEUROSURG, V118, P287, DOI 10.3171/2012.10.JNS12895
   Sollmann N, 2016, J NEUROSCI METH, V267, P45, DOI 10.1016/j.jneumeth.2016.04.002
   Sollmann N, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1299-5
   Souza VH, 2018, J NEUROSCI METH, V309, P109, DOI 10.1016/j.jneumeth.2018.08.023
   Stummer W, 2000, J NEUROSURG, V93, P1003, DOI 10.3171/jns.2000.93.6.1003
   Takahashi S, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.1.FOCUS133
   Tamkus AA, 2018, SPINE J, V18, P276, DOI 10.1016/j.spinee.2017.07.005
   Tonn Jorg-Christian, 2008, Clin Neurosurg, V55, P20
   YATES JW, 1980, CANCER, V45, P2220, DOI 10.1002/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q
   Yen PS, 2009, SURG NEUROL, V72, P464, DOI 10.1016/j.surneu.2009.05.008
   Zhang NN, 2017, BIOMED RES INT, DOI 10.1155/2017/7865747
NR 84
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E378
EP E390
DI 10.1016/j.wneu.2019.04.158
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100044
PM 31029822
DA 2020-05-12
ER

PT J
AU Raper, DMS
   Chen, CJ
   Kumar, J
   Kalani, MY
   Park, MS
AF Raper, Daniel M. S.
   Chen, Ching-Jen
   Kumar, Jeyan
   Kalani, M. Yashar
   Park, Min S.
TI Predicting Outcomes for Cerebral Aneurysms Treated with Flow Diversion:
   A Comparison Between 4 Grading Scales
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Endovascular; Flow diversion; Outcomes
ID PIPELINE EMBOLIZATION DEVICE; INTRACRANIAL ANEURYSMS; ARTERY ANEURYSMS;
   COIL EMBOLIZATION; SAFETY; EXPERIENCE
AB OBJECTIVE: Despite the development of 4 grading scales of angiographic outcome after flow diversion for cerebral aneurysms, none have been widely adopted in the neurosurgical literature, nor have any been validated in an independent dataset. We evaluated the reported grading scales for their ability to predict aneurysm occlusion at follow-up.
   METHODS: Four reported grading scales were applied in a retrospective analysis of our prospectively maintained institutional database of patients with intracranial aneurysms treated with flow-diverting stents. Analysis of patient factors, aneurysm factors, and outcomes was made to compare the grading scales' ability to predict aneurysm occlusion.
   RESULTS: Ninety-nine aneurysms in 90 patients treated at our institution between 2011 and 2018 were included in the analysis. Lower Flow-Diverting Stent Score (FDSS) scores were associated with higher rates of aneurysm occlusion at final follow-up (P=0.004). The OKM, Kamran-Byrne, and SMART scales scores were not associated with aneurysm occlusion at final follow-up even after adjustments for baseline differences. Area under the receiver operating characteristic curve for the FDSS was 0.675 (0.534-0.816).
   CONCLUSIONS: Although the FDSS was the only reported grading scale that was significantly associated with occlusion at follow-up, its ability to predict occlusion fell below the typical level for widespread clinical utility. The high rate of eventual occlusion of most aneurysms after flow diversion likely limits the clinical utility of a grading score for this application.
C1 [Raper, Daniel M. S.; Chen, Ching-Jen; Kumar, Jeyan; Kalani, M. Yashar; Park, Min S.] Univ Virginia, Dept Neurosurg, Charlottesville, VA 22904 USA.
RP Park, MS (reprint author), Univ Virginia, Dept Neurosurg, Charlottesville, VA 22904 USA.
EM mp2tq@hscmail.mcc.virginia.edu
CR Albuquerque FC, 2015, J NEUROINTERV SURG, V7, P641, DOI 10.1136/neurintsurg-2014-011340
   Becske T, 2017, J NEUROSURG, V127, P81, DOI 10.3171/2015.6.JNS15311
   Bhogal P, 2017, J NEUROINTERV SURG, V9, P471, DOI 10.1136/neurintsurg-2016-012781
   Chalouhi N, 2017, NEUROSURGERY, V81, P92, DOI 10.1093/neuros/nyw070
   Chalouhi N, 2014, J NEUROINTERV SURG, V6, P19, DOI 10.1136/neurintsurg-2012-010612
   Clarencon F, 2017, CLIN NEURORADIOL, V27, P51, DOI 10.1007/s00062-015-0441-8
   Dabus G, 2017, J NEUROINTERV SURG, V9, P147, DOI 10.1136/neurintsurg-2016-012519
   de Carvalho FM, 2017, J NEUROINTERV SURG, V9, P674, DOI 10.1136/neurintsurg-2016-012443
   Grunwald IQ, 2012, ACTA NEUROCHIR, V154, P21, DOI 10.1007/s00701-011-1177-0
   Gupta R, 2018, J NEUROSURG, P1
   Kallmes DF, 2017, J NEUROSURG, V127, P775, DOI 10.3171/2016.8.JNS16467
   Kamran M, 2011, NEURORADIOLOGY, V53, P501, DOI 10.1007/s00234-010-0767-5
   Levitt MR, 2016, AM J NEURORADIOL, V37, P487, DOI 10.3174/ajnr.A4550
   Lin N, 2016, NEUROSURGERY, V79, P14, DOI 10.1227/NEU.0000000000001117
   Martinez-Galdamez M, 2015, J NEUROINTERV SURG, V7, P816, DOI 10.1136/neurintsurg-2014-011355
   Mazur MD, 2016, J NEUROINTERV SURG, V8, P1294, DOI 10.1136/neurintsurg-2015-012193
   McAuliffe W, 2012, AM J NEURORADIOL, V33, P164, DOI 10.3174/ajnr.A2727
   Munich SA, 2014, J NEUROSURG, V121, P1077, DOI 10.3171/2014.7.JNS132595
   Nossek E, 2017, J CLIN NEUROSCI, V35, P133, DOI 10.1016/j.jocn.2016.10.041
   O'Kelly CJ, 2013, AM J NEURORADIOL, V34, P381, DOI 10.3174/ajnr.A3224
   O'Kelly CJ, 2010, INTERV NEURORADIOL, V16, P133, DOI 10.1177/159101991001600204
   Park MS, 2016, AM J NEURORADIOL, V37, P1127, DOI 10.3174/ajnr.A4678
   Park MS, 2017, J NEUROINTERV SURG, V9, P1060, DOI 10.1136/neurintsurg-2016-012688
   Park MS, 2016, J NEUROSURG, V125, P137, DOI 10.3171/2015.7.JNS15582
   Phillips TJ, 2012, AM J NEURORADIOL, V33, P1225, DOI 10.3174/ajnr.A3166
   Puri AS, 2016, NEURORADIOLOGY, V58, P267, DOI 10.1007/s00234-015-1630-5
   Zanaty M, 2014, NEURORADIOLOGY, V56, P381, DOI 10.1007/s00234-014-1339-x
   Zou KH, 2007, CIRCULATION, V115, P654, DOI 10.1161/CIRCULATIONAHA.105.594929
   Zumofen DW, 2015, AM J NEURORADIOL, V36, P1299, DOI 10.3174/ajnr.A4261
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E209
EP E216
DI 10.1016/j.wneu.2019.04.099
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100023
PM 31004852
DA 2020-05-12
ER

PT J
AU Rasmussen, R
   Bache, S
   Stavngaard, T
   Moller, K
AF Rasmussen, Rune
   Bache, Soren
   Stavngaard, Trine
   Moller, Kirsten
TI Plasma Levels of IL-6, IL-8, IL-10, ICAM-1, VCAM-1, IFN gamma, and TNF
   alpha are not Associated with Delayed Cerebral Ischemia, Cerebral
   Vasospasm, or Clinical Outcome in Patients with Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biomarkers; Delayed cerebral ischemia; Inflammation; Subarachnoid
   hemorrhage; Vasospasm
ID C-REACTIVE PROTEIN; INTERCELLULAR-ADHESION MOLECULE-1;
   CEREBROSPINAL-FLUID; INTERLEUKIN-6; SERUM; MARKERS; PROSTACYCLIN;
   PREDICTOR; DEFICITS; DAMAGE
AB BACKGROUND: Delayed cerebral ischemia (DCI) is a serious and frequent complication following subarachnoid hemorrhage (SAH). The pathophysiology behind DCI remains poorly understood, but inflammation has been proposed to play a significant role. This study investigated the relationship between plasma levels of some of the most important inflammatory markers and DCI, cerebral vasospasm, and functional outcome in patients with SAH.
   METHODS: In 90 patients with SAH, interleukin-6, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, high sensitivity C-reactive protein (HsCRP), interleukin-8, interleukin-10, interferon gamma, and tumor necrosis factor alpha were measured in peripheral blood day 3 and day 8 after SAH. Any occurrence of DCI or infection was recorded, and computed tomography angiography was performed on day 8. Clinical outcome was assessed after 3 months.
   RESULTS: HsCRP on day 3 was higher in patients with angiographic vasospasm (P = 0.003), and HsCRP on day 8 was higher in patients with poor outcome (P = 0.014). No association with DCI, vasospasm, or outcome was found for any of the remaining analyzed substances.
   CONCLUSIONS: High plasma levels of HsCRP were significantly associated with angiographic vasospasm and clinical outcome. Plasma levels of interleukin-6, vascular cell adhesion molecule-1, intercellular adhesion molecule-1, interleukin-8, interleukin-10, interferon gamma, and tumor necrosis factor alpha were not associated with DCI, angiographic vasospasm, or clinical outcome at 3 months.
C1 [Rasmussen, Rune] Copenhagen Univ Hosp, Rigshosp, Neurosci Ctr, Dept Neurosurg, Copenhagen, Denmark.
   [Bache, Soren; Moller, Kirsten] Copenhagen Univ Hosp, Rigshosp, Neurosci Ctr, Dept Neuroanesthesiol, Copenhagen, Denmark.
   [Stavngaard, Trine] Copenhagen Univ Hosp, Rigshosp, Diagnost Ctr, Dept Radiol, Copenhagen, Denmark.
RP Rasmussen, R (reprint author), Copenhagen Univ Hosp, Rigshosp, Neurosci Ctr, Dept Neurosurg, Copenhagen, Denmark.
EM rune333@gmail.com
CR Al-Drawi AS, 2016, ANN AGR ENV MED, V23, P654, DOI 10.5604/12321966.1226862
   CASTELL JV, 1988, FEBS LETT, V232, P347, DOI 10.1016/0014-5793(88)80766-X
   Chaudhry SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122580
   Csajbok LZ, 2015, ACTA ANAESTH SCAND, V59, P255, DOI 10.1111/aas.12441
   DORSCH NWC, 1995, BRIT J NEUROSURG, V9, P403, DOI 10.1080/02688699550041403
   Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102
   Fountas KN, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS08311
   Frijns CJM, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.081539
   Gybel-Brask M, 2017, ACTA NEUROCHIR, V159, P1073, DOI 10.1007/s00701-017-3168-2
   Hendryk S, 2004, NEUROENDOCRINOL LETT, V25, P141
   Hollig A, 2015, CLIN NEUROL NEUROSUR, V138, P177, DOI 10.1016/j.clineuro.2015.08.030
   Juvela S, 2012, ACTA NEUROCHIR, V154, P397, DOI 10.1007/s00701-011-1243-7
   Kao HY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139252
   Kaynar MY, 2004, J NEUROSURG, V101, P1030, DOI 10.3171/jns.2004.101.6.1030
   Kiiski Heikki, 2017, eNeurologicalSci, V6, P55, DOI 10.1016/j.ensci.2016.11.010
   Kubo Y, 2008, SURG NEUROL, V69, P592, DOI 10.1016/j.surneu.2008.02.014
   Kwon KY, 2001, J KOREAN MED SCI, V16, P774, DOI 10.3346/jkms.2001.16.6.774
   Lopez-Cortes LF, 2000, CRIT CARE MED, V28, P215, DOI 10.1097/00003246-200001000-00035
   Macdonald RL, 2014, NAT REV NEUROL, V10, P44, DOI 10.1038/nrneurol.2013.246
   Mack WJ, 2002, J NEUROSURG, V96, P71, DOI 10.3171/jns.2002.96.1.0071
   MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562
   McMahon CJ, 2013, J NEUROINTERV SURG, V5, P512, DOI 10.1136/neurintsurg-2012-010386
   Mocco J, 2002, J NEUROSURG, V97, P537, DOI 10.3171/jns.2002.97.3.0537
   Nakahara T, 2009, NEUROCRIT CARE, V11, P362, DOI 10.1007/s12028-009-9276-y
   Osuka K, 1998, ACTA NEUROCHIR, V140, P943, DOI 10.1007/s007010050197
   Rasmussen R, 2015, STROKE, V46, P37, DOI 10.1161/STROKEAHA.114.007470
   Rasmussen R, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-102
   Romero FR, 2014, ACTA CIR BRAS, V29, P340, DOI 10.1590/S0102-86502014000500009
   Rothoerl RD, 2006, CEREBROVASC DIS, V22, P143, DOI 10.1159/000093243
   Sarrafzadeh A, 2010, NEUROCRIT CARE, V13, P339, DOI 10.1007/s12028-010-9432-4
   Schoch B, 2007, NEUROSURGERY, V60, P828, DOI 10.1227/01.NEU.0000255440.21495.80
   Srinivasan A, 2016, WORLD NEUROSURG, V90, P91, DOI 10.1016/j.wneu.2016.02.049
   Stein SC, 2006, NEUROSURGERY, V59, P781, DOI 10.1227/01.NEU.0000227519.27569.45
   Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275
   Willeke P, 2009, SEMIN ARTHRITIS RHEU, V39, P197, DOI 10.1016/j.semarthrit.2008.04.002
   Witkowska AM, 2009, ARCH IMMUNOL THER EX, V57, P137, DOI 10.1007/s00005-009-0010-4
   Zhou Y, 2017, WORLD NEUROSURG, V108, P206, DOI 10.1016/j.wneu.2017.08.091
NR 37
TC 1
Z9 1
U1 3
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1131
EP E1136
DI 10.1016/j.wneu.2019.05.102
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100130
PM 31121365
DA 2020-05-12
ER

PT J
AU Richetta, C
   Shofty, B
   Gurevich, A
   Grossman, R
AF Richetta, Carla
   Shofty, Ben
   Gurevich, Alexey
   Grossman, Rachel
TI Valve Failure in Ventriculoperitoneal Shunts of Neuro-Oncologic
   Patients: A Historical Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Shunt revision; Valve failure; Ventriculoperitoneal shunt
ID COMMUNICATING HYDROCEPHALUS; ADJUVANT RADIOCHEMOTHERAPY; MANAGEMENT;
   HEMORRHAGE; RESECTION; SURVIVAL
AB OBJECTIVE: To investigate malfunctioning of ventriculoperitoneal shunt (VPS) valves in patients with brain tumors compared with patients with VPS for nontumoral etiologies to identify risk factors for shunt malfunction.
   METHODS: Medical charts of all adult patients who underwent VPS surgery for hydrocephalus between 2011 and 2016 were reviewed. Incidence and risk factors for revision surgery due to valve malfunction were identified in patients with brain tumors (group A) and patients without brain tumors (group B).
   RESULTS: Group A comprised 89 patients, and group B comprised 164 patients. The median follow-up time was 17 months for the entire cohort (9.4 months for group A vs. 25 months for group B, P< 0.001). VPS revision was performed in 60 patients (23.7%); 11 revisions involved valve failures necessitating valve replacement. Valve failures were significantly more common in group A (10 group A patients vs. 1 group B patient, P < 0.001). The distal or proximal shunt revision rate for reasons other than the valve was similar for both groups. Group A patients had a significantly higher cerebrospinal fluid protein level (44.5 mg/dL vs. 27.79 mg/dL, P< 0.05), and patients with valve failure had a 3-fold higher cerebrospinal fluid protein level compared with group A patients who experienced any type of shunt failure (96.3 mg/dL vs. 30.6 mg/dL, P < 0.05).
   CONCLUSIONS: Shunt malfunction occurred mainly in patients with brain tumors and high cerebrospinal fluid protein levels. These patients are at high risk of valve failure and should be closely observed for emergent valve revision.
C1 [Richetta, Carla; Shofty, Ben; Gurevich, Alexey; Grossman, Rachel] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Med Ctr, Dept Neurosurg, Tel Aviv, Israel.
RP Grossman, R (reprint author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv Med Ctr, Dept Neurosurg, Tel Aviv, Israel.
EM rachelgr@tasmc.health.gov.il
OI Gurevich, Alexey/0000-0001-8031-2028; grossman,
   rachel/0000-0001-7741-375X
CR Bergsneider M, 2008, NEUROSURGERY, V62, P643, DOI [10.1227/01.NEU.0000296954.22901.C6, 10.1227/01.neu.0000316269.82467.f7]
   de la Fuente MI, 2014, ANN CLIN TRANSL NEUR, V1, P45, DOI 10.1002/acn3.17
   Fischer CM, 2014, CLIN NEUROL NEUROSUR, V120, P27, DOI 10.1016/j.clineuro.2014.02.012
   Hamilton MG, 2009, SEMIN PEDIATR NEUROL, V16, P34, DOI 10.1016/j.spen.2009.02.001
   Hoh BL, 2008, NEUROSURGERY, V63, P70, DOI 10.1227/01.NEU.0000335072.32105.38
   Hong BJ, 2018, FLUIDS BARRIERS CNS, V15, DOI 10.1186/s12987-018-0101-x
   Inamasu J, 2003, CLIN NEUROL NEUROSUR, V106, P9, DOI 10.1016/S0303-8467(03)00060-X
   Jeremiah KJ, 2016, J CLIN NEUROSCI, V27, P95, DOI 10.1016/j.jocn.2015.07.026
   Khan F, 2016, TURK NEUROSURG, V26, P369, DOI 10.5137/1019-5149.JTN.11447-14.1
   Lee L, 2014, J NEUROSURG, V121, P899, DOI 10.3171/2014.3.JNS131088
   Marquardt G, 2002, ACTA NEUROCHIR, V144, P227, DOI 10.1007/s007010200030
   Montano N, 2011, J NEUROSURG, V115, P1126, DOI 10.3171/2011.8.JNS11738
   Nigim F, 2015, MOL CLIN ONCOL, V3, P1381, DOI 10.3892/mco.2015.627
   Omuro AMP, 2005, NEUROLOGY, V64, P1625, DOI 10.1212/01.WNL.0000160396.69050.DC
   Reddy GK, 2011, J NEURO-ONCOL, V103, P333, DOI 10.1007/s11060-010-0393-4
   Rekate HL, 2009, SEMIN PEDIATR NEUROL, V16, P9, DOI 10.1016/j.spen.2009.01.002
   Roth J, 2008, ACTA NEUROCHIR, V150, P41, DOI 10.1007/s00701-007-1454-0
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E329
EP E333
DI 10.1016/j.wneu.2019.04.144
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100037
PM 31028985
DA 2020-05-12
ER

PT J
AU Ridwan, S
   Bohrer, AM
   Grote, A
   Simon, M
AF Ridwan, Sami
   Bohrer, Anna-Margarete
   Grote, Alexander
   Simon, Matthias
TI Surgical Treatment of Chronic Subdural Hematoma: Predicting Recurrence
   and Cure
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic subdural hematoma; Cure; Predictors; Recurrence; Volumetric
   analysis
ID BURR-HOLE DRAINAGE; RISK-FACTORS; POSTOPERATIVE RECURRENCE; EVACUATION;
   MANAGEMENT; ANTICOAGULANT; RESUMPTION
AB BACKGROUND: Chronic subdural hematoma (CSDH) is a common neurosurgical condition, especially among elderly patients. Here we have analyzed our institutional experience with surgical management of CSDH. We aimed at identifying predictors of hematoma recurrence and cure, and the respective time course.
   METHODS: Pertinent data were collected from all 208 patients (136 males; median age, 78 years) treated for unilateral CSDH in our department from 2014 to 2016 after exclusion of cases with CSDH following previous head surgery or missing postoperative imaging. Pre- and post-operative neuroimaging studies were subjected to computer-assisted volumetric analyses. CSDH composition and anatomy were assessed using a modified Nakaguchi classification.
   RESULTS: A total of 67.8% of the patients presented with neurologic deficits, and 51.4% were at least on 1 anticoagulant agent. Burr hole trephinations were performed in 94.7%. The median residual hematoma volume was 35.0 mL (44.1 mL including air). Surgical recurrences were seen in 17.8%. The median time to repeat surgery was 17 days, and 91.9% of recurrences occurred within 60 days. Recurrence rates varied between 36.4% (separated or trabecular subtypes and postoperative CSDH volume >= 35.0 mL) and 3.7% (all other subtypes and postoperative CSDH volume <35.0 mL). A neuroimaging proven cure could be documented in an estimated 90% of cases at 145 days after first surgery.
   CONCLUSIONS: Postoperative CSDH volume and the Nakaguchi classification subtypes proved the most powerful predictors of recurrence, cure, and the time to recurrence and cure. Although our results demonstrate the important impact of CSDH volume, composition, and anatomy, they also show that other so far unknown factors play a significant role as well.
C1 [Ridwan, Sami; Bohrer, Anna-Margarete; Grote, Alexander; Simon, Matthias] Bethel Clin, Dept Neurosurg, Bielefeld, Germany.
RP Ridwan, S (reprint author), Bethel Clin, Dept Neurosurg, Bielefeld, Germany.
EM sami.ridwan@yahoo.de
CR Aspegren OP, 2013, CLIN NEUROL NEUROSUR, V115, P981, DOI 10.1016/j.clineuro.2012.10.008
   Baechli H, 2004, NEUROSURG REV, V27, P263, DOI 10.1007/s10143-004-0337-6
   Brennan PM, 2017, J NEUROSURG, V127, P732, DOI 10.3171/2016.8.JNS16134
   De Bonis P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068732
   Gelabert-Gonzalez M, 2018, NEUROSURG REV, V41, P983, DOI 10.1007/s10143-017-0852-x
   Glancz LJ, 2018, NEUROSURGERY, V374, P1067
   Guha D, 2016, J NEUROSURG, V124, P750, DOI 10.3171/2015.2.JNS141889
   Hostalot-Panisello C, 2002, REV NEUROLOGIA, V35, P123, DOI 10.33588/rn.3502.2002020
   Kamenova M, 2017, WORLD NEUROSURG, V100, P594, DOI 10.1016/j.wneu.2017.01.065
   Kamenova M, 2016, NEUROSURGERY, V79, P715, DOI 10.1227/NEU.0000000000001393
   Karibe Hiroshi, 2011, No Shinkei Geka, V39, P1149
   Katsigiannis Sotirios, 2020, J Neurosurg Sci, V64, P133, DOI 10.23736/S0390-5616.17.04056-5
   Kawamata T, 1995, SURG NEUROL, V44, P438, DOI 10.1016/0090-3019(95)00249-9
   Leroy HA, 2015, J CLIN NEUROSCI, V22, P1895, DOI 10.1016/j.jocn.2015.03.064
   Motoie R, 2018, WORLD NEUROSURG, V118, pE87, DOI 10.1016/j.wneu.2018.06.124
   Nakaguchi H, 2001, J NEUROSURG, V95, P256, DOI 10.3171/jns.2001.95.2.0256
   Nakajima H, 2002, SURG NEUROL, V58, P385, DOI 10.1016/S0090-3019(02)00921-7
   Nathan S, 2017, NEUROLOGY, V88, P1889, DOI 10.1212/WNL.0000000000003918
   Oishi M, 2001, NEUROL MED-CHIR, V41, P382, DOI 10.2176/nmc.41.382
   Okano A, 2014, BRIT J NEUROSURG, V28, P204, DOI 10.3109/02688697.2013.829563
   Ooba S, 2006, NEUROL SURG TOKYO, V34, P273
   Pencalet P, 2001, NEUROCHIRURGIE, V47, P491
   Phang I, 2015, ANN ROY COLL SURG, V97, P584, DOI 10.1308/rcsann.2015.0042
   Potdar NV, 2017, INT J RES MED SCI, V5, P2947
   Pripp AH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186838
   Qian ZR, 2017, BRIT J NEUROSURG, V31, P84, DOI 10.1080/02688697.2016.1260686
   Ro HW, 2016, ACTA NEUROCHIR, V158, P135, DOI 10.1007/s00701-015-2625-z
   Rohde V, 2002, NEUROSURG REV, V25, P89, DOI 10.1007/s101430100182
   Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6
   Shofty B, 2016, WORLD NEUROSURG, V87, P529, DOI 10.1016/j.wneu.2015.09.035
   Stanisic M, 2005, ACTA NEUROCHIR, V147, P1249, DOI 10.1007/s00701-005-0616-1
   Stanisic M, 2017, NEUROSURGERY, V81, P752, DOI 10.1093/neuros/nyx090
   Stanisic M, 2012, INFLAMM RES, V61, P845, DOI 10.1007/s00011-012-0476-0
   Stanisic M, 2012, ACTA NEUROCHIR, V154, P113, DOI 10.1007/s00701-011-1203-2
   Taussky P, 2008, BRIT J NEUROSURG, V22, P279, DOI 10.1080/02688690701818885
   Uno M, 2017, NEUROL MED-CHIR, V57, P402, DOI 10.2176/nmc.ra.2016-0337
NR 36
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1010
EP E1023
DI 10.1016/j.wneu.2019.05.063
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100120
PM 31102774
DA 2020-05-12
ER

PT J
AU Roth, J
   Ber, R
   Constantini, S
AF Roth, Jonathan
   Ber, Roee
   Constantini, Shlomi
TI Neurofibromatosis Type 1-Related Hydrocephalus: Treatment Options and
   Considerations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic third ventriculostomy; Hydrocephalus; NF1; Optic pathway
   glioma; Ventriculoperitoneal shunt
ID ENDOSCOPIC 3RD VENTRICULOSTOMY; AQUEDUCTAL STENOSIS; CHILDREN;
   MANAGEMENT; TUMORS
AB OBJECTIVE: Neurofibromatosis type I (NF1) will be associated with hydrocephalus in <= 13% of cases. Currently, very little data are available describing the actual etiologies and treatment options of NF1-associated hydrocephalus. We, therefore, have described our experience in treating NF1-associated hydrocephalus.
   METHODS: We completed a retrospective data analysis 1020 patients with NF1 treated at the Gilbert's Israeli International Neurofibromatosis Center during a period of 20 years. The patients presenting with, and treated for, related hydrocephalus were included. The clinical, radiological, and surgical data are presented.
   RESULTS: We included 22 patients (2.1% of the entire patient cohort), with 17 aged <19 years. Twenty patients had obstructive hydrocephalus. The most common etiologies included aqueductal or third ventricular obstruction, Of the 22 patients, 15 had underwent endoscopic procedures (14 third ventriculostomies) and 7 had undergone shunt procedures. The corresponding failure rates (including the need for additional cerebrospinal fluid procedures) were 60% and 71%.
   CONCLUSIONS: Hydrocephalus in the context of NF1 been caused mostly by obstructive etiologies. A tailored treatment approach is recommended to address the specific etiology. Regardless of the treatment approach, a relatively high rate of failure has been described.
C1 [Roth, Jonathan; Ber, Roee; Constantini, Shlomi] Tel Aviv Med Ctr & Sch Med, Dana Childrens Hosp, Dept Pediat Neurosurg, Tel Aviv, Israel.
   [Roth, Jonathan; Constantini, Shlomi] Tel Aviv Med Ctr & Sch Med, Gilbert Israeli Int Neurofibromatosis Ctr, Tel Aviv, Israel.
RP Roth, J (reprint author), Tel Aviv Med Ctr & Sch Med, Dana Childrens Hosp, Dept Pediat Neurosurg, Tel Aviv, Israel.; Roth, J (reprint author), Tel Aviv Med Ctr & Sch Med, Gilbert Israeli Int Neurofibromatosis Ctr, Tel Aviv, Israel.
EM jonaroth@gmail.com
OI Roth, Jonathan/0000-0002-4267-8835
CR AFIFI AK, 1988, J CHILD NEUROL, V3, P125, DOI 10.1177/088307388800300210
   Allen JC, 2000, PEDIATR NEUROSURG, V32, P154, DOI 10.1159/000028922
   BALESTRAZZI P, 1989, Neurofibromatosis, V2, P322
   Bilaniuk LT, 1997, NEURORADIOLOGY, V39, P642, DOI 10.1007/s002340050484
   Binning Mandy J, 2007, Neurosurg Focus, V23, pE2
   Cinalli G, 2017, J NEUROSURG-PEDIATR, V19, P325, DOI 10.3171/2016.10.PEDS16352
   Clementi M, 1996, HEADACHE, V36, P10, DOI 10.1046/j.1526-4610.1996.3601010.x
   Creange A, 1999, BRAIN, V122, P473, DOI 10.1093/brain/122.3.473
   Dincer A, 2011, AM J NEURORADIOL, V32, P643, DOI 10.3174/ajnr.A2357
   El Beltagy MA, 2016, WORLD NEUROSURG, V89, P525, DOI 10.1016/j.wneu.2016.02.042
   Garg P, 2016, NEUROL INDIA, V64, P1384, DOI 10.4103/0028-3886.193836
   Gil Z, 2001, CHILD NERV SYST, V17, P395, DOI 10.1007/s003810100460
   Goodden J, 2014, J NEUROSURG-PEDIATR, V13, P1, DOI 10.3171/2013.8.PEDS12546
   Hirabaru K, 2018, PEDIATR INT, V60, P70, DOI 10.1111/ped.13388
   HOSODA K, 1986, NEUROSURGERY, V19, P1035, DOI 10.1227/00006123-198612000-00024
   Kang YS, 2017, CHILD NERV SYST, V33, P767, DOI 10.1007/s00381-017-3370-9
   MOLLOY PT, 1995, NEUROLOGY, V45, P1897, DOI 10.1212/WNL.45.10.1897
   Pollack IF, 1996, NEUROLOGY, V46, P1652, DOI 10.1212/WNL.46.6.1652
   Riviello J J Jr, 1988, Neurofibromatosis, V1, P312
   Roth J, 2017, WORLD NEUROSURG, V107, P623, DOI 10.1016/j.wneu.2017.08.053
   Roth Jonathan, 2015, Surg Neurol Int, V6, P56, DOI 10.4103/2152-7806.154467
   Schulz M, 2015, CHILD NERV SYST, V31, P1499, DOI 10.1007/s00381-015-2787-2
   SENVELI E, 1989, NEUROSURGERY, V24, P99, DOI 10.1227/00006123-198901000-00017
   Shofty B, 2018, HDB PEDIAT NEUROSURG
   Shuper A, 2000, PEDIATR HEMAT ONCOL, V17, P463, DOI 10.1080/08880010050120818
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E664
EP E668
DI 10.1016/j.wneu.2019.04.231
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100078
PM 31059857
DA 2020-05-12
ER

PT J
AU Sadrameli, SS
   Chu, JK
   Chan, TM
   Steele, WJ
   Curry, DJ
   Lam, SK
AF Sadrameli, Saeed S.
   Chu, Jason K.
   Chan, Tiffany M.
   Steele, William J.
   Curry, Daniel J.
   Lam, Sandi K.
TI Minimally Invasive Tubular Tethered Cord Release in the Pediatric
   Population
SO WORLD NEUROSURGERY
LA English
DT Article
DE Minimally invasive spine; Tethered cord syndrome; Tethered cord release;
   Tubular laminectomy
ID LUMBAR INTERBODY FUSION; SURGICAL-MANAGEMENT; FILUM TERMINALE; CHILDREN;
   OUTCOMES; MICRODISCECTOMY; RESECTION
AB BACKGROUND: Tethered cord syndrome (TCS) refers to a clinical constellation of signs and symptoms associated with tension in the spinal cord and associated with pathologies related to abnormally low-lying conus medul-laris. As minimally invasive spinal operations have become more prevalent in the past decade, we applied expanding indications to selected intradural procedures, such as tethered cord release (TCR). We present the first series of minimally invasive muscle-sparing TCR in the pediatric population.
   METHODS: A retrospective review of the Texas Children's Hospital, Houston, neurosurgical database was conducted for patients who underwent TCR between 2010 and 2017. Charts were reviewed to determine the source of TCS and whether surgery was conducted in a minimally invasive fashion. To establish a cohort of control population, age-matched cases of open TCR were selected in the same. Exclusion criterion was non-fatty filum sources of TCS. The length of stay, operative time, estimated blood loss, and postoperative complications were recorded.
   RESULTS: Eleven patients underwent minimally invasive TCR. Mean age of the patients was 10.1 years. All patients underwent L4-5 tubular laminotomy and cord detethering by 2 pediatric neurosurgeons at Texas Children's Hospital. The average length of stay in the hospital was 2.6 days. The average operative time was 167 minutes and average estimated blood loss was 8.2 mL. Ten patients reported clinical improvement and 1 patient was lost to follow-up.
   CONCLUSIONS: Minimally invasive TCR is a safe and represents a viable alternative to the open approach with advantages such as minimal estimated blood loss, shortened length of stay, and postoperative pain control.
C1 [Sadrameli, Saeed S.; Steele, William J.] Houston Methodist Neurol Inst, Dept Neurosurg, Houston, TX USA.
   [Chu, Jason K.; Curry, Daniel J.; Lam, Sandi K.] Texas Childrens Hosp, Div Pediat Neurosurg, Houston, TX 77030 USA.
   [Chan, Tiffany M.] Texas A&M Coll Med, Bryan, TX USA.
RP Lam, SK (reprint author), Texas Childrens Hosp, Div Pediat Neurosurg, Houston, TX 77030 USA.
EM sklam@texaschildrens.org
CR Afathi M, 2015, NEUROCHIRURGIE, V61, P333, DOI 10.1016/j.neuchi.2015.05.001
   Aldave G, 2017, J NEUROSURG-PEDIATR, V19, P703, DOI 10.3171/2017.1.PEDS16533
   Arts MP, 2011, NEUROSURGERY, V69, P135, DOI 10.1227/NEU.0b013e318214a98c
   Beaubien BP, 2016, J BIOMECH, V49, P216, DOI 10.1016/j.jbiomech.2015.12.012
   Clark AJ, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17202
   Di X, 2009, CHILD NERV SYST, V25, P577, DOI 10.1007/s00381-008-0800-8
   Fujiwara A, 2000, SPINE, V25, P358, DOI 10.1097/00007632-200002010-00017
   Goldstein CL, 2016, J NEUROSURG-SPINE, V24, P416, DOI 10.3171/2015.2.SPINE14973
   Grunert P., 2013, MINIM INVASIVE SURG, V2013, P1
   Gurbuz Mehmet Sabri, 2015, Korean J Spine, V12, P287, DOI 10.14245/kjs.2015.12.4.287
   Hayashi T, 2018, NEUROL MED-CHIR, V58, P132, DOI 10.2176/nmc.oa.2017-0200
   Huang SL, 2010, WORLD J PEDIATR, V6, P361, DOI 10.1007/s12519-010-0210-3
   Huang TJ, 2005, J ORTHOP RES, V23, P406, DOI 10.1016/j.orthres.2004.08.010
   Kang JK, 2009, J KOREAN NEUROSURG S, V46, P468, DOI 10.3340/jkns.2009.46.5.468
   Katz JN, 2014, BEST PRACT RES CL RH, V28, P143, DOI 10.1016/j.berh.2014.01.008
   Kulkarni AG, 2016, INDIAN J ORTHOP, V50, P464, DOI 10.4103/0019-5413.189607
   Lee GYF, 2006, J NEUROSURG-SPINE, V4, P123, DOI 10.3171/spi.2006.4.2.123
   Lu DC, 2011, J NEUROSURG-SPINE, V14, P758, DOI 10.3171/2011.1.SPINE09860
   Magrassi L, 2008, MINIM INVAS NEUROSUR, V51, P350, DOI 10.1055/s-0028-1087189
   Marchiori D M, 1996, J Manipulative Physiol Ther, V19, P265
   MAYER TG, 1989, SPINE, V14, P33, DOI 10.1097/00007632-198901000-00006
   Nzokou A, 2013, J NEUROSURG-SPINE, V19, P708, DOI 10.3171/2013.9.SPINE121061
   Oktay K, 2017, PEDIATR NEUROSURG, V52, P323, DOI 10.1159/000479281
   Parikh K, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/8/E14
   Potts MB, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.3.FOCUS1077
   Ryang YM, 2008, NEUROSURGERY, V62, P174, DOI 10.1227/01.NEU.0000311075.56486.C5
   Sasaoka R, 2006, EUR SPINE J, V15, P577, DOI 10.1007/s00586-005-0912-8
   Sharif S, 2018, WORLD NEUROSURG, V119, P472, DOI 10.1016/j.wneu.2018.06.094
   SIHVONEN T, 1993, SPINE, V18, P575, DOI 10.1097/00007632-199304000-00009
   Staartjes VE, 2017, WORLD NEUROSURG, V107, P28, DOI [10.1016/J.WNEU.2017.07.121, 10.1016/j.wneu.2017.07.121]
   Telfeian Albert Edward, 2017, J Spine Surg, V3, P278, DOI 10.21037/jss.2017.06.10
   Terman SW, 2014, J NEUROSURG-SPINE, V20, P644, DOI 10.3171/2014.2.SPINE13794
   Tredway TL, 2007, NEUROSURGERY, V60, P70, DOI 10.1227/01.NEU.0000249254.63546.D7
   von Koch CS, 2002, PEDIATR NEUROSURG, V37, P81, DOI 10.1159/000065109
   Wehby MC, 2004, PEDIATR NEUROSURG, V40, P51, DOI 10.1159/000078908
   Wong AP, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15129
   Xu J, 2018, WORLD NEUROSURG, V109, pE110, DOI 10.1016/j.wneu.2017.09.114
   Yong RL, 2011, NEUROSURGERY, V68, P1594, DOI 10.1227/NEU.0b013e31821246c6
   Yorukoglu AG, 2016, WORLD NEUROSURG, V92, P402, DOI 10.1016/j.wneu.2016.05.055
   Zheng G, 2015, FRONT SURG, V2, P218
NR 40
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E912
EP E917
DI 10.1016/j.wneu.2019.05.026
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100107
PM 31096033
DA 2020-05-12
ER

PT J
AU Sakai, N
   Imamura, H
   Arimura, K
   Funatsu, T
   Beppu, M
   Suzuki, K
   Adachi, H
   Okuda, T
   Matsui, Y
   Kawabata, S
   Akiyama, R
   Horiuchi, K
   Tani, S
   Adachi, H
   Sakai, C
   Kaneko, N
   Tateshima, S
AF Sakai, Nobuyuki
   Imamura, Hirotoshi
   Arimura, Koichi
   Funatsu, Takayuki
   Beppu, Mikiya
   Suzuki, Keita
   Adachi, Hiromasa
   Okuda, Tomohiro
   Matsui, Yuichi
   Kawabata, Shuhei
   Akiyama, Ryo
   Horiuchi, Kazufumi
   Tani, Shoichi
   Adachi, Hidemitsu
   Sakai, Chiaki
   Kaneko, Naoki
   Tateshima, Satoshi
TI PulseRider-Assisted Coil Embolization for Treatment of Intracranial
   Bifurcation Aneurysms: A Single-Center Case Series with 24-Month
   Follow-up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular treatment; Follow-up; Intracranial aneurysm; PulseRider
ID WIDE-NECKED ANEURYSMS; ENDOVASCULAR TREATMENT; INITIAL-EXPERIENCE;
   SAFETY; DEVICE
AB BACKGROUND: Although endovascular coiling of unruptured aneurysms is widely accepted, the endovascular treatment of wide-neck bifurcation aneurysms remains one of the most challenging morphologies. Our purpose was to describe our experience with 24-month follow-up for the treatment of unruptured intracranial bifurcation aneurysms using the PulseRider (Cerenovus, New Brunswick, NJ).
   METHODS: This study is a single-center, single-arm registry performed under institutional review board control to evaluate efficacy and safety of the PulseRider. Patients with bifurcation aneurysms were identified and enrolled prospectively. Angiography immediately after treatment and at 6 months, and magnetic resonance imaging and magnetic resonance angiography at 12- and 24-month follow-up were retrospectively analyzed. A modified Rankin score was obtained prior to procedure, at discharge, and at 6-, 12- and 24-month follow-up visits.
   RESULTS: Eight patients with a mean age of 66 years were treated with the PulseRider. All patients had bifurcation aneurysms (2 anterior communicating, 2 carotid terminus, and 4 basilar apex). The aneurysm diameters ranged from 4.6 to 13.6 mm (mean 7.4 mm) with dome/neck ratio ranging from 1.4 to 2.2 (mean 1.6). In all cases, the PulseRider was successfully deployed. Complete occlusion was demonstrated at 6-month follow-up on 6 of 8 (75%), near complete occlusion in 1 of 8 (12.5%), and residual aneurysm in 1 of 8 (12.5%) patients. There was no change or recurrence on magnetic resonance angiography, nor clinical complication after the procedure through 24-month follow-up.
   CONCLUSIONS: Our experience with 24-month followup demonstrated favorable efficacy in the treatment of intracranial wide-neck bifurcation aneurysms using the PulseRider.
C1 [Sakai, Nobuyuki; Imamura, Hirotoshi; Arimura, Koichi; Funatsu, Takayuki; Beppu, Mikiya; Suzuki, Keita; Adachi, Hiromasa; Okuda, Tomohiro; Matsui, Yuichi; Kawabata, Shuhei; Akiyama, Ryo; Horiuchi, Kazufumi; Tani, Shoichi; Adachi, Hidemitsu; Sakai, Chiaki] Kobe City Med Ctr Gen Hosp, Dept Neurosurg, Kobe, Hyogo, Japan.
   [Kaneko, Naoki; Tateshima, Satoshi] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Div Intervent Neuroradiol, Los Angeles, CA 90095 USA.
RP Tateshima, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Div Intervent Neuroradiol, Los Angeles, CA 90095 USA.
EM stateshi@g.ucla.edu
OI arimura, koichi/0000-0003-2455-9506; Sakai,
   Nobuyuki/0000-0002-3289-1210; Beppu, Mikiya/0000-0003-3484-5733
CR Aguilar-Salinas P, 2018, WORLD NEUROSURG, V115, P288, DOI 10.1016/j.wneu.2018.04.102
   Benitez RP, 2004, NEUROSURGERY, V54, P1359, DOI 10.1227/01.NEU.0000124484.87635.CD
   Chow MM, 2004, AM J NEURORADIOL, V25, P509
   Fargen KM, 2013, NEUROSURGERY, V73, P466, DOI 10.1227/NEU.0000000000000015
   Fiorella D, 2017, J NEUROINTERV SURG, V9, P1197, DOI 10.1136/neurintsurg-2017-013223
   Gory B, 2016, AM J NEURORADIOL, V37, P130, DOI 10.3174/ajnr.A4506
   Gory B, 2017, WORLD NEUROSURG, V99, P605, DOI 10.1016/j.wneu.2016.12.065
   Hong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082311
   Malek AM, 2000, NEUROSURGERY, V46, P1397, DOI 10.1097/00006123-200006000-00022
   Mukherjee S, 2017, J NEUROSURG, V127, P61, DOI 10.3171/2016.2.JNS152334
   Pierot L, 2012, AM J NEURORADIOL, V33, P12, DOI 10.3174/ajnr.A2403
   Raymond J, 2001, RADIOLOGY, V221, P318, DOI 10.1148/radiol.2212010474
   Roy D, 2001, STROKE, V32, P1998, DOI 10.1161/hs0901.095600
   Sheth SA, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011836.rep
   Spiotta AM, 2018, AM J NEURORADIOL, V39, P848, DOI 10.3174/ajnr.A5599
   Spiotta AM, 2017, NEUROSURGERY, V81, P56, DOI 10.1093/neuros/nyx085
   Spiotta AM, 2016, J NEUROINTERV SURG, V8, P186, DOI 10.1136/neurintsurg-2014-011531
   Spiotta AM, 2011, NEUROSURGERY, V69, P421, DOI 10.1227/NEU.0b013e318214abbd
   Turk A, 2013, J NEUROINTERV SURG, V5, P346, DOI 10.1136/neurintsurg-2012-010312
NR 19
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E461
EP E467
DI 10.1016/j.wneu.2019.04.177
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100053
PM 31042599
DA 2020-05-12
ER

PT J
AU Sang, HF
   Yin, CG
   Xia, WQ
   Huang, H
   Liu, KQ
   Chen, TW
   Si, XL
   Jiang, L
AF Sang, Hong-Fei
   Yin, Cong-Guo
   Xia, Wen-Qing
   Huang, Huan
   Liu, Ke-Qin
   Chen, Tian-Wen
   Si, Xiao-Li
   Jiang, Lin
TI Mechanical Thrombectomy Using Solitaire in Acute lschemic Stroke
   Patients with Vertebrobasilar Occlusion: A Prospective Observational
   Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Endovascular treatment; Mechanical thrombectomy;
   Posterior circulation; Vertebrobasilar occlusion
ID BASILAR ARTERY-OCCLUSION; INTRAARTERIAL TREATMENT; ENDOVASCULAR
   TREATMENT; ANTERIOR CIRCULATION; ISCHEMIC-STROKE; OUTCOMES; PREDICTORS;
   DEVICE; ANGIOGRAPHY; THERAPY
AB BACKGROUND: The safety and effectiveness of endovascular mechanical thrombectomy in patients with acute vertebrobasilar occlusion (VBO) are debatable and undergoing evaluation. We report the clinical outcome and prognostic factors in a prospective cohort of acute ischemic stroke patients with VBO.
   METHODS: In total, 48 consecutive patients with acute VBO underwent mechanical thrombectomy using Solitaire. We analyzed clinical and imaging data and searched for predictors of good clinical outcome (modified Rankin scale score: 0-3).
   RESULTS: The median prethrombectomy National Institutes of Health Stroke Scale score was 22.0. The median duration from symptom onset to recanalization was 493.5 minutes. A total of 35.4% of the patients received rescue therapy. Recanalization (modified Thrombolysis In Cerebral Infarction: 2b-3) was successful in all patients. Clinically relevant intracranial hemorrhage was observed in 2 patients. After 90 days, good outcomes were obtained in 27 patients. The baseline National Institutes of Health Stroke Scale score, posterior circulation Acute Stroke Prognosis Early CT Score (pc-ASPECTS), anesthesia type, and posterior communicating artery (PComA) patency were significantly associated with outcomes at 90 days in univariate analysis. Multivariate logistic regression indicated that high pc-ASPECTS at admission and PComA patency were independent predictors of good outcome at 90 days.
   CONCLUSIONS: Up to 60.4% of the patients reached good outcomes after endovascular treatment and 35.4% of the patients received rescue therapy, suggesting that mechanical thrombectomy using Solitaire in patients with stroke with VBO is safe and effective and that rescue therapy is readily required and employed. High baseline pc-ASPECTS and PComA patency were associated with better outcomes after thrombectomy in these patients.
C1 [Sang, Hong-Fei; Yin, Cong-Guo; Xia, Wen-Qing; Huang, Huan; Liu, Ke-Qin; Chen, Tian-Wen; Si, Xiao-Li; Jiang, Lin] Zhejiang Univ, Sch Med, Hangzhou Peoples Hosp 1, Dept Neurol, Hangzhou, Zhejiang, Peoples R China.
RP Jiang, L (reprint author), Zhejiang Univ, Sch Med, Hangzhou Peoples Hosp 1, Dept Neurol, Hangzhou, Zhejiang, Peoples R China.
EM jianglin0229@126.com
OI Jiang, Lin/0000-0002-7796-3820
FU Zhejiang Provincial Natural Science Foundation of ChinaNatural Science
   Foundation of Zhejiang Province [GF18H090036]; Hangzhou Science and
   Technology Plan Guiding Project [20181228Y01]
FX This study was supported by Zhejiang Provincial Natural Science
   Foundation of China (GF18H090036) and Hangzhou Science and Technology
   Plan Guiding Project (20181228Y01).
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Alemseged F, 2017, STROKE, V48, P631, DOI 10.1161/STROKEAHA.116.015492
   Bang OY, 2014, J STROKE, V16, P27, DOI 10.5853/jos.2014.16.1.27
   Bang OY, 2011, STROKE, V42, P693, DOI 10.1161/STROKEAHA.110.595256
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Berkhemer OA, 2016, STROKE, V47, P768, DOI 10.1161/STROKEAHA.115.011788
   Bouslama M, 2017, STROKE, V48, P3252, DOI 10.1161/STROKEAHA.117.018270
   Castano C, 2010, STROKE, V41, P1836, DOI 10.1161/STROKEAHA.110.584904
   Gory B, 2018, CEREBROVASC DIS, V45, P61, DOI 10.1159/000486690
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Huo XC, 2016, WORLD NEUROSURG, V89, P301, DOI 10.1016/j.wneu.2016.02.017
   Jiang WJ, 2001, ANGIOPLASTY STENTING
   Jung S, 2011, STROKE, V42, P1946, DOI 10.1161/STROKEAHA.110.606038
   Karameshev A, 2011, CEREBROVASC DIS, V32, P393, DOI 10.1159/000330644
   Lee JS, 2016, J STROKE, V18, P96, DOI 10.5853/jos.2015.01347
   Li C, 2018, NEURORADIOLOGY, V60, P1
   Lindsberg PJ, 2015, NEUROLOGY, V85, P1806, DOI 10.1212/WNL.0000000000002129
   Luo G, 2018, WORLD NEUROSURG, V109, pE318, DOI 10.1016/j.wneu.2017.09.171
   Mohlenbruch M, 2014, AM J NEURORADIOL, V35, P959, DOI 10.3174/ajnr.A3796
   Mordasini P, 2013, AM J NEURORADIOL, V34, P159, DOI 10.3174/ajnr.A3168
   Pfefferkorn T, 2008, STROKE, V39, P1496, DOI 10.1161/STROKEAHA.107.505123
   Phan K, 2016, J NEUROINTERV SURG, V8, P1107, DOI 10.1136/neurintsurg-2015-012089
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Schonewille WJ, 2009, LANCET NEUROL, V8, P724, DOI 10.1016/S1474-4422(09)70173-5
   van der Hoeven EJRJ, 2016, INT J STROKE, V11, P768, DOI 10.1177/1747493016641951
   van Houwelingen RC, 2017, JAMA NEUROL, V74, P130, DOI 10.1001/jamaneurol.2016.4870
   Zhang XL, 2019, CLIN NEURORADIOL, V29, P693, DOI 10.1007/s00062-018-0731-z
NR 28
TC 0
Z9 0
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E355
EP E361
DI 10.1016/j.wneu.2019.04.152
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100041
PM 31029819
DA 2020-05-12
ER

PT J
AU Semeraro, V
   Ganimede, MP
   Lucarelli, NM
   Lozupone, E
   Vidali, S
   Gisone, V
   Burdi, N
AF Semeraro, Vittorio
   Ganimede, Maria Porzia
   Lucarelli, Nicola Maria
   Lozupone, Emilio
   Vidali, Sofia
   Gisone, Vito
   Burdi, Nicola
TI Rescue Stenting Using Neuroform Atlas Stent During Coiling Protrusion
   for Ruptured Intracranial Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain ruptured aneurysms; Complications management; Endovascular
   treatment; Hemorrhagic stroke; Interventional neuroradiology
ID GUGLIELMI DETACHABLE COIL; WIDE-NECKED ANEURYSMS; ENDOVASCULAR
   TREATMENT; EMBOLIZATION; PLACEMENT; EXPERIENCE; HERNIATION; DEPLOYMENT;
   RETRIEVAL; OUTCOMES
AB BACKGROUND: Endovascular coiling is generally considered as an effective treatment option for ruptured intracranial aneurysms. Increasing operator experience and quality of tools determined an improvement of endovascular cerebral aneurysms' treatment. However, procedure-related complications still occur.
   The purpose of this study is to report a series of rescue stenting procedures with the Neuroform Atlas (NA) opencell stent, for intraprocedural complications during coil embolization in patients with ruptured intracranial aneurysms.
   METHODS: Between April 2016 and January 2018, 12 consecutive coil protrusions that occurred during ruptured aneurysms' embolizations were rescued using NA stenting together with tirofiban therapy.
   Follow-up was performed with initial magnetic resonance angiography (MRA) at 1 month and then MRA plus standard digital subtraction angiography at 11-13 months after the procedure.
   RESULTS: Technical success was achieved in 100% of patients. No NA stent delivery/deployment complication occurred. Initial MRA showed complete occlusion of the aneurysm, with evidence of blood flow into parent vessels in 12 out of 12 cases.
   At 11-13 months, MRA and digital subtraction angiography showed 10 complete occlusion cases and 1 partial occlusion case. At 2 months, 1 death occurred due to subarachnoid hemorrhage.
   CONCLUSIONS: The open-cell NA stent represents a rescue option for coil protrusion during endovascular treatment of ruptured intracranial aneurysms allowing regular restoration of blood flow and minimizing thromboembolic events.
C1 [Semeraro, Vittorio; Ganimede, Maria Porzia; Lucarelli, Nicola Maria; Gisone, Vito; Burdi, Nicola] SS Annunziata Hosp, Dept Diagnost Imaging & Radiat Therapy, Taranto, Italy.
   [Lozupone, Emilio] Univ Hosp Policlin A Gemelli IRCCS, Dept Diagnost Imaging Oncol Radiat Therapy & Hema, Rome, Italy.
   [Vidali, Sofia] Univ Hosp Policlin Tor Vergata, Dept Diagnost Imaging Mol Imaging Intervent Radio, Rome, Italy.
RP Semeraro, V (reprint author), SS Annunziata Hosp, Dept Diagnost Imaging & Radiat Therapy, Taranto, Italy.
EM vittoriosemeraro@hotmail.it
RI LUCARELLI, NICOLA MARIA/AAC-1775-2019; Lozupone, Emilio/T-5682-2019
OI LUCARELLI, NICOLA MARIA/0000-0002-6654-4751; Lozupone,
   Emilio/0000-0003-3992-9071; Semeraro, Vittorio/0000-0002-7546-4251
CR Abdihalim M, 2011, AM J NEURORADIOL, V32, P1392, DOI 10.3174/ajnr.A2572
   Amenta PS, 2012, NEUROSURGERY, V70, P1415, DOI 10.1227/NEU.0b013e318246a4b1
   Bechan RS, 2016, AM J NEURORADIOL, V37, P502, DOI 10.3174/ajnr.A4542
   Benitez RP, 2004, NEUROSURGERY, V54, P1359, DOI 10.1227/01.NEU.0000124484.87635.CD
   Biondi A, 2007, NEUROSURGERY, V61, P460, DOI 10.1227/01.NEU.0000290890.62201.A9
   Cay F, 2018, INTERV NEURORADIOL, V24, P263, DOI 10.1177/1591019917753710
   Chung J, 2013, ACTA NEUROCHIR, V155, P223, DOI 10.1007/s00701-012-1528-5
   Dinc H, 2006, NEURORADIOLOGY, V48, P269, DOI 10.1007/s00234-006-0051-x
   Fessler RD, 2000, NEUROSURGERY, V46, P248
   Fiorella D, 2005, NEUROSURGERY, V57, P210, DOI 10.1227/01.NEU.0000163685.23846.DD
   Fiorella D, 2004, NEUROSURGERY, V54, P6, DOI 10.1227/01.NEU.0000097194.35781.EA
   FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001
   Fourie P, 2003, AM J NEURORADIOL, V24, P630
   HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014
   Hwang G, 2014, RADIOLOGY, V273, P194, DOI 10.1148/radiol.14140070
   Kwon OK, 2005, AM J NEURORADIOL, V26, P894
   Lanzino G, 1999, J NEUROSURG, V91, P538, DOI 10.3171/jns.1999.91.4.0538
   Lavine SD, 2000, NEUROSURGERY, V46, P1013, DOI 10.1097/00006123-200004000-00051
   Luo CB, 2008, AM J NEURORADIOL, V29, P1951, DOI 10.3174/ajnr.A1268
   Meckel S, 2011, AM J NEURORADIOL, V32, P764, DOI 10.3174/ajnr.A2392
   O'Hare A, 2009, INTERV NEURORADIOL, V15, P219, DOI 10.1177/159101990901500214
   Pelz DM, 1998, AM J NEURORADIOL, V19, P1541
   Schutz A, 2005, NEURORADIOLOGY, V47, P874, DOI 10.1007/s00234-005-1430-4
   STANDARD SC, 1994, NEUROSURGERY, V35, P994, DOI 10.1227/00006123-199411000-00038
   Sugiu K, 2002, J NEUROSURG, V96, P373, DOI 10.3171/jns.2002.96.2.0373
   ten Brinck MFM, 2019, NEUROSURGERY, V84, P179, DOI 10.1093/neuros/nyy048
   The International Study of Unruptured Intracranial Aneurysms Investigators, 1999, J NEUROSURG ANESTHES, V11, P218
   Ulfert C, 2018, J NEUROINTERV SURG, V10, P1192, DOI 10.1136/neurintsurg-2017-013516
   Vinuela F, 1997, J NEUROSURG, V86, P475, DOI 10.3171/jns.1997.86.3.0475
   Wermer MJH, 2007, STROKE, V38, P1404, DOI 10.1161/01.STR.0000260955.51401.cd
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Yoo E, 2009, AM J NEURORADIOL, V30, P1028, DOI 10.3174/ajnr.A1482
NR 32
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E454
EP E460
DI 10.1016/j.wneu.2019.04.176
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100052
PM 31051305
DA 2020-05-12
ER

PT J
AU Serrano, LE
   Archavlis, E
   Ayyad, A
   Schwandt, E
   Nimer, A
   Ringel, F
   Kantelhardt, SR
AF Serrano, Lucas Ezequiel
   Archavlis, Eleftherios
   Ayyad, Ali
   Schwandt, Eike
   Nimer, Amr
   Ringel, Florian
   Kantelhardt, Sven Rainer
TI Comprehensive Anatomic Assessment of Ipsilateral Pterional Versus
   Contralateral Subfrontal Approaches to the Internal Carotid Ophthalmic
   Segment: A Cadaveric Study and Three-Dimensional Simulation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Contralateral approach; Internal carotid artery; Ipsilateral approach;
   Ophthalmic segment
ID BILATERAL CEREBRAL ANEURYSMS; OPTIC-NERVE MOBILIZATION; SURGICAL
   ANATOMY; MICROSURGICAL ANATOMY; ARTERY; SURGERY; CRANIOTOMY; BONE
AB OBJECTIVE: Medially pointing aneurysms of the ophthalmic segment of the internal carotid artery (oICA) represent a neurosurgical challenge. Conventional ipsilateral approaches require internal carotid artery and optic nerve (ON) mobilization as well as anterior clinoidectomy (AC), all associated with increased surgical risk. Contralateral approaches could provide a better exposure of the superomedial aspect of the oICA, ophthalmic artery, and superior hypophyseal artery, sparing AC and internal carotid artery or ON mobilization. However, the microsurgical anatomy of this approach has not been systematically studied. In the present work, we exhaustibly analyzed the anatomic and morphometric characteristics of contralateral approaches to the oICA and compared them with those from ipsilateral approaches.
   METHODS: We assessed 36 ipsilateral and contralateral approaches to the oICAs in cadaveric specimens and live patients, using for the latter a three-dimensional virtual reality (VR) system.
   RESULTS: Contralateral approaches spared sylvian fissure dissection and required only minimal frontal lobe retraction. The ipsilateral and contralateral oICA were found at a depth of 49.21 +/- 1.8 mm (VR, 50.1 +/- 2.92 mm) and 65.1 +/- 1.5 mm (VR, 66.05 +/- 3.364 mm) respectively. The exposure of the superomedial aspect of oICA was 7.25 +/- 0.86 mm (VR: 6 +/- 1 mm) contralaterally without ON mobilization and 2.44 +/- 0.51 mm (VR, 2 +/- 1 mm) ipsilaterally even after AC. Statistical analysis showed that, for nonprefixed chiasm, contralateral approaches achieved a significantly higher exposure of the ophthalmic artery, superior hypophyseal artery, and the superomedial aspect of the oICA with its perforating branches (all P< 0.01).
   CONCLUSIONS: Contralateral approaches may enable successful exposure of the oICA and related vascular structures, reducing the need for AC or ON mobilization. Systematic clinical/surgical studies are needed to further determine the effectiveness and safety of the approach.
C1 [Serrano, Lucas Ezequiel; Archavlis, Eleftherios; Schwandt, Eike; Ringel, Florian; Kantelhardt, Sven Rainer] Maine Univ, Dept Neurosurg, Med Ctr, Mainz, Germany.
   [Ayyad, Ali] Saarland Univ Hosp, Dept Neurosurg, Homburg, Germany.
   [Nimer, Amr] Charing Cross Hosp, Imperial Coll Healthcare, Dept Neurosurg, London, England.
RP Serrano, LE (reprint author), Maine Univ, Dept Neurosurg, Med Ctr, Mainz, Germany.
EM Lucas.Serrano@unimedizin-mainz.de
RI Ringel, Florian/E-4933-2014
CR AKABANE A, 1995, J NEUROSURG, V82, P284, DOI 10.3171/jns.1995.82.2.0284
   Andrade-Barazarte H, 2015, NEUROSURGERY, V77, P104, DOI 10.1227/NEU.0000000000000742
   Chandela S, 2011, WORLD NEUROSURG, V75, P78, DOI 10.1016/j.wneu.2010.06.028
   Chang DJ, 2009, NEUROSURGERY S, V64
   Chang DJ, 2009, NEUROSURGERY, V64, pS96, DOI 10.1227/01.NEU.0000335172.68267.01
   Chang HS, 2006, J NEUROSURG, V104, P621, DOI 10.3171/jns.2006.104.4.621
   Chen SF, 2013, J NEUROL SURG PART A, V74, P18, DOI 10.1055/s-0032-1326944
   Clatterbuck RE, 2005, NEUROSURGERY, V57, P160, DOI 10.1227/01.NEU.0000163601.37465.6E
   DAY AL, 1990, J NEUROSURG, V72, P677, DOI 10.3171/jns.1990.72.5.0677
   De Jesus O, 1999, SURG NEUROL, V51, P477, DOI 10.1016/S0090-3019(98)00137-2
   deOliveira E, 1996, ACTA NEUROCHIR, V138, P1
   DOLENC VV, 1985, J NEUROSURG, V62, P667, DOI 10.3171/jns.1985.62.5.0667
   Fries G, 1997, NEUROSURGERY, V41, P333, DOI 10.1097/00006123-199708000-00001
   GELBER BR, 1980, J NEUROSURG, V52, P1, DOI 10.3171/jns.1980.52.1.0001
   Germanwala Anand V, 2017, Surg Neurol Int, V8, P52, DOI 10.4103/sni.sni_17_17
   GIBO H, 1981, J NEUROSURG, V55, P560, DOI 10.3171/jns.1981.55.4.0560
   Hayreh S., 1974, RADIOLOGY SKULL BRAI, VII, P1333
   Hayreh S S, 1962, Br J Ophthalmol, V46, P65, DOI 10.1136/bjo.46.2.65
   Hong T, 2009, SURG NEUROL, V72, pS23, DOI 10.1016/j.surneu.2007.12.031
   Hongo K, 2001, NEUROSURGERY, V48, P955, DOI 10.1097/00006123-200104000-00059
   Kakizawa Y, 2000, NEUROSURGERY, V47, P1130, DOI 10.1097/00006123-200011000-00022
   Kang S, 1997, ACTA NEUROCHIR, V139, P221, DOI 10.1007/BF01844755
   Kassam AB, 2007, J NEUROSURG, V107, P1047, DOI 10.3171/JNS-07/11/1047
   Kobayashi K, 2015, DEEP BRAIN STIMULATI, V42
   KOBAYASHI S, 1989, J NEUROSURG, V70, P216, DOI 10.3171/jns.1989.70.2.0216
   Kockro RA, 2016, WORLD NEUROSURG, V96, P489, DOI 10.1016/j.wneu.2016.08.124
   KOROSUE K, 1992, NEUROSURGERY, V31, P356, DOI 10.1227/00006123-199208000-00024
   MACCARTY CS, 1972, J NEUROSURG, V36, P114, DOI 10.3171/jns.1972.36.1.0114
   MATTHEWS LS, 1972, J BONE JOINT SURG AM, VA 54, P297, DOI 10.2106/00004623-197254020-00008
   McMahon JHA, 2001, J CLIN NEUROSCI, V8, P319, DOI 10.1054/jocn.2000.0820
   Metwali H, 2016, J NEUROSURG, V125, P683, DOI 10.3171/2015.6.JNS141847
   MILENKOVIC Z, 1982, J NEUROSURG, V57, P823, DOI 10.3171/jns.1982.57.6.0823
   Nacar OA, 2014, TURK NEUROSURG, V24, P937, DOI 10.5137/1019-5149.JTN.12586-14.1
   NAKAO S, 1981, J NEUROSURG, V54, P532, DOI 10.3171/jns.1981.54.4.0532
   NISHIO S, 1985, ACTA NEUROCHIR, V76, P82, DOI 10.1007/BF01418465
   Oikawa S, 1998, J NEUROSURG, V89, P250, DOI 10.3171/jns.1998.89.2.0250
   Oshiro EM, 1997, J NEUROSURG, V87, P163, DOI 10.3171/jns.1997.87.2.0163
   Ota N, 2015, WORLD NEUROSURG, V83, P635, DOI 10.1016/j.wneu.2014.12.014
   Park J, 2009, NEUROSURGERY, V65, P727, DOI 10.1227/01.NEU.0000350225.36099.0B
   Phuong HL, 2004, J CLIN NEUROSCI, V11, P283, DOI 10.1016/j.jocn.2003.08.005
   RENN WH, 1975, J NEUROSURG, V43, P288, DOI 10.3171/jns.1975.43.3.0288
   Rhoton Jr AI, 2002, NEUROSURGERY, V53, P1
   RIZZO JF, 1995, OPHTHALMOLOGY, V102, P905, DOI 10.1016/S0161-6420(95)30936-0
   Rozen WM, 2009, ANZ J SURG, V79, P913, DOI 10.1111/j.1445-2197.2009.05143.x
   Salunke P, 2016, WORLD NEUROSURG, V95, P292, DOI 10.1016/j.wneu.2016.08.015
   Santana Pereira R S, 2006, J Neurosurg Sci, V50, P1
   Serrano LE, 2019, NEUROSURG REV, V42, P877, DOI 10.1007/s10143-018-01063-3
   Sheikh B, 2000, ACTA NEUROCHIR, V142, P33, DOI 10.1007/s007010050004
   Sheikh B, 2000, NEUROSURGERY, V46, P1156, DOI 10.1097/00006123-200005000-00027
   SHIOKAWA Y, 1988, ACTA NEUROCHIR, V93, P154, DOI 10.1007/BF01402900
   Stephens R. B., 1969, ARTERIES VEINS HUMAN
   VAJDA J, 1988, NEUROSURGERY, V22, P662, DOI 10.1227/00006123-198804000-00007
   van Lindert E, 1998, SURG NEUROL, V49, P481, DOI 10.1016/S0090-3019(96)00539-3
   XU DS, 1994, BRAIN, V117, P375, DOI 10.1093/brain/117.2.375
   YAMADA K, 1984, NEUROSURGERY, V15, P5, DOI 10.1227/00006123-198407000-00003
   Yasargil M G, 1975, Surg Neurol, V3, P7
   Yasargil MG, 1984, CLIN CONSIDERATIONS, V2
   Yu LH, 2017, WORLD NEUROSURG, V108, P572, DOI 10.1016/j.wneu.2017.09.048
   ZIMMERMAN CF, 1995, OPHTHALMOLOGY, V102, P594, DOI 10.1016/S0161-6420(95)30979-7
NR 59
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E261
EP E275
DI 10.1016/j.wneu.2019.04.134
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100030
PM 31026658
DA 2020-05-12
ER

PT J
AU Sewell, MD
   Vachhani, K
   Hockings, J
   Chan, J
   Alrawi, A
   Williams, R
AF Sewell, Mathew David
   Vachhani, Kathak
   Hockings, Jason
   Chan, Jonathan
   Alrawi, Asif
   Williams, Richard
TI A Hemodynamic Safety Checklist Can Improve Blood Pressure Monitoring in
   Patients with Acute Spinal Cord Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blood pressure; Checklist; MAP; Monitoring; Spinal cord injury
ID TRAUMA; MANAGEMENT
AB OBJECTIVE: The American Association and Congress of Neurological Surgeons recommended mean arterial blood pressure (MAP) in patients with acute spinal cord injury (SCI) should be 85-90 mm Hg for the first 7 days. We evaluated whether hemodynamic management differed between a primary-receiving and tertiary hospital in the first 24 hours for patients with acute SCI and assessed whether use of a checklist could improve hemodynamic management.
   METHODS: Observational review was performed of 79 patients with acute SCI before and after introduction of a blood pressure monitoring checklist and staff educational program designed to improve tertiary center management. Hemodynamic management in the primary-receiving hospital was compared with the tertiary center before and after checklist introduction.
   RESULTS: At the primary-receiving center, mean number of documented MAP readings/hour was 2.2 and 3 before and after checklist introduction. The proportion having >50% of MAP recordings <80 mm Hg was 26% and 22%. The proportion having >50% of MAP recordings <70 mm Hg was 8.5% and 7%. At the tertiary center, mean number of MAP readings/hour was 1.3 and 2.7 before and after checklist introduction (P = 0.02). The proportion having >50% of MAP recordings <80 mm Hg decreased from 36.5% to 16% after checklist introduction (P = 0.05). The proportion having >50% of MAP recordings <70 mm Hg decreased from 9% to 5.5% (P = 0.6). Polytrauma, inotrope use, and head injury significantly correlated with low MAP recordings (P < 0.05). Polytrauma was an independent risk predictor for low MAP recordings (P < 0.05).
   CONCLUSIONS: Achieving MAP targets for patients with acute SCI is challenging. Checklist use and staff education were associated with improved hemodynamic management. Presence of polytrauma identified patients at particular risk.
C1 [Sewell, Mathew David; Vachhani, Kathak; Hockings, Jason; Chan, Jonathan; Williams, Richard] Univ Queensland, Princess Alexandra Hosp, Spinal Unit, Brisbane, Qld, Australia.
   [Alrawi, Asif] James Cook Univ Hosp, Spinal Unit, Middlesbrough, Cleveland, England.
RP Sewell, MD (reprint author), Univ Queensland, Princess Alexandra Hosp, Spinal Unit, Brisbane, Qld, Australia.
EM matbuzz1@hotmail.com
CR Berenholtz SM, 2004, CRIT CARE MED, V32, P2014, DOI 10.1097/01.CCM.0000142399.70913.2F
   Casha S, 2011, J NEUROTRAUM, V28, P1479, DOI 10.1089/neu.2009.1156
   Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751
   Consortium Spinal Cord Med, 2008, J SPINAL CORD MED, V31, P403
   Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037
   Felleiter P, 2012, SPINE, V37, P953, DOI 10.1097/BRS.0b013e31823a07a2
   Furlan JC, 2011, J NEUROTRAUM, V28, P1371, DOI 10.1089/neu.2009.1147
   Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119
   Kong CY, 2013, SPINAL CORD, V51, P466, DOI 10.1038/sc.2013.32
   Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007
   LEVI L, 1993, NEUROSURGERY, V33, P1007, DOI 10.1097/00006123-199312000-00008
   Lingard L, 2004, QUAL SAF HEALTH CARE, V13, P330, DOI 10.1136/qshc.2003.008425
   Mayo E., 2004, HUMAN PROBLEMS IND C
   RIVLIN AS, 1978, J NEUROSURG, V49, P844, DOI 10.3171/jns.1978.49.6.0844
   Ryken TC, 2013, NEUROSURGERY, V72, P84, DOI 10.1227/NEU.0b013e318276ee16
   Sewell M, 2011, INT ORTHOP, V35, P897, DOI 10.1007/s00264-010-1112-7
   Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239
   Wyndaele M, 2006, SPINAL CORD, V44, P523, DOI 10.1038/sj.sc.3101893
NR 18
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E225
EP E230
DI 10.1016/j.wneu.2019.04.106
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100025
PM 31048060
DA 2020-05-12
ER

PT J
AU Skarupa, D
   Madbak, F
   Ebler, D
   Hsu, A
   Torres, MB
   Johnson, D
   Rahmathulla, G
   Kerwin, AJ
   Ra, J
   Shiber, J
   Crandall, M
AF Skarupa, David
   Madbak, Firas
   Ebler, David
   Hsu, Albert
   Torres, Madeline B.
   Johnson, Donald
   Rahmathulla, Gazanfar
   Kerwin, Andrew J.
   Ra, Jin
   Shiber, Joseph
   Crandall, Marie
TI Prolonged Antibiotics for Drains After Spine Injury Instrumentation for
   Trauma: Not Prophylactic or Necessary
SO WORLD NEUROSURGERY
LA English
DT Article
DE Spine fractures; Surgical drains; Surgical site infections; Trauma
ID SURGICAL SITE INFECTION; RISK-FACTORS; SURGERY; PREVENTION; GUIDELINE
AB BACKGROUND: Antibiotics after spine instrumentation are often extended while the surgical drain is in place, particularly for traumatic injuries. We sought to study if continuing antibiotics past 24 hours affected outcomes.
   METHODS: We performed a retrospective observational study of all patients who underwent spine fixation with hardware and surgical drains for trauma at our institution. We compared the effect of perioperative (<= 24 hours of antibiotics) versus prolonged (>24 hours) antibiotics on surgical outcomes. Bivariate and multivariable logistic and linear regression statistics were performed
   RESULTS: Three hundred and forty-six patients were included in the analysis. On multivariate analysis, antibiotic duration >24 hours did not predict surgical site infection (odds ratio, 2.68; 95% confidence interval, 0.88-8.10, P = 0.08) or mortality (odds ratio, 0.59; 95% confidence interval, 0.10-3.44; P = 0.56).
   CONCLUSIONS: Continuing antibiotics past 24 hours after traumatic spine instrumentation was not associated with improved outcomes. A prospective study to verify these findings may be warranted.
C1 [Skarupa, David; Madbak, Firas; Ebler, David; Hsu, Albert; Kerwin, Andrew J.; Ra, Jin; Crandall, Marie] Univ Florida, Coll Med Jacksonville, Dept Surg, Jacksonville, FL 32209 USA.
   [Torres, Madeline B.] NCI, Surg Oncol Program, Ctr Canc Res, Bethesda, MD 20892 USA.
   [Johnson, Donald] Univ Florida, Coll Med Jacksonville, Dept Pharm, Jacksonville, FL USA.
   [Skarupa, David; Rahmathulla, Gazanfar; Shiber, Joseph] Univ Florida, Coll Med Jacksonville, Dept Neurosurg, Jacksonville, FL USA.
   [Shiber, Joseph] Univ Florida, Coll Med Jacksonville, Dept Emergency Med, Jacksonville, FL USA.
   [Shiber, Joseph] Univ Florida, Coll Med Jacksonville, Dept Surg, Jacksonville, FL USA.
RP Crandall, M (reprint author), Univ Florida, Coll Med Jacksonville, Dept Surg, Jacksonville, FL 32209 USA.
EM Marie.crandall@jax.ufl.edu
RI Rahmathulla, Gazanfar/D-1890-2014; Skarupa, David/AAI-1894-2019
OI Rahmathulla, Gazanfar/0000-0002-0904-1840; 
CR Anderson DJ, 2014, INFECT CONT HOSP EP, V35, P605, DOI [10.1086/676022, 10.1017/S0899823X00193869]
   Ban KA, 2017, J AM COLL SURGEONS, V224, P1
   Berrios SI, 2017, JAMA SURG, V152, P784, DOI 10.1001/jamasurg.2017.0904
   Blam OG, 2003, SPINE, V28, P1475, DOI 10.1097/00007632-200307010-00022
   Bratzler Dale W, 2013, Am J Health Syst Pharm, V70, P195, DOI 10.2146/ajhp120568
   Bratzler DW, 2005, ARCH SURG-CHICAGO, V140, P174, DOI 10.1001/archsurg.140.2.174
   Brown MD, 2004, SPINE, V29, P1066, DOI 10.1097/00007632-200405150-00003
   Chang MC, AM COLL SURG NATL TR
   Glassman SD, 1996, SPINE, V21, P2163, DOI 10.1097/00007632-199609150-00021
   Harbarth S, 2000, CIRCULATION, V101, P2916, DOI 10.1161/01.CIR.101.25.2916
   Herrick DB, 2018, J NEUROSURG-SPINE, V29, P628, DOI 10.3171/2018.5.SPINE171313
   Hoth JJ, 2003, J TRAUMA, V55, P249, DOI 10.1097/01.TA.0000083334.93868.65
   Hu R, 1996, SPINE, V21, P492, DOI 10.1097/00007632-199602150-00016
   Kasliwal Manish K, 2013, Surg Neurol Int, V4, pS392, DOI 10.4103/2152-7806.120783
   Kou J, 2002, SPINE, V27, P1670, DOI 10.1097/00007632-200208010-00016
   Mauldin PD, 2010, ANTIMICROB AGENTS CH, V54, P109, DOI 10.1128/AAC.01041-09
   Patel SB, 2017, EUR SPINE J, V26, P2729, DOI 10.1007/s00586-017-4983-0
   Rao SB, 2011, CLIN INFECT DIS, V53, P686, DOI 10.1093/cid/cir506
   Rechtine GR, 2001, J ORTHOP TRAUMA, V15, P566, DOI 10.1097/00005131-200111000-00006
   Shaffer WO, 2013, SPINE J, V13, P1387, DOI 10.1016/j.spinee.2013.06.030
   STONE HH, 1976, ANN SURG, V184, P443, DOI 10.1097/00000658-197610000-00007
   Takemoto RC, 2015, J BONE JOINT SURG AM, V97A, P979, DOI 10.2106/JBJS.L.00782
   ter Gunne AFP, 2009, SPINE, V34, P1422, DOI 10.1097/BRS.0b013e3181a03013
   US Centers for Disease Control and Prevention, LEAD CAUS DEATH
   Ventola C Lee, 2015, P T, V40, P277
NR 25
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E552
EP E555
DI 10.1016/j.wneu.2019.04.193
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100064
PM 31051302
DA 2020-05-12
ER

PT J
AU Song, Y
   Sheen, JJ
   Jia, ZY
   Kim, JG
   Chung, J
   Park, D
   Shin, JH
   Lee, D
   Suh, DC
AF Song, Yunsun
   Sheen, Jae Jon
   Jia, Zhen Yu
   Kim, Joong-Goo
   Chung, Jaewoo
   Park, Danbi
   Shin, Jae Ho
   Lee, Dongwhane
   Suh, Dae Chul
TI Stent-Assisted Coil Embolization of MCA Bifurcation Aneurysms at a
   Hypoplastic M1 Branch by Use of Hook Technique
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Aneurysm; Embolization; Middle cerebral artery
ID CEREBRAL-ARTERY ANEURYSMS; CLASSIFICATION; OCCLUSION; UPDATE
AB BACKGROUND: We describe the Hook technique enabling coil embolization in unfavorable M1 bifurcation aneurysms and analyze the morphologic variations in M1 bifurcation to evaluate how often such aneurysms can be seen.
   METHODS: Among 42 MCA aneurysms treated by stent-assisted coil embolization, aneurysms arising at the acute-angled hypoplastic M1 branch (n = 14) were treated by the Hook technique, in which a short stent was deployed only to protect the aneurysm neck after micro-catheter selection of the hypoplastic M2, followed by subsequent coiling of the aneurysm. Outcome was evaluated, including Raymond classification, coil packing density, final modified Rankin Scale (mRS), and recurrence. Separately, 100 middle cerebral artery (MCA) bifurcation aneurysms were analyzed to assess the proportion of such unfavorable aneurysms.
   RESULTS: Procedural success of the Hook technique was obtained in 13 of 14 patients (93%). A mean packing density of 30% was achieved. Magnetic resonance angio-graphic follow-up at a median 4 months (range, 1-26 months) showed complete occlusion in 11 patients and residual neck filling in 3 patients. There was no clinical event (mRS = 0) over a median 17 months (range, 2-26 months) of clinical follow-up. One patient had a thrombotic occlusion during the procedure, which was resolved after tirofiban infusion, without evidence of an infarct or deficit. Of the 100 MCA bifurcation aneurysms, aneurysm arising in asymmetric hypoplastic M2 division was the most common type (48%).
   CONCLUSIONS: The Hook technique enabled stent-assisted coiling of M1 bifurcation aneurysm with extension along the asymmetric hypoplastic M2 division and also securing the M2 branch.
C1 [Song, Yunsun; Sheen, Jae Jon; Jia, Zhen Yu; Kim, Joong-Goo; Chung, Jaewoo; Park, Danbi; Shin, Jae Ho; Lee, Dongwhane; Suh, Dae Chul] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol,Neurointervent Clin, Seoul, South Korea.
RP Suh, DC (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol,Neurointervent Clin, Seoul, South Korea.
EM dcsuh@amc.seoul.kr
RI ; Suh, Dae Chul/F-5949-2014
OI Kim, Joong-Goo/0000-0002-4166-6023; Suh, Dae Chul/0000-0003-1561-5596;
   Chung, Jaewoo/0000-0002-3512-6610
FU National Research Foundation of Korea - Korea government (MSIT)
   [2018R1A2B6003143]
FX Supported by a National Research Foundation of Korea grant funded by the
   Korea government (MSIT) (No. 2018R1A2B6003143).
CR Adeeb N, 2018, NEUROSURGERY, V82, P710, DOI 10.1093/neuros/nyx310
   Aguilar-Perez M, 2014, AM J NEURORADIOL, V35, P965, DOI 10.3174/ajnr.A3807
   Brzegowy P, 2018, FOLIA MORPHOL, V77, P434, DOI 10.5603/FM.a2017.0112
   Cekirge HS, 2016, AM J NEURORADIOL, V37, P19, DOI 10.3174/ajnr.A4489
   Chung J, 2015, WORLD NEUROSURG, V83, P666, DOI 10.1016/j.wneu.2015.01.023
   Jia ZY, 2018, ACTA NEUROCHIR, V160, P1755, DOI 10.1007/s00701-018-3642-5
   Jia ZY, 2018, J STROKE, V20, P46, DOI 10.5853/jos.2017.02229
   Johnson AK, 2013, J NEUROSURG, V118, P950, DOI 10.3171/2013.1.JNS121298
   Kim Byung Moon, 2011, Neurointervention, V6, P53, DOI 10.5469/neuroint.2011.6.2.53
   Kumar MVK, 2007, MINIM INVAS NEUROSUR, V50, P132, DOI 10.1055/s-2007-985153
   Mascitelli JR, 2015, J NEUROINTERV SURG, V7, P496, DOI 10.1136/neurintsurg-2014-011258
   Rinne J, 1996, NEUROSURGERY, V38, P2, DOI 10.1097/00006123-199601000-00002
   Rodriguez-Hernandez A, 2013, NEUROSURGERY, V72, P415, DOI 10.1227/NEU.0b013e3182804aa2
   Sheen JJ, 2017, NEURORADIOLOGY, V59, P1053, DOI 10.1007/s00234-017-1879-y
   Spiotta AM, 2018, AM J NEURORADIOL, V39, P848, DOI 10.3174/ajnr.A5599
   van Dijk JMC, 2011, ACTA NEUROCHIR, V153, P2111, DOI 10.1007/s00701-011-1139-6
   Yang W, 2015, CHIN NEUROSURG J, V1, P1, DOI [10.1186/s41016-015-0001-8, DOI 10.1186/S41016-015-0001-8]
   Yavuz K, 2014, AM J NEURORADIOL, V35, P529, DOI 10.3174/ajnr.A3692
   Zhu W, 2013, ACTA NEUROCHIR, V155, P1481, DOI 10.1007/s00701-013-1751-8
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E615
EP E620
DI 10.1016/j.wneu.2019.04.219
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100071
PM 31054347
DA 2020-05-12
ER

PT J
AU Sweeney, J
   Zyck, S
   Tovar-Spinoza, Z
   Krishnamurthy, S
   Chin, L
   Bodman, A
AF Sweeney, Jared
   Zyck, Stephanie
   Tovar-Spinoza, Zulma
   Krishnamurthy, Satish
   Chin, Lawrence
   Bodman, Alexa
TI Evidence-Based Perioperative Protocol for Ventriculoperitoneal Shunt
   Infection Reduction at a Single Institution
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hydrocephalus; Infection; Protocol; Shunt; Ventriculoperitoneal
ID SUTURE WOUND CLOSURE; HYDROCEPHALUS; MANAGEMENT; CATHETERS; CHILDREN;
   COST
AB OBJECTIVE: Ventriculoperitoneal shunt infections are common and result in significant morbidity, mortality, and health care expenditure. The objective of this study was to create an evidence-based perioperative shunt infection prevention protocol and analyze its efficacy by comparing the incidence of shunt infection before and after implementation at one institution.
   METHODS: A perioperative ventriculoperitoneal shunt surgery protocol was developed based on a systematic literature review with the goal of reducing infection rates. Patients undergoing shunt surgery at Upstate Medical University Hospital, from before and after implantation of the perioperative shunt surgery protocol, were retrospectively analyzed and compared. Retrospective data collection included shunt infection incidence as a primary outcome and clinical features of patients from both cohorts.
   RESULTS: The pre-protocol and post-protocol cohorts included 226 and 285 patients, respectively. Twenty (8.8%) pre-protocol shunt infections and 16 (5.6%) post-protocol shunt infections were identified (P = 0.156). The relative risk of shunt infection between cohorts was 0.97 (95% confidence interval: 0.92-1.02).
   CONCLUSIONS: Although shunt infection rates pre-protocol and post-protocol were not significantly different, a trend toward fewer shunt infections was observed with protocol implementation. Suboptimal compliance at our institution may have limited assessment of protocol efficacy. Similar future studies may benefit from objectively assessing protocol compliance.
C1 [Sweeney, Jared; Zyck, Stephanie; Tovar-Spinoza, Zulma; Krishnamurthy, Satish; Chin, Lawrence] SUNY Upstate Med Univ, Dept Neurosurg, Syracuse, NY 13210 USA.
   [Bodman, Alexa] Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA.
RP Bodman, A (reprint author), Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA.
EM alexa.bodman@emory.edu
OI Zyck, Stephanie/0000-0002-1743-1056; Krishnamurthy,
   Satish/0000-0001-7808-7407
CR Anderson DJ, 2014, INFECT CONT HOSP EP, V35, P605, DOI [10.1086/676022, 10.1017/S0899823X00193869]
   Attenello FJ, 2010, NEUROSURGERY, V66, P284, DOI 10.1227/01.NEU.0000363405.12584.4D
   Bayston R, 1990, Z Kinderchir, V45 Suppl 1, P5
   Blount J P, 1993, Neurosurg Clin N Am, V4, P633
   Burrows AM, 2016, WORLD NEUROSURG, V89, P108, DOI 10.1016/j.wneu.2016.01.077
   Choksey MS, 2004, J NEUROL NEUROSUR PS, V75, P87
   CHOUX M, 1992, J NEUROSURG, V77, P875, DOI 10.3171/jns.1992.77.6.0875
   Edwards NC, 2015, J NEUROSURG, V122, P139, DOI 10.3171/2014.9.JNS131277
   Erps A, 2018, PEDIATR INT, V60, P1056, DOI 10.1111/ped.13709
   FAILLACE WJ, 1995, SURG NEUROL, V43, P344, DOI 10.1016/0090-3019(95)80060-T
   Farber SH, 2010, WORLD NEUROSURG, V74, P528, DOI 10.1016/j.wneu.2010.07.014
   Hayashi T, 2010, J NEUROSURG-PEDIATR, V6, P273, DOI 10.3171/2010.5.PEDS1018
   Hommelstad J, 2013, ACTA NEUROCHIR, V155, P523, DOI 10.1007/s00701-012-1574-z
   James G, 2014, J NEUROSURG-PEDIATR, V13, P101, DOI 10.3171/2013.10.PEDS13189
   JAMES HE, 1980, NEUROSURGERY, V7, P459, DOI 10.1227/00006123-198011000-00006
   JAMES HE, 1981, ACTA NEUROCHIR, V59, P157, DOI 10.1007/BF01406345
   Jeelani NUO, 2009, J NEUROS-PEDIATR, V4, P166, DOI 10.3171/2009.3.PEDS08458
   Kestle JRW, 2016, J NEUROSURG-PEDIATR, V17, P391, DOI 10.3171/2015.8.PEDS15253
   Kestle JRW, 2011, J NEUROSURG-PEDIATR, V8, P22, DOI 10.3171/2011.4.PEDS10551
   Khalil A, 2016, BRIT J NEUROSURG, V30, P427, DOI 10.3109/02688697.2015.1119235
   Kulkarni AV, 2001, PEDIATR NEUROSURG, V35, P66, DOI 10.1159/000050393
   Lee RP, 2018, NEUROSURGERY, V83, P508, DOI 10.1093/neuros/nyx478
   McGirt MJ, 2003, CLIN INFECT DIS, V36, P858, DOI 10.1086/368191
   McGirt MJ, 2002, PEDIATR NEUROSURG, V36, P248, DOI 10.1159/000058428
   Omrani O, 2018, CHILD NERV SYST, V34, P2407, DOI 10.1007/s00381-018-3953-0
   Paff M, 2018, INTERDISCIP NEUROSUR, V13, P66, DOI 10.1016/j.inat.2018.04.004
   Patwardhan RV, 2005, NEUROSURGERY, V56, P139, DOI 10.1227/01.NEU.0000146206.40375.41
   Pirotte BJM, 2007, CHILD NERV SYST, V23, P1251, DOI 10.1007/s00381-007-0415-5
   Rotim K, 1997, CHILD NERV SYST, V13, P584, DOI 10.1007/s003810050144
   Rozzelle CJ, 2008, J NEUROSURG-PEDIATR, V2, P111, DOI 10.3171/PED/2008/2/8/111
   Schreffler RT, 2002, PEDIATR INFECT DIS J, V21, P632, DOI 10.1097/00006454-200207000-00006
   Stone J, 2010, PEDIATR NEUROSURG, V46, P19, DOI 10.1159/000314053
   Tanner J, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003087, DOI 10.1002/14651858.CD003087]
   The Joint Commission, 2010, MAN JOINT COMM NAT Q
   Tunkel AR, 2004, CLIN INFECT DIS, V39, P1267, DOI 10.1086/425368
   WALTERS BC, 1984, J NEUROSURG, V60, P1014, DOI 10.3171/jns.1984.60.5.1014
   Whitehead WE, 2001, PEDIATR NEUROSURG, V35, P205, DOI 10.1159/000050422
NR 37
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E814
EP E822
DI 10.1016/j.wneu.2019.04.261
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100096
PM 31078805
OA Bronze
DA 2020-05-12
ER

PT J
AU Taslimi, S
   Zuccato, JA
   Mansouri, A
   Hachem, LD
   Badhiwala, J
   Kuchta, J
   Chen, J
   Pirouzmand, F
AF Taslimi, Shervin
   Zuccato, Jeffrey A.
   Mansouri, Alireza
   Hachem, Laureen D.
   Badhiwala, Jetan
   Kuchta, Johannes
   Chen, Joseph
   Pirouzmand, Farhad
TI Novel Statistical Analyses to Assess Hearing Outcomes After ABI
   Implantation in NF2 Patients: Systematic Review and Individualized
   Patients Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Audition; Auditory brainstem implant; Neurofibromatosis; Outcome
   research; Primary brain tumor
ID BRAIN-STEM IMPLANT; SPEECH RECOGNITION; NEUROFIBROMATOSIS TYPE-2;
   COCHLEAR; RESTORATION; PERFORMANCE; ELECTRODES; NUMBER
AB BACKGROUND: Patients with neurofibromatosis type 2 develop bilateral vestibular schwannomas with progressive hearing loss. Auditory brainstem implants (ABIs) stimulate hearing in the cochlear nuclei and show promise in improving hearing. Here, we assess the impact of ABI on hearing over time by systematically reviewing the literature and re-analyzing available individual patient data.
   METHODS: A multidatabase search identified 3 studies with individual patient data of longitudinal hearing outcomes after ABI insertion in adults. Data were collected on hearing outcomes of different sound complexities from sound to speech using an ABI +/- lip reading ability plus demographic data. Because of heterogeneity each study was analyzed separately using random effects multilevel mixed linear modeling.
   RESULTS: Across all 3 studies (n = 111 total) there were significant improvements in hearing over time from ABI placement (P < 0.000 in all). Improvements in comprehension of sounds, words, sentences, and speech occurred over time with ABI use + lip reading but lip reading ability did not improve over time. All categories of hearing complexity had over 50% comprehension after over 1 year of ABI use and some subsets had over 75% or near 100% comprehension. Vowel comprehension was greater than consonant, and word comprehension was greater than sentence comprehension (P < 0.0001 in both). Age and sex did not predict outcomes.
   CONCLUSIONS: ABIs improve hearing beyond lip reading alone, which represents baseline patient function prior to treatment, and the benefits continue to improve with time. These findings may be used to guide patient counseling regarding ABI insertion, rehabilitation course after insertion, and future studies.
C1 [Taslimi, Shervin; Zuccato, Jeffrey A.; Mansouri, Alireza; Hachem, Laureen D.; Badhiwala, Jetan] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.
   [Kuchta, Johannes] Univ Cologne, Dept Neurosurg, Cologne, Germany.
   [Chen, Joseph] Sunnybrook Hlth Sci Ctr, Dept Otolaryngol, Toronto, ON, Canada.
   [Pirouzmand, Farhad] Sunnybrook Hlth Sci Ctr, Div Neurosurg, Dept Surg, Toronto, ON, Canada.
RP Zuccato, JA (reprint author), Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.
EM jeff.zuccato@mail.utoronto.ca
OI Mansouri, Alireza/0000-0002-7442-7539
CR Behr R, 2007, SKULL BASE-INTERD AP, V17, P91, DOI 10.1055/s-2006-950390
   Bento Ricardo Ferreira, 2008, Rev. Bras. Otorrinolaringol., V74, P647, DOI [10.1590/S0034-72992008000500002, 10.1016/S1808-8694(15)31371-9]
   Colletti V, 2005, LARYNGOSCOPE, V115, P1974, DOI 10.1097/01.mlg.0000178327.42926.ec
   Colletti V, 2005, OTOLARYNG HEAD NECK, V133, P126, DOI 10.1016/j.otohns.2005.03.022
   Colletti Vittorio, 2006, Adv Otorhinolaryngol, V64, P167, DOI 10.1159/000094651
   Ebinger K, 2000, J LARYNGOL OTOL, V114, P50
   Evans DG, 2010, AM J MED GENET A, V152A, P327, DOI 10.1002/ajmg.a.33139
   Fishman KE, 1997, J SPEECH LANG HEAR R, V40, P1201, DOI 10.1044/jslhr.4005.1201
   Friesen LM, 2001, J ACOUST SOC AM, V110, P1150, DOI 10.1121/1.1381538
   Grayeli AB, 2008, OTOL NEUROTOL, V29, P1140, DOI 10.1097/MAO.0b013e31818b6238
   Kanowitz SJ, 2004, LARYNGOSCOPE, V114, P2135, DOI 10.1097/01.mlg.0000149447.52888.f6
   Kuchta J, 2004, J NEUROSURG, V100, P16, DOI 10.3171/jns.2004.100.1.0016
   LASZIG R, 1995, J LARYNGOL OTOL, V109, P385, DOI 10.1017/S0022215100130257
   Lenarz M, 2002, OTOL NEUROTOL, V23, P694, DOI 10.1097/00129492-200209000-00015
   Lenarz T, 2001, OTOL NEUROTOL, V22, P823, DOI 10.1097/00129492-200111000-00019
   Maini Sangeeta, 2009, Cochlear Implants Int, V10 Suppl 1, P33, DOI 10.1179/cim.2009.10.Supplement-1.33
   Marangos N, 2000, J LARYNGOL OTOL, V114, P27
   Matthies C, 2013, ORL J OTO-RHINO-LARY, V75, P282, DOI 10.1159/000350568
   Monteiro TA, 2012, BRAZ J OTORHINOLAR, V78, P128, DOI 10.5935/1808-8694.20120020
   Nevison B, 2002, EAR HEARING, V23, P170, DOI 10.1097/00003446-200206000-00002
   Otto SR, 2002, J NEUROSURG, V96, P1063, DOI 10.3171/jns.2002.96.6.1063
   Otto SR, 2008, OTOL NEUROTOL, V29, P1147, DOI 10.1097/MAO.0b013e31818becb4
   Sanna M, 2012, OTOL NEUROTOL, V33, P154, DOI 10.1097/MAO.0b013e318241bc71
   Schwartz MS, 2003, STEREOT FUNCT NEUROS, V81, P110, DOI 10.1159/000075113
   Sollmann WP, 2000, J LARYNGOL OTOL, V114, P23
   Vincent C, 2002, OTOL NEUROTOL, V23, P56, DOI 10.1097/00129492-200201000-00014
   Vincenti V, 2008, AUDIOL NEURO-OTOL, V13, P273, DOI 10.1159/000115437
NR 27
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E669
EP E682
DI 10.1016/j.wneu.2019.04.232
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100079
PM 31059859
DA 2020-05-12
ER

PT J
AU Trott, S
   Vsevolozhskaya, O
   Pennypacker, K
   Alhajeri, A
   Fraser, JF
AF Trott, Skylar
   Vsevolozhskaya, Olga
   Pennypacker, Keith
   Alhajeri, Abdulnasser
   Fraser, Justin F.
TI Immune System Activation in Perioperative Thrombectomy Patients:
   Preliminary Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Immune activation; Mechanical thrombectomy; Sex differences; White blood
   cells
ID ISCHEMIC-STROKE; EXPRESSION; BLOOD
AB BACKGROUND: Ischemic stroke is a devastating condition resulting in significant morbidity. Mechanical thrombectomy is now standard for large vessel occlusive stroke. Neuroinflammation is known to play important roles in ischemic stroke. Our aims were to examine our thrombectomy procedures and preliminarily examine systemic immune response in relation to thrombectomy changes.
   METHODS: A retrospective review was conducted on mechanical thrombectomy cases from July 2011 through December 2015. Primary outcomes were time to recanalization, final Thrombolysis in Cerebral Infarction score, procedural complications, National Institutes of Health Stroke Scale improvement, and changes in white blood cell (WBC) count.
   RESULTS: One-hundred and twenty-nine procedures performed. We found a significant difference between WBC count on admission and WBC count post thrombectomy day 1 for patients with >90 minutes to recanalization (P = 0.006107). There was a positive association between WBC change and absolute National Institutes of Health Stroke Scale change among females (P = 0.0273) but not among males.
   CONCLUSIONS: Overall, we found that systemic immune response has close relationships with speed of recanalization and preliminarily may shift differently on the basis of sex.
C1 [Trott, Skylar; Alhajeri, Abdulnasser; Fraser, Justin F.] Univ Kentucky, Coll Med, Lexington, KY 40506 USA.
   [Vsevolozhskaya, Olga] Univ Kentucky, Coll Publ Hlth, Dept Biostat, Lexington, KY USA.
   [Pennypacker, Keith; Alhajeri, Abdulnasser; Fraser, Justin F.] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA.
   [Pennypacker, Keith; Fraser, Justin F.] Univ Kentucky, Dept Neurosci, Lexington, KY 40506 USA.
   [Alhajeri, Abdulnasser; Fraser, Justin F.] Univ Kentucky, Dept Neurosurg, Lexington, KY 40506 USA.
   [Alhajeri, Abdulnasser; Fraser, Justin F.] Univ Kentucky, Dept Radiol, Lexington, KY 40506 USA.
RP Fraser, JF (reprint author), Univ Kentucky, Coll Med, Lexington, KY 40506 USA.; Fraser, JF (reprint author), Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA.; Fraser, JF (reprint author), Univ Kentucky, Dept Neurosci, Lexington, KY 40506 USA.; Fraser, JF (reprint author), Univ Kentucky, Dept Neurosurg, Lexington, KY 40506 USA.; Fraser, JF (reprint author), Univ Kentucky, Dept Radiol, Lexington, KY 40506 USA.
EM jfr235@uky.edu
OI Fraser, Justin/0000-0002-5980-3989
CR Barouch R, 2000, J NEUROIMMUNOL, V103, P112, DOI 10.1016/S0165-5728(99)00233-7
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Elkind Mitchell S V, 2004, J Stroke Cerebrovasc Dis, V13, P220, DOI 10.1016/j.jstrokecerebrovasdis.2004.07.004
   Fraser JF, 2019, J NEUROINTERV SURG, V11, P265, DOI 10.1136/neurintsurg-2018-014118
   Frenkel D, 2005, J NEUROL SCI, V233, P125, DOI 10.1016/j.jns.2005.03.022
   Gory B, 2013, AM J NEURORADIOL, V34, P2192, DOI 10.3174/ajnr.A3531
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Huber T, 2016, CEREBROVASC DIS, V42, P32, DOI 10.1159/000444369
   Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766
   Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Tian YF, 2012, J CEREBR BLOOD F MET, V32, P780, DOI 10.1038/jcbfm.2011.179
   Zha A, 2018, TRANSL STROKE RES, V9, P484, DOI 10.1007/s12975-017-0596-5
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E966
EP E969
DI 10.1016/j.wneu.2019.05.044
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100114
PM 31100531
DA 2020-05-12
ER

PT J
AU Vivas-Buitrago, T
   Lokossou, A
   Jusue-Torres, I
   Pinilla-Monsalve, G
   Blitz, AM
   Herzka, DA
   Robison, J
   Xu, JD
   Guerrero-Cazares, H
   Mori, S
   Quinones-Hinojosa, A
   Baledent, O
   Rigamonti, D
AF Vivas-Buitrago, Tito
   Lokossou, Armelle
   Jusue-Torres, Ignacio
   Pinilla-Monsalve, Gabriel
   Blitz, Ari M.
   Herzka, Daniel A.
   Robison, Jamie
   Xu, Jiadi
   Guerrero-Cazares, Hugo
   Mori, Susumu
   Quinones-Hinojosa, Alfredo
   Baledent, Olivier
   Rigamonti, Daniele
TI Aqueductal Cerebrospinal Fluid Stroke Volume Flow in a Rodent Model of
   Chronic Communicating Hydrocephalus: Establishing a Homogeneous Study
   Population for Cerebrospinal Fluid Dynamics Exploration
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aqueduct; Chronic; Communicating hydrocephalus; iNPH; Phase-contrast
   MRI; Stroke volume
ID NORMAL-PRESSURE HYDROCEPHALUS; PHASE-CONTRAST MRI; MAGNETIC-RESONANCE;
   SHUNT SURGERY; DIAGNOSIS; MORPHOLOGY
AB BACKGROUND: Idiopathic normal pressure hydrocephalus (iNPH) is a cause of dementia that can be reversed when treated timely with cerebrospinal fluid (CSF) diversion. Understanding CSF dynamics throughout the development of hydrocephalus is crucial to identify prognostic markers to estimate benefit/risk to shunts.
   OBJECTIVE: To explore the cerebral aqueduct CSF flow dynamics with phase-contrast magnetic resonance imaging (MRI) in a novel rodent model of adult chronic communicating hydrocephalus.
   METHODS: Kaolin was injected into the subarachnoid space at the convexities in Sprague-Dawley adult rats. 11.7-T Bruker MRI was used to acquire T2-weighted images for anatomic identification and phase-contrast MRI at the cerebral aqueduct. Aqueductal stroke volume (ASV) results were compared with the ventricular volume (VV) at 15, 60, 90, and 120 days.
   RESULTS: Significant ventricular enlargement was found in kaolin-injected animals at all times (P < 0.001). ASV differed between cases and controls/shams at every time point (P = 0.004, 0.001, 0.001, and <0.001 at 15, 60, 90, and 120 days, respectively). After correlation between the ASV and the VV, there was a significant correlation at 15 (P = 0.015), 60 (P = 0.001), 90 (P < 0.001), and 120 days. Moreover, there was a significant positive correlation between the VV expansion and the aqueductal CSF stroke between 15 and 60 days.
   CONCLUSIONS: An initial active phase of rapid ventricular enlargement shows a strong correlation between the expansion of the VV and the increment in the ASV during the first 60 days, followed by a second phase with less ventricular enlargement and heterogeneous behavior in the ASV. Further correlation with complementary data from intracranial pressure and histologic/microstructural brain parenchyma assessments are needed to better understand the ASV variations after 60 days.
C1 [Vivas-Buitrago, Tito; Pinilla-Monsalve, Gabriel; Robison, Jamie; Rigamonti, Daniele] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Blitz, Ari M.; Mori, Susumu] Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD USA.
   [Rigamonti, Daniele] Johns Hopkins Aramco Healthcare, Dept Neurosurg, Dhahran, Saudi Arabia.
   [Xu, Jiadi; Mori, Susumu] Kirby Res Ctr Funct Brain Imaging, Kennedy Krieger Inst, Dept Neurosurg, Baltimore, MD USA.
   [Vivas-Buitrago, Tito; Guerrero-Cazares, Hugo; Quinones-Hinojosa, Alfredo] Mayo Clin Florida, Dept Neurosurg, Jacksonville, FL USA.
   [Lokossou, Armelle; Baledent, Olivier] Univ Picardie Jules Verne, Chimere EA, Res Team Head & Neck, Amiens, France.
   [Baledent, Olivier] Jules Verne Univ Hosp, Dept Image Proc, Amiens, France.
   [Jusue-Torres, Ignacio] Loyola Univ, Sch Med, Dept Neurosurg, Maywood, IL 60153 USA.
   [Herzka, Daniel A.] Johns Hopkins Sch Engn, Dept Biomed Engn, Baltimore, MD USA.
   [Vivas-Buitrago, Tito] Univ Santander UDES, Sch Med, Fac Hlth Sci, Bucaramanga, Colombia.
RP Rigamonti, D (reprint author), Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.; Rigamonti, D (reprint author), Johns Hopkins Aramco Healthcare, Dept Neurosurg, Dhahran, Saudi Arabia.
EM Daniele.Rigamonti@jhah.com
RI Jusue-Torres, Ignacio/C-5979-2013
OI Jusue-Torres, Ignacio/0000-0002-9749-1912
FU Salisbury Family Endowed Professorship; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [R01NS070024, R21CA199295, R43CA221490, R01CA200399, R01CA183827,
   R01CA195503, R01CA216855]; Mayo Clinic
FX This work was funded by the Salisbury Family Endowed Professorship.
   H.G.C. and A.Q.H. were funded by NIH R01NS070024 and R21CA199295. A.Q.H.
   was supported by the Mayo Clinic Professorship and a Clinician
   Investigator award as well as the NIH (R43CA221490, R01CA200399,
   R01CA183827, R01CA195503, R01CA216855).
CR Abbey P, 2009, J CLIN NEUROSCI, V16, P514, DOI 10.1016/j.jocn.2008.05.009
   Aoki Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep07775
   Baledent O, 2001, INVEST RADIOL, V36, P368, DOI 10.1097/00004424-200107000-00003
   Boon AJW, 1997, J NEUROSURG, V87, P687, DOI 10.3171/jns.1997.87.5.0687
   Bradley WG, 1996, RADIOLOGY, V198, P523, DOI 10.1148/radiology.198.2.8596861
   Bradley WG, 2016, SEMIN ULTRASOUND CT, V37, P120, DOI 10.1053/j.sult.2016.01.005
   Chiang WW, 2009, INVEST RADIOL, V44, P192, DOI 10.1097/RLI.0b013e31819a640b
   Cicchetti D., 1994, PSYCHOL ASSESSMENTS, V6, P284, DOI [DOI 10.1037/1040-3590.6.4.284, 10.1037/1040-3590.6.4.284]
   Daouk J, 2014, ACTA RADIOL, V55, P992, DOI 10.1177/0284185113508112
   Dixon GR, 2002, MAYO CLIN PROC, V77, P509, DOI 10.4065/77.6.509
   Duinkerke Anja, 2004, Cogn Behav Neurol, V17, P179, DOI 10.1097/01.wnn.0000124916.16017.6a
   El Sankari S, 2012, ACTA NEUROCHIR SUPPL, V113, P43, DOI 10.1007/978-3-7091-0923-6_9
   Giner JF, 2014, NEUROLOGIA, V29, P68, DOI 10.1016/j.nrl.2013.02.016
   Forner J, 2007, NEUROLOGIA, V22, P213
   Hakim S, 1965, J Neurol Sci, V2, P307, DOI 10.1016/0022-510X(65)90016-X
   Hebb AO, 2001, NEUROSURGERY, V49, P1166, DOI 10.1097/00006123-200111000-00028
   Henry-Feugeas MC, 2001, INVEST RADIOL, V36, P146, DOI 10.1097/00004424-200103000-00003
   Hikida T, 2007, P NATL ACAD SCI USA, V104, P14501, DOI 10.1073/pnas.0704774104
   Hung AL, 2017, CLIN NEUROL NEUROSUR, V157, P1, DOI 10.1016/j.clineuro.2017.03.014
   Jusue-Torres I, 2016, NEUROSURGERY, V79, P746, DOI 10.1227/NEU.0000000000001405
   Kahlon B, 2007, NEUROSURGERY, V60, P9
   Kahlon B, 2007, NEUROSURGERY, V60, P124, DOI 10.1227/01.NEU.0000249208.04344.A3
   Kim DS, 1999, CHILD NERV SYST, V15, P461, DOI 10.1007/s003810050440
   Marmarou A, 2005, NEUROSURGERY, V57, P17, DOI 10.1227/01.NEU.0000168184.01002.60
   McGirt MJ, 2005, NEUROSURGERY, V57, P699, DOI 10.1227/01.NEU.0000175724.00147.10
   Pujari S, 2008, J NEUROL NEUROSUR PS, V79, P1282, DOI 10.1136/jnnp.2007.123620
   Razay G, 2009, J CLIN NEUROSCI, V16, P1180, DOI 10.1016/j.jocn.2008.12.007
   Relkin Norman, 2005, Neurosurgery, V57, pS4
   Saliou G, 2009, J NEURORADIOLOGY, V36, P41, DOI 10.1016/j.neurad.2008.07.004
   Saliou G, 2012, J NEUROIMAGING, V22, P343, DOI 10.1111/j.1552-6569.2011.00594.x
   Scollato A, 2008, AM J NEURORADIOL, V29, P192, DOI 10.3174/ajnr.A0785
   Scollato A, 2009, AM J NEURORADIOL, V30, P1580, DOI 10.3174/ajnr.A1616
   Tawfik AM, 2017, AM J ROENTGENOL, V208, P838, DOI 10.2214/AJR.16.16995
   Tekaya I, 2018, PEDIAT HYDROCEPHALUS, P327
   VANNESTE J, 1992, NEUROLOGY, V42, P54, DOI 10.1212/WNL.42.1.54
   Wagshul ME, 2009, EXP NEUROL, V218, P33, DOI 10.1016/j.expneurol.2009.03.034
   Wagshul ME, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-5
   Williams MA, 2008, AM J PHYS MED REHAB, V87, P39, DOI 10.1097/PHM.0b013e31815b6461
   Yin LK, 2017, ACTA NEUROL SCAND, V136, P434, DOI 10.1111/ane.12750
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1118
EP E1125
DI 10.1016/j.wneu.2019.05.093
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100128
PM 31121363
DA 2020-05-12
ER

PT J
AU Waqas, M
   Shakir, HJ
   Shallwani, H
   Beecher, JS
   Rangel-Castilla, L
   Siddiqui, AH
   Levy, EI
AF Waqas, Muhammad
   Shakir, Hakeem J.
   Shallwani, Hussain
   Beecher, Jeffrey S.
   Rangel-Castilla, Leonardo
   Siddiqui, Adnan H.
   Levy, Elad, I
TI Accredited Endovascular Surgical Neuroradiology Programs: Current
   Specialty Composition and Academic Impact Using the h Index
SO WORLD NEUROSURGERY
LA English
DT Article
DE Academic productivity; Bibliometrics; Citation analysis; h index;
   Neuroendovascular surgery; Neurointervention
AB BACKGROUND: Concerns exist that neurosurgery might fail to lead the field of endovascular surgical neuroradiology (ESN), as other specialties are allowed to train and practice ESN. This study aimed to assess the current breakdown of specialties and their relative academic productivity in accredited ESN fellowship programs.
   METHODS: A list of fellowship programs was obtained from the Accreditation Council for Graduate Medical Education and Committee on Advanced Subspecialty Training directories. Primary specialty (i.e., residency) training for each faculty member in these programs was determined using information provided by the programs. A bibliometric search was performed for each member using Web of Science (Clarivate Analytics, Philadelphia, Pennsylvania, USA). Cumulative and ESN-specific h indices were calculated; h indices were compared between each specialty group and between international medical graduates and US medical graduates, regardless of specialty training.
   RESULTS: Thirty-one ESN fellowship programs with 88 faculty members were included. Neurosurgeons constituted 61.4% (n = 54) of the total ESN faculty, followed by radiologists with 30.7% (n = 27), and neurologists with 7.9% (n = 7). The mean ESN-specific h index for neurosurgery-trained ESN faculty was 16.2 +/- 14.6 compared with 14.4 +/- 10.9 for radiologists and 13.0 +/- 12.6 for neurologists (P = 0.76). There were 12 IMGs and 76 USMGs. The mean ESN-specific h index was greater for IMGs than USMGs, 24.7 +/- 14.3 versus 14.0 +/- 12.7 (P = 0.008), respectively.
   CONCLUSIONS: Neurosurgery is leading the ESN field in numbers; however, the h index is not significantly different among ESN faculty based on primary training. The number of IMGs is relatively small, yet IMGs have significantly higher mean h indices.
C1 [Waqas, Muhammad; Shallwani, Hussain; Siddiqui, Adnan H.; Levy, Elad, I] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14260 USA.
   [Siddiqui, Adnan H.; Levy, Elad, I] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Radiol, Buffalo, NY 14260 USA.
   [Siddiqui, Adnan H.; Levy, Elad, I] Univ Buffalo, Canon Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.
   [Waqas, Muhammad; Shallwani, Hussain; Siddiqui, Adnan H.; Levy, Elad, I] Univ Buffalo, Gates Vasc Inst Kaleida Hlth, Dept Neurosurg, Buffalo, NY 14260 USA.
   [Shakir, Hakeem J.] Practicing Neurosurg, Oklahoma City, OK USA.
   [Beecher, Jeffrey S.] New Hanover Reg Med Ctr, Cerebrovasc & Endovasc Neurosurg, Wilmington, NC USA.
   [Rangel-Castilla, Leonardo] Mayo Clin, Dept Neurosurg & Radiol, Rochester, MN USA.
   [Siddiqui, Adnan H.] Jacobs Inst, Buffalo, NY USA.
RP Levy, EI (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14260 USA.; Levy, EI (reprint author), Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Radiol, Buffalo, NY 14260 USA.; Levy, EI (reprint author), Univ Buffalo, Canon Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.; Levy, EI (reprint author), Univ Buffalo, Gates Vasc Inst Kaleida Hlth, Dept Neurosurg, Buffalo, NY 14260 USA.
EM elevy@ubns.com
RI Siddiqui, Adnan H./AAG-9781-2019
CR Akl EA, 2007, J GEN INTERN MED, V22, P264, DOI 10.1007/s11606-006-0022-2
   Bekelis K, 2017, J NEUROSURG, V126, P29, DOI 10.3171/2015.11.JNS151725
   Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI 10.1161/CIR.0000000000000485
   Chen PR, 2006, NEUROSURGERY, V59, P58
   Costas R, 2007, J INFORMETR, V1, P193, DOI 10.1016/j.joi.2007.02.001
   Fennell VS, 2016, J NEUROSURG, V124, P13, DOI 10.3171/2014.11.JNS141030
   Fiorella D, 2012, J NEUROINTERV SURG, V4, DOI 10.1136/neurintsurg-2012-010471
   Harbaugh RE, 2006, NEUROSURGERY S3, V59, pS3
   Harbaugh Robert E, 2006, Neurosurgery, V59, pS277
   Lakomkin N, 2019, J NEUROINTERV SURG, V11, P241, DOI 10.1136/neurintsurg-2018-014239
   Sonig A, 2017, J NEUROSURG, V127, P1181, DOI 10.3171/2016.9.JNS161857
   Strozyk Dorothea, 2010, World Neurosurg, V74, P28, DOI 10.1016/j.wneu.2010.04.006
   Zaidat OO, 2012, NEUROLOGY, V79, pS35, DOI 10.1212/WNL.0b013e31826957ef
NR 13
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E923
EP E928
DI 10.1016/j.wneu.2019.05.038
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100109
PM 31096030
DA 2020-05-12
ER

PT J
AU Watanabe, J
   Natsumeda, M
   Okada, M
   Kanemaru, Y
   Tsukamoto, Y
   Oishi, M
   Kakita, A
   Fujii, Y
AF Watanabe, Jun
   Natsumeda, Manabu
   Okada, Masayasu
   Kanemaru, Yu
   Tsukamoto, Yoshihiro
   Oishi, Makoto
   Kakita, Akiyoshi
   Fujii, Yukihiko
TI Podoplanin Expression and IDH-Wildtype Status Predict Venous
   Thromboembolism in Patients with High-Grade Gliomas in the Early
   Postoperative Period
SO WORLD NEUROSURGERY
LA English
DT Article
DE D-dimer; Deep venous thrombosis; Isocitrate dehydrogenase; Malignant
   glioma; Podoplanin; Venous thromboembolism
ID PLATELET-AGGREGATION; RECEPTOR CLEC-2; BRAIN-TUMORS; MUTANT IDH1; CELLS
AB OBJECTIVE: Venous thromboembolism (VTE) often is encountered in patients with high-grade gliomas. The un-derlying mechanisms are unclear, as is the optimal prophylactic protocol. The purpose of the present study was to identify risk factors of VTE and examine the validity of early VTE detection in high-grade gliomas.
   METHODS: We reviewed the medical records of 165 patients with newly diagnosed high-grade glioma treated at Niigata University Hospital during the years 2009 to 2016. If the serum D-dimer levels increased to 5.0 mu g/mL or more, computed tomography was performed to detect VTE. Furthermore, immunohistochemistry with antibodies against podoplanin was performed on available 101 tumor tissues.
   RESULTS: Of the 165 patients, 44 (26.7%) developed VTE. Of the 44 patients, 34 (79.5%) developed VTE within 7 days after surgery. No fatal VTE occurred and major complications secondary to anticoagulation occurred in only 2 (1.2%) patients. On multivariate analysis, lower Karnofsky Performance Scale status, podoplanin expression, and isocitrate dehydrogenase-wildtype status were independently associated with the risk of VTE (P < 0.05).
   CONCLUSIONS: We found that most VTEs occurred early in the postoperative period and commonly in patients with lower Karnofsky Performance Scale status and isocitrate dehydrogenase-wildtype gliomas, which expressed podoplanin.
C1 [Watanabe, Jun; Natsumeda, Manabu; Okada, Masayasu; Kanemaru, Yu; Tsukamoto, Yoshihiro; Oishi, Makoto; Fujii, Yukihiko] Niigata Univ, Dept Neurosurg, Niigata, Japan.
   [Kakita, Akiyoshi] Niigata Univ, Brain Res Inst, Dept Pathol, Niigata, Japan.
RP Watanabe, J (reprint author), Niigata Univ, Dept Neurosurg, Niigata, Japan.
EM jwatanabe@bri.niigata-u.ac.jp
RI Natsumeda, Manabu/Z-2072-2019
OI Natsumeda, Manabu/0000-0003-3098-8323; Watanabe, Jun/0000-0001-9474-2483
CR Al Megren M, 2017, THROMB RES, V156, P105, DOI 10.1016/j.thromres.2017.06.010
   Birner P, 2014, CANCER-AM CANCER SOC, V120, P2440, DOI 10.1002/cncr.28732
   Bralten LBC, 2011, ANN NEUROL, V69, P455, DOI 10.1002/ana.22390
   Cancer Therapy Evaluation Program, COMM TERM CRIT ADV E
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   Eisemann T, 2019, NEURO-ONCOLOGY, V21, P326, DOI 10.1093/neuonc/noy184
   Figueroa JM, 2018, J NEUROSURG, V129, P334, DOI 10.3171/2017.3.JNS162280
   FUJII Y, 1994, NEUROSURGERY, V35, P26, DOI 10.1227/00006123-199407000-00004
   Kato Y, 2008, CANCER SCI, V99, P54, DOI 10.1111/j.1349-7006.2007.00634.x
   Kawaguchi T, 2011, J NEURO-ONCOL, V101, P495, DOI 10.1007/s11060-010-0276-8
   Khorana AA, 2010, THROMB RES, V125, P490, DOI 10.1016/j.thromres.2009.12.023
   Locasale JW, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.014688
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Mishima K, 2006, ACTA NEUROPATHOL, V111, P483, DOI 10.1007/s00401-006-0063-y
   Motomura K, 2012, CANCER SCI, V103, P1871, DOI 10.1111/j.1349-7006.2012.02377.x
   Natsumeda M, 2018, WORLD NEUROSURG, V112, pE103, DOI [10.1016/wneu.2017.12.139, 10.1016/j.wneu.2017.12.139]
   Nazari PMS, 2018, J THROMB HAEMOST, V16, P1121, DOI 10.1111/jth.14129
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Ogura R, 2015, NEUROPATHOLOGY, V35, P324, DOI 10.1111/neup.12196
   Payne H, 2017, BLOOD, V129, P2013, DOI 10.1182/blood-2016-09-742999
   Perry JR, 2010, J THROMB HAEMOST, V8, P1959, DOI 10.1111/j.1538-7836.2010.03973.x
   Perry JR, 2012, NEURO-ONCOLOGY, V14, P73, DOI 10.1093/neuonc/nos197
   Peterziel H, 2012, NEURO-ONCOLOGY, V14, P426, DOI 10.1093/neuonc/nos055
   QUEVEDO JF, 1994, MAYO CLIN PROC, V69, P329, DOI 10.1016/S0025-6196(12)62216-2
   Riedl J, 2017, BLOOD, V129, P1831, DOI 10.1182/blood-2016-06-720714
   Semrad TJ, 2007, J NEUROSURG, V106, P601, DOI 10.3171/jns.2007.106.4.601
   Shiina S, 2016, CANCER IMMUNOL RES, V4, P259, DOI 10.1158/2326-6066.CIR-15-0060
   Simanek R, 2007, NEURO-ONCOLOGY, V9, P89, DOI 10.1215/15228517-2006-035
   Smith TR, 2014, J NEURO-ONCOL, V120, P347, DOI 10.1007/s11060-014-1557-4
   Smith-Bindman R, 2010, NEW ENGL J MED, V363, P1, DOI 10.1056/NEJMp1002530
   Sullivan JP, 2014, CANCER DISCOV, V4, P1299, DOI 10.1158/2159-8290.CD-14-0471
   Suzuki-Inoue K, 2011, J THROMB HAEMOST, V9, P44, DOI 10.1111/j.1538-7836.2011.04335.x
   Suzuki-Inoue K, 2010, J BIOL CHEM, V285, P24494, DOI 10.1074/jbc.M110.130575
   Unruh D, 2016, ACTA NEUROPATHOL, V132, P917, DOI 10.1007/s00401-016-1620-7
   Watson SP, 2010, J THROMB HAEMOST, V8, P1457, DOI 10.1111/j.1538-7836.2010.03875.x
   Yust-Katz S, 2015, J NEURO-ONCOL, V124, P87, DOI 10.1007/s11060-015-1805-2
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E982
EP E988
DI 10.1016/j.wneu.2019.05.049
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100117
PM 31100523
DA 2020-05-12
ER

PT J
AU Wu, WC
   Li, ZC
   Wang, SL
   Zhang, HJ
   Lin, RQ
   Lin, JH
AF Wu, Wence
   Li, Zhechen
   Wang, Shenglin
   Zhang, Hongjie
   Lin, Renqin
   Lin, Jianhua
TI One-Stage Surgical Treatment for Consecutive Multisegment Thoracic
   Spinal Tuberculosis with Kyphosis by Posterior-Only Debridement,
   Interbody Fusion, and Instrumentation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Consecutive multisegment thoracic spinal tuberculosis; Kyphosis;
   Posterior-only approach
ID ANTERIOR RADICAL DEBRIDEMENT; LUMBAR SPINE; MANAGEMENT; DECOMPRESSION;
   THORACOLUMBAR; DISEASE
AB OBJECTIVE: To evaluate the clinical efficacy and feasibility of one-stage surgical treatment for consecutive multisegment thoracic spinal tuberculosis with kyphosis by posterior-only debridement, interbody fusion, and instrumentation.
   METHODS: Sixty-two patients who underwent posterior debridement, interbody fusion, and instrumentation were reviewed for radiographic fusion, region kyphosis, neurologic status, and clinical outcomes. Thoracic Cobb's angle and Frankel grading system were used to assess kyphosis and neurologic improvements, respectively. Operation time, blood loss, erythrocyte sedimentation rate, C-reactive protein, visual analogue scale score, and postoperative complications were recorded to evaluate efficacy and feasibility.
   RESULTS: The surgery duration was 234.5 +/- 91.3 minutes, with blood loss of 761.3 +/- 598.5 mL. The levels of erythrocyte sedimentation rate and C-reactive protein in all patients decreased gradually to normal within 3 months after the surgery. Kyphosis angle was corrected from 16.9 +/- 10.9 degrees preoperatively to 10.4 +/- 6.3 degrees postoperatively (P < 0.001, t = 5.2) and remained at 12.0 +/- 6.6 degrees at final follow-up (P < 0.001, t = 4.6). Twenty-seven patients obtained neurologic improvement by 1-3 grades. The average visual analogue scale score decreased from preoperative 3.7 +/- 1.0 to postoperative 0.7 +/- 0.9 (P < 0.001, t = 16.4), and then to 0.5 +/- 0.3 at final follow-up (P < 0.001, t = 21.5). All patients achieved bony fusion. Recurrence of tuberculosis was not found in all patients.
   CONCLUSIONS: One-stage posterior surgery of debridement, interbody fusion and instrumentation could serve as an efficient way to cure patients with consecutive multisegment thoracic spinal tuberculosis.
C1 [Wu, Wence; Li, Zhechen; Wang, Shenglin; Zhang, Hongjie; Lin, Renqin; Lin, Jianhua] Fujian Med Univ, Affiliated Hosp 1, Dept Spinal Surg, Fuzhou, Fujian, Peoples R China.
RP Lin, JH (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Spinal Surg, Fuzhou, Fujian, Peoples R China.
EM 710489558@qq.com
CR Ansari Sajid, 2013, N Am J Med Sci, V5, P404, DOI 10.4103/1947-2714.115775
   Benli IT, 2003, EUR SPINE J, V12, P224, DOI 10.1007/s00586-002-0403-0
   Cui X, 2016, ORTHOP SURG, V8, P454, DOI 10.1111/os.12288
   Cui X, 2013, MED PRIN PRACT, V22, P346, DOI 10.1159/000346626
   DARBYSHIRE J, 1993, J BONE JOINT SURG BR, V75, P240
   Garg B, 2012, INDIAN J ORTHOP, V46, P165, DOI 10.4103/0019-5413.93682
   Hassan K, 2016, EUR SPINE J, V25, P1056, DOI 10.1007/s00586-016-4451-2
   Jain AK, 2010, J BONE JOINT SURG BR, V92B, P905, DOI 10.1302/0301-620X.92B7.24668
   Jain AK, 2007, CLIN ORTHOP RELAT R, P39, DOI 10.1097/BLO.0b013e318065b7c3
   Kotil K, 2007, J NEUROSURG-SPINE, V6, P222, DOI 10.3171/spi.2007.6.3.222
   Laheri VJ, 2001, SPINAL CORD, V39, P429, DOI 10.1038/sj.sc.3101185
   LEE CK, 1995, SPINE, V20, P356, DOI 10.1097/00007632-199502000-00018
   Lee TC, 1999, J NEUROSURG, V91, P163, DOI 10.3171/spi.1999.91.2.0163
   Muthukumar N, 2006, SURG NEUROL, V66, P69, DOI 10.1016/j.surneu.2005.10.024
   Pang XY, 2013, ARCH ORTHOP TRAUM SU, V133, P1033, DOI 10.1007/s00402-013-1751-4
   Qureshi MA, 2013, EUR SPINE J, V22, P618, DOI 10.1007/s00586-012-2459-9
   Ramdurg SR, 2009, CLIN NEUROL NEUROSUR, V111, P115, DOI 10.1016/j.clineuro.2008.09.029
   Shi JD, 2014, ORTHOP SURG, V6, P259, DOI 10.1111/os.12140
   Sun L, 2013, ORTHOPEDICS, V36, pE1082, DOI 10.3928/01477447-20130724-28
   Talu U, 2006, J SPINAL DISORD TECH, V19, P554, DOI 10.1097/01.bsd.0000211202.93125.c7
   Tamura M, 2005, J NEUROSURG-SPINE, V2, P226, DOI 10.3171/spi.2005.2.2.0226
   Turgut M, 2001, NEUROSURG REV, V24, P8, DOI 10.1007/PL00011973
   Zeng H, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0640-0
   Zhang HQ, 2007, J SPINAL DISORD TECH, V20, P263, DOI 10.1097/01.bsd.0000211281.68400.1b
   Zhang HQ, 2013, ARCH ORTHOP TRAUM SU, V133, P333, DOI 10.1007/s00402-012-1669-2
   Zhang Hong-Qi, 2010, Orthopedics, V33, P808, DOI 10.3928/01477447-20100924-10
   Zhang XF, 2013, J INT MED RES, V41, P1395, DOI 10.1177/0300060513498023
   Zhong NZ, 2018, TURK NEUROSURG, V28, P439, DOI 10.5137/1019-5149.JTN.19263-16.2
NR 28
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E238
EP E244
DI 10.1016/j.wneu.2019.04.122
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100027
PM 31009788
DA 2020-05-12
ER

PT J
AU Xiao, ZP
   Zhao, JL
   Rong, WL
   Jiang, JW
   Li, MH
AF Xiao, Zhi-peng
   Zhao, Jian-lan
   Rong, Wei-lin
   Jiang, Jin-wen
   Li, Mei-hua
TI Role of Vascular Endothelial-Cadherin and p120-Catenin in the Formation
   o Experimental Intracranial Aneurysm in Animals
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endothelial cells; Hemodynamics; Intracerebral aneurysm; p120-catenin;
   VE-cadherin
ID SMOOTH-MUSCLE-CELLS; VE-CADHERIN; BASILAR TERMINUS; HEMODYNAMICS;
   TRANSCRIPTION; RESPONSES; GROWTH; INJURY; CIRCLE; WILLIS
AB BACKGROUND: Dysfunction of endothelial cells (ECs) constitutes a critical factor in the formation of intracranial aneurysms (IAs). However, little is known about the response of ECs to hemodynamic insults and its contribution to IA formation.
   METHODS: IAs models were constructed in both adult female New Zealand white rabbits and male Sprague-Dawley rats. Morphologic changes of vessel wall were detected by hematoxylin and eosin staining. Molecular and cellular changes, including p120-catenin (p120ctn) and vascular endothelial- cadherin, in the median sagittal section of the artery bifurcation were analyzed by fluorescent staining.
   RESULTS: Destructive aneurysmal remodeling and the formation of morphologic IAs were observed at the basilar termini of experimental rabbits and the anterior cerebral artery-olfactory artery bifurcation of rats. The expression of p120ctn colocalized with vascular endothelial - cadherin in ECs decreased. Moreover, the expression of p120ctn colocalized with nucleus of ECs increased. These events suggested that p120ctn was transported from the membrane to the nucleus of ECs.
   CONCLUSIONS: The potential mechanism, that IAs are always localizing in the bifurcation apices, may be that the endothelium injury of vessel wall can be induced by different hemodynamic conditions. Hemodynamic changes in artery bifurcation may initiate the formation of IAs.
C1 [Xiao, Zhi-peng; Zhao, Jian-lan; Rong, Wei-lin; Jiang, Jin-wen; Li, Mei-hua] Nanchang Univ, Affiliated Hosp 1, Dept Neurosurg, Nanchang, Jiangxi, Peoples R China.
   [Xiao, Zhi-peng] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Zhao, Jian-lan] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Li, MH (reprint author), Nanchang Univ, Affiliated Hosp 1, Dept Neurosurg, Nanchang, Jiangxi, Peoples R China.
EM xzhp2018@sina.com; limeihua2000@sina.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81860225]
FX This study was supported by the National Natural Science Foundation of
   China (grant no. 81860225).
CR Alcaide P, 2012, AM J PHYSIOL-CELL PH, V303, pC385, DOI 10.1152/ajpcell.00126.2012
   Alfano JM, 2013, NEUROSURGERY, V73, P497, DOI 10.1227/NEU.0000000000000016
   Chalouhi N, 2013, STROKE, V44, P3613, DOI 10.1161/STROKEAHA.113.002390
   Daniel JM, 1999, MOL CELL BIOL, V19, P3614
   Dejana E, 2013, PROG MOL BIOL TRANSL, V116, P119, DOI 10.1016/B978-0-12-394311-8.00006-6
   Fan XJ, 2015, GENET MOL RES, V14, P9062, DOI 10.4238/2015.August.7.15
   Frosen J, 2014, TRANSL STROKE RES, V5, P347, DOI 10.1007/s12975-014-0340-3
   Gao L, 2008, STROKE, V39, P2085, DOI 10.1161/STROKEAHA.107.509422
   Hashimoto T, 2006, NEUROL RES, V28, P372, DOI 10.1179/016164106X14973
   Hatzfeld M, 2005, EUR J CELL BIOL, V84, P205, DOI 10.1016/j.ejcb.2004.12.016
   Jamous MA, 2007, J NEUROSURG, V107, P405, DOI 10.3171/JNS-07/08/0405
   Kolega J, 2011, J VASC RES, V48, P429, DOI 10.1159/000324840
   Li MH, 2014, W INDIAN MED J, V63, P167, DOI 10.7727/wimj.2013.129
   Meng H, 2007, STROKE, V38, P1924, DOI 10.1161/STROKEAHA.106.481234
   O'Donnell JJ, 2011, MICROVASC RES, V82, P105, DOI 10.1016/j.mvr.2011.04.008
   Oas RG, 2013, MOL BIOL CELL, V24, P704, DOI 10.1091/mbc.E12-06-0471
   Sakamoto N, 2010, BIOCHEM BIOPH RES CO, V398, P426, DOI 10.1016/j.bbrc.2010.06.092
   Starke RM, 2014, TRANSL STROKE RES, V5, P338, DOI 10.1007/s12975-013-0290-1
   SUZUKI S, 1991, CELL REGUL, V2, P261
   Tutino VM, 2015, ANAT REC, V298, P1903, DOI 10.1002/ar.23205
   Tutino VM, 2014, J CEREBR BLOOD F MET, V34, P415, DOI 10.1038/jcbfm.2013.209
   Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001
   Xiao KY, 2005, MOL BIOL CELL, V16, P5141, DOI 10.1091/mbc.E05-05-0440
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E177
EP E184
DI 10.1016/j.wneu.2019.04.077
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100020
PM 30995547
DA 2020-05-12
ER

PT J
AU Xiong, Y
   Cao, H
   Zhang, YQ
   Pan, Z
   Dong, SY
   Wang, GSY
   Wang, FYF
   Li, XJ
AF Xiong, Yi
   Cao, Hang
   Zhang, Yueqi
   Pan, Zou
   Dong, Siyuan
   Wang, Gousiyi
   Wang, Feiyifan
   Li, Xuejun
TI Nomogram-Predicted Survival of Breast Cancer Brain Metastasis: a
   SEER-Based Population Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastasis; Breast neoplasms; Nomogram; Prognosis; SEER program
ID GRADED PROGNOSTIC ASSESSMENT; VALIDATION; CARCINOMA; PROPOSITION;
   ONCOLOGY; THERAPY; WOMEN; TOOL
AB OBJECTIVE: The prognosis of patients with breast cancer brain metastasis (BCBM) was dismal and the prognoses varied according to different prognostic factors. In this study, we used the SEER (Surveillance Epidemiology and End Results) database to identify prognostic factors with the BCBMs.
   METHODS: We identified and built a robust prognostic model and developed reliable nomograms to estimate the individualized overall survival (OS) and breast cancer-specific survival (BCSS) of patients with BCBM. A total of 789 patients with newly diagnosed BCBM were identified from the SEER database and randomly divided into training (n = 554) and testing (n = 235) cohorts. The log-rank tests and the Cox proportional hazards model were applied to evaluate the prognostic effects of multiple clinicopathologic variables on the survival of training cohorts. Significant prognostic factors were combined to build the nomograms that were evaluated using the concordance index and calibration plots for internal and external validations.
   RESULTS: Two nomograms shared the common prognostic indicators including age, tumor subtype, chemotherapy, surgery, number of metastatic sites except the brain, and median household income. In the training cohort, the Harrell concordance index for the constructed nomogram to predict OS and BCSS was 0.668 and 0.676, respectively. The calibration plots were consistent between nomogram-predicted survival probability and actual survival probability. These results were reproducible when nomograms were applied to the testing cohort for external validation.
   CONCLUSIONS: Nomograms that predicted 6-month, 1-year, and 2-year OS and BCSS for patients with newly diagnosed BCBM with satisfactory performance were constructed to help physicians in evaluating the high risk of mortality in patients.
C1 [Xiong, Yi; Cao, Hang; Zhang, Yueqi; Pan, Zou; Dong, Siyuan; Wang, Gousiyi; Wang, Feiyifan; Li, Xuejun] Cent S Univ, Dept Neurosurg, Xiangya Hosp, Changsha, Hunan, Peoples R China.
RP Li, XJ (reprint author), Cent S Univ, Dept Neurosurg, Xiangya Hosp, Changsha, Hunan, Peoples R China.
EM lxjneuro@csu.edu.cn
OI Li, Xuejun/0000-0001-6406-4423
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81472594, 81770781]
FX This work was supported by the National Natural Science Foundation of
   China (number 81472594, 81770781).
CR Anders CK, 2011, CANCER-AM CANCER SOC, V117, P1602, DOI 10.1002/cncr.25746
   Balachandran VP, 2015, LANCET ONCOL, V16, pE173, DOI 10.1016/S1470-2045(14)71116-7
   Barnholtz-Sloan JS, 2012, NEURO-ONCOLOGY, V14, P910, DOI 10.1093/neuonc/nos087
   Barnholtz-Sloan JS, 2004, J CLIN ONCOL, V22, P2865, DOI 10.1200/JCO.2004.12.149
   Bendell JC, 2003, CANCER, V97, P2972, DOI 10.1002/cncr.11436
   Bowman KM, 2018, FUTURE ONCOL, V14, P391, DOI 10.2217/fon-2017-0255
   Bureau UC, 2010 2014 AM COMM SU
   Cummings MC, 2014, J PATHOL, V232, P23, DOI 10.1002/path.4288
   Dawood S, 2009, ANN ONCOL, V20, P621, DOI 10.1093/annonc/mdn682
   de Robles P, 2015, NEURO-ONCOLOGY, V17, P776, DOI 10.1093/neuonc/nou283
   Doll KM, 2018, JAMA SURG, V153, P588, DOI 10.1001/jamasurg.2018.0501
   Dong F, 2018, J CANCER, V9, P1152, DOI 10.7150/jca.23344
   Eichler AF, 2008, CANCER, V112, P2359, DOI 10.1002/cncr.23468
   Guerin A, 2016, J MED ECON, V19, P526, DOI 10.3111/13696998.2016.1138962
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   Harrell Jr F. E., 2018, RMS REGRESSION MODEL
   Huang Z, 2018, ONCOL LETT, V15, P7090, DOI 10.3892/ol.2018.8259
   Jang G, 2011, BREAST CANCER RES TR, V128, P171, DOI 10.1007/s10549-011-1526-y
   Le Scodan R, 2007, INT J RADIAT ONCOL, V69, P839, DOI 10.1016/j.ijrobp.2007.04.024
   Le Scodan R, 2012, J NEURO-ONCOL, V106, P169, DOI 10.1007/s11060-011-0654-x
   Lentzsch S, 1999, EUR J CANCER, V35, P580, DOI 10.1016/S0959-8049(98)00421-3
   Liang WH, 2015, J CLIN ONCOL, V33, P861, DOI 10.1200/JCO.2014.56.6661
   Lin NU, 2008, CANCER-AM CANCER SOC, V113, P2638, DOI 10.1002/cncr.23930
   Lin NU, 2004, J CLIN ONCOL, V22, P3608, DOI 10.1200/JCO.2004.01.175
   Martin AM, 2017, JAMA ONCOL, V3, P1069, DOI 10.1001/jamaoncol.2017.0001
   Nam BH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1870
   Nieder C, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-105
   Noone AM, 2018, SEER CANC STAT REV 1
   Ogawa K, 2008, J NEURO-ONCOL, V86, P231, DOI 10.1007/s11060-007-9469-1
   Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sperduto PW, 2012, INT J RADIAT ONCOL, V82, P2111, DOI 10.1016/j.ijrobp.2011.02.027
   Sperduto PW, 2012, J CLIN ONCOL, V30, P419, DOI 10.1200/JCO.2011.38.0527
   Subbiah IM, 2015, J CLIN ONCOL, V33, P2239, DOI 10.1200/JCO.2014.58.8517
   Tabouret E, 2014, NEURO-ONCOLOGY, V16, P421, DOI 10.1093/neuonc/not200
   Takahashi H, 2018, CHIN CLIN ONCOL, V7, DOI 10.21037/cco.2018.05.06
   TSUKADA Y, 1983, CANCER-AM CANCER SOC, V52, P2349, DOI 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B
NR 37
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E823
EP E834
DI 10.1016/j.wneu.2019.04.262
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100097
PM 31096027
DA 2020-05-12
ER

PT J
AU Xu, J
   Zhuang, WD
   Zheng, W
   Xiao, YH
   Lin, Y
AF Xu, Jie
   Zhuang, WeiDa
   Zheng, Wu
   Xiao, Yuhua
   Lin, Yuan
TI Microscopic Ventral Neural Decompression in Oblique Lateral Interbody
   Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lumbar degenerative disease; Microscope; Oblique lateral interbody
   fusion; Ventral decompression
ID COMPLICATIONS; POSITION
AB OBJECTIVE: To describe the operative methods and to investigate the efficacy of ventral neural decompression under microscopic vision with oblique lumbar interbody fusion (OLIF).
   METHODS: Twelve patients with extruded or sequestered disk were treated with ventral neural decompression under microscopic vision via the working corridor of routine OLIF Their clinical data were gathered and analyzed retrospectively. The clinical efficacy was evaluated by the Oswestry Disability Index (ODI), visual analog scale (VAS), and relevant radiographic parameters.
   RESULTS: All operations went smoothly, with average operative time of 151.7 +/- 24.5 minutes and blood loss of 58.5 +/- 21.3 mL. Well-decompressed canal observed in postoperative magnetic resonance imaging, significant improvements in VAS score for leg (P< 0.01) and ODI score (P < 0.01) confirmed satisfactory ventral neural decompression. Radiographic parameters including disk height (P< 0.01) and segmental disk angle improved significantly (P < 0.01). There was no significant difference between pre- and postoperative lumbar lordosis (P = 0.255). During the follow-up, end plate fracture was observed in 1 case. No major vessels, neural, or dural injury was observed.
   CONCLUSIONS: Microscopic ventral neural decompression with OLIF could achieve satisfactory clinical results with minimal complications in selected patients with extruded or sequestered disk.
C1 [Xu, Jie; Zheng, Wu; Xiao, Yuhua; Lin, Yuan] Fujian Med Univ, Fujian Prov Hosp, Dept Orthoped Surg, Div Spine Surg, Fuzhou, Fujian, Peoples R China.
   [Zhuang, WeiDa] Southern Med Univ, Shenzhen Hosp, Dept Orthoped, Shenzhen, Guangdong, Peoples R China.
RP Xu, J (reprint author), Fujian Med Univ, Fujian Prov Hosp, Dept Orthoped Surg, Div Spine Surg, Fuzhou, Fujian, Peoples R China.
EM jiexu1520@163.com
FU Natural Science Foundation of Fujian Province, ChinaNatural Science
   Foundation of Fujian Province [2019J01173]
FX This study was supported by a The Natural Science Foundation of Fujian
   Province, China (2019J01173).
CR Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   Been E, 2014, SPINE J, V14, P87, DOI 10.1016/j.spinee.2013.07.464
   Chaleat-Valayer Emmanuelle, 2011, Eur Spine J, V20 Suppl 5, P634, DOI 10.1007/s00586-011-1931-2
   Cummock MD, 2011, J NEUROSURG-SPINE, V15, P11, DOI 10.3171/2011.2.SPINE10374
   Davis TT, 2014, J NEUROSURG-SPINE, V21, P785, DOI 10.3171/2014.7.SPINE13564
   Fujibayashi S, 2015, SPINE, V40, pE175, DOI 10.1097/BRS.0000000000000703
   Jin J, 2018, CLIN SPINE SURG, V31, P31, DOI 10.1097/BSD.0000000000000474
   Johnson RD, 2013, J CLIN NEUROSCI, V20, P576, DOI 10.1016/j.jocn.2012.05.032
   Kanno K, 2014, CASE REP ORTHOP, V2014, DOI DOI 10.1155/2014/603531
   Kepler Christopher K, 2012, Orthop Surg, V4, P71, DOI 10.1111/j.1757-7861.2012.00175.x
   Mauch F, 2010, SPINE, V35, P1002, DOI 10.1097/BRS.0b013e3181bdb2d3
   Mayer HM, 1997, SPINE, V22, P691, DOI 10.1097/00007632-199703150-00023
   Melikian R, 2016, SPINE, V41, pE1016, DOI 10.1097/BRS.0000000000001562
   Ohtori S, 2015, YONSEI MED J, V56, P1051, DOI 10.3349/ymj.2015.56.4.1051
   Oliveira L, 2010, SPINE, V35, P331
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Sato J, 2015, ASIAN SPINE J, V9, P565
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Woods KRM, 2017, SPINE J, V17, P545, DOI 10.1016/j.spinee.2016.10.026
NR 19
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E315
EP E321
DI 10.1016/j.wneu.2019.04.142
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100035
PM 31028987
DA 2020-05-12
ER

PT J
AU Xu, KY
   Liu, F
   Xu, W
   Liu, J
   Chen, SX
   Wu, GF
AF Xu, Kaya
   Liu, Feng
   Xu, Wei
   Liu, Jian
   Chen, Shuxuan
   Wu, Guofeng
TI Transplanting GABAergic Neurons Differentiated from Neural Stem Cells
   into Hippocampus Inhibits Seizures and Epileptiform Discharges in
   Pilocarpine-Induced Temporal Lobe Epilepsy Model
SO WORLD NEUROSURGERY
LA English
DT Article
DE GABAergic neurons; Hippocampal GABA concentration; Intrahippocampal
   transplantation; Neural stem cells; Pharmacoresistant epilepsy
ID RAT MODEL; GENE THERAPIES; GRAFTS; EXPRESSION; INTERNEURONS;
   STIMULATION; EPILEPTOGENESIS; CARBAMAZEPINE; SOMATOSTATIN; PROGENITORS
AB OBJECTIVE: This study aimed to explore whether intrahippocampal transplantation of GABAergic neurons generated in vitro ameliorated seizures and epileptiform discharges via increasing gamma-aminobutyric acid (GABA)-associated inhibition mediated by the addition of new GABAergic neurons.
   METHODS: Neural stem cells (NSCs) isolated from newborn rats were induced and differentiated into GABAergic neurons. A total of 36 Pilocarpine-induced pharmacoresistant epileptic rats were divided into 3 groups: PBS (phosphatebuffered saline) group, NSCs group, and GABAergic neurons group (GABA group), with an additional 10 normal rats used (normal rat control group). The effects of grafting on spontaneous recurrent seizures (SRS) were examined and hippocampal GABA content was measured after grafting.
   RESULTS: In the GABA group, the frequency of electroencephalography decreased significantly compared with the PBS group (P< 0.001), but there was no significant difference between the GABA group and NSCs group. Compared with the PBS group, the overall frequency and duration of SRS significantly decreased in the transplantation group, especially in the GABA group (P< 0.01). The number of GABAergic neurons was highest in the GABA group compared with the other groups (P < 0.001). Furthermore, hippocampal GABA concentrations significantly increased in the GABA group.
   CONCLUSIONS: We show that GABAergic neurons generated in vitro from NSCs and grafted into the hippocampi of chronically epileptic rats can significantly reduce the frequency of electroencephalography and frequency and duration of SRS via increasing GABA-associated inhibition mediated by the addition of new GABAergic neurons.
C1 [Xu, Kaya; Liu, Feng; Liu, Jian] Guizhou Med Univ, Affiliated Hosp, Dept Neurosurg, Guiyang, Guizhou, Peoples R China.
   [Chen, Shuxuan; Wu, Guofeng] Guizhou Med Univ, Affiliated Hosp, Dept Neurol, Guiyang, Guizhou, Peoples R China.
   [Xu, Wei] Guizhou Med Univ, Publ Hlth Sch, Guiyang, Guizhou, Peoples R China.
RP Wu, GF (reprint author), Guizhou Med Univ, Affiliated Hosp, Dept Neurol, Guiyang, Guizhou, Peoples R China.
EM wuguofeng3013@sina.com
OI xu, kaya/0000-0002-5649-9678
CR Acosta SA, 2015, STROKE, V46, P2616, DOI 10.1161/STROKEAHA.115.009854
   Baraban SC, 2009, P NATL ACAD SCI USA, V106, P15472, DOI 10.1073/pnas.0900141106
   Bethmann K, 2007, EPILEPSIA, V48, P816, DOI 10.1111/j.1528-1167.2007.00980.x
   Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x
   Brandt C, 2004, EPILEPSIA, V45, P1488, DOI 10.1111/j.0013-9580.2004.16904.x
   Capella HM, 2002, EPILEPSIA, V43, P110, DOI 10.1046/j.1528-1157.43.s.5.9.x
   Chakir A, 2006, BRAIN RES BULL, V71, P127, DOI 10.1016/j.brainresbull.2006.08.009
   Clarke G, 2007, J NEUROSCI METH, V160, P223, DOI 10.1016/j.jneumeth.2006.09.006
   CORNISH SM, 1989, NEUROSCIENCE, V28, P563, DOI 10.1016/0306-4522(89)90005-5
   Cunningham M, 2014, CELL STEM CELL, V15, P559, DOI 10.1016/j.stem.2014.10.006
   Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019
   DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5
   FINE A, 1990, NEUROPSYCHOLOGIA, V28, P627, DOI 10.1016/0028-3932(90)90038-P
   Harkin A, 2001, LIFE SCI, V68, P1367, DOI 10.1016/S0024-3205(00)01039-0
   Hattiangady B, 2008, EXP NEUROL, V212, P468, DOI 10.1016/j.expneurol.2008.04.040
   Helmstaedter C, 2008, NAT CLIN PRACT NEURO, V4, P66, DOI 10.1038/ncpneuro0657
   Henderson KW, 2014, J NEUROSCI, V34, P13492, DOI 10.1523/JNEUROSCI.0005-14.2014
   Hunt RF, 2013, NAT NEUROSCI, V16, P692, DOI 10.1038/nn.3392
   Jobst BC, 2015, JAMA-J AM MED ASSOC, V313, P285, DOI 10.1001/jama.2014.17426
   Kabos P, 2002, J BIOL CHEM, V277, P8763, DOI 10.1074/jbc.C100758200
   Ko AR, 2015, SEIZURE-EUR J EPILEP, V31, P133, DOI 10.1016/j.seizure.2015.07.019
   Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x
   Lee HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095530
   Leonard BW, 2009, J COMP NEUROL, V515, P269, DOI 10.1002/cne.22040
   Lindvall O, 1992, Adv Neurol, V57, P561
   Lloyd K G, 1986, Adv Neurol, V44, P1033
   Loscher W, 2008, TRENDS NEUROSCI, V31, P62, DOI 10.1016/j.tins.2007.11.012
   Loscher W, 2010, EPILEPSIA, V51, P89, DOI 10.1111/j.1528-1167.2009.02183.x
   Loscher W, 1998, J NEUROSCI RES, V51, P196
   Loscher W., 2012, JASPERS BASIC MECH E
   Maisano X, 2012, J NEUROSCI, V32, P46, DOI 10.1523/JNEUROSCI.2683-11.2012
   Marco P, 1996, BRAIN, V119, P1327, DOI 10.1093/brain/119.4.1327
   Mattsson B, 1997, STROKE, V28, P1225, DOI 10.1161/01.STR.28.6.1225
   McKeown MJ, 2001, NEURON, V30, P1, DOI 10.1016/S0896-6273(01)00253-7
   Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009
   Naegele JR, 2010, NEUROPHARMACOLOGY, V58, P855, DOI 10.1016/j.neuropharm.2010.01.019
   NUSSBAUM MA, 1992, ANAL CHEM, V64, P1259, DOI 10.1021/ac00035a012
   Palmer TD, 1999, J NEUROSCI, V19, P8487
   PINEL JPJ, 1978, EXP NEUROL, V58, P190, DOI 10.1016/0014-4886(78)90133-4
   RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0
   Raedt R, 2007, SEIZURE-EUR J EPILEP, V16, P565, DOI 10.1016/j.seizure.2007.05.003
   REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558
   ROBBINS RJ, 1991, ANN NEUROL, V29, P325, DOI 10.1002/ana.410290316
   Saha K, 2009, CELL STEM CELL, V5, P584, DOI 10.1016/j.stem.2009.11.009
   Shamim S, 2009, EPILEPSY BEHAV, V16, P311, DOI 10.1016/j.yebeh.2009.07.040
   Sharma AK, 2007, TOXICOL PATHOL, V35, P984, DOI 10.1080/01926230701748305
   Shetty AK, 2000, J NEUROSCI, V20, P8788
   Shetty AK, 2007, HIPPOCAMPUS, V17, P943, DOI 10.1002/hipo.20311
   Shetty AK, 2016, BRAIN RES, V1638, P74, DOI 10.1016/j.brainres.2015.09.019
   Shetty AK, 2014, EPILEPSY BEHAV, V38, P117, DOI 10.1016/j.yebeh.2013.12.001
   Shetty AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043286
   Southwell DG, 2014, SCIENCE, V344, P167, DOI 10.1126/science.1240622
   Spreafico R, 1998, NEUROLOGY, V50, P27, DOI 10.1212/WNL.50.1.27
   Srivastava AK, 2013, EPILEPSIA, V54, P1186, DOI 10.1111/epi.12234
   Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x
   Waldau B, 2010, STEM CELLS, V28, P1153, DOI 10.1002/stem.446
   Wang LK, 2014, EPILEPSY RES, V108, P1483, DOI 10.1016/j.eplepsyres.2014.07.005
   Wieser HG, 2004, EPILEPSIA, V45, P32
   Wu GF, 2013, NEUROMODULATION, V16, P105, DOI 10.1111/j.1525-1403.2012.00493.x
   Yamanaka S, 2010, CELL STEM CELL, V7, P1, DOI 10.1016/j.stem.2010.06.009
   Zhang SC, 2008, PHILOS T R SOC B, V363, P87, DOI 10.1098/rstb.2006.2014
   Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009
NR 62
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E1
EP E11
DI 10.1016/j.wneu.2019.01.245
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100002
PM 30790741
DA 2020-05-12
ER

PT J
AU Xu, XL
   Ji, W
   Liu, X
   Kong, GG
   Huang, ZC
   Chen, JT
AF Xu, Xiaolin
   Ji, Wei
   Liu, Xiang
   Kong, Ganggang
   Huang, Zucheng
   Chen, Jianting
TI Anterior Atlanto-Occipital Transarticular Screw Fixation: A Radiological
   Evaluation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior transarticular screw; Atlanto-occipital fixation; Computed
   tomography; Occipitocervical junction; Radiological
ID OCCIPITOATLANTAL DISLOCATION; MORPHOMETRIC-ANALYSIS; FORAMEN MAGNUM;
   INJURIES; ANATOMY; TRANSCONDYLAR
AB BACKGROUND: In situations in which posterior atlanto-occipital fixation might not be possible or might require supplemental fixation, anterior fixation might add stability in obtaining arthrodesis. The present study aimed to provide a radiographic evaluation of the safety and feasibility in the anterior approach.
   METHODS: The bilateral craniocervical computed tomography slices of 60 patients were examined. The anterior screw entry point was the lowest point at the middle anterior aspect of C1 (atlas) lateral mass. To avoid hypoglossal canal and craniocerebral injury, the height of the hypoglossal canal and occipital condyle and occipital condyle width were obtained. The mandible occlusion angle (MOA), anterior screw trajectory above, under, and distal to the hypoglossal canal (AHA, UHA, and DHA) relative to the tangent line of C1 front border were measured, together with the maximum screw length under each angle (AHL, UHL and DHL). An independent samples t test was used for statistical analysis.
   RESULTS: The height of the hypoglossal canal and occipital condyle and occipital condyle width were all larger in the men than in the women. The MOA, AHA, UHA, and DHA were 55.0 degrees , 18.7 degrees , 41.0 degrees, and 55.0 degrees, respectively, and were similar between genders. The AHL, UHL, and DHL were 34.5, 30.9, and 31.3 mm, with the measurements for the men generally longer than those for the women by 3-4 mm. A total of 10 of 120 bilateral measurements showed the possibility of mandible occlusion, and the potential success rate of the anterior approach could reach 91.7%.
   CONCLUSIONS: The ideal entry angle for anterior atlanto-occipital fixation ranges from 41.0 degrees to 55.0 degrees, with a safe screw length from 30.9 to 31.3 mm. The potential success rate could reach >90%.
C1 [Xu, Xiaolin; Ji, Wei; Kong, Ganggang; Huang, Zucheng; Chen, Jianting] Southern Med Univ, Nanfang Hosp, Dept Spinal Surg, Guangzhou, Guangdong, Peoples R China.
   [Liu, Xiang] Chancheng Dist Cent Hosp, Dept Spinal Surg, Foshan, Peoples R China.
RP Ji, W (reprint author), Southern Med Univ, Nanfang Hosp, Dept Spinal Surg, Guangzhou, Guangdong, Peoples R China.
EM spineji@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81702192]; Outstanding Youths Development Scheme of
   Nanfang Hospital, Southern Medical University, China [2017J008];
   President Foundation of Nanfang Hospital, Southern Medical University,
   China [2016C021]
FX The present study was sponsored by the National Natural Science
   Foundation of China (grant 81702192), the Outstanding Youths Development
   Scheme of Nanfang Hospital, Southern Medical University, China (grant
   2017J008), and the President Foundation of Nanfang Hospital, Southern
   Medical University, China (grant 2016C021).
CR ADAMS VI, 1992, J FORENSIC SCI, V37, P556
   Bulsara KR, 2008, NEUROSURG REV, V31, P299, DOI 10.1007/s10143-008-0143-7
   DeGusta D, 1999, P NATL ACAD SCI USA, V96, P1800, DOI 10.1073/pnas.96.4.1800
   DICKMAN CA, 1993, J SPINAL DISORD, V6, P300, DOI 10.1097/00002517-199306040-00004
   Dvorak Marcel F S, 2003, Spine (Phila Pa 1976), V28, pE54
   Dvorak MFS, 2003, SPINE, V28, P239, DOI 10.1097/00007632-200302010-00007
   Feiz-Erfan I, 2005, J NEUROSURG-SPINE, V2, P381, DOI 10.3171/spi.2005.2.3.0381
   Garrett M, 2010, NEUROSURGERY, V66, pA48, DOI 10.1227/01.NEU.0000365802.02410.C5
   Gonzalez LF, 2004, J NEUROSURG-SPINE, V1, P273, DOI 10.3171/spi.2004.1.3.0273
   Gonzalez LF, 2003, J NEUROSURG, V98, P202, DOI 10.3171/spi.2003.98.2.0202
   Grob D, 2001, SPINE, V26, P703, DOI 10.1097/00007632-200103150-00030
   Gupta T, 2008, SURG RADIOL ANAT, V30, P239, DOI 10.1007/s00276-008-0313-x
   Hall GC, 2015, WORLD J ORTHOP, V6, P236, DOI 10.5312/wjo.v6.i2.236
   Horn EM, 2007, J NEUROSURG-SPINE, V6, P113, DOI 10.3171/spi.2007.6.2.113
   Jeszenszky D, 2010, SPINE, V35, pE421, DOI 10.1097/BRS.0b013e3181c91fa1
   Ji W, 2019, SPINE, V44, pE1010, DOI 10.1097/BRS.0000000000003056
   Kumar S, 2017, J CLIN DIAGN RES, V11, pAC8, DOI 10.7860/JCDR/2017/24333.9365
   Lyrtzis C, 2017, FOLIA MORPHOL, V76, P446, DOI 10.5603/FM.a2017.0002
   Muthukumar N, 2005, ACTA NEUROCHIR, V147, P889, DOI 10.1007/s00701-005-0555-x
   Naderi S, 2005, CLIN NEUROL NEUROSUR, V107, P191, DOI 10.1016/j.clineuro.2004.07.014
   Paraskevas GK, 2009, MED SCI MONITOR, V15, pBR75
   Senoglu M, 2010, NEUROSURGERY, V66, P173, DOI 10.1227/01.NEU.0000350982.03929.05
   Steinmetz MP, 2003, NEUROSURG FOCUS, V15, P1
   Wen HT, 1997, J NEUROSURG, V87, P555, DOI 10.3171/jns.1997.87.4.0555
   Wu AM, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000242
   Zhou JS, 2016, J NEUROSURG-SPINE, V25, P572, DOI 10.3171/2016.4.SPINE151431
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E488
EP E494
DI 10.1016/j.wneu.2019.04.183
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100056
PM 31048054
DA 2020-05-12
ER

PT J
AU Xu, YF
   Zhang, Q
   Le, XF
   Liu, B
   He, D
   Sun, YQ
   Liu, YJ
   Yuan, Q
   Lang, Z
   Han, XG
   Tian, W
AF Xu, Yun-Feng
   Zhang, Qi
   Le, Xiao-Feng
   Liu, Bo
   He, Da
   Sun, Yu-Qin
   Liu, Ya-Jun
   Yuan, Qiang
   Lang, Zhao
   Han, Xiao-Guang
   Tian, Wei
TI Comparison of the One-Time Accuracy of Simulated Freehand and Navigation
   Simulated Pedicle Screw Insertion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraoperative screw adjustment; Navigation simulated; One-time
   accuracy; Pedicle screw placement; Simulated freehand
ID RADIATION-EXPOSURE; LUMBAR SPINE; INTERNAL-FIXATION; COMPLICATIONS;
   PLACEMENT; SCOLIOSIS
AB OBJECTIVE: To compare one-time accuracy rate between simulated freehand (SFH) and navigation simulated (NS) pedicle screw insertion, assuming no second chance to correct screws.
   METHODS: A simulated, comparative, cross-sectional study was conducted on 69 patients undergoing lumbar spine surgery. An intraoperative registration system captured the planned point of entry and trajectory of pedicle screws for both SFH under direct visualization and NS under navigation-aided visualization. Pedicle screw insertion was simulated for each captured image (370 screws) using Surgimap. Rajasekaran's method helped evaluate the point of entry accuracy and trajectory.
   RESULTS: Accuracy rate was better for the NS method than for the SFH method (63.8%). Of 370 screws in the SFH group, 134 penetrated the cortex, with 31 resulting in >4 mm penetration. Of 370 screws in the NS group, 8 penetrated the cortex, <4 mm penetration. Of 134 misplaced screws in the SFH group, 64 were due to error in the point of entry, 63 were due to error in the trajectory angle, and 7 were due to both errors. Of 8 errors in the NS group, 7 were due to the point of entry.
   CONCLUSIONS: lntraoperative navigation had significantly better one-time accuracy of pedicle screw insertion than freehand insertion and should be used to avoid injury to the pedicle and surrounding tissue from screw reinsertion.
C1 [Tian, Wei] Beijing Jishuitan Hosp, Dept Spine Surg, Beijing, Peoples R China.
   Peking Univ, Sch Clin Med 4, Beijing, Peoples R China.
RP Tian, W (reprint author), Beijing Jishuitan Hosp, Dept Spine Surg, Beijing, Peoples R China.
EM tianwei_spine@sina.com
RI Tian, Wei/AAJ-7853-2020; Xiaofeng, Le/V-9474-2017
OI Tian, Wei/0000-0002-1067-600X; Xiaofeng, Le/0000-0002-2381-5929; Zhang,
   Qi/0000-0002-1953-3427
FU Beijing Natural Science Foundation of ChinaBeijing Natural Science
   Foundation [7174311, Z170001]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [U1713221]
FX This study was funded by the Beijing Natural Science Foundation of China
   (Grant Nos. 7174311 and Z170001) and National Natural Science Foundation
   of China (Grant No. U1713221).
CR Acikbas SC, 2003, ACTA NEUROCHIR, V145, P949, DOI 10.1007/s00701-003-0116-0
   Castro WHM, 1996, SPINE, V21, P1320, DOI 10.1097/00007632-199606010-00008
   Chi JH, 2007, NEUROSURG CLIN N AM, V18, P325, DOI 10.1016/j.nec.2007.02.004
   Coe JD, 2006, SPINE, V31, P345, DOI 10.1097/01.brs.0000197188.76369.13
   Di Silvestre M, 2007, SPINE, V32, P1655, DOI 10.1097/BRS.0b013e318074d604
   Ebraheim NA, 1997, SPINE, V22, P2338, DOI 10.1097/00007632-199710150-00003
   Gaines RW, 2000, J BONE JOINT SURG AM, V82A, P1458, DOI 10.2106/00004623-200010000-00013
   Iampreechakul Prasert, 2011, Journal of the Medical Association of Thailand, V94, P337
   Jones DPG, 2000, SPINE, V25, P1538, DOI 10.1097/00007632-200006150-00013
   Jutte PC, 2002, EUR SPINE J, V11, P594, DOI 10.1007/s00586-002-0469-8
   Kosmopoulos V, 2007, SPINE, V32, pE111, DOI 10.1097/01.brs.0000254048.79024.8b
   KRAG MH, 1989, SPINE, V14, P879, DOI 10.1097/00007632-198908000-00020
   Lien SB, 2007, EUR SPINE J, V16, P1215, DOI 10.1007/s00586-006-0245-2
   MAGERL FP, 1984, CLIN ORTHOP RELAT R, P125
   Marmor M, 2016, J ORTHOP TRAUMA, V30, P682, DOI 10.1097/BOT.0000000000000685
   Matityahu A, 2013, J ORTHOP TRAUMA, V27, P170, DOI 10.1097/BOT.0b013e31825490b1
   Pihlajamaki H, 1997, J BONE JOINT SURG BR, V79B, P183, DOI 10.1302/0301-620X.79B2.7224
   Rajasekaran S, 2007, SPINE, V32, pE56, DOI 10.1097/01.brs.0000252094.64857.ab
   Rampersaud YR, 2000, SPINE, V25, P2637, DOI 10.1097/00007632-200010150-00016
   ROYCAMILLE R, 1986, CLIN ORTHOP RELAT R, P7
   Samdani AF, 2008, J VASC SURG, V48, P1067, DOI 10.1016/j.jvs.2008.06.045
   Stratakis J, 2006, J VASC INTERV RADIOL, V17, P863, DOI 10.1097/01.RVI.0000217959.86251.11
   Tian W, 2014, CHINESE MED J-PEKING, V127, P3852, DOI 10.3760/cma.j.issn.0366-6999.20141860
   Verma R, 2010, EUR SPINE J, V19, P370, DOI 10.1007/s00586-009-1258-4
   Villavicencio AT, 2005, J SPINAL DISORD TECH, V18, P369, DOI 10.1097/01.bsd.0000168511.67189.64
   Wegener B, 2008, EUR SPINE J, V17, pS351, DOI 10.1007/s00586-008-0715-9
   WEINSTEIN JN, 1988, SPINE, V13, P1012, DOI 10.1097/00007632-198809000-00008
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E347
EP E354
DI 10.1016/j.wneu.2019.04.151
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100040
PM 31029816
DA 2020-05-12
ER

PT J
AU Yao, Y
   Qin, RQ
   Feng, QJ
   Jiang, XJ
   Zhou, P
   Guo, ZY
   Zhang, F
AF Yao, Yu
   Qin, Rongqing
   Feng, Qijie
   Jiang, Xingjie
   Zhou, Pin
   Guo, Ziyi
   Zhang, Feng
TI Percutaneous Endoscopic Transforaminal Decompression in the Treatment of
   Patients with Migrated Lumbar Disc Herniation: A Retrospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lumbar disc herniation; Migrated; Minimally invasive; Percutaneous
   endoscopic transforaminal decompression
ID SURGERY
AB OBJECTIVE: We aimed to discuss the surgical strategies, safety and clinical efficacy of percutaneous endoscopic transforaminal decompression for the treatment of patients with migrated lumbar disc herniation.
   METHODS: This is a retrospective study. From May 2014 to April 2017, a total of 56 patients (32 men and 24 women) with migrated lumbar disc herniation were operated on by percutaneous endoscopic decompression via transforaminal approach. All enrolled patients had clinical symptoms with radiculopathy, and were identified as single-level, soft herniated disc by computed tomography and magnetic resonance imaging. Clinical efficacy were evaluated chiefly by leg pain visual analogue scale score, Oswestry disability index score, and modified MacNab criteria.
   RESULTS: Patients were all successfully treated by percutaneous endoscopic transforaminal decompression, with an mean operation time of 63 +/- 12 minutes. The patients were followed up for a mean duration of 15 +/- 2.7 months (range 12-18 months). The leg pain visual analogue scale score was dropped from 8.2 +/- 1.9 preoperatively to 2.4 +/- 1.5, 2.2 +/- 1.3, and 1.8 +/- 1.1 at 1, 6, and 12 months after the operation, respectively. Similarly, the Oswestry disability index score was also decreased from 62.4 +/- 8.2 preoperatively to 18.4 +/- 6.2, 12.6 +/- 5.1, and 9.2 +/- 3.4 at 1, 6, and 12 months postoperatively. There were 38 excellent cases, 13 good cases, and 5 fair cases by the assessment method of modified MacNab criteria at 12 months after the operation, with an excellent and good rate of 91.07%. Two cases were complicated with low extremity numbness, which were recovered by conservative treatment in 3 weeks. No persistent neurological deficit or infection occurred in this group postoperatively.
   CONCLUSIONS: We consider that percutaneous endoscopic decompression via transforaminal approach provided a safe, effective and minimally invasive alternative for the treatment of patients with migrated lumbar disc herniation.
C1 [Yao, Yu; Jiang, Xingjie; Zhang, Feng] Nantong Univ, Affiliated Hosp, Dept Orthoped, Nantong, Peoples R China.
   [Yao, Yu; Jiang, Xingjie; Zhang, Feng] Jiangsu Clin Med Ctr Tissue Engn & Nerve Injury R, Nantong, Peoples R China.
   [Qin, Rongqing; Zhou, Pin] Soochow Univ, Gaoyou Peoples Hosp, Dept Orthoped, Yangzhou, Jiangsu, Peoples R China.
   [Qin, Rongqing; Feng, Qijie] Nantong Univ, Coll Med, Nantong, Peoples R China.
   [Guo, Ziyi] Shulan Hangzhou Hosp, Dept Orthoped Surg, Hangzhou, Zhejiang, Peoples R China.
   [Guo, Ziyi] Zhejiang Univ, Dept Orthoped Surg, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China.
RP Zhang, F (reprint author), Nantong Univ, Affiliated Hosp, Dept Orthoped, Nantong, Peoples R China.; Zhang, F (reprint author), Jiangsu Clin Med Ctr Tissue Engn & Nerve Injury R, Nantong, Peoples R China.
EM zhangfengdoctor@sina.com
OI Qin, Rongqing/0000-0003-1894-8361
CR Ahn Y, 2014, EXPERT REV MED DEVIC, V11, P605, DOI 10.1586/17434440.2014.940314
   CASPAR W, 1977, ADV NEUROSURG, V4, P74, DOI DOI 10.1007/978-3-642-66578-3_15
   Chen Hsien-Te, 2011, Surg Neurol Int, V2, P93, DOI 10.4103/2152-7806.82570
   Choi G, 2010, MINIM INVAS NEUROSUR, V53, P147, DOI 10.1055/s-0030-1254145
   Choi G, 2008, SPINE, V33, pE508, DOI 10.1097/BRS.0b013e31817bfa1a
   Da VDW, 2010, COCHRANE DB SYST REV, V65, pD7431
   Daffner SD, 2010, SPINE J, V10, P463, DOI 10.1016/j.spinee.2010.02.005
   Destandau J, 1999, NEUROL RES, V21, P39, DOI 10.1080/01616412.1999.11740889
   Fan GX, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006684
   Gempt J, 2013, ACTA NEUROCHIR, V155, P2333, DOI 10.1007/s00701-013-1901-z
   Hao DJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008676
   Hoogland T, 2006, SPINE, V31, pE890, DOI 10.1097/01.brs.0000245955.22358.3a
   Joh JY, 2009, SPINE, V34, P2033, DOI 10.1097/BRS.0b013e3181b20250
   Kambin P, 1996, J NEUROSURG, V84, P462, DOI 10.3171/jns.1996.84.3.0462
   Kim CH, 2012, J SPINAL DISORD TECH, V25, pE104, DOI 10.1097/BSD.0b013e31825bd111
   Kim HS, 2009, J KOREAN NEUROSURG S, V45, P67, DOI 10.3340/jkns.2009.45.2.67
   Kitagawa Y, 2012, ASIAN J ENDOSC SURG, V5, P183, DOI 10.1111/j.1758-5910.2012.00144.x
   Lee S, 2007, EUR SPINE J, V16, P431, DOI 10.1007/s00586-006-0219-4
   Ozer AF, 2017, WORLD NEUROSURG, V100, P498, DOI 10.1016/j.wneu.2017.01.057
   Perez-Cruet MJ, 2002, NEUROSURGERY, V51, pS129, DOI 10.1227/01.NEU.0000031004.69814.2D
   Rasouli MR, 2012, J INJ VIOLENCE RE S1, V4
   Xie H, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011283
   Yeom KS, 2011, J ORTHOP SCI, V16, P263, DOI 10.1007/s00776-011-0048-0
NR 23
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E562
EP E569
DI 10.1016/j.wneu.2019.04.195
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100066
PM 31048055
DA 2020-05-12
ER

PT J
AU Yeap, MC
   Tu, PH
   Liu, ZH
   Hsieh, PC
   Liu, YT
   Lee, CY
   Lai, HY
   Chen, CT
   Huang, YC
   Wei, KC
   Wu, CT
   Chen, CC
AF Yeap, Mun-Chun
   Tu, Po-Hsun
   Liu, Zhuo-Hao
   Hsieh, Po-Chuan
   Liu, Yu-Tse
   Lee, Ching-Yi
   Lai, Hung-Yi
   Chen, Chun-Ting
   Huang, Yin-Cheng
   Wei, Kuo-chen
   Wu, Chieh-Tsai
   Chen, Ching-Chang
TI Long-Term Complications of Cranioplasty Using Stored Autologous Bone
   Graft, Three-Dimensional Polymethyl Methacrylate, or Titanium Mesh After
   Decompressive Craniectomy: A Single-Center Experience After 596
   Procedures
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D polymethyl methacrylate; Autologous bone graft; Complication;
   Cranioplasty; Titanium mesh
ID RETROSPECTIVE ANALYSIS; FLAP RESORPTION; CRANIAL DEFECT; RISK-FACTORS;
   INFECTION; HEMICRANIECTOMY; MULTICENTER; OUTCOMES; SURGERY; STROKE
AB OBJECTIVE: Cranioplasty is a technically simple procedure intended to repair defects of the skull to provide protection after craniectomy, improve functional outcomes, and restore cosmesis. Several materials have been used for the restoration of skull defects, including autologous bone grafts (AGs), polymethyl methacrylate (PMMA) flaps, and titanium mesh (T-mesh). However, the long-term results of cranioplasty after use of these materials are controversial.
   METHODS: Medical records of 596 patients who underwent cranioplasty at our medical center between 2009 and 2015 with at least 2.5 years of follow-up were retrospectively reviewed. Patients were classified into 3 groups according to the materials used: AG, three-dimensional PMMA, and T-mesh. Demographic and clinical characteristics and postoperative complications were analyzed.
   RESULTS: Cranioplasty with AG had the highest bone flap depression rate (4.9%; P = 0.02) and was associated with a 26% long-term bone flap resorption. Younger age was a risk factor for bone flap resorption. T-mesh had a higher risk of postoperative skin erosion and bone exposure (17%; P = 0.004). Patients with diabetes, previous craniotomy, or hydrocephalus showed a higher risk of postoperative skin erosion. PMMA was associated with the highest rate of postoperative infection (14.4% <3 months, 28.1% >3 months; P < 0.05), and previous craniotomy may increase the infection risk after cranioplasty with PMMA.
   CONCLUSIONS: Complications after cranioplasty are high, and the various types of cranioplasty materials used are associated with different complications. Surgeons need to be aware of these potential complications and should choose the appropriate material for each individual patient.
C1 [Yeap, Mun-Chun; Tu, Po-Hsun; Liu, Zhuo-Hao; Hsieh, Po-Chuan; Liu, Yu-Tse; Lee, Ching-Yi; Lai, Hung-Yi; Chen, Chun-Ting; Huang, Yin-Cheng; Wei, Kuo-chen; Wu, Chieh-Tsai; Chen, Ching-Chang] Chang Gung Med Coll & Univ, Chang Gung Mem Hosp, Linkou Med Ctr, Dept Neurosurg, Taoyuan, Taiwan.
RP Chen, CC (reprint author), Chang Gung Med Coll & Univ, Chang Gung Mem Hosp, Linkou Med Ctr, Dept Neurosurg, Taoyuan, Taiwan.
EM jcchen130@gmail.com
FU Chang Gung Memorial HospitalChang Gung Memorial Hospital [CMRPG3G1941]
FX This study is supported by grants from Chang Gung Memorial Hospital
   (CMRPG3G1941). The authors thank Alfred Hsing-Fen Lin for assisting in
   the statistical analysis. We also acknowledge GERE Medical Writers Co.
   for editing this manuscript.
CR Annan M, 2015, BRIT J NEUROSURG, V29, P314, DOI 10.3109/02688697.2015.1012047
   Archavlis E, 2012, ACTA NEUROCHIR, V154, P1055, DOI 10.1007/s00701-012-1333-1
   Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2
   Bender A, 2013, BRAIN INJURY, V27, P1073, DOI 10.3109/02699052.2013.794972
   Bohman LE, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0392-x
   Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133
   Chaturvedi J, 2016, BRIT J NEUROSURG, V30, P264, DOI 10.3109/02688697.2015.1054356
   Chen CC, 2019, WORLD NEUROSURG, V125, pE282, DOI 10.1016/j.wneu.2019.01.062
   Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022
   Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020
   Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd
   Coulter IC, 2014, ACTA NEUROCHIR, V156, P1361, DOI 10.1007/s00701-014-2081-1
   De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116
   Di Stefano C, 2016, BRAIN INJURY, V30, P164, DOI 10.3109/02699052.2015.1090013
   Feroze AH, 2015, J NEUROSURG, V123, P1098, DOI 10.3171/2014.11.JNS14622
   Fung C, 2012, STROKE, V43, P3207, DOI 10.1161/STROKEAHA.112.666537
   Geurts MI, 2009, LANCET NEUROL, V8, P326
   Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962
   Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163
   Heo J, 2014, J NEUROSURG, V121, P313, DOI 10.3171/2014.2.JNS131480
   Hng D, 2015, CRANIOMAX TRAUM REC, V8, P190, DOI 10.1055/s-0034-1395383
   Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532
   Im SH, 2012, J KOREAN NEUROSURG S, V52, P396, DOI 10.3340/jkns.2012.52.4.396
   Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46
   Jaberi J, 2013, J ORAL MAXIL SURG, V71, pE81, DOI 10.1016/j.joms.2012.09.023
   Jiang JW, 2016, CLIN NEUROL NEUROSUR, V145, P101, DOI 10.1016/j.clineuro.2016.01.022
   Kim H, 2013, ACTA NEUROCHIR, V155, P2171, DOI 10.1007/s00701-013-1877-8
   Kim Sung Hoon, 2017, Korean J Neurotrauma, V13, P15, DOI 10.13004/kjnt.2017.13.1.15
   Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005
   Kurland DB, 2015, NEUROCRIT CARE, V23, P292, DOI 10.1007/s12028-015-0144-7
   Lazaridis C, 2012, NEUROCRIT CARE, V16, P478, DOI 10.1007/s12028-012-9685-1
   Leao RD, 2018, BRAZ ORAL RES, V32, DOI 10.1590/1807-3107bor-2018.vol32.0031
   Lee L, 2013, BRIT J NEUROSURG, V27, P629, DOI 10.3109/02688697.2013.815313
   Li A, 2017, WORLD NEUROSURG, V102, P209, DOI 10.1016/j.wneu.2017.03.022
   Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6
   Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003
   Morton RP, 2018, J NEUROSURG, V128, P1648, DOI 10.3171/2016.11.JNS161917
   Mukherjee S, 2014, ACTA NEUROCHIR, V156, P989, DOI 10.1007/s00701-014-2024-x
   Paredes I, 2015, NEUROCIRUGIA, V26, P115, DOI 10.1016/j.neucir.2014.10.001
   Park SP, 2017, J KOREAN NEUROSURG S, V60, P749, DOI 10.3340/jkns.2017.0203.002
   Piedra Mark P, 2014, Surg Neurol Int, V5, P25, DOI 10.4103/2152-7806.127762
   Piedra MP, 2013, J NEUROSURG, V118, P109, DOI 10.3171/2012.10.JNS121037
   Piitulainen JM, 2015, WORLD NEUROSURG, V83, P708, DOI 10.1016/j.wneu.2015.01.014
   Rocque BG, 2013, J NEUROSURG-PEDIATR, V12, P120, DOI 10.3171/2013.4.PEDS12605
   Rosseto RS, 2015, WORLD NEUROSURG, V84, P431, DOI 10.1016/j.wneu.2015.03.045
   Schimidek H., 2000, OPERATIVE NEUROSURGI
   Schuss P, 2013, J NEUROTRAUM, V30, P91, DOI 10.1089/neu.2012.2542
   Schutz A, 2019, J NEUROSURG, V131, P1607, DOI 10.3171/2018.6.JNS172605
   Shin HS, 2015, J KOREAN NEUROSURG S, V57, P242, DOI 10.3340/jkns.2015.57.4.242
   Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850
   Tsang ACO, 2015, J CLIN NEUROSCI, V22, P834, DOI 10.1016/j.jocn.2014.11.021
   Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002
   Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626
   Wen L, 2007, J CRANIOFAC SURG, V18, P526
   Weng ZJ, 2018, DIABETES RES CLIN PR, V142, P385, DOI 10.1016/j.diabres.2018.06.019
   Williams LR, 2015, INT J ORAL MAX SURG, V44, P599, DOI 10.1016/j.ijom.2014.09.006
   Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053
   Xu H, 2015, CLIN NEUROL NEUROSUR, V136, P33, DOI 10.1016/j.clineuro.2015.05.031
   Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470
   Yeap MC, 2019, J NEUROSURG, V131, P936, DOI 10.3171/2018.4.JNS172519
   Zanotti B, 2016, J CRANIOFAC SURG, V27, P2061, DOI 10.1097/SCS.0000000000003025
NR 61
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E841
EP E850
DI 10.1016/j.wneu.2019.05.005
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100099
PM 31082551
DA 2020-05-12
ER

PT J
AU Yolcu, Y
   Wahood, W
   Kerezoudis, P
   Alvi, MA
   Habermann, EB
   Bydon, M
AF Yolcu, Yagiz
   Wahood, Waseem
   Kerezoudis, Panagiotis
   Alvi, Mohammed Ali
   Habermann, Elizabeth B.
   Bydon, Mohamad
TI Primary Central Nervous System Tumors: Comparing Two National Cancer
   Registries
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; National cancer database; Spinal cord tumor; Surveillance
   epidemiology and end results program
ID DATA-BASE; EPIDEMIOLOGY; SURVEILLANCE; RESECTION; ANTERIOR; BREAST
AB OBJECTIVE: The National Cancer Database (NCDB) and the SEER (Surveillance Epidemiology and End Results) program are the 2 largest cancer registries in the United States. However, considerable differences exist between them regarding the sampling frame as well as the participating facility characteristics. In this study, NCDB and SEER are compared for primary central nervous system (CNS) tumors with the aims of discussing the implications for researchers and evaluating the generalizability of both databases.
   METHODS: Patients with primary CNS (brain and spinal cord) tumors from 2004 to 2013 were identified using the International Classification of Diseases for Oncology, Third Edition topographic codes. Patient demographics, tumor characteristics, and treatment-related variables were compared between the 2 databases using standardized differences, with values >0.1 denoting statistical significance.
   RESULTS: A total of 588,534 primary brain tumor (NCDB, 416,162; SEER, 172,372) and 34,827 primary spinal cord tumor (NCDB, 26,602; SEER, 8225) cases were identified. We found significant differences regarding age (sd. diff., 0.16 for brain; 0.13 for spinal cord), and Hispanic origin (sd. diff., 0.34 for brain; 0.61 for spinal cord). For NCDB and SEER patients, estimated 5-year overall survival was 59% and 64%, respectively.
   CONCLUSIONS: Analysis of 623,361 patients with primary CNS tumors, which are identified using both the NCDB and SEER databases, showed significant differences in age, histopathologic classification of tumors, tumor behavior, and treatment of tumors between 2 databases. Overall, the differences observed between 2 databases provide helpful points for the researchers who would like to use NCDB or SEER. These observations should be taken into account when researchers design studies using these databases and discuss the generalizability of their findings.
C1 [Yolcu, Yagiz; Wahood, Waseem; Kerezoudis, Panagiotis; Alvi, Mohammed Ali; Bydon, Mohamad] Mayo Clin, Neuroinformat Lab, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Yolcu, Yagiz; Wahood, Waseem; Kerezoudis, Panagiotis; Alvi, Mohammed Ali; Bydon, Mohamad] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Habermann, Elizabeth B.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
RP Bydon, M (reprint author), Mayo Clin, Neuroinformat Lab, Dept Neurol Surg, Rochester, MN 55905 USA.; Bydon, M (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM bydon.mohamad@mayo.edu
RI Alvi, Mohammed Ali/AAE-1490-2019
OI Alvi, Mohammed Ali/0000-0002-7131-079X; Wahood,
   Waseem/0000-0002-2963-4096
CR Agency for Healthcare Research and Quality, 2008, CREAT NEW RAC ETHN C
   Alattar AA, 2018, J NEUROSURG, V128, P1076, DOI 10.3171/2016.11.JNS161974
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Luksik AS, 2017, J NEUROSURG-PEDIATR, V19, P711, DOI 10.3171/2017.1.PEDS16528
   Martin AM, 2017, JAMA ONCOL, V3, P1069, DOI 10.1001/jamaoncol.2017.0001
   Mettlin CJ, 1997, CANCER, V79, P2052, DOI 10.1002/(SICI)1097-0142(19970515)79:10<2052::AID-CNCR29>3.0.CO;2-S
   Mohanty S, 2014, J SURG ONCOL, V109, P629, DOI 10.1002/jso.23568
   National Cancer Database, 2018, PUF DAT DICT IT
   Pan Y, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0784-3
   Park Henry S, 2012, Curr Probl Cancer, V36, P183, DOI 10.1016/j.currproblcancer.2012.03.007
   Tian W, 2017, CLIN SPINE SURG, V30, pE1306, DOI 10.1097/BSD.0000000000000493
   Trifiletti DM, 2017, WORLD NEUROSURG, V103, P330, DOI 10.1016/j.wneu.2017.04.035
   U. S. Census Bureau, 2010, AM FACTFINDER RES
   Walraevens J, 2010, NEUROSURGERY, V67, P679, DOI 10.1227/01.NEU.0000377039.89725.F3
   Yan SZ, 2017, MED SCI MONITOR, V23, P2692, DOI 10.12659/MSM.905178
   Yang D., 2012, SAS GLOBAL FORUM, P335
   Yolcu Y, 2019, NEUROSURGERY, pE1, DOI [10.1016/j.wneu.2019.04.070, DOI 10.1016/J.WNEU.2019.04.070]
NR 17
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E719
EP E731
DI 10.1016/j.wneu.2019.04.247
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100085
PM 31077903
DA 2020-05-12
ER

PT J
AU Yu, LB
   Ma, L
   Huang, Z
   Shi, ZY
   Wang, R
   Zhao, YL
   Zhang, D
AF Yu, Lebao
   Ma, Li
   Huang, Zheng
   Shi, Zhiyong
   Wang, Rong
   Zhao, Yuanli
   Zhang, Dong
TI Revascularization Surgery in Patients with Ischemic-Type Moyamoya
   Disease: Predictors for Postoperative Stroke and Long-Term Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral ischemia; Moyamoya disease; Outcome; Revascularization; Stroke
ID EXTRACRANIAL-INTRACRANIAL BYPASS; CAROTID OCCLUSION SURGERY;
   CLINICAL-FEATURES; SURGICAL-TREATMENT; ADULT PATIENTS; ANTERIOR;
   INVOLVEMENT; FLOW
AB BACKGROUND: Recurrent stroke after surgical revascularization is still a big issue for moyamoya disease (MMD). This study aims to identify predictors for postoperative stroke and unfavorable outcome in ischemic-type MMD.
   METHODS: We identified a consecutive series of patients with ischemic-type MMD who underwent revascularization between January 2005 and December 2012. Predictors for postoperative stroke and functional outcomes were assessed with logistic and Cox regression analysis.
   RESULTS: A total of 346 patients underwent 437 revascularization procedures and the mean follow-up period was 4.0 years. The incidence of perioperative stroke was 6.9%. Being adult at onset (odds ratio [OR], 5.033; 95% confidence interval [CI], 1.447-17.506; P = 0.011) and posterior cerebral artery (PCA) stenosis (OR, 3.364; 95% CI, 1.588-7.265; P = 0.002) before surgery were predictors of perioperative stroke. The annual subsequent stroke rate beyond 30 days after surgery was 1.2%. Subsequent stroke events tended to occur throughout the first 5 years after surgery in adults, whereas in children they mainly occurred within the first 2 years after surgery. Age at onset (OR, 1.025; 95% CI, 1.003-1.048; P = 0.023), ischemic stroke or transient ischemic attack at presentation (OR, 2.703; 95% CI, 1.062-6.875; P = 0.037), and PCA involvement (OR, 2.664; 95% CI, 1.462-4.854; P = 0.001) were associated with higher risk of overall postoperative stroke. PCA involvement (OR, 2.62; 95% CI, 1.33-5.15; P = 0.005), internal carotid artery supraclinoid segment occlusion (OR, 2.76; 95% CI, 1.27-6.03; P = 0.011), and older age at onset (OR, 1.03; 95% CI, 1.01-1.05; P = 0.033) were predictive of unfavorable outcome.
   CONCLUSIONS: Patients with ischemic-type MMD at an older age and more severe angiopathy might be at higher risk of recurrent stroke and unfavorable outcome after revascularization.
C1 [Yu, Lebao; Ma, Li; Shi, Zhiyong; Wang, Rong; Zhao, Yuanli; Zhang, Dong] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Yu, Lebao; Ma, Li; Shi, Zhiyong; Wang, Rong; Zhao, Yuanli; Zhang, Dong] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Huang, Zheng] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China.
RP Huang, Z (reprint author), Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Hunan, Peoples R China.
EM hzter1985@163.com
RI Ma, Li/AAD-6532-2020
OI Ma, Li/0000-0003-0894-7867
FU China National Clinical Research Center for Neurosurgical Diseases
   (NCRCND) [2015BAI12B04]
FX The China National Clinical Research Center for Neurosurgical Diseases
   (NCRCND) (2015BAI12B04).
CR Bao XY, 2015, CEREBROVASC DIS, V39, P75, DOI 10.1159/000369524
   Bao XY, 2012, CEREBROVASC DIS, V34, P305, DOI 10.1159/000343225
   Chiu D, 1998, STROKE, V29, P1347, DOI 10.1161/01.STR.29.7.1347
   Cho WS, 2014, STROKE, V45, P3025, DOI 10.1161/STROKEAHA.114.005624
   Duan L, 2012, STROKE, V43, P56, DOI 10.1161/STROKEAHA.111.621300
   Fujimura M, 2012, NEUROL MED-CHIR, V52, P327, DOI 10.2176/nmc.52.327
   Fukui M, 1997, CLIN NEUROL NEUROSUR, V99, pS238
   Gesang DZ, 2009, CHINESE MED J-PEKING, V122, P2412, DOI 10.3760/cma.j.issn.0366-6999.2009.20.003
   Grubb RL, 2013, J NEUROSURG, V118, P25, DOI 10.3171/2012.9.JNS12551
   Guzman R, 2009, J NEUROSURG, V111, P927, DOI 10.3171/2009.4.JNS081649
   Hallemeier CL, 2006, STROKE, V37, P1490, DOI 10.1161/01.STR.0000221787.70503.ca
   Han DH, 2000, ACTA NEUROCHIR, V142, P1263, DOI 10.1007/s007010070024
   Hishikawa T, 2014, ACTA NEUROCHIR, V156, P1745, DOI 10.1007/s00701-014-2136-3
   Hishikawa T, 2013, J NEUROSURG, V119, P961, DOI 10.3171/2013.6.JNS122099
   Houkin Kiyohiro, 1996, Neurologia Medico-Chirurgica, V36, P783, DOI 10.2176/nmc.36.783
   Huang APH, 2009, CEREBROVASC DIS, V28, P247, DOI 10.1159/000228254
   Huang Z, 2015, NEUROL RES, V37, P886, DOI 10.1179/1743132815Y.0000000073
   Ikezaki K, 1997, STROKE, V28, P2513, DOI 10.1161/01.STR.28.12.2513
   Jung YJ, 2011, J KOREAN NEUROSURG S, V50, P492, DOI 10.3340/jkns.2011.50.6.492
   KARASAWA J, 1992, J NEUROSURG, V77, P84, DOI 10.3171/jns.1992.77.1.0084
   Kazumata K, 2014, J NEUROSURG, V121, P432, DOI 10.3171/2014.1.JNS13946
   Kim SK, 2010, ANN NEUROL, V68, P92, DOI 10.1002/ana.21981
   Kim SK, 2004, NEUROSURGERY, V54, P840, DOI 10.1227/01.NEU.0000114140.41509.14
   Kim T, 2016, J NEUROSURG, V124, P1788, DOI 10.3171/2015.6.JNS151105
   Kleinloog R, 2012, J NEUROL NEUROSUR PS, V83, P531, DOI 10.1136/jnnp-2011-301387
   Kraemer M, 2008, STROKE, V39, P3193, DOI 10.1161/STROKEAHA.107.513408
   Kuroda S, 2000, NEUROL MED-CHIR, V40, P315, DOI 10.2176/nmc.40.315
   Kuroda S, 2005, STROKE, V36, P2148, DOI 10.1161/01.STR.0000182256.32489.99
   Kuroda S, 2003, NEUROL SURG TOKYO, V31, P1073
   Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0
   Kurokawa T, 1985, Pediatr Neurol, V1, P274, DOI 10.1016/0887-8994(85)90027-X
   Kwag HJ, 2008, J CLIN NEUROL, V4, P67, DOI 10.3988/jcn.2008.4.2.67
   Lin N, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.10.FOCUS11228
   Liu XJ, 2015, J NEUROSURG, V122, P392, DOI 10.3171/2014.10.JNS132369
   Liu XJ, 2013, J NEUROL NEUROSUR PS, V84, P258, DOI 10.1136/jnnp-2012-302236
   MATSUSHIMA Y, 1984, CHILD BRAIN, V11, P155
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   Morioka M, 2003, STROKE, V34, P90, DOI 10.1161/01.STR.0000047120.67507.0D
   Mugikura S, 2002, STROKE, V33, P1497, DOI 10.1161/01.STR.0000016828.62708.21
   Noh HJ, 2015, J NEUROL SCI, V359, P381, DOI 10.1016/j.jns.2015.11.018
   Reynolds MR, 2013, J NEUROSURG, V119, P988, DOI 10.3171/2013.6.JNS13312
   Smith ER, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E17
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Uchino H, 2012, STROKE, V43, P2610, DOI 10.1161/STROKEAHA.112.654723
   Ye X, 2013, CHINESE MED J-PEKING, V126, P4232, DOI 10.3760/cma.j.issn.0366-6999.20131649
NR 45
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E582
EP E596
DI 10.1016/j.wneu.2019.04.214
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100068
PM 31059856
DA 2020-05-12
ER

PT J
AU Yuchi, CX
   Sun, GM
   Chen, C
   Liu, G
   Zhao, D
   Yang, HY
   Xu, BS
   Deng, SC
   Ma, XL
   Du, CF
   Yang, Q
AF Yuchi, Chen-Xi
   Sun, Guiming
   Chen, Chao
   Liu, Gang
   Zhao, Dong
   Yang, Haiyun
   Xu, Baoshan
   Deng, Shucai
   Ma, Xinlong
   Du, Cheng-Fei
   Yang, Qiang
TI Comparison of the Biomechanical Changes After Percutaneous
   Full-Endoscopic Anterior Cervical Discectomy versus Posterior Cervical
   Foraminotomy at C5-C6: A Finite Element-Based Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biomechanics; Finite element study; Percutaneous full-endoscopic
   anterior cervical discectomy; Posterior cervical foraminotomy
ID STRUCTURAL-PROPERTIES; DISC REPLACEMENT; SPINE; SEGMENT; STABILITY;
   MOTION; VALIDATION; PREDICTION; COMPONENTS; STRENGTHS
AB OBJECTIVE: Percutaneous full-endoscopic anterior cervical discectomy (PEACD) and posterior cervical foraminotomy (PCF) have been reported as effective treatments for the cervical spondylosis radiculopathy (CSR), but the biomechanical effects on the discs and facet joints of PEACD and PCF remain largely unclear. The purpose of this paper is to investigate and compare the biomechanical changes on cervical spine after PECAD and PCF procedures, thus providing evidences for surgeons to select a more appropriate approach.
   METHODS: An intact cervical C5-C6 digital model was constructed and then modified to obtain the PCF and PEACD models using finite element method. All the models were subjected to a 73.6N preload accompanied by a 1.8 Nm moment during flexion, extension, axial rotation, lateral bending. The range of motion (ROM), intervertebral disc pressure (IDP), facet joint contact area, and contact pressure were calculated under different loading conditions.
   RESULTS: The ROM of the PCF model changed slightly (0.28%), whereas that of the PEACD model increased significantly (20.49%) compared with intact model. The trend of IDP changes in these 2 surgical models were similar to ROM in the corresponding motion state. The contact pressure on the facet joint of the PEACD model increased by 20.53%, 33.38%, and 17.46% during extension, lateral bending, and axial bending, respectively, compared with the intact model, and the PCF increased by 33.53% and 16.16% during extension and lateral bending, respectively, whereas it decreased 0.97% in axial rotation. The facet joint contact area of the PCF model increased by 85.71%, 1.54%, and 2.17% during extension, lateral bending, and axial rotation, respectively, and the area of the PEACD model increased by 157.14% and 36.96% during extension and axial rotation, whereas it decreased by 13.85% during lateral bending.
   CONCLUSIONS: This is the first biomechanical finite element study comparing PEACD with PCF for the treatment of CSR. Our results showed that PEACD led to hypermobility with high IDP within the cervical segment undergone surgery, whereas the ROM and IDP changed slightly after PCF. The variations of the contact stress indicated that both procedures changed the transmission path of the force on the facet joint and may accelerate the degeneration of the facet joint. PCF may be a better choice for the treatment of CSR compared with PEACD.
C1 [Yuchi, Chen-Xi; Du, Cheng-Fei] Tianjin Univ Technol, Sch Mech Engn, Tianjin Key Lab Adv Machatron Syst Design & Intel, Tianjin, Peoples R China.
   [Yuchi, Chen-Xi; Du, Cheng-Fei] Tianjin Univ Technol, Natl Demonstrat Ctr Expt Alechameal & Elect Engn, Tianjin, Peoples R China.
   [Sun, Guiming; Chen, Chao; Liu, Gang; Zhao, Dong; Yang, Haiyun; Xu, Baoshan; Deng, Shucai; Ma, Xinlong; Yang, Qiang] Tianjin Hosp, Dept Spine Surg, Tianjin, Peoples R China.
RP Yang, Q (reprint author), Tianjin Hosp, Dept Spine Surg, Tianjin, Peoples R China.
EM yangqiangspine@163.com
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China [11602172, 11432016]; Tianjin's Fund for
   Distinguished Young Scholar; Tianjin's Fund for Top Medical Talent
FX Financial support for this work has been provided by the General
   Programs of National Natural Science Foundation of China (NSFC Nos.
   11602172 and 11432016), Tianjin's Fund for Distinguished Young Scholar
   (Q.Y.), Tianjin's Fund for Top Medical Talent (Q.Y.).
CR ABUMI K, 1990, SPINE, V15, P1142, DOI 10.1097/00007632-199011010-00011
   Carrier CS, 2013, SPINE J, V13, P1370, DOI 10.1016/j.spinee.2013.05.050
   Clarke MJ, 2007, J NEUROSURG-SPINE, V6, P5, DOI 10.3171/spi.2007.6.1.2
   Clausen JD, 1997, J ORTHOPAED RES, V15, P342, DOI 10.1002/jor.1100150305
   Dodwad SJM, 2016, CLIN SPINE SURG, V29, P177, DOI 10.1097/BSD.0000000000000384
   Faught RW, 2016, CLIN NEUROL NEUROSUR, V142, P22, DOI 10.1016/j.clineuro.2016.01.013
   GILAD I, 1986, SPINE, V11, P154, DOI 10.1097/00007632-198603000-00010
   Goel VK, 1998, SPINE, V23, P684, DOI 10.1097/00007632-199803150-00008
   Hartman RA, 2016, EUR SPINE J, V25, P2129, DOI 10.1007/s00586-016-4541-1
   Jung TG, 2013, INT J PRECIS ENG MAN, V14, P819, DOI 10.1007/s12541-013-0107-x
   Kerry G, 2015, BRIT J NEUROSURG, V31, P39
   Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509
   Kumaresan S, 1997, J SPINAL DISORD, V10, P40
   Kumaresan S, 1998, J BIOMECH, V31, P371, DOI 10.1016/S0021-9290(98)00008-6
   Lafage V, 2008, SPINE, V33, P1572, DOI 10.1097/BRS.0b013e31817886a2
   Lee SH, 2011, SPINE, V36, P700, DOI 10.1097/BRS.0b013e3181f5cb87
   Lee YS, 2017, J KOREAN NEUROSURG S, V60, P433, DOI 10.3340/jkns.2015.0909.006
   Levin KH, 1987, DIG WORLD LATEST MED, V7, P486
   Mo ZJ, 2014, EUR SPINE J, V23, P613, DOI 10.1007/s00586-013-3070-4
   Mo ZJ, 2017, EUR SPINE J, V26, P1181, DOI 10.1007/s00586-016-4777-9
   Mo ZJ, 2015, SPINE, V40, pE469, DOI 10.1097/BRS.0000000000000818
   Ng HW, 2004, P I MECH ENG H, V218, P183, DOI 10.1243/095441104323118905
   Nightingale RW, 2007, J BIOMECH, V40, P535, DOI 10.1016/j.jbiomech.2006.02.015
   Nightingale RW, 2002, J BIOMECH, V35, P725, DOI 10.1016/S0021-9290(02)00037-4
   Northrup BE, 1999, SPINE, V24, P2363, DOI 10.1097/00007632-199911150-00013
   Schwab F, 2006, SPINE, V31, pE959, DOI 10.1097/01.brs.0000248126.96737.0f
   Tzaan WC, 2011, J SPINAL DISORD TECH, V24, P421, DOI 10.1097/BSD.0b013e31820ef328
   Wheeldon JA, 2006, J BIOMECH, V39, P375, DOI 10.1016/j.jbiomech.2004.11.014
   Wheeldon JA, 2008, ANN BIOMED ENG, V36, P1458, DOI 10.1007/s10439-008-9534-8
   Yoganandan N, 2000, J BIOMECH ENG-T ASME, V122, P623, DOI 10.1115/1.1322034
   Yu CC, 2016, SPINE J, V16, P1384, DOI 10.1016/j.spinee.2016.06.019
   ZDEBLICK TA, 1992, J BONE JOINT SURG AM, V74A, P22, DOI 10.2106/00004623-199274010-00004
NR 32
TC 2
Z9 2
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E905
EP E911
DI 10.1016/j.wneu.2019.05.025
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100106
PM 31096026
DA 2020-05-12
ER

PT J
AU Zhang, N
   Zeng, XJ
   He, LC
   Liu, ZL
   Liu, JM
   Zhang, ZH
   Chen, XY
   Shu, Y
AF Zhang, Ning
   Zeng, Xianjun
   He, Laichang
   Liu, Zhili
   Liu, Jiaming
   Zhang, Zhihong
   Chen, Xuanyin
   Shu, Yong
TI The Value of MR Imaging in Comparative Analysis of Spinal Infection in
   Adults: Pyogenic Versus Tuberculous
SO WORLD NEUROSURGERY
LA English
DT Article
DE Infectious; Magnetic resonance imaging; Spondylitis; Tuberculosis
ID SPONDYLITIS; DIAGNOSIS
AB OBJECTIVE: Differentiating pyogenic spondylitis (PS) and tuberculous spondylitis (TS) is challenging but critical in clinical practice. Accurate diagnosis and early treatment are crucial to preventing further progression of disease. Magnetic resonance imaging (MRI) is considered the best method for the diagnosis of spinal infection, but results remain imprecise; therefore, by comparing and analyzing the MRI findings of spinal infections, we intend to identify key distinguishing features between PS and TS, and with that establish a systematic scoring method to help clinicians.
   METHODS: The MRI features of 70 cases of spinal infection (32 cases of PS, 38 cases of TS), confirmed by pathology or clinical diagnosis, were retrospectively analyzed. The receiver operating characteristic curve was used to analyze the diagnostic efficacy of the MRI parameter scores in PS and TS.
   RESULTS: Among the 70 cases, the average age was 54.5 years, and 43 were male. Sixteen parameters were significantly different between the PS and TS groups. We hypothesized that a diagnosis of PS could be made when the number of parameters characteristic of PS exceeded the number of parameters characteristic of TS, and vice versa. We randomly selected 70% (49 patients) of the 70 patients for analysis, and then validated in the remaining 30% (21 patients) of cases. Using 0.5 as the cutoff value, of the remaining 21 patients, the correct coincidence rate was 95.23%, sensitivity was 91.67%, specificity was 100%, false-positive rate was 0%, and false-negative rate was 8.3%. The MRI parameter scores of PS and TS were analyzed with the receiver operating characteristic; area under the curve was 1.00.
   CONCLUSIONS: Our systematic scoring system of MRI parameters is helpful in differentiating PS and TS.
C1 [Zhang, Ning; Zeng, Xianjun; He, Laichang] Nanchang Univ, Affiliated Hosp 1, Dept Radiol, Nanchang, Jiangxi, Peoples R China.
   [Liu, Zhili; Liu, Jiaming; Zhang, Zhihong; Chen, Xuanyin; Shu, Yong] Nanchang Univ, Affiliated Hosp 1, Dept Orthoped Surg, Nanchang, Jiangxi, Peoples R China.
RP Liu, ZL (reprint author), Nanchang Univ, Affiliated Hosp 1, Dept Orthoped Surg, Nanchang, Jiangxi, Peoples R China.
EM zgm7977@163.com
FU Key Research & Development Project of Jiangxi Science and Technology
   Department [20171BBG70014]
FX This work was supported by the Key Research & Development Project of
   Jiangxi Science and Technology Department (20171BBG70014).
CR ALMULHIM FA, 1995, SPINE, V20, P2287, DOI 10.1097/00007632-199511000-00005
   Babic M, 2017, INFECT DIS CLIN N AM, V31, P279, DOI 10.1016/j.idc.2017.01.003
   Chang MC, 2006, SPINE, V31, P782, DOI 10.1097/01.brs.0000206385.11684.d5
   Darouiche RO, 2006, NEW ENGL J MED, V355, P2012, DOI 10.1056/NEJMra055111
   DEMAEREL P, 1994, J NEURORADIOLOGY, V21, P245
   DEROOS A, 1986, AM J ROENTGENOL, V147, P79, DOI 10.2214/ajr.147.1.79
   Frel M, 2017, POL J RADIOL, V82, P71, DOI 10.12659/PJR.899606
   Galhotra Ritu Dhawan, 2015, J Nat Sci Biol Med, V6, P388, DOI 10.4103/0976-9668.160016
   Harada Y, 2008, CLIN IMAG, V32, P303, DOI 10.1016/j.clinimag.2007.03.015
   Hong SH, 2001, RADIOLOGY, V218, P848, DOI 10.1148/radiology.218.3.r01fe27848
   Joseffer SS, 2005, J NEUROSURG-SPINE, V2, P145, DOI 10.3171/spi.2005.2.2.0145
   Jung NY, 2004, AM J ROENTGENOL, V182, P1405, DOI 10.2214/ajr.182.6.1821405
   Kourbeti IS, 2008, CURR OPIN RHEUMATOL, V20, P471, DOI 10.1097/BOR.0b013e3282ff5e66
   Lee Y, 2018, J KOREAN NEUROSURG S, V61, P81, DOI 10.3340/jkns.2016.1212.005
   MODIC MT, 1985, RADIOLOGY, V157, P157, DOI 10.1148/radiology.157.1.3875878
   Moorthy S, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.4.1790979
   SHARIF HS, 1992, AM J ROENTGENOL, V158, P1333, DOI 10.2214/ajr.158.6.1590137
   Tali ET, 2015, NEUROIMAG CLIN N AM, V25, P193, DOI 10.1016/j.nic.2015.01.003
   WEAVER P, 1984, SKELETAL RADIOL, V12, P178, DOI 10.1007/BF00361084
NR 19
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E806
EP E813
DI 10.1016/j.wneu.2019.04.260
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100095
PM 31103765
DA 2020-05-12
ER

PT J
AU Zhang, QH
   Wang, ZX
   Guo, HC
   Yan, B
   Wang, ZL
   Zhao, HL
   Sahyouni, R
   Kuan, EC
AF Zhang, Qiuhang
   Wang, Zaixing
   Guo, Hongchuan
   Yan, Bo
   Wang, Zhenlin
   Zhao, Hailiang
   Sahyouni, Ronald
   Kuan, Edward C.
TI Direct Transcavernous Sinus Approach for Endoscopic Endonasal Resection
   of Intracavernous Sinus Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous sinus; Endoscopic endonasal surgery; Pituitary tumors; Sella
   and parasellar tumors; Skull base
ID TERM-FOLLOW-UP; CAVERNOUS SINUS; PITUITARY-ADENOMAS; TRANSSPHENOIDAL
   APPROACH; CLINICAL-IMPLICATIONS; SURGERY; MENINGIOMAS; INFILTRATION;
   EXPERIENCE; MANAGEMENT
AB OBJECTIVE: Because of its vascular supply and neurovascular contents, the cavernous sinus (CS) is a challenging area to dissect in the setting of skull base tumors with intracavernous extension or invasion. In the present study, we report the clinical outcomes of 14 patients with tumors with CS invasion that were surgically treated using a direct transcavernous sinus approach for endoscopic endonasal resection of their intracavernous sinus tumors.
   METHODS: Fourteen patients had undergone surgery using a direct endoscopic endonasal transcavernous sinus approach. The pathologic entities included Knosp grade 3-4 pituitary adenomas (n = 8), meningioma (n = 3), squamous cell carcinoma (n = 2), and chondrosarcoma (n = 1). The indications, surgical technique, and outcomes are discussed.
   RESULTS: Gross total resection was achieved in 11 patients (78.6%). All patients experienced resolution or improvement of symptoms. One patient experienced a transient oculomotor nerve palsy, which had resolved within 2 months postoperatively. No other complications occurred. For those tumors that had been grossly resected, no recurrence developed in any patient (mean follow-up, 40.4 +/- 24.8 months; range 10-84).
   CONCLUSIONS: Depending on the space created by intracavernous sinus tumors, use of the transanterior wall for the CS approach in endoscopic endonasal surgery could adequately treat most patients in our case series. This approach provided good visualization of the CS and can be used to treat tumors with favorable outcomes and a low incidence of complications in appropriately evaluated patients.
C1 [Zhang, Qiuhang; Guo, Hongchuan; Yan, Bo; Wang, Zhenlin] Capital Med Univ, Xuanwu Hosp, Skull Base Surg Ctr, Dept Neurosurg, Beijing, Peoples R China.
   [Wang, Zaixing; Zhao, Hailiang] Longgang ENT Hosp, Shenzhen, Peoples R China.
   [Sahyouni, Ronald; Kuan, Edward C.] Univ Calif Irvine, Med Ctr, Dept Otolaryngol Head & Neck Surg, Orange, CA USA.
RP Zhang, QH (reprint author), Capital Med Univ, Xuanwu Hosp, Skull Base Surg Ctr, Dept Neurosurg, Beijing, Peoples R China.
EM 13701267977@163.com
RI Kuan, Edward C/I-3715-2019
OI Kuan, Edward C/0000-0003-3475-0718; Sahyouni,
   Ronald/0000-0002-2124-0535; Wang, Zaixing/0000-0003-0743-4437
CR Ajlan A, 2017, J NEUROL SURG PART B, V78, P273, DOI 10.1055/s-0036-1598022
   Alfieri A, 2001, NEUROSURGERY, V49, P354, DOI 10.1097/00006123-200108000-00017
   ALMEFTY O, 1987, NEUROSURGERY, V21, P474, DOI 10.1227/00006123-198710000-00006
   Arita K, 2000, ACTA NEUROCHIR, V142, P1055, DOI 10.1007/s007010070062
   Couldwell WT, 1997, NEUROSURGERY, V40, P1307, DOI 10.1097/00006123-199706000-00040
   Couldwell WT, 2004, NEUROSURGERY, V55, P539, DOI 10.1227/01.NEU.0000134287.19377.A2
   CUSIMANO MD, 1995, NEUROSURGERY, V37, P1
   DeJesus O, 1996, NEUROSURGERY, V39, P915, DOI 10.1097/00006123-199611000-00005
   DEMONTE F, 1994, J NEUROSURG, V81, P245, DOI 10.3171/jns.1994.81.2.0245
   Dolenc VV, 1999, ACT NEUR S, V72, P99
   ELKALLINY M, 1992, J NEUROSURG, V77, P508, DOI 10.3171/jns.1992.77.4.0508
   Eloy P, 2005, RHINOLOGY, V43, P271
   Ferreli F, 2015, RHINOLOGY, V53, P308, DOI 10.4193/Rhin14.309
   FRAIOLI B, 1995, J NEUROSURG, V82, P63, DOI 10.3171/jns.1995.82.1.0063
   Fraser JF, 2008, SKULL BASE-INTERD AP, V18, P309, DOI 10.1055/s-0028-1086059
   Graillon T, 2014, NEUROCHIRURGIE, V60, P42, DOI 10.1016/j.neuchi.2014.01.004
   Hanakita S, 2018, WORLD NEUROSURG, V116, pE169, DOI 10.1016/j.wneu.2018.04.146
   HASHIMOTO N, 1990, J NEUROSURG, V73, P513, DOI 10.3171/jns.1990.73.4.0513
   INOUE T, 1990, NEUROSURGERY, V26, P903, DOI 10.1227/00006123-199006000-00001
   Jho HD, 2004, MINIM INVAS NEUROSUR, V47, P9, DOI 10.1055/s-2004-818346
   Jiang WH, 2012, J CRANIOFAC SURG, V23, P1699, DOI 10.1097/SCS.0b013e31826b83c3
   Juraschka K, 2014, J NEUROSURG, V121, P75, DOI 10.3171/2014.3.JNS131679
   Kassam Amin B, 2005, Neurosurg Focus, V19, pE6
   KOTAPKA MJ, 1994, J NEUROSURG, V81, P252, DOI 10.3171/jns.1994.81.2.0252
   Koutourousiou M, 2013, J NEUROSURG, V118, P621, DOI 10.3171/2012.11.JNS121190
   LARSON JJ, 1995, J NEUROSURG, V83, P596, DOI 10.3171/jns.1995.83.4.0596
   OSullivan MG, 1997, NEUROSURGERY, V40, P238, DOI 10.1097/00006123-199702000-00003
   Patrona A, 2017, J NEUROSURG, V126, P880, DOI 10.3171/2015.8.JNS15275
   Raithatha R, 2012, INT FORUM ALLERGY RH, V2, P9, DOI 10.1002/alr.20097
   RHOTON AL, 1991, CLIN NEUR, V37, P391
   SEKHAR LN, 1989, NEUROSURGERY, V24, P18, DOI 10.1227/00006123-198901000-00004
   Sen C, 1997, J NEUROSURG, V87, P535, DOI 10.3171/jns.1997.87.4.0535
   Sepehrnia A, 1991, Acta Neurochir Suppl (Wien), V53, P122
   Sindou M, 2007, J NEUROSURG, V107, P937, DOI 10.3171/JNS-07/11/0937
   Wakuta N, 2014, NEUROL MED-CHIR, V54, P612, DOI 10.2176/nmc.oa.2013-0237
   Walsh MT, 2009, J NEURO-ONCOL, V92, P307, DOI 10.1007/s11060-009-9824-5
   Woodworth GF, 2014, J NEUROSURG, V120, P1086, DOI 10.3171/2014.1.JNS131228
   Zoli M, 2016, J NEUROSURG SCI, V60, P485
NR 38
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E478
EP E487
DI 10.1016/j.wneu.2019.04.182
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100055
PM 31048053
DA 2020-05-12
ER

PT J
AU Zou, F
   Yang, S
   Jiang, JY
   Lu, FZ
   Xia, XL
   Ma, XS
AF Zou, Fei
   Yang, Shuo
   Jiang, Jianyuan
   Lu, Feizhou
   Xia, Xinlei
   Ma, Xiaosheng
TI Adjacent Intervertebral Disk Height Decrease Phenomenon After
   Single-Level Transforaminal Lumbar Interbody Fusion of the Lumbar Spine
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent intervertebral disk; Disk height decrease; Intervertebral
   height distraction; Radiographic study; Transforaminal lumbar interbody
   fusion
ID SEGMENT DISEASE; SPONDYLOLISTHESIS; DEGENERATION; DECOMPRESSION;
   ORIENTATION; TROPISM
AB BACKGROUND: The increase of intradiskal pressure on the upper segment resulting from intervertebral distraction after lumbar intervertebral fusion decreases intervertebral height and aggravates degeneration. However, the incidence rate and risk factors of the adjacent intervertebral disk height decrease phenomenon have not been studied. The purpose of this study was to identify the incidence rate and risk factors of the adjacent intervertebral disk height decrease phenomenon after single-level transforaminal lumbar interbody fusion (TLIF) of the lumbar spine.
   METHODS: A retrospection of 68 patients who underwent L4-5 TLIF. Patient age, sex, and body mass index were collected. Lumbar lordosis, facet sagittalization, Pfirrmann classification, L4-5 distraction height, and L3-4 reduction height were evaluated by radiologic image. The patients were divided into 2 groups based on whether their L3-4 intervertebral height decreased.
   RESULTS: Forty of 68 patients (58.8%) had L3-4 interver-tebral height decrease. The patients' mean age was 62.05 +/- 10.90 years in the L3-4 interver-tebral height decrease positive (IHDP) group, significantly higher than the 56.14 +/- 12.06 years in the L3-4 intervertebral height decrease negative (IHDN) group (P = 0.039). The mean facet sagittalization angle in the IHDP group was 67.5 degrees +/- 20.36 degrees , significantly larger than the 55.43 degrees +/- 14.97 degrees in the IHDN group (P = 0.010). The preoperative lumbar lordosis was significantly higher in the IHDP group (P = 0.049). No significant effects of other factors on L3-4 height decrease were observed (P > 0.05).
   CONCLUSIONS: Distraction of the L4-5 intervertebral space by cage insertion leads to a reduced height on the adjacent 13-4 segment in some patients. In addition, the decrease in 13-4 intervertebral height resulting from L4-5 distraction was correlated with age, preoperative lumbar lordosis, and facet joint sagittalization.
C1 [Zou, Fei; Yang, Shuo; Jiang, Jianyuan; Lu, Feizhou; Xia, Xinlei; Ma, Xiaosheng] Fudan Univ, Dept Orthopaed, Huashan Hosp, Shanghai, Peoples R China.
RP Ma, XS (reprint author), Fudan Univ, Dept Orthopaed, Huashan Hosp, Shanghai, Peoples R China.
EM mxs893@126.com
FU General Program of the National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [81601914, 81871552]
FX This work was supported by the General Program of the National Natural
   Science Foundation of China (81601914 and 81871552).
CR Aihara T, 2018, ASIAN SPINE J, V12, P132, DOI 10.4184/asj.2018.12.1.132
   Alonso F, 2017, WORLD NEUROSURG, V102, P91, DOI 10.1016/j.wneu.2017.02.114
   Cheh G, 2007, SPINE, V32, P2253, DOI 10.1097/BRS.0b013e31814b2d8e
   Chosa E, 2004, J SPINAL DISORD TECH, V17, P134, DOI 10.1097/00024720-200404000-00010
   de Kunder SL, 2017, SPINE J, V17, P1712, DOI 10.1016/j.spinee.2017.06.018
   Hashimoto K, 2019, INT ORTHOP, V43, P987, DOI 10.1007/s00264-018-4241-z
   Houten John K, 2006, Neurosurg Focus, V20, pE8
   Kaito T, 2010, J NEUROSURG-SPINE, V12, P671, DOI 10.3171/2009.12.SPINE08823
   Lan T, 2018, WORLD NEUROSURG, V112, P86, DOI [10.1016/J.WNEU.2018.01.021, 10.1016/j.wneu.2018.01.021]
   Lee SY, 2019, METAB SYNDR RELAT D, V17, P60, DOI 10.1089/met.2018.0051
   Liu X, 2018, SPINE, V43, P955, DOI 10.1097/BRS.0000000000002493
   Liu X, 2018, SPINE, V43, pE216, DOI 10.1097/BRS.0000000000002290
   Liu ZY, 2017, CLIN NEUROL NEUROSUR, V161, P41, DOI 10.1016/j.clineuro.2017.08.005
   Murphy ME, 2017, J NEUROSURG-SPINE, V26, P353, DOI 10.3171/2016.8.SPINE16616
   Okuda S, 2004, SPINE, V29, P1535, DOI 10.1097/01.BRS.0000131417.93637.9D
   Park P, 2004, SPINE, V29, P1938, DOI 10.1097/01.brs.0000137069.88904.03
   Pfirrmann CWA, 2001, SPINE, V26, P1873, DOI 10.1097/00007632-200109010-00011
   Rohlmann A, 2007, EUR SPINE J, V16, P1223, DOI 10.1007/s00586-006-0292-8
   Sudo H, 2006, J NEUROSURG-SPINE, V5, P150, DOI 10.3171/spi.2006.5.2.150
   Tang SJ, 2011, J ORTHOP SCI, V16, P221, DOI 10.1007/s00776-011-0037-3
   Teraguchi M, 2018, SCOLIOSIS SPINAL DIS, V13, DOI 10.1186/s13013-018-0168-9
   Trouillier Hans, 2006, Acta Orthop Belg, V72, P460
   Vazifehdan F, 2019, INT ORTHOP, V43, P891, DOI 10.1007/s00264-018-4222-2
   Weishaupt D, 1999, SKELETAL RADIOL, V28, P215, DOI 10.1007/s002560050503
   Wong AYL, 2017, SCOLIOSIS SPINAL DIS, V12, DOI 10.1186/s13013-017-0121-3
NR 25
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD AUG
PY 2019
VL 128
BP E308
EP E314
DI 10.1016/j.wneu.2019.04.141
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IJ4SX
UT WOS:000475895100034
PM 31028983
DA 2020-05-12
ER

PT J
AU Perez-Sanchez, R
   Manzano-Roman, R
   Obolo-Mvoulouga, P
   Oleaga, A
AF Perez-Sanchez, Ricardo
   Manzano-Roman, Raul
   Obolo-Mvoulouga, Prosper
   Oleaga, Ana
TI Function-guided selection of midgut antigens from Ornithodoros erraticus
   ticks and an evaluation of their protective efficacy in rabbits
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Omithodoros erraticus; Mialome; Vaccines; Aquaporins; ABC transporters;
   Selenoproteins
ID B-CELL EPITOPES; ANTITICK IMMUNE-RESPONSES; IXODES-RICINUS; CATTLE TICK;
   VACCINES; IDENTIFICATION; SELENOPROTEIN; AQUAPORINS; PREDICTION; ACARI
AB The identification of candidate protective antigens for the development of tick vaccines may be approached by selecting antigen candidates that play key biological functions. Tick midgut proteins that play essential functions in tick survival and disease transmission are upregulated in response to blood feeding and digestion. In this study, Ornithodoros erraticus midgut transcriptomic and proteomic data upon feeding were inspected to select functionally relevant antigens to be assessed as vaccine candidate antigens. For this, we primarily focused on proteins with relevant biological functions in key physiological processes for ticks and tick-host-pathogen interactions. Later, we used additional criteria based on overexpression after feeding, predicted antigenicity and cellular localisation, resulting in the selection of four theoretical candidates, two aquaporins (OeAQP, OeAQP1), one ABC transporter (OeABC) and one selenoprotein T (OeSEL). Rabbit vaccination with synthetic immunogenic peptides designed from the extracellular antigenic regions of the selected candidates induced humoral responses that reduced tick feeding and reproduction performance. Both AQPs and OeSEL demonstrated significant protection efficacy against the homologous species O. erraticus, but lower non-significant cross-species protection against Ornithodoros moubata. Conversely, OeABC showed no protection against the homologous species O. erraticus, but significant cross-species protection against O. moubata. These results are the first demonstration of the protective potential of argasid aquaporins, suggesting that they might be included in vaccines for the control of multiple tick species. Additionally, these results also unveiled two novel protective antigens from argasid ticks, OeABC and OeSEL, belonging to functional protein families that have never been explored as a source of vaccine candidates and are deserving of further studies. Finally, our data add value to the midgut as a protective candidate antigen source in argasids for the control of tick infestations.
C1 [Perez-Sanchez, Ricardo; Manzano-Roman, Raul; Obolo-Mvoulouga, Prosper; Oleaga, Ana] CSIC, IRNASA, Inst Recursos Nat & Agrobiol Salamanca, Parasitol Anim, Corda de Merinos 40, Salamanca 37008, Spain.
   [Manzano-Roman, Raul] IBMCC CSIC USAL IBSAL, Canc Res Ctr, Prote Unit, Salamanca 37007, Spain.
RP Perez-Sanchez, R (reprint author), CSIC, IRNASA, Inst Recursos Nat & Agrobiol Salamanca, Parasitol Anim, Corda de Merinos 40, Salamanca 37008, Spain.
EM ricardo.perez@irnasa.csic.es; rmanzano@usal.es;
   prosper.obolo@irnasa.csic.es; ana.oleaga@irnasa.csic.es
RI OLEAGA, ANA/E-9564-2011; Perez-Sanchez, Ricardo/B-7656-2008
OI OLEAGA, ANA/0000-0002-8019-7354; Perez-Sanchez,
   Ricardo/0000-0001-8875-439X
FU Spanish Ministry of Economy and Competitiveness [AGL2013-42745-P]
FX This work was supported by project AGL2013-42745-P, funded by a grant
   from the Spanish Ministry of Economy and Competitiveness.
CR Adamson S, 2014, INSECT MOL BIOL, V23, P497, DOI 10.1111/imb.12098
   Adamson SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082012
   Akov S., 1982, PHYSL TICKS, P197
   Arias M, 2017, T EMER DIS, V65, P235
   Authie E, 2014, EFSA J, V12, DOI 10.2903/j.efsa.2014.3628
   Ball A, 2009, INSECT BIOCHEM MOLEC, V39, P105, DOI 10.1016/j.ibmb.2008.10.006
   Benoit JB, 2014, J COMP PHYSIOL B, V184, P811, DOI 10.1007/s00360-014-0836-x
   Berg C, 2015, EFSA J, V13, DOI 10.2903/j.efsa.2015.4163
   Boinas F, 2014, J VECTOR ECOL, V39, P238, DOI 10.1111/jvec.12098
   Bowman AS, 2004, PARASITOLOGY, V129, pS67, DOI 10.1017/S0031182004006468
   Budachetri K, 2015, INSECT MOL BIOL, V24, P570, DOI 10.1111/imb.12184
   Budachetri K, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0524-2
   Budachetri K, 2017, INSECT BIOCHEM MOLEC, V88, P37, DOI 10.1016/j.ibmb.2017.07.006
   Campbell EM, 2008, J COMP PHYSIOL B, V178, P935, DOI 10.1007/s00360-008-0288-2
   Campbell EM, 2010, INT J PARASITOL, V40, P15, DOI 10.1016/j.ijpara.2009.06.010
   Canales M, 1997, VACCINE, V15, P414, DOI 10.1016/S0264-410X(96)00192-2
   Gallardo MC, 2015, PORCINE HEALTH MANAG, V1, DOI 10.1186/s40813-015-0013-y
   Caro-Aguilar I, 2005, MICROBES INFECT, V7, P1324, DOI 10.1016/j.micinf.2005.04.020
   Chen Z, 2010, EXP APPL ACAROL, V51, P393, DOI 10.1007/s10493-010-9335-2
   Contreras M, 2017, VACCINE, V35, P1323, DOI 10.1016/j.vaccine.2017.01.052
   Contreras M, 2016, VACCINE, V34, P3010, DOI 10.1016/j.vaccine.2016.04.092
   de la Fuente J, 2016, PARASITE IMMUNOL, V38, P754, DOI 10.1111/pim.12339
   de la Fuente J, 2018, TICKS TICK-BORNE DIS, V9, P1354, DOI 10.1016/j.ttbdis.2018.04.001
   de la Fuente J, 2015, EXPERT REV VACCINES, V14, P1367, DOI 10.1586/14760584.2015.1076339
   Dermauw W, 2014, INSECT BIOCHEM MOLEC, V45, P89, DOI 10.1016/j.ibmb.2013.11.001
   Diaz-Martin V, 2015, TICKS TICK-BORNE DIS, V6, P211, DOI 10.1016/j.ttbdis.2015.03.006
   Diaz-Martin V, 2013, J PROTEOMICS, V80, P216, DOI 10.1016/j.jprot.2013.01.015
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Doytchinova IA, 2007, VACCINE, V25, P856, DOI 10.1016/j.vaccine.2006.09.032
   FAO, 2018, AFR SWIN FEV THREAT, P1
   Fletcher JI, 2016, DRUG RESIST UPDATE, V26, P1, DOI 10.1016/j.drup.2016.03.001
   Flower Darren R, 2010, Immunome Res, V6 Suppl 2, pS1, DOI 10.1186/1745-7580-6-S2-S1
   Garcia-Varas S, 2010, INT J PARASITOL, V40, P313, DOI 10.1016/j.ijpara.2009.08.011
   Gomes D, 2009, BBA-BIOMEMBRANES, V1788, P1213, DOI 10.1016/j.bbamem.2009.03.009
   Guerrero FD, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0475-9
   Hussein HE, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1226-2
   Jurado C, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00077
   Kocan KM, 2004, PARASITOLOGY, V129, pS285, DOI 10.1017/S0031182003004700
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   Kumar D, 2016, INSECT MOL BIOL, V25, P283, DOI 10.1111/imb.12218
   Kumar D, 2016, PROTEOMICS, V16, P2533, DOI 10.1002/pmic.201600140
   Lara FA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134779
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Le Gall VL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30907-7
   Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036
   Mangia C, 2016, PARASITE VECTOR, V9, P1497
   Mangia C, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3020-4
   Manzano-Roman R, 2006, VET PARASITOL, V135, P65, DOI 10.1016/j.vetpar.2005.08.004
   Manzano-Roman R, 2007, VET PARASITOL, V145, P314, DOI 10.1016/j.vetpar.2007.01.011
   Manzano-Roman R, 2015, VACCINE, V33, P1046, DOI 10.1016/j.vaccine.2015.01.015
   Maritz-Olivier C, 2012, TICKS TICK-BORNE DIS, V3, P179, DOI 10.1016/j.ttbdis.2012.01.003
   Matsuo T, 2003, PARASITOL RES, V90, P243, DOI 10.1007/s00436-003-0833-6
   Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646
   Ni ZX, 2017, MOL MED REP, V15, P3943, DOI 10.3892/mmr.2017.6505
   Obolo-Mvoulouga P, 2018, TICKS TICK-BORNE DIS, V9, P1158, DOI 10.1016/j.ttbdis.2018.04.015
   Oleaga A, 2018, TICKS TICK-BORNE DIS, V9, P1537, DOI 10.1016/j.ttbdis.2018.06.018
   Oleaga A, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2300-8
   Oleaga A, 2017, TICKS TICK-BORNE DIS, V8, P693, DOI 10.1016/j.ttbdis.2017.05.002
   Oleaga A, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1148-z
   Perner J, 2016, SCI REP-UK, V6, DOI 10.1038/srep36695
   Perner J, 2016, ELIFE, V5, DOI [10.7754/eLife.12318, 10.7554/eLife.12318]
   Aguirre ADR, 2015, INT J PARASITOL, V45, P357, DOI 10.1016/j.ijpara.2015.02.003
   Rappuoli R, 2011, VACCINE DESIGN: INNOVATIVE APPROACHES AND NOVEL STRATEGIES, pIX
   Rebaudet S, 2006, FEMS IMMUNOL MED MIC, V48, P11, DOI 10.1111/j.1574-695X.2006.00104.x
   Richards SA, 2015, TICKS TICK-BORNE DIS, V6, P695, DOI 10.1016/j.ttbdis.2015.06.002
   Saha S, 2004, LECT NOTES COMPUT SC, V3239, P197
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Schorderet-Weber S, 2017, INT J PARASITOL-DRUG, V7, P90, DOI 10.1016/j.ijpddr.2017.01.004
   Smit R, 2016, EXPERT REV VACCINES, V15, P5, DOI 10.1586/14760584.2016.1111142
   Sojka D, 2016, TICKS TICK-BORNE DIS, V7, P604, DOI 10.1016/j.ttbdis.2015.12.014
   Sojka D, 2013, TRENDS PARASITOL, V29, P276, DOI 10.1016/j.pt.2013.04.002
   Szollosi D, 2018, BBA-BIOMEMBRANES, V1860, P818, DOI 10.1016/j.bbamem.2017.10.028
   Talagrand-Reboul E, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00098
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Yoo YJ, 2016, MOL PLANT, V9, P1004, DOI 10.1016/j.molp.2016.04.012
NR 75
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 1
EP 12
DI 10.1016/j.vetpar.2019.06.016
PG 12
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800001
PM 31395198
DA 2020-05-12
ER

PT J
AU Di Cesare, A
   Gueldner, EK
   Traversa, D
   Veronesi, F
   Morelli, S
   Crisi, PE
   Pampurini, F
   Strube, C
   Schnyder, M
AF Di Cesare, Angela
   Gueldner, Emily Katharina
   Traversa, Donato
   Veronesi, Fabrizia
   Morelli, Simone
   Crisi, Paolo Emidio
   Pampurini, Fabrizio
   Strube, Christina
   Schnyder, Manuela
TI Seroprevalence of antibodies against the cat lungworm Aelurostrongylus
   abstrusus in cats from endemic areas of Italy
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Aelurostrongylus abstrusus; Cat; ELISA; Antibodies; Diagnosis; Italy;
   Lungworm
ID INFECTIONS; ANTIGEN; ELISA; IMMUNOFLUORESCENCE; PARASITES; FEATURES;
   ASSAY
AB Aelurostrongylus abstrusus (Nematoda, Metastrongyloidea) is a worldwide occurring lungworm causing verminous pneumonia in cats. To date the Baermann method is the most used procedure to diagnose A. abstrusus infection by isolating first stage larvae from faeces, though its sensitivity and specificity can be impaired by several factors. An enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against A. abstrusus has been recently developed as a diagnostic alternative. The present study evaluated the seroprevalence for A. abstrusus infection in cats from two endemic areas of Italy. Overall, 250 sera were sampled and tested for the presence of antibodies against A. abstrusus. Based on the results obtained from 20 cats proven to be infected by A. abstrusus using Baermann technique and molecular methods, and from 20 negative cats (Subset A), a cut off value of 0.347 optical density (OD) was determined, leading to a sensitivity of 95% and a specificity of 100%. Two-hundred and ten cats (142 and 68 from Abruzzo and Umbria regions, respectively) were included in Subset B (i.e. 202 negative by Baermann examination and 8 positive for Troglostrongylus brevior). Antibodies against A. abstrusus were detected in forty-five (21.4%, 95% CI: 16.1-27.6%) samples. This study confirms the occurrence of A. abstrusus in endemic areas of Italy and indicates that one-fifth of randomly selected cats have or had a lungworm infection with production of antibodies.
C1 [Di Cesare, Angela; Traversa, Donato; Morelli, Simone; Crisi, Paolo Emidio] Univ Teramo, Fac Vet Med, I-64100 Teramo, Italy.
   [Gueldner, Emily Katharina; Schnyder, Manuela] Univ Zurich, Vetsuisse Fac, Inst Parasitol, Winterthurerstr 266A, CH-8057 Zurich, Switzerland.
   [Veronesi, Fabrizia] Univ Perugia, Dept Vet Med, Via San Costanzo 4, I-06126 Perugia, Italy.
   [Pampurini, Fabrizio] Bayer Anim Hlth, Viale Certosa 130, I-20156 Milan, Italy.
   [Strube, Christina] Univ Vet Med Hannover, Ctr Infect Med, Inst Parasitol, Buenteweg 17, D-30559 Hannover, Germany.
RP Di Cesare, A (reprint author), Univ Teramo, Fac Vet Med, I-64100 Teramo, Italy.
EM adicesare@unite.it
OI Schnyder, Manuela/0000-0002-6523-7952; Veronesi,
   Fabrizia/0000-0003-1082-5666
FU Bayer Italy
FX The cat samples have been collected in the framework of a study
   conducted in Italy for evaluating the occurrence of extra-intestinal
   nematodes of dogs and cats supported by Bayer Italy, of which FP is an
   employee.
CR Brianti E, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-178
   Briggs KR, 2013, J FELINE MED SURG, V15, P1114, DOI 10.1177/1098612X13489977
   Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404
   Conboy G, 2009, VET CLIN N AM-SMALL, V39, P1109, DOI 10.1016/j.cvsm.2009.06.006
   Crisi PE, 2017, J FELINE MED SURG, V19, P1017, DOI [10.1177/1098612x16670563, 10.1177/1098612X16670563]
   Deplazes PEJ, 2016, PARASITOLOGY VET MED
   Di Cesare A, 2015, PARASITOL RES, V114, P4463, DOI 10.1007/s00436-015-4687-5
   Di Cesare A, 2015, J CLIN MICROBIOL, V53, P3009, DOI 10.1128/JCM.00901-15
   Genchi M, 2014, VET PARASITOL, V206, P182, DOI 10.1016/j.vetpar.2014.10.030
   Gerdin JA, 2011, J FELINE MED SURG, V13, P959, DOI 10.1016/j.jfms.2011.07.021
   Giannelli A, 2017, INT J PARASITOL, V47, P517, DOI 10.1016/j.ijpara.2017.02.003
   Gueldner EK, 2019, VET PARASITOL, V266, P27, DOI 10.1016/j.vetpar.2018.12.013
   HAMILTON JM, 1968, VET REC, V83, P401, DOI 10.1136/vr.83.16.401
   Jezewski W, 2013, VET PARASITOL, V198, P401, DOI 10.1016/j.vetpar.2013.09.003
   Ribeiro VM, 2001, REV MED VET-TOULOUSE, V152, P815
   Schnyder M, 2014, PARASITOL RES, V113, P1425, DOI 10.1007/s00436-014-3783-2
   Schnyder M, 2011, VET PARASITOL, V179, P152, DOI 10.1016/j.vetpar.2011.01.054
   Schnyder M, 2017, PARASITOL RES, V116, pS31, DOI 10.1007/s00436-017-5489-8
   Traversa D, 2008, PARASITOL RES, V103, P1191, DOI 10.1007/s00436-008-1115-0
   Traversa D, 2018, TRENDS PARASITOL, V34, P41, DOI 10.1016/j.pt.2017.09.002
   Traversa D, 2016, J FELINE MED SURG, V18, P7, DOI 10.1177/1098612X15623113
   Traversa D, 2013, TRENDS PARASITOL, V29, P423, DOI 10.1016/j.pt.2013.07.004
   Ulrich SA, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1054-4
   von Holtum C, 2008, VET PARASITOL, V151, P218, DOI 10.1016/j.vetpar.2007.11.006
   Zottler EM, 2019, PARASITOL INT, V69, P75, DOI 10.1016/j.parint.2018.12.005
   Zottler EM, 2017, VET PARASITOL, V235, P75, DOI 10.1016/j.vetpar.2017.01.015
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 13
EP 16
DI 10.1016/j.vetpar.2019.06.017
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800002
PM 31395199
DA 2020-05-12
ER

PT J
AU Silva, TPDE
   Bompadre, TFV
   Danasekaran, DK
   Sakita, GZ
   Abdalla, ALA
   Jimenez, CR
   Pinto, ACBDF
   do Amarante, AFT
   McManus, C
   Louvandini, H
AF Dias e Silva, Tairon Pannunzio
   Ventoso Bompadre, Thiago Francisco
   Danasekaran, Dinesh Kumar
   Sakita, Gabriel Zanuto
   Abdalla Filho, Adibe Luiz
   Jimenez, Carolina Rodrigues
   de Campos Fonseca Pinto, Ana Carolina Brandao
   Talamini do Amarante, Alessandro Francisco
   McManus, Concepta
   Louvandini, Helder
TI Trichostrongylus colubriformis infection: Impact on digesta passage rate
   and lamb performance
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Endoparasite; Feed intake; Digesta passage rate; Ruminants
ID NEUTRAL DETERGENT FIBER; FATTY-ACIDS; FOOD-INTAKE; SHEEP; NUTRITION;
   NEMATODE; GROWTH; BODY
AB In this study we aimed to evaluate the effect of Trichostrongylus colubriformis infection on digesta passage rate, rumen fermentation and lamb performance. Eighteen three-month-old Santa Ines castrated male lambs (16.9 +/- 1.43 kg of body weight) were randomly distributed in two experimental treatments: Infected with T. colubriformis (I, n = 9) and Uninfected (U, n = 9). The I lambs received a total of 45,000 L-3 larvae of T. colubriformis (5,000 infective larvae, three times per week for three weeks). Daily feed intake was assessed using the I lambs as a reference for their respective pairs on the U group (pair-fed). Weight, body condition score and faeces (stool) samples were obtained every 15 days for 75 days. In both treatments, faecal egg count (FEC), digesta passage rate, rumen fermentation parameters, protozoa count and short chain fatty acids (SCFA) were evaluated. The lambs presented moderate infection (FEC = 620). The retention time of the digesta in the rumen-reticulum segment was lower (P < 0.05) in I lambs. The I lambs presented no inappetence, however, lower concentrations of total SCFA and butyrate, while higher acetate concentration were observed in these lambs (P < 0.05). The present findings highlight that T. colubriformis infection decreased the retention time (solid and liquid content) of the digesta in the rumen-reticulum, as well as negatively affected lamb growth.
C1 [Dias e Silva, Tairon Pannunzio; Ventoso Bompadre, Thiago Francisco; Danasekaran, Dinesh Kumar; Sakita, Gabriel Zanuto; Abdalla Filho, Adibe Luiz; Jimenez, Carolina Rodrigues; Louvandini, Helder] Univ Sao Paulo, CENA, Lab Nutr Anim, Sao Paulo, SP, Brazil.
   [de Campos Fonseca Pinto, Ana Carolina Brandao] Univ Sao Paulo, Fac Med Vet & Zootecnia, Dept Cirurgia, Sao Paulo, Brazil.
   [Talamini do Amarante, Alessandro Francisco] Univ Estadual Paulista, UNESP, Inst Biociencias, Botucatu, SP, Brazil.
   [McManus, Concepta] Univ Brasilia, Inst Ciencias Biol, Brasilia, DF, Brazil.
   [Louvandini, Helder] Univ Florida, Inst Food & Agr Sci, Dept Anim Sci, POB 110910, Gainesville, FL 32611 USA.
RP Silva, TPDE (reprint author), Univ Sao Paulo, CENA, Lab Nutr Anim, Sao Paulo, SP, Brazil.
EM tairon.mvet@gmail.com
RI Sakita, Gabriel Z/C-8965-2015; Silva, Tairon/W-4605-2019; McManus,
   Concepta/AAF-4679-2020; Jimenez, Carolina Rodriguez/AAC-5287-2019;
   Filho, Adibe Luiz Abdalla/C-4499-2013; Amarante, Alessandro/C-8773-2012
OI Sakita, Gabriel Z/0000-0003-0034-2775; Silva,
   Tairon/0000-0002-4786-1399; McManus, Concepta/0000-0002-1106-8962;
   Jimenez, Carolina Rodriguez/0000-0001-7731-4858; Filho, Adibe Luiz
   Abdalla/0000-0001-5968-5380; Amarante, Alessandro/0000-0003-3995-5501
FU National Council of Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [2014/05023-1, 2018/06191-6]; Coordination for the Improvement of
   Higher Education Personnel (CAPES)CAPES [2014/05023-1, 2018/06191-6];
   Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2014/05023-1, 2018/06191-6]
FX The authors would like to thank the National Council of Technological
   and Scientific Development (CNPq), Coordination for the Improvement of
   Higher Education Personnel (CAPES) and Sao Paulo Research Foundation
   (FAPESP) for providing financial support (process number 2014/05023-1
   and process number 2018/06191-6).
CR Abdalla AL, 2017, SMALL RUMINANT RES, V154, P70, DOI [10.1016/j.smallrumres.2017.07.005, 10.10164/j.smallrtunres.2017.07.005]
   AOAC, 2011, OFFICIAL METHODS ANA
   BARKER I K, 1973, International Journal for Parasitology, V3, P743, DOI 10.1016/0020-7519(73)90066-0
   BARKER IK, 1975, PARASITOLOGY, V70, P173, DOI 10.1017/S0031182000049635
   Cantacessi C, 2010, INFECT GENET EVOL, V10, P1199, DOI 10.1016/j.meegid.2010.07.024
   Cardia DFF, 2011, VET PARASITOL, V182, P248, DOI 10.1016/j.vetpar.2011.05.017
   Clauss M, 2016, SMALL RUMINANT RES, V138, P12, DOI 10.1016/j.smallrumres.2016.03.029
   Coop RL, 1999, VET PARASITOL, V84, P187, DOI 10.1016/S0304-4017(99)00070-9
   COOP RL, 1982, J AGR SCI, V98, P247, DOI 10.1017/S0021859600041782
   de Vega A, 1998, BRIT J NUTR, V80, P381, DOI 10.1079/096582198388337
   DEHORITY BA, 1983, APPL ENVIRON MICROB, V45, P1394, DOI 10.1128/AEM.45.4.1394-1397.1983
   Silva TPDE, 2018, EXP PARASITOL, V188, P13, DOI 10.1016/j.exppara.2018.03.011
   Fox MT, 1997, VET PARASITOL, V72, P285, DOI 10.1016/S0304-4017(97)00102-7
   Gordon H. McL., 1939, Journal of the Council for Scientific and Industrial Research Australia, V12, P50
   JONES WO, 1982, INT J PARASITOL, V12, P295, DOI 10.1016/0020-7519(82)90032-7
   Kyriazakis I, 1996, VET PARASITOL, V61, P297, DOI 10.1016/0304-4017(95)00824-1
   Leng R. A, 1981, ISOTOPES RAD PARASIT, V4, P191
   MACRAE JC, 1993, P NUTR SOC, V52, P121, DOI 10.1079/PNS19930044
   Mertens DR, 2002, J AOAC INT, V85, P1217
   NOCEK JE, 1987, J DAIRY SCI, V70, P601, DOI 10.3168/jds.S0022-0302(87)80047-4
   O'Connor LJ, 2006, VET PARASITOL, V142, P1, DOI 10.1016/j.vetpar.2006.08.035
   PALMQUIST DL, 1971, J DAIRY SCI, V54, P1025, DOI 10.3168/jds.S0022-0302(71)85966-0
   PRESTON TR, 1995, TROPICAL ANIMAL FEED
   ROSEBY FB, 1974, AUST J AGR RES, V25, P363, DOI 10.1071/AR9740363
   Silva H. M, 2014, REV CIENC AGROVET, V13, P199
   Steel W. J., 1972, P AUST SOC ANIM PROD, V9, P402
   SYKES AR, 1976, J AGR SCI, V86, P507, DOI 10.1017/S0021859600061049
   SYKES AR, 1979, RES VET SCI, V26, P372, DOI 10.1016/S0034-5288(18)32896-0
   Taylor MA, 2010, PARASITOLOGIA VET
   Thompson S, 2006, TLS-TIMES LIT SUPPL, P28
   UDEN P, 1980, J SCI FOOD AGR, V31, P625, DOI 10.1002/jsfa.2740310702
   Ueno H., 1998, MANUAL DIAGNOSTIC HE
   VAN SOEST P. J., 1994, NUTR ECOLOGY RUMINAN
   VANSOEST PJ, 1991, J DAIRY SCI, V74, P3583, DOI 10.3168/jds.S0022-0302(91)78551-2
   VANSOEST PJ, 1992, J THEOR BIOL, V159, P135, DOI 10.1016/S0022-5193(05)80698-8
NR 35
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 17
EP 22
DI 10.1016/j.vetpar.2019.06.018
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800003
PM 31395200
DA 2020-05-12
ER

PT J
AU Cavallero, S
   Nejsum, P
   Cutillas, C
   Callejon, R
   Dolezalova, J
   Modry, D
   D'Amelio, S
AF Cavallero, Serena
   Nejsum, Peter
   Cutillas, Cristina
   Callejon, Rocio
   Dolezalova, Jana
   Modry, David
   D'Amelio, Stefano
TI Insights into the molecular systematics of Trichuris infecting captive
   primates based on mitochondrial DNA analysis
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Trichuris; Captive primates; Zoonosis; mtDNA; Genetic diversity; Host
   specificity
ID SP NEMATODA TRICHURIDAE; NONHUMAN-PRIMATES; POPULATION-STRUCTURE;
   GENETIC-ANALYSIS; TRICHIURA; PHYLOGENY; SUIS; MTDNA; TRANSMISSION;
   WHIPWORMS
AB Nematodes belonging to the Trichuris genus are prevalent soil-transmitted helminths with a worldwide distribution in mammals, while humans are mainly affected in areas with insufficient sanitation such as in Africa, Asia and South America. Traditionally, whipworms infecting primates are referred to Trichuris trichiura, but recent molecular and morphological evidence suggests that more than one species may be able to infect humans and non-human primates. Here, we analyzed the genetic diversity and phylogeny of Trichuris infecting five different non-human primate species kept in captivity using sequencing of three mitochondrial genes (cox1, rrnL and cob).
   Phylogenetic analyses of both single and concatenated datasets suggested the presence of two main evolutionary lineages and several highly supported clades likely existing as separate taxa. The first lineage included Trichuris infecting the mantled guereza (Colobus guereza kikuyensis), the chacma baboon (Papio ursinus) and the green monkeys (Chlorocebus spp.), clustering together with Trichuris suis; the second lineage included Trichuris infecting the Japanese macaque (Macaca fuscata) and the hamadryas baboon (Papio hamadryas), clustering together with Trichuris spp. infecting humans. These results were supported by the genetic distance between samples, which suggested that at least two taxa are able to infect macaques, baboons and humans.
   The present study improves our understanding of the taxonomy and evolutionary relationships among Trichuris spp. infecting primates. It moreover suggests that multiple Trichuris spp. may circulate among host species and that Trichuris in non human primates (NHPs) may be zoonotic. Further studies are important to better understand the epidemiology of Trichuris in primates and for implementing appropriate control and/or conservation measures.
C1 [Cavallero, Serena; D'Amelio, Stefano] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
   [Nejsum, Peter] Aarhus Univ, Dept Clin Med, Palle Juul Jensens Blvd 82, DK-8200 Aarhus, Denmark.
   [Cutillas, Cristina; Callejon, Rocio] Univ Seville, Dept Microbiol & Parasitol, Fac Pharm, Calle Prof Garcia Gonzalez 2, E-41012 Seville, Spain.
   [Dolezalova, Jana] Univ Vet & Pharmaceut Sci Brno, Dept Physiol, Fac Vet Med, Brno, Czech Republic.
   [Modry, David] Univ Vet & Pharmaceut Sci, Fac Vet Med, Dept Pathol & Parasitol, Brno, Czech Republic.
RP D'Amelio, S (reprint author), Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM stefano.damelio@uniroma1.it
RI CAVALLERO, Serena/AAF-3218-2020; CUTILLAS, CRISTINA/L-1738-2014
OI CAVALLERO, Serena/0000-0002-2245-9694; Nejsum,
   Peter/0000-0002-6673-8505; D'Amelio, Stefano/0000-0002-1871-9553;
   CUTILLAS, CRISTINA/0000-0002-3886-1231
FU Independent Research Fund Denmark [DFF-6111-00521]; Starting Grant
   Sapienza 2016; Ministry of Education and Culture [CGL2017-83057]; V Plan
   Propio de Investigacion of the University of Seville, Spain
FX PN was supported by a grant from Independent Research Fund Denmark
   (DFF-6111-00521); SC and SD were supported by Starting Grant Sapienza
   2016. This research has been partially funded by a grant from the
   Ministry of Education and Culture (CGL2017-83057) and by a grant from
   the V Plan Propio de Investigacion of the University of Seville, Spain.
CR Agnarsson I, 2008, MOL PHYLOGENET EVOL, V48, P964, DOI 10.1016/j.ympev.2008.05.046
   Anderson RC, 2000, NEMATODE PARASITES V, P672
   Areekul P, 2010, ASIAN BIOMED, V4, P49, DOI 10.2478/abm-2010-0006
   Betson M, 2014, J INFECT DIS, V210, P932, DOI 10.1093/infdis/jiu193
   Blouin MS, 1998, MOL BIOL EVOL, V15, P1719, DOI 10.1093/oxfordjournals.molbev.a025898
   Blouin MS, 2002, INT J PARASITOL, V32, P527, DOI 10.1016/S0020-7519(01)00357-5
   Callejon R, 2017, INFECT GENET EVOL, V51, P182, DOI 10.1016/j.meegid.2017.04.002
   Callejon R, 2015, PARASITOL RES, V114, P4591, DOI 10.1007/s00436-015-4705-7
   Callejon R, 2013, PARASITOL RES, V112, P3933, DOI 10.1007/s00436-013-3584-z
   Cavallero S, 2015, INFECT GENET EVOL, V34, P450, DOI 10.1016/j.meegid.2015.06.009
   Cavallero S, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002170
   Cutillas C, 2014, PARASITOL RES, V113, P2725, DOI 10.1007/s00436-014-3933-6
   Dolezalova J, 2015, FOLIA PARASIT, V62, DOI 10.14411/fp.2015.063
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Edwards SV, 2016, MOL PHYLOGENET EVOL, V94, P447, DOI 10.1016/j.ympev.2015.10.027
   Finstermeier K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069504
   Ghai RR, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003256
   Hansen TVA, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-236
   Hawash MBF, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1325-8
   Hawash MBF, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004059
   Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142
   Huang X, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012087
   Karim MR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117991
   Kuhnert D, 2016, MOL BIOL EVOL, V33, P2102, DOI 10.1093/molbev/msw064
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Lavrov DV, 2001, GENETICS, V157, P621
   LeBreton M, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.7
   Liu GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066249
   Liu GH, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001539
   Loytynoja A, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-579
   Meekums H, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0782-9
   Mohandas N, 2014, INT J PARASITOL, V44, P1073, DOI 10.1016/j.ijpara.2014.08.010
   Narat V, 2017, ECOHEALTH, V14, P840, DOI 10.1007/s10393-017-1283-4
   Nei M, 2000, MOL EVOLUTION PHYLOG, P348
   Nejsum P, 2010, VET PARASITOL, V171, P273, DOI 10.1016/j.vetpar.2010.03.030
   Nissen S, 2012, VET PARASITOL, V188, P68, DOI 10.1016/j.vetpar.2012.03.004
   Omland KE, 1999, MOL PHYLOGENET EVOL, V12, P224, DOI 10.1006/mpev.1999.0611
   OOI HK, 1993, J VET MED SCI, V55, P363, DOI 10.1292/jvms.55.363
   Perelman P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001342
   Phosuk I, 2018, AM J TROP MED HYG, V98, P39, DOI 10.4269/ajtmh.17-0651
   Pullan RL, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-37
   Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032
   Ravasi DF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044187
   Scholmerich J, 2013, DIGEST DIS, V31, P391, DOI 10.1159/000354708
   Skrjabin K. I., 1957, ESSENTIALS NEMATODOL, P1
   Wang HB, 2019, J HELMINTHOL, V93, P601, DOI 10.1017/S0022149X18000500
   Xie Y, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3100-5
   Yamaguti S., 1961, P1261
   Yao Chaoqun, 2018, Vet Parasitol Reg Stud Reports, V11, P22, DOI 10.1016/j.vprsr.2017.11.004
   2013, SUST DRIV OV GLOB, P1
NR 50
TC 1
Z9 1
U1 3
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 23
EP 30
DI 10.1016/j.vetpar.2019.06.019
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800004
PM 31395201
DA 2020-05-12
ER

PT J
AU Li, XC
   Cheng, GF
   Qin, FL
   Liu, JM
   Li, H
   Jin, YM
AF Li, Xiaochun
   Cheng, Guifeng
   Qin, Fanglin
   Liu, Jinming
   Li, Hao
   Jin, Yamei
TI Function of the lesswright (lwr) gene in the growth, development, and
   reproduction of Schistosoma japonicum
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Schistosoma japonicum; Lesswright; Quantitative RT-PCR; Gene silencing
ID UBIQUITIN-CONJUGATING ENZYME; SUMO PATHWAY; EXPRESSION; INFECTION;
   PROTEINS; VACCINES; TIME
AB The lesswright (lwr) gene and its products are essential molecules in mitosis, DNA repair, and embryo formation in many eukaryotes. In this study, immunohistochemical analysis revealed that the Lwr protein was located in the internal tissues and the surface layer of the adult Schistosoma japonicum (Sj) worms. The mRNA expression levels of SjLwr at different points were evaluated by quantitative real-time RT-PCR. The expression of SjLwr peaked at 14 days and then decreased thereafter. SjLwr expression was relatively more stable in male worms than in female worms. The functions of SjLwr were explored by siRNA-based gene silencing with a simple soaking method. The results showed that knockdown of the SjLwr gene impaired the growth and development of S. japonicum in mice, as well as survival, morphology, reproductive capacity, and egg vitality. These observations imply that SjLwr presents a novel target for the development of immuno- and/or small molecule-based therapeutics for the control and treatment of schistosome infections.
C1 [Li, Xiaochun; Cheng, Guifeng; Qin, Fanglin; Liu, Jinming; Li, Hao; Jin, Yamei] Chinese Acad Agr Sci, Shanghai Vet Res Inst, Key Lab Anim Parasitol, Minist Agr China, 518 Ziyue Rd, Shanghai 200241, Peoples R China.
   [Li, Xiaochun; Qin, Fanglin] Shanghai Normal Univ, Coll Life Sci, Shanghai, Peoples R China.
   [Cheng, Guifeng] Shanxi Agr Univ, Coll Anim Sci & Vet Med, Jinzhong, Shanxi, Peoples R China.
RP Jin, YM (reprint author), Chinese Acad Agr Sci, Shanghai Vet Res Inst, Key Lab Anim Parasitol, Minist Agr China, 518 Ziyue Rd, Shanghai 200241, Peoples R China.
EM yameijin@shvri.ac.cn
FU Chinese National Natural Science FoundationNational Natural Science
   Foundation of China [31672245]; Natural Science Foundation of
   ShanghaiNatural Science Foundation of Shanghai [16ZR1444100]
FX This work was supported by grants from the Chinese National Natural
   Science Foundation (no. 31672245) and the Natural Science Foundation of
   Shanghai (no. 16ZR1444100). The authors thank International Science
   Editing for revising the manuscript and their valuable comments.
CR ALKHODAIRY F, 1995, J CELL SCI, V108, P475
   Apionishev S, 2001, GENES CELLS, V6, P215, DOI 10.1046/j.1365-2443.2001.00413.x
   Bergquist NR, 1998, PARASITOL TODAY, V14, P99, DOI 10.1016/S0169-4758(97)01207-6
   CAMPBELL WC, 1986, J PARASITOL, V72, P45, DOI 10.2307/3281795
   Cao YF, 2014, PARASITOL RES, V113, P1, DOI 10.1007/s00436-013-3620-z
   Deshpande G, 2014, PLOS ONE, V14
   Diemert DJ, 2012, J ALLERGY CLIN IMMUN, V130, P169, DOI 10.1016/j.jaci.2012.04.027
   Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011
   Hoeller D, 2007, MOL CELL, V26, P891, DOI 10.1016/j.molcel.2007.05.014
   Huang L, 2005, DEV BIOL, V280, P407, DOI 10.1016/j.ydbio.2005.02.006
   Jiang WD, 1996, MOL GEN GENET, V251, P153
   Kumagai T, 2009, MOL BIOCHEM PARASIT, V164, P26, DOI 10.1016/j.molbiopara.2008.11.002
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007
   Ndegwa D, 2007, EXP PARASITOL, V117, P284, DOI 10.1016/j.exppara.2007.07.012
   SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0
   Siddiqui SA, 2011, J PAK MED ASSOC, V61, P1165
   SMITHERS SR, 1965, PARASITOLOGY, V55, P695, DOI 10.1017/S0031182000086248
   van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9
   Van Doren M, 1998, CURR BIOL, V8, P243
   Yang QY, 2015, EUKARYOT CELL, V14, P1240, DOI 10.1128/EC.00115-15
NR 21
TC 0
Z9 0
U1 2
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 31
EP 39
DI 10.1016/j.vetpar.2019.06.010
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800005
PM 31395202
DA 2020-05-12
ER

PT J
AU Duarte, ER
   Matias, AD
   Bastos, GA
   Maia, RC
   Martins, VS
   Soares, ACM
   Magaco, FD
   de Oliveira, NJF
   dos Santos, TAX
AF Duarte, Eduardo Robson
   Matias, Abigair Duarte
   Bastos, Gabriela Almeida
   Maia, Roberta Cordeiro
   Martins Junior, Valdo Soares
   Maia Soares, Ana Claudia
   Magaco, Fernando dos Santos
   Faria de Oliveira, Neide Judith
   Xavier dos Santos, Thiago Alves
TI Anthelmintic efficacy of trichlorfon and blood parameters of young lambs
   infected with Haemonchus contortus
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Small ruminant; Gastrointestinal nematode; Anthelmintic resistance;
   Plasmatic enzymes; Haemonchosis
ID SHEEP; RESISTANCE; NEMATODES; GOATS
AB In this study we evaluated the efficacy of trichlorfon against Haemonchus contortus, monitoring its influence on blood parameters and plasma enzymes of lambs with haemonchosis. A lamb group was orally treated with trichlorfon at 100 mg kg(-1) while the other group was untreated. Split-plot design analysis was performed with the lamb groups defined as plots while the subplots were the four periods (weeks) of collection. The trichlorfon treatment promoted a significant and effective reduction of fecal egg counts after one week, with efficacies > 99%. After 21 days of treatment, detected blood parameters and serum levels of plasma enzymes were normal. Additionally, serum albumin and urea concentrations increased to normal values, which were not observed in untreated lambs. The treatment with this organophosphate, using a correct oral administration, may represent an effective therapeutic alternative for sheep infected with multi resistant strain of H. contortus.
C1 [Duarte, Eduardo Robson; Matias, Abigair Duarte; Bastos, Gabriela Almeida; Maia, Roberta Cordeiro; Martins Junior, Valdo Soares; Maia Soares, Ana Claudia; Magaco, Fernando dos Santos; Faria de Oliveira, Neide Judith; Xavier dos Santos, Thiago Alves] Univ Fed Minas Gerais, Inst Ciencias Agr, Ave Univ 1000, BR-39400006 Montes Claros, MG, Brazil.
RP Duarte, ER (reprint author), Univ Fed Minas Gerais, Inst Ciencias Agr, Ave Univ 1000, BR-39400006 Montes Claros, MG, Brazil.
EM duartevet@pq.cnpq.br
OI Maia Soares, Ana Claudia/0000-0003-0078-9518; ALVES XAVIER DOS SANTOS,
   THIAGO/0000-0003-1922-2490
FU Coordination of Improvement of Higher Education Personnel (CAPES)CAPES
   [001]
FX The authors thank the Coordination of Improvement of Higher Education
   Personnel (CAPES, fund 001), the National Council for Scientific and
   Technological Development (CNPq), Foundation for Research Support of
   Minas Gerais (FAPEMIG and Prof Reitoria de Pesquisa of the Universidade
   Federal de Minas Gerais.
CR Almeida FA, 2010, PARASITOL INT, V59, P622, DOI 10.1016/j.parint.2010.09.006
   Bichuette MA, 2015, SMALL RUMINANT RES, V133, P93, DOI 10.1016/j.smallrumres.2015.09.009
   Bricarello PA, 2004, SMALL RUMINANT RES, V51, P75, DOI 10.1016/S0921-4488(03)00188-3
   Burke JM, 2007, VET PARASITOL, V147, P89, DOI 10.1016/j.vetpar.2007.03.033
   Dalto AGC, 2011, ACTA SCI VET, V39
   Chaparro Jenny J, 2017, Vet Parasitol Reg Stud Reports, V10, P29, DOI 10.1016/j.vprsr.2017.07.005
   COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U
   Duarte ER, 2012, PESQUI VET BRASIL, V32, P147, DOI 10.1590/S0100-736X2012000200010
   Fiel Cesar, 2011, Parasitol Res, V109 Suppl 1, pS139, DOI 10.1007/s00436-011-2410-8
   Gordon H. McL., 1939, Journal of the Council for Scientific and Industrial Research Australia, V12, P50
   KEITH RK, 1953, AUST J ZOOL, V1, P223, DOI 10.1071/ZO9530223
   Payne J. M, 1987, METABOLIC PROFILE TE, P1987
   Pugh D.G., 2004, CLIN OVINOS CAPRINOS
   Ribeiro Luiz Alberto Oliveira, 2004, Revista Portuguesa de Ciencias Veterinarias, V99, P155
   Santos BL, 2014, PESQUI VET BRASIL, V34, P655, DOI 10.1590/S0100-736X2014000700008
   Vercruysse J, 2001, VET PARASITOL, V96, P171, DOI 10.1016/S0304-4017(00)00443-X
   VIEIRA LS, 1992, VET PARASITOL, V45, P111, DOI 10.1016/0304-4017(92)90032-5
   Vijayasarathi MK, 2016, TROP ANIM HEALTH PRO, V48, P1455, DOI 10.1007/s11250-016-1117-3
   Lopes WDZ, 2014, PESQUI VET BRASIL, V34, P114, DOI 10.1590/S0100-736X2014000200003
   Lopes WDZ, 2009, VET PARASITOL, V166, P98, DOI 10.1016/j.vetpar.2009.07.045
NR 20
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 40
EP 43
DI 10.1016/j.vetpar.2019.06.015
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800006
PM 31395203
DA 2020-05-12
ER

PT J
AU Franco-Martinez, L
   Tvarijonaviciute, A
   Horvatic, A
   Guillemin, N
   Bernal, LJ
   Rafaj, RB
   Ceron, JJ
   Thomas, MD
   Lopez, MC
   Tecles, F
   Martinez-Subiela, S
   Mrljak, V
AF Franco-Martinez, Lorena
   Tvarijonaviciute, Asta
   Horvatic, Anita
   Guillemin, Nicolas
   Jesus Bernal, Luis
   Barie Rafaj, Renata
   Joaquin Ceron, Jose
   del Carmen Thomas, Maria
   Lopez, Manuel C.
   Tecles, Fernando
   Martinez-Subiela, Silvia
   Mrljak, Vladimir
TI Changes in saliva of dogs with canine leishmaniosis: A proteomic
   approach
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Biomarkers; Saliva; Leishmaniosis; Dog; Gel-free proteomics; Tandem mass
   tag
ID C-REACTIVE PROTEIN; GLUTAMINE-SYNTHETASE; MONITORING TREATMENT; IRON
   STATUS; FOLLOW-UP; BIOMARKERS; DIAGNOSIS; SERUM; IDENTIFICATION;
   INHIBITION
AB In the present study, a quantitative proteomic approach to study changes in saliva proteins associated with canine leishmaniosis (CanL) was performed. For this, canine salivary proteins were analysed and compared between dogs before (TO) and after (T1) experimental infection with Leishmania infantum by high-throughput label-based quantitative LC-MS/MS proteomic approach and bioinformatic analysis of the in silico inferred interactome protein network was created from the initial list of differential proteins. More than 2000 proteins were identified, and of the 90 differentially expressed proteins between TO and T1, 12 were down-regulated with log2 fold change lower than -0.5849, and 19 were up-regulated with log2 fold change greater than 0.5849. This study provides evidence of changes in salivary proteome that can occur in canine leishmaniosis and revealed biological pathways in saliva modulated in canine leishmaniosis with potential for further targeted research.
C1 [Franco-Martinez, Lorena; Tvarijonaviciute, Asta; Jesus Bernal, Luis; Joaquin Ceron, Jose; Tecles, Fernando; Martinez-Subiela, Silvia] Univ Murcia, Interdisciplinary Lab Clin Anal Interlab UMU, Reg Campus Int Excellence Mare Nostrum, Ed 16,4th Floor, E-30100 Murcia, Spain.
   [Horvatic, Anita; Guillemin, Nicolas; Mrljak, Vladimir] Univ Zagreb, Fac Vet Med, Internal Dis Clin, ERA Chair FP7, Heinzelova 55, Zagreb 10000, Croatia.
   [Barie Rafaj, Renata] Univ Zagreb, Fac Vet Med, Dept Chem & Biochem, Heinzelova 55, Zagreb 10000, Croatia.
   [del Carmen Thomas, Maria; Lopez, Manuel C.] CSIC, Mol Biol Dept, Inst Parasitol & Biomed Lopez Neyra, Granada, Spain.
RP Martinez-Subiela, S (reprint author), Univ Murcia, Interdisciplinary Lab Clin Anal Interlab UMU, Reg Campus Int Excellence Mare Nostrum, Ed 16,4th Floor, E-30100 Murcia, Spain.
EM silviams@um.es
RI Martinez-Subiela, Sylvia/H-5719-2015; Thomas, Maria Carmen
   PhD/D-9065-2016; Tecles, Fernando/Z-4602-2019; Tvarijonaviciute,
   Asta/U-4303-2017; Bernal, luis/AAA-1952-2019; Lopez, Manuel/Z-5641-2019;
   Ceron, Jose J/H-9043-2015
OI Martinez-Subiela, Sylvia/0000-0002-1524-1558; Tvarijonaviciute,
   Asta/0000-0002-5323-5001; Bernal, luis/0000-0002-3648-7012; Lopez,
   Manuel/0000-0003-0002-3678; Ceron, Jose J/0000-0002-8654-1793; Franco,
   Lorena/0000-0003-3375-4274; Thomas, M Carmen/0000-0003-3586-9657
FU "Ministerio de Economia y Competitividad", Spain; "Programa Estatal
   I+D+I" (MINECO) [RTC 2016 -50005-1]; Program for Research Groups of
   Excellence of the Seneca Foundation, Murcia, Spain [19894/GERM/15];
   European Commission ERA chair FP7 grant (VetMedZg) [621394]
FX LFM was granted with predoctoral contract 'FPU' of University of Murcia,
   Spain. AT has a post-doctoral fellowship "Juan de la Cierva
   Incorporacion" supported by the "Ministerio de Economia y
   Competitividad", Spain. MCT and MCL were supported by grants RTC 2016
   -50005-1 from the "Programa Estatal I+D+I" (MINECO). This work was
   supported by a grant from the Program for Research Groups of Excellence
   of the Seneca Foundation, Murcia, Spain (grant 19894/GERM/15) and
   European Commission ERA chair FP7 grant (VetMedZg #621394).
CR Baeumlisberger D, 2010, PROTEOMICS, V10, P3905, DOI 10.1002/pmic.201000288
   Bildik A, 2004, RES VET SCI, V77, P63, DOI 10.1016/j.rvsc.2004.01.005
   Bilic P, 2018, J PROTEOMICS, V179, P110, DOI 10.1016/j.jprot.2018.03.007
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Bosello S, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1134-7
   Brenten Thomas, 2016, Vet Rec Open, V3, pe000166, DOI 10.1136/vetreco-2015-000166
   Britti D, 2010, VET RES COMMUN, V34, pS91, DOI 10.1007/s11259-010-9410-5
   BURILLO FL, 1994, REV MED VET-TOULOUSE, V145, P171
   Cantos-Barreda A, 2017, VET PARASITOL, V242, P54, DOI 10.1016/j.vetpar.2017.05.017
   Chun RF, 2008, J ENDOCRINOL, V198, P261, DOI 10.1677/JOE-08-0170
   Corpas-Lopez V, 2016, VET PARASITOL, V223, P20, DOI 10.1016/j.vetpar.2016.04.001
   Dayon L, 2011, J PROTEOME RES, V10, P1043, DOI 10.1021/pr101123t
   De Santis M, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-22
   Delius J, 2017, COLLOID SURFACE B, V152, P68, DOI 10.1016/j.colsurfb.2017.01.005
   Contreras-Aguilar MD, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1191-4
   Escribano D, 2017, MICROB PATHOGENESIS, V113, P34, DOI 10.1016/j.micpath.2017.10.024
   Escribano D, 2016, COMP IMMUNOL MICROB, V49, P82, DOI 10.1016/j.cimid.2016.10.002
   Franco-Martinez L, 2018, COMP IMMUNOL MICROB, V60, P1, DOI 10.1016/j.cimid.2018.09.011
   Giron P, 2011, J PROTEOME RES, V10, P249, DOI 10.1021/pr100535f
   Gramiccia M, 2005, INT J PARASITOL, V35, P1169, DOI 10.1016/j.ijpara.2005.07.001
   Guillemin N, 2016, MOL BIOSYST, V12, P2036, DOI 10.1039/c6mb00220j
   Harper EJ, 2003, J AM VET MED ASSOC, V223, P1436, DOI 10.2460/javma.2003.223.1436
   Hernandez L, 2015, VET PARASITOL, V207, P149, DOI 10.1016/j.vetpar.2014.10.035
   Huang Y, 2014, NAT MED, V20, P193, DOI 10.1038/nm.3459
   Jaegger CF, 2017, MOL BIOSYST, V13, P1946, DOI 10.1039/c7mb00306d
   Kules J, 2016, RES VET SCI, V105, P222, DOI 10.1016/j.rvsc.2016.02.011
   Kules J, 2016, MOL BIOSYST, V12, P2680, DOI 10.1039/c6mb00268d
   Kules J, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-111
   Kumar V, 2017, MICROB PATHOGENESIS, V107, P164, DOI 10.1016/j.micpath.2017.03.024
   Li HJ, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-21
   Martinez-Subiela S, 2017, VET IMMUNOL IMMUNOP, V191, P60, DOI 10.1016/j.vetimm.2017.08.004
   Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468
   Mohapatra S, 2016, J ARTHROPOD-BORNE DI, V10, P87
   Nabity MB, 2011, VET CLIN PATH, V40, P222, DOI 10.1111/j.1939-165X.2011.00307.x
   Nilsson MT, 2009, J MOL BIOL, V393, P504, DOI 10.1016/j.jmb.2009.08.028
   Paranhos-Silva M, 2003, VET PARASITOL, V114, P97, DOI 10.1016/S0304-4017(03)00132-8
   Parra MD, 2005, J VET DIAGN INVEST, V17, P139, DOI 10.1177/104063870501700207
   RStudio Team, 2015, RSTUDIO INT DEV ENV
   Ruiz-Romero C, 2010, OSTEOARTHR CARTILAGE, V18, P500, DOI 10.1016/j.joca.2009.11.012
   Saunders EC, 2010, PARASITOLOGY, V137, P1303, DOI 10.1017/S0031182010000077
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Silvestrini P, 2014, J SMALL ANIM PRACT, V55, P95, DOI 10.1111/jsap.12172
   Solano-Gallego L, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-86
   Solter P. F, 1991, AM J VET RES, DOI [10.1016/S0168-1699(99)00043-5, DOI 10.1016/S0168-1699(99)00043-5]
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Taslimi Y, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005750
   Torres SMF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191307
   Vaish M, 2012, AM J TROP MED HYG, V86, P598, DOI 10.4269/ajtmh.2012.11-0127
   Vermelho AB, 2017, BIOORGAN MED CHEM, V25, P1543, DOI 10.1016/j.bmc.2017.01.034
   Wang XY, 2018, WORLD J GASTROENTERO, V24, P1881, DOI 10.3748/wjg.v24.i17.1881
   Westermeier R., 2008, PROTEOMICS PRACTICE
   Yoshizawa JM, 2013, CLIN MICROBIOL REV, V26, P781, DOI 10.1128/CMR.00021-13
NR 52
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 44
EP 52
DI 10.1016/j.vetpar.2019.06.014
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800007
PM 31395204
DA 2020-05-12
ER

PT J
AU Napravnikova, J
   Petrtyl, M
   Stupka, R
   Vadlejch, J
AF Napravnikova, J.
   Petrtyl, M.
   Stupka, R.
   Vadlejch, J.
TI Reliability of three common fecal egg counting techniques for detecting
   strongylid and ascarid infections in horses
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE McMaster; Mini-FLOTAC; Strongylid; Ascarid; Reliability
ID PARASCARIS-EQUORUM INFECTION; MINI-FLOTAC; ANTHELMINTIC RESISTANCE;
   PRECISION; ACCURACY; MCMASTER; DIAGNOSIS; PARASITES
AB The detection and quantification of nematode eggs using fecal egg count techniques have an irreplaceable role in equine parasitic control. The reliability, particularly precision and accuracy, of individual techniques have been described only for strongylid infections. The aim of this study was to compare three fecal egg count techniques used for the detection of the two most common equine nematode infections: strongylid and ascarid. The Simple McMaster, Concentration McMaster and Mini-FLOTAC techniques were tested on spiked fecal samples with various levels of egg concentration (50, 100, 200, 500, 1000 and 3000 eggs per gram) and naturally infected mixed strongylid-ascarid samples with 30 replicates. The Simple McMaster, Concentration McMaster and Mini-FLOTAC techniques had precision coefficients of variation of 44.33, 35.64 and 18.25% for the strongylid infection and 62.95, 35.71 and 18.95% for the ascarid infection, and percent accuracies (mean count/number of eggs spiked) of 97.53, 88.39 and 74.18% for the strongylid infection and 65.53, 83.18 and 90.28% for the ascarid infection, respectively. Accuracy depended greatly on the type of nematode, but precision did not. The Mini-FLOTAC technique was more precise than the Simple and Concentration McMaster techniques regardless of nematode type. Simple McMaster was the most accurate technique for detecting strongylid eggs, and Mini-FLOTAC was the most accurate technique for detecting ascarid eggs. Our results indicated that none of the current techniques were universally and sufficiently reliable for the simultaneous quantification of both of these common equine nematodes.
C1 [Napravnikova, J.; Petrtyl, M.; Vadlejch, J.] Czech Univ Life Sci Prague, Fac Agrobiol Food & Nat Resources, Dept Zool & Fisheries, Kamycka 129, Prague 16500, Suchdol, Czech Republic.
   [Stupka, R.] Czech Univ Life Sci Prague, Fac Agrobiol Food & Nat Resources, Dept Anim Sci, Kamycka 129, Prague 16500, Suchdol, Czech Republic.
RP Vadlejch, J (reprint author), Czech Univ Life Sci Prague, Fac Agrobiol Food & Nat Resources, Dept Zool & Fisheries, Kamycka 129, Prague 16500, Suchdol, Czech Republic.
EM vadlejch@af.czu.cz
RI Petrtyl, Miloslav/AAB-9648-2020; Vadlejch, Jaroslav/M-1189-2018
OI Petrtyl, Miloslav/0000-0003-0697-0772; Vadlejch,
   Jaroslav/0000-0002-5958-7606
CR Barda BD, 2013, PLOS NEGLECT TROP D, V7, P8
   Bosco A, 2018, BMC VET RES, V14, DOI 10.1186/s12917-017-1326-7
   CLAYTON HM, 1979, RES VET SCI, V26, P383, DOI 10.1016/S0034-5288(18)32899-6
   Coles GC, 2006, VET PARASITOL, V136, P167, DOI 10.1016/j.vetpar.2005.11.019
   Cringoli G, 2004, VET PARASITOL, V123, P121, DOI 10.1016/j.vetpar.2004.05.021
   Cringoli G, 2017, NAT PROTOC, V12, P1723, DOI 10.1038/nprot.2017.067
   Cringoli G, 2010, NAT PROTOC, V5, P503, DOI 10.1038/nprot.2009.235
   Dias de Castro Luciana L, 2017, Vet Parasitol Reg Stud Reports, V10, P132, DOI 10.1016/j.vprsr.2017.10.003
   EGWANG TG, 1982, CAN J COMP MED, V46, P133
   Ghazali K. H., 2013, Modern Applied Science, V7, P98
   Godber OF, 2015, VET PARASITOL, V207, P342, DOI 10.1016/j.vetpar.2014.12.029
   Gordon H. McL., 1939, Journal of the Council for Scientific and Industrial Research Australia, V12, P50
   Love S, 1999, VET PARASITOL, V85, P113, DOI 10.1016/S0304-4017(99)00092-8
   Matthews JB, 2014, INT J PARASITOL-DRUG, V4, P310, DOI 10.1016/j.ijpddr.2014.10.003
   Mes THM, 2007, NAT PROTOC, V2, P486, DOI 10.1038/nprot.2007.56
   Nielsen M., 2016, AAEP PARASITE CONTRO
   Nielsen MK, 2016, EQUINE VET EDUC, V28, P224, DOI 10.1111/eve.12536
   Noel ML, 2017, J EQUINE VET SCI, V48, P182, DOI 10.1016/j.jevs.2016.09.006
   Paras KL, 2018, VET PARASITOL, V257, P21, DOI 10.1016/j.vetpar.2018.05.015
   ROEPSTORFF A, 1998, EPIDEMIOLOGY DIAGNOS
   Scare JA, 2017, VET PARASITOL, V247, P85, DOI 10.1016/j.vetpar.2017.10.005
   Slusarewicz P, 2016, INT J PARASITOL, V46, P485, DOI 10.1016/j.ijpara.2016.02.004
   *STATSOFT INC, 2001, STAT DAT AN SOFTW SY
   STOLL NORMAN R., 1930, PARASITOLOGY, V22, P116
   Tatz AJ, 2012, EQUINE VET J, V44, P111, DOI 10.1111/j.2042-3306.2012.00607.x
   Team R., 2014, R LANG ENV STAT COMP
   Vidyashankar AN, 2012, VET PARASITOL, V185, P45, DOI 10.1016/j.vetpar.2011.10.011
   Went HA, 2018, VET PARASITOL, V261, P91, DOI 10.1016/j.vetpar.2018.09.001
   Wickham H, 2016, J STAT SOFTW
   Zajac AM, 2002, J AM ANIM HOSP ASSOC, V38, P221, DOI 10.5326/0380221
NR 30
TC 0
Z9 0
U1 7
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 53
EP 57
DI 10.1016/j.vetpar.2019.07.001
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800008
PM 31395205
DA 2020-05-12
ER

PT J
AU Liu, YC
   Yang, YD
   Xu, J
   Dong, XW
   Gu, XB
   Xie, Y
   Lai, WM
   Jing, B
   Peng, XR
   Yang, GY
AF Liu, Yuchen
   Yang, Yingdong
   Xu, Jing
   Dong, Xiaowei
   Gu, Xiaobin
   Xie, Yue
   Lai, Weimin
   Jing, Bo
   Peng, Xuerong
   Yang, Guangyou
TI Expression and serodiagnostic potential of antigen B and thioredoxin
   peroxidase from Taenia multiceps
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Taenia multiceps; Coenurus cerebralis; Metacestode; Indirect ELISA;
   Antigen B; Thioredoxin peroxidase
ID LIGAND-BINDING PROTEIN; ANNEXIN
AB Coenurosis is a serious parasitic disease of herbivorous animals caused by the metacestode of Taenia multiceps (Coenurus cerebralis). Accordingly, a significant amount of research is currently dedicated to the development of appropriate antigens for use in rapid and accurate coenurosis diagnosis kits. In the present study, antigen B (AgB) and thioredoxin peroxidase (TPx) from T. multiceps were cloned and expressed using a prokaryotic system, molecular characterization of Tm-AgB was determined by bioinformatical analyses. The serological diagnostic potentials of rTm-AgB and rTm-TPx were evaluated by indirect ELISA and compared with those of previously reported rTm-AnxB2, rTm-HSP70, and rTm-GST. The results showed that Tm-AgB is a specific lipoprotein of cestodes with good thermal stability. The ELISA assay showed that rTm-AgB exhibited a sensitivity of 95.8% and a specificity of 87.5%, indicating its strong potential for serological diagnosis of T. multiceps.
C1 [Liu, Yuchen; Xu, Jing; Dong, Xiaowei; Gu, Xiaobin; Xie, Yue; Lai, Weimin; Jing, Bo; Yang, Guangyou] Sichuan Agr Univ, Coll Vet Med, Dept Parasitol, Wenjiang 611130, Peoples R China.
   [Yang, Yingdong] Panzhihua Acad Agr & Forestry Sci, Panzhihua 617000, Peoples R China.
   [Peng, Xuerong] Sichuan Agr Univ, Coll Life & Basic Sci, Dept Chem, Wenjiang 611130, Peoples R China.
RP Yang, GY (reprint author), Sichuan Agr Univ, Coll Vet Med, Dept Parasitol, Wenjiang 611130, Peoples R China.
EM liuyuchen1229@163.com; pzhyydong@163.com; xujing90@hotmail.com;
   dongxiaowei1226@outlook.com; guxiaobin198225@126.com;
   zhandegaokandey123@163.com; nwm_mm2004@163.com; jingbo@sicau.edu.cn;
   pxuerong@aliyun.com; guangyou1963@aliyun.com
FU Key Technology R&D Program of Sichuan Province, China [2015NZ0041]
FX This work was supported by a grant from the Key Technology R&D Program
   of Sichuan Province, China (no. 2015NZ0041; http://www.scst.gov.cn/).The
   funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Arend AC, 2004, EXP PARASITOL, V108, P76, DOI 10.1016/j.exppara.2004.07.009
   Asghari M, 2013, IRAN J PUBLIC HEALTH, V42, P391
   Chander A, 2007, BBA-MOL CELL BIOL L, V1771, P1308, DOI 10.1016/j.bbalip.2007.07.004
   Crowther JR, 2000, METHOD MOL BIOL, V149, P1
   Dehghani M, 2016, PARASITOL RES, V115, P2715, DOI 10.1007/s00436-016-5018-1
   Eung-Goo L., 2010, PROTEOMICS, V7, P4016
   Gao YJ, 2007, ACTA TROP, V101, P192, DOI 10.1016/j.actatropica.2006.10.014
   Ghosh I, 1998, MOL BIOCHEM PARASIT, V91, P207, DOI 10.1016/S0166-6851(97)00213-2
   Guo C, 2018, GENES-BASEL, V9, DOI 10.3390/genes9110559
   Guo C, 2017, PARASITOL RES, V116, P2845, DOI 10.1007/s00436-017-5568-x
   Henkle-Duhrsen K, 2001, MOL BIOCHEM PARASIT, V114, P129, DOI 10.1016/S0166-6851(01)00252-3
   HERMOS JA, 1970, J AMER MED ASSOC, V213, P1461
   Huang X, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3704-8
   Huang X, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1915-5
   Huang X, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1220-8
   Kamenetzky L, 2005, PARASITOLOGY, V131, P805, DOI 10.1017/S0031182005008474
   Kwatia MA, 2000, J PARASITOL, V86, P908, DOI 10.1645/0022-3395(2000)086[0908:MAECOS]2.0.CO;2
   Li J, 2004, GENE, V326, P157, DOI 10.1016/j.gene.2003.10.027
   Li WH, 2018, DNA RES, V25, P499, DOI 10.1093/dnares/dsy020
   Li Yong-guang, 2009, Zhongguo Shouyi Kexue, V39, P251
   Liu YC, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3352-8
   Mamuti W, 2006, EXP PARASITOL, V113, P75, DOI 10.1016/j.exppara.2005.12.007
   Monteiro KM, 2007, BBA-PROTEINS PROTEOM, V1774, P278, DOI 10.1016/j.bbapap.2006.11.006
   Mortimer JC, 2008, J EXP BOT, V59, P533, DOI 10.1093/jxb/erm344
   Obal G, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001642
   Olson PD, 2012, PARASITE IMMUNOL, V34, P130, DOI 10.1111/j.1365-3024.2011.01319.x
   Oryan A, 2015, SMALL RUMINANT RES, V132, P44, DOI 10.1016/j.smallrumres.2015.10.008
   PAU A, 1990, British Journal of Neurosurgery, V4, P39, DOI 10.3109/02688699009000680
   PAU A, 1987, SURG NEUROL, V27, P548, DOI 10.1016/0090-3019(87)90153-4
   Rescher U, 2004, J CELL SCI, V117, P2631, DOI 10.1242/jcs.01245
   Saghir N, 2000, FEBS LETT, V487, P181, DOI 10.1016/S0014-5793(00)02191-8
   SANCHEZ F, 1991, PARASITE IMMUNOL, V13, P583, DOI 10.1111/j.1365-3024.1991.tb00554.x
   Silva-Alvarez V, 2015, PROSTAG LEUKOTR ESS, V93, P17, DOI 10.1016/j.plefa.2014.09.008
   Solano S, 2006, VET PARASITOL, V140, P171, DOI 10.1016/j.vetpar.2006.03.006
   Song XJ, 2016, AM J TROP MED HYG, V94, P626, DOI 10.4269/ajtmh.15-0452
   Sun Y, 2017, VET PARASITOL, V242, P31, DOI 10.1016/j.vetpar.2017.05.013
   Wang N, 2018, VET PARASITOL, V251, P7, DOI 10.1016/j.vetpar.2017.12.017
   Wang Y, 2015, VET PARASITOL, V212, P469, DOI 10.1016/j.vetpar.2015.06.020
   Williams DL, 2001, INFECT IMMUN, V69, P1134, DOI 10.1128/IAI.69.2.1134-1141.2001
   Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8
   Wu XS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031249
   Wu XH, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-162
   Zhang RH, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-336
   Zhang WB, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000784
NR 44
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 58
EP 63
DI 10.1016/j.vetpar.2019.07.002
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800009
PM 31395206
DA 2020-05-12
ER

PT J
AU Horn, TB
   Granich, J
   da Silva, VL
   Ferla, NJ
AF Horn, Tamara Bianca
   Granich, Juliana
   da Silva, Vinicius Leao
   Ferla, Noeli Juarez
TI Population fluctuation of predatory and sanitary importance mites
   (Acari) in commercial laying hens: Ecological interactions
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Megninia ginglymura; Tuccioglyphus setosus; Cheyletus malaccensis;
   Biodiversity
ID POULTRY RED MITE; DERMANYSSUS-GALLINAE; CHEYLETIDAE; SYSTEMS
AB This study aimed to evaluate the mite fauna and their ecological interactions in commercial laying hen farms in the state of Rio Grande do Sul, Brazil. It was conducted from August 2013 through August 2014 with two sampling strategies (feathers and traps) in three different production systems: automated (A(1,2,3)), semi-automated (S-1,S-2) and free-range (FR). A total of 38,383 mites were collected belonging to 23 families and 33 species, most of which were collected in feathers (74%) followed by traps (26%). There was higher abundance at S1 (10,774-28.1%) and S-2 (11,023-28.7%) followed by FR (6972-18.2%), A(1) (1896-4.9%), A(2) (4775-12.4%), and A(3) (2943-7.7%). Higher richness was observed at S-1 (23 species), S-2 (18 species), and FR (19 species). Megninia ginglymura (Megnin) (Analgidae) was the species with the highest health importance, eudominant on feathers, and its populations seems to be related with increased temperature. Tuccioglyphus setosus Horn et al. (Pyroglyphidae) seems to be influenced by relative air humidity and temperature. Predators with the highest populations were Cheyletus malaccensis (Oudemans) (Cheyletidae), Typhlodromus transvaalensis (Nesbitt) (Phytoseiidae), Blattisocius keegani (Fox), and Blattisocius dentriticus (Berlese) (Blattisocidae).
C1 [Horn, Tamara Bianca; Granich, Juliana; da Silva, Vinicius Leao; Ferla, Noeli Juarez] Univ Vale Taquari, UNIVATES, Lab Acarol, Tecnovates, BR-95900000 Lajeado, RS, Brazil.
   [Ferla, Noeli Juarez] CNPq, Brasilia, DF, Brazil.
RP Horn, TB (reprint author), Univ Vale Taquari, UNIVATES, Lab Acarol, Tecnovates, BR-95900000 Lajeado, RS, Brazil.
EM tamarahorn83@hotmail.com
RI Ferla, Noeli Juarez NJ/G-3820-2012
OI silva, vinicius/0000-0001-9246-415X
FU Granja Cageri; TECNOVATES; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq); Secretaria da Ciencia, Inovacao e
   Desenvolvimento Tecnologico of Rio Grande do Sul State (SLIT);
   CAPESCAPES [1805977];  [310035/2017-1]
FX We thank Granja Cageri, TECNOVATES, Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) and Secretaria da Ciencia, Inovacao e
   Desenvolvimento Tecnologico of Rio Grande do Sul State (SLIT) for their
   financial support. We also grateful Dra. Edna Clara Tucci (Laboratorio
   de Parasitologia do Instituto Biologico), Dra. Nilce Maria Soares
   (Unidade de Pesquisa e Desenvolvimento de Bastos Instituto Biologico)
   for their contributions on methodology and the anonymous reviewers for
   their constructive comments. N.J. Feria is supported by productivity
   scholarship (310035/2017-1) and V. L. Silva (Postdoctoral scholarship
   CAPES no. 1805977).
CR ALSHAMMERY KA, 2014, [No title captured], V11, P260
   ARLIAN LG, 1991, EXP APPL ACAROL, V10, P167, DOI 10.1007/BF01198649
   AXTELL RC, 1986, POULTRY SCI, V65, P657, DOI 10.3382/ps.0650657
   BERGER WH, 1970, SCIENCE, V168, P1345, DOI 10.1126/science.168.3937.1345
   Bodenheimer FS, 1955, PRECIS ECOLOGIE ANIM
   BROWER J. E., 1984, FIELD LAB METHODS GE
   Cebolla R, 2009, BIOL CONTROL, V50, P1, DOI 10.1016/j.biocontrol.2009.03.008
   Clarke K. R., 2002, PRIMER 5 2 9 USER MA
   da Silva GL, 2016, INT J ACAROL, V42, P405, DOI 10.1080/01647954.2016.1210674
   da Silva Guilherme Liberato, 2013, Biotemas, V26, P253
   Fain A., 1990, P11
   Faleiro DCC, 2015, SYST APPL ACAROL-UK, V20, P861, DOI 10.11158/saa.20.8.3
   Fenilli R., 1990, Anais da Escola Superior de Agricultura 'Luiz de Queiroz', V47, P243
   Friebe B., 1983, Carolinea, V41, P45
   Granich J, 2016, SYST APPL ACAROL-UK, V21, P1604, DOI 10.11158/saa.21.12.2
   Guimaraes J. H., 2009, DOENCAS DAS AVES, P867
   HERNANDEZ M, 2006, REV CUB CIENC AVIC, V30, P49
   HERNANDEZ M, 2007, REV CUB CIENC AVIC, V31, P127
   Horn TB, 2017, ZOOTAXA, V4244, P301, DOI 10.11646/zootaxa.4244.3.1
   Horn TB, 2016, PARASITOL RES, V115, P355, DOI 10.1007/s00436-015-4756-9
   Lesna I, 2009, EXP APPL ACAROL, V48, P63, DOI 10.1007/s10493-009-9239-1
   Lloyd CM, 2009, NAT MED, V15, P366, DOI 10.1038/nm0409-366
   Magurran EA, 1988, ECOLOGICAL DIVERSITY
   Marangi M, 2009, EXP APPL ACAROL, V48, P11, DOI 10.1007/s10493-008-9224-0
   MAURER V, 2001, DGS MAGAZIN STUTTGAR, V40, P49
   Nero LA, 2007, CIENCIA TECNOL ALIME, V27, P201, DOI 10.1590/S0101-20612007000100035
   Palyvos NE, 2011, EXP APPL ACAROL, V54, P139, DOI 10.1007/s10493-011-9427-7
   Palyvos N, 2009, EXP APPL ACAROL, V47, P147, DOI 10.1007/s10493-008-9200-8
   PULPAN J, 1965, CAN J ZOOLOG, V43, P417, DOI 10.1139/z65-042
   Quintero MT, 2010, TRENDS IN ACAROLOGY, P537, DOI 10.1007/978-90-481-9837-5_92
   REIS J., 1939, ARQ INST BIOL [SAO PAULO], V10, P147
   Rezende LD, 2015, REV BRAS PARASITOL V, V24, P198, DOI 10.1590/S1984-29612015027
   Rezende LD, 2013, CIENC RURAL, V43, P1230
   Rodrigues WC, 2005, DIVES DIVERSIDADE ES
   SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x
   Sparagano O, 2009, EXP APPL ACAROL, V48, P1, DOI 10.1007/s10493-009-9259-x
   Thomas HQ, 2011, B ENTOMOL RES, V101, P499, DOI 10.1017/S0007485310000404
   TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0
   Tucci E. C., 2005, Arquivos do Instituto Biologico (Sao Paulo), V72, P121
   TUCCI EC, 1988, ARQ I BIOL-SAO PAULO, V56, P114
   Walter D.E., 2009, MANUAL ACAROLOGY, P83
   Wright HW, 2009, EXP APPL ACAROL, V48, P81, DOI 10.1007/s10493-009-9243-5
NR 42
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 64
EP 74
DI 10.1016/j.vetpar.2019.06.002
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800010
PM 31395207
DA 2020-05-12
ER

PT J
AU Ek-Huchim, JP
   Jimenez-Garcia, I
   Rodriguez-Canul, R
AF Pablo Ek-Huchim, Juan
   Jimenez-Garcia, Isabel
   Rodriguez-Canul, Rossanna
TI DNA detection of Gyrodactylus spp. in skin mucus of Nile tilapia
   Oreochromis niloticus
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Non-destructive diagnosis; PCR test; Gyrodactylus spp.; Nile tilapia
   mucus
ID PLATYHELMINTHES MONOGENEA; CICHLIDARUM
AB Monogeneans Gyrodactylus von Nordmann 1832, cause outbreaks of gyrodactylosis in aquaculture settings worldwide. Detection of Gyrodactylus spp. is based on the morphological identification of isolated parasites after fish necropsy. Contributing to the diagnosis of gyrodactylosis, in this study, a non-destructive PCR assay was standardized; the PCR was first performed using genomic DNA of Gyrodactylus spp. isolated from the surface of the Nile tilapia Oreochromis niloticus (Linnaeus 1758), and subsequently tested with mucus samples of infected and uninfected Nile tilapia fish. The primers (Ekgyrol) were designed from the ribosomal Internal Transcriber Spacer (ITS) RNA region (ITS1, 5.8S and ITS2 rRNA gene) of Gyrodactylus cichlidarum Paperna 1968. The positive control group included the DNA of 30 monogeneans Gyrodactylus spp. The heterologous control group included 75 monogeneans Cichlidogyrus Paperna 1960, 75 protozoans Ichthyophthirius multifiliis Fouquet 1876 and 75 Trichodina Ehrenberg 1830. PCR products of each parasite and from the external mucus samples (described as P and M respectively), were sequenced. The average DNA concentration of the ectoparasites was of 13.5 ng/mu l. The PCR test had an analytical sensitivity of 0.0039 ng mu l-1 of DNA of Gyrodactylus spp. No cross reactions were observed with the heterologous group. The sensitivity and specificity of the PCR test were of 100% either with genomic DNA or with DNA from mucus samples. Six DNA consensus sequences with sizes ranging from 568 bp to 571 bp were obtained and the BLAST analysis matched with DNA sequences of G. cichlidarum.
C1 [Pablo Ek-Huchim, Juan; Rodriguez-Canul, Rossanna] Inst Politecn Nacl, Unidad Merida, Lab Inmunol & Biol Mol, Ctr Invest & Estudios Avanzados,CORDEMEX, Km 6 Antigua,Carretera Progreso, Merida 97310, Yucatan, Mexico.
   [Jimenez-Garcia, Isabel] Inst Tecnol Boca del Rio, Carretera Veracruz Cordoba Km 12, Boca Del Rio 94290, Veracruz, Mexico.
RP Rodriguez-Canul, R (reprint author), Inst Politecn Nacl, Unidad Merida, Lab Inmunol & Biol Mol, Ctr Invest & Estudios Avanzados,CORDEMEX, Km 6 Antigua,Carretera Progreso, Merida 97310, Yucatan, Mexico.
EM jpabloekhu06@gmail.com; isajim09@yahoo.com.mx;
   rossanna.rodriguez@cinvestav.mx
RI del Pilar Rodriguez-Canul, Rossanna/AAH-1895-2020
OI del Pilar Rodriguez-Canul, Rossanna/0000-0003-0469-1489
FU laboratory of Immunology and Molecular Biology at CINVESTAV-IPN Unidad
   Merida [3769]; Project SEP-DGEST "Parasitosis y su efecto en el
   desemperio productivo del cultivo de crias de tilapia"
   [PROMEP/103.5/09/4061]; ConacytConsejo Nacional de Ciencia y Tecnologia
   (CONACyT) [216404]
FX Special thanks to Conacyt (Reference 216404). This project was funded by
   own resources of the laboratory of Immunology and Molecular Biology at
   CINVESTAV-IPN Unidad Merida (Reference 3769) (granted to RRC). And the
   Project SEP-DGEST "Parasitosis y su efecto en el desemperio productivo
   del cultivo de crias de tilapia" (PROMEP/103.5/09/4061) (granted to
   IJG). We truly appreciate the comments of the Anonymous reviewers.
CR Bakke TA, 2007, ADV PARASIT, V64, P161, DOI 10.1016/S0065-308X(06)64003-7
   Clerc M, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.2820
   Coleman W. B, 2017, DIAGNOSTIC MOL PATHO
   Cone DK, 2013, J PARASITOL, V99, P183, DOI 10.1645/GE-3224.1
   Davey JW, 2011, NAT REV GENET, V12, P499, DOI 10.1038/nrg3012
   Fajer-Avila E. J, 2017, ACTA AGRICOLA PECUAR, V3, P25
   Garcia-Vasquez A, 2007, FOLIA PARASIT, V54, P129, DOI 10.14411/fp.2007.018
   Garcia-Vasquez A, 2017, VET PARASITOL, V235, P37, DOI 10.1016/j.vetpar.2017.01.014
   Grano-Maldonado M, 2018, FISHES, V3, P20
   Martins ML, 2010, AN ACAD BRAS CIENC, V82, P493, DOI 10.1590/S0001-37652010000200024
   Ek-Huchim JP, 2012, DIS AQUAT ORGAN, V98, P155, DOI 10.3354/dao02435
   Parikh R, 2008, INDIAN J OPHTHALMOL, V56, P45, DOI 10.4103/0301-4738.37595
   Perez-Jvostov F, 2015, INT J PARASITOL, V45, P409, DOI 10.1016/j.ijpara.2015.01.010
   Priyanka B, 2016, INDIAN J MED RES, V144, P327, DOI 10.4103/0971-5916.198677
   Santoro M, 2013, DIS AQUAT ORGAN, V105, P139, DOI 10.3354/dao02626
   Shokere LA, 2009, FOOD CONTROL, V20, P391, DOI 10.1016/j.foodcont.2008.07.009
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   Vanhove MPM, 2011, PARASITOLOGY, V138, P364, DOI 10.1017/S0031182010001356
   Ye F, 2017, J FISH DIS, V40, P541, DOI 10.1111/jfd.12539
   Zahradnickova P, 2016, SYST PARASITOL, V93, P679, DOI 10.1007/s11230-016-9652-x
NR 21
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 75
EP 78
DI 10.1016/j.vetpar.2019.07.004
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800011
PM 31395208
DA 2020-05-12
ER

PT J
AU Sturgess-Osborne, C
   Burgess, S
   Mitchell, S
   Wall, R
AF Sturgess-Osborne, C.
   Burgess, S.
   Mitchell, S.
   Wall, R.
TI Multiple resistance to macrocyclic lactones in the sheep scab mite
   Psoroptes ovis
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Acariasis; Disease; Mange; Parasite
ID GREAT-BRITAIN; P-OVIS; PREVALENCE; BEHAVIOR; DISEASE; MANGE
AB The astigmatid mite Psoroptes ovis (Acari: Proroptidae) causes the highly contagious and debilitating ovine disease, sheep scab. This ectoparasitic infection has a high economic and animal welfare impact on British sheep farming. Following recent work demonstrating resistance of Psoroptes mites to moxidectin, a widely used macrocyclic lactone (ML) treatment for scab, the current study compared the toxicity of three of the commonly administered macrocylic lactone therapeutic treatments (moxidectin, ivermectin and doramectin) to P. ovis from outbreak populations that had appeared unresponsive to treatment. These outbreak populations were from Wales and south west England. The data presented demonstrate that there is resistance to all three available ML compounds in populations of Psoroptes mites. However, considerable variation in response suggested that resistance alone was not responsible for the reported lack of efficacy in all of the submitted cases; lack of response in others may be associated with inappropriate treatment application or management. These data highlight the importance of the appropriate use of these compounds to manage national scab incidence at levels that are consistent with acceptable animal welfare standards, while attempting to reduce the development and spread of resistance.
C1 [Sturgess-Osborne, C.; Wall, R.] Univ Bristol, Sch Biol Sci, 24 Tyndall Ave, Bristol BS8 1TQ, Avon, England.
   [Burgess, S.] Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland.
   [Mitchell, S.] APHA Carmarthen Vet Invest Ctr, Carmarthen SA31 3EZ, Dyfed, Wales.
RP Wall, R (reprint author), Univ Bristol, Sch Biol Sci, 24 Tyndall Ave, Bristol BS8 1TQ, Avon, England.
EM richard.wall@bristol.ac.uk
OI burgess, stewart/0000-0002-9268-7641
FU Zoetis Animal Health
FX The authors would like to thank Zoetis Animal Health for their financial
   support of CS-O.
CR Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a
   Babcock OG, 1933, TEX AES B, V479, P1
   Bates P., 1997, State Veterinary Journal, V7, P11
   Bates P, 2000, VET REC, V146, P528, DOI 10.1136/vr.146.18.528
   Bates P.G., 1998, P SHEEP VET SOC, V21, P117
   Berriatua E, 2001, APPL ANIM BEHAV SCI, V71, P43, DOI 10.1016/S0168-1591(00)00166-0
   Bisdorff B, 2006, VET REC, V158, P749, DOI 10.1136/vr.158.22.749
   Bisdorff B, 2008, VET PARASITOL, V155, P120, DOI 10.1016/j.vetpar.2008.04.002
   BRIMER L, 1995, VET PARASITOL, V59, P249, DOI 10.1016/0304-4017(94)00759-6
   BYGRAVE AC, 1993, VET REC, V132, P394, DOI 10.1136/vr.132.15.394
   Chivers CA, 2018, MED VET ENTOMOL, V32, P244, DOI 10.1111/mve.12290
   Coles GC, 1998, PARASITOL TODAY, V14, P86, DOI 10.1016/S0169-4758(97)01200-3
   Doherty E, 2018, VET REC, V182, DOI 10.1136/vr.104657
   French NP, 1999, VET PARASITOL, V83, P187, DOI 10.1016/S0304-4017(99)00057-6
   GEORGHIOU GP, 1977, J ECON ENTOMOL, V70, P319, DOI 10.1093/jee/70.3.319
   KIRKWOOD AC, 1980, VET REC, V107, P469, DOI 10.1136/vr.107.20.469
   Nieuwhof GJ, 2005, ANIM SCI, V81, P23, DOI 10.1079/ASC41010023
   Nixon EJ, 2017, PREV VET MED, V137, P43, DOI 10.1016/j.prevetmed.2016.12.015
   Rose H, 2009, VET PARASITOL, V165, P112, DOI 10.1016/j.vetpar.2009.06.037
   Rose H, 2012, PREV VET MED, V104, P101, DOI 10.1016/j.prevetmed.2011.10.010
   Sanders A, 2000, MED VET ENTOMOL, V14, P131, DOI 10.1046/j.1365-2915.2000.00223.x
   Scott PR, 2007, VET J, V173, P522, DOI 10.1016/j.tvjl.2006.02.007
   SYNGE BA, 1995, VET REC, V137, P51, DOI 10.1136/vr.137.2.51-b
   TARRY DW, 1974, VET REC, V95, P530, DOI 10.1136/vr.95.23.530
   van den Broek AH, 2003, J COMP PATHOL, V128, P79, DOI 10.1053/jcpa.2002.0627
   van den Broek AHM, 2003, VET IMMUNOL IMMUNOP, V91, P105, DOI 10.1016/S0165-2427(02)00292-1
   Wolstenholme AJ, 2012, CURR PHARM BIOTECHNO, V13, P873
NR 27
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 79
EP 82
DI 10.1016/j.vetpar.2019.07.007
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800012
PM 31395209
DA 2020-05-12
ER

PT J
AU Kang, Q
   Vahl, CI
   Fan, HH
   Geurden, T
   Ameis, KA
   Taylor, LP
AF Kang, Qing
   Vahl, Christopher, I
   Fan, Huihao
   Geurden, Thomas
   Ameis, Keith A.
   Taylor, Lucas P.
TI Statistical analyses of chicken intestinal lesion scores in battery cage
   studies of anti-coccidial drugs
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Battery cage study; Coccidiosis; Generalized linear mixed model; Lesion
   score
ID BROILER-CHICKENS; ANTICOCCIDIAL DRUGS; PERFORMANCE; RESPONSES;
   CHALLENGE; EFFICACY; TENELLA; MAXIMA; LEVEL
AB Establishing the efficacy of an anti-coccidial drug in poultry begins with conducting multiple battery cage studies, where the target animals are challenged with single and mixed Eimeria species inoculum under controlled laboratory conditions. One of the primary outcomes in a battery cage study is the intestinal lesion score defined on a discrete ordinal scale of 0 to 4. So far, the statistical analysis of lesion scores has routinely employed the linear mixed model (LMM). This present work proposes to apply the generalized linear mixed model (GLMM) with the cumulative logit link to statistically analyze coccidial lesion scores collected from battery cage studies. Upon applying this new approach on 9 datasets generated by challenging battery-cage-housed broilers with various mixtures of Eimeria species, it is observed that the GLMM fitted adequately to the data, produced variance component estimates that agreed with the experimental setup, and, at the 0.05 significance level, generated statistical results in complete concordance with the LMM approach. Advantages of the proposed GLMM over the LMM are discussed from several standpoints. Parallel to the regulatory requirement of a >= 1-unit reduction in the mean lesion score for clinical relevant efficacy under the LMM, the clinical relevancy criterion under the GLMM could be set as a >= 10-fold increase in the odds of having low lesion scores. That is, the effect of an anti-coccidial drug product would be deemed clinically relevant in battery-cage studies when the odds of having low lesion scores with the medication is 10 times or more than the odds without the medication.
C1 [Kang, Qing] Stat Intelligence Grp LLC, Manhattan, KS 66503 USA.
   [Vahl, Christopher, I] Kansas State Univ, Dept Stat, 101 Dickens Hall, Manhattan, KS 66506 USA.
   [Fan, Huihao; Ameis, Keith A.; Taylor, Lucas P.] Zoetis, Vet Med Res & Dev, Kalamazoo, MI 49007 USA.
   [Geurden, Thomas] Zoetis, Vet Med Res & Dev, Mercuriusstr 20, B-1930 Zaventem, Belgium.
RP Vahl, CI (reprint author), Kansas State Univ, Dept Stat, 101 Dickens Hall, Manhattan, KS 66506 USA.
EM kangqing@hotmail.com; vahl@ksu.edu; huihao.fan@zoetis.com;
   thomas.geurden@zoetis.com; keith.ameiss@Zoetis.com;
   lucas.p.taylor@zoetis.com
FU Zoetis Inc.
FX This research was supported by Zoetis Inc.
CR Abad AA, 2010, BIOSTATISTICS, V11, P771, DOI 10.1093/biostatistics/kxq019
   Abdelrahman W, 2014, POULTRY SCI, V93, P3002, DOI 10.3382/ps.2014-04212
   Agresti A., 2002, CATEGORICAL DATA ANA
   Amerah AM, 2015, POULTRY SCI, V94, P673, DOI 10.3382/ps/pev022
   Bafundo KW, 2008, POULTRY SCI, V87, P1760, DOI 10.3382/ps.2008-00129
   Bell J. F., 2000, MULTILEVEL MODELLING, V12, P4
   Casterlow S, 2011, POULTRY SCI, V90, P1212, DOI 10.3382/ps.2010-01110
   Conway D. P, 1986, P GEORG COCC C NOV 1, P239
   CONWAY DP, 1993, AVIAN DIS, V37, P118, DOI 10.2307/1591464
   Cox CM, 2010, POULTRY SCI, V89, P2597, DOI 10.3382/ps.2010-00987
   da Costa MJ, 2017, POULTRY SCI, V96, P1615, DOI 10.3382/ps/pew475
   Dalloul RA, 2006, EXPERT REV VACCINES, V5, P143, DOI 10.1586/14760584.5.1.143
   Elmusharaf MA, 2007, POULTRY SCI, V86, P2139, DOI 10.1093/ps/86.10.2139
   Faes C, 2009, AM STAT, V63, P389, DOI 10.1198/tast.2009.08196
   FDA-CVM, 1999, NADA 140 951 OR APPR
   FDA-CVM, 1994, NADA 140 940 OR APPR
   FDA-CVM, 2012, GUID IND EV EFF ANT
   FDA-CVM, 2007, NADA 141 281 OR APPR
   FDA-CVM, 1989, NADA 138 952 OR APPR
   Federation of Animal Science Societies, 1999, GUID CAR US AGR AN R
   Holdsworth PA, 2004, VET PARASITOL, V121, P189, DOI 10.1016/j.vetpar.2004.03.006
   JOHNSON J, 1970, EXP PARASITOL, V28, P30, DOI 10.1016/0014-4894(70)90063-9
   Jordan A, 2011, POULTRY SCI, V90, P990, DOI 10.3382/ps.2010-01228
   Kenward MG, 1997, BIOMETRICS, V53, P983, DOI 10.2307/2533558
   Kenward MG, 2009, COMPUT STAT DATA AN, V53, P2583, DOI 10.1016/j.csda.2008.12.013
   Lan L, 2016, POULTRY SCI, V95, P811, DOI 10.3382/ps/pev441
   Lee JT, 2011, POULTRY SCI, V90, P1916, DOI 10.3382/ps.2011-01362
   Lensing M, 2012, POULTRY SCI, V91, P1590, DOI 10.3382/ps.2011-01508
   Li P, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0026-x
   McDougald L.R., 2008, DIS POULTRY, P1068
   Milliken G. A., 1992, ANAL MESSY DATA, V1
   O'Connell AA, 2008, QUANT METH EDUC BEHA, P199
   Pan ZY, 2005, BIOMETRICS, V61, P1000, DOI 10.1111/j.1541-0420.2005.00365.x
   Parker J, 2007, POULTRY SCI, V86, P643, DOI 10.1093/ps/86.4.643
   Ritzi MM, 2014, POULTRY SCI, V93, P2772, DOI 10.3382/ps.2014-04207
   SAS Institute Inc, 2011, SAS STAT 9 3 US GUID
   Siev D, 2005, J MOD APPL STAT METH, V4, P500
   Stroup W. W, 2013, P 25 ANN C APP STAT, P103
   Wang ML, 2008, POULTRY SCI, V87, P2273, DOI 10.3382/ps.2008-00077
   Williams RB, 1999, INT J PARASITOL, V29, P1209, DOI 10.1016/S0020-7519(99)00086-7
NR 40
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD AUG
PY 2019
VL 272
BP 83
EP 94
DI 10.1016/j.vetpar.2018.12.002
PG 12
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA IT0AT
UT WOS:000482509800013
PM 30579754
DA 2020-05-12
ER

PT J
AU Jochmans, D
   Neyts, J
AF Jochmans, Dirk
   Neyts, Johan
TI The path towards effective antivirals against rabies
SO VACCINE
LA English
DT Article
DE Rabies; Antivirals
ID FAVIPIRAVIR T-705; RNA
AB Rabies virus remains an important burden of disease claiming an estimated 60,000 lives each year, mainly children, and having a huge economical and societal cost. Post-exposure prophylaxis (PEP) is highly effective, however in patients that present with neurological symptoms the case-fatality ratio is extremely high (>99%). During the last decades several attempts to identify potent and effective antivirals were made. Only a few of these demonstrated improvement in clinical signs in animal studies and none of the trials in humans showed significant efficacy. Here we explore novel opportunities to identify more potent anti-rabies molecules. In particular important progress has been made on antivirals against other Mononegavirales (paramyxoviruses, filoviruses) which should be an impetus to test and optimize these molecules towards anti-rabies virus therapies. Effective rabies antivirals for therapeutic use need to be molecules that can be dosed into the cerebrospinal fluid and that rapidly and potently block ongoing virus replication and as such stop the further spread of the virus. Antivirals for prophylactic use can also be envisaged and these should be able to prevent infection of peripheral nerve cells and should have the potential to replace the current anti-rabies immunoglobulins that are used in PEP. (C) 2017 The Authors. Published by Elsevier Ltd.
C1 [Jochmans, Dirk; Neyts, Johan] Univ Leuven, Rega Inst Med Res, KU Leuven, Leuven, Belgium.
RP Jochmans, D (reprint author), Univ Leuven, Rega Inst Med Res, KU Leuven, Leuven, Belgium.
EM dirk.jochmans@kuleuven.be
RI NEYTS, Johan/U-8267-2017; JOCHMANS, DIRK/T-6223-2017
OI NEYTS, Johan/0000-0002-0033-7514; JOCHMANS, DIRK/0000-0002-9265-6028
FU European Union Seventh Framework Program under the ASKLEPIOS grant
   agreement [602825]
FX This work was supported by the European Union Seventh Framework Program
   under the ASKLEPIOS grant agreement (Grant No. 602825). The funders had
   no role in study design, data collection and interpretation, or the
   decision to submit the work for publication.
CR Appolinario CM, 2015, ANTIVIR THER, V20, P1, DOI 10.3851/IMP2851
   Baranovich T, 2013, J VIROL, V87, P3741, DOI 10.1128/JVI.02346-12
   Castel G, 2009, J VIROL, V83, P10808, DOI 10.1128/JVI.00977-09
   Clarke MO, 2015, BIOORG MED CHEM LETT, V25, P2484, DOI 10.1016/j.bmcl.2015.04.073
   de Souza A, 2014, J NEUROL SCI, V339, P8, DOI 10.1016/j.jns.2014.02.013
   Deval J, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004995
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Siegel D, 2017, J MED CHEM
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
   Wilde H, 2015, PEDIATR INFECT DIS J, V34, P678, DOI 10.1097/INF.0000000000000641
   Yamada K, 2016, J INFECT DIS, V213, P1253, DOI 10.1093/infdis/jiv586
NR 12
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4660
EP 4662
DI 10.1016/j.vaccine.2017.12.051
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000002
PM 29279280
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Marosi, A
   Forgach, P
   Gyuranecz, M
   Sulyok, KM
   Bakonyi, T
AF Marosi, Andras
   Forgach, Petra
   Gyuranecz, Miklos
   Sulyok, Kinga M.
   Bakonyi, Tamas
TI Evaluation of in vitro inhibitory potential of type-I interferons and
   different antiviral compounds on rabies virus replication
SO VACCINE
LA English
DT Article
DE Rabies virus; Sorafenib; Interferon; Ribavirin; Favipiravir; Combination
ID FAVIPIRAVIR T-705; INITIAL TREATMENT; PHOSPHOPROTEIN-P; TISSUE-CULTURE;
   HEPATITIS-C; REAL-TIME; RIBAVIRIN; SURVIVAL; KINASE; COMBINATION
AB Five different compounds were tested for their in vitro inhibitory effect against RABV multiplication in mouse neuroblastoma (N2A) cell line. N2A cells were infected with the fixed RABV strain CVS-11 one hour prior to adding antivirals or their respective combinations. The infectious titre of RABV as well as the quantity of viral RNA was determined in the cell culturing medium after 48 h. All five tested compounds (mouse interferon (IFN)-alpha and -beta, ribavirin, favipiravir (T-705) and sorafenib) reduced viral replication in a concentration-dependent manner: IFN-beta and sorafenib both provided 73.71% relative inhibition of viral replication in the highest non-cytotoxic concentration, while ribavirin caused 48.07%, IFN-alpha caused 44.87% and favipiravir caused 35.25% relative inhibition, respectively. When applied in combination, their antiviral activity was not synergistic, but a pronounced inhibition was detected when IFN-beta was combined with sorafenib, ribavirin, or favipiravir. The highest antiviral effect was caused by the combination of IFN-beta and sorafenib (77.19% relative inhibition). In other combinations there was an antagonistic effect detected in the reduction of viral replication. The results demonstrate that these compounds can be promising candidates for a potential combination treatment of rabies, noting that some combinations are not favourable in vitro, which makes thorough in vivo studies necessary. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Marosi, Andras; Forgach, Petra; Bakonyi, Tamas] Univ Vet Med, Dept Microbiol & Infect Dis, Hungaria Krt 23-25, H-1143 Budapest, Hungary.
   [Gyuranecz, Miklos; Sulyok, Kinga M.] Hungarian Acad Sci, Ctr Agr Res, Inst Vet Med Res, Hungaria Krt 21, H-1143 Budapest, Hungary.
   [Bakonyi, Tamas] Univ Vet Med Vienna, Inst Virol, Viral Zoonoses Emerging & Vector Borne Infect Grp, Vet Pl 1, A-1210 Vienna, Austria.
RP Marosi, A (reprint author), Univ Vet Med, Dept Microbiol & Infect Dis, Hungaria Krt 23-25, H-1143 Budapest, Hungary.
EM Marosi.Andras@univet.hu
FU EUEuropean Union (EU) [FP7-602825 ASKLEPIOS]
FX This study was partially funded by the EU grant FP7-602825 ASKLEPIOS
   (http://asklepiosfp7.eu/). The contents of this publication are the sole
   responsibility of the authors and do not necessarily reflect the views
   of the European Commission.
CR Appolinario CM, 2015, ANTIVIR THER, V20, P1, DOI 10.3851/IMP2851
   Appolinario CM, 2013, J VIROL ANTIVIR RES, V2, P2, DOI DOI 10.4172/2324-8955.1000111
   Baranovich T, 2013, J VIROL, V87, P3741, DOI 10.1128/JVI.02346-12
   Roberto JVB, 2014, J ANIM BEHAV BIOMETE, V2, P11, DOI 10.14269/2318-1265.v02n01a03
   BOURHY H, 1989, J CLIN MICROBIOL, V27, P519, DOI 10.1128/JCM.27.3.519-523.1989
   Brzozka K, 2005, J VIROL, V79, P7673, DOI 10.1128/JVI.79.12.7673-7681.2005
   Brzozka K, 2006, J VIROL, V80, P2675, DOI 10.1128/JVI.80.6.2675-2683.2006
   BUSSEREAU F, 1983, ANN INST PASTEUR VIR, V134, P127, DOI 10.1016/S0769-2617(83)80048-3
   Chavez JH, 2006, VET MICROBIOL, V116, P53, DOI 10.1016/j.vetmic.2006.03.019
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Chopy D, 2011, J NEUROVIROL, V17, P353, DOI 10.1007/s13365-011-0041-6
   Crotty S, 2000, NAT MED, V6, P1375
   Descamps V, 2015, ANTIVIR RES, V118, P93, DOI 10.1016/j.antiviral.2015.03.012
   Ono EAD, 2013, BRAZ J MICROBIOL, V44, P879, DOI 10.1590/S1517-83822013005000050
   Fooks AR, 2014, LANCET, V384, P1389, DOI 10.1016/S0140-6736(13)62707-5
   Furuta Y, 2005, ANTIMICROB AGENTS CH, V49, P981, DOI 10.1128/AAC.49.3.981-986.2005
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   GOSWAMI BB, 1979, BIOCHEM BIOPH RES CO, V89, P830, DOI 10.1016/0006-291X(79)91853-9
   Gustafsson RKL, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-311
   Himmelsbach K, 2009, GUT, V58, P1644, DOI 10.1136/gut.2009.182212
   Israsena N, 2009, ANTIVIR RES, V84, P76, DOI 10.1016/j.antiviral.2009.07.012
   Ito N, 2010, J VIROL, V84, P6699, DOI 10.1128/JVI.00011-10
   Jackson AC, 2013, ANTIVIR RES, V99, P61, DOI 10.1016/j.antiviral.2013.01.003
   Jonsson N, 2009, MICROBIOL IMMUNOL, V53, P149, DOI 10.1111/j.1348-0421.2009.00107.x
   Karande S, 2015, INT J INFECT DIS, V36, P1, DOI 10.1016/j.ijid.2015.05.005
   KARBER G, 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   Kumar KVSH, 2015, NEUROL INDIA, V63, P255, DOI 10.4103/0028-3886.156295
   Leroy M, 2006, NEUROBIOL DIS, V21, P515, DOI 10.1016/j.nbd.2005.08.015
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Ludwig S., 2007, Signal Transduction, V7, P81, DOI 10.1002/sita.200600114
   Luig C, 2010, FASEB J, V24, P4068, DOI 10.1096/fj.10-158766
   Luo ZC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140586
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   Manoj S, 2016, MILITARY MED RES, V3, DOI 10.1186/s40779-016-0089-y
   Masatani T, 2010, MICROBIOL IMMUNOL, V57, P511, DOI [10.1111/1348-042112058, DOI 10.1111/1348-042112058]
   McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101
   Mehta S., 2015, VirusDisease, V26, P163, DOI 10.1007/s13337-015-0269-5
   Mendenhall M, 2011, ANTIMICROB AGENTS CH, V55, P782, DOI 10.1128/AAC.01219-10
   Moreno H, 2011, J VIROL, V85, P7246, DOI 10.1128/JVI.00614-11
   Nakamichi K, 2005, J VIROL, V79, P11801, DOI 10.1128/JVI.79.18.11801-11812.2005
   Netravathi M, 2015, J CLIN VIROL, V70, P83, DOI 10.1016/j.jcv.2015.07.003
   Niu XF, 2013, ARCH VIROL, V158, P2297, DOI 10.1007/s00705-013-1743-2
   Oestereich L, 2016, J INFECT DIS, V213, P934, DOI 10.1093/infdis/jiv522
   Oestereich L, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002804
   Oestereich L, 2014, ANTIVIR RES, V105, P17, DOI 10.1016/j.antiviral.2014.02.014
   Roberts JL, 2015, J CELL PHYSIOL, V230, P2552, DOI 10.1002/jcp.25014
   Roy S, 2016, PHARMACOGN RES, V8, P265, DOI 10.4103/0974-8490.188874
   Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x
   Vidy A, 2007, J VIROL, V81, P4255, DOI 10.1128/JVI.01930-06
   Virojanapirom P, 2016, J INFECT DIS, V214, P502, DOI 10.1093/infdis/jiw174
   Wakeley PR, 2005, J CLIN MICROBIOL, V43, P2786, DOI 10.1128/JCM.43.6.2786-2792.2005
   Wang XH, 2011, J MICROBIOL BIOTECHN, V21, P366, DOI 10.4014/jmb.1010.10003
   Westover JB, 2016, ANTIVIR RES, V126, P62, DOI 10.1016/j.antiviral.2015.12.006
   Weyer J, 2016, SOUTH AFR J INFECT D, V31, P66, DOI 10.1080/23120053.2016.1128151
   Willoughby RE, 2005, NEW ENGL J MED, V352, P2508, DOI 10.1056/NEJMoa050382
   Yamada K, 2016, J INFECT DIS, V213, P1253, DOI 10.1093/infdis/jiv586
NR 56
TC 3
Z9 3
U1 3
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4663
EP 4672
DI 10.1016/j.vaccine.2018.01.082
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000003
PM 29459063
DA 2020-05-12
ER

PT J
AU Phoolcharoen, W
   Banyard, AC
   Prehaud, C
   Selden, D
   Wu, GH
   Birch, CPD
   Szeto, TH
   Lafon, M
   Fooks, AR
   Ma, JLKC
AF Phoolcharoen, Waranyoo
   Banyard, Ashley C.
   Prehaud, Christophe
   Selden, David
   Wu, Guanghui
   Birch, Colin P. D.
   Szeto, Tim H.
   Lafon, Monique
   Fooks, Anthony R.
   Ma, Julian K-C
TI In vitro and in vivo evaluation of a single chain antibody fragment
   generated in planta with potent rabies neutralisation activity
SO VACCINE
LA English
DT Article
DE Rabies virus; Single-chain antibody (ScFv); Blood brain barrier (BBB);
   Clinical disease; Immunoglobulin; N-acetylcholine receptor; Nicotiana
   benthamiana
ID TARGETED DELIVERY; POSTEXPOSURE PROPHYLAXIS; MONOCLONAL-ANTIBODY;
   SYNTHETIC PEPTIDES; FUSION PROTEIN; BRAIN UPTAKE; VIRUS; PREVENTION;
   RECEPTOR; NANOPARTICLES
AB Rabies causes more than 60,000 human deaths annually in areas where the virus is endemic. Importantly, rabies is one of the few pathogens for which there is no treatment following the onset of clinical disease with the outcome of infection being death in almost 100% of cases. Whilst vaccination, and the combination of vaccine and rabies immunoglobulin treatment for post-exposure administration are available, no tools have been identified that can reduce or prevent rabies virus replication once clinical disease has initiated. The search for effective antiviral molecules to treat those that have already developed clinical disease associated with rabies virus infection is considered one of the most important goals in rabies research. The current study assesses a single chain antibody molecule (ScFv) based on a monoclonal antibody that potently neutralises rabies in vitro as a potential therapeutic candidate. The recombinant ScFv was generated in Nicotiana benthamiana by transient expression, and was chemically conjugated (ScFv/RVG) to a 29 amino acid peptide, specific for nicotinic acetylcholine receptor (nAchR) binding in the CNS. This conjugated molecule was able to bind nAchR in vitro and enter neuronal cells more efficiently than ScFv. The ability of the ScFv/RVG to neutralise virus in vivo was assessed using a staggered administration where the molecule was inoculated either four hours before, two days after or four days after infection. The ScFv/RVG conjugate was evaluated in direct comparison with HRIG and a potential antiviral molecule, Favipiravir (also known as T-705) to indicate whether there was greater bioavailability of the ScFv in the brains of treated mice. The study indicated that the approach taken with the ScFv/RVG conjugate may have utility in the design and implementation of novel tools targetting rabies virus infection in the brain. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Phoolcharoen, Waranyoo; Szeto, Tim H.; Ma, Julian K-C] Univ London, St Georges Hosp, Inst Infect & Immun, Med Sch, London, England.
   [Phoolcharoen, Waranyoo] Chulalongkom Univ, Fac Pharmaceut Sci, Pharmacognosy & Pharmaceut Bot, Bangkok, Thailand.
   [Banyard, Ashley C.; Selden, David; Wu, Guanghui; Fooks, Anthony R.] APHA, Wildlife Zoonoses & Vector Borne Dis Res Grp, Addlestone KT15 3NB, Surrey, England.
   [Prehaud, Christophe; Lafon, Monique] Inst Pasteur, Dept Virol Paris, Unite Neuroimmunol Virale, Paris, France.
   [Birch, Colin P. D.] APHA, Biomath & Risk Res Grp, Addlestone KT15 3NB, Surrey, England.
RP Ma, JLKC (reprint author), Univ London, St Georges Hosp, Inst Infect & Immun, Med Sch, London, England.
EM jma@sgul.ac.uk
OI Ma, Julian/0000-0003-0767-0042
FU Royal Society (Newton International fellowship); Wellcome TrustWellcome
   Trust [WT093092MA]; Hotung Foundation; ERC award
   [ERC-2010-AdG_20100317]; EU FP7 projectEuropean Union (EU) [ASKLEPIOS
   602825]; UK Department for Environment, Food and Rural Affairs
   (Defra)Department for Environment, Food & Rural Affairs (DEFRA) [SE0426,
   SE0431]
FX This work was supported by the Royal Society (Newton International
   fellowship to W. Phoolcharoen), a Wellcome Trust grant (WT093092MA), the
   Hotung Foundation and an ERC award (ERC-2010-AdG_20100317). The studies
   undertaken at APHA received partial financial support from the EU FP7
   project (ASKLEPIOS 602825) and by the UK Department for Environment,
   Food and Rural Affairs (Defra projects SE0426 and SE0431).
CR Andersen JT, 2010, J BIOL CHEM, V285, P4826, DOI 10.1074/jbc.M109.081828
   Boado RJ, 2008, BIOTECHNOL BIOENG, V99, P475, DOI 10.1002/bit.21602
   Boado RJ, 2010, MOL PHARMACEUT, V7, P237, DOI 10.1021/mp900235k
   Both L, 2013, FASEB J, V27, P2055, DOI 10.1096/fj.12-219964
   Both L, 2012, LANCET INFECT DIS, V12, P397, DOI 10.1016/S1473-3099(11)70340-1
   BURRAGE TG, 1985, VIRUS RES, V2, P273, DOI 10.1016/0168-1702(85)90014-0
   Dietzgen R.G., 2011, VIRUS TAXONOMY, P686
   DONNELLY-ROBERTS D L, 1989, Peptide Research, V2, P221
   Eigenmann DE, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-33
   Fu AL, 2012, PHARM RES-DORDR, V29, P1562, DOI 10.1007/s11095-012-0667-y
   Hanlon CA, 2001, VACCINE, V19, P2273, DOI 10.1016/S0264-410X(00)00516-8
   Hemachudha T, 2002, LANCET NEUROL, V1, P101, DOI 10.1016/S1474-4422(02)00041-8
   Huang Z, 2009, BIOTECHNOL BIOENG, V103, P706, DOI 10.1002/bit.22299
   Hwang DW, 2011, BIOMATERIALS, V32, P4968, DOI 10.1016/j.biomaterials.2011.03.047
   Johnson N, 2008, EMERG INFECT DIS, V14, P1950, DOI 10.3201/eid1412.080944
   KAPLAN MM, 1962, B WORLD HEALTH ORGAN, V26, P765
   Kim JY, 2013, BIOMATERIALS, V34, P1170, DOI 10.1016/j.biomaterials.2012.09.047
   Kristensen M, 2017, J PHARM SCI
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Lafon M, 2005, J NEUROVIROL, V11, P82, DOI 10.1080/13550280590900427
   LAFON M, 1993, RES IMMUNOL, V144, P209, DOI 10.1016/0923-2494(93)80121-E
   Lentz T L, 1990, J Mol Recognit, V3, P82, DOI 10.1002/jmr.300030205
   LENTZ TL, 1982, SCIENCE, V215, P182, DOI 10.1126/science.7053569
   LENTZ TL, 1988, ADV BIOCHEM PSYCHOPH, V44, P57
   LENTZ TL, 1987, PROTEINS, V2, P298, DOI 10.1002/prot.340020406
   Lewis P, 2000, MUSCLE NERVE, V23, P720, DOI 10.1002/(SICI)1097-4598(200005)23:5<720::AID-MUS9>3.0.CO;2-5
   Li CH, 2015, TOXICOL SCI, V148, P192, DOI 10.1093/toxsci/kfv176
   LIN FT, 1988, REV INFECT DIS, V10, pS766
   Markoutsa E, 2011, EUR J PHARM BIOPHARM, V77, P265, DOI 10.1016/j.ejpb.2010.11.015
   Megret F, 2005, VACCINE, V23, P5342, DOI 10.1016/j.vaccine.2005.06.027
   Meng X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03123-y
   Morimoto K, 1996, P NATL ACAD SCI USA, V93, P5653, DOI 10.1073/pnas.93.11.5653
   Muller T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000542
   Nga BL, 2014, J EXP MED, V211, P233, DOI 10.1084/jem.20131660
   Niewoehner J, 2014, NEURON, V81, P49, DOI 10.1016/j.neuron.2013.10.061
   Pardridge WM, 2010, J DRUG TARGET, V18, P157, DOI 10.3109/10611860903548354
   PARDRIDGE WM, 1995, PHARMACEUT RES, V12, P807, DOI 10.1023/A:1016244500596
   Phoolcharoen W, 2017, PLANT BIOTECHNOL J
   Phoolcharoen W, 2017, PLANT BIOTECHNOL J, V15, P1331, DOI 10.1111/pbi.12719
   Portioli C, 2017, J BIOMED MATER RES A, V105, P847, DOI 10.1002/jbm.a.35961
   Rip Jaap, 2016, Drug Discov Today Technol, V20, P53, DOI 10.1016/j.ddtec.2016.07.005
   Schnell MJ, 2010, NAT REV MICROBIOL, V8, P51, DOI 10.1038/nrmicro2260
   Shantavasinkul P, 2011, ADV VIRUS RES, V79, P291, DOI 10.1016/B978-0-12-387040-7.00013-5
   Teh AYH, 2014, PLANT BIOTECHNOL J, V12, P300, DOI 10.1111/pbi.12137
   Thoulouze MI, 1997, J VIROL, V71, P7372, DOI 10.1128/JVI.71.10.7372-7380.1997
   Tian XH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11990
   Uwanyiligira M, 2012, CLIN INFECT DIS, V55, P201, DOI 10.1093/cid/cis384
   Velasco-Aguirre C, 2015, INT J NANOMED, V10, P4919, DOI 10.2147/IJN.S82310
   Warrell MJ, 2016, TROP MED INT HEALTH, V21, P456, DOI 10.1111/tmi.12668
   Weksler BB, 2005, FASEB J, V19, P1872
   WHO, 2013, WHO TECH REP SER, V982, P1
   Xiang LX, 2011, J DRUG TARGET, V19, P632, DOI 10.3109/1061186X.2010.523788
   Yamauchi JG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016519
   Zhang DD, 2016, J CONTROL RELEASE, V229, P130, DOI 10.1016/j.jconrel.2016.03.020
   Zou ZY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122104
NR 55
TC 3
Z9 3
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4673
EP 4680
DI 10.1016/j.vaccine.2018.02.057
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000004
PM 29523449
OA Green Accepted, Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Koraka, P
   Martina, BEE
   Smreczak, M
   Orlowska, A
   Marzec, A
   Trebas, P
   Roose, JM
   Begeman, L
   Gerhauser, I
   Wohlsein, P
   Baumgartner, W
   Zmudzinski, J
   Osterhaus, ADME
AF Koraka, Penelope
   Martina, Byron E. E.
   Smreczak, Marcin
   Orlowska, Anna
   Marzec, Anna
   Trebas, Pawel
   Roose, Jouke M.
   Begeman, Lineke
   Gerhauser, Ingo
   Wohlsein, Peter
   Baumgaertner, Wolfgang
   Zmudzinski, Jan
   Osterhaus, Albert D. M. E.
TI Inhibition of caspase-1 prolongs survival of mice infected with rabies
   virus
SO VACCINE
LA English
DT Article
DE Rabies; Treatment; Pyroptosis
ID IMMUNE-RESPONSE; DISEASE
AB Rabies virus infects almost all mammals resulting in lethal disease. To date there is no treatment available for symptomatic rabies and there is an urgent need to develop treatment strategies that would prolong survival, thereby providing a window of opportunity for the host to mount a protective immune response. We hypothesized that both virus and excessive immune response contribute to disease and that interfering with both is necessary to prevent lethal disease. Here, we have inhibited the pro-inflammatory response associated with pyroptosis and showed that inhibition of CASP-1 had a beneficial effect on survival time. Our results confirm that some inflammatory responses may be involved in the pathogenesis of severe disease and the results suggest that effective intervention includes inhibition of virus and host response. (C) 2018 The Author(s). Published by Elsevier Ltd.
C1 [Koraka, Penelope; Martina, Byron E. E.; Begeman, Lineke] Erasmus MC, Rotterdam, Netherlands.
   [Martina, Byron E. E.; Roose, Jouke M.; Osterhaus, Albert D. M. E.] Artemis One Hlth Res Fdn, Delft, Netherlands.
   [Smreczak, Marcin; Orlowska, Anna; Marzec, Anna; Trebas, Pawel; Zmudzinski, Jan] Natl Vet Res Inst, Dept Virol, Partyzantow 57 Ave, PL-24100 Pulawy, Poland.
   [Osterhaus, Albert D. M. E.] Univ Vet Med, Res Ctr Emerging Infect & Zoonoses RIZ, Hannover, Germany.
   [Gerhauser, Ingo; Wohlsein, Peter; Baumgaertner, Wolfgang] Univ Vet Med Hannover, Dept Pathol, Hannover, Germany.
   [Baumgaertner, Wolfgang] Ctr Syst Neurosci ZSN, Hannover, Germany.
RP Koraka, P (reprint author), Erasmus MC, Rotterdam, Netherlands.
EM koraka@viroclinics.com
RI Smreczak, Marcin/D-2168-2012; Smreczak, Marcin/AAL-1027-2020; Grzadziel,
   Anna Marzec/AAB-5497-2019
OI Grzadziel, Anna Marzec/0000-0002-0589-0714
FU EU FP7 project ASKLEPIOS [602825]; Niedersachsen-Research Network on
   Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of
   Lower Saxony
FX This study was funded through EU FP7 project ASKLEPIOS (602825). The
   authors would like to thank all partners (and their teams) and
   scientific advisors of ASKLEPIOS consortium for fruitful discussions:
   Anthony Fooks (AHPA, UK), Tamas Bakonyi (Szent Istavan Egyetem,
   Hungary), Miklos Gyuranecz (Centre for Agricultural research, the
   Hungarian Academy of Science, Hungary), Daniel Ruzek (Veterinary
   Research Institute, Czech Republic), Johan Neyts (Katholieke
   Universiteit Leuven, Belgium), Noel Tordo (Institute Pasteur, France),
   Thomas Muller (Friedrich-Loeffler-Institut, Germany), Charles E.
   Rupprecht (Global Alliance for Rabies Control, USA), Pieter P. van Thiel
   (Amsterdam Medical Centre, The Netherlands). This study was in part
   supported by the Niedersachsen-Research Network on Neuroinfectiology
   (N-RENNT) of the Ministry of Science and Culture of Lower Saxony.
CR Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940
   Fooks AR, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.91
   Hemachudha T, 2002, LANCET NEUROL, V1, P101, DOI 10.1016/S1474-4422(02)00041-8
   IWASAKI Y, 1977, INFECT IMMUN, V18, P220, DOI 10.1128/IAI.18.1.220-225.1977
   Jackson AC, 2011, ADV VIRUS RES, V79, P365, DOI 10.1016/B978-0-12-387040-7.00017-2
   Koraka P, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00397
   Koraka P, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002682
   Laothamatas J, 2008, J NEUROVIROL, V14, P119, DOI 10.1080/13550280701883857
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mani RS, 2016, PLOS NEGLECT TROP D, V10, DOI DOI 10.1371/JOURNAL.PNTD.000477427467381
   PRABHAKAR BS, 1981, NATURE, V290, P590, DOI 10.1038/290590a0
   Rupprecht Charles, 2017, F1000Res, V6, P184, DOI 10.12688/f1000research.10416.1
   SINCHAISRI TA, 1992, J VET MED SCI, V54, P409, DOI 10.1292/jvms.54.409
   SMITH JS, 1982, INFECT IMMUN, V35, P213, DOI 10.1128/IAI.35.1.213-221.1982
   Tan MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.348
   Wang ZW, 2005, J VIROL, V79, P12554, DOI 10.1128/JVI.79.19.12554-12565.2005
   WARRELL MJ, 1989, BMJ-BRIT MED J, V299, P830, DOI 10.1136/bmj.299.6703.830
   Willoughby RE, 2005, NEW ENGL J MED, V352, P2508, DOI 10.1056/NEJMoa050382
NR 18
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4681
EP 4685
DI 10.1016/j.vaccine.2018.04.002
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000005
PM 29653845
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Banyard, AC
   Mansfield, KL
   Wu, GH
   Selden, D
   Thorne, L
   Birch, C
   Koraka, P
   Osterhaus, ADME
   Fooks, AR
AF Banyard, Ashley C.
   Mansfield, Karen L.
   Wu, Guanghui
   Selden, David
   Thorne, Leigh
   Birch, Colin
   Koraka, Penelope
   Osterhaus, Albert D. M. E.
   Fooks, Anthony R.
TI Re-evaluating the effect of Favipiravir treatment on rabies virus
   infection
SO VACCINE
LA English
DT Article; Proceedings Paper
CT 28th International Conference on Antiviral Research (ICAR)
CY MAY 11-15, 2015
CL Rome, ITALY
DE Rabies; Antiviral; Favipiravir; HRIG; T-705; In vivo
ID T-705 FAVIPIRAVIR; KNOWLEDGE; EFFICACY; THERAPY
AB There is no antiviral treatment available once clinical disease following rabies virus infection has initiated. Considered a neglected tropical disease, >60,000 human rabies deaths are estimated each year despite the availability of pre- and post-exposure prophylaxis for pre-immunisation or administration following a potential exposure before the onset of clinical disease. Such post-exposure treatments include administration of rabies immunoglobulin (RIG) and vaccination at a distant site to prime a humoral immune response. However, current therapeutic options are limited. Regardless there is a need for molecules that target virus infection following the onset of clinical disease where the outcome of infection is invariably fatal., Numerous molecules have been assessed as potential antivirals against rabies virus (RABV) but with little promise. Favipiravir (T-705) is a broad-spectrum RNA polymerase inhibitor, which has been shown to have antiviral activity against a range of RNA viruses including some against RABV. In the present study, the utility of T-705 has been reassessed in vitro as well as in vivo in a murine model using intraperitoneal administration to investigate any immune protective effect of the molecule. In vitro T-705 effectively reduces RABV replication. However, in vivo, following assessment of various applications of the molecule in both pre- and post-exposure scenarios, the effect was limited. T-705 treatment delayed the onset of clinical signs when virus was delivered intramuscularly at a higher dose (10(6.8) TCID50/ml) and reduced the number of mice that developed clinical signs when virus was delivered at a lower dose (10(5.8) TCID50/ml) during the observation period. The day at which treatment commenced did not appear to have a statistically significant effect on the results in either experiment. The use of T-705 as a single biological entity may be limited, however, further work is required to assess the synergistic effect of T-705 as a component of a multi-drug therapy for treating human rabies infections. (C) 2017 Published by Elsevier Ltd.
C1 [Banyard, Ashley C.; Mansfield, Karen L.; Wu, Guanghui; Selden, David; Thorne, Leigh; Fooks, Anthony R.] APHA, OIE Reference Lab, Wildlife Zoonoses & Vector Borne Dis Res Grp, Addlestone KT15 3NB, Surrey, England.
   [Banyard, Ashley C.; Mansfield, Karen L.; Wu, Guanghui; Selden, David; Thorne, Leigh; Fooks, Anthony R.] APHA, WHO Collaborating Ctr, Addlestone KT15 3NB, Surrey, England.
   [Birch, Colin] APHA, Biomath & Risk Res Grp, Addlestone KT15 3NB, Surrey, England.
   [Koraka, Penelope; Osterhaus, Albert D. M. E.] EMC, Rotterdam, Netherlands.
   [Fooks, Anthony R.] Univ London, St Georges Hosp, Med Sch, Inst Infect & Immun, London, England.
RP Fooks, AR (reprint author), APHA, OIE Reference Lab, Wildlife Zoonoses & Vector Borne Dis Res Grp, Addlestone KT15 3NB, Surrey, England.; Fooks, AR (reprint author), APHA, WHO Collaborating Ctr, Addlestone KT15 3NB, Surrey, England.
EM Tony.Fooks@apha.gsi.gov.uk
FU EU FP7 project ASKLEPIOS - Advanced Studies towards Knowledge on
   Lyssavirus Encephalitis Pathogenesis Improving Options for Survival
   [602825]; Defra grant [SE0431]
FX This study was funded through EU FP7 project ASKLEPIOS - Advanced
   Studies towards Knowledge on Lyssavirus Encephalitis Pathogenesis
   Improving Options for Survival (grant 602825) and Defra grant (SE0431).
   We wish to thank all members of the Asklepios consortium for their
   support. We thank Ian Mawhinney for statistical support. We thank Mrs
   Samantha Watson and Mr Nick Rose for extensive assistance with in vivo
   studies. The authors acknowledge extensive discussions with both Dr
   Thomas Muller, Professor Noel Tordo and Professor Charles Rupprecht in
   the design of the experiments and interpretation of outputs.
CR Appolinario CM, 2015, ANTIVIR THER, V20, P1, DOI 10.3851/IMP2851
   Arias A, 2014, ELIFE, V3, DOI 10.7554/eLife.03679
   Both L, 2012, LANCET INFECT DIS, V12, P397, DOI 10.1016/S1473-3099(11)70340-1
   Bourhy H, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000839
   Buys Kristin K., 2011, Antiviral Chemistry & Chemotherapy, V21, P193, DOI 10.3851/IMP1729
   Caroline AL, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002790
   Castel G, 2015, CURRENT LAB TECHNIQU
   Cliquet F, 1998, J IMMUNOL METHODS, V212, P79, DOI 10.1016/S0022-1759(97)00212-3
   Dean D J, 1973, Monogr Ser World Health Organ, P73
   Fooks AR, 2014, LANCET, V384, P1389, DOI 10.1016/S0140-6736(13)62707-5
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Hayman DTS, 2011, J VIROL METHODS, V177, P87, DOI 10.1016/j.jviromet.2011.07.002
   Healy DM, 2013, VIRUS RES, V172, P46, DOI 10.1016/j.virusres.2012.12.011
   Hodge RAV, 2015, ANTIVIR RES, V123, P172, DOI 10.1016/j.antiviral.2015.09.015
   Jackson AC, 2013, ANTIVIR RES, V99, P61, DOI 10.1016/j.antiviral.2013.01.003
   Jackson AC, 2010, EXPERT REV ANTI-INFE, V8, P623, DOI 10.1586/ERI.10.50
   Kiso M, 2010, P NATL ACAD SCI USA, V107, P882, DOI 10.1073/pnas.0909603107
   Matibag GC, 2009, J INFECT DEV COUNTR, V3, P55
   Mendenhall M, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001342
   Moran David, 2015, BMC Res Notes, V8, P955, DOI 10.1186/s13104-014-0955-1
   Morimoto K, 1996, P NATL ACAD SCI USA, V93, P5653, DOI 10.1073/pnas.93.11.5653
   Morrey JD, 2008, ANTIVIR RES, V80, P377, DOI 10.1016/j.antiviral.2008.07.009
   Oestereich L, 2014, ANTIVIR RES, V105, P17, DOI 10.1016/j.antiviral.2014.02.014
   Rupprecht CE, 2016, EXPERT REV VACCINES, P1
   Virojanapirom P., 2016, J INFECT DIS, V213, P1253
   WARRELL DA, 1976, T ROY SOC TROP MED H, V70, P188, DOI 10.1016/0035-9203(76)90037-7
   Warrell MJ, 2008, CURR OPIN INFECT DIS, V21, P251, DOI 10.1097/QCO.0b013e3282fc705b
   WHO, 2010, HUM DOG RAB PREV CON
   Widyastuti MDW, 2015, INFECT DIS POVERTY, V4, DOI 10.1186/s40249-015-0061-1
   Yamada K, 2016, J INFECT DIS, V213, P1253, DOI 10.1093/infdis/jiv586
   2013, WHO TECHN REP SER, V982, P1
NR 31
TC 7
Z9 7
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4686
EP 4693
DI 10.1016/j.vaccine.2017.10.109
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000006
PM 29132993
DA 2020-05-12
ER

PT J
AU Ben Mechlia, M
   Belaid, A
   Castel, G
   Jallet, C
   Mansfield, KL
   Fooks, AR
   Hani, K
   Tordo, N
AF Ben Mechlia, Mohamed
   Belaid, Afifa
   Castel, Guillaume
   Jallet, Corinne
   Mansfield, Karen L.
   Fooks, Anthony R.
   Hani, Khaled
   Tordo, Noel
TI Dermaseptins as potential antirabies compounds
SO VACCINE
LA English
DT Article
DE Antiviral; Rabies; Dermaseptin
ID VITRO ANTIVIRAL ACTIVITY; ANTIMICROBIAL PEPTIDES; SELECTIVE
   CYTOTOXICITY; PHYLLOMEDUSA-DISTINCTA; MEMBRANE CURVATURE;
   BINDING-PROPERTIES; MODEL MEMBRANES; AMPHIBIAN SKIN; RABIES; S4
AB Over the last 20 years, natural peptides playing a key role in defense mechanisms and innate immunity have been isolated from unicellular organisms. Amphibian skin secretes dermaseptins, 24-34 amino acids in length that have a wide antimicrobial spectrum incorporating yeast, fungi, protozoa, bacteria and enveloped viruses. The anti-rabies virus (RABV) activity of dermaseptins S3 (30aa) and S4 (28aa) from Phyllomedusa sauvagei has been investigated, and further dissected its molecular basis by comparing punctual mutation or deletion of S4 analogues. The results showed that: (1) S4 is more active than S3 against RABV infection, 89% versus 38% inhibition at 7.5 mu M; (2) the 5 NH2-aa of S4 are crucial for its inhibitory potential (S4(6-28) lost any inhibition) but the COOH terminus stabilizes the inhibitory potential (S4(1-16) showed only 23% inhibition at 7.5 mu M); (3) there is a correlation between viral inhibition and dermaseptin cytotoxicity, which remains however moderated for BSR cells (<= 12% at 10 mu M). A single mutation in position 4 (S4(M4K)) slightly reduced cytotoxicity while keeping its antiviral activity, 97% at 7.5 mu M. S4 and S4(M4K )showed an antiviral activity in vitro when provided 1 h after infection. In vivo experiments in mice by intramuscular injection of non-toxic doses of dermaseptin S4(M4K) 1 h post-infection by a lethal dose of RABV at the same site allowed more than 50% improvement in mice survival. This study highlights the potential interest of dermaseptins as non-expansive alternatives to rabies immunoglobulins for the treatment of rabies that continues to claim about 60,000 human lives per year worldwide, almost exclusively in developing countries. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Ben Mechlia, Mohamed; Jallet, Corinne; Tordo, Noel] Inst Pasteur, Unit Antiviral Strategies, 25 Rue Docteur Roux, F-75724 Paris 15, France.
   [Ben Mechlia, Mohamed; Belaid, Afifa; Hani, Khaled] Med Fac, Biochem Unit, Ave Mohamed Karoui, Sousse 4002, Tunisia.
   [Castel, Guillaume] INRA, IRD, Cirad, Montpellier SupAgro,UMR 1062 CBGP, Campus Baillarguet, F-34988 Montferrier Sur Lez, France.
   [Mansfield, Karen L.; Fooks, Anthony R.] APHA, Wildlife Zoonosis & Vector Borne Dis Res Grp, Addlestone KT15 3NB, Surrey, England.
   [Tordo, Noel] Univ Carnal Abdel Nasser, Inst Pasteur Guinee, Conakry, Guinea.
RP Ben Mechlia, M (reprint author), Inst Pasteur, Unit Antiviral Strategies, 25 Rue Docteur Roux, F-75724 Paris 15, France.
EM mchteoui@yahoo.fr
FU EUEuropean Union (EU) [FP7-60282]; Fondation Merieux, rue Bourgelat,
   Lyon; University Paris VI of Institut Pasteur; French National Research
   AgencyFrench National Research Agency (ANR) [ANR-10-INSB-04-01]; Conseil
   de la Region Ile-de-France (program Sesame 2007, projet Imagopole, S.
   Shorte); Fondation Francaise pour la Recherche Medicale (FRM, Programme
   Grands Equipements)
FX This work was supported by the EU grant FP7-60282 Asklepios "Advanced
   Studies towards Knowledge on Lyssavirus Encephalitis Pathogenesis
   Improving Options for Survival". Mohamed Chteoui (MC) was recipient of a
   fellowship of Fondation Merieux, 17, rue Bourgelat, Lyon. Guillaume
   Castel (GC) was recipient of fellowships of the University Paris VI of
   Institut Pasteur. We thank Frederic Tangy (Unite de Genomiquevirale et
   vaccination - CNRS URA-3015, Institut Pasteur, 25, rue du Docteur Roux,
   75724 Paris Cedex 15, France) for critical input throughout the
   development of the work. The imaging and quantifications have been
   performed at the Imagopole-CiTech. The Imagopole is part of the France
   BioImaging infrastructure supported by the French National Research
   Agency (ANR-10-INSB-04-01, "Investments for the future" and is
   gratefully supported by Conseil de la Region Ile-de-France (program
   Sesame 2007, projet Imagopole, S. Shorte) and by the Fondation Francaise
   pour la Recherche Medicale (FRM, Programme Grands Equipements to N.
   Aulner).
CR Aisenbrey C, 2008, J MOL BIOL, V375, P376, DOI 10.1016/j.jmb.2007.10.053
   Amiche M, 2008, PEPTIDES, V29, P2074, DOI 10.1016/j.peptides.2008.06.017
   Appolinario CM, 2015, ANTIVIR THER, V20, P1, DOI 10.3851/IMP2851
   Bechinger B, 2006, BBA-BIOMEMBRANES, V1758, P1529, DOI 10.1016/j.bbamem.2006.07.001
   Belaid A, 2002, J MED VIROL, V66, P229, DOI 10.1002/jmv.2134
   Bergaoui I, 2013, J MED VIROL, V85, P272, DOI 10.1002/jmv.23450
   Brand GD, 2002, J BIOL CHEM, V277, P49332, DOI 10.1074/jbc.M209289200
   Chinchar VG, 2004, VIROLOGY, V323, P268, DOI 10.1016/j.virol.2004.02.029
   Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1
   De Benedictis P, 2016, EMBO MOL MED, V8, P407, DOI 10.15252/emmm.201505986
   De Lucca AJ, 1998, MED MYCOL, V36, P291, DOI 10.1080/02681219880000461
   Duclohier H, 2002, MINI-REV MED CHEM, V2, P331, DOI 10.2174/1389557023405963
   Duda TF, 2002, MOL BIOL EVOL, V19, P858, DOI 10.1093/oxfordjournals.molbev.a004143
   Efron L, 2002, J BIOL CHEM, V277, P24067, DOI 10.1074/jbc.M202089200
   Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4
   Feder R, 2000, J BIOL CHEM, V275, P4230, DOI 10.1074/jbc.275.6.4230
   Galanth C, 2009, BIOCHEMISTRY-US, V48, P313, DOI 10.1021/bi802025a
   Ghosh JK, 1997, J BIOL CHEM, V272, P31609, DOI 10.1074/jbc.272.50.31609
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hemachudha T, 2002, LANCET NEUROL, V1, P101, DOI 10.1016/S1474-4422(02)00041-8
   Hemachudha T, 2006, J NEUROVIROL, V12, P407, DOI 10.1080/13550280600902295
   Huang HW, 2000, BIOCHEMISTRY-US, V39, P8347, DOI 10.1021/bi000946l
   Jackson AC, 2003, CLIN INFECT DIS, V36, P60, DOI 10.1086/344905
   Jackson AC, 2006, CURR OPIN NEUROL, V19, P267, DOI 10.1097/01.wco.0000227036.93199.3b
   Jean-Francois F, 2008, BIOPHYS J, V95, P5748, DOI 10.1529/biophysj.108.136655
   Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056-05
   Perez-Cordero JJ, 2011, PEPTIDES, V32, P683, DOI 10.1016/j.peptides.2011.01.011
   Krugliak M, 2000, ANTIMICROB AGENTS CH, V44, P2442, DOI 10.1128/AAC.44.9.2442-2451.2000
   Kustanovich I, 2002, J BIOL CHEM, V277, P16941, DOI 10.1074/jbc.M111071200
   Leite JRSA, 2008, COMP BIOCHEM PHYS A, V151, P336, DOI 10.1016/j.cbpa.2007.03.016
   LENTZ TL, 1982, SCIENCE, V215, P182, DOI 10.1126/science.7053569
   Lorin C, 2005, VIROLOGY, V334, P264, DOI 10.1016/j.virol.2005.02.002
   Marynka K, 2007, CHEM BIOL, V14, P75, DOI 10.1016/j.chembiol.2006.11.009
   Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y
   MOR A, 1994, J BIOL CHEM, V269, P1934
   MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x
   MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014
   Morton CO, 2007, MOL MICROBIOL, V65, P494, DOI 10.1111/j.1365-2958.2007.05801.x
   Muller T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000542
   Neiva M, 2013, TOXICON, V61, P139, DOI 10.1016/j.toxicon.2012.10.016
   NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425
   Nicolas P, 2009, BBA-BIOMEMBRANES, V1788, P1537, DOI 10.1016/j.bbamem.2008.09.006
   Pinto EG, 2013, EXP PARASITOL, V135, P655, DOI 10.1016/j.exppara.2013.09.016
   POUNY Y, 1992, BIOCHEMISTRY-US, V31, P12416, DOI 10.1021/bi00164a017
   Radzishevsky IS, 2007, NAT BIOTECHNOL, V25, P657, DOI 10.1038/nbt1309
   Rinaldi AC, 2002, CURR OPIN CHEM BIOL, V6, P799, DOI 10.1016/S1367-5931(02)00401-5
   Rotem S, 2006, ANTIMICROB AGENTS CH, V50, P2666, DOI 10.1128/AAC.00030-06
   SATO M, 1977, ARCH VIROL, V54, P333, DOI 10.1007/BF01314778
   Savoia D, 2010, APMIS, V118, P674, DOI 10.1111/j.1600-0463.2010.02637.x
   Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X
   Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260
   Shalev DE, 2006, J BIOL CHEM, V281, P9432, DOI 10.1074/jbc.M513051200
   Sitaram N, 1999, BBA-BIOMEMBRANES, V1462, P29, DOI 10.1016/S0005-2736(99)00199-6
   Smith JYP, 1996, RAPID FLUORESCENT FO
   Thoulouze MI, 1998, J VIROL, V72, P7181, DOI 10.1128/JVI.72.9.7181-7190.1998
   Tossi A, 2000, BIOPOLYMERS, V55, P4
   Tuffereau C, 2001, J GEN VIROL, V82, P2861, DOI 10.1099/0022-1317-82-12-2861
   Wang GS, 2010, ANTIMICROB AGENTS CH, V54, P1343, DOI 10.1128/AAC.01448-09
   Willoughby RE, 2005, NEW ENGL J MED, V352, P2508, DOI 10.1056/NEJMoa050382
   Zairi A, 2014, ANTIMICROB AGENTS CH, V58, P2221, DOI 10.1128/AAC.02142-13
NR 60
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4694
EP 4700
DI 10.1016/j.vaccine.2018.01.066
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000007
PM 29439871
DA 2020-05-12
ER

PT J
AU Smreczak, M
   Orlowska, A
   Marzec, A
   Trebas, P
   Kycko, A
   Reichert, M
   Koraka, P
   Osterhaus, ADME
   Zmudzinski, JF
AF Smreczak, Marcin
   Orlowska, Anna
   Marzec, Anna
   Trebas, Pawel
   Kycko, Anna
   Reichert, Michal
   Koraka, Penelope
   Osterhaus, Albert D. M. E.
   Zmudzinski, Jan Franciszek
TI The effect of combined drugs therapy on the course of clinical rabies
   infection in a murine model
SO VACCINE
LA English
DT Article
DE Clinical rabies; SHBRV-18; Antivirals; Host immune response modulators;
   Interferon alpha/beta
ID PROLONGS SURVIVAL; FAVIPIRAVIR T-705; INTERFERON; INHIBITION; EFFICACY
AB Rabies is a fatal disease of all mammals causing almost 60,000 human deaths every year. To date, there is no effective treatment of clinical rabies once the symptoms appear. Here, we describe the promising effect of combination therapy composed of molecules that target replication of the rabies virus (RV) at different stages of life cycle and molecules that inhibit some pathways of the innate host immune response accompanied by a blood-brain barrier opener on the outcome of RV infection. The study reports statistically significant extension of survival of mice treated with the drug cocktail containing T-705, ribavirin, interferon alpha/beta, caspase-1 inhibitor, TNF-alpha inhibitor, MAPKs inhibitor and HRIG compared to the survival of mice in the virus control group (p = 0.0312). Furthermore, the study points to the significant impact of interferon alpha/beta on the survival of RV-infected mice. We have shown a significant down regulation of pro-inflammatory molecules (caspase-1 and TNF-a) in the CNS in RV-infected mice treated with a combination of drugs including interferon alpha/beta. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Smreczak, Marcin; Orlowska, Anna; Marzec, Anna; Trebas, Pawel; Kycko, Anna; Reichert, Michal; Zmudzinski, Jan Franciszek] Natl Vet Res Inst, Dept Virol, Av Partyzantow 57, PL-24100 Pulawy, Poland.
   [Koraka, Penelope; Osterhaus, Albert D. M. E.] EMC, Rotterdam, Netherlands.
   [Koraka, Penelope] Viroclin Biosci BV, Rotterdam, Netherlands.
   [Osterhaus, Albert D. M. E.] Univ Vet Med, Res Ctr Emerging Infect & Zoonoses RIZ, Hannover, Germany.
RP Smreczak, M (reprint author), Natl Vet Res Inst, Dept Virol, Av Partyzantow 57, PL-24100 Pulawy, Poland.
EM smreczak@piwet.pulawy.pl
RI Smreczak, Marcin/D-2168-2012; Grzadziel, Anna Marzec/AAB-5497-2019;
   Smreczak, Marcin/AAL-1027-2020
OI Grzadziel, Anna Marzec/0000-0002-0589-0714; 
FU EU FP7 project ASKLEPIOS - Advanced Studies towards Knowledge on
   Lyssavirus Encephalitis Pathogenesis Improving Options for Survival
   [602825]
FX This study was funded through EU FP7 project ASKLEPIOS - Advanced
   Studies towards Knowledge on Lyssavirus Encephalitis Pathogenesis
   Improving Options for Survival (grant 602825). We want to thank all
   members of the Consortium for the excellent cooperation, fruitful
   discussions and the members of AB for their support during meetings
   presented interim reports.
CR APPOLINARIO CM, 2013, J VIROL ANTIVIR RES, V2, P1, DOI DOI 10.4172/2324-8955.1000111
   Banyard AC, 2019, VACCINE, V37, P4686, DOI 10.1016/j.vaccine.2017.10.109
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Jackson AC, 2017, MANAG RABIES HUMANS, V36, P9
   Koraka P, 2019, VACCINE, V37, P4681, DOI 10.1016/j.vaccine.2018.04.002
   Koraka P, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002682
   Lu CT, 2014, INT J NANOMED, V9, P2241, DOI 10.2147/IJN.S61288
   Manjunatha V, 2017, MICROB PATHOGENESIS, V112, P38, DOI 10.1016/j.micpath.2017.09.044
   Mehta S., 2015, VirusDisease, V26, P163, DOI 10.1007/s13337-015-0269-5
   Mehta S, 2014, NEUROIMMUNOMODULAT, V21, P250, DOI 10.1159/000357309
   MERIGAN TC, 1984, ANN NEUROL, V16, P82, DOI 10.1002/ana.410160116
   Nakamichi K, 2005, J VIROL, DOI [10.1128/JVI.79.18.11801-118122009, DOI 10.1128/JVI.79.18.11801-118122009]
   Oestereich L, 2016, J INFECT DIS, V213, P934, DOI 10.1093/infdis/jiv522
   OIE. Rabies (infection with RABV), 2013, MAN DIAGN TESTS VACC
   Rao Xiayu, 2013, Biostat Bioinforma Biomath, V3, P71
   Smreczak M, 2019, VACCINE, V37, P4715, DOI 10.1016/j.vaccine.2017.10.098
   WARRELL MJ, 1989, BMJ-BRIT MED J, V299, P830, DOI 10.1136/bmj.299.6703.830
   Warrell MJ, 2004, LANCET, V363, P959, DOI 10.1016/S0140-6736(04)15792-9
   Weyer J, 2016, SOUTH AFR J INFECT D, V31, P66, DOI 10.1080/23120053.2016.1128151
   Willoughby RE, 2005, NEW ENGL J MED, V352, P2508, DOI 10.1056/NEJMoa050382
   Yamada K, 2016, J INFECT DIS, V213, P1253, DOI 10.1093/infdis/jiv586
NR 21
TC 4
Z9 5
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4701
EP 4709
DI 10.1016/j.vaccine.2018.04.003
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000008
PM 29650384
DA 2020-05-12
ER

PT J
AU Dufkova, L
   Sirmarova, J
   Salat, J
   Honig, V
   Palus, M
   Ruzek, D
   Fooks, AR
   Mansfield, KL
   Tordo, N
   Jochmans, D
   Neyts, J
   Martina, B
   Koraka, P
   Osterhaus, ADME
AF Dufkova, Lucie
   Sirmarova, Jana
   Salat, Jiri
   Honig, Vaclav
   Palus, Martin
   Ruzek, Daniel
   Fooks, Anthony R.
   Mansfield, Karen L.
   Tordo, Noel
   Jochmans, Dirk
   Neyts, Johan
   Martina, Byron
   Koraka, Penelope
   Osterhaus, Albert D. M. E.
CA ASKLEPIOS Consortium
TI Mannitol treatment is not effective in therapy of rabies virus infection
   in mice
SO VACCINE
LA English
DT Article
DE Rabies; Blood-brain barrier; Mannitol; Therapy
ID BLOOD-BRAIN-BARRIER; INNATE IMMUNE-RESPONSES; CENTRAL-NERVOUS-SYSTEM;
   PERMEABILITY; DELIVERY
AB Rabies is a deadly viral disease with an extremely high fatality rate in humans. Previously, it was suggested that an enhancement of the blood-brain barrier (BBB) permeability, which allows immune cells and/or antibodies to enter the central nervous system (CNS) tissue, is critical to clear the infection. In this study, we utilised mannitol to increase BBB permeability in mice infected with highly pathogenic silver-haired bat rabies virus (SHBRV). We found that intraperitoneal injection of mannitol causes a slight, transient increase of BBB permeability in the treated mice. SHBRV-infected mice were treated with intraperitoneally administered mannitol daily from day 3 or day 4 post-infection, but no effect of this treatment on the time of disease onset, clinical signs or survival was observed. This data indicates that the increase of BBB permeability by mannitol is not efficient in promoting CNS virus clearance in SHBRV-infected mice. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Dufkova, Lucie; Sirmarova, Jana; Salat, Jiri; Honig, Vaclav; Palus, Martin; Ruzek, Daniel] Vet Res Inst, Dept Virol, Hudcova 70, CZ-62100 Brno, Czech Republic.
   [Honig, Vaclav; Palus, Martin; Ruzek, Daniel] Czech Acad Sci, Biol Ctr, Inst Parasitol, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic.
   [Fooks, Anthony R.; Mansfield, Karen L.] APHA, Woodham Lane, New Haw KT15 3NB, Surrey, England.
   [Fooks, Anthony R.; Mansfield, Karen L.] Univ Liverpool, Inst Infect & Global Hlth, 8 West Derby St, Liverpool L69 7BE, Merseyside, England.
   [Tordo, Noel] Inst Pasteur, Antiviral Strategies, 25 Rue Dr Roux, F-75724 Paris 15, France.
   [Tordo, Noel] Gamal Abdel Nasser Univ, Inst Pasteur Guinee, Conakry, Guinea.
   [Jochmans, Dirk; Neyts, Johan] Univ Leuven KU Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, B-3000 Leuven, Belgium.
   [Martina, Byron; Koraka, Penelope; Osterhaus, Albert D. M. E.] Erasmus MC, Virosci Lab, POB 2040,Ee1726, NL-3000 CA Rotterdam, Netherlands.
   [Martina, Byron] Artemis One Hlth Res Inst, Molengraaffsingel 10, NL-2629 JD Delft, Netherlands.
RP Ruzek, D (reprint author), Vet Res Inst, Hudcova 70, CZ-62100 Brno, Czech Republic.
EM ruzekd@paru.cas.cz
RI Honig, Vaclav/M-4715-2015; Ruzek, Daniel/G-9275-2014; Palus,
   Martin/N-1263-2017; JOCHMANS, DIRK/T-6223-2017; NEYTS, Johan/U-8267-2017
OI Honig, Vaclav/0000-0003-0469-4604; Ruzek, Daniel/0000-0003-4655-2380;
   Palus, Martin/0000-0002-4279-7092; Salat, Jiri/0000-0002-9915-8953;
   Bojcukova, Jana/0000-0002-7612-8807; JOCHMANS, DIRK/0000-0002-9265-6028;
   NEYTS, Johan/0000-0002-0033-7514
FU European FP7 Collaborative Project on "Neglected Infectious Diseases in
   Central and Eastern Europe" [602825]
FX The study was supported by the European FP7 Collaborative Project on
   "Neglected Infectious Diseases in Central and Eastern Europe" No.
   602825, named ASKLEPIOS (Advanced Studies towards Knowledge on
   Lyssavirus Pathogenesis Improving Options for Survival).
CR Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994
   Brown RC, 2004, BRAIN RES, V1014, P221, DOI 10.1016/j.brainres.2004.04.034
   COSOLO WC, 1989, AM J PHYSIOL, V256, pR443
   Fooks AR, 2014, LANCET, V384, P1389, DOI 10.1016/S0140-6736(13)62707-5
   Gonzales-Portillo GS, 2014, CELL TRANSPLANT, V23, P531, DOI 10.3727/096368914X678337
   Healy DW, 2012, BMC ANESTHESIOL, V12, DOI 10.1186/1471-2253-12-11
   Huang CT, 2014, ANTIVIR RES, V110, P132, DOI 10.1016/j.antiviral.2014.07.013
   Jackson Alan C, 2009, Curr Infect Dis Rep, V11, P296, DOI 10.1007/s11908-009-0044-0
   Lafon M, 2011, ADV VIRUS RES, V79, P33, DOI 10.1016/B978-0-12-387040-7.00003-2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Louboutin JP, 2010, NAT METHODS, V7, P905, DOI 10.1038/nmeth.1518
   Phares TW, 2006, J IMMUNOL, V176, P7666, DOI 10.4049/jimmunol.176.12.7666
   Roy A, 2007, J VIROL, V81, P7993, DOI 10.1128/JVI.00710-07
   Ruzek D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020472
   Sugiura N, 2011, JPN J INFECT DIS, V64, P463
   Wang LH, 2013, PROTEIN CELL, V4, P901, DOI 10.1007/s13238-013-3918-8
   Wang ZW, 2005, J VIROL, V79, P12554, DOI 10.1128/JVI.79.19.12554-12565.2005
   Willoughby RE, 2005, NEW ENGL J MED, V352, P2508, DOI 10.1056/NEJMoa050382
   Zhao PS, 2011, COMP IMMUNOL MICROB, V34, P503, DOI 10.1016/j.cimid.2011.09.003
NR 19
TC 4
Z9 4
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4710
EP 4714
DI 10.1016/j.vaccine.2017.12.028
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000009
PM 29274698
DA 2020-05-12
ER

PT J
AU Smreczak, M
   Marzec, A
   Orlowska, A
   Trebas, P
   Reichert, M
   Kycko, A
   Koraka, P
   Osterhaus, A
   Zmudzinski, JF
AF Smreczak, Marcin
   Marzec, Anna
   Orlowska, Anna
   Trebas, Pawel
   Reichert, Michal
   Kycko, Anna
   Koraka, Penelopa
   Osterhaus, Ab
   Zmudzinski, Jan Franciszek
TI The effect of selected molecules influencing the detrimental host immune
   response on a course of rabies virus infection in a murine model
SO VACCINE
LA English
DT Article
DE Rabies; SHBRV-18; Cytokines; Inhibitors; Remicade; RoActemra; Sorafenib
ID CENTRAL-NERVOUS-SYSTEM; RECEPTOR ANTIBODY; TOCILIZUMAB; ACTIVATION;
   EXPRESSION; APOPTOSIS; SURVIVAL; THERAPY; STRAINS; TNF
AB Rabies is invariably fatal, when post-exposure prophylaxis is administered after the onset of clinical symptoms. In many countries, rabies awareness is very low and the availability of post-exposure prophylaxis, as recommended by WHO guidelines, is very limited or non-existent, probably as a consequence of high cost. Therefore, new concepts for rabies therapy are needed. Innate immune mechanisms involving the production of pro-inflammatory cytokines and chemokines, activated after rabies infection, are thought to be involved in the neuropathogenesis of rabies. These mechanisms can contribute to a detrimental host response to the rabies virus (RABV) infection. The use of inhibitors of cytokines/chemokines are supposed to extend the survival of a sick individual. Inhibitors of TNF-alpha, IL-6 and MAPKs were used in RABV inoculated mice to define their influence on the survival time of rabid mice. The study demonstrated that all inhibitors extended mice survival, but at different rates. A log-rank test confirmed the statistically significant survival of mice treated with TNF-alpha (p = .0087) and MAPKs inhibitors (p = .0024). A delay in the time of onset of rabies was also recorded, in mice given TNF-alpha and MAPKs inhibitors. The highest virus load was found in the spinal cord and the lowest in the cortex, regardless of the experimental group. Significant TNF-alpha (p <=.0001) and IL-6 (p <= .0001) gene upregulation was observed in mice, as a consequence of RABV infection. Regarding MAPK5 pathways, there was significant upregulation of the caspase 3 (p = .012, p = .0026) and Mcl-1 (p = .0348, p = .0153) genes, whereas significant downregulation of the cytochrome C (p <= .0001), Bcl2 (p = .0002, p = .0007) and JNK3 (p = .042) genes. Rabies pathogenesis is multifactorial, involving both virus and host influences on the course of the infection. (C) 2017 Published by Elsevier Ltd.
C1 [Smreczak, Marcin; Marzec, Anna; Orlowska, Anna; Trebas, Pawel; Zmudzinski, Jan Franciszek] Natl Vet Res Inst, Dept Virol, Av Partyzantow 57, PL-24100 Pulawy, Poland.
   [Reichert, Michal; Kycko, Anna] Natl Vet Res Inst, Dept Pathol, Av Partyzantow 57, PL-24100 Pulawy, Poland.
   [Koraka, Penelopa; Osterhaus, Ab] EMC, Rotterdam, Netherlands.
RP Zmudzinski, JF (reprint author), Natl Vet Res Inst, Dept Virol, Av Partyzantow 57, PL-24100 Pulawy, Poland.
EM jfzmudzi@piwet.pulawy.pl
RI Smreczak, Marcin/AAL-1027-2020; Grzadziel, Anna Marzec/AAB-5497-2019;
   Smreczak, Marcin/D-2168-2012
OI Grzadziel, Anna Marzec/0000-0002-0589-0714; 
FU EU FP7 project ASKLEPIOS - Advanced Studies towards Knowledge on
   Lyssavirus Encephalitis Pathogenesis Improving Options for Survival
   [602825]
FX This study was funded through EU FP7 project ASKLEPIOS - Advanced
   Studies towards Knowledge on Lyssavirus Encephalitis Pathogenesis
   Improving Options for Survival (grant 602825). We would like to thank
   all members of the Consortium for their excellent cooperation, fruitful
   discussions and members of AB for their support during meetings, where
   interim reports were presented.
CR Alten R, 2013, ANN MED, V45, P357, DOI 10.3109/07853890.2013.771986
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P77
   Appolinario CM, 2016, AM J TROP MED HYG, V94, P378, DOI 10.4269/ajtmh.15-0361
   Astrakhantseva IV, 2014, BIOCHEMISTRY-MOSCOW+, V79, P1308, DOI 10.1134/S0006297914120049
   Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06
   Burgess S, 2010, CNS NEUROL DISORD-DR, V9, P120, DOI 10.2174/187152710790966632
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10
   Chopy D, 2011, J NEUROVIROL, V17, P353, DOI 10.1007/s13365-011-0041-6
   Chopy D, 2011, J VIROL, V85, P6657, DOI 10.1128/JVI.00302-11
   Guo Y, 2013, J APPL MATH, V2013, P2013, DOI [10.1155/2013/581631, DOI 10.1155/2013]
   Healy DW, 2012, BMC ANESTHESIOL, V12, DOI 10.1186/1471-2253-12-11
   Hennigan Stephanie, 2008, Ther Clin Risk Manag, V4, P767
   Huang Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0146-y
   Huynh H, 2009, MOL CANCER THER, V8, P152, DOI 10.1158/1535-7163.MCT-08-0553
   Ito N, 2016, J VET MED SCI, V78, P1089, DOI 10.1292/jvms.16-0092
   Ma XX, 2013, BIOMED REP, V1, P177, DOI 10.3892/br.2012.42
   Mansfield KL, 2008, J NEUROVIROL, V14, P218, DOI 10.1080/13550280802008297
   Mehta S., 2015, VirusDisease, V26, P163, DOI 10.1007/s13337-015-0269-5
   Nakamichi K, 2005, J VIROL, V79, P11801, DOI 10.1128/JVI.79.18.11801-11812.2005
   OIE, 2013, MAN DIAGN TESTS AQ A, P1
   Rao Xiayu, 2013, Biostat Bioinforma Biomath, V3, P71
   Roberts JL, 2015, J CELL PHYSIOL, V230, P2552, DOI 10.1002/jcp.25014
   Sarmento L, 2005, J NEUROVIROL, V11, P571, DOI 10.1080/13550280500385310
   Sedger LM, 2014, CYTOKINE GROWTH F R, V25, P453, DOI 10.1016/j.cytogfr.2014.07.016
   Sugiura N, 2011, JPN J INFECT DIS, V64, P463
   Tanaka T, 2011, FEBS LETT, V585, P3699, DOI 10.1016/j.febslet.2011.03.023
   Weyer J, 2016, SOUTH AFR J INFECT D, V31, P66, DOI 10.1080/23120053.2016.1128151
   Yan XZ, 2001, J NEUROVIROL, V7, P518, DOI 10.1080/135502801753248105
   Yin JF, 2014, BIOMED ENVIRON SCI, V27, P749, DOI 10.3967/bes2014.034
NR 29
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4715
EP 4723
DI 10.1016/j.vaccine.2017.10.098
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000010
PM 29153584
DA 2020-05-12
ER

PT J
AU Marosi, A
   Dufkova, L
   Forro, B
   Felde, O
   Erdelyi, K
   Sirmarova, J
   Palus, M
   Honig, V
   Salat, J
   Tikos, R
   Gyuranecz, M
   Ruzek, D
   Martina, B
   Koraka, P
   Osterhaus, ADME
   Bakonyi, T
AF Marosi, Andras
   Dufkova, Lucie
   Forro, Barbara
   Felde, Orsolya
   Erdelyi, Karoly
   Sirmarova, Jana
   Palus, Martin
   Honig, Vaclav
   Salat, Jiri
   Tikos, Reka
   Gyuranecz, Miklos
   Ruzek, Daniel
   Martina, Byron
   Koraka, Penelope
   Osterhaus, Albert D. M. E.
   Bakonyi, Tunas
TI Combination therapy of rabies-infected mice with inhibitors of
   pro-inflammatory host response, antiviral compounds and human rabies
   immunoglobulin
SO VACCINE
LA English
DT Article
DE Rabies virus; Survival; Combination; Infliximab; Sorafenib; HRIG
ID VIRUS NEUTRALIZING ANTIBODIES; FAVIPIRAVIR T-705; IMMUNE-RESPONSES;
   PARALYTIC RABIES; SURVIVAL; BRAIN; EXPRESSION; DELIVERY; PATHWAY; KINASE
AB Recent studies demonstrated that inhibitors of pro-inflammatory molecular cascades triggered by rabies infection in the central nervous system (CNS) can enhance survival in mouse model and that certain antiviral compounds interfere with rabies virus replication in vitro. In this study different combinations of therapeutics were tested to evaluate their effect on survival in rabies-infected mice, as well as on viral load in the CNS. C57Bl/6 mice were infected with Silver-haired bat rabies virus (SHBRV)-18 at virus dose approaching LD50 and LD100. In one experimental group daily treatments were initiated 4 h before-, in other groups 48 or 96 h after challenge. In the first experiment therapeutic combination contained inhibitors of tumour necrosis factor-alpha (infliximab), caspase-1 (Ac-YVAD-cmk), and a multikinase inhibitor (sorafenib). In the treated groups there was a notable but not significant increase of survival compared to the virus infected, non-treated mice. The addition of human rabies immunoglobulins (HRIG) to the combination in the second experiment almost completely prevented mortality in the pre-exposure treatment group along with a significant reduction of viral titres in the CNS. Post-exposure treatments also greatly improved survival rates. As part of the combination with immunomodulatory compounds, HRIG had a higher impact on survival than alone. In the third experiment the combination was further supplemented with type-I interferons, ribavirin and favipiravir (T-705). As a blood-brain barrier opener, mannitol was also administered. This treatment was unable to prevent lethal consequences of SHBRV-18 infection; furthermore, it caused toxicity in treated mice, presumably due to interaction among the components. In all experiments, viral loads in the CNS were similar in mice that succumbed to rabies regardless of treatment. According to the findings, inhibitors of detrimental host response to rabies combined with antibodies can be considered among the possible therapeutic and post-exposure options in human rabies cases. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Marosi, Andras; Tikos, Reka; Bakonyi, Tunas] Univ Vet Med, Dept Microbiol & Infect Dis, Hungaria Krt 23-25, H-1143 Budapest, Hungary.
   [Dufkova, Lucie; Sirmarova, Jana; Palus, Martin; Honig, Vaclav; Salat, Jiri; Ruzek, Daniel] Vet Res Inst, Dept Virol, Hudcova 70, CZ-62100 Brno, Czech Republic.
   [Forro, Barbara; Felde, Orsolya; Gyuranecz, Miklos] Hungarian Acad Sci, Ctr Agr Res, Inst Vet Med Res, Hungaria Krt 21, H-1143 Budapest, Hungary.
   [Erdelyi, Karoly] Natl Food Chain Safety Off, Vet Diagnost Directorate, Tabornok U 2, H-1149 Budapest, Hungary.
   [Ruzek, Daniel] Czech Acad Sci, Inst Parasitol, Biol Ctr, Branisovska 31, CZ-37005 Ceske Budejovice, Czech Republic.
   [Martina, Byron; Osterhaus, Albert D. M. E.] Artemis One Hlth Res Fdn, Delft, Netherlands.
   [Koraka, Penelope] Erasmus MC, Virosci Lab, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.
   [Osterhaus, Albert D. M. E.] Univ Vet Med Hannover, Res Ctr Emerging Infect & Zoonoses RIZ, Hannover, Germany.
   [Bakonyi, Tunas] Univ Vet Med Vienna, Inst Virol, Viral Zoonoses, Emerging & Vector Borne Infect Grp, Vet Pl 1, A-1210 Vienna, Austria.
   [Koraka, Penelope] Viroclin Biosci BV, Rotterdam, Netherlands.
RP Marosi, A (reprint author), Univ Vet Med, Dept Microbiol & Infect Dis, Hungaria Krt 23-25, H-1143 Budapest, Hungary.
EM Marosi.Andras@univet.hu
RI Honig, Vaclav/M-4715-2015; Palus, Martin/N-1263-2017; Ruzek,
   Daniel/G-9275-2014
OI Honig, Vaclav/0000-0003-0469-4604; Palus, Martin/0000-0002-4279-7092;
   Ruzek, Daniel/0000-0003-4655-2380; Salat, Jiri/0000-0002-9915-8953;
   Bojcukova, Jana/0000-0002-7612-8807
FU EUEuropean Union (EU) [FP7-602825 ASKLEPIOS]
FX This study was partially funded by the EU grant FP7-602825 ASKLEPIOS
   (http://asklepiosfp7.eu/).The contents of this publication are the sole
   responsibility of the authors and do not necessarily reflect the views
   of the European Commission.
CR Appolinario CM, 2013, J VIROL ANTIVIR RES, V2, P2, DOI DOI 10.4172/2324-8955.1000111
   Chopy D, 2011, J NEUROVIROL, V17, P353, DOI 10.1007/s13365-011-0041-6
   Chopy D, 2011, J VIROL, V85, P6657, DOI 10.1128/JVI.00302-11
   Davidson S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4864
   de Souza A, 2014, J NEUROL SCI, V339, P8, DOI 10.1016/j.jns.2014.02.013
   Dietzschold B, 2008, FUTURE VIROL, V3, P481, DOI 10.2217/17460794.3.5.481
   Dorfmeier CL, 2012, J VIROL, V86, P11533, DOI 10.1128/JVI.00615-12
   Dufkova L, 2019, VACCINE, V37, P4710, DOI 10.1016/j.vaccine.2017.12.028
   Fendrich V, 2012, SCI WORLD J, DOI 10.1100/2012/529151
   Fooks AR, 2014, LANCET, V384, P1389, DOI 10.1016/S0140-6736(13)62707-5
   Gnanadurai CW, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002375
   Gonzales-Portillo GS, 2014, CELL TRANSPLANT, V23, P531, DOI 10.3727/096368914X678337
   Gowen BB, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002614
   Healy DM, 2013, VIRUS RES, V172, P46, DOI 10.1016/j.virusres.2012.12.011
   Hemachudha T, 2013, LANCET NEUROL, V12, P498, DOI 10.1016/S1474-4422(13)70038-3
   Huang CT, 2014, ANTIVIR RES, V110, P132, DOI 10.1016/j.antiviral.2014.07.013
   Jackson AC, 2014, J NEUROL SCI, V339, P5, DOI 10.1016/j.jns.2014.02.012
   Jackson AC, 2013, ANTIVIR RES, V99, P61, DOI 10.1016/j.antiviral.2013.01.003
   Kip E, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.12
   Koraka P, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00397
   Laothamatas J, 2008, J NEUROVIROL, V14, P119, DOI 10.1080/13550280701883857
   Li JW, 2012, J VIROL, V86, P3200, DOI 10.1128/JVI.06699-11
   ligo M, 1997, CANCER IMMUNOL IMMUN, V44, P65, DOI [10.1007/s0026200.5035.6, DOI 10.1007/S0026200.5035.6]
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   Louboutin JP, 2010, NAT METHODS, V7, P905, DOI 10.1038/nmeth.1518
   Madhusudana SN, 2013, HUM VACC IMMUNOTHER, V9, P1914, DOI 10.4161/hv.25431
   Manjunatha V, 2017, MICROB PATHOGENESIS, V112, P38, DOI 10.1016/j.micpath.2017.09.044
   Marosi A, 2019, VACCINE, V37, P4663, DOI 10.1016/j.vaccine.2018.01.082
   Mehta S., 2015, VirusDisease, V26, P163, DOI 10.1007/s13337-015-0269-5
   Miao FM, 2017, ARCH VIROL, V162, P247, DOI 10.1007/s00705-016-3081-7
   Morimoto K, 1996, P NATL ACAD SCI USA, V93, P5653, DOI 10.1073/pnas.93.11.5653
   Nakamichi K, 2005, J VIROL, V79, P11801, DOI 10.1128/JVI.79.18.11801-11812.2005
   Oestereich L, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002804
   OIE, 2013, MANUAL DIAGNOSTIC TE
   Park CH, 2006, J VET MED SCI, V68, P589, DOI 10.1292/jvms.68.589
   Roy A, 2007, J VIROL, V81, P7993, DOI 10.1128/JVI.00710-07
   Katz ISS, 2017, ARCH VIROL, V162, P3251, DOI 10.1007/s00705-017-3484-0
   Smreczak M, 2019, VACCINE, V37, P4701, DOI 10.1016/j.vaccine.2018.04.003
   Sonntag R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.557
   Sugiura N, 2011, JPN J INFECT DIS, V64, P463
   Wakeley PR, 2005, J CLIN MICROBIOL, V43, P2786, DOI 10.1128/JCM.43.6.2786-2792.2005
   Westover JB, 2016, ANTIVIR RES, V126, P62, DOI 10.1016/j.antiviral.2015.12.006
   Weyer J, 2016, SOUTH AFR J INFECT D, V31, P66, DOI 10.1080/23120053.2016.1128151
   Yamada K, 2016, J INFECT DIS, V213, P1253, DOI 10.1093/infdis/jiv586
NR 44
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4724
EP 4735
DI 10.1016/j.vaccine.2018.05.066
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000011
PM 29805091
DA 2020-05-12
ER

PT J
AU Martina, BEE
   Smreczak, M
   Orlowska, A
   Marzec, A
   Trebas, P
   Roose, JM
   Zmudzinski, J
   Gerhauser, I
   Wohlsein, P
   Baumgartner, W
   Osterhaus, ADME
   Koraka, P
AF Martina, Byron E. E.
   Smreczak, Marcin
   Orlowska, Anna
   Marzec, Anna
   Trebas, Pawel
   Roose, Jouke M.
   Zmudzinski, Jan
   Gerhauser, Ingo
   Wohlsein, Peter
   Baumgaertner, Wolfgang
   Osterhaus, Albert D. M. E.
   Koraka, Penelope
TI Combination drug treatment prolongs survival of experimentally infected
   mice with silver-haired bat rabies virus
SO VACCINE
LA English
DT Article
DE Rabies; Therapy; Combination treatment; Blood-brain barrier
ID IMMUNE-RESPONSES; ALPHA; APOPTOSIS; MANNITOL; STRAINS; BARRIER
AB Rabies is a lethal disease in humans and animals, killing approximately 60,000 people every year. Currently, there is no treatment available, except post-exposure prophylaxis (PEP) that can be administered whenever exposure to a rabid animal took place. Here we describe the beneficial effects of a combination treatment initiated at day 4 post infection, containing anti-viral drugs and immune modulators in infected mice. Combination therapy resulted in significant increase in survival time (P < 0.05) and significantly lowers viral RNA in the brain and spinal cord (P < 0.05). Furthermore, treatment influenced markers of pyroptosis and apoptosis and early inflammatory response as measured by the levels of TNF-alpha. Morphological lesions were absent in rabies virus infected mice with few signs of inflammation. However, these were not significant between the different groups. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Martina, Byron E. E.; Roose, Jouke M.; Osterhaus, Albert D. M. E.] Artemis One Hlth Res Fdn, Delft, Netherlands.
   [Martina, Byron E. E.; Koraka, Penelope] Erasmus MC, Rotterdam, Netherlands.
   [Smreczak, Marcin; Orlowska, Anna; Marzec, Anna; Trebas, Pawel; Zmudzinski, Jan] Natl Vet Res Inst, Dept Virol, Partyzantow 57 Ave, PL-24100 Pulawy, Poland.
   [Osterhaus, Albert D. M. E.] Univ Vet Med, Res Ctr Emerging Infect & Zoonoses RIZ, Hannover, Germany.
   [Gerhauser, Ingo; Wohlsein, Peter; Baumgaertner, Wolfgang] Univ Vet Med Hannover, Dept Pathol, Hannover, Germany.
   [Baumgaertner, Wolfgang] Ctr Syst Neurosci ZSN, Hannover, Germany.
RP Koraka, P (reprint author), Viroclin Biosci BV, Rotterdam, Netherlands.
EM koraka@viroclinics.com
RI Smreczak, Marcin/AAL-1027-2020; Grzadziel, Anna Marzec/AAB-5497-2019;
   Smreczak, Marcin/D-2168-2012
OI Grzadziel, Anna Marzec/0000-0002-0589-0714; 
FU EU FP7 project ASKLEPIOS [602825]; Niedersachsen Research Network on
   Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of
   Lower Saxony
FX This study was funded through EU FP7 project ASKLEPIOS (602825). The
   authors would like to thank all partners (and their teams) and
   scientific advisors of ASKLEPIOS consortium for fruitful discussions:
   Antony Fooks (AHPA, UK), Tamas Bakonyi (Szent Istavan Egyetem, Hungary),
   Miklos Gyuranecz (Center for Agricultural research, the Hungarian
   Academy of Science, Hungary), Daniel Ruzek (Veterinary Research
   Institute, Czech Republic), Johan Neyts (Katholieke Universiteit Leuven,
   Belgium), Noel Tordo (Institute Pasteur, France), Thomas Mailer
   (Friedrich-Loeffler-Institut, Germany), Charles E. Rupprecht (Global
   Alliance for Rabies Control, USA), Pieter P. van Thiel (Amsterdam
   Medical Centre, The Netherlands). This study was in part supported by
   the Niedersachsen Research Network on Neuroinfectiology (N-RENNT) of the
   Ministry of Science and Culture of Lower Saxony.
CR Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236
   Appolinario CM, 2016, AM J TROP MED HYG, V94, P378, DOI 10.4269/ajtmh.15-0361
   Banyard AC, 2019, VACCINE, V37, P4686, DOI 10.1016/j.vaccine.2017.10.109
   Bartanusz V, 2011, ANN NEUROL, V70, P194, DOI 10.1002/ana.22421
   Basgoz N, 1998, NEW ENGL J MED, V339, P105, DOI 10.1056/NEJM199807093390208
   Brookes SM, 2006, DEV BIOLOGICALS, V125, P185
   Brown RC, 2004, BRAIN RES, V1014, P221, DOI 10.1016/j.brainres.2004.04.034
   Camelo S, 2000, J NEUROVIROL, V6, P507, DOI 10.3109/13550280009091951
   de Souza A, 2014, J NEUROL SCI, V339, P8, DOI 10.1016/j.jns.2014.02.013
   Fooks AR, 2014, LANCET, V384, P1389, DOI 10.1016/S0140-6736(13)62707-5
   Ho DH, 2017, BIOCHEM BIOPH RES CO, V482, P1088, DOI 10.1016/j.bbrc.2016.11.163
   Hooper DC, 2005, J NEUROVIROL, V11, P88, DOI 10.1080/13550280590900418
   Jackson AC, 2003, CLIN INFECT DIS, V36, P60, DOI 10.1086/344905
   Karber G., 1931, ARCH EXP PHARMKOL, V162
   Kesdangsakonwut S, 2014, NEUROPATHOLOGY, V34, P277, DOI 10.1111/neup.12094
   Koraka P, 2019, VACCINE, V37, P4681, DOI 10.1016/j.vaccine.2018.04.002
   Koraka P, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00397
   Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631
   Marosi A, 2019, VACCINE, V37, P4663, DOI 10.1016/j.vaccine.2018.01.082
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000
   Sharma N, 2015, NEUROCHEM INT, V87, P92, DOI 10.1016/j.neuint.2015.06.004
   Shi JF, 2010, VACCINE, V28, P2573, DOI [10.1016/j.vaccine.2010.08.082, 10.1016/j.vaccine.2010.01.051]
   SINCHAISRI TA, 1992, J VET MED SCI, V54, P409, DOI 10.1292/jvms.54.409
   Smreczak M, 2019, VACCINE, V37, P4715, DOI 10.1016/j.vaccine.2017.10.098
   Smreczak M, 2019, VACCINE, V37, P4701, DOI 10.1016/j.vaccine.2018.04.003
   Soares-Silva M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00183
   Tan MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.348
   Wakeley PR, 2005, J CLIN MICROBIOL, V43, P2786, DOI 10.1128/JCM.43.6.2786-2792.2005
   Wang KZ, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0853-2
   Wang ZW, 2005, J VIROL, V79, P12554, DOI 10.1128/JVI.79.19.12554-12565.2005
   WARRELL MJ, 1989, BMJ-BRIT MED J, V299, P830, DOI 10.1136/bmj.299.6703.830
NR 32
TC 2
Z9 3
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4736
EP 4742
DI 10.1016/j.vaccine.2018.05.065
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000012
PM 29843998
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Smith, TG
   Millien, M
   Vos, A
   Fracciterne, FA
   Crowdis, K
   Chirodea, C
   Medley, A
   Chipman, R
   Qin, YL
   Blanton, J
   Wallace, R
AF Smith, Todd G.
   Millien, Max
   Vos, Ad
   Fracciterne, Franso A.
   Crowdis, Kelly
   Chirodea, Cornelius
   Medley, Alexandra
   Chipman, Richard
   Qin, Yunlong
   Blanton, Jesse
   Wallace, Ryan
TI Evaluation of immune responses in dogs to oral rabies vaccine under
   field conditions
SO VACCINE
LA English
DT Article
DE Rabies virus; Canine rabies vaccine; Oral rabies vaccine; Immune
   response; Serology
ID CANINE RABIES; VIRUS; SAG2; BAITS; EFFICACY; RACCOONS; COVERAGE;
   NDJAMENA; SPREAD; SAFETY
AB During the 20th century parenteral vaccination of dogs at central-point locations was the foundation of successful canine rabies elimination programs in numerous countries. However, countries that remain enzootic for canine rabies have lower infrastructural development compared to countries that have achieved elimination, which may make traditional vaccination methods less successful. Alternative vaccination methods for dogs must be considered, such as oral rabies vaccine (ORV). In 2016, a traditional mass dog vaccination campaign in Haiti was supplemented with ORV to improve vaccination coverage and to evaluate the use of ORV in dogs. Blisters containing live-attenuated, vaccine strain SPBNGAS-GAS were placed in intestine bait and distributed to dogs by hand. Serum was collected from 107 dogs, aged 3-12 months with no reported prior rabies vaccination, pre-vaccination and from 78/107 dogs (72.9%) 17 days post-vaccination. The rapid florescent focus inhibition test (RFFIT) was used to detect neutralizing antibodies and an ELISA to detect rabies binding antibodies. Post-vaccination, 38/41 (92.7%) dogs that received parenteral vaccine had detectable antibody (REFIT >0.05 IU/mL), compared to 16/27 (59.3%, p < 0.01) dogs that received ORV or 21/27 (77.8%) as measured by ELISA (>40% blocking, p < 0.05). The fate of 291 oral vaccines was recorded; 283 dogs (97.2%) consumed the bait; 272 dogs (93.4%) were observed to puncture the blister, and only 14 blisters (4.8%) could not be retrieved by vaccinators and were potentially left in the environment. Pre-vaccination antibodies (RFFIT >0.05 IU/mL) were detected in 10/107 reportedly vaccine-naive dogs (9.3%). Parenteral vaccination remains the most reliable method for ensuring adequate immune response in dogs, however ORV represents a viable strategy to supplement existing parental vaccination campaigns in hard-to-reach dog populations. The hand-out model reduces the risk of unintended contact with ORV through minimizing vaccine blisters left in the community. Published by Elsevier Ltd.
C1 [Smith, Todd G.; Medley, Alexandra; Qin, Yunlong; Blanton, Jesse; Wallace, Ryan] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd NE, Atlanta, GA 30329 USA.
   [Millien, Max] Minist Agr Nat Resources & Rural Dev, Port Au Prince, Haiti.
   [Vos, Ad] IDT Biol GmbH, D-06861 Dessau Rosslau, Germany.
   [Fracciterne, Franso A.] Haiti Vet Serv, Port Au Prince, Haiti.
   [Crowdis, Kelly; Chirodea, Cornelius] Christian Vet Mission, Port Au Prince, Haiti.
   [Chipman, Richard] USDA, Wildlife Serv, Natl Rabies Management Program, Concord, NH USA.
RP Smith, TG (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, 1600 Clifton Rd NE, Atlanta, GA 30329 USA.
FU Humane Society International; Solution One Industries, Inc.; CDCCentre
   National de la Recherche Scientifique (CNRS)United States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
FX We thank David Guerrier and Emanuel Maciel for assistance in the field;
   Humane Society International, Richard Franka, Michael Niezgoda, Emily
   Pieracci, Mary Reynolds, Jennifer McQuiston, and Inger Damon for support
   of this study. Supported in part by a contract between Solution One
   Industries, Inc. and CDC. This research did not receive any specific
   grant from funding agencies in the public, commercial, or not-for-profit
   sectors.
CR Anderson A, 2015, TRANSBOUND EMERG DIS, V62, P446, DOI 10.1111/tbed.12168
   Anyiam F., 2016, ACTA TROP
   Babes V., 1912, TRAITE RAGE
   BALTAZARD M, 1954, Bull World Health Organ, V10, P797
   Ben Youssef S, 1998, AM J TROP MED HYG, V58, P835, DOI 10.4269/ajtmh.1998.58.835
   Berentsen AR, 2016, J VET BEHAV, V15, P20, DOI 10.1016/j.jveb.2016.08.007
   Berentsen AR, 2015, J WILDLIFE DIS, V51, P896, DOI 10.7589/2015-01-016
   BIGLER WJ, 1973, AM J EPIDEMIOL, V98, P326, DOI 10.1093/oxfordjournals.aje.a121562
   Blanton JD, 2007, VACCINE, V25, P7296, DOI 10.1016/j.vaccine.2007.08.004
   Castillo-Neyra R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005460
   Chang JC, 2015, J WILDLIFE DIS, V51, P923, DOI 10.7589/2015-04-090
   Cliquet F, 2007, VACCINE, V25, P3409, DOI 10.1016/j.vaccine.2006.12.054
   Cliquet F, 2003, REV SCI TECH OIE, V22, P857, DOI 10.20506/rst.22.3.1437
   Cliquet F, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001535
   Darkaoui S, 2014, CLIN EXP VACCINE RES, V3, P220, DOI 10.7774/cevr.2014.3.2.220
   Ellison JA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003070
   Elser JL, 2018, TRANSBOUND EMERG DIS, V65, P135, DOI 10.1111/tbed.12637
   Estrada R, 2001, BMC INFECT DIS, V1, part. no., DOI 10.1186/1471-2334-1-23
   Faber M, 2005, J VIROL, V79, P14141, DOI 10.1128/JVI.79.22.14141-14148.2005
   Faber M, 2002, J VIROL, V76, P3374, DOI 10.1128/JVI.76.7.3374-3381.2002
   Fleiss Joseph L., 2013, STAT METHODS RATES P
   Fooks AR, 2014, LANCET, V384, P1389, DOI 10.1016/S0140-6736(13)62707-5
   FRONTINI MG, 1992, AM J TROP MED HYG, V47, P310, DOI 10.4269/ajtmh.1992.47.310
   Gibson AD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004824
   Hammami S, 1999, VET RES, V30, P353
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Jackman J., 2007, STATE ANIMALS, P55
   Kayali U, 2003, B WORLD HEALTH ORGAN, V81, P739
   Kennedy LJ, 2007, VACCINE, V25, P8500, DOI 10.1016/j.vaccine.2007.10.015
   Lankester FJ, 2016, VACCINE, V34, P5504, DOI 10.1016/j.vaccine.2016.10.015
   Lechenne M, 2016, VACCINE, V34, P571, DOI 10.1016/j.vaccine.2015.11.033
   Moore Susan M, 2017, Trop Med Infect Dis, V2, DOI 10.3390/tropicalmed2030031
   Moore SM, 2016, BIOLOGICALS, V44, P481, DOI 10.1016/j.biologicals.2016.09.007
   Muthiani Y, 2015, PREV VET MED, V120, P203, DOI 10.1016/j.prevetmed.2015.04.007
   Orciari LA, 2001, VACCINE, V19, P4511, DOI 10.1016/S0264-410X(01)00186-4
   Pimburage RMS, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1038-z
   Robbins AH, 1998, J AM VET MED ASSOC, V213, P1407
   Schildecker S, 2017, TRANSBOUND EMERG DIS, V64, P1433, DOI 10.1111/tbed.12531
   Sidwa TJ, 2005, JAVMA-J AM VET MED A, V227, P785, DOI 10.2460/javma.2005.227.785
   Sillero-Zubiri C, 2016, VACCINE, V34, P4792, DOI 10.1016/j.vaccine.2016.08.021
   Smith TG, 2013, VACCINE, V31, P3333, DOI 10.1016/j.vaccine.2013.05.081
   Wallace RM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005761
   Wallace RM, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00009
   Wallace RM, 2016, EMERG INFECT DIS, V22, P1963, DOI 10.3201/eid2211.160826
   Wallace RM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004245
   World Health Organization, 2007, OR VACC DOGS RAB
   World Health Organization, 1988, REP WHO CONS DOG EC
   Yager ML, 2015, CURRENT LAB TECHNIQU, V2, P199, DOI DOI 10.1016/B978-0-12-801919-1.00017-8
   Zienius D, 2011, ACTA VET SCAND, V53, DOI 10.1186/1751-0147-53-58
NR 49
TC 5
Z9 5
U1 4
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4743
EP 4749
DI 10.1016/j.vaccine.2017.09.096
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000013
PM 29054727
DA 2020-05-12
ER

PT J
AU Freuling, CM
   Eggerbauer, E
   Finke, S
   Kaiser, C
   Kaiser, C
   Kretzschmar, A
   Nolden, T
   Ortmann, S
   Schroder, C
   Teifke, JP
   Schuster, P
   Vos, A
   Mettenleiter, TC
   Muller, T
AF Freuling, Conrad M.
   Eggerbauer, Elisa
   Finke, Stefan
   Kaiser, Christiane
   Kaiser, Christian
   Kretzschmar, Antje
   Nolden, Tobias
   Ortmann, Steffen
   Schroeder, Charlotte
   Teifke, Jens P.
   Schuster, Peter
   Vos, Ad
   Mettenleiter, Thomas C.
   Mueller, Thomas
TI Efficacy of the oral rabies virus vaccine strain SPBN GASGAS in foxes
   and raccoon dogs
SO VACCINE
LA English
DT Article
DE Oral rabies vaccines; Rabies; Genetically engineered vaccine; Wildlife;
   Efficacy; Immunogenicity; SPBN GASGAGS
ID RECOMBINANT RABIES; VULPES-VULPES; RED FOXES; TERRESTRIAL RABIES; CANINE
   ADENOVIRUS; STRIPED SKUNKS; DOMESTIC DOG; ERA VACCINE; FIELD TRIAL; SAD
   B19
AB To test the immunogenicity and efficacy of a new oral rabies virus vaccine strain SPBN GASGAS in wildlife target species, one group of foxes and two groups of raccoon dogs were offered a bait containing 1.7 ml of the vaccine (10(6.6) FFU/ml; 10(6.8) FFU/close) and subsequently challenged approximately 180 days later with a fox rabies virus isolate. One group of raccoon dogs (n = 30) received the same challenge dose (10(0.7) MICLD50/ml) as the red foxes (n = 29). The other group with raccoon dogs (n = 28) together with 8 animals that received the vaccine dose by direct instillation into the oral cavity (DIOC) were infected with a 40-fold higher dose of the challenge virus (10(2.3 )MICLD(50)/ml). All but one of the 29 vaccinated foxes survived the challenge infection; meanwhile all 12 control foxes succumbed to rabies. Twenty-eight of 30 vaccinated raccoon dogs challenged with the same dose survived the infection, however only six of 12 control animals succumbed. When the higher challenge dose was administered, all 12 control animals died from rabies and all 36 vaccinated animals (28 baited plus 8 DIOC) survived. Blood samples were collected at different time points post vaccination and examined by both RFFIT and ELISA. The kinetics of the measured immune response was similar for both species, although in RFFIT slightly higher values were observed in foxes than in raccoon dogs. However, the immune response as measured in ELISA was identical for both species. The oral rabies virus vaccine SPBN GASGAS meets the efficacy requirements for live rabies virus vaccines as laid down by the European Pharmacopoeia. (C) 2017 The Authors. Published by Elsevier Ltd.
C1 [Freuling, Conrad M.; Eggerbauer, Elisa; Finke, Stefan; Mettenleiter, Thomas C.; Mueller, Thomas] WHO, Collaborating Ctr Rabies Surveillance & Res, OIE Reference Lab Rabies, Friedrich Loeffler Inst,Inst Mol Virol & Cell Bio, D-17493 Greifswald, Germany.
   [Schroeder, Charlotte; Teifke, Jens P.] Friedrich Loeffler Inst, Dept Expt Anim Facil & Bior Management, D-17493 Greifswald, Germany.
   [Kaiser, Christiane; Kaiser, Christian; Kretzschmar, Antje; Ortmann, Steffen; Schuster, Peter; Vos, Ad] IDT Biol GmbH, D-06861 Dessau Rosslau, Germany.
   [Nolden, Tobias] ViraTherapeut, A-6020 Innsbruck, Austria.
RP Muller, T (reprint author), WHO, Collaborating Ctr Rabies Surveillance & Res, OIE Reference Lab Rabies, Friedrich Loeffler Inst,Inst Mol Virol & Cell Bio, D-17493 Greifswald, Germany.
EM Thomas.Mueller@fli.de
CR Artois M, 1997, VET REC, V140, P57, DOI 10.1136/vr.140.3.57
   ARTOIS M, 1992, VACCINE, V10, P524, DOI 10.1016/0264-410X(92)90351-J
   ARTOIS M, 1993, VET MICROBIOL, V38, P167, DOI 10.1016/0378-1135(93)90083-J
   BAER GM, 1989, AM J VET RES, V50, P836
   Bankovskiy D, 2008, DEV BIOLOGICALS, V131, P461
   Berg C, 2015, EFSA J, V13, DOI 10.2903/j.efsa.2015.4164
   BLACK JG, 1980, CAN J COMP MED, V44, P169
   BLANCOU J, 1989, ANN RECH VET, V20, P195
   BLANCOU J, 1986, NATURE, V322, P373, DOI 10.1038/322373a0
   Blancou J., 1986, VIRAL INFECTIONS, P134
   Blanton JD, 2007, VACCINE, V25, P7296, DOI 10.1016/j.vaccine.2007.08.004
   Bourhy H, 1999, J GEN VIROL, V80, P2545, DOI 10.1099/0022-1317-80-10-2545
   Brochier B, 2001, ANN MED VET, V145, P293
   BROCHIER BM, 1990, VET REC, V127, P165
   Brown LJ, 2014, VACCINE, V32, P3675, DOI 10.1016/j.vaccine.2014.04.029
   Brown LJ, 2014, VACCINE, V32, P984, DOI 10.1016/j.vaccine.2013.12.015
   Cliquet F, 2008, DEV BIOLOGICALS, V131, P257
   Cliquet F, 2006, VACCINE, V24, P4386, DOI 10.1016/j.vaccine.2006.02.057
   Cliquet F, 2006, DEV BIOLOGICALS, V125, P119
   Cliquet F, 1998, J IMMUNOL METHODS, V212, P79, DOI 10.1016/S0022-1759(97)00212-3
   Cliquet F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141537
   Cliquet F, 2014, EXPERT REV ANTI-INFE, V12, P905, DOI 10.1586/14787210.2014.921570
   Cliquet F, 2013, ANTIVIR RES, V100, P84, DOI 10.1016/j.antiviral.2013.07.012
   COX JH, 1976, J CLIN MICROBIOL, V3, P96
   Dean D. J., 1996, P88
   European Commission, OR VACC FOX RAB
   Faber M, 2005, J VIROL, V79, P15405, DOI 10.1128/JVI.79.24.15405-15416.2005
   Faber M, 2005, J VIROL, V79, P14141, DOI 10.1128/JVI.79.22.14141-14148.2005
   Faber M, 2002, J VIROL, V76, P3374, DOI 10.1128/JVI.76.7.3374-3381.2002
   Faber M, 2009, ZOONOSES PUBLIC HLTH, V56, P262, DOI 10.1111/j.1863-2378.2008.01215.x
   Fehiner-Gardiner C, 2008, J WILDLIFE DIS, V44, P71
   Fehlner-Gardiner C, 2012, J WILDLIFE DIS, V48, P157, DOI 10.7589/0090-3558-48.1.157
   FLAMAND A, 1993, VIROLOGY, V194, P302, DOI 10.1006/viro.1993.1261
   Follmann EH, 2004, J WILDLIFE DIS, V40, P328, DOI 10.7589/0090-3558-40.2.328
   Freuling CM, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0142
   Gnanadurai CW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004023
   Guzel T., 1998, J ETLIK VET MICROBIO, V1998, P103
   Hartinger J, 2000, ALTEX, V18, P37
   Hoper D, 2015, VACCINE, V33, P5829, DOI 10.1016/j.vaccine.2015.08.091
   Hostnik P, 2014, J WILDLIFE DIS, V50, P397, DOI 10.7589/2013-07-183
   Irie T, 2002, J GEN VIROL, V83, P3045, DOI 10.1099/0022-1317-83-12-3045
   Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914
   KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0
   Kuzmin IV, 2004, J WILDLIFE DIS, V40, P617, DOI 10.7589/0090-3558-40.4.617
   LAFAY F, 1994, VACCINE, V12, P317, DOI 10.1016/0264-410X(94)90095-7
   Lawson KF, 1997, CAN J VET RES, V61, P39
   Li JW, 2012, J VIROL, V86, P3200, DOI 10.1128/JVI.06699-11
   MacInnes CD, 2001, J WILDLIFE DIS, V37, P119, DOI 10.7589/0090-3558-37.1.119
   Mahl P, 2014, VET RES, V45, DOI 10.1186/s13567-014-0077-8
   Mebatsion T, 2001, J VIROL, V75, P11496, DOI 10.1128/JVI.75.23.11496-11502.2001
   Mebatsion T., 2001, VIROLOGY R D, V1, P1
   Moore SM, 2005, BIOLOGICALS, V33, P269, DOI 10.1016/j.biologicals.2005.06.005
   Moore SM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000595
   Muller T, 2006, DEV BIOLOGICALS, V125, P195
   Muller T, 2015, VET J, V203, P10, DOI 10.1016/j.tvjl.2014.10.026
   Muller T, 2009, ARCH VIROL, V154, P1081, DOI 10.1007/s00705-009-0408-7
   Muller TF, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003953
   Neubert A, 2001, J VET MED B, V48, P179, DOI 10.1046/j.1439-0450.2001.00440.x
   OIE, 2017, MANUAL DIAGNOSTIC TE, P1
   Picard-Meyer E, 2012, ARCH VIROL, V157, P1689, DOI 10.1007/s00705-012-1351-6
   PREVEC L, 1990, J INFECT DIS, V161, P27, DOI 10.1093/infdis/161.1.27
   Rieder M, 2011, J VIROL, V85, P842, DOI 10.1128/JVI.01427-10
   Rosatte RC, 2007, EMERG INFECT DIS, V13, P25, DOI 10.3201/eid1301.060622
   Rosatte RC, 2009, J WILDLIFE DIS, V45, P363, DOI 10.7589/0090-3558-45.2.363
   Schneider L, 1986, Deutschland patent, Patent No. [0210552B1, 0210552]
   SCHNEIDER LG, 1983, TIERARZTL UMSCHAU, V38, P315
   SCHNELL MJ, 1994, EMBO J, V13, P4195, DOI 10.1002/j.1460-2075.1994.tb06739.x
   Schuster P, 2001, ACTA VET HUNG, V49, P285, DOI 10.1556/AVet.49.2001.3.4
   Schutsky K, 2013, J VIROL, V87, P1834, DOI 10.1128/JVI.02589-12
   Slate D, 2014, J WILDLIFE DIS, V50, P582, DOI 10.7589/2013-08-207
   Slate D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000549
   Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x
   Turcitu MA, 2010, VIRUS RES, V150, P28, DOI 10.1016/j.virusres.2010.02.008
   Vos A, 1999, EPIDEMIOL INFECT, V123, P165, DOI 10.1017/S0950268899002666
   Vuta V, 2016, VACCINE, V34, P5021, DOI 10.1016/j.vaccine.2016.08.013
   Wachendorfer G., 1992, P19
   Wasniewski M, 2013, J VIROL METHODS, V187, P264, DOI 10.1016/j.jviromet.2012.11.022
   Wasniewski M, 2012, J VIROL METHODS, V179, P166, DOI 10.1016/j.jviromet.2011.10.019
   Webster WA, 1996, LAB TECHNIQUES RABIE, P93
   Weyer J, 2007, VACCINE, V25, P4213, DOI 10.1016/j.vaccine.2007.02.084
   WHO, 2005, WHO TECH REP SER, V931, P1
   WHO, 2013, WHO TECH REP SER, V982, P1
   Wright N, 2013, VACCINE, V31, P4177, DOI 10.1016/j.vaccine.2013.06.089
   Xiang ZQ, 1996, VIROLOGY, V219, P220, DOI 10.1006/viro.1996.0239
   Zhang SF, 2008, VACCINE, V26, P345, DOI 10.1016/j.vaccine.2007.11.029
NR 85
TC 5
Z9 5
U1 2
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4750
EP 4757
DI 10.1016/j.vaccine.2017.09.093
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000014
PM 29042202
OA Other Gold
DA 2020-05-12
ER

PT J
AU Pfaff, F
   Muller, T
   Freuling, CM
   Fehlner-Gardiner, C
   Nadin-Davis, S
   Robardet, E
   Cliquet, F
   Vuta, V
   Hostnik, P
   Mettenleiter, TC
   Beer, M
   Hoper, D
AF Pfaff, Florian
   Mueller, Thomas
   Freuling, Conrad M.
   Fehlner-Gardiner, Christine
   Nadin-Davis, Susan
   Robardet, Emmanuelle
   Cliquet, Florence
   Vuta, Vlad
   Hostnik, Peter
   Mettenleiter, Thomas C.
   Beer, Martin
   Hoeper, Dirk
TI In-depth genome analyses of viruses from vaccine-derived rabies cases
   and corresponding live-attenuated oral rabies vaccines
SO VACCINE
LA English
DT Article
DE Vaccine-derived rabies; Live-attenuated vaccines; Viral populations;
   Deep sequencing; Population distances
ID FOXES VULPES-VULPES; RED FOXES; RNA VIRUS; TERRESTRIAL RABIES;
   PATHOGENICITY; ELIMINATION; POPULATION; STRAIN; WILDLIFE; GERMANY
AB Live-attenuated rabies virus strains such as those derived from the field isolate Street Alabama Dufferin (SAD) have been used extensively and very effectively as oral rabies vaccines for the control of fox rabies in both Europe and Canada. Although these vaccines are safe, some cases of vaccine-derived rabies have been detected during rabies surveillance accompanying these campaigns. In recent analysis it was shown that some commercial SAD vaccines consist of diverse viral populations, rather than clonal genotypes. For cases of vaccine-derived rabies, only consensus sequence data have been available to date and information concerning their population diversity was thus lacking.
   In our study, we used high-throughput sequencing to analyze 11 cases of vaccine-derived rabies, and compared their viral population diversity to the related oral rabies vaccines using pairwise Manhattan distances. This extensive deep sequencing analysis of vaccine-derived rabies cases observed during oral vaccination programs provided deeper insights into the effect of accidental in vivo replication of genetically diverse vaccine strains in the central nervous system of target and non-target species under field conditions. The viral population in vaccine-derived cases appeared to be clonal in contrast to their parental vaccines. The change from a state of high population diversity present in the vaccine batches to a clonal genotype in the affected animal may indicate the presence of a strong bottleneck during infection. In conclusion, it is very likely that these few cases are the consequence of host factors and not the result of the selection of a more virulent genotype. Furthermore, this type of vaccine-derived rabies leads to the selection of clonal genotypes and the selected variants were genetically very similar to potent SAD vaccines that have undergone a history of in vitro selection. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Pfaff, Florian; Beer, Martin; Hoeper, Dirk] Friedrich Loeffler Inst, Inst Diagnost Virol, Fed Res Inst Anim Hlth, Greifswald, Germany.
   [Mueller, Thomas; Freuling, Conrad M.; Mettenleiter, Thomas C.] Friedrich Loeffler Inst, Inst Mol Virol & Cell Biol, Fed Res Inst Anim Hlth, Greifswald, Germany.
   [Fehlner-Gardiner, Christine; Nadin-Davis, Susan] Canadian Food Inspect Agcy, Ottawa Lab Fallowfield, Ctr Expertise Rabies, Ottawa, ON, Canada.
   [Robardet, Emmanuelle; Cliquet, Florence] French Agcy Food Environm & Occupat Hlth & Safety, Nancy Lab Rabies & Wildlife, Malzeville, France.
   [Vuta, Vlad] Univ Agron Study & Vet Med, Fac Vet Med, Inst Diag & Anim Hlth, Bucharest, Romania.
   [Hostnik, Peter] Univ Ljubljana, Vet Fac, Inst Microbiol & Parasitol, Virol Unit, Ljubljana, Slovenia.
RP Hoper, D (reprint author), Friedrich Loeffler Inst, Inst Diagnost Virol, Fed Res Inst Anim Hlth, Greifswald, Germany.
EM Florian.Pfaff@fli.de; Thomas.Mueller@fli.de; Conrad.Freuling@fli.de;
   Christine.Fehlner-Gardiner@inspection.gc.ca;
   Susan.Nadin-Davis@inspection.gc.ca; Emmanuelle.ROBARDET@anses.fr;
   Florence.CLIQUET@anses.fr; vuta.vlad@idah.ro;
   peter.hostnik@vf.uni-lj.si; ThomasC.Mettenleiter@fli.de;
   Martin.Beer@fli.de; Dirk.Hoeper@fli.de
OI CLIQUET, Florence/0000-0003-2237-1243; Pfaff,
   Florian/0000-0003-0178-6183
FU intramural collaborative research grant on Lyssaviruses at the
   Friedrich-Loeffler-Institut [Ri-0373]
FX This study was supported by an intramural collaborative research grant
   on Lyssaviruses at the Friedrich-Loeffler-Institut [grant number
   Ri-0373]. We gratefully acknowledge Patrick Zitzow and Jeannette Kliemt
   for excellent technical assistance. Furthermore, we thank Mr. Alex
   Beath, Artemis Technologies, Inc. (Guelph, Canada), for providing the
   ERA vaccine lot 016, Dr. Adriaan Vos, IDT Biologika GmbH (Dessau,
   Germany) for providing SAD B19 vaccine lots, and Dr. Vladimir Vrzal,
   Bioveta, a.s. (Ivanovice na Haile, Czech Republic), for providing SAD
   Bern vaccine lots.
CR Abelseth M K, 1964, Can Vet J, V5, P84
   Artois M, 1997, VET REC, V140, P57, DOI 10.1136/vr.140.3.57
   ARTOIS M, 1992, VACCINE, V10, P524, DOI 10.1016/0264-410X(92)90351-J
   BAER GM, 1971, AM J EPIDEMIOL, V93, P487, DOI 10.1093/oxfordjournals.aje.a121283
   Bankovskiy D, 2008, DEV BIOLOGICALS, V131, P461
   BINGHAM J, 1992, VET REC, V131, P55, DOI 10.1136/vr.131.3.55
   Bonneau KR, 2001, J VIROL, V75, P8298, DOI 10.1128/JVI.75.17.8298-8305.2001
   Minh BQ, 2013, MOL BIOL EVOL, V30, P1188, DOI 10.1093/molbev/mst024
   CANN AJ, 1984, NUCLEIC ACIDS RES, V12, P7787, DOI 10.1093/nar/12.20.7787
   Cliquet F, 2004, DEV BIOLOGICALS, V119, P185
   Cliquet F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141537
   Davlin SL, 2012, VACCINE, V30, P3492, DOI 10.1016/j.vaccine.2012.03.069
   DEBBIE JG, 1972, AM J EPIDEMIOL, V96, P231, DOI 10.1093/oxfordjournals.aje.a121453
   Eggerbauer E, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005668
   ESH JB, 1982, J AM VET MED ASSOC, V180, P1336
   Fehiner-Gardiner C, 2008, J WILDLIFE DIS, V44, P71
   FEKADU M, 1993, ONDERSTEPOORT J VET, V60, P421
   FENJE P, 1960, CAN J MICROBIOL, V6, P480, DOI 10.1139/m60-055
   Fooks AR, 2014, LANCET, V384, P1389, DOI 10.1016/S0140-6736(13)62707-5
   Freuling CM, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0142
   Geue L, 2008, VACCINE, V26, P3227, DOI 10.1016/j.vaccine.2008.04.007
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hanke D, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004779
   Hoper D, 2015, VACCINE, V33, P5829, DOI 10.1016/j.vaccine.2015.08.091
   Hostnik P, 2014, J WILDLIFE DIS, V50, P397, DOI 10.7589/2013-07-183
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Kew OM, 2005, ANNU REV MICROBIOL, V59, P587, DOI 10.1146/annurev.micro.58.030603.123625
   Kissi B, 1999, J GEN VIROL, V80, P2041, DOI 10.1099/0022-1317-80-8-2041
   LAFAY F, 1994, VACCINE, V12, P317, DOI 10.1016/0264-410X(94)90095-7
   Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300
   Li HY, 2004, J VIROL, V78, P10582, DOI 10.1128/JVI.78.19.10582-10587.2004
   MacInnes CD, 2001, J WILDLIFE DIS, V37, P119, DOI 10.7589/0090-3558-37.1.119
   Muller T, 2012, BERL MUNCH TIERARZTL, V125, P178, DOI 10.2376/0005-9366-125-178
   Muller T, 2009, ARCH VIROL, V154, P1081, DOI 10.1007/s00705-009-0408-7
   Muller TF, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003953
   Pfeiffer JK, 2006, P NATL ACAD SCI USA, V103, P5520, DOI 10.1073/pnas.0600834103
   Quinlan AR, 2007, NAT METHODS, V4, P192, DOI 10.1038/nmeth0307-192
   R Development Core Team, 2014, R LANG ENV STAT COMP
   Robardet E, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004432
   RStudio Team, 2016, RSTUDIO INT DEV R
   Rupprecht CE, 2008, DEV BIOLOGICALS, V131, P95
   Rupprecht C.E., 2013, VACCINES, P646
   RUPPRECHT CE, 1990, J WILDLIFE DIS, V26, P99, DOI 10.7589/0090-3558-26.1.99
   Schneider WL, 2001, J VIROL, V75, P6566, DOI 10.1128/JVI.75.14.6566-6571.2001
   STECK F, 1982, COMP IMMUNOL MICROB, V5, P165, DOI 10.1016/0147-9571(82)90031-5
   Vos A, 1999, EPIDEMIOL INFECT, V123, P165, DOI 10.1017/S0950268899002666
   Vos A, 2017, VACCINE, V35, P3938, DOI 10.1016/j.vaccine.2017.06.022
   Vuta V, 2016, VACCINE, V34, P5021, DOI 10.1016/j.vaccine.2016.08.013
   Wandeler AI, 2008, DEV BIOLOGICALS, V131, P19
   Wang CL, 2007, GENOME RES, V17, P1195, DOI 10.1101/gr.6468307
NR 51
TC 8
Z9 8
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 2
PY 2019
VL 37
IS 33
SI SI
BP 4758
EP 4765
DI 10.1016/j.vaccine.2018.01.083
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IQ3RO
UT WOS:000480669000015
PM 29439868
DA 2020-05-12
ER

PT J
AU Barry, E
   Cassels, F
   Riddle, M
   Walker, R
   Wierzba, T
AF Barry, Eileen
   Cassels, Fred
   Riddle, Mark
   Walker, Richard
   Wierzba, Thomas
TI Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A
   summary of the 2018 VASE Conference
SO VACCINE
LA English
DT Article
DE Diarrhea; Stunting; ETEC; Shigella; Immunization; Vaccines
AB PATH hosted the second Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference in Mexico City in June 2018, again providing experts from around the world an opportunity to participate in a highly collaborative forum to discuss progress in the development of new enteric vaccines. Through a combination of plenary sessions and posters, keynote presentations, and workshops, the 2018 VASE Conference aimed to accelerate communication and progress among those working to achieve the goal of licensed vaccines against these two bacterial pathogens. Many presentations recognized the importance of diarrheal disease and long-term sequelae caused by infections with Shigella and enterotoxigenic E. coli (ETEC). Other presentations explored new strategies for vaccine development, including the search for novel, possibly conserved, antigens for more effective vaccines. Much progress is being made as some vaccine candidates are now moving through clinical trials. Research presented in oral and poster presentations at the VASE Conference covered a range of topics, including: the global burden of disease, epidemiology, and health economics; host parameters and genomics that predict responses to infection and disease; preclinical evaluations of vaccine antigens and models of enteric diseases; and vaccine candidates in clinical trials and human challenge studies. This article reviews key points and highlighted research presented in each of the plenary conference sessions and poster presentations at the 2018 VASE Conference. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Barry, Eileen] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
   [Cassels, Fred; Walker, Richard; Wierzba, Thomas] PATH, 4555 Massachusetts Ave NW, Washington, DC 20001 USA.
   [Riddle, Mark] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biostat, Bethesda, MD 20814 USA.
RP Walker, R (reprint author), PATH, 4555 Massachusetts Ave NW, Washington, DC 20001 USA.
EM Rwalker@path.org
NR 0
TC 2
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 7
PY 2019
VL 37
IS 34
SI SI
BP 4768
EP 4774
DI 10.1016/j.vaccine.2019.02.070
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YA
UT WOS:000526035100002
PM 31358236
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wierzba, TF
AF Wierzba, Thomas F.
TI Implications and measurement of herd protection (indirect effects) for
   enteric vaccine development
SO VACCINE
LA English
DT Article
DE Diarrhea; Indirect effects; Herd protection; Herd effects;
   Cost-effectiveness
ID RESEARCH-AND-DEVELOPMENT; ORAL CHOLERA VACCINES; COST-EFFECTIVENESS;
   IMMUNITY
AB Diarrhea remains one of the top five causes of disease and death among young children in developing nations. Fortunately, scientists are making progress developing vaccines against enterotoxigenic E. coli (ETEC) and Shigella, two of the leading diarrhea pathogens. As vaccine developers start to consider field efficacy trials of these vaccines, they should be aware of the importance of evaluating not only vaccine direct effects on the immunized, but also the herd effects that vaccination can afford to the unimmunized in a community. In a workshop held at the conference titled "Vaccines against Shigella and ETEC (VASE)", we described to participants what herd effects are and we presented on methods used in cholera and rotavirus studies that could be useful for future ETEC and Shigella vaccine trials conducted in low and middle-income nations. We also presented evidence on the effects of vaccine herd effects for estimates of vaccine cost-effectiveness. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Wierzba, Thomas F.] Wake Forest Sch Med, Dept Internal Med, Sect Infect Dis, 1 Med Ctr Blvd, Winston Salem, VA 27157 USA.
   [Wierzba, Thomas F.] PATH, Enter Vaccines Initiat, 455 Massachusetts Ave NW, Washington, DC 20001 USA.
RP Wierzba, TF (reprint author), Wake Forest Sch Med, Dept Internal Med, Sect Infect Dis, 1 Med Ctr Blvd, Winston Salem, VA 27157 USA.; Wierzba, TF (reprint author), PATH, Enter Vaccines Initiat, 455 Massachusetts Ave NW, Washington, DC 20001 USA.
EM twierzba@wakehealth.edu
CR Ali M, 2005, LANCET, V366, P44, DOI 10.1016/S0140-6736(05)66550-6
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Ali M, 2013, CLIN INFECT DIS, V56, P1123, DOI 10.1093/cid/cit009
   Atherly DE, 2012, VACCINE, V30, pA7, DOI 10.1016/j.vaccine.2011.12.096
   Atkins KE, 2012, VACCINE, V30, P6766, DOI 10.1016/j.vaccine.2012.09.025
   Bennett A, 2018, Vaccine, V36, P7142, DOI 10.1016/j.vaccine.2018.04.030
   Bourgeois AL, 2016, VACCINE, V34, P2880, DOI 10.1016/j.vaccine.2016.02.076
   Caro J Jaime, 2005, Pediatr Infect Dis J, V24, pS75, DOI 10.1097/01.inf.0000160918.72953.51
   Clark AD, 2013, J PEDIATR-US, V163, pS60, DOI 10.1016/j.jpeds.2013.03.032
   CLEMENS JD, 1986, AM J EPIDEMIOL, V123, P710, DOI 10.1093/oxfordjournals.aje.a114291
   Clemens J, 2011, PHILOS T R SOC B, V366, P2799, DOI 10.1098/rstb.2011.0033
   Halloran ME, 2010, DESIGN ANAL VACCINE
   Jeuland M, 2009, VALUE HEALTH, V12, P899, DOI 10.1111/j.1524-4733.2009.00562.x
   Khan AI, 2018, HUM VACCIN IMMUNOTHE
   Khan AI, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006652
   Khatib AM, 2012, LANCET INFECT DIS, V12, P837, DOI 10.1016/S1473-3099(12)70196-2
   Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797
   Mani S, 2016, VACCINE, V34, P2887, DOI 10.1016/j.vaccine.2016.02.075
   Nymark LS, 2017, VACCINE, V35, P6828, DOI 10.1016/j.vaccine.2017.10.024
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 7
PY 2019
VL 37
IS 34
SI SI
BP 4775
EP 4777
DI 10.1016/j.vaccine.2019.02.061
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YA
UT WOS:000526035100003
PM 31358237
OA Other Gold
DA 2020-05-12
ER

PT J
AU Giersing, BK
   Porter, CK
   Kotloff, K
   Neels, P
   Cravioto, A
   MacLennan, CA
AF Giersing, Birgitte K.
   Porter, Chad K.
   Kotloff, Karen
   Neels, Pieter
   Cravioto, Alejandro
   MacLennan, Calman A.
TI How can controlled human infection models accelerate clinical
   development and policy pathways for vaccines against Shigella?
SO VACCINE
LA English
DT Article
DE Shigella; Challenge; Vaccine; Development; Policy
ID TOXOID CONJUGATE VACCINE; ORAL CHOLERA VACCINE; DOUBLE-BLIND;
   IMMUNOGENICITY; SAFETY; EFFICACY; VI; MULTICENTER; INFANTS; ADULTS
AB Controlled Human Infection Models (CHIMs) now exist for several infectious diseases. CHIMs offer significant insight into disease pathogenesis, as well the potential to rapidly test clinical proof-of-concept of vaccine candidates. The application of CHIMs to identify a correlate of protection that may reduce the sample size of, or obviate the need for clinical efficacy studies to achieve licensure is of considerable interest to vaccine developers and public health stakeholders. This topic was the subject of a workshop at the 2018 Vaccines Against Shigella and ETEC (VASE) conference, in the context of O-antigen-based Shigella vaccines. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Giersing, Birgitte K.] WHO Headquarters, Dept Immunizat Vaccines & Biol, Initiat Vaccine Res, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
   [Porter, Chad K.] Naval Med Res Ctr, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
   [Kotloff, Karen] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA.
   [Kotloff, Karen] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
   [Neels, Pieter] Int Alliance Biol Standardizat, Geneva, Switzerland.
   [Cravioto, Alejandro] Univ Nacl Autonoma Mexico, Fac Med, Ciudad De Mexico, Mexico.
   [MacLennan, Calman A.] Bill & Melinda Gates Fdn, Global Hlth, Enter & Diarrheal Dis, Seattle, WA USA.
RP Giersing, BK (reprint author), WHO Headquarters, Dept Immunizat Vaccines & Biol, Initiat Vaccine Res, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
EM giersingb@who.int
FU Bill and Melinda Gates FoundationGates Foundation [OPP1135836]
FX This work was supported by the Bill and Melinda Gates Foundation
   (OPP1135836).
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P477
   [Anonymous], 2010, Wkly Epidemiol Rec, V85, P117
   [Anonymous], 2018, WEEKLY EPIDEMIOL REC, V93, P153
   Baay MFD, 2018, HUMAN CHALLENGE TRIA
   Bodhidatta L, 2012, VACCINE, V30, P7040, DOI 10.1016/j.vaccine.2012.09.061
   Chaignat CL, 2007, J HEALTH POPUL NUTR, V25, P244
   Chen WH, 2016, CLIN INFECT DIS, V62, P1329, DOI 10.1093/cid/ciw145
   Cohen D, 1997, LANCET, V349, P155, DOI 10.1016/S0140-6736(96)06255-1
   Cohen D, 2017, VACC ENTERIC DIS POR
   Colombara DV, 2016, AM J GASTROENTEROL S, V3, P4, DOI DOI 10.1038/AJGSUP.2016.9
   Council for International Organisations of Medical Sciences (CIOMS), 2016, INT ETH GUID HLTH RE
   Darton TC, 2015, LANCET INFECT DIS, V15, P840, DOI 10.1016/S1473-3099(15)00068-7
   Giersing BK, 2017, WHO 3 PROD DEV VACC
   Gordon Stephen B, 2017, Wellcome Open Res, V2, P70, DOI 10.12688/wellcomeopenres.12256.1
   Groome MJ, 2017, LANCET INFECT DIS, V17, P843, DOI [10.1016/S1473-3099(17)30242-6, 10.1016/s1473-3099(17)30242-6]
   Jin C, 2017, LANCET, V390, P2472, DOI 10.1016/S0140-6736(17)32149-9
   Khalil IA, 2018, LANCET INFECT DIS
   Launay O, 2017, EBIOMEDICINE, V22, P164, DOI 10.1016/j.ebiom.2017.07.013
   Livio S, 2014, CLIN INFECT DIS, V59, P933, DOI 10.1093/cid/ciu468
   Luthra K, 2018, INT S PNEUM PNEUM DI
   Mohan VK, 2015, CLIN INFECT DIS, V61, P393, DOI 10.1093/cid/civ295
   O'Brien KL, 2016, LANCET, V387, P1887, DOI 10.1016/S0140-6736(16)30394-4
   Obiero CW, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01884
   Organization WH, 2017, VACC DEV POL BRIEF R
   Organization WH, 2014, PRINC CONS ADD VACC
   Organization WH, 2017, GLOB PRIOR LIST ANT
   Organization WH. WHO, 2001, WEEKLY EPIDEMIOL REC, V76, P117
   Passwell JH, 2010, VACCINE, V28, P2231, DOI 10.1016/j.vaccine.2009.12.050
   Porter CK, 2017, VACCINE, V35, P6813, DOI 10.1016/j.vaccine.2017.05.068
   Riddle MS, 2016, CLIN VACCINE IMMUNOL, V23, P908, DOI 10.1128/CVI.00224-16
   Riddle MS, 2011, VACCINE, V29, P7009, DOI 10.1016/j.vaccine.2011.07.033
   Roestenberg M, 2018, LANCET INFECT DIS, V18, pE312, DOI 10.1016/S1473-3099(18)30177-4
   SHAUGHNESSY HJ, 1946, JAMA-J AM MED ASSOC, V132, P362, DOI 10.1001/jama.1946.02870420002002
   Standardization W.H.O.E.C.O.B, 2016, HUM CHALL TRIALS VAC
   Talaat Kawsar R, 2017, VACC ENTERIC DIS POR
   Turbyfill KR, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00583-17
   Thiem VD, 2011, CLIN VACCINE IMMUNOL, V18, P730, DOI 10.1128/CVI.00532-10
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 7
PY 2019
VL 37
IS 34
SI SI
BP 4778
EP 4783
DI 10.1016/j.vaccine.2019.03.036
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YA
UT WOS:000526035100004
PM 31358238
OA Other Gold
DA 2020-05-12
ER

PT J
AU Khalil, I
   Troeger, CE
   Blacker, BF
   Reiner, RC
AF Khalil, Ibrahim
   Troeger, Christopher E.
   Blacker, Brigette F.
   Reiner, Robert C., Jr.
TI Capturing the true burden of Shigella and ETEC: The way forward
SO VACCINE
LA English
DT Article
DE Burden of Disease; Diarrhea; Shigella; ETEC
ID SYSTEMATIC ANALYSIS; GLOBAL BURDEN; DISEASE; MORTALITY; DEATH
AB The mortality and morbidity burden estimation of diarrheal diseases (DD), and Shigella and Enterotoxigenic E. Coli (ETEC) varies among different studies and by the models used for producing these estimates. Understanding the real burden of these important pathogens will guide public health and policy makers to prioritize resources for accelerating interventions against these enteric infections. In addition, long term effects, in the form of growth faltering, cognitive impairment and decreased school performance are important aspects of burden that has not been well captured. Efforts to incorporate these effects and refine their estimation, in the form of Disability Adjusted Life years (DALYs) are very important to inform the burden of diarrheal diseases and Shigella and ETEC specifically. The Institute for Health Metrics and Evaluation (IHME) at the University of Washington conducted a workshop at the VASE 2018 meeting to discuss IHME Global Burden of Diseases (GBD) modelling methods for diarrheal diseases, with a focus on ETEC and Shigella estimates in relation to other pathogens, including limitations, areas of improvements, and IHME plans for future GBD iterations. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Khalil, Ibrahim; Troeger, Christopher E.; Blacker, Brigette F.; Reiner, Robert C., Jr.] Univ Washington, IHME, Seattle, WA 98195 USA.
RP Khalil, I (reprint author), Univ Washington, IHME, Seattle, WA 98195 USA.
EM ikhalil@uw.edu; ctroeger@uw.edu; bfb3@uw.edu; bcreiner@uw.edu
FU Bill and Melinda Gates FoundationGates Foundation
FX Bill and Melinda Gates Foundation.
CR Foreman KJ, 2018, LANCET, V392, P2052, DOI [10.1016/s0140-6736(18)31694-5, 10.1016/S0140-6736(18)31694-5]
   GBD 2016 Diarrhoeal Disease Collaborators, 2018, LANCET INFECT DIS
   Guerrant RL, 2008, NUTR REV, V66, P487, DOI 10.1111/j.1753-4887.2008.00082.x
   Guerrant RL, 2013, NAT REV GASTRO HEPAT, V10, P220, DOI 10.1038/nrgastro.2012.239
   Khalil IA, MMWR-MORBID MORTAL W, DOI [10.1016/S1473-3099(18)30475-4, DOI 10.1016/S1473-3099(18)30475-4]
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4
   Reiner RC, 2018, NEW ENGL J MED, V379, P1128, DOI 10.1056/NEJMoa1716766
   Rheingans R, 2012, CLIN INFECT DIS, V55, pS317, DOI 10.1093/cid/cis763
   Troeger C, 2018, LANCET INFECT DIS, V18, P1211, DOI 10.1016/S1473-3099(18)30362-1
   Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 7
PY 2019
VL 37
IS 34
SI SI
BP 4784
EP 4786
DI 10.1016/j.vaccine.2019.01.031
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YA
UT WOS:000526035100005
PM 30711317
OA Other Gold
DA 2020-05-12
ER

PT J
AU Mani, S
   Toapanta, FR
   McArthur, MA
   Qadri, F
   Svennerholm, AM
   Devriendt, B
   Phalipon, A
   Cohen, D
   Sztein, MB
AF Mani, Sachin
   Toapanta, Franklin R.
   McArthur, Monica A.
   Qadri, Firdausi
   Svennerholm, Ann-Mari
   Devriendt, Bert
   Phalipon, Armelle
   Cohen, Daniel
   Sztein, Marcelo B.
TI Role of antigen specific T and B cells in systemic and mucosal immune
   responses in ETEC and Shigella infections, and their potential to serve
   as correlates of protection in vaccine development
SO VACCINE
LA English
DT Article
DE Immunocorrelate; Enterotoxigenic; Escherichia coli (ETEC); Shigella; T
   cells; B cells; Mucosal antibodies; IgA; IgG; Correlates of protection
   (CoP)
ID ENTEROTOXIGENIC ESCHERICHIA-COLI; O-SPECIFIC POLYSACCHARIDE;
   RESEARCH-AND-DEVELOPMENT; FLEXNERI 2A; ANTIBODY-RESPONSES; CONJUGATE
   VACCINE; DOUBLE-BLIND; SERUM ANTIBODIES; ORAL VACCINE; SAFETY
AB The generation of robust systemic and mucosal antibody and cell-mediated immune (CMI) responses that are protective, long-lasting, and can quickly be recalled upon subsequent re-exposure to the cognate antigen is the key to the development of effective vaccine candidates. These responses, whether they represent mechanistic or non-mechanistic immunological correlates of protection, usually entail the activation of T cell memory and effector subsets (T-CMI) and induction of long-lasting memory B cells. However, for ETEC and Shigella, the precise role of these key immune cells in primary and secondary (anamnestic) immune responses remains ill-defined. A workshop to address immune correlates for ETEC and Shigella, in general, and to elucidate the mechanistic role of T-cell subsets and B-cells, both systemically and in the mucosal microenvironment, in the development of durable protective immunity against ETEC and Shigella was held at the recent 2nd Vaccines against Shigella and ETEC (VASE) conference in June 2018. This report is a summary of the presentations and the discussion that ensued at the workshop. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Mani, Sachin] PATH, Washington, DC USA.
   [Toapanta, Franklin R.; McArthur, Monica A.; Sztein, Marcelo B.] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
   [Qadri, Firdausi] Int Ctr Diarrheal Dis Res, Infect Dis Div, Dhaka, Bangladesh.
   [Svennerholm, Ann-Mari] Univ Gothenburg, Inst Biomed, Dept Microbiol & Immunol, Gothenburg, Sweden.
   [Devriendt, Bert] Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Ghent, Belgium.
   [Phalipon, Armelle] Inst Pasteur, INSERM U1202, Mol Microbial Pathogenesis, Paris, France.
   [Cohen, Daniel] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Tel Aviv, Israel.
RP Sztein, MB (reprint author), Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.; Mani, S (reprint author), Moderna Therapeut, Cambridge, MA 02139 USA.
EM sach.mani@gmail.com; msztein@som.umaryland.edu
OI Toapanta, Franklin/0000-0001-9439-0828; Cohen,
   Daniel/0000-0003-2664-2303
FU National Institute of Allergy and Infectious Diseases (NIAID) at the
   National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01-AI036525,
   U19-AI082655, U19-AI109776]; PATH Enteric Vaccine Inititative (EVI)
   [GR01263]; Bill and Melinda Gates FoundationGates Foundation; Swedish
   Research CouncilSwedish Research Council; European UnionEuropean Union
   (EU) [261472]; Fonds voor Wetenschappelijk Onderzoek -Vlaanderen [FWO;
   Research Foundation, Flanders]FWO
FX Research outlined in this manuscript were supported in part by the
   following grants - grants R01-AI036525, U19-AI082655 (Cooperative Center
   for Human Immunology [CCHI]) and U19-AI109776 (Center of Excellence for
   Translational Research [CETR] from the National Institute of Allergy and
   Infectious Diseases (NIAID) at the National Institutes of Health (NIH);
   grant GR01263 through PATH Enteric Vaccine Inititative (EVI), with
   additional support from the Bill and Melinda Gates Foundation and the
   Swedish Research Council; and grant 261472 "STOPENTERICS" from the
   European Union Seventh Framework Programme. In addition, B. Devriendt
   was supported by a postdoctoral grant from Fonds voor Wetenschappelijk
   Onderzoek -Vlaanderen [FWO; Research Foundation, Flanders]. The
   manuscript content is solely the responsibility of the authors and does
   not necessarily represent the official views of the National Institute
   of Allergy and Infectious Diseases or the National Institutes of Health
   or any other granting/funding organizations or agencies.
CR Akhtar M, 2019, VACCINE, V37, P5645, DOI 10.1016/j.vaccine.2018.11.040
   Alam MM, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002822
   [Anonymous], WHOIVB1301
   Ashida H, 2011, CURR OPIN IMMUNOL, V23, P448, DOI 10.1016/j.coi.2011.06.001
   Ashida H, 2011, CURR OPIN MICROBIOL, V14, P16, DOI 10.1016/j.mib.2010.08.014
   Bhuiyan TR, 2016, CLIN VACCINE IMMUNOL, V23, P27, DOI 10.1128/CVI.00526-15
   BLACK RE, 1987, J INFECT DIS, V155, P1260, DOI 10.1093/infdis/155.6.1260
   Bourgeois AL, 2016, VACCINE, V34, P2880, DOI 10.1016/j.vaccine.2016.02.076
   Cardeno A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20740-3
   Coddens A, 2009, J BIOL CHEM, V284, P9713, DOI 10.1074/jbc.M807866200
   COHEN D, 1988, J INFECT DIS, V157, P1068, DOI 10.1093/infdis/157.5.1068
   COHEN D, 1991, J CLIN MICROBIOL, V29, P386, DOI 10.1128/JCM.29.2.386-389.1991
   Cohen D, 1997, LANCET, V349, P155, DOI 10.1016/S0140-6736(96)06255-1
   Cohen D, 2014, EPIDEMIOL INFECT, V142, P2583, DOI 10.1017/S0950268814000260
   Cohen D, 1996, INFECT IMMUN, V64, P4074, DOI 10.1128/IAI.64.10.4074-4077.1996
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Darton TC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004926
   Devriendt B, 2010, DEV COMP IMMUNOL, V34, P1175, DOI 10.1016/j.dci.2010.06.009
   Dubreuil JD, 2016, ECOSAL PLUS, V7, P1, DOI DOI 10.1128/EC0SALPLUS.ESP-0006-2016
   DUPONT HL, 1972, J INFECT DIS, V125, P12, DOI 10.1093/infdis/125.1.12
   FERRECCIO C, 1991, AM J EPIDEMIOL, V134, P614, DOI 10.1093/oxfordjournals.aje.a116134
   FORMAL SB, 1991, J INFECT DIS, V164, P533, DOI 10.1093/infdis/164.3.533
   Fresnay S, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0819-7
   Hall ER, 2001, INFECT IMMUN, V69, P2853, DOI 10.1128/IAI.69.5.2853-2857.2001
   Holmgren J, 2017, VACCINE, V35, P3355, DOI 10.1016/j.vaccine.2017.05.005
   Jertborn M, 2001, CLIN DIAGN LAB IMMUN, V8, P424, DOI 10.1128/CDLI.8.2.424-428.2001
   KARNELL A, 1995, VACCINE, V13, P88, DOI 10.1016/0264-410X(95)80017-8
   Khalil IA, 2018, LANCET INFECT DIS, V18, P1229, DOI [10.1016/S1473-3099(18)30475-4, 10.1016/s1473-3099(18)30475-4]
   Kotloff KL, 2007, HUM VACCINES, V3, P268, DOI 10.4161/hv.4746
   Kotloff KL, 2002, INFECT IMMUN, V70, P2016, DOI 10.1128/IAI.70.4.2016-2021.2002
   Kotloff KL, 1996, INFECT IMMUN, V64, P4542, DOI 10.1128/IAI.64.11.4542-4548.1996
   LERMAN Y, 1994, J CLIN MICROBIOL, V32, P1092, DOI 10.1128/JCM.32.4.1092-1094.1994
   Lundgren A, 2016, VACCINE, V34, P3132, DOI 10.1016/j.vaccine.2016.04.055
   Lundgren A, 2014, VACCINE, V32, P7077, DOI 10.1016/j.vaccine.2014.10.069
   Luo Y, 2015, VET RES, V46, DOI 10.1186/s13567-015-0264-2
   Mani S, 2016, VACCINE, V34, P2887, DOI 10.1016/j.vaccine.2016.02.075
   McArthur MA, 2017, VACCINE, V35, P6803, DOI 10.1016/j.vaccine.2017.05.034
   McArthur MA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005291
   Melkebeek V, 2012, MUCOSAL IMMUNOL, V5, P635, DOI 10.1038/mi.2012.37
   Meurens F, 2012, TRENDS MICROBIOL, V20, P50, DOI 10.1016/j.tim.2011.11.002
   Mokomane M, 2018, THER ADV INFECT DIS, V5, P29, DOI 10.1177/2049936117744429
   Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742
   Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012
   Nguyen UV, 2015, VET RES, V46, DOI 10.1186/s13567-015-0210-3
   Nothelfer K, 2015, NAT REV MICROBIOL, V13, P173, DOI 10.1038/nrmicro3415
   Nothelfer K, 2014, J EXP MED, V211, P1215, DOI 10.1084/jem.20130914
   Passwell JH, 2010, VACCINE, V28, P2231, DOI 10.1016/j.vaccine.2009.12.050
   Phalipon A, 2009, J IMMUNOL, V182, P2241, DOI 10.4049/jimmunol.0803141
   Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Pozsgay V, 1999, P NATL ACAD SCI USA, V96, P5194, DOI 10.1073/pnas.96.9.5194
   Qadri F, 2007, INFECT IMMUN, V75, P3961, DOI 10.1128/IAI.00459-07
   Rao MR, 2005, J INFECT DIS, V191, P562, DOI 10.1086/427662
   Raqib R, 1996, GUT, V38, P328, DOI 10.1136/gut.38.3.328
   RAQIB R, 1995, INFECT IMMUN, V63, P289, DOI 10.1128/IAI.63.1.289-296.1995
   ROBBINS JB, 1990, J INFECT DIS, V161, P821, DOI 10.1093/infdis/161.5.821
   ROBBINS JB, 1992, CLIN INFECT DIS, V15, P346, DOI 10.1093/clinids/15.2.346
   Sack DA, 2007, VACCINE, V25, P4392, DOI 10.1016/j.vaccine.2007.03.034
   Samandari T, 2000, J IMMUNOL, V164, P2221, DOI 10.4049/jimmunol.164.4.2221
   Savarino SJ, 1999, J INFECT DIS, V179, P107, DOI 10.1086/314543
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Sellge G, 2010, J IMMUNOL, V184, P2076, DOI 10.4049/jimmunol.0900978
   Simon JK, 2011, CLIN IMMUNOL, V139, P185, DOI 10.1016/j.clim.2011.02.003
   Simon JK, 2009, VACCINE, V27, P565, DOI 10.1016/j.vaccine.2008.10.081
   Svennerholm AM, 2012, EXPERT REV VACCINES, V11, P495, DOI [10.1586/erv.12.12, 10.1586/ERV.12.12]
   Toapanta FR, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1439-1
   Van den Broeck W, 1999, INFECT IMMUN, V67, P520, DOI 10.1128/IAI.67.2.520-526.1999
   van der Put RMF, 2016, BIOCONJUGATE CHEM, V27, P883, DOI 10.1021/acs.bioconjchem.5b00617
   Verdonck F, 2002, VACCINE, V20, P2995, DOI 10.1016/S0264-410X(02)00220-7
   Virdi V, 2013, P NATL ACAD SCI USA, V110, P11809, DOI 10.1073/pnas.1301975110
   Wahid R, 2013, CLIN IMMUNOL, V148, P35, DOI 10.1016/j.clim.2013.03.009
   Way SS, 1998, INFECT IMMUN, V66, P1342, DOI 10.1128/IAI.66.4.1342-1348.1998
   Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212
NR 73
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 7
PY 2019
VL 37
IS 34
SI SI
BP 4787
EP 4793
DI 10.1016/j.vaccine.2019.03.040
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YA
UT WOS:000526035100006
PM 31230883
OA Green Published
DA 2020-05-12
ER

PT J
AU Hanevik, K
   Chen, WH
   Talaat, KR
   Porter, C
   Bourgeois, L
AF Hanevik, Kurt
   Chen, Wilbur H.
   Talaat, Kawsar R.
   Porter, Chad
   Bourgeois, Lou
TI The way forward for ETEC controlled human infection models (CHIMs)
SO VACCINE
LA English
DT Article
DE Enterotoxic; Escherichia coli; ETEC; Controlled human infection models;
   CHIM; VASE; Workshop; Strain; Selection; Sampling; Standardization;
   Screening
ID ENTEROTOXIGENIC ESCHERICHIA-COLI; HUMAN CHALLENGE MODEL;
   IMMUNE-RESPONSES; DOUBLE-BLIND; DIARRHEA; VACCINE; VOLUNTEERS; EFFICACY;
   IMMUNIZATION; PROTECTION
AB In the absence of good animal models, Controlled Human Infection Models (CHIMs) are useful to assess efficacy of new vaccine candidates against Enterotoxic Escherichia coli (ETEC), as well as other preventive or therapeutic interventions. At the 2018 Vaccines Against Shigella and ETEC (VASE) conference, a workshop was held to further review and discuss new challenge model developments and key issues related to further model standardization. During the workshop, invited speakers briefly summarized for attendees recent developments and main agenda issues before workshop participants were divided into four groups for more focused discussions.
   The main issues discussed were: (1) whether there is a need for more ETEC strains to test a diversity of vaccine candidates, and if so, what criteria/qualities are desirable in strain selection; (2) how ETEC CHIMs could be more standardized to better support ETEC vaccine development; (3) how volunteer selection criteria and screening should be performed, and; (4) how an expanded sample collection schema and collaborative analysis plan may facilitate a more in-depth assessment of the role of antigen-specific humoral and cellular immune responses in ETEC infection, and provide better insights into ETEC pathogenesis and correlates of protection.
   The workshop concluded that additional challenge strains may need to be developed to better support new vaccines and therapeutics that are advancing in the development pipeline. In this regard, the need for a well characterized ST-only expressing ETEC strain was highlighted as a priority given that promising new heat stable toxoid based vaccine candidates are on the horizon. In addition, further standardization of the ETEC CHIMs was strongly encouraged, noting that it may not be realistic to standardize across all strains. Also, intensified volunteer screening may result in higher attack rates, although more stringent eligibility criteria may contribute to a more limited application of the model and diminish its representativeness. Finally, a sampling schedule and priority list for minimum set of samples was also proposed. Future workshops could be held to further refine standards for ETEC CHIMS and to facilitate more collaborative work on stored sample sets from previous and future ETEC CHIMs to maximize the contribution of these trials to our understanding of ETEC pathogenesis and our development of better prevention and control measures for this important pathogen. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Hanevik, Kurt] Haukeland Hosp, Dept Med, Norwegian Natl Advisory Unit Trop Infect Dis, Bergen, Norway.
   [Hanevik, Kurt] Univ Bergen, Ctr Int Hlth, Dept Global Publ Hlth & Primary Care, Bergen, Norway.
   [Chen, Wilbur H.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
   [Talaat, Kawsar R.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Baltimore, MD USA.
   [Porter, Chad] Naval Med Res Ctr, Forest Glen, MD USA.
   [Bourgeois, Lou] PATH, Washington, DC USA.
RP Hanevik, K (reprint author), Univ Bergen, Dept Clin Sci, Jonas Lies Vei 87, N-5020 Bergen, Norway.
EM kurt.hanevik@med.uib.no
RI Hanevik, Kurt/I-1159-2012
OI Hanevik, Kurt/0000-0002-1466-2326
CR Aase A., 2015, MUCOSAL IMMUNOL
   Ahmed T, 2009, INFECT IMMUN, V77, P2059, DOI 10.1128/IAI.01571-08
   Cardeno A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20740-3
   Chakraborty S, 2018, J INFECT DIS, V218, P1436, DOI 10.1093/infdis/jiy312
   Chakraborty S, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006442
   Chakraborty S, 2016, CLIN VACCINE IMMUNOL, V23, P55, DOI 10.1128/CVI.00617-15
   CLEMENTS ML, 1981, ANTIMICROB AGENTS CH, V20, P104, DOI 10.1128/AAC.20.1.104
   Crofts AA, 2018, P NATL ACAD SCI USA, V115, pE8968, DOI 10.1073/pnas.1808982115
   Darsley MJ, 2012, CLIN VACCINE IMMUNOL, V19, P1921, DOI 10.1128/CVI.00364-12
   Davies EV, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnw015
   Del Canto F, 2017, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00200
   DUPONT HL, 1971, NEW ENGL J MED, V285, P1, DOI 10.1056/NEJM197107012850101
   Evans D G, 1988, FEMS Microbiol Immunol, V1, P117
   Evans D J Jr, 1988, FEMS Microbiol Immunol, V1, P9
   EVANS DG, 1978, INFECT IMMUN, V19, P883, DOI 10.1128/IAI.19.3.883-888.1978
   EVANS DG, 1984, GASTROENTEROLOGY, V87, P934
   EVANS DJ, 1973, INFECT IMMUN, V8, P322, DOI 10.1128/IAI.8.3.322-328.1973
   Fleckenstein JM, 2013, GUT MICROBES, V4, P392, DOI 10.4161/gmic.25861
   Harro C, 2016, 50 US JAP CHOL REL D
   Harro C, 2011, CLIN VACCINE IMMUNOL, V18, P1719, DOI 10.1128/CVI.05194-11
   Holmgren J, 2017, VACCINE, V35, P3355, DOI 10.1016/j.vaccine.2017.05.005
   Kansal R, 2013, INFECT IMMUN, V81, P259, DOI 10.1128/IAI.00919-12
   Kumar P, 2018, J CLIN INVEST, V128, P3298, DOI 10.1172/JCI97659
   LEVINE MM, 1980, AM J EPIDEMIOL, V111, P347, DOI 10.1093/oxfordjournals.aje.a112906
   LEVINE MM, 1982, SCAND J INFECT DIS, P83
   LEVINE MM, 1979, INFECT IMMUN, V23, P729, DOI 10.1128/IAI.23.3.729-736.1979
   Lindsay BR, 2014, FEMS MICROBIOL LETT, V352, P25, DOI 10.1111/1574-6968.12362
   McArthur MA, 2017, VACCINE, V35, P6803, DOI 10.1016/j.vaccine.2017.05.034
   McArthur MA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005291
   McKenzie R, 2008, VACCINE, V26, P4731, DOI 10.1016/j.vaccine.2008.06.064
   McKenzie R, 2007, VACCINE, V25, P3684, DOI 10.1016/j.vaccine.2007.01.043
   McKenzie R, 2011, J INFECT DIS, V204, P60, DOI 10.1093/infdis/jir220
   Pop M, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2777-0
   Porter CK, 2017, VACCINE, V35, P6813, DOI 10.1016/j.vaccine.2017.05.068
   Porter CK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149358
   Porter CK, 2011, VACCINE, V29, P5869, DOI 10.1016/j.vaccine.2011.05.021
   Qadri F, 2007, INFECT IMMUN, V75, P3961, DOI 10.1128/IAI.00459-07
   Rao MR, 2005, J INFECT DIS, V191, P562, DOI 10.1086/427662
   Skrede S, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-482
   TACKET CO, 1994, VACCINE, V12, P1270, DOI 10.1016/S0264-410X(94)80038-2
   Talaat KR, 2017, VACC ENTERIC DIS
   Vedoy OB, 2018, GUT PATHOG, V10, DOI 10.1186/s13099-018-0273-6
   Walker RI, 2017, VACCINE, V35, P6775, DOI 10.1016/j.vaccine.2017.09.045
   WHO, 2018, WHO PROD DEV VACC AD
   Yang WE, 2016, J INFECT DIS, V213, P1495, DOI 10.1093/infdis/jiv593
NR 45
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 7
PY 2019
VL 37
IS 34
SI SI
BP 4794
EP 4799
DI 10.1016/j.vaccine.2019.01.003
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YA
UT WOS:000526035100007
PM 30709728
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU White, JA
   Lal, M
AF White, Jessica A.
   Lal, Manjari
TI Technical product attributes in development of an oral enteric vaccine
   for infants
SO VACCINE
LA English
DT Article
DE Shigella; Oral vaccine; ETEC; Antacid buffer; Infant vaccination;
   Enteric vaccine development
ID ENTEROTOXIGENIC ESCHERICHIA-COLI; ATTENUATED ROTAVIRUS VACCINE;
   DIARRHEAL DISEASES; CHILDREN; CHALLENGES; SHIGELLA; DELIVERY; STABILITY;
   ETIOLOGY; INSIGHTS
AB Development of an oral enteric vaccine for infants is important for Shigella and enterotoxigenic Escherichia coli (ETEC) vaccine development. At a recent workshop titled "Technical Product Attributes in Development of an Oral Enteric Vaccine for Infants," at the 2nd International Vaccines Against Shigella and ETEC Conference (VASE Conference), the preferred product attributes for development were discussed for these vaccines. The aims of this workshop were to identify gaps and gather opinions from key experts from preclinical, process development, manufacturing, regulatory, and clinical areas to fine-tune and refine key target product attributes for infant oral vaccine development. The workshop used some examples of marketed oral infant vaccines to discuss potential improvements that can be made, such as inclusion of preservatives, multidose vials, and antacid buffer presentation (liquid or lyophilized) in novel oral enteric vaccine development. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [White, Jessica A.; Lal, Manjari] PATH, POB 900922, Seattle, WA 98109 USA.
RP Lal, M (reprint author), PATH, POB 900922, Seattle, WA 98109 USA.
EM mlal@path.org
FU Bill & Melinda Gates FoundationGates Foundation [OPP1038301, OPP1112376]
FX The authors would like to thank Leslie Barrett for assistance in the
   development of this article and Dr. Richard Walker for critical review
   of the draft manuscript. This work was funded by grants from the Bill &
   Melinda Gates Foundation (OPP1038301 and OPP1112376). The views
   expressed herein are solely those of the authors and do not necessarily
   reflect the views of the Bill & Melinda Gates Foundation.
CR Ashok A, 2017, VACCINE, V35, P2217, DOI 10.1016/j.vaccine.2016.08.045
   Chandrasekaran L, 2015, VACCINE, V33, P6156, DOI 10.1016/j.vaccine.2015.09.063
   Chen DX, 2009, EXPERT REV VACCINES, V8, P547, DOI [10.1586/erv.09.20, 10.1586/ERV.09.20]
   Chirico G, 2014, MINERVA PEDIATR, V66, P549
   Gavi The Vaccine Alliance, VACC ALL OR CHOL VAC
   Giersing B., 2016, UPD IMM PRACT ADV CO
   Giersing BK, 2017, VACCINE, V35, P6793, DOI 10.1016/j.vaccine.2017.04.063
   Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629
   Kotloff KL, 2017, VACCINE, V35, P6783, DOI 10.1016/j.vaccine.2017.07.036
   Kotloff KL, 2017, PEDIATR CLIN N AM, V64, P799, DOI 10.1016/j.pcl.2017.03.006
   Kristensen D, 2011, VACCINE, V29, P7122, DOI 10.1016/j.vaccine.2011.05.070
   Kristensen D, 2010, HUM VACCINES, V6, P229
   Lal M, 2017, HUM VACC IMMUNOTHER, V13, P46, DOI 10.1080/21645515.2016.1238536
   Lal M, 2016, VACCINE, V34, P2483, DOI 10.1016/j.vaccine.2016.03.093
   Lal M, 2013, VACCINE, V31, P4759, DOI 10.1016/j.vaccine.2013.08.010
   Madan M, 2018, HUM VACC IMMUNOTHER, V14, P2132, DOI 10.1080/21645515.2018.1487499
   Mani S, 2016, VACCINE, V34, P2887, DOI 10.1016/j.vaccine.2016.02.075
   Mansoor OD, 2013, B WORLD HEALTH ORGAN, V91, P75, DOI 10.2471/BLT.12.110700
   McAdams D, 2012, EXPERT REV VACCINES, V11, P1211, DOI [10.1586/ERV.12.101, 10.1586/erv.12.101]
   Naik SP, 2017, VACCINE, V35, P2962, DOI 10.1016/j.vaccine.2017.04.025
   Odevall L, 2018, VACCINE, V36, P6606, DOI 10.1016/j.vaccine.2018.09.026
   Pavot V, 2012, VACCINE, V30, P142, DOI 10.1016/j.vaccine.2011.11.003
   Pedersen GK, 2012, HUM VACC IMMUNOTHER, V8, P690, DOI 10.4161/hv.19568
   Qadri F, 2013, VACCINE, V31, P452, DOI 10.1016/j.vaccine.2012.11.012
   Sedita J, 2018, VACCINE, V36, P1700, DOI 10.1016/j.vaccine.2018.01.011
   Walker RI, 2005, VACCINE, V23, P5432, DOI 10.1016/j.vaccine.2005.01.161
   Walker RI, 2005, VACCINE, V23, P3369, DOI 10.1016/j.vaccine.2004.12.029
   Walker RI, 2005, EXPERT REV VACCINES, V4, P807, DOI 10.1586/14760584.4.6.807
   Walker RI, 2017, VACCINE, V35, P6775, DOI 10.1016/j.vaccine.2017.09.045
   Walker RI, 2015, VACCINE, V33, P954, DOI 10.1016/j.vaccine.2014.11.049
   White JA, 2017, J IMMUNOL METHODS, V451, P83, DOI 10.1016/j.jim.2017.09.003
   World Health Organization (WHO), 2012, WHOIVB1210
   Zehrung D, 2017, VACCINE, V35, P2265, DOI 10.1016/j.vaccine.2016.11.095
   Zheng ZC, 2018, HUM VACC IMMUNOTHER, V14, P1717, DOI 10.1080/21645515.2018.1461296
NR 34
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 7
PY 2019
VL 37
IS 34
SI SI
BP 4800
EP 4804
DI 10.1016/j.vaccine.2019.02.060
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YA
UT WOS:000526035100008
PM 31358239
OA Other Gold
DA 2020-05-12
ER

PT J
AU Mottram, L
   Chakraborty, S
   Cox, E
   Fleckenstein, J
AF Mottram, Lynda
   Chakraborty, Subhra
   Cox, Eric
   Fleckenstein, James
TI How genomics can be used to understand host susceptibility to enteric
   infection, aiding in the development of vaccines and immunotherapeutic
   interventions
SO VACCINE
LA English
DT Article
DE Genomics; Shigella; ETEC; Host genetic factors; Vaccine antigen
   candidates; Host-pathogen interactions
ID ENTEROTOXIGENIC ESCHERICHIA-COLI; BLOOD-GROUP; IDENTIFICATION; RECEPTOR;
   ADHESIN; DISEASE; ANTIGEN; BINDING; EATA
AB Thanks to the modern sequencing era, the extent to which infectious disease imposes selective pressures on the worldwide human population is being revealed. This is aiding our understanding of the underlying immunological and host mechanistic defenses against these pathogens, as well as potentially assisting in the development of vaccines and therapeutics to control them. As a consequence, the workshop ``How genomics can be used to understand host susceptibility to enteric infection, aiding in the development of vaccines and immunotherapeutic interventions" at the VASE 2018 meeting, aimed to discuss how genomics and related tools could be used to assist Shigella and ETEC vaccine development. The workshop featured four short presentations which highlighted how genomic applications can be used to assist in the identification of genetic patterns related to the virulence of disease, or host genetic factors that could contribute to immunity or successful vaccine responses. Following the presentations, there was an open debate with workshop attendees to discuss the best ways to utilise such genomic studies, to improve or accelerate the process of both Shigella and ETEC vaccine development. The workshop concluded by making specific recommendations on how genomic research methods could be strengthened and harmonised within the ETEC and Shigella research communities. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Mottram, Lynda] Univ Gothenburg, Inst Biomed, Dept Microbiol & Immunol, Sahlgrenska Acad, Gothenburg, Sweden.
   [Chakraborty, Subhra] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   [Cox, Eric] Univ Ghent, Fac Vet Med, Dept Virol Parasitol & Immunol, Merelbeke, Belgium.
   [Fleckenstein, James] Washington Univ, Sch Med, Dept Med, Div Infect Dis, St Louis, MO 63110 USA.
   [Fleckenstein, James] Vet Affairs Med Ctr, Med Serv, St Louis, MO USA.
RP Mottram, L (reprint author), Univ Gothenburg, Inst Biomed, Dept Microbiol & Immunol, Sahlgrenska Acad, Gothenburg, Sweden.
EM lynda.mottram@gu.se
OI Cox, Eric/0000-0003-4281-2990; Fleckenstein, James/0000-0002-1148-697X;
   Mottram, Lynda/0000-0003-0007-3229
FU Swedish Research CouncilSwedish Research Council [2013-6615, 2011-3435];
   Swedish Strategic Foundation [SB12-0072]; PATHUnited States Agency for
   International Development (USAID); National Institute of Allergy and
   Infectious Diseases (NIAID) of the National Institutes of Health
   (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI089894, R01AI126887]; Washington
   University Institute of Clinical and Translational Sciences from the
   National Center for Advancing Translational Sciences (NCATS) of the NIH
   [UL1 TR000448]; Department of Veterans AffairsUS Department of Veteran
   Affairs [5I01BX001469]
FX We thank Dr Susannah Leach of the University of Gothenburg, Sweden for
   transcribing during this VASE workshop. The work described by Mottram's
   research in this publication was funded by the Swedish Research Council
   (grants 2013-6615 and 2011-3435) and the Swedish Strategic Foundation
   (grant SB12-0072). Dr Fleckenstein's research in this publication was
   supported in part by PATH, funding from National Institute of Allergy
   and Infectious Diseases (NIAID) of the National Institutes of Health
   (NIH) under Award Numbers R01AI089894, R01AI126887 (jmf), the Washington
   University Institute of Clinical and Translational Sciences grant UL1
   TR000448 from the National Center for Advancing Translational Sciences
   (NCATS) of the NIH, and the Department of Veterans Affairs
   (5I01BX001469, jmf). The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   NIH, NIAID, NCATS, the Department of Veterans Affairs, or PATH.
CR Ahmed T, 2009, INFECT IMMUN, V77, P2059, DOI 10.1128/IAI.01571-08
   Aken BL, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw093
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Barton AJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01839
   Bentley SD, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2015.0488
   Bucardo F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19718-y
   Chakraborty S, 2018, J INFECT DIS, V218, P1436, DOI 10.1093/infdis/jiy312
   Chakraborty S, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006442
   Coddens A, 2007, VET MICROBIOL, V122, P332, DOI 10.1016/j.vetmic.2007.02.007
   Coddens A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023309
   Coddens A, 2009, J BIOL CHEM, V284, P9713, DOI 10.1074/jbc.M807866200
   Cooling L, 2015, CLIN MICROBIOL REV, V28, P801, DOI 10.1128/CMR.00109-14
   Davies DH, 2015, VACCINE, V33, P7496, DOI 10.1016/j.vaccine.2015.09.059
   Delany I, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a012476
   Dellagostin OA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010158
   Fleckenstein JM, 2006, INFECT IMMUN, V74, P2245, DOI 10.1128/IAI.74.4.2245-2258.2006
   Goetstouwers T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105013
   Gordon Stephen B, 2017, Wellcome Open Res, V2, P70, DOI 10.12688/wellcomeopenres.12256.1
   Hegde NR, 2018, EXPERT OPIN DRUG DIS, V13, P117, DOI 10.1080/17460441.2018.1413088
   Hosangadi D, 2018, WHO CONSULTATION ETE
   Jansson L, 2006, INFECT IMMUN, V74, P3488, DOI 10.1128/IAI.02006-05
   Kaufmann SHE, 2016, TUBERCULOSIS, V99, pS8, DOI 10.1016/j.tube.2016.05.010
   Kuhlmann FM, 2016, AM J TROP MED HYG, V95, P440, DOI 10.4269/ajtmh.16-0161
   Kumar P, 2018, J CLIN INVEST, V128, P3298, DOI 10.1172/JCI97659
   Kumar P, 2014, INFECT IMMUN, V82, P500, DOI 10.1128/IAI.01078-13
   Kurata M, 2018, J HUM GENET, V63, P179, DOI 10.1038/s10038-017-0376-9
   Lowe R, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005457
   Luo QW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003446
   Mason DM, 2018, NUCLEIC ACIDS RES, V46, P7436, DOI 10.1093/nar/gky550
   McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4
   Meijerink E, 1997, MAMM GENOME, V8, P736, DOI 10.1007/s003359900556
   Moonens K, 2012, MOL MICROBIOL, V86, P82, DOI 10.1111/j.1365-2958.2012.08174.x
   Mottram L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29258-0
   Mottram L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10854-5
   Nguyen UV, 2017, VET MICROBIOL, V202, P52, DOI 10.1016/j.vetmic.2016.01.014
   Noel G, 2017, SCI REP-UK, V7, DOI 10.1038/srep45270
   Patel SK, 2004, INFECT IMMUN, V72, P1786, DOI 10.1128/IAI.72.3.1786-1794.2004
   Pop M, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2777-0
   Qadri F, 2007, INFECT IMMUN, V75, P3961, DOI 10.1128/IAI.00459-07
   Robinson K, 2017, HELICOBACTER, V22, DOI 10.1111/hel.12406
   Rossi G, 2018, NAT REV GENET
   Roy K, 2009, NATURE, V457, P594, DOI 10.1038/nature07568
   Shalem O, 2015, NAT REV GENET, V16, P299, DOI 10.1038/nrg3899
   Vogeli P, 1997, SCHWEIZ ARCH TIERH, V139, P479
   Walker RI, 2017, VACCINE, V35, P6775, DOI 10.1016/j.vaccine.2017.09.045
   White JK, 2013, CELL, V154, P452, DOI 10.1016/j.cell.2013.06.022
   Yang WE, 2016, J INFECT DIS, V213, P1495, DOI 10.1093/infdis/jiv593
NR 47
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 7
PY 2019
VL 37
IS 34
SI SI
BP 4805
EP 4810
DI 10.1016/j.vaccine.2019.01.016
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YA
UT WOS:000526035100009
PM 30709726
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Randall, H
   Kallen, LE
AF Randall, Hope
   Kallen, Laura Edison
TI Using advocacy to increase investment in enteric vaccine development
SO VACCINE
LA English
DT Article
DE Advocacy; Communications; Enteric vaccines; Shigella; ETEC; Vaccine
   research & development
ID DIARRHEAL DISEASES; CHILDREN; BURDEN
AB Catalyzing and sustaining momentum for long-term research investments can be a challenge, especially for enteric pathogens like ETEC and Shigella that are most threatening to the health of children in low-resource areas, and whose vaccines would not be for global use. The 2018 Vaccines Against Shigella and ETEC (VASE) Conference included a workshop focused on building the capacity of scientists to communicate about their own research and advocate for additional attention and funding for enteric disease and vaccines research. Workshop presenters shared best practices and examples of advocacy, communications, and messaging tactics that have been used successfully during early stages of vaccine development research for other pathogens. The presentations were followed by an interactive, hands-on training for real-life communication opportunities for scientists that could result in increased research funding, including developing resonant messaging for relevant audiences and practicing interviews. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Randall, Hope; Kallen, Laura Edison] PATH, 455 Massachusetts Ave NW,Suite 1000, Washington, DC 20001 USA.
RP Kallen, LE (reprint author), PATH, 455 Massachusetts Ave NW,Suite 1000, Washington, DC 20001 USA.
EM lkallen@path.org
CR InterAction, 2014, INTERACTION
   Khalil IA, 2018, LANCET INFECT DIS, V18, P1229, DOI [10.1016/S1473-3099(18)30475-4, 10.1016/s1473-3099(18)30475-4]
   Kotloff KL, 2017, VACCINE, V35, P6783, DOI 10.1016/j.vaccine.2017.07.036
   Troeger C, 2018, LANCET GLOB HEALTH, V6, pE255, DOI 10.1016/S2214-109X(18)30045-7
   Walker RI, 2017, VACCINE, V35, P6775, DOI 10.1016/j.vaccine.2017.09.045
   WaterAid and PATH, 2018, COORDINATE INTEGRATE
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 7
PY 2019
VL 37
IS 34
SI SI
BP 4811
EP 4813
DI 10.1016/j.vaccine.2018.12.033
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YA
UT WOS:000526035100010
PM 30737042
OA Other Gold
DA 2020-05-12
ER

PT J
AU Porter, CK
   Gutierrez, RL
   Kotloff, KL
AF Porter, Chad K.
   Gutierrez, Ramiro L.
   Kotloff, Karen L.
TI Clinical endpoints for efficacy studies
SO VACCINE
LA English
DT Article
DE Controlled human infection model; Shigella; Enterotoxigenic E. coli;
   ETEC; Vaccine; Endpoints; Efficacy; Diarrheal diseases; Travelers'
   diarrhea; CHIM
ID ENTEROTOXIGENIC ESCHERICHIA-COLI; HUMAN CHALLENGE MODEL; ORAL CHOLERA
   VACCINE; HEAT-LABILE TOXIN; TRAVELERS DIARRHEA; DOUBLE-BLIND;
   DEVELOPING-COUNTRIES; ROTAVIRUS VACCINE; US MILITARY; FIELD TRIAL
AB Well-established, validated and clinically meaningful primary and secondary endpoints are critical in advancing vaccines through proof of principal studies, licensure and pre-qualification. To that end, the field of vaccine development for Shigella, enterotoxigenic Escherichia coli (ETEC) as well as other enteric pathogens would benefit greatly from a focused review of clinical endpoints and the use of common endpoints across the field to enable study-to-study comparisons as well as comparative assessments between vaccine candidates. A workshop was conducted to review clinical endpoints from controlled human challenge studies, field studies in naive adult travelers and pediatric studies in low-middle income countries and to develop a consensus on clinical endpoints for future vaccine trials.
   Following sequential presentations on different study designs (CHIM, travelers' efficacy and pediatric efficacy), workshop participants broke into three simultaneous workgroups focused on those study designs to discuss a number of topics key to clinical endpoints specific to each study design. Previously utilized endpoints were reviewed with an eye towards potentially novel endpoints for future studies and consideration of the disease parameters and spectrum of disease targeted for prevention. The strength of support among workshop participants for the use of various endpoints is summarized as are recommendations for additional endpoints to be considered in future studies. It is anticipated that this report will facilitate endpoint determination in future efficacy trials of vaccine candidates. Published by Elsevier Ltd.
C1 [Porter, Chad K.; Gutierrez, Ramiro L.] Naval Med Res Ctr, Enter Dis Dept, Silver Spring, MD 20910 USA.
   [Kotloff, Karen L.] Univ Maryland, Sch Med, Div Infect Dis & Trop Pediat, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
RP Porter, CK (reprint author), Naval Med Res Ctr, Enter Dis Dept, Silver Spring, MD 20910 USA.
EM chad.k.porter2.civ@mail.mil
CR [Anonymous], 2006, Wkly Epidemiol Rec, V81, P97
   [Anonymous], 2006, WKLY EPIDEMIOL REC
   Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Behrens RH, 2014, LANCET INFECT DIS, V14, P197, DOI 10.1016/S1473-3099(13)70297-4
   Bines JE, 2018, NEW ENGL J MED, V378, P719, DOI 10.1056/NEJMoa1706804
   BLACK RE, 1987, J INFECT DIS, V155, P1260, DOI 10.1093/infdis/155.6.1260
   Brown JA, 2009, TRAVEL MED INFECT DI, V7, P337, DOI 10.1016/j.tmaid.2009.09.001
   Carlin P, 2018, ASHGATE STUD ARCHIT, P2
   Chen WH, 2016, CLIN INFECT DIS, V62, P1329, DOI 10.1093/cid/ciw145
   Clemens J, 2004, J INFECT DIS, V189, P2299, DOI 10.1086/386288
   Coster TS, 1999, INFECT IMMUN, V67, P3437, DOI 10.1128/IAI.67.7.3437-3443.1999
   Darsley MJ, 2012, CLIN VACCINE IMMUNOL, V19, P1921, DOI 10.1128/CVI.00364-12
   DUPONT HL, 1972, J INFECT DIS, V125, P12, DOI 10.1093/infdis/125.1.12
   DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126
   DUPONT HL, 1969, J INFECT DIS, V119, P296, DOI 10.1093/infdis/119.3.296
   Frech SA, 2008, LANCET, V371, P2019, DOI 10.1016/S0140-6736(08)60839-9
   Frenck Jr RW, 2017, VACCINES ENTERIC DIS
   GBD, 2017, LANCET INFECT DIS
   Gutierrez R, 2016, WORLD VACC C 2016 WA
   Harro C, 2011, CLIN VACCINE IMMUNOL, V18, P1719, DOI 10.1128/CVI.05194-11
   HERRINGTON DA, 1990, VACCINE, V8, P353, DOI 10.1016/0264-410X(90)90094-3
   Kotloff KL, 2017, VACCINE, V35, P6783, DOI 10.1016/j.vaccine.2017.07.036
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   KOTLOFF KL, 1995, VACCINE, V13, P495, DOI 10.1016/0264-410X(94)00011-B
   KOTLOFF KL, 1992, INFECT IMMUN, V60, P2218, DOI 10.1128/IAI.60.6.2218-2224.1992
   KOTLOFF KL, 1995, VACCINE, V13, P1488, DOI 10.1016/0264-410X(95)00102-7
   Kulkarni PS, 2017, VACCINE, V35, P6228, DOI 10.1016/j.vaccine.2017.09.014
   LEVINE MM, 1973, J INFECT DIS, V127, P261, DOI 10.1093/infdis/127.3.261
   LEVINE MM, 1977, J INFECT DIS, V136, P577, DOI 10.1093/infdis/136.4.577
   Leyten EMS, 2005, VACCINE, V23, P5120, DOI 10.1016/j.vaccine.2005.05.022
   Liu J, 2016, LANCET, V388, P1291, DOI 10.1016/S0140-6736(16)31529-X
   MACKOWIAK PA, 1992, J INFECT DIS, V166, P1181, DOI 10.1093/infdis/166.5.1181
   Monteville MR, 2006, AM J TROP MED HYG, V75, P762, DOI 10.4269/ajtmh.2006.75.762
   MUNOZ C, 1995, AM J TROP MED HYG, V53, P47, DOI 10.4269/ajtmh.1995.53.47
   PELTOLA H, 1991, LANCET, V338, P1285, DOI 10.1016/0140-6736(91)92590-X
   Porter CK, 2013, EPIDEMIOL INFECT, V141, P223, DOI 10.1017/S0950268812001677
   Porter CK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194325
   Porter CK, 2017, VACCINE, V35, P6813, DOI 10.1016/j.vaccine.2017.05.068
   Porter CK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149358
   Porter CK, 2011, VACCINE, V29, P5869, DOI 10.1016/j.vaccine.2011.05.021
   Riddle MS, 2006, AM J TROP MED HYG, V74, P891, DOI 10.4269/ajtmh.2006.74.891
   Riddle MS, 2017, J TRAVEL MED, V24, pS63, DOI 10.1093/jtm/tax026
   Riddle MS, 2015, AM J TROP MED HYG, V93, P912, DOI 10.4269/ajtmh.15-0200
   Rogawski ET, 2018, LANCET GLOB HEALTH, V6, pE1319, DOI [10.1016/S2214-109X(18)30351-6, 10.1016/s2214-109x(18)30351-6]
   Sack DA, 2007, VACCINE, V25, P4392, DOI 10.1016/j.vaccine.2007.03.034
   Savarino A-E, 2003, EFFICACY ORAL INACTI
   Savarino SJ, 2002, PEDIATR INFECT DIS J, V21, P322, DOI 10.1097/00006454-200204000-00012
   Scerpella, 1995, J Travel Med, V2, P22, DOI 10.1111/j.1708-8305.1995.tb00615.x
   TACKET CO, 1992, AM J TROP MED HYG, V47, P276, DOI 10.4269/ajtmh.1992.47.276
   Talaat KR, VACCINES ENTERIC DIS, V201
   Taylor DN, 2006, CLIN INFECT DIS, V42, P1283, DOI 10.1086/503039
   Vidal RM, PLOS NEGLECTED TROPI
   Wiedermann G, 2000, J TRAVEL MED, V7, P27
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
NR 54
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 7
PY 2019
VL 37
IS 34
SI SI
BP 4814
EP 4822
DI 10.1016/j.vaccine.2019.03.051
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YA
UT WOS:000526035100011
PM 30981626
OA Other Gold
DA 2020-05-12
ER

PT J
AU Panu, M
   Topolski, K
   Abrash, S
   El-Halwagi, MM
AF Panu, Marc
   Topolski, Kevin
   Abrash, Sarah
   El-Halwagi, Mahmoud M.
TI CO2 footprint reduction via the optimal design of Carbon-Hydrogen-Oxygen
   SYmbiosis Networks (CHOSYNs)
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Industrial symbiosis; Process integration; Synthesis; CO2; Mass
   integration
ID PROCESS INTEGRATION
AB Carbon dioxide (CO2) has significant potential as a chemical feedstock as it is an abundant source of carbon atoms, entails zero or negative acquisition costs and utilization reduces environmental impact. However, significant challenges remain as the use of this feedstock involves unfavorable thermodynamics in reaction and separation, material transportation and end use application. Opportunities exist to overcome these limitations especially within eco-industrial parks which involve a group of facilities cooperating by exchanging materials and energy. An important class of EIPs, Carbon-Hydrogen-Oxygen SYmbiosis Networks (CHOSYN), has been recently introduced to integrate hydrocarbon streams from multiple plants while allowing for chemical conversion (in addition to the conventional exchange, separation, and allocation) through a multiscale targeting approach. The objective of this work is to address the problem of designing a CHOSYN with the conversion of CO2 into value-added chemicals while reducing the carbon footprint for the whole system. A multi-scale synthesis and optimization approach is proposed. First, atomic-level information coupled with economic data are used to establish benchmarks for the utilization of process streams, the purchase of external sources, and the discharge of CO2. A presynthesis approach is adopted to develop optimal policies for the CO2-separation technologies. Candidate CO2-utilization reactions are integrated with the existing plants to produce value-added chemicals while addressing economic and environmental objectives. Carbon-footprint constraints are added based on life-cycle analysis of the used sources and energy associated with the various reaction and separation steps. This systematic procedure captures significant interactions between surrounding CO2 sources and CO2 sinks while reducing the difficulty of selection and design of the CO2 capture process. A case study is developed and solved to demonstrate the application of this new method. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Panu, Marc; Topolski, Kevin; Abrash, Sarah; El-Halwagi, Mahmoud M.] Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA.
   [El-Halwagi, Mahmoud M.] Texas A&M Engn Expt Stn, Gas & Fuels Res Ctr, College Stn, TX 77843 USA.
RP El-Halwagi, MM (reprint author), Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA.; El-Halwagi, MM (reprint author), Texas A&M Engn Expt Stn, Gas & Fuels Res Ctr, College Stn, TX 77843 USA.
EM El-Halwagi@tamu.edu
RI El-Halwagi, Mahmoud/F-7464-2011
OI El-Halwagi, Mahmoud/0000-0002-0020-2281
CR Agarwal A, 2018, ACS SUSTAIN CHEM ENG, V6, P2407, DOI 10.1021/acssuschemeng.7b03854
   Al-Fadhli FM, 2018, ACS SUSTAIN CHEM ENG, V6, P9130, DOI 10.1021/acssuschemeng.8b01462
   Al-Mohannadi DM, 2016, J CLEAN PROD, V112, P4053, DOI 10.1016/j.jclepro.2015.05.094
   Aresta M., 2010, CARBON DIOXIDE CHEM
   Bao BP, 2011, COMPUT CHEM ENG, V35, P1374, DOI 10.1016/j.compchemeng.2011.04.013
   Bao B, 2010, FUEL PROCESS TECHNOL, V91, P703, DOI 10.1016/j.fuproc.2010.02.001
   Bhanage B.M., 2014, TRANSFORMATION UTILI
   Buxton A, 1997, COMPUT CHEM ENG, V21, pS959, DOI 10.1016/S0098-1354(97)00173-7
   Challiwala MS, 2017, J CO2 UTIL, V17, P99, DOI 10.1016/j.jcou.2016.11.008
   EIA, 2016, CARB DIOX EM COEFF
   El-Halwagi M.M., 2017, PROCESS INTEGRATION, V1, P3, DOI DOI 10.1007/S41660-016-0001-Y
   El-Halwagi MM, 2017, CLEAN TECHNOL ENVIR, V19, P611, DOI 10.1007/s10098-016-1280-2
   Forman GS, 2015, ENVIRON SCI TECHNOL, V49, P4372, DOI 10.1021/es505994w
   Gabriel KJ, 2014, IND ENG CHEM RES, V53, P7087, DOI 10.1021/ie4042998
   Guillen-Cuevas K, 2018, ACS SUSTAIN CHEM ENG, V6, P1411, DOI 10.1021/acssuschemeng.7b03802
   Jasper S, 2015, PROCESSES, V3, P684, DOI 10.3390/pr3030684
   Juarez-Garcia M., 2019, P FIN C COST 1403 AD, V3, P199, DOI DOI 10.1007/S41660-018-0065-Y
   Kamrava S, 2015, CLEAN TECHNOL ENVIR, V17, P119, DOI 10.1007/s10098-014-0767-y
   Koroneos C, 2004, INT J HYDROGEN ENERG, V29, P1443, DOI 10.1016/j.ijhydene.2004.01.016
   Li KK, 2016, APPL ENERG, V165, P648, DOI 10.1016/j.apenergy.2015.12.109
   Miettinen K., 2012, NONLINEAR MULTIOBJEC
   Mukherjee R, 2018, SMART SUSTAIN MANUF, V2, P132, DOI 10.1520/SSMS20180022
   Noureldin MMB, 2015, AICHE J, V61, P1242, DOI 10.1002/aic.14714
   Noureldin MMB, 2015, ACS SUSTAIN CHEM ENG, V3, P625, DOI 10.1021/sc5007736
   Song RR, 2017, ENERGY, V140, P1018, DOI 10.1016/j.energy.2017.09.039
   Song RR, 2017, ENERGY, V135, P382, DOI 10.1016/j.energy.2017.06.136
   Spigarelli BP, 2013, J CO2 UTIL, V1, P69, DOI 10.1016/j.jcou.2013.03.002
   Tilak Pooja, 2018, CARBON RESOURCES CON
   Topolski Kevin, 2018, COMPUT CHEM ENG
   United Nations, 2015, FRAM CONV CLIM CHANG
   Pham V, 2012, AICHE J, V58, P1212, DOI 10.1002/aic.12640
   Wang Michael, 2017, WORKSH OPP CHALL MET
   Zhang C, 2017, CHEM ENG PROG, V113, P28
   Zhao L, 2010, J MEMBRANE SCI, V359, P160, DOI 10.1016/j.memsci.2010.02.003
NR 34
TC 5
Z9 5
U1 4
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 1
EP 11
DI 10.1016/j.ces.2019.03.066
PG 11
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600001
DA 2020-05-12
ER

PT J
AU Bhoi, S
   Das, A
   Kumar, J
   Sarkar, D
AF Bhoi, Stutee
   Das, Ashok
   Kumar, Jitendra
   Sarkar, Debasis
TI Sonofragmentation of two-dimensional plate-like crystals: Experiments
   and Monte Carlo simulations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sonofragmentation; Ultrasound; Monte Carlo simulation; Two-dimensional
   breakage; Particle size distribution; Pyrazinamide
ID PARTICLE BREAKAGE PROCESS; ASPECT-RATIO CRYSTALS; COOLING
   CRYSTALLIZATION; BATCH CRYSTALLIZATION; POPULATION BALANCES; SIZE
   DISTRIBUTION; AGGREGATION; MODEL; PYRAZINAMIDE; COAGULATION
AB A series of sonofragmentation experiments were performed by varying the sonication time and ultrasonic amplitude in order to investigate and simulate the two-dimensional ultrasound-assisted breakage of delta-form of pyrazinamide crystals using Monte Carlo (MC) method. An event driven constant number MC algorithm is presented to predict the evolution of two-dimensional size distribution of the product crystals. The MC simulations were performed by considering the breakage across the width of the particles and restricting the randomness of the break up point to a particular region along the length axis. The results obtained are in excellent agreement with the experimental observations. The proposed MC method reproduces both mode and span of the experimental size distribution with remarkable accuracy for all the cases. Further, it has only one tuning parameter depending on the ultrasonic amplitude. A graphical correlation has been obtained for selection of this tuning parameter for a given ultrasonic amplitude. Thus the proposed MC approach can be used to obtain quantitative view about the effect of sonofragmentation of two-dimensional plate-like crystals. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bhoi, Stutee; Sarkar, Debasis] Indian Inst Technol Kharagpur, Dept Chem Engn, Kharagpur 721302, W Bengal, India.
   [Das, Ashok; Kumar, Jitendra] Indian Inst Technol Kharagpur, Dept Math, Kharagpur 721302, W Bengal, India.
RP Sarkar, D (reprint author), Indian Inst Technol Kharagpur, Dept Chem Engn, Kharagpur 721302, W Bengal, India.
EM dsarkar@che.iitkgp.ernet.in
RI Bhoi, Stutee/AAG-1620-2019
FU Science and Engineering Research Board (SERB), Government of India, New
   Delhi [EMR/2015/002266]
FX The financial assistance received from the Science and Engineering
   Research Board (SERB), Government of India, New Delhi (Project File
   Number: EMR/2015/002266) is gratefully acknowledged.
CR Alexopoulos AH, 2007, CHEM ENG SCI, V62, P5048, DOI 10.1016/j.ces.2007.01.039
   Bari AH, 2014, CAN J CHEM ENG, V92, P2046, DOI 10.1002/cjce.22072
   Bartos C, 2015, CHEM ENG PROCESS, V87, P26, DOI 10.1016/j.cep.2014.10.015
   Bhoi S, 2016, CRYSTENGCOMM, V18, P4863, DOI 10.1039/c6ce00937a
   Castro RAE, 2010, CRYST GROWTH DES, V10, P274, DOI 10.1021/cg900890n
   Dernedde M, 2012, AICHE J, V58, P3016, DOI 10.1002/aic.13709
   Dernedde M, 2011, CHEM ENG TECHNOL, V34, P1177, DOI 10.1002/ceat.201100052
   Faraji M, 2013, J DISPER SCI TECHNOL, V34, P455, DOI 10.1080/01932691.2012.681609
   Frances C, 2014, AICHE J, V60, P1621, DOI 10.1002/aic.14358
   GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3
   Hatkar UN, 2012, IND ENG CHEM RES, V51, P12901, DOI 10.1021/ie202220q
   Hermanto MW, 2015, ORG PROCESS RES DEV, V19, P1987, DOI 10.1021/acs.oprd.5b00234
   Hussain M, 2014, AICHE J, V60, P855, DOI 10.1002/aic.14332
   Hussain M, 2013, CHEM ENG SCI, V101, P35, DOI 10.1016/j.ces.2013.06.004
   Jordens J, 2016, CRYST GROWTH DES, V16, P6167, DOI 10.1021/acs.cgd.6b00088
   Khalili S, 2010, AICHE J, V56, P3137, DOI 10.1002/aic.12233
   Kruis FE, 2000, AICHE J, V46, P1735, DOI 10.1002/aic.690460905
   Lee K, 2000, POWDER TECHNOL, V110, P82, DOI 10.1016/S0032-5910(99)00270-3
   Lu SW, 2016, POWDER TECHNOL, V301, P186, DOI 10.1016/j.powtec.2016.05.059
   METROPOLIS N, 1949, J AM STAT ASSOC, V44, P335, DOI 10.2307/2280232
   Mishra BK, 2000, POWDER TECHNOL, V110, P246, DOI 10.1016/S0032-5910(99)00281-8
   Narducci O, 2011, CHEM ENG SCI, V66, P1069, DOI 10.1016/j.ces.2010.12.008
   Qamar S, 2011, COMPUT CHEM ENG, V35, P412, DOI 10.1016/j.compchemeng.2010.03.016
   Raman V, 2011, AICHE J, V57, P2025, DOI 10.1002/aic.12415
   Rasche ML, 2018, CHEM ENG RES DES, V132, P170, DOI 10.1016/j.cherd.2018.01.014
   Rhodes M, 2008, PARTICLE SIZE REDUCT, P311, DOI DOI 10.1002/9780470727102.CH12
   Sander JRG, 2014, ULTRASON SONOCHEM, V21, P1908, DOI 10.1016/j.ultsonch.2014.02.005
   Sato K, 2008, CHEM ENG SCI, V63, P3271, DOI 10.1016/j.ces.2008.03.013
   Smith M, 1998, CHEM ENG SCI, V53, P1777, DOI 10.1016/S0009-2509(98)00045-1
   Szilagyi B, 2017, COMPUT CHEM ENG, V98, P180, DOI 10.1016/j.compchemeng.2016.11.028
   Terrazas-Velarde K, 2011, CHEM ENG SCI, V66, P1866, DOI 10.1016/j.ces.2011.01.037
   Terrazas-Velarde K, 2011, AICHE J, V57, P3012, DOI 10.1002/aic.12506
   Terrazas-Velarde K, 2009, CHEM ENG SCI, V64, P2631, DOI 10.1016/j.ces.2009.02.041
   Wu C., 2016, PARTICLE TECHNOLOGY, P39, DOI DOI 10.1016/B978-0-08-098337-0.00003-5
   Yu ZQ, 2016, ORG PROCESS RES DEV, V20, P2100, DOI 10.1021/acs.oprd.6b00327
   Zeiger BW, 2011, J AM CHEM SOC, V133, P14530, DOI 10.1021/ja205867f
   Zhao H, 2007, POWDER TECHNOL, V173, P38, DOI 10.1016/j.powtec.2006.12.010
NR 37
TC 3
Z9 3
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 12
EP 27
DI 10.1016/j.ces.2019.03.070
PG 16
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600002
DA 2020-05-12
ER

PT J
AU Lee, K
   Kosaka, H
   Sato, S
   Yokoi, T
   Choi, B
AF Lee, Kyungseok
   Kosaka, Hidenori
   Sato, Susumu
   Yokoi, Toshiyuki
   Choi, Byungchul
TI Effect of Cu content and zeolite framework of n-C4H10-SCR catalysts on
   de-NOx performances
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE C4H10-selective catalytic reduction; de-NOx; Cu/zeolite; Chabazite;
   ZSM-5; BETA
ID SELECTIVE REDUCTION; NITROGEN-OXIDES; HYDROCARBON-SCR; REMOVAL;
   EMISSIONS; CU/ZSM-5; EXHAUST; ENGINE; MECHANISMS; GENERATION
AB The catalytic activity of Cu/zeolites with different types of zeolite frameworks (SSZ-13, ZSM-5, and BETA) was investigated in the selective catalytic reduction of NOx with n-C4H10. The Cu content and zeolite framework significantly affected the catalytic performance in the C4H10-SCR process, where the lowCu-impregnated medium-pore ZSM-5 structure (2Cu/ZSM-5) exhibited the optimal de-NOx performance, followed by the high- and medium Cu-impregnated large- and small-pore BETA and SSZ-13 zeolites (10Cu/BETA and 5Cu/SSZ-13), respectively. The effects of coexistent gases (CO(2 )and O-2) and hydrothermal aging were also evaluated for 2Cu/ZSM-5. CO2 in the feed gas induced an unfavorable effect on NOx reduction because it competed with NO and C4H10 adsorption on the catalyst surface. O-2 in the feed gas had a positive effect on NOx conversion, CO oxidation, and partial oxidation of C4H10, and N-2 selectivity was highly affected by the O-2 concentration, producing a large amount of NH3 in the absence of O-2. The deactivation of the catalytic activity after hydrothermal aging was attributed to collapse of the pore structures and a drop in the zeolite crystallinity. However, there was no catalytic deactivation due to the coke formation by hydrocarbons within 24 h in the steady-state stability test. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lee, Kyungseok] Tokyo Inst Technol, Grad Sch Sci & Engn, Dept Mech & Aerosp Engn, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528550, Japan.
   [Kosaka, Hidenori; Sato, Susumu] Tokyo Inst Technol, Sch Engn, Dept Syst & Control Engn, Meguro Ku, 2-12-1 Ookayama, Tokyo 2121, Japan.
   [Yokoi, Toshiyuki] Tokyo Inst Technol, Inst Innovat Res, Dept Chem Sci & Engn, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.
   [Choi, Byungchul] Chonnam Natl Univ, Sch Mech Engn, Yongbong Ro 77, Gwangiu 61186, South Korea.
RP Sato, S (reprint author), Tokyo Inst Technol, Sch Engn, Dept Syst & Control Engn, Meguro Ku, 2-12-1 Ookayama, Tokyo 2121, Japan.; Choi, B (reprint author), Chonnam Natl Univ, Sch Mech Engn, Yongbong Ro 77, Gwangiu 61186, South Korea.
EM sato.s.ay@m.titech.ac.jp; bcchoi@chonnam.ac.kr
RI Yokoi, Toshiyuki/E-8047-2014; Lee, Kyungseok/AAK-1089-2020
OI Yokoi, Toshiyuki/0000-0002-3315-3172; Lee, Kyungseok/0000-0002-4138-6259
FU Sasamura Foundation for the Promotion of Engineering of Japan; Basic
   Science Research Program through the National Research Foundation of
   Korea (NRF) - Korea Ministry of Science, ICT & Future Planning (MSIP)
   [NRF-2015R1A4A1041746]
FX This research was supported by the Sasamura Foundation for the Promotion
   of Engineering of Japan (2017-2018), and partially supported by the
   Basic Science Research Program through the National Research Foundation
   of Korea (NRF) grant funded by the Korea Ministry of Science, ICT &
   Future Planning (MSIP) (Grant NRF-2015R1A4A1041746). The authors express
   appreciation to Mr. G. G. Jeong and Ms. J. W. Na (Center for Research
   Facilities at Chonnam National University) for assistance with the XRD
   and XPS analyses.
CR [Anonymous], 2019, DATABASE ZEOLITE STR
   Arellano U, 2015, FUEL, V149, P15, DOI 10.1016/j.fuel.2014.11.001
   Baerlocher C., 2007, ATLAS ZEOLITE FRAMEW, DOI [10.1016/B978-0-444-53064-6.X5186-X, DOI 10.1016/B978-0-444-53064-6.X5186-X]
   Baran R, 2012, MICROPOR MESOPOR MAT, V163, P122, DOI 10.1016/j.micromeso.2012.06.055
   Bartholomew CH, 2001, APPL CATAL A-GEN, V212, P17, DOI 10.1016/S0926-860X(00)00843-7
   Battiston AA, 2003, J CATAL, V218, P163, DOI 10.1016/S0021-9517(03)00120-9
   Beale AM, 2015, CHEM SOC REV, V44, P7371, DOI 10.1039/c5cs00108k
   Cant NW, 2000, CATAL TODAY, V63, P133, DOI 10.1016/S0920-5861(00)00453-3
   Capek L, 2005, APPL CATAL B-ENVIRON, V60, P201, DOI 10.1016/j.apcatb.2005.02.033
   Chen CM, 2018, SCI TOTAL ENVIRON, V612, P1424, DOI 10.1016/j.scitotenv.2017.09.019
   Chen XY, 2019, CHEM ENG SCI, V194, P105, DOI 10.1016/j.ces.2018.02.016
   Cheng XX, 2014, PARTICUOLOGY, V16, P1, DOI 10.1016/j.partic.2014.01.006
   Choi B, 2014, CHEM ENG J, V240, P476, DOI 10.1016/j.cej.2013.10.100
   Eilertsen EA, 2008, STUD SURF SCI CATAL, V174, P265
   Erkfeldt S, 2011, APPL CATAL B-ENVIRON, V102, P547, DOI 10.1016/j.apcatb.2010.12.037
   Gao X., 2003, J NAT GAS CHEM, V12, P264
   Gou X, 2015, ENERGIES, V8, P12331, DOI 10.3390/en81112319
   Granger P, 2011, CHEM REV, V111, P3155, DOI 10.1021/cr100168g
   Guesh K, 2016, APPL SURF SCI, V378, P473, DOI 10.1016/j.apsusc.2016.04.029
   Heinrich F, 2002, J CATAL, V212, P157, DOI 10.1006/jcat.2002.3775
   Held W, 1990, 900496 SAE, P13, DOI 10.4271/900496
   Houel V, 2007, APPL CATAL B-ENVIRON, V73, P203, DOI 10.1016/j.apcatb.2006.12.005
   Imai H, 2014, MICROPOR MESOPOR MAT, V196, P341, DOI 10.1016/j.micromeso.2014.05.043
   IWAMOTO M, 1991, J PHYS CHEM-US, V95, P3727, DOI 10.1021/j100162a053
   IWAMOTO M, 1986, J CHEM SOC CHEM COMM, P1272, DOI 10.1039/c39860001272
   IWAMOTO M, 1989, STUDIES SURFACE SCI, V44, P219
   Iwamoto M., 1990, SHOKUBAI, V32, P430
   Jung Y, 2017, CHEM ENG J, V326, P853, DOI 10.1016/j.cej.2017.06.020
   Karnjanakom S, 2018, CATAL COMMUN, V110, P33, DOI 10.1016/j.catcom.2018.03.002
   Kaspar J, 2003, CATAL TODAY, V77, P419, DOI 10.1016/S0920-5861(02)00384-X
   Kim MY, 2014, CATAL TODAY, V231, P90, DOI 10.1016/j.cattod.2013.12.021
   Kim PS, 2013, J CATAL, V301, P65, DOI 10.1016/j.jcat.2013.01.026
   Kim YJ, 2014, CHEMCATCHEM, V6, P1186, DOI 10.1002/cctc.201400093
   Lai SS, 2015, RSC ADV, V5, P90235, DOI 10.1039/c5ra12505g
   Lee K, 2019, J IND ENG CHEM, V72, P73, DOI 10.1016/j.jiec.2018.12.005
   Li JR, 2009, CHEM SOC REV, V38, P1477, DOI 10.1039/b802426j
   Li LD, 2005, ENVIRON SCI TECHNOL, V39, P2841, DOI 10.1021/es049744t
   Li LD, 2004, J CATAL, V228, P12, DOI 10.1016/j.jcat.2004.08.016
   Lin QJ, 2018, DALTON T, V47, P15038, DOI 10.1039/c8dt03156h
   Liu ZM, 2006, CATAL REV, V48, P43, DOI 10.1080/01614940500439891
   Moliner M, 2019, REACT CHEM ENG, V4, P223, DOI 10.1039/c8re00193f
   Mongkolsiri N, 2000, CHEM ENG SCI, V55, P2249, DOI 10.1016/S0009-2509(99)00476-5
   Nasser GA, 2019, MICROPOR MESOPOR MAT, V274, P277, DOI 10.1016/j.micromeso.2018.07.020
   Nishitoba T, 2018, IND ENG CHEM RES, V57, P3914, DOI 10.1021/acs.iecr.7b04985
   OBUCHI A, 1993, APPL CATAL B-ENVIRON, V2, P71, DOI 10.1016/0926-3373(93)80027-B
   Park S, 2018, INT J AUTO TECH-KOR, V19, P199, DOI 10.1007/s12239-018-0019-y
   Pereda-Ayo B, 2014, APPL CATAL B-ENVIRON, V147, P420, DOI 10.1016/j.apcatb.2013.09.010
   Piumetti M, 2015, CATAL STRUCT REACT, V1, P155, DOI 10.1080/2055074X.2015.1105615
   Rahman MM, 2018, J IND ENG CHEM, V61, P304, DOI 10.1016/j.jiec.2017.12.028
   RUCKENSTEIN E, 1973, AICHE J, V19, P356, DOI 10.1002/aic.690190222
   Satsuma A, 2003, CATTECH, V7, P42, DOI 10.1023/A:1022489729769
   Schuricht F, 2012, MICROPOR MESOPOR MAT, V164, P135, DOI 10.1016/j.micromeso.2012.07.018
   Serra RM, 2015, APPL CATAL B-ENVIRON, V166, P592, DOI 10.1016/j.apcatb.2014.11.061
   Shan YL, 2019, CATAL TODAY, V320, P84, DOI 10.1016/j.cattod.2017.11.006
   Shichi A, 2001, APPL CATAL B-ENVIRON, V30, P25, DOI 10.1016/S0926-3373(00)00216-2
   Sitshebo S, 2009, INT J HYDROGEN ENERG, V34, P7842, DOI 10.1016/j.ijhydene.2009.07.059
   Sun PL, 2018, RSC ADV, V8, P36604, DOI 10.1039/c8ra07658h
   Tang JJ, 2017, CHEM ENG SCI, V168, P414, DOI 10.1016/j.ces.2017.04.053
   Traa Y, 1999, MICROPOR MESOPOR MAT, V30, P3, DOI 10.1016/S1387-1811(99)00030-X
   Wang H, 2019, CATAL TODAY, V327, P295, DOI 10.1016/j.cattod.2018.04.035
   Wang JC, 2015, CHEM ENG J, V263, P9, DOI 10.1016/j.cej.2014.10.086
   Watling TC, 2018, CHEM ENG SCI, V178, P312, DOI 10.1016/j.ces.2017.12.007
   WITZEL F, 1994, J CATAL, V149, P229, DOI 10.1006/jcat.1994.1289
   Worch D, 2011, CATAL TODAY, V176, P309, DOI 10.1016/j.cattod.2010.12.008
   Xu GY, 2017, APPL CATAL B-ENVIRON, V207, P60, DOI 10.1016/j.apcatb.2017.02.001
   Xue HY, 2018, CATAL COMMUN, V112, P53, DOI 10.1016/j.catcom.2018.04.020
   Yeom YH, 2004, J PHYS CHEM B, V108, P5386, DOI 10.1021/jp037504e
   Zelekew OA, 2017, APPL SURF SCI, V393, P110, DOI 10.1016/j.apsusc.2016.10.016
   Zhang RD, 2016, CHEM REV, V116, P3658, DOI 10.1021/acs.chemrev.5b00474
   Zhao XH, 2015, KOREAN J CHEM ENG, V32, P1528, DOI 10.1007/s11814-015-0028-8
NR 70
TC 0
Z9 0
U1 15
U2 58
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 28
EP 42
DI 10.1016/j.ces.2019.03.028
PG 15
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600003
DA 2020-05-12
ER

PT J
AU Xia, H
   Li, ZX
   Zhong, X
   Li, BH
   Jiang, YP
   Jiang, YB
AF Xia, Huan
   Li, Zhixian
   Zhong, Xue
   Li, Binghui
   Jiang, Yunpeng
   Jiang, Yanbin
TI HKUST-1 catalyzed efficient in situ regeneration of NAD(+) for
   dehydrogenase mediated oxidation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Alcohol dehydrogenase; Enzyme immobilization; Metal-organic framework;
   Cofactor regeneration; Enzyme catalysis; Chemo-catalysis
ID METAL-ORGANIC FRAMEWORKS; SUFFICIENT HETEROGENEOUS BIOCATALYSTS;
   MIMICKING HORSERADISH-PEROXIDASE; ENZYME IMMOBILIZATION; EMBEDDING
   ENZYMES; NADH PEROXIDASE; STABILITY; MOF; NANOPARTICLES; STRATEGIES
AB The combination of enzymatic and chemical reactions to achieve co-operative chemo-enzymatic processes has presented many challenges for decades. In this work, alcohol dehydrogenase (ADH) was encapsulated into metal-organic framework HKUST-1 crystals through an in situ approach to construct a synergistic chemo- and bio-catalysis system, where ADH was for the conversion of benzyl alcohol to benzaldehyde, and HKUST-1 was in charge for the regeneration of beta-nicotinamide adenine dinucleotide (NAD(+), the oxidized cofactor). It was found that HKUST-1 was a versatile catalyst for efficient oxidation of NADH in different buffers. The Michaelis-Menten kinetic parameters of immobilized ADH exhibited an increased K-M (approximately 1.3-fold) and a decreased V-max (approximately 4.7-fold) compared to free ADH. Due to the protection of HKUST-1, the immobilized enzyme showed a better resistance against urea and organic solvents compared with free enzyme, and still maintained 93% of its original activity after 6 cycles. The immobilized enzyme was successfully applied to the enzymatic transformation of benzyl alcohol to benzaldehyde in aqueous media at room temperature. Owing to the oxidized cofactor regeneration by HKUST-1, ADH@HKUST-1 composites achieved a benzaldehyde yield of 28.5%, which was approximately 4.3-fold higher than that of the individual bio-catalysis. This concept of combining chemo- and bio-catalysis may provide a novel and versatile technique for applications in biochemical catalysis, biosensors and drug delivery. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xia, Huan; Li, Zhixian; Zhong, Xue; Li, Binghui; Jiang, Yunpeng; Jiang, Yanbin] South China Univ Technol, Sch Chem & Chem Engn, Guangdong Prov Key Lab Green Chem Prod Technol, Guangzhou 510640, Guangdong, Peoples R China.
RP Jiang, YB (reprint author), South China Univ Technol, Sch Chem & Chem Engn, Guangdong Prov Key Lab Green Chem Prod Technol, Guangzhou 510640, Guangdong, Peoples R China.
EM cebjiang@scut.edu.cn
OI Jiang, Yanbin/0000-0001-8984-0302
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21706079, 21776102]; Natural Science Foundation of
   Guangdong ProvinceNational Natural Science Foundation of Guangdong
   Province [2014A030312007]
FX Financial support from the National Natural Science Foundation of China
   (Nos. 21706079, 21776102) and Natural Science Foundation of Guangdong
   Province (No. 2014A030312007) is greatly appreciated.
CR Agarwal N, 2017, SCIENCE, V358, P223, DOI 10.1126/science.aan6515
   Barbosa O, 2013, BIOMACROMOLECULES, V14, P2433, DOI 10.1021/bm400762h
   Benitez-Mateos AI, 2017, CHEM-EUR J, V23, P16843, DOI 10.1002/chem.201703475
   Bornscheuer UT, 2012, NATURE, V485, P185, DOI 10.1038/nature11117
   Brondani PB, 2014, J AM CHEM SOC, V136, P16966, DOI 10.1021/ja508265b
   Chen WH, 2018, NAT CATAL, V1, P689, DOI 10.1038/s41929-018-0117-2
   Chen Y, 2014, INORG CHEM, V53, P10006, DOI 10.1021/ic501062r
   Chen Y, 2012, J AM CHEM SOC, V134, P13188, DOI 10.1021/ja305144x
   de Graaf RA, 2014, NMR BIOMED, V27, P802, DOI 10.1002/nbm.3121
   Deng HX, 2012, SCIENCE, V336, P1018, DOI 10.1126/science.1220131
   Doonan C, 2017, ACCOUNTS CHEM RES, V50, P1423, DOI 10.1021/acs.accounts.7b00090
   dos Santos JCS, 2015, CHEMCATCHEM, V7, P2413, DOI 10.1002/cctc.201500310
   Feng DW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6979
   Fernandes RA, 2017, CHEM ENG SCI, V158, P599, DOI 10.1016/j.ces.2016.11.011
   Garcia-Galan C, 2011, ADV SYNTH CATAL, V353, P2885, DOI 10.1002/adsc.201100534
   Gascon V, 2017, CHEMCATCHEM, V9, P1182, DOI 10.1002/cctc.201601342
   Gkaniatsou E, 2017, MATER HORIZ, V4, P55, DOI 10.1039/c6mh00312e
   Golub E, 2011, ANGEW CHEM INT EDIT, V50, P11710, DOI 10.1002/anie.201103853
   Hernandez K, 2012, CURR ORG CHEM, V16, P2652, DOI 10.2174/138527212804004526
   Hogan MC, 2000, CHEM ENG SCI, V55, P2001, DOI 10.1016/S0009-2509(99)00478-9
   Kara S, 2014, APPL MICROBIOL BIOT, V98, P1517, DOI 10.1007/s00253-013-5441-5
   Knowles RR, 2010, P NATL ACAD SCI USA, V107, P20678, DOI 10.1073/pnas.1006402107
   Koeller KM, 2001, NATURE, V409, P232, DOI 10.1038/35051706
   Kong LN, 2012, ACS CATAL, V2, P2577, DOI 10.1021/cs300534y
   Lavandera I, 2008, ORG LETT, V10, P2155, DOI 10.1021/ol800549f
   Li CB, 2003, ANGEW CHEM INT EDIT, V42, P5063, DOI 10.1002/anie.200351902
   Li P, 2016, CHEM-US, V1, P154, DOI 10.1016/j.chempr.2016.05.001
   Li ZX, 2017, NANOSCALE, V9, P15298, DOI 10.1039/c7nr06315f
   Li ZX, 2016, NANOSCALE, V8, P17440, DOI 10.1039/c6nr06115j
   Lian XZ, 2017, CHEM SOC REV, V46, P3386, DOI 10.1039/c7cs00058h
   Liang H, 2016, NANOSCALE, V8, P6071, DOI 10.1039/c5nr08734a
   Liang K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8240
   Liao FS, 2017, J AM CHEM SOC, V139, P6530, DOI 10.1021/jacs.7b01794
   Ling PH, 2018, ANGEW CHEM INT EDIT, V57, P6819, DOI 10.1002/anie.201801369
   Liu WF, 2007, BIOTECHNOL ADV, V25, P369, DOI 10.1016/j.biotechadv.2007.03.002
   Lopez-Gallego F, 2019, METHOD ENZYMOL, V617, P385, DOI 10.1016/bs.mie.2018.12.013
   Lopez-Gallego F, 2017, CHEM-EUR J, V23, P17841, DOI 10.1002/chem.201703593
   Lyu FJ, 2014, NANO LETT, V14, P5761, DOI 10.1021/nl5026419
   Mateo C, 2007, ENZYME MICROB TECH, V40, P1451, DOI 10.1016/j.enzmictec.2007.01.018
   Nath I, 2016, CHEM SOC REV, V45, P4127, DOI 10.1039/c6cs00047a
   Ning D, 2019, SENSOR ACTUAT B-CHEM, V282, P443, DOI 10.1016/j.snb.2018.11.088
   Pang YX, 2018, J AM CHEM SOC, V140, P16032, DOI 10.1021/jacs.8b09257
   Goncalves MCP, 2019, PROCESS BIOCHEM, V76, P95, DOI 10.1016/j.procbio.2018.09.016
   Rauch M, 2017, GREEN CHEM, V19, P376, DOI 10.1039/c6gc02008a
   Rodrigues RC, 2013, CHEM SOC REV, V42, P6290, DOI 10.1039/c2cs35231a
   Rodrigues RC, 2011, ADV SYNTH CATAL, V353, P2216, DOI 10.1002/adsc.201100163
   Schmid A, 2001, NATURE, V409, P258, DOI 10.1038/35051736
   Schmid A, 2002, CURR OPIN BIOTECH, V13, P359, DOI 10.1016/S0958-1669(02)00336-1
   SHARMA VS, 1969, J AM CHEM SOC, V91, P6291, DOI 10.1021/ja01051a017
   Shieh FK, 2015, J AM CHEM SOC, V137, P4276, DOI 10.1021/ja513058h
   Sholl DS, 2015, J PHYS CHEM LETT, V6, P3437, DOI 10.1021/acs.jpclett.5b01135
   Vazquez-Gonzalez M, 2017, ACS NANO, V11, P3247, DOI 10.1021/acsnano.7b00352
   Velasco-Lozano S, 2017, ANGEW CHEM INT EDIT, V56, P771, DOI 10.1002/anie.201609758
   Wang MF, 2015, CHEM ENG SCI, V135, P21, DOI 10.1016/j.ces.2015.03.051
   Wang S, 2017, NANO LETT, V17, P2043, DOI 10.1021/acs.nanolett.7b00093
   Wang XD, 2017, CHEM-US, V2, P621, DOI 10.1016/j.chempr.2017.04.009
   Wang XD, 2016, ACS CATAL, V6, P1880, DOI 10.1021/acscatal.5b02820
   Wu H, 2013, GREEN CHEM, V15, P1773, DOI 10.1039/c3gc37129h
   Xia H, 2019, J COLLOID INTERF SCI, V533, P1, DOI 10.1016/j.jcis.2018.08.052
   Xu L, 2018, ACS APPL MATER INTER, V10, P14321, DOI 10.1021/acsami.7b18005
   Yang Q, 2015, CHEM SOC REV, V44, P2305, DOI 10.1039/c4cs00496e
   Yuan SA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15356
   Zhang YL, 2017, AICHE J, V63, P4920, DOI 10.1002/aic.15841
   Zhu CJ, 2016, ACS CATAL, V6, P4989, DOI 10.1021/acscatal.6b01261
   Zhu QQ, 2018, ACS APPL MATER INTER, V10, P16066, DOI 10.1021/acsami.8b00072
   Zhuang JL, 2011, ADV FUNCT MATER, V21, P1442, DOI 10.1002/adfm.201002529
NR 66
TC 2
Z9 2
U1 51
U2 214
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 43
EP 53
DI 10.1016/j.ces.2019.03.076
PG 11
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600004
DA 2020-05-12
ER

PT J
AU Kohler, MH
   Bordin, JR
   de Matos, CF
   Barbosa, MC
AF Kohler, Mateus H.
   Bordin, Jose R.
   de Matos, Carolina F.
   Barbosa, Marcia C.
TI Water in nanotubes: The surface effect
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Review
DE Nanotube; Water; Hydrophobic surface; Hydrophilic nanotubes
ID MULTIWALLED CARBON NANOTUBES; LIQUID-LIQUID TRANSITION; FLOW
   ENHANCEMENT; MOLECULAR-DYNAMICS; COVALENT MODIFICATION;
   PHASE-TRANSITION; ICE NANOTUBES; TRANSPORT; WALL; DIFFUSION
AB Recent advances in nanotube synthesis and functionalization have allowed for new insights into several physical-chemical aspects of nanofluidics. Processes thought possible only in theory are now attainable experimentally. This raises new questions about the distinctions between fluid behavior in bulk or under extreme confinement. Particularly, the interaction between water molecules and the nanotube wall is expected to play a major role in fluid structure and dynamics. In fact, the very definition of surface hydrophobicity is a sensitive subject, which demands further investigation. Here we present an overview of how changes in interaction and confining distances between water molecules and the nanotube wall can induce freezing, wet/dry transitions and even produce high flow rates. We suggest that the changes in water dynamics due to wall's nature (if hydrophobic or hydrophilic or mixed) indicates that polarity is the key factor for the high mobility of confined water. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kohler, Mateus H.] Univ Fed Santa Maria, Dept Fis, BR-97105900 Santa Maria, RS, Brazil.
   [Kohler, Mateus H.; Barbosa, Marcia C.] Univ Fed Rio Grande do Sul, Inst Fis, BR-91501970 Porto Alegre, RS, Brazil.
   [Bordin, Jose R.] Univ Fed Pelotas, Inst Fis & Matemat, Dept Fis, POB 354, BR-96010900 Pelotas, Brazil.
   [de Matos, Carolina F.] Univ Fed Pampa, Campus Cacapava do Sul, BR-96570000 Cappava Do Sul, Brazil.
RP Kohler, MH (reprint author), Univ Fed Santa Maria, Dept Fis, BR-97105900 Santa Maria, RS, Brazil.
EM mateus.kohler@ufsm.br
RI Kohler, Mateus Henrique/F-1836-2017; Barbosa, Marcia C/C-8809-2012;
   Bordin, Jose Rafael/L-3503-2013; DE MATOS JAURIS, CAROLINA
   FERREIRA/M-5832-2016
OI Kohler, Mateus Henrique/0000-0001-9733-9630; Barbosa, Marcia
   C/0000-0001-5663-6102; Bordin, Jose Rafael/0000-0002-8025-6529; Ferreira
   de Matos, Carolina/0000-0001-8134-1656
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [001]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); INCT-FCx; Fundacao de Amparo a Pesquisa do Estado do Rio Grande
   do Sul (FAPERGS)Foundation for Research Support of the State of Rio
   Grande do Sul (FAPERGS)
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Finance Code 001, Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq), INCT-FCx, and
   Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS).
CR Abbasi HR, 2016, J MOL LIQ, V224, P165, DOI 10.1016/j.molliq.2016.09.083
   Agrawal KV, 2017, NAT NANOTECHNOL, V12, P267, DOI [10.1038/nnano.2016.254, 10.1038/NNANO.2016.254]
   Ahmad M, 2015, ADV FUNCT MATER, V25, P4419, DOI 10.1002/adfm.201501214
   Alabarse FG, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.035701
   Amara MS, 2015, CHEM MATER, V27, P1488, DOI 10.1021/cm503428q
   Andreev S, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2104529
   Aryal P, 2015, J MOL BIOL, V427, P121, DOI 10.1016/j.jmb.2014.07.030
   Bai JE, 2006, P NATL ACAD SCI USA, V103, P19664, DOI 10.1073/pnas.0608401104
   Balasubramanian K, 2005, SMALL, V1, P180, DOI 10.1002/smll.200400118
   BARRAT JL, 1990, MOL PHYS, V70, P535, DOI 10.1080/00268979000101181
   Bensghaier A, 2017, LANGMUIR, V33, P6677, DOI 10.1021/acs.langmuir.7b00711
   Bernardina SD, 2016, J AM CHEM SOC, V138, P10437, DOI 10.1021/jacs.6b02635
   Beu TA, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3387972
   Bocquet L, 2007, SOFT MATTER, V3, P685, DOI 10.1039/b616490k
   Bocquet L, 2014, LAB CHIP, V14, P3143, DOI 10.1039/c4lc00325j
   Bonthuis DJ, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.209401
   Bonthuis DJ, 2010, LANGMUIR, V26, P12614, DOI 10.1021/la9034535
   Bordin JR, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4746748
   Bordin JR, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.031914
   Bordin JR, 2016, EUR PHYS J-SPEC TOP, V225, P1693, DOI 10.1140/epjst/e2016-60150-1
   Bordin JR, 2017, PHYSICA A, V467, P137, DOI 10.1016/j.physa.2016.10.007
   Bordin JR, 2014, J CHEM PHYS, V140, DOI 10.1063/1.4876555
   Bordin JR, 2014, J PHYS CHEM C, V118, P9497, DOI 10.1021/jp5010506
   Bordin JR, 2013, J PHYS CHEM B, V117, P7047, DOI 10.1021/jp402141f
   Borg MK, 2017, MRS BULL, V42, P294, DOI 10.1557/mrs.2017.59
   Calabro F, 2013, APPL MATH LETT, V26, P991, DOI 10.1016/j.aml.2013.05.004
   Calabro F, 2017, MRS BULL, V42, P289, DOI 10.1557/mrs.2017.58
   Chen QW, 2011, SMALL, V7, P2225, DOI 10.1002/smll.201100287
   Christenson HK, 2001, J PHYS-CONDENS MAT, V13, pR95, DOI 10.1088/0953-8984/13/11/201
   Cicero G, 2008, J AM CHEM SOC, V130, P1871, DOI 10.1021/ja074418+
   de Groot BL, 2005, CURR OPIN STRUC BIOL, V15, P176, DOI 10.1016/j.sbi.2005.02.003
   Duan RX, 2013, ACS NANO, V7, P8344, DOI 10.1021/nn405092w
   Farimani AB, 2016, J PHYS CHEM C, V120, P23763, DOI 10.1021/acs.jpcc.6b06156
   Fumagalli L, 2018, SCIENCE, V360, P1339, DOI 10.1126/science.aat4191
   Gallo P, 2016, CHEM REV, V116, P7463, DOI 10.1021/acs.chemrev.5b00750
   Gavazzoni C, 2017, J CHEM PHYS, V146, DOI 10.1063/1.4985626
   Georgakilas V, 2007, J MATER CHEM, V17, P2679, DOI 10.1039/b700857k
   Ghosh S, 2003, SCIENCE, V299, P1042, DOI 10.1126/science.1079080
   Goh KL, 2017, NANO TODAY, V14, P13, DOI 10.1016/j.nantod.2016.12.015
   Goh PS, 2013, DESALINATION, V308, P2, DOI 10.1016/j.desal.2012.07.040
   Gomes D, 2009, BBA-BIOMEMBRANES, V1788, P1213, DOI 10.1016/j.bbamem.2009.03.009
   Gong XJ, 2007, NAT NANOTECHNOL, V2, P709, DOI 10.1038/nnano.2007.320
   Gong XJ, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.257801
   Gravelle S, 2013, P NATL ACAD SCI USA, V110, P16367, DOI 10.1073/pnas.1306447110
   Guo SR, 2015, ADV MATER, V27, P5726, DOI 10.1002/adma.201500372
   Hassan J, 2018, J PHYS CHEM C, V122, P10600, DOI 10.1021/acs.jpcc.8b01377
   He YZ, 2014, SCI REP-UK, V4, DOI 10.1038/srep03635
   Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048
   Hirsch A, 2002, ANGEW CHEM INT EDIT, V41, P1853, DOI 10.1002/1521-3773(20020603)41:11<1853::AID-ANIE1853>3.0.CO;2-N
   Holland DM, 2015, MICROFLUID NANOFLUID, V18, P461, DOI 10.1007/s10404-014-1443-6
   Holt JK, 2006, SCIENCE, V312, P1034, DOI 10.1126/science.1126298
   Hou X, 2010, J AM CHEM SOC, V132, P11736, DOI 10.1021/ja1045082
   Hsiao CH, 2017, CARBON, V124, P637, DOI 10.1016/j.carbon.2017.09.023
   Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535
   Ibrahim I, 2016, ACS NANO, V10, P7248, DOI 10.1021/acsnano.6b03744
   Jianlong K, 2015, ANGEW CHEM, V127, P2381
   Joly L, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3664622
   Joseph S, 2008, NANO LETT, V8, P452, DOI 10.1021/nl072385q
   Joseph S, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.064502
   Kannam SK, 2017, MRS BULL, V42, P283, DOI 10.1557/mrs.2017.61
   Kannam SK, 2013, J CHEM PHYS, V138, DOI 10.1063/1.4793396
   Kim J, 2016, ACS APPL MATER INTER, V8, P29877, DOI 10.1021/acsami.6b10965
   Koga K, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2172592
   Koga K, 2000, J CHEM PHYS, V113, P5037, DOI 10.1063/1.1289554
   Koga K, 2001, NATURE, V412, P802, DOI 10.1038/35090532
   Koga K, 2002, PHYSICA A, V314, P462, DOI 10.1016/S0378-4371(02)01074-9
   Kohler MH, 2019, J MOL LIQ, V277, P516, DOI 10.1016/j.molliq.2018.12.077
   Kohler MH, 2018, J PHYS CHEM C, V122, P6684, DOI 10.1021/acs.jpcc.8b00112
   Kohler MH, 2018, J CHEM PHYS, V148, DOI 10.1063/1.5013926
   Kohler MH, 2018, PHYSICA A, V490, P331, DOI 10.1016/j.physa.2017.08.030
   Kohler MH, 2017, PHYS CHEM CHEM PHYS, V19, P12921, DOI 10.1039/c7cp02058a
   Kohler MH, 2016, CHEM PHYS LETT, V645, P38, DOI 10.1016/j.cplett.2015.12.020
   Kolesnikov AI, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.035503
   Kou JL, 2014, NANO LETT, V14, P4931, DOI 10.1021/nl500664y
   Kou JL, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.056301
   Kral P, 2001, PHYS REV LETT, V86, P131, DOI 10.1103/PhysRevLett.86.131
   Kumar H, 2015, RSC ADV, V5, P1893, DOI 10.1039/c4ra08730e
   Kumar P, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.051503
   Kyakuno H, 2016, J CHEM PHYS, V145, DOI 10.1063/1.4960609
   Kyakuno H, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3593064
   Lee B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8109
   Lee KP, 2012, NANOSCALE, V4, P2621, DOI 10.1039/c2nr30098b
   Lee SH, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3634209
   Lee SH, 2018, CHEM ENG SCI, V192, P655, DOI 10.1016/j.ces.2018.07.041
   Li JX, 2016, J PHYS CHEM C, V120, P6493, DOI 10.1021/acs.jpcc.5b11040
   Li JY, 2007, P NATL ACAD SCI USA, V104, P3687, DOI 10.1073/pnas.0604541104
   Li XP, 2013, APPL PHYS LETT, V103, DOI 10.1063/1.4824441
   Li XM, 2014, RSC ADV, V4, P3245, DOI 10.1039/c3ra43545h
   Liao Y, 2018, NANO RES, V11, P1
   Liu BL, 2013, NANO LETT, V13, P4416, DOI 10.1021/nl402259k
   Liu JW, 2007, J APPL PHYS, V101, DOI 10.1063/1.2710776
   Liu KH, 2013, J CHEM PHYS, V139, DOI 10.1063/1.4817186
   Liu L, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2857474
   Liu YC, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.085420
   Liu YC, 2005, LANGMUIR, V21, P12025, DOI 10.1021/la0517181
   Liu YC, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.125438
   Lobo AO, 2012, MATER LETT, V70, P89, DOI 10.1016/j.matlet.2011.11.071
   Machado FM, 2016, J PHYS CHEM C, V120, P18296, DOI 10.1021/acs.jpcc.6b03884
   Maillet P, 2011, PHYS CHEM CHEM PHYS, V13, P2682, DOI 10.1039/c0cp01851a
   Majumder M, 2005, NATURE, V438, P44, DOI 10.1038/43844a
   Majumder M, 2008, J MEMBRANE SCI, V316, P89, DOI 10.1016/j.memsci.2007.09.068
   Majumder M, 2011, CHEM COMMUN, V47, P7683, DOI 10.1039/c1cc11134e
   Maniwa Y, 2005, CHEM PHYS LETT, V401, P534, DOI 10.1016/j.cplett.2004.11.112
   Maniwa Y, 2007, NAT MATER, V6, P135, DOI 10.1038/nmat1823
   Matos CF, 2012, CARBON, V50, P4685, DOI 10.1016/j.carbon.2012.05.060
   Mattia D, 2012, MICROFLUID NANOFLUID, V13, P125, DOI 10.1007/s10404-012-0949-z
   Mauter MS, 2008, ENVIRON SCI TECHNOL, V42, P5843, DOI 10.1021/es8006904
   Melillo M, 2011, J PHYS CHEM LETT, V2, P2978, DOI 10.1021/jz2012319
   Mendonca BHS, 2019, PHYSICA A, V517, P491, DOI 10.1016/j.physa.2018.11.042
   Merz PT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202764
   Michaelides A, 2016, NATURE, V537, P171, DOI 10.1038/537171a
   Misra A, 2009, ACS NANO, V3, P3903, DOI 10.1021/nn900878d
   Miyauchi M, 2007, J MATER CHEM, V17, P2095, DOI 10.1039/b700387k
   Mochizuki K, 2015, P NATL ACAD SCI USA, V112, P8221, DOI 10.1073/pnas.1422829112
   Moskowitz I, 2014, J CHEM PHYS, V141, DOI 10.1063/1.4897974
   Mukherjee S, 2007, J AM CHEM SOC, V129, P6820, DOI 10.1021/ja070124c
   Naguib N, 2004, NANO LETT, V4, P2237, DOI 10.1021/nl0484907
   Nomura K, 2017, P NATL ACAD SCI USA, V114, P4066, DOI 10.1073/pnas.1701609114
   Noon WH, 2002, CHEM PHYS LETT, V355, P445, DOI 10.1016/S0009-2614(02)00209-9
   Noy A, 2007, NANO TODAY, V2, P22, DOI 10.1016/S1748-0132(07)70170-6
   Ohba T., 2014, ANGEW CHEM, V126, P8170, DOI DOI 10.1002/ANGE.201403839
   Ohba T, 2015, LANGMUIR, V31, P1058, DOI 10.1021/la504522x
   Oytun F, 2017, THIN SOLID FILMS, V625, P168, DOI 10.1016/j.tsf.2017.01.066
   Palmer JC, 2014, NATURE, V510, P385, DOI 10.1038/nature13405
   Park MJ, 2006, CHEM MATER, V18, P1546, DOI 10.1021/cm0511421
   Pascal TA, 2011, P NATL ACAD SCI USA, V108, P11794, DOI 10.1073/pnas.1108073108
   Patel AJ, 2012, J PHYS CHEM B, V116, P2498, DOI 10.1021/jp2107523
   Perebeinos V, 2014, NANO LETT, V14, P4376, DOI 10.1021/nl5012646
   Porada S, 2012, ACS APPL MATER INTER, V4, P1194, DOI 10.1021/am201683j
   Pugliese P, 2017, J PHYS CHEM B, V121, P10371, DOI 10.1021/acs.jpcb.7b06306
   Qu LT, 2006, J AM CHEM SOC, V128, P5523, DOI 10.1021/ja060296u
   Ramazani F, 2016, J PHYS CHEM C, V120, P12871, DOI 10.1021/acs.jpcc.6b03182
   Roy D, 2015, J PHYS CHEM C, V119, P716, DOI 10.1021/jp509537b
   Sanchez-Valencia JR, 2014, NATURE, V512, P61, DOI 10.1038/nature13607
   Scatena LF, 2001, SCIENCE, V292, P908, DOI 10.1126/science.1059514
   Schaffel D, 2016, PHYS REV LETT, V116, DOI 10.1103/PhysRevLett.116.134501
   Schoch RB, 2008, REV MOD PHYS, V80, P839, DOI 10.1103/RevModPhys.80.839
   Schweiger M, 2015, CARBON, V95, P452, DOI 10.1016/j.carbon.2015.08.058
   Secchi E, 2016, NATURE, V537, P210, DOI 10.1038/nature19315
   Setaro A, 2017, J PHYS-CONDENS MAT, V29, DOI 10.1088/1361-648X/aa8248
   Shayeganfar F, 2018, LANGMUIR, V34, P11176, DOI 10.1021/acs.langmuir.8b00856
   Shim M, 2002, NANO LETT, V2, P285, DOI 10.1021/nl015692j
   Shiomi J, 2007, J PHYS CHEM C, V111, P12188, DOI 10.1021/jp071508s
   Shtogun YV, 2009, J PHYS CHEM C, V113, P4792, DOI 10.1021/jp807206m
   Siria A, 2013, NATURE, V494, P455, DOI 10.1038/nature11876
   Smallenburg F, 2014, NAT PHYS, V10, P653, DOI [10.1038/nphys3030, 10.1038/NPHYS3030]
   Sotthewes K, 2017, ACS NANO, V11, P12723, DOI 10.1021/acsnano.7b07472
   Strano MS, 2003, SCIENCE, V301, P1519, DOI 10.1126/science.1087691
   Striolo A, 2016, ANNU REV CHEM BIOMOL, V7, P533, DOI 10.1146/annurev-chembioeng-080615-034455
   Striolo A, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/47/475704
   Su JY, 2011, ACS NANO, V5, P351, DOI 10.1021/nn1014616
   Suk ME, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2907333
   Takaiwa D, 2008, P NATL ACAD SCI USA, V105, P39, DOI 10.1073/pnas.0707917105
   Tanaka H, 2005, J CHEM PHYS, V123, DOI 10.1063/1.2031127
   Tao JB, 2018, CHEM ENG SCI, V192, P1252, DOI 10.1016/j.ces.2018.05.018
   TARJUS G, 1995, J CHEM PHYS, V103, P3071, DOI 10.1063/1.470495
   Ternes P, 2018, PHYS REV E, V97, DOI 10.1103/PhysRevE.97.033104
   Thomas JA, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.184502
   Thomas M, 2015, PHILOS T R SOC A, V374, P2060
   Thomas M, 2014, SMALL, V10, P1453, DOI 10.1002/smll.201302968
   Vaitheeswaran S, 2004, J CHEM PHYS, V121, P7955, DOI 10.1063/1.1796271
   Vukovic L, 2014, J PHYS CHEM LETT, V5, P2131, DOI 10.1021/jz500761s
   Waghe A, 2002, J CHEM PHYS, V117, P10789, DOI 10.1063/1.1519861
   Wang HJ, 2008, SCIENCE, V322, P80, DOI 10.1126/science.1162412
   Wang J, 2016, J MATER CHEM A, V4, P7565, DOI 10.1039/c6ta02034h
   Wei XL, 2013, ACS NANO, V7, P3491, DOI 10.1021/nn400423y
   Wei XF, 2018, J PHYS CHEM C, V122, P5131, DOI 10.1021/acs.jpcc.7b11657
   Won CY, 2008, J PHYS CHEM C, V112, P1812, DOI 10.1021/jp076747u
   Wong-ekkabut J, 2016, BBA-BIOMEMBRANES, V1858, P2529, DOI 10.1016/j.bbamem.2016.02.004
   Wu KL, 2017, P NATL ACAD SCI USA, V114, P3358, DOI 10.1073/pnas.1612608114
   Xie L, 2017, LANGMUIR, V33, P3911, DOI 10.1021/acs.langmuir.6b04669
   Xu BX, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3651158
   Xu YS, 2016, J PHYS D APPL PHYS, V49, DOI 10.1088/0022-3727/49/28/285302
   Yang HY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3220
   Yao MG, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.205411
   Yesilbas M, 2018, ACS EARTH SPACE CHEM, V2, P38, DOI 10.1021/arsearthspacechem.7b00103
   Yesilbas M, 2016, J PHYS CHEM LETT, V7, P2849, DOI 10.1021/acs.jpclett.6b01037
   Yuet PK, 2010, J PHYS CHEM B, V114, P13786, DOI 10.1021/jp1067022
   Zang J, 2009, ACS NANO, V3, P1548, DOI 10.1021/nn9001837
   Zhang L, 2018, J MOL LIQ, V258, P98, DOI 10.1016/j.molliq.2017.12.065
   Zhang MN, 2006, CARBON, V44, P276, DOI 10.1016/j.carbon.2005.07.021
   Zhou M, 2017, CHEM PHYS LETT, V686, P173, DOI 10.1016/j.cplett.2017.08.022
   Zuo GC, 2010, ACS NANO, V4, P205, DOI 10.1021/nn901334w
NR 183
TC 8
Z9 8
U1 29
U2 91
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 54
EP 67
DI 10.1016/j.ces.2019.03.062
PG 14
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600005
DA 2020-05-12
ER

PT J
AU Bulfin, B
   Lapp, J
   Richter, S
   Guban, D
   Vieten, J
   Brendelberger, S
   Roeb, M
   Sattler, C
AF Bulfin, Brendan
   Lapp, Justin
   Richter, Sebastian
   Guban, Dorottya
   Vieten, Josua
   Brendelberger, Stefan
   Roeb, Martin
   Sattler, Christian
TI Air separation and selective oxygen pumping via temperature and pressure
   swing oxygen adsorption using a redox cycle of SrFeO3 perovskite
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Thermochemical redox cycle; Oxygen pump; Gas separation; Nitrogen
   production
ID ENERGETICS; NONSTOICHIOMETRY; CHEMISTRY; CARRIERS; SORPTION; CRYSTAL;
   OXIDES; SYSTEM
AB The achievement of low oxygen partial pressures is beneficial in a number of applications, including the production of nitrogen for the Habor-Bosch process, one of the largest industrial chemical processes. It has been suggested in the literature that a redox cycle can be utilized for selective oxygen adsorption, with the potential for application in oxygen separation and compression processes. In this work we demonstrate this concept and show the feasibility of using a temperature and pressure swing redox cycle to chemically absorb oxygen gas at a low partial pressure of 10(-6) bar. The redox material used was the perovskite oxide SrFeO3, chosen for its relatively low reduction temperature and strong oxygen affinity. The material's intrinsic thermodynamics and low temperature kinetics were both investigated using thermogravimetric analysis. Multiple reduction and oxidation experiments were conducted, with oxidation performed under both synthetic air and inert gas with 1% O-2 concentration. The results show successful trials of oxygen removal resulting in inert gasses with ppm level oxygen impurities and no degradation of the material over multiple cycles. Thermodynamic considerations suggest that with further development this technology could offer a very attractive, reversible cycle for the removal of oxygen impurities from gas streams, particularly in combination with conventional pressure swing adsorption. (C) 2019 Published by Elsevier Ltd.
C1 [Bulfin, Brendan; Lapp, Justin; Richter, Sebastian; Guban, Dorottya; Vieten, Josua; Brendelberger, Stefan; Roeb, Martin; Sattler, Christian] German Aerosp Ctr DLR, Inst Solar Res, D-51147 Cologne, Germany.
RP Roeb, M (reprint author), German Aerosp Ctr DLR, Inst Solar Res, D-51147 Cologne, Germany.
EM martin.roeb@dlr.de
RI Sattler, Christian/A-7860-2012
OI Sattler, Christian/0000-0002-4314-1124; Richter,
   Sebastian/0000-0002-6403-6796; Bulfin, Brendan/0000-0001-9361-0075
FU Helmholtz AssociationHelmholtz Association [VH-VI-509]; project DUSOL -
   Klimaschutzwettbewerb "ErneuerbareEnergien.NRW" by the state of
   Northrhine-Westphalia, Germany [EFRE-0800603]; European EFRE fund
FX This work has received funding from the Helmholtz Association VH-VI-509
   in the framework of the virtual institute SolarSyngas, and the project
   DUSOL (EFRE-0800603) which is co-funded in the Klimaschutzwettbewerb
   "ErneuerbareEnergien.NRW" by the state of Northrhine-Westphalia,
   Germany, and the European EFRE fund.
CR Bakken E, 2004, SOLID STATE IONICS, V167, P367, DOI 10.1016/j.ssi.2004.01.014
   BATTLE PD, 1989, J SOLID STATE CHEM, V79, P75, DOI 10.1016/0022-4596(89)90252-1
   Brendelberger S, 2017, SOL ENERGY, V141, P91, DOI 10.1016/j.solener.2016.11.023
   Bulfin B, 2017, J MATER CHEM A, V5, P18951, DOI 10.1039/c7ta05025a
   Bulfin B, 2017, J MATER CHEM A, V5, P7912, DOI 10.1039/c7ta00822h
   Chueh WC, 2010, SCIENCE, V330, P1797, DOI 10.1126/science.1197834
   Danks A, MAT HORIZ
   Erisman JW, 2008, NAT GEOSCI, V1, P636, DOI 10.1038/ngeo325
   Ezbiri M, 2015, CHEMSUSCHEM, V8, P1966, DOI 10.1002/cssc.201500239
   Haavik C, 2002, PHYS CHEM CHEM PHYS, V4, P1082, DOI 10.1039/b109683d
   Haavik C, 2001, PHYS CHEM CHEM PHYS, V3, P3863, DOI 10.1039/b104401j
   Holt A, 1999, IONICS, V5, P434, DOI 10.1007/BF02376010
   Ikeda H, 2016, CHEM ENG SCI, V147, P166, DOI 10.1016/j.ces.2016.03.034
   Jennings J. R, 2013, CATALYTIC AMMONIA SY
   Kawabe M, 1997, ENERGY, V22, P1041, DOI 10.1016/S0360-5442(97)00044-3
   Kozhevnikov VL, 2001, J SOLID STATE CHEM, V158, P320, DOI 10.1006/jssc.2001.9120
   Krishnamurthy K, 2008, TECH REP
   Kubicek M, 2017, J MATER CHEM A, V5, P11983, DOI 10.1039/c7ta00987a
   Lau CY, 2017, ENERG ENVIRON SCI, V10, P818, DOI 10.1039/c6ee02763f
   Mattisson T, 2009, INT J GREENH GAS CON, V3, P11, DOI 10.1016/j.ijggc.2008.06.002
   Merkulov OV, 2016, SOLID STATE IONICS, V292, P116, DOI 10.1016/j.ssi.2016.05.009
   Moghtaderi B, 2010, ENERG FUEL, V24, P190, DOI 10.1021/ef900553j
   Neises M, 2012, SOL ENERGY, V86, P3040, DOI 10.1016/j.solener.2012.07.012
   Ryden M, 2014, APPL ENERG, V113, P1924, DOI 10.1016/j.apenergy.2013.06.016
   Schmidt M, 2001, J SOLID STATE CHEM, V156, P292, DOI 10.1006/jssc.2000.8998
   Shah K, 2012, ENERG FUEL, V26, P2038, DOI 10.1021/ef300132c
   Stokes RG, 2015, BUILDING AIR HIST IN
   TAKEDA Y, 1986, J SOLID STATE CHEM, V63, P237, DOI 10.1016/0022-4596(86)90174-X
   TOFIELD BC, 1975, MATER RES BULL, V10, P737, DOI 10.1016/0025-5408(75)90059-8
   Vieten J, 2016, J MATER CHEM A, V4, P13652, DOI 10.1039/c6ta04867f
   Wang K, 2013, J THERM ANAL CALORIM, V112, P747, DOI 10.1007/s10973-012-2596-8
   Wong B., 2011, THERMOCHEMICAL HEAT, DOI [10.2172/1039304, DOI 10.2172/1039304]
   Yang ZH, 2003, IND ENG CHEM RES, V42, P4376, DOI 10.1021/ie030313d
   Yang ZH, 2002, IND ENG CHEM RES, V41, P2775, DOI 10.1021/ie010736k
   Yoo J, 2017, J AM CERAM SOC, V100, P2690, DOI 10.1111/jace.14755
NR 35
TC 5
Z9 5
U1 11
U2 45
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 68
EP 75
DI 10.1016/j.ces.2019.03.057
PG 8
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600006
DA 2020-05-12
ER

PT J
AU Wenzel, M
   Sundmacher, K
AF Wenzel, Marcus
   Sundmacher, Kai
TI Derivation of rate equations for equilibrium limited gas-solid reactions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Rate equation; Gas-solid reaction; Equilibrium; Process modeling;
   Thermodynamics; Dynamic simulation
ID FIXED-BED REACTOR; CARBON DEPOSITION; HYDROGEN-PRODUCTION; KINETICS;
   CO2; METHANE; STEAM; GASIFICATION; CALCINATION; SIMULATION
AB In this work the differences between the formulation of reaction rate equations for equilibrium limited reactions in homogeneous and heterogeneous systems are investigated. A rigorous derivation for equilibrium limited gas-solid reactions is proposed based on the core ideas of homogeneous gas phase reactions. The resulting reaction rate expression allows for two distinct reaction rate mechanisms for the forward and reverse reaction direction and is, therefore, valid in both reaction directions. The thermodynamic consistency and the validity of the proposed reaction rate expression is shown using a simple reactor model. The results are compared to traditional reaction rate expressions and it is explained why they are not able to appropriately describe the true reaction behavior in some cases. The implications and use cases for process modeling are investigated and suggestions are proposed for solving numerical challenges associated with the proposed reaction rate equations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wenzel, Marcus; Sundmacher, Kai] Max Planck Inst Dynam Complex Tech Syst, Sandtorstr 1, D-39106 Magdeburg, Germany.
   [Sundmacher, Kai] Otto von Guericke Univ, Univ Pl 2, D-39106 Magdeburg, Germany.
RP Wenzel, M (reprint author), Max Planck Inst Dynam Complex Tech Syst, Sandtorstr 1, D-39106 Magdeburg, Germany.
EM wenzel@mpi-magdeburg.mpg.de
OI Wenzel, Marcus/0000-0002-9921-6973
CR Abanades JC, 2003, ENERG FUEL, V17, P308, DOI 10.1021/ef020152a
   Abbas HF, 2010, INT J HYDROGEN ENERG, V35, P1160, DOI 10.1016/j.ijhydene.2009.11.036
   [Anonymous], 1998, J PHYS CHEM REFERENC
   Atkins P, 2010, PHYS CHEM
   Atsonios K, 2015, FUEL, V153, P370, DOI 10.1016/j.fuel.2015.03.014
   BARKER R, 1973, J APPL CHEM BIOTECHN, V23, P733
   BARTHOLOMEW CH, 1982, CATAL REV, V24, P67, DOI 10.1080/03602458208079650
   Baskan  O., 2016, OPTIMIZATION ALGORIT, DOI [10.5772/61426, DOI 10.5772/61426]
   Benguerba Y, 2015, REACT KINET MECH CAT, V115, P483, DOI 10.1007/s11144-015-0849-9
   Benguerba Y, 2015, REACT KINET MECH CAT, V114, P109, DOI 10.1007/s11144-014-0772-5
   Biegler LT, 2010, NONLINEAR PROGRAMMIN
   Bogdandy L. v, 2013, REDUKTION EISENERZE
   Bremer J, 2017, AICHE J, V63, P23, DOI 10.1002/aic.15496
   Broda M, 2014, GREEN CHEM SUSTAIN T, P181, DOI 10.1007/978-3-642-54646-4_6
   Christensen KO, 2006, APPL CATAL A-GEN, V314, P9, DOI 10.1016/j.apcata.2006.07.028
   Denbigh K. G., 1981, PRINCIPLES CHEM EQUI
   Garcia-Labiano F, 2002, CHEM ENG SCI, V57, P2381, DOI 10.1016/S0009-2509(02)00137-9
   Grasa G, 2014, ENERG FUEL, V28, P4033, DOI 10.1021/ef500331t
   Hacker V, 2000, J POWER SOURCES, V86, P531, DOI 10.1016/S0378-7753(99)00458-9
   Hertel C, 2012, INT J HYDROGEN ENERG, V37, P2195, DOI 10.1016/j.ijhydene.2011.10.085
   HEWLETT PC, 1998, LEAS CHEM CEMENT CON
   Iliuta I, 2010, AICHE J, V56, P1063, DOI 10.1002/aic.11967
   Kambolis A, 2015, CHIMIA, V69, P608, DOI 10.2533/chimia.2015.608
   Kenny M, 2000, LIME AND LIMESTONE
   Khawam A, 2006, J PHYS CHEM B, V110, P17315, DOI 10.1021/jp062746a
   Levenspiel O, 2005, CHEM REACTION ENG
   Lorente E, 2008, INT J HYDROGEN ENERG, V33, P615, DOI 10.1016/j.ijhydene.2007.09.026
   Maestri M, 2012, CHEM ENG SCI, V74, P296, DOI 10.1016/j.ces.2012.02.043
   Marin G., 2011, KINETICS CHEM REACTI
   Messerschmitt, 1911, VERF ERZ WASS DURCH
   Oeters F, 2000, IRON 1 FUNDAMENTALS
   Pedernera MN, 2007, CHEM ENG J, V134, P138, DOI 10.1016/j.cej.2007.03.051
   Ramezani M, 2017, ENRGY PROCED, V114, P259, DOI 10.1016/j.egypro.2017.03.1168
   Silaban A, 1996, CHEM ENG COMMUN, V146, P149, DOI 10.1080/00986449608936487
   Snoeck JW, 2002, IND ENG CHEM RES, V41, P4252, DOI 10.1021/ie010666h
   Sohn HY, 2014, METALL MATER TRANS B, V45, P1600, DOI 10.1007/s11663-014-0113-0
   Stamnore BR, 2005, FUEL PROCESS TECHNOL, V86, P1707, DOI 10.1016/j.fuproc.2005.01.023
   Sun D, 2017, CHEM ENG J, V329, P165, DOI 10.1016/j.cej.2017.06.160
   TAMAI Y, 1977, CARBON, V15, P103, DOI 10.1016/0008-6223(77)90024-0
   Valverde JM, 2015, J PHYS CHEM C, V119, P1623, DOI 10.1021/jp508745u
   Wang HT, 2013, METALL MATER TRANS B, V44, P133, DOI 10.1007/s11663-012-9754-z
   Wang Z., 2010, COMPREHENSIVE ORGANI
   Wenzel M, 2018, CHEM ENG J, V336, P278, DOI 10.1016/j.cej.2017.12.031
   Wenzel M, 2017, AICHE J, V63, P15, DOI 10.1002/aic.15445
   Yan M, 2012, APPL ENERG, V97, P754, DOI 10.1016/j.apenergy.2012.02.055
   Ylatalo J, 2012, INT J GREENH GAS CON, V9, P130, DOI 10.1016/j.ijggc.2012.03.008
   Yuan ZX, 2013, METALL MATER TRANS B, V44, P1520, DOI 10.1007/s11663-013-9910-0
NR 47
TC 0
Z9 0
U1 3
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 76
EP 85
DI 10.1016/j.ces.2019.03.064
PG 10
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600007
DA 2020-05-12
ER

PT J
AU Liu, HL
   Idem, R
   Tontiwachwuthikul, P
AF Liu, Helei
   Idem, Raphael
   Tontiwachwuthikul, Paitoon
TI Novel models for correlation of Solubility constant and diffusivity of
   N2O in aqueous 1-dimethylamino-2-propanol
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE 1DMA2P; Solubility constant; Diffusivity; Novel model; Proposed
   mechanism
ID METHYLDIETHANOLAMINE PLUS WATER; CARBON-DIOXIDE; NITROUS-OXIDE; PHYSICAL
   SOLUBILITY; HYDROGEN-SULFIDE; CO2 CAPTURE; MONOETHANOLAMINE; KINETICS;
   DIETHANOLAMINE; ALKANOLAMINES
AB The solubility constant of N2O in aqueous 1-dimethylamino-2-propanol (1DMA2P) solution in the concentration range of 0-3.0 mol/L was measured over the temperature range of 298-333 K, and the data used to fit existing models: Redlich-lister, semi-empirical, and polynomial. A new model has also been developed to predict the solubility constant. Also, N2O diffusivity in aqueous 1DMA2P solution was measured over the concentration range of 0.5-2.0 mol/L and temperature range of 298-313 K. All models used fitted the solubility constant of N2O solubility in 1DMA2P solution data with absolute average deviations (ADDs) for the Redlich-Kister, semi-empirical, polynomial models and a new model of 12.2%, 8.1%, 0.2% and 2.2%, respectively. The data for N2O diffusivity in aqueous 1DMA2P solution were represented by the modified Stokes-Einstein and semi-empirical models (AADs of 2.3% and 13.6%, respectively). A new mechanism-based model was equally developed to better correlate experimental results and understand the process of diffusivity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Helei; Idem, Raphael; Tontiwachwuthikul, Paitoon] Univ Regina, Fac Engn & Appl Sci, CETRI, Regina, SK S4S 0A2, Canada.
RP Idem, R (reprint author), Univ Regina, Fac Engn & Appl Sci, CETRI, Regina, SK S4S 0A2, Canada.
EM raphael.idem@uregina.ca
RI Liu, Helei/D-5279-2017
OI Liu, Helei/0000-0002-8230-5865; Idem, Raphael/0000-0002-2708-0608
FU Natural Science and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada;
   China Scholarship Council (CSC), ChinaChina Scholarship Council
FX The financial support by the Natural Science and Engineering Research
   Council of Canada (NSERC), and the China Scholarship Council (CSC),
   China is gratefully acknowledge.
CR Aboudheir A, 2004, IND ENG CHEM RES, V43, P2568, DOI 10.1021/ie0341606
   ALGHAWAS HA, 1989, J CHEM ENG DATA, V34, P385, DOI 10.1021/je00058a004
   CLARKE JKA, 1964, IND ENG CHEM FUND, V3, P239, DOI 10.1021/i160011a012
   D'Alessandro DM, 2010, ANGEW CHEM INT EDIT, V49, P6058, DOI 10.1002/anie.201000431
   Haghtalab A, 2014, J CHEM THERMODYN, V71, P71, DOI 10.1016/j.jct.2013.11.025
   Hartono A, 2008, J CHEM ENG DATA, V53, P2696, DOI 10.1021/je800409d
   Kadiwala S, 2012, CHEM ENG J, V179, P262, DOI 10.1016/j.cej.2011.10.093
   Ko JJ, 2001, J CHEM ENG DATA, V46, P160, DOI 10.1021/je000138x
   Lewis WK, 1924, IND ENG CHEM, V16, P1215, DOI 10.1021/ie50180a002
   LI MH, 1995, J CHEM ENG DATA, V40, P486, DOI 10.1021/je00018a029
   Li MH, 1996, J CHEM ENG DATA, V41, P551, DOI 10.1021/je950224a
   Liu H, 2019, FUEL, V249, P61, DOI 10.1016/j.fuel.2019.02.088
   Liu HL, 2018, AICHE J, V64, P2515, DOI 10.1002/aic.16165
   Liu YD, 1999, IND ENG CHEM RES, V38, P2080, DOI 10.1021/ie980600v
   Mandal BP, 2005, J CHEM ENG DATA, V50, P352, DOI 10.1021/je049826x
   Mandal BP, 2004, J CHEM ENG DATA, V49, P264, DOI 10.1021/je0301951
   Maneeintr K, 2008, PROCESS SAF ENVIRON, V86, P291, DOI 10.1016/j.psep.2008.03.006
   MARTIN JL, 1978, J CHEM ENG DATA, V23, P163, DOI 10.1021/je60077a001
   Park MK, 2001, J CHEM ENG DATA, V46, P166, DOI 10.1021/je000190t
   PENG D, 1976, IND ENG CHEM FUND, V15, P59, DOI 10.1021/i160057a011
   Rao AB, 2002, ENVIRON SCI TECHNOL, V36, P4467, DOI 10.1021/es0158861
   REDLICH O, 1948, IND ENG CHEM, V40, P345, DOI 10.1021/ie50458a036
   Rochelle G. T, 1991, P 17 ANN CONV
   SADA E, 1977, J CHEM ENG DATA, V22, P277, DOI 10.1021/je60074a011
   Sema T, 2012, IND ENG CHEM RES, V51, P925, DOI 10.1021/ie200832c
   TAMIMI A, 1994, J CHEM ENG DATA, V39, P330, DOI 10.1021/je00014a031
   VERSTEEG GF, 1988, J CHEM ENG DATA, V33, P29, DOI 10.1021/je00051a011
   VERSTEEG GF, 1988, CHEM ENG SCI, V43, P573, DOI 10.1016/0009-2509(88)87017-9
   WANG YW, 1992, CHEM ENG J BIOCH ENG, V48, P31, DOI 10.1016/0300-9467(92)85004-S
   XU S, 1991, J CHEM ENG DATA, V36, P71, DOI 10.1021/je00001a021
NR 30
TC 14
Z9 14
U1 2
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 86
EP 103
DI 10.1016/j.ces.2019.03.073
PG 18
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600008
DA 2020-05-12
ER

PT J
AU Chen, X
   Zhong, WQ
   Heindel, TJ
AF Chen, Xi
   Zhong, Wenqi
   Heindel, Theodore J.
TI Orientation of cylindrical particles in a fluidized bed based on stereo
   X-ray particle tracking velocimetry (XPTV)
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Binary fluidized bed; Cylindrical particle fluidization; Particle
   orientation; XPTV
ID NONSPHERICAL PARTICLES; BIOMASS PARTICLES; PACKING; MIXTURES; POROSITY;
   MODEL; DRAG; PREDICTION; VELOCITY; SAND
AB Fluidization of non-spherical particles commonly exists in the biomass utilization and municipal solid waste (MSW) processing industries. In this study, cylindrical particles are used as a typical type of non-spherical particle and its orientation distribution is investigated when being co-fluidized with small spherical bed material. X-ray particle tracking velocimetry (XPTV), based on an X-ray stereography imaging system, is used to measure the 3D orientation of a single tracer particle over a long time period in the fluidized bed. The effects of gas velocity (u(f)), cylindrical particle mass fraction (omega), particle sphericity (Phi), and bed material size on the orientation distribution of the cylindrical particle are investigated and discussed in detail. An orientation distribution probability density function (PDF) model is proposed based on all experimental results.
   The distribution probability P of the angle between the cylindrical particle central axis and vertical direction lambda across the bed shows two minima in the ranges 0 degrees <= lambda< 10 degrees and 40 degrees <= lambda < 50 degrees, and two maxima in the ranges 20 degrees <= lambda < 30 degrees and 70 degrees <= lambda < 80 degrees. Increasing u(f) reduces lambda, while the effect of particle sphericity Phi and cylindrical particle mass fraction omega increases with increasing u(f). (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Xi; Zhong, Wenqi] Southeast Univ, Sch Energy & Environm, Minist Educ, Key Lab Energy Thermal Convers & Control, Nanjing 210096, Jiangsu, Peoples R China.
   [Heindel, Theodore J.] Iowa State Univ, Dept Mech Engn, Ctr Multiphase Flow Res & Educ, Ames, IA 50011 USA.
RP Zhong, WQ (reprint author), Southeast Univ, Sch Energy & Environm, Minist Educ, Key Lab Energy Thermal Convers & Control, Nanjing 210096, Jiangsu, Peoples R China.
EM wqzhong@seu.edu.cn
FU NSFCNational Natural Science Foundation of China [51390492]; US National
   Science FoundationNational Science Foundation (NSF) [CTS-0216367]
FX Financial support from the Major Program of NSFC (No. 51390492) is
   sincerely acknowledged. The X-ray facility used in this work was
   developed with support from the US National Science Foundation under
   Grant No. CTS-0216367 and Iowa State University.
CR ADAMCZYK Z, 1983, INT J MULTIPHAS FLOW, V9, P203, DOI 10.1016/0301-9322(83)90054-X
   BATCHELOR GK, 1970, J FLUID MECH, V44, P419, DOI 10.1017/S002211207000191X
   Buist KA, 2017, AICHE J, V63, P5335, DOI 10.1002/aic.15854
   Buist KA, 2014, AICHE J, V60, P3133, DOI 10.1002/aic.14512
   Cai J, 2016, IND ENG CHEM RES, V55, P12806, DOI 10.1021/acs.iecr.6b04022
   Cai J, 2012, PARTICUOLOGY, V10, P89, DOI 10.1016/j.partic.2011.03.012
   Chen X, 2019, AICHE J, V65, P520, DOI 10.1002/aic.16485
   Chen X, 2017, ADV POWDER TECHNOL, V28, P820, DOI 10.1016/j.apt.2016.12.008
   Chen X, 2014, INT J CHEM REACT ENG, V12, DOI 10.1515/ijcre-2013-0117
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Escudero D, 2011, CHEM ENG SCI, V66, P3648, DOI 10.1016/j.ces.2011.04.036
   Feng Y, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4821812
   Fotovat F, 2014, AICHE J, V60, P869, DOI 10.1002/aic.14337
   HAIDER A, 1989, POWDER TECHNOL, V58, P63, DOI 10.1016/0032-5910(89)80008-7
   Heindel TJ, 2008, FLOW MEAS INSTRUM, V19, P67, DOI 10.1016/j.flowmeasinst.2007.09.003
   Heindel TJ, 2011, J FLUID ENG-T ASME, V133, DOI 10.1115/1.4004367
   Jeffery GB, 1922, P R SOC LOND A-CONTA, V102, P161, DOI 10.1098/rspa.1922.0078
   Kingston TA, 2015, POWDER TECHNOL, V278, P211, DOI 10.1016/j.powtec.2015.02.061
   Kingston TA, 2014, FLOW MEAS INSTRUM, V39, P64, DOI 10.1016/j.flowmeasinst.2014.06.002
   MALEKIARDEBILI M, 1995, INT J MULTIPHAS FLOW, V21, P285, DOI 10.1016/0301-9322(94)00074-T
   Meng LY, 2012, POWDER TECHNOL, V228, P284, DOI 10.1016/j.powtec.2012.05.033
   Nan WG, 2016, ADV POWDER TECHNOL, V27, P2265, DOI 10.1016/j.apt.2016.08.015
   Oschmann T, 2014, POWDER TECHNOL, V258, P304, DOI 10.1016/j.powtec.2014.03.046
   OUCHIYAMA N, 1981, IND ENG CHEM FUND, V20, P66, DOI 10.1021/i100001a013
   OUCHIYAMA N, 1980, IND ENG CHEM FUND, V19, P338, DOI 10.1021/i160076a002
   Prior JMV, 2013, POWDER TECHNOL, V249, P482, DOI 10.1016/j.powtec.2013.09.006
   Ren B, 2012, PARTICUOLOGY, V10, P562, DOI 10.1016/j.partic.2012.03.011
   Ren B, 2011, IND ENG CHEM RES, V50, P7593, DOI 10.1021/ie102263u
   Seelen LJH, 2018, CHEM ENG SCI, V189, P84, DOI 10.1016/j.ces.2018.05.034
   Shao YJ, 2013, POWDER TECHNOL, V234, P67, DOI 10.1016/j.powtec.2012.09.019
   Soria-Verdugo A, 2011, CHEM ENG SCI, V66, P78, DOI 10.1016/j.ces.2010.10.006
   Tran-Cong S, 2004, POWDER TECHNOL, V139, P21, DOI 10.1016/j.powtec.2003.10.002
   Vincenzi D, 2013, J FLUID MECH, V719, P465, DOI 10.1017/jfm.2013.8
   Vollmari K, 2016, POWDER TECHNOL, V291, P506, DOI 10.1016/j.powtec.2015.11.045
   YU AB, 1993, J AM CERAM SOC, V76, P2813, DOI 10.1111/j.1151-2916.1993.tb04021.x
   YU AB, 1992, J AM CERAM SOC, V75, P2765, DOI 10.1111/j.1151-2916.1992.tb05502.x
   Zhang Y, 2013, INT J CHEM REACT ENG, V11, P453, DOI 10.1515/ijcre-2013-0067
   Zhao T, 2017, INTRO DEM CFD COUPLI, P91
   Zhong WQ, 2016, POWDER TECHNOL, V302, P108, DOI 10.1016/j.powtec.2016.07.010
   Zhong WQ, 2013, POWDER TECHNOL, V247, P197, DOI 10.1016/j.powtec.2013.07.022
   Zhong WQ, 2008, ENERG FUEL, V22, P4170, DOI 10.1021/ef800495u
NR 41
TC 4
Z9 4
U1 4
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 104
EP 112
DI 10.1016/j.ces.2019.03.067
PG 9
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600009
DA 2020-05-12
ER

PT J
AU Iijima, M
   Hayakawa, M
   Tatami, J
   Nakamura, K
   Nagashima, S
AF Iijima, Motoyuki
   Hayakawa, Masahiro
   Tatami, Junichi
   Nakamura, Koichiro
   Nagashima, Shinichi
TI Design of nanoscale structured composite particles through mechanical
   process for fabricating a powder layer with rapid drying properties
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Composite particle; H-1 pulsed NMR; Drying; Microstructure; Mechanical
   process
ID HEAT-TRANSFER; SPRAY; MICRO; POLYMER
AB Nanoscale structured composite particles consisting of spherical porous SiO2 particles with nanoscaled surface roughness as the core particles and SiO2 nanoparticles as the depositing particles were designed using a high-shear mechanical composing process to develop a powder material that can form a layer with apparent rapid drying properties. The spherical porous SiO2 core particles and depositing nanoparticles were selected to enhance the water extension on the core particle surface and amongst the composite particles in the powder layer, respectively. The effects of the composite particle nanoparticle content on the morphology of the composite particles and their relationships with the water droplet extending and drying properties in the powder layer of the designed composite particles were systematically investigated based on FE-SEM observations, characterization of N-2 adsorption/desorption isotherms, and H-1 spin-spin relaxation rate measurements of composite particles. The FE-SEM observations show that the pulverized nanoparticles could be successfully attached to porous core particles without the core particles collapsing. The reduction of the specific surface area and increase of the particle specific external surface area after the compositing process strongly supported the fact of nanoparticle attachment. While a small amount of nanoparticle attachment decreased the water droplet extended area, wet area circularity, and apparent drying rate, 15 wt% loading of the pulverized nanoparticles resulted in a drastic increase of the water extended area, wet area circularity, and apparent drying rate. Keywords: Composite particle H-1 pulsed NMR Drying Microstructure Mechanical process (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Iijima, Motoyuki; Tatami, Junichi] Yokohama Natl Univ, Fac Environm & Informat Sci, Hodogaya Ku, 79-7 Tokiwadai, Kanagawa, Kanagawa 2408501, Japan.
   [Iijima, Motoyuki; Hayakawa, Masahiro; Tatami, Junichi] Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Hodogaya ku, 79-7 Tokiwadai, Kanagawa, Kanagawa 2408501, Japan.
   [Nakamura, Koichiro; Nagashima, Shinichi] Lion Corp, Res & Dev Headquarters, Edogawa Ku, 7-2-1 Hirai, Tokyo 1320035, Japan.
RP Iijima, M (reprint author), Yokohama Natl Univ, Fac Environm & Informat Sci, Hodogaya Ku, 79-7 Tokiwadai, Kanagawa, Kanagawa 2408501, Japan.
EM iijima@ynu.ac.jp
RI Tatami, Junichi/B-4848-2012; Iijima, Motoyuki/E-6709-2013
OI Tatami, Junichi/0000-0002-4713-460X; Iijima,
   Motoyuki/0000-0003-1576-1403
FU Instrumental Analysis Center of Yokohama National University
FX The authors are grateful for the support provided by the Instrumental
   Analysis Center of Yokohama National University. Ms. Junko Ikeda (Nihon
   Rufuto Co., Ltd.) is also gratefully acknowledged for the measurement
   and discussion of the pulsed <SUP>1</SUP>H NMR.
CR Alam SN, 2014, B MATER SCI, V37, P1583, DOI 10.1007/s12034-014-0716-8
   BARRETT EP, 1951, J AM CHEM SOC, V73, P373, DOI 10.1021/ja01145a126
   Brown PS, 2015, SCI REP-UK, V5, DOI 10.1038/srep08701
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   de Castro LDC, 2018, THIN SOLID FILMS, V651, P138, DOI 10.1016/j.tsf.2018.01.045
   Deng WW, 2011, INT J HEAT MASS TRAN, V54, P2270, DOI 10.1016/j.ijheatmasstransfer.2011.02.038
   Elliott LN, 2018, POWDER TECHNOL, V333, P458, DOI 10.1016/j.powtec.2018.04.050
   Hsieh CC, 2006, INT J HEAT MASS TRAN, V49, P962, DOI 10.1016/j.ijheatmasstransfer.2005.09.013
   Jain S.P., 1974, BUILDING SCI, V9, P9
   Jeong K, 2016, CERAM INT, V42, P11554, DOI 10.1016/j.ceramint.2016.04.012
   Kondo K, 2013, INT J PHARMACEUT, V453, P523, DOI 10.1016/j.ijpharm.2013.06.028
   LIPPENS BC, 1965, J CATAL, V4, P319, DOI 10.1016/0021-9517(65)90307-6
   Ma HY, 2014, J MATER SCI, V49, P8123, DOI 10.1007/s10853-014-8521-8
   Qiu R, 2011, ELECTROCHIM ACTA, V58, P699, DOI 10.1016/j.electacta.2011.10.028
   Romashevskiy SA, 2018, HIGH TEMP+, V56, P255, DOI 10.1134/S0018151X18020244
   Rukosuyev M, 2017, J COAT TECHNOL RES, V14, P347, DOI 10.1007/s11998-016-9852-y
   Sanchis R, 2009, J PROCESS CONTR, V19, P1073, DOI 10.1016/j.jprocont.2009.01.007
   Sasaki K, 2016, ACS APPL MATER INTER, V8, P651, DOI 10.1021/acsami.5b09782
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schneider L, 2016, SCI REP-UK, V6, DOI 10.1038/srep21400
   Tatami J, 2008, J CERAM SOC JPN, V116, P749, DOI 10.2109/jcersj2.116.749
   Wang HB, 2016, APPL SURF SCI, V372, P7, DOI 10.1016/j.apsusc.2016.02.146
   Yokohama T., 2005, KONA, V23, P7
   Zhang Z, 2015, INT J HEAT MASS TRAN, V80, P26, DOI 10.1016/j.ijheatmasstransfer.2014.08.085
   Zhang Z, 2014, INT J HEAT MASS TRAN, V76, P366, DOI 10.1016/j.ijheatmasstransfer.2014.04.010
   Zheng S, 2016, ADV FUNCT MATER, V26, P9018, DOI 10.1002/adfm.201602843
   Zhou Q, 2011, POWDER TECHNOL, V207, P414, DOI 10.1016/j.powtec.2010.11.028
   Zhou QT, 2010, INT J PHARMACEUT, V394, P50, DOI 10.1016/j.ijpharm.2010.04.032
NR 28
TC 1
Z9 1
U1 2
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 113
EP 121
DI 10.1016/j.ces.2019.03.071
PG 9
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600010
DA 2020-05-12
ER

PT J
AU Chen, SH
   Li, XF
AF Chen, Shih Hsin
   Li, Xin-Fang
TI Boundary and concentration effects on the creeping motions of core-shell
   particles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Core-shell particle; Emulsion; Boundary effect; Concentration effect;
   Cell model
ID OIL-IN-WATER; SEDIMENTATION-VELOCITY; BROWNIAN DIFFUSION; DILUTE
   DISPERSION; SOFT PARTICLE; VISCOUS FLOW; CELL MODEL; SUSPENSION;
   DIFFUSIOPHORESIS; ELECTROPHORESIS
AB In this study, the creeping motions of core-shell particles at low-Reynolds numbers were analyzed and discussed in three cases: (i) a freely translating particle; (ii) a particle in a concentric hole; (iii) particles in a monodisperse suspension. The core and shell were assumed concentric and consist of immiscible liquids. The results revealed the particle motions were significantly influenced by the radius (or volume fraction) and viscosity of the shell and core, especially the shell viscosity. In the limiting situations, our general results for two-phase particles could be simplified to the studies of single-phase particles (solid, liquid or gas bubble) in literature. For the case of a freely suspending particle with the same volume fraction of shell and core, the modified coefficient was reduced by more than 30% as the dimensionless shell viscosity reduced from 100 to 0.01 at eta(c)* =1; however, the coefficient was only slightly reduced by less than 1.5% as the dimensionless core viscosity reduced from 100 to 0.01 at eta(s)* = 1. For the translation of a particle in a concentric hole, the boundary effect of the cavity wall performed to significantly hinder the particle motion. When the volume fraction of the particle in the hole was 0.01 and 0.1, in the case of a(21) = 1.25, eta(c)* = 1 and eta(s)* = 0.01, the boundary effect retarded the particle velocity to 2/3 and 1/3 of the free particle velocity, respectively. In a monodisperse system, the mean translational velocity of particles was hindered by the hydrodynamic interaction between the particles, and the hindrance effect increased as the particle concentration increased. Particle concentration and shell viscosity were the main properties affecting the fluid dynamics of the suspension. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Shih Hsin; Li, Xin-Fang] Natl Ilan Univ, Coll Bioresources, Dept Food Sci, 1 Shen Lung Rd,Sec 1, Ilan 26047, Taiwan.
RP Chen, SH (reprint author), Natl Ilan Univ, Coll Bioresources, Dept Food Sci, 1 Shen Lung Rd,Sec 1, Ilan 26047, Taiwan.
EM shchen@niu.edu.tw
CR Basset A.B., 1961, TREATISE HYDRODYNAMI, V2nd
   BATCHELOR GK, 1972, J FLUID MECH, V52, P245, DOI 10.1017/S0022112072001399
   BATCHELOR GK, 1976, J FLUID MECH, V74, P1, DOI 10.1017/S0022112076001663
   BATCHELOR GK, 1977, J FLUID MECH, V83, P97, DOI 10.1017/S0022112077001062
   Bird RB, 2007, TRANSPORT PHENOMENA
   Chen SH, 1998, J CHIN INST CHEM ENG, V29, P55
   Chen SH, 1999, J COLLOID INTERF SCI, V209, P31, DOI 10.1006/jcis.1998.5828
   Chen SH, 1999, J CHEM ENG JPN, V32, P635, DOI 10.1252/jcej.32.635
   Chen SH, 2000, J CHIN INST CHEM ENG, V31, P545
   Chen WJ, 2013, J PHYS CHEM B, V117, P9757, DOI 10.1021/jp405357e
   Chiu YS, 2014, COLLOID SURFACE A, V440, P185, DOI 10.1016/j.colsurfa.2012.08.069
   Desai KGH, 2005, DRY TECHNOL, V23, P1361, DOI 10.1081/DRT-200063478
   HADAMARD J., 1911, CR HEBD ACAD SCI, V152, P1735
   HAPPEL J, 1954, IND ENG CHEM, V46, P1194, DOI 10.1021/ie50534a034
   HAPPEL J, 1958, AICHE J, V4, P197, DOI 10.1002/aic.690040214
   Happel J., 2012, LOW REYNOLDS NUMBER
   Huang HY, 2015, J PHYS CHEM B, V119, P2040, DOI 10.1021/jp510448x
   Huang PY, 2012, J PHYS CHEM B, V116, P7575, DOI 10.1021/jp302836g
   JEFFREY DJ, 1973, PROC R SOC LON SER-A, V335, P355, DOI 10.1098/rspa.1973.0130
   KARRILA S. J, 1991, MICROHYDRODYNAMICS P
   Keh HJ, 2004, CHEM ENG SCI, V59, P407, DOI 10.1016/j.ces.2003.10.006
   Keh HJ, 1997, CHEM ENG SCI, V52, P1789, DOI 10.1016/S0009-2509(96)00514-3
   KUWABARA S, 1959, J PHYS SOC JPN, V14, P527, DOI 10.1143/JPSJ.14.527
   Kvashnin A. G., 1979, Fluid Dynamics, V4, P598
   Li CY, 2018, AEROSOL SCI TECH, V52, P269, DOI 10.1080/02786826.2017.1398397
   Liu HC, 2016, COLLOID POLYM SCI, V294, P1129, DOI 10.1007/s00396-016-3863-1
   Nedovic V, 2011, PROC FOOD SCI, V1, P1806, DOI 10.1016/j.profoo.2011.09.265
   REED CC, 1980, AICHE J, V26, P816, DOI 10.1002/aic.690260515
   Rybczyn ski W., 1911, Bulletin de l'Academie des Sciences de Cracovie, P40
   Sherwood JD, 2006, CHEM ENG SCI, V61, P6727, DOI 10.1016/j.ces.2006.07.016
   Stokes G. G., 1851, T CAMBRIDGE PHILOS S, V9, P8, DOI DOI 10.1017/CBO9780511702266.002
   van Antwerpen W, 2012, NUCL ENG DES, V247, P183, DOI 10.1016/j.nucengdes.2012.03.012
   Wandrey C, 2010, ENCAPSULATION TECHNOLOGIES FOR ACTIVE FOOD INGREDIENTS AND FOOD PROCESSING, P31, DOI 10.1007/978-1-4419-1008-0_3
   Yang CY, 2003, AEROSOL SCI TECH, V37, P494, DOI 10.1080/02786820300965
   Zholkovskiy EK, 2007, CAN J CHEM ENG, V85, P701
   Zhu QM, 2018, FOOD CHEM, V253, P63, DOI 10.1016/j.foodchem.2018.01.119
   Zhu QM, 2017, FOOD CHEM, V220, P452, DOI 10.1016/j.foodchem.2016.10.016
   ZYDNEY AL, 1995, J COLLOID INTERF SCI, V169, P476, DOI 10.1006/jcis.1995.1058
NR 38
TC 2
Z9 2
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 122
EP 137
DI 10.1016/j.ces.2019.03.065
PG 16
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600011
DA 2020-05-12
ER

PT J
AU Helland, JO
   Pedersen, J
   Friis, HA
   Jettestuen, E
AF Helland, Johan Olav
   Pedersen, Janne
   Friis, Helmer Andre
   Jettestuen, Espen
TI A multiphase level set approach to motion of disconnected fluid ganglia
   during capillary-dominated three-phase flow in porous media: Numerical
   validation and applications
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multiphase level set method; Pore-scale model; Three-phase capillary
   pressure; Double displacement; Oil layers; Foam dynamics
ID IN-SITU CHARACTERIZATION; PORE-SCALE; RELATIVE PERMEABILITY; PARALLEL
   CYLINDERS; CONTACT-ANGLE; DISPLACEMENT MECHANISMS; ENTRY PRESSURES;
   OIL-RECOVERY; DRAINAGE; SIMULATION
AB We present a multiphase level set (MLS) approach to capillary-controlled, three-phase displacement in porous media, and use it to simulate displacements of disconnected fluid ganglia surrounded by two other fluid phases (i.e., double displacements), which are important pore-scale mechanisms for oil recovery and CO2 storage. After a comprehensive model validation on several new benchmark cases, including 3-D simulations of double displacements in a straight angular tube, we show two new applications of the MLS method. First, we simulate three-phase capillary pressure curves for gas invasion along constant oil saturation paths in sandstone. The results show significant oil redistribution by double displacements, which leads to fluctuations of gas/oil capillary pressure due to oil volume preservation, whereas oil/water capillary pressure increases mostly monotonically, yet the pressure level is lower than in the corresponding two-phase oil/water system. Further, gas/water capillary pressure is lower when mobile oil is present in the sample. The second application demonstrates the suitability of MLS method to describe foam dynamics both with and without oil present in the pore space. MLS method successfully describes well-known foam interfacial properties, and it also captures the rise of displacement capillary pressure when adding gas bubbles between continuous gas and water inside a pore channel. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Helland, Johan Olav; Pedersen, Janne; Friis, Helmer Andre] NORCE Norwegian Res Ctr Prof Olav Hanssensvei, N-4021 Stavanger, Norway.
   [Jettestuen, Espen] NORCE Norwegian Res Ctr, Essendropsgate 3, N-0368 Oslo, Norway.
RP Helland, JO (reprint author), NORCE Norwegian Res Ctr Prof Olav Hanssensvei, N-4021 Stavanger, Norway.
EM jhel@norceresearch.no
OI Helland, Johan Olav/0000-0002-4330-101X
CR Al Mansoori SK, 2009, ADV WATER RESOUR, V32, P1535, DOI 10.1016/j.advwatres.2009.07.006
   Al-Dhahli A, 2013, TRANSPORT POROUS MED, V98, P259, DOI 10.1007/s11242-013-0144-z
   Alizadeh AH, 2014, FUEL, V132, P219, DOI 10.1016/j.fuel.2014.04.080
   Alizadeh AH, 2014, WATER RESOUR RES, V50, P1636, DOI 10.1002/2013WR014914
   Almajid MM, 2016, ADV COLLOID INTERFAC, V233, P65, DOI 10.1016/j.cis.2015.10.008
   Amaechi B, 2014, TRANSPORT POROUS MED, V103, P421, DOI 10.1007/s11242-014-0309-4
   Anderson R., 2013, LLNLSM617092DRAFT
   Andrew M, 2015, TRANSPORT POROUS MED, V110, P1, DOI 10.1007/s11242-015-0553-2
   Berg S, 2013, P NATL ACAD SCI USA, V110, P3755, DOI 10.1073/pnas.1221373110
   BERGER MJ, 1989, J COMPUT PHYS, V82, P64, DOI 10.1016/0021-9991(89)90035-1
   BLUNT M, 1995, TRANSPORT POROUS MED, V20, P77, DOI 10.1007/BF00616926
   Bradford SA, 1996, WATER RESOUR RES, V32, P251, DOI 10.1029/95WR03239
   BRADFORD SA, 1995, J CONTAM HYDROL, V20, P89, DOI 10.1016/0169-7722(95)00027-S
   Carroll KC, 2015, WATER RESOUR RES, V51, P7189, DOI 10.1002/2015WR017490
   CHATZIS I, 1984, SOC PETROL ENG J, V24, P555, DOI 10.2118/10114-PA
   Conn CA, 2014, LAB CHIP, V14, P3968, DOI 10.1039/c4lc00620h
   Dehghanpour H, 2013, TRANSPORT POROUS MED, V100, P297, DOI 10.1007/s11242-013-0217-z
   Dinariev O, 2016, COMPUTAT GEOSCI, V20, P835, DOI 10.1007/s10596-015-9527-2
   Dong S, 2017, J COMPUT PHYS, V338, P21, DOI 10.1016/j.jcp.2017.02.048
   Esedoglu S, 2010, J COMPUT PHYS, V229, P1017, DOI 10.1016/j.jcp.2009.10.002
   Farajzadeh R, 2012, ADV COLLOID INTERFAC, V183, P1, DOI 10.1016/j.cis.2012.07.002
   Feali M, 2012, SPE RESERV EVAL ENG, V15, P706, DOI 10.2118/151609-PA
   Friis HA, 2019, TRANSPORT POROUS MED, V128, P123, DOI 10.1007/s11242-019-01238-6
   Geraud B, 2016, WATER RESOUR RES, V52, P773, DOI 10.1002/2015WR017936
   Grate JW, 2012, LANGMUIR, V28, P7182, DOI 10.1021/la204322k
   Grivot P, 1995, INT S SOC COR AN SAN
   Helland JO, 2016, WATER RESOUR RES, V52, P5376, DOI 10.1002/2016WR018912
   Helland JO, 2017, GEOPHYS RES LETT, V44, P4933, DOI 10.1002/2017GL073442
   Hilfer R, 1996, TRANSPORT POROUS MED, V22, P53, DOI 10.1007/BF00974311
   Hornung RD, 2002, CONCURR COMP-PRACT E, V14, P347, DOI 10.1002/cpe.652
   Hornung RD, 2006, ENG COMPUT-GERMANY, V22, P181, DOI 10.1007/s00366-006-0038-6
   Hui MH, 2000, J PHYS CHEM B, V104, P3833, DOI 10.1021/jp9933222
   Iglauer S, 2013, FUEL, V103, P905, DOI 10.1016/j.fuel.2012.06.094
   Jettestuen E, 2013, WATER RESOUR RES, V49, P4645, DOI 10.1002/wrcr.20334
   Jiang F, 2017, WATER RESOUR RES, V53, P11, DOI 10.1002/2016WR019098
   Khishvand M, 2016, ADV WATER RESOUR, V97, P279, DOI 10.1016/j.advwatres.2016.10.009
   Kim J, 2005, INTERFACE FREE BOUND, V7, P435
   Kralchevsky P. A, 2001, STUDIES INTERFACE SC
   Krimi A, 2018, J COMPUT PHYS, V358, P53, DOI 10.1016/j.jcp.2017.12.006
   Lago M, 2001, J COLLOID INTERF SCI, V243, P219, DOI 10.1006/jcis.2001.7872
   LENHARD RJ, 1988, WATER RESOUR RES, V24, P373, DOI 10.1029/WR024i003p00373
   Liang H, 2017, ARXIV171009534PHYSIC
   Losasso F, 2006, ACM T GRAPHIC, V25, P812, DOI 10.1145/1141911.1141960
   Ma SX, 1996, COLLOID SURFACE A, V117, P273, DOI 10.1016/0927-7757(96)03702-8
   MALOY KJ, 1992, PHYS REV LETT, V68, P2161, DOI 10.1103/PhysRevLett.68.2161
   MAYER RP, 1965, J COLL SCI IMP U TOK, V20, P893, DOI 10.1016/0095-8522(65)90061-9
   MERRIMAN B, 1994, J COMPUT PHYS, V112, P334, DOI 10.1006/jcph.1994.1105
   Moebius F, 2012, J COLLOID INTERF SCI, V377, P406, DOI 10.1016/j.jcis.2012.03.070
   Mohammadmoradi P, 2017, ADV WATER RESOUR, V110, P120, DOI 10.1016/j.advwatres.2017.10.010
   OREN PE, 1995, TRANSPORT POROUS MED, V20, P105, DOI 10.1007/BF00616927
   Osher S., 2003, LEVEL SET METHODS DY
   Piri M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.026301
   PRINCEN HM, 1969, J COLLOID INTERF SCI, V30, P69, DOI 10.1016/0021-9797(69)90379-8
   PRINCEN HM, 1970, J COLLOID INTERF SCI, V34, P171, DOI 10.1016/0021-9797(70)90167-0
   PRINCEN HM, 1969, J COLLOID INTERF SCI, V30, P359, DOI 10.1016/0021-9797(69)90403-2
   Prodanovic M, 2006, J COLLOID INTERF SCI, V304, P442, DOI 10.1016/j.jcis.2006.08.048
   Prodanovic M, 2013, TRANSPORT POROUS MED, V96, P39, DOI 10.1007/s11242-012-0072-3
   Ruuth SJ, 1998, J COMPUT PHYS, V145, P166, DOI 10.1006/jcph.1998.6028
   Saye RI, 2012, J COMPUT PHYS, V231, P6051, DOI 10.1016/j.jcp.2012.04.004
   Saye RI, 2011, P NATL ACAD SCI USA, V108, P19498, DOI 10.1073/pnas.1111557108
   Scanziani A, 2018, ADV WATER RESOUR, V121, P446, DOI 10.1016/j.advwatres.2018.09.010
   Sheppard A., 2015, DIGITAL ROCKS PORTAL, DOI [10.17612/P7059V, DOI 10.17612/P7059V]
   Sheppard AP, 2005, TRANSPORT POROUS MED, V59, P155, DOI 10.1007/s11242-004-1488-1
   Shi Y, 2016, J COMPUT PHYS, V314, P228, DOI 10.1016/j.jcp.2016.03.011
   Smith KA, 2002, INTERFACE FREE BOUND, V4, P263
   Sohrabi M, 2004, SPE J, V9, P290, DOI 10.2118/89000-PA
   Spiteri EJ, 2006, J PETROL SCI ENG, V50, P115, DOI 10.1016/j.petrol.2005.09.004
   SUSSMAN M, 1994, J COMPUT PHYS, V114, P146, DOI 10.1006/jcph.1994.1155
   Svadlenka K, 2014, J COMPUT APPL MATH, V257, P157, DOI 10.1016/j.cam.2013.08.027
   van Dijke MIJ, 2004, J COLLOID INTERF SCI, V277, P184, DOI 10.1016/j.jcis.2004.05.021
   van Dijke MIJ, 2003, J COLLOID INTERF SCI, V260, P385, DOI 10.1016/S0021-9797(02)00228-X
   van Dijke MIJ, 2002, J PETROL SCI ENG, V33, P39, DOI 10.1016/S0920-4105(01)00174-7
   van Kats FM, 1999, TRANSPORT POROUS MED, V37, P55, DOI 10.1023/A:1006502831641
   Van Kats FM, 2001, TRANSPORT POROUS MED, V43, P225, DOI 10.1023/A:1010699316671
   Wei B, 2018, CHEM ENG SCI, V176, P35, DOI 10.1016/j.ces.2017.10.025
   Xie CY, 2018, PHYS REV E, V97, DOI 10.1103/PhysRevE.97.023312
   Yu Y, 2018, ARXIV180808555PHYSIC
   Zhang Q, 2016, J COMPUT PHYS, V319, P79, DOI 10.1016/j.jcp.2016.05.016
   Zhang X, 2008, INTERACTION MULTISCA, V1, P191, DOI DOI 10.12989/IMM.2008.1.2.191
   Zhao HK, 1996, J COMPUT PHYS, V127, P179, DOI 10.1006/jcph.1996.0167
   Zhou YF, 2014, ADV WATER RESOUR, V69, P49, DOI 10.1016/j.advwatres.2014.03.006
   Zolfaghari A, 2017, TRANSPORT POROUS MED, V116, P1093, DOI 10.1007/s11242-016-0814-8
   Zolfaghari A, 2017, TRANSPORT POROUS MED, V116, P1139, DOI 10.1007/s11242-016-0815-7
NR 83
TC 0
Z9 0
U1 7
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 138
EP 162
DI 10.1016/j.ces.2019.03.060
PG 25
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600012
DA 2020-05-12
ER

PT J
AU Wan, YL
   Guo, Q
   Wang, K
   Wang, XT
AF Wan, Yongli
   Guo, Qiang
   Wang, Kang
   Wang, Xitao
TI Efficient and selective photocatalytic oxidation of cyclohexane using
   O-2 as oxidant in VOCl2 solution and mechanism insight
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE VOCl2; Photocatalytic oxidation; Cyclohexane; KA-oil
ID VISIBLE-LIGHT; TITANIUM-DIOXIDE; MOLECULAR-OXYGEN; PHOTOOXIDATION;
   CATALYSTS; IRON(III); ALKANES; TIO2; OXOFUNCTIONALIZATION; NANOPARTICLES
AB The efficient selective oxidation of cyclohexane to cyclohexanone and cyclohexanol (KA-oil) under mild conditions remains one of the most challenging and interesting projects in catalytic chemistry. Here, photocatalytic oxidation of cyclohexane was carried out in acetonitrile (MeCN) solution of VOCl2 under Xe lamp irradiation and pure O-2 atmosphere. The results show that VOCl2 has high photocatalytic activity in pure MeCN solution, and a cyclohexane conversion of 17.8% with ca. 99% selectivity for KA-oil can be obtained after light irradiation of 4 h. It is worth noting that the use of hydrochloric acid as an additive can effectively enhance the photo-catalytic oxidation of cyclohexane, providing a cyclohexane conversion of 23.3%, which may be due to the important role of HCl in improving the light absorption, decreasing the oxidation-reduction potential of V5+/V4+ and promoting the redox process of photocatalyst. The effects of photocatalyst concentration, hydrochloric acid addition amount, O-2 pressure and reaction time on photocatalytic performance were also studied. It was found that the optimization of these reaction conditions can further improve the conversion of cyclohexane and selectivity of KA-oil. A possible reaction mechanism for the photocatalytic oxidation of cyclohexane was proposed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wan, Yongli; Guo, Qiang; Wang, Xitao] Tianjin Univ, Coll Chem Engn & Technol, Tianjin Key Lab Appl Catalysis Sci & Technol, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
   [Wang, Kang] Tianjin Univ, Coll Chem Engn & Technol, Chem Engn Res Ctr, Tianjin 300072, Peoples R China.
RP Wang, XT (reprint author), Tianjin Univ, Coll Chem Engn & Technol, Tianjin Key Lab Appl Catalysis Sci & Technol, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
EM wangk72@tju.edu.cn; wangxt@tju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21276190, 20806059]; Tianjin Natural Science
   FoundationNatural Science Foundation of Tianjin [15 JCYBJC20900]
FX We gratefully acknowledge the financial supports from the National
   Natural Science Foundation of China (No. 21276190 and 20806059) and
   Tianjin Natural Science Foundation (15 JCYBJC20900).
CR Almeida AR, 2008, J PHYS CHEM C, V112, P1552, DOI 10.1021/jp077143t
   Almeida AR, 2011, PHYS CHEM CHEM PHYS, V13, P1345, DOI 10.1039/c0cp00879f
   Almeida AR, 2010, J CATAL, V273, P116, DOI 10.1016/j.jcat.2010.05.006
   Almquist CB, 2001, APPL CATAL A-GEN, V214, P259, DOI 10.1016/S0926-860X(01)00495-1
   Carneiro JT, 2011, J PHOTOCH PHOTOBIO A, V217, P326, DOI 10.1016/j.jphotochem.2010.10.027
   Chen LF, 2017, J MATER SCI, V52, P7186, DOI 10.1007/s10853-017-0954-4
   Ciambelli P, 2007, CATAL TODAY, V128, P251, DOI 10.1016/j.cattod.2007.07.006
   Ciambelli P, 2008, INT J PHOTOENERGY, DOI 10.1155/2008/258631
   Ciambelli P, 2008, APPL CATAL A-GEN, V349, P140, DOI 10.1016/j.apcata.2008.07.019
   Ebadi A, 2007, APPL CATAL A-GEN, V321, P135, DOI 10.1016/j.apcata.2007.01.040
   Guo Q, 2018, J MATER SCI-MATER EL, V29, P20280, DOI 10.1007/s10854-018-0162-2
   Henriquez A, 2017, APPL CATAL B-ENVIRON, V206, P252, DOI 10.1016/j.apcatb.2017.01.022
   Hu BC, 2008, CATAL COMMUN, V10, P83, DOI 10.1016/j.catcom.2008.07.044
   Huang G, 2007, J MOL CATAL A-CHEM, V261, P125, DOI 10.1016/j.molcata.2006.08.014
   JI LN, 1991, J MOL CATAL, V70, P247, DOI 10.1016/0304-5102(91)80166-Z
   Khenkin AM, 1999, J CATAL, V182, P82, DOI 10.1006/jcat.1998.2323
   Labinger JA, 2002, NATURE, V417, P507, DOI 10.1038/417507a
   Li SX, 2012, DYES PIGMENTS, V95, P188, DOI 10.1016/j.dyepig.2012.04.006
   Li XY, 2003, J CHEM TECHNOL BIOT, V78, P1246, DOI 10.1002/jctb.872
   Li XY, 2003, NEW J CHEM, V27, P1264, DOI 10.1039/b301998e
   Li Y, 2008, CATAL LETT, V123, P123, DOI 10.1007/s10562-008-9404-x
   Liu J, 2014, GREEN CHEM, V16, P4559, DOI 10.1039/c4gc01126k
   Liu RH, 2014, ACS CATAL, V4, P328, DOI 10.1021/cs400913h
   Ma DS, 2009, CATAL COMMUN, V10, P781, DOI 10.1016/j.catcom.2008.11.037
   Maldotti A, 2002, CHEM REV, V102, P3811, DOI 10.1021/cr010364p
   Maldotti A, 1996, J MOL CATAL A-CHEM, V113, P147, DOI 10.1016/S1381-1169(96)00107-0
   Musser MT, 2000, ULLMANNS ENCY IND CH, DOI [10.1002/14356007.a08_217.pub2, DOI 10.1002/14356007.A08_217.PUB2]
   Newhouse T, 2011, ANGEW CHEM INT EDIT, V50, P3362, DOI 10.1002/anie.201006368
   Olsen MHN, 2005, J SUPERCRIT FLUID, V34, P119, DOI 10.1016/j.supflu.2004.11.004
   Pal N, 2014, J MOL CATAL A-CHEM, V392, P299, DOI 10.1016/j.molcata.2014.05.027
   PARSHALL GW, 1992, HOMOGENOUS CATALYSIS
   Pokutsa A, 2017, REACT KINET MECH CAT, V122, P757, DOI 10.1007/s11144-017-1274-z
   Pokutsa A, 2017, MOL CATAL, V434, P194, DOI 10.1016/j.mcat.2017.02.013
   Pokutsa A, 2010, APPL CATAL A-GEN, V390, P190, DOI 10.1016/j.apcata.2010.10.010
   Qiao S, 2015, RSC ADV, V5, P43058, DOI 10.1039/c5ra04753f
   Ramasarma T., 2003, Proceedings of the Indian National Science Academy Part B Biological Sciences, V69, P649
   Martins LMDRD, 2017, CHEMCATCHEM, V9, P1211, DOI 10.1002/cctc.201601442
   Sannino D, 2013, J ADV OXID TECHNOL, V16, P71
   Schuchardt U, 2001, APPL CATAL A-GEN, V211, P1, DOI 10.1016/S0926-860X(01)00472-0
   Schuchardt U, 1998, J MOL CATAL A-CHEM, V135, P257, DOI 10.1016/S1381-1169(97)00314-2
   SHELDON RA, 1981, METAL CATALYZED OXID
   Shimizu KI, 2007, J PHYS CHEM C, V111, P19043, DOI 10.1021/jp0767821
   Shimizu KI, 2002, APPL CATAL A-GEN, V225, P185, DOI 10.1016/S0926-860X(01)00863-8
   Shiraishi Y, 2005, CHEM COMMUN, P4569, DOI 10.1039/b508172f
   Shiraishi Y, 2017, ACS CATAL, V7, P293, DOI 10.1021/acscatal.6b02611
   Shulpin G. B, 1996, NEW J CHEM
   SHULPIN GB, 1992, MENDELEEV COMMUN, P36
   Sokmen K, 2003, J COLLOID INTERF SCI, V264, P208, DOI 10.1016/S0021-9797(03)00408-9
   Sun H, 1996, J AM CHEM SOC, V118, P6873, DOI 10.1021/ja953273g
   Takaki K, 2004, B CHEM SOC JPN, V77, P2251, DOI 10.1246/bcsj.77.2251
   Tang SP, 2015, CHEMCATCHEM, V7, P2637, DOI 10.1002/cctc.201500314
   Teramura K, 2004, J MOL CATAL A-CHEM, V208, P299, DOI 10.1016/S1381-1169(03)00544-2
   Teramura K, 2001, J MOL CATAL A-CHEM, V165, P299, DOI 10.1016/S1381-1169(00)00417-9
   Teramura K, 2009, J PHYS CHEM C, V113, P17018, DOI 10.1021/jp902955b
   VANOPPEN DL, 1995, ANGEW CHEM INT EDIT, V34, P560, DOI 10.1002/anie.199505601
   Vinu R, 2009, APPL CATAL A-GEN, V366, P130, DOI 10.1016/j.apcata.2009.06.048
   Wang YJ, 2014, J MOL CATAL A-CHEM, V383, P46, DOI 10.1016/j.molcata.2013.11.022
   Wang ZM, 2012, J ENVIRON ENG, V138, P923, DOI 10.1061/(ASCE)EE.1943-7870.0000542
   WITTCOFF HA, 1996, IND ORGANIC CHEM
   Wu WF, 2014, APPL CATAL A-GEN, V469, P483, DOI 10.1016/j.apcata.2013.08.045
   Wu WF, 2012, J CATAL, V286, P6, DOI 10.1016/j.jcat.2011.09.034
   Zhang YL, 2016, RSC ADV, V6, P60394, DOI 10.1039/c6ra09235g
   Zhong WZ, 2015, J CATAL, V330, P208, DOI 10.1016/j.jcat.2015.06.013
NR 63
TC 4
Z9 4
U1 20
U2 53
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 163
EP 172
DI 10.1016/j.ces.2019.03.079
PG 10
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600013
DA 2020-05-12
ER

PT J
AU Rossi, E
   Paloni, M
   Storti, G
   Rota, R
AF Rossi, Ester
   Paloni, Matteo
   Storti, Giuseppe
   Rota, Renato
TI Modeling dual reflux-pressure swing adsorption processes: Numerical
   solution based on the finite volume method
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pressure swing adsorption; Dual-reflux; Gas separation; Cyclic
   adsorption process; Finite volume method; Finite difference method
ID EQUILIBRIUM-THEORY ANALYSIS; PSA PROCESS; OPTIMAL-DESIGN; SIMULATION;
   GAS; SEPARATION; CYCLES; UNITS; CO2; OPTIMIZATION
AB Even if the suitability of Finite Volume discretization methods for Pressure Swing Adsorption modelling is well-established, when simulating the peculiar process called Dual Reflux-Pressure Swing Adsorption, simulations relying only on Finite Difference discretization methods are available in literature. Therefore, a detailed single-bed model of the Dual Reflux-Pressure Swing Adsorption process, the solution of which is based on the Finite Volume discretization method, is proposed in this work and validated against experimental data. Details of the system representation, the numerical schemes and the implementation of the boundary conditions are given. Moreover, a comparison between the performances and limitations of the Finite Volume and Finite Difference discretization methods when simulating a Dual Reflux-Pressure Swing Adsorption process are discussed through two case studies, leading to conclude that Finite Volume Method is the most effective approach for simulating this specific separation process. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rossi, Ester; Rota, Renato] Politecn Milan, Chem Mat & Chem Engn Dept Giulio Natta, Via Mancinelli 7, I-20131 Milan, Italy.
   [Paloni, Matteo] Ctr Biochim Struct, CNRS UMR 5048, UM, INSERM U1054, 29 Rue Navacelles, FR-34090 Montpellier, France.
   [Storti, Giuseppe] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Vladimir Prelog Weg 1-5-10,HCI F 125, CH-8093 Zurich, Switzerland.
RP Rota, R (reprint author), Politecn Milan, Chem Mat & Chem Engn Dept Giulio Natta, Via Mancinelli 7, I-20131 Milan, Italy.
EM renato.rota@polimi.it
OI Paloni, Matteo/0000-0003-4841-9321
CR Baines M, 1994, MOVING FINITE ELEMEN
   Bhatt TS, 2017, CHEM ENG J, V311, P385, DOI 10.1016/j.cej.2016.11.111
   Bhatt TS, 2015, CHEM ENG SCI, V122, P34, DOI 10.1016/j.ces.2014.09.013
   Bhatt TS, 2014, IND ENG CHEM RES, V53, P13448, DOI 10.1021/ie502057k
   Bhatt TS, 2013, CHEM ENG SCI, V102, P42, DOI 10.1016/j.ces.2013.07.040
   Casas N, 2013, SEP PURIF TECHNOL, V104, P183, DOI 10.1016/j.seppur.2012.11.018
   Coimbra M, 2016, MOVING FINITE ELEMEN
   DIAGNE D, 1994, J CHEM ENG JPN, V27, P85, DOI 10.1252/jcej.27.85
   DIAGNE D, 1995, ENERG CONVERS MANAGE, V36, P431, DOI 10.1016/0196-8904(95)00037-E
   Ebner AD, 2004, AICHE J, V50, P2418, DOI 10.1002/aic.10191
   Ebner AD, 2002, AICHE J, V48, P1679, DOI 10.1002/aic.690480810
   FAROOQ S, 1989, CHEM ENG SCI, V44, P2809, DOI 10.1016/0009-2509(89)85090-0
   Fox RO, 1996, REV I FR PETROL, V51, P215, DOI 10.2516/ogst:1996020
   Friedrich D, 2013, IND ENG CHEM RES, V52, P8897, DOI 10.1021/ie3036349
   Grande CA, 2012, IND ENG CHEM RES, V51, P8695, DOI 10.1021/ie300341v
   Haghpanah R, 2013, IND ENG CHEM RES, V52, P4249, DOI 10.1021/ie302658y
   Kearns DT, 2006, CHEM ENG SCI, V61, P7223, DOI 10.1016/j.ces.2006.07.040
   Kearns DT, 2006, CHEM ENG SCI, V61, P7234, DOI 10.1016/j.ces.2006.07.043
   LeVeque Randall J., 2002, FINITE VOLUME METHOD
   Li DD, 2016, CHEM ENG J, V297, P315, DOI 10.1016/j.cej.2016.03.075
   Liao HT, 2000, AICHE J, V46, P1168, DOI 10.1002/aic.690460609
   May EF, 2017, SEP PURIF TECHNOL, V177, P161, DOI 10.1016/j.seppur.2016.12.007
   Mc Intyre JA, 2002, IND ENG CHEM RES, V41, P3499, DOI 10.1021/ie020139d
   McIntyre JA, 2010, IND ENG CHEM RES, V49, P1848, DOI 10.1021/ie901266y
   Ruthven D.M., 1984, PRINCIPLES ADSORPTIO
   Saleman TL, 2015, CHEM ENG J, V281, P739, DOI 10.1016/j.cej.2015.07.001
   Sholl DS, 2016, NATURE, V532, P435, DOI 10.1038/532435a
   Sivakumar SV, 2011, IND ENG CHEM RES, V50, P3437, DOI 10.1021/ie200175h
   Sivakumar SV, 2011, IND ENG CHEM RES, V50, P3426, DOI 10.1021/ie101177x
   SKARSTROM CW, 1959, ANN NY ACAD SCI, V72, P751, DOI 10.1111/j.1749-6632.1959.tb44201.x
   Thakur RS, 2011, COMPUT CHEM ENG, V35, P973, DOI 10.1016/j.compchemeng.2011.01.024
   Tian CX, 2017, SEP PURIF TECHNOL, V189, P54, DOI 10.1016/j.seppur.2017.06.041
   Webley PA, 2000, COMPUT CHEM ENG, V23, P1701, DOI 10.1016/S0098-1354(99)00320-8
   Yoshida M, 2003, IND ENG CHEM RES, V42, P1795, DOI 10.1021/ie010114z
   Zhang YC, 2016, CHEM ENG J, V292, P366, DOI 10.1016/j.cej.2016.02.018
   Zhang YC, 2014, COMPUT-AIDED CHEM EN, V33, P103
   Zou Y, 2017, CHEM ENG RES DES, V126, P76, DOI 10.1016/j.cherd.2017.08.011
NR 37
TC 2
Z9 2
U1 3
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 173
EP 185
DI 10.1016/j.ces.2019.03.055
PG 13
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600014
DA 2020-05-12
ER

PT J
AU Besseris, GJ
AF Besseris, George J.
TI Synchronous screening-and-optimization of nano-engineered blood
   pressure-drop using rapid robust non-linear Taguchi profiling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Atherosclerotic coronary artery; Nano-bioengineering;
   Screening/optimization engineering; Robust blood pressure-drop
   profiling; Non-linear non-normal data; Data messiness
ID DRUG CARRIER; FLOW; NANOPARTICLES; DESIGN; UNCERTAINTY; VISCOSITY
AB Atherosclerosis induces abnormal blood-flow patterns in coronary arteries mainly because of the irregular accumulation of fibrofatty plaque on the artery walls. Morphological alterations of the wall-surface attributes downgrade vascular elasticity, which compromises the normal blood-pressure gradient behavior by sporadically interfering with the effective-flow cross-section adjustment. An iron-oxide booster has been recently studied as a potential nano-particle treatment to regulate an elevated blood-pressure condition. Taguchi-type multi-factorial experimentation rapidly generates small and dense datasets in order to expedite arterial flow screening/optimization predictions. The optimal blood pressure-drop performance is investigated against four vital controlling factors. We show that tracking down inherently complex blood-flow phenomena often entails the elucidation of non-linear and messy data structures. Translating such data demands robust and agile techniques to decipher governing relationships while guarding against spurious effects from uncertainty asymmetry. We also show that by using distribution-free profiling, we may synchronously accomplish the screening and optimization tasks more accurately in comparison to other competing techniques. Illustrating our technique on a chemical engineering paradigm, we found that out of the four investigated factors only the blood behavior index to be strongly influential. A blood behavior index setting of 0.5, which is below the normal physiological limit, minimizes the blood pressure drop at an optimal value of 385 Pa/m. The proposed methodology demonstrates how the required sampling size may be further reduced, thus making the study even more economically and practically efficient. This was shown to be achieved without relinquishing important information about the dominant phenomena, hence rendering our solution to be also lean and agile. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Besseris, George J.] Univ West Attica, Mech Engn Dept, Aigaleo, Attica, Greece.
   [Besseris, George J.] Kingston Univ, Adv Ind & Mfg Syst, London, England.
RP Besseris, GJ (reprint author), Univ West Attica, Mech Engn Dept, Aigaleo, Attica, Greece.; Besseris, GJ (reprint author), Kingston Univ, Adv Ind & Mfg Syst, London, England.
EM besseris@uniwa.gr
CR ADAMS AL, 1978, J COLLOID INTERF SCI, V65, P468, DOI 10.1016/0021-9797(78)90098-X
   Anselmo AC, 2016, AICHE J, V62, P966, DOI 10.1002/aic.15189
   Apostolidis AJ, 2014, J RHEOL, V58, P607, DOI 10.1122/1.4866296
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Besseris GJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108973
   Besseris GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073275
   Box G.E.P., 2005, STAT EXPT DESIGN INN
   Briggs W, 2016, UNCERTAINTY SOUL MOD
   Cicha I, 2014, EUR J NANOMED, V6, P63, DOI 10.1515/ejnm-2014-0001
   Cicha I, 2013, NANOTECHNOL REV, V2, P449, DOI 10.1515/ntrev-2013-0009
   Davies PF, 2009, NAT CLIN PRACT CARD, V6, P16, DOI 10.1038/ncpcardio1397
   Floudas CA, 2005, AICHE J, V51, P1872, DOI 10.1002/aic.10620
   Gao Y, 2017, AICHE J, V63, P1804, DOI 10.1002/aic.15546
   Hahn MA, 2011, ANAL BIOANAL CHEM, V399, P3, DOI 10.1007/s00216-010-4207-5
   Hoaglin DC, 2000, UNDERSTANDING ROBUST
   Ijaz S, 2017, EUR PHYS J PLUS, V132, DOI 10.1140/epjp/i2017-11703-6
   Kanaris AG, 2012, CHEM ENG SCI, V71, P202, DOI 10.1016/j.ces.2011.12.015
   Kelley WJ, 2016, WIRES NANOMED NANOBI, V8, P909, DOI 10.1002/wnan.1414
   Ketokivi M, 2014, J OPER MANAG, V32, P232, DOI 10.1016/j.jom.2014.03.004
   Klabunde R. E, 2013, NORMAL ABNORMAL BLOO
   Marcoulaki EC, 1999, AICHE J, V45, P1977, DOI 10.1002/aic.690450914
   Milliken G.A., 1989, ANAL MESSY DATA
   Milliken G. A, 2004, ANAL MESSY DATA, VI
   Mimouni Z., 2016, OPEN J BIOPHYS, V6, P5
   Nadeem S, 2016, J MAGN MAGN MATER, V410, P230, DOI 10.1016/j.jmmm.2016.02.100
   Nadeem S, 2016, INT J HEAT MASS TRAN, V93, P1137, DOI 10.1016/j.ijheatmasstransfer.2015.10.041
   Nadeem S, 2014, EUR PHYS J PLUS, V129, DOI 10.1140/epjp/i2014-14249-1
   Nematollahzadeh A, 2018, CHEM ENG SCI, V177, P293, DOI 10.1016/j.ces.2017.11.048
   Neofytou P, 2004, BIORHEOLOGY, V41, P693
   Nishihara H, 2014, ADV DRUG DELIVER REV, V74, P19, DOI 10.1016/j.addr.2014.01.005
   Pereira JMC, 2013, CHEM ENG SCI, V101, P253, DOI 10.1016/j.ces.2013.05.033
   Pernot P, 2017, AICHE J, V63, P4642, DOI 10.1002/aic.15781
   Rao Ravella Sreenivas, 2008, Biotechnology Journal, V3, P510, DOI 10.1002/biot.200700201
   Sankar DS, 2008, J MECH SCI TECHNOL, V22, P1008, DOI 10.1007/s12206-008-0123-4
   Schrauwen JTC, 2014, J BIOMECH, V47, P1810, DOI 10.1016/j.jbiomech.2014.03.028
   Sen Gupta A, 2016, WIRES NANOMED NANOBI, V8, P255, DOI 10.1002/wnan.1362
   Silver N., 2015, SIGNAL NOISE WHY SO
   Stack SW, 2009, CHEM ENG SCI, V64, P4701, DOI 10.1016/j.ces.2009.07.017
   Steimel J, 2016, AICHE J, V62, P3404, DOI 10.1002/aic.15400
   Taguchi G., 2000, ROBUST ENG LEARN BOO
   Taguchi G., 2004, QUALITY ENG HDB
   Toulfatzis AI, 2016, INT J ADV MANUF TECH, V86, P3241, DOI 10.1007/s00170-016-8435-5
   Wang YJ, 2016, PROG POLYM SCI, V57, P153, DOI 10.1016/j.progpolymsci.2016.01.002
   Wilcox RR, 2010, FUNDAMENTAL OF MODERN STATISTICAL METHODS: SUBSTANTIALLY IMPROVING POWER AND ACCURACY, SECOND EDITION, P1, DOI 10.1007/978-1-4419-5525-8
   World Health Organization, TOP 10 CAUS DEATH
   Zeng JS, 2014, AICHE J, V60, P148, DOI 10.1002/aic.14230
NR 46
TC 0
Z9 0
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 186
EP 200
DI 10.1016/j.ces.2019.03.035
PG 15
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600015
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Bascone, D
   Angeli, P
   Fraga, ES
AF Bascone, Davide
   Angeli, Panagiota
   Fraga, Eric S.
TI A modelling approach for the comparison between intensified extraction
   in small channels and conventional solvent extraction technologies
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Liquid-liquid extraction; Small channels; Spent nuclear fuel
   reprocessing; Optimisation; Process design
ID LIQUID PLUG-FLOW; MASS-TRANSFER; SCALE-OUT; DESIGN; SIZE;
   DIOXOURANIUM(VI); HYDRODYNAMICS; MICROREACTOR; MOTION
AB In this paper, the application of small channels to the extraction separations in spent nuclear fuel reprocessing has been investigated via a modelling approach. The results are compared with conventional liquid-liquid extraction technologies such as mixer-settlers and pulsed columns, using models from the literature.
   In the model mass transfer, redox reactions, pressure drop and nuclear criticality are taken into account, as well as manifold and two-phase separator designs for the small-scale technology. The resulting model, posed as an optimisation problem, is a mixed integer nonlinear problem, implemented in the General Algebraic Modeling System (GAMS).
   An alternative flowsheet for the codecontamination section of the PUREX process, as a case study, has been investigated. The results show that the small-scale technology could be beneficial, in particular in terms of volumetric mass transfer coefficients, nuclear criticality safety and short residence time, which improves neptunium separation and reduces solvent degradation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bascone, Davide; Angeli, Panagiota; Fraga, Eric S.] UCL, Dept Chem Engn, Ctr Proc Syst Engn, London WC1E 6BT, England.
RP Bascone, D (reprint author), UCL, Dept Chem Engn, Ctr Proc Syst Engn, London WC1E 6BT, England.
EM davide.bascone.14@ucl.ac.uk
OI Angeli, Panagiota/0000-0001-9575-4259
FU UK Engineering and Physical Sciences Research Council (EPSRC)Engineering
   & Physical Sciences Research Council (EPSRC) [EP/L018616/1]; University
   College London
FX The authors would like to acknowledge the UK Engineering and Physical
   Sciences Research Council (EPSRC) for funding provided as the PACIFIC
   project, EP/L018616/1. Davide Bascone would also like to thank
   University College London for his studentship.
CR Alfredson P. G, 1975, TECH REP
   Amador C, 2004, CHEM ENG J, V101, P379, DOI 10.1016/j.cej.2003.11.031
   Angeli P, 2008, P I MECH ENG C-J MEC, V222, P737, DOI 10.1243/09544062JMES776
   Arm S, 2011, WOODHEAD PUBL SER EN, P58
   Asakura T., 2005, J NUCL RADIOCHEM SCI, V6, P271
   Assmann N, 2013, CHEM ENG TECHNOL, V36, P921, DOI 10.1002/ceat.201200557
   Bascone D, 2018, NUCL ENG DES, V332, P162, DOI 10.1016/j.nucengdes.2018.03.030
   Benedict M., 1980, NUCL CHEM ENG
   BIER W, 1993, CHEM ENG PROCESS, V32, P33, DOI 10.1016/0255-2701(93)87004-E
   Birkett JE, 2007, J NUCL SCI TECHNOL, V44, P337, DOI 10.3327/jnst.44.337
   BRETHERTON FP, 1961, J FLUID MECH, V10, P166, DOI 10.1017/S0022112061000160
   Carter R. D., 1968, CRITICALITY HDB, VI
   Chen HY, 2017, SOLVENT EXTR ION EXC, V35, P1, DOI 10.1080/07366299.2016.1273684
   Commenge JM, 2011, CHEM ENG J, V173, P541, DOI 10.1016/j.cej.2011.07.060
   Commenge JM, 2002, AICHE J, V48, P345, DOI 10.1002/aic.690480218
   Dore V, 2012, CHEM ENG SCI, V80, P334, DOI 10.1016/j.ces.2012.06.030
   GAMS Development Corporation, 2013, GEN ALG MOD SYST GAM
   Gharehbagh FS, 2009, J TAIWAN INST CHEM E, V40, P302, DOI 10.1016/j.jtice.2008.07.016
   GONDA K, 1986, J NUCL SCI TECHNOL, V23, P472, DOI 10.3327/jnst.23.472
   GONDA K, 1986, J NUCL SCI TECHNOL, V23, P883, DOI 10.3327/jnst.23.883
   Guillaume B., 1984, EXTRACTION 84, P31
   Hanson B, 2015, WOODHEAD PUBLISHING, P125
   Herbst RS, 2011, WOODHEAD PUBL SER EN, P141
   International Atomic Energy Agency (IAEA), 2008, IAEATECDOC1587
   JEALOUS AC, 1955, IND ENG CHEM, V47, P1168
   Jubin R.T., 2009, TECH REP
   Kashid MN, 2010, CHEM ENG J, V158, P233, DOI 10.1016/j.cej.2010.01.020
   Kashid MN, 2007, CHEM ENG J, V131, P1, DOI 10.1016/j.cej.2006.11.020
   Koltunov V.S., 1974, KINETIKA REAKTSII AK
   Kumar A, 1999, IND ENG CHEM RES, V38, P1040, DOI 10.1021/ie980455l
   Kumar A., 1994, LIQUID LIQUID EXTRAC, P625
   Kumar S, 2001, INDIAN J CHEM TECHN, V8, P41
   Law J.D., 2008, INLCON0815151
   Luo L, 2007, APPL THERM ENG, V27, P1708, DOI 10.1016/j.applthermaleng.2006.07.018
   MATSUDA T, 1986, J NUCL SCI TECHNOL, V23, P633, DOI 10.3327/jnst.23.633
   Natarajan R, 2012, PROCEDIA CHEM, V7, P302, DOI 10.1016/j.proche.2012.10.048
   OECD/NEA, NUCL EN DAT
   Ortega EG, 2018, CHEM ENG J, V351, P589, DOI 10.1016/j.cej.2018.06.020
   Richardson G.L., 1975, TECH REP
   Saber M, 2009, CHEM ENG PROCESS, V48, P723, DOI 10.1016/j.cep.2008.09.001
   Scheiff F, 2011, LAB CHIP, V11, P1022, DOI [10.1039/c0lc00442a, 10.1039/c01c00442a]
   Seider W.D., 2004, PRODUCT PROCESS DESI
   Silverio LB, 2011, ENERG POLICY, V39, P281, DOI 10.1016/j.enpol.2010.09.040
   Smith R., 2005, CHEM PROCESS DESIGN
   Steiner L, 1994, LIQUID LIQUID EXTRAC, P116
   Tachimori S., 1994, TECH REP
   Todd T. A., 2008, P NUCL REG COMM SEM
   Tonkovich A, 2005, CHEM ENG RES DES, V83, P634, DOI 10.1205/cherd.04354
   Treybal R. E., 1963, LIQUID EXTRACTION
   Tsaoulidis D, 2016, AICHE J, V62, P315, DOI 10.1002/aic.15026
   Tsaoulidis D, 2015, CHEM ENG J, V262, P785, DOI 10.1016/j.cej.2014.10.012
   Tsaoulidis D, 2013, CHEM ENG J, V227, P151, DOI 10.1016/j.cej.2012.08.064
   Tsaoulidis D, 2013, CHEM ENG RES DES, V91, P681, DOI 10.1016/j.cherd.2013.01.008
   Uchiyama G, 1998, SOLVENT EXTR ION EXC, V16, P1177, DOI 10.1080/07360299808934575
   Wang K, 2017, CHEM ENG SCI, V169, P18, DOI 10.1016/j.ces.2016.10.025
NR 55
TC 3
Z9 3
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 201
EP 211
DI 10.1016/j.ces.2019.03.074
PG 11
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600016
DA 2020-05-12
ER

PT J
AU Zhang, YJ
   Xu, YX
   Xu, JB
   Yang, C
AF Zhang, Yujia
   Xu, Yinxiang
   Xu, Junbo
   Yang, Chao
TI Computational screening of zeolites for C3H7Cl/C3H5Cl separation and a
   conformation based separation mechanism
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Alkanes-olefins separation; Conformation recognition; Zeolite; Dihedral
   angle; GCMC; NEMD
ID METAL-ORGANIC FRAMEWORK; MOLECULAR-SIEVE; HYDROCARBON SEPARATIONS;
   ADSORPTIVE SEPARATION; NANOPOROUS GRAPHENE; MEMBRANES; ETHANE;
   SIMULATIONS; ETHYLENE; INSIGHTS
AB The separation of alkanes-olefins plays an essential role in petrochemical industry and is also challenging because of their similar physicochemical properties, especially for halogenated alkanes-olefins mixtures. In this work, we quickly screened a series of zeolites to separate 1-chloropropane/allyl chloride (C3H7Cl/C3H5Cl) mixture by molecular simulation. The results show that zeolites with specific pore geometry (e.g., AHT type) only adsorb C3H7Cl thus C3H7Cl can be selectively separated from C3H7Cl completely. These zeolites have one-dimensional elliptical pores with similar sizes, which match with the low energy conformation of C3H5Cl. The flux data of membrane based on these zeolites were also investigated, which confirmed that they can separate C3H7Cl and C3H7Cl with an ultrahigh selectivity. Based on the thermodynamics analysis, we proposed a pore geometry based conformation recognition mechanism of this special adsorption and separation phenomena. In conclusion, this paper provides an avenue to design or screen nano-porous materials for alkanes-olefins separation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Yujia; Xu, Yinxiang; Xu, Junbo; Yang, Chao] Chinese Acad Sci, Inst Proc Engn, Green Manufacture Inst, CAS Key Lab Green Proc & Engn, Beijing 100190, Peoples R China.
   [Zhang, Yujia; Yang, Chao] Univ Chinese Acad Sci, Sch Chem Engn, Beijing 100190, Peoples R China.
   [Xu, Yinxiang] Beihang Univ, Sch Space & Environm, Beijing 100191, Peoples R China.
   [Xu, Yinxiang] Sichuan Univ Sci & Engn, Coll Mech Engn, Chengdu 643000, Sichuan, Peoples R China.
RP Xu, JB; Yang, C (reprint author), Chinese Acad Sci, Inst Proc Engn, Green Manufacture Inst, CAS Key Lab Green Proc & Engn, Beijing 100190, Peoples R China.
EM jbxu@ipe.ac.cn; chaoyang@ipe.ac.cn
RI Yang, Chao/B-4039-2008
OI Yang, Chao/0000-0001-6067-7505; Xu, Junbo/0000-0002-7976-389X
FU National Key R&D Program of China [2016YFB0301702]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [21490584, 91534105, 21878298, 51808362]; Key Research Program of
   Frontier Sciences of CAS [QYZDJ-SSW-JSC030]; Key Research Program of
   Provincial Science and Technology Department in Sichuan [2017SZ0167]
FX This work was supported by Financial supports from the National Key R&D
   Program of China (2016YFB0301702), the National Natural Science
   Foundation of China (21490584, 91534105, 21878298, 51808362), Key
   Research Program of Frontier Sciences of CAS (QYZDJ-SSW-JSC030) and Key
   Research Program of Provincial Science and Technology Department in
   Sichuan (2017SZ0167).
CR Ackley MW, 2003, MICROPOR MESOPOR MAT, V61, P25, DOI 10.1016/S1387-1811(03)00353-6
   Adil K, 2017, CHEM SOC REV, V46, P3402, DOI 10.1039/c7cs00153c
   Bereciartua PJ, 2017, SCIENCE, V358, P1068, DOI 10.1126/science.aao0092
   Bernardo P, 2010, PETROL CHEM+, V50, P271, DOI 10.1134/S0965544110040043
   Bloch ED, 2012, SCIENCE, V335, P1606, DOI 10.1126/science.1217544
   Cadiau A, 2016, SCIENCE, V353, P137, DOI 10.1126/science.aaf6323
   Chu YH, 2018, J MEMBRANE SCI, V548, P609, DOI 10.1016/j.memsci.2017.11.052
   DELLEY B, 1990, J CHEM PHYS, V92, P508, DOI 10.1063/1.458452
   Dubbeldam D, 2016, MOL SIMULAT, V42, P81, DOI 10.1080/08927022.2015.1010082
   Gadipelli S, 2015, PROG MATER SCI, V69, P1, DOI 10.1016/j.pmatsci.2014.10.004
   Gucuyener C, 2010, J AM CHEM SOC, V132, P17704, DOI 10.1021/ja1089765
   HAGLER AT, 1974, J AM CHEM SOC, V96, P5319, DOI 10.1021/ja00824a004
   Herm ZR, 2014, CHEM MATER, V26, P323, DOI 10.1021/cm402897c
   Jiang JW, 2011, CHEM SOC REV, V40, P3599, DOI 10.1039/c0cs00128g
   KENNEDY GJ, 1995, SOLID STATE NUCL MAG, V4, P173, DOI 10.1016/0926-2040(94)00046-F
   Kosinov N, 2016, J MEMBRANE SCI, V499, P65, DOI 10.1016/j.memsci.2015.10.049
   Liao PQ, 2017, SCIENCE, V356, P1193, DOI 10.1126/science.aam7232
   Lin RB, 2017, J AM CHEM SOC, V139, P8022, DOI 10.1021/jacs.7b03850
   Liu HJ, 2013, NANOSCALE, V5, P9984, DOI 10.1039/c3nr02852f
   Maghsoudi H, 2016, ADSORPTION, V22, P985, DOI 10.1007/s10450-016-9805-x
   Mofarahi M, 2013, ADSORPTION, V19, P101, DOI 10.1007/s10450-012-9423-1
   Pandey RK, 2007, CATAL COMMUN, V8, P379, DOI 10.1016/j.catcom.2006.07.007
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Ravanchi MT, 2009, DESALINATION, V235, P199, DOI 10.1016/j.desal.2007.10.042
   Shi M, 2011, CHEM ENG SCI, V66, P2817, DOI 10.1016/j.ces.2011.03.046
   van Miltenburg A, 2006, CHEM ENG RES DES, V84, P350, DOI 10.1205/cherd05021
   Wang Y, 2016, PHYS CHEM CHEM PHYS, V18, P8352, DOI 10.1039/c5cp06569k
   Wu GQ, 2017, CHEM ENG J, V320, P1, DOI 10.1016/j.cej.2017.03.030
   Yuan QZ, 2015, PHYS CHEM CHEM PHYS, V17, P31887, DOI 10.1039/c5cp06649b
   Zhang G, 2009, APPL SURF SCI, V255, P7197, DOI 10.1016/j.apsusc.2009.03.058
NR 31
TC 0
Z9 0
U1 11
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 212
EP 219
DI 10.1016/j.ces.2019.03.084
PG 8
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600017
DA 2020-05-12
ER

PT J
AU Deneff, JI
   Walton, KS
AF Deneff, Jacob, I
   Walton, Krista S.
TI Production of metal-organic framework-bearing polystyrene fibers by
   solution blow spinning
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE MOF composite; Gas adsorption; Fibers; Solution blow spinning
ID MIXED-MATRIX MEMBRANES; REMOVAL; DEGRADATION; ADSORPTION; NANOFIBERS;
   SEPARATION; STABILITY; MONOLITHS; HKUST-1; UIO-66
AB Solution blow spinning (SBS) is examined in this work as a platform method for creating MOF-bearing fiber composites for application in separations and catalysis. Composite fibers were produced from MOF suspensions in polymer solutions and examined for both MOF stability and accessibility. The composites were found to have more MOF accessibility than bulk polymers, but adsorption was hindered by the formation of a glassy polymer skin. The fibers were found to have better accessibility to water vapor and carbon dioxide at room temperature compared to nitrogen adsorption at 77 K, suggesting that they may be applicable for gases that have high permeability in the polymer. MOF-polymer fibers produced by SBS provide an interesting platform for delivery of different MOFs to target a variety of applications, particularly those requiring scale-up or in-situ production. Ultimately, this system combines a low-hazard, low-cost polymer and a highly stable MOF to enable a systematic evaluation of the effects of the process on the accessibility of active materials. Going forward, an examination of a broader set of polymers and MOFs is necessary to further characterize and optimize this method and to create and refine synergy between the MOF and the polymer. (C) 2019 Published by Elsevier Ltd.
C1 [Deneff, Jacob, I; Walton, Krista S.] Georgia Inst Technol, Sch Chem & Biomol Engn, 311 Ferst Dr NW, Atlanta, GA 30332 USA.
RP Walton, KS (reprint author), Georgia Inst Technol, Sch Chem & Biomol Engn, 311 Ferst Dr NW, Atlanta, GA 30332 USA.
EM krista.walton@chbe.gatech.edu
OI Walton, Krista/0000-0002-0962-9644
FU U.S. Army Research Office [W911NF-15-1-0640]; Georgia Tech's School of
   Chemical & Biomolecular Engineering; Georgia Tech Specialty Separations
   Center
FX This material is based upon work supported by the U.S. Army Research
   Office Award W911NF-15-1-0640, Georgia Tech's School of Chemical &
   Biomolecular Engineering, and the Georgia Tech Specialty Separations
   Center.
CR Abdelhameed RM, 2016, RSC ADV, V6, P42324, DOI 10.1039/c6ra04719j
   Adatoz E, 2015, SEP PURIF TECHNOL, V152, P207, DOI 10.1016/j.seppur.2015.08.020
   Ahmed A, 2014, CHEM COMMUN, V50, P14314, DOI 10.1039/c4cc06967f
   Armstrong M, 2018, MICROPOR MESOPOR MAT, V270, P34, DOI 10.1016/j.micromeso.2018.05.004
   Burtch NC, 2014, CHEM REV, V114, P10575, DOI 10.1021/cr5002589
   Chen G, 2016, ACS APPL MATER INTER, V8, P9700, DOI 10.1021/acsami.6b00897
   Cmarik GE, 2012, LANGMUIR, V28, P15606, DOI 10.1021/la3035352
   Parize DDD, 2016, J APPL POLYM SCI, V133, DOI 10.1002/app.43379
   Daristotle JL, 2016, ACS APPL MATER INTER, V8, P34951, DOI 10.1021/acsami.6b12994
   Darunte L. A, 2017, ACS APPL MAT INTERFA
   DeCoste JB, 2016, CHEM SCI, V7, P2711, DOI 10.1039/c5sc04368a
   DeCoste JB, 2015, NEW J CHEM, V39, P2396, DOI 10.1039/c4nj02093f
   DeCoste JB, 2014, CHEM REV, V114, P5695, DOI 10.1021/cr4006473
   DeCoste JB, 2013, J MATER CHEM A, V1, P5642, DOI 10.1039/c3ta10662d
   Denny MS, 2015, ANGEW CHEM INT EDIT, V54, P9029, DOI 10.1002/anie.201504077
   Falcaro P, 2014, CHEM SOC REV, V43, P5513, DOI 10.1039/c4cs00089g
   Ferey G, 2008, CHEM SOC REV, V37, P191, DOI 10.1039/b618320b
   Fu YY, 2013, CHEM COMMUN, V49, P7162, DOI 10.1039/c3cc43017k
   Garibay SJ, 2010, CHEM COMMUN, V46, P7700, DOI 10.1039/c0cc02990d
   Hong WY, 2015, MICROPOR MESOPOR MAT, V214, P149, DOI 10.1016/j.micromeso.2015.05.014
   Jeazet HBT, 2012, DALTON T, V41, P14003, DOI 10.1039/c2dt31550e
   Katz MJ, 2015, CHEM SCI, V6, P2286, DOI 10.1039/c4sc03613a
   Katz MJ, 2014, ANGEW CHEM INT EDIT, V53, P497, DOI 10.1002/anie.201307520
   Kolbasov A, 2016, IND ENG CHEM RES, V55, P323, DOI 10.1021/acs.iecr.5b04277
   Kusgens P, 2010, J AM CERAM SOC, V93, P2476, DOI 10.1111/j.1551-2916.2010.03824.x
   Li WB, 2015, CHEM ENG SCI, V135, P232, DOI 10.1016/j.ces.2015.04.011
   Lopez-Maya E, 2015, ANGEW CHEM INT EDIT, V54, P6790, DOI 10.1002/anie.201502094
   Lu AX, 2017, ACS APPL MATER INTER, V9, P13632, DOI 10.1021/acsami.7b01621
   Luo CJ, 2012, CHEM SOC REV, V41, P4708, DOI 10.1039/c2cs35083a
   Medeiros ES, 2009, J APPL POLYM SCI, V113, P2322, DOI 10.1002/app.30275
   MOHANTY KK, 1982, CHEM ENG SCI, V37, P905, DOI 10.1016/0009-2509(82)80179-6
   Moreton JC, 2016, CHEM COMMUN, V52, P14376, DOI 10.1039/c6cc07329h
   Oliveira JE, 2011, J APPL POLYM SCI, V122, P3396, DOI 10.1002/app.34410
   Peterson G. W, 2017, ACS APPL MAT INTERFA
   Peterson GW, 2016, ANGEW CHEM INT EDIT, V55, P6235, DOI 10.1002/anie.201601782
   Peterson GW, 2014, IND ENG CHEM RES, V53, P701, DOI 10.1021/ie403366d
   Rezaei F, 2010, SEP PURIF TECHNOL, V70, P243, DOI 10.1016/j.seppur.2009.10.004
   Shi Q, 2011, J MATER CHEM, V21, P10330, DOI 10.1039/c1jm11492a
   Zhang YY, 2016, J AM CHEM SOC, V138, P5785, DOI 10.1021/jacs.6b02553
   Zhao JJ, 2014, ADV MATER INTERFACES, V1, DOI 10.1002/admi.201400040
NR 40
TC 2
Z9 2
U1 12
U2 115
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 220
EP 227
DI 10.1016/j.ces.2019.03.012
PG 8
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600018
DA 2020-05-12
ER

PT J
AU Ma, YY
   Gan, J
   Pan, MJ
   Zhang, YF
   Fu, WZ
   Duan, XZ
   Chen, WY
   Chen, D
   Qian, G
   Zhou, XG
AF Ma, Yuanyuan
   Gan, Jie
   Pan, Minjian
   Zhang, Yanfang
   Fu, Wenzhao
   Duan, Xuezhi
   Chen, Wenyao
   Chen, De
   Qian, Gang
   Zhou, Xinggui
TI Reaction mechanism and kinetics for Pt/CNTs catalyzed base-free
   oxidation of glycerol
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Base-free oxidation of glycerol; Solvent effects; DFT calculations;
   Kinetic isotope effects; Kinetics analysis
ID TOTAL-ENERGY CALCULATIONS; SELECTIVE OXIDATION; AMMONIA BORANE; OXYGEN;
   NANOPARTICLES; INSIGHTS; POINTS; SIZE; AU; PD
AB Fundamental understanding of heterogeneously catalyzed aerobic, base-free oxidation of glycerol is highly desirable for sustainable and highly efficient chemical synthesis. In this work, Pt/CNTs catalyzed base-free oxidation of glycerol is investigated by combining experiments, DFT calculations and kinetics analysis. The solvent effects and kinetic isotope effects measurements as well as DFT calculations reveal that water-assisted O-2 activation to form active OH* intermediates is not in rate-determining step (RDS) but in equilibrium. Then, Langmuir-Hinshelwood kinetic models are developed and fitted with the experimental data. The OH*-assisted C-H bond cleavage of glycerol is discriminated as the RDS for the two parallel oxidation pathways of glycerol via primary or secondary hydroxyl groups, where the former case exhibits lower activation energy. The insights revealed here could guide the design and optimization of this catalytic process to generate the targeted products. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ma, Yuanyuan; Gan, Jie; Pan, Minjian; Zhang, Yanfang; Fu, Wenzhao; Duan, Xuezhi; Chen, Wenyao; Qian, Gang; Zhou, Xinggui] East China Univ Sci & Technol, State Key Lab Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
   [Chen, De] Norwegian Univ Sci & Technol, Dept Chem Engn, N-7491 Trondheim, Norway.
RP Duan, XZ; Qian, G (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
EM xzduan@ecust.edu.cn; carlqg@ecust.edu.cn
RI QIAN, LIU/S-1353-2019
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [21776077]; Shanghai Natural Science FoundationNatural Science
   Foundation of Shanghai [17ZR1407300, 17ZR1407500]; Program for Professor
   of Special Appointment (Eastern Scholar) at Shanghai Institutions of
   Higher Learning; Shanghai Rising-Star Program [17QA1401200]; Open
   Project of State Key Laboratory of Chemical Engineering [SKLChe-15C03];
   State Key Laboratory of Organic-Inorganic Composites [oic-201801007];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [222201718003]; 111 Project
   of the Ministry of Education of China [B08021]
FX This work was financially supported by the Natural Science Foundation of
   China (21776077), the Shanghai Natural Science Foundation (17ZR1407300
   and 17ZR1407500), the Program for Professor of Special Appointment
   (Eastern Scholar) at Shanghai Institutions of Higher Learning, the
   Shanghai Rising-Star Program (17QA1401200), the Open Project of State
   Key Laboratory of Chemical Engineering (SKLChe-15C03), the State Key
   Laboratory of Organic-Inorganic Composites (oic-201801007), the
   Fundamental Research Funds for the Central Universities (222201718003),
   and the 111 Project of the Ministry of Education of China (B08021).
CR Bianchi CL, 2005, CATAL TODAY, V102, P203, DOI 10.1016/j.cattod.2005.02.003
   BLOCHL PE, 1994, PHYS REV B, V50, P17953, DOI 10.1103/PhysRevB.50.17953
   Chang CR, 2013, ACS CATAL, V3, P1693, DOI 10.1021/cs400344r
   Chen WY, 2017, J CATAL, V356, P186, DOI 10.1016/j.jcat.2017.10.016
   Chen WY, 2017, AICHE J, V63, P60, DOI 10.1002/aic.15389
   Dodekatos G, 2018, CATAL SCI TECHNOL, V8, P4891, DOI 10.1039/c8cy01284a
   Dodekatos G, 2018, ACS CATAL, V8, P6301, DOI 10.1021/acscatal.8b01317
   Duan XZ, 2018, AICHE J, V64, P3979, DOI 10.1002/aic.16217
   Henkelman G, 2000, J CHEM PHYS, V113, P9901, DOI 10.1063/1.1329672
   Hibbitts DD, 2013, J CATAL, V299, P261, DOI 10.1016/j.jcat.2012.11.016
   Tran HV, 2016, CURR OPIN CHEM ENG, V13, P100, DOI 10.1016/j.coche.2016.08.010
   Ide MS, 2014, ACCOUNTS CHEM RES, V47, P825, DOI 10.1021/ar4001907
   Kaskow I, 2018, APPL SURF SCI, V444, P197, DOI 10.1016/j.apsusc.2018.02.285
   Kresse G, 1996, PHYS REV B, V54, P11169, DOI 10.1103/PhysRevB.54.11169
   KRESSE G, 1993, PHYS REV B, V47, P558, DOI 10.1103/PhysRevB.47.558
   Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758
   Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0
   KRESSE G, 1994, PHYS REV B, V50, P13181, DOI 10.1103/PhysRevB.50.13181
   Lei JQ, 2016, IND ENG CHEM RES, V55, P420, DOI 10.1021/acs.iecr.5b03076
   Lei JQ, 2014, IND ENG CHEM RES, V53, P16309, DOI 10.1021/ie502706r
   Li Y, 2015, J CATAL, V326, P116, DOI 10.1016/j.jcat.2015.04.009
   Li Z, 2017, CHEM SCI, V8, P781, DOI 10.1039/c6sc02456d
   Liang D, 2011, CATAL COMMUN, V12, P1059, DOI 10.1016/j.catcom.2011.03.019
   METHFESSEL M, 1989, PHYS REV B, V40, P3616, DOI 10.1103/PhysRevB.40.3616
   MONKHORST HJ, 1976, PHYS REV B, V13, P5188, DOI 10.1103/PhysRevB.13.5188
   Nie RF, 2012, APPL CATAL B-ENVIRON, V127, P212, DOI 10.1016/j.apcatb.2012.08.026
   Ning XM, 2016, J CATAL, V335, P95, DOI 10.1016/j.jcat.2015.12.020
   Ou LH, 2009, J PHYS CHEM C, V113, P20657, DOI 10.1021/jp9059505
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Pestana CFM, 2013, J BRAZIL CHEM SOC, V24, P100, DOI 10.1590/S0103-50532013000100014
   Shen YH, 2015, J ENERGY CHEM, V24, P669, DOI 10.1016/j.jechem.2015.08.015
   Villa A, 2010, ANGEW CHEM INT EDIT, V49, P4499, DOI 10.1002/anie.201000762
   Wang FF, 2015, CHEM ENG J, V264, P336, DOI 10.1016/j.cej.2014.11.115
   Westaway KC, 2007, J LABELLED COMPD RAD, V50, P989, DOI 10.1002/jlcr.1434
   Xiao Y, 2017, AICHE J, V63, P705, DOI 10.1002/aic.15418
   Xu CW, 2008, ELECTROCHIM ACTA, V53, P2610, DOI 10.1016/j.electacta.2007.10.036
   Zhang MY, 2015, CATAL COMMUN, V59, P5, DOI 10.1016/j.catcom.2014.09.036
   Zhou CHC, 2008, CHEM SOC REV, V37, P527, DOI 10.1039/b707343g
   Zope BN, 2010, SCIENCE, V330, P74, DOI 10.1126/science.1195055
NR 39
TC 5
Z9 5
U1 23
U2 105
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 228
EP 236
DI 10.1016/j.ces.2019.03.068
PG 9
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600019
DA 2020-05-12
ER

PT J
AU Yue, XJ
   Zhang, T
   Yang, DY
   Qiu, FX
   Li, ZD
AF Yue, Xuejie
   Zhang, Tao
   Yang, Dongya
   Qiu, Fengxian
   Li, Zhangdi
TI Superwetting rape pollen layer for emulsion switchable separation with
   high flux
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Rape pollen; Superwetting; Emulsions separation; Absorption
ID EFFICIENT OIL ABSORPTION; ENHANCED OILS; WASTE PAPER; WATER; CARBON;
   MEMBRANES; MESH; NANOSCALE; STRATEGY; AEROGELS
AB The treatment of various kinds of oil-in-water and water-in-oil emulsions is increasingly desired but is still a considerable challenge. Although traditional two-dimensional superwetting separation materials have been widely studied, they still suffer from disadvantages such as single wettability and low separation flux. In this work, three-dimensional hollow porous rape pollen with switchable wettability was fabricated via simple solvent extraction and subsequent calcination using the pristine rape pollen as starting material. The obtained rape pollen was developed into a superwetting rape pollen layer, which achieves controllable wettability transition between hydrophobicity/underwater superoleophilicity and superhydrophilicity/underoil superhydrophilicity via calcination and steam modification alternately, without the addition of toxic modification reagents. Moreover, the wettability of rape pollens could be reversibly switched for many times. The obtained rape pollen layer can be used for on-demand separation of various oil-in-water and water-in-oil emulsions in one single device. After calcination, the hydrophobic/underwater superoleophilic rape pollen layer can absorb tiny oil droplets from oil-in-water emulsion, and the wetting properties can be rapidly switched to be superhydrophilicity/underoil superhydrophilicity to capture the water droplets from water-in-oil emulsion, with both high separation efficiency and separation flux. This work not only provides a novel emulsion separation approach that is different from membrane separation, but also has high potential in practical applications relating to wastewater treatment, fuel purification, microfluidics, and so on. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yue, Xuejie; Zhang, Tao; Yang, Dongya; Qiu, Fengxian; Li, Zhangdi] Jiangsu Univ, Sch Chem & Chem Engn, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Zhang, Tao] Jiangsu Univ, Inst Green Chem & Chem Technol, Zhenjiang 212013, Jiangsu, Peoples R China.
RP Zhang, T; Qiu, FX (reprint author), Jiangsu Univ, Sch Chem & Chem Engn, Zhenjiang 212013, Jiangsu, Peoples R China.
EM zhangtaochem@163.com; fxqiu@ujs.edu.cn
OI Zhang, Tao/0000-0001-9255-9802
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21706100, 21878132]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2018T110452];
   Postgraduate Research & Practice Innovation Program of Jiangsu Province
   [SJKY19_ 2577]; Qing Lan ProjectJiangsu Polytech Institute [20182021];
   Society Development Fund of Zhenjiang City [SH2018009]; 333 High-Level
   Personnel Training Project of Jiangsu Province [BRA2016142]; Natural
   Science Foundation of Jiangsu ProvinceJiangsu Planned Projects for
   Postdoctoral Research FundsNatural Science Foundation of Jiangsu
   Province [BK20160500, BK20161362, BK20161264]
FX The authors gratefully acknowledge financial support from the National
   Natural Science Foundation of China (21706100 and 21878132), China
   Postdoctoral Science Foundation (2018T110452), Postgraduate Research &
   Practice Innovation Program of Jiangsu Province (SJKY19_ 2577), Qing Lan
   Project (20182021), Society Development Fund of Zhenjiang City
   (SH2018009), the 333 High-Level Personnel Training Project of Jiangsu
   Province (BRA2016142), and Natural Science Foundation of Jiangsu
   Province (BK20160500, BK20161362 and BK20161264).
CR Cao CY, 2016, J MATER CHEM A, V4, P12179, DOI 10.1039/c6ta04420d
   Cheng Y, 2019, CHEM ENG J, V355, P290, DOI 10.1016/j.cej.2018.08.113
   Cheng ZJ, 2015, LANGMUIR, V31, P1393, DOI 10.1021/la503676a
   Duong PHH, 2014, ENVIRON SCI TECHNOL, V48, P4537, DOI 10.1021/es405644u
   Feng L, 2004, ANGEW CHEM INT EDIT, V43, P2012, DOI 10.1002/anie.200353381
   Gao SJ, 2015, J MATER CHEM A, V3, P2895, DOI 10.1039/c4ta05624h
   Ge MZ, 2018, NANOSCALE HORIZ, V3, P235, DOI 10.1039/c7nh00185a
   Goodwin WB, 2013, CHEM MATER, V25, P4529, DOI 10.1021/cm402226w
   Gu JC, 2017, ACS APPL MATER INTER, V9, P5968, DOI 10.1021/acsami.6b13547
   Gu JC, 2014, J MATER CHEM A, V2, P15268, DOI 10.1039/c4ta01603c
   Jiang X, 2018, ACS SUSTAIN CHEM ENG, V6, P882, DOI 10.1021/acssuschemeng.7b03228
   Li GF, 2015, J MEMBRANE SCI, V495, P439, DOI 10.1016/j.memsci.2015.08.042
   Li J, 2018, J MATER CHEM A, V6, P223, DOI 10.1039/c7ta08076j
   Li LX, 2017, J MATER CHEM A, V5, P14858, DOI 10.1039/c7ta03511j
   Liu N, 2015, J MATER CHEM A, V3, P20113, DOI 10.1039/c5ta06314k
   Ma QL, 2017, ADV MATER, V29, DOI 10.1002/adma.201605361
   Mundargi RC, 2016, SMALL, V12, P1167, DOI 10.1002/smll.201500860
   Rong J, 2017, CHEM ENG J, V322, P397, DOI 10.1016/j.cej.2017.04.049
   Wang ZD, 2017, J MATER CHEM A, V5, P5895, DOI 10.1039/c6ta10248d
   Wei L, 2016, ACS SUSTAIN CHEM ENG, V4, P6463, DOI 10.1021/acssuschemeng.6b01227
   Yue XJ, 2018, J CLEAN PROD, V199, P411, DOI 10.1016/j.jclepro.2018.07.181
   Yue XJ, 2018, IND ENG CHEM RES, V57, P10439, DOI 10.1021/acs.iecr.8b02577
   Yue XJ, 2017, CHEM ENG J, V328, P117, DOI 10.1016/j.cej.2017.07.026
   Zeng XJ, 2017, ACS NANO, V11, P760, DOI 10.1021/acsnano.6b07182
   Zhang GY, 2014, J MATER CHEM A, V2, P15284, DOI 10.1039/c4ta03034f
   Zhang JP, 2011, ADV FUNCT MATER, V21, P4699, DOI 10.1002/adfm.201101090
   Zhang T, 2017, CHEM ENG J, V309, P7, DOI 10.1016/j.cej.2016.08.085
   Zhang WF, 2015, ADV MATER, V27, P7349, DOI 10.1002/adma.201502695
   Zhou H, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201604261
   Zhu WJ, 2015, ELECTROCHIM ACTA, V152, P286, DOI 10.1016/j.electacta.2014.11.092
   Zhu YZ, 2014, NPG ASIA MATER, V6, DOI 10.1038/am.2014.23
NR 31
TC 2
Z9 2
U1 14
U2 69
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 237
EP 246
DI 10.1016/j.ces.2019.03.081
PG 10
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600020
DA 2020-05-12
ER

PT J
AU Arastoopour, H
AF Arastoopour, Hamid
TI The critical contribution of chemical engineering to a pathway to
   sustainability
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
ID MGO-BASED SORBENT; HYDROGEN-PRODUCTION; CO2 CAPTURE; PROCESS
   INTENSIFICATION; NUMERICAL-SIMULATION; STEAM GASIFICATION; CFD
   SIMULATION; HIGH-CAPACITY; SOLAR-ENERGY; BIOMASS
AB The vision of a pathway to a sustainable society is based on the three-pillar conception of sustainability (economic, environmental, and social) that is expected to result in a significant improvement in the reliability, security, and affordability of energy, materials, water, and food. This pathway should include launching a multidisciplinary and least-cost strategy to move from today's carbon-based economy toward a sustainable economy and, at the same time, to provide the needed energy, water, food, and materials for present and future generations. It is imperative that chemical engineers do not relinquish their leadership role in research and development as global energy systems continue to evolve in a historical cycle from primary reliance on wood to coal and oil, to current reliance on natural gas as a transitional fuel in contributing to a pathway to sustainable global energy systems. Although multidisciplinary research and development is needed to move forward on a pathway to sustainability, in this paper, specific areas of research and development are discussed in which chemical engineers should assume a leadership role or become major contributors in this critical initiative. These areas include, but are not limited to: carbon capture, utilization, and sequestration; process intensification; material recycling; water management and desalination; biofuel; natural gas production and conversion; energy storage; and renewable energy, including concentrated solar energy use in chemical, pharmaceutical, and biological processes, and advanced materials for photovoltaics. (C) 2019 Published by Elsevier Ltd.
C1 [Arastoopour, Hamid] IIT, Dept Chem & Biol Engn, Wanger Inst Sustainable Energy Res, Chicago, IL 60616 USA.
RP Arastoopour, H (reprint author), IIT, Dept Chem & Biol Engn, Wanger Inst Sustainable Energy Res, Chicago, IL 60616 USA.
EM arastoopour@iit.edu
CR Abbasi E., 2011, CFB, V10, P736
   Abbasi E, 2015, POWDER TECHNOL, V286, P616, DOI 10.1016/j.powtec.2015.09.002
   Abbasi E, 2014, FUEL, V137, P260, DOI 10.1016/j.fuel.2014.07.088
   Abbasi E, 2013, CHEM ENG SCI, V102, P432, DOI 10.1016/j.ces.2013.08.034
   Agrawal R, 2001, AICHE J, V47, P967, DOI 10.1002/aic.690470503
   Ahmad H, 2015, RENEW SUST ENERG REV, V43, P599, DOI 10.1016/j.rser.2014.10.101
   Ahmadzadeh A, 2003, IND ENG CHEM RES, V42, P2627, DOI 10.1021/ie020740b
   Ahmadzadeh A, 2008, CHEM ENG RES DES, V86, P329, DOI 10.1016/j.cherd.2008.02.004
   Andenaes E, 2018, SOL ENERGY, V159, P318, DOI 10.1016/j.solener.2017.10.078
   Andrew M, 2014, INT J GREENH GAS CON, V22, P1, DOI 10.1016/j.ijggc.2013.12.018
   Vu AT, 2014, CHEM ENG J, V258, P254, DOI 10.1016/j.cej.2014.07.088
   [Anonymous], 2014, INTERGOVERNMENTAL PA
   Arastoopour H, 2001, POWDER TECHNOL, V119, P59, DOI 10.1016/S0032-5910(00)00417-4
   Arastoopour H, 2017, MECH ENG SERIES
   Arastoopour H, 2017, AICHE J, V63, P5375, DOI 10.1002/aic.15928
   Asadi M, 2018, NATURE, V555, P502, DOI 10.1038/nature25984
   Asadi M, 2016, SCIENCE, V353, P467, DOI 10.1126/science.aaf4767
   Ashuri M, 2016, NANOSCALE, V8, P74, DOI 10.1039/c5nr05116a
   BARBIER EB, 1987, ENVIRON CONSERV, V14, P101, DOI 10.1017/S0376892900011449
   BARTLETT AA, 1994, POPUL ENVIRON, V16, P5, DOI 10.1007/BF02208001
   Bilgili E, 2001, POWDER TECHNOL, V115, P265, DOI 10.1016/S0032-5910(00)00353-3
   Boswell R, 2011, ENERG ENVIRON SCI, V4, P1206, DOI 10.1039/c0ee00203h
   Breault RW, 2016, CHEM ENG RES DES, V112, P251, DOI 10.1016/j.cherd.2016.06.020
   Brew KW, 2017, THIN SOLID FILMS, V642, P110, DOI 10.1016/j.tsf.2017.09.009
   Brunetti A, 2010, J MEMBRANE SCI, V359, P115, DOI 10.1016/j.memsci.2009.11.040
   Cecilia JA, 2016, INT J GREENH GAS CON, V52, P344, DOI 10.1016/j.ijggc.2016.07.018
   Chheda JN, 2007, ANGEW CHEM INT EDIT, V46, P7164, DOI 10.1002/anie.200604274
   Chueh WC, 2010, SCIENCE, V330, P1797, DOI 10.1126/science.1197834
   Clift R, 2012, PROCEDIA ENGINEER, V46, P39, DOI 10.1016/j.proeng.2012.09.443
   Clune W. H, 2018, J ENV PROTECT, V9, P211, DOI DOI 10.4236/jep.2018.93015
   Dallimore S. R, 2008, P 6 INT C GAS HYDR I
   Darunte LA, 2017, ACS APPL MATER INTER, V9, P17043, DOI 10.1021/acsami.7b02035
   de Chalendar JA, 2018, J FLUID MECH, V835, P363, DOI 10.1017/jfm.2017.720
   EIA (Energy Information Administration), 2013, TECHN REC SHAL OIL S
   Eltayeb AE, 2010, COMPUT CHEM ENG, V34, P1323, DOI 10.1016/j.compchemeng.2010.02.019
   Energy Information Administration, 2017, INT EN OUTL REP
   Energy Information Administration (EIA), 2016, INT EN STAT 2016
   Eskandari M, 2009, POWDER TECHNOL, V189, P454, DOI 10.1016/j.powtec.2008.07.009
   Fang HHP, 2004, WA SCI TECHNOL, V4, P77
   FLETCHER EA, 1977, SCIENCE, V197, P1050, DOI 10.1126/science.197.4308.1050
   Ghadirian E, 2017, POWDER TECHNOL, V318, P314, DOI 10.1016/j.powtec.2017.06.012
   Ghadirian E, 2016, POWDER TECHNOL, V288, P35, DOI 10.1016/j.powtec.2015.10.034
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Gidaspow D, 2015, CHEM ENG SCI, V134, P784, DOI 10.1016/j.ces.2015.05.054
   Gough I, 2017, HEAT GRID HUMAN NEED
   Gude VG, 2016, WATER RES, V89, P87, DOI 10.1016/j.watres.2015.11.012
   Gupta AR, 2018, ENERG CONVERS MANAGE, V171, P126, DOI 10.1016/j.enconman.2018.05.050
   Hages CJ, 2016, SOL ENERG MAT SOL C, V145, P342, DOI 10.1016/j.solmat.2015.10.039
   Hirsch D, 2004, INT J HYDROGEN ENERG, V29, P47, DOI 10.1016/S0360-3199(03)00048-X
   Igci Y, 2008, AICHE J, V54, P1431, DOI 10.1002/aic.11481
   Jackson T, 2016, PROSPERITY GROWTH, DOI [10.4324/9781315677453, DOI 10.4324/9781315677453]
   Joseph K, 2018, CHEM ENG PROG, V14
   Li J., 1994, PARTICLE FLUID 2 PHA
   Li JR, 2011, COORDIN CHEM REV, V255, P1791, DOI 10.1016/j.ccr.2011.02.012
   Liu Y, 2009, IND ENG CHEM RES, V48, P2451, DOI 10.1021/ie8005275
   Macco B, 2018, SOL ENERG MAT SOL C, V184, P98, DOI 10.1016/j.solmat.2018.04.037
   Marchisio DL, 2003, AICHE J, V49, P1266, DOI 10.1002/aic.690490517
   Matsubara K, 2014, ENRGY PROCED, V49, P447, DOI 10.1016/j.egypro.2014.03.048
   Milshtein JD, 2017, J ELECTROCHEM SOC, V164, pE3265, DOI 10.1149/2.0201711jes
   Mondal MK, 2012, ENERGY, V46, P431, DOI 10.1016/j.energy.2012.08.006
   Moya D, 2017, ENRGY PROCED, V134, P286, DOI 10.1016/j.egypro.2017.09.618
   Muhich CL, 2013, SCIENCE, V341, P540, DOI 10.1126/science.1239454
   Nagaraj V, 2018, J ENVIRON MANAGE, V223, P586, DOI 10.1016/j.jenvman.2018.05.088
   Nazridoust K, 2007, CHEM ENG SCI, V62, P6155, DOI 10.1016/j.ces.2007.06.038
   Ni M, 2007, RENEW SUST ENERG REV, V11, P401, DOI 10.1016/j.rser.2005.01.009
   Ozalp N, 2018, CURR OPIN CHEM ENG, V21, P111, DOI 10.1016/j.coche.2018.10.001
   Pang SH, 2017, J AM CHEM SOC, V139, P3627, DOI 10.1021/jacs.7b00235
   Park Y, 2011, PHYS CHEM CHEM PHYS, V13, P18115, DOI 10.1039/c1cp22631b
   Peppas N. A, 2008, 1 CENTURY CHEM ENG
   Pevida C, 2008, APPL SURF SCI, V254, P7165, DOI 10.1016/j.apsusc.2008.05.239
   Purvis B, 2018, SUSTAIN SCI
   Raworth K., 2018, DOUGHNUT EC 7 WAYS T
   Rockstrom J, 2009, NATURE, V461, P472, DOI 10.1038/461472a
   Sawicki M, 2015, RSC ADV, V5, P53129, DOI 10.1039/c5ra08321d
   Sayari A, 2011, CHEM ENG J, V171, P760, DOI 10.1016/j.cej.2011.02.007
   Selvaraj K, 2018, DESALINATION, V435, P181, DOI 10.1016/j.desal.2017.09.031
   Sengodan S, 2018, RENEW SUST ENERG REV, V82, P761, DOI 10.1016/j.rser.2017.09.071
   Shahidi N, 2004, POLYMER, V45, P5183, DOI 10.1016/j.polymer.2004.04.061
   Shahidi N, 2010, U.S. Patent, Patent No. [7,816,446, 7816446]
   Shahidi N, 2006, J APPL POLYM SCI, V102, P119, DOI 10.1002/app.23259
   Shutov F, 1997, U.S. Patent, Patent No. [5,688,448, 5688448]
   Siirola JJ, 2014, AICHE J, V60, P810, DOI 10.1002/aic.14368
   Sinclair J, 1998, P FEDSM 98 ASME FLUI, V4, P7
   Sophia AC, 2016, J ENVIRON CHEM ENG, V4, P3468, DOI 10.1016/j.jece.2016.07.024
   Stankiewicz AI, 2000, CHEM ENG PROG, V96, P22
   Strumendo M, 2008, CHEM ENG SCI, V63, P2624, DOI 10.1016/j.ces.2008.02.010
   Swain PK, 2011, RENEW SUST ENERG REV, V15, P4917, DOI 10.1016/j.rser.2011.07.061
   Tregambi C, 2016, SOL ENERGY, V129, P85, DOI 10.1016/j.solener.2016.01.057
   Velmurugan V, 2008, ENERG CONVERS MANAGE, V49, P2602, DOI 10.1016/j.enconman.2008.05.010
   Vilarrasa-Garcia E, 2015, MICROPOR MESOPOR MAT, V209, P172, DOI 10.1016/j.micromeso.2014.08.032
   Walker ME, 2013, ENERGY, V60, P139, DOI 10.1016/j.energy.2013.07.066
   Walker ME, 2012, ENERGY, V44, P429, DOI 10.1016/j.energy.2012.06.010
   Wang CL, 2015, ELECTROCHIM ACTA, V161, P322, DOI 10.1016/j.electacta.2015.02.125
   Wang HL, 2010, J AM CHEM SOC, V132, P13978, DOI 10.1021/ja105296a
   Wang HY, 2017, CHEM ENG PROCESS, V118, P78, DOI 10.1016/j.cep.2017.04.007
   Wang JL, 2018, RENEW SUST ENERG REV, V92, P284, DOI 10.1016/j.rser.2018.04.033
   Weldekidan H, 2018, FUEL, V233, P396, DOI 10.1016/j.fuel.2018.06.061
   Yan LB, 2016, BIORESOURCE TECHNOL, V221, P625, DOI 10.1016/j.biortech.2016.09.089
   Zarghami S, 2015, IND ENG CHEM RES, V54, P5398, DOI 10.1021/acs.iecr.5b00049
   Zeaiter J, 2018, RENEW ENERG, V123, P44, DOI 10.1016/j.renene.2018.02.030
   Zhang ZY, 2017, FUEL, V188, P628, DOI 10.1016/j.fuel.2016.10.074
   Zhao X, 2017, ENERG ENVIRON SCI, V10, P1885, DOI 10.1039/c6ee03718f
NR 102
TC 5
Z9 5
U1 5
U2 53
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 247
EP 258
DI 10.1016/j.ces.2019.03.069
PG 12
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600021
DA 2020-05-12
ER

PT J
AU Yu, W
   Liu, XD
   Zhao, YJ
   Chen, YP
AF Yu, Wei
   Liu, Xiangdong
   Zhao, Yuanjin
   Chen, Yongping
TI Droplet generation hydrodynamics in the microfluidic cross-junction with
   different junction angles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Droplet generation; Microfluidic cross-junction; Junction angle;
   Hydrodynamics; Scaling relation
ID LATTICE BOLTZMANN; ASYMMETRIC BREAKUP; FLOW; SIMULATION; DEVICES;
   MICROCHANNEL; DYNAMICS; SYSTEMS
AB A 3D numerical study is performed to investigate the hydrodynamics of droplet generation in microfluidic cross-junctions with different junction angles theta. Four flow regimes during droplet generation are identified, namely squeezing, dripping, jetting and threading, and the regime diagrams are plotted to represent them. Droplet generation performance changes with the flow regime, especially when theta deviates from 90 degrees. In addition, variation in theta changes the hydrodynamic characteristics in and around the cross-junction region, which can affect its interface profile and evolution. However, it is insufficient to fundamentally alter the flow regimes under the current conditions. Considering the length of the dispersed phase entering and blocking the main channel of the cross-junction, as well as the influence of theta on the hydrodynamics of droplet generation, a scaling correlation is developed to predict the size of the generated droplets under the squeezing regime in the microfluidic cross-junction. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yu, Wei; Chen, Yongping] Southeast Univ, Sch Energy & Environm, Minist Educ, Key Lab Energy Thermal Convers & Control, Nanjing 210096, Jiangsu, Peoples R China.
   [Liu, Xiangdong; Chen, Yongping] Yangzhou Univ, Sch Hydraul Energy & Power Engn, Yangzhou 225127, Jiangsu, Peoples R China.
   [Zhao, Yuanjin] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.
   [Chen, Yongping] Suzhou Univ Sci & Technol, Sch Environm Sci & Engn, Jiangsu Key Lab Micro & Nano Heat Fluid Flow Tech, Suzhou 215009, Peoples R China.
RP Chen, YP (reprint author), Southeast Univ, Sch Energy & Environm, Minist Educ, Key Lab Energy Thermal Convers & Control, Nanjing 210096, Jiangsu, Peoples R China.
EM ypchen@seu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51876184, 51725602]; NSAF [U1530260]; 333 Project
   of Jiangsu ProvinceNatural Science Foundation of Jiangsu Province
   [BRA2016393]
FX This work was supported by National Natural Science Foundation of China
   (Grant No. 51876184 and 51725602), NSAF (Grant No. U1530260) and 333
   Project of Jiangsu Province (Grant No. BRA2016393).
CR Bashir S, 2014, INT J MULTIPHAS FLOW, V60, P40, DOI 10.1016/j.ijmultiphaseflow.2013.11.012
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Chen YP, 2017, J FLUID MECH, V819, P401, DOI 10.1017/jfm.2017.181
   Chen YP, 2015, INT J HEAT MASS TRAN, V82, P42, DOI 10.1016/j.ijheatmasstransfer.2014.11.027
   Cubaud T, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2911716
   Dang MH, 2015, CHEM ENG J, V262, P616, DOI 10.1016/j.cej.2014.10.017
   Dang MH, 2013, CHEM ENG J, V223, P99, DOI 10.1016/j.cej.2013.02.108
   De Menech M, 2008, J FLUID MECH, V595, P141, DOI 10.1017/S002211200700910X
   Dickinson E, 2013, J SCI FOOD AGR, V93, P710, DOI 10.1002/jsfa.6013
   Dollet B, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.034504
   Eggers J, 1997, REV MOD PHYS, V69, P865, DOI 10.1103/RevModPhys.69.865
   Fu TT, 2012, CHEM ENG SCI, V84, P207, DOI 10.1016/j.ces.2012.08.039
   Gallarate M, 1999, INT J PHARM, V188, P233, DOI 10.1016/S0378-5173(99)00228-8
   Garstecki P, 2006, LAB CHIP, V6, P693
   Gong S, 2012, INT J HEAT MASS TRAN, V55, P4923, DOI 10.1016/j.ijheatmasstransfer.2012.04.037
   Gueyffier D, 1999, J COMPUT PHYS, V152, P423, DOI 10.1006/jcph.1998.6168
   Guillot P, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.066301
   Gulati S, 2016, MICROFLUID NANOFLUID, V20, DOI 10.1007/s10404-015-1680-3
   Gupta A, 2016, EUR PHYS J E, V39, DOI 10.1140/epje/i2016-16002-1
   Haeberle S, 2007, LAB CHIP, V7, P1094, DOI 10.1039/b706364b
   Hoang DA, 2013, J FLUID MECH, V717, DOI 10.1017/jfm.2013.18
   Kang CW, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.066308
   Liu HH, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3615643
   Liu HH, 2011, COMMUN COMPUT PHYS, V9, P1235, DOI 10.4208/cicp.231009.101110s
   Liu XD, 2018, INT J HEAT MASS TRAN, V121, P377, DOI 10.1016/j.ijheatmasstransfer.2018.01.021
   Ma YL, 2018, CHEM ENG SCI, V179, P104, DOI 10.1016/j.ces.2018.01.011
   McClements DJ, 2010, ADV COLLOID INTERFAC, V159, P213, DOI 10.1016/j.cis.2010.06.010
   Ngo IL, 2016, J FLUID ENG-T ASME, V138, DOI 10.1115/1.4031881
   Ngo IL, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4916228
   Nie ZH, 2008, MICROFLUID NANOFLUID, V5, P585, DOI 10.1007/s10404-008-0271-y
   Nunes JK, 2013, J PHYS D APPL PHYS, V46, DOI 10.1088/0022-3727/46/11/114002
   Peng BL, 2017, INT J HEAT FLUID FL, V68, P53, DOI 10.1016/j.ijheatfluidflow.2017.09.009
   Peng BL, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4799650
   Peng L, 2011, BIOMED MICRODEVICES, V13, P559, DOI 10.1007/s10544-011-9526-6
   RAYLEIGH L, 1879, P R SOC LONDON, V29, P71, DOI DOI 10.1098/RSPL.1879.0015
   Reyes DR, 2002, ANAL CHEM, V74, P2623, DOI 10.1021/ac0202435
   Seemann R, 2012, REP PROG PHYS, V75, DOI 10.1088/0034-4885/75/1/016601
   Song H, 2006, ANGEW CHEM INT EDIT, V45, P7336, DOI 10.1002/anie.200601554
   Song Y, 2018, NAT COMMUN, V9
   Sontti SG, 2017, CHEM ENG J, V330, P245, DOI 10.1016/j.cej.2017.07.097
   Tan J, 2008, CHEM ENG J, V136, P306, DOI 10.1016/j.cej.2007.04.011
   Tan J, 2011, AICHE J, V57, P2647, DOI 10.1002/aic.12487
   Tan J, 2009, CHEM ENG J, V146, P428, DOI 10.1016/j.cej.2008.10.024
   Tan YC, 2007, MICROFLUID NANOFLUID, V3, P495, DOI 10.1007/s10404-006-0136-1
   van Loo S, 2016, MICROFLUID NANOFLUID, V20, DOI 10.1007/s10404-016-1807-1
   Wang JT, 2015, MICROFLUID NANOFLUID, V18, P709, DOI 10.1007/s10404-014-1458-z
   Wang K, 2017, REACT CHEM ENG, V2, P611, DOI 10.1039/c7re00082k
   Wu LY, 2017, CHEM ENG SCI, V163, P56, DOI 10.1016/j.ces.2017.01.022
   Wu LY, 2014, CHEM ENG PROCESS, V85, P77, DOI 10.1016/j.cep.2014.08.006
   Wu L, 2008, INT J MULTIPHAS FLOW, V34, P852, DOI 10.1016/j.ijmultiphaseflow.2008.02.009
   Xu JH, 2008, MICROFLUID NANOFLUID, V5, P711, DOI 10.1007/s10404-008-0306-4
   Yukuyama MN, 2016, INT J COSMETIC SCI, V38, P13, DOI 10.1111/ics.12260
   Zhu PA, 2017, LAB CHIP, V17, P34, DOI 10.1039/c6lc01018k
NR 53
TC 4
Z9 4
U1 23
U2 86
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 259
EP 284
DI 10.1016/j.ces.2019.03.082
PG 26
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600022
DA 2020-05-12
ER

PT J
AU Luo, XM
   Gong, HY
   Cao, JH
   Yin, HR
   Yan, YP
   He, LM
AF Luo, Xiaoming
   Gong, Haiyang
   Cao, Juhang
   Yin, Haoran
   Yan, Yaipeng
   He, Limin
TI Enhanced separation of water-in-oil emulsions using ultrasonic standing
   waves
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ultrasonic separation; Demulsification; Ultrasonic standing waves;
   Droplet banding; acoustic Acoustic cavitation
ID CRUDE-OIL; FREQUENCY ULTRASOUND; DEMULSIFICATION; COALESCENCE; DROPLET;
   DEHYDRATION; EMULSIFICATION; FRACTIONATION; TECHNOLOGY; MICROWAVE
AB This paper focuses on the application range and optimal parameters for separating water-in-oil (W/O) emulsions using ultrasonic standing waves (USWs). Firstly, the effect of droplet bandings on the demulsification process is theoretically analyzed. The formation of droplet bandings coincides with droplet sedimentation when horizontal irradiation is applied, which improves the separation efficiency. On this basis, the effects of acoustic parameters and oil-water properties on demulsification are analyzed in detail. It is shown that ultrasonic treatment is an efficient demulsification method, and that maximum demulsification efficiency can be achieved by optimizing the acoustic intensity and treatment time. Excessive acoustic intensity causes acoustic cavitation in low-frequency USWs and acoustic streaming in high-frequency USWs, resulting in a low separation efficiency. Acoustic cavitation also causes secondary emulsification, dispersing tiny oil droplets into separated water. In addition, ultrasonic separation is significantly affected by oil-water properties. The demulsification efficiency of W/O emulsions decreases with increasing oil viscosity and decreasing oil-water interfacial tension. Ultrasonic treatment has significant advantages for separation of emulsions with low water content and interfacial tension. This study presents an in-depth analysis of ultrasonic separation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Luo, Xiaoming; Gong, Haiyang; Cao, Juhang; Yin, Haoran; Yan, Yaipeng; He, Limin] China Univ Petr East China, Shandong Key Lab Oil & Gas Storage & Transportat, 66 Changjiang West Rd, Qingdao 266580, Shandong, Peoples R China.
RP Luo, XM (reprint author), China Univ Petr East China, Shandong Key Lab Oil & Gas Storage & Transportat, 66 Changjiang West Rd, Qingdao 266580, Shandong, Peoples R China.
EM upclxm@163.com
RI 罗, 小明/AAC-7450-2019
OI 罗, 小明/0000-0003-1797-9924
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51874341, 51574273]
FX We gratefully acknowledge the financial support of National Natural
   Science Foundation of China (Grant No. 51874341, No. 51574273).
CR Al-Juboori RA, 2016, ULTRASON SONOCHEM, V28, P357, DOI 10.1016/j.ultsonch.2015.08.013
   Antes FG, 2017, ULTRASON SONOCHEM, V35, P541, DOI 10.1016/j.ultsonch.2016.03.031
   Antes FG, 2015, ULTRASON SONOCHEM, V25, P70, DOI 10.1016/j.ultsonch.2015.01.003
   Check GR, 2014, CHEM ENG PROCESS, V81, P72, DOI 10.1016/j.cep.2014.04.011
   Check GR, 2013, ULTRASON SONOCHEM, V20, P378, DOI 10.1016/j.ultsonch.2012.06.007
   de Sarabia ERF, 2000, ULTRASONICS, V38, P642
   Eow JS, 2001, CHEM ENG J, V84, P173, DOI 10.1016/S1385-8947(00)00386-7
   Esche R., 1952, ACUSTICA          AB, V4, P208
   Fortuny M, 2007, ENERG FUEL, V21, P1358, DOI 10.1021/ef0603885
   Gao YX, 2018, ULTRASONICS, V90, P1, DOI 10.1016/j.ultras.2018.05.013
   Gomez EH, 2015, BIOTECHNOL PROGR, V31, P414, DOI 10.1002/btpr.2031
   Grenoble Z, 2018, ADV COLLOID INTERFAC, V260, P32, DOI 10.1016/j.cis.2018.08.003
   Hu GJ, 2013, J HAZARD MATER, V261, P470, DOI 10.1016/j.jhazmat.2013.07.069
   Johansson L, 2016, ULTRASON SONOCHEM, V28, P346, DOI 10.1016/j.ultsonch.2015.08.003
   Juliano P, 2013, J AM OIL CHEM SOC, V90, P579, DOI 10.1007/s11746-012-2191-y
   Juliano P, 2017, ULTRASON SONOCHEM, V35, P577, DOI 10.1016/j.ultsonch.2016.04.032
   Kailey I, 2013, IND ENG CHEM RES, V52, P785, DOI 10.1021/ie3028137
   Khajehesamedini A, 2018, ULTRASON SONOCHEM, V48, P383, DOI 10.1016/j.ultsonch.2018.05.032
   Leong T, 2016, ULTRASON SONOCHEM, V28, P118, DOI 10.1016/j.ultsonch.2015.06.023
   Leong T, 2013, IND ENG CHEM RES, V52, P16555, DOI 10.1021/ie402295r
   LI MK, 1978, J FLUID MECH, V88, P499, DOI 10.1017/S0022112078002232
   Liu YC, 2016, ENG FAIL ANAL, V60, P307, DOI 10.1016/j.engfailanal.2015.11.049
   Luo XM, 2018, CHEM ENG SCI, V191, P350, DOI 10.1016/j.ces.2018.07.002
   Luo XM, 2018, ULTRASON SONOCHEM, V48, P287, DOI 10.1016/j.ultsonch.2018.06.006
   Luo XM, 2018, CHEM ENG PROCESS, V123, P214, DOI 10.1016/j.cep.2017.11.014
   Luo XM, 2018, ULTRASON SONOCHEM, V41, P319, DOI 10.1016/j.ultsonch.2017.09.055
   Luo XM, 2017, ULTRASON SONOCHEM, V39, P461, DOI 10.1016/j.ultsonch.2017.05.006
   Luo XM, 2017, ULTRASON SONOCHEM, V34, P839, DOI 10.1016/j.ultsonch.2016.07.024
   Martinez-Palou R, 2013, FUEL, V113, P407, DOI 10.1016/j.fuel.2013.05.094
   Mohsin M, 2015, ULTRASON SONOCHEM, V22, P573, DOI 10.1016/j.ultsonch.2014.05.014
   Nii S, 2009, ULTRASON SONOCHEM, V16, P145, DOI 10.1016/j.ultsonch.2008.07.005
   Pangu GD, 2009, CHEM ENG SCI, V64, P1445, DOI 10.1016/j.ces.2008.12.004
   Pangu GD, 2007, ULTRASONICS, V46, P289, DOI 10.1016/j.ultras.2007.03.004
   Martinez-Padilla LP, 2018, ULTRASON SONOCHEM, V40, P720, DOI 10.1016/j.ultsonch.2017.08.008
   Pedrotti MF, 2018, ULTRASON SONOCHEM, V40, P53, DOI 10.1016/j.ultsonch.2017.03.056
   Plasencia J, 2013, J PETROL SCI ENG, V101, P35, DOI 10.1016/j.petrol.2012.11.009
   Trujillo FJ, 2014, ULTRASON SONOCHEM, V21, P2151, DOI 10.1016/j.ultsonch.2014.02.016
   Umar AA, 2018, J PETROL SCI ENG, V165, P673, DOI 10.1016/j.petrol.2018.03.014
   Wang ZJ, 2018, ULTRASON SONOCHEM, V40, P1014, DOI 10.1016/j.ultsonch.2017.08.037
   Xie W, 2015, KOREAN J CHEM ENG, V32, P643, DOI 10.1007/s11814-014-0253-6
   Xie Wei, 2015, SONOCHEMISTRY, V26, P736
   YASUDA K, 1995, JPN J APPL PHYS 1, V34, P2715, DOI 10.1143/JJAP.34.2715
   Ye GX, 2010, J PETROL SCI ENG, V70, P135, DOI 10.1016/j.petrol.2009.11.005
   Zolfaghari R, 2016, SEP PURIF TECHNOL, V170, P377, DOI 10.1016/j.seppur.2016.06.026
NR 44
TC 1
Z9 1
U1 29
U2 83
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 285
EP 292
DI 10.1016/j.ces.2019.04.002
PG 8
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600023
DA 2020-05-12
ER

PT J
AU Das, SK
AF Das, Sandipan Kumar
TI General Dusty Gas Model for porous media with a specified pore size
   distribution
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dusty Gas Model; Pore size distribution; Multicomponent diffusion;
   Porous medium; Tortuosity
ID CARBONATE FUEL-CELLS; MATHEMATICAL-MODEL; MASS-TRANSPORT; PREDICTION;
   TORTUOSITY; DIFFUSION; BEHAVIOR; FLOW
AB The standard Dusty Gas Model (DGM) for multicomponent diffusion in a porous medium assumes a single pore size in the domain. It is more appropriate to consider a distribution of pore sizes, which is addressed in this article. It derives a general form for the DGM that accounts for any pore size distribution of the porous medium. A few numerical examples demonstrate the strength of the general model. It predicts different diffusive behaviors for diverse pore size distributions possessing the same mean size. Specifically, the bimodal nature of the distribution exhibits a greater effect. The article further elucidates on the effects of the temperature and the pore size dependent variable tortuosity. All the phenomena are backed by physical arguments. The article concludes by recognizing the need for new targeted experiments for further validation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Das, Sandipan Kumar] ExxonMobil Res & Engn Co, Proc Technol Dept, 22777 Springwoods Village Pkwy, Spring, DC 77389 USA.
RP Das, SK (reprint author), ExxonMobil Res & Engn Co, Proc Technol Dept, 22777 Springwoods Village Pkwy, Spring, DC 77389 USA.
EM skdas@alumni.stanford.edu
FU ExxonMobil
FX The author gratefully acknowledges the financial support provided by
   ExxonMobil. The author would also like to take the opportunity to thank
   one anonymous reviewer who pointed out previous research in the
   literature (Weber et al., 2004; Eikerling, 2006; Zhou et al., 2017) on
   similar themes and helped make the current paper more relevant in the
   field.
CR Al Hinai A, 2014, J UNCONV OIL GAS RES, V8, P1, DOI 10.1016/j.juogr.2014.06.002
   Armatas GS, 2006, CHEM ENG SCI, V61, P4662, DOI 10.1016/j.ces.2006.02.036
   Boulin PF, 2012, TRANSPORT POROUS MED, V93, P609, DOI 10.1007/s11242-012-9972-5
   Eikerling M, 2006, J ELECTROCHEM SOC, V153, pE58, DOI 10.1149/1.2160435
   Freeman CM, 2011, TRANSPORT POROUS MED, V90, P253, DOI 10.1007/s11242-011-9761-6
   FULLER EN, 1966, IND ENG CHEM, V58, P19, DOI 10.1021/ie50677a007
   Garcia-Camprubi M, 2011, J POWER SOURCES, V196, P7290, DOI 10.1016/j.jpowsour.2011.04.037
   Garcia-Camprubi M, 2010, CHEM ENG SCI, V65, P1668, DOI 10.1016/j.ces.2009.11.006
   Kerkhof PJAM, 1996, CHEM ENG J, V64, P319, DOI 10.1016/S0923-0467(96)03121-1
   Kong W, 2012, J POWER SOURCES, V206, P171, DOI 10.1016/j.jpowsour.2012.01.107
   Krishna R, 1997, CHEM ENG SCI, V52, P861, DOI 10.1016/S0009-2509(96)00458-7
   Mason E.A, 1983, GAS TRANSPORT POROUS
   Pant LM, 2013, INT J HEAT MASS TRAN, V58, P70, DOI 10.1016/j.ijheatmasstransfer.2012.11.023
   Ramandi MY, 2013, J POWER SOURCES, V231, P134, DOI 10.1016/j.jpowsour.2012.12.104
   Ramandi MY, 2012, J POWER SOURCES, V218, P192, DOI 10.1016/j.jpowsour.2012.06.062
   REMICK RR, 1974, CHEM ENG SCI, V29, P1447, DOI 10.1016/0009-2509(74)80169-7
   Shen WJ, 2018, TRANSPORT POROUS MED, V123, P521, DOI 10.1007/s11242-017-0985-y
   Tseronis K, 2008, CHEM ENG SCI, V63, P5626, DOI 10.1016/j.ces.2008.07.037
   Weber AZ, 2004, J ELECTROCHEM SOC, V151, pA1715, DOI 10.1149/1.1792891
   Wejrzanowski T, 2018, J POWER SOURCES, V373, P85, DOI 10.1016/j.jpowsour.2017.11.009
   Yu Z, 2012, FUEL CELLS, V12, P557, DOI 10.1002/fuce.201200017
   Zhou J, 2017, J ELECTROCHEM SOC, V164, pF530, DOI 10.1149/2.0381706jes
NR 22
TC 2
Z9 2
U1 2
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 293
EP 301
DI 10.1016/j.ces.2019.03.085
PG 9
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600024
DA 2020-05-12
ER

PT J
AU Di, XN
   Ma, J
   Huang, Y
AF Di, Xiaoning
   Ma, Jun
   Huang, Yi
TI Mass-transfer area in a pilot-scale structured-packing column under
   different types of ship motion
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mass-transfer area; Structured-packing column; Pilot scale; Ship motion;
   Offshore gas production
ID GAS-LIQUID FLOW; TRANSFER PERFORMANCE; CO2 ABSORPTION; PACKED-COLUMN;
   HYDRODYNAMICS; MODEL; TILT
AB To investigate the working performance of structured-packing columns on offshore floating platforms, the effects of different typical ship motions on the mass-transfer area of a column with M250X structured-packing were measured with an Air-NaOH system. A pilot-scale column with an 800 mm diameter was adopted, and tilt, roll, heave and sway motion were mimicked by a six-degree-offreedom parallel platform. The mass-transfer area was affected differently for each type of motion depending on the operating conditions. Therein, the gas velocity was the key factor that the mass-transfer area was more likely to decrease with a high gas velocity in all cases. For typical motions, their influences on the mass-transfer area were different, which were associated with moving periods. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Di, Xiaoning; Ma, Jun; Huang, Yi] Dalian Univ Technol, Sch Naval Architecture, 2 Linggong Rd, Dalian, Liaoning, Peoples R China.
RP Huang, Y (reprint author), Dalian Univ Technol, Sch Naval Architecture, 2 Linggong Rd, Dalian, Liaoning, Peoples R China.
EM huangyi@dlut.edu.cn
FU Research Project of Marine Engineering Equipment in the Ministry of
   Industry and Information Technology (China); Fundamental Research Funds
   for the Central UniversitiesFundamental Research Funds for the Central
   Universities [DUT17JC28]; Collaborative Innovation Center of Major
   Machine Manufacturing in Liaoning
FX The authors are grateful to all organizations that funded the research
   in this paper, including the following: the Research Project of Marine
   Engineering Equipment in the Ministry of Industry and Information
   Technology (China); the Fundamental Research Funds for the Central
   Universities (Grant No. DUT17JC28); and the Collaborative Innovation
   Center of Major Machine Manufacturing in Liaoning.
CR Aroonwilas A, 2000, CHEM ENG SCI, V55, P3651, DOI 10.1016/S0009-2509(00)00035-X
   Aroonwilas A, 2003, CHEM ENG SCI, V58, P4037, DOI 10.1016/S0009-2509(03)00315-4
   DANCKWERTS PV, 1970, GAS LIQUID REACTIONS
   Davit Y, 2019, HEAT TRANSFER ENG, V40, P391, DOI 10.1080/01457632.2018.1432018
   DEBRITO MH, 1994, IND ENG CHEM RES, V33, P647, DOI 10.1021/ie00027a023
   Di XN, 2018, CHEM ENG SCI, V177, P27, DOI 10.1016/j.ces.2017.11.008
   Di XN, 2018, CHEM ENG PROCESS, V123, P89, DOI 10.1016/j.cep.2017.10.028
   Fourati M, 2013, CHEM ENG SCI, V100, P266, DOI 10.1016/j.ces.2013.02.041
   Fourati M, 2012, CHEM ENG SCI, V80, P1, DOI 10.1016/j.ces.2012.05.031
   Gao HX, 2017, AICHE J, V63, P3048, DOI 10.1002/aic.15673
   Huang Y, 2019, CAN J CHEM ENG, V97, P1172, DOI 10.1002/cjce.23292
   Iliuta I, 2017, OCEAN ENG, V144, P157, DOI 10.1016/j.oceaneng.2017.08.023
   Iliuta I, 2017, AICHE J, V63, P1064, DOI 10.1002/aic.15450
   Nezamian A, 2014, OFFSH TECGHN C AS
   Pasquier S, 2017, CHEM ENG SCI, V165, P131, DOI 10.1016/j.ces.2017.01.063
   Pham DA, 2015, CHEM ENG SCI, V132, P259, DOI 10.1016/j.ces.2015.04.009
   Pham DA, 2015, AICHE J, V61, P4412, DOI 10.1002/aic.14962
   POHORECKI R, 1988, CHEM ENG SCI, V43, P1677, DOI 10.1016/0009-2509(88)85159-5
   Raynal L, 2007, CHEM ENG SCI, V62, P7196, DOI 10.1016/j.ces.2007.08.010
   Son Y, 2017, CHEM ENG SCI, V166, P168, DOI 10.1016/j.ces.2017.03.044
   Son Y, 2016, CHEM ENG SCI, V153, P199, DOI 10.1016/j.ces.2016.07.039
   Soulaine C, 2014, AICHE J, V60, P3665, DOI 10.1002/aic.14550
   Tanner RK, 1996, CHEM ENG RES DES, V74, P177
   Tsai RE, 2008, IND ENG CHEM RES, V47, P1253, DOI 10.1021/ie070780l
   Tsai RE, 2011, AICHE J, V57, P1173, DOI 10.1002/aic.12345
   Waldie B., 2003, CHEM ENG T, V3, P385
   Wang C, 2016, IND ENG CHEM RES, V55, P5373, DOI 10.1021/acs.iecr.5b04635
   Weiss C, 2014, OFFSH TECHN C
   Won W, 2014, KOREAN J CHEM ENG, V31, P732, DOI 10.1007/s11814-014-0047-x
   Yang W, 2015, CHINESE J CHEM ENG, V23, P42, DOI 10.1016/j.cjche.2014.10.003
   Zhang MX, 2017, APPL THERM ENG, V112, P585, DOI 10.1016/j.applthermaleng.2016.10.049
   Zhang XW, 2017, APPL ENERG, V202, P673, DOI 10.1016/j.apenergy.2017.05.135
   Zhao WH, 2011, OCEAN ENG, V38, P1555, DOI 10.1016/j.oceaneng.2011.07.018
NR 33
TC 1
Z9 1
U1 1
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 302
EP 311
DI 10.1016/j.ces.2019.03.056
PG 10
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600025
DA 2020-05-12
ER

PT J
AU Wang, N
   Zhang, ZR
   Huang, JR
   Hu, YX
AF Wang, Ning
   Zhang, Zhongren
   Huang, Juanru
   Hu, Yunxia
TI Facile synthesis of copper ions chelated sand via dopamine chemistry for
   recyclable and sustainable catalysis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Cu ions; Dopamine; Catalytic reduction; Organic dyes; Color removal
ID SITU GREEN SYNTHESIS; SILVER NANOPARTICLES; HIGHLY EFFICIENT; AZO-DYE;
   GOLD NANOPARTICLES; AQUEOUS-SOLUTIONS; HIGH-STABILITY; REDUCTION;
   REMOVAL; 4-NITROPHENOL
AB Metal-based catalysts present highly efficient catalytic activities towards organic dyes and their intermediates for color removal. However, several issues are needed to be addressed urgently for their large-scale practical applications, such as the cost, stability and recyclable use of these catalysts. In this work, we developed a facile approach to chelate Cu ions on the polydopamine-coated sand (Cu-PDA@Sand) and investigated their catalytic properties towards the decoloration of organic dyes or intermediate including 4-nitrophenol (4-NP), methylene blue (MB), and congo red (CR). Our results found that the copper ions from Cu-PDA@Sand were the mixture of Cu (I) and Cu (II), and the molar fraction of Cu (I) over Cu (II) was increased from the original 3:2 to 4:1 in the presence of NaBH4. The reduction of these organic dyes or intermediate followed the first order kinetics, and the apparent reduction rate k up of CR was larger than that of MB and 4-NP under similar conditions. Additionally, the optimized k up of 4-NP could reach to 1.28 min (1), which is much higher than the reported results from literature. The recyclability test of CuPDA@Sand showed that the reduction efficiency of Cu-PDA@Sand maintained 100% during the successive 20 cycles. Additionally, Cu-PDA@Sand was demonstrated to present long-term stability and catalytic activities after soaking Cu-PDA@Sand in water for 30 days. Our research demonstrated that the easy-prepared low-cost Cu-PDA@Sand catalyst would have a great potential in the practical applications for color removal of the dye-containing wastewater. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Ning; Zhang, Zhongren] Chinese Acad Sci, Yantai Inst Coastal Zone Res, CAS Key Lab Coastal Environm Proc & Ecol Remediat, Yantai 264003, Shandong, Peoples R China.
   [Huang, Juanru; Hu, Yunxia] Tianjin Polytech Univ, State Key Lab Separat Membranes & Membrane Proc, Natl Ctr Int Res Membrane Sci & Technol, Sch Mat Sci & Engn, Tianjin 300387, Peoples R China.
RP Hu, YX (reprint author), Tianjin Polytech Univ, State Key Lab Separat Membranes & Membrane Proc, Natl Ctr Int Res Membrane Sci & Technol, Sch Mat Sci & Engn, Tianjin 300387, Peoples R China.
EM yunxiahu@yic.ac.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21476249]; Chang-jiang Scholars and Innovative
   Research Team in the University of Ministry of Education, China
   [IRT-17R80]; Program for Innovative Research Team in University of
   Tianjin [TD13-5044]; Science and Technology Plans of Tianjin
   [17PT-SYJC00060]; Key Science and Technology Program of Yantai City
   [2018ZHGY075]
FX The authors gratefully acknowledge the funding support from National
   Natural Science Foundation of China (No. 21476249), Chang-jiang Scholars
   and Innovative Research Team in the University of Ministry of Education,
   China (No. IRT-17R80), Program for Innovative Research Team in
   University of Tianjin (No. TD13-5044), the Science and Technology Plans
   of Tianjin (No. 17PT-SYJC00060), and Key Science and Technology Program
   of Yantai City (No. 2018ZHGY075).
CR Ali I, 2012, CHEM REV, V112, P5073, DOI 10.1021/cr300133d
   Ayati A, 2016, CHEMOSPHERE, V160, P30, DOI 10.1016/j.chemosphere.2016.06.065
   Bastus NG, 2014, CHEM MATER, V26, P2836, DOI 10.1021/cm500316k
   Bradu C, 2010, APPL CATAL B-ENVIRON, V96, P548, DOI 10.1016/j.apcatb.2010.03.019
   Chaplin BP, 2012, ENVIRON SCI TECHNOL, V46, P3655, DOI 10.1021/es204087q
   de Luna LAV, 2014, J HAZARD MATER, V276, P332, DOI 10.1016/j.jhazmat.2014.05.047
   Dong ZP, 2014, APPL CATAL B-ENVIRON, V158, P129, DOI 10.1016/j.apcatb.2014.04.015
   Eggen RIL, 2014, ENVIRON SCI TECHNOL, V48, P7683, DOI 10.1021/es500907n
   Fan J, 2009, J AM CHEM SOC, V131, P15568, DOI 10.1021/ja9032499
   Feng J, 2013, CHEM ENG J, V221, P16, DOI 10.1016/j.cej.2013.02.009
   Gao S, 2016, APPL CATAL B-ENVIRON, V188, P245, DOI 10.1016/j.apcatb.2016.01.074
   Ghosh BK, 2015, POWDER TECHNOL, V269, P371, DOI 10.1016/j.powtec.2014.09.027
   Hassan MM, 2018, CHEMOSPHERE, V209, P201, DOI 10.1016/j.chemosphere.2018.06.043
   Hu HW, 2013, CHEMPLUSCHEM, V78, P1483, DOI 10.1002/cplu.201300124
   Huang CJ, 2014, ACS APPL MATER INTER, V6, P14469, DOI 10.1021/am5037737
   Huang XQ, 2012, CHEM-EUR J, V18, P9505, DOI 10.1002/chem.201200817
   Kurt E, 2012, DESALINATION, V302, P24, DOI 10.1016/j.desal.2012.05.019
   Laszlo JA, 2000, ENVIRON SCI TECHNOL, V34, P167, DOI 10.1021/es990918u
   Li J, 2012, J MATER CHEM, V22, P8426, DOI 10.1039/c2jm16386a
   Lipatova IM, 2018, CHEMOSPHERE, V212, P1155, DOI 10.1016/j.chemosphere.2018.08.158
   Liu YL, 2014, CHEM REV, V114, P5057, DOI 10.1021/cr400407a
   Liu ZY, 2016, CHEM COMMUN, V52, P12245, DOI 10.1039/c6cc06015c
   Luo J, 2014, RSC ADV, V4, P64816, DOI 10.1039/c4ra11950a
   Okesola BO, 2016, CHEM SOC REV, V45, P4226, DOI 10.1039/c6cs00124f
   Ong YK, 2014, CHEM ENG SCI, V114, P51, DOI 10.1016/j.ces.2014.04.007
   Panacek A, 2014, CHEM MATER, V26, P1332, DOI 10.1021/cm400635z
   Subair R, 2016, CHEM ENG J, V295, P358, DOI 10.1016/j.cej.2016.02.105
   Subramanian V, 2004, J AM CHEM SOC, V126, P4943, DOI 10.1021/ja0315199
   Sulakova R, 2007, DYES PIGMENTS, V73, P19, DOI 10.1016/j.dyepig.2005.10.004
   Sun HQ, 2014, APPL CATAL B-ENVIRON, V146, P162, DOI 10.1016/j.apcatb.2013.03.027
   Sun Y, 2013, J MATER CHEM A, V1, P12361, DOI 10.1039/c3ta12526b
   Szpyrkowicz L, 2001, WATER RES, V35, P2129, DOI 10.1016/S0043-1354(00)00487-5
   Tang JT, 2015, IND ENG CHEM RES, V54, P3299, DOI 10.1021/acs.iecr.5b00177
   Tang MY, 2014, MATER CHEM PHYS, V148, P639, DOI 10.1016/j.matchemphys.2014.08.029
   Verma AK, 2012, J ENVIRON MANAGE, V93, P154, DOI 10.1016/j.jenvman.2011.09.012
   Wang N, 2017, APPL CLAY SCI, V150, P47, DOI 10.1016/j.clay.2017.08.024
   Wang XH, 2018, CHEMOSPHERE, V206, P587, DOI 10.1016/j.chemosphere.2018.04.183
   Xie YJ, 2014, ACS APPL MATER INTER, V6, P8845, DOI 10.1021/am501632f
   Yao TJ, 2014, NANOSCALE, V6, P7666, DOI 10.1039/c4nr00023d
   Zeng T, 2013, APPL CATAL B-ENVIRON, V134, P26, DOI 10.1016/j.apcatb.2012.12.037
   Zhang C, 2019, CHEMOSPHERE, V216, P379, DOI 10.1016/j.chemosphere.2018.10.164
   Zhang PH, 2013, J MATER CHEM A, V1, P1632, DOI 10.1039/c2ta00350c
   Zhang XY, 2017, APPL MATER TODAY, V7, P222, DOI 10.1016/j.apmt.2017.04.001
   Zhang XY, 2015, APPL SURF SCI, V343, P19, DOI 10.1016/j.apsusc.2015.03.081
   Zhang YW, 2011, CATAL SCI TECHNOL, V1, P1142, DOI 10.1039/c1cy00205h
   Zhang Y, 2014, J MATER CHEM A, V2, P11966, DOI 10.1039/c4ta01920b
   Zheng Y, 2012, J MATER CHEM, V22, P16552, DOI 10.1039/c2jm32774k
   Zhu MY, 2013, J MATER CHEM A, V1, P2118, DOI 10.1039/c2ta00669c
NR 48
TC 2
Z9 2
U1 13
U2 60
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 312
EP 320
DI 10.1016/j.ces.2019.04.009
PG 9
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600026
DA 2020-05-12
ER

PT J
AU Pan, H
   Wu, X
   Qiu, J
   He, GC
   Ling, H
AF Pan, Hui
   Wu, Xiang
   Qiu, Jie
   He, Guichun
   Ling, Hao
TI Pressure compensated temperature control of Kaibel divided-Wall column
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Divided-wall column; Kaibel column; Temperature control;
   Pressure-compensated temperature control
ID CONTROL-STRUCTURE SELECTION; STABILIZING CONTROL-STRUCTURES; SWING
   DISTILLATION; VAPOR RECOMPRESSION; STEADY-STATE; OPERATION; DESIGN;
   SYSTEM
AB The focus of this work is to study the control of a Kaibel divided-wall column (KDWC) for separating benzene, toluene, o-xylene and 1, 3, 5-trimethylbenzene mixtures. Two control structures based on a simple single-loop (decentralized) PI controller are proposed: five-temperature control loops (CS1), improved control structure (CS2) with combining pressure-compensated scheme into CS1. The control performance of CS1 and CS2 are investigated in terms of the control of component purities under various disturbances in feed conditions, which indicates that CS1 weakly controls product purity of the lower-side stream. Due to pressure compensation, CS2 is superior to CS1 in terms of purity control at the lower-side stream product under larger disturbances in feed conditions. CS2 that is based on temperature measurements can be easily implemented during practical operation of a KDWC in industry. From an industrial operation perspective, the pressure-compensated temperature control structure (CS2) provides potential solutions for a four-product KDWC. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Pan, Hui; Wu, Xiang; Qiu, Jie; He, Guichun; Ling, Hao] East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
RP Ling, H (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
EM linghao@ecust.edu.cn
RI QIAN, LIU/S-1353-2019
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21476081]; Scientific Research Innovation Project
   of Shanghai Municipal Education Commission [14ZZ058]
FX The authors thank the National Natural Science Foundation of China (No.
   21476081) and the Scientific Research Innovation Project of Shanghai
   Municipal Education Commission (No. 14ZZ058) for supporting this work.
CR Agrawal R, 2000, CHEM ENG RES DES, V78, P454, DOI 10.1205/026387600527356
   Chen YX, 2018, CHEM ENG PROCESS, V123, P233, DOI 10.1016/j.cep.2017.11.013
   Dejanovic I, 2011, CHEM ENG RES DES, V89, P1155, DOI 10.1016/j.cherd.2011.01.016
   Dejanovic I, 2010, CHEM ENG PROCESS, V49, P559, DOI 10.1016/j.cep.2010.04.001
   Dwivedi D, 2013, CHEM ENG PROCESS, V67, P49, DOI 10.1016/j.cep.2012.07.013
   Dwivedi D, 2013, CHEM ENG PROCESS, V64, P57, DOI 10.1016/j.cep.2012.11.006
   Dwivedi D, 2012, IND ENG CHEM RES, V51, P15696, DOI 10.1021/ie301432z
   Dwivedi D, 2012, IND ENG CHEM RES, V51, P15176, DOI 10.1021/ie3014346
   Fan GL, 2016, CHEM ENG RES DES, V109, P675, DOI 10.1016/j.cherd.2016.03.025
   Ghadrdan M, 2011, CHEM ENG RES DES, V89, P1382, DOI 10.1016/j.cherd.2011.02.007
   Halvorsen IJ, 1999, J PROCESS CONTR, V9, P407, DOI 10.1016/S0959-1524(99)00009-8
   Jia SK, 2018, CHINESE J CHEM ENG, V26, P1621, DOI 10.1016/j.cjche.2017.10.018
   Kaibel G., 1987, CHEM ENG TECHNOL, V10, P92, DOI DOI 10.1002/CEAT.270100112
   Kiss AA, 2011, COMPUT CHEM ENG, V35, P2896, DOI 10.1016/j.compchemeng.2011.03.024
   Ling H, 2018, CHEM ENG TECHNOL, V41, P1359, DOI 10.1002/ceat.201700426
   Ling H, 2011, IND ENG CHEM RES, V50, P12694, DOI 10.1021/ie201610g
   Ling H, 2010, IND ENG CHEM RES, V49, P189, DOI 10.1021/ie900125w
   Ling H, 2009, IND ENG CHEM RES, V48, P6034, DOI 10.1021/ie801373b
   Luo HT, 2014, IND ENG CHEM RES, V53, P15167, DOI 10.1021/ie502735g
   Luyben WL, 2017, SEP PURIF TECHNOL, V174, P232, DOI 10.1016/j.seppur.2016.10.020
   Luyben WL, 2006, J PROCESS CONTR, V16, P115, DOI 10.1016/j.jprocont.2005.05.004
   Luyben WL, 2006, DISTILLATION DESIGN
   Madenoor R. G, 2017, AICHE J, V64, P649
   Madenoor R. G, 2017, AICHE J, V64, P660
   Petlyuk F. B, 1965, THERMODYNAMICALLY OP
   Qian X, 2016, IFAC PAPERSONLINE, V49, P729, DOI 10.1016/j.ifacol.2016.07.271
   Qian X, 2016, COMPUT CHEM ENG, V93, P372, DOI 10.1016/j.compchemeng.2016.07.019
   Rewagad RR, 2012, CHEM ENG SCI, V68, P132, DOI 10.1016/j.ces.2011.09.022
   Tututi-Avila S, 2017, CHEM ENG PROCESS, V114, P1, DOI 10.1016/j.cep.2017.01.010
   Tututi-Avila S, 2014, PROCESSES, V2, P180, DOI 10.3390/pr2010180
   Tututi-Avila S, 2013, IND ENG CHEM RES, V52, P7492, DOI 10.1021/ie302836y
   Wang QY, 2012, IND ENG CHEM RES, V51, P1281, DOI 10.1021/ie201946d
   Wu H, 2018, CAN J CHEM ENG, V9999, P1
   Wu N, 2013, IND ENG CHEM RES, V52, P5365, DOI 10.1021/ie303395d
   Xu LH, 2018, CHEM ENG RES DES, V134, P382, DOI 10.1016/j.cherd.2018.04.023
   Xu LH, 2017, CHEM ENG RES DES, V120, P138, DOI 10.1016/j.cherd.2017.02.007
   Xu LH, 2017, IND ENG CHEM RES, V56, P2188, DOI 10.1021/acs.iecr.6b03802
   Yildirim O, 2011, SEP PURIF TECHNOL, V80, P403, DOI 10.1016/j.seppur.2011.05.009
   Yu BR, 2012, IND ENG CHEM RES, V51, P1293, DOI 10.1021/ie201949q
   Yuan Y, 2017, CHEM ENG RES DES, V123, P84, DOI 10.1016/j.cherd.2017.04.023
NR 40
TC 3
Z9 3
U1 4
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 321
EP 332
DI 10.1016/j.ces.2019.03.061
PG 12
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600027
DA 2020-05-12
ER

PT J
AU Fontana, E
   Mancusi, E
   de Souza, AAU
   de Souza, SMAGU
AF Fontana, Eliton
   Mancusi, Erasmo
   Ulson de Souza, Antonio A.
   de Souza, Selene M. A. Guelli U.
TI Stability analysis of stratified Rayleigh-Benard-Poiseuille convection.
   Part III: Interface deformation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Linear stability analysis; Hydrodynamic stability; Computational fluid
   dynamics; Multiphase flow; Mixed convection; Interface deformation
ID MARANGONI CONVECTION; INSTABILITY; CHANNEL; SIMULATION; FLOW
AB Interface deformation is a common phenomenon in multi-layered systems that can significantly impact the velocity and temperature fields. In order to track the interface position in a two-layered system subjected to vertical temperature gradient and shear flow, techniques of linear stability analysis (LSA) and computational fluid dynamics (CFD) were applied. The LSA results show that the interface can be deformed for low Reynolds numbers if the fluids in each layer have different viscosity or thermal conductivity or if the thermocapillary effect is significant. The interface can be stabilized by increasing the ratio between the density of each fluid. The limits where the interface deformation can be neglected are defined for several cases. Comparisons with CFD results reveal that the linear analysis is consistent near the convection onset; however, as the Rayleigh number is increased and the non-linear terms become more significant, strong interface deformation can occur and the linear approximation no longer predicts the system behavior. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fontana, Eliton; Mancusi, Erasmo; Ulson de Souza, Antonio A.; de Souza, Selene M. A. Guelli U.] Univ Fed Santa Catarina, Dept Engn Quim & Alimentos, BR-88040970 Florianopolis, SC, Brazil.
   [Fontana, Eliton] Univ Fed Parana, Dept Engn Quim, BR-89065300 Curitiba, Parana, Brazil.
   [Mancusi, Erasmo] Univ Sannio, Fac Ingn, I-82100 Benevento, Italy.
RP Fontana, E (reprint author), Univ Fed Parana, Dept Engn Quim, BR-89065300 Curitiba, Parana, Brazil.
EM eliton.fontana@ufpr.br
RI Guelli Souza, Selene/A-4909-2008
OI Guelli Souza, Selene/0000-0001-8981-3056; Mancusi,
   Erasmo/0000-0003-0320-6461
FU CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   Brazil)National Council for Scientific and Technological Development
   (CNPq) [143152/2011-4]
FX The authors would like to thank CNPq (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico Brazil) through the process
   143152/2011-4 for the financial support.
CR Barmak I, 2019, INT J MULTIPHAS FLOW, V111, P122, DOI 10.1016/j.ijmultiphaseflow.2018.10.020
   CARDIN P, 1991, J PHYS II, V1, P599
   Chandrasekhar S., 1961, HYDRODYNAMIC HYDROMA
   Chattopadhyay G, 2016, CHEM ENG SCI, V145, P214, DOI 10.1016/j.ces.2016.02.012
   Fontana E, 2016, BRAZ J CHEM ENG, V33, P607, DOI 10.1590/0104-6632.20160333s20150050
   Fontana E, 2016, CHEM ENG SCI, V155, P99, DOI 10.1016/j.ces.2016.07.045
   Fontana E, 2015, CHEM ENG SCI, V126, P67, DOI 10.1016/j.ces.2014.12.005
   Fontana E, 2013, J POWER SOURCES, V234, P260, DOI 10.1016/j.jpowsour.2013.01.171
   Ge K, 2019, INT J HEAT MASS TRAN, V133, P359, DOI 10.1016/j.ijheatmasstransfer.2018.12.117
   Horstmann GM, 2018, J FLUID MECH, V845, P1, DOI 10.1017/jfm.2018.223
   Kundu P., 2015, FLUID MECH
   Leal L. G., 2007, CAMBRIDGE SERIES CHE
   Lyubimova T, 2019, INT J HEAT MASS TRAN, V129, P610, DOI 10.1016/j.ijheatmasstransfer.2018.09.099
   Mokbel M, 2017, INT J HEAT MASS TRAN, V115, P1064, DOI 10.1016/j.ijheatmasstransfer.2017.08.002
   Pinarbasi A, 2002, EUR J MECH B-FLUID, V21, P225, DOI 10.1016/S0997-7546(01)01169-4
   Reddy VTSRK, 2011, CHEM ENG SCI, V66, P6272, DOI 10.1016/j.ces.2011.09.003
   Shankar V, 2004, J COLLOID INTERF SCI, V274, P294, DOI 10.1016/j.jcis.2003.12.024
   Sun XS, 2016, CHEM ENG SCI, V139, P221, DOI 10.1016/j.ces.2015.09.031
   Valluri P, 2010, J FLUID MECH, V656, P458, DOI 10.1017/S0022112010001230
   Yamamoto T, 2017, J CRYST GROWTH, V470, P75, DOI 10.1016/j.jcrysgro.2017.04.016
   Yang QZ, 2017, INT J HEAT MASS TRAN, V109, P690, DOI 10.1016/j.ijheatmasstransfer.2017.02.049
NR 21
TC 0
Z9 0
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 333
EP 345
DI 10.1016/j.ces.2019.03.086
PG 13
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600028
DA 2020-05-12
ER

PT J
AU Hossain, MI
   Cunningham, JD
   Becker, TM
   Grabick, BE
   Walton, KS
   Rabideau, BD
   Glover, TG
AF Hossain, Mohammad, I
   Cunningham, Jackson D.
   Becker, Tim M.
   Grabick, Bogna E.
   Walton, Krista S.
   Rabideau, Brooks D.
   Glover, T. Grant
TI Impact of MOF defects on the binary adsorption of CO2 and water in
   UiO-66
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE MOF; Co-adsorption; CO2; Defect sites
ID METAL-ORGANIC FRAMEWORK; ADSORBED SOLUTION THEORY; CARBON-DIOXIDE;
   MULTICOMPONENT ADSORPTION; GAS-ADSORPTION; CO2-CH4 MIXTURES;
   FORCE-FIELD; FLUE-GAS; SEPARATION; VAPOR
AB Metal organic frameworks are frequently examined as potential solutions to complex gas phase separations problems. In many cases, the gas phase adsorption properties of these materials are quantified using single component gas adsorption isotherms and breakthrough experiments. In adsorption separations, however, it is common that the adsorbent participates in a multicomponent adsorption event. In the literature there is a general absence of multicomponent adsorption data with most data predicted via the Ideal Adsorbed Solution Theory or molecular simulations. Therefore, in this work, binary adsorption data of CO2 and water on UiO-66 were measured experimentally using a volumetric method at three different water loadings. Molecular simulations of isotherms were compared to the experimental measurements and the impact of two different MOF defect sites on the multicomponent CO2/H2O adsorption behavior was determined. The experimental data show a slight enhancement of CO2 loading when CO2 is co-adsorbed with water, which is a result that was confirmed via molecular simulations. Also, the simulation results show that defect sites can have a greater influence on low-pressure CO2 adsorption in MOFs than the co-adsorption of water. Furthermore, the simulations provide a molecular-level understanding of the role of these defects on the single and binary adsorption behavior. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hossain, Mohammad, I; Cunningham, Jackson D.; Rabideau, Brooks D.; Glover, T. Grant] Univ S Alabama, Mobile, AL 36688 USA.
   [Becker, Tim M.] Delft Univ Technol, Delft, Netherlands.
   [Grabick, Bogna E.; Walton, Krista S.] Georgia Inst Technol, Atlanta, GA 30332 USA.
RP Glover, TG (reprint author), Univ S Alabama, Mobile, AL 36688 USA.
EM glover@southalabama.edu
RI Hossain, Mohammad/T-6905-2019
OI Hossain, Mohammad/0000-0003-0315-709X; Walton,
   Krista/0000-0002-0962-9644
FU NASANational Aeronautics & Space Administration (NASA) [NNH16ZHA001C,
   NNX16AT47A]; Space Grant Foundation NASA X-Hab Program; Alabama EPSCoR
   Graduate Student Fellowship Program
FX The authors graciously acknowledge financial support from NASA
   Cooperative Agreement Notice NNH16ZHA001C Experimental Program to
   Stimulate Competitive Research under contract NNX16AT47A, the Space
   Grant Foundation NASA X-Hab Program, and the Alabama EPSCoR Graduate
   Student Fellowship Program.
CR Bai P, 2012, LANGMUIR, V28, P15566, DOI 10.1021/la303247c
   Bambalaza SE, 2018, J MATER CHEM A, V6, P23569, DOI 10.1039/c8ta09227c
   Benoit V, 2018, J MATER CHEM A, V6, P2081, DOI 10.1039/c7ta09696h
   BERTSCH L, 1963, J PHYS CHEM-US, V67, P1621, DOI 10.1021/j100802a013
   Bobbitt NS, 2017, CHEM SOC REV, V46, P3357, DOI 10.1039/c7cs00108h
   Britt D, 2009, P NATL ACAD SCI USA, V106, P20637, DOI 10.1073/pnas.0909718106
   Bunge MA, 2018, IND ENG CHEM RES, V57, P9151, DOI 10.1021/acs.iecr.8b01010
   Burtch NC, 2014, CHEM REV, V114, P10575, DOI 10.1021/cr5002589
   Campana C, 2009, J CHEM THEORY COMPUT, V5, P2866, DOI 10.1021/ct9003405
   Canivet J, 2014, CHEM SOC REV, V43, P5594, DOI 10.1039/c4cs00078a
   Cessford NF, 2012, IND ENG CHEM RES, V51, P4911, DOI 10.1021/ie202219w
   Chanut N, 2017, CHEMSUSCHEM, V10, P1543, DOI 10.1002/cssc.201601816
   Chen HB, 2007, LANGMUIR, V23, P6431, DOI 10.1021/la700351c
   Cmarik GE, 2012, LANGMUIR, V28, P15606, DOI 10.1021/la3035352
   DeCoste JB, 2014, CHEM REV, V114, P5695, DOI 10.1021/cr4006473
   Doonan CJ, 2010, NAT CHEM, V2, P235, DOI [10.1038/NCHEM.548, 10.1038/nchem.548]
   Dubbeldam D, 2016, MOL SIMULAT, V42, P81, DOI 10.1080/08927022.2015.1010082
   Eum K, 2015, J AM CHEM SOC, V137, P4191, DOI 10.1021/jacs.5b00803
   Farrusseng D, 2011, METAL-ORGANIC FRAMEWORKS: APPLICATIONS FROM CATALYSIS TO GAS STORAGE, P1, DOI 10.1002/9783527635856
   Furukawa H, 2014, J AM CHEM SOC, V136, P4369, DOI 10.1021/ja500330a
   Geier SJ, 2013, CHEM SCI, V4, P2054, DOI 10.1039/c3sc00032j
   Getman RB, 2012, CHEM REV, V112, P703, DOI 10.1021/cr200217c
   Ghosh P, 2014, CHEM COMMUN, V50, P11329, DOI 10.1039/c4cc04945d
   Glover T.G., 2018, GAS ADSORPTION METAL
   Glover TG, 2011, CHEM ENG SCI, V66, P163, DOI 10.1016/j.ces.2010.10.002
   Gustafson JA, 2017, J PHYS CHEM C, V121, P6033, DOI 10.1021/acs.jpcc.6b09740
   Hamon L, 2012, DALTON T, V41, P4052, DOI 10.1039/c2dt12102f
   Hamon L, 2009, J AM CHEM SOC, V131, P17490, DOI 10.1021/ja907556q
   Hossain MI, 2019, IND ENG CHEM RES, V58, P1352, DOI 10.1021/acs.iecr.8b05275
   Hu ZQ, 2017, AICHE J, V63, P4103, DOI 10.1002/aic.15837
   Huang R, 2017, 47INT C ENV SYST CHA
   Jasuja H, 2014, DEV DESIGN CRITERIA
   Jasuja H, 2013, EFFECT SOLVENT REDUC
   Jasuja H, 2012, J PHYS CHEM C, V116, P23526, DOI 10.1021/jp308657x
   Jorge M, 2010, COLLOID SURFACE A, V357, P27, DOI 10.1016/j.colsurfa.2009.08.025
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kaskel S., 2016, CHEM METAL ORGANIC F
   Liu J, 2010, LANGMUIR, V26, P14301, DOI 10.1021/la102359q
   Llewellyn PL, 2006, ANGEW CHEM INT EDIT, V45, P7751, DOI 10.1002/anie.200602278
   Mason JA, 2015, J AM CHEM SOC, V137, P4787, DOI 10.1021/jacs.5b00838
   MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010
   McDonald TM, 2015, NATURE, V519, P303, DOI 10.1038/nature14327
   McDonald TM, 2012, J AM CHEM SOC, V134, P7056, DOI 10.1021/ja300034j
   MYERS AL, 1965, AICHE J, V11, P121, DOI 10.1002/aic.690110125
   Myers AL, 2005, ADSORPTION, V11, P37, DOI 10.1007/s10450-005-5895-6
   Ortiz AU, 2012, LANGMUIR, V28, P494, DOI 10.1021/la203925y
   Peterson GW, 2013, MICROPOR MESOPOR MAT, V179, P48, DOI 10.1016/j.micromeso.2013.02.025
   Potoff JJ, 2001, AICHE J, V47, P1676, DOI 10.1002/aic.690470719
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Rege SU, 2001, CHEM ENG SCI, V56, P3781, DOI 10.1016/S0009-2509(01)00095-1
   Rios RB, 2013, BRAZ J CHEM ENG, V30, P939, DOI 10.1590/S0104-66322013000400024
   RUDISILL EN, 1992, IND ENG CHEM RES, V31, P1122, DOI 10.1021/ie00004a022
   Schoenecker PM, 2012, IND ENG CHEM RES, V51, P6513, DOI 10.1021/ie202325p
   Shearer GC, 2016, CHEM MATER, V28, P3749, DOI 10.1021/acs.chemmater.6b00602
   Sholl DS, 2015, J PHYS CHEM LETT, V6, P3437, DOI 10.1021/acs.jpclett.5b01135
   Sircar S, 2006, IND ENG CHEM RES, V45, P5435, DOI 10.1021/ie051056a
   Sumida K, 2012, CHEM REV, V112, P724, DOI 10.1021/cr2003272
   Talu O, 1998, ADV COLLOID INTERFAC, V76, P227, DOI 10.1016/S0001-8686(98)00048-7
   Tan K, 2015, CHEM MATER, V27, P2203, DOI 10.1021/acs.chemmater.5b00315
   Taqvi SM, 1999, IND ENG CHEM RES, V38, P240, DOI 10.1021/ie980324k
   Thompson JA, 2013, J PHYS CHEM C, V117, P8198, DOI 10.1021/jp312590r
   VALENZUELA DP, 1989, ADSORPTION EQUILIBRI
   Van Assche TRC, 2014, LANGMUIR, V30, P7878, DOI 10.1021/la5020253
   Walton KS, 2015, AICHE J, V61, P2757, DOI 10.1002/aic.14878
   Wang Y, 2010, J CHEM ENG DATA, V55, P3189, DOI 10.1021/je100053g
   Wang Y, 2009, J CHEM ENG DATA, V54, P2839, DOI 10.1021/je800900a
   Wiersum AD, 2011, CHEM-ASIAN J, V6, P3270, DOI 10.1002/asia.201100201
   Wu H, 2013, J PHYS CHEM LETT, V4, P925, DOI 10.1021/jz4002345
   Yang QY, 2013, ANGEW CHEM INT EDIT, V52, P10316, DOI 10.1002/anie.201302682
   Yang R.T., 1997, GAS SEPARATION ADSOR
   Yazaydin AO, 2009, J AM CHEM SOC, V131, P18198, DOI 10.1021/ja9057234
   Yazaydin AO, 2009, CHEM MATER, V21, P1425, DOI 10.1021/cm900049x
   Zhang K, 2013, J PHYS CHEM C, V117, P7214, DOI 10.1021/jp401548b
   Zhang K, 2013, CHEM COMMUN, V49, P3245, DOI 10.1039/c3cc39116g
   Zou D, 2019, MATER TODAY CHEM, V12, P139, DOI 10.1016/j.mtchem.2018.12.004
NR 75
TC 13
Z9 13
U1 17
U2 148
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 346
EP 357
DI 10.1016/j.ces.2019.03.053
PG 12
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600029
DA 2020-05-12
ER

PT J
AU McGuire, AD
   Mosbach, S
   Reynolds, GK
   Patterson, RIA
   Bringley, E
   Eaves, N
   Dreyer, JAH
   Kraft, M
AF McGuire, Andrew D.
   Mosbach, Sebastian
   Reynolds, Gavin K.
   Patterson, Robert I. A.
   Bringley, Eric
   Eaves, Nick
   Dreyer, Jochen A. H.
   Kraft, Markus
TI Analysing the effect of screw configuration using a stochastic
   twin-screw granulation model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Granulation; Twin-screw; Stochastic; Population balance
ID POPULATION BALANCE-EQUATIONS; WEIGHTED PARTICLE METHOD; SHEAR WET
   GRANULATION; FILL-LEVEL; COAGULATION; SIMULATION; DISCRETIZATION;
   ATTRIBUTES; MULTISCALE; ALGORITHM
AB In this work, a framework for modelling twin-screw granulation processes with variable screw configurations using a high-dimensional stochastic population balance method is presented. A modular compartmental approach is presented and a method for estimating residence times for model compartments based on screw element geometry is introduced. The model includes particle mechanisms for nucleation, primary particle layering, coalescence, breakage, and consolidation. A new twin-screw breakage model is introduced, which takes into account the differing breakage dynamics between two types of screw element. Additionally, a new sub-model for the layering of primary particles onto larger agglomerates is presented. The resulting model is used to simulate a twin-screw system with a number of different screw configurations and the predictive power of the model is assessed through comparison with an existing experimental data set in the literature. For most of the screw configurations simulated, the model predicts the product particle size distribution at large particle sizes with a reasonable degree of accuracy. However, the model has a tendency to over-predict the amount of fines in the final product. Nevertheless, the model qualitatively captures the reduction in fines associated with an increase in the number of kneading elements, as observed experimentally. Based on model results, a number of key areas for future model development are identified and discussed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [McGuire, Andrew D.; Mosbach, Sebastian; Bringley, Eric; Eaves, Nick; Dreyer, Jochen A. H.; Kraft, Markus] Univ Cambridge, Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
   [Reynolds, Gavin K.] AstraZeneca, Pharmaceut Technol & Dev, Charter Way, Macclesfield SK10 2NA, Cheshire, England.
   [Patterson, Robert I. A.] Weierstrass Inst Appl Anal & Stochast, Mohrenstr 39, D-10117 Berlin, Germany.
   [Kraft, Markus] Nanyang Technol Univ, Sch Chem & Biomed Engn, 62 Nanyang Dr, Singapore 637459, Singapore.
RP Kraft, M (reprint author), Univ Cambridge, Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England.
EM mk306@cam.ac.uk
OI Bringley, Eric/0000-0003-4101-4874; Mosbach,
   Sebastian/0000-0001-7018-9433; Reynolds, Gavin/0000-0002-9592-8228
FU EPSRCEngineering & Physical Sciences Research Council (EPSRC) [1486478];
   AstraZenecaAstraZeneca; Deutsche Forschungsgemeinschaft (DFG)German
   Research Foundation (DFG) [CRC 1114]; National Research Foundation
   (NRF), Prime Minister's Office, Singapore under its Campus for Research
   Excellence and Technological Enterprise (CREATE) programme
FX ADM acknowledge funding from EPSRC Grant 1486478 and AstraZeneca. ADM
   would also like to thank C.T. Lao for useful conversations regarding the
   implementation of the nucleation process. RP acknowledges support from
   the Deutsche Forschungsgemeinschaft (DFG) through grant CRC 1114
   "Scaling Cascades in Complex Systems", Project C08. This project was
   partly funded by the National Research Foundation (NRF), Prime
   Minister's Office, Singapore under its Campus for Research Excellence
   and Technological Enterprise (CREATE) programme.
CR Barrasso D, 2016, J PHARM INNOV, V11, P231, DOI 10.1007/s12247-015-9240-7
   Barrasso D, 2015, PROCEDIA ENGINEER, V102, P1295, DOI 10.1016/j.proeng.2015.01.260
   Barrasso D, 2015, CHEM ENG SCI, V123, P500, DOI 10.1016/j.ces.2014.11.011
   Barrasso D, 2015, POWDER TECHNOL, V270, P612, DOI 10.1016/j.powtec.2014.06.035
   Barrasso D, 2013, POWDER TECHNOL, V241, P85, DOI 10.1016/j.powtec.2013.03.001
   Boje A, 2017, CHEM ENG SCI, V164, P219, DOI 10.1016/j.ces.2017.02.019
   BRATLEY P, 1988, ACM T MATH SOFTWARE, V14, P88, DOI 10.1145/42288.214372
   Braumann A, 2007, CHEM ENG SCI, V62, P4717, DOI 10.1016/j.ces.2007.05.028
   Braumann A, 2011, AICHE J, V57, P3105, DOI 10.1002/aic.12526
   Braumann A, 2010, J COMPUT PHYS, V229, P7672, DOI 10.1016/j.jcp.2010.06.021
   Braumann A, 2010, CHEM ENG SCI, V65, P1088, DOI 10.1016/j.ces.2009.09.063
   Braumann A, 2010, IND ENG CHEM RES, V49, P428, DOI 10.1021/ie901230u
   Braumann A, 2010, POWDER TECHNOL, V197, P196, DOI 10.1016/j.powtec.2009.09.014
   Cao L, 2008, 2008010021 SAE, DOI [10.4271/2008-01-0021, DOI 10.4271/2008-01-0021]
   Celnik M, 2007, COMBUST FLAME, V148, P158, DOI 10.1016/j.combustflame.2006.10.007
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Dhenge RM, 2012, POWDER TECHNOL, V229, P126, DOI 10.1016/j.powtec.2012.06.019
   Eibeck A, 2000, STOCH ANAL APPL, V18, P921, DOI 10.1080/07362990008809704
   Eibeck A, 2001, ANN APPL PROBAB, V11, P1137
   Eitzlmayr A, 2014, INT J PHARMACEUT, V474, P157, DOI 10.1016/j.ijpharm.2014.08.005
   El Hagrasy AS, 2013, AICHE J, V59, P4100, DOI 10.1002/aic.14180
   El Hagrasy AS, 2013, POWDER TECHNOL, V238, P108, DOI 10.1016/j.powtec.2012.04.035
   Gantt JA, 2006, AICHE J, V52, P3067, DOI 10.1002/aic.10911
   GILLESPIE DT, 1975, J ATMOS SCI, V32, P1977, DOI 10.1175/1520-0469(1975)032<1977:AEMFNS>2.0.CO;2
   Goodson M, 2004, CHEM ENG SCI, V59, P3865, DOI 10.1016/j.ces.2004.05.029
   Gorringe LJ, 2017, INT J PHARMACEUT, V519, P165, DOI 10.1016/j.ijpharm.2017.01.029
   Hao XM, 2013, AEROSOL SCI TECH, V47, P1125, DOI 10.1080/02786826.2013.823642
   HOOKE R, 1961, J ACM, V8, P212, DOI 10.1145/321062.321069
   Iveson SM, 2001, POWDER TECHNOL, V117, P3, DOI 10.1016/S0032-5910(01)00313-8
   Kumar A, 2016, COMPUT CHEM ENG, V89, P62, DOI 10.1016/j.compchemeng.2016.03.007
   Kumar A, 2015, EUR J PHARM SCI, V71, P25, DOI 10.1016/j.ejps.2015.02.004
   Kumar A, 2014, INT J PHARMACEUT, V475, P485, DOI 10.1016/j.ijpharm.2014.09.020
   Kumar A, 2014, EUR J PHARM BIOPHARM, V87, P279, DOI 10.1016/j.ejpb.2014.04.004
   Kumar A, 2013, EUR J PHARM BIOPHARM, V85, P814, DOI 10.1016/j.ejpb.2013.09.013
   Kumar S, 1997, CHEM ENG SCI, V52, P4659, DOI 10.1016/S0009-2509(97)00307-2
   Kumar S, 1996, CHEM ENG SCI, V51, P1311, DOI 10.1016/0009-2509(96)88489-2
   Kumar S, 1996, CHEM ENG SCI, V51, P1333, DOI 10.1016/0009-2509(95)00355-X
   Lee KT, 2012, EUR J PHARM BIOPHARM, V81, P666, DOI 10.1016/j.ejpb.2012.04.011
   Lee KF, 2017, COMPUT CHEM ENG, V99, P171, DOI 10.1016/j.compchemeng.2017.01.022
   Lee KF, 2015, J COMPUT PHYS, V303, P1, DOI 10.1016/j.jcp.2015.09.031
   Lee KF, 2015, COMPUT CHEM ENG, V75, P1, DOI 10.1016/j.compchemeng.2015.01.009
   Lute SV, 2016, CHEM ENG RES DES, V110, P43, DOI 10.1016/j.cherd.2016.03.008
   McGuire AD, 2018, CHEM ENG SCI, V188, P18, DOI 10.1016/j.ces.2018.04.077
   McGuire AD, 2018, CHEM ENG SCI, V188, P221, DOI 10.1016/j.ces.2018.04.076
   McGuire AD, 2017, ADV POWDER TECHNOL, V28, P2239, DOI 10.1016/j.apt.2017.06.005
   Meier R, 2017, EUR J PHARM BIOPHARM, V115, P102, DOI 10.1016/j.ejpb.2017.02.010
   Meng W, 2016, INT J PHARMACEUT, V513, P357, DOI 10.1016/j.ijpharm.2016.09.041
   Menz WJ, 2014, J COMPUT PHYS, V256, P615, DOI 10.1016/j.jcp.2013.09.021
   Menz WJ, 2013, J COMPUT PHYS, V248, P221, DOI 10.1016/j.jcp.2013.04.010
   MoDS, 2015, MOD DEV SUIT
   Mosbach S, 2007, INT J ENGINE RES, V8, P41, DOI 10.1243/14680874JER01806
   Patterson RIA, 2006, SIAM J SCI COMPUT, V28, P303, DOI 10.1137/040618953
   Patterson RIA, 2013, STOCH ANAL APPL, V31, P800, DOI 10.1080/07362994.2013.817245
   Patterson RIA, 2012, SIAM J SCI COMPUT, V34, pB290, DOI 10.1137/110843319
   Patterson RIA, 2011, J COMPUT PHYS, V230, P7456, DOI 10.1016/j.jcp.2011.06.011
   Pradhan SU, 2017, POWDER TECHNOL, V315, P290, DOI 10.1016/j.powtec.2017.04.011
   RAMKRISHNA D, 2000, POPULATION BALANCES
   Rjasanow S, 1996, J COMPUT PHYS, V124, P243, DOI 10.1006/jcph.1996.0057
   Rjasanow S, 2001, MATH COMPUT MODEL, V33, P907, DOI 10.1016/S0895-7177(00)00289-2
   Saleh MF, 2015, INT J PHARMACEUT, V496, P571, DOI 10.1016/j.ijpharm.2015.10.069
   Sayin R, 2015, CHEM ENG SCI, V125, P165, DOI 10.1016/j.ces.2014.06.040
   Seem TC, 2016, EUR J PHARM BIOPHARM, V106, P50, DOI 10.1016/j.ejpb.2016.01.013
   Seem TC, 2015, POWDER TECHNOL, V276, P89, DOI 10.1016/j.powtec.2015.01.075
   Shah U., 2005, PHARM TECHNOL, V6, P52
   Tan HS, 2004, POWDER TECHNOL, V142, P103, DOI 10.1016/j.powtec.2004.04.030
   Vercruysse J, 2015, EUR J PHARM BIOPHARM, V89, P239, DOI 10.1016/j.ejpb.2014.12.017
   Vercruysse J, 2015, INT J PHARMACEUT, V479, P171, DOI 10.1016/j.ijpharm.2014.12.071
   Vercruysse J, 2012, EUR J PHARM BIOPHARM, V82, P205, DOI 10.1016/j.ejpb.2012.05.010
   ZADOW JG, 1984, J DAIRY SCI, V67, P2654, DOI 10.3168/jds.S0022-0302(84)81625-2
   Zhao HB, 2013, COMPUT FLUIDS, V71, P196, DOI 10.1016/j.compfluid.2012.09.025
   Zhao HB, 2010, J COMPUT PHYS, V229, P6931, DOI 10.1016/j.jcp.2010.05.031
   Zhao HB, 2009, J COMPUT PHYS, V228, P1412, DOI 10.1016/j.jcp.2008.10.033
   Zhao HB, 2005, POWDER TECHNOL, V154, P164, DOI 10.1016/j.powtec.2005.04.042
NR 73
TC 0
Z9 0
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 358
EP 379
DI 10.1016/j.ces.2019.03.078
PG 22
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600030
DA 2020-05-12
ER

PT J
AU Garcia, ES
   Lo, C
   Eppink, MHM
   Wijffels, RH
   van den Berg, C
AF Garcia, E. Suarez
   Lo, C.
   Eppink, M. H. M.
   Wijffels, R. H.
   van den Berg, C.
TI Understanding mild cell disintegration of microalgae in bead mills for
   the release of biomolecules
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bead mill; Energy efficient; Disintegration; Selective release;
   Microalgae; Biorefinery
ID STIRRED MEDIA MILLS; STRESS INTENSITY; MECHANICAL-PROPERTIES;
   TETRASELMIS-SUECICA; CHLORELLA-VULGARIS; GRINDING BEADS; SHEAR-STRESS;
   BALL MILLS; DISRUPTION; MOTION
AB Cell disintegration is, in general, the first step in the biorefinery of algae, since it allows the release of biomolecules of interest from the cells into the bulk medium. For high-value commercial applications, the disintegration process must be selective, energy efficient and mild. Developing a process with such features would demand extensive experimental effort. In the present study, we attempt to provide a tool for developing an efficient disintegration process via bead milling, by proposing a modelling strategy that allows the prediction of the kinetics of cell disintegration while having as input not only process parameters but also strain-specific parameters like cell size and cell-wall strength. The model was validated for two different algal strains (Tetraselmis suecica and Chlorella vulgaris), at various values of bead size (0.3-1 mm) and bead fillings (2.5-75%) and at two different scales of 80 and 500 mL. Since the kinetics of disintegration is proportional to the kinetics of release of biomolecules, the model can be further used for scale-up studies and to establish a window of operation to selectively target cells or metabolites of interest. Furthermore, the energy consumption in the mill was evaluated and it was found that operating at high bead fillings (>65%) is crucial to ensure an energy efficient process. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Garcia, E. Suarez; Lo, C.; Eppink, M. H. M.; Wijffels, R. H.; van den Berg, C.] Wageningen Univ & Res, Bioproc Engn, POB 16, NL-6700 AA Wageningen, Netherlands.
   [Wijffels, R. H.] Nord Univ, Fac Biosci & Aquaculture, N-8049 Bodo, Norway.
RP Garcia, ES (reprint author), Wageningen Univ & Res, Bioproc Engn, POB 16, NL-6700 AA Wageningen, Netherlands.
EM edgar.suarezgarcia@wur.nl
OI Lo, Calvin/0000-0002-8087-452X; Eppink, Michel/0000-0001-8297-9985
FU Dutch Technology Foundation STWTechnologiestichting STW [12635]
FX This study was financed by the Dutch Technology Foundation STW under the
   project AlgaePro4You, nr. 12635. From January 2017, STW continued its
   activities as NWO (Dutch national science foundation) Applied and
   Engineering Sciences (TTW). The authors are grateful to Dorinde
   Kleinegris (UniResearch Bergen, Norway) and Jeroen de Vree (University
   of Bergen, Norway) for providing Chlorella vulgaris for the
   disintegration experiments.
CR ABOSHADY AM, 1993, BIOL PLANTARUM, V35, P629, DOI 10.1007/BF02928041
   Adarme-Vega TC, 2012, MICROB CELL FACT, V11, DOI 10.1186/1475-2859-11-96
   Alhattab M, 2019, J APPL PHYCOL, V31, P61, DOI 10.1007/s10811-018-1560-9
   Atkins P., 2006, PHYS CHEM
   AUSTIN LG, 1973, IND ENG CHEM PROC DD, V12, P121, DOI 10.1021/i260046a001
   Becker M, 2001, INT J MINER PROCESS, V61, P189, DOI 10.1016/S0301-7516(00)00037-5
   Beinert S, 2015, CHEM ENG SCI, V134, P648, DOI 10.1016/j.ces.2015.05.063
   Bird R. B., 2002, TRANSPORT PHENOMENA
   Blecher L, 1996, POWDER TECHNOL, V86, P59, DOI 10.1016/0032-5910(95)03038-7
   BROOKMAN JS, 1974, BIOTECHNOL BIOENG, V16, P371
   BUNGE F, 1992, CHEM ENG SCI, V47, P225, DOI 10.1016/0009-2509(92)80216-Y
   Cabanelas ITD, 2016, BIOTECHNOL BIOFUELS, V9, DOI 10.1186/s13068-016-0595-x
   Chen CY, 2013, BIOCHEM ENG J, V78, P1, DOI 10.1016/j.bej.2013.03.006
   Coons JE, 2014, ALGAL RES, V6, P250, DOI 10.1016/j.algal.2014.08.005
   Cuellar-Bermudez SP, 2015, MICROB BIOTECHNOL, V8, P190, DOI 10.1111/1751-7915.12167
   de Winter L, 2013, ALGAL RES, V2, P313, DOI 10.1016/j.algal.2013.09.001
   Dixon C, 2018, BIORESOUR BIOPROCESS, V5, DOI 10.1186/s40643-018-0199-3
   Dogonchi AS, 2015, POWDER TECHNOL, V274, P186, DOI 10.1016/j.powtec.2015.01.018
   Doucha J, 2008, APPL MICROBIOL BIOT, V81, P431, DOI 10.1007/s00253-008-1660-6
   Draaisma RB, 2013, CURR OPIN BIOTECH, V24, P169, DOI 10.1016/j.copbio.2012.09.012
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   Garcia ES, 2018, BIORESOURCE TECHNOL, V268, P197, DOI 10.1016/j.biortech.2018.07.131
   GEANKOPLIS CJ, 1993, TRANSPORT PROCESSES
   Geresh S, 2002, J BIOCHEM BIOPH METH, V50, P179, DOI 10.1016/S0165-022X(01)00185-3
   Gers R, 2010, CHEM ENG SCI, V65, P2052, DOI 10.1016/j.ces.2009.12.003
   Gunther S, 2016, CHEM ENG TECHNOL, V39, P1693, DOI 10.1002/ceat.201400632
   Gunerken E, 2015, BIOTECHNOL ADV, V33, P243, DOI 10.1016/j.biotechadv.2015.01.008
   Hagen C, 2016, ULTRASTRUCTURAL CHEM, DOI [10.1017/S0967026202003669, DOI 10.1017/S0967026202003669]
   HEDENSKO.G, 1969, BIOTECHNOL BIOENG, V11, P37, DOI 10.1002/bit.260110104
   Kermanshahi-Pour A, 2014, BIORESOURCE TECHNOL, V173, P415, DOI 10.1016/j.biortech.2014.09.048
   KULA MR, 1987, BIOTECHNOL PROGR, V3, P31, DOI 10.1002/btpr.5420030107
   Kwade A, 2002, POWDER TECHNOL, V122, P109, DOI 10.1016/S0032-5910(01)00406-5
   Kwade A, 1996, POWDER TECHNOL, V86, P69, DOI 10.1016/0032-5910(95)03039-5
   Kwade A, 1999, POWDER TECHNOL, V105, P382, DOI 10.1016/S0032-5910(99)00162-X
   Lee AK, 2013, BIORESOURCE TECHNOL, V128, P199, DOI 10.1016/j.biortech.2012.10.032
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mashmoushy H, 1998, BIOTECHNOL TECH, V12, P925, DOI 10.1023/A:1008825830928
   Melendres A V, 1991, Bioseparation, V2, P231
   Michels MHA, 2016, J APPL PHYCOL, V28, P53, DOI 10.1007/s10811-015-0559-8
   Michels MHA, 2014, ALGAL RES, V4, P12, DOI 10.1016/j.algal.2013.11.011
   Michels MHA, 2010, BIOPROC BIOSYST ENG, V33, P921, DOI 10.1007/s00449-010-0415-9
   MIDDELBERG APJ, 1995, BIOTECHNOL ADV, V13, P491, DOI 10.1016/0734-9750(95)02007-P
   Montalescot V, 2015, BIORESOURCE TECHNOL, V196, P339, DOI 10.1016/j.biortech.2015.07.075
   Pan ZD, 2017, BIORESOURCE TECHNOL, V245, P641, DOI 10.1016/j.biortech.2017.08.146
   Phong WN, 2018, ALGAL RES, V31, P506, DOI 10.1016/j.algal.2017.04.005
   Postma PR, 2017, BIORESOURCE TECHNOL, V224, P670, DOI 10.1016/j.biortech.2016.11.071
   Postma PR, 2015, BIORESOURCE TECHNOL, V184, P297, DOI 10.1016/j.biortech.2014.09.033
   Schneider N, 2016, FUEL PROCESS TECHNOL, V152, P390, DOI 10.1016/j.fuproc.2016.06.039
   Shiu C, 2002, APPL MICROBIOLOGY, P155
   Smith AE, 2000, P NATL ACAD SCI USA, V97, P9871, DOI 10.1073/pnas.97.18.9871
   Vanthoor-Koopmans M, 2013, BIORESOURCE TECHNOL, V135, P142, DOI 10.1016/j.biortech.2012.10.135
   Wang CC, 2018, BIOTECHNOL ADV, V36, P986, DOI 10.1016/j.biotechadv.2018.03.001
   Yamamoto Y, 2012, INT J MINER PROCESS, V114, P93, DOI 10.1016/j.minpro.2012.10.001
   Zinkone TR, 2018, BIORESOURCE TECHNOL, V267, P458, DOI 10.1016/j.biortech.2018.07.080
NR 54
TC 1
Z9 1
U1 0
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 380
EP 390
DI 10.1016/j.ces.2019.04.008
PG 11
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600031
OA Other Gold
DA 2020-05-12
ER

PT J
AU Singla, R
   Tripathy, S
   Das, SK
AF Singla, Rashmi
   Tripathy, Snehashish
   Das, Suchandan Kumar
TI An integrated phenomenological process model for prediction of oxygen
   pickup during open air tapping and pouring of liquid steel
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mathematical modeling; Diffusion; Ranz-Marshall correlation; Boundary
   layer; Air entrainment
ID REOXIDATION BEHAVIOR; OXIDATION RATE; MOLTEN STEEL; JETS
AB Re-oxidation inclusion formation being a major concern in open air induction melting and casting facilities has acquired significant attention worldwide. Mathematical modeling has been attempted to understand the contributions from the two major sources of oxygen pickup viz. diffusion of oxygen through gaseous boundary layer and air entrainment in the past. In this work, an integrated approach has been developed to estimate the total oxygen pickup content from the aforementioned sources. The developed model consists of a fairly comprehensive and plausible formulation by incorporating refinements like time dependent velocity modification and application of modified Ranz-Marshall correlation which has not yet been addressed. The consolidated model predictions are in good agreement with the data obtained from literature. For further validation, a customized experimental setup was designed and oxygen pickup studies were performed upon it. The model predictions of oxygen and nitrogen pick up pertaining to the designed experiments have been found to be in concurrence with the measured total oxygen and nitrogen contents respectively. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Singla, Rashmi; Tripathy, Snehashish; Das, Suchandan Kumar] CSIR, Natl Met Lab, Jamshedpur 831007, Bihar, India.
RP Tripathy, S (reprint author), CSIR, Natl Met Lab, Jamshedpur 831007, Bihar, India.
EM snehashish@nmlindia.org
CR Aring;nmark N, 2015, MATERIALS, V8, P751, DOI 10.3390/ma8020751
   Beckermann C, 1992, P 46 SFSA TECHN OP C
   Blair M, 1993, 47 SFSA TECHN OP
   Brabie V, 1976, SCAND J METALL, V5, P185
   EMI T, 1974, METALL TRANS, V5, P1959, DOI 10.1007/BF02644486
   ERVINE DA, 1987, P I CIVIL ENG PT 2, V83, P295, DOI 10.1680/iicep.1987.353
   Farrell J. W, 1970, ELECTRIC FURNACE P, V28, P64
   Goto H, 1998, ISIJ INT, V38, P256, DOI 10.2355/isijinternational.38.256
   Griffin J. A, 1986, SORIEAS86682 SFSA RE
   Griffin J. A, 1991, 104 SFSA RES
   Griffin J. A, 1986, SORIEAS86810 SFSA
   Guthrie R I L, 1989, ENG PROCESS METALLUR
   Heaslip L. J, 1983, CONTINUOUS CASTING I, V1, P1
   Kobus H, 1991, AIR ENTRAINMENT FREE, P29, DOI [10.18419/opus-551, DOI 10.18419/OPUS-551]
   Kumar Vig S, 1969, OXIDATION KINETICS F
   LANGE KW, 1977, ARCH EISENHUTTENWES, V48, P415, DOI 10.1002/srin.197705038
   MADDEVER WJ, 1973, CAN METALL QUART, V12, P79
   Majidi SH, 2017, INT J CAST METAL RES, V30, P301, DOI 10.1080/13640461.2017.1307624
   MARRERO TR, 1972, J PHYS CHEM REF DATA, V1, P1, DOI DOI 10.1063/1.3253094)
   Park JH, 2010, ISIJ INT, V50, P1333, DOI 10.2355/isijinternational.50.1333
   RANZ WE, 1952, CHEM ENG PROG, V48, P141
   RANZ WE, 1952, CHEM ENG PROG, V48, P173
   Samarasekera I. V, 1995, P INT S NEAR NET SHA, P135
   Sasai K, 1996, ISIJ INT, V36, P388, DOI 10.2355/isijinternational.36.388
   Sasai K, 1998, ISIJ INT, V38, P332, DOI 10.2355/isijinternational.38.332
   Sasai K, 2000, ISIJ INT, V40, P40, DOI 10.2355/isijinternational.40.40
   Sommerville I. D, 1981, CONTINUOUS CASTING S, P256
   Sun HP, 1995, METALL MATER TRANS B, V26, P335, DOI 10.1007/BF02660976
   Sun HP, 1996, METALL MATER TRANS B, V27, P854, DOI 10.1007/BF02915615
   Svoboda J. M, 1987, AFS T, V95, P187
   VISHKAREV AF, 1991, STEEL USSR, V21, P196
   Wang L, 2006, METALL MATER TRANS B, V37, P571, DOI 10.1007/s11663-006-0041-8
   Zhang LF, 2003, ISIJ INT, V43, P271, DOI 10.2355/isijinternational.43.271
NR 33
TC 0
Z9 0
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 391
EP 401
DI 10.1016/j.ces.2019.03.019
PG 11
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600032
DA 2020-05-12
ER

PT J
AU Chen, YQ
   Gani, R
   Kontogeorgis, GM
   Woodley, JM
AF Chen, Yuqiu
   Gani, Rafiqul
   Kontogeorgis, Georgios M.
   Woodley, John M.
TI Integrated ionic liquid and process design involving azeotropic
   separation processes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ionic liquids; CAMD; Azeotrope separation; UNIFAC-IL model; Group
   contribution method
ID UNIFAC GROUP-CONTRIBUTION; VOLUMETRIC PROPERTIES; MOLECULAR DESIGN;
   CARBON-DIOXIDE; COSMO-RS; PREDICTION; MODEL; SOLVENT; EQUILIBRIA;
   REVISION
AB In process industries, separation techniques need to be employed to match product quality and purity specifications. Most vapour-liquid based separation techniques involving the separation of close-boiling or azeotropic as well as gaseous mixtures are energy intensive. Downstream separations from bioreactors are, on the other hand, difficult because of relatively small amounts of products in large amounts of reactants and carriers such as water. With growing energy and environmental challenges, novel, sustainable and innovative separation techniques are receiving increasing attention. Because of their non-volatility and other tuneable properties, ionic liquids (ILs) based separation techniques are promising alternatives. In this work, a systematic method that combines group contribution (GC)-based property prediction and IL-based separation process design is presented. That is, the optimal IL molecular structure and the corresponding optimal flow sheet configuration for a specific IL-based separation process are simultaneously identified. Case studies involving the separation of azeotropic mixtures such as ethanol-water and acetone-methanol are presented to highlight the application of the method for synthesis-design of the IL-based separation technology. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Yuqiu; Kontogeorgis, Georgios M.; Woodley, John M.] Tech Univ Denmark, Dept Chem & Biochem Engn, DK-2800 Lyngby, Denmark.
   [Gani, Rafiqul] PSE SPEED, Skyttemosen 6, DK-3450 Allerod, Denmark.
   [Gani, Rafiqul] Zhejiang Univ, Coll Control Sci & Engn, State Key Lab Ind Control Technol, Hangzhou 310027, Zhejiang, Peoples R China.
RP Woodley, JM (reprint author), Tech Univ Denmark, Dept Chem & Biochem Engn, DK-2800 Lyngby, Denmark.
EM jw@kt.dtu.dk
RI Gani, Rafiqul/A-4865-2011
OI Gani, Rafiqul/0000-0002-6719-9283; Woodley, John/0000-0002-7976-2483
FU China Scholarship CouncilChina Scholarship Council [201708440264];
   Technical University of Denmark
FX This research work was supported by the China Scholarship Council (No.
   201708440264) and the Technical University of Denmark. The authors would
   like to thank PhD student Nipun Garg from the Technical University of
   Denmark. His suggestions and comments were much appreciated.
CR Babi DK, 2015, COMPUT CHEM ENG, V81, P218, DOI 10.1016/j.compchemeng.2015.04.030
   Barton P I, 2000, Curr Opin Drug Discov Devel, V3, P707
   BENEDICT M, 1945, T AM INST CHEM ENG, V41, P353
   BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001
   Burger J, 2015, AICHE J, V61, P3249, DOI 10.1002/aic.14838
   Chao H, 2017, SEP PURIF TECHNOL
   Chen Y, 2018, COMP AIDED CHEM ENG, V44, P1045
   Chen YQ, 2019, IND ENG CHEM RES, V58, P4277, DOI 10.1021/acs.iecr.8b05040
   Chong FK, 2016, COMPUT CHEM ENG, V91, P219, DOI 10.1016/j.compchemeng.2016.04.006
   Chong FK, 2015, CLEAN TECHNOL ENVIR, V17, P1301, DOI 10.1007/s10098-015-0938-5
   Corderi S, 2013, FLUID PHASE EQUILIBR, V337, P11, DOI 10.1016/j.fluid.2012.10.004
   Dai CN, 2013, AICHE J, V59, P4399, DOI 10.1002/aic.14166
   Diedenhofen M, 2003, J CHEM ENG DATA, V48, P475, DOI 10.1021/je025626e
   Douglas J. M., 1988, CONCEPTUAL DESIGN CH
   Fang J, 2016, AICHE J, V62, P2853, DOI 10.1002/aic.15247
   GANI R, 1991, AICHE J, V37, P1318, DOI 10.1002/aic.690370905
   Gardas RL, 2009, AICHE J, V55, P1274, DOI 10.1002/aic.11737
   GMEHLING J, 1982, IND ENG CHEM PROC DD, V21, P118, DOI 10.1021/i200016a021
   GMEHLING J, 1977, VAPOR LIQUID EQUILIB
   Harper PM, 1999, FLUID PHASE EQUILIBR, V158, P337, DOI 10.1016/S0378-3812(99)00089-8
   Hector T, 2014, FLUID PHASE EQUILIBR, V371, P82, DOI 10.1016/j.fluid.2014.03.006
   Holbrey J.D., 1999, CLEAN PRODUCTS PROCE, V1, P223, DOI DOI 10.1007/S100980050036
   Huang Y, 2013, AICHE J, V59, P1348, DOI 10.1002/aic.13910
   Jacquemin J, 2008, J CHEM ENG DATA, V53, P2133, DOI 10.1021/je8002817
   Jacquemin J, 2008, J CHEM ENG DATA, V53, P716, DOI 10.1021/je700707y
   Karunanithi A, 2013, COMPUTER AIDED DESIG
   Kato R, 2005, J CHEM THERMODYN, V37, P603, DOI 10.1016/j.jct.2005.04.010
   KLAMT A, 1995, J PHYS CHEM-US, V99, P2224, DOI 10.1021/j100007a062
   Klamt A, 1998, J PHYS CHEM A, V102, P5074, DOI 10.1021/jp980017s
   Klamt A, 2000, FLUID PHASE EQUILIBR, V172, P43, DOI 10.1016/S0378-3812(00)00357-5
   Kohl A.L, 1997, GAS PURIFICATION
   Lazzus JA, 2009, J TAIWAN INST CHEM E, V40, P213, DOI 10.1016/j.jtice.2008.08.001
   Lei ZG, 2007, CHEM ENG SCI, V62, P3940, DOI 10.1016/j.ces.2007.04.021
   Lei ZG, 2014, AICHE J, V60, P3312, DOI 10.1002/aic.14537
   Lei ZG, 2014, CHEM REV, V114, P1289, DOI 10.1021/cr300497a
   Lei ZG, 2014, AICHE J, V60, P716, DOI 10.1002/aic.14294
   Lei ZG, 2012, IND ENG CHEM RES, V51, P12135, DOI 10.1021/ie301159v
   Lei ZG, 2012, CHEM ENG SCI, V75, P1, DOI 10.1016/j.ces.2012.03.002
   Lei ZG, 2009, IND ENG CHEM RES, V48, P2697, DOI 10.1021/ie801496e
   Lin ST, 2004, J PHYS CHEM A, V108, P7429, DOI 10.1021/jp048813n
   Lin ST, 2002, IND ENG CHEM RES, V41, P899, DOI 10.1021/ie001047w
   Lutze P, 2010, CHEM ENG PROCESS, V49, P547, DOI 10.1016/j.cep.2010.05.002
   LYGEROS AI, 1986, HYDROCARB PROCESS, V65, P43
   Mortazavi-Manesh S, 2013, AICHE J, V59, P2993, DOI 10.1002/aic.14081
   Mousazadeh MH, 2011, FLUID PHASE EQUILIBR, V301, P13, DOI 10.1016/j.fluid.2010.11.006
   Palomar J, 2011, IND ENG CHEM RES, V50, P3452, DOI 10.1021/ie101572m
   Pereira FE, 2011, COMPUT CHEM ENG, V35, P474, DOI 10.1016/j.compchemeng.2010.06.016
   Pereiro AB, 2010, AICHE J, V56, P381, DOI 10.1002/aic.11937
   Perry R.H., 1997, PERRYS CHEM ENG HDB
   Petkovic M, 2011, CHEM SOC REV, V40, P1383, DOI 10.1039/c004968a
   Plechkova NV, 2008, CHEM SOC REV, V37, P123, DOI 10.1039/b006677j
   Poling B. E, 2001, PROPERTIES GASESAND
   Rogers RD, 2003, SCIENCE, V302, P792, DOI 10.1126/science.1090313
   Roughton BC, 2012, COMPUT CHEM ENG, V42, P248, DOI 10.1016/j.compchemeng.2012.02.021
   Santiago RS, 2009, FLUID PHASE EQUILIBR, V278, P54, DOI 10.1016/j.fluid.2009.01.002
   Seiler M, 2004, AICHE J, V50, P2439, DOI 10.1002/aic.10249
   Shamsuri A. A., 2011, MAKARA J SCI
   Sholl DS, 2016, NATURE, V532, P435, DOI 10.1038/532435a
   Simoni LD, 2008, IND ENG CHEM RES, V47, P256, DOI 10.1021/ie070956j
   Simoni LD, 2010, COMPUT CHEM ENG, V34, P1406, DOI 10.1016/j.compchemeng.2010.02.020
   Song Z, 2018, AICHE J
   TIEGS D, 1987, IND ENG CHEM RES, V26, P159, DOI 10.1021/ie00061a030
   Valencia-Marquez D, 2012, IND ENG CHEM RES, V51, P5866, DOI 10.1021/ie201726r
   Vooradi R, 2017, CHEM ENG RES DES
   Welton T, 1999, CHEM REV, V99, P2071, DOI 10.1021/cr980032t
   Wittig R, 2003, IND ENG CHEM RES, V42, P183, DOI 10.1021/ie020506l
   Woodley J. M., 2017, COMP CHEM ENG
   Woodley JM, 2008, J CHEM TECHNOL BIOT, V83, P121, DOI 10.1002/jctb.1790
   Zhao YS, 2017, AICHE J, V63, P1353, DOI 10.1002/aic.15618
   Zhou T, 2015, AICHE J, V61, P147, DOI 10.1002/aic.14630
NR 70
TC 6
Z9 6
U1 7
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 402
EP 414
DI 10.1016/j.ces.2019.04.005
PG 13
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600033
DA 2020-05-12
ER

PT J
AU Rana, C
   De Malsche, W
   De Wit, A
AF Rana, C.
   De Malsche, W.
   De Wit, A.
TI Decreased peak tailing during transport of solutes in porous media with
   alternate adsorption properties
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Heterogeneous porous media; Langmuir adsorption; Anti-Langmuir
   adsorption; Accordion effect; Chromatography; Spreading; Peak tailing
ID LIQUID-CHROMATOGRAPHY; EQUILIBRIUM; PROFILES; LAYERS; PH
AB In adsorption based separation techniques or in environmental applications where adsorption on a porous matrix is involved, the broadening of migrating bands of solutes varies with the characteristics of the adsorption isotherms and is generally overwhelming at solute concentrations deep in the non-linear region. We introduce here a novel concept to minimize concentration overloading dispersion: We show theoretically that a spatial alternation of Langmuir (L) and Anti-Langmuir (AL) zones along the displacement direction induces an accordion effect, i.e. an alternation of sharpening and dilution of the solute zones, reducing in the end the final broadening of the peak. We quantify in the parameter space of the problem the reduction in concentration overloading related band widening of the L-AL system compared to the pure L or AL cases. A numerical analysis of the solute transport reveals a dependence of solute spreading on the ratio of sample to stationary phase zone widths and on the intensity of the adsorption parameter. The initial position of the sample solvent in its surrounding liquid i.e. whether the displacement starts in a L or AL zone is also shown to have an influence on the dispersive behavior. An analysis is performed to highlight the optimal alternance geometry to minimize solute spreading. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rana, C.; De Wit, A.] Univ Libre Bruxelles, Nonlinear Phys Chem Unit, B-1050 Brussels, Belgium.
   [De Malsche, W.] Vrije Univ Brussel, Dept Chem Engn, Pl Laan 2, B-1050 Brussels, Belgium.
RP Rana, C (reprint author), Univ Libre Bruxelles, Nonlinear Phys Chem Unit, B-1050 Brussels, Belgium.
EM chinar.rana@ulb.ac.be
RI De Malsche, Wim/Y-9320-2019
OI RANA, CHINAR/0000-0002-3685-6076
CR ABRIOLA LM, 1987, REV GEOPHYS, V25, P125, DOI 10.1029/RG025i002p00125
   Callewaert M, 2014, ANALYST, V139, P618, DOI 10.1039/c3an02023a
   Canuto C., 1988, SPECTRAL METHODS FLU
   Cavazzini A, 2002, J CHROMATOGR A, V957, P111, DOI 10.1016/S0021-9673(02)00320-5
   De Wit A, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1909188
   DeVault D, 1943, J AM CHEM SOC, V65, P532, DOI 10.1021/ja01244a011
   Farajzadeh R, 2012, ADV COLLOID INTERFAC, V183, P1, DOI 10.1016/j.cis.2012.07.002
   Fornstedt T, 1999, J AM CHEM SOC, V121, P1164, DOI 10.1021/ja9831296
   Futagami S, 2017, J CHROMATOGR A, V1523, P234, DOI 10.1016/j.chroma.2017.06.062
   GILES CH, 1974, J COLLOID INTERF SCI, V47, P755, DOI 10.1016/0021-9797(74)90252-5
   GOLSHANSHIRAZI S, 1989, ANAL CHEM, V61, P2380, DOI 10.1021/ac00196a012
   Gritti F, 2005, J CHROMATOGR A, V1099, P1, DOI 10.1016/j.chroma.2005.09.082
   Gritti F, 2003, J CHROMATOGR A, V1003, P43, DOI 10.1016/S0021-9673(03)00685-X
   Gritti F, 2002, J CHROMATOGR A, V978, P81, DOI 10.1016/S0021-9673(02)01279-7
   Guiochon G., 2006, FUNDAMENTALS PREPARA
   HELFFERICH FG, 1993, J CHROMATOGR, V629, P97, DOI 10.1016/0021-9673(93)87026-I
   HOMSY GM, 1987, ANNU REV FLUID MECH, V19, P271, DOI 10.1146/annurev.fluid.19.1.271
   LIN BC, 1995, J CHROMATOGR A, V708, P1, DOI 10.1016/0021-9673(95)00380-6
   Luhrmann L, 1998, WATER RESOUR RES, V34, P421, DOI 10.1029/97WR03468
   Mazzotti M, 2006, J CHROMATOGR A, V1126, P311, DOI 10.1016/j.chroma.2006.06.022
   Metz  B., 2005, IPCC SPECIAL REPORT
   Meyer V., 2010, PRACTICAL HIGH PERFO
   Mishra M, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3200870
   Nicoud R-M, 2015, CHROMATOGRAPHIC PROC
   Ortner F, 2014, J CHROMATOGR A, V1373, P131, DOI 10.1016/j.chroma.2014.11.026
   Rana C, 2018, EPL-EUROPHYS LETT, V124, DOI 10.1209/0295-5075/124/64003
   Rana C, ARXIV180800699
   Rhee H.-K., 1989, 1 ORDER PARTIAL DIFF, VII
   Rhee H.-K., 1986, 1 ORDER PARTIAL DIFF, VI
   Ruthven D.M., 1984, PRINCIPLES ADSORPTIO
   Strong JC, 1997, J CHROMATOGR A, V769, P129, DOI 10.1016/S0021-9673(96)01049-7
   WHITHAM GB, 1957, J FLUID MECH, V2, P145, DOI 10.1017/S002211205700004X
NR 32
TC 2
Z9 2
U1 2
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 415
EP 424
DI 10.1016/j.ces.2019.04.003
PG 10
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600034
OA Green Published
DA 2020-05-12
ER

PT J
AU Agahzamin, S
   Pakzad, L
AF Agahzamin, Siamak
   Pakzad, Leila
TI CFD investigation of the gas dispersion and liquid mixing in bubble
   columns with dense vertical internals
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble column; Dense internals; Gas dispersion; Liquid mixing; CFD
ID PHASE DISPERSION; AXIAL-DISPERSION; MASS-TRANSFER; FLUID-DYNAMICS;
   EULERIAN SIMULATIONS; NUMERICAL-SIMULATION; FLOW; HOLDUP; REACTORS;
   MODEL
AB Bubble columns are widely equipped with vertical internals for heat removal in slurry/bubble column reactors or providing the light source in photobioreactors. Understanding the effect of internals on the hydrodynamics of a bubble column reactor is crucial for the reactor design and scale-up. The gas dispersion and liquid mixing are two important parameters in design of bubble columns. In this study, the Eulerian-Eulerian simulation coupled with the population balance model was developed for the bubble column with dense vertical internals. The impulse tracer injection was applied to study the gas dispersion. The effect of the gas flow fluctuations, the time span of tracer injection, and the presence of internals was assessed at different superficial gas velocities. The results showed that the presence of internals has a notable effect on gas behavior. A stronger gas velocity gradient with less turbulence and dispersion were observed in the presence of internals. To study the liquid mixing, the tracer technique was applied, and the sensitivity of results to the tracer injection and detector points have been discussed. The presence of internals reduced the fluctuating liquid velocities, which led to a lower mixing performance in the bubble column. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Agahzamin, Siamak; Pakzad, Leila] Lakehead Univ, Dept Chem Engn, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.
RP Pakzad, L (reprint author), Lakehead Univ, Dept Chem Engn, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.
EM lpakzad@lakeheadu.ca
OI Agahzamin, Siamak/0000-0002-7304-9214
FU Natural Sciences and Engineering Council of Canada (NSERC)Natural
   Sciences and Engineering Research Council of Canada
FX We gratefully acknowledge the financial support of the Natural Sciences
   and Engineering Council of Canada (NSERC). We would also like to
   acknowledge the support of Compute Canada for providing the solving
   platform and technical support.
CR Agahzamin S, 2019, CHEM ENG SCI, V193, P421, DOI 10.1016/j.ces.2018.08.052
   Al Mesfer MK, 2017, CHEM ENG SCI, V161, P228, DOI 10.1016/j.ces.2016.12.001
   Al Mesfer MK, 2016, CHEM ENG J, V300, P317, DOI 10.1016/j.cej.2016.04.075
   ANSYS&reg; FLUENT, 2017, ANSYS FLUENT USER GU
   ANTAL SP, 1991, INT J MULTIPHAS FLOW, V17, P635, DOI 10.1016/0301-9322(91)90029-3
   Bai W, 2012, IND ENG CHEM RES, V51, P1949, DOI 10.1021/ie102557h
   Baird M.H.I., 1975, CHEM ENG J, V9, P171, DOI DOI 10.1016/0300-9467(75)80010-4
   Bhusare VH, 2017, CHEM ENG J, V317, P157, DOI 10.1016/j.cej.2017.01.128
   Bhusare VH, 2018, CAN J CHEM ENG, V96, P1957, DOI 10.1002/cjce.23162
   Buwa VV, 2003, CAN J CHEM ENG, V81, P402
   CARLETON AJ, 1967, CHEM ENG SCI, V22, P1839, DOI 10.1016/0009-2509(67)80214-8
   Chen JW, 1999, CHEM ENG SCI, V54, P2187, DOI 10.1016/S0009-2509(99)00003-2
   Chen P, 2005, CHEM ENG SCI, V60, P1085, DOI 10.1016/j.ces.2004.09.070
   Cokljat D, 2006, PROG COMPUT FLUID DY, V6, P168, DOI 10.1504/PCFD.2006.009494
   Degaleesan S, 1998, AICHE J, V44, P2369, DOI 10.1002/aic.690441105
   DEGALEESAN S, 1997, FLUID DYNAMIC MEASUR
   Ekambara K, 2003, CHEM ENG RES DES, V81, P987, DOI 10.1205/026387603322482220
   Ekambara K, 2008, IND ENG CHEM RES, V47, P8505, DOI 10.1021/ie071393e
   FIELD RW, 1980, T I CHEM ENG-LOND, V58, P228
   Forret A, 2003, CAN J CHEM ENG, V81, P360
   George KJH, 2017, CHEM ENG SCI, V170, P297, DOI 10.1016/j.ces.2017.03.018
   Gholamzadehdevin M, 2018, CAN J CHEM ENG, V9999, P1
   GODBOLE SP, 1982, CHEM ENG COMMUN, V16, P119, DOI 10.1080/00986448208911090
   Guan XP, 2017, CHEM ENG RES DES, V126, P109, DOI 10.1016/j.cherd.2017.08.019
   Guo XF, 2017, CHEM ENG SCI, V174, P311, DOI 10.1016/j.ces.2017.09.004
   Hamed M, 2012, 1006 ETDS
   Haque SME, 2009, EXP THERM FLUID SCI, V33, P322, DOI 10.1016/j.expthermflusci.2008.09.010
   Hikita H., 1974, Chemical Engineering Journal, V8, P191, DOI 10.1016/0300-9467(74)85024-0
   HINZE JO, 1975, TURBULENCE
   HUGHMARK GA, 1967, IND ENG CHEM PROC DD, V6, P218, DOI 10.1021/i260022a011
   Hunt J.C.R., 1987, ICHMT INT SEM TRANS, P103
   Jiang XD, 2016, PARTICUOLOGY, V27, P95, DOI 10.1016/j.partic.2015.05.011
   JOSHI JB, 1982, CHEM ENG J BIOCH ENG, V24, P213, DOI 10.1016/0300-9467(82)80036-1
   JOSHI JB, 1979, T I CHEM ENG-LOND, V57, P244
   Kagumba M, 2015, IND ENG CHEM RES, V54, P1359, DOI 10.1021/ie503490h
   Kalaga D. V, 2017, AICHE J
   Kalaga DV, 2018, INT J CHEM REACT ENG, V16, DOI 10.1515/ijcre-2018-0012
   Kalaga DV, 2017, CHEM ENG SCI, V170, P332, DOI 10.1016/j.ces.2017.02.022
   KANTAK MV, 1995, CHEM ENG J BIOCH ENG, V59, P91, DOI 10.1016/0923-0467(94)02922-9
   Kastanek F., 1993, CHEM REACTORS GAS LI
   KAWASE Y, 1987, CHEM ENG SCI, V42, P1609, DOI 10.1016/0009-2509(87)80165-3
   KAWASE Y, 1989, J CHEM TECHNOL BIOT, V44, P63
   Kolbel H, 1962, DECHEMA MONOGR, V41, P225
   Kolmogoroff A, 1941, CR ACAD SCI URSS, V30, P301
   Krishna R, 2000, CHEM ENG J, V78, P43, DOI 10.1016/S1385-8947(99)00167-9
   KRISHNA R, 1991, CHEM ENG SCI, V46, P2491, DOI 10.1016/0009-2509(91)80042-W
   Krishna R, 2001, CHEM ENG SCI, V56, P6249, DOI 10.1016/S0009-2509(01)00274-3
   Larachi F, 2006, CHEM ENG SCI, V61, P4195, DOI 10.1016/j.ces.2006.01.053
   Levenspiel O, 1999, IND ENG CHEM RES, V38, P4140, DOI 10.1021/ie990488g
   Lia G, 2009, CHEM ENG SCI, V64, P5104, DOI 10.1016/j.ces.2009.08.016
   Luo H, 1996, AICHE J, V42, P1225, DOI 10.1002/aic.690420505
   Luo H., 1993, COALESCENCE BREAKUP
   Mahmoodi B., 2012, INT J COMPUT APPL, V39, P1
   Majumder SK, 2008, CHEM ENG SCI, V63, P3160, DOI 10.1016/j.ces.2008.03.029
   MANGARTZ KH, 1981, CHEM ENG SCI, V36, P1069, DOI 10.1016/0009-2509(81)80093-0
   MARUYAMA T, 1981, J CHEM ENG JPN, V14, P352, DOI 10.1252/jcej.14.352
   McClure DD, 2015, CHEM ENG J, V264, P291, DOI 10.1016/j.cej.2014.11.090
   Men'shchikov V. A, 1968, J ENG PHYS, V15, P697
   Miyauchi T, 1970, KAGAKU KOGAKU, V34, P958
   MYERS KJ, 1987, CHEM ENG SCI, V42, P2301, DOI 10.1016/0009-2509(87)80103-3
   Olmos E, 2001, CHEM ENG SCI, V56, P6359, DOI 10.1016/S0009-2509(01)00204-4
   Pilhofer T. H., 1978, ACS SYM SER, P372
   PRADHAN AK, 1993, CAN J CHEM ENG, V71, P468, DOI 10.1002/cjce.5450710319
   RAMKRISHNA D, 2000, POPULATION BALANCES
   Rampure MR, 2007, IND ENG CHEM RES, V46, P8431, DOI 10.1021/ie070079h
   Ranade VV, 2001, CHEM ENG SCI, V56, P1667, DOI 10.1016/S0009-2509(00)00395-X
   Roy S, 2008, ASIA-PAC J CHEM ENG, V3, P97, DOI 10.1002/apj.122
   SAXENA SC, 1992, CHEM ENG J BIOCH ENG, V49, P151, DOI 10.1016/0300-9467(92)80051-B
   Schiller L., 1935, Z VER DTSCH ING, V77, P318
   Seher A, 1979, GER CHEM ENG, V2, P117
   SHAH YT, 1978, AICHE J, V24, P369, DOI 10.1002/aic.690240302
   SHETTY SA, 1992, AICHE J, V38, P1013, DOI 10.1002/aic.690380705
   Simonin C., 1990, NUMER METHODS MULTIP, V91, P65
   Sokolichin A, 2004, AICHE J, V50, P24, DOI 10.1002/aic.10003
   Tabib MV, 2008, CHEM ENG J, V139, P589, DOI 10.1016/j.cej.2007.09.015
   TAYLOR G, 1953, PROC R SOC LON SER-A, V219, P186, DOI 10.1098/rspa.1953.0139
   Thakre SS, 1999, CAN J CHEM ENG, V77, P826, DOI 10.1002/cjce.5450770507
   Towell G. D., 1972, P 5 EUR 2 INT S CHEM
   van Baten JM, 2001, CHEM ENG SCI, V56, P503, DOI 10.1016/S0009-2509(00)00254-2
   VERMEER DJ, 1981, IND ENG CHEM PROC DD, V20, P475, DOI 10.1021/i200014a014
   WACHI S, 1990, CHEM ENG SCI, V45, P901, DOI 10.1016/0009-2509(90)85012-3
   YAMASHITA F, 1987, J CHEM ENG JPN, V20, P204, DOI 10.1252/jcej.20.204
   Youssef A. A, 2010, 393 ETDS
   Zahradnik J, 1997, CHEM ENG SCI, V52, P3811, DOI 10.1016/S0009-2509(97)00226-1
   Zahradnik J, 1996, CHEM ENG SCI, V51, P2491, DOI 10.1016/0009-2509(96)00107-8
NR 85
TC 3
Z9 3
U1 2
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 425
EP 438
DI 10.1016/j.ces.2019.03.048
PG 14
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600035
DA 2020-05-12
ER

PT J
AU Marefatallah, M
   Breakey, D
   Sanders, RS
AF Marefatallah, Maedeh
   Breakey, David
   Sanders, R. Sean
TI Study of local solid volume fraction fluctuations using high speed
   electrical impedance tomography: Particles with low Stokes number
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Solid-liquid flow; Fluidization; Electrical impedance tomography; Solid
   volume fraction fluctuations
ID LIQUID; VELOCITY; FLOW; TURBULENCE; PRESSURE; PHASE
AB The instantaneous local solid volume fraction in a two-phase solid-liquid fluidization system is measured using high-speed Electrical Impedance Tomography (EIT). The unique aspect of EIT is that it provides local volume fraction fluctuations even for opaque, concentrated mixtures. A two-meter tall and 10.16 cm diameter fluidized bed loop is used for the experiments. Mono-sized spherical Delrin particles (d(p) = 3.34 - mm, rho(s )= 1400 kg/m(3)) with relatively low Stokes number (approximate to 100) are tested as the solid phase. The root mean square (RMS) of the solid fraction fluctuations in the near-wall region was found to be 3-4 times higher than the RMS at the center of the bed. The maximum magnitude of the fluctuations occurred at the bulk solid fraction ((C) over bar) of 0.31. Increasing (C) over bar had a notable effect on both the magnitudes and extent of the rates of decay in the power spectra. The spectra suggest that void fraction waves arising naturally in the bed act as an external driving force coupled with the turbulent spectrum, which leads to a predominantly two-dimensional turbulence within the bed. Cross-sectional-averaged fluctuations for a wide range of (C) over bar were found to be in good agreement with previous studies. Since most of the previous experimental studies on solid fraction fluctuations have been limited to cross-sectional-averaged values, the local measurements reported here provide a better understanding of the nature of small-scale fluctuations. (C) 2019 Published by Elsevier Ltd.
C1 [Marefatallah, Maedeh; Breakey, David; Sanders, R. Sean] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB T6G 1H9, Canada.
RP Sanders, RS (reprint author), Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB T6G 1H9, Canada.
EM sean.sanders@ualberta.ca
OI Breakey, David/0000-0002-9272-8845
FU Natural Sciences and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada;
   Canadian Natural Resources Limited; Nexen Inc.; Paterson & Cooke Canada
   Inc.; Shell Canada Energy; Saskatchewan Research Council; Suncor Energy
   Inc.; Syncrude Canada Ltd.; Teck Resources Ltd.; Total American Services
   through the NSERC Industrial Chair in Pipeline Transport Processes
FX This work has been funded by the Natural Sciences and Engineering
   Research Council of Canada (NSERC), Canadian Natural Resources Limited,
   Nexen Inc., Paterson & Cooke Canada Inc., Shell Canada Energy,
   Saskatchewan Research Council, Suncor Energy Inc., Syncrude Canada Ltd.,
   Teck Resources Ltd., and Total American Services through the NSERC
   Industrial Chair in Pipeline Transport Processes.
CR Abbas M, 2010, AICHE J, V56, P2523, DOI 10.1002/aic.12192
   Azzi A, 2010, 7 INT C MULT FLOW FL
   Azzopardi BJ, 2008, CHEM ENG SCI, V63, P2548, DOI 10.1016/j.ces.2008.02.013
   Bolton GT, 2004, CHEM ENG SCI, V59, P1989, DOI 10.1016/j.ces.2004.01.049
   BUYEVICH YA, 1994, CHEM ENG SCI, V49, P1229, DOI 10.1016/0009-2509(94)85093-3
   DIDWANIA AK, 1981, INT J MULTIPHAS FLOW, V7, P563, DOI 10.1016/0301-9322(81)90031-8
   Dyakowski T, 2000, POWDER TECHNOL, V112, P174, DOI 10.1016/S0032-5910(00)00292-8
   El-Kaissy M. M., 1976, International Journal of Multiphase Flow, V2, P379, DOI 10.1016/0301-9322(76)90021-5
   Epstein N, 2003, INT J CHEM REACT ENG, V1, DOI 10.2202/1542-6580.1010
   Fangary YS, 1998, POWDER TECHNOL, V95, P61, DOI 10.1016/S0032-5910(97)03317-2
   Gevrin F, 2008, CHEM ENG SCI, V63, P2450, DOI 10.1016/j.ces.2008.01.031
   Gevrin F, 2010, AICHE J, V56, P2781, DOI 10.1002/aic.12209
   Gibilaro L, 1990, 2 PHASE FLOW WAVES, P56
   HAM JM, 1990, INT J MULTIPHAS FLOW, V16, P171, DOI 10.1016/0301-9322(90)90052-K
   Hashemi SA, 2014, INT J MULTIPHAS FLOW, V66, P46, DOI 10.1016/j.ijmultiphaseflow.2014.06.007
   Hashemi S. A, 2013, THESIS
   Industrial Tomography Systems, 2014, ITS TOM TOOLS V7 32
   Kechroud N, 2010, POWDER TECHNOL, V200, P149, DOI 10.1016/j.powtec.2010.02.018
   KOTRE CJ, 1994, PHYSIOL MEAS, V15, pA125, DOI 10.1088/0967-3334/15/2A/017
   KRAICHNAN RH, 1967, PHYS FLUIDS, V10, P1417, DOI 10.1063/1.1762301
   LEMMIN U, 1974, J GEOPHYS RES, V79, P3442, DOI 10.1029/JC079i024p03442
   Lilly DK, 1969, PHYS FLUIDS       S2, V12, pII, DOI DOI 10.1063/1.1692444
   Norman JT, 2005, CAN J CHEM ENG, V83, P24
   Pope S. B., 2000, TURBULENT FLOWS
   SOMMERIA J, 1982, J FLUID MECH, V118, P507, DOI 10.1017/S0022112082001177
   Thais L, 1996, J FLUID MECH, V328, P313, DOI 10.1017/S0022112096008749
   Wang M, 2002, MEAS SCI TECHNOL, V13, P101, DOI 10.1088/0957-0233/13/1/314
   Wei K, 2015, FLOW MEAS INSTRUM, V46, P292, DOI 10.1016/j.flowmeasinst.2015.08.001
   Zenit R, 1997, J FLUID MECH, V353, P261, DOI 10.1017/S0022112097007647
   Zenit R, 2000, INT J MULTIPHAS FLOW, V26, P763, DOI 10.1016/S0301-9322(99)00066-X
   Zhu KW, 2003, CHEM ENG SCI, V58, P4225, DOI 10.1016/S0009-2509(03)00306-3
NR 31
TC 0
Z9 0
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 439
EP 449
DI 10.1016/j.ces.2019.03.075
PG 11
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600036
DA 2020-05-12
ER

PT J
AU Bertei, A
   Tellini, B
   Mauri, R
AF Bertei, A.
   Tellini, B.
   Mauri, R.
TI Dynamic transition of dendrite orientation in the diffusive spinodal
   decomposition of binary mixtures under a thermal gradient
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Phase separation; Diffuse interface model; Simulation; Heat and mass
   transport
ID HEAT-TRANSFER ENHANCEMENT; PHASE-SEPARATION; LIQUID-LIQUID;
   THERMODYNAMIC THEORY; NUCLEATION; MORPHOLOGY; INTERFACE; SEGREGATION;
   NONUNIFORM; KINETICS
AB While the spinodal decomposition of mixtures in unbounded systems has been largely investigated, little is known about phase separation constrained within a slab. In this study, spinodal decomposition of a very viscous regular binary mixture bounded within two walls cooled at different temperatures is simulated by using the diffuse interface model in 2D. Under a temperature gradient, phase separation starts from the cooler wall forming dendritic structures growing anisotropically with time. Two remarkably different dynamics are identified depending on whether heat propagates slower or faster than mass. For small thermal conductivity (i.e., small Lewis number), dendrites grow parallelly to the temperature gradient, keeping such an alignment until the steady-state. On the other hand, for large Lewis number, during the early stages phase separation proceeds within stripes oriented along iso-temperature lines, i.e., with dendrites aligned perpendicularly to the temperature gradient, which, however, gradually shift their orientation parallel to the temperature gradient as the steady-state is approached. Such a dynamic transition of dendrite orientation upon a temperature gradient when heat propagates faster than mass is found to hold also for non-equimolar mixtures and for different species thermal conductivities. These results shed light on the dynamics of phase separation in constrained systems and anisotropic conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bertei, A.; Mauri, R.] Univ Pisa, Dept Civil & Ind Engn, Largo Lucio Lazzarino 2, I-56122 Pisa, Italy.
   [Tellini, B.] Univ Pisa, Dept Engn Energy Syst Terr & Construct, Largo Lucio Lazzarino 2, I-56122 Pisa, Italy.
RP Bertei, A (reprint author), Univ Pisa, Dept Civil & Ind Engn, Largo Lucio Lazzarino 2, I-56122 Pisa, Italy.
EM antonio.bertei@unipi.it
RI Mauri, Roberto/O-6852-2017
OI Mauri, Roberto/0000-0001-9594-0035; Bertei, Antonio/0000-0002-3202-6825
FU PROT-ONE project, FAR-FAS 2014 - Regione Toscana (Italy) [CUP
   4421.02102014.07200099]
FX This work was supported by the PROT-ONE project, FAR-FAS 2014, CUP
   4421.02102014.07200099, funded by Regione Toscana (Italy). Helpful
   discussions with Dr. Andrea Lamorgese (University of Pisa) are
   gratefully acknowledged.
CR Bazant MZ, 2017, FARADAY DISCUSS, V199, P423, DOI 10.1039/c7fd00037e
   Bazant MZ, 2013, ACCOUNTS CHEM RES, V46, P1144, DOI 10.1021/ar300145c
   Bird RB, 2007, TRANSPORT PHENOMENA
   CAHN JW, 1961, ACTA METALL MATER, V9, P795, DOI 10.1016/0001-6160(61)90182-1
   CAHN JW, 1958, J CHEM PHYS, V28, P258, DOI 10.1063/1.1744102
   CAHN JW, 1965, J CHEM PHYS, V42, P93, DOI 10.1063/1.1695731
   Califano F, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2065887
   Chen LQ, 2002, ANNU REV MATER RES, V32, P113, DOI 10.1146/annurev.matsci.32.112001.132041
   Cogswell DA, 2015, PHYS REV E, V92, DOI 10.1103/PhysRevE.92.011301
   Colombani J, 2004, J NON-EQUIL THERMODY, V29, P389, DOI 10.1515/JNETDY.2004.063
   Comsol Inc, 2016, COMS MULT US GUID VE
   de Groot SR, 1962, NONEQUILIBRIUM THERM
   Debenedetti P. G., 1996, METASTABLE LIQUIDS C
   DEGENNES PG, 1980, J CHEM PHYS, V72, P4756, DOI 10.1063/1.439809
   DENBIGH KG, 1959, AICHE J, V5, P20, DOI 10.1002/aic.690050106
   Deshmukh KD, 2015, ENERG ENVIRON SCI, V8, P332, DOI 10.1039/c4ee03059a
   Di Fede F, 2012, INT J HEAT MASS TRAN, V55, P897, DOI 10.1016/j.ijheatmasstransfer.2011.10.019
   EVANS R, 1979, ADV PHYS, V28, P143, DOI 10.1080/00018737900101365
   Evans R., 1992, FUNDAMENTALS INHOMOG, P85
   Farise S, 2012, EXP THERM FLUID SCI, V42, P38, DOI 10.1016/j.expthermflusci.2012.03.024
   GUNTON JD, 1983, PHASE TRANSITION CRI, V8
   Han DZ, 2015, J COMPUT PHYS, V290, P139, DOI 10.1016/j.jcp.2015.02.046
   Herminghaus S, 1998, SCIENCE, V282, P916, DOI 10.1126/science.282.5390.916
   Hildebrand J. H, 1970, REGULAR RELATED SOLU, DOI [10.1002/aic.690170304, DOI 10.1002/AIC.690170304]
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864
   HOHENBERG PC, 1977, REV MOD PHYS, V49, P435, DOI 10.1103/RevModPhys.49.435
   Keestra BJ, 2003, PHYS FLUIDS, V15, P2567, DOI 10.1063/1.1597454
   KEMPERS LJTM, 1989, J CHEM PHYS, V90, P6541, DOI 10.1063/1.456321
   Krankel M, 2018, SPRINGER P MATH STAT, V237, P243, DOI [10.1007/978-3-319-91548-7_19, DOI 10.1007/978-3-319-91548-7_19]
   Krishna R, 2015, CHEM SOC REV, V44, P2812, DOI 10.1039/c4cs00440j
   Lamorgese A, 2017, PHYS REP, V675, P1, DOI 10.1016/j.physrep.2017.01.002
   Lamorgese AG, 2008, INT J MULTIPHAS FLOW, V34, P987, DOI 10.1016/j.ijmultiphaseflow.2008.03.003
   Lamorgese AG, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1863752
   Lamorgese AG, 2011, MILAN J MATH, V79, P597, DOI 10.1007/s00032-011-0171-6
   LANGER JS, 1971, ANN PHYS-NEW YORK, V65, P53, DOI 10.1016/0003-4916(71)90162-X
   LANGER JS, 1980, PHYS REV A, V21, P948, DOI 10.1103/PhysRevA.21.948
   Li W, 2000, CHEM ENG J, V78, P179, DOI 10.1016/S1385-8947(00)00137-6
   LIFSHITZ EM, 1984, PHYS KINETICS
   Loh ND, 2017, NAT CHEM, V9, P77, DOI [10.1038/nchem.2618, 10.1038/NCHEM.2618]
   Mauri R, 1996, PHYS REV E, V53, P2613, DOI 10.1103/PhysRevE.53.2613
   Mauri R, 2013, NONEQUILIBRIUM THERM, DOI [10.1007/978-94-007-5461-4, DOI 10.1007/978-94-007-5461-4]
   Molin D, 2008, CHEM ENG SCI, V63, P2402, DOI 10.1016/j.ces.2008.01.028
   Onsager L, 1931, PHYS REV, V37, P405, DOI 10.1103/PhysRev.37.405
   Otto F, 2013, COMMUN MATH SCI, V11, P441
   Pismen LM, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.021603
   Poesio P, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.066306
   Prusty M, 2007, CHEM ENG SCI, V62, P1825, DOI 10.1016/j.ces.2006.12.023
   ROWLINSON JS, 1979, J STAT PHYS, V20, P197, DOI 10.1007/BF01011513
   Russ J.0, 2000, PRACTICAL STEREOLOGY, DOI [10.1007/978-1-4615-1233-2, DOI 10.1007/978-1-4615-1233-2, 10.1007/978-1-4615-1233-2.]
   SANDLER SL, 1999, CHEM ENG THERMODYNAM
   SIGGIA ED, 1979, PHYS REV A, V20, P595, DOI 10.1103/PhysRevA.20.595
   Thiele U, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2824404
   vandeWitte P, 1996, J MEMBRANE SCI, V117, P1, DOI 10.1016/0376-7388(96)00088-9
   Vladimirova N, 2004, CHEM ENG SCI, V59, P2065, DOI 10.1016/j.ces.2004.01.052
   Vladimirova N, 1998, PHYS REV E, V58, P7691, DOI 10.1103/PhysRevE.58.7691
   Vladimirova N, 1999, PHYS REV E, V60, P6968, DOI 10.1103/PhysRevE.60.6968
   Vonka M, 2016, CHEM ENG J, V284, P357, DOI 10.1016/j.cej.2015.08.105
   Vonka M, 2012, CHEM ENG J, V207, P895, DOI 10.1016/j.cej.2012.06.091
   WIENER O, 1912, ABH SACHS GES AKAD W, V32, P509
   WONG NC, 1977, J CHEM PHYS, V66, P4707, DOI 10.1063/1.433684
   Xiao XP, 2016, J ALLOY COMPD, V660, P178, DOI 10.1016/j.jallcom.2015.11.103
   Zhang RY, 2008, MACROMOLECULES, V41, P6818, DOI 10.1021/ma800646s
NR 62
TC 1
Z9 1
U1 3
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 450
EP 463
DI 10.1016/j.ces.2019.04.014
PG 14
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600037
DA 2020-05-12
ER

PT J
AU Loubiere, C
   Delafosse, A
   Guedon, E
   Chevalot, I
   Toye, D
   Olmos, E
AF Loubiere, C.
   Delafosse, A.
   Guedon, E.
   Chevalot, I
   Toye, D.
   Olmos, E.
TI Dimensional analysis and CFD simulations of microcarrier
   'just-suspended' state in mesenchymal stromal cells bioreactors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microcarrier suspension; Bioreactor; Critical just-suspended agitation
   rate; Computational Fluid Dynamics (CFD); Dimensional analysis
ID STEM-CELLS; COMPLETE SUSPENSION; IMPELLER CLEARANCE; EXPANSION; CULTURE;
   LIQUID; AGITATION; SOLIDS; SCALE; SPEED
AB Large-scale mesenchymal stem/stromal cells culture uses 3D culture systems involving spherical solid particles, called microcarriers. Cells adhere on these spheres, which are then set in suspension in stirred tank bioreactors. This work was more particularly focused on the determination of the critical impeller agitation rate N-js, allowing complete beads suspension. It is indeed generally assumed that this value is a good compromise between sufficient nutrients homogenization, mass transfer and minimization of hydromechanical stress encountered by the cells. However, no robust correlation predicting N-js in the case of microcarriers can be found in literature. To fill this lack, a set of various operating conditions was carried out, dealing with geometrical variables and two different microcarriers, and N-js were experimentally determined for 140 conditions. An empirical correlation was established and a dimensional analysis was performed, showing that the impact of the particle concentration on N-js was function of the impeller design. Moreover, two dimensionless numbers characterizing the number of particle and an Archimede number applied on the particle cloud were found to better describe the impact of particle diameter and density on N-js. Simultaneously, a strategy based on Computational Fluid Dynamics simulations was conducted in order to predict N-js and was validated with the N-js experimental values. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Loubiere, C.; Guedon, E.; Chevalot, I; Olmos, E.] Univ Lorraine, CNRS, Lab React & Genie Proc, LRGP, F-54000 Nancy, France.
   [Delafosse, A.; Toye, D.] Univ Liege, Lab Chem Engn, Allee Chim 3,B6C, B-4000 Liege, Belgium.
   [Delafosse, A.; Toye, D.] Fonds Rech Sci FRS FNRS, Rue Egemont 5, B-1000 Brussels, Belgium.
RP Olmos, E (reprint author), Univ Lorraine, CNRS, Lab React & Genie Proc, LRGP, F-54000 Nancy, France.
EM eric.olmos@univ.lorraine.fr
OI chevalot, isabelle/0000-0002-8807-5351; GUEDON,
   Emmanuel/0000-0001-8758-3779
FU French Agence Nationale de la Recherche (ANR)French National Research
   Agency (ANR); Interreg VA Grande Region program
FX The authors would like to thank the French Agence Nationale de la
   Recherche (ANR) and the Interreg VA Grande Region program for their
   financial support. They also acknowledge Fabrice Blanchard (LRGP, Nancy)
   and Thierry Salmon (PEPs, Liege) for their technical contribution to
   this work.
CR Aravinth S, 1996, BIOPROCESS ENG, V14, P97, DOI 10.1007/s004490050188
   Armenante PM, 1998, CHEM ENG SCI, V53, P1757, DOI 10.1016/S0009-2509(98)00001-3
   BALDI G, 1978, CHEM ENG SCI, V33, P21, DOI 10.1016/0009-2509(78)85063-5
   CHERRY RS, 1988, BIOTECHNOL BIOENG, V32, P1001, DOI 10.1002/bit.260320808
   CHUDACEK MW, 1985, CHEM ENG SCI, V40, P385, DOI 10.1016/0009-2509(85)85100-9
   Collignon ML, 2016, BIOCHEM ENG J, V108, P30, DOI 10.1016/j.bej.2015.10.020
   Collignon ML, 2010, CHEM ENG SCI, V65, P5929, DOI 10.1016/j.ces.2010.08.027
   CROUGHAN MS, 1988, BIOTECHNOL BIOENG, V32, P975, DOI 10.1002/bit.260320805
   CROUGHAN MS, 1987, BIOTECHNOL BIOENG, V29, P130, DOI 10.1002/bit.260290117
   Delafosse A, 2018, CHEM ENG SCI, V180, P52, DOI 10.1016/j.ces.2018.01.001
   Ferrari C, 2012, BIOTECHNOL PROGR, V28, P780, DOI 10.1002/btpr.1527
   Fluent, 2013, ANS FLUENT THEOR GUI
   Heathman TRJ, 2018, BIOCHEM ENG J, V136, P9, DOI 10.1016/j.bej.2018.04.011
   Hewitt CJ, 2011, BIOTECHNOL LETT, V33, P2325, DOI 10.1007/s10529-011-0695-4
   Ibrahim S, 2004, CHEM ENG RES DES, V82, P1082, DOI 10.1205/cerd.82.9.1082.44161
   Jossen V, 2014, PHARM BIOPROCESS, V2, P311, DOI 10.4155/PBP.14.29
   Kaiser SC, 2013, CHEM-ING-TECH, V85, P95, DOI 10.1002/cite.201200180
   Kee NCS, 2002, CAN J CHEM ENG, V80, P721
   Kraume M., 1992, CHEM ENG TECHNOL, V15, P313, DOI DOI 10.1002/CEAT.270150505
   Lawson T, 2017, BIOCHEM ENG J, V120, P49, DOI 10.1016/j.bej.2016.11.020
   Ma T, 2016, BIOCHEM ENG J, V108, P44, DOI 10.1016/j.bej.2015.07.014
   Maul TM, 2011, BIOMECH MODEL MECHAN, V10, P939, DOI 10.1007/s10237-010-0285-8
   Mersmann A, 1998, CHEM ENG PROCESS, V37, P503, DOI 10.1016/S0255-2701(98)00057-9
   Montante G, 2001, CHEM ENG SCI, V56, P3751, DOI 10.1016/S0009-2509(01)00089-6
   Montante G, 1999, CAN J CHEM ENG, V77, P649, DOI 10.1002/cjce.5450770405
   NEINOW AW, 1968, CHEM ENG SCI, V23, P1453
   Olmos E, 2015, CHEM ENG SCI, V122, P545, DOI 10.1016/j.ces.2014.08.063
   Rafiq QA, 2016, BIOTECHNOL J, V11, P473, DOI 10.1002/biot.201400862
   Rafiq QA, 2013, BIOTECHNOL LETT, V35, P1233, DOI 10.1007/s10529-013-1211-9
   RAO KSMSR, 1988, AICHE J, V34, P1332
   Rowley JA, 2012, BIOPROCESS INT, V10, P7
   Schirmaier C, 2014, ENG LIFE SCI, V14, P292, DOI 10.1002/elsc.201300134
   Schnitzler AC, 2016, BIOCHEM ENG J, V108, P3, DOI 10.1016/j.bej.2015.08.014
   Simaria AS, 2014, BIOTECHNOL BIOENG, V111, P69, DOI 10.1002/bit.25008
   Stolzing A, 2008, MECH AGEING DEV, V129, P163, DOI 10.1016/j.mad.2007.12.002
   Tamburini A, 2012, INT J NONLIN SCI NUM, V13, P427, DOI 10.1515/ijnsns-2012-0027
   Tamburini A, 2011, CHEM ENG J, V178, P324, DOI 10.1016/j.cej.2011.10.016
   VANWEZEL AL, 1967, NATURE, V216, P64, DOI 10.1038/216064a0
   WICHTERLE K, 1988, CHEM ENG SCI, V43, P467, DOI 10.1016/0009-2509(88)87007-6
   ZWIETERING TN, 1958, CHEM ENG SCI, V8, P244, DOI 10.1016/0009-2509(58)85031-9
NR 40
TC 1
Z9 1
U1 2
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 464
EP 474
DI 10.1016/j.ces.2019.04.001
PG 11
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600038
DA 2020-05-12
ER

PT J
AU Bankole, T
   Bhattacharyya, D
   Gebreslassie, B
   Diwekar, U
AF Bankole, Temitayo
   Bhattacharyya, Debangsu
   Gebreslassie, Berhane
   Diwekar, Urmila
TI A biomimetic approach to fast selection of optimal controlled variables
   using multiagent algorithms and a decomposition approach
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Controlled variable selection; Multiagent optimization; Biomimetic;
   Connectivity; Decomposition
ID CONTROL-STRUCTURE DESIGN; SELF-OPTIMIZING CONTROL; PLANTWIDE CONTROL;
   OPTIMIZATION; FRAMEWORK
AB Selection of primary controlled variables (CVs) with due consideration of economic loss and ease of control is an important step for achieving optimal plant operation under design and off-design conditions. However, the computational expense of the combinatorial optimization step that is undertaken for CV selection renders the existing approaches unaffordable for fast selection of optimal CVs. Two approaches are proposed in this paper for improving the computational efficiency of the optimization step. Typically, the CV selection process is typically executed by considering the entire plant together. Opposed to that, the first approach proposed here seeks to decompose the process plant into multiple partitions based on the connectivity strength. Then the CV selection algorithm can be executed on each partition independently. The decomposition algorithm is biomimetic and has been developed, in analogy to neuroscience, mimicking how the information about the connectivity information is extracted using a dynamic casual model. This approach can significantly decrease the number of combinatorial optimization problems that needs to be solved and facilitates parallelization of the solution. In the second approach, a multiagent optimization framework is proposed that utilizes metaheuristic optimization strategies such as the efficient ant colony algorithm, simulated annealing and the genetic algorithm. These two approaches can be used by themselves or in combination. This framework enables cooperative search by a group of algorithmic agents facilitated through an information sharing protocol. These two approaches are applied to a toy problem and an acid gas removal unit as part of an integrated gasification combined cycle. The study shows how the computational time and economic and control performance of the optimal CV sets vary as the number of partitions are changed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bankole, Temitayo; Bhattacharyya, Debangsu] West Virginia Univ, Dept Chem & Biomed Engn, Morgantown, WV 26506 USA.
   [Gebreslassie, Berhane; Diwekar, Urmila] Viswamitra Res Inst, Chicago, IL USA.
RP Bhattacharyya, D (reprint author), West Virginia Univ, Dept Chem & Biomed Engn, Morgantown, WV 26506 USA.
EM Debangsu.Bhattacharyya@mail.wvu.edu
OI Bankole, Temitayo/0000-0002-5840-9824; Diwekar,
   Urmila/0000-0002-0933-5865
FU U.S DOE through the project titled "Development of Integrated Biomimetic
   Framework with Intelligent Monitoring, Cognition and Decision
   Capabilities for Control of Advanced Energy Plants" [DE-FE0012451]
FX The work was funded by the U.S DOE through the project titled
   "Development of Integrated Biomimetic Framework with Intelligent
   Monitoring, Cognition and Decision Capabilities for Control of Advanced
   Energy Plants" (Grant # DE-FE0012451).
CR Arbel A, 1996, IND ENG CHEM RES, V35, P2215, DOI 10.1021/ie9507080
   Bankole T, 2018, J PROCESS CONTR, V71, P116, DOI 10.1016/j.jprocont.2018.09.002
   Bankole T, 2018, COMPUT CHEM ENG, V109, P30, DOI 10.1016/j.compchemeng.2017.10.025
   Bankole T, 2016, P AMER CONTR CONF, P5038, DOI 10.1109/ACC.2016.7526152
   Bhattacharyya D, 2011, IND ENG CHEM RES, V50, P1674, DOI 10.1021/ie101502d
   Braccia L, 2015, IEEE C PUBLICATIONS, P1
   Braccia L, 2017, IND ENG CHEM RES, V56, P11228, DOI 10.1021/acs.iecr.7b02270
   Bucklin R, 1984, ENERGY PROG US, V4
   Cao Y, 2008, COMPUT CHEM ENG, V32, P2306, DOI 10.1016/j.compchemeng.2007.11.011
   Dorigo M, 1991, ANT COLONY OPTIMIZAT, P101
   FISHER WR, 1985, CHEM ENG RES DES, V63, P353
   Gebreslassie B. H, 2015, AICHE ANN M 2015 SAL
   Gebreslassie BH, 2018, CLEAN TECHNOL ENVIR, V20, P137, DOI 10.1007/s10098-017-1464-4
   Gebreslassie BH, 2017, CHEM ENG SCI, V159, P194, DOI 10.1016/j.ces.2016.05.026
   Halvorsen IJ, 2003, IND ENG CHEM RES, V42, P3273, DOI 10.1021/ie020833t
   Hayes-Roth F, 1975, ACM SIGART B, P15
   Jaschke J, 2017, ANNU REV CONTROL, V43, P199, DOI 10.1016/j.arcontrol.2017.03.001
   Jones D, 2014, COMPUT CHEM ENG, V71, P220, DOI 10.1016/j.compchemeng.2014.08.004
   Kariwala V, 2008, IND ENG CHEM RES, V47, P1150, DOI 10.1021/ie070897+
   Kariwala V, 2009, COMPUT CHEM ENG, V33, P1402, DOI 10.1016/j.compchemeng.2009.01.014
   Kim KJ, 2002, IND ENG CHEM RES, V41, P1276, DOI 10.1021/ie0101689
   KIRKPATRICK S, 1984, J STAT PHYS, V34, P975, DOI 10.1007/BF01009452
   Konda NVSNM, 2005, IND ENG CHEM RES, V44, P8300, DOI 10.1021/ie048951z
   Kookos IK, 2016, AICHE J, V62, P3056, DOI 10.1002/aic.15284
   Luppi PA, 2018, IND ENG CHEM RES, V57, P268, DOI 10.1021/acs.iecr.7b02966
   Luyben ML, 1997, AICHE J, V43, P3161, DOI 10.1002/aic.690431205
   McAvoy T, 2003, IND ENG CHEM RES, V42, P6155, DOI 10.1021/ie0300225
   MORARI M, 1980, AICHE J, V26, P220, DOI 10.1002/aic.690260205
   Narraway L. T., 1991, Journal of Process Control, V1, P243, DOI 10.1016/0959-1524(91)85015-B
   Psaltis A, 2013, COMPUT CHEM ENG, V52, P240, DOI 10.1016/j.compchemeng.2013.01.005
   RIJNSDORP JE, 1991, INTEGRATED PROCESS C
   Salgado ME, 2004, INT J CONTROL, V77, P367, DOI 10.1080/0020717042000197631
   Samuelsson P, 2005, IEEE T CONTR SYST T, V13, P955, DOI 10.1109/TCST.2005.854322
   Skogestad S, 2004, COMPUT CHEM ENG, V28, P219, DOI 10.1016/j.compchemeng.2003.08.002
   Skogestad S, 2007, MULTIVARIABLE FEEDBA
   Yelchuru R., 2010, IFAC P, V43, P61
   Zheng A, 1999, AICHE J, V45, P1255, DOI 10.1002/aic.690450611
   Zitney S. E, 2012, P 29 ANN INT PITTSB
   Zumoffen D, 2013, COMPUT CHEM ENG, V50, P54, DOI 10.1016/j.compchemeng.2012.11.004
NR 39
TC 0
Z9 0
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 475
EP 488
DI 10.1016/j.ces.2019.04.007
PG 14
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600039
OA Bronze
DA 2020-05-12
ER

PT J
AU Ibarra, R
   Nossen, J
   Tutkun, M
AF Ibarra, Roberto
   Nossen, Jan
   Tutkun, Murat
TI Two-phase gas-liquid flow in concentric and fully eccentric annuli. Part
   I: Flow patterns, holdup, slip ratio and pressure gradient
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Annulus flow; Concentric; Fully eccentric; Flow regimes; Flow regime
   transitions; Liquid holdup
ID VOID FRACTION; SLUG FLOW; VELOCITY
AB Horizontal and upward low-inclination gas-water and gas-oil flows are investigated using an annulus pipe configuration in a high-pressure system (similar to 400 kPa). The annulus test section, or the so-called pipe-in-pipe configuration, consists of an outer pipe of 99 mm inside diameter and an inner pipe of 50 mm outside diameter. Two different vertical positions of the inner pipe with respect to outer pipe have been tested; namely concentric configuration where both pipes have the same centreline and fully eccentric where the inner pipe is placed at the bottom wall of outer pipe. The flow is studied using high-speed photography, differential pressure transducers, and broad-beam gamma densitometers to characterise the flow as function of the liquid phase properties, annulus eccentricity, and pipe inclination. Flow regime maps reveal that slug flow appears to be the most common flow feature across the conditions studied in this paper. Flow in the eccentric annulus shows a more consistent behaviour (i.e. well-defined flow structures axially and in time) than that observed in the concentric annulus. Gas-oil flows show more stable phase fraction behaviour across the cross-section compared to that observed in gas-water flows in which the interface shows significant activity promoting the formation of droplets and ligaments that break from the liquid film. This is especially the case with the concentric annulus configuration. The oil phase regardless of the geometrical configuration tends to fully wet the pipe (made of PVC) as the gas velocity increases, creating a continuous film along the pipe walls. Conversely, the thin film in gas-water flow is not continuous. Discontinuity in the thin film increases with an increase in effective pipe roughness. Given the same inlet flow conditions, the concentric annulus configuration causes larger pressure drop along the pipe than that obtained in the eccentric. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ibarra, Roberto; Nossen, Jan; Tutkun, Murat] Inst Energy Technol IFE, N-2007 Keller, Norway.
RP Ibarra, R (reprint author), Inst Energy Technol, Dept Fluid Flow & Environm Technol, Inst Veien 18, N-2007 Kjeller, Norway.
EM roberto.jose.ibarra-hernandez@ife.no; jan.nossen@ife.no;
   murat.tutkun@ife.no
RI Tutkun, Murat/AAD-2753-2020
FU Research Council of Norway through the PETROMAKS2 programmeResearch
   Council of Norway
FX This work has been performed thanks to the funding of the Research
   Council of Norway through the PETROMAKS2 programme. The authors would
   like to express their gratitude to Joar Amundsen and Hans-Gunnar
   Sleipnaes for their assistance during the experimental campaign.
CR CAETANO EF, 1992, J ENERG RESOUR-ASME, V114, P1, DOI 10.1115/1.2905917
   Choueiri GH, 2014, J FLUID MECH, V752, P521, DOI 10.1017/jfm.2014.343
   Das G, 1999, J FLUID ENG-T ASME, V121, P895, DOI 10.1115/1.2823552
   Dieck R. H., 2006, MEASUREMENT UNCERTAI
   Dou HS, 2010, J PETROL SCI ENG, V73, P41, DOI 10.1016/j.petrol.2010.05.003
   Ekberg NP, 1999, NUCL ENG DES, V192, P59, DOI 10.1016/S0029-5493(99)00078-3
   Julia JE, 2011, INT J HEAT FLUID FL, V32, P164, DOI 10.1016/j.ijheatfluidflow.2010.09.003
   HANKS RW, 1971, IND ENG CHEM FUND, V10, P105, DOI 10.1021/i160037a018
   Harvel GD, 1999, FLOW MEAS INSTRUM, V10, P259, DOI 10.1016/S0955-5986(99)00008-4
   HASAN AR, 1992, INT J MULTIPHAS FLOW, V18, P279, DOI 10.1016/0301-9322(92)90089-Y
   Hibiki T, 2003, INT J HEAT MASS TRAN, V46, P1479, DOI 10.1016/S0017-9310(02)00421-0
   Hu B, 2010, 7 N AM C MULT TECH B
   Hu B, 2009, 14 INT C MULT PROD T
   Ibarra R, 2018, CHEM ENG SCI, V192, P774, DOI 10.1016/j.ces.2018.08.022
   JONSSON VK, 1966, J FLUID MECH, V25, P65, DOI 10.1017/S0022112066000053
   Karami H, 2017, INT J MULTIPHAS FLOW, V89, P45, DOI 10.1016/j.ijmultiphaseflow.2016.10.011
   KELESSIDIS VC, 1989, INT J MULTIPHAS FLOW, V15, P173, DOI 10.1016/0301-9322(89)90069-4
   KELESSIDIS VC, 1990, INT J MULTIPHAS FLOW, V16, P375, DOI 10.1016/0301-9322(90)90070-Y
   LIN PY, 1987, INT J MULTIPHAS FLOW, V13, P13, DOI 10.1016/0301-9322(87)90003-6
   Mantilla I, 2012, 8 N AM C MULT TECHN
   Nicklin D.J., 1962, T I CHEM ENG-LOND, V40, P61
   Osamusali S. I., 1988, ASME, V72, P63
   Ozar B, 2008, CHEM ENG SCI, V63, P3998, DOI 10.1016/j.ces.2008.04.042
   Ozbayoglu AM, 2012, J PETROL SCI ENG, V81, P31, DOI 10.1016/j.petrol.2011.12.008
   Parsi M, 2017, INT J MULTIPHAS FLOW, V96, P1, DOI 10.1016/j.ijmultiphaseflow.2017.06.007
   Soedarmo A, 2018, INT J MULTIPHAS FLOW, V103, P61, DOI 10.1016/j.ijmultiphaseflow.2018.02.001
   Sveen J. K, 2013, SUBSEA OPTICS IMAGIN, V14, P353
   Tayebi D, 2000, INT J MULTIPHAS FLOW, V26, P741, DOI 10.1016/S0301-9322(99)00054-3
   Wongwises S, 2006, EXP THERM FLUID SCI, V30, P345, DOI 10.1016/j.expthermflusci.2005.08.002
NR 29
TC 2
Z9 2
U1 2
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 489
EP 500
DI 10.1016/j.ces.2019.01.064
PG 12
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600040
DA 2020-05-12
ER

PT J
AU Ibarra, R
   Nossen, J
   Tutkun, M
AF Ibarra, Roberto
   Nossen, Jan
   Tutkun, Murat
TI Two-phase gas-liquid flow in concentric and fully eccentric annuli. Part
   II: Model development, flow regime transition algorithm and pressure
   gradient
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Annulus flow; Concentric; Fully eccentric; Flow regimes; Model; Flow
   regime transitions
ID SLUG FLOW; PATTERN TRANSITIONS; MECHANISTIC MODEL; FRICTION FACTOR;
   VELOCITY; STEADY; HOLDUP; WAVES
AB A model has been developed for the prediction of flow regime transitions, liquid holdup and pressure gradient for horizontal and low-inclination upward two-phase gas-liquid flow in annuli. The model is based on the hydrodynamic behaviour of slug flow and closure relationships developed for full pipe flow, which are adapted to account for the annulus diameter ratio and eccentricity. This includes the improvement of the model for the prediction of the single-phase friction factor in annuli. Model predictions are compared with the experimental data presented in Ibarra et al. (2019) and the model shows good agreement for gas-water and gas-oil flow in both concentric and fully eccentric annuli. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ibarra, Roberto; Nossen, Jan; Tutkun, Murat] Inst Energy Technol IFE, N-2007 Kjeller, Norway.
RP Ibarra, R (reprint author), Inst Energy Technol, Dept Fluid Flow & Environm Technol, Inst Veien 18, N-2007 Kjeller, Norway.
EM roberto.jose.ibarra-hernandez@ife.no; jan.nossen@ife.no;
   murat.tutkun@ife.no
RI Tutkun, Murat/AAD-2753-2020
FU Research Council of Norway through the PETROMAKS2 programmeResearch
   Council of Norway
FX This work has been performed thanks to the funding of the Research
   Council of Norway through the PETROMAKS2 programme. The authors would
   like to express their gratitude to Joar Amundsen and Hans-Gunnar
   Sleipnaes for their assistance during the experimental campaign.
CR ANDRITSOS N, 1987, AICHE J, V33, P444, DOI 10.1002/aic.690330310
   BARNEA D, 1985, INT J MULTIPHAS FLOW, V11, P43, DOI 10.1016/0301-9322(85)90004-7
   CAETANO EF, 1992, J ENERG RESOUR-ASME, V114, P1, DOI 10.1115/1.2905917
   COHEN LS, 1968, J FLUID MECH, V31, P467, DOI 10.1017/S0022112068000285
   Das G, 1999, J FLUID ENG-T ASME, V121, P902, DOI 10.1115/1.2823553
   Julia JE, 2011, INT J HEAT FLUID FL, V32, P993, DOI 10.1016/j.ijheatfluidflow.2011.06.001
   GREGORY GA, 1978, INT J MULTIPHAS FLOW, V4, P33, DOI 10.1016/0301-9322(78)90023-X
   Grolman E, 1997, CHEM ENG SCI, V52, P4461, DOI 10.1016/S0009-2509(97)00291-1
   HASAN AR, 1992, INT J MULTIPHAS FLOW, V18, P279, DOI 10.1016/0301-9322(92)90089-Y
   Ibarra R, 2019, CHEM ENG SCI, V203, P489, DOI 10.1016/j.ces.2019.01.064
   Ibarra R, 2018, CHEM ENG SCI, V192, P774, DOI 10.1016/j.ces.2018.08.022
   KELESSIDIS VC, 1989, INT J MULTIPHAS FLOW, V15, P173, DOI 10.1016/0301-9322(89)90069-4
   MISHIMA K, 1984, INT J HEAT MASS TRAN, V27, P723
   Nicklin D.J., 1962, T I CHEM ENG-LOND, V40, P61
   Nuland S, 1998, 3 INT C MULT FLOW JU
   Smith IE, 2015, J DISPER SCI TECHNOL, V36, P1394, DOI 10.1080/01932691.2014.989568
   Soedarmo A, 2018, J NAT GAS SCI ENG, V60, P125, DOI 10.1016/j.jngse.2018.10.006
   Sun X, 2004, EXP FLUIDS, V37, P458, DOI 10.1007/s00348-004-0809-z
   TAITEL Y, 1980, AICHE J, V26, P345, DOI 10.1002/aic.690260304
   TAITEL Y, 1976, AICHE J, V22, P47, DOI 10.1002/aic.690220105
   Taitel Y., 1990, ADV HEAT TRANSFER, P83, DOI [DOI 10.1016/S0065-2717(08)70026-1, 10.1016/S0065-2717(08)70026-1]
   Tzotzi C, 2013, INT J MULTIPHAS FLOW, V54, P43, DOI 10.1016/j.ijmultiphaseflow.2013.03.003
   Yu TT, 2010, SPE PROD OPER, V25, P285, DOI 10.2118/124181-PA
   Zhang HQ, 2003, J ENERG RESOUR-ASME, V125, P266, DOI 10.1115/1.1615246
   Zhang HQ, 2003, INT J MULTIPHAS FLOW, V29, P97, DOI 10.1016/S0301-9322(02)00111-8
   ZIGRANG DJ, 1982, AICHE J, V28, P514, DOI 10.1002/aic.690280323
NR 26
TC 0
Z9 0
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 501
EP 510
DI 10.1016/j.ces.2019.02.021
PG 10
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600041
DA 2020-05-12
ER

PT J
AU Bellan, S
   Kodama, T
   Matsubara, K
   Goko, N
   Cho, YS
   Inoue, K
AF Bellan, Selvan
   Kodama, Tatsuya
   Matsubara, Koji
   Goko, Nobuyuki
   Cho, Yun Seok
   Inoue, Kousuke
TI Heat transfer and particulate flow analysis of a 30 kW directly
   irradiated solar fluidized bed reactor for thermochemical cycling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Circulating fluidized bed; Solar thermochemical cycles; DEM modeling;
   Particle-gas flow; Solar fuels
ID HYDROGEN-PRODUCTION; COAL COKES; CFD-DEM; STEAM GASIFICATION;
   MASS-TRANSFER; POROUS CERIA; PLASMA-JET; PARTICLES; RADIATION; SYNGAS
AB To perform thermochemical cycles using non-volatile metal oxides to split water and produce hydrogen, a directly irradiated fluidized bed reactor is designed and fabricated for beam-down configuration. As the main aim of this investigation is to analyze the heat transfer and particulate flow of the reactor, chemically inert particles are used. A transient 3D heat and mass transfer model is formulated by the combined approach of discrete element method and computational fluid dynamics. The radiative transfer is solved using the discrete ordinate radiation model. Experimental validation is accomplished by the measured temperatures, obtained with the fluidized bed reactor prototype tested under 30 kW(th) high-flux solar simulator. The model is applied to analyze the granular flow characteristics and efficiency of the reactor for various superficial gas velocities and bed masses. The results indicate that higher gas flow rate increases the velocity and convection loss of the bed and decreases the bed temperature and efficiency of the reactor. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Bellan, Selvan; Goko, Nobuyuki] Niigata Univ, Ctr Transdisciplinary Res, 8050 Ikarashi 2 Nocho, Niigata 9502181, Japan.
   [Kodama, Tatsuya; Matsubara, Koji] Niigata Univ, Fac Engn, 8050 Ikarashi 2 Nocho, Niigata 9502181, Japan.
   [Bellan, Selvan; Kodama, Tatsuya; Matsubara, Koji; Goko, Nobuyuki; Cho, Yun Seok] Niigata Univ, Pacific Rim Solar Fuels Res Ctr, 8050 Ikarashi 2 Nocho, Niigata 9502181, Japan.
   [Cho, Yun Seok] Niigata Univ, Inst Sci & Technol, 8050 Ikarashi 2 Nocho, Niigata 9502181, Japan.
   [Inoue, Kousuke] Niigata Univ, Grad Sch Sci & Technol, 8050 Ikarashi 2 Nocho, Niigata 9502181, Japan.
RP Bellan, S (reprint author), Niigata Univ, Ctr Transdisciplinary Res, 8050 Ikarashi 2 Nocho, Niigata 9502181, Japan.; Bellan, S (reprint author), Niigata Univ, Pacific Rim Solar Fuels Res Ctr, 8050 Ikarashi 2 Nocho, Niigata 9502181, Japan.
EM selvan@eng.nligata-u.ac.jp
OI Gokon, Nobuyuki/0000-0002-8647-9336
FU Tenure Track Program, The Ministry of Education, Culture, and Sports,
   Science and Technology of Japan
FX This study has been supported by the Tenure Track Program, The Ministry
   of Education, Culture, and Sports, Science and Technology of Japan.
CR Abanades S, 2006, SOL ENERGY, V80, P1611, DOI 10.1016/j.solener.2005.12.005
   Ackermann S, 2017, INT J HEAT MASS TRAN, V107, P439, DOI 10.1016/j.ijheatmasstransfer.2016.11.032
   Agrafiotis C, 2005, SOL ENERGY, V79, P409, DOI 10.1016/j.solener.2005.02.026
   Ansys Inc, 2016, ANSYS FLUENT THEOR G
   Bader R, 2017, WOODHEAD PUBL SER EN, P403, DOI 10.1016/B978-0-08-100516-3.00018-6
   Bellan S, 2018, ENERGY, V160, P245, DOI 10.1016/j.energy.2018.06.212
   Bellan S, 2018, INT J HYDROGEN ENERG, V43, P16443, DOI 10.1016/j.ijhydene.2018.06.033
   Bellan S, 2018, INT J HEAT MASS TRAN, V116, P377, DOI 10.1016/j.ijheatmasstransfer.2017.09.015
   Bellan S, 2017, POWDER TECHNOL, V319, P228, DOI 10.1016/j.powtec.2017.06.060
   Bellan S, 2014, APPL THERM ENG, V71, P481, DOI 10.1016/j.applthermaleng.2014.07.009
   Bellan S, 2013, CHEM ENG SCI, V101, P81, DOI 10.1016/j.ces.2013.06.033
   Chandran RB, 2015, INT J THERM SCI, V92, P138, DOI 10.1016/j.ijthermalsci.2015.01.016
   Chu KW, 2011, CHEM ENG SCI, V66, P834, DOI 10.1016/j.ces.2010.11.026
   Chueh WC, 2009, CHEMSUSCHEM, V2, P735, DOI 10.1002/cssc.200900138
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Fotovat F, 2017, CHEM ENG SCI, V173, P303, DOI 10.1016/j.ces.2017.08.001
   Furler P, 2015, CHEM ENG SCI, V137, P373, DOI 10.1016/j.ces.2015.05.056
   Furler P, 2012, ENERG ENVIRON SCI, V5, P6098, DOI 10.1039/c1ee02620h
   Gokon N, 2015, ENERGY, V79, P264, DOI 10.1016/j.energy.2014.11.012
   Gokon N, 2014, INT J HYDROGEN ENERG, V39, P11082, DOI 10.1016/j.ijhydene.2014.05.124
   Gokon N, 2012, INT J HYDROGEN ENERG, V37, P12128, DOI 10.1016/j.ijhydene.2012.05.133
   Gui N, 2010, CHEM ENG SCI, V65, P3268, DOI 10.1016/j.ces.2010.02.026
   GUNN DJ, 1978, INT J HEAT MASS TRAN, V21, P467, DOI 10.1016/0017-9310(78)90080-7
   Hou QF, 2012, AICHE J, V58, P1422, DOI 10.1002/aic.12700
   Klein HH, 2006, J SOL ENERG-T ASME, V128, P406, DOI 10.1115/1.2212441
   Kodama T, 2007, CHEM REV, V107, P4048, DOI 10.1021/cr050188a
   Kodama T, 2017, SOL ENERGY, V156, P113, DOI 10.1016/j.solener.2017.05.084
   Kodama T, 2008, J SOL ENERG-T ASME, V130, DOI 10.1115/1.2807213
   Kodama T, 2010, J SOL ENERG-T ASME, V132, DOI 10.1115/1.4001359
   Kuang SB, 2011, AICHE J, V57, P2708, DOI 10.1002/aic.12480
   Lapp J, 2014, J SOL ENERG-T ASME, V136, DOI 10.1115/1.4026465
   Li Z, 2017, CHEM ENG J, V317, P242, DOI 10.1016/j.cej.2017.02.055
   Li Z, 2017, CHEM ENG SCI, V169, P299, DOI 10.1016/j.ces.2016.04.046
   Lichtenegger T, 2017, CHEM ENG SCI, V172, P310, DOI 10.1016/j.ces.2017.06.022
   Lipinski W, 2013, J THERM SCI ENG APPL, V5, DOI 10.1115/1.4024088
   Meier A, 1996, CHEM ENG SCI, V51, P3181, DOI 10.1016/0009-2509(96)00217-5
   NAKAMURA T, 1977, SOL ENERGY, V19, P467, DOI 10.1016/0038-092X(77)90102-5
   Patil AV, 2014, CHEM ENG SCI, V105, P121, DOI 10.1016/j.ces.2013.11.001
   Rightley M, SOL ENERGY, V48, P363
   Segal A, 2008, J SOLAR ENERGY ENG T, V130, P1
   Segal A, 2010, J SOL ENERGY ENG, V132, P1
   Selvan B, 2011, J THERM SPRAY TECHN, V20, P534, DOI 10.1007/s11666-010-9587-8
   Steinfeld A, 2005, SOL ENERGY, V78, P603, DOI 10.1016/j.solener.2003.12.012
   Steinfeld A, 1998, ENERGY, V23, P803, DOI 10.1016/S0360-5442(98)00026-7
   Sutkar VS, 2016, CHEM ENG J, V288, P185, DOI 10.1016/j.cej.2015.11.044
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   Wahyudi H, 2016, INT J HEAT MASS TRAN, V97, P521, DOI 10.1016/j.ijheatmasstransfer.2016.02.038
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Yugeswaran S, 2013, VACUUM, V88, P139, DOI 10.1016/j.vacuum.2012.02.002
   Zhong WQ, 2006, CHEM ENG SCI, V61, P1571, DOI 10.1016/j.ces.2005.09.015
NR 50
TC 3
Z9 3
U1 1
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 10
PY 2019
VL 203
BP 511
EP 525
DI 10.1016/j.ces.2018.09.012
PG 15
WC Engineering, Chemical
SC Engineering
GA HU6BM
UT WOS:000465363600042
DA 2020-05-12
ER

PT J
AU Innis, BL
   Scorza, FB
   Blum, JS
   Jain, VK
   Aguilar, AO
   Post, DJ
   Roberts, PC
   Wairagkar, N
   White, J
   Bresee, J
AF Innis, Bruce L.
   Scorza, Francesco Berlanda
   Blum, Jeremy S.
   Jain, Varsha K.
   Aguilar, Anastazia Older
   Post, Diane J.
   Roberts, Paul C.
   Wairagkar, Niteen
   White, Janet
   Bresee, Joseph
TI Meeting report: Convening on the influenza human viral challenge model
   for universal influenza vaccines, Part 1: Value; challenge virus
   selection; regulatory, industry and ethical considerations; increasing
   standardization, access and capacity
SO VACCINE
LA English
DT Article
DE Influenza; Influenza vaccine; Universal vaccine; Human challenge trial;
   Vaccine development
ID INFECTION; REPRODUCIBILITY
AB In response to global interest in the development of a universal influenza vaccine, the Bill & Melinda Gates Foundation, PATH, and the Global Funders Consortium for Universal Influenza Vaccine Development convened a meeting of experts (London, UK, May 2018) to assess the role of a standardized controlled human influenza virus infection model (CHIVIM) towards the development of novel influenza vaccine candidates. This report (in two parts) summarizes those discussions and offers consensus recommendations. This article (Part 1) covers challenge virus selection, regulatory and ethical considerations, and issues concerning standardization, access, and capacity. Part 2 covers specific methodologic considerations.
   Current methods for influenza vaccine development and licensure require large costly field trials. The CHIVIM requires fewer subjects and the controlled setting allows for better understanding of influenza transmission and host immunogenicity. The CHIVIM can be used to identify immune predictors of disease for at-risk populations and to measure efficacy of potential vaccines for further development.
   Limitations to the CHIVIM include lack of standardization, limited access to challenge viruses and assays, lack of consensus regarding role of the CHIVIM in vaccine development pathway, and concerns regarding risk to study participants and community. To address these issues, the panel of experts recommended that WHO and other key stakeholders provide guidance on standardization, challenge virus selection, and risk management. A common repository of well-characterized challenge viruses, harmonized protocols, and standardized assays should be made available to researchers. A network of research institutions performing CHIVIM trials should be created, and more study sites are needed to increase capacity.
   Experts agreed that a research network of institutions working with a standardized CHIVIM could contribute important data to support more rapid development and licensure of novel vaccines capable of providing long-lasting protection against seasonal and pandemic influenza strains. (C) 2019 Elsevier Ltd.
C1 [Innis, Bruce L.; Scorza, Francesco Berlanda] PATH, Ctr Vaccine Innovat & Access, 455 Massachusetts Ave NW,Suite 1000, Washington, DC 20001 USA.
   [Blum, Jeremy S.; Jain, Varsha K.; Aguilar, Anastazia Older; Wairagkar, Niteen; White, Janet] Bill & Melinda Gates Fdn, POB 23350, Seattle, WA 98102 USA.
   [Post, Diane J.; Roberts, Paul C.] NIAID, Div Microbiol & Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Bresee, Joseph] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
   [Bresee, Joseph] Task Force Global Hlth, Atlanta, GA USA.
RP White, J (reprint author), Bill & Melinda Gates Fdn, POB 23350, Seattle, WA 98102 USA.
EM binnis@path.org; fberlanda-scorza@path.org;
   Jeremy.Blum@gatesfoundation.org; elderAguilar@gatesfoundation.org;
   postd@niaid.nih.gov; paul.robeits@nih.gov;
   Janet.White@gatesfoundation.org; jbresee@taskforce.org
FU Bill & Melinda Gates FoundationGates Foundation
FX The convening was funded by the Bill & Melinda Gates Foundation.
CR [Anonymous], 2017, RECOMMENDED POLICY G
   Balasingam S, 2016, INT J INFECT DIS, V49, P18, DOI 10.1016/j.ijid.2016.05.013
   Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375
   Centers for Disease Control and Prevention, 2017, DUAL US RES CONC BIR
   Centers for Disease Control and Prevention, 2016, INFL RISK ASS TOOL
   Chen WH, 2016, CLIN INFECT DIS, V62, P1329, DOI 10.1093/cid/ciw145
   Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103
   FRANCIS T, 1945, J CLIN INVEST, V24, P536, DOI 10.1172/JCI101633
   Innis BL, 2019, VACCINE, V37, P4830, DOI 10.1016/j.vaccine.2019.06.053
   LITTLE JW, 1979, J MED VIROL, V3, P177, DOI 10.1002/jmv.1890030303
   Memoli MJ, 2015, CLIN INFECT DIS, V60, P693, DOI 10.1093/cid/ciu924
   Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238
   SALK JE, 1945, J CLIN INVEST, V24, P547, DOI 10.1172/JCI101634
   Shah K KJ, 2017, ETHICAL CONSIDERATIO
   Sherman AC, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00107
   The Bill and Melinda Gates Foundation, 2018, END PAND THREAT GRAN
   Waddington CS, 2014, CLIN INFECT DIS, V58, P1230, DOI 10.1093/cid/ciu078
   Wagner R, 2012, VACCINE, V30, P4113, DOI 10.1016/j.vaccine.2012.02.077
   World Health Organization, 2017, WHO PREF PROD CHAR N
   World Health Organization, 2016, HUM CHALL TRIALS VAC
   World Health Organization, 2016, TOOL INFL PAND RISK
   Zacour M, 2016, CLIN VACCINE IMMUNOL, V23, P236, DOI 10.1128/CVI.00613-15
NR 22
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4823
EP 4829
DI 10.1016/j.vaccine.2019.06.080
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100001
PM 31362819
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Innis, BL
   Scorza, FB
   Blum, JS
   Jain, VK
   Aguilar, AO
   Post, DJ
   Roberts, PC
   Wairagkar, N
   White, J
   Bresee, J
AF Innis, Bruce L.
   Scorza, Francesco Berlanda
   Blum, Jeremy S.
   Jain, Varsha K.
   Aguilar, Anastazia Older
   Post, Diane J.
   Roberts, Paul C.
   Wairagkar, Niteen
   White, Janet
   Bresee, Joseph
TI Convening on the influenza human viral challenge model for universal
   influenza vaccines, Part 2: Methodologic considerations
SO VACCINE
LA English
DT Article
DE Influenza; Influenza vaccine; Universal vaccine; Human challenge trial;
   Research methods
ID PROTECTION; DISEASE; ADULTS; VIRUS
AB In response to global interest in the development of a universal influenza vaccine, the Bill & Melinda Gates Foundation, PATH, and the Global Funders Consortium for Universal Influenza Vaccine Development convened a meeting of experts (London, UK, May 2018) to assess the role of a standardized controlled human influenza virus infection model (CHIVIM) towards the development of novel influenza vaccine candidates. This report (in two parts) summarizes those discussions and offers consensus recommendations. Part 1 covers challenge virus selection, regulatory and ethical considerations, and issues concerning standardization, access, and capacity. This article (Part 2) summarizes the discussion and recommendations concerning CHIVIM methods.
   The panelists identified an overall need for increased standardization of CHIVIM trials, in order to produce comparable results that can support universal vaccine licensure. Areas of discussion included study participant selection and screening, route of exposure and dose, devices for administering challenge, rescue therapy, protection of participants and institutions, clinical outcome measures, and other considerations. The panelists agreed upon specific recommendations to improve the standardization and usefulness of the model for vaccine development.
   Experts agreed that a research network of institutions working with a standardized CHIVIM could contribute important data to support more rapid development and licensure of novel vaccines capable of providing long-lasting protection against seasonal and pandemic influenza strains. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Innis, Bruce L.; Scorza, Francesco Berlanda] PATH, Ctr Vaccine Innovat & Access, 455 Massachusetts Ave NW,Suite 1000, Washington, DC 20001 USA.
   [Blum, Jeremy S.; Jain, Varsha K.; Aguilar, Anastazia Older; Wairagkar, Niteen; White, Janet] Bill & Melinda Gates Fdn, POB 23350, Seattle, WA 98102 USA.
   [Post, Diane J.; Roberts, Paul C.] NIAID, Div Microbiol & Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Bresee, Joseph] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
   [Bresee, Joseph] Task Force Global Hlth, Atlanta, GA USA.
RP White, J (reprint author), Bill & Melinda Gates Fdn, POB 23350, Seattle, WA 98102 USA.
EM binnis@path.org; fberlanda-scorza@path.org;
   Jeremy.Blum@gatesfoundation.org;
   Anastazia.OlderAguilar@gatesfoundation.org; postd@niaid.nih.gov;
   paul.roberts@nih.gov; Janet.White@gatesfoundation.org;
   jbresee@taskforce.org
FU Bill & Melinda Gates FoundationGates Foundation
FX The convening was funded by the Bill & Melinda Gates Foundation.
CR ALFORD RH, 1966, P SOC EXP BIOL MED, V122, P800, DOI 10.3181/00379727-122-31255
   AOKI FY, 1976, BRIT J CLIN PHARMACO, V3, P869, DOI 10.1111/j.1365-2125.1976.tb00640.x
   Balasingam S, 2016, INT J INFECT DIS, V49, P18, DOI 10.1016/j.ijid.2016.05.013
   Beigel JH, 2017, LANCET RESP MED, V5, P500, DOI 10.1016/S2213-2600(17)30174-1
   Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375
   COUCH RB, 1971, J INFECT DIS, V124, P473, DOI 10.1093/infdis/124.5.473
   Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1
   Finberg RW, 2018, J INFECT DIS
   Forrest BD, 2008, CLIN VACCINE IMMUNOL, V15, P1042, DOI 10.1128/CVI.00397-07
   FRANCIS T, 1945, J CLIN INVEST, V24, P536, DOI 10.1172/JCI101633
   Gould VMW, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00900
   Han A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3220-8
   HASLETON PS, 1972, J ANAT, V112, P391
   Hayden FG, 2019, CURR OPIN INFECT DIS, V32, P176, DOI 10.1097/QCO.0000000000000532
   Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197
   Innis BL, 2019, VACCINE, V37, P4823, DOI 10.1016/j.vaccine.2019.06.080
   Ito T, 2018, INTERNAL MED, V57, P1819, DOI 10.2169/internalmedicine.0316-17
   Killingley B, 2012, J INFECT DIS, V205, P35, DOI 10.1093/infdis/jir701
   LITTLE JW, 1979, J MED VIROL, V3, P177, DOI 10.1002/jmv.1890030303
   MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103
   Memoli MJ, 2016, MBIO, V7, DOI 10.1128/mBio.00417-16
   National Institute for Health Research, CLIN TRIALS TOOLK RI
   Oh DY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00080
   Oxford JS, 2012, EXPERT REV VACCINES, V11, P929, DOI [10.1586/ERV.12.77, 10.1586/erv.12.77]
   Park JK, 2018, MBIO, V9, DOI [10.1128/mBio.02284-17, 10.1128/mbio.02284-17]
   Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238
   SALK JE, 1945, J CLIN INVEST, V24, P547, DOI 10.1172/JCI101634
   Sherman AC, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00107
   Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350
   Venkatesan S, 2017, CLIN INFECT DIS, V64, P1328, DOI 10.1093/cid/cix127
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   World Health Organization, 2012, MEASL AER VACC PROJ
   Yu H, 2010, EFFECTIVENESS OSELTA
NR 33
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4830
EP 4834
DI 10.1016/j.vaccine.2019.06.053
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100002
PM 31362820
OA Other Gold
DA 2020-05-12
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Dengue vaccine: WHO position paper, September 2018-Recommendations
SO VACCINE
LA English
DT Article
DE WHO position paper; Vaccine position paper; Dengue vaccine
AB This article presents the World Health Organizations (WHO) recommendations on the use of dengue vaccine excerpted from the WHO position paper on dengue vaccine September 2018, published in the Weekly Epidemiological Record [1]. This position paper replaces the July 2016 WHO position paper concerning the first licensed dengue vaccine, CYD-TDV [2]. The position paper presents new evidence that became available in November 2017. A retrospective analysis of data from clinical trials, using a new serological assay classified trial participants according to their dengue serostatus prior to receipt of the first vaccine dose. The analysis revealed an excess risk of severe dengue in seronegative vaccine recipients compared to seronegative non-vaccinated individuals, while confirming long-term protection in seropositive individuals [3]. The paper provides revised guidance on dengue vaccination strategies from a population health perspective.
   Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation table. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. (C) 2018 World Health Organization. Published by Elsevier Ltd. All rights reserved.
CR [Anonymous], 2016, Wkly Epidemiol Rec, V91, P349
   [Anonymous], 2018, EV REC TABL 1 CONS D
   [Anonymous], 2018, EV REC TABL 2 SER SC
   [Anonymous], 2018, WKLY EPIDEMIOL REC, V93, P457
NR 4
TC 13
Z9 13
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4848
EP 4849
DI 10.1016/j.vaccine.2018.09.063
PG 2
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100006
PM 30424888
DA 2020-05-12
ER

PT J
AU Gessner, BD
   Theilacker, C
   Jodar, L
AF Gessner, Bradford D.
   Theilacker, Christian
   Jodar, Luis
TI Rethinking results from the Japanese 23-valent pneumococcal
   polysaccharide vaccine randomized clinical trial
SO VACCINE
LA English
DT Article
DE Japan; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide
   vaccine; Pneumococcus; Randomized clinical trial; Vaccine; Vaccine
   efficacy; Validity
ID RESPIRATORY-TRACT INFECTIONS; PNEUMONIA; MANAGEMENT; ADULTS; GUIDELINES;
   EFFICACY
AB We review a previously published randomized clinical trial of 23-valent pneumococcal polysaccharide vaccine (PPSV23) that has been used extensively globally to support PPSV23 use among adults. We argue that serious issues with internal and external validity exist that affect the usefulness of these data when evaluating pneumococcal vaccines for the general adult population. As one example of internal data inconsistency, the values reported for the percent of all pneumonia cases due to pneumococcus and the vaccine efficacy (VE) for all cause pneumonia are mutually inconsistent, even based on unrealistically high values for PPSV23 VE against vaccine serotypes and the proportion of pneumococcal pneumonias due to vaccine serotypes. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Gessner, Bradford D.; Theilacker, Christian; Jodar, Luis] Pfizer Vaccines, 500 Arcola Rd, Collegeville, PA 19426 USA.
RP Gessner, BD (reprint author), Pfizer Vaccines, 500 Arcola Rd, Collegeville, PA 19426 USA.
EM Bradford.gessner@pfizer.com
FU Pfizer Inc.Pfizer
FX This study was sponsored by Pfizer Inc. The corresponding author had
   full access to the study data and had final responsibility for the
   decision to submit for publication.
CR Australian and New, 2016, AUSTRALAS J AGEING, V35, P67
   Blasi F, 2012, CLIN MICROBIOL INFEC, V18, P7, DOI 10.1111/j.1469-0691.2012.03937.x
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Diao WQ, 2016, VACCINE, V34, P1496, DOI 10.1016/j.vaccine.2016.02.023
   El-Solh AA, 2010, CHEST, V138, P1480, DOI 10.1378/chest.10-1135
   Falkenhorst G, 2016, BUNDESGESUNDHEITSBLA, V59, P1623, DOI 10.1007/s00103-016-2466-9
   Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Ishida T, 2001, INTERNAL MED, V40, P873, DOI 10.2169/internalmedicine.40.873
   Kolditz M, 2018, CLIN MICROBIOL INFEC, V24, P500, DOI 10.1016/j.cmi.2017.08.010
   Kolditz M, 2018, CLIN INFECT DIS
   Kuhlmann A, 2016, ABSCHLUSSBERICHT, P26
   Maruyama T, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1004
   Metersky ML, 2010, CHEST, V138, P486, DOI 10.1378/chest.10-0738
   Ruiz-Gonzalez A, 1999, AM J MED, V106, P385, DOI 10.1016/S0002-9343(99)00050-9
   Said MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060273
   Suzuki M, 2017, LANCET INFECT DIS, V17, P803, DOI 10.1016/S1473-3099(17)30411-5
   Weinberger B, 2012, CLIN MICROBIOL INFEC, V18, P100, DOI 10.1111/j.1469-0691.2012.03944.x
   Woodhead M, 2011, CLIN MICROBIOL INFEC, V17, pE1, DOI 10.1111/j.1469-0691.2011.03672.x
   Woodhead M, 2011, CLIN MICROBIOL INFEC, V17, P1, DOI 10.1111/j.1469-0691.2011.03602.x
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4853
EP 4857
DI 10.1016/j.vaccine.2019.07.040
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100010
PM 31327653
OA Other Gold
DA 2020-05-12
ER

PT J
AU Safadi, MAP
   Martinon-Torres, F
   Weckx, LY
   Moreira, ED
   Lima, EJD
   Willemsen, A
   Toneatto, D
   Habib, A
   Borys, D
AF Safadi, Marco Aurelio P.
   Martinon-Torres, Federico
   Weckx, Lily Yin
   Moreira, Edson Duarte
   da Fonseca Lima, Eduardo Jorge
   Willemsen, Arnold
   Toneatto, Daniela
   Habib, Ahsan
   Borys, Dorota
TI Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae
   protein D conjugate vaccine (PHiD-CV) administered concomitantly with
   the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc
   analysis in a phase 3b, randomised, controlled trial
SO VACCINE
LA English
DT Article
DE Pneumococcal conjugate vaccine; Meningococcal conjugate vaccine;
   Co-administration; Immunogenicity; Infants
ID IMPACT; 10-VALENT; CHILDREN; DISEASE
AB Background: No data are currently available on immunogenicity of higher-valent pneumococcal conjugate vaccines when co-administered with a 4-component meningococcal serogroup B vaccine (4CMenB).
   Methods: Post-hoc analysis of pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) immunogenicity when co-administered with 4CMenB (2 + 1 schedule) and/or a CRM-conjugated meningococcal serogroup C vaccine (MenC-CRM) in a trial assessing 4CMenB reduced schedules and co-administration with MenC-CRM (NCT01339923). Infants were randomized to receive 4CMenB and MenC-CRM (Group 1) or MenC-CRM (Group 2) at 3, 5, and 12 months (M) of age. Both groups received PHiD-CV (3 + 1 schedule) as part of the Brazilian national immunisation programme at 3 M, 5 M, 7 M, and 12 M of age. Antibody responses were assessed pre-vaccination, 1 M post-dose 2, pre-booster, and 1 M post-booster.
   Results: Anti-pneumococcal antibody responses were in similar ranges in the two study groups.
   Conclusions: 4CMenB co-administration did not seem to impact antibody responses to PHiD-CV in infants. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Safadi, Marco Aurelio P.] Santa Casa Sao Paulo Sch Med Sci, Sao Paulo, Brazil.
   [Safadi, Marco Aurelio P.] CDEC, Sao Paulo, Brazil.
   [Martinon-Torres, Federico] Univ Santiago de Compostela, Hosp Clin, Santiago De Compostela, Spain.
   [Martinon-Torres, Federico] Univ Santiago de Compostela, Inst Invest Sanitaria Santiago, Genet Vaccines & Pediat Res Grp GENVIP, Santiago De Compostela, Spain.
   [Weckx, Lily Yin] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Moreira, Edson Duarte] CPEC, Assoc Obras Sociais Irma Dulce, Salvador, BA, Brazil.
   [Moreira, Edson Duarte] Brazilian Minist Hlth, Oswaldo Cruz Fdn, Salvador, BA, Brazil.
   [da Fonseca Lima, Eduardo Jorge] CPEC, Inst Med Integral Prof Fernando Figueira, Boa Vista Recife, PE, Brazil.
   [Willemsen, Arnold] GSK, Biostat, Plus 100 BV, Amsterdam, Netherlands.
   [Toneatto, Daniela] GSK, Siena, Italy.
   [Habib, Ahsan; Borys, Dorota] GSK, Wavre, Belgium.
RP Safadi, MAP (reprint author), Santa Casa Sao Paulo Sch Med Sci, Sao Paulo, Brazil.; Safadi, MAP (reprint author), CDEC, Sao Paulo, Brazil.
EM masafadi@uol.com.br; federico.martinon.torres@sergas.es;
   lily.crie@huhsp.org.br; edson@bahia.fiocruz.br;
   eduardojorge@imip.org.br; arnold.x.willemsen@gsk.com;
   daniela.x.toneatto@gsk.com; ahsan.m.habib@gsk.com;
   dorota.d.borys@gsk.com
RI ; Martinon-Torres, Federico/E-4982-2016; safadi, marco/B-7157-2015
OI Willemsen, Arnold/0000-0001-6944-4249; WECKX, LILY/0000-0003-4949-3582;
   Martinon-Torres, Federico/0000-0002-9023-581X; safadi,
   marco/0000-0002-4401-9446
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX This work was supported by GlaxoSmithKline Biologicals SA.
   GlaxoSmithKline Biologicals SA was involved in all stages of the conduct
   and analysis of the studies. GlaxoSmithKline Biologicals SA covered the
   costs associated with the development and the publishing of the present
   manuscript.
CR Acevedo R, 2019, EXPERT REV VACCINES, V18, P15, DOI 10.1080/14760584.2019.1557520
   Alicino C, 2017, VACCINE, V35, P5776, DOI 10.1016/j.vaccine.2017.09.005
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129
   [Anonymous], 2016, PNEUM FACT SHEET
   Dominguez A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183191
   Esposito S, 2015, J IMMUNOL RES, DOI 10.1155/2015/591580
   Feyssaguet M, 2019, VACCINE, V37, P2208, DOI 10.1016/j.vaccine.2019.03.011
   Harboe ZB, 2014, CLIN INFECT DIS, V59, P1066, DOI 10.1093/cid/ciu524
   Harrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063
   Henckaerts I, 2006, CLIN VACCINE IMMUNOL, V13, P356, DOI 10.1128/CVI.13.3.356-360.2006
   Hirose TE, 2015, J PEDIAT-BRAZIL, V91, P130, DOI 10.1016/j.jped.2014.07.002
   Jodar L, 2003, VACCINE, V21, P3265, DOI 10.1016/S0264-410X(03)00230-5
   Martinon-Torres F, 2018, LANCET CHILD ADOLESC, V2, P404, DOI 10.1016/S2352-4642(18)30113-5
   Martinon-Torres F, 2017, VACCINE, V35, P3548, DOI 10.1016/j.vaccine.2017.05.023
   McIntyre PB, 2012, LANCET, V380, P1703, DOI 10.1016/S0140-6736(12)61187-8
   Medini D, 2015, VACCINE, V33, P2629, DOI 10.1016/j.vaccine.2015.04.015
   Ministry of Health Brazil, 1492015 MIN HLTH BRA
   Moreira M, 2016, VACCINE, V34, P2766, DOI 10.1016/j.vaccine.2016.04.006
   Mrkvan T, 2018, EXPERT REV VACCINES, V17, P797, DOI 10.1080/14760584.2018.1516551
   Parikh SR, 2016, LANCET, V388, P2775, DOI 10.1016/S0140-6736(16)31921-3
   Pelton SI, 2016, J ADOLESCENT HEALTH, V59, pS3, DOI 10.1016/j.jadohealth.2016.04.012
   Pickering JW, 2002, AM J CLIN PATHOL, V117, P589
   Safadi MAP, 2017, VACCINE, V35, P2052, DOI 10.1016/j.vaccine.2017.03.002
   World Health Organization, TRAIN MAN ENZ LINK I
   World Health Organization, IMM COV
   Wysocki J, 2009, PEDIATR INFECT DIS J, V28, pS77, DOI 10.1097/INF.0b013e318199f609
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4858
EP 4863
DI 10.1016/j.vaccine.2019.07.021
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100011
PM 31327652
OA Other Gold
DA 2020-05-12
ER

PT J
AU Gocko, X
   Poulteau, S
   Beyens, MN
   Bertholon, P
   Pozzetto, B
AF Gocko, Xavier
   Poulteau, Sylvain
   Beyens, Marie-Noelle
   Bertholon, Pierre
   Pozzetto, Bruno
TI Case report: Recurrent peripheral facial paralysis following two
   influenza vaccinations in 2009 and 2016
SO VACCINE
LA English
DT Article
DE Influenza vaccination; Peripheral facial paralysis; Adverse effects
ID BELLS-PALSY
AB A 57-year-old female experienced two successive peripheral facial paralysis (PFP) episodes following influenza immunization in 2009 and 2016 with two different vaccines. The similarity of chronology and semiology between the two events and the absence of alternative etiology plead for intrinsic accountability. Extrinsic accountability relies on previous case reports of PFP related to flu vaccination (26 cases in the French pharmacovigilance database and 4 cases in the medical literature). (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gocko, Xavier; Poulteau, Sylvain] Univ Lyon, Fac Med St Etienne, Dept Family Practice, Lyon, France.
   [Beyens, Marie-Noelle] Univ Hosp St Etienne, Reg Pharmacovigilance Unit, St Priest En Jarez, France.
   [Bertholon, Pierre] Univ Hosp St Etienne, Neurol Otorhinolaryngol Unit, St Priest En Jarez, France.
   [Pozzetto, Bruno] Univ Hosp St Etienne, Lab Infect Agents & Hyg, St Priest En Jarez, France.
RP Gocko, X (reprint author), Univ Lyon, Fac Med St Etienne, Dept Family Practice, Lyon, France.
EM xavier.gocko@univ-st-etienne.fr
OI POZZETTO, Bruno/0000-0002-2603-8467; gocko, xavier/0000-0002-3395-747X
CR Bardage C, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5956
   Botelho-Nevers E, 2017, MED MALADIES INFECT, V47, P81, DOI 10.1016/j.medmal.2016.11.003
   Chou CH, 2007, VACCINE, V25, P2839, DOI 10.1016/j.vaccine.2006.10.006
   DOSHI P, 2018, BMJ-BRIT MED J, V362, DOI DOI 10.1136/BMJ.K3948
   Equipes de surveillance de la grippe, 2017, B EPIDEMIOL HEBD, P466
   Lee SJ, 2012, PEDIATR INT, V54, P325, DOI 10.1111/j.1442-200X.2012.03568.x
   Lessa R, 2014, ARQ NEURO-PSIQUIAT, V72, P496, DOI 10.1590/0004-282X20140064
   Miremont-Salame G, 2016, THERAPIE, V71, P179, DOI 10.1016/j.therap.2016.02.010
   Oosterveer DM, 2012, J LARYNGOL OTOL, V126, P833, DOI 10.1017/S002221511200120X
   Zandian A, 2014, MED SCI MONITOR, V20, P83, DOI 10.12659/MSM.889876
   Zhou WG, 2004, PHARMACOEPIDEM DR S, V13, P505, DOI 10.1002/pds.998
NR 11
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4864
EP 4866
DI 10.1016/j.vaccine.2019.07.025
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100012
PM 31311685
DA 2020-05-12
ER

PT J
AU Gunaratne, K
   Coomes, EA
   Haghbayan, H
AF Gunaratne, Keith
   Coomes, Eric A.
   Haghbayan, Hourmazd
TI Temporal trends in anti-vaccine discourse on Twitter
SO VACCINE
LA English
DT Article
DE Vaccine; Vaccine hesitancy; Measles; Twitter; Medicine and media
AB Despite vaccination's role in preventing communicable diseases, misinformation threatens uptake. Social media may disseminate such anti-vaccination messages. We characterized trends in pro- and antivaccination discourse on Twitter. All tweets between 2010 and 2019 containing vaccine-related hashtags were identified. Pro- and anti-vaccine tweets and users per quarter (3-months) were tabulated; discussion subcommunities were identified with network analysis. 1,637,712 vaccine-related tweets were identified from 154 pro-vaccine and 125 anti-vaccine hashtags, with 86% of users posting exclusively pro-vaccine and 12% posting exclusively anti-vaccine hashtags. Pro-vaccine tweet volumes are larger than anti-vaccine tweets and consistently increase over time. In contrast, anti-vaccine tweet volumes have decreased since 2014, despite an increasing anti-vaccine user-base. Users infrequently responded across pro/anti-vaccine alignment (0.2%). Despite greater volumes of pro-vaccination discourse in recent years, and the anti-vaccination content userbase being smaller, the anti-vaccine community continues to grow in size. This finding coupled with the minimal inter-communication between communities suggests possible ideological isolation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gunaratne, Keith; Haghbayan, Hourmazd] Univ Toronto, Dept Med, Suite RFE 3-805,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.
   [Coomes, Eric A.] Univ Toronto, Dept Med, Div Infect Dis, Toronto, ON, Canada.
   [Haghbayan, Hourmazd] Western Univ, London Hlth Sci Ctr, Div Cardiol, London, ON, Canada.
   [Haghbayan, Hourmazd] Univ Laval, Dept Social & Prevent Med, Quebec City, PQ, Canada.
RP Coomes, EA (reprint author), Univ Toronto, Dept Med, Suite RFE 3-805,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.
EM eric.coomes@mail.utoronto.ca
RI Haghbayan, Hourmazd/Q-9699-2016
OI Haghbayan, Hourmazd/0000-0002-3384-0650
CR Barry K., 2015, VACCINE WHISTLEBLOWE, P176
   Betsch C, 2012, VACCINE, V30, P3723, DOI 10.1016/j.vaccine.2012.03.078
   Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008
   Coomes EA, 2019, CAN J CARDIOL, V35, P791, DOI 10.1016/j.cjca.2019.03.015
   Dunn AG, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4343
   Glanz JM, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1117
   Golbeck J., 2013, ANAL SOCIAL WEB, P25, DOI [10.1016/B978-0-12-405531-5.00003-1., DOI 10.1016/B978-0-12-405531-5.00003-1]
   Gu ZY, 2018, NATL SCI REV, V5, P8, DOI 10.1093/nsr/nwx098
   Health Care Complaints Commission, PUBL STAT WARN AUSTR
   Hill HA, 2018, MMWR-MORBID MORTAL W, V67, P1123, DOI 10.15585/mmwr.mm6740a4
   Larson HJ, 2019, HUM VACC IMMUNOTHER, V15, P625, DOI 10.1080/21645515.2018.1522468
   Madara J., AMA VACCINES LETT SO
   Pilkington E, GUARDIAN
   Royal Society for Public Health, MOV NEEDL PROM VACC
   Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040
   Wakefield A., 2016, VAXXED COVER UP CATA
   Ward JK, 2016, HUM VACC IMMUNOTHER, V12, P1924, DOI 10.1080/21645515.2016.1146430
   World Health Organization, MEASL RUB SURV DAT
   World Health Organization, 10 THREATS GLOB HLTH
   Zipprich J, 2015, MMWR-MORBID MORTAL W, V64, P153
NR 20
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4867
EP 4871
DI 10.1016/j.vaccine.2019.06.086
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100013
PM 31300292
DA 2020-05-12
ER

PT J
AU Perrett, SE
   Cottrell, S
   Shankar, AG
AF Perrett, Stephanie E.
   Cottrell, Simon
   Shankar, Anandar Giri
TI Hepatitis B vaccine coverage in short and long stay prisons in Wales, UK
   2013-2017 and the impact of the global vaccine shortage
SO VACCINE
LA English
DT Article
DE Hepatitis B; Prison; Vaccination
ID ENGLAND
AB Data on hepatitis B vaccination coverage across prisons in Wales 2013-2017 were analysed to describe coverage of one dose, and the full hepatitis B vaccine course for men in prison. Whilst vaccination coverage increased in both short and long stay prisons, annual coverage was consistently lower in short stay prisons compared to long-stay prisons, despite short-stay prisons delivering a higher numbers of vaccine doses. The exception of this pattern was in 2017, at a time of global vaccine shortage. The data demonstrate the need for all prisons to work together to ensure men in prison can receive the full hepatitis B vaccine course. Collaborative working will be required to recover from the vaccine shortage and to achieve higher coverage than the plateau in 2016. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Perrett, Stephanie E.; Shankar, Anandar Giri] Publ Hlth Wales, Hlth Protect Team, 2 Capital Quarter,Tyndall Way, Cardiff CF10 4BQ, Wales.
   [Cottrell, Simon] Publ Hlth Wales, Vaccine Preventable Dis Programme, 2 Capital Quarter,Tyndall Way, Cardiff CF10 4BQ, Wales.
RP Perrett, SE (reprint author), Publ Hlth Wales, Hlth Protect Team, 2 Capital Quarter,Tyndall Way, Cardiff CF10 4BQ, Wales.
EM stephanie.perrett@wales.nhs.uk
CR Beck CR, 2012, VACCINE, V30, P1965, DOI 10.1016/j.vaccine.2012.01.020
   Gilbert R L, 2004, Commun Dis Public Health, V7, P306
   Judd A, 2007, J VIRAL HEPATITIS, V14, P584, DOI 10.1111/j.1365-2893.2007.00844.x
   Ministry of Justice, 2018, PROV REOFF STAT Q B
   Ministry of Justice, 2018, PRIS POP STAT DEC 20
   NHS Wales, 2019, HEALTHC SERV PRIS
   NICE, 2016, PHYS HLTH PEOPL PRIS
   Palmateer NE, 2018, ADDICTION, V113, P80, DOI 10.1111/add.13944
   Public Health England, 2017, HEP B VACC AD CHILDR
   StataCorp, 2015, STAT STAT SOFTW REL
   Welsh Government, 2015, TOG HLTH LIV DIS DEL
   World Health Organization, 2016, COMB HEP B C REACH E
NR 12
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4872
EP 4876
DI 10.1016/j.vaccine.2019.02.065
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100014
PM 31362822
OA Other Gold
DA 2020-05-12
ER

PT J
AU Seale, AC
   Baker, CJ
   Berkley, JA
   Madhi, SA
   Ordi, J
   Saha, SK
   Schrag, SJ
   Sobanjo-ter Meulen, A
   Vekemans, J
AF Seale, Anna C.
   Baker, Carol J.
   Berkley, James A.
   Madhi, Shabir A.
   Ordi, Jaume
   Saha, Samir K.
   Schrag, Stephanie J.
   Sobanjo-ter Meulen, Ajoke
   Vekemans, Johan
TI Vaccines for maternal immunization against Group B Streptococcus
   disease: WHO perspectives on case ascertainment and case definitions
SO VACCINE
LA English
DT Review
DE Streptococcus agalactiae; Group B; Case definition; Case ascertainment;
   Vaccine
ID PREGNANT-WOMEN; GENOME SEQUENCE; WORLDWIDE; AGALACTIAE; CHILDREN;
   COLONIZATION; INFECTIONS; STILLBIRTHS; PREVENTION; GUIDELINES
AB Group B Streptococcus (GBS) is an important cause of disease in young infants, stillbirths, pregnant and post-partum women. GBS vaccines for maternal immunization are in development aiming to reduce this burden. Standardisation of case definitions and ascertainment methodologies for GBS disease is needed to support future trials of maternal GBS vaccines. Considerations presented here may also serve to promote consistency in observational studies and surveillance, to better establish disease burden. The World Health Organization convened a working group to provide consensus guidance for case ascertainment and case definitions of GBS disease in stillbirths, infants, pregnant and post-partum women, with feedback sought from external stakeholders. In intervention studies, case capture and case ascertainment for GBS disease should be based on antenatal recruitment of women, with active follow-up, systematic clinical assessment, standardised sampling strategies and optimised laboratory methods. Confirmed cases of invasive GBS disease in stillbirths or infants should be included in a primary composite endpoint for vaccine efficacy studies, with GBS cultured from a usually sterile body site (may be post-mortem). For additional endpoints, or observational studies, confirmed cases of GBS sepsis in pregnant and post-partum women should be assessed. Culture independent diagnostic tests (CIDTs) may detect additional presumed cases, however, the use of these diagnostics needs further evaluation. Efficacy of vaccination against maternal and neonatal GBS colonisation, and maternal GBS urinary tract infection could be included as additional, separate, endpoints and/or in observational studies. Whilst the focus here is on specific GBS disease outcomes, intervention studies also present an opportunity to establish the contribution of GBS across adverse perinatal outcomes, including all-cause stillbirth, preterm birth and neonatal encephalopathy. (C) 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Seale, Anna C.] London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
   [Seale, Anna C.] Haramaya Univ, Coll Hlth & Med Sci, Harar, Ethiopia.
   [Seale, Anna C.; Berkley, James A.] KEMRI Wellcome Trust Res Programme, Kilifi, Kenya.
   [Baker, Carol J.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, McGovern Med Sch, Houston, TX USA.
   [Berkley, James A.] Univ Oxford, Ctr Trop Med, Oxford, England.
   [Madhi, Shabir A.] Univ Witwatersrand, Resp & Meningeal Pathogens Res Un, Fac Hlth Sci, MRC, Johannesburg, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa.
   [Ordi, Jaume] Barcelona Inst Global Hlth, ISGlobal, Barcelona, Spain.
   [Ordi, Jaume] Univ Barcelona, Hosp Clin Barcelona, Dept Pathol, Barcelona, Spain.
   [Saha, Samir K.] Bangladesh Inst Child Hlth, Dhaka, Bangladesh.
   [Schrag, Stephanie J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Sobanjo-ter Meulen, Ajoke] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [Vekemans, Johan] WHO, Geneva, Switzerland.
RP Seale, AC (reprint author), London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM anna.seale@lshtm.ac.uk
OI Seale, Anna/0000-0002-0129-3146
FU Wellcome TrustWellcome Trust [205184]; Bill & Melinda Gates
   FoundationGates Foundation [OPP1134011]
FX ACS is funded by The Wellcome Trust (205184). This work was supported by
   a grant from the Bill & Melinda Gates Foundation to WHO (OPP1134011).
   The corresponding author had access to all data in the study and had
   responsibility for the decision to submit for publication.
CR [Anonymous], 1996, MMWR Recomm Rep, V45, P1
   BADRI MS, 1977, J INFECT DIS, V135, P308, DOI 10.1093/infdis/135.2.308
   Bartlett LA, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0124-1
   Bassat Q, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002317
   Bianchi Jassir F, 2017, CLIN INFECT DIS
   Bianchi-Jassir F, 2017, CLIN INFECT DIS, V65, pS133, DOI 10.1093/cid/cix661
   BLANCO JD, 1981, OBSTET GYNECOL, V58, P621
   Blencowe H, 2016, LANCET GLOB HEALTH, V4, pE98, DOI 10.1016/S2214-109X(15)00275-2
   Bonet M, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0321-6
   BOWDY BD, 1990, PEDIATR RES, V27, P344, DOI 10.1203/00006450-199004000-00005
   Carlin JB, 2008, LANCET, V371, P135, DOI 10.1016/S0140-6736(08)60106-3
   Chemotherapy BSfA, 2017, SUSCEPTIBILITY TESTI
   Clinical and Laboratory Standards Institute, 2017, GLOB STAND HLTH WORL
   Da Cunha V, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5544
   Drew RJ, 2015, INFECT DIS OBSTET GY, V2015
   Farag TH, 2017, AM J TROPICAL MED HY
   GIBBS RS, 1981, AM J OBSTET GYNECOL, V140, P405, DOI 10.1016/0002-9378(81)90034-X
   Glaser P, 2002, MOL MICROBIOL, V45, P1499, DOI 10.1046/j.1365-2958.2002.03126.x
   Group B Streptococcus Vaccine Development Technology Roadmap, 2017, PRIOR ACT DEV TEST L
   Hall J, 2017, CLIN INFECT DIS, V65, pS112, DOI 10.1093/cid/cix660
   Heath PGT, 2004, LANCET, V363, P292, DOI 10.1016/S0140-6736(03)15389-5
   Herbert HK, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001183
   Hillier SL, 2018, CLIN INFECT DIS
   Imperi M, 2010, J MICROBIOL METH, V80, P212, DOI 10.1016/j.mimet.2009.11.010
   Jones N, 2003, J CLIN MICROBIOL, V41, P2530, DOI 10.1128/JCM.41.6.2530-2536.2003
   Knowles SJ, 2015, BJOG-INT J OBSTET GY, V122, P663, DOI 10.1111/1471-0528.12892
   Kobayashi M, 2016, M HELD 27 28 APR 201
   Kobayashi Miwako, 2016, F1000Res, V5, P2355
   Kohli-Lynch M, 2017, CLIN INFECT DIS
   Kohli-Lynch M, 2017, CLIN INFECT DIS, V65, pS190, DOI 10.1093/cid/cix663
   Kwatra G, 2016, LANCET INFECT DIS, V16, P1076, DOI 10.1016/S1473-3099(16)30055-X
   Lawn JE, 2004, LANCET, V364, P2020, DOI 10.1016/S0140-6736(04)17511-9
   Lawn JE, 2017, CLIN INFECT DIS, V65, pS89, DOI 10.1093/cid/cix653
   Le Doare K, 2017, CLIN INFECT DIS
   LEDGER W J, 1978, Clinical Obstetrics and Gynecology, V21, P455, DOI 10.1097/00003081-197806000-00017
   Madhi SA, 2013, VACCINE, V31, pD52, DOI 10.1016/j.vaccine.2013.02.029
   Madrid L, 2017, CLIN INFECT DIS
   McMillan DJ, 2006, CLIN INFECT DIS, V43, P884, DOI 10.1086/507537
   Menendez C, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002318
   Orafu C, 2002, OBSTET GYNECOL, V99, P1036, DOI 10.1016/S0029-7844(02)01979-8
   Quinlan LCDRJD, 2000, J FAM PRACTICE, V49, P447
   Reingold A., 2007, Morbidity and Mortality Weekly Report, V56, P701
   Rosa-Fraile M, 2005, J CLIN MICROBIOL, V43, P928, DOI 10.1128/JCM.43.2.928-930.2005
   Russell N, 2017, CLIN INFECT DIS
   Saha SK, 2018, LANCET, V392, P145, DOI 10.1016/S0140-6736(18)31127-9
   Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X
   Schrag SJ, 2000, NEW ENGL J MED, V342, P15, DOI 10.1056/NEJM200001063420103
   Seale AC, 2017, CLIN INFECT DIS
   Seale AC, 2017, CLIN INFECT DIS, V65, pS125, DOI 10.1093/cid/cix585
   Seale AC, 2017, CLIN INFECT DIS, V65, pS200, DOI 10.1093/cid/cix664
   Seale Anna C, 2017, Wellcome Open Res, V2, P92, DOI 10.12688/wellcomeopenres.12527.1
   Seale AC, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.67, 10.1038/nmicrobiol.2016.67]
   Sheppard AE, 2016, J CLIN MICROBIOL, V54, P1388, DOI 10.1128/JCM.03142-15
   Simen-Kapeu A, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/1471-2393-15-S2-S6
   Slotved HC, 2007, J CLIN MICROBIOL, V45, P2929, DOI 10.1128/JCM.00117-07
   Surgers L, 2013, EUR J CLIN MICROBIOL, V32, P107, DOI 10.1007/s10096-012-1724-5
   Tann CJ, 2017, CLIN INFECT DIS, V65, pS173, DOI 10.1093/cid/cix662
   TANN CJ, 2017, CLIN INFECT DIS
   The European Committee on Antimicrobial Susceptibility Testing-EUCAST, 2017, ANTIMICROBIAL SUSCEP
   Trappe KL, 2011, OBSTET GYNECOL, V118, P313, DOI 10.1097/AOG.0b013e318225383b
   Vekemans J, 2019, VACCINE, V37, P3190, DOI 10.1016/j.vaccine.2019.04.039
   Verani Jennifer R., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Vergnano S, 2016, VACCINE, V34, P6038, DOI 10.1016/j.vaccine.2016.03.046
   Weber MW, 2003, PEDIATR INFECT DIS J, V22, P711, DOI 10.1097/01.inf.0000078163.80807.88
   World Health Organisation, 2013, PROBL NEON YOUNG INF, P45
   World Health Organisation, 2015, MAN POSS SER BACT IN
   Yao KH, 2013, J CLIN MICROBIOL, V51, P503, DOI 10.1128/JCM.02417-12
NR 67
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4877
EP 4885
DI 10.1016/j.vaccine.2019.07.012
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100015
PM 31303524
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Reid, MC
   Peebles, K
   Stansfield, SE
   Goodreau, SM
   Abernethy, N
   Gottlieb, GS
   Mittler, JE
   Herbeck, JT
AF Reid, Molly C.
   Peebles, Kathryn
   Stansfield, Sarah E.
   Goodreau, Steven M.
   Abernethy, Neil
   Gottlieb, Geoffrey S.
   Mittler, John E.
   Herbeck, Joshua T.
TI Models to predict the public health impact of vaccine resistance: A
   systematic review
SO VACCINE
LA English
DT Review
DE Vaccine resistance; Mathematical modeling
ID UNITED-STATES; DISEASE; EVOLUTION; COMPETITION; DYNAMICS; TRENDS
AB Pathogen evolution is a potential threat to the long-term benefits provided by public health vaccination campaigns. Mathematical modeling can be a powerful tool to examine the forces responsible for the development of vaccine resistance and to predict its public health implications. We conducted a systematic review of existing literature to understand the construction and application of vaccine resistance models. We identified 26 studies that modeled the public health impact of vaccine resistance for 12 different pathogens. Most models predicted that vaccines would reduce overall disease burden in spite of evolution of vaccine resistance. Relatively few pathogens and populations for which vaccine resistance may be problematic were covered in the reviewed studies, with low- and middle-income countries particularly under-represented. We discuss the key components of model design, as well as patterns of model predictions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Reid, Molly C.; Peebles, Kathryn; Stansfield, Sarah E.; Goodreau, Steven M.] Magnuson Hlth Sci Ctr, Dept Epidemiol, 1959 NE Pacific St,Room F-262, Seattle, WA 98195 USA.
   [Reid, Molly C.; Peebles, Kathryn; Herbeck, Joshua T.] Int Clin Res Ctr, Dept Global Hlth, 908 Jefferson St, Seattle, WA 98104 USA.
   [Stansfield, Sarah E.; Goodreau, Steven M.] Univ Washington, Dept Anthropol, Denny Hall, Seattle, WA 98195 USA.
   [Abernethy, Neil] Univ Washington, Dept Biomed Informat & Med Educ, Box 358047, Seattle, WA 98195 USA.
   [Abernethy, Neil] Magnuson Hlth Sci Ctr, Dept Hlth Serv, 1959 NE Pacific St,Room H-680, Seattle, WA 98195 USA.
   [Gottlieb, Geoffrey S.] Div Allergy & Infect Dis, 750 Republican St,Bldg E, Seattle, WA 98109 USA.
   [Gottlieb, Geoffrey S.] Ctr Emerging & Re Emerging Infect Dis, Dept Med, 750 Republican St,Bldg E, Seattle, WA 98109 USA.
   [Gottlieb, Geoffrey S.] Dept Global Hlth, 750 Republican St,Bldg E, Seattle, WA 98109 USA.
   [Mittler, John E.] Dept Microbiol, 750 Republican St,Bldg F, Seattle, WA 98109 USA.
RP Reid, MC (reprint author), Magnuson Hlth Sci Ctr, Dept Epidemiol, 1959 NE Pacific St,Room F-262, Seattle, WA 98195 USA.
EM mollyr6@uw.edu; kpeebles@uw.edu; sestans@uw.edu; goodreau@uw.edu;
   neila@uw.edu; gottlieb@uw.edu; jmittler@uw.edu; herbeck@uw.edu
OI Goodreau, Steven/0000-0003-1009-5763
FU Modeling of Infectious Disease Agent Study, National Institute of
   General Medical Sciences Grant [R01 GM125440]
FX This work was funded by the Modeling of Infectious Disease Agent Study,
   National Institute of General Medical Sciences Grant #R01 GM125440.
CR Alexander ME, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S1-S8
   Alizon S, 2009, J EVOLUTION BIOL, V22, P245, DOI 10.1111/j.1420-9101.2008.01658.x
   Andre JB, 2006, EVOLUTION, V60, P13, DOI 10.1111/j.0014-3820.2006.tb01077.x
   Bottomley C, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0786
   CDC, 2018, VACC TEST APPR PROC
   Choi YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039927
   Choi YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026190
   Cohen T, 2008, P NATL ACAD SCI USA, V105, P16302, DOI 10.1073/pnas.0808746105
   De Gregorio E, 2012, MICROB BIOTECHNOL, V5, P149, DOI 10.1111/j.1751-7915.2011.00276.x
   Elbasha EH, 2005, MATH BIOSCI, V197, P88, DOI 10.1016/j.mbs.2005.05.004
   Flasche S, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.1939
   Fryer HR, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002289
   Gandon S, 2001, NATURE, V414, P751, DOI 10.1038/414751a
   Herbeck JT, 2018, VACCINE, V36, P514, DOI 10.1016/j.vaccine.2017.12.004
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hogea C, 2016, HUM VACC IMMUNOTHER, V12, P451, DOI 10.1080/21645515.2015.1080400
   Huppert A, 2013, CLIN MICROBIOL INFEC, V19, P999, DOI 10.1111/1469-0691.12308
   Iwami S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004915
   Iwami S, 2009, J THEOR BIOL, V259, P219, DOI 10.1016/j.jtbi.2009.03.040
   Kennedy DA, 2017, P ROY SOC B-BIOL SCI, V284, DOI 10.1098/rspb.2016.2562
   Kroger A, 2014, GEN BEST PRACTICE GU
   Levin BR, 1999, SCIENCE, V283, P806, DOI 10.1126/science.283.5403.806
   Link-Gelles R, 2013, VACCINE, V31, P2572, DOI 10.1016/j.vaccine.2013.03.049
   Lipsitch M, 1997, P NATL ACAD SCI USA, V94, P6571, DOI 10.1073/pnas.94.12.6571
   Melegaro A, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-90
   Mooi FR, 1998, INFECT IMMUN, V66, P670, DOI 10.1128/IAI.66.2.670-675.1998
   Nurhonen M, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003477
   Nurhonen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056079
   Pitzer VE, 2015, SCI REP-UK, V5, DOI 10.1038/srep18585
   Pitzer VE, 2011, P NATL ACAD SCI USA, V108, P19353, DOI 10.1073/pnas.1110507108
   Read A. F., 2008, EVOLUTION HLTH DIS, V2, P139
   Rohani P, 2010, SCIENCE, V330, P982, DOI 10.1126/science.1194134
   Takahashi S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001958
   Temime L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003244
   Van Effelterre T, 2010, VACCINE, V28, P3650, DOI 10.1016/j.vaccine.2010.03.030
   Vickers DM, 2015, VACCINE, V33, P268, DOI 10.1016/j.vaccine.2013.09.034
   WHO, 2011, WHO PNEUM DIS
   WHO, 2012, WHO GLOB VACC ACT PL
   WHO, 2018, WHO VACC DIS
   Wilson JN, 2000, EPIDEMIOL INFECT, V124, P295, DOI 10.1017/S0950268800003605
   Worby CJ, 2017, EPIDEMICS-NETH, V19, P74, DOI 10.1016/j.epidem.2017.02.008
   Zhang Y, 2004, EPIDEMIOL INFECT, V132, P1073, DOI 10.1017/S0950268804002894
NR 42
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4886
EP 4895
DI 10.1016/j.vaccine.2019.07.013
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100016
PM 31307874
DA 2020-05-12
ER

PT J
AU Sheldenkar, A
   Lim, F
   Yung, CF
   Lwin, MO
AF Sheldenkar, Anita
   Lim, Fann
   Yung, Chee Fu
   Lwin, May O.
TI Acceptance and uptake of influenza vaccines in Asia: A systematic review
SO VACCINE
LA English
DT Review
DE Influenza; Motivators; Vaccine uptake; Asia
ID HEALTH-CARE WORKERS; A H1N1 VACCINATION; PANDEMIC INFLUENZA; HONG-KONG;
   PREGNANT-WOMEN; OLDER-PEOPLE; ATTITUDES; DETERMINANTS; COVERAGE;
   WILLINGNESS
AB In Asia, the public health burden of influenza is significant despite the existence of efficacious influenza vaccines. Annual seasonal influenza vaccination can reduce the incidence of influenza significantly, yet influenza vaccination coverage remains low in this part of the world. As a densely populated region with varying climatic zones and a larger proportion of developing countries compared to the West, Asia is at increased risk of influenza. To provide a more comprehensive and nuanced understanding of the Asian region, the key objective of this systematic review is to examine the determinants of vaccination uptake in Asia, beyond that of existing studies that have largely been western-centric.
   We carried out a systematic review of peer-reviewed scientific research, examining the key determinants, acceptance and uptake of influenza vaccinations across Asia. A comprehensive search strategy was defined to capture studies that met the inclusion criteria of articles published in English, from 2008 to 2018, focusing on adult populations within Asia. A total of 83 relevant studies were appraised in this review. Analyses of the extant data confirmed that vaccination rates within Asia are low, and that most countries lack scientific research on vaccination behaviours. Studies were categorised into four different population groups: healthcare workers, high risk groups, general population and uniform groups. The motivators and deterrents for vaccine uptake varied according to population groups and characteristics. Both general populations and healthcare workers were concerned with vaccine safety and efficacy, and recommendations from health authorities were influential in vaccine uptake within the other populations.
   The findings suggest that further research is needed within a broader range of Asian countries to garner greater in-depth knowledge of vaccination behaviours in the region. In particular, influenza vaccination programs within Asia should focus on improving engagement more effectively, through greater relatability and transparency of data when educating the public. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sheldenkar, Anita; Lim, Fann; Lwin, May O.] Nanyang Technol Univ, Wee Kim Wee Sch Commun & Informat, 31 Nanyang Link, Singapore 637718, Singapore.
   [Yung, Chee Fu] KK Womens & Childrens Hosp ICKH, Singapore, Singapore.
   [Yung, Chee Fu] Duke NUS Grad Med Sch, Singapore, Singapore.
RP Sheldenkar, A (reprint author), Nanyang Technol Univ, Wee Kim Wee Sch Commun & Informat, 31 Nanyang Link, Singapore 637718, Singapore.
EM anitas@ntu.edu.sg
FU Singapore Ministry of Health's Communicable Diseases Public Health
   Research GrantMinistry of Health-Singapore [MOH/CDPHRG/0017/2015]
FX This research is supported by the Singapore Ministry of Health's
   Communicable Diseases Public Health Research Grant MOH/CDPHRG/0017/2015.
   The funder had no involvement in study design, data collection,
   analysis, interpretation of data, writing of this manuscript or decision
   to submit for publication.
CR Ahmed M, 2018, INFLUENZA OTHER RESP, V12, P65, DOI 10.1111/irv.12490
   Bali NK, 2013, INFLUENZA OTHER RESP, V7, P540, DOI 10.1111/j.1750-2659.2012.00416.x
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Chai SJ, 2013, AM J PREV MED, V45, P190, DOI 10.1016/j.amepre.2013.03.014
   Chan EYY, 2015, VACCINE, V33, P4737, DOI 10.1016/j.vaccine.2015.07.046
   Chan TF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082004
   Chang YC, 2013, VACCINE, V31, P410, DOI 10.1016/j.vaccine.2012.10.086
   Cheung EKH, 2017, J HOSP INFECT, V97, P376, DOI 10.1016/j.jhin.2017.08.005
   Chor JSY, 2011, VACCINE, V29, P7364, DOI 10.1016/j.vaccine.2011.07.079
   Chor JSY, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3391
   Dawood FS, 2012, LANCET INFECT DIS, V12, P687, DOI 10.1016/S1473-3099(12)70121-4
   Ditsungnoen D, 2016, VACCINE, V34, P2141, DOI 10.1016/j.vaccine.2016.01.056
   Gargano LM, 2013, INT HEALTH, V5, P205, DOI 10.1093/inthealth/iht018
   Heo JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064230
   Honda H, 2012, J HOSP INFECT, V80, P316, DOI 10.1016/j.jhin.2011.12.014
   Honda H, 2013, INFECT CONT HOSP EP, V34, P1194, DOI 10.1086/673452
   Hou ZY, 2014, VACCINE, V32, P4471, DOI 10.1016/j.vaccine.2014.06.047
   Hu Y, 2017, INT J ENV RES PUBLIC, V14
   Huang JH, 2012, EUR J PUBLIC HEALTH, V22, P796, DOI 10.1093/eurpub/ckr167
   Iwasa T, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-647
   Jennings LC, 2013, INFLUENZA OTHER RESP, V7, P44, DOI 10.1111/irv.12180
   Jion LDI, FORCE MED PROTECTION
   Jung EJ, 2016, HUM VACC IMMUNOTHER, V12, P1997, DOI 10.1080/21645515.2015.1119347
   Kang HS, 2015, HEALTH CARE WOMEN IN, V36, P1026, DOI 10.1080/07399332.2014.942903
   Kenah E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019515
   Khan AA, 2015, VACCINE, V33, P5103, DOI 10.1016/j.vaccine.2015.08.014
   Khan TM, 2016, VACCINE, V34, P1393, DOI 10.1016/j.vaccine.2016.01.045
   Kondo M, 2009, HEALTH POLICY, V91, P269, DOI 10.1016/j.healthpol.2008.12.014
   Koul PA, 2017, INDIAN HEART J, V69, P28, DOI 10.1016/j.ihj.2016.07.012
   Koul PA, 2014, INT J GYNECOL OBSTET, V127, P234, DOI 10.1016/j.ijgo.2014.05.021
   Kwon Y, 2010, VACCINE, V29, P161, DOI 10.1016/j.vaccine.2010.10.063
   Kwong EWY, 2010, J ADV NURS, V66, P2297, DOI 10.1111/j.1365-2648.2010.05397.x
   Kwong Enid Wai-yung, 2008, Nurs Older People, V20, P29
   Kwong EWY, 2009, J CLIN NURS, V18, P960, DOI 10.1111/j.1365-2702.2008.02548.x
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lau JTF, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4164
   Lau JTF, 2012, AM J INFECT CONTROL, V40, pE225, DOI 10.1016/j.ajic.2012.01.036
   Lau JTF, 2010, VACCINE, V28, P4632, DOI 10.1016/j.vaccine.2010.04.076
   Lee PH, 2017, AM J INFECT CONTROL, V45, P575, DOI 10.1016/j.ajic.2016.05.038
   Lee SS, 2013, EMERG INFECT DIS, V19, P1660, DOI 10.3201/eid1910.130195
   Lee YK, 2012, AM J INFECT CONTROL, V40, P481, DOI 10.1016/j.ajic.2011.05.015
   Li YC, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-603
   Li YC, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-275
   Liao Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023786
   Liao SB, 2013, FRONT PHILOS CHINA, V8, P1, DOI 10.3868/s030-002-013-0001-2
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Lin YL, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-128
   Liu SJ, 2011, HUM VACCINES, V7, P1072, DOI 10.4161/hv.7.10.16781
   Mak KK, 2013, EUR J PUBLIC HEALTH, V23, P257, DOI 10.1093/eurpub/cks014
   Matsui D, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-149
   Naing Cho, 2012, J Infect Public Health, V5, P412, DOI 10.1016/j.jiph.2012.07.005
   Ng TC, 2009, INFECT CONT HOSP EP, V30, P292, DOI 10.1086/595690
   Noh JY, 2016, J KOREAN MED SCI, V31, P1063, DOI 10.3346/jkms.2016.31.7.1063
   Nordfeldt C, 2010, FORUM DEV STUD, V37, P327, DOI 10.1080/08039410.2010.513402
   Organization W.H., 2010, EM PREP RESP PAND H1
   Oshitani H, 2008, EMERG INFECT DIS, V14, P875, DOI 10.3201/eid1406.070839
   Payaprom Y, 2010, J PUBLIC HEALTH-UK, V32, P26, DOI 10.1093/pubmed/fdp086
   Peng Y, 2013, PUBLIC HEALTH, V127, P930, DOI 10.1016/j.puhe.2013.06.007
   Praphasiri P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169221
   Rashid ZZ, 2015, SE ASIAN J TROP MED, V46, P215
   Rodas JR, 2012, PUBLIC HEALTH, V126, P1007, DOI 10.1016/j.puhe.2012.09.011
   Ryu SY, 2011, INT J ENV RES PUB HE, V8, P4197, DOI 10.3390/ijerph8114197
   Saha S, 2014, B WORLD HEALTH ORGAN, V92, P318, DOI 10.2471/BLT.13.124412
   Seale H, 2011, VACCINE, V29, P1605, DOI 10.1016/j.vaccine.2010.12.077
   Seale H, 2010, OCCUP MED-OXFORD, V60, P335, DOI 10.1093/occmed/kqq037
   Song Y, 2017, VACCINE, V35, P4060, DOI 10.1016/j.vaccine.2017.06.054
   Sundaram N, 2018, VACCINE, V36, P1996, DOI 10.1016/j.vaccine.2018.02.102
   Sundaram N, 2017, INT J PUBLIC HEALTH, V62, P103, DOI 10.1007/s00038-016-0903-z
   Sundaram N, 2015, HUM VACC IMMUNOTHER, V11, P2376, DOI 10.1080/21645515.2015.1062956
   Suresh PS, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-205
   Tam DKP, 2008, INFECT CONT HOSP EP, V29, P256, DOI 10.1086/527507
   Tan EK, 2010, SINGAP MED J, V51, P623
   Tarrant M, 2013, MATERN CHILD HLTH J, V17, P23, DOI 10.1007/s10995-011-0943-1
   Thoon KC, 2010, ANN ACAD MED SINGAP, V39, P307
   Tilburt JC, 2008, VACCINE, V26, pD27, DOI 10.1016/j.vaccine.2008.07.068
   To KW, 2015, HUM VACC IMMUNOTHER, V11, P1345, DOI 10.1080/21645515.2015.1034916
   To KW, 2010, AM J INFECT CONTROL, V38, P623, DOI 10.1016/j.ajic.2010.05.015
   Toh MPHS, 2012, VACCINE, V30, P1064, DOI 10.1016/j.vaccine.2011.12.037
   Tsai YY, 2014, VACCINE, V32, P6667, DOI 10.1016/j.vaccine.2014.08.080
   Wada K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059272
   Wong LP, 2010, VACCINE, V28, P4499, DOI 10.1016/j.vaccine.2010.04.043
   Wong SYS, 2012, INT J INFECT DIS, V16, pE687, DOI 10.1016/j.ijid.2012.03.015
   Wong SYS, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-316
   Worasathit R, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0137-6
   World Health Organization, 2018, INFLUENZA
   Wu SS, 2018, VACCINE, V36, P491, DOI 10.1016/j.vaccine.2017.12.008
   Wu SS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017459
   Wu SS, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-636
   Yang HJ, 2014, INT J ENV RES PUB HE, V11, P12162, DOI 10.3390/ijerph111212162
   Yang L, 2017, VACCINE, V35, P889, DOI 10.1016/j.vaccine.2017.01.004
   Yang L, 2015, VACCINE, V33, P6525, DOI 10.1016/j.vaccine.2015.10.012
   Yap J, 2010, BMC PUBLIC HEALTH, P10
   Yi SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018893
   Yu DSF, 2014, PREDICTING INFLUENZA, P270
   Yu MC, 2014, INFLUENZA VACCINATIO, P1028
   Yuen CYS, 2016, VACCINE, V34, P33, DOI 10.1016/j.vaccine.2015.11.032
   Zhou L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057382
NR 97
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4896
EP 4905
DI 10.1016/j.vaccine.2019.07.011
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100017
PM 31301918
DA 2020-05-12
ER

PT J
AU Madeddu, G
   Vroling, H
   Oordt-Speets, A
   Babudieri, S
   O'Moore, E
   Noordegraaf, MV
   Monarca, R
   Lopalco, PL
   Hedrich, D
   Tavoschi, L
AF Madeddu, Giordano
   Vroling, Hilde
   Oordt-Speets, Anouk
   Babudieri, Sergio
   O'Moore, Eamonn
   Noordegraaf, Marije Vonk
   Monarca, Roberto
   Lopalco, Pier Luigi
   Hedrich, Dagmar
   Tavoschi, Lara
TI Vaccinations in prison settings: A systematic review to assess the
   situation in EU/EEA countries and in other high income countries
SO VACCINE
LA English
DT Review
DE Vaccination; Prison; Systematic review; EU/EAA countries; High income
   countries
ID HEPATITIS-B VACCINATION; CORRECTIONAL FACILITIES; HEALTH LITERACY;
   TUBERCULOSIS; SCHEDULE; INMATES; BURDEN; WOMEN; A/B; HIV
AB Introduction: In 2016, more than 600,000 persons were being held in EU/EEA correctional facilities on a given day. People in prison may be at risk of vaccine-preventable diseases. While vaccination recommendations for people in prison exist, little is known on coverage and implementation options.
   Methods: We performed a systematic review on existing evidence on vaccination in prison settings in the EU/EEA. We searched peer-reviewed and grey literature following international methodology and reporting standards, to gather records published between 1980 and 2016 in all languages. We analysed quantitative (acceptance, uptake, cost-effectiveness) and qualitative (barriers) outcomes.
   Results: Out of 7041 identified records, 19 full-text articles were included from peer-reviewed literature and two from grey literature. Of these, 18 reported on hepatitis A and/or B virus (HAV/HBV), two on influenza and one on MMR vaccination. Two studies on HAV vaccine reported varying acceptance (5-91%) and uptake rates (62.9-70.5%). Seven studies reported on HBV vaccination. A comparative study showed a significantly higher uptake of the third HBV vaccine dose with the very rapid (63%) compared to the standard schedule (20%). HBV vaccination was generally well accepted (54-100%), whereas uptake was variable (dose 1:23-100%, dose 2:48-92%, dose 3:19-80%). One study on the combined HAV/HBV vaccine reported an acceptance rate of 34%, and declining uptake following dose 1. One study on influenza vaccine showed an uptake of 42-46%, while another reported a MMR vaccine acceptance of 80% and an uptake of 74%. Overall, main reasons for non-vaccination included release from/or transfer between prisons, and refusal.
   Conclusions: This systematic review highlighted important knowledge gaps and operational challenges for vaccination in prison settings. Vaccination is an effective measure that warrants comprehensive and tailored implementation to reduce the preventable disease burden, avoid risks of large outbreaks of vaccine-preventable diseases, and contribute to health equity for people in prison. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Madeddu, Giordano; Babudieri, Sergio] Univ Sassari, Dept Med Surg & Expt Sci, Unit Infect Dis, Viale San Pietro 43, I-07100 Sassari, Italy.
   [Vroling, Hilde; Oordt-Speets, Anouk; Noordegraaf, Marije Vonk] Pallas Hlth Res & Consultancy BV, Rotterdam, Netherlands.
   [O'Moore, Eamonn] Publ Hlth England, Hlth & Justice Team, Reading, Berks, England.
   [O'Moore, Eamonn] WHO Hlth Prisons Programme Europe, UK Collaborating Ctr, Reading, Berks, England.
   [Monarca, Roberto] Hlth Barriers European Federat Prison Hlth, Viterbo, Italy.
   [Lopalco, Pier Luigi; Tavoschi, Lara] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy.
   [Hedrich, Dagmar] European Monitoring Ctr Drugs & Drug Addict, Lisbon, Portugal.
   [Tavoschi, Lara] European Ctr Dis Prevent & Control, Stockholm, Sweden.
RP Madeddu, G (reprint author), Univ Sassari, Dept Med Surg & Expt Sci, Unit Infect Dis, Viale San Pietro 43, I-07100 Sassari, Italy.
EM giordano@uniss.it
RI Lopalco, Pier Luigi/K-1293-2018; Tavoschi, Lara/K-1729-2018
OI Lopalco, Pier Luigi/0000-0002-3181-8054; MADEDDU,
   Giordano/0000-0001-6099-2273; Tavoschi, Lara/0000-0002-2217-4664
FU European Centre for Disease Prevention and Control [ECDC/2015/028,
   ECD.5855]; European Monitoring Centre on Drugs and Drug Addiction
   (EMCDDA)
FX This work was supported by the European Centre for Disease Prevention
   and Control (framework contract number ECDC/2015/028, specific contract
   number ECD.5855) and is part of a wider joint undertaking with the
   European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) to
   develop European guidance on the prevention of communicable diseases in
   the prison setting.
CR Aebi M, 2018, SPACE 1 C STRASBOURG
   [Anonymous], 2012, Wkly Epidemiol Rec, V87
   [Anonymous], GLOB VACC ACT PLAN 2
   [Anonymous], 2017, POSITION PAPER, V92, P369
   Awofeso N, 2001, VACCINE, V19, P4245, DOI 10.1016/S0264-410X(01)00172-4
   BAYAS JM, 1993, VACCINE, V11, P1441, DOI 10.1016/0264-410X(93)90174-V
   Beck CR, 2012, VACCINE, V30, P1965, DOI 10.1016/j.vaccine.2012.01.020
   Biasio LR, 2018, HUM VACC IMMUNOTHER, V14, P1515, DOI 10.1080/21645515.2018.1434382
   Carrillo-Santisteve P, 2017, LANCET INFECT DIS, V17, pE306, DOI 10.1016/S1473-3099(17)30392-4
   Christensen PB, 2004, VACCINE, V22, P3897, DOI 10.1016/j.vaccine.2004.04.011
   Clarke J, 2003, J HEALTH CARE POOR U, V14, P318, DOI 10.1177/1049208903255440
   Commission of the European Communities, 2009, PROP COUNC REC SEAS
   Costumbrado J, 2012, VACCINE, V30, P6878, DOI 10.1016/j.vaccine.2012.09.006
   Devine A, 2007, AUST NZ J PUBL HEAL, V31, P127, DOI 10.1111/j.1753-6405.2007.00029.x
   Dolan K, 2016, LANCET, V388, P1089, DOI 10.1016/S0140-6736(16)30466-4
   ECDC, 2016, IMM
   European Centre for Disease Prevention and Control, 2015, SEAS INFL VACC EUR O
   European Centre for Disease Prevention and Control European Monitoring Centre for Drugs and Drug Addiction, 2018, PUBL HLTH GUID PREV
   Falla AM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2988-x
   Fazel S, 2017, ADDICTION, V112, P1725, DOI 10.1111/add.13877
   Fournet N, 2018, BMC PUBLIC HEALTH, V18, P196, DOI [10.1186/s12889-018-5103-8, DOI 10.1186/S12889-018-5103-8.REVIEW]
   Gabbuti A., 2014, VALUTAZIONE PE UNPUB
   Gabbuti A., 2014, RICHIESTA PRED UNPUB
   Gilbert R L, 2004, Commun Dis Public Health, V7, P289
   Gilbert R L, 2004, Commun Dis Public Health, V7, P306
   Hammett TM, 2002, AM J PUBLIC HEALTH, V92, P1789, DOI 10.2105/AJPH.92.11.1789
   Herlihy EJ, 2007, PUBLIC HEALTH REP, V122, P36, DOI 10.1177/00333549071220S207
   Higgins JPT, 2011, COCHRANE HDB SYSTEMA
   Jacobs RJ, 2004, VACCINE, V22, P1241, DOI 10.1016/j.vaccine.2003.09.018
   Jacobs RJ, 2003, PUBLIC HEALTH REP, V118, P550, DOI 10.1016/S0033-3549(04)50291-1
   Jacomet C, 2016, EUR J PUBLIC HEALTH, V26, P122, DOI 10.1093/eurpub/ckv183
   Junghans C, 2018, EPIDEMIOL INFECT, V146, P1689, DOI [10.1017/S0950268818001991, 10.1017/s0950268818001991]
   Kamarulzaman A, 2016, LANCET, V388, P1115, DOI 10.1016/S0140-6736(16)30769-3
   Kotsopoulos N, 2015, HEALTH ECON REV, V5, DOI 10.1186/s13561-015-0054-6
   Lorini C, 2018, HUM VACC IMMUNOTHER, V14, P478, DOI 10.1080/21645515.2017.1392423
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Mipatrini D, 2017, PATHOG GLOB HEALTH, V111, P59, DOI 10.1080/20477724.2017.1281374
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Murphy M, 2018, VACCINE, V36, P5651, DOI 10.1016/j.vaccine.2018.07.031
   Ndumbi P, 2018, EURO SURVEILL, V23
   Nijhawan AE, 2010, J WOMENS HEALTH, V19, P17, DOI 10.1089/jwh.2009.1469
   Palmateer NE, 2018, ADDICTION, V113, P80, DOI 10.1111/add.13944
   Pisu M, 2002, VACCINE, V21, P312, DOI 10.1016/S0264-410X(02)00457-7
   Public Health England, 2013, SEAS FLU PRIS DET CE
   Public Health England, 2014, HLTH JUST HLTH NEEDS
   Public Health England, 2014, PAND INFL STRAT FRAM
   Robinson Sara, 2012, Morbidity and Mortality Weekly Report, V61, P229
   Seib K, 2013, PUBLIC HEALTH REP, V128, P198, DOI 10.1177/003335491312800310
   Skarupski KA, 2018, EPIDEMIOL REV, V40, P157, DOI 10.1093/epirev/mxx020
   Tavoschi L, 2019, LANCET INFECT DIS, VS1473-3099, P30756
   Tavoschi L, 2018, EPIDEMIOL REV, V40, P105, DOI 10.1093/epirev/mxy001
   Vallabhaneni S, 2004, PREV MED, V38, P828, DOI 10.1016/j.ypmed.2003.12.024
   Walkty A, 2011, CAN J PUBLIC HEALTH, V102, P341, DOI 10.1007/BF03404173
   WHO, WHO REC ROUT IMM SUM
   World Health Organization, 2014, PRIS HLTH
NR 55
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4906
EP 4919
DI 10.1016/j.vaccine.2019.07.014
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100018
PM 31327651
DA 2020-05-12
ER

PT J
AU Zhao, BB
   Marciniuk, K
   Gibbs, E
   Yousefi, M
   Napper, S
   Cashman, NR
AF Zhao, Beibei
   Marciniuk, Kristen
   Gibbs, Ebrima
   Yousefi, Masoud
   Napper, Scott
   Cashman, Neil R.
TI Therapeutic vaccines for amyotrophic lateral sclerosis directed against
   disease specific epitopes of superoxide dismutase 1
SO VACCINE
LA English
DT Article
ID AMYLOID-BASED IMMUNOTHERAPY; NEURODEGENERATIVE DISEASES; MOUSE MODEL;
   IMMUNIZATION; ANTIBODY; SOD1; VACCINATION; INDUCTION; PATHOLOGY;
   DELIVERY
AB Emerging evidence suggests seeding and prion-like propagation of mutant Superoxide Dismutase 1 (SOD1) misfolding to be a potential mechanism for ALS pathogenesis and progression. Immunotargeting of misfolded SOD1 has shown positive clinical outcomes in mutant SOD1 transgenic mice. However, a major challenge in developing active immunotherapies for proteinopathies such as ALS is the design of immunogens enabling exclusive recognition of pathogenic species of a self-protein. Ideally, one would achieve a robust antibody response against the disease-misfolded protein while sparing the natively folded conformer to avoid inducing deleterious autoimmune complications, or inhibiting its normal function. Using a motor neuron disease mouse model expressing human SOD1-G37R, we herein report the immunogenicity and therapeutic efficacy of two ALS vaccines, tgG-DSE2lim and tgG-DSE5b, based on the notion that native SOD1 would undergo early unfolding in disease to present "disease specific epitopes" (DSE). Both vaccines elicited rapid, robust, and well-sustained epitope-specific antibody responses with a desirable Th2-biased immune response. Both vaccines significantly extended the life expectancy of hSOD1(G37R) mice, with tgG-DSE2lim displaying greater protection than tgG-DSE5b at earlier pre-symptomatic stage. tgG-DSE5b, but not tgG-DSE2lim, significantly delayed disease onset and appreciably slowed disease progression. This implies that conformationally distinct species of misfolded SOD1 may derive from the same mutation, thereby modifying disease phenotypes in a different fashion. Our results validate the rationale for conformation-based immuno-targeting of misfolded SOD1 as a promising therapeutic strategy to slow or even halt disease progression in familial ALS associated with SOD1 mutations, as well as a prophylactic intervention for carriers of SOD1 mutations. Our study not only provides important proof-of-principle data for the development of a safe and effective human therapeutic/prophylactic ALS vaccine against misfolded SOD1, but also predicts a great potential to extend our DSE-based vaccination approach to other types of ALS, such as those associated with TDP-43 proteinopathies. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Zhao, Beibei; Gibbs, Ebrima; Yousefi, Masoud; Cashman, Neil R.] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V6T 2B5, Canada.
   [Marciniuk, Kristen; Napper, Scott] Univ Saskatchewan, Dept Biochem Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada.
   [Marciniuk, Kristen; Napper, Scott] Univ Saskatchewan, Vaccine & Infect Dis Org Int Vaccine Res Ctr, Saskatoon, SK S7N 5E3, Canada.
RP Cashman, NR (reprint author), Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC V6T 2B5, Canada.
EM neil.cashman@vch.ca
OI Zhao, BeiBei/0000-0002-4445-8967
FU Weston Brain Institute (Toronto, ON, Canada)
FX We thank Dr. Luke McAlary for reviewing the manuscript and constructive
   input. This work was funded by Weston Brain Institute (Toronto, ON,
   Canada).
CR Abou Ezzi S, 2010, J NEUROCHEM, V115, P1102, DOI 10.1111/j.1471-4159.2010.06979.x
   Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544
   Barneoud P, 1997, NEUROREPORT, V8, P2861, DOI 10.1097/00001756-199709080-00012
   Barrera-Ocampo A, 2016, COLOMB MEDICA, V47, P203
   Bergh J, 2015, P NATL ACAD SCI USA, V112, P4489, DOI 10.1073/pnas.1419228112
   Bidhendi EE, 2016, J CLIN INVEST, V126, P2249, DOI 10.1172/JCI84360
   Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244
   Cashman NR, 2011, US Patent, Patent No. [12/978,478, 201112978478]
   Cashman NR, 2011, US Patent, Patent No. [2011/0212097 A1, 20110212097A1]
   Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901
   Elam JS, 2003, NAT STRUCT BIOL, V10, P461, DOI 10.1038/nsb935
   Gillam JE, 2013, J PHYS-CONDENS MAT, V25, DOI 10.1088/0953-8984/25/37/373101
   Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C
   Grad LI, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a024117
   Grad LI, 2011, P NATL ACAD SCI USA, V108, P16398, DOI 10.1073/pnas.1102645108
   Gros-Louis F, 2010, J NEUROCHEM, V113, P1188, DOI 10.1111/j.1471-4159.2010.06683.x
   Guest WC, 2011, J TOXICOL ENV HEAL A, V74, P1433, DOI 10.1080/15287394.2011.618967
   Hedlin PD, 2010, VACCINE, V28, P981, DOI 10.1016/j.vaccine.2009.10.134
   Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101
   Ido A, 2011, INT J MOL SCI, V12, P6980, DOI 10.3390/ijms12106980
   Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110
   Khare SD, 2005, PROTEINS, V61, P617, DOI 10.1002/prot.20629
   Lee CC, 2007, BIOPHYS J, V92, P3448, DOI 10.1529/biophysj.106.098608
   Li L, 2010, IMMUNOTHERAPY-UK, V2, P269, DOI 10.2217/IMT.10.3
   Liu HN, 2012, J NEUROSCI, V32, P8791, DOI 10.1523/JNEUROSCI.5053-11.2012
   Lobello Kasia, 2012, Int J Alzheimers Dis, V2012, P628070, DOI 10.1155/2012/628070
   Mandler M, 2014, ACTA NEUROPATHOL, V127, P861, DOI 10.1007/s00401-014-1256-4
   Marciniuk K, 2016, METHODS MOL BIOL, V1403, P657, DOI 10.1007/978-1-4939-3387-7_37
   Marciniuk K, 2015, BIOINFORMATICS, V31, P2388, DOI 10.1093/bioinformatics/btv136
   Marciniuk K, 2014, VACCINE, V32, P1988, DOI 10.1016/j.vaccine.2014.01.027
   Marciniuk K, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/473706
   Masliah E, 2005, NEUROLOGY, V64, P129, DOI 10.1212/01.WNL.0000148590.39911.DF
   Miller RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub3
   Molnar KS, 2009, J BIOL CHEM, V284, P30965, DOI 10.1074/jbc.M109.023945
   Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116
   Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8
   Panza F, 2014, EXPERT REV CLIN IMMU, V10, P405, DOI 10.1586/1744666X.2014.883921
   Panza F, 2014, CURR OPIN PSYCHIATR, V27, P128, DOI 10.1097/YCO.0000000000000041
   Peng X, 2018, J PHYS CHEM B
   Petrushina I, 2003, NEUROSCI LETT, V338, P5, DOI 10.1016/S0304-3940(02)01357-5
   Qualls DA, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-46
   Rakhit R, 2006, BBA-MOL BASIS DIS, V1762, P1025, DOI 10.1016/j.bbadis.2006.05.004
   ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0
   Rotunno MS, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00253
   Schenk D, 2004, CURR OPIN IMMUNOL, V16, P599, DOI 10.1016/j.coi.2004.07.012
   Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124
   Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323
   SHINNICK TM, 1983, ANNU REV MICROBIOL, V37, P425, DOI 10.1146/annurev.mi.37.100183.002233
   Soto C, 2009, P NATL ACAD SCI USA, V106, P10, DOI 10.1073/pnas.0811625106
   Southwell AL, 2010, REV NEUROSCIENCE, V21, P273
   Takeuchi S, 2010, J NEUROPATH EXP NEUR, V69, P1044, DOI 10.1097/NEN.0b013e3181f4a90a
   Taschuk R, 2015, J IMMOL VACC, V1, P101
   Urushitani M, 2007, P NATL ACAD SCI USA, V104, P2495, DOI 10.1073/pnas.0606201104
   Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647
   Valera E, 2013, PHARMACOL THERAPEUT, V138, P311, DOI 10.1016/j.pharmthera.2013.01.013
NR 55
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4920
EP 4927
DI 10.1016/j.vaccine.2019.07.044
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100019
PM 31324499
OA Other Gold
DA 2020-05-12
ER

PT J
AU Daugherty, MA
   Hinman, AR
   Cochi, SL
   Garon, JR
   Rodewald, LE
   Nowak, G
   McKinlay, MA
   Mast, EE
   Orenstein, WA
AF Daugherty, Michael A.
   Hinman, Alan R.
   Cochi, Stephen L.
   Garon, Julie R.
   Rodewald, Lance E.
   Nowak, Glen
   McKinlay, Mark A.
   Mast, Eric E.
   Orenstein, Walter A.
TI The Global Vaccine Action Plan - insights into its utility, application,
   and ways to strengthen future plans
SO VACCINE
LA English
DT Article
DE Global vaccine action plan; Vaccine-preventable diseases; Vaccines;
   Immunization; Immunization programs; Surveys and questionnaires
AB Background: The pace of global progress must increase if the Global Vaccine Action Plan (GVAP) goals are to be achieved by 2020. We administered a two-phase survey to key immunization stakeholders to assess the utility and application of GVAP, including how it has impacted country immunization programs, and to find ways to strengthen the next 10-year plan.
   Methods: For the Phase I survey, an online questionnaire was sent to global immunization stakeholders in summer 2017. The Phase II survey was sent to regional and national immunization stakeholders in summer 2018, including WHO Regional Advisors on Immunization, Expanded Programme on Immunization managers, and WHO and UNICEF country representatives from 20 countries. Countries were selected based on improvements (10) versus decreases (10) in DTP3 coverage from 2010 to 2016.
   Results: Global immunization stakeholders (n = 38) cite global progress in improving vaccine delivery (88%) and engaging civil society organizations as advocates for vaccines (83%). Among regional and national immunization stakeholders (n = 58), 70% indicated reaching mobile and underserved populations with vaccination activities as a major challenge. The top ranked activities for helping country programs achieve progress toward GVAP goals include improved monitoring of vaccination coverage and upgrading disease surveillance systems. Most respondents (96%) indicated GVAP as useful for determining immunization priorities and 95% were supportive of a post-2020 GVAP strategy.
   Conclusions: Immunization stakeholders see GVAP as a useful tool, and there is cause for excitement as the global immunization community looks toward the next decade of vaccines. The next 10-year plan should attempt to increase political will, align immunization activities with other health system agendas, and address important issues like reaching mobile/migrant populations and improving data reporting systems. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Daugherty, Michael A.; Garon, Julie R.; Orenstein, Walter A.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA.
   [Hinman, Alan R.; McKinlay, Mark A.] Task Force Global Hlth, Ctr Vaccine Equ, Decatur, GA USA.
   [Cochi, Stephen L.; Mast, Eric E.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA.
   [Rodewald, Lance E.] Chinese Ctr Dis Control & Prevent, Natl Immunizat Program, Beijing, Peoples R China.
   [Nowak, Glen] Univ Georgia, Ctr Hlth & Risk Commun, Grady Coll Journalism & Mass Commun, Athens, GA 30602 USA.
   [Orenstein, Walter A.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
RP Daugherty, MA (reprint author), Emory Vaccine Ctr, 1462 Clifton Rd NE,DSB 446, Atlanta, GA 30322 USA.
EM michael.daugherty@emory.edu
OI Nowak, Glen/0000-0002-9153-2189; Rodewald, Lance/0000-0003-2593-542X
FU U.S. Centers for Disease Control and PreventionUnited States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
   [5NU2RGH001906-04-00]
FX We would like to thank our survey respondents for their time and
   consideration, as well as Vincent Fenimore for providing guidance on the
   survey project process and Patrick Lydon, Christoph Steffen, and Noni
   MacDonald for providing helpful feedback on the manuscript. We
   appreciate the assistance of WHO and UNICEF leadership for providing
   contact information for some of our survey participants. This
   publication was supported by Cooperative Agreement number
   5NU2RGH001906-04-00, funded by the U.S. Centers for Disease Control and
   Prevention to the Task Force for Global Health. Its contents are solely
   the responsibility of the authors and do not necessarily represent the
   official views of the U.S. Centers for Disease Control and Prevention or
   the U.S. Department of Health and Human Services.
CR Alonso PL, 2013, VACCINE, V31, pB3, DOI 10.1016/j.vaccine.2013.02.035
   [Anonymous], 2018, WKLY EPIDEMIOL REC, V93, P661
   Cernuschi T, 2018, VACCINE, V36, P6858, DOI 10.1016/j.vaccine.2018.06.012
   Danovaro-Holliday MC, 2018, VACCINE, V36, P5150, DOI 10.1016/j.vaccine.2018.07.019
   Fatima K, 2018, J GLOB HEALTH, V8, DOI [10.7189/jogh.08.020312, 10.7189/jogh.08-020312]
   Henaff L, 2018, NITAG RESOURCE CTR S
   Hinman AR, 2004, J INFECT DIS, V189, pS17, DOI 10.1086/377694
   Hui C, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15102065
   Lydon P., 2018, PROPOSED OUTLINE POS
   Lydon P., 2018, GLOBAL IMMUNIZATION
   Mantel C, 2017, SEG M 18 OCT 2017
   Ndiaye SM, 2014, J INFECT DIS, V210, pS74, DOI 10.1093/infdis/jit564
   United Nations, 2018, SUST DEV GOAL 3 ENS
   World Health Organization, 2016, 2016 MIDT REV GLOB V
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   World Health Organization, 2018, 2018 ASS REP GLOB VA
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4928
EP 4936
DI 10.1016/j.vaccine.2019.07.042
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100020
PM 31326253
DA 2020-05-12
ER

PT J
AU Sarkissian, CA
   Alteri, CJ
   Mobley, HLT
AF Sarkissian, Christina A.
   Alteri, Christopher J.
   Mobley, Harry L. T.
TI UTI patients have pre-existing antigen-specific antibody titers against
   UTI vaccine antigens
SO VACCINE
LA English
DT Article
DE UTI; Uropathogenic Escherichia coli; Humoral immunity; Recurrent UTI;
   Iron receptors
ID URINARY-TRACT-INFECTION; VAGINAL MUCOSAL IMMUNIZATION; ESCHERICHIA-COLI;
   UROLOGIC DISEASES; IMMUNE-RESPONSES; AMERICA PROJECT; PYELONEPHRITIS;
   PROTECTION; GENOME; MODEL
AB Urinary tract infection (UTI) is most frequently caused by uropathogenic Escherichia coli (UPEC). Our laboratory has been developing an experimental vaccine targeting four UPEC outer membrane receptors involved in iron acquisition - IreA, FyuA, IutA, and Hma - to elicit protection against UTI. These vaccine targets are all expressed in humans during UTI. In the murine model, high titers of antigen-specific serum IgG or bladder IgA correlate with protection against transurethral challenge with UPEC. Our aim was to measure levels of pre-existing serum antibodies to UTI vaccine antigens in our target population. To accomplish this, we obtained sera from 64 consenting female patients attending a clinic for symptoms of cystitis. As a control, we also collected sera from 20 healthy adult male donors with no history of UTI. Total IgG and antigen-specific IgG titers were measured by ELISA. Of the 64 female patients, 29 had significant bacteriuria (>10(4) cfu/ml urine) and uropathogenic E. coli (UPEC). Thirty-five patients had non-significant bacteriuria (<10(4) cfu/ml). Antigen-specific IgG titers did not correlate with the presence or absence of the gene encoding the antigen in the infecting strain (when present), but rather titers were proportional to prevalence of genes encoding antigens among representative collections of UPEC isolates. Surprisingly, we obtained similar results when sera from healthy male patients without history of UTI were tested. Thus, unvaccinated adults have non-protective levels of pre-existing antibodies to UTI vaccine antigens, establishing an important baseline for our target population. This suggests that a UTI vaccine would need to boost pre-existing humoral responses beyond these background levels to protect from infection. (C) 2019 Published by Elsevier Ltd.
C1 [Sarkissian, Christina A.; Alteri, Christopher J.; Mobley, Harry L. T.] Univ Michigan, Sch Med, Dept Microbiol & Immunol, 5641 Med Sci Bldg 2,1150 West Med Ctr Dr, Ann Arbor, MI 48109 USA.
   [Alteri, Christopher J.] Univ Michigan, Dept Nat Sci, 114 Sci Fac Ctr,4901 Evergreen Rd, Dearborn, MI 48128 USA.
RP Mobley, HLT (reprint author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, 5641 Med Sci Bldg 2,1150 West Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM hmobley@med.umich.edu
RI Alteri, Christopher/G-3243-2015
OI Alteri, Christopher/0000-0002-6367-5684
FU Public Health Service grants from the National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI116791, DK094777]
FX The authors would like to thank Dr. Donald Giacherio from the Department
   of Pathology at the University of Michigan Medical School for providing
   the healthy control sera, Dr. Michael Engstrom for his assistance
   organizing the Broad data set for analysis, and to members of the Mobley
   and Michael Bachman Laboratories for helpful feedback and discussion.
   This work was supported by Public Health Service grants AI116791 and
   DK094777 from the National Institutes of Health.
CR Alteri CJ, 2007, INFECT IMMUN, V75, P2679, DOI 10.1128/IAI.00076-06
   Alteri CJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000586
   Brumbaugh AR, 2015, INFECT IMMUN, V83, P1443, DOI 10.1128/IAI.02904-14
   Brumbaugh AR, 2013, INFECT IMMUN, V81, P3309, DOI 10.1128/IAI.00470-13
   Brumbaugh AR, 2012, EXPERT REV VACCINES, V11, P663, DOI [10.1586/ERV.12.36, 10.1586/erv.12.36]
   FOXMAN B, 1990, AM J PUBLIC HEALTH, V80, P331, DOI 10.2105/AJPH.80.3.331
   Foxman B, 2000, ANN EPIDEMIOL, V10, P509, DOI 10.1016/S1047-2797(00)00072-7
   Foxman B, 2010, NAT REV UROL, V7, P653, DOI 10.1038/nrurol.2010.190
   Goluszko P, 2005, INFECT IMMUN, V73, P627, DOI 10.1128/IAI.73.1.627-631.2005
   Griebling TL, 2005, J UROLOGY, V173, P1281, DOI 10.1097/01.ju.0000155596.98780.82
   Gupta K, 2001, ANN INTERN MED, V135, P41, DOI 10.7326/0003-4819-135-1-200107030-00012
   Hagan EC, 2007, INFECT IMMUN, V75, P3941, DOI 10.1128/IAI.00337-07
   Hagan EC, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001187
   Hopkins WJ, 2007, J UROLOGY, V177, P1349, DOI 10.1016/j.juro.2006.11.093
   Hopkins Walter J., 2002, Curr Infect Dis Rep, V4, P509, DOI 10.1007/s11908-002-0037-8
   Koukalova D, 1999, Bratisl Lek Listy, V100, P246
   Koukalova D, 1999, Bratisl Lek Listy, V100, P92
   Koukalova D, 1999, Bratisl Lek Listy, V100, P129
   KRUZE D, 1992, UROL RES, V20, P177, DOI 10.1007/BF00296534
   KRUZE D, 1989, UROL RES, V17, P361, DOI 10.1007/BF00510527
   Litwin MS, 2005, J UROLOGY, V173, P933, DOI 10.1097/01.ju.0000152365.43125.3b
   Lloyd AL, 2007, J BACTERIOL, V189, P3532, DOI 10.1128/JB.01744-06
   Marinova S, 2005, INT J IMMUNOPATH PH, V18, P457, DOI 10.1177/039463200501800306
   Mellata M, 2016, VACCINE, V34, P656, DOI 10.1016/j.vaccine.2015.12.014
   Mobley HLT, 2015, PATHOGENS, V5
   Mobley HLT, 2016, PATHOGENS, V5
   Moriel DG, 2010, P NATL ACAD SCI USA, V107, P9072, DOI 10.1073/pnas.0915077107
   Moura A, 2009, J APPL MICROBIOL, V106, P1779, DOI 10.1111/j.1365-2672.2008.04115.x
   OHANLEY P, 1991, INFECT IMMUN, V59, P1153, DOI 10.1128/IAI.59.3.1153-1161.1991
   Roberts JA, 2004, J UROLOGY, V171, P1682, DOI 10.1097/01.ju.0000116123.05160.43
   Schappert SM, 2006, NATL HLTH STAT REP, V2008, P1
   Schappert Susan M, 2011, Vital Health Stat 13, P1
   Snyder JA, 2004, INFECT IMMUN, V72, P6373, DOI 10.1128/IAI.72.11.6373-6381.2004
   Spurbeck RR, 2012, INFECT IMMUN, V80, P4115, DOI 10.1128/IAI.00752-12
   Subashchandrabose S, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.UTI-0015-2012
   Subashchandrabose S, 2014, P NATL ACAD SCI USA, V111, P18327, DOI 10.1073/pnas.1415959112
   Thumbikat P, 2006, J IMMUNOL, V176, P3080, DOI 10.4049/jimmunol.176.5.3080
   Uehling DT, 2003, J UROLOGY, V170, P867, DOI 10.1097/01.ju.0000075094.54767.6e
   Uehling DT, 1997, J UROLOGY, V157, P2049, DOI 10.1016/S0022-5347(01)64671-8
   Uehling DT, 2001, J INFECT DIS, V183, pS81, DOI 10.1086/318839
   UEHLING DT, 1991, J UROLOGY, V146, P223, DOI 10.1016/S0022-5347(17)37756-X
   Welch RA, 2002, P NATL ACAD SCI USA, V99, P17020, DOI 10.1073/pnas.252529799
NR 42
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4937
EP 4946
DI 10.1016/j.vaccine.2019.07.031
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100021
PM 31320216
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Mac Keon, S
   Bentivegna, S
   Levy, EM
   Marks, MS
   Mantegazza, AR
   Wainstok, R
   Mordoh, J
AF Mac Keon, Soledad
   Bentivegna, Sofia
   Levy, Estrella M.
   Marks, Michael S.
   Mantegazza, Adriana R.
   Wainstok, Rosa
   Mordoh, Jose
TI Syngeneic B16-F1 cells are more efficient than allogeneic Cloudman cells
   as antigen source in DC-based vaccination in the B16-F1 murine melanoma
   model
SO VACCINE
LA English
DT Article
DE Anti-melanoma vaccination; Dendritic cells; Tumor-associated antigens;
   Neoepitopes; Allogeneic cells; Syngeneic cells
ID MHC CLASS-II; CYTOLYTIC T-LYMPHOCYTES; NEURAL-NETWORKS; CANCER;
   EXPRESSION
AB A major obstacle to obtaining relevant results in cancer vaccination has been the lack of identification of immunogenic antigens. Dendritic cell (DC)-based cancer vaccines used preventively may afford protection against tumor inoculation, but the effect of antigen choice on anti-tumor protection is not clear. When using irradiated syngeneic tumor cells to load DCs, tumor self-antigens are provided, including tumor-associated antigens (TAAs) and neoantigens generated by tumor mutations. On the other hand, allogeneic tumor cells could only supply shared TAAs. To assess the advantages of each source in protective vaccination, we analyzed in C57BL/6 mice the effect of loading DCs with irradiated syngeneic B16-F1 or allogeneic Cloudman melanoma cells; both cell lines were characterized by whole exome sequencing and RNAseq. Tumor cell components from the two irradiated cell lines were efficiently internalized by DCs, and transported to MHC-class II positive tubulovesicular compartments (MIICs). DCs loaded with allogeneic irradiated Cloudman cells (DC-ApoNecALLO) induced a partially effective anti-melanoma protection, although Cloudman and B16-F1 cells share the expression of melanocyte differentiation antigens (MDAs), cancer-testis antigens (CTAs) and other TAAs. DCs loaded with syngeneic B16-F1 cells (DC-ApoNecSYN) established a more potent and long-lasting protection and induced a humoral anti-B16F1 response, thus suggesting that neoepitopes are needed for inducing long-lasting protection. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Mac Keon, Soledad; Bentivegna, Sofia; Wainstok, Rosa; Mordoh, Jose] Fdn Inst Leloir IIBBA CONICET, Cancerol Lab, Buenos Aires, DF, Argentina.
   [Levy, Estrella M.; Mordoh, Jose] Fdn Canc, Ctr Invest Oncol, Buenos Aires, DF, Argentina.
   [Marks, Michael S.; Mantegazza, Adriana R.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Wainstok, Rosa] IQUIBICEN CONICET UBA, Tumor Biol Lab, Buenos Aires, DF, Argentina.
   [Wainstok, Rosa] UBA, Tumor Biol Lab, Dept Biol Chem, FCEN, Buenos Aires, DF, Argentina.
   [Mordoh, Jose] Inst Alexander Fleming, Buenos Aires, DF, Argentina.
RP Mac Keon, S (reprint author), Fdn Inst Leloir IIBBA CONICET, Cancerol Lab, Buenos Aires, DF, Argentina.
EM smackeon@leloir.org.ar
OI Mantegazza, Adriana/0000-0002-7583-0231; Marks,
   Michael/0000-0001-7435-7262
FU Agencia para el Desarrollo Cientifico y Tecnologico, Argentina
   [PRE-STAMO BID PICT 2014-1932]; Fundacion SALES, Argentina; Fundacion
   Maria Calderon de la Barca, Argentina
FX This work was supported by grants from the following institutions:
   Agencia para el Desarrollo Cientifico y Tecnologico (PRE-STAMO BID PICT
   2014-1932), Fundacion SALES and Fundacion Maria Calderon de la Barca,
   Argentina.
CR Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Bobisse S, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.17
   BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0
   Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004
   Bogyo M, 1998, NATURE, V396, P625, DOI 10.1038/25238
   Castle JC, 2012, CANCER RES, V72, P1081, DOI 10.1158/0008-5472.CAN-11-3722
   Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006
   COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35
   Fratta E, 2011, MOL ONCOL, V5, P164, DOI 10.1016/j.molonc.2011.02.001
   GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921
   Gjerstorff MF, 2015, ONCOTARGET, V6, P15772, DOI 10.18632/oncotarget.4694
   Goldszmid RS, 2003, J IMMUNOL, V171, P5940, DOI 10.4049/jimmunol.171.11.5940
   KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P6458, DOI 10.1073/pnas.91.14.6458
   Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438
   Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202
   Mac Keon S, 2010, VACCINE, V28, P8162, DOI 10.1016/j.vaccine.2010.09.095
   Mantegazza AR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006785
   Mantegazza AR, 2014, P NATL ACAD SCI USA, V111, P15508, DOI 10.1073/pnas.1412998111
   Arriaga JM, 2012, HUM PATHOL, V43, P197, DOI 10.1016/j.humpath.2011.04.015
   Melero I, 2014, NAT REV CLIN ONCOL, V11, P509, DOI 10.1038/nrclinonc.2014.111
   NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Palucka K, 2013, IMMUNITY, V39, P38, DOI 10.1016/j.immuni.2013.07.004
   Peters B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-132
   Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161
   Sidney John, 2008, Immunome Res, V4, P2, DOI 10.1186/1745-7580-4-2
   van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521
   VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703
   Von Euw EM, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-6
   von Euw EM, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-19
   Wittrup KD, 2017, TRENDS CANCER, V3, P615, DOI 10.1016/j.trecan.2017.07.001
   WOLFEL T, 1994, EUR J IMMUNOL, V24, P759, DOI 10.1002/eji.1830240340
NR 35
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4947
EP 4955
DI 10.1016/j.vaccine.2019.07.018
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100022
PM 31307876
OA Other Gold
DA 2020-05-12
ER

PT J
AU Chowdhury, IR
   Yeddula, SGR
   Pierce, BG
   Samal, SK
   Kim, SH
AF Chowdhury, Ishita Roy
   Yeddula, Sai Goutham Reddy
   Pierce, Brian G.
   Samal, Siba K.
   Kim, Shin-Hee
TI Newcastle disease virus vectors expressing consensus sequence of the H7
   HA protein protect broiler chickens and turkeys against highly
   pathogenic H7N8 virus
SO VACCINE
LA English
DT Article
DE Highly pathogenic avian influenza virus; Newcastle disease virus
   vectors; Vaccines; Prime-boost vaccination; Chickens; Turkeys
ID AVIAN INFLUENZA-VIRUSES; VACCINES; HEMAGGLUTININ; VACCINATION; CHALLENGE
AB Continuous outbreaks of highly pathogenic avian influenza (HPAI) viruses in commercial poultry have caused devastating losses to domestic poultry with a raising public health concern. The outbreaks of HPAI viruses have increased worldwide, including the North America. Therefore, vaccination has been considered as an alternative strategy for an efficient control of HPAI viruses. In this study, we aimed to generate Newcastle disease virus (NDV) vectored H7 serotype-specific vaccines by expressing the consensus sequence of the HA protein. Conventional NDV strain LaSota vector and a chimeric NDV vector containing the avian paramyxovirus type-2 F and HN protein were able to express the consensus sequence of HA protein. The protective efficacy of vaccines was evaluated in broiler chickens and in turkeys. One-day-old poults were prime immunized with the chimeric vector expressing the HA protein followed by boost immunization with LaSota vector expressing the HA protein or co-expressing the HA and NA proteins. Our vaccine candidates provided complete protection of broiler chickens from mortality and shedding of H7N8 HPAI challenge virus. Turkeys were better protected by boosting with the LaSota vector co-expressing the HA and NA proteins than the LaSota vector expressing only the HA protein. Our study demonstrated a potential use of heterologous prime and boost vaccination strategy to protect poultry against H7 HPAI viruses. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chowdhury, Ishita Roy; Yeddula, Sai Goutham Reddy; Samal, Siba K.; Kim, Shin-Hee] Univ Maryland, VA MD Coll Vet Med, College Pk, MD 20742 USA.
   [Pierce, Brian G.] Univ Maryland, Inst Biosci & Biotechnol Res, Rockville, MD USA.
   [Pierce, Brian G.] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.
RP Kim, SH (reprint author), Univ Maryland, VA MD Coll Vet Med, College Pk, MD 20742 USA.
EM shinkim@umd.edu
FU NIH Biodefense and Emerging Infections Research Resources Repository,
   NIAID, NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [A/Netherlands/219/2003 (H7N7),
   A/Anhui/1/2013 (H7N9)]; Agriculture and Food Research Initiative
   competitive grant from the USDA National Institute of Food and
   Agriculture [2015-68004-23131]
FX We thank Girmay Gebreluul, Johanna Lavigne, Yonas Araya, and Alexis
   Aguin-Pino for excellent technical assistance. We also thank Dr.
   Nathaniel L. Tablante, Mark Dekich, and Don White for providing us with
   broiler chickens. The following reagent was obtained through the NIH
   Biodefense and Emerging Infections Research Resources Repository, NIAID,
   NIH: anti-influenza virus H7 HA, A/Netherlands/219/2003 (H7N7) and
   A/Anhui/1/2013 (H7N9). This project was supported by Agriculture and
   Food Research Initiative competitive grant number 2015-68004-23131 from
   the USDA National Institute of Food and Agriculture.
CR Abdelwhab EM, 2014, EPIDEMIOL INFECT, V142, P896, DOI 10.1017/S0950268813003324
   Barber MRW, 2013, MOL IMMUNOL, V54, P89, DOI 10.1016/j.molimm.2012.10.038
   Bertran K, 2017, VACCINE, V35, P6336, DOI 10.1016/j.vaccine.2017.05.051
   Carter DM, 2016, J VIROL, V90, P4720, DOI 10.1128/JVI.03152-15
   Chen MW, 2008, P NATL ACAD SCI USA, V105, P13538, DOI 10.1073/pnas.0806901105
   Cho Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35337-z
   DiNapoli JM, 2010, J VIROL, V84, P1489, DOI 10.1128/JVI.01946-09
   Gerhard W, 2001, CURR TOP MICROBIOL, V260, P171
   HORIMOTO T, 1995, VIROLOGY, V206, P755, DOI 10.1016/S0042-6822(95)80004-2
   Hu ZL, 2017, VACCINE, V35, P6585, DOI 10.1016/j.vaccine.2017.10.010
   Killian ML, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00457-16
   Kim SH, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030300
   Kim Shin-Hee, 2018, Curr Protoc Microbiol, V48, DOI 10.1002/cpmc.44
   Kim SH, 2017, VACCINE, V35, P4133, DOI 10.1016/j.vaccine.2017.06.055
   Kim SH, 2017, VIROLOGY, V503, P31, DOI 10.1016/j.virol.2017.01.006
   Lee DH, 2017, EMERG INFECT DIS, V23, P1860, DOI 10.3201/eid2311.171013
   Liu QF, 2015, J VIROL, V89, P7401, DOI 10.1128/JVI.00031-15
   Memoli MJ, 2016, MBIO, V7, DOI 10.1128/mBio.00417-16
   PALESE P., 2007, FIELDS VIROLOGY, V2, P1647, DOI DOI 10.1371/JOURNAL.PPAT.1003019
   Park MS, 2006, P NATL ACAD SCI USA, V103, P8203, DOI 10.1073/pnas.0602566103
   Schroer D, 2011, AVIAN DIS, V55, P201, DOI 10.1637/9539-092710-Reg.1
   Sonnberg S, 2013, VIRUS RES, V178, P63, DOI 10.1016/j.virusres.2013.05.009
   Suarez DL, 2017, VET MICROBIOL, V206, P144, DOI 10.1016/j.vetmic.2016.11.025
   Subbarao K, 2007, NAT REV IMMUNOL, V7, P267, DOI 10.1038/nri2054
   Swayne DE, 2013, DEV BIOLOGICALS, V135, P79, DOI 10.1159/000325276
   Swayne DE, 2011, REV SCI TECH OIE, V30, P839
   Swayne DE, 2012, AVIAN DIS, V56, P818, DOI 10.1637/10183-041012-Review.1
   WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992
   WEBSTER RG, 1989, VIROLOGY, V171, P484, DOI 10.1016/0042-6822(89)90618-1
   WHO/OIE/FAO H5N1 Evolution Working Group, 2008, Emerg Infect Dis, V14, pe1, DOI 10.3201/eid1407.071681
   Yang L, 2017, J VIROL, V91, DOI [10.1128/JVI.01277-17, 10.1128/jvi.01277-17]
NR 31
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4956
EP 4962
DI 10.1016/j.vaccine.2019.07.028
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100023
PM 31320218
DA 2020-05-12
ER

PT J
AU Volckmar, J
   Knop, L
   Stegemann-Koniszewski, S
   Schulze, K
   Ebensen, T
   Guzman, CA
   Bruder, D
AF Volckmar, Julia
   Knop, Laura
   Stegemann-Koniszewski, Sabine
   Schulze, Kai
   Ebensen, Thomas
   Guzman, Carlos A.
   Bruder, Dunja
TI The STING activator c-di-AMP exerts superior adjuvant properties than
   the formulation poly(I:C)/CpG after subcutaneous vaccination with
   soluble protein antigen or DEC-205-mediated antigen targeting to
   dendritic cells
SO VACCINE
LA English
DT Article
DE Adjuvant; c-di-AMP; Poly(I:C)/CpG; DEC-205; DC targeting; Subcutaneous
   route; Cell mediated immunity
ID IFN-GAMMA; I IFN; IMMUNE-RESPONSES; T-CELLS; ALPHA; IMMUNOGENICITY;
   MATURATION; RECEPTORS; INDUCTION; DELIVERY
AB Vaccination is the most efficient strategy to protect from infectious diseases and the induction of a protective immune response not only depends on the nature of the antigen, but is also influenced by the vaccination strategy and the co-administration of adjuvants. Therefore, the precise monitoring of adjuvant candidates and their immune modulatory properties is a crucial step in vaccine development. Here, one central aspect is the induction of appropriate humoral and cellular effector mechanisms.
   In our study we performed a direct comparison of two promising candidates in adjuvant development, the STING activator bis-(3,5)-cyclic dimeric adenosine monophosphate (c-di-AMP) and the Toll-like receptor ligand formulation poly(I:C)/CpG. These were evaluated in C57BL/6 mice using the model antigen ovalbumin (OVA) in subcutaneous vaccination with soluble protein as well as in a dendritic cell (DC) targeting approach (aDEC-OVA). Strikingly, c-di-AMP as compared to poly(I:C)/CpG resulted in significantly higher antigen-specific IgG antibody levels when used in immunization with soluble OVA as well as in antigen targeting to DC. In vaccination with soluble OVA, c-di-AMP induced a significantly stronger CTL, Th1 and IFNc-producing CD8(+) memory T cell response than poly(I:C)/CpG. The response was CTL and Th1 cell dominated, a profile shared by both adjuvants. In the context of targeting OVA to DC, c-di-AMP induced significantly increased Th1 and Th2 cell responses as compared to poly(I:C)/CpG. Interestingly, the Th1 response dominated the overall T cell response only when c-di-AMP was used, indicating a distinct modulatory property of c-di-AMP when the DC targeting immunization approach was exploited.
   Taken together, we describe superior properties of c-di-AMP as compared to poly(I:C)/CpG in subcutaneous vaccination with soluble antigen as well as antigen targeting to DC. This indicates exceptionally effective adjuvant properties for c-di-AMP and provides compelling evidence of its potential for further adjuvant development, especially also when using DC targeting approaches. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Volckmar, Julia; Knop, Laura; Stegemann-Koniszewski, Sabine; Bruder, Dunja] Otto von Guericke Univ, Inst Med Microbiol Infect Control & Prevent, Infect Immunol Grp, Hlth Campus Immunol Infectiol & Inflammat, D-39120 Magdeburg, Germany.
   [Volckmar, Julia; Knop, Laura; Stegemann-Koniszewski, Sabine; Bruder, Dunja] Helmholtz Ctr Infect Res, Immune Regulat Grp, Inhoffenstr 7, D-38124 Braunschweig, Germany.
   [Stegemann-Koniszewski, Sabine] Otto von Guericke Univ, Univ Hosp Pneumol, Expt Pneumol, Hlth Campus Immunol Infectiol & Inflammat, D-39120 Magdeburg, Germany.
   [Schulze, Kai; Ebensen, Thomas; Guzman, Carlos A.] Helmholtz Ctr Infect Res, Dept Vaccinol & Appl Microbiol, Inhoffenstr 7, D-38124 Braunschweig, Germany.
   [Knop, Laura] Otto von Guericke Univ, Inst Mol & Clin Immunol, Magdeburg, Germany.
RP Bruder, D (reprint author), Otto von Guericke Univ, Inst Med Microbiol Infect Control & Prevent, Leipziger Str 44, D-39120 Magdeburg, Germany.
EM dunja.bruder@med.ovgu.de
OI Knop, Laura/0000-0003-2900-5326
FU Helmholtz Association of German Research Centers (HGF)Helmholtz
   Association; President's Initiative and Networking Fund of the HGF
   [W2/W3-029]; European CommissionEuropean Commission Joint Research
   Centre [601738, 228403]
FX We thank Tatjana Hirsch, Silvia Prettin and Elena Reinhard for expert
   technical assistance. This work was supported by a grant of the
   Helmholtz Association of German Research Centers (HGF) which was
   provided in frame of the Helmholtz Alliance ``Immunotherapy of
   Cancers"(HCC_WP2b). Moreover, D.B. was supported by the President's
   Initiative and Networking Fund of the HGF under contract number
   W2/W3-029. The work was supported in part by the European Commission
   under the project ``Univax" (contract no. 601738) and ``TRANSVAC"
   (contract no. 228403).
CR Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Blaauboer SM, 2014, J IMMUNOL, V192, P492, DOI 10.4049/jimmunol.1301812
   Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220
   Boscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639
   BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655
   Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821
   Davis HL, 1998, J IMMUNOL, V160, P870
   Do Y, 2012, VACCINE, V30, P6359, DOI 10.1016/j.vaccine.2012.08.051
   Ebensen T, 2007, CLIN VACCINE IMMUNOL, V14, P952, DOI 10.1128/CVI.00119-07
   Ebensen T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01223
   Ebensen T, 2011, VACCINE, V29, P5210, DOI 10.1016/j.vaccine.2011.05.026
   Fujimoto C, 2004, INT IMMUNOL, V16, P55, DOI 10.1093/intimm/dxh025
   Gray PM, 2012, CELL IMMUNOL, V278, P113, DOI 10.1016/j.cellimm.2012.07.006
   Grossmann C, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-43
   Henri S, 2001, J IMMUNOL, V167, P741, DOI 10.4049/jimmunol.167.2.741
   Ichinohe T, 2005, J VIROL, V79, P2910, DOI 10.1128/JVI.79.5.2910-2919.2005
   Idoyaga J, 2011, P NATL ACAD SCI USA, V108, P2384, DOI 10.1073/pnas.1019547108
   Jelinek I, 2011, J IMMUNOL, V186, P2422, DOI 10.4049/jimmunol.1002845
   Johnson TS, 2008, CLIN CANCER RES, V14, P8169, DOI 10.1158/1078-0432.CCR-08-1474
   Kastenmuller W, 2014, NAT REV IMMUNOL, V14, P705, DOI 10.1038/nri3727
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821
   Lakhrif Z, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00317
   Landi A, 2017, VACCINE, V35, P6949, DOI 10.1016/j.vaccine.2017.10.072
   Lehmann CHK, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020008
   Libanova R, 2010, VACCINE, V28, P2249, DOI 10.1016/j.vaccine.2009.12.045
   Lirussi D, 2017, EBIOMEDICINE, V22, P100, DOI 10.1016/j.ebiom.2017.07.016
   Liu CB, 2018, HUM VACC IMMUNOTHER, V14, P931, DOI 10.1080/21645515.2017.1420446
   Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247
   Lycke N, 2012, NAT REV IMMUNOL, V12, P592, DOI 10.1038/nri3251
   Macri C, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.6
   Mittal A, 2015, NANOMED-NANOTECHNOL, V11, P147, DOI 10.1016/j.nano.2014.08.009
   Moffat JM, 2013, EUR J IMMUNOL, V43, P595, DOI 10.1002/eji.201242799
   Mohanan D, 2010, J CONTROL RELEASE, V147, P342, DOI 10.1016/j.jconrel.2010.08.012
   Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595
   Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223
   Parvatiyar K, 2012, NAT IMMUNOL, V13, P1155, DOI 10.1038/ni.2460
   Pedersen GK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026973
   Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006
   Reuter A, 2015, J IMMUNOL, V194, P2696, DOI 10.4049/jimmunol.1402535
   Rueckert C, 2017, FASEB J, V31, P3107, DOI 10.1096/fj.201601093R
   Sanchez MV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104824
   Sauer JD, 2011, INFECT IMMUN, V79, P688, DOI 10.1128/IAI.00999-10
   Schwarz K, 2003, EUR J IMMUNOL, V33, P1465, DOI 10.1002/eji.200323919
   Skrnjug I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095728
   Soares H, 2007, J EXP MED, V204, P1095, DOI 10.1084/jem.20070176
   Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8
   Stahl-Hennig C, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000373
   Steinhagen F, 2011, VACCINE, V29, P3341, DOI 10.1016/j.vaccine.2010.08.002
   Stern BV, 2002, J IMMUNOL, V168, P6099, DOI 10.4049/jimmunol.168.12.6099
   Trumpfheller C, 2006, J EXP MED, V203, P607, DOI 10.1084/jem.20052005
   Trumpfheller C, 2012, J INTERN MED, V271, P183, DOI 10.1111/j.1365-2796.2011.02496.x
   Trumpfheller C, 2008, P NATL ACAD SCI USA, V105, P2574, DOI 10.1073/pnas.0711976105
   Volckmar J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43985
   Vremec D, 1997, J IMMUNOL, V159, P565
   Wenner CA, 1996, J IMMUNOL, V156, P1442
   Woodward JJ, 2010, SCIENCE, V328, P1703, DOI 10.1126/science.1189801
   Zhu Q, 2008, P NATL ACAD SCI USA, V105, P16260, DOI 10.1073/pnas.0805325105
NR 59
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4963
EP 4974
DI 10.1016/j.vaccine.2019.07.019
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100024
PM 31320219
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU de Groot, C
   Musken, M
   Bleckmann, M
   Ebensen, T
   Guzman, CA
   Muller-Goymann, CC
AF de Groot, Carolin
   Muesken, Mathias
   Bleckmann, Maren
   Ebensen, Thomas
   Guzman, Carlos A.
   Mueller-Goymann, Christel C.
TI Novel colloidal associations of soyasaponins and lipid components (DPPC,
   cholesterol) as potential adjuvants for vaccines
SO VACCINE
LA English
DT Article
DE Saponin; Soybean; Microstructure; Adjuvant; Vaccine; Langmuir monolayer;
   Transmission electron microscopy; Viability; Dendritic cells
ID TRITERPENOID SAPONINS; HEMOLYTIC-ACTIVITY; SOYASAPOGENOL-A; IMMUNE;
   BISDESMOSIDE; COMPLEXES; SAPOGENOL; SEEDS; ISCOM
AB Soyasaponins from soybean (Glycine max) represent promising new potent adjuvants for vaccine research because of their immunostimulating properties and weak hemolytic activity. In the present study, saponin microstructures of soyasaponins (soyasaponin Bb, soyasaponin Ab) with lipid components (cholesterol, DPPC (dipalmitoylphosphatidylcholine)) were designed by the lipid film method. In interaction studies between soyasaponins (soyasaponin Ab/Bb) and Langmuir monolayers (model membranes), composed of cholesterol and DPPC, marked interactions between soyasaponins and a pure cholesterol monolayer were observed. No interaction was detected for soyasaponins with a pure DPPC monolayer. The intercalation of soyasaponins in a mixed DPPC/cholesterol (3:1, w/w) monolayer was only observed for the monodesmosidic soyasaponin Bb whereas the second sugar chain of the bidesmosidic soyasaponin Ab impaired the access to the monolayer. Transmission electron microscopy was used for visualizing particle formation of soyasaponins and lipid components. Pseudo-binary systems (soyasaponin Ab/Bb, cholesterol) formed colloidal associations built up from ring-like subunits in the nanometer size range. In pseudo-ternary systems (soyasaponin, cholesterol, DPPC) soyasaponin Bb attacked the liposomal membrane by forming colloidal associations. Colloidal associations in pseudo-ternary systems with soyasaponin Ab, cholesterol and a phospholipid were only observed in the presence of PE (phosphatidylethanolamine) instead of DPPC. In an MTT assay with a HaCaT cell line (keratinocyte cell line) the cell viability was neither affected by the soyasaponins nor by the corresponding formulations. Both the pure soyasaponin solution and the saponin formulations may be promising adjuvant systems for the intradermal vaccine application. Furthermore, interaction studies between the model antigen ovalbumin and colloidal associations of saponins and cholesterol using MST (Microscale Thermophoresis) gave first indications of an antigen binding to colloidal associations. Ex vivo T-cell proliferation in the presence of soyasaponin Ab was confirmed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [de Groot, Carolin; Mueller-Goymann, Christel C.] Tech Univ Carolo Wilhelmina Braunschweig, Inst Pharmazeut Technol, Mendelssohnstr 1, D-38106 Braunschweig, Germany.
   [Muesken, Mathias] Helmholtz Ctr Infect Res, Cent Facil Microscopy, Braunschweig, Germany.
   [Bleckmann, Maren] Tech Univ Carolo Wilhelmina Braunschweig, Inst Biotechnol, Braunschweig, Germany.
   [Ebensen, Thomas; Guzman, Carlos A.] Helmholtz Ctr Infect Res, Dept Vaccinol & Appl Microbiol, D-38124 Braunschweig, Germany.
   [Mueller-Goymann, Christel C.] Tech Univ Carolo Wilhelmina Braunschweig, Ctr Pharmaceut Engn PVZ, Braunschweig, Germany.
RP Muller-Goymann, CC (reprint author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Pharmazeut Technol, Mendelssohnstr 1, D-38106 Braunschweig, Germany.
EM c.mueller-goymann@tu-braunschweig.de
CR BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6
   BANGHAM AD, 1962, NATURE, V196, P952, DOI 10.1038/196952a0
   Barr IG, 1996, IMMUNOL CELL BIOL, V74, P8, DOI 10.1038/icb.1996.2
   Beck Z, 2015, BBA-BIOMEMBRANES, V1848, P775, DOI 10.1016/j.bbamem.2014.12.005
   Bot A, 1998, J IMMUNOL, V160, P4500
   Daveby YD, 1997, J SCI FOOD AGR, V73, P391, DOI 10.1002/(SICI)1097-0010(199703)73:3&lt;391::AID-JSFA740&gt;3.0.CO;2-O
   de Groot C, 2018, PLANTA MED, V84, P1219, DOI 10.1055/a-0624-2706
   Ebensen T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01223
   Guang CE, 2014, J AGR FOOD CHEM, V62, P8247, DOI 10.1021/jf503047a
   Hu J, 2002, J AGR FOOD CHEM, V50, P2587, DOI 10.1021/jf0114740
   KERSTEN GFA, 1991, BIOCHIM BIOPHYS ACTA, V1062, P165, DOI 10.1016/0005-2736(91)90388-O
   KITAGAWA I, 1985, CHEM PHARM BULL, V33, P598
   KITAGAWA I, 1985, CHEM PHARM BULL, V33, P1069
   MOREIN B, 1984, NATURE, V308, P457, DOI 10.1038/308457a0
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Vo NNQ, 2017, J NAT MED-TOKYO, V71, P50, DOI 10.1007/s11418-016-1026-9
   Oda K, 2000, BIOL CHEM, V381, P67, DOI 10.1515/BC.2000.009
   OZEL M, 1989, J ULTRA MOL STRUCT R, V102, P240, DOI 10.1016/0889-1605(89)90018-9
   Paepenmuller T, 2014, INT J PHARMACEUT, V475, P138, DOI 10.1016/j.ijpharm.2014.08.007
   Qiao N, 2014, INT IMMUNOPHARMACOL, V18, P333, DOI 10.1016/j.intimp.2013.12.017
   RONNBERG B, 1995, VACCINE, V13, P1375, DOI 10.1016/0264-410X(95)00105-A
   SALMON JK, 1994, WESTERN J MED, V160, P146
   SHIRAIWA M, 1991, AGR BIOL CHEM TOKYO, V55, P911, DOI 10.1080/00021369.1991.10870686
   SHIRAIWA M, 1991, AGR BIOL CHEM TOKYO, V55, P315, DOI 10.1080/00021369.1991.10870574
   Song XM, 2009, VACCINE, V27, P2306, DOI 10.1016/j.vaccine.2009.02.040
   Sun HX, 2006, INT IMMUNOPHARMACOL, V6, P14, DOI 10.1016/j.intimp.2005.07.003
   Sun T, 2014, PHYTOMEDICINE, V21, P1759, DOI 10.1016/j.phymed.2014.09.002
   TANI T, 1985, CHEM PHARM BULL, V33, P3829
   Taylor WG, 2004, J AGR FOOD CHEM, V52, P7484, DOI 10.1021/jf0308051
   Welsby I, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00663
   Yoshiki Y, 1998, BIOSCI BIOTECH BIOCH, V62, P2291, DOI 10.1271/bbb.62.2291
   Zhang W, 2009, MOLECULES, V14, P2959, DOI 10.3390/molecules14082959
   Zhu D, 2016, NAT PROD CHEM RES, V3, pe113, DOI DOI 10.4172/2329-6836.1000E113
NR 33
TC 0
Z9 0
U1 5
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4975
EP 4986
DI 10.1016/j.vaccine.2019.07.020
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100025
PM 31320217
DA 2020-05-12
ER

PT J
AU Lee, H
   Park, SY
   Clark, A
   Debellut, F
   Pecenka, C
   Kim, DS
   Kim, HM
   Kim, JH
   Cho, H
   Kim, AY
   Lee, M
   Jung, SY
   Seong, BL
   Kang, HY
AF Lee, Hankil
   Park, Seon Young
   Clark, Andrew
   Debellut, Frederic
   Pecenka, Clint
   Kim, Dong Soo
   Kim, Hwang Min
   Kim, Ji Hong
   Cho, Hyeonseok
   Kim, Ah-Young
   Lee, Minjun
   Jung, Sun-Young
   Seong, Baik Lin
   Kang, Hye-Young
TI Cost-effectiveness analysis of the implementation of a National
   Immunization Program for rotavirus vaccination in a country with a low
   rotavirus gastroenteritis-related mortality: A South Korean study
SO VACCINE
LA English
DT Article
DE Cost-effectiveness; Enteritis; Rotavirus; South Korea; Vaccination
ID HERD-IMMUNITY; ECONOMIC EVALUATIONS; DISEASE; INTUSSUSCEPTION; CHILDREN;
   BURDEN; INFECTION; INFANTS; RISK
AB Rotavirus is a leading cause of severe gastroenteritis among children younger than 5 years in South Korea. Two rotavirus vaccines (RVs), pentavalent human-bovine reassortant vaccine (Rotateq (R); RV5) and attenuated human strain originated monovalent vaccine (Rotarix (R); RV1), have been available for voluntary vaccination using out-of-pocket payment since 2007 and 2008, respectively. Yet, RVs are not included in the National Immunization Program (NIP), partly because of the low associated mortality rate. We assessed the cost-effectiveness of RVs to assist the evidence-based decision-making process for NIP implementation in South Korea. Using a transparent age-structured static cohort model, we simulated the experience of ten annual birth cohorts of South Korean children from 2018 to 2027. Model inputs included rotavirus gastroenteritis (RVGE) incidence and mortality rates, RVGE treatment costs, vaccine coverage and timeliness, and vaccine effectiveness and price. The incremental costs of including RVs in the NIP compared to no vaccination were 59,662,738 USD and 152,444,379 USD for RV1 and RV5, respectively. The introduction of RV1 and RV5 can prevent 4799 disability-adjusted life years (DALYs) and 5068 DALYs. From the societal perspective, the incremental cost-effectiveness ratios (ICERs) for adopting RV into the NIP versus no vaccination were 12,432 USD per DALY averted for RV1 and 30,081 USD per DALY averted for RV 5. The weighted average for the ICERs of the two vaccines computed using the market share of each vaccine in the current voluntary use as a weight, was 21,698 USD per DALY averted. The estimated ICER was below 1 x gross domestic product per capita (30,000 USD), which has been a commonly used willingness-to-pay threshold for health care technology assessment in South Korea, suggesting that introducing RVs into the NIP would be cost-effective. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Lee, Hankil; Cho, Hyeonseok; Kang, Hye-Young] Yonsei Univ, Coll Pharm, Yonsei Inst Pharmaceut Sci, 85 Songdogwahak Ro, Incheon 21983, South Korea.
   [Park, Seon Young; Kim, Ah-Young; Lee, Minjun] Yonsei Univ, Coll Med & Pharm, Dept Pharmaceut Med & Regulatory Sci, Incheon, South Korea.
   [Clark, Andrew] London Sch Hyg & Trop Med, Keppel St, London, England.
   [Debellut, Frederic] PATH, Ctr Vaccine Innovat & Access, Geneva, Switzerland.
   [Pecenka, Clint] PATH, Ctr Vaccine Innovat & Access, Seattle, WA USA.
   [Kim, Dong Soo] Yonsei Univ, Severance Childrens Hosp, Dept Pediat, Coll Med, Seoul, South Korea.
   [Kim, Hwang Min] Yonsei Univ, Wonju Severance Christian Hosp, Dept Pediat, Wonju Coll Med, Wonju, South Korea.
   [Kim, Ji Hong] Yonsei Univ, Gangnam Severance Hosp, Dept Pediat, Coll Med, Seoul, South Korea.
   [Jung, Sun-Young] Chung Ang Univ, Coll Pharm, Seoul, South Korea.
   [Seong, Baik Lin] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul, South Korea.
RP Kang, HY (reprint author), Yonsei Univ, Coll Pharm, Yonsei Inst Pharmaceut Sci, 85 Songdogwahak Ro, Incheon 21983, South Korea.
EM hykang2@yonsei.ac.kr
OI Lee, Hankil/0000-0002-7780-159X; kim, ji hong/0000-0001-5352-5423;
   Debellut, Frederic/0000-0002-3027-2838
FU Korea Centers for Disease Control Prevention [2017N-E2401-00]
FX Financial support for this study was provided by a grant from Korea
   Centers for Disease Control & Prevention (grant number: 2017N-E2401-00).
   The funding source was not involved in the study design, collection,
   analysis and interpretation of data, writing of the report, and the
   decision to submit the article for publication.
CR [Anonymous], 2009, Wkly Epidemiol Rec, V84, P533
   Anwari P, 2018, VACCINE, V36, P7769, DOI 10.1016/j.vaccine.2017.10.058
   Bae EY., 2013, KOREAN ASS HLTH TECH, V1, P43
   Bernard S, 2013, CAN J INFECT DIS MED, V24, P138, DOI 10.1155/2013/919124
   Bilcke J, 2008, EUR J PEDIATR, V167, P1409, DOI 10.1007/s00431-008-0684-3
   Clark AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188267
   Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007
   Jauregui B, 2015, VACCINE, V33, pA21, DOI 10.1016/j.vaccine.2014.12.080
   Jonesteller CL, 2017, CLIN INFECT DIS, V65, P840, DOI 10.1093/cid/cix369
   Kang HY, 2013, ASIA-PAC J PUBLIC HE, V25, P145, DOI 10.1177/1010539511416806
   Kim JS, 2005, J INFECT DIS, V192, pS49, DOI 10.1086/431506
   Korea Centers for Disease Control and Prevention, KCDC INT REP 2017 VA
   Korea Centers for Disease Control and Prevention, KCDC INT REP 2017 DT
   Korean Statistical Information Service, KOSIS NAT STAT PORT
   Kotirum S, 2017, VACCINE, V35, P3364, DOI 10.1016/j.vaccine.2017.04.051
   Lamberti LM, 2016, PEDIATR INFECT DIS J, V35, P992, DOI 10.1097/INF.0000000000001232
   Murphy BR, 2003, J INFECT DIS, V187, P1301, DOI 10.1086/367895
   Murphy TV, 2003, J INFECT DIS, V187, P1309, DOI 10.1086/374420
   Nymark LS, 2017, VACCINE, V35, P6828, DOI 10.1016/j.vaccine.2017.10.024
   Ock M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162478
   Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562
   Parashar UD, 2006, EMERG INFECT DIS, V12, P304
   Parashar Umesh D., 2006, Morbidity and Mortality Weekly Report, V55, P1
   Parashar UD, 2009, J INFECT DIS, V200, pS9, DOI 10.1086/605025
   Pecenka C, 2017, VACCINE, V35, P3982, DOI 10.1016/j.vaccine.2017.05.087
   Phua KB, 2009, VACCINE, V27, P5936, DOI 10.1016/j.vaccine.2009.07.098
   Pollard SL, 2015, VACCINE, V33, P3795, DOI 10.1016/j.vaccine.2015.06.064
   Rosillon D, 2015, PEDIATR INFECT DIS J, V34, P763, DOI 10.1097/INF.0000000000000715
   Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8
   The World Bank, 2017, GDP PER CAP REP KOR
   Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404
   VIEW-hub, 2017, CURR VACC INTR STAT
   Yih WK, 2014, NEW ENGL J MED, V370, P503, DOI 10.1056/NEJMoa1303164
   Yim EY, 2012, VALUE HEALTH, V15, pS104, DOI 10.1016/j.jval.2011.11.026
   양봉민, 2008, Korean Journal of Pediatrics, V51, P977
NR 35
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4987
EP 4995
DI 10.1016/j.vaccine.2019.07.030
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100026
PM 31326252
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU De Serres, G
   Billard, MN
   Gariepy, MC
   Roy, MC
   Boucher, FD
   Gagne, H
   Belley, S
   Toth, E
   Landry, M
   Skowronski, DM
AF De Serres, Gaston
   Billard, Marie-Noelle
   Gariepy, Marie-Claude
   Roy, Marie-Claude
   Boucher, Francois D.
   Gagne, Helene
   Belley, Sylvie
   Toth, Eveline
   Landry, Monique
   Skowronski, Danuta M.
TI Nephrotic syndrome following four-component meningococcal B vaccination:
   Epidemiologic investigation of a surveillance signal
SO VACCINE
LA English
DT Article
DE Meningococcal vaccine; 4CMenB; Adverse event; Nephrotic syndrome
ID OUTER-MEMBRANE VESICLES; ROUTINE INFANT; HEALTHY ADOLESCENTS; 4CMENB
   VACCINE; OPEN-LABEL; IMMUNOGENICITY; SAFETY; MULTICOMPONENT;
   RECOMBINANT; IMMUNIZATION
AB Background: In May 2014, a mass vaccination campaign with four-component meningococcal serogroup B (4CMenB) vaccine was launched in a localized region of Quebec, Canada experiencing high invasive meningococcal B disease endemicity. Active post-marketing surveillance identified several cases of nephrotic syndrome (NS) among similar to 49,000 vaccinated individuals aged 2 months to 20 years. We report the epidemiologic investigation of this potential vaccine safety signal.
   Methods: Active vaccine safety surveillance was conducted electronically, with participants completing an online questionnaire prompted at 7 days after each dose and 6 months following the last dose. Additional NS cases were sought from provincial hospitalization and emergency room databases.
   Results: In the year following the first dose of 4CMenB vaccination, four confirmed NS cases (three hospitalized) were identified among vaccinated children 2-5-years-old with onset several months post-vaccination. None had renal biopsy but given their age, and positive response to steroids, idiopathic NS was presumptively diagnosed. Among vaccinated children 1-9-years-old, the NS incidence in the year post-vaccination was 17.7 per 100,000 (1 per 5650 vaccinees) with an NS hospitalization rate (i.e. excluding the outpatient case) that was 3.6-fold higher (95%CI = 0.7-11.8; p = 0.12) than the rest of the province for the same period, and 8.3-fold greater (95%CI = 1.1-62.0; p = 0.039) than during the eight years preceding the immunization campaign in the affected region.
   Conclusion: Active safety surveillance identified an unexpected increase in NS incidence following 4CMenB vaccination. Further epidemiological investigation identified four vaccinated cases in total over a 12 month period of follow up. The greater risk in vaccinees had wide confidence intervals with he lower limit including or just above the nul value, an observation with no or marginal statistical significance. The temporal association with vaccination may be explained by other causes and/or chance clustering of a rare event unrelated to vaccination. To confirm or refute a potential link to vaccination, surveillance in other jurisdictions administering 4CMenB to children 1-9-years-old is needed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [De Serres, Gaston] Inst Natl Sante Publ Quebec, 2400 Av Estimauville, Quebec City, PQ G1E 7G9, Canada.
   [De Serres, Gaston; Billard, Marie-Noelle; Gariepy, Marie-Claude; Roy, Marie-Claude; Boucher, Francois D.] CHU Quebec Univ Lav, Quebec City, PQ, Canada.
   [Gagne, Helene; Belley, Sylvie] Direct Sante Publ CIUSSS Saguenay Lac St Jean, Saguenay, PQ, Canada.
   [Toth, Eveline; Landry, Monique] Minist Sante & Serv Sociaux Quebec, Montreal, PQ, Canada.
   [Skowronski, Danuta M.] British Columbia Ctr Dis Control, Vancouver, BC, Canada.
RP De Serres, G (reprint author), Inst Natl Sante Publ Quebec, 2400 Av Estimauville, Quebec City, PQ G1E 7G9, Canada.
EM gaston.deserres@inspq.qc.ca
FU Quebec Ministry of Health (Ministere de la Sante et des Services sociaux
   du Quebec)
FX This study was supported by the Quebec Ministry of Health (Ministere de
   la Sante et des Services sociaux du Quebec). The Ministry had no role in
   study design, or the collection, analysis, or interpretation of data,
   and did not alter the contents or conclusions in the writing or
   submission of this report.
CR Banh THM, 2016, CLIN J AM SOC NEPHRO, V11, P1760, DOI 10.2215/CJN.00380116
   Bettinger JA, 2015, EUROSURVEILLANCE, V20, P2, DOI 10.2807/1560-7917.ES2015.20.29.21189
   BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S
   Boyer O, 2017, ARCH PEDIATRIE, V24, P1338, DOI 10.1016/j.arcped.2017.09.022
   Bryan P, 2018, LANCET CHILD ADOLESC, V2, P395, DOI 10.1016/S2352-4642(18)30103-2
   Centers for Diseases Control and Prevention, VACC ADV EV REP SYST
   Chanchlani R, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00039
   De Serres G, 2018, VACCINE, V36, P8039, DOI 10.1016/j.vaccine.2018.10.095
   De Serres G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038563
   De Wals P, 2017, CLIN INFECT DIS, V64, P1263, DOI 10.1093/cid/cix154
   DeBraekeleer M, 1996, ANN HUM GENET, V60, P51, DOI 10.1111/j.1469-1809.1996.tb01171.x
   Santolaya ME, 2012, LANCET, V379, P617, DOI 10.1016/S0140-6736(11)61713-3
   Esposito S, 2014, HUM VACC IMMUNOTHER, V10, P2005, DOI 10.4161/hv.29218
   Findlow J, 2015, VACCINE, V33, P3322, DOI 10.1016/j.vaccine.2015.05.027
   Findlow J, 2010, CLIN INFECT DIS, V51, P1127, DOI 10.1086/656741
   GlaxoSmithKline, 2018, PRODUCT MONOGRAPH
   Gossger N, 2012, JAMA-J AM MED ASSOC, V307, P573, DOI 10.1001/jama.2012.85
   Holst J, 2013, HUM VACC IMMUNOTHER, V9, P1241, DOI 10.4161/hv.24129
   Holst J, 2009, VACCINE, V27, pB3, DOI 10.1016/j.vaccine.2009.04.071
   Institut de la statistique du Quebec, POP SEL AG SEX REG A
   Iro MA, 2017, VACCINE, V35, P395, DOI 10.1016/j.vaccine.2016.11.009
   Lee HJ, 2016, VACCINE, V34, P1180, DOI 10.1016/j.vaccine.2016.01.033
   Martinon-Torres F, 2018, J INFECTION, V76, P258, DOI 10.1016/j.jinf.2017.12.005
   Martinon-Torres F, 2017, VACCINE, V35, P3548, DOI 10.1016/j.vaccine.2017.05.023
   McNicholas A, 2007, HUM VACCINES, V3, P196, DOI 10.4161/hv.3.5.4458
   Mentzer Dirk, 2018, Euro Surveill, V23, DOI 10.2807/1560-7917.ES.2018.23.17.17-00468
   Ministere de la sante et des services sociaux du Quebec, SOURC DONN MET BANQ
   Ministere de la sante et des services sociaux du Quebec, SOURC DONN MET MED E
   Niaudet P, 2016, PEDIAT NEPHROLOGY, P839
   Noone DG, 2018, LANCET, V392, P61, DOI 10.1016/S0140-6736(18)30536-1
   Perrett KP, 2015, VACCINE, V33, P5217, DOI 10.1016/j.vaccine.2015.06.103
   Sadarangani M, 2017, CAN MED ASSOC J, V189, pE1276, DOI 10.1503/cmaj.161288
   Skowronski DM, 2015, EUROSURVEILLANCE, V20, P11, DOI 10.2807/1560-7917.ES.2015.20.43.30047
   Skowronski DM, 2016, CLIN INFECT DIS, V63, P21, DOI 10.1093/cid/ciw176
   Snape MD, 2010, PEDIATR INFECT DIS J, V29, pE71, DOI 10.1097/INF.0b013e3181f59f6d
   Snape MD, PERSISTENCE BACTERIC
   Sotolongo Franklin, 2008, MEDICC Rev, V9, P16
   Vesikari T, 2015, VACCINE, V33, P3850, DOI 10.1016/j.vaccine.2015.06.079
   Vesikari T, 2013, LANCET, V381, P825, DOI 10.1016/S0140-6736(12)61961-8
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 4996
EP 5002
DI 10.1016/j.vaccine.2019.07.017
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100027
PM 31307873
DA 2020-05-12
ER

PT J
AU Decker, MD
   Greenberg, DP
   Johnson, DR
   Pool, V
AF Decker, Michael D.
   Greenberg, David P.
   Johnson, David R.
   Pool, Vitali
TI Randomized study of immune responses to two Tdap vaccines among
   adolescents primed with DTaP and comparison with results among
   adolescents primed with DTwP
SO VACCINE
LA English
DT Article
DE Pertussis vaccine; Vaccines, acellular; Tdap vaccine; Immunogenicity
ID WHOLE-CELL; PERTUSSIS-VACCINE; DIPHTHERIA; TETANUS
AB Background: It has been reported that persons primed with acellular (DTaP) pertussis vaccines have reduced duration of pertussis protection compared with those primed with whole-cell (DTwP) vaccines. However, due to the rapid transition to acellular vaccines, studies attempting directly to compare protection among DTaP-primed vs DTwP-primed individuals are subject to confounding by age and other limitations of ecological studies. Using validated assay results and stored sera from multiple Tdap studies, we evaluated two licensed Tdap vaccines among DTaP-primed adolescents to allow comparison with results obtained in the same laboratory from earlier studies involving DTwP-primed adolescents.
   Methods: Participants 11-12 years of age who had received exactly 5 doses of DTaP vaccine prior to 7 years of age were randomly assigned in 2012 to receive one of two licensed Tdap vaccines. Serum specimens obtained pre- and post-vaccination were assayed for responses to the vaccines. Current results were then compared to results obtained in the same laboratory from prior randomized Tdap studies conducted among adolescents primed with DTwP or DTaP.
   Results: Both Tdap vaccines produced strong antibody responses to diphtheria and tetanus; responses to contained pertussis antigens were consistent with the differing levels of those antigens in each Tdap vaccine. However, postvaccination pertussis antibody responses were as much as 71% lower in these DTaP-primed adolescents compared with responses among DTwP-primed adolescents in a prior study of the same two Tdap vaccines. In contrast, results from the present study were similar to those seen in another study of Tdap among DTaP-primed adolescents.
   Discussion: Taken together, these results from randomized clinical trials provide direct evidence of reduced antibody responses to both licensed Tdap vaccines among adolescents primed with DTaP vaccine, compared with adolescents primed with DTwP vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Decker, Michael D.; Greenberg, David P.; Pool, Vitali] Sanofi Pasteur, US Med Affairs, Swiftwater, PA USA.
   [Decker, Michael D.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA.
   [Greenberg, David P.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.
   [Johnson, David R.] Sanofi Pasteur, Global Med Affairs, Swiftwater, PA USA.
RP Decker, MD (reprint author), POB 425, Baxter, TN 38544 USA.
EM td551@mdd1.org
OI Decker, Michael/0000-0003-1008-7472
FU Sanofi Pasteur
FX The authors thank the investigators, their staff, and their patients for
   their participation in this study and thank Julie Gage for draft
   generation. This work was funded by Sanofi Pasteur. Study data may be
   sought through https://clinicalstudydatarequest.com/Default.aspx.
CR Englund JA, 2013, PED AC SOC ANN M WAS
   Arlant LHF, 2014, EXPERT REV ANTI-INFE, V12, P1265, DOI 10.1586/14787210.2014.948846
   Heininger U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155949
   ISRCTN Registry, LONG TERM CELL MEM I, DOI [10.1186/ISRCTN65428640, DOI 10.1186/ISRCTN65428640]
   Liko J, 2013, NEW ENGL J MED, V368, P581, DOI 10.1056/NEJMc1212006
   Marshall GS, 2014, CLIN VACCINE IMMUNOL, V21, P1560, DOI 10.1128/CVI.00474-14
   Murphy T., 2000, DATA NATL PERTUSSIS
   Pichichero ME, 2005, JAMA-J AM MED ASSOC, V293, P3003, DOI 10.1001/jama.293.24.3003
   Pinto MV, 2017, J INFECTION, V74, pS114, DOI 10.1016/S0163-4453(17)30201-3
   Sheridan SL, 2014, EXPERT REV VACCINES, V13, P1081, DOI 10.1586/14760584.2014.944167
   Skoff TH, 2019, CLIN INFECT DIS, V68, P1634, DOI 10.1093/cid/ciy757
   Smallridge WE, 2014, J INFECT DIS, V209, P1981, DOI 10.1093/infdis/jiu030
   Smits K, 2013, VACCINE, V32, P111, DOI 10.1016/j.vaccine.2013.10.056
   Tan TN, 2015, PEDIATR INFECT DIS J, V34, pE222, DOI 10.1097/INF.0000000000000795
   van der Lee S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00051
NR 15
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5003
EP 5008
DI 10.1016/j.vaccine.2019.07.015
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100028
PM 31301919
DA 2020-05-12
ER

PT J
AU Si, S
   Zomer, E
   Fletcher, S
   Lee, J
   Liew, D
AF Si, Si
   Zomer, Ella
   Fletcher, Samantha
   Lee, Jenny
   Liew, Danny
TI ost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135
   and Y conjugate vaccine in Australian adolescents
SO VACCINE
LA English
DT Article
DE MenACWY vaccine; Young adults; Cost-effectiveness analysis; Australia
ID COST-EFFECTIVENESS; BACTERIAL-MENINGITIS; IMMUNOGENICITY; DISEASE;
   EPIDEMIOLOGY; HEALTH; IMPACT; SAFETY; ADULTS; TRANSMISSION
AB Objectives: The incidence of invasive meningitis disease (IMD) is increasing in Australia. A conjugate vaccine of meningococcal polysaccharide serogroups A, C, W and Y (MenACWY) is currently indicated for infants aged 12 months on the Australian National Immunisation Program. This study sought to determine the cost-effectiveness of a broader MenACWY vaccination program for Australians aged 15 to 19 years.
   Methods: A Markov model was constructed to simulate the incidence and consequences of IMD in Australians aged 0-84 years, with follow up until age 85 years. The model comprised four health states: 'Alive with no previous IMD', 'Alive, post IMD without long-term complications', 'Alive, post IMD with long-term complications' and 'Dead'. Decision analysis compared the clinical consequences and costs of a vaccination program versus no vaccination from the perspective of the Australian health care system. Age-specific incidence of IMD and fatality rates were derived from Australian surveillance data. Vaccine coverage, vaccine efficacy and herd immunity were based on published data. The total cost for MenACWY vaccination was AU$56 per dose. Costs and health outcomes were discounted by 5% per annum (in the base-case analysis).
   Results: Compared to no vaccination, a MenACWY vaccination program targeted at Australians aged 1519 years was expected to prevent 1664 IMD cases in the Australian population aged 0-84 years followed up until age 85 years. The program would lead to 1131 life years (LYs) and 2058 quality adjusted life years (QALYs) gained at a total cost of AU$115 million (all discounted values). These equated to incremental cost-effectiveness ratios of AU$101,649 per LY gained and AU$55,857 per QALY gained. A probabilistic sensitivity analysis demonstrated a likelihood of cost-effectiveness of 34.6%, assuming a willingness to pay threshold of AU$50,000 per QALY gained.
   Conclusion: The likelihood of this program being cost-effective under a willingness to pay threshold AU $50,000 per QALY gained is 35%. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Si, Si; Zomer, Ella; Liew, Danny] Monash Univ, Sch Publ Hlth & Prevent Med, 553 St Kilda Rd, Melbourne, Vic 3000, Australia.
   [Fletcher, Samantha; Lee, Jenny] Pfizer Australia, Sydney, NSW, Australia.
RP Si, S (reprint author), Monash Univ, Sch Publ Hlth & Prevent Med, 553 St Kilda Rd, Melbourne, Vic 3000, Australia.
EM si.si@monash.edu
RI Zomer, Ella/AAE-2462-2019
FU Pfizer AustraliaPfizerPfizer Australia
FX The Centre of Cardiovascular Research and Education in Therapeutics,
   School of Public Health and Preventive Medicine, Monash University was
   contracted by Pfizer Australia to undertake an independent economic
   evaluation of Nimenrix. DL, SS and EZ received no personal payment for
   the work undertaken.
CR Aplasca-De Los Reyes MR, 2012, HUM VACC IMMUNOTHER, V8, P881, DOI 10.4161/hv.20212
   Archer BN, 2017, MED J AUSTRALIA, V207, P382, DOI 10.5694/mja16.01340
   Australian Government DoH, 2017, INV MEN DIS NAT SURV
   Australian Institute of Health and Welfare, 2016, HLTH EXP AUSTR 2014
   Baxter R, 2011, PEDIATR INFECT DIS J, V30, pE41, DOI 10.1097/INF.0b013e3182054ab9
   Bermal N, 2011, HUM VACCINES, V7, P239, DOI 10.4161/hv.7.2.14068
   Borja-Tabora C, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-116
   Brigham KS, 2009, CURR OPIN PEDIATR, V21, P437, DOI 10.1097/MOP.0b013e32832c9668
   Brotherton JML, 2013, MED J AUSTRALIA, V199, P614, DOI 10.5694/mja13.10272
   Carroll AE, 2009, J PEDIATR-US, V155, P21, DOI 10.1016/j.jpeds.2009.01.040
   Cohen E, 2012, PEDIATRICS, P2012
   Dbaibo G, 2012, HUM VACC IMMUNOTHER, V8, P873, DOI 10.4161/hv.20211
   Dbaibo G, 2012, INT J INFECT DIS, V16, pE608, DOI 10.1016/j.ijid.2012.04.006
   De Wals P, 2007, VACCINE, V25, P5433, DOI 10.1016/j.vaccine.2007.04.071
   Dirmesropian S, 2017, VACCINE, V35, P4307, DOI 10.1016/j.vaccine.2017.06.085
   GORSE GJ, 1984, ARCH INTERN MED, V144, P1603, DOI 10.1001/archinte.144.8.1603
   Halperin SA, 2014, J PEDIAT INF DIS SOC, V3, P33, DOI 10.1093/jpids/pit058
   Hawthorne G, 2013, AUST NZ J PUBL HEAL, V37, P7, DOI 10.1111/1753-6405.12004
   Hepkema H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065036
   IHPA, 2017, NAT HOSP COST DAT CO
   Karnon J, 2018, J HEALTH SERV RES PO, V23, P116, DOI 10.1177/1355819617751816
   Lahra MM, 2016, COMMUN DIS INTELL, V40, pE503
   Lawrence GL, 2016, EPIDEMIOL INFECT, V144, P2382, DOI 10.1017/S0950268816000704
   Lupisan S, 2013, CLIN VACCINE IMMUNOL, V20, P1499, DOI 10.1128/CVI.00162-13
   National centre for immunisation research and surveillance, 2018, MEN VACC AUSTR INF I
   Ortega-Sanchez IR, 2008, PEDIATRICS, V121, pS63, DOI 10.1542/peds.2007-1115H
   Ostergaard L, 2012, VACCINE, V30, P774, DOI 10.1016/j.vaccine.2011.11.051
   Ostergaard L, 2009, VACCINE, V27, P161, DOI 10.1016/j.vaccine.2008.08.075
   PFISTER HW, 1993, ARCH NEUROL-CHICAGO, V50, P575, DOI 10.1001/archneur.1993.00540060015010
   Pharmaceutical Benefits Advisory Committee, 2016, GUID PREP SUBM PHARM
   Quinn HE, 2011, B WORLD HEALTH ORGAN, V89, P666, DOI 10.2471/BLT.11.086538
   Ramasamy MN, 2014, CLIN VACCINE IMMUNOL, V21, P1164, DOI 10.1128/CVI.00099-14
   Ramsay ME, 2003, BRIT MED J, V326, P365, DOI 10.1136/bmj.326.7385.365
   Roed C, 2010, AM J EPIDEMIOL, V172, P309, DOI 10.1093/aje/kwq126
   Shepard CW, 2005, PEDIATRICS, V115, P1220, DOI 10.1542/peds.2004-2514
   Trotter CL, 2006, MED DECIS MAKING, V26, P38, DOI 10.1177/0272989X05284109
   Tu HAT, 2014, VACCINE, V32, P5436, DOI 10.1016/j.vaccine.2014.07.096
   Vetter V, 2016, EXPERT REV VACCINES, V15, P641, DOI 10.1586/14760584.2016.1130628
   Vyse A, 2013, EXPERT REV ANTI-INFE, V11, P597, DOI [10.1586/ERI.13.42, 10.1586/eri.13.42]
   Wang B, 2014, VACCINE, V32, P4791, DOI 10.1016/j.vaccine.2014.05.069
   Wang B, 2014, PEDIATR INFECT DIS J, V33, P316, DOI 10.1097/INF.0000000000000043
   Ward Kirsten F, 2010, N S W Public Health Bull, V21, P237, DOI 10.1071/NB10046
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5009
EP 5015
DI 10.1016/j.vaccine.2019.07.008
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100029
PM 31301916
DA 2020-05-12
ER

PT J
AU MacIntyre, CR
   Ridda, I
   Trent, MJ
   McIntyre, P
AF MacIntyre, C. Raina
   Ridda, Iman
   Trent, Mallory J.
   McIntyre, Peter
TI Persistence of immunity to conjugate and polysaccharide pneumococcal
   vaccines in frail, hospitalised older adults in long-term follow up
SO VACCINE
LA English
DT Article
DE Pneumococcal polysaccharide vaccines; Pneumococcal conjugate vaccines;
   Adult vaccination; Elderly; Frailty; Immunology
ID COMMUNITY-ACQUIRED PNEUMONIA; ZOSTER SUBUNIT VACCINE;
   STREPTOCOCCUS-PNEUMONIAE; ANTIBODY PERSISTENCE; DISEASE SURVEILLANCE;
   IMMUNOGENICITY; SAFETY; REVACCINATION; RESPONSES; EFFICACY
AB Background: Data on long-term antibody responses to pneumococcal vaccines in the elderly, especially the frail elderly at greatest risk of severe disease, are limited. We followed up participants in a randomised trial of the immunogenicity of 23-valent polysaccharide vaccine (23vPPV) and 7 valent pneumococcal conjugate vaccines (PCV7) in hospitalised older adults.
   Methods: We measured antibody to vaccine serotypes by standardised enzyme-linked immunosorbent assay (ELISA) and opsonophagocytic (OPA) assays. A follow up study was conducted six years after vaccination with 23vPPV alone or with PCV7 followed by 23vPPV six months later.
   Results: Of 215 surviving trial participants, 136 (63%) completed follow up; 62 received 23vPPV and 74 received PCV7 + 23vPPV. There was no significant difference in death and readmission between arms. Antibody levels by ELISA and OPA did not differ significantly between the two study arms at 72 months post-vaccination. ELISA and OPA antibody remained higher than baseline except for OPA antibody to 4, 6A, 6B, 9v, 19F and 23F, including in subjects with undetectable immunity at baseline.
   Discussion: While ELISA responses in both study arms remained high 6 years post-vaccination, considerable waning was observed by OPA in both study arms, which should be considered given the current single-dose recommendation in Australia. Further research is needed to inform pneumococcal vaccine recommendations in people over the age of 65. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [MacIntyre, C. Raina; Trent, Mallory J.] Univ New South Wales, Fac Med, Kirby Inst, Biosecur Program, Sydney, NSW, Australia.
   [McIntyre, Peter] Univ Sydney, Natl Ctr Immunisat Res & Surveillance, Sydney, NSW, Australia.
RP Trent, MJ (reprint author), Univ New South Wales, Kirby Inst, Wallace Wurth Bldg Room 644, Kensington, NSW 2052, Australia.
EM r.macintyre@unsw.edu.au; mallory.trent@unsw.edu.au;
   peter.mcintyre@sydney.edu.au
OI McIntyre, Peter/0000-0001-5808-7450
FU National Health and Medical Research Council of Australia
   (NHMRC)National Health and Medical Research Council of Australia
   [352337]; Pfizer, USAPfizer
FX This investigator-driven and designed research was funded by the
   National Health and Medical Research Council of Australia (NHMRC Project
   Grant ##352337). The laboratory testing was conducted and funded by
   Pfizer, USA. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Advisory Committee on Immunization Practices (ACIP), 2018, SUMM REP JUN 20 21 2
   Australian Government Department of Health, 2019, MARCH 2019 PBAC OUTC
   Australian Technical Advisory Group on Immunisation (ATAGI), 2017, AUSTR IMM HDB 10 ED
   Backhaus E, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1648-2
   Bechini A, 2015, HUM VACC IMMUNOTHER, V11, P156, DOI 10.4161/hv.34418
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Collins DA, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0038-x
   Cooper D, 2011, VACCINE, V29, P7207, DOI 10.1016/j.vaccine.2011.06.056
   Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800
   Cunningham AL, 2018, J INFECT DIS, V217, P1750, DOI 10.1093/infdis/jiy095
   Dransfield MT, 2012, CLIN INFECT DIS, V55, pE35, DOI 10.1093/cid/cis513
   Drijkoningen JJC, 2014, CLIN MICROBIOL INFEC, V20, P45, DOI 10.1111/1469-0691.12461
   European Centre for Disease Prevention and Control (ECDC), 2018, PNEUM DIS REC VACC
   Frenck RW, 2016, VACCINE, V34, P3454, DOI 10.1016/j.vaccine.2016.04.093
   Htar MTT, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1147-x
   Imai K, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018553
   Isturiz RE, 2016, EXPERT REV VACCINES, V15, P279, DOI 10.1586/14760584.2016.1132171
   Jayasinghe S, 2017, CLIN INFECT DIS, V64, P175, DOI 10.1093/cid/ciw720
   Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5
   LaFon DC, 2018, J IMMUNOL METHODS, V461, P37, DOI 10.1016/j.jim.2018.08.002
   Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184
   MacIntyre CR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094578
   Manoff SB, 2010, J INFECT DIS, V201, P525, DOI 10.1086/651131
   Marrie TJ, 2018, AM J MED, V131, DOI 10.1016/j.amjmed.2017.06.039
   Musher DM, 2011, HUM VACCINES, V7, P919, DOI 10.4161/hv.7.9.15996
   Musher DM, 2010, J INFECT DIS, V201, P516, DOI 10.1086/649839
   Namkoong H, 2016, HUM VACC IMMUNOTHER, V12, P336, DOI 10.1080/21645515.2015.1075678
   National Centre for Immunisation Research & Surveillance, 2018, SIGN EV PNEU VACC PR
   National Centre for Immunisation Research & Surveillance, 2018, PENUM VACC AUSTR INF
   Pennington K, 2018, ENHANCED INVASIVE PN
   Pennington K, 2017, ENHANCED INVASIVE PN
   Pennington K, 2017, COMMUN DIS INTELL, V41, pE481
   Pennington K, 2017, COMMUN DIS INTELL, V41, pE472
   Pharmaceutical Benefits Advisory Committee (PBAC), 2018, M AG NOV 2018 PBAC M
   Public Health England, 2018, PNEUM GREEN BOOK
   Quataert S, 2001, IMMUNOL INVEST, V30, P191, DOI 10.1081/IMM-100105064
   Remschmidt C, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2040-y
   Ridda I, 2007, HUM VACCINES, V3, P83, DOI 10.4161/hv.3.3.3925
   Sankilampi U, 1997, J INFECT DIS, V176, P1100, DOI 10.1086/516521
   StataCorp, 2015, STAT STAT SOFTW REL
   Stevens JR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176124
   United States Centers for Disease Control and Prevention, 2018, REC IMM SCHED AD AG
   Valenzuela MT, 2007, BRAZ J INFECT DIS, V11, P322, DOI 10.1590/S1413-86702007000300005
   van Deursen AMM, 2017, CLIN INFECT DIS, V65, P787, DOI 10.1093/cid/cix419
   World Health Organization, 2017, VACC PREV DIS VACC
   Yin JK, 2017, MED J AUSTRALIA, V207, P396, DOI 10.5694/mja16.01102
NR 46
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5016
EP 5024
DI 10.1016/j.vaccine.2019.07.005
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100030
PM 31300288
DA 2020-05-12
ER

PT J
AU Sirdar, MM
   Fosgate, GT
   Blignaut, B
   Gummow, B
   Shileyi, B
   Lazarus, DD
   Mutowembwa, P
   van der Merwe, D
   Heath, L
AF Sirdar, Mohamed M.
   Fosgate, Geoffrey T.
   Blignaut, Belinda
   Gummow, Bruce
   Shileyi, Bernard
   Lazarus, David D.
   Mutowembwa, P.
   van der Merwe, Danica
   Heath, Livio
TI A novel method for performing antigenic vaccine matching for
   foot-and-mouth disease in absence of the homologous virus
SO VACCINE
LA English
DT Article
DE FMD; Southern African Territories (SAT); Vaccine matching; R-1-value;
   VNT
ID IMMUNOSORBENT-ASSAY ELISA; HETEROLOGOUS CHALLENGE; CROSS-PROTECTION;
   ANTIBODIES; STRAINS; CATTLE; EPIDEMIOLOGY; INTERFACE; INFECTION;
   SELECTION
AB Foot-and-mouth-disease (FMD) is a highly contagious transboundary animal disease that has negative consequences on regional and international trade. Vaccination is an important approach for FMD control and an essential consideration is the degree of cross-protection conferred by the vaccine against currently circulating field viruses. The objective of this study was to evaluate a new vaccine matching technique that does not require knowledge concerning the homologous vaccine virus. As a proof of concept, the vaccine-match was assessed for 41 FMD field viruses isolated from southern Africa over a 25-year period.
   A diverse group of 20 SAT1 and 21 SAT2 FMDV isolates collected from cattle and wildlife during 1991-2015 were selected for this study. Virus neutralization tests were performed against two sets of pooled sera for each serotype: vaccinated cattle sera (4-16 weeks post-vaccination) and convalescent cattle sera (3 weeks post-experimental challenge). Novel r(1)-values were calculated as the ratio of the titre of the vaccinated sera to the titre for convalescent cattle sera. A validation r(1)-value was calculated based on an assumption concerning the true homologous vaccine virus. There was a strong positive correlation between r(1)-values for the novel and the validation methods for SAT1 viruses (Spearman's rho = 0.84, P < 0.01) and a very strong correlation for SAT2 viruses (Spearman's rho = 0.90, P < 0.01). In addition, there was moderate to good agreement between the novel and validation methods for both serotypes based on a r(1)-value cut-off of 0.3, which is presumed to represent a good vaccine-match. The agreement between methods using prevalence-adjusted and bias-adjusted kappa (PABAK) was 0.67 and 0.84 for SAT1 and SAT2 viruses, respectively.
   The new r(1)-value method provides a feasible, alternative vaccine matching approach that could benefit FMD control in southern Africa. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sirdar, Mohamed M.; Fosgate, Geoffrey T.; Blignaut, Belinda; Gummow, Bruce; Lazarus, David D.; van der Merwe, Danica] Univ Pretoria, Fac Vet Sci, Dept Prod Anim Studies, ZA-0110 Onderstepoort, South Africa.
   [Sirdar, Mohamed M.; Blignaut, Belinda; Shileyi, Bernard; Mutowembwa, P.; van der Merwe, Danica; Heath, Livio] Agr Res Council, Onderstepoort Vet Res, Transboundary Anim Dis Programme, ZA-0110 Onderstepoort, South Africa.
   [Gummow, Bruce] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, Australia.
   [Lazarus, David D.] Natl Vet Res Inst, Foot & Mouth Dis Lab, PMB 01, Vom, Nigeria.
   [Sirdar, Mohamed M.] Agr Res Council, Onderstepoort Vet Res, 100 Old Soutpan Rd,Private Bag X05, ZA-0110 Onderstepoort, South Africa.
RP Sirdar, MM (reprint author), Agr Res Council, Onderstepoort Vet Res, 100 Old Soutpan Rd,Private Bag X05, ZA-0110 Onderstepoort, South Africa.
EM SirdarM@arc.agric.za
RI Lazarus, David/J-3631-2013
OI Lazarus, David/0000-0001-5683-7887; Sirdar, Mohamed/0000-0003-1830-702X
FU National Research Foundation of South AfricaNational Research Foundation
   - South Africa [90578, 76734]
FX This work was partially supported by the National Research Foundation of
   South Africa (Grant Numbers 90578 and 76734).
CR Alonso Albino, 1993, Viral Immunology, V6, P219, DOI 10.1089/vim.1993.6.219
   BACHRACH HL, 1968, ANNU REV MICROBIOL, V22, P201, DOI 10.1146/annurev.mi.22.100168.001221
   Bastos ADS, 2003, J GEN VIROL, V84, P1595, DOI 10.1099/vir.0.18859-0
   Bastos ADS, 2001, ARCH VIROL, V146, P1537, DOI 10.1007/s007050170077
   Brehm KE, 2008, VACCINE, V26, P1681, DOI 10.1016/j.vaccine.2008.01.038
   Brito BP, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00528
   Brocchi E, 2006, VACCINE, V24, P6966, DOI 10.1016/j.vaccine.2006.04.050
   Bruckner GK, 2002, REV SCI TECH OIE, V21, P751, DOI 10.20506/rst.21.3.1368
   BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V
   DAFF, 2014, VET PROC NOT FOOT MO, P73
   Di Nardo A, 2011, REV SCI TECH OIE, V30, P63
   Doel TR, 2003, VIRUS RES, V91, P81, DOI 10.1016/S0168-1702(02)00261-7
   DOMINGO E, 1985, GENE, V40, P1, DOI 10.1016/0378-1119(85)90017-4
   Ferris N P, 1992, Rev Sci Tech, V11, P657
   Goris N, 2008, VACCINE, V26, P3432, DOI 10.1016/j.vaccine.2008.04.034
   Goris N, 2007, VACCINE, V25, P3373, DOI 10.1016/j.vaccine.2006.12.049
   Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004
   Hall T. A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI citeulike-article-id:691774
   HAMBLIN C, 1987, EPIDEMIOL INFECT, V99, P733, DOI 10.1017/S0950268800066590
   HAMBLIN C, 1986, J IMMUNOL METHODS, V93, P115, DOI 10.1016/0022-1759(86)90441-2
   Haydon DT, 2001, GENETICS, V157, P7
   Jori F, 2016, TRANSBOUND EMERG DIS, V63, pE58, DOI 10.1111/tbed.12231
   Kitching RP, 2005, CURR TOP MICROBIOL, V288, P133
   Kitching RP, 2005, VET J, V169, P197, DOI 10.1016/j.tvjl.2004.06.001
   Kitching RP, 2002, REV SCI TECH OIE, V21, P531, DOI 10.20506/rst.21.3.1365
   Kitching RP, 1998, J COMP PATHOL, V118, P89, DOI 10.1016/S0021-9975(98)80002-9
   Knowles NJ, 2003, VIRUS RES, V91, P65, DOI 10.1016/S0168-1702(02)00260-5
   Lanyon SR, 2013, AUST VET J, V91, P52, DOI 10.1111/j.1751-0813.2012.01010.x
   Larska M, 2009, EPIDEMIOL INFECT, V137, P549, DOI 10.1017/S0950268808001088
   Lazarus DD, 2018, PREV VET MED, V158, P89, DOI 10.1016/j.prevetmed.2018.08.003
   Ludbrook J, 2002, CLIN EXP PHARMACOL P, V29, P527, DOI 10.1046/j.1440-1681.2002.03686.x
   Maradei E, 2011, VACCINE, V29, P8230, DOI 10.1016/j.vaccine.2011.08.120
   Maree FF, 2011, J GEN VIROL, V92, P2297, DOI 10.1099/vir.0.032839-0
   Maree FF, 2010, VIRUS RES, V153, P82, DOI 10.1016/j.virusres.2010.07.010
   Mattion N, 2009, VACCINE, V27, P741, DOI 10.1016/j.vaccine.2008.11.026
   MCVICAR JW, 1974, ARCH GES VIRUSFORSCH, V44, P168, DOI 10.1007/BF01250230
   NDIRITU CG, 1983, J HYG-CAMBRIDGE, V91, P335, DOI 10.1017/S0022172400060356
   OIE, 2019, FOOT MOUTH DIS
   OIE, FOOT MOUTH DIS INF F, P1
   PARE J, 1995, J VET DIAGN INVEST, V7, P352, DOI 10.1177/104063879500700310
   Paton DJ, 2005, REV SCI TECH OIE, V24, P981, DOI 10.20506/rst.24.3.1632
   Brito BP, 2014, VACCINE, V32, P433, DOI 10.1016/j.vaccine.2013.12.007
   PHOLOGANE BS, 2008, J VET RES, V75, P267
   Reeve R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159360
   Reeve R, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1001027
   Rweyemamu M, 2008, TRANSBOUND EMERG DIS, V55, P57, DOI 10.1111/j.1865-1682.2007.01013.x
   RWEYEMAMU MM, 1978, J HYG-CAMBRIDGE, V81, P107, DOI 10.1017/S002217240005381X
   RWEYEMAMU MM, 1984, J BIOL STAND, V12, P323, DOI 10.1016/S0092-1157(84)80013-X
   Sinkala Y, 2014, ONDERSTEPOORT J VET, V81, DOI 10.4102/ojvr.v81i2.741
   Smith TG, 2017, TROP MED INFECT DIS, V2
   Sutmoller P, 2003, VIRUS RES, V91, P101, DOI 10.1016/S0168-1702(02)00262-9
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   TAYLOR R, 1990, J DIAGN MED SONOG, V6, P35, DOI 10.1177/875647939000600106
   Valdazo-Gonzalez B, 2012, J VIROL, V86, P8901, DOI 10.1128/JVI.01231-12
   Vosloo W, 2007, VET MICROBIOL, V120, P226, DOI 10.1016/j.vetmic.2006.11.002
   Vosloo W, 2002, REV SCI TECH OIE, V21, P437, DOI 10.20506/rst.21.3.1349
NR 56
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5025
EP 5034
DI 10.1016/j.vaccine.2019.07.002
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100031
PM 31296377
DA 2020-05-12
ER

PT J
AU Groves, PJ
   Williamson, SL
   Sharpe, SM
   Gerber, PF
   Gao, YSK
   Hirn, TJ
   Walkden-Brown, SW
AF Groves, Peter J.
   Williamson, Sarah L.
   Sharpe, Sue M.
   Gerber, Priscilla F.
   Gao, Yuanshuo K.
   Hirn, Tabitha J.
   Walkden-Brown, Stephen W.
TI Uptake and spread of infectious laryngotracheitis vaccine virus within
   meat chicken flocks following drinking water vaccination
SO VACCINE
LA English
DT Article
DE Infectious laryngotracheitis; Vaccination
ID REPLICATION; TRANSMISSIBILITY; ANTIBODY
AB Vaccination against infectious laryngotracheitis virus (ILTV) in commercial broiler flocks in the field, which is only undertaken in the face of a local outbreak, requires mass administration techniques, usually via drinking water. This is often fraught with difficulties such as variable vaccination reactions and sometimes, vaccination failure. Laboratory testing of the outbreak strains however invariably shows the vaccines in use to be protective. To investigate this paradox, the dynamics of an ILT vaccine virus was examined within broiler flocks during a natural outbreak. In an initial flock, 70 birds were individually identified and had tracheal swabs collected sequentially at intervals from 1 to 26 days after vaccination and submitted for ILTV detection using qPCR. This evaluation was extended by collection of tracheal swabs from 40 to 45 random birds at 4, 7-8, 12-13 and 25-26 days post vaccination (pv) across a further 7 flocks. The results showed a very variable early uptake of vaccine virus from the drinking water (between 3% and 52% of tested birds with detectable virus in trachea at 4 days pv) and revealed that actual vaccination of the flocks relied on bird to bird transmission of the vaccine virus. In flocks with very low (<10%) initial bird uptake, successful exposure of vaccine virus to the majority of the flock can be delayed, leaving a large proportion of birds as susceptible at the likely time of possible exposure to wild virus. This may explain the cases of apparent failure of vaccination in the field. The variable bird to bird spread can be associated with reversion to virulence, this may explain the rolling vaccine reactions often observed. The variation in initial vaccine uptake may be affected by some factors involved with the administration technique and this requires further study in a larger sample size. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Groves, Peter J.; Hirn, Tabitha J.] Univ Sydney, Poultry Res Fdn, Fac Sci, Sydney Sch Vet Sci, 425 Werombi Rd, Camden, NSW 2570, Australia.
   [Williamson, Sarah L.; Sharpe, Sue M.] Birling Avian Labs, 975 Northern Rd, Bringelly, NSW 2556, Australia.
   [Gerber, Priscilla F.; Walkden-Brown, Stephen W.] Univ New England, Sch Environm & Rural Sci, Armidale, NSW, Australia.
   [Gao, Yuanshuo K.] Zootechny Pty Ltd, Austral, NSW 2179, Australia.
RP Groves, PJ (reprint author), Univ Sydney, Poultry Res Fdn, Fac Sci, Sydney Sch Vet Sci, 425 Werombi Rd, Camden, NSW 2570, Australia.
EM peter.groves@sydney.edu.au; sarah.williamson@baiada.com.au;
   sue.sharpe@baiada.com.au; pgerber2@une.edu.au; karen_gao@bigpond.com;
   thir5445@uni.sydney.edu.au; swalkden@une.edu.au
RI Gerber, Priscilla F./K-4771-2012
OI Gerber, Priscilla F./0000-0002-8343-8299; Walkden-Brown,
   Stephen/0000-0002-0638-5533
FU AgriFutures Australia [010639]
FX This work was supported by AgriFutures Australia (project number
   010639).
CR Agnew-Crumpton R, 2016, INFECT GENET EVOL, V43, P67, DOI 10.1016/j.meegid.2016.05.023
   Arzey GG, 2008, P SCI M AUSTR VET PO
   Callison SA, 2007, J VIROL METHODS, V139, P31, DOI 10.1016/j.jviromet.2006.09.001
   Coppo MJC, 2013, AVIAN PATHOL, V42, P195, DOI 10.1080/03079457.2013.800634
   Coppo MJC, 2012, AVIAN PATHOL, V41, P195, DOI 10.1080/03079457.2012.660132
   Coppo MJC, 2012, AVIAN PATHOL, V41, P99, DOI 10.1080/03079457.2011.643222
   DAF Queensland, 2017, QUEENSL INF LAR
   Davidson I, 2016, VACCINE, V34, P1630, DOI 10.1016/j.vaccine.2016.01.006
   De Wit JJ, 2013, P 18 C WORLD VET POU, V18, P63
   Dhand NK, 2014, STATULATOR ONLINE ST
   Finn A., 2018, VACCINE KNOWLEDGE PR
   Groves PJ, 2009, P SCI M AUSTR VET PO
   GUY JS, 1991, AVIAN DIS, V35, P348, DOI 10.2307/1591188
   Guy JS, 2003, DIS POULTRY, P121
   HANCOCK DD, 1988, VET CLIN N AM-FOOD A, V4, P33, DOI 10.1016/S0749-0720(15)31074-4
   Johnson Y. J., 2005, International Journal of Poultry Science, V4, P263
   Keck L., POULTRY HLTH TODAY
   Kirkpatrick NC, 2006, AVIAN DIS, V50, P28, DOI 10.1637/7414-072205R.1
   Korsa MG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137719
   MARTINS NRD, 1992, AVIAN PATHOL, V21, P97, DOI 10.1080/03079459208418822
   Menendez KR, 2014, AVIAN PATHOL, V43, P108, DOI 10.1080/03079457.2014.886004
   ROBERTSON GM, 1981, AUST VET J, V57, P119, DOI 10.1111/j.1751-0813.1981.tb00472.x
   Rodriguez-Avila A, 2007, AVIAN DIS, V51, P905, DOI 10.1637/8011-041907-REGR.1
   Rodriguez-Avila A, 2008, AVIAN PATHOL, V37, P287, DOI 10.1080/03079450802043742
   Williamson SL, 2019, P SCI M AUSTR VET OP
   YORK JJ, 1989, AVIAN PATHOL, V18, P643, DOI 10.1080/03079458908418639
NR 26
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5035
EP 5043
DI 10.1016/j.vaccine.2019.06.087
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100032
PM 31300291
DA 2020-05-12
ER

PT J
AU Park, S
   Nixon, CE
   Pond-Tor, S
   Kabyemela, ER
   Fried, M
   Duffy, PE
   Kurtis, JD
   Friedman, JF
AF Park, Sangshin
   Nixon, Christina E.
   Pond-Tor, Sunthorn
   Kabyemela, Edward R.
   Fried, Michal
   Duffy, Patrick E.
   Kurtis, Jonathan D.
   Friedman, Jennifer F.
TI Impact of maternally derived antibodies to Plasmodium falciparum
   Schizont Egress Antigen-1 on the endogenous production of anti-PfSEA-1
   in offspring
SO VACCINE
LA English
DT Article
DE Malaria; Vaccine; Schizont Egress Antigen-1; PfSEA-1; Maternal antibody
ID MEROZOITE SURFACE PROTEIN-1; AFRICAN INFANTS; IMMUNE-RESPONSES;
   PREGNANT-WOMEN; ANTIMALARIAL ANTIBODIES; 1ST YEAR; MALARIA; INFECTION;
   PROTECTION; DOMAIN
AB Background: We evaluated whether maternally-derived antibodies to a malarial vaccine candidate, Plasmodium falciparum Schizont Egress Antigen-1 (PfSEA-1), in cord blood interfered with the development of infant anti-PfSEA-1 antibodies in response to natural exposure.
   Methods: We followed 630 Tanzanian infants who were measured their antibodies against PfSEA-1 (aa 810-1023; PfSEA-1A) at birth and 6, 12, 18, and 24 months of age, and examined the changes in anti-PfSEA-1A antibody levels in response to parasitemia, and evaluated whether maternally-derived anti-PfSEA-1A antibodies in cord blood modified infant anti-PfSEA-1A immune responses.
   Results: Infants who experienced parasitemia during the first 6 months of life had significantly higher anti-PfSEA-1A antibodies at 6 and 12 months of age compared to uninfected infants. Maternally-derived anti-PfSEA-1A antibodies in cord blood significantly modified this effect during the first 6 months. During this period, infant anti-PfSEA-1A antibody levels were significantly associated with their P. falciparum exposure when they were born with low, but not higher, maternally-derived anti-PfSEA-1A antibody levels in cord blood. Nevertheless, during the first 6 months of life, maternally-derived anti-PfSEA-1A antibodies in cord blood did not abrogate the parasitemia driven development of infant anti-PfSEA-1A: parasitemia were significantly correlated with anti-PfSEA-1A antibody levels at 6 months of age in the infants born with low maternally-derived anti-PfSEA-1A antibody levels in cord blood and borderline significantly correlated in those infants born with middle and high levels.
   Conclusions: Maternal vaccination with PfSEA-1A is unlikely to interfere with the development of naturally acquired anti-PfSEA-1A immune responses following exposure during infancy. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Park, Sangshin; Nixon, Christina E.; Pond-Tor, Sunthorn; Kurtis, Jonathan D.; Friedman, Jennifer F.] Brown Univ, Rhode Isl Hosp, Ctr Int Hlth Res, Warren Alpert Med Sch, Providence, RI 02903 USA.
   [Park, Sangshin; Friedman, Jennifer F.] Brown Univ, Dept Pediat, Warren Alpert Med Sch, Providence, RI 02903 USA.
   [Park, Sangshin] Univ Seoul, Grad Sch Urban Publ Hlth, 163 Seoulsiripdae Ro, Seoul 02504, South Korea.
   [Nixon, Christina E.; Pond-Tor, Sunthorn; Kurtis, Jonathan D.] Brown Univ, Dept Pathol & Lab Med, Warren Alpert Med Sch, Providence, RI 02903 USA.
   [Kabyemela, Edward R.] Seattle Biomed Res Inst, Mother Offspring Malaria Studies MOMS Project, Seattle, WA 98109 USA.
   [Kabyemela, Edward R.] Muheza Designated Dist Hosp, Muheza, Tanzania.
   [Kabyemela, Edward R.] Tumaini Univ, Moshi, Tanzania.
   [Fried, Michal; Duffy, Patrick E.] NIAID, Lab Malaria Immunol & Vaccinol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Park, S (reprint author), Univ Seoul, Grad Sch Urban Publ Hlth, 163 Seoulsiripdae Ro, Seoul 02504, South Korea.
EM spark@uos.ac.kr
RI Park, Sangshin/K-6889-2014
OI Park, Sangshin/0000-0003-2407-0962
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [P20GM104317-01,
   R01-AI52059, R01-AI076353, R01 AI110699-01, T32-DA013911, K24 AI112964];
   Bill & Melinda Gates FoundationGates Foundation [1364]; Intramural
   Research Program of the NIAID-NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID); Thrasher Research
   Fund
FX This work was supported by grants from the US National Institutes of
   Health [grant R01-AI52059] and the Bill & Melinda Gates Foundation
   [grant 1364] to PED, the Intramural Research Program of the NIAID-NIH,
   and by grants from the US National Institutes of Health [grants
   R01-AI076353, R01 AI110699-01] to JDK. CEN was supported by the US
   National Institutes of Health [grant T32-DA013911] and The Thrasher
   Research Fund. JFF and SP were supported by US National Institutes of
   Health [grant P20GM104317-01] and JFF by US National Institutes of
   Health [grant K24 AI112964].
CR Achidi EA, 2005, INT J INFECT DIS, V9, P159, DOI 10.1016/j.ijid.2004.06.012
   Afolabi BM, 2001, AM J TROP MED HYG, V65, P822, DOI 10.4269/ajtmh.2001.65.822
   Branch OH, 1998, AM J TROP MED HYG, V58, P211, DOI 10.4269/ajtmh.1998.58.211
   Broen K, 2007, MOL BIOCHEM PARASIT, V151, P1, DOI 10.1016/j.molbiopara.2006.10.001
   BRUCECHWATT LJ, 1952, ANN TROP MED PARASIT, V46, P173, DOI 10.1080/00034983.1952.11685522
   Charnaud SC, 2016, SCI REP-UK, V6, DOI 10.1038/srep20859
   Clinical RTSS, 2015, LANCET, V386, P31
   Dechavanne C, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002403
   Dechavanne C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145464
   Deloron P, 1997, CLIN EXP IMMUNOL, V110, P212
   DESOWITZ RS, 1993, INFECT IMMUN, V61, P988, DOI 10.1128/IAI.61.3.988-993.1993
   Dobbs KR, 2016, PARASITOLOGY, V143, P129, DOI 10.1017/S0031182015001626
   ENGLUND JA, 1995, PEDIATRICS, V96, P580
   Falade C, 2007, TROP MED INT HEALTH, V12, P1279, DOI 10.1111/j.1365-3156.2007.01931.x
   Franks S, 2001, J INFECT DIS, V183, P796, DOI 10.1086/318834
   Gottschau A, 1995, STAT MED, V14, P2727, DOI 10.1002/sim.4780142411
   Harrington WE, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12573
   Harrington WE, 2017, J INFECT DIS, V215, P1445, DOI 10.1093/infdis/jix129
   Hodgins DC, 2012, VACCINE, V30, P1541, DOI 10.1016/j.vaccine.2011.12.047
   Jones C, 2014, VACCINE, V32, P996, DOI 10.1016/j.vaccine.2013.11.104
   Kabyemela ER, 2008, J INFECT DIS, V198, P163, DOI 10.1086/589512
   Kane Elizabeth G, 2011, Malar Res Treat, V2011, P764845, DOI 10.4061/2011/764845
   Kangoye DT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107965
   King CL, 2002, J IMMUNOL, V168, P356, DOI 10.4049/jimmunol.168.1.356
   Kitua AY, 1996, TROP MED INT HEALTH, V1, P475, DOI 10.1046/j.1365-3156.1996.d01-89.x
   Kurtis JD, CLIN INFECT DIS
   McGuinness D, 1998, T ROY SOC TROP MED H, V92, P527, DOI 10.1016/S0035-9203(98)90902-6
   McLean ARD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186577
   Moro L, 2015, J INFECT DIS, V211, P1004, DOI 10.1093/infdis/jiu547
   Mutabingwa TK, 2005, PLOS MED, V2, P1260, DOI 10.1371/journal.pmed.0020407
   Mwaniki MK, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-313
   Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446
   Raj DK, 2014, SCIENCE, V344, P871, DOI 10.1126/science.1254417
   RASHEED FN, 1995, PARASITE IMMUNOL, V17, P1, DOI 10.1111/j.1365-3024.1995.tb00960.x
   Richie TL, 2015, VACCINE, V33, P7452, DOI 10.1016/j.vaccine.2015.09.096
   Riley EM, 2000, INFECT IMMUN, V68, P5856, DOI 10.1128/IAI.68.10.5856-5863.2000
   Riley EM, 2001, PARASITE IMMUNOL, V23, P51, DOI 10.1046/j.1365-3024.2001.00364.x
   Sehgal V M, 1989, Trans R Soc Trop Med Hyg, V83 Suppl, P105, DOI 10.1016/0035-9203(89)90616-0
   Snow RW, 1998, J INFECT DIS, V177, P819, DOI 10.1086/517818
   Tassi Yunga S, 2017, PLOS ONE, V12
   Tena-Tomas C, 2007, PARASITOL RES, V101, P1045, DOI 10.1007/s00436-007-0585-9
   White MT, 2014, J INFECT DIS, V210, P1115, DOI 10.1093/infdis/jiu219
   World Health Organization, 2018, WORLD MAL REP 2018
   World Health Organization, MAL VACC RAINB TABL
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5044
EP 5050
DI 10.1016/j.vaccine.2019.06.084
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100033
PM 31288996
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Kingstad-Bakke, BA
   Chandrasekar, SS
   Phanse, Y
   Ross, KA
   Hatta, M
   Suresh, M
   Kawaoka, Y
   Osorio, JE
   Narasimhan, B
   Talaat, AM
AF Kingstad-Bakke, Brock A.
   Chandrasekar, Shaswath S.
   Phanse, Yashdeep
   Ross, Kathleen A.
   Hatta, Masato
   Suresh, M.
   Kawaoka, Yoshihiro
   Osorio, Jorge E.
   Narasimhan, Balaji
   Talaat, Adel M.
TI Effective mosaic-based nanovaccines against avian influenza in poultry
SO VACCINE
LA English
DT Article
DE Nanoparticle vaccine; Modified vaccinia Ankara; Avian influenza; Vaccine
   vector
ID A VIRUSES; IMMUNE-RESPONSE; CELL RESPONSES; HEMAGGLUTININ; EFFICACY;
   H5N1; VACCINES; PROTECTION; EMERGENCE; CHICKENS
AB Avian influenza virus (AIV) is an extraordinarily diverse pathogen that causes significant morbidity in domesticated poultry populations and threatens human life with looming pandemic potential. Controlling avian influenza in susceptible populations requires highly effective, economical and broadly reactive vaccines. Several AIV vaccines have proven insufficient despite their wide use, and better technologies are needed to improve their immunogenicity and broaden effectiveness. Previously, we developed a "mosaic" H5 subtype hemagglutinin (HA) AIV vaccine and demonstrated its broad protection against diverse highly pathogenic H5N1 and seasonal H1N1 virus strains in mouse and non-human primate models. There is a significant interest in developing effective and safe vaccines against AIV that cannot contribute to the emergence of new strains of the virus once circulating in poultry. Here, we report on the development of an H5 mosaic (H5M) vaccine antigen formulated with polyanhydride nanoparticles (PAN) that provide sustained release of encapsulated antigens. H5M vaccine constructs were immunogenic whether delivered by the modified virus Ankara (MVA) strain or encapsulated within PAN. Both humoral and cellular immune responses were generated in both specific-pathogen free (SPF) and commercial chicks. Importantly, chicks vaccinated by H5M constructs were protected in terms of viral shedding from divergent challenge with a low pathogenicity avian influenza (LPAI) strain at 8 weeks post-vaccination. In addition, protective levels of humoral immunity were generated against highly pathogenic avian influenza (HPAI) of the similar H5N1 and genetically dissimilar H5N2 viruses. Overall, the developed platform technologies (MVA vector and PAN encapsulation) were safe and provided high levels of sustained protection against AIV in chickens. Such approaches could be used to design more efficacious vaccines against other important poultry infections. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kingstad-Bakke, Brock A.; Chandrasekar, Shaswath S.; Hatta, Masato; Suresh, M.; Kawaoka, Yoshihiro; Osorio, Jorge E.; Talaat, Adel M.] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.
   [Kingstad-Bakke, Brock A.; Phanse, Yashdeep; Talaat, Adel M.] Pan Genome Syst, Madison, WI USA.
   [Ross, Kathleen A.; Narasimhan, Balaji] Iowa State Univ, Dept Chem & Biol Engn, Ames, IA USA.
RP Talaat, AM (reprint author), Univ Wisconsin, Robert P Hanson Biomed Sci Labs, Sch Vet Med, 1656 Linden Dr,Room 303, Madison, WI 53706 USA.
EM adel.talaat@wisc.edu
OI Suresh, Marulasiddappa/0000-0003-1794-3358
FU USDA NIFAUnited States Department of Agriculture (USDA) [2015-07821];
   University of Wisconsin-WARF Seed Grant; Iowa State University
   Nanovaccine Institute
FX This work was partially supported by grants USDA NIFA (2015-07821) and
   University of Wisconsin-WARF Seed Grant awarded to AMT. BN and AMT
   acknowledge support from the Iowa State University Nanovaccine Institute
   and BN is grateful to the Vlasta Klima Balloun Faculty Chair.
CR Al-Halifa S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00022
   Aleflali M, 2015, HUM VACCIN IMMUNOTHE
   [Anonymous], 2014, AVIAN INFLUENZA
   Ariaans MP, 2008, DEV COMP IMMUNOL, V32, P1398, DOI 10.1016/j.dci.2008.05.007
   Banks J, 2001, ARCH VIROL, V146, P963, DOI 10.1007/s007050170128
   Barton HD, 2013, J ANIM ECOL
   BEAN WJ, 1985, J VIROL, V54, P151, DOI 10.1128/JVI.54.1.151-160.1985
   Bertran K, 2018, VACCINE, V36, P6361, DOI 10.1016/j.vaccine.2018.09.015
   Chahroudi A, 2006, J VIROL, V80, P8469, DOI 10.1128/JVI.02749-05
   Chen LJ, 2016, J GEN VIROL, V97, P844, DOI 10.1099/jgv.0.000399
   Cox RJ, 2004, SCAND J IMMUNOL, V59, P1, DOI 10.1111/j.0300-9475.2004.01382.x
   Crawford J, 1999, VACCINE, V17, P2265, DOI 10.1016/S0264-410X(98)00494-0
   Dhakal S, 2017, VACCINE, V35, P1124, DOI 10.1016/j.vaccine.2017.01.019
   DiazGranados CA, 2012, VACCINE, V31, P49, DOI 10.1016/j.vaccine.2012.10.084
   Ehrlich HJ, 2008, NEW ENGL J MED, V358, P2573, DOI 10.1056/NEJMoa073121
   Florek NW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181738
   Gao WT, 2006, J VIROL, V80, P1959, DOI 10.1128/JVI.80.4.1959-1964.2006
   Gelb J, 2016, AVIAN DIS, V60, P603, DOI 10.1637/11344-120815-Reg.1
   Gerloff NA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152131
   Gerloff NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068522
   Haughney SL, 2013, ACTA BIOMATER, V9, P8262, DOI 10.1016/j.actbio.2013.06.006
   Herfst S, 2012, SCIENCE, V336, P1534, DOI 10.1126/science.1213362
   HORIMOTO T, 1995, VIROLOGY, V213, P223, DOI 10.1006/viro.1995.1562
   Huntimer L, 2013, ADV HEALTHC MATER, V2, P369, DOI 10.1002/adhm.201200181
   Huntimer L, 2013, J BIOMED MATER RES B, V101B, P91, DOI 10.1002/jbm.b.32820
   Jhung MA, 2015, MMWR-MORBID MORTAL W, V64, P111
   Kamlangdee A, 2016, J VIROL, V90, P6771, DOI 10.1128/JVI.00730-16
   Kamlangdee A, 2014, J VIROL, V88, P13300, DOI 10.1128/JVI.01532-14
   Kapczynski DR, 2015, VACCINE, V33, P1197, DOI 10.1016/j.vaccine.2014.12.028
   Kaur K, 2011, TRENDS IMMUNOL, V32, P524, DOI 10.1016/j.it.2011.08.007
   Killian ML, 2014, METHODS MOL BIOL, V1161, P3, DOI 10.1007/978-1-4939-0758-8_1
   Kipper MJ, 2006, J BIOMED MATER RES A, V76A, P798, DOI 10.1002/jbm.a.30545
   Lee DH, 2016, VIROLOGY, V488, P225, DOI 10.1016/j.virol.2015.11.023
   Lopac SK, 2009, J BIOMED MATER RES B, V91B, P938, DOI 10.1002/jbm.b.31478
   McGill JL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21292-2
   Medina RA, 2011, NAT REV MICROBIOL, V9, P590, DOI 10.1038/nrmicro2613
   Monne I, 2014, J VIROL, V88, P4375, DOI 10.1128/JVI.03181-13
   MOSTOW SR, 1979, INFECT IMMUN, V26, P193, DOI 10.1128/IAI.26.1.193-196.1979
   Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345
   Pandey A, 2010, HUM VACCINES, V6, P178, DOI 10.4161/hv.6.2.9899
   Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0
   Ping JH, 2012, J GEN VIROL, V93, P1649, DOI 10.1099/vir.0.042895-0
   Read AF, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002198
   Renu S, 2018, INT J NANOMED, V13, P8195, DOI 10.2147/IJN.S185588
   Richard-Mazet A, 2014, VET RES, V45, DOI 10.1186/s13567-014-0107-6
   Ross K, 2016, ACS BIOMATER SCI ENG, V2, P368, DOI 10.1021/acsbiomaterials.5b00477
   Ross KA, 2015, INT J NANOMED, V10, P229, DOI 10.2147/IJN.S72264
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Sonnberg S, 2013, VIRUS RES, V178, P63, DOI 10.1016/j.virusres.2013.05.009
   Spicer CD, 2018, CHEM SOC REV, V47, P3574, DOI 10.1039/c7cs00877e
   STONE HD, 1987, AVIAN DIS, V31, P483, DOI 10.2307/1590728
   Suarez DL, 2004, EMERG INFECT DIS, V10, P693, DOI 10.3201/eid1004.030396
   Torres MP, 2007, BIOMATERIALS, V28, P108, DOI 10.1016/j.biomaterials.2006.08.047
   Ulery BD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017642
   Veits J, 2008, VACCINE, V26, P1688, DOI 10.1016/j.vaccine.2008.01.016
   Vela-Ramirez JE, 2015, AAPS J, V17, P256, DOI 10.1208/s12248-014-9699-z
   Wagner-Muniz DA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00325
   Wang Y, 2018, EXPERT REV VACCINES, V17, P967, DOI 10.1080/14760584.2018.1541408
   Wright PF, 2008, NEW ENGL J MED, V358, P2540, DOI 10.1056/NEJMp0803650
   Zacharias ZR, 2018, FRONT IMMUNOL
NR 60
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5051
EP 5058
DI 10.1016/j.vaccine.2019.06.077
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100034
PM 31300285
DA 2020-05-12
ER

PT J
AU Ork, V
   Woodring, J
   Hossain, MS
   Wasley, A
   Nagashima, S
   Yamamoto, C
   Chuon, C
   Sugiyama, A
   Ohisa, M
   Akita, T
   Ko, K
   Mao, B
   Tanaka, J
AF Ork, Vichit
   Woodring, Joseph
   Hossain, Md Shafiqul
   Wasley, Annemarie
   Nagashima, Shintaro
   Yamamoto, Chikako
   Chuon, Channarena
   Sugiyama, Aya
   Ohisa, Masayuki
   Akita, Tomoyuki
   Ko, Ko
   Mao, Bunsoth
   Tanaka, Junko
TI Hepatitis B surface antigen seroprevalence among pre- and post-vaccine
   cohorts in Cambodia, 2017
SO VACCINE
LA English
DT Article
DE Hepatitis B virus; Cambodia; Seroprevalence; Vaccine
AB Background: Hepatitis B virus (HBV) infection is highly endemic in most low income countries including Cambodia. This nationwide serosurvey was conducted to assess the impact of hepatitis B vaccination and to determine whether Cambodia met the WHO regional 2017 target of hepatitis B surface antigen (HBsAg) seroprevalence less than 1% in five-year-old children.
   Methods: A cross-sectional multi-stage cluster survey was conducted among children born during 2010-2012 and their mothers in Cambodia. HBsAg prevalence was estimated by rapid point-of-care testing, and demographic data, including vaccination history, was collected. Vaccine coverage in children and the prevalence of HBsAg among children and mothers was calculated taking into account the complex survey design. Factors associated with childrens failure to receive timely (within 24 h) vaccination were analysed by multivariate logistic analysis.
   Findings: A total of 2,520 children 5-7 years old and 2,028 mothers were recruited. In total, 78.4% of children received hepatitis B vaccination birth-dose (HepB-BD); of these, 58.7% were administered <= 24 h. Birth at home or other location were independent risk factors for childrens failure to receive timely HepB-BD. Overall HBsAg seroprevalence was 4.39% (95%CI: 3.53%-5.45%) among mothers and 0.56% (95%CI: 0.32%-0.98%) among children. The prevalence among children without hepatitis B vaccination was 4.62% (95%CI: 1.31%-14.97%). Among children with a HBsAg-positive mother, prevalence was 10.11% (95%CI: 5.41%-18.11%).
   Interpretation: Having achieved the 2017 target of less than 1% HBsAg prevalence among 5 years old children, Cambodia can now focus on eliminating mother-to-child transmission of HBV. Moreover, the high HBsAg prevalence among mothers suggests that routine screening with proper linkage to care and treatment is needed. Strengthening measures to improve vaccination coverage further and eliminate mother-to-child transmission by coordinated programming with other services offering additional HBV interventions will help move towards the global goal of hepatitis B elimination by 2030. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Ork, Vichit] Minist Hlth, Natl Immunizat Programme, 151-152 Kampuchea Krom Ave, Phonm Penh, Cambodia.
   [Woodring, Joseph] World Hlth Org Reg Off Western Pacific, Expanded Programme Immunizat, Manila 1000, Philippines.
   [Hossain, Md Shafiqul] World Hlth Org Country Off, Expanded Programme Immunizat, Phnom Penh, Cambodia.
   [Wasley, Annemarie] Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   [Nagashima, Shintaro; Yamamoto, Chikako; Chuon, Channarena; Sugiyama, Aya; Ohisa, Masayuki; Akita, Tomoyuki; Ko, Ko; Tanaka, Junko] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Epidemiol Infect Dis Control & Prevent, Hiroshima, Hiroshima, Japan.
   [Mao, Bunsoth] Univ Hlth Sci, 73 Monivong Blvd, Phnom Penh, Cambodia.
RP Tanaka, J (reprint author), Hiroshima Univ, Dept Epidemiol Infect Dis Control & Prevent, Grad Sch Biomed & Hlth Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima, Hiroshima 7348551, Japan.
EM orkvichit@yahoo.com; woodringj@who.int; hossains@who.int; acw5@cdc.gov;
   s-nagashima@hiroshima-u.ac.jp; c-yamamoto@hiroshima-u.ac.jp;
   chuonchannarena@rocketmail.com; aya-sugiyama@hiroshima-u.ac.jp;
   ohisam@hiroshima-u.ac.jp; tomo-akita@hiroshima-u.ac.jp;
   d161800@hiroshima-u.ac.jp; maobunsoth@uhs.edu.kh;
   jun-tanaka@hiroshima-u.ac.jp
RI Tanaka, Junko/G-6166-2019
OI Tanaka, Junko/0000-0002-5669-4051
FU Hiroshima University, Department of Epidemiology, Infectious Disease
   Control and Prevention, Japan; Project Research Centre for epidemiology
   and prevention of viral hepatitis and hepatocellular carcinoma,
   Hiroshima University, Japan; World Health Organization: WHO, The
   Expanded Programme on Immunization (EPI); Viral hepatitis Research
   Foundation of Japan (AAOHELP: Asia-Africa-Oceania Hepatitis Experts
   Linkage Promotion); National Center for Global Health and Medicine: NCGM
   [29-2]
FX This study was financially supported by.; 1) Hiroshima University,
   Department of Epidemiology, Infectious Disease Control and Prevention,
   Japan.; 2) Project Research Centre for epidemiology and prevention of
   viral hepatitis and hepatocellular carcinoma, Hiroshima University,
   Japan (Director: J. Tanaka); 3) World Health Organization: WHO, The
   Expanded Programme on Immunization (EPI).; 4) Viral hepatitis Research
   Foundation of Japan (AAOHELP: Asia-Africa-Oceania Hepatitis Experts
   Linkage Promotion); 5) National Center for Global Health and Medicine:
   NCGM (Contact Number: 29-2)
CR Department of planning & health information ministry of health in Kingdom of Cambodia, 2016, HLTH STRAT PLAN 2016
   Department of planning & health information ministry of health in Kingdom of Cambodia, 2017, HLTH SECT PROGR 2016
   Fujimoto M, 2018, HEPATOL RES, V48, pE172, DOI 10.1111/hepr.12941
   Goldstein ST, 2005, INT J EPIDEMIOL, V34, P1329, DOI 10.1093/ije/dyi206
   Kabudula CW, 2017, SOC INDIC RES, V133, P1047, DOI 10.1007/s11205-016-1397-z
   Mao B, 2013, VACCINE, V31, P4459, DOI 10.1016/j.vaccine.2013.05.009
   Organization WH, 2016, GLOB HLTH SECT STRAT
   Soeung SC, 2009, AM J TROP MED HYG, V81, P252, DOI 10.4269/ajtmh.2009.81.252
   Tanaka J, 2018, SERO EPIDEMIOLOGICAL
   UNICEF, 2016, 4 UNICEF MICS
   Wiesen E, 2016, VACCINE, V34, P2855, DOI 10.1016/j.vaccine.2016.03.060
   Woodring Joseph, 2017, Western Pac Surveill Response J, V8, P1, DOI 10.5365/wpsar.2017.8.3.005
   World Health Organization, 2017, GLOB HEP REP 2017
   World health organization, 2012, SAMPL DES PROC HEP B
   World health organization regional office of the western pacific, 2013, REG COMM RES HEP CON
   World health organization regional office of the western pacific, 2003, REG COMM RES MEASL H
NR 16
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5059
EP 5066
DI 10.1016/j.vaccine.2019.06.073
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100035
PM 31285088
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Abbott, S
   Christensen, H
   Lalor, MK
   Zenner, D
   Campbell, C
   Ramsay, ME
   Brooks-Pollock, E
AF Abbott, Sam
   Christensen, Hannah
   Lalor, Maeve K.
   Zenner, Dominik
   Campbell, Colin
   Ramsay, Mary E.
   Brooks-Pollock, Ellen
TI Exploring the effects of BCG vaccination in patients diagnosed with
   tuberculosis: Observational study using the Enhanced Tuberculosis
   Surveillance system
SO VACCINE
LA English
DT Article
DE Tuberculosis; BCG; Surveillance; Non-specific; Mortality
ID PROTECTION; ENGLAND; WALES; UK; METAANALYSIS; PREVENTION; EFFICACY; SCAR
AB Background: Bacillus Calmette-Guerin (BCG) is one of the most widely-used vaccines worldwide. BCG primarily reduces the progression from infection to disease, however there is evidence that BCG may provide additional benefits. We aimed to investigate whether there is evidence in routinely-collected surveillance data that BCG vaccination impacts outcomes for tuberculosis (TB) cases in England.
   Methods: We obtained all TB notifications for 2009-2015 in England from the Enhanced Tuberculosis surveillance system. We considered five outcomes: All-cause mortality, death due to TB (in those who died), recurrent TB, pulmonary disease, and sputum smear status. We used logistic regression, with complete case analysis, to investigate each outcome with BCG vaccination, years since vaccination and age at vaccination, adjusting for potential confounders. All analyses were repeated using multiply imputed data.
   Results: We found evidence of an association between BCG vaccination and reduced all-cause mortality (aOR:0.76 (95%CI 0.64-0.89), P:0.001) and weak evidence of an association with reduced recurrent TB (aOR:0.90 (95%CI 0.81-1.00), P:0.056). Analyses using multiple imputation suggested that the benefits of vaccination for all-cause mortality were reduced after 10 years.
   Conclusions: e found that BCG vaccination was associated with reduced all-cause mortality in people with TB although this benefit was less pronounced more than 10 years after vaccination. There was weak evidence of an association with reduced recurrent TB. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Abbott, Sam; Christensen, Hannah; Brooks-Pollock, Ellen] Univ Bristol, Bristol Med Sch Populat Hlth Sci, Bristol BS8 2BN, Avon, England.
   [Lalor, Maeve K.; Campbell, Colin] Publ Hlth England, TB Unit, TARGET Natl Infect Serv NIS, London, England.
   [Zenner, Dominik] UCL, Inst Global Hlth, London, England.
   [Ramsay, Mary E.] Publ Hlth England, Immunisat Hepatitis & Blood Safety Dept, London, England.
RP Abbott, S (reprint author), Univ Bristol, Bristol Med Sch Populat Hlth Sci, Bristol BS8 2BN, Avon, England.
EM sam.abbott@bristol.ac.uk
RI ramsay, mary elizabeth/S-8281-2016
OI ramsay, mary elizabeth/0000-0002-7156-7640; Zenner,
   Dominik/0000-0002-9200-6180; Campbell, Colin/0000-0002-6239-3378;
   Abbott, Sam/0000-0001-8057-8037
FU National Institute for Health Research Health Protection Research Unit
   (NIHR HPRU) in Evaluation of Interventions at the University of Bristol;
   Public Health England (PHE)
FX SEA, HC, and EBP are funded by the National Institute for Health
   Research Health Protection Research Unit (NIHR HPRU) in Evaluation of
   Interventions at the University of Bristol in partnership with Public
   Health England (PHE). The views expressed are those of the author(s) and
   not necessarily those of the NHS, the NIHR, the Department of Health or
   Public Health England.
CR Aaby P, 2015, T ROY SOC TROP MED H, V109, P77, DOI 10.1093/trstmh/tru186
   Abubakar I, 2008, ARCH DIS CHILD, V93, P1017, DOI 10.1136/adc.2008.139543
   Abubakar I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17370
   Barnard J, 1999, BIOMETRIKA, V86, P948, DOI 10.1093/biomet/86.4.948
   Barreto ML, 2014, VACCINE, V32, P3759, DOI 10.1016/j.vaccine.2014.05.042
   BHATTI N, 1995, BRIT MED J, V310, P967, DOI 10.1136/bmj.310.6985.967
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Department of Communities and Local Government, 2011, ENGLISH INDICES DEPR
   Djuretic T, 2002, ANTIBIOTIC RESISTANT, P477
   Fine P, 2005, BRIT MED J, V331, P647, DOI 10.1136/bmj.331.7518.647
   French CE, 2007, INT J TUBERC LUNG D, V11, P577
   Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6
   Higgins JPT, DTP MEASLES CONTAINI, DOI [10.1136/bmj.i5170, DOI 10.1136/BMJ.I5170]
   Jeremiah K, 2010, THORAX, V65, P1072, DOI 10.1136/thx.2010.134767
   Kandasamy R, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5225
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790
   Parslow R, 2001, ARCH DIS CHILD, V84, P109, DOI 10.1136/adc.84.2.109
   Pollard AJ, 2017, ARCH DIS CHILD, V102, P1077, DOI 10.1136/archdischild-2015-310282
   R Core Team, 2016, R LANG ENV STAT COMP
   Rieckmann A, 2017, INT J EPIDEMIOL, V46, P695, DOI 10.1093/ije/dyw120
   RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154
   Roth A, 2006, EPIDEMIOLOGY, V17, P562, DOI 10.1097/01.ede.0000231546.14749.ab
   Roy A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4643
   TEALE C, 1993, AGE AGEING, V22, P289, DOI 10.1093/ageing/22.4.289
   Teo SSS, 2006, ARCH DIS CHILD, V91, P529, DOI 10.1136/adc.2005.085043
   The World Health Organization, 2004, WKLY EPIDEMIOL REC, V79, P27
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   World Health Organization, 2018, Vaccine, V36, P3408, DOI 10.1016/j.vaccine.2018.03.009
   Zwerling A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001012
NR 30
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5067
EP 5072
DI 10.1016/j.vaccine.2019.06.056
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100036
PM 31296375
DA 2020-05-12
ER

PT J
AU Bogler, L
   Jantos, N
   Barnighausen, T
   Vollmer, S
AF Bogler, Lisa
   Jantos, Nina
   Baernighausen, Till
   Vollmer, Sebastian
TI Estimating the effect of measles vaccination on child growth using 191
   DHS from 65 low- and middle-income countries
SO VACCINE
LA English
DT Article
DE Child health; Anthropometric measurements; Measles vaccination;
   Demographic and Health Surveys; Household- and mother-fixed effects
ID IMMUNIZATION; HEALTH; VACCINES; UNDERNUTRITION; CONSEQUENCES;
   MALNUTRITION; PREVENTION; INFECTION; PNEUMONIA; MORTALITY
AB Background: Childhood vaccinations reduce morbidity and mortality and are highly cost-effective. They may also protect children from malnutrition and lead to improved child growth. Stunting, wasting and underweight are targets used to monitor progress towards the achievement of the sustainable development goals (SDGs).
   Methods: We use data from Demographic and Health Surveys (DHS) covering the period from 1990 to 2017 to estimate the effect of measles vaccination at 12 months of age on stunting, wasting, and underweight. For causal estimation, we use household- and mother-fixed effects, which allows us to compare outcomes across siblings while controlling for all observed and unobserved confounders that are shared by the siblings, such as household social characteristics and home location. In addition, we control for a wide range of sibling-varying confounders, including sex, age, birth order and mother's age at birth, as well as vaccination with diphtheria-tetanus-polio (DPT), as a broad indicator of general likelihood to receive vaccinations.
   Results: Our samples include 347,808 individuals in 132 surveys from 59 countries (for stunting), 430,963 individuals in 190 surveys from 65 countries (for wasting), and 353,520 individuals in 130 surveys from 59 countries (for underweight). Measles vaccination is associated with significantly reduced odds of stunting (odds ratio 0.90 [95% CI 0.86-0.94], p < 0.001) and underweight (odds ratio 0.90 [95% CI 0.86-0.95], p < 0.001). The association with wasting is weaker and not statistically significant (odds ratio 0.95 [95% CI 0.89-1.02], p = 0.143). Our results remain robust across several alternative specifications of our regression models.
   Conclusions: Measles vaccination substantially reduces stunting and underweight among children in low- and middle-income countries. Increasing measles coverage from the current low to near-universal levels would provide a large boost to child growth and the attainment of the SDGs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bogler, Lisa; Jantos, Nina; Vollmer, Sebastian] Univ Gottingen, Gottingen, Germany.
   [Baernighausen, Till] Heidelberg Univ, Heidelberg, Germany.
RP Bogler, L (reprint author), Univ Gottingen, Gottingen, Germany.
EM lisa.bogler@cemis.uni-goettingen.de
RI Vollmer, Sebastian/U-6496-2017
OI Vollmer, Sebastian/0000-0002-7863-0462; Bogler, Lisa/0000-0002-5679-9777
CR AABY P, 1988, REV INFECT DIS, V10, P478
   Aaby P, 2003, INT J EPIDEMIOL, V32, P106, DOI 10.1093/ije/dyg005
   Aaby P, 2015, T ROY SOC TROP MED H, V109, P16, DOI 10.1093/trstmh/tru174
   Aaby P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6495
   Alderman H, 2006, OXFORD ECON PAP, V58, P450, DOI 10.1093/oep/gpl008
   Anekwe TD, 2015, VACCINE, V33, P5020, DOI 10.1016/j.vaccine.2015.04.072
   Anekwe TD, 2012, J PUBLIC HEALTH-UK, V34, P489, DOI 10.1093/pubmed/fds032
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205
   Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Barnighausen T, 2014, P NATL ACAD SCI USA, V111, P12313, DOI 10.1073/pnas.1400475111
   Baqui AH, 2007, PEDIATR INFECT DIS J, V26, P565, DOI 10.1097/INF.0b013e31806166a0
   Berendsen MLT, 2016, EBIOMEDICINE, V8, P341, DOI 10.1016/j.ebiom.2016.05.010
   Borghi E, 2006, STAT MED, V25, P247, DOI 10.1002/sim.2227
   Breiman RF, 2004, LANCET, V364, P2204, DOI 10.1016/S0140-6736(04)17593-4
   Calder PC, 2000, NUTR RES REV, V13, P3, DOI 10.1079/095442200108728981
   Currie J, 2013, ANNU REV ECON, V5, P1, DOI 10.1146/annurev-economics-081412-103704
   De Onis M., 2017, NUTR HLTH DEV WORLD, P119
   Deogaonkar R, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-878
   DHS, 2016, DHS TEAM PARTN
   Doshi RH, 2015, VACCINE, V33, P6786, DOI 10.1016/j.vaccine.2015.10.020
   Doshi RH, 2015, VACCINE, V33, P3407, DOI 10.1016/j.vaccine.2015.04.067
   Frongillo EA, 1997, J NUTR, V127, P2302
   Greene W., 2004, ECONOMET J, V7, P98, DOI DOI 10.1111/J.1368-423X.2004.00123.X
   Hoddinott J, 2013, MATERN CHILD NUTR, V9, P69, DOI 10.1111/mcn.12080
   ICF International, 2012, SURV ORG MAN DEM HLT
   KATZ E, 2001, POLITICAL, V0009
   Kumar SA, 2013, INT J CURR RES REV, V5, P105
   Levine R., 2007, CASE STUDIES GLOBAL
   Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790
   McGovern ME, 2015, AM J EPIDEMIOL
   Milman A, 2005, J NUTR, V135, P1415
   Ozawa S, 2012, VACCINE, V31, P96, DOI 10.1016/j.vaccine.2012.10.103
   Prendergast AJ, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0141
   Rutstein SO, 2006, GUIDE DHS STAT
   Salako A. A., 2015, British Journal of Medicine and Medical Research, V5, P160, DOI 10.9734/BJMMR/2015/4333
   Semba Richard D., 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P120
   Shann F, 2013, CLIN THER, V35, P109, DOI 10.1016/j.clinthera.2013.01.007
   Shibeshi ME, 2014, VACCINE, V32, P1798, DOI 10.1016/j.vaccine.2014.01.089
   Sudfeld CR, 2010, INT J EPIDEMIOL, V39, P48, DOI 10.1093/ije/dyq021
   UNICEF (United Nations Children's Fund), 2013, IMPR CHILD NUTR ACH
   Victora CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4
   Walker CLF, 2013, EPIDEMIOL INFECT, V141, P115, DOI 10.1017/S0950268812001525
   WHO, 2018, IMM SURB ASS MON INT
   WHO, 2016, TABL 2 SUMM WHO POS
   WHO, 2018, IMM COV
   WHO, 2014, M STRAT ADV GROUP EX
   WHO, 2006, MULT GROWTH REF STUD
   Wooldridge JM, 2009, INTRO ECONOMETRICS
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   Yung CF, 2016, BMJ-BRIT MED J, V355, pi5434, DOI DOI 10.1080/00031305.2016.1154108
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5073
EP 5088
DI 10.1016/j.vaccine.2019.06.054
PG 16
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100037
PM 31300290
DA 2020-05-12
ER

PT J
AU Bresee, JS
   Lafond, KE
   McCarron, M
   Azziz-Baumgartner, E
   Chu, SY
   Ebama, M
   Hinman, AR
   Xeuatvongsa, A
   Bino, S
   Richardson, D
   Porter, RM
   Moen, A
   McKinlay, M
AF Bresee, Joseph S.
   Lafond, Kathryn E.
   McCarron, Margaret
   Azziz-Baumgartner, Eduardo
   Chu, Susan Y.
   Ebama, Malembe
   Hinman, Alan R.
   Xeuatvongsa, Anonh
   Bino, Silvia
   Richardson, Dominique
   Porter, Rachael M.
   Moen, Ann
   McKinlay, Mark
CA PIVI Partners Grp
TI The partnership for influenza vaccine introduction (PIVI): Supporting
   influenza vaccine program development in low and middle-income countries
   through public-private partnerships
SO VACCINE
LA English
DT Article
DE Influenza, Influenza vaccine, low and, middle-income countries;
   Vaccination programs; Vaccine policy; NITAG
ID SEASONAL INFLUENZA; DOSE DISTRIBUTION; BIRTH OUTCOMES; PREGNANT-WOMEN;
   LESSONS; IMMUNIZATION; CAPACITY; BURDEN
AB Influenza vaccination remains the most effective tool for reducing seasonal influenza disease burden. Few Low and Middle-Income Countries (LMICs) have robust, sustainable annual influenza national vaccination programs. The Partnership for Influenza Vaccine Introduction (PIVI) was developed as a public-private partnership to support LMICs to develop and sustain national vaccination programs through time-limited vaccine donations and technical support. We review the first 5?years of experience with PIVI, including the concept, country progress toward sustainability, and lesson learned. Between 2013 and 2018, PIVI worked with Ministries of Health in 17 countries. Eight countries have received donated vaccines and technical support; of these, two have transitioned to sustained national support of influenza vaccination and six are increasing national support of the vaccine programs towards full transition to local vaccine program support by 2023. Nine additional countries have received technical support for building the evidence base for national policy development and/or program evaluation. PIVI has resulted in increased use of vaccines in partner countries, and early countries have demonstrated progress towards sustainability, suggesting that a model of vaccine and technical support can work in LMICs. PIVI expects to add new country partners as current countries transition to self-reliance. Published by Elsevier Ltd.
C1 [Bresee, Joseph S.; Lafond, Kathryn E.; McCarron, Margaret; Azziz-Baumgartner, Eduardo; Porter, Rachael M.; Moen, Ann] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.
   [Bresee, Joseph S.; Ebama, Malembe; Hinman, Alan R.] Task Force Global Hlth, Ctr Vaccine Equ, Atlanta, GA USA.
   [Chu, Susan Y.; Richardson, Dominique; McKinlay, Mark] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA.
   [Xeuatvongsa, Anonh] Minist Hlth, Viangchan, Laos.
   [Bino, Silvia] Minist Hlth, Tirana, Albania.
RP Bresee, JS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA.
EM Jsb6@cdc.gov
FU Centers for Disease Control and Prevention, Atlanta, GA, USAUnited
   States Department of Health & Human ServicesCenters for Disease Control
   & Prevention - USA [CDC-RFA-IP16-1607]; Bill & Melinda Gates Foundation,
   Seattle, WA, Seattle, WA, USA [OPP1088249]
FX This work was supported by Centers for Disease Control and Prevention,
   Atlanta, GA, USA [CDC-RFA-IP16-1607] and the Bill & Melinda Gates
   Foundation, Seattle, WA, Seattle, WA, USA [OPP1088249]
CR Adjagba A, 2017, VACCINE, V35, P3007, DOI 10.1016/j.vaccine.2017.04.039
   Adjagba A, 2015, VACCINE, V33, P4365, DOI 10.1016/j.vaccine.2015.06.106
   Adjagba A, 2015, VACCINE, V33, P588, DOI 10.1016/j.vaccine.2014.12.026
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   [Anonymous], 2003, PREVENTION CONTROL I, P1
   Arriola CS, 2018, VACCINE, V36, P3686, DOI 10.1016/j.vaccine.2018.05.013
   Arriola CS, 2017, VACCINE, V35, P3056, DOI 10.1016/j.vaccine.2017.04.045
   Arriola CS, 2016, VACCINE, V34, P1086, DOI 10.1016/j.vaccine.2015.12.065
   Bell L, 2018, WPSAR S1, V9, P1
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Bresee J, 2018, EMERG INFECT DIS, V24, P1173, DOI 10.3201/eid2407.171270
   Cohen C, 2010, CLIN INFECT DIS, V51, P1362, DOI 10.1086/657314
   Dawa J, 2019, VACCINE, V37, P464, DOI 10.1016/j.vaccine.2018.11.062
   Eastwood K, 2010, MED J AUSTRALIA, V192, P33, DOI 10.5694/j.1326-5377.2010.tb03399.x
   Friede M, 2011, VACCINE, V29, pA2, DOI 10.1016/j.vaccine.2011.02.079
   GAVI, 2018, PAND INFL PREP
   Gellin BG, 2014, VACCINE, V32, P7037, DOI 10.1016/j.vaccine.2014.10.062
   Iuliano AD, 2017, LANCET
   Johnson LEA, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-209
   Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019
   Kieny MP, 2006, VACCINE, V24, P6367, DOI 10.1016/j.vaccine.2006.07.021
   Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
   Levine OS, 2010, HUM VACCINES, V6, P1021, DOI 10.4161/hv.6.12.13076
   McQuillian Geraldine M, 2010, NCHS Data Brief, P1
   Mihigo R, 2012, J INFECT DIS, V206, pS22, DOI 10.1093/infdis/jis535
   Moen A, 2014, INFLUENZA OTHER RESP, V8, P201, DOI 10.1111/irv.12214
   Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9
   Olsen SJ, 2016, CLIN INFECT DIS, V63, P487, DOI 10.1093/cid/ciw290
   Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045
   Palache A, 2015, VACCINE, V33, P5598, DOI 10.1016/j.vaccine.2015.08.082
   Palache A, 2014, VACCINE, V32, P6369, DOI 10.1016/j.vaccine.2014.07.012
   Phengxay M, 2015, INFLUENZA OTHER RESP, V9, P94, DOI 10.1111/irv.12299
   Poland GA, 2010, VACCINE, V28, pD3, DOI 10.1016/j.vaccine.2010.08.024
   Polansky LS, 2016, EMERG INFECT DIS, V22, P993, DOI [10.3201/eid2206.151521, 10.3201/eid.2206.151521]
   Ropero-Alvarez AM, 2012, VACCINE, V30, P916, DOI 10.1016/j.vaccine.2011.11.092
   Ropero-Alvarez AM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-361
   Samaan G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070003
   WHO, 2017, EV INFL VACC EFF GUI
   WHO, 2016, GUID EC EV INFL VACC
   WHO, 2016, WORLD MALARIA REPORT, P1, DOI DOI 10.1017/CBO9781107415324.004
   WHO, 2018, INFL VACC PROGR EV I
   WHO, 2012, REP WHO PAND INFL HI
   WHO, 2016, WHO FLUT PLANN COST
   WHO, 2015, GLOB ACT PLAN INFL V
   Zhang WQ, 2017, VACCINE, V35, P851, DOI 10.1016/j.vaccine.2016.12.056
NR 45
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5089
EP 5095
DI 10.1016/j.vaccine.2019.06.049
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100038
PM 31288998
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Valdarchi, C
   Dorrucci, M
   Mancini, F
   Farchi, F
   de Araujo, FP
   Corongiu, M
   Ciervo, A
   Rezza, G
   Pantosti, A
   Camilli, R
AF Valdarchi, Catia
   Dorrucci, Maria
   Mancini, Fabiola
   Farchi, Francesca
   de Araujo, Fernanda Pimentel
   Corongiu, Maria
   Ciervo, Alessandra
   Rezza, Giovanni
   Pantosti, Annalisa
   Camilli, Romina
CA FIMMG Grp
TI Pneumococcal carriage among adults aged 50 years and older with
   co-morbidities attending medical practices in Rome, Italy
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Carriage; Adults; PCV13; PPV23; Risk factors;
   Co-morbidities
ID COMMUNITY-ACQUIRED PNEUMONIA; VACCINE DOSING SCHEDULES;
   STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; NASOPHARYNGEAL CARRIAGE;
   DISEASE; COLONIZATION; SEROTYPES; IMPACT; RISK
AB Background: Data on Streptococcus pneumoniae carriage in adults with co-morbidities are limited. In this study we estimated the pneumococcal carriage among adults with co-morbidities and evaluated socio-demographic and clinical risk factors. The potential coverage of the current pneumococcal vaccines recommended for adults (PCV13 and PPV23) was also investigated.
   Methods: A cross-sectional study on S. pneumoniae carriage among unvaccinated adults >= 50 years with co-morbidities, presenting with or without acute respiratory symptoms at general practitioners in Rome, Italy, between October 2015 and July 2016 was conducted. Pneumococcal carriage was investigated by both cultural and molecular methods. Socio-demographic variables and co-morbidities were evaluated by logistic models as possible risk factors for pneumococcal carriage.
   Results: Out of 248 patients (median age: 73 yrs; IQR: 65-79), 12 (4.8%) and 83 (33.5%) individuals were found colonized using cultural or molecular methods, respectively. Potential risk factors for pneumococcal colonization as ascertained by molecular methods were: low level of education (adjusted OR = 3.71, 95% CI: 1.62-9.40), winter months (December-March vs other months, adjusted OR = 2.56, 95% CI: 1.29-5.14), and presence of chronic lung diseases (adjusted OR = 2.18, 95% CI: 1.15-4.16). The combination of serotype-specific multiplex RT-PCR and conventional PCR allowed to identify 22 serotypes/group of serotypes, of which the most common were: 24F/24A/24B, 12F/12A/12B/44/46, 6A/6B, 14, 15B/15C, and 22F/22A. Prevalence of pneumococcal carriage due to PCV13 serotypes and non-PCV13 serotypes was 23.6% and 67.3%, respectively. Prevalence of colonization due to PPV23 serotypes was estimated to be 54.6%.
   Conclusions: A high prevalence of S. pneumoniae carriage was observed among adults with co-morbidities, especially among individuals affected by chronic lung diseases. These results support vaccine strategies based on the sequential administration of PCV13 and PPV23 to control potentially invasive pneumococcal strains in adults, especially in subjects with co-morbidities. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Valdarchi, Catia; Dorrucci, Maria; Mancini, Fabiola; Farchi, Francesca; de Araujo, Fernanda Pimentel; Ciervo, Alessandra; Rezza, Giovanni; Pantosti, Annalisa; Camilli, Romina] Ist Super Sanita, Dept Infect Dis, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Corongiu, Maria] FIMMG, Rome, Italy.
RP Camilli, R (reprint author), Ist Super Sanita, Dept Infect Dis, Viale Regina Elena 299, I-00161 Rome, Italy.
EM romina.camilli@iss.it
OI Pimentel de Araujo, Fernanda/0000-0002-9446-5807
FU PfizerPfizer
FX This study was supported in part by a Research Grant from Pfizer to the
   Italian Federation of General Practitioners (Federazione Italiana Medici
   di Medicina Generale, FIMMG).
CR Almeida ST, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090974
   Ansaldi F, 2013, HUM VACC IMMUNOTHER, V9, P614, DOI 10.4161/hv.23253
   Azzari C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009282
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Branche AR, 2018, VACCINE, V36, P4304, DOI 10.1016/j.vaccine.2018.05.107
   Camilli R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076309
   Carvalho MDG, 2013, PEERJ, V1, DOI 10.7717/peerj.97
   Carvalho MD, 2010, J CLIN MICROBIOL, V48, P1611, DOI 10.1128/JCM.02243-09
   Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06
   Cole SR, 2014, AM J EPIDEMIOL, V179, P252, DOI 10.1093/aje/kwt245
   Conklin L, 2014, PEDIATR INFECT DIS J, V33, pS109, DOI 10.1097/INF.0000000000000078
   Cui YDA, 2017, HUM VACC IMMUNOTHER, V13, P1229, DOI 10.1080/21645515.2016.1277300
   Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005
   Esposito S, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0057-0
   Feikin DR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001517
   Flamaing J, 2010, J AM GERIATR SOC, V58, P396, DOI 10.1111/j.1532-5415.2009.02700.x
   Flasche S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001017
   Gillis HD, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015008
   Krone CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119875
   Lang ALS, 2015, J MED MICROBIOL, V64, P836, DOI 10.1099/jmm.0.000097
   Loo JD, 2014, PEDIATR INFECT DIS J, V33, pS161, DOI 10.1097/INF.0000000000000084
   Pimenta FC, 2013, J CLIN MICROBIOL, V51, P647, DOI 10.1128/JCM.02927-12
   Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632, DOI 10.1086/381547
   Rozenbaum MH, 2013, EUR J CLIN MICROBIOL, V32, P305, DOI 10.1007/s10096-012-1778-4
   Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062
   Shea KM, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu024
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Spijkerman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039730
   Torres A, 2015, THORAX, V70, P984, DOI 10.1136/thoraxjnl-2015-206780
   van Deursen AMM, 2016, VACCINE, V34, P4, DOI 10.1016/j.vaccine.2015.11.014
   van Hoek AJ, 2012, J INFECTION, V65, P17, DOI 10.1016/j.jinf.2012.02.017
   VENZON DJ, 1988, J R STAT SOC C-APPL, V37, P87, DOI 10.2307/2347496
   Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   Wyllie AL, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170074
   Wyllie AL, 2016, SCI REP-UK, V6, DOI 10.1038/srep34888
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5096
EP 5103
DI 10.1016/j.vaccine.2019.06.052
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100039
PM 31285086
DA 2020-05-12
ER

PT J
AU Gooding, E
   Spiliotopoulou, E
   Yadav, P
AF Gooding, Emily
   Spiliotopoulou, Eirini
   Yadav, Prashant
TI Impact of vaccine stockouts on immunization coverage in Nigeria
SO VACCINE
LA English
DT Article
DE Vaccine supply chain; Vaccine stockouts; Immunization; Nigeria;
   Immunization coverage
ID SUPPLY CHAINS; CHILDREN; COUNTRIES; BARRIERS; REASONS
AB Improving immunization coverage requires creating reliable supply of vaccines and immunization supplies; trained and incentivized health workers; and strategies to improve the demand for immunization. Yet, the interplay of demand and supply side factors on immunization coverage has not been evaluated in literature with data. We use data from Nigeria and a mixed-effects general linear model to estimate the effect of vaccine availability on routine immunization coverage and to identify demand and health system factors which affect this relationship. We find that when vaccine stockouts occur at Local Government Area stores in Nigeria, they significantly decrease the number of children immunized, and for most vaccines, the effect lasts for several months after a stockout. Some of the demand lost when a stockout occurs is recovered over the following six months as children catch up with the regimen. The magnitude of the impact varies across different vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gooding, Emily] Africa Resource Ctr Nigeria, 2 Ajose Adeogun, Lagos, Nigeria.
   [Spiliotopoulou, Eirini] Tilburg Univ, TiSEM, NL-5037 AB Tilburg, Netherlands.
   [Yadav, Prashant] Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA.
RP Gooding, E (reprint author), Africa Resource Ctr Nigeria, 2 Ajose Adeogun, Lagos, Nigeria.
EM emily.gooding@fulbrightmail.org; E.Spiliotopoulou@uvt.nl;
   Prashant_Yadav@hms.harvard.edu
OI Spiliotopoulou, Eirini/0000-0002-0478-8195
FU Fulbright Program, a program of the United States Department of State,
   Bureau of Educational and Cultural Affairs
FX The authors gratefully acknowledge the collaboration of Nigeria's
   National Primary Health Care Development Agency and its partners. We
   especially thank the many health and immunization experts who assisted
   in data collection and provided feedback on the study. EG was hosted by
   the Africa Resource Centre in Nigeria and supported by the Fulbright
   Program, a program of the United States Department of State, Bureau of
   Educational and Cultural Affairs. The views and information presented
   here are the authors' and do not represent the views of their employers
   or funding organizations.
CR Aina M, 2017, VACCINE, V35, P2175, DOI 10.1016/j.vaccine.2016.11.100
   Anand S, 2007, LANCET, V369, P1277, DOI 10.1016/S0140-6736(07)60599-6
   Awodele O, 2010, TANZAN J HLTH RES, V12, P172, DOI DOI 10.4314/THRB.V12I3.51112
   Banerjee AV, 2010, BMJ-BRIT MED J, DOI [DOI 10.1136/BMJ.C2220, 10.1136/bmj.c2220.]
   Bloom DE, 2005, WORLD ECON, V6, P15, DOI DOI 10.1007/978-1-4419-7185-2_1
   Daff BM, 2014, GLOB HEALTH-SCI PRAC, V2, P245, DOI 10.9745/GHSP-D-13-00171
   De Boeck K, 2018, KU LEUVEN FACULTY EC
   Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447
   Favin M, 2012, INT HEALTH, V4, P229, DOI 10.1016/j.inhe.2012.07.004
   FREEMAN PA, 1992, PAPUA NEW GUINEA MED, V35, P179
   Garcia DA, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-669
   Gilbert SS, 2017, VACCINE, V35, P2203, DOI 10.1016/j.vaccine.2016.11.101
   Lydon P, 2017, VACCINE, V35, P2121, DOI 10.1016/j.vaccine.2016.12.071
   Matsumura T, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-59
   Moeti M, 2017, VACCINE, V35, P2101, DOI 10.1016/j.vaccine.2017.02.061
   Naira Metrics, WORLD HLTH ORG WHO I
   National Primary Healthcare Development Agency and National Bureau of Statistics, NIG NAT IMM COV SURV
   Ophori Endurance A, 2014, Trop Med Health, V42, P67, DOI 10.2149/tmh.2013-13
   Prosser W, 2016, LESSONS LEARNED REAC
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Roodpeyma S, 2007, J PEDIAT INF DIS-GER, V2, P29
   Sarley D, 2017, VACCINE, V35, P2167, DOI 10.1016/j.vaccine.2016.11.068
   Topuzoglu A, 2007, EUR J PUBLIC HEALTH, V17, P348, DOI 10.1093/eurpub/ckl250
   Torun SD, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-125
   Vledder M, 2015, OPTIMAL SUPPLY CHAIN
   World Health Organization, 2018, EXPL IN CHILDH IMM, DOI [10.1093/innovait/inn167., DOI 10.1093/INNOVAIT/INN167]
   World Health Organization, 2016, ANN GVAP SECR ANN RE
   World Health Organization, 2005, WHO UNICEF GLOB IMM
   World Health Organization, 2014, IMM SUPPL CHAIN LOG
   World Health Organization, 2018, SAGE 2018 ASS REP GL
   World Health Organization UNICEF, 2017, PROGR CHALL ACH UN I
   Zaffran M, 2013, VACCINE, V31, pB73, DOI 10.1016/j.vaccine.2012.11.036
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5104
EP 5110
DI 10.1016/j.vaccine.2019.06.006
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100040
PM 31320215
DA 2020-05-12
ER

PT J
AU Bridges, CB
   Watson, TL
   Nelson, NP
   Chavez-Torres, M
   Fineis, P
   Ntiri-Reid, B
   Wake, E
   Leahy, JM
   Kurian, AK
   Hall, MAK
   Kennedy, ED
AF Bridges, Carolyn B.
   Watson, Tureka L.
   Nelson, Noele P.
   Chavez-Torres, Maribel
   Fineis, Patrick
   Ntiri-Reid, Boatemaa
   Wake, Edward
   Leahy, Judith M.
   Kurian, Anita K.
   Hall, Mary Ann K.
   Kennedy, Erin D.
TI Challenges with hepatitis B vaccination of high risk adults - A pilot
   program
SO VACCINE
LA English
DT Article
DE Hepatitis B; Hepatitis B vaccine; Immunization information systems;
   Vaccine registry; Adults; Vaccine implementation; Vaccination rates;
   Dose-series completion
ID ADVISORY-COMMITTEE; NATURAL-HISTORY; UNITED-STATES; VIRUS;
   IMMUNOGENICITY; SAFETY; HBSAG-1018; RECOMMENDATIONS; PREVENTION;
   INFECTION
AB Background: Acute hepatitis B virus (HBV) infections in the United States occur predominantly among persons aged 30-59 years. The Centers for Disease Control and Prevention (CDC) recommends vaccination of adults at increased risk for HBV infection. Completing the hepatitis B (HepB) vaccine dose-series is critical for optimal immune response.
   Objectives: CDC funded 14 health departments (awardees) from 2012 to 2015 to implement a pilot HepB vaccination program for high-risk adults. We evaluated the pilot program to assess vaccine utilization; vaccine dose-series completion, including by vaccination location type; and implementation challenges.
   Methods: Awardees collaborated with sites providing health care to persons at increased risk for HBV infection. Awardees collected information on doses administered, vaccine dose-series completion, and challenges completing and tracking vaccinations, including use of immunization information systems (IIS). Data were reported by each awardee in aggregate to CDC.
   Results: Six of 14 awardees administered 47,911 doses and were able to report patient-level dose-series completion. Among persons who received dose 1, 40.4% received dose 2, and 22.3% received dose 3. Local health department clinics had the highest 3-dose-series completion, 60.6% (531/876), followed by federally qualified health centers at 38.0% (923/2432). While sexually transmitted diseases (STD) clinics administered the most doses in total (17,173 [35.8% of 47,911 doses]), 3-dose-series completion was low (17.1%). The 14 awardees reported challenges regarding completing and tracking dose-series, including reaching high-risk adults for follow-up and inconsistencies in use of IIS or other tracking systems across sites.
   Conclusions: Dose-series completion was low in all settings, but lowest where patients may be less likely to return for follow-up (e.g., STD clinics). Routinely assessing HepB vaccination needs of high-risk adults, including through use of IIS where available, may facilitate HepB vaccine dose-series completion. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bridges, Carolyn B.] Berry Technol Solut Inc, Peachtree City, GA 30269 USA.
   [Watson, Tureka L.] IHRC Inc, Atlanta, GA USA.
   [Nelson, Noele P.] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.
   [Chavez-Torres, Maribel] Chicago Dept Publ Hlth, Communicable Dis Program, Chicago, IL USA.
   [Fineis, Patrick] Michigan Dept Hlth & Human Serv, Div Immunizat, Lansing, MI USA.
   [Ntiri-Reid, Boatemaa] Prevent & Hlth Promot Adm, Infect Dis Prevent & Hlth Serv Bur, Maryland Dept Hlth, Baltimore, MD USA.
   [Wake, Edward] CDC, Immunizat Serv Div, NCIRD, New York, NY USA.
   [Wake, Edward] New York City Dept Hlth & Mental Hyg, Adult Immunizat Unit, New York, NY USA.
   [Leahy, Judith M.] Oregon Hlth Author, Publ Hlth Div, Portland, OR USA.
   [Kurian, Anita K.] San Antonio Metropolitan Hlth Dist, San Antonio, TX USA.
   [Hall, Mary Ann K.] Cherokee Nation Assurance, Atlanta, GA USA.
   [Kennedy, Erin D.] CDC, Immunizat Serv Div, NCIRD, Atlanta, GA 30333 USA.
   [Bridges, Carolyn B.] Ctr Dis Control & Prevent Cdc, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Kennedy, Erin D.] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA.
RP Bridges, CB (reprint author), Berry Technol Solut Inc, Peachtree City, GA 30269 USA.
EM carolyn.bridges@immunize.org; twatson@cdc.gov; nnelson@cdc.gov;
   maribel.chavez-torres@cityofchicago.org; fineisp@michigan.gov;
   boatemaa.ntiri-reid@maryland.gov; ewake@health.nyc.gov;
   Judith.m.leahy@state.or.us; anita.kurian@sanantonio.gov; nmp8@cdc.gov;
   edkennedy@cdc.gov
OI Nelson, Noele/0000-0001-9831-0717
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
FX Funding for this pilot project was provided by the Centers for Disease
   Control and Prevention.
CR ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1
   Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P1
   BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J
   Bridges CB, 2015, VACCINE, V33, pD114, DOI 10.1016/j.vaccine.2015.09.054
   Bruce MG, 2016, J INFECT DIS, V214, P16, DOI 10.1093/infdis/jiv748
   CDC. Division of Viral Hepatitis, VIR HEP SURV US, P201
   Community Preventive Services Task Force, VACC
   Glazner Judith E, 2009, Pediatrics, V124 Suppl 5, pS492, DOI 10.1542/peds.2009-1542H
   Gunn RA, 2007, SEX TRANSM DIS, V34, P663, DOI 10.1097/01.olq.0000258306.20287.a7
   Halperin SA, 2012, VACCINE, V30, P2556, DOI 10.1016/j.vaccine.2012.01.087
   HOOFNAGLE JH, 1991, SEMIN LIVER DIS, V11, P73, DOI 10.1055/s-2008-1040426
   Jackson S, 2018, VACCINE, V36, P668, DOI 10.1016/j.vaccine.2017.12.038
   Janssen JM, 2015, VACCINE, V33, P3614, DOI 10.1016/j.vaccine.2015.05.070
   Janssen RS, 2013, VACCINE, V31, P5306, DOI 10.1016/j.vaccine.2013.05.067
   KRUGMAN S, 1979, NEW ENGL J MED, V300, P101, DOI 10.1056/NEJM197901183000301
   McMahon BJ, 2009, HEPATOLOGY, V49, pS45, DOI 10.1002/hep.22898
   Mitchell T, 2013, PLOS ONE, V8, DOI 10.1371
   National Association of County and City Health Officials, EX SUMM FIN REP FORM
   Nelson JC, 2009, AM J PUBLIC HEALTH, V99, pS389, DOI 10.2105/AJPH.2008.151332
   Roberts H, 2016, HEPATOLOGY, V63, P388, DOI 10.1002/hep.28109
   Sackey DM, 2018, INT J INTEGR CARE, V18, DOI 10.5334/ijic.s1079
   Schillie S, 2018, MMWR-MORBID MORTAL W, V67, P455, DOI 10.15585/mmwr.mm6715a5
   Schillie S, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6701a1
   Van der Meeren O, 2016, HUM VACC IMMUNOTHER, V12, P2197, DOI 10.1080/21645515.2016.1164362
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   ZAJAC BA, 1986, J INFECTION, V13, P39, DOI 10.1016/S0163-4453(86)92668-X
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5111
EP 5120
DI 10.1016/j.vaccine.2019.05.089
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100041
PM 31303523
DA 2020-05-12
ER

PT J
AU Saulsberry, L
   Fowler, EF
   Nagler, RH
   Gollust, SE
AF Saulsberry, Loren
   Fowler, Erika Franklin
   Nagler, Rebekah H.
   Gollust, Sarah E.
TI Perceptions of politicization and HPV vaccine policy support
SO VACCINE
LA English
DT Article
DE HPV vaccine; Legislation; Public health; Health policy; Politics; Cancer
   prevention
ID HUMAN-PAPILLOMAVIRUS VACCINATION; SCHOOL-ENTRY; ADVISORY-COMMITTEE;
   UNITED-STATES; IMMUNIZATION REQUIREMENTS; RECOMMENDATIONS; ADOLESCENTS;
   CONTROVERSY; EXEMPTIONS; POLITICS
AB Background: Since its FDA approval in 2006, the Human papillomavirus (HPV) vaccine has been politically-charged, given its association with sexual health among young women and its history of controversial, and largely unsuccessful, legislative mandates. The extent to which perceived politicization is related to public support for the vaccine's use, however, is not clear. We sought to examine the relationship between public perceptions of politicization of the HPV vaccine and public support for HPV vaccine policies.
   Methods: We fielded a survey from May-June 2016 using a nationally representative sample of U.S. adults (18-59 years). Among respondents aware of the HPV vaccine (n = 290), we predict support for HPV vaccine policies based on respondents' perceptions of three characteristics of the vaccine's portrayal in public discourse: degree of controversy, certainty of the scientific evidence supporting the vaccine's use, and frequency with which the vaccine appears in political discussion.
   Results: Respondents who perceived greater certainty about the scientific evidence for the HPV vaccine were more supportive of HPV vaccine policies (p < 0.0001) than respondents who perceived the scientific evidence to be uncertain, after adjusting for respondents' characteristics, including demographics and partisanship.
   Conclusions: Public perceptions of the HPV vaccine's politicization, particularly the portrayal of scientific evidence, are associated with receptivity to legislative mandates.
   Policy implications: How the certainty of a body of evidence gets communicated to the public may influence the policy process for a critical cancer prevention intervention. (C) 2019 Published by Elsevier Ltd.
C1 [Saulsberry, Loren] Univ Chicago, Dept Publ Hlth Sci, 5841 S Maryland Ave, Chicago, IL 60637 USA.
   [Fowler, Erika Franklin] Wesleyan Univ, Govt Dept, Middletown, CT USA.
   [Nagler, Rebekah H.] Univ Minnesota, Hubbard Sch Journalism & Mass Commun, Minneapolis, MN USA.
   [Gollust, Sarah E.] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA.
RP Saulsberry, L (reprint author), Univ Chicago, Dept Publ Hlth Sci, 5841 S Maryland Ave, Chicago, IL 60637 USA.
EM lsaulsberry@uchicago.edu
FU American Cancer SocietyAmerican Cancer Society [RSG-14-166-01-CPPB];
   Building Interdisciplinary Research Careers in Women's Health Grant from
   the Eunice Kennedy Shriver National Institutes of Child Health and Human
   Development [K12-HD055887]; Office of Research on Women's HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Office of Research on Women's Health (ORWH);
   National Institute on AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA)
FX This study was funded, in part, by a Research Scholar Grant from the
   American Cancer Society (RSG-14-166-01-CPPB) (PI: Gollust). R.H. Nagler
   also acknowledges support from the Building Interdisciplinary Research
   Careers in Women's Health Grant (K12-HD055887) from the Eunice Kennedy
   Shriver National Institutes of Child Health and Human Development, the
   Office of Research on Women's Health, and the National Institute on
   Aging, administered by the University of Minnesota Women's Health
   Research Program. The study sponsors had no role in study design;
   collection, analysis, and interpretation of data; writing the report;
   nor the decision to submit the report for publication.
CR Abiola SE, 2013, J HEALTH POLIT POLIC, V38, P645, DOI 10.1215/03616878-2208567
   Accelerating HPV Vaccine Uptake, 2014, URGENCY ACTION PREVE
   American Academy of Pediatrics, 2015, HPV CHAMP TOOLK PDSA
   Attwell K, 2018, VACCINE, V36, P7377, DOI 10.1016/j.vaccine.2018.10.019
   Barraza L, 2016, PUBLIC HEALTH REP, V131, P728, DOI 10.1177/0033354916663184
   Bernstein S, 2016, AM J PUBLIC HEALTH, V106, P1879, DOI 10.2105/AJPH.2016.303381
   Bolsen T, 2015, J COMMUN, V65, P745, DOI 10.1111/jcom.12171
   Bolsen T, 2014, PUBLIC OPIN QUART, V78, P1, DOI 10.1093/poq/nft044
   Bradford WD, 2015, HEALTH AFFAIR, V34, P1383, DOI 10.1377/hlthaff.2014.1428
   Calo WA, 2016, CANCER EPIDEM BIOMAR, V25, P1317, DOI 10.1158/1055-9965.EPI-15-1159
   Centers for Disease Control and Prevention (CDC), HUM PAP HPV
   Centers for Disease Control and Prevention (CDC), MEN STAT HEALTHC FAC
   Centers for Disease Control and Prevention (CDC), 2010, MMWR-MORBID MORTAL W, V59, P625
   Chesson HW, 2014, SEX TRANSM DIS, V41, P660, DOI 10.1097/OLQ.0000000000000193
   Colgrove J, 2006, NEW ENGL J MED, V355, P2389, DOI 10.1056/NEJMp068248
   Cuff RD, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2016.03.022
   Daley E, 2019, JAMA PEDIATR, V173, P6, DOI 10.1001/jamapediatrics.2018.3327
   Dixon G, 2018, SCI COMMUN, V40, P393, DOI 10.1177/1075547018769907
   Doke K, 2018, VACCINE, V36, P6819, DOI 10.1016/j.vaccine.2018.08.076
   Fowler EF, 2017, PUBLIC VIEWS POLITIC
   Fowler EF, 2015, ANN AM ACAD POLIT SS, V658, P155, DOI 10.1177/0002716214555505
   Fowler EF, 2012, INT J PRESS/POLIT, V17, P169, DOI 10.1177/1940161211425687
   Gilkey MB, 2015, CANCER EPIDEM BIOMAR, V24, P1
   Gilkey MB, 2018, CANCER EPIDEM BIOMAR, V27, P762, DOI 10.1158/1055-9965.EPI-17-1067
   Gollust SE, 2016, HUM VACC IMMUNOTHER, V12, P1430, DOI 10.1080/21645515.2015.1109169
   Gollust SE, 2010, HEALTH AFFAIR, V29, P2041, DOI 10.1377/hlthaff.2010.0174
   Jones M, 2018, HEALTH AFFAIR, V37, P1494, DOI 10.1377/hlthaff.2018.0437
   Kahan DM, 2015, POLIT PSYCHOL, V36, P1, DOI 10.1111/pops.12244
   Keim-Malpass J, 2017, RISK MANAG HEALTHC P, V10, P29, DOI 10.2147/RMHP.S128247
   Lindley MC, 2007, AM J PREV MED, V32, P459, DOI 10.1016/j.amepre.2007.02.009
   Margolis MA, 2019, PREV MED, V118, P251, DOI 10.1016/j.ypmed.2018.11.005
   Markowitz LE, 2018, ACAD PEDIATR, V18, pS3, DOI 10.1016/j.acap.2017.09.014
   Markowitz LE, 2014, MMWR RECOMM REP, V63, P1
   Meites E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/mmwr.mm6549a5
   National Conference of State Legislatures (NCSL), 2018, HPV VACC STAT LEG ST
   Niccolai LM, 2018, J PUBLIC HEALTH RES, V7, P29, DOI 10.4081/jphr.2018.1324
   North AL, 2016, AM J PUBLIC HEALTH, V106, P1765, DOI 10.2105/AJPH.2016.303286
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Perkins RB, 2016, HUM VACC IMMUNOTHER, V12, P1615, DOI 10.1080/21645515.2016.1150394
   Petrosky E, 2015, MMWR-MORBID MORTAL W, V64, P300
   Pierre-Victor D, 2017, J WOMENS HEALTH, V26, P266, DOI 10.1089/jwh.2016.5869
   Quick JD, 2018, TIME MAGAZINE, P28
   Schwartz JL, 2015, JAMA-J AM MED ASSOC, V314, P185, DOI 10.1001/jama.2015.6041
   StataCorp, 2017, STAT STAT SOFTW REL
   Stewart A, 2008, PUBLIC HEALTH REP, V123, P801, DOI 10.1177/003335490812300617
   Thompson EL, 2018, AM J PUBLIC HEALTH, V108, P1421, DOI 10.2105/AJPH.2018.304552
   Wang E, 2014, AM J PUBLIC HEALTH, V104, pE62, DOI 10.2105/AJPH.2014.302190
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5121
EP 5128
DI 10.1016/j.vaccine.2019.05.062
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100042
PM 31296376
DA 2020-05-12
ER

PT J
CA Collaborative Grp
TI Duration of immunity in recipients of two doses of 17DD yellow fever
   vaccine
SO VACCINE
LA English
DT Article
DE Yellow fever 17DD vaccine; Yellow fever antibody; Duration of immunity;
   Plaque reduction neutralization test; Dengue IgG antibodies
ID NEUTRALIZATION TEST; IMMUNIZATION; VIRUS; PERSISTENCE; ANTIBODIES;
   CHALLENGE
AB Antibody levels following yellow fever vaccination (YFV) decrease considerably with time, leaving a substantial proportion of single-dose recipients seronegative after 10 years. Little is known about the persistence of immunity after two or more doses of the vaccine. This study was designed to verify the current immune status of adults who had received two or more doses of YFV.
   A cross-sectional study assessed the immune status for yellow fever according to time since the latest YFV: second dose at 30-45 days (reference group), 1-5 years, 6-9 years and 10 years or more; and three or more doses. Volunteers had their vaccination cards checked and were interviewed before having a blood sample drawn for titration of neutralizing YF antibodies, and being tested for dengue IgG. The proportion seropositive (titer >= 1:50) and the geometric mean titers (GMT) were compared among the subgroups of time since the latest YFV.
   Participants (n = 323) were predominantly female (80.5%) and had a median age of 34 years (range 1876). In the reference group (n = 99), 69% were seropositive before the second dose. After revaccination, the proportions seropositive (95% C.I.) were 100% (96-100%) in the reference subgroup, 90% (83-95%) in the 1-5 year subgroup (n = 109), 86% (77-92%) in the 6-9 year subgroup (n = 92) and 86% (57-98%) in the 10+ years subgroup (n = 14). Only 9 participants with more than 2 previous doses of YFV were eligible for the study, and 8 of them were seropositive. Sociodemographic variables, age at vaccination and previous dengue infection did not confound the association of seropositivity to time since the last YFV.
   The results support the need of booster doses of the YFV to maintain antibody levels consistent with protection, and indicate that a small proportion of individuals may need more than two doses, provided that priority is given to primovaccination of all susceptibles. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Collaborative Grp] Fiocruz MS, Escola Nacl Saude Publ, Dept Epidemiol & Quantitat Methods Hlth, Rua Leopoldo Bulhoes 1480,Sala 803, BR-21041210 Rio De Janeiro, RJ, Brazil.
RP Fiocruz MS, Escola Nacl Saude Publ, Dept Epidemiol & Quantitat Methods Hlth, Rua Leopoldo Bulhoes 1480,Sala 803, BR-21041210 Rio De Janeiro, RJ, Brazil.
OI Barbosa de Lima, Sheila Maria/0000-0001-9234-1678
FU Secretaria de Vigilancia em Saude, Ministerio da Saude, Brazil
   [210/2011]; Instituto de Tecnologia em Imunobiologicos, Bio-Manguinhos -
   Fiocruz; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Ministerio da Ciencia, Tecnologia, Inovacoes e Comunicacoes
   [304008/2017-6]; Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ) [277/2013]
FX Secretaria de Vigilancia em Saude, Ministerio da Saude, Brazil, Term of
   Cooperation No. 210/2011 - FNS/Fiocruz; Instituto de Tecnologia em
   Imunobiologicos, Bio-Manguinhos - Fiocruz; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Ministerio da Ciencia,
   Tecnologia, Inovacoes e Comunicacoes, Proc. no. 304008/2017-6; Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ), Term of Cooperation No. 277/2013.
CR Abramson Joseph H, 2011, Epidemiol Perspect Innov, V8, P1, DOI 10.1186/1742-5573-8-1
   Amanna IJ, 2016, EXPERT REV VACCINES, V15, P1519, DOI 10.1080/14760584.2016.1198259
   [Anonymous], 2013, Wkly Epidemiol Rec, V88, P269
   Brasil. Ministerio da Saude. Programa Nacional de Imunizacao, 2009, MAN VIG EP EV ADV PO
   Brasil. Ministerio da Saude. Secretaria de Vigilancia em Saude, 2005, NORM MAN TECN A
   Caldas IR, 2014, VACCINE, V32, P4977, DOI 10.1016/j.vaccine.2014.07.021
   Camacho LAB, 2004, REV SAUDE PUBL, V38, P671, DOI 10.1590/S0034-89102004000500009
   Campi-Azevedo AC, 2016, HUM VACC IMMUNOTHER, V12, P491, DOI 10.1080/21645515.2015.1082693
   Gerais Minas. Secretaria de Estado de Saude de Minas Gerais, 2018, B EPIDEMIOLOGICO
   Gotuzzo E, 2013, AM J TROP MED HYG, V89, P434, DOI 10.4269/ajtmh.13-0264
   Hennessey KA, 1999, AM J EPIDEMIOL, V150, P1250, DOI 10.1093/oxfordjournals.aje.a009952
   Hepburn MJ, 2006, VACCINE, V24, P2843, DOI 10.1016/j.vaccine.2005.12.055
   Julander JG, 2011, VACCINE, V29, P6008, DOI 10.1016/j.vaccine.2011.06.034
   MASON RA, 1973, APPL MICROBIOL, V25, P539, DOI 10.1128/AEM.25.4.539-544.1973
   National Institute for Biological Standards and Control, 2008, WHO REF REAG 1 INT R
   Niedrig M, 1999, TROP MED INT HEALTH, V4, P867, DOI 10.1046/j.1365-3156.1999.00496.x
   Nogueira RMR, 2008, DENGUE DIAGNOSTICO T, P97
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   ROSENZWEIG EC, 1963, AM J TROP MED HYG, V12, P230, DOI 10.4269/ajtmh.1963.12.230
   Simoes M, 2012, BIOLOGICALS, V40, P399, DOI 10.1016/j.biologicals.2012.09.005
   Staples JE, 2015, MMWR-MORBID MORTAL W, V64, P647
   Strebel PM, 2018, VACCINES
   VASCONCELOS PFC, 2003, REV SOC BRAS MED TRO, V36, P275, DOI DOI 10.1590/S0037-86822003000200012
   World Health Organisation (WHO), 2005, INT HLTH REG
   World Health Organization, 2003, Wkly Epidemiol Rec, V78, P349
   World Medical Association WMA, 2013, DECL HELS ETH PRINC
NR 27
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 14
PY 2019
VL 37
IS 35
BP 5129
EP 5135
DI 10.1016/j.vaccine.2019.05.048
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LD4YK
UT WOS:000526036100043
PM 31171393
DA 2020-05-12
ER

PT J
AU Wilder-Smith, A
   Smith, PG
   Luo, R
   Kelly-Cirino, C
   Curry, D
   Larson, H
   Durbin, A
   Chu, M
   Tharmaphornpilas, P
   Ng, LC
   Sartori, AMC
   Luna, EJA
   Gublerj, DJ
   Espana, G
   Yoon, IK
   Flasche, S
AF Wilder-Smith, A.
   Smith, P. G.
   Luo, R.
   Kelly-Cirino, C.
   Curry, D.
   Larson, H.
   Durbin, A.
   Chu, M.
   Tharmaphornpilas, P.
   Ng, L. C.
   Sartori, A. M. C.
   Luna, E. J. A.
   Gublerj, D. J.
   Espana, G.
   Yoon, I. K.
   Flasche, S.
TI Pre-vaccination screening strategies for the use of the CYD-TDV dengue
   vaccine: A meeting report
SO VACCINE
LA English
DT Article
DE WHO; Rapid diagnostic tests; Dengue; Vaccine hesitancy; Communication;
   Ethics; Brazil; Philippines; National vaccination programmes
ID ZIKA
AB The first licensed dengue vaccine, CYD-TDV (Dengvaxia) is efficacious in seropositive individuals, but increases the risk for severe dengue in seronegative persons about two years after administration of the first dose. For countries considering the introduction of Dengvaxia, WHO recommends a pre-vaccination screening strategy whereby only persons with evidence of a past dengue infection would be vaccinated. Policy-makers need to consider the risk-benefit of vaccination strategies based on such screening tests, the optimal age to introduce the vaccine, communication and implementation strategies. To address these questions, the Global Dengue and Aedes-transmitted diseases Consortium (GDAC) organized a 3-day workshop in January 2019 with country representatives from Asia and Latin America.
   The meeting discussions highlighted many challenges in introducing Dengvaxia, in terms of screening test characteristics, costs of such tests combined with a 3-dose schedule, logistics, achieving high coverage rates, vaccine confidence and communication; more challenges than for any other vaccine introduction programme. A screening test would require a high specificity to minimize individual risk, and at the same time high sensitivity to maximize individual and population benefit. The underlying seroprevalence dependent positive predictive value is the best indicator for an acceptable safety profile of a pre-vaccination screening strategy. The working groups discussed many possible implementation strategies. Addressing the bottlenecks in school-based vaccine introduction for Dengvaxia will also benefit other vaccines such as HPV and booster doses for tetanus and pertussis. Levels of public trust are highly variable and context specific, and understanding of population perceptions and concerns is essential to tailor interventions, monitor and mitigate risks.
C1 [Wilder-Smith, A.; Smith, P. G.; Luo, R.; Larson, H.; Flasche, S.] London Sch Hyg & Trop Med, London, England.
   [Wilder-Smith, A.] Heidelberg Univ, Heidelberg Inst Global Hlth, Heidelberg, Germany.
   [Luo, R.; Kelly-Cirino, C.] Fdn Innovat New Diagnost, Geneva, Switzerland.
   [Curry, D.] GE2P2 Global Fdn, Ctr Vaccine Eth & Policy, Washington, DC USA.
   [Durbin, A.] Johns Hopkins Univ, Baltimore, MD USA.
   [Chu, M.] George Washington Univ, Washington, DC 20052 USA.
   [Tharmaphornpilas, P.] Minist Publ Hlth, Dept Dis Control, Bangkok, Thailand.
   [Ng, L. C.] Natl Environm Agcy, Singapore, Singapore.
   [Sartori, A. M. C.; Luna, E. J. A.] Univ Sao Paolo, Sao Paulo, Brazil.
   [Gublerj, D. J.] Duke NUS Med Sch, Singapore, Singapore.
   [Gublerj, D. J.; Yoon, I. K.] Global Dengue & Aedes Transmitted Dis Consortium, Seoul, South Korea.
   [Espana, G.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.
   [Espana, G.] Univ Notre Dame, Eck Inst Global Hlth, Notre Dame, IN 46556 USA.
   [Yoon, I. K.] Int Vaccine Inst, Seoul, South Korea.
RP Wilder-Smith, A (reprint author), London Sch Hyg & Trop Med, London, England.; Wilder-Smith, A (reprint author), Heidelberg Univ, Heidelberg Inst Global Hlth, Heidelberg, Germany.
RI Sartori, Ana Marli Christovam/I-6663-2012
OI Sartori, Ana Marli Christovam/0000-0003-3777-0757; Kelly-Cirino,
   Cassandra/0000-0002-4526-8487
FU Sanofi Pasteur; bioMerieux; Chembio Diagnostic Systems
FX The meeting was financially supported through unrestricted grants by
   Sanofi Pasteur, bioMerieux and Chembio Diagnostic Systems. The funders
   did not play a role in the organization of the workshop, nor in the
   writing of the meeting report.
CR Achee NL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003655
   Andersson N, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3267
   Angelo KM, 2019, J TRAVEL MED, V26, DOI 10.1093/jtm/taz046
   [Anonymous], 2018, WKLY EPIDEMIOL REC, V93, P457
   Arien KK, 2018, LANCET GLOB HEALTH, pe30, DOI [10.1016/52214-109X(18)30295-X, DOI 10.1016/52214-109X(18)30295-X]
   Batchelor T, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay092
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Ceccarelli G, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tax080
   Chatterjee P, 2019, LANCET INFECT DIS, V19, P584, DOI 10.1016/S1473-3099(19)30212-9
   Cousins S, 2019, LANCET INFECT DIS, V19, P362, DOI 10.1016/S1473-3099(19)30129-X
   Durrheim DN, 2019, INT J INFECT DIS, V83, P95, DOI 10.1016/j.ijid.2019.04.016
   Espana G, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007482
   Flasche S, 2019, LANCET INFECT DIS, V19, P465, DOI 10.1016/S1473-3099(19)30167-7
   Goncalves A, 2017, J INFECT DIS, DOI [10.1093/infdis/jjx678, DOI 10.1093/INFDIS/JJX678]
   Goncalves A, 2018, J INFECT DIS, V217, P1060, DOI 10.1093/infdis/jix678
   Goodyer L, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay005
   Gubler DJ, 2015, VACCINE, V33, P1233, DOI 10.1016/j.vaccine.2015.01.002
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Jaenisch T, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0601-z
   Jentes ES, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw062
   Katzelnick LC, 2018, CURR OPIN VIROL, V29, P51, DOI 10.1016/j.coviro.2018.03.004
   Kittayapong P, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005197
   Lalani T, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw043
   Larson HJ, 2018, LANCET, V392, P2244, DOI 10.1016/S0140-6736(18)32608-4
   Larson HJ, 2019, HUM VACC IMMUNOTHER, V15, P625, DOI 10.1080/21645515.2018.1522468
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Larson HJ, 2015, PLOS CURR, V7, DOI DOI 10.1371/CURRENTS.OUTBREAKS.CE0F6177BC97332602A8E3FE7D7F7CC4
   Leong WY, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay080
   Luo R, 2019, CLIN MICROBIOL INFEC, V25, P659, DOI 10.1016/j.cmi.2019.01.002
   Massad E., 2018, J TRAVEL MED, V25, DOI [10.1093/itm/tay091, DOI 10.1093/ITM/TAY091]
   Masyeni S, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay061
   Memish ZA, 2019, J TRAVEL MED, V26, DOI 10.1093/jtm/taz041
   Neuberger A, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw003
   O'Neill SL, 2018, ADV EXP MED BIOL, V1062, P355, DOI 10.1007/978-981-10-8727-1_24
   Perez-Molina JA, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax035
   Perman S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4168-0
   Rabinowicz S, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax062
   Ribeiro GS, 2018, LANCET GLOB HEALTH, V6, pE140, DOI 10.1016/S2214-109X(17)30496-5
   Riddell A, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax015
   Ritchie SA, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay084
   Rodriguez-Barraquer I, 2019, LANCET INFECT DIS, V19, P132, DOI 10.1016/S1473-3099(18)30799-0
   Sadarangani SP, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax014
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Staehelin C, 2019, J TRAVEL MED, V26, DOI 10.1093/jtm/taz035
   Tan LK, 2019, AM J EPIDEMIOL, V188, P1529, DOI 10.1093/aje/kwz110
   Tomashek KM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006497
   Tustin JL, 2018, JMIR PUBLIC HLTH SUR, V4, P238, DOI 10.2196/publichealth.8921
   van Meer MPA, 2017, J CLIN VIROL, V92, P25, DOI 10.1016/j.jcv.2017.05.001
   Wilder-Smith A, 2017, LANCET INFECT DIS, V17, pe101, DOI DOI 10.1016/S1473-3099(16)30518-7
   Wilder-Smith A, 2018, CURR INFECT DIS REP, V20, DOI 10.1007/s11908-018-0656-3
   Wilder-Smith A, 2019, LANCET INFECT DIS, V19, pE31, DOI 10.1016/S1473-3099(18)30494-8
   Wilder-Smith A, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay057
   Wilder-Smith A, 2016, J INFECT DIS, V214, P1796, DOI 10.1093/infdis/jiw341
NR 53
TC 5
Z9 5
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5137
EP 5146
DI 10.1016/j.vaccine.2019.07.016
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300001
PM 31377079
DA 2020-05-12
ER

PT J
AU Chen, CH
   Su, LH
   Li, HC
   Hsu, MH
   Wu, TL
   Chen, CL
   Kuo, KC
   Hsiao, CC
   Chiu, CH
AF Chen, Chih-Ho
   Su, Lin-Hui
   Li, Hsin-Chieh
   Hsu, Mei-Hua
   Wu, Tsu-Lan
   Chen, Chyi-Liang
   Kuo, Kuang-Che
   Hsiao, Chang-Chun
   Chiu, Cheng-Hsun
TI Evaluation of the impact of 13-valent pneumococcal conjugate vaccine
   immunization in children by surveillance of culture-confirmed
   pneumococcal disease: A prospective clinical microbiological study
SO VACCINE
LA English
DT Article
DE Children; Surveillance; Impact; 13-valent pneumococcal; Conjugate
   vaccine; Culture-confirmed pneumococcal disease; Serotype
ID 19A ST320 CLONE; STREPTOCOCCUS-PNEUMONIAE; SEROTYPE REPLACEMENT;
   PREVENTION; MANAGEMENT; DIAGNOSIS; ENGLAND; TAIWAN; WALES
AB The study aimed to investigate the impact of 13-valent pneumococcal conjugate vaccine (PCV13) immunization on the overall pneumococcal disease in children in Taiwan by surveillance of culture-confirmed pneumococcal disease (CCPD). This study was conducted in a medical center from 2012 to 2016. Clinical isolates of Streptococcus pneumoniae were prospectively collected from pediatric patients. Serotyping, multi-locus sequence typing, and antimicrobial susceptibility testing were performed. A total of 473 patients with CCPD, including 58 with invasive pneumococcal disease (IPD), were identified. The incidence of CCPD per 10,000 admissions decreased from 71.7 in 2012 to 27.0 in 2016. The proportion of additional PCV13 serotypes significantly decreased from 52.0% in 2012 to 21.7% in 2015 but increased slightly to 26.7% because of serotype 19A in 2016 (P < 0.0001). The proportion of non-vaccine serotypes (NVTs) increased significantly from 18.4% in 2012 to 66.7% in 2016, but the increase of the incidence of CCPD caused by NVTs was not considered significant (P = 0.0885). Genotyping identified predominant clones, ST63(15A), ST83(15B), and ST166/338(23A), for major NVTs. The penicillin non-susceptibility of PCV13 serotypes was significantly higher than that of NVTs (P < 0.0001). Surveillance of CCPD appears superior to IPD alone for evaluation of the overall impact of pneumococcal immunization. Serotype replacement occurred quickly after the use of PCV13, while the incidence of NVT infection did not show a significant increase in children over the years. The gradual introduction of PCV13 into national immunization program is effective in reducing overall pneumococcal disease in children. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Chih-Ho; Kuo, Kuang-Che] Kaohsiung Chang Gung Mem Hosp, Dept Pediat, Kaohsiung, Taiwan.
   [Chen, Chih-Ho; Su, Lin-Hui; Wu, Tsu-Lan; Hsiao, Chang-Chun; Chiu, Cheng-Hsun] Chang Gung Univ Coll Med, Grad Inst Clin Med Sci, Taoyuan, Taiwan.
   [Su, Lin-Hui; Li, Hsin-Chieh; Wu, Tsu-Lan] Chang Gung Mem Hosp, Dept Lab Med, Taoyuan, Taiwan.
   [Su, Lin-Hui; Hsu, Mei-Hua; Chen, Chyi-Liang; Chiu, Cheng-Hsun] Chang Gung Mem Hosp, Mol Infect Dis Res Ctr, Taoyuan, Taiwan.
   [Hsiao, Chang-Chun] Kaohsiung Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Kaohsiung, Taiwan.
   [Chiu, Cheng-Hsun] Chang Gung Mem Hosp, Dept Pediat, Taoyuan, Taiwan.
RP Chiu, CH (reprint author), 5 Fu Hsin St, Taoyuan 333, Taiwan.
EM chchiu@adm.cgmh.org.tw
OI Chen, Chih-Ho/0000-0002-4326-1089; Hsiao,
   Chang-Chun/0000-0002-7275-4675; Kuo, Kuang-Che/0000-0002-3350-6724
FU Chang Gung Memorial HospitalChang Gung Memorial Hospital [CMRPG3H0041,
   CMRPG3G1971, CMRP3F1143, CRRPG3F0083]; Ministry of Science and
   TechnologyMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT) [1053011-F-182A-001]
FX The study was supported by grants from Chang Gung Memorial Hospital
   (CMRPG3H0041, CMRPG3G1971, CMRP3F1143, and CRRPG3F0083) and Ministry of
   Science and Technology (1053011-F-182A-001), Taiwan.
CR Bennett NM, 2013, MMWR-MORBID MORTAL W, V62, P521
   Centers for Disease Control and Prevention, CDC 24 7 SAV LIV PRO
   Chi H, 2018, J MICROBIOL IMMUNOL, V51, P337, DOI 10.1016/j.jmii.2016.08.002
   Chiang CS, 2014, VACCINE, V32, P3345, DOI 10.1016/j.vaccine.2014.04.061
   Cho EY, 2016, J KOREAN MED SCI, V31, P1082, DOI 10.3346/jkms.2016.31.7.1082
   Clinical and Laboratory Standards Institute (CLSI), 2013, M100S23 CLSI
   Enright MC, 1998, MICROBIOL-UK, V144, P3049, DOI 10.1099/00221287-144-11-3049
   Fukusumi M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2113-y
   Hsieh YC, 2013, J INFECT DIS, V208, P203, DOI 10.1093/infdis/jit145
   Hsieh YC, 2009, VACCINE, V27, P5513, DOI 10.1016/j.vaccine.2009.06.091
   Jolley KA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-595
   Kuo CY, 2011, VACCINE, V29, P5171, DOI 10.1016/j.vaccine.2011.05.034
   Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5
   Levine OS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e28
   Lieberthal AS, 2013, PEDIATRICS, V131, pE964, DOI 10.1542/peds.2012-3488
   Lu CY, 2019, CLIN INFECT DIS
   Makwana A, 2018, PEDIATR INFECT DIS J, V37, P697, DOI 10.1097/INF.0000000000001845
   McFarland M, 2017, VACCINE, V35, P4389, DOI 10.1016/j.vaccine.2017.06.047
   Pai R, 2006, J CLIN MICROBIOL, V44, P124, DOI 10.1128/JCM.44.1.124-131.2006
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Shin J, 2011, J ANTIMICROB CHEMOTH, V66, P1001, DOI 10.1093/jac/dkr048
   Spratt BG, 2000, LANCET, V356, P1210, DOI 10.1016/S0140-6736(00)02779-3
   Tyrrell GJ, 2009, VACCINE, V27, P3553, DOI 10.1016/j.vaccine.2009.03.063
   van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4
   Versalovic J, 2011, MANUAL CLIN MICROBIO
   Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X
   Wald ER, 2013, PEDIATRICS, V132, pE262, DOI 10.1542/peds.2013-1071
   Wei SH, 2015, CLIN EXP VACCINE RES, V4, P121, DOI 10.7774/cevr.2015.4.2.121
   Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5147
EP 5152
DI 10.1016/j.vaccine.2019.07.073
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300002
PM 31377076
DA 2020-05-12
ER

PT J
AU Choi, JK
   Park, SH
   Park, S
   Cho, SY
   Lee, HJ
   Kim, SH
   Choi, SM
   Lee, DG
   Choi, JH
   Yoo, JH
AF Choi, Jae-Ki
   Park, Sun Hee
   Park, Sanghyun
   Cho, Sung-Yeon
   Lee, Hyo-Jin
   Kim, Si-Hyun
   Choi, Su-Mi
   Lee, Dong-Gun
   Choi, Jung-Hyun
   Yoo, Jin-Hong
TI The changing epidemiology of herpes zoster over a decade in South Korea,
   2006-2015
SO VACCINE
LA English
DT Article
DE Herpes zoster; Epidemiology; South Korea; Population-based; Age
ID VARICELLA VACCINATION; VIRUS-DNA; LONG-TERM; TRANSMISSION; PATIENT;
   PERIOD
AB Background: In South Korea, the population is rapidly aging and the prevalence of comorbidities has increased. We investigated longitudinal changes in the herpes zoster (HZ) considering demographic changes and comorbidities in the era of universal single-dose varicella vaccination.
   Methods: We used the population-based database of the National Health Insurance Service in South Korea, with approximately 50 million subscribers during 2006-2015. HZ cases were identified using ICD-10 codes and comorbid conditions were also collected. Incidence rates (IRs) and incidence rate ratios (IRRs) per year were calculated adjusting for age, sex, comorbidities and socioeconomic status, and the temporal trends were examined using segmented negative binomial regression analysis.
   Results: Over a decade, the adjusted HZ IR increased significantly from 4.23 to 9.22 per 1000 person-years (adjusted IRR 1.05, 95% confidence interval [CI] 1.04-1.06). However, during 2012-2015, the increasing trends decelerated (adjusted IRR per year 1.01, 95% CI 0.98-1.04) and slope changes differed by age. There was a declining trend in children under 9 years, sustained increase in adults aged 30-39 years, and near-plateau in those aged 50-69 years. Nonetheless, the age distribution of HZ incidence did not change over a decade, with the peak in adults aged 60-79 years. HZ-associated hospitalization rates also increased, with a deceleration in the increasing trends during 2012-2015.
   Conclusions: The HZ burden increased independently of demographic changes and prevalence of comorbidities. However, different trajectories by age group necessitate continuous HZ surveillance for better understanding of these changes, and to provide evidence for development of preventive strategies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Choi, Jae-Ki; Park, Sun Hee; Cho, Sung-Yeon; Lee, Hyo-Jin; Kim, Si-Hyun; Choi, Su-Mi; Lee, Dong-Gun; Choi, Jung-Hyun; Yoo, Jin-Hong] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea.
   [Choi, Jae-Ki; Park, Sun Hee; Cho, Sung-Yeon; Lee, Hyo-Jin; Kim, Si-Hyun; Choi, Su-Mi; Lee, Dong-Gun; Choi, Jung-Hyun; Yoo, Jin-Hong] Catholic Univ Korea, Coll Med, Vaccine Bio Res Inst, Seoul, South Korea.
   [Park, Sanghyun] Catholic Univ Korea, Coll Med, Dept Biostat, Seoul, South Korea.
RP Park, SH (reprint author), Catholic Univ Korea, Daejeon St Marys Hosp, 64 Daeheung Ro, Daejeon City 34943, South Korea.
EM mdcjk@catholic.ac.kr; zenithbr@catholic.ac.kr; ujk8774@naver.com;
   cho.sy@catholic.ac.kr; happyjinns@naver.com; ksihyun@catholic.ac.kr;
   sumichoi@catholic.ac.kr; symonlee@catholic.ac.kr; cmcjh@catholic.ac.kr;
   jhyoo@catholic.ac.kr
OI Choi, Jae-ki/0000-0003-4666-960X
FU National Research Foundation of Korea (NRF) - Korea Government (Ministry
   of Science and ICT) [2018R1A2B6006178]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Korea Government (Ministry of Science and ICT) (No.
   2018R1A2B6006178).
CR Amirthalingam G, 2018, LANCET PUBLIC HEALTH, V3, pE82, DOI 10.1016/S2468-2667(17)30234-7
   Bresnitz EA., 2017, P WHO M IMM ELD GEN
   Chao DY, 2012, EPIDEMIOL INFECT, V140, P1131, DOI 10.1017/S0950268811001786
   Chen LK, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2198-y
   Choi Jounghwa, 2019, Health Commun, P1, DOI 10.1080/10410236.2019.1613476
   Choi WS, 2015, INFECT CHEMOTHER, V47, P68, DOI 10.3947/ic.2015.47.1.68
   Choi WS, 2010, J CLIN VIROL, V47, P325, DOI 10.1016/j.jcv.2010.01.003
   Erskine N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181565
   Gershon AA, 2017, J INFECTION, V74, pS27, DOI 10.1016/S0163-4453(17)30188-3
   Gong KY, 2014, EMPIRICAL REV NATL H
   Ha JW, 2017, ANN DERMATOL, V29, P602, DOI 10.5021/ad.2017.29.5.602
   Harpaz R, 2019, CLIN INFECT DIS, V69, P345, DOI 10.1093/cid/ciy954
   Harpaz R, 2019, CLIN INFECT DIS, V69, P341, DOI 10.1093/cid/ciy953
   Harpaz R, 2018, J INFECT DIS, V218, pS57, DOI 10.1093/infdis/jiy418
   Hillebrand K, 2015, J INFECTION, V70, P178, DOI 10.1016/j.jinf.2014.08.018
   HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106
   Johnson JA, 2011, CLIN INFECT DIS, V52, P907, DOI 10.1093/cid/cir033
   Johnson Robert W, 2015, Ther Adv Vaccines, V3, P109, DOI 10.1177/2051013615599151
   JOSEPHSON A, 1988, J INFECT DIS, V158, P238, DOI 10.1093/infdis/158.1.238
   Jung KW, 2018, CANCER RES TREAT, V50, P303, DOI 10.4143/crt.2018.143
   Kawai K, 2017, MAYO CLIN PROC, V92, P1806, DOI 10.1016/j.mayocp.2017.10.009
   Kawai K, 2016, CLIN INFECT DIS, V63, P221, DOI 10.1093/cid/ciw296
   Kawai K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004833
   Kim ES, 2015, NATL CHILDCARE SURVE
   Kim SW, 2018, YONSEI MED J, V59, P781, DOI 10.3349/ymj.2018.59.6.781
   KIM YJ, 2019, J KOREAN MED SCI, V34, DOI DOI 10.3346/JKMS.2019.34.E1E1
   Kim YS, 2018, ANN DERMATOL, V30, P253, DOI 10.5021/ad.2018.30.2.253
   Klompas M, 2011, MAYO CLIN PROC, V86, P1146, DOI 10.4065/mcp.2011.0305
   Lopez AS, 2008, J INFECT DIS, V197, P646, DOI 10.1086/527419
   Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074
   Noh J, 2016, ENDOCRINOL METAB, V31, P349, DOI 10.3803/EnM.2016.31.3.349
   Ogunjimi B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01024-8
   Ogunjimi B, 2015, ELIFE, V4, DOI 10.7554/eLife.07116
   Ogunjimi B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066485
   Oh SH, 2014, CLIN VACCINE IMMUNOL, V21, P762, DOI 10.1128/CVI.00645-13
   Sauboin C, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3759-z
   Seong SC, 2017, INT J EPIDEMIOL, V46, P799, DOI 10.1093/ije/dyw253
   Statistics Korea, 2016, POP PROJ KOR 2015 20
   Suzuki K, 2002, J MED VIROL, V66, P567, DOI 10.1002/jmv.2182
   Suzuki K, 2004, J INFECT DIS, V189, P1009, DOI 10.1086/382029
   Toyama N, 2018, J DERMATOL SCI, V92, P89, DOI 10.1016/j.jdermsci.2018.07.003
   Toyama N, 2009, J MED VIROL, V81, P2053, DOI 10.1002/jmv.21599
   Viner K, 2012, J INFECT DIS, V205, P1336, DOI 10.1093/infdis/jis207
   Wutzler P, 2017, EXPERT REV VACCINES, V16, P833, DOI 10.1080/14760584.2017.1343669
   Yanni EA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020528
   Yoshikawa T, 2001, J MED VIROL, V63, P64, DOI 10.1002/1096-9071(200101)63:1&lt;64::AID-JMV1009&gt;3.0.CO;2-6
   Zoch-Lesniak B, 2018, HUM VACC IMMUNOTHER, P1, DOI [10.1080/21645515.2018.1446718, DOI 10.1080/21645515.2018.1446718]
NR 47
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5153
EP 5160
DI 10.1016/j.vaccine.2019.07.086
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300003
PM 31377077
DA 2020-05-12
ER

PT J
AU Munoz, FM
   Anderson, EJ
   Bernstein, DI
   Harrison, CJ
   Pahud, B
   Anderson, E
   Creech, CB
   Berry, AA
   Kotloff, KL
   Walter, EB
   Atmar, RL
   Bellamy, AR
   Chang, SJ
   Keitel, WA
AF Munoz, Flor M.
   Anderson, Evan J.
   Bernstein, David, I
   Harrison, Christopher J.
   Pahud, Barbara
   Anderson, Edwin
   Creech, C. Buddy
   Berry, Andrea A.
   Kotloff, Karen L.
   Walter, Emmanuel B.
   Atmar, Robert L.
   Bellamy, Abbie R.
   Chang, Soju
   Keitel, Wendy A.
TI Safety and immunogenicity of unadjuvanted subvirion monovalent
   inactivated influenza H3N2 variant (H3N2v) vaccine in children and
   adolescents
SO VACCINE
LA English
DT Article
DE Influenza; H3N2 variant; Children; Adolescents; Safety; Immunogenicity;
   Cross-reactive antibodies
ID A H5N1 VIRUS; SWINE INFLUENZA; UNITED-STATES; ANTIBODY; INFECTION;
   INDIANA; AUGUST
AB Objective: In response to the emergence of influenza viruses with pandemic potential, we evaluated a swine-origin influenza A/H3N2 variant (H3N2v) vaccine in children.
   Study design: This multicenter phase II open-label study assessed the safety and immunogenicity of two doses, 21 days apart, of investigational unadjuvanted subvirion monovalent inactivated H3N2v vaccine administered via intramuscular injection. Children 6-35 months of age received 7.5mcg or 15mcg of hemagglutinin (HA)/dose; children 3-17 years of age received 15mcg HA/dose. Safety and reactogenicity were assessed by measuring the occurrence of solicited injection site and systemic reactions in the 7 days after each vaccination; adverse events were assessed for 42 days and serious adverse events for 7 months after the first vaccination. Immunogenicity was evaluated by measuring hemagglutination inhibition (HAI) and neutralizing (Neut) antibodies to H3N2v prior to and 21 days after each vaccination. Cross-reactivity against seasonal H3N2 strains was evaluated.
   Results: The H3N2v vaccine was well tolerated. Transient mild to moderate injection site tenderness, pain and erythema was observed, with the most commonly reported systemic reactogenicity being irritability in children 6-35 months, and headache and fatigue in children 9-17 years old. Children 6-35 months old, whether they received 7.5mcg or 15mcg/dose, had low HAI and Neut antibody responses after two doses compared to older children. Children under 9 years of age required two doses of vaccine to demonstrate a response, while 9-17 year olds responded well after one dose. Previous influenza vaccination and older age were associated with higher immune responses to H3N2v vaccine. Children 9-17 years of age also developed cross-reactive antibodies against recent seasonal H3N2 influenza viruses.
   Conclusion: The H3N2v vaccine was safe and immunogenic in children and adolescents. Age-related increases in immunogenicity against H3N2v and seasonal H3N2 viruses were observed, suggesting prior priming via infection and/or immunization. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Munoz, Flor M.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   [Munoz, Flor M.; Atmar, Robert L.; Keitel, Wendy A.] Baylor Coll Med, Mol Virol & Microbiol, Houston, TX 77030 USA.
   [Atmar, Robert L.; Keitel, Wendy A.] Baylor Coll Med, Med, Houston, TX 77030 USA.
   [Anderson, Evan J.] Emory Univ, Sch Med, Dept Pediat & Med, Atlanta, GA USA.
   [Bernstein, David, I] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
   [Harrison, Christopher J.; Pahud, Barbara] Childrens Mercy Hosp, Dept Pediat, Kansas City, MO 64108 USA.
   [Anderson, Edwin] St Louis Univ, Sch Med, Dept Pediat, St Louis, MO 63104 USA.
   [Creech, C. Buddy] Vanderbilt Univ, Sch Med, Dept Pediat, Vanderbilt Vaccine Res Program, Nashville, TN USA.
   [Berry, Andrea A.; Kotloff, Karen L.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA.
   [Berry, Andrea A.; Kotloff, Karen L.] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
   [Walter, Emmanuel B.] Duke Univ, Sch Med, Dept Pediat, Durham, NC USA.
   [Bellamy, Abbie R.] Emmes Corp, Rockville, MD USA.
   [Chang, Soju] NIAID, Rockville, MD USA.
RP Munoz, FM (reprint author), Baylor Coll Med, One Baylor Plaza,BCM 280, Houston, TX 77030 USA.
EM florm@bcm.edu
OI Munoz, Flor/0000-0002-0457-7689; Pahud, Barbara/0000-0001-5379-7605;
   Creech, Clarence/0000-0002-8276-9053
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272200800002C, HHSN272201300015I, HHSN272200800005C,
   HHSN272201300018I, HHSN272200800006C, HHSN272200800008C, 61-12-0016,
   HHSN272200800003C, HHSN272200800007C, HHSN272201300023I, HHSN
   2722013000221, HHSN272201300017I, HHSN272201500002C]
FX This project was supported by the National Institute of Allergy and
   Infectious Diseases, contract numbers: HHSN272200800002C and
   HHSN272201300015I to Baylor College of Medicine; HHSN272200800005C and
   HHSN272201300018I to Emory University; HHSN272200800006C to University
   of Cincinnati; HHSN272200800008C, Option 61-12-0016 to Children's Mercy
   Hospital Kansas City; HHSN272200800003C to St. Louis University;
   HHSN272200800007C and HHSN272201300023I to Vanderbilt University Medical
   Center; HHSN 2722013000221 to University of Maryland School of Medicine;
   HHSN272201300017I to Duke University; and HHSN272201500002C (The Emmes
   Corporation).
CR Blanton L, 2017, MMWR-MORBID MORTAL W, V66, P1043, DOI 10.15585/mmwr.mm6639a3
   Branch Alicia, 2012, Morbidity and Mortality Weekly Report, V61, P237
   CDC, CDC REP CAS 18 29 H3
   Centers for Disease Control and Prevention, 2018, INFL H3N2 VAR VIR
   Centers for Disease Control and Prevention (CDC), 2012, MMWR Morb Mortal Wkly Rep, V61, P561
   Centers for Disease Control and Prevention (CDC), 2012, MMWR Morb Mortal Wkly Rep, V60, P1741
   Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P1615
   Jernigan D, 2013, MMWR-MORBID MORTAL W, V62, P366
   Keitel WA, 2015, J INFECT DIS, V212, P552, DOI 10.1093/infdis/jiv056
   Lindstrom S, 2012, EMERG INFECT DIS, V18, P834, DOI 10.3201/eid1805.111922
   Lu Y, 2009, AM J GASTROENTEROL, V104, P444, DOI 10.1038/ajg.2008.120
   Myers KP, 2007, CLIN INFECT DIS, V44, P1084, DOI 10.1086/512813
   Nalluswami Kumar, 2011, Morbidity and Mortality Weekly Report, V60, P1213
   Peiris M, 1999, LANCET, V354, P916, DOI 10.1016/S0140-6736(99)03311-5
   Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999
   Skowronski DM, 2012, EUROSURVEILLANCE, V17, P2
   Skowronski DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054015
   Skowronski DM, 2012, J INFECT DIS, V206, P1852, DOI 10.1093/infdis/jis500
   Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393
   Waalen K, 2012, EUROSURVEILLANCE, V17, P5
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5161
EP 5170
DI 10.1016/j.vaccine.2019.07.085
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300004
PM 31375440
DA 2020-05-12
ER

PT J
AU Noh, JY
   Jang, YS
   Lee, SN
   Choi, MJ
   Yoon, JG
   Yu, DH
   Song, JY
   Cheong, HJ
   Kim, WJ
AF Noh, Ji Yun
   Jang, Ye Seul
   Lee, Saem Na
   Choi, Min Joo
   Yoon, Jin Gu
   Yu, Du Hyeon
   Song, Joon Young
   Cheong, Hee Jin
   Kim, Woo Joo
TI Randomized, single-blind, active-controlled phase I clinical trial to
   evaluate the immunogenicity and safety of GC3114 (high-dose,
   quadrivalent influenza vaccine) in healthy adults
SO VACCINE
LA English
DT Article
DE Influenza, human; Influenza vaccines; Frail elderly
ID MORTALITY
AB Influenza is a major medically attended respiratory illness. The impact of influenza on morbidity and mortality is particularly high in the elderly. Immunosenescence attenuates the immune response of influenza vaccine in the elderly. High-dose influenza vaccine contains 60 mu g of hemagglutinin per strain, four times more compared with standard-dose (SD) influenza vaccine. This study is a phase I clinical trial investigating the immunogenicity and safety of the GC3114, high-dose, quadrivalent inactivated influenza vaccine (HD-QIV) in healthy adults aged 19-64 years during the 2017-2018 season. Seroprotection rates of HD-QIV were 100.0% for A/H1N1, 96.67% for A/H3N2, 83.33% for B/Yamagata, and 96.67% for B/Victoria. Seroconversion rate for A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains were 86.67%, 90.0%, 53.33%, and 53.33%, respectively, in the HD-QIV group. The post-/pre-vaccination geometric mean titer ratio (GMTR) was 15.28 for A/H1N1, 8.19 for A/H3N2, 3.56 for B/Yamagata, and 3.03 for B/Victoria in the HD-QIV group. Seroconversion rate and post-/pre-vaccination GMTR for A/H3N2 were significantly higher in the HD-QIV group than in the SD-QIV group (control). No serious adverse events were reported. In conclusion, GC3114 was safe, well-tolerated, and immunogenic in healthy adults. (C) 2019 Published by Elsevier Ltd.
C1 [Noh, Ji Yun; Jang, Ye Seul; Lee, Saem Na; Choi, Min Joo; Yoon, Jin Gu; Yu, Du Hyeon; Song, Joon Young; Cheong, Hee Jin; Kim, Woo Joo] Korea Univ, Dept Internal Med, Div Infect Dis, Coll Med, Seoul, South Korea.
   [Noh, Ji Yun; Choi, Min Joo; Song, Joon Young; Cheong, Hee Jin; Kim, Woo Joo] Korea Univ, Asia Pacific Influenza Inst, Coll Med, Seoul, South Korea.
RP Kim, WJ (reprint author), Korea Univ, Guro Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Gurodong Ro 148, Seoul 08308, South Korea.
EM wjkim@korea.ac.kr
FU GC Pharma
FX This study was supported by GC Pharma, who also designed, executed, and
   analyzed the study. GC Pharma was given the opportunity to review a
   preliminary version of this manuscript for factual accuracy but the
   authors are responsible for final content and interpretation. The
   authors received no financial support or other form of compensation
   related to the development of the manuscript.
CR Ambrose CS, 2012, HUM VACC IMMUNOTHER, V8, P81, DOI 10.4161/hv.8.1.17623
   Chen WH, 2011, VACCINE, V29, P2865, DOI 10.1016/j.vaccine.2011.02.017
   Couch RB, 2007, VACCINE, V25, P7656, DOI 10.1016/j.vaccine.2007.08.042
   DiazGranados CA, 2015, VACCINE, V33, P7188, DOI 10.1016/j.vaccine.2015.10.131
   DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727
   Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137
   Haq K, 2014, CURR OPIN IMMUNOL, V29, P38, DOI 10.1016/j.coi.2014.03.008
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Kaka AS, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx001
   Kim JH, 2016, VACCINE, V34, P4594, DOI 10.1016/j.vaccine.2016.07.018
   Kim YK, 2018, PHARMACOECONOMICS, V36, P1475, DOI 10.1007/s40273-018-0715-5
   Lee JKH, 2018, EXPERT REV VACCINES, V17, P435, DOI 10.1080/14760584.2018.1471989
   Natori Y, 2018, CLIN INFECT DIS, V66, P1698, DOI 10.1093/cid/cix1082
   Noh JY, 2018, VACCINE, V36, P5304, DOI 10.1016/j.vaccine.2018.07.021
   Park Minah, 2016, Am J Prev Med, V50, pe111, DOI 10.1016/j.amepre.2015.09.028
   Pilkinton MA, 2017, VACCINE, V35, P329, DOI 10.1016/j.vaccine.2016.11.059
   Robertson CA, 2016, EXPERT REV VACCINES, V15, P1495, DOI 10.1080/14760584.2016.1254044
   Shay DK, 2017, J INFECT DIS, V215, P510, DOI 10.1093/infdis/jiw641
   Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Trombetta CM, 2014, VACCINES-BASEL, V2, P707, DOI 10.3390/vaccines2040707
   US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, 2007, TOX GRAD SCAL HLTH A
   Wijnans L, 2016, INFLUENZA OTHER RESP, V10, P2, DOI 10.1111/irv.12351
   You JHS, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0618-9
   Young-Xu YN, 2018, J INFECT DIS, V217, P1718, DOI 10.1093/infdis/jiy088
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5171
EP 5176
DI 10.1016/j.vaccine.2019.07.076
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300005
PM 31377075
DA 2020-05-12
ER

PT J
AU Privatt, SR
   Bullard, BL
   Weaver, EA
   Wood, C
   West, JT
AF Privatt, Sara R.
   Bullard, Brianna L.
   Weaver, Eric A.
   Wood, Charles
   West, John T.
TI Longitudinal quantification of adenovirus neutralizing responses in
   Zambian mother-infant pairs: Impact of HIV-1 infection and its treatment
SO VACCINE
LA English
DT Article
DE Adenovirus; Seroprevalence; Vector; Sub-Saharan Africa; HIV
ID PREEXISTING IMMUNITY; VACCINE VECTORS; DOUBLE-BLIND; EPIDEMIOLOGY;
   ANTIBODIES; IMMUNOGENICITY; SEROPREVALENCE; PREVALENCE; SEROTYPES;
   CHILDREN
AB Vaccination offers the most cost-effective approach to limiting the adverse impact of infectious and neoplastic diseases that reduce the quality of life in sub-Saharan Africa (SSA). However, it is unclear what vaccine vectors would be most readily implementable in the setting and at what age they should be applied for maximal efficacy. Adenoviruses (Ad) and Ad-based vectors have been demonstrated to induce effective humoral and cellular immune responses in animal models and in humans. However, because immunity associated with Ad infection is lifelong, there exists a debate as to whether pre-existing immunity might decrease the efficacy of Ad vectored vaccines. In order to begin to nationally develop vaccination strategies for SSA, we have quantified neutralizing antibodies (nAb) against Ad4, Ad5, Ad7, Ad26, Ad28, Ad45 and Ad48 in 67 adult women and their infants. We are the first to define the decay kinetics of transferred maternal nAb in infants as well as the apparent initiation of de novo Ad responses. Our findings demonstrate that in Zambian adults, robust nAb responses exist against each of the Ads tested and are efficiently transferred to newborns. With few exceptions, neither the HIV-1 infection status of the mothers or the antiretroviral therapy (ART) treatment of HIV-1 disease had significant impact on maternal Ad nAb responses or their transfer to infants. However, maternal Ad nAb decays in infants to a nadir at 12 months of age such that any of the seven Ad types could function as vaccine vectors. The definition of this 'window of opportunity' provides important foundational data for rational design and implementation of Ad vectors in this setting. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [West, John T.] Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68588 USA.
   Univ Nebraska, Sch Biol Sci, Lincoln, NE USA.
RP West, JT (reprint author), Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68588 USA.
EM jwest2@unl.edu
OI Bullard, Brianna/0000-0002-6702-0079
FU PHS grants from the National Institute of Health; National Cancer
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA75903]; National Cancer Institute/Fogarty International Program [U54
   CA221204-01]; National Institute of Allergy and Infectious Diseases Ruth
   L. Kirschstein National Research Service Award [T32 AI125207]
FX The authors would like to graciously thank the Zambian mothers and
   infants who were participants in this study. We also thank Ms. Brigette
   Corder for assistance in preparation of the final manuscript. This study
   was supported in part of PHS grants from the National Institute of
   Health; National Cancer Institute grants (R01 CA75903), National Cancer
   Institute/Fogarty International Program grant U54 CA221204-01, and
   National Institute of Allergy and Infectious Diseases Ruth L.
   Kirschstein National Research Service Award (T32 AI125207) to CW. SP is
   a Ruth L. Kirschstein fellow.
CR Abbink P, 2007, J VIROL, V81, P4654, DOI 10.1128/JVI.02696-06
   Abbink P, 2015, J VIROL, V89, P1512, DOI 10.1128/JVI.02950-14
   Alexander J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031177
   Alonso-Padilla J, 2016, MOL THER, V24, P6, DOI 10.1038/mt.2015.194
   [Anonymous], 2019, TUBERCULOSIS TB
   [Anonymous], 2018, HIV AIDS
   [Anonymous], 2018, WHO DATA STAT
   [Anonymous], 2016, WHO 10 FACTS MALARIA
   Baden LR, 2015, J INFECT DIS, V211, P518, DOI 10.1093/infdis/jiu485
   Barouch DH, 2011, VACCINE, V29, P5203, DOI 10.1016/j.vaccine.2011.05.025
   Barry M, 2018, EXPERT REV VACCINES, V17, P163, DOI 10.1080/14760584.2018.1419067
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Bullard BL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35755-z
   Chen RF, 2014, INT REV IMMUNOL, V33, P45, DOI 10.3109/08830185.2013.823420
   Choudhry A, 2016, VACCINE, V34, P4558, DOI 10.1016/j.vaccine.2016.07.033
   Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385
   Duffy MR, 2018, J GEN VIROL, V99, P135, DOI 10.1099/jgv.0.000978
   Farrow AL, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8030078
   Fausther-Bovendo H, 2014, HUM VACC IMMUNOTHER, V10, P2875, DOI 10.4161/hv.29594
   Flasche S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002181
   Gach JS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160341
   Geisbert TW, 2011, J VIROL, V85, P4222, DOI 10.1128/JVI.02407-10
   Halstead SB, 2017, VACCINE, V35, P6355, DOI 10.1016/j.vaccine.2017.09.089
   Kostense S, 2004, AIDS, V18, P1213, DOI 10.1097/00002030-200405210-00019
   Lion T, 2014, CLIN MICROBIOL REV, V27, P441, DOI 10.1128/CMR.00116-13
   Lynch JP, 2016, SEMIN RESP CRIT CARE, V37, P586, DOI 10.1055/s-0036-1584923
   Mayindou G, 2016, J MED VIROL, V88, P596, DOI 10.1002/jmv.24382
   Nalwoga A, 2018, PEDIATR INFECT DIS J, V37, pE225, DOI [10.1097/INF.0000000000001909, 10.1097/inf.0000000000001909]
   Nwanegbo E, 2004, CLIN DIAGN LAB IMMUN, V11, P351, DOI 10.1128/CDLI.11.2.351-357.2004
   Olp LN, 2016, J MED VIROL, V88, P1973, DOI 10.1002/jmv.24546
   Pauly M, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-25
   Pereira BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145260
   Saxena M, 2013, MICROBIOL-SGM, V159, P1, DOI 10.1099/mic.0.049601-0
   Scott MK, 2016, EMERG INFECT DIS, V22, P1044, DOI 10.3201/eid2206.151898
   Stephenson KE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205139
   Sun CJ, 2011, VACCINE, V29, P3837, DOI 10.1016/j.vaccine.2011.03.042
   Weaver EA, 2014, HUM VACC IMMUNOTHER, V10, P544, DOI 10.4161/hv.27238
   Weaver EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073313
   Yang WX, 2016, VACCINE, V34, P5579, DOI 10.1016/j.vaccine.2016.09.043
   Zhang XF, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1049-9
   Zhu FC, 2017, LANCET, V389, P621, DOI [10.1016/s0140-6736(16)32617-4, 10.1016/S0140-6736(16)32617-4]
NR 41
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5177
EP 5184
DI 10.1016/j.vaccine.2019.07.074
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300006
PM 31378535
DA 2020-05-12
ER

PT J
AU Yan, R
   He, H
   Zhou, Y
   Xie, SY
   Deng, X
   Tang, XW
AF Yan, Rui
   He, Hanging
   Zhou, Yang
   Xie, Shuyun
   Deng, Xuan
   Tang, Xuewen
TI Study on factors associated with seroprotection after measles
   vaccination in children of 6-14 years in Eastern China
SO VACCINE
LA English
DT Article
DE Measles; Immunity; Measles-containing vaccine (MCV)
ID ZHEJIANG PROVINCE; ANTIBODY-TITERS; WANING IMMUNITY; PERSISTENCE;
   IMMUNIZATION; INDIVIDUALS; ELIMINATION; SCHEDULE; COVERAGE; VACCINES
AB Measles cases have occurred in individuals with histories of vaccination against the disease in Zhejiang Province, China. The purposes of this study were to determine the seroprevalence of immunoglobulin G (IgG) measles antibodies in vaccinated individuals, to explore the waning kinetics of measles antibody among children after receipt of a measles-containing vaccine, and to define high-risk groups in the population. A seroprevalence survey of measles antibody was conducted with 1900 randomly selected and age-stratified participants aged 6-14 years in Zhejiang province. In our study, seronegative persons accounted for 7.17% of study participants. A case-control study of participants who had received at least one dose of measles-containing vaccine was conducted, with 123 cases of immune failure and 1593 controls with immune success. Multivariate logistic regression analysis showed that age, and number of doses were the influencing factors for measles immunization failure. The older a participant (odds ratio [OR] = 1.164), the more likely that measles vaccine immunity failed. In addition, immune failure was more likely to occur after one dose of MCV than two doses (OR = 0.008) or three doses and more (OR = 0.047). In a univariate logistic regression analysis, we found that immune failure was more likely to occur with MCV vaccination beginning at 8 months than at 9-11 months (OR = 0.562) and the subjects whose registration residence was in other cities in Zhejiang province (OR = 3.527). However, these differences in seropositivity were not significant in the multivariate logistic regression analysis. The exponential regression equation of the attenuation model after measles immunization was y = 884.64e(-0.057x) (R-2 = 0.0521, p < 0.001), and results showed that the measles geometric mean concentration of IgG antibodies was approximately 884.64 mIU/ml after the last MCV vaccination and decreased with time since last vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yan, Rui; He, Hanging; Zhou, Yang; Xie, Shuyun; Deng, Xuan; Tang, Xuewen] Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou 310051, Zhejiang, Peoples R China.
RP He, H (reprint author), Zhejiang Prov Ctr Dis Control & Prevent, Hangzhou 310051, Zhejiang, Peoples R China.
EM hanqinghe@cdc.zj.cn
OI YAN, RUI/0000-0001-7254-0725
CR BIN D, 1991, B WORLD HEALTH ORGAN, V69, P415
   Chen CJ, 2012, VACCINE, V30, P6721, DOI 10.1016/j.vaccine.2012.05.019
   CHRISTENSON B, 1994, VACCINE, V12, P129, DOI 10.1016/0264-410X(94)90049-3
   Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054
   De Serres G, 2012, CLIN INFECT DIS, V55, P394, DOI 10.1093/cid/cis439
   Defay F, 2013, PEDIATRICS, V132, pE1126, DOI 10.1542/peds.2012-3975
   Feng Yan, 2015, Zhonghua Liu Xing Bing Xue Za Zhi, V36, P983
   Guerra FM, 2018, VACCINE, V36, P1248, DOI 10.1016/j.vaccine.2018.01.002
   Haralambieva IH, 2011, VACCINE, V29, P4485, DOI 10.1016/j.vaccine.2011.04.037
   He H Q, 2017, Zhonghua Yu Fang Yi Xue Za Zhi, V51, P336, DOI 10.3760/cma.j.issn.0253-9624.2017.04.011
   He HG, 2014, VACCINE, V32, P4001, DOI 10.1016/j.vaccine.2014.04.044
   He HQ, 2013, VACCINE, V31, P533, DOI 10.1016/j.vaccine.2012.11.014
   Hu Y, 2015, HUM VACC IMMUNOTHER, V11, P761, DOI 10.1080/21645515.2015.1012015
   LeBaron CW, 2007, ARCH PEDIAT ADOL MED, V161, P294, DOI 10.1001/archpedi.161.3.294
   Leung AKC, 2018, HONG KONG MED J, V24, P512, DOI 10.12809/hkmj187470
   Lexova P., 2011, MEASLES IMPORTANCE D, V20, P103
   Mossong J, 2000, VACCINE, V19, P523, DOI 10.1016/S0264-410X(00)00175-4
   Mossong J, 2003, VACCINE, V21, P4597, DOI 10.1016/S0264-410X(03)00449-3
   Pei L, 2017, VACCINE, V35, P7250, DOI 10.1016/j.vaccine.2017.11.012
   Poland GA, 2001, VACCINE, V20, P430, DOI 10.1016/S0264-410X(01)00346-2
   Rabenau HF, 2007, MED MICROBIOL IMMUN, V196, P151, DOI 10.1007/s00430-007-0037-2
   Smetana J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170257
   Trmal J, 2014, EPIDEMIOL MIKROBI IM, V63, P154
   Uzicanin A, 2011, J INFECT DIS, V204, pS133, DOI 10.1093/infdis/jir102
   van Boven M, 2010, J R SOC INTERFACE, V7, P1537, DOI 10.1098/rsif.2010.0086
   van den Hof S, 2003, VACCINE, V21, P4210, DOI 10.1016/S0264-410X(03)00490-0
   Vandermeulen C, 2007, VACCINE, V25, P6672, DOI 10.1016/j.vaccine.2007.07.008
   Voigt EA, 2016, VACCINE, V34, P4913, DOI 10.1016/j.vaccine.2016.08.060
   Wood JG, 2009, VACCINE, V27, P313, DOI 10.1016/j.vaccine.2008.09.095
   World Health Organization, 2016, MEASL JAB SAV 20 MIL
   Xiong YZ, 2014, HUM VACC IMMUNOTHER, V10, P1097, DOI 10.4161/hv.27734
   Xu CP, 2017, J MICROBIOL IMMUNOL, V50, P578, DOI 10.1016/j.jmii.2015.10.004
   Yan R, 2015, DIS SURVEILLANCE, V30, P712
   Yang ZC, 2014, HUM VACC IMMUNOTHER, V10, P1091, DOI 10.4161/hv.27895
   Zhang DL, 2015, VACCINE, V33, P4100, DOI 10.1016/j.vaccine.2015.06.066
NR 35
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5185
EP 5190
DI 10.1016/j.vaccine.2019.07.075
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300007
PM 31377078
DA 2020-05-12
ER

PT J
AU Kwak, HW
   Park, HJ
   Ko, HL
   Park, H
   Cha, MH
   Lee, SM
   Kang, KW
   Kim, RH
   Ryu, SR
   Kim, HJ
   Kim, JO
   Song, M
   Kim, H
   Jeong, DG
   Shin, EC
   Nam, JH
AF Kwak, Hye Won
   Park, Hyo-Jung
   Ko, Hae Li
   Park, Hyelim
   Cha, Min Ho
   Lee, Sang-Myeong
   Kang, Kyung Won
   Kim, Rhoon-Ho
   Ryu, Seung Rok
   Kim, Hye-Jung
   Kim, Jae-Ouk
   Song, Manki
   Kim, Hun
   Jeong, Dae Gwin
   Shin, Eui-Cheol
   Nam, Jae-Hwan
TI Cricket paralysis virus internal ribosome entry site-derived RNA
   promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2
   response
SO VACCINE
LA English
DT Article
DE MERS; HPV; CrPV; IRES; RNA; Adjuvant; Vaccine; Th1/Th2; Alum
ID YELLOW-FEVER VACCINE; IMMUNE-RESPONSES; MOUSE MODEL; T-CELLS; RIG-I;
   ADJUVANTS; TLR; GENERATION; INFECTION; DELIVERY
AB An ideal adjuvant should increase vaccine efficacy through balanced Th1/Th2 responses and be safe to use. Recombinant protein-based vaccines are usually formulated with aluminum (alum)-based adjuvants to ensure an adequate immune response. However, use of alum triggers a Th2-biased immune induction, and hence is not optimal. Although the adjuvanticity of RNA has been reported, a systematic and overall investigation on its efficacy is lacking. We found that single strand RNA (termed RNA adjuvant) derived from cricket paralysis virus intergenic region internal ribosome entry site induced the expression of various adjuvant-function-related genes, such as type 1 and 2 interferon (IFN) and toll-like receptor (TLR), T cell activation, and leukocyte chemotaxis in human peripheral blood mononuclear cells; furthermore, its innate and IFN transcriptome profile patterns were similar to those of a live-attenuated yellow fever vaccine. This suggests that protein-based vaccines formulated using RNA adjuvant function as live attenuated vaccines. Application of the RNA adjuvant in mouse enhanced the efficacy of Middle East respiratory syndrome spike protein, a protein-subunit vaccine and human papillomavirus L1 protein, a virus-like particle vaccine, by activating innate immune response through TLR7 and enhancing pAPC chemotaxis, leading to a balanced Th1/Th2 responses. Moreover, the combination of alum and the RNA adjuvant synergistically induced humoral and cellular immune responses and endowed long-term immunity. Therefore, RNA adjuvants have broad applicability and can be used with all conventional vaccines to improve vaccine efficacy qualitatively and quantitively. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kwak, Hye Won; Park, Hyo-Jung; Ko, Hae Li; Park, Hyelim; Kim, Rhoon-Ho; Kim, Hye-Jung; Nam, Jae-Hwan] Catholic Univ Korea, Dept Biotechnol, Bucheon 14662, Gyeonggi Do, South Korea.
   [Cha, Min Ho] Korea Inst Oriental Med, KM Applicat Ctr, Daegu, South Korea.
   [Lee, Sang-Myeong; Kang, Kyung Won; Ryu, Seung Rok] Chonbuk Natl Univ, Div Biotechnol, Iksan, South Korea.
   [Kim, Jae-Ouk; Song, Manki] Seoul Natl Univ, Int Vaccine Inst, Clin Res Lab, Res Pk, Seoul, South Korea.
   [Kim, Hun] SK Biosci, Life Sci Res Inst, Seongnam, South Korea.
   [Jeong, Dae Gwin] Korea Res Inst Biosci & Biotechnol, Infect Dis Res Ctr, Daejeon, South Korea.
   [Shin, Eui-Cheol] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea.
RP Nam, JH (reprint author), Catholic Univ Korea, Dept Biotechnol, Bucheon 14662, Gyeonggi Do, South Korea.
EM jhnam@catholic.ac.kr
RI Shin, Eui-Cheol/C-1690-2011
OI Shin, Eui-Cheol/0000-0002-6308-9503; Hae Li, Ko/0000-0002-7709-3343
FU Korean Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI15C2955]; Basic Science Research Program through the NRF -
   Ministry of Science, ICT & Future Planning [NRF-2015M3A9B5030157];
   Catholic University of Korea; Ministry of Health & Welfare, Republic of
   KoreaMinistry of Health & Welfare, Republic of Korea [HI15C2971]
FX J.-H. Nam was supported by the Korean Health Technology R&D Project
   through the Korea Health Industry Development Institute (KHIDI) funded
   by the Ministry of Health & Welfare, Republic of Korea (HI15C2955), the
   Basic Science Research Program through the NRF funded by the Ministry of
   Science, ICT & Future Planning (NRF-2015M3A9B5030157), and the Catholic
   University of Korea, Research Fund 2018. M. Song was supported by the
   Ministry of Health & Welfare, Republic of Korea (HI15C2971).
CR Agrawal AS, 2015, J VIROL, V89, P3659, DOI 10.1128/JVI.03427-14
   Antonelli LRV, 2010, J CLIN INVEST, V120, P1674, DOI 10.1172/JCI40817
   Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114
   Barba-Spaeth G, 2005, J EXP MED, V202, P1179, DOI 10.1084/jem.20051352
   Bracci L, 2008, EXPERT REV VACCINES, V7, P373, DOI 10.1586/14760584.7.3.373
   Caskey M, 2011, J EXP MED, V208, P2357, DOI 10.1084/jem.20111171
   Chow KT, 2018, ANNU REV IMMUNOL, V36, P667, DOI 10.1146/annurev-immunol-042617-053309
   Christensen D, 2016, HUM VACC IMMUNOTHER, V12, P2709, DOI 10.1080/21645515.2016.1219003
   Crow MK, 2014, J IMMUNOL, V192, P5459, DOI 10.4049/jimmunol.1002795
   Decker T, 2002, J CLIN INVEST, V109, P1271, DOI 10.1172/JCI200215770
   Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001
   Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x
   Fierer J, 2006, J INFECT DIS, V193, P1323, DOI 10.1086/502972
   Fotin-Mleczek M, 2011, J IMMUNOTHER, V34, P1, DOI 10.1097/CJI.0b013e3181f7dbe8
   Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292
   Hafner AM, 2013, ADV DRUG DELIVER REV, V65, P1386, DOI 10.1016/j.addr.2013.05.013
   He P, 2015, HUM VACC IMMUNOTHER, V11, P477, DOI 10.1080/21645515.2014.1004026
   Hillmer EJ, 2016, CYTOKINE GROWTH F R, V31, P1, DOI 10.1016/j.cytogfr.2016.05.001
   Ko HL, 2019, J MICROBIOL BIOTECHN, V29, P127, DOI 10.4014/jmb.1811.11019
   Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510
   Martinez-Gil L, 2013, J VIROL, V87, P1290, DOI 10.1128/JVI.02338-12
   Martins KA, 2015, EXPERT REV VACCINES, V14, P447, DOI 10.1586/14760584.2015.966085
   McKee AS, 2017, CURR OPIN IMMUNOL, V47, P44, DOI 10.1016/j.coi.2017.06.005
   Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032
   Moyer TJ, 2016, J CLIN INVEST, V126, P799, DOI 10.1172/JCI81083
   Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450
   Pilipow K, 2015, CANCER RES, V75, P5187, DOI 10.1158/0008-5472.CAN-15-1498
   Provine NM, 2016, J VIROL, V90, P4278, DOI 10.1128/JVI.00039-16
   Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688
   Shukla RS, 2014, MOL PHARMACEUT, V11, P3395, DOI 10.1021/mp500426r
   SINGH B, 1970, J INFECT DIS, V122, P339, DOI 10.1093/infdis/122.4.339
   Smith J, 2011, LANCET, V378, P428, DOI 10.1016/S0140-6736(11)60478-9
   Smits ELJM, 2008, ONCOLOGIST, V13, P859, DOI 10.1634/theoncologist.2008-0097
   Sofi MH, 2009, MOL IMMUNOL, V46, P1443, DOI 10.1016/j.molimm.2008.12.014
   Steinhagen F, 2011, VACCINE, V29, P3341, DOI 10.1016/j.vaccine.2010.08.002
   Suschak JJ, 2016, J IMMUNOL, V196, P310, DOI 10.4049/jimmunol.1501836
   Wang JW, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0101576e101576, DOI 10.1371/JOURNAL.PONE.0101576E101576]
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Ziegler A, 2017, J IMMUNOL, V198, P1595, DOI 10.4049/jimmunol.1601129
NR 39
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5191
EP 5202
DI 10.1016/j.vaccine.2019.07.070
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300008
PM 31371226
OA Bronze, Green Published
DA 2020-05-12
ER

PT J
AU Lucero, MS
   Richetta, M
   Zoth, SC
   Jaton, J
   Pint, S
   Canet, Z
   Berinstein, A
   Gomez, E
AF Lucero, Maria S.
   Richetta, Madras
   Chimeno Zoth, Silvina
   Jaton, Juan
   Pint, Silvina
   Canet, Zulma
   Berinstein, Analia
   Gomez, Evangelina
TI Plant-based vaccine candidate against Infectious bursal disease: An
   alternative to inactivated vaccines for breeder hens
SO VACCINE
LA English
DT Article
DE Plant-based vaccine; VP2; Infectious bursal disease; Breeder hens;
   Maternally derived antibodies
ID MATERNALLY DERIVED ANTIBODIES; TRANSIENT EXPRESSION; PASSIVE PROTECTION;
   VIRUS; CHICKENS; PROGENY; VP2; PATHOGENESIS; POULTRY
AB Infectious bursal disease (IBD) is an acute, highly contagious immunosuppressive disease that affects young birds causing important economic losses in the poultry industry worldwide. Strict hygiene management together with effective vaccination programs are the most important strategies to prevent Infectious bursal disease virus entry in poultry production facilities. Hyperimmunisation of dams with inactivated vaccines just before the laying period provides passive immunity to the progeny that protects them during the critical first few weeks after hatching before vaccination with live attenuated virus takes place. In the present study, a safe and economic plant-based vaccine candidate against IBD intended for breeder hens was evaluated. We demonstrated that the recombinant immunogen is effective as booster for previously primed hens since it increases specific antibodies against VP2 that are transmitted to the offspring with titres and decay rate similar to those achieved by inactivated vaccine. Moreover, these maternally derived antibodies have virus neutralising activity and are able to confer protection against challenge in progeny, as evidenced by absence of bursal damage and low viral titres in this organ. Taking into account the disadvantages of inactivated vaccines as well as the benefits of plants as expression systems, such as time and cost efficiency, lower risk of contamination from animal pathogens and nearly unlimited scalability, a plant-based subunit IBD vaccine represents a viable alternative in the veterinary field. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lucero, Maria S.; Chimeno Zoth, Silvina; Jaton, Juan; Berinstein, Analia; Gomez, Evangelina] Consejo Nacl Invest Cient & Tecn, Inst Agrobiotecnol & Biol Mol IABIMO, INTA, Reseros & Nicolas Repetto S-N, RA-1686 Hurlingham, Buenos Aires, Argentina.
   [Richetta, Madras] INTA, Ctr Invest Ciencias Vet & Agron CICVyA, CNIA, Reseros & Nicolas Repetto S-N, RA-1686 Hurlingham, Buenos Aires, Argentina.
   [Pint, Silvina] Univ Buenos Aires, Fac Ciencias Vet, Catedra Patol, Av Chorroarin 280,CI427CWN, Caba, Argentina.
   [Canet, Zulma] Estn Expt Agr Pergamino INTA, Pergamino CC 31 B2700WAA, Buenos Aires, DF, Argentina.
RP Berinstein, A; Gomez, E (reprint author), Consejo Nacl Invest Cient & Tecn, Inst Agrobiotecnol & Biol Mol IABIMO, INTA, Reseros & Nicolas Repetto S-N, RA-1686 Hurlingham, Buenos Aires, Argentina.
EM berinstein.analia@inta.gob.ar; gomez.evangelina@inta.gob.ar
OI Lucero, Maria Soledad/0000-0002-2281-3446
FU CONICETConsejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET) [PIP 11220110100064]; ANCPyT [PICT 2016-313]; INTAConsejo
   Superior de Investigaciones Cientificas (CSIC) [PNBIO 1131032]
FX This work was supported by CONICET (PIP 11220110100064), ANCPyT (PICT
   2016-313) and INTA (PNBIO 1131032).
CR Abdel-Moneim AS, 2006, VET MICROBIOL, V114, P16, DOI 10.1016/j.vetmic.2005.10.037
   Agrawal R, 2016, VET WORLD, V9, P425, DOI 10.14202/vetworld.2016.425-431
   AHMED Z, 2003, INT J POULT SCI, V2, P251, DOI DOI 10.3923/UPS.2003.251.255
   Al-Natour MQ, 2004, AVIAN DIS, V48, P177, DOI 10.1637/5319
   Alkie TN, 2016, VET MED-RES REP, V7, P9, DOI 10.2147/VMRR.S68905
   [Anonymous], 2018, INF BURS DIS
   Aricibasi M, 2010, VET IMMUNOL IMMUNOP, V135, P79, DOI 10.1016/j.vetimm.2009.11.005
   Bendandi M, 2010, ANN ONCOL, V21, P2420, DOI 10.1093/annonc/mdq256
   Chanie M, 2014, BRI J POUL SCI, V3, P68, DOI 10.5829/idosi.bjps.2014.3.3.8556
   Delrue I, 2012, EXPERT REV VACCINES, V11, P695, DOI [10.1586/erv.12.38, 10.1586/ERV.12.38]
   DOBOS P, 1979, J VIROL, V32, P593, DOI 10.1128/JVI.32.2.593-605.1979
   FAHEY KJ, 1991, AVIAN PATHOL, V20, P447, DOI 10.1080/03079459108418783
   Gharaibeh S, 2013, POULTRY SCI, V92, P2333, DOI 10.3382/ps.2013-03249
   Gomez E, 2013, VACCINE, V31, P2623, DOI 10.1016/j.vaccine.2013.03.064
   Gomez E, 2009, J BIOTECHNOL, V144, P337, DOI 10.1016/j.jbiotec.2009.09.015
   Hamal KR, 2006, POULTRY SCI, V85, P1364, DOI 10.1093/ps/85.8.1364
   Lucero M. S., 2012, CAB Reviews, V7, P1, DOI 10.1079/PAVSNNR20127070
   Lucero MS, 2016, J VIROL ANTIVIR RES, V5, DOI [10.4172/2324-8955.1000161, DOI 10.4172/2324-8955.1000161]
   MACREADIE IG, 1990, VACCINE, V8, P549, DOI 10.1016/0264-410X(90)90006-8
   Menassa R, 2001, MOL BREEDING, V8, P177, DOI 10.1023/A:1013376407362
   Moraes HLS, 2005, Rev. Bras. Cienc. Avic., V7, P51, DOI 10.1590/S1516-635X2005000100009
   Muller H, 2012, AVIAN PATHOL, V41, P133, DOI 10.1080/03079457.2012.661403
   MULLER H, 1979, J VIROL, V31, P584
   Nandi S, 2016, MABS-AUSTIN, V8, P1456, DOI 10.1080/19420862.2016.1227901
   R Core Team, 2013, R LANG ENV STAT COMP
   SAIF YM, 1991, VET IMMUNOL IMMUNOP, V30, P45, DOI 10.1016/0165-2427(91)90007-Y
   Sainsbury F, 2009, PLANT BIOTECHNOL J, V7, P682, DOI 10.1111/j.1467-7652.2009.00434.x
   Sharma JM, 2000, DEV COMP IMMUNOL, V24, P223, DOI 10.1016/S0145-305X(99)00074-9
   Sohrab SS, 2017, CURR DRUG METAB, V18, P831, DOI 10.2174/1389200218666170711121810
   Stephan A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010095
   Takeyama Natsumi, 2015, Ther Adv Vaccines, V3, P139, DOI 10.1177/2051013615613272
   Tippenhauer M, 2013, DEV COMP IMMUNOL, V40, P1, DOI 10.1016/j.dci.2012.10.013
   VAKHARIA VN, 1994, VACCINE, V12, P452, DOI 10.1016/0264-410X(94)90124-4
   van den Berg TP, 2000, REV SCI TECH OIE, V19, P527
   VANDENBERG TP, 1991, AVIAN PATHOL, V20, P409, DOI 10.1080/03079459108418779
   Yehuda H, 2000, AVIAN PATHOL, V29, P13, DOI 10.1080/03079450094225
   Zhao S, 2016, POULTRY SCI, V95, P2786, DOI 10.3382/ps/pew192
NR 37
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5203
EP 5210
DI 10.1016/j.vaccine.2019.07.069
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300009
PM 31351795
DA 2020-05-12
ER

PT J
AU Andrews, N
   Stowe, J
   Thomas, SL
   Walker, JL
   Miller, E
AF Andrews, Nick
   Stowe, Julia
   Thomas, Sara L.
   Walker, Jemma L.
   Miller, Elizabeth
TI The risk of non-specific hospitalised infections following MMR
   vaccination given with and without inactivated vaccines in the second
   year of life. Comparative self-controlled case-series study in England
SO VACCINE
LA English
DT Article
DE MMR; Non-specific effects; Inactivated vaccines; Self-controlled
   case-series; Infections
ID ADMISSIONS; RUBELLA; MEASLES; MUMPS; BACTERIAL; CHILDREN
AB Observational cohort studies in high-income settings have suggested that vaccination order may affect children's subsequent risk of a heterologous infection, with live vaccines reducing and inactivated vaccines (given on their own or with a live vaccine), increasing the risk. We used the self-controlled case-series method, which automatically controls for the individual level confounding to which such cohort studies are prone, to test this hypothesis. We compared the relative incidence (RI) of infections post-vaccination in two calendar periods in England; in Period 1 (September 2002-August 2006) live measles, mumps, rubella (MMR) vaccine was given on its own and in Period 2 (September 2006-April 2010) inactivated vaccines (7-valent pneumococcal conjugate vaccine (PCV7) and sometimes the combined Haemophilus influenzae type b/meningococcal group C vaccine (Hib-MenC)) were given concomitantly with MMR. Admissions for an infection of the upper or lower respiratory tract, gastrointestinal system or other site in children aged 11-23 months were selected from the Hospital Episode Statistics database in England and linked to child health immunisation histories. The analysis included a total of 24,144 infections in 21,067 children in Period 1 and 36,880 in 31,616 children in Period 2. The RI of admission for any infection in Period I was 1.00 (95% confidence interval 0.95-1.06) compared with 0.95 (95% confidence interval 0.90-1.00) in Period 2. Comparing the two periods showed no evidence of a difference in the relative incidence estimates with a ratio of RI of 0.94 (95% confidence interval 0.87-1.02), RIs within 90 days of vaccination were 0,94 (0.91-0.97) in Period 1 and 0.94 (0.91-0.97) in Period 2, consistent with a temporary healthy vaccinee effect. In conclusion, we found no evidence to support the hypothesis that there is a reduction in heterologous infections after MMR on its own or an increase after MMR given concomitantly with an inactivated vaccine. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Andrews, Nick; Walker, Jemma L.] Publ Hlth England, Stat Modelling & Econ Dept, 61 Colindale Ave, London NW9 5EQ, England.
   [Thomas, Sara L.; Walker, Jemma L.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Keppel St, London, England.
   [Stowe, Julia; Miller, Elizabeth] Publ Hlth England, Immunisat & Countermeasures, 61 Colindale Ave, London, England.
RP Andrews, N (reprint author), Publ Hlth England, Stat Modelling & Econ Dept, 61 Colindale Ave, London NW9 5EQ, England.
EM nick.andrews@phe.gov.uk
OI Stowe, Julia/0000-0002-3999-6461
FU National Institute for Health Research Health Protection Research Unit
   in Immunisation at the London School of Hygiene and Tropical Medicine;
   Public Health England
FX ST and JW are funded by the National Institute for Health Research
   Health Protection Research Unit in Immunisation at the London School of
   Hygiene and Tropical Medicine in partnership with Public Health England
   https://www.nihr.ac.uk/about-usi
   how-we-are-managediour-structure/researchihealth-protection-research-uni
   ts.htm The views expressed are those of the authors and not necessarily
   those of the NHS, the NIHR, the Department of Health, or Public Health
   England. No funding bodies had any role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Andrews N, 2010, VACCINE, V28, P7215, DOI 10.1016/j.vaccine.2010.08.062
   Bardenheier BH, 2017, CLIN INFECT DIS, V65, P729, DOI 10.1093/cid/cix442
   Djuretic T, 1998, J INFECTION, V37, P54, DOI 10.1016/S0163-4453(98)90604-1
   Higgins JPT, SYSTEMATIC REV NONSP
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Lau DT, 2012, BMJ-BRIT MED J, V26, P606, DOI DOI 10.1136/BMJ.I4515
   Miller E, 2003, ARCH DIS CHILD, V88, P222, DOI 10.1136/adc.88.3.222
   Saadatian-Elahi M, 2016, VACCINE, V34, P3923, DOI 10.1016/j.vaccine.2016.06.020
   Sorup S, 2016, VACCINE, V34, P6172, DOI 10.1016/j.vaccine.2016.11.005
   Sorup S, 2014, JAMA-J AM MED ASSOC, V311, P826, DOI 10.1001/jama.2014.470
   Stowe J, 2009, VACCINE, V27, P1422, DOI 10.1016/j.vaccine.2008.12.038
   Thorrington D, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1004-z
   Tielemans SMAJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3862
   Virtanen M, 2000, PEDIATRICS, V106, part. no., DOI 10.1542/peds.106.5.e62
   Whitaker HJ, 2018, STAT MED, V37, P643, DOI 10.1002/sim.7536
NR 15
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5211
EP 5217
DI 10.1016/j.vaccine.2019.07.059
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300010
PM 31375437
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Chantler, T
   Letley, L
   Paterson, P
   Yarwood, J
   Saliba, V
   Mounier-Jack, S
AF Chantler, Tracey
   Letley, Louise
   Paterson, Pauline
   Yarwood, Joanne
   Saliba, Vanessa
   Mounier-Jack, Sandra
TI Optimising informed consent in school-based adolescent vaccination
   programmes in England: A multiple methods analysis
SO VACCINE
LA English
DT Article
DE Adolescence; Vaccination; Immunisation; Multiple-methods research;
   Informed consent; Communication
ID HPV VACCINE; INTERVENTION; DAUGHTERS; STRATEGY; PARENTS
AB The process of obtaining informed consent for school-based adolescent immunisation provides an opportunity to engage families. However, the fact that parental consent needs to be obtained remotely adds complexity to the process and can have a detrimental effect on vaccine uptake. We conducted a multiple methods analysis to examine the practice of obtaining informed consent in adolescent immunisation programmes. This involved a thematic analysis of consent related data from 39 interviews with immunisation managers and providers collected as part of a 2017 service evaluation of the English adolescent girls' HPV vaccine programme and a descriptive statistical analysis of data from questions related to consent included in a 2017 survey of parents' and adolescents' attitudes to adolescent vaccination. The findings indicated that the non-return of consent forms was a significant logistical challenge for immunisation teams, and some were piloting opt-out consent mechanisms, increasing the proportion of adolescents consenting for their own immunisations, and introducing electronic consent. Communicating vaccine related information to parents and schools and managing uncertainties about obtaining adolescent self-consent for vaccination were the main practical challenges encountered. Survey data showed that parents and adolescents generally agreed on vaccine decisions although only 32% of parents discussed vaccination with their teenager. Parental awareness about the option for adolescents to self-consent for vaccination was limited and adolescents favoured leaving the decision-making to parents. From the interviews and variability of consent forms it was evident that health professionals were not always clear about the best way to manage the consent process. Some were also unfamiliar with self-consent processes and lacked confidence in assessing for 'Gillick competency'. Developing pathways and related interventions to improve the logistics and practice of consent in school-based adolescent immunisation programmes could help improve uptake. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Chantler, Tracey; Mounier-Jack, Sandra] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Dept Global Hlth & Dev, London, England.
   [Letley, Louise; Yarwood, Joanne; Saliba, Vanessa] Publ Hlth England, Dept Immunisat Hepatitis & Blood Safety, London, England.
   [Paterson, Pauline] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, London, England.
RP Chantler, T (reprint author), London Sch Hyg & Trop Med, 15-17 Tavistock Pl, London WC1H 9SH, England.
EM tracey.chantler@lshtm.ac.uk
OI Chantler, Tracey/0000-0001-7776-7339
FU National Institute for Health Research Health Protection Research Unit
   (NIHR HPRU) in Immunisation at the London School of Hygiene and Tropical
   Medicine [HPRU-2012-10096]; Public Health England (PHE)
FX The research was funded by the National Institute for Health Research
   Health Protection Research Unit (NIHR HPRU) in Immunisation (Grant
   reference: HPRU-2012-10096) at the London School of Hygiene and Tropical
   Medicine in partnership with Public Health England (PHE). The views
   expressed are those of the author(s) and not necessarily those of the
   NHS, the NIHR, the Department of Health or Public Health England.
CR Audrey S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021321
   Bassani DG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S30
   Bentley C., 2015, TACKLING GAPS INEQUA
   Boyce T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043416
   Brabin L, 2008, BRIT MED J, V336, P1056, DOI 10.1136/bmj.39541.534109.BE
   Brabin L, 2011, VACCINE, V29, P3192, DOI 10.1016/j.vaccine.2011.02.038
   Caskey RN, 2013, J PEDIATR INFECT DIS, V2, P198, DOI 10.1093/jpids/pit001
   Cates JR, 2011, SOC MARK Q, V17, P4, DOI 10.1080/15245004.2010.546943
   Ferrer HB, 2016, J PUBLIC HEALTH-UK, V38, P569, DOI 10.1093/pubmed/fdv073
   Ferrer HB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-700
   Fiordelli M, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2430
   Forster AS, 2017, BRIT J CANCER, V117, P1121, DOI 10.1038/bjc.2017.284
   Fu LY, 2014, VACCINE, V32, P1901, DOI 10.1016/j.vaccine.2014.01.091
   Gillick V., 1985, W NORFOLK WISBECH AR
   Golden SD, 2014, HEALTH EDUC BEHAV, V41, P625, DOI 10.1177/1090198114531773
   Gottvall M, 2015, HEALTH CARE ANAL, V23, P50, DOI 10.1007/s10728-012-0237-9
   Jones R, 2018, YEAR 9 TEENAGE BOOST
   Kabakama S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3517-8
   Katz ML, 2014, J CANCER EDUC, V29, P318, DOI 10.1007/s13187-013-0604-8
   Khairat S, 2018, JMIR RES PROTOC, V7, P87, DOI 10.2196/11239
   Kharbanda EO, 2011, VACCINE, V29, P2537, DOI 10.1016/j.vaccine.2011.01.065
   Li LC, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-11
   Mak DB, 2011, AUST NZ J PUBL HEAL, V35, P89, DOI 10.1111/j.1753-6405.2010.00669.x
   Marshall HS, 2014, VACCINE, V32, P2434, DOI 10.1016/j.vaccine.2014.02.098
   McDonald PW, 2007, HEALTH PROMOT PRACT, V8, P140, DOI 10.1177/1524839906298494
   Moon Margaret, 2012, Virtual Mentor, V14, P805, DOI 10.1001/virtualmentor.2012.14.10.msoc1-1210
   Opel DJ, 2009, ARCH PEDIAT ADOL MED, V163, P432, DOI 10.1001/archpediatrics.2009.42
   Paterson P, 2019, J PUBLIC HLTH
   Paul P, 2014, VACCINE, V32, P320, DOI 10.1016/j.vaccine.2013.11.070
   Perman S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4168-0
   Public Health England, 2017, HUM PAP HPV VACC COV
   Public Health England, 2018, ROUT IMM SCH
   Public Health England, 2016, HUM PAP HPV VACC COV
   Public Health England, 2013, CONS GREEN BOOK GREE
   Public Health England, 2018, PAT GROUP DIR ADM HU
   Reiter PL, 2012, J BEHAV MED, V35, P651, DOI 10.1007/s10865-012-9397-1
   Robbins SCC, 2011, VACCINE, V29, P9588, DOI 10.1016/j.vaccine.2011.10.033
   Seok J, 2018, PUBLIC HEALTH, V164, P128, DOI 10.1016/j.puhe.2018.08.002
   Skinner SR, 2000, AUST NZ J PUBL HEAL, V24, P298, DOI 10.1111/j.1467-842X.2000.tb01572.x
   Spear HJ, 2004, PUBLIC HEALTH NURS, V21, P144, DOI 10.1111/j.0737-1209.2004.021208.x
   Starling R, 2014, J CONS HLTH INTERNET, V18, P226, DOI 10.1080/15398285.2014.931771
   Stewart P, 1997, CAN J PUBLIC HEALTH, V88, P192, DOI 10.1007/BF03403886
   Stockwell MS, 2012, AM J PUBLIC HEALTH, V102, pE15, DOI 10.2105/AJPH.2011.300331
   Stretch R, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-254
   Unti LM, 1997, J SCHOOL HEALTH, V67, P265, DOI 10.1111/j.1746-1561.1997.tb03446.x
   Vanderpool RC, 2015, AM J PREV MED, V49, P317, DOI 10.1016/j.amepre.2015.05.001
   Wood F, 2011, J MED ETHICS, V37, P466, DOI 10.1136/jme.2010.038562
   World Health Organisation, 2014, CONS REG CONS VACC C
   World Health Organization, ADOLESCENT HEALTH
NR 49
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5218
EP 5224
DI 10.1016/j.vaccine.2019.07.061
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300011
PM 31351797
OA Other Gold
DA 2020-05-12
ER

PT J
AU Haredy, AM
   Takei, M
   Iwamoto, S
   Ohno, M
   Kosaka, M
   Hirota, K
   Koketsu, R
   Okuno, T
   Ikuta, K
   Yamanishi, K
   Ebina, H
AF Haredy, Ahmad M.
   Takei, Michihiro
   Iwamoto, Shin-ichi
   Ohno, Masafumi
   Kosaka, Mitsuyo
   Hirota, Kazue
   Koketsu, Ritsuko
   Okuno, Toshiomi
   Ikuta, Kazuyoshi
   Yamanishi, Koichi
   Ebina, Hirotaka
TI Quantification of a cell-mediated immune response against varicella
   zoster virus by assessing responder CD4(high) memory cell proliferation
   in activated whole blood cultures
SO VACCINE
LA English
DT Article
DE VZV-specific CD4 memory T cells; Herpes zoster immune response; VZV cell
   mediated immunity; Memory response; Whole blood assay; CD4(high)
ID CD4(+) T-CELLS; HERPES-ZOSTER; INTERFERON-GAMMA; OKA STRAIN; SKIN-TEST;
   ANTIGEN; ASSAY; VZV; FREQUENCIES; INFECTION
AB Background: Herpes zoster (HZ) is caused by reactivation of a latent varicella zoster virus (VZV). The potential to develop HZ increases with age due to waning of memory cell-mediated immunity (CMI), mainly the CD4 response. Therefore, VZV-CD4-memory T cells (CD4-M) count in blood could serve as a barometer for HZ protection. However, direct quantification of these cells is known to be difficult because they are few in number in the blood. We thus developed a method to measure the proliferation level of CD4-M cells responding to VZV antigen in whole blood culture.
   Methods: Blood samples were collected from 32 children (2-15 years old) with or without a history of varicella infection, 18 young adults (28-45 years old), and 80 elderly (50-86 years old) with a history of varicella infection. The elderly group was vaccinated, and blood samples were taken 2 months and 1 year after VZV vaccination. Then, 1 mL of blood was mixed with VZV, diluted 1/10 in medium, and cultured. CD4-M cells were identified and measured by flow cytometry.
   Results: There was distinct proliferation of CD3(+)CD4(high)CD45RA(-)RO(+) (CD4(high)-M) cells specific to VZV antigen at day 9. The majority of CD4(high)-M cells had the effector memory phenotype CCR7(-) and was granzyme B-positive. CD48(high)-M cells were detected in blood culture from varicella-immune but not varicella-non-immune children. Meanwhile, a higher level of CD4(high)-M proliferation was observed in young adults than in the elderly. The CD4(high)-M proliferation level was boosted 2 months after VZV vaccination and maintained for at least 1 year in the elderly.
   Conclusion: Quantifying VZV responder CD4(high)-M cell proliferation is a convenient way to measure VZV CMI using small blood volumes. Our method can be applied to measure VZV vaccine-induced CMI in the elderly. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Haredy, Ahmad M.; Kosaka, Mitsuyo; Hirota, Kazue; Koketsu, Ritsuko; Ikuta, Kazuyoshi; Yamanishi, Koichi; Ebina, Hirotaka] Osaka Univ BIKEN, Res Fdn Microbial Dis, Biken Ctr Innovat Vaccine Res & Dev, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.
   [Takei, Michihiro] Takei Clin, Osaka, Japan.
   [Iwamoto, Shin-ichi] Iwamoto Med Clin, Osaka, Japan.
   [Ohno, Masafumi] Ohno Clin, Osaka, Japan.
   [Okuno, Toshiomi] Hyogo Coll Med, Dept Microbiol, Nishinomiya, Hyogo, Japan.
RP Haredy, AM (reprint author), Osaka Univ BIKEN, Res Fdn Microbial Dis, Biken Ctr Innovat Vaccine Res & Dev, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.
EM mahmad@mail.biken.or.jp
OI Haredy, Ahmad/0000-0002-9548-0742
FU Research Foundation for Microbial Diseases of Osaka University (BIKEN)
FX This work was completely funded by the Research Foundation for Microbial
   Diseases of Osaka University (BIKEN).
CR Abebe F, 2012, CLIN EXP IMMUNOL, V169, P213, DOI 10.1111/j.1365-2249.2012.04614.x
   Abendroth A, 2001, J VIROL, V75, P6183, DOI 10.1128/JVI.75.13.6183-6192.2001
   Abendroth A, 2010, CURR TOP MICROBIOL, pXIV
   Asanuma H, 2000, J INFECT DIS, V181, P859, DOI 10.1086/315347
   BERGER R, 1981, INFECT IMMUN, V32, P24, DOI 10.1128/IAI.32.1.24-27.1981
   Campbell TM, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006999
   Deenadayalan Anbarasu, 2013, BMC Res Notes, V6, P120, DOI 10.1186/1756-0500-6-120
   Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567
   Godoy-Ramirez K, 2004, J IMMUNOL METHODS, V292, P1, DOI 10.1016/j.jim.2004.04.028
   HAYWARD A, 1989, Viral Immunology, V2, P175, DOI 10.1089/vim.1989.2.175
   HAYWARD A, 1992, J INFECT DIS, V166, P260, DOI 10.1093/infdis/166.2.260
   HAYWARD AR, 1990, J VIROL, V64, P651, DOI 10.1128/JVI.64.2.651-655.1990
   HAYWARD AR, 1994, J IMMUNOL METHODS, V170, P27, DOI 10.1016/0022-1759(94)90242-9
   Jones L, 2006, J VIROL, V80, P9772, DOI 10.1128/JVI.00564-06
   Juno JA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00019
   Landmeier S, 2007, CANCER RES, V67, P8335, DOI 10.1158/0008-5472.CAN-06-4426
   Levin MJ, 2008, J INFECT DIS, V197, P825, DOI 10.1086/528696
   Levin MJ, 2003, J INFECT DIS, V188, P1336, DOI 10.1086/379048
   Levin MJ, 1998, J INFECT DIS, V178, pS109, DOI 10.1086/514264
   Leyten EMS, 2007, CLIN VACCINE IMMUNOL, V14, P880, DOI 10.1128/CVI.00132-07
   Milikan JCM, 2009, INVEST OPHTH VIS SCI, V50, P743, DOI 10.1167/iovs.08-2611
   Nomura LE, 2000, CYTOMETRY, V40, P60, DOI 10.1002/(SICI)1097-0320(20000501)40:1<60::AID-CYTO8>3.0.CO;2-J
   Novak EJ, 2001, INT IMMUNOL, V13, P799, DOI 10.1093/intimm/13.6.799
   Okuno Y, 2013, EPIDEMIOL INFECT, V141, P706, DOI 10.1017/S0950268812002671
   Otani N, 2012, J IMMUNOL METHODS, V377, P53, DOI 10.1016/j.jim.2012.01.003
   Otani N, 2009, J IMMUNOL METHODS, V351, P71, DOI 10.1016/j.jim.2009.09.010
   Oxman MN, 2009, J AM OSTEOPATH ASSOC, V109, pS13
   Park HB, 2004, J RHEUMATOL, V31, P2151
   Patterson-Bartlett J, 2007, VACCINE, V25, P7087, DOI 10.1016/j.vaccine.2007.07.051
   PETROVSKY N, 1995, J IMMUNOL METHODS, V186, P37, DOI 10.1016/0022-1759(95)00127-V
   Phetsouphanh C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01729
   Sadaoka K, 2008, J INFECT DIS, V198, P1327, DOI 10.1086/592219
   Sei JJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00553
   SHARP M, 1992, J INFECT DIS, V165, P852, DOI 10.1093/infdis/165.5.852
   Silva D, 2013, ACTA TROP, V127, P75, DOI 10.1016/j.actatropica.2013.04.002
   Smith JG, 2001, CLIN DIAGN LAB IMMUN, V8, P871, DOI 10.1128/CDLI.8.5.871-879.2001
   Soong W, 2000, J VIROL, V74, P1864, DOI 10.1128/JVI.74.4.1864-1870.2000
   Svahn A, 2003, J IMMUNOL METHODS, V277, P17, DOI 10.1016/S0022-1759(03)00111-X
   Tau G, 1999, ALLERGY, V54, P1233, DOI 10.1034/j.1398-9995.1999.00099.x
   Toyama N, 2009, J MED VIROL, V81, P2053, DOI 10.1002/jmv.21599
   Trannoy E, 2000, VACCINE, V18, P1700, DOI 10.1016/S0264-410X(99)00510-1
   van der Heiden M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00046
   Vossen MTM, 2004, J INFECT DIS, V190, P72, DOI 10.1086/421277
   Weinberg A, 2017, J IMMUNOL, V199, P604, DOI 10.4049/jimmunol.1700290
   Weinberg A, 2009, J INFECT DIS, V200, P1068, DOI 10.1086/605611
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5225
EP 5232
DI 10.1016/j.vaccine.2019.07.068
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300012
PM 31358406
OA Other Gold
DA 2020-05-12
ER

PT J
AU Guidry, JPD
   Carlyle, KE
   Perrin, PB
   LaRose, JG
   Ryan, M
   Messner, M
AF Guidry, Jeanine P. D.
   Carlyle, Kellie E.
   Perrin, Paul B.
   LaRose, Jessica G.
   Ryan, Mark
   Messner, Marcus
TI A path model of psychosocial constructs predicting future Zika vaccine
   uptake intent
SO VACCINE
LA English
DT Article
DE Zika; Zika vaccine; EPPM; Path modeling
ID HEALTH BELIEF MODEL; HUMAN-PAPILLOMAVIRUS; INFLUENZA VACCINATION; FIT
   INDEXES; VIRUS; ACCEPTABILITY; IMMUNIZATION; HESITANCY; PERCEPTIONS;
   ACCEPTANCE
AB Objective: The recent Zika virus outbreak, while no longer an international public health emergency, is still a serious threat, particularly to pregnant women and babies born to pregnant women infected with the virus. This study examined the predictive effects of psychosocial constructs on self-reported intent to get a future Zika vaccine among women of reproductive age.
   Methods: Data were collected using an online survey with a representative sample of 339 women ages 18-49 from the continental United States. The survey addressed variables originating with the Extended Parallel Processing Model (EPPM) as related to future Zika vaccine uptake intent.
   Results: Three quarters of all respondents reported intention to get a future Zika vaccine. Path modeling revealed a direct effect of perceived susceptibility, self-efficacy, and response efficacy on future Zika vaccine uptake intent, as well as an indirect effect of perceived susceptibility through both self-efficacy and response efficacy. In addition, the final model showed an indirect effect of perceived severity on Zika vaccine uptake intent through self-efficacy and response efficacy and accounted for 54.6% of the variance in vaccination intent.
   Conclusions: These findings have implications for future Zika vaccine promotion campaigns.
   This study confirms the importance of perceived susceptibility, self-efficacy, and response efficacy for use in Zika vaccine uptake campaigns: in addition, when using perceived severity, both self-efficacy and response efficacy should be considered in message design. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Guidry, Jeanine P. D.; Carlyle, Kellie E.; Perrin, Paul B.; LaRose, Jessica G.; Ryan, Mark; Messner, Marcus] Virginia Commonwealth Univ, Richmond, VA 23284 USA.
RP Guidry, JPD (reprint author), Virginia Commonwealth Univ, Richmond, VA 23284 USA.
EM guidryjd@vcu.edu
RI Perrin, Paul/L-5373-2015
OI Perrin, Paul/0000-0003-2070-215X; Guidry, Jeanine/0000-0002-6903-7464
FU Department of Health Behavior and Policy, Virginia Commonwealth
   University
FX Provided by Department of Health Behavior and Policy, Virginia
   Commonwealth University.
CR AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Ajzen I, 1985, INTENTIONS ACTIONS T
   Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660
   Bennett KK, 2012, J SOC PSYCHOL, V152, P480, DOI 10.1080/00224545.2011.639408
   BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238
   Betsch C, 2015, P NATL ACAD SCI USA, V112, pE6725, DOI 10.1073/pnas.1516350112
   Betsch C, 2013, HEALTH PSYCHOL, V32, P146, DOI 10.1037/a0027387
   Brabin L, 2006, VACCINE, V24, P3087, DOI 10.1016/j.vaccine.2006.01.048
   Brewer NT, 2007, PREV MED, V45, P107, DOI 10.1016/j.ypmed.2007.05.013
   Byrne B.M., 1994, BASIC CONCEPTS APPL
   Cameron KA, 2009, HEALTH COMMUN, V24, P316, DOI 10.1080/10410230902889258
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Centers for Disease Control and Prevention, 2017, ZIK VIR
   Chapman GB, 1999, PREV MED, V29, P249, DOI 10.1006/pmed.1999.0535
   Chen MF, 2011, J COMMUN HEALTH NURS, V28, P29, DOI 10.1080/07370016.2011.539087
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Ding H, 2011, AM J OBSTET GYNECOL, V204, pS96, DOI 10.1016/j.ajog.2011.03.003
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Englund JA, 2003, VACCINE, V21, P3460, DOI 10.1016/S0264-410X(03)00351-7
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Fisher BM, 2011, AM J OBSTET GYNECOL, V204, pS107, DOI 10.1016/j.ajog.2011.02.041
   Fridman D, 2011, AM J OBSTET GYNECOL, V204, pS124, DOI 10.1016/j.ajog.2011.04.011
   Frieden TR, 2016, JAMA-J AM MED ASSOC, V316, P1443, DOI 10.1001/jama.2016.11941
   Gargano LM, 2011, HUM VACCINES, V7, P89, DOI 10.4161/hv.7.1.13460
   Gerend MA, 2012, ANN BEHAV MED, V44, P171, DOI 10.1007/s12160-012-9366-5
   Gorman JR, 2012, VACCINE, V31, P213, DOI 10.1016/j.vaccine.2012.10.064
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Johnson KL, 2017, J COMMUN HEALTH, V42, P522, DOI 10.1007/s10900-016-0284-5
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Kenny D.A., 2014, MEASURING MODEL FIT
   Krieger JL, 2013, HEALTH COMMUN, V28, P5, DOI 10.1080/10410236.2012.734914
   Kumar S, 2012, HEALTH EDUC BEHAV, V39, P229, DOI 10.1177/1090198111415105
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lindley MC, 2006, AM J PREV MED, V31, P281, DOI 10.1016/j.amepre.2006.06.025
   Lipsitch M, 2016, SCIENCE, V353, P1094, DOI 10.1126/science.aai8126
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P405, DOI 10.1016/S1473-3099(16)00138-9
   Maurer J, 2009, VACCINE, V27, P5732, DOI 10.1016/j.vaccine.2009.07.080
   Meyers L. S., 2013, APPL MULTIVARIATE RE
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Mo PKH, 2015, HEALTH EDUC RES, V30, P706, DOI 10.1093/her/cyv038
   Montano D. E., 2015, HLTH BEHAV THEORY RE, V5, P95
   Muhsen K, 2012, VACCINE, V30, P2109, DOI 10.1016/j.vaccine.2012.01.044
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Myers LB, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-15
   Nan XL, 2012, HEALTH COMMUN, V27, P559, DOI 10.1080/10410236.2011.617243
   NIH, 2017, PHAS 2 ZIK VACC TRIA
   O'Keefe DJ, 2012, HEALTH COMMUN, V27, P776, DOI 10.1080/10410236.2011.640974
   Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013
   Setbon M, 2010, EUR J PUBLIC HEALTH, V20, P490, DOI 10.1093/eurpub/ckq054
   Shahrabani S, 2012, HEALTH EDUC BEHAV, V39, P612, DOI 10.1177/1090198111427411
   Siu W, 2008, PSYCHOL REP, V102, P539, DOI 10.2466/PR0.102.2.539-550
   Southwell BG, 2018, EMERG INFECT DIS, V24, P938, DOI 10.3201/eid2405.171570
   Stockwell MS, 2011, PUBLIC HEALTH REP, V126, P24, DOI 10.1177/00333549111260S204
   Tabachnick BG, 2001, USING MULTIVARIATE S
   Teitler-Regev Sharon, 2011, Adv Prev Med, V2011, P353207, DOI 10.4061/2011/353207
   Vogel G, 2016, SCIENCE, V351, P110, DOI 10.1126/science.351.6269.110
   Wei FF, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-18
   Wheldon CW, 2015, J HEALTH PSYCHOL, V20, P427, DOI 10.1177/1359105313502693
   WITTE K, 1992, COMMUN MONOGR, V59, P329, DOI 10.1080/03637759209376276
   World Health Organization, 2017, ZIK VIR COMPL
   World Health Organization, 2011, GLOB PREV AN 2011
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 65
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5233
EP 5241
DI 10.1016/j.vaccine.2019.07.064
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300013
PM 31375439
DA 2020-05-12
ER

PT J
AU Carter, ED
   Tam, Y
   Walker, N
AF Carter, Emily D.
   Tam, Yvonne
   Walker, Neff
TI Impact of vaccination delay on deaths averted by pneumococcal conjugate
   vaccine: Modeled effects in 8 country scenarios
SO VACCINE
LA English
DT Article
DE Pneumococcal conjugate vaccine; Vaccination delay; Vaccination; Timing;
   Child mortality; Mathematical model
ID AGE-APPROPRIATE VACCINATION; HERD-IMMUNITY; MORTALITY; TIMELINESS;
   COVERAGE; CHILDREN; LIST
AB Delay in vaccination from schedule has been frequently documented and varies by vaccine, dose, and setting. Vaccination delay may result in the failure to prevent deaths that would have been averted by on-schedule vaccination.
   We constructed a model to assess the impact of delay in vaccination with pneumococcal conjugate vaccine (PCV) on under-five mortality. The model accounted for the week of age-specific risk of pneumococcal mortality, direct effect of vaccination, and herd protection. For each model run, a cohort of children were exposed to the risk of mortality and protective effect of PCV for each week of age from birth to age five. The model was run with and without vaccination delay and difference in number of deaths averted was calculated. We applied the model to eight country-specific vaccination scenarios, reflecting variations in observed vaccination delay, PCV coverage, herd effect, mortality risk, and vaccination schedule. As PCV is currently being scaled up in India, we additionally evaluated the impact of vaccination delay in India under various delay scenarios and coverage levels.
   We found deaths averted by PCV with and without delay to be comparable in all of the country scenarios when accounting for herd protection. In India, the greatest relative difference in deaths averted was observed at low coverage levels and greatest absolute difference was observed around 60% vaccination coverage. Under moderate delay scenarios, vaccination delay had modest impact on deaths averted by PCV in India across levels of coverage or vaccination schedule. Without accounting for herd protection, vaccination delay resulted in much greater failure to avert deaths.
   Our model suggests that realistic vaccination delay has a minimal impact on the number of deaths averted by PCV when accounting for herd effect. High population coverage can largely over-ride the deleterious effect of vaccination delay through herd protection. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Carter, Emily D.; Tam, Yvonne; Walker, Neff] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Int Programs, 615 North Wolfe St, Baltimore, MD 21205 USA.
RP Carter, ED (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Inst Int Programs, 615 North Wolfe St, Baltimore, MD 21205 USA.
EM ecarter@jhu.edu
OI Carter, Emily/0000-0003-1649-5274; Walker, Neff/0000-0003-3526-2978
FU Bill and Melinda Gates FoundationGates Foundation [OPP1117555]
FX This work was supported by the Bill and Melinda Gates Foundation [grant
   number OPP1117555].
CR Amouzou A, 2010, INT J EPIDEMIOL, V39, P186, DOI 10.1093/ije/dyq034
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129
   Clark A., 2015, COMMUNICATION    AUG
   Clark A, 2009, LANCET, V373, P1543, DOI 10.1016/S0140-6736(09)60317-2
   David L, 2008, CONTROL COMMUNICABLE
   Davis MV, 2013, DISASTER MED PUBLIC, V7, P578, DOI 10.1017/dmp.2013.108
   Dayan GH, 2006, AM J EPIDEMIOL, V163, P561, DOI 10.1093/aje/kwj074
   Delrieu I, 2015, VACCINE, V33, P7290, DOI 10.1016/j.vaccine.2015.10.107
   Fadnes LT, 2011, VACCINE, V29, P3564, DOI 10.1016/j.vaccine.2011.02.093
   Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007
   Friberg IK, 2010, INT J EPIDEMIOL, V39, P11, DOI 10.1093/ije/dyq017
   Gallo G, 2002, VACCINE, V20, P993, DOI 10.1016/S0264-410X(01)00449-2
   GARCIA JM, 2016, EUROSURVEILLANCE, V21, DOI DOI 10.3390/MOLECULES21121729
   Gavi, 2017, ANN PROGR REPORT
   Hughes MM, 2016, VACCINE, V34, P933, DOI 10.1016/j.vaccine.2015.12.061
   John TJ, 2000, EUR J EPIDEMIOL, V16, P601, DOI 10.1023/A:1007626510002
   Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348
   Larsen DA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S34
   Lee LA, 2013, VACCINE, V31, pB61, DOI 10.1016/j.vaccine.2012.11.035
   Liu L, 2015, UNPUB
   Lucero MG, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004977.pub2
   Luman ET, 2005, JAMA-J AM MED ASSOC, V293, P1204, DOI 10.1001/jama.293.10.1204
   Ricca J, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S35
   Rudan I, 2013, J GLOB HEALTH, V3, DOI 10.7189/jogh.03.010401
   Russell FM, 2011, GLOBAL REV DISTRIBUT
   Shrivastwa N, 2016, PEDIATR INFECT DIS J, V35, P955, DOI 10.1097/INF.0000000000001223
   Tauil MD, 2016, VACCINE, V34, P2635, DOI 10.1016/j.vaccine.2016.04.016
   UNICEF, 2016, ONE IS TOO MAN END C
   Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2
NR 29
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5242
EP 5249
DI 10.1016/j.vaccine.2019.07.063
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300014
PM 31375441
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Trent, MJ
   Zhang, EJ
   Chughtai, AA
   MacIntyre, CR
AF Trent, Mallory J.
   Zhang, Elissa J.
   Chughtai, Abrar Ahmad
   MacIntyre, C. Raina
TI Parental opinions towards the "No Jab, No Pay" policy in Australia
SO VACCINE
LA English
DT Article
DE Vaccine; Mandatory immunisation; Vaccine hesitancy; Incentive; Parent;
   Child health
ID SCHOOL IMMUNIZATION REQUIREMENTS; VACCINE REFUSAL; UNITED-STATES;
   MEDICAL EXEMPTIONS; CHILD-CARE; RATES; ASSOCIATION; INCENTIVES;
   GOVERNMENT; HESITANCY
AB Background: In 2016, Australia introduced the "No Jab, No Pay" legislation, which removed the option of non-medical exemptions from the vaccination requirements to receive certain family and child care tax benefits. We aimed to gauge parental support for "No Jab, No Pay" and explore how it has impacted parental attitudes towards vaccination, particularly among families that are reliant on the tax benefits linked to vaccination under "No Jab, No Pay".
   Methods: An online survey distributed to parents with children under 5 in Australia assessed parental knowledge and opinions towards childhood vaccination and the "No Jab, No Pay" policy.
   Results: A total of 411 parents completed the survey. The majority of parents reported their child was either fully vaccinated or they intended to fully vaccinate. Eighty-two percent of parents were in favour of "No Jab, No Pay." The belief that vaccine-preventable diseases are a significant risk to unvaccinated children was a predictor of supporting the "No jab, No Pay" policy (AOR = 5.95, 95% CI = [3.60, 10.94], p < 0.001). Parents that depend on the financial benefits associated with "No jab, No Pay" and parents that utilize child care services were significantly more likely to reconsider vaccination, if they previously hesitated or objected, because of the policy (AOR = 9.66, 95% CI = [4.98, 18.72], p < 0.001 and AOR = 2.09, 95% CI = [1.04, 4.17], p = 0.04).
   Conclusion: We found that there is widespread support for "No Jab, No Pay" among parents of young children, but parents that depend on the financial benefits or utilize child care services may be disproportionately affected by the policy. Childhood vaccination coverage in Australia could best be improved by increasing access to vaccination services and by imposing significant administrative barriers to obtaining non-medical exemptions. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Trent, Mallory J.; MacIntyre, C. Raina] Univ New South Wales, Fac Med, Kirby Inst, Biosecur Program, Sydney, NSW, Australia.
   [Zhang, Elissa J.; Chughtai, Abrar Ahmad] Univ New South Wales, Fac Med, Sch Publ Hlth & Community Med, Sydney, NSW, Australia.
RP Trent, MJ (reprint author), Univ New South Wales, Fac Med, Kirby Inst, Biosecur Program, Wallace Wurth Bldg Room 644, Kensington, NSW 2052, Australia.
EM mallory.trent@unsw.edu.au; elissa.zhang@student.unsw.edu.au;
   abrar.chughtai@unsw.edu.au; r.macintyre@unsw.edu.au
FU NHMRC Centre for Research Excellence, Integrated Systems for Epidemic
   Response (ISER)National Health and Medical Research Council of Australia
   [1107393]; NHMRC Principal Research FellowshipNational Health and
   Medical Research Council of Australia [1137582]
FX This study was supported by the NHMRC Centre for Research Excellence,
   Integrated Systems for Epidemic Response (ISER) (grant number 1107393).
   Raina MacIntyre is supported by a NHMRC Principal Research Fellowship,
   grant number 1137582.
CR Abrevaya J, 2011, J HEALTH ECON, V30, P966, DOI 10.1016/j.jhealeco.2011.06.003
   Adams J, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19940
   Australian Government Department of Education and Training, 2017, CHILD CAR FEE ASS SU
   Australian Government Department of Health, 2018, NAT VACC OBJ CONSC O
   Australian Government Department of Health, 2018, HIST COV DAT TABL AL
   Australian Government Department of Health, 2017, NO JAB NO PAY NEW IM
   Australian Government Department of Health, 2018, CHILDH IMM COV
   Australian Government Department of Health, 2017, COMMUN DIS INTEL, V41
   Baker R, 2010, PUBLIC OPIN QUART, V74, P711, DOI 10.1093/poq/nfq048
   Beard Frank H, 2016, Med J Aust, V204, P275
   Birnbaum MS, 2013, VACCINE, V31, P750, DOI 10.1016/j.vaccine.2012.11.092
   Blank NR, 2013, HEALTH AFFAIR, V32, P1282, DOI 10.1377/hlthaff.2013.0239
   Bond L, 2002, AUST NZ J PUBL HEAL, V26, P58, DOI 10.1111/j.1467-842X.2002.tb00272.x
   Centers for Disease Control and Prevention, 1999, JAMA-J AM MED ASSOC, V281, P1482, DOI DOI 10.1001/JAMA.281.16.1482-JWR0428-2-1
   Delamater PL, 2017, JAMA-J AM MED ASSOC, V318, P863, DOI 10.1001/jama.2017.9242
   Doherty M, 2016, VACCINE, V34, P6707, DOI 10.1016/j.vaccine.2016.10.025
   Erens B, 2014, J MED INTERNET RES, V16, P98, DOI 10.2196/jmir.3382
   Fraser AC, 2016, NSW PUB HLTH RES PRA, V26
   Gualano MR, 2018, VACCINE, V36, P3368, DOI 10.1016/j.vaccine.2018.04.029
   Haire B, 2018, J BIOETHIC INQ, V15, P199, DOI 10.1007/s11673-018-9841-1
   Hall J, 2002, HEALTH ECON, V11, P457, DOI 10.1002/hec.694
   Harmsen IA, 2012, VACCINE, V30, P4771, DOI 10.1016/j.vaccine.2012.05.034
   Haverkate M, 2012, EUROSURVEILLANCE, V17, P12
   Holleman B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164184
   IBM Corp, 2016, IBM SPSS STAT WIND V
   Kamoen N, 2011, DISCOURSE PROCESS, V48, P355, DOI 10.1080/0163853X.2011.578910
   Kerpelman LC, 2000, JAMA-J AM MED ASSOC, V284, P53, DOI 10.1001/jama.284.1.53
   Klapdor M, 2015, BUDGET REV 2015 16 J
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lawrence GL, 2004, VACCINE, V22, P2345, DOI 10.1016/j.vaccine.2003.10.038
   Lawrence Glenda L, 2004, Aust Fam Physician, V33, P568
   Lee C, 2016, VACCINE, V34, P3972, DOI 10.1016/j.vaccine.2016.06.048
   Looker C, 2011, B WORLD HEALTH ORGAN, V89, P371, DOI 10.2471/BLT.10.081901
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Maclntyre CR, 2017, CONVERS 2017
   McNeil MM, 2016, J ALLERGY CLIN IMMUN, V137, P868, DOI 10.1016/j.jaci.2015.07.048
   Najjar Z, 2014, WEST PAC SURVEILL RE, V5, DOI [10.5365/wpsar.2013.4.4.002, 10.5365/WPSAR.2013.4.4.002]
   NATHANSON N, 1995, AM J EPIDEMIOL, V142, P109, DOI 10.1093/oxfordjournals.aje.a117611
   Nathanson N, 1963, AM J EPIDEMIOL, V142, P7
   National Centre for Immunisation Research & Surveillance, 2017, NO JAB NO PLAY NO JA
   National Centre for Immunisation Research & Surveillance, 2017, SIGN EV IMM POL PRAC
   Omer SB, 2006, JAMA-J AM MED ASSOC, V296, P1757, DOI 10.1001/jama.296.14.1757
   Omer SB, 2012, NEW ENGL J MED, V367, P1170, DOI 10.1056/NEJMc1209037
   Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477
   Pearce A, 2015, VACCINE, V33, P3377, DOI 10.1016/j.vaccine.2015.04.089
   Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353
   Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470
   Salmon DA, 2015, LANCET INFECT DIS, V15, P872, DOI 10.1016/S1473-3099(15)00156-5
   Saul N, 2017, WEST PAC SURVEILL RE, V8, DOI [10.5365/wpsar.2016.7.3.006, 10.5365/WPSAR.2016.7.3.006]
   Stadlin S, 2012, J INFECT DIS, V206, P989, DOI 10.1093/infdis/jis436
   StataCorp, 2015, STAT STAT SOFTW REL
   Thomas S, 2018, VACCINE, V36, P2596, DOI 10.1016/j.vaccine.2018.03.072
   Vesikari T, 2012, CLIN MICROBIOL INFEC, V18, P57, DOI 10.1111/j.1469-0691.2012.03981.x
NR 53
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5250
EP 5256
DI 10.1016/j.vaccine.2019.07.066
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300015
PM 31371225
OA Other Gold
DA 2020-05-12
ER

PT J
AU Esteban-Vasallo, MD
   Dominguez-Berjon, MF
   Garcia-Riolobos, C
   Zoni, AC
   Torres, JLA
   Sanchez-Perruca, L
   Astray-Mochales, J
AF Esteban-Vasallo, M. D.
   Dominguez-Berjon, M. F.
   Garcia-Riolobos, C.
   Zoni, A. C.
   Arejula Torres, J. L.
   Sanchez-Perruca, L.
   Astray-Mochales, J.
TI Effect of mobile phone text messaging for improving the uptake of
   influenza vaccination in patients with rare diseases
SO VACCINE
LA English
DT Article
DE Influenza vaccines; Program evaluation; Rare diseases; Text messaging;
   Vaccination coverage
ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE WORKERS; HIGH-RISK SUBJECTS;
   SEASONAL INFLUENZA; COVERAGE; POPULATION; INTERVENTIONS; TEXT4HEALTH;
   TECHNOLOGY; REMINDERS
AB Objectives: Influenza vaccine is recommended in some chronic medical conditions, including several rare diseases. The objectives of the study were to assess the effect of text message reminders on influenza vaccination uptake of patients with selected rare diseases and delayed vaccination, and to describe their characteristics.
   Methods: Quasi-experimental pre-post intervention study performed along the 2016 influenza vaccination campaign in the Autonomous Community of Madrid. Unvaccinated patients diagnosed with a selected rare disease were targeted for intervention. SMS were sent to them at least one month after the beginning of the campaign, in four consecutive weeks. Those with no mobile phones available or no certainty of message reception, were assigned as controls. The association between the reception of the SMS and vaccination uptake was assessed using multiple poisson regression models.
   Results: Of 69.040 patients with delayed vaccination, 87.2% received an SMS reminder in the asigned contact mobile telephone. Global influenza vaccine coverage reached 41.3%. The uptake of influenza vaccine was significantly higher among those receiving the reminder (9.3% vs. 7.1% in the control group, p < 0.001). Those who received a SMS reminder were 30% more likely to uptake seasonal influenza vaccine. By sex and age, the reception of the reminder was associated with a significantly higher probability of vaccination in men >= 65 years with at least a concurrent chronic condition (IRR: 1.58, C195%: 1.25-2.00). Among women, this higher probability was detected in those between 14 and 64 years of age (IRR: 1.41, CI95%: 1.22-1.63), and >= 65 years without concurrent chronic conditions (IRR: 1.40, CI95%: 1.05-1.89).
   Conclusion: Although the intervention was modestly effective, it proved beneficial in some cases. It can be an additional strategy to improve vaccine uptake, since it is simple, feasible, affordable and easily scalable, particularly when immunization and target population data are available in population registries. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Esteban-Vasallo, M. D.; Dominguez-Berjon, M. F.; Garcia-Riolobos, C.; Zoni, A. C.] Autonomous Community Madrid, Serv Informes Salud & Estudios, Subdirecc Gen Epidemiol, Direcc Gen Salud Publ, Madrid, Spain.
   [Arejula Torres, J. L.; Sanchez-Perruca, L.] Autonomous Community Madrid, Direcc Tecn Sistemas Informac, Gerencia Adjunta Atenc Primaria, Madrid, Spain.
   [Astray-Mochales, J.] Autonomous Community Madrid, Serv Epidemiol, Subdirecc Gen Epidemiol, Direcc Gen Salud Publ, Madrid, Spain.
RP Esteban-Vasallo, MD (reprint author), San Martin de Porres 6, Madrid 28035, Spain.
EM maria.estebanv@salud.madrid.org
OI Dominguez-Berjon, Maria Felicitas/0000-0003-3551-0660; Esteban-Vasallo,
   Maria Dolores/0000-0002-3991-610X
FU Foundation for Biomedical Research and Innovation of Primary Care of the
   Community of Madrid (FIIBAP)
FX The translation of this publication was funded by the Foundation for
   Biomedical Research and Innovation of Primary Care of the Community of
   Madrid (FIIBAP) through the call for aid for translations/publications
   2017.
CR Ahlers-Schmidt CR, 2012, J MED INTERNET RES, V14, P253, DOI 10.2196/jmir.1976
   Astray-Mochales J, 2016, VACCINE, V34, P4898, DOI 10.1016/j.vaccine.2016.08.065
   Bangure D, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1470-6
   Bay SL, 2017, J PEDIATR HEALTH CAR, V31, P155, DOI 10.1016/j.pedhc.2016.06.007
   Direccion General De Salud Publica, 2016, CAL VAC AD
   Doherty M, 2016, VACCINE, V34, P6681, DOI 10.1016/j.vaccine.2016.11.015
   Dominguez-Berjon MF, 2008, GAC SANIT, V22, P179, DOI 10.1157/13123961
   Esposito S, 2016, HUM VACC IMMUNOTHER, V12, P801, DOI 10.1080/21645515.2015.1086046
   European Commission Dg Health And Food Safety, 2008, COMM RAR DIS EUR CHA
   Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1
   Haji A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2823-5
   Hall AK, 2015, ANNU REV PUBL HEALTH, V36, P393, DOI 10.1146/annurev-publhealth-031914-122855
   Herrett E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016604
   Hofstetter AM, 2015, AM J PREV MED, V48, P392, DOI 10.1016/j.amepre.2014.10.023
   Hofstetter AM, 2013, PREV MED, V57, P75, DOI 10.1016/j.ypmed.2013.04.007
   Househ M, 2013, STUD HEALTH TECHNOL, V183, P244, DOI 10.3233/978-1-61499-203-5-244
   Jimenez-Garcia R, 2014, VACCINE, V32, P4386, DOI 10.1016/j.vaccine.2014.06.074
   Jimenez-Garcia R, 2014, HUM VACC IMMUNOTHER, V10, P449, DOI 10.4161/hv.27152
   Jimenez-Garcia R, 2014, VACCINE, V32, P350, DOI 10.1016/j.vaccine.2013.11.040
   Kannisto KA, 2014, J MED INTERNET RES, V16, P100, DOI 10.2196/jmir.3442
   Kharbanda EO, 2009, AM J PUBLIC HEALTH, V99, P2176, DOI 10.2105/AJPH.2009.161364
   Morris J, 2015, J ADOLESCENT HEALTH, V56, pS27, DOI 10.1016/j.jadohealth.2015.01.010
   O'Leary ST, 2015, PEDIATRICS, V136, pE1220, DOI 10.1542/peds.2015-1089
   Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313
   Oliva J, 2018, INFLUENZA OTHER RESP, V12, P161, DOI 10.1111/irv.12499
   Peek STM, 2014, INT J MED INFORM, V83, P235, DOI 10.1016/j.ijmedinf.2014.01.004
   Rand CM, 2017, J ADOLESCENT HEALTH, V60, P113, DOI 10.1016/j.jadohealth.2016.09.011
   Regan AK, 2017, ANN FAM MED, V15, P507, DOI 10.1370/afm.2120
   Stockwell MS, 2012, JAMA-J AM MED ASSOC, V307, P1702, DOI 10.1001/jama.2012.502
   Stockwell MS, 2012, AM J PUBLIC HEALTH, V102, pE15, DOI 10.2105/AJPH.2011.300331
   Vann JCJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003941.pub3
   Zoni AC, 2015, PUBLIC HEALTH, V129, P271, DOI 10.1016/j.puhe.2014.12.013
NR 32
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5257
EP 5264
DI 10.1016/j.vaccine.2019.07.062
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300016
PM 31353257
DA 2020-05-12
ER

PT J
AU Neves, FPG
   Cardoso, NT
   Cardoso, CAA
   Teixeira, LM
   Riley, LW
AF Neves, Felipe P. G.
   Cardoso, Nayara T.
   Cardoso, Claudete A. A.
   Teixeira, Lucia M.
   Riley, Lee W.
TI Direct effect of the 13-valent pneumococcal conjugate vaccine use on
   pneumococcal colonization among children in Brazil
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Nasopharyngeal carriage; Serotypes;
   Antimicrobial resistance; Pneumococcal conjugate vaccine
ID STREPTOCOCCUS-PNEUMONIAE; CARRIAGE; SEROTYPES; DISEASE; RESISTANCE;
   IMPACT; PCV13; 6C
AB Background: The 13-valent pneumococcal conjugate vaccine (PCV13) has been commercially available in Brazil since 2010. We investigated the carriage prevalence, capsular types, and antimicrobial resistance among pneumococci isolated from children immunized with PCV13 in Brazil.
   Methods: We analyzed 500 children < 6 years old attending public (n = 270) and private (n = 230) clinics in Niteroi/Rj, Brazil, in 2014. We determined the antimicrobial susceptibility and capsular types for all isolates.
   Results: Thirty-eight (7.6%) of 500 children had received at least one PCV13 dose. Since only two (0.7%) of 270 children at the public clinic were vaccinated with PCV13, major analyses focused on 36 (15.7%) of 230 children attending private clinics. Nine (25%) of 36 children were pneumococcal carriers. Characteristics associated with carriage were age >= 2 years, cough/expectoration, and childcare center attendance (p <= 0.01). The capsular types found were 15B/C (n = 2), 6C, 11A/D, 16F, 23A, and 23F. Two isolates were non-typeable (NT). Three (33.3%) isolates were multidrug resistant. We found four (44.4%) penicillin non-susceptible pneumococci, with penicillin and ceftriaxone MICs ranging from 0.12 to 4.0 mu g/ml and 0.023-0.5 mu g/ml, respectively. We also detected two (22.2%) erythromycin resistant isolates (MICs of 3.0 and 256 mu g/ml).
   Conclusions: Colonization with PCV13 serotype was rare among the vaccinated children. Increasing PCV13 coverage might help reduce the frequency of major serotypes currently associated with invasive pneumococcal diseases in Brazil, such as 3 and 19A. The isolation of multidrug-resistant serotype 6C and NT isolates in carriage, however, requires close monitoring. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Neves, Felipe P. G.; Cardoso, Nayara T.] Univ Fed Fluminense, Inst Biomed, Rua Prof Hernani Melo 101, BR-24210130 Niteroi, RJ, Brazil.
   [Cardoso, Claudete A. A.] Univ Fed Fluminense, Fac Med, Av Marques Parana 303, BR-24033900 Niteroi, RJ, Brazil.
   [Teixeira, Lucia M.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Av Carlos Chagas Filho 373,Bloco 1,Cidade Univ, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Riley, Lee W.] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, 530E Li Ka Shing Ctr, Berkeley, CA 94720 USA.
RP Neves, FPG (reprint author), Univ Fed Fluminense, Inst Biomed, Rua Prof Hernani Melo 101, BR-24210130 Niteroi, RJ, Brazil.
EM fpgneves@id.uff.br; claudetecardoso@id.uff.br; lmt2@micro.ufrj.br;
   lwriley@berkeley.edu
RI Neves, Felipe Piedade Goncalves/U-3284-2019
OI Neves, Felipe Piedade Goncalves/0000-0002-3606-2540
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) via
   Science without Borders programNational Council for Scientific and
   Technological Development (CNPq) [234873/2014-0]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES [001];
   Fundacao de Amparo Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); ProReitoria de Pesquisa, Pos-Graduacao e Inovacao da
   Universidade Federal Fluminense (PROPPi/UFF)
FX The authors thank Mariel Asbury Marlow of the Centers for Disease
   Control and Prevention (CDC, Atlanta, GA, USA) for helping in the study
   design. We also thank all healthcare institutions and professionals that
   contributed to this study, especially Dr. Carlos Campbell and Dr. Paulo
   Monnerat, and the CDC for kindly providing the antisera for Quellung
   reactions. This work was supported by the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) via Science without
   Borders program (grant number 234873/2014-0), Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES) - Finance Code 001,
   Fundacao de Amparo Pesquisa do Estado do Rio de Janeiro (FAPERJ), and
   ProReitoria de Pesquisa, Pos-Graduacao e Inovacao da Universidade
   Federal Fluminense (PROPPi/UFF).
CR Andrade AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184204
   Brandileone MCC, 2018, VACCINE, V36, P2559, DOI 10.1016/j.vaccine.2018.04.010
   Brandileone MCD, 2016, VACCINE, V34, P5604, DOI 10.1016/j.vaccine.2016.09.027
   Brazil. Ministry of Health [database on the Internet], TABNET WIN32 3 0 MEN
   Brazilian Institute of Geography and Statistics, NIT INF GEN DAT MUN
   Clinical and Laboratory Standards Institute, 2018, M100S28 CLIN LAB STA
   Cooper D, 2011, VACCINE, V29, P7207, DOI 10.1016/j.vaccine.2011.06.056
   Dias CA, 2007, J MED MICROBIOL, V56, P1185, DOI 10.1099/jmm.0.47347-0
   Galanis I, 2016, EUR RESPIR J, V47, P1208, DOI 10.1183/13993003.01451-2015
   Neves FPG, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-318
   Isturiz R, 2017, EXPERT REV VACCINES, V16, P1007, DOI 10.1080/14760584.2017.1362339
   Kawaguchiya M., 2016, New Microbes and New Infections, V9, P66, DOI 10.1016/j.nmni.2015.11.001
   Mendonca-Souza CRV, 2004, MICROB DRUG RESIST, V10, P313, DOI 10.1089/mdr.2004.10.313
   Moreira M, 2016, VACCINE, V34, P2766, DOI 10.1016/j.vaccine.2016.04.006
   Naucler P, 2017, CLIN INFECT DIS, V65, P1780, DOI 10.1093/cid/cix685
   Neves FPG, 2018, J ANTIMICROB CHEMOTH, V73, P1206, DOI 10.1093/jac/dky001
   Neves FPG, 2017, VACCINE, V35, P2794, DOI 10.1016/j.vaccine.2017.04.019
   Organizacion Panamericana de la Salud, 2011, 2 SIREVA ORG PAN SAL
   Organizacion Panamericana de la Salud, 2017, INF REG SIR 2 2014
   Richter SS, 2013, EMERG INFECT DIS, V19, P1074, DOI 10.3201/eid1907.121830
   Rudolph K, 2013, DIAGN MICR INFEC DIS, V75, P271, DOI 10.1016/j.diagmicrobio.2012.11.021
   Selva L, 2012, EUR J CLIN MICROBIOL, V31, P1487, DOI 10.1007/s10096-011-1468-7
   Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8
   Wroe PC, 2012, PEDIATR INFECT DIS J, V31, P249, DOI 10.1097/INF.0b013e31824214ac
NR 24
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5265
EP 5269
DI 10.1016/j.vaccine.2019.07.056
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300017
PM 31337592
DA 2020-05-12
ER

PT J
AU Han, BF
   Wang, S
   Wan, YM
   Liu, J
   Zhao, TS
   Cui, JH
   Zhuang, H
   Cui, FQ
AF Han, Bingfeng
   Wang, Shuai
   Wan, Yongmei
   Liu, Jiang
   Zhao, Tianshuo
   Cui, Jiahao
   Zhuang, Hui
   Cui, Fuqiang
TI Has the public lost confidence in vaccines because of a vaccine scandal
   in China
SO VACCINE
LA English
DT Article
DE Vaccine; Scandal; Confidence; Regulation
AB Background: A vaccine manufacturer in China and regulatory authorities have been the focus of widespread outrage due to a vaccine scandal. We conducted a rapid survey during a time of intense mainstream and social media attention to determine whether the public's confidence in vaccines was affected.
   Methods: We selected 7 cities that were not involved in the scandal as the setting for the survey, which was conducted in August 2018. We used a convenience sampling strategy to select subjects in urban streets and rural villages for a face-to-face questionnaire-based survey. Subjects were asked to describe their levels of confidence on a scale from 0 to 9, in which 0 means no confidence, and 9 means very confident. Respondents were asked to assess confidence for two points in time - recollection of their level of confidence before hearing about the scandal and their level of confidence at the time of the survey.
   Results: In total, 683 individuals were invited to participate and 591 questionnaires were completed, for a response rate of 86.5%. Among respondents, 86.80% had heard of the vaccine scandal. The most common channel for hearing about the scandal was social media (e.g., WeChat), 40.6% of respondents. Regardless of gender, age, education level, province, town or country, or having children under 15 years old, respondents reported a significant decrease in confidence in domestically-produced vaccines. The mean pre-scandal confidence level recalled by respondents was 6.7, and the mean confidence level at the time of the survey was 3.2. Confidence in vaccine manufacturers, institutes for drug control, and drug supervision authorities decreased from 5.6 to 6.0 before the vaccine scandal to 2.0-3.2 at the time of the survey. Confidence in vaccine manufacturers decreased the most, from 5.6 before the scandal to 2.0; confidence in institutes for drug control decreased from 5.8 before the scandal to 2.6 at the time of the survey.
   Conclusion: This study demonstrated that public confidence was significantly affected by the vaccine scandal, particularly for vaccine producers and drug regulators. The decline in confidence is a reminder to governments that in order to build public confidence for vaccination, regulators have to reform regulatory practices and manufacturers have to ensure vaccine quality. (C) 2019 Published by Elsevier Ltd.
C1 [Han, Bingfeng; Wang, Shuai; Liu, Jiang; Zhao, Tianshuo; Cui, Fuqiang] Peking Univ, Dept Lab Sci & Technol, Sch Publ Hlth, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Han, Bingfeng; Wang, Shuai; Liu, Jiang; Zhao, Tianshuo; Cui, Fuqiang] Peking Univ, Vaccine Res Ctr, Sch Publ Hlth, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Wan, Yongmei] Chinese Ctr Dis Control & Prevent, Natl Immunizat Program, Beijing, Peoples R China.
   [Cui, Jiahao] Beihang Univ, Int Sch, Beijing, Peoples R China.
   [Zhuang, Hui] Peking Univ, Dept Microbiol, Sch Basic Med Sci, Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
   [Zhuang, Hui] Peking Univ, Ctr Infect Dis, Sch Basic Med Sci, Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
RP Cui, FQ (reprint author), Peking Univ, Dept Lab Sci & Technol, Sch Publ Hlth, 38 Xueyuan Rd, Beijing 100191, Peoples R China.; Cui, FQ (reprint author), Peking Univ, Vaccine Res Ctr, Sch Publ Hlth, 38 Xueyuan Rd, Beijing 100191, Peoples R China.; Zhuang, H (reprint author), Peking Univ, Dept Microbiol, Sch Basic Med Sci, Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.; Zhuang, H (reprint author), Peking Univ, Ctr Infect Dis, Sch Basic Med Sci, Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM hanbingfeng@pku.edu.cn; zhuangbmu@126.com; cuifuq@126.com
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities; Peking University Health
   Science CenterPeking University [BMU20170607]
FX This research was funded by the Fundamental Research Funds for the
   Central Universities and Peking University Health Science Center
   (BMU20170607).
CR [Anonymous], XINHUA NEWS
   [Anonymous], SO METROPOLIS DAILY
   Cao L, 2018, HUM VACC IMMUNOTHER, V14, P1672, DOI 10.1080/21645515.2018.1473697
   China food and drug administration, INV TEAM STAT COUNC
   China food and drug administration, NOT STAT DRUG ADM PR
   Dyda A, 2019, HUM VACC IMMUNOTHER, P1, DOI DOI 10.1080/21645515.2019.1596712
   Jiang C, CHINA DAILY
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Li B, PEOPLES DAILY
   Murphy F, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3244
   National health and family planning commission, OV NAT LEG INF DIS E
   Phillips N, 2018, NATURE, V560, P14, DOI 10.1038/d41586-018-05835-1
   Sina Fcous, SINA FCOUS
   Sina Finance, 7 PROV MIN OFF HAV B
   Wang XM, 2018, J HEALTH COMMUN, V23, P413, DOI 10.1080/10810730.2018.1455771
   Xinhua News Agency, PEOPLES DAILY
   Yu WZ, 2016, INT J EPIDEMIOL, V45, P441, DOI 10.1093/ije/dyv349
   Yuan X, 2018, LANCET, V392, P371, DOI 10.1016/S0140-6736(18)31725-2
   Zhu G, PEOPLES DAILY
NR 19
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5270
EP 5275
DI 10.1016/j.vaccine.2019.07.052
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300018
PM 31345640
DA 2020-05-12
ER

PT J
AU Lemieux, M
   Lorbetskie, B
   Luebbert, CC
   Walrond, L
   Li, C
   Li, X
   Cyr, T
   Sauve, S
   Johnston, MJW
   Farnsworth, A
AF Lemieux, M.
   Lorbetskie, B.
   Luebbert, C. C.
   Walrond, L.
   Li, C.
   Li, X.
   Cyr, T.
   Sauve, S.
   Johnston, M. J. W.
   Farnsworth, A.
TI The differential effect of sub-micron level HA aggregates on influenza
   potency assays
SO VACCINE
LA English
DT Article
DE Hemagglutinin; Influenza; Potency; Vaccine
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; HEMAGGLUTININ CONTENT; WHOLE VIRUS;
   VACCINE; IMMUNOGENICITY; QUANTIFICATION; ANTIBODIES; PARTICLES;
   PROTEINS; ANTIGEN
AB Influenza vaccines remain the most effective public health measure for the prevention of influenza related illnesses. The primary immunogen in inactivated influenza vaccines is hemagglutinin (HA), the receptor binding protein of influenza. The concentration of HA during vaccine production and testing is standardized according to the level of antigen as measured by Single Radial Immunodiffusion Assay (SRID). This allows vaccine potency to be controlled such that individuals receive a dose known to provoke a clinically protective immune response. As compared to alternatives, SRID has the advantage of quantifying immunologically relevant forms of HA, but it depends on timely generation of novel reagents for each new vaccine strain. In recent years, a number of alternative assays have been suggested based on either epitope recognition, receptor binding or protection from proteolysis but it is unclear how they relate to vaccine potency in clinical trials. In this report we describe the development of a lectin-based, ELISA-type assay for HA potency and find it provides similar potency estimates to SRID except in the case of a vaccine with aggregated HA and other viral proteins. In that case, SRID predicted the immunologically active HA present and ELISA techniques did not This difference was due to tested antibodies failing to pull down or bind to the HA present unless particle aggregates were first dissociated. Furthermore, detergent treatment alone was insufficient to complete this dissociation. While others have previously demonstrated that immunocapture-based techniques can misestimate the potency of influenza vaccines depending on the individual antibodies used we demonstrate that in this case the failure was due to an inability of all antibodies to capture HA contained in the aggregated influenza vaccine. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Lemieux, M.; Lorbetskie, B.; Luebbert, C. C.; Walrond, L.; Li, X.; Cyr, T.; Sauve, S.; Johnston, M. J. W.; Farnsworth, A.] Hlth Canada, HPFB, Biol & Genet Therapies Directorate, Ctr Biol Evaluat, Ottawa, ON, Canada.
   [Lemieux, M.; Lorbetskie, B.; Luebbert, C. C.; Walrond, L.; Li, X.; Cyr, T.; Sauve, S.; Johnston, M. J. W.; Farnsworth, A.] WHO Collaborating Ctr Standardizat & Evaluat Biol, Ottawa, ON, Canada.
   [Li, C.] Natl Inst Food & Drug Control, Beijing, Peoples R China.
   [Li, C.] WHO Collaborating Ctr Standardizat & Evaluat Biol, Beijing, Peoples R China.
RP Farnsworth, A (reprint author), Hlth Canada, HPFB, Biol & Genet Therapies Directorate, Ctr Biol Evaluat, Ottawa, ON, Canada.; Farnsworth, A (reprint author), WHO Collaborating Ctr Standardizat & Evaluat Biol, Ottawa, ON, Canada.
EM aaron.farnsworth@canada.ca
CR Babiuk S, 2004, J MED VIROL, V72, P138, DOI 10.1002/jmv.10540
   BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784
   Capitani Melamia, 2014, Curr Gene Ther, V14, P161
   Carpenter JF, 2009, J PHARM SCI-US, V98, P1201, DOI 10.1002/jps.21530
   Cox NJ, 2011, 2 WHO CONSULTATION G
   Farnsworth A, 2011, VACCINE, V29, P1529, DOI 10.1016/j.vaccine.2010.12.120
   Fathallah AM, 2015, J PHARM SCI-US, V104, P3691, DOI 10.1002/jps.24592
   FDA, 2014, GUID IND IMM ASS THE
   Feshchenko E, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-77
   Filipe V, 2010, PHARM RES-DORDR, V27, P796, DOI 10.1007/s11095-010-0073-2
   Fradkin AH, 2011, J PHARM SCI-US, V100, P4953, DOI 10.1002/jps.22683
   Garcia-Canas V, 2007, ANAL CHEM, V79, P3164, DOI 10.1021/ac0621120
   Getie-Kebtie M, 2013, INFLUENZA OTHER RESP, V7, P521, DOI 10.1111/irv.12001
   Griffiths D, 2010, NANOTECHNOLOGY, V3, P176
   Hardy Stephanie, 2011, Influenza Other Respir Viruses, V5, P438, DOI 10.1111/j.1750-2659.2011.00250.x
   Hashem AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055428
   HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610
   HUGHES RC, 1978, NATURE, V274, P637, DOI 10.1038/274637a0
   JOHANNSEN R, 1983, J BIOL STAND, V11, P341, DOI 10.1016/S0092-1157(83)80023-7
   Khurana S, 2014, VACCINE, V32, P2188, DOI 10.1016/j.vaccine.2014.02.049
   Kramberger P, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-265
   Kristiansen T, 1983, J BIOSCIENCE, V5, P149
   Kuck LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109616
   LARBAIGT G, 1980, COMP IMMUNOL MICROB, V3, P207, DOI 10.1016/0147-9571(80)90059-4
   Legastelois I, 2011, J VIROL METHODS, V178, P129, DOI 10.1016/j.jviromet.2011.08.027
   Li CG, 2010, BIOLOGICALS, V38, P284, DOI 10.1016/j.biologicals.2009.12.004
   Li CG, 2010, NAT PROTOC, V5, P14, DOI 10.1038/nprot.2009.200
   Lorbetskie B, 2017, J CHROMATOGR A, V1528, P18, DOI 10.1016/j.chroma.2017.10.041
   Lorbetskie B, 2011, VACCINE, V29, P3377, DOI 10.1016/j.vaccine.2011.02.090
   Luebbert CC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189814
   Minor PD, 2015, VACCINES-BASEL, V3, P90, DOI 10.3390/vaccines3010090
   Moussa EM, 2016, J PHARM SCI-US, V105, P417, DOI 10.1016/j.xphs.2015.11.002
   Narhi LO, 2012, J PHARM SCI-US, V101, P493, DOI 10.1002/jps.22790
   Nicholson KG, 2003, LANCET, V362, P1733, DOI 10.1016/S0140-6736(03)14854-4
   OKUNO Y, 1993, J VIROL, V67, P2552, DOI 10.1128/JVI.67.5.2552-2558.1993
   Orr MT, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-018-0094-0
   Parupudi A, 2017, J VIROL METHODS, V247, P91, DOI 10.1016/j.jviromet.2017.06.002
   Ratanji KD, 2016, TOXICOL SCI, V153, P258, DOI 10.1093/toxsci/kfw121
   Rosenberg AS, 2006, AAPS J, V8, pE501
   RUIGROK RWH, 1986, VIROLOGY, V155, P484, DOI 10.1016/0042-6822(86)90210-2
   Schmeisser F, 2014, INFLUENZA OTHER RESP, V8, P587, DOI 10.1111/irv.12272
   Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372
   Sharon N, 2004, GLYCOBIOLOGY, V14, p53R, DOI 10.1093/glycob/cwh122
   Singh SK, 2010, J PHARM SCI-US, V99, P3302, DOI 10.1002/jps.22097
   Thompson MG, 2018, VACCINE, V36, P5916, DOI 10.1016/j.vaccine.2018.07.028
   van Beers MMC, 2010, J INTERF CYTOK RES, V30, P767, DOI 10.1089/jir.2010.0086
   Vasudevan A, 2018, INFLUENZA OTHER RESP, V12, P250, DOI 10.1111/irv.12528
   Wanda I, 2016, DETERMINATION HEMAGG
   Wen YX, 2018, VACCINE, V36, P3010, DOI 10.1016/j.vaccine.2018.04.021
   Wen YX, 2015, VACCINE, V33, P5342, DOI 10.1016/j.vaccine.2015.08.077
   Williams TL, 2008, VACCINE, V26, P2510, DOI 10.1016/j.vaccine.2008.03.014
   Wood J M, 1977, Dev Biol Stand, V39, P193
   WOOD JM, 1977, J BIOL STAND, V5, P237, DOI 10.1016/S0092-1157(77)80008-5
   Wood JM, 2018, INFLUENZA OTHER RESP, V12, P195, DOI 10.1111/irv.12543
   Xue MG, 2015, VACCINE, V33, P2606, DOI 10.1016/j.vaccine.2015.03.068
   Zhang LJ, 2016, CURR BIOL, V26, pR14, DOI 10.1016/j.cub.2015.11.017
NR 56
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5276
EP 5287
DI 10.1016/j.vaccine.2019.07.050
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300019
PM 31337591
DA 2020-05-12
ER

PT J
AU Spitteler, MA
   Romo, A
   Magi, N
   Seo, MG
   Yun, SJ
   Barroumeres, F
   Regulier, EG
   Bellinzoni, R
AF Spitteler, Marcelo A.
   Romo, Ana
   Magi, Nicolas
   Seo, Min-Goo
   Yun, Seon-Jong
   Barroumeres, Fernando
   Regulier, Emmanuel G.
   Bellinzoni, Rodolfo
TI Validation of a high performance liquid chromatography method for
   quantitation of foot-and-mouth disease virus antigen in vaccines and
   vaccine manufacturing
SO VACCINE
LA English
DT Article
DE Foot-and-mouth-disease; FMD; FMDV; Vaccine; 140S; 146S; GPC; Size
   exclusion high performance liquid chromatography; HPLC; SE-HPLC;
   Validation
ID QUANTIFICATION; PARTICLES; KOREA; 146S; VECTORS
AB Foot-and-mouth disease (FMD) is an infectious viral disease that affects the main meat and dairy production animals, including cattle, sheep, goats and swine. It is readily transmissible and countries where the disease is present suffer harsh international trade restrictions on livestock products and serious economic losses. Vaccines are important tools to contain outbreaks and maintain the status of free with or without vaccination, as defined by the World Organization for Animal Health (OIE). The efficacy of vaccines is reliant on the content and integrity of inactivated virus particles. The long-established method to quantify the viral content of vaccines along the manufacturing process and in the final product is the 140S sucrose density gradient analysis. This method has been a valuable tool for many decades. However, it requires gradient preparation for each sample, a lengthy ultracentrifugation and a manual UV reading of the gradient, rendering it highly operator dependent and almost impossible to automate. We present a method to quantify FMDV particles in vaccines and intermediate process samples that is based on separation of components by size exclusion high performance liquid chromatography (SE-HPLC) and measurement of virus by absorption at 254 nm. The method has been extensively validated; it is accurate, precise and linear. It is applicable to all FMDV strains and sample materials and has a good concordance with the 140S test. The proposed method uses off the shelf HPLC equipment and columns. It is easily automated for high throughput operation, affording a useful process analytical technology and a novel tool for control of final product by manufacturers and regulatory agencies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Spitteler, Marcelo A.; Romo, Ana; Magi, Nicolas; Barroumeres, Fernando; Regulier, Emmanuel G.; Bellinzoni, Rodolfo] Biogenesis Bago SA, Res & Dev, Ruta Panamer Km 38-5,B1619IEA, Garin, Buenos Aires, Argentina.
   [Seo, Min-Goo; Yun, Seon-Jong] Anim & Plant Quarantine Agcy, Vet Drugs & Biol Div, Gimcheon 39660, Gyeongbuk, South Korea.
RP Spitteler, MA (reprint author), Biogenesis Bago SA, Res & Dev, Ruta Panamer Km 38-5,B1619IEA, Garin, Buenos Aires, Argentina.
EM marcelo.spitteler@biogenesisbago.com
OI Seo, Min-Goo/0000-0003-1752-5105
FU Argentine Technological Fund, FONTAR, National Agency for Science and
   Technology Promotion, Ministry of Science, Technology and Innovative
   Production, Buenos Aires, Argentina [CF BA 004/11]
FX This work was partly funded by the Argentine Technological Fund, FONTAR,
   National Agency for Science and Technology Promotion, Ministry of
   Science, Technology and Innovative Production, Buenos Aires, Argentina,
   project CF BA 004/11.
CR BAHNEMANN HG, 1990, VACCINE, V8, P299, DOI 10.1016/0264-410X(90)90083-X
   BARTELING SJ, 1974, ARCH GES VIRUSFORSCH, V45, P362, DOI 10.1007/BF01242879
   Barteling SJ, 1999, NEED FURTHER STANDAR
   BROWN F, 1961, NATURE, V192, P1163, DOI 10.1038/1921163a0
   CARTWRIGHT B, 1980, J GEN VIROL, V50, P369, DOI 10.1099/0022-1317-50-2-369
   Committee for medicinal products for veterinary use of the European Medicines Agency, 2004, EMENCVMP77502 VET ME
   DOEL TR, 1985, J BIOL STAND, V13, P335, DOI 10.1016/S0092-1157(85)80048-2
   DOEL TR, 1982, ARCH VIROL, V73, P185, DOI 10.1007/BF01314726
   European Pharmacopoeia Commission, 2018, EUR PHARM, P1062
   FDA, 2015, AN PROC METH VAL DRU
   Geering WA, 2002, FAO ANIMAL HLTH MANU, P8
   Harris DC, 2010, QUANTITATIVE CHEM AN, P106
   Knight-Jones TJD, 2013, PREV VET MED, V112, P161, DOI 10.1016/j.prevetmed.2013.07.013
   LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051
   Lin LI-K, 2000, BIOMETRICS, V56, P324, DOI DOI 10.1111/J.0006-341X.2000.00324.X
   Ludbrook J, 1997, CLIN EXP PHARMACOL P, V24, P193, DOI 10.1111/j.1440-1681.1997.tb01807.x
   McBride GB, 2005, PROPOSAL STRENGTH OF, P1
   Merck KGaA, 2018, MILLIPORESIGMA BENZ, P40
   Morenweiser R, 2005, GENE THER, V12, pS103, DOI 10.1038/sj.gt.3302624
   Muroga N, 2012, J VET MED SCI, V74, P399, DOI 10.1292/jvms.11-0271
   Park JH, 2018, J VET SCI, V19, P271, DOI 10.4142/jvs.2018.19.2.271
   Park JH, 2016, CLIN EXP VACCINE RES, V5, P83, DOI 10.7774/cevr.2016.5.1.83
   Park JH, 2014, EMERG INFECT DIS, V20, P2158, DOI 10.3201/eid2012.130518
   Spitteler MA, 2011, VACCINE, V29, P7182, DOI 10.1016/j.vaccine.2011.05.078
   Steppert P, 2017, J CHROMATOGR A, V1487, P89, DOI 10.1016/j.chroma.2016.12.085
   Transfiguracion J, 2004, J CHROMATOGR B, V813, P167, DOI 10.1016/j.jchromb.2004.09.034
   Whitfield RJ, 2009, J CHROMATOGR A, V1216, P2725, DOI 10.1016/j.chroma.2008.11.010
   WILD TF, 1968, ARCH GES VIRUSFORSCH, V24, P86, DOI 10.1007/BF01242904
NR 28
TC 1
Z9 1
U1 4
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5288
EP 5296
DI 10.1016/j.vaccine.2019.07.051
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300020
PM 31353259
DA 2020-05-12
ER

PT J
AU Dalal, J
   Rana, R
   Harale, K
   Hanif, S
   Kumar, N
   Singh, D
   Chhikara, MK
AF Dalal, Juned
   Rana, Rakesh
   Harale, Kishore
   Hanif, Sarmad
   Kumar, Nitin
   Singh, Deepti
   Chhikara, Manoj Kumar
TI Development and pre-clinical evaluation of a synthetic
   oligosaccharide-protein conjugate vaccine against Neisseria meningitidis
   serogroup C
SO VACCINE
LA English
DT Article
DE Neisseria meningitidis serogroup C; Oligosaccharide; Synthesis;
   Conjugate vaccine; lmmunogenicity
ID INFLUENZAE TYPE-B; CAPSULAR POLYSACCHARIDE; STEREOSELECTIVE-SYNTHESIS;
   IMMUNOLOGICAL HYPORESPONSIVENESS; IMMUNOGENICITY; TETRASACCHARIDE; ACIDS
AB Significant improvement has been made in the development of vaccines against Neisseria meningitidis infections since the introduction of polysaccharide-protein conjugate vaccines. Conventional bacterial capsular polysaccharide (PS) based conjugate vaccines require unique and expensive manufacturing facilities, complex production processes and extensive quality testing. Synthetic oligosaccharide (OS) based approach is one of the novel technologies that is being developed to simplify production of conjugate vaccines. OSs can be chemically synthesized to a desired length long enough to represent the antigenic epitopes which often present as a homogenous mixture. We prepared OSs corresponding to tetramer and octamer of N. meningitidis serogroup C (MenC) PS by organic synthesis. The MenC tetramer and octamer were further conjugated with tetanus toxoid to produce respective monovalent conjugates having the desired physico-chemical characteristics. The conjugates were evaluated in a mouse model for immunogenicity and compared with a licensed PS conjugate vaccine. Synthetic conjugates could induce anti-MenC PS IgG as well as serum bactericidal titers at levels comparable to those elicited by the licensed vaccine. The increase in length of synthetic oligomers from tetramer to octamer did not appear to increase immunogenicity. The results establish the pre-clinical proof of concept for a synthetic MenC oligosaccharide conjugate vaccine candidate. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Dalal, Juned; Rana, Rakesh; Harale, Kishore; Hanif, Sarmad; Kumar, Nitin; Singh, Deepti; Chhikara, Manoj Kumar] MSD Wellcome Trust Hilleman Labs Pvt Ltd, Jamia Hamdard, 2nd Floor,Nanotechnol Bldg, New Delhi 110062, India.
RP Chhikara, MK (reprint author), MSD Wellcome Trust Hilleman Labs Pvt Ltd, Jamia Hamdard, 2nd Floor,Nanotechnol Bldg, New Delhi 110062, India.
EM manoj.kumar@hillemanlabs.org
RI Chhikara, Manoj Kumar/H-9985-2019
OI Chhikara, Manoj Kumar/0000-0002-7650-0306
CR Anish C, 2014, CHEM BIOL, V21, P38, DOI 10.1016/j.chembiol.2014.01.002
   CHU CY, 1983, INFECT IMMUN, V40, P245, DOI 10.1128/IAI.40.1.245-256.1983
   Chu KC, 2011, ANGEW CHEM INT EDIT, V50, P9391, DOI 10.1002/anie.201101794
   ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6
   English M, 2000, VACCINE, V19, P1232, DOI 10.1016/S0264-410X(00)00241-3
   Fallarini S, 2015, ACS INFECT DIS, V1, P487, DOI 10.1021/acsinfecdis.5b00071
   Fernandez-Santana V, 2004, INFECT IMMUN, V72, P7115, DOI 10.1128/IAI.72.12.7115-7123.2004
   GHEESLING LL, 1994, J CLIN MICROBIOL, V32, P1475, DOI 10.1128/JCM.32.6.1475-1482.1994
   Guo YY, 1998, BIOLOGICALS, V26, P33, DOI 10.1006/biol.1997.0121
   Harale KR, 2017, ORG CHEM FRONT, V4, P2348, DOI 10.1039/c7qo00468k
   Harale KR, 2015, RSC ADV, V5, P41332, DOI 10.1039/c5ra02993g
   Johnson MA, 2013, CHEM SOC REV, V42, P4327, DOI 10.1039/c2cs35382b
   Jokhdar H, 2004, CLIN DIAGN LAB IMMUN, V11, P83, DOI 10.1128/CDLI.11.1.83-88.2004
   KABAT EA, 1960, J IMMUNOL, V84, P82
   Lee CH, 2009, VACCINE, V27, P726, DOI 10.1016/j.vaccine.2008.11.065
   Lin CC, 2010, J ORG CHEM, V75, P4921, DOI 10.1021/jo100824s
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Maslanka SE, 1997, CLIN DIAGN LAB IMMUN, V4, P156, DOI 10.1128/CDLI.4.2.156-167.1997
   Michon F, 2000, Dev Biol (Basel), V103, P151
   Morelli L, 2014, BEILSTEIN J ORG CHEM, V10, P2367, DOI 10.3762/bjoc.10.247
   Peltola H, 2000, CLIN MICROBIOL REV, V13, P302, DOI 10.1128/CMR.13.2.302-317.2000
   Ramsay ME, 2001, LANCET, V357, P195, DOI 10.1016/S0140-6736(00)03594-7
   Rana R, 2015, VACCINE, V33, P2646, DOI 10.1016/j.vaccine.2015.04.031
   Richmond P, 1999, J INFECT DIS, V179, P1569, DOI 10.1086/314753
   Richmond P, 2000, J INFECT DIS, V181, P761, DOI 10.1086/315284
   Safari D, 2008, INFECT IMMUN, V76, P4615, DOI 10.1128/IAI.00472-08
   SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361
   SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8
   Vella M, 2015, EXPERT OPIN BIOL TH, V15, P529, DOI 10.1517/14712598.2015.993375
   Verez-Bencomo V, 2004, SCIENCE, V305, P522, DOI 10.1126/science.1095209
   Wang CH, 2013, ANGEW CHEM INT EDIT, V52, P9157, DOI 10.1002/anie.201302540
   WHO, 2017, SIT UPD MEN C EP RIS
   Yang L, 2011, CHEM-EUR J, V17, P14518, DOI 10.1002/chem.201102615
NR 33
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5297
EP 5306
DI 10.1016/j.vaccine.2019.07.053
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300021
PM 31371227
OA Other Gold
DA 2020-05-12
ER

PT J
AU Janewongwirot, P
   Jantarabenjakul, W
   Anugulruengkitt, S
   Anunsittichai, O
   Saengseesom, W
   Buranapraditkun, S
   Sophonphan, J
   Wacharachaisurapol, ABN
   Jitrungruengnij, N
   Pancharoen, C
   Puthanakit, T
AF Janewongwirot, Pakpoom
   Jantarabenjakul, Watsamon
   Anugulruengkitt, Suvaporn
   Anunsittichai, Orawan
   Saengseesom, Wachiraporn
   Buranapraditkun, Supranee
   Sophonphan, Jiratchaya
   Wacharachaisurapol, Noppadol A. B.
   Jitrungruengnij, Nattapong
   Pancharoen, Chitsanu
   Puthanakit, Thanyawee
TI A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies
   prophylaxis among Thai children
SO VACCINE
LA English
DT Article
DE Purified Vero cell rabies vaccine; Pre-exposure rabies prophylaxis;
   Children
ID FOLLOW-UP; VACCINATION; IMMUNOGENICITY; VIRUS; ANTIBODY; CLEARANCE;
   VACCINES
AB Background: World Health Organization changed the recommendation for pre-exposure rabies prophylaxis from 3-dose to 2-dose regimen in 2018. Given limited data of 2-dose regimens in pediatric population, this study aimed to compare the immunogenicity between 2-dose and 3-dose pre-exposure rabies immunization.
   Methods: This study was conducted among healthy children aged 2-12 years. They were randomized to 2-dose vaccination (2D) on days 0 and 28 or 3-dose vaccination (3D) on days 0, 7, and 28. Purified Vero cell rabies vaccine (PVRV-Verorab (TM)) was administered intramuscularly. Rabies virus neutralizing antibody (RVNA) titers were measured at 3 time points: 14-day after complete vaccination, 1-year pre booster vaccination, and 7-day post-booster dose to mimic scenario of rabies exposure. RVNA titers >= 0.5 IU/ml were considered adequate antibody. T cell specific response to rabies vaccine antigen was measured using the interferon-gamma enzyme linked immunospot assay.
   Results: From September to October 2017, 107 participants (51% males), 78 in 2D group and 29 in 3D group were enrolled. Median age was 5.8 years (IQR 4.4-7.3). All participants had RVNA titers >= 0.5 IU/ml after primary vaccination [GMT 2D: 18.6 (95%Cl 15.9-21.8) and 3D: 16.3 (95%Cl 13.2-20.1 IU/ml), p = 0.35]. At 1-year prior to receiving the booster, only 80% of the children in 2D group maintained RVNA titers >= 0.51 U/ml compared to 100% of the children in 3D group (p = 0.01). However, all participants in both groups had RVNA >= 0.5 IU/ml at 7-day post booster vaccination [GMT 2D: 20.9 (95%Cl 17.4-25.3) and 3D: 22.2 (95%Cl 15.8-31.4) IU/ml (P = 0.75)]. The median number of IFN-gamma secreting cells at 7-day post-booster dose was 98 and 128 SFCs per 10(6) PBMCs in the 2D and 3D groups, respectively (P = 0.30).
   Conclusions: Two-dose primary rabies immunization provided adequate antibody at post primary vaccination and post booster. The results support 2-dose regimen of pre-exposure rabies immunization in the pediatric population. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Janewongwirot, Pakpoom; Jantarabenjakul, Watsamon; Anugulruengkitt, Suvaporn; Anunsittichai, Orawan; Wacharachaisurapol, Noppadol A. B.; Jitrungruengnij, Nattapong; Pancharoen, Chitsanu; Puthanakit, Thanyawee] Chulalongkorn Univ, Fac Med, Dept Pediat, Rama 4 Rd, Bangkok 10330, Thailand.
   [Janewongwirot, Pakpoom; Jantarabenjakul, Watsamon; Anugulruengkitt, Suvaporn; Anunsittichai, Orawan; Wacharachaisurapol, Noppadol A. B.; Jitrungruengnij, Nattapong; Pancharoen, Chitsanu; Puthanakit, Thanyawee] Chulalongkorn Univ, Fac Med, Ctr Excellence Pediat Infect Dis & Vaccines, Bangkok, Thailand.
   [Jantarabenjakul, Watsamon] King Chulalongkorn Mem Hosp, Thai Red Cross Emerging Infect Dis Clin Ctr TRC E, Bangkok, Thailand.
   [Saengseesom, Wachiraporn] Thai Red Cross Soc, Queen Saovabha Mem Inst, Bangkok, Thailand.
   [Buranapraditkun, Supranee] Chulalongkorn Univ, Fac Med, Dept Med, Cellular Immunol Lab,Allergy & Clin Immunol Unit, Bangkok, Thailand.
   [Sophonphan, Jiratchaya] Thai Red Cross Aids Res Ctr, HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand.
   [Wacharachaisurapol, Noppadol A. B.] Chulalongkorn Univ, Fac Med, Dept Pharmacol, Bangkok, Thailand.
RP Janewongwirot, P (reprint author), Chulalongkorn Univ, Fac Med, Dept Pediat, Rama 4 Rd, Bangkok 10330, Thailand.
EM Pakpoom.J@chula.ac.th
OI Anugulruengkitt, Suvaporn/0000-0002-6965-5537
FU Ratchadaphiseksomphot Endowment Fund, Faculty of Medicine, Chulalongkorn
   University [RA61/003]; National Vaccine Institute Fund, National Vaccine
   Institute, Thailand [2561.1/6]
FX This study was supported by the Ratchadaphiseksomphot Endowment Fund
   (RA61/003), Faculty of Medicine, Chulalongkorn University and National
   Vaccine Institute Fund (2561.1/6), National Vaccine Institute, Thailand.
CR Angsuwatcharakon P., 2018, NEUTRALIZING ANTIBOD
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P515
   Aubert MF, 1996, METHODS CALCULATION, P445
   Buranapraditkun S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023603
   Bureau of Epidemiology Ministry of Public Health Thailand, 2016, 506 ANN EP SURV REP
   Department of Health, 2012, NAT RAB PREV CONTR P
   Dodet B, 2010, Vaccine, V28, P3265, DOI 10.1016/j.vaccine.2010.02.093
   Dodet B, 2014, VACCINE, V32, P2017, DOI 10.1016/j.vaccine.2013.12.031
   FLAMAND A, 1993, VIROLOGY, V194, P302, DOI 10.1006/viro.1993.1261
   Grondahl-Yli-Hannuksela K, 2016, VACCINE, V34, P341, DOI 10.1016/j.vaccine.2015.11.049
   Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709
   Hooper DC, 2011, ADV VIRUS RES, V79, P55, DOI 10.1016/B978-0-12-387040-7.00004-4
   Hooper DC, 1998, J VIROL, V72, P3711, DOI 10.1128/JVI.72.5.3711-3719.1998
   Jonker EFF, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax033
   Kamoltham T, 2007, J PEDIATR-US, V151, P173, DOI 10.1016/j.jpeds.2007.02.044
   Kaplan M, 1973, LAB TECHNIQUE RABIES, P314
   Kasempimolporn S, 2007, PREV VET MED, V78, P325, DOI 10.1016/j.prevetmed.2006.11.003
   Khawplod P, 2002, J TRAVEL MED, V9, P153, DOI 10.2310/7060.2002.23189
   Khawplod P, 2007, J TRAVEL MED, V14, P173, DOI 10.1111/j.1708-8305.2007.00120.x
   Khawplod P, 2012, VACCINE, V30, P2918, DOI 10.1016/j.vaccine.2011.12.028
   Lang J, 2009, J TROP PEDIATRICS, V55, P26, DOI 10.1093/tropej/fmm100
   Lau CL, 2013, TRAVEL MED INFECT DI, V11, P427, DOI 10.1016/j.tmaid.2013.09.006
   Manning Susan E., 2008, Morbidity and Mortality Weekly Report, V57, P1
   Mills DJ, 2011, J TRAVEL MED, V18, P327, DOI 10.1111/j.1708-8305.2011.00540.x
   NICHOLSON KG, 1990, LANCET, V335, P1201, DOI 10.1016/0140-6736(90)92710-Y
   Pediatric Infectious Disease Society of Thailand, 2019, IMM SCHED THAI CHILD
   Pengsaa K, 2009, PEDIATR INFECT DIS J, V28, P335, DOI 10.1097/INF.0b013e3181906351
   SMITH JS, 1973, B WORLD HEALTH ORGAN, V48, P535
   Soentjens P, 2019, CLIN INFECT DIS, V68, P607, DOI 10.1093/cid/ciy513
   Sriaroon Chakrapol, 2006, Travel Med Infect Dis, V4, P270, DOI 10.1016/j.tmaid.2005.06.001
   Strady A, 1998, J INFECT DIS, V177, P1290, DOI 10.1086/515267
   Venkataswamy MM, 2015, CLIN EXP VACCINE RES, V4, P68, DOI 10.7774/cevr.2015.4.1.68
   World Health Organization, 2010, WKLY EPIDEMIOL REC, V85, P309
   World Health Organization, 2018, WHO TECHN SER REP, V1012
NR 34
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5307
EP 5313
DI 10.1016/j.vaccine.2019.07.055
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300022
PM 31358408
DA 2020-05-12
ER

PT J
AU Fabiani, M
   Volpe, E
   Faraone, M
   Bella, A
   Rizzo, C
   Marchetti, S
   Pezzotti, P
   Chini, F
AF Fabiani, Massimo
   Volpe, Enrico
   Faraone, Maurizio
   Bella, Antonino
   Rizzo, Caterina
   Marchetti, Stefano
   Pezzotti, Patrizio
   Chini, Francesco
TI Influenza vaccine uptake in the elderly population: Individual and
   general practitioner's determinants in Central Italy, Lazio region,
   2016-2017 season
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine uptake; Elderly; General practitioners; Determinants
ID ADULTS; OLDER; EFFICACY
AB Background: Elderly people are a priority target group for influenza vaccination and their decision to be vaccinated might partly depend on advice received from general practitioners (GP). This study aims to investigate the association between influenza vaccine uptake in the elderly residents in the Lazio region of Italy and the demographic and professional characteristics of their GPs, taking simultaneously into account the elderly's individual characteristics.
   Methods: We used data retrieved from different administrative sources to retrospectively analyse the cohort of 1,255,657 elderly residents aged >= 65 years who were alive and registered in the regional healthcare service at the beginning of the 2016-2017 influenza vaccination campaign (1 Oct. 2016-31 Jan. 2017). We assessed influenza vaccine uptake at the end of the vaccination campaign and evaluated its association with both individual and GP-related characteristics through a multilevel Poisson regression models accounting for clustering at physician level.
   Results: Overall, vaccination coverage at the end of vaccination campaign was 50.6%. Elderly residents who were male, older, vaccinated in the previous seasons, living in smaller provinces, and spending more money for specialist medical care showed a significantly increased probability to be vaccinated. Vaccine uptake was also significantly higher in the elderly residents assisted by GPs who got master's degree more recently, assisted a relatively high proportion of elderly patients, received influenza vaccination, had a computer assistant, and were associated with other physicians.
   Conclusions: Our results indicate that influenza vaccination coverage in the elderly residents of the Lazio region is still unsatisfactorily low. We identified several determinants of influenza vaccine uptake, related to both individual and GP characteristics. Understanding how GP characteristics affected influenza vaccine uptake in the elderly population might provide insight on GPs' attitudes and concerns regarding influenza vaccination, allowing the implementation of targeted evidence-based interventions to sensitise GPs and increase vaccination coverage. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fabiani, Massimo; Bella, Antonino; Pezzotti, Patrizio] Italian Natl Inst Hlth ISS, Dept Infect Dis, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Volpe, Enrico; Faraone, Maurizio; Chini, Francesco] Reg Directorate Hlth & Social Policy, Via R Raimondi Garibaldi 7, I-00145 Rome, Italy.
   [Rizzo, Caterina] Bambino Gesu Paediat Hosp, Piazza St Onofrio 4, I-00165 Rome, Italy.
   [Marchetti, Stefano] Italian Natl Inst Stat ISTAT, Via Cesare Balbo 16, I-00184 Rome, Italy.
RP Fabiani, M (reprint author), Italian Natl Inst Hlth ISS, Dept Infect Dis, Viale Regina Elena 299, I-00161 Rome, Italy.
EM massimo.fabiani@iss.it
RI Bella, Antonino/AAB-9943-2019; Rizzo, Caterina/H-4092-2012
OI Rizzo, Caterina/0000-0002-5583-7508; Fabiani,
   Massimo/0000-0002-5893-7117
CR Abbas KM, 2018, PEERJ, V6, DOI 10.7717/peerj.5171
   Ang LW, 2017, EPIDEMIOL INFECT, V145, P775, DOI 10.1017/S0950268816002491
   Austin PC, 2017, INT STAT REV, V85, P185, DOI 10.1111/insr.12214
   Barr IG, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0079-z
   Bella A, 2017, B EPIDEMIOLOGICO NAZ
   Blank Patricia, 2012, Hum Vaccin Immunother, V8, P328, DOI 10.4161/hv.18629
   Bodeker B, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1970-4
   Chiatti C, 2011, HUM VACCINES, V7, P1021, DOI 10.4161/hv.7.10.16849
   Chini F, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-688
   Chit A, 2015, LANCET INFECT DIS, V15, P1459, DOI 10.1016/S1473-3099(15)00249-2
   de Gomensoro E, 2018, ANN MED, V50, P181, DOI 10.1080/07853890.2017.1417632
   Desiante F, 2017, ANN IG MED PREV COMU, V29, P256, DOI 10.7416/ai.2017.2157
   Dexter LJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000851
   Dunkle LM, 2017, NEW ENGL J MED, V376, P2427, DOI [10.1056/NEJMoa1608862, 10.1056/nejmoa1608862]
   European Centre for Disease Prevention and Control, 2018, ANN EP REP 2017
   Fausto F, 2018, SCAND J PUBLIC HEALT, V46, P170, DOI 10.1177/1403494817720102
   Isenor JE, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5697-x
   Italia. Ministry of Health, 2018, PREV CONTR INFL RACC
   Italian Ministry of Health, 2018, DAT COP VACC DAT VAC
   Italian National Institute of Statistics (ISTAT), 2017, ANN 2015 ANZ COND SA
   Izurieta Hs, RELATIVE EFFECTIVENE, DOI [10.1093/infdis/jiy716, DOI 10.1093/INFDIS/JIY716]
   Kan T, 2018, PUBLIC HEALTH, V156, P67, DOI 10.1016/j.puhe.2017.12.007
   Kassianos George, 2016, Drugs Context, V5, P212293, DOI 10.7573/dic.212293
   Kissling E, 2013, EUROSURVEILLANCE, V18, P33
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Lazio Region Department of Epidemiology, STAT SAL POP RES NEL
   Mak DB, 2015, AUST NZ J OBSTET GYN, V55, P131, DOI 10.1111/ajo.12292
   Newby KV, 2016, FAM PRACT, V33, P318, DOI 10.1093/fampra/cmw016
   Public Health England, ANN FLU PROGR 2014
   Rizzo C, 2007, EMERG INFECT DIS, V13, P694, DOI 10.3201/eid1305.061309
   ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8
   Signorelli C, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h116
   Thomas RE, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005188.pub4
   Wilkinson K, 2017, VACCINE, V35, P2775, DOI 10.1016/j.vaccine.2017.03.092
NR 34
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5314
EP 5322
DI 10.1016/j.vaccine.2019.07.054
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300023
PM 31331778
DA 2020-05-12
ER

PT J
AU Carryn, S
   Feyssaguet, M
   Povey, M
   Di Paolo, E
AF Carryn, Stephane
   Feyssaguet, Muriel
   Povey, Michael
   Di Paolo, Emmanuel
TI Long-term immunogenicity of measles, mumps and rubella-containing
   vaccines in healthy young children: A 10-year follow-up
SO VACCINE
LA English
DT Article
DE Long-term antibody persistence; Measles, mumps and rubella vaccine;
   Immunogenicity; Booster effect
ID IMMUNE-RESPONSES; VARICELLA VACCINE; 2ND YEAR; PERSISTENCE; OUTBREAK;
   RECOMMENDATION; IMMUNIZATION; INDIVIDUALS; PROTECTION; ANTIBODIES
AB Measles and mumps outbreaks still occur in countries that have successfully implemented universal routine immunization programs. Measles outbreaks are mostly associated to absent or incomplete vaccination, whereas for mumps outbreaks the combined effects of waning of immunity and circulating new strains are incriminated. It is therefore increasingly useful to characterize the long-lasting immunity induced by measles-, mumps, and rubella (MMR)-containing vaccines.
   In this 10-year study, 1887 healthy children aged 12-22 months, randomized to receive 1 or 2 doses of MMR-containing vaccines (Priorix or Priorix-Tetra; GSK), were included in an antibody persistence analysis. A total of 364 children in the 1-dose group received a second dose out of study according to their local vaccination schedule between Years 4 and 10 post-dose 1, and were included in a separate post hoc analysis to evaluate the effect of the second dose when given later. Anti-measles,-mumps and rubella antibody titers were measured by commercial ELISA kits (Enzygnost, Siemens) after each vaccine dose and at Years 1, 2, 4, 6, 8 and 10 post-vaccination.
   Antibodies against measles and rubella declined moderately after vaccination but remained well above the seropositivity threshold after 10 years. The anti-measles antibody titers elicited by Priorix-Tetra remained about 2-fold higher throughout the study as compared with Priorix. A second dose of MMR vaccine later in life had a minor and transient effect on anti-measles and anti-rubella waning titers. In contrast, anti-mumps antibody levels remained relatively stable over the 10-year follow-up and a second dose of MMR vaccine, given anytime over the 10-year period, had a boosting effect on anti-mumps antibody titers and seropositivity rates.
   In conclusion, 1 or 2 doses of MMR-containing vaccines given to children in their second year of life induced antibody responses against measles, mumps and rubella viruses that persisted at least up to 10 years post-vaccination. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Carryn, Stephane] GSK, R&D Ctr Belgium, Wavre, Belgium.
   [Feyssaguet, Muriel; Di Paolo, Emmanuel] GSK, Clin Lab Sci, Rixensart, Belgium.
   [Povey, Michael] GSK, Biostat, Wavre, Belgium.
RP Carryn, S (reprint author), GSK, R&D Live Virus Vaccine, Ave Fleming 20, B-1300 Wavre, Belgium.
EM stephane.x.carryn@gsk.com; muriel.m.feyssaguet@gsk.com;
   michael.x.povey@gsk.com; emmanuel.di-paolo@gsk.com
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX This work was supported by GlaxoSmithKline Biologicals SA, which was the
   funding source and was involved in all stages of the study conduct and
   analysis. GlaxoSmithKline Biologicals SA also took responsibility for
   all costs associated with the development and publishing of the present
   manuscript.
CR Abu-Elyazeed R, 2018, HUM VACC IMMUNOTHER, V14, P2624, DOI 10.1080/21645515.2018.1489186
   Albertson JP, 2016, MMWR-MORBID MORTAL W, V65, P731, DOI 10.15585/mmwr.mm6529a2
   ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A
   Barskey AE, 2009, VACCINE, V27, P6186, DOI 10.1016/j.vaccine.2009.06.109
   Cardemil CV, 2017, NEW ENGL J MED, V377, P947, DOI 10.1056/NEJMoa1703309
   Centers for Disease Control and Prevention, 2018, MEASL CAS OUTBR
   Centers for disease control and prevention, 2012, EPIDEMIOLOGY PREVENT, P325
   Centers for Disease Control and Prevention (CDC), 2018, MUMPS CAS OUTBR
   Dabbagh A, 2017, MMWR-MORBID MORTAL W, V66, P1148, DOI 10.15585/mmwr.mm6642a6
   Davidkin I, 2008, J INFECT DIS, V197, P950, DOI 10.1086/528993
   Dayan GH, 2008, NEW ENGL J MED, V358, P1580, DOI 10.1056/NEJMoa0706589
   Dhiman N, 2005, CLIN IMMUNOL, V115, P154, DOI 10.1016/j.clim.2004.12.010
   European Medicines Agency, 2012, PRIOR ANN 3 SUMM PRO
   Fiebelkorn AP, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu094
   GlaxoSmithKline, 2018, SUMMARY PRODUCT CHAR
   GlaxoSmithKline, 2017, SUMMARY PRODUCT CHAR
   Hamami D, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00233
   Hanna C, 2009, VACCINE, V27, P6504, DOI 10.1016/j.vaccine.2009.07.076
   Haralambieva IH, 2011, VACCINE, V29, P4485, DOI 10.1016/j.vaccine.2011.04.037
   Haralambieva LH, 2014, VACCINE, V32, P1946, DOI 10.1016/j.vaccine.2014.01.090
   Henry O, 2018, VACCINE, V36, P381, DOI 10.1016/j.vaccine.2017.11.081
   Latner DR, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx263
   Lee Chin-Yun, 2002, International Journal of Infectious Diseases, V6, P202, DOI 10.1016/S1201-9712(02)90112-8
   Lewnard JA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5945
   Marin M, 2018, MMWR-MORBID MORTAL W, V67, P33, DOI 10.15585/mmwr.mm6701a7
   Nelson GE, 2013, PEDIATR INFECT DIS J, V32, P374, DOI 10.1097/INF.0b013e318279f593
   Ogbuanu IU, 2012, PEDIATRICS, V130, pE1567, DOI 10.1542/peds.2012-0177
   Perez SC, 2018, EPIDEMIOL INFECT, V146, P1584, DOI 10.1017/S0950268818001474
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Povey M, 2019, LANCET INFECT DIS, V19, P287, DOI 10.1016/S1473-3099(18)30716-3
   Prymula R, 2014, LANCET, V383, P1313, DOI 10.1016/S0140-6736(12)61461-5
   Rager-Zisman B, 2004, CLIN DIAGN LAB IMMUN, V11, P913, DOI 10.1128/CDLI.11.5.913-918.2004
   Schuster V, 2008, PEDIATR INFECT DIS J, V27, P724, DOI 10.1097/INF.0b013e318170bb22
   Seagle EE, 2018, VACCINE, V36, P818, DOI 10.1016/j.vaccine.2017.12.075
   Umlauf BJ, 2012, VIRAL IMMUNOL, V25, P29, DOI 10.1089/vim.2011.0051
   Vandermeulen C, 2009, J INFECT DIS, V199, P1457, DOI 10.1086/598482
   Voigt EA, 2016, VACCINE, V34, P4913, DOI 10.1016/j.vaccine.2016.08.060
   Vygen S, 2016, EUROSURVEILLANCE, V21, P12, DOI 10.2807/1560-7917.ES.2016.21.10.30156
   World Health Organization, 2007, WKLY EPIDEMIOL REC, V82, P49
NR 39
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5323
EP 5331
DI 10.1016/j.vaccine.2019.07.049
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300024
PM 31345639
OA Other Gold
DA 2020-05-12
ER

PT J
AU Tiendrebeogo, RW
   Spallek, R
   Oehlmann, W
   Singh, M
   Theisen, M
   Nebie, I
   Moret, R
   Roussilhon, C
   Corradin, G
AF Tiendrebeogo, Regis Wendpayangde
   Spallek, Ralf
   Oehlmann, Wulf
   Singh, Mahavir
   Theisen, Michael
   Nebie, Issa
   Moret, Remy
   Roussilhon, Christian
   Corradin, Giampietro
TI Immunogenicity of a recombinant fusion construct composed of
   intrinsically unstructured, low polymorphic segments derived from
   merozoite surface protein 2 and trophozoite exported protein 1
SO VACCINE
LA English
DT Article
DE Malaria; Parasite; Vaccine; Antigen; Protection
ID STAGE MALARIA VACCINE; PLASMODIUM-FALCIPARUM; PARASITE GROWTH;
   IMMUNOGLOBULIN G3; HOLOENDEMIC AREA; IGG3 ANTIBODIES; ANTIGENS;
   MECHANISMS; INHIBITION; INVASION
AB To overcome the extensive polymorphism found in human Plasmodium antigens and to avoid the lengthy characterization of their 3 dimensional structure and subsequent production of the native proteins we have been concentrated in large unstructured, non-or low-polymorphic fragments present in the blood stage of P. falciparum. Three fragments derived from the 2 family-specific and constant regions of merozoite surface protein (MSP2) and PFF0165c protein were previously selected for evaluation as potential single vaccine candidates. In order to increase and optimize their potential efficacy against P. falciparum infection the 3 antigens were combined in a single DNA recombinant product (FusN) and compared its antigenicity with that of single antigens in sera of volunteers living in endemic countries. Immunogenicity of the FusN was then compared with that of the mixture of 3 antigens in 3 strains of mice. Antigen specific, affinity purified human antibodies were then tested in antibody dependent cellular inhibition and merozoite opsonization assays. In addition, the antigen specific antibody response and its association with protection from malaria infection were determined. The data collected indicate that the recombinant product is an equal or better antigen /immunogen than fragments used either alone or as a mixture for vaccination in combination with adjuvant. In addition, antibody response to FusN shows a stronger association with protection than single fragments. The use of a single construct as vaccine would drastically reduce the cost of manufacturing and development of the GMP product. (C) 2019 Published by Elsevier Ltd.
C1 [Tiendrebeogo, Regis Wendpayangde; Theisen, Michael] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Ctr Med Parasitol, Copenhagen, Denmark.
   [Tiendrebeogo, Regis Wendpayangde; Theisen, Michael] Copenhagen Univ Hosp, Rigshosp, Dept Infect Dis, Copenhagen, Denmark.
   [Tiendrebeogo, Regis Wendpayangde; Theisen, Michael] Statens Serum Inst, Dept Congenital Disorders, Copenhagen, Denmark.
   [Spallek, Ralf; Oehlmann, Wulf; Singh, Mahavir] LIONEX Diagnost & Therapeut GmbH, D-38126 Braunschweig, Germany.
   [Nebie, Issa] Ctr Natl Rech & Format Paludisme, BP 2208, Ouagadougou 01, Burkina Faso.
   [Moret, Remy] ASAREN 01BP3916, Ouagadougou 01, Burkina Faso.
   [Roussilhon, Christian] Inst Pasteur, 28 Rue Dr Roux, F-75015 Paris, France.
   [Corradin, Giampietro] Univ Lausanne, Biochem Dept, CH-1066 Epalinges, Switzerland.
RP Corradin, G (reprint author), Univ Lausanne, Biochem Dept, CH-1066 Epalinges, Switzerland.
EM giampietro.corradin@unil.ch
OI Theisen, Michael/0000-0003-4412-1392
FU European Community grant LSHP-CT-2003 [503240]; Bill and Melinda Gates
   FoundationGates Foundation [42387]
FX Part of this work was sponsored by the European Community grant
   LSHP-CT-2003-503240. The GLA-SE used in the mouse immunization
   experiments was provided in part under a grant #42387 to Steve Reed
   (Infectious Disease Research Institute, Seattle, WA, USA) from the Bill
   and Melinda Gates Foundation. We thank Drs Marcel Tanner and Ingrid
   Felger for having provided anonymous Tanzanian samples, which received
   research and ethical clearance from the Tanzanian Commission for Science
   and Technology (NSR/RCA 90). The valuable work of Ms Geraldine Frank is
   also acknowledged.
CR Adda CG, 2009, MOL BIOCHEM PARASIT, V166, P159, DOI 10.1016/j.molbiopara.2009.03.012
   ANDERS RF, 1989, BLOOD, V74, P1865
   Aribot G, 1996, AM J TROP MED HYG, V54, P449, DOI 10.4269/ajtmh.1996.54.449
   Balam S, 2016, VACCINE, V34, P1566, DOI 10.1016/j.vaccine.2016.02.013
   Balam S, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-510
   BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633
   BOUHAROUNTAYOUN H, 1995, J EXP MED, V182, P409, DOI 10.1084/jem.182.2.409
   BOUHAROUNTAYOUN H, 1992, INFECT IMMUN, V60, P1473, DOI 10.1128/IAI.60.4.1473-1481.1992
   Carvalho LJM, 2002, SCAND J IMMUNOL, V56, P327, DOI 10.1046/j.1365-3083.2002.01160.x
   CORRADIN G, 1977, J IMMUNOL, V119, P1048
   Corradin G, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001387
   Cowman AF, 2000, FEBS LETT, V476, P84, DOI 10.1016/S0014-5793(00)01703-8
   Diop F, 2014, SENEGAL MALAR J, V6, P83, DOI [10.1186/1475-2875-13-83.12, DOI 10.1186/1475-2875-13-83.12]
   Druilhe P, 2005, PLOS MED, V2, P1135, DOI 10.1371/journal.pmed.0020344
   Felger I, 1997, J MOL EVOL, V45, P154, DOI 10.1007/PL00006215
   Feng ZP, 2006, MOL BIOCHEM PARASIT, V150, P256, DOI 10.1016/j.molbiopara.2006.08.011
   Flueck C, 2009, VACCINE, V27, P2653, DOI 10.1016/j.vaccine.2009.02.081
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Genton B, 2000, VACCINE, V18, P2504, DOI 10.1016/S0264-410X(00)00036-0
   Jogdand PS, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-235
   Kulangara C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046112
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   McCarthy JS, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0021914, 10.1371/journal.pone.0024413]
   Metzger WG, 2003, PARASITE IMMUNOL, V25, P307, DOI 10.1046/j.1365-3024.2003.00636.x
   Olugbile S, 2009, INFECT IMMUN, V77, P5701, DOI 10.1128/IAI.00652-09
   Roussilhon C, 2007, PLOS MED, V4, P1791, DOI 10.1371/journal.pmed.0040320
   Sarthou JL, 1997, INFECT IMMUN, V65, P3271, DOI 10.1128/IAI.65.8.3271-3276.1997
   Saul A, 1999, VACCINE, V17, P3145, DOI 10.1016/S0264-410X(99)00175-9
   Steiner-Monard V, 2019, CLIN INFECT DIS, V68, P466, DOI 10.1093/cid/ciy514
   TAYLOR RR, 1995, INFECT IMMUN, V63, P4382, DOI 10.1128/IAI.63.11.4382-4388.1995
   Taylor RR, 1998, AM J TROP MED HYG, V58, P406, DOI 10.4269/ajtmh.1998.58.406
   Tebo AE, 2001, EXP PARASITOL, V98, P20, DOI 10.1006/expr.2001.4619
   Theisen M, 1998, INFECT IMMUN, V66, P11, DOI 10.1128/IAI.66.1.11-17.1998
   Tiendrebeogo RW, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-412
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   TRAPE JF, 1994, AM J TROP MED HYG, V51, P123, DOI 10.4269/ajtmh.1994.51.123
   Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110
NR 37
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5332
EP 5340
DI 10.1016/j.vaccine.2019.07.048
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300025
PM 31358409
DA 2020-05-12
ER

PT J
AU Yao, PP
   Miao, ZP
   Xu, F
   Lu, HJ
   Sun, YS
   Xia, Y
   Chen, C
   Yang, ZN
   Xia, SC
   Jiang, JM
   Hu, CG
   Mao, ZA
   Gao, M
   Xu, ZY
   Ying, HP
   Yao, CH
   Zhu, ZY
   Zhu, HP
   Xiang, HQ
AF Yao, Ping-Ping
   Miao, Zi-Ping
   Xu, Fang
   Lu, Hang-Jing
   Sun, Yi-Sheng
   Xia, Yong
   Chen, Chen
   Yang, Zhang-Nv
   Xia, Shi-Chang
   Jiang, Jian-min
   Hu, Chong-Gao
   Mao, Zi-An
   Gao, Meng
   Xu, Zhi-Yao
   Ying, Han-ping
   Yao, Chen-hui
   Zhu, Zhi-Yong
   Zhu, Han-Ping
   Xiang, Hai-qing
TI An adult gerbil model for evaluating potential coxsackievirus A16
   vaccine candidates
SO VACCINE
LA English
DT Article
DE Coxsackievirus A16; Animal model; Gerbils; Inactivated vaccine
ID NEONATAL MOUSE MODEL; ENTEROVIRUS 71; MOUTH-DISEASE; MONGOLIAN GERBILS;
   HAND; FOOT; INFECTION; VIRUS; EPIDEMIOLOGY; OUTBREAK
AB A suitable animal model of CVA16 infection is crucial in order to understand its pathogenesis and to help develop antiviral vaccines or screen therapeutic drugs. The neonatal mouse model has a short sensitivity period to CA16 infection, which is a major limitation. In this study, we demonstrate that adult (60-day-old) gerbils are susceptible to CVA16 infection at high doses (10(8.0) TCID50). A clinical isolate strain of CVA16 was inoculated intraperitoneally into adult gerbils, which subsequently developed significant clinical symptoms, including hind limb weakness, paralysis of one or both hind limbs, tremors, and eventual death from neurological disorders. Real-time RT-PCR revealed that viral loads in the spinal cord and brainstem were higher than those in other organs/tissues. Histopathological changes, such as neuronal degeneration, neuronal loss, and neuronophagia, were observed in the spinal cord, brainstem, and heart muscle, along with necrotizing myositis. Gerbils receiving both prime and boost immunizations of alum adjuvant inactivated vaccine exhibited no clinical signs of disease or mortality following challenge by CVA16, whereas 80% of control animals showed obvious clinical signs, including slowness, paralysis of one or both hind limbs, and eventual death, suggesting that the CVA16 vaccine can fully protect gerbils against CVA16 challenge. These results demonstrate that an adult gerbil model provides us with a useful tool for studying the pathogenesis and evaluating antiviral reagents of CVA16 infection. The development of this animal model would also be conducive to screening promising CVA16 vaccine candidates as well as further vaccination evaluation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yao, Ping-Ping; Miao, Zi-Ping; Xu, Fang; Lu, Hang-Jing; Sun, Yi-Sheng; Xia, Yong; Chen, Chen; Yang, Zhang-Nv; Xia, Shi-Chang; Jiang, Jian-min; Hu, Chong-Gao; Zhu, Zhi-Yong; Zhu, Han-Ping] Zhejiang Prov Ctr Dis Control & Prevent, Key Lab Vaccine Prevent & Control Infect Dis Zhej, Hangzhou, Zhejiang, Peoples R China.
   [Mao, Zi-An; Gao, Meng] Zhejiang Pukang Biotechnol Co LTD, Hangzhou, Zhejiang, Peoples R China.
   [Xu, Zhi-Yao; Ying, Han-ping] Zhejiang Univ, Hangzhou, Zhejiang, Peoples R China.
   [Yao, Chen-hui] China Med Univ, Shenyang, Liaoning, Peoples R China.
   [Xiang, Hai-qing] Hlth Serv Dev Ctr Hangzhou, Hangzhou, Zhejiang, Peoples R China.
RP Zhu, HP (reprint author), Zhejiang Prov Ctr Dis Control & Prevent, Key Lab Vaccine Prevent & Control Infect Dis Zhej, Hangzhou, Zhejiang, Peoples R China.; Xiang, HQ (reprint author), Hlth Serv Dev Ctr Hangzhou, Hangzhou, Zhejiang, Peoples R China.
EM hpzhu@cdc.zj.cn; xhq87065651@163.com
FU Major Science and Technology Project of the Science and Technology
   Department of Zhejiang Province [2018C03070]; Commonwealth Project of
   the Science and Technology Department of Zhejiang Province
   [LGF18H100002]; Zhejiang Provincial Foundation for Scientific Research
   in Medicine and HealthNatural Science Foundation of Zhejiang Province
   [WKJ-ZJ-1816]; Zhejiang Provincial Natural Science Foundation of
   ChinaNatural Science Foundation of Zhejiang Province [LY18H190003]
FX This work was supported by the Major Science and Technology Project of
   the Science and Technology Department of Zhejiang Province (Grant Number
   2018C03070), the Commonwealth Project of the Science and Technology
   Department of Zhejiang Province (LGF18H100002), the Zhejiang Provincial
   Foundation for Scientific Research in Medicine and Health (WKJ-ZJ-1816),
   and the Zhejiang Provincial Natural Science Foundation of China
   (LY18H190003).
CR Cai YC, 2014, VACCINE, V32, P2406, DOI 10.1016/j.vaccine.2014.03.012
   Chang LY, 1999, PEDIATR INFECT DIS J, V18, P1092, DOI 10.1097/00006454-199912000-00013
   Chaudhary R, 2018, CURR ATHEROSCLER REP, V20, DOI 10.1007/s11883-018-0746-6
   Chen CS, 2007, J VIROL, V81, P8996, DOI 10.1128/JVI.00236-07
   Chen YC, 2004, J GEN VIROL, V85, P69, DOI 10.1099/vir.0.19423-0
   Chong P, 2015, CLIN INFECT DIS, V60, P797, DOI 10.1093/cid/ciu852
   Chou AH, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/831282
   Foo DGW, 2007, MICROBES INFECT, V9, P1299, DOI 10.1016/j.micinf.2007.06.002
   Fujimoto T, 2002, MICROBIOL IMMUNOL, V46, P621, DOI 10.1111/j.1348-0421.2002.tb02743.x
   Geoghegan JL, 2015, J VIROL, V89, P8871, DOI 10.1128/JVI.00706-15
   GILBERT GL, 1988, PEDIATR INFECT DIS J, V7, P484, DOI 10.1097/00006454-198807000-00007
   Goto K, 2009, EMERG INFECT DIS, V15, P1689, DOI 10.3201/eid1510.090594
   Han JF, 2014, VIRUS RES, V179, P212, DOI 10.1016/j.virusres.2013.10.020
   He SJ, 2013, INT J INFECT DIS, V17, pE1025, DOI 10.1016/j.ijid.2013.04.003
   Iwai M, 2009, JPN J INFECT DIS, V62, P254
   Kelly JT, 2015, ANTIVIR RES, V124, P77, DOI 10.1016/j.antiviral.2015.10.006
   Kim Kyung Hyo, 2010, Korean J Pediatr, V53, P616, DOI 10.3345/kjp.2010.53.5.616
   Koh WM, 2016, PEDIATR INFECT DIS J, V35, pE285, DOI 10.1097/INF.0000000000001242
   Lee BJ, 2003, MICROBES INFECT, V5, P1195, DOI 10.1016/j.micinf.2003.07.007
   Lee Kyung Yeon, 2016, Korean J Pediatr, V59, P395
   Lee MS, 2010, PEDIATR INFECT DIS J, V29, P1030, DOI 10.1097/INF.0b013e3181e52945
   Legay F, 2007, EMERG INFECT DIS, V13, P1084, DOI 10.3201/eid1307.070295
   Li JJ, 2012, INT J NEUROSCI, V122, P338, DOI 10.3109/00207454.2012.657379
   Li JL, 2014, J GEN VIROL, V95, P1083, DOI 10.1099/vir.0.063560-0
   Li LL, 2005, J CLIN MICROBIOL, V43, P3835, DOI 10.1128/JCM.43.8.3835-3839.2005
   Li WG, 2009, J MED VIROL, V81, P1591, DOI 10.1002/jmv.21573
   Liu SL, 2015, REV MED VIROL, V25, P115, DOI 10.1002/rmv.1827
   Lu GW, 2011, J VIROL, V85, P10319, DOI 10.1128/JVI.00787-11
   Ma E, 2010, INT J INFECT DIS, V14, pE775, DOI 10.1016/j.ijid.2010.02.2265
   Mao QY, 2012, J VIROL, V86, P11967, DOI 10.1128/JVI.00902-12
   MATSUZAKI H, 1989, VET PATHOL, V26, P11, DOI 10.1177/030098588902600103
   Nomoto T, 2003, NEUROSCI LETT, V340, P153, DOI 10.1016/S0304-3940(03)00095-8
   Ohka S, 1998, VIROLOGY, V250, P67, DOI 10.1006/viro.1998.9360
   Omana-Cepeda Carlos, 2016, BMC Res Notes, V9, P165, DOI 10.1186/s13104-016-1973-y
   Ranganathan Shoba, 2002, Appl Bioinformatics, V1, P43
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   SICKLES GM, 1955, P SOC EXP BIOL MED, V90, P529
   Sun YS, 2016, SCI REP-UK, V6, DOI 10.1038/srep34299
   Wang CY, 2004, PEDIATR INFECT DIS J, V23, P275, DOI 10.1097/01.inf.0000115950.63906.78
   Wang SM, 1999, CLIN INFECT DIS, V29, P184, DOI 10.1086/520149
   Wang YF, 2004, J VIROL, V78, P7916, DOI 10.1128/JVI.78.15.7916-7924.2004
   Wei W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094746
   WRIGHT HT, 1963, NEW ENGL J MED, V268, P1041, DOI 10.1056/NEJM196305092681904
   Wu Y, 2010, INT J INFECT DIS, V14, pE1076, DOI 10.1016/j.ijid.2010.07.006
   Xu F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119173
   Yamayoshi S, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.49
   Yang EX, 2014, HUM VACC IMMUNOTHER, V10, P1266, DOI 10.4161/hv.28083
   Yang F, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-508
   Yang WX, 1997, VIROLOGY, V229, P421, DOI 10.1006/viro.1997.8450
   Yao PP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051996
   ZHU ZY, 1986, CHINESE MED J-PEKING, V99, P760
NR 51
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5341
EP 5349
DI 10.1016/j.vaccine.2019.07.046
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300026
PM 31351798
DA 2020-05-12
ER

PT J
AU Gupta, S
   Chaudhary, S
   Bubber, P
   Ray, P
AF Gupta, Shipra
   Chaudhary, Sanjeev
   Bubber, Parvesh
   Ray, Pratima
TI Epidemiology and genetic diversity of group A rotavirus in acute
   diarrhea patients in pre-vaccination era in Himachal Pradesh, India
SO VACCINE
LA English
DT Article
DE Rotavirus; Prevalence; Children; Diarrhea; Genotype; Vaccine; Rotavae
   (R); Himachal Pradesh
ID HOSPITAL-BASED SURVEILLANCE; CHILDREN LESS-THAN-5 YEARS; ACUTE
   GASTROENTERITIS; MOLECULAR EPIDEMIOLOGY; NEW-DELHI; STRAINS; PREVALENCE;
   EMERGENCE; IDENTIFICATION; MULTICENTER
AB Acute gastroenteritis due to Group A rotaviruses remains the leading cause of mortality and morbidity in children in developing countries. India introduced its indigenous rotavirus vaccine Rotavac (R) in 2016 and Himachal Pradesh (HP) the first state to launch it. The present study aimed to evaluate rotavirus strain diversity associated with AGE prior to vaccine introduction in HP. A total of 331 fecal specimens collected from diarrheic children hospitalized at RPGMC Tanda, HP between July-2014 and June-2016 were screened for RVA by EIA. Rotavirus RNA was extracted by TRIZOL method and analyzed by RNA-PAGE. G/P typing was performed using semi-nested multiplex reverse transcriptase PCR. Rotavirus was detected in 45% (n = 149/331) of diarrheic children, with highest rate observed in the 6-11 months age group (47%). Vomiting was found more frequently associated with RV-infection. Among G-types, G12 was found most prevalent (33.1%) followed by G1 (28.4%), G9 (12.2%), G2 (9.5%), G3 (3.4%) and G10 (2.7%). G4 (0.7%) strains were rarely detected. Among P-types, P[6] was the most prevalent (40.5%) followed by P[8] (29.1%) and P[4] (14.2%). Of note, genotypes G3 and 1311 1 were detected for the first time in HP. Among GIP combinations, G1 2P[6] was most prevalent (30.4%) followed by G1 P[8] (20.3%), G2P[4] (4.7%), G1 P[6] (3.4%) and G3P[8] (2.7%). Interestingly, our study observed high percentage of unusual strains (14.2%) namely G9P[4], G2P[6], G2P[8], G12P[4] and G1P[11]. The regionally common strains G3P[6], G4P[6], G9P[6], G9P[8], G10P[6], G1 OP[8] and G1 2P[8] strains were very rarely detected. Of interest, RNA migration pattern of G1 P[8] was DS-1 like and genomic heterogeneity was observed within G12P[4] strains with both long and short electropherotypes. Our study highlights rich genetic diversity with emergence of rare rotavirus strains circulating in HP and provides baseline data prior to Rotavac (R) introduction that will help to gauge the impact of the Rotavac (R) vaccine in HP. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gupta, Shipra; Ray, Pratima] Jamia Hamdard, Sch Chem & Life Sci, Dept Biotechnol, New Delhi 110062, India.
   [Chaudhary, Sanjeev] Dr Rajendra Prasad Govt Med Coll, Dept Pediat, Tanda 176001, Himachal Prades, India.
   [Gupta, Shipra; Bubber, Parvesh] IGNOU, Sch Sci, Dept Biochem, New Delhi 110068, India.
RP Ray, P (reprint author), Jamia Hamdard, Sch Chem & Life Sci, Dept Biotechnol, New Delhi 110062, India.
EM pray@jamiahamdard.ac.in
CR [Anonymous], 2013, Wkly Epidemiol Rec, V88, P49
   Aupiais C, 2009, J CLIN VIROL, V46, P282, DOI 10.1016/j.jcv.2009.07.021
   Babji S, 2018, VACCINE, V36, P7816, DOI 10.1016/j.vaccine.2017.08.035
   Babji S, 2014, VACCINE, V32, pA10, DOI 10.1016/j.vaccine.2014.03.001
   Bahl R, 2005, J INFECT DIS, V192, pS114, DOI 10.1086/431497
   Broor S, 2003, INDIAN J MED RES, V118, P59
   Chitambar SD, 2014, VACCINE, V32, pA29, DOI 10.1016/j.vaccine.2014.03.027
   Das S, 2003, J CLIN MICROBIOL, V41, P2760, DOI 10.1128/JCM.41.6.2760-2762.2003
   de Rougemont A, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.05.025
   Dian ZQ, 2017, ARCH VIROL, V162, P281, DOI 10.1007/s00705-016-3102-6
   Estes M. K., 2013, FIELDS VIROLOGY, P1347
   GENTSCH JR, 1992, J CLIN MICROBIOL, V30, P1365, DOI 10.1128/JCM.30.6.1365-1373.1992
   Giri S, 2018, VACCINE, V36, P7851, DOI 10.1016/j.vaccine.2018.02.092
   Gomara MI, 2004, J CLIN MICROBIOL, V42, P2541, DOI 10.1128/JCM.42.6.2541-2547.2004
   Gomara MI, 2001, J CLIN MICROBIOL, V39, P3796, DOI 10.1128/JCM.39.10.3796-3798.2001
   Gupta S, 2018, J MED VIROL, V90, P469, DOI 10.1002/jmv.24980
   Jain S, 2016, INFECT GENET EVOL, V46, P65, DOI 10.1016/j.meegid.2016.10.021
   Jain Swapnil, 2016, VirusDisease, V27, P77, DOI 10.1007/s13337-016-0303-2
   Jain S, 2014, VACCINE, V32, P3367, DOI 10.1016/j.vaccine.2014.04.037
   Jain V, 2001, J CLIN MICROBIOL, V39, P3524, DOI 10.1128/JCM.39.10.3524-3529.2001
   Jere KC, 2018, J VIROL, V92, DOI 10.1128/JVI.01246-17
   John J, 2014, VACCINE, V32, pA5, DOI 10.1016/j.vaccine.2014.03.004
   Kang G, 2013, VACCINE, V31, P2879, DOI 10.1016/j.vaccine.2013.04.030
   Kang G, 2009, J INFECT DIS, V200, pS147, DOI 10.1086/605031
   Kaplon J, 2018, CLIN MICROBIOL INFEC, V24, DOI 10.1016/j.cmi.2017.10.009
   Mehendale S, 2016, INDIAN PEDIATR, V53, P575, DOI 10.1007/s13312-016-0891-3
   Miles MG, 2012, VACCINE, V30, pA131, DOI 10.1016/j.vaccine.2011.10.002
   Mohanty E, 2017, INFECT GENET EVOL, V53, P77, DOI 10.1016/j.meegid.2017.04.016
   Mukherjee A, 2012, INFECT GENET EVOL, V12, P467, DOI 10.1016/j.meegid.2011.11.007
   Mukherjee A, 2010, INFECT GENET EVOL, V10, P311, DOI 10.1016/j.meegid.2010.01.002
   Mullick S, 2014, VACCINE, V32, pA20, DOI 10.1016/j.vaccine.2014.03.018
   Nitiema LW, 2011, INT J INFECT DIS, V15, pE646, DOI 10.1016/j.ijid.2011.05.009
   O'Ryan M, 2006, J PEDIATR-US, V149, P448, DOI 10.1016/j.jpeds.2006.07.018
   Quaye O, 2013, EMERG INFECT DIS, V19, P1332, DOI 10.3201/eid1908.130288
   Rahman M, 2007, J VIROL, V81, P2382, DOI 10.1128/JVI.01622-06
   Rajendran P, 2014, VACCINE, V32, pA89, DOI 10.1016/j.vaccine.2014.03.026
   Ramachandran M, 1996, J CLIN MICROBIOL, V34, P436, DOI 10.1128/JCM.34.2.436-439.1996
   Ramani S, 2007, J CLIN MICROBIOL, V45, P432, DOI 10.1128/JCM.01710-06
   Ray P, 2007, J CLIN MICROBIOL, V45, P3824, DOI 10.1128/JCM.01288-07
   RUUSKA T, 1991, ACTA PAEDIATR SCAND, V80, P500, DOI 10.1111/j.1651-2227.1991.tb11893.x
   Saluja T, 2014, VACCINE, V32, pA13, DOI 10.1016/j.vaccine.2014.03.030
   Samajdar S, 2008, J CLIN VIROL, V43, P334, DOI 10.1016/j.jcv.2008.07.007
   Seheri L. M, 2017, VACCINE, V36, P7222
   Sharma S, 2008, J CLIN MICROBIOL, V46, P1343, DOI 10.1128/JCM.02358-07
   Sharma S, 2009, J CLIN MICROBIOL, V47, P3998, DOI 10.1128/JCM.00809-09
   Tiku VR, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0767-8
   Tiku VR, 2014, VACCINE, V32, pA62, DOI 10.1016/j.vaccine.2014.03.005
   Trojnar E, 2013, J GEN VIROL, V94, P136, DOI 10.1099/vir.0.047381-0
   Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404
   Yamamoto SP, 2015, J MED VIROL, V87, P1311, DOI 10.1002/jmv.24121
NR 50
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5350
EP 5356
DI 10.1016/j.vaccine.2019.07.037
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300027
PM 31331769
DA 2020-05-12
ER

PT J
AU Brandileone, MCD
   Zanella, RC
   Almeida, SCG
   Cassiolato, AP
   de Lemos, APS
   Salgado, MM
   Higa, FT
   Minamisava, R
   Andrade, AL
AF Brandileone, Maria-Cristina de C.
   Zanella, Rosemeire C.
   Almeida, Samanta C. G.
   Cassiolato, Ana Paula
   de Lemos, Ana Paula S.
   Salgado, Maristela M.
   Higa, Fabio T.
   Minamisava, Ruth
   Andrade, Ana Lucia
TI Long-term effect of 10-valent pneumococcal conjugate vaccine on
   nasopharyngeal carriage of Streptococcus pneumoniae in children in
   Brazil
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Nasopharyngeal carriage; Ten-valent
   pneumococcal conjugate vaccine; Children
ID SEROTYPE 19A PNEUMOCOCCI; HAEMOPHILUS-INFLUENZAE; CAPSULAR SEROTYPES;
   UNITED-STATES; DISEASE; IMPACT; COLONIZATION; EMERGENCE; ASSAY; 6C
AB Brazil introduced the 10-valent pneumococcal vaccine (PCV10) to the routine national immunization program (NIP) in March 2010. In 2017, we investigated the effects of PCV10 on nasopharyngeal carriage of vaccine-types (VT) and non-vaccine-types (NVT) of Streptococcus pneumoniae (Spn) among children living in Sao Paulo city. We also compared the prevalence of VT and NVT with previous carriage surveys performed in 2010 (baseline) and 2013.
   Method: The carriage survey was conducted among 531 children, aged 12 months to <24 months, recruited from public Primary Health Units during the immunization campaign, using previous surveys methodology, except for qPCR, which was performed in the 2017 survey only.
   Results: No statistical difference was found in the prevalence of Spn either by culture (59.7%) or by qPCR (61.2%). Spn carriage increased from 40.3% (baseline) to 59.7% (2017 survey) (p < 0.001). Colonization by VT isolates significantly decreased by 90.9% (19.8-1.8%) and 95.5% (19.8-0.9%) in the 2013 and 2017 surveys, respectively, compared to that at baseline. NVT isolates increased significantly by 128% (19.6-44.8%) and 185% (19.6-55.9%) in the respective post-PCV10 surveys, most led to high prevalence of serotypes 6C (27%), 15B (9.8%), 19A (9.2%), 15A (6.0%), and 16F (5.7%). In 2017, reduction in serotype 6A (4.2-0.6%, p < 0.001) and increase in serotype 19A (1.8-6.0%, p = 0.001) were found; serotype 3 isolate was not detected in the present survey. We identified the emergence of 19A isolates CC320, associated with high penicillin (MIC >= 2.0 mg/L) and cefotaxime (MIC >= 1.0 mg/L) values.
   Conclusion: After 7 years of PCV10 introduction in the NIP, colonization by VT among toddlers decreased substantially to a residual level, along with substantial serotype replacement by novel serotypes not present in any current conjugated pneumococcal vaccine and serotype 19A. The present findings can assist policy decisions in Brazil. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Brandileone, Maria-Cristina de C.; Zanella, Rosemeire C.; Almeida, Samanta C. G.; Cassiolato, Ana Paula; de Lemos, Ana Paula S.] Ctr Bacteriol, Natl Lab Meningitis & Pneumococcal Infect, Lab Meningitis Pneumonia & Pneumococcal Infect, Sao Paulo, Brazil.
   [Salgado, Maristela M.; Higa, Fabio T.] IAL, Ctr Immunol, Mol Biol Lab, Sao Paulo, SP, Brazil.
   [Minamisava, Ruth] Univ Fed Goias, Fac Nursing, Goiania, Go, Brazil.
   [Andrade, Ana Lucia] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Goiania, Go, Brazil.
RP Brandileone, MCD (reprint author), Ctr Bacteriol, Natl Lab Meningitis & Pneumococcal Infect, Lab Meningitis Pneumonia & Pneumococcal Infect, Sao Paulo, Brazil.
EM maria.brandileone@ial.sp.gov.br; rosemeire.zanella@ial.sp.gov.br;
   samanta.almeida@ial.sp.gov.br; ana.lemos@ial.sp.gov.br;
   maristela.salgado@ial.sp.ov.br; fabio.higa@ial.sp.gov.br
RI Almeida, Samanta Cristine Grassi/J-2798-2017
OI Almeida, Samanta Cristine Grassi/0000-0002-0714-8142
FU Adolfo Lutz Institute (IAL); Coordinator of Disease Control;
   Pan-American Health Organization, WDC, USA; Pfizer, Inc., USA.Pfizer
   [302338/2018-7, 306096/2010-2]; National Council for Scientific and
   Technological Development/CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX The 2010 and 2013 surveys were supported by Adolfo Lutz Institute (IAL)
   and by the Coordinator of Disease Control (CCD) of the Secretary of
   Health of the State of Sao Paulo (SES-SP), Brazil; IAL received
   laboratory supplies from the Streptococcus Laboratory at CDC, Atlanta,
   GA, USA, and donation of pneumococcal antisera from the Pan-American
   Health Organization, WDC, USA. All the 2017 surveys were supported by
   Pfizer, Inc., USA.; M.C.C. Brandileone (Grant No. 302338/2018-7) and A.
   L. Andrade (Grant No. 306096/2010-2) received grants from The National
   Council for Scientific and Technological Development/CNPq.
CR Andrade AL, 2016, HUM VACC IMMUNOTHER, V12, P285, DOI 10.1080/21645515.2015.1117713
   Ardanuy C, 2009, J ANTIMICROB CHEMOTH, V64, P507, DOI 10.1093/jac/dkp210
   Balsells E, 2018, J INFECTION, V77, P368, DOI 10.1016/j.jinf.2018.06.004
   Beall BW, 2011, J INFECT DIS, V203, P1360, DOI 10.1093/infdis/jir052
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Brandileone MCC, 2018, VACCINE, V36, P2559, DOI 10.1016/j.vaccine.2018.04.010
   Brandileone MCD, 2016, VACCINE, V34, P5604, DOI 10.1016/j.vaccine.2016.09.027
   Brazil. Ministerio da saude, NOV CAL VAC 2017
   Carvalho MD, 2010, J CLIN MICROBIOL, V48, P1611, DOI 10.1128/JCM.02243-09
   Carvalho MDS, 2007, J CLIN MICROBIOL, V45, P2460, DOI 10.1128/JCM.02498-06
   Cassiolato AP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208211
   Clinical and Laboratory Standards Institute (CLSI), 2009, M10019 CLSI
   Dagan R, 2009, CLIN MICROBIOL INFEC, V15, P16, DOI 10.1111/j.1469-0691.2009.02726.x
   De Wals P, 2014, VACCINE, V32, P1501, DOI 10.1016/j.vaccine.2013.11.028
   Devine VT, 2015, J IMMUNOL RES, DOI 10.1155/2015/394368
   Domingues CMAS, 2014, LANCET RESP MED, V2, P464, DOI 10.1016/S2213-2600(14)70060-8
   Emery SL, 2004, EMERG INFECT DIS, V10, P311, DOI 10.3201/eid1002.030759
   Enright MC, 1998, MICROBIOL-UK, V144, P3049, DOI 10.1099/00221287-144-11-3049
   Feikin DR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001517
   Feil EJ, 2004, J BACTERIOL, V186, P1518, DOI 10.1128/JB.186.5.1518-1530.2004
   Green MC, 2011, J CLIN MICROBIOL, V49, P2097, DOI 10.1128/JCM.02207-10
   Hammitt LL, 2014, LANCET GLOB HEALTH, V2, pE397, DOI 10.1016/S2214-109X(14)70224-4
   Kayhty H, 2006, EXPERT REV VACCINES, V5, P651, DOI 10.1586/14760584.5.5.651
   Millar EV, 2010, CLIN INFECT DIS, V51, P1258, DOI 10.1086/657070
   Moore MR, 2008, J INFECT DIS, V197, P1016, DOI 10.1086/528996
   Naucler P, 2017, CLIN INFECT DIS, V65, P1780, DOI 10.1093/cid/cix685
   Neves FPG, 2017, VACCINE, V35, P2794, DOI 10.1016/j.vaccine.2017.04.019
   O'Brien KL, 2007, J INFECT DIS, V196, P1211, DOI 10.1086/521833
   O'Brien Katherine L, 2003, Pediatr Infect Dis J, V22, pe1, DOI 10.1097/00006454-200302000-00010
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   O'Brien KL, 2001, J CLIN MICROBIOL, V39, P1021, DOI 10.1128/JCM.39.3.1021-1024.2001
   Pai R, 2006, J CLIN MICROBIOL, V44, P124, DOI 10.1128/JCM.44.1.124-131.2006
   Park IH, 2008, J INFECT DIS, V198, P1818, DOI 10.1086/593339
   Pimenta FC, 2013, J CLIN MICROBIOL, V51, P647, DOI 10.1128/JCM.02927-12
   Potin M, 2016, REV CHIL INFECTOL, V33, P304, DOI 10.4067/S0716-10182016000300009
   Ramos V, 2014, VACCINE, V32, P755, DOI 10.1016/j.vaccine.2013.12.024
   Rinta-Kokko H, 2018, VACCINE, V36, P1934, DOI 10.1016/j.vaccine.2018.03.001
   Sacchi CT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020675
   Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1
   Weinberger DM, 2013, AM J EPIDEMIOL, V178, P1488, DOI 10.1093/aje/kwt156
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   World Health Organization, 2011, LAB METH DIAGN MEN C
NR 42
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5357
EP 5363
DI 10.1016/j.vaccine.2019.07.043
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300028
PM 31351796
OA Other Gold
DA 2020-05-12
ER

PT J
AU Eickhoff, CS
   Blazevic, A
   Killoran, EA
   Morris, MS
   Hoft, DF
AF Eickhoff, Christopher S.
   Blazevic, Azra
   Killoran, Emma A.
   Morris, Mary S.
   Hoft, Daniel F.
TI Induction of mycobacterial protective immunity by sublingual BCG
   vaccination
SO VACCINE
LA English
DT Article
DE Tuberculosis; T cell immunity; Vaccine; Sublingual
ID TUBERCULOSIS; IMMUNIZATION; PREVENTION; METAANALYSIS; INFECTION;
   EFFICACY
AB Tuberculosis (TB) remains a tremendous global health problem, with 1/4 of the world's population infected and causing > 1 million deaths annually. Intradermal Bacillus Calmette-Guerin (BCG) vaccine given during infancy protects against severe forms of acute disease but does not prevent chronic infection or development of pulmonary TB. TB vaccine mucosal targeting potentially could induce mucosal resident immune cells with increased protective capacity against pulmonary infection and disease. Sublingual (SL) administration of vaccines may be an optimal mucosal delivery platform based on the high absorptive capacity of this mucosal surface, the extensive lymphoid tissue, and published preclinical studies demonstrating efficacy of SL vaccination against other pathogens. To this end, we performed preliminary testing of sublingual TB vaccines. Vaccination of mice with SL BCG elicited potent mycobacteria-specific T cell responses which persisted 16 weeks post-immunization. The magnitudes of the T cell responses were similarly induced after sublingual, intranasal, and subcutaneous BCG vaccination. Interestingly, serum mycobacteria-specific antibody responses and systemic recovery of BCG post vaccination were lower after SL BCG compared with systemic BCG immunization. However, more importantly, SL BCG vaccinated mice were significantly protected against an aerosolized virulent M. tuberculosis challenge (P < 0.0001 compared to unvaccinated mice). Furthermore, this protection was long-lived, persisting for 16 weeks with >1 log CFU reduction compared with naive challenged mice in both lungs and spleens (P < 0.0001 and P < 0.0028, respectively). These exciting results provide strong support for further studies exploring the mechanisms of protective immunity induced by sublingual BCG vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Eickhoff, Christopher S.; Blazevic, Azra; Hoft, Daniel F.] St Louis Univ, Div Infect Dis Allergy & Immunol, Dept Internal Med, 1100 South Grand Blvd, St Louis, MO 63104 USA.
   [Hoft, Daniel F.] St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA.
   [Killoran, Emma A.] Washington Univ, Sch Med, St Louis, MO USA.
   [Morris, Mary S.] Allergy Associates La Crosse, Onalaska, WI USA.
RP Hoft, DF (reprint author), St Louis Univ, Div Infect Dis Allergy & Immunol, Dept Internal Med, 1100 South Grand Blvd, St Louis, MO 63104 USA.; Hoft, DF (reprint author), St Louis Univ, Dept Mol Microbiol, Div Infect Dis Allergy & Immunol, 1100 South Grand Blvd, St Louis, MO 63104 USA.
EM Daniel.Hoft@health.slu.edu
FU La Crosse Community Foundation
FX Work funded by the La Crosse Community Foundation.
CR Alecsandru D, 2011, CLIN EXP IMMUNOL, V164, P100, DOI 10.1111/j.1365-2249.2011.04320.x
   [Anonymous], 2018, TUB FACT SHEET
   BARCLAY WR, 1973, AM REV RESPIR DIS, V107, P351
   Blanco G, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1432328
   Blazevic A, 2014, MICROBES INFECT, V16, P73, DOI 10.1016/j.micinf.2013.09.006
   Chen LH, 2004, INFECT IMMUN, V72, P238, DOI 10.1128/IAI.72.1.238-246.2004
   COLDITZ GA, 1995, PEDIATRICS, V96, P29
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Derrick SC, 2014, CLIN VACCINE IMMUNOL, V21, P1443, DOI 10.1128/CVI.00394-14
   Eickhoff CS, 2015, HUM VACC IMMUNOTHER, V11, P2322, DOI 10.1080/21645515.2015.1061160
   Fu YH, 2014, ANTIVIR RES, V105, P72, DOI 10.1016/j.antiviral.2014.02.003
   Gallorini S, 2014, VACCINE, V32, P2382, DOI 10.1016/j.vaccine.2013.12.043
   Garcia-Contreras L, 2008, P NATL ACAD SCI USA, V105, P4656, DOI 10.1073/pnas.0800043105
   Hoft DF, 2018, MUCOSAL IMMUNOL, V11, P486, DOI 10.1038/mi.2017.67
   Huo ZM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033736
   Khan A, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040047
   Lee HB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143355
   Lorenzo-Gomez MF, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00050
   Munoz-Wolf N, 2014, JOVE-J VIS EXP, DOI 10.3791/52036
   Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]
   Orme IM, 2001, ANIMAL MODELS MYCOBA
   Park HK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032847
   ROSENTHAL S R, 1968, Journal of Asthma Research, V5, P309, DOI 10.3109/02770906809100348
   Sharpe S, 2016, TUBERCULOSIS, V101, P174, DOI 10.1016/j.tube.2016.09.004
   Song JH, 2008, P NATL ACAD SCI USA, V105, P1644, DOI 10.1073/pnas.0708684105
   Tosca MA, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00231
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3
NR 27
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5364
EP 5370
DI 10.1016/j.vaccine.2019.07.034
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300029
PM 31331776
DA 2020-05-12
ER

PT J
AU Eickhoff, CS
   Terry, FE
   Peng, LD
   Meza, KA
   Sakala, IG
   Van Aartsen, D
   Moise, L
   Martin, WD
   Schriewer, J
   Buller, RM
   De Groot, AS
   Hoft, DF
AF Eickhoff, Christopher S.
   Terry, Frances E.
   Peng, Linda
   Meza, Krystal A.
   Sakala, Isaac G.
   Van Aartsen, Daniel
   Moise, Leonard
   Martin, William D.
   Schriewer, Jill
   Buller, R. Mark
   De Groot, Anne S.
   Hoft, Daniel F.
TI Highly conserved influenza T cell epitopes induce broadly protective
   immunity
SO VACCINE
LA English
DT Article
DE Influenza vaccines; Cellular immunity; Bioinformatics; Pandemics
ID PANDEMIC INFLUENZA; A VIRUS; VACCINE; CD8(+); H1N1; IDENTIFICATION;
   MICE; IMMUNOGENICITY; SUSCEPTIBILITY; HEMAGGLUTININ
AB Influenza world-wide causes significant morbidity and mortality annually, and more severe pandemics when novel strains evolve to which humans are immunologically nalve. Because of the high viral mutation rate, new vaccines must be generated based on the prevalence of circulating strains every year. New approaches to induce more broadly protective immunity are urgently needed. Previous research has demonstrated that influenza-specific T cells can provide broadly heterotypic protective immunity in both mice and humans, supporting the rationale for developing a T cell-targeted universal influenza vaccine. We used state-of-the art immunoinformatic tools to identify putative pan-HLA-DR and HLA-A2 supertype-restricted T cell epitopes highly conserved among > 50 widely diverse influenza A strains (representing hemagglutinin types 1, 2, 3, 5, 7 and 9). We found influenza peptides that are highly conserved across influenza subtypes that were also predicted to be class I epitopes restricted by HLA-A2. These peptides were found to be immunoreactive in HLA-A2 positive but not HLA-A2 negative individuals. Class II restricted T cell epitopes that were highly conserved across influenza subtypes were identified. Human CD4(+) T cells were reactive with these conserved CD4 epitopes, and epitope expanded T cells were responsive to both H1N1 and H3N2 viruses. Dendritic cell vaccines pulsed with conserved epitopes and DNA vaccines encoding these epitopes were developed and tested in HLA transgenic mice. These vaccines were highly immunogenic, and more importantly, vaccine-induced immunity was protective against both H1N1 and H3N2 influenza challenges. These results demonstrate proof-of-principle that conserved T cell epitopes expressed by widely diverse influenza strains can induce broadly protective, heterotypic influenza immunity, providing strong support for further development of universally relevant multi-epitope T cell-targeting influenza vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Eickhoff, Christopher S.; Peng, Linda; Meza, Krystal A.; Sakala, Isaac G.; Van Aartsen, Daniel; Hoft, Daniel F.] St Louis Univ, Div Infect Dis Allergy & Immunol, Dept Internal Med, 1100 S Grand Blvd,Edward A Doisy Res Ctr, St Louis, MO 63104 USA.
   [Schriewer, Jill; Buller, R. Mark; Hoft, Daniel F.] St Louis Univ, Dept Mol Microbiol & Immunol, 1100 S Grand Blvd,Edward A Doisy Res Ctr, St Louis, MO 63104 USA.
   [Terry, Frances E.; Moise, Leonard; Martin, William D.; De Groot, Anne S.] EpiVax Inc, 188 Valley St,Suite 424, Providence, RI 02909 USA.
   [Moise, Leonard; De Groot, Anne S.] Univ Rhode Isl, Inst Immunol & Informat, Dept Cell & Mol Biol, 80 Washington St, Providence, RI 02903 USA.
RP Hoft, DF (reprint author), St Louis Univ, Div Infect Dis Allergy & Immunol, Dept Internal Med, 1100 S Grand Blvd,Edward A Doisy Res Ctr, St Louis, MO 63104 USA.; Hoft, DF (reprint author), St Louis Univ, Dept Mol Microbiol & Immunol, 1100 S Grand Blvd,Edward A Doisy Res Ctr, St Louis, MO 63104 USA.; Hoft, DF (reprint author), St Louis Univ, Div Infect Dis Allergy & Immunol, Dept Mol Microbiol, 1100 South Grand Blvd,Edward A Doisy Res Ctr, St Louis, MO 63104 USA.
EM Daniel.Hoft@health.slu.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R21-AI105605-01]
FX We would like to thank the Institut Pasteur for providing HLA-A2 and
   HLA-A2/DR1 transgenic mice[20, 21]. The following reagent was obtained
   through BEI Resources, NIAID, NIH: Influenza A Virus, A/Puerto
   Rico/8/1934 (H1N1), NR-3169 (used for stimulation of human PBMC). This
   work was funded by NIH R21-AI105605-01 to D.F.H.
CR Alexander J, 2010, VACCINE, V28, P664, DOI 10.1016/j.vaccine.2009.10.103
   Asahara S, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-291
   Assarsson E, 2008, J VIROL, V82, P12241, DOI 10.1128/JVI.01563-08
   Atsmon J, 2014, VACCINE, V32, P5816, DOI 10.1016/j.vaccine.2014.08.031
   Atsmon J, 2012, J CLIN IMMUNOL, V32, P595, DOI 10.1007/s10875-011-9632-5
   Bao YM, 2008, J VIROL, V82, P596, DOI 10.1128/JVI.02005-07
   Belshe RB, 2005, NEW ENGL J MED, V353, P2209, DOI 10.1056/NEJMp058281
   Benton KA, 2001, J IMMUNOL, V166, P7437, DOI 10.4049/jimmunol.166.12.7437
   Bocchia M, 2005, LANCET, V365, P657
   Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207
   Cameron BJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006034
   Clemens EB, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020018
   De Groot AS, 2014, HUM VACC IMMUNOTHER, V10, P3570, DOI 10.4161/hv.36134
   De Groot AS, 2009, VACCINE, V27, P5740, DOI 10.1016/j.vaccine.2009.07.040
   De Groot AS, 2005, VACCINE, V23, P2136, DOI 10.1016/j.vaccine.2005.01.097
   De Groot AS, 2011, IMMUNOME RES, V7
   Eickhoff CS, 2015, HUM VACC IMMUNOTHER, V11, P2322, DOI 10.1080/21645515.2015.1061160
   Epstein SL, 2006, J INFECT DIS, V193, P49, DOI 10.1086/498980
   Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103
   Gorse GJ, 2008, VACCINE, V26, P215, DOI 10.1016/j.vaccine.2007.10.061
   Gregory SH, 2009, VACCINE, V27, P5299, DOI 10.1016/j.vaccine.2009.06.101
   Hoft DF, 2011, J INFECT DIS, V204, P845, DOI 10.1093/infdis/jir436
   Ichihashi T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024626
   Jameson J, 1999, J IMMUNOL, V162, P7578
   Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097
   Koita OA, 2006, HUM VACCINES, V2, P119, DOI 10.4161/hv.2869
   Krammer F, 2013, J VIROL, V87, P6542, DOI 10.1128/JVI.00641-13
   Laidlaw BJ, 2016, NAT REV IMMUNOL, V16, P102, DOI 10.1038/nri.2015.10
   Lennerz V, 2014, CANCER IMMUNOL IMMUN, V63, P381, DOI 10.1007/s00262-013-1516-5
   LIANG SH, 1994, J IMMUNOL, V152, P1653
   Linette GP, 2013, BLOOD, V122, P863, DOI 10.1182/blood-2013-03-490565
   Liu R, 2015, HUM VACC IMMUNOTHER, V11, P2241, DOI 10.1080/21645515.2015.1052197
   Losikoff PT, 2015, J HEPATOL, V62, P48, DOI 10.1016/j.jhep.2014.08.026
   MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103
   McMurry JA, 2007, VACCINE, V25, P3179, DOI 10.1016/j.vaccine.2007.01.039
   Moise L, 2015, HUM VACC IMMUNOTHER, V11, P2312, DOI 10.1080/21645515.2015.1061159
   Moise L, 2013, HUM VACC IMMUNOTHER, V9, P2060, DOI 10.4161/hv.26511
   Moise L, 2013, HUM VACC IMMUNOTHER, V9, P1598, DOI 10.4161/hv.25598
   Moise L, 2013, HUM VACC IMMUNOTHER, V9, P1577, DOI 10.4161/hv.24615
   Moise L, 2011, VACCINE, V29, P501, DOI 10.1016/j.vaccine.2010.10.064
   Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991
   Pajot A, 2004, EUR J IMMUNOL, V34, P3060, DOI 10.1002/eji.200425463
   Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043
   Rosloniec EF, 1997, J EXP MED, V185, P1113, DOI 10.1084/jem.185.6.1113
   Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003
   Savic M, 2016, IMMUNOLOGY, V147, P165, DOI 10.1111/imm.12548
   SCHULMAN JL, 1965, J BACTERIOL, V89, P170, DOI 10.1128/JB.89.1.170-174.1965
   Shrestha SS, 2011, CLIN INFECT DIS, V52, pS75, DOI 10.1093/cid/ciq012
   Snyder JT, 2004, J VIROL, V78, P7052, DOI 10.1128/JVI.78.13.7052-7060.2004
   SONOGUCHI T, 1985, J INFECT DIS, V151, P81, DOI 10.1093/infdis/151.1.81
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   Wada Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01372-5
   Wilson CC, 2008, CLIN VACCINE IMMUNOL, V15, P986, DOI 10.1128/CVI.00492-07
   Zhao SY, 2017, MOLECULES, V22, DOI 10.3390/molecules22101721
NR 54
TC 1
Z9 1
U1 3
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5371
EP 5381
DI 10.1016/j.vaccine.2019.07.033
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300030
PM 31331771
DA 2020-05-12
ER

PT J
AU Tateishi, K
   Fujihashi, K
   Yamamoto, N
   Hasegawa, H
   Ainai, A
   Sato, K
   Iho, S
   Yamamoto, S
   Maeyama, J
   Odagiri, T
   Asanuma, H
AF Tateishi, Koichiro
   Fujihashi, Kohtaro
   Yamamoto, Norio
   Hasegawa, Hideki
   Ainai, Akira
   Sato, Kayoko
   Iho, Sumiko
   Yamamoto, Saburo
   Maeyama, Jun-ichi
   Odagiri, Takato
   Asanuma, Hideki
TI CpG ODN G9.1 as a novel nasal ODN adjuvant elicits complete protection
   from influenza virus infection without causing inflammatory immune
   responses
SO VACCINE
LA English
DT Article
DE Influenza; Nasal vaccination; Adjuvant; CpG ODN G9.1; IgA
ID CROSS-PROTECTION; IGA ANTIBODIES; VACCINE; CELLS; RECOGNITION; TOXIN;
   DNA; OLIGONUCLEOTIDES; STIMULATION; MOTIFS
AB This study examined the protective efficacy of and immune response to a nasal influenza vaccine combined with a novel mucosal oligodeoxynucleotide (ODN) adjuvant, CpG ODN G9.1 (G9.1), in a model of infection limited to the upper respiratory tract (URT) and a model of infection in the lower respiratory tract (LRT). Mice were nasally primed with an A/California/7/2009 (Cal7) split vaccine (X179A) plus G9.1 and were then nasally given a booster with X179A alone. When mice were challenged with either a large (infection of the LRT) or small (infection limited to the URT) volume of live Cal7 influenza virus, mice nasally given G9.1 combined with X179A had a markedly higher rate of protection against infection limited to the URT. Moreover, this group of mice promptly recovered from an infection of the LRT. When mice were subcutaneously (s.c.) given X179A as a current form of vaccination, they had no protection from an infection limited to the URT but they did recover from an infection of the LRT. The patterns of protection were closely correlated with influenza virus-specific mucosa! secretory IgA (SIgA) or serum IgG antibody (Ab) responses. Thus, SIgA Abs responses play an important role in protection from an infection limited to the URT while influenza virus-specific serum IgG Ab responses help to protect from an infection of the LRT. A finding of note is that lungs from mice nasally given G9.1 had low levels of type I IFN-associated protein- and transcription factor-specific mRNA expression. These results suggest that nasal G9.1 can be used as an effective and safe mucosal adjuvant for influenza vaccines since this nasal vaccine system elicits both mucosal SIgA and serum IgG Ab responses that provide complete protection without inducing potent inflammatory responses. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tateishi, Koichiro; Yamamoto, Norio; Sato, Kayoko; Odagiri, Takato; Asanuma, Hideki] Natl Inst Infect Dis, Influenza Virus Res Ctr, Gakuen 4-7-1, Musashimurayama, Tokyo 2080011, Japan.
   [Tateishi, Koichiro] Japan Agcy Med Res & Dev, Chiyoda Ku, 1-7-1 Otemachi, Tokyo 1000004, Japan.
   [Fujihashi, Kohtaro] Univ Tokyo, Int Res & Dev Ctr Mucosal Vaccines, Inst Med Sci, Div Clin Vaccinol,Minato Ku, Shirokanedai 4-6-1, Tokyo 1088639, Japan.
   [Fujihashi, Kohtaro] Univ Alabama Birmingham, Inst Oral Hlth Res, Dept Pediat Dent, Birmingham, AL 35294 USA.
   [Yamamoto, Norio] Juntendo Univ, Dept Infect Control Sci, Tokyo, Japan.
   [Hasegawa, Hideki; Ainai, Akira; Asanuma, Hideki] Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.
   [Iho, Sumiko] Univ Fukui, Fac Med Sci, Div Med, Fukui, Japan.
   [Iho, Sumiko] Niigata Univ, Grad Sch Med, Dept Bacteriol, Niigata, Niigata, Japan.
   [Yamamoto, Saburo] Japan BCG Lab, Cent Lab, Kiyose, Tokyo, Japan.
   [Maeyama, Jun-ichi] Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, Musashimurayama, Tokyo, Japan.
RP Asanuma, H (reprint author), Natl Inst Infect Dis, Influenza Virus Res Ctr, Gakuen 4-7-1, Musashimurayama, Tokyo 2080011, Japan.
EM asa@nih.go.jp
OI Tateishi, Koichiro/0000-0001-5964-4140
FU Japan Agency for Medical Research and Development (AMED), JapanJapan
   Agency for Medical Research and Development (AMED) [18fk0108012j0103,
   18ak0101071 j0102]
FX This study was supported by grants under the Emerging/Re-emerging
   Infectious Diseases Project (grant nos. 18fk0108012j0103 and 18ak0101071
   j0102) Of the Japan Agency for Medical Research and Development (AMED),
   Japan.
CR Ainai A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130208
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Asanuma H, 2008, BIOCHEM BIOPH RES CO, V366, P445, DOI 10.1016/j.bbrc.2007.11.135
   Asanuma H, 2012, VACCINE, V30, P803, DOI 10.1016/j.vaccine.2011.10.093
   Ciabattini A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00430
   Cooper CL, 2004, VACCINE, V22, P3136, DOI 10.1016/j.vaccine.2004.01.058
   Couch RB, 2004, NEW ENGL J MED, V350, P860, DOI 10.1056/NEJMp048006
   ELSON CO, 1984, J IMMUNOL METHODS, V67, P101, DOI 10.1016/0022-1759(84)90089-9
   Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499
   Glezen WP, 2003, JAMA-J AM MED ASSOC, V289, P2500, DOI 10.1001/jama.289.19.2500-a
   Hayden FG, 1999, ADV EXP MED BIOL, V458, P55
   Ichinohe T, 2005, J VIROL, V79, P2910, DOI 10.1128/JVI.79.5.2910-2919.2005
   Iho S, 2015, HUM VACC IMMUNOTHER, V11, P755, DOI 10.1080/21645515.2014.1004033
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Lipford GB, 1997, EUR J IMMUNOL, V27, P2340, DOI 10.1002/eji.1830270931
   Maeyama J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088846
   Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154
   Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246
   MEYER HM, 1978, AM J CLIN PATHOL, V70, P146
   Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595
   National Institute of Infectious Diseases, 2006, MIN REQ BIOL PROD, P10
   Nicholson KG, 1996, EPIDEMIOL INFECT, V116, P51, DOI 10.1017/S0950268800058957
   O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061
   Pisetsky DS, 2000, SPRINGER SEMIN IMMUN, V22, P21, DOI 10.1007/s002810000021
   Pohar J, 2017, J IMMUNOL, V198, P2093, DOI 10.4049/jimmunol.1600757
   Pohar J, 2015, J IMMUNOL, V195, P4396, DOI 10.4049/jimmunol.1500600
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   ROBINSON RA, 1976, JNCI-J NATL CANCER I, V57, P599, DOI 10.1093/jnci/57.3.599
   Sagara I, 2009, VACCINE, V27, P7292, DOI 10.1016/j.vaccine.2009.10.087
   Sasaki E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191896
   Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065
   Schultze V, 2008, VACCINE, V26, P3209, DOI 10.1016/j.vaccine.2008.03.093
   Sun SQ, 1998, J EXP MED, V188, P2335, DOI 10.1084/jem.188.12.2335
   Suzuki T, 2015, P NATL ACAD SCI USA, V112, P7809, DOI 10.1073/pnas.1503885112
   Tamura S, 1998, J GEN VIROL, V79, P291, DOI 10.1099/0022-1317-79-2-291
   TAMURA S, 1990, VACCINE, V8, P479, DOI 10.1016/0264-410X(90)90250-P
   TAMURA S, 1991, EUR J IMMUNOL, V21, P1337, DOI 10.1002/eji.1830210602
   TAMURA S, 1988, VACCINE, V6, P409, DOI 10.1016/0264-410X(88)90140-5
   TAMURA S, 1994, VACCINE, V12, P419, DOI 10.1016/0264-410X(94)90118-X
   TAMURA SI, 1992, J IMMUNOL, V149, P981
   TOBITA K, 1975, MED MICROBIOL IMMUN, V162, P9, DOI 10.1007/BF02123572
   Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7
   World Health Organization Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU
   Wright PF, 2007, FIELDS VIROLOGY, P2501
   Yamamoto S, 2000, SPRINGER SEMIN IMMUN, V22, P11, DOI 10.1007/s002810000019
NR 45
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5382
EP 5389
DI 10.1016/j.vaccine.2019.07.032
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300031
PM 31345642
DA 2020-05-12
ER

PT J
AU Reed, L
   Tarini, BA
   Andreae, MC
AF Reed, Lauren
   Tarini, Beth A.
   Andreae, Margie C.
TI Vaccine administration error rates at a large academic medical center
   and its affiliated clinics - Familiarity matters
SO VACCINE
LA English
DT Article
DE Vaccine; Errors
ID UNITED-STATES; CHILDREN
AB Objective: The purpose of this study was to track and describe the absolute number of vaccine administration errors and corresponding error rates over time and by patient age and vaccine type.
   Methods: Total vaccines administered to patients aged 0 through 19 years 364 days from 1/1/2006 through 12/31/2017 at a large academic health system in the Midwest United States with primary, specialty and school-based clinics, and a pediatric hospital were obtained from an electronic medical record. Vaccine administration errors over the same time period for the same patient criteria were analyzed from the health system's incident reporting system and further compared to the frequency of all incidents reported. Vaccine administration error rates were calculated. Data were analyzed by patient age, vaccine type and year administered.
   Results: Of the 1,431,206 vaccine doses given, 552 vaccine administration errors were identified (0.04%). The highest error rates occurred in children aged 2, 3, and 19 years. Vaccine types with the highest error rate were Td, rabies and pneumococcal polysaccharide vaccines. Overall vaccine doses given and errors reported increased over the study period. However, the increase was disproportionate, resulting in an increase in the error rate initially followed by a stabilization at the end of the study period.
   Conclusions: Vaccine administration errors are uncommon. The error rate appears to be stabilizing. Errors are more likely at ages when vaccines are not commonly given, with vaccines that have age-specific dosing and with vaccines that are given less often. This suggests more safety checks are needed for vaccines that are rarely used or given off-schedule, and manufacturers should avoid vaccines with age-specific dosing. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Reed, Lauren; Andreae, Margie C.] Univ Michigan, Div Gen Pediat, Michigan Med, Med Sch, Ann Arbor, MI 48105 USA.
   [Tarini, Beth A.] Childrens Natl Hlth Syst, Ctr Translat Res, Washington, DC 20010 USA.
RP Reed, L (reprint author), Dept Pediat, 3399 E Grand River 202, Howell, MI 48843 USA.
EM laurenre@med.umich.edu
OI Reed, Lauren/0000-0002-7715-9832
FU University of Michigan Department of General Pediatrics Primary Care
   Research Program [U059930]
FX This research received a grant from the University of Michigan
   Department of General Pediatrics Primary Care Research Program (Grant
   U059930).
CR Bundy DG, 2009, VACCINE, V27, P3890, DOI 10.1016/j.vaccine.2009.04.005
   Centers for Disease Control, 2011, CDC REP DET INFL PRE
   Centers for Disease Control, 2018, IMM SCHED
   Centers For Disease Control, 2010, KEY FACTS 2009 H1N1
   Coronado F., 2008, Morbidity and Mortality Weekly Report, V57, P1252
   Dempsey AF, 2011, PEDIATRICS, V128, P848, DOI 10.1542/peds.2011-0400
   Hibbs BF, 2015, VACCINE, V33, P3171, DOI 10.1016/j.vaccine.2015.05.006
   Immunization Action Coalition, 2016, ERR IS HUM NOT ERR I, V201
   Institute for Safe Medication Practices, 2014, CONF AB 2 YEAR SUM 1
   Institute for Safe Medication Practices, 2015, REC PRACT PREV VAC 2
   Kempe A, 2010, PEDIATRICS, V125, P914, DOI 10.1542/peds.2009-1710
   Michigan Medicine, 2015, UMHHC POL 03 07 001
   Muhammad RD, 2011, PEDIATR INFECT DIS J, V30, pE1, DOI 10.1097/INF.0b013e3181ff9795
   Pickering LK, 2009, CLIN INFECT DIS, V49, P817, DOI 10.1086/605430
   Rees P, 2015, VACCINE, V33, P3873, DOI 10.1016/j.vaccine.2015.06.068
   Rodgers L, 2018, J PEDIATR-US, V193, P164, DOI 10.1016/j.jpeds.2017.09.057
   Stanhope N, 1999, J EVAL CLIN PRACT, V5, P5, DOI 10.1046/j.1365-2753.1999.00146.x
   Westbrook JI, 2011, BMJ QUAL SAF, V20, P1027, DOI 10.1136/bmjqs-2011-000089
   Wise KA, 2017, J AM PHARM ASSOC, V57, P356, DOI 10.1016/j.japh.2017.02.025
   World Health Organization, 2014, GLOB MAN SURV ADV EV
   Zhan CL, 2008, JT COMM J QUAL PATIE, V34, P36, DOI 10.1016/S1553-7250(08)34006-9
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5390
EP 5396
DI 10.1016/j.vaccine.2019.07.027
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300032
PM 31350155
DA 2020-05-12
ER

PT J
AU Simoes, EAF
   Nunes, MC
   Carosone-Link, P
   Madimabe, R
   Ortiz, JR
   Neuzil, KM
   Klugman, KP
   Cutland, CL
   Madhi, SA
AF Simoes, Eric A. F.
   Nunes, Marta C.
   Carosone-Link, Phyllis
   Madimabe, Richard
   Ortiz, Justin R.
   Neuzil, Kathleen M.
   Klugman, Keith P.
   Cutland, Clare L.
   Madhi, Shabir A.
CA Matflu Team
TI Trivalent influenza vaccination randomized control trial of pregnant
   women and adverse fetal outcomes
SO VACCINE
LA English
DT Article
DE Low birth weight; Prematurity; Randomized controlled trial; Small for
   gestational age
ID MATERNAL INFLUENZA; GESTATIONAL-AGE; NEONATAL OUTCOMES; PRETERM BIRTH;
   PHASE 4; IMMUNIZATION; CONSULTATION; ASSOCIATION; PREVENTION; INFECTION
AB Introduction: The purpose of this study was to evaluate the association of influenza vaccine during pregnancy and adverse fetal outcomes. Preventing fetal death, low birth weight, small for gestational age birth and preterm birth are important potential effects of antenatal maternal influenza immunization for which there are conflicting data.
   Materials and methods: A double-blind, randomized, placebo-controlled clinical trial of trivalent inactivated influenza vaccine was conducted in South Africa from March 2011 until after the 2012 influenza season when the infants born had reached the age of 24 weeks. Mothers were administered the vaccine or placebo during pregnancy at a gestation of 20 to 36 weeks. A comparison of rates of fetal death, low birth weight, small for gestational age birth, and preterm birth, between vaccinated and placebo groups was made. Fetal outcome differences between the groups were measured using Student's t-tests, vaccine efficacy with 95% confidence intervals, and Poisson regression for incidence rates. All analyses except fetal death excluded mothers who were administered vaccine or placebo after 34 weeks gestational age.
   Results: There were 2116 HIV-uninfected pregnant women age 18 to 38 years in the trial; 2005 infants were born to mothers where vaccine or placebo had been administered >= 14 days prior to delivery, and there were 6 miscarriages and 23 stillbirths. There was no significant vaccine efficacy (with [95% confidence interval]) on fetal death (-21.2% [-150.8, 41.4]), low birth weight (-11.1% [-42.3, 12.5]), small for gestational age birth (-9.9% [-35.6, 11.01), or preterm birth (-21.3% [-60.5, 8.3]). Neither was vaccine efficacy demonstrated when the analysis was restricted to infants of mothers who were exposed to an influenza season (1832 outcomes available).
   Conclusion: We did not find a beneficial effect of trivalent inactivated influenza vaccine during pregnancy on adverse fetal outcomes. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Simoes, Eric A. F.; Nunes, Marta C.; Madimabe, Richard; Cutland, Clare L.; Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, Resp & Meningeal Pathogens Res Unit, MRC, York Rd, ZA-2193 Johannesburg, South Africa.
   [Simoes, Eric A. F.] Univ Colorado, Sch Med, Ctr Global Hlth, Colorado Sch Publ Hlth, 13123 E 16th Ave,B055, Aurora, CO USA.
   [Simoes, Eric A. F.; Carosone-Link, Phyllis] Univ Colorado Denver, Dept Pediat Infect Dis, 13123 E 16th Ave,B055, Aurora, CO USA.
   [Nunes, Marta C.; Madimabe, Richard; Cutland, Clare L.; Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Dept Sci & Technol, York Rd, ZA-2193 Johannesburg, South Africa.
   [Ortiz, Justin R.; Neuzil, Kathleen M.] Univ Maryland, Ctr Vaccine Dev, 685 W Baltimore St, Baltimore, MD USA.
   [Klugman, Keith P.] Bill & Melinda Gates Fdn, 500 5th Ave N, Seattle, WA USA.
   [Madhi, Shabir A.] Natl Inst Communicable Dis, Ctr Vaccines & Immunol, 1 Modderfontein Rd, Johannesburg, South Africa.
RP Carosone-Link, P (reprint author), Childrens Hosp Colorado, 13123 E 16th Ave,B055, Aurora, CO 80045 USA.
EM Phyllis.CarosoneLink@ucdenver.edu
OI Nunes, Marta/0000-0003-3788-878X
FU Bill & Melinda Gates Foundation, Seattle, Washington [OPP1002747];
   National Institutes of Health/National Center for Advancing
   Translational Sciences/Colorado Clinical & Translational Sciences
   Institute [UL1 TR000154]; South African Research Chairs Initiative of
   the Department of Science and Technology (DST); National Research
   Foundation (NRF) in Vaccine Preventable Diseases; Medical Research
   Council: Respiratory and Meningeal Pathogens Research Unit, Parktown,
   South Africa
FX This trial was supported by the Bill & Melinda Gates Foundation,
   Seattle, Washington [grant number OPP1002747]. Support for REDCAP was
   received from National Institutes of Health/National Center for
   Advancing Translational Sciences/Colorado Clinical & Translational
   Sciences Institute [grant number UL1 TR000154]. There was also partial
   support from the South African Research Chairs Initiative of the
   Department of Science and Technology (DST) and National Research
   Foundation (NRF) in Vaccine Preventable Diseases; and the Medical
   Research Council: Respiratory and Meningeal Pathogens Research Unit,
   Parktown, South Africa. The contents of this report are solely the
   responsibility of the authors and do not necessarily represent the
   official views of their institutions or organizations or of the
   sponsors. The funders did not participate in any aspect of the study,
   including study -conduct, data collection, analyses of the data or the
   write-up of the manuscript. The authors report no competing interests.
CR Adegbola R, 2012, AM J OBSTET GYNECOL, V207, pS28, DOI 10.1016/j.ajog.2012.07.001
   ARMITAGE P, 1994, STAT METHODS MED RES
   Azziz-Baumgartner E, 2012, B WORLD HEALTH ORGAN, V90, P12, DOI 10.2471/BLT.11.090209
   BALLARD JL, 1991, J PEDIATR-US, V119, P417, DOI 10.1016/S0022-3476(05)82056-6
   Dodds L, 2012, J OBSTET GYNAECOL CA, V34, P714, DOI 10.1016/S1701-2163(16)35336-1
   Fell DB, 2015, BJOG-INT J OBSTET GY, V122, P17, DOI 10.1111/1471-0528.12977
   Fell DB, 2017, VACCINE, V35, P2279, DOI 10.1016/j.vaccine.2017.03.056
   GOURBIN C, 1995, B WORLD HEALTH ORGAN, V73, P449
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hutcheon JA, 2016, AM J EPIDEMIOL, V184, P227, DOI 10.1093/aje/kww048
   Launay O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052303
   Legge A, 2014, CAN MED ASSOC J, V186, pE157, DOI 10.1503/cmaj.130499
   Liu L, 2014, LANCET
   Ludvigsson JF, 2013, EUR J EPIDEMIOL, V28, P579, DOI 10.1007/s10654-013-9813-z
   Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480
   Nordin JD, 2014, J PEDIATR-US, V164, P1051, DOI 10.1016/j.jpeds.2014.01.037
   Nunes MC, 2015, J INFECT DIS, V212, P1976, DOI 10.1093/infdis/jiv339
   Nunes MC, 2017, CLIN INFECT DIS
   Omer SB, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000441
   ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055
   Ortiz JR, 2012, VACCINE, V30, P7134, DOI 10.1016/j.vaccine.2012.09.034
   Pasternak B, 2012, JAMA-J AM MED ASSOC, V308, P165, DOI 10.1001/jama.2012.6131
   Pasternak B, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2794
   Puleston R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0047448
   Richards JL, 2013, CLIN INFECT DIS, V56, P1216, DOI 10.1093/cid/cit045
   Steinhoff MC, 2017, LANCET INFECT DIS, V17, P981, DOI 10.1016/S1473-3099(17)30252-9
   Steinhoff MC, 2014, LANCET, V383, P1611, DOI 10.1016/S0140-6736(14)60583-3
   Steinhoff MC, 2012, CAN MED ASSOC J, V184, P645, DOI 10.1503/cmaj.110754
   Tapia MD, 2016, LANCET INFECT DIS, V16, P1026, DOI 10.1016/S1473-3099(16)30054-8
   Tavares F, 2011, VACCINE, V29, P6358, DOI 10.1016/j.vaccine.2011.04.114
   Trotta F, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3361
   Villar J, 2014, LANCET, V384, P857, DOI 10.1016/S0140-6736(14)60932-6
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
NR 33
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5397
EP 5403
DI 10.1016/j.vaccine.2019.07.024
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300033
PM 31331777
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Kennedy, EM
   Dowall, SD
   Salguero, FJ
   Yeates, P
   Aram, M
   Hewson, R
AF Kennedy, E. M.
   Dowall, S. D.
   Salguero, F. J.
   Yeates, P.
   Aram, M.
   Hewson, R.
TI A vaccine based on recombinant modified Vaccinia Ankara containing the
   nucleoprotein from Lassa virus protects against disease progression in a
   guinea pig model
SO VACCINE
LA English
DT Article
DE Lassa; Modified Vaccinia Ankara (MVA); Vaccine; Nucleoprotein;
   Immunogenicity; Efficacy; Recombinant vaccine
ID SENSORINEURAL HEARING-LOSS; DOUBLE-BLIND; FEVER; IMMUNOGENICITY;
   INFECTION; SAFETY; MVA; PATHOGENESIS; EFFICACY; MONKEYS
AB Lassa fever remains the most imported viral haemorrhagic fever in Europe and is responsible for 5000 deaths per year throughout Western Africa. There is no vaccine and treatment is often ineffective. We have developed a vaccine based on modified Vaccinia Ankara expressing the nucleoprotein from Lassa virus (MVALassaNP). This study investigated the immunogenicity (in mice) and efficacy (in guinea pigs) of the MVALassaNP vaccine as a prime/boost or single vaccination regime. ELISA and ELISpot assays confirmed humoral and T-cell immunity following both a prime and prime/boost vaccination, with the prime/boost regime producing a statistically increased response compared to a prime only vaccine (P < 0.0001). The vaccine offered protection in guinea pigs against disease manifestations after challenge with virulent Lassa virus. Clinical signs, weight loss and temperature increases were observed in all animals receiving a control MVA vaccine, after challenge with Lassa virus. In contrast, no clinical signs, fever or weight loss were observed in any of the MVALassaNP vaccinated animals demonstrating that both a single immunisation, and prime/boost regime confer protection against disease progression.
   In conclusion, the MVALassaNP vaccine candidate elicits an immune response, demonstrates efficacy against Lassa virus disease and is suitable for further preclinical and clinical development. Crown Copyright (C) 2019 Published by Elsevier Ltd.
C1 [Kennedy, E. M.; Dowall, S. D.; Salguero, F. J.; Yeates, P.; Aram, M.; Hewson, R.] Publ Hlth England, Salisbury SP4 0JG, Wilts, England.
RP Kennedy, EM (reprint author), Publ Hlth England, Salisbury SP4 0JG, Wilts, England.
EM emma.kennedy@phe.gov.uk
OI Dowall, Stuart/0000-0001-7378-8167; Salguero, Francisco
   Javier/0000-0002-5315-3882
FU Department of Health and Social Care [972223]; Official Development
   Assistance (ODA)
FX This report is work commissioned by Innovate UK and the Department of
   Health and Social Care (Project title "SRBI New Vaccines for Global
   Epidemics: LassaVacc; File Ref. 972223) and is funded through Official
   Development Assistance (ODA). The views expressed in this publication
   are those of the author(s) and not necessarily those of employing
   institutions or funding bodies.
CR Abreu-Mota T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06741-w
   Amato RJ, 2010, CLIN CANCER RES, V16, P5539, DOI 10.1158/1078-0432.CCR-10-2082
   Bell TM, 2017, VET PATHOL, V54, P549, DOI 10.1177/0300985816677153
   Blanchard TJ, 1998, J GEN VIROL, V79, P1159, DOI 10.1099/0022-1317-79-5-1159
   Bowen MD, 2000, J VIROL, V74, P6992, DOI 10.1128/JVI.74.15.6992-7004.2000
   Branco LM, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-279
   Buttigieg KR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091516
   CLEGG JCS, 1987, LANCET, V2, P186
   Cottingham MG, 2013, VACCINE, V31, P4247, DOI 10.1016/j.vaccine.2013.03.021
   CUMMINS D, 1990, JAMA-J AM MED ASSOC, V264, P2093
   Fisher-Hoch SP, 2000, J VIROL, V74, P6777, DOI 10.1128/JVI.74.15.6777-6783.2000
   FISHERHOCH SP, 1995, BRIT MED J, V311, P857, DOI 10.1136/bmj.311.7009.857
   FISHERHOCH SP, 1989, P NATL ACAD SCI USA, V86, P317, DOI 10.1073/pnas.86.1.317
   Geisbert TW, 2005, PLOS MED, V2, P537, DOI 10.1371/journal.pmed.0020183
   Grahn A, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw198
   GRUNDY DJ, 1980, LANCET, V2, P649
   Guimaraes-Walker A, 2008, VACCINE, V26, P6671, DOI 10.1016/j.vaccine.2008.09.016
   HALLAM HJ, 2018, VACCINES, V3, DOI DOI 10.1038/S41541-018-0049-5
   Ibekwe TS, 2011, EUR ARCH OTO-RHINO-L, V268, P197, DOI 10.1007/s00405-010-1370-4
   JAHRLING PB, 1982, INFECT IMMUN, V37, P771, DOI 10.1128/IAI.37.2.771-778.1982
   Jiang XH, 2011, VACCINE, V29, P1248, DOI 10.1016/j.vaccine.2010.11.079
   Kreijtz JHCM, 2014, LANCET INFECT DIS, V14, P1196, DOI [10.1016/S1473-3099(14)70963-6, 10.1016/s1473-3099(14)70963-6]
   Leski TA, 2015, EMERG INFECT DIS, V21, P609, DOI 10.3201/eid2104.141469
   LIAO BS, 1992, OTOLARYNG HEAD NECK, V106, P226, DOI 10.1177/019459989210600303
   LLOYD G, 1989, LANCET, V2, P1222
   Lukashevich IS, 2008, VACCINE, V26, P5246, DOI 10.1016/j.vaccine.2008.07.057
   McCurdy LH, 2004, J VIROL, V78, P12471, DOI 10.1128/JVI.78.22.12471-12479.2004
   MEYER H, 1991, J GEN VIROL, V72, P1031, DOI 10.1099/0022-1317-72-5-1031
   MORRISON HG, 1989, VIROLOGY, V171, P179, DOI 10.1016/0042-6822(89)90525-4
   Okokhere Peter O, 2009, J Med Case Rep, V3, P36, DOI 10.1186/1752-1947-3-36
   PRICE ME, 1988, BRIT MED J, V297, P584, DOI 10.1136/bmj.297.6648.584
   Radoshitzky SR, 2015, ARCH VIROL, V160, P1851, DOI 10.1007/s00705-015-2418-y
   Rodriguez-Carreno MP, 2005, VIROLOGY, V335, P87, DOI 10.1016/j.virol.2005.01.019
   Salazar-Bravo J, 2002, CURR TOP MICROBIOL, V262, P25
   Stittelaar KJ, 2001, VACCINE, V19, P3700, DOI 10.1016/S0264-410X(01)00075-5
   ter Meulen J, 2004, VIROLOGY, V321, P134, DOI 10.1016/j.virol.2003.12.013
   terMeulen J, 1996, AM J TROP MED HYG, V55, P661
   von Krempelhuber A, 2010, VACCINE, V28, P1209, DOI 10.1016/j.vaccine.2009.11.030
   WALKER DH, 1975, B WORLD HEALTH ORGAN, V52, P523
   Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002
   WHO, 2018, LASS FEV OUTBR CONT
   World Health Organization, 2018, WHO WORKSH
   Yun NE, 2016, J VIROL, V90, P2920, DOI 10.1128/JVI.02948-15
   Yun NE, 2012, VIRUSES-BASEL, V4, P2031, DOI 10.3390/v4102031
NR 44
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5404
EP 5413
DI 10.1016/j.vaccine.2019.07.023
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300034
PM 31331770
OA Other Gold
DA 2020-05-12
ER

PT J
AU Hozbor, D
   Ulloa-Gutierrez, R
   Marino, C
   von Konig, CHW
   Tan, T
   Forsyth, K
AF Hozbor, Daniela
   Ulloa-Gutierrez, Rolando
   Marino, Cristina
   von Koenig, Carl Heinz Wirsing
   Tan, Tina
   Forsyth, Kevin
TI Pertussis in Latin America: Recent epidemiological data presented at the
   2017 Global Pertussis Initiative meeting
SO VACCINE
LA English
DT Article
DE Bordeteila pertussis; Epidemiology; Latin America; Pertussis;
   Vaccination
ID MATERNAL IMMUNIZATION; BORDETELLA-PERTUSSIS; STRATEGIES; ARGENTINA;
   VACCINES
AB The Global Pertussis Initiative (GPI) is an expert scientific forum that publishes consensus recommendations for pertussis monitoring, prevention, and treatment across many regions of the world. Here, we report on the regional 2017 GPI meeting on the Americas, focusing on Latin America. Information on current pertussis epidemiology, surveillance, vaccine strategies, diagnostic capabilities, disease awareness, and major local obstacles was presented by researchers from Argentina, Brazil, Colombia, Costa Rica, El Salvador, Mexico, Peru, Puerto Rico, Uruguay, and Venezuela. Pertussis outbreaks have occurred during the last decade in the majority of participant countries and have been followed by improvements in surveillance. In the countries that introduced maternal immunization during pregnancy, a reduction in the infant case fatality rate has been detected. All countries need to maintain and improve pertussis surveillance to reach primary vaccination coverage >90%. Moreover, countries without maternal immunization programs should strongly consider them. (C) 2019 Published by Elsevier Ltd.
C1 [Hozbor, Daniela] Univ Nacl La Plata, CONICET, Fac Ciencias Exactas, Inst Biotecnol & Biol Mol, La Plata, Buenos Aires, Argentina.
   [Ulloa-Gutierrez, Rolando] PediaClinic, Ctr Especialidades Pediat, San Jose, Costa Rica.
   [Marino, Cristina] Hosp Mil Cent, Med Infect, Bogota, Colombia.
   [von Koenig, Carl Heinz Wirsing] Lab Med Krefeld MVZ, Krefeld, Germany.
   [Tan, Tina] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Forsyth, Kevin] Flinders Univ S Australia, Bedford Pk, Adelaide, SA, Australia.
   [Forsyth, Kevin] Flinders Med Ctr, Bedford Pk, Adelaide, SA, Australia.
RP Hozbor, D (reprint author), Univ Nacl La Plata, CONICET La Plata, Lab VacSal Inst Biotecnol & Biol Mol, Fac Ciencias Exactas, Calles 50 & 115, RA-1900 La Plata, Buenos Aires, Argentina.
EM hozbor.daniela@gmail.com
OI Hozbor, Daniela/0000-0001-6379-0482; Ulloa-Gutierrez,
   Rolando/0000-0002-9157-9227; Forsyth, Kevin/0000-0002-2748-0353
FU Sanofi Pasteur
FX GPI is funded by Sanofi Pasteur. This article is an output of the Global
   Pertussis Initiative Roundtable Meeting, November 11-13, 2017, Cancun,
   Mexico. Sanofi Pasteur had no input in the content of this article.
   Editorial support in the preparation of this manuscript was provided by
   Phase Five Communications, supported by Sanofi Pasteur.
CR [Anonymous], 2015, Wkly Epidemiol Rec, V90, P433
   [Anonymous], 2009, EP ESTR CONTR PREV T
   Aquino-Andrade A, 2017, J PEDIATR-US, V188, P217, DOI 10.1016/j.jpeds.2017.05.032
   Bailon H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1700-2
   Bart MJ, 2014, MBIO, V5, DOI 10.1128/mBio.01074-14
   Borkner L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01764
   Brummelman J, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv067
   Carrasquilla G, 2017, 35 ANN M EUR SOC PAE
   Centers for Disease Control and Prevention, 2012, MMWR-MORBID MORTAL W, V62, P131
   Conrad DA, 1999, POSTGRAD MED, V105, P165
   Edwards KM, 2014, J INFECT DIS, V209, pS10, DOI 10.1093/infdis/jit560
   Edwards KM, 2014, P NATL ACAD SCI USA, V111, P575, DOI 10.1073/pnas.1321360111
   Edwards KM, 2005, PEDIATR INFECT DIS J, V24, pS104, DOI 10.1097/01.inf.0000166154.47013.47
   EDWARDS KM, 1990, PEDIATR CLIN N AM, V37, P549
   Fabricius G, 2018, EPIDEMIOL INFECT, V146, P858, DOI 10.1017/S0950268818000808
   Arlant LHF, 2014, EXPERT REV ANTI-INFE, V12, P1265, DOI 10.1586/14787210.2014.948846
   Forsyth K, 2015, PEDIATRICS, V135, pE1475, DOI 10.1542/peds.2014-3925
   Gentile A, 2018, VACCINE, V36, P1375, DOI [10.1016/j.vaccine.2018.01.091, 10.1016/j.vaccine.2018.01.0]
   Guimaraes LM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1222-3
   Hozbor D, 2009, J INFECTION, V59, P225, DOI 10.1016/j.jinf.2009.07.014
   Klein NP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3326
   Mooi FR, 2014, EPIDEMIOL INFECT, V142, P685, DOI 10.1017/S0950268813000071
   Pinell-McNamara VA, 2017, EMERG INFECT DIS, V23, pS94, DOI 10.3201/eid2313.170457
   Romanin V, 2014, ARCH ARGENT PEDIATR, V112, P413, DOI [10.5546/aap.2014.413, 10.1590/S0325-00752014000500005]
   Smith T, 2014, Can Commun Dis Rep, V40, P21
   Vizzotti C, 2015, VACCINE, V33, P6413, DOI 10.1016/j.vaccine.2015.07.109
   von Konig CHW, 2002, LANCET INFECT DIS, V2, P744, DOI 10.1016/S1473-3099(02)00452-8
   *WHO, WHO REC SURV STAND P
   World Health Organization, 2018, REP EST IMM VACC COV
   World Health Organization, 2012, REVIEW OF THE CURREN
   Yeung KHT, 2017, LANCET INFECT DIS, V17, P974, DOI 10.1016/S1473-3099(17)30390-0
   Zlamy M, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00052
NR 32
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5414
EP 5421
DI 10.1016/j.vaccine.2019.07.007
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300035
PM 31331774
DA 2020-05-12
ER

PT J
AU Klein, NP
   Bartlett, J
   Fireman, B
   Marks, MA
   Hansen, J
   Lewis, E
   Aukes, L
   Saddier, P
AF Klein, Nicola P.
   Bartlett, Joan
   Fireman, Bruce
   Marks, Morgan A.
   Hansen, John
   Lewis, Edwin
   Aukes, Laurie
   Saddier, Patricia
TI Long-term effectiveness of zoster vaccine live for postherpetic
   neuralgia prevention
SO VACCINE
LA English
DT Article
DE Herpes zoster; Zoster vaccine live (ZVL); Postherpetic neuralgia (PHN);
   Effectiveness
ID HERPES-ZOSTER; RISK-FACTORS; SHINGLES
AB Background: Postherpetic neuralgia (PHN) occurs in 5-30% of individuals with herpes zoster (HZ) and is characterized by long-lasting pain. Zoster vaccine live (ZVL) is licensed for people 50 years and older to prevent HZ and PHN. This study evaluated vaccine effectiveness (VE) of ZVL against PHN.
   Methods: We conducted an open cohort study within Kaiser Permanente Northern California with continuous accrual of people as they became age-eligible for ZVL. We defined PHN using a PHN diagnosis between 90 and 365 days after an incident episode of HZ. We estimated VE against PHN using Cox regression with a calendar timeline stratified by year of birth and adjusted for sex, race, influenza vaccination, outpatient visit frequency, comorbidities, and immune compromise status.
   Results: From 2007 to 2016, 1.5 million people entered the study population and 33% received ZVL During 7.6 million person-years of follow-up, there were 62,205 HZ cases, 4150 (6.7%) of which went on to develop PHN. Overall VE for PHN was 64.8% (95% CI 61.3, 68). VE was 82.8% (95% CI 77-6, 86.7) during the first year after vaccination, 58.3% (95% CI 50.1, 65.2) during the third year, and then waned more gradually to 48-7% (95% CI 30.2, 62-3) during the eighth year. VE in persons vaccinated when aged 80 years or older was similar to VE in younger vaccinees. VE in persons vaccinated when immune compromised was similar to VE in immune competent.
   Conclusions: Overall, ZVL was 65% effective against PHN. It was effective in all age groups and provided moderate protection through 8 years. (C) 2019 Merck Sharp & Dohme Corp. and the Authors. Published by Elsevier Ltd.
C1 [Klein, Nicola P.; Bartlett, Joan; Fireman, Bruce; Hansen, John; Lewis, Edwin; Aukes, Laurie] Kaiser Permanente, Vaccine Study Ctr, One Kaiser Plaza,16th Floor, Oakland, CA 94612 USA.
   [Marks, Morgan A.; Saddier, Patricia] Merck & Co Inc, Pharmacoepidemiol Dept, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA.
RP Klein, NP (reprint author), Kaiser Permanente, Vaccine Study Ctr, One Kaiser Plaza,16th Floor, Oakland, CA 94612 USA.
EM nicola.klein@kp.org
FU Merck Sharp & Dohme Corp., USA, a subsidiary of Merck Co., Inc., USA
   [NCT01600079]
FX Merck Sharp & Dohme Corp., USA, a subsidiary of Merck & Co., Inc., USA
   funded this study (ClinicalTrials.gov number NCT01600079), and all costs
   related to the development of this publication.
CR Baxter R, 2018, AM J EPIDEMIOL, V187, P161, DOI 10.1093/aje/kwx245
   Czernichow S, 2001, ANN DERMATOL VENER, V128, P497
   Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5
   Forbes HJ, 2016, NEUROLOGY, V87, P94, DOI 10.1212/WNL.0000000000002808
   HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106
   Izurieta HS, 2017, CLIN INFECT DIS, V64, P785, DOI 10.1093/cid/ciw854
   Johnson Robert W, 2007, Expert Rev Neurother, V7, P1581, DOI 10.1586/14737175.7.11.1581
   Jung BF, 2004, NEUROLOGY, V62, P1545, DOI 10.1212/01.WNL.0000123261.00004.29
   Langan SM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001420
   Opstelten W, 2002, FAM PRACT, V19, P471, DOI 10.1093/fampra/19.5.471
   Oxman MN, 2008, J INFECT DIS, V197, pS228, DOI 10.1086/522159
   Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016
   Paparatti UD, 1999, J INFECTION, V38, P116, DOI 10.1016/S0163-4453(99)90079-8
   Schmader KE, 2012, CLIN INFECT DIS, V55, P1320, DOI 10.1093/cid/cis638
   Thomas SL, 2004, LANCET INFECT DIS, V4, P26, DOI 10.1016/S1473-3099(03)00857-0
   Yawn BP, 2007, MAYO CLIN PROC, V82, P1341, DOI 10.4065/82.11.1341
NR 16
TC 1
Z9 1
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5422
EP 5427
DI 10.1016/j.vaccine.2019.07.004
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300036
PM 31301920
OA Other Gold
DA 2020-05-12
ER

PT J
AU O'Neill, LM
   Keane, OM
   Ross, PJ
   Nally, JE
   Seshu, J
   Markey, B
AF O'Neill, L. M.
   Keane, O. M.
   Ross, P. J.
   Nally, J. E.
   Seshu, J.
   Markey, B.
TI Evaluation of protective and immune responses following vaccination with
   recombinant MIP and CPAF from Chlamydia abortus as novel vaccines for
   enzootic abortion of ewes
SO VACCINE
LA English
DT Article
DE Chlamydia abortus; Recombinant proteins; MIP; CPAF; Multi-subunit
   vaccine
ID OUTER-MEMBRANE PROTEIN; GAMMA EXPRESSION; MESSENGER-RNA; STRAIN 1B;
   OVINE; INFECTION; SHEEP; FIELD; PCR; IDENTIFICATION
AB MIP and CPAF from Chlamydia have been shown to be effective in inducing immune responses important in clearing chlamydial infections. This study evaluates the protection conferred by MIP and CPAF as novel vaccines in pregnant C. abortus challenged ewes. Fifty C. abortus sero-negative sheep were randomly allocated into 5 groups of 10 according to the treatment they were to receive (1) 100 mu g of MBP-MIP (2) 100 mu g CPAF (3) 50 mu g MBP-M1P and 50 mu g CPAF (4) Tris-buffer (negative control) (5) Enzovax (positive control). Booster inoculations were administered 3 weeks after primary inoculations. Blood samples were taken pre-vaccination and weekly for 5 weeks. Five months after vaccination the ewes were mated. Pregnant ewes were then challenged on day 90 of gestation. Blood samples taken at four time-points post challenge were analysed for IFN gamma levels, TNF alpha and IL-10 expression and anti-chlamydial antibody levels. Vaginal swabs, placental and foetal tissue and bacterial shedding were analysed using qPCR to quantify levels of C. abortus. Enzovax was 100% effective with no abortions occurring. The MIP/CPAF combined vaccine offered the greatest protection of the novel vaccines with 67% of ewes giving birth to one or more live lambs equating to a 50% vaccine efficacy rate. MIP and CPAF administered singly did not confer protection. Enzovax and MIP/CPAF vaccinated ewes had longer gestations and lambs with higher birth weights than negative control ewes. Aborting ewes shed higher numbers of C. abortus than ewes that had live lambs, all vaccinated ewes demonstrated lower levels of bacterial shedding than negative control ewes with Enzovax ewes shedding significantly fewer bacteria. Ewes that went on to abort had significantly higher levels of IFN gamma and IL-10 at day 35 post challenge and significantly higher levels of anti-chlamydial antibodies at 24 h post lambing compared to ewes that had live lambs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [O'Neill, L. M.; Markey, B.] Univ Coll Dublin, Sch Vet Med, Dublin 4, Ireland.
   [O'Neill, L. M.; Keane, O. M.] Teagasc Grange, Anim & Biosci Dept, Dunsany, Meath, Ireland.
   [Ross, P. J.] Cent Vet Res Lab, Dept Agr Food & Marine, Backweston, Kildare, Ireland.
   [Nally, J. E.] ARS, Infect Bacterial Dis, Natl Anim Dis Ctr, USDA, Ames, IA USA.
   [Seshu, J.] Univ Texas San Antonio, South Texas Ctr Emerging Infect Dis, Ctr Excellence Infect Genom, San Antonio, TX USA.
   [Seshu, J.] Univ Texas San Antonio, Dept Biol, San Antonio, TX USA.
RP O'Neill, LM (reprint author), Univ Coll Dublin, Sch Vet Med, Dublin 4, Ireland.
EM lauren.o-neill@ucdconnect.ie
CR AITKEN ID, 1990, VET REC, V126, P136, DOI 10.1136/vr.126.6.136
   Arulanandam B, 2011, FRONT IMMUNOL, V2, P73
   BAVOIL P, 1984, INFECT IMMUN, V44, P479, DOI 10.1128/IAI.44.2.479-485.1984
   Bayraktar M, 2009, AM J REPROD IMMUNOL, V62, P390, DOI 10.1111/j.1600-0897.2009.00756.x
   Brown J, 2001, VET IMMUNOL IMMUNOP, V82, P107, DOI 10.1016/S0165-2427(01)00351-8
   Budhia S, 2006, J IMMUNOL METHODS, V309, P160, DOI 10.1016/j.jim.2005.12.006
   Buendia AJ, 1999, INFECT IMMUN, V67, P2110
   Buxton D, 2002, J COMP PATHOL, V127, P133, DOI 10.1053/jcpa.2002.0573
   CALDWELL HD, 1982, INFECT IMMUN, V38, P960, DOI 10.1128/IAI.38.3.960-968.1982
   CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981
   Chalmers WSK, 1997, VET REC, V141, P63, DOI 10.1136/vr.141.3.63
   del Rio L, 2013, MICROB PATHOGENESIS, V56, P1, DOI 10.1016/j.micpath.2012.12.003
   Entrican G, 2012, COMP IMMUNOL MICROB, V35, P271, DOI 10.1016/j.cimid.2011.12.001
   Entrican G, 2010, AM J REPROD IMMUNOL, V64, P287, DOI 10.1111/j.1600-0897.2010.00907.x
   Entrican G, 2009, VET MICROBIOL, V135, P98, DOI 10.1016/j.vetmic.2008.09.028
   Farris CM, 2011, INFECT IMMUN, V79, P986, DOI 10.1128/IAI.00881-10
   Foggie A., 1973, Veterinary Bulletin, V43, P587
   Forsbach-Birk V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080310
   Garcia-Seco T, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00067
   Gorivodsky M, 1998, J IMMUNOL, V160, P4280
   Gutierrez J, 2011, VET MICROBIOL, V147, P119, DOI 10.1016/j.vetmic.2010.06.015
   Haddad EK, 1997, J IMMUNOL, V158, P4886
   Hagemann JB, 2016, J CLIN MICROBIOL, V54, P1883, DOI 10.1128/JCM.00351-16
   Hechard C, 2003, J MED MICROBIOL, V52, P35, DOI 10.1099/jmm.0.04983-0
   Herring AJ, P 9 INT S HUM CHLAM, P434
   JONES GE, 1995, VACCINE, V13, P715, DOI 10.1016/0264-410X(94)00068-X
   Laroucau K, 2010, VACCINE, V28, P5653, DOI 10.1016/j.vaccine.2010.06.064
   Lennette DA, 1995, DIAGNOSTIC PROCEDURE, P3
   LINKLATER KA, 1979, VET REC, V105, P387, DOI 10.1136/vr.105.17.387
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Longbottom D, 2006, VET J, V171, P263, DOI 10.1016/j.tvjl.2004.09.006
   Longbottom D, 2003, J COMP PATHOL, V128, P217, DOI 10.1053/jcpa.2002.0629
   Longbottom D, 2018, VACCINE, V36, P3593, DOI 10.1016/j.vaccine.2018.05.042
   Lu CX, 2013, MICROBES INFECT, V15, P329, DOI 10.1016/j.micinf.2013.02.001
   Markey B, 1996, IRISH VET J, V49, P282
   Marques PX, 2010, CLIN VACCINE IMMUNOL, V17, P1274, DOI 10.1128/CVI.00163-10
   MCEWEN A. D., 1956, Veterinary Record, V68, P686
   Murphey C, 2006, CELL IMMUNOL, V242, P110, DOI 10.1016/j.cellimm.2006.10.002
   Murthy AK, 2007, INFECT IMMUN, V75, P666, DOI 10.1128/IAI.01280-06
   Murthy AK, 2011, VACCINE, V29, P2519, DOI 10.1016/j.vaccine.2011.01.074
   Navarro JA, 2004, VET PATHOL, V41, P498, DOI 10.1354/vp.41-5-498
   ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055
   Pantchev A, 2010, COMP IMMUNOL MICROB, V33, P473, DOI 10.1016/j.cimid.2009.08.002
   PAPP JR, 1994, INFECT IMMUN, V62, P3786, DOI 10.1128/IAI.62.9.3786-3792.1994
   Piacenza L, 1999, INFECT IMMUN, V67, P1954
   Puech C, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0382-0
   Rocchi MS, 2009, VET MICROBIOL, V135, P112, DOI 10.1016/j.vetmic.2008.09.030
   Rodolakis A, 1983, ANN RECHERCHES VET F
   TAN TW, 1990, INFECT IMMUN, V58, P3101, DOI 10.1128/IAI.58.9.3101-3108.1990
   Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14194, DOI 10.1074/jbc.M200409200
   WARFORD AL, 1984, AM J CLIN PATHOL, V81, P762, DOI 10.1093/ajcp/81.6.762
   Wheelhouse N, 2010, VACCINE, V28, P5657, DOI 10.1016/j.vaccine.2010.04.114
   WILSMORE AJ, 1990, VET REC, V126, P40
   Worrall S, 2011, J REPROD IMMUNOL, V90, P214, DOI 10.1016/j.jri.2011.03.011
NR 54
TC 0
Z9 0
U1 5
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5428
EP 5438
DI 10.1016/j.vaccine.2019.06.088
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300037
PM 31375438
DA 2020-05-12
ER

PT J
AU Giambi, C
   Del Manso, M
   Marchetti, G
   Olsson, K
   Ali, KA
   Declich, S
   Tiefengraber, D
   Grammens, T
   Wyndham-Thomas, C
   Neyts, M
   Top, G
   Carrillo-Santisteve, P
   Vladimirova, N
   Jordanova, S
   Parmakova, K
   Petrovic, G
   Vucina, VV
   Koliou, M
   Castkova, J
   Knudsen, LK
   Valentiner-Branth, P
   Filippova, I
   Tiittala, P
   Nohynek, H
   Bouscaillou, J
   Herida, M
   Levy-Bruhl, D
   Wichmann, O
   Vygen-Bonnet, S
   Georgakopoulou, T
   Panagiotopoulos, T
   Stavrou, T
   Molnar, Z
   Thorolfur, G
   Cotter, S
   Clarke, A
   Fitzgerald, M
   Iannazzo, S
   Kantsone, I
   Kupreviciene, N
   Berthet, F
   Weicherding, P
   Melillo, T
   Melillo, JM
   Veldhuijzen, I
   de Melker, H
   Bergsaker, MAR
   Paradowska-Stankiewicz, I
   Cale, E
   Valente, P
   Fernandes, T
   Stanescu, A
   Hudecova, H
   Bakoss, I
   Vitek, MG
   Limia, A
   Cejudo, LSC
   Lindstrand, A
   Saliba, V
   Crawshaw, AF
   Ramsay, M
AF Giambi, Cristina
   Del Manso, Martina
   Marchetti, Giulia
   Olsson, Kate
   Ali, Karam Adel
   Declich, Silvia
   Tiefengraber, Daniel
   Grammens, Tine
   Wyndham-Thomas, Chloe
   Neyts, Mie
   Top, Geert
   Carrillo-Santisteve, Paloma
   Vladimirova, Nadezhda
   Jordanova, Sonia
   Parmakova, Kremena
   Petrovic, Goranka
   Vucina, Vesna Visekruna
   Koliou, Maria
   Castkova, Jitka
   Knudsen, Lisbet Krause
   Valentiner-Branth, Palle
   Filippova, Irina
   Tiittala, Paula
   Nohynek, Hanna
   Bouscaillou, Julie
   Herida, Magid
   Levy-Bruhl, Daniel
   Wichmann, Ole
   Vygen-Bonnet, Sabine
   Georgakopoulou, Theano
   Panagiotopoulos, Takis
   Stavrou, Theodora
   Molnar, Zsuzsanna
   Thorolfur, Gudnason
   Cotter, Suzanne
   Clarke, Anna
   Fitzgerald, Margaret
   Iannazzo, Stefania
   Kantsone, Ieva
   Kupreviciene, Nerija
   Berthet, Francoise
   Weicherding, Pierre
   Melillo, Tanya
   Melillo, Jackie M.
   Veldhuijzen, Irene
   de Melker, Hester
   Bergsaker, Marianne A. Riise
   Paradowska-Stankiewicz, Iwona
   Cale, Etelvina
   Valente, Paula
   Fernandes, Teresa
   Stanescu, Aurora
   Hudecova, Helena
   Bakoss, Ivan
   Vitek, Marta Grgic
   Limia, Aurora
   Sanchez-Cambronero Cejudo, Laura
   Lindstrand, Ann
   Saliba, Vanessa
   Crawshaw, Alison F.
   Ramsay, Mary
CA Venice Survey Working Grp
TI Immunisation of migrants in EWEEA countries: Policies and practices
SO VACCINE
LA English
DT Article
DE Migrants; Vaccination; Policy; Vaccine preventable diseases; Europe
ID VACCINATION
AB In recent years various EU/EEA countries have experienced an influx of migrants from low and middle income countries. In 2018, the "Vaccine European New Integrated Collaboration Effort (VENICE)" survey group conducted a survey among 30 EU/EEA countries to investigate immunisation policies and practices targeting irregular migrants, refugees and asylum seekers (later called "migrants" in this report). Twenty-nine countries participated in the survey. Twenty-eight countries reported having national policies targeting children/adolescent and adult migrants, however vaccinations offered to adult migrants are limited to specific conditions in seven countries. All the vaccinations included in the National Immunisation Programme (NIP) are offered to children/adolescents in 27/28 countries and to adults in 13/28 countries. In the 15 countries offering only certain vaccinations to adults, priority is given to diphtheria-tetanus, measles-mumps-rubella and polio vaccinations. Information about the vaccines given to child/adolescent migrants is recorded in 22 countries and to adult migrants in 19 countries with a large variation in recording methods found across countries. Individual and aggregated data are reportedly not shared with other centres/institutions in 13 and 15 countries, respectively. Twenty countries reported not collecting data on vaccination uptake among migrants; only three countries have these data at the national level. Procedures to guarantee migrants' access to vaccinations at the community level are available in 13 countries. In conclusion, although diversified, strategies for migrant vaccination are in place in all countries except for one, and the strategies are generally in line with international recommendations. Efforts are needed to strengthen partnerships and implement initiatives across countries of origin, transit and destination to develop and better share documentation in order to guarantee a completion of vaccination series and to avoid unnecessary re-vaccination. Development of migrant-friendly strategies to facilitate migrants' access to vaccination and collection of vaccination uptake data among migrants is needed to meet existing gaps. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Giambi, Cristina; Del Manso, Martina; Marchetti, Giulia; Declich, Silvia] Ist Super Sanita, Wale Regina Elena 299, I-00161 Rome, Italy.
   [Marchetti, Giulia] Sapienza Univ Roma, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
   [Olsson, Kate; Ali, Karam Adel] European Ctr Dis Prevent & Control, Gustav IIIS Blvd 40, S-16973 Solna, Sweden.
   [Tiefengraber, Daniel] Fed Minist Labour Social Affairs Hlth & Consumer, Vienna, Austria.
   [Grammens, Tine; Wyndham-Thomas, Chloe] Sciensano, Brussels, Belgium.
   [Neyts, Mie] Fed Agcy Recept Asylum Seekers, Brussels, Belgium.
   [Top, Geert] Flemish Agcy Care & Hlth, Brussels, Belgium.
   [Carrillo-Santisteve, Paloma] Off Birth & Childhood, Brussels, Belgium.
   [Vladimirova, Nadezhda] Natl Ctr Infect & Parasit Dis, Sofia, Bulgaria.
   [Jordanova, Sonia; Parmakova, Kremena] Minist Hlth, Sofia, Bulgaria.
   [Petrovic, Goranka; Vucina, Vesna Visekruna] Croatian Inst Publ Hlth, Zagreb, Croatia.
   [Koliou, Maria] Minist Hlth, Nicosia, Cyprus.
   [Castkova, Jitka] Natl Inst Publ Hlth, Prague, Czech Republic.
   [Knudsen, Lisbet Krause; Valentiner-Branth, Palle] Statens Serum Inst, Copenhagen, Denmark.
   [Filippova, Irina] Republ Estonia Hlth Board, Tallinn, Estonia.
   [Tiittala, Paula; Nohynek, Hanna] Natl Inst Hlth & Welf, Helsinki, Finland.
   [Bouscaillou, Julie; Herida, Magid] Minist Solidar & Hlth, Paris, France.
   [Levy-Bruhl, Daniel] French Inst Publ Hlth Surveillance, Paris, France.
   [Wichmann, Ole; Vygen-Bonnet, Sabine] Robert Koch Inst, Berlin, Germany.
   [Georgakopoulou, Theano] Hellen Ctr Dis Control & Prevent, Athens, Greece.
   [Panagiotopoulos, Takis; Stavrou, Theodora] Natl Sch Publ Hlth, Athens, Greece.
   [Molnar, Zsuzsanna] Natl Publ Hlth Ctr, Budapest, Hungary.
   [Thorolfur, Gudnason] Directorate Hlth, Reykjavik, Iceland.
   [Cotter, Suzanne; Clarke, Anna; Fitzgerald, Margaret] Hlth Serv Execut, Dublin, Ireland.
   [Iannazzo, Stefania] Minist Hlth, Rome, Italy.
   [Kantsone, Ieva] Ctr Dis Prevent & Control, Riga, Latvia.
   [Kupreviciene, Nerija] Minist Hlth, Vilnius, Lithuania.
   [Berthet, Francoise; Weicherding, Pierre] Minist Hlth, Luxembourg, Luxembourg.
   [Melillo, Tanya; Melillo, Jackie M.] Minist Hlth, Msida, Malta.
   [Veldhuijzen, Irene; de Melker, Hester] Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands.
   [Bergsaker, Marianne A. Riise] Norwegian Inst Publ Hlth, Oslo, Norway.
   [Paradowska-Stankiewicz, Iwona] Natl Inst Hyg, Natl Inst Publ Hlth, Warsaw, Poland.
   [Cale, Etelvina; Valente, Paula; Fernandes, Teresa] Directorate Gen Hlth, Lisbon, Portugal.
   [Stanescu, Aurora] Aurora Stanescu Natl Inst Publ Hlth, Bucharest, Romania.
   [Hudecova, Helena; Bakoss, Ivan] Publ Hlth Author, Bratislava, Slovakia.
   [Vitek, Marta Grgic] Natl Inst Publ Hlth, Ljubljana, Slovenia.
   [Limia, Aurora; Sanchez-Cambronero Cejudo, Laura] Minist Hlth Consumer Affairs & Social Welf, Madrid, Spain.
   [Lindstrand, Ann] Publ Hlth Agcy Sweden, Solna, Sweden.
   [Saliba, Vanessa; Crawshaw, Alison F.; Ramsay, Mary] Publ Hlth England, London, England.
RP Giambi, C (reprint author), Ist Super Sanita, Dept Infect Dis, Viale Regina Elena 299, I-00161 Rome, Italy.
EM cristina.giambi@iss.it; martina.delmanso@iss.it;
   giulia.marchetti@iss.it; kate.olsson@ecdc.europa.eu;
   karam.adelali@ecdc.europa.eu; silvia.declich@iss.it
OI Declich, Silvia/0000-0002-5916-3889
FU ECDC [5 ECD.7691, 2013/014]
FX The survey was conducted in the framework of the VENICE project (Vaccine
   European New Integrated Collaboration Effort)
   (http://venice.cineca.org/) and received funding from the ECDC (specific
   Agreement No.5 ECD.7691 implementing Framework Partnership Agreement No.
   ECDC/GRANT/2013/014).
CR Abubakar I, 2018, LANCET, V392, P2606, DOI 10.1016/S0140-6736(18)32114-7
   [Anonymous], 2018, LANCET, V391, P1638, DOI [10.1016/S0140-6736(18)30942-5, 10.1016/S0140-6736(18)30943-7]
   [Anonymous], 2009, MIGR HLTH BACKGR NOT
   [Anonymous], 2019, MONTHL MEASL RUB MON
   Bica MA, 2018, EUR J PUBLIC HEALTH, V28, P439, DOI 10.1093/eurpub/ckx197
   D'Ancona F, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.22.1800238
   De Vito E, 2017, REV EVIDENCE EQUITAB
   ECDC, 2018, MONTHL MEASL RUB MON
   ECDC, 2018, PUBL HLTH GUID SCREE
   EUROPEAN CENTER FOR DISEASE CONTROL (ECDC), 2015, INF DIS SPEC REL NEW
   EUROPEAN CENTER FOR DISEASE CONTROL (ECDC), 2016, HDB US ECDC PREP CHE
   European Centre for Disease Prevention and Control (ECDC), 2016, EP UPD MEASL AS SEEK
   European Centre for Disease Prevention and Control (ECDC), 2019, WHO IS RISK MEASL EU
   European Commission, COM2018244 EUR COMM
   Fefferman NH, 2015, LANCET INFECT DIS, V15, P922, DOI 10.1016/S1473-3099(15)00053-5
   Giambi C, 2019, VACCINE, V37, P4610, DOI 10.1016/j.vaccine.2018.01.060
   Giambi C, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14050459
   Haas EJ, 2014, INT HEALTH, V6, P203, DOI 10.1093/inthealth/ihu017
   Hargreaves S, 2018, EUROSURVEILLANCE, V23, P21, DOI 10.2807/1560-7917.ES.2018.23.41.1700772
   Hargreaves S, 2018, LANCET, V391, P1752, DOI 10.1016/S0140-6736(18)30846-8
   Hui C, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15102065
   International Organization of Migration (IOM), 2018, MIGR FLOWS EUR 2017
   International Organization of Migration (IOM), 2019, EUR FLOW MON 2019
   IOM (International Organization for Migration), KEY MIGR TERMS
   Jones G, 2016, EUROSURVEILLANCE, V21, DOI [10.2807/1560-7917.es2016.21.11.30167, DOI 10.2807/1560-7917ES.2016.21.011.30167]
   Kanitz EE, 2012, VACCINE, V30, P5222, DOI 10.1016/j.vaccine.2012.06.012
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Riccardo F, 2012, HEALTH POLICY, V105, P17, DOI 10.1016/j.healthpol.2012.02.004
   Rosano A, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2549-9
   Vairo F, 2017, EUROSURVEILLANCE, V22, P8, DOI 10.2807/1560-7917.ES.2017.22.46.17-00020
   Vespe M, 2017, MIGRATION POLICY PRA, VVII, P26
   WHO UNHCR UNICEF, 2015, JOINT STAT GEN PRINC, P1
   Williams GA, 2016, SCAND J PUBLIC HEALT, V44, P6, DOI 10.1177/1403494815610182
   World Health Organization (WHO), 2018, HLTH REF MIGR REG SI
   World Health Organization (WHO), 2018, WHO EX BOARD 144 SES
   World Health Organization (WHO), WHO VACC PREV DIS MO
   World Health Organization (WHO) Regional Office for Europe, 2014, EUR VACC ACT PLAN 20
   World Health Organization (WHO) Regional Office for Europe, 2019, MIGR HLTH KEY ISS 20
   World Health Organization (WHO) Regional Office for Europe, 2015, CIRC VACC DER POL TY
NR 39
TC 2
Z9 2
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5439
EP 5451
DI 10.1016/j.vaccine.2019.06.068
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300038
PM 31296374
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Susarla, SK
   Gupta, M
   Mantan, M
   Dhongade, R
   Bhave, S
   Das, RK
   Ray, RK
   Babu, TR
   Ravi, MD
   Krishnamurthy, B
   James, S
   Sandhya, G
   Satish, M
   Sahoo, DP
AF Susarla, Sai Krishna
   Gupta, Madhu
   Mantan, Mukta
   Dhongade, Ramchandra
   Bhave, Sheila
   Das, Rajat Kumar
   Ray, Rajib Kumar
   Babu, T. Ramesh
   Ravi, M. D.
   Krishnamurthy, B.
   James, Saji
   Sandhya, G.
   Satish, M.
   Sahoo, Devi Prasad
TI Immunogenicity and safety of a liquid Pentavalent (DTwP-Hb-Hib)
   combination vaccine manufactured by Human Biologicals Institute in 6-8
   weeks old healthy infants: A phase III, randomized, single blind,
   non-inferiority study
SO VACCINE
LA English
DT Article
DE Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine;
   Pentavac SD (R) vaccine; Immunogenicity; Safety; Non-inferiority; Infant
ID INFLUENZAE TYPE-B; COMBINED DIPHTHERIA; MULTICENTER; ANTIBODY; TETANUS
AB Background: A liquid Pentavalent (DTwP-Hb-Hib) combination vaccine, developed by Human Biologicals Institute, underwent a Phase III clinical study in India. In this randomized, single blind, non-inferiority study, the immunogenicity and safety of this Investigational vaccine was compared with Pentavac SD (R) vaccine in 6-8 weeks old healthy infants.
   Methods: A total of 405 healthy infants aged 6-8 weeks old were randomized in 2:1 ratio to receive three doses of either the Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine or Pentavac SD (R) vaccine at four to six weelcs interval. lmmunogenicity was compared by estimation of antibody titers before the first dose and 4-6 weeks after the third dose of vaccination. Safety of each vaccine was assessed and compared by collection of data on solicited and unsolicited adverse events throughout the study period.
   Results: Out of a total of 405 enrolled subjects, 387 subjects completed the study. The seroconversion rates, seroprotection rates and geometric mean titres of the Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine group were found to be comparable and non-inferior to the Pentavac SD (R) vaccine group at 4-6 weeks after the third dose of vaccination. Pain, erythema and swelling at the site of injection were found to be the most common local adverse events whereas fever, irritability and unusual crying were found to be the most common systemic adverse events in both the vaccine groups. No vaccine related serious adverse event was reported. In this study, both the Investigational vaccine as well as the Comparator vaccine were found to be immunogenic and well tolerated.
   Conclusion: After assessment of the results of the study it was concluded that the Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine developed by Human Biologicals Institute was immunogenic and safe when administered to infants aged 6-8 weeks and was non-inferior in immunogenicity and safety to Pentavac SD (R) vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gupta, Madhu] Postgrad Inst Med Educ & Res, Sch Publ Hlth, Dept Community Med, Chandigarh, India.
   [Mantan, Mukta] Maulana Azad Med Coll, Dept Paediat, New Delhi, India.
   [Dhongade, Ramchandra] St Dnyaneshwar Med Educ Res Ctr, Dept Paediat, Pune, Maharashtra, India.
   [Bhave, Sheila] KEM Hosp Res Ctr, Paediat Res, Pune, Maharashtra, India.
   [Das, Rajat Kumar] KPC Med Coll & Hosp, Dept Paediat, Kolkata, India.
   [Ray, Rajib Kumar] Hitech Med Coll & Hosp, Dept Paediat, Bhubaneswar, India.
   [Babu, T. Ramesh] Gandhi Med Coll & Hosp, Dept Paediat, Secunderabad, India.
   [Ravi, M. D.] JSS Med Coll & Hosp, Dept Paediat, Mysore, Karnataka, India.
   [Krishnamurthy, B.] Mysore Med Coll & Res Inst, Dept Paediat, Mysore, Karnataka, India.
   [James, Saji] Sri Ramachandra Med Ctr, Dept Pediat, Chennai, Tamil Nadu, India.
   [Susarla, Sai Krishna; Sandhya, G.; Satish, M.; Sahoo, Devi Prasad] Human Biol Inst, Hyderabad 500032, Telangana, India.
RP Susarla, SK (reprint author), Human Biol Inst, Hyderabad 500032, Telangana, India.
EM s.saikrishna@indimmune.com
OI Susarla, Sai Krishna/0000-0003-0435-6170; Gupta,
   Madhu/0000-0003-3877-9956
FU Human Biologicals Institute (A division of Indian Immunologicals
   Limited), India
FX This study was sponsored by Human Biologicals Institute (A division of
   Indian Immunologicals Limited), India which was involved in all stages
   of the study conduct and analysis. It provided support for all the costs
   associated with the development and publication of this article.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P417
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P369
   [Anonymous], 1999, MMWR Recomm Rep, V48, P1
   [Anonymous], 2018, UN 1 INTR ROL HLTH W, P3
   [Anonymous], 2014, DIS, V5
   [Anonymous], 2011, NZ EN STRAT 2011 202, P17
   Bavdekar SB, 2007, INDIAN PEDIATR, V44, P505
   BOOY R, 1992, LANCET, V339, P507, DOI 10.1016/0140-6736(92)90336-2
   Chatterjee S, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-298
   Cherry JD, 2015, CURR EPIDEMIOL REV, V2, P120
   Dalvi S, 2015, HUM VACC IMMUNOTHER, V11, P901, DOI 10.1080/21645515.2015.1010953
   Eregowda A, 2013, HUM VACC IMMUNOTHER, V9, P1903, DOI 10.4161/hv.25166
   Gupta M, 2010, INDIAN J MED RES, V131, P649
   Howie SRC, 2013, CLIN INFECT DIS, V57, P1527, DOI 10.1093/cid/cit598
   Jones C, 2014, VACCINE, V32, P996, DOI 10.1016/j.vaccine.2013.11.104
   Kovitwanichkanont T, 2017, AUST NZ J PUBL HEAL, V41, P557, DOI 10.1111/1753-6405.12732
   Lewis RF, 2008, B WORLD HEALTH ORGAN, V86, P292, DOI 10.2471/BLT.07.045336
   Maman K, 2015, HUM VACC IMMUNOTHER, V11, P2132, DOI 10.1080/21645515.2015.1044180
   Muliyil JP, 2009, INDIAN PEDIATR, V46, P945
   Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446
   Rusmil K, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0525-2
   Skibinski DAG, 2011, J GLOB INFECT DIS, V3, P63, DOI 10.4103/0974-777X.77298
   Verma R, 2013, HUM VACC IMMUNOTHER, V9, P1497, DOI 10.4161/hv.24382
   Voysey M, 2017, JAMA PEDIATR, V171, P637, DOI 10.1001/jamapediatrics.2017.0638
   Watt JP, 2009, LANCET, V374, P903, DOI 10.1016/S0140-6736(09)61203-4
   World Health Organization, 2006, Wkly Epidemiol Rec, V81, P445
   World Health Organization, 2015, DEP IMM VACC BIOL ST, P41
   Yewale V, 2011, IAP GUIDEBOOK IMMUNI, P74
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5452
EP 5459
DI 10.1016/j.vaccine.2019.06.067
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300039
PM 31331773
DA 2020-05-12
ER

PT J
AU van Schalkwyk, C
   Moodley, J
   Welte, A
   Johnson, LF
AF van Schalkwyk, Can
   Moodley, Jennifer
   Welte, Alex
   Johnson, Leigh F.
TI Estimated impact of human papillomavirus vaccines on infection burden:
   The effect of structural assumptions
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Vaccine; Latency; Reactivation; Immunity;
   Individual-based model
ID RISK HUMAN-PAPILLOMAVIRUS; POPULATION-LEVEL IMPACT; HPV VACCINATION;
   NATURAL-HISTORY; AS04-ADJUVANTED VACCINE; CERVICAL-CANCER; FOLLOW-UP;
   TRANSMISSION; QUADRIVALENT; REACTIVATION
AB Mathematical models have been used to estimate the impact of human papillomavirus (HPV) vaccines on infection burden and cervical cancer. Models assume different mechanisms of naturally acquired immunity against re-infection, but processes of latency and reactivation of latent infection have not been explored. This study uses an individual-based dynamic model to simulate randomised controlled trials (RCTs) for vaccine efficacy, using different assumptions about naturally acquired immunity and viral latency after clearance of HPV infection. Model estimates of vaccine effectiveness are compared to those from published RCTs. We then estimate the impact of the bivalent vaccine on HPV-16 and -18 infection burden in South Africa under these different assumptions. When assuming no latency, simulated vaccine effectiveness overestimates results from RCTs and the model cannot match the observed difference in vaccine effectiveness between total vaccinated cohorts and more HPV-naive cohorts. The reduction in HPV-16 and -18 burden by 2045, following roll-out of vaccination in 2014, does not depend on assumptions about natural immunity, but models that assume no latency predict similar to 25% greater reduction in HPV-16 and -18 burden than models that include reactivation of latent infection for all men and women. Mathematical models that do not allow for reactivation of latent HPV infections may therefore overestimate the long-term impact of HPV vaccines. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [van Schalkwyk, Can; Welte, Alex] Stellenbosch Univ, South African Dept Sci & Technol, Natl Res Fdn, Ctr Excellence Epidemiol Modelling & Anal, Stellenbosch, South Africa.
   [Moodley, Jennifer] Univ Cape Town, Sch Publ Hlth & Family Med, Womens Hlth Res Unit, Anzio Rd, ZA-7925 Cape Town, South Africa.
   [Moodley, Jennifer] Univ Cape Town, Fac Hlth Sci, Canc Res Initiat, Anzio Rd, ZA-7925 Cape Town, South Africa.
   [Moodley, Jennifer] Univ Cape Town, Fac Hlth Sci, SAMRC Gynaecol Canc Res Ctr, Cape Town, South Africa.
   [Johnson, Leigh F.] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa.
RP van Schalkwyk, C (reprint author), SACEMA, Private Bag X1, ZA-7602 Matieland, South Africa.
EM carivs@sun.ac.za
FU Cancer Association of South Africa; South African Department of Science
   and Technology; National Research Foundation
FX This study was supported in part by the Cancer Association of South
   Africa (http://www.cansa.org.za) and by the South African Department of
   Science and Technology and National Research Foundation.
CR Baskerville EB, 2017, P NATL ACAD SCI
   Baussano I, 2017, J INFECT DIS, V216, P336, DOI 10.1093/infdis/jix299
   Beachler DC, 2016, J INFECT DIS, V213, P1444, DOI 10.1093/infdis/jiv753
   Bogaards JA, 2010, AM J EPIDEMIOL, V171, P817, DOI 10.1093/aje/kwp466
   Bosch FX, 2015, NAT REV CLIN ONCOL
   Brisson M, 2016, LANCET PUBLIC HEALTH, V1, pE8, DOI 10.1016/S2468-2667(16)30001-9
   Campos NG, 2014, AM J EPIDEMIOL, V180, P545, DOI 10.1093/aje/kwu159
   Choi YH, 2010, VACCINE, V28, P4091, DOI 10.1016/j.vaccine.2009.09.125
   de Blasio BF, 2012, J PUBLIC HEALTH-UK, V34, P539, DOI 10.1093/pubmed/fds040
   Delany-Moretlwe S, 2018, GLOB HEALTH-SCI PRAC, V6, P425, DOI 10.9745/GHSP-D-18-00090
   Fu TC, 2016, INT J CANCER, V139, P2201, DOI 10.1002/ijc.30283
   Giuliano AR, 2015, PAPILLOMAVIRUS RES, V1, P109, DOI [10.1016/j.pvr.2015.06.007, 10.1016/j.pvr.2016.05.001]
   Gravitt PE, 2011, J CLIN INVEST, V121, P4593, DOI 10.1172/JCI57149
   Gravitt PE., 2012, OPEN VIROLL, V6
   Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0
   Johnson LF, 2016, SEX TRANSM DIS, V43, P139, DOI 10.1097/OLQ.0000000000000412
   Jordaan S, 2016, HLTH CARE CURR REV, V04, DOI [10.4172/2375-4273.1000180, DOI 10.4172/2375-4273.1000180]
   Kelly H, 2018, J INFECT DIS, V218, P927, DOI 10.1093/infdis/jiy252
   Korostil IA, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-312
   Kreimer AR, 2015, LANCET ONCOL, V16, P775, DOI 10.1016/S1470-2045(15)00047-9
   Maglennon GA, 2014, J VIROL, V88, P710, DOI 10.1128/JVI.02589-13
   Matthijsse SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116618
   Mollers M, 2013, J MED VIROL, V85, P1379, DOI 10.1002/jmv.23616
   Olsen J, 2010, INT J TECHNOL ASSESS, V26, P183, DOI 10.1017/S0266462310000085
   Rositch AF, 2012, CANCER RES, P1
   Shew ML, 2015, J MED VIROL, V87, P2122, DOI 10.1002/jmv.24284
   Skinner SR, 2014, LANCET, V384, P2213, DOI 10.1016/S0140-6736(14)60920-X
   SMITH AFM, 1992, AM STAT, V46, P84, DOI 10.2307/2684170
   Smith MA, 2011, VACCINE, V29, P9112, DOI 10.1016/j.vaccine.2011.02.091
   Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073
   Theiler RN, 2010, OBSTET GYNECOL, V115, P1150, DOI 10.1097/AOG.0b013e3181e00927
   Van de Velde N, 2012, JNCI-J NATL CANCER I, V104, P1712, DOI 10.1093/jnci/djs395
   Vanni T, 2012, VACCINE, V30, P4866, DOI 10.1016/j.vaccine.2012.04.087
   VanSchalkwyk C, 2018, SEX TRANSM INFECT, V2, P1
   Wellings K, 2006, LANCET, V368, P1706, DOI 10.1016/S0140-6736(06)69479-8
   Winer RL, 2016, J INFECT DIS, V214, P665, DOI 10.1093/infdis/jiw074
   Winer RL, 2014, INT J CANCER, V134, P1889, DOI 10.1002/ijc.28509
NR 37
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5460
EP 5465
DI 10.1016/j.vaccine.2019.06.013
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300040
PM 31331772
DA 2020-05-12
ER

PT J
AU LeBlanc, JJ
   ElSherif, M
   Ye, L
   MacKinnon-Cameron, D
   Ambrose, A
   Hatchette, TF
   Lang, ALS
   Gillis, HD
   Martin, I
   Demczuk, W
   Andrew, MK
   Boivin, G
   Bowie, W
   Green, K
   Johnstone, J
   Loeb, M
   McCarthy, AE
   McGeer, A
   Semret, M
   Trottier, S
   Valiquette, L
   Webster, D
   McNeil, SA
AF LeBlanc, Jason J.
   ElSherif, May
   Ye, Lingyun
   MacKinnon-Cameron, Donna
   Ambrose, Ardith
   Hatchette, Todd F.
   Lang, Amanda L. S.
   Gillis, Hayley D.
   Martin, Irene
   Demczuk, Walter
   Andrew, Melissa K.
   Boivin, Guy
   Bowie, William
   Green, Karen
   Johnstone, Jennie
   Loeb, Mark
   McCarthy, Anne E.
   McGeer, Allison
   Semret, Makeda
   Trottier, Sylvie
   Valiquette, Louis
   Webster, Duncan
   McNeil, Shelly A.
TI Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd
   immunity in Canadian adults hospitalized with community acquired
   pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network
   of the Canadian immunization research Network (CIRN)
SO VACCINE
LA English
DT Article
DE Community-acquired pneumonia (CAP); Pneumococcal vaccine; PCV13;
   Surveillance; Herd immunity; Streptococcus pneumoniae; Serotype; Adult;
   Burden
ID INVASIVE PNEUMOCOCCAL DISEASE; CONJUGATE VACCINE; POLYSACCHARIDE
   VACCINE; 13-VALENT; CHILDREN; POPULATION; PROTECTION; ENGLAND; BURDEN;
   WALES
AB Background: The 13-valent pneumococcal conjugate vaccine (PCV13) was recently shown to be effective against PCV13-type invasive pneumococcal disease (IPD) and pneumococcal community acquired pneumonia (CAP(Spn)) in healthy adults aged >= 65 years, prompting many countries to re-assess adult immunization. In Canada, the potential benefits of adult PCV13 immunization were unclear given anticipated herd immunity from PCV13 childhood immunization introduced since 2010. This study describes the serotype distribution and clinical outcomes of Canadian adults aged >= 16 years, who were hospitalized with CAP(Spn) and IPD from 2010 to 2015.
   Methods: Active surveillance for CAP and IPD was performed in adult hospitals across five Canadian provinces. IPD was identified when Streptococcus pneumoniae was isolated from sterile sites. Bacteremic and non-bacteremic CAP(Spn) were identified using blood culture, and sputum culture or PCV13-specific urine antigen detection (UAD(PCV13)), respectively. Serotype was assigned using Quellung reaction, PCR, or UAD(PCV13).
   Results: Of 6687 CAP cases where a test was performed, S. pneumoniae positivity decreased from 15.9% in 2011 to 8.8% in 2014, but increased to 12.9% in 2015. CAP(Spn) attributed to PCV13 serotypes followed a similar trend, dropping from 8.3% in 2010 to 4.6% in 2014, but increasing to 6.3% in 2015. The decline was primarily attributed to serotypes 7F and 19A, and the proportional increase to serotype 3. Similar trends were noted for bacteremic and non-bacteremic CAP(Spn). Serious outcomes such as 30-day mortality, intensive care unit admission, and requirement for mechanical ventilation were prominent in CAP(Spn) and IPD cases, but remained unchanged over the study years.
   Conclusion: Herd immunity afforded primarily by serotypes 7F and 19A appears to be partly masked by a concomitant proportional increase of serotype 3. Despite evidence of herd immunity, these PCV13 serotypes remain persistent in Canadian adults hospitalized with CAP(Spn), and represent between 5 and 10% of all CAP in this patient population. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [McNeil, Shelly A.] NSHA, IWK Hlth Ctr, Canadian Ctr Vaccinol CCfV, Halifax, NS, Canada.
   [McNeil, Shelly A.] Dalhousie Univ, Halifax, NS, Canada.
   [Martin, Irene; Demczuk, Walter] Natl Microbiol Lab, Winnipeg, MB, Canada.
   [Boivin, Guy; Trottier, Sylvie] Ctr Hosp Univ Quebec, Quebec City, PQ, Canada.
   [Bowie, William] Vancouver Gen Hosp, Vancouver, BC, Canada.
   [Bowie, William] Univ British Columbia, Vancouver, WA USA.
   [Green, Karen; McGeer, Allison] Mt Sinai Hosp, Toronto, ON, Canada.
   [Johnstone, Jennie] Publ Hlth Ontario, Toronto, ON, Canada.
   [Johnstone, Jennie] Univ Toronto, Toronto, ON, Canada.
   [Loeb, Mark] McMaster Univ, Hamilton, ON, Canada.
   [McCarthy, Anne E.] Ottawa Hosp Gen Campus, Ottawa, ON, Canada.
   [McCarthy, Anne E.] Univ Ottawa, Ottawa, ON, Canada.
   [Semret, Makeda] McGill Univ Hlth Ctr, Montreal, PQ, Canada.
   [Valiquette, Louis] CHU Sherbrooke, Ctr Integre Univ Sante & Serv Sociaux Estrie, Sherbrooke, PQ, Canada.
   [Webster, Duncan] St Johns Hosp, St John, NB, Canada.
   [McNeil, Shelly A.] Canadian Ctr Vaccinol CCfV, IWK Hlth Ctr, 4th Floor Goldbloom Pavill,5850-5980 Univ Ave, Halifax, NS B3K 6R8, Canada.
RP LeBlanc, JJ; McNeil, SA (reprint author), Queen Elizabeth 2 Hlth Sci Ctr, NSHA, Div Microbiol, Room 404B,Mackenzie Bldg,5788 Univ Ave, Halifax, NS B3H 1V8, Canada.
EM jason.leblanc@nshealth.ca; shelly.mcneil@nshealth.ca
RI McGeer, Allison/AAB-6885-2020
OI McGeer, Allison/0000-0001-5647-6137
FU Public Health Agency of Canada (PHAC); Canadian Institutes of Health
   Research (CIHR)Canadian Institutes of Health Research (CIHR); Pfizer
   CanadaPfizer;  [CIHR 23338];  [GSK1106];  [PF1001]
FX This work was supported by the Public Health Agency of Canada (PHAC),
   the Canadian Institutes of Health Research (CIHR), and by an
   investigator -initiated research grant to CIRN from Pfizer Canada. No
   study sponsors were involved in study design, specimen collection,
   analysis and interpretation of data, scientific writing, or decision to
   submit the paper for publication. The grant identification numbers
   associated with the funding were CIHR 23338, GSK1106, and PF1001.
CR Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9
   AUSTRIAN R, 1976, MT SINAI J MED, V43, P699
   Azzari C, 2016, HUM VACC IMMUNOTHER, V12, P344, DOI 10.1080/21645515.2015.1102811
   Bettinger JA, 2010, VACCINE, V28, P2130, DOI 10.1016/j.vaccine.2009.12.026
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Castiglia P, 2014, ADV THER, V31, P1011, DOI 10.1007/s12325-014-0157-1
   Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P893
   Chalmers JD, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0242-0
   Cooper D, 2011, VACCINE, V29, P7207, DOI 10.1016/j.vaccine.2011.06.056
   Dagan R, 2013, CLIN INFECT DIS, V57, P952, DOI 10.1093/cid/cit428
   De Wals P, 2018, VACCINE, V36, P5495, DOI 10.1016/j.vaccine.2018.07.069
   De Wals P, 2018, VACCINE, V36, P421, DOI 10.1016/j.vaccine.2017.11.054
   De Wals P, 2016, VACCINE, V34, P2053, DOI 10.1016/j.vaccine.2015.06.104
   Deceuninck G, 2015, VACCINE, V33, P2684, DOI 10.1016/j.vaccine.2015.04.005
   Demczuk WHB, 2013, CAN J MICROBIOL, V59, P778, DOI 10.1139/cjm-2013-0614
   Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368
   Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15
   Grant LR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074906
   Griffin MR, 2013, NEW ENGL J MED, V369, P155, DOI 10.1056/NEJMoa1209165
   Guevara M, 2016, EUROSURVEILLANCE, V21, P14, DOI 10.2807/1560-7917.ES.2016.21.14.30186
   Hays C, 2017, EUR J CLIN MICROBIOL, V36, P831, DOI 10.1007/s10096-016-2868-5
   Horacio AN, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01616
   Htar MTT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177985
   Huijts SM, 2013, EUR RESPIR J, V42, P1283, DOI 10.1183/09031936.00137412
   Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245
   Kaplan SL, 2015, CLIN INFECT DIS, V60, P1339, DOI 10.1093/cid/civ067
   Kellner JD, 2009, CLIN INFECT DIS, V49, P205, DOI 10.1086/599827
   Kraicer-Melamed H, 2016, VACCINE, V34, P1540, DOI 10.1016/j.vaccine.2016.02.024
   Lang ALS, 2016, J EPIDEMIOL RES, V3, P28
   Lang ALS, 2015, J MED MICROBIOL, V64, P836, DOI 10.1099/jmm.0.000097
   Latifi-Navid H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29280-2
   LeBlanc JJ, 2017, VACCINE, V35, P3647, DOI 10.1016/j.vaccine.2017.05.049
   McNeil SA, 2015, CAN RESPIR J, P17154
   Miller E, 2011, VACCINE, V29, P9127, DOI 10.1016/j.vaccine.2011.09.112
   Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1
   Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3
   Morrow A, 2007, CAN J INFECT DIS MED, V18, P121, DOI 10.1155/2007/713576
   Nieddu F, 2017, VACCINE, V35, P1544, DOI 10.1016/j.vaccine.2017.01.064
   Oligbu G, 2017, CLIN INFECT DIS, V65, P1191, DOI 10.1093/cid/cix418
   Picazo J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172222
   Pride MW, 2012, CLIN VACCINE IMMUNOL, V19, P1131, DOI 10.1128/CVI.00064-12
   Public Agency of Canada (PHAC), 2016, ANN SUMM 2016
   Regev-Yochay G, 2017, VACCINE, V35, P2449, DOI 10.1016/j.vaccine.2017.03.031
   Rodrigo C, 2015, EUR RESPIR J, V45, P1632, DOI 10.1183/09031936.00183614
   Rudnick W, 2013, VACCINE, V31, P5863, DOI 10.1016/j.vaccine.2013.09.049
   Said MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060273
   Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822
   van Werkhoven CH, 2016, VACCINE, V34, P3275, DOI 10.1016/j.vaccine.2016.05.002
   Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7
   WHO, 2015, PNEUM DIS
   Wunderink RG, 2018, CLIN INFECT DIS, V66, P1504, DOI 10.1093/cid/cix1066
NR 51
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5466
EP 5473
DI 10.1016/j.vaccine.2019.05.003
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300041
PM 31345638
OA Other Gold
DA 2020-05-12
ER

PT J
AU Vaz-de-Lima, LRA
   Sato, HK
   Fernandes, EG
   Sato, APS
   Pawloski, LC
   Tondella, ML
   de Brito, CA
   Luna, EJA
   Carvalhanas, TRMP
   de Castilho, EA
   de Souza, EM
   Atobe, JH
   Oliveira, CAF
   Leite, D
   Silva, MR
   Mariani-Neto, C
   Bersusa, A
   Calabresi, RDS
   dos Santos, RA
   Tesser, DT
   Ramos, MLB
AF Vaz-de-Lima, Lourdes R. A.
   Sato, Helena Keico
   Fernandes, Eder Gatti
   Sayuri Sato, Ana Paula
   Pawloski, Lucia C.
   Tondella, Maria Lucia
   de Brito, Cyro A.
   Luna, Expedito J. A.
   Carvalhanas, Telma Regina M. P.
   de Castilho, Euclides A.
   de Souza, Edna M.
   Atobe, Jane H.
   Oliveira, Carmem A. F.
   Leite, Daniela
   Silva, Marcela R.
   Mariani-Neto, Corintio
   Bersusa, Ana
   Calabresi, Rita de Cassia S.
   dos Santos, Rosemary A.
   Tesser, Diva T.
   Bacciotte Ramos, Maria Ligia
CA Maternal Pertussis Vaccine Working
TI Association between the timing of maternal vaccination and newborns'
   anti-pertussis toxin antibody levels
SO VACCINE
LA English
DT Article
DE Pertussis; Maternal vaccination; Newborn infants; Maternal antibodies;
   Tdap
ID TDAP IMMUNIZATION; PREGNANCY; DIPHTHERIA; TETANUS; INFANTS;
   RECOMMENDATIONS; PROTECTION; INFECTION
AB Background: Pertussis remains an important global public health concern, despite the presence of extensive immunization programs. Incidence and severity of pertussis are typically higher in neonates and young infants. As a strategy to protect these young infants, maternal vaccination with Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) has been recommended in Brazil. The objective of this study was to evaluate the effects of Tdap vaccination during pregnancy on the anti-pertussis toxin (PT) IgG response in mothers and their infants at birth.
   Material and methods: Maternal and cord blood samples were collected from vaccinated (n = 243) and unvaccinated (n = 75) pregnant women, at the time of delivery, from July 2015 to August 2016 in Sao Paulo, Brazil. Anti-PT IgG antibodies were quantified by Enzyme-Linked Immunosorbent Assay (ELISA) and geometric mean concentrations (GMC) were calculated. Relationship between timing of vaccination and antibody concentrations were evaluated.
   Results: Maternal and cord blood GMCs among the vaccinated group were 5.4 and 5.6 fold higher [66.5 International Units (IU)/mL and 89.8 IU/mL] compared to the unvaccinated group (12.4 IU/mL and 16.1 IU/mL), respectively (p < 0.001). Higher anti-PT IgG GMCs were observed when vaccination occurred >= 60 days before delivery compared to <60 days, suggesting that vaccination early in the third trimester may be more effective than later in pregnancy.
   Conclusion: Tdap maternal vaccination results in significantly higher anti-FT IgG in newborn infants and supports the current recommendation of the Brazilian Immunization Program. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Vaz-de-Lima, Lourdes R. A.; de Brito, Cyro A.] Adolfo Lutz Inst, Ctr Imunol, Sao Paulo, Brazil.
   [Sato, Helena Keico; Fernandes, Eder Gatti] Coordenadoria Controle Doencas Secretaria Estado, Ctr Vigilancia Epidemiol Prof Alexandre Vranjac, Div Imunizacao, Sao Paulo, Brazil.
   [Sayuri Sato, Ana Paula] Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, Sao Paulo, Brazil.
   [Pawloski, Lucia C.; Tondella, Maria Lucia] Ctr Dis Control & Prevent, Pertussis & Diphtheria Lab, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Luna, Expedito J. A.] Univ Sao Paulo, Inst Med Trop, Sao Paulo, Brazil.
   [Carvalhanas, Telma Regina M. P.] Coordenadoria Controle Doencas Secretaria Estado, Div Doencas Transmissao Resp, Ctr Vigilancia Epidemiol Prof Alexandre Vranjac, Sao Paulo, SP, Brazil.
   [de Castilho, Euclides A.] Univ Sao Paulo, Fac Med, Dept Med Prevent, Sao Paulo, Brazil.
   [de Souza, Edna M.; Atobe, Jane H.; Oliveira, Carmem A. F.] Adolfo Lutz Inst, Immunol Ctr, Sao Paulo, Brazil.
   [Leite, Daniela] Adolfo Lutz Inst, Natl Reference Ctr Pertussis, Bacteriol Ctr, Sao Paulo, Brazil.
   [Silva, Marcela R.] Secretaria Estado Saude SP, Resp Div, Ctr Vigilancia Epidemiol, Sao Paulo, Brazil.
   [Mariani-Neto, Corintio; Bersusa, Ana] Hosp & Maternidade Leonor Mendes Barros, Sao Paulo, Brazil.
   [Calabresi, Rita de Cassia S.; dos Santos, Rosemary A.; Tesser, Diva T.] Hosp Maternidade Interlagos, Sao Paulo, Brazil.
   [Bacciotte Ramos, Maria Ligia] Secretaria Municipal Saude SP, Coordenacao Vigilancia Saude, Ctr Controle Doencas, Sao Paulo, Brazil.
RP Vaz-de-Lima, LRA (reprint author), Adolfo Lutz Inst, Ctr Imunol, Sao Paulo, Brazil.
EM lourlima@uol.com.br
OI Brito, Cyro/0000-0002-9934-6102; /0000-0002-9608-5736
FU Fundo Especial de Sagde para Imunizactio em Massa e Controle de Doencas
   (FESIMA); Institut Adolfo Lutz; Coordenadoria de Controle de Doencas,
   Secretaria de Estado da Satide de Sao Paulo SP; Fundaciao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2015/16157-1]; US Centers for Disease
   Control and PreventionUnited States Department of Health & Human
   ServicesCenters for Disease Control & Prevention - USA; Pan American
   Health Organization; Sabin Vaccine Institute; selected ministries of
   health to strengthen pertussis surveillance in Latin America
FX This work was supported by the Fundo Especial de Sagde para Imunizactio
   em Massa e Controle de Doencas (FESIMA), Institut Adolfo Lutz,
   Coordenadoria de Controle de Doencas, Secretaria de Estado da Satide de
   Sao Paulo SP, Fundaciao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP 2015/16157-1), and the Latin American Pertussis Project, a
   collaboration between the US Centers for Disease Control and Prevention,
   the Pan American Health Organization, the Sabin Vaccine Institute, and
   selected ministries of health to strengthen pertussis surveillance in
   Latin America.
CR Abraham C, 2018, OBSTET GYNECOL, V131, P364, DOI 10.1097/AOG.0000000000002438
   Abu Raya B, 2016, CLIN INFECT DIS, V63, P143, DOI 10.1093/cid/ciw233
   Abu Raya B, 2014, VACCINE, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P433
   [Anonymous], 2017, NOVO CALENCLARIO VAC
   [Anonymous], 2012, PREGN WOM OFF WHOOP
   [Anonymous], 2015, PROGRAMA NACL IMUNIZ
   [Anonymous], 2015, B EPIDEMIOLOGICO
   [Anonymous], 2012, SISTEMA NACL AGRAVOS
   Baughman AL, 2004, CLIN DIAGN LAB IMMUN, V11, P1045, DOI 10.1128/CDLI.11.6.1045-1053.2004
   Becker-Dreps S, 2018, AM J PREV MED
   Calvert A, 2017, CURR OPIN INFECT DIS, V30, P268, DOI 10.1097/QCO.0000000000000372
   Eberhardt CS, 2016, CLIN INFECT DIS, V62, P829, DOI 10.1093/cid/ciw027
   Englund JA, 2007, J COMP PATHOL, V137, pS16, DOI 10.1016/j.jcpa.2007.04.006
   Ercan TE, 2013, VACCINE, V31, P4172, DOI 10.1016/j.vaccine.2013.06.088
   Arlant LHF, 2014, EXPERT REV ANTI-INFE, V12, P1265, DOI 10.1586/14787210.2014.948846
   Fallo AA, 2018, J PEDIAT INF DIS SOC, V7, P11, DOI 10.1093/jpids/piw069
   Fernandes EG, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3004-1
   Gall SA, 2008, CLIN OBSTET GYNECOL, V51, P486, DOI 10.1097/GRF.0b013e318181dde1
   Gall SA, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.11.024
   Gkentzi D, 2017, ARCH DIS CHILD-FETAL, V102, pF456, DOI 10.1136/archdischild-2016-312341
   Guimaraes LM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1222-3
   Guiso N, 2017, TOXINS, V9, DOI 10.3390/toxins9090277
   Healy CM, 2018, JAMA-J AM MED ASSOC, V320, P1464, DOI 10.1001/jama.2018.14298
   Heininger U, 2013, PEDIATR INFECT DIS J, V32, P695, DOI 10.1097/INF.0b013e318288b610
   Hincapie-Palacio D, 2018, VACCINE, V36, P3984, DOI 10.1016/j.vaccine.2018.05.020
   Kapasi A, 2012, CLIN VACCINE IMMUNOL, V19, P64, DOI 10.1128/CVI.05460-11
   Leuridan E, 2017, VACCINE, V35, P4453, DOI 10.1016/j.vaccine.2017.03.061
   Menzies SL, 2009, CLIN VACCINE IMMUNOL, V16, P1781, DOI 10.1128/CVI.00248-09
   Ministry of Health, 2014, INF TECN IMPL VAC AD
   Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
   Naidu MA, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.03.002
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   Skoff TH, 2017, CLIN INFECT DIS, V65, P1977, DOI 10.1093/cid/cix724
   Skoff TH, 2015, PEDIATRICS, V136, P635, DOI 10.1542/peds.2015-1120
   Storsaeter J, 1998, VACCINE, V16, P1907, DOI 10.1016/S0264-410X(98)00227-8
   Taranger J, 2000, J INFECT DIS, V181, P1010, DOI 10.1086/315318
   Vilajeliu A, 2016, VACCINE, V34, P3719, DOI 10.1016/j.vaccine.2016.05.051
   Warfel JM, 2014, J INFECT DIS, V210, P604, DOI 10.1093/infdis/jiu090
   Wiley KE, 2013, VACCINE, V31, P618, DOI 10.1016/j.vaccine.2012.11.052
NR 40
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5474
EP 5480
DI 10.1016/j.vaccine.2019.04.079
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300042
PM 31153689
DA 2020-05-12
ER

PT J
AU Fernandes, EG
   Sato, APS
   Vaz-de-Lima, LRA
   Rodrigues, M
   Leite, D
   de Brito, CA
   Luna, EJA
   Carvalhanas, TRMP
   Ramos, MLBN
   Sato, HK
   de Castilho, EA
   de Souza, EM
   Atobe, JH
   Oliveira, CAF
   de Moraes, JC
   Gaspar, JC
   de Oliveira, SS
AF Fernandes, Eder Gatti
   Sato, Ana Paula S.
   Vaz-de-Lima, Lourdes R. A.
   Rodrigues, Marcela
   Leite, Daniela
   de Brito, Cyro A.
   Luna, Expedito J. A.
   Carvalhanas, Telma Regina M. P.
   Bacciote Nerger Ramos, Maria Ligia
   Sato, Helena Keico
   de Castilho, Euclides A.
   de Souza, Edna M.
   Atobe, Jane H.
   Oliveira, Carmem A. F.
   de Moraes, Jose Cassio
   Gaspar, Jaqueline Correia
   de Oliveira, Silvia Silva
CA Maternal Pertussis Vaccine Working
TI The effectiveness of maternal pertussis vaccination in protecting
   newborn infants in Brazil: A case-control study
SO VACCINE
LA English
DT Article
DE Bordetella pertussis; Maternal immunization; Pertussis vaccine;
   Case-control study; Brazil
ID IMMUNIZATION; EPIDEMIOLOGY
AB Introduction: In 2014, the Brazilian Ministry of Health (MoH) recommended Tdap to pregnant women in response to a significant increase in the incidence of pertussis among infants. The present study assessed the effectiveness of maternal immunization in preventing pertussis in infants.
   Methods: An unmatched case-control study was undertaken in Sao Paulo State, Brazil from February 2015 to July 2016. Cases were infants aged <8 weeks at onset of pertussis reported to the Surveillance System and confirmed by real-time polymerase chain reaction or culture. Four to six healthy infants were selected as controls per case from birth certificates in the Information System on Live Births database. General characteristics and mother's vaccination status were compared between cases and controls. The vaccine effectiveness (VE) was calculated as 1 - odds ratio (OR). For the adjusted VE, the OR was calculated using logistic regression analysis.
   Results: Forty-two cases and 248 controls were enrolled in the study. Mothers of 8 cases (19.1%) and 143 controls (57.4%) were vaccinated during pregnancy, resulting in an unadjusted VE of 82.6% (95% confidence interval [CI], 60.8-92.3%). The VE was unchanged after adjusting for maternal age and monthly household income.
   Conclusion: Maternal pertussis vaccination during pregnancy was effective in protecting infants aged <8 weeks from pertussis. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fernandes, Eder Gatti; Sato, Helena Keico] Secretaria Estado Saude Sao Paulo, Controle Doencas, Ctr Vigilancia Epidemiol Prof Alexandre Vranjac, Div Imunizacao, Av Dr Arnaldo 351,6 Andar, BR-01246000 Sao Paulo, SP, Brazil.
   [Sato, Ana Paula S.] Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, Sao Paulo, Brazil.
   [Vaz-de-Lima, Lourdes R. A.; de Brito, Cyro A.; de Souza, Edna M.; Atobe, Jane H.; Oliveira, Carmem A. F.] Adolfo Lutz Inst, Ctr Imunol, Sao Paulo, Brazil.
   [Rodrigues, Marcela; Carvalhanas, Telma Regina M. P.] Secretaria Estado Saude Sao Paulo, Controle Doencas, Ctr Vigilancia Epidemiol Prof Alexandre Vranjac, Div Doencas Transmissao Resp, Sao Paulo, Brazil.
   [Leite, Daniela] Adolfo Lutz Inst, Ctr Bacteriol, Ctr Referencia Nacl Coqueluche, Sao Paulo, Brazil.
   [Luna, Expedito J. A.] Univ Sao Paulo, Inst Med Trop, Sao Paulo, Brazil.
   [Bacciote Nerger Ramos, Maria Ligia] Secretaria Municipal Saude Sao Paulo, Vigilancia Saude COVISA, Sao Paulo, Brazil.
   [de Castilho, Euclides A.] Univ Sao Paulo, Fac Med, Dept Med Prevent, Sao Paulo, Brazil.
   [de Moraes, Jose Cassio] Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil.
   [Gaspar, Jaqueline Correia] Secretaria Estado Saude Sao Paulo, Controle Doencas, Ctr Vigilancia Epidemiol Prof Alexandre Vranjac, Nucleo Informacao Vigilancia Epidemiol, Sao Paulo, Brazil.
   [de Oliveira, Silvia Silva] Secretaria Municipal Saude Sao Paulo, Vigilancia Saude, Sao Paulo, Brazil.
RP Fernandes, EG (reprint author), Secretaria Estado Saude Sao Paulo, Controle Doencas, Ctr Vigilancia Epidemiol Prof Alexandre Vranjac, Div Imunizacao, Av Dr Arnaldo 351,6 Andar, BR-01246000 Sao Paulo, SP, Brazil.
EM edergatti@saude.gov.br
OI /0000-0002-9608-5736
FU Fundo Especial de Saude para Imunizacao em Massa e Controle de Doencas
   (FESIMA); Institut Adolfo Lutz; Coordenadoria de Controle de Doencas,
   Secretaria de Estado da Saude de Sao Paulo - SP; Sao Paulo Research
   Foundation, FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2015/16157-1]
FX This work was supported by the Fundo Especial de Saude para Imunizacao
   em Massa e Controle de Doencas (FESIMA), Institut Adolfo Lutz,
   Coordenadoria de Controle de Doencas, Secretaria de Estado da Saude de
   Sao Paulo - SP, and the Sao Paulo Research Foundation, FAPESP
   [2015/16157-1].
CR Abu Raya B, 2016, CLIN INFECT DIS, V63, P143, DOI 10.1093/cid/ciw233
   Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P433
   Baxter R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4091
   Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821
   Eberhardt CS, 2016, CLIN INFECT DIS, V62, P829, DOI 10.1093/cid/ciw027
   Arlant LHF, 2014, EXPERT REV ANTI-INFE, V12, P1265, DOI 10.1586/14787210.2014.948846
   Fernandes EG, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3004-1
   Guimaraes LM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1222-3
   Mattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005
   Naidu MA, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.03.002
   Skoff TH, 2017, CLIN INFECT DIS, V65, P1977, DOI 10.1093/cid/cix724
   Tan Tina, 2005, Pediatr Infect Dis J, V24, pS10, DOI 10.1097/01.inf.0000160708.43944.99
NR 13
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5481
EP 5484
DI 10.1016/j.vaccine.2019.03.049
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300043
PM 30948222
DA 2020-05-12
ER

PT J
AU Ozgen, MH
   Blume, S
AF Ozgen, M. Heval
   Blume, Stuart
TI The continuing search for an addiction vaccine
SO VACCINE
LA English
DT Article
DE Addiction; Synthetic opioids; Metabolites; Unconventional carriers;
   Behavioural endpoints; Ethics
ID CONJUGATE VACCINE; COCAINE; NICOTINE; BRAIN; ABUSE; MORPHINE;
   METHAMPHETAMINE; EFFICACY; OPIOIDS; CRISIS
AB Inspired by advances in immunology, in the 1970s scientists began to study the possibilities of mobilizing the human immune system against intruders other than pathogenic viruses and bacteria. In 1972 the suggestion was first made that it might be possible to provoke immunity to narcotic dependence. Because molecules of narcotics such as heroin and cocaine are too small to stimulate an immune response, researchers sought ways of coupling them to immunogenic proteins. The substances they developed soon became known as addiction vaccines. However, despite fifty years of research, and despite the growing problem of addiction, no vaccine against heroin, cocaine, methamphetamine or nicotine addiction has yet been licensed for clinical use. This paper reviews the history of addiction vaccinology, seeks to explain the unique appeal of a vaccinological approach to addiction, and argues for broad discussion of how such vaccines should ultimately be used. (C) 2019 Published by Elsevier Ltd.
C1 [Ozgen, M. Heval] Parnassia Acad, Parnassia Psychiat Inst, Interculturel Psychiat i Psy, The Hague, Netherlands.
   [Ozgen, M. Heval] Parnassia Acad, Addict Res Ctr PARC, Interculturel Psychiat i Psy, The Hague, Netherlands.
   [Blume, Stuart] Univ Amsterdam, Dept Anthropol, Amsterdam, Netherlands.
RP Ozgen, MH (reprint author), Parnassia Acad, Parnassia Addict Res Ctr, Kiwistr 43, NL-2552 DH The Hague, Netherlands.
EM m.h.ozgen@parnassiagroep.nl
CR Anton B, 2006, VACCINE, V24, P3232, DOI 10.1016/j.vaccine.2006.01.047
   Arora R, 2019, AM J ADDICTION, V28, P119, DOI 10.1111/ajad.12867
   Bachmann MF, 2019, EXPERT OPIN BIOL TH, V19, P73, DOI 10.1080/14712598.2019.1554646
   Banks ML, 2018, TRENDS PHARMACOL SCI, V39, P908, DOI 10.1016/j.tips.2018.08.001
   BERKOWITZ B, 1972, SCIENCE, V178, P1290, DOI 10.1126/science.178.4067.1290
   Blume S., 2008, IMMUNIZATION VACCINE
   BONESE KF, 1974, NATURE, V252, P708, DOI 10.1038/252708a0
   Brady KT, 2016, AM J PSYCHIAT, V173, P18, DOI 10.1176/appi.ajp.2015.15020262
   Bremer PT, 2017, J AM CHEM SOC, V139, P8601, DOI 10.1021/jacs.7b03334
   Bremer PT, 2016, ANGEW CHEM INT EDIT, V55, P3772, DOI 10.1002/anie.201511654
   Burris S, 2018, PUBLIC HEALTH REP, V133, P29, DOI 10.1177/0033354917743500
   Carfora A, 2018, J BIOETHIC INQ, V15, P45, DOI 10.1007/s11673-017-9834-5
   CARRERA MRA, 1995, NATURE, V378, P727, DOI 10.1038/378727a0
   Choi J, 1998, J CHROMATOGR B, V705, P277, DOI 10.1016/S0378-4347(97)00527-6
   Cohen PJ, 1997, DRUG ALCOHOL DEPEN, V48, P167, DOI 10.1016/S0376-8716(97)00075-6
   Council of Europe Experts Committee on Ethical Issues and Professional Standards, ETH QUEST RAIS IMM A
   Courtwright DT, 2010, BIOSOCIETIES, V5, P137, DOI 10.1057/biosoc.2009.3
   Desai RI, 2015, NEUROPSYCHOPHARMACOL, V40, P2207, DOI 10.1038/npp.2015.64
   Emens LA, 2012, EXPERT REV ANTICANC, V12, P1597, DOI [10.1586/ERA.12.147, 10.1586/era.12.147]
   Evans SM, 2016, PHARMACOL BIOCHEM BE, V150, P76, DOI 10.1016/j.pbb.2016.09.008
   Fox BS, 1997, DRUG ALCOHOL DEPEN, V48, P153, DOI 10.1016/S0376-8716(97)00121-X
   Gartner CE, 2012, ADDICTION, V107, P1199, DOI 10.1111/j.1360-0443.2012.03812.x
   Hall W, 2011, CURR OPIN PSYCHIATR, V24, P191, DOI 10.1097/YCO.0b013e328345922b
   Heekin RD, 2017, EXPERT REV VACCINES, V16, P1067, DOI 10.1080/14760584.2017.1378577
   HILL JH, 1975, J IMMUNOL, V114, P1363
   Hu Y, 2016, BIOMATERIALS, V106, P228, DOI 10.1016/j.biomaterials.2016.08.028
   Janero DR, 2014, EXPERT OPIN DRUG DIS, V9, P1265, DOI 10.1517/17460441.2014.951631
   Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957
   Kosten TR, 2014, DRUG ALCOHOL DEPEN, V140, P42, DOI 10.1016/j.drugalcdep.2014.04.003
   Leshner AI, 1999, FUTURIST, V33, P22
   Martell BA, 2005, BIOL PSYCHIAT, V58, P158, DOI 10.1016/j.biopsych.2005.04.032
   Monteiro MP, 2014, HUM VACC IMMUNOTHER, V10, P887, DOI 10.4161/hv.27537
   Moreno AY, 2009, PHARMACOL BIOCHEM BE, V92, P199, DOI 10.1016/j.pbb.2009.01.015
   Naz RK, 2014, EXPERT REV VACCINES, V13, P145, DOI 10.1586/14760584.2014.869420
   Olson ME, 2018, EMBO REP, V19, P5, DOI 10.15252/embr.201745322
   Pentel PR, 2000, PHARMACOL BIOCHEM BE, V65, P191, DOI 10.1016/S0091-3057(99)00206-3
   Raleigh MD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184876
   Rothman David J., 1997, BEGINNINGS COUNT TEC
   Satel S, 2014, FRONT PSYCHIATRY, V4, DOI 10.3389/fpsyt.2013.00141
   Schuster M, 2015, VACCINE, V33, P4158, DOI [10.1016/ivacrine201904.035, DOI 10.1016/IVACRINE201904.035]
   Shen XY, 2012, CLIN PHARMACOL THER, V91, P60, DOI 10.1038/clpt.2011.281
   SPECTOR S, 1970, SCIENCE, V168, P1347, DOI 10.1126/science.168.3937.1347
   Stevens MW, 2016, INT IMMUNOPHARMACOL, V35, P137, DOI 10.1016/j.intimp.2016.03.028
   Stowe GN, 2011, J MED CHEM, V54, P5195, DOI 10.1021/jm200461m
   van Schayck OCP, 2014, ADDICTION, V109, P1223, DOI 10.1111/add.12569
   Vocci FJ, 2001, CNS DRUGS, V15, P505, DOI 10.2165/00023210-200115070-00001
   Volkow ND, 2017, NEW ENGL J MED, V377, P1798
   Volkow ND, 2015, LANCET PSYCHIAT, V2, P677, DOI 10.1016/S2215-0366(15)00236-9
   White W. L, 1998, SLAYING DRAGON HIST
   Young MJ, 2012, NAT IMMUNOL, V13, P521, DOI 10.1038/ni.2321
   Zalewska-Kaszubska J, 2015, VACCINE, V33, P6545, DOI 10.1016/j.vaccine.2015.09.079
NR 51
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5485
EP 5490
DI 10.1016/j.vaccine.2019.06.074
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300044
PM 31266675
DA 2020-05-12
ER

PT J
AU Zhao, MC
   Vandersluis, M
   Stout, J
   Haupts, U
   Sanders, M
   Jacquemart, R
AF Zhao, Mochao
   Vandersluis, Melissa
   Stout, James
   Haupts, Ulrich
   Sanders, Matthew
   Jacquemart, Renaud
TI Affinity chromatography for vaccines manufacturing: Finally ready for
   prime time?
SO VACCINE
LA English
DT Article
DE Affinity; Chromatography media; Process economics; Process
   intensification; Bioprocessing; Ligand development
ID VIRUS-LIKE PARTICLES; ONE-STEP PURIFICATION; EXCHANGE MEMBRANE
   CHROMATOGRAPHY; ADENOASSOCIATED VIRUS; CELL-CULTURE; GENE-THERAPY;
   DISEASE VIRUS; INFLUENZA-A; PLASMID DNA; RAPID PURIFICATION
AB Affinity chromatography is among the most powerful separation techniques, achieving the finest separation with high yields even in the most challenging feed streams. Incorporating affinity chromatography in vaccine purification has long been attempted by researchers to improve unit yield and purity with the secondary goal of reducing the number of downstream process operations. Despite the success in laboratory-scale proof of concept, implementation of this technique in pilot or cGMP manufacturing has rarely been realised due to technical and economic challenges in design and manufacturing of ideal ligands as well as availability of high-productivity chromatography media. This paper reviews evolving technologies in engineered ligands and chromatography media that are encouraging companies to revisit the possible use of affinity chromatography in larger scale vaccine purification. It is postulated that commercial-scale implementation of high throughput single-use affinity chromatography can significantly simplify process architecture, improve productivity and flexibility, and reduce cost of goods. (C) 2018 The Authors. Published by Elsevier Ltd.
C1 [Zhao, Mochao; Vandersluis, Melissa; Stout, James; Jacquemart, Renaud] Natrix Separat Inc, 5295 John Lucas Dr Unit 6, Burlington, ON, Canada.
   [Haupts, Ulrich] Navigo Prot GmbH, Heinrich Damerow Str 1, D-06120 Halle, Saale, Germany.
   [Sanders, Matthew] GSK, 89 Rue Inst, B-1330 Rixensart, Belgium.
RP Jacquemart, R (reprint author), 5295 John Lucas Dr Unit 6, Burlington, ON, Canada.
EM renaud@natrixseparations.com
OI Zhao, Mochao/0000-0002-9244-4076
CR Adriaenssens EM, 2012, VIROLOGY, V434, P265, DOI 10.1016/j.virol.2012.09.018
   Amorim LFA, 2017, ELECTROPHORESIS, V38, P2975, DOI 10.1002/elps.201700147
   Anderson R, 2000, J VIROL METHODS, V85, P23, DOI 10.1016/S0166-0934(99)00150-0
   Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   Camperi SA, 2014, METHODS MOL BIOL, V1129, P277, DOI 10.1007/978-1-62703-977-2_22
   Arimitsu H, 2003, INFECT IMMUN, V71, P1599, DOI 10.1128/IAI.71.3.1599-1603.2003
   Arimitsu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083577
   Arnold GS, 2006, MOL THER, V14, P97, DOI 10.1016/j.ymthe.2006.02.014
   Auricchio A, 2001, MOL THER, V4, P372, DOI 10.1006/mthe.2001.0462
   Bandeira V, 2012, HUM GENE THER METHOD, V23, P255, DOI 10.1089/hgtb.2012.059
   Banjac M, 2014, VACCINE, V32, P2487, DOI 10.1016/j.vaccine.2014.02.086
   Baraldo K, 2004, INFECT IMMUN, V72, P4884, DOI 10.1128/IAI.72.8.4884-4887.2004
   BARNHART HM, 1976, J FOOD SCI, V41, P903, DOI [10.1111/j.1365-2621.1976.tb00749.x, 10.1111/j.1365-2621.1976.tb00749_41_4.x]
   Behar G, 2016, J CHROMATOGR A, V1441, P44, DOI 10.1016/j.chroma.2016.02.068
   Besnard L, 2016, BIOTECHNOL ADV, V34, P1, DOI 10.1016/j.biotechadv.2015.11.005
   Bicho D, 2015, SEP PURIF TECHNOL, V154, P320, DOI 10.1016/j.seppur.2015.09.046
   Binning JM, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00029
   Biotechnology Innovation Organisation, 2016, CLIN DEV SUCCESS RAT
   Biswal JK, 2015, BIOLOGICALS, V43, P390, DOI 10.1016/j.biologicals.2015.06.001
   Bratkovic T, 2010, CELL MOL LIFE SCI, V67, P749, DOI 10.1007/s00018-009-0192-2
   Brgles M, 2016, J CHROMATOGR A, V1447, P107, DOI 10.1016/j.chroma.2016.04.022
   BROWN F, 1979, J MED VIROL, V4, P315, DOI 10.1002/jmv.1890040409
   Brown R, 2016, CELL, V166, DOI 10.1016/j.cell.2016.07.048
   Burden CS, 2012, J CHROMATOGR B, V880, P82, DOI 10.1016/j.jchromb.2011.10.044
   Carvalho SB, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201700031
   Cheeks MC, 2009, J CHROMATOGR A, V1216, P2705, DOI 10.1016/j.chroma.2008.08.029
   Chen GY, 2009, BIOTECHNOL PROGR, V25, P1669, DOI 10.1002/btpr.253
   Cheung RCF, 2012, APPL MICROBIOL BIOT, V96, P1411, DOI 10.1007/s00253-012-4507-0
   Chevrel A, 2016, WORLD VACC C EUR
   Childs RF, 2012, Patent No. [US 8211682 B2, 8211682]
   Clark KR, 1999, HUM GENE THER, V10, P1031, DOI 10.1089/10430349950018427
   Clement N, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.2
   DANIEL TM, 1978, AM REV RESPIR DIS, V117, P533
   Davison M, 2011, AUTHENTICATION BULK, P97
   delCanizo AAN, 1996, APPL BIOCHEM BIOTECH, V61, P399
   DETMERS F, 2010, BIOPROCESS INT, V8, P50
   Dias AMGC, 2017, BIOTECHNOL BIOENG, V114, P481, DOI 10.1002/bit.26090
   Dorokhov YL, 2007, TUBERCULOSIS, V87, P218, DOI 10.1016/j.tube.2006.10.001
   Douglas RG, 2013, VACCINE IND, P33, DOI [10.1016/B978-1-4557-0090-5.00018-5, DOI 10.1016/B978-1-4557-0090-5.00018-5]
   Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0
   EINARSSON M, 1978, VOX SANG, V35, P224, DOI 10.1111/j.1423-0410.1978.tb02926.x
   ELKANA Y, 1979, J IMMUNOL METHODS, V25, P185, DOI 10.1016/0022-1759(79)90054-1
   Facciuolo A, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00133
   Forcic D, 2011, J CHROMATOGR B, V879, P981, DOI 10.1016/j.jchromb.2011.03.012
   Fratelli F, 2011, TOXICON, V57, P1093, DOI 10.1016/j.toxicon.2011.04.015
   Gagnon P., 2008, BIOPROCESS INT, V6, P24
   GRABOW WOK, 1973, J INFECT DIS, V127, P183, DOI 10.1093/infdis/127.2.183
   Grimm D, 1998, HUM GENE THER, V9, P2745, DOI 10.1089/hum.1998.9.18-2745
   Guan DL, 2014, BIOTECHNOL LETT, V36, P1391, DOI 10.1007/s10529-014-1509-2
   Hagen A, 2000, BIOPROCESS ENG, V23, P439, DOI 10.1007/s004499900157
   Han Y, 2008, J CHROMATOGR B, V874, P21, DOI 10.1016/j.jchromb.2008.08.025
   Hardick O, 2015, J BIOTECHNOL, V213, P74, DOI 10.1016/j.jbiotec.2015.01.031
   Hattori T, 1997, MICROBIOL IMMUNOL, V41, P717, DOI 10.1111/j.1348-0421.1997.tb01916.x
   HAYMAN MJ, 1973, FEBS LETT, V29, P185, DOI 10.1016/0014-5793(73)80557-5
   Hebben M., 2015, BIOINNOVATION LEADER
   Heldt CL, 2012, BIOTECHNOL J, V7, P558, DOI 10.1002/biot.201000397
   Hou Y, 2015, BIOTECHNOL PROGR, V31, P974, DOI 10.1002/btpr.2113
   Hu JZ, 2010, J CHROMATOGR A, V1217, P3489, DOI 10.1016/j.chroma.2010.03.023
   Hu YC, 2003, ENZYME MICROB TECH, V33, P445, DOI 10.1016/S0141-0229(03)00143-1
   Imai T, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-123
   Jacquemart R, 2016, WORLD VACC C EUR
   Jacquemart R, 2017, PHARM TECHNOL BIOPHA, V2017, P39
   Jacquemart R., 2016, WORLD VACC C WASH
   Jacquemart R, 2016, COMPUT STRUCT BIOTEC, V14, P309, DOI 10.1016/j.csbj.2016.06.007
   JANSON JC, 1984, TRENDS BIOTECHNOL, V2, P31, DOI 10.1016/0167-7799(84)90004-0
   Jiang CP, 2004, J VIROL, V78, P8994, DOI 10.1128/JVI.78.17.8994-9006.2004
   Johnson A, 2012, ANAL CHEM, V84, P6553, DOI 10.1021/ac300835b
   JONES K, 1991, CHROMATOGRAPHIA, V32, P469, DOI 10.1007/BF02327982
   Josefsberg JO, 2012, BIOTECHNOL BIOENG, V109, P1443, DOI 10.1002/bit.24493
   Kalashnikova I, 2008, ANAL CHEM, V80, P2188, DOI 10.1021/ac702258t
   Kalbfuss B, 2014, VACCINE DEV MANUF, P97, DOI DOI 10.1002/9781118870914.CH5
   Kalbfuss B, 2007, J MEMBRANE SCI, V299, P251, DOI 10.1016/j.memsci.2007.04.048
   Kanlaya R, 2016, J VIROL METHODS, V234, P174, DOI 10.1016/j.jviromet.2016.04.023
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9
   Karger A, 1998, J VIROL METHODS, V70, P219, DOI 10.1016/S0166-0934(97)00200-0
   Kelley B, 2009, MABS-AUSTIN, V1, P443, DOI 10.4161/mabs.1.5.9448
   Kennedy MA, 2009, MOL THER, V17, P1664, DOI 10.1038/mt.2009.202
   KENYON AJ, 1973, SCIENCE, V179, P187, DOI 10.1126/science.179.4069.187
   Kim H, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1186/1556-276X-7-408
   Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444
   Koerber JT, 2007, HUM GENE THER, V18, P367, DOI 10.1089/hum.2006.139
   Koho T, 2014, ANTIVIR RES, V104, P93, DOI 10.1016/j.antiviral.2014.01.013
   Kramberger P, 2007, J CHROMATOGR A, V1144, P143, DOI 10.1016/j.chroma.2006.10.055
   Kramberger P, 2010, J VIROL METHODS, V166, P60, DOI 10.1016/j.jviromet.2010.02.020
   Kuiper M, 2002, BIOTECHNOL BIOENG, V80, P445, DOI 10.1002/bit.10388
   KUO J, 1995, INFECT IMMUN, V63, P2706, DOI 10.1128/IAI.63.7.2706-2713.1995
   Lee JC, 2007, FEMS IMMUNOL MED MIC, V51, P201, DOI 10.1111/j.1574-695X.2007.00301.x
   Lee SF, 2002, APPL ENVIRON MICROB, V68, P4253, DOI 10.1128/AEM.68.9.4253-4258.2002
   Lightfoot EN, 2004, BIOTECHNOL BIOENG, V87, P259, DOI 10.1002/bit.20111
   Lipovsek D, 2011, PROTEIN ENG DES SEL, V24, P3, DOI 10.1093/protein/gzq097
   Liu HY, 2009, NAT PROD REP, V26, P313, DOI 10.1039/b819896a
   Liu KY, 2012, J VIROL METHODS, V186, P7, DOI 10.1016/j.jviromet.2012.07.016
   Lorey S, 2014, J BIOL CHEM, V289, P8493, DOI 10.1074/jbc.M113.519884
   Luitjens A, 2016, WORLD VACCINE CONGR
   Lv YQ, 2013, BIOTECHNOL ADV, V31, P1172, DOI 10.1016/j.biotechadv.2013.02.005
   MAGNUSSON P, 1967, ARCH GES VIRUSFORSCH, V20, P374, DOI 10.1007/BF01241955
   Maira-Litran T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043813
   Menegatti S, 2016, J CHROMATOGR A, V1445, P93, DOI 10.1016/j.chroma.2016.03.087
   Mietzsch M, 2014, HUM GENE THER, V25, P212, DOI 10.1089/hum.2013.184
   Mietzsch M, 2014, J VIROL, V88, P2991, DOI 10.1128/JVI.03371-13
   Morenweiser R, 2005, GENE THER, V12, pS103, DOI 10.1038/sj.gt.3302624
   Moser AC, 2010, BIOANALYSIS, V2, P769, DOI [10.4155/bio.10.31, 10.4155/BIO.10.31]
   MURPHY BR, 1989, VACCINE, V7, P533, DOI 10.1016/0264-410X(89)90278-8
   Murphy JC, 2003, BIOTECHNOL PROGR, V19, P982, DOI 10.1021/bp025563o
   Naik AD, 2011, J CHROMATOGR A, V1218, P1691, DOI 10.1016/j.chroma.2010.11.071
   Nasimuzzaman M, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.71
   NELSON LD, 1992, AM J VET RES, V53, P1315
   NEURATH AR, 1973, J GEN VIROL, V19, P391, DOI 10.1099/0022-1317-19-3-391
   Newman CC, 1997, RESURRECTION, P59
   Nitsche A, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-48
   NJAYOU M, 1991, J VIROL METHODS, V32, P67, DOI 10.1016/0166-0934(91)90186-4
   NORD K, 1995, PROTEIN ENG, V8, P601, DOI 10.1093/protein/8.6.601
   O'Keeffe RS, 1999, BIOTECHNOL BIOENG, V62, P537, DOI 10.1002/(SICI)1097-0290(19990305)62:5<537::AID-BIT5>3.0.CO;2-1
   Offit PA, 2005, HEALTH AFFAIR, V24, P622, DOI 10.1377/hlthaff.24.3.622
   Ohtake S, 2012, AMINO ACIDS, PEPTIDES AND PROTEINS IN ORGANIC CHEMISTRY, VOL 5: ANALYSIS AND FUNCTION OF AMINO ACIDS AND PEPTIDES, P277
   Ohtaki N, 2011, J VIROL METHODS, V174, P131, DOI 10.1016/j.jviromet.2011.03.021
   Okada T, 2009, HUM GENE THER, V20, P1013, DOI 10.1089/hum.2009.006
   Oksanen HM, 2012, VIROLOGY, V434, P271, DOI 10.1016/j.virol.2012.09.019
   OLOFSSON S, 1981, J VIROL, V38, P564, DOI 10.1128/JVI.38.2.564-570.1981
   Ongkudon CM, 2014, J SEP SCI, V37, P455, DOI 10.1002/jssc.201300995
   Opitz L, 2008, J VIROL METHODS, V154, P61, DOI 10.1016/j.jviromet.2008.09.004
   Opitz L, 2007, VACCINE, V25, P939, DOI 10.1016/j.vaccine.2006.08.043
   Opitz L, 2009, J VIROL METHODS, V161, P312, DOI 10.1016/j.jviromet.2009.06.025
   Oranje PPA, 2004, MOL THER, V9, pS162
   Peixoto C, 2008, BIOTECHNOL PROGR, V24, P1290, DOI 10.1002/btpr.25
   Perez L, 1998, J VIROL METHODS, V76, P1, DOI 10.1016/S0166-0934(98)00028-7
   Pfaunmiller EL, 2013, ANAL BIOANAL CHEM, V405, P2133, DOI 10.1007/s00216-012-6568-4
   Pralong A, 2015, BIOPHARMA DEV PROD W
   Pralong A, 2014, ENG LIFE SCI, V14, P244, DOI 10.1002/elsc.201400027
   Pulicherla N, 2011, GENE THER, V18, P1020, DOI 10.1038/gt.2011.46
   Qu JX, 2011, PROTEIN EXPRES PURIF, V75, P225, DOI 10.1016/j.pep.2010.10.003
   Rajamanickam V., 2015, CHROMATOGRAPHY, V2, P195
   Rappuoli R, 2014, P NATL ACAD SCI USA, V111, P12288, DOI 10.1073/pnas.1402981111
   Reichert U, 2002, J MEMBRANE SCI, V199, P161, DOI 10.1016/S0376-7388(01)00693-7
   REYNOLDS D, 1988, APPL ENVIRON MICROB, V54, P1761, DOI 10.1128/AEM.54.7.1761-1765.1988
   RIMMELZWAAN GF, 1987, J VIROL METHODS, V15, P313, DOI 10.1016/0166-0934(87)90154-6
   Roy Ipsita, 2006, V22, P107
   Rupar M, 2013, J CHROMATOGR A, V1272, P33, DOI 10.1016/j.chroma.2012.11.058
   Sakoda Y, 2012, MICROBIOL IMMUNOL, V56, P490, DOI 10.1111/j.1348-0421.2012.00468.x
   SAKURAI J, 1977, INFECT IMMUN, V18, P741, DOI 10.1128/IAI.18.3.741-745.1977
   Sano D, 2004, APPL ENVIRON MICROB, V70, P3434, DOI 10.1128/AEM.70.6.3434-3442.2004
   Sano D, 2010, J APPL MICROBIOL, V109, P1923, DOI 10.1111/j.1365-2672.2010.04821.x
   Schwark S, 2016, RSC ADV, V6, P53162, DOI 10.1039/c6ra06632a
   SCOTT VN, 1975, INFECT IMMUN, V12, P536, DOI 10.1128/IAI.12.3.536-543.1975
   Segura Maria de las Mercedes, 2008, V434, P1, DOI 10.1007/978-1-60327-248-3_1
   Segura MM, 2007, BIOTECHNOL BIOENG, V98, P789, DOI 10.1002/bit.21467
   SEKURA RD, 1983, J BIOL CHEM, V258, P4647
   SHEPPARD AJ, 1987, J APPL BACTERIOL, V62, P335, DOI 10.1111/j.1365-2672.1987.tb04929.x
   Shoji Y, 2012, INFLUENZA OTHER RESP, V6, P204, DOI 10.1111/j.1750-2659.2011.00295.x
   Silacci M, 2016, MABS-AUSTIN, V8, P141, DOI 10.1080/19420862.2015.1093266
   Silva RJS, 2015, PHARM BIOPROCESS, V3, P489, DOI 10.4155/pbp.15.29
   Skerra A, 2000, J MOL RECOGNIT, V13, P167, DOI 10.1002/1099-1352(200007/08)13:4<167::AID-JMR502>3.3.CO;2-0
   Smith J, 2011, LANCET, V378, P428, DOI 10.1016/S0140-6736(11)60478-9
   Smith RH, 2009, MOL THER, V17, P1888, DOI 10.1038/mt.2009.128
   Smrekar F, 2008, J CHROMATOGR B, V861, P177, DOI 10.1016/j.jchromb.2007.05.048
   Smrekar F, 2011, J CHROMATOGR A, V1218, P2438, DOI 10.1016/j.chroma.2010.12.083
   Soares A, 2013, J CHROMATOGR A, V1320, P72, DOI 10.1016/j.chroma.2013.10.053
   Sousa A, 2011, J CHROMATOGR B, V879, P3507, DOI 10.1016/j.jchromb.2011.09.032
   Specht R, 2004, BIOTECHNOL BIOENG, V88, P465, DOI 10.1002/bit.20270
   Steppert P, 2016, J CHROMATOGR A, V1455, P93, DOI 10.1016/j.chroma.2016.05.053
   Stojicevic I, 2011, J CHROMATOGR B, V879, P2213, DOI 10.1016/j.jchromb.2011.06.003
   Sugden EA, 1996, CLIN DIAGN LAB IMMUN, V3, P541, DOI 10.1128/CDLI.3.5.541-546.1996
   SVOBODA M, 1986, ANAL BIOCHEM, V159, P402, DOI 10.1016/0003-2697(86)90360-X
   Tan LCM, 2010, PROTEIN EXPRES PURIF, V74, P129, DOI 10.1016/j.pep.2010.06.015
   Tan YP, 2006, PROCESS BIOCHEM, V41, P874, DOI 10.1016/j.procbio.2005.11.003
   Tardieu M, 2014, HUM GENE THER, V25, P506, DOI 10.1089/hum.2013.238
   Trilisky EI, 2007, J CHROMATOGR A, V1142, P2, DOI 10.1016/j.chroma.2006.12.094
   UESAKA Y, 1994, MICROB PATHOGENESIS, V16, P71, DOI 10.1006/mpat.1994.1007
   Urthalera J, 2005, J CHROMATOGR A, V1065, P93, DOI 10.1016/j.chroma.2004.12.007
   Vazquez-Lombardi R, 2015, DRUG DISCOV TODAY, V20, P1271, DOI 10.1016/j.drudis.2015.09.004
   Venkatachalam ARK, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-99
   Vicalvi J. J., 2013, USA Patent, Patent No. [US 2015/0210986A1, 20150210986]
   Vicente T, 2009, GENE THER, V16, P766, DOI 10.1038/gt.2009.33
   Vicente T, 2008, J MEMBRANE SCI, V311, P270, DOI 10.1016/j.memsci.2007.12.021
   Wang Q, 2015, MOL THER-METH CLIN D, V2, DOI 10.1038/mtm.2015.40
   Wang XZ, 2015, J BIOL CHEM, V290, P3576, DOI 10.1074/jbc.M114.585281
   Weigel T, 2016, J BIOTECHNOL, V220, P12, DOI 10.1016/j.jbiotec.2015.12.022
   Williams D, 1998, Chimeric toxins, Patent No. [US5763250 A, 5763250]
   Williams SL, 2005, BIOTECHNOL BIOENG, V89, P783, DOI 10.1002/bit.20382
   Wils P, 1997, GENE THER, V4, P323, DOI 10.1038/sj.gt.3300388
   Wizemann H, 1999, J VIROL METHODS, V77, P189, DOI 10.1016/S0166-0934(98)00152-9
   Wolff MW, 2010, BIOTECHNOL BIOENG, V107, P312, DOI 10.1002/bit.22797
   Wolff MW, 2010, BIOTECHNOL BIOENG, V105, P761, DOI 10.1002/bit.22595
   Wu CX, 2007, HUM GENE THER, V18, P665, DOI 10.1089/hum.2007.020
   Wu YG, 2015, J CHROMATOGR A, V1375, P92, DOI 10.1016/j.chroma.2014.11.083
   Wu ZJ, 2006, MOL THER, V14, P316, DOI 10.1016/j.ymthe.2006.05.009
   WULFF G, 1972, ANGEW CHEM INT EDIT, V11, P341
   Yang Y, 2014, VACCINE DEV MANUF, P181, DOI [10.1002/9781118870914.ch6, DOI 10.1002/9781118870914.CH6]
   Ye GJ, 2014, HUM GENE THER CL DEV, V25, P212, DOI 10.1089/humc.2014.060
   Ye KM, 2004, J VIROL, V78, P9820, DOI 10.1128/JVI.78.18.9820-9827.2004
   Yu MR, 2014, J CHROMATOGR A, V1331, P69, DOI 10.1016/j.chroma.2014.01.027
   Yu Z, 2013, J PHARM SCI-US, V102, P4284, DOI 10.1002/jps.23746
   Zahn R, 2010, INT GEOSCI REMOTE SE, P677, DOI 10.1109/IGARSS.2010.5651829
   Zaveckas M, 2015, J CHROMATOGR B, V991, P21, DOI 10.1016/j.jchromb.2015.04.004
   Zeller Skye J., 2011, Yale Journal of Biology and Medicine, V84, P301
   Zhang H., 2015, MOL IMPRINTING, V3, DOI [10.1515/molim-2015-0005, DOI 10.1515/MOLIM-2015-0005]
   Zhao M, 2016, POSTER VACCINE TECHN
   Zhao M, 2015, WORLD VACC C EUR
   Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938
   Zolotukhin S, 2002, METHODS, V28, P158, DOI 10.1016/S1046-2023(02)00220-7
NR 200
TC 6
Z9 6
U1 5
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 23
PY 2019
VL 37
IS 36
BP 5491
EP 5503
DI 10.1016/j.vaccine.2018.02.090
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA IU2PM
UT WOS:000483422300045
PM 29627235
OA Other Gold
DA 2020-05-12
ER

PT J
AU Chen, ZH
   Hou, YL
   Yang, YF
   Cai, DL
   Song, WL
   Wang, N
   Qian, WZ
AF Chen, Zhaohui
   Hou, Yilin
   Yang, Yifeng
   Cai, Dali
   Song, Wenlong
   Wang, Ning
   Qian, Weizhong
TI A multi-stage fluidized bed strategy for the enhanced conversion of
   methanol into aromatics
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Methanol; Multi-stage fluidized bed; Aromatization; Dehydrogenation;
   Paraffins; ZSM-5 zeolite
ID N-BUTANE AROMATIZATION; HIGH-QUALITY TAR; HYDROGEN-TRANSFER; CATALYTIC
   PERFORMANCE; HYDROCARBON POOL; MFI ZEOLITE; ZSM-5; PROPANE; OLEFINS;
   DEACTIVATION
AB A three-stage fluidized bed strategy was proposed to enhance the conversion of methanol into aromatics (MTA) with Zn/ZSM-5 catalyst, where the 1st stage (near the bottom) served the aromatization of methanol, the 2nd stage (in the middle) served the aromatization of C-3-C-5 paraffins and the 3rd stage (near the exit) served mainly the aromatization of C-2-C-4 olefins in sequence. The yield of aromatics in the 2nd stage increased by 7.0-9.0% compared with the 1st stage. And the final yield of aromatics at the exit of 3rd stage was kept at 62-66% for a long time, 8.0-15.0% higher than that of the exit of 1st stage. The effect of coke deposition in different stages on the evolution of aromatics, olefins and alkanes was investigated to clarify the consecutive reaction chain during MTA. As fully meeting the requirements of the different conversion characteristics of methanol and their intermediates, very high-yield production of aromatics by the single-pass conversion of methanol was achieved with this strategy. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Zhaohui; Hou, Yilin; Yang, Yifeng; Cai, Dali; Song, Wenlong; Wang, Ning; Qian, Weizhong] Tsinghua Univ, Dept Chem Engn, Beijing 100084, Peoples R China.
RP Chen, ZH; Qian, WZ (reprint author), Tsinghua Univ, Dept Chem Engn, Beijing 100084, Peoples R China.
EM chenzh8i@163.com; qianwz@tsinghua.edu.cn
RI Qian, Weizhong/AAK-8321-2020
OI Qian, Weizhong/0000-0002-1684-1061; Cai, Dali/0000-0001-5611-323X
FU National Key Research and Development Program of China [2018YFB0604803]
FX The authors are grateful to the financial support from the National Key
   Research and Development Program of China (2018YFB0604803).
CR Amblard B, 2017, CHEM ENG SCI, V170, P731, DOI 10.1016/j.ces.2016.12.055
   Bjorgen M, 2010, J CATAL, V275, P170, DOI 10.1016/j.jcat.2010.08.001
   Cai DL, 2018, NANOSCALE, V10, P16431, DOI 10.1039/c8nr04652b
   Chen Z., 2018, ANGEW CHEM, V130, P12729
   Chen ZH, 2018, APPL ENERG, V215, P348, DOI 10.1016/j.apenergy.2018.02.023
   Chen ZH, 2017, APPL ENERG, V208, P1527, DOI 10.1016/j.apenergy.2017.08.227
   Chen ZY, 2019, CHEM ENG SCI, V195, P619, DOI 10.1016/j.ces.2018.10.007
   Cheng Y, 2017, MULTIPHASE REACTOR ENGINEERING FOR CLEAN AND LOW-CARBON ENERGY APPLICATIONS, P1
   Chowdhury A. D., 2018, ANGEW CHEM, V130, P8227
   Conte M, 2012, CATAL SCI TECHNOL, V2, P105, DOI 10.1039/c1cy00299f
   Diao SG, 2005, APPL CATAL A-GEN, V286, P30, DOI 10.1016/j.apcata.2005.02.026
   Du Z, 2018, PARTICUOLOGY, V41, P11, DOI 10.1016/j.partic.2018.03.001
   Gao P, 2017, ACS CATAL, V7, P6060, DOI 10.1021/acscatal.7b02508
   HARRIS JL, 1992, APPL CATAL A-GEN, V83, P59, DOI 10.1016/0926-860X(92)80026-9
   Hou YL, 2017, RSC ADV, V7, P14309, DOI 10.1039/c6ra28844h
   Hu QF, 2017, RSC ADV, V7, P28940, DOI 10.1039/c7ra04111j
   Ilias S, 2013, ACS CATAL, V3, P18, DOI 10.1021/cs3006583
   Kazemi A, 2017, CHEM ENG SCI, V172, P385, DOI 10.1016/j.ces.2017.06.051
   LEVANMAO R, 1991, APPL CATAL, V79, P77
   Liu Ru-ling, 2015, Journal of Fuel Chemistry and Technology, V43, P961, DOI 10.1016/S1872-5813(15)30027-X
   Martinez-Espin JS, 2017, ACS CATAL, V7, P5773, DOI 10.1021/acscatal.7b01643
   Muller S, 2016, J AM CHEM SOC, V138, P15994, DOI 10.1021/jacs.6b09605
   Nguyen LH, 2006, CHEM ENG SCI, V61, P5881, DOI 10.1016/j.ces.2006.05.017
   Olsbye U, 2012, ANGEW CHEM INT EDIT, V51, P5810, DOI 10.1002/anie.201103657
   Pinilla-Herrero I, 2018, J CATAL, V362, P146, DOI 10.1016/j.jcat.2018.03.032
   Qian WH, 2004, APPL CATAL A-GEN, V260, P223, DOI 10.1016/j.apcata.2003.10.018
   Roshanaei A, 2018, FUEL PROCESS TECHNOL, V176, P197, DOI 10.1016/j.fuproc.2018.03.020
   Shen K, 2014, CATAL SCI TECHNOL, V4, P3840, DOI 10.1039/c4cy01010h
   Shen K, 2013, J AM CHEM SOC, V135, P15322, DOI 10.1021/ja408624x
   Song C, 2014, FUEL PROCESS TECHNOL, V126, P60, DOI 10.1016/j.fuproc.2014.04.018
   Su C, 2016, CATAL TODAY, V264, P63, DOI 10.1016/j.cattod.2015.09.022
   Tian P, 2015, ACS CATAL, V5, P1922, DOI 10.1021/acscatal.5b00007
   Tian T, 2010, ACTA PHYS-CHIM SIN, V26, P3305, DOI 10.3866/PKU.WHXB20101228
   Wang C, 2017, J CATAL, V354, P138, DOI 10.1016/j.jcat.2017.08.003
   Wang CM, 2016, CATAL SCI TECHNOL, V6, P3279, DOI 10.1039/c5cy01419k
   Wang N, 2019, APPL CATAL B-ENVIRON, V243, P721, DOI 10.1016/j.apcatb.2018.11.023
   Wang N, 2018, J CATAL, V360, P89, DOI 10.1016/j.jcat.2017.12.024
   Wang N, 2013, ACS CATAL, V3, P1638, DOI 10.1021/cs4003113
   Wang S, 2019, J CATAL, V369, P382, DOI 10.1016/j.jcat.2018.11.018
   Wang T, 2014, CATAL TODAY, V233, P8, DOI 10.1016/j.cattod.2014.02.007
   Yarulina I, 2018, NAT CATAL, V1, P398, DOI 10.1038/s41929-018-0078-5
   Zhang CX, 2019, CAN J CHEM ENG, V97, P636, DOI 10.1002/cjce.23425
   Zhang JG, 2013, ACTA PHYS-CHIM SIN, V29, P1281, DOI 10.3866/PKU.WHXB201304101
   Zhang JY, 2018, CHEM ENG SCI, V189, P212, DOI 10.1016/j.ces.2018.05.056
   Zhang MZ, 2016, CHINESE J CATAL, V37, P1413, DOI 10.1016/S1872-2067(16)62466-X
   Zhou YF, 2016, AICHE J, V62, P1454, DOI 10.1002/aic.15157
NR 46
TC 3
Z9 3
U1 20
U2 53
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 1
EP 8
DI 10.1016/j.ces.2019.04.013
PG 8
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600001
DA 2020-05-12
ER

PT J
AU Govender, N
   Wilke, DN
   Wu, CY
   Tuzun, U
   Kureck, H
AF Govender, Nicolin
   Wilke, Daniel N.
   Wu, Chuan-Yu
   Tuzun, Ugur
   Kureck, Hermann
TI A numerical investigation into the effect of angular particle shape on
   blast furnace burden topography and percolation using a GPU solved
   discrete element model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE DEM; Blast furnace charging; Particle shape; GPU; Large scale
ID CHARGING SYSTEM; SIZE SEGREGATION; RECENT PROGRESS; SIMULATION; FLOW;
   DEM; BEHAVIOR; MOTION; MILLS; OPTIMIZATION
AB In blast furnaces, burden topography and packing density affect the stability of the burden, permeability of gas flow as well as the heat transfer efficiency. A fundamental understanding of the influence and interaction of coke and ore particles on the burden topography and packing density is therefore essential, in particular, the influence of particle shape polydispersity and particle size polydispersity. In this paper we analyze the effect of particle shape and size polydispersity on the coke and ore charge distribution inside a bell-less blast furnace using the discrete element method (DEM). We first validate experimentally the polyhedral particle model with a simplified lab-scale charging experiment. A comparative study between spheres, with rolling friction to account for shape, and polyhedra is conducted for shape and size polydisperse particle systems. It was found that shape polydispersity mainly influenced the topography of the burden, whereas the size polydispersity mainly influenced the inter-layer percolation, i.e. localized particle diffusion, hence the local spatial packing density. The differences between the spherical particle models and polyhedral particle models on the burden topography are also quantitatively and qualitatively presented, especially on the role of particle shape on the push-up of coke in the centre. This study demonstrates that modelling particle shape effects using spheres with rolling friction is insufficient to fully describe the complex behaviour of shaped particles in a blast furnace, as the particle shape has a noteworthy influence on the burden characteristics. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Govender, Nicolin; Wu, Chuan-Yu] Univ Surrey, Dept Chem Engn, Guildford, Surrey, England.
   [Wilke, Daniel N.] Univ Pretoria, Dept Mech & Aeronaut Engn, Pretoria, South Africa.
   [Tuzun, Ugur] Churchill Coll, Cambridge, England.
   [Kureck, Hermann] Res Ctr Pharmaceut Engn GmbH, Graz, Austria.
RP Govender, N (reprint author), Univ Surrey, Dept Chem Engn, Guildford, Surrey, England.
EM n.govender@surrey.ac.uk
OI govender, nicolin/0000-0002-5068-5429
FU MARIE Sklodowska-CURIE Individual Fellowships with acronym DECRON
   through the People Programme (MARIE Sklodowska-CURIE Actions) of the
   European Union's H2020 under REA [747963]; National Research Foundation
   (NRF) of South AfricaNational Research Foundation - South Africa
FX This work was supported by the MARIE Sklodowska-CURIE Individual
   Fellowships with acronym DECRON, funded through the People Programme
   (MARIE Sklodowska-CURIE Actions) of the European Union's H2020 under REA
   grant agreement No. 747963. We gratefully acknowledge the support of the
   NVIDIA Corporation with the donation of the Titan X Pascal GPU used for
   this research. The financial support of the National Research Foundation
   (NRF) of South Africa is acknowledged.
CR Abou-Chakra H, 2000, POWDER TECHNOL, V111, P200, DOI 10.1016/S0032-5910(99)00285-5
   Abou-Chakra H, 2004, ADV POWDER TECHNOL, V15, P63, DOI 10.1163/15685520460740070
   Adema A., 2014, THESIS
   Alchikh-Sulaiman B, 2016, PARTICUOLOGY, V25, P133, DOI 10.1016/j.partic.2015.05.006
   Alizadeh E, 2014, COMPUT CHEM ENG, V64, P1, DOI 10.1016/j.compchemeng.2013.12.009
   Ariyama T, 2014, ISIJ INT, V54, P1457, DOI 10.2355/isijinternational.54.1457
   Baath L., 2008, SURFACE TOPOGRAPHY P
   Baniasadi M., 2018, 1806 ARXIV, P1
   Barr A. H., 1981, IEEE Computer Graphics and Applications, V1, P11
   Basinskas G, 2016, POWDER TECHNOL, V287, P380, DOI 10.1016/j.powtec.2015.10.017
   Battey-Pratt E., 1980, INT J THEOR PHYS, V19, P6
   Biswas A.K., 1981, PRINCIPLES BLAST FUR
   Boon CW, 2013, POWDER TECHNOL, V248, P94, DOI 10.1016/j.powtec.2012.12.040
   Christov IC, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3653280
   Cleary PW, 2013, POWDER TECHNOL, V248, P103, DOI 10.1016/j.powtec.2013.06.010
   Cleary PW, 1998, APPL MATH MODEL, V22, P995, DOI 10.1016/S0307-904X(98)10032-X
   Dahlstedt A., 1999, LKABS EXPT BLAST FUR, P235
   Davalos C, 2015, INT J SOLIDS STRUCT, V71, P99, DOI 10.1016/j.ijsolstr.2015.06.013
   de Gennes PG, 1999, REV MOD PHYS, V71, pS374, DOI 10.1103/RevModPhys.71.S374
   Dudinski A, 2006, METALLURGIST+, V50, P368, DOI 10.1007/s11015-006-0090-x
   Fang MM, 2013, IND ENG CHEM RES, V52, P7556, DOI 10.1021/ie400306m
   Feng YT, 2012, COMPUT METHOD APPL M, V205, P169, DOI 10.1016/j.cma.2011.02.010
   Fujita K, 2010, INT S IRONMAK SUSTAI, V1, P28
   Ghosk A, 2008, IRONMAKING STEELMAKI
   Govender Nicolin, 2016, SoftwareX, V5, P62, DOI 10.1016/j.softx.2016.04.004
   Govender N., 2014, NVIDIA GTC 2014
   Govender N., 2015, P INT C PART BAS MET
   GOVENDER N, 2014, J COMPUTAT APPL MATH, V270, P63
   Govender N, 2018, MINER ENG, V129, P71, DOI 10.1016/j.mineng.2018.09.019
   Govender N, 2018, ADV POWDER TECHNOL, V29, P2476, DOI 10.1016/j.apt.2018.06.028
   Govender N, 2018, APPL MATH COMPUT, V319, P318, DOI 10.1016/j.amc.2017.03.037
   Govender N, 2015, APPL MATH COMPUT, V267, P810, DOI 10.1016/j.amc.2014.10.013
   Govender N, 2015, MINER ENG, V79, P152, DOI 10.1016/j.mineng.2015.05.010
   Gui N, 2013, AICHE J, V59, P1906, DOI 10.1002/aic.13999
   Guo S.-Y, 2004, EXPT STUDY RACEWAY C, V16, P21
   HAFF PK, 1983, J FLUID MECH, V134, P401, DOI 10.1017/S0022112083003419
   Harada T, 2008, GPU GEMS 3 REAL TIME, V3
   Hassanpour A., 2015, DISCRETE ELEMENT MET, P459, DOI [10.1002/9781118682692.ch17, DOI 10.1002/9781118682692.CH17]
   Hilton JE, 2012, CHEM ENG SCI, V80, P306, DOI 10.1016/j.ces.2012.06.044
   Hohner D, 2011, POWDER TECHNOL, V208, P643, DOI 10.1016/j.powtec.2011.01.003
   Hou QF, 2017, POWDER TECHNOL, V314, P557, DOI 10.1016/j.powtec.2016.12.017
   Hromnik M, 2013, THESIS U CAPE TOWN
   International I., 2012, MIN ENG, V52, P943
   Jaelee S., 2014, THESIS
   JENNINGS BR, 1988, P ROY SOC LOND A MAT, V419, P137, DOI 10.1098/rspa.1988.0100
   Kempton L, 2014, THESIS
   Khakhar DV, 2001, POWDER TECHNOL, V116, P232, DOI 10.1016/S0032-5910(00)00390-9
   Kildashti K, 2018, CHEM ENG SCI, V177, P1, DOI 10.1016/j.ces.2017.11.004
   Kuang S. B., 2017, STEEL RES INT, V89, P1
   Kuo HP, 2004, ADV POWDER TECHNOL, V15, P297, DOI 10.1163/156855204774150109
   Lacey P.M.C., 1943, T I CHEM ENG-LOND, V21, P53
   Longmore JP, 2013, POWDER TECHNOL, V235, P983, DOI 10.1016/j.powtec.2012.10.056
   Mack S, 2011, POWDER TECHNOL, V214, P431, DOI 10.1016/j.powtec.2011.08.043
   Meier SW, 2007, ADV PHYS, V56, P757, DOI 10.1080/00018730701611677
   Mio H, 2007, ISIJ INT, V47, P1745, DOI 10.2355/isijinternational.47.1745
   Mio H, 2017, ISIJ INT, V57, P272, DOI 10.2355/isijinternational.ISIJINT-2016-530
   Mio H, 2009, ISIJ INT, V49, P479, DOI 10.2355/isijinternational.49.479
   MISHRA BK, 1994, INT J MINER PROCESS, V40, P171, DOI 10.1016/0301-7516(94)90042-6
   Mitra Tamoghna, 2015, IFAC - Papers Online, V48, P183, DOI 10.1016/j.ifacol.2015.10.100
   Mitra T., 2016, THESIS
   Nassauer B, 2013, GRANUL MATTER, V15, P85, DOI 10.1007/s10035-012-0381-9
   Natsui S, 2009, ISIJ INT, V49, P1308, DOI 10.2355/isijinternational.49.1308
   Nouchi T., 2009, JFE TECH REP, V13, P28
   Pasha M, 2016, POWDER TECHNOL, V296, P29, DOI 10.1016/j.powtec.2015.10.055
   Pathak SN, 2017, PHYS REV E, V96, DOI 10.1103/PhysRevE.96.042901
   Peters B., 2018, EXTENDED DISCRETE EL, P125
   Potapov A. V, 2011, PRESENT ROCKY PARTIC
   Qi FL, 2017, POWDER TECHNOL, V308, P334, DOI 10.1016/j.powtec.2016.12.043
   Qiu J. Z. J., 2017, DEM SIMULATION PARTI
   Radeke CA, 2010, CHEM ENG SCI, V65, P6435, DOI 10.1016/j.ces.2010.09.035
   Rajamani R, 2011, P SAG C VANC
   Sakai M, 2015, CHEM ENG J, V279, P821, DOI 10.1016/j.cej.2015.04.130
   SCOTT AM, 1975, IND ENG CHEM FUND, V14, P22, DOI 10.1021/i160053a004
   Sen M, 2017, PROCESSES, V5, DOI 10.3390/pr5020022
   Shen YS, 2014, MINER ENG, V63, P91, DOI 10.1016/j.mineng.2014.01.008
   Shigeto Y, 2011, PARTICUOLOGY, V9, P398, DOI 10.1016/j.partic.2011.04.002
   Sinnott MD, 2016, COMPUT PART MECH, V3, P477, DOI 10.1007/s40571-015-0065-4
   TAKAHASHI H, 1993, ISIJ INT, V33, P655, DOI 10.2355/isijinternational.33.655
   Terui K, 2017, ISIJ INT, V57, P1804, DOI 10.2355/isijinternational.ISIJINT-2017-204
   The Iron and Steel Institute of Japan, 2009, BLAST FURN PHEN MOD
   Tsuzuki S., 2013, LARGE SCALE AGITATIO
   Ueda S, 2010, ISIJ INT, V50, P914, DOI 10.2355/isijinternational.50.914
   Venugopal R, 2001, POWDER TECHNOL, V115, P157, DOI 10.1016/S0032-5910(00)00333-8
   Wei H, 2017, ADV POWDER TECHNOL, V28, P2482, DOI 10.1016/j.apt.2017.05.012
   Wilke DN, 2017, SPRINGER PROC PHYS, V188, P1371, DOI 10.1007/978-981-10-1926-5_141
   Xu J, 2011, APPL MATH MODEL, V35, P1439, DOI 10.1016/j.apm.2010.09.021
   [徐万仁 XU Wanren], 2006, [钢铁, Iron and Steel], V41, P10
   Xu Y, 2018, POWDER TECHNOL, V328, P245, DOI 10.1016/j.powtec.2018.01.020
   Xua J, 2011, PARTICUOLOGY, V9, P446, DOI 10.1016/j.partic.2011.01.003
   Yu YW, 2014, POWDER TECHNOL, V262, P233, DOI 10.1016/j.powtec.2014.04.010
   Zhang JL, 2014, PARTICUOLOGY, V16, P167, DOI 10.1016/j.partic.2014.01.003
   Zhang L, 2013, ADV ENG SOFTW, V60-61, P70, DOI 10.1016/j.advengsoft.2012.10.006
   Zhao DW, 2006, ENG COMPUTATION, V23, P749, DOI 10.1108/02644400610689884
NR 93
TC 6
Z9 6
U1 3
U2 32
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 9
EP 26
DI 10.1016/j.ces.2019.03.077
PG 18
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600002
DA 2020-05-12
ER

PT J
AU Hoang, V
   Park, JM
AF Van Thanh Hoang
   Park, Jang Min
TI A Taylor analogy model for droplet dynamics in planar extensional flow
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Droplet dynamics; Microfluidics; Extensional flow; Numerical simulation;
   Taylor analogy model
ID LATTICE BOLTZMANN; THERMOCAPILLARY FLOWS; VISCOELASTIC DROP;
   DEFORMATION; BREAKUP; SIMULATION; STEADY; TRANSIENT
AB The dynamics of a droplet suspended in a medium fluid is determined by the hydrodynamic forces and surface tension force, and the Taylor analogy had been successfully employed to predict droplet deformation and breakup in a spray. This paper aims to extend the Taylor analogy for prediction of droplet dynamics in planar extensional flow which has great significance in droplet-based microfluidic systems. Performance of the proposed model is compared with the three-dimensional numerical simulation results over a wide range of capillary number and viscosity ratio. Experimental data available in the literature is also compared with the prediction results for verification purpose. The proposed model could describe both the time scale and the magnitude of droplet deformation accurately. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Van Thanh Hoang; Park, Jang Min] Yeungnam Univ, Sch Mech Engn, Daehak Ro 280, Gyongsan 38541, South Korea.
   [Van Thanh Hoang] Univ Danang, Univ Sci & Technol, Dept Mech Engn, 54 Nguyen Luong Bang St, Danang, Vietnam.
RP Park, JM (reprint author), Yeungnam Univ, Sch Mech Engn, Daehak Ro 280, Gyongsan 38541, South Korea.
EM jpark@yu.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT & Future Planning
   [NRF-2017R1E1A1A03070443]
FX Authors would like to thank the financial support from Basic Science
   Research Program through the National Research Foundation of Korea (NRF)
   Grant funded by the Ministry of Science, ICT & Future Planning
   (NRF-2017R1E1A1A03070443).
CR ACRIVOS A, 1978, J FLUID MECH, V86, P641, DOI 10.1017/S0022112078001329
   Aramendia I, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15030423
   Bae YB, 2016, LAB CHIP, V16, P96, DOI 10.1039/c5lc01006c
   Baroud CN, 2010, LAB CHIP, V10, P2032, DOI 10.1039/c001191f
   BARTHESBIESEL D, 1973, J FLUID MECH, V61, P1, DOI 10.1017/S0022112073000534
   Basu S, 2008, ACTA MATER, V56, P2750, DOI 10.1016/j.actamat.2008.02.007
   BENTLEY BJ, 1986, J FLUID MECH, V167, P241, DOI 10.1017/S0022112086002811
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Brimmo AT, 2017, RSC ADV, V7, P51206, DOI 10.1039/c7ra11155j
   Castillo-Leon J., 2015, LAB ON A CHIP DEVICE
   COX RG, 1969, J FLUID MECH, V37, P601, DOI 10.1017/S0022112069000759
   Dahl JB, 2016, SOFT MATTER, V12, P3787, DOI 10.1039/c5sm03004h
   Dos Santos F, 2011, OIL GAS SCI TECHNOL, V66, P801, DOI 10.2516/ogst/2011116
   Fu TT, 2015, CHEM ENG SCI, V135, P343, DOI 10.1016/j.ces.2015.02.016
   FULLER GG, 1981, J POLYM SCI POL PHYS, V19, P557, DOI 10.1002/pol.1981.180190402
   Giesekus H., 1962, RHEOL ACTA, V2, P112
   Guillou L, 2016, BIOPHYS J, V111, P2039, DOI 10.1016/j.bpj.2016.09.034
   Ha JW, 2001, PHYS FLUIDS, V13, P1568, DOI 10.1063/1.1358306
   Hsu AS, 2009, J NON-NEWTON FLUID, V160, P176, DOI 10.1016/j.jnnfm.2009.03.004
   Hu YT, 2003, J RHEOL, V47, P349, DOI 10.1122/1.1545078
   Hu YT, 2001, J RHEOL, V45, P1453, DOI 10.1122/1.1413506
   Ioannou N, 2016, J COMPUT SCI-NETH, V17, P463, DOI 10.1016/j.jocs.2016.03.009
   Lee JS, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2472528
   Li XB, 2012, CHEM ENG SCI, V69, P340, DOI 10.1016/j.ces.2011.10.048
   Liu HH, 2018, J FLUID MECH, V837, P381, DOI 10.1017/jfm.2017.859
   Liu HH, 2015, J COMPUT PHYS, V280, P37, DOI 10.1016/j.jcp.2014.09.015
   Liu HH, 2014, J COMPUT PHYS, V256, P334, DOI 10.1016/j.jcp.2013.08.054
   Liu HH, 2012, J COMPUT PHYS, V231, P4433, DOI 10.1016/j.jcp.2012.02.015
   Maffettone PL, 1998, J NON-NEWTON FLUID, V78, P227, DOI 10.1016/S0377-0257(98)00065-2
   Nishad K, 2018, INT J HEAT FLUID FL, V70, P247, DOI 10.1016/j.ijheatfluidflow.2018.02.017
   O'Rouke P.J., 1987, SAE TECHNICAL PAPER
   Park JM, 2012, LAB CHIP, V12, P2672, DOI 10.1039/c2lc21235h
   Pozrikidis C., 2011, INTRO THEORETICAL CO, P439
   Ramaswamy S, 1999, J NON-NEWTON FLUID, V85, P127, DOI 10.1016/S0377-0257(98)00212-2
   RUMSCHEL.F, 1961, J COLL SCI IMP U TOK, V16, P238, DOI 10.1016/0095-8522(61)90003-4
   Seemann R, 2012, REP PROG PHYS, V75, DOI 10.1088/0034-4885/75/1/016601
   Tanyeri M, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3431664
   Taylor GI, 1934, P R SOC LOND A-CONTA, V146, P0501, DOI 10.1098/rspa.1934.0169
   Taylor GI, 1963, SCI PAPERS GI TAYLOR, V3, P457
   Turner MR, 2012, FUEL, V97, P288, DOI 10.1016/j.fuel.2012.01.076
   Hoang VT, 2018, CHEM ENG SCI, V176, P59, DOI 10.1016/j.ces.2017.10.020
   Wang NN, 2017, J RHEOL, V61, P741, DOI 10.1122/1.4984757
   Yan Y, 2012, CHEM ENG SCI, V84, P591, DOI 10.1016/j.ces.2012.08.055
   Yu DM, 2016, CHINESE J CHEM ENG, V24, P63, DOI 10.1016/j.cjche.2015.07.016
   Zill D. G., 2014, ADV ENG MATH, P154
NR 45
TC 0
Z9 0
U1 5
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 27
EP 34
DI 10.1016/j.ces.2019.04.015
PG 8
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600003
DA 2020-05-12
ER

PT J
AU Fu, YC
   Liu, Y
AF Fu, Yucheng
   Liu, Yang
TI BubGAN: Bubble generative adversarial networks for synthesizing
   realistic bubbly flow images
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Realistic bubble synthesis; Object counting; Bubble segmentation; Deep
   learning; Image processing
ID SIZE DISTRIBUTION; 2-PHASE FLOW; HYDRODYNAMICS
AB Bubble segmentation and size detection algorithms have been developed in recent years for their high efficiency and accuracy in measuring bubbly two-phase flows. In this work, we proposed an architecture called bubble generative adversarial networks (BubGAN) for the generation of realistic synthetic images which could be further used as training or benchmarking data for the development of advanced image processing algorithms. The BubGAN is trained initially on a labeled bubble dataset consisting of ten thousand images. By learning the distribution of these bubbles, the BubGAN can generate more realistic bubbles compared to the conventional models used in the literature. The trained BubGAN is conditioned on bubble feature parameters and has full control of bubble properties in terms of aspect ratio, rotation angle, circularity and edge ratio. A million bubble dataset is pre-generated using the trained BubGAN. One can then assemble realistic bubbly flow images using this dataset and associated image processing tool. These images contain detailed bubble information, therefore do not require additional manual labeling. This is more useful compared with the conventional GAN which generates images without labeling information. The tool could be used to provide benchmarking and training data for existing image processing algorithms and to guide the future development of bubble detecting algorithms. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fu, Yucheng; Liu, Yang] Virginia Tech, Mech Engn Dept, Nucl Engn Program, 635 Prices Fork Rd, Blacksburg, VA 24061 USA.
RP Liu, Y (reprint author), Virginia Tech, Mech Engn Dept, Nucl Engn Program, 635 Prices Fork Rd, Blacksburg, VA 24061 USA.
EM ycfu@vt.edu; liu130@vt.edu
OI Fu, Yucheng/0000-0002-8257-0845
CR Bengio Y., 2013, INT C MACH LEARN
   Broder D, 2007, MEAS SCI TECHNOL, V18, P2513, DOI 10.1088/0957-0233/18/8/028
   Cerqueira RFL, 2018, CHEM ENG SCI, V189, P1, DOI 10.1016/j.ces.2018.05.029
   Chattopadhyay Prithvijit, 2017, 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR). Proceedings, P4428, DOI 10.1109/CVPR.2017.471
   Chinak AV, 2018, INT J HEAT MASS TRAN, V118, P785, DOI 10.1016/j.ijheatmasstransfer.2017.11.022
   Ferrari A, 2017, PATTERN RECOGN, V61, P629, DOI 10.1016/j.patcog.2016.07.016
   Fu YC, 2018, MEAS SCI TECHNOL, V29, DOI 10.1088/1361-6501/aac4aa
   Fu YC, 2016, NUCL ENG DES, V310, P570, DOI 10.1016/j.nucengdes.2016.10.044
   Fu YC, 2016, INT J MULTIPHAS FLOW, V84, P217, DOI 10.1016/j.ijmultiphaseflow.2016.04.011
   Goodfellow IJ, 2014, ADV NEUR IN, V27
   Honkanen M, 2005, MEAS SCI TECHNOL, V16, P1760, DOI 10.1088/0957-0233/16/9/007
   Hosokawa S, 2009, Journal of Physics: Conference Series, V147, DOI 10.1088/1742-6596/147/1/012016
   Ilonen J, 2018, PATTERN RECOGN LETT, V101, P60, DOI 10.1016/j.patrec.2017.11.014
   Karn A, 2015, CHEM ENG SCI, V122, P240, DOI 10.1016/j.ces.2014.09.036
   Kumar S, 2018, MULTIMED TOOLS APPL, V77, P11017, DOI 10.1007/s11042-017-4966-5
   Lau YM, 2013, CHEM ENG SCI, V94, P20, DOI 10.1016/j.ces.2013.02.043
   Lelouvetel J, 2011, EXP FLUIDS, V50, P813, DOI 10.1007/s00348-010-0906-0
   Liu Y, 2013, INT J MULTIPHAS FLOW, V56, P25, DOI 10.1016/j.ijmultiphaseflow.2013.05.006
   Liu Y, 2013, INT J HEAT FLUID FL, V39, P173, DOI 10.1016/j.ijheatfluidflow.2012.10.002
   Lu Z, 2017, IEEE J BIOMED HEALTH, V21, P441, DOI 10.1109/JBHI.2016.2519686
   Marsden M., 2016, FULLY CONVOLUTIONAL, DOI [10.5220/0006097300270033, DOI 10.5220/0006097300270033]
   Moranduzzo T, 2014, IEEE T GEOSCI REMOTE, V52, P1635, DOI 10.1109/TGRS.2013.2253108
   Paolinelli LD, 2018, INT J MULTIPHAS FLOW, V99, P132, DOI 10.1016/j.ijmultiphaseflow.2017.09.014
   POLETAEV IE, 2016, J PHYS C SER, V754, P1, DOI DOI 10.1088/1742-6596/754/7/072002
   Prakash VN, 2016, J FLUID MECH, V791, P174, DOI 10.1017/jfm.2016.49
   Radford A., 2015, NETWORKS, P1, DOI [10.1051/0004-6361/201527329, DOI 10.1051/0004-6361/201527329]
   Reed S., 2016, INT C MACH LEARN, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]
   Song K, 2018, MEAS SCI TECHNOL, V29, DOI 10.1088/1361-6501/aaa283
   Strokina N, 2016, MACH VISION APPL, V27, P387, DOI 10.1007/s00138-016-0749-7
   Tremblay J, 2018, IEEE COMPUT SOC CONF, P1082, DOI 10.1109/CVPRW.2018.00143
   Wang DW, 2018, MEAS SCI TECHNOL, V29, DOI 10.1088/1361-6501/aad640
   Worosz T, 2016, NUCL ENG DES, V310, P552, DOI 10.1016/j.nucengdes.2016.10.046
   Xiaoran Yu, 2009, Journal of Physics: Conference Series, V147, DOI 10.1088/1742-6596/147/1/012053
   Xie WD, 2018, COMP M BIO BIO E-IV, V6, P283, DOI 10.1080/21681163.2016.1149104
   Zaruba A, 2005, FLOW MEAS INSTRUM, V16, P277, DOI 10.1016/j.flowmeasinst.2005.03.009
   Zhong S, 2016, CHEM ENG SCI, V141, P143, DOI 10.1016/j.ces.2015.10.033
NR 36
TC 4
Z9 4
U1 3
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 35
EP 47
DI 10.1016/j.ces.2019.04.004
PG 13
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600004
DA 2020-05-12
ER

PT J
AU Xia, XX
   Cao, M
   Liu, ZL
   Li, W
   Li, S
AF Xia, Xiaoxiao
   Cao, Meng
   Liu, Zhilu
   Li, Wei
   Li, Song
TI Elucidation of adsorption cooling characteristics of Zr-MOFs: Effects of
   structure property and working fluids
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Adsorption cooling; Adsorbent; Specific cooling effect; Coefficient of
   performance
ID METAL-ORGANIC FRAMEWORKS; DRIVEN HEAT-PUMPS; WATER-ADSORPTION; ISOBARIC
   STAGES; CYCLE; STABILITY; UIO-66; PAIRS
AB The use of metal-organic frameworks (MOFs) for adsorption cooling has won increasing research interests due to their outstanding adsorption performance. Zr-MOFs with relatively stable water stability and distinct structure properties are potential adsorbents for cooling. In this work, three Zr-MOFs: UiO-66 UiO-67 and NU-1000 with varying pore sizes were synthesized, and their water and ethanol adsorption isotherms were measured. The specific cooling effects (SCE) and coefficient of performance (COP) of MOF/water and MOF/ethanol working pairs in adsorption cooling system (ACS) were evaluated by adsorption system modeling. The results revealed that the MOFs with small pores and low steps (P/P-0) (i.e. UiO-66) in isotherms are favorable for water working fluid, which can achieve high SCE and COP at relative low temperatures. In contrast, MOFs with large pores and suitable steps (i.e. NU-1000) is preferential for ethanol working fluid due to the high uptake. Although water working fluid generally exhibited higher SCE and COP than ethanol, MOF/ethanol outperformed MOF/water because the equivalent cooling performance can be achieved at low temperature as well as the high recycle stability of MOFs/ethanol working pairs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xia, Xiaoxiao; Cao, Meng; Liu, Zhilu; Li, Wei; Li, Song] Huazhong Univ Sci & Technol, State Key Lab Coal Combust, Wuhan 430074, Hubei, Peoples R China.
RP Li, S (reprint author), Huazhong Univ Sci & Technol, State Key Lab Coal Combust, Wuhan 430074, Hubei, Peoples R China.
EM songli@hust.edu.cn
OI Xia, Xiaoxiao/0000-0001-9001-3662
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China [51606081]
FX This work was supported by the National Natural Science Foundation of
   China (NSFC) under Project No. 51606081. The computational part was
   carried out at National Supercomputer Center in Shenzhen. We also would
   like to thank Huazhong University of Science and Technology Analytical &
   Testing Center for providing support on material characterizations.
CR Alrsheedi S., 2016, 2 IEICES
   Aristov YI, 2008, CHEM ENG SCI, V63, P2907, DOI 10.1016/j.ces.2008.03.011
   Aristov YI, 2013, APPL THERM ENG, V50, P1610, DOI 10.1016/j.applthermaleng.2011.09.003
   Boman DB, 2017, APPL THERM ENG, V123, P422, DOI 10.1016/j.applthermaleng.2017.04.153
   Burtch NC, 2014, CHEM REV, V114, P10575, DOI 10.1021/cr5002589
   Cai GR, 2017, ANGEW CHEM INT EDIT, V56, P563, DOI 10.1002/anie.201610914
   Canivet J, 2014, CHEM SOC REV, V43, P5594, DOI 10.1039/c4cs00078a
   Canivet J, 2014, NEW J CHEM, V38, P3102, DOI 10.1039/c4nj00076e
   Chen YR, 2018, LANGMUIR, V34, P4180, DOI 10.1021/acs.langmuir.7b04399
   Choi J, 2018, J PHYS CHEM C, V122, P5545, DOI 10.1021/acs.jpcc.8b00014
   Coasne B, 2013, CHEM SOC REV, V42, P4141, DOI 10.1039/c2cs35384a
   Coulomb D, 2015, 29 INFORM NOTE REFRI
   de Lange MF, 2015, CHEM REV, V115, P12205, DOI 10.1021/acs.chemrev.5b00059
   de Lange MF, 2015, LANGMUIR, V31, P12783, DOI 10.1021/acs.langmuir.5b03272
   Deria P, 2015, CHEM SCI, V6, P5172, DOI 10.1039/c5sc01784j
   El-Sharkawy I. I., 2014, CHARACTERIZATION ADS
   Elsayed E, 2016, APPL THERM ENG, V99, P802, DOI 10.1016/j.applthermaleng.2016.01.129
   Farha OK, 2012, J AM CHEM SOC, V134, P15016, DOI 10.1021/ja3055639
   Furukawa H, 2014, J AM CHEM SOC, V136, P4369, DOI 10.1021/ja500330a
   Ghosh P, 2014, CHEM COMMUN, V50, P11329, DOI 10.1039/c4cc04945d
   Glaznev IS, 2009, INT J HEAT MASS TRAN, V52, P1774, DOI 10.1016/j.ijheatmasstransfer.2008.09.031
   Henninger SK, 2012, INT J REFRIG, V35, P543, DOI 10.1016/j.ijrefrig.2011.10.004
   Henninger SK, 2010, APPL THERM ENG, V30, P1692, DOI 10.1016/j.applthermaleng.2010.03.028
   Henninger SK, 2009, J AM CHEM SOC, V131, P2776, DOI 10.1021/ja808444z
   Jeremias F, 2014, NEW J CHEM, V38, P1846, DOI 10.1039/c3nj01556d
   Jeremias F, 2012, J MATER CHEM, V22, P10148, DOI 10.1039/c2jm15615f
   Kim M, 2012, CHEM SCI, V3, P126, DOI 10.1039/c1sc00394a
   Kummer H, 2017, APPL THERM ENG, V117, P689, DOI 10.1016/j.applthermaleng.2016.11.026
   Li W, 2019, J MATER CHEM A, V7, P7470, DOI 10.1039/c8ta07909a
   Low JJ, 2009, J AM CHEM SOC, V131, P15834, DOI 10.1021/ja9061344
   Mondloch JE, 2014, CHEM COMMUN, V50, P8944, DOI 10.1039/c4cc02401j
   Ng KC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11156-6
   Nguyen BT, 2016, CHEM MATER, V28, P6243, DOI 10.1021/acs.chemmater.6b02431
   Oien-Odegaard S, 2016, INORG CHEM, V55, P1986, DOI 10.1021/acs.inorgchem.5b02257
   Okunev BN, 2013, APPL THERM ENG, V53, P89, DOI 10.1016/j.applthermaleng.2013.01.018
   Planas N, 2014, J PHYS CHEM LETT, V5, P3716, DOI 10.1021/jz501899j
   Pons M, 1999, INT J REFRIG, V22, P5, DOI 10.1016/S0140-7007(98)00048-6
   Rezk A, 2013, APPL ENERG, V112, P1025, DOI 10.1016/j.apenergy.2013.06.041
   Rezk A, 2012, INT J HEAT MASS TRAN, V55, P7366, DOI 10.1016/j.ijheatmasstransfer.2012.07.068
   Saha Dipendu, 2010, Tsinghua Science and Technology, V15, P363, DOI 10.1016/S1007-0214(10)70075-4
   Sapienza A, 2012, APPL THERM ENG, V32, P141, DOI 10.1016/j.applthermaleng.2011.09.014
   Schaate A, 2011, CHEM-EUR J, V17, P6643, DOI 10.1002/chem.201003211
   Solmus I, 2010, APPL ENERG, V87, P2062, DOI 10.1016/j.apenergy.2009.11.027
   Taddei M, 2017, COORDIN CHEM REV, V343, P1, DOI 10.1016/j.ccr.2017.04.010
   Wang LW, 2009, RENEW SUST ENERG REV, V13, P518, DOI 10.1016/j.rser.2007.12.002
   Wang TC, 2016, NAT PROTOC, V11, P149, DOI 10.1038/nprot.2016.001
   Wiersum AD, 2011, CHEM-ASIAN J, V6, P3270, DOI 10.1002/asia.201100201
   Yang QY, 2011, CHEM COMMUN, V47, P9603, DOI 10.1039/c1cc13543k
NR 48
TC 2
Z9 2
U1 16
U2 106
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 48
EP 58
DI 10.1016/j.ces.2019.04.006
PG 11
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600005
DA 2020-05-12
ER

PT J
AU Celebi, AD
   Sharma, H
   Ensinas, AV
   Marechal, F
AF Celebi, Ayse Dilan
   Sharma, Hivom
   Ensinas, Adriano Viana
   Marechal, Francois
TI Next generation cogeneration system for industry - Combined heat and
   fuel plant using biomass resources
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Industrial process heat demand; Biomass gasification; Carbon Capture and
   Sequestration (CCS); Power-to-Gas (P2G); Combined Heat and Fuel (CHF)
   plant; Process integration
ID BIO-SNG PRODUCTION; PROCESS INTEGRATION; PROCESS DESIGN; GAS;
   GASIFICATION; IMPACT; PULP; MILL
AB The requirement for sustainable development has prompted the researchers to explore solutions for better utilization of renewable energy resources in the future. Biomass is a promising resource and it can be converted to multiple products and services including fuels, chemicals, heat and electricity via different conversion routes. Hence, replacement of fossil-based services with biomass-based services is critical to mitigate fossil CO2 emissions, and innovative design of new and efficient energy conversion systems is necessary. Different industries need heat for their operations at different temperature levels. Today, these demands are satisfied using conventional natural gas boilers by imposing a CO2 tax to account for their emissions. In this study, we discuss the potential of replacing conventional boilers with a combined heat and fuel (CHF) plant design which utilizes lignocellulosic biomass in thermochemical conversion to generate heat for different industrial sectors together with biofuels cogeneration. Heat is generated due to the exothermic nature of the thermochemical conversion processes that operate at high temperatures. Gasification process produces syngas which is converted into fuels such as synthetic natural gas, Fischer-Tropsch crude, methanol and dimethyl ether and electricity. Different scenarios are evaluated considering the CO2 produced via this system is either released, sequestrated, or stored and used in a co-electrolysis unit in which surplus renewable electricity available during summer is converted into additional syngas. A parametric analysis has been performed considering type and size of plants, CO2 tax, and purchase and transportation costs of wood to compare the price of heat for the industrial sectors. Natural gas and wood boilers are used as the basis to calculate the breakeven CO2 tax values for the same heat prices for the proposed CHF systems. The results of this study present a state-of-the-art renewable energy system as an alternative to conventional boilers. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Celebi, Ayse Dilan; Sharma, Hivom; Marechal, Francois] Ecole Polytech Fed Lausanne, EPFL Valais Wallis, IPESE, CH-1951 Sion, Switzerland.
   [Ensinas, Adriano Viana] Fed Univ Lavras UFLA, Dept Engn DEG, BR-37200000 Lavras, MG, Brazil.
RP Celebi, AD (reprint author), Ecole Polytech Fed Lausanne, EPFL Valais Wallis, IPESE, CH-1951 Sion, Switzerland.
EM ayse.celebi@epfl.ch
RI Marechal, Francois M. A./B-5685-2009
OI Marechal, Francois M. A./0000-0003-1752-5690
FU Swiss Innovation Agency lnnosuisse
FX This research project is financially supported by the Swiss Innovation
   Agency lnnosuisse and is part of the Swiss Competence Center for Energy
   Research SCCER BIOSWEET.
CR Andersson E, 2007, ENERGY, V32, P399, DOI 10.1016/j.energy.2006.06.021
   [Anonymous], 2017, LA FORET         DEC
   [Anonymous], 2017, ENERGY, V10, P57
   Arvidsson M, 2012, CHEM ENGINEER TRANS, V29, P331, DOI 10.3303/CET1229056
   Betz R., 2015, DISENTANGLING EFFECT
   Caliandro P, 2014, ENERG CONVERS MANAGE, V85, P764, DOI 10.1016/j.enconman.2014.02.009
   Candra DI, 2018, ENERGIES, V11, DOI 10.3390/en11092365
   Consonni S, 2009, CHEM ENG RES DES, V87, P1293, DOI 10.1016/j.cherd.2009.07.017
   Conti J, 2016, INT ENERGY OUTLOOK 2, V0484, DOI [10.2172/1296780, DOI 10.2172/1296780]
   Damartzis T, 2011, RENEW SUST ENERG REV, V15, P366, DOI 10.1016/j.rser.2010.08.003
   Densing M., 2014, 1405 PSI
   Egeskog A, 2009, ENERG POLICY, V37, P5260, DOI 10.1016/j.enpol.2009.07.071
   Energy and Environmental Analysis Inc, CHAR US IND CO UNPUB
   Fahlen E, 2009, ENERGY, V34, P2184, DOI 10.1016/j.energy.2008.10.018
   Fleiter T, 2017, MAPPING ANAL CURRENT
   Fleiter T, 2016, MAPPING ANAL CURRENT
   Garcia N., 2012, BEST AVAILABLE TECHN
   Gassner M., 2010, THESIS
   Gassner M, 2009, BIOMASS BIOENERG, V33, P1587, DOI 10.1016/j.biombioe.2009.08.004
   Gassner M, 2009, COMPUT CHEM ENG, V33, P769, DOI 10.1016/j.compchemeng.2008.09.017
   Girones VC, 2018, FRONT ENERGY RES, V5, DOI 10.3389/fenrg.2017.00037
   Hackl R., 2010, OPPORTUNITIES PROCES
   Hannula I., 2011, LIQUID TRANSPORTATIO
   Haro P, 2016, ENERGY, V101, P380, DOI 10.1016/j.energy.2016.02.037
   Henrich E, 2015, CHEM-ING-TECH, V87, P1667, DOI 10.1002/cite.201500056
   Heyne S, 2014, INT J ENERG RES, V38, P299, DOI 10.1002/er.3038
   Holmgren K. M., 2015, THESIS
   Holmgren KM, 2016, ENERGY, V111, P272, DOI 10.1016/j.energy.2016.05.059
   Huisman GH, 2011, BIOMASS BIOENERG, V35, pS155, DOI 10.1016/j.biombioe.2011.04.038
   Isaksson J, 2012, ENERGY, V44, P420, DOI 10.1016/j.energy.2012.06.013
   Johansson D, 2013, ENERGY, V59, P387, DOI 10.1016/j.energy.2013.07.024
   Kannan R., 2015, IAEE 2017 C, P2050
   Kantor I., 2018, P ECOS 2018 PORT
   Lazic T, 2014, P I MECH ENG E-J PRO, V228, P210, DOI 10.1177/0954408913500447
   Li HL, 2011, APPL ENERG, V88, P3567, DOI 10.1016/j.apenergy.2011.03.052
   Marechal F, 1998, COMPUT CHEM ENG, V22, pS149, DOI 10.1016/S0098-1354(98)00049-0
   Methanex, 2018, METH PRIC N AM EUR A
   Migrol, 2018, IND PRIX MAZ MONTR F
   Naegler T, 2015, INT J ENERG RES, V39, P2019, DOI 10.1002/er.3436
   Peduzzi E., 2015, THESIS
   Peduzzi E., 2013, PRES 13 16 C PROC IN
   Perez-Linkenheil C, 2019, TRENDS DEV ELECT PRI
   Pihl E, 2010, ENERGY, V35, P4042, DOI 10.1016/j.energy.2010.06.008
   Pollitt MG, 2016, ENERG J, V37, P69, DOI 10.5547/01956574.37.SI2.mpol
   Sharma S, 2017, ENERGY, V137, P811, DOI 10.1016/j.energy.2017.04.146
   Sinn HW, 2017, EUR ECON REV, V99, P130, DOI 10.1016/j.euroecorev.2017.05.007
   Sterner M, 2009, BIOENERGY RENEWABLE, V14
   Steubing B, 2014, RENEW ENERG, V61, P57, DOI 10.1016/j.renene.2012.08.018
   Steurer M, 2017, EUROPE'S ENERGY TRANSITION: INSIGHTS FOR POLICY MAKING, P97, DOI 10.1016/B978-0-12-809806-6.00015-8
   Stocker T.F., 2013, IPCC 2013 CLIMATE CH
   Thema M, 2016, ENRGY PROCED, V99, P392, DOI 10.1016/j.egypro.2016.10.129
   Tock L, 2010, BIOMASS BIOENERG, V34, P1838, DOI 10.1016/j.biombioe.2010.07.018
   Turton R., 2009, ANAL SYNTHESIS DESIG
   Ulrich G., 2003, GUIDE CHEM ENG PROCE
   Waldheim L., 2017, BUILDING FUTURE COST
   Wang LG, 2018, APPL ENERG, V211, P1060, DOI 10.1016/j.apenergy.2017.11.050
   Werner S., 2006, TECHNICAL REPORT
   West K, 2018, COMMENTARY CLEAN EFF
   Wetterlund E, 2011, ENERGY, V36, P932, DOI 10.1016/j.energy.2010.12.017
   Woudstra N., 2003, P INT ECOS C COP DEN
   Yoo MJ, 2015, COMPUT-AIDED CHEM EN, V37, P587
   Zeman P., 2017, Agronomy Research, V15, P2226, DOI 10.15159/AR.17.067
NR 62
TC 3
Z9 3
U1 4
U2 51
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 59
EP 75
DI 10.1016/j.ces.2019.04.018
PG 17
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600006
DA 2020-05-12
ER

PT J
AU Zhuo, YT
   Li, CX
   Wu, CL
   Shen, YS
AF Zhuo, Yuting
   Li, Changxing
   Wu, Chenglin
   Shen, Yansong
TI A combined numerical and experimental approach to study the
   carbonization of low-rank coal ellipsoidal briquettes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Carbonization; Modelling; Low rank coal; Ellipsoid; Experiment
ID COKE-OVEN GAS; MULTIPHYSICS SIMULATIONS; DEVOLATILIZATION MODELS;
   THERMAL-DECOMPOSITION; BIOMASS PYROLYSIS; BLAST-FURNACE; HEAT-TRANSFER;
   CFD MODEL; PART I; FLOW
AB This paper reports a combined numerical and experimental approach to study the coal carbonization process. It is applied to low rank coal ellipsoidal briquettes carbonization in a pilot-scale coke oven for demonstration. The integrated mathematical model integrates a DEM model to simulate the packing process of ellipsoidal briquettes in the oven and a CFD model to simulate the flow and thermochemical behaviours related to the carbonization process. The model is validated against the experimental measurements in the pilot-scale coke oven. The comprehensive in-furnace phenomena in the carbonization process are simulated, in terms of flow, temperature, gas composition, and carbonization characteristics. The simulation results indicate that it is necessary to include the briquettes packing structure evolution in the carbonization modelling for reliably describing the in-furnace phenomena. Then the effects of some briquette packing parameters, including briquette dropping height and vertical vibration, on the evolutions of packing structure and carbonization behaviour are studied. It is indicated that the dense packing structure resulting from higher dropping height and one-dimensional vertical vibration before the carbonization can improve the heat and mass transfers between the gas and bed, and thus can improve the carbonization efficiency. The computational cost of this approach as well as its future application are discussed. This model provides a cost-effective tool for understanding and optimizing the carbonization process of non-spherical low rank coal briquettes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhuo, Yuting; Li, Changxing; Shen, Yansong] Univ New South Wales, Sch Chem Engn, Sydney, NSW 2052, Australia.
   [Wu, Chenglin] Thermoenergy Co Ltd, Sinosteel Anshan Res Inst, Anshan 114044, Liaoning, Peoples R China.
RP Shen, YS (reprint author), Univ New South Wales, Sch Chem Engn, Sydney, NSW 2052, Australia.
EM ys.shen@unsw.edu.au
RI Shen, Yansong/A-9037-2010
OI Shen, Yansong/0000-0001-8472-8805
FU Australian Research CouncilAustralian Research Council [LP150100112,
   LP160101100]; Baosteel and Coal Energy Australia
FX The authors thank the Australian Research Council (LP150100112 and
   LP160101100), Baosteel and Coal Energy Australia for the financial
   support of this project. SinoSteel is acknowledged for providing the
   experimental data used in the model validation.
CR Abani N, 2013, FUEL, V104, P664, DOI 10.1016/j.fuel.2012.06.006
   An XZ, 2011, COMPUT PHYS COMMUN, V182, P1989, DOI 10.1016/j.cpc.2011.02.006
   ANTHONY DB, 1976, FUEL, V55, P121, DOI 10.1016/0016-2361(76)90008-9
   Backreedy RI, 2006, COMBUST SCI TECHNOL, V178, P763, DOI 10.1080/00102200500248532
   BADZIOCH S, 1970, IND ENG CHEM PROC DD, V9, P521, DOI 10.1021/i260036a005
   BOROSON ML, 1989, AICHE J, V35, P120, DOI 10.1002/aic.690350113
   Bruchmuller J, 2012, AICHE J, V58, P3030, DOI 10.1002/aic.13705
   Carlson F.B., 1974, T SOC MIN ENG, V255, P128
   Chen CJ, 2012, APPL ENERG, V100, P218, DOI 10.1016/j.apenergy.2012.05.013
   Chen CX, 2000, CHEM ENG SCI, V55, P3861, DOI 10.1016/S0009-2509(00)00030-0
   Chen YP, 2014, POWDER TECHNOL, V253, P722, DOI 10.1016/j.powtec.2013.11.042
   Cortez D.H., 1982, COPRODUCTION SYNCRUD, P331
   CYPRES R, 1981, FUEL, V60, P768, DOI 10.1016/0016-2361(81)90137-X
   Dziugys A, 2001, GRANUL MATTER, V3, P231, DOI 10.1007/PL00010918
   EISERMANN W, 1980, FUEL PROCESS TECHNOL, V3, P39, DOI 10.1016/0378-3820(80)90022-3
   Fang MM, 2013, CHEM ENG SCI, V101, P213, DOI 10.1016/j.ces.2013.06.038
   Gharebaghi M, 2011, FUEL PROCESS TECHNOL, V92, P2455, DOI 10.1016/j.fuproc.2011.08.015
   GIBBINS JR, 1991, FUEL, V70, P621, DOI 10.1016/0016-2361(91)90176-B
   Golightly D. W., 1988, US GEOL SURV B, V1823, P107
   GRANT DM, 1989, ENERG FUEL, V3, P175, DOI 10.1021/ef00014a011
   Gregory D. R., 1965, BR COAL UTIL RES ASS, V29, P6
   Guo SC, 1995, J DALIAN U TECHNOL, V35, P46
   Guo Z., 2005, CHINA PART, V3, P373, DOI [10.1.016/S1672-2515(07)60217-6, DOI 10.1016/S1672-2515(07)60217-6]
   JONES WP, 1988, COMBUST FLAME, V73, P233, DOI 10.1016/0010-2180(88)90021-1
   Karthikeyan M, 2009, DRY TECHNOL, V27, P403, DOI 10.1080/07373930802683005
   Katalambula H, 2009, ENERG FUEL, V23, P3392, DOI 10.1021/ef801140t
   Kishore N, 2011, CHEM ENG TECHNOL, V34, P1551, DOI 10.1002/ceat.201100007
   Kobayashi H., 1977, S INT COMBUST, V16, P411, DOI DOI 10.1016/S0082-0784(77)80341-X
   Ku XK, 2015, ENERG FUEL, V29, P5127, DOI 10.1021/acs.energyfuels.5b00953
   Ku XK, 2015, CHEM ENG SCI, V122, P270, DOI 10.1016/j.ces.2014.08.045
   Kumar M, 2012, ENERG FUEL, V26, P464, DOI 10.1021/ef2008858
   Kumar M, 2012, ENERG FUEL, V26, P451, DOI 10.1021/ef200884j
   Kwiatkowski K, 2013, NUMER HEAT TR A-APPL, V64, P216, DOI 10.1080/10407782.2013.779166
   Li CX, 2018, POWDER TECHNOL, V333, P286, DOI 10.1016/j.powtec.2018.04.035
   Li CX, 2013, AIP CONF PROC, V1542, P767, DOI 10.1063/1.4812044
   Li CY, 2015, FUEL, V159, P590, DOI 10.1016/j.fuel.2015.07.023
   Liao JH, 2017, POWDER TECHNOL, V314, P550, DOI 10.1016/j.powtec.2016.11.005
   Lin W, 2015, APPL THERM ENG, V81, P353, DOI 10.1016/j.applthermaleng.2015.02.056
   Liu J, 2016, HEAT MASS TRANSFER, V52, P2101, DOI 10.1007/s00231-015-1727-8
   LOWRY HH, 1963, CHEM COAL UTILIZATIO
   Mahmoudi AH, 2014, J ANAL APPL PYROL, V106, P9, DOI 10.1016/j.jaap.2013.12.001
   Mandl C, 2010, FUEL, V89, P3795, DOI 10.1016/j.fuel.2010.07.014
   MERRICK D, 1983, FUEL, V62, P547, DOI 10.1016/0016-2361(83)90224-7
   Namiki Y, 2007, CLEAN COAL DAY JAP L, VL-15, P1
   NIKSA S, 1991, ENERG FUEL, V5, P673, DOI 10.1021/ef00029a008
   Osman H, 2011, DRY TECHNOL, V29, P1763, DOI 10.1080/07373937.2011.616443
   Pawlak-Kruczek H, 2014, DRY TECHNOL, V32, P1334, DOI 10.1080/07373937.2014.909845
   Popa SG, 2015, ROM J MORPHOL EMBRYO, V56, P1495
   Rammler RN, 1982, ENERGY PROGR, V2, P121
   Rangarajan D, 2014, IND ENG CHEM RES, V53, P4983, DOI 10.1021/ie301936r
   Sakai M, 2009, CHEM ENG SCI, V64, P533, DOI 10.1016/j.ces.2008.10.003
   SASS A, 1974, CHEM ENG PROG, V70, P72
   Shen YS, 2011, STEEL RES INT, V82, P532, DOI 10.1002/srin.201100045
   Silaen A, 2010, INT J HEAT MASS TRAN, V53, P2074, DOI 10.1016/j.ijheatmasstransfer.2009.12.047
   Slupik L, 2015, FUEL, V150, P415, DOI 10.1016/j.fuel.2015.02.044
   Smolka J, 2016, FUEL, V165, P94, DOI 10.1016/j.fuel.2015.10.039
   SOLOMON PR, 1988, ENERG FUEL, V2, P405, DOI 10.1021/ef00010a006
   STROM AH, 1971, CHEM ENG PROG, V67, P75
   Tsunazawa Y, 2015, CHEM ENG SCI, V138, P791, DOI 10.1016/j.ces.2015.09.014
   Wang Y, 2016, FUEL PROCESS TECHNOL, V144, P85, DOI 10.1016/j.fuproc.2015.12.011
   Watanabe H, 2006, FUEL, V85, P1935, DOI 10.1016/j.fuel.2006.02.002
   White L.C., 1997, FUEL EN ABSTR, V38, P76
   Yip K, 2007, ENERG FUEL, V21, P419, DOI 10.1021/ef060396l
   Yu JL, 2013, FUEL PROCESS TECHNOL, V106, P9, DOI 10.1016/j.fuproc.2012.09.051
   Yu PL, 2018, FUEL, V231, P234, DOI 10.1016/j.fuel.2018.05.104
   Yu Y, 2007, P COMBUST INST, V31, P1947, DOI 10.1016/j.proci.2006.07.116
   Zhang ZP, 2001, POWDER TECHNOL, V116, P23, DOI 10.1016/S0032-5910(00)00356-9
   Zheng QQ, 2013, ENERG FUEL, V27, P3570, DOI 10.1021/ef400218y
   Zhou GF, 2014, CHEM ENG SCI, V116, P9, DOI 10.1016/j.ces.2014.04.025
   Zhou Q, 2013, FUEL PROCESS TECHNOL, V116, P35, DOI 10.1016/j.fuproc.2013.04.022
   Zhou ZY, 2011, IND ENG CHEM RES, V50, P9787, DOI 10.1021/ie200862n
   Zhuo YT, 2018, ENERG FUEL, V32, P4189, DOI 10.1021/acs.energyfuels.7b03224
NR 72
TC 3
Z9 3
U1 1
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 76
EP 90
DI 10.1016/j.ces.2019.04.019
PG 15
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600007
DA 2020-05-12
ER

PT J
AU Feng, XD
   Liu, XF
   Jia, JT
   Chen, XY
   Jiang, T
   Li, C
AF Feng, Xudong
   Liu, Xiaofei
   Jia, Jintong
   Chen, Xinyi
   Jiang, Tian
   Li, Chun
TI Enhancing the thermostability of beta-glucuronidase from T. pinophilus
   enables the biotransformation of glycyrrhizin at elevated temperature
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Glycyrrhizin; Glycyrrhetinic acid 3-O-mono-beta-D-glucuronide;
   beta-glucuronidase; Thermostability; High-temperature biotransformation
ID ACID 3-O-MONO-BETA-D-GLUCURONIDE GAMG; DIRECTED EVOLUTION; STABILITY;
   DELETION; ENZYME
AB Glycosidases have been widely used in natural products modification by precisely hydrolyzing sugar moieties to modulate the biological activities. However, the low stability of the glycosidases under harsh conditions and the low solubility of substrate have largely impeded the biotransformation efficiency. To solve this problem, in this study, we selected the biotransformation of glycyrrhizin (GL) into glycyrrhetinic acid 3-O-mono-beta-D-glucuronide (GAMG) catalyzed by beta-glucuronidase from T. pinophilus Li-93 (TpGUS79A-P) as a model reaction. We combined three strategies including random mutagenesis, computation-aided design and rational introduction of "clamp" to TIM-barrel domain to enhance the thermostability of TpGUS79A-P, and one mutant TpGUS79A-P4 was obtained with thermostability at 55 degrees C increased by 2.9-fold. The enzymatic properties of TpGUS79A-P4 were extensively characterized. Finally, a novel high-temperature biotransformation process of GL into GAMG catalyzed by TpGUS79A-P4 was established at 50 degrees C, with GAMG concentration increased by 84% than that at 30 degrees C. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Feng, Xudong; Liu, Xiaofei; Jia, Jintong; Chen, Xinyi; Jiang, Tian; Li, Chun] Beijing Inst Technol, Inst Synthet Biosyst, Sch Chem & Chem Engn, Dept Biochem Engn, Beijing 100081, Peoples R China.
RP Li, C (reprint author), Beijing Inst Technol, Inst Synthet Biosyst, Sch Chem & Chem Engn, Dept Biochem Engn, Beijing 100081, Peoples R China.
EM lichun@bit.edu.cn
OI Li, Chun/0000-0003-4262-6848
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21425624, 21878021, 21736002]; Beijing Institute of
   Technology Research Fund Program for Young Scholars
FX This research was funded by grants from the National Natural Science
   Foundation of China (No. 21425624, No. 21878021, No. 21736002), and
   Beijing Institute of Technology Research Fund Program for Young
   Scholars.
CR Arnold FH, 1996, CHEM ENG SCI, V51, P5091, DOI 10.1016/S0009-2509(96)00288-6
   Asl MN, 2008, PHYTOTHER RES, V22, P709, DOI 10.1002/ptr.2362
   Bommarius AS, 2013, CHEM SOC REV, V42, P6534, DOI 10.1039/c3cs60137d
   Boone CD, 2015, FEBS J, V282, P1445, DOI 10.1111/febs.13232
   Bornscheuer UT, 2016, NAT CHEM BIOL, V12, P54, DOI 10.1038/nchembio.1989
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cobb RE, 2013, AICHE J, V59, P1432, DOI 10.1002/aic.13995
   Damnjanovic J, 2014, BIOTECHNOL BIOENG, V111, P674, DOI 10.1002/bit.25149
   Donald JE, 2011, PROTEINS, V79, P898, DOI 10.1002/prot.22927
   Feng XD, 2016, IND ENG CHEM RES, V55, P5474, DOI 10.1021/acs.iecr.6b00535
   Foo JL, 2013, BIOTECHNOL BIOFUELS, V6, DOI 10.1186/1754-6834-6-81
   Guo LC, 2018, COMPR REV FOOD SCI F, V17, P905, DOI 10.1111/1541-4337.12353
   Han S. W., 2017, SCI REP, P7
   Hosseinzadeh H, 2015, PHYTOTHER RES, V29, P1868, DOI 10.1002/ptr.5487
   Huang PS, 2016, NAT CHEM BIOL, V12, P29, DOI [10.1038/NCHEMBIO.1966, 10.1038/nchembio.1966]
   Jiang T., 2019, FRONT CHEM SCI ENG, DOI [10.1007/s11705-11019-11834-z, DOI 10.1007/S11705-11019-11834-Z]
   Kaleem I, 2014, CHEM ENG SCI, V106, P136, DOI 10.1016/j.ces.2013.10.023
   Korkegian A, 2005, SCIENCE, V308, P857, DOI 10.1126/science.1107387
   Krausse R, 2004, J ANTIMICROB CHEMOTH, V54, P243, DOI 10.1093/jac/dkh287
   Liang DM, 2015, CHEM SOC REV, V44, P8350, DOI 10.1039/c5cs00600g
   Luo YZ, 2016, NAT PROD REP, V33, P174, DOI 10.1039/c5np00085h
   Lv B, 2018, J BIOL CHEM, V293, P433, DOI 10.1074/jbc.M117.801910
   MIZUTANI K, 1994, BIOSCI BIOTECH BIOCH, V58, P554, DOI 10.1271/bbb.58.554
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Ozbakir HF, 2018, AICHE J, V64, P12, DOI 10.1002/aic.15893
   Pucci F, 2017, CURR OPIN STRUC BIOL, V42, P117, DOI 10.1016/j.sbi.2016.12.007
   Reetz MT, 2007, NAT PROTOC, V2, P891, DOI 10.1038/nprot.2007.72
   Sterner R, 2005, CHEM REV, V105, P4038, DOI 10.1021/cr030191z
   Su XT, 2017, BIOMED PHARMACOTHER, V95, P670, DOI 10.1016/j.biopha.2017.08.123
   Taguchi S, 2017, FRONT CHEM SCI ENG, V11, P139, DOI 10.1007/s11705-017-1636-0
   Wang W, 2016, FRONT CHEM SCI ENG, V10, P1, DOI 10.1007/s11705-016-1562-6
   Whitmore L, 2008, BIOPOLYMERS, V89, P392, DOI 10.1002/bip.20853
   Xiao JB, 2014, BIOTECHNOL ADV, V32, P1145, DOI 10.1016/j.biotechadv.2014.04.006
   Xu YH, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.00755-18
   Xu YH, 2017, CHEM ENG SCI, V167, P145, DOI 10.1016/j.ces.2017.04.011
   Yu HR, 2014, BIOTECHNOL ADV, V32, P308, DOI 10.1016/j.biotechadv.2013.10.012
   Yu JY, 2015, MOLECULES, V20, P13041, DOI 10.3390/molecules200713041
   Zhao YJ, 2017, J AGR FOOD CHEM, V65, P11147, DOI 10.1021/acs.jafc.7b04470
NR 38
TC 0
Z9 0
U1 1
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 91
EP 98
DI 10.1016/j.ces.2019.04.020
PG 8
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600008
DA 2020-05-12
ER

PT J
AU Abadikhah, H
   Kalali, EN
   Behzadi, S
   Khan, SA
   Xu, X
   Shabestari, ME
   Agathopoulos, S
AF Abadikhah, Hamidreza
   Kalali, Ehsan Naderi
   Behzadi, Shabnam
   Khan, Sayed Ali
   Xu, Xin
   Shabestari, Marjan E.
   Agathopoulos, Simeon
TI High flux thin film nanocomposite membrane incorporated with
   functionalized TiO2@reduced graphene oxide nanohybrids for organic
   solvent nanofiltration
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Thin film nanocomposite membrane; Organic solvent filtration; TiO2@rGO
   nanohybrid; Interfacial polymerization; Dye removal
ID WALLED CARBON NANOTUBES; RESISTANT NANOFILTRATION; COMPOSITE MEMBRANES;
   TIO2 NANOPARTICLES; WATER; PERFORMANCE; SEPARATION; POLYMERIZATION;
   POLYIMIDE; OSN
AB In this paper, graphene oxide based nanohybrids decorated with TiO2 nanoparticles (TiO2@rGO) were synthesized and incorporated into the thin film nanocomposite (TFN) membrane for efficient organic solvent nanofiltration (OSN) with antifouling properties. In order to improve the compatibility of TiO2@rGO in the polyamide active layer, the nanohybrids were amino-functionalized before their incorporation in the interfacial polymerization process. TiO2@rGO incorporated TFN membranes showed intense permeability increment and antifouling characteristics in comparison with the controlled composite membrane and graphene oxide (GO) incorporated TFN membrane. The GO nanosheets structure favors solvent channeling and TiO2 provides super hydrophilic characteristics, both resulted in a super permeable-hydrophilic OSN membrane with high structural stability and premium antifouling properties. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Abadikhah, Hamidreza; Khan, Sayed Ali; Xu, Xin] Univ Sci & Technol China, Dept Mat Sci & Engn, CAS Key Lab Mat Energy Convers, Hefei 230026, Anhui, Peoples R China.
   [Kalali, Ehsan Naderi] Univ Sci & Technol China, CAS Key Lab Fire Sci & Engn, Hefei 230026, Anhui, Peoples R China.
   [Behzadi, Shabnam] Univ Sci & Technol China, Chinese Acad Sci, Dept Polymer Sci & Engn, Key Lab Soft Matter Chem, Hefei 230026, Anhui, Peoples R China.
   [Shabestari, Marjan E.] Carlos III Univ Madrid, Polytech Sch, Dept Mat Sci & Engn & Chem Engn, Ave Univ 30, Madrid 28911, Spain.
   [Agathopoulos, Simeon] Univ Ioannina, Dept Mat Sci & Engn, GR-45110 Ioannina, Greece.
RP Xu, X (reprint author), Univ Sci & Technol China, Sch Chem & Mat Sci, Dept Mat Sci & Engn, Hefei 230026, Anhui, Peoples R China.
EM xuxin@ustc.edu.cn
RI kalali, Ehsan Naderi/AAF-2627-2020
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1732115, 51372238]; CNPC-CAS strategic cooperation
   research program [2015A-4812]
FX This research was supported by the National Natural Science Foundation
   of China (Grant no. U1732115 and 51372238), and the CNPC-CAS strategic
   cooperation research program (2015A-4812).
CR Aba NFD, 2015, J MEMBRANE SCI, V484, P87, DOI 10.1016/j.memsci.2015.03.001
   Abadikhah H, 2018, POLYMER, V154, P200, DOI 10.1016/j.polymer.2018.09.007
   Abadikhah H, 2018, J EUR CERAM SOC, V38, P4384, DOI 10.1016/j.jeurceramsoc.2018.05.035
   Abadikhah H, 2015, DESALIN WATER TREAT, V56, P2783, DOI 10.1080/19443994.2014.966331
   Ali MEA, 2016, DESALINATION, V386, P67, DOI 10.1016/j.desal.2016.02.034
   Basu S, 2009, J MEMBRANE SCI, V344, P190, DOI 10.1016/j.memsci.2009.07.051
   Chae HR, 2015, J MEMBRANE SCI, V483, P128, DOI 10.1016/j.memsci.2015.02.045
   Darvishmanesh S, 2010, PHYS CHEM CHEM PHYS, V12, P13333, DOI 10.1039/c0cp00230e
   de Lannoy CF, 2012, J MEMBRANE SCI, V415, P718, DOI 10.1016/j.memsci.2012.05.061
   Diawara CK, 2008, SEP PURIF REV, V37, P303, DOI 10.1080/15422110802228770
   Ding R, 2015, CHEM ENG SCI, V138, P227, DOI 10.1016/j.ces.2015.08.019
   Dong GY, 2016, J MEMBRANE SCI, V520, P860, DOI 10.1016/j.memsci.2016.08.059
   Dreyer DR, 2014, CHEM SOC REV, V43, P5288, DOI 10.1039/c4cs00060a
   Farahani MHDA, 2018, J MEMBRANE SCI, V548, P319, DOI 10.1016/j.memsci.2017.11.037
   Fathizadeh M, 2017, J MATER CHEM A, V5, P20860, DOI 10.1039/c7ta06307e
   Gao Y, 2014, J MEMBRANE SCI, V455, P349, DOI 10.1016/j.memsci.2014.01.011
   Han Y, 2013, ADV FUNCT MATER, V23, P3693, DOI 10.1002/adfm.201202601
   Hoek E. M. V, 2013, ENCY MEMBRANE SCI TE, DOI [10.1002/9781118522318, DOI 10.1002/9781118522318>]
   Hu M, 2013, ENVIRON SCI TECHNOL, V47, P3715, DOI 10.1021/es400571g
   Jansen JC, 2013, J MEMBRANE SCI, V447, P107, DOI 10.1016/j.memsci.2013.07.009
   Jeong BH, 2007, J MEMBRANE SCI, V294, P1, DOI 10.1016/j.memsci.2007.02.025
   Karatrantos A, 2017, J CHEM PHYS, V146, DOI 10.1063/1.4981258
   Khorshidi B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22069
   Kim JH, 2018, J MEMBRANE SCI, V550, P322, DOI 10.1016/j.memsci.2018.01.008
   Lai GS, 2016, DESALINATION, V387, P14, DOI 10.1016/j.desal.2016.03.007
   Li ZP, 2011, J MATER CHEM, V21, P3397, DOI 10.1039/c0jm02650f
   Lim SK, 2016, J MEMBRANE SCI, V501, P152, DOI 10.1016/j.memsci.2015.11.016
   Lind ML, 2009, LANGMUIR, V25, P10139, DOI 10.1021/la900938x
   Lind ML, 2009, J MATER RES, V24, P1624, DOI 10.1557/JMR.2009.0189
   Liu XJ, 2011, RSC ADV, V1, P1245, DOI 10.1039/c1ra00298h
   Mao H, 2015, ACS SUSTAIN CHEM ENG, V3, P1925, DOI 10.1021/acssuschemeng.5b00435
   Marchetti P, 2014, CHEM REV, V114, P10735, DOI 10.1021/cr500006j
   Nair RR, 2012, SCIENCE, V335, P442, DOI 10.1126/science.1211694
   Peyravi M, 2014, CHEM ENG J, V241, P155, DOI 10.1016/j.cej.2013.12.024
   Rajaeian B, 2013, DESALINATION, V313, P176, DOI 10.1016/j.desal.2012.12.012
   Sairam M, 2009, J MEMBRANE SCI, V330, P166, DOI 10.1016/j.memsci.2008.12.067
   Shah MSAS, 2012, ACS APPL MATER INTER, V4, P3893, DOI 10.1021/am301287m
   Shao L, 2014, J MEMBRANE SCI, V452, P82, DOI 10.1016/j.memsci.2013.10.021
   Soroko I, 2009, J MEMBRANE SCI, V343, P189, DOI 10.1016/j.memsci.2009.07.026
   Sorribas S, 2013, J AM CHEM SOC, V135, P15201, DOI 10.1021/ja407665w
   Teli SB, 2011, J MEMBRANE SCI, V371, P171, DOI 10.1016/j.memsci.2011.01.033
   Tiraferri A, 2011, ACS APPL MATER INTER, V3, P2869, DOI 10.1021/am200536p
   Vandezande P, 2008, CHEM SOC REV, V37, P365, DOI 10.1039/b610848m
   Wang CB, 2017, J MEMBRANE SCI, V523, P273, DOI 10.1016/j.memsci.2016.09.055
   Wu H, 2012, CARBON, V50, P1135, DOI 10.1016/j.carbon.2011.10.026
   Wu HQ, 2013, J MEMBRANE SCI, V428, P341, DOI 10.1016/j.memsci.2012.10.053
   Wu HQ, 2013, J MEMBRANE SCI, V428, P425, DOI 10.1016/j.memsci.2012.10.042
   Wu XL, 2016, J MEMBRANE SCI, V515, P175, DOI 10.1016/j.memsci.2016.05.048
   Xu C, 2013, CARBON, V62, P465, DOI 10.1016/j.carbon.2013.06.035
   Xu YC, 2017, J MEMBRANE SCI, V526, P32, DOI 10.1016/j.memsci.2016.12.026
   Yang Z, 2017, J MEMBRANE SCI, V544, P351, DOI 10.1016/j.memsci.2017.09.046
   Ye L, 2007, LANGMUIR, V23, P5630, DOI 10.1021/la0626656
   Yin J, 2016, DESALINATION, V379, P93, DOI 10.1016/j.desal.2015.11.001
   Yuan ZJ, 2018, J MEMBRANE SCI, V549, P1, DOI 10.1016/j.memsci.2017.11.051
   Zargar M, 2017, J MEMBRANE SCI, V541, P19, DOI 10.1016/j.memsci.2017.06.085
   Zargar M, 2017, J MEMBRANE SCI, V521, P53, DOI 10.1016/j.memsci.2016.08.069
   Zhang CF, 2017, ACS APPL MATER INTER, V9, P11082, DOI 10.1021/acsami.6b12826
   Zhang HQ, 2014, J MEMBRANE SCI, V470, P70, DOI 10.1016/j.memsci.2014.07.019
   Zhu JY, 2017, ACS APPL MATER INTER, V9, P28990, DOI 10.1021/acsami.7b05930
NR 59
TC 7
Z9 7
U1 32
U2 149
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 99
EP 109
DI 10.1016/j.ces.2019.04.022
PG 11
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600009
DA 2020-05-12
ER

PT J
AU Dang, Y
   Yao, Y
   Liu, YB
   Wei, B
   Feng, X
   Chen, XB
   Yang, CH
AF Dang, Yu
   Yao, Yuan
   Liu, Yibin
   Wei, Bin
   Feng, Xiang
   Chen, Xiaobo
   Yang, Chaohe
TI Diffusion properties of aromatic hydrocarbons in mesoporous alumina: A
   molecular dynamics study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Aromatic hydrocarbons; Diffusion; Alumina pores; Molecular dynamics
ID CANONICAL MONTE-CARLO; CAPILLARY CONDENSATION; PORE MORPHOLOGY;
   GAMMA-ALUMINA; SURFACE; ADSORPTION; ZEOLITES; HYDROGENATION; KNUDSEN;
   SIMULATIONS
AB The hydrogenation of aromatic compounds is mainly controlled by diffusion; hence, the diffusion of reactants into the pores of a catalyst has a significant effect on the catalytic reaction. However, the diffusivity of reactant molecules is poorly characterized due to the limitations of experimental technology. In this study, the diffusion behavior of benzene, naphthalene, and anthracene in alumina pores of three different sizes, namely, 3.1 nm, 5.2 nm, and 6.8 nm pores, at 623.15-723.15 K is investigated using a molecular dynamics (MD) method. The effects of temperature and pore size on the diffusion performance were investigated. The three aromatic hydrocarbons were distributed parallel to the pore surface through electrostatic interactions. The Arrhenius equation can accurately fit the relationship between temperature and the self-diffusion coefficient, and the calculated diffusion activation energy shows that the diffusivity of the larger molecules is more sensitive to temperature variation. Furthermore, the self-diffusion coefficients of three aromatic hydrocarbons and their corresponding dynamic diameters show a good linear relationship. The larger molecules showed smaller variations in their self-diffusion coefficients with an increase in pore size. The results reported herein provide theoretical guidance for the characterization of the diffusion behavior of different aromatics in catalyst pores. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dang, Yu; Liu, Yibin; Wei, Bin; Feng, Xiang; Chen, Xiaobo; Yang, Chaohe] China Univ Petr, State Key Lab Heavy Oil Proc, Qingdao 266580, Shandong, Peoples R China.
   [Yao, Yuan] Petrochina Co Ltd, Petrochem Res Inst, Beijing 102206, Peoples R China.
RP Liu, YB (reprint author), China Univ Petr, State Key Lab Heavy Oil Proc, Qingdao 266580, Shandong, Peoples R China.
EM liuyibin@upc.edu.cn
OI Liu, Yibin/0000-0003-2623-3868
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [18CX02130A, 18CX02014A];
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [21776312, 21606254]; Key research and development plan of
   Shandong Province [2018GGX107005, 2017GSF17126]
FX This work was supported by Fundamental Research Funds for the Central
   Universities (18CX02130A, 18CX02014A), Natural Science Foundation of
   China (21776312, 21606254), Key research and development plan of
   Shandong Province (2018GGX107005, 2017GSF17126).
CR Abu-Reziq R, 2002, J MOL CATAL A-CHEM, V185, P179, DOI 10.1016/S1381-1169(02)00012-2
   Bai P, 2016, ACS NANO, V10, P7612, DOI 10.1021/acsnano.6b02856
   Bu LT, 2018, CATAL TODAY, V312, P73, DOI 10.1016/j.cattod.2018.02.012
   Caravella A, 2016, MICROPOR MESOPOR MAT, V235, P87, DOI 10.1016/j.micromeso.2016.07.049
   Cheah S, 2016, TOP CATAL, V59, P109, DOI 10.1007/s11244-015-0510-x
   Chen C, 2011, CHEM ENG J, V166, P646, DOI 10.1016/j.cej.2010.11.038
   Choudhary VR, 1997, IND ENG CHEM RES, V36, P1812, DOI 10.1021/ie960411h
   Coasne B, 2004, J CHEM PHYS, V120, P2913, DOI 10.1063/1.1632897
   Coasne B, 2004, J CHEM PHYS, V121, P3767, DOI 10.1063/1.1772757
   Coasne B, 2006, LANGMUIR, V22, P11097, DOI 10.1021/la061728h
   Combariza AF, 2013, CHEM SOC REV, V42, P114, DOI 10.1039/c2cs35243e
   Digne M, 2004, J CATAL, V226, P54, DOI 10.1016/j.jcat.2004.04.020
   Fu H., 2017, J PHYS CHEM C, P121
   He YF, 2003, LANGMUIR, V19, P10132, DOI 10.1021/la035047n
   Hlushkou D., 2017, J PHYS CHEM C, P121
   HUGGINS BA, 1992, J AM CHEM SOC, V114, P2098, DOI 10.1021/ja00032a025
   Jiang JW, 2011, CHEM SOC REV, V40, P3599, DOI 10.1039/c0cs00128g
   Jin N, 2016, IND ENG CHEM RES, V55, P5108, DOI 10.1021/acs.iecr.6b00360
   Jobic H, 2000, J MOL CATAL A-CHEM, V158, P135, DOI 10.1016/S1381-1169(00)00057-1
   Kwak JH, 2009, SCIENCE, V325, P1670, DOI 10.1126/science.1176745
   Ho LN, 2011, LANGMUIR, V27, P8187, DOI 10.1021/la2012765
   Liu XS, 2008, J PHYS CHEM C, V112, P5066, DOI 10.1021/jp711901s
   Liu XS, 1997, J AM CHEM SOC, V119, P9856, DOI 10.1021/ja971214s
   Lunsford JH, 1997, TOP CATAL, V4, P91, DOI 10.1023/A:1019171702160
   Morin C, 2004, J PHYS CHEM B, V108, P12084, DOI 10.1021/jp048733j
   Nose S, 1999, J PHYS CONDENS MATT, V2, pSa115
   Paglia G., 2006, CHEM MATER, P18
   Pellenq RJM, 2002, MOL PHYS, V100, P2059, DOI 10.1080/00268970210129265
   Pellenq RJM, 2001, PHYS CHEM CHEM PHYS, V3, P1207
   PERDEW JP, 1992, PHYS REV B, V46, P12947, DOI 10.1103/PhysRevB.46.12947
   Pujro R, 2016, J CHEM TECHNOL BIOT, V91, P336, DOI 10.1002/jctb.4570
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Rimola A, 2010, PHYS CHEM CHEM PHYS, V12, P6357, DOI 10.1039/c000009d
   Ruthven DM, 2009, CHEM ENG SCI, V64, P3201, DOI 10.1016/j.ces.2009.03.049
   Sabbe MK, 2015, J CATAL, V330, P406, DOI 10.1016/j.jcat.2015.08.003
   Santana RC, 2006, FUEL, V85, P643, DOI 10.1016/j.fuel.2005.08.028
   Sizova AA, 2015, COLLOID SURFACE A, V474, P76, DOI 10.1016/j.colsurfa.2015.03.008
   Smit B, 2008, CHEM REV, V108, P4125, DOI 10.1021/cr8002642
   TopsOe H., 1996, CATALYSIS SCI TECHNO, P1, DOI DOI 10.1007/978-3-642-61040-03
   Topsoe H., 1996, APPL MICROBIOL BIOTE
   Yang JZ, 2008, J MEMBRANE SCI, V318, P327, DOI 10.1016/j.memsci.2008.02.059
   Yuan T, 2005, J HAZARD MATER, V126, P149, DOI 10.1016/j.jhazmat.2005.06.022
   Zhang C, 2013, ACTA PETROL SIN, V29, P217
   Zhang H., 2013, IND CATAL, V21, P64
   Zito PF, 2017, J MEMBRANE SCI, V523, P456, DOI 10.1016/j.memsci.2016.10.016
NR 45
TC 2
Z9 2
U1 7
U2 50
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 110
EP 117
DI 10.1016/j.ces.2019.04.023
PG 8
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600010
DA 2020-05-12
ER

PT J
AU Kolb, HE
   Kasper, G
AF Kolb, H. E.
   Kasper, G.
TI Mist filters: How steady is their "steady state"?
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Filtration; Oil mist; Coalescence filter; Pressure drop; Steady state
ID PRESSURE-DROP; LIQUID DISTRIBUTION; FILTRATION; SATURATION; AEROSOLS;
   MOTION
AB This paper addresses the phenomenon of a slow Delta p increase ("creep") sometimes observed in mist filters during their so-called steady-state operation, especially at relatively high flow rates and aerosol loads (Kolb et al., 2017). This creep phenomenon draws into question the concept of steady state and awaits a physical explanation on the basis of more systematic data. The present study was performed with conventional glass microfiber filter media at filter face velocities in the range of 1-70 cm/s, using submicron oil aerosol at loading rates up to 1.1 g/(m(2) s). Experiments started either with a dry filter (designated as S-0 = 0, where S stands for the liquid saturation level), or with a completely pre-saturated filter (designated as S-0 = 1). The S-0 = 0 runs reached "steady state" (defined here as the onset of drainage) after approximately 0.3 h and were then loaded continually for another 100 h. Runs starting at S-0 =1 reached a steady state very quickly.
   With regard to Delta p, all filters featured Delta p creep when starting from S-0 = 0. For coarse filter grades, Delta p creep effectively ended in less than 40 h at moderate flow velocities; finer grades crept further and did not stop creeping within any reasonable loading time. When starting from S-0 = 1, a steady Delta p endpoint was reached rapidly, but was considerably higher than the level attained by creep. It was further shown that creep is associated with a slow increase in the saturation level and that S approached the (higher) level of pre-saturated filters. The increase in S during creep was associated with the formation of additional fine oil channels. Conversely, oil channels were completely absent in pre-saturated filters and the liquid was uniformly dispersed. Using simple theoretical considerations for flow in porous media, the observed differences in Delta p are explained in part by the difference in S betweenS(0) = 0 and S-0 =1 filters, and in additionally also by taking into account the different liquid distribution patterns.
   We conclude that the onset of drainage under steady external conditions - the stage conventionally viewed as the beginning of steady-state operation - does not automatically represent an internal steady state with regard to saturation levels or pressure drop; and presumably also not for the oil distribution pattern. The internal saturation reaches a stable endpoint sooner than the pressure drop, which may continue to creep for the lifetime of the filter. Of and when a transition from channel patterns to homogeneous oil distribution occurs during steady operation is not known. However, the transition can be forced rather quickly by operating the filter intermittently at a very low flow velocity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kolb, H. E.; Kasper, G.] Karlsruhe Inst Technol, Inst Mech Verfahrenstech & Mech, D-76131 Karlsruhe, Germany.
RP Kolb, HE (reprint author), Donaldson Europe Bvba, Res Pk Zone 1,Interleuvenlaan 1, B-3001 Leuven, Belgium.
EM eckhard.kolb@kit.edu
FU Atlas Copco Airpower n. v.
FX The authors would like to thank Atlas Copco Airpower n. v. for partial
   support of this work as well as Ann-Kathrin Muller who conducted
   experiments with air flow interruptions.
CR Agranovski IE, 1998, AICHE J, V44, P2775, DOI 10.1002/aic.690441218
   Bredin A, 2012, SEP PURIF TECHNOL, V90, P53, DOI 10.1016/j.seppur.2012.02.009
   Calle-Chazelet S., 1996, 1 JOURN FILTR AER
   Chang C, 2018, SEP PURIF TECHNOL, V194, P355, DOI 10.1016/j.seppur.2017.11.052
   Chang C, 2017, CHEM ENG SCI, V160, P354, DOI 10.1016/j.ces.2016.10.047
   Charvet A, 2010, CHEM ENG SCI, V65, P1875, DOI 10.1016/j.ces.2009.11.037
   Contal P, 2004, J AEROSOL SCI, V35, P263, DOI 10.1016/j.jaerosci.2003.07.003
   Davies C.N., 1973, AIR FILTRATION
   Dawar S, 2008, SEP PURIF TECHNOL, V60, P6, DOI 10.1016/j.seppur.2007.07.027
   Dawar S, 2010, SEP PURIF TECHNOL, V72, P282, DOI 10.1016/j.seppur.2010.02.018
   Frising T, 2005, CHEM ENG SCI, V60, P2751, DOI 10.1016/j.ces.2004.12.026
   Frising T, 2004, FILTR SEPARAT, V41, P36, DOI 10.1016/S0015-1882(04)00075-8
   Frising T., 2005, FILTRATION, V5, P286
   Kampa D, 2014, INT J MULTIPHAS FLOW, V58, P313, DOI 10.1016/j.ijmultiphaseflow.2013.10.007
   Kampa D., 2015, THESIS
   Kolb HE, 2018, J AEROSOL SCI, V123, P219, DOI 10.1016/j.jaerosci.2018.05.013
   Kolb HE, 2018, SEP PURIF TECHNOL, V199, P198, DOI 10.1016/j.seppur.2018.01.024
   Kolb HE, 2017, CHEM ENG SCI, V166, P107, DOI 10.1016/j.ces.2017.03.028
   LIEW TP, 1985, J AEROSOL SCI, V16, P497, DOI 10.1016/0021-8502(85)90002-3
   May K. R., 1973, Journal of Aerosol Science, V4, P235, DOI 10.1016/0021-8502(73)90006-2
   Mead-Hunter R, 2014, SEP PURIF TECHNOL, V133, P484, DOI 10.1016/j.seppur.2014.06.057
   Mead-Hunter R, 2013, SEP PURIF TECHNOL, V104, P121, DOI 10.1016/j.seppur.2012.11.019
   Mullins BJ, 2006, J COLLOID INTERF SCI, V300, P704, DOI 10.1016/j.jcis.2006.02.059
   Wurster S, 2015, CHEM ENG SCI, V132, P72, DOI 10.1016/j.ces.2015.04.012
NR 24
TC 0
Z9 0
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 118
EP 127
DI 10.1016/j.ces.2019.03.072
PG 10
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600011
DA 2020-05-12
ER

PT J
AU Moharir, M
   Pourkargar, DB
   Almansoori, A
   Daoutidis, P
AF Moharir, Manjiri
   Pourkargar, Davood B.
   Almansoori, Ali
   Daoutidis, Prodromos
TI Graph representation and distributed control of
   diffusion-convection-reaction system networks
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Distributed control; Graph theory; Process network decomposition;
   Distributed parameter systems; Model predictive control; Process control
ID MODEL-PREDICTIVE CONTROL; CONTROL CONFIGURATIONS; INTEGRATED PROCESS;
   DECOMPOSITION; OPTIMIZATION; ARCHITECTURES; SELECTION; IMPACT
AB Equation graph representations are proposed for generic diffusion-convection-reaction systems described by parabolic partial differential equations. A measure of structural input-output closeness is proposed, and its relationship with the equation graph representation is established. A graph-based algorithm to obtain network decompositions for distributed control is extended to networks that have diffusion-convection-reaction systems, and the effectiveness of the decomposition is demonstrated through a case study on a prototypical reaction-separation plant. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Moharir, Manjiri; Pourkargar, Davood B.; Daoutidis, Prodromos] Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.
   [Almansoori, Ali] Khalifa Univ Sci Technol & Res, Dept Chem Engn, Abu Dhabi, U Arab Emirates.
RP Daoutidis, P (reprint author), Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.
EM mohar006@umn.edu; dbp@umn.edu; aalmansoori@pi.ac.ae; daout001@umn.edu
OI Almansoori, Ali/0000-0002-0789-5105
FU Khalifa University, Abu Dhabi, UAE
FX Financial support from the Khalifa University, Abu Dhabi, UAE is
   gratefully acknowledged.
CR Antoniades C, 2001, NONLINEAR ANAL-THEOR, V47, P5933, DOI 10.1016/S0362-546X(01)00699-X
   Biegler LT, 2010, NONLINEAR PROGRAMMIN
   Camponogara E, 2002, IEEE CONTR SYST MAG, V22, P44, DOI 10.1109/37.980246
   Christofides P. D., 2012, NONLINEAR ROBUST CON
   Christofides PD, 2013, COMPUT CHEM ENG, V51, P21, DOI 10.1016/j.compchemeng.2012.05.011
   Christofides PD, 2011, ADV IND CONTROL, P1, DOI 10.1007/978-0-85729-582-8
   Christofides PD, 1996, AICHE J, V42, P3063, DOI 10.1002/aic.690421108
   DAOUTIDIS P, 1992, CHEM ENG SCI, V47, P1091, DOI 10.1016/0009-2509(92)80234-4
   Ellis M, 2014, AICHE J, V60, P3230, DOI 10.1002/aic.14514
   FRIEDLY JC, 1972, DYNAMIC BEHAV PROCES
   Hangos KM, 2001, COMPUT CHEM ENG, V25, P1521, DOI 10.1016/S0098-1354(01)00716-5
   Heo S, 2016, AICHE J, V62, P3177, DOI 10.1002/aic.15323
   Heo S, 2015, CHEM ENG SCI, V136, P76, DOI 10.1016/j.ces.2015.03.049
   Jogwar SS, 2017, CHEM ENG SCI, V172, P434, DOI 10.1016/j.ces.2017.06.043
   Kang LX, 2016, J PROCESS CONTR, V46, P43, DOI 10.1016/j.jprocont.2016.07.009
   Kiss AA, 2010, CHEM ENG J, V158, P241, DOI 10.1016/j.cej.2010.01.023
   Leicht EA, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.118703
   Luyben W.L., 1989, PROCESS MODELING SIM
   Maidi A., 2011, IFAC P, P10910
   Mayne DQ, 2014, AUTOMATICA, V50, P2967, DOI 10.1016/j.automatica.2014.10.128
   Moharir M, 2018, IND ENG CHEM RES, V57, P13103, DOI 10.1021/acs.iecr.8b01291
   Moharir M, 2017, COMPUT CHEM ENG, V106, P532, DOI 10.1016/j.compchemeng.2017.07.005
   Pourkargar DB, 2018, CHEM ENG RES DES, V134, P553, DOI 10.1016/j.cherd.2018.04.045
   Pourkargar DB, 2017, IFAC PAPERSONLINE, V50, P12452, DOI 10.1016/j.ifacol.2017.08.1920
   Pourkargar DB, 2017, IND ENG CHEM RES, V56, P9606, DOI 10.1021/acs.iecr.7b00644
   Rawlings J. B., 2017, MODEL PREDICTIVE CON
   ROMAN S, 1980, AM MATH MON, V87, P805, DOI 10.2307/2320788
   Scattolini R, 2009, J PROCESS CONTR, V19, P723, DOI 10.1016/j.jprocont.2009.02.003
   Schne T, 2011, INT J SYST SCI, V42, P1023, DOI 10.1080/00207720903282964
   Tang WT, 2018, COMPUT CHEM ENG, V111, P43, DOI 10.1016/j.compchemeng.2017.12.010
   Yin XY, 2016, AICHE J, V62, P1995, DOI 10.1002/aic.15170
NR 31
TC 2
Z9 2
U1 2
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 128
EP 139
DI 10.1016/j.ces.2018.11.062
PG 12
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600012
DA 2020-05-12
ER

PT J
AU Na, SJ
   Hwang, SJ
   Kim, H
   Baek, IH
   Lee, KS
AF Na, Sujin
   Hwang, Sung June
   Kim, Hoonsik
   Baek, Il-Hyun
   Lee, Kwang Soon
TI Modeling of CO2 solubility of an aqueous polyamine solvent for CO2
   capture
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CO2 absorption; Aqueous polyamine solvent; CO2 solubility modeling;
   Vapor-liquid equilibrium; Electrolyte NRTL model; NMR; Solvent
   development
ID TERTIARY AMINE ABSORBENTS; VAPOR-LIQUID-EQUILIBRIA; LOCAL COMPOSITION
   MODEL; EXCESS GIBBS ENERGY; CARBON-DIOXIDE; ABSORPTION; MEA; PIPERAZINE;
   SYSTEMS
AB Development of absorbents with large absorption capacities is important for improvements in the CO2 capture technology. Polyamines include more than two amine groups in their molecular structures and may exhibit great potential as candidate solvents. In this study, CO2 solubility and speciation in aqueous 3,3'-iminobis(N,N-dimethylpropylamine) (IBDMPA) was experimentally investigated and a chemical equilibrium reaction model was proposed. Solubility measurements were conducted at four different IBDMPA contents (9.37, 18.7, 31.6 and 37.5 mass%) in the temperature range from 40 to 120 degrees C and CO 2 partial pressure in the range of from 2 kPa to 480 kPa. In addition, both proton and carbon nuclear magnetic resonance (NMR) spectroscopic techniques were employed for the quantitative and qualitative analyses of various species in CO2-loaded solutions. Using these experimental results, a chemical equilibrium reaction model was developed for the IBDMPA-H2O-CO2 system based on the electrolyte NRTL model. (C) 2019 Published by Elsevier Ltd.
C1 [Na, Sujin; Hwang, Sung June; Lee, Kwang Soon] Sogang Univ, Dept Chem & Biomol Engn, 35 Baekbeom Ro, Seoul, South Korea.
   [Kim, Hoonsik] Kyung Hee Univ, Dept Chem, 26 Kyungheedae Ro, Seoul, South Korea.
   [Baek, Il-Hyun] Korea Inst Energy Res, 71-2 Jang Dong, Daejeon, South Korea.
RP Lee, KS (reprint author), Sogang Univ, Dept Chem & Biomol Engn, 35 Baekbeom Ro, Seoul, South Korea.
EM kslee@sogang.ac.kr
FU Korea Carbon Capture and Sequestration Research and Development Center
   (KCRC) - Korean Government (Ministry of Education, Science and
   Technology) [2012-0008886]
FX This work was supported by the Korea Carbon Capture and Sequestration
   Research and Development Center (KCRC) Grant funded by the Korean
   Government (Ministry of Education, Science and Technology,
   2012-0008886).
CR Aronu UE, 2011, CHEM ENG SCI, V66, P6393, DOI 10.1016/j.ces.2011.08.042
   AUSTGEN DM, 1989, IND ENG CHEM RES, V28, P1060, DOI 10.1021/ie00091a028
   Bishnoi S, 2002, AICHE J, V48, P2788, DOI 10.1002/aic.690481208
   BRELVI SW, 1972, AICHE J, V18, P1239, DOI 10.1002/aic.690180622
   Chen C.-C., 1980, COMPUTER SIMULATION
   CHEN CC, 1982, AICHE J, V28, P588, DOI 10.1002/aic.690280410
   CHEN CC, 1986, AICHE J, V32, P444, DOI 10.1002/aic.690320311
   Chowdhury FA, 2013, IND ENG CHEM RES, V52, P8323, DOI 10.1021/ie400825u
   Chowdhury FA, 2009, ENRGY PROCED, V1, P1241, DOI 10.1016/j.egypro.2009.01.163
   Corporation H, 2012, PERFORMANCE PRODUCTS
   Derks PWJ, 2006, CHEM ENG SCI, V61, P6837, DOI 10.1016/j.ces.2006.07.009
   Du Y, 2014, ENRGY PROCED, V63, P997, DOI 10.1016/j.egypro.2014.11.108
   Dugas RE., 2009, CARBON DIOXIDE ABSOR
   EDWARDS TJ, 1978, AICHE J, V24, P966, DOI 10.1002/aic.690240605
   Freeman SA, 2010, INT J GREENH GAS CON, V4, P119, DOI 10.1016/j.ijggc.2009.10.008
   Freguia S, 2003, AICHE J, V49, P1676, DOI 10.1002/aic.690490708
   Gupta M, 2012, ENRGY PROCED, V23, P140, DOI 10.1016/j.egypro.2012.06.076
   Hartono A, 2007, IND ENG CHEM RES, V46, P249, DOI 10.1021/ie0603868
   Hilliard MD, 2008, PREDICTIVE THERMODYN
   Hwang SJ, 2017, J CHEM ENG DATA, V62, P2428, DOI 10.1021/acs.jced.7b00364
   Jakobsen JP, 2008, J MAGN RESON, V191, P304, DOI 10.1016/j.jmr.2007.12.022
   JOBACK KG, 1987, CHEM ENG COMMUN, V57, P233, DOI 10.1080/00986448708960487
   JOU FY, 1994, IND ENG CHEM RES, V33, P2002, DOI 10.1021/ie00032a016
   Kim I, 2011, INT J GREENH GAS CON, V5, P390, DOI 10.1016/j.ijggc.2010.05.003
   PITZER KS, 1980, J AM CHEM SOC, V102, P2902, DOI 10.1021/ja00529a006
   REDLICH O, 1949, CHEM REV, V44, P233, DOI 10.1021/cr60137a013
   Robinson R. A., 2002, ELECTROLYTE SOLUTION
   Rochelle G, 2011, CHEM ENG J, V171, P725, DOI 10.1016/j.cej.2011.02.011
   Sigma-Aldrich, 3 3 IM N N DIM
   Vrachnos A, 2006, IND ENG CHEM RES, V45, P5148, DOI 10.1021/ie0600792
   Zhang Y, 2011, FLUID PHASE EQUILIBR, V311, P67, DOI 10.1016/j.fluid.2011.08.025
NR 31
TC 1
Z9 1
U1 1
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 140
EP 150
DI 10.1016/j.ces.2019.04.021
PG 11
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600013
DA 2020-05-12
ER

PT J
AU Liu, DH
   Xiang, L
   Chang, H
   Chen, K
   Wang, CQ
   Pan, YC
   Li, YS
   Jiang, ZY
AF Liu, Donghui
   Xiang, Long
   Chang, Hao
   Chen, Ke
   Wang, Chongqing
   Pan, Yichang
   Li, Yanshuo
   Jiang, Zhongyi
TI Rational matching between MOFs and polymers in mixed matrix membranes
   for propylene/propane separation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mixed matrix membrane; Matching criteria; ZIF-8; Propylene/propane; Gas
   separation
ID IMIDAZOLATE FRAMEWORK MEMBRANES; METAL-ORGANIC FRAMEWORKS;
   GAS-SEPARATION; COMPOSITE MEMBRANES; CO2; PERFORMANCE; PERMEABILITY;
   PERMEATION; CO2/N-2; NANOCOMPOSITES
AB Mixed matrix membranes (MMMs) have attracted tremendous attention in the field of gas separation, which adopts the synergistic advantages of the polymer and inorganic phase. However, the MMMs rarely generate sufficient selectivity for energy-efficient gas separation, even if the dispersed molecular sieve is highly selective. Here, an unprecedented improvement (similar to 4.5-fold) of both C3H6/C3H8 permeability and selectivity on the crosslinked poly(ethylene oxide) (XLPEO) membranes containing ZIF-8 nanocrystals. When the ratio of polymer-to-sieve permeability (R-c/d) is in the range of 0.004-0.36, both C3H6/C3H8 permeability and selectivity increases with the ZIF-8 loading, and the separation performance on MMMs can approach and surpass the-state-of-the-art polymer upper bound. Besides C3H6/C3H8 separation, the universality of this proposed polymer-sieve matching law is suitable for other gas-pairs on MOF-based MMMs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Donghui; Xiang, Long; Chang, Hao; Chen, Ke; Wang, Chongqing; Pan, Yichang] Nanjing Tech Univ, Coll Chem Engn, State Key Lab Mat Oriented Chem Engn, Nanjing 210009, Jiangsu, Peoples R China.
   [Li, Yanshuo] Ningbo Univ, Sch Mat Sci & Chem Engn, Ningbo 315211, Zhejiang, Peoples R China.
   [Jiang, Zhongyi] Tianjin Univ, Sch Chem Engn & Technol, Key Lab Green Chem Technol, Minist Educ, Tianjin 300072, Peoples R China.
RP Pan, YC (reprint author), Nanjing Tech Univ, Coll Chem Engn, State Key Lab Mat Oriented Chem Engn, Nanjing 210009, Jiangsu, Peoples R China.; Li, YS (reprint author), Ningbo Univ, Sch Mat Sci & Chem Engn, Ningbo 315211, Zhejiang, Peoples R China.; Jiang, ZY (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Key Lab Green Chem Technol, Minist Educ, Tianjin 300072, Peoples R China.
EM panyc@njtech.edu.cn; liyanshuo@nbu.edu.cn; zhyjiang@tju.edu.cn
RI Pan, Yichang/E-4856-2015; Li, Yanshuo/F-2526-2012
OI Pan, Yichang/0000-0003-2990-6917; Li, Yanshuo/0000-0002-7722-7962
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21622607, 21776124, 21761132009, 21838008]; Jiangsu
   Provincial NSFC [BK20171459]; Zhejiang Provincial NSFC [LR18B060002];
   Foundation of Jiangsu Educational Committee of China [17KJA530004];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD); Six Talent Peaks Project; Qing-Lan Engineering
   Project of Jiangsu Province
FX This This work was supported by the National Natural Science Foundation
   of China (21622607, 21776124, 21761132009, 21838008), Jiangsu Provincial
   NSFC (BK20171459), Zhejiang Provincial NSFC (LR18B060002), Foundation of
   Jiangsu Educational Committee of China (17KJA530004), and the Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD). Y. P. also appreciate the support from the Six Talent Peaks
   Project and Qing-Lan Engineering Project of Jiangsu Province. Y. L.
   Appreciate the K. C. Wong Magna Fund in Ningbo University.
CR Adams RT, 2011, J MEMBRANE SCI, V367, P197, DOI 10.1016/j.memsci.2010.10.059
   Ahn JY, 2008, J MEMBRANE SCI, V314, P123, DOI 10.1016/j.memsci.2008.01.031
   Al-Maythalony BA, 2017, ACS APPL MATER INTER, V9, P33401, DOI 10.1021/acsami.6b15803
   An H, 2017, J MEMBRANE SCI, V526, P367, DOI 10.1016/j.memsci.2016.12.053
   Askari M, 2013, J MEMBRANE SCI, V444, P173, DOI 10.1016/j.memsci.2013.05.016
   Bachman JE, 2016, NAT MATER, V15, P845, DOI [10.1038/NMAT4621, 10.1038/nmat4621]
   Bachman JE, 2016, ENERG ENVIRON SCI, V9, P2031, DOI 10.1039/c6ee00865h
   Bae TH, 2013, ENERG ENVIRON SCI, V6, P3565, DOI 10.1039/c3ee42394h
   Bae TH, 2010, ANGEW CHEM INT EDIT, V49, P9863, DOI 10.1002/anie.201006141
   Bansal A, 2005, NAT MATER, V4, P693, DOI 10.1038/nmat1447
   Boroglu MS, 2017, SEP PURIF TECHNOL, V173, P269, DOI 10.1016/j.seppur.2016.09.037
   Brown AJ, 2014, SCIENCE, V345, P72, DOI 10.1126/science.1251181
   Chen XY, 2013, RSC ADV, V3, P24266, DOI 10.1039/c3ra43486a
   Cruise GM, 1998, BIOMATERIALS, V19, P1287, DOI 10.1016/S0142-9612(98)00025-8
   Dechnik J, 2017, ANGEW CHEM INT EDIT, V56, P9292, DOI 10.1002/anie.201701109
   Denny MS, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.78
   Denny MS, 2015, ANGEW CHEM INT EDIT, V54, P9029, DOI 10.1002/anie.201504077
   Dong GX, 2013, J MATER CHEM A, V1, P4610, DOI 10.1039/c3ta00927k
   Ehsani A, 2016, J TAIWAN INST CHEM E, V66, P414, DOI 10.1016/j.jtice.2016.07.005
   Freeman BD, 1999, MACROMOLECULES, V32, P375, DOI 10.1021/ma9814548
   Ghalei B, 2017, NAT ENERGY, V2, DOI 10.1038/nenergy.2017.86
   Hoang VT, 2013, CHEM REV, V113, P4980, DOI 10.1021/cr3003888
   Islam MN, 2005, J MEMBRANE SCI, V261, P17, DOI 10.1016/j.memsci.2005.02.019
   Kelman S, 2007, J MEMBRANE SCI, V305, P57, DOI 10.1016/j.memsci.2007.07.035
   Knebel A, 2017, SCIENCE, V358, P347, DOI 10.1126/science.aal2456
   Koros WJ, 2017, NAT MATER, V16, P289, DOI [10.1038/NMAT4805, 10.1038/nmat4805]
   Lee MJ, 2018, ANGEW CHEM INT EDIT, V57, P156, DOI 10.1002/anie.201708924
   Li KH, 2009, J AM CHEM SOC, V131, P10368, DOI 10.1021/ja9039983
   Li SZ, 2015, NANOSCALE, V7, P7482, DOI 10.1039/c5nr00518c
   Li T, 2013, J MEMBRANE SCI, V425, P235, DOI 10.1016/j.memsci.2012.09.006
   Li YF, 2014, ENERG ENVIRON SCI, V7, P1489, DOI 10.1039/c3ee43163k
   Lin HQ, 2006, SCIENCE, V311, P639, DOI 10.1126/science.1118079
   Lin HQ, 2005, MACROMOLECULES, V38, P8381, DOI 10.1021/ma0510136
   Liu JQ, 2009, J MEMBRANE SCI, V343, P157, DOI 10.1016/j.memsci.2009.07.018
   Lively RP, 2017, NAT MATER, V16, P276, DOI 10.1038/nmat4860
   Ma XL, 2018, SCIENCE, V361, P1008, DOI 10.1126/science.aat4123
   Nafisi V, 2014, J MEMBRANE SCI, V459, P244, DOI 10.1016/j.memsci.2014.02.002
   Pan YC, 2011, CHEM COMMUN, V47, P2071, DOI 10.1039/c0cc05002d
   Park HB, 2017, SCIENCE, V356, DOI 10.1126/science.aab0530
   Rezakazemi M, 2014, PROG POLYM SCI, V39, P817, DOI 10.1016/j.progpolymsci.2014.01.003
   Rittigstein P, 2007, NAT MATER, V6, P278, DOI 10.1038/nmat1870
   Robeson LM, 2008, J MEMBRANE SCI, V320, P390, DOI 10.1016/j.memsci.2008.04.030
   Rodenas T, 2015, NAT MATER, V14, P48, DOI [10.1038/NMAT4113, 10.1038/nmat4113]
   Rodenas T, 2014, ADV FUNCT MATER, V24, P249, DOI 10.1002/adfm.201203462
   Sanchez-Lainez J, 2016, J MATER CHEM A, V4, P14334, DOI 10.1039/c6ta06438h
   Sanchez-Lainez J, 2015, J MATER CHEM A, V3, P6549, DOI 10.1039/c4ta06820c
   Seoane B, 2015, CHEM SOC REV, V44, P2421, DOI 10.1039/c4cs00437j
   Shah M, 2012, IND ENG CHEM RES, V51, P2179, DOI 10.1021/ie202038m
   Sheng LQ, 2017, CHEM COMMUN, V53, P7760, DOI 10.1039/c7cc03887a
   Sholl DS, 2016, NATURE, V532, P435, DOI 10.1038/532435a
   Song QL, 2012, ENERG ENVIRON SCI, V5, P8359, DOI 10.1039/c2ee21996d
   Su NC, 2016, ENERG ENVIRON SCI, V9, P922, DOI 10.1039/c5ee02660a
   Su NC, 2015, CHEM MATER, V27, P2421, DOI 10.1021/cm504463c
   Sutrisna PD, 2017, J MEMBRANE SCI, V524, P266, DOI 10.1016/j.memsci.2016.11.048
   Thornton AW, 2012, ENERG ENVIRON SCI, V5, P7637, DOI 10.1039/c2ee21743k
   Vu DQ, 2003, J MEMBRANE SCI, V211, P311, DOI 10.1016/S0376-7388(02)00429-5
   Wang SF, 2016, ENERG ENVIRON SCI, V9, P1863, DOI 10.1039/c6ee00811a
   Wang ZG, 2016, ADV MATER, V28, P3399, DOI 10.1002/adma.201504982
   Xiang L, 2017, ADV MATER, V29, DOI 10.1002/adma.201606999
   Xiang L, 2017, CHEM ENG SCI, V160, P236, DOI 10.1016/j.ces.2016.11.037
   Xiang L, 2016, J MEMBRANE SCI, V500, P66, DOI 10.1016/j.memsci.2015.11.017
   Xin QP, 2015, ACS APPL MATER INTER, V7, P1065, DOI 10.1021/am504742q
   Yu J, 2018, CHEM ENG SCI, V179, P1, DOI 10.1016/j.ces.2017.12.051
   Zhang C, 2012, J PHYS CHEM LETT, V3, P2130, DOI 10.1021/jz300855a
   Zhang C, 2012, J MEMBRANE SCI, V389, P34, DOI 10.1016/j.memsci.2011.10.003
   Zhang YY, 2016, INORG CHEM FRONT, V3, P896, DOI 10.1039/c6qi00042h
   Zhou S, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau1393
   Zornoza B, 2011, CHEM COMMUN, V47, P9522, DOI 10.1039/c1cc13431k
NR 68
TC 6
Z9 6
U1 51
U2 193
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 151
EP 160
DI 10.1016/j.ces.2019.04.032
PG 10
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600014
DA 2020-05-12
ER

PT J
AU Engh, M
   Solsvik, J
   Jakobsen, HA
AF Engh, Mathias
   Solsvik, Jannike
   Jakobsen, Hugo A.
TI An hp-adaptive quadrature method for irregular integrands: Application
   to the population balance equation birth term
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Population balance; Adaptive quadrature; hp-adaptive; Weighted residual
   methods; Bubble column; Multiphase flow
ID LEAST-SQUARES; MODEL; COALESCENCE; SIMULATION; FLOWS
AB The solution of the population balance equation requires the integration of several source terms. In the numerical weighted residuals methods, Gaussian quadrature is a natural candidate for numerical integration. Previous works using the weighted residuals methods for solving the population balance equation did use a fixed grid of quadrature points. This work shows that the use of adaptive quadrature points for the numerical integration can lead to more efficient and accurate solutions of the equation. For cases where the integrand shows a high degree of irregularity, the hp-optimization method distributes the quadrature points such that the method becomes more efficient than with a fixed grid. An additional improvement is that the amount of quadrature points changes to fit the need for each integral present, rather than having one set of quadrature points for all cases. A simple population balance model demonstrates the use of the adaptive quadrature approach. (C)2019 Elsevier Ltd. All rights reserved.
C1 [Engh, Mathias; Solsvik, Jannike; Jakobsen, Hugo A.] Norwegian Univ Sci & Technol, Dept Chem Engn, N-7491 Trondheim, Norway.
RP Engh, M (reprint author), Norwegian Univ Sci & Technol, Dept Chem Engn, N-7491 Trondheim, Norway.
EM mathias.engh@ntnu.no; jannike.solsvik@ntnu.no; hugo.a.jakobsen@ntnu.no
FU program "NTNU Biotechnology - the confluence of Life Sciences,
   Mathematical Sciences and Engineering"
FX This work was supported by the program "NTNU Biotechnology - the
   confluence of Life Sciences, Mathematical Sciences and Engineering" (M.
   Engh).
CR Attarakih M., 2018, 6 INT C POP BAL MOD
   Attarakih MM, 2009, CHEM ENG SCI, V64, P742, DOI 10.1016/j.ces.2008.05.006
   Canuto C, 2006, SCIENTIF COMPUT
   COULALOGLOU CA, 1977, CHEM ENG SCI, V32, P1289, DOI 10.1016/0009-2509(77)85023-9
   Dorao CA, 2008, APPL NUMER MATH, V58, P563, DOI 10.1016/j.apnum.2006.12.005
   Dorao C. A., 2006, THESIS
   Finlayson B. A., 1966, APPL MECH REV, P735
   GOLUB GH, 1969, MATH COMPUT, V23, P221, DOI 10.2307/2004418
   Hale N, 2013, SIAM J SCI COMPUT, V35, pA652, DOI 10.1137/120889873
   Houston P, 2005, COMPUT METHOD APPL M, V194, P229, DOI 10.1016/j.cma.2004.04.009
   Houston P., 2003, ADV APPL, P619, DOI DOI 10.1007/978-88-470-2089-4_58
   Jakobsen HA, 2014, CHEM REACTOR MODELIN, DOI [10.1007/978-3-319-05092-8, DOI 10.1007/978-3-319-05092-8]
   Karniadakis George E., 2013, SPECTRAL HP ELEMENT, DOI [10.1093/acprof:oso/9780198528692.001.0001, DOI 10.1093/ACPROF:OSO/9780198528692.001.0001]
   Kumar S, 1996, CHEM ENG SCI, V51, P1311, DOI 10.1016/0009-2509(96)88489-2
   Marchisio D.L, 2013, COMPUTATIONAL MODELS
   Marchisio DL, 2005, J AEROSOL SCI, V36, P43, DOI 10.1016/j.jaerosci.2004.07.009
   Martinez-Bazan C, 2010, J FLUID MECH, V661, P159, DOI 10.1017/S0022112010003186
   McGraw R, 1997, AEROSOL SCI TECH, V27, P255, DOI 10.1080/02786829708965471
   Mead L. R., 1984, J MATH PHYS, V2404
   Nayak AK, 2011, IND ENG CHEM RES, V50, P1786, DOI 10.1021/ie101664w
   Nguyen TT, 2016, J COMPUT PHYS, V325, P129, DOI 10.1016/j.jcp.2016.08.017
   Pigou M., 2018, 6 INT C POP BAL MOD
   PRINCE MJ, 1990, AICHE J, V36, P1485, DOI 10.1002/aic.690361004
   Quarteroni A., 2012, NUMERICAL MODELS DIF, DOI [10.1007/978-88-470-5522-3, DOI 10.1007/978-88-470-5522-3]
   RAMKRISHNA D, 2000, POPULATION BALANCES
   Solsvik J, 2017, J DISPER SCI TECHNOL, V38, P973, DOI 10.1080/01932691.2016.1216440
   Solsvik J, 2016, J DISPER SCI TECHNOL, V37, P80, DOI 10.1080/01932691.2015.1028550
   Solsvik J, 2013, IND ENG CHEM RES, V52, P15988, DOI 10.1021/ie402033b
   Solsvik J, 2013, REV CHEM ENG, V29, P241, DOI 10.1515/revce-2013-0009
   Solsvik J, 2013, REV CHEM ENG, V29, P63, DOI 10.1515/revce-2012-0018
   Vik CB, 2018, COMPUT CHEM ENG, V110, P115, DOI 10.1016/j.compchemeng.2017.11.023
   Wulkow M, 2001, CHEM ENG SCI, V56, P2575, DOI 10.1016/S0009-2509(00)00432-2
   Yaghini N, 2014, CHEM ENG SCI, V116, P144, DOI 10.1016/j.ces.2014.04.039
   Yuan C, 2012, J AEROSOL SCI, V51, P1, DOI 10.1016/j.jaerosci.2012.04.003
   Yuan C, 2011, J COMPUT PHYS, V230, P8216, DOI 10.1016/j.jcp.2011.07.020
   Zhu ZJ, 2008, MATH COMPUT SIMULAT, V79, P716, DOI 10.1016/j.matcom.2008.05.001
NR 36
TC 1
Z9 1
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 161
EP 176
DI 10.1016/j.ces.2019.03.083
PG 16
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600015
DA 2020-05-12
ER

PT J
AU Tang, Q
   Qin, XY
   Dong, HF
   Zhang, XP
   Wang, XD
   Wang, KS
AF Tang, Qi
   Qin, Xueying
   Dong, Haifeng
   Zhang, Xiangping
   Wang, Xiaodong
   Wang, Kuisheng
TI Novel drag coefficient models of ionic liquid - spherical particle
   system
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Drag coefficient (C-D); Ionic liquids (ILs); Particle; Correlation;
   Interfacial tension
ID NUMERICAL-SIMULATION; REYNOLDS-NUMBER; BUBBLE BEHAVIOR; CAPTURE SYSTEMS;
   CARBON CAPTURE; SINGLE-BUBBLE; MASS-TRANSFER; GAS-BUBBLES; FLOW; CO2
AB Ionic liquids (ILs) have been proved to be excellently potential catalysts and solvents in a few chemical processes. In order to provide fundamental data for the reactor design and process optimization, it is essential to investigate the hydrodynamics and the mass transfer phenomena of liquid-solid twophase systems containing ILs. In this work, we focus on the investigation of the hydrodynamic properties of a spherical particle in ILs, and a series of experiments are implemented in a cylindrical bubble column with three different diameters of spherical particles made of borosilicate glass (2 mm, 3 mm and 4 mm) in three kinds of ILs ([Bmim][BE4], [Bmim][PF6] and [Bmim][Tf2N]). Moreover, Two key physical quantities (terminal velocity of particle and contact angle) are measured with a high-speed camera system and an automatic contact angle meter. Based on dimensional analysis, two novel empirical models of the drag coefficient (C-D) between a spherical particle and ILs are developed in the range of particle's Reynolds number (Re) from 0.1 to 85. The first model is simple and the calculated C-D agrees fairly well with the experimental data. Furthermore, in order to evaluate the effects of surface properties on C-D, a newly defined dimensionless number (Mo') is introduced into IL-particle flow studies for the first time, which comes into being a more rigorous model. The average predicted deviations of the two models are +/- 1.1% and +/- 1.5% respectively, which is much lower than that of contrastive models in the same situations (about 13.3% or more). These two models are significant for studying the hydrodynamics and mass transfer characteristics of IL-particle systems as well as the fluid dynamics simulation in related reactors. (C) 2019 Published by Elsevier Ltd.
C1 [Tang, Qi; Qin, Xueying; Dong, Haifeng; Zhang, Xiangping] Chinese Acad Sci, Inst Proc Engn, Beijing 100190, Peoples R China.
   [Tang, Qi; Wang, Kuisheng] Beijing Univ Chem Technol, Coll Mech Elect & Elect Engn, Beijing 100029, Peoples R China.
   [Zhang, Xiangping; Wang, Xiaodong] Univ Chinese Acad Sci, Beijing 100190, Peoples R China.
   [Qin, Xueying] China Univ Petr, Coll Chem Engn, Beijing 102249, Peoples R China.
   [Zhang, Xiangping] Dalian Natl Lab Clean Energy, Dalian 116023, Peoples R China.
RP Zhang, XP (reprint author), Chinese Acad Sci, Inst Proc Engn, Beijing 100190, Peoples R China.; Wang, KS (reprint author), Beijing Univ Chem Technol, Coll Mech Elect & Elect Engn, Beijing 100029, Peoples R China.
EM xpzhang@ipe.ac.cn; wangks@mail.buct.edu.cn
OI Zeng, Shaojuan/0000-0002-0070-6711
FU National Key Projects for Fundamental Research and Development of China
   [2018YFB0605802]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [21838010, 21676271, 21776277];
   Instrument Developing Project of the Chinese Academy of Sciences
   [YZ201567]; DNL Cooperation Fund, CAS [DNL180406]; Beijing hundreds of
   leading talents training project of science and technology
   [Z171100001117154]
FX This work was financially supported by the National Key Projects for
   Fundamental Research and Development of China (2018YFB0605802), the
   National Natural Science Foundation of China (No. 21838010, 21676271,
   21776277), the Instrument Developing Project of the Chinese Academy of
   Sciences (No. YZ201567), the DNL Cooperation Fund, CAS (DNL180406) and
   the Beijing hundreds of leading talents training project of science and
   technology (No. Z171100001117154).
CR Agudo JR, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4874604
   Agudo JR, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.4753941
   Ali MF, 2018, CHEM ENG RES DES, V129, P356, DOI 10.1016/j.cherd.2017.11.034
   Alvarez-Guerra M, 2015, ENERG ENVIRON SCI, V8, P2574, DOI 10.1039/c5ee01486g
   Bao D, 2018, CHEM ENG PROCESS, V125, P266, DOI 10.1016/j.cep.2018.02.012
   Bao D, 2015, CHEM ENG SCI, V135, P76, DOI 10.1016/j.ces.2015.06.035
   Barati R, 2014, POWDER TECHNOL, V257, P11, DOI 10.1016/j.powtec.2014.02.045
   Beetstra R, 2007, AICHE J, V53, P489, DOI 10.1002/aic.11065
   Carvajal D, 2015, CHEM ENG TECHNOL, V38, P473, DOI 10.1002/ceat.201400449
   Clift R., 1978, BUBBLES DROPS PARTIC
   da Silva NMP, 2014, CHEM ENG TECHNOL, V37, P1929, DOI 10.1002/ceat.201400028
   DALLAVALLE JM, 1948, MICROMERITICS
   Dong HF, 2010, CHEM ENG SCI, V65, P3240, DOI 10.1016/j.ces.2010.02.011
   FLEMMER RLC, 1986, POWDER TECHNOL, V48, P217, DOI 10.1016/0032-5910(86)80044-4
   Huang Y, 2014, IND ENG CHEM RES, V53, P15270, DOI 10.1021/ie502571b
   Kelbaliyev G, 2007, CHEM ENG COMMUN, V194, P1623, DOI 10.1080/00986440701446128
   Kreith E. F., 1999, MECH ENG HDB
   Luo X., 2007, SCI TECHNOL ENG, V7, P4997
   MEI R, 1992, PHYS FLUIDS A-FLUID, V4, P63, DOI 10.1063/1.858501
   Meiron TS, 2004, J COLLOID INTERF SCI, V274, P637, DOI 10.1016/j.jcis.2004.02.036
   Mikhailov MD, 2013, POWDER TECHNOL, V237, P432, DOI 10.1016/j.powtec.2012.12.033
   Mo JY, 2015, AICHE J, V61, P1455, DOI 10.1002/aic.14756
   Okuno M, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2353808
   Ouyang ZL, 2015, SCI CHINA CHEM, V58, P1918, DOI 10.1007/s11426-015-5446-2
   Rodrigue D, 2001, CAN J CHEM ENG, V79, P119, DOI 10.1002/cjce.5450790118
   Rosen BA, 2011, SCIENCE, V334, P643, DOI 10.1126/science.1209786
   Schiller L, 1933, Z VER DTSCH ING, V77, P318
   Sui T, 2011, J COLLOID INTERF SCI, V358, P284, DOI 10.1016/j.jcis.2011.02.060
   ten Cate A, 2002, PHYS FLUIDS, V14, P4012, DOI 10.1063/1.1512918
   Tomiyama A, 1998, MULTIPHASE SCIENCE AND TECHNOLOGY, VOL 10 ISSUE 4 1998, P369
   Tomiyama A., 2004, P 3 INT S 2 PHAS FLO, P22
   TURTON R, 1986, POWDER TECHNOL, V47, P83, DOI 10.1016/0032-5910(86)80012-2
   Wang C, 2018, CHEM ENG RES DES, V132, P831, DOI 10.1016/j.cherd.2018.02.035
   Wang Q, 2015, ACS SUSTAIN CHEM ENG, V3, P340, DOI 10.1021/sc5007522
   Wang XL, 2010, CHEM ENG TECHNOL, V33, P1615, DOI 10.1002/ceat.201000009
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Zeng SJ, 2017, CHEM REV, V117, P9625, DOI 10.1021/acs.chemrev.7b00072
   Zeng SJ, 2015, IND ENG CHEM RES, V54, P10854, DOI 10.1021/acs.iecr.5b01807
   Zhang XP, 2012, ENERG ENVIRON SCI, V5, P6668, DOI 10.1039/c2ee21152a
   Zhang X, 2014, AICHE J, V60, P2929, DOI 10.1002/aic.14507
   Zhang X, 2012, CHEM ENG J, V209, P607, DOI 10.1016/j.cej.2012.08.047
   Zhao YS, 2015, PHYS CHEM CHEM PHYS, V17, P3761, DOI 10.1039/c4cp04712e
   Zhu D.Y., 2007, SCI TECHNOL ENG, V7, P3063
NR 43
TC 0
Z9 0
U1 10
U2 49
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 177
EP 185
DI 10.1016/j.ces.2019.04.017
PG 9
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600016
DA 2020-05-12
ER

PT J
AU Klein, M
   Zenker, C
   Schmidt, H
AF Klein, Marten
   Zenker, Christian
   Schmidt, Heiko
TI Small-scale resolving simulations of the turbulent mixing in confined
   planar jets using one-dimensional turbulence
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE High Schmidt number; One-dimensional turbulence; Passive scalar; Planar
   jet; Turbulent mixing
ID MODEL FORMULATION; PASSIVE SCALARS; INFLOW DATA; LAYER; GENERATION;
   TRANSPORT; FLOW
AB Small-scale effects of turbulent mixing are numerically investigated by applying the map-based, stochastic, one-dimensional turbulence (ODT) model to confined planar jets. The model validation is carried out for the momentum transport by comparing ODT results to available reference data for the bulk Reynolds numbers Re = 20, 000 and 40, 000. Various pointwise statistical quantities are computed and compared to the available reference data. We show that these quantities can be captured well, or at least to a reasonable extent, by the stand-alone model formulation and for fixed model parameters. Only the rootmean-square velocity fluctuations remain systematically underestimated in the ODT results (by an approximate factor of 1.5). Afterwards, the turbulent transport of a passive scalar is addressed for the Schmidt numbers Sc = 1 and 1250. For the high Schmidt number and in contrast to the velocity fluctuations, it is shown that the scalar fluctuation variance is up to ten times larger in the ODT simulations resolving the Batchelor scale. The fluctuation variance is notably smaller for the lower Schmidt number, but exhibits better agreement with the references at a nominally higher Schmidt number. We suggest that this is due to implicit filtering in the references, which barely resolve the Kolmogorov scale. ODT turbulence spectra support this interpretation since a Batchelor-like scalar turbulence spectrum is only observed for the higher Schmidt number. With the aid of these spectra and the fluctuation statistics we conclude that implicit filtering has a similar effect as a reduction of the Schmidt number. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Klein, Marten; Zenker, Christian; Schmidt, Heiko] Brandenburg Tech Univ BTU Cottbus Senftenberg, Lehrstuhl Numer Stromungs & Gasdynam, Siemens Halske Ring 14, D-03046 Cottbus, Germany.
RP Klein, M (reprint author), Brandenburg Tech Univ BTU Cottbus Senftenberg, Lehrstuhl Numer Stromungs & Gasdynam, Siemens Halske Ring 14, D-03046 Cottbus, Germany.
EM marten.klein@b-tu.de
OI Klein, Marten/0000-0003-0609-8961
FU European Regional Development Funds (EFRE)European Union (EU) [StaF
   23035000]; Federal Ministry of Education and Research (BMBF)Federal
   Ministry of Education & Research (BMBF) [PPP-USA-2017, 57316240];
   Mobility Grant `` Research Stay Abroad"from the Graduate Research School
   (GRS) of the BTU Cottbus-Senftenberg; German Academic Exchange Service
   (DAAD)Deutscher Akademischer Austausch Dienst (DAAD)
FX This work has been partly supported by the European Regional Development
   Funds (EFRE), Grant No. StaF 23035000; the German Academic Exchange
   Service (DAAD), which is funded by the Federal Ministry of Education and
   Research (BMBF), Grant No. PPP-USA-2017 (ID-57316240); and by a Mobility
   Grant `` Research Stay Abroad"from the Graduate Research School (GRS) of
   the BTU Cottbus-Senftenberg.
CR Adrian RJ, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2717527
   Arshad S, 2018, INT J NUMER METHOD H, V28, P2463, DOI 10.1108/HFF-09-2017-0387
   Ashurst WT, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1847413
   Ashurst WT, 2003, PHYS FLUIDS, V15, P579, DOI 10.1063/1.1531994
   BATCHELOR GK, 1959, J FLUID MECH, V5, P113, DOI 10.1017/S002211205900009X
   BOUSSINESQ J, 2003, THEORIE ANAL CHALEUR, V2
   Brethouwer G, 2018, J FLUID MECH, V844, P297, DOI 10.1017/jfm.2018.198
   Donzis DA, 2010, FLOW TURBUL COMBUST, V85, P549, DOI 10.1007/s10494-010-9271-6
   Dreeben TD, 2000, INT J HEAT MASS TRAN, V43, P3823, DOI 10.1016/S0017-9310(00)00012-0
   Echekki T, 2001, COMBUST FLAME, V125, P1083, DOI 10.1016/S0010-2180(01)00228-0
   Feng H, 2005, AICHE J, V51, P2649, DOI 10.1002/aic.10527
   Ferziger J.H., 2002, COMPUTATIONAL METHOD
   Fragner MM, 2017, J TURBUL, V18, P899, DOI 10.1080/14685248.2017.1335869
   Giddey V, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5055752
   Glawe C, 2018, ZAMM-Z ANGEW MATH ME, V98, P1907, DOI 10.1002/zamm.201800098
   Gonzalez-Juez ED, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3664123
   Gotoh T, 2012, PHYSICA D, V241, P141, DOI 10.1016/j.physd.2010.12.009
   Hewson JC, 2001, COMBUST THEOR MODEL, V5, P669, DOI 10.1088/1364-7830/5/4/309
   Kerstein AR, 2006, BOUND-LAY METEOROL, V118, P325, DOI 10.1007/s10546-005-9004-x
   Kerstein AR, 2001, J FLUID MECH, V447, P85, DOI 10.1017/SO022112001005778
   Kerstein AR, 1999, J FLUID MECH, V392, P277, DOI 10.1017/S0022112099005376
   Klein Marten, 2018, Proceedings in Applied Mathematics and Mechanics, V18, DOI 10.1002/pamm.201800238
   Klein M, 2003, J COMPUT PHYS, V186, P652, DOI 10.1016/S0021-9991(03)00090-1
   Klein M., 2017, P 10 INT S TURB SHEA, V1
   Kolmogorov A., 1941, DOKL AKAD NAUK SSSR, V30, P299, DOI DOI 10.1098/RSPA.1991.0075
   Kong B, 2012, CHEM ENG SCI, V69, P240, DOI 10.1016/j.ces.2011.10.042
   LAM K, 1992, PHYS FLUIDS A-FLUID, V4, P306, DOI 10.1063/1.858306
   Lee M, 2015, J FLUID MECH, V774, P395, DOI 10.1017/jfm.2015.268
   Lignell DO, 2013, THEOR COMP FLUID DYN, V27, P273, DOI 10.1007/s00162-012-0267-9
   Lund TS, 1998, J COMPUT PHYS, V140, P233, DOI 10.1006/jcph.1998.5882
   Modesti D, 2018, J FLUID MECH, V847, DOI 10.1017/jfm.2018.391
   Monson EI, 2016, FIRE TECHNOL, V52, P167, DOI 10.1007/s10694-014-0441-2
   Pope S. B., 2000, TURBULENT FLOWS
   Press W. H., 2007, NUMERICAL RECIPES AR
   Schmidt RC, 2003, J COMPUT PHYS, V186, P317, DOI 10.1016/S0021-9991(03)00071-8
   Schulz FT, 2013, ENVIRON EARTH SCI, V70, P3739, DOI 10.1007/s12665-013-2461-5
   Smagorinsky J., 1963, MON WEATHER REV, V91, P99, DOI [10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)091, 10.1175/1520-0493(1963)091<less than>0099:GCEWTP<greater than>2.3.CO;2]
   Vinuesa R, 2018, PHYS REV FLUIDS, V3, DOI 10.1103/PhysRevFluids.3.054606
   Warhaft Z, 2000, ANNU REV FLUID MECH, V32, P203, DOI 10.1146/annurev.fluid.32.1.203
   Wunsch S, 2005, J FLUID MECH, V528, P173, DOI 10.1017/S0022112004003258
NR 40
TC 1
Z9 1
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 186
EP 202
DI 10.1016/j.ces.2019.04.024
PG 17
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600017
DA 2020-05-12
ER

PT J
AU Lu, JT
   Peters, EAJF
   Kuipers, JAM
AF Lu, Jiangtao
   Peters, E. A. J. F.
   Kuipers, J. A. M.
TI Direct numerical simulation of fluid flow and dependently coupled heat
   and mass transfer in fluid-particle systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Immersed boundary method; Gas-solid system; Surface reaction; Coupled
   heat and mass transfer; Damkohler number; Arrhenius equation
ID IMMERSED BOUNDARY METHOD; DISCRETIZED BOLTZMANN-EQUATION; CARTESIAN GRID
   METHOD; PARTICULATE SUSPENSIONS; TRANSFER COEFFICIENTS; BIOMASS
   GASIFICATION; SPHERICAL-PARTICLES; PARTIAL OXIDATION; BED REACTORS;
   METHOD IBM
AB In this paper, an efficient ghost-cell based immersed boundary method (IBM) is used to perform direct numerical simulation (DNS) of reactive fluid-particle systems. With an exothermic first order reaction proceeding at the exterior particle surface, the solid temperature rises and consequently increases the reaction rate via an Arrhenius temperature dependence. In other words, the heat and mass transport is dependently coupled through the particle thermal energy equation and the Arrhenius equation, and they offer dynamic boundary conditions for the fluid phase thermal energy equation and species equation respectively. The fluid-solid coupling is enforced at the exact position of the particle surface by implicit incorporation of the boundary conditions into the discretized momentum, species and thermal energy conservation equations of the fluid phase. Different fluid-particle systems are studied with increasing complexity: a single sphere, three spheres and a dense array consisting of hundreds of randomly generated particles. In these systems the mutual impacts between heat and mass transport processes are investigated. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lu, Jiangtao; Peters, E. A. J. F.; Kuipers, J. A. M.] Eindhoven Univ Technol, Dept Chem Engn & Chem, Multiphase Reactors Grp, POB 513, NL-5600 MB Eindhoven, Netherlands.
RP Peters, EAJF (reprint author), Eindhoven Univ Technol, Dept Chem Engn & Chem, Multiphase Reactors Grp, POB 513, NL-5600 MB Eindhoven, Netherlands.
EM E.A.J.F.Peters@tue.nl
RI Peters, Frank/V-1293-2018
OI Peters, Frank/0000-0001-6099-3583; Lu, Jiangtao/0000-0003-3340-942X
FU Netherlands Center for Multiscale Catalytic Energy Conversion (MCEC) an
   NWO Gravitation programme - Ministry of Education, Culture and Science
   of the government of the Netherlands; SURF Cooperative
FX This work was supported by the Netherlands Center for Multiscale
   Catalytic Energy Conversion (MCEC), an NWO Gravitation programme funded
   by the Ministry of Education, Culture and Science of the government of
   the Netherlands.; This work was carried out on the Dutch national
   e-infrastructure with the support of SURF Cooperative.
CR Abdelsamie A, 2016, COMPUT FLUIDS, V131, P123, DOI 10.1016/j.compfluid.2016.03.017
   Akiki G, 2016, PHYS REV FLUIDS, V1, DOI 10.1103/PhysRevFluids.1.044202
   Boukharfane R, 2018, COMPUT FLUIDS, V162, P91, DOI 10.1016/j.compfluid.2017.11.018
   CHESSHIRE G, 1990, J COMPUT PHYS, V90, P1, DOI 10.1016/0021-9991(90)90196-8
   Das S, 2017, AICHE J, V63, P1152, DOI 10.1002/aic.15487
   Deen NG, 2014, CHEM ENG SCI, V116, P645, DOI 10.1016/j.ces.2014.05.036
   Deen NG, 2013, IND ENG CHEM RES, V52, P11266, DOI 10.1021/ie303411k
   Deen NG, 2012, CHEM ENG SCI, V81, P329, DOI 10.1016/j.ces.2012.06.055
   DeGroote AM, 1996, APPL CATAL A-GEN, V138, P245, DOI 10.1016/0926-860X(95)00299-5
   Di SB, 2015, PARTICUOLOGY, V18, P22, DOI 10.1016/j.partic.2014.05.004
   Dixon AG, 2017, CHEM ENG SCI, V168, P156, DOI 10.1016/j.ces.2017.04.039
   Fadlun EA, 2000, J COMPUT PHYS, V161, P35, DOI 10.1006/jcph.2000.6484
   Feng ZG, 2000, INT J HEAT MASS TRAN, V43, P219, DOI 10.1016/S0017-9310(99)00133-7
   Feng ZG, 2009, INT J HEAT MASS TRAN, V52, P777, DOI 10.1016/j.ijheatmasstransfer.2008.07.023
   Ghias R, 2007, J COMPUT PHYS, V225, P528, DOI 10.1016/j.jcp.2006.12.007
   GOLDSTEIN D, 1993, J COMPUT PHYS, V105, P354, DOI 10.1006/jcph.1993.1081
   Gonga XB, 2014, J COMPUT PHYS, V278, P148, DOI 10.1016/j.jcp.2014.08.025
   GUNN DJ, 1978, INT J HEAT MASS TRAN, V21, P467, DOI 10.1016/0017-9310(78)90080-7
   Holloway W, 2012, CHEM ENG SCI, V82, P132, DOI 10.1016/j.ces.2012.07.019
   Hu HH, 2001, J COMPUT PHYS, V169, P427, DOI 10.1006/jcph.2000.6592
   HUGHMARK GA, 1980, IND ENG CHEM FUND, V19, P198, DOI 10.1021/i160074a012
   Jackson R, 1997, CHEM ENG SCI, V52, P2457, DOI 10.1016/S0009-2509(97)00065-1
   Kim J, 2001, J COMPUT PHYS, V171, P132, DOI 10.1006/jcph.2001.6778
   Kim SD, 1997, CHEM ENG SCI, V52, P3639, DOI 10.1016/S0009-2509(97)00269-8
   Kravets B, 2017, POWDER TECHNOL, V318, P293, DOI 10.1016/j.powtec.2017.05.039
   Ku XK, 2015, CHEM ENG SCI, V122, P270, DOI 10.1016/j.ces.2014.08.045
   KUMAR S, 1994, AICHE J, V40, P745, DOI 10.1002/aic.690400502
   LADD AJC, 1994, J FLUID MECH, V271, P311, DOI 10.1017/S0022112094001783
   LADD AJC, 1994, J FLUID MECH, V271, P285, DOI 10.1017/S0022112094001771
   Link JM, 2005, CHEM ENG SCI, V60, P3425, DOI 10.1016/j.ces.2005.01.027
   Liu C, 2014, J COMPUT PHYS, V274, P654, DOI 10.1016/j.jcp.2014.06.042
   Lu JT, 2019, CHEM ENG SCI, V198, P317, DOI 10.1016/j.ces.2018.08.046
   Lu JT, 2018, IND ENG CHEM RES, V57, P15565, DOI 10.1021/acs.iecr.8b03158
   Lu JT, 2018, IND ENG CHEM RES, V57, P4664, DOI 10.1021/acs.iecr.8b00268
   Lu JT, 2018, CHEM ENG SCI, V176, P1, DOI 10.1016/j.ces.2017.10.018
   Marella S, 2005, J COMPUT PHYS, V210, P1, DOI 10.1016/j.jcp.2005.03.031
   Melchiori T, 2014, APPL CATAL A-GEN, V486, P239, DOI 10.1016/j.apcata.2014.08.040
   Mittal R, 2008, J COMPUT PHYS, V227, P4825, DOI 10.1016/j.jcp.2008.01.028
   MOHDYUSOF J, 1997, COMBINED IMMERSED BO, P317
   PESKIN CS, 1977, J COMPUT PHYS, V25, P220, DOI 10.1016/0021-9991(77)90100-0
   Richter A, 2012, INT J HEAT MASS TRAN, V55, P1343, DOI 10.1016/j.ijheatmasstransfer.2011.09.005
   Saiki EM, 1996, J COMPUT PHYS, V123, P450, DOI 10.1006/jcph.1996.0036
   Schulze S, 2017, FUEL, V207, P655, DOI 10.1016/j.fuel.2017.05.071
   Takeuchi S, 2010, INT J NUMER METH FL, V64, P1084, DOI 10.1002/fld.2272
   Tenneti S, 2013, INT J HEAT MASS TRAN, V58, P471, DOI 10.1016/j.ijheatmasstransfer.2012.11.006
   Tseng YH, 2003, J COMPUT PHYS, V192, P593, DOI 10.1016/j.jcp.2003.07.024
   Udaykumar HS, 2001, J COMPUT PHYS, V174, P345, DOI 10.1006/jcph.2001.6916
   Uhlmann M, 2005, J COMPUT PHYS, V209, P448, DOI 10.1016/j.jcp.2005.03.017
   Validi A, 2017, COMBUST FLAME, V186, P65, DOI 10.1016/j.combustflame.2017.07.032
   Vanella M, 2009, J COMPUT PHYS, V228, P6617, DOI 10.1016/j.jcp.2009.06.003
   Wagner I, 1997, IND ENG CHEM RES, V36, P227, DOI 10.1021/ie9600194
   WAKAO N, 1978, CHEM ENG SCI, V33, P1375, DOI 10.1016/0009-2509(78)85120-3
   Wehinger GD, 2015, CHEM ENG SCI, V122, P197, DOI 10.1016/j.ces.2014.09.007
   Xia JJ, 2015, INT J HEAT MASS TRAN, V89, P856, DOI 10.1016/j.ijheatmasstransfer.2015.05.098
   Xu Y, 2013, CHEM ENG SCI, V104, P201, DOI 10.1016/j.ces.2013.09.023
   Xue Q, 2014, POWDER TECHNOL, V254, P187, DOI 10.1016/j.powtec.2014.01.025
   Zhuang YQ, 2014, COMPUT CHEM ENG, V60, P1, DOI 10.1016/j.compchemeng.2013.08.007
NR 57
TC 3
Z9 2
U1 7
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 203
EP 219
DI 10.1016/j.ces.2019.02.043
PG 17
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600018
DA 2020-05-12
ER

PT J
AU Yang, LP
   Song, JJ
   Zhang, LH
   Li, HY
   Yang, Y
   Shen, SQ
AF Yang, Luopeng
   Song, Jiajun
   Zhang, Linhua
   Li, Hongyou
   Yang, Yan
   Shen, Shengqiang
TI Microscopic mechanisms of wave effect on heat transfer enhancement in
   condensate films
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Wave; Heat transfer enhancement; Normal velocity; Condensate film;
   Hydrodynamic behavior
ID FALLING LIQUID-FILM; NUMERICAL-SIMULATION; MASS-TRANSFER; FLOW;
   TEMPERATURE; THICKNESS; HYDRODYNAMICS; EVOLUTION; SURFACE
AB In order to deeply understand the inherent links between hydrodynamic behaviors and heat transfer enhancement in wavy condensate films, a numerical model using a non-orthogonal coordinate transformation was developed to simulate the evolution of wavy films. A sinusoidal disturbance was introduced by a fictitious body force to sustain waves. Two major pressure gradients are established at the wave front. One parallel to the stream-wise direction accelerates fluids and the other normal to the wall increases the normal velocity. The temperature profiles prove that both convection and conduction contribute microscopic mechanisms to heat transfer enhancement in the condensate films. The normal velocity close to the wall significantly influences the temperature gradient at the wall. The predicted heat transfer coefficient for the wavy film was found to be 30% greater than the Nusselt solution for the given parameters. Under the given conditions, the effects of film thinning and convection account for 6% and 24% of the heat transfer enhancement, respectively. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Luopeng; Song, Jiajun; Li, Hongyou; Yang, Yan; Shen, Shengqiang] Dalian Univ Technol, Key Lab Ocean Energy Utilizat & Energy Conservat, Minist Educ, Dalian 116024, Peoples R China.
   [Yang, Luopeng; Zhang, Linhua] Shandong Jianzhu Univ, Shandong Key Lab Renewable Energy Technol Bldg, Jinan 250101, Shandong, Peoples R China.
RP Yang, LP (reprint author), Dalian Univ Technol, Key Lab Ocean Energy Utilizat & Energy Conservat, Minist Educ, Dalian 116024, Peoples R China.; Yang, LP (reprint author), Shandong Jianzhu Univ, Shandong Key Lab Renewable Energy Technol Bldg, Jinan 250101, Shandong, Peoples R China.
EM yanglp@dlut.edu.cn
FU National Natural Science Foundation of China, ChinaNational Natural
   Science Foundation of China [51576028]; Fundamental Research Funds for
   the Central Universities, ChinaFundamental Research Funds for the
   Central Universities [DUT17GF206]; China Postdoctoral Science
   Foundation, ChinaChina Postdoctoral Science Foundation [ZX20160052]
FX This work was supported by the National Natural Science Foundation of
   China, China (Grant No. 51576028), the Fundamental Research Funds for
   the Central Universities, China (Grant No. DUT17GF206), and the Project
   funded by China Postdoctoral Science Foundation, China (Grant No.
   ZX20160052).
CR Adomeit P, 2000, INT J MULTIPHAS FLOW, V26, P1183, DOI 10.1016/S0301-9322(99)00079-8
   Adomeit P., 2000, P 3 EUR THERM SCI C
   Aktershev SP, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4816644
   BENJAMIN TB, 1957, J FLUID MECH, V2, P554, DOI 10.1017/S0022112057000373
   Boyack Ch. ad. E, 2002, EXPT NUMERICAL STUDY
   Cao S, 2017, INT J THERM SCI, V115, P197, DOI 10.1016/j.ijthermalsci.2017.01.029
   CHANG HC, 1993, J FLUID MECH, V250, P433, DOI 10.1017/S0022112093001521
   Chard AN, 2018, SUBST USE MISUSE, V53, P42, DOI 10.1080/10826084.2017.1322985
   Charef A, 2017, DESALINATION, V409, P21, DOI 10.1016/j.desal.2017.01.018
   Charogiannis A., 2018, EXP THERM FLUID SCI
   Charogiannis Alexandros, 2018, 3 THERM FLUIDS ENG C, P985
   Chinnov EA, 2012, HIGH TEMP+, V50, P98, DOI 10.1134/S0018151X12010038
   Dietze GF, 2009, J FLUID MECH, V637, P73, DOI 10.1017/S0022112009008155
   Dou B., 2019, ENERGY FUELS
   FAGHRI M, 1984, NUMER HEAT TRANSFER, V7, P183, DOI 10.1080/10407798408546948
   Haroun Y, 2010, CHEM ENG SCI, V65, P2896, DOI 10.1016/j.ces.2010.01.012
   Holmas H, 2010, CHEM ENG SCI, V65, P1811, DOI 10.1016/j.ces.2009.11.031
   Ishikawa H, 2016, CHEM ENG SCI, V149, P104, DOI 10.1016/j.ces.2016.04.021
   Kabov OA, 2002, INT J THERM SCI, V41, P664, DOI 10.1016/S1290-0729(02)01361-3
   Kapitsa P, 1949, ZH EKSPERIMENTALNNOI, V9, P16
   Kunugi T, 2003, FUSION ENG DES, V65, P387, DOI 10.1016/S0920-3796(03)00007-3
   KUTATELADZE SS, 1982, INT J HEAT MASS TRAN, V25, P653, DOI 10.1016/0017-9310(82)90170-3
   Lel VV, 2008, EXP FLUIDS, V44, P341, DOI 10.1007/s00348-007-0408-x
   Li G, 2017, APPL THERM ENG, V123, P1484, DOI 10.1016/j.applthermaleng.2017.05.080
   Liu L, 2017, CHEM ENG SCI, V164, P279, DOI 10.1016/j.ces.2017.02.023
   Markides CN, 2016, INT J HEAT MASS TRAN, V93, P872, DOI 10.1016/j.ijheatmasstransfer.2015.10.062
   Mascarenhas N, 2014, INT J HEAT MASS TRAN, V73, P716, DOI 10.1016/j.ijheatmasstransfer.2014.02.054
   Mendez MA, 2017, CHEM ENG SCI, V170, P122, DOI 10.1016/j.ces.2016.12.050
   Meza CE, 2008, CHEM ENG SCI, V63, P4704, DOI 10.1016/j.ces.2007.12.030
   Miyara A, 2000, INT J THERM SCI, V39, P1015, DOI 10.1016/S1290-0729(00)01192-3
   Moran K, 2002, INT J MULTIPHAS FLOW, V28, P731, DOI 10.1016/S0301-9322(02)00006-X
   Mouza AA, 2005, CHEM ENG SCI, V60, P4981, DOI 10.1016/j.ces.2005.04.014
   Mudawar I, 2012, INT J HEAT MASS TRAN, V55, P11
   NAKAYA C, 1967, J PHYS SOC JPN, V23, P638, DOI 10.1143/JPSJ.23.638
   NUSSELT W, 2016, Z VEREINES DTSCH ING, V541, P569
   Patankar S.V., 1981, NUMER HEAT TRANSFER, V4, P409, DOI DOI 10.1080/01495728108961801
   Piper M, 2015, CHEM ENG SCI, V130, P129, DOI 10.1016/j.ces.2015.03.005
   Quan XY, 2015, CHEM ENG SCI, V135, P52, DOI 10.1016/j.ces.2015.06.055
   Schagen A, 2006, INT J HEAT MASS TRAN, V49, P5049, DOI 10.1016/j.ijheatmasstransfer.2006.06.010
   Serifi K, 2004, INT J THERM SCI, V43, P761, DOI 10.1016/j.ijthermalsci.2004.02.016
   Sisoev GM, 2010, CHEM ENG SCI, V65, P950, DOI 10.1016/j.ces.2009.09.046
   Sisoev GM, 2009, CHEM ENG SCI, V64, P3094, DOI 10.1016/j.ces.2009.03.044
   Sisoev GA, 2005, CHEM ENG SCI, V60, P827, DOI 10.1016/j.ces.2004.09.057
   Talens-Alesson FI, 1999, CHEM ENG SCI, V54, P1871, DOI 10.1016/S0009-2509(98)00497-7
   Wang K, 2017, CHEM ENG SCI, V174, P82, DOI 10.1016/j.ces.2017.08.031
   Wang K, 2013, CHEM ENG SCI, V104, P638, DOI 10.1016/j.ces.2013.09.022
   Wehinger GD, 2013, CHEM ENG SCI, V104, P934, DOI 10.1016/j.ces.2013.10.027
   Xu ZF, 2008, CHEM ENG SCI, V63, P2559, DOI 10.1016/j.ces.2008.02.014
   Yoshimura PN, 1996, CHEM ENG SCI, V51, P1231, DOI 10.1016/0009-2509(95)00387-8
   Zhao CY, 2016, APPL THERM ENG, V103, P177, DOI 10.1016/j.applthermaleng.2016.02.090
   Zhou DW, 2009, EXP THERM FLUID SCI, V33, P273, DOI 10.1016/j.expthermflusci.2008.09.003
NR 51
TC 0
Z9 0
U1 6
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 220
EP 227
DI 10.1016/j.ces.2019.04.012
PG 8
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600019
DA 2020-05-12
ER

PT J
AU Zhu, LT
   Liu, YX
   Tang, JX
   Luo, ZH
AF Zhu, Li-Tao
   Liu, Yuan-Xing
   Tang, Jia-Xun
   Luo, Zheng-Hong
TI A material-property-dependent sub-grid drag model for coarse-grained
   simulation of 3D large-scale CFB risers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Computational fluid dynamics; Fluidization; Meso-scale structures;
   Material property dependence; Sub-grid model development; Coarse-grained
   simulation
ID GAS-SOLID FLOWS; DIRECT NUMERICAL-SIMULATION; AVERAGED 2-FLUID MODEL;
   THEORY-BASED PREDICTIONS; FLUIDIZED-BEDS; PARTICLE FLOWS; CONSTITUTIVE
   MODELS; EULERIAN SIMULATION; BOUNDARY-CONDITIONS; FILTERED MODEL
AB Developing, verifying and validating sub-grid methods is of crucial significance for enabling accurate coarse-grained two-fluid modeling of rapid gas-fluidized flows. However, very few studies in the literature so far have been focused on how the sub-grid modification depends on material properties. As an extension of previous sub-grid efforts, this fundamental investigation attempts to derive a materialproperty-dependent drag modification based on generated data from an initially homogeneous state of periodic gas-particle suspensions. The newly constituted model is then verified by highly-resolved two-fluid simulation results. We further validate the accuracy of model predictions via systematic assessments to experimental results that encompass a wide variety of material properties in five three-dimensional large-scale circulating fluidized bed (CFB) risers. Besides, we introduce a deviation index (DI) to quantify the predictive capability of the extended model. Computational results demonstrate an essential dependence of drag correction on material properties as an additional factor. Hydrodynamic validation predictions achieve satisfactory accordance with experiments. The current model is potential to serve as a more general tool for efficiently reducing the number of pilot-scale tests and effectively designing and controlling industrial process devices. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhu, Li-Tao; Liu, Yuan-Xing; Luo, Zheng-Hong] Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Engn, State Key Lab Met Matrix Composites, Shanghai 200240, Peoples R China.
   [Tang, Jia-Xun] Shanghai Univ Engn Sci, Sch Elect & Elect Engn, Dept Comp Engn, Shanghai 201620, Peoples R China.
RP Luo, ZH (reprint author), Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Engn, State Key Lab Met Matrix Composites, Shanghai 200240, Peoples R China.
EM luozh@sjtu.edu.cn
RI QIAN, LIU/S-1353-2019; Zhu, Li-Tao/G-6000-2018
OI Zhu, Li-Tao/0000-0001-6514-8864
FU National Ministry of Science and Technology of ChinaMinistry of Science
   and Technology, China [2017YFB0602401]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [21625603, 21776173, U1862201, 91834303]; Program of Shanghai Subject
   Chief Scientist [18XD1402000]; Center for High Performance Computing,
   Shanghai Jiao Tong University
FX The authors appreciate Dr. Hao Luo from the Technical University of
   Denmark for useful discussions on periodic flow simulations and Dr. Feng
   Shao from the Shanghai Jiao Tong University for active suggestions on
   the model constitution. The authors thank the National Ministry of
   Science and Technology of China (No. 2017YFB0602401), the National
   Natural Science Foundation of China (No. 21625603, 21776173, U1862201
   and 91834303), the Program of Shanghai Subject Chief Scientist (No.
   18XD1402000) and the Center for High Performance Computing, Shanghai
   Jiao Tong University for supporting this work.
CR Abbasi MR, 2019, REV CHEM ENG, V35, P311, DOI 10.1515/revce-2017-0040
   Adnan M, 2018, CAN J CHEM ENG, V96, P1403, DOI 10.1002/cjce.23071
   Agrawal K, 2001, J FLUID MECH, V445, P151, DOI 10.1017/S0022112001005663
   Andalib M, 2010, CHEM ENG J, V162, P616, DOI 10.1016/j.cej.2010.06.009
   Baltussen MW, 2017, CHEM ENG SCI, V158, P561, DOI 10.1016/j.ces.2016.11.013
   Benyahia S, 2012, AICHE J, V58, P3589, DOI 10.1002/aic.13826
   Benyahia S, 2012, AICHE J, V58, P427, DOI 10.1002/aic.12603
   Buelens LC, 2016, SCIENCE, V354, P449, DOI 10.1126/science.aah7161
   Capecelatro J, 2015, J FLUID MECH, V780, P578, DOI 10.1017/jfm.2015.459
   Chen J, 2015, POWDER TECHNOL, V274, P112, DOI 10.1016/j.powtec.2015.01.010
   Chen S, 2016, CHEM ENG SCI, V153, P58, DOI 10.1016/j.ces.2016.07.003
   Chen X., 2018, ARXIV181100714
   Chen X., 2018, ARXIV180804489
   Cloete JH, 2018, CHEM ENG SCI, V192, P930, DOI 10.1016/j.ces.2018.06.041
   Cloete JH, 2016, POWDER TECHNOL, V303, P156, DOI 10.1016/j.powtec.2016.07.009
   Cloete S, 2018, CHEM ENG SCI, V182, P93, DOI 10.1016/j.ces.2018.02.032
   Cloete S, 2015, POWDER TECHNOL, V269, P153, DOI 10.1016/j.powtec.2014.08.055
   Darmana D, 2007, CHEM ENG SCI, V62, P2556, DOI 10.1016/j.ces.2007.01.065
   Das S, 2018, CHEM ENG SCI, V183, P260, DOI 10.1016/j.ces.2018.03.022
   Dixon AG, 2017, CHEM ENG SCI, V168, P156, DOI 10.1016/j.ces.2017.04.039
   Du SH, 2019, CHEM ENG J, V368, P687, DOI 10.1016/j.cej.2019.03.009
   Fan XQ, 2018, IND ENG CHEM RES, V57, P5616, DOI 10.1021/acs.iecr.7b04883
   Fox RO, 2014, J FLUID MECH, V742, P368, DOI 10.1017/jfm.2014.21
   Fullmer WD, 2017, J FLUID MECH, V823, P433, DOI 10.1017/jfm.2017.295
   Fullmer WD, 2017, ANNU REV FLUID MECH, V49, P485, DOI 10.1146/annurev-fluid-010816-060028
   Fullmer WD, 2016, AICHE J, V62, P11, DOI 10.1002/aic.15052
   Gao X, 2018, AICHE J, V64, P3565, DOI 10.1002/aic.16341
   Gao X, 2018, CHEM ENG SCI, V184, P33, DOI 10.1016/j.ces.2018.03.038
   Gao X, 2012, POWDER TECHNOL, V228, P1, DOI 10.1016/j.powtec.2012.04.025
   Gao X, 2012, CHEM ENG SCI, V78, P98, DOI 10.1016/j.ces.2012.03.030
   Ge W, 2019, CHEM ENG SCI, V198, P198, DOI 10.1016/j.ces.2018.12.037
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Gidaspow D, 2018, REV CHEM ENG, V34, P299, DOI 10.1515/revce-2016-0044
   Harshe YM, 2004, CHEM ENG SCI, V59, P5145, DOI 10.1016/j.ces.2004.09.005
   Hartge EU, 2009, PARTICUOLOGY, V7, P283, DOI 10.1016/j.partic.2009.04.005
   Herbert P, 1999, AICHE SYM S, V95, P61
   Hong K, 2016, POWDER TECHNOL, V296, P2, DOI 10.1016/j.powtec.2015.07.003
   Igci Y, 2008, AICHE J, V54, P1431, DOI 10.1002/aic.11481
   Igci Y, 2011, IND ENG CHEM RES, V50, P13190, DOI 10.1021/ie200190q
   Jiang Y, 2018, POWDER TECHNOL, V346, P403
   Lai CH, 2017, POWDER TECHNOL, V322, P202, DOI 10.1016/j.powtec.2017.07.062
   Li J., 1994, PARTICLE FLUID 2 PHA
   Li JG, 2017, CHEM ENG J, V329, P100, DOI 10.1016/j.cej.2017.05.164
   Li J, 2013, IND ENG CHEM RES, V52, P11084, DOI 10.1021/ie400250c
   Li JH, 2018, CHEM ENG J, V333, P327, DOI 10.1016/j.cej.2017.09.162
   Li TW, 2008, POWDER TECHNOL, V184, P89, DOI 10.1016/j.powtec.2007.08.007
   Li TW, 2017, AICHE J, V63, P1203, DOI 10.1002/aic.15507
   Li TW, 2010, POWDER TECHNOL, V203, P447, DOI 10.1016/j.powtec.2010.06.005
   Liu PY, 2018, PHYS REV LETT, V121, DOI 10.1103/PhysRevLett.121.238001
   Liu XW, 2017, AICHE J, V63, P3, DOI 10.1002/aic.15489
   Liu XH, 2012, CHEM ENG PROG, V108, P28
   Lu BN, 2017, CHEM ENG SCI, V171, P244, DOI 10.1016/j.ces.2017.05.007
   Lu BN, 2011, CHEM ENG SCI, V66, P4624, DOI 10.1016/j.ces.2011.06.026
   Lu BN, 2009, CHEM ENG SCI, V64, P3437, DOI 10.1016/j.ces.2009.04.024
   Lu LQ, 2018, CHEM ENG SCI, V179, P53, DOI 10.1016/j.ces.2018.01.003
   Lu LQ, 2016, CHEM ENG SCI, V155, P314, DOI 10.1016/j.ces.2016.08.013
   Lu YJ, 2018, ADV POWDER TECHNOL, V29, P2765, DOI 10.1016/j.apt.2018.07.024
   Luo H, 2017, CHEM ENG J, V326, P47, DOI 10.1016/j.cej.2017.04.145
   Ma JS, 2006, CHEM ENG SCI, V61, P7096, DOI 10.1016/j.ces.2006.07.042
   Milioli CC, 2013, AICHE J, V59, P3265, DOI 10.1002/aic.14130
   Mori Y, 2019, POWDER TECHNOL, V343, P101, DOI 10.1016/j.powtec.2018.11.015
   Mouallem J, 2019, CHEM ENG SCI, V195, P553, DOI 10.1016/j.ces.2018.09.054
   Nayak SV, 2005, CHEM ENG SCI, V60, P6049, DOI 10.1016/j.ces.2005.04.046
   OBrien T., 1993, PREPRINT VOLUME CFB, P430
   Pan H, 2017, IND ENG CHEM RES, V56, P10199, DOI 10.1021/acs.iecr.7b02912
   Phuakpunk K, 2018, CHEM ENG SCI, V192, P1041, DOI 10.1016/j.ces.2018.08.042
   Queteschiner D, 2018, POWDER TECHNOL, V338, P614, DOI 10.1016/j.powtec.2018.07.033
   Radl S, 2014, CHEM ENG SCI, V117, P416, DOI 10.1016/j.ces.2014.07.011
   Sakai M, 2014, CHEM ENG J, V244, P33, DOI 10.1016/j.cej.2014.01.029
   Sarkar A, 2016, CHEM ENG SCI, V152, P443, DOI 10.1016/j.ces.2016.06.023
   Schneiderbauer S, 2019, INT J MULTIPHASE FLO
   Schneiderbauer S, 2018, AICHE J, V64, P1606, DOI 10.1002/aic.16141
   Schneiderbauer S, 2018, AICHE J, V64, P1591, DOI 10.1002/aic.16142
   Schneiderbauer S, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5017004
   Schneiderbauer S, 2017, AICHE J, V63, P3544, DOI 10.1002/aic.15684
   Schneiderbauer S, 2015, CHEM ENG J, V264, P99, DOI 10.1016/j.cej.2014.11.058
   Schneiderbauer S, 2014, AICHE J, V60, P839, DOI 10.1002/aic.14321
   Schneiderbauer S, 2013, AICHE J, V59, P4077, DOI 10.1002/aic.14155
   Schneiderbauer S, 2012, CHEM ENG SCI, V80, P279, DOI 10.1016/j.ces.2012.06.041
   Schneiderbauer S, 2012, INT J MULTIPHAS FLOW, V43, P149, DOI 10.1016/j.ijmultiphaseflow.2012.03.006
   Soleimani A, 2015, INT J MULTIPHAS FLOW, V71, P94, DOI 10.1016/j.ijmultiphaseflow.2014.12.008
   Sundaresan S, 2018, ANNU REV CHEM BIOMOL, V9, P61, DOI 10.1146/annurev-chembioeng-060817-084025
   Tung Y, 1988, FLUIDIZATION 88 SCI
   Wei F, 1998, POWDER TECHNOL, V100, P183, DOI 10.1016/S0032-5910(98)00139-9
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Xiong QG, 2018, CHEM ENG PROCESS, V127, P206, DOI 10.1016/j.cep.2018.04.005
   Xiong QG, 2012, CHEM ENG SCI, V71, P422, DOI 10.1016/j.ces.2011.10.059
   Xu M, 2007, CHEM ENG SCI, V62, P2302, DOI 10.1016/j.ces.2006.12.008
   Xue Q, 2011, CHEM ENG SCI, V66, P2440, DOI 10.1016/j.ces.2011.03.010
   Yan WC, 2018, J CLEAN PROD, V178, P476, DOI 10.1016/j.jclepro.2018.01.009
   Yan WC, 2011, CHEM ENG SCI, V66, P5148, DOI 10.1016/j.ces.2011.07.004
   Yang N, 2003, CHEM ENG J, V96, P71, DOI 10.1016/j.cej.2003.08.006
   Zaabout A, 2019, INT J GREENH GAS CON, V81, P170, DOI 10.1016/j.ijggc.2018.12.027
   Zhang N, 2010, CHEM ENG J, V162, P821, DOI 10.1016/j.cej.2010.06.033
   Zhang N, 2008, PARTICUOLOGY, V6, P529, DOI 10.1016/j.partic.2008.07.013
   Zheng Y, 2001, CHEM ENG SCI, V56, P6813, DOI 10.1016/S0009-2509(01)00319-0
   Zhou GF, 2014, CHEM ENG SCI, V116, P9, DOI 10.1016/j.ces.2014.04.025
   Zhu LT, 2019, CHEM ENG SCI, V196, P478, DOI 10.1016/j.ces.2018.11.026
   Zhu LT, 2018, CHEM ENG RES DES, V137, P141, DOI 10.1016/j.cherd.2018.07.005
   Zhu LT, 2018, CHEM ENG SCI, V192, P759, DOI 10.1016/j.ces.2018.08.026
   Zhu LT, 2016, IND ENG CHEM RES, V55, P11887, DOI 10.1021/acs.iecr.6b02819
   Zhu LT, 2016, CHEM ENG SCI, V143, P369, DOI 10.1016/j.ces.2016.01.006
   2007, CHEM ENG SCI, V62, P2989, DOI DOI 10.1016/J.CES.2007.02.022
   2005, CHEM ENG SCI, V60, P4567, DOI DOI 10.1016/J.CES.2005.03.017
NR 104
TC 8
Z9 8
U1 2
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 228
EP 245
DI 10.1016/j.ces.2019.04.026
PG 18
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600020
DA 2020-05-12
ER

PT J
AU Wiggins, C
   Patel, N
   Bingham, Z
   Ruggles, A
AF Wiggins, Cody
   Patel, Nitant
   Bingham, Zachary
   Ruggles, Arthur
TI Qualification of multiple-particle positron emission particle tracking
   (M-PEPT) technique for measurements in turbulent wall-bounded flow
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Positron emission particle tracking; Multiple-particle tracking; Pipe
   flow; Flow measurement
ID DIRECT NUMERICAL-SIMULATION; PIPE-FLOW; BUBBLE-COLUMN; FLUID-FLOW;
   HYDRODYNAMICS; REACTOR; PET; ACCELERATIONS; INTERNALS; BED
AB Positron emission particle tracking (PEPT) has been shown to be useful for flow interrogation in opaque systems. In this work, a recently developed method for multiple-particle PEPT (M-PEPT) is employed for measurement of flow in a pipe at Rep = 42 600, and results are compared to direct numerical simulation (DNS) data to test the capability of M-PEPT for measurement of statistical quantities in turbulent flow. Correction for photon depth of interaction in detectors is seen to be needed and is applied. M-PEPT is shown to be capable of measuring quantities such as mean velocity and acceleration, Reynolds stress, and turbulent kinetic energy budget outside of the near-wall region. Further refinement of the technique is needed to resolve near-wall turbulence features. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wiggins, Cody] Univ Tennessee, Dept Phys & Astron, Knoxville, TN 37996 USA.
   [Patel, Nitant; Bingham, Zachary; Ruggles, Arthur] Univ Tennessee, Dept Nucl Engn, Knoxville, TN 37996 USA.
RP Wiggins, C (reprint author), Univ Tennessee, Dept Phys & Astron, Knoxville, TN 37996 USA.
EM cwiggin2@vols.utk.edu
FU National Nuclear Security Administration Stewardship Science Academic
   Alliances [DE-NA0001983]; Nuclear Energy University Program Integrated
   University Program; Integrated University Program Graduate Fellowship
FX The authors are grateful to Alan Stuckey, Dustin Osborne, and Jon Wall
   of the University of Tennessee Medical Center for access to their
   equipment and facilities for the preparation of our tracers and to
   Howard Cyr for access to the Mastersizer 3000 for particle size
   analysis. This work was supported by the National Nuclear Security
   Administration Stewardship Science Academic Alliances award DE-NA0001983
   and the Nuclear Energy University Program Integrated University Program.
   This material is based upon work supported under an Integrated
   University Program Graduate Fellowship.
CR Bao Q, 2009, J NUCL MED, V50, P401, DOI 10.2967/jnumed.108.056374
   Bashiri H, 2016, CHEM ENG SCI, V140, P233, DOI 10.1016/j.ces.2015.10.005
   Bhusare VH, 2017, CHEM ENG J, V317, P157, DOI 10.1016/j.cej.2017.01.128
   Bickell M, 2012, NUCL INSTRUM METH A, V682, P36, DOI 10.1016/j.nima.2012.04.037
   Boucher D, 2016, CHEM ENG SCI, V140, P217, DOI 10.1016/j.ces.2015.10.018
   Boyjoo Y, 2013, CHEM ENG SCI, V101, P764, DOI 10.1016/j.ces.2013.06.035
   Brady M. R, 2006, THESIS
   Chang YF, 2015, EXP FLUIDS, V56, DOI 10.1007/s00348-014-1875-5
   Chara Z, 2016, APPL MATH COMPUT, V272, P614, DOI 10.1016/j.amc.2015.06.044
   Charonko John J., 2017, Journal of Fluid Mechanics, V825, P887, DOI 10.1017/jfm.2017.379
   Chiti F, 2011, CHEM ENG RES DES, V89, P1947, DOI 10.1016/j.cherd.2011.01.015
   de Caprariis B, 2012, CHEM ENG SCI, V76, P73, DOI 10.1016/j.ces.2012.03.043
   Dryer FL, 2014, PROG ENERG COMBUST, V44, P19, DOI 10.1016/j.pecs.2014.04.002
   El Khoury GK, 2013, FLOW TURBUL COMBUST, V91, P475, DOI 10.1007/s10494-013-9482-8
   Gerashchenko S, 2008, J FLUID MECH, V617, P255, DOI 10.1017/S0022112008004187
   Gesemann S, 2016, 18 INT S APPL LAS IM
   Goertzen AL, 2006, IEEE NUCL SCI CONF R, P2323
   Hampel U, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2795648
   Hultmark M, 2013, J FLUID MECH, V728, P376, DOI 10.1017/jfm.2013.255
   Hultmark M, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.094501
   Jan S, 2004, PHYS MED BIOL, V49, P4543, DOI 10.1088/0031-9155/49/19/007
   Kalaga DV, 2017, AICHE J, V63, P4881, DOI 10.1002/aic.15829
   Langford ST, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180503
   Lavezzo V, 2010, J FLUID MECH, V658, P229, DOI 10.1017/S0022112010001655
   Lawson JM, 2018, EXP FLUIDS, V59, DOI 10.1007/s00348-018-2622-0
   Le Moullec Y, 2010, CHEM ENG SCI, V65, P492, DOI 10.1016/j.ces.2009.03.021
   Lee KS, 2015, IEEE T MED IMAGING, V34, P994, DOI 10.1109/TMI.2014.2373351
   Lee S, 2013, MOL IMAGING, V12, DOI 10.2310/7290.2013.00058
   Liu ZP, 2019, CHEM ENG SCI, V193, P66, DOI 10.1016/j.ces.2018.08.020
   Lu YJ, 2014, CHEM ENG SCI, V117, P283, DOI 10.1016/j.ces.2014.06.032
   Montoya G, 2016, CHEM ENG SCI, V141, P86, DOI 10.1016/j.ces.2015.09.011
   Mordant N, 2004, PHYSICA D, V193, P245, DOI 10.1016/j.physd.2004.01.041
   Morrison AJ, 2016, CHEM ENG SCI, V152, P186, DOI 10.1016/j.ces.2016.06.022
   Moses WW, 2011, NUCL INSTRUM METH A, V648, pS236, DOI 10.1016/j.nima.2010.11.092
   Oliveira JLG, 2013, FLOW TURBUL COMBUST, V91, P105, DOI 10.1007/s10494-013-9457-9
   Parker DJ, 2017, REV SCI INSTRUM, V88, DOI 10.1063/1.4983046
   PARKER DJ, 1993, NUCL INSTRUM METH A, V326, P592, DOI 10.1016/0168-9002(93)90864-E
   Patel N, 2017, EXP FLUIDS, V58, DOI 10.1007/s00348-017-2330-1
   Perez-Mohedano R, 2015, CHEM ENG J, V259, P724, DOI 10.1016/j.cej.2014.08.033
   Ramskill NP, 2017, CHEM ENG SCI, V158, P497, DOI 10.1016/j.ces.2016.10.017
   Ranganathan P, 2011, CHEM ENG SCI, V66, P3108, DOI 10.1016/j.ces.2011.03.007
   Rebrov EV, 2011, CHEM ENG SCI, V66, P1374, DOI 10.1016/j.ces.2010.05.044
   Reynolds O., 1883, P R SOC LONDON, V35, P84, DOI [10.1098/rspl.1883.0018, DOI 10.1098/RSPL.1883.0018]
   Rosenberg BJ, 2013, J FLUID MECH, V731, P46, DOI 10.1017/jfm.2013.359
   Sbalzarini IF, 2005, J STRUCT BIOL, V151, P182, DOI 10.1016/j.jsb.2005.06.002
   Soloff SM, 1997, MEAS SCI TECHNOL, V8, P1441, DOI 10.1088/0957-0233/8/12/008
   Stelzenmuller N, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.054602
   van Doorne CWH, 2007, EXP FLUIDS, V42, P259, DOI 10.1007/s00348-006-0235-5
   Wiggins C, 2017, NUCL INSTRUM METH A, V843, P22, DOI 10.1016/j.nima.2016.10.057
   Wiggins C, 2016, NUCL INSTRUM METH A, V811, P18, DOI 10.1016/j.nima.2015.11.136
   Willert C, 1997, MEAS SCI TECHNOL, V8, P1465, DOI 10.1088/0957-0233/8/12/010
   Wu XH, 2008, J FLUID MECH, V608, P81, DOI 10.1017/S0022112008002085
   Yang Z, 2006, NUCL INSTRUM METH A, V564, P332, DOI 10.1016/j.nima.2006.04.054
   Zagarola MV, 1998, J FLUID MECH, V373, P33, DOI 10.1017/S0022112098002419
   2015, CHEM ENGR SCI, V137, P1014, DOI DOI 10.1016/J.CES.2015.07.015
NR 55
TC 0
Z9 0
U1 2
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 246
EP 256
DI 10.1016/j.ces.2019.04.030
PG 11
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600021
OA Bronze
DA 2020-05-12
ER

PT J
AU Matic, J
   Witschnigg, A
   Zagler, M
   Eder, S
   Khinast, J
AF Matic, Josip
   Witschnigg, Andreas
   Zagler, Michaela
   Eder, Simone
   Khinast, Johannes
TI A novel in silico scale-up approach for hot melt extrusion processes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pharmaceutical hot melt extrusion; Scale-up; SPH; 1D mechanistic process
   modelling
AB The goal of our study was to develop a rational in silico scale-up and process transfer approach for hot melt extrusion processes occurring in the pharmaceutical and other industries. To that end, we performed high-fidelity simulations of individual twin-screw extruder elements via the Lagrangian-based Smoothed Particle Hydrodynamics (SPH) method. To parametrize a mechanistic 1D hot-melt extrusion (HME) model, the data generated by the SPH simulations was used together with the material properties. Two co-rotating twin-screw extruder setups were compared: the Coperion ZSK18 and the Leistritz MIC27 extruders. The pressure and power characteristics of the two extruders with different screw elements and geometries were obtained and compared. The impact of the HME process parameters (throughput, screw speed and barrel temperature) on the filling degree, melt temperature, axial specific mechanical energy consumption (SMEC) and residence time distribution in the two extruders was established. The torque and SMEC values obtained in silico were then compared to experiments to ensure that the 1D HME simulations were set up correctly.
   Next, scale-up methods from the literature were evaluated, yielding an unsatisfactory set of process parameters that might lead to material degradation. Finally, a rational scale-up approach was proposed. Based on this novel method alternative parameter settings on the MIC27 extruder were established, assuring equivalent thermo-mechanical load on the product compared to the process using the ZSK18 extruder. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Matic, Josip; Khinast, Johannes] Graz Univ Technol, Inst Proc & Particle Engn, A-8010 Graz, Austria.
   [Matic, Josip; Witschnigg, Andreas; Zagler, Michaela; Eder, Simone; Khinast, Johannes] Res Ctr Pharmaceut Engn GmbH, A-8010 Graz, Austria.
RP Khinast, J (reprint author), Graz Univ Technol, Inst Proc & Particle Engn, A-8010 Graz, Austria.
EM khinast@tugraz.at
FU Austrian COMET Program by the Austrian Federal Ministry of
   Transportation, Innovation and Technology (BMVIT); Austrian Federal
   Ministry of Economy, Family and Youth (BMWFJ); State of Styria (Styrian
   Funding Agency SFG)
FX This work has been funded through the Austrian COMET Program by the
   Austrian Federal Ministry of Transportation, Innovation and Technology
   (BMVIT), the Austrian Federal Ministry of Economy, Family and Youth
   (BMWFJ) and by the State of Styria (Styrian Funding Agency SFG).
CR Baumgartner R, 2016, INT J PHARMACEUT, V506, P35, DOI 10.1016/j.ijpharm.2016.04.029
   Breitenbach J, 2002, EUR J PHARM BIOPHARM, V54, P107, DOI 10.1016/S0939-6411(02)00061-9
   Douroumis D, 2012, HOT MELT EXTRUSION P
   Eggenreich K, 2016, INT J PHARMACEUT, V505, P341, DOI 10.1016/j.ijpharm.2016.03.034
   Eitzlmayr A, 2017, AICHE J, V63, P2451, DOI 10.1002/aic.15607
   Eitzlmayr A, 2015, CHEM ENG SCI, V134, P861, DOI 10.1016/j.ces.2015.04.055
   Eitzlmayr A, 2014, INT J PHARMACEUT, V474, P157, DOI 10.1016/j.ijpharm.2014.08.005
   Eitzlmayr A, 2014, COMPUT PHYS COMMUN, V185, P2436, DOI 10.1016/j.cpc.2014.05.014
   Herwig H, 2008, STROMUNGSMECHANIK
   Kohlgruber K., 2008, COROTATING TWIN SCRE
   LIU GR, 2003, MESH FREE METHODS
   Liu GR, 2003, SMOOTHED PARTICLE HY
   Liu GR, 2005, INTRO MESHFREE METHO, DOI [10.1007/1-4020-3468-7, DOI 10.1007/1-4020-3468-7]
   Liu MB, 2010, ARCH COMPUT METHOD E, V17, P25, DOI 10.1007/s11831-010-9040-7
   Maniruzzaman Mohammed, 2012, ISRN Pharm, V2012, P436763, DOI 10.5402/2012/436763
   Menges G, 1984, ADV POLYM TECHNOL, V4, P123, DOI [10.1002/adv.1984.060040204, DOI 10.1002/ADV.1984.060040204]
   Menges G, 1983, ADV POLYM TECHNOL, V3, P157, DOI 10.1002/adv.1983.060030210
   Monaghan JJ, 2005, REP PROG PHYS, V68, P1703, DOI 10.1088/0034-4885/68/8/R01
   Morgan DR, 2000, BIOMATERIALS, V21, P1897, DOI 10.1016/S0142-9612(00)00067-3
   Morris JP, 1997, J COMPUT PHYS, V136, P214, DOI 10.1006/jcph.1997.5776
   Patil H, 2016, AAPS PHARMSCITECH, V17, P20, DOI 10.1208/s12249-015-0360-7
   Pawlowski J, 1971, AHNLICHKEITSTHEORIE, DOI [10.1007/978-3-642-65095-6, DOI 10.1007/978-3-642-65095-6]
   RAUWENDAAL C, 1987, POLYM ENG SCI, V27, P1059, DOI 10.1002/pen.760271406
   Rauwendaal C, 2014, POLYM EXTRUSION, P697
   Rauwendaal  Chris, 2014, RAUWENDAAL POLYM EXT, DOI [10.1016/B978-1-56990-516-6.50001-0, DOI 10.1016/B978-1-56990-516-6.50001-0]
   Singh S, 2012, B PHARM RES, V2, P159
   Terife G, 2012, POLYM ENG SCI, V52, P1629, DOI 10.1002/pen.23106
   Thiry J, 2015, INT J PHARMACEUT, V479, P227, DOI 10.1016/j.ijpharm.2014.12.036
   Violeau D, 2012, FLUID MECHANICS AND THE SPH METHOD: THEORY AND APPLICATIONS, P1, DOI 10.1093/acprof:oso/9780199655526.001.0001
   Zlokarnik M, 2005, SCALE UP MODELLUEBER, P3
   2007, DRUG DEV IND PHARM, V33, P909, DOI DOI 10.1080/03639040701498759
   2013, AICHE J, V59, P4440, DOI DOI 10.1002/AIC
NR 32
TC 0
Z9 0
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 257
EP 269
DI 10.1016/j.ces.2019.04.016
PG 13
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600022
DA 2020-05-12
ER

PT J
AU Gallassi, M
   Goncalves, GFN
   Botti, TC
   Moura, MJB
   Carneiro, JNE
   Carvalho, MS
AF Gallassi, Mariana
   Goncalves, Gabriel F. N.
   Botti, Talita Coffler
   Moura, Maria J. B.
   Carneiro, Joao N. E.
   Carvalho, Marcio S.
TI Numerical and experimental evaluation of droplet breakage of O/W
   emulsions in rotor-stator mixers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Rotor-stator mixer; Drop breakup; Drop size distribution; High speed
   visualization; Population balance model; CFD
ID LIQUID-LIQUID DISPERSIONS; NONIDEAL STIRRED-TANK; TURBULENT-FLOW;
   POPULATION BALANCES; ENERGY-DISSIPATION; MODEL; SIMULATION; SIZE;
   EMULSIFICATION; SYSTEMS
AB Emulsification of a high viscosity oil in water mixture was studied in a rotor-stator mixer. Experimental characterization of drop sizes and high-speed visualizations of drop breakup phenomena were performed, combined with computational fluid dynamics analysis of the flow field and population balance modeling. Single-phase flow simulations were carried out with a sliding mesh CFD model and combined with analysis of streamlines, turbulent eddy dissipation fields and high-speed visualizations of drop breakage. From frames taken over few seconds, with the oil-water system initially fully segregated, three drop breakage mechanisms were identified, supported by the CFD analysis: (i) a combination of the large scale circular motion in the tank and the fluid jet emanating from the stator holes; (ii) droplets that are pulled into the rotor - stator system from the bottom and flow through the gap between the stator and rotor, undergoing extremely high shear stresses, being expelled through the stator slots in several fragments, and iii) droplets that remain caught at the recirculation zones in the stator holes, increasing exposure time to high shear during the rotor blade passage. Finally, an optimization algorithm was coupled to a population balance model and the measured drop size distributions were reproduced in good agreement with experimental data, including the bimodal behavior attributed to the generation of satellite droplets. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gallassi, Mariana; Goncalves, Gabriel F. N.; Carneiro, Joao N. E.] ISDB FlowTech, Rio De Janeiro, RJ, Brazil.
   [Botti, Talita Coffler; Moura, Maria J. B.; Carvalho, Marcio S.] Pontificia Univ Catolica Rio de Janeiro, Dept Mech Engn, Rio De Janeiro, RJ, Brazil.
RP Carneiro, JNE (reprint author), ISDB FlowTech, Rio De Janeiro, RJ, Brazil.; Carvalho, MS (reprint author), Pontificia Univ Catolica Rio de Janeiro, Dept Mech Engn, Rio De Janeiro, RJ, Brazil.
EM joao.carneiro@isdbflowtech.com; msc@puc-rio.br
FU Equinor Brazil, ANP ("Compromisso de Investimentos com Pesquisa e
   Desenvolvimento"); PRH/ANP
FX The authors would like to thank Equinor Brazil, ANP ("Compromisso de
   Investimentos com Pesquisa e Desenvolvimento") and PRH/ANP for providing
   financial support for this work.
CR Alopaeus V, 2002, CHEM ENG SCI, V57, P1815, DOI 10.1016/S0009-2509(02)00067-2
   Alopaeus V, 1999, CHEM ENG SCI, V54, P5887, DOI 10.1016/S0009-2509(99)00170-0
   Ashar M, 2018, CHEM ENG SCI, V181, P186, DOI 10.1016/j.ces.2018.02.021
   Aubin J, 2004, EXP THERM FLUID SCI, V28, P431, DOI 10.1016/j.expthermflusci.2003.04.001
   Baldyga J, 1998, CAN J CHEM ENG, V76, P456, DOI 10.1002/cjce.5450760316
   Bratton D, 2007, 2007 IEEE SWARM INTELLIGENCE SYMPOSIUM, P120, DOI 10.1109/SIS.2007.368035
   Buffo A, 2016, CHEM ENG SCI, V153, P382, DOI 10.1016/j.ces.2016.07.032
   Calabrese RV, 2000, 10TH EUROPEAN CONFERENCE ON MIXING, P149, DOI 10.1016/B978-044450476-0/50020-0
   CHATZI EG, 1989, IND ENG CHEM RES, V28, P1704, DOI 10.1021/ie00095a022
   COULALOGLOU CA, 1977, CHEM ENG SCI, V32, P1289, DOI 10.1016/0009-2509(77)85023-9
   DAVIES JT, 1987, CHEM ENG SCI, V42, P1671, DOI 10.1016/0009-2509(87)80172-0
   De Hert SC, 2017, CHEM ENG SCI, V172, P423, DOI 10.1016/j.ces.2017.07.002
   Fehlberg E, 1969, 315 NASA
   Gao ZM, 2016, CHEM ENG SCI, V142, P277, DOI 10.1016/j.ces.2015.11.040
   Hakansson A, 2017, CHEM ENG SCI, V171, P625, DOI 10.1016/j.ces.2017.06.042
   Hall S, 2011, CHEM ENG SCI, V66, P2068, DOI 10.1016/j.ces.2011.01.054
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   Jasinska M, 2013, APPL THERM ENG, V57, P172, DOI 10.1016/j.applthermaleng.2012.06.036
   Kennedy J, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1-6, P1942, DOI 10.1109/ICNN.1995.488968
   Kumar S, 1996, CHEM ENG SCI, V51, P1311, DOI 10.1016/0009-2509(96)88489-2
   LAGISETTY JS, 1986, CHEM ENG SCI, V41, P65, DOI 10.1016/0009-2509(86)85198-3
   Launder B, 1972, LECT MATH MODELS TUR
   Liao Y, 2018, INT J NUMER METH FL, V87, P202, DOI 10.1002/fld.4491
   Mitre J. F, 2014, CHEM ENG RES DES
   Mortensen HH, 2011, CAN J CHEM ENG, V89, P1076, DOI 10.1002/cjce.20587
   NARSIMHAN G, 1979, CHEM ENG SCI, V34, P257, DOI 10.1016/0009-2509(79)87013-X
   Ozcan-Taskin G, 2011, CAN J CHEM ENG, V89, P1005, DOI 10.1002/cjce.20553
   Rodgers TL, 2012, CHEM ENG RES DES, V90, P323, DOI 10.1016/j.cherd.2011.07.018
   Sanjuan-Galindo R, 2015, CHEM ENG COMMUN, V202, P1251, DOI 10.1080/00986445.2014.923994
   SHINNAR R, 1961, J FLUID MECH, V10, P259, DOI 10.1017/S0022112061000214
   Solsvik J, 2016, IND ENG CHEM RES, V55, P2872, DOI 10.1021/acs.iecr.6b00591
   Utomo A, 2009, CHEM ENG RES DES, V87, P533, DOI 10.1016/j.cherd.2008.12.011
   Utomo AT, 2008, CHEM ENG RES DES, V86, P1397, DOI 10.1016/j.cherd.2008.07.012
   Vankova N, 2007, J COLLOID INTERF SCI, V312, P363, DOI 10.1016/j.jcis.2007.03.059
   Vankova N, 2007, J COLLOID INTERF SCI, V313, P612, DOI 10.1016/j.jcis.2007.04.064
   Zhou GW, 1998, CHEM ENG SCI, V53, P2063, DOI 10.1016/S0009-2509(97)00438-7
   2018, CHEM ENG SCI, V177, P340, DOI DOI 10.1016/J.CES.2017.11.037
   1949, DOKL AKAD NAVK SSSR, V66, P825
NR 38
TC 2
Z9 2
U1 12
U2 41
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 270
EP 286
DI 10.1016/j.ces.2019.04.011
PG 17
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600023
DA 2020-05-12
ER

PT J
AU Wei, Q
   Sun, GG
   Yang, JX
AF Wei, Qing
   Sun, Guogang
   Yang, Jingxuan
TI A model for prediction of maximum-efficiency inlet velocity in a
   gas-solid cyclone separator
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Cyclone separator; Inlet velocity; Efficiency; Temperature; Soft sphere
   model
ID PRESSURE-DROP; SWIRLING FLOW; PERFORMANCE; TEMPERATURE; COLLECTION;
   SIMULATION
AB A new model for determining maximum-efficiency inlet velocity in the gas-solid cyclone separator was developed analytically in this study. Previous maximum-efficiency inlet velocity (V-MEIV) models are derived at normal temperature and do not function properly under high-temperature conditions. The new model not only accounts for gas physical properties and cyclone structure dimensions, but also various particle characteristics as well as temperature; it can be applied to predict V-MEIV at both normal and high temperatures. Based on Yang's model, a hard sphere analogy of the soft sphere model was used to directly manage particle-wall collision as per the flow field of the cyclone. This model yields more accurate downward flow region width information than previously proposed models. If the radial displacement of a rebounded particle after collision is equal to the width of the downward flow region, then the corresponding inlet velocity is defined as the maximum-efficiency inlet velocity. Comparisons among different experimental results and other models' results indicate that the proposed model more accurately predicts maximum-efficiency inlet velocity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wei, Qing; Sun, Guogang] China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
   [Wei, Qing; Sun, Guogang] Beijing Key Lab Proc Fluid Filtrat & Separat, Beijing 102249, Peoples R China.
   [Yang, Jingxuan] Taiyuan Univ Technol, Coll Chem & Chem Engn, Taiyuan 030024, Shanxi, Peoples R China.
RP Sun, GG (reprint author), China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
EM ggsunbj@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21506139]; National Key Project of Basic Research
   of the Ministry for Science and Technology of China [2014CB744304]
FX The authors grateful acknowledge the financial assistance from National
   Natural Science Foundation of China (grant No. 21276274); the National
   Key Project of Basic Research of the Ministry for Science and Technology
   of China (grant No. 2014CB744304); and the National Natural Science
   Foundation of China (grant No. 21506139).
CR Alahmadi YH, 2016, CHEM ENG SCI, V147, P150, DOI 10.1016/j.ces.2016.03.023
   Alexander R.M., 1949, P AUSTRALAS I MIN M, V152-153, P203
   ALLEN T, 1990, PARTICLE SIZE MEASUR
   Bird R. B., 2002, TRANSPORT PHENOMENA
   Bohnet M, 1993, P 6 WORLD FILTR C NA, P479
   Bohnet M, 1993, GAS CLEANING HIGH TE, P17
   Chen J, 2007, SEPARATION THEORY OP, P96
   Chu KW, 2012, CHEM ENG SCI, V73, P123, DOI 10.1016/j.ces.2012.01.007
   Chu KW, 2011, CHEM ENG SCI, V66, P834, DOI 10.1016/j.ces.2010.11.026
   Coelho MAZ, 2001, CHEM ENG J, V84, P7, DOI 10.1016/S1385-8947(00)00265-5
   Derksen JJ, 2000, AICHE J, V46, P1317, DOI 10.1002/aic.690460706
   Diao Y F, 2000, CHEM ENG MACH, V27, P16
   Elsayed K, 2012, POWDER TECHNOL, V217, P84, DOI 10.1016/j.powtec.2011.10.015
   Elsayed K, 2010, CHEM ENG SCI, V65, P6048, DOI 10.1016/j.ces.2010.08.042
   Fassani FL, 2000, POWDER TECHNOL, V107, P60, DOI 10.1016/S0032-5910(99)00091-1
   Gao JM, 2012, CHEM ENG J, V213, P97, DOI 10.1016/j.cej.2012.09.076
   GOLDSMITH W, 1960, IMPACT
   Hu LY, 2005, AICHE J, V51, P740, DOI 10.1002/aic.10354
   Jianyi C., 2003, CHINA PART, V1, P20, DOI DOI 10.1016/51672-2515(07)60095-5
   Jiao JY, 2007, SEP PURIF TECHNOL, V53, P266, DOI 10.1016/j.seppur.2006.07.011
   Kalen B., 1974, AICHE S SER, V137, P388
   KANG SK, 1989, POWDER TECHNOL, V58, P211, DOI 10.1016/0032-5910(89)80116-0
   Lee H, 2014, POWDER TECHNOL, V262, P36, DOI 10.1016/j.powtec.2014.04.057
   Leith D., 1972, AICHE S SERIES, V68, P196
   [李文琦 LI Wenqi], 2006, [中国石油大学学报. 自然科学版, Journal of China University of Petroleum. Edition of Natrual Science], V30, P97
   Liu F, 2015, SEPARATION MECH GAS, P45
   Liu ZL, 2006, CHEM ENG SCI, V61, P4252, DOI 10.1016/j.ces.2006.01.024
   MEISSNER P, 1978, CHEM-ING-TECH, V50, P471, DOI 10.1002/cite.330500619
   Mothes H., 1988, INT CHEM ENG, V23, P231
   PARKER R, 1981, ENVIRON SCI TECHNOL, V15, P451, DOI 10.1021/es00086a010
   Peng W, 2002, POWDER TECHNOL, V127, P212, DOI 10.1016/S0032-5910(02)00148-1
   Shi M. X., 1993, CHEM ENG MACHINERY, V20, P187
   Solero G, 2002, EXP THERM FLUID SCI, V27, P87, DOI 10.1016/S0894-1777(02)00221-2
   Ter Linden A., 1949, P LONDON I MECH ENG, V160, P233, DOI DOI 10.1243/PIME_PROC_1949_160_025_02
   Thornton C, 1997, J APPL MECH-T ASME, V64, P383, DOI 10.1115/1.2787319
   WALTON OR, 1986, J RHEOL, V30, P949, DOI 10.1122/1.549893
   [王佰长 Wang Baichang], 2011, [石油炼制与化工, Petroleum Processing and Petrochemicals], V42, P59
   Wang W. D., 2012, CHINA POWDER SCI TEC, V18, P70
   Whiton L.C, 1932, CHEM METALL ENG, V39, P150
   Yang JX, 2015, POWDER TECHNOL, V286, P124, DOI 10.1016/j.powtec.2015.07.024
   Zhao B, 2004, CHEM ENG TECHNOL, V27, P1105, DOI 10.1002/ceat.200402089
   Zhao BT, 2012, SEP PURIF TECHNOL, V85, P171, DOI 10.1016/j.seppur.2011.10.006
   Zhou FQ, 2018, SEP PURIF TECHNOL, V193, P175, DOI 10.1016/j.seppur.2017.11.017
   1999, CHEM ENG SCI, V54, P2055
NR 44
TC 2
Z9 2
U1 8
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 287
EP 297
DI 10.1016/j.ces.2019.03.054
PG 11
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600024
DA 2020-05-12
ER

PT J
AU Dejam, M
AF Dejam, Morteza
TI Derivation of dispersion coefficient in an electro-osmotic flow of a
   viscoelastic fluid through a porous-walled microchannel
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dispersion; Microchannel; Porous walls; Electro-osmotic flow;
   Viscoelastic fluid
ID CONTROLLED GRAVITY DRAINAGE; LAPLACE INVERSION METHODS; COMBINED
   PRESSURE-DRIVEN; SHEAR DISPERSION; EQUATION; VALIDITY; FRACTURE;
   CHANNEL; SOLUTE
AB An analytical expression for the dispersion coefficient in an electro-osmotic flow of a viscoelastic fluid (which obeys the simplified Phan-Thien-Tanner rheological model) through a porous-walled microchannel is theoretically developed. The decomposition technique in combination with the assumptions behind the Taylor-Aris theory of the solute species dispersion is used to derive the dispersion coefficient in a porous-walled microchannel. The microchannel-porous medium interaction via the exchange of the solute species between the two media is included in derivation of the dispersion coefficient in a porous-walled microchannel. In other words, the continuity of the solute species concentration and its flux is considered at the interface between the microchannel and the porous medium. The developed dispersion coefficient in a porous-walled microchannel is a function of three parameters, which characterize the Peclet number, the fluid elasticity, and the nondimensional Debye-Flfickel parameter. The proposed model is also capable to deliver the dispersion coefficient in a nonporous-walled microchannel (where a no-flux boundary condition is considered at the walls), which is in agreement with the existing model in literature. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dejam, Morteza] Univ Wyoming, Coll Engn & Appl Sci, Dept Petr Engn, 1000 E Univ Ave, Laramie, WY 82071 USA.
RP Dejam, M (reprint author), Univ Wyoming, Coll Engn & Appl Sci, Dept Petr Engn, 1000 E Univ Ave, Laramie, WY 82071 USA.
EM mdejam@uwyo.edu
RI Dejam, Morteza/F-5313-2011
OI Dejam, Morteza/0000-0002-3435-3838
FU Department of Petroleum Engineering in the College of Engineering and
   Applied Science at the University of Wyoming
FX The author is gratefully appreciative of the financial support from the
   Department of Petroleum Engineering in the College of Engineering and
   Applied Science at the University of Wyoming.
CR Afonso AM, 2009, J NON-NEWTON FLUID, V159, P50, DOI 10.1016/j.jnnfm.2009.01.006
   Arcos JC, 2018, J FLUID MECH, V839, P348, DOI 10.1017/jfm.2018.11
   ARIS R, 1956, PROC R SOC LON SER-A, V235, P67, DOI 10.1098/rspa.1956.0065
   Bautista O, 2013, J FLUID MECH, V722, P496, DOI 10.1017/jfm.2013.107
   BEAVERS GS, 1967, J FLUID MECH, V30, P197, DOI 10.1017/S0022112067001375
   Bird R.B., 1960, TRANSPORT PHENOMENA
   Bird R. B., 1987, DYNAMICS POLYM LIQUI
   Campo-Deano L, 2013, BIOMICROFLUIDICS, V7, DOI 10.1063/1.4804649
   DATTA R, 1990, AICHE J, V36, P916, DOI 10.1002/aic.690360613
   Datta S, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2828098
   Dejam M, 2019, INT J HEAT MASS TRAN, V136, P87, DOI 10.1016/j.ijheatmasstransfer.2019.02.081
   Dejam M, 2019, INT J HEAT MASS TRAN, V128, P1307, DOI 10.1016/j.ijheatmasstransfer.2018.09.061
   Dejam M, 2018, SPE J, V23, P1669, DOI 10.2118/189994-PA
   Dejam M, 2018, CHEM ENG SCI, V189, P296, DOI 10.1016/j.ces.2018.05.058
   Dejam M, 2016, J CONTAM HYDROL, V185, P87, DOI 10.1016/j.jconhyd.2016.01.007
   Dejam M, 2015, AICHE J, V61, P3981, DOI 10.1002/aic.14897
   Dejam M, 2015, CHEM ENG SCI, V137, P205, DOI 10.1016/j.ces.2015.06.028
   Dejam M, 2014, ADV WATER RESOUR, V74, P14, DOI 10.1016/j.advwatres.2014.08.005
   Fam H, 2007, BIORHEOLOGY, V44, P59
   Fischer H. B., 1979, MIXING INLAND COASTA
   Ghosal S, 2003, J FLUID MECH, V491, P285, DOI 10.1017/S0022112003005330
   Hassanzadeh H, 2007, APPL MATH COMPUT, V189, P1966, DOI 10.1016/j.amc.2006.12.072
   Herr AE, 2000, ANAL CHEM, V72, P1053, DOI 10.1021/ac990489i
   Hesse F, 2013, ADV WATER RESOUR, V56, P35, DOI 10.1016/j.advwatres.2013.03.003
   Hoshyargar V, 2018, MICROFLUID NANOFLUID, V22, DOI 10.1007/s10404-017-2021-5
   Jougnot D, 2010, WATER RESOUR RES, V46, DOI 10.1029/2009WR008552
   Kaji N, 2004, ANAL CHEM, V76, P15, DOI 10.1021/ac030303m
   Le Bars M, 2006, J FLUID MECH, V550, P149, DOI 10.1017/S0022112005007998
   Mashayekhizadeh V, 2011, PETROL SCI TECHNOL, V29, P695, DOI 10.1080/10916460903394060
   Molla SH, 2005, J COLLOID INTERF SCI, V287, P338, DOI 10.1016/j.jcis.2004.06.096
   Molla SH, 2005, J MEMBRANE SCI, V255, P187, DOI 10.1016/j.memsci.2005.01.034
   Ng CO, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.4766598
   Revil A, 2011, WATER RESOUR RES, V47, DOI 10.1029/2010WR010002
   Revil A, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013480
   Roubinet D, 2012, WATER RESOUR RES, V48, DOI 10.1029/2011WR011168
   SANKARASUBRAMANIAN R, 1973, PROC R SOC LON SER-A, V333, P115, DOI 10.1098/rspa.1973.0051
   Scales N, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2335846
   Song J, 2014, J HYDRODYN, V26, P363, DOI 10.1016/S1001-6058(14)60041-X
   Tallarek U, 2000, ANAL CHEM, V72, P2292, DOI 10.1021/ac991303i
   TAYLOR G, 1953, PROC R SOC LON SER-A, V219, P186, DOI 10.1098/rspa.1953.0139
   TAYLOR JA, 1993, ANAL CHEM, V65, P2928, DOI 10.1021/ac00068a035
   THIEN NP, 1977, J NON-NEWTON FLUID, V2, P353, DOI 10.1016/0377-0257(77)80021-9
   Wu ZX, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5021903
   Zendehboudi S, 2011, J CAN PETROL TECHNOL, V50, P56, DOI 10.2118/145158-PA
   Zendehboudi S, 2011, ENERG FUEL, V25, P4452, DOI 10.1021/ef200689q
   Zholkovskij EK, 2004, ANAL CHEM, V76, P2708, DOI 10.1021/ac0303160
   2011, ENERG FUEL, V25, P1731, DOI DOI 10.1021/EF101506N
NR 47
TC 11
Z9 10
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 298
EP 309
DI 10.1016/j.ces.2019.04.027
PG 12
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600025
DA 2020-05-12
ER

PT J
AU Daldrup, AG
   Crine, M
   Marchot, P
   Toye, D
   Kenig, EY
AF Daldrup, A. Grosse
   Crine, M.
   Marchot, P.
   Toye, D.
   Kenig, E. Y.
TI An approach to separation efficiency modelling of structured packings
   based on X-ray tomography measurements: Application to aqueous viscous
   systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Structured packing; Liquid viscosity; X-ray tomography; Liquid
   morphology; Flow pattern; Hydrodynamic analogy model
ID HYDRODYNAMIC ANALOGY APPROACH; MASS-TRANSFER; DISTILLATION-COLUMNS;
   HOLD-UP; PERFORMANCE; VISCOSITY; AREA
AB The objective of this work is the development of a model to predict the separation efficiency of structured packings for aqueous viscous systems. The modelling approach is based on a hydrodynamic analogy between the real complex flow patterns and simplified fluid dynamic elements. Understanding of dominating liquid flow patterns inside structured packing is essential for the model development. Therefore, in this work, X-ray tomography is used to investigate liquid flow morphology. To study the influence of viscosity, water and water/glycerine mixtures are employed as working liquids.
   X-ray tomography permits the spatial distribution of liquid in the cross-section of a column filled with MellapakPlus 752.Y packing elements to be determined. The resulting images are used to evaluate liquid hold-up and gas-liquid interfacial area. Furthermore, liquid flow patterns (film flow, contact-point liquid, flooded regions) are identified, and their contribution to the overall hold-up is determined in dependence on flow rate and liquid viscosity.
   The results of the liquid flow morphology analysis help to develop a hydrodynamic analogy model. To implement the gas-liquid contact area and the flooded regions into this model, the packing is represented as a bundle of dry, filled and irrigated cylindrical channels, while the ratio between different channel types is determined from the analysis of tomographic images. This simplified hydrodynamic description allows a direct application of rigorous partial differential transport equations, and their solution yields local concentration fields which are used for the evaluation of the separation efficiency.
   The new modelling approach is validated by comparison with separation efficiency data obtained from experiments with CO2 desorption from saturated water-glycerine mixtures into air. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Daldrup, A. Grosse; Kenig, E. Y.] Univ Paderborn, Chair Fluid Proc Engn, Paderborn, Germany.
   [Crine, M.; Marchot, P.; Toye, D.] Univ Liege, Lab Chem Engn, Liege, Belgium.
   [Kenig, E. Y.] Gubkin Russian State Univ Oil & Gas, Moscow, Russia.
RP Kenig, EY (reprint author), Univ Paderborn, Chair Fluid Proc Engn, Paderborn, Germany.
EM eugeny.keing@upb.de
RI Kenig, Eugeny Y./E-9346-2010
OI Kenig, Eugeny Y./0000-0002-7521-9408
FU Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG)
   [KE 837/19-1]; Sulzer Chemtech AG; Max-Buchner-Forschungsstiftung [2842]
FX The authors are grateful to the Deutsche Forschungsgemeinschaft (DFG)
   for financial support (research project KE 837/19-1) and to Sulzer
   Chemtech AG for providing the MellapakPlus 752. Y packing elements.
   Furthermore, the financial support of Max-Buchner-Forschungsstiftung
   (research project No. 2842) is greatly acknowledged.
CR Aferka S, 2011, CHEM ENG SCI, V66, P3413, DOI 10.1016/j.ces.2011.01.022
   Billet R, 1999, CHEM ENG RES DES, V77, P498, DOI 10.1205/026387699526520
   Bocker S, 2005, CHEM ENG TECHNOL, V28, P25, DOI 10.1002/ceat.200407050
   Brinkmann U, 2010, CHEM ENG SCI, V65, P298, DOI 10.1016/j.ces.2009.06.049
   Brinkmann U, 2014, CHEM ENG J, V250, P342, DOI 10.1016/j.cej.2014.03.066
   Ferziger J.H., 2002, COMPUTATIONAL METHOD
   Green CW, 2007, IND ENG CHEM RES, V46, P5734, DOI 10.1021/ie0701827
   Janzen A, 2013, CHEM ENG SCI, V102, P451, DOI 10.1016/j.ces.2013.08.035
   Kenig EY, 1997, COMPUT CHEM ENG, V21, pS355, DOI 10.1016/S0098-1354(97)00074-4
   KENIG EY, 2000, MODELING MULTICOMPON
   Kiss A. V., 1937, Z ANORG ALLG CHEM, V233, P346
   Marchot P, 2001, AICHE J, V47, P1471, DOI 10.1002/aic.690470622
   Mueller I, 2011, CHEM ENG COMMUN, V198, P629, DOI 10.1080/00986445.2011.532699
   Olujic Z, 1997, CHEM BIOCHEM ENG Q, V11, P31
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   Petre CF, 2003, CHEM ENG SCI, V58, P163, DOI 10.1016/S0009-2509(02)00473-6
   Rocha JA, 1996, IND ENG CHEM RES, V35, P1660, DOI 10.1021/ie940406i
   Schmit CE, 2004, CHEM ENG SCI, V59, P1255, DOI 10.1016/j.ces.2003.09.045
   Schmit CE, 2001, CHEM ENG SCI, V56, P3431, DOI 10.1016/S0009-2509(01)00036-7
   Shetty S, 1997, IND ENG CHEM RES, V36, P771, DOI 10.1021/ie960627j
   Shilkin A, 2006, AICHE J, V52, P3055, DOI 10.1002/aic.10937
   Shilkin A, 2005, CHEM ENG J, V110, P87, DOI 10.1016/j.cej.2005.03.018
   Shilkin A., 2007, MODELLING TRANSPORT
   Sidi-Boumedine R, 2005, CATAL TODAY, V105, P673, DOI 10.1016/j.cattod.2005.06.040
   Stoter F., 1993, MODELLING MALDISTRIB
   SUESS P, 1992, CHEM ENG PROCESS, V31, P119, DOI 10.1016/0255-2701(92)85005-M
   Tsai RE, 2009, ENRGY PROCED, V1, P1197, DOI 10.1016/j.egypro.2009.01.157
   Viva A, 2011, CHEM ENG RES DES, V89, P1414, DOI 10.1016/j.cherd.2011.02.009
   Wang GQ, 2005, IND ENG CHEM RES, V44, P8715, DOI 10.1021/ie050017w
   ZHAO L, 1992, INT J MULTIPHAS FLOW, V18, P495, DOI 10.1016/0301-9322(92)90048-L
   ZOGG M, 1973, CHEM-ING-TECH, V45, P67, DOI 10.1002/cite.330450205
NR 31
TC 0
Z9 0
U1 1
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 310
EP 319
DI 10.1016/j.ces.2019.03.059
PG 10
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600026
DA 2020-05-12
ER

PT J
AU Han, D
   Karmakar, T
   Bjelobrk, Z
   Gong, J
   Parrinello, M
AF Han, Dandan
   Karmakar, Tarak
   Bjelobrk, Zoran
   Gong, Junbo
   Parrinello, Michele
TI Solvent-mediated morphology selection of the active pharmaceutical
   ingredient isoniazid: Experimental and simulation studies
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Isoniazid; Morphology; Aspect ratio; Molecular dynamics simulation;
   Growth mechanism
ID CRYSTAL-GROWTH; FORCE-FIELD; PREDICTION; GROMACS; SHAPE; POLYMORPHS;
   NUCLEATION; COMPASS; DETAILS; NACL
AB In solution crystallization, solvent has a profound effect on controlling crystal morphology. However, the role played by solvents in affecting crystal morphology remains elusive. Here, we accompany experiments with molecular dynamics simulations to investigate crystallization of an anti-tuberculosis drug, isoniazid, in different solvents. Experiments show that isoniazid grows as needle-like crystals in water, while in alcohols such as methanol, ethanol and isopropanol, it exhibits a rod-like crystal habit. The aspect ratio of isoniazid crystals decreases with the decrease in the relative solvent polarity. We modeled these experiments by performing molecular dynamics simulations of isoniazid crystallization in different solvents at constant chemical potential thus keeping the solution concentration constant. The simulation results reveal a rough growth mechanism for the fast growing (1 1 0) surface, and bulk transport of the solute from solution to the growing surface is the limiting-step. In accordance with experiments, the relative growth rate of this surface decreases from methanol, ethanol to isopropanol. On the other hand, the slow growing (0 0 2) surface appears to follow a stepwise growth mechanism, with a surface integration step chiefly controlling the growth. The relative growth rate of this surface increases from methanol to ethanol and isopropanol. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Han, Dandan; Gong, Junbo] Tianjin Univ, Sch Chem Engn & Technol, Collaborat Innovat Ctr Chem Sci & Engn, Tianjin 300072, Peoples R China.
   [Karmakar, Tarak; Parrinello, Michele] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland.
   [Bjelobrk, Zoran] Swiss Fed Inst Technol, Inst Proc Engn, CH-8093 Zurich, Switzerland.
   [Karmakar, Tarak; Parrinello, Michele] Univ Svizzera Italiana, Fac Informat, Ist Sci Computaz, CH-6900 Lugano, Switzerland.
RP Gong, J (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Collaborat Innovat Ctr Chem Sci & Engn, Tianjin 300072, Peoples R China.; Parrinello, M (reprint author), Swiss Fed Inst Technol, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland.; Parrinello, M (reprint author), Univ Svizzera Italiana, Fac Informat, Ist Sci Computaz, CH-6900 Lugano, Switzerland.
EM junbo_gong@tju.edu.cn; mchele.parrinello@phys.chem.ethz.ch
RI Karmakar, Tarak/V-3108-2019
OI Karmakar, Tarak/0000-0002-8721-6247
FU China Scholarship Council (CSC)China Scholarship Council; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [NNSFC 81361140344, NNSFC 91634117]; European UnionEuropean
   Union (EU) [ERC-2014-AdG-670227/VARMET]; Novartis pharma AG, Basel,
   Switzerland; Swiss National Science FoundationSwiss National Science
   Foundation (SNSF)
FX D.D. acknowledges funding support from the China Scholarship Council
   (CSC), and J.B thanks for the financial support of National Natural
   Science Foundation of China (NNSFC 81361140344 and NNSFC 91634117). T.K.
   and M.P. thank the European Union Grant (No. ERC-2014-AdG-670227/VARMET)
   for the financial support. Z.B. is thankful for the financial support
   provided by Novartis pharma AG, Lichtstrasse 35, CH-4056, Basel,
   Switzerland. The computational resources are provided by the CSCS, Swiss
   National Supercomputing Centre. We acknowledge the NCCR MARVEL, funded
   by the Swiss National Science Foundation. We also thank Yifu Chen for
   the design and drawing of the front cover.
CR [Anonymous], 2012, MAT STUD 6 0
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Beyer T, 2001, J AM CHEM SOC, V123, P5086, DOI 10.1021/ja0102787
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Caleman C, 2012, J CHEM THEORY COMPUT, V8, P61, DOI 10.1021/ct200731v
   Chen J, 2010, CRYST GROWTH DES, V10, P4379, DOI 10.1021/cg1004903
   Chernov A., 1963, SOV PHYS-CRYSTALLOGR, V7, P728
   Coombes DS, 2005, CRYST GROWTH DES, V5, P879, DOI 10.1021/cg049707d
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002
   Duff N, 2011, J CHEM PHYS, V135, DOI 10.1063/1.3638268
   Frisch MJ, 2009, GAUSSIAN 09 REVISION
   Gibbs J. W., 1961, SCI PAPERS THERMODYN
   Gibertihi F, 2015, CHEM ENG SCI, V121, P51, DOI 10.1016/j.ces.2014.08.032
   Han DD, 2018, CRYST GROWTH DES, V18, P775, DOI 10.1021/acs.cgd.7b01202
   HARTMAN P, 1980, J CRYST GROWTH, V49, P145, DOI 10.1016/0022-0248(80)90075-5
   Haynes WM, 2014, CRC HDB CHEM PHYS
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   JONES AG, 2002, CRYSTALLIZATION PROC
   Joswiak MN, 2018, CRYST GROWTH DES, V18, P6302, DOI 10.1021/acs.cgd.8b01184
   Karmakar T, 2018, J CHEM THEORY COMPUT, V14, P2678, DOI 10.1021/acs.jctc.8b00191
   Klapwijk AR, 2016, CRYST GROWTH DES, V16, P4349, DOI 10.1021/acs.cgd.6b00465
   Kossel W., 1927, NACHR GES WISS GOTT, V1927, P135
   Lemmerer A, 2012, CRYSTENGCOMM, V14, P2465, DOI 10.1039/c1ce06310c
   Lovette MA, 2008, IND ENG CHEM RES, V47, P9812, DOI 10.1021/ie800900f
   Ma CY, 2008, AICHE J, V54, P209, DOI 10.1002/aic.11365
   Majumder A, 2013, CHEM ENG SCI, V101, P593, DOI 10.1016/j.ces.2013.07.017
   Mennucci B, 1997, J PHYS CHEM B, V101, P10506, DOI 10.1021/jp971959k
   Perego C, 2015, J CHEM PHYS, V142, DOI 10.1063/1.4917200
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002
   Rosbottom I, 2017, CRYST GROWTH DES, V17, P4151, DOI 10.1021/acs.cgd.7b00425
   Salvalaglio M, 2014, ACTA CRYSTALLOGR C, V70, P132, DOI 10.1107/S2053229613026946
   Salvalaglio M, 2013, ANGEW CHEM INT EDIT, V52, P13369, DOI 10.1002/anie.201304562
   Salvalaglio M, 2012, J AM CHEM SOC, V134, P17221, DOI 10.1021/ja307408x
   Santiso EE, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3548889
   Stranski I. N., 1928, Z PHYS CHEM-STOCH VE, V136, P259
   Sullivan RA, 2015, CRYSTENGCOMM, V17, P1015, DOI 10.1039/c4ce01857e
   Sun H, 1998, COMPUT THEOR POLYM S, V8, P229, DOI 10.1016/S1089-3156(98)00042-7
   Sun H, 1998, J PHYS CHEM B, V102, P7338, DOI 10.1021/jp980939v
   Tribello GA, 2014, COMPUT PHYS COMMUN, V185, P604, DOI 10.1016/j.cpc.2013.09.018
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang Y, 2017, CRYSTENGCOMM, V19, P3198, DOI 10.1039/c7ce00474e
   WILCOX WR, 1993, PROG CRYST GROWTH CH, V26, P153, DOI 10.1016/0960-8974(93)90014-U
   Winn D, 2002, CHEM ENG SCI, V57, P1805, DOI 10.1016/S0009-2509(02)00056-8
   Wulff G, 1901, Z KRYSTALLOGR MINERA, V34, P449, DOI 10.1524/zkri.1901.34.1.449
   Zimmermann NER, 2018, J CHEM PHYS, V148, DOI 10.1063/1.5024009
NR 49
TC 7
Z9 7
U1 19
U2 73
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD AUG 31
PY 2019
VL 204
BP 320
EP 328
DI 10.1016/j.ces.2018.10.022
PG 9
WC Engineering, Chemical
SC Engineering
GA HW9YC
UT WOS:000467045600027
DA 2020-05-12
ER

PT J
AU Sarmiento, LM
   Clavier, KA
   Paris, JM
   Ferraro, CC
   Townsend, TG
AF Sarmiento, Linda Monroy
   Clavier, Kyle A.
   Paris, Jerry M.
   Ferraro, Christopher C.
   Townsend, Timothy G.
TI Critical examination of recycled municipal solid waste incineration ash
   as a mineral source for portland cement manufacture - A case study
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Recycling; Beneficial use; Cement; Clinker; MSW; Incineration; Ash
AB Municipal solid waste incineration (MSWI) ash has the potential to be used as mineral feed for portland cement manufacture but is not currently used in this manner in much of the world. A scoping study was performed using samples and data from Florida, US, to assess the potential magnitude of material that may be recycled to create a viable clinker. Results indicate that MSWI ash possesses the elemental ingredients to serve as a partial kiln feed replacement. Large amounts of MSWI can be used based on mineralogy alone, but chloride and alkali content limitations decrease allowable replacement amounts, especially for fly ash. Average allowable replacement percentages that did not exceed standard chloride and alkali limits were 6.4%, 0.33%, and 1.17% for bottom ash, fly ash and combined ash, respectively. MSWI bottom ash may be the preferred material stream in the absence of pre-processing techniques such as washing. The scoping study found that available MSWI ash could supply a large amount of the current kiln feed demand, and a feasibility and cost assessment supports that both MSWI facility and cement kiln operators have justification to pursue this technology with more detailed evaluations.
C1 [Sarmiento, Linda Monroy; Clavier, Kyle A.; Townsend, Timothy G.] Univ Florida, Engn Sch Sustainable Infrastruct & Environm Dept, Dept Environm Engn Sci, POB 116450, Gainesville, FL 32611 USA.
   [Paris, Jerry M.; Ferraro, Christopher C.] Univ Florida, Dept Civil & Coastal Engn, Engn Sch Sustainable Infrastruct & Environm, POB 116580, Gainesville, FL 32611 USA.
RP Townsend, TG (reprint author), Univ Florida, Engn Sch Sustainable Infrastruct & Environm Dept, Dept Environm Engn Sci, POB 116450, Gainesville, FL 32611 USA.
EM ttown@ufl.edu
RI Ferraro, Christopher/K-6172-2017
OI Ferraro, Christopher/0000-0001-5639-8247; Clavier,
   Kyle/0000-0003-2840-5336
FU Hinkley Center for Solid and Hazardous Waste Management
FX This work was funded by the Hinkley Center for Solid and Hazardous Waste
   Management. The authors thank the regional cement companies that offered
   support and information for this study. We also thank the MSWI
   facilities for supplying materials.
NR 0
TC 2
Z9 2
U1 13
U2 56
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 1
EP 10
DI 10.1016/j.resconrec.2019.05.002
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800001
DA 2020-05-12
ER

PT J
AU Wei, J
   Chen, H
   Long, RY
   Zhao, F
AF Wei, Jia
   Chen, Hong
   Long, Ruyin
   Zhao, Fang
TI Application of the capability maturity model to evaluating the carbon
   capability maturity of urban residents in 10 Eastern provinces of China
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Carbon capability; Capability maturity model; Maturity level; Urban
   resident
ID CONSUMPTION BEHAVIOR; HOUSEHOLD CARBON; CLIMATE-CHANGE; EMISSIONS;
   DECOMPOSITION
AB A carbon capability maturity model was constructed to measure the capability of urban residents to voluntarily reduce carbon emissions. This model distinguished five maturity levels: the initial level, growth level, standard level, integration level, and optimization level. Based on the empirical study about urban residents in 10 eastern provinces (cities) of China, this study found that the carbon capability maturity of the urban residents exhibited an obvious "pyramidal" distribution, which ranged from the initial level to the optimization level. About 71.7% of the residents were at the initial level, but the proportions of those at the standard level, integration level, and optimization level were less than 10%. Shanghai, Fujian, Guangdong, and Hainan were at the growth level, whereas the urban residents in Beijing, Tianjin, Hebei, Jiangsu, Zhejiang, and Shandong were at the initial level. The main reason for this gap was the difference in the carbon identification capability. The maturity gap of the urban residents in Shandong was the largest, whereas the gap in Tianjin and Hebei was relatively small. Based on the conclusions, policy implications were proposed to promote the improvement of the carbon capability maturity.
C1 [Wei, Jia; Zhao, Fang] Xi An Jiao Tong Univ, Sch Econ & Finance, Xian, Shaanxi, Peoples R China.
   [Chen, Hong; Long, Ruyin] China Univ Min & Technol, Sch Management, Xuzhou, Jiangsu, Peoples R China.
RP Wei, J (reprint author), 74 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.; Chen, H (reprint author), 1 Daxue Rd, Xuzhou 221116, Jiangsu, Peoples R China.
EM jiawei0626@xjtu.edu.cn; hongchenxz@163.com; longruyin@163.com;
   fangzhao87@163.com
OI Wei, Jia/0000-0001-5564-2172; Gong, Likun/0000-0001-8821-641X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71804141, 71874188, 71473248, 71673271, 71473247,
   71273258, 71603255]; Major project of National Social Science Foundation
   of China [16ZDA056]; Jiangsu Philosophy and Social Sciences Excellent
   Innovation Cultivation Team (2017); 333 High-level Talents Project of
   Jiangsu Province (2016); Teaching Education Reform and Practice of
   Jiangsu Province [JGZZ16_078]; Innovation Team Program of the China
   University of Mining and Technology [2015ZY003]; Social Science
   Foundation of Jiangsu Province Project [14JD026]; "13th Five Year" Brand
   Discipline Construction Funding Project of China University of Mining
   and Technology (2017); Think Tank of Green Safety Management and Policy
   Science (2018 "Double First-Class" Initiative Project for Cultural
   Evolution and Creation of CUMT) [2018WHCC03]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2017M620459,
   2018T111080]
FX This study was financially supported by the National Natural Science
   Foundation of China (Grant Nos. 71804141, 71874188, 71473248, 71673271,
   71473247, 71273258, and 71603255), Major project of National Social
   Science Foundation of China (Grant No. 16ZDA056), Jiangsu Philosophy and
   Social Sciences Excellent Innovation Cultivation Team (2017), 333
   High-level Talents Project of Jiangsu Province (2016), Teaching
   Education Reform and Practice of Jiangsu Province (Grant No.
   JGZZ16_078), Innovation Team Program of the China University of Mining
   and Technology (Grant No. 2015ZY003), Social Science Foundation of
   Jiangsu Province Project (Grant No. 14JD026), "13th Five Year" Brand
   Discipline Construction Funding Project of China University of Mining
   and Technology (2017), Think Tank of Green Safety Management and Policy
   Science (2018 "Double First-Class" Initiative Project for Cultural
   Evolution and Creation of CUMT) (Grant No. 2018WHCC03), and the China
   Postdoctoral Science Foundation (Grant No. 2017M620459 and 2018T111080).
CR Abas A.S., 2015, APPL MECH MAT, V747, P290, DOI [10.4028/www.scientific.net/AMM.747.290, DOI 10.4028/WWW.SCIENTIFIC.NET/AMM.747.290]
   Allinson D, 2016, APPL ENERG, V164, P871, DOI 10.1016/j.apenergy.2015.11.054
   Amulen Christine, 2016, International Journal of Agile Systems and Management, V9, P1
   Bentzen J, 2004, ENERG ECON, V26, P123, DOI 10.1016/S0140-9883(03)00047-1
   Cai BF, 2018, J ENVIRON MANAGE, V206, P786, DOI 10.1016/j.jenvman.2017.11.038
   Chen H, 2014, APPL ENERG, V116, P376, DOI 10.1016/j.apenergy.2013.11.027
   Chen SQ, 2015, APPL ENERG, V138, P99, DOI 10.1016/j.apenergy.2014.10.055
   China State Council, 2011, MAJ DAT 6 NAT POP CE
   China State Council, 2014, NAT NEW URB PLAN 201
   Damert M, 2018, RESOUR CONSERV RECY, V136, P276, DOI 10.1016/j.resconrec.2018.05.002
   Ding ZH, 2018, RESOUR CONSERV RECY, V132, P3, DOI 10.1016/j.resconrec.2018.01.013
   Doss D. A., 2017, ENERGY ENV ENG, V5, P67
   Energy Information Administration (EIA), 2018, EN REL CO2 EM EXP RI
   Finnerty N, 2017, J CLEAN PROD, V167, P1232, DOI 10.1016/j.jclepro.2017.07.192
   Geng JC, 2018, J ENVIRON MANAGE, V217, P47, DOI 10.1016/j.jenvman.2018.03.091
   Jin SH, 2007, ENERG POLICY, V35, P5622, DOI 10.1016/j.enpol.2007.05.028
   Lacerda TC, 2018, COMPUT STAND INTER, V55, P95, DOI 10.1016/j.csi.2017.06.001
   Lee CT, 2018, J CLEAN PROD, V176, P726, DOI 10.1016/j.jclepro.2017.12.110
   Li QW, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10041292
   Liao X., 2014, SCI TECH MANAG RES, V34, P232
   Lin H. C., 2015, ACAD MANAG ANN M P, V1, P17230
   Mi Lingyun, 2011, RES LOW CARBON ENERG
   National Bureau of Statistics, 2017, CHIN EN STAT YB 2016
   Ngai EWT, 2013, INT J PROD ECON, V146, P453, DOI 10.1016/j.ijpe.2012.12.018
   Trevino GO, 2014, KNOWL MAN RES PRACT, V12, P289, DOI 10.1057/kmrp.2014.5
   Parikh K, 2012, ENERGY, V40, P31, DOI 10.1016/j.energy.2012.01.013
   Song W., 2012, CANADIAN SOCIAL SCI, V8, P38
   Strutt JE, 2006, ENVIRON INT, V32, P1094, DOI 10.1016/j.envint.2006.06.016
   Sun Y., 2012, CHINESE J MANAGEMENT, P2197
   Torrecilla-Salinas CJ, 2016, INFORM SOFTWARE TECH, V71, P92, DOI 10.1016/j.infsof.2015.11.002
   Urban F, 2018, ENERG POLICY, V113, P320, DOI 10.1016/j.enpol.2017.11.007
   Wang QW, 2015, APPL ENERG, V151, P85, DOI 10.1016/j.apenergy.2015.04.034
   Wang QW, 2012, APPL ENERG, V90, P161, DOI 10.1016/j.apenergy.2011.02.022
   Wei J, 2016, APPL ENERG, V173, P635, DOI 10.1016/j.apenergy.2016.04.068
   Whitmarsh L., 2009, WORKING PAPER
   Whitmarsh L, 2011, GLOBAL ENVIRON CHANG, V21, P56, DOI 10.1016/j.gloenvcha.2010.07.011
   Yu SW, 2015, ENERG POLICY, V77, P46, DOI 10.1016/j.enpol.2014.11.035
   Zhang M., 2010, STAT DECIS, V8, P191
   Zhang XL, 2017, ENERG POLICY, V102, P116, DOI 10.1016/j.enpol.2016.12.010
NR 39
TC 0
Z9 0
U1 7
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 11
EP 22
DI 10.1016/j.resconrec.2019.04.029
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800002
DA 2020-05-12
ER

PT J
AU Palacios, JL
   Abadias, A
   Valero, A
   Valero, A
   Reuter, MA
AF Palacios, Jose-Luis
   Abadias, Alejandro
   Valero, Alicia
   Valero, Antonio
   Reuter, Markus A.
TI Producing metals from common rocks: The case of gold
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Mineral processing; Gold; Crust; Thanatia; Exergy replacement cost;
   Thermodynamic rarity
ID COMMINUTION ENERGY; TRENDS; RESOURCES; EFFICIENCY; SCARCITY; CYANIDE;
   EXERGY; COPPER
AB The depletion of the mineral capital is a topic of concern because the worldwide demand for minerals is rapidly increasing. Moreover, since the energy consumption increases as ore grades decline, there is growing stress on energy resources and the environment associated with mining activities. The energy costs associated with the exhaustion of mineral deposits is ruled by the entropy law through a negative logarithmic pattern, in which as the ore grade tends to zero, the energy tends to infinity. This study analyzes through a model developed in HSC Chemistry software, the energy that would be required to produce gold from common bare rock. In this way, we evaluate the maximum energy consumption with current technologies, to obtain gold at the final ore grade, i.e., when all mineral deposits were completely exhausted until reaching crustal concentration. The final theoretical concentration of gold is assumed to be that of the model of Thanatia, which is a resource exhausted Earth with the most abundant minerals found at crustal concentrations. The results are then compared to theoretical values obtained in previous studies for gold and serve to update with a more accurate methodology, the so-called thermodynamic rarity of minerals, as a way to assess the avoided mining energy for having minerals concentrated in mines and not dispersed throughout the crust. This then serves to assess the mineral capital and its degradation velocity from a thermodynamic point of view.
C1 [Palacios, Jose-Luis] Escuela Politec Nacl, Dept Ingn Mecan, Ladron Guevara E11-25, Quito 170517, Ecuador.
   [Abadias, Alejandro; Reuter, Markus A.] Helmholtz Inst Freiberg Resource Technol HIF, Chemnitzer Str 40, D-09599 Freiberg, Germany.
   [Valero, Alicia; Valero, Antonio] Univ Zaragoza, Res Ctr Energy Resources & Consumpt, CIRCE Inst, CIRCE Bldg Campus Rio Ebro,Mariano Esquillor Gome, Zaragoza 50018, Spain.
RP Palacios, JL (reprint author), Escuela Politec Nacl, Dept Ingn Mecan, Ladron Guevara E11-25, Quito 170517, Ecuador.
EM jose.palacios@epn.edu.ec; a.abadias@hzdr.de; aliciavd@unizar.es;
   valero@unizar.es; m.reuter@hzdr.de
RI Delgado, Alicia Valero/Z-6141-2019
OI Delgado, Alicia Valero/0000-0003-3330-1793; Reuter,
   Markus/0000-0003-0500-4863; Palacios, Jose Luis/0000-0002-2738-5276
FU National Secretary of Science and Education of Ecuador (SENESCYT) of the
   Spanish Ministry of Economy, Industry, and Competitiveness
   [ENE2017-85224R]
FX We thank the National Secretary of Science and Education of Ecuador
   (SENESCYT) for the support for research activities and for the financial
   support of the Spanish Ministry of Economy, Industry, and
   Competitiveness through project ENE2017-85224R. We want to thank Prof.
   Dr. Oscar Restrepo of Universidad Nacional de Colombia for providing a
   valuable bibliography. Thanks to Ivan Fernandes of Helmholtz Institute
   Freiberg for Resource Technology for the revision of the first versions
   of this paper. We are grateful to the anonymous reviewers whose comments
   improved the quality of the paper.
CR ADAMS MD, 1994, MINER ENG, V7, P1165, DOI 10.1016/0892-6875(94)90004-3
   AMC Consultants, 2019, CAN LTDA PUEBL VIEJ
   [Anonymous], 2017, WORLD STEEL ASS STEE
   Asiri AM, 2016, CHEM SOC REV, V45, P4471, DOI 10.1039/c6cs00023a
   Ayres R.U, 2016, COMPLEXITY WEALTH MA
   Ballantyne GR, 2014, MINER ENG, V65, P109, DOI 10.1016/j.mineng.2014.05.017
   Bardi U., 2014, QUEST MINERAL WEALTH
   Bejan A., 1996, THERMAL DESIGN OPTIM
   Beyuo M., 2016, 4 UMAT BIENN INT M M, P161
   BRANDON NP, 1987, HYDROMETALLURGY, V18, P305, DOI 10.1016/0304-386X(87)90072-7
   CALVO G, 2016, RESOURCES, V2016, P36, DOI DOI 10.3390/RES0URCES5040036
   Calvo G, 2018, J IND ECOL, V22, P839, DOI 10.1111/jiec.12624
   Calvo G, 2015, RESOURCES-BASEL, V4, P857, DOI 10.3390/resources4040857
   Carrasco O. H., 2016, REV MET, V38, P38
   Cengel Y. A., 2008, THERMODYNAMICS ENG A
   Chapman P.F., 1983, METAL RESOURCES ENER
   Christine B., 2014, 43101 NI EL GOLD PRO
   Craig J., 2014, EARTH RESOURCES ENV
   Dewulf J., 2006, RENEWABLES BASED TEC, P111
   Dominguez A., 2013, J ENV ACC MANAG, V1, P85, DOI DOI 10.5890/JEAM.2012.01.007
   Dykman LA, 2011, ACTA NATURAE, V3, P34, DOI 10.32607/20758251-2011-3-2-34-56
   Ellis S., 2016, GOLD ORE PROCESSING
   Fuerstenau M.C., 2007, FROTH FLOTATION CENT
   Garcia A., 2018, HSC CHEM, P9
   Gupta A, 2006, MINERAL PROCESSING DESIGN AND OPERATIONS: AN INTRODUCTION, P1
   Harmsen JHM, 2013, ENERGY, V50, P62, DOI 10.1016/j.energy.2012.12.006
   Hashmi ASK, 2006, ANGEW CHEM INT EDIT, V45, P7896, DOI 10.1002/anie.200602454
   Henckens MLCM, 2016, RESOUR POLICY, V49, P102, DOI 10.1016/j.resourpol.2016.04.012
   Hewitt A., 2015, GOLD RECYCLING UNDER
   Higby G J, 1982, Gold Bull, V15, P130
   International Energy Agency Energy Technology Perspectives, 2010, SCEN STRAT 2050
   Jankovic A, 2010, J S AFR I MIN METALL, V110, P141
   King R.P., 2001, MODELING SIMULATION
   Lindroos E. W., 1985, SME MINERAL PROCESSI
   Lipiec I., 2016, 43001 NI FRUT NORT P
   Lu L, 2015, IRON ORE MINERALOGY
   Marsden J., 1992, CHEM GOLD EXTRACTION
   Marsden J.O., 2006, CHEM GOLD EXTRACTION, P80127
   Matos G. R., 2019, US GEOLOGICAL SURVEY, P896
   Moran M. J., 2011, FUNDAMENTALS ENG THE
   Morrell J. B., 2016, GLOB MIN STAND GUIDE
   Mudd GM, 2008, J ENVIRON RADIOACTIV, V99, P288, DOI 10.1016/j.jenvrad.2007.08.001
   Mudd GM, 2007, ENVIRON SCI POLICY, V10, P629, DOI 10.1016/j.envsci.2007.04.006
   Mudd GM, 2007, ORE GEOL REV, V32, P227, DOI 10.1016/j.oregeorev.2006.05.005
   Mudd GM, 2007, RESOUR POLICY, V32, P42, DOI 10.1016/j.resourpol.2007.05.002
   Mudd GM, 2010, ORE GEOL REV, V38, P9, DOI 10.1016/j.oregeorev.2010.05.003
   MUIR DM, 1985, HYDROMETALLURGY, V14, P47, DOI 10.1016/0304-386X(85)90005-2
   Norgate T, 2010, MINER ENG, V23, P65, DOI 10.1016/j.mineng.2009.10.002
   Norgate T, 2012, J CLEAN PROD, V29-30, P53, DOI 10.1016/j.jclepro.2012.01.042
   Palacios JL, 2018, SUSTAINABILITY-BASEL, V10, DOI 10.3390/su10030723
   Pflasterer D, 2016, CHEM SOC REV, V45, P1331, DOI 10.1039/c5cs00721f
   Pricker SP, 1996, GOLD BULL, V29, P53, DOI DOI 10.1007/BF03215464
   Rankin WJ, 2011, MINERALS, METALS AND SUSTAINABILITY: MEETING FUTURE MATERIAL NEEDS, P1
   Redmond D., 2015, 43101 NI
   Reuter M, 2016, GOLD ORE PROCESSING: PROJECT DEVELOPMENT AND OPERATIONS, 2ND EDITION, P937, DOI 10.1016/B978-0-444-63658-4.00053-0
   Rowland C.A, 1982, DESIGN INSTALLATION, P393
   Rowland C.A, 2002, MINERAL PROCESSING P, P710
   Sawyer S, 2016, GLOBAL WIND ENERGY O
   Sen S, 2010, REM-REV ESC MINAS, V63, P539, DOI 10.1590/S0370-44672010000300017
   Skarin O. I., 2015, EURASIAN MIN, V1, P5
   SKINNER BJ, 1976, AM SCI, V64, P258
   Steen B, 2002, ECOL ECON, V42, P401, DOI 10.1016/S0921-8009(02)00123-4
   Szargut J, 2002, ENERG CONVERS MANAGE, V43, P1149, DOI 10.1016/S0196-8904(02)00005-5
   SZARGUT J, 1989, APPL ENERG, V32, P269, DOI 10.1016/0306-2619(89)90016-0
   Szargut J., 2015, P ECOS, P409
   Tripp A., 2015, 43101 NI
   Valdivieso A. L., 1999, 23 CONV AIMMGM, P1
   Valero A., 2014, THANATIA DESTINY EAR
   Valero A., 2013, J ENV ACCOUNT MANAGE, V1, P147, DOI DOI 10.5890/JEAM.2013.05.004
   Valero A., 2018, RENEW SUSTAIN ENERGY
   Valero A, 2015, RESOUR CONSERV RECY, V94, P110, DOI 10.1016/j.resconrec.2014.12.001
   Valero A, 2012, RESOUR CONSERV RECY, V68, P126, DOI 10.1016/j.resconrec.2012.08.004
   Valero A, 2011, ENERGY, V36, P694, DOI 10.1016/j.energy.2010.09.034
   Valero A, 2012, ENERGY, V44, P1085, DOI 10.1016/j.energy.2012.04.021
   Valero A, 2010, ENERGY, V35, P229, DOI 10.1016/j.energy.2009.09.013
   Weiss N. L., 1985, SME HDB MINERAL PROC
   Wills B.A., 2006, WILLS MINERAL PROCES
   Yang WB, 2014, CHEM SOC REV, V43, P2941, DOI 10.1039/c3cs60441a
   Yannopoulos J.C., 1991, EXTRACTIVE METALLURG
   Zhang J, 2010, INT J MIN MET MATER, V17, P1, DOI [10.1007/s12613-010-0101-6, 10.1007/S12613-010-0101-6]
NR 80
TC 3
Z9 3
U1 3
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 23
EP 35
DI 10.1016/j.resconrec.2019.04.026
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800003
DA 2020-05-12
ER

PT J
AU Asadi, S
   Nilashi, M
   Safaei, M
   Abdullah, R
   Saeed, F
   Yadegaridehkordi, E
   Samad, S
AF Asadi, Shahla
   Nilashi, Mehrbakhsh
   Safaei, Mahmood
   Abdullah, Rush
   Saeed, Faisal
   Yadegaridehkordi, Elaheh
   Samad, Sarminah
TI Investigating factors influencing decision-makers' intention to adopt
   Green IT in Malaysian manufacturing industry
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Manufacturing sector decision-makers perspectives; Norm activation
   theory; Theory of planned behavior; Green IS; Green IT
ID CITIZENS ENVIRONMENTAL COMPLAINT; PLANNED BEHAVIOR MODEL; ENERGY-SAVING
   BEHAVIOR; NORM ACTIVATION MODEL; PERSONAL NORMS; INFORMATION-TECHNOLOGY;
   EXTENDED THEORY; SELF-EFFICACY; MANAGERIAL INTERPRETATIONS; INTEGRATING
   THEORY
AB Green IT has attracted policy makers and IT managers within organizations to use IT resources in cost-effective and energy-efficient ways. Investigating the factors that influence decision-makers' intention towards the adoption of Green IT is important in the development of strategies that promote the organizations to use Green IT. Therefore, the objective of this study stands to understand potential factors that drive decisions makers in Malaysian manufacturing sector to adopt Green IT. This research accordingly developed a model by integrating two theoretical models, Theory of Planned Behavior and Norm Activation Theory, to explore individual factors that influence decision' makers in manufacturing sector in Malaysia to adopt Green IT via the mediation of personal norms. Accordingly, to determine predictive factors that influence managerial intention toward Green IT adoption, the researchers conducted a comprehensive literature review. The data was collected from 183 decision-makers from Malaysian manufacturing sector and analyzed by Structural Equation Modelling. This research provides important preliminary insights in understanding the most significant factors that determined managerial intention towards Green IT adoption. The model of Green IT adoption explained factors which encourages individual decision-makers in the Malaysian organizations to adopt Green IT initiatives for environment sustainability.
C1 [Asadi, Shahla; Abdullah, Rush] Univ Putra Malaysia, Fac Comp Sci & Informat Technol, Dept Software Engn & Informat Syst, Seri Kembangan 43400, Selangor, Malaysia.
   [Nilashi, Mehrbakhsh] Ton Duc Thang Univ, Dept Management Sci & Technol Dev, Ho Chi Minh City, Vietnam.
   [Nilashi, Mehrbakhsh] Ton Duc Thang Univ, Fac Informat Technol, Ho Chi Minh City, Vietnam.
   [Safaei, Mahmood] Univ Teknol Malaysia, Fac Engn, Sch Comp, Skudai Johor 81310, Malaysia.
   [Saeed, Faisal] Taibah Univ, Coll Comp Sci & Engn, Dept Informat Syst, Medina, Saudi Arabia.
   [Yadegaridehkordi, Elaheh] Univ Malaya, Fac Comp Sci & Informat Technol, Dept Informat Syst, Kuala Lumpur 50603, Malaysia.
   [Samad, Sarminah] Princess Nourah Bint Abdulrahman Univ, Dept Business Adm, Collage Business & Adm, Riyadh, Saudi Arabia.
RP Nilashi, M (reprint author), Ton Duc Thang Univ, Dept Management Sci & Technol Dev, Ho Chi Minh City, Vietnam.; Nilashi, M (reprint author), Ton Duc Thang Univ, Fac Informat Technol, Ho Chi Minh City, Vietnam.
EM nilashi@tdtu.edu.vn
RI Nilashi, Mehrbakhsh/AAM-2215-2020; Yadegaridehkordi,
   Elaheh/AAD-1613-2019
OI Nilashi, Mehrbakhsh/0000-0002-2804-3227; Yadegaridehkordi,
   Elaheh/0000-0003-1576-9210; Safaei, Mahmood/0000-0002-3924-6927; Asadi,
   Shahla/0000-0002-8199-2122
CR Abdullah M., 2015, REV MANAG SCI
   Abrahamse W, 2009, J ECON PSYCHOL, V30, P711, DOI 10.1016/j.joep.2009.05.006
   Abrahamse W, 2009, TRANSPORT RES F-TRAF, V12, P317, DOI 10.1016/j.trf.2009.04.004
   Adebamo H.O., 2014, ANTECEDENTS OUTCOME, V3, P147
   Ahmed E. M., 2006, World Review of Science, Technology and Sustainable Development, V3, P58
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   AJZEN I, 1986, J EXP SOC PSYCHOL, V22, P453, DOI 10.1016/0022-1031(86)90045-4
   Akman I, 2015, COMPUT HUM BEHAV, V49, P477, DOI 10.1016/j.chb.2015.03.009
   Akman I, 2014, PROBL EKOROZW, V9, P47
   Al Bizri A, 2014, 3 ESSAYS ROLE IT ENV
   Amrina E, 2011, IND ENG ENG MAN IEEM
   Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939
   Asadi Shahla, 2018, International Journal of Business Information Systems, V29, P106
   Asadi S, 2017, TELEMAT INFORM, V34, P1191, DOI 10.1016/j.tele.2017.05.009
   Bamberg S, 2003, ENVIRON BEHAV, V35, P264, DOI 10.1177/0013916502250134
   Bamberg S, 2007, J ENVIRON PSYCHOL, V27, P190, DOI 10.1016/j.jenvp.2007.04.001
   Bamberg S, 2007, J ENVIRON PSYCHOL, V27, P14, DOI 10.1016/j.jenvp.2006.12.002
   BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191
   BANDURA A, 1982, AM PSYCHOL, V37, P122, DOI 10.1037/0003-066X.37.2.122
   Bandura A, 1997, SELF EFFICACY EXERCI
   Banerjee P, 2012, BEHAV INFORM TECHNOL, V31, P815, DOI 10.1080/0144929X.2010.497564
   Banerjee SB, 2003, J MARKETING, V67, P106, DOI 10.1509/jmkg.67.2.106.18604
   Bansal P, 2005, STRATEGIC MANAGE J, V26, P197, DOI 10.1002/smj.441
   Barclay D. W., 1995, TECHNOL STUDIES, V2, P285, DOI DOI 10.1017/CB09781107415324.004
   Bodur M, 2005, ENVIRON BEHAV, V37, P487, DOI 10.1177/0013916504269666
   Bohas A, 2016, J CLEAN PROD, V122, P240, DOI 10.1016/j.jclepro.2016.02.029
   Bose R, 2012, INT J ACCOUNT INF MA, V20, P63, DOI 10.1108/18347641211201081
   Bose R, 2011, J STRATEGIC INF SYST, V20, P38, DOI 10.1016/j.jsis.2011.01.003
   Brooks S., 2012, UNPACKING GREEN IS R, P3
   Butler T, 2009, EUR C INF SYST ECIS
   Butler T, 2011, J STRATEGIC INF SYST, V20, P6, DOI 10.1016/j.jsis.2010.09.006
   Cai S, 2013, INT J PROD ECON, V146, P491, DOI 10.1016/j.ijpe.2013.01.030
   Cai SJ, 2019, J CLEAN PROD, V212, P602, DOI 10.1016/j.jclepro.2018.12.072
   Carlet F, 2015, ENVIRON SCI POLICY, V51, P65, DOI 10.1016/j.envsci.2015.03.007
   Chan K, 1998, J ENVIRON MANAGE, V52, P317, DOI 10.1006/jema.1998.0189
   Chang J., 2014, KNOWLEDGE MANAGEMENT, P205
   Chen MF, 2014, INT J HOSP MANAG, V36, P221, DOI 10.1016/j.ijhm.2013.09.006
   Chin WW, 1998, QUANT METH SER, P295
   Chow WS, 2009, J COMPUT INFORM SYST, V50, P136
   CIALDINI RB, 1991, ADV EXP SOC PSYCHOL, V24, P201
   COMPEAU DR, 1995, MIS QUART, V19, P189, DOI 10.2307/249688
   Conner M, 1998, J APPL SOC PSYCHOL, V28, P1429, DOI 10.1111/j.1559-1816.1998.tb01685.x
   Corbett J., 2010, ICIS 2010 P, P198
   DAVIS FD, 1992, J APPL SOC PSYCHOL, V22, P1111, DOI 10.1111/j.1559-1816.1992.tb00945.x
   Davis LL, 1992, APPL NURS RES, V5, P194, DOI [10.1016/s0897-1897(05)80008-4, DOI 10.1016/S0897-1897(05)80008-4]
   De Groot JIM, 2009, J SOC PSYCHOL, V149, P425, DOI 10.3200/SOCP.149.4.425-449
   Dedrick J, 2010, COMMUN ASSOC INF SYS, V27, P173
   Aguilar-Luzon MD, 2012, J APPL SOC PSYCHOL, V42, P2797, DOI 10.1111/j.1559-1816.2012.00962.x
   Dick Geoffrey N., 2011, P SO ASS INF SYST C
   Do Valle PO, 2005, ENVIRON BEHAV, V37, P364, DOI 10.1177/0013916504272563
   duBuisson W, 2014, P S AFR I COMP SCI I
   DUTTON JE, 1987, ACAD MANAGE REV, V12, P76, DOI 10.2307/257995
   El-Khasawneh BS, 2012, J MANUF TECHNOL MANA, V23, P328, DOI 10.1108/17410381211217407
   Elliot S, 2011, MIS QUART, V35, P197
   Esfahani M, 2015, PACIS 2015 P, P1
   Esfahani M. D., 2015, MODELLING UPPER ECHE, P20
   Fadzlin A., 2012, J EC SUSTAINABLE DEV, V3, P130
   Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149
   Fishbein M., 1975, BELIEF ATTITUDE INTE
   Flannery BL, 2000, ACAD MANAGE J, V43, P642, DOI 10.2307/1556359
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Forrester Consulting, 2009, ITS ROL RED CORP ENV
   Frambach RT, 2002, J BUS RES, V55, P163, DOI 10.1016/S0148-2963(00)00152-1
   Gan PL, 2017, ADV BUS STRATEGY COM, P48, DOI 10.4018/978-1-5225-2165-5.ch003
   Gao L, 2017, RESOUR CONSERV RECY, V127, P107, DOI 10.1016/j.resconrec.2017.08.030
   Garling T, 2003, J ENVIRON PSYCHOL, V23, P1, DOI 10.1016/S0272-4944(02)00081-6
   Gartner, 2008, GOING GREEN CIOS ROL
   Gholami R, 2013, INFORM MANAGE-AMSTER, V50, P431, DOI 10.1016/j.im.2013.01.004
   GINSBERG A, 1992, STRATEGIC MANAGE J, V13, P37, DOI 10.1002/smj.4250131005
   Goldstein NJ, 2008, J CONSUM RES, V35, P472, DOI 10.1086/586910
   Gollnow H., 2014, FACTORS INFLUENCING
   Gorbett T., 2005, UNDERSTANDING BUSINE
   Greaves M, 2013, J ENVIRON PSYCHOL, V34, P109, DOI 10.1016/j.jenvp.2013.02.003
   Gupta P, 2013, INT J INFORM MANAGE, V33, P861, DOI 10.1016/j.ijinfomgt.2013.07.001
   Hair J.F., 2006, MULTIVARIATE DATA AN, V6
   Hair J. F., 2013, PRIMER PARTIAL LEAST
   Hair Jr JF, 2016, PRIMER PARTIAL LEAST
   Ham M, 2015, ECON RES-EKON ISTRAZ, V28, P738, DOI 10.1080/1331677X.2015.1083875
   Han H, 2019, TOURISM MANAGE, V70, P430, DOI 10.1016/j.tourman.2018.09.006
   Han H, 2017, J TRAVEL TOUR MARK, V34, P1155, DOI 10.1080/10548408.2017.1304317
   Han H, 2015, INT J HOSP MANAG, V47, P96, DOI 10.1016/j.ijhm.2015.03.013
   Han H, 2014, J ENVIRON PSYCHOL, V40, P462, DOI 10.1016/j.jenvp.2014.10.006
   Handy J., 2001, Australian Journal of Information Systems, V9, P39
   Harland P, 1999, J APPL SOC PSYCHOL, V29, P2505, DOI 10.1111/j.1559-1816.1999.tb00123.x
   Harland P, 2007, BASIC APPL SOC PSYCH, V29, P323, DOI 10.1080/01973530701665058
   He XH, 2018, J CLEAN PROD, V172, P3546, DOI 10.1016/j.jclepro.2017.05.088
   Helm S., 2010, HDB PARTIAL LEAST SQ, P515, DOI [DOI 10.1007/978-3-540-32827-8_23, 10.1007/978-3-540-32827-8_23]
   Hernandez AA, 2018, INT J ASIAN BUS INF, V9, P21, DOI 10.4018/IJABIM.2018100102
   HOPPER JR, 1991, ENVIRON BEHAV, V23, P195, DOI 10.1177/0013916591232004
   Hossain M. A., 2014, INF SYST FRONT
   Hossain MA, 2011, INFORM TECHNOL PEOPL, V24, P236, DOI 10.1108/09593841111158365
   Hsu MH, 2004, BEHAV INFORM TECHNOL, V23, P359, DOI 10.1080/01449290410001669969
   Hunecke M, 2001, ENVIRON BEHAV, V33, P830, DOI 10.1177/00139160121973269
   Info-Tech Research Group, 2009, GREEN IT WHY MIDS CO
   JACKSON SE, 1988, ADMIN SCI QUART, V33, P370, DOI 10.2307/2392714
   Jansson J, 2011, J CONSUM BEHAV, V10, P51, DOI 10.1002/cb.346
   Jenkin TA, 2011, BUS SOC, V50, P266, DOI 10.1177/0007650311398640
   Ji S, 2015, ORG GREEN IT ADOPTIO, P1
   Jin KG, 2007, J BUS ETHICS, V71, P149, DOI 10.1007/s10551-006-9131-4
   Joshi Y., 2015, INT STRATEGIC MANAGE, V3, P128, DOI [10.1016/j.ism.2015.04.001, DOI 10.1016/J.ISM.2015.04.001]
   Kaiser FG, 2005, J APPL SOC PSYCHOL, V35, P2150, DOI 10.1111/j.1559-1816.2005.tb02213.x
   Kals E., 2002, PSYCHOL SUSTAINABLE, P97, DOI DOI 10.1007/978-1-4615-0995-0_6
   Khalifa M, 2006, IEEE T ENG MANAGE, V53, P275, DOI 10.1109/TEM.2006.872251
   Kim YG, 2018, INT J HOSP MANAG, V72, P109, DOI 10.1016/j.ijhm.2018.01.008
   Klockner CA, 2013, GLOBAL ENVIRON CHANG, V23, P1028, DOI 10.1016/j.gloenvcha.2013.05.014
   Klockner CA, 2010, J ENVIRON PSYCHOL, V30, P574, DOI 10.1016/j.jenvp.2010.03.001
   Klockner CA, 2009, BRIT FOOD J, V111, P1173, DOI 10.1108/00070700911001013
   Koo C, 2015, INT J INFORM MANAGE, V35, P64, DOI 10.1016/j.ijinfomgt.2014.10.001
   KRUEGER N, 1994, DECISION SCI, V25, P385, DOI 10.1111/j.1540-5915.1994.tb01849.x
   Kujala J, 2011, J BUS ETHICS, V100, P191, DOI 10.1007/s10551-010-0467-4
   Kuo Ben N., 2010, Australian Journal of Information Systems, V16, P81
   Kuo B. N, 2010, P OFC MAR, P1
   Lam SP, 2006, ENVIRON BEHAV, V38, P318, DOI 10.1177/0013916505278327
   Lauper E., 2015, ENV BEHAV
   Lei C., 2014, RES AGENDA MANAGERIA
   Lei C., 2014, PACIS
   Lei C. F., 2013, GREEN INFORM TECHNOL
   Li JR, 2018, J CLEAN PROD, V172, P1399, DOI 10.1016/j.jclepro.2017.10.138
   Liang HG, 2007, MIS QUART, V31, P59
   Lin CY, 2011, J BUS ETHICS, V98, P67, DOI 10.1007/s10551-010-0535-9
   Macovei O. I, 2015, OECONOMICA, V11, P15
   Malaysian Investment Development Authority (MIDA), 2011, MAL INV PERF REP
   Mancha RM, 2015, J ENVIRON PSYCHOL, V43, P145, DOI 10.1016/j.jenvp.2015.06.005
   Mann H, 2009, AMCIS 2009 P, P121
   MARTOCCHIO JJ, 1992, PERS PSYCHOL, V45, P529
   Mishra D, 2014, COMPUT HUM BEHAV, V36, P29, DOI 10.1016/j.chb.2014.03.030
   Molla A., 2009, BUSINESS
   Molla A, 2009, ICIS 2009 P, P1, DOI DOI 10.13140/2.1.4340.5605
   Molla A, 2014, INFORM TECHNOL PEOPL, V27, P129, DOI 10.1108/ITP-10-2012-0109
   Nedbal D., 2011, P 17 AM C INF SYST D, V3, P2282
   Nordin N, 2014, IN C IND ENG ENG MAN, P687, DOI 10.1109/IEEM.2014.7058726
   Nordlund AM, 2003, J ENVIRON PSYCHOL, V23, P339, DOI 10.1016/S0272-4944(03)00037-9
   Ong TF, 2011, CURR ISSUES TOUR, V14, P779, DOI 10.1080/13683500.2010.545370
   Opala O. J., 2012, THESIS
   PAINE LS, 1997, CASES LEADERSHIP ETH
   Papagiannakis G, 2012, J ENVIRON MANAGE, V100, P41, DOI 10.1016/j.jenvman.2012.01.023
   Park J, 2014, FAM CONSUM SCI RES J, V42, P278, DOI 10.1111/fcsr.12061
   Perugini M, 2003, EUR J PERSONALITY, V17, P251, DOI 10.1002/per.474
   Poortvliet PM, 2018, WATER RES, V131, P90, DOI 10.1016/j.watres.2017.12.032
   Pradhananga A. K., 2015, JAWRA J AM WATER RES, V55401
   Przychodzen W, 2018, J CLEAN PROD, V201, P570, DOI 10.1016/j.jclepro.2018.08.081
   Rahim A., 2013, RESOURCE, V6, P18
   Raisinghani M.S., 2019, GREEN BUSINESS CONCE, P565, DOI [10.4018/978-1-5225-7915-1.ch028, DOI 10.4018/978-1-5225-7915-1.CH028]
   Rezaei R, 2019, J ENVIRON MANAGE, V236, P328, DOI 10.1016/j.jenvman.2019.01.097
   Rivis A, 2009, J APPL SOC PSYCHOL, V39, P2985, DOI 10.1111/j.1559-1816.2009.00558.x
   Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68
   Saedi A, 2013, INT CONF RES INNOV, P481, DOI 10.1109/ICRIIS.2013.6716757
   Sarkhel P., 2009, PACIS 2009 P PACIS C, P1
   Schmermbeck H, 2019, P 52 HAW INT C SYST, V6
   Schwartz SH, 1977, ADV EXPT SOCIAL PSYC, V10, P221, DOI DOI 10.1016/S0065-2601(08)60358-5
   Schwartz SH, 1981, ALTRUISM HELP BEHAV, P189
   Seidel S., 2010, P 16 AM C INF SYST S, P12, DOI 10.2495/UT150491
   Sekaran U., 2010, RES METHODS BUSINESS
   Setiawan R., 2014, CIVIL ENG DIMENSION, V16, P117
   Sharma S, 2000, ACAD MANAGE J, V43, P681, DOI 10.2307/1556361
   SHARMA S, 1999, J APPL BEHAV SCI, V35, P87, DOI DOI 10.1177/0021886399351008
   Sherif M., 1936, PSYCHOL SOCIAL NORMS
   Shin YH, 2018, INT J HOSP MANAG, V69, P21, DOI 10.1016/j.ijhm.2017.10.011
   Sitkin SB, 1995, ACAD MANAGE J, V38, P1573, DOI 10.2307/256844
   Steg L, 2005, J ENVIRON PSYCHOL, V25, P415, DOI 10.1016/j.jenvp.2005.08.003
   Steg L, 2010, BRIT J SOC PSYCHOL, V49, P725, DOI 10.1348/014466609X477745
   Stern PC, 2000, J SOC ISSUES, V56, P407, DOI 10.1111/0022-4537.00175
   STERN PC, 1993, ENVIRON BEHAV, V25, P322, DOI 10.1177/0013916593255002
   Sung B, 2013, TECHNOL FORECAST SOC, V80, P1387, DOI 10.1016/j.techfore.2012.11.006
   Taylor D, 2006, REV USE HLTH BELIEF
   TAYLOR S, 1995, INFORM SYST RES, V6, P144, DOI 10.1287/isre.6.2.144
   Thogersen J, 2006, J APPL SOC PSYCHOL, V36, P1758, DOI 10.1111/j.0021-9029.2006.00080.x
   Tushi BT, 2014, AM C INF SYST, P1
   Uddin M, 2012, RENEW SUST ENERG REV, V16, P4078, DOI 10.1016/j.rser.2012.03.014
   Ulhoi J., 2013, J GLOB STRATEG MANAG, V1, P166
   Venkatesh V, 2003, MIS QUART, V27, P425
   Vidaver-Cohen D, 1998, J BUS ETHICS, V17, P1211, DOI 10.1023/A:1005763713265
   Wang B, 2018, ENERG POLICY, V116, P68, DOI 10.1016/j.enpol.2018.01.055
   Wang Y., 2015, P INT C INF RES MAN
   Wang ZH, 2018, RESOUR CONSERV RECY, V133, P1, DOI 10.1016/j.resconrec.2018.01.014
   Wati Y, 2011, INT C COMMERCE BUS, P428, DOI 10.1109/CEC.2011.70
   Watson RT, 2010, MIS QUART, V34, P23
   Willuweit L., 2009, PROMOTING PROENVIRON
   WOOD R, 1989, ACAD MANAGE REV, V14, P361, DOI 10.2307/258173
   Wunderlich P., 2013, GREEN INFORM SYSTEMS
   Yadegaridehkordi E, 2018, TOURISM MANAGE, V66, P364, DOI 10.1016/j.tourman.2017.11.012
   Yoon C, 2018, COMPUT HUM BEHAV, V83, P129, DOI 10.1016/j.chb.2018.01.032
   Yu L., 2017, P COGN COMM AER APPL, P1, DOI DOI 10.14722/NDSS.2017.23241
   Zhang XJ, 2018, RESOUR CONSERV RECY, V134, P121, DOI 10.1016/j.resconrec.2018.03.003
   Zhang XJ, 2017, J CLEAN PROD, V166, P148, DOI 10.1016/j.jclepro.2017.08.020
   Zhang YX, 2013, ENERG POLICY, V62, P1120, DOI 10.1016/j.enpol.2013.07.036
   Zhou T, 2010, COMPUT HUM BEHAV, V26, P760, DOI 10.1016/j.chb.2010.01.013
NR 187
TC 4
Z9 4
U1 7
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 36
EP 54
DI 10.1016/j.resconrec.2019.04.028
PG 19
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800004
DA 2020-05-12
ER

PT J
AU Anshassi, M
   Laux, SJ
   Townsend, TG
AF Anshassi, Malak
   Laux, Steven J.
   Townsend, Timothy G.
TI Approaches to integrate sustainable materials management into waste
   management planning and policy
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Sustainable materials management; Waste; Recycling; Policy; Life cycle
   assessment
ID CIRCULAR ECONOMY; STRATEGIES
AB Many solid waste policy makers are adopting sustainability practices following one of the three most commonly followed approaches: zero-waste, circular economy, and sustainable materials management (SMM). Although some communities have embraced these models, challenges remain to integrate these concepts into solid waste policy and planning. Several approaches for integrating SMM were demonstrated. The approaches centered on using SMM concepts to prioritize and strategically plan for more sustainable waste management and to create performance metrics to track solid waste management system progress. Waste information from five regions were compiled to assess current data adequacy; necessary data were in many cases limited. Findings showed that many of the regions will need to better track and report their individual materials generated and disposed of to more accurately apply SMM. Among the common outcomes of the SMM approaches illustrated was the need to better target specific materials in the waste stream for recovery, such as metal and paper products. Other findings included the need to more effectively promote and track waste reduction efforts given the dramatic beneficial outcomes when using an SMM-based performance metric, such as an energy use reduction goal.
C1 [Anshassi, Malak; Laux, Steven J.; Townsend, Timothy G.] Univ Florida, Dept Environm Engn Sci, POB 116450, Gainesville, FL 32611 USA.
RP Townsend, TG (reprint author), Univ Florida, Dept Environm Engn Sci, POB 116450, Gainesville, FL 32611 USA.
EM ttown@ufl.edu
FU Florida Department of Environmental Protection; Hinkley Center for Solid
   and Hazardous Waste Management in Gainesville, Florida; American
   Institute for Packaging and the Environment (AMERIPEN)
FX This work was funded by the Florida Department of Environmental
   Protection in conjunction with the Hinkley Center for Solid and
   Hazardous Waste Management in Gainesville, Florida, and the American
   Institute for Packaging and the Environment (AMERIPEN). We thank them
   for their assistance in this research.
CR Andrews D, 2015, LOCAL ECON, V30, P305, DOI 10.1177/0269094215578226
   Anshassi M, 2018, ENVIRON SCI TECHNOL, V52, P6544, DOI 10.1021/acs.est.7b06007
   Banar M, 2009, WASTE MANAGE, V29, P54, DOI 10.1016/j.wasman.2007.12.006
   Bocken NMP, 2016, J IND PROD ENG, V33, P308, DOI 10.1080/21681015.2016.1172124
   Bureau U. C., STAT POP TOT 2010 20
   Cascadia Consulting Group Inc, 2015, 2014 DISP FAC BAS CH
   Cascadia Consulting Group Inc, 2004, 2004 CAL STAT WAST C
   Chen PC, 2017, SUSTAIN ENVIRON RES, V27, P135, DOI 10.1016/j.serj.2017.02.001
   Chen PC, 2017, J CLEAN PROD, V150, P16, DOI 10.1016/j.jclepro.2017.02.173
   Christis M, 2015, RESOUR CONSERV RECY, V103, P110, DOI 10.1016/j.resconrec.2015.07.014
   Contreras F, 2008, RESOUR CONSERV RECY, V52, P979, DOI 10.1016/j.resconrec.2008.03.003
   Crowell B., 2017, MINNESOTA REPORT SCO
   Department of Environmental Quality, 2012, MAT MAN OR 2050 VIS
   Florida Department of Environmental Protection, 2006, SOL WAST MAN FLOR 20
   Florida Department of Environmental Protection, 2016, SOL WAST MAN FLOR 20
   Franchetti M, 2012, RESOUR CONSERV RECY, V58, P107, DOI 10.1016/j.resconrec.2011.11.004
   Geissdoerfer M, 2017, J CLEAN PROD, V143, P757, DOI 10.1016/j.jclepro.2016.12.048
   Genovese A, 2017, OMEGA-INT J MANAGE S, V66, P344, DOI 10.1016/j.omega.2015.05.015
   Ghisellini P, 2016, J CLEAN PROD, V114, P11, DOI 10.1016/j.jclepro.2015.09.007
   Coelho LMG, 2018, RESOUR CONSERV RECY, V128, P438, DOI 10.1016/j.resconrec.2016.09.026
   Green Spectrum Consulting LLC Resource Recycling Inc, 2015, MAK SENS MIX AN IMPL
   ICF International, 2016, DOC GREENH GAS EM EN
   Intergovernmental Panel on Climate Change, 2014, CLIM CHANG 2014 MIT
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Korhonen J, 2018, ECOL ECON, V143, P37, DOI 10.1016/j.ecolecon.2017.06.041
   Land and Materials Administration, 2018, WAST RED RES REC PLA
   Lieder M, 2016, J CLEAN PROD, V115, P36, DOI 10.1016/j.jclepro.2015.12.042
   Littlemore J, 2013, REV ESP LINGUIST APL, P23
   Liu YL, 2017, RESOUR CONSERV RECY, V125, P98, DOI 10.1016/j.resconrec.2017.06.005
   Malinauskaite J, 2017, ENERGY, V141, P2013, DOI 10.1016/j.energy.2017.11.128
   MSW Consultants, 2017, 2016 MAR STAT WAST C
   Philbrick K., 2006, ANN REPORT SOLID WAS
   Philbrick K., 2006, MARYLAND WASTE DIVER
   Rayer S., 2016, MAR SOL WAST MAN DIV, V174
   Rayer S., 2016, MAR SOL WAST MAN DIV, V49
   Resource Management Program & Land and Materials Administration, 2016, MAR SOL WAST MAN DIV
   Silva A, 2017, WASTE MANAGE, V61, P547, DOI 10.1016/j.wasman.2016.11.038
   Silva A, 2016, J CLEAN PROD, V115, P224, DOI 10.1016/j.jclepro.2015.12.069
   Smithline S., 2018, BIANNUAL REPORT BEVE
   Smithline S., 2016, STATE DISPOSAL CALIF
   Tencati A, 2016, WASTE MANAGE, V56, P35, DOI 10.1016/j.wasman.2016.06.025
   U.S. Environmental Protection Agency, 2018, ADV SUST MAT MAN 201
   US EPA (U.S. Environmental Protection Agency), 2009, SUST MAT MAN ROAD AH
   Vee A., 2006, MINNESOTA REPORT SCO
   Vergara SE, 2011, RESOUR CONSERV RECY, V57, P87, DOI 10.1016/j.resconrec.2011.09.011
   Witjes S, 2016, RESOUR CONSERV RECY, V112, P37, DOI 10.1016/j.resconrec.2016.04.015
   Zaman AU, 2013, J CLEAN PROD, V50, P123, DOI 10.1016/j.jclepro.2012.11.041
NR 47
TC 3
Z9 3
U1 7
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 55
EP 66
DI 10.1016/j.resconrec.2019.04.011
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800005
DA 2020-05-12
ER

PT J
AU da Costa, TP
   Quinteiro, P
   Tarelho, LAC
   Arroja, L
   Dias, AC
AF da Costa, Tamiris Pacheco
   Quinteiro, Paula
   Tarelho, Luis A. C.
   Arroja, Luis
   Dias, Ana Claudia
TI Environmental assessment of valorisation alternatives for woody biomass
   ash in construction materials
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Adhesive mortar; Ash management; Bituminous asphalt; Cement mortar;
   Concrete blocks; Life cycle assessment
ID LIFE-CYCLE ASSESSMENT; FLY-ASH; BOTTOM ASH; UNBURNED CARBON; WASTE;
   COMBUSTION; CEMENT; MANAGEMENT; DURABILITY; RESISTANCE
AB Ash generated during the combustion of woody biomass for energy production is an industrial waste that should be properly managed in order to minimise the respective environmental impacts. Woody biomass ash valorisation in construction materials to replace conventional materials is an alternative that has proven to be technically feasible. On the other hand, it can present potential environmental impacts that should be evaluated to support the choice of more sustainable alternatives. Thus, the purpose of this work is to assess the potential impacts of woody biomass ash valorisation of through incorporation in construction materials using life cycle assessment. The valorisation alternatives consider the incorporation of woody biomass ash in cement mortars, adhesive mortars, concrete blocks, and bituminous asphalts. In addition, a base scenario consisting of ash landfilling is also assessed. Four types of woody biomass ashes were considered, namely fly and bottom ashes generated in a vibrating grate and fly and bottom ashes generated in a fluidised bed. The impact assessment method used is that suggested in the International Reference Life Cycle Data System for selected impact categories. The results showed that the impacts of ash transport and pre-processing and the impacts of producing the avoided materials are factors that affect the net impact of the valorisation scenarios and should be considered in the end-of-life management of biomass ash. Nevertheless, all valorisation scenarios had a lower impact than landfilling in all the impact categories under study, resulting in a significant decrease of the environmental impacts in some scenarios.
C1 [da Costa, Tamiris Pacheco; Quinteiro, Paula; Tarelho, Luis A. C.; Arroja, Luis; Dias, Ana Claudia] Univ Aveiro, Dept Environm & Planning, Ctr Environm & Marine Studies CESAM, Campus Univ Santiago, P-3810193 Aveiro, Portugal.
RP Dias, AC (reprint author), Univ Aveiro, Dept Environm & Planning, CESAM, P-3810193 Aveiro, Portugal.
EM acdias@ua.pt
RI Dias, Ana Claudia/G-6148-2011; da Costa, Tamiris Pacheco/U-9738-2018;
   Quinteiro, Paula Sofia Gil Neto/C-5280-2015; da Cruz Tarelho, Luis
   Antonio/A-8278-2013
OI Dias, Ana Claudia/0000-0001-8881-3564; da Costa, Tamiris
   Pacheco/0000-0002-4383-9557; Quinteiro, Paula Sofia Gil
   Neto/0000-0002-0924-5034; da Cruz Tarelho, Luis
   Antonio/0000-0003-0385-5621; Arroja, Luis/0000-0002-6067-4766
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ
   -Brazil)National Council for Scientific and Technological Development
   (CNPq) [203483/2014-6]; Science and Technology Foundation
   (FCT)Portuguese Foundation for Science and Technology
   [SFRH/BPD/114992/2016, IF/00587/2013]; POHP/FSE [SFRH/BPD/114992/2016,
   IF/00587/2013]; CESAM [UID/AMB/50017/2019]; FCT/MCTESPortuguese
   Foundation for Science and Technology; FEDER, within the PT2020
   Partnership Agreement; FEDER, within the Compete 2020; FEDER, through
   COMPETE2020 -Programa Operacional Competitividade e Internacionalizacdo
   (POCI) [PTDC/AAG-MAA/6234/2014 -POCI-01-0145-FEDER-016765,
   PTDC/AGR-FOR/1510/2014 -POCI-01-0145-FEDER-016764, 3599-PPCDT];
   FCT/MCTESPortuguese Foundation for Science and Technology
   [PTDC/AAG-MAA/6234/2014 -POCI-01-0145-FEDER-016765,
   PTDC/AGR-FOR/1510/2014 -POCI-01-0145-FEDER-016764, 3599-PPCDT]
FX The authors would like to thank the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPQ -Brazil) for the scholarship granted to
   Tamiris Pacheco da Costa (203483/2014-6) and to the Science and
   Technology Foundation (FCT) and POHP/FSE funding program for the
   scholarship granted to Paula Quinteiro (SFRH/BPD/114992/2016) and
   contract granted to Ana Claudia Dias (IF/00587/2013). Thanks are also
   due for the financial support to CESAM (UID/AMB/50017/2019), to
   FCT/MCTES through national funds, and the co-funding by the FEDER,
   within the PT2020 Partnership Agreement and Compete 2020. This work is a
   contribution to the projects SABIOS (PTDC/AAG-MAA/6234/2014
   -POCI-01-0145-FEDER-016765) and SustainFor (PTDC/AGR-FOR/1510/2014
   -POCI-01-0145-FEDER-016764) both funded under the project 3599-PPCDT by
   FEDER, through COMPETE2020 -Programa Operacional Competitividade e
   Internacionalizacdo (POCI), and by national funds (OE), through
   FCT/MCTES.
CR Ahmaruzzaman M, 2010, PROG ENERG COMBUST, V36, P327, DOI 10.1016/j.pecs.2009.11.003
   Allegrini E, 2015, WASTE MANAGE, V38, P474, DOI 10.1016/j.wasman.2014.12.018
   Alves J.C.L.C.M, 2013, AVALIACAO IMPACTE AM
   [Anonymous], 2006, INT J LIFE CYCLE ASS, P652, DOI [10.1007/s11367-011-0297-3, 2006, DOI 10.1007/S11367-011-0297-3, 10.1007/s11367-011-0297-3]
   Barbosa R, 2013, CONSTR BUILD MATER, V48, P457, DOI 10.1016/j.conbuildmat.2013.07.031
   Bastos D. R. S, 2014, AVALIACAO CASOS VALO
   Beltran MG, 2014, CONSTR BUILD MATER, V72, P231, DOI 10.1016/j.conbuildmat.2014.09.019
   Berra M, 2015, CONSTR BUILD MATER, V76, P286, DOI 10.1016/j.conbuildmat.2014.11.052
   Bjurstrom H, 2014, FUEL, V117, P890, DOI 10.1016/j.fuel.2013.10.020
   Borghi G, 2018, J CLEAN PROD, V184, P815, DOI 10.1016/j.jclepro.2018.02.287
   Chowdhury S, 2015, AIN SHAMS ENG J, V6, P429, DOI 10.1016/j.asej.2014.11.005
   Coelho A. M. S. L., 2010, GESTAO CINZAS PRODUZ
   Cruz NC, 2017, ENVIRON SCI POLLUT R, V24, P14770, DOI 10.1007/s11356-017-9013-6
   Dahl O, 2010, FUEL PROCESS TECHNOL, V91, P1634, DOI 10.1016/j.fuproc.2010.06.012
   De Schepper M, 2014, MATERIALS, V7, P6010, DOI 10.3390/ma7086010
   Demertzi M, 2015, WASTE MANAGE, V46, P668, DOI 10.1016/j.wasman.2015.09.026
   Di Gianfilippo M, 2016, WASTE MANAGE, V47, P285, DOI 10.1016/j.wasman.2015.05.032
   Dias D. A. C. M, 2011, ESTUDO VALORIZACAO C
   Dias V. D. M, 2012, APLICACAO RESIDUOS S
   Doka G., 2003, 13 SWISS CTR LIF C 3
   EC-JRC, 2012, CHAR FACT ILCD REC L, DOI [10.2788/60825, DOI 10.2788/60825]
   Ecoinvent, 2017, EC DAT V 3 4
   Esteves TC, 2012, CONSTR BUILD MATER, V26, P687, DOI 10.1016/j.conbuildmat.2011.06.075
   European Commission-Joint Research Centre (EC-JRC), 2010, INT REF LIF CYCL DAT, DOI [10.2788/38479, DOI 10.2788/38479]
   Freire M, 2015, WASTE MANAGE, V46, P304, DOI 10.1016/j.wasman.2015.08.036
   Garcia MD, 2013, CONSTR BUILD MATER, V41, P897, DOI 10.1016/j.conbuildmat.2012.11.081
   Gavriletea MD, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9071118
   Gentil L. V., 2015, Floresta, V45, P281
   Gunaseelan A, 2016, INT J INNOV RES SCI, V2, P187
   Habert G, 2016, SUST BUILT ENV SBE R
   Huang TY, 2017, RESOUR CONSERV RECY, V123, P255, DOI 10.1016/j.resconrec.2016.07.001
   Huang TY, 2015, PROCEDIA ENGINEER, V118, P984, DOI 10.1016/j.proeng.2015.08.539
   Huber F, 2018, WASTE MANAGE, V73, P392, DOI 10.1016/j.wasman.2017.06.004
   Kasser U, 1998, GRAUE ENERGIE BAUSTO
   Kellenberger D, 2007, 7 EC
   Lessard JM, 2017, CONSTR BUILD MATER, V132, P565, DOI 10.1016/j.conbuildmat.2016.12.009
   Locher F. W, 2001, ULLMANNS ENCY IND CH, DOI [10.1002/14356007.a05_489, DOI 10.1002/14356007.A05_489]
   Maschio S, 2011, CHEMOSPHERE, V85, P666, DOI 10.1016/j.chemosphere.2011.06.070
   Melotti R, 2013, WASTE MANAGE, V33, P1906, DOI 10.1016/j.wasman.2013.05.015
   Modolo RCE, 2015, FUEL PROCESS TECHNOL, V129, P192, DOI 10.1016/j.fuproc.2014.09.015
   Modolo RCE, 2014, FUEL PROCESS TECHNOL, V125, P170, DOI 10.1016/j.fuproc.2014.03.040
   Modolo RCE, 2013, CONSTR BUILD MATER, V45, P275, DOI 10.1016/j.conbuildmat.2013.03.093
   Modolo R. C. E, 2014, VALORIZACAO RESIDUOS
   Modolo R. C. E, 2006, VALORIZACAO RESIDUOS
   Ondova M, 2014, INT J ENV CHEM ECOL, V8, P313
   Pasandin AR, 2016, J CLEAN PROD, V112, P853, DOI 10.1016/j.jclepro.2015.06.016
   Pinho P. A. M, 2014, VALORIZACAO RESIDUOS
   Rajamma R, 2015, COMPOS PART B-ENG, V77, P1, DOI 10.1016/j.compositesb.2015.03.019
   Rajamma R, 2009, J HAZARD MATER, V172, P1049, DOI 10.1016/j.jhazmat.2009.07.109
   Ramos T, 2013, CONSTR BUILD MATER, V49, P343, DOI 10.1016/j.conbuildmat.2013.08.026
   Ribbing C, 2007, WASTE MANAGE, V27, P1428, DOI 10.1016/j.wasman.2007.03.012
   Sabedot S, 2011, 3 C BRAS CARV MIN, P15
   Scheetz BE, 1998, CURR OPIN SOLID ST M, V3, P510, DOI 10.1016/S1359-0286(98)80017-X
   Seto KE, 2017, J CLEAN PROD, V157, P65, DOI 10.1016/j.jclepro.2017.04.093
   Silva D. F. R, 2016, VALORIZACAO CINZAS C
   Straka P, 2014, THERMOCHIM ACTA, V575, P188, DOI 10.1016/j.tca.2013.10.033
   Tarelho LAC, 2015, ENERGY, V90, P387, DOI 10.1016/j.energy.2015.07.036
   Tosti L, 2018, RESOUR CONSERV RECY, V134, P25, DOI 10.1016/j.resconrec.2018.03.004
   Ukrainczyk N, 2016, CHEM BIOCHEM ENG Q, V30, P137, DOI 10.15255/CABEQ.2015.2231
   Vassilev SV, 2013, FUEL, V105, P19, DOI 10.1016/j.fuel.2012.10.001
   Williams P. T, 2013, WASTE TREATMENT DISP
   Xuan DX, 2016, CONSTR BUILD MATER, V113, P664, DOI 10.1016/j.conbuildmat.2016.03.109
   Yoshitake I, 2016, CONSTR BUILD MATER, V112, P440, DOI 10.1016/j.conbuildmat.2016.02.185
NR 63
TC 2
Z9 2
U1 2
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 67
EP 79
DI 10.1016/j.resconrec.2019.04.022
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800006
DA 2020-05-12
ER

PT J
AU Long, XF
   Ge, JL
   Shu, T
   Liu, Y
AF Long, Xiaofeng
   Ge, Jiali
   Shu, Tong
   Liu, Yu
TI Analysis for recycling and remanufacturing strategies in a supply chain
   considering consumers' heterogeneous WTP
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Willingness to pay; Hybrid remanufacturing mode; Patent license;
   Recycling rate; Stackelberg game; Closed loop supply chain
ID E-WASTE; QUALITY; MARKET; COMPETITION; COLLECTION; WILLINGNESS;
   DECISIONS; QUANTITY; BEHAVIOR; SERVICE
AB Empirical and theoretical research has shown that consumers' willingness to pay (WTP) has a significant impact on manufacturers' decisions. Based on these findings, we establish models for multiple remanufacturing modes considering WTP heterogeneity or different remanufactured products, in one-period and two-period closed-loop supply chain (CLSC) scenarios, to identify the optimal recycling and remanufacturing decisions of manufacturers. We find that manufacturers should participate in remanufacturing in one-period or two-period settings to earn more profits. In the one-period scenario, hybrid remanufacturing is better for the manufacturer than single remanufacturing, and the manufacturer chooses its remanufacturing partner based on the lower remanufacturing cost. In the two-period scenario, when the WTP ratio is above a certain threshold, the manufacturer chooses the third party as its joint recycling partner to obtain higher consumer surplus, a higher recycling rate, and higher profits. If the WTP ratio is high enough, hybrid remanufacturing is better for the manufacturer. The manufacturer does not authorize the distributor to engage in remanufacturing, for this choice yields the lowest profits for the manufacturer independent of WTP ratio. These results have policy implications from the perspective of CLSC cooperative recycling and remanufacturing.
C1 [Long, Xiaofeng; Ge, Jiali; Shu, Tong] Hunan Univ, Sch Business Adm, Changsha 410082, Hunan, Peoples R China.
   [Long, Xiaofeng] Hunan Univ Finance & Econ, Dept Business Adm, Changsha 410205, Hunan, Peoples R China.
   [Liu, Yu] Chinese Acad Sci, Inst Sci & Dev, Beijing 100190, Peoples R China.
RP Ge, JL (reprint author), Hunan Univ, Sch Business Adm, Changsha 410082, Hunan, Peoples R China.; Liu, Y (reprint author), Chinese Acad Sci, Inst Sci & Dev, Beijing 100190, Peoples R China.
EM logjiali@163.com; Liuyu@casipm.ac.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [71771080, 71790593, 71521061, 71221001, 71642006,
   71473155]
FX This article is financially supported by the National Natural Science
   Foundation of China (71771080, 71790593, 71521061, 71221001, 71642006,
   and 71473155)
CR Abbey JD, 2017, PROD OPER MANAG, V26, P100, DOI 10.1111/poms.12628
   Abbey JD, 2015, J OPER MANAG, V36, P130, DOI 10.1016/j.jom.2015.03.007
   Agrawal S, 2015, RESOUR CONSERV RECY, V97, P76, DOI 10.1016/j.resconrec.2015.02.009
   Agrawal VV, 2015, MANAGE SCI, V61, P60, DOI 10.1287/mnsc.2014.2099
   Atasu A, 2008, MANAGE SCI, V54, P1731, DOI 10.1287/mnsc.1080.0893
   Atasu A, 2008, PROD OPER MANAG, V17, P483, DOI 10.3401/poms.1080.0051
   Atasu A, 2013, PROD OPER MANAG, V22, P991, DOI 10.1111/j.1937-5956.2011.01290.x
   Atasu A, 2010, CALIF MANAGE REV, V52, P56, DOI 10.1525/cmr.2010.52.2.56
   Bagchi A, 2014, INT REV ECON FINANC, V29, P455, DOI 10.1016/j.iref.2013.07.005
   Blue and Green Tomorrow, 2016, LOOK WHY GREEN CONS
   Bulmus SC, 2014, EUR J OPER RES, V233, P105, DOI 10.1016/j.ejor.2013.08.025
   Chang XY, 2017, J CLEAN PROD, V152, P281, DOI 10.1016/j.jclepro.2017.02.175
   De Giovanni P, 2014, EUR J OPER RES, V232, P22, DOI 10.1016/j.ejor.2013.06.032
   Debo LG, 2005, MANAGE SCI, V51, P1193, DOI 10.1287/mnsc.1050.0369
   Ferguson ME, 2006, PROD OPER MANAG, V15, P351
   Ferrer G, 2006, MANAGE SCI, V52, P15, DOI 10.1287/mnsc.1050.0465
   Neto JQF, 2016, INT J PROD ECON, V171, P371, DOI 10.1016/j.ijpe.2015.02.006
   Govindan K, 2015, EUR J OPER RES, V240, P603, DOI 10.1016/j.ejor.2014.07.012
   Guide V. D. R.  Jr., 2003, Manufacturing & Service Operations Management, V5, P303, DOI 10.1287/msom.5.4.303.24883
   Hong IH, 2012, TRANSPORT RES E-LOG, V48, P817, DOI 10.1016/j.tre.2012.01.006
   Hong XP, 2017, EUR J OPER RES, V256, P820, DOI 10.1016/j.ejor.2016.06.051
   Huang M, 2013, INT J PROD ECON, V144, P510, DOI 10.1016/j.ijpe.2013.04.002
   Huang YT, 2017, INT J PROD ECON, V191, P113, DOI 10.1016/j.ijpe.2017.06.008
   Huang YT, 2017, J CLEAN PROD, V142, P3917, DOI 10.1016/j.jclepro.2016.10.065
   Kleber R, 2018, EUR J OPER RES, V269, P1027, DOI 10.1016/j.ejor.2018.02.052
   Kumar A, 2017, RESOUR CONSERV RECY, V122, P32, DOI 10.1016/j.resconrec.2017.01.018
   Li W, 2017, J CLEAN PROD, V161, P581, DOI 10.1016/j.jclepro.2017.05.157
   Liao HL, 2019, J CLEAN PROD, V206, P987, DOI 10.1016/j.jclepro.2018.09.167
   Liu G., 2017, CHIN J MANAG, V14, P625
   Liu ZJ, 2018, INT J PROD ECON, V204, P290, DOI 10.1016/j.ijpe.2018.07.015
   Majumder P, 2001, PROD OPER MANAG, V10, P125
   Marques R, 2016, WATER SCI TECH-W SUP, V16, P1721, DOI 10.2166/ws.2016.090
   Mitra S, 2016, INT J PROD RES, V54, P1285, DOI 10.1080/00207543.2015.1067376
   Orsdemir A, 2014, PROD OPER MANAG, V23, P48, DOI 10.1111/poms.12040
   Ovchinnikov A, 2014, PROD OPER MANAG, V23, P744, DOI 10.1111/poms.12070
   Ovchinnikov A, 2011, PROD OPER MANAG, V20, P824, DOI 10.1111/J.1937-5956.2010.01214.x
   Qiang Q, 2013, OMEGA-INT J MANAGE S, V41, P186, DOI 10.1016/j.omega.2011.08.011
   Savaskan RC, 2004, MANAGE SCI, V50, P239, DOI 10.1287/mnsc.1030.0186
   Shi JM, 2011, RESOUR CONSERV RECY, V55, P639, DOI 10.1016/j.resconrec.2010.05.016
   Subramanian R, 2013, PROD OPER MANAG, V22, P36, DOI 10.1111/j.1937-5956.2012.01350.x
   Subramanian R, 2012, M&SOM-MANUF SERV OP, V14, P315, DOI 10.1287/msom.1110.0368
   Wang B, 2019, RESOUR CONSERV RECY, V143, P218, DOI 10.1016/j.resconrec.2019.01.005
   Wang HD, 2018, RESOUR CONSERV RECY, V134, P44, DOI 10.1016/j.resconrec.2018.03.006
   Wei J, 2015, INT J PROD RES, V53, P258, DOI 10.1080/00207543.2014.951088
   Xiong Y, 2013, EUR J OPER RES, V230, P15, DOI 10.1016/j.ejor.2013.03.034
   Xiong Z. K., 2011, J MANAGEMENT SCI CHI, V14, P1
   Xu X, 2017, INT J PROD ECON, V187, P113, DOI 10.1016/j.ijpe.2017.02.019
   Zhu XX, 2016, EUR J OPER RES, V248, P856, DOI 10.1016/j.ejor.2015.07.053
NR 48
TC 2
Z9 2
U1 35
U2 75
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 80
EP 90
DI 10.1016/j.resconrec.2019.05.001
PG 11
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800007
DA 2020-05-12
ER

PT J
AU Watari, T
   McLellan, BC
   Giurco, D
   Dominish, E
   Yamasue, E
   Nansai, K
AF Watari, Takuma
   McLellan, Benjamin C.
   Giurco, Damien
   Dominish, Elsa
   Yamasue, Eiji
   Nansai, Keisuke
TI Total material requirement for the global energy transition to 2050: A
   focus on transport and electricity
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Material Flow Analysis (MFA); Total Material Requirement (TMR); Life
   Cycle Assessment (LCA); Energy scenario; Critical material;
   Energy-mineral nexus
ID LIFE-CYCLE ASSESSMENT; MATERIAL FLOW-ANALYSIS; RENEWABLE ENERGY;
   ENVIRONMENTAL-IMPACT; SUPPLY CONSTRAINTS; ECONOMY; METALS; STOCKS;
   SCENARIOS; INDIUM
AB Global energy transitions could fundamentally change flows of both minerals and energy resources over time. It is, therefore, increasingly important to holistically and dynamically capture the impacts of large-scale energy transitions on resource flows including hidden flows such as mine waste, as well as direct flows. Here we demonstrate a systematic model that can quantify resource flows of both minerals and energy resources under the energy transition by using stock-flow dynamics and the concept of Total Material Requirement (TMR). The proposed model was applied to the International Energy Agency's scenarios up to 2050, targeting 15 electricity generation and 5 transport technologies. Results indicate that the global energy transition could increase TMR flows associated with mineral production by around 200-900% in the electricity sector and 350-700% in the transport sector respectively from 2015 to 2050, depending on the scenarios. Such a drastic increase in TMR flows is largely associated with an increased demand for copper, silver, nickel, lithium and cobalt, as well as steel. Our results highlight that the decarbonization of the electricity sector can reduce energy resource flows and support the hypothesis that the expansion of low-carbon technologies could reduce total resource flows expressed as TMR. In the transport sector, on the other hand, the dissemination of Electric Vehicles could cause a sharp increase in TMR flows associated with mineral production, which could offset a decrease in energy resource flows. Findings in this study emphasize that a sustainable transition would be unachievable without designing resource cycles with a nexus approach.
C1 [Watari, Takuma; McLellan, Benjamin C.] Kyoto Univ, Grad Sch Energy Sci, Sakyo Ku, Kyoto 6068501, Japan.
   [Watari, Takuma; Giurco, Damien; Dominish, Elsa] Univ Technol Sydney, Inst Sustainable Futures, Ultimo, NSW 2007, Australia.
   [Yamasue, Eiji] Ritsumeikan Univ, Sch Sci & Engn, 1-1-1 Noji Higashi, Kusatsu, Shiga 5258577, Japan.
   [Nansai, Keisuke] Natl Inst Environm Studies, Ctr Mat Cycles & Waste Management Res, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.
   [Nansai, Keisuke] Univ Sydney, Sch Phys, Integrated Sustainabil Anal, Camperdown, NSW 2006, Australia.
RP Watari, T (reprint author), Kyoto Univ, Grad Sch Energy Sci, Sakyo Ku, Kyoto 6068501, Japan.
EM wataritakuma.0930@gmail.com
RI Nansai, Keisuke/C-2516-2008; McLellan, Benjamin/B-7833-2009
OI Watari, Takuma/0000-0002-6072-3679; Giurco, Damien/0000-0002-1707-9531;
   McLellan, Benjamin/0000-0002-4802-3864; /0000-0002-2449-1874
FU Japanese Ministry of Education, Culture, Sports, Science and
   TechnologyMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT) [18KT0056, 18KT0010, 15H02862]; Kyoto
   University Ishizue Grant
FX This research was supported in part by Grants-in-Aid for Research (No.
   18KT0056, 18KT0010 and 15H02862) from the Japanese Ministry of
   Education, Culture, Sports, Science and Technology and Kyoto University
   Ishizue Grant.
CR Adriaanse A., 1997, RESOURCE FLOWS MAT B
   Ali S. H., 2018, RESOURCING GREEN TEC, DOI [10.7916/D8FX8SWK, DOI 10.7916/D8FX8SWK]
   Ali SH, 2017, NATURE, V543, P367, DOI 10.1038/nature21359
   Ali SH, 2014, RESOURCES-BASEL, V3, P123, DOI 10.3390/resources3010123
   Amnesty International, 2016, THIS IS WHAT WE HUM
   Andersson BA, 2000, ENERG POLICY, V28, P1037, DOI 10.1016/S0301-4215(00)00090-2
   Arto I, 2009, J IND ECOL, V13, P775, DOI 10.1111/j.1530-9290.2009.00172.x
   Ashby MF, 2013, MATERIALS AND THE ENVIRONMENT: ECO-INFORMED MATERIAL CHOICE, 2ND EDITION, P349
   Berry C., 2012, CASE STUDY GROWTH DR
   BGR, 2017, COMMODITY TOP NEWS
   Bleiwas D. I., 2010, USGS CIRCULAR
   Bodeker JM, 2010, ALUMINIUM RENEWABLE
   Bontron C., 2012, GUARDIAN
   Bridge G, 2000, GEOFORUM, V31, P237, DOI 10.1016/S0016-7185(99)00046-9
   Bringezu S, 2004, ECOL ECON, V51, P97, DOI 10.1016/j.ecolecon.2004.04.010
   Bringezu S., 1993, FRESEN ENVIRON BULL, V8, P437
   Bringezu S., 2003, J IND ECOL, V7, P43, DOI DOI 10.1162/108819803322564343
   Bringezu S., 2001, MAT USE INDICATORS E, P1980
   Brunner P.H., 2016, HDB MAT FLOW ANAL EN
   Busch J, 2017, J CLEAN PROD, V149, P751, DOI 10.1016/j.jclepro.2017.02.166
   Busch J, 2014, ENVIRON SCI TECHNOL, V48, P1298, DOI 10.1021/es404877u
   Castleden WM, 2011, MED J AUSTRALIA, V195, P333, DOI 10.5694/mja11.10169
   de Koning A, 2018, RESOUR CONSERV RECY, V129, P202, DOI 10.1016/j.resconrec.2017.10.040
   Du XY, 2011, J IND ECOL, V15, P836, DOI 10.1111/j.1530-9290.2011.00362.x
   Earth Policy Institute, 2018, DAT CTR CLIM EN TRAN
   Elshkaki A, 2013, J CLEAN PROD, V59, P260, DOI 10.1016/j.jclepro.2013.07.003
   Falconer I., 2009, METALS REQUIRED UKS
   Fischer-Kowalski M, 2011, J IND ECOL, V15, P855, DOI 10.1111/j.1530-9290.2011.00366.x
   Fishman T, 2018, RESOURCES-BASEL, V7, DOI 10.3390/resources7010009
   Fizaine F, 2015, ECOL ECON, V110, P106, DOI 10.1016/j.ecolecon.2014.12.001
   Forster J., 2011, LITHIUM SHORTAGE ARE
   Fthenakis V, 2012, MRS BULL, V37, P425, DOI 10.1557/mrs.2012.50
   Garcia-Olivares A, 2012, ENERG POLICY, V41, P561, DOI 10.1016/j.enpol.2011.11.018
   Gerst MD, 2009, ENVIRON SCI TECHNOL, V43, P6320, DOI 10.1021/es900845v
   GIURCO D., 2009, PEAK MINERALS AUSTR
   Giurco D, 2019, ACHIEVING THE PARIS CLIMATE AGREEMENT GOALS: GLOBAL AND REGIONAL 100% RENEWABLE ENERGY SCENARIOS WITH NON-ENERGY GHG PATHWAYS FOR +1.5(DEGREE)C AND +2(DEGREE)C, P437, DOI 10.1007/978-3-030-05843-2_11
   Giurco D, 2014, J CLEAN PROD, V84, P322, DOI 10.1016/j.jclepro.2014.05.102
   Global Wind Energy Council, 2018, GLOB STAT
   Grandell L, 2016, RENEW ENERG, V95, P53, DOI 10.1016/j.renene.2016.03.102
   Guezuraga B, 2012, RENEW ENERG, V37, P37, DOI 10.1016/j.renene.2011.05.008
   Habib K, 2016, J CLEAN PROD, V112, P3852, DOI 10.1016/j.jclepro.2015.07.064
   Habib K, 2016, J CLEAN PROD, V133, P850, DOI 10.1016/j.jclepro.2016.05.118
   Habib K, 2014, J CLEAN PROD, V84, P348, DOI 10.1016/j.jclepro.2014.04.035
   Halada K, 2001, J JPN I MET, V65, P564, DOI 10.2320/jinstmet1952.65.7_564
   Halada K., 2007, MAT JAPAN, V46, P543
   Hatayama H, 2010, ENVIRON SCI TECHNOL, V44, P6457, DOI 10.1021/es100044n
   Hawkins TR, 2013, J IND ECOL, V17, P53, DOI 10.1111/j.1530-9290.2012.00532.x
   Hertwich EG, 2015, P NATL ACAD SCI USA, V112, P6277, DOI 10.1073/pnas.1312753111
   Hoenderdaal S, 2013, ENERGY, V49, P344, DOI 10.1016/j.energy.2012.10.043
   IEA, 2010, EN TECHN SYST AN PRO, DOI [10.1007/978-3-319-18639-9, DOI 10.1007/978-3-319-18639-9]
   IEA, 2017, EN TECHN PERSP 2017, DOI [10.1787/energy_tech-2017-en, DOI 10.1787/ENERGY_TECH-2017-EN]
   IEA, 2018, GLOB EV OUTL 2018
   IEA, 2018, KEY WORLD EN STAT 20, DOI [10.1787/key_energ_stat-2018-en, DOI 10.1787/KEY_ENERG_STAT-2018-EN, 10.1787/KEY_ENERG_STAT-2018-EN]
   Kavlak G, 2015, ENERG ENVIRON SCI, V8, P1651, DOI 10.1039/c5ee00585j
   Kleijn R, 2010, RENEW SUST ENERG REV, V14, P2784, DOI 10.1016/j.rser.2010.07.066
   Kosai S, 2019, SCI TOTAL ENVIRON, V651, P1764, DOI 10.1016/j.scitotenv.2018.10.085
   Krausmann F, 2018, GLOBAL ENVIRON CHANG, V52, P131, DOI 10.1016/j.gloenvcha.2018.07.003
   Krausmann F, 2017, P NATL ACAD SCI USA, V114, P1880, DOI 10.1073/pnas.1613773114
   Kristof K., 2010, FINAL REPORT MAT EFF
   Lacal-Arantegui R, 2015, J CLEAN PROD, V87, P275, DOI 10.1016/j.jclepro.2014.09.047
   Lee JCK, 2018, NAT SUSTAIN, V1, P598, DOI 10.1038/s41893-018-0154-5
   Liu JG, 2018, NAT SUSTAIN, V1, P466, DOI 10.1038/s41893-018-0135-8
   Manberger A, 2018, ENERG POLICY, V119, P226, DOI 10.1016/j.enpol.2018.04.056
   Mancini L, 2018, RESOUR POLICY, V57, P98, DOI 10.1016/j.resourpol.2018.02.002
   Martinez E, 2009, RENEW ENERG, V34, P667, DOI 10.1016/j.renene.2008.05.020
   McLellan BC, 2012, J CLEAN PROD, V32, P32, DOI 10.1016/j.jclepro.2012.03.016
   McLellan BC, 2016, RESOURCES-BASEL, V5, DOI 10.3390/resources5020019
   McLellan BC, 2013, MINERALS-BASEL, V3, P304, DOI 10.3390/min3030304
   Meyer B., 2012, MACROECONOMIC MODELL
   Moriguchi Y., 2010, TAKING STOCK IND ECO, DOI [10.1007/978-3-319-20571-7, DOI 10.1007/978-3-319-20571-7]
   Moss RL, 2013, ENERG POLICY, V55, P556, DOI 10.1016/j.enpol.2012.12.053
   Moss R. L., 2011, JRC SCI TECHNICAL RE, DOI [10.2790/35600, DOI 10.2790/35600]
   Moss R. L., 2013, CRITICAL METALS PATH, DOI [10.2790/46338, DOI 10.2790/46338]
   Mostert C, 2018, ENERGIES, V11, DOI 10.3390/en11123386
   Mudd G. M., 2009, RR5 MON U MIN POL I
   Mudd GM, 2007, ENVIRON SCI POLICY, V10, P629, DOI 10.1016/j.envsci.2007.04.006
   Mudd GM, 2010, ORE GEOL REV, V38, P9, DOI 10.1016/j.oregeorev.2010.05.003
   Muller E, 2014, ENVIRON SCI TECHNOL, V48, P2102, DOI 10.1021/es403506a
   Muller D.B., 2005, ECOL ECON, V59, P82
   Murakami S, 2010, J IND ECOL, V14, P598, DOI 10.1111/j.1530-9290.2010.00250.x
   Nakajima K, 2006, J LIFE CYCLE ASSESSM, V2, P152
   Nakajima K, 2019, ENVIRON SCI TECHNOL, V53, P1555, DOI 10.1021/acs.est.8b04575
   Natural Resource Governance Institute, 2017, RES GOV IND 2017
   Ngosa K, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3547-2
   Nkulu CBL, 2018, NAT SUSTAIN, V1, P495, DOI 10.1038/s41893-018-0139-4
   Nugent D, 2014, ENERG POLICY, V65, P229, DOI 10.1016/j.enpol.2013.10.048
   Nuss P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101298
   Oguchi M, 2010, J IND ECOL, V14, P613, DOI 10.1111/j.1530-9290.2010.00251.x
   Pehnt M, 2006, RENEW ENERG, V31, P55, DOI 10.1016/j.renene.2005.03.002
   Pihl E, 2012, ENERGY, V44, P944, DOI 10.1016/j.energy.2012.04.057
   Plotz P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16684-9
   Prior T, 2012, GLOBAL ENVIRON CHANG, V22, P577, DOI 10.1016/j.gloenvcha.2011.08.009
   Prior T, 2013, GEOFORUM, V44, P316, DOI 10.1016/j.geoforum.2012.07.009
   Redlinger M, 2015, SOL ENERG MAT SOL C, V138, P58, DOI 10.1016/j.solmat.2015.02.027
   Risku-Norja H, 1999, AGR FOOD SCI FINLAND, V8, P393, DOI 10.23986/afsci.5637
   Roelich K, 2014, APPL ENERG, V123, P378, DOI 10.1016/j.apenergy.2014.01.052
   Scasny M, 2003, ECOL ECON, V45, P41, DOI 10.1016/S0921-8009(02)00260-4
   Schutz H., 2000, SUSTAINABLE DEV DEMA
   Spangenberg J., 1999, INT J SUST DEV WORLD, V2, P491, DOI [DOI 10.1504/IJSD.1999.004339, 10.1504/IJSD.1999.004339]
   Stamp A, 2014, RESOUR CONSERV RECY, V93, P156, DOI 10.1016/j.resconrec.2014.10.012
   Stiller H., 1999, MAT INTENSITY ADV CO
   Stowhas T, 2018, CHEMOSPHERE, V209, P960, DOI 10.1016/j.chemosphere.2018.06.166
   Sun QS, 2015, ATMOS ENVIRON, V118, P1, DOI 10.1016/j.atmosenv.2015.07.034
   Taelman SE, 2016, SCI TOTAL ENVIRON, V550, P143, DOI 10.1016/j.scitotenv.2016.01.055
   Teske S., 2016, RENEWABLE ENERGY DEE
   The Warren Centre, 2016, COPP TECHN ROADM 203
   Tokimatsu K, 2017, APPL ENERG, V207, P494, DOI 10.1016/j.apenergy.2017.05.151
   Tsurukawa N., 2011, SOCIAL IMPACTS ARTIS, DOI [10.1109/EMICC.2008.4772236, DOI 10.1109/EMICC.2008.4772236]
   U.S. Department of Energy, 2011, CRIT MAT STRAT 2011
   U.S. Energy Information Administration, 2018, INT EN STAT
   U.S. Geological Survey, 2018, MINERAL COMMODITY SU, DOI [10.3133/70194932, DOI 10.3133/70194932]
   Valero A, 2018, RENEW SUST ENERG REV, V93, P178, DOI 10.1016/j.rser.2018.05.041
   Van der Voet E., 2018, J IND ECOL, DOI [10.1111/jiec.12722.00, DOI 10.1111/JIEC.12722.00]
   VESTAS, 2006, LIF CYCL ASS OFFSH O
   Vidal O, 2013, NAT GEOSCI, V6, P894, DOI 10.1038/ngeo1993
   Wang HM, 2013, RESOURCES-BASEL, V2, P270, DOI 10.3390/resources2030270
   Wanger TC, 2011, CONSERV LETT, V4, P202, DOI 10.1111/j.1755-263X.2011.00166.x
   Watari T, 2018, MINERALS-BASEL, V8, DOI 10.3390/min8040156
   White Sarah Jane O, 2016, Curr Environ Health Rep, V3, P459
   Wiedenhofer D, 2019, ECOL ECON, V156, P121, DOI 10.1016/j.ecolecon.2018.09.010
   Wilburn D. R., 2011, SCI INVESTIGATIONS R
   Woodhouse M, 2013, IEEE J PHOTOVOLT, V3, P833, DOI 10.1109/JPHOTOV.2013.2242960
   World Bank, 2017, GROW ROL MIN MET LOW
   Wuppertal Institute, 2011, MAT INT MAT FUELS TR
   Wuppertal Institute, 2014, MAT INT MAT FUELS TR, DOI [10.1177/0959683608098959, DOI 10.1177/0959683608098959]
   Yamasue E, 2013, J IND ECOL, V17, P722, DOI 10.1111/jiec.12047
   Yamasue E, 2013, J IND ECOL, V17, P555, DOI 10.1111/jiec.12014
   Yamasue E, 2009, MATER TRANS, V50, P2165, DOI 10.2320/matertrans.MAW200908
   Yamasue E, 2009, MATER TRANS, V50, P1536, DOI 10.2320/matertrans.MBW200816
   Zimmermann T, 2013, INT J LIFE CYCLE ASS, V18, P49, DOI 10.1007/s11367-012-0467-y
NR 130
TC 3
Z9 3
U1 12
U2 23
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 91
EP 103
DI 10.1016/j.resconrec.2019.05.015
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800008
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Lansing, S
   Hulsemann, B
   Choudhury, A
   Schueler, J
   Lisboa, MS
   Oechsner, H
AF Lansing, Stephanie
   Huelsemann, Benedikt
   Choudhury, Abhinav
   Schueler, Jenna
   Lisboa, Maria Sol
   Oechsner, Hans
TI Food waste co-digestion in Germany and the United States: From lab to
   full-scale systems
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Biogas; Methane; Anaerobic; Policy; Biochemical; Manure
ID ANAEROBIC-DIGESTION; BIOGAS PRODUCTION; CATTLE MANURE; DAIRY MANURE;
   MAIZE
AB Using food waste (FW) as a co-substrate in anaerobic digestion (AD) results in increased energy production, decreases in greenhouse gas emissions, and recycles the FW nutrients back to the land for producing crops. This research investigated food waste AD systems in the United States (US) and Germany (DE) that co-digested FW with dairy manure at the lab and full-scale. In DE, the post-consumer FW had 32-49% more CH4 potential (477-499 mL(CH4)/gvs) than maize and grass silage (368 and 331 mL(CH4)/g(VS)) and solid and liquid manure (243 and 91 mL(CH4)/gvs). Methane production in the full-scale DE system with 66% FW (by volume) was 882 m(CH4)(3)/d, which was 37% higher than the laboratory results due to the 86-day retention and 42 degrees C AD conditions in the field. The pre-consumer FW in the US had a similar CH4 potential (264-553 mL(CH4)/g(VS)), but due to the lack of heating in the full-scale system, 62% less CH4 was produced than the lab-based potential. While DE requires pasteurization of FW for AD and bans FW bans to landfills, the US does not have specific requirements for FW treatment in AD or federal FW landfill policies, with a few forthcoming FW bans in some municipalities and states. As FW diversion and utilization in AD systems is expected to grow, it is important to understand the effect of FW in biogas production and nutrient content, comparisons between lab and field-scale results, and the effect of policy on FW utilization.
C1 [Lansing, Stephanie; Choudhury, Abhinav; Schueler, Jenna; Lisboa, Maria Sol] Univ Maryland, Dept Environm Sci & Technol, College Pk, MD 20742 USA.
   [Huelsemann, Benedikt; Oechsner, Hans] Univ Hohenheim, State Inst Agr Engn & Bioenergy, Stuttgart, Germany.
   [Lisboa, Maria Sol] Cornell Univ, Dept Biol & Environm Engn, Ithaca, NY USA.
RP Lansing, S (reprint author), 1429 Anim Sci Ag Engn Bldg, College Pk, MD 20742 USA.
EM slansing@umd.edu
OI Oechsner, Hans/0000-0002-6718-1358; Lansing,
   Stephanie/0000-0001-9169-3823
FU National Institute of Food and Agriculture U.S. Department of
   Agriculture (USDA) [2016-68003-24601]; USDA Northeast Sustainable
   Agriculture Research and Education (SARE) [LNE15-341]; Deutscher
   Akademischer Austauschdienst (DAAD) Research Fellowship; USDA NIFA Hatch
   [1014496]; University of Hohenheim
FX This research was financially supported by the National Institute of
   Food and Agriculture U.S. Department of Agriculture
   (USDA)(#2016-68003-24601), a USDA Northeast Sustainable Agriculture
   Research and Education (SARE) grant (#LNE15-341), a Deutscher
   Akademischer Austauschdienst (DAAD) Research Fellowship, USDA NIFA
   Hatch#1014496, and the University of Hohenheim. The authors would like
   to thank the participating farmers for their continual support and great
   assistance with the project as well as continual access to food waste
   and digester samples. A special thank you to the laboratory staff and
   students at the University of Hohenheim State Institute of Agricultural
   Engineering and Bioenergy, and the University of Maryland Waste to
   Energy laboratory, and Carlton Poindexter for this assistance on the
   policy analysis. Any opinions, findings, conclusions, or recommendations
   expressed in this publication are those of the author (s) and do not
   necessarily reflect the view of the U.S. Department of Agriculture.
CR Amon T, 2007, AGR ECOSYST ENVIRON, V118, P173, DOI 10.1016/j.agee.2006.05.007
   [Anonymous], 2005, STANDARD METHODS EXA
   Appels L, 2011, RENEW SUST ENERG REV, V15, P4295, DOI 10.1016/j.rser.2011.07.121
   Banks CJ, 2011, RESOUR CONSERV RECY, V56, P71, DOI 10.1016/j.resconrec.2011.09.006
   BMU, 2012, CLOS SUBST CYCL ARCT, P212
   Buzby J. C., 2014, USDA ERS EC INFORM B, P121
   Callaghan FJ, 1999, BIORESOURCE TECHNOL, V67, P117, DOI 10.1016/S0960-8524(98)00108-4
   CHO JK, 1995, BIORESOURCE TECHNOL, V52, P245, DOI 10.1016/0960-8524(95)00031-9
   El-Mashad HM, 2010, BIORESOURCE TECHNOL, V101, P4021, DOI 10.1016/j.biortech.2010.01.027
   European Commission, 2010, COMMUNICATION
   Evans AI, 2018, NAT RESOUR J, V58, P177
   FNR, 2018, CULT REN RES GERM
   Haag NL, 2015, BIORESOURCE TECHNOL, V178, P217, DOI 10.1016/j.biortech.2014.08.048
   Helffrich D., 2003, Landtechnik, V58, P148
   Heo NH, 2004, J ENVIRON SCI HEAL A, V39, P1739, DOI 10.1081/ESE-120037874
   Klavon KH, 2013, BIOMASS BIOENERG, V54, P36, DOI 10.1016/j.biombioe.2013.03.009
   KTBL, 2013, BAS FIG BIOG, V1
   Lemmer A, 2017, APPL ENERG, V185, P885, DOI 10.1016/j.apenergy.2016.10.073
   Levis JW, 2011, ENVIRON SCI TECHNOL, V45, P5470, DOI 10.1021/es200721s
   Li R, 2009, ENERG SOURCE PART A, V31, P1848, DOI 10.1080/15567030802606038
   Li RP, 2010, APPL BIOCHEM BIOTECH, V160, P643, DOI 10.1007/s12010-009-8533-z
   Lisboa MS, 2014, WASTE MANAGE, V34, P1299, DOI 10.1016/j.wasman.2014.03.005
   Lorenz H, 2013, WASTE MANAGE, V33, P2434, DOI 10.1016/j.wasman.2013.06.018
   Mast B, 2014, IND CROP PROD, V58, P194, DOI 10.1016/j.indcrop.2014.04.017
   Mittweg G, 2012, ENG LIFE SCI, V12, P270, DOI 10.1002/elsc.201100181
   Monch-Tegeder M, 2014, ENERGY, V73, P523, DOI 10.1016/j.energy.2014.06.051
   Moody LB, 2011, APPL ENG AGRIC, V27, P433
   Mukengele M., 2007, Landtechnik, V62, P20
   Neves L, 2009, BIORESOURCE TECHNOL, V100, P1957, DOI 10.1016/j.biortech.2008.10.030
   Pandey P, 2016, J CLEAN PROD, V112, P205, DOI 10.1016/j.jclepro.2015.09.045
   Poschl M, 2010, APPL ENERG, V87, P3305, DOI 10.1016/j.apenergy.2010.05.011
   Ra Labatut, 2012, P GOT MAN ENH ENV EC, P209
   Raposo F, 2012, RENEW SUST ENERG REV, V16, P861, DOI 10.1016/j.rser.2011.09.008
   Resch C, 2008, WATER SCI TECHNOL, V57, P73, DOI 10.2166/wst.2008.733
   Ruile S, 2015, BIORESOURCE TECHNOL, V178, P341, DOI 10.1016/j.biortech.2014.10.053
   Scano EA, 2014, ENERG CONVERS MANAGE, V77, P22, DOI 10.1016/j.enconman.2013.09.004
   Lisboa MS, 2013, WASTE MANAGE, V33, P2664, DOI 10.1016/j.wasman.2013.09.004
   SPEECE RE, 1996, ANAEROBIC BIOTECHNOL
   US EPA, 2018, LIV AN DIG DAT
   US EPA, 2018, EXC FOOD OPP MAP TEC
   VDI, 2014, 4630 VDI
   Weiland P., 2009, BIOGAS MEASUREMENT P
   Weiltbach F., 2008, LANDTECHNIK, V63, P356
   Wilkinson KG, 2011, BIOMASS BIOENERG, V35, P1613, DOI 10.1016/j.biombioe.2011.01.013
   Zhang L, 2012, WASTE MANAGE, V32, P1509, DOI 10.1016/j.wasman.2012.03.015
   Zhang W, 2017, ENERG FUEL, V31, P10890, DOI 10.1021/acs.energyfuels.7b01719
NR 46
TC 1
Z9 1
U1 8
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 104
EP 113
DI 10.1016/j.resconrec.2019.05.014
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800009
DA 2020-05-12
ER

PT J
AU Venkatesan, M
   Zaib, Q
   Shah, IH
   Park, HS
AF Venkatesan, Mayandi
   Zaib, Qammer
   Shah, Izhar Hussain
   Park, Hung Suck
TI Optimum utilization of waste foundry sand and fly ash for geopolymer
   concrete synthesis using D-optimal mixture design of experiments
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Waste utilization; Waste foundry sand (WFS) and fly ash; D-Optimal
   mixture design/response surface methodology/design of experiments;
   Statistical optimization; Geopolymer concrete (GPC); Compressive
   strength
ID COMPRESSIVE STRENGTH; OPTIMIZATION; WATER; BEHAVIOR; MICRO; PASTE
AB This work examines the partial replacement of fine aggregates with waste foundry sand (WFS) and fly ash, process by-products, to synthesize geopolymer concrete (GPC). D-optimal mixture design of experiments was adopted to guide the proportion of mixture constituents (fine aggregates, WFS, and fly ash) to obtain desired responses (high compressive strengths). The experimentally measured responses/compressive strengths were successfully fitted to Scheffe polynomial model to obtain cubic models which represent compressive strengths of solidified GPC at 7th day curing time (CS 7) and at 28th day curing time (CS 28). The models were statistically evaluated by the standard error of design estimation and experimentally verified by comparing their predicted responses to the independently performed experiments. The models were subjected to analysis of variance (ANOVA) and residuals (diagnostics) for statistical significance and validation, respectively. The established models, hence obtained, were used to assess the impacts of relative proportions of mixture constituents at CS 7 and CS 28. It was observed that, although the highest compressive strength requires a high proportion of fine aggregates, yet, some mixture compositions could be proposed for better utilization of waste materials. Finally, the optimization was performed to maximize the usage of WFS and fly ash. A recipe was identified which yielded 18.9 N/mm(2) CS 7 and 22.3 N/rnm(2) CS 28 by mere 32 wt. % contribution of fine aggregates in a (fine aggregates + WFS + fly ash) mixture. This study can be helpful in designing experiments and optimizing the utilization of similar waste materials into useful products.
C1 [Venkatesan, Mayandi; Zaib, Qammer; Shah, Izhar Hussain; Park, Hung Suck] Univ Ulsan, Dept Civil & Environm Engn, Daehak Ro 93, Ulsan 680749, South Korea.
   [Shah, Izhar Hussain] NUST, Sch Civil & Environm Engn, Inst Environm Sci & Engn, H-12 Campus, Islamabad 44000, Pakistan.
RP Park, HS (reprint author), Univ Ulsan, Dept Civil & Environm Engn, Daehak Ro 93, Ulsan 680749, South Korea.
EM parkhs@ulsan.ac.kr
RI Zaib, Qammer/H-5811-2017
OI Zaib, Qammer/0000-0002-1924-4131; /0000-0002-0066-0012
FU University of Ulsan [2018-0337]
FX This research work was financially supported by 2018 research fund of
   the University of Ulsan (Grant number: 2018-0337).
CR Abdollahnejad Z., 2015, Advanced Materials Research, V1129, P565, DOI 10.4028/www.scientific.net/AMR.1129.565
   Anderson M.J., 2016, RSM SIMPLIFIED OPTIM, P311, DOI [10.1201/9781315382326., DOI 10.1201/9781315382326, 10.1201/9781315382326]
   Anderson M. J, 2015, DOE SIMPLIFIED PRACT, DOI [10.1201/b18479, DOI 10.1201/B18479]
   Anderson M. J, 2018, FORMULATION SIMPLIFI, DOI [10.4324/9781315165578, DOI 10.4324/9781315165578]
   Arroyo-Lopez FN, 2009, FOOD MICROBIOL, V26, P396, DOI 10.1016/j.fm.2009.01.009
   Baek JW, 2017, WASTE MANAGE, V70, P139, DOI 10.1016/j.wasman.2017.09.010
   Bakharev T, 2006, CEMENT CONCRETE RES, V36, P1134, DOI 10.1016/j.cemconres.2006.03.022
   Basar HM, 2012, CONSTR BUILD MATER, V35, P508, DOI 10.1016/j.conbuildmat.2012.04.078
   Bernal SA, 2014, J AM CERAM SOC, V97, P997, DOI 10.1111/jace.12831
   Bhardwaj B, 2017, CONSTR BUILD MATER, V156, P661, DOI 10.1016/j.conbuildmat.2017.09.010
   Calle M, 2017, GEOMORPHOLOGY, V285, P333, DOI 10.1016/j.geomorph.2017.02.026
   Cornell J.A., 2011, EXPT MIXTURES DESIGN
   COX DR, 2000, THEORY DESIGN EXPT
   Duxson P, 2007, J MATER SCI, V42, P2917, DOI 10.1007/s10853-006-0637-z
   Edwards B, 2015, FINANC DEV
   Eriksson L, 1998, CHEMOMETR INTELL LAB, V43, P1, DOI 10.1016/S0169-7439(98)00126-9
   Etxeberria M, 2010, CONSTR BUILD MATER, V24, P1594, DOI 10.1016/j.conbuildmat.2010.02.034
   Gavriletea MD, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9071118
   Gunst R. F., 1996, TECHNOMETRICS, V38, P284, DOI DOI 10.1080/00401706.1996.10484509
   Gurumoorthy N, 2016, CONSTR BUILD MATER, V123, P184, DOI 10.1016/j.conbuildmat.2016.06.143
   Hamami AA, 2012, CEMENT CONCRETE RES, V42, P490, DOI 10.1016/j.cemconres.2011.11.019
   Hardjito D, 2005, AUST J STRUCT ENG, V6, P77, DOI 10.1080/13287982.2005.11464946
   Jeirani Z, 2012, CHEMOMETR INTELL LAB, V112, P1, DOI 10.1016/j.chemolab.2011.10.008
   Khan A, 2017, J CONSTR ENG M, V143, DOI 10.1061/(ASCE)CO.1943-7862.0001230
   Khatib JM, 2001, ACI SPEC PUBL, V200, P733, DOI DOI 10.14359/10612
   Li X, 2009, BIORESOURCE TECHNOL, V100, P3613, DOI 10.1016/j.biortech.2009.03.001
   Lloyd NA, 2010, P 35 C OUR WORLD CON, P307
   Lohani T, 2012, INT J APPL SCI ENG R, V1, P3613, DOI [10.6088/ijaser.0020101040, DOI 10.6088/IJASER.0020101040]
   Madhavan S, 2016, INT J ENG SCI ADV CO, V6, P4222, DOI [10.4010/2016.969, DOI 10.4010/2016.969]
   Mauroux T, 2012, CEMENT CONCRETE RES, V42, P1014, DOI 10.1016/j.cemconres.2012.04.002
   Muteki K, 2007, CHEMOMETR INTELL LAB, V86, P17, DOI 10.1016/j.chemolab.2006.08.003
   Myers R. H., 2016, RESPONSE SURFACE MET
   OLUTOGE F.A, 2015, INT J EMERG TECHNOL, V5, P35
   Pan Z, 2011, MAG CONCRETE RES, V63, P763, DOI 10.1680/macr.2011.63.10.763
   Pattanaik A, 2018, ADV POWDER TECHNOL, V29, P3404, DOI 10.1016/j.apt.2018.09.021
   Pillai NS, 2017, RENEW ENERG, V104, P185, DOI 10.1016/j.renene.2016.12.035
   Provis JL, 2018, CEMENT CONCRETE RES, V114, P40, DOI 10.1016/j.cemconres.2017.02.009
   Provis JL, 2015, CEMENT CONCRETE RES, V78, P110, DOI 10.1016/j.cemconres.2015.04.013
   Provis JL, 2014, MATER STRUCT, V47, P11, DOI 10.1617/s11527-013-0211-5
   Reddy MS, 2016, MICROPOR MESOPOR MAT, V234, P12, DOI 10.1016/j.micromeso.2016.07.005
   Saha S, 2017, CONSTR BUILD MATER, V146, P615, DOI 10.1016/j.conbuildmat.2017.04.139
   Sahmaran M, 2011, MATER STRUCT, V44, P1193, DOI 10.1617/s11527-010-9692-7
   Saviour M. N, 2012, IOSR J PHARM, V2, P2250
   Sengupta D, 2014, RECENT TRENDS MODELL, DOI [10.1007/978-81-322-1783-1, DOI 10.1007/978-81-322-1783-1]
   Siddique R, 2009, CONSTR BUILD MATER, V23, P976, DOI 10.1016/j.conbuildmat.2008.05.005
   Singh B, 2015, CONSTR BUILD MATER, V85, P78, DOI 10.1016/j.conbuildmat.2015.03.036
   Singh G, 2012, CONSTR BUILD MATER, V28, P421, DOI 10.1016/j.conbuildmat.2011.08.087
   Sun ZQ, 2018, CONSTR BUILD MATER, V189, P797, DOI 10.1016/j.conbuildmat.2018.09.067
   Tennakoon C, 2014, AUSTR BRIDG C 12
   Trabelsi A, 2011, MAG CONCRETE RES, V63, P333, DOI 10.1680/macr.9.00161
   Turcry P, 2014, CEMENT CONCRETE RES, V57, P70, DOI 10.1016/j.cemconres.2014.01.003
   Ubbriaco P, 2001, J THERM ANAL CALORIM, V66, P293, DOI 10.1023/A:1012468505722
   van Jaarsveld JGS, 2003, MATER LETT, V57, P1272, DOI 10.1016/S0167-577X(02)00971-0
   Varanda C, 2017, CONSTR BUILD MATER, V156, P611, DOI 10.1016/j.conbuildmat.2017.08.146
   Vijai K, 2010, INT J PHYS SCI, V5, P1419
   Xu G, 2018, RESOUR CONSERV RECY, V136, P95, DOI 10.1016/j.resconrec.2018.04.010
   Zafar M, 2017, J ENVIRON SCI, V54, P114, DOI 10.1016/j.jes.2016.06.008
   Zaib Q, 2019, ACS OMEGA, V4, P849, DOI 10.1021/acsomega.8b02965
   Zaib Q, 2019, ACS OMEGA, V4, P535, DOI 10.1021/acsomega.8b02706
   Zhang P, 2018, COMPOS PART B-ENG, V152, P79, DOI 10.1016/j.compositesb.2018.06.031
NR 60
TC 1
Z9 1
U1 9
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 114
EP 123
DI 10.1016/j.resconrec.2019.05.008
PG 10
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800010
DA 2020-05-12
ER

PT J
AU Bartolacci, F
   Del Gobbo, R
   Paolini, A
   Soverchia, M
AF Bartolacci, Francesca
   Del Gobbo, Roberto
   Paolini, Antonella
   Soverchia, Michela
TI Efficiency in waste management companies: A proposal to assess scale
   economies
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Efficiency; Elasticity coefficient; Scale economies; Interaction effect;
   Separate waste collection; Waste management companies
ID CIRCULAR ECONOMY; ENVIRONMENTAL EFFICIENCY; SUSTAINABLE CONSUMPTION;
   COST-ANALYSIS; SERVICES; INDICATORS; GENERATION; DISPOSAL; MODELS;
   IMPACT
AB This article analyzes the economic efficiency of waste management companies with the aim of verifying the existence of scale economies with respect to separate waste collection preceding reuse, recycling, and recovery. For this purpose, an approach based on partial elasticity is used for a group of companies providing waste management services throughout Italy. Results show that the greater the separate waste collection rate, the higher the total costs incurred by the analyzed companies; this relationship is non-linear since a rise in the separate waste collection rate increases total costs less than proportionally, which gives evidence for the existence of scale economies. The findings also reveal that such a cost advantage is strengthened by a positive interaction effect with population density. These results show that a significant increase in separate waste collection rate could be realized in an efficient way and, thus, without jeopardizing companies' economic sustainability, which is essential to continue ensuring such important services for the community. One of the main implications of these results concerns policy makers: considering the population density impact, working in certain territories can be more economically convenient for companies; thus, policy makers should support those firms that could be penalized by the contextual conditions.
C1 [Bartolacci, Francesca; Paolini, Antonella; Soverchia, Michela] Univ Macerata, Dept Econ & Law, Via Armaroli 43, I-62100 Macerata, Italy.
   [Del Gobbo, Roberto] Univ Pisa, Dept Econ & Management, Via Ridolfi 10, I-56124 Pisa, Italy.
RP Soverchia, M (reprint author), Univ Macerata, Dept Econ & Law, Via Armaroli 43, I-62100 Macerata, Italy.
EM francesca.bartolacci@unimc.it; robdelgobbo@gmail.com;
   antonella.paolini@unimc.it; michela.soverchia@unimc.it
OI SOVERCHIA, Michela/0000-0002-7558-3795
CR Abrate G, 2014, REG STUD, V48, P896, DOI 10.1080/00343404.2012.689425
   Ali G., 2013, J BIODIVERS ENVIRON, V3, P111
   Ali G, 2016, RENEW SUST ENERG REV, V61, P25, DOI 10.1016/j.rser.2016.03.014
   Ali G, 2012, RENEW SUST ENERG REV, V16, P5423, DOI 10.1016/j.rser.2012.05.021
   Aminoff A, 2016, SMART INNOV SYST TEC, V52, P61, DOI 10.1007/978-3-319-32098-4_6
   Bartolacci F, 2018, WASTE MANAGE, V79, P571, DOI 10.1016/j.wasman.2018.07.050
   Bartolacci F, 2018, SUSTAIN PROD CONSUMP, V14, P129, DOI 10.1016/j.spc.2018.02.002
   Bartolacci F, 2017, ENVIRON ENG MANAG J, V16, P1789
   Bel G, 2010, RESOUR CONSERV RECY, V54, P187, DOI 10.1016/j.resconrec.2009.07.015
   Blomsma F, 2017, J IND ECOL, V21, P603, DOI 10.1111/jiec.12603
   Bureecam C, 2015, SONGKLA J SCI TECHNO, V37, P449
   Callan SJ, 2001, LAND ECON, V77, P548, DOI 10.2307/3146940
   Caputo A, 2018, INT J CONFL MANAGE, V29, P519, DOI 10.1108/IJCMA-02-2018-0027
   Carvalho P, 2015, WASTE MANAGE, V39, P277, DOI 10.1016/j.wasman.2015.01.024
   CHAMBERS RG, 1988, APPL PRODUCTION ANAL
   Chifari R, 2017, WASTE MANAGE, V60, P32, DOI 10.1016/j.wasman.2017.01.015
   Citroni G, 2016, GOV PUBLIC MANAG, P103, DOI 10.1057/978-1-137-57499-2_8
   Cobo S, 2018, RESOUR CONSERV RECY, V135, P279, DOI 10.1016/j.resconrec.2017.08.003
   Cooper H. M., 1988, INTEGRATIVE RES REV
   D'Onza G, 2016, J ENVIRON MANAGE, V167, P59, DOI 10.1016/j.jenvman.2015.09.002
   Dawson JF, 2014, J BUS PSYCHOL, V29, P1, DOI 10.1007/s10869-013-9308-7
   Neto GCD, 2017, RESOUR CONSERV RECY, V127, P42, DOI 10.1016/j.resconrec.2017.08.011
   Debnath S, 2014, RESOUR CONSERV RECY, V83, P87, DOI 10.1016/j.resconrec.2013.12.007
   Di Maio F, 2017, RESOUR CONSERV RECY, V122, P163, DOI 10.1016/j.resconrec.2017.02.009
   Dijkgraaf E., 2003, EMPIRICA, V30, P149, DOI DOI 10.1023/A:1024175730230
   European Commission Closing the loop - an EU action plan for the cir- cular economy, 2015, COM2015614 EUR COMM
   Geissdoerfer M, 2018, J CLEAN PROD, V190, P712, DOI 10.1016/j.jclepro.2018.04.159
   Geissdoerfer M, 2017, J CLEAN PROD, V143, P757, DOI 10.1016/j.jclepro.2016.12.048
   Gordeeva YM, 2017, J EUR ENVIRON PLAN L, V14, P233, DOI 10.1163/18760104-01402007
   Greco G, 2015, J CLEAN PROD, V106, P364, DOI 10.1016/j.jclepro.2014.07.011
   Gujarati D., 2010, ESSENTIALS ECONOMETR
   Halkos G, 2016, J ENVIRON PLANN MAN, V59, P62, DOI 10.1080/09640568.2014.983592
   Halkos GE, 2018, J ENVIRON MANAGE, V211, P334, DOI 10.1016/j.jenvman.2018.01.067
   Iacovidou E, 2017, J CLEAN PROD, V166, P910, DOI 10.1016/j.jclepro.2017.07.100
   International Solid Waste Association, 2015, INT SOL WAST ASS REP
   Kirchherr J, 2017, RESOUR CONSERV RECY, V127, P221, DOI 10.1016/j.resconrec.2017.09.005
   Lo AY, 2018, J ENVIRON MANAGE, V214, P416, DOI 10.1016/j.jenvman.2018.03.029
   Moore H. L., 1920, SYNTHETIC EC
   Moraga G, 2019, RESOUR CONSERV RECY, V146, P452, DOI 10.1016/j.resconrec.2019.03.045
   Ohlsson H, 2003, FISC STUD, V24, P451
   PANZAR JC, 1977, Q J ECON, V91, P481, DOI 10.2307/1885979
   Dong PAV, 2018, RESOUR CONSERV RECY, V133, P63, DOI 10.1016/j.resconrec.2018.01.024
   Prieto-Sandoval V, 2018, J CLEAN PROD, V179, P605, DOI 10.1016/j.jclepro.2017.12.224
   Reeves E, 2000, ECON SOC REV, V31, P129
   The World Bank, 2012, WHAT WASTE GLOBAL RE
   Tseng ML, 2018, RESOUR CONSERV RECY, V128, P118, DOI 10.1016/j.resconrec.2017.02.014
   Utilitatis, 2016, GREEN BOOK DATI GEST
   Wallace D., 2017, ENV POLICY IND INNOV
NR 48
TC 2
Z9 2
U1 3
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 124
EP 131
DI 10.1016/j.resconrec.2019.05.019
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800011
DA 2020-05-12
ER

PT J
AU Sfez, S
   De Meester, S
   Vlaeminck, SE
   Dewulf, J
AF Sfez, Sophie
   De Meester, Steven
   Vlaeminck, Siegfried E.
   Dewulf, Jo
TI Improving the resource footprint evaluation of products recovered from
   wastewater: A discussion on appropriate allocation in the context of
   circular economy
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Wastewater; Life Cycle Assessment; Allocation; Cascading; Struvite;
   Water resource recovery facility
ID LIFE-CYCLE ASSESSMENT; ENVIRONMENTAL IMPACTS; SLUDGE
AB Shifting from a linear to a circular economy has consequences on how the sustainability of products is assessed. This is the case for products recovered from resources such as sewage sludge. The "zero-burden" assumption is commonly used in Life Cycle Assessment and considers that waste streams are burden-free, which becomes debatable when comparing waste-based with virgin material-based products in the context of the growing circular economy. If waste streams are considered as resources rather than waste, upstream burdens should be partly allocated to all products to allow a fair comparison with their virgin material-based equivalents. In this paper, five allocation approaches are applied to allocate the resource use of upstream processes (consumer goods production) to products recovered from the processing of sewage sludge in the Netherlands, which produces biogas, (phosphorus-based) chemicals and building materials.
   Except for the approach which allocates 100% of the impact from resource recovery processes to the preceding consumer goods, the allocation approaches show a resource use 27 to 80% higher than with the "zero-burden" assumption. In this particular case, using these allocation approaches is likely to find little support from recyclers. The producers of household products, recyclers and policy makers should find a consensus to consider the shift from a linear to a circular economy in sustainability assessment studies while avoiding discouraging the implementation of recovery technologies. This paper suggests starting the discussion with the approach which allocates the impacts from upstream processes degressively to the downstream products as it best translates the industrial ecology principles.
C1 [Sfez, Sophie; Dewulf, Jo] Univ Ghent, Res Grp STEN, Fac Biosci Engn, Dept Green Chem & Technol, Campus Coupure,Coupure Links 653, B-9000 Ghent, Belgium.
   [De Meester, Steven] Univ Ghent, Fac Biosci Engn, Dept Green Chem & Technol, Campus Kortrijk,Graaf Karel Goedelaan 5, B-8500 Kortrijk, Belgium.
   [Vlaeminck, Siegfried E.] Univ Antwerp, Fac Sci, Dept Biosci Engn, Res Grp Sustainable Energy Air & Water Technol, Groenenborgerlaan 171, B-2020 Antwerp, Belgium.
RP Sfez, S (reprint author), Univ Ghent, Res Grp STEN, Fac Biosci Engn, Dept Green Chem & Technol, Campus Coupure,Coupure Links 653, B-9000 Ghent, Belgium.
EM sophie.sfez@ugent.be; steven.demeester@ugent.be;
   siegfried.vlaeminck@uantwerpen.be; jo.dewulf@ugent.be
FU Ghent UniversityGhent University
FX The authors thank Ghent University for providing funding for this
   research. The authors thank Alexandra Deeke from Waterschap De Dommel
   and Faezeh Mandavi from Ghent University for their help in data
   collection and scenario definition as well as Fabrice Mathieux from the
   Joint Research Centre (European Commission), Arne Verliefde and Sue
   Ellen Taelman from Ghent University and Gert Vanhoof and Diederik
   Schowanek from Procter & Gamble for their valuable feedback on the
   manuscript.
CR AISE, 2014, PAN EUR CONS SURV SU
   Allacker K, 2017, INT J LIFE CYCLE ASS, V22, P1441, DOI 10.1007/s11367-016-1244-0
   Alloul A, 2018, ENVIRON SCI TECHNOL, V52, P6729, DOI 10.1021/acs.est.7b05712
   Amann A, 2018, RESOUR CONSERV RECY, V130, P127, DOI 10.1016/j.resconrec.2017.11.002
   [Anonymous], 2006, 14040 ISO
   [Anonymous], 2006, 14044 ISO
   Birgisdottir H, 2007, WASTE MANAGE, V27, pS75, DOI 10.1016/j.wasman.2007.02.016
   Blom B, 2013, MILIEUPRESTATIE 2013
   Chen C, 2010, RESOUR CONSERV RECY, V54, P1231, DOI 10.1016/j.resconrec.2010.04.001
   Consultants, 2003, LCA FOOD DAT 2 0
   Dewulf J, 2007, ENVIRON SCI TECHNOL, V41, P8477, DOI 10.1021/es0711415
   Ekvall T, 2007, WASTE MANAGE, V27, P989, DOI 10.1016/j.wasman.2007.02.015
   Ellen MacArthur Foundation, 2017, CIRC EC WEALTH FLOWS
   Finnveden G, 1999, RESOUR CONSERV RECY, V26, P173, DOI 10.1016/S0921-3449(99)00005-1
   Frischknecht R, 2005, J CLEAN PROD, V13, P1337, DOI 10.1016/j.jclepro.2005.05.002
   Frischknecht R, 2013, ENV STUDIES, V1330
   Golsteijn L, 2015, ENVIRON SCI EUR, V27, P1, DOI 10.1186/s12302-015-0055-4
   Gouda PJ, 2017, AGR FOOTPR DAT
   Guyonnet D, 2009, GEOTEXT GEOMEMBRANES, V27, P321, DOI 10.1016/j.geotexmem.2009.02.002
   Ilic DD, 2018, J CLEAN PROD, V182, P352, DOI 10.1016/j.jclepro.2018.02.031
   Ishii SKL, 2015, WATER RES, V79, P88, DOI 10.1016/j.watres.2015.04.010
   IWA, 2016, WAT UT PATHW CIRC EC
   Jossa P, 2015, LIFE CYCLE ASSESSMEN
   Linderholm K, 2012, RESOUR CONSERV RECY, V66, P27, DOI 10.1016/j.resconrec.2012.04.006
   LNV, 2010, FACT SHEET FOOD WAST
   Mady CEK, 2013, INT J THERMODYN, V16, P73, DOI 10.5541/ijot.453
   Mahmood AU, 1998, ENZYME MICROB TECH, V22, P130, DOI 10.1016/S0141-0229(97)00150-6
   Notarnicola B, 2017, J CLEAN PROD, V140, P753, DOI 10.1016/j.jclepro.2016.06.080
   OECD, 2018, ENV DAT MUN WAST GEN
   Oldfield T., 2014, EVALUATION UPSTREAM, V8-10, P926
   Pradel M, 2016, J CLEAN PROD, V131, P60, DOI 10.1016/j.jclepro.2016.05.076
   Puyol D, 2017, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02106
   RIVM, 2011, DUTCH NATL FOOD CONS
   Sijstermans L, 2013, MILILEUJAARVERSLAG 2
   Spinosa L, 2011, WATER-SUI, V3, P702, DOI 10.3390/w3020702
   van Oers L., 2002, ABIOTIC RESOURCE DEP
   Vaneeckhaute C., 2014, IWA SPECIALIST C PAP
   Verstraete W, 2016, BIORESOURCE TECHNOL, V215, P199, DOI 10.1016/j.biortech.2016.04.094
   Verstraete W, 2011, INT J SUST DEV WORLD, V18, P253, DOI 10.1080/13504509.2011.570804
   Weidema B.P., 2013, OVERVIEW METHODOLOGY
NR 40
TC 3
Z9 3
U1 12
U2 34
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 132
EP 144
DI 10.1016/j.resconrec.2019.03.029
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800012
DA 2020-05-12
ER

PT J
AU Gkargkavouzi, A
   Halkos, G
   Matsiori, S
AF Gkargkavouzi, Anastasia
   Halkos, George
   Matsiori, Steriani
TI Environmental behavior in a private-sphere context: Integrating theories
   of planned behavior and value belief norm, self-identity and habit
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Theory of planned behavior; Value-belief-norm theory; Habit; Identity;
   Private-sphere environmental behavior
ID ENERGY-SAVING BEHAVIOR; WILLINGNESS-TO-PAY; BIOSPHERIC VALUES;
   ACTIVATION MODEL; EXTENDED THEORY; GREEN; INTENTION; DETERMINANTS;
   RESIDENTS; PSYCHOLOGY
AB This study explores the determinants of environmental behavior in a private-sphere context and proposes an integrative model that includes the constructs from two theoretical frameworks, the theory of planned behavior (TPB) and the value belief norm theory (VBN), along with two additional variables, habits and self-identity. A questionnaire survey method was used to collect the survey data and statistical analysis relied on application of structural equation modeling (SEM). The results show that intention is the best predictor of environmental behavior followed by habits and subjective norm is the main attendant of intention. Awareness of consequences has a positive impact on personal and subjective norms, attitudes and perceived behavioral control, while these constructs have in turn a significant influence on behavioral intention. Self-identity moderates the relationships between biospheric values and personal norm, attitudes, subjective norm, and perceived behavioral control. The proposed model exhibit superior predictive ability compared to the original TPB and VBN models verifying its utility and effectiveness in explaining environmental behavior. The results of this work can be used by governments and policymakers to design and implement conservation programs to promote a more sustainable lifestyle. Recommendations for future research are discussed in the last section of this paper.
C1 [Gkargkavouzi, Anastasia; Matsiori, Steriani] Univ Thessaly, Dept Ichthyol & Aquat Environm, Sch Agr Sci, Volos 38445, Nea Ionia, Greece.
   [Halkos, George] Univ Thessaly, Dept Econ, Fac Humanities & Social Sci, Lab Operat Res, Volos 38221, Greece.
   [Gkargkavouzi, Anastasia; Matsiori, Steriani] Univ Thessaly, Dept Agr Sci Ichthyol & Aquat Environm, Sch Agr Sci, St Fytokou, Volos 38445, Nea Ionia, Greece.
   [Halkos, George] Univ Thessaly, Dept Econ, Fac Humanities & Social Sci, 28hs Octovriou 78 St, Volos 38333, Greece.
RP Gkargkavouzi, A (reprint author), Univ Thessaly, Dept Agr Sci Ichthyol & Aquat Environm, Fytokou St, Nea Ionia 38445, Volos, Greece.; Gkargkavouzi, A (reprint author), Univ Thessaly, Dept Agr Sci Ichthyol & Aquat Environm, Sch Agr Sci, St Fytokou, Volos 38445, Nea Ionia, Greece.
EM agkargkavouzi@uth.gr; halkos@econ.uth.gr; steriani@uth.gr
RI Halkos, George/AAE-4772-2020; Gkargkavouzi, Anastasia/AAH-1026-2020
OI GKARGKAVOUZI, ANASTASIA/0000-0001-5757-7968; HALKOS,
   GEORGE/0000-0002-2772-5306
FU European Union (European Social Fund- ESF) through the Operational
   Programme Human Resources Development, Education and Lifelong Learning
   [MIS-5000432]
FX This research is co-financed by Greece and the European Union (European
   Social Fund- ESF) through the Operational Programme Human Resources
   Development, Education and Lifelong Learning in the context of the
   project "Strengthening Human Resources Research Potential via Doctorate
   Research" (MIS-5000432), implemented by the State Scholarships
   Foundation (IKY) (MIS 5000432).
CR Abrahamse W., 2011, HUM ECOL REV, DOI [10.2307/24707684, DOI 10.2307/24707684]
   Ait K., 2015, PROCEDIA SOC BEHAV S
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Ajzen I, 1985, ACTION CONTROL COGNI, P11, DOI DOI 10.1007/978-3-642-69746-3_2
   Ajzen I., 2005, WORLD, DOI [10.1007/BF02294218, DOI 10.1007/BF02294218]
   Ajzen I, 1975, BELIEF ATTITUDE INTE, DOI [10.2307/2065853, DOI 10.2307/2065853]
   Ajzen I., 2002, HDB CONSUM PSYCHOL
   Ajzen I, 2011, PSYCHOL HEALTH, V26, P1113, DOI 10.1080/08870446.2011.613995
   Alisat S, 2015, J ENVIRON PSYCHOL, V43, P13, DOI 10.1016/j.jenvp.2015.05.006
   Asilsoy B, 2018, SUSTAIN CITIES SOC, V39, P765, DOI 10.1016/j.scs.2018.02.036
   Bamberg S, 2007, J ENVIRON PSYCHOL, V27, P14, DOI 10.1016/j.jenvp.2006.12.002
   Barbarossa C, 2017, ECOL ECON, V140, P190, DOI 10.1016/j.ecolecon.2017.05.015
   Becker P., 2014, SUSTAINABILITY SCI M, P57, DOI [10.1016/B978-0-444-62709-4.00004-X, DOI 10.1016/B978-0-444-62709-4.00004-X]
   Bentler P. M., 2005, EQS VERSION 6 COMPUT
   Bergek A, 2017, ENERG POLICY, V106, P547, DOI 10.1016/j.enpol.2017.04.016
   Binder M, 2016, ECOL ECON, V124, P1, DOI 10.1016/j.ecolecon.2016.01.009
   Bollen K. A., 1993, TESTING STRUCTURAL E, P111
   Botetzagias I, 2015, RESOUR CONSERV RECY, V95, P58, DOI 10.1016/j.resconrec.2014.12.004
   Bouscasse H, 2018, TRANSPORT RES D-TR E, V59, P205, DOI 10.1016/j.trd.2018.01.007
   Brick C, 2017, J ENVIRON PSYCHOL, V51, P226, DOI 10.1016/j.jenvp.2017.04.004
   Byrne BM, 2016, STRUCTURAL EQUATION
   Chan L, 2013, J ENVIRON PSYCHOL, V36, P96, DOI 10.1016/j.jenvp.2013.07.010
   Chen MF, 2016, J CLEAN PROD, V112, P1746, DOI 10.1016/j.jclepro.2015.07.043
   Chen MF, 2015, ASIAN J SOC PSYCHOL, V18, P145, DOI 10.1111/ajsp.12096
   Clayton S, 2016, AM PSYCHOL, V71, P199, DOI 10.1037/a0039482
   de Groot JIM, 2009, CONSERV LETT, V2, P61, DOI 10.1111/j.1755-263X.2009.00048.x
   de Groot JM, 2010, J ENVIRON PSYCHOL, V30, P368, DOI 10.1016/j.jenvp.2010.04.002
   De Silva DG, 2014, APPL ECON, V46, P573, DOI 10.1080/00036846.2013.857003
   Doran R, 2016, INT J TOUR RES, V18, P159, DOI 10.1002/jtr.2042
   Dunlap RE, 2000, J SOC ISSUES, V56, P425, DOI 10.1111/0022-4537.00176
   Fabi V, 2017, ENRGY PROCED, V134, P462, DOI 10.1016/j.egypro.2017.09.604
   Field AP, 2013, DISCOVERING STAT USI
   Fielding KS, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00121
   Fishbein M., 2010, PREDICTING CHANGING
   Fornara F, 2016, J ENVIRON PSYCHOL, V45, P1, DOI 10.1016/j.jenvp.2015.11.001
   FORNELL C, 1981, J MARKETING RES, V18, P382, DOI 10.2307/3150980
   Gao L, 2017, RESOUR CONSERV RECY, V127, P107, DOI 10.1016/j.resconrec.2017.08.030
   Gatersleben B, 2014, CONTEMP SOC SCI, V9, P374, DOI 10.1080/21582041.2012.682086
   Gifford RD, 2017, CLIMATIC CHANGE, V140, P165, DOI 10.1007/s10584-016-1830-y
   Hair J.F., 2010, MULTIVARIATE DATA AN
   Han H, 2017, J ENVIRON PSYCHOL, V51, P1, DOI 10.1016/j.jenvp.2017.03.003
   Han H, 2015, TOURISM MANAGE, V47, P164, DOI 10.1016/j.tourman.2014.09.014
   Hancock G. R, 2012, HDB STRUCTURAL EQUAT
   Harman H.H., 1976, MODERN FACTOR ANAL
   Hellenic Statistical Authority (ELSTAT), 2011, RES CEN 2011
   Hiratsuka J, 2018, TRANSPORT RES F-TRAF, V53, P74, DOI 10.1016/j.trf.2017.12.015
   Ioannou T, 2013, FRESEN ENVIRON BULL, V22, P2035
   Jyoti J, 2016, INT J EDUC MANAG, V30, P1123, DOI 10.1108/IJEM-01-2015-0011
   Kaiser FG, 2005, J APPL SOC PSYCHOL, V35, P2150, DOI 10.1111/j.1559-1816.2005.tb02213.x
   Kiriakidis S, 2017, SPRINGER P BUSINESS
   Kline R. B., 2016, PRINCIPLES PRACTICE
   Kline RB, 2011, PRINCIPLES PRACTICE
   Klockner CA, 2004, J ENVIRON PSYCHOL, V24, P319, DOI 10.1016/j.jenvp.2004.08.004
   Klockner CA, 2013, GLOBAL ENVIRON CHANG, V23, P1028, DOI 10.1016/j.gloenvcha.2013.05.014
   Klockner CA, 2010, J ENVIRON PSYCHOL, V30, P574, DOI 10.1016/j.jenvp.2010.03.001
   Kurz T, 2015, WIRES CLIM CHANGE, V6, P113, DOI 10.1002/wcc.327
   Lavelle MJ, 2015, GLOBAL ENVIRON CHANG, V35, P368, DOI 10.1016/j.gloenvcha.2015.09.021
   Lhoitka J. M, 2012, INTEGRATED RESOURCE
   Li L, 2018, SUSTAIN CITIES SOC, V37, P637, DOI 10.1016/j.scs.2017.11.036
   Liao CH, 2018, SUSTAIN CITIES SOC, V41, P186, DOI 10.1016/j.scs.2018.05.046
   Liobikiene G, 2016, ECOL ECON, V125, P38, DOI 10.1016/j.ecolecon.2016.02.008
   Lopez-Mosquera N, 2016, J ENVIRON PSYCHOL, V45, P165, DOI 10.1016/j.jenvp.2016.01.006
   Lopez-Mosquera N, 2012, J ENVIRON MANAGE, V113, P251, DOI 10.1016/j.jenvman.2012.08.029
   Ma J, 2018, SUSTAIN CITIES SOC, V37, P336, DOI 10.1016/j.scs.2017.11.037
   Malhotra N. K., 2011, MARKETING RES APPL O, P126
   Mancha RM, 2015, J ENVIRON PSYCHOL, V43, P145, DOI 10.1016/j.jenvp.2015.06.005
   Matthies E, 2012, J ENVIRON PSYCHOL, V32, P277, DOI 10.1016/j.jenvp.2012.04.003
   Morren M, 2016, J ENVIRON PSYCHOL, V47, P91, DOI 10.1016/j.jenvp.2016.05.003
   Moser AK, 2015, J CONSUM MARK, V32, P167, DOI 10.1108/JCM-10-2014-1179
   Moser S, 2018, ENVIRON BEHAV, V50, P626, DOI 10.1177/0013916517710685
   Noppers EH, 2014, GLOBAL ENVIRON CHANG, V25, P52, DOI 10.1016/j.gloenvcha.2014.01.012
   Onwezen MC, 2013, J ECON PSYCHOL, V39, P141, DOI 10.1016/j.joep.2013.07.005
   Orbell S, 2015, HEALTH PSYCHOL REV, V9, P311, DOI 10.1080/17437199.2014.992031
   Ouellette JA, 1998, PSYCHOL BULL, V124, P54, DOI 10.1037/0033-2909.124.1.54
   Pakpour AH, 2014, WASTE MANAGE, V34, P980, DOI 10.1016/j.wasman.2013.10.028
   Paquin RS, 2017, J SOC PSYCHOL, V157, P47, DOI 10.1080/00224545.2016.1152217
   Pisano I, 2017, ENVIRON BEHAV, V49, P31, DOI 10.1177/0013916515600494
   Podsakoff PM, 2016, ORGAN RES METHODS, V19, P159, DOI 10.1177/1094428115624965
   Podsakoff PM, 2012, ANNU REV PSYCHOL, V63, P539, DOI 10.1146/annurev-psych-120710-100452
   Podsakoff PM, 2003, J APPL PSYCHOL, V88, P879, DOI 10.1037/0021-9010.88.5.879
   Pothitou M, 2016, APPL ENERG, V184, P1217, DOI 10.1016/j.apenergy.2016.06.017
   Ruepert AM, 2017, J ENVIRON PSYCHOL, V54, P65, DOI 10.1016/j.jenvp.2017.10.006
   Sanchez M, 2018, J CLEAN PROD, V177, P144, DOI 10.1016/j.jclepro.2017.12.210
   Schwartz S.H, 1977, ADV EXPT SOCIAL PSYC, V10, P221, DOI DOI 10.1016/S0065-2601(08)60358-5
   SCHWARTZ SH, 1980, SOC PSYCHOL QUART, V43, P441, DOI 10.2307/3033965
   Shi HX, 2017, J CLEAN PROD, V145, P64, DOI 10.1016/j.jclepro.2016.12.169
   Sopha BM, 2011, RENEW SUST ENERG REV, V15, P2756, DOI 10.1016/j.rser.2011.03.027
   Steg L., 2012, OXFORD HDB ENV CONSE
   Steg L., 2013, ENV PSYCHOL INTRO, P185
   Steg L, 2014, J ENVIRON PSYCHOL, V38, P104, DOI 10.1016/j.jenvp.2014.01.002
   Steg L, 2009, J ENVIRON PSYCHOL, V29, P309, DOI 10.1016/j.jenvp.2008.10.004
   Stern P.C., 1999, HUMAN ECOLOGY REVIEW, V6, P81, DOI DOI 10.2307/2083693
   Stern PC, 2000, J SOC ISSUES, V56, P407, DOI 10.1111/0022-4537.00175
   STERN PC, 1994, J SOC ISSUES, V50, P65, DOI 10.1111/j.1540-4560.1994.tb02420.x
   Tabachnick BG, 2013, USING MULTIVARIATE S
   Tam KP, 2017, J ENVIRON PSYCHOL, V53, P213, DOI 10.1016/j.jenvp.2017.09.001
   Taufique KMR, 2018, J CLEAN PROD, V183, P46, DOI 10.1016/j.jclepro.2018.02.097
   Thogersen J., 2012, OXFORD HDB ENV CONSE
   Triandis H C, 1980, Nebr Symp Motiv, V27, P195
   van der Werff E, 2016, ENERGY RES SOC SCI, V22, P107, DOI 10.1016/j.erss.2016.08.022
   van der Werff E, 2013, J ENVIRON PSYCHOL, V34, P55, DOI 10.1016/j.jenvp.2012.12.006
   van Riper CJ, 2014, J ENVIRON PSYCHOL, V38, P288, DOI 10.1016/j.jenvp.2014.03.002
   Verplanken B., 1999, EUROPEAN REV SOCIAL, V10, P101, DOI DOI 10.1080/14792779943000035
   Verplanken B, 2016, J ENVIRON PSYCHOL, V45, P127, DOI 10.1016/j.jenvp.2015.11.008
   Vesely S, 2018, ENVIRON BEHAV, V50, P247, DOI 10.1177/0013916517702190
   Wan C, 2017, J ENVIRON PSYCHOL, V50, P69, DOI 10.1016/j.jenvp.2017.02.006
   Wang B, 2018, ENERG POLICY, V116, P68, DOI 10.1016/j.enpol.2018.01.055
   Wang P, 2014, J CLEAN PROD, V63, P152, DOI 10.1016/j.jclepro.2013.05.007
   Wittenberg I, 2018, J ENVIRON PSYCHOL, V55, P110, DOI 10.1016/j.jenvp.2018.01.002
   Wood W, 2016, ANNU REV PSYCHOL, V67, P289, DOI 10.1146/annurev-psych-122414-033417
   Xiao CY, 2019, SOC NATUR RESOUR, V32, P53, DOI 10.1080/08941920.2018.1501529
   Yadav R, 2016, J CLEAN PROD, V135, P732, DOI 10.1016/j.jclepro.2016.06.120
   Zhang XJ, 2018, RESOUR CONSERV RECY, V134, P121, DOI 10.1016/j.resconrec.2018.03.003
   Zhang XJ, 2017, J CLEAN PROD, V166, P148, DOI 10.1016/j.jclepro.2017.08.020
   Zhang YL, 2014, J ENVIRON PSYCHOL, V40, P131, DOI 10.1016/j.jenvp.2014.06.001
NR 115
TC 5
Z9 5
U1 26
U2 62
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 145
EP 156
DI 10.1016/j.resconrec.2019.01.039
PG 12
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800013
DA 2020-05-12
ER

PT J
AU Mohmmed, A
   Li, ZH
   Arowolo, AO
   Su, HB
   Deng, XZ
   Najmuddin, O
   Zhang, Y
AF Mohmmed, Alnail
   Li, Zhihui
   Arowolo, Aisha Olushola
   Su, Hongbo
   Deng, Xiangzheng
   Najmuddin, Omaid
   Zhang, Yue
TI Driving factors of CO2 emissions and nexus with economic growth,
   development and human health in the Top Ten emitting countries
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Carbon dioxide emission; Energy intensity effect; LMDI; Human
   development index (HDI); Healthy life expectancy (HLE)
ID GREENHOUSE-GAS EMISSIONS; ENERGY-CONSUMPTION; DECOMPOSITION ANALYSIS;
   DECOUPLING INDICATOR; LMDI DECOMPOSITION; COAL CONSUMPTION; CHINA;
   REGION
AB This study explored the drivers of carbon dioxide (CO2) emission (million metric tons) in the top 10 emitting countries (China, United States, India, Russian Federation, Japan, Germany, South Korea, Iran, Canada, and Saudi Arabia). The logarithmic mean Divisia index (LMDI) method was used to analyse the drive of CO2 emission change pertinent to population (thousand people), per capita income, energy intensity (metric ton energy/$GDP) and carbon intensity effects (metric ton CO2/ton energy) from 1991 to 2014. Further, analysis was carried out for the impact of CO2 emitted by different sectors (Agriculture, Energy, Fugitive, Industrial, Manufacturing, Transportation and Waste), the corresponding Human Development Index (HDI) and economic growth (EG%) using the panel model. This was done along with predictions for the total CO2 emissions over the next 16 years. The general results showed that the CO2 emission change has a significant effect by population and income, especially in China and the United states. Also, there is a strong relationship between human development index, economic growth, as well as Healthy Life Expectancy (HLE) with sector CO2 emission for most of the investigated countries. The forecast of sectors CO2 emission for the year 2030, showed an increase of CO2 for all the countries, which requires a policy plan aimed at decreasing their CO2 emission for a safer environment.
C1 [Mohmmed, Alnail; Li, Zhihui; Arowolo, Aisha Olushola; Su, Hongbo; Deng, Xiangzheng; Najmuddin, Omaid; Zhang, Yue] Chinese Acad Sci, Inst Geog Sci & Nat Resources Res, Beijing 100101, Peoples R China.
   [Mohmmed, Alnail; Li, Zhihui; Arowolo, Aisha Olushola; Deng, Xiangzheng; Najmuddin, Omaid; Zhang, Yue] Chinese Acad Sci, Ctr Chinese Agr Policy, Beijing 100101, Peoples R China.
   [Arowolo, Aisha Olushola; Deng, Xiangzheng; Najmuddin, Omaid; Zhang, Yue] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Deng, Xiangzheng] Chinese Acad Sci, Key Lab Land Surface Pattern & Simulat, Beijing 100101, Peoples R China.
RP Deng, XZ (reprint author), Chinese Acad Sci, Inst Geog Sci & Nat Resources Res, Beijing 100101, Peoples R China.; Deng, XZ (reprint author), Chinese Acad Sci, Ctr Chinese Agr Policy, Beijing 100101, Peoples R China.; Deng, XZ (reprint author), Univ Chinese Acad Sci, Beijing, Peoples R China.; Deng, XZ (reprint author), Chinese Acad Sci, Key Lab Land Surface Pattern & Simulat, Beijing 100101, Peoples R China.
EM dengxz@igsnrr.ac.cn
RI Su, Hongbo/C-9490-2009; Su, Hongbo/Z-3572-2019
FU National Key Research and Development Program of China [2016YFA0602500];
   Strategic Priority Research Program of Chinese Academy of Sciences
   [XDA20010302]; State Key Program of National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China [71533004]
FX This research was supported by the research funds from the National Key
   Research and Development Program of China (Grant No. 2016YFA0602500),
   the Strategic Priority Research Program of Chinese Academy of Sciences,
   (Grant No. XDA20010302) and the State Key Program of National Natural
   Science Foundation of China (Grant No. 71533004).
CR Ang BW, 2015, ENERG POLICY, V86, P233, DOI 10.1016/j.enpol.2015.07.007
   Apergis N, 2011, ENERG ECON, V33, P770, DOI 10.1016/j.eneco.2010.12.018
   Aye GC, 2017, COGENT ECON FINANC, V5, DOI 10.1080/23322039.2017.1379239
   Bandyopadhyay S, 2017, CLEAN TECHNOL ENVIR, V19, P293, DOI 10.1007/s10098-017-1335-z
   Bayati M, 2013, INT J HEALTH POLICY, V1, P57, DOI 10.15171/ijhpm.2013.09
   Belloumi M, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8040375
   Boqiang L, 2017, SUSTAINABILITY, V9
   Box G. E. P., 1994, TIME SERIES ANAL FOR
   Bringezu S, 2009, J CLEAN PROD, V17, pS57, DOI 10.1016/j.jclepro.2009.03.007
   Cadenas E, 2016, ENERGIES, V9, DOI 10.3390/en9020109
   Chong CH, 2015, ENERGY, V85, P366, DOI 10.1016/j.energy.2015.03.100
   Carmona MJC, 2016, ENERG EFFIC, V9, P807, DOI 10.1007/s12053-015-9402-y
   Costa L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029262
   Eggoh JC, 2011, ENERG POLICY, V39, P7408, DOI 10.1016/j.enpol.2011.09.007
   Erixon F, 2011, WHAT IS DRIVING RISE
   Frondel M, 2010, ENERG POLICY, V38, P4048, DOI 10.1016/j.enpol.2010.03.029
   Gardner BL, 2000, AM J AGR ECON, V82, P1059, DOI 10.1111/0002-9092.00104
   Hatzigeorgiou E, 2008, ENERGY, V33, P492, DOI 10.1016/j.energy.2007.09.014
   IEA, 2015, MOB INN ACC CLIM ACT, P14
   IPCC, 2013, CLIM CHANG ACT TREND
   Issaoui F, 2015, J ENERGY DEV, V41, P223
   Jordaan SM, 2017, RENEW SUST ENERG REV, V78, P1397, DOI 10.1016/j.rser.2017.05.162
   Jorgenson AK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123920
   Ke X, 2011, DETERMINANTS HLTH EX, P26
   Kelly Twomey S, 2014, ENVIRON RES LETT, V9
   Kijewska Anna, 2016, Journal of Sustainable Mining, V15, P133, DOI 10.1016/j.jsm.2017.02.001
   Lau A, 2010, ANN APPL STAT, V4, P1311, DOI 10.1214/09-AOAS320
   Lee D, 2016, INT REGIONAL SCI REV, V39, P177, DOI 10.1177/0160017615571585
   Li L, 2016, ADV METEOROL, V2016, P9
   Li N, 2017, RESOUR CONSERV RECY, V121, P11, DOI 10.1016/j.resconrec.2016.03.016
   Ligon E., 2008, ESTIMATING EFFECTS A
   Loayza N, 2006, STRUCTURAL DETERMINA
   Lotfalipour M.R., 2013, INT J ENERGY EC POLI, V3, P229
   Magazzino C, 2016, INT J SUSTAIN ENERGY, V35, P844, DOI 10.1080/14786451.2014.953160
   Magazzino C, 2015, INT J SUST DEV WORLD, V22, P89, DOI 10.1080/13504509.2014.991365
   Makido Y, 2012, URBAN CLIM, V2, P55, DOI 10.1016/j.uclim.2012.10.006
   Malik A. S, 2012, HDB CLIMATE CHANGE M, P197
   Mohiuddin O, 2016, COGENT ENG, V3, DOI 10.1080/23311916.2016.1210491
   Mousavi B, 2017, APPL ENERG, V206, P804, DOI 10.1016/j.apenergy.2017.08.199
   Narayan PK, 2010, ENERG POLICY, V38, P661, DOI 10.1016/j.enpol.2009.09.005
   Nejat P, 2015, RENEW SUST ENERG REV, V43, P843, DOI 10.1016/j.rser.2014.11.066
   O'Neill BC, 2010, P NATL ACAD SCI USA, V107, P17521, DOI 10.1073/pnas.1004581107
   Olivier J. G. J., 2012, TRENDS GLOBAL CO2 EM
   Pao HT, 2012, ENERGY, V40, P400, DOI 10.1016/j.energy.2012.01.037
   Reyers B, 2017, CURR OPIN ENV SUST, V26-27, P97, DOI 10.1016/j.cosust.2017.05.003
   Roman R, 2018, RENEW ENERG, V116, P402, DOI 10.1016/j.renene.2017.09.016
   Saidi K, 2015, ENERGY REP, V1, P62, DOI 10.1016/j.egyr.2015.01.003
   Schlomann B, 2010, ENERGY EFFICIENCY PO
   Shen XB, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9040646
   Sim SK, 2019, ENERGIES, V12, DOI 10.3390/en12010069
   Song Y, 2017, NAT HAZARDS, V88, P1013, DOI 10.1007/s11069-017-2903-6
   Squalli J, 2007, ENERG ECON, V29, P1192, DOI 10.1016/j.eneco.2006.10.001
   Su B, 2012, ENERG ECON, V34, P177, DOI 10.1016/j.eneco.2011.10.009
   Sultan B, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.01262
   Tyagi S, 2016, ATMOS POLLUT RES, V7, P808, DOI 10.1016/j.apr.2016.04.008
   Vinuya F, 2010, APPL ECON LETT, V17, P925, DOI 10.1080/00036840902762688
   Wang GK, 2015, SUSTAINABILITY-BASEL, V7, P14408, DOI 10.3390/su71014408
   Wang M, 2018, RENEW SUST ENERG REV, V82, P2652, DOI 10.1016/j.rser.2017.09.103
   Wang NN, 2014, ENERGY, V68, P61, DOI 10.1016/j.energy.2014.01.060
   Wang WW, 2017, ENERGY, V128, P11, DOI 10.1016/j.energy.2017.04.004
   Wang WW, 2014, ENERGY, V67, P617, DOI 10.1016/j.energy.2013.12.064
   Wu R, 2016, SUSTAINABILITY-BASEL, V8, DOI 10.3390/su8070661
   Xu J, 2018, RESOUR CONSERV RECY, V129, P326, DOI 10.1016/j.resconrec.2016.08.027
   Xu SC, 2014, APPL ENERG, V127, P182, DOI 10.1016/j.apenergy.2014.03.093
   Yeo Y, 2015, SUSTAINABILITY-BASEL, V7, P16108, DOI 10.3390/su71215805
   Zhang M, 2018, J CLEAN PROD, V194, P253, DOI 10.1016/j.jclepro.2018.05.122
   Zhang M, 2018, RESOUR CONSERV RECY, V129, P454, DOI 10.1016/j.resconrec.2016.06.021
   Zhang M, 2015, ENERG EFFIC, V8, P1231, DOI 10.1007/s12053-015-9348-0
NR 68
TC 6
Z9 6
U1 22
U2 71
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 157
EP 169
DI 10.1016/j.resconrec.2019.03.048
PG 13
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800014
DA 2020-05-12
ER

PT J
AU Resende, JD
   Nolasco, MA
   Pacca, SA
AF Resende, Juliana Dalia
   Nolasco, Marcelo Antunes
   Pacca, Sergio Almeida
TI Life cycle assessment and costing of wastewater treatment systems
   coupled to constructed wetlands
SO RESOURCES CONSERVATION AND RECYCLING
LA English
DT Article
DE Life cycle assessment; Constructed wetlands; Wastewater treatment;
   Decentralized small-scale wastewater treatment; Life cycle costs
ID HORIZONTAL SUBSURFACE FLOW; ACTIVATED-SLUDGE; TREATMENT PLANTS; NITROGEN
   REMOVAL; SUSTAINABILITY; PERFORMANCE; EFFICIENCY; QUALITY; ORGANICS;
   IMPACT
AB This study evaluates the environmental and economic performance (ecoefficiency) of two decentralized, small-scale, wastewater treatment systems coupled to constructed wetlands. System One comprises a vertical and a horizontal flow wetland. System Two comprises a vertical subsurface flow wetland with artificial aeration. A life cycle assessment based on data from two actual pilot structures was carried out. The functional unit was 1 m(3) of treated water over a 20-year long lifetime. The systems were modeled in open LCA software, with the aid of Ecoinvent 3.3 data, and the impact assessment was based on the ReCIPe method. Results have demonstrated that foreground emissions such as direct greenhouse gas released from the septic tank and nutrients released in the effluent have driven potential impacts related to Climate Change, Photochemical Oxidants, and Freshwater Eutrophication. Artificial aeration reduces the area required for the installation of the system and electricity consumption was responsible for only 7% of total Climate Change related potential impact. Technologies that reduce direct (foreground) liquid and airborne emissions will improve the environmental performance of the systems. The analysis of the aerated wetland has shown that the operation stage had the greatest environmental impact potential for all analyzed impact categories, with results varying between 64% for Human Toxicity and 100% for Freshwater Eutrophication. The life cycle cost per cubic meter of treated sewage for the aerated system was 1.8 times smaller than that of the system without aeration. Thus, aeration is cost-effective for small-scale wastewater treatment systems coupled to constructed wetlands.
C1 [Resende, Juliana Dalia; Nolasco, Marcelo Antunes; Pacca, Sergio Almeida] Univ Sao Paulo, Sch Arts Sci & Humanities, Sustainabil Program, Rua Arlindo Bettio 1000, BR-03828000 Sao Paulo, Brazil.
RP Pacca, SA (reprint author), Univ Sao Paulo, Sch Arts Sci & Humanities, Sustainabil Program, Rua Arlindo Bettio 1000, BR-03828000 Sao Paulo, Brazil.
EM jdresende@usp.br; mnolasco@usp.br; spacca@usp.br
RI Nolasco, Marcelo A./A-2082-2010; PACCA, SERGIO ALMEIDA/Q-7022-2019;
   Nolasco, Marcelo/S-1963-2019
OI Nolasco, Marcelo A./0000-0002-1408-2954; PACCA, SERGIO
   ALMEIDA/0000-0001-7609-5139; Nolasco, Marcelo/0000-0002-1408-2954
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]
FX Juliana Dalia Resende is grateful to Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brasil (CAPES) for finance in part this
   study - Finance Code 001.
CR [Anonymous], 2006, 14040 ISO
   [Anonymous], 2006, 14044 ISO
   Bodik I, 2013, ENVIRON PROT ENG, V39, P15, DOI 10.5277/EPE130202
   Brix H, 2005, ECOL ENG, V25, P491, DOI 10.1016/j.ecoleng.2005.07.009
   Brown C, 2016, THESIS, P59
   Castro A. L, 2015, C BRAS CONCR BON BRA
   Cerezo RG, 2001, ECOL ENG, V16, P501
   Chang YJ, 2014, SCI TOTAL ENVIRON, V487, P49, DOI 10.1016/j.scitotenv.2014.03.114
   Chen GQ, 2011, ECOL ENG, V37, P622, DOI 10.1016/j.ecoleng.2010.12.027
   Corbella C, 2017, SCI TOTAL ENVIRON, V584, P355, DOI 10.1016/j.scitotenv.2016.12.186
   Corominas L, 2013, WATER RES, V47, P5480, DOI 10.1016/j.watres.2013.06.049
   de Faria ABB, 2015, WATER RES, V84, P99, DOI 10.1016/j.watres.2015.06.048
   De Feo G, 2017, J CLEAN PROD, V164, P124, DOI 10.1016/j.jclepro.2017.06.205
   Dixon A, 2003, ECOL ENG, V20, P297, DOI 10.1016/S0925-8574(03)00007-7
   Empresa De Pesquisa Energetica - Epe, 2016, BAL EN NAC REL SINT, P61
   Fan JL, 2013, BIORESOURCE TECHNOL, V141, P117, DOI 10.1016/j.biortech.2013.03.077
   Foley J, 2007, 3 INT C LIF CYCL ASS, P27
   Foley J, 2010, WATER RES, V44, P1654, DOI 10.1016/j.watres.2009.11.031
   Fuchs V., 2009, THESIS
   Fuchs VJ, 2011, WATER RES, V45, P2073, DOI 10.1016/j.watres.2010.12.021
   Gallego A, 2008, RESOUR CONSERV RECY, V52, P931, DOI 10.1016/j.resconrec.2008.02.001
   Garfi M, 2017, J CLEAN PROD, V161, P211, DOI 10.1016/j.jclepro.2017.05.116
   Garfi M, 2012, SCI TOTAL ENVIRON, V437, P61, DOI 10.1016/j.scitotenv.2012.07.087
   Guo JB, 2016, SCI TOTAL ENVIRON, V547, P331, DOI 10.1016/j.scitotenv.2015.12.102
   Hospido A, 2012, DESALINATION, V285, P263, DOI 10.1016/j.desal.2011.10.011
   Hu WQ, 2019, RESOUR CONSERV RECY, V141, P176, DOI 10.1016/j.resconrec.2018.10.020
   Intergovernmental Panel on Climate Change (IPCC), 2013, 2006 IPCC GUID NAT S
   Intergovernmental Panel on Climate Change IPCC, 2006, GUID NAT GREENH GAS
   Liu D, 2012, NAT CLIM CHANGE, V2, P190, DOI 10.1038/NCLIMATE1370
   Lopsik K, 2013, INT J ENVIRON SCI TE, V10, P1295, DOI 10.1007/s13762-012-0159-y
   Lorenzo-Toja Y, 2015, CONVENTIONAL LIFE CY, V1
   Lutterbeck CA, 2017, J CLEAN PROD, V148, P527, DOI 10.1016/j.jclepro.2017.02.024
   Machado PA, 2006, P 10 INT C WETL SYST, P1203
   Maltais-Landry G, 2009, WATER RES, V43, P535, DOI 10.1016/j.watres.2008.10.040
   Masi E, 2018, J ENVIRON MANAGE, V216, P275, DOI 10.1016/j.jenvman.2017.11.086
   Mburu N, 2013, J ENVIRON MANAGE, V128, P220, DOI 10.1016/j.jenvman.2013.05.031
   McNamara G., 2018, THESIS
   Molinos-Senante M, 2014, SCI TOTAL ENVIRON, V497, P607, DOI 10.1016/j.scitotenv.2014.08.026
   Moraga G. L., 2017, THESIS
   Moreno Ruiz E, 2016, DOCUMENTATION CHANGE, P113
   Niero M, 2014, J CLEAN PROD, V68, P25, DOI 10.1016/j.jclepro.2013.12.051
   Pan T, 2011, ECOL ENG, V37, P248, DOI 10.1016/j.ecoleng.2010.11.014
   Rawal N, 2016, NATL ACAD SCI LETT, V39, P103, DOI 10.1007/s40009-016-0429-1
   Roeleveld PJ, 1997, WATER SCI TECHNOL, V35, P221, DOI 10.1016/S0273-1223(97)00199-6
   Roux P, 2010, P 12 IWA INT C WETL, P1
   Saeed T, 2012, J ENVIRON MANAGE, V112, P429, DOI 10.1016/j.jenvman.2012.08.011
   Sena M, 2018, RESOUR CONSERV RECY, V139, P194, DOI 10.1016/j.resconrec.2018.08.009
   Shutes RBE, 2001, ENVIRON INT, V26, P441, DOI 10.1016/S0160-4120(01)00025-3
   Singh P, 2018, RESOUR CONSERV RECY, V128, P499, DOI 10.1016/j.resconrec.2016.07.014
   Slagstad H, 2014, URBAN WATER J, V11, P323, DOI 10.1080/1573062X.2013.795232
   Souza A, 2012, THESIS, P118
   Taylor CR, 2011, ECOL ENG, V37, P703, DOI 10.1016/j.ecoleng.2010.05.007
   Vymazal J, 2009, ECOL ENG, V35, P1, DOI 10.1016/j.ecoleng.2008.08.016
   Vymazal J, 2013, WATER RES, V47, P4795, DOI 10.1016/j.watres.2013.05.029
   Vymazal J, 2011, HYDROBIOLOGIA, V674, P133, DOI 10.1007/s10750-011-0738-9
   Weidema B. P., 2013, ECOINVENT REPORT, V1
   Wu HM, 2015, BIORESOURCE TECHNOL, V176, P163, DOI 10.1016/j.biortech.2014.11.041
   Wu SB, 2014, WATER RES, V57, P40, DOI 10.1016/j.watres.2014.03.020
   Yoshida H, 2014, WATER RES, V56, P292, DOI 10.1016/j.watres.2014.03.014
   Zang YW, 2015, J CLEAN PROD, V107, P676, DOI 10.1016/j.jclepro.2015.05.060
   Zeng SY, 2017, RESOUR CONSERV RECY, V120, P157, DOI 10.1016/j.resconrec.2016.12.005
NR 61
TC 2
Z9 2
U1 27
U2 54
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0921-3449
EI 1879-0658
J9 RESOUR CONSERV RECY
JI Resour. Conserv. Recycl.
PD SEP
PY 2019
VL 148
BP 170
EP 177
DI 10.1016/j.resconrec.2019.04.034
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA IE2VN
UT WOS:000472242800015
DA 2020-05-12
ER

PT J
AU Queiros, C
   Parei, A
   Louisy, A
   Listrat, A
   Travers, N
   Joly, A
   Laure, B
AF Queiros, Chrystelle
   Parei, Arnaud
   Louisy, Agathe
   Listrat, Antoine
   Travers, Nadine
   Joly, Aline
   Laure, Boris
TI Is It Safe To Use Frontofacial Monobloc Advancement and Cutting Guides
   on Adult Patients with Crouzon Syndrome? Introducing 2 Cases on 41-and
   56-Year-Old Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adults; Crouzon syndrome; Cutting guides; Frontofacial monobloc
   advancement
ID LEFORT III; DISTRACTION
AB BACKGROUND: Patients with Crouzon syndrome are mainly treated in childhood by frontofacial monobloc advancement to avoid ophthalmic, neurologic, and maxillary complications. There is no reported case of surgery on adult patients with Crouzon syndrome in the literature. However, when faced with 2 cases of adult patients showing severe quality of life deterioration, our team decided to make an attempt using monobloc advancement technique.
   CASE DESCRIPTION: Two women aged 41 and 56 presented with untreated Crouzon syndrome and suffered from exorbitism, intracranial hypertension with chronic headaches, and hypoplastic maxillary. We decided to perform frontofacial monobloc advancement with internal distraction despite their advanced age using planned surgery and cutting guides. Distraction began 7-10 days after surgery and was of 15 mm. Distractors were taken off at 6 months. Surgical treatment corrected chronic headaches, ocular symptoms due to exorbitism, and hypoplastic maxillary. Patients were satisfied with the functional and aesthetic results. We noticed that this heavy surgery was more difficult to bear by these adults than children. CONCLUSIONS: Adults with craniofacial malformations have a lower self-esteem, lower quality of life, and less satisfaction with their facial look as compared with individuals without facial malformations. There is also an increased risk of psychosocial problems. Despite postoperative difficulties and minor complications, our 2 patients were satisfied with the functional and aesthetic results. This led to the conclusion that surgically addressing adult patients with Crouzon syndrome via monobloc advancement is appropriate and secure when performed by a trained team.
C1 [Queiros, Chrystelle; Parei, Arnaud; Louisy, Agathe; Joly, Aline; Laure, Boris] CHU Tours, Clocheville Hosp, Dept Maxillofacial Surg, Tours, France.
   [Louisy, Agathe; Listrat, Antoine; Travers, Nadine] CHU Tours, Clocheville Hosp, Dept Pediat Neurosurg, Tours, France.
   [Listrat, Antoine; Travers, Nadine; Laure, Boris] CHU Tours, Clocheville Hosp, Dept Craniofacial Surg, Tours, France.
   [Queiros, Chrystelle; Parei, Arnaud; Joly, Aline; Laure, Boris] Univ Med Francois Rabelais, Tours, France.
RP Queiros, C (reprint author), CHU Tours, Clocheville Hosp, Dept Maxillofacial Surg, Tours, France.; Queiros, C (reprint author), Univ Med Francois Rabelais, Tours, France.
EM chrystelle.queiros@etu.univ-tours.fr
CR Ahmad F, 2012, PLAST RECONSTR SURG, V129, p488E, DOI 10.1097/PRS.0b013e3182412820
   Al-Namnam NMN, 2018, BRIT J ORAL MAX SURG, V56, P353, DOI 10.1016/j.bjoms.2018.03.002
   Bender CA, 2013, J CRANIO MAXILL SURG, V41, pE146, DOI 10.1016/j.jcms.2012.12.002
   Knackstedt R, 2018, J CRANIOFAC SURG, V29, P144, DOI 10.1097/SCS.0000000000004132
   Mardini S, 2014, J PLAST RECONSTR AES, V67, P336, DOI 10.1016/j.bjps.2013.11.004
   Meling TR, 2011, BRIT J ORAL MAX SURG, V49, P131, DOI 10.1016/j.bjoms.2009.11.015
   ORTIZMONASTERIO F, 1978, PLAST RECONSTR SURG, V61, P507
   Queiros C, 2017, J CRANIO MAXILL SURG, V45, P1062, DOI 10.1016/j.jcms.2017.03.011
   Rahimov Chingiz, 2016, Ann Maxillofac Surg, V6, P135, DOI 10.4103/2231-0746.186144
   Sarwer David B, 2002, Facial Plast Surg, V18, P125, DOI 10.1055/s-2002-32203
   Sarwer DB, 1999, PLAST RECONSTR SURG, V103, P412, DOI 10.1097/00006534-199902000-00008
   Sastre-Ibanez M, 2015, J FR OPHTALMOL, V38, pE177, DOI 10.1016/j.jfo.2014.11.019
   Schlund M, 2018, J ORAL MAXIL SURG, V76, DOI 10.1016/j.joms.2017.12.013
   Snyder HT, 2005, CLEFT PALATE-CRAN J, V42, P548, DOI 10.1597/04-078R.1
   Tessier P, 1981, CRANIOFACIOSTENOSES, P200
   Way BLM, 2019, PLAST RECONSTR SURG, V143, p121E, DOI 10.1097/PRS.0000000000005105
NR 16
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 1
EP 4
DI 10.1016/j.wneu.2019.05.207
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900114
PM 31152887
DA 2020-05-12
ER

PT J
AU Yokoya, S
   Hino, A
   Goto, Y
   Oka, H
AF Yokoya, Shigeomi
   Hino, Akihiko
   Goto, Yukihiro
   Oka, Hideki
TI Middle Meningeal-Middle Cerebral Artery Anastomosis for Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Middle meningeal artery; Middle cerebral artery; Moyamoya disease
ID REVASCULARIZATION; BYPASS
AB BACKGROUND: We describe a unique anastomosis procedure involving successful middle meningeal artery (MMA) to cortical middle cerebral artery (MCA) bypass, as well as superficial temporal artery (STA) to cortical MCA bypass.
   CASE DESCRIPTION: A 46-year-old woman with hemorrhagic Moyamoya disease underwent an anastomosis procedure with the MMA and STA serving as donor arteries. We performed a small craniotomy at the areas closest to the donor STA, MMA, and recipient cortical MCA, and completed STA-MCA and MMA-MCA direct bypass procedures.
   CONCLUSIONS: This is a rare case of successful MMA-to-MCA revascularization to prevent rebleeding in a patient with Moyamoya disease. The MMA can be used as a donor artery for extracranial-intracranial anastomosis procedures in clinical practice settings.
C1 [Yokoya, Shigeomi; Hino, Akihiko; Goto, Yukihiro; Oka, Hideki] Imperial Gift Fdn Inc, Saiseikai Shiga Hosp, Dept Neurosurg, Ritto, Shiga, Japan.
RP Yokoya, S (reprint author), Imperial Gift Fdn Inc, Saiseikai Shiga Hosp, Dept Neurosurg, Ritto, Shiga, Japan.
EM yokoya@ks.kyorin-u.ac.jp
OI Goto, Yukihiro/0000-0001-8151-3999
CR Burkhardt JK, 2019, WORLD NEUROSURG, V125, pE408, DOI 10.1016/j.wneu.2019.01.089
   Dusick JR, 2012, J NEUROSURG, V117, P94, DOI 10.3171/2012.4.JNS111103
   Feng R, 2016, WORLD NEUROSURG, V95, DOI 10.1016/j.wneu.2016.08.081
   Fujishima H, 2009, SHOWA IGAKKAI ZASSHI, V69, P277
   Kawashima M, 2005, J NEUROSURG, V102, P116, DOI 10.3171/jns.2005.102.1.0116
   MILLER CF, 1979, J NEUROSURG, V50, P802, DOI 10.3171/jns.1979.50.6.0802
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   Niknejad HR, 2018, OPER NEUROSURG, V15, P89, DOI 10.1093/ons/opx200
   NISHIKAWA M, 1979, SURG NEUROL, V12, P205
   Sayama T, 2008, JPN J NEUROSURG TOKY, V17, P533
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 5
EP 8
DI 10.1016/j.wneu.2019.05.168
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900115
PM 31146043
DA 2020-05-12
ER

PT J
AU Kandemirli, SG
   Candan, S
   Bilgin, C
AF Kandemirli, Sedat Giray
   Candan, Selman
   Bilgin, Cem
TI Post-Traumatic Occipital Intradiploic Encephalocele
SO WORLD NEUROSURGERY
LA English
DT Article
DE Encephalocele; Intradiploic; Trauma
ID EROSION GROWING FRACTURE; BRAIN HERNIATION; SURROUNDING CSF; SKULL;
   ADULT; MENINGOENCEPHALOCELE; PSEUDOMENINGOCELE; CHILDREN; PATIENT
AB BACKGROUND: Brain parenchyma herniation through a disrupted inner table into an enlarged diploic cavity with an intact outer table is described as intradiploic encephalocele. Intradiploic encephaloceles share common morphologic characteristics with expanding skull fractures and intradiploic arachnoid cysts. Herein, we describe a case of traumatic occipital intradiploic encephalocele.
   CASE DESCRIPTION: Cranial computed tomography of an 11-year-old boy revealed erosion of the inner table of the left side of occipital bone and expansion of the cranial diploe by a soft-tissue density with a gyral pattern. His medical history was positive for head trauma at the age of 3 years to the same region. Magnetic resonance imaging showed herniation of left occipital parenchyma with cystic encephalomalacic changes into the diploe.
   CONCLUSIONS: Intradiploic encephaloceles have different features compared with the classic encephalocele and can be considered as a variant of expanding skull fracture and intradiploic arachnoid cyst.
C1 [Kandemirli, Sedat Giray; Candan, Selman; Bilgin, Cem] Uludag Univ, Dept Radiol, Fac Med, Bursa, Turkey.
RP Kandemirli, SG (reprint author), Uludag Univ, Dept Radiol, Fac Med, Bursa, Turkey.
EM gskandemirli@yahoo.com
CR Arevalo-Perez J, 2015, NEURORADIOL J, V28, P264, DOI 10.1177/1971400915592554
   Battal B, 2015, J NEURORADIOLOGY, V42, P187, DOI 10.1016/j.neurad.2015.02.005
   Battal B, 2018, J NEUROSURG, V128, P949
   Battal B, 2016, EUR RADIOL, V26, P1723, DOI 10.1007/s00330-015-3959-x
   Battal B, 2014, NEURORADIOL J, V27, P55, DOI 10.15274/NRJ-2014-10006
   Chakkalakkoombil Sunitha V, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2017-223262
   Dobrin N, 2011, ROMANIAN NEUROSURG, P18
   Edward JK, 1976, J NEUROSURG, V44, P617
   Froelich S, 2006, NEUROCHIRURGIE, V52, P551, DOI 10.1016/S0028-3770(06)71366-2
   Kim HS, 2015, J KOREAN SOC RADIOL, V72, P423
   Lenthall R, 1999, BRIT J RADIOL, V72, P714, DOI 10.1259/bjr.72.859.10624333
   Liebo GB, 2016, J NEUROIMAGING, V26, P592, DOI 10.1111/jon.12366
   Loumiotis I, 2010, NEUROLOGY, V75, P1027, DOI 10.1212/WNL.0b013e3181f25f31
   Mahaney KB, 2014, J NEUROSURG-SPINE, V21, P769, DOI 10.3171/2014.6.SPINE13785
   MAHAPATRA AK, 1989, ACTA NEUROCHIR, V100, P120, DOI 10.1007/BF01403598
   MartinezLage JF, 1997, J NEUROSURG, V87, P468, DOI 10.3171/jns.1997.87.3.0468
   Mazzucchi E, 2017, CHILD NERV SYST, V33, P217, DOI 10.1007/s00381-016-3323-8
   McPheeters Matthew James, 2015, Surg Neurol Int, V6, pS651, DOI 10.4103/2152-7806.171221
   MEALEY J, 1970, J NEUROSURG, V32, P209, DOI 10.3171/jns.1970.32.2.0209
   Patil AA, 1996, J NEUROSURG, V84, P284, DOI 10.3171/jns.1996.84.2.0284
   Peters J, 2002, EUR RADIOL, V12, pS25, DOI 10.1007/s00330-002-1449-4
   Placantonakis DG, 2006, J NEUROSURG, V104, P356, DOI 10.3171/ped.2006.104.5.356
   ROY S, 1987, ACTA NEUROCHIR, V87, P112, DOI 10.1007/BF01476061
   Sato TS, 2009, AM J NEURORADIOL, V30, P635, DOI 10.3174/ajnr.A1320
   Shi C, 2017, J NEUROL SURG REP, V78, pE40, DOI 10.1055/s-0037-1599799
   TANDON PN, 1987, ACTA NEUROCHIR, V88, P1, DOI 10.1007/BF01400508
   Teriitehau CA, 2004, J RADIOL, V85, P646
   Tsuboi Y, 2007, NEUROL MED-CHIR, V47, P240, DOI 10.2176/nmc.47.240
   Valci L, 2018, J NEUROSURG, V128, P871, DOI 10.3171/2016.11.JNS162426
   Vavro H, 2018, NEURORADIOLOGY EXPEC, P125
   WINSTON K, 1983, J NEUROSURG, V59, P839, DOI 10.3171/jns.1983.59.5.0839
NR 31
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 9
EP 12
DI 10.1016/j.wneu.2019.05.174
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900116
PM 31150845
DA 2020-05-12
ER

PT J
AU Ng, S
   Le Corre, M
   Aloy, E
   Gras-Combe, G
   Duffau, H
   Boetto, J
AF Ng, Sam
   Le Corre, Marine
   Aloy, Emilie
   Gras-Combe, Guillaume
   Duffau, Hugues
   Boetto, Julien
TI Herpes Simplex Encephalitis Shortly After Surgery for a Secondary
   Glioblastoma: A Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain tumor; Encephalitis; Glioblastoma; Glioma; Herpes simplex virus;
   Herpetic encephalitis
ID VIRUS ENCEPHALITIS; PRIMARY BRAIN; TEMOZOLOMIDE; GLIOMA; INFECTIONS;
   CANCER; TYPE-1; TUMORS
AB BACKGROUND: Herpes simplex encephalitis (HSE) and glioblastoma multiforme (GBM) co-occurrence has been described in few cases presenting immunocompromised status related to chemotherapy or chemoradiotherapy. Focal encephalitis over surgical edge of resection occurring shortly after GBM resection is rarely reported, and such infection has never been reported in low-grade glioma with secondary malignant transformation (i.e., secondary GBM). Here, we report a case of HSE misdiagnosed in the early postoperative course following a secondary GBM resection. We also provide a review of the literature about HSE occurring after glioma surgery.
   CASE DESCRIPTION: We report a case of an acute HSE with a fatal outcome occurring shortly after surgery for a secondary GBM. The patient presented with hyperthermia 12 days after the surgery and was treated with empirical antibiotics. She later suffered from seizure and neurologic deterioration, leading to death despite delayed antiviral administration. Magnetic resonance imaging revealed considerable fluid-attenuated inversion-recovery signal progression at the edge of the surgical resection and polymerase chain reaction amplification of herpes simplex virus (HSV) 1 DNA was positive.
   CONCLUSIONS: Clinicians should be aware of the existing co-occurrence between HSV infections and GBM during the postoperative course. Cerebrospinal fluid analysis with HSV polymerase chain reaction testing should be promptly undertaken, and some keys clinical elements should justify early empirical treatment, including acyclovir administration. The significant prognostic implication of HSE complicating GBM must raise the attention of neurosurgeon and neuro-oncologist about this entity.
C1 [Ng, Sam; Le Corre, Marine; Aloy, Emilie; Duffau, Hugues; Boetto, Julien] Montpellier Univ, Gui de Chauliac Hosp, Dept Neurosurg, Med Ctr, Montpellier, France.
   [Gras-Combe, Guillaume] Clin Les Franciscaines, Dept Neurosurg, Nimes, France.
   [Duffau, Hugues] Montpellier Univ, Team Plastic Cent Nervous Syst Human Stem Cells &, St Eloi Hosp, Inst Neurosci Montpellier,INSERM U1051,Med Ctr, Montpellier, France.
RP Ng, S (reprint author), Montpellier Univ, Gui de Chauliac Hosp, Dept Neurosurg, Med Ctr, Montpellier, France.
EM s-ng@chu-montpellier.fr
OI Duffau, Hugues/0000-0002-6558-2342
CR Aldea S, 2003, CLIN INFECT DIS, V36, pE96, DOI 10.1086/368090
   Baden LR, 2016, J NATL COMPR CANC NE, V14, P882, DOI 10.6004/jnccn.2016.0093
   Berger A, 2016, WORLD NEUROSURG, V88, DOI 10.1016/j.wneu.2015.11.101
   Berzero G, 2015, J NEUROL NEUROSUR PS, V86, P374, DOI 10.1136/jnnp-2013-307198
   Christman MP, 2014, OXF MED CASE REP, DOI 10.1093/omcr/omu001
   Cunha BA, 2014, J CLIN MED, V3, P1392, DOI 10.3390/jcm3041392
   Darlix A, 2017, J NEURO-ONCOL, V131, P525, DOI 10.1007/s11060-016-2318-3
   Dix AR, 1999, J NEUROIMMUNOL, V100, P216, DOI 10.1016/S0165-5728(99)00203-9
   Jakob NJ, 2012, CRIT CARE MED, V40, P1304, DOI 10.1097/CCM.0b013e3182374a34
   Kennedy PGE, 2002, J NEUROL NEUROSUR PS, V73, P237, DOI 10.1136/jnnp.73.3.237
   Kleffmann J, 2012, FORTSCHR NEUROL PSYC, V80, P162, DOI 10.1055/s-0031-1281962
   Kocher M, 2005, STRAHLENTHER ONKOL, V181, P157, DOI 10.1007/s00066-005-1314-x
   Lin H, 2004, CLIN NEUROL NEUROSUR, V106, P335, DOI 10.1016/j.clineuro.2003.12.002
   Mateen FJ, 2014, MAYO CLIN PROC, V89, P274, DOI 10.1016/j.mayocp.2013.12.003
   Moon SM, 2014, J MED VIROL, V86, P1766, DOI 10.1002/jmv.23999
   Nam TS, 2011, J KOREAN NEUROSURG S, V50, P119, DOI 10.3340/jkns.2011.50.2.119
   Navarro R, 2013, J NEUROSURG, V118, P1385, DOI 10.3171/2013.2.JNS13216
   Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002
   Okada M, 2013, J NEUROSURG, V118, P258, DOI 10.3171/2012.9.JNS12177
   Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189
   Perry JD, 1998, AM J OPHTHALMOL, V126, P456, DOI 10.1016/S0002-9394(98)00108-1
   Piper K, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00008
   Rees JH, 1999, POSTGRAD MED J, V75, P728, DOI 10.1136/pgmj.75.890.727
   Riel-Romero RMS, 2003, PEDIATR NEUROL, V29, P69, DOI 10.1016/S0887-8994(03)00044-4
   Sayal Parag, 2018, Asian J Neurosurg, V13, P78, DOI 10.4103/1793-5482.181141
   Schiff D, 1998, HUM PATHOL, V29, P215, DOI 10.1016/S0046-8177(98)90038-7
   Sheleg SV, 2001, J NEUROSURG, V95, P721, DOI 10.3171/jns.2001.95.4.0721
   Spacca B, 2007, CHILD NERV SYST, V23, P1347, DOI 10.1007/s00381-007-0389-3
   Steiner I, 2007, LANCET NEUROL, V6, P1015, DOI 10.1016/S1474-4422(07)70267-3
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Wang JW, 2015, J FORMOS MED ASSOC, V114, P1295, DOI 10.1016/j.jfma.2014.07.012
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 13
EP 17
DI 10.1016/j.wneu.2019.05.173
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900117
PM 31150854
DA 2020-05-12
ER

PT J
AU Lacerda, RAV
   Teixeira, AG
   Sauaia, EN
   de Macedo, LJM
   Antonio, AS
   Cabral, JA
   Ramos, F
   Valenca, JT
AF Vicente Lacerda, Rafael Antonio
   Teixeira Junior, Antonio Gilvan
   Sauaia Filho, Euler Nicolau
   Monteiro de Macedo Filho, Leonardo Jose
   Antonio, Andre Soldati
   Cabral, Jan Aratijo
   Ramos Junior, Francisco
   Valenca Junior, Jose Telmo
TI Dural-Based Frontal Lobe Hemangioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Frontal; Hemangioblastoma; Supratentorial
ID HIPPEL-LINDAU-DISEASE; SUPRATENTORIAL HEMANGIOBLASTOMA; LEPTOMENINGEAL
   HEMANGIOBLASTOMA; CAPILLARY HEMANGIOBLASTOMA; NATURAL-HISTORY; LOCATION;
   TUMOR
AB BACKGROUND: Hemangioblastomas are benign vascular neoplasms that may be associated with von HippelLLindau disease. They are more common in men, with a mean age of 36 years, and rarely affect the supratentorial region and, when present in this topography, do not have meningeal impairment. Diagnosis by the radiologic and histopathologic study is difficult, since they are rare and, therefore, forgotten diagnosis, besides they are differential diagnoses with other supratentorial neoplasms.
   CASE DESCRIPTION: The present report describes a case of a frontal hemangioblastoma in a 64-year-old woman who presented with seizures. Our imaging studies had as a main hypothesis a frontal meningioma because of dural tail sign, lack of edema, contrast enhancement pattern, and extra-axial location in the supratentorial region, in the frontal lobe, which is uncommon for a hemangioblastoma. The patient underwent microneurosurgery for tumor resection, and the excised tissue was submitted for anatomopathologic evaluation. This study clarified the diagnosis as hemangioblastoma. We followed up the patient at the outpatient clinic for 2 years, with clinical improvement, without tumor recurrence. We also compared the clinical, radiologic, epidemiologic, and anatomopathologic data of the reported case with data from a literature review conducted through the PubMed portal.
   CONCLUSIONS: Definitive treatment for these lesions is surgical resection. Physicians should be aware that supratentorial meningeal hemangioblastomas can be developed in a patient without von HippelLLindau disease and regular follow-up is mandatory.
C1 [Vicente Lacerda, Rafael Antonio] Med Sch Juazeiro do Norte, Internal Med Dept, Juazeiro Do Norte, Ceara, Brazil.
   [Teixeira Junior, Antonio Gilvan] Fed Univ Cariri, Internal Med Dept, Barbalha, Ceara, Brazil.
   [Sauaia Filho, Euler Nicolau; Antonio, Andre Soldati; Cabral, Jan Aratijo; Ramos Junior, Francisco] Gen Hosp Fortaleza, Dept Neurosurg, Fortaleza, Ceara, Brazil.
   [Monteiro de Macedo Filho, Leonardo Jose] Univ Fortaleza, Hlth Sci Ctr, Fortaleza, Ceara, Brazil.
   [Valenca Junior, Jose Telmo] Univ Fed Ceara, Med Sch, Fortaleza, Ceara, Brazil.
RP Sauaia, EN (reprint author), Gen Hosp Fortaleza, Dept Neurosurg, Fortaleza, Ceara, Brazil.
EM reonardomacedofilho@edu.uniforbr
RI de Macedo Filho, Leonardo Jose Monteiro/AAB-4214-2019
OI de Macedo Filho, Leonardo Jose Monteiro/0000-0002-8146-7889
CR Acikalin MF, 2003, ARCH PATHOL LAB MED, V127, P382
   Agostinelli C, 2004, J NEUROSURG, V101, P122, DOI 10.3171/ped.2004.101.2.0122
   Ammerman JM, 2006, J NEUROSURG, V105, P248, DOI 10.3171/jns.2006.105.2.248
   [Anonymous], 1929, ANN INTERN MED, V2, P1232
   Choi DH, 1998, J KOREAN NEUROSURG S, V27, P1299
   Chung Sun-Yoon, 2014, Brain Tumor Res Treat, V2, P96, DOI 10.14791/btrt.2014.2.2.96
   Cosar M, 2006, NEUROL MED-CHIR, V46, P294, DOI 10.2176/nmc.46.294
   Cushing H, 1928, Trans Am Ophthalmol Soc, V26, P182
   Diguet A, 2002, PRENATAL DIAG, V22, P979, DOI 10.1002/pd.452
   Ding XH, 2007, SURG NEUROL, V67, P239, DOI 10.1016/j.surneu.2006.08.073
   Elguezabal A, 2010, NEUROCIRUGIA, V21, P401
   Epari S, 2014, INDIAN J PATHOL MICR, V57, P542, DOI 10.4103/0377-4929.142645
   Heffner RR., 1995, INT J SURG PATHOL, V2, P337
   Johnson MD, 2004, PEDIATR NEUROSURG, V40, P124, DOI 10.1159/000079854
   Kaloostian Pe, 2012, J Surg Case Rep, V2012, P11, DOI 10.1093/jscr/2012.6.11
   Karabagli H, 2007, J NEUROSURG, V107, P515, DOI 10.3171/PED-07/12/515
   Keith J, 2008, ACTA CYTOL, V52, P260, DOI 10.1159/000325496
   Kim H, 2013, J KOREAN NEUROSURG S, V54, P415, DOI 10.3340/jkns.2013.54.5.415
   Kim JM, 2006, J NEURO-ONCOL, V77, P59, DOI 10.1007/s11060-005-9002-3
   Lindvall P, 2008, ACTA NEUROCHIR, V150, P73, DOI 10.1007/s00701-007-1453-1
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Lozano-Tangua CF, 2012, PAN ARAB J NEUROSURG, V34
   lyigun OL, 2004, TURKISH NEUROSURG, V14, P25
   Mills SA, 2012, NEURO-ONCOLOGY, V14, P1097, DOI 10.1093/neuonc/nos133
   Murali R, 2007, BRAIN PATHOL, V17, P460, DOI 10.1111/j.1750-3639.2007.00091_1.x
   Orakcioglu B, 2007, ACTA NEUROCHIR, V149, P419, DOI 10.1007/s00701-006-1100-2
   Ozveren MF, 2001, NEUROL MED-CHIR, V41, P201, DOI 10.2176/nmc.41.201
   PERKS WH, 1976, J NEUROL NEUROSUR PS, V39, P218, DOI 10.1136/jnnp.39.3.218
   Peyre M, 2010, NEUROSURGERY, V67, P577, DOI 10.1227/01.NEU.0000374846.86409.A7
   RICHMOND BK, 1995, J NEUROSURG, V82, P113, DOI 10.3171/jns.1995.82.1.0113
   Robson D. K., 2001, J PATHOL, V193, P276
   Rocha L, 2018, INT J NEUROSCI, V128, P295, DOI 10.1080/00207454.2017.1385613
   Russell DS, 1978, AM J SURG PATHOL, V2, P113
   SHARMA RR, 1995, BRIT J NEUROSURG, V9, P81, DOI 10.1080/02688699550041809
   She DJ, 2013, CLIN NEURORADIOL, V23, P243, DOI 10.1007/s00062-012-0183-9
   Sherman JH, 2007, ACTA NEUROCHIR, V149, P969, DOI 10.1007/s00701-007-1180-7
   Takeuchi H, 2008, NEUROPATHOLOGY, V28, P98, DOI 10.1111/j.1440-1789.2007.00834.x
   Tekkok IH, 2006, CHILD NERV SYST, V22, P1177, DOI 10.1007/s00381-006-0052-4
   Vortmeyer AO, 1997, HUM PATHOL, V28, P540, DOI 10.1016/S0046-8177(97)90075-7
   Wilkins RH, 1996, SHOCK, V6, P453
   Yang BJ, 2011, NEUROSCIENCES, V16, P150
   Zamzuri I, 2005, Med J Malaysia, V60, P360
   Zeitlin H., 1942, J NEUROPATHOL EXP NE, V1, P14
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 18
EP 23
DI 10.1016/j.wneu.2019.05.175
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900118
PM 31150863
DA 2020-05-12
ER

PT J
AU La Corte, E
   de Laurentis, C
   Acerbi, F
   Broggi, M
   Pipolo, C
   Maccari, A
   Felisati, G
   Ferroli, P
AF La Corte, Emanuele
   de Laurentis, Camilla
   Acerbi, Francesco
   Broggi, Morgan
   Pipolo, Carlotta
   Maccari, Alberto
   Felisati, Giovanni
   Ferroli, Paolo
TI Peel-Away Catheter Introducer Sheath for Reducing Nasal Traumatic Injury
   During Pediatric Endoscopic Skull Base Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopy; Pediatrics; Peel-away catheter; Sinonasal morbidity; Skull
   base surgery
ID TRANSSPHENOIDAL APPROACH; RESECTION
AB OBJECTIVE: Pediatric endoscopic endonasal surgery represents a still-growing discipline to approach complex skull base lesions and is characterized by unfavorable anatomical conditions. Children have very small nostrils and narrow rhinosinusal corridors, which could lead more easily to accidental injury to the nasal structures. We describe the use of a peel-away catheter introducer sheath as an innovative and minimally invasive technique to further reduce surgical trauma to the nasal mucosa and structures in pediatric rhinoneurosurgery.
   METHODS: From January 2009 to December 2018, the peel-away sheath technique was used in 6 pediatric endoscopic procedures for biopsy and/or removal of skull base tumors.
   RESULTS: The endoscopic technique with the use of the peel-away catheter allowed clear visualization of the surgical field during the whole course of the procedure and good surgical maneuverability. The use of the peel-away sheath did not prolong the surgical operation time and provided a good working channel. No intraoperative or postoperative major complications were observed. No nasal short-term complications were registered in all patients.
   CONCLUSIONS: The use of a peel-away catheter introducer sheath technique represents a valid adjunct in the endoscopic pediatric skull base surgery repertoire. It can help in avoiding inadvertent surgical traumas to the sinonasal structures, especially by residents and junior surgeons. This could potentially reduce postoperative nasal morbidity.
C1 [La Corte, Emanuele] Univ Milan, Dept Hlth Sci, ASST Santi Paolo & Carlo, PhD Sch Mol & Translat Med, Milan, Italy.
   [Pipolo, Carlotta; Maccari, Alberto; Felisati, Giovanni] Univ Milan, Dept Hlth Sci, ASST Santi Paolo & Carlo, Otolaryngol Unit, Milan, Italy.
   [La Corte, Emanuele; de Laurentis, Camilla; Acerbi, Francesco; Broggi, Morgan; Ferroli, Paolo] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurosurg, Milan, Italy.
RP La Corte, E (reprint author), Univ Milan, Dept Hlth Sci, ASST Santi Paolo & Carlo, PhD Sch Mol & Translat Med, Milan, Italy.; La Corte, E (reprint author), Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurosurg, Milan, Italy.
EM emanuele.lacorte@unimi.it
RI La Corte, Emanuele/F-1194-2016
OI La Corte, Emanuele/0000-0003-3752-8629; de Laurentis,
   Camilla/0000-0003-1867-7899
CR ANAND V, 2007, PRACTICAL ENDOSCOPIC
   Banu MA, 2014, J NEUROSURG-PEDIATR, V13, P155, DOI 10.3171/2013.10.PEDS13303
   Bedrosian JC, 2013, INT FORUM ALLERGY RH, V3, P664, DOI 10.1002/alr.21161
   Benoit MM, 2009, INT J PEDIATR OTORHI, V73, P1452, DOI 10.1016/j.ijporl.2009.07.017
   Bhatki AM, 2010, ORAL MAXIL SURG CLIN, V22, P157, DOI 10.1016/j.coms.2009.10.005
   Chen W, 2019, J NEUROSURG PEDIAT, V1, P1
   Chivukula S, 2013, J NEUROSURG-PEDIATR, V11, P227, DOI 10.3171/2012.10.PEDS12160
   de Almeida JR, 2011, HEAD NECK-J SCI SPEC, V33, P547, DOI 10.1002/hed.21483
   de Divitiis E, 2000, CHILD NERV SYST, V16, P692, DOI 10.1007/s003810000350
   Giovannetti F, 2018, J CRANIO MAXILL SURG, V46, P2017, DOI 10.1016/j.jcms.2018.09.013
   Jane JA, 2010, J NEUROSURG-PEDIATR, V5, P49, DOI 10.3171/2009.7.PEDS09252
   Kassam A, 2007, J NEUROSURG, V106, P75, DOI 10.3171/ped.2007.106.2.75
   Kassam Amin, 2005, Neurosurg Focus, V19, pE4
   Kassam Amin, 2005, Neurosurg Focus, V19, pE3
   Komotar RJ, 2013, WORLD NEUROSURG, V80, P148, DOI 10.1016/j.wneu.2012.12.003
   Locatelli D, 2010, INT J PEDIATR OTORHI, V74, P1298, DOI 10.1016/j.ijporl.2010.08.009
   LoPresti MA, 2018, J NEUROL SURG PART B, V79, P3, DOI 10.1055/s-0037-1617449
   Dolci RLL, 2017, BRAZ J OTORHINOLAR, V83, P349, DOI 10.1016/j.bjorl.2016.04.020
   Massimi L, 2011, ACTA NEUROCHIR, V153, P843, DOI 10.1007/s00701-010-0929-6
   Munson PD, 2010, CURR OPIN OTOLARYNGO, V18, P571, DOI 10.1097/MOO.0b013e3283401fdc
   Rigante M, 2011, INT J PEDIATR OTORHI, V75, P1132, DOI 10.1016/j.ijporl.2011.06.004
   Shah RN, 2009, LARYNGOSCOPE, V119, P1067, DOI 10.1002/lary.20216
   Stapleton AL, 2015, J NEUROL SURG PART B, V76, P39, DOI 10.1055/s-0034-1390019
   Tatreau JR, 2010, LARYNGOSCOPE, V120, P1730, DOI 10.1002/lary.20964
   Tsai Eve C, 2002, Neurosurg Focus, V12, pe1
NR 25
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 24
EP 27
DI 10.1016/j.wneu.2019.05.192
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900119
PM 31426253
DA 2020-05-12
ER

PT J
AU Morinaga, Y
   Nii, K
   Sakamoto, K
   Inoue, R
   Mitsutake, T
   Hanada, H
AF Morinaga, Yusuke
   Nii, Kouhei
   Sakamoto, Kimiya
   Inoue, Ritsurou
   Mitsutake, Takafumi
   Hanada, Hayatsura
TI Revascularization for In-Hospital Acute Ischemic Stroke After
   Video-Assisted Thoracic Surgery: Report of 2 Cases and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Acute ischemic stroke; Revascularization; VATS
ID PULMONARY VEIN STUMP; LEFT UPPER LOBECTOMY; THROMBOSIS
AB BACKGROUND: Postoperative cerebral embolism after left upper lobectomy caused by a thrombus in the pulmonary vein stump (PVS) is a serious complication. However, it is unclear whether cerebral embolism can develop after other types of lobectomy. We present 2 cases of revascularization for in-hospital acute ischemic stroke after video-assisted thoracic surgery (VATS).
   CASE DESCRIPTION: Patient 1 is a 71-year-old man with a history of hypertension and dyslipidemia. VATS was performed for lung cancer in the left upper lobe. On day 0 after VATS, he developed an acute ischemic stroke (left M3 occlusion). Revascularization was performed, and TICI 2b was obtained. He was transferred to a recovery rehabilitation hospital with a modified Rankin Scale score of 3. No ischemic or hemorrhagic stroke was observed 12 months postoperatively.
   Patient 2 is a 76-year-old man who had a history of hypertension. VATS was performed for metastatic lung cancer in the left lower lobe. On day 6 after VATS, he developed an acute ischemic stroke (left M1 occlusion). Revascularization was performed and TICI 3 was obtained. He was transferred to a recovery rehabilitation hospital with a modified Rankin Scale score of 1. No ischemic or hemorrhagic stroke was observed 13 months postoperatively.
   CONCLUSIONS: Postoperative PVS thrombosis causes embolisms, and dabigatran has been effective in preventing postoperative recurrences. Further study of preventive and perioperative management is necessary.
C1 [Morinaga, Yusuke; Nii, Kouhei; Sakamoto, Kimiya; Inoue, Ritsurou; Mitsutake, Takafumi; Hanada, Hayatsura] Fukuoka Univ, Chikushi Hosp, Dept Neurosurg, Chikushino City, Japan.
RP Morinaga, Y (reprint author), Fukuoka Univ, Chikushi Hosp, Dept Neurosurg, Chikushino City, Japan.
EM yu_the_morio@yahoo.co.jp
CR Gual-Capllonch F, 2013, J CLIN ULTRASOUND, V41, P321, DOI 10.1002/jcu.21913
   Kamori T, 2017, J THORAC DIS, V9, pE210, DOI 10.21037/jtd.2017.02.58
   Ohtaka K, 2013, ANN THORAC SURG, V95, P1924, DOI 10.1016/j.athoracsur.2013.03.005
   Ohtaka K, 2012, J THORAC CARDIOV SUR, V143, pE3, DOI 10.1016/j.jtcvs.2011.09.025
   Usui G, 2019, INTERNAL MED, V58, P1349, DOI 10.2169/internalmedicine.1962-18
   Wakita Y, 2013, JAP J CHEST DIS, V72, P742
   Yamamoto T, 2016, SURG TODAY, V46, P780, DOI 10.1007/s00595-015-1233-0
   Yamauchi T, 2017, NIHON KYUKYU IGAKUKA, V28
NR 8
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 28
EP 33
DI 10.1016/j.wneu.2019.05.203
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900120
PM 31150859
DA 2020-05-12
ER

PT J
AU Zervos, T
   Walters, BC
AF Zervos, Thomas
   Walters, Beverly C.
TI Diagnosis of Ventricular Shunt Infection in Children: A Systematic
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Hydrocephalus; PCR; Pseudocyst; Risk factors; Shunt malfunction;
   Ventriculoatrial; Ventriculoperitoneal
ID CEREBROSPINAL-FLUID SHUNT; VENTRICULOPERITONEAL SHUNT; RISK-FACTORS;
   MANAGEMENT; CSF; EOSINOPHILIA; INFANTS; ACNES; MENINGITIS; CULTURES
AB BACKGROUND: No widely accepted gold standard for diagnosis of shunt infection exists, with definitions variable among clinicians and publications. This article summarizes the utility of commonly used diagnostic tools and provides a comprehensive review of optimal measures for diagnosis.
   METHODS: A query of PubMed was performed extracting articles related to shunt infection in children. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed, resulting in 1756 articles related to shunt infection, 49 of which ultimately met inclusion criteria.
   RESULTS: Of the 49 articles included in the analysis, 9 did not define infection, 9 used culture alone, 9 used cultures and/or symptomatology, and 4 used a combination of cultures, cerebral spinal fluid (CSF) pleocytosis and symptomatology. The remainder of the studies used definitions from the Centers for Disease Control and Prevention (n = 2) and the Hydrocephalus Clinical Research Network (n = 2) or borrowed elements from these definitions. Variation in definition stems from the lack of sensitivity and specificity of commonly used signs, symptoms, and tests. Shunt tap alone is considered half as sensitive as hardware culture. Fever upon presentation was present in 16% to 42% of cases. CSF pleocytosis combined with fever has a sensitivity of 82% and specificity of 99%. CSF eosinophilia, lactic acid, serum anti-Staphylococcus epidermidis titer, procalcitonin, and C-reactive protein are non-specific and their utility is not well established.
   CONCLUSIONS: The definition of shunt infection is variable across studies, with CSF culture and/or symptomatology being the most commonly utilized parameters.
C1 [Zervos, Thomas; Walters, Beverly C.] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
RP Zervos, T (reprint author), Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA.
EM zervos1@hfhs.org
OI Walters, Beverly/0000-0002-5244-4282
CR Anderson EJ, 2005, PEDIATR INFECT DIS J, V24, P557, DOI 10.1097/01.inf.0000165307.29619.82
   Arnell K, 2008, J NEUROSURG-PEDIATR, V1, P366, DOI 10.3171/PED/2008/1/5/366
   Banks JT, 2005, NEUROSURGERY, V57, P1237, DOI 10.1227/01.NEU.0000186038.98817.72
   Barnes NP, 2002, ARCH DIS CHILD, V87, P198, DOI 10.1136/adc.87.3.198
   BAYSTON R, 1981, MED LAB SCI, V38, P259
   BAYSTON R, 1994, EUR J CLIN MICROBIOL, V13, P417, DOI 10.1007/BF01972001
   Berger C, 2002, CRIT CARE MED, V30, P1778, DOI 10.1097/00003246-200208000-00017
   Bolster F, 2016, EMERG RADIOL, V23, P117, DOI 10.1007/s10140-015-1368-8
   Brook I, 2002, PEDIATR NEUROL, V26, P99, DOI 10.1016/S0887-8994(01)00330-7
   Brown EM, 2006, NEUROSURGERY, V58, P657, DOI 10.1227/01.NEU.0000204126.54417.46
   CHOUX M, 1992, J NEUROSURG, V77, P875, DOI 10.3171/jns.1992.77.6.0875
   Conen A, 2008, CLIN INFECT DIS, V47, P73, DOI 10.1086/588298
   Dabdoub CB, 2014, CHILD NERV SYST, V30, P579, DOI 10.1007/s00381-014-2370-2
   Deutch S, 2007, NEUROSURGERY, V61, P306, DOI 10.1227/01.NEU.0000255526.34956.E4
   Fulkerson DH, 2008, J NEUROSURG-PEDIATR, V1, P288, DOI 10.3171/PED/2008/1/4/288
   Fulkerson DH, 2011, J NEUROSURG-PEDIATR, V8, P613, DOI 10.3171/2011.8.PEDS11236
   Gulsen I, 2015, PAK J MED SCI, V31, P435, DOI 10.12669/pjms.312.6515
   Hanekom W A, 1996, Adv Pediatr Infect Dis, V11, P29
   HUBSCHMANN OR, 1980, ARCH SURG-CHICAGO, V115, P305
   JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389
   James G, 2014, J NEUROSURG-PEDIATR, V13, P101, DOI 10.3171/2013.10.PEDS13189
   JAMES HE, 1980, NEUROSURGERY, V7, P459, DOI 10.1227/00006123-198011000-00006
   Jost GF, 2014, J CLIN NEUROSCI, V21, P578, DOI 10.1016/j.jocn.2013.05.025
   Kestle JRW, 2011, J NEUROSURG-PEDIATR, V8, P22, DOI 10.3171/2011.4.PEDS10551
   KONTNY U, 1993, INFECTION, V21, P89, DOI 10.1007/BF01710738
   Kormanik K, 2010, J PERINATOL, V30, P218, DOI 10.1038/jp.2009.154
   Lan Cheng-Chou, 2003, Journal of Microbiology Immunology and Infection, V36, P47
   Lee JK, 2012, J KOREAN MED SCI, V27, P1563, DOI 10.3346/jkms.2012.27.12.1563
   Lenfestey RW, 2007, J NEUROSURG, V107, P209, DOI 10.3171/PED-07/09/209
   Lolak S, 2013, SURG INFECT, V14, P192, DOI 10.1089/sur.2011.070
   Mancao M, 1998, ACTA PAEDIATR, V87, P667, DOI 10.1080/080352598750014085
   Mandell GL, 2015, MANDELL DOUGLAS BENN
   McClinton D, 2001, PEDIATR INFECT DIS J, V20, P593, DOI 10.1097/00006454-200106000-00009
   MOHER D, 2009, PLOS MED, V339, DOI DOI 10.1136/BMJ.B2535
   Moussa WMM, 2016, CLIN NEUROL NEUROSUR, V143, P144, DOI 10.1016/j.clineuro.2016.02.034
   Naradzay JFX, 1999, J EMERG MED, V17, P311, DOI 10.1016/S0736-4679(98)00168-1
   NOETZEL MJ, 1984, J NEUROSURG, V61, P328, DOI 10.3171/jns.1984.61.2.0328
   ODIO C, 1984, AM J DIS CHILD, V138, P1103, DOI 10.1001/archpedi.1984.02140500009004
   Parker SL, 2009, CHILD NERV SYST, V25, P77, DOI 10.1007/s00381-008-0743-0
   Piatt JH, 2008, PEDIATR EMERG CARE, V24, P201, DOI 10.1097/PEC.0b013e31816a8d43
   POPLE IK, 1992, J NEUROSURG, V77, P29, DOI 10.3171/jns.1992.77.1.0029
   Prusseit J, 2009, PEDIATR NEUROSURG, V45, P325, DOI 10.1159/000257520
   Quinones-Hinojosa A, 2012, SCHMIDEK SWEETS OPER
   Ramos TN, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87919
   Rehman AU, 2010, J NEUROSURG-PEDIATR, V5, P569, DOI 10.3171/2010.2.PEDS09151
   RONAN A, 1995, PEDIATR INFECT DIS J, V14, P782, DOI 10.1097/00006454-199509000-00010
   Rowensztein H, 2015, ARCH ARGENT PEDIATR, V113, P244, DOI [10.5546/aap.2015.eng.244, 10.5546/aap.2015.244]
   SCHMIDT K, 1985, NEUROSURGERY, V17, P1
   Simon TD, 2014, J PEDIATR-US, V164, P1462, DOI 10.1016/j.jpeds.2014.02.013
   Simon TD, 2010, J NEUROSURG-PEDIATR, V6, P277, DOI 10.3171/2010.5.PEDS09457
   Simon TE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105159
   STAMOS JK, 1993, NEUROSURGERY, V33, P858
   Steinbok P, 1996, J NEUROSURG, V84, P617, DOI 10.3171/jns.1996.84.4.0617
   Steinbok P, 2010, NEUROSURGERY, V67, P1303, DOI 10.1227/NEU.0b013e3181f07e76
   Stevens NT, 2012, BRIT J NEUROSURG, V26, P792, DOI 10.3109/02688697.2011.651514
   Stone JJ, 2013, J NEUROSURG-PEDIATR, V11, P15, DOI 10.3171/2012.9.PEDS1298
   STROMBLAD LG, 1987, SCAND J INFECT DIS, V19, P211, DOI 10.3109/00365548709032400
   Tamber MS, 2014, J NEUROSURG-PEDIATR, V14, P60, DOI 10.3171/2014.7.PEDS14328
   Thompson TP, 1998, CHILD NERV SYST, V14, P378, DOI 10.1007/s003810050248
   Tuan TJ, 2011, PEDIATR INFECT DIS J, V30, P731, DOI 10.1097/INF.0b013e318218ac0e
   TUNG H, 1991, J NEUROSURG, V75, P541, DOI 10.3171/jns.1991.75.4.0541
   Turgut M, 2005, PEDIATR NEUROSURG, V41, P131, DOI 10.1159/000085869
   Vinchon M, 2006, CHILD NERV SYST, V22, P692, DOI 10.1007/s00381-005-0037-8
   VINCHON M, 1992, NEUROPEDIATRICS, V23, P235, DOI 10.1055/s-2008-1071349
   von der Brelie C, 2012, ACTA NEUROCHIR, V154, P1691, DOI 10.1007/s00701-012-1329-x
   Walcott BP, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.8.FOCUS12245
   Walters B C, 1992, Neurosurg Clin N Am, V3, P387
   WALTERS BC, 1984, J NEUROSURG, V60, P1014, DOI 10.3171/jns.1984.60.5.1014
   WALTERS BC, 1985, Z KINDERCHIR, V40, P15
   WALTERS BC, 1992, CHILD NERV SYST, V8, P253, DOI 10.1007/BF00300791
   Westergren H, 1997, ACTA NEUROCHIR, V139, P33, DOI 10.1007/BF01850865
   Whitehead WE, 2001, PEDIATR NEUROSURG, V35, P205, DOI 10.1159/000050422
   Wiersbitzky SKW, 1998, ACTA NEUROL SCAND, V97, P201
   Winn RH, 2011, YOUMANS NEUROLOGICAL
   Winston KR, 2011, J NEUROSURG-PEDIATR, V7, P452, DOI 10.3171/2011.2.PEDS10304
NR 75
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 34
EP 44
DI 10.1016/j.wneu.2019.05.057
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900121
PM 31100520
DA 2020-05-12
ER

PT J
AU Villalonga, JF
   Pilonieta, M
   Barbero, JMR
   Carrau, RL
   Prevedello, DM
AF Villalonga, Juan F.
   Pilonieta, Martin
   Barbero, Juan M. Revuelta
   Carrau, Ricardo L.
   Prevedello, Daniel M.
TI Pituitary Adenoma Concomitant with Chiari I Malformation: Case Report
   and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chiari I malformation; Endoscopic endonasal approach; Pituitary adenoma;
   Skull base
ID PREVALENCE; HERNIATION; RESOLUTION; SURGERY
AB BACKGROUND: Pituitary adenomas (PA) are usually benign neoplasms. Chiari I malformation (CIM) is an uncommon finding. Isolated cases associating functional PA and CIM have been reported. The concomitant presence of a nonfunctional PA and a CIM has not yet been described in the literature.
   CASE DESCRIPTION: We present the case of a 35-year-old patient whose symptoms were compatible with CIM. Magnetic resonance imaging of the brain, with and without contrast material, confirmed the CIM and incidentally encountered a PA. The patient was treated initially for her PA through an endoscopic endonasal approach with complete tumor resection, confirming a nonfunctional PA. Posterior fossa decompression was successfully accomplished 3 months later. The patient has been followed up for 5 years and has been free of symptoms, with no recurrence of her PA. This represents the first reported case of a nonfunctional PA with a concomitant CIM.
   CONCLUSION: This is the first reported case of a concomitant CIM and a nonfunctional PA. We discuss our successful management and conduct a systematic review of the literature to provide the most up-to-date guidance on managing these singular cases with concomitant pathologic conditions.
C1 [Villalonga, Juan F.] Univ Nacl Tucuman, Fac Med, LINT, San Miguel De Tucuman, Argentina.
   [Pilonieta, Martin] Univ Nacl Colombia, Dept Neurol Surg, Bogota, Colombia.
   [Barbero, Juan M. Revuelta; Carrau, Ricardo L.; Prevedello, Daniel M.] Ohio State Univ, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Carrau, Ricardo L.; Prevedello, Daniel M.] Ohio State Univ, Dept Otolaryngol Head & Neck Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
RP Prevedello, DM (reprint author), Ohio State Univ, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.; Prevedello, DM (reprint author), Ohio State Univ, Dept Otolaryngol Head & Neck Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
EM daniel.prevedello@osumc.edu
OI Prevedello, Daniel/0000-0003-0214-2339
CR Agostinis C, 2000, SURG NEUROL, V53, P396, DOI 10.1016/S0090-3019(00)00179-8
   Agustsson TT, 2015, EUR J ENDOCRINOL, V173, P655, DOI 10.1530/EJE-15-0189
   Ammerman JM, 2006, J NEUROSURG, V104, P980, DOI 10.3171/jns.2006.104.6.980
   Ammirati M, 2013, J NEUROL NEUROSUR PS, V84, P843, DOI 10.1136/jnnp-2012-303194
   Arnett BC, 2004, NEUROL CLIN, V22, P229, DOI 10.1016/S0733-8619(03)00101-4
   Baig MN, 2007, NEUROSURG FOCUS, V23, P15
   Boswell SB, 2014, CLIN IMAG, V38, P384, DOI 10.1016/j.clinimag.2014.02.014
   Chiari H, 1891, DEUT MED WOCHENSCHR, V17, P1172, DOI 10.1055/s-0029-1206803
   Daly AF, 2006, J CLIN ENDOCR METAB, V91, P4769, DOI 10.1210/jc.2006-1668
   ELSTER AD, 1992, RADIOLOGY, V183, P347, DOI 10.1148/radiology.183.2.1561334
   Fernandez A, 2010, CLIN ENDOCRINOL, V72, P377, DOI 10.1111/j.1365-2265.2009.03667.x
   Fontana E, 2009, Rev Med Suisse, V5, P2172
   Gruppetta M, 2013, PITUITARY, V16, P545, DOI 10.1007/s11102-012-0454-0
   Gupta A, 2008, CHILD NERV SYST, V24, P1345, DOI 10.1007/s00381-008-0675-8
   HALL WA, 1994, ANN INTERN MED, V120, P817, DOI 10.7326/0003-4819-120-10-199405150-00001
   Hara M, 1996, INTERNAL MED, V35, P803, DOI 10.2169/internalmedicine.35.803
   Langridge B, 2017, WORLD NEUROSURG, V104, P213, DOI 10.1016/j.wneu.2017.04.082
   Larkin S, 2017, PATHOLOGY PATHOGENES, P2
   Lee LA, 2006, ANESTHESIOLOGY, V105, P652, DOI 10.1097/00000542-200610000-00007
   LEMAR HJ, 1994, SOUTHERN MED J, V87, P284, DOI 10.1097/00007611-199402000-00031
   Manara R, 2013, PITUITARY, V16, P122, DOI 10.1007/s11102-012-0385-9
   Milhorat TH, 2010, ACTA NEUROCHIR, V152, P1117, DOI 10.1007/s00701-010-0636-3
   Mori O, 1990, PEDIAT JPN, V31, P1213
   Naftel RP, 2013, CHILD NERV SYST, V29, P2291, DOI 10.1007/s00381-013-2080-1
   O'Grady MJ, 2011, J PEDIATR-US, V158, P686, DOI 10.1016/j.jpeds.2010.09.079
   Raappana A, 2010, J CLIN ENDOCR METAB, V95, P4268, DOI 10.1210/jc.2010-0537
   Takakuwa Satoshi, 1996, Endocrine Journal, V43, pS129, DOI 10.1507/endocrj.43.Suppl_S129
   Tjornstrand A, 2014, EUR J ENDOCRINOL, V171, P519, DOI 10.1530/EJE-14-0144
   Vasil'ev SA, 2011, ZH VOPR NEIROKHIR NN, V76, P45
NR 29
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 45
EP 48
DI 10.1016/j.wneu.2019.05.088
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900122
PM 31121377
DA 2020-05-12
ER

PT J
AU Kang, SS
   Lee, SC
   Kim, SK
AF Kang, Sang-Soo
   Lee, Su-Chan
   Kim, Seung-Kook
TI A Novel Percutaneous Biportal Endoscopic Technique for Symptomatic
   Spinal Epidural Lipomatosis: Technical Note and Case Presentations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biportal endoscopic spine surgery; Percutaneous biportal endoscopic
   surgery; Spinal epidural lipomatosis; Unilateral biportal endoscopy
ID DECOMPRESSION
AB OBJECTIVE: To describe a minimally invasive decompression technique for symptomatic spinal epidural lipomatosis using percutaneous biportal endoscopic surgery.
   METHODS: In this report, we describe the indirect decompressive effect that was gained by partial laminotomy and ligamentum flavectomy under biportal endoscopic view. Direct neural decompression was then performed by removal of proliferated fat. We described the technical process and compared pre-and postoperative radiating leg pain, life quality, and a radiologic grading system of neural compression.
   RESULTS: This technique was performed successfully in 3 patients with idiopathic spinal epidural lipomatosis. Radiating pain was reduced, and functional disability and radiologic compression were improved. Postoperative instability and surgical complications related to the procedure were not observed.
   CONCLUSIONS: Percutaneous spinal endoscopy is a minimally invasive muscle-preserving technique for spinal lipomatosis that achieves neural decompression directly by lipoma removal and indirectly by partial bone and ligament removal.
C1 [Kang, Sang-Soo] Chung Hosp, Dept Orthoped Surg, Seoul, South Korea.
   [Lee, Su-Chan; Kim, Seung-Kook] Himchan Hosp, Orthoped Surg, Joint & Arthrit Res, Seoul, South Korea.
   [Kim, Seung-Kook] Hurisarang Hosp, Dept Neurosurg, Daejeon, South Korea.
   [Kim, Seung-Kook] Yonsei Univ, Coll Med & Pharm, Dept Pharmaceut Med & Regulatory Sci, Incheon, South Korea.
RP Kim, SK (reprint author), Himchan Hosp, Orthoped Surg, Joint & Arthrit Res, Seoul, South Korea.; Kim, SK (reprint author), Hurisarang Hosp, Dept Neurosurg, Daejeon, South Korea.; Kim, SK (reprint author), Yonsei Univ, Coll Med & Pharm, Dept Pharmaceut Med & Regulatory Sci, Incheon, South Korea.
EM deux8888@naver.com
OI Kang, Sang Soo/0000-0003-1581-3744
CR BADAMI JP, 1982, AM J NEURORADIOL, V3, P664
   Botwin KP, 2004, AM J PHYS MED REHAB, V83, P926, DOI 10.1097/01.PHM.0000143397.02251.56
   Ferlic PW, 2016, SPINE J, V16, P1333, DOI 10.1016/j.spinee.2016.06.022
   Fogel Guy R, 2005, Spine J, V5, P202, DOI 10.1016/j.spinee.2004.05.252
   Frank E, 1998, SURG NEUROL, V50, P333, DOI 10.1016/S0090-3019(98)00016-0
   Heo DH, 2018, WORLD NEUROSURG, V120, pE684, DOI 10.1016/j.wneu.2018.08.144
   Heo DH, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17146
   Ishikawa Y, 2006, J NEUROSURG-SPINE, V4, P24, DOI 10.3171/spi.2006.4.1.24
   KAMBIN P, 1992, ARTHROSCOPY, V8, P287, DOI 10.1016/0749-8063(92)90058-J
   Kambin P, 1987, CLIN ORTHOP RELAT R, V223, P14554
   Kim JE, 2018, CLIN ORTHOP SURG, V10, P328, DOI 10.4055/cios.2018.10.3.328
   Kim SK, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0725-1
   Lee GY, 2011, SKELETAL RADIOL, V40, P1127, DOI 10.1007/s00256-011-1153-z
   Lisai P, 2001, SPINE, V26, P307, DOI 10.1097/00007632-200102010-00017
   Sairyo K, 2008, MINIM INVAS NEUROSUR, V51, P43, DOI 10.1055/s-2007-1004569
   SELMI F, 1994, BRIT J NEUROSURG, V8, P355, DOI 10.3109/02688699409029626
   VANROOIJ WJJ, 1994, CLIN NEUROL NEUROSUR, V96, P181
NR 17
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 49
EP 54
DI 10.1016/j.wneu.2019.05.214
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900123
PM 31154106
DA 2020-05-12
ER

PT J
AU Amato, MCM
   Aprile, BC
   de Oliveira, CA
   Cameiro, VM
   de Oliveira, RS
AF Moraes Amato, Marcelo Campos
   Aprile, Bruno Cesar
   de Oliveira, Cezar Augusto
   Cameiro, Vinicius Marques
   de Oliveira, Ricardo Santos
TI Experimental Model for Interlaminar Endoscopic Spine Procedures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Disc herniation; Endoscopic discectomy; Interlaminar; learning curve;
   Lumbar spine; Porcine model
ID SURGICAL TECHNIQUE; LUMBAR DISKECTOMY; DISC HERNIATION; LEARNING-CURVE;
   PORCINE; SURGERY; ANATOMY
AB BACKGROUND: Endoscopic spinal surgery is becoming quite popular, and the pursuit of a training model to improve surgeons' skills is imperative to overcome the limited availability of human cadavers. Our goal was to determine whether the porcine spine could be a representative model for learning and practicing interlaminar percutaneous endoscopic lumbar procedures (IL-PELPs).
   METHODS: Lumbar and cervical segments of the porcine cadaver spine were used for the IL-PELP. We have described the technical notes on the difficulties of the procedure and the relevant anatomical features. To endorse the porcine cadaver for this procedure, 5 neurosurgeons underwent 1 day of training and completed a survey.
   RESULTS: The porcine lumbar spine has small interlaminar windows, and laminectomy is necessary, mimicking the translaminar approaches for higher human lumbar spine levels. The porcine cervical spine has wide and high interlaminar windows and mimics the human L5-S1 interlaminar approach. Entering the spinal canal with the working sheath and endoscope and training the rotation maneuver to access the disc space is only possible in the lumbar segment. It was possible to perform flavectomy and to identify and dissect the dural sac and nerve root in both the lumbar and cervical spine. The neurosurgeons considered the porcine model of good operability and, although different, possible to apply in humans.
   CONCLUSIONS: The porcine spine is an effective and representative model for learning and practicing IL-PELPs. Although the described anatomical differences should be known, they did not interfere in performing the main surgical steps and maneuvers for IL-PELPs in the porcine model.
C1 [Moraes Amato, Marcelo Campos; Aprile, Bruno Cesar; de Oliveira, Cezar Augusto] Amato Inst Med Avancada, Sao Paulo, Brazil.
   [Cameiro, Vinicius Marques; de Oliveira, Ricardo Santos] Univ Sao Paulo, Univ Hosp, Div Neurosurg, Dept Surg & Anat,Ribeirao Preto Med Sch, Ribeirao Preto, Brazil.
RP Amato, MCM (reprint author), Amato Inst Med Avancada, Sao Paulo, Brazil.
EM amato@neurocirurgia.com
CR Bazan AA, 2018, ARCH ESP UROL, V71, P85
   Ahn Y, 2004, SPINE, V29, pE326, DOI 10.1097/01.BRS.0000134591.32462.98
   Ahn Y, 2013, SPINE, V38, P617, DOI 10.1097/BRS.0b013e318275ca58
   Birkenmaier C, 2013, PAIN PHYSICIAN, V16, P335
   Bozkus H, 2005, SURG ENDOSC, V19, P1652, DOI 10.1007/s00464-005-0159-9
   Busscher I, 2010, EUR SPINE J, V19, P1104, DOI 10.1007/s00586-010-1326-9
   Choi KC, 2016, PAIN PHYSICIAN, V19, pE291
   Dath R, 2007, CLIN BIOMECH, V22, P607, DOI 10.1016/j.clinbiomech.2007.01.014
   Garg B, 2016, J ORTHOP SURG-HONG K, V19, P30
   Goel VK, 2006, J BONE JOINT SURG AM, V88A, P103, DOI 10.2106/JBJS.E.01363
   Kong L, 2019, ORTHOPADE, V48, P157, DOI 10.1007/s00132-018-3610-z
   Lee DY, 2008, NEUROL MED-CHIR, V48, P383, DOI 10.2176/nmc.48.383
   Markovic M, 2016, J NEUROSURG SCI
   McLain Robert F, 2002, Spine (Phila Pa 1976), V27, pE200
   Mladina R, 2018, J CRANIOFAC SURG, V29, P498, DOI 10.1097/SCS.0000000000004208
   Amato MCM, 2018, ACTA CIR BRAS, V33, P1078, DOI 10.1590/s0102-865020180120000005
   Muhlbauer M, 1998, MINIM INVAS NEUROSUR, V41, P1, DOI 10.1055/s-2008-1052005
   Olinger A, 1999, SURG ENDOSC-ULTRAS, V13, P118, DOI 10.1007/s004649900918
   Rasouli MR, 2014, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD010328.PUB2
   Rubino F, 2009, J LAPAROENDOSC ADV S, V10, P309
   Sheng SR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148610
   Sheng SR, 2010, EUR SPINE J, V19, P46, DOI 10.1007/s00586-009-1192-5
   Soliman HM, 2013, EUR SPINE J, V22, P1037, DOI 10.1007/s00586-013-2701-0
   Teli M, 2010, EUR SPINE J, V19, P443, DOI 10.1007/s00586-010-1290-4
   Wang B, 2011, SPINE J, V11, P122, DOI 10.1016/j.spinee.2010.12.006
   Yeung AT, 2002, SPINE, V27, P722, DOI 10.1097/00007632-200204010-00009
   Yingling VR, 1999, J SPINAL DISORD, V12, P415
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 55
EP 61
DI 10.1016/j.wneu.2019.05.199
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900124
PM 31152884
DA 2020-05-12
ER

PT J
AU Ilyas, A
   Chen, CJ
   Ironside, N
   Buell, TJ
   Chagoya, G
   Schmalz, PG
   Stetler, WR
   Andaluz, N
   James, RF
   Ding, D
AF Ilyas, Adeel
   Chen, Ching-Jen
   Ironside, Natasha
   Buell, Thomas J.
   Chagoya, Gustavo
   Schmalz, Philip G.
   Stetler, William R.
   Andaluz, Norberto
   James, Robert F.
   Ding, Dale
TI Medical Management Versus Surgical Bypass for Symptomatic Intracranial
   Atherosclerotic Disease: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bypass; Intracranial atherosclerotic disease; Medical; Review; Stroke
ID SUPERFICIAL TEMPORAL ARTERY; DIABETIC CHINESE PATIENTS;
   CEREBRAL-BLOOD-FLOW; ISCHEMIC-STROKE; INDUCED ANGIOGENESIS;
   RISK-FACTORS; STENOSIS; OCCLUSION; ASSOCIATION; SURGERY
AB INTRODUCTION: Intracranial atherosclerotic disease (ICAD) is a major cause of stroke worldwide. The optimal management of patients with symptomatic ICAD is controversial. Therefore, the aim of this systematic review is to compare medical management versus surgical bypass for the treatment of symptomatic ICAD.
   METHODS: A literature review was performed to identify studies reporting outcomes of patients with ICAD who were managed medically or surgically with either direct or indirect bypass. Baseline, treatment, and outcomes data were analyzed. Complications included ischemic stroke, intracranial hemorrhage, and cerebrovascular death. Secondary analyses of the surgically treated cohort were performed to compare the outcomes of direct versus indirect bypass.
   RESULTS: The pooled analysis was derived from 18 studies, comprising a total of 2160 patients with ICAD, including 1790 managed medically and 370 treated with surgical bypass. The rates of ischemic stroke, intracranial hemorrhage, and cerebrovascular death were 16%, 1%, and 4.5% in the medical cohort, respectively, versus 8%, 0.6%, and 1.9% in the surgical cohort, respectively. Among patients with ICAD who underwent bypass surgery, the rates of ischemic stroke and cerebrovascular death were 7% and 1.9% in the direct bypass group, respectively, versus 19% and 2.1% in the indirect bypass group, respectively.
   CONCLUSIONS: Direct or indirect bypass surgery is a reasonable treatment option for appropriately selected patients with ICAD. Careful preoperative evaluation of hemodynamic parameters and the relevant donor and recipient vessels is crucial to maximizing the success of bypass for ICAD. Further studies remain necessary to clarify the roles of medical versus surgical management for ICAD.
C1 [Ilyas, Adeel; Chagoya, Gustavo; Schmalz, Philip G.; Stetler, William R.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
   [Chen, Ching-Jen; Buell, Thomas J.] Univ Virginia Hlth Syst, Dept Neurol Surg, Charlottesville, VA USA.
   [Ironside, Natasha] Columbia Univ, Med Ctr, Dept Neurosurg, New York Presbyterian, New York, NY USA.
   [Andaluz, Norberto; James, Robert F.; Ding, Dale] Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA.
RP Ilyas, A (reprint author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
EM ailyas@uab.edu
RI Ding, Dale/AAN-3583-2020; Chagoya, Gustavo/S-8172-2019; Chen,
   Ching-Jen/F-5976-2013
OI Chagoya, Gustavo/0000-0002-8337-4467; Chen,
   Ching-Jen/0000-0002-7830-9273
CR ANDREWS BT, 1985, J NEUROSURG, V62, P831, DOI 10.3171/jns.1985.62.6.0831
   Arenillas JF, 2005, STROKE, V36, P92, DOI 10.1161/01.STR.0000149617.65372.5d
   AWAD I, 1984, J NEUROSURG, V60, P771, DOI 10.3171/jns.1984.60.4.0771
   BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904
   Bekavac I, 1999, J Stroke Cerebrovasc Dis, V8, P33, DOI 10.1016/S1052-3057(99)80037-8
   Boyle PJ, 2007, AM J MED, V120, pS12, DOI 10.1016/j.amjmed.2007.07.003
   Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335
   Chimowitz MI, 2005, NEW ENGL J MED, V352, P1305, DOI 10.1056/NEJMoa043033
   Chou CW, 2012, BRIT J NEUROSURG, V26, P823, DOI 10.3109/02688697.2012.690910
   Cui M, 2017, INT J NEUROSCI, V127, P427, DOI 10.1080/00207454.2016.1190716
   Ding D, 2013, BIOMED RES INT, DOI 10.1155/2013/304320
   Ding D, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.3.FOCUS1149
   Gonzalez NR, 2015, J NEUROSURG, V123, P654, DOI 10.3171/2014.10.JNS141426
   Gonzalez NR, 2013, NEUROSURG REV, V36, P175, DOI 10.1007/s10143-012-0432-z
   Harrigan MR, 2018, HDB CEREBROVASCULAR
   Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13
   Kalita J, 2011, DIS MARKERS, V31, P191, DOI [10.3233/DMA-2011-0810, 10.1155/2011/232490]
   Kasner SE, 2006, CIRCULATION, V113, P555, DOI 10.1161/CIRCULATIONAHA.105.578229
   Kass-Hout T, 2016, INTERV NEUROL, V5, P157, DOI 10.1159/000447025
   Katsuda Y, 2007, J ATHEROSCLER THROMB, V14, P19, DOI 10.5551/jat.14.19
   Kern R, 2005, NEUROLOGY, V65, P859, DOI 10.1212/01.wnl.0000175983.76110.59
   Klijn CJM, 1997, STROKE, V28, P2084, DOI 10.1161/01.STR.28.10.2084
   Komotar RJ, 2009, J NEUROSURG, V110, P896, DOI 10.3171/2008.9.JNS17658
   Lee SB, 2013, CLIN NEUROL NEUROSUR, V115, P1238, DOI 10.1016/j.clineuro.2012.11.022
   Ma Y, 2017, WORLD NEUROSURG, V104, P74, DOI 10.1016/j.wneu.2017.04.057
   Massot A, 2013, CEREBROVASC DIS, V35, P81, DOI 10.1159/000346097
   Mazighi M, 2006, NEUROLOGY, V66, P1187, DOI 10.1212/01.wnl.0000208404.94585.b2
   Munshi A, 2012, J NEUROL SCI, V318, P51, DOI 10.1016/j.jns.2012.04.006
   Nahab F, 2008, STROKE, V39, P1039, DOI 10.1161/STROKEAHA.107.499475
   NARIAI T, 1994, STROKE, V25, P1014, DOI 10.1161/01.STR.25.5.1014
   Otsuka M, 2019, ACTA NEUROCHIR, V161, P799, DOI 10.1007/s00701-019-03841-4
   Ovbiagele B, 2006, NEUROLOGY, V66, P1344, DOI 10.1212/01.wnl.0000210530.46058.5c
   Povedano G, 2010, J ENDOVASC THER, V17, P308, DOI 10.1583/09-2975.1
   Qureshi AI, 2014, LANCET, V383, P984, DOI 10.1016/S0140-6736(13)61088-0
   Qureshi AI, 2009, ANN NEUROL, V66, P730, DOI 10.1002/ana.21768
   Sangha RS, 2017, STROKE, V48, P2158, DOI 10.1161/STROKEAHA.116.016254
   SCHMIEDEK P, 1994, J NEUROSURG, V81, P236, DOI 10.3171/jns.1994.81.2.0236
   Schubert GA, 2014, WORLD NEUROSURG, V82, P672, DOI 10.1016/j.wneu.2013.06.010
   Thomas GN, 2004, DIABETES CARE, V27, P1121, DOI 10.2337/diacare.27.5.1121
   Thomas GN, 2003, CEREBROVASC DIS, V16, P217, DOI 10.1159/000071119
   Tsai ST, 2009, J CLIN NEUROSCI, V16, P1013, DOI 10.1016/j.jocn.2008.08.017
   WEINSTEIN PR, 1984, NEUROSURGERY, V15, P787, DOI 10.1227/00006123-198412000-00003
   White H, 2005, CIRCULATION, V111, P1327, DOI 10.1161/01.CIR.0000157736.19739.D0
   White TG, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2018.11.FOCUS18536
   Wong KS, 1998, NEUROLOGY, V50, P812, DOI 10.1212/WNL.50.3.812
   Wong LKS, 2006, INT J STROKE, V1, P158, DOI 10.1111/j.1747-4949.2006.00045.x
   YONAS H, 1993, J NEUROSURG, V79, P483, DOI 10.3171/jns.1993.79.4.0483
   Zaidat OO, 2015, JAMA-J AM MED ASSOC, V313, P1240, DOI 10.1001/jama.2015.1693
   Zechariah A, 2013, ARTERIOSCL THROM VAS, V33, P1561, DOI 10.1161/ATVBAHA.112.300749
NR 49
TC 1
Z9 1
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 62
EP 71
DI 10.1016/j.wneu.2019.05.223
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900125
PM 31158534
DA 2020-05-12
ER

PT J
AU El Asri, AC
   Arnaout, MM
   Gerges, MM
   Gazzaz, M
   El Mostarchid, B
   Schwartz, TH
AF El Asri, Abad Cherif
   Arnaout, Mohamed M.
   Gerges, Mina M.
   Gazzaz, Miloudi
   El Mostarchid, Brahim
   Schwartz, Theodore H.
TI Prognosis Factor in Oculomotor Schwannoma: A Case of Endoscopic
   Endonasal Approach and Systematic Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cavernous sinus; Endoscopic endonasal; Extended approach; Oculomotor
   nerve; Palsy; Schwannoma; Surgery; Transsphenoidal
ID GAMMA-KNIFE SURGERY; NERVE SCHWANNOMA; NONVESTIBULAR SCHWANNOMAS; PALSY;
   MANAGEMENT; CISTERN; TUMOR; MRI
AB BACKGROUND: We report the first case of oculomotor nerve (ON) schwannoma treatment through an endonasal endoscopic approach. We also review the literature to determine prognosis factors of ON function after treatment.
   METHODS: A complete MEDLINE search was undertaken for all articles reporting data for oculomotor schwannoma. We divided the patient population into 2 groups; Group I: patients who conserved or recovered good ON function and Group II: patients with either new, worsening, or unchanged third-nerve palsy at the last available follow-up. We conducted a comparative statistical analysis of data between the 2 groups.
   RESULTS: We identified 55 reported cases of ON schwannoma, all of whom were treated with open transcranial surgery, stereotactic radiosurgery, or observation. There were 22 patients in group I and 33 in group II. At admission, 29 patients had complete oculomotor nerve palsy (34.7% in group I and 67.7% in group II; P = 0.02). Surgical treatment was performed in 36 cases. Radiosurgery was performed in 3 cases. Among patients with good preoperative ON function, 34.6% worsened at last follow-up (26.6% after surgery and 50% with observation; P[0.03). In total, 31% of patients with total or near-total palsy at admission had an improvement of their ON function (all after surgical resection; P = 0.05).
   CONCLUSIONS: ON function at admission and surgical resection of schwannoma appears to be a predictive factor of favorable prognosis regardless of location and tumor size. The endonasal endoscopic approach can be used to biopsy tumors in cases in which open surgery is considered too risky, such as cavernous sinus schwannomas.
C1 [El Asri, Abad Cherif; Arnaout, Mohamed M.; Gerges, Mina M.; Schwartz, Theodore H.] New York Presbyterian Hosp, Dept Neurosurg, Weill Cornell Med, New York, NY 10032 USA.
   [Schwartz, Theodore H.] New York Presbyterian Hosp, Dept Otolaryngol & Neurosci, Weill Cornell Med, New York, NY 10032 USA.
   [El Asri, Abad Cherif; Gazzaz, Miloudi; El Mostarchid, Brahim] Mohamed V Mil Hosp, Dept Neurosurg, Rabat, Morocco.
   [Arnaout, Mohamed M.] Zagazig Univ, Fac Med, Dept Neurosurg, Shargia, Egypt.
   [Gerges, Mina M.] Ain Shams Univ, Fac Med, Dept Neurosurg, Cairo, Egypt.
RP El Asri, AC (reprint author), New York Presbyterian Hosp, Dept Neurosurg, Weill Cornell Med, New York, NY 10032 USA.; El Asri, AC (reprint author), Mohamed V Mil Hosp, Dept Neurosurg, Rabat, Morocco.
EM abad20031@gmail.ocm
RI Schwartz, Theodore/AAK-3320-2020
OI Arnaout, Mohamed/0000-0003-3592-5129
CR Abo-Shasha R, 2018, CAN J OPHTHALMOL, V53, pE167, DOI 10.1016/j.jcjo.2017.12.014
   Amin SM, 2018, ANN OTO RHINOL LARYN, V127, P903, DOI 10.1177/0003489418803386
   Asaoka K, 1999, NEUROSURGERY, V45, P630, DOI 10.1097/00006123-199909000-00039
   Beijani GK, 1997, NEUROCHIRURGIE, V43, P164
   Bisdorff AR, 2006, CEPHALALGIA, V26, P1157, DOI 10.1111/j.1468-2982.2006.01167.x
   Chewning RH, 2008, J NEUROSURG, V108, P1037, DOI 10.3171/JNS/2008/108/5/1037
   Cho Yong-Hwan, 2014, Brain Tumor Res Treat, V2, P43, DOI 10.14791/btrt.2014.2.1.43
   Elsharkawy M, 2012, J NEUROSURG, V116, P66, DOI 10.3171/2011.8.JNS11215
   Fang CB, 2017, JAMA OPHTHALMOL, V135, P23, DOI 10.1001/jamaophthalmol.2016.4456
   Furtado SV, 2012, NEUROSURG REV, V35, P27, DOI 10.1007/s10143-011-0344-3
   Goel A, 2010, ACTA NEUROCHIR, V152, P1721, DOI 10.1007/s00701-010-0690-x
   Hatakeyama H, 2003, NEUROL MED-CHIR, V43, P95, DOI 10.2176/nmc.43.95
   Iijima K, 2014, NEUROL MED-CHIR, V54, P654, DOI 10.2176/nmc.cr2012-0418
   Kachhara R, 1998, ACTA NEUROCHIR, V140, P1147, DOI 10.1007/s007010050229
   Katoh M, 2000, J CLIN NEUROSCI, V7, P458, DOI 10.1054/jocn.1999.0240
   Kauser Hina, 2014, J Ophthalmic Vis Res, V9, P514, DOI 10.4103/2008-322X.150833
   Kawasaki A, 1999, AM J OPHTHALMOL, V128, P658, DOI 10.1016/S0002-9394(99)00242-1
   Kim IY, 2008, J NEUROSURG, V109, P149, DOI 10.3171/JNS/2008/109/12/S23
   Kim R, 2015, CEPHALALGIA, V35, P825, DOI 10.1177/0333102414558886
   Kozic D, 2006, ACTA RADIOL, V47, P595, DOI 10.1080/02841850600690413
   Kumar LP, 2014, J CANCER RES THER, V10, P1098, DOI 10.4103/0973-1482.146111
   Lee D, 2018, INDIAN J OPHTHALMOL, V66, P1367, DOI 10.4103/ijo.IJO_340_18
   Lingawi SS, 2000, CLIN IMAG, V24, P86, DOI 10.1016/S0899-7071(00)00180-7
   Mariniello G, 2018, OPER NEUROSURG, V14, P627, DOI 10.1093/ons/opx174
   Murakami T, 2005, NEUROPEDIATRICS, V36, P395, DOI 10.1055/s-2005-873056
   Nagashima H, 2012, J NEUROSURG-PEDIATR, V9, P165, DOI 10.3171/2011.11.PEDS1192
   Netuka D, 2003, BRIT J NEUROSURG, V17, P168, DOI 10.1080/0268869031000110816
   NIAZI W, 1994, SKULL BASE SURG, V4, P219, DOI 10.1055/s-2008-1058958
   Nonaka Y, 2014, WORLD NEUROSURG, V81, P798, DOI 10.1016/j.wneu.2012.11.067
   Norman AA, 2001, J AAPOS, V5, P9, DOI 10.1067/mpa.2001.112442
   Ohata K, 2006, NEUROL INDIA, V54, P437, DOI 10.4103/0028-3886.28125
   Patrona A, 2017, J NEUROSURG, V126, P880, DOI 10.3171/2015.8.JNS15275
   Peciu-Florianu I, 2017, ACTA NEUROCHIR, V159, P2409, DOI 10.1007/s00701-017-3348-0
   Prabhu Sujit S, 2010, Surg Neurol Int, V1, P15, DOI 10.4103/2152-7806.63910
   Sarma S, 2002, NEUROSURGERY, V50, P437, DOI 10.1097/00006123-200203000-00002
   Scheller C, 2013, J NEUROL SURG PART A, V74, P120, DOI 10.1055/s-0032-1313641
   Senapati SB, 2014, NEUROL INDIA, V62, P548, DOI 10.4103/0028-3886.144459
   Shamim MS, 2008, CAN J NEUROL SCI, V35, P528, DOI 10.1017/S0317167100009288
   Shin RK, 2015, J NEURO-OPHTHALMOL, V35, P139, DOI 10.1097/WNO.0000000000000220
   Suenaga J, 2014, AUSTIN NEUROSURG OPE, V1, P1013
   Tanriover N, 2007, SURG NEUROL, V67, P83, DOI 10.1016/j.surneu.2006.06.012
   Wang QJ, 2013, CLIN IMAG, V37, P947, DOI 10.1016/j.clinimag.2013.06.002
   Yang SS, 2013, PEDIATR NEUROL, V48, P321, DOI 10.1016/j.pediatrneurol.2012.12.012
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 72
EP 80
DI 10.1016/j.wneu.2019.05.170
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900126
PM 31150851
DA 2020-05-12
ER

PT J
AU Neale, N
   Ramayya, A
   Welch, W
AF Neale, Natalie
   Ramayya, Ashwin
   Welch, William
TI Surgical Management of Idiopathic Thoracic Spinal Cord Herniation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brown-Sequard; Cord herniation; Operative video; Surgery; Thoracic spine
AB BACKGROUND: Idiopathic spinal cord herniation is a rare condition that involves spinal cord herniation through a defect in the ventral dura.
   CASE DESCRIPTION: We present a case of a 61-year-old woman who initially presented in 2016 with an approximately 1-year history of burning right lower extremity pain and gait instability. Her neurologic examination was consistent with thoracic BrownLSequard syndrome, and spinal magnetic resonance imaging showed a focal defect in the ventral dura at the superior aspect of T4 with the left aspect of the cord herniating into the defect. In 2018, she underwent a T3-T4 laminectomy with T3 pedicle take down and medial facetectomy, with reduction of the herniated cord.
   CONCLUSIONS: Idiopathic spinal cord herniation is an uncommon spinal cord disorder with a paucity of data reported. Our case report of a classic case of idiopathic spinal cord herniation presenting as BrownLSequard syndrome and managed surgically will contribute to the data in this field.
C1 [Neale, Natalie; Ramayya, Ashwin; Welch, William] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
RP Welch, W (reprint author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.
EM william.welch@uphs.upenn.edu
CR Darbar A, 2006, SPINE, V31, pE600, DOI 10.1097/01.brs.0000229247.69171.a1
   Ellger T, 2006, CLIN NEUROL NEUROSUR, V108, P388, DOI 10.1016/j.clineuro.2004.07.005
   Groen RJM, 2009, NEUROSURGERY, V64, pS145, DOI 10.1227/01.NEU.0000327686.99072.E7
   Haber MD, 2014, RADIOGRAPHICS, V34, P313, DOI 10.1148/rg.342125136
   Hawasli AH, 2014, OPER NEUROSURG, V10, pE498, DOI 10.1227/NEU.0000000000000437
   Ju MW, 2015, J KOREAN NEUROSURG S, V58, P294, DOI 10.3340/jkns.2015.58.3.294
   Najjar MW, 2004, SURG NEUROL, V62, P161, DOI 10.1016/j.surneu.2003.10.030
   Nakamura M, 2011, J ORTHOP SCI, V16, P347, DOI 10.1007/s00776-011-0065-z
   Novak K, 2012, J NEUROSURG-SPINE, V16, P114, DOI 10.3171/2011.10.SPINE11109
   Parmar H, 2008, RADIOGRAPHICS, V28, P511, DOI 10.1148/rg.282075030
   Selviaridis Panagiotis, 2009, Spine J, V9, pe17, DOI 10.1016/j.spinee.2008.03.013
   Singh P, 2011, ANN INDIAN ACAD NEUR, V14, P136, DOI 10.4103/0972-2327.82814
   Summers Johanne C, 2013, Asian J Neurosurg, V8, P97, DOI 10.4103/1793-5482.116386
   Tekkok IH, 2000, NEUROSURGERY, V46, P485, DOI 10.1097/00006123-200002000-00044
   WORTZMAN G, 1974, J NEUROSURG, V41, P631, DOI 10.3171/jns.1974.41.5.0631
NR 15
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 81
EP 84
DI 10.1016/j.wneu.2019.05.219
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900127
PM 31158530
DA 2020-05-12
ER

PT J
AU Roldan, P
   Najarro, R
   Di Somma, A
   Culebras, D
   Hoyos, JA
   Compta, Y
   Camara, A
   Munoz, E
   Marti, MJ
   Valldeoriola, F
   Rumia, J
AF Roldan, Pedro
   Najarro, Rafael
   Di Somma, Alberto
   Culebras, Diego
   Alexander Hoyos, Jhon
   Compta, Yaroslau
   Camara, Ana
   Munoz, Esteban
   Jose Marti, Maria
   Valldeoriola, Francesc
   Rumia, Jordi
TI Malignant Glioma Developed on a Patient Under Deep Brain Stimulation:
   Pitfalls in Management
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Deep brain stimulation; Dystonia; Neuroimaging;
   Neurostimulation
ID GLIOBLASTOMA; RELIABILITY; SCALE
AB BACKGROUND: Glioblastoma (GBM) is the most common aggressive malignant primary brain tumor, rarely concurrent in patients who require deep brain stimulation (DBS) implants. Despite the high incidence of these circumstances alone, the coexistence of both in a patient has been seldom reported. In this paper, we report a case of a patient suffering from a movement disorder treated with DBS who developed a GBM.
   CASE DESCRIPTION: A patient with bilateral DBS of the globus pallidus internus for refractory secondary dystonia developed a GBM close to the electrode leads, 2.5 years after implantation. The clinical findings, medical management and pitfalls, and possible relationship between the DBS device and the tumor development are discussed. We withdrew the system to perform brain magnetic resonance imaging safely. This revealed an extended lesion that was biopsied. The removal led to a clinical worsening that resulted in fatality, without the possibility of receiving adjuvant treatment. The available literature shows similar management, which depends mainly on the stimulation system used.
   CONCLUSIONS: We advise the use of magnetic resonance imaging-safe devices; otherwise, we recommend keeping the system and proceeding with computed tomography imaging for diagnostic and management if necessary. The true relationship between chronic DBS stimulation and GBM is to be clarified.
C1 [Roldan, Pedro; Najarro, Rafael; Di Somma, Alberto; Culebras, Diego; Alexander Hoyos, Jhon; Rumia, Jordi] Univ Barcelona, Hosp Clin Barcelona, ICN, Dept Neurol Surg, Barcelona, Spain.
   [Roldan, Pedro; Compta, Yaroslau; Camara, Ana; Munoz, Esteban; Jose Marti, Maria; Valldeoriola, Francesc; Rumia, Jordi] Univ Barcelona, Inst Neurociencies, Parkinsons Dis & Movement Disorders Unit, Neurol Dept,Hosp Clin Barcelona,IDIBAPS, Barcelona, Spain.
RP Di Somma, A (reprint author), Univ Barcelona, Hosp Clin Barcelona, ICN, Dept Neurol Surg, Barcelona, Spain.
EM albertodisomma87@gmail.com
RI Di Somma, Alberto/AAG-5690-2020; ARBOIX, JORDI RUMIA/AAA-3408-2019;
   Roldan, Pedro/AAA-2827-2019
OI Di Somma, Alberto/0000-0002-3253-3448; ARBOIX, JORDI
   RUMIA/0000-0002-8755-8124; 
CR American Society for Testing and Materials (ASTM) International, 2005, STAND PRACT MARK MED
   BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344
   BURKE RE, 1985, NEUROLOGY, V35, P73, DOI 10.1212/WNL.35.1.73
   Fahn S, 2011, MOVEMENT DISORD, V26, P947, DOI 10.1002/mds.23759
   Krystkowiak P, 2007, MOVEMENT DISORD, V22, P685, DOI 10.1002/mds.21392
   Mindermann T, 2016, ACTA NEUROCHIR, V158, P915, DOI 10.1007/s00701-016-2773-9
   Nirenberg MJ, 2013, CURRENT CLIN NEUROLO, P125
   Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319
   Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158
   Yamamoto T, 2016, STEREOT FUNCT NEUROS, V94, P320, DOI 10.1159/000448925
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 85
EP 89
DI 10.1016/j.wneu.2019.05.234
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900128
PM 31158542
DA 2020-05-12
ER

PT J
AU Mooney, J
   Bemstock, JD
   Ilyas, A
   Ibrahim, A
   Yamashita, D
   Markert, JM
   Nakano, L
AF Mooney, James
   Bemstock, Joshua D.
   Ilyas, Adeel
   Ibrahim, Ahmed
   Yamashita, Daisuke
   Markert, James M.
   Nakano, Lchiro
TI Current Approaches and Challenges in the Molecular Therapeutic Targeting
   of Glioblastoma
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chimeric antigen receptor (CAR) T cell; Dendritic/tumor vaccination;
   Experimental therapeutics; Glioblastoma (GBM); Glioma stem cells (GSCs);
   Tumor heterogeneity; Virotherapy
ID CHIMERIC ANTIGEN RECEPTOR; HERPES-SIMPLEX VIRUS-1; BLOOD-BRAIN-BARRIER;
   RECURRENT GLIOBLASTOMA; STEM-CELLS; ACQUIRED-RESISTANCE; MALIGNANT
   GLIOMAS; MISMATCH REPAIR; TEMOZOLOMIDE; BEVACIZUMAB
AB Surgical resection continues to predominate as the primary treatment modality in glioblastoma (GBM). Effective chemotherapeutic/biologic agents capable of targeting GBM have yet to be developed in part because of the exceptionally heterogeneous nature and unique microenvironmental conditions associated with this malignant neoplasm. Temozolomide and bevacizumab represent the only U.S. Food and Drug Administrationeapproved agents for primary and recurrent GBM, respectively. Given the high therapeutic resistance of GBM to current therapies, as well as the failure of bevacizumab to prolong overall survival, new therapeutic agents are urgently warranted and are now in the preclinical and clinical phases of development. Accordingly, clinical trials evaluating the efficacy of immune checkpoint inhibition, chimeric antigen receptor T cell therapy, virotherapies, and tumor vaccination therapy are all under way in GBM. Herein, we review the application of current/novel therapeutics in GBM and in so doing attempt to highlight the most promising solutions to overcome current failures.
C1 [Mooney, James; Bemstock, Joshua D.; Ilyas, Adeel; Ibrahim, Ahmed; Yamashita, Daisuke; Markert, James M.; Nakano, Lchiro] Univ Alabama Birmingham, Comprehens Canc Ctr, Dept Neurosurg, Birmingham, AL 35294 USA.
   [Bemstock, Joshua D.] Univ Alabama Birmingham, Comprehens Canc Ctr, Dept Neurosurg, Med Scientist Training Program, Birmingham, AL USA.
RP Nakano, L (reprint author), Univ Alabama Birmingham, Comprehens Canc Ctr, Dept Neurosurg, Birmingham, AL 35294 USA.
EM inakano@uabmc.edu
OI Bernstock, Joshua/0000-0002-7814-3867; Yamashita,
   Daisuke/0000-0002-5829-7287
FU NIH/National Cancer Institute (NCI)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [P01 CA163205, R21 CA175875]; NIH/National
   Institute of Neurological Disorders and Stroke (NINDS)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [R01 NS083767, R01 NS087913]; University of Alabama Medical Scientist
   Training Program (MSTP)
FX This work was supported by NIH/National Cancer Institute (NCI) grants
   P01 CA163205 and R21 CA175875 and NIH/National Institute of Neurological
   Disorders and Stroke (NINDS) grants R01 NS083767 and R01 NS087913, to
   I.N. In addition, J.D.B. is supported by the University of Alabama
   Medical Scientist Training Program (MSTP). J.D.B. has positions/equity
   in CITC Ltd. and Avidea Technologies.
CR Abiko K, 2015, BRIT J CANCER, V112, P1501, DOI 10.1038/bjc.2015.101
   Ahmed AU, 2013, JNCI-J NATL CANCER I, V105, P968, DOI 10.1093/jnci/djt141
   Ahmed MS, 2014, CLIN EXP VACCINE RES, V3, P113, DOI 10.7774/cevr.2014.3.2.113
   Ahmed N, 2017, JAMA ONCOL, V3, P1094, DOI 10.1001/jamaoncol.2017.0184
   Alonso A, 2014, ANN NEUROSCI, V21, P22, DOI 10.5214/ans.0972.7531.210107
   An ZY, 2018, ONCOGENE, V37, P1561, DOI 10.1038/s41388-017-0045-7
   Bach PB, 2017, JAMA-J AM MED ASSOC, V318, P1861, DOI 10.1001/jama.2017.15218
   Belcaid Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101764
   Benencia F, 2008, CANCER BIOL THER, V7, P1194, DOI 10.4161/cbt.7.8.6216
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bernstock JD, 2020, CANCER GENE THER, V27, P246, DOI 10.1038/s41417-019-0091-0
   Boussiotis VA, 2018, ONCOGENE, V37, P1121, DOI 10.1038/s41388-017-0024-z
   Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497
   Brown CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077769
   Brown CE, 2012, CLIN CANCER RES, V18, P2199, DOI 10.1158/1078-0432.CCR-11-1669
   Brown MC, 2015, CURR OPIN VIROL, V13, P81, DOI 10.1016/j.coviro.2015.05.007
   Burger MC, 2017, ONCOL REP, V38, P3291, DOI 10.3892/or.2017.6013
   Burris HA, 2013, CANCER CHEMOTH PHARM, V71, P829, DOI 10.1007/s00280-012-2043-3
   Carruthers Ross, 2012, CNS Oncol, V1, P85, DOI 10.2217/cns.12.13
   Chinot OL, 2016, NEURO-ONCOLOGY, V18, P1313, DOI 10.1093/neuonc/now046
   Chinot OL, 2014, NEW ENGL J MED, V370, P2049, DOI 10.1056/NEJMc1403303
   Chiocca EA, 2019, NEURO-ONCOLOGY, V21, P14, DOI 10.1093/neuonc/noy170
   Chiocca EA, 2014, CANCER IMMUNOL RES, V2, P295, DOI 10.1158/2326-6066.CIR-14-0015
   Choi BD, 2019, CLIN CANCER RES, V25, P2042, DOI 10.1158/1078-0432.CCR-18-1625
   Choi BD, 2014, J CLIN NEUROSCI, V21, P189, DOI 10.1016/j.jocn.2013.03.012
   Chongsathidkiet P, 2018, NAT MED, V24, P1459, DOI 10.1038/s41591-018-0135-2
   CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860
   CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247
   Clark PA, 2012, NEOPLASIA, V14, P420, DOI 10.1596/neo.12432
   Cloughesy TF, 2019, NAT MED, V25, P477, DOI 10.1038/s41591-018-0337-7
   Cohen MH, 2012, ONCOLOGIST, V17, P1482, DOI 10.1634/theoncologist.2009-0121erratum
   Conry RM, 2018, HUM VACC IMMUNOTHER, V14, P839, DOI 10.1080/21645515.2017.1412896
   Dahiya S, 2014, NEURO-ONCOLOGY, V16, P318, DOI 10.1093/neuonc/not146
   De Felice F, 2017, CURR CANCER DRUG TAR, V17, P282, DOI 10.2174/1568009616666160813183738
   Desjardins A, 2018, NEW ENGL J MED, V379, P150, DOI 10.1056/NEJMoa1716435
   Dotti G, 2014, IMMUNOL REV, V257, P107, DOI 10.1111/imr.12131
   Fecci PE, 2007, CLIN CANCER RES, V13, P2158, DOI 10.1158/1078-0432.CCR-06-2070
   Friedman GK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32353-x
   Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721
   Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652
   Garzon-Muvdi Tomas, 2018, Oncotarget, V9, P20681, DOI 10.18632/oncotarget.25061
   Gil-Gil MJ, 2013, CLIN MED INSIGHTS-ON, V7, P123, DOI 10.4137/CMO.S8503
   Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573
   Goetz C, 2011, FUTURE VIROL, V6, P1045, DOI 10.2217/FVL.11.76
   Gromeier M, 2018, ANNU REV MED, V69, P289, DOI 10.1146/annurev-med-050715-104655
   Guo YG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01499
   Herrlinger U, 2019, LANCET, V393, P678, DOI 10.1016/S0140-6736(18)31791-4
   Hodges TR, 2017, NEURO-ONCOLOGY, V19, P1047, DOI 10.1093/neuonc/nox026
   Hu JL, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.e13010
   Hung AL, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1466769
   Jan CI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00727
   Johnson LA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4963
   Kaley T, 2018, J CLIN ONCOL, V36, P3477, DOI 10.1200/JCO.2018.78.9990
   Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9
   Khagi Y, 2017, CANCER METAST REV, V36, P179, DOI 10.1007/s10555-016-9652-y
   Kohsaka S, 2012, MOL CANCER THER, V11, P1289, DOI 10.1158/1535-7163.MCT-11-0801
   Ladomersky E, 2018, CLIN CANCER RES, V24, P2559, DOI 10.1158/1078-0432.CCR-17-3573
   Lang FF, 2018, J CLIN ONCOL, V36, P1419, DOI 10.1200/JCO.2017.75.8219
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734
   Lee JK, 2017, NAT GENET, V49, P594, DOI 10.1038/ng.3806
   Lesueur P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22022-4
   Li MH, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-21
   Li XM, 2016, ONCOTARGET, V7, P33440, DOI [10.18632/oncotarget.7961, 10.18632/oncotarget.6497]
   Liang SC, 2003, EUR J IMMUNOL, V33, P2706, DOI 10.1002/eji.200324228
   Liu HL, 2010, RADIOLOGY, V255, P415, DOI 10.1148/radiol.10090699
   Lynn GM, 2015, NAT BIOTECHNOL, V33, P1201, DOI 10.1038/nbt.3371
   Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110
   Markert JM, 2014, MOL THER, V22, P1048, DOI 10.1038/mt.2014.22
   Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228
   Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205
   Martin-Orozco N, 2006, J IMMUNOL, V177, P8291, DOI 10.4049/jimmunol.177.12.8291
   MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332
   Mellai M, 2008, ANTICANCER RES, V28, P109
   Merrill MK, 2004, NEURO-ONCOLOGY, V6, P208, DOI 10.1215/S1152851703000577
   Messaoudi K, 2015, DRUG DISCOV TODAY, V20, P899, DOI 10.1016/j.drudis.2015.02.011
   Miao H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093755
   Miller DS, 2008, PHARMACOL REV, V60, P196, DOI 10.1124/pr.107.07109
   MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938
   Naidoo J, 2015, ANN ONCOL, V26, P2375, DOI 10.1093/annonc/mdv383
   Nduom EK, 2015, NEURO-ONCOLOGY, V17, P9, DOI 10.1093/neuonc/nov151
   Ohno M, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-21
   Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319
   Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991
   Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517
   Passaro C, 2019, CLIN CANCER RES, V25, P290, DOI 10.1158/1078-0432.CCR-18-2311
   Perry JR, 2017, NEW ENGL J MED, V376, P1027, DOI 10.1056/NEJMoa1611977
   Piao Y, 2013, CLIN CANCER RES, V19, P4392, DOI 10.1158/1078-0432.CCR-12-1557
   Platten M, 2016, CANCER IMMUNOL IMMUN, V65, P1269, DOI 10.1007/s00262-016-1874-x
   Prins RM, 2011, CLIN CANCER RES, V17, P1603, DOI 10.1158/1078-0432.CCR-10-2563
   Reardon DA, 2008, EXPERT OPIN BIOL TH, V8, P541, DOI [10.1517/14712598.8.4.541, 10.1517/14712598.8.4.541 ]
   Reardon DA, 2018, CANCER-AM CANCER SOC, V124, P1438, DOI 10.1002/cncr.31172
   Reardon DA, 2016, CANCER IMMUNOL RES, V4, P124, DOI 10.1158/2326-6066.CIR-15-0151
   Sampson J, 2015, NEUROONCOL S5, V17, pv107
   Sampson JH, 2008, SEMIN IMMUNOL, V20, P267, DOI 10.1016/j.smim.2008.04.001
   Samson A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7577
   Schaff LR, 2014, NEURO-ONCOLOGY, V16, DOI 10.1093/neuonc/nou255.50
   Schalper KA, 2019, NAT MED, V25, P470, DOI 10.1038/s41591-018-0339-5
   Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013
   Singer E, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.566
   Sonabend AM, 2008, STEM CELLS, V26, P831, DOI 10.1634/stemcells.2007-0758
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Tabet A, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801391
   Tamura R, 2017, BRAIN TUMOR PATHOL, V34, P62, DOI 10.1007/s10014-017-0284-x
   Tawbi HA, 2018, NEW ENGL J MED, V379, P722, DOI 10.1056/NEJMoa1805453
   Thaci B, 2014, NEURO-ONCOLOGY, V16, P1304, DOI 10.1093/neuonc/nou045
   Topalian SL, 2012, CURR OPIN IMMUNOL, V24, P207, DOI 10.1016/j.coi.2011.12.009
   van Tellingen O, 2015, DRUG RESIST UPDATE, V19, P1, DOI 10.1016/j.drup.2015.02.002
   van Thuijl HF, 2015, ACTA NEUROPATHOL, V129, P597, DOI 10.1007/s00401-015-1403-6
   Vatner RE, 2015, SEMIN RADIAT ONCOL, V25, P18, DOI 10.1016/j.semradonc.2014.07.008
   Wang JG, 2016, NAT GENET, V48, P768, DOI 10.1038/ng.3590
   Weller M, 2013, NEURO-ONCOLOGY, V15, P4, DOI 10.1093/neuonc/nos273
   Westphal M, 2003, NEURO-ONCOLOGY, V5, P79, DOI 10.1215/15228517-5-2-79
   Wiendl H, 2003, FASEB J, V17, P1892, DOI 10.1096/fj.03-0039fje
   Xu QJ, 2009, STEM CELLS, V27, P1734, DOI 10.1002/stem.102
   Yu SN, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0444-9
   Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311
   Zeng J, 2013, INT J RADIAT ONCOL, V86, P343, DOI 10.1016/j.ijrobp.2012.12.025
   Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932
   Zhai LJ, 2015, J NEURO-ONCOL, V123, P395, DOI 10.1007/s11060-014-1687-8
   Zhang CC, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv375
   Zhang GB, 2012, J CLIN NEUROSCI, V19, P1636, DOI 10.1016/j.jocn.2011.12.028
   Zhao J, 2019, NAT MED, V25, P462, DOI 10.1038/s41591-019-0349-y
NR 123
TC 4
Z9 4
U1 9
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 90
EP 100
DI 10.1016/j.wneu.2019.05.205
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900129
PM 31152883
DA 2020-05-12
ER

PT J
AU Schwartz, C
   Jahromi, BR
   Hafez, A
   Numminen, J
   Lehecka, M
   Niemela, M
AF Schwartz, Christoph
   Jahromi, Behnam Rezai
   Hafez, Ahmad
   Numminen, Jussi
   Lehecka, Martin
   Niemela, Mika
TI Mirror Distal Anterior Cerebral Artery Aneurysms in a Patient with
   Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coil embolization; Distal anterior cerebral artery aneurysms;
   Endovascular treatment; Intracerebral hemorrhage; Mirror aneurysms;
   Outcome; Subarachnoid hemorrhage
AB BACKGROUND: Mirror distal anterior cerebral artery aneurysms (DACAAs) are a rare finding in patients with subarachnoid hemorrhage, with only a few cases reported.
   CASE DESCRIPTION: A 40-year-old man was admitted for sudden-onset headache, nausea and vomiting, and transient right arm hypoesthesia. Computed tomography scan showed a subarachnoid hemorrhage with intracerebral hemorrhage within the interhemispheric fissure, but computed tomography angiography failed to identify any aneurysms. Subsequent digital subtraction angiography with three-dimensional reconstructions revealed 1.5-mm-diameter mirror DACAAs on the A3 segments. However, the definite rupture site remained unidentifiable. After interdisciplinary consultation, endovascular treatment was favored, and complete occlusion of both DACAAs was achieved by coiling without stent placement. During coiling of the right DACAA, a thrombus in the right callosomarginal artery formed, and treatment with abciximab (ReoPro) was initiated to dissolve the thrombus. After treatment, the patient presented with right leg paresis; however, computed tomography did not show any ischemia, intracerebral hemorrhage increase, or vasospasm. Over the following days, the leg paresis improved, and the patient achieved increased mobilization. He was transferred for further rehabilitation 16 days after hemorrhage. The leg paresis had recovered to a grade 3/5.
   CONCLUSIONS: Rapid identification of the rupture site in patients with subarachnoid hemorrhage and multiple aneurysms is crucial for initiating optimal treatment. In patients with mirror aneurysms in close proximity to each other, this is not easily accomplished, complicating treatment decisions. Although clipping has been the standard for DACAA occlusion, coiling should be taken into consideration as a viable alternative.
C1 [Schwartz, Christoph; Jahromi, Behnam Rezai; Hafez, Ahmad; Lehecka, Martin; Niemela, Mika] Univ Helsinki, Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland.
   [Numminen, Jussi] Univ Helsinki, Helsinki Univ Hosp, Dept Neuroradiol, Helsinki, Finland.
   [Schwartz, Christoph] Paracelsus Med Univ, Univ Hosp Salzburg, Dept Neurosurg, Salzburg, Austria.
RP Schwartz, C (reprint author), Univ Helsinki, Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland.; Schwartz, C (reprint author), Paracelsus Med Univ, Univ Hosp Salzburg, Dept Neurosurg, Salzburg, Austria.
EM ext-christoph.schwartz@hus.fi
OI Lehecka, Martin/0000-0003-4088-1116; Rezai Jahromi,
   Behnam/0000-0003-3937-2816
CR Bhogal P, 2018, Surg Neurol Int, V9, P1, DOI 10.4103/sni.sni_339_17
   Choudhari KA, 2004, BRIT J NEUROSURG, V18, P253, DOI 10.1080/02688690410001732698
   Dashti R, 2007, SURG NEUROL, V67, P441, DOI 10.1016/j.surneu.2006.11.056
   de Sousa AA, 1999, SURG NEUROL, V52, P128, DOI 10.1016/S0090-3019(99)00066-X
   Ellamushi HE, 2001, J NEUROSURG, V94, P728, DOI 10.3171/jns.2001.94.5.0728
   Endo H, 2005, SURG NEUROL, V64, P135, DOI 10.1016/j.surneu.2004.12.019
   GREENE KA, 1995, NEUROLOGY, V45, P45, DOI 10.1212/WNL.45.1.45
   INAGAWA T, 1990, ACTA NEUROCHIR, V106, P119, DOI 10.1007/BF01809453
   Lehecka M, 2008, NEUROSURGERY, V62, P590, DOI 10.1227/01.neu.0000317307.16332.03
   Mizunari T, 2011, J NIPPON MED SCH, V78, P178, DOI 10.1272/jnms.78.178
   MORI T, 1995, SURG NEUROL, V43, P497, DOI 10.1016/0090-3019(95)80097-Z
   Proust F, 1997, STROKE, V28, P2405, DOI 10.1161/01.STR.28.12.2405
   Singh Saraj K, 2018, Surg Neurol Int, V9, P80, DOI 10.4103/sni.sni_478_17
   Sousa J, 2002, ACTA NEUROCHIR, V144, P933, DOI 10.1007/s00701-002-0986-6
   Steven DA, 2007, NEUROSURGERY, V60, P227, DOI 10.1227/01.NEU.0000249267.33945.E7
NR 15
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 101
EP 104
DI 10.1016/j.wneu.2019.05.259
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900130
PM 31176835
DA 2020-05-12
ER

PT J
AU Khatri, D
   Gosal, JS
   Joseph, J
   Das, KK
   Bhaisora, KS
   Kumar, R
AF Khatri, Deepak
   Gosal, Jaskaran S.
   Joseph, Jeena
   Das, Kuntal Kanti
   Bhaisora, Kamlesh Singh
   Kumar, Raj
TI Surgical Outcome in an Iniencephaly Survivor: Case Report and Review of
   the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Encephalocele; Iniencephaly; Outcome; Surgery; Survivors
ID LONG-TERM SURVIVAL; DIAGNOSIS; FEATURES
AB BACKGROUND: Iniencephaly is an extremely rare congenital neural tube defect (NTD) involving the occipital region with rachischisis of the cervico-thoracic spine and fixed retroflexion deformity of the head. It affects an estimated 0.1-10 out of 10,000 pregnancies and carries a dismal prognosis. Most affected children are either stillborn or perish within a few hours of delivery. Pathological and postmortem studies of iniencephaly significantly outnumber the limited amount of literature available on patients surviving with this disorder. To date, surgical repair has been attempted in only 3 of the 8 patients with iniencephaly who have survived long-term. Thus, a huge knowledge gap remains regarding the neurosurgical nuances and postsurgical outcomes in iniencephaly.
   CASE DESCRIPTION: A 4-year-old girl presented with soft, fluctuant swelling in the suboccipital region and was subsequently diagnosed with iniencephaly. She underwent a successful surgical repair of the encephalocele with dural plication. No recurrence of swelling or new neurologic deficits were noted at a 1-year follow-up.
   CONCLUSION: Iniencephaly is a complex NTD associated with high perinatal mortality that requires a vigilant antenatal diagnosis. Surgical repair may be attempted in the lucky few survivors after a thorough evaluation of the anomaly.
C1 [Khatri, Deepak; Gosal, Jaskaran S.; Joseph, Jeena; Das, Kuntal Kanti; Bhaisora, Kamlesh Singh; Kumar, Raj] Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
RP Das, KK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
EM drkuntalkantidas@gmail.com
CR Amiri RS, 2010, PEDIATR NEUROSURG, V46, P290, DOI 10.1159/000320145
   Balci S, 2001, PRENATAL DIAG, V21, P558, DOI 10.1002/pd.97
   Chikkannaiah P, 2014, J NEUROSCI RURAL PRA, V5, P389, DOI 10.4103/0976-3147.139994
   Erdincler P, 1998, J NEUROSURG, V89, P317, DOI 10.3171/jns.1998.89.2.0317
   GARTMAN JJ, 1991, J NEUROSURG, V75, P126, DOI 10.3171/jns.1991.75.1.0126
   Aytar MH, 2007, CHILD NERV SYST, V23, P719, DOI 10.1007/s00381-007-0309-6
   Khatami A, 2015, IRAN J RADIOL, V12, DOI 10.5812/iranjradiol.4790v2
   Kulkarni PR, 2011, J PEDIATR NEUROSCI, V6, P121, DOI 10.4103/1817-1745.92831
   Lewis HL, 1897, AM J OBSTET, V35, P11
   Pungavkar SA, 2007, KOREAN J RADIOL, V8, P351, DOI 10.3348/kjr.2007.8.4.351
   Saint-Hilaire IG, 1836, HIST ANOMALIES ORG, V2, P308
NR 11
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 105
EP 109
DI 10.1016/j.wneu.2019.05.202
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900131
PM 31150861
DA 2020-05-12
ER

PT J
AU Fiorenza, V
   Ascanio, F
AF Fiorenza, Vito
   Ascanio, Francesco
TI Safety and Efficacy of Posterior Atlanto-Axial Stabilization Using
   Intraoperative Navigation System with Preoperative Computed Tomographic
   Scan
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D intraoperative imaging; Atlanto-axial joint; Atlanto-occipital joint;
   Axis; Cervical atlas; Cervical; Neuro-navigation; Spine
ID TRANSARTICULAR SCREW FIXATION; VERTEBRAL ARTERY; FUSION; GROOVE; AXIS;
   PLACEMENT; ACCURACY
AB BACKGROUND: Surgical approaches for posterior C1-C2 arthrodesis, such as C1-C2 transarticular and C1-C2 screw stabilization, are known to be demanding because of the anatomic close proximity of cervical vertebrae to neurovascular structures. Currently, navigation by fluoroscopy or intraoperative computed tomography (ICT) is the standard practice. However, fluoroscopy has various limitations, and ICT is time consuming and not available in many centers; furthermore, both diagnostic tools lead to exposure of the operating room staff to radiation exposure. We evaluate the safety, efficacy, and facility of a navigation system using only preoperative cervical computed tomography and computed tomographic angiography (CT/CTA), to prevent the risk of neurovascular damage in atlantoaxial stabilization.
   METHODS: The authors report a series of 21 patients who underwent posterior upper cervical spine fixation using a navigation system with intraoperative single-level vertebral registration on preoperative cervical CT/CTA (software BrainLab IPlan Spine 3.0). Intraoperative and postoperative comparative analysis was performed to verify the correspondence between the virtual anatomic position of the surgical instruments and screws represented on the neuronavigator, and the actual positions verified intraoperatively and on postoperative CT.
   RESULTS: Thirteen patients underwent C1-C2 arthrodesis with a Harms construct, 1 patient with transarticular screw fixation and 4 patients with occipitocervical stabilization. Three patients underwent C1-C2-C3 stabilization with C1 hooks, C2-C3 screws, and rod construct. On postoperative CT, the position of all screws appeared satisfactory. No neurovascular damage occurred in any patients.
   CONCLUSIONS: The use of a neuronavigation system, based on preoperative acquired cervical CT and intraoperative single-vertebra registration, may provide a valuable support for the improvement of the surgical accuracy of posterior C1-C2 screw fixation.
C1 [Fiorenza, Vito; Ascanio, Francesco] ARNAS Civ Di Cristina Benfratelli Hosp, Neurosurg Dept, Palermo, Italy.
RP Fiorenza, V (reprint author), ARNAS Civ Di Cristina Benfratelli Hosp, Neurosurg Dept, Palermo, Italy.
EM vito.fiorenza1@gmail.com
OI Fiorenza, Vito/0000-0002-0981-4639
CR AbouMadawi A, 1997, J BONE JOINT SURG BR, V79B, P820
   Alosh H, 2010, J SPINAL DISORD TECH, V23, P9, DOI 10.1097/BSD.0b013e318194e746
   BROOKS AL, 1978, J BONE JOINT SURG AM, V60, P279, DOI 10.2106/00004623-197860030-00001
   Elliott RE, 2013, WORLD NEUROSURG, V80, P627, DOI 10.1016/j.wneu.2012.03.012
   Fried L C, 1973, J Bone Joint Surg Br, V55, P490
   Gallie WE, 1939, AM J SURG, V46, P495, DOI DOI 10.1016/S0002-9610(39)90309-0
   Goel A, 2005, NEUROL INDIA, V53, P280, DOI 10.4103/0028-3886.16922
   GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872
   Haher TR, 1999, SPINE, V24, P5, DOI 10.1097/00007632-199901010-00003
   Harms J, 2001, SPINE, V26, P2467, DOI 10.1097/00007632-200111150-00014
   Igarashi T, 2003, CLIN ORTHOP RELAT R, P162, DOI 10.1097/01.blo.0000048136.30533.4f
   Kazan S, 2000, CLIN ANAT, V13, P237, DOI 10.1002/1098-2353(2000)13:4<237::AID-CA2>3.0.CO;2-K
   Kosmopoulos V, 2007, SPINE, V32, pE111, DOI 10.1097/01.brs.0000254048.79024.8b
   Kotani Y, 2003, J NEUROSURG, V99, P257, DOI 10.3171/spi.2003.99.3.0257
   Kuroki Hiroshi, 2005, Neurosurgery, V56, P151
   Lall R, 2010, NEUROSURGERY, V67, P1396, DOI 10.1227/NEU.0b013e3181f1ec73
   Lu JK, 1998, SPINE, V23, P1229, DOI 10.1097/00007632-199806010-00011
   Magerl F, 1987, CERVICAL SPINE, P322, DOI DOI 10.1007/978-3-7091-8882-8_59
   Mandel IM, 2000, SPINE, V25, P1542, DOI 10.1097/00007632-200006150-00014
   Melcher RP, 2002, SPINE, V27, P2435, DOI 10.1097/00007632-200211150-00004
   Mueller CA, 2010, EUR SPINE J, V19, P809, DOI 10.1007/s00586-010-1291-3
   Naderi S, 1998, SPINE, V23, P1946, DOI 10.1097/00007632-199809150-00005
   Oda I, 1999, SPINE, V24, P2377, DOI 10.1097/00007632-199911150-00015
   Ogihara N, 2010, WORLD NEUROSURG, V73, P722, DOI 10.1016/j.wneu.2010.02.067
   Paramore CG, 1996, J NEUROSURG, V85, P221, DOI 10.3171/jns.1996.85.2.0221
   SIMMONS EH, 1978, ORTHOP CLIN N AM, V9, P1101
   Vaccaro AR, 1999, ORTHOPEDICS, V22, P1165, DOI 10.3928/0147-7447-19991201-10
   Yamazaki M, 2012, SPINE, V37, pE1389, DOI 10.1097/BRS.0b013e31826a0c9f
   Yeom JS, 2008, SPINE, V33, pE942, DOI 10.1097/BRS.0b013e3181870441
NR 29
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 110
EP 119
DI 10.1016/j.wneu.2019.05.242
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900132
PM 31170507
DA 2020-05-12
ER

PT J
AU Desai, VR
   Sadrameli, SS
   Hoppe, S
   Lee, JJ
   Jenson, A
   Steele, WJ
   Nguyen, H
   McDonagh, DL
   Britz, GW
AF Desai, Virendra R.
   Sadrameli, Saeed S.
   Hoppe, Szymon
   Lee, Jonathan J.
   Jenson, Amanda
   Steele, William J., III
   Nguyen, Huong
   McDonagh, David L.
   Britz, Gavin W.
TI Contemporary Management of Increased Intraoperative Intracranial
   Pressure: Evidence-Based Anesthetic and Surgical Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain bulk; Brain edema; Brain swelling; Cerebral edema; Cerebral
   swelling; Intracranial pressure
ID CEREBRAL-BLOOD-FLOW; HYPERTONIC SALINE; CEREBROSPINAL-FLUID; BRAIN
   RELAXATION; NITROUS-OXIDE; DECOMPRESSIVE HEMICRANIECTOMY;
   PHARMACOLOGICAL-TREATMENT; SUBARACHNOID HEMORRHAGE; PROPOFOL-FENTANYL;
   RISK-FACTORS
AB Increased intracranial pressure (ICP) is frequently encountered in the neurosurgical setting. A multitude of tactics exists to reduce ICP, ranging from patient position and medications to cerebrospinal fluid diversion and surgical decompression. A vast amount of literature has been published regarding ICP management in the critical care setting, but studies specifically tailored toward the management of intraoperative acute increases in ICP or brain bulk are lacking. Compartmentalizing the intracranial space into blood, brain tissue, and cerebrospinal fluid and understanding the numerous techniques available to affect these individual compartments can guide the surgical team to quickly identify increased brain bulk and respond appropriately. Rapidly instituting measures for brain relaxation in the operating room is essential in optimizing patient outcomes. Knowledge of the efficacy, rapidity, feasibility, and risks of the various available interventions can aid the team to properly tailor their approach to each individual patient. In this article, we present the first evidence-based review of intraoperative management of ICP and brain bulk.
C1 [Desai, Virendra R.; Sadrameli, Saeed S.; Hoppe, Szymon; Lee, Jonathan J.; Jenson, Amanda; Steele, William J., III; Britz, Gavin W.] Houston Methodist Hosp, Dept Neurosurg, Houston, TX 77030 USA.
   [Hoppe, Szymon] Med Univ Gdansk, Gdansk, Poland.
   [Nguyen, Huong; McDonagh, David L.] Univ Texas Southwestern, Dept Anesthesiol, Dallas, TX USA.
   [Nguyen, Huong; McDonagh, David L.] Univ Texas Southwestern, Dept Neurol Surg, Dallas, TX USA.
   [Nguyen, Huong; McDonagh, David L.] Univ Texas Southwestern, Dept Neurol, Dallas, TX USA.
RP Desai, VR (reprint author), Houston Methodist Hosp, Dept Neurosurg, Houston, TX 77030 USA.
EM vrdesai@houstonmethodist.org
CR ALBANESE J, 1993, ANESTHESIOLOGY, V79, P493, DOI 10.1097/00000542-199309000-00012
   Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050
   Alnemari AM, 2017, WORLD NEUROSURG, V106, P509, DOI 10.1016/j.wneu.2017.07.009
   Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581
   Asehnoune K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1918-4
   Balak N, 2014, BRIT J NEUROSURG, V28, P98, DOI 10.3109/02688697.2013.815324
   Biousse V, 1999, NEUROLOGY, V53, P1537, DOI 10.1212/WNL.53.7.1537
   BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015
   Britz GWZY, 2016, YOUMANS WINN NEUROLO, V4
   Burns PB, 2011, PLAST RECONSTR SURG, V128, P305, DOI 10.1097/PRS.0b013e318219c171
   Caricato A, 2005, J TRAUMA, V58, P571, DOI 10.1097/01.TA.0000152806.19198.DB
   Celebisoy N, 2007, ACTA NEUROL SCAND, V116, P322, DOI 10.1111/j.1600-0404.2007.00905.x
   Colton K, 2016, J INTENSIVE CARE MED, V31, P263, DOI 10.1177/0885066614555692
   Colton K, 2014, J TRAUMA ACUTE CARE, V77, P47, DOI 10.1097/TA.0000000000000270
   Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077
   Dashdorj N, 2013, ANESTHESIOLOGY, V118, P577, DOI 10.1097/ALN.0b013e3182800d58
   Davanzo JR, 2017, SURG CLIN N AM, V97, P1237, DOI 10.1016/j.suc.2017.08.001
   Engelhard K, 2004, ACTA ANAESTH SCAND, V48, P396, DOI 10.1111/j.0001-5172.2004.00348.x
   Fattahian Reza, 2018, Med Arch, V72, P214, DOI 10.5455/medarh.2018.72.214-219
   Fodstad H, 2006, NEUROSURGERY, V59, P1132, DOI 10.1227/01.NEU.0000245582.08532.7C
   Forster Nicole, 2004, Curr Opin Anaesthesiol, V17, P371, DOI 10.1097/00001503-200410000-00004
   Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41
   Godoy DA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00250
   Goren O, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS1324
   HOFFMAN WE, 1995, J NEUROSURG ANESTH, V7, P82, DOI 10.1097/00008506-199504000-00002
   HORIKOSHI T, 1992, Neurologia Medico-Chirurgica, V32, P136, DOI 10.2176/nmc.32.136
   Wen HT, 2017, WORLD NEUROSURG, V98, P347, DOI 10.1016/j.wneu.2016.10.090
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Inoue K., 2010, AORN J, V91, P516
   Inoue Kelly, 2010, AORN J, V91, P511, DOI 10.1016/j.aorn.2009.12.025
   Joo Myung Sung, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P223, DOI 10.7461/jcen.2016.18.3.223
   Kenning TJ, 2012, J NEUROSURG, V116, P1289, DOI 10.3171/2012.2.JNS111772
   Kenning TJ, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0960
   Kim F, 2005, CIRCULATION, V112, P715, DOI 10.1161/CIRCULATIONAHA.105.544528
   Lang Shih-Shan, 2012, Anesthesiol Clin, V30, P289, DOI 10.1016/j.anclin.2012.05.008
   Langsjo JW, 2005, ANESTHESIOLOGY, V103, P258
   LEE EJ, 1995, J FORMOS MED ASSOC, V94, P341
   Lehto H, 2009, NEUROSURGERY, V64, P430, DOI 10.1227/01.NEU.0000338433.81852.75
   Leinonen V, 2018, HAND CLINIC, V145, P25, DOI 10.1016/B978-0-12-802395-2.00004-3
   Li J, 2016, BRIT J ANAESTH, V116, P759, DOI 10.1093/bja/aew096
   Li MX, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002133
   LORENZO AV, 1986, Z KINDERCHIR, V41, P10
   Lu XC, 2014, SCI REP-UK, V4, DOI 10.1038/srep07070
   Luostarinen T, 2011, NEUROCRIT CARE, V14, P238, DOI 10.1007/s12028-010-9475-6
   Mangat HS, 2015, ANN NY ACAD SCI, V1345, P83, DOI 10.1111/nyas.12704
   MELBY JM, 1982, CAN J PHYSIOL PHARM, V60, P405, DOI 10.1139/y82-059
   Muirhead WR, 2012, BRIT J NEUROSURG, V26, P710, DOI 10.3109/02688697.2012.671973
   Munch EC, 2001, CRIT CARE MED, V29, P976
   NAROTAM PK, 1993, BRIT J NEUROSURG, V7, P281, DOI 10.3109/02688699309023810
   Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0
   PAPAZIAN L, 1993, BRIT J ANAESTH, V71, P267, DOI 10.1093/bja/71.2.267
   Park J, 2012, ACTA NEUROCHIR, V154, P1869, DOI 10.1007/s00701-012-1467-1
   Park J, 2008, SURG NEUROL, V70, P503, DOI 10.1016/j.surneu.2007.09.018
   Pasarikovski CR, 2017, WORLD NEUROSURG, V105, P1, DOI 10.1016/j.wneu.2017.05.085
   Petersen KD, 2003, ANESTHESIOLOGY, V98, P329, DOI 10.1097/00000542-200302000-00010
   Pitsika M, 2013, J NEUROSURG-PEDIATR, V12, P604, DOI 10.3171/2013.8.PEDS13168
   Policicchio D, 2018, ACTA NEUROCHIR, V160, P1175, DOI 10.1007/s00701-018-3532-x
   Prabhakar H, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010026.pub2
   Randell T, 2006, CURR OPIN ANESTHESIO, V19, P492, DOI 10.1097/01.aco.0000245273.92163.8e
   Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003
   Rasmussen M, 2004, J NEUROSURG, V101, P621, DOI 10.3171/jns.2004.101.4.0621
   Rickard AC, 2014, EMERG MED J, V31, P679, DOI 10.1136/emermed-2013-202679
   Roberts I, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000033.pub2
   Ropper Allan H, 2014, Pract Neurol, V14, P152, DOI 10.1136/practneurol-2014-000811
   Sacco TL, 2018, DIMENS CRIT CARE NUR, V37, P120, DOI 10.1097/DCC.0000000000000293
   Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2
   Saito T, 2003, ACTA NEUROCHIR SUPPL, V86, P351
   Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016
   Schaller K, 2016, ACTA NEUROCHIR, V158, P161, DOI 10.1007/s00701-015-2640-0
   Schirmer CM, 2007, STROKE, V38, P987, DOI 10.1161/01.STR.0000257962.58269.e2
   Smith M, 2017, ANESTH ANALG, V125, P1999, DOI 10.1213/ANE.0000000000002399
   Stevanovic A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156448
   Sundaram SC, 2016, J CLIN DIAGN RES, V10, pUC1, DOI 10.7860/JCDR/2016/18377.7850
   Tartara F, 2018, WORLD NEUROSURG, V115, pE80, DOI 10.1016/j.wneu.2018.03.178
   TATEISHI A, 1981, ANESTHESIOLOGY, V54, P335, DOI 10.1097/00000542-198104000-00016
   TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002
   Viswanathan A, 2009, SURG NEUROL, V71, P681, DOI 10.1016/j.surneu.2008.04.013
   Wessel O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183781
   Whittle IR, 1996, J NEUROL NEUROSUR PS, V61, P584, DOI 10.1136/jnnp.61.6.584
   Wu CT, 2010, ANESTH ANALG, V110, P903, DOI 10.1213/ANE.0b013e3181cb3f8b
   Yang MH, 2015, SURG-J R COLL SURG E, V13, P230, DOI 10.1016/j.surge.2014.12.002
   Zeiler FA, 2014, NEUROCRIT CARE, V21, P163, DOI 10.1007/s12028-013-9950-y
   Zhao HX, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-015-0524-9
NR 83
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 120
EP 129
DI 10.1016/j.wneu.2019.05.224
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900133
PM 31158533
DA 2020-05-12
ER

PT J
AU Baranoski, JF
   Wanebo, JE
   Heiland, KE
   Zabramski, JM
AF Baranoski, Jacob F.
   Wanebo, John E.
   Heiland, Kurt E.
   Zabramski, Joseph M.
TI Superficial Femoral Artery Interposition Graft for Repair of a Ruptured
   Mycotic Common Carotid Artery Pseudoaneurysm: Case Report and Review of
   the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Carotid artery bypass; Common carotid artery pseudoaneurysm;
   Interposition graft; Superficial femoral artery
ID ADVANCED HEAD; NECK; RECONSTRUCTION; RESECTION; REPLACEMENT
AB BACKGROUND: Indications for reconstruction of the common carotid artery (CCA) include trauma, iatrogenic injury, neoplastic growth (such as invasive neck carcinomas), postoperative infection, and cervical carotid aneurysm. Although various techniques and conduits have been described, the clinical scenario may preclude the use of the most commonly used grafts. We describe a case using a superficial femoral artery (SFA) interposition graft to repair the CCA and review the available literature, highlighting the feasibility of this technique for carotid artery reconstruction.
   CASE DESCRIPTION: A patient aged 51 years presented with a ruptured mycotic CCA pseudoaneurysm that developed in the setting of a pharyngeal-carotid fistula. Because of the presence of a pharyngeal-carotid fistula and active infection within the vessel wall, endovascular treatment of the pseudoaneurysm was not feasible, and open surgical correction was required to repair the fistulous connection. Furthermore, owing to the extensive soft tissue infection, the use of a synthetic or venous autograft conduit for repair of the artery was contraindicated. Therefore, we harvested a segment of the SFA and used it as an interposition graft to reconstruct the diseased CCA, achieving an excellent anatomic and clinical result.
   CONCLUSIONS: This case highlights the feasibility of using an SFA interposition graft for short-segment CCA reconstruction, which can provide significant utility in the setting of a hostile operative field due to prior infection or radiation.
C1 [Baranoski, Jacob F.; Wanebo, John E.; Zabramski, Joseph M.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Heiland, Kurt E.] HonorHlth Scottsdale Osborn Mod Ctr, Dept Otolanngol, Scottsdale, AZ USA.
RP Zabramski, JM (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
CR DAVIES MG, 1994, SURGERY, V116, P557
   El-Sabrout R, 2000, ANN VASC SURG, V14, P239, DOI 10.1007/s100169910041
   JACOBS JR, 1994, LARYNGOSCOPE, V104, P689
   Lauder C, 2003, J VASC SURG, V38, P1025, DOI 10.1016/S0741-5214(03)00418-X
   Lozano FS, 2008, J CARDIOVASC SURG, V49, P653
   Miao BP, 2008, LARYNGOSCOPE, V118, P2135, DOI 10.1097/MLG.0b013e318182a50e
   Mourad M, 2015, OTOLARYNG HEAD NECK, V153, P225, DOI 10.1177/0194599815586719
   Naughton PA, 2010, EUR J VASC ENDOVASC, V40, P492, DOI 10.1016/j.ejvs.2010.07.005
   Nishinari K, 2014, ANN VASC SURG, V28, P1878, DOI 10.1016/j.avsg.2014.07.011
   Pons Y, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-19
   REILLY MK, 1992, J VASC SURG, V15, P324, DOI 10.1016/0741-5214(92)90254-6
   Sessa CN, 1998, ANN VASC SURG, V12, P229, DOI 10.1007/s100169900145
NR 12
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 130
EP 132
DI 10.1016/j.wneu.2019.05.215
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900134
PM 31154100
DA 2020-05-12
ER

PT J
AU Torikoshi, S
   Yamao, Y
   Ogino, E
   Taki, W
   Sunohara, T
   Nishimura, M
AF Torikoshi, Sadaharu
   Yamao, Yukihiro
   Ogino, Eiji
   Taki, Waro
   Sunohara, Tadashi
   Nishimura, Masaki
TI A Staged Therapy for Internal Carotid Artery Dissection Caused by
   Vascular Eagle Syndrome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid stenting; Eagle syndrome; Internal carotid artery; Stroke;
   Styloid process
ID ELONGATED STYLOID PROCESS; COMPRESSION; ISCHEMIA
AB BACKGROUND: Eagle syndrome with stroke onset is a rare condition. Carotid stenting of dissected arteries and/or surgical resection of the elongated styloid process are frequently performed; however, there are no definitive criteria for selecting these treatments.
   CASE DESCRIPTION: A 46-year-old man presented with left hemiplegia. Acute infarction in the right frontal and parietal lobes and bilateral internal carotid artery (ICA) dissection due to the elongated styloid process were diagnosed via magnetic resonance imaging and computed tomography angiography. He was treated with stenting of the left ICA dissection, with observation of the right ICA dissection. However, the right ICA dissection deteriorated 4 days after the initial event, and additional stenting was performed. He underwent bilateral prophylactic styloidectomy with an extraoral approach 8 months after symptom onset. At >3 years after the styloidectomy, he has not experienced recurrence of the infarction.
   CONCLUSIONS: Stenting in the acute phase prevented the recurrence of stroke, and styloid process resection in the chronic phase cured vascular Eagle syndrome. This staged therapy could be beneficial in the treatment of vascular Eagle syndrome.
C1 [Torikoshi, Sadaharu; Yamao, Yukihiro; Ogino, Eiji; Taki, Waro; Nishimura, Masaki] Koseikai Takeda Hosp, Dept Neurosurg, Kyoto, Japan.
   [Torikoshi, Sadaharu; Yamao, Yukihiro; Sunohara, Tadashi] Kyoto Univ, Dept Neurosurg, Grad Sch Med, Kyoto, Japan.
   [Ogino, Eiji] Uji Tokushukai Med Ctr, Dept Neurosurg, Kyoto, Japan.
   [Sunohara, Tadashi] Kobe City Med Ctr Gen Hosp, Dept Neurosurg & Neurol, Kobe, Hyogo, Japan.
   [Nishimura, Masaki] Natl Cerebral & Cardiovasc Ctr, Dept Neurosurg, Osaka, Japan.
RP Nishimura, M (reprint author), Koseikai Takeda Hosp, Dept Neurosurg, Kyoto, Japan.; Nishimura, M (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Neurosurg, Osaka, Japan.
EM masakins@kuhp.kyoto-u.ac.jp
OI Yamao, Yukihiro/0000-0002-9615-2353
CR Aydin E, 2018, TURK NEUROSURG, V28, P219, DOI 10.5137/1019-5149.JTN.17905-16.6
   Cano LM, 2010, NEUROLOGIA, V25, P266, DOI 10.1016/j.nrl.2010.04.001
   Chuang WC, 2007, AM J NEURORADIOL, V28, P143
   David J, 2014, J VASC SURG, V60, P1661, DOI 10.1016/j.jvs.2014.05.048
   Debette S, 2009, LANCET NEUROL, V8, P668, DOI 10.1016/S1474-4422(09)70084-5
   Dewan MC, 2016, CLIN NEUROL NEUROSUR, V141, P30, DOI 10.1016/j.clineuro.2015.12.004
   Elimairi I, 2015, HEAD NECK PATHOL, V9, P499, DOI 10.1007/s12105-014-0599-4
   Faivre A, 2009, J NEUROL NEUROSUR PS, V80, P1154, DOI 10.1136/jnnp.2008.159954
   Farhat HI, 2009, J NEUROSURG, V110, P90, DOI 10.3171/2008.3.17435
   Hamade YJ, 2016, OPER NEUROSURG, V12, P90, DOI 10.1227/NEU.0000000000000990
   Hooker JD, 2016, J RADIOL CASE REP, V10, P1, DOI 10.3941/jrcr.v10i6.1618
   Infante-Cossio P, 2004, REV NEUROLOGIA, V39, P339, DOI 10.33588/rn.3904.2004191
   Jelodar S, 2018, J STROKE CEREBROVASC, V27, pE89, DOI 10.1016/j.jstrokecerebrovasdis.2017.12.018
   Miyata H, 2016, SURG CEREB STROKE, V44, P145
   Nagoya H, 2011, NOSOTCHU, V33, P59
   Nakagawa D, 2011, NEUROSURGERY, V68, pE847, DOI 10.1227/NEU.0b013e318207ac74
   Nedeltchev K, 2009, STROKE, V40, P499, DOI 10.1161/STROKEAHA.108.519694
   Ogura Takenori, 2015, NMC Case Rep J, V2, P21, DOI 10.2176/nmccrj.2014-0179
   Ohara N, 2012, J STROKE CEREBROVASC, V21, DOI 10.1016/j.jstrokecerebrovasdis.2012.05.014
   Razak A, 2014, J NEUROIMAGING, V24, P298, DOI 10.1111/j.1552-6569.2012.00759.x
   Smoot TW, 2017, INTERV NEURORADIOL, V23, P433, DOI 10.1177/1591019917706050
   Soo OYY, 2004, NEUROLOGY, V62, P1647, DOI 10.1212/01.WNL.0000123016.81648.B6
   Subedi R, 2017, BMJ CASE REP, V2017
   Sveinsson O, 2013, BMJ CASE REP, V11, P13
   Todo T, 2012, ANN VASC SURG, V26, DOI 10.1016/j.avsg.2011.12.005
   Yamamoto S, 2013, INTERNAL MED, V52, P1005, DOI 10.2169/internalmedicine.52.0024
   Zuber M, 1999, NEUROLOGY, V53, P1886, DOI 10.1212/WNL.53.8.1886
NR 27
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 133
EP 139
DI 10.1016/j.wneu.2019.05.208
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900135
PM 31154103
DA 2020-05-12
ER

PT J
AU Yin, MC
   Ma, JM
   Ye, J
   Xu, H
   Mo, W
AF Yin, Mengchen
   Ma, Junming
   Ye, Jie
   Xu, Hua
   Mo, Wen
TI 8-Year Follow-up for Woman with Spinal Meningeal Melanocytoma in S1
   Nerve Root: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE HMB-45; Literature review; Nerve root; Spinal meningeal melanocytoma;
   Surgical resection
ID MALIGNANT-TRANSFORMATION; IMAGING CHARACTERISTICS; MELANOMA; MR;
   RADIOTHERAPY; TUMORS; CORD
AB BACKGROUND: Primary melanocytic neoplasms in the central nervous system are rare lesions arising from leptomeningeal melanocytes. These lesions produce neural deficits that resemble those of a meningioma or a schwannoma radiologically.
   CASE DESCRIPTION: A tumor around the left S1 root with an extension into the left paraspinal compartment was identified in a 32-year-old female with persistent left leg pain for 6 months. The tumor was hyperintense on T1-weighted image and hypointense on T2-weighted image with a homogeneous enhancement. The clinical features, radiologic presentations, treatment choice, and pathologic characteristic were illustrated. The treatment outcome was compared with those reported in the previous literature. The tumor was en-bloc resected with the S1 nerve root reserved. Grossly, the tumor was a soft, capsulated, well-circumscribed, black pigmented lesion. Immunohistochemistry revealed that the tumor cells were positive for HMB-45, S-100 protein, and vimentin. The patient's symptoms were greatly relieved postoperatively. No signs of local recurrence were observed.
   CONCLUSIONS: Spinal meningeal melanocytoma inside the nerve root is rare and benign. It is difficult to diagnose and often misdiagnosed as schwannoma or meningioma. HMB-45 has been suggested as a significant marker for the diagnosis of meningeal melanocytoma. Complete surgical resection is recommended as the primary treatment. Radiotherapy, chemotherapy, and other treatments can be selected as adjuvant therapies, but their effects are controversial. The recurrence and metastasis rates also remain unclear.
C1 [Yin, Mengchen; Ma, Junming; Ye, Jie; Xu, Hua; Mo, Wen] Shanghai Univ Tradit Chinese Med, Dept Orthopaed, LongHua Hosp, Shanghai, Peoples R China.
RP Mo, W (reprint author), Shanghai Univ Tradit Chinese Med, Dept Orthopaed, LongHua Hosp, Shanghai, Peoples R China.
EM mw2218@126.com
OI , yinmengchen/0000-0001-7404-1495
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [81603635, 81403419]; Research Project of Shanghai
   Health and Family Planning Commission [20164Y0081, ZYKC201701003,
   201840010]; Research Project of Shanghai Science and Technology
   Commission [16401930600, 17401934400]; Research Project of Shanghai
   Shenkang Hospital Development Center [16CR3074B, 16CR4011A]; Research
   Project of National TCM clinical research base of Longhua Hospital
   [LYTD-60]; "Tengfei" Project of Shanghai Sports Science and Technology
   Commission [18 T009]; " Sailing Program" of the Shanghai Science and
   Technology Committee [19YF1449600]
FX This work was sponsored by research grants from the National Nature
   Science Foundation of China (81603635 and 81403419), Research Project of
   Shanghai Health and Family Planning Commission (20164Y0081,
   ZYKC201701003, and 201840010), Research Project of Shanghai Science and
   Technology Commission (16401930600 and 17401934400), Research Project of
   Shanghai Shenkang Hospital Development Center (16CR3074B and 16CR4011A),
   Research Project of National TCM clinical research base of Longhua
   Hospital (LYTD-60), the "Tengfei" Project of Shanghai Sports Science and
   Technology Commission (18 T009), and the " Sailing Program" of the
   Shanghai Science and Technology Committee (19YF1449600).
CR Ali Y, 2009, J NEUROSURG, V111, P488, DOI 10.3171/2009.3.JNS081096
   Beseoglu K, 2006, ACTA NEUROCHIR, V148, P485, DOI 10.1007/s00701-005-0705-1
   Brat DJ, 1999, AM J SURG PATHOL, V23, P745, DOI 10.1097/00000478-199907000-00001
   Bydon A, 2003, J NEURO-ONCOL, V64, P259, DOI 10.1023/A:1025628802228
   Classen J, 2002, J NEURO-ONCOL, V58, P39, DOI 10.1023/A:1015872207398
   Cordoba A, 1989, Arch Neurobiol (Madr), V52, P93
   Czarnecki EJ, 1997, AM J NEURORADIOL, V18, P180
   Das A, 2001, INTERN MED J, V31, P562, DOI 10.1046/j.1445-5994.2001.00119.x
   FAILLACE WJ, 1984, J NEUROSURG, V61, P782, DOI 10.3171/jns.1984.61.4.0782
   FERRACINI R, 1974, TUMORI, V60, P197
   Franken S P G, 2009, Br J Radiol, V82, pe182, DOI 10.1259/bjr/30756805
   Goyal A, 2003, SPINE, V28, pE140, DOI 10.1097/00007632-200304010-00025
   GRAHAM DI, 1976, J PATHOL, V118, P83, DOI 10.1002/path.1711180204
   Ibanez J, 1997, HISTOPATHOLOGY, V30, P576, DOI 10.1046/j.1365-2559.1997.5660798.x
   ISIKLAR I, 1995, AM J ROENTGENOL, V165, P1503, DOI 10.2214/ajr.165.6.7484597
   JELLINGER K, 1988, ACTA NEUROCHIR, V94, P78, DOI 10.1007/BF01406621
   Kawara S, 1989, Nihon Hifuka Gakkai Zasshi, V99, P561
   LACH B, 1988, NEUROSURGERY, V22, P773, DOI 10.1227/00006123-198804000-00030
   Leonardi MA, 1998, ACTA NEUROCHIR, V140, P621, DOI 10.1007/s007010050151
   LIMAS C, 1972, CANCER, V30, P1286, DOI 10.1002/1097-0142(197211)30:5<1286::AID-CNCR2820300522>3.0.CO;2-V
   LITOFSKY NS, 1992, NEUROSURGERY, V31, P945, DOI 10.1227/00006123-199211000-00019
   Liu WC, 2009, EUR RADIOL, V19, P2707, DOI 10.1007/s00330-009-1466-7
   Liubinas SV, 2010, J CLIN NEUROSCI, V17, P1227, DOI 10.1016/j.jocn.2010.01.017
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Maiuri F, 1995, SURG NEUROL, V44, P556, DOI 10.1016/0090-3019(95)00182-4
   Matsumoto S, 1998, J NEUROSURG, V88, P890, DOI 10.3171/jns.1998.88.5.0890
   NAUL LG, 1991, AM J NEURORADIOL, V12, P315
   Oruckaptan HH, 2000, PEDIATR NEUROSURG, V32, P240, DOI 10.1159/000028945
   Painter TJ, 2000, AM J NEURORADIOL, V21, P1349
   Rades D, 2004, CANCER-AM CANCER SOC, V100, P2442, DOI 10.1002/cncr.20296
   Rades D, 2002, STRAHLENTHER ONKOL, V178, P336, DOI 10.1007/s00066-002-0930-y
   Rades D, 2001, J NEUROSURG, V95, P225, DOI 10.3171/spi.2001.95.2.0225
   Roser F, 2004, J NEUROSURG, V101, P528, DOI 10.3171/jns.2004.101.3.0528
   Ruelle A, 1996, NEUROSURG REV, V19, P39, DOI 10.1007/BF00346608
   Sankhla SK, 1996, BRIT J NEUROSURG, V10, P205, DOI 10.1080/02688699650040395
   Shimoda H, 1999, CLIN NEUROPATHOL, V18, P80
   Somers KE, 2013, J CLIN ONCOL, V31, pE9, DOI 10.1200/JCO.2012.41.6115
   STEINBERG JM, 1978, J NEUROSURG, V48, P818, DOI 10.3171/jns.1978.48.5.0818
   TATAGIBA M, 1992, NEUROSURGERY, V31, P958, DOI 10.1227/00006123-199211000-00023
   UEMATSU Y, 1992, J NEUROSURG, V76, P705, DOI 10.3171/jns.1992.76.4.0705
   Uozumi Yoichi, 2003, Brain Tumor Pathol, V20, P21, DOI 10.1007/BF02478943
   VERMA DS, 1979, JAMA-J AM MED ASSOC, V242, P2435, DOI 10.1001/jama.242.22.2435
   Wang FL, 2007, J NEUROSURG-SPINE, V6, P451, DOI 10.3171/spi.2007.6.5.451
   Wang FL, 2011, NEUROPATHOLOGY, V31, P414, DOI 10.1111/j.1440-1789.2010.01160.x
   Wang YB, 2016, SPINE J, V16, pE59, DOI 10.1016/j.spinee.2015.09.036
   YAMANE K, 1994, SURG NEUROL, V42, P433, DOI 10.1016/0090-3019(94)90353-0
NR 46
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 143
EP 147
DI 10.1016/j.wneu.2019.05.147
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900137
PM 31426249
DA 2020-05-12
ER

PT J
AU Pijpker, PAJ
   Wagemakers, M
   Kraeima, J
   Vergeer, RA
   Kuijlen, JMA
   Groen, RJM
AF Pijpker, Peter A. J.
   Wagemakers, Michiel
   Kraeima, Joep
   Vergeer, Rob A.
   Kuijlen, Jos M. A.
   Groen, Rob J. M.
TI Three-Dimensional Printed Polymethylmethacrylate Casting Molds for
   Posterior Fossa Reconstruction in the Surgical Treatment of Chiari I
   Malformation: Technical Note and Illustrative Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D printing; 3D surgery; Chiari malformation type 1; Cranioplasty;
   Template; Virtual surgical planning
ID SUBOCCIPITAL CRANIOPLASTY; DECOMPRESSION; DURAPLASTY
AB OBJECTIVE: To describe a new method for cranial reconstruction after posterior fossa craniectomy in the surgical treatment of Chiari 1 malformation through a technical note and presentation of 3 illustrative cases.
   METHODS AND MATERIALS: A virtual surgical planning workflow was established for planning posterior fossa decompression, designing the suboccipital reconstruction, and manufacturing a 3D-printed polymethylmethacrylate (PMMA) casting mold. The casting accuracy was assessed by conducting a phantom experiment, and clinical data were provided by means of 3 illustrative cases.
   RESULTS: The accuracy of implant fabrication was found to be excellent, particularly when PMMA is introduced into the mold in a malleable state. In all 3 clinical cases, the implants were fabricated and positioned with success. Postoperative analysis revealed that accurate placement was achieved, with only minor deviation from the preoperative plan.
   CONCLUSIONS: 3D virtual surgical planning provides feasible tools for the planning of posterior fossa decompression and intraoperative fabrication of accurate patient-specific suboccipital cranioplasty.
C1 [Pijpker, Peter A. J.; Wagemakers, Michiel; Vergeer, Rob A.; Kuijlen, Jos M. A.; Groen, Rob J. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosurg, Groningen, Netherlands.
   [Kraeima, Joep] Univ Groningen, Univ Med Ctr Groningen, Dept Oral & Maxillofacial Surg, Groningen, Netherlands.
RP Pijpker, PAJ (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurosurg, Groningen, Netherlands.
EM p.a.j.pijpker@umcg.nl
OI Groen, Rob J.M./0000-0003-3067-763X
CR Abdel Hay J, 2017, WORLD NEUROSURG, V105
   Abla AA, 2010, J CRANIOVERTEBRAL JU, V1, P29, DOI 10.4103/0974-8237.65479
   Assina R, 2014, J CLIN NEUROSCI, V21, P1641, DOI 10.1016/j.jocn.2014.03.006
   Bunck AC, 2012, EUR RADIOL, V22, P1860, DOI 10.1007/s00330-012-2457-7
   Feghali JG, 1998, LARYNGOSCOPE, V108, P1450, DOI 10.1097/00005537-199810000-00006
   Gnanalingham KK, 2002, J NEUROSURG, V97, P821, DOI 10.3171/jns.2002.97.4.0821
   Guerrini F, 2017, WORLD NEUROSURG, V107, DOI 10.1016/j.wneu.2017.08.111
   Heller JB, 2007, J CRANIOFAC SURG, V18, P274, DOI 10.1097/scs.0b013e31802c05ab
   Holly LT, 2001, J NEUROSURG, V94, P21, DOI 10.3171/jns.2001.94.1.0021
   Kim BJ, 2012, J KOREAN NEUROSURG S, V52, P541, DOI 10.3340/jkns.2012.52.6.541
   Lee SC, 2009, J CLIN NEUROSCI, V16, P56, DOI 10.1016/j.jocn.2008.04.001
   Morales-Gomez JA, 2019, J NEUROSURG, V130, P1721, DOI 10.3171/2017.12.JNS172574
   Moser M, 2017, J CRANIO MAXILL SURG, V45, P295, DOI 10.1016/j.jcms.2016.11.016
   Munshi I, 2000, NEUROSURGERY, V46, P1384, DOI 10.1097/00006123-200006000-00018
   Oro JJ, 2011, NEUROL RES, V33, P261, DOI 10.1179/016164111X12962202723841
   Rosen DS, 2003, PEDIATR NEUROSURG, V38, P186, DOI 10.1159/000069097
   SAHUQUILLO J, 1994, NEUROSURGERY, V35, P874, DOI 10.1227/00006123-199411000-00011
   SCHESSEL DA, 1993, AM J OTOL, V14, P491
   Schijman E, 2004, CHILD NERV SYST, V20, P323, DOI 10.1007/s00381-003-0878-y
   Shaffer N, 2011, NEUROL RES, V33, P247, DOI 10.1179/016164111X12962202723805
   Shoja MM, 2018, CLIN ANAT, V31, P466, DOI 10.1002/ca.23049
   Takayasu M, 2004, NEUROSURG REV, V27, P173, DOI 10.1007/s10143-004-0338-5
   Udani V, 2014, WORLD NEUROSURG, V81, P836, DOI 10.1016/j.wneu.2013.01.081
NR 23
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 148
EP 156
DI 10.1016/j.wneu.2019.05.191
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900138
PM 31150856
DA 2020-05-12
ER

PT J
AU Mathkour, M
   Heibig, B
   McCormack, E
   Amenta, PS
AF Mathkour, Mansour
   Heibig, Brian
   McCormack, Erin
   Amenta, Peter S.
TI Acute Presentation of Vestibular Schwannoma Secondary to Intratumoral
   Hemorrhage: A Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Facial palsy; Hearing loss; Intratumoral hemorrhage; Vestibular
   schwannoma
ID TUMOR-ASSOCIATED HEMORRHAGE; ACOUSTIC NEUROMA; SUBARACHNOID HEMORRHAGE;
   CLINICAL PRESENTATION; MASSIVE HEMORRHAGE; POSSIBLE MECHANISM;
   RESECTION; GROWTH
AB BACKGROUND: Vestibular schwannomas (VS) are common slow-growing tumors that typically present with the insidious progression of unilateral hearing loss, tinnitus, vertigo, and gait imbalance. Clinically significant intratumoral acute hemorrhage is exceedingly rare and can present with the acute onset of symptoms, neurologic deterioration, and significant dysfunction of cranial nerves VII and VIII. We discuss a 40-year-old man who developed mild hearing loss and headaches over the course of a month before presenting with a large acutely hemorrhagic vestibular schwannoma. In addition, we review the current literature pertaining to this pathology.
   CASE PRESENTATION: A previously healthy 40-year-old man with a 1-month history of mild headaches, dizziness, and left-sided hearing loss, tinnitus, and facial numbness presented with the acute onset of severe headache, vomiting, complete left-sided hearing loss, and left-sided facial weakness. Computed tomography and magnetic resonance imaging revealed a 4.1 x 2.7 cm hemorrhagic mass in the left cerebellopontine angle most consistent with VS. The patient subsequently underwent a retrosigmoid craniotomy and resection of the tumor. Pathology was consistent with hemorrhagic VS. Imaging at 1-year follow-up demonstrated no residual or recurrent disease, and facial motor function had completely recovered.
   CONCLUSIONS: Histologically, vascular abnormalities and micro-hemorrhages are nearly ubiquitous across vestibular schwannomas and may contribute to cystic degeneration and rapid tumor growth. However, clinically significant hemorrhage is rarely encountered and is more commonly associated with more profound neurologic sequelae and cranial nerve VII dysfunction. Surgical resection at the time of presentation should be strongly considered to remove the risk of repeat hemorrhage and further deterioration. Our case represents a typical presentation and clinical course for a patient presenting with this rarely encountered pathology.
C1 [Mathkour, Mansour; Heibig, Brian; McCormack, Erin; Amenta, Peter S.] Tulane Univ Med Ctr Hosp & Clin, Dept Neurosurg, New Orleans, LA 70112 USA.
   [Mathkour, Mansour; McCormack, Erin] Ochsner Med Ctr, Dept Neurosurg, New Orleans, LA USA.
RP Amenta, PS (reprint author), Tulane Univ Med Ctr Hosp & Clin, Dept Neurosurg, New Orleans, LA 70112 USA.
EM peter.aments@gmail.com
RI Mathkour, Mansour/N-7878-2015
OI Mathkour, Mansour/0000-0002-1913-3677
CR ASARI S, 1992, NEUROSURGERY, V31, P406, DOI 10.1227/00006123-199209000-00004
   BABA M, 1980, Neurological Surgery, V8, P193
   Banaama Saeed, 2016, Surg Neurol Int, V7, pS869, DOI 10.4103/2152-7806.194494
   Benhaiem-Sigaux N, 1999, NEURORADIOLOGY, V41, P795, DOI 10.1007/s002340050844
   Bigner D. D., 1998, RUSSELL RUBINSTEINS, P141
   Bowden G, 2017, NEUROSURGERY, V81, P490, DOI 10.1093/neuros/nyx027
   Carlson ML, 2017, LARYNGOSCOPE, V127, P1420, DOI 10.1002/lary.26193
   CASTILLO R, 1982, J NEUROSURG, V56, P417, DOI 10.3171/jns.1982.56.3.0417
   Chee PC, 1987, BRIT J NEUROSURG, V1, P489
   Chou D, 1998, Neurosurg Focus, V5, pe9, DOI 10.3171/foc.1998.5.3.15
   Chu M, 2007, CHINESE MED J-PEKING, V120, P83, DOI 10.1097/00029330-200701010-00017
   Dehdashti AR, 2009, BRIT J NEUROSURG, V23, P431, DOI 10.1080/02688690902968828
   Fundova P, 2000, J LARYNGOL OTOL, V114, P935
   Ganslandt O, 2008, ZBL NEUROCHIR, V69, P204, DOI 10.1055/s-2008-1077074
   GOETTING MG, 1987, SURG NEUROL, V27, P168, DOI 10.1016/0090-3019(87)90290-4
   Grahnke K, 2017, J NEUROL SURG PART B, V78, P454, DOI 10.1055/s-0037-1604077
   Hassanabad MF, 2019, J CLIN NEUROSCI, V61, P304, DOI 10.1016/j.jocn.2018.10.052
   Karampelas I, 2007, ACTA NEUROCHIR, V149, P313, DOI 10.1007/s00701-006-1107-8
   KASANTIKUL V, 1980, J NEUROSURG, V52, P28, DOI 10.3171/jns.1980.52.1.0028
   Kim SH, 1998, CLIN NEUROL NEUROSUR, V100, P68
   Ko Y, 1989, J KOREAN NEUROSURG S, V18, P1093
   KOJIMA Y, 1990, Neurologia Medico-Chirurgica, V30, P972, DOI 10.2176/nmc.30.972
   Kurata A, 1989, Neurol Med Chir (Tokyo), V29, P328, DOI 10.2176/nmc.29.328
   Kwon Y, 2002, J NEUROSURG, V97, P657, DOI 10.3171/jns.2002.97.supplement_5.0657
   LEE JP, 1989, NEUROSURGERY, V24, P764, DOI 10.1227/00006123-198905000-00020
   Maimone Giuseppe, 2013, Surg Neurol Int, V4, P67, DOI 10.4103/2152-7806.112605
   Mandl ES, 2009, ACTA NEUROCHIR, V151, P1325, DOI 10.1007/s00701-009-0213-9
   Mateo-Sierra O, 2002, REV NEUROLOGIA, V35, P656, DOI 10.33588/rn.3507.2002311
   MCCOYD K, 1974, J NEUROSURG, V41, P391, DOI 10.3171/jns.1974.41.3.0391
   Metwali H, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.07.011
   MISRA BK, 1995, BRIT J NEUROSURG, V9, P219, DOI 10.1080/02688699550041593
   Moffat DA, 2014, J LARYNGOL OTOL, V128, P406, DOI 10.1017/S0022215114000541
   Moon KS, 2007, J NEUROSURG, V106, P866, DOI 10.3171/jns.2007.106.5.866
   Niknafs YS, 2014, WORLD NEUROSURG, V82, P751, DOI 10.1016/j.wneu.2013.02.069
   Nikolopoulos TP, 2010, OTOL NEUROTOL, V31, P478, DOI 10.1097/MAO.0b013e3181d279a3
   Odabasi AO, 2000, AM J OTOL, V21, P706
   Ohta S, 1998, BRIT J NEUROSURG, V12, P455, DOI 10.1080/02688699844709
   Palaoglu S, 1990, J Neurosurg Sci, V34, P65
   Park CK, 2006, J NEUROSURG, V105, P576, DOI 10.3171/jns.2006.105.4.576
   Piccirillo E, 2009, OTOL NEUROTOL, V30, P826, DOI 10.1097/MAO.0b013e3181b04e18
   SASAKI K, 1985, Neurological Surgery, V13, P1013
   Schlieter M, 2005, J NEURORADIOLOGY, V32, P210, DOI 10.1016/S0150-9861(05)83139-6
   SHEPHARD RH, 1981, J NEUROL NEUROSUR PS, V44, P1057, DOI 10.1136/jnnp.44.11.1057
   Sughrue ME, 2011, J NEUROSURG, V114, P386, DOI 10.3171/2010.5.JNS10256
   Takeuchi S, 2012, J CLIN NEUROSCI, V19, P1305, DOI 10.1016/j.jocn.2011.11.028
   Uzun C, 2003, LARYNGOSCOPE, V113, P1751, DOI 10.1097/00005537-200310000-00017
   Vellin JF, 2006, OTOL NEUROTOL, V27, P209, DOI 10.1097/01.mao.0000188339.45772.be
   Wojno TH, 2011, OPHTHAL PLAST RECONS, V27, P119, DOI 10.1097/IOP.0b013e318201d1d3
   Yang X, 2018, ACTA NEUROCHIR, V160, P1563, DOI 10.1007/s00701-018-3588-7
   Yates CW, 2010, ANN OTO RHINOL LARYN, V119, P402, DOI 10.1177/000348941011900607
   YONEMITSU T, 1983, SURG NEUROL, V20, P125, DOI 10.1016/0090-3019(83)90462-7
NR 51
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 157
EP 163
DI 10.1016/j.wneu.2019.05.075
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900139
PM 31103763
DA 2020-05-12
ER

PT J
AU Griffin, A
   Cutler, A
   Gonzalez, LF
AF Griffin, Andrew
   Cutler, Andrew
   Gonzalez, L. Fernando
TI Treatment of a Fusiform Anterior Cerebral Artery Aneurysm by Remodeling
   the Circle of Willis with Flow Diversion: A Novel Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Flow diversion; Pipeline stent
ID ENDOVASCULAR TREATMENT; CAROTID-ARTERY; MANAGEMENT; OCCLUSION; PIPELINE
AB BACKGROUND: Fusiform aneurysms are challenging lesions to manage given their poorly understood natural history and lack of a distinct neck. Historically, they have been treated surgically but endovascular management has recently evolved as a viable alternative. In this case, we describe a novel flow diversion technique for treatment of a fusiform anterior cerebral artery (ACA) aneurysm by jailing the compromised parent vessel obtaining endovascular aneurysm trapping.
   METHODS: A 25-year-old man underwent brain magnetic resonance imaging and magnetic resonance angiography for workup of a headache, which revealed a fusiform right ACA A1 segment aneurysm. The patient subsequently underwent catheter digital subtraction angiography, which confirmed a 9 x 5.5 mm fusiform right ACA A1 segment aneurysm. The patient elected to undergo endovascular treatment. A Pipeline Embolization Device (Medtronic, Dublin, Ireland) was placed from the right anterior cerebral artery to the right middle cerebral artery, thereby jailing the right ACA A1 segment.
   RESULTS: At 6-month follow-up, the patient was asymptomatic and his headache had resolved. An angiogram was obtained, showing patency of the Pipeline Embolization Device and near complete occlusion of the right ACA A1 segment. The right ACA A2 segment remained patent via collateral flow through the anterior communicating artery. These findings were confirmed on magnetic resonance imaging. The patient remained asymptomatic for the duration of the follow-up.
   CONCLUSIONS: This case illustrates the efficacy of the Pipeline Embolization Device for treatment of a fusiform anterior circulation aneurysm via remodeling the circle of Willis.
C1 [Griffin, Andrew; Cutler, Andrew; Gonzalez, L. Fernando] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27708 USA.
RP Cutler, A (reprint author), Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27708 USA.
EM asg32@duke.edu
OI Griffin, Andrew/0000-0003-3266-1359; Cutler, Andrew/0000-0003-4064-1139
CR Anson JA, 1996, J NEUROSURG, V84, P185, DOI 10.3171/jns.1996.84.2.0185
   Awad AJ, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1748
   Barletta Enrico Affonso, 2018, Surg Neurol Int, V9, P189, DOI 10.4103/sni.sni_133_18
   Becske T, 2017, NEUROSURGERY, V80, P40, DOI 10.1093/neuros/nyw014
   Bhogal P, 2017, WORLD NEUROSURG, V103, P789, DOI 10.1016/j.wneu.2017.04.092
   Briganti F, 2015, NEURORADIOL J, V28, P365, DOI 10.1177/1971400915602803
   Cebral JR, 2011, AM J NEURORADIOL, V32, P27, DOI 10.3174/ajnr.A2398
   Cho Su-Hee, 2017, Neurointervention, V12, P31, DOI 10.5469/neuroint.2017.12.1.31
   Cooper A, 1836, GUYS HOSP REP, V1, P53
   CROWFORD FA, 1977, J CARDIOVASC SURG, V18, P49
   CRUTCHFIELD WG, 1959, J NEUROSURG, V16, P471, DOI 10.3171/jns.1959.16.4.0471
   Dashti R, 2007, SURG NEUROL, V68, P366, DOI 10.1016/j.surneu.2007.07.084
   Devulapalli KK, 2013, J NEUROINTERV SURG, V5, P110, DOI 10.1136/neurintsurg-2011-010233
   Drake C G, 1985, Clin Neurosurg, V32, P41
   Drake CG, 1997, J NEUROSURG, V87, P141, DOI 10.3171/jns.1997.87.2.0141
   Elhammady MS, 2010, NEUROSURGERY, V67, P1431, DOI 10.1227/NEU.0b013e3181f076ac
   Friedman JA, 2001, NEUROLOGY, V57, P1212, DOI 10.1212/WNL.57.7.1212
   KAK VK, 1973, J NEUROSURG, V39, P503, DOI 10.3171/jns.1973.39.4.0503
   Kim Byung Moon, 2016, Neurointervention, V11, P10, DOI 10.5469/neuroint.2016.11.1.10
   Lee JM, 2010, WORLD NEUROSURG, V74, P478, DOI 10.1016/j.wneu.2010.06.040
   Lin LM, 2019, STROKE VASC NEUROL, V4, P141, DOI 10.1136/svn-2018-000204
   Maiti TK, 2016, WORLD NEUROSURG, V85, P85, DOI 10.1016/j.wneu.2015.07.022
   Monteith SJ, 2014, J NEUROSURG, V120, P945, DOI 10.3171/2013.12.JNS13945
   Mut F, 2012, AM J NEURORADIOL, V33, P2010, DOI 10.3174/ajnr.A3080
   Natarajan SK, 2016, J NEUROSURG, V125, P111, DOI 10.3171/2015.6.JNS1565
   Neki H, 2015, J NEUROSURG, V123, P1540, DOI 10.3171/2014.11.JNS141603
   Park Hyun-Seok, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P13, DOI 10.7461/jcen.2013.15.1.13
   Puffer RC, 2012, J NEUROSURG, V116, P892, DOI 10.3171/2011.11.JNS111612
   Rangel-Castilla L, 2017, J NEUROSURG, V126, P1064, DOI 10.3171/2016.4.JNS16147
   Sacho RH, 2014, STROKE, V45, P3251, DOI 10.1161/STROKEAHA.114.006292
   Trivelato FP, 2019, J NEUROSURG, V130, P543, DOI 10.3171/2017.10.JNS172175
   van Rooij WJ, 2012, AM J NEURORADIOL, V33, P323, DOI 10.3174/ajnr.A2759
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 164
EP 169
DI 10.1016/j.wneu.2019.05.245
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900140
PM 31426250
DA 2020-05-12
ER

PT J
AU Sledler, DG
   Beechey, JC
   Jessup, PJ
   Thani, NB
AF Sledler, Declan G.
   Beechey, Jessica C.
   Jessup, Peter J.
   Thani, Nova B.
TI Infantile Optic Pathway Glioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Case report; GBM; Glioblastoma; Optic pathway glioma; Pediatric
ID GLIOMA; MULTIFORME; CHILDHOOD; CHILDREN; TUMORS; YOUNG; FETAL
AB BACKGROUND: Optic pathway gliomas and glioblastomas remain a rare entity within the infant population.
   CASE DESCRIPTION: We outline the case of a 6-month-old female who presented with failure to thrive, nystagmus and features of raised intracranial pressure. Subsequent magnetic resonance imaging demonstrated an infiltrating tumor radiating from the optic nerves bilaterally. She underwent emergent ventriculoperitoneal shunting and biopsy. Histology confirmed a World Health Organization grade IV glioblastoma.
   CONCLUSIONS: The patient remained clinically and radiologically stable at 1 year. Optic pathway glioblastoma in this population is a previously undescribed entity that requires multidisciplinary input to guide ongoing therapy.
C1 [Sledler, Declan G.; Thani, Nova B.] Royal Hobart Hosp, Dept Neurosurg, Hobart, Tas, Australia.
   [Beechey, Jessica C.; Jessup, Peter J.] Royal Hobart Hosp, Dept Anat Pathol, Hobart, Tas, Australia.
RP Thani, NB (reprint author), Royal Hobart Hosp, Dept Neurosurg, Hobart, Tas, Australia.
EM novathani@gmail.com
CR Birbilis TA, 2010, SPINE, V35, pE264, DOI 10.1097/BRS.0b013e3181c11748
   Brar R, 2009, J RADIOL CASE REP, V3, P22, DOI 10.3941/jrcr.v3i9.277
   Caffo M, 2004, ACTA NEUROCHIR, V146, P1113, DOI 10.1007/s00701-004-0344-y
   Caroli E, 2005, SPINAL CORD, V43, P565, DOI 10.1038/sj.sc.3101749
   Cirak B, 2000, ACTA RADIOL, V41, P375, DOI 10.1080/028418500127345505
   Davis T, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1241
   Dinh TT, 2007, J CLIN NEUROSCI, V14, P502, DOI 10.1016/j.jocn.2006.04.012
   Donmez FY, 2012, CHILD NERV SYST, V28, P1831, DOI 10.1007/s00381-012-1914-6
   Fouladi M, 2009, CANCER, V115, P3243, DOI 10.1002/cncr.24362
   GIBBERD FB, 1973, BRIT J OPHTHALMOL, V57, P788, DOI 10.1136/bjo.57.10.788
   Hargrave D, 2009, BRIT J NEUROSURG, V23, P351, DOI 10.1080/02688690903158809
   Isaacs H, 2016, CHILD NERV SYST, V32, P2085, DOI 10.1007/s00381-016-3215-y
   Kameda M, 2017, WORLD NEUROSURG, V101, DOI 10.1016/j.wneu.2017.02.026
   Klein O, 2009, BRIT J NEUROSURG, V21, P411
   Korones DN, 2003, NEURO-ONCOLOGY, V5, P116, DOI 10.1215/15228517-5-2-116
   Lang SS, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.09.012
   LAVERY MA, 1984, OPHTHALMOLOGY, V91, P425
   Lin CY, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0415-5
   Lundar T, 2015, CHILD NERV SYST, V31, P2283, DOI 10.1007/s00381-015-2792-5
   Lyapichev K, 2016, SURG NEUROL INT, V7, P485
   Mastorakos P, 2018, J NEUROSURG, V128, P406, DOI 10.3171/2016.10.JNS161443
   Prasad Vangala Bramha, 2017, Asian J Neurosurg, V12, P72, DOI 10.4103/1793-5482.145103
   Rasool N, 2017, CURR OPIN OPHTHALMOL, V28, P289, DOI 10.1097/ICU.0000000000000370
   Rekate H, 2006, CHILD NERV SYST, V22, P1433, DOI 10.1007/s00381-006-0116-5
   Rickert CH, 1999, ACTA NEUROPATHOL, V98, P567, DOI 10.1007/s004010051120
   SAEBO J, 1949, BRIT J OPHTHALMOL, V33, P701, DOI 10.1136/bjo.33.11.701
   Seker A, 2006, J NEUROSURG, V105, P473, DOI 10.3171/ped.2006.105.6.473
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 172
EP 175
DI 10.1016/j.wneu.2019.05.236
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900142
PM 31158532
DA 2020-05-12
ER

PT J
AU Cheng, C
   Wang, JZ
   Zhao, SQ
   Tao, BZ
   Bai, SC
   Shang, AJ
AF Cheng, Cheng
   Wang, Jianzhen
   Zhao, Shuiqiang
   Tao, Benzhang
   Bai, Shaocong
   Shang, Aijia
TI Intramedullary Thoracic Meningioma: A Rare Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intramedullary; Meningioma; Thoracic spine
ID SPINAL-CORD MENINGIOMA; MANAGEMENT; NEOPLASMS; DIAGNOSIS
AB BACKGROUND: Quite a few cases of intramedullary meningioma have been described in previously reported studies. We have presented a rare case of intramedullary thoracic meningioma, which was quite different from subdural extramedullary meningioma, and the preliminary diagnosis was mistakenly given as hemangioblastoma.
   CASE DESCRIPTION: A 46-year-old man with complaints of gait problems and pain in the right lower extremity was admitted to our hospital. The neurological examination revealed 3 of 5 motor strength, spastic paraparesis, hyperreflexia, increased tone, and sensory deficits in the right lower extremity. Contrast-enhanced images showed a T6-T7 intramedullary lesion and an evident and homogeneously enhanced lesion with clearly defined borders on the sagittal, coronal, and axial views. The preliminary diagnosis was hemangioblastoma. However, he underwent tumor resection, and the histopathological examination findings confirmed the diagnosis of intramedullary meningioma.
   CONCLUSION: Intramedullary thoracic meningiomas are extremely rare and differ from the common subdural extramedullary meningiomas. Clinicians should be aware of this when diagnosing intramedullary tumors. Gross total resection using a microsurgical technique will be the best treatment strategy.
C1 [Cheng, Cheng; Wang, Jianzhen; Zhao, Shuiqiang] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 3, Dept Neurosurg, Beijing, Peoples R China.
   [Tao, Benzhang; Bai, Shaocong; Shang, Aijia] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Neurosurg, Beijing, Peoples R China.
RP Shang, AJ (reprint author), Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Neurosurg, Beijing, Peoples R China.
EM shangaj@126.com
CR Chamberlain MC, 2011, CURR NEUROL NEUROSCI, V11, P320, DOI 10.1007/s11910-011-0190-2
   Covert S, 2003, CAN ASSOC RADIOL J, V54, P177
   Gokden M, 1997, SEMIN DIAGN PATHOL, V14, P253
   Hafiz M G, 2013, Mymensingh Med J, V22, P180
   Jallo GI, 2001, NEUROSURGERY, V48, P218, DOI 10.1097/00006123-200101000-00042
   Koeller KK, 2000, RADIOGRAPHICS, V20, P1721, DOI 10.1148/radiographics.20.6.g00nv151721
   MIRIMANOFF RO, 1985, J NEUROSURG, V62, P18, DOI 10.3171/jns.1985.62.1.0018
   Moriuchi Shusuke, 1996, Neurologia Medico-Chirurgica, V36, P888, DOI 10.2176/nmc.36.888
   Pant I, 2014, INDIAN J PATHOL MICR, V57, P308, DOI 10.4103/0377-4929.134726
   Park SH, 2006, ACTA NEUROCHIR, V148, P463, DOI 10.1007/s00701-005-0695-z
   Perven G, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1110-8
   Piazza MA, 2016, WORLD NEUROSURG, V92, DOI 10.1016/j.wneu.2016.01.073
   Ravindra VM, 2016, NEUROSURG CLIN N AM, V27, P195, DOI 10.1016/j.nec.2015.11.010
   Raza SM, 2005, J SPINAL DISORD TECH, V18, P449, DOI 10.1097/01.bsd.0000155032.69394.23
   Sahni D, 2008, J CLIN NEUROSCI, V15, P1176, DOI 10.1016/j.jocn.2007.08.025
   Sakaki S, 1987, Neurol Med Chir (Tokyo), V27, P658, DOI 10.2176/nmc.27.658
   Salehpour F, 2008, SPINAL CORD, V46, P648, DOI 10.1038/sj.sc.3102175
   SALVATI M, 1992, SURG NEUROL, V37, P42, DOI 10.1016/0090-3019(92)90064-T
   Senturk S, 2009, SPINE, V34, pE45, DOI 10.1097/BRS.0b013e318189fd20
   Yuan D, 2013, J NEUROL SURG PART A, V74, pE136, DOI 10.1055/s-0032-1330959
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 176
EP 180
DI 10.1016/j.wneu.2019.05.172
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900143
PM 31146040
DA 2020-05-12
ER

PT J
AU Zhu, J
   Sun, KA
   Xu, XM
   Sun, JC
   Kong, QJ
   Wang, SM
   Shi, JG
AF Zhu, Jian
   Sun, Kakiang
   Xu, Ximing
   Sun, Jingchuan
   Kong, Qingjie
   Wang, Shunmin
   Shi, Jiangang
TI A Preliminary Attempt of Nonintervention in the Treatment of Patients
   with Intervertebral Disc Calcification Combined with Ossification of the
   Posterior Longitudinal Ligament
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spine; Etiology; Intervertebral disc calcification;
   Nonintervention; Ossification of posterior longitudinal ligament;
   Treatment principles
ID DEGENERATION; EXPRESSION; CHILDHOOD; CHILDREN; GIRL
AB BACKGROUND: Calcification of intervertebral disc is a common impairment, which has been considered as the degenerative condition of the spine. In clinical practice, we note that the onset of intervertebral disc calcification (IDC) and ossification of the posterior longitudinal ligament (OPLL) can exist simultaneously in some cases, especially in younger children. However, only 8 cases have been reported in detail previously. In addition, controversy remains in terms of the best way to treat this condition.
   CASE DESCRIPTION: An 8-year-old female child was referred to our department in March 2018 complaining of severe back pain and neck pain with a sign of neurologic dysfunction. Computed tomography and magnetic resonance imaging revealed the calcified intervertebral disc and OPLL at the C5-C6 level and spinal cord compression. We performed a noninterventional strategy for the patient. The patient's symptom recovered significantly in approximately 1 month. At 6 months of follow-up, the patient felt no discomfort, and computed tomography revealed the complete resorption of ossified lesion. Magnetic resonance imaging also showed no sign of compression on the spinal cord and nerve root at the involved segment.
   CONCLUSIONS: Pediatric IDC accompanied with OPLL is much less frequent, but we must be aware of this disease. Since the distribution of this disease is age-specific and sex-specific, further research is necessary. Treatment for IDC combined with OPLL needs to follow the treatment principles as described in the text.
C1 [Zhu, Jian; Sun, Kakiang; Xu, Ximing; Sun, Jingchuan; Kong, Qingjie; Wang, Shunmin; Shi, Jiangang] Second Mil Med Univ, Changzheng Hosp, Spine Ctr, Dept Orthoped Surg, Shanghai, Peoples R China.
RP Shi, JG (reprint author), Second Mil Med Univ, Changzheng Hosp, Spine Ctr, Dept Orthoped Surg, Shanghai, Peoples R China.
EM changzhengspine@smmu.edu.cn
CR Ayotte DC, 2000, J BIOMECH ENG-T ASME, V122, P587, DOI 10.1115/1.1319658
   Bajard X, 2010, CHILD NERV SYST, V26, P973, DOI 10.1007/s00381-010-1117-y
   Beluffi G, 2009, RADIOL MED, V114, P331, DOI 10.1007/s11547-009-0368-8
   Boody BS, 2018, INT ORTHOP S2, P1
   Chu JJ, 2015, CHILD NERV SYST, V31, P123, DOI 10.1007/s00381-014-2539-8
   Dai LY, 2004, J BONE JOINT SURG AM, V86A, P1467, DOI 10.2106/00004623-200407000-00015
   Du JJ, 2012, J SPINAL DISORD TECH, V25, P59, DOI 10.1097/BSD.0b013e31820bb883
   Epstein Nancy, 2002, Spine J, V2, P436, DOI 10.1016/S1529-9430(02)00394-7
   Fu ZY, 2011, SPINE, V36, pE808, DOI 10.1097/BRS.0b013e3181faa95a
   GIRODIAS JB, 1991, PEDIATR RADIOL, V21, P541, DOI 10.1007/BF02012591
   Hsieh AH, 2010, J BIOMECH, V43, P137, DOI 10.1016/j.jbiomech.2009.09.019
   Lernout C, 2009, CHILD NERV SYST, V25, P1019, DOI 10.1007/s00381-009-0869-8
   Li CH, 2016, J ORTHOP SURG-HONG K, V24, P424, DOI 10.1177/1602400331
   Matsunaga S, 2012, SPINE, V37, pE309, DOI 10.1097/BRS.0b013e318241ad33
   Mizukawa K, 2017, PEDIATR INT, V59, P3
   Moore RJ, 2006, EUR SPINE J, V15, pS333, DOI 10.1007/s00586-006-0170-4
   O'Dell MC, 2016, PEDIATR NEUROL, V61, P115, DOI 10.1016/j.pediatrneurol.2016.04.009
   RUDERT M, 1993, ANN ANAT, V175, P237, DOI 10.1016/S0940-9602(11)80009-9
   Rutges J, 2010, OSTEOARTHR CARTILAGE, V18, P416, DOI 10.1016/j.joca.2009.09.009
   Smith LJ, 2011, DIS MODEL MECH, V4, P31, DOI 10.1242/dmm.006403
   Song XX, 2014, JOINT BONE SPINE, V81, P250, DOI 10.1016/j.jbspin.2013.09.002
   SONNABEND DH, 1982, J BONE JOINT SURG BR, V64, P25
   Spapens N, 2010, EUR J PEDIATR, V169, P577, DOI 10.1007/s00431-009-1076-z
   Tsutsumi S, 2011, CHILD NERV SYST, V27, P1045, DOI 10.1007/s00381-011-1431-z
   Urban JPG, 2004, SPINE, V29, P2700, DOI 10.1097/01.brs.0000146499.97948.52
   VENTURA N, 1995, INT ORTHOP, V19, P291
   Wang GQ, 2016, CHILD NERV SYST, V32, P381, DOI 10.1007/s00381-015-2840-1
   Yang HS, 2010, SPINE, V35, pE434, DOI 10.1097/BRS.0b013e3181c71ebe
NR 28
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 181
EP 185
DI 10.1016/j.wneu.2019.05.169
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900144
PM 31146042
DA 2020-05-12
ER

PT J
AU Altafulla, J
   Bordes, S
   Jenkins, S
   Litvack, Z
   Iwanaga, J
   Loukas, M
   Tubbs, RS
AF Altafulla, Juan
   Bordes, Stephen
   Jenkins, Skyler
   Litvack, Zachary
   Iwanaga, Joe
   Loukas, Marios
   Tubbs, R. Shane
TI The Basal Subarachnoid Cisterns: Surgical and Anatomical Considerations
SO WORLD NEUROSURGERY
LA English
DT Review
DE Basal cisterns; Cerebrospinal fluid; Cranial nerves; Endoscopic; Third
   ventriculostomy
ID ARACHNOIDAL TRABECULAR MEMBRANES; MICROSURGICAL ANATOMY;
   CEREBROSPINAL-FLUID; POSTERIOR-FOSSA; SPACE; 3RD-VENTRICLE; MORPHOLOGY;
   PHYSIOLOGY; RELEVANCE; MENINGES
AB The basal subarachnoid cisterns are expansions of the subarachnoid space and transmit cranial nerves and intracranial vessels. Providing neurosurgeons with key concepts, anatomical landmarks, and techniques can result in safer procedures and better patient outcomes. In this review, we discuss the major basal subarachnoid cisterns including their embryology, history, anatomical descriptions, and use during surgical approaches.
C1 [Altafulla, Juan; Iwanaga, Joe; Tubbs, R. Shane] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [Altafulla, Juan; Litvack, Zachary] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA USA.
   [Bordes, Stephen; Jenkins, Skyler; Loukas, Marios; Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Iwanaga, J (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.
EM joei@seattlesciencefoundation.org
RI Bordes, Stephen/AAF-8704-2019
OI Bordes, Stephen/0000-0002-7507-0674; Altafulla,
   Juan/0000-0002-2110-8665; Jenkins, Skyler/0000-0001-9594-3869
CR ADAM R, 1978, J NEUROSURG, V48, P190, DOI 10.3171/jns.1978.48.2.0190
   Adeeb N, 2013, CHILD NERV SYST, V29, P17, DOI 10.1007/s00381-012-1910-x
   Bahuleyan B, 2008, J CLIN NEUROSCI, V15, P1159, DOI 10.1016/j.jocn.2007.06.015
   Barshes N, 2005, CANC TREAT, V125, P1
   Brunori A., 1992, Annali Italiani di Chirurgia, V63, P579
   Catala M., 1998, Archives d'Anatomie et de Cytologie Pathologiques, V46, P153
   Charalampaki P, 2008, SKULL BASE-INTERD AP, V18, P117, DOI 10.1055/s-2007-1003927
   Charalampaki P, 2008, NEUROSURGERY, V62, P1049, DOI [10.1227/01.NEU.0000176638.86772.2D, 10.1227/01.neu.0000333770.58693.ed]
   Charalampaki P, 2005, NEUROSURGERY, V57, P302, DOI 10.1227/01.NEU.0000176638.86772.2D
   Cinalli G, 2005, EXPERT REV MED DEVIC, V2, P351, DOI 10.1586/17434440.2.3.351
   Dandy WE, 1919, ANN SURG, V70, P397, DOI 10.1097/00000658-191910000-00004
   DAVSON H, 1973, BRAIN, V96, P329, DOI 10.1093/brain/96.2.329
   Di Ieva A, 2012, NEUROSURG REV, V35, P341, DOI 10.1007/s10143-011-0371-0
   Figueiredo EG, 2016, WORLD NEUROSURG, V87, P584, DOI 10.1016/j.wneu.2015.10.063
   Fries G, 1996, MINIM INVAS NEUROSUR, V39, P99, DOI 10.1055/s-2008-1052226
   Gonsette R, 1968, Acta Neurol Psychiatr Belg, V68, P559
   GREENBERG RW, 1994, SEMIN ULTRASOUND CT, V15, P454, DOI 10.1016/S0887-2171(05)80017-4
   GRUNERT P, 1994, MINIM INVAS NEUROSUR, V37, P2, DOI 10.1055/s-2008-1053440
   HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017
   Johnston M, 2002, NEWS PHYSIOL SCI, V17, P227, DOI 10.1152/nips.01400.2002
   KAINZ J, 1993, HNO, V41, P146
   KARS Z, 1986, NEUROCHIRURGIA, V29, P114
   Key A, 1875, STUDIEN ANATOMIE NER
   Kim MK, 2013, KOREAN J RADIOL, V14, P829, DOI 10.3348/kjr.2013.14.5.829
   Locke CE, 1924, ARCH NEURO PSYCHIATR, V12, P411, DOI 10.1001/archneurpsyc.1924.02200040054004
   Lu J, 2005, SURG RADIOL ANAT, V27, P472, DOI 10.1007/s00276-005-0025-4
   Lu J, 2005, J NEUROSURG, V103, P337, DOI 10.3171/jns.2005.103.2.0337
   Magill ST, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17753
   MATSUNO H, 1988, NEUROSURGERY, V23, P58, DOI 10.1227/00006123-198807000-00012
   MCLONE DG, 1975, AM J ANAT, V142, P273, DOI 10.1002/aja.1001420302
   MCLONE DG, 1980, CHILD BRAIN, V6, P113
   Mortazavi MM, 2018, WORLD NEUROSURG, V111, P279, DOI 10.1016/j.wneu.2017.12.041
   NABESHIMA S, 1975, J COMP NEUROL, V164, P127, DOI 10.1002/cne.901640202
   NAUTA HJW, 1983, SURG NEUROL, V19, P431, DOI 10.1016/0090-3019(83)90141-6
   Olry R, 2001, J Hist Neurosci, V10, P198, DOI 10.1076/jhin.10.2.198.7257
   ONO M, 1984, NEUROSURGERY, V15, P621, DOI 10.1227/00006123-198411000-00002
   Papaiconomou C, 2002, AM J PHYSIOL-REG I, V283, pR869, DOI 10.1152/ajpregu.00173.2002
   PARKINSON D, 1991, AM J ANAT, V192, P498, DOI 10.1002/aja.1001920414
   Qi ST, 2011, J NEUROSURG, V115, P171, DOI 10.3171/2011.2.JNS101365
   Qi ST, 2010, NEUROSURGERY, V66, P585, DOI 10.1227/01.NEU.0000365371.50165.06
   QUEST DO, 1980, NEUROSURGERY, V6, P385, DOI 10.1227/00006123-198004000-00006
   ROBERTSON EG, 1949, J NEUROL NEUROSUR PS, V12, P39, DOI 10.1136/jnnp.12.1.39
   Ruysch F., 1699, EPISTOLA ANATOMICA P
   Saboori P, 2015, ANAT RES INT, V2015, DOI [10.1155/2015/279814, DOI 10.1155/2015/279814]
   Sakka L, 2011, EUR ANN OTORHINOLARY, V128, P309, DOI 10.1016/j.anorl.2011.03.002
   SATO O, 1972, J NEUROSURG, V36, P276, DOI 10.3171/jns.1972.36.3.0276
   Shoja MM, 2018, CLIN ANAT, V31, P466, DOI 10.1002/ca.23049
   Shoja MM, 2018, CLIN ANAT, V31, P488, DOI 10.1002/ca.23048
   Sinha S, 2018, CHILD NERV SYST, V34, P1397, DOI 10.1007/s00381-018-3797-7
   Snell RS, 2010, CLIN NEUROANATOMY
   Sweetman B, 2011, ANN BIOMED ENG, V39, P484, DOI 10.1007/s10439-010-0141-0
   Tsutsumi S, 2017, SURG RADIOL ANAT, V39, P323, DOI 10.1007/s00276-016-1725-7
   Unsold R, 1982, COMPUTER REFORMATION
   Vaezi A, 2015, LARYNGOSCOPE, V125, P577, DOI 10.1002/lary.24989
   Vandenabeele F, 1996, J ANAT, V189, P417
   VANDERREST M, 1991, FASEB J, V5, P2814
   VINAS FC, 1994, NEUROL RES, V16, P417
   Vinas FC, 1996, NEUROL RES, V18, P305
   Vinas FC, 1996, NEUROL RES, V18, P117
   Vinas FC, 2001, MINIM INVAS NEUROSUR, V44, P104, DOI 10.1055/s-2001-15999
   Vinas FC, 1996, MINIM INVAS NEUROSUR, V39, P116, DOI 10.1055/s-2008-1052230
   WACKENHEIM A, 1973, NEURORADIOLOGY, V5, P82, DOI 10.1007/BF00337488
   Wang SS, 2008, MICROSURG, V28, P65, DOI 10.1002/micr.20448
   Wang SS, 2011, J CLIN NEUROSCI, V18, P253, DOI 10.1016/j.jocn.2010.03.065
   WELCH K, 1960, BRAIN, V83, P454, DOI 10.1093/brain/83.3.454
   Weller R. O., 2005, Morphologie, V89, P22, DOI 10.1016/S1286-0115(05)83235-7
   Yang A, 2018, J NEUROSURG SCI, V62, P658, DOI 10.23736/S0390-5616.18.04474-0
   YASARGIL MG, 1976, J NEUROSURG, V44, P298
   Yasargil MG, 1984, MICROSURGICAL ANATOM, V1
NR 69
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 190
EP 199
DI 10.1016/j.wneu.2019.05.087
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900147
PM 31136838
DA 2020-05-12
ER

PT J
AU Splayski, B
   Rotim, K
   Lakicevic, G
   Gienapp, AJ
   Boop, FA
   Arnautovic, KI
AF Splayski, Bruno
   Rotim, Kresimir
   Lakicevic, Goren
   Gienapp, Andrew J.
   Boop, Frederick A.
   Arnautovic, Kenan, I
TI Andreas Vesalius, the Predecessor of Neurosurgery: How his Progressive
   Scientific Achievements Affected his Professional Life and Destiny
SO WORLD NEUROSURGERY
LA English
DT Article
DE 16th Century; Anatomy; Andreas Vesalius; Death; Neuroscience; Pilgrimage
ID HENRY-II; RESPECTFUL IMAGE; DEATH; ANATOMY; REVENGE
AB Andreas Vesalius, the father of modern anatomy and a predecessor of neuroscience, was a distinguished medical scholar and Renaissance figure of the 16th Century Scientific Revolution. He challenged traditional anatomy by applying empirical methods of cadaveric dissection to the study of the human body. His revolutionary book, De Humani Corporis Fabrica, established anatomy as a scientific discipline that challenged conventional medical knowledge, but often caused controversy. Charles V, the Holy Roman Emperor and King of Spain to whom De Humani was dedicated, appointed Vesalius to his court. While in Spain, Vesalius' work antagonized the academic establishment, current medical knowledge, and ecclesial authority. Consequently, his methods were unacceptable to the academic and religious status quo, therefore, we believe that his professional life-as well as his tragic death-was affected by the political state of affairs that dominated 16th Century Europe. Ultimately, he went on a pilgrimage to the Holy Land that jeopardized his life. While returning home, his ship was driven ashore on the Greek island of Zakynthos (Zante) where he became ill and suddenly died in 1564 at the age of 49. Vesalius' ideas helped free medicine from the limitations of the 16th Century and advanced scientific knowledge. His influence is still felt more than 500 years later. In this article, we acknowledge Vesalius' neuroanatomic contributions and we discuss the historical facts and political circumstances that influenced his scientific career and personal life, emphasizing the conditions of his pilgrimage to the Holy Land that led to his untimely death.
C1 [Splayski, Bruno; Rotim, Kresimir] Sestre Milosrdnice Univ Hosp Ctr, Dept Neurosurg, Zagreb, Croatia.
   [Splayski, Bruno; Rotim, Kresimir] Osijek Univ, Sch Med, Osijek, Croatia.
   [Splayski, Bruno] Osijek Univ, Sch Dent Med & Hlth, Osijek, Croatia.
   [Lakicevic, Goren] Mostar Univ Hosp, Mostar, Bosnia & Herceg.
   [Gienapp, Andrew J.; Boop, Frederick A.] Le Bonheur Childrens Hosp, Neurosci Inst, Memphis, TN USA.
   [Gienapp, Andrew J.; Boop, Frederick A.; Arnautovic, Kenan, I] Semmes Murphey Clin, Memphis, TN 38120 USA.
   [Boop, Frederick A.; Arnautovic, Kenan, I] Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA.
RP Arnautovic, KI (reprint author), Semmes Murphey Clin, Memphis, TN 38120 USA.; Arnautovic, KI (reprint author), Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA.
EM kenanarnaut@yahoo.com
RI Arnautovic, Kenan/AAI-6898-2020
OI Arnautovic, Kenan/0000-0003-3745-288X
CR Ambrose CT, 2014, ACTA MED-HIST ADRIAT, V12, P217
   Bagwell CE, 2005, ANN SURG, V241, P872, DOI 10.1097/01.sla.0000165185.88634.d0
   Barr J, 2015, J VASC SURG, V61, P1370, DOI 10.1016/j.jvs.2014.11.080
   Bay NSY, 2010, ANAT CELL BIOL, V43, P280, DOI 10.5115/acb.2010.43.4.280
   Benini A, 1996, SPINE, V21, P1388, DOI 10.1097/00007632-199606010-00024
   Biesbrouck M, 2016, ACTA CHIR BELG, V116, P126, DOI 10.1080/00015458.2016.1162993
   Biesbrouck M, 2015, ACTA MED-HIST ADRIAT, V13, P265
   Biesbrouck Maurits, 2012, Vesalius, V18, P70
   Biesbrouck Maurits, 2011, Vesalius, V17, P30
   Bylebyl JJ, 1979, MED MORTALITY 16 CEN, P335
   Cantor NF, 1969, 17 CENTURY RATIONALI
   Castiglioni A, 1943, Bull N Y Acad Med, V19, P766
   Chareyron N., 2005, PILGRIMAGE JERUSALEM
   Crivellato E, 2006, CLIN ANAT, V19, P581, DOI 10.1002/ca.20308
   Cullen GM, 1928, LANCET, V1, P105
   Cunningham Andrew, 1997, ANATOMICAL RENAISSAN
   Cushing H., 1962, BIOBIBLIOGRAPHY A VE
   Dominiczak MH, 2013, CLIN CHEM, V59, P587, DOI 10.1373/clinchem.2012.199851
   Douglas C., 2001, BMJ-BRIT MED J, V322, P373
   Dowling KA, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.4.FOCUS15119
   Drucker Charles B, 2008, Yale J Biol Med, V81, P199
   Dunn PM, 2003, ARCH DIS CHILD-FETAL, V88, pF157, DOI 10.1136/fn.88.2.F157
   FARIA MA, 1992, J NEUROSURG, V77, P964, DOI 10.3171/jns.1992.77.6.0964
   Friedman SG, 2018, J VASC SURG, V68, P646, DOI 10.1016/j.jvs.2018.04.053
   Fullerton Joseph B, 2009, Clin Cardiol, V32, pE82, DOI 10.1002/clc.20388
   Ghosh SK, 2015, ANAT CELL BIOL, V48, P153, DOI 10.5115/acb.2015.48.3.153
   Gomes MD, 2015, ARQ NEURO-PSIQUIAT, V73, P155, DOI 10.1590/0004-282X20140201
   Goodrich J T, 1985, Med Herit, V1, P280
   GOTTLIEB LS, 1964, ARCH INTERN MED, V114, P294, DOI 10.1001/archinte.1964.03860080144015
   Haas L F, 1991, J Neurol Neurosurg Psychiatry, V54, P287, DOI 10.1136/jnnp.54.4.287
   HAAS LF, 1992, J NEUROL NEUROSUR PS, V55, P3, DOI 10.1136/jnnp.55.1.3
   Halkin LE, 1987, ERASMUS ROTTERDAM SO, V7, P96
   Haller JA, 2005, ANN SURG, V241, P878
   Joffe SN., 1973, A VESALIUS MAKING MA
   Joffe Stephen N, 2009, Int Arch Med, V2, P26, DOI 10.1186/1755-7682-2-26
   KING LS, 1973, AM J PATHOL, V73, P514
   Koehler PJ, 1997, J HIST NEUROSCI, V6, P90
   Lanska DJ, 2014, J HIST NEUROSCI, V23, P211, DOI 10.1080/0964704X.2014.884885
   LASKY II, 1990, CLIN ORTHOP RELAT R, P304
   Markatos K, 2017, WORLD NEUROSURG, V106, P442, DOI 10.1016/j.wneu.2017.07.039
   Martinez-Vidal A, 2005, MED HIST, V49, P251, DOI 10.1017/S0025727300008875
   Nutton V, 2012, MED HIST, V56, P415, DOI 10.1017/mdh.2012.26
   O'MALLEY C D, 1964, Med Hist, V8, P299
   Olry R, 1997, J Hist Neurosci, V6, P113
   OMalley CD, 1954, ISIS, V45, P138
   OMalley CD, 1964, A VESALIUS BRUSSELS
   PARK K, 1994, RENAISSANCE QUART, V47, P1, DOI 10.2307/2863109
   Popa CC, 2018, ROM J MORPHOL EMBRYO, V59, P637
   Rengachary SS, 2009, NEUROSURGERY, V65, P787, DOI 10.1227/01.NEU.0000324991.45949.E4
   Scatliff JH, 2014, AM J NEURORADIOL, V35, P19, DOI 10.3174/ajnr.A3766
   Serageldin Ismail, 2013, Glob Cardiol Sci Pract, V2013, P395, DOI 10.5339/gcsp.2013.47
   Sutherland-Foggio H, 2017, PEDIATR NEUROL, V75, P6, DOI 10.1016/j.pediatrneurol.2017.07.004
   Tubbs RS, 2007, CLIN ANAT, V20, P868, DOI 10.1002/ca.20553
   Wharton E., 1902, N AM REV, V175, P625
   Zanello M, 2015, ACTA NEUROCHIR, V157, P145, DOI 10.1007/s00701-014-2280-9
NR 55
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 202
EP 209
DI 10.1016/j.wneu.2019.06.008
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900149
PM 31201946
DA 2020-05-12
ER

PT J
AU Camacho, JE
   Usman, MF
   Ho, CP
   Sansur, CA
   Ludwig, SC
AF Camacho, Jael E.
   Usman, M. Farooq
   Ho, Cheng-Ping
   Sansur, Charles A.
   Ludwig, Steven C.
TI Perineal and Radicular Pain Caused by Contralateral Sacral Nerve Root
   Schwannoma: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Nerve sheath tumor; Perineal pain; Radiculopathy; Sacrum; Schwannoma
ID RETROSPECTIVE ANALYSIS; SPINAL SCHWANNOMA; TUMORS; DIAGNOSIS; RESECTION;
   OUTCOMES
AB BACKGROUND: Sacral schwannomas are very rare nerve sheath tumors. Patients usually present with a variety of nonspecific symptoms, which often lead to a delay in diagnosis. Although most schwannomas are benign, they present surgical challenges owing to their proximity to neurologic and other anatomic structures.
   CASE DESCRIPTION: This 58-year-old female presented with a 2-month old history of left-sided perineal and radicular pain secondary to a right S2 sacral nerve root schwannoma. The sacral mass demonstrated homogenous enhancement with cystic changes in a T2-weighted magnetic resonance imaging sequence. The patient underwent S1-S3 laminectomy and tumor excision through a posterior surgical approach. Intraoperative monitoring was used to distinguish nonfunctional tissue during tumor resection. The patient had an unremarkable postoperative course.
   CONCLUSIONS: Sacral schwannomas can present with a variety of nonspecific symptoms. They pose unique challenges given their location, size, and involvement of surrounding structures. Complete surgical resection is the main goal of sacral schwannoma treatment. A combined anterior-posterior surgical approach and a multidisciplinary surgical team are associated with improved outcomes.
C1 [Camacho, Jael E.; Usman, M. Farooq; Ludwig, Steven C.] Univ Maryland, Sch Med, Dept Orthoped, Baltimore, MD 21201 USA.
   [Ho, Cheng-Ping] Univ Maryland, Sch Med, Dept Pathol & Neurol, Baltimore, MD 21201 USA.
   [Sansur, Charles A.] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA.
RP Ludwig, SC (reprint author), Univ Maryland, Sch Med, Dept Orthoped, Baltimore, MD 21201 USA.
EM sludwig@som.umaryland.edu
OI Camacho Matos, Jael E/0000-0002-2153-455X
CR Attiah MA, 2016, EUR SPINE J, V25, pS84, DOI 10.1007/s00586-015-4128-2
   BHATIA S, 1992, SURG NEUROL, V37, P118, DOI 10.1016/0090-3019(92)90187-R
   Cagli S, 2012, J NEURO-ONCOL, V110, P105, DOI 10.1007/s11060-012-0941-1
   Conti P, 2004, SURG NEUROL, V61, P34, DOI 10.1016/S0090-3019(03)00537-8
   El-Mahdy W, 1999, BRIT J NEUROSURG, V13, P550, DOI 10.1080/02688699943042
   Emel E, 2017, TURK NEUROSURG, V27, P217, DOI 10.5137/1019-5149.JTN.15678-15.1
   FELDENZER JA, 1989, NEUROSURGERY, V25, P884, DOI 10.1227/00006123-198912000-00006
   Fourney DR, 2005, J NEUROSURG-SPINE, V3, P111, DOI 10.3171/spi.2005.3.2.0111
   Giuliano AE, 2017, CA-CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393
   Jeon JH, 2008, J KOREAN NEUROSURG S, V43, P135, DOI 10.3340/jkns.2008.43.3.135
   Khan UA, 2018, WORLD NEUROSURG, V115, P65, DOI 10.1016/j.wneu.2018.03.203
   KIM P, 1989, J NEUROSURG, V71, P810, DOI 10.3171/jns.1989.71.6.0810
   Klimo Paul Jr, 2003, Neurosurg Focus, V15, pE12
   Lin J, 2001, AM J ROENTGENOL, V176, P75, DOI 10.2214/ajr.176.1.1760075
   Llauger J, 2000, AM J ROENTGENOL, V174, P417, DOI 10.2214/ajr.174.2.1740417
   Mavrogenis AF, 2017, TUMORS SACRUM, P163
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   Ozturk C, 2009, ACTA ORTHOP BELG, V75, P705
   Pan WB, 2017, ONCOTARGET, V8, P38061, DOI 10.18632/oncotarget.16968
   Safaee MM, 2017, J NEUROSURG-SPINE, V26, P103, DOI 10.3171/2016.5.SPINE15974
   Schellinger KA, 2008, J NEURO-ONCOL, V87, P173, DOI 10.1007/s11060-007-9507-z
   Senapati Satya B, 2016, Asian J Neurosurg, V11, P451
   SEPPALA MT, 1995, J NEUROSURG, V83, P621, DOI 10.3171/jns.1995.83.4.0621
   Sun W, 2016, ORTHOP SURG, V8, P162, DOI 10.1111/os.12245
   Togral G, 2014, NEUROSCIENCES, V19, P224
   TURNER ML, 1981, JAMA-J AM MED ASSOC, V245, P275, DOI 10.1001/jama.245.3.275
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 210
EP 215
DI 10.1016/j.wneu.2019.06.012
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900150
PM 31203077
DA 2020-05-12
ER

PT J
AU Panagopoulos, D
   Themistocleous, M
   Apostolopoulou, K
   Sfakianos, G
AF Panagopoulos, Dimitrios
   Themistocleous, Marios
   Apostolopoulou, Katerina
   Sfakianos, Georgios
TI Primary, Dural-Based, Ewing Sarcoma Manifesting with Seizure Activity:
   Presentation of a Rare Tumor Entity with Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bone invasion; Ewing sarcoma; Intracranial-extracranial extension
ID SKULL
AB BACKGROUND: Primary Ewing sarcoma arising from the calvarial bone and/or underlying dura matter are relatively rarely reported in the literature. Even rarer are considered to be those that originate from the dura and proliferate in both directions, toward the brain parenchyma and through the dura invading the overlying bone.
   CASE DESCRIPTION: We report the case of a girl aged 11 years who presented with an ictus of generalized tonic-clonic seizures, without known focal neurologic deficit. Neuroradiologic work-up verified the existence of a tumor in the right fronto-parietal area of the brain, invading both the bone and brain parenchyma and emanating from the dura. No other tumor location was discovered after radiologic work-up, and gross total resection was undertaken followed by adjuvant radiation therapy and chemotherapy.
   CONCLUSIONS: The patient had an uneventful neurologic recovery without persistent neurologic deficit. One year after the operation, with the patient under close clinical and radiologic surveillance, no recurrence of the disease was detected. This case illustrates an extremely uncommon location of primary Ewing sarcoma, along with a constellation of clinical signs and symptoms that are fairly uncommon for this location of this rare disease entity.
C1 [Panagopoulos, Dimitrios; Themistocleous, Marios; Apostolopoulou, Katerina; Sfakianos, Georgios] Pediat Hosp Athens, Neurosurg Dept, Attica, Greece.
RP Panagopoulos, D (reprint author), Pediat Hosp Athens, Neurosurg Dept, Attica, Greece.
EM dimpanayop@gmail.com
CR Aydin S, 2018, WORLD NEUROSURG, V115, P278, DOI 10.1016/j.wneu.2018.04.158
   Balasubramaniam S, 2008, J CLIN NEUROSCI, V15, P712, DOI 10.1016/j.jocn.2007.04.023
   Carlotti CG, 1999, PEDIATR NEUROSURG, V31, P307, DOI 10.1159/000028881
   Chen J, 2019, WORLD NEUROSURG, V122, pE1606, DOI 10.1016/j.wneu.2018.11.151
   Choi SW, 2019, HEAD NECK-J SCI SPEC, V41, pE38, DOI 10.1002/hed.25449
   Desai K, 2000, BRIT J NEUROSURG, V14, P143
   Desai KI, 2000, NEUROSURGERY, V46, P62
   El Asri AC, 2018, WORLD NEUROSURG, V115, P346, DOI 10.1016/j.wneu.2018.04.164
   Fielding Allen Fred, 2002, J Clin Pediatr Dent, V26, P409
   Ganjoo KN, 2013, CURR ONCOL REP, V15, P372, DOI 10.1007/s11912-013-0317-5
   HaDuong JH, 2015, PEDIATR CLIN N AM, V62, P179, DOI 10.1016/j.pcl.2014.09.012
   Naama O, 2007, J NEURORADIOLOGY, V34, P68, DOI 10.1016/j.neurad.2007.01.004
   Salunke PS, 2011, ACTA NEUROCHIR, V153, P1477, DOI 10.1007/s00701-011-1028-z
   Sato Shinsuke, 2009, Neurosurgery, V64, pE384, DOI 10.1227/01.NEU.0000337128.67045.70
   Wang DW, 2015, INT J CLIN EXP PATHO, V8, P7575
   Womer RB, 2012, J CLIN ONCOL, V30, P4148, DOI 10.1200/JCO.2011.41.5703
   Yang MJ, 2018, CHILD NERV SYST, V34, P441, DOI 10.1007/s00381-017-3684-7
NR 17
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 216
EP 220
DI 10.1016/j.wneu.2019.06.036
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900151
PM 31203070
DA 2020-05-12
ER

PT J
AU Elsayed, GA
   Chagoya, G
   Bernstock, JD
   Omar, N
   Tabibian, E
   Gessler, F
   Bellew, MP
   Hellinger, F
AF Elsayed, Galal A.
   Chagoya, Gustavo
   Bernstock, Joshua D.
   Omar, Nidal
   Tabibian, Ethan
   Gessler, Florian
   Bellew, Michael P.
   Hellinger, Frank, Jr.
TI Magnetic Resonance Imaging Safety of Retained Tip and Protective Coils
   after Faulty Deployment of an Intracranial Pipeline Embolization Device:
   A Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Magnetic resonance imaging; MRI; PED; Pipeline embolization device;
   Retained coils
ID ANTIPLATELET; THERAPY
AB BACKGROUND: The development of flow-diverters such as the Pipeline embolization device (PED) have allowed for safe and effective treatment of challenging and/or previously untreatable intracranial aneurysms. A rare but serious complication during PED deployment involves fracture of single or multiple components, which can lead to retained hardware. To date, there are little data regarding the safety of performing magnetic resonance imaging (MRI) when tip or capture coils remain intracranially.
   CASE DESCRIPTION: To the best of our knowledge, we present the first case demonstrating the safe completion of MRI after treatment of 2 posterior circulation aneurysms in a woman aged 69 years presenting with subarachnoid hemorrhage whose treatment was complicated by fracture and subsequent retention of the PED tip and capture coils.
   CONCLUSIONS: MRI (1.5T) appears safe and effective in patients who have retained PED tips and/or capture coils.
C1 [Elsayed, Galal A.; Chagoya, Gustavo; Bernstock, Joshua D.; Omar, Nidal; Tabibian, Ethan] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
   [Gessler, Florian] Goethe Univ Hosp, Dept Neurosurg, Frankfurt, Germany.
   [Bellew, Michael P.; Hellinger, Frank, Jr.] Florida Hosp, Dept Radiol, Orlando, FL USA.
RP Elsayed, GA (reprint author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
EM gelsayed@uabmc.edu
RI Chagoya, Gustavo/S-8172-2019
OI Chagoya, Gustavo/0000-0002-8337-4467; Bernstock,
   Joshua/0000-0002-7814-3867; Elsayed, Galal/0000-0002-0894-9486
CR Administration F.a.D., 2011, INTR AN FLOW DIV PMA
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Cruz JP, 2013, AM J NEURORADIOL, V34, P271, DOI 10.3174/ajnr.A3380
   Fargen KM, 2012, WORLD NEUROSURG, V77, P403, DOI 10.1016/j.wneu.2012.02.038
   Heller RS, 2013, J NEUROSURG, V119, P1603, DOI 10.3171/2013.7.JNS122178
   Leung GKK, 2012, CLIN NEURORADIOL, V22, P295, DOI 10.1007/s00062-012-0178-6
   McTaggart RA, 2013, NEUROSURGERY, V72, P237, DOI 10.1227/NEU.0b013e31827fc9be
   Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702
   Tan LA, 2015, J NEUROINTERV SURG, V7, P217, DOI 10.1136/neurintsurg-2014-011111
   Tse MMY, 2013, WORLD NEUROSURG, V80, P829, DOI 10.1016/j.wneu.2012.09.023
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 221
EP 224
DI 10.1016/j.wneu.2019.06.007
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900152
PM 31201945
DA 2020-05-12
ER

PT J
AU Kaushal, M
   Shabani, S
   Cochran, EJ
   Samra, H
   Zwagerman, NT
AF Kaushal, Mayank
   Shabani, Saman
   Cochran, Elizabeth J.
   Samra, Hasan
   Zwagerman, Nathan T.
TI Cerebral Trypanosomiasis in an Immunocompromised Patient: Case Report
   and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Benznidazole; Chagas disease; Kinetoplasts; Trypanosoma cruzi
ID CENTRAL-NERVOUS-SYSTEM; ACQUIRED-IMMUNODEFICIENCY-SYNDROME;
   CHAGAS-DISEASE; CRUZI MENINGOENCEPHALITIS; AMERICAN TRYPANOSOMIASIS;
   PROLONGED SURVIVAL; HIV-INFECTION; REACTIVATION; AIDS; ENCEPHALITIS
AB BACKGROUND: We document a case of central nervous system infection with Trypanosoma cruzi.
   CASE DESCRIPTION: An 88-year-old woman presented with altered mental status, right-sided weakness, and slurred speech. Her medical history was significant for methotrexate intake for rheumatoid arthritis, and she tested negative for human immunodeficiency virus. Magnetic resonance imaging of the brain showed bilateral thick and peripherally enhancing white matter lesions in the frontoparietal region with extensive surrounding vasogenic edema. A lumbar puncture revealed increased protein and lymphocytic pleocytosis, and needle biopsy highlighted brain necrosis, chronic inflammation, and numerous intracellular organisms suggestive of T. cruzi amastigotes. Despite treatment with benznidazole, the patient expired soon after presentation.
   CONCLUSION: Chagas disease should be included in the differential diagnosis of an immunocompromised patient presenting with a central nervous system mass, meningoencephalitis, or focal neurologic signs.
C1 [Kaushal, Mayank; Shabani, Saman; Zwagerman, Nathan T.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
   [Cochran, Elizabeth J.; Samra, Hasan] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA.
RP Zwagerman, NT (reprint author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
EM nzwagerman@mcw.edu
RI Kaushal, Mayank/AAK-7667-2020
OI Kaushal, Mayank/0000-0002-4121-6751
CR Alyemni D, 2017, HUM PATHOL CASE REPO, V7, P23, DOI [10.1016/j.ehpc.2016.06.002, DOI 10.1016/J.EHPC.2016.06.002]
   Antunes ACM, 2002, ARQ NEURO-PSIQUIAT, V60, P730, DOI 10.1590/S0004-282X2002000500009
   Bernabeu A, 2013, J NEUROL RES, V3, P150
   Bisio M, 2013, EMERG INFECT DIS, V19, P1490, DOI 10.3201/eid1909.130667
   Buccheri R, 2015, REV INST MED TROP SP, V57, P531, DOI 10.1590/S0036-46652015000600014
   Burgos JM, 2005, AM J TROP MED HYG, V73, P1016, DOI 10.4269/ajtmh.2005.73.1016
   Burgos JM, 2008, AM J TROP MED HYG, V78, P294, DOI 10.4269/ajtmh.2008.78.294
   Campo M, 2010, CLIN INFECT DIS, V50, P239, DOI 10.1086/649538
   Cicora F, 2014, TRANSPL INFECT DIS, V16, P813, DOI 10.1111/tid.12265
   Cohen JE, 1998, SURG NEUROL, V49, P324, DOI 10.1016/S0090-3019(97)00173-0
   Cordova E, 2008, INT J INFECT DIS, V12, P587, DOI 10.1016/j.ijid.2007.12.007
   Cordova E, 2010, NEUROL RES, V32, P238, DOI 10.1179/016164110X12644252260637
   Corti M, 2000, AIDS PATIENT CARE ST, V14, P581, DOI 10.1089/10872910050193752
   Corti M, 2006, REV SOC BRAS MED TRO, V39, P85, DOI 10.1590/S0037-86822006000100018
   Coura JR, 2007, MEM I OSWALDO CRUZ, V102, P113, DOI 10.1590/S0074-02762007000900018
   Coura JR, 2010, ACTA TROP, V115, P5, DOI 10.1016/j.actatropica.2010.03.008
   Da Mata JR, 2000, BRAIN RES BULL, V53, P153, DOI 10.1016/S0361-9230(00)00326-9
   Santos Eder de Oliveira, 2002, Braz J Infect Dis, V6, P317, DOI 10.1590/S1413-86702002000600009
   DELCASTILLO M, 1990, AM J MED, V88, P693, DOI 10.1016/0002-9343(90)90544-N
   DiazGranados CA, 2009, LANCET INFECT DIS, V9, P324, DOI 10.1016/S1473-3099(09)70088-X
   DiLorenzo GA, 1996, J NEUROIMAGING, V6, P94
   dos Santos SD, 1999, T ROY SOC TROP MED H, V93, P535
   Fernandes HJ, 2017, AM J TROP MED HYG, V96, P292, DOI 10.4269/ajtmh.16-0225
   Ferreira MS, 2002, MEM I OSWALDO CRUZ, V97, P443, DOI 10.1590/S0074-02762002000400001
   Ferreira MS, 1997, CLIN INFECT DIS, V25, P1397, DOI 10.1086/516130
   Gallo P, 1992, Arq Neuropsiquiatr, V50, P375
   GLUCKSTEIN D, 1992, AM J MED, V92, P429, DOI 10.1016/0002-9343(92)90275-G
   Harms G, 2005, INFECT DIS CLIN N AM, V19, P121, DOI 10.1016/j.idc.2004.10.002
   HOFF R, 1978, NEW ENGL J MED, V298, P604, DOI 10.1056/NEJM197803162981106
   Pittella JEH, 2009, T ROY SOC TROP MED H, V103, P973, DOI 10.1016/j.trstmh.2009.04.012
   Karp CL, 2007, CLIN INFECT DIS, V45, P1208, DOI 10.1086/522181
   Lages-Silva E, 2002, CLIN INFECT DIS, V34, P118, DOI 10.1086/324355
   Lambert N, 2006, ANN INTERN MED, V144, P941, DOI 10.7326/0003-4819-144-12-200606200-00018
   Lury KM, 2005, AM J ROENTGENOL, V185, P550, DOI 10.2214/ajr.185.2.01850550
   MADALOSSO G, 2004, REV INST MED TROP SP, V46, P199
   Marchiori PE, 2007, J HEART LUNG TRANSPL, V26, P1091, DOI 10.1016/j.healun.2007.07.043
   METZE K, 1993, NEUROLOGY, V43, P447, DOI 10.1212/WNL.43.2.447-a
   Nijjar SS, 2007, CAN MED ASSOC J, V176, P448, DOI 10.1503/cmaj.060540
   NISHIOKA SD, 1993, MEM I OSWALDO CRUZ, V88, P493
   ODDO D, 1992, HUM PATHOL, V23, P41, DOI 10.1016/0046-8177(92)90009-R
   Pagano MA, 1999, ANN NEUROL, V45, P403, DOI 10.1002/1531-8249(199903)45:3&lt;403::AID-ANA20&gt;3.0.CO;2-K
   Pimentel PCA, 1996, ARQ NEURO-PSIQUIAT, V54, P102, DOI 10.1590/S0004-282X1996000100017
   Pittella Jose Eymard Homem, 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P111, DOI 10.1590/S0036-46651993000200001
   Rocha Ademir, 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P205, DOI 10.1590/S0036-46651993000200014
   ROSEMBERG S, 1992, NEUROLOGY, V42, P640, DOI 10.1212/WNL.42.3.640
   Spadafora MSR, 2014, ANAL CELL PATHOL, V2014, DOI 10.1155/2014/124795
   Salgado Pedro Rippel, 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P285, DOI 10.1590/S0036-46651996000400008
   SARTORI AMC, 1995, CLIN INFECT DIS, V21, P1297, DOI 10.1093/clinids/21.5.1297
   Sica REP, 2008, ARQ NEURO-PSIQUIAT, V66, P881, DOI 10.1590/S0004-282X2008000600021
   Silva N, 1999, J ACQ IMMUN DEF SYND, V20, P342, DOI 10.1097/00042560-199904010-00004
   SOLARI A, 1993, CLIN INFECT DIS, V16, P255, DOI 10.1093/clind/16.2.255
   Vaidian Anil K, 2004, Kinetoplastid Biol Dis, V3, P2, DOI 10.1186/1475-9292-3-2
   Verdu J, 2009, INT J INFECT DIS, V13, pE527, DOI 10.1016/j.ijid.2009.02.013
   Yasukawa K, 2014, AM J TROP MED HYG, V91, P84, DOI 10.4269/ajtmh.14-0058
   Yoo TW, 2004, CLIN INFECT DIS, V39, pE30, DOI 10.1086/422456
NR 55
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 225
EP 231
DI 10.1016/j.wneu.2019.05.260
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900153
PM 31176839
DA 2020-05-12
ER

PT J
AU Mackel, CE
   Devaiah, A
   Holsapple, J
   Moore, JM
AF Mackel, Charles E.
   Devaiah, Anand
   Holsapple, James
   Moore, Justin M.
TI Neural Crest Cell Failure as Embryogenesis for Fusiform Aneurysm of the
   Anterior Communicating Artery: Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Anterior communicating artery; Encephalocele; Fusiform aneurysm; Neural
   crest; Pituitary
ID INTERNAL CAROTID-ARTERY; PITUITARY HYPOPLASIA; HORMONE DEFICIENCY; FLOW
   DIVERSION; AGENESIS; MANAGEMENT; STENTS
AB BACKGROUND: Pure fusiform aneurysms of the anterior communicating artery (AcomA) are rare. We report a unique case of a patient with an AComA fusiform aneurysm in the setting of several unusual cranial neurocristopathies, including a hypoplastic internal carotid artery (ICA), persistent craniopharyngeal canal, transsphenoidal encephalocele, and ectopic, duplicated pituitary gland. We also review the literature on cranial base neurocristopathies and AComA fusiform aneurysms.
   CASE DESCRIPTION: This 46-year-old patient had a history of short stature, osteoporosis, obesity, cleft lip, decreased libido, congenital left eye blindness, headaches, and chronic nasal congestion. Magnetic resonance imaging revealed a 25 x 25 x 33 mm heterogenous soft tissue mass with an ectopic pituitary gland extending transsphenoidally and a duplicated pituitary stalk. A hormone panel revealed undetectable insulin-like growth factor 1 and growth hormone, central hypogonadism, and elevated prolactin. Before presentation, computed tomography angiography (CTA) had revealed a congenitally hypoplastic right ICA and 4.7 x 10.7 mm fusiform aneurysm of the AComA. Digital subtraction angiography confirmed stable morphology after 9 years. Nonoperative management of aneurysm and cephalocele was elected, with repeat CTA in 1 year.
   CONCLUSIONS: This case provides evidence that inherent arterial wall defects can contribute to fusiform aneurysm formation in the AComA. We propose that small AComA fusiform aneurysms without sclerotic or symptomatic features can be safely observed by describing the longest reported conservative management for this type of aneurysm. A high degree of suspicion for cerebrovascular anomalies should be maintained in patients who present with cranial neurocristopathy.
C1 [Mackel, Charles E.; Moore, Justin M.] Beth Israel Deaconess Med Ctr, Dept Neurosurg, Boston, MA 02215 USA.
   [Devaiah, Anand] Boston Med Ctr, Dept Otolaryngol Head & Neck Surg, Boston, MA USA.
   [Holsapple, James] Boston Med Ctr, Dept Neurosurg, Boston, MA USA.
RP Mackel, CE (reprint author), Beth Israel Deaconess Med Ctr, Dept Neurosurg, Boston, MA 02215 USA.
EM cmackel@bidmc.harvard.edu
CR Blustajn J, 1999, AM J NEURORADIOL, V20, P1154
   Clarencon F, 2017, CLIN NEURORADIOL, V27, P51, DOI 10.1007/s00062-015-0441-8
   Colby GP, 2017, J NEUROINTERV SURG, V9, P679, DOI 10.1136/neurintsurg-2016-012946
   Dabus G, 2017, J NEUROINTERV SURG, V9, P147, DOI 10.1136/neurintsurg-2016-012519
   DIEBLER C, 1983, NEURORADIOLOGY, V25, P199, DOI 10.1007/BF00540233
   Hernesniemi J, 2008, SURG NEUROL, V70, P8, DOI 10.1016/j.surneu.2008.01.056
   Inamo Y, 2003, EUR J PEDIATR, V162, P610, DOI 10.1007/s00431-003-1272-1
   Kjellin IB, 1999, PEDIATR RADIOL, V29, P586, DOI 10.1007/s002470050654
   Komiyama M, 2017, CHILD NERV SYST, V33, P567, DOI 10.1007/s00381-017-3369-2
   Lamine Faiza, 2012, Pituitary, V15 Suppl 1, pS81, DOI 10.1007/s11102-012-0411-y
   LITTLE JR, 1981, STROKE, V12, P183, DOI 10.1161/01.STR.12.2.183
   Marsot-Dupuch K, 2004, AM J NEURORADIOL, V25, P285
   Mellado JM, 2001, NEURORADIOLOGY, V43, P237, DOI 10.1007/s002340000460
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Michelozzi C, 2019, J NEUROSURG, V131, P1751, DOI 10.3171/2018.7.JNS18654
   Moon J, 2019, CLIN NEURORADIOL, V29, P717, DOI 10.1007/s00062-018-0695-z
   Moon WJ, 2002, NEURORADIOLOGY, V44, P138, DOI 10.1007/s002340100678
   NAKASU Y, 1984, SURG NEUROL, V21, P511, DOI 10.1016/0090-3019(84)90460-9
   Nakatomi H, 2000, STROKE, V31, P896, DOI 10.1161/01.STR.31.4.896
   Padget Dorcas Hager, 1948, CONTRIBUTIONS TO EMBRYOLOGY [CARNEGIE INST OF WASHINGTON PUBL], V32, P205
   PERLMUTTER D, 1976, J NEUROSURG, V45, P259, DOI 10.3171/jns.1976.45.3.0259
   Pia HW, 1979, CEREBRAL ANEURYSMS A, P109
   Pico F, 2003, NEUROLOGY, V61, P1736, DOI 10.1212/01.WNL.0000103168.14885.A8
   Pico F, 2015, LANCET NEUROL, V14, P833, DOI 10.1016/S1474-4422(15)00089-7
   Sacho RH, 2014, STROKE, V45, P3251, DOI 10.1161/STROKEAHA.114.006292
   Saleme S, 2014, NEUROSURGERY, V75, P623, DOI 10.1227/NEU.0000000000000522
   Sampath R, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181faaa45
   Savasta S, 2012, J CLIN ENDOCR METAB, V97, P3414, DOI 10.1210/jc.2011-3389
   Seixas D, 2006, Neuroradiol J, V19, P629
   Shimada A, 2016, HORM RES PAEDIAT, V86, P62, DOI 10.1159/000446280
   Shulman DI, 1996, J PEDIATR ENDOCR MET, V9, P539
   Stagi S, 2015, BMC ENDOCR DISORD, V15, DOI 10.1186/s12902-015-0037-y
   Takaya R, 1996, CLIN PEDIAT ENDOC S8, V5, P127
   Tarulli E, 2010, AM J NEURORADIOL, V31, P1186, DOI 10.3174/ajnr.A2065
   TRIULZI F, 1994, PEDIATRICS, V93, P409
   Ujiie H, 1996, STROKE, V27, P2086, DOI 10.1161/01.STR.27.11.2086
   Vega-Lopez GA, 2018, DEV BIOL, V444, pS110, DOI 10.1016/j.ydbio.2018.05.013
   Zurkirchen L, 2017, CURR OPIN NEUROBIOL, V47, P16, DOI 10.1016/j.conb.2017.07.001
NR 38
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 232
EP 236
DI 10.1016/j.wneu.2019.06.011
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900154
PM 31203061
DA 2020-05-12
ER

PT J
AU Aydin, S
AF Aydin, Seckin
TI Intracranial Penetrating Trauma Caused by Fishing Sinker
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fishing sinker; Foreign body; Intracranial penetrating trauma;
   Sports-related injury
ID BRAIN-INJURY; GUNSHOT WOUNDS
AB BACKGROUND: Intracranial penetrating traumas (IPTs) are rarely encountered in neurosurgery practice. Here, we report the case of a patient with orbital and cranial trauma caused by an unexpected object.
   CASE DESCRIPTION: A 37-year-old male presenting with a right orbital penetrating injury was referred to our emergency department. Neurologic examination of the patient revealed right periorbital ecchymosis, a dilated and fixed right pupil, and right hemiparesis. Cranial computed tomography showed fractures of the right orbital medial wall and the anterior skull base, as well as bifrontal and left parietal intracerebral hemorrhage accompanied by a metallic foreign body artifact. Emergency left frontoparietal decompressive craniectomy was performed, and the foreign body, identified as a fishing sinker, was removed. No additional postoperative complications were observed, and cranioplasty was performed 6 months postoperatively.
   CONCLUSIONS: IPTs have high morbidity and mortality rates. Early surgical intervention is often the first treatment option. Intracranial injury caused by a fishing sinker is an extremely rare low-energy intracranial penetrating trauma, and in the literature, this is the first reported case in which the patient survived.
C1 [Aydin, Seckin] Univ Hlth Sci, Okmeydani Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
RP Aydin, S (reprint author), Univ Hlth Sci, Okmeydani Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
EM seckin047@hotmail.com
RI aydin, seckin/F-8538-2015
CR Agrawal A, 2016, CRANIOMAX TRAUM REC, V9, P145, DOI 10.1055/s-0035-1551545
   Alfaro DV, 2005, AM J OPHTHALMOL, V139, P488, DOI 10.1016/j.ajo.2004.10.011
   Aydin S, 2011, J NEUROSCI RURAL PRA, V2, P162, DOI 10.4103/0976-3147.83584
   Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Chen PC, 2014, J KOREAN NEUROSURG S, V55, P293, DOI 10.3340/jkns.2014.55.5.293
   Ding XH, 2018, CLIN EXP OPTOM, V101, P297, DOI 10.1111/cxo.12587
   DOUCET TW, 1983, ANN OPHTHALMOL, V15, P325
   Erisen L, 2001, J ORAL MAXIL SURG, V59, P945, DOI 10.1053/joms.2001.25045
   Ferraz V.R., 2016, CASE REP NEUROL MED, V2016
   Kazim Syed Faraz, 2011, J Emerg Trauma Shock, V4, P395, DOI 10.4103/0974-2700.83871
   Kelly DF, 1996, YOUMANS NEUROLOGICAL, P1618
   Liu WH, 2011, J EMERG MED, V41, P482, DOI 10.1016/j.jemermed.2008.03.041
   Malhotra R, 1999, EYE, V13, P260, DOI 10.1038/eye.1999.64
   Ribeiro ALR, 2009, ORAL MAXILLOFAC SURG, V13, P243, DOI 10.1007/s10006-009-0177-1
   Santiago LA, 2012, BRAIN INJURY, V26, P107, DOI 10.3109/02699052.2011.635363
   Seitelman E, 2009, ANN EMERG MED, V54, P854, DOI 10.1016/j.annemergmed.2009.04.014
   Solmaz I, 2009, TURK NEUROSURG, V19, P216
   STONE JL, 1995, NEUROSURGERY, V37, P1104, DOI 10.1227/00006123-199512000-00010
   Vakil MT, 2017, EMERG RADIOL, V24, P301, DOI 10.1007/s10140-016-1477-z
   Weaver AA, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4003328
   Werner Jr JK, 2012, OPERATIVE NEUROSURGI, P1619
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 237
EP 240
DI 10.1016/j.wneu.2019.06.051
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900155
PM 31207368
DA 2020-05-12
ER

PT J
AU Toljan, K
   Jovanovic, I
   Nemir, J
   Ozretic, D
   Poljakovic, Z
   Stambolija, V
   Mrak, G
AF Toljan, Karlo
   Jovanovic, Ivan
   Nemir, Jakob
   Ozretic, David
   Poljakovic, Zdravka
   Stambolija, Vasilije
   Mrak, Goran
TI Emergent Rescue Extracranial-Intracranial Bypass for Acute Carotid Stent
   Thrombosis Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid artery thrombosis; Extracranial-intracranial arterial bypass;
   Internal carotid artery dissection; Stent
AB BACKGROUND: Acute stent thrombosis is a rare adverse event following endovascular treatment of carotid artery. Experience on the topic is scarce, making the therapeutic approach a clinical challenge. In cases of intraprocedural acute carotid stent thrombosis, thromboaspiration, thrombectomy, and thrombolysis have been used as successful modalities for achieving recanalization.
   CASE DESCRIPTION: We describe a case of carotid artery dissection treated endovascularly and complicated by intraprocedural stent thrombosis, which was ultimately managed by emergent extracranial-intracranial bypass with radial artery graft connecting the external carotid artery to the ipsilateral middle cerebral artery.
   CONCLUSIONS: Neurosurgical management may represent a rescue option for otherwise unmanageable acute carotid stent thrombosis.
C1 [Toljan, Karlo; Poljakovic, Zdravka] Univ Hosp Ctr Zagreb, Univ Dept Anesthesiol Reanimatol & Intens Care, Dept Neurol, Zagreb, Croatia.
   [Jovanovic, Ivan; Ozretic, David] Univ Hosp Ctr Zagreb, Univ Dept Anesthesiol Reanimatol & Intens Care, Dept Diagnost & Intervent Radiol, Zagreb, Croatia.
   [Nemir, Jakob; Mrak, Goran] Univ Hosp Ctr Zagreb, Univ Dept Anesthesiol Reanimatol & Intens Care, Dept Neurosurg, Zagreb, Croatia.
   [Stambolija, Vasilije] Univ Hosp Ctr Zagreb, Univ Dept Anesthesiol Reanimatol & Intens Care, Div Neuroanesthesia & Neurocrit Care, Zagreb, Croatia.
RP Toljan, K (reprint author), Univ Hosp Ctr Zagreb, Univ Dept Anesthesiol Reanimatol & Intens Care, Dept Neurol, Zagreb, Croatia.
EM karlo.toljan@gmail.com
RI Toljan, Karlo/AAN-2295-2020
OI Toljan, Karlo/0000-0002-3189-9659
CR Burkhardt JK, 2018, WORLD NEUROSURG, V109, pE476, DOI 10.1016/j.wneu.2017.10.005
   Hu W, 2018, INTERV NEUROL, V7, P265, DOI 10.1159/000486247
   Moulakakis KG, 2016, VASC ENDOVASC SURG, V50, P511, DOI 10.1177/1538574416665986
   Reynolds MR, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.10.FOCUS13427
   Sorkin Grant C, 2015, J Vasc Interv Neurol, V8, P50
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 242
EP 244
DI 10.1016/j.wneu.2019.06.052
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900157
PM 31207372
DA 2020-05-12
ER

PT J
AU Pesce, A
   Palmieri, M
   Armocida, D
   Frai, A
   Miscusi, M
   Raco, A
AF Pesce, Alessandro
   Palmieri, Mauro
   Armocida, Daniele
   Frai, Alessandro
   Miscusi, Massimo
   Raco, Antonino
TI Spinal Myxopapillary Ependymoma: The Sapienza University Experience and
   Comprehensive Literature Review Concerning the Clinical Course of 1602
   Patients
SO WORLD NEUROSURGERY
LA English
DT Review
DE Conus medullaris; MRI; Spinal cord; Spinal myxopapillary ependymoma;
   Tumors
ID ANDERSON CANCER CENTER; LONG-TERM OUTCOMES; RADIATION-THERAPY; SURGICAL
   RESECTION; PROGNOSTIC FACTORS; CORD EPENDYMOMAS; RADIOTHERAPY; SURGERY;
   METASTASIS; MANAGEMENT
AB BACKGROUND: Spinal myxopapillary ependymoma (sMPE) is an uncommon primary spinal neoplasm infiltrating the spinal cord, conus medullaris (CM), and nerve roots. It is associated with low resection and high recurrence rates. The purpose of this literature review is to evaluate the exact impact of the involvement of the CM and the role played by gross total resection (GTR) on overall survival (OS).
   METHODS: The English literature was systematically investigated using MEDLINE, the NIH Library, PubMed, and Google Scholar search engines with relevant queries. Case series reporting details concerning OS, GTR, and CM involvement rate were included, with a differential statistical weight given by the number of patients enrolled. A final cohort of 1602 clinical records was analyzed according to the 3 selected end point variables.
   RESULTS: The average age was 36.44 +/- 3.41 years, and the CM was involved in 28.4% +/- 28.2% of cases. The average GTR rate was 53.94% +/- 22.20%. Five- and 10-year OS rates were respectively available in 1170 and 1167 cases, with an average 5- and 10-year OS rate of 94.99% +/- 3.87% and 92.31% +/- 5.73%. By means of analyses performed both on aggregated and disaggregated data a strong positive statistical connection between GTR and increased OS was demonstrated despite the real clinical advantage could range as low as around 1% of increased OS rate.
   CONCLUSIONS: Given the indolent sMPE behavior, it is difficult to evaluate the exact impact of GTR and CM involvement on OS; however, GTR could be associated with a limited survival advantage, whereas CM involvement could be associated with a survival disadvantage.
C1 [Pesce, Alessandro; Frai, Alessandro] IRCCS, Neuromed, Pozzilli, IS, Italy.
   [Palmieri, Mauro; Raco, Antonino] Sapienza Univ Rome, Neurosurg Div, NESMOS Dept, AOU St Andrea, Rome, Italy.
   [Armocida, Daniele] Sapienza Univ Rome, Neurosurg Div, Human Neurosci Dept, AOU Policlin Umberto 1, Rome, Italy.
   [Miscusi, Massimo] Sapienza Univ Corso della Repubbl, Medicosurg Sci & Biotechnol Dept, Neurosurg Div, Latina, LT, Italy.
RP Pesce, A (reprint author), IRCCS, Neuromed, Pozzilli, IS, Italy.
EM ale_pesce83@yahoo.it
RI Pesce, Alessandro/AAC-2223-2020
OI Palmieri, Mauro/0000-0001-5131-1392
CR Abdulaziz M, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15164
   Akyurek S, 2006, J NEURO-ONCOL, V80, P177, DOI 10.1007/s11060-006-9169-2
   Al-Habib A, 2011, SPINAL CORD, V49, P1073, DOI 10.1038/sc.2011.67
   Al-Halabi H, 2010, PEDIATR BLOOD CANCER, V55, P639, DOI 10.1002/pbc.22614
   Andoh H, 2011, ASIAN SPINE J, V5, P68, DOI 10.4184/asj.2011.5.1.68
   Bagley CA, 2009, NEUROSURG REV, V32, P321, DOI 10.1007/s10143-009-0190-8
   Bates JE, 2016, J NEURO-ONCOL, V129, P251, DOI 10.1007/s11060-016-2167-0
   Behmanesh B, 2017, J NEURO-ONCOL, V135, P93, DOI 10.1007/s11060-017-2552-3
   CELLI P, 1993, ACTA NEUROCHIR, V124, P99, DOI 10.1007/BF01401130
   Chang UK, 2002, J NEURO-ONCOL, V57, P133
   Chen X, 2016, ACTA NEUROCHIR, V158, P101, DOI 10.1007/s00701-015-2637-8
   Cimino PJ, 2014, PEDIATR BLOOD CANCER, V61, P1969, DOI 10.1002/pbc.25125
   CLOVER LL, 1993, AM J CLIN ONCOL-CANC, V16, P350, DOI 10.1097/00000421-199308000-00016
   Frati A, 2019, NEUROSURG REV, V42, P115, DOI 10.1007/s10143-018-0961-1
   Gilbert MR, 2010, CURR NEUROL NEUROSCI, V10, P240, DOI 10.1007/s11910-010-0109-3
   Kaner T, 2010, J KOREAN NEUROSURG S, V47, P102, DOI 10.3340/jkns.2010.47.2.102
   Kernohan JW, 1932, CYTOLOGY CELLULAR PA, V3, P993
   Khalatbari MR, 2014, CHILD NERV SYST, V30, P181, DOI 10.1007/s00381-013-2218-1
   Khan NR, 2017, WORLD NEUROSURG, V99, DOI 10.1016/j.wneu.2016.12.022
   Kittel K, 2001, HNO, V49, P298, DOI 10.1007/s001060050749
   Klekamp J, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15151
   Landriel Federico, 2012, Surg Neurol Int, V3, P102, DOI 10.4103/2152-7806.100859
   Lee SH, 2013, NEURO-ONCOLOGY, V15, P921, DOI 10.1093/neuonc/not038
   Lin YH, 2005, J NEURO-ONCOL, V71, P205, DOI 10.1007/s11060-004-1386-y
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Macedo LT, 2011, J CLIN ONCOL, V29, pE795, DOI 10.1200/JCO.2011.36.6625
   McLaughlin N, 2011, CAN J NEUROL SCI, V38, P151, DOI 10.1017/S0317167100011227
   McLendon R, 2007, WHO CLASSIFICATION T, P72
   Nakamura M, 2009, SPINE, V34, pE756, DOI 10.1097/BRS.0b013e3181b34d16
   Ogul H, 2015, SPINE J, V15, pE3, DOI 10.1016/j.spinee.2015.05.005
   Oh MC, 2013, J NEUROSURG-SPINE, V18, P226, DOI 10.3171/2012.12.SPINE12591
   Pica A, 2009, INT J RADIAT ONCOL, V74, P1114, DOI 10.1016/j.ijrobp.2008.09.034
   Raco A, 2005, NEUROSURGERY, V56, P972, DOI 10.1227/01.NEU.0000158318.66568.CC
   Raco A, 2018, J NEUROL SURG PART A, V79, P453, DOI 10.1055/s-0037-1617756
   Raco A, 2017, NEUROSURGERY, V80, P602, DOI 10.1093/neuros/nyw092
   Rege Shrikant V, 2016, J Spine Surg, V2, P216
   Rickert CH, 1999, ACTA NEUROCHIR, V141, P781, DOI 10.1007/s007010050376
   Sakai Y, 2009, SPINE, V34, P1619, DOI 10.1097/BRS.0b013e3181a983d8
   Samuel N, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16147
   Schild SE, 1998, INT J RADIAT ONCOL, V42, P953, DOI 10.1016/S0360-3016(98)00350-2
   Shapey J, 2011, BRIT J NEUROSURG, V25, P122, DOI 10.3109/02688697.2010.503817
   SHAW EG, 1986, INT J RADIAT ONCOL, V12, P323, DOI 10.1016/0360-3016(86)90345-7
   Shelekhova KV, 2018, INT J SURG PATHOL, V26, P364, DOI 10.1177/1066896917748195
   SONNELAND PRL, 1985, CANCER, V56, P883, DOI 10.1002/1097-0142(19850815)56:4<883::AID-CNCR2820560431>3.0.CO;2-6
   Straus D, 2014, BRIT J NEUROSURG, V28, P691, DOI 10.3109/02688697.2014.881464
   Tsai CJ, 2014, NEUROSURGERY, V75, P205, DOI 10.1227/NEU.0000000000000408
   WALDRON JN, 1993, INT J RADIAT ONCOL, V27, P223, DOI 10.1016/0360-3016(93)90231-J
   Wang H, 2013, ONCOL LETT, V6, P487, DOI 10.3892/ol.2013.1397
   Weber DC, 2015, NEURO-ONCOLOGY, V17, P588, DOI 10.1093/neuonc/nou293
   WHITAKER SJ, 1991, J NEUROSURG, V74, P720, DOI 10.3171/jns.1991.74.5.0720
   Woesler B, 1998, NEUROSURG REV, V21, P62, DOI 10.1007/BF01111488
   Wu J, 2016, NEURO-ONCOLOGY, V18, P902, DOI 10.1093/neuonc/now016
   Yener Ulas, 2016, Korean J Spine, V13, P33, DOI 10.14245/kjs.2016.13.1.33
NR 53
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 245
EP 253
DI 10.1016/j.wneu.2019.05.206
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900158
PM 31152881
DA 2020-05-12
ER

PT J
AU Liu, LP
   Liu, XR
   Qu, LM
   Zhang, Y
   Li, YQ
AF Liu, Liping
   Liu, Xinrui
   Qu, Limei
   Zhang, Yi
   Li, Yunqian
TI Giant Saddle Area Lymphoid Epithelial Carcinoma: A Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Giant saddle area; Lymphoid epithelial carcinoma; Radiotherapy
ID EPSTEIN-BARR-VIRUS; LYMPHOEPITHELIOMA-LIKE CARCINOMA; LESION
AB BACKGROUND: This paper reports the case of a giant saddle area lymphoid epithelial carcinoma as reference for clinical diagnosis and treatment. The clinical data of 1 patient who suffered from giant saddle area lymphoid epithelial carcinoma that invaded the bilateral cavernous sinus and surrounding internal carotid artery, slope, nasopharynx, oropharynx, sphenoid sinus, and ethmoid sinus were retrospectively analyzed. The treatment process and relevant literature were summarized.
   CASE DESCRIPTION: The 68-year-old man was admitted to the hospital because of headache and dizziness for one half a year and aggravation of visual deterioration for 2 months. Magnetic resonance imaging showed a large mass in the saddle area, about 8.11 x 8.12 x 6.2 cm in size. Successful removal of the saddle mass was achieved under transnasal endoscopic approach, and postoperative pathology indicated lymphoid epithelial carcinoma. Visual acuity improved, and the patient recovered well after the operation.
   CONCLUSIONS: Giant saddle area lymphoid epithelial carcinoma is rare. Surgical removal should be selected as the initial treatment, and postoperative radiotherapy is indispensable for lymphoid epithelial carcinoma of the skull base and sinus.
C1 [Liu, Liping; Liu, Xinrui; Zhang, Yi; Li, Yunqian] Jilin Univ, First Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China.
   [Qu, Limei] Jilin Univ, First Hosp 1, Dept Pathol, Changchun, Jilin, Peoples R China.
RP Li, YQ (reprint author), Jilin Univ, First Hosp 1, Dept Neurosurg, Changchun, Jilin, Peoples R China.
EM yunqian@jlu.edu.cn
CR BEGIN LR, 1987, J SURG ONCOL, V36, P280, DOI 10.1002/jso.2930360413
   Chen PCH, 2003, HUM PATHOL, V34, P407, DOI 10.1053/hupa.2003.71
   Hajiioannou JK, 2006, J OTOLARYNGOL, V35, P147, DOI 10.2310/7070.2005.5012
   HILDERMAN WC, 1962, CANCER, V15, P606, DOI 10.1002/1097-0142(196205/06)15:3<606::AID-CNCR2820150322>3.0.CO;2-U
   IEZZONI JC, 1995, AM J CLIN PATHOL, V103, P308, DOI 10.1093/ajcp/103.3.308
   Jakobiec FA, 2017, OPHTHAL PLAST RECONS, V33, pE1, DOI 10.1097/IOP.0000000000000358
   Jung H, 2009, AURIS NASUS LARYNX, V36, P487, DOI 10.1016/j.anl.2008.10.013
   Kermani W, 2015, EUR ANN OTORHINOLARY, V132, P231, DOI 10.1016/j.anorl.2015.05.004
   Kim YH, 2012, AURIS NASUS LARYNX, V39, P519, DOI 10.1016/j.anl.2011.10.005
   Liang Y, 2012, CANCER-AM CANCER SOC, V118, P4748, DOI 10.1002/cncr.27452
   Mohammed Darouichi, 2012, J Med Case Rep, V6, P416, DOI 10.1186/1752-1947-6-416
   Moona MS, 2011, J PAK MED ASSOC, V61, P1235
   Muthayam SR, 2014, QUANT IMAGING MED SU, V4, P512, DOI 10.3978/j.issn.2223-4292.2014.07.01
   Narozny W, 1998, HEAD NECK-J SCI SPEC, V20, P425, DOI 10.1002/(SICI)1097-0347(199808)20:5<425::AID-HED11>3.0.CO;2-F
   Rytkonen AE, 2011, HEAD NECK PATHOL, V5, P327, DOI 10.1007/s12105-011-0278-7
   Sathirareuangchai S, 2019, ARCH PATHOL LAB MED, V143, P1027, DOI 10.5858/arpa.2018-0149-RS
   Takakura H, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011371
   Trabelsi Amel, 2010, World J Oncol, V1, P91, DOI 10.4021/wjon2010.04.204w
   Wu FY, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-18
   Zhao W, 2014, INT J CLIN EXP PATHO, V7, P7951
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 254
EP 260
DI 10.1016/j.wneu.2019.05.176
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900159
PM 31150850
DA 2020-05-12
ER

PT J
AU Ramos, MB
   Teixeira, MJ
   Preul, MC
   Spetzler, RF
   Figueiredo, EG
AF Ramos, Miguel Bertelli
   Teixeira, Manoel Jacobsen
   Preul, Mark C.
   Spetzler, Robert F.
   Figueiredo, Eberval Gadelha
TI A Bibliometric Study of the Most Cited Reports in Central Nervous System
   Arteriovenous Malformations
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arteriovenous malformations; Bibliometrics; Central nervous system;
   Embolization; Microsurgery; Radiosurgery; Therapeutic
ID TOP 50; MANAGEMENT; CLASSIFICATION; PUBLICATIONS; ARTICLES; FISTULAS;
   HEMORRHAGE; WORKS
AB OBJECTIVE: We performed a bibliometric analysis of studies reporting cases of brain and spinal arteriovenous malformations (AVMs).
   METHODS: We retrieved the 100 most cited reports in brain and spinal AVM research from Scopus and assessed the citation count, journal of publication and its impact factor, year of publication, first author and corresponding authors and their h-index, country, institution, department, and study category.
   RESULTS: The median number of citations per article was 215. The Journal of Neurosurgery was the most prolific journal (39 reports and 12,069 citations), including 9 of the 10 most cited reports. Seventy reports (19,251 citations), including 8 of the 10 most cited, were from the United States. The Barrow Neurological Institute was the most cited institution (7 reports; 2792 citations), and the Mayo Clinic had the greatest number of reports (8 reports; 1994 citations). Most studies had been reported before 2000 (71 reports; 19,262 citations). The most discussed topics were treatment (40 studies; 9560 citations) and natural history and/or clinical features (37 studies; 9595 citations). Neurosurgery was the most prolific department (58 studies; 15,860 citations). Spetzler was the author with the highest number of articles (n = 7) and citations (n = 2792).
   CONCLUSIONS: Brain and spinal AVM research was centralized in the United States, has been mainly reported in specific neurosurgical journals, and has been more often related to treatment and natural history and/or clinical features. It is possible that high impact AVM research has been decreasing recently. Because the best approach to these pathological entities remains controversial, research stimulation within this field should be encouraged.
C1 [Ramos, Miguel Bertelli] Univ Caxias do Sul, Sch Med, Caxias Do Sul, Brazil.
   [Teixeira, Manoel Jacobsen; Figueiredo, Eberval Gadelha] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Preul, Mark C.; Spetzler, Robert F.] Barrow Neurol Inst, Phoenix, AZ 85013 USA.
RP Figueiredo, EG (reprint author), Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
EM ebgadelha@yahoo.com
RI Figueiredo, Eberval Gadelha/H-3488-2012
CR Abecassis IJ, 2017, HAND CLINIC, V143, P135, DOI 10.1016/B978-0-444-63640-9.00013-8
   Alan N, 2017, J CLIN NEUROSCI, V42, P19, DOI 10.1016/j.jocn.2017.02.019
   Alfaifi A, 2018, WORLD NEUROSURG, V111, pE454, DOI 10.1016/j.wneu.2017.12.090
   Almutairi O, 2017, WORLD NEUROSURG, V107, P1025, DOI 10.1016/j.wneu.2017.08.021
   Alotaibi NM, 2016, WORLD NEUROSURG, V89, P587, DOI 10.1016/j.wneu.2015.11.072
   Badhiwala JH, 2018, SPINE, V43, P1746, DOI 10.1097/BRS.0000000000002735
   Bohl MA, 2017, WORLD NEUROSURG, V104, P927, DOI 10.1016/j.wneu.2017.03.149
   BORDEN JA, 1995, J NEUROSURG, V82, P166, DOI 10.3171/jns.1995.82.2.0166
   Brinjikji W, 2017, HAND CLINIC, V143, P161, DOI 10.1016/B978-0-444-63640-9.00016-3
   BROWN RD, 1994, J NEUROSURG, V81, P531, DOI 10.3171/jns.1994.81.4.0531
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   Derdeyn CP, 2017, STROKE, V48, pE200, DOI 10.1161/STR.0000000000000134
   Falagas ME, 2008, FASEB J, V22, P338, DOI 10.1096/fj.07-9492LSF
   Gandhi D, 2012, AM J NEURORADIOL, V33, P1007, DOI 10.3174/ajnr.A2798
   Garner RM, 2018, J NEUROINTERV SURG, V10, P102, DOI 10.1136/neurintsurg-2017-013265
   Guo XP, 2018, WORLD NEUROSURG, V116, pE1153, DOI 10.1016/j.wneu.2018.05.189
   Hu KJ, 2017, BRIT J NEUROSURG, V31, P587, DOI 10.1080/02688697.2017.1324109
   Jusue-Torres I, 2018, WORLD NEUROSURG, V119, pE910, DOI 10.1016/j.wneu.2018.08.004
   Kim Louis J, 2006, Neurosurgery, V59, pS195
   Kim LJ, 2006, NEUROSURGERY, V59, P53, DOI 10.1227/01.NEU.0000219219.97287.91
   LASJAUNIAS P, 1986, J NEUROSURG, V64, P724, DOI 10.3171/jns.1986.64.5.0724
   Lawton MT, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.8
   Li L, 2018, WORLD NEUROSURG, V113, pE82, DOI 10.1016/j.wneu.2018.01.164
   Masic Izet, 2016, Acta Inform Med, V24, P228
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   Mulholland CB, 2017, HAND CLINIC, V143, P117, DOI 10.1016/B978-0-444-63640-9.00011-4
   O'Sullivan KE, 2015, IRISH J MED SCI, V184, P91, DOI 10.1007/s11845-014-1193-1
   Ozpinar A, 2017, HAND CLINIC, V143, P145, DOI 10.1016/B978-0-444-63640-9.00014-X
   Rutkowski MJ, 2017, HAND CLINIC, V143, P107, DOI 10.1016/B978-0-444-63640-9.00010-2
   Shekhani HN, 2017, AM J ROENTGENOL, V209, P1191, DOI 10.2214/AJR.17.18077
   Solomon RA, 2017, NEW ENGL J MED, V376, P1859, DOI 10.1056/NEJMra1607407
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Sussman ES, 2017, HAND CLINIC, V143, P175, DOI 10.1016/B978-0-444-63640-9.00017-5
   Tripathi RS, 2011, BMC ANESTHESIOL, V11, DOI 10.1186/1471-2253-11-24
   Wilcox MA, 2013, CHILD NERV SYST, V29, P2201, DOI 10.1007/s00381-013-2228-z
   Xu DS, 2017, HAND CLINIC, V143, P153, DOI 10.1016/B978-0-444-63640-9.00015-1
   Zhou JJ, 2017, SPINE, V42, P336, DOI 10.1097/BRS.0000000000001860
NR 37
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 261
EP 268
DI 10.1016/j.wneu.2019.06.048
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900160
PM 31207367
DA 2020-05-12
ER

PT J
AU Fatima, N
   Meola, A
   Pollom, E
   Chaudhary, N
   Soltys, S
   Chang, SD
AF Fatima, Nida
   Meola, Antonio
   Pollom, Erqi
   Chaudhary, Navjot
   Soltys, Scott
   Chang, Steven D.
TI Stereotactic Radiosurgery in Large Intracranial Meningiomas: A
   Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Gamma knife radiosurgery; Large intracranial meningioma; Stereotactic
   radiosurgery
ID GAMMA-KNIFE RADIOSURGERY; PETROCLIVAL MENINGIOMAS; BRAIN-TUMORS;
   EXPERIENCE; SURGERY; MANAGEMENT; CLIVUS
AB Gross total resection of large intracranial meningiomas (LIMs) can be challenging and cause significant morbidity and mortality. The aim of this systematic review is to determine the clinical effectiveness and safety of stereotactic radiosurgery (SRS) either as primary or adjuvant therapy for LIMs with tumors >= 2.5 cm in maximum dimension (tumor volume >= 8.1 cm(3)). A total of 452 tumors in 496 patients (350 female [69.3%] and 146 male [30.6%]) with median age 60 years (48-65 years) were included. The median tumor volume at the time of diagnosis was 16.7 cm(3) (10-53.3 cm(3)). The tumors typically were located in the skull base (77.2%), whereas only 14.6% were in the supratentorial space. The median follow-up after SRS was 54 months (18-90 months). In total, 87.8% of patients were treated with single-session (SS) Gamma Knife radiosurgery (GKS), whereas the remaining 12.1% patients received non-SS GKS. Of 452 LIMs assessed for clinical response, 45.1% showed improvement and 15.7% deteriorated after SRS. Radiographic tumor control at last follow-up (2-7.5 years) ranged from 84% to 100%. Overall, radiation-induced toxicity occurred in 23% of patients, with the most common adverse effect being cranial nerve neuropathy (5.5%) and peritumoral edema (5.3%). Subgroup analysis revealed that there is 2-fold greater likelihood of improvement in clinical symptoms in patients with non-SS GKS than SS GKS (odds ratio 2.47; 95% confidence interval 1.38-4.44; P = 0.002). SRS is safe and effective in the treatment of LIMs as primary or adjuvant treatment. Further prospective studies are required to validate our results.
C1 [Fatima, Nida; Meola, Antonio; Chaudhary, Navjot; Chang, Steven D.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
   [Pollom, Erqi; Soltys, Scott] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA.
RP Fatima, N (reprint author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
EM fatima@stanford.edu
OI Meola, Antonio/0000-0003-2426-2884
CR Attia M, 2012, J NEUROSURG, V117, P654, DOI 10.3171/2012.7.JNS111675
   Bledsoe JM, 2010, J NEUROSURG, V112, P951, DOI 10.3171/2009.8.JNS09703
   CHAN RC, 1984, J NEUROSURG, V60, P52, DOI 10.3171/jns.1984.60.1.0052
   Chuang CC, 2004, J NEURO-ONCOL, V66, P241, DOI 10.1023/B:NEON.0000013500.11150.36
   Chung CE, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2005JD006356
   Colombo F, 2009, NEUROSURGERY, V64, pA7, DOI 10.1227/01.NEU.0000338947.84636.A6
   Couldwell WT, 1996, J NEUROSURG, V84, P20, DOI 10.3171/jns.1996.84.1.0020
   Ganz J, 2009, ACTA NEUROCHIR, V151, P1, DOI 10.1007/s00701-008-0166-4
   Gosal JS, 2018, NEUROL INDIA, V66, P1434, DOI 10.4103/0028-3886.241354
   Han MS, 2017, WORLD NEUROSURG, V99, P477, DOI 10.1016/j.wneu.2016.12.056
   Haselsberger K, 2009, J NEUROL NEUROSUR PS, V80, P1172, DOI 10.1136/jnnp.2008.156745
   Iwai Y, 2001, SURG NEUROL, V56, P308, DOI 10.1016/S0090-3019(01)00622-X
   Li MS, 2014, J NEUROSURG, V120, P315, DOI 10.3171/2013.11.JNS13552
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Linzer D, 1998, STEREOT FUNCT NEUROS, V70, P11, DOI 10.1159/000056402
   Mathiesen T, 2007, NEUROSURGERY, V60, P982, DOI 10.1227/01.NEU.0000255476.06247.F1
   MAYBERG MR, 1986, J NEUROSURG, V65, P160, DOI 10.3171/jns.1986.65.2.0160
   Morita A, 1999, J NEUROSURG, V90, P42, DOI 10.3171/jns.1999.90.1.0042
   Nguyen JH, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.07.042
   Nishimura S, 1989, Neurol Med Chir (Tokyo), V29, P1004, DOI 10.2176/nmc.29.1004
   Novotny J, 2006, J NEUROSURG, V105, P120
   Park HR, 2018, EXP NEUROBIOL, V27, P245, DOI 10.5607/en.2018.27.3.245
   Pollock BE, 2000, NEUROSURG CLIN N AM, V11, P659, DOI 10.1016/S1042-3680(18)30091-3
   Pollock BE, 2003, INT J RADIAT ONCOL, V55, P1000, DOI 10.1016/S0360-3016(02)04356-0
   Pollock BE, 2012, INT J RADIAT ONCOL, V83, P1414, DOI 10.1016/j.ijrobp.2011.10.033
   Rashid A, 2012, J RADIOSURGERY SBRT, V2, P29
   Sanai N, 2010, J NEUROSURG, V112, P907, DOI 10.3171/2009.6.JNS09120
   SEKHAR LN, 1990, NEUROSURGERY, V27, P764, DOI 10.1227/00006123-199011000-00015
   SPETZLER RF, 1992, J NEUROSURG, V76, P588, DOI 10.3171/jns.1992.76.4.0588
   Starke RM, 2015, J NEUROSURG, V122, P363, DOI 10.3171/2014.10.JNS14198
   Su CF, 2017, J CHIN MED ASSOC, V80, P697, DOI 10.1016/j.jcma.2017.03.011
   Yang J, 2013, CHINESE MED J-PEKING, V126, P4470, DOI 10.3760/cma.j.issn.0366-6999.20131029
   Yang J, 2011, BRIT J NEUROSURG, V25, P78, DOI 10.3109/02688697.2010.539716
NR 33
TC 2
Z9 3
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 269
EP 275
DI 10.1016/j.wneu.2019.06.064
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900161
PM 31226450
DA 2020-05-12
ER

PT J
AU Kim, JH
   Yoon, D
   Kim, KN
   Shin, DA
   Yi, S
   Kang, J
   Ha, Y
AF Kim, Jung Hwa
   Yoon, Do Heum
   Kim, Keung Nyun
   Shin, Dong Ah
   Yi, Seong
   Kang, Jiin
   Ha, Yoon
TI Surgical Management of Gorham-Stout Disease in Cervical Compression
   Fracture with Cervicothoracic Fusion: Case Report and Review of
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cervicothoracic fusion; Compression fracture; Gorham-Stout disease;
   Spine
ID SPINE
AB BACKGROUND: Gorham-Stout disease (GSD) or "vanishing bone" disease is characterized by progressive osteolysis with intraosseous lymphangiomatosis (hemangiomatosis). Given its rarity, with about 300 reported cases, its pathophysiology, etiology, and treatment guidelines are not established yet.
   CASE DESCRIPTION: A 22-year-old man was admitted to Severance Hospital with the chief complaint of neck pain from an injury due to falling. Initial cervical radiography showed a C4 burst fracture, and cervical magnetic resonance imaging revealed diffuse osteolytic lesions with coarse trabeculation with T2 hyperintensity and T1 enhancement in the entire cervical and upper thoracic area. He had a previous history of chylothorax that was still noticeable on a chest radiograph at the time of admission. A 2-stage operation was conducted. First, anterior corpectomy of C4 and anterior plate fixation of C3-5 were performed. Second, a week later, posterior fixation of C3-5 was performed. Thereafter, the patient was discharged without any neurologic complications. However, during the 1-month follow-up, asymptomatic progressive kyphosis was detected via radiography, and posterior cervical fusion of C2-T4 was performed. A minimal postoperative symptom of an intermittent left arm pain of 4-5 on the visual analog scale was experienced. No further deformity progression was noted until the last outpatient follow-up.
   CONCLUSIONS: Spinal GSD can cause severe deformity and neurologic deficits such as paralysis. Although treatment for GSD is not established, surgical treatment is recommended in severe deformity or aggravated neurologic deficit. The appropriate timing of surgery is after the arrest of osteolysis. Magnetic resonance imaging could be helpful in determining stable GSD.
C1 [Kim, Jung Hwa; Yoon, Do Heum; Kim, Keung Nyun; Shin, Dong Ah; Yi, Seong; Kang, Jiin; Ha, Yoon] Yonsei Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.
RP Kang, J (reprint author), Yonsei Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.
EM JIINHANES@yuhs.ad
OI Shin, Dong Ah/0000-0002-5225-4083; Yoon, Do Heum/0000-0003-1452-5724;
   Kim, Keung Nyun/0000-0003-2248-9188
CR Aizawa T, 2005, TOHOKU J EXP MED, V205, P187, DOI 10.1620/tjem.205.187
   Barman A, 2013, NEUROREHABILITATION, V33, P121, DOI 10.3233/NRE-130935
   Colucci S, 2006, J BONE MINER RES, V21, P207, DOI 10.1359/JBMR.051019
   Dellinger MT, 2014, BONE, V63, P47, DOI 10.1016/j.bone.2014.02.011
   Franchi A, 2009, J CLIN PATHOL, V62, P163, DOI 10.1136/jcp.2008.060160
   Gondivkar SM, 2010, ORAL SURG ORAL MED O, V109, pE41, DOI 10.1016/j.tripleo.2009.08.043
   GORHAM LW, 1954, AM J MED, V17, P674, DOI 10.1016/0002-9343(54)90027-3
   Gowin W, 1985, Rontgenpraxis, V38, P128
   Hagendoorn J, 2014, PEDIATR BLOOD CANCER, V61, P401, DOI 10.1002/pbc.24832
   HARDEGGER F, 1985, J BONE JOINT SURG BR, V67, P89
   Harvey NL, 2012, VASC CELL, V4, DOI 10.1186/2045-824X-4-15
   HEFFEZ L, 1983, ORAL SURG ORAL MED O, V55, P331, DOI 10.1016/0030-4220(83)90185-8
   Heyd R, 2011, INT J RADIAT ONCOL, V81, pE179, DOI 10.1016/j.ijrobp.2011.01.006
   Franco-Barrera MJ, 2017, CLIN REV ALLERG IMMU, V52, P125, DOI 10.1007/s12016-016-8594-z
   Kato H, 2017, JPN J RADIOL, V35, P606, DOI 10.1007/s11604-017-0674-3
   Lee WS, 2002, J KOREAN MED SCI, V17, P826, DOI 10.3346/jkms.2002.17.6.826
   Liu Y, 2016, CLIN RHEUMATOL, V35, P813, DOI 10.1007/s10067-014-2780-2
   Renacci RM, 2017, CLIN IMAG, V41, P83, DOI 10.1016/j.clinimag.2016.10.007
   Schell A, 2016, SPINE J, V16, pE467, DOI 10.1016/j.spinee.2016.02.020
   Sekharappa V, 2013, ASIAN SPINE J, V7, P242, DOI 10.4184/asj.2013.7.3.242
   Tateda S, 2017, TOHOKU J EXP MED, V241, P249, DOI 10.1620/tjem.241.249
   VINEE P, 1994, J COMPUT ASSIST TOMO, V18, P985, DOI 10.1097/00004728-199411000-00028
   Yeter HH, 2017, ALEX J MED, V53, P193, DOI 10.1016/j.ajme.2016.03.006
NR 23
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 277
EP 281
DI 10.1016/j.wneu.2019.05.235
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900163
PM 31158540
DA 2020-05-12
ER

PT J
AU Nakashima, T
   Iijima, K
   Muraoka, S
   Koketsu, N
AF Nakashima, Takuma
   Iijima, Kentaro
   Muraoka, Shinsuke
   Koketsu, Naoki
TI Acute Hydrocephalus Requiring External Ventricular Drainage Following
   Perimesencephalic Nonaneurysmal Subarachnoid Hemorrhage in a Pediatric
   Patient: Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Acute hydrocephalus; Basal vein of Rosenthal; External ventricular
   drainage; Pediatric neurosurgery; Perimesencephalic nonaneurysmal
   subarachnoid hemorrhage
AB BACKGROUND: Perimesencephalic nonaneurysmal subarachnoid hemorrhage (PNSAH) is a well-described subset of subarachnoid hemorrhage with an excellent prognosis in adults. However, its characteristics in the pediatric population have not yet been fully understood. We present a case of acute hydrocephalus requiring external ventricular drainage following pediatric PNSAH.
   CASE DESCRIPTION: A previously healthy 10-year-old girl was admitted to our neurosurgical department after sudden onset of severe headache with vomiting during exercise. Cerebral non-contrast computed tomography detected subarachnoid hemorrhage filling all perimesencephalic cisterns. However, digital subtraction angiography could not locate the hemorrhage source. Her consciousness deteriorated within 7 hours of onset, and a computed tomography scan revealed acute hydrocephalus. We subjected the patient to external ventricular drainage for 10 days. She was discharged after 38 days of hospitalization, when she was physically and neuropsychologically healthy. Repeated digital subtraction angiography performed at the 6-month follow-up did not show any obvious source of hemorrhage except for a variant drainage pattern of the basal vein of Rosenthal. Based on the observations, we diagnosed the patient with PNSAH of a venous origin.
   CONCLUSIONS: We propose that acute hydrocephalus be suspected in pediatric patients with nonaneurysmal subarachnoid hemorrhage filling all perimesencephalic cisterns, as in adults. We also propose that one of the possible causes of pediatric PNSAH as of venous origin and related to the abnormal drainage pattern of basal vein of Rosenthal and elevation of venous pressure with exercise. Immediate surgical drainage could obtain a good outcome in a symptomatic case.
C1 [Nakashima, Takuma; Iijima, Kentaro; Muraoka, Shinsuke; Koketsu, Naoki] Tosei Gen Hosp, Dept Neurosurg, Seto, Aichi, Japan.
   [Iijima, Kentaro] Chikuma Cent Hosp, Dept Neurosurg, 58 Kuiseke, Chikuma, Nagano 3878512, Japan.
RP Nakashima, T (reprint author), Tosei Gen Hosp, Dept Neurosurg, Seto, Aichi, Japan.
EM t.nakasima1028@gmail.com
OI Muraoka, Shinsuke/0000-0003-4225-110X
CR Anderson RC, 2002, PEDIATR NEUROSURG, V37, P258, DOI 10.1159/000066218
   BACHOFEN H, 1968, PEDIATR RES, V2, P119, DOI 10.1203/00006450-196803000-00007
   Boswell S, 2013, J STROKE CEREBROVASC, V22, P750, DOI 10.1016/j.jstrokecerebrovasdis.2012.02.001
   Fukumura S, 2008, NIPPON SHONIKA GAKKA, V112, P848
   Kim SE, 2018, WORLD NEUROSURG, V119, pE216, DOI 10.1016/j.wneu.2018.07.119
   Linn FHH, 1998, J NEUROL NEUROSUR PS, V65, P791, DOI 10.1136/jnnp.65.5.791
   Matsuyama T, 2006, NEUROL MED-CHIR, V46, P277, DOI 10.2176/nmc.46.277
   Mensing LA, 2018, STROKE, V49, P1363, DOI 10.1161/STROKEAHA.117.019843
   Naglieri JA, 1997, INTERPRETIVE HDB
   RINKEL GJE, 1991, LANCET, V338, P964, DOI 10.1016/0140-6736(91)91836-J
   RINKEL GJE, 1992, NEUROLOGY, V42, P1805, DOI 10.1212/WNL.42.9.1805
   Rouchaud A, 2016, AM J NEURORADIOL, V37, P1657, DOI 10.3174/ajnr.A4806
   SCHIEVINK WI, 1994, STROKE, V25, P1507, DOI 10.1161/01.STR.25.7.1507
   Sert A, 2005, PEDIATR NEUROL, V32, P275, DOI 10.1016/j.pediatrneurol.2004.09.011
   Shirai K., 2010, No To Hattatsu, V42, P60
   VANGIJN J, 1985, NEUROLOGY, V35, P493, DOI 10.1212/WNL.35.4.493
   Watanabe A, 2002, NEURORADIOLOGY, V44, P319, DOI 10.1007/s00234-001-0741-3
   Wechsler D, 2004, INTEGRATED TECHNICAL
   Yamakawa H, 2008, CLIN NEUROL NEUROSUR, V110, P587, DOI 10.1016/j.clineuro.2008.03.001
NR 19
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 283
EP 286
DI 10.1016/j.wneu.2019.06.090
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900165
PM 31229747
DA 2020-05-12
ER

PT J
AU Derraz, I
   Lefevre, PH
   Cagnazzo, F
   Dargazanli, C
   Gascou, G
   Costalat, V
AF Derraz, Imad
   Lefevre, Pierre-Henri
   Cagnazzo, Federico
   Dargazanli, Cyril
   Gascou, Gregory
   Costalat, Vincent
TI Recurrent Bleeding After Perimesencephalic Hemorrhage: Case Report and
   Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Angiography; Computed tomography angiography; Perimesencephalic
   hemorrhage; Recurrence
ID NONANEURYSMAL SUBARACHNOID HEMORRHAGE; FOLLOW-UP; VENOUS DRAINAGE;
   PATTERNS; YIELD
AB BACKGROUND: Perimesencephalic hemorrhage (PMH), a subtype of non-aneurysmal subarachnoid hemorrhage, is characterized by a typical pattern of localized hemorrhage on head computed tomography. PMH is usually associated with a benign clinical course, and a lower incidence of complications such as vasospasm and rebleeding.
   CASE DESCRIPTION: We present the cases of a man aged 28 years and a woman aged 21 years with no relevant medical history who experienced recurrent, spontaneous episodes of PMH within the course of 7 days and 29 months. No precipitating causes were identified.
   CONCLUSIONS: There are only a couple of case reports of recurrent PMH, some of which were defined questionably. We review the reported cases and discuss the possible causes and long-term outcomes. Neurointerventionalists and neurosurgeons should be aware that the risk of recurrent hemorrhage of PMH does exist, although it is rather low. Even after early or late rebleeding, prognosis of PMH is excellent.
C1 [Derraz, Imad; Lefevre, Pierre-Henri; Cagnazzo, Federico; Dargazanli, Cyril; Gascou, Gregory; Costalat, Vincent] Montpellier Univ, Med Ctr, Hop Gui de Chauliac, Dept Neuroradiol, Montpellier, France.
RP Derraz, I (reprint author), Montpellier Univ, Med Ctr, Hop Gui de Chauliac, Dept Neuroradiol, Montpellier, France.
EM i-derraz@chu-montpellier.fr
OI Lefevre, Pierre-Henri/0000-0002-6196-3869
CR Alen JF, 2003, J NEUROSURG, V98, P529, DOI 10.3171/jns.2003.98.3.0529
   Andaluz N, 2008, NEUROSURGERY, V62, P1040, DOI 10.1227/01.neu.0000325865.22011.1f
   Boerboom W, 2014, J REHABIL MED, V46, P28, DOI 10.2340/16501977-1236
   Burke T, 2018, NEUROPSYCHOL REV, V28, P453, DOI 10.1007/s11065-018-9389-1
   Chavent A, 2014, J NEUROSURG, V121, P1107, DOI 10.3171/2014.7.JNS132411
   GIJN J, 1985, NEUROLOGY, V35, P493
   Hafez A, 2016, ACTA NEUROCHIR, V158, P1045, DOI 10.1007/s00701-016-2801-9
   Hong Y, 2017, WORLD NEUROSURG, V107, P877, DOI 10.1016/j.wneu.2017.08.079
   Ildan F, 2002, SURG NEUROL, V57, P160, DOI 10.1016/S0090-3019(02)00630-4
   Kalra VB, 2015, STROKE, V46, P401, DOI 10.1161/STROKEAHA.114.007370
   Kalra VB, 2014, STROKE, V45, P3576, DOI 10.1161/STROKEAHA.114.006679
   Kauw F, 2017, WORLD NEUROSURG, V108, DOI 10.1016/j.wneu.2017.08.134
   Kim SE, 2018, WORLD NEUROSURG, V119, pE216, DOI 10.1016/j.wneu.2018.07.119
   Konczalla J, 2016, J NEUROSURG, V124, P1731, DOI 10.3171/2015.5.JNS15161
   Konczalla J, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-140
   Lee SU, 2018, WORLD NEUROSURG, V115, pE558, DOI 10.1016/j.wneu.2018.04.096
   Madureira S, 2000, J NEUROL, V247, P862, DOI 10.1007/s004150070074
   Malhotra A, 2016, WORLD NEUROSURG, V94, DOI 10.1016/j.wneu.2016.07.112
   Marquardt G, 2000, J NEUROL NEUROSUR PS, V69, P127, DOI 10.1136/jnnp.69.1.127
   Mensing LA, 2018, STROKE, V49, P1363, DOI 10.1161/STROKEAHA.117.019843
   Potter CA, 2016, RADIOLOGY, V281, P858, DOI 10.1148/radiol.2016152402
   Rahme R, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.07.040
   Reynolds MR, 2011, J NEUROSURG, V115, P612, DOI 10.3171/2011.5.JNS102020
   RINKEL GJE, 1991, LANCET, V338, P964, DOI 10.1016/0140-6736(91)91836-J
   RINKEL GJE, 1991, AM J NEURORADIOL, V12, P829
   Rouchaud A, 2016, AM J NEURORADIOL, V37, P1657, DOI 10.3174/ajnr.A4806
   Schievink WI, 2000, MAYO CLIN PROC, V75, P1169, DOI 10.4065/75.11.1169
   van der Schaaf IC, 2004, STROKE, V35, P1614, DOI 10.1161/01.STR.0000131657.08655.ce
   van der Worp HB, 2009, NEUROCRIT CARE, V10, P209, DOI 10.1007/s12028-008-9160-1
   White JB, 2008, NEUROLOGY, V71, P1375, DOI 10.1212/01.wnl.0000327684.85469.b2
NR 30
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 287
EP 291
DI 10.1016/j.wneu.2019.06.050
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900166
PM 31207375
DA 2020-05-12
ER

PT J
AU Jain, A
   Goyal, K
   Meher, R
   Passey, JC
AF Jain, Avani
   Goyal, Kavita
   Meher, Ravi
   Passey, J. C.
TI Internal Carotid Artery Bleed: A Rare Complication of Invasive
   Sphenoidal Aspergillosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aspergillosis; Internal carotid artery; Invasive Aspergillus sinusitis
AB BACKGROUND: Invasive sinonasal aspergillosis is rarely seen in immunocompetent individuals. It may involve adjacent intracranial and intraorbital structures causing high morbidity and mortality.
   CASE DESCRIPTION: We report a rare case of invasive Aspergillus sinusitis in a young, immunocompetent woman causing headache and vision loss. Endoscopic debridement under general anesthesia was complicated by rupture of a mycotic cavernous carotid artery aneurysm. This was managed by packing with muscle and fascia followed by endovascular coiling. Subsequently, the aneurysm extended intradurally and caused fatal subarachnoid hemorrhage.
   CONCLUSIONS: This case emphasizes the need for early diagnosis of invasive fungal sinusitis to prevent intracranial complications and fatal outcome. When the diagnosis is made, aggressive treatment with surgical debridement and adjuvant antifungal therapy is required. Internal carotid artery involvement is a rare but life-threatening complication of invasive fungal sinusitis.
C1 [Jain, Avani] Maulana Azad Med Coll, Dept ENT, New Delhi, India.
   Associated Lok Nayak Hosp, New Delhi, India.
RP Jain, A (reprint author), Maulana Azad Med Coll, Dept ENT, New Delhi, India.
EM avanijain87@hotmail.com
CR Baumann A, 2007, ORL-J OTO-RHIN-LARYN, V69, P121, DOI 10.1159/000097858
   COUCH L, 1988, ARCH OTOLARYNGOL, V114, P791
   DeShazo RD, 1997, NEW ENGL J MED, V337, P254, DOI 10.1056/NEJM199707243370407
   HORTEN BC, 1976, ARCH NEUROL-CHICAGO, V33, P577, DOI 10.1001/archneur.1976.00500080055008
   Hurst RW, 2001, AM J NEURORADIOL, V22, P858
   KOTHARY MH, 1984, INFECT IMMUN, V43, P320, DOI 10.1128/IAI.43.1.320-325.1984
   Kountakis SE, 1997, AM J OTOLARYNG, V18, P19, DOI 10.1016/S0196-0709(97)90043-0
   Scully R, 1988, NEW ENGL J MED, V317, P427
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 292
EP 294
DI 10.1016/j.wneu.2019.06.014
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900167
PM 31203084
DA 2020-05-12
ER

PT J
AU Entezami, P
   Rubino, S
   O'Brien, MW
   Spurgas, M
   DiRisio, DJ
AF Entezami, Pouya
   Rubino, Sebastian
   O'Brien, Michael W.
   Spurgas, Morgan
   DiRisio, Darryl J.
TI Stabbing Injury of the Cervical Spinal Cord Resulting in Complete Loss
   of Bilateral Proprioception
SO WORLD NEUROSURGERY
LA English
DT Article
DE Spinal cord injury; Stabbing
AB BACKGROUND: Direct penetrating trauma to the spinal cord as a result of stabbing is rare. The vertebral column is strongly suited to protecting the vital neural structures underneath, especially in the midline.
   CASE DESCRIPTION: A 25-year-old woman experienced a direct stabbing injury to her spinal cord, through the midline structures, resulting in bilateral dorsal column injury. She remained intact with regard to motor function despite bilateral sensory and proprioception loss.
   CONCLUSIONS: Owing to the strength of the protective elements of the osseous structures surrounding the spinal cord, direct stabbing injuries usually result in incomplete neurologic deficits. This is generally manifested as a Brown-Sequard syndrome because of the midline ligamentous structures and spinous processes deflecting injuries laterally. Our patient experienced a direct midline puncture, resulting in a unique case of bilateral dorsal column injury. These injuries are generally treated conservatively, in the absence of a retained foreign body. Spinal cord stabbing injuries are a rare entity with interesting clinical and anatomic correlations.
C1 [Entezami, Pouya; Rubino, Sebastian; O'Brien, Michael W.; Spurgas, Morgan; DiRisio, Darryl J.] Albany Med Ctr, Dept Neurosurg, Albany, NY 12208 USA.
RP Entezami, P (reprint author), Albany Med Ctr, Dept Neurosurg, Albany, NY 12208 USA.
EM entezap@amc.edu
CR Almon EB, 2016, AM SURGEON, V82, pE290
   Beer-Furlan AL, 2014, INT J CLIN EXP MED, V7, P316
   Enicker B, 2015, INJURY, V46, P1726, DOI 10.1016/j.injury.2015.05.037
   McCaughey EJ, 2016, J NEUROTRAUM, V33, P1416, DOI 10.1089/neu.2015.4375
   Meena US, 2016, J Neurosci Rural Pra, V7, P324, DOI 10.4103/0976-3147.178664
   PEACOCK WJ, 1977, S AFR MED J, V51, P961
   Wang FY, 2015, J PHYS THER SCI, V27, P3671, DOI 10.1589/jpts.27.3671
   Zhang XY, 2016, SPINE J, V16, pE403, DOI 10.1016/j.spinee.2016.01.189
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 295
EP 297
DI 10.1016/j.wneu.2019.06.098
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900168
PM 31229754
DA 2020-05-12
ER

PT J
AU Dayyani, M
   Zabihyan, S
AF Dayyani, Mojtaba
   Zabihyan, Samira
TI A Self-Made, Reusable, and Adjustable Device for Making Burr Hole Bone
   Plugs: Doing More with Less
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone dust; Bone packer; Bone plug; Burr hole; Craniotomy; Skin dent
AB BACKGROUND: Burr hole craniotomy is a daily procedure in neurosurgery. Defects after burr hole craniotomies will not spontaneously heal and can result in skin dents and cosmetic dissatisfaction. We have introduced a self-made, reusable, and adjustable bone plug packer to use in the repair of burr holes via packing of autologous bone dust. Our bone plug packer is free of charge and can be readily available in neurosurgical operating rooms.
   METHODS: We have produced a stainless steel bone packer device that can be assembled without the use of a special wrench. The instrument consists of a container plate and a main cylinder for packing, in which an adjustable airtight piston is placed to compress the bone dust and create a bone plug of the desired dimensions.
   RESULTS: Some recent studies have shown that burr holes filled by autologous bone dust will result in good cosmetic and osteogenic outcomes. Although we did not perform a long-term follow-up assessment of the burr holes filled with bone plugs, in the short term, we have not seen any local reactions or infections in our patients. The autologous bone plug is a more affordable and available option with no technical or clinical complications in the short term.
   CONCLUSION: We have introduced a practical, convenient, and cost-effective bone packer device. Bone plugs formed using our device can be a potential substitute for expensive covering materials in countries with limited access to other repair options. Providing proper evidence will require the performance of large studies to assess our suggested method in the long term and, possibly, compare it with the usual options in controlled studies.
C1 [Dayyani, Mojtaba; Zabihyan, Samira] Mashhad Univ Med Sci, Dept Neurosurg, Ghaem Teaching Hosp, Fac Med, Mashhad, Razavi Khorasan, Iran.
   [Zabihyan, Samira] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran.
RP Zabihyan, S (reprint author), Mashhad Univ Med Sci, Dept Neurosurg, Ghaem Teaching Hosp, Fac Med, Mashhad, Razavi Khorasan, Iran.; Zabihyan, S (reprint author), Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran.
EM zabihyans@mums.ac.ir
RI Dayyani, Mojtaba/AAB-1733-2019
OI Dayyani, Mojtaba/0000-0002-1802-0662; Zabihyan,
   Samira/0000-0003-0742-6664
CR Ichimura S, 2019, CLIN NEUROL NEUROSUR, V176, P41, DOI 10.1016/j.clineuro.2018.11.019
   Koh TJ, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001943
   Kubota Hisashi, 2017, Surg Neurol Int, V8, P204, DOI 10.4103/sni.sni_195_17
   Moteki Y, 2019, WORLD NEUROSURG, V122, P632, DOI 10.1016/j.wneu.2018.11.198
   Roberts TT, 2012, ORGANOGENESIS, V8, P114, DOI 10.4161/org.23306
   Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033
   Zabihyan S, 2010, WORLD NEUROSURG, V74, P7, DOI 10.1016/j.wneu.2010.08.014
NR 7
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 298
EP 301
DI 10.1016/j.wneu.2019.05.257
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900169
PM 31181356
DA 2020-05-12
ER

PT J
AU Shabani, S
   Kaushal, M
   Kaufman, B
   Knipstein, J
   Lawlor, MW
   Lew, S
   Foy, A
AF Shabani, Saman
   Kaushal, Mayank
   Kaufman, Bruce
   Knipstein, Jeffrey
   Lawlor, Michael W.
   Lew, Sean
   Foy, Andrew
TI Intracranial Extraskeletal Mesenchymal Chondrosarcoma: Case Report and
   Review of the Literature of Reported Cases in Adults and Children
SO WORLD NEUROSURGERY
LA English
DT Review
DE Gross total resection; Intracranial; Mesenchymal chondrosarcoma;
   Outcome; Radiation
ID METASTASES; DIAGNOSIS; TUMORS; BONE
AB BACKGROUND: Intracranial extraskeletal mesenchymal chondrosarcoma is a rare, malignant variant of chondrosarcoma that is characterized by undifferentiated mesenchymal cells interspersed with pockets of mature hyaline cartilage.
   CASE DESCRIPTION: In this study, we report a 23-year-old female patient who underwent multiple craniotomies for tumor resection, as well as adjuvant radiotherapy and chemotherapy. We review the literature for reported cases and discuss the histopathologic features, radiologic findings, therapeutic approaches, and outcomes associated with this rare tumor.
   CONCLUSIONS: Intracranial extra-skeletal mesenchymal chondrosarcomas are very aggressive tumors, and their management should emphasize attempting gross total resection followed by adjuvant treatment modalities, including radiation therapy and/or chemotherapy.
C1 [Shabani, Saman; Kaushal, Mayank; Kaufman, Bruce; Lew, Sean; Foy, Andrew] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
   [Knipstein, Jeffrey] Med Coll Wisconsin, Dept Pediat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
   [Lawlor, Michael W.] Med Coll Wisconsin, Dept Pathol & Lab Med, Milwaukee, WI 53226 USA.
   [Lawlor, Michael W.] Med Coll Wisconsin, Neurosci Res Ctr, Milwaukee, WI 53226 USA.
RP Shabani, S (reprint author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.
EM sshabani@mcw.edu
RI Kaushal, Mayank/AAK-7667-2020
OI Kaushal, Mayank/0000-0002-4121-6751; Knipstein,
   Jeffrey/0000-0002-0632-2751
CR Bingaman KD, 2000, NEUROSURGERY, V46, P207
   Bose B, 2003, NEUROSURG QUART, V13, P30, DOI 10.1097/00013414-200303000-00003
   Chen Jun-Yih, 2004, Kaohsiung Journal of Medical Sciences, V20, P240
   CHHEM RK, 1992, CLIN RADIOL, V45, P422, DOI 10.1016/S0009-9260(05)81007-4
   CHO BK, 1993, CHILD NERV SYST, V9, P295, DOI 10.1007/BF00306279
   Crosswell H, 2000, MED PEDIATR ONCOL, V34, P370, DOI 10.1002/(SICI)1096-911X(200005)34:5<370::AID-MPO14>3.0.CO;2-L
   DAHLIN DC, 1962, CANCER, V15, P410, DOI 10.1002/1097-0142(196203/04)15:2<410::AID-CNCR2820150225>3.0.CO;2-L
   Nguyen DV, 2013, MALAYS J MED SCI, V20, P71
   De Cecio R, 2008, PEDIATR DEVEL PATHOL, V11, P309, DOI 10.2350/07-05-0279.1
   ELGINDI S, 1974, J NEUROSURG, V40, P651, DOI 10.3171/jns.1974.40.5.0651
   Fanburg-Smith JC, 2010, ANN DIAGN PATHOL, V14, P8, DOI 10.1016/j.anndiagpath.2009.09.003
   FLYGER G, 1963, ACTA PATHOL MIC SC, V58, P299
   GONZALEZCAMPORA R, 1995, ACTA CYTOL, V39, P1237
   GUCCION JG, 1973, ARCH PATHOL, V95, P336
   HARSH GR, 1984, J NEUROSURG, V61, P375, DOI 10.3171/jns.1984.61.2.0375
   HARWOOD AR, 1981, CLIN ORTHOP RELAT R, P144
   HASSOUNAH M, 1985, ACTA NEUROCHIR, V78, P123, DOI 10.1007/BF01808691
   HEROS RC, 1980, SURG NEUROL, V14, P311
   HOSHINO M, 1981, Neurological Surgery, V9, P843
   HUANG YL, 2004, CHIN J RADIOL, V29, P337
   Kan ZS, 2012, BRIT J NEUROSURG, V26, P912, DOI 10.3109/02688697.2012.697219
   KOBAYASHI T, 1980, Neurological Surgery, V8, P881
   KUBOTA T, 1982, NEUROSURGERY, V10, P105, DOI 10.1227/00006123-198201000-00021
   La Spina M, 2003, CHILD NERV SYST, V19, P680, DOI 10.1007/s00381-003-0727-z
   LICHTENSTEIN L, 1959, CANCER-AM CANCER SOC, V12, P1142, DOI 10.1002/1097-0142(195911/12)12:6<1142::AID-CNCR2820120610>3.0.CO;2-D
   Lin L, 2012, NEUROPATHOLOGY, V32, P82, DOI 10.1111/j.1440-1789.2011.01224.x
   LYNCH PG, 1973, J NEUROSURG, V39, P261, DOI 10.3171/jns.1973.39.2.0261
   Malik SN, 1996, ANN CLIN LAB SCI, V26, P496
   Marshman LAG, 2001, BRIT J NEUROSURG, V15, P419, DOI 10.1080/02688690120082431
   Merimsky O, 2000, ONCOLOGY-BASEL, V58, P210, DOI 10.1159/000012102
   Misra V, 2008, ACTA CYTOL, V52, P366, DOI 10.1159/000325525
   NAGATA S, 1986, SURG NEUROL, V25, P505, DOI 10.1016/0090-3019(86)90092-3
   NAKASHIMA Y, 1986, CANCER-AM CANCER SOC, V57, P2444, DOI 10.1002/1097-0142(19860615)57:12<2444::AID-CNCR2820571233>3.0.CO;2-K
   NOKES SR, 1987, AM J NEURORADIOL, V8, P1137
   Nozaki K, 1999, ACTA NEUROCHIR, V141, P327, DOI 10.1007/s007010050307
   PARKER JR, 1989, ANN CLIN LAB SCI, V19, P401
   Ramesh VG, 2011, NEUROL INDIA, V59, P929, DOI 10.4103/0028-3886.91392
   RASKIND R, 1966, J NEUROSURG, V24, P676, DOI 10.3171/jns.1966.24.3.0676
   Reyaz Nadeem, 2006, J Ayub Med Coll Abbottabad, V18, P86
   RODDA RA, 1984, AUST NZ J SURG, V54, P387
   ROLLO JL, 1979, ARCH PATHOL LAB MED, V103, P239
   Rushing EJ, 1996, CANCER, V77, P1884
   Saito Yuki, 2010, No Shinkei Geka, V38, P441
   SALVADOR AH, 1971, CANCER, V28, P605, DOI 10.1002/1097-0142(197109)28:3<605::AID-CNCR2820280312>3.0.CO;2-R
   Salvati M, 2005, J EXP CLIN CANC RES, V24, P317
   Sardi I, 2011, PEDIATR BLOOD CANCER, V56, P685, DOI 10.1002/pbc.22906
   SCHEITHAUER BW, 1978, CANCER, V42, P2744, DOI 10.1002/1097-0142(197812)42:6<2744::AID-CNCR2820420633>3.0.CO;2-L
   SCHUT L, 1994, PEDIATR NEUROSURG, V20, P207, DOI 10.1159/000120790
   Sheth RN, 2009, CASE REP FRCS ANN NE, V9, P1
   STEINER GC, 1973, CANCER, V32, P926, DOI 10.1002/1097-0142(197310)32:4<926::AID-CNCR2820320427>3.0.CO;2-T
   Thakar S, 2013, CLIN NEUROPATHOL, V32, P393, DOI 10.5414/NP300611
   Trembath DG, 2003, CANCER CYTOPATHOL, V99, P211, DOI 10.1002/cncr.11300
   Vergeer RA, 2012, J CLIN NEUROSCI, V19, P1170, DOI 10.1016/j.jocn.2011.08.042
   Vij M, 2011, DIAGN CYTOPATHOL, V39, P837, DOI 10.1002/dc.21554
   WAGA S, 1972, J NEUROSURG, V36, P790, DOI 10.3171/jns.1972.36.6.0790
   WALAAS L, 1990, DIAGN CYTOPATHOL, V6, P396, DOI 10.1002/dc.2840060605
   Waliuddin A, 2006, NEUROSCIENCES, V11, P205
   WU WQ, 1970, J NEUROL NEUROSUR PS, V33, P469, DOI 10.1136/jnnp.33.4.469
   Xiao AQ, 2014, NEUROL NEUROCHIR POL, V48, P287, DOI 10.1016/j.pjnns.2014.06.001
   Yassa M, 2005, J NEURO-ONCOL, V74, P329, DOI 10.1007/s11060-005-0374-1
   ZUCKER DK, 1978, J NEUROSURG, V48, P829, DOI 10.3171/jns.1978.48.5.0829
NR 61
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 302
EP 310
DI 10.1016/j.wneu.2019.05.221
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900170
PM 31158544
DA 2020-05-12
ER

PT J
AU Moldovan, K
   Konakondla, S
   Barber, SM
   Nakhla, J
   Fridley, JS
   Telfeian, AE
   Gokaslan, ZL
   Oyelese, AA
AF Moldovan, Krisztina
   Konakondla, Sanjay
   Barber, Sean M.
   Nakhla, Jonathan
   Fridley, Jared S.
   Telfeian, Albert E.
   Gokaslan, Ziya L.
   Oyelese, Adetokunbo A.
TI Intraoperative Computed Tomography Navigation-Assisted Resection of
   Symptomatic Intramedullary Spinal Cord Cavernoma: A Technical Note and
   Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE AIRO intraoperative CT; Image guidance intramedullary cavernoma; MRI-CT
   fusion; Spinal navigation
ID BRAIN-STEM; NATURAL-HISTORY; MICROSURGICAL RESECTION; SURGICAL
   RESECTION; MALFORMATIONS; SERIES; SURGERY
AB BACKGROUND: Intramedullary spinal cord cavernous malformations (ISCCMs) are a rare entity. Most commonly, ISCCMs present with neurologic decline from lesion hemorrhage, which can be catastrophic and irreversible irrespective of surgical intervention. Given the challenging anatomic location of these lesions in highly critical neurologic areas, precise surgical localization and visualization is necessary to limit collateral damage during resection particularly for deep ISCCMs that do not present to a pial surface.
   CASE DESCRIPTION: We present a case of a 54-year-old man who presented with incomplete paraplegia after hemorrhage of a deep ISCCM at T11. Surgical resection was undertaken using intraoperative computed tomography (CT) navigation assistance autofused with high-resolution preoperative magnetic resonance imaging for precise intramedullary lesion targeting and localization for myelotomy. Complete resection was demonstrated on postoperative imaging. At a 6-week follow-up appointment, the patient endorsed return of his bladder function and was noted to have some return of motor function to his left foot with 3 of 5 dorsiflexion. At 4 months, he had improved to 3 of 5 proximal, 4 of 5 distal on the left and 2 of 5 proximal, and 3 of 5 distal on the right.
   CONCLUSIONS: The approach represents a novel application of intraoperative CT navigation assistance in the resection of deep ISCCMs.
C1 [Oyelese, Adetokunbo A.] Brown Univ, Warren Alpert Med Sch, Dept Neurosurg, Providence, RI 02912 USA.
   Rhode Isl Hosp, Norman Prince Neurosci Inst, Providence, RI USA.
RP Oyelese, AA (reprint author), Brown Univ, Warren Alpert Med Sch, Dept Neurosurg, Providence, RI 02912 USA.
EM AOyelese@Lifespan.org
CR Ardeshiri A, 2016, NEUROSURG REV, V39, P269, DOI 10.1007/s10143-015-0674-7
   Badhiwala JH, 2014, J NEUROSURG-SPINE, V21, P662, DOI 10.3171/2014.6.SPINE13949
   Bandela JR, 2013, WORLD NEUROSURG, V79, P390, DOI 10.1016/j.wneu.2011.05.019
   COSGROVE GR, 1988, J NEUROSURG, V68, P31, DOI 10.3171/jns.1988.68.1.0031
   D'Andrea K, 2015, WORLD NEUROSURG, V84, P1804, DOI 10.1016/j.wneu.2015.07.072
   DELCURLING O, 1991, J NEUROSURG, V75, P702, DOI 10.3171/jns.1991.75.5.0702
   Desai B, 2017, J NEURO-ONCOL, V131, P425, DOI 10.1007/s11060-016-2325-4
   Ferroli P, 2005, NEUROSURGERY, V56, P1203, DOI 10.1227/01.NEU.0000159644.04757.45
   FRITSCHI JA, 1994, ACTA NEUROCHIR, V130, P35, DOI 10.1007/BF01405501
   Giammattei L, 2017, NEUROCHIRURGIE, V63, P426, DOI 10.1016/j.neuchi.2016.04.005
   Gross BA, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.6.FOCUS10144
   Gross BA, 2009, NEUROSURGERY, V64, P805, DOI [10.1227/01.NEU.0000343667.14177.72, 10.1227/01.NEU.0000343668.44288.18]
   Huntley GD, 2017, J STROKE CEREBROVASC, V26, pE72, DOI 10.1016/j.jstrokecerebrovasdis.2017.02.013
   Imagama S, 2017, GLOB SPINE J, V7, P246, DOI 10.1177/2192568217707938
   Kim DS, 1997, SURG NEUROL, V48, P9, DOI 10.1016/S0090-3019(96)00425-9
   Kivelev J, 2011, NEUROSURGERY, V69, P807, DOI 10.1227/NEU.0b013e31821ffbb5
   Konakondla S, 2019, WORLD NEUROSURG, V125, pE1125, DOI 10.1016/j.wneu.2019.01.257
   Li JQ, 2018, WORLD NEUROSURG, V118, pE105, DOI 10.1016/j.wneu.2018.06.134
   Maduri R, 2017, WORLD NEUROSURG, V98, P594, DOI 10.1016/j.wneu.2016.05.092
   Navarro-Ramirez R, 2017, WORLD NEUROSURG, V100, P325, DOI 10.1016/j.wneu.2017.01.025
   Overley SC, 2017, NEUROSURGERY, V80, pS86, DOI 10.1093/neuros/nyw077
   Pandey P, 2013, NEUROSURGERY, V72, P573, DOI 10.1227/NEU.0b013e318283c9c2
   Park JH, 2015, WORLD J CLIN CASES, V3, P765, DOI 10.12998/wjcc.v3.i9.765
   Sindou M, 2000, ACTA NEUROCHIR, V142, P843, DOI 10.1007/s007010070069
   Sindou M, 2000, ACTA NEUROCHIR WIEN, V142, P852
   Stefini R, 2018, OPER NEUROSURG, V15, P54, DOI 10.1093/ons/opx179
   Zhang PH, 2018, WORLD NEUROSURG, V118, P246, DOI 10.1016/j.wneu.2018.07.034
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 311
EP 317
DI 10.1016/j.wneu.2019.06.101
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900171
PM 31229746
DA 2020-05-12
ER

PT J
AU Choi, BS
   Lee, H
   Jin, SC
AF Choi, Byung-Sam
   Lee, Hyungon
   Jin, Sung-Chul
TI Contralateral Mechanical Thrombectomy of Partial Deployed Stent
   Retrieval for Acute Anterior Inferior Cerebellar Artery Occlusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior inferior cerebellar artery; Posterior inferior cerebellar
   artery; Thrombectomy
AB BACKGROUND: Acute anterior inferior cerebellar artery (AICA) occlusion is considered an acute ischemic stroke requiring medical treatment without mechanical thrombectomy (MT). There is a procedural risk of parent vessel rupture, but neurologic deficits are not generally severe. Here, we report a case of MT performed using partially deployed stent retrieval for acute AICA occlusion.
   CASE DESCRIPTION: A 53-year-old male patient presented with acute-onset drowsiness and visual disturbance. The initial National Institutes of Health Stroke Scale score of the patient was 5. Computed tomography angiography showed no definite vascular occlusion, but computed tomography perfusion imaging suggested decreased cerebral blood flow and cerebral blood volume, with an increased mean transit time and time to peak in the left posterior inferior cerebellar artery territory. Conventional angiography showed occlusion of the left proximal AICA and posterior inferior cerebellar artery cortical branches, which were reconstituted by the muscular branches of the left vertebral artery. We decided to perform intra-arterial thrombectomy for proximal left AICA occlusion because the patient's symptoms seemed to be aggravated, and neurologic deficits were not expected. MT was performed using a Trevo stent (Stryker Neurovascular, Fremont, California, USA) in the left proximal AICA via a right vertebral artery approach and resulted in complete recanalization of the occluded AICA. The patient recovered and had an National Institutes of Health Stroke Scale score of 0 at 1 day after MT.
   CONCLUSIONS: Our case suggests that MT can be performed in a highly selective manner in patients with the occlusion of a posterior circulation branch, such as the AICA, and yield a good clinical outcome.
C1 [Choi, Byung-Sam; Lee, Hyungon; Jin, Sung-Chul] Inje Univ, Dept Neurosurg, Haeundae Paik Hosp, Busan, South Korea.
RP Jin, SC (reprint author), Inje Univ, Dept Neurosurg, Haeundae Paik Hosp, Busan, South Korea.
EM kusmaljin@gmail.com
CR Chen CJ, 2017, WORLD NEUROSURG, V107, P684, DOI 10.1016/j.wneu.2017.08.108
   Cho DY, 2019, WORLD NEUROSURG, V121, pE22, DOI 10.1016/j.wneu.2018.08.184
   Crockett MT, 2019, J NEUROINTERV SURG, V11, P714, DOI 10.1136/neurintsurg-2018-014385
   Datar S, 2014, NEUROL CLIN, V32, P979, DOI 10.1016/j.ncl.2014.07.007
   Edlow JA, 2008, LANCET NEUROL, V7, P951, DOI 10.1016/S1474-4422(08)70216-3
   Kim MJ, 2012, AM J NEURORADIOL, V33, P348, DOI 10.3174/ajnr.A2741
   Tang J, 2016, NEUROSCIENCES, V21, P236, DOI 10.17712/nsj.2016.3.20160076
NR 7
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 318
EP 321
DI 10.1016/j.wneu.2019.06.044
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900172
PM 31203076
DA 2020-05-12
ER

PT J
AU Close, LN
   Park, B
   Woodroffe, RW
   Hitchon, PW
AF Close, Liesl N.
   Park, Brian
   Woodroffe, Royce W.
   Hitchon, Patrick W.
TI Thoracic Meningocele and Cervical Syringomyelia Treated with
   Ventriculoperitoneal Shunt
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neurofibromatosis; Syringomyelia; Syrinx; Thoracic meningocele;
   Ventriculoperitoneal shunt
ID NEUROFIBROMATOSIS TYPE-1; CHIARI I; PATHOPHYSIOLOGY; PATIENT
AB BACKGROUND: Spinal meningocele is the herniation of dura mater and cerebrospinal fluid through a spinal defect, be it congenital, iatrogenic, or traumatic. Intrathoracic meningoceles are rare and are most commonly associated with neurofibromatosis. When indicated, surgical management of symptomatic thoracic meningocele is aimed at decreasing the size of the meningocele, which can be accomplished by a variety of procedures.
   CASE DESCRIPTION: A 59-year-old woman with neurofibromatosis type 1 and a known thoracic meningocele was initially managed conservatively. However, she developed syringomyelia and subsequently became symptomatic from the syrinx. She was ultimately treated successfully with ventriculoperitoneal shunt. Shunting resulted in complete resolution of the syrinx, while the thoracic meningocele remained stable in size.
   CONCLUSIONS: Ventriculoperitoneal shunt can be used to successfully treat a symptomatic syrinx in a patient with an asymptomatic thoracic meningocele. Alterations in normal cerebrospinal fluid flow dynamics from the thoracic meningocele likely contributed to the development of syringomyelia in this patient.
C1 [Close, Liesl N.; Park, Brian; Woodroffe, Royce W.; Hitchon, Patrick W.] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
RP Hitchon, PW (reprint author), Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
EM patrick-hitchon@uiowa.edu
CR Abubaker K, 2011, BRIT J NEUROSURG, V25, P94, DOI 10.3109/02688697.2010.544781
   BARBARO NM, 1984, J NEUROSURG, V61, P531, DOI 10.3171/jns.1984.61.3.0531
   CHEE CP, 1987, NEUROSURGERY, V21, P749, DOI 10.1227/00006123-198711000-00031
   Chen HC, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/1749-8090-9-85
   Cho DG, 2015, J CARDIOTHORAC SURG, V10, DOI 10.1186/s13019-015-0374-y
   Das P, 2017, J NEUROSURG-SPINE, V27, P291, DOI 10.3171/2017.2.SPINE16699
   Davidson KA, 2018, WORLD NEUROSURG, V110, pE53, DOI 10.1016/j.wneu.2017.09.205
   de Andrade GC, 2003, ARQ NEURO-PSIQUIAT, V61, P677, DOI 10.1590/S0004-282X2003000400029
   Ebara S, 2003, J CLIN NEUROSCI, V10, P268, DOI 10.1016/S0967-5868(03)00003-1
   Giner J, 2016, NEUROLOGIA
   Heiss JD, 2012, J NEUROSURG-SPINE, V17, P367, DOI 10.3171/2012.8.SPINE111059
   Karam Y, 2014, CLIN NEUROL NEUROSUR, V124, P44, DOI 10.1016/j.clineuro.2014.06.007
   Maldonado R G, 1992, Zentralbl Neurochir, V53, P11
   Matsumoto M, 2013, CHILD NERV SYST, V29, P1953, DOI 10.1007/s00381-013-2133-5
   OGILVY CS, 1988, NEUROSURGERY, V22, P748, DOI 10.1227/00006123-198804000-00023
   Oldfield EH, 2017, NEUROSURGERY, V64, P66, DOI 10.1093/neuros/nyx377
   OLDFIELD EH, 1994, J NEUROSURG, V80, P3, DOI 10.3171/jns.1994.80.1.0003
   Phol R., 1933, RONTGENPRAXIS, V5, P747
   SAMII M, 1994, NEUROSURGERY, V35, P865, DOI 10.1227/00006123-199411000-00010
   Vanhauwaert DJ, 2008, SURG NEUROL, V69, P535, DOI 10.1016/j.surneu.2007.02.058
   Williams B, 1987, Br J Neurosurg, V1, P63, DOI 10.3109/02688698709034342
   Yeo J, 2017, AM J NEURORADIOL, V38, P1839, DOI 10.3174/ajnr.A5304
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 322
EP 326
DI 10.1016/j.wneu.2019.05.204
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900173
PM 31152885
DA 2020-05-12
ER

PT J
AU Joris, V
   Vaz, JGR
   Lelotte, J
   Dupreic, T
   Raftopoulos, C
AF Joris, Vincent
   Vaz, Jose-Geraldo Ribeiro
   Lelotte, Julie
   Dupreic, Thierry
   Raftopoulos, Christian
TI Large Epileptogenic Type IIIb Dysplasia: A Radiological and
   Anatomopathological Challenge
SO WORLD NEUROSURGERY
LA English
DT Article
DE IIIb dysplasia; Differential diagnosis; Drug-resistant epilepsy
ID FOCAL CORTICAL DYSPLASIAS; EPILEPSY SURGERY; TUMORS; GANGLIOGLIOMAS;
   CLASSIFICATION; MALFORMATIONS; EPIDEMIOLOGY; MUTATION
AB BACKGROUND: Type IIIb dysplasia is a subtype of focal cortical dysplasia associated with a tumor, most frequently with gangliogliomas then with dysembryoplastic neuroepithelial tumors (DNETs). Their preoperative diagnosis often remains equivocal since specific features are missing. The functional results (i.e., seizure free) is good with 81%-87% of Engel Ia at 5-year follow-up.
   CASE DESCRIPTION: A 4-year-old boy presented with a 1-year history of severe, invalidating, drug-resistant epilepsy. Imaging workup demonstrated a huge left limbic lesion, of which diagnosis remained speculative. Because of worsening neurological status, resective surgery was recommended after multidisciplinary discussion. The resection was performed through left transtemporal approach under neuronavigation (C.R.). Postoperative magnetic resonance imaging assessed uncomplicated near-total resection. Histopathological analysis showed combined features of a DNET of nonspecific type and a focal cortical dysplasia.
   CONCLUSION: We describe a rare condition of type IIIb dysplasia combining a focal cortical dysplasia with a DNET. Preoperative diagnosis of the lesion was of utmost difficultly, thereby rendering mandatory a thorough histopathological examination of resected specimen in the vast majority of cases. Increased recognition of the condition brings up the hypothesis of a genetic continuum or linkage between the 2 conditions. Functional results on seizure activity after ablative surgery are good and maximal safe resection should be the goal.
C1 [Joris, Vincent; Vaz, Jose-Geraldo Ribeiro; Raftopoulos, Christian] Clin Univ St Luc, Dept Neurosurg, Brussels, Belgium.
   [Lelotte, Julie] Clin Univ St Luc, Dept Pathol, Brussels, Belgium.
   [Dupreic, Thierry] Clin Univ St Luc, Dept Neuroradiol, Brussels, Belgium.
RP Raftopoulos, C (reprint author), Clin Univ St Luc, Dept Neurosurg, Brussels, Belgium.
EM christian.raftopoulos@uclouvain.be
CR Blumcke I, 2011, EPILEPSIA, V52, P158, DOI 10.1111/j.1528-1167.2010.02777.x
   Chappe C, 2013, BRAIN PATHOL, V23, P574, DOI 10.1111/bpa.12048
   Colombo N, 2003, AM J NEURORADIOL, V24, P724
   Cossu M, 2013, EPILEPSIA, V54, P115, DOI 10.1111/epi.12455
   Deb P, 2006, NEUROPATH APPL NEURO, V32, P461, DOI 10.1111/j.1365-2990.2006.00734.x
   Eye PG, 2017, J NEUROL SCI, V373, P280, DOI 10.1016/j.jns.2016.11.003
   Nguyen HS, 2017, WORLD NEUROSURG, V103, P380, DOI 10.1016/j.wneu.2017.04.093
   Lim KC, 2013, NEUROSCIENCE, V252, P262, DOI 10.1016/j.neuroscience.2013.07.037
   Marucci G, 2014, ANN CLIN TRANSL NEUR, V1, P130, DOI 10.1002/acn3.31
   Marucci G, 2013, APMIS, V121, P22, DOI 10.1111/j.1600-0463.2012.02938.x
   Muhlebner A, 2014, EPILEPSY RES, V108, P1652, DOI 10.1016/j.eplepsyres.2014.08.012
   Phi JH, 2010, J NUCL MED, V51, P728, DOI 10.2967/jnumed.109.070920
   Prayson RA, 2010, MODERN PATHOL, V23, P1097, DOI 10.1038/modpathol.2010.94
   Racz A, 2018, SEIZURE-EUR J EPILEP, V58, P82, DOI 10.1016/j.seizure.2018.04.002
   Rickert CH, 2001, CHILD NERV SYST, V17, P503, DOI 10.1007/s003810100496
   Rivera B, 2016, ACTA NEUROPATHOL, V131, P847, DOI 10.1007/s00401-016-1549-x
   Santos MV, 2014, CHILD NERV SYST, V30, P1869, DOI 10.1007/s00381-014-2519-z
   Uzun R, 2018, 2018 INNOVATIONS IN INTELLIGENT SYSTEMS AND APPLICATIONS CONFERENCE (ASYU), P1
NR 18
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 330
EP 333
DI 10.1016/j.wneu.2019.06.106
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900175
PM 31233930
DA 2020-05-12
ER

PT J
AU Lu, L
   Chen, HW
   Weng, ST
   Xu, YM
AF Lu, Liang
   Chen, Hongwu
   Weng, Shaotao
   Xu, Yimin
TI Endoscopic Third Ventriculostomy versus Ventriculoperitoneal Shunt in
   Patients with Obstructive Hydrocephalus: Meta-Analysis of Randomized
   Controlled Trials
SO WORLD NEUROSURGERY
LA English
DT Review
DE Endoscopic third ventriculostomy; Obstructive hydrocephalus;
   Ventriculoperitoneal shunt
ID HEMORRHAGE; TUMORS
AB OBJECTIVE: Endoscopic third ventriculostomy (ETV) and ventriculoperitoneal shunt (VPS) are 2 surgical methods used for the treatment of obstructive hydrocephalus. However, the efficacy and safety of these 2 procedures are unknown. Therefore we conducted a meta-analysis to compare the safety and efficiency of ETV and VPS in patients with obstructive hydrocephalus.
   METHODS: In January 2019, a comprehensive search strategy of 3 electronic databases was initiated. A systematic search from database inception to December 30, 2018, on clinical outcome, safety, and efficiency of ETV and VPS in the treatment of obstructive hydrocephalus was conducted. The following electronic databases were searched: PubMed, Embase, and Cochrane Library for related randomized controlled trials (RCTs). Main outcomes included postoperative hematoma, postoperative infection, postoperative cerebrospinal fluid leakage, blockage rate, and mortality.
   RESULTS: Of the 546 studies identified, 4 RCTs involving 250 patients met our inclusion criteria. The pooled results show that ETV was associated with lower incidence of postoperative infection (risk ratio [RR] 0.09, 95% confidence interval [CI]: 0.02-0.32, P = 0.0002); postoperative hematoma (RR 0.26, 95% CI: 0.08-0.88, P = 0.03); and blockage rate (RR 0.28, 95% CI: 0.13-0.60, P = 0.001) compared with VPS. Compared with VPS, ETV had no significant effect on incidence rate of postoperative cerebrospinal fluid leakage (RR 2.00, 95% CI: 0.30-13.16, P = 0.47) and mortality rates (RR 0.19, 95% CI: 0.03-1.09, P = 0.06), but there have been no deaths in patients treated with ETV.
   CONCLUSIONS: On the basis of the meta-analysis of RCTs evaluating ETV and VPS, the incidence of complications and mortality was higher with the VPS procedure, and therefore greater benefits can be achieved using ETV.
C1 [Lu, Liang; Chen, Hongwu; Weng, Shaotao; Xu, Yimin] Shantou Univ, Med Coll, Affiliated Hosp 1, Dept Neurosurg, Shantou, Guangdong, Peoples R China.
RP Xu, YM (reprint author), Shantou Univ, Med Coll, Affiliated Hosp 1, Dept Neurosurg, Shantou, Guangdong, Peoples R China.
EM xuym777@163.com
CR Cage TA, 2011, J CLIN NEUROSCI, V18, P649, DOI 10.1016/j.jocn.2010.08.028
   Calayag M, 2015, J NEUROSURG-PEDIATR, V16, P42, DOI 10.3171/2014.11.PEDS14246
   El-Ghandour NMF, 2011, CHILD NERV SYST, V27, P117, DOI 10.1007/s00381-010-1263-2
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Jiang L, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012139
   Kalani MYS, 2013, J CLIN NEUROSCI, V20, P462, DOI 10.1016/j.jocn.2012.04.027
   Kamikawa S, 2001, MINIM INVAS NEUROSUR, V44, P25, DOI 10.1055/s-2001-13587
   Kousi M, 2016, ANNU REV NEUROSCI, V39, P409, DOI 10.1146/annurev-neuro-070815-014023
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   MIXTER WJ, 1923, BOSTON MED SURG J, V188, P277
   Navaei Amir Amini, 2018, Asian J Neurosurg, V13, P1042, DOI 10.4103/ajns.AJNS_63_17
   Rahman Mohammad Mahfuzur, 2018, Asian J Neurosurg, V13, P1001, DOI 10.4103/ajns.AJNS_376_16
   Reddy GK, 2014, WORLD NEUROSURG, V81, P404, DOI 10.1016/j.wneu.2013.01.096
   Reddy GK, 2011, J NEURO-ONCOL, V103, P333, DOI 10.1007/s11060-010-0393-4
   Rekate HL, 2009, SEMIN PEDIATR NEUROL, V16, P9, DOI 10.1016/j.spen.2009.01.002
   Simon TD, 2014, J PEDIATR-US, V164, P1462, DOI 10.1016/j.jpeds.2014.02.013
   Takasuna H, 2012, J CLIN NEUROSCI, V19, P1553, DOI 10.1016/j.jocn.2012.01.033
   Vieneke P, 1998, MINIM INVASIV THER, V731, P233
   Zhou F, 2012, INT J MED SCI, V9, P65, DOI 10.7150/ijms.9.65
NR 20
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 334
EP 340
DI 10.1016/j.wneu.2019.04.255
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900176
PM 31136836
DA 2020-05-12
ER

PT J
AU Saez-Alegre, M
   Lopez, CP
   Garcia, JG
   Flores, AJP
   Feijoo, PG
   Sanchez, CV
   Guerrero, AI
AF Saez-Alegre, Miguel
   Perez Lopez, Carlos
   Giner Garcia, Javier
   Palpan Flores, Alexis Junnior
   Garcia Feijoo, Pablo
   Vivancos Sanchez, Catalina
   Guerrero, Alberto Isla
TI Epidural Lipomatosis and Syringomyelia in Adulthood: Case Report and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Case report; Epidural; Spinal lipomatosis; Syringomyelia; Syrinx
AB BACKGROUND: We review 2 previously published cases of epidural lipomatosis associated with syringomyelia. We also present the case of a 42-year-old woman with a medullary syrinx from C1 to T3, initially only with upper limb paresthesias that presented after 10 years of follow-up for left hemiparesis and paresthesias in the tongue. Chiari malformation and cerebral or spinal space-occupying lesions were ruled out, as were other causes of syrinx except the presence of epidural lipomatosis extending from T1 to T12.
   CASE DESCRIPTION: Right laminotomies were performed from T1 to T12, removing excessive epidural fat tissue. After surgery the symptoms remained stable. At discharge the patient progressively recovered from the hemiparesis, and in follow-up magnetic resonance imaging the resolution of the syrinx was confirmed.
   CONCLUSIONS: This is the third case of a patient with a spinal syrinx and no other related causes except from spinal lipomatosis, although with only 3 cases it is not possible to completely state that lipomatosis caused the syrinx. Our case supports the trend established by the 2 previous cases. For treatment, initially patients should be managed conservatively, trying to correct the underlying etiologies of spinal lipomatosis. In case of failed conservative treatment, removal of adipose epidural excess in the most appropriate way is preferred.
C1 [Saez-Alegre, Miguel; Perez Lopez, Carlos; Giner Garcia, Javier; Palpan Flores, Alexis Junnior; Garcia Feijoo, Pablo; Vivancos Sanchez, Catalina; Guerrero, Alberto Isla] Hosp La Paz, Madrid, Spain.
RP Saez-Alegre, M (reprint author), Hosp La Paz, Madrid, Spain.
EM miksaezalegre@gmail.com
CR Al-Yafeai R, 2017, INT J SURG CASE REP, V37, P225, DOI 10.1016/j.ijscr.2017.06.041
   Citow JS, 2000, SURG NEUROL, V53, P589, DOI 10.1016/S0090-3019(00)00230-5
   Heiss JD, 2012, J NEUROSURG-SPINE, V17, P367, DOI 10.3171/2012.8.SPINE111059
   Malone JB, 2018, J ORTHOP, V15, P36, DOI 10.1016/j.jor.2017.11.001
   Noel P, 2014, Ann Phys Rehabil Med, V57, P734, DOI 10.1016/j.rehab.2014.08.001
   Rustom David H, 2013, J Anaesthesiol Clin Pharmacol, V29, P410, DOI 10.4103/0970-9185.117070
   Tucer B, 2014, TURK NEUROSURG, V24, P606, DOI 10.5137/1019-5149.JTN.8700-13.0
NR 7
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 341
EP 344
DI 10.1016/j.wneu.2019.06.075
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900177
PM 31228704
DA 2020-05-12
ER

PT J
AU Zheng, X
   Han, FG
   Luo, L
   Feng, QQ
AF Zheng, Xue
   Han, Fu-Gang
   Luo, Li
   Feng, Qian-Qian
TI Angiomatoid Fibrous Histiocytoma Mimicking Eosinophilic Granuloma in a
   Pediatric Patient
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiomatoid fibrous histiocytoma; Case report; Eosinophilic granuloma;
   Radiology
ID LESIONS; TUMORS; MRI
AB BACKGROUND: Angiomatoid fibrous histiocytoma (AFH) is a rare low-grade malignant tumor mainly occurring in soft tissues, and its incidence in the bones is extremely rare. Although most of the existing reports focus on the pathological features of AFH, only a few describe its imaging features. To our knowledge, this is the first case of AFH in the skull, and it is distinguished from eosinophilic granuloma based on imaging results.
   CASE DESCRIPTION: A boy aged 10 years presented with a painless mass of parietal bone after trauma. Cranial computed tomography angiography showed local bone defects near the sagittal suture of the left parietal bone and a soft tissue mass with relatively uniform density in the same area. The signals of this mass were heterogeneous in all sequences of magnetic resonance imaging and presented septal enhancement after the injection of contrast agent. The patient underwent complete resection of the mass, and the histopathological and immunohistochemical diagnosis of the mass was AFH. No complications occurred after the operation and no recurrence occurred during the follow-up.
   CONCLUSIONS: To our knowledge, this is the first AFH that occured in the skull, and the main imaging manifestations of AFH are bone destruction with soft tissue mass. The characteristic features of AFH are its fibrillar component that showed low signal on T2-weighted imaging and septal or peripheral enhancement, and no dead bone in the mass.
C1 [Zheng, Xue; Han, Fu-Gang; Luo, Li; Feng, Qian-Qian] Southwest Med Univ, Dept Radiol, Affiliated Hosp, Luzhou, Sichuan, Peoples R China.
RP Han, FG (reprint author), Southwest Med Univ, Dept Radiol, Affiliated Hosp, Luzhou, Sichuan, Peoples R China.
EM 8311hfg@163.com
CR Ajlan AM, 2010, J COMPUT ASSIST TOMO, V34, P791, DOI 10.1097/RCT.0b013e3181e39755
   Billings SD, 2004, AM J DERMATOPATH, V26, P141, DOI 10.1097/00000372-200404000-00035
   Chow L T, 1998, J Foot Ankle Surg, V37, P235
   Colas L, 2015, AM J ROENTGENOL, V205, P840, DOI 10.2214/AJR.14.13415
   COSTA MJ, 1990, AM J SURG PATHOL, V14, P1126, DOI 10.1097/00000478-199012000-00004
   De Beuckeleer L., 2001, IMAGING SOFT TISSUE, P181
   ENZINGER FM, 1979, CANCER, V44, P2147, DOI 10.1002/1097-0142(197912)44:6<2147::AID-CNCR2820440627>3.0.CO;2-8
   Fletcher CD, 2013, 2013 WHO CLASSIFICAT, P204
   FLETCHER CDM, 1991, HUM PATHOL, V22, P563, DOI 10.1016/0046-8177(91)90233-F
   Hasegawa T, 2000, PATHOL INT, V50, P731, DOI 10.1046/j.1440-1827.2000.01112.x
   Khung S, 2013, INSIGHTS IMAGING, V4, P569, DOI 10.1007/s13244-013-0271-7
   Koletsa T, 2007, PATHOL INT, V57, P513, DOI 10.1111/j.1440-1827.2007.02133.x
   Lai ECH, 2006, ANZ J SURG, V76, P538, DOI 10.1111/j.1445-2197.2006.03769.x
   Li CS, 2004, SKELETAL RADIOL, V33, P604, DOI 10.1007/s00256-004-0769-7
   Lloret I, 2009, ACTA RADIOL, V50, P531, DOI 10.1080/02841850902795274
   MURPHEY MD, 1994, RADIOGRAPHICS, V14, P807, DOI 10.1148/radiographics.14.4.7938770
   Petrey WB, 2011, SKELETAL RADIOL, V40, P233, DOI 10.1007/s00256-010-1023-0
   Pratibha R, 2006, INT J PAEDIATR DENT, V16, P363, DOI 10.1111/j.1365-263X.2006.00734.x
   Thway K, 2008, ARCH PATHOL LAB MED, V132, P273, DOI 10.1043/1543-2165(2008)132[273:AFHARW]2.0.CO;2
   TSAI JC, 1990, RADIOLOGY, V175, P779, DOI 10.1148/radiology.175.3.2160676
   Yalcin O, 2007, DIAGN INTERV RADIOL, V13, P68
   Yikilmaz A, 2015, PEDIATR RADIOL, V45, P1796, DOI 10.1007/s00247-015-3404-y
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 345
EP 348
DI 10.1016/j.wneu.2019.06.102
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900178
PM 31233924
DA 2020-05-12
ER

PT J
AU Waldron, MA
   Halpern, SL
   Sikorskyj, T
   Mazzola, CA
AF Waldron, Madison A.
   Halpern, Steven L.
   Sikorskyj, Tatiana
   Mazzola, Catherine A.
TI Stage IV Neuroblastoma with Metastatic Spread to the Mandible in a Young
   Child: Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Child; Infant; Metastases; Metastatic spread; Neuroblastoma; Skull
ID HIGH-RISK NEUROBLASTOMA; HIGH-DOSE CHEMOTHERAPY; BUSULFAN-MELPHALAN;
   CELL; GENOTYPES; KIR
AB BACKGROUND: Infants and young children with neuroblastoma (NB) may present with metastases. The primary tumor most commonly originates in the abdomen and metastasizes to lymph nodes, liver, and bone marrow. Infants and young children presenting with multiple skull metastases are rare.
   METHODS: We present a rare case of a 20-month-old child who presented with metastatic neuroblastoma and multiple skull lesions. The child responded well to induction chemotherapy followed by myeloablative busulfan/melphalan consolidation.
   RESULTS: The child had substantial tumor reduction after chemotherapy was started. There was a significant decrease in tumor sizes and uptake, as seen in the metaiodobenzylguanidine study. The 6-month follow-up examination showed complete remission, and the remission continues.
   CONCLUSIONS: Infants and young children with neuroblastoma rarely present with metastatic lesions to the skull. Even large lesions involving the skull base may be successfully treated with chemotherapy. The use of myeloablative busulfan/melphalan consolidation after induction chemotherapy can decrease the overall metastatic tumor burden. Craniofacial specialists should be aware of treatment options for these young children.
C1 [Waldron, Madison A.; Halpern, Steven L.; Sikorskyj, Tatiana; Mazzola, Catherine A.] Atlantic Hlth Syst Goryeb Childrens Hosp, Morristown, NJ 07960 USA.
RP Waldron, MA (reprint author), Atlantic Hlth Syst Goryeb Childrens Hosp, Morristown, NJ 07960 USA.
EM Madisonwaldron2@gmail.com
OI Waldron, Madison/0000-0002-6592-8147
CR Applebaum MA, 2017, EXPERT OPIN ORPHAN D, V5, P355, DOI 10.1080/21678707.2017.1304212
   Bhattacharyya I, 1999, ORAL SURG ORAL MED O, V88, P586, DOI 10.1016/S1079-2104(99)70090-9
   BORAZ R A, 1985, Pediatric Dentistry, V7, P315
   BORLE RM, 1991, J ORAL MAXIL SURG, V49, P1124, DOI 10.1016/0278-2391(91)90150-K
   Chan Anabel R., 1994, Pediatric Dentistry, V16, P310
   Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526
   Delgado DC, 2010, CANCER RES, V70, P9554, DOI 10.1158/0008-5472.CAN-10-2211
   Desai AV, 2016, BONE MARROW TRANSPL, V51, P1204, DOI 10.1038/bmt.2016.84
   Desai N, 2006, CLIN CANCER RES, V12, P1317, DOI 10.1158/1078-0432.CCR-05-1634
   Erbe AK, 2018, CLIN CANCER RES, V24, P189, DOI 10.1158/1078-0432.CCR-17-1767
   Esposito MR, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0319-y
   Handgretinger R, 2018, CHIN CLIN ONCOL, V7, DOI 10.21037/cco.2018.04.06
   Jiang MR, 2011, CURR TOP DEV BIOL, V94, P77, DOI 10.1016/B978-0-12-380916-2.00004-8
   MacFarland S, 2019, CURR OPIN PEDIATR, V31, P14, DOI 10.1097/MOP.0000000000000711
   Mittal D, 2015, J CANCER RES THER, V11, DOI 10.4103/0973-1482.147389
   Nakagawara A, 2018, JPN J CLIN ONCOL, V48, P214, DOI 10.1093/jjco/hyx176
   Nawale Kundan Kisanrao, 2016, J Oral Maxillofac Pathol, V20, P252, DOI 10.4103/0973-029X.185920
   NEWLAND JR, 1985, J ORAL MAXIL SURG, V43, P549
   Otmani N, 2007, MED ORAL PATOL ORAL, V12, P201
   Papaioannou Georgia, 2005, Cancer Imaging, V5, P116, DOI 10.1102/1470-7330.2005.0104
   Pasqualini C, 2016, BONE MARROW TRANSPL, V51, P227, DOI 10.1038/bmt.2015.264
   Pellegrino SV, 2000, ORAL SURG ORAL MED O, V90, P135, DOI 10.1067/moe.2000.107053
   Proust-Houdemont S, 2016, BONE MARROW TRANSPL, V51, P1076, DOI 10.1038/bmt.2016.75
   Le TP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01640
   Wade Gregory, 2018, Radiol Case Rep, V13, P289, DOI 10.1016/j.radcr.2017.10.016
   Yaris N, 2003, INT J PEDIATR OTORHI, V67, P1255, DOI 10.1016/j.ijporl.2003.07.008
NR 26
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 349
EP 353
DI 10.1016/j.wneu.2019.06.013
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900179
PM 31203066
DA 2020-05-12
ER

PT J
AU Patel, AR
   Connors, S
   Wardak, Z
   Brugarolas, J
   Patel, TR
AF Patel, Ankur R.
   Connors, Scott
   Wardak, Zabi
   Brugarolas, James
   Patel, Toral R.
TI Inflammatory Reaction Secondary to Immune Checkpoint Inhibitor Therapy
   Mimicking a Post-Operative Brain Abscess
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain abscess; Brain metastasis; ICI; Immune checkpoint inhibitor;
   Inflammation; Ipilimumab; Kidney cancer; Nivolumab; Opdivo; RCC; Renal
   cell carcinoma
ID ANTI-PD-1; ANTIBODY; SAFETY
AB BACKGROUND: Immune checkpoint inhibitors have revolutionized the treatment of many cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma. These therapeutics increase the activity of T cells against neoplastic cells, although the immune response generated also has the potential to target normal cells, resulting in immune related adverse events (irAEs). Most irAEs occur outside of the nervous system, but cases of limbic encephalitis, hypophysitis, optic neuritis, and pseudoprogression have been reported.
   CASE DESCRIPTION: Here, we present a case of an intracranial irAE after neoadjuvant stereotactic radiosurgery and craniotomy for resection of a left parietal lobe metastasis. The patient presented with headache, right-sided apraxia, and a pronator drift 2 weeks after surgery. Imaging findings were suggestive of an intracranial abscess. The lack of fever, normal white blood cell count, and benign clinical appearance in the setting of combination nivolumab and ipilimumab therapy argued in favor of an irAE, however. After initiation of dexamethasone, the neurologic deficits resolved and the magnetic resonance imaging of the brain normalized over 7 weeks.
   CONCLUSIONS: This is the first report of an acute surgical-site irAE after stereotactic radiosurgery and craniotomy in a patient receiving nivolumab and ipilimumab. These immune-mediated responses can be treated with corticosteroids and close observation.
C1 [Patel, Ankur R.; Connors, Scott; Patel, Toral R.] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA.
   [Wardak, Zabi] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA.
   [Brugarolas, James] Univ Texas Southwestern Med Ctr Dallas, Kidney Canc Program, Simmons Comprehens Canc Ctr, Div Hematol Oncol,Dept Internal Med, Dallas, TX 75390 USA.
RP Patel, TR (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA.
EM toral.patel@utsouthwestern.edu
OI Brugarolas, James/0000-0002-8575-499X
CR Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Cuzzubbo S, 2017, EUR J CANCER, V73, P1, DOI [10.1016/j.ejca.2016.12:001, 10.1016/j.ejca.2016.12.001]
   Fellner A, 2018, J NEURO-ONCOL, V137, P601, DOI 10.1007/s11060-018-2752-5
   Good-Jacobson KL, 2010, NAT IMMUNOL, V11, P535, DOI 10.1038/ni.1877
   Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126
   Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665
   Naidoo J, 2015, ANN ONCOL, V26, P2375, DOI 10.1093/annonc/mdv383
   Patel AR, 2018, WORLD NEUROSURG, V120, pE480, DOI 10.1016/j.wneu.2018.08.107
   Ranjan S, 2018, BMC CANCER, V18, P1
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Zhang I, 2018, ONCOLOGY-NY, V32, pE33
NR 11
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 354
EP 358
DI 10.1016/j.wneu.2019.06.024
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900180
PM 31203078
DA 2020-05-12
ER

PT J
AU Sharma, S
   Vaishya, S
   Ahlawat, S
   Gupta, RK
AF Sharma, Shalini
   Vaishya, Sandeep
   Ahlawat, Sunita
   Gupta, Rakesh K.
TI Intraspinal Degenerative Cyst Causing Compression Of Cervicomedullary
   Junction
SO WORLD NEUROSURGERY
LA English
DT Article
DE CV junction decompression; Intradural degenerative cyst; Intraspinal
   cyst; Myelopathy
ID FILLED INTRADURAL CYST
AB BACKGROUND: Intraspinal degenerative cysts in the cervical region are rare disorders that may cause myelopathy or radiculopathy. Most of the intraspinal degenerative cysts reported are extradural cysts. This case report includes the neuroimaging, intraoperative, pathologic, and postoperative findings obtained in a patient with a degenerative intradural cyst at the craniovertebral (CV) junction.
   CASE DESCRIPTION: We report a patient presenting with progressive spastic quadriparesis resulting from compressive myelopathy due to intradural degenerative cyst at the CV junction. Preoperative magnetic resonance imaging showed the intradural cyst at the cervicomedullary junction with degenerative changes causing myelopathy. We performed decompression of the CV junction, and histopathology of the cyst revealed degenerative cyst. Postoperatively the symptoms were relieved with no apparent complication. Intraspinal degenerative cysts causing compressive myelopathy are rare. To the best of our knowledge, this is the first case of intradural degenerative cyst at the CV junction.
   CONCLUSIONS: In this case report, we demonstrated the clinical, imaging, intraoperative, and pathologic features of a degenerative intraspinal cyst at the CV junction that was intradural in location. Compression of the spinal cord resulted in a gradually progressive myelopathy that showed remarkable improvement immediately after decompression by cystectomy.
C1 [Sharma, Shalini; Gupta, Rakesh K.] SRL Diagnost Ltd, Fortis Mem Res Inst, Dept Radiol, Gurugram, Haryana, India.
   [Vaishya, Sandeep] SRL Diagnost Ltd, Fortis Mem Res Inst, Dept Neurosurg, Gurugram, Haryana, India.
   [Ahlawat, Sunita] SRL Diagnost Ltd, Dept Pathol, Gurugram, Haryana, India.
RP Gupta, RK (reprint author), SRL Diagnost Ltd, Fortis Mem Res Inst, Dept Radiol, Gurugram, Haryana, India.
EM rakeshree1@gmail.com
CR Ewald C, 2005, ZBL NEUROCHIR, V66, P147, DOI 10.1055/s-2005-836475
   Gazzeri R, 2005, EUR SPINE J, V14, P807, DOI 10.1007/s00586-005-0913-7
   Giger R, 2002, AM J OTOLARYNG, V23, P390, DOI 10.1053/ajot.2002.126323
   Hamamcioglu Mustafa Kemal, 2006, Eur Spine J, V15 Suppl 5, P595, DOI 10.1007/s00586-005-0041-4
   Hatem O, 2001, J NEUROSURG, V95, P139, DOI 10.3171/spi.2001.95.1.0139
   Kudo Y, 2008, J NEUROSURG-SPINE, V8, P482, DOI 10.3171/SPI/2008/8/5/482
   Maiuri F, 2006, J NEUROL NEUROSUR PS, V77, P1185, DOI 10.1136/jnnp.2006.092312
   NABORS MW, 1988, J NEUROSURG, V68, P366, DOI 10.3171/jns.1988.68.3.0366
   Nam KH, 2013, SPINE J, V13, pE11, DOI 10.1016/j.spinee.2013.06.009
   SHIMA Y, 2002, SPINE, V27, P18
   Sun J., 2016, CHIN NEUROSUG J, V2, P7
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 359
EP 362
DI 10.1016/j.wneu.2019.06.141
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900181
PM 31254712
DA 2020-05-12
ER

PT J
AU Susarla, SM
   Hauptman, J
   Ettinger, R
   Sittler, B
   Ellenbogen, RG
AF Susarla, Srinivas M.
   Hauptman, Jason
   Ettinger, Russell
   Sittler, Bay
   Ellenbogen, Richard G.
TI Myelomeningocele Defect in the Setting of Severe Lumbar Kyphosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acellular dermal matrix; Gibbous deformity; Lumbar kyphosis;
   Myelomeningocele
ID DERMAL MATRIX ALLOGRAFT; SHUNT REVISION; KYPHECTOMY; CLOSURE;
   RECONSTRUCTION; REPAIR; TREAT
AB BACKGROUND: Severe kyphosis is infrequently seen in neonates with myelomeningoceles. Spinal skeletal dysmorphology complicates repair, as local tissue may be insufficient to cover the dural repair. Although neonatal kyphectomy has been proposed as a potential solution to this problem, it carries significant potential risks that may not be acceptable to families.
   CASE DESCRIPTION: A neonate presented with a large myelomeningocele defect with associated severe lumbar kyphosis. Kyphectomy was both declined by the family owing to the potential surgical risks and deemed not appropriate by the surgeons based on the challenging anatomic considerations. Soft tissue closure was not possible with local tissue rearrangement. Acellular dermal matrix was used as a definitive soft tissue coverage option, with complete epithelialization noted at 8 weeks postoperatively.
   CONCLUSIONS: Acellular dermal matrix is a potentially useful adjunct for definitive reconstruction of complex neonatal soft tissue defects where local tissue is not available.
C1 [Susarla, Srinivas M.; Ettinger, Russell; Sittler, Bay] Seattle Childrens Hosp, Div Plast & Craniofacial Surg, Seattle, WA 98105 USA.
   [Hauptman, Jason; Ellenbogen, Richard G.] Seattle Childrens Hosp, Dept Neurol Surg, Seattle, WA USA.
RP Susarla, SM (reprint author), Seattle Childrens Hosp, Div Plast & Craniofacial Surg, Seattle, WA 98105 USA.
EM ssusarla@uw.edu
RI Susarla, Srinivas/P-1051-2019
OI Susarla, Srinivas/0000-0003-0155-8260
CR Agag RL, 2004, ANN PLAS SURG, V52, P571, DOI 10.1097/01.sap.0000122651.12811.3d
   Alatas I, 2018, CHILD NERV SYST, V34, P919, DOI 10.1007/s00381-017-3663-z
   Banda CH, 2018, PRS-GLOB OPEN, V6, DOI 10.1097/GOX.0000000000002012
   Blanco-Davila F, 2000, J CRANIOFAC SURG, V11, P500, DOI 10.1097/00001665-200011050-00012
   Crawford AH, 2003, SPINE, V28, P260, DOI 10.1097/00007632-200302010-00011
   Deneve JL, 2013, AM SURGEON, V79, P476
   Duddy JC, 2013, ACTA NEUROCHIR, V155, P1965, DOI 10.1007/s00701-013-1805-y
   ECKSTEIN H B, 1972, Journal of Bone and Joint Surgery British Volume, V54, P328
   Fosnot J, 2011, AESTHET SURG J, V31, p5S, DOI 10.1177/1090820X11417576
   Grigoryants V, 2007, PEDIATR NEUROSURG, V43, P512, DOI 10.1159/000108798
   Hill SM, 2012, J NEUROSURG-PEDIATR, V9, P156, DOI 10.3171/2011.11.PEDS11249
   Karlin LI, 2007, NEUROSURG CLIN N AM, V18, P357, DOI 10.1016/j.nec.2007.02.005
   Lien SC, 2010, CHILD NERV SYST, V26, P1091, DOI 10.1007/s00381-010-1099-9
   LINDSETH RE, 1979, J BONE JOINT SURG AM, V61, P699, DOI 10.2106/00004623-197961050-00008
   McDowell MM, 2018, PEDIATR NEUROSURG, V53, P100, DOI 10.1159/000485251
   Ozdemir N, 2019, CHILD NERV SYST, V35, P673, DOI 10.1007/s00381-018-4006-4
   Pourtaheri N, 2018, J CRANIOFAC SURG, V29, P1137, DOI 10.1097/SCS.0000000000004598
   RAMASASTRY SS, 1995, NEUROSURG CLIN N AM, V6, P279
   Roussalis JL, 2014, INT J BURNS TRAUMA, V4, P49
   Shitrit SB, 2014, INT J BURNS TRAUMA, V4, P62
   Tervonen J, 2017, WORLD NEUROSURG, V101, P615, DOI 10.1016/j.wneu.2017.02.030
   Yoshioka K, 2011, SCOLIOSIS SPINAL DIS, V6, DOI 10.1186/1748-7161-6-5
NR 22
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 363
EP 366
DI 10.1016/j.wneu.2019.06.116
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900182
PM 31247357
DA 2020-05-12
ER

PT J
AU Close, LN
   Zanaty, M
   Kirby, P
   Dlouhy, BJ
AF Close, Liesl N.
   Zanaty, Mario
   Kirby, Patricia
   Dlouhy, Brian J.
TI Acute Hydrocephalus Resulting from Neuromyelitis Optica: A Case Report
   and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebrospinal fluid; Communicating hydrocephalus; Demyelinating;
   Hydrocephalus; Neuromyelitis optica; Shunt
ID FLUID
AB BACKGROUND: Neuromyelitis optica is an autoimmune disorder of the central nervous system that predominantly affects the optic nerves and spinal cord. The neuropathologic hallmark of the disease is deposits of antibodies and complement, loss of astrocytes, secondary degeneration of oligodendrocytes and neurons, and necrotic lesions with infiltration of neutrophilic and eosinophilic granulocytes. It can rarely be associated with hydrocephalus, but the cause and mechanisms that result in hydrocephalus are not clear.
   CASE DESCRIPTION: A 35-year-old woman with a history of neuromyelitis optica presented with a 5-day history of progressively worsening lethargy, fatigue, somnolence, and headaches. Imaging demonstrated new hydrocephalus without evidence of obstruction, and extensive periventricular enhancement concerning for active demyelination. She underwent placement of a ventriculostomy, and subsequently underwent endoscopic biopsy and ventriculoperitoneal shunt placement. Pathology confirmed demyelination secondary to neuromyelitis optica.
   CONCLUSIONS: This case provides evidence of the rapid development of hydrocephalus in association with periventricular inflammation, without aqueductal stenosis. In a state of aquaporin-4 dysfunction such as in neuromyelitis optica, altered cerebrospinal fluid resorption could lead to acute hydrocephalus by a nonobstructive mechanism.
C1 [Close, Liesl N.; Zanaty, Mario; Dlouhy, Brian J.] Univ Iowa, Univ Iowa Hosp & Clin, Stead Family Childrens Hosp, Dept Neurosurg, Iowa City, IA 52242 USA.
   [Dlouhy, Brian J.] Univ Iowa, Carver Coll Med, Iowe Neurosci Inst, Iowa City, IA 52242 USA.
   [Kirby, Patricia] Univ Iowa Hosp & Clin, Dept Pathol, Iowa City, IA 52242 USA.
   [Dlouhy, Brian J.] Univ Iowa, Carver Coll Med, Pappajohn Biomed Inst, Iowa City, IA 52242 USA.
RP Dlouhy, BJ (reprint author), Univ Iowa, Univ Iowa Hosp & Clin, Stead Family Childrens Hosp, Dept Neurosurg, Iowa City, IA 52242 USA.; Dlouhy, BJ (reprint author), Univ Iowa, Carver Coll Med, Iowe Neurosci Inst, Iowa City, IA 52242 USA.; Dlouhy, BJ (reprint author), Univ Iowa, Carver Coll Med, Pappajohn Biomed Inst, Iowa City, IA 52242 USA.
EM brian-dlouhy@uiowa.edu
CR Bloch O, 2005, J NEUROCHEM, V95, P254, DOI 10.1111/j.1471-4159.2005.03362.x
   Bloch O, 2006, J CEREBR BLOOD F MET, V26, P1527, DOI 10.1038/sj.jcbfm.9600306
   Brinker T, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-10
   Clardy SL, 2014, NEUROLOGY, V82, P1841, DOI 10.1212/WNL.0000000000000428
   Dlouhy BJ, 2012, J NEUROSURG-PEDIATR, V9, P182, DOI 10.3171/2011.11.PEDS11495
   Guo Y, 2017, ACTA NEUROPATHOL, V133, P597, DOI 10.1007/s00401-017-1682-1
   Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748
   Mader S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010455
   Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje
   Tait MJ, 2010, NEUROSCIENCE, V167, P60, DOI 10.1016/j.neuroscience.2010.01.053
   Verkman AS, 2011, ACTA PHARMACOL SIN, V32, P702, DOI 10.1038/aps.2011.27
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 367
EP 371
DI 10.1016/j.wneu.2019.05.177
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900183
PM 31200081
DA 2020-05-12
ER

PT J
AU Kournoutas, I
   Vigo, V
   Chae, R
   Wang, MH
   Gurrola, J
   Abla, AA
   El-Sayed, I
   Rubio, RR
AF Kournoutas, Ioannis
   Vigo, Vera
   Chae, Ricky
   Wang, Minghao
   Gurrola, Jose, II
   Abla, Adib A.
   El-Sayed, Ivan
   Rubio, Roberto Rodriguez
TI Acquisition of Volumetric Models of Skull Base Anatomy Using Endoscopic
   Endonasal Approaches: 3D Scanning of Deep Corridors Via Photogrammetry
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D scanning; Education; Endoscope; Extended reality; Photogrammetry;
   Surgical neuroanatomy; Volumetric models
ID VIRTUAL-REALITY; VISUALIZATION; IMPACT
AB OBJECTIVE: In this study we aim to evaluate the feasibility of creating volumetric models of highly intricate skull-base anatomy-previously not amenable to volumetric reconstruction-using endoscopic endonasal approaches.
   METHODS: Ten human cadaveric heads were dissected through the nasal corridor to expose anterior, middle, and posterior cranial fossi structures and the pterygopalatine and infratemporal fossi. A rigid endoscope with a 30 degrees lens was used to capture the images. Subsequently, a photogrammetry software was used to align, smooth, and texturize the images into a complete 3-dimensional model.
   RESULTS: An average of 174 photographs were used to construct each model (n = 10). In the end, we achieved high-definition stereoscopic volumetric models of the nasal corridor; paranasal fossae; and anterior, middle and posterior fossae structures that preserved structural integrity. Strategic points of interests were labeled and animated for educational use.
   CONCLUSIONS: Endoscopic volumetric models represent a new way to depict the anatomy of the skull base; their use with 3-dimensional technologies could potentially improve the visuospatial understanding of narrow surgical corridors for education and surgical-planning purposes.
C1 [Kournoutas, Ioannis; Vigo, Vera; Chae, Ricky; Wang, Minghao; Abla, Adib A.; El-Sayed, Ivan; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
   [Vigo, Vera; Abla, Adib A.; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Gurrola, Jose, II; El-Sayed, Ivan; Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
RP Rubio, RR (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Rubio, RR (reprint author), Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
EM neurodriguez@gmail.com
OI Chae, Ricky/0000-0001-5014-9303; Wang, Minghao/0000-0003-1705-0891;
   Gurrola II, Jose/0000-0001-6801-5768
CR Abuzayed B, 2010, SURG RADIOL ANAT, V32, P499, DOI 10.1007/s00276-010-0651-3
   Agarwal N, 2012, BMJ CASE REP, P1
   Aso-Escario J, 2011, REV NEUROLOGIA, V53, P494, DOI 10.33588/rn.5308.2009075
   Balogh A, 2004, J NEUROSURG, V100, P591, DOI 10.3171/jns.2004.100.4.0591
   Balogh AA, 2006, NEUROSURGERY, V58, P157, DOI 10.1227/01.NEU.0000193514.07866.F0
   Barry ME, 2016, WORLD NEUROSURG, V92, P637, DOI 10.1016/j.wneu.2016.06.036
   Baskaran V, 2016, FRONT NEUROANAT, V10, DOI 10.3389/fnana.2016.00069
   Berney S, 2015, ANAT SCI EDUC, V8, P452, DOI 10.1002/ase.1524
   Cunningham J, 1909, STEREOSCOPIC STUDIES
   Das AJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179264
   De Benedictis A, 2018, WORLD NEUROSURG, V115, pE279, DOI 10.1016/j.wneu.2018.04.036
   Ding HL, 2017, J CLIN NEUROSCI, V42, P209, DOI 10.1016/j.jocn.2017.04.021
   El-Gamal FEA, 2016, EGYPT INFORM J, V17, P99, DOI 10.1016/j.eij.2015.09.002
   Fernandez-Miranda JC, 2016, WORLD NEUROSURG, V92, P590, DOI 10.1016/j.wneu.2016.06.028
   FRASER CS, 1993, ISPRS J PHOTOGRAMM, V48, P12, DOI 10.1016/0924-2716(93)90060-Z
   Garcia J, 2018, BMJ SIMUL TECHNOL EN, V4, P27, DOI 10.1136/bmjstel-2017-000234
   Hendricks BK, 2018, OPER NEUROSURG, V15, P368, DOI 10.1093/ons/opy166
   Ibn al-Haytham A, 1992, SPECULUM, V67, P977
   Javaid MA, 2018, ANAT SCI EDUC, V11, P81, DOI 10.1002/ase.1711
   King RD, 2013, WILEY INTERDISCIP RE, V5, P334, DOI 10.1002/wics.1264
   Krause G, 1994, MICROSURGICAL ANATOM
   Labib MA, 2014, OPER NEUROSURG, V10, P448, DOI 10.1227/NEU.0000000000000362
   Loke YH, 2017, BMC MED EDUC, V17, DOI 10.1186/s12909-017-0889-0
   Marcus HJ, 2014, BRIT J NEUROSURG, V28, P606, DOI 10.3109/02688697.2014.887654
   Merril JR, 1997, ANN NY ACAD SCI, V820, P229, DOI 10.1111/j.1749-6632.1997.tb46198.x
   Nguyen N, 2014, ANAT SCI EDUC, V7, P280, DOI 10.1002/ase.1415
   Poletti CE, 1985, STEREO ATLAS OPERATI
   Robertson JH, 2016, J NEUROL SURG PART B, V77, P291, DOI 10.1055/s-0036-1584943
   Rodriguez Rubio R, 2018, OPER NEUROSURG, V16
   Rubio RR, 2019, WORLD NEUROSURG, V126, P359, DOI 10.1016/j.wneu.2019.03.099
   Shimizu Satoru, 2006, Neurosurgery, V58, pE1000, DOI 10.1227/01.NEU.0000210247.37628.43
   Silen C, 2008, MED TEACH, V30, pE115, DOI 10.1080/01421590801932228
   Sivapatham T, 2010, NEUROSURGERY, V67, P1816
   Sorenson J, 2016, J NEUROL SURG PART B, V77, P294, DOI 10.1055/s-0036-1584944
   Stepan K, 2017, INT FORUM ALLERGY RH, V7, P1006, DOI 10.1002/alr.21986
   Tanrikulu L, 2007, J NEUROSURG, V107, P1137, DOI 10.3171/JNS-07/12/1137
   Valenca J, 2012, EXP TECHNIQUES, V36, P71, DOI 10.1111/j.1747-1567.2011.00731.x
   Vidal FP, 2006, COMPUT GRAPH FORUM, V25, P113, DOI 10.1111/j.1467-8659.2006.00822.x
   Wade NJ, 2012, PERCEPTION, V41, P901, DOI 10.1068/p7270
   Yang TY, 2018, J INT MED RES, V46, P1570, DOI 10.1177/0300060518755267
NR 40
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 372
EP 377
DI 10.1016/j.wneu.2019.05.251
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900184
PM 31181359
DA 2020-05-12
ER

PT J
AU Flores, RE
   Beltran, JQ
   Ogando-Rivas, E
AF Flores, Ruben E.
   Beltran, Jesus Q.
   Ogando-Rivas, Elizabeth
TI An Affordable and Feasible Technique for Minimally Invasive Tubular
   Lumbar Discectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Back pain; Herniated disc; Lumbar; Minimally invasive spine surgery;
   Surgical technique; Syringes
ID SPINAL STENOSIS
AB BACKGROUND: The benefits of minimally invasive spine surgery are attainable only if hospitals have the financial resources to acquire essential equipment. We present a surgical approach readily available to countries where unacceptably expensive materials are the main limitation for use of minimally invasive spine surgery.
   METHODS: This retrospective study included 30 patients who underwent minimally invasive spine surgery using syringes as dilators and retractors for posterior lumbar approaches. Inclusion criteria were lumbar radicular/back pain, degenerative disc, spondylolysis, unilateral approach, and maximum of 2 affected spine levels. Demographic characteristics, affected radicular level, diagnosis, type and length of surgery, hospital length of stay, MacNab criteria, complications, and resumption of daily activities were analyzed.
   RESULTS: Of 30 patients, 17 (56.6%) presented with S1 radicular pain. Pain was mainly due to posterolateral hernia (70%; n = 21) requiring 1-level discectomy. In 6 patients (20%), discectomy and an interspinous process device were required. One patient (3.33%) underwent 2-level discectomy. All surgeries were performed using syringes as dilators and retractors. Maximum syringe diameter used was 2 cm (20-mL syringes) in 29 patients (96.6%) and 3 cm (60-mL syringe) in 1 patient. Average length of surgery was 1.5 hours, and average hospital stay was 1.8 days. Based on MacNab criteria, excellent, good, and fair outcomes were achieved in 25 patients (83%), 3 patients (10%), and 2 patients (6.7%). Complications were observed in 5 patients (16.7%).
   CONCLUSIONS: This is a safe and feasible technique with excellent results obtained at low cost and is becoming an attractive surgical option in developing countries.
C1 [Flores, Ruben E.] Hosp Gen Zona 7 IMSS, Dept Neurosurg, Monclova, Mexico.
   [Flores, Ruben E.] Hosp St Marie, Monclova, Mexico.
   [Beltran, Jesus Q.] Hosp Gen Mexico City, Dept Neurosurg, Mexico City, DF, Mexico.
   [Ogando-Rivas, Elizabeth] Univ Florida, Dept Neurosurg, Gainesville, FL 32611 USA.
   [Ogando-Rivas, Elizabeth] Univ Florida, Brain Tumor Immunotherapy Program, Gainesville, FL 32611 USA.
RP Ogando-Rivas, E (reprint author), Univ Florida, Dept Neurosurg, Gainesville, FL 32611 USA.; Ogando-Rivas, E (reprint author), Univ Florida, Brain Tumor Immunotherapy Program, Gainesville, FL 32611 USA.
EM elizabeth.ogando-rivas@neurosurgery.ufl.edu
OI Ogando-Rivas, Elizabeth/0000-0001-7192-6714
CR Alimi M, 2015, J NEUROSURG-SPINE, V22, P339, DOI 10.3171/2014.11.SPINE13597
   Anderle Diogo Valli, 2010, Coluna/Columna, V9, P145, DOI 10.1590/S1808-18512010000200010
   Arts MP, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017882
   Asgarzadie F, 2007, ORTHOP CLIN N AM, V38, P387, DOI 10.1016/j.ocl.2007.02.006
   Boos N., 2008, SPINAL DISORDERS FUN
   Boukebir MA, 2017, OPER NEUROSURG, V13, P232, DOI 10.1227/NEU.0000000000001407
   Clark AJ, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17202
   Dhandapani S, 2018, SPINE J, V18, P1592, DOI 10.1016/j.spinee.2018.02.002
   Foley KT, 1997, TECH NEUROSURG, V3, P301
   Goldstein CL, 2016, J NEUROSURG-SPINE, V24, P416, DOI 10.3171/2015.2.SPINE14973
   Hirst A, 2019, ANN SURG, V269, P211, DOI 10.1097/SLA.0000000000002794
   Huang TJ, 2005, J ORTHOP RES, V23, P406, DOI 10.1016/j.orthres.2004.08.010
   Palmer S, 2002, J NEUROSURG, V97, P213, DOI 10.3171/spi.2002.97.2.0213
   Popov V, 2012, ADV ORTHOP, V2012, DOI 10.1155/2012/645321
NR 14
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 378
EP 385
DI 10.1016/j.wneu.2019.06.118
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900185
PM 31252081
DA 2020-05-12
ER

PT J
AU Machino, M
   Imagama, S
   Ishiguro, N
AF Machino, Masaaki
   Imagama, Shiro
   Ishiguro, Naoki
TI Detection of Spinal Dural Defect in Superficial Siderosis by
   Intraoperative Ultrasonography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural defect; Fluid collection; Imaging detection; Intraoperative
   ultrasonography; Superficial siderosis; Surgical repair
AB Superficial siderosis of the central nervous system is a rare disease caused by repeated hemorrhages in the subarachnoid space. We describe surgical treatment of a case in which a tiny dural defect with fluid collection in the spinal canal was detected by intraoperative ultrasonography (US). After laminectomy, intraoperative US imaging confirmed epidural fluid collection around the ventral dural defect before incision of the posterior dura mater. Intraoperative US also showed a dural defect at the ventral and right side of the spinal cord. The ventral dural defect was repaired by direct sutures. After repair, intraoperative US imaging confirmed dural hole closure and resolution of the collected fluid. Intraoperative US is useful for detecting the level of dural defect before repair and confirming closure of the dural defect and successful resolution of fluid collection after repair.
C1 [Machino, Masaaki; Imagama, Shiro; Ishiguro, Naoki] Nagoya Univ, Dept Orthoped Surg, Grad Sch Med, Nagoya, Aichi, Japan.
RP Imagama, S (reprint author), Nagoya Univ, Dept Orthoped Surg, Grad Sch Med, Nagoya, Aichi, Japan.
EM imagama@med.nagoya-u.ac.jp
OI Kobayashi, Kazuyoshi/0000-0003-1721-9626
CR Egawa S, 2013, J NEUROSURG-SPINE, V18, P388, DOI 10.3171/2013.1.SPINE12649
   FEARNLEY JM, 1995, BRAIN, V118, P1051, DOI 10.1093/brain/118.4.1051
   Kumar N, 2009, NEUROLOGY, V72, P671, DOI 10.1212/01.wnl.0000342457.22536.af
   McCarron MO, 2003, J NEUROL NEUROSUR PS, V74, P1326, DOI 10.1136/jnnp.74.9.1326
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 386
EP 388
DI 10.1016/j.wneu.2019.06.123
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900186
PM 31252076
DA 2020-05-12
ER

PT J
AU Sakoda, R
   Fujihara, R
   Komatsubara, S
   Kagawa, S
   Yamamoto, T
AF Sakoda, Ryunosuke
   Fujihara, Ryuji
   Komatsubara, Satoshi
   Kagawa, Seiko
   Yamamoto, Tetsuji
TI Spontaneous Spinal Epidural Hematoma with Lumbar Facet Joint Destruction
   Mimicking Pigmented Villonodular Synovitis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Facet joint destruction; Intracapsular bleeding; Necrotic bone;
   Pigmented villonodular synovitis; Spontaneous spinal epidural hematoma
ID ARTHROPATHY
AB BACKGROUND: Spontaneous spinal epidural hematoma (SSEH) is a spinal emergency that requires early diagnosis and decompression surgery. Here, we report a case of SSEH that was difficult to differentiate from pigmented villonodular synovitis (PVS) because of combined facet joint destruction and that required gross total resection, a procedure not typically indicated for SSEH.
   CASE DESCRIPTION: A 58-year-old woman complained of sudden-onset walk disturbance after backache without any traumatic episode. Physical examination revealed motor paralysis in the leg. Moreover, extensive destruction of the L4/5 right facet joint and an epidural mass continuing from the facet was observed. The epidural mass showed heterogeneous intensity in magnetic resonance imaging, suggesting different stages of bleeding. These hemorrhagic changes combined with the facet joint destruction suggested PVS, and preoperative and intraoperative pathologic examinations could not rule out PVS. After surgical treatment of PVS, the lesion in the articular process was resected and decompression was performed. The pathologic diagnosis was hematoma with bone necrosis in the articular process, without neoplastic finding suggesting PVS.
   CONCLUSIONS: SSEH could be combined with facet joint destruction composed of bone necrosis. Awareness of SSEH with facet joint destruction can facilitate early diagnosis and appropriate surgical treatment.
C1 [Sakoda, Ryunosuke; Fujihara, Ryuji; Komatsubara, Satoshi; Yamamoto, Tetsuji] Kagawa Univ, Fac Med, Dept Orthopaed Surg, Takamatsu, Kagawa, Japan.
   [Kagawa, Seiko] Kagawa Univ, Fac Med, Dept Diagnost Pathol, Takamatsu, Kagawa, Japan.
RP Sakoda, R (reprint author), Kagawa Univ, Fac Med, Dept Orthopaed Surg, Takamatsu, Kagawa, Japan.
EM ryuji@med.kagawa-u.ac.jp
OI Fujihara, Ryuji/0000-0002-7795-9725
CR Adam G, 2006, DIFFERENTIAL DIAGNOS, P487
   Alexiadou-Rudolf C, 1998, SPINE, V23, P1810, DOI 10.1097/00007632-199808150-00018
   Braun P, 2007, EUR J RADIOL, V64, P119, DOI 10.1016/j.ejrad.2007.02.014
   Donald S, 1995, RESNICK D DIAGNOSIS, P3445
   Furlong MA, 2003, HUM PATHOL, V34, P670, DOI 10.1016/S0046-8177(03)00250-8
   Ishiguro N, 2001, HAEMOPHILIA, V7, P127, DOI 10.1046/j.1365-2516.2001.00475.x
   Kaneko K, 2000, J BONE JOINT SURG BR, V82B, P583, DOI 10.1302/0301-620X.82B4.10444
   Lang N, 2015, J COMPUT ASSIST TOMO, V39, P601, DOI 10.1097/RCT.0000000000000244
   Liao CC, 2004, J NEUROSURG, V100, P38, DOI 10.3171/spi.2004.100.1.0038
   MITROVIC DR, 1992, RHEUMATOL INT, V12, P17
   Musluman Ahmet Murat, 2009, Spine J, V9, pe6, DOI 10.1016/j.spinee.2008.12.010
   Nishida K, 2003, SPINE, V28, pE206
   Roguski M, 2014, J CLIN NEUROSCI, V21, P1679, DOI 10.1016/j.jocn.2014.03.012
   Somerhausen NS, 2013, WHO CLASSIFICATION T, P102
   Yener U, 2010, TURK NEUROSURG, V20, P251, DOI 10.5137/1019-5149.JTN.1590-08.3
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 390
EP 393
DI 10.1016/j.wneu.2019.06.140
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900188
PM 31254704
DA 2020-05-12
ER

PT J
AU Choy, WJ
   Abi-Hanna, D
   Cassar, LP
   Hardcastle, P
   Phan, K
   Mobbs, RJ
AF Choy, Wen Jie
   Abi-Hanna, David
   Cassar, Lachlan P.
   Hardcastle, Philip
   Phan, Kevin
   Mobbs, Ralph J.
TI History of Integral Fixation for Anterior Lumbar Interbody Fusion
   (ALIF): The Hartshill Horseshoe
SO WORLD NEUROSURGERY
LA English
DT Article
DE ALIF; Anterior lumbar interbody fusion; Hartshill Horseshoe; Integral
   fixation; Lumbar; Spinal fusion; Spinal implant; Spine
ID STAINLESS-STEEL; SPINE FUSION; IMPLANTS; TITANIUM; CAGES; MULTICENTER;
   SURGERY; SAFETY
AB OBJECTIVE: Anterior lumbar interbody fusion (ALIF) is a common spinal fusion option for different spinal pathologies. In the early years, implant migrations/expulsions were potential complications of ALIFs due to the lack of integral fixation. We present a historical vignette on the inception and development of the first stand-alone ALIF (SA-ALIF) implant-the Hartshill Horseshoe (HH).
   METHODS: A Preferred Reporting Items for Systematic Reviews and Meta-Analyses systematic search was carried out for 3 online databases focusing on implant development for ALIF, refining the search to before 1995. A personal communication with the original patent holders of the HH was used due to the lack of formal publication of the HH during its early years.
   RESULTS: Since 1932, the idea of anterior lumbar fusion was proposed and was carried out in 1933 using a tibial peg. Autografts were first reported in 1936 as interbody spacers for ALIF. Since then, bone grafts were commonly used for ALIF. However, ALIFs were not commonly performed due to variable reported outcomes. A pilot study in 1971 reported the use titanium mesh blocks as interbody implants in 6 patients. No articles reporting the use of integral fixation for SA-ALIF implants were found before the development of the HH in 1984.
   CONCLUSIONS: The HH was the first synthetic SA-ALIF implant developed. Since the HH, multiple SA-ALIF implants have been designed. The benefits of integral fixation in a SA-ALIF device include immediate implant stability, ability to reduce and correct deformity postimplantation, prevention of implant migration, and increased implantLbony endplate contact for early osseointegration.
C1 [Choy, Wen Jie; Abi-Hanna, David; Cassar, Lachlan P.; Phan, Kevin; Mobbs, Ralph J.] Univ New South Wales, Fac Med, Sydney, NSW, Australia.
   [Choy, Wen Jie; Abi-Hanna, David; Cassar, Lachlan P.; Phan, Kevin; Mobbs, Ralph J.] NeuroSpine Surg Res Grp NSURG, Sydney, NSW, Australia.
   [Choy, Wen Jie; Abi-Hanna, David; Cassar, Lachlan P.; Phan, Kevin; Mobbs, Ralph J.] Prince Wales Private Hosp, NeuroSpine Clin, Randwick, NSW, Australia.
   [Hardcastle, Philip] Philip Hardcastle Clin, Perth, WA, Australia.
RP Mobbs, RJ (reprint author), Univ New South Wales, Fac Med, Sydney, NSW, Australia.; Mobbs, RJ (reprint author), NeuroSpine Surg Res Grp NSURG, Sydney, NSW, Australia.; Mobbs, RJ (reprint author), Prince Wales Private Hosp, NeuroSpine Clin, Randwick, NSW, Australia.
EM r.mobbs@unsw.edu.au
CR ALBERT K, 1994, BIO-MED MATER ENG, V4, P345
   BAGBY GW, 1988, ORTHOPEDICS, V11, P931
   Bal BS, 2012, ACTA BIOMATER, V8, P2889, DOI 10.1016/j.actbio.2012.04.031
   Beckers L, 1999, RIV NEURORADIOL, V12, P75, DOI 10.1177/19714009990120S109
   BRANTIGAN JW, 1993, SPINE, V18, P2106, DOI 10.1097/00007632-199310001-00030
   Burns BH, 1933, LANCET, V1, P1233
   Calandruccio R A, 1964, Clin Orthop Relat Res, V35, P63
   Capener N, 1932, BRIT J SURG, V19, P374, DOI 10.1002/bjs.1800197505
   de Kunder SL, 2018, SPINE, V43, P1161, DOI 10.1097/BRS.0000000000002534
   DEBOWES RM, 1984, AM J VET RES, V45, P191
   Dick JC, 2001, SPINE, V26, P1668, DOI 10.1097/00007632-200108010-00008
   Dick JC, 1997, SPINE, V22, P744, DOI 10.1097/00007632-199704010-00005
   DISEGI JA, 1992, INJURY, V23, pS1, DOI 10.1016/S0020-1383(10)80001-4
   Dove J, 1990, Spinal implants US, Patent, Patent No. 4904261
   Fang H S, 1964, Clin Orthop Relat Res, V35, P16
   Giang G, 2017, WORLD NEUROSURG, V104, P259, DOI 10.1016/j.wneu.2017.05.011
   HARMON P H, 1963, Clin Orthop Relat Res, V26, P107
   HARMON PH, 1959, AM J SURG, V97, P649, DOI 10.1016/0002-9610(59)90259-4
   HARMON PH, 1950, AM J SURG, V80, P829, DOI 10.1016/0002-9610(50)90616-7
   Hertlein H, 1992, Eur Spine J, V1, P131, DOI 10.1007/BF00300940
   INOUE S, 1984, CLIN ORTHOP RELAT R, P22
   Jacobs JJ, 1998, J BONE JOINT SURG AM, V80A, P268, DOI 10.2106/00004623-199802000-00015
   Kakinuma H, 2015, J BIOMED MATER RES A, V103, P57, DOI 10.1002/jbm.a.35157
   Kuslich SD, 1998, SPINE, V23, P1267, DOI 10.1097/00007632-199806010-00019
   LANE JD, 1948, ANN SURG, V127, P537, DOI 10.1097/00000658-194803000-00013
   LEONG JCY, 1994, CLIN ORTHOP RELAT R, P52
   Li JF, 2010, SPINE, V35, pE1564, DOI 10.1097/BRS.0b013e3181ef5c14
   Li YB, 2015, J SPINAL DISORD TECH, V28, P398, DOI 10.1097/BSD.0000000000000032
   Madan S, 2003, EUR SPINE J, V12, P361, DOI 10.1007/s00586-002-0488-5
   Madan S, 2001, J SPINAL DISORD, V14, P104, DOI 10.1097/00002517-200104000-00003
   Mercer Walter, 1936, Edinb Med J, V43, P545
   Mobbs RJ, 2019, WORLD NEUROSURG, V124, P452, DOI 10.1016/j.wneu.2018.12.144
   Mobbs RJ, 2018, WORLD NEUROSURG, V120, P256, DOI 10.1016/j.wneu.2018.08.237
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Mobbs RJ, 2013, ORTHOP SURG, V5, P153, DOI [10.1111/os.12048, 10.1111/j.1757-7861.2012.00185.x]
   Nambiar M, 2017, EUR SPINE J, V26, P2258, DOI 10.1007/s00586-017-5015-9
   OBRIEN JP, 1986, CLIN ORTHOP RELAT R, P191
   Peckett W, 2000, J MUSCULOSKELET RES, V4, P209
   Penta M, 1997, SPINE, V22, P2429, DOI 10.1097/00007632-199710150-00021
   Phan K, 2019, ORTHOP SURG, V11, P52, DOI 10.1111/os.12413
   Phan K, 2016, ORTHOP SURG, V8, P270, DOI 10.1111/os.12259
   Phan K, 2016, J CLIN NEUROSCI, V24, P138, DOI 10.1016/j.jocn.2015.07.017
   Ramakrishna S, 2001, COMPOS SCI TECHNOL, V61, P1189, DOI 10.1016/S0266-3538(00)00241-4
   Rao PJ, 2014, ORTHOP SURG, V6, P81, DOI 10.1111/os.12098
   Ray CD, 1997, SPINE, V22, P667, DOI 10.1097/00007632-199703150-00019
   RUPP R, 1993, SPINE, V18, P379
   Sacks S, 1966, Clin Orthop Relat Res, V44, P163
   SACKS S, 1965, J Bone Joint Surg Br, V47, P211
   SORENSEN KH, 1978, ACTA ORTHOP SCAND, V49, P269, DOI 10.3109/17453677809005764
   Sorrell C, 2004, 7 WORLD BIOM C SYDN
   Spruit M, 2002, EUR SPINE J, V11, P428, DOI 10.1007/s00586-002-0400-3
   STAUFFER RN, 1972, J BONE JOINT SURG AM, VA 54, P756, DOI 10.2106/00004623-197254040-00006
   STROVER AE, 1985, CLIN ORTHOP RELAT R, P88
   Tafazal S, 2006, ORTHOP P B S2, V88-B, P221
   Tarpada SP, 2017, J ORTHOP, V14, P134, DOI 10.1016/j.jor.2016.10.029
   Tiusanen H, 1996, CLIN ORTHOP RELAT R, P153
   TSUJI H, 1990, J SPINAL DISORD, V3, P77
   Weiner BK, 1998, SPINE, V23, P634, DOI 10.1097/00007632-199803010-00020
NR 58
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 394
EP 400
DI 10.1016/j.wneu.2019.06.134
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900189
PM 31254709
DA 2020-05-12
ER

PT J
AU Pastor-Escartin, F
   Garcia-Catalan, G
   Holanda, VM
   Lahirish, IAM
   Quintero, RB
   Neto, MR
   Quilis-Quesada, V
   Ibaoc, KB
   Darder, JMG
   de Oliveira, E
AF Pastor-Escartin, Felix
   Garcia-Catalan, Guillermo
   Holanda, Vanessa M.
   Lahirish, Issa Ali Muftah
   Quintero, Ruben Batista
   Neto, Mateus Regin
   Quilis-Quesada, Vicent
   Ibaoc, Khalil Bergado
   Gonzalez Darder, Jose Manuel
   de Oliveira, Evandro
TI Microsurgical Anatomy of the Insular Region and Operculoinsular
   Association Fibers and its Neurosurgical Application
SO WORLD NEUROSURGERY
LA English
DT Review
DE Insula; Microsurgical anatomy; Middle cerebral artery; Sylvian fissure;
   White matter fiber tracts
ID WHITE-MATTER; TEMPORAL-LOBE; IN-VIVO; DISSECTION; BRAIN; GLIOMAS
AB OBJECTIVE: To analyze the three-dimensional relationships of the operculoinsular compartments, using standard hemispheric and white matter fiber dissection and review the anatomy of association fibers related to the operculoinsular compartments of the Sylvian fissure and the main white matter tracts located deep into the insula. The secondary aim of this study was to improve the knowledge on this complex region to safely address tumor, vascular, and epilepsy lesions with an integrated perspective of the topographic and white matter fiber anatomy using 2D and 3D photographs.
   METHODS: Six cadaveric hemispheres were dissected. Two were fixed with formalin and the arteries were injected with red latex dye; the remaining four were prepared using the Kingler method and white fiber dissections were performed.
   RESULTS: The insula is located entirely inside the Sylvian fissure. The topographic hemispheric anatomy, Sylvian fissure, opercula, surrounding sulci and gyri, as well as the M2, M3, and M4 segments were identified. The anatomy of the insula, with the sulci and gyri and the limiting sulci, were also identified and described. The main white matter fiber tracts of the operculoinsular compartments of the Sylvian fissure as well as the main association and commissural fibers located deep in the insula were dissected and demonstrated.
   CONCLUSIONS: Complementing topographic anatomy with detailed study of white matter fibers and their integration can help the neurosurgeon to safely approach lesions in the insular region, improving postoperative results in the microsurgical treatment of aneurysmal lesions, insular tumors, or epilepsy surgery.
C1 [Pastor-Escartin, Felix; Garcia-Catalan, Guillermo; Lahirish, Issa Ali Muftah; Quintero, Ruben Batista; Neto, Mateus Regin; Quilis-Quesada, Vicent; Ibaoc, Khalil Bergado; de Oliveira, Evandro] Inst Neurol Sci ICNE, Sao Paulo, Brazil.
   [Pastor-Escartin, Felix; Garcia-Catalan, Guillermo; Lahirish, Issa Ali Muftah; Quintero, Ruben Batista; Neto, Mateus Regin; Ibaoc, Khalil Bergado; de Oliveira, Evandro] Beneficencia Portuguesa Hosp, Microneurosurg Lab, Sao Paulo, Brazil.
   [Pastor-Escartin, Felix; Holanda, Vanessa M.] Beneficencia Portuguesa Hosp, Dept Microsurg Anat & Neurosurg, Sao Paulo, Brazil.
   [Pastor-Escartin, Felix; Quilis-Quesada, Vicent; Gonzalez Darder, Jose Manuel] Hosp Clin Univ Valencia, Dept Neurosurg, Valencia, Spain.
   [Garcia-Catalan, Guillermo] Hosp Univ Marques Valdecilla, Dept Neurosurg, Santander, Cantabria, Spain.
   [Holanda, Vanessa M.; Neto, Mateus Regin; Quilis-Quesada, Vicent; de Oliveira, Evandro] Mayo Clin, Coll Med & Sci, Jacksonville, FL 32224 USA.
   [Pastor-Escartin, Felix; Quilis-Quesada, Vicent; Gonzalez Darder, Jose Manuel] Hosp Clin Univ Valencia, Valencia, Spain.
   [Quilis-Quesada, Vicent] Dept Human Anat & Embriol, Valencia, Spain.
   [Pastor-Escartin, Felix; Quilis-Quesada, Vicent; Gonzalez Darder, Jose Manuel] Univ Valencia, Fac Med, Valencia, Spain.
RP Holanda, VM (reprint author), Beneficencia Portuguesa Hosp, Dept Microsurg Anat & Neurosurg, Sao Paulo, Brazil.; Holanda, VM (reprint author), Mayo Clin, Coll Med & Sci, Jacksonville, FL 32224 USA.
EM Vanessamila@gmail.com
OI Reghin Neto, Mateus/0000-0003-4448-8231; Pastor Escartin,
   Felix/0000-0002-6756-3487
CR Bucheli C, 2014, NEUROCIRUGIA, V25, P268, DOI 10.1016/j.neucir.2014.07.003
   Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004
   Duffau H, 2003, NEUROREPORT, V14, P2005, DOI 10.1097/00001756-200310270-00026
   Duffau H, 2000, NEUROSURGERY, V47, P801, DOI 10.1097/00006123-200010000-00001
   Ferandez-Miranda JC, 2008, J NEUROSURG, V108, P764, DOI 10.3171/JNS/2008/108/4/0764
   Fernandez-Miranda JC, 2008, NEUROSURGERY, V62, P989, DOI [10.1227/01.NEU.0000297076.98175.67, 10.1227/01.neu.0000333767.05328.49]
   Forkel SJ, 2015, CORTEX, V62, P182, DOI 10.1016/j.cortex.2014.10.023
   Makris N, 2009, CEREB CORTEX, V19, P777, DOI 10.1093/cercor/bhn124
   Mandonnet E, 2006, J NEURO-ONCOL, V78, P179, DOI 10.1007/s11060-005-9084-y
   Martino J, 2015, J NEUROSURG, V123, P1081, DOI 10.3171/2014.11.JNS141992
   Martino J, 2011, J ANAT, V219, P531, DOI 10.1111/j.1469-7580.2011.01414.x
   Martino J, 2010, CORTEX, V46, P691, DOI 10.1016/j.cortex.2009.07.015
   Martino J, 2010, NEUROSURGERY, V66, P4, DOI 10.1227/01.NEU.0000348564.28415.FA
   Mazza M, 2004, BRAIN COGNITION, V55, P525, DOI 10.1016/j.bandc.2004.03.005
   Rhoton Jr AL, 2003, NEUROSURGERY, V53, P29
   SCHLESINGER B, 1953, AM J ROENTGENOL, V70, P555
   Son YJ, 2007, NEUROSURGERY, V61, P266, DOI [10.1227/01.neu.0000303979.88880.06, 10.1227/01.NEU.0000280088.06737.BA]
   Swanson KR, 2003, J NEUROL SCI, V216, P1, DOI 10.1016/j.jns.2003.06.001
   Tanriover N, 2004, J NEUROSURG, V100, P891, DOI 10.3171/jns.2004.100.5.0891
   Ture U, 1999, J NEUROSURG, V90, P720, DOI 10.3171/jns.1999.90.4.0720
   Ture U, 2000, NEUROSURGERY, V47, P417, DOI 10.1097/00006123-200008000-00028
   Ture U, 2000, J NEUROSURG, V92, P676, DOI 10.3171/jns.2000.92.4.0676
   Waddington MM, 1974, ATLAS CEREBRAL ANGIO, P38
   Wen HT, 2004, J NEUROSURG, V101, P747, DOI 10.3171/jns.2004.101.5.0747
   Wen HT, 1999, NEUROSURGERY, V45, P549, DOI 10.1097/00006123-199909000-00028
   Wen HT, 2009, NEUROSURGERY, V65, P1, DOI 10.1227/01.NEU.0000336314.20759.85
   Yasargil M G, 1975, Surg Neurol, V3, P7
   Yasargil MG, 1996, MICRONEUROSURGERY B, VIV-B, P252
NR 28
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 407
EP 420
DI 10.1016/j.wneu.2019.05.071
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900192
PM 31132493
DA 2020-05-12
ER

PT J
AU Panagopoulos, D
   Themistocleous, M
   Apostolopoulou, K
   Sfakianos, G
AF Panagopoulos, Dimitrios
   Themistocleous, Marios
   Apostolopoulou, Katerina
   Sfakianos, Georgios
TI Herpes Simplex Encephalitis Initially Erroneously Diagnosed as Glioma of
   the Cerebellum: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Herpes encephalitis; Posterior fossa glioma; Spectroscopy
AB BACKGROUND: Herpes simplex encephalitis caused by herpes simplex has an estimated annual prevalence in the order of 1 in 250,000 to 500,000 patients and is considered to be the most usually encountered nonendemic pathogenic cause of lethal encephalitis in well-developed countries. There are a few cases reported in the literature in which a diagnostic dilemma between was raised between herpes simplex encephalitis and brain glioma and a definitive diagnosis was difficult to obtain.
   CASE DESCRIPTION: We report the case of a 5-year-old girl with a previous medical history of premature thelarche. As a part of her investigation, magnetic resonance imaging of the brain was performed, which revealed a space-occupying lesion of the posterior fossa. Magnetic resonance spectroscopy was performed, which advocated for the diagnosis of glioma. She was operated on, but the histopathologic analysis failed to verify the imaging findings. Herpes simplex virus (HSV) 1 was detected in cerebrospinal fluid (CSF) samples. Follow-up magnetic resonance imaging scans illustrated the progression of the disease.
   CONCLUSIONS: The accumulation of data regarding CSF sample analysis, electroencephalography, brain biopsy, and imaging findings, along with the progression of the clinical picture of our patient, verified the diagnosis of HSV encephalitis. When confronted with confounding data that can pose a diagnostic dilemma between HSV encephalitis and glioma, brain biopsy and polymerase chain reaction of CSF samples could be able to verify the definitive diagnosis. When interpreting our results, we always have to consider the evolution of the clinical picture.
C1 [Panagopoulos, Dimitrios; Themistocleous, Marios; Apostolopoulou, Katerina; Sfakianos, Georgios] Pediat Hosp Athens, Neurosurg Dept, Athens, Greece.
RP Panagopoulos, D (reprint author), Pediat Hosp Athens, Neurosurg Dept, Athens, Greece.
EM dimpanayop@gmail.com
CR Hitosugi M, 1996, Rinsho Shinkeigaku, V36, P839
   Krouwer HGJ, 1998, AM J NEURORADIOL, V19, P1695
   Peeraully T, 2011, ISRN NEUROL
   Rees JH, 1999, POSTGRAD MED J, V75, P728, DOI 10.1136/pgmj.75.890.727
   Takanashi J, 1997, J NEUROL SCI, V149, P99, DOI 10.1016/S0022-510X(97)05401-4
   Talathi S, 2015, EUR J PAEDIATR NEURO, V19, P722, DOI 10.1016/j.ejpn.2015.07.007
   Wang JW, 2015, J FORMOS MED ASSOC, V114, P1295, DOI 10.1016/j.jfma.2014.07.012
   Weil AA, 2002, CLIN INFECT DIS, V34, P1154, DOI 10.1086/339550
   WHITLEY RJ, 1982, JAMA-J AM MED ASSOC, V247, P317, DOI 10.1001/jama.247.3.317
   WHITLEY RJ, 1995, CLIN INFECT DIS, V20, P414, DOI 10.1093/clinids/20.2.414
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 421
EP 427
DI 10.1016/j.wneu.2019.06.158
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900193
PM 31254700
DA 2020-05-12
ER

PT J
AU Dornbos, D
   Khandpur, U
   Youssef, PP
AF Dornbos, David, III
   Khandpur, Umang
   Youssef, Patrick P.
TI T-Configuration Horizontal Low-Profile Visualized Intraluminal Support
   (LVIS Jr) Device-Assisted Coiling for Treatment of Basilar Tip
   Aneurysms: A Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coil embolization; Endovascular; Intracranial aneurysm; Intracranial
   stent
ID MULTICENTER
AB BACKGROUND: Provided certain anatomic considerations, stent-assisted coiling of basilar apex aneurysms can be performed using a single stent placed in a horizontal T-configuration across the aneurysm neck prior to coil deployment, although this has predominantly been described using older-generation stents. The development of the Low-profile Visualized Intraluminal Support (LVIS Jr) device has provided greater versatility than previous stents, including use in smaller vessels, the ability to be resheathed, and improved flow diversion properties.
   METHODS: To our knowledge, we report the first use of the LVIS Jr device in a horizontal T-configuration across the aneurysm neck prior to coil deployment in 2 patients for the treatment of basilar apex aneurysms. This technique requires robust posterior communicating artery aneurysms and a second site of vascular access.
   RESULTS: Both patients demonstrated good outcomes following the procedure with no adverse sequelae. One patient required retreatment for recurrence after 1 year and was able to undergo further coiling without difficulty.
   CONCLUSIONS: Use of the LVIS Jr device allows greater versatility in horizontal T-configuration stent-assisted coil embolization, when compared with other available intracranial stents. This provides another tool to treat basilar apex aneurysms with improved coil occlusion and a theoretically decreased risk of thromboembolic events.
C1 [Dornbos, David, III; Khandpur, Umang; Youssef, Patrick P.] Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
RP Dornbos, D (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
EM David.Dornbos@osumc.edu
RI Dornbos, David/AAF-5091-2019
CR Blackburn SL, 2013, J NEUROINTERV SURG, V5, P212, DOI 10.1136/neurintsurg-2012-010301
   Chow MM, 2004, AM J NEURORADIOL, V25, P509
   Conrad MD, 2014, J NEUROINTERV SURG, V6, P296, DOI 10.1136/neurintsurg-2013-010818
   Cross DT, 2005, AM J NEURORADIOL, V26, P2578
   Fargen KM, 2013, NEUROSURGERY, V73, P466, DOI 10.1227/NEU.0000000000000015
   Grossberg JA, 2017, J NEUROINTERV SURG, V9, P1098, DOI 10.1136/neurintsurg-2016-012687
   Wanke I, 2006, NEURORADIOLOGY, V48, P817, DOI 10.1007/s00234-006-0128-6
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 428
EP 431
DI 10.1016/j.wneu.2019.05.220
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900194
PM 31158535
DA 2020-05-12
ER

PT J
AU Inoue, T
   Endo, T
   Sato, K
   Fesli, R
   Ogawa, Y
   Fujimura, M
   Matsumoto, Y
   Tominaga, T
AF Inoue, Tomoo
   Endo, Toshiki
   Sato, Kenichi
   Fesli, Ramazan
   Ogawa, Yoshikazu
   Fujimura, Miki
   Matsumoto, Yasushi
   Tominaga, Teiji
TI Massive Intramedullary Hemorrhage After Subarachnoid Hemorrhage in
   Patient with Vertebrovertebral Arteriovenous Fistula
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intramedullary hemorrhage; Myelopathy; Subarachnoid hemorrhage;
   Vertebrovertebral arteriovenous fistula
ID ENDOVASCULAR TREATMENT; EMBOLIZATION; MANAGEMENT
AB BACKGROUND: Hemorrhagic presentations are rare in vertebrovertebral arteriovenous fistula (VVAVF). To the best of our knowledge, this is the first report of a patient initially presenting with subarachnoid hemorrhage and progressing to intramedullary hemorrhage.
   CASE DESCRIPTION: The authors report on a 59-year-old man with VVAVF who developed massive intramedullary hemorrhage. Twelve months before ictus, the patient presented with subarachnoid hemorrhage. Although we recommended endovascular surgery, the patient refused treatment. Twelve months after the initial attack, the massive intramedullary hemorrhage in cervical spinal cord caused complete spinal cord injury. Emergent endovascular intervention was performed after the intramedullary hemorrhage, but there was no neurologic improvement.
   CONCLUSIONS: Identification of this phenomenon is important in VVAVF because intramedullary hemorrhage dramatically degrades patient outcome. Prompt surgical intervention is mandatory for VVAVF cases presenting with subarachnoid hemorrhage.
C1 [Inoue, Tomoo; Endo, Toshiki; Ogawa, Yoshikazu; Fujimura, Miki] Tohoku Univ, Dept Neurosurg, Sendai, Miyagi, Japan.
   [Sato, Kenichi; Matsumoto, Yasushi] Tohoku Univ, Kohnan Hosp, Dept Neuroendovasc Therapy, Sendai, Miyagi, Japan.
   [Inoue, Tomoo; Endo, Toshiki] Tohoku Univ, Sendai Med Ctr, Dept Neurosurg, Kohnan Hosp, Sendai, Miyagi, Japan.
   [Tominaga, Teiji] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi, Japan.
   [Fesli, Ramazan] Med Pk Private Hosp, Dept Neurosurg, Mersin, Turkey.
RP Endo, T (reprint author), Tohoku Univ, Dept Neurosurg, Sendai, Miyagi, Japan.; Endo, T (reprint author), Tohoku Univ, Sendai Med Ctr, Dept Neurosurg, Kohnan Hosp, Sendai, Miyagi, Japan.
EM endo@nsg.med.tohoku.ac.jp
OI Endo, Toshiki/0000-0002-5609-200X
CR Aadland TD, 2010, AM J NEURORADIOL, V31, P476, DOI 10.3174/ajnr.A1840
   Akabane A, 2002, J NEUROSURG, V97, P1436, DOI 10.3171/jns.2002.97.6.1436
   Ashour R, 2016, J NEUROINTERV SURG, V8, P643, DOI 10.1136/neurintsurg-2015-011677
   BAHAR S, 1984, NEURORADIOLOGY, V26, P45, DOI 10.1007/BF00328203
   BEAUJEUX RL, 1992, RADIOLOGY, V183, P361, DOI 10.1148/radiology.183.2.1561336
   Breda Miguel Sa, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2017-222815
   Briganti F, 2013, NEURORADIOL J, V26, P339, DOI 10.1177/197140091302600315
   de Keukeleire K, 2006, CARDIOVASC INTER RAD, V29, P311, DOI 10.1007/s00270-004-9197-2
   FREITAG HJ, 1989, NEURORADIOLOGY, V31, P174, DOI 10.1007/BF00698849
   Gross BA, 2013, NEUROSURGERY, V73, P141, DOI 10.1227/01.neu.0000429848.91707.73
   HALBACH VV, 1993, NEUROSURGERY, V33, P972
   Herrera DA, 2008, AM J NEURORADIOL, V29, P1585, DOI 10.3174/ajnr.A1123
   Honarmand AR, 2013, INTERV NEURORADIOL, V19, P215, DOI 10.1177/159101991301900211
   Kai Y, 2005, AM J NEURORADIOL, V26, P1949
   Kinouchi H, 1998, J NEUROSURG, V89, P755, DOI 10.3171/jns.1998.89.5.0755
   Maki Y, 2018, NEUROL MED-CHIR, V58, P185, DOI 10.2176/nmc.cr.2017-0241
   Miralbes S, 1998, NEURORADIOLOGY, V40, P761, DOI 10.1007/s002340050680
   Mitchell P, 2018, J CLIN NEUROSCI, V53, P220, DOI 10.1016/j.jocn.2018.04.013
   Nakstad PH, 1997, ACTA RADIOL, V38, P25
   Niizuma K, 2013, NEUROSURGERY, V73, pE287, DOI 10.1227/NEU.0000000000000189
   Shirakawa M, 2008, NEUROL MED-CHIR, V48, P167, DOI 10.2176/nmc.48.167
   Tenjin H, 2005, SURG NEUROL, V63, P80, DOI 10.1016/j.surneu.2004.01.026
   Tse GH, 2017, INTERV NEURORADIOL, V23, P399, DOI 10.1177/1591019917708569
   Vinchon M, 1994, Cardiovasc Surg, V2, P359
   Wang QH, 2011, ACTA NEUROCHIR, V153, P347, DOI 10.1007/s00701-010-0850-z
   Yeh CH, 2014, INTERV NEURORADIOL, V20, P766, DOI 10.15274/INR-2014-10072
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 432
EP 436
DI 10.1016/j.wneu.2019.06.076
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900195
PM 31226458
DA 2020-05-12
ER

PT J
AU Goel, A
   Vaja, T
   Shah, A
   Dandpat, S
   Bakale, N
AF Goel, Atul
   Vaja, Tejas
   Shah, Abhidha
   Dandpat, Saswat
   Bakale, Nilesh
TI Atlantoaxial Fixation as Treatment of Trigeminal Neuralgia in a Patient
   Having Basilar Invagination
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial instability; Basilar invagination; Trigeminal neuralgia
AB BACKGROUND: Trigeminal neuralgia can rarely be identified in association with basilar invagination. The presented case report observes that the treatment of basilar invagination by atlantoaxial fixation can result in lasting relief from trigeminal neuralgia.
   CASE DESCRIPTION: We report a case of a 36-year-old male patient who presented with the primary symptom of trigeminal neuralgia for a period of 2 years. Investigations revealed the presence of basilar invagination and an ectatic vertebral artery loop in the vicinity of the trigeminal nerve. The patient underwent atlantoaxial fixation on the basis of the concept that atlantoaxial instability is the nodal point of pathogenesis of basilar invagination. Atlantoaxial fixation resulted in complete and lasting relief from symptom of trigeminal neuralgia.
   CONCLUSIONS: The pathogenesis of trigeminal neuralgia and its relationship with atlantoaxial instability is speculated.
C1 [Goel, Atul; Vaja, Tejas; Shah, Abhidha; Dandpat, Saswat; Bakale, Nilesh] KEM Hosp & Seth GS Med Coll, Dept Neurosurg, Parel, India.
   [Goel, Atul] Lilavati Hosp & Res Ctr, Mumbai, Maharashtra, India.
RP Goel, A (reprint author), KEM Hosp & Seth GS Med Coll, Dept Neurosurg, Parel, India.; Goel, A (reprint author), Lilavati Hosp & Res Ctr, Mumbai, Maharashtra, India.
EM atulgoel62@hotmail.com
CR Bhayani R, 1996, BRIT J NEUROSURG, V10, P603, DOI 10.1080/02688699646943
   da Silva J A, 1982, Arq Neuropsiquiatr, V40, P165
   Desai K, 2002, NEUROL MED-CHIR, V42, P162, DOI 10.2176/nmc.42.162
   Goel A, 2017, J CRANIOVERTEBRAL JU, V8, P165, DOI 10.4103/jcvjs.JCVJS_101_17
   Goel A, 2017, WORLD NEUROSURG, V99, P164, DOI 10.1016/j.wneu.2016.11.093
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P3, DOI 10.4103/0974-8237.135206
   Goel A, 2009, J NEUROSURG, V111, P1220, DOI 10.3171/2009.6.JNS09469
   Goel A, 2009, J NEUROSURG-SPINE, V10, P220, DOI 10.3171/2008.12.SPINE08499
   REILLY MM, 1995, J NEUROL NEUROSUR PS, V58, P665, DOI 10.1136/jnnp.58.6.665
NR 9
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 437
EP 439
DI 10.1016/j.wneu.2019.06.099
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900196
PM 31229744
DA 2020-05-12
ER

PT J
AU Say, I
   Dodson, V
   Tomycz, L
   Mazzola, C
AF Say, Irene
   Dodson, Vincent
   Tomycz, Luke
   Mazzola, Catherine
TI Endoscopic Fourth Ventriculostomy: Suboccipital Transaqueductal Approach
   for Fenestration of Isolated Fourth Ventricle: Case Report and Technical
   Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic; Isolated fourth ventricle; Suboccipital; Transaqueductal
ID AQUEDUCTAL STENT PLACEMENT; TRAPPED 4TH-VENTRICLE; AQUEDUCTOPLASTY;
   MANAGEMENT; COMPLICATIONS
AB BACKGROUND: Trapped or isolated fourth ventricle is a known, late sequela after lateral ventricular shunt placement for hydrocephalus, particularly after infection or hemorrhage. It may cause brainstem compression and insidiously present with ataxia, dysarthria, and intracranial hypertension, further delaying diagnosis. There is no universally agreed on treatment algorithm, and options include open fenestration through a suboccipital craniotomy, fourth ventricle shunting, and minimally invasive options including endoscopic stenting and fenestration through a precoronal approach.
   CASE DESCRIPTION: We describe a young child with epilepsy and symptomatic brainstem compression from a dilated fourth ventricle, with a history of streptococcal parietal abscess and posthemorrhagic hydrocephalus requiring shunt placement. Given his history of infection and nearly neurologically intact examination, we pursued minimally invasive endoscopy through a suboccipital, transaqueductal approach to fenestrate his fourth ventricle.
   CONCLUSIONS: Magnetic resonance imaging (MRI) demonstrated complex, loculated hydrocephalus and a dilated fourth ventricle. Under electromagnetic navigation, we endoscopically fenestrated his fourth ventricle using a rarely described suboccipital, transaqueductal approach. He tolerated the procedure without complication and improved neurologically, although his follow-up MRI demonstrated no change in fourth ventricular dilation at 1 year. Although there was no decrease in size of the fourth ventricle on follow-up MRI, we describe an alternative, well-tolerated, suboccipital approach for the management of a trapped fourth ventricle. Fenestration of a web of tissue in the aqueduct of Sylvius provided long-term clinical improvement and may provide a rescue approach for patients who are not candidates for standard approaches.
C1 [Say, Irene; Dodson, Vincent; Tomycz, Luke; Mazzola, Catherine] Rutgers New Jersey Med Sch, Dept Neurosurg, Newark, NJ 07103 USA.
RP Mazzola, C (reprint author), Rutgers New Jersey Med Sch, Dept Neurosurg, Newark, NJ 07103 USA.
EM cmazzola@njpni.com
OI Dodson, Vincent/0000-0001-9009-2217
CR Cinalli G, 2006, J NEUROSURG, V104, P21, DOI 10.3171/ped.2006.104.1.21
   Colpan ME, 2003, MINIM INVAS NEUROSUR, V46, P57, DOI 10.1055/s-2003-37960
   Dollo C, 2001, CHILD NERV SYST, V17, P483, DOI 10.1007/s003810100444
   Eder HG, 1997, CHILD NERV SYST, V13, P13, DOI 10.1007/s003810050031
   Frassanito P, 2015, J NEUROSURG-PEDIATR, V16, P540, DOI 10.3171/2015.3.PEDS14619
   Gallo P, 2012, NEUROL INDIA, V60, P271, DOI 10.4103/0028-3886.98507
   Harter DH, 2004, CHILD NERV SYST, V20, P710, DOI 10.1007/s00381-004-1004-5
   LEE M, 1995, PEDIATR NEUROSURG, V22, P309, DOI 10.1159/000120921
   Longatti P, 2006, J NEUROSURG, V105, P924, DOI 10.3171/jns.2006.105.6.924
   Matula C, 1996, MINIM INVAS NEUROSUR, V39, P86, DOI 10.1055/s-2008-1052224
   Mohanty A, 2005, J NEUROSURG, V103, P73, DOI 10.3171/ped.2005.103.1.0073
   Mohanty A, 2018, OPER NEUROSURG, V14, P483, DOI 10.1093/ons/opx136
   PIATT JH, 1993, PEDIATR NEUROSURG, V19, P233, DOI 10.1159/000120738
   Sagan LM, 2006, J NEUROSURG, V105, P275, DOI 10.3171/ped.2006.105.4.275
   Sansone JM, 2005, J NEUROSURG, V103, P388, DOI 10.3171/ped.2005.103.5.0388
   Schulz M, 2012, NEUROSURGERY, V70, P847, DOI 10.1227/NEU.0b013e318236717f
   Sharma RR, 2001, CLIN NEUROL NEUROSUR, V103, P143, DOI 10.1016/S0303-8467(01)00129-9
   Shin M, 2000, J NEUROSURG, V92, P1036, DOI 10.3171/jns.2000.92.6.1036
   Spennato P, 2005, CHILD NERV SYST, V21, P309, DOI 10.1007/s00381-004-1046-8
   Teo C, 1999, NEUROSURGERY, V44, P1257, DOI 10.1097/00006123-199906000-00049
   Udayakumaran S, 2011, J NEUROSURG-PEDIATR, V7, P52, DOI 10.3171/2010.10.PEDS10139
NR 21
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 440
EP 444
DI 10.1016/j.wneu.2019.06.010
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900197
PM 31203068
DA 2020-05-12
ER

PT J
AU Khairy, S
   Al-Ahmari, AN
   Saeed, MA
   Azzubi, M
AF Khairy, Sami
   Al-Ahmari, Ahmed Nasser
   Saeed, Mahfood Abdullah
   Azzubi, Moutasem
TI Pediatric Rhabdoid Meningioma with Extension to the Heart: A First Case
   Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Extracranial; Heart; Pediatric; Rhabdoid meningioma
ID PAPILLARY MENINGIOMA; CHILD; EXPRESSION; TUMORS
AB BACKGROUND: Meningiomas are the most common benign intracranial neoplasms in adults, but they have a lower incidence in children. Rhabdoid meningioma is a rare subtype of meningioma and is classified as World Health Organization grade III.
   CASE DESCRIPTION: We present a very rare case of a 9-year-old boy who presented to our institution with a history of headache, dizziness, and vomiting without neurologic deficit. The investigation showed a posterior fossa tumor with hemorrhage inside and hydrocephalus. He underwent tumor resection, and pathology showed rhabdoid meningioma. The patient had extensive recurrence after only 5 months, including extension to the neck, mediastinal veins, and heart. He was treated surgically and received adjuvant chemotherapy followed by radiation therapy.
   CONCLUSIONS: Rhabdoid meningioma is a malignant subtype of meningioma that occurs very rarely in pediatric patients. Additionally, rhabdoid meningioma, when it does occur in pediatric patients, has a high tendency to recur. Radical surgical resection with adjuvant radiotherapy is essential to prolonging survival. This is the first case with extracranial extension to the mediastinal veins and heart.
C1 [Khairy, Sami; Saeed, Mahfood Abdullah; Azzubi, Moutasem] Minist Natl Guard Hlth Affairs, Dept Surg, King Abdulaziz Med City, Div Neurosurg, Riyadh, Saudi Arabia.
   [Khairy, Sami; Saeed, Mahfood Abdullah; Azzubi, Moutasem] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia.
   [Khairy, Sami; Saeed, Mahfood Abdullah; Azzubi, Moutasem] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia.
   [Al-Ahmari, Ahmed Nasser] King Faisal Specialist Hosp & Res Ctr, Dept Neurosci, Div Neurosurg, Riyadh, Saudi Arabia.
RP Khairy, S (reprint author), Minist Natl Guard Hlth Affairs, Dept Surg, King Abdulaziz Med City, Div Neurosurg, Riyadh, Saudi Arabia.; Khairy, S (reprint author), King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia.; Khairy, S (reprint author), King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia.
EM Drsami2009@hotmail.com
CR BECKWITH JB, 1978, CANCER-AM CANCER SOC, V41, P1937, DOI 10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO;2-U
   Buccoliero AM, 2011, NEUROPATHOLOGY, V31, P59, DOI 10.1111/j.1440-1789.2010.01113.x
   Cai Chunquan, 2008, Chinese Journal of Clinical Oncology, V5, P67, DOI 10.1007/s11805-008-0067-6
   Chaturvedi S, 2008, CLIN NEUROPATHOL, V27, P248
   El Jamal SM, 2011, PEDIATR DEVEL PATHOL, V14, P333, DOI 10.2350/10-11-0939-CR.1
   Gao X, 2009, CHILD NERV SYST, V25, P1571, DOI 10.1007/s00381-009-0964-x
   Han Huixia, 2009, Clinical Oncology and Cancer Research, V6, P303, DOI 10.1007/s11805-009-0303-8
   Hojo H, 2001, AM J SURG PATHOL, V25, P964, DOI 10.1097/00000478-200107000-00018
   Jansen JC, 2003, SKULL BASE-INTERD AP, V13, P51, DOI 10.1055/s-2003-37553
   Jia WT, 2014, CHILD NERV SYST, V30, P2151, DOI 10.1007/s00381-014-2470-z
   Kar A, 2013, J CANC SCI THER, V5, P343
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Martinez-Lage J, 2006, CHILD NERV SYST, V22, P325, DOI 10.1007/s00381-004-1094-0
   Matyja E, 2014, TUMORS CENTRAL NERVO, V11, P305
   Mordechai O, 2015, PEDIATR HEMAT ONCOL, V32, P207, DOI 10.3109/08880018.2014.936058
   Morina Arsim, 2010, Med Arh, V64, P123
   Nozza P, 2005, ACTA NEUROPATHOL, V110, P205, DOI 10.1007/s00401-005-1048-y
   Perry A, 1998, AM J SURG PATHOL, V22, P1482, DOI 10.1097/00000478-199812000-00005
   Reddy CK, 2015, J CLIN DIAGN RES, V9, pPD5, DOI 10.7860/JCDR/2015/11163.5571
   Rittierodt M, 2001, J NEUROIMMUNOL, V120, P129, DOI 10.1016/S0165-5728(01)00425-8
   Tian Q, 2014, CHILD NERV SYST, V30, P189, DOI 10.1007/s00381-013-2247-9
   Vachhrajani S, 2008, J NEUROSURG-PEDIATR, V2, P391, DOI 10.3171/PED.2008.2.12.391
   Vaquero J, 2000, SURG NEUROL, V53, P432, DOI 10.1016/S0090-3019(00)00213-5
   Wakabayashi K, 2005, ACTA NEUROPATHOL, V110, P196, DOI 10.1007/s00401-005-1037-1
   Wang DJ, 2013, INT J CLIN EXP PATHO, V6, P878
   Yesiltas YS, 2018, J NEUROSURG-PEDIATR, V22, P151, DOI 10.3171/2018.1.PEDS17557
   景洪标, 2006, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V33, P353
   辜虎臣, 2005, [中华放射学杂志, Chinese Journal of Radiology], V39, P1087
NR 28
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 445
EP 450
DI 10.1016/j.wneu.2019.06.117
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900198
PM 31247353
DA 2020-05-12
ER

PT J
AU Silva, N
   Cerasiello, S
   Semonche, A
   Sotayo, A
   Luis, J
   Shao, B
   Richardson, A
   Eloy, JA
AF Silva, Nicole
   Cerasiello, Samantha
   Semonche, Alexa
   Sotayo, Alaba
   Luis, Justin
   Shao, Belinda
   Richardson, Angela
   Eloy, Jean Anderson
TI Gender Representation at Neurological Surgery Conferences
SO WORLD NEUROSURGERY
LA English
DT Article
DE Conferences; Gender disparity; Gender gap; Gender representation;
   Neurological surgery conferences; Neurosurgery; Women in neurosurgery
ID SCHOLARLY PRODUCTIVITY; ACADEMIC MEDICINE; WOMEN PHYSICIANS;
   NEUROSURGERY
AB BACKGROUND: Women constitute a minority (9.2%) of academic neurosurgeons. We previously found that women in academic medicine are disadvantaged in funding and career advancement opportunities. We hypothesized that women are also underrepresented at neurosurgical society conferences.
   METHODS: Programs from the 2014-2018 meetings of the Congress of Neurological Surgeons (CNS), American Association of Neurological Surgery (AANS), and North American Skull Base Society (NASBS) were analyzed. Demographic data, including name, gender, and geographic region of practice, were collected for speaker, moderator, or leadership positions. chi(2) statistical analysis was performed for difference in gender representation across all opportunity spots.
   RESULTS: In the period 2014-2018, there was no female presidents or honored guest at any academic meetings analyzed; 53.8% of executive committees comprised all men. Women often constituted a minority (<15%) of speakers and moderators at CNS, AANS, and NASBS meetings: speakers (% female, range), 8.6 (5.5-11.7), 13.6 (10.1-19.7), and 10.5 (5.6-16.6); moderators (% female, range), 7.8 (0-14.3), 23.0 (81.3-91.3), and 13.0 (8.6-18.7). Conference panels frequently comprised all men (58% CNS, 20.7% AANS, 61% NASBS). chi(2) analysis found a disparity in male and female participation across all opportunity spots (P = 0.002). Additionally, female participants are often repeated, decreasing total number of unique women participating. There was no significant increase in female participation across the study period.
   CONCLUSIONS: In 2014-2018, underrepresentation of women in national neurosurgical conferences either matched or exceeded the baseline gender disparity seen in academic neurosurgery. We discussed potential causes of and strategies to address these findings.
C1 [Silva, Nicole; Sotayo, Alaba; Luis, Justin; Shao, Belinda; Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
   [Cerasiello, Samantha; Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Dept Otolaryngol Head & Neck Surg, Newark, NJ 07103 USA.
   [Semonche, Alexa] Rutgers State Univ, Dept Neurol Surg, Robert Wood Johnson Med Sch, New Brunswick, NJ USA.
   [Richardson, Angela] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.
RP Eloy, JA (reprint author), Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.; Eloy, JA (reprint author), Rutgers New Jersey Med Sch, Dept Otolaryngol Head & Neck Surg, Newark, NJ 07103 USA.
EM eloyj1@njms.rutgers.edu
OI Richardson, Angela/0000-0003-2656-7438; Shao,
   Belinda/0000-0002-6392-0643
CR AAMC, 2015, ACT PHYS SEX SPEC 20
   Abosch A, 2018, J NEUROSURG, V129, P277, DOI 10.3171/2018.4.JNS172878
   Achkar E, 2008, AM J GASTROENTEROL, V103, P1587, DOI 10.1111/j.1572-0241.2008.01988.x
   Benzil DL, 2008, J NEUROSURG, V109, P378, DOI 10.3171/JNS/2008/109/9/0378
   Carley S, 2016, EMERG MED J, V33, P681, DOI 10.1136/emermed-2015-205581
   Cohen MA, 2012, ORL J OTO-RHINO-LARY, V74, P325, DOI 10.1159/000345099
   Corley J, 2018, WORLD NEUROSURG, V111, P130, DOI 10.1016/j.wneu.2017.12.086
   Davids JS, 2019, DIS COLON RECTUM, V62, P357, DOI 10.1097/DCR.0000000000001274
   Debarre F, 2018, EVOL LETT, V2, P148, DOI 10.1002/evl3.49
   Dixon A, 2019, WORLD NEUROSURG, V122, P245, DOI 10.1016/j.wneu.2018.10.166
   Eloy JA, 2013, OTOLARYNG HEAD NECK, V149, P77, DOI 10.1177/0194599813486083
   Eloy JA, 2013, OTOLARYNG HEAD NECK, V148, P215, DOI 10.1177/0194599812466055
   Ferster APO, 2017, OTOLARYNG HEAD NECK, V157, P173, DOI 10.1177/0194599817706496
   Kalejta RF, 2017, J VIROL, V91, DOI 10.1128/JVI.00739-17
   Kerr HL, 2016, POSTGRAD MED J, V92, P576, DOI 10.1136/postgradmedj-2015-133273
   Lin TR, 2017, UROLOGY, V110, P40, DOI 10.1016/j.urology.2017.07.051
   Masur SK, 2013, MOL BIOL CELL, V24, P57, DOI 10.1091/mbc.E12-07-0517
   Mehta S, 2018, CRIT CARE MED, V46, P991, DOI 10.1097/CCM.0000000000003114
   Metaxa V, 2013, CRIT CARE, V17, DOI 10.1186/cc11859
   Nonnemaker L, 2000, NEW ENGL J MED, V342, P399, DOI 10.1056/NEJM200002103420606
   Renfrow JJ, 2018, NEUROSURGERY, V82, P576, DOI 10.1093/neuros/nyx251
   Sarkiss CA, 2017, NEUROSURGERY, V80, P975, DOI 10.1093/neuros/nyx071
   Sexton KW, 2012, J SURG EDUC, V69, P84, DOI 10.1016/j.jsurg.2011.07.008
   Shaikh AT, 2019, WORLD NEUROSURG, V123, P95, DOI 10.1016/j.wneu.2018.11.145
   Spetzler Robert F, 2011, Asian J Neurosurg, V6, P6, DOI 10.4103/1793-5482.85627
   Surawicz CM, 2016, J AM COLL RADIOL, V13, P1433, DOI 10.1016/j.jacr.2016.08.026
   TESCH BJ, 1995, JAMA-J AM MED ASSOC, V273, P1022, DOI 10.1001/jama.273.13.1022
   Tomei KL, 2014, J CLIN NEUROSCI, V21, P1102, DOI 10.1016/j.jocn.2013.11.006
   Waisbren SE, 2008, J WOMENS HEALTH, V17, P207, DOI 10.1089/jwh.2007.0412
   Wright AL, 2003, ACAD MED, V78, P500, DOI 10.1097/00001888-200305000-00015
   Ying ZG, 2011, ANN SURG, V253, P637, DOI 10.1097/SLA.0b013e3182111120
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 453
EP 459
DI 10.1016/j.wneu.2019.06.062
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900200
PM 31212029
DA 2020-05-12
ER

PT J
AU Wolfert, C
   Rohde, V
   Mielke, D
   Hernandez-Duran, S
AF Wolfert, Christina
   Rohde, Veit
   Mielke, Dorothee
   Hernandez-Duran, Silvia
TI Female Neurosurgeons in Europe-On a Prevailing Glass Ceiling
SO WORLD NEUROSURGERY
LA English
DT Article
DE EANS; Glass ceiling; Women in medicine; Women in neurosurgery; Women in
   surgery
ID ACADEMIC MEDICINE; WOMEN; SURGERY; FACULTY; FUTURE; GENDER; FIELD; STILL
AB BACKGROUND: Almost one half of currently practicing physicians in Europe are women. Despite advances in access to training positions and the entry of women into neurosurgery, it has remained a male-dominated field, with an underrepresentation of female leaders. We designed a 2-part study to better understand the current situation of European female neurosurgeons.
   METHODS: The European Association of Neurosurgical Societies and its member societies were analyzed for female participation in leadership positions. Additionally, an online survey was designed, containing 33 questions about career choice, mentorship, family planning, and perceived obstacles, for women in neurosurgery.
   RESULTS: A total of 116 responses were received. Most female neurosurgeons lacked same-gender role models (76%), although most reported that having a female mentor would be important (58%). An overwhelming majority (86%) believe family planning takes on a more important role for women, and 72% reported worrying their career prospects could be negatively affected by their desire to have children. The greatest obstacle perceived was the prevailing inequality in opportunities (30%) and attaining leadership positions (24%). Most (81%) reported that women have different concerns regarding their career from men, and 72% also reported feeling at a disadvantage as a woman. Most (66%) also believe should be a "Women in Neurosurgery" committee within the European Association of Neurosurgical Societies.
   CONCLUSIONS: Unfortunately, a gender gap still exists in European neurosurgery. The extent thereof has not yet been systematically analyzed. Our project offers a glimpse into the inequalities and obstacles women perceive in our field; however, more comprehensive data are required.
C1 [Wolfert, Christina; Rohde, Veit; Mielke, Dorothee; Hernandez-Duran, Silvia] Gottingen Univ Hosp, Dept Neurol Surg, Gottingen, Germany.
RP Hernandez-Duran, S (reprint author), Gottingen Univ Hosp, Dept Neurol Surg, Gottingen, Germany.
EM silvia.hernandez@med.uni-goettingen.de
CR Ash AS, 2004, ANN INTERN MED, V141, P205, DOI 10.7326/0003-4819-141-3-200408030-00009
   Benzil DL, 2008, J NEUROSURG, V109, P378, DOI 10.3171/JNS/2008/109/9/0378
   BENZIL DL, 2006, AANS B, V15, P7
   Bern S., 1974, J CONSULT CLIN PSYCH, V42, P544
   Brown EG, 2014, JAMA SURG, V149, P893, DOI 10.1001/jamasurg.2014.1227
   Carnes Molly, 2015, Trans Am Clin Climatol Assoc, V126, P197
   Carnes M, 2008, J WOMENS HEALTH, V17, P1453, DOI 10.1089/jwh.2007.0688
   Donington JS, 2012, ANN THORAC SURG, V94, P452, DOI 10.1016/j.athoracsur.2012.03.102
   Eagly AH, 2002, PSYCHOL REV, V109, P573, DOI 10.1037//0033-295X.109.3.573
   Fan WM, 2010, COMPUT HUM BEHAV, V26, P132, DOI 10.1016/j.chb.2009.10.015
   Faucett EA, 2017, AM J SURG, V214, P640, DOI 10.1016/j.amjsurg.2017.07.005
   Jonasson O, 2002, SURGERY, V131, P672, DOI 10.1067/msy.2002.124880
   Kato Y, 2004, MINIM INVAS NEUROSUR, V47, P65, DOI 10.1055/s-2004-818470
   Keizer M, 1997, NETH J SOC SCI, V33, P94
   Kerr HL, 2016, POSTGRAD MED J, V92, P576, DOI 10.1136/postgradmedj-2015-133273
   Longo P, 2008, GENDER MED, V5, P88, DOI 10.1016/S1550-8579(08)80011-3
   Morahan PS, 2001, ACAD MED, V76, P19, DOI 10.1097/00001888-200101000-00008
   Morton MJ, 2007, J NATL MED ASSOC, V99, P764
   National Academy of Sciences National Academy of Engineering Institute of Medicine of the National Academies, 2006, BIAS BARR FULF POT W
   Pololi LH, 2012, ACAD MED, V87, P859, DOI 10.1097/ACM.0b013e3182582b18
   Renfrow JJ, 2018, NEUROSURGERY, V82, P576, DOI 10.1093/neuros/nyx251
   Schroen AT, 2004, ACAD MED, V79, P310, DOI 10.1097/00001888-200404000-00006
   Seemann NM, 2016, AM J SURG, V211, P343, DOI 10.1016/j.amjsurg.2015.08.036
   Spetzler Robert F, 2011, Asian J Neurosurg, V6, P6, DOI 10.4103/1793-5482.85627
   Voytko ML, 2018, J WOMENS HEALTH, V27, P1045, DOI 10.1089/jwh.2017.6661
   Williams C, 2000, MED EDUC, V34, P602, DOI 10.1046/j.1365-2923.2000.00666.x
   Woodrow SI, 2006, NEUROSURGERY, V59, P749, DOI 10.1227/01.NEU.0000232671.44297.DF
   World Economic Forum, GLOB GEND GAP REP 20
   Ying ZG, 2011, ANN SURG, V253, P637, DOI 10.1097/SLA.0b013e3182111120
NR 29
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 460
EP 466
DI 10.1016/j.wneu.2019.05.137
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900201
PM 31132491
DA 2020-05-12
ER

PT J
AU Ghali, MGZ
   Kan, P
   Britz, GW
AF Ghali, Michael George Zaki
   Kan, Peter
   Britz, Gavin W.
TI Curative Embolization of Arteriovenous Malformations
SO WORLD NEUROSURGERY
LA English
DT Review
DE Arteriovenous malformations; AVMs; Curative; Embolization;
   Spetzler-Martin; Transvenous; Transarterial
ID N-BUTYL CYANOACRYLATE; GAMMA-KNIFE RADIOSURGERY; PRESSURE COOKER
   TECHNIQUE; INTRACRANIAL VASCULAR MALFORMATIONS; RETROGRADE NIDUS
   SCLEROTHERAPY; CONTROLLED HYPOTENSION TRENSH; LIQUID EMBOLIC AGENTS;
   CEREBRAL-BLOOD-FLOW; ENDOVASCULAR TREATMENT; TRANSVENOUS EMBOLIZATION
AB Arteriovenous malformations have a significant cumulative risk for hemorrhage. Treatment options include observation, microsurgical resection, stereotactic radiosurgery, embolization, and multimodal treatment. Treatment selection and timing are based on arteriovenous malformation (AVM) features including size, location in eloquent versus noneloquent parenchyma, pattern of venous drainage, surgical access, rupture status, and previous treatments. Spetzler-Martin grading is the most commonly used classification system used to select treatment, with grades I and II lesions amenable to surgical resection alone, grade III lesions typically treated via a multimodal approach entailing preoperative embolization followed by microsurgical resection, and grades IV and V lesions generally observed unless ruptured. Embolization in the treatment of AVMs is thus most commonly used as a preoperative or, occasionally, pre-radiosurgical adjunct. The concept of curative AVM embolization is an attractive one that has emerged within the past few decades, with increasing clinical evidence for its safety and efficacy in recent years. Obliteration rates for curative AVM embolization will be improved by innovation in endovascular techniques and technologies.
C1 [Ghali, Michael George Zaki; Britz, Gavin W.] Houston Methodist Hosp, Dept Neurol Surg, Houston, TX 77030 USA.
   [Ghali, Michael George Zaki; Kan, Peter] Baylor Coll Med, Dept Neurol Surg, Houston, TX 77030 USA.
RP Ghali, MGZ (reprint author), Houston Methodist Hosp, Dept Neurol Surg, Houston, TX 77030 USA.; Ghali, MGZ (reprint author), Baylor Coll Med, Dept Neurol Surg, Houston, TX 77030 USA.
EM mgzghali@gmail.com
CR Abud DG, 2011, AM J NEURORADIOL, V32, P152, DOI 10.3174/ajnr.A2247
   Abud DG, 2016, J NEURORADIOLOGY, V43, P218, DOI 10.1016/j.neurad.2016.01.146
   Abud DG, 2013, J NEURORADIOLOGY, V40, P45, DOI 10.1016/j.neurad.2012.03.010
   ADAMS DC, 1995, J THORAC CARDIOV SUR, V109, P565, DOI 10.1016/S0022-5223(95)70290-3
   Albuquerque FC, 2014, J NEUROINTERV SURG, V6, P281, DOI 10.1136/neurintsurg-2012-010628
   Aletich VA, 1999, INTERV NEURORADIOL, P240
   Alexander E 3rd, 1992, Clin Neurosurg, V39, P273
   Andrade-Souza YM, 2007, NEUROSURGERY, V60, P443, DOI 10.1227/01.NEU.0000255347.25959.D0
   Andreou A, 2008, NEURORADIOLOGY, V50, P267, DOI 10.1007/s00234-007-0322-1
   Andreou A, 2008, J NEUROSURG, V109, P1091, DOI 10.3171/JNS.2008.109.12.1091
   ApSimon HT, 2002, STROKE, V33, P2794, DOI 10.1161/01.STR.0000043674.99741.9B
   Ashour R, 2012, NEUROSURGERY, V71, P773, DOI 10.1227/NEU.0b013e3182648db6
   Baharvahdat H, 2014, AM J NEURORADIOL, V35, P978, DOI 10.3174/ajnr.A3906
   Baskaya MK, 2006, J NEUROSURG, V104, P183, DOI 10.3171/jns.2006.104.2.183
   BATJER H, 1986, NEUROSURG REV, V9, P287, DOI 10.1007/BF01743635
   Benabu Y, 2010, J NEUROIMAGING, V20, P373, DOI 10.1111/j.1552-6569.2009.00391.x
   Bendok BR, 2014, NEUROSURGERY, V74, pS60, DOI 10.1227/NEU.0000000000000230
   Bendok BR, 2007, INTRACRANIAL ARTERIO, P73
   Berenstein A, 1992, SURG NEUROANGIOGRAPH, V4
   Berenstein A, 2010, CHILD NERV SYST, V26, P1345, DOI 10.1007/s00381-010-1206-y
   Blamek S, 2013, CHILD NERV SYST, V29, P651, DOI 10.1007/s00381-012-1983-6
   Blauwblomme T, 2014, STROKE, V45, P1664, DOI 10.1161/STROKEAHA.113.004292
   Borcek AO, 2014, CHILD NERV SYST, V30, P1485, DOI 10.1007/s00381-014-2469-5
   Braun M, 1988, THESIS, P154
   BROTHERS MF, 1989, AM J NEURORADIOL, V10, P777
   Brown RD, 1996, NEUROLOGY, V46, P949, DOI 10.1212/WNL.46.4.949
   Buklina S B, 2005, Neurosci Behav Physiol, V35, P473, DOI 10.1007/s11055-005-0082-5
   Campos J, 2005, INTERV NEURORADIOL, V11, P81, DOI 10.1177/15910199050110S113
   Chapot R, 2014, J NEURORADIOLOGY, V41, P87, DOI 10.1016/j.neurad.2013.10.001
   Choi HJ, 2012, J KOREAN NEUROSURG S, V52, P534, DOI 10.3340/jkns.2012.52.6.534
   Choudhri O, 2015, NEUROSURGERY, V77, P644, DOI 10.1227/NEU.0000000000000869
   Chyatte D, 1997, J Stroke Cerebrovasc Dis, V6, P130, DOI 10.1016/S1052-3057(97)80229-7
   COLOMBO F, 1994, NEUROSURGERY, V34, P14
   Connors JJ, 1999, STRATEGIES PRACTICAL, P227
   Consoli A, 2013, AM J NEURORADIOL, V34, P1805, DOI 10.3174/ajnr.A3497
   Cronqvist M, 2006, AM J NEURORADIOL, V27, P162
   Crowley RW, 2015, J NEUROSURG, V122, P1492, DOI 10.3171/2015.2.JNS131368
   Crowley RW, 2014, NEUROSURGERY, V74, pS74, DOI 10.1227/NEU.0000000000000176
   D'Aliberti G, 2014, WORLD NEUROSURG, V82, P160, DOI 10.1016/j.wneu.2013.02.005
   Dalyai R, 2014, BIOMED RES INT, DOI 10.1155/2014/306518
   Darsaut TE, 2011, NEUROSURGERY, V69, P540, DOI 10.1227/NEU.0b013e3182181c00
   DAWBARN RHM, 1904, JAMA-J AM MED ASSOC, V17, P792
   DAY AL, 1982, NEUROSURGERY, V11, P625, DOI 10.1227/00006123-198211000-00007
   de Castro-Afonso LH, 2016, NEURORADIOLOGY, V58, P585, DOI 10.1007/s00234-016-1666-1
   Debrun GM, 1997, NEUROSURGERY, V40, P112, DOI 10.1097/00006123-199701000-00026
   DEMERITT JS, 1995, AM J NEURORADIOL, V16, P1801
   DERUTY R, 1993, ACTA NEUROCHIR, V123, P101, DOI 10.1007/BF01401864
   Deruty R, 1998, ACTA NEUROCHIR WIEN, V138, P119
   Desal HA, 2005, INTERV NEURORADIOL, V11, P125, DOI 10.1177/15910199050110S116
   Dorfer C, 2010, CHILD NERV SYST, V26, P681, DOI 10.1007/s00381-009-1039-8
   DRAKE CG, 1986, J NEUROSURG, V64, P1, DOI 10.3171/jns.1986.64.1.0001
   Duong DH, 1999, NEW ENGL J MED, V340, P1812
   Duong DH, 1998, STROKE, V29, P1167, DOI 10.1161/01.STR.29.6.1167
   EIRAS J, 1987, CHILD NERV SYST, V3, P156, DOI 10.1007/BF00717892
   Ellis Jason A, 2014, Methodist Debakey Cardiovasc J, V10, P234, DOI 10.14797/mdcj-10-4-234
   Fang YB, 2019, J NEUROSURG SCI, V63, P468, DOI 10.23736/S0390-5616.18.04342-4
   Flickinger JC, 1998, INT J RADIAT ONCOL, V40, P273, DOI 10.1016/S0360-3016(97)00718-9
   FOURNIER D, 1991, J NEUROSURG, V75, P228, DOI 10.3171/jns.1991.75.2.0228
   Friedlander RM, 2007, NEW ENGL J MED, V356, P2704, DOI 10.1056/NEJMcp067192
   FRIZZEL RT, 1995, NEUROSURGERY, V37, P1031, DOI 10.1227/00006123-199512000-00001
   FULTS D, 1984, NEUROSURGERY, V15, P658, DOI 10.1227/00006123-198411000-00003
   Gaballah M, 2014, J NEUROSURG-PEDIATR, V13, P222, DOI 10.3171/2013.10.PEDS13291
   Guidetti B, 1982, Neurol Res, V4, P253
   HAMILTON MG, 1994, NEUROSURGERY, V34, P2
   Han PP, 2003, J NEUROSURG, V98, P3, DOI 10.3171/jns.2003.98.1.0003
   Han SJ, 2015, J NEUROSURG, V122, P107, DOI 10.3171/2014.8.JNS1483
   Hartmann A, 2002, STROKE, V33, P1816, DOI 10.1161/01.STR.0000020123.80940.B2
   Haw CS, 2006, J NEUROSURG, V104, P226, DOI 10.3171/jns.2006.104.2.226
   He YK, 2018, WORLD NEUROSURG, V116, pE421, DOI 10.1016/j.wneu.2018.04.223
   Henkes H, 1998, NEUROL RES, V20, P479
   Hernesniemi JA, 2008, NEUROSURGERY, V63, P823, DOI 10.1227/01.NEU.0000330401.82582.5E
   Heros RC, 2004, J NEUROSURG, V100, P807, DOI 10.3171/jns.2004.100.5.0807
   HEROS RC, 1990, NEUROSURGERY, V26, P570, DOI 10.1227/00006123-199004000-00003
   Hillman J, 2001, J NEUROSURG, V95, P633, DOI 10.3171/jns.2001.95.4.0633
   Howington JU, 2005, NEUROSURG CLIN N AM, V16, P355, DOI 10.1016/j.nec.2004.08.013
   HUANG ZS, 1995, CHINESE MED J-PEKING, V108, P413
   Huo XC, 2015, INTERV NEURORADIOL, V21, P80, DOI 10.15274/INR-2014-10090
   HURST RW, 1995, J NEUROSURG, V82, P190, DOI 10.3171/jns.1995.82.2.0190
   Iosif C, 2015, J NEUROSURG, V122, P1229, DOI 10.3171/2014.9.JNS141714
   Izawa M, 2009, SURG NEUROL, V71, P43, DOI 10.1016/j.surneu.2007.11.016
   JAFAR JJ, 1993, J NEUROSURG, V78, P60, DOI 10.3171/jns.1993.78.1.0060
   Jagadeesan BD, 2013, NEUROSURGERY, V73, P238, DOI 10.1227/NEU.0000000000000186
   Jahan R, 2001, NEUROSURGERY, V48, P984, DOI 10.1097/00006123-200105000-00003
   Jayaraman M, 2009, AM J NEURORADIOL, V30, P107, DOI 10.3174/ajnr.A1394
   Jermakowicz Walter J, 2012, J Med Case Rep, V6, P113, DOI 10.1186/1752-1947-6-113
   Jiang CH, 2007, NEURORADIOL J, V20, P726, DOI 10.1177/197140090702000618
   Kano H, 2012, J NEUROSURG, V117, P265, DOI 10.3171/2012.4.JNS111935
   Kano H, 2012, J NEUROSURG, V116, P44, DOI 10.3171/2011.9.JNS11176
   Karlsson B, 1997, RADIOTHER ONCOL, V43, P275, DOI 10.1016/S0167-8140(97)00060-1
   Katsaridis V, 2008, NEURORADIOLOGY, V50, P589, DOI 10.1007/s00234-008-0382-x
   KERBER CW, 1979, AM J ROENTGENOL, V132, P207, DOI 10.2214/ajr.132.2.207
   Kessler I, 2011, NEUROSURGERY, V69, P184, DOI 10.1227/NEU.0b013e318212bb34
   Khatibi K, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.07.025
   Kim LJ, 2006, NEUROSURGERY, V59, P53, DOI 10.1227/01.NEU.0000219219.97287.91
   KO KR, 1990, AM J PHYSIOL, V259, pH1703
   Konan AV, 1999, NEUROSURGERY, V44, P663, DOI 10.1097/00006123-199903000-00130
   Kurita H, 2000, J NEUROL NEUROSUR PS, V68, P563, DOI 10.1136/jnnp.68.5.563
   Laakso A, 2012, NEUROSURG CLIN N AM, V23, P1, DOI 10.1016/j.nec.2011.09.012
   LASJAUNIAS P, 1986, NEUROSURG REV, V9, P265, DOI 10.1007/BF01743633
   LAWTON MT, 1995, NEUROSURGERY, V37, P29, DOI 10.1227/00006123-199507000-00004
   Liu HM, 2003, NEURORADIOLOGY, V45, P644, DOI 10.1007/s00234-003-1055-4
   Liu HM, 2000, J FORMOS MED ASSOC, V99, P906
   Liu J, 2014, INTERV NEURORADIOL, V20, P722, DOI 10.15274/INR-2014-10063
   Lobato RD, 2002, NEUROCIRUGIA, V13, P209
   Lobato RD, 2002, NEUROCIRUGIA, V13, P15
   Loh Y, 2010, J NEUROSURG, V113, P733, DOI 10.3171/2010.3.JNS09370
   LUESSENHOP AJ, 1960, JAMA-J AM MED ASSOC, V172, P1153, DOI 10.1001/jama.1960.63020110001009
   Lv XL, 2008, NEUROL RES, V30, P852, DOI 10.1179/174313208X310313
   Lv XL, 2017, INTERV NEURORADIOL, V23, DOI 10.1177/1591019917716817
   Lv XL, 2013, NEURORADIOL J, V26, P661, DOI 10.1177/197140091302600609
   Lv XL, 2012, NEUROL RES, V34, P552, DOI 10.1179/1743132812Y.0000000044
   Lv XL, 2012, NEURORADIOLOGY, V54, P349, DOI 10.1007/s00234-011-0880-0
   Lv XL, 2008, INTERV NEURORADIOL, V14, P415, DOI 10.1177/159101990801400407
   Maimon S, 2010, AM J NEURORADIOL, V31, P947, DOI 10.3174/ajnr.A1959
   MARKS MP, 1990, RADIOLOGY, V176, P807, DOI 10.1148/radiology.176.3.2389040
   Martinez-Galdamez M, 2014, J NEUROINTERV SURG, V6, DOI 10.1136/neurintsurg-2012-010603.rep
   Maruyama K, 2004, J NEUROSURG, V100, P407, DOI 10.3171/jns.2004.100.3.0407
   Massoud TF, 2013, NEUROSURGERY, V73, P332, DOI 10.1227/01.neu.0000430765.80102.77
   Massoud TF, 1999, NEUROSURGERY, V45, P351, DOI 10.1097/00006123-199908000-00031
   Mast H, 1997, LANCET, V350, P1065, DOI 10.1016/S0140-6736(97)05390-7
   MATSUMURA H, 1977, J NEUROSURG, V47, P50, DOI 10.3171/jns.1977.47.1.0050
   MCCORMIC.WF, 1968, J NEUROSURG, V28, P241, DOI 10.3171/jns.1968.28.3.0241
   Meisel HJ, 2002, ACTA NEUROCHIR, V144, P879, DOI 10.1007/s00701-002-0978-6
   Mendes GAC, 2018, NEUROSURGERY, V83, P957, DOI 10.1093/neuros/nyx581
   Mendes GAC, 2016, NEUROSURGERY, V78, P34, DOI 10.1227/NEU.0000000000000982
   Mendes GAC, 2015, J NEUROSURG, V123, P1120, DOI 10.3171/2014.10.JNS141359
   Miyamoto S, 2000, NEUROSURGERY, V46, P589, DOI 10.1097/00006123-200003000-00013
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   MONACO RG, 1990, NEURORADIOLOGY, V31, P471, DOI 10.1007/BF00340124
   MONTAUT J, 1971, NEURO-CHIR, V17, P379
   Moon JH, 2011, J KOREAN NEUROSURG S, V50, P191, DOI 10.3340/jkns.2011.50.3.191
   Morgan MK, 2013, J NEUROSURG, V118, P969, DOI 10.3171/2012.11.JNS112064
   MORII S, 1987, AM J PHYSIOL, V253, pH165
   Mounayer C, 2007, AM J NEURORADIOL, V28, P518
   MULLAN S, 1994, J NEUROSURG, V80, P606, DOI 10.3171/jns.1994.80.4.0606
   Murayama Y, 1998, NEUROSURGERY, V43, P1164, DOI 10.1097/00006123-199811000-00081
   Nair AP, 2012, CHILD NERV SYST, V28, P593, DOI 10.1007/s00381-011-1668-6
   Nataf F, 2004, NEUROSURGERY, V55, P298, DOI 10.1227/01.NEU.0000129473.52172.B5
   Natarajan SK, 2008, NEUROSURGERY, V62, P1213, DOI 10.1227/01.neu.0000333293.74986.e5
   Nguyen TN, 2010, J NEUROINTERV SURG, V2, P150, DOI 10.1136/jnis.2009.001289
   ONDRA SL, 1990, J NEUROSURG, V73, P387, DOI 10.3171/jns.1990.73.3.0387
   Orlov K Yu, 2015, Zh Vopr Neirokhir Im N N Burdenko, V79, P85, DOI 10.17116/neiro201579385-89
   Orozco Ludwig D, 2013, J Neurointerv Surg, V5, pe18, DOI 10.1136/neurintsurg-2012-010388
   Pabaney Aqueel H, 2016, Surg Neurol Int, V7, pS228, DOI 10.4103/2152-7806.179579
   Panagiotopoulos V, 2009, AM J NEURORADIOL, V30, P99, DOI 10.3174/ajnr.A1314
   PARAMASIVAM S, 2014, J NEUROINTERV SUR S1, V6, pA14
   Paramasivam S, 2015, J NEUROINTERV SURG, V7, P458, DOI 10.1136/neurintsurg-2014-011165
   Paulsen RD, 1999, NEUROSURGERY, V44, P991, DOI 10.1097/00006123-199905000-00031
   Pereira VM, 2013, INTERV NEURORADIOL, V19, P27, DOI 10.1177/159101991301900104
   Perrini P, 2004, ACTA NEUROCHIR, V146, P755, DOI 10.1007/s00701-004-0268-6
   Picard Luc, 1996, Neurologia Medico-Chirurgica, V36, P851, DOI 10.2176/nmc.36.851
   Pierot L, 2004, J NEURORADIOLOGY, V31, P369, DOI 10.1016/S0150-9861(04)97018-6
   Pierot L, 2013, EUR RADIOL, V23, P2838, DOI 10.1007/s00330-013-2870-6
   Pierot L, 2013, AM J NEURORADIOL, V34, P1395, DOI 10.3174/ajnr.A3409
   Pile-Spellman J, 1999, NEUROSURGERY, V44, P881, DOI 10.1097/00006123-199904000-00117
   Plasencia AR, 2012, SURG NEUROL INT S2, V2, P90, DOI DOI 10.4103/2152-7806.95420
   Pollock BE, 2002, J NEUROSURG, V96, P79, DOI 10.3171/jns.2002.96.1.0079
   Potts MB, 2014, J NEUROSURG-PEDIATR, V14, P1, DOI 10.3171/2014.3.PEDS13381
   Prestigiacomo CJ, 2007, INTRACRANIAL ARTERIO, P159
   PRITZ MB, 1994, ACTA NEUROCHIR, V131, P314, DOI 10.1007/BF01808635
   PRITZ MB, 1994, ACTA NEUROCHIR, V128, P150, DOI 10.1007/BF01400666
   Purdy P, 2002, AM J NEURORADIOL, V23, P748
   Raffi L, 2007, NEURORADIOLOGY, V49, P829, DOI 10.1007/s00234-007-0238-9
   Reig AS, 2010, J NEUROINTERV SURG, V2, P202, DOI 10.1136/jnis.2009.001636
   Renieri L, 2015, J NEUROSURG-PEDIATR, V15, P445, DOI 10.3171/2014.11.PEDS13437
   Richling B, 1991, Acta Neurochir Suppl (Wien), V53, P50
   RIGAMONTI D, 1990, J NEUROSURG, V73, P560, DOI 10.3171/jns.1990.73.4.0560
   Robert T, 2015, J NEUROINTERV SURG, V7, P715, DOI 10.1136/neurintsurg-2014-011271
   RODESCH G, 1995, CHILD NERV SYST, V11, P231, DOI 10.1007/BF00277659
   Rubin BA, 2014, NEUROSURGERY, V74, pS50, DOI 10.1227/NEU.0000000000000219
   RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346
   Saatci I, 2011, J NEUROSURG, V115, P78, DOI 10.3171/2011.2.JNS09830
   Sackey FNA, 2017, CUREUS, V9, DOI 10.7759/cureus.1266
   Sahlein DH, 2012, J NEUROSURG, V117, P65, DOI 10.3171/2012.3.JNS111405
   Salman RAS, 2014, JAMA-J AM MED ASSOC, V311, P1661, DOI 10.1001/jama.2014.3200
   Sandoval-Garcia C, 2016, J NEUROINTERV SURG, V8, P300, DOI 10.1136/neurintsurg-2014-011534
   Sasaki T, 1998, J Clin Neurosci, V5 Suppl, P95, DOI 10.1016/S0967-5868(98)90023-6
   Schaller B, 2009, J NEUROSURG ANESTH, V21, P187, DOI 10.1097/ANA.0b013e3181a2bf22
   Schlosser MJ, 1997, STROKE, V28, P1130, DOI 10.1161/01.STR.28.6.1130
   Schwyzer L, 2012, NEUROSURGERY, V71, P1139, DOI 10.1227/NEU.0b013e3182720280
   SERBINENKO FA, 1974, J NEUROSURG, V41, P125, DOI 10.3171/jns.1974.41.2.0125
   Sheth SA, 2014, CHILD NERV SYST, V30, P241, DOI 10.1007/s00381-013-2231-4
   Shi ZS, 2013, J NEUROINTERV SURG, V5, P311, DOI 10.1136/neurintsurg-2012-010303
   Skjoth-Rasmussen J, 2012, CHILD NERV SYST, V28, P587, DOI 10.1007/s00381-011-1640-5
   SOLOMON RA, 1986, J NEUROSURG, V64, P857, DOI 10.3171/jns.1986.64.6.0857
   Soltanolkotabi M, 2013, J NEUROSURG-PEDIATR, V11, P431, DOI 10.3171/2013.1.PEDS12286
   Sorimachi T, 1999, AM J NEURORADIOL, V20, P1323
   SPETZLER RF, 1992, J NEUROSURG, V76, P918, DOI 10.3171/jns.1992.76.6.0918
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Stapf C, 2001, Neurosurg Focus, V11, pe1
   Stapf C, 2006, NEUROLOGY, V66, P1350, DOI 10.1212/01.wnl.0000210524.68507.87
   Stapf C, 2003, STROKE, V34, pE29, DOI 10.1161/01.STR.0000068784.36838.19
   Starke RM, 2011, YOUMANS NEUROLOGICAL, V4, P4065
   Starke RM, 2009, STROKE, V40, P2783, DOI 10.1161/STROKEAHA.108.539775
   Stefani MA, 2002, STROKE, V33, P1220, DOI 10.1161/01.STR.0000013738.53113.33
   STEIN BM, 1984, J NEUROSURG, V60, P23, DOI 10.3171/jns.1984.60.1.0023
   Stein BM, 1984, INTRACRANIAL ARTERIO, P156
   STEINER L, 1992, J NEUROSURG, V77, P1, DOI 10.3171/jns.1992.77.1.0001
   Strauss I, 2013, ACTA NEUROCHIR, V155, P611, DOI 10.1007/s00701-013-1633-0
   Sugita K., 1985, MICRONEUROSURGICAL A, P136
   Szajner M, 2013, POL J RADIOL, V78, P35, DOI 10.12659/PJR.889120
   Taylor CL, 2004, J NEUROSURG, V100, P810, DOI 10.3171/jns.2004.100.5.0810
   TEW JM, 1995, NEUROSURGERY, V36, P1065, DOI 10.1227/00006123-199506000-00001
   Thiex R, 2010, AM J NEURORADIOL, V31, P112, DOI 10.3174/ajnr.A1786
   Thines L, 2012, NEUROSURGERY, V70, P155, DOI 10.1227/NEU.0b013e31822670ac
   Toma AK, 2013, NEUROIMAG CLIN N AM, V23, P757, DOI 10.1016/j.nic.2013.05.001
   Valavanis A, 1998, ADV TECH STAND NEUR, V24, P131
   Valavanis A, 2005, INTERV NEURORADIOL, V11, P37, DOI 10.1177/15910199050110S107
   Valavanis A, 1999, NEUROINTERVENTIONIST, V1, P34
   van Beijnum J, 2007, J NEUROL NEUROSUR PS, V78, P1213, DOI 10.1136/jnnp.2006.112227
   van Beijnum J, 2011, JAMA-J AM MED ASSOC, V306, P2011, DOI 10.1001/jama.2011.1632
   van Rooij WJ, 2007, AM J NEURORADIOL, V28, P172
   van Rooij WJ, 2012, AM J NEURORADIOL, V33, P1299, DOI 10.3174/ajnr.A2947
   Velat GJ, 2008, NEUROSURGERY, V63, P73, DOI [10.1227/01.NEU.0000320136.05677.91, 10.1227/01.neu.0000335015.83616.12]
   VENTUREYRA ECG, 1987, CHILD NERV SYST, V3, P12, DOI 10.1007/BF00707187
   Viana DC, 2017, J NEUROINTERV SURG, V9, P1053, DOI 10.1136/neurintsurg-2017-013113
   VINUELA F, 1991, J NEUROSURG, V75, P856, DOI 10.3171/jns.1991.75.6.0856
   VINUELA F, 1985, J NEUROSURG, V63, P180, DOI 10.3171/jns.1985.63.2.0180
   Vitek JJ, 2009, J NEUROINTERV SURG, V1, P108, DOI 10.1136/jnis.2009.000067
   Weber W, 2007, AM J NEURORADIOL, V28, P371
   Weber W, 2007, NEUROSURGERY, V61, P244, DOI 10.1227/01.NEU.0000255473.60505.84
   Wikholm G, 1996, NEUROSURGERY, V39, P448, DOI 10.1097/00006123-199609000-00004
   Wikholm G, 2001, NEUROSURGERY, V49, P799, DOI 10.1097/00006123-200110000-00004
   WILKINS RH, 1985, NEUROSURGERY, V16, P421, DOI 10.1227/00006123-198503000-00026
   Wilms G, 1993, J Belge Radiol, V76, P299
   YAMAMOTO Y, 1995, J NEUROSURG, V83, P832, DOI 10.3171/jns.1995.83.5.0832
   YAMASHITA K, 1994, AM J NEURORADIOL, V15, P1103
   Yang WY, 2016, WORLD NEUROSURG, V94, P64, DOI 10.1016/j.wneu.2016.06.082
   Yasargil M G, 1976, Surg Neurol, V5, P67
   Yasargil M G, 1976, Surg Neurol, V5, P5
   YASARGIL MG, 1987, MICRONEUROSURGERY A, V3
   Yasargil MG, 1988, MICRONEUROSURGERY B, VIII
   Yasargil MG, 1998, MICRONEUROSURGERY
   Yu SCH, 2004, AM J NEURORADIOL, V25, P1139
   Zhang G, 2017, INTERV NEURORADIOL, V23, P194, DOI 10.1177/1591019916682357
NR 235
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 467
EP 486
DI 10.1016/j.wneu.2019.01.166
PG 20
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900202
PM 30735875
DA 2020-05-12
ER

PT J
AU Fadel, HA
   El Ahmadieh, TY
   Plitt, AR
   Neeley, OJ
   Johnson, Z
   Aoun, SG
   Mohamad, O
   Timmerman, R
   Weprin, BE
AF Fadel, Hassan A.
   El Ahmadieh, Tarek Y.
   Plitt, Aaron R.
   Neeley, Om J.
   Johnson, Zachary
   Aoun, Salah G.
   Mohamad, Osama
   Timmerman, Robert
   Weprin, Bradley E.
TI Oculomotor Schwannomas: A Systematic Review and Report of Two Pediatric
   Cases Treated with Fractionated Cyberknife Stereotactic Radiotherapy
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cyberknife; Fractionated radiotherapy; Oculomotor; Pediatric; Schwannoma
ID GAMMA-KNIFE SURGERY; NERVE SCHWANNOMA; VESTIBULAR SCHWANNOMAS; CRANIAL
   NERVES; NONVESTIBULAR SCHWANNOMAS; RADIATION-THERAPY; RADIOSURGERY;
   MANAGEMENT; NEUROMAS; OUTCOMES
AB OBJECTIVE: Pediatric oculomotor nerve schwannomas are rare and challenging lesions due to the high morbidity associated with surgical intervention and their proximity to critical structures limiting the opportunity for stereotactic radiosurgery. We aim to report and review the novel use of fractionated Cyberknife (Accuray, Inc., Sunnyvale, California, USA) stereotactic radiotherapy in pediatric patients with oculomotor schwannomas.
   METHODS: A systematic review of PubMed, Embase, and Cochrane was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Two patients, ages 8 and 10 years, with tumor volumes of 0.1 cm(3) and 0.2 cm(3), respectively, were treated with fractionated Cyberknife radiotherapy at our institution. A total dose of 45-50 Gy was administered over 25 fractions (1.8-.0 Gy per fraction) to the 82%-84% isodose line. Serial magnetic resonance imaging was obtained for long-term follow-up (56e58 months).
   RESULTS: We found 14 articles published between 1982 and 2018 that reported a total of 18 pediatric patients with intracranial oculomotor schwannomas. No previously described cases of pediatric intracranial oculomotor schwannomas were treated with radiation therapy. In both of our patients, radiographic tumor control was achieved at a mean follow-up of 57 months, with 1 patient displaying a decrease in tumor volume. Neither patient exhibited any worsening of their presenting symptoms, nor did either patient develop any new neurocognitive deficits following treatment. -
   CONCLUSIONS: Fractionated Cyberknife radiotherapy is an effective and well-tolerated treatment option for intracranial oculomotor nerve schwannomas with excellent tumor control rates, similar to surgical and radiosurgical techniques, while sparing critical surrounding structures.
C1 [Fadel, Hassan A.] Wayne State Univ, Sch Med, Detroit, MI USA.
   [El Ahmadieh, Tarek Y.; Plitt, Aaron R.; Neeley, Om J.; Johnson, Zachary; Aoun, Salah G.; Timmerman, Robert; Weprin, Bradley E.] Univ Texas Southwestern, Dept Neurol Surg, Dallas, TX 75390 USA.
   [Mohamad, Osama; Timmerman, Robert; Weprin, Bradley E.] Univ Texas Southwestern, Dept Radiat Oncol, Dallas, TX USA.
RP El Ahmadieh, TY (reprint author), Univ Texas Southwestern, Dept Neurol Surg, Dallas, TX 75390 USA.
EM tarek.elahmadieh@phs.org
RI Aoun, Salah G./J-2406-2019
OI Aoun, Salah G./0000-0003-3499-7569
CR Abo-Shasha R, 2018, CAN J OPHTHALMOL, V53, pE167, DOI 10.1016/j.jcjo.2017.12.014
   Aoyama H, 2013, INT J RADIAT ONCOL, V85, P329, DOI 10.1016/j.ijrobp.2012.05.003
   Apicella G, 2016, REP PRACT ONCOL RADI, V21, P399, DOI 10.1016/j.rpor.2016.02.002
   Beijani GK, 1997, NEUROCHIRURGIE, V43, P164
   Bindal S, 2019, J CLIN NEUROSCI, V62, P162, DOI 10.1016/j.jocn.2018.11.037
   Bisdorff AR, 2006, CEPHALALGIA, V26, P1157, DOI 10.1111/j.1468-2982.2006.01167.x
   CELLI P, 1992, SURG NEUROL, V38, P216, DOI 10.1016/0090-3019(92)90172-J
   Chewning RH, 2008, J NEUROSURG, V108, P1037, DOI 10.3171/JNS/2008/108/5/1037
   Collins SP, 2006, RADIAT ONCOL, V1, DOI 10.1186/1748-717X-1-46
   Combs SE, 2015, RADIOTHER ONCOL, V114, P378, DOI 10.1016/j.radonc.2015.01.011
   Elsharkawy M, 2012, J NEUROSURG, V116, P66, DOI 10.3171/2011.8.JNS11215
   Furtado SV, 2012, NEUROSURG REV, V35, P27, DOI 10.1007/s10143-011-0344-3
   Goel A, 2010, ACTA NEUROCHIR, V152, P1721, DOI 10.1007/s00701-010-0690-x
   Hasegawa T, 2007, J NEUROSURG, V106, P18, DOI 10.3171/jns.2007.106.1.18
   Hasegawa T, 2013, J NEUROSURG, V118, P557, DOI 10.3171/2012.10.JNS12523
   Huang CF, 1999, NEUROSURGERY, V45, P11, DOI 10.1097/00006123-199907000-00002
   Iijima K, 2014, NEUROL MED-CHIR, V54, P654, DOI 10.2176/nmc.cr2012-0418
   KANSU T, 1982, J CLIN NEURO-OPHTHAL, V2, P271
   Kida Y, 2007, J NEUROSURG, V106, P24, DOI 10.3171/jns.2007.106.1.24
   Kim IY, 2008, J NEUROSURG, V109, P149, DOI 10.3171/JNS/2008/109/12/S23
   Kimball MM, 2011, NEUROSURGERY, V68, P974, DOI 10.1227/NEU.0b013e318208f3a1
   Konovalov AN, 1996, ACTA NEUROCHIR, V138, P1027, DOI 10.1007/BF01412304
   Kumar LP, 2014, J CANCER RES THER, V10, P1098, DOI 10.4103/0973-1482.146111
   Langlois AM, 2018, WORLD NEUROSURG, V110, pE1031, DOI 10.1016/j.wneu.2017.11.163
   Leber KA, 1998, J NEUROSURG, V88, P43, DOI 10.3171/jns.1998.88.1.0043
   Lee D, 2018, INDIAN J OPHTHALMOL, V66, P1367, DOI 10.4103/ijo.IJO_340_18
   LEUNDA G, 1982, J NEUROSURG, V57, P563, DOI 10.3171/jns.1982.57.4.0563
   Litre F, 2013, RADIOTHER ONCOL, V106, P169, DOI 10.1016/j.radonc.2012.10.013
   Marchetti M, 2011, NEUROSURGERY, V69, P1116, DOI 10.1227/NEU.0b013e31822932fe
   Mariniello G, 1999, J NEUROSURG, V91, P1045, DOI 10.3171/jns.1999.91.6.1045
   Mariniello G, 2018, OPER NEUROSURG, V14, P627, DOI 10.1093/ons/opx174
   Martin JJ, 2007, NEUROSURGERY, V61, P76, DOI 10.1227/01.neu.0000279726.90650.6d
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Murakami T, 2005, NEUROPEDIATRICS, V36, P395, DOI 10.1055/s-2005-873056
   Netuka D, 2003, BRIT J NEUROSURG, V17, P168, DOI 10.1080/0268869031000110816
   NIAZI W, 1994, SKULL BASE SURG, V4, P219, DOI 10.1055/s-2008-1058958
   Nishioka K, 2009, INT J RADIAT ONCOL, V75, P1415, DOI 10.1016/j.ijrobp.2008.12.063
   Nonaka Y, 2014, WORLD NEUROSURG, V81, P798, DOI 10.1016/j.wneu.2012.11.067
   Norman AA, 2001, J AAPOS, V5, P9, DOI 10.1067/mpa.2001.112442
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   Pan L, 2005, J NEUROSURG, V102, P220, DOI 10.3171/jns.2005.102.s_supplement.0220
   Peciu-Florianu I, 2017, ACTA NEUROCHIR, V159, P2409, DOI 10.1007/s00701-017-3348-0
   Persson O, 2017, ACTA NEUROCHIR, V159, P1013, DOI 10.1007/s00701-017-3164-6
   Plitt A, 2018, WORLD NEUROSURG, V110, P240, DOI 10.1016/j.wneu.2017.11.069
   Pollock BE, 2002, INT J RADIAT ONCOL, V52, P1002, DOI 10.1016/S0360-3016(01)02711-0
   Purdy JA, 2008, HEALTH PHYS, V95, P666, DOI 10.1097/01.HP.0000326342.47348.06
   Saetia Kriangsak, 2011, Journal of the Medical Association of Thailand, V94, P1002
   Safavi-Abbasi S, 2010, ACTA NEUROCHIR, V152, P35, DOI 10.1007/s00701-009-0403-5
   SAMII M, 1995, J NEUROSURG, V82, P711, DOI 10.3171/jns.1995.82.5.0711
   Sarma S, 2002, NEUROSURGERY, V50, P437, DOI 10.1097/00006123-200203000-00002
   Showalter TN, 2008, NEUROSURGERY, V63, P734, DOI 10.1227/01.NEU.0000325496.10148.B3
   SYMON L, 1993, BRIT J NEUROSURG, V7, P13, DOI 10.3109/02688699308995051
   TAN LC, 1990, SURG NEUROL, V34, P205, DOI 10.1016/0090-3019(90)90130-H
   Thomas C, 2007, J NEUROSURG, V107, P917, DOI 10.3171/JNS-07/11/0917
   Yang SS, 2013, PEDIATR NEUROL, V48, P321, DOI 10.1016/j.pediatrneurol.2012.12.012
   Zabel A, 2001, INT J CANCER, V96, P356, DOI 10.1002/ijc.1036
NR 56
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 487
EP 496
DI 10.1016/j.wneu.2019.05.114
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900203
PM 31125775
DA 2020-05-12
ER

PT J
AU Lu, VM
   Rechberger, JS
   Himes, BT
   Daniels, DJ
AF Lu, Victor M.
   Rechberger, Julian S.
   Himes, Benjamin T.
   Daniels, David J.
TI The 100 Most-Cited Articles About Convection-Enhanced Delivery to the
   Brain: A Bibliometric Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bibliometric; Brain; CED; Convection-enhanced delivery; Glioma;
   Most-cited
ID RECURRENT MALIGNANT GLIOMA; REAL-TIME; NEUROTROPHIC FACTOR;
   DRUG-DELIVERY; RODENT BRAINS; GLUCOCEREBROSIDASE; STRIATUM; THERAPY;
   LIGAND; MACROMOLECULES
AB BACKGROUND: Convection-enhanced delivery (CED) overcomes the blood-brain barrier to deliver therapy within the central nervous system. Our aim was to evaluate citation and other bibliometric characteristics of the 100 most-cited articles about CED to the brain to better understand the state of research efforts in the field.
   METHODS: Elsevier's Scopus database was searched for the 100 most-cited articles that focused on CED to the brain. Articles were dichotomized as either primarily basic science (BSc) or clinical (CL) articles. Various bibliometric parameters were summarized, and BSc and CL articles were compared.
   RESULTS: Of the 100 most-cited articles, 64 (64%) were BSc and 36 (36%) were CL. The most common indications reported were brain tumors (59%) and Parkinson disease (5%). Overall median values were as follows: citation count, 102 (range, 70-933); citation rate per year, 9.0 (range, 3.7-49.4); number of authors, 5 (range, 1-25); and publication year, 2006 (range, 1994-2015). Articles were published in a total of 48 different journals, and predominately originated in the United States (n = 78, 78%). BSc and CL articles were statistically comparable in terms of bibliometric parameters.
   CONCLUSIONS: In the 100 most-cited articles about CED to the brain, there were more BSc articles compared with CL articles; however, they were comparable with respect to the reported bibliometric parameters. Given that the peak year of publication of these articles was more than a decade ago, we anticipate that the field will shift toward more CL articles once effective therapies to be delivered via CED are discovered.
C1 [Lu, Victor M.; Rechberger, Julian S.; Himes, Benjamin T.; Daniels, David J.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
RP Daniels, DJ (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM daniels.david@mayo.edu
CR Abrams DJ, 2009, NEUROMODULATION, VOLS 1 AND 2, P977, DOI 10.1016/B978-0-12-374248-3.00083-5
   Bankiewicz KS, 2000, EXP NEUROL, V164, P2, DOI 10.1006/exnr.2000.7408
   Banks WA, 2016, NAT REV DRUG DISCOV, V15, P275, DOI 10.1038/nrd.2015.21
   Barua NU, 2014, BRAIN PATHOL, V24, P117, DOI 10.1111/bpa.12082
   Biddlestone-Thorpe L, 2013, CLIN CANCER RES, V19, P3189, DOI 10.1158/1078-0432.CCR-12-3408
   BOBO RH, 1994, P NATL ACAD SCI USA, V91, P2076, DOI 10.1073/pnas.91.6.2076
   Bogdahn U, 2011, NEURO-ONCOLOGY, V13, P132, DOI 10.1093/neuonc/noq142
   Cachon-Gonzalez MB, 2012, MOL THER, V20, P1489, DOI 10.1038/mt.2012.44
   Chen MY, 2005, J NEUROSURG, V103, P311, DOI 10.3171/jns.2005.103.2.0311
   Chen MY, 1999, J NEUROSURG, V90, P315, DOI 10.3171/jns.1999.90.2.0315
   Falagas ME, 2008, FASEB J, V22, P338, DOI 10.1096/fj.07-9492LSF
   Fiandaca MS, 2008, NEUROTHERAPEUTICS, V5, P123, DOI 10.1016/j.nurt.2007.10.064
   Fiandaca MS, 2009, NEUROIMAGE, V47, pT27, DOI 10.1016/j.neuroimage.2008.11.012
   Forsayeth JR, 2006, MOL THER, V14, P571, DOI 10.1016/j.ymthe.2006.04.008
   Garfield J, 1975, Clin Oncol, V1, P213
   Hadaczek P, 2006, MOL THER, V14, P69, DOI 10.1016/j.ymthe.2006.02.018
   Hadaczek P, 2006, HUM GENE THER, V17, P291, DOI 10.1089/hum.2006.17.291
   Hamilton JF, 2001, EXP NEUROL, V168, P155, DOI 10.1006/exnr.2000.7571
   Kells AP, 2010, J NEUROSCI, V30, P9567, DOI 10.1523/JNEUROSCI.0942-10.2010
   Khan Nickalus R, 2013, World Neurosurg, V80, P766, DOI 10.1016/j.wneu.2013.07.011
   Krauze MT, 2007, NEURO-ONCOLOGY, V9, P393, DOI 10.1215/15228517-2007-019
   Krauze MT, 2005, J NEUROSURG, V103, P923, DOI 10.3171/jns.2005.103.5.0923
   Kreuter J, 2014, ADV DRUG DELIVER REV, V71, P2, DOI 10.1016/j.addr.2013.08.008
   KROIN JS, 1982, NEUROSURGERY, V10, P349, DOI 10.1227/00006123-198203000-00009
   Kunwar S, 2003, ACT NEUR S, V88, P105
   Kunwar S, 2007, J CLIN ONCOL, V25, P837, DOI 10.1200/JCO.2006.08.1117
   Kunwar S, 2010, NEURO-ONCOLOGY, V12, P871, DOI 10.1093/neuonc/nop054
   Lam MF, 2011, J CLIN NEUROSCI, V18, P1163, DOI 10.1016/j.jocn.2011.01.012
   Lidar Z, 2004, J NEUROSURG, V100, P472, DOI 10.3171/jns.2004.100.3.0472
   LIEBERMAN DM, 1995, J NEUROSURG, V82, P1021, DOI 10.3171/jns.1995.82.6.1021
   Lim KJ, 2012, RADIOLOGY, V264, P796, DOI 10.1148/radiol.12111976
   Lonser RR, 2007, NEUROLOGY, V68, P254, DOI 10.1212/01.wnl.0000247744.10990.e6
   Lonser RR, 2005, ANN NEUROL, V57, P542, DOI 10.1002/ana.20444
   Lonser RR, 2002, J NEUROSURG, V97, P905, DOI 10.3171/jns.2002.97.4.0905
   Mamot C, 2004, J NEURO-ONCOL, V68, P1, DOI 10.1023/B:NEON.0000024743.56415.4b
   Miners JS, 2011, J NEUROPATH EXP NEUR, V70, P944, DOI 10.1097/NEN.0b013e3182345e46
   Modi G, 2010, ANN NY ACAD SCI, V1184, P154, DOI 10.1111/j.1749-6632.2009.05108.x
   Murad GJA, 2006, CLIN CANCER RES, V12, P3145, DOI 10.1158/1078-0432.CCR-05-2583
   Nguyen JB, 2001, NEUROREPORT, V12, P1961, DOI 10.1097/00001756-200107030-00037
   Nguyen TT, 2003, J NEUROSURG, V98, P584, DOI 10.3171/jns.2003.98.3.0584
   Oiwa Y, 2002, BRAIN RES, V947, P271, DOI 10.1016/S0006-8993(02)02934-7
   Saito R, 2004, CANCER RES, V64, P6858, DOI 10.1158/0008-5472.CAN-04-1683
   Saito R, 2005, EXP NEUROL, V196, P381, DOI 10.1016/j.expneurol.2005.08.016
   Saito R, 2006, J NEUROSCI METH, V154, P225, DOI 10.1016/j.jneumeth.2005.12.027
   Saito R, 2006, NEURO-ONCOLOGY, V8, P205, DOI 10.1215/15228517-2006-001
   Sampson JH, 2003, J NEURO-ONCOL, V65, P27, DOI 10.1023/A:1026290315809
   Slevin JT, 2007, J NEUROSURG, V106, P614, DOI 10.3171/jns.2007.106.4.614
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   van Tellingen O, 2015, DRUG RESIST UPDATE, V19, P1, DOI 10.1016/j.drup.2015.02.002
   Weaver M, 2003, J NEURO-ONCOL, V65, P3, DOI 10.1023/A:1026246500788
   Zirzow GC, 1999, NEUROCHEM RES, V24, P301, DOI 10.1023/A:1022578424693
NR 51
TC 0
Z9 0
U1 5
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 497
EP +
DI 10.1016/j.wneu.2019.05.179
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900204
PM 31150865
DA 2020-05-12
ER

PT J
AU Texakalidis, P
   Charisis, N
   Giannopoulos, S
   Xenos, D
   Rangel-Castilla, L
   Tassiopoulos, AK
   Jabbour, P
   Grossberg, JA
   Machinis, T
AF Texakalidis, Pavlos
   Charisis, Nektarios
   Giannopoulos, Stefanos
   Xenos, Dimitrios
   Rangel-Castilla, Leonardo
   Tassiopoulos, Apostolos K.
   Jabbour, Pascal
   Grossberg, Jonathan A.
   Machinis, Theofilos
TI Role of Preoperative Embolization in Carotid Body Tumor Surgery: A
   Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Carotid body tumor; Embolization; Paraganglioma; Resection
ID SURGICAL-MANAGEMENT; TRANSARTERIAL EMBOLIZATION; SINGLE-CENTER;
   PARAGANGLIOMAS; OUTCOMES; IMPACT; CLASSIFICATION; ANGIOGRAPHY;
   RESECTION; HEAD
AB BACKGROUND: Carotid body tumors (CBTs) are highly vascularized tumors which can render tumor resection surgery challenging. There is evidence suggesting that preoperative selective embolization can reduce blood loss during surgery and decrease the risk of perioperative complications; however, recent reports have questioned the benefits that preoperative embolization provides. The objective of this study is to investigate the impact of preoperative embolization on CBT surgical resection.
   METHODS: This study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible studies were identified through a search of PubMed, Scopus, and Cochrane Central Register of Controlled Trials until March 2019. A random effects model metaanalysis was conducted, and the I2 statistic was used to assess for heterogeneity.
   RESULTS: Twenty-five studies comprising 1326 patients were included. Patients who received preoperative embolization had statistically significant lower intraoperative blood loss (weighted mean difference [WMD], -135.32; 95% confidence interval [CI], -224.58 to -46.06; I-2 = 78.6%). Duration of the procedure was statistically significantly shorter in the preembolization group than the nonembolization group (WMD, -38.61; 95% CI, -65.61 to -L11.62; I-2 = 71.9%). There were no differences in the rates of cranial nerve (CN) injuries (odds ratio [OR], 1.13; 95% CI, 0.68-1.86; I-2 = 12.9%), stroke (OR, 1.75; 95% CI, 0.70-4.36; I-2 = 0%), transient ischemic attacks (TIAs) (OR, 0.55; 95% CI, 0.11-2.65; I-2 [0%), or length of stay (WMD, 0.32; 95% CI, -1.35 to 1.98; I-2 = 96.4%) between the 2 groups.
   CONCLUSIONS: Patients who received embolization prior to CBT resection had statistically significant lower blood loss and shorter duration of operation. The rates of CN palsy, stroke, TIA, and length of stay were similar between patients who had preoperative embolization and those who did not.
C1 [Texakalidis, Pavlos; Grossberg, Jonathan A.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.
   [Charisis, Nektarios; Tassiopoulos, Apostolos K.] SUNY Stony Brook, Dept Surg, Long Isl City, NY USA.
   [Giannopoulos, Stefanos] 251 Helen Airforce Hose, Dept Vasc Surg, Athens, Greece.
   [Xenos, Dimitrios] Aristotle Univ Thessaloniki, Med Sch, Thessaloniki, Greece.
   [Rangel-Castilla, Leonardo] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Jabbour, Pascal] Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA 19107 USA.
   [Machinis, Theofilos] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA.
RP Texakalidis, P (reprint author), Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA 30322 USA.
EM Pavlos.texakalidis@emory.edu
OI Giannopoulos, Stefanos/0000-0002-1942-911X
CR Abu-Ghanem S, 2016, HEAD NECK-J SCI SPEC, V38, pE2386, DOI 10.1002/hed.24381
   Arnold D, 2009, CENT EUR J MED, V4, P337, DOI 10.2478/s11536-009-0023-8
   Avgerinos ED, 2011, VASCULAR, V19, P250, DOI 10.1258/vasc.2011.oa0291
   Bercin S, 2015, AURIS NASUS LARYNX, V42, P226, DOI 10.1016/j.anl.2014.10.013
   Cobb AN, 2018, ANN VASC SURG, V46, P54, DOI 10.1016/j.avsg.2017.06.149
   Dardik Alan, 2002, Vasc Endovascular Surg, V36, P277, DOI 10.1177/153857440203600405
   Darouassi Y, 2017, ANN VASC SURG, V43, P265, DOI 10.1016/j.avsg.2017.03.167
   Gwon JG, 2011, WORLD J SURG, V35, P2154, DOI 10.1007/s00268-011-1167-7
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13
   Ikeda A, 2018, ONCOL LETT, V15, P5318, DOI 10.3892/ol.2018.7925
   Jackson RS, 2015, OTOLARYNG HEAD NECK, V153, P943, DOI 10.1177/0194599815605323
   Kasper Gregory C, 2006, Vasc Endovascular Surg, V40, P467
   Kiris M, 2018, ANN VASC SURG, V49, P320, DOI 10.1016/j.avsg.2018.01.064
   Kruger AJ, 2010, J VASC SURG, V52, P1518, DOI 10.1016/j.jvs.2010.06.153
   LAMURAGLIA GM, 1992, J VASC SURG, V15, P1038, DOI 10.1016/0741-5214(92)90461-G
   Law Y, 2017, VASCULAR, V25, P184, DOI 10.1177/1708538116657504
   Lee JH, 2002, CANCER, V94, P730, DOI 10.1002/cncr.10252
   Li JP, 2010, NEUROSURGERY, V67, P941, DOI 10.1227/NEU.0b013e3181eda61d
   Lim JY, 2010, CLIN EXP OTORHINOLAR, V3, P91, DOI 10.3342/ceo.2010.3.2.91
   Litle VR, 1996, ANN VASC SURG, V10, P464, DOI 10.1007/BF02000594
   Liu DG, 2006, ORAL SURG ORAL MED O, V101, P102, DOI 10.1016/j.tripleo.2005.05.062
   Liu JL, 2018, HEAD NECK-J SCI SPEC, V40, P2590, DOI 10.1002/hed.25387
   Luna-Ortiz K, 2006, EUR ARCH OTO-RHINO-L, V263, P171, DOI 10.1007/s00405-005-0968-4
   Luna-Ortiz K, 2005, ORAL ONCOL, V41, P56, DOI 10.1016/j.oraloncology.2004.06.006
   Mourad M, 2016, LARYNGOSCOPE, V126, P2282, DOI 10.1002/lary.26006
   NORA JD, 1988, MAYO CLIN PROC, V63, P348, DOI 10.1016/S0025-6196(12)64856-3
   Ozay B, 2008, ACTA CHIR BELG, V108, P107, DOI 10.1080/00015458.2008.11680186
   Pellitteri PK, 2004, ORAL ONCOL, V40, P563, DOI 10.1016/j.oraloncology.2003.09.004
   Power AH, 2012, J VASC SURG, V56, P979, DOI 10.1016/j.jvs.2012.03.037
   SCHICK PM, 1980, SURGERY, V87, P459
   Sen I, 2013, J VASC SURG, V57, p64S, DOI 10.1016/j.jvs.2012.06.114
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]
   Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002
   Tikkakoski T, 1997, LARYNGOSCOPE, V107, P821, DOI 10.1097/00005537-199706000-00018
   Wang SJ, 2000, OTOLARYNG HEAD NECK, V123, P202, DOI 10.1067/mhn.2000.106709
   WARD PH, 1988, LARYNGOSCOPE, V98, P1287
   Zeitler DM, 2010, ANN OTO RHINOL LARYN, V119, P279, DOI 10.1177/000348941011900501
   Zhang JB, 2018, INT J SURG, V54, P48, DOI 10.1016/j.ijsu.2018.04.032
   Zhang TH, 2012, ANN VASC SURG, V26, P775, DOI 10.1016/j.avsg.2012.01.020
NR 41
TC 0
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 503
EP +
DI 10.1016/j.wneu.2019.05.209
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900205
PM 31154101
DA 2020-05-12
ER

PT J
AU Zanaty, M
   Roa, JA
   Piscopo, AJ
   Kritikos, ME
   Teferi, N
   Howard, MA
AF Zanaty, Mario
   Roa, Jorge A.
   Piscopo, Anthony J.
   Kritikos, Michael E.
   Teferi, Nahom
   Howard, Matthew A., III
TI Methods and Devices for Posterior Ventriculoperitoneal Shunt Placement
   Surgery: 25 Years of Iterative Refinement
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hydrocephalus; Normal-pressure hydrocephalus; Posterior shunt;
   Ventriculoperitoneal shunt
AB BACKGROUND: The posterior ventriculoperitoneal shunt (VPS) placement procedure is technically efficient and cosmetically appealing. The main limitations of the posterior approach relate to the technical challenges associated with accurately placing the ventricular catheter. In this report, we describe methods and simple devices used for posterior VPS surgery that have evolved over a >25-year period to enhance catheter placement accuracy and reduce complication rates.
   OBJECTIVE: We describe the combination of methods and customized devices used at a single institution to perform posterior VPS surgery. Results are presented for the most recent 11-year epoch, along with a description of sources of technical errors and plans for further methodologic refinements.
   MATERIALS AND METHODS: The medical records and imaging studies of 468 patients undergoing posterior VPS, from 2007 to 2018 were reviewed. Ventricular catheter placement accuracy data were collected and complications were identified and recorded.
   RESULTS: Optimal ventricular catheter placement was achieved in 98.29%. Of the remaining 1.71%, one half (0.85%) required acute revision surgery. Four patients (0.85%) developed new neurologic deficits following surgery; 2 were related to intraparenchymal hemorrhages and 2 (0.43%) as a result of a misplaced catheter. The deficits resulting from poor catheter placement were transient. The complication rates due to causes other than catheter placement accuracy compared favorably with those reported previously in the literature.
   CONCLUSIONS: Using the methods and devices described in this series, posterior VPS operations can be performed safely with a high degree of ventricular catheter placement accuracy.
C1 [Zanaty, Mario; Roa, Jorge A.; Piscopo, Anthony J.; Kritikos, Michael E.; Teferi, Nahom; Howard, Matthew A., III] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
RP Howard, MA (reprint author), Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
EM matthew-howard@uiowa.edu
OI Roa, Jorge/0000-0003-4987-8853; Howard, Matthew/0000-0003-3935-8889
CR Bir SC, 2017, J NEUROL SURG PART B, V78, P30, DOI 10.1055/s-0036-1584309
   Dacey RG, 2018, J NEUROSURG, V129, P1200, DOI 10.3171/2017.6.JNS171108
   Garell P. Charles, 1998, Journal of Clinical Engineering, V23, P29
   Garell PC, 1998, J NEUROSURG, V89, P157, DOI 10.3171/jns.1998.89.1.0157
   HOWARD MA, 1995, J NEUROSURG, V82, P300, DOI 10.3171/jns.1995.82.2.0300
   Junaid M, 2018, PAK J MED SCI, V34, P691, DOI 10.12669/pjms.343.14081
   Jung N, 2013, J KOREAN NEUROSURG S, V53, P150, DOI 10.3340/jkns.2013.53.3.150
   Khan Farid, 2015, Surg Neurol Int, V6, P25, DOI 10.4103/2152-7806.151388
   Lind CRP, 2008, J NEUROSURG, V108, P930, DOI 10.3171/JNS/2008/108/5/0930
   Nesvick CL, 2015, NEUROSURGERY, V77, P321, DOI 10.1227/NEU.0000000000000849
   OKA K, 1993, NEUROSURGERY, V33, P236, DOI 10.1227/00006123-199308000-00009
   Park MK, 2015, J KOREAN NEUROSURG S, V57, P359, DOI 10.3340/jkns.2015.57.5.359
   Quinones-Hinojosa A, 2006, J NEURO-ONCOL, V76, P65, DOI 10.1007/s11060-005-2915-z
   Zrinzo Ludvic, 2012, Surg Neurol Int, V3, pS53, DOI 10.4103/2152-7806.91612
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 514
EP +
DI 10.1016/j.wneu.2019.05.148
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900206
PM 31132499
DA 2020-05-12
ER

PT J
AU Vanek, P
   Benes, V
AF Vanek, Petr
   Benes, Vladimir
TI Successful Management of a Giant Anterior Sacral Meningocele Associated
   with Low-Dysplastic Spondylolisthesis from a Single Posterior Approach:
   Case Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior; Approach; Meningocele; Posterior; Sacral; Spondylolisthesis
ID LAPAROSCOPIC TREATMENT; SPONDYLOLYSIS; ADOLESCENTS; DIAGNOSIS; CHILDREN;
   FISTULA
AB BACKGROUND: Anterior sacral meningocele (ASM) is characterized by a herniation of the dural sac through a bony defect of the anterior sacral wall. Symptoms of ASMs are usually directly related to their mass effect on the adjacent pelvic structures, often causing chronic constipation and urinary disturbances. The low-dysplastic spondylolisthesis results from congenital abnormalities of the upper sacral facets or the neural arch of L5. Its symptoms are related to neural compression and/or segmental instability. The main aim of this case report is to present a patient who underwent surgery for low dysplastic spondylolisthesis combined with an ASM that were both considered symptomatic.
   CASE DESCRIPTION: A 23-year-old male patient, with no medical history, no signs of neurologic deficit was admitted for lower back pain and irritation, numbness and paresthesia in the L5 dermatomes bilaterally, together with alternating constipation and diarrhea with no response to conservative treatment. Computed tomography and magnetic resonance imaging of the lumbar spine and pelvis showing a large retroperitoneal mass with fluid contend causing compression and displacement of the pelvic structures, in particular the bladder and the colon and there was also a low-dysplastic spondylolisthesis of L5/S1 with pressure on both L5 nerve roots. Surgery was done in one session purely from a posterior approach with no complications.
   CONCLUSIONS: In the present case, we have demonstrated the suitability of a standard midline posterior approach in the treatment not only for ASM itself, but also for a low-dysplastic spondylolisthesis in 1 session.
C1 [Vanek, Petr] Charles Univ Prague, Dept Neurosurg & Neurooncol, Fac Med 1, Prague, Czech Republic.
   Mil Univ Hosp, Prague, Czech Republic.
RP Vanek, P (reprint author), Charles Univ Prague, Dept Neurosurg & Neurooncol, Fac Med 1, Prague, Czech Republic.
EM petr.vanek@uvn.cz
CR Adson AW, 1938, MINN MED, V21, P468
   Bai X, 2007, EUR SPINE J, V26, P606
   BARLOW D, 1963, BRIT J SURG, V50, P732, DOI 10.1002/bjs.18005022510
   Bergeron E, 2010, NEUROSURGERY, V67, pE1464, DOI 10.1227/NEU.0b013e3181f352ba
   Beyazal M., 2013, CASE REP RADIOL, V2013
   BRIGGS J D, 1953, Calif Med, V78, P59
   Castelli E, 2013, UROLOGY, V81, pE9, DOI 10.1016/j.urology.2012.11.015
   Cavalier R, 2006, J AM ACAD ORTHOP SUR, V14, P417, DOI 10.5435/00124635-200607000-00004
   Cheung EV, 2006, J AM ACAD ORTHOP SUR, V14, P488, DOI 10.5435/00124635-200608000-00006
   Clatterbuck RE, 2000, J NEUROSURG, V92, P246, DOI 10.3171/spi.2000.92.2.0246
   Cools MJ, 2013, J NEUROSURG-SPINE, V19, P384, DOI 10.3171/2013.6.SPINE12956
   Cretolle C, 2008, HUM MUTAT, V29, P903, DOI 10.1002/humu.20718
   CURRARINO G, 1981, AM J ROENTGENOL, V137, P395, DOI 10.2214/ajr.137.2.395
   DYCK P, 1980, J NEUROSURG, V53, P548, DOI 10.3171/jns.1980.53.4.0548
   Fitzpatrick MO, 1999, J NEUROSURG, V91, P124, DOI 10.3171/spi.1999.91.1.0124
   Hino Akihiko, 1993, Neurologia Medico-Chirurgica, V33, P700, DOI 10.2176/nmc.33.700
   Isik N, 2008, TURK NEUROSURG, V18, P254
   Gilete-Tejero IJ, 2018, EUR SPINE J, V27, pS276, DOI 10.1007/s00586-017-5128-1
   Klenerman L, 1973, J Bone Joint Surg Br, V55, P331
   Lamartina C, 2009, EUR SPINE J, V18, pS133, DOI 10.1007/s00586-009-0984-y
   LEE KS, 1988, J NEUROSURG, V69, P628, DOI 10.3171/jns.1988.69.4.0628
   Massimi L, 2003, CHILD NERV SYST, V19, P722, DOI 10.1007/s00381-003-0814-1
   Okuda S, 2014, J NEUROSURG-SPINE, V21, P171, DOI 10.3171/2014.4.SPINE13925
   Polat AV, 2013, MED ULTRASON, V15, P67, DOI 10.11152/mu.2013.2066.151.avp1asm2
   Sahin Neslin, 2015, Clin Pract, V5, P752, DOI 10.4081/cp.2015.752
   Schijman E, 2005, CHILD NERV SYST, V21, P91, DOI 10.1007/s00381-004-1086-0
   Somuncu S, 1997, J PEDIATR SURG, V32, P730, DOI 10.1016/S0022-3468(97)90018-X
   Stone JG, 2015, J NEUROSURG-SPINE, V23, P77, DOI 10.3171/2014.11.SPINE131086
   Sunna TP, 2016, J NEUROSURG-SPINE, V24, P862, DOI 10.3171/2015.8.SPINE15129
   Tani S, 2003, NEUROL MED-CHIR, V43, P204, DOI 10.2176/nmc.43.204
   Trapp C, 2007, SURG NEUROL, V68, P443, DOI 10.1016/j.surneu.2006.11.067
   Versteegh Hendt P, 2013, BMC Res Notes, V6, P412, DOI 10.1186/1756-0500-6-412
   VILLAREJO F, 1983, SURG NEUROL, V19, P57, DOI 10.1016/0090-3019(83)90212-4
NR 33
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 522
EP 525
DI 10.1016/j.wneu.2019.04.105
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900207
PM 31009790
DA 2020-05-12
ER

PT J
AU Zhang, HK
   Deng, G
   Liu, BH
   Wang, JM
   Wang, L
   Tian, DF
   Chen, QX
AF Zhang, Huikai
   Deng, Gang
   Liu, Baohui
   Wang, Junmin
   Wang, Long
   Tian, Daofeng
   Chen, Qianxue
TI Thrombotic Aneurysm of Posterior Inferior Cerebellar Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Posterior inferior cerebellar artery; Spontaneous thrombosis;
   Subarachnoid hemorrhage
ID SUBARACHNOID HEMORRHAGE
AB BACKGROUND: Spontaneous thrombosis of an intracranial aneurysm is rare but is common in fusiform or large cystic aneurysms, which result in subarachnoid hemorrhage after rupture. This case reports a 47-year-old woman with subarachnoid hemorrhage who developed spontaneous thrombosis of an aneurysm due to rupture of the posterior inferior cerebellar aneurysm.
   CASE DESCRIPTION: The patient was admitted to the hospital with history of sudden headache and vomiting for 3 days. According to early imaging findings, she was initially diagnosed as having a cavernous hemangioma with hemorrhage in the left cerebellum, but according to the intraoperative pictures and postoperative pathologic results, the diagnosis was an aneurysm with thrombosis. -
   CONCLUSIONS: This case represents a rare but important complication of ruptured intracranial aneurysm, which can be easily misdiagnosed or ignored. It should be given great attention and considered in patients with subarachnoid hemorrhage who are negative for imaging examinations.
C1 [Zhang, Huikai; Deng, Gang; Liu, Baohui; Wang, Junmin; Wang, Long; Tian, Daofeng; Chen, Qianxue] Wuhan Univ, Dept Neurosurg, Renmin Hosp, Wuhan, Hubei, Peoples R China.
RP Chen, QX (reprint author), Wuhan Univ, Dept Neurosurg, Renmin Hosp, Wuhan, Hubei, Peoples R China.
EM chenqx666@whu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81572489, 81372683, 81502075]
FX This work was supported by the National Natural Science Foundation of
   China (81572489, 81372683, and 81502075). The project supports the costs
   associated with publishing.
CR Das KK, 2018, WORLD NEUROSURG, V118, P132, DOI 10.1016/j.wneu.2018.07.072
   de Aguiar Guilherme Brasileiro, 2016, Surg Neurol Int, V7, P15, DOI 10.4103/2152-7806.175898
   EONER G, 1978, J NEUROSURG, V48, P450
   FERGUSON GG, 1970, J NEUROSURG, V33, P485, DOI 10.3171/jns.1970.33.5.0485
   GOLDING R, 1980, CLIN RADIOL, V31, P41, DOI 10.1016/S0009-9260(80)80079-1
   Lee KC, 1999, SURG NEUROL, V51, P94, DOI 10.1016/S0090-3019(97)00346-7
   Little AS, 2007, NEUROSURGERY, V61, P1139, DOI 10.1227/01.neu.0000306091.30517.e7
   Mathur T, 2013, BMJ CASE REP, V2013
   MIKABE T, 1980, Neurological Surgery, V8, P749
   WHITTLE IR, 1982, J NEUROSURG, V56, P287, DOI 10.3171/jns.1982.56.2.0287
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 526
EP +
DI 10.1016/j.wneu.2019.04.245
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900208
PM 31077899
DA 2020-05-12
ER

PT J
AU Chin, BZJ
   Ji, T
   Tang, XD
   Yang, RL
   Guo, W
AF Chin, Brian Zhaojie
   Ji, Tao
   Tang, Xiaodong
   Yang, Rongli
   Guo, Wei
TI Three-Level Lumbar En Bloc Spondylectomy with Three-Dimensional-Printed
   Vertebrae Reconstruction for Recurrent Giant Cell Tumor
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D printing; Giant cell tumor; Oncology; Prosthesis; Spondylectomy;
   Total en bloc
ID VASCULARIZED FIBULAR GRAFTS; SPINAL TUMORS
AB BACKGROUND: Primary malignancies involving the mobile spine often require total en bloc spondylectomy with complex mechanical reconstruction, which can be augmented with novel application of the 3-dimensional (3D)printing technique.
   CASE DESCRIPTION: A 51-year-old man presented with a 12-month history of progressive thigh pain and lower limb motor function loss, 36 months after T12-L4 instrumentation and fusion for giant cell tumor (GCT) of the L2 vertebrae before referral. The patient subsequently underwent successful curative management of recurrent GCT through denosumab treatment, L1-L3 total en bloc spondylectomy (TES), and a novel lumbopelvic reconstruction method with a 3D-printed lumbar vertebrae and screw-rod system.
   CONCLUSIONS: To our knowledge, this is the first reported case of multilevel lumbar TES for GCT reconstructed using a 3D-printed vertebrae. Although TES-specifically in the lumbosacral spine-remains challenging due to its unique anatomy and increased risk of neurologic insult, it is an effective option for curative management of GCTs.
C1 [Chin, Brian Zhaojie; Ji, Tao; Tang, Xiaodong; Yang, Rongli; Guo, Wei] Peking Univ, Musculoskeletal Tumor Ctr, Peoples Hosp, Beijing, Peoples R China.
   [Chin, Brian Zhaojie] Natl Univ Hlth Syst, Univ Orthopaed Hand & Reconstruct Microsurg Clust, Singapore, Singapore.
RP Ji, T (reprint author), Peking Univ, Musculoskeletal Tumor Ctr, Peoples Hosp, Beijing, Peoples R China.
EM jitaomd@163.com
RI Ji, Tao/AAI-2685-2020
OI Ji, Tao/0000-0001-6876-7361
CR Auricchio F, 2016, EFORT OPEN REV, V1, P121, DOI 10.1302/2058-5241.1.000012
   Bhojraj Shekhar Y, 2007, Indian J Orthop, V41, P146, DOI 10.4103/0019-5413.32047
   Boriani S, 2012, SPINE, V37, pE37, DOI 10.1097/BRS.0b013e3182233ccd
   Bumbasirevic M, 2014, INT ORTHOP, V38, P1277, DOI 10.1007/s00264-014-2281-6
   Chen Dong, 2017, J Spine Surg, V3, P650, DOI 10.21037/jss.2017.10.09
   Gargiulo P, 2017, J HEALTHC ENG, DOI 10.1155/2017/1439643
   Hoang D, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.12.18
   Huang L, 2013, EUR SPINE J, V22, P556, DOI 10.1007/s00586-012-2460-3
   Jones Morgan, 2018, J Spine Surg, V4, P663, DOI 10.21037/jss.2018.06.12
   Krepler P, 2003, SPINE, V28, pE334, DOI 10.1097/01.BRS.0000090504.32585.AC
   Liu SY, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012605
   Luzzati AD, 2015, CLIN ORTHOP RELAT R, V473, P858, DOI 10.1007/s11999-014-3578-x
   Martin Christopher, 2010, Iowa Orthop J, V30, P69
   Matsumoto M, 2011, J NEUROSURG-SPINE, V15, P320, DOI 10.3171/2011.5.SPINE10813
   McDonald PJ, 2010, CAN J SURG, V53, P133
   Moran SL, 2009, MICROSURG, V29, P393, DOI 10.1002/micr.20655
   Mulford JS, 2016, ANZ J SURG, V86, P648, DOI 10.1111/ans.13533
   Santiago-Dieppa David R, 2014, Evid Based Spine Care J, V5, P151, DOI 10.1055/s-0034-1387804
   Shah FA, 2016, ACTA BIOMATER, V30, P357, DOI 10.1016/j.actbio.2015.11.013
   Shimada Y, 2007, SPINE J, V7, P499, DOI 10.1016/j.spinee.2006.01.016
   Tomita K, 1997, SPINE, V22, P324, DOI 10.1097/00007632-199702010-00018
   Tomita K, 2006, J ORTHOP SCI, V11, P3, DOI 10.1007/s00776-005-0964-y
   Tu J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010799
   van der Heijden L, 2014, ONCOLOGIST, V19, P550, DOI 10.1634/theoncologist.2013-0432
   Viswanathan A, 2012, EUR SPINE J, V21, P84, DOI 10.1007/s00586-011-1882-7
   Wilcox Ben, 2017, J Spine Surg, V3, P433, DOI 10.21037/jss.2017.09.01
   Yokogawa N, 2015, ORTHOPEDICS, V38, pE561, DOI 10.3928/01477447-20150701-52
   Yokogawa N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098797
   Yonezawa N, 2017, EUR SPINE J, V26, pS236, DOI 10.1007/s00586-017-5086-7
   Yu H, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011484
NR 30
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP 531
EP +
DI 10.1016/j.wneu.2019.06.056
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900209
PM 31207371
DA 2020-05-12
ER

PT J
AU Aghaebrahim, A
   Cranja, MF
   Agnoletto, GJ
   Aguilar-Salinas, P
   Cortez, GM
   Santos, R
   Monteiro, A
   Camp, W
   Day, J
   Dellorso, S
   Naval, N
   Chmayssani, M
   Stromberg, R
   Rill, MC
   Sauvageau, E
   Hanel, R
AF Aghaebrahim, Amin
   Cranja, Manuel F.
   Agnoletto, Guilherme J.
   Aguilar-Salinas, Pedro
   Cortez, Gustavo M.
   Santos, Roberta
   Monteiro, Andre
   Camp, Wendy
   Day, Jason
   Dellorso, Scott
   Naval, Neeraj
   Chmayssani, Mohamad
   Stromberg, Richard
   Rill, Matthew C.
   Sauvageau, Eric
   Hanel, Ricardo
TI Workflow Optimization for Ischemic Stroke in a Community-Based Stroke
   Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular treatment; Reperfusion; Stroke; Thrombectomy; Workflow
ID ENDOVASCULAR THROMBECTOMY; TIME; THERAPY; DOOR
AB BACKGROUND: We analyzed the effect of specific optimization steps to reduce treatment delays in a nonacademic stroke hospital setting.
   METHODS: The data from patients with ischemic stroke who had been treated with intravenous tissue plasminogen activator or endovascular therapy, or both, were analyzed. The metrics were divided into 2 periods: preoptimization period (October 1, 2015 to September 30, 2016) and postoptimization period (October 1, 2016 to September 30, 2017). The key interventions were 1) notification by the emergency medical service to the emergency department and stroke team; 2) division of the stroke alert between level 1 (intravenous/intra-arterial candidate) and level 2; 3) direct transportation of level 1 patients to brain computed tomography; 4) limitation of nonessential interventions; 5) stroke orientation; 6) 24-hour, 7-day code stroke response by a vascular neurologist; 7) earlier notification of the interventional radiology team; 8) direct transportation from computed tomography to angiography suite for large vessel occlusion; and 9) multidisciplinary monthly meetings to discuss delayed cases.
   RESULTS: A total of 279 patients were identified. No significant differences in any of the baseline characteristics were documented. Almost all metrics favored the postoptimization period, with remarkable improvement in the door-to-puncture time (median, 64 minutes; interquartile range, 36-86; vs. 47 minutes; interquartile range, 20-62; P = 0.001). We observed an increased percentage of good clinical outcomes in the postoptimization group (60.1% vs. 54.8%; P = 0.500). We found an 8.4% increase in patients with good clinical outcomes in the postoptimization group compared with our previously reported work.
   CONCLUSIONS: For acute reperfusion therapies, significant reductions in workflow intervals can be achieved after simple optimization methods in a nonacademic community-based hospital.
C1 [Aghaebrahim, Amin; Cranja, Manuel F.; Agnoletto, Guilherme J.; Aguilar-Salinas, Pedro; Cortez, Gustavo M.; Santos, Roberta; Monteiro, Andre; Camp, Wendy; Day, Jason; Dellorso, Scott; Naval, Neeraj; Chmayssani, Mohamad; Sauvageau, Eric; Hanel, Ricardo] Baptist Hlth, Baptist Neurol Inst, Lyerly Neurosurg, Louisville, KY USA.
   [Stromberg, Richard; Rill, Matthew C.] Baptist Med Ctr, Emergency Dept, Jacksonville, FL USA.
RP Aghaebrahim, A (reprint author), Baptist Hlth, Baptist Neurol Inst, Lyerly Neurosurg, Louisville, KY USA.
EM Amin.Aghaebrahim@bmcjax.com
RI Aguilar-Salinas, Pedro/AAJ-4444-2020
OI Aguilar-Salinas, Pedro/0000-0002-5268-6548; Cortez,
   Gustavo/0000-0003-4227-0378
CR Aghaebrahim A, 2017, J NEUROINTERV SURG, V9, P340, DOI 10.1136/neurintsurg-2016-012324
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kansagra AP, 2018, CLIN NEUROL NEUROSUR, V166, P71, DOI 10.1016/j.clineuro.2018.01.026
   Llanes Jennifer N, 2004, Prehosp Emerg Care, V8, P46
   Menon BK, 2016, CIRCULATION, V133, P2279, DOI 10.1161/CIRCULATIONAHA.115.019983
   Mokin M, 2016, NAT REV NEUROL, V12, P86, DOI 10.1038/nrneurol.2015.240
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Noorian AR, 2018, STROKE, V49, P565, DOI 10.1161/STROKEAHA.117.019228
   Saver JL, 2016, JAMA-J AM MED ASSOC, V316, P1279, DOI 10.1001/jama.2016.13647
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959
   Schregel K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169192
NR 15
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E273
EP E278
DI 10.1016/j.wneu.2019.05.127
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900033
PM 31146041
DA 2020-05-12
ER

PT J
AU Agosti, E
   Flemming, KD
   Lanzino, G
AF Agosti, Edoardo
   Flemming, Kelly D.
   Lanzino, Giuseppe
TI Symptomatic Cavernous Malformation Presenting with Seizure without
   Hemorrhage: Analysis of Factors Influencing Clinical Presentation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernoma; Cavernous malformation; Clinical presentation; Seizure
ID NATURAL-HISTORY; BLEEDING RISK
AB BACKGROUND: Supratentorial cavernous malformations (CMs) can be epileptogenic lesions. However, little is known about clinical comorbidities, medication use, and radiologic features that predict a first seizure presentation without associated CM hemorrhage.
   METHODS: We queried a prospective registry of consecutive patients with CM established in January 2015. Data regarding clinical presentation, comorbid conditions, daily medication use, and radiologic CM characteristics were collected. Univariate and multivariate regression analysis was performed assessing variables for presentation with seizure without hemorrhage with P values, odds ratios, and 95% confidence intervals reported.
   RESULTS: Of 202 patients, 58.4% were women, and the average age at diagnosis was 43.7 +/- 16.5 years. Of the patients, 59.4% were symptomatic. In 40.6%, the CM was an incidental finding. Of the 30 patients who presented with a first-time seizure without concomitant hemorrhage, the mean age at diagnosis was 38.4 +/- 14.6 years, and 56.7% were women. Compared with incidental CM, patients with seizure without hemorrhage were younger, had a cortically based, supratentorial lesion, and were less likely to have chronic inflammatory disease or to use aspirin, vitamin D, or statin. Compared with other supratentorial lesions, patients with seizure without hemorrhage more commonly had a temporal lobe CM.
   CONCLUSIONS: These prospective data provide possible clues to radiologic factors, clinical comorbidities, and medication influences on seizure presentation in patients with CM. Further multicenter studies would be helpful to determine if disease-modifying agents in addition to epileptic medications or surgery might be helpful.
C1 [Agosti, Edoardo; Lanzino, Giuseppe] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Flemming, Kelly D.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
   [Agosti, Edoardo] Univ Brescia, Fac Med & Chirurg, Brescia, Italy.
RP Flemming, KD (reprint author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
EM Flemming.Kelly@mayo.edu
CR Al-Shahi SR, 2012, LANCET NEUROL, V11, P217, DOI DOI 10.1016/S1474-4422(12)70004-2
   Bervini D, 2019, J NEUROSURG, V130, P1922, DOI 10.3171/2018.1.JNS172547
   Chohan MO, 2018, JAMA NEUROL, V4, P429
   Flemming KD, 2012, NEUROLOGY, V78, P632, DOI 10.1212/WNL.0b013e318248de9b
   Flemming KD, 2013, J NEUROSURG, V118, P43, DOI 10.3171/2012.8.JNS112050
   Gibson CC, 2015, CIRCULATION, V131, P289, DOI 10.1161/CIRCULATIONAHA.114.010403
   Horne MA, 2016, LANCET NEUROL, V15, P166, DOI 10.1016/S1474-4422(15)00303-8
   KONDZIOLKA D, 1995, J NEUROSURG, V83, P820, DOI 10.3171/jns.1995.83.5.0820
   Kumar S, 2019, J STROKE CEREBROVASC, V28, P1662, DOI 10.1016/j.jstrokecerebrovasdis.2019.02.025
   Labauge P, 2000, NEURORADIOLOGY, V42, P327, DOI 10.1007/s002340050893
   Menzler K, 2010, NEUROSURGERY, V67, P918, DOI 10.1227/NEU.0b013e3181eb5032
   Polster SP, 2019, NEUROSURGERY, V84, P954, DOI 10.1093/neuros/nyy108
   Porter PJ, 1997, J NEUROSURG, V87, P190, DOI 10.3171/jns.1997.87.2.0190
   Retta SF, 2016, INT J BIOCHEM CELL B, V81, P254, DOI 10.1016/j.biocel.2016.09.011
   RIGAMONTI D, 1988, NEW ENGL J MED, V319, P343, DOI 10.1056/NEJM198808113190605
   ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709
   Rosenow F, 2013, EPILEPSIA, V54, P2025, DOI 10.1111/epi.12402
   Salman RAS, 2008, STROKE, V39, P3222, DOI 10.1161/STROKEAHA.108.515544
   Schneble HM, 2012, STROKE, V43, P3196, DOI 10.1161/STROKEAHA.112.668533
   Shenkar R, 2019, STROKE, V50, P738, DOI 10.1161/STROKEAHA.118.024058
   ZABRAMSKI JM, 1994, J NEUROSURG, V80, P422, DOI 10.3171/jns.1994.80.3.0422
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E387
EP E392
DI 10.1016/j.wneu.2019.05.157
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900049
PM 31132505
DA 2020-05-12
ER

PT J
AU Akinduro, OO
   Lu, VM
   Izzo, A
   De Biase, G
   Vilanilam, G
   Van Gompel, JJ
   Bernet, V
   Donaldson, A
   Olomu, O
   Meyer, FB
   Quinones-Hinojosa, A
   Chaichana, KL
AF Akinduro, Oluwaseun O.
   Lu, Victor M.
   Izzo, Alessandro
   De Biase, Gaetano
   Vilanilam, George
   Van Gompel, Jamie J.
   Bernet, Victor
   Donaldson, Angela
   Olomu, Osarenoma
   Meyer, Fredric B.
   Quinones-Hinojosa, Alfredo
   Chaichana, Kaisorn L.
TI Radiographic and Hormonal Regression in Prolactinomas: An Analysis of
   Treatment Failure
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bromocriptine; Cabergoline; Dopamine agonist; Pituitary adenoma;
   Prolactinoma
ID PITUITARY-ADENOMAS; CABERGOLINE TREATMENT; MEDICAL THERAPY; MANAGEMENT;
   DIAGNOSIS; BROMOCRIPTINE; PREVALENCE; GUIDELINES; RESISTANT; SOCIETY
AB OBJECTIVE: First-line treatment for prolactin-producing pituitary adenomas is dopamine agonist (DA) therapy. This is the first study to analyze the rate of radiographic and hormonal regression of prolactinomas in response to DA therapy to better understand what time frame we consider DA treatment failure.
   METHODS: We searched the electronic medical records of 3 tertiary care medical institutions for patients with prolactinomas. The primary outcome was tumor volume and prolactin (PRL) levels at various time points. The secondary outcome was indicators of treatment failure. Modeling by both linear and exponential models was tested to determine potential predictors of response magnitude and treatment failure by multivariate and regression analyses respectively.
   RESULTS: There were 99 patients (53% male) included in this analysis. The mean patient age was 42.7 years +/- 14.5, and mean width/volume of tumor at diagnosis was 12.3 mm and 1.3 cm(3), respectively. The mean PRL level at diagnosis was 593.2 ng/mL (79-7913). Modeling indicated a plateau at 68.2% initial volume (95% confidence interval 61.7-73.5) by 12.6 months and a PRL plateau of 21.4 ng/mL (95% confidence interval 0-92.5) by 3.3 months. Multivariate analyses revealed male sex (odds ratio 0.168; P = 0.036) to be a predictor of faster PRL response to DA therapy.
   CONCLUSIONS: Prolactinomas plateau in PRL levels and the rate of size regression within the first year of DA treatment. Prolactinomas with lack of size regression and failure to reach normalization of PRL levels by 12 months may be considered for other management strategies.
C1 [Akinduro, Oluwaseun O.; Vilanilam, George; Quinones-Hinojosa, Alfredo; Chaichana, Kaisorn L.] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
   [Bernet, Victor] Mayo Clin, Dept Endocrinol, Jacksonville, FL 32224 USA.
   [Donaldson, Angela; Olomu, Osarenoma] Mayo Clin, Dept Otolaryngol, Jacksonville, FL 32224 USA.
   [Lu, Victor M.; Van Gompel, Jamie J.; Meyer, Fredric B.] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
   [Izzo, Alessandro; De Biase, Gaetano] Catholic Univ, Dept Neurosurg, Rome, Italy.
RP Chaichana, KL (reprint author), Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
EM chaichana.kaisom@mayo.edu
RI Vilanilam, George Koshy/AAJ-3847-2020
OI Vilanilam, George/0000-0003-0845-670X
FU RACER Clinical Investigator's award; Mayo Professorship; Mayo Clinic
   Clinician Investigator Award
FX Dr. Chaichana was supported by the RACER Clinical Investigator's award.
   Dr. Quinones was supported by the Mayo Professorship and the Mayo Clinic
   Clinician Investigator Award.
CR Akinduro OO, 2018, WORLD NEUROSURG, V112, P227, DOI 10.1016/j.wneu.2018.01.112
   Anagnostis P, 2012, PITUITARY, V15, P25, DOI 10.1007/s11102-011-0303-6
   Casanueva FF, 2006, CLIN ENDOCRINOL, V65, P265, DOI 10.1111/j.1365-2265.2006.02562.x
   CHIODINI P, 1981, J CLIN ENDOCR METAB, V53, P737, DOI 10.1210/jcem-53-4-737
   Ciccarelli Antonio, 2005, Pituitary, V8, P3, DOI 10.1007/s11102-005-5079-0
   Colao A, 2000, J CLIN ENDOCR METAB, V85, P2247, DOI 10.1210/jc.85.6.2247
   Colao A, 2009, REV ENDOCR METAB DIS, V10, P111, DOI 10.1007/s11154-008-9107-z
   Corsello SM, 2003, CLIN ENDOCRINOL, V58, P662, DOI 10.1046/j.1365-2265.2003.01770.x
   Daly AF, 2006, J CLIN ENDOCR METAB, V91, P4769, DOI 10.1210/jc.2006-1668
   Del Dotto P, 2003, CLIN PHARMACOKINET, V42, P633, DOI 10.2165/00003088-200342070-00003
   Delgrange E, 2005, ACTA NEUROCHIR, V147, P751, DOI 10.1007/s00701-005-0498-2
   Delgrange E, 2009, EUR J ENDOCRINOL, V160, P747, DOI 10.1530/EJE-09-0012
   ESIRI MM, 1986, J CLIN ENDOCR METAB, V63, P383, DOI 10.1210/jcem-63-2-383
   Fahie-Wilson MN, 2007, CLIN ENDOCRINOL, V67, P638, DOI 10.1111/j.1365-2265.2007.02940.x
   Gillam MP, 2006, ENDOCR REV, V27, P485, DOI 10.1210/er.2005-9998
   Gruppetta M, 2013, PITUITARY, V16, P545, DOI 10.1007/s11102-012-0454-0
   Guitelman M, 2006, FRONT HORM RES, V35, P88, DOI 10.1159/000094312
   Heesterman BL, 2019, J NEUROL SURG PART B, V80, P72, DOI 10.1055/s-0038-1667148
   Karavitaki N, 2012, ANN ENDOCRINOL-PARIS, V73, P79, DOI 10.1016/j.ando.2012.03.039
   Cuevas JL, 2013, REV MED CHILE, V141, P687, DOI 10.4067/S0034-98872013000600001
   Maiter D, 2018, NEUROENDOCRINOLOGY, V18, P1
   MBANYA JCN, 1993, BRIT J NEUROSURG, V7, P519, DOI 10.3109/02688699308995074
   Melmed S, 2011, J CLIN ENDOCR METAB, V96, P273, DOI 10.1210/jc.2010-1692
   Menucci M, 2011, PITUITARY, V14, P68, DOI 10.1007/s11102-010-0261-4
   Molitch ME, 2017, JAMA-J AM MED ASSOC, V317, P516, DOI 10.1001/jama.2016.19699
   Molitch ME, 2014, J NEURO-ONCOL, V117, P421, DOI 10.1007/s11060-013-1270-8
   MORI H, 1988, PATHOL RES PRACT, V183, P580, DOI 10.1016/S0344-0338(88)80015-3
   Musolino Nina R.C., 2005, Arq Bras Endocrinol Metab, V49, P641, DOI 10.1590/S0004-27302005000500005
   Olafsdottir A, 2006, NAT CLIN PRACT ENDOC, V2, P552, DOI 10.1038/ncpendmet0290
   Ono M, 2008, J CLIN ENDOCR METAB, V93, P4721, DOI 10.1210/jc.2007-2758
   Song YJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005833
   Sun DQ, 2011, NEUROSURG REV, V34, P181, DOI 10.1007/s10143-010-0285-2
   Tasan E, 2015, NEUROENDOCRINOL LETT, V36, P28
   Vasilev V, 2011, J ENDOCRINOL INVEST, V34, P312, DOI [10.1007/BF03347092, 10.3275/7604]
   Vilar L, 2008, J ENDOCRINOL INVEST, V31, P436, DOI 10.1007/BF03346388
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   Vroonen L, 2019, NEUROENDOCRINOLOGY, V109, P20, DOI 10.1159/000497746
   Vroonen L, 2012, EUR J ENDOCRINOL, V167, P651, DOI 10.1530/EJE-12-0236
   WEBSTER J, 1994, NEW ENGL J MED, V331, P904, DOI 10.1056/NEJM199410063311403
NR 39
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E686
EP E694
DI 10.1016/j.wneu.2019.05.249
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900087
PM 31181361
DA 2020-05-12
ER

PT J
AU Al-Khindi, T
   Shen, CJ
   Peng, LK
   Redmond, KJ
   Lim, M
   Kleinberg, LR
   Bettegowda, C
AF Al-Khindi, Timour
   Shen, Colette J.
   Peng, Luke
   Redmond, Kristin J.
   Lim, Michael
   Kleinberg, Lawrence R.
   Bettegowda, Chetan
TI Assessing the Effectiveness of Systemic Therapy after Stereotactic
   Radiosurgery on Cancer Recurrence and All-Cause Mortality
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chemotherapy; Metastasis; Neoplasm recurrence; Stereotactic
   radiosurgery; Survival
ID BRAIN METASTASES; CEREBROSPINAL-FLUID; BREAST-CANCER; MELANOMA;
   SURVIVAL; TUMORS; PENETRATION; MANAGEMENT; ERLOTINIB
AB BACKGROUND: Patients with cancer often present with brain metastases in the setting of controlled extracranial disease, for which they receive stereotactic radiosurgery (SRS) and surgical resection. The role of systemic therapy after SRS is unclear. Brain metastasis indicates active cancer dissemination, and microscopic systemic disease may be present despite absence of gross disease as assessed by conventional imaging modalities.
   OBJECTIVE: The aim was to determine if post-SRS systemic therapy reduces the risk of brain relapse, systemic relapse, and death in patients with brain metastases and controlled extracranial disease.
   METHODS: We retrospectively reviewed the medical records of 67 patients with controlled extracranial disease who received SRS for brain metastases. Kaplan-Meier analysis and Cox proportional hazards regression were used to assess how post-SRS systemic therapy affected the risk of brain relapse, systemic relapse, and all-cause mortality.
   RESULTS: In our sample, 31% of patients received systemic therapy after SRS. Post-SRS systemic therapy did not affect median time to brain relapse (P = 0.43), systemic relapse (P = 0.16), or death (P = 0.33) by univariate analysis. After accounting for confounding factors such as cancer histology and age, post-SRS systemic therapy significantly reduced the risk of brain relapse (hazard ratio [HR], 0.22; P = 0.002) but not systemic relapse (HR, 0.38; P = 0.09) or all-cause mortality (HR, 2.16; P = 0.09).
   CONCLUSIONS: Only a minority of patients with brain metastases and controlled extracranial disease receive adjuvant systemic therapy after SRS, but those that do have a reduced risk of brain relapse. Post-SRS systemic therapy may act prophylactically to reduce the risk of intracranial cancer recurrence.
C1 [Al-Khindi, Timour; Lim, Michael; Bettegowda, Chetan] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Peng, Luke; Redmond, Kristin J.; Kleinberg, Lawrence R.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA.
   [Shen, Colette J.] Univ N Carolina, Dept Radiat Oncol, Sch Med, Chapel Hill, NC 27515 USA.
RP Bettegowda, C (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM cbetteg1@jhmi.edu
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30
   CA016086]
CR BOURKE RS, 1973, CANCER RES, V33, P1735
   Boyle FM, 2004, NEURO-ONCOLOGY, V6, P300, DOI 10.1215/S1152851703000516
   Chalmers AJ, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.2025
   Chang AY, 2015, BREAST CANCER-BASIC, V9, P19, DOI 10.4137/BCBCR.S21176
   Chen H-M, 2014, J CANC RES PRAC, V1, P146
   Choong ES, 2017, EUR J CANCER, V75, P169, DOI 10.1016/j.ejca.2017.01.007
   Chukwueke U, 2016, J ONCOL PRACT, V12, P536, DOI 10.1200/JOP.2016.011882
   Clocchiatti A, 2016, NAT REV CANCER, V16, P330, DOI 10.1038/nrc.2016.30
   Cohen JV, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00049
   Cook MB, 2011, CANCER EPIDEM BIOMAR, V20, P1629, DOI 10.1158/1055-9965.EPI-11-0246
   Costa DB, 2011, J CLIN ONCOL, V29, pE443, DOI 10.1200/JCO.2010.34.1313
   Davis JR, 1999, AUST NZ J MED, V29, P831, DOI 10.1111/j.1445-5994.1999.tb00795.x
   Deng YM, 2014, MOL CLIN ONCOL, V2, P116, DOI 10.3892/mco.2013.190
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5
   Faller BA, 2011, CLIN MED INSIGHTS-ON, V5, P131, DOI 10.4137/CMO.S5074
   HEIMANS JJ, 1994, ANN ONCOL, V5, P951, DOI 10.1093/oxfordjournals.annonc.a058736
   Hingorani Mohan, 2014, World J Oncol, V5, P223, DOI 10.14740/wjon843w
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Jacobs SS, 2005, CLIN CANCER RES, V11, P1669, DOI 10.1158/1078-0432.CCR-04-1807
   Jacus MO, 2016, CLIN PHARMACOKINET, V55, P297, DOI 10.1007/s40262-015-0319-6
   Kamath SD, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00414
   Kimelberg Harold K, 2008, Recent Pat CNS Drug Discov, V3, P104, DOI 10.2174/157488908784534603
   Knisely JPS, 2012, J NEUROSURG, V117, P227, DOI 10.3171/2012.5.JNS111929
   Koba T, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006087
   Lampson LA, 2011, MABS-AUSTIN, V3, P153, DOI 10.4161/mabs.3.2.14239
   Li PC, 2017, INT J RADIAT ONCOL, V99, pE30, DOI 10.1016/j.ijrobp.2017.06.662
   Ma DJ, 2015, NEURO-ONCOLOGY, V17, P1261, DOI 10.1093/neuonc/nou328
   Miyajima M, 2013, J PHARM SCI-US, V102, P3309, DOI 10.1002/jps.23600
   Morikawa A, 2013, J CLIN ONCOL S, V15, P514
   Nieder C, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0927-2
   Niwinska A, 2016, CLIN EXP METASTAS, V33, P677, DOI 10.1007/s10585-016-9802-1
   Ramakrishna N, 2014, J CLIN ONCOL, V32, P2100, DOI 10.1200/JCO.2013.54.0955
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   ten Tije AJ, 2004, ANTI-CANCER DRUG, V15, P715, DOI 10.1097/01.cad.0000136882.19552.8f
   Vaidhyanathan S, 2014, DRUG METAB DISPOS, V42, P1292, DOI 10.1124/dmd.114.058339
   Vergote I, 2006, ANN ONCOL, V17, P200, DOI 10.1093/annonc/mdj047
   VONHOLST H, 1990, ACTA NEUROCHIR, V104, P13, DOI 10.1007/BF01842886
   Vredenburgh JJ, 2009, NEURO-ONCOLOGY, V11, P80, DOI 10.1215/15228517-2008-075
   Wisnivesky JP, 2007, J CLIN ONCOL, V25, P1705, DOI 10.1200/JCO.2006.08.1455
   Wong ET, 2004, ONCOLOGIST, V9, P68, DOI 10.1634/theoncologist.9-1-68
   Yule SM, 1997, CLIN CANCER RES, V3, P1985
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E572
EP E581
DI 10.1016/j.wneu.2019.05.218
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900073
PM 31158536
DA 2020-05-12
ER

PT J
AU Alarcon-Ruiz, CA
   Diaz-Barrera, ME
   Vera-Monge, VA
   Alva-Diaz, C
   Metcalf, T
AF Alarcon-Ruiz, Christoper A.
   Diaz-Barrera, Mario E.
   Vera-Monge, Victor A.
   Alva-Diaz, Carlos
   Metcalf, Tatiana
TI A Bibliometric Analysis of the Latin American Research on Stroke
   2003-2017
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bibliometrics; Biomedical research; Latin America and Caribbean;
   Research output; Stroke
ID GLOBAL BURDEN; CARDIOVASCULAR-DISEASE; HEMORRHAGIC STROKE; REGIONAL
   BURDEN; CITED ARTICLES; OUTCOMES; IMPACT
AB BACKGROUND: Stroke is a leading cause of mortality and disability worldwide. Research activity in Latin American countries might be the key to solving, or at least improving, the understanding of stroke-related issues in the region. Our aim was to describe and analyze the research output on stroke in Latin America.
   METHODS: We performed a bibliometric analysis of studies on stroke in Latin America reported from 2003 to 2017 in Scopus-indexed journals. We extracted the annual research, countries, journals, authors, institutions, citation frequency, and journal metrics. The data were quantitatively analyzed. Publication activity was adjusted to the countries by population size. Also, the results from an author and country co-occurrence analysis are presented as network visualization maps using VOSviewer.
   RESULTS: A total of 2298 Latin American stroke-related reports were identified, most were original research reports (72%). The number of reported studies had increased from 2003 to 2017 (P < 0.001). Brazil was the country with the greatest production with 1273 reports (55.4%), followed by Argentina and Mexico. No association was found between stroke prevalence and mortality and the scientific production of the country. Six universities and three hospitals were the most prolific institutions. A collaborative relationship was found between the United States and Brazil, Argentina, and Mexico. The intraregional collaboration of research on stroke was low among Latin American countries.
   CONCLUSIONS: Despite the continuous increase in research output from Latin American countries, more effort is needed to strengthen the research capacity by developing networks and collaborative research projects, ideally among the Latin American countries themselves.
C1 [Alarcon-Ruiz, Christoper A.] Univ San Ignacio Loyola, Unidad Invest Generac & Sintesis Evidencias Salud, Lima, Peru.
   [Diaz-Barrera, Mario E.] Univ Nacl Trujil SOCEMUNT, Soc Cient Estudiantes Med, Trujillo, Peru.
   [Diaz-Barrera, Mario E.] Univ Nacl Trujillo, Fac Med, Trujillo, Peru.
   [Vera-Monge, Victor A.] Univ Complutense Madrid, Madrid, Spain.
   [Vera-Monge, Victor A.] Hosp Melilla, Melilla, Spain.
   [Alva-Diaz, Carlos; Metcalf, Tatiana] Hosp Daniel Alcides Carrion, Serv Neurol, Dept Med & Oficina Apoyo Docencia & Invest OADI, Callao, Peru.
   [Alva-Diaz, Carlos] Univ Cient Sur, Fac Ciencias Salud, Lima, Peru.
   [Alva-Diaz, Carlos; Metcalf, Tatiana] Red Eficacia Clin & Sanitaria REDECS, Lima, Peru.
RP Alarcon-Ruiz, CA (reprint author), Univ San Ignacio Loyola, Unidad Invest Generac & Sintesis Evidencias Salud, Lima, Peru.
EM christoper.alarconr20@gmail.com
OI Alarcon-Ruiz, Christoper A/0000-0003-3907-2784
CR Agarwal A, 2016, ASIAN J ANDROL, V18, P296, DOI 10.4103/1008-682X.171582
   [Anonymous], 2017, RED INDICADORES CIEN, P10
   [Anonymous], 2018, SCIMAGO J COUNTRY RA
   Arocena R, 2001, RES POLICY, V30, P1221, DOI 10.1016/S0048-7333(00)00143-8
   Asplund K, 2012, STROKE, V43, P830, DOI 10.1161/STROKEAHA.111.637249
   Avezum A, 2015, GLOB HEART, V10, P323, DOI 10.1016/j.gheart.2014.01.006
   Ciocca DR, 2017, CELL STRESS CHAPERON, V22, P847, DOI 10.1007/s12192-017-0815-8
   Culquichicon Carlos, 2018, Infez Med, V26, P28
   Culquichicon Carlos, 2017, F1000Res, V6, P194, DOI 10.12688/f1000research.10936.1
   Delgado-Osorio Nathalia, 2014, Recent Pat Antiinfect Drug Discov, V9, P202
   Downing A, 2017, GUT, V66, P89, DOI 10.1136/gutjnl-2015-311308
   Feigin VL, 2015, NEUROEPIDEMIOLOGY, V45, P161, DOI 10.1159/000441085
   Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4
   Fernando L, 2014, PROG CARDIOVASC DIS, V57, P262, DOI 10.1016/j.pcad.2014.07.007
   Jahangir E, 2011, WORLD J CARDIOL, V3, P383, DOI 10.4330/wjc.v3.i12.383
   Kim Y, 2017, EUR NEUROL, V78, P210, DOI 10.1159/000479626
   Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Majumdar SR, 2008, ARCH INTERN MED, V168, P657, DOI 10.1001/archinternmed.2007.124
   Malhotra K, 2018, WORLD NEUROSURG, V111, pE649, DOI 10.1016/j.wneu.2017.12.140
   Martins SCO, 2019, LANCET NEUROL, V18, P674, DOI 10.1016/S1474-4422(19)30068-7
   Miguel Sandra, 2011, Rev. Interam. Bibliot, V34, P187
   Mohammed MF, 2018, CURR PROBL DIAGN RAD, V47, P161, DOI 10.1067/j.cpradiol.2017.06.003
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   Rocha JA, 2011, ANTI-CANCER DRUG, V22, pS9, DOI 10.1097/01.cad.0000398727.68461.77
   Samb B, 2010, LANCET, V376, P1785, DOI 10.1016/S0140-6736(10)61353-0
   Selby P, 2011, ANN ONCOL, V22, P5, DOI 10.1093/annonc/mdr419
   Silva GS, 2018, J STROKE MED, V1, P51
   Simbaqueba E, 2016, VALUE HEALTH, V19, pA292, DOI 10.1016/j.jval.2016.03.840
   van Raan AFJ, 2001, SCIENTOMETRICS, V51, P347, DOI 10.1023/A:1010501820393
   Van Raan Anthony F.J., 2003, TECHNIKFOLGENABSCHAT, V1, P20
   Wahlgren N, 2015, INT J STROKE, V10, P135
   WHO, 2016, GLOB HLTH EST
NR 33
TC 1
Z9 1
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E545
EP E554
DI 10.1016/j.wneu.2019.05.212
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900069
PM 31152886
DA 2020-05-12
ER

PT J
AU Alsofy, SZ
   Stroop, R
   Fusek, I
   Saravia, HW
   Sakellaropoulou, I
   Yavuz, M
   Ewelt, C
   Nakamura, M
   Fortmann, T
AF Alsofy, Samer Zawy
   Stroop, Ralf
   Fusek, Ivo
   Saravia, Heinz Wetzel
   Sakellaropoulou, Ioanna
   Yavuz, Murat
   Ewelt, Christian
   Nakamura, Makoto
   Fortmann, Thomas
TI Virtual Reality-Based Evaluation of Surgical Planning and Outcome of
   Monosegmental, Unilateral Cervical Foraminal Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D reconstruction; Cervical spine; Dorsal approach; Foraminal stenosis;
   Surgical strategy; Ventral approach; Virtual reality
ID NEURAL FORAMINA; SPINE; DISC; RADICULOPATHY; IMAGES; FUSION; MRI; CT
AB BACKGROUND: Foraminal cervical nerve root compression can be caused by lateral disk herniation or osteophyte formation of the vertebrae. Improved diagnosis and evaluation can be achieved using different imaging techniques: radiographs, computed tomography (CT), and magnetic resonance imaging. We retrospectively evaluated the potential influence of a virtual reality (VR) visualization technique on surgery planning and evaluation of postoperative results in patients with monosegmental, unilateral osseous cervical neuroforaminal stenosis.
   METHODS: Seventy-three patients were included. Ventral decompression of the neuroforamen was performed in 41 patients, dorsal decompression in 32 patients. Patients' files were evaluated. CT scans were visualized via VR software to measure the smallest cross-sectional area of the intervertebral neuroforamen in the lateral resection region. A questionnaire evaluated the influence of VR technique on surgical planning and strategy.
   RESULTS: The VR-technique had a moderate influence on the choice of the approach (ventral or dorsal), a significant influence on the ventral approach strategy, and no influence on the positioning of the patient or the dorsal approach strategy. A significant difference was found in the size of the smallest cross-sectional area of the intervertebral neuroforamen in the lateral resection region between ventral and dorsal approaches, with no correlation to the clinical outcome.
   CONCLUSIONS: Reconstruction of pre- and post-operative 2D-CT images of the cervical spine into 3D images, and the spatial and anatomical reconstructions in VR models, can be helpful in planning surgical approaches and treatment strategies for patients with cervical foraminal stenoses, and for evaluation of their postoperative results.
C1 [Alsofy, Samer Zawy; Fusek, Ivo; Saravia, Heinz Wetzel; Sakellaropoulou, Ioanna; Ewelt, Christian; Fortmann, Thomas] Westfalische Wilhelms Univ Munster, St Barbara Hosp, Acad Hosp, Dept Neurosurg, Hamm, Germany.
   [Stroop, Ralf] Westfalische Wilhelms Univ Munster, St Barbara Hosp, Acad Hosp, Dept Stereotact Neurosurg, Hamm, Germany.
   [Yavuz, Murat] Univ Hosp Munster, Dept Neurosurg, Munster, Germany.
   [Nakamura, Makoto] Witten Herdecke Univ, Acad Hosp Cologne Merheim, Dept Neurosurg, Cologne, Germany.
RP Alsofy, SZ (reprint author), Westfalische Wilhelms Univ Munster, St Barbara Hosp, Acad Hosp, Dept Neurosurg, Hamm, Germany.
EM SZawyAlsofy@barbaraklinik.de
CR An HS, 1999, SEMIN SPINE SURG, V11, P184
   Broekema AEH, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012829
   Burtscher J, 1998, Comput Aided Surg, V3, P27, DOI 10.1002/(SICI)1097-0150(1998)3:1<27::AID-IGS4>3.3.CO;2-H
   Bydon M, 2014, J NEUROSURG-SPINE, V21, P727, DOI 10.3171/2014.7.SPINE131110
   Cho Tack Geun, 2014, Korean J Spine, V11, P1, DOI 10.14245/kjs.2014.11.1.1
   de Ribaupierre S, 2017, HEALTHC TECHNOL LETT, V4, P151, DOI 10.1049/htl.2017.0077
   EHRICKE HH, 1990, J COMPUT ASSIST TOMO, V14, P846, DOI 10.1097/00004728-199009000-00041
   Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001
   Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521
   FRYKHOLM R, 1951, ACTA CHIR SCAND, V102, P10
   HOUSER OW, 1993, J NEUROSURG, V79, P84, DOI 10.3171/jns.1993.79.1.0084
   Jeon Hyo-Cheol, 2015, Chonnam Med J, V51, P129, DOI 10.4068/cmj.2015.51.3.129
   Kaiser JA, 1998, SPINE, V23, P2701, DOI 10.1097/00007632-199812150-00009
   Kamogawa J, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0898-6
   Kim CH, 2015, EUR SPINE J, V24, P3005, DOI 10.1007/s00586-015-4198-1
   Konakondla S, 2017, ADV MED EDUC PRACT, V8, P465, DOI 10.2147/AMEP.S113565
   Mark G, 2017, P 2017 CHI C HUM FAC
   MODIC MT, 1986, RADIOLOGY, V161, P753, DOI 10.1148/radiology.161.3.3786728
   Nakamura S, 2017, ASIAN SPINE J, V11, P968, DOI 10.4184/asj.2017.11.6.968
   ODOM GL, 1958, JAMA-J AM MED ASSOC, V166, P23, DOI 10.1001/jama.1958.02990010025006
   Ong Chin Siang, 2018, J Vasc Interv Neurol, V10, P17
   Oshina M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34458-9
   PECH P, 1985, RADIOLOGY, V155, P143, DOI 10.1148/radiology.155.1.3975392
   Schell A, 2017, GLOB SPINE J, V7, P266, DOI 10.1177/2192568217699190
   Shim JH, 2009, EUR SPINE J, V18, P1109, DOI 10.1007/s00586-009-0932-x
   Singrakhia Manoj Dayalal, 2018, Asian J Neurosurg, V13, P1118, DOI 10.4103/ajns.AJNS_14_17
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   Sohn HM, 2004, J KOREAN MED SCI, V19, P101, DOI 10.3346/jkms.2004.19.1.101
   Tanaka N, 2000, SPINE, V25, P286, DOI 10.1097/00007632-200002010-00005
   Tschugg A, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-437
   YOUSEM DM, 1991, AM J NEURORADIOL, V12, P229
NR 31
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E857
EP E865
DI 10.1016/j.wneu.2019.06.057
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900108
PM 31300351
DA 2020-05-12
ER

PT J
AU Apra, C
   Enachescu, C
   Lapras, V
   Raverot, G
   Jouanneau, E
AF Apra, Caroline
   Enachescu, Ciprian
   Lapras, Veronique
   Raverot, Gerald
   Jouanneau, Emmanuel
TI Is Gross Total Resection Reasonable in Adults with Craniopharyngiomas
   with Hypothalamic Involvement?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Body mass index; Endoscopic endonasal surgery; Hypothalamus; Pituitary;
   Subtotal resection
ID OUTCOMES
AB OBJECTIVE: The treatment of hypothalamus-invading craniopharyngiomas, based on pediatric experience, is subtotal resection (STR) with radiotherapy. This strategy sometimes leads to uncontrollable tumor progression. In adults, with the use of endoscopic endonasal surgery (EES), does removing the hypothalamic part of the tumor-whenever possible-compromise the outcome of the patients?
   METHODS: We included adults with craniopharyngioma treated by a first EES in 2008-2016 by senior neurosurgeon (E.J.). Endocrine, ophthalmologic, and hypothalamic data were retrospectively collected, including body mass index (BMI), cognitive and social status, with a systematic follow-up interview. Magnetic resonance imaging scans were graded according to Puget classification: 0, no hypothalamic involvement; 1, hypothalamic displacement; and 2, hypothalamic involvement. Grade 2 tumors were separated into gross total resection (GTR) or STR.
   RESULTS: We included 22 patients aged 18-79 years. Presenting symptoms were visual (14, 64%), endocrine dysfunction (10, 45%), BMI >30 (8, 36%), and cognitive/ psychiatric impairment (9, 41%). Fourteen (64%) were grade 2 craniopharyngiomas. GTR was performed in 14 (64%) patients. Postoperatively, 12/14 (86%) cases improved visually, and 20 (91%) needed hormone replacement therapy. There was no difference in BMI evolution in the GTR versus STR group, cognitive status was stable or improved in all patients except 1;4/8 patients with STR experienced progression needing adjuvant treatment versus no patient with GTR.
   CONCLUSIONS: EES GTR of grade 2 craniopharyngiomas does not cause major hypothalamic worsening, in contrast with children operated by cranial approaches. The surgeon's experience is key in deciding when to stop the dissection. Offering GTR whenever possible aims at avoiding tumor progression and radiotherapy.
C1 [Apra, Caroline; Jouanneau, Emmanuel] Hosp Civils Lyon, Skull Base & Pituitary Surg Dept, Neurol Hosp Pierre Wertheimer, Lyon, France.
   [Apra, Caroline] Sorbonne Univ, Univ Pierre & Marie Curie, Paris, France.
   [Apra, Caroline] Brain & Spine Inst, CNRS UMR7225, Inserm U1127, Paris, France.
   [Enachescu, Ciprian] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Radiotherapy Dept, Lyon, France.
   [Lapras, Veronique] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Radiol Dept, Lyon, France.
   [Raverot, Gerald] Hosp Civils Lyon, Endocrine Dept, Grp Hosp Est, Lyon, France.
   [Raverot, Gerald; Jouanneau, Emmanuel] Lyon 1 Univ, Canc Ctr Lyon, CNRS UMR5286, Inserm U1052,Signaling Metab & Tumor Progress, Lyon, France.
   [Raverot, Gerald; Jouanneau, Emmanuel] Univ Lyon, Univ Claude Bernard, Lyon, France.
RP Apra, C (reprint author), Hosp Civils Lyon, Skull Base & Pituitary Surg Dept, Neurol Hosp Pierre Wertheimer, Lyon, France.; Apra, C (reprint author), Sorbonne Univ, Univ Pierre & Marie Curie, Paris, France.; Apra, C (reprint author), Brain & Spine Inst, CNRS UMR7225, Inserm U1127, Paris, France.
EM caroline.apra@neurochirurgie.fr
RI Raverot, Gerald/C-3859-2013
OI Raverot, Gerald/0000-0002-9517-338X; Apra, Caroline/0000-0003-0944-9544
CR Asa SL, 2004, ENCY ENDOCRINE DIS, P678
   De Divitiis E, 2007, NEUROSURGERY, V61, P219, DOI 10.1227/01.neu.0000303220.55393.73
   de Notaris M, 2012, J NEUROSURG, V116, P622, DOI 10.3171/2011.11.JNS111162
   Deopujari CE, 2018, CHILD NERV SYST, V34, P871, DOI 10.1007/s00381-018-3735-8
   Forbes JA, 2019, J NEUROSURG, V131, P1152, DOI 10.3171/2018.5.JNS18198
   Garcia-Navarro V, 2013, WORLD NEUROSURG, V80, P563, DOI 10.1016/j.wneu.2011.08.034
   Holsken A, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0287-6
   Mou JM, 2019, WORLD NEUROSURG, V124, pE424, DOI 10.1016/j.wneu.2018.12.110
   Ordonez-Rubiano EG, 2019, J NEUROSURG, V131, P1163, DOI 10.3171/2018.6.JNS18901
   Prieto R, 2018, WORLD NEUROSURG, V110, pE404, DOI 10.1016/j.wneu.2017.11.012
   Prieto R, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16304
   Puget S, 2007, J NEUROSURG, V106, P3, DOI 10.3171/ped.2007.106.1.3
   Puget Stephanie, 2012, Front Endocrinol (Lausanne), V3, P64, DOI 10.3389/fendo.2012.00064
   Yano S, 2017, WORLD NEUROSURG, V100, P288, DOI 10.1016/j.wneu.2017.01.005
   Zacharia BE, 2012, NEURO-ONCOLOGY, V14, P1070, DOI 10.1093/neuonc/nos142
   Zenonos GA, 2018, J NEUROL SURG PART B, V79, pS241, DOI 10.1055/s-0038-1623522
NR 16
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E803
EP E811
DI 10.1016/j.wneu.2019.06.037
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900101
PM 31203080
DA 2020-05-12
ER

PT J
AU Balcioncini, M
   Campero, A
   Cruz, JCP
   Rocldle, R
   Parraga, R
   Gonzalez, FJS
   Fortte, M
   Lopez, PG
AF Balcioncini, Matias
   Campero, Alvaro
   Perez Cruz, Julio Cesar
   Rocldle, Rodolfo
   Parraga, Richard
   Sanchez Gonzalez, Federico J.
   Fortte, Martin
   Gonzalez Lopez, Pablo
TI Microsurgical Anatomy and Approaches to the Cerebral Central Core
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral central core; Microsurgery; Neurosurgical approaches;
   Neuroanatomy
ID TRANSCALLOSAL APPROACH; INSULA
AB OBJECTIVE: Through a cadaveric study, we divided the cerebral central core (CCC) into different areas and have proposed a corresponding neurosurgical approach for each sector. As a secondary objective, we analyzed the cortical and subcortical microsurgical anatomy of the CCC. The CCC includes the insula, extreme capsule, claustrum, external capsule, lenticular nucleus, internal capsule, caudate nucleus, and thalamus.
   METHODS: Twelve adult human brain hemispheres and one cadaveric head specimen were dissected and studied at the Laboratory of Neuroanatomic Microsurgical of the University of Buenos Aires. Nine cases of CCC neurosurgical pathologies were included in the present study and analyzed. Digital drawings were created of the approaches proposed for each sector of the CCC showing the most relevant surgical details. Photographs of each dissection and measurements obtained were taken.
   RESULTS: We divided the CCC into a medial, intermediate, and lateral sector, with specific subdivisions for the lateral and medial sectors. The lateral projection of the foramen of Monro was found deep to the third short gyri of the insula with the following distances: anterior insular limen margin, 23.95 mm; posterior insular limen margin, 22.92 mm; superior limiting sulcus, 14.99 mm, and inferior limiting sulcus, 13.76 mm. We have proposed the following approaches: an ipsilateral transcallosal approach, a contralateral transcallosal approach, a choroidal transfissure approach, a trans-splenial approach, transparietal access entering the intraparietal sulcus, and trans-sylvian approach. The preoperative imaging studies should be analyzed using our method to select the most accurate and safe approach.
   CONCLUSIONS: We have provided a description of the limits and anatomy of the CCC using brain dissection, an analysis of operated cases, and useful measurements for the neurosurgeon.
C1 [Balcioncini, Matias] San Fernando Hosp, Dept Neurol Surg, Buenos Aires, DF, Argentina.
   [Balcioncini, Matias; Campero, Alvaro] Univ Buenos Aires, Med Sch, Div Anat 2, Lab Neuroanat Microsurg, Buenos Aires, DF, Argentina.
   [Campero, Alvaro] Padilla Hosp, Dept Neurol Surg, San Miguel De Tucuman, Argentina.
   [Perez Cruz, Julio Cesar] Autonomous Natl Univ Mexico, Inst Politecn Nacl Neurosci, Fac Med, Anat Acad,Higher Sch Med, Mexico City, DF, Mexico.
   [Rocldle, Rodolfo] Univ Buenos Aires, Clin Hosp, Neurosurg Div, Skull Base Sect & Neuroanat Lab, Buenos Aires, DF, Argentina.
   [Parraga, Richard] Hosp Univalle, Dept Neurol Surg, Cochabamba Cercado, Bolivia.
   [Parraga, Richard] Inst Neurol Sci, Sao Paulo, Brazil.
   [Sanchez Gonzalez, Federico J.] Univ Buenos Aires, Clin Hosp, Neurosurg Div, Epilespy Surg Sect, Buenos Aires, DF, Argentina.
   [Sanchez Gonzalez, Federico J.] Clin Cuyo, Neurosurg Div, Mendoza, Argentina.
   [Fortte, Martin] Interzonal Specialized Childrens Hosp, Div Neurosurg, Mar Del Plata, Buenos Aires, Argentina.
   [Fortte, Martin] Belgrano Clin, Mar Del Plata, Buenos Aires, Argentina.
   [Fortte, Martin] 25 Mayo Clin, Mar Del Plata, Buenos Aires, Argentina.
   [Gonzalez Lopez, Pablo] Hosp Gen Alicante, Dept Neurosurg, Alicante, Spain.
RP Balcioncini, M (reprint author), San Fernando Hosp, Dept Neurol Surg, Buenos Aires, DF, Argentina.; Balcioncini, M (reprint author), Univ Buenos Aires, Med Sch, Div Anat 2, Lab Neuroanat Microsurg, Buenos Aires, DF, Argentina.
EM drbaldoncinimatias@gmail.com
OI Baldoncini, Matias/0000-0001-9323-8306
CR Baldoncini M, 2018, REV ARGENT NEUROCIR, V32, P1
   BRODAL A, 1981, NEUROLOGICAL ANATOMY
   Campero A, 2013, ABORDAJES NEUROQUIRU
   Duvernoy H. M., 1999, THE HUMAN BRAIN
   Ehni G, 1978, NEUROSURGERY, V3, P343
   Federative Committee on Anatomical Terminology, 1998, TERM AN INT AN TERM
   Garcia Navarro V, 2015, ESTRATEGIAS ABORDAJE
   Kasowski H, 2001, Neurosurg Focus, V10, pE3
   Koutsarnakis C, 2016, J NEUROSURG, V124, P450, DOI 10.3171/2015.3.JNS142680
   Lawton MT, 1996, NEUROSURGERY, V39, P729, DOI 10.1097/00006123-199610000-00016
   Ludwig E., 1956, ATLAS CEREBRI HUMANI
   Naidich TP, 2004, AM J NEURORADIOL, V25, P222
   NEHLS DG, 1985, J NEUROSURG, V62, P304, DOI 10.3171/jns.1985.62.2.0304
   Nieuenhuys R, 2008, HUMAN CENTRAL NERVOU
   Nieuwenhuys R, 2008, HUMAN CENTRAL NERVOU
   Ono M, 2017, ATLAS CEREBRAL SULCI
   Potts MB, 2012, NEUROSURGERY, V70, P824, DOI 10.1227/NEU.0b013e318236760d
   Rangel-Castilla L, 2015, J NEUROSURG, V123, P676, DOI 10.3171/2014.11.JNS14381
   Refojos M, 2003, PREPARACION ANATOMIC
   Rhoton AL, 2002, NEUROSURGERY, V51, pS375, DOI 10.1227/01.NEU.0000028833.01529.E7
   Ribas EC, 2018, J NEUROSURG, V129, P752, DOI 10.3171/2017.5.JNS162897
   Ribas GC, 2007, ARQ NEURO-PSIQUIAT, V65, P92, DOI 10.1590/S0004-282X2007000100020
   Ribas GC, 2007, REV BRAS PSIQUIATR, V29, P63, DOI 10.1590/S1516-44462007000100017
   Ribas GC, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.11.FOCUS09245
   Rubino P, 2012, REV ARGENTINA ANATOM, V3, P97
   Sanai N, 2010, J NEUROSURG, V112, P1, DOI 10.3171/2009.6.JNS0952
   Stein BM, 1977, CURRENT TECHNIQUES O, P247
   Tanriover N, 2004, J NEUROSURG, V100, P891, DOI 10.3171/jns.2004.100.5.0891
   Terminologia Anatomica Internacional, 2001, COM FED TERM AN
   Testut L, 1988, TRATADO ANATOMIA HUM
   Ture U, 1999, J NEUROSURG, V90, P720, DOI 10.3171/jns.1999.90.4.0720
   Ture U, 2000, NEUROSURGERY, V47, P417, DOI 10.1097/00006123-200008000-00028
   Ture U, 2000, J NEUROSURG, V92, P676, DOI 10.3171/jns.2000.92.4.0676
   Wen HT, 1998, NEUROSURGERY, V42, P1205, DOI 10.1097/00006123-199806000-00001
   Yasargil GM, 2002, CONT NEUROSURG, V24, P1, DOI [10.1097/00029679-200206010-00001, DOI 10.1097/00029679-200206150-00001]
   Yasargil M Gazi, 2005, Neurosurg Focus, V18, pE1
   Yasargil MG, 1996, MICRONEUROSURGERY B, VIV, P54
NR 37
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E23
EP E34
DI 10.1016/j.wneu.2019.04.139
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900005
PM 31103755
DA 2020-05-12
ER

PT J
AU Beuriat, PA
   Lohkamp, LN
   Szathmari, A
   Rousselle, C
   Sabatier, I
   Di Rocco, F
   Mottolese, C
AF Beuriat, Pierre-Aurelien
   Lohkamp, Laura-Nanna
   Szathmari, Alexandru
   Rousselle, Christophe
   Sabatier, Isabelle
   Di Rocco, Federico
   Mottolese, Carmine
TI Repair of Cranial Bone Defects in Children Using Synthetic
   Hydroxyapatite Cranioplasty (CustomBone)
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone defect; Cranial implant; Cranioplasty; Pediatric neurosurgery;
   Reconstructive surgery; Synthetic hydroxyapatite
ID DECOMPRESSIVE CRANIECTOMY; CEMENT; FLAP; RECONSTRUCTION; IMPLANTS;
   EXPERIENCE
AB BACKGROUND: In pediatric cases, the use of autologous bone tissue to repair cranial bone defects is often impossible. The synthetic hydroxyapatite bone substitute (CustomBone) can be a good alternative, especially in case of a large bone defect that has to be repaired.
   METHODS: This study focuses on a pediatric series of 30 children who underwent cranioplasty with a CustomBone implant. Patient age ranged from 8 months to 16 years, with a mean age of 7 years and 8 months. The most common indication for cranioplasty was posttraumatic decompressive craniectomy.
   RESULTS: No complications were reported. Cosmetic results were satisfactory in every patient. Only 1 implant had to be changed after severe head trauma because of an epileptic seizure in the early postoperative period. In all patients, cerebral blood flow improved during the postoperative phase. Complete implant osteointegration is a long process because mean time to begin was 13 months (range, 3-22 months). Mean patient follow-up was 6.7 years. Successful prosthesis integration depends on the accuracy of the preoperative model. The minimum thickness of the implant (4 mm) represents a challenge in very young children, but we used it with success in this series. Moreover, high costs represent another limitation for its use.
   CONCLUSIONS: The CustomBone implant meets all necessary conditions for good clinical outcome: excellent protective properties, restoration of normal intracranial physiology, satisfactory cosmetic results, good integration in the autologous bone, and good resistance in case of trauma.
C1 [Beuriat, Pierre-Aurelien; Lohkamp, Laura-Nanna; Szathmari, Alexandru; Rousselle, Christophe; Sabatier, Isabelle; Di Rocco, Federico; Mottolese, Carmine] Hop Femme Mere Enfant, Dept Pediat Neurosurg, Lyon, France.
   [Rousselle, Christophe; Sabatier, Isabelle] Hop Femme Mere Enfant, Dept Pediat Neurol, Lyon, France.
RP Mottolese, C (reprint author), Hop Femme Mere Enfant, Dept Pediat Neurosurg, Lyon, France.
EM carmine.mottolese@chu-lyon.fr
OI Di Rocco, Federico/0000-0003-2145-5533
CR ABBOTT KH, 1953, J NEUROSURG, V10, P380, DOI 10.3171/jns.1953.10.4.0380
   Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2
   Beuriat PA, 2015, REV STOMATOL CHIR, V116, P239, DOI 10.1016/j.revsto.2015.06.006
   Bowers CA, 2013, J NEUROSURG-PEDIATR, V11, P526, DOI 10.3171/2013.1.PEDS12483
   Boyde A, 1999, BONE, V24, P579, DOI 10.1016/S8756-3282(99)00083-6
   Burstein FD, 1999, PLAST RECONSTR SURG, V104, P1270, DOI 10.1097/00006534-199910000-00005
   Cocchi R, 1999, BIOCERAMICS, V12, P57
   Constantino P, 1991, ARCH OTOLARYNGOL, V123, P319
   Costantino PD, 2000, OTOLARYNG HEAD NECK, V123, P409, DOI 10.1067/mhn.2000.107679
   Donati L, 1997, INT SURG, V82, P325
   Durand J L, 1997, Ann Chir Plast Esthet, V42, P75
   Durham SR, 2003, NEUROSURGERY, V52, P842, DOI 10.1227/01.NEU.0000054220.01290.8E
   Eppley BL, 2003, J CRANIOFAC SURG, V14, P209, DOI 10.1097/00001665-200303000-00014
   FABBRI M, 1995, BIOMATERIALS, V16, P225, DOI 10.1016/0142-9612(95)92121-L
   Frassanito P, 2015, ACTA NEUROCHIR, V157, P115, DOI 10.1007/s00701-014-2254-y
   Geib F., 1941, JAMA-J AM MED ASSOC, V117, P8
   Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163
   Hardy H, 2012, NEUROCHIRURGIE, V58, P25, DOI 10.1016/j.neuchi.2011.09.006
   Klieverik VM, 2019, CHILD NERV SYST, V35, P1481, DOI 10.1007/s00381-018-4025-1
   KREUZ FP, 1951, J BONE JOINT SURG AM, V33-A, P863, DOI 10.2106/00004623-195133040-00005
   Lam S, 2015, CRANIOMAX TRAUM REC, V8, P159, DOI 10.1055/s-0034-1395880
   Lemee JM, 2013, NEUROCHIRURGIE, V59, P60, DOI 10.1016/j.neuchi.2012.10.138
   Marcacci M, 1999, CALCIFIED TISSUE INT, V64, P83, DOI 10.1007/s002239900583
   Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701-014-2021-0
   MATUKAS VJ, 1988, J NEUROSURG, V69, P514, DOI 10.3171/jns.1988.69.4.0514
   Messina G, 2011, ACTA NEUROCHIR, V153, P1717, DOI 10.1007/s00701-011-1014-5
   ODOM GL, 1952, J NEUROSURG, V9, P606, DOI 10.3171/jns.1952.9.6.0606
   RAWLINGS CE, 1993, NEUROSURGERY, V33, P935
   Rocque BG, 2013, J NEUROSURG-PEDIATR, V12, P120, DOI 10.3171/2013.4.PEDS12605
   Shah AM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13561
   Staffa G, 2012, J CRANIO MAXILL SURG, V40, pE65, DOI 10.1016/j.jcms.2011.04.014
   Stefini Roberto, 2013, Surg Neurol Int, V4, P12, DOI 10.4103/2152-7806.106290
   Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245
   Venable CS, 1937, ANN SURG, V105, P917, DOI 10.1097/00000658-193706000-00006
   Wegeforth P, 1919, ANN SURG, V69, P384, DOI 10.1097/00000658-191904000-00005
   Wen L, 2015, BRAIN INJURY, V29, P1654, DOI 10.3109/02699052.2015.1075248
   Wiltfang J, 2004, J ORAL MAXIL SURG, V62, P29, DOI 10.1016/j.joms.2003.02.002
   Woolf JI, 1945, INT ABSTR SURG, V81, P1
   Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166
NR 39
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E104
EP E113
DI 10.1016/j.wneu.2019.05.052
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900015
PM 31100525
DA 2020-05-12
ER

PT J
AU Breun, M
   Nickl, R
   Perez, J
   Hagen, R
   Lohr, M
   Vince, G
   Trautner, H
   Ernestus, RI
   Matthies, C
AF Breun, Maria
   Nickl, Robert
   Perez, Jose
   Hagen, Rudolf
   Loehr, Mario
   Vince, Giles
   Trautner, Herbert
   Ernestus, Ralf-Ingo
   Matthies, Cordula
TI Vestibular Schwannoma Resection in a Consecutive Series of 502 Cases via
   the Retrosigmoid Approach: Technical Aspects, Complications, and
   Functional Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acoustic neuromas/acoustic neurinomas/vestibular schwannomas;
   Complications; Functional outcome; Morbidity; Retrosigmoid approach;
   Semi-sitting position; Surgery; Technique
ID VENOUS AIR-EMBOLISM; GAMMA-KNIFE SURGERY; FACIAL-NERVE FUNCTION;
   ACOUSTIC NEUROMAS; SITTING POSITION; STEREOTACTIC RADIOSURGERY;
   FRACTIONATED RADIOTHERAPY; CEREBELLOPONTINE ANGLE; HEARING PRESERVATION;
   MANAGEMENT
AB OBJECTIVE: Outcome in vestibular schwannoma (VS) surgery has improved enormously over the last decades. Surgical positioning remains a matter of discussion. A standardized protocol for diagnostics and management has been applied and evaluated for complications and functional outcome.
   METHODS: We examined 502 VS tumors in 483 patients (227 men and 256 women) between 2005 and 2016. According to our patient selection and treatment algorithm, 488 operations (97%) were performed in the semi-sitting position, and 14 (3%) were in the supine position. Auditory and facial functions were analyzed before and after surgery as were perioperative complications.
   RESULTS: There were 182 patients (36%) with small tumors (Hannover classification T1-T3A) and 320 (64%) large tumors (T3B or T4). Of the patients, 14% were neurofibromatosis type 2 cases. Complete tumor resection was achieved in 96.4%. Hearing preservation occurred in 44% of patients with small tumors and 23% of those with large tumors (Hannover classification), and correlated significantly with tumor size (P < 0.001). Facial palsy (House Brackmann grades II-VI) was present in 63 patients before and in 185 patients after surgery. Useful facial function (House Brackmann grades I-III) early after surgery was maintained in 86% of patients with small tumors and in 77% of patients with large tumors. Intraoperative complications included air embolism in 45 cases (9%), sinus injury in 3 cases, cerebrospinal fluid leakage in 46 cases (9%), and local hemorrhage in 19 cases (4%). Surgical revision was indicated in 31 cases (6%).
   CONCLUSIONS: In a standardized setting, the semi-sitting position allowed a safe approach. This setting offers the advantage of bimanual tumor nerve handling by the surgeon and an optimal visualization of important functional structures.
C1 [Breun, Maria; Nickl, Robert; Perez, Jose; Loehr, Mario; Vince, Giles; Ernestus, Ralf-Ingo; Matthies, Cordula] Univ Hosp Wurzburg, Dept Neurosurg, Wurzburg, Germany.
   [Hagen, Rudolf] Univ Hosp Wurzburg, Dept Otolaryngol, Wurzburg, Germany.
   [Trautner, Herbert] Univ Hosp Wurzburg, Dept Anesthesiol, Wurzburg, Germany.
RP Breun, M (reprint author), Univ Hosp Wurzburg, Dept Neurosurg, Wurzburg, Germany.
EM Breun_M@ukw.de
RI Nickl, Robert/AAE-6948-2019; Breun, Maria/AAE-6927-2019; Matthies,
   Cordula/AAE-5708-2019; Lohr, Mario/AAD-4542-2019
OI Breun, Maria/0000-0001-7548-9451; 
CR Ruiz MAA, 2016, ACTA OTORRINOLAR ESP, V67, P201, DOI 10.1016/j.otorri.2015.09.003
   Betka J, 2014, BIOMED RES INT, DOI 10.1155/2014/315952
   BLACK S, 1988, ANESTHESIOLOGY, V69, P49, DOI 10.1097/00000542-198807000-00008
   Brokinkel B, 2014, J CLIN NEUROSCI, V21, P2077, DOI 10.1016/j.jocn.2014.03.037
   Browne JD, 2008, NEUROSURG CLIN N AM, V19, P265, DOI 10.1016/j.nec.2008.02.008
   Cole T, 2015, CUREUS, V7, DOI 10.7759/cureus.369
   Combs SE, 2015, RADIOTHER ONCOL, V114, P378, DOI 10.1016/j.radonc.2015.01.011
   Duke DA, 1998, NEUROSURGERY, V42, P1282, DOI 10.1097/00006123-199806000-00047
   Feigl GC, 2014, WORLD NEUROSURG, V81, P159, DOI 10.1016/j.wneu.2013.01.003
   GARDNER G, 1988, ANN OTO RHINOL LARYN, V97, P55, DOI 10.1177/000348948809700110
   Golfinos JG, 2016, J NEUROSURG, V125, P1472, DOI 10.3171/2015.12.JNS151857
   Gracia I, 2014, CURR OPIN ANESTHESIO, V27, P474, DOI 10.1097/ACO.0000000000000104
   Henzel M, 2009, STRAHLENTHER ONKOL, V185, P567, DOI 10.1007/s00066-009-1959-y
   Huang X, 2017, WORLD NEUROSURG, V99, P326, DOI 10.1016/j.wneu.2016.12.055
   Jadik S, 2009, NEUROSURGERY, V64, P533, DOI 10.1227/01.NEU.0000338432.55235.D3
   Kessel KA, 2017, STRAHLENTHER ONKOL, V193, P192, DOI 10.1007/s00066-016-1070-0
   Kopp C, 2011, INT J RADIAT ONCOL, V80, P1485, DOI 10.1016/j.ijrobp.2010.04.057
   Leslie K, 2006, J CLIN NEUROSCI, V13, P419, DOI 10.1016/j.jocn.2005.08.007
   Mahboubi H, 2015, OTOLARYNG HEAD NECK, V153, P822, DOI 10.1177/0194599815573223
   Malis LI, 2001, NEUROSURGERY, V49, P337, DOI 10.1097/00006123-200108000-00015
   Martin TPC, 2009, OTOL NEUROTOL, V30, P381, DOI 10.1097/MAO.0b013e31819a8df6
   Matthies C, 1997, NEUROSURGERY, V40, P1
   Matthies C, 2011, CLIN NEUROL NEUROSUR, V113, P872, DOI 10.1016/j.clineuro.2011.06.011
   McCutcheon BA, 2016, WORLD NEUROSURG, V89, P101, DOI 10.1016/j.wneu.2016.01.089
   MONSELL EM, 1995, OTOLARYNG HEAD NECK, V113, P179
   Muacevic A, 2004, ACT NEUR S, V91, P75
   Nonaka Y, 2013, NEUROSURGERY, V72, P103, DOI 10.1227/NEU.0b013e3182752b05
   PAPADOPOULOS G, 1994, ACTA NEUROCHIR, V126, P140, DOI 10.1007/BF01476424
   Porter JM, 1999, BRIT J ANAESTH, V82, P117
   Regis J, 2010, J NEUROSURG, V113, P105, DOI 10.3171/2010.8.GKS101058
   Roessler K, 2016, WORLD NEUROSURG, V87, P290, DOI 10.1016/j.wneu.2015.11.089
   Rowe JG, 2003, J NEUROL NEUROSUR PS, V74, P1536, DOI 10.1136/jnnp.74.11.1536
   Saladino A, 2017, J NEUROSURG, V127, P867, DOI 10.3171/2016.8.JNS16719
   Samii M, 1997, NEUROSURGERY, V40, P696, DOI 10.1097/00006123-199704000-00007
   Samii M, 2008, Prog Neurol Surg, V21, P169, DOI 10.1159/000156905
   Samii M, 1997, NEUROSURGERY, V40, P684, DOI 10.1097/00006123-199704000-00006
   Samii M, 1997, NEUROSURGERY, V40, P11, DOI 10.1097/00006123-199701000-00002
   Samii M, 1997, NEUROSURGERY, V40, P248, DOI 10.1097/00006123-199702000-00005
   Samii M, 2006, J NEUROSURG, V105, P527, DOI 10.3171/jns.2006.105.4.527
   Samii M, 2010, J NEUROSURG, V112, P860, DOI 10.3171/2009.7.JNS0989
   Sampath P, 2004, YOUMANS NEUROLOGICAL, P1147
   Scheich M, 2013, LARYNGO RHINO OTOL, V92, P823, DOI 10.1055/s-0033-1354379
   Spektor S, 2015, J CLIN NEUROSCI, V22, P705, DOI 10.1016/j.jocn.2014.12.005
   Sughrue ME, 2011, J NEUROSURG, V114, P381, DOI 10.3171/2010.4.JNS091962
   Tatagiba M, 2008, SAMIIS ESSENTIALS NE, P175
   Tatagiba M, 2014, ACTA NEUROCHIR, V156, P421, DOI 10.1007/s00701-013-1915-6
   Tonn JC, 2000, J NEUROL NEUROSUR PS, V69, P161, DOI 10.1136/jnnp.69.2.161
   Tonn JC, 2004, ACT NEUR S, V91, P103
   van Eck ATCJ, 2005, J NEUROSURG, V102, P204, DOI 10.3171/jns.2005.102.s_supplement.0204
   Wowra B, 2013, J NEUROSURG, V119, P77
NR 50
TC 1
Z9 1
U1 4
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E114
EP E127
DI 10.1016/j.wneu.2019.05.056
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900016
PM 31100515
DA 2020-05-12
ER

PT J
AU Chang, HS
   Baba, T
   Matsumae, M
AF Chang, Han Soo
   Baba, Tanefumi
   Matsumae, Mitsunori
TI Radical Intracapsular Dissection Technique for Dumbbell-Shaped Spinal
   Schwannoma with Intradural and Extradural Components
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dumbbell shaped; Spinal schwannoma; Subcapsular removal; Surgical
   technique
ID SURGICAL-MANAGEMENT; TUMORS; NERVE; OUTCOMES; SERIES; ENUCLEATION;
   RESECTION
AB BACKGROUND: Dumbbell-shaped spinal schwannomas with intradural and extradural components are associated with higher complication rates. This may be in part due to epineurial dissection of the extradural component, which inevitably damages the functioning nerve fibers beneath the epineurium and may lead to dural defects that are often difficult to repair.
   OBJECTIVE: The objective was to describe a radical intracapsular dissection technique that provides a simpler operative field with no need for dural repair and a better chance of preserving functioning nerve fibers.
   METHODS: The technique comprised the following: 1) exposure of the tumor while preserving spinal stability; 2) a single incision encompassing the dura and epineurium; 3) microsurgical dissection of the tumor just beneath the epineurium, preserving the viable nerve fibers; and 4) primary closure of the duroepineurial incision. We describe a case series of 7 patients in whom this type of tumor was excised using this technique.
   RESULTS: Gross total excision was achieved in 5 patients. In 1 patient with a large paravertebral component, the remaining tumor was removed with an additional anterior approach. No cerebrospinal fluid leak was noted, and no recurrence was observed in the median follow-up period of 36 months.
   CONCLUSIONS: The radical intracapsular dissection technique described herein represents an alternative technique for the removal of dumbbell-shaped spinal schwannomas with intradural and extradural components.
C1 [Chang, Han Soo; Baba, Tanefumi; Matsumae, Mitsunori] Tokai Univ, Dept Neurosurg, Isehara, Kanagawa, Japan.
RP Chang, HS (reprint author), Tokai Univ, Dept Neurosurg, Isehara, Kanagawa, Japan.
EM chang-ind@umin.ac.jp
CR Asazuma T, 2004, SPINE, V29, pE10, DOI 10.1097/01.BRS.0000103662.13689.76
   Bakkouri Wissame El, 2009, J Neurosurg, V110, P662, DOI 10.3171/2007.5.16836
   Carpenter MB, 1983, HUMAN NEUROANATOMY, P85
   Chang HS, 2017, WORLD NEUROSURG, V105, P755, DOI 10.1016/j.wneu.2017.06.085
   Date R, 2012, ACTA NEUROCHIR, V154, P173, DOI 10.1007/s00701-011-1213-0
   Eden K, 1941, BRIT J SURG, V28, P549, DOI 10.1002/bjs.18002811205
   Hooper J, 2017, ORTHOPEDICS, V40, pE1036, DOI 10.3928/01477447-20170925-05
   Illuminati G, 2016, INT J SURG, V29, P74, DOI 10.1016/j.ijsu.2016.03.020
   Klekamp J, 1998, NEUROSURGERY, V42, P279, DOI 10.1097/00006123-199802000-00042
   Lot G, 1997, NEUROSURGERY, V41, P813, DOI 10.1097/00006123-199710000-00010
   McCormick PC, 2014, NEUROSURG FOCUS, V37
   McCormick PC, 1996, NEUROSURGERY, V38, P294, DOI 10.1097/00006123-199602000-00012
   Netterville JL, 2015, CURR OPIN OTOLARYNGO, V23, P176, DOI 10.1097/MOO.0000000000000147
   Ozawa H, 2007, J NEUROSURG-SPINE, V7, P587, DOI 10.3171/SPI-07/12/587
   Safaee MM, 2017, J NEUROSURG-SPINE, V26, P103, DOI 10.3171/2016.5.SPINE15974
   Salcman M., 2004, KEMPES OPERATIVE NEU, V2, P149
   Sowash M, 2017, J NEUROSURG-SPINE, V26, P494, DOI 10.3171/2016.9.SPINE16778
   Stone JJ, 2018, WORLD NEUROSURG, V119, pE986, DOI 10.1016/j.wneu.2018.08.022
   Zheng ZW, 2016, J CRANIO MAXILL SURG, V44, P1963, DOI 10.1016/j.jcms.2016.09.012
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E634
EP E640
DI 10.1016/j.wneu.2019.05.232
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900080
PM 31158529
DA 2020-05-12
ER

PT J
AU Chang, KW
   Noh, SH
   Park, JM
   Cho, YE
   Chin, DK
AF Chang, Kyung Won
   Noh, Sung Hyun
   Park, Jeong-Moon
   Cho, Yong-Eun
   Chin, Dong-Kyu
TI Retrospective Study on Accuracy of Intraoperative Frozen Section Biopsy
   in Spinal Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Astrocytoma; Ependymoma; Frozen biopsy; Intramedullary tumor; Spinal
   cord; Spinal tumor
ID DIAGNOSIS; MANAGEMENT; RESECTION; OUTCOMES
AB OBJECTIVE: Histologic types and grades are critical in the diagnosis and treatment of spinal tumors. Intraoperative frozen section is a fast and easy method in confirming pathologic diagnosis during the operation. This study was undertaken to reveal the accuracy of intra-operative frozen section biopsy in order to make proper treatment plans.
   METHODS: This retrospective study concerned patients who underwent spinal tumor surgeries from 1 January, 2012 to 31 December, 2016. Frozen section biopsy and permanent biopsy were compared, and cases that had differences were counted.
   RESULTS: Thirty-seven cases out of 324 patients had discrepancies (11.4%). In discrepant cases 11 cases were ependymoma (29.7%) and 6 cases were schwannoma (16.2%). Among 34 patients who were finally diagnosed with an ependymoma, 11 cases had discrepancies, which was the highest mismatch rate among tumor final pathologic types. By frozen biopsy, astrocytoma (n=5) and ependymoma (n=5) turned out to be the most discrepant pathologic types and 16 frozen section biopsy cases were "null." Frozen biopsy astrocytoma (n=5) mostly turned out to be ependymoma in 4 cases.
   CONCLUSIONS: Pathologic findings from frozen biopsy for spinal cord tumors could not be corresponded to final diagnosis, especially when the results of frozen biopsy were ependymoma or astrocytoma. Therefore careful decision making for treatment plans is required.
C1 [Chang, Kyung Won; Noh, Sung Hyun; Park, Jeong-Moon; Cho, Yong-Eun; Chin, Dong-Kyu] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Spine & Spinal Cord Inst,Dept Neurosurg, Seoul, South Korea.
RP Chin, DK (reprint author), Yonsei Univ, Coll Med, Gangnam Severance Hosp, Spine & Spinal Cord Inst,Dept Neurosurg, Seoul, South Korea.
EM dkc001@yahoo.com
CR Ahmed R, 2016, J NEUROSURG-PEDIATR, V18, P594, DOI 10.3171/2016.5.PEDS15356
   Amraei Razie, 2017, Asian Pac J Cancer Prev, V18, P659
   Beall DP, 2007, CURR PROBL DIAGN RAD, V36, P185, DOI 10.1067/j.cpradiol.2006.12.002
   Bellut D, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15163
   Choi SK, 2016, BRAIN TUMOR PATHOL, V33, P19, DOI 10.1007/s10014-015-0237-1
   Garces-Ambrossi GL, 2009, J NEUROSURG-SPINE, V11, P591, DOI 10.3171/2009.4.SPINE08159
   Jaafar H, 2006, MALAYS J MED SCI, V13, P4
   Kobayashi K, 2018, CLIN NEUROL NEUROSUR, V167, P117, DOI 10.1016/j.clineuro.2018.02.025
   Mitra S, 2010, J CYTOL, V27, P81, DOI 10.4103/0970-9371.71870
   Quinlivan JA, 2001, BRIT J OBSTET GYNAEC, V108, P798, DOI 10.1111/j.1471-0528.2001.00196.x
   Roonprapunt C, 2006, NEUROSURG CLIN N AM, V17, P29, DOI 10.1016/j.nec.2005.10.006
   Roychoudhury S, 2017, DIAGN CYTOPATHOL, V45, P789, DOI 10.1002/dc.23765
   Ryu SJ, 2016, EUR SPINE J, V25, P4067, DOI 10.1007/s00586-016-4475-7
   Samuel N, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16147
   Tihan T, 2006, NEUROSURG CLIN N AM, V17, P7, DOI 10.1016/j.nec.2005.11.002
   Van Goethem JWM, 2004, EUR J RADIOL, V50, P159, DOI 10.1016/j.ejrad.2003.10.021
   Viereck MJ, 2016, J NEUROSURG-SPINE, V25, P640, DOI 10.3171/2016.4.SPINE151149
NR 17
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E152
EP E157
DI 10.1016/j.wneu.2019.05.080
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900020
PM 31108252
DA 2020-05-12
ER

PT J
AU Chiarullo, M
   Mura, J
   Rubino, P
   Rabelo, NN
   Martinez-Perez, R
   Figueiredo, EG
   Rhoton, A
AF Chiarullo, Marcos
   Mura, Jorge
   Rubino, Pablo
   Rabelo, Nicollas Nunes
   Martinez-Perez, Rafael
   Figueiredo, Eberval Gadelha
   Rhoton, Albert
TI Y Technical Description of Minimally Invasive Extradural Anterior
   Clinoidectomy and Optic Nerve Decompression. Study of Feasibility and
   Proof of Concept
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extradural anterior clinoidectomy; Keyhole approach; Optic canal; Optic
   nerve; Pterional approach
ID TUBERCULUM SELLAE MENINGIOMAS; MINIPTERIONAL CRANIOTOMY;
   SURGICAL-MANAGEMENT; PRESERVATION; EXPERIENCE; RECOVERY; FEATURES;
   OUTCOMES; REMOVAL; ANATOMY
AB BACKGROUND: Several diseases that involve the optic canal or its contained structures may cause visual impairment. Several techniques have been developed to decompress the optic nerve.
   OBJECTIVE: To describe minimally invasive extradural anterior clinoidectomy (MiniEx) for optic nerve decompression, detail its surgical anatomy, present clinical cases, and established a proof of concept.
   METHODS: Anatomic dissections were performed in cadaver heads to show the surgical anatomy and to show stepwise the MiniEx approach. In addition, these surgical concepts were applied to decompress the optic nerve in 6 clinical cases.
   RESULTS: The MiniEx approach allowed the extradural anterior clinoidectomy and a nearly 270 degrees optic nerve decompression using the no-drill technique. In the MiniEx approach, the skin incision, dissection of the temporal muscle, and craniotomy were smaller and provided the same extent of exposure of the optic nerve, anterior clinoid process, and superior orbital fissure as that usually provided by standard techniques. All patients who underwent operation with this technique had improved visual status.
   CONCLUSIONS: The MiniEx approach is an excellent alternative to traditional approaches for extradural anterior clinoidectomy and optic nerve decompression. It may be used as a part of more complex surgery or as a single surgical procedure.
C1 [Chiarullo, Marcos; Rhoton, Albert] Univ Florida, Coll Med, Dept Neurosurg, Gainesville, FL USA.
   [Mura, Jorge] Inst Neurosurg, Cerebrovasc & Skull Base Dept, Santiago, Chile.
   [Mura, Jorge] Univ Chile, Dept Neurol Sci, Santiago, Chile.
   [Chiarullo, Marcos; Rubino, Pablo] El Cruce Hosp, Dept Neurosurg, Buenos Aires, DF, Argentina.
   [Rabelo, Nicollas Nunes; Figueiredo, Eberval Gadelha] Univ Sao Paulo, Dept Neurosurg, Sao Paulo, Brazil.
   [Martinez-Perez, Rafael] Ohio State Univ, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
RP Figueiredo, EG (reprint author), Univ Sao Paulo, Dept Neurosurg, Sao Paulo, Brazil.
EM ebgadelha@yahoo.com
RI Figueiredo, Eberval Gadelha/H-3488-2012
CR Almeida JP, 2018, J NEUROSURG, V128, P1885, DOI 10.3171/2017.3.JNS163110
   Avci E, 2005, MINIM INVAS NEUROSUR, V48, P268, DOI 10.1055/s-2005-915595
   Berhouma M, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14303
   Bulters DO, 2009, ACTA NEUROCHIR, V151, P325, DOI 10.1007/s00701-009-0192-x
   Carlson AP, 2013, J NEUROL SURG PART B, V74, P20, DOI 10.1055/s-0032-1329624
   Chang DJ, 2009, NEUROSURGERY, V64, pS96, DOI 10.1227/01.NEU.0000335172.68267.01
   Chen FH, 2014, N AM J MED SCI, V6, P270, DOI 10.4103/1947-2714.134372
   Cornelius CP, 2014, FACIAL PLAST SURG, V30, P487, DOI 10.1055/s-0034-1394303
   Coscarella E, 2003, NEUROSURGERY, V53, P162, DOI 10.1227/01.NEU.0000068866.22176.07
   DOLENC VV, 1994, ACTA NEUROCHIR, V130, P55, DOI 10.1007/BF01405503
   DOLENC VV, 1985, J NEUROSURG, V62, P667, DOI 10.3171/jns.1985.62.5.0667
   Dolenc VV, 1994, NEUROVASCULAR SURG, P673
   Ellis D, 1999, AN ATLAS OF ORBITOCR
   Figueiredo EG, 2007, NEUROSURGERY, V61, P256, DOI 10.1227/01.neu.0000303978.11752.45
   Figueiredo EG, 2016, J CLIN NEUROSCI, V27, P34, DOI 10.1016/j.jocn.2015.07.032
   Froelich SC, 2007, NEUROSURGERY, V61, P179, DOI 10.1227/01.neu.0000303215.76477.cd
   Fukuda H, 2014, J NEUROL SURG PART B, V75, P125, DOI 10.1055/s-0033-1359302
   Galal A, 2010, ACTA NEUROCHIR, V152, P69, DOI 10.1007/s00701-009-0492-1
   Kim JM, 2000, NEUROSURGERY, V46, P670, DOI 10.1097/00006123-200003000-00029
   Komatsu F, 2011, NEUROSURGERY, V68, P334, DOI 10.1227/NEU.0b013e31821144e5
   Li XG, 2007, J CLIN NEUROSCI, V14, P1150, DOI 10.1016/j.jocn.2006.09.003
   Liu Y, 2019, J CRANIO MAXILL SURG, V47, P328, DOI 10.1016/j.jcms.2018.12.009
   Lubbe D, 2017, CLIN OTOLARYNGOL, V42, P876, DOI 10.1111/coa.12722
   Margalit N, 2013, J NEUROL SURG PART B, V74, P247, DOI 10.1055/s-0033-1342920
   Margalit NS, 2003, NEUROSURGERY, V53, P523, DOI 10.1227/01.NEU.0000079506.75164.F4
   Mathiesen T, 2006, NEUROSURGERY, V59, P570, DOI 10.1227/01.NEU.0000228683.79123.F9
   Moe KS, 2010, NEUROSURGERY, V67, P16, DOI 10.1227/01.NEU.0000373431.08464.43
   Noguchi A, 2005, J NEUROSURG, V102, P945, DOI 10.3171/jns.2005.102.5.0945
   Nozaki K, 2008, NEUROSURGERY, V62, P839, DOI 10.1227/01.neu.0000318169.75095.cb
   Ohta K, 2001, J CLIN NEUROSCI, V8, P26, DOI 10.1054/jocn.2001.0873
   Park CK, 2006, NEUROSURGERY, V59, P238, DOI 10.1227/01.NEU.0000223341.08402.C5
   Perneczky A, 2008, CONCEPT SURG TECHNIQ, V1, P179
   Poblete T, 2015, J NEUROSURG, V122, P1274, DOI 10.3171/2014.10.JNS142061
   Rhoton AL, 2002, NEUROSURGERY, V51, pS121, DOI 10.1227/01.NEU.0000028227.73143.A7
   Rhoton AL, 2002, NEUROSURGERY, V51, pS303, DOI 10.1227/01.NEU.0000028329.38986.47
   Rhoton AL, 2002, NEUROSURGERY, V51, pS335, DOI 10.1227/01.NEU.0000028680.51299.00
   Rhoton AL, 2002, NEUROSURGERY, V51, pS375, DOI 10.1227/01.NEU.0000028833.01529.E7
   Rhoton AL, 2002, NEUROSURGERY, V51, pS273, DOI 10.1227/01.NEU.0000028087.76279.41
   Rigante L, 2015, J NEUROL SURG PART B, V76, P239, DOI 10.1055/s-0034-1543964
   Sade B, 2009, SURG NEUROL, V72, P118, DOI 10.1016/j.surneu.2008.08.007
   Schick U, 2005, J NEUROL NEUROSUR PS, V76, P977, DOI 10.1136/jnnp.2004.039974
   Singh H, 2017, J NEUROSURG, V126, P940, DOI 10.3171/2016.3.JNS1634
   Stahr K, 2019, ORBIT-ABINGDON, V38, P433, DOI 10.1080/01676830.2018.1552709
   Tripathi M, 2015, OPER NEUROSURG, V11, P147, DOI 10.1227/NEU.0000000000000599
   Vaitheeswaran K, 2014, ORBIT, V33, P456, DOI 10.3109/01676830.2014.950282
   Wang XD, 2017, TURK NEUROSURG, V27, P212, DOI 10.5137/1019-5149.JTN.15298-15.1
   Welling LC, 2015, J NEUROSURG, V122, P1012, DOI 10.3171/2014.11.JNS146
   Wen HT, 2001, OPERATIVE TECHNIQUE, V4, P60, DOI DOI 10.1053/OTNS.2001.25567
   Yang Y, 2006, NEUROSURGERY, V59, P253, DOI 10.1227/01.NEU.0000236122.28434.13
   YASARGIL MG, 1987, J NEUROSURG, V67, P463, DOI 10.3171/jns.1987.67.3.0463
   Yasargil MG, 1984, MICRONEUROSURGERY, V1, P215
NR 51
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E502
EP E513
DI 10.1016/j.wneu.2019.05.196
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900064
PM 31152882
DA 2020-05-12
ER

PT J
AU Cho, JY
   Goh, TS
   Son, SM
   Kim, DS
   Lee, JS
AF Cho, Jae Young
   Goh, Tae Sik
   Son, Seung Min
   Kim, Dong Suk
   Lee, Jung Sub
TI Comparison of Anterior Approach and Posterior Approach to Instrumented
   Interbody Fusion for Spondylolisthesis: A Meta-analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior lumbar interbody fusion; Lateral lumbar interbody fusion;
   Posterior lumbar interbody fusion; Spodylolisthesis; Transforaminal
   lumbar interbody fusion
ID PEDICLE SCREW FIXATION; CIRCUMFERENTIAL FUSION; POSTEROLATERAL FUSION;
   OUTCOMES; QUALITY
AB OBJECTIVE: To compare outcomes of instrumented interbody fusion by the anterior approach (anterior lumbar interbody fusion [ALIF] with posterior pedicle screw fixation [PPF] or lateral lumbar interbody fusion [XLIF] with PPF) or the posterior approach (transforaminal lumbar interbody fusion [TLIF] or posterior lumbar interbody fusion [PLIF]) for spondylolisthesis through meta-analysis.
   METHODS: The MEDLINE via PubMed, Cochrane, Scopus, and Embase databases were searched for studies published between January 2010 and January 2019 evaluating outcomes including lumbar lordosis (LL), segmental lordosis (SL), slip rate, disc height (DH), back visual analogue scale (VAS), leg VAS, and Oswestry disability index (ODI) of ALIF with PPF or XLIF with PPF and TLIF or PLIF for spondylolisthesis. Two authors performed the data extraction independently. Any discrepancies were resolved by a consensus.
   RESULTS: Eight comparative studies were identified. There was no significant difference between the anterior approach and the posterior approach for preoperative LL, SL, and DH. In addition, postoperative back and leg VAS, and ODI between the 2 groups were not different. However, the anterior approach was more effective for restoration of postoperative LL, SL, and DH than the posterior approach.
   CONCLUSIONS: A literature review identified 8 comparative studies reporting outcomes of the anterior approach and the posterior approach in instrumented interbody fusion for spondylolisthesis. Despite heterogeneity, a limited meta-analysis showed that the postoperative restoration of LL, SL, and DH was better in the anterior approach group. Further large multicenter studies would be necessary to substantiate our results.
C1 [Cho, Jae Young] Bumin Hosp Haeundae, Dept Orthopaed Surg, Busan, South Korea.
   [Goh, Tae Sik; Kim, Dong Suk; Lee, Jung Sub] Pusan Natl Univ Hosp, Biomed Res Inst, Dept Orthopaed Surg, Busan, South Korea.
   [Son, Seung Min] Pusan Natl Univ, Yangsan Hosp, Dept Orthopaed Surg, Yangsan, South Korea.
RP Lee, JS (reprint author), Pusan Natl Univ Hosp, Biomed Res Inst, Dept Orthopaed Surg, Busan, South Korea.
EM jungsublee@pusan.ac.kr
FU Basic Science Research Program through a National Research Foundation of
   Korea - Korea government (MSIT) [2018R1A2B6007351]
FX Supported by Basic Science Research Program through a National Research
   Foundation of Korea grant funded by the Korea government (MSIT), No.
   2018R1A2B6007351.
CR Ahsan M K, 2014, Mymensingh Med J, V23, P471
   Chaleat-Valayer Emmanuelle, 2011, Eur Spine J, V20 Suppl 5, P634, DOI 10.1007/s00586-011-1931-2
   Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016
   Egger M, 2002, INT J EPIDEMIOL, V31, P1, DOI 10.1093/ije/31.1.1
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012
   Ha KY, 2008, J SPINAL DISORD TECH, V21, P229, DOI 10.1097/BSD.0b013e3180eaa202
   Isaacs RE, 2016, SPINE, V41, pS133, DOI 10.1097/BRS.0000000000001472
   Ishihara H, 2001, J SPINAL DISORD, V14, P91, DOI 10.1097/00002517-200104000-00001
   Kaiser MG, 2002, NEUROSURGERY, V50, P229, DOI 10.1097/00006123-200202000-00001
   Kim JS, 2010, WORLD NEUROSURG, V73, P565, DOI 10.1016/j.wneu.2010.02.057
   Kim JS, 2009, J SPINAL DISORD TECH, V22, P114, DOI 10.1097/BSD.0b013e318169bff5
   Kono Y, 2018, ASIAN SPINE J, V12, P356, DOI 10.4184/asj.2018.12.2.356
   Lee CW, 2017, WORLD NEUROSURG, V105, P612, DOI 10.1016/j.wneu.2017.06.005
   Lee GW, 2014, SPINE, V39, pE1475, DOI 10.1097/BRS.0000000000000596
   Lee Sang-Ho, 2004, Spine J, V4, P644, DOI 10.1016/j.spinee.2004.04.012
   Liu XY, 2014, J SPINAL DISORD TECH, V27, pE282, DOI 10.1097/BSD.0000000000000116
   LOGUIDICE VA, 1988, SPINE, V13, P366, DOI 10.1097/00007632-198803000-00027
   Luo JQ, 2017, CLIN SPINE SURG, V30, pE915, DOI 10.1097/BSD.0000000000000297
   Min JH, 2007, J NEUROSURG-SPINE, V7, P21, DOI 10.3171/SPI-07/07/021
   Ohba T, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1775-y
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Swan Justin, 2006, Spine J, V6, P606, DOI 10.1016/j.spinee.2006.02.032
   THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351
   Tye EY, 2018, SPINE J, V18, P464, DOI 10.1016/j.spinee.2017.08.227
NR 24
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E286
EP E293
DI 10.1016/j.wneu.2019.05.130
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900035
PM 31129223
DA 2020-05-12
ER

PT J
AU Choi, JH
   Shin, YS
   Kim, BS
AF Choi, Jai Ho
   Shin, Yong Sam
   Kim, Bum-soo
TI Making Microguidewire Loop Facilitates Navigation Through Tortuous or
   Abruptly Angulated Head and Neck Veins to Access Cavernous Sinus Dural
   Arteriovenous Fistulas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural arteriovenous fistula; Embolization; Head and neck vein;
   Microguidewire loop
ID SUPERIOR OPHTHALMIC VEIN; INFERIOR PETROSAL SINUS; TRANSVENOUS
   EMBOLIZATION; FACIAL VEIN; ENDOVASCULAR TREATMENT; MANAGEMENT; PUNCTURE
AB BACKGROUND: The transvenous approach via the inferior petrosal sinus (IPS) is the most commonly used route to access cavernous sinus dural arteriovenous fistulas (CSDAVF). The facial (FV) or superficial temporal vein (STV) are alternatives in cases with IPS occlusion. However, navigation through the ophthalmic vein via FV or STV is difficult because of its specific anatomical features, such as abrupt angulations and tortuous course. Herein, we introduce a microwire looping method to overcome these obstacles, thus enabling access to cavernous sinus.
   METHODS: We initially tried to navigate a microcatheter through the vein using a conventionally shaped microguide-wire tip. If the traditional method failed, we made a single-or double-looped microguidewire. After anchoring the microguidewire, we pushed the microcatheter to add microcatheter tension and steered the microguidewire. Then, looping was formed and the looped microguidewire tip was easily passed through the abruptly angulated or tortuous vein.
   RESULTS: This looping technique was applied in 7 CSDAVFs (4 were through FV and 3 were through STV) that were unable to pass through IPS. In all cases, a total of 10 microcatheters (4 with single microcatheter and 3 with double microcatheters) successfully approached CSDAVF, achieving effective transvenous coil embolization. The clinical and radiologic outcomes were excellent in all patients. There was 1 postprocedural cranial nerve palsy without any morbidity or mortality.
   CONCLUSIONS: Making a microguidewire loop to pass through abruptly angulated or tortuous head and neck veins might be an effective and safe alternative for when catheterization is not feasible by the traditional method.
C1 [Choi, Jai Ho; Shin, Yong Sam] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
   [Kim, Bum-soo] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Radiol, Seoul, South Korea.
RP Kim, BS (reprint author), Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Radiol, Seoul, South Korea.
EM bkim.neurorad@gmail.com
RI KIM, Bum-soo/F-3086-2018
OI KIM, Bum-soo/0000-0002-3870-6813
CR Alexandre AM, 2017, WORLD NEUROSURG, V99, DOI 10.1016/j.wneu.2016.12.048
   Benndorf G, 2000, SURG NEUROL, V54, P42, DOI 10.1016/S0090-3019(00)00260-3
   Biondi A, 2003, AM J NEURORADIOL, V24, P1240
   BROWN RD, 1994, J NEUROSURG, V81, P531, DOI 10.3171/jns.1994.81.4.0531
   Cho YD, 2016, INTERV NEURORADIOL, V22, P590, DOI 10.1177/1591019916653251
   Choi JH, 2017, ACTA NEUROCHIR, V159, P1479, DOI 10.1007/s00701-017-3226-9
   Choi JH, 2015, NEURORADIOLOGY, V57, P1153, DOI 10.1007/s00234-015-1597-2
   DERANG J, 1999, SURG NEUROL, V52, P292
   Elhammady MS, 2011, J NEUROSURG, V114, P129, DOI 10.3171/2010.1.JNS091433
   Gemmete JJ, 2009, NEUROIMAG CLIN N AM, V19, P241, DOI 10.1016/j.nic.2009.01.006
   Goldberg RA, 1996, ARCH OPHTHALMOL-CHIC, V114, P707, DOI 10.1001/archopht.1996.01100130699011
   HALBACH VV, 1987, RADIOLOGY, V163, P437, DOI 10.1148/radiology.163.2.3562823
   Jiao DR, 1999, SURG NEUROL, V52, P286, DOI 10.1016/S0090-3019(99)00078-6
   Karygiannis MN, 2006, INTERV NEURORADIOL, V12, P25, DOI 10.1177/159101990601200105
   Kim Myeong Jin, 2013, Neurointervention, V8, P15, DOI 10.5469/neuroint.2013.8.1.15
   KOMIYAMA M, 1990, SURG NEUROL, V33, P57, DOI 10.1016/0090-3019(90)90227-G
   Mortazavi MM, 2014, CHILD NERV SYST, V30, P831, DOI 10.1007/s00381-014-2378-7
   Naito I, 2002, INTERV NEURORADIOL, V8, P67, DOI 10.1177/159101990200800112
   Oishi H, 1999, ACTA NEUROCHIR, V141, P1265, DOI 10.1007/s007010050429
   Quinones D, 1997, AM J NEURORADIOL, V18, P921
   Soderman M, 2008, STROKE, V39, P1735, DOI 10.1161/STROKEAHA.107.506485
   TRESS BM, 1983, J NEUROSURG, V59, P1076, DOI 10.3171/jns.1983.59.6.1076
   van Dijk JMC, 2002, STROKE, V33, P1233, DOI 10.1161/01.STR.0000014772.02908.44
   Venturi C, 2003, NEURORADIOLOGY, V45, P574, DOI 10.1007/s00234-003-1020-2
   YAMASHITA K, 1993, NEURORADIOLOGY, V35, P475, DOI 10.1007/BF00602836
NR 25
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E561
EP E565
DI 10.1016/j.wneu.2019.05.216
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900071
PM 31158531
DA 2020-05-12
ER

PT J
AU Clifton, W
   Nottmeier, E
   Edwards, S
   Damon, A
   Dove, C
   Refaey, K
   Pichelmann, M
AF Clifton, William
   Nottmeier, Eric
   Edwards, Steven
   Damon, Aaron
   Dove, Conrad
   Refaey, Karim
   Pichelmann, Mark
TI Development of a Novel 3D Printed Phantom for Teaching Neurosurgical
   Trainees the Freehand Technique of C2 Laminar Screw Placement
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D printed spine; 3D printing; C2 laminar screws; Medical simulation;
   Neurosurgical training; Resident education; Spine phantom
ID PEDICLE; FIXATION; TRANSLAMINAR; SIMULATION; ACCURACY; PROGRAM; SPINE
AB BACKGROUND: 3D printed models have grown in popularity for resident training. Currently there is a paucity of simulators specifically designed for advanced cervical instrumentation. Our institution created a unique simulator for the instruction of freehand placement of C2 laminar screws using a specific 3-dimensional printing technique to replicate the corticocancellous interface. This study was designed to determine the efficacy of the simulator for teaching neurosurgical residents the freehand technique of C2 laminar screw placement.
   METHODS: Ten participants with different experience levels participated in the study. The participants were separated into 2 groups based on experience level. Primary outcome assessments were breach rates, screw-screw interaction, and the ability to successfully place 2 screws in 1 model. Participants were graded based on a performance scoring system, and the outcomes of the 2 groups were compared.
   RESULTS: All participants in the novice group showed improved technical ability on repeated use of the simulator and were able to successfully place bilateral screws by the fourth attempt. Statistical analysis indicated an association between operative experience level and successful bilateral screw placement, implying that the simulator accurately represented an in vivo intraoperative scenario.
   CONCLUSIONS: By utilizing our novel 3D printing production method, we have created a unique simulator for the freehand placement of C2 laminar screws. To our knowledge, this is the first report of a study investigating the use of a 3-dimensional printed simulator specifically designed to teach the freehand placement of C2 laminar screws to neurosurgical trainees.
C1 [Clifton, William; Nottmeier, Eric; Edwards, Steven; Refaey, Karim; Pichelmann, Mark] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
   [Damon, Aaron; Dove, Conrad] Mayo Clin, Dept Educ, Jacksonville, FL 32224 USA.
RP Clifton, W (reprint author), Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
EM Clifton.William@maye.edu
RI Clifton, William/AAA-6109-2019
OI Clifton, William/0000-0003-3533-8776; ReFaey, Karim/0000-0001-7227-1529
CR Beal MD, 2017, SIMUL HEALTHC, V12, P104, DOI 10.1097/SIH.0000000000000189
   Bohl MA, 2018, CUREUS, V10, DOI 10.7759/cureus.2491
   Bohl MA, 2018, SPINE, V43, pE1368, DOI 10.1097/BRS.0000000000002715
   Clifton W, 2019, CUREUS, V11, DOI 10.7759/cureus.4440
   Cramer J, 2017, J DIGIT IMAGING, V30, P296, DOI 10.1007/s10278-017-9950-0
   Jahnke P, 2019, EUR RADIOL, V29, P1384, DOI 10.1007/s00330-018-5654-1
   Kaneko N, 2019, INTERV NEURORADIOL
   Lehman RA, 2008, SPINE, V33, P960, DOI 10.1097/BRS.0b013e31816c915b
   Lehman RA, 2007, SPINE, V32, P3036, DOI 10.1097/BRS.0b013e31815cdab9
   Lehman RA, 2014, SPINE J, V14, P137, DOI 10.1016/j.spinee.2013.06.092
   Lim S, 2015, J NEUROSURG, V122, P962, DOI 10.3171/2014.11.JNS1494
   Ma XY, 2010, SPINE, V35, P704, DOI 10.1097/BRS.0b013e3181bb8831
   Makris DN, 2019, PHYS MED BIOL, V64, DOI 10.1088/1361-6560/ab1758
   Masiello I, 2017, LAKARTIDNINGEN, V114
   Parker SL, 2009, NEUROSURGERY, V64, P343, DOI 10.1227/01.NEU.0000338955.36649.4F
   REHN DA, 2018, 3D PRINT MED, V4, DOI DOI 10.1038/S41524-017-0059-2
   St John KR, 2014, SPINE J, V14, P3038, DOI 10.1016/j.spinee.2014.08.012
   Sundar SJ, 2016, J NEUROSURG-SPINE, V24, P850, DOI 10.3171/2015.8.SPINE15119
   Tesei G, 2012, J PHYS CHEM B, V116, P10008, DOI 10.1021/jp305296p
   Tortolani PJ, 2013, ORTHOPEDICS, V36, pE1128, DOI 10.3928/01477447-20130821-13
   Wright NM, 2004, J SPINAL DISORD TECH, V17, P158, DOI 10.1097/00024720-200404000-00014
NR 21
TC 4
Z9 5
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E812
EP E820
DI 10.1016/j.wneu.2019.06.038
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900102
PM 31203082
DA 2020-05-12
ER

PT J
AU Cole, TS
   Potla, S
   Sarris, CE
   Przybylowski, CJ
   Baranoski, JF
   Mooney, MA
   Barranco, FD
   White, WL
   Eschbacher, JM
   Little, AS
AF Cole, Tyler S.
   Potla, Subodh
   Sarris, Christina E.
   Przybylowski, Colin J.
   Baranoski, Jacob F.
   Mooney, Michael A.
   Barranco, F. David
   White, William L.
   Eschbacher, Jennifer M.
   Little, Andrew S.
TI Rare Thyroid Transcription Factor 1-Positive Tumors of the Sellar
   Region: Barrow Neurological Institute Retrospective Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Granular cell tumor; Pituicytoma; Pituitary; Sellar tumors; Spindle cell
   oncocytoma; TTF-1
ID GRANULAR-CELL TUMOR; PITUICYTOMA; ONCOCYTOMA; PITUITARY; NEUROHYPOPHYSIS
AB OBJECTIVE: Granular cell tumors (GCTs), pituicytomas, and spindle cell oncocytomas are rare, nonfunctioning pituitary tumors sharing positive staining of thyroid transcription factor 1. We present our series, the first single-institutional report with long-term surgical follow-up of all 3 tumor types.
   METHODS: Our institutional pathology database was queried for these 3 pathologic diagnoses. Clinical records were assessed for clinical presentation, preoperative and postoperative endocrine status, tumor location on imaging, surgical characteristics, pathology results, and tumor recurrence.
   RESULTS: Data were analyzed for 4 patients with GCTs, 4 with pituicytomas, and 3 with spindle cell oncocytomas. The most common symptoms at presentation were vision changes (64%), headache (55%), endocrine abnormalities (55%), and fatigue (46%). GCTs were the only subtype to present exclusively in the infundibulum and the only subtype in our series to be treated with a transcranial trans-sylvian approach to resection (n = 2). In our study, in contrast to other reports, estimated blood loss was less than 300 mL in all patients. Imaging confirmed gross total resection in all 11 cases with no known recurrences at a mean (standard deviation) follow-up of 4.7 (3.7) years.
   CONCLUSIONS: We present a single-institution series of rare thyroid transcription factor 1-staining posterior pituitary tumors of the sellar region. Key novel findings include gross total resection with no tumor recurrence at nearly 5 years of mean follow-up and no cases of excess or uncontrolled blood loss. Our findings reinforce the observation that GCTs present in the suprasellar space.
C1 [Cole, Tyler S.; Potla, Subodh; Sarris, Christina E.; Przybylowski, Colin J.; Baranoski, Jacob F.; Mooney, Michael A.; Barranco, F. David; White, William L.; Eschbacher, Jennifer M.; Little, Andrew S.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Little, AS (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM neuropub@barrowneuro.org
CR Agha RA, 2018, INT J SURG, V60, P279, DOI 10.1016/j.ijsu.2018.10.031
   Aquilina K, 2006, BRIT J NEUROSURG, V20, P51, DOI 10.1080/02688690600600996
   Borges MT, 2011, J NEURO-ONCOL, V101, P145, DOI 10.1007/s11060-010-0229-2
   Brat DJ, 2000, AM J SURG PATHOL, V24, P362, DOI 10.1097/00000478-200003000-00004
   Cohen-Gadol AA, 2003, MAYO CLIN PROC, V78, P567, DOI 10.4065/78.5.567
   Covington MF, 2011, AM J NEURORADIOL, V32, P2067, DOI 10.3174/ajnr.A2717
   Demssie YN, 2011, PITUITARY, V14, P367, DOI 10.1007/s11102-009-0170-6
   Feng M, 2014, PITUITARY, V17, P399, DOI 10.1007/s11102-013-0515-z
   Islamian AP, 2012, PITUITARY, V15, P227, DOI 10.1007/s11102-011-0317-0
   Koutourousiou M, 2013, J NEUROL SURG PART B, V74, P1, DOI 10.1055/s-0032-1329619
   Lee EB, 2009, J NEUROPATH EXP NEUR, V68, P482, DOI 10.1097/NEN.0b013e3181a13fca
   Lopes MBS, 2017, ACTA NEUROPATHOL, V134, P521, DOI 10.1007/s00401-017-1769-8
   Mete O, 2013, AM J SURG PATHOL, V37, P1694, DOI 10.1097/PAS.0b013e31829723e7
   Nishio S, 1998, CLIN NEUROL NEUROSUR, V100, P144, DOI 10.1016/S0303-8467(98)00017-1
   Ogiwara Hideki, 2011, Surg Neurol Int, V2, P116, DOI 10.4103/2152-7806.83932
   Orning JL, 2013, J CASE REP MED, V2
   Roncaroli F, 2002, AM J SURG PATHOL, V26, P1048, DOI 10.1097/00000478-200208000-00010
   Saiegh L, 2013, NEUROENDOCRINOL LETT, V34, P331
   Wolie SQ, 2008, NEUROSURGERY, V63, P173, DOI 10.1227/01.NEU.0000319520.30043.27
   Zygourakis CC, 2015, PITUITARY, V18, P150, DOI 10.1007/s11102-014-0568-7
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E294
EP E302
DI 10.1016/j.wneu.2019.05.132
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900036
PM 31132506
DA 2020-05-12
ER

PT J
AU d'Avella, E
   Fazzolari, B
   Schiariti, M
   Delitala, A
   Ferroli, P
   Cappabianca, P
   Servadei, F
AF d'Avella, Elena
   Fazzolari, Benedetta
   Schiariti, Marco
   Delitala, Alberto
   Ferroli, Paolo
   Cappabianca, Paolo
   Servadei, Franco
TI Common Practice in the Management of Dural Closure: An Italian
   Questionnaire
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delphi method; Dural closure; Italy; Survey
ID CEREBROSPINAL-FLUID LEAK; LUMBAR SPINE SURGERY; PROSPECTIVE
   RANDOMIZED-TRIAL; RISK-FACTORS; CLINICAL-EXPERIENCE; WATERTIGHT CLOSURE;
   SEALANT SYSTEM; REPAIR; TEARS; ADHESIVE
AB OBJECTIVE: The optimal management of dural closure is unclear; therefore, we aimed to survey current common practices among Italian practitioners.
   METHODS: The Delphi method was used to achieve a consensus on dura mater closing techniques in Italy. A steering committee decided 3 major topics to be investigated: pre- and postoperative conditions associated with cerebrospinal fluid (CSF) leak, indications to perform watertight dural closure, and dural closure technique. A questionnaire containing 12 statements was then submitted to Italian neurosurgeons.
   RESULTS: The response rate was 60%. Among 60 items, 36 reached a positive consensus, 5 reached a negative consensus, and 19 did not reach consensus. Intrathecal hypertension, arachnoid opening, previous treatments, spinal incidental durotomy, wide size of osteo-dural defect, and lack of nasoseptal flap were considered major risk factors for CSF leak. Early mobilization, avoidance of stress maneuvers, and use of CSF external drainage were considered to reduce CSF leak rate. Italian neurosurgeons always attempt watertight dural closure, ideally with monofilament nonabsorbable sutures. Both autologous and heterologous dural grafts are used. Among dural sealants, fibrin glues are preferred, which are used most commonly in transsphenoidal surgery.
   CONCLUSIONS: This study elucidates the areas of consensus and uncertainty on dural closure management among a group of Italian neurosurgeons. It provides reliable and comparable data for the investigation of the departments' daily practice in dural closure. Given the lack of solid evidence, there is a need for further comparative studies of dural repair strategies.
C1 [d'Avella, Elena; Cappabianca, Paolo] Univ Napoli Federico II, Dept Neurosci & Reprod & Odontostomatol Sci, Div Neurosurg, Naples, Italy.
   [Fazzolari, Benedetta; Delitala, Alberto] Hosp San Camillo Forlanini, Dept Neurosurg, Rome, Italy.
   [Schiariti, Marco; Ferroli, Paolo] Fdn IRCCS Ist Neurol C Fiesta, Dept Neurosurg, Milan, Italy.
   [Servadei, Franco] Univ & Res Hosp, Dept Neurosurg Humanitas, Milan, Italy.
RP d'Avella, E (reprint author), Univ Napoli Federico II, Dept Neurosci & Reprod & Odontostomatol Sci, Div Neurosurg, Naples, Italy.
EM elenadavella@gmail.com
FU Takeda Italia S.p.A.
FX The consensus Delphi project for this paper was initiated and funded by
   Takeda Italia S.p.A. Management of the meeting during the Delphi
   consensus project and medical writing and editing was provided by Ethos
   S.r.l. and was funded by Takeda Italia S.p.A. Ethos S.r.l. suggested the
   board, and Takeda Italia S.p.A. approved that. Takeda Italia S.p.A
   supported the Delphi consensus conference and publication concept. The
   authors received financial reimbursement for the Delphi consensus
   activities, literature review, and statistical analysis. The
   reimbursement was provided by Ethos S.r.l. and supported by Takeda
   Italia S.p.A.
CR Ahn JY, 2009, NEUROSURGERY, V65, P65, DOI 10.1227/01.NEU.0000327695.32775.BB
   Anson JA, 1996, NEUROSURGERY, V39, P764, DOI 10.1097/00006123-199610000-00025
   Barth M, 2008, NEUROSURGERY, V63, P352, DOI 10.1227/01.NEU.0000310696.52302.99
   Battaglia P, 2016, ACTA OTORHINOLARYNGO, V36, P194, DOI 10.14639/0392-100X-748
   Black P, 2000, Neurosurg Focus, V9, pe4, DOI 10.3171/foc.2000.9.1.4
   Black P, 2002, J NEUROSURG, V96, P250, DOI 10.3171/spi.2002.96.2.0250
   Bohoun CA, 2019, WORLD NEUROSURG, V127, pE896, DOI 10.1016/j.wneu.2019.03.293
   Boogaarts JD, 2005, NEUROSURGERY, V57, P146, DOI 10.1227/01.NEU.0000164384.05351.59
   Borg A, 2016, WORLD NEUROSURG, V95, P383, DOI 10.1016/j.wneu.2015.12.105
   Bosacco SJ, 2001, CLIN ORTHOP RELAT R, P238
   Cavallo LM, 2019, WORLD NEUROSURG, V126, P439, DOI 10.1016/j.wneu.2019.03.125
   Clajus C, 2015, ACTA NEUROCHIR, V157, P525, DOI 10.1007/s00701-014-2325-0
   Copeland WR, 2015, J NEUROSURG, V122, P312, DOI 10.3171/2014.10.JNS14432
   Costa BS, 2011, ARQ NEURO-PSIQUIAT, V69, P217, DOI 10.1590/S0004-282X2011000200015
   Cushing H, 1908, SURGERY ITS PRINCIPL, V3, P17
   Dafford EE, 2015, SPINE J, V15, P1099, DOI 10.1016/j.spinee.2013.06.044
   Diamond IR, 2014, J CLIN EPIDEMIOL, V67, P401, DOI 10.1016/j.jclinepi.2013.12.002
   Espiritu MT, 2010, J AM ACAD ORTHOP SUR, V18, P537, DOI 10.5435/00124635-201009000-00005
   Esposito F, 2008, CLIN NEUROL NEUROSUR, V110, P343, DOI 10.1016/j.clineuro.2007.12.016
   Esposito F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151533
   Ferroli P, 2013, WORLD NEUROSURG, V79, P551, DOI 10.1016/j.wneu.2011.09.022
   Fraser S, 2018, J NEUROSURG, V128, P1066, DOI 10.3171/2016.12.JNS1694
   Grannum S, 2014, EUR SPINE J, V23, P904, DOI 10.1007/s00586-013-3159-9
   Grotenhuis JA, 2005, SURG NEUROL, V64, P490, DOI 10.1016/j.surneu.2005.03.041
   Hasson F, 2000, J ADV NURS, V32, P1008, DOI 10.1046/j.1365-2648.2000.01567.x
   Ivan ME, 2015, J CLIN NEUROSCI, V22, P48, DOI 10.1016/j.jocn.2014.08.009
   Kamenova M, 2016, WORLD NEUROSURG, V87, P455, DOI 10.1016/j.wneu.2015.11.045
   Khazim R, 2015, EUR SPINE J, V24, P2069, DOI 10.1007/s00586-015-3830-4
   Kim KD, 2011, SPINE, V36, P1906, DOI 10.1097/BRS.0b013e3181fdb4db
   Kinaci A, 2019, WORLD NEUROSURG, V127, P567, DOI 10.1016/j.wneu.2019.02.236
   Kitano M, 2004, NEUROSURGERY, V54, P653, DOI 10.1227/01.NEU.0000108780.72365.DC
   Kumar A, 2003, J CLIN NEUROSCI, V10, P661, DOI 10.1016/S0967-5868(03)00163-2
   Luszczyk MJ, 2014, SPINE J, V14, P49, DOI 10.1016/j.spinee.2013.03.049
   Malliti M, 2004, NEUROSURGERY, V54, P599, DOI 10.1227/01.NEU.0000108640.45371.1A
   Moon J, 2019, EURASIP J IMAGE VIDE, DOI 10.1186/s13640-018-0389-0
   Moskowitz SI, 2009, NEUROSURGERY, V64, pS28, DOI 10.1227/01.NEU.0000334414.79963.59
   Moskowitz SI, 2009, NEUROSURGERY S, V64
   Muller SJ, 2018, WORLD NEUROSURG, V119, P494, DOI 10.1016/j.wneu.2018.05.251
   Murphy ME, 2017, NEUROL RES, V39, P97, DOI 10.1080/01616412.2016.1261236
   Nair R, 2011, SEMIN ARTHRITIS RHEU, V41, P95, DOI 10.1016/j.semarthrit.2010.12.001
   Nakamura H, 2005, SPINE, V30, pE347, DOI 10.1097/01.brs.0000167820.54413.8e
   Narotam PK, 2004, SPINE, V29, P2861, DOI 10.1097/01.brs.0000148049.69541.ad
   Narotam PK, 2004, SPINE, V29, P2868
   Oitment C, 2018, GLOB SPINE J, V8, P359, DOI 10.1177/2192568217724132
   Osbun JW, 2012, WORLD NEUROSURG, V78, P498, DOI 10.1016/j.wneu.2011.12.011
   Ozisik PA, 2006, SURG NEUROL, V65, P42, DOI 10.1016/j.surneu.2005.04.047
   Roth J, 2018, WORLD NEUROSURG, V114, pE743, DOI 10.1016/j.wneu.2018.03.070
   Schebesch KM, 2019, CUREUS, V11, DOI 10.7759/cureus.4013
   Takahashi Y, 2013, J NEUROSURG-SPINE, V18, P165, DOI 10.3171/2012.10.SPINE12271
   von der Brelie C, 2012, BRIT J NEUROSURG, V26, P231, DOI 10.3109/02688697.2011.619597
   Woodroffe RW, 2018, CLIN NEUROL NEUROSUR, V170, P61, DOI 10.1016/j.clineuro.2018.04.017
   Wright NM, 2015, SPINE, V40, P505, DOI 10.1097/BRS.0000000000000810
NR 52
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E255
EP E263
DI 10.1016/j.wneu.2019.05.125
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900031
PM 31128310
DA 2020-05-12
ER

PT J
AU Ding, CY
   Peng, L
   Lin, YX
   Yu, LH
   Wang, DL
   Kang, DZ
AF Ding, Chen-Yu
   Peng, Lei
   Lin, Yuan Xiang
   Yu, Liang-Hong
   Wang, Deng-Liang
   Kang, De-Zhi
TI Elevated Lactate Dehydrogenase Level Predicts Postoperative Pneumonia in
   Patients with Aneurysmal Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysmal subarachnoid hemorrhage; Lactate dehydrogenase; Postoperative
   pneumonia
ID DELAYED CEREBRAL-ISCHEMIA; ACQUIRED PNEUMONIA; COMPLICATIONS;
   RECOMMENDATIONS; INFECTIONS; ISOENZYMES; BIOMARKER; STROKE; BLOOD; RISK
AB BACKGROUND: Lactate dehydrogenase (LDH) is a nonspecific inflammatory biomarker and has been reported to be useful in predicting community-acquired pneumonia and Mycoplasma pneumoniae pneumonia. The connection between LDH level and postoperative pneumonia (POP) in patients with aneurysmal subarachnoid hemorrhage (aSAH) is still unclear. The aim of this study was to assess feasibility of predicting POP in patients with aSAH using LDH.
   METHODS: Admission serum LDH level was obtained in 647 patients with aSAH enrolled in a prospective observational study. The relationship between LDH level and POP was analyzed.
   RESULTS: POP occurred in 187 patients (28.90%). Patients with POP had significantly higher LDH levels than patients without POP (261.26 +/- 126.51 U/L vs. 189.00 +/- 69.20 U/L, P < 0.001). Multivariate analysis showed that LDH level remained a significant independent factor associated with POP in patients with aSAH, even after adjusting for possible confounding factors. Receiver operating characteristic curve analysis showed that LDH level had a sensitivity of 63.6% and a specificity of 71.3% for predicting POP based on best threshold of 203.5 U/L. There were additive interactions between elevated LDH level and World Federation of Neurosurgical Societies grade or mechanical ventilator use. When patients were classified by World Federation of Neurosurgical Societies grade or mechanical ventilator use, regardless of World Federation of Neurosurgical Societies grade (<III or >= III) or length of mechanical ventilator use (0-24 hours or >= 24 hours), the POP-free rate of patients with admission LDH >= 250 U/L was significantly worse compared with patients with LDH <250 U/L.
   CONCLUSIONS: LDH might be a helpful predictor of POP occurrence in patients with aSAH.
C1 [Ding, Chen-Yu; Peng, Lei; Lin, Yuan Xiang; Yu, Liang-Hong; Wang, Deng-Liang; Kang, De-Zhi] Fujian Med Univ, Dept Neurosurg, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China.
RP Kang, DZ (reprint author), Fujian Med Univ, Dept Neurosurg, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China.
EM kdz99988@vip.sina.com
FU Key Clinical Specialty Discipline Construction Program of Fujian
   Province, China; Fujian Provincial Major Project of Department of
   Science and Technology [2014YZ0003]
FX This study was supported by grants from the Key Clinical Specialty
   Discipline Construction Program of Fujian Province, China, and the
   Fujian Provincial Major Project of Department of Science and Technology
   (Grant No. 2014YZ0003).
CR Abecassis IJ, 2017, WORLD NEUROSURG, V105, P108, DOI 10.1016/j.wneu.2017.05.110
   Alaraj A, 2017, J CLIN NEUROSCI, V42, P66, DOI 10.1016/j.jocn.2017.03.049
   Breuer O, 2018, CHEST, V153, P172, DOI 10.1016/j.chest.2017.09.021
   Claassen J, 2001, STROKE, V32, P2012, DOI 10.1161/hs0901.095677
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Dasenbrock HH, 2016, WORLD NEUROSURG, V88, P459, DOI 10.1016/j.wneu.2015.10.054
   Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9
   Drent M, 1996, EUR RESPIR J, V9, P1736, DOI 10.1183/09031936.96.09081736
   Frontera JA, 2008, NEUROSURGERY, V62, P80, DOI 10.1227/01.NEU.0000311064.18368.EA
   Galea JP, 2017, STROKE, V48, P2958, DOI 10.1161/STROKEAHA.117.017777
   Gaspar P, 2014, INFECT IMMUN, V82, P5099, DOI 10.1128/IAI.02005-14
   Hilker R, 2003, STROKE, V34, P975, DOI 10.1161/01.STR.0000063373.70993.CD
   Kamp MA, 2017, TRANSL STROKE RES, V8, P206, DOI 10.1007/s12975-016-0513-3
   Laban KG, 2015, INT J STROKE, V10, P763, DOI 10.1111/ijs.12494
   Leone M, 2018, ANAESTH CRIT CARE PA, V37, P83, DOI 10.1016/j.accpm.2017.11.006
   Levine J, 2010, NEUROSURGERY, V66, P312, DOI 10.1227/01.NEU.0000363747.47587.6C
   Liu TY, 2018, PEDIATR NEONATOL, V59, P501, DOI 10.1016/j.pedneo.2017.12.008
   Lu AZ, 2015, RESP CARE, V60, P1469, DOI 10.4187/respcare.03920
   Sogame LCM, 2008, J NEUROSURG, V109, P222, DOI 10.3171/JNS/2008/109/8/0222
   Mura M, 2007, SHOCK, V28, P227, DOI 10.1097/SHK.0b013e318033e927
   Nam KW, 2018, STROKE, V49, P1886, DOI 10.1161/STROKEAHA.118.021228
   Radolf S, 2014, TRANSL STROKE RES, V5, P278, DOI 10.1007/s12975-013-0292-z
   Rass V, 2018, CRIT CARE MED, V46, pE1152, DOI 10.1097/CCM.0000000000003429
   Saraya T, 2018, RESPIR INVESTIG, V56, P320, DOI 10.1016/j.resinv.2018.03.001
   Sarrafzadeh A, 2011, STROKE, V42, P53, DOI 10.1161/STROKEAHA.110.594705
   Savardekar Amey, 2013, Surg Neurol Int, V4, P24, DOI 10.4103/2152-7806.107894
   Schertz M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155945
   Smith CJ, 2015, STROKE, V46, P2335, DOI 10.1161/STROKEAHA.115.009617
   Tao RJ, 2018, J THORAC DIS, V10, P4387, DOI 10.21037/jtd.2018.06.33
   Taufique Z, 2016, NEUROSURGERY, V78, P256, DOI 10.1227/NEU.0000000000001042
   Zhang LM, 2018, SHOCK, V50, P421, DOI 10.1097/SHK.0000000000001095
   Zhao B, 2017, J NEUROSURG, V126, P1764, DOI 10.3171/2016.4.JNS152587
NR 32
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E821
EP E830
DI 10.1016/j.wneu.2019.06.041
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900103
PM 31203058
DA 2020-05-12
ER

PT J
AU El Damaty, A
   Fleck, S
   Matthes, M
   Baldauf, J
   Schroeder, HWS
AF El Damaty, Ahmed
   Fleck, Steffen
   Matthes, Marc
   Baldauf, Joerg
   Schroeder, Henry W. S.
TI Pineal Cyst without Hydrocephalus: Clinical Presentation and
   Postoperative Clinical Course After Infratentorial Supracerebellar
   Resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Microsurgical resection; Pineal cyst; Ventriculomegaly
ID SYMPTOMATIC GLIAL CYSTS; NATURAL-HISTORY; GLAND; PREVALENCE; CHILDREN;
   REGION; MANAGEMENT; HEADACHES; SURGERY; LESIONS
AB BACKGROUND: Surgical indications for patients with pineal cysts are controversial. There are absolute indications such as hydrocephalus or tectal compression; otherwise, it is difficult to decide whether surgery would be beneficial when symptoms are not distinct.
   OBJECTIVE: We tried to clarify the indications and clinical course of patients after resection of pineal cysts without ventriculomegaly.
   METHODS: We reviewed our database for all patients operated on for pineal cyst without ventriculomegaly from 2003 to 2018. We studied the presenting symptoms, cyst size, surgical approach, extent of resection, and clinical and radiologic follow-up. Follow-up ranged from 3 months to 14 years (mean 3.74 years).
   RESULTS: Forty-three patients underwent surgery for pineal cyst in absence of ventriculomegaly; 36 female patients, 7 male patients, mean age 25.63 years (+/-10.62 years, range 4-52 years). Presenting symptoms included headache (41/43), nausea and vomiting (31/43), dizziness (19/43), visual disturbances (10/43), and sleep disturbances (8/43). Mean cyst size was 15.7 mm (+/-4.9 mm, range 9-27 mm). In total, 41 of 43 patients reported a good outcome, represented by a Chicago Chiari Outcome Scale score of 11 or greater and only 2 of 43 patients reported a bad outcome, defined by Chicago Chiari Outcome Scale score of 10 or less.
   CONCLUSIONS: We suggest that pineal cysts without ventriculomegaly are an indication for surgery when patients present with headache and/or visual disturbances and other causes have been excluded. Resolution of symptoms and quality of life in our cohort may denote a good indication for resection. However, we must admit that there is still no evidence to recommend this technique as a treatment of headache in these patients.
C1 [El Damaty, Ahmed] Heidelberg Univ Hosp, Dept Neurosurg, Heidelberg, Germany.
   [El Damaty, Ahmed] Cairo Univ, Dept Neurosurg, Cairo, Egypt.
   [Fleck, Steffen; Matthes, Marc; Baldauf, Joerg; Schroeder, Henry W. S.] Greifswald Univ Med, Dept Neurosurg, Greifswald, Germany.
RP El Damaty, A (reprint author), Heidelberg Univ Hosp, Dept Neurosurg, Heidelberg, Germany.; El Damaty, A (reprint author), Cairo Univ, Dept Neurosurg, Cairo, Egypt.
EM ahmed.eldamaty@med.uni-heidelberg.de
OI El Damaty, Ahmed/0000-0003-0146-8943
CR Al-Holou WN, 2011, J NEUROSURG, V115, P1106, DOI 10.3171/2011.6.JNS11506
   Al-Holou WN, 2010, J NEUROSURG-PEDIATR, V5, P162, DOI 10.3171/2009.9.PEDS09297
   Al-Holou WN, 2009, J NEUROSURG-PEDIATR, V4, P230, DOI 10.3171/2009.4.PEDS0951
   Aliaga L, 2012, NEUROSURGERY, V70, P656, DOI 10.1227/NEU.0b013e31823200a6
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Chandy MJ, 1998, BRIT J NEUROSURG, V12, P228
   Choy W, 2011, NEUROSURG CLIN N AM, V22, P341, DOI 10.1016/j.nec.2011.06.001
   Costa F, 2008, MINIM INVAS NEUROSUR, V51, P231, DOI 10.1055/s-2008-1073171
   DICOSTANZO A, 1993, J NEUROL NEUROSUR PS, V56, P207, DOI 10.1136/jnnp.56.2.207
   Eide PK, 2017, ACTA NEUROCHIR, V159, P349, DOI 10.1007/s00701-016-3029-4
   Eide PK, 2016, J NEUROL SCI, V367, P247, DOI 10.1016/j.jns.2016.06.028
   Engel U, 2000, NEURORADIOLOGY, V42, P399, DOI 10.1007/s002340000308
   Evans RW, 2010, HEADACHE, V50, P666, DOI 10.1111/j.1526-4610.2010.01652.x
   FAIN JS, 1994, J NEUROSURG, V80, P454, DOI 10.3171/jns.1994.80.3.0454
   FETELL MR, 1991, NEUROLOGY, V41, P1034, DOI 10.1212/WNL.41.7.1034
   GOLZARIAN J, 1993, NEURORADIOLOGY, V35, P251, DOI 10.1007/BF00602604
   Gore Pankaj A, 2008, Neurosurgery, V62, P108, DOI 10.1227/01.neu.0000317380.60938.79
   HASEGAWA A, 1987, BRAIN RES, V409, P343, DOI 10.1016/0006-8993(87)90720-7
   Kalani MYS, 2015, J NEUROSURG, V123, P352, DOI 10.3171/2014.9.JNS141081
   Kang HS, 1998, J NEUROSURG, V88, P138, DOI 10.3171/jns.1998.88.1.0138
   KLEIN P, 1989, J NEUROL NEUROSUR PS, V52, P991, DOI 10.1136/jnnp.52.8.991
   Majovsky M, 2017, WORLD NEUROSURG, V105, P199, DOI 10.1016/j.wneu.2017.05.155
   MAMOURIAN AC, 1986, AM J NEURORADIOL, V7, P1081
   Mandera M, 2003, CHILD NERV SYST, V19, P750, DOI 10.1007/s00381-003-0813-2
   MAURER PK, 1990, NEUROSURGERY, V27, P451, DOI 10.1227/00006123-199009000-00019
   McNeely PD, 2003, CAN J NEUROL SCI, V30, P67, DOI 10.1017/S031716710000247X
   Michielsen G, 2002, ACTA NEUROCHIR, V144, P233, DOI 10.1007/s007010200031
   OECKLER R, 1991, ACTA NEUROCHIR, V108, P40, DOI 10.1007/BF01407665
   OSBORN RE, 1989, NEURORADIOLOGY, V31, P187, DOI 10.1007/BF00698853
   Patel Akash J, 2005, Neurosurgery, V57, pE1066, DOI 10.1227/01.NEU.0000179990.46401.66
   Pu Y, 2007, AM J NEURORADIOL, V28, P1706, DOI 10.3174/ajnr.A0656
   SAWAMURA Y, 1995, NEUROSURGERY, V37, P11, DOI 10.1227/00006123-199507000-00002
   Seifert CL, 2008, HEADACHE, V48, P448, DOI 10.1111/j.1526-4610.2007.00965.x
   STERN JD, 1993, NEUROSURGERY, V32, P310, DOI 10.1227/00006123-199302000-00024
   TAPP E, 1972, J PATHOL, V108, P137, DOI 10.1002/path.1711080207
   Tartara F, 2000, J Neurosurg Sci, V44, P89
   Tirakotai W, 2004, CHILD NERV SYST, V20, P842, DOI 10.1007/s00381-004-0941-3
   TURTZ AR, 1995, NEUROSURGERY, V37, P1013, DOI 10.1227/00006123-199511000-00025
   VAQUERO J, 1988, SURG NEUROL, V30, P468, DOI 10.1016/0090-3019(88)90033-X
   Weimer K, 2013, PEDIATR RES, V74, P96, DOI 10.1038/pr.2013.66
   WISOFF JH, 1992, J NEUROSURG, V77, P896, DOI 10.3171/jns.1992.77.6.0896
NR 41
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E530
EP E537
DI 10.1016/j.wneu.2019.05.200
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900067
PM 31154104
DA 2020-05-12
ER

PT J
AU Elsamadicy, AA
   Charalambous, L
   Adif, SM
   Drysdale, N
   Lee, M
   Koo, AB
   Chouairi, F
   Kundishora, AJ
   Camara-Quintana, J
   Qureshi, T
   Kolb, L
   Laurans, M
   Abbed, K
   Karikari, IO
AF Elsamadicy, Aladine A.
   Charalambous, Lefko
   Adif, Syed M.
   Drysdale, Nicolas
   Lee, Megan
   Koo, Andrew B.
   Chouairi, Fouad
   Kundishora, Adam J.
   Camara-Quintana, Joaquin
   Qureshi, Tariq
   Kolb, Luis
   Laurans, Maxwell
   Abbed, Khalid
   Karikari, Isaac O.
TI Reduced Influence of Affective Disorders on 6-Week and 3-Month Narcotic
   Refills After Primary Complex Spinal Fusions for Adult Deformity
   Correction: A Single-Institutional Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult deformity correction; Affective disorders; Complex spine fusion;
   Narcotic refills; Patient-reported pain scores; Postoperative pain
ID QUALITY-OF-LIFE; PRESCRIPTION OPIOID-USE; PREOPERATIVE DEPRESSION;
   MENTAL-HEALTH; CLINICAL-OUTCOMES; ELDERLY-PATIENTS; LUMBAR SURGERY;
   RISK-FACTORS; ANXIETY; IMPACT
AB OBJECTIVE: Previous studies have identified the impact of affective disorders on preoperative and postoperative perception of pain. However, there is a scarcity of data identifying the impact of affective disorders on post-discharge narcotic refills. The aim of this study was to determine whether patients with affective disorders have more narcotic refills after complex spinal fusion for deformity correction.
   METHODS: The medical records of 121 adult (>= 18 years old) spine deformity patients undergoing elective, primary complex spinal fusion (>= 5 level) for deformity correction at a major academic institution from 2010 to 2015 were reviewed. Patient demographics, comorbidities, intra-operative and postoperative complication rates, baseline and postoperative patient-reported pain scores, ambulatory status, and narcotic refills were collected for each patient. The primary outcome was the rate of 6-week and 3-month narcotic refills.
   RESULTS: Of the 121 patients, 43 (35.5%) had a clinical diagnosis of anxiety or depression (affective disorder) (AD n = 43; No-AD n = 78). Preoperative narcotic use was significantly higher in the AD cohort (AD 65.9% vs. No-AD 37.7%, P = 0.0035). The AD cohort had significantly higher pain scores at baseline (AD 6.5 +/- 2.9 vs. No-AD 4.7 +/- 3.1, P = 0.004) and at the first postoperative pain score reported (AD 6.7 +/- 2.6 vs. No-AD 5.6 +/- 2.9, P = 0.049). However, there were no significant differences in narcotic refills at 6 weeks (AD 34.9% vs. No-AD 25.6%, P = 0.283) and 3 months (AD 23.8% vs. No-AD 17.4%, P = 0.411) after discharge between the cohorts.
   CONCLUSIONS: Our study suggests that whereas spinal deformity patients with affective disorders may have a higher baseline perception of pain and narcotic use, the impact of affective disorders on narcotic refills at 6 weeks and 3 months may be minimal after complex spinal fusion.
C1 [Elsamadicy, Aladine A.; Lee, Megan; Koo, Andrew B.; Chouairi, Fouad; Kundishora, Adam J.; Camara-Quintana, Joaquin; Qureshi, Tariq; Kolb, Luis; Laurans, Maxwell; Abbed, Khalid] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA.
   [Charalambous, Lefko; Adif, Syed M.; Drysdale, Nicolas; Karikari, Isaac O.] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC USA.
RP Elsamadicy, AA (reprint author), Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT 06520 USA.
EM aladine.elsamadicy@yale.edu
CR Aalto TJ, 2006, SPINE, V31, pE648, DOI 10.1097/01.brs.0000231727.88477.da
   Adogwa O, 2017, WORLD NEUROSURG, V107, P471, DOI 10.1016/j.wneu.2017.07.165
   Adogwa O, 2016, WORLD NEUROSURG, V94, P432, DOI 10.1016/j.wneu.2016.07.045
   Adogwa O, 2014, J NEUROSURG-SPINE, V21, P153, DOI 10.3171/2014.4.SPINE12668
   Akins PT, 2015, SPINE, V40, P1022, DOI 10.1097/BRS.0000000000000916
   Alentado VJ, 2017, SPINE J, V17, P236, DOI 10.1016/j.spinee.2016.09.011
   Alvin MD, 2015, SPINE J, V15, P79, DOI 10.1016/j.spinee.2014.07.001
   [Anonymous], 2010, ANX MOOD DIS US EXP
   Armaghani SJ, 2014, SPINE, V39, pE1524, DOI 10.1097/BRS.0000000000000622
   Askari MS, 2017, J AFFECT DISORDERS, V220, P1, DOI 10.1016/j.jad.2017.05.027
   Bakhsheshian J, 2017, J NEUROSURG-SPINE, V26, P116, DOI 10.3171/2016.5.SPINE151428
   Chapin L, 2017, CLIN SPINE SURG, V30, pE725, DOI 10.1097/BSD.0000000000000331
   CHAPMAN CR, 1977, J PSYCHOSOM RES, V21, P7, DOI 10.1016/0022-3999(77)90020-4
   Connolly J, 2017, SPINE, V42, P1405, DOI 10.1097/BRS.0000000000002133
   Davis MA, 2017, J AM BOARD FAM MED, V30, P407, DOI 10.3122/jabfm.2017.04.170112
   deGroot KI, 1997, PAIN, V69, P19, DOI 10.1016/S0304-3959(96)03228-9
   Devin CJ, 2015, J CLIN NEUROSCI, V22, P930, DOI 10.1016/j.jocn.2015.01.003
   Dunn LK, 2018, J NEUROSURG-SPINE, V28, P119, DOI 10.3171/2017.5.SPINE1734
   Elsamadicy AA, 2016, WORLD NEUROSURG, V87, P214, DOI 10.1016/j.wneu.2015.11.067
   Glowacki M, 2013, J DEV PHYS DISABIL, V25, P203, DOI 10.1007/s10882-012-9296-y
   Greenough C G, 1994, Eur Spine J, V3, P225, DOI 10.1007/BF02221598
   Hasin DS, 2018, JAMA PSYCHIAT, V75, P336, DOI 10.1001/jamapsychiatry.2017.4602
   IDLER EL, 1993, MOTIV EMOTION, V17, P205, DOI 10.1007/BF00992220
   KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8
   Kessler RC, 2012, INT J METH PSYCH RES, V21, P169, DOI 10.1002/mpr.1359
   Martins SS, 2012, PSYCHOL MED, V42, P1261, DOI 10.1017/S0033291711002145
   Nayar G, 2017, WORLD NEUROSURG, V100, P69, DOI 10.1016/j.wneu.2016.12.098
   Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10
   Payne WK, 1997, SPINE, V22, P1380, DOI 10.1097/00007632-199706150-00017
   Quello Susan B, 2005, Sci Pract Perspect, V3, P13
   REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511
   Schoenfeld AJ, 2017, J BONE JOINT SURG AM, V99, P1247, DOI 10.2106/JBJS.16.01075
   Sinikallio S, 2007, EUR SPINE J, V16, P905, DOI 10.1007/s00586-007-0349-3
   Tetreault L, 2017, SPINE, V42, P372, DOI 10.1097/BRS.0000000000001777
   Theologis AA, 2016, J NEUROSURG-SPINE, V25, P477, DOI 10.3171/2016.2.SPINE15980
   Tones M, 2006, SPINE, V31, P3027, DOI 10.1097/01.brs.0000249555.87601.fc
   Trief PM, 2000, SPINE, V25, P2616, DOI 10.1097/00007632-200010150-00012
   Wahlman M, 2014, EUR SPINE J, V23, P129, DOI 10.1007/s00586-013-2896-0
   Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6
   Zhang JT, 2011, SPINE, V36, P741, DOI 10.1097/BRS.0b013e3181e0f034
   Zwack A, 2014, MENT HLTH CLIN, V4, P146
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E311
EP E316
DI 10.1016/j.wneu.2019.05.135
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900038
PM 31132486
DA 2020-05-12
ER

PT J
AU Fan, SM
   Chen, YX
   Cao, Y
   Liu, LX
   Liu, FJ
   Zhang, CW
   Zhou, LX
AF Fan, ShuangMin
   Chen, YaXin
   Cao, Yi
   Liu, LunXin
   Liu, FuJun
   Zhang, ChangWei
   Zhou, LiangXue
TI The Effectiveness of Lumbar Drainage in the Management of Delayed or
   Recurrent Cerebrospinal Fluid Leaks: A Retrospective Case Series in a
   Single Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delayed CSF leaks; Lumbar drainage; Recurrent CSF leaks
ID TRANSSPHENOIDAL SURGERY; BASE FRACTURES; CSF LEAK; EXPERIENCE; FISTULA
AB OBJECTIVE: Little is known about the effectiveness of lumbar drainage (LD) in the treatment of delayed or recurrent cerebrospinal fluid (CSF) leaks. We report our institutional experience and the effectiveness of LD in the management of delayed or recurrent CSF leaks.
   METHODS: Between January 2014 and December 2018, a total 21 patients with delayed or recurrent CSF leaks were enrolled in the research. All patients were treated conservatively for 48 hours, and LD was prescribed if CSF leaks still existed after 48 hours. If LD failed, endoscopic endonasal surgery (EES) was performed as soon as possible. Medical records were collected to analyze the effectiveness of LD.
   RESULTS: Among 21 patients, 4 patients experienced resolution with conservative treatment, and 17 patients were treated by CSF diversion by LD. The total cure rate of LD was 9/17 (52.9%). The cure rate was not statistically significantly different (relative risk [3.33; Fisher exact test P = 0.131) between the traumatic group (8/12, 66.7%) and the transsphenoidal surgery group (1/5, 20.0%). During the follow-up time, no recurrence of CSF leaks was observed.
   CONCLUSIONS: The cure rate of LD in delayed or recurrent CSF leaks was lower than that of initial treatment with LD. The cure rate in the traumatic group tended to be higher than that in the transsphenoidal surgery group. EES can be used as a remedial treatment for patients in whom LD has failed.
C1 [Fan, ShuangMin; Chen, YaXin; Cao, Yi; Liu, LunXin; Liu, FuJun; Zhang, ChangWei; Zhou, LiangXue] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
RP Zhou, LX (reprint author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM zhixlll@163.com
FU Science and Technology Bureau of Sichuan Province [0040205301G04]
FX Supported by grants from the Science and Technology Bureau of Sichuan
   Province (Project code: 0040205301G04).
CR Albu S, 2016, CLIN NEUROL NEUROSUR, V142, P43, DOI 10.1016/j.clineuro.2016.01.019
   Caggiano C, 2018, WORLD NEUROSURG, V117, pE575, DOI 10.1016/j.wneu.2018.06.090
   Dalgic A, 2008, MINIM INVAS NEUROSUR, V51, P154, DOI 10.1055/s-2008-1042437
   Friedman JA, 2001, WORLD J SURG, V25, P1062, DOI 10.1007/s00268-001-0059-7
   Hussein K, 2019, ACTA NEUROCHIR, V161, P517, DOI 10.1007/s00701-019-03801-y
   Konuthula N, 2017, AM J RHINOL ALLERGY, V31, pE48, DOI 10.2500/ajra.2017.31.4487
   Phang SY, 2016, BRIT J NEUROSURG, V30, P596, DOI 10.1080/02688697.2016.1229746
   Rocchi G, 2005, SURG NEUROL, V63, P559, DOI 10.1016/j.surneu.2004.07.047
   Sanders-Taylor C, 2015, J NEUROL SURG PART B, V76, P281, DOI 10.1055/s-0034-1544118
   Scholsem M, 2008, NEUROSURGERY, V62, P463, DOI [10.1227/01.NEU.0000297037.51609.07, 10.1227/01.neu.0000316014.97926.82, 10.1227/01.neu.0000325884.05871.aa]
   Shiley SG, 2003, LARYNGOSCOPE, V113, P1283, DOI 10.1097/00005537-200308000-00003
   Strickland BA, 2018, J NEUROSURG, V129, P425, DOI 10.3171/2017.4.JNS162451
   Yeo NK, 2013, ACTA OTO-LARYNGOL, V133, P82, DOI 10.3109/00016489.2012.717180
   Yilmazlar S, 2006, NEUROSURG REV, V29, P64, DOI 10.1007/s10143-005-0396-3
   Zhan RC, 2015, J CRANIOFAC SURG, V26, P1261, DOI 10.1097/SCS.0000000000001691
   Zhang C, 2017, ACTA OTORHINOLARYNGO, V37, P303, DOI 10.14639/0392-100X-1086
   Ziu M, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.4.FOCUS1244
   Zwagerman NT, 2019, J NEUROSURG, V131, P1172, DOI 10.3171/2018.4.JNS172447
NR 18
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E845
EP E850
DI 10.1016/j.wneu.2019.06.054
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900106
PM 31212030
DA 2020-05-12
ER

PT J
AU Feng, CC
   Zhang, YQ
   Chong, FL
   Yang, MH
   Liu, C
   Liu, LBX
   Huang, C
   Huang, C
   Feng, XQ
   Wang, X
   Chu, TW
   Zhou, Y
   Huang, B
AF Feng, Chencheng
   Zhang, Yaqing
   Chong, Fanli
   Yang, Minghui
   Liu, Chang
   Liu, Libangxi
   Huang, Cong
   Huang, Chen
   Feng, Xiaoqing
   Wang, Xuan
   Chu, Tongwei
   Zhou, Yue
   Huang, Bo
TI Establishment and Implementation of an Enhanced Recovery After Surgery
   (ERAS) Pathway Tailored for Minimally Invasive Transforaminal Lumbar
   Interbody Fusion Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cost; Enhanced recovery after surgery; Length of stay; Minimally
   invasive transforaminal lumbar interbody fusion; Multimodal
ID SPINAL SURGERY; POSTOPERATIVE PAIN; MANAGEMENT; THERAPY; CARE
AB PURPOSE: The concept of enhanced recovery after surgery (ERAS) spread to different surgical specialties to minimize surgical stress response and to reduce length of hospital stay (LOS) and cost. Recently, several studies have reported experience with the ERAS program for spine surgery. The aim of this study is to introduce the establishment and implementation of the ERAS pathway for minimally invasive surgery (MIS) transforaminal lumbar interbody fusion (TLIF).
   METHODS: A multidisciplinary ERAS team was created to develop and implement a multimodal and evidence-based ERAS protocol for patients undergoing MIS-TLIF at a single spine center from January 2018. Fourty four cases in the ERAS group were compared with a historical cohort of 30 cases (from January 2017 to December 2017) who underwent MIS-TLIF before the pathway implementation (pre-ERAS group). We reviewed the compliance with ERAS components. The primary outcome was LOS. The secondary outcomes included 30-day readmission rate, 30-day reoperation rate, and financial cost. Perioperative factors and perioperative complications were also assessed.
   RESULTS: The protocol was composed of 11 ERAS components. The ERAS group showed high compliance with the ERAS program. The ERAS group manifested shorter LOS and lower cost compared with the the pre-ERAS group. There were no significant differences in complication rate, 30-day readmission and reoperation rates. Furthermore, the blood loss, operative time, intraoperative fluid infusion and postoperative drainage of the ERAS group decreased.
   CONCLUSIONS: Our ERAS program tailored for MIS-TLIF is able to reduce LOS and cost with minimal complications. The ERAS pathway expedites recovery in patients undergoing lumbar spine fusion.
C1 [Feng, Chencheng; Zhang, Yaqing; Chong, Fanli; Yang, Minghui; Liu, Chang; Liu, Libangxi; Huang, Cong; Chu, Tongwei; Zhou, Yue; Huang, Bo] Third Mil Med Univ, Xinqiao Hosp, Dept Orthoped, Chongqing, Peoples R China.
   [Huang, Chen; Feng, Xiaoqing] Third Mil Med Univ, Xinqiao Hosp, Dept Nutr, Chongqing, Peoples R China.
   [Wang, Xuan] Third Mil Med Univ, Xinqiao Hosp, Dept Pharm, Chongqing, Peoples R China.
RP Huang, B (reprint author), Third Mil Med Univ, Xinqiao Hosp, Dept Orthoped, Chongqing, Peoples R China.
EM bighuang2000@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81572186]; New Technologies for Clinical Use in
   Xinqiao Hospital [2018JSLC002]
FX This study was supported by the National Natural Science Foundation of
   China (81572186) and New Technologies for Clinical Use in Xinqiao
   Hospital (2018JSLC002).
CR Al-Sukhun J, 2012, J CRANIOFAC SURG, V23, P526, DOI 10.1097/SCS.0b013e31824cd4fb
   Ali ZS, 2018, CLIN NEUROL NEUROSUR, V164, P142, DOI 10.1016/j.clineuro.2017.12.003
   Bacchin MR, 2016, SPINE, V41, pE1131, DOI 10.1097/BRS.0000000000001601
   Brusko GD, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18692
   Carli F, 2015, CAN J ANESTH, V62, P110, DOI 10.1007/s12630-014-0264-0
   Dagal A, 2019, SPINE, V44, P959, DOI 10.1097/BRS.0000000000002968
   Devin CJ, 2015, J CLIN NEUROSCI, V22, P930, DOI 10.1016/j.jocn.2015.01.003
   Diaz-Borjon E, 2017, PAIN THER, V6, P61, DOI 10.1007/s40122-017-0066-5
   Elsarrag M, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18700
   Epstein Nancy E, 2014, Surg Neurol Int, V5, pS66, DOI 10.4103/2152-7806.130674
   Fleege C, 2014, ORTHOPADE, V43, P1062, DOI 10.1007/s00132-014-3040-5
   Ge DH, 2018, SPINE, V44, pE555
   Grant MC, 2018, J AM COLL SURGEONS, V226, P267, DOI 10.1016/j.jamcollsurg.2017.12.010
   Grasu RM, 2018, J NEUROSURG-SPINE, V29, P588, DOI 10.3171/2018.4.SPINE171317
   Guest James D, 2004, Spine J, V4, P130, DOI 10.1016/j.spinee.2003.08.027
   Kashefi Parviz, 2012, Adv Biomed Res, V1, P66, DOI 10.4103/2277-9175.100197
   Kehlet H, 1997, BRIT J ANAESTH, V78, P606
   Kehlet H, 2008, ANN SURG, V248, P189, DOI 10.1097/SLA.0b013e31817f2c1a
   Kehlet H, 2008, LANCET, V371, P791, DOI 10.1016/S0140-6736(08)60357-8
   Kim JC, 2011, SPINE, V36, P428, DOI 10.1097/BRS.0b013e3181d26708
   Kjaergaard M, 2012, ACTA ANAESTH SCAND, V56, P282, DOI 10.1111/j.1399-6576.2011.02629.x
   Lamperti M, 2017, CURR OPIN ANESTHESIO, V30, P551, DOI 10.1097/ACO.0000000000000494
   Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952
   Ljungqvist O, 2009, BEST PRACT RES-CLIN, V23, P401, DOI 10.1016/j.bpa.2009.08.004
   McDonald S, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003526.pub3
   McQuay H, 2003, EUR J ANAESTH, V20, P19
   Phan K, 2015, EUR SPINE J, V24, P1017, DOI 10.1007/s00586-015-3903-4
   Rogers LJ, 2018, J THORAC CARDIOV SUR, V155, P1843, DOI 10.1016/j.jtcvs.2017.10.151
   Savitz MH, 2003, NEUROSURGERY, V53, P243, DOI 10.1227/01.NEU.0000072304.16102.2F
   Singh K, 2017, SPINE, V42, P1145, DOI 10.1097/BRS.0000000000001992
   Smith MD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009161.pub2
   Soffin EM, 2018, SPINE, V44, pE561
   Staartjes VE, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18646
   Street JT, 2016, J NEUROSURG-SPINE, V25, P332, DOI 10.3171/2016.2.SPINE151018
   Wainwright TW, 2016, BEST PRACT RES-CLIN, V30, P91, DOI 10.1016/j.bpa.2015.11.001
   Wang MY, 2017, J NEUROSURG-SPINE, V26, P411, DOI 10.3171/2016.9.SPINE16375
   Yu L, 2013, SPINE, V38, P1947, DOI 10.1097/BRS.0b013e3182a69b90
   Zhang F, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-448
   Zhang YQ, 2017, WORLD NEUROSURG, V106, P291, DOI [10.1016/J.WNEU.2017.06.174, 10.1016/j.wneu.2017.06.174]
NR 39
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E317
EP E323
DI 10.1016/j.wneu.2019.05.139
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900039
PM 31132490
DA 2020-05-12
ER

PT J
AU Fluss, R
   Ligas, BA
   Chan, AW
   Ellis, JA
   Ortiz, RA
   Langer, DJ
   Rahme, R
AF Fluss, Rose
   Ligas, Barbara A.
   Chan, Amber W.
   Ellis, Jason A.
   Ortiz, Rafael A.
   Langer, David J.
   Rahme, Ralph
TI Moyamoya-Related Stroke Risk During Pregnancy: An Evidence-Based
   Reappraisal
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delivery; Moyamoya; Postpartum; Pregnancy; Puerperium; Stroke
ID CLINICAL-FEATURES; VAGINAL DELIVERY; DISEASE; WOMEN; EXPERIENCE
AB BACKGROUND: Moyamoya is a rare, yet classic etiology of stroke in young adults, affecting predominately women of childbearing age. The impact of pregnancy on the natural history of symptomatic moyamoya remains a matter of extensive debate, however.
   METHODS: In October 2017, a MEDLINE search was performed using 14 keywords. A total of 12 original articles reporting on cohorts of at least 5 patients were retrieved and reviewed. Individual study data were extracted, pooled, and analyzed.
   RESULTS: A total of 736 pregnancies in 483 patients were included in our analysis. The mean age at delivery was 31 years, and the mean age at diagnosis (before pregnancy) was 22.6 years. Clinical presentation was ischemic stroke in 50.8%, hemorrhagic stroke in 45.9%, headaches in 2.1%, and ischemic-hemorrhagic stroke in 1.2%. After excluding patients first diagnosed during or after pregnancy (n = 283) and those who had been revascularized before pregnancy (n = 183), a total of 270 pregnancies in 188 patients were analyzed. During 224.6 patient-years of follow-up, 22 moyamoya-related neurologic events occurred (annual event rate 9.8%), more than two-thirds of which were transient (12 transient ischemic attacks and 3 seizures). Seven strokes occurred (6 hemorrhagic and 1 ischemic), yielding an annual stroke risk of 3.1%. As a result, 1 patient died and 2 were permanently disabled (annual death/disability rate 1.3%). All remaining patients experienced favorable functional outcomes.
   CONCLUSIONS: The risk of moyamoya-related stroke during pregnancy, delivery, and the postpartum period appears to be similar to or lower than that suggested by published natural history studies in symptomatic patients. A neuroprotective effect of pregnancy in moyamoya patients cannot be excluded.
C1 [Fluss, Rose; Rahme, Ralph] SBH Hlth Syst, Div Neurosurg, New York, NY 10457 USA.
   [Fluss, Rose] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Ligas, Barbara A.; Chan, Amber W.; Ellis, Jason A.; Ortiz, Rafael A.; Langer, David J.; Rahme, Ralph] Zucker Sch Med Hofstra Northwell, Dept Neurosurg, Lenox Hill Hosp, Hempstead, NY 11549 USA.
   [Rahme, Ralph] CUNY, Sch Med, New York, NY 10031 USA.
RP Rahme, R (reprint author), SBH Hlth Syst, Div Neurosurg, New York, NY 10457 USA.; Rahme, R (reprint author), Zucker Sch Med Hofstra Northwell, Dept Neurosurg, Lenox Hill Hosp, Hempstead, NY 11549 USA.; Rahme, R (reprint author), CUNY, Sch Med, New York, NY 10031 USA.
EM rrahme@sbhny.org
OI Rahme, Ralph/0000-0003-1796-7296
CR Acker G, 2018, NEUROSURG REV, V41, P615, DOI 10.1007/s10143-017-0901-5
   Chiu D, 1998, STROKE, V29, P1347, DOI 10.1161/01.STR.29.7.1347
   Derdeyn CP, 2017, STROKE, V48, P894, DOI 10.1161/STROKEAHA.116.014538
   Fujimura M, 2013, NEUROL MED-CHIR, V53, P561, DOI 10.2176/nmc.53.561
   Fukushima K, 2012, J CLIN NEUROSCI, V19, P1358, DOI 10.1016/j.jocn.2011.12.021
   Hallemeier CL, 2006, STROKE, V37, P1490, DOI 10.1161/01.STR.0000221787.70503.ca
   Johnson AC, 2015, PHYSIOLOGY, V30, P139, DOI 10.1152/physiol.00048.2014
   Jung YJ, 2015, YONSEI MED J, V56, P793, DOI 10.3349/ymj.2015.56.3.793
   Kato R, 2006, INT J OBSTET ANESTH, V15, P152, DOI 10.1016/j.ijoa.2005.06.012
   Koellhoffer EC, 2013, TRANSL STROKE RES, V4, P390, DOI 10.1007/s12975-012-0230-5
   Komiyama M, 1998, NEUROSURGERY, V43, P360, DOI 10.1097/00006123-199808000-00114
   Lee SU, 2016, WORLD NEUROSURG, V90, P66, DOI 10.1016/j.wneu.2016.02.062
   Liu XJ, 2014, INT J GYNECOL OBSTET, V125, P150, DOI 10.1016/j.ijgo.2013.10.020
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   Nevo O, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.05.031
   Sato K, 2015, J STROKE CEREBROVASC, V24, P921, DOI 10.1016/j.jstrokecerebrovasdis.2014.11.030
   Sei K, 2015, CLIN CASE REP, V3, P251, DOI 10.1002/ccr3.199
   Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007
   Takahashi JC, 2012, NEUROL MED-CHIR, V52, P304, DOI 10.2176/nmc.52.304
   Tanaka H, 2015, J OBSTET GYNAECOL RE, V41, P517, DOI 10.1111/jog.12557
   Tate J, 2011, WOMENS HEALTH, V7, P363, DOI [10.2217/WHE.11.19, 10.2217/whe.11.19]
   White TG, 2017, PRACT NEUROL, V16, P34
NR 22
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E582
EP E585
DI 10.1016/j.wneu.2019.05.225
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900074
PM 31176061
DA 2020-05-12
ER

PT J
AU Gao, F
   Zhao, W
   Zheng, Y
   Li, SH
   Lin, GW
   Ji, M
   Duan, Y
   Li, J
   Hua, YQ
AF Gao, Feng
   Zhao, Wei
   Zheng, Yu
   Li, Shihong
   Lin, Guangwu
   Ji, Ming
   Duan, Yu
   Li, Jian
   Hua, Yanqing
TI Phase-Contrast Magnetic Resonance Imaging Analysis of Cerebral
   Hyperperfusion Syndrome After Surgery in Adult Patients with Moyamoya
   Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral hyperperfusion syndrome; Moyamoya disease; Phase-contrast
   magnetic resonance imaging
ID EXTRACRANIAL-INTRACRANIAL BYPASS; REVASCULARIZATION SURGERY; ARTERY
   ANASTOMOSIS; BLOOD-FLOW; NEUROLOGIC DETERIORATION; DIAGNOSIS; EFFICACY
AB OBJECTIVE: To investigate potential risk factors for cerebral hyperperfusion syndrome (CHS) after surgery in patients with moyamoya disease (MMD) using phase-contrast magnetic resonance imaging (MRI).
   METHODS: The study included 84 adult patients (89 brain hemispheres) with MMD who underwent surgery. Preoperative phase-contrast MRI scans were performed for all patients. Peak velocity, average velocity, average flow, forward volume, and region of interest area of the bilateral internal and external carotid arteries, superficial temporal artery, and vertebral artery were calculated and analyzed. Patients were divided into CHS and non-CHS groups. Patients' age, sex, clinical symptoms, Suzuki stage, and MRI flow examination results were compared between the 2 groups.
   RESULTS: Nineteen of 84 patients (89 hemispheres) with MMD were in the CHS group. Patients with ischemic onset symptoms were more likely to develop CHS after surgery (P < 0.05). There were no significant differences in age, sex, and Suzuki stage between the 2 groups. For surgery ipsilateral vessels, peak velocity, average flow and forward volume of superficial temporal artery and average flow of external carotid artery and region of interest area of internal carotid artery in the CHS group were significantly lower compared with the non-CHS group (P < 0.05). For surgery contralateral vessels, forward volume of superficial temporal artery and external carotid artery in the CHS group was significantly lower compared with the non-CHS group (P < 0.05).
   CONCLUSIONS: Patients with MMD and ischemic onset symptoms are more likely to develop CHS after surgery. Preoperative phase-contrast MRI analysis may be helpful to predict CHS in patients with MMD after surgery.
C1 [Gao, Feng; Zhao, Wei; Zheng, Yu; Li, Shihong; Lin, Guangwu; Ji, Ming; Hua, Yanqing] Fudan Univ, Huadong Hosp, Dept Radiol, Shanghai, Peoples R China.
   [Duan, Yu; Li, Jian] Fudan Univ, Dept Neurosurg, Shanghai, Peoples R China.
RP Hua, YQ (reprint author), Fudan Univ, Huadong Hosp, Dept Radiol, Shanghai, Peoples R China.
EM hyq_hd@163.com
FU National Natural Science Foundation ProjectNational Natural Science
   Foundation of China [81771816]
FX This study was funded by the National Natural Science Foundation Project
   (grant number 81771816).
CR Alexandrov AV, 2012, J NEUROIMAGING, V22, P215, DOI 10.1111/j.1552-6569.2010.00523.x
   Arias EJ, 2014, NEUROSURGERY, V74, pS116, DOI 10.1227/NEU.0000000000000229
   Brunser AM, 2016, J NEUROIMAGING, V26, P420, DOI 10.1111/jon.12334
   Dusick JR, 2011, NEUROSURGERY, V68, P34, DOI 10.1227/NEU.0b013e3181fc5ec2
   Fujimoto S, 2013, J NEUROL SCI, V325, P10, DOI 10.1016/j.jns.2012.11.006
   Fujimura M, 2007, CHILD NERV SYST, V23, P1195, DOI 10.1007/s00381-007-0361-2
   Fujimura M, 2007, SURG NEUROL, V67, P273, DOI 10.1016/j.surneu.2006.07.017
   Fujimura M, 2015, NEUROL RES, V37, P131, DOI 10.1179/1743132814Y.0000000432
   Fujimura M, 2012, CEREBROVASC DIS, V33, P436, DOI 10.1159/000336765
   Fujimura M, 2011, NEUROSURGERY, V68, P957, DOI 10.1227/NEU.0b013e318208f1da
   Fujimura M, 2009, SURG NEUROL, V71, P442, DOI 10.1016/j.surneu.2008.02.031
   Fukui M, 1997, CLIN NEUROL NEUROSUR, V99, pS238
   Gatehouse PD, 2005, EUR RADIOL, V15, P2172, DOI 10.1007/s00330-005-2829-3
   Hayashi K, 2012, WORLD NEUROSURG, V78, P447, DOI 10.1016/j.wneu.2011.10.041
   Hayashi T, 2010, J NEUROSURG-PEDIATR, V6, P73, DOI 10.3171/2010.4.PEDS09478
   Hokari M, 2012, NEUROL MED-CHIR, V52, P350, DOI 10.2176/nmc.52.350
   Iwata T, 2014, NEUROSURGERY, V75, P546, DOI 10.1227/NEU.0000000000000485
   Kaku Y, 2012, J CEREBR BLOOD F MET, V32, P2066, DOI 10.1038/jcbfm.2012.110
   Kawamata T, 2011, NEUROSURG REV, V34, P355, DOI 10.1007/s10143-011-0331-8
   Kim JE, 2008, CEREBROVASC DIS, V25, P580, DOI 10.1159/000132205
   Neff K Wolfgang, 2006, AJR Am J Roentgenol, V187, pW107, DOI 10.2214/AJR.05.0219
   Noguchi T, 2015, EUR J RADIOL, V84, P1137, DOI 10.1016/j.ejrad.2015.03.011
   Ogasawara K, 2005, NEUROSURGERY, V56, P1380, DOI 10.1227/01.NEU.0000159719.47528.2E
   Okada Y, 2012, J NEUROSURG, V116, P672, DOI 10.3171/2011.11.JNS11944
   PELC LR, 1992, RADIOLOGY, V185, P809, DOI 10.1148/radiology.185.3.1438767
   SUZUKI J, 1969, ARCH NEUROL-CHICAGO, V20, P288, DOI 10.1001/archneur.1969.00480090076012
   Uno M, 1998, NEUROL MED-CHIR, V38, P420, DOI 10.2176/nmc.38.420
   van Mook WNKA, 2005, LANCET NEUROL, V4, P877, DOI 10.1016/S1474-4422(05)70251-9
   Zhao JB, 2018, EXP THER MED, V15, P3570, DOI 10.3892/etm.2018.5850
   Zhao WG, 2013, BRIT J NEUROSURG, V27, P321, DOI 10.3109/02688697.2012.757294
NR 30
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E48
EP E55
DI 10.1016/j.wneu.2019.04.191
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900008
PM 31051310
DA 2020-05-12
ER

PT J
AU Giammattei, L
   Starnoni, D
   Levivier, M
   Messerer, M
   Daniel, RT
AF Giammattei, Lorenzo
   Starnoni, Daniele
   Levivier, Marc
   Messerer, Mahmoud
   Daniel, Roy Thomas
TI Surgery for Clinoidal Meningiomas: Case Series and Meta-Analysis of
   Outcomes and Complications
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior clinoid process; Clinoidal meningiomas; Extradural anterior
   clinoidectomy; Skull base
ID EXTRADURAL ANTERIOR CLINOIDECTOMY; SPHENOID WING MENINGIOMAS; TUBERCULUM
   SELLAE; CAVERNOUS SINUS; SURGICAL-MANAGEMENT; PLANUM SPHENOIDALE;
   OPERATIVE NUANCES; OPTIC-NERVE; RECURRENCE; RESECTION
AB OBJECTIVE: Clinoidal meningiomas present specific characteristics related to their peculiar site of anatomic origin. Clinical series focusing on pure clinoidal meningiomas are not numerous. We performed a systematic review and meta-analysis, including our own case series, of the available literature to better identify the specific features of these tumors.
   METHODS: A systematic review and meta-analysis were performed for surgically treated pure clinoidal meningiomas using PubMed, Cochrane, and Embase databases. A retrospective review of a cohort of 18 consecutive patients treated between 2010 and 2018 in our department was also included in this meta-analysis.
   RESULTS: A total of 1208 patients were included in the analysis. With a weighted mean follow-up of 48.1 months, the pooled rate of gross total resection was 64.2% (95% confidence interval [CI], 57.3%-71.0%) in the overall population, 11.8% (95% CI, 2.4%-21.1%) in the Al-Mefty I subgroup, 92.6% (95% CI, 88.9%-96.3%) in the Al-Mefty II subgroup, and 84.2% (95% CI, 70.8%-97.6%) in the Al-Mefty III subgroup. Overall visual improvement after treatment was found in 48% (95% CI, 38.6%-57.4%) of patients with a pooled deterioration rate of 4.5% (95% CI, 3%-6%). Pooled overall recurrence was observed in 8.9% of patients (95% CI, 6.0%-11.8%) and mortality occurred in 1.2% (95% CI, 0.6%-1.8%).
   CONCLUSIONS: The rate of gross total resection is proportional to the dural origin of these tumors, which is intimately related to critical neurovascular structures. Complementary radiosurgery could represent a valid treatment strategy. Postoperative visual improvement remains less satisfying compared with other suprasellar meningiomas. The introduction of skull-base techniques, such as extradural anterior clinoidectomy, has enabled improvements in visual outcome without any increase in approach-related morbidity.
C1 [Giammattei, Lorenzo; Starnoni, Daniele; Levivier, Marc; Messerer, Mahmoud; Daniel, Roy Thomas] Lausanne Univ Hosp CHUV, Dept Clin Neurosci, Serv Neurosurg, Lausanne, Switzerland.
   [Giammattei, Lorenzo; Starnoni, Daniele; Levivier, Marc; Messerer, Mahmoud; Daniel, Roy Thomas] Lausanne Univ Hosp CHUV, Gamma Knife Ctr, Lausanne, Switzerland.
   [Levivier, Marc; Messerer, Mahmoud; Daniel, Roy Thomas] Univ Lausanne, Fac Biol & Med, Lausanne, Switzerland.
RP Daniel, RT (reprint author), Lausanne Univ Hosp CHUV, Dept Clin Neurosci, Serv Neurosurg, Lausanne, Switzerland.; Daniel, RT (reprint author), Lausanne Univ Hosp CHUV, Gamma Knife Ctr, Lausanne, Switzerland.; Daniel, RT (reprint author), Univ Lausanne, Fac Biol & Med, Lausanne, Switzerland.
EM roy.daniel@chuv.ch
CR Alam S, 2018, NEUROL-NEUROIMMUNOL, V5, P21
   ALMEFTY O, 1990, J NEUROSURG, V73, P840, DOI 10.3171/jns.1990.73.6.0840
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Attia M, 2012, J NEUROSURG, V117, P654, DOI 10.3171/2012.7.JNS111675
   Bassiouni H, 2009, J NEUROSURG, V111, P1078, DOI 10.3171/2009.3.17685
   BONNAL J, 1980, J NEUROSURG, V53, P587, DOI 10.3171/jns.1980.53.5.0587
   Campero Alvaro, 2018, Surg Neurol Int, V9, P140, DOI 10.4103/sni.sni_135_18
   Chang HS, 2006, J NEUROSURG, V104, P621, DOI 10.3171/jns.2006.104.4.621
   Chernov S V, 2017, VOPR NEIROKHIR, V81, P74
   Cui H, 2007, SURG NEUROL, V68, P6, DOI 10.1016/j.sumeu.2007.09.013
   Cushing HEL, 1938, MENINGIOMAS THEIR CL, P311
   Czernicki T, 2015, NEUROL NEUROCHIR POL, V49, P29, DOI 10.1016/j.pjnns.2015.01.003
   Danesh-Meyer HV, 2008, J CLIN NEUROSCI, V15, P95, DOI 10.1016/j.jocn.2007.09.004
   DeJesus O, 1996, NEUROSURGERY, V39, P915, DOI 10.1097/00006123-199611000-00005
   DEMONTE F, 1994, J NEUROSURG, V81, P245, DOI 10.3171/jns.1994.81.2.0245
   DOLENC VV, 1985, J NEUROSURG, V62, P667, DOI 10.3171/jns.1985.62.5.0667
   Evans JJ, 2000, NEUROSURGERY, V46, P1018, DOI 10.1097/00006123-200004000-00053
   Fahlbusch R, 2002, J NEUROSURG, V96, P235, DOI 10.3171/jns.2002.96.2.0235
   Faramand A, 2018, J NEURO-ONCOL, V139, P341, DOI 10.1007/s11060-018-2866-9
   Froelich SC, 2007, NEUROSURGERY, V61, P179, DOI 10.1227/01.neu.0000303215.76477.cd
   Galal A, 2010, ACTA NEUROCHIR, V152, P69, DOI 10.1007/s00701-009-0492-1
   Goel A, 2000, NEUROL MED-CHIR, V40, P610, DOI 10.2176/nmc.40.610
   Gozal YM, 2020, J NEUROSURG, V132, P380, DOI 10.3171/2018.10.JNS181480
   Kim JH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006594
   Lee JH, 2001, NEUROSURGERY, V48, P1012, DOI 10.1097/00006123-200105000-00009
   Leroy HA, 2018, ACTA NEUROCHIR, V160, P2367, DOI 10.1007/s00701-018-3711-9
   Lieber BA, 2014, ACTA NEUROCHIR, V156, P1947, DOI 10.1007/s00701-014-2187-5
   Liu DY, 2012, TURK NEUROSURG, V22, P547, DOI 10.5137/1019-5149.JTN.5142-11.1
   Lu VM, 2018, CLIN NEUROL NEUROSUR, V174, P13, DOI 10.1016/j.clineuro.2018.08.029
   Magill ST, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17753
   Mahmoud M, 2010, NEUROSURGERY S, V67
   Mahmoud M, 2010, NEUROSURGERY, V67, P108, DOI 10.1227/01.NEU.0000383153.75695.24
   Mariniello G, 2013, ACTA NEUROCHIR, V155, P77, DOI 10.1007/s00701-012-1485-z
   Mathiesen T, 1996, NEUROSURGERY, V39, P2, DOI 10.1097/00006123-199607000-00002
   Milano Michael T, 2018, Int J Radiat Oncol Biol Phys, DOI 10.1016/j.ijrobp.2018.01.053
   Minniti G, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-158
   MIRIMANOFF RO, 1985, J NEUROSURG, V62, P18, DOI 10.3171/jns.1985.62.1.0018
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Mortazavi MM, 2016, WORLD NEUROSURG, V86, P270, DOI [10.1016/J.WNEU.2015.09.043, 10.1016/j.wneu.2015.09.043]
   Nagata T, 2013, WORLD NEUROSURG, V79, P116, DOI 10.1016/j.wneu.2011.05.022
   Nakamura M, 2006, NEUROSURGERY, V58, P626, DOI 10.1227/01.NEU.0000197104.78684.5D
   Nanda A, 2016, CLIN NEUROL NEUROSUR, V142, P31, DOI 10.1016/j.clineuro.2016.01.005
   Nimmannitya P, 2016, NEUROSURG REV, V39, P691, DOI 10.1007/s10143-016-0735-6
   Noguchi A, 2005, J NEUROSURG, V102, P945, DOI 10.3171/jns.2005.102.5.0945
   Nozaki K, 2008, NEUROSURGERY, V62, P844
   Nozaki K, 2008, NEUROSURGERY, V62, P839, DOI 10.1227/01.neu.0000318169.75095.cb
   OSullivan MG, 1997, NEUROSURGERY, V40, P238, DOI 10.1097/00006123-199702000-00003
   Oya S, 2018, J NEUROL SURG PART B, V79, pS231, DOI 10.1055/s-0038-1623521
   Pamir MN, 2008, ACTA NEUROCHIR, V150, P625, DOI 10.1007/s00701-008-1594-x
   Park CK, 2006, NEUROSURGERY, V59, P238, DOI 10.1227/01.NEU.0000223341.08402.C5
   Park K, 2018, J SPORT REHABIL, V27, P485, DOI 10.1123/jsr.2016-0222
   Puzzilli F, 1999, Neuro Oncol, V1, P188, DOI 10.1093/neuonc/1.3.188
   RISI P, 1994, BRIT J NEUROSURG, V8, P295, DOI 10.3109/02688699409029617
   Romani R, 2011, NEUROSURGERY, V68, P1632, DOI 10.1227/NEU.0b013e318214a840
   Ruggeri AG, 2016, WORLD NEUROSURG, V88, P374, DOI 10.1016/j.wneu.2015.11.002
   Russell SM, 2008, NEUROSURGERY, V62, P1169, DOI [10.1227/01.NEU.0000297019.60125.71, 10.1227/01.neu.0000333783.96810.58]
   Sade B, 2008, ACTA NEUROCHIR, V150, P1127, DOI 10.1007/s00701-008-0143-y
   Lopez LS, 2018, NEUROCIRUGIA, V29, P225, DOI 10.1016/j.neucir.2018.04.002
   Sekhar L N, 1996, Acta Neurochir Suppl, V65, P58
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Sindou M, 2015, ADV TECH STAND NEURO, V42, P103, DOI 10.1007/978-3-319-09066-5_6
   SLAVIN ML, 1993, AM J OPHTHALMOL, V115, P368, DOI 10.1016/S0002-9394(14)73590-1
   Sughrue M, 2015, CUREUS, V7, DOI 10.7759/cureus.321
   Talacchi A, 2020, NEUROSURG REV, V43, P109, DOI 10.1007/s10143-018-1018-1
   Tobias S, 2003, NEUROSURG FOCUS, V14, P5
   Tomasello F, 2003, ACTA NEUROCHIR, V145, P273, DOI 10.1007/s00701-003-0003-8
   Tsukiyama A, 2017, WORLD NEUROSURG, V107, DOI 10.1016/j.wneu.2017.08.080
   Verma SK, 2016, NEUROL INDIA, V64, P465, DOI 10.4103/0028-3886.181548
   Yonekawa Y, 1997, J NEUROSURG, V87, P636, DOI 10.3171/jns.1997.87.4.0636
NR 69
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E700
EP E717
DI 10.1016/j.wneu.2019.05.253
PG 18
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900089
PM 31176836
DA 2020-05-12
ER

PT J
AU Grasso, G
   Torregrossa, F
   Leone, L
   Frisella, A
   Landi, A
AF Grasso, Giovanni
   Torregrossa, Fabio
   Leone, Ludovica
   Frisella, Antonino
   Landi, Alessandro
TI Long-Term Efficacy of Shunt Therapy in Idiopathic Normal Pressure
   Hydrocephalus
SO WORLD NEUROSURGERY
LA English
DT Article
DE Idiopathic normal pressure hydrocephalus; Outcome; Shunt
ID ADULT HYDROCEPHALUS; PREDICTIVE-VALUE; MANAGEMENT; DIAGNOSIS; SURGERY;
   SIGNS; CSF; MULTICENTER; PREVALENCE; SYMPTOMS
AB BACKGROUND: Idiopathic normal pressure hydrocephalus (iNPH) is one of the very few treatable types of dementia. Shunt therapy has been shown to be effective in improving symptoms. However, the long-term results of cerebrospinal fluid diversion are variable. The aim of this retrospective study was to investigate long-term outcomes of patients with idiopathic normal pressure hydrocephalus treated with ventriculoperitoneal shunt by using programmable valves.
   METHODS: Symptoms before treatment were recorded. Clinical symptoms and outcome after ventriculoperitoneal shunt were assessed based on changes in gait, urinary incontinence, and cognitive dysfunction at yearly follow-up spanning at least 10 years.
   RESULTS: Among 50 patients treated, 5 had died at the time of the evaluation. Median age was 71 years, and mean follow-up time of the surviving patients was 120.2 +/- 2.3 years. Overall, there was a significant and lasting improvement among all symptoms compared with the baseline (P < 0.05). Gait showed better and sustained improvement compared with the baseline (P < 0.05). Cognitive impairment and urinary incontinence improved in the early follow-up (P < 0.05) followed by declines in long-term follow-up. Ten patients (20%) required surgical revisions for shunt malfunction. Change in valve pressure was performed in 20 patients (40%). Overall, 93.3% revisions resulted in clinical improvement.
   CONCLUSIONS: Surgical treatment for idiopathic normal pressure hydrocephalus by ventriculoperitoneal shunt is a safe modality that improves symptoms in most patients, including in the long-term. Strict follow-up is necessary for early diagnosis of shunt malfunction or need for valve adjustment.
C1 [Grasso, Giovanni; Torregrossa, Fabio; Leone, Ludovica; Frisella, Antonino] Univ Palermo, Sect Neurosurg, Dept Biomed Neurosci & Adv Diagnost, Palermo, Italy.
   [Landi, Alessandro] Univ Roma La Sapienza, Dept Neurol & Psychiat, Div Neurosurg, Rome, Italy.
RP Grasso, G (reprint author), Univ Palermo, Sect Neurosurg, Dept Biomed Neurosci & Adv Diagnost, Palermo, Italy.
EM giovanni.grasso@unipa.it
RI grasso, giovanni/K-3774-2018
OI grasso, giovanni/0000-0001-5362-0092
CR Abrams P, 2006, J UROLOGY, V175, P1063, DOI 10.1016/S0022-5347(05)00348-4
   Aygok G, 2005, ACT NEUR S, V95, P241
   Bech-Azeddine R, 2007, J NEUROL NEUROSUR PS, V78, P157, DOI 10.1136/jnnp.2006.095117
   Bergsneider M, 2005, NEUROSURGERY, V57, P29, DOI 10.1227/01.NEU.0000168186.45363.4D
   Black P M, 1985, Clin Neurosurg, V32, P632
   BORGESEN SE, 1984, ACTA NEUROCHIR, V71, P1, DOI 10.1007/BF01401149
   Brean A, 2008, ACTA NEUROL SCAND, V118, P48, DOI 10.1111/j.1600-0404.2007.00982.x
   Brean A, 2009, ACTA NEUROL SCAND, V120, P314, DOI 10.1111/j.1600-0404.2009.01250.x
   CLARFIELD AM, 1988, ANN INTERN MED, V109, P476, DOI 10.7326/0003-4819-109-6-476
   Conn Harold O, 2007, Pract Neurol, V7, P252, DOI 10.1136/jnnp.2007.124404
   Eide PK, 2016, WORLD NEUROSURG, V86, P186, DOI 10.1016/j.wneu.2015.09.067
   FOLSTEIN MF, 1983, ARCH GEN PSYCHIAT, V40, P812
   Golz L, 2014, J NEUROSURG, V121, P771, DOI 10.3171/2014.6.JNS131211
   Hebb AO, 2001, NEUROSURGERY, V49, P1166, DOI 10.1097/00006123-200111000-00028
   Jaraj D, 2014, NEUROLOGY, V82, P1449, DOI 10.1212/WNL.0000000000000342
   Kiefer M, 2006, ACTA NEUROCHIR SUPPL, V96, P364
   Kiefer M, 2012, DTSCH ARZTEBL INT, V109, P15, DOI 10.3238/arztebl.2012.0015
   Klinge P, 2005, NEUROSURGERY, V57, P40, DOI 10.1227/01.NEU.0000168187.01077.2F
   Klinge P, 2012, ACTA NEUROL SCAND, V126, P145, DOI 10.1111/j.1600-0404.2012.01676.x
   Krauss JK, 1997, NEUROL RES, V19, P357, DOI 10.1080/01616412.1997.11740825
   Krauss JK, 2004, ACTA NEUROCHIR, V146, P379, DOI 10.1007/s00701-004-0234-3
   Malm J, 2000, NEUROLOGY, V55, P576, DOI 10.1212/WNL.55.4.576
   Marmarou A, 2005, NEUROSURGERY, V57, P17, DOI 10.1227/01.NEU.0000168184.01002.60
   Meier U, 1998, FORTSCHR NEUROL PSYC, V66, P176, DOI 10.1055/s-2007-995254
   Meier U, 1999, ACTA NEUROCHIR, V141, P1039, DOI 10.1007/s007010050480
   Mihalj M, 2016, J NEUROL SCI, V362, P78, DOI 10.1016/j.jns.2016.01.028
   Mori E, 2012, NEUROL MED-CHIR, V52, P775, DOI 10.2176/nmc.52.775
   Mori K, 2001, J NEUROSURG, V95, P970, DOI 10.3171/jns.2001.95.6.0970
   PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x
   Pujari S, 2008, J NEUROL NEUROSUR PS, V79, P1282, DOI 10.1136/jnnp.2007.123620
   Relkin Norman, 2005, Neurosurgery, V57, pS4
   Savolainen S, 2002, ACTA NEUROCHIR, V144, P515, DOI 10.1007/s00701-002-0936-3
   TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5
   Tisell M, 2006, BRIT J NEUROSURG, V20, P214, DOI 10.1080/02688690600852324
   Tisell M, 2005, ACTA NEUROL SCAND, V112, P72, DOI 10.1111/j.1600-0404.2005.00451.x
   Vakili S, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.6.FOCUS16146
   VANNESTE J, 1992, NEUROLOGY, V42, P54, DOI 10.1212/WNL.42.1.54
   Vanneste JAL, 2000, J NEUROL, V247, P5, DOI 10.1007/s004150050003
NR 38
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E458
EP E463
DI 10.1016/j.wneu.2019.05.183
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900058
PM 31154105
DA 2020-05-12
ER

PT J
AU Gungor, A
   Danyeli, AE
   Akbas, A
   Eksi, MS
   Guduk, M
   Ozduman, K
   Pamir, MN
AF Gungor, Abuzer
   Danyeli, Ayca Ersen
   Akbas, Ahmet
   Eksi, Murat Sakir
   Guduk, Mustafa
   Ozduman, Koray
   Pamir, M. Necmettin
TI Ventricular Meningiomas: Surgical Strategies and a New Finding That
   Suggest an Origin From the Choroid Plexus Epithelium
SO WORLD NEUROSURGERY
LA English
DT Article
DE Choroid plexus; Intraventricular meningioma; Origin; OTX2; Trigone;
   Ventricular surgery
ID INTRAVENTRICULAR MENINGIOMAS; LATERAL VENTRICLE; CONSECUTIVE SERIES;
   RISK-FACTORS; MANAGEMENT; CELLS; SURGERY; TUMORS
AB BACKGROUND: The aim of this study is to share our experiences on a series of 21 patients with intraventricular meningiomas (IVMs). Histopathologic examinations are reviewed in detail and the cell of origin of IVMs is discussed.
   METHODS: We retrospectively reviewed 1372 patients with intracranial meningioma who were surgically treated between September 1986 and July 2018. From this cohort, 21 patients with IVM were identified. The clinical, radiologic, surgical, and follow-up records were analyzed. The archival pathologic specimens were reviewed. Tissue microarray blocks were performed from the formalin-fixed, paraffin-embedded samples of all IVM cases, 2 choroid plexus tissue adjacent to the tumors, and 10 extraventricular fibrous meningioma cases selected as control randomly. Immunohistochemical staining with the antibodies S-100, SOX10, NGFR, and OTX2 was performed according to the protocols indicated by the manufacturers.
   RESULTS: Surgical complications included hemiparesis in 1 patient (5%), postoperative seizure in 1 patient (5%), sensorial aphasia in 1 patient (5%), and preexisting headache in 1 patient (5%). Seventeen (81%) of the IVMs had grade I pathology and 4 (19%) had grade II pathology. The immunoprofile of IVMs is identical to the immunoprofile of normal choroid plexus epithelium.
   CONCLUSIONS: Transcortical approaches using intra-operative ultrasonography and intraoperative monitoring with avoidance of eloquent cortical areas can achieve good outcomes. Resection of the choroidal attachments should be attempted. Our results indicate that IVMs do not show arachnoid cap cell phenotype and the findings support that IVMs originate from the choroid plexus epithelium or the progenitors of the choroid plexus epithelium.
C1 [Gungor, Abuzer; Eksi, Murat Sakir; Guduk, Mustafa; Ozduman, Koray; Pamir, M. Necmettin] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey.
   [Danyeli, Ayca Ersen] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Pathol, Istanbul, Turkey.
   [Akbas, Ahmet] Hlth Sci Univ, Bakirkoy Res & Training, Hosp Psychiat Neurol & Neurosurg, Dept Neurosurg, Istanbul, Turkey.
RP Gungor, A (reprint author), Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey.
EM abuzergungor@gmail.com
RI Danyeli, Ayca Ersen/X-3384-2018; Eksi, Murat Sakir/I-3699-2012
OI Danyeli, Ayca Ersen/0000-0001-8015-9916; Eksi, Murat
   Sakir/0000-0002-3036-0061; gungor, abuzer/0000-0002-2792-7610
CR Bertalanffy A, 2006, NEUROSURG REV, V29, P30, DOI 10.1007/s10143-005-0414-5
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Bhatoe Harjinder S, 2006, Neurosurg Focus, V20, pE9, DOI 10.3171/foc.2006.20.3.10
   Bolos M, 2013, CELL MOL LIFE SCI, V70, P2787, DOI 10.1007/s00018-013-1300-x
   Choi JW, 2011, J KOREAN NEUROSURG S, V50, P538, DOI 10.3340/jkns.2011.50.6.538
   Cushing H, 1922, BRAIN, V45, P282, DOI 10.1093/brain/45.2.282
   Elwatidy SM, 2017, NEUROSCIENCES, V22, P274, DOI 10.17712/nsj.2017.4.20170149
   Fu ZY, 2011, INT J MED SCI, V8, P711, DOI 10.7150/ijms.8.711
   Fusco DJ, 2015, WORLD NEUROSURG, V83, P460, DOI 10.1016/j.wneu.2014.08.042
   Grujicic D, 2017, WORLD NEUROSURG, V97, P178, DOI 10.1016/j.wneu.2016.09.068
   Gungor A, 2017, J NEUROSURG, V126, P945, DOI 10.3171/2016.1.JNS152082
   Itokazu Y, 2006, GLIA, V53, P32, DOI 10.1002/glia.20255
   Johansson PA, 2013, DEVELOPMENT, V140, P1055, DOI 10.1242/dev.090860
   Jung TY, 2007, SURG NEUROL, V68, P172, DOI 10.1016/j.surneu.2006.10.065
   Kalamarides M, 2011, ONCOGENE, V30, P2333, DOI 10.1038/onc.2010.609
   Kawashima M, 2006, SURG NEUROL, V65, P436, DOI 10.1016/j.surneu.2005.09.033
   Kelsh RN, 2006, BIOESSAYS, V28, P788, DOI 10.1002/bies.20445
   Kendall SE, 2003, DEV BRAIN RES, V144, P151, DOI 10.1016/S0165-3806(03)00166-4
   Kim BW, 2011, J KOREAN NEUROSURG S, V49, P26, DOI 10.3340/jkns.2011.49.1.26
   Kim JH, 2018, WORLD NEUROSURG, V118, pE436, DOI 10.1016/j.wneu.2018.06.211
   Kourbeti IS, 2007, NEUROSURGERY, V60, P317, DOI 10.1227/01.NEU.0000249266.26322.25
   LEWIS N, 2016, WHO CLASSIFICATION T, V1, DOI DOI 10.1038/S41550-016-00013
   Li F, 2011, CLIN NEUROL NEUROSUR, V113, P564, DOI 10.1016/j.clineuro.2011.03.017
   Liddelow SA, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00032
   Lyngdoh BT, 2007, J CLIN NEUROSCI, V14, P442, DOI 10.1016/j.jocn.2006.01.005
   Ma J, 2014, WORLD NEUROSURG, V82, P757, DOI 10.1016/j.wneu.2014.05.026
   Menon G, 2009, BRIT J NEUROSURG, V23, P297, DOI 10.1080/02688690902721862
   Mortazavi MM, 2014, CHILD NERV SYST, V30, P205, DOI 10.1007/s00381-013-2326-y
   Nakamura M, 2003, SURG NEUROL, V59, P491, DOI 10.1016/S0090-3019(03)00082-X
   Nanda A, 2016, WORLD NEUROSURG, V88, P526, DOI 10.1016/j.wneu.2015.10.071
   Nayar VV, 2010, CLIN NEUROL NEUROSUR, V112, P400, DOI 10.1016/j.clineuro.2010.02.005
   Nishizaki T, 2009, ACTA NEUROCHIR, V151, P1717, DOI 10.1007/s00701-009-0310-9
   Odegaard KM, 2013, NEUROSURG REV, V36, P57, DOI 10.1007/s10143-012-0410-5
   Oppong MD, 2017, J CLIN NEUROSCI, V43, P157, DOI 10.1016/j.jocn.2017.05.036
   Pereira Benedito Jamilson Araujo, 2020, Neurosurg Rev, V43, P513, DOI 10.1007/s10143-018-1019-0
   Qiu LH, 2014, EXP THER MED, V7, P1393, DOI 10.3892/etm.2014.1550
   RUSSELL DS, 1950, J CLIN PATHOL, V3, P191, DOI 10.1136/jcp.3.3.191
   SCHMIDT MB, 1902, VIRCHOWS ARCH, V170, P429
   Schramm J, 2015, WORLD NEUROSURG, V83, P486, DOI 10.1016/j.wneu.2014.09.012
   Secer HI, 2008, TURK NEUROSURG, V18, P345
   Sizdahkhani S, 2017, WORLD NEUROSURG, V106, P878, DOI 10.1016/j.wneu.2017.07.067
   Sunday-Krishnan S, 2018, NEUROL NEUROCHIR POL, V52, P606, DOI 10.1016/j.pjnns.2018.08.005
   TANAKA Y, 1989, ACTA NEUROCHIR, V99, P20, DOI 10.1007/BF01407772
   TEW JM, 1995, NEUROSURGERY, V36, P1065, DOI 10.1227/00006123-199506000-00001
   Tugcu B, 2016, J NEUROSURG SCI, V60, P159
   Vuckovic N, 2010, J NEUROIMAGING, V20, P294, DOI 10.1111/j.1552-6569.2008.00345.x
   Wang X, 2007, MINIM INVAS NEUROSUR, V50, P346, DOI 10.1055/s-2007-993205
   Wang YZ, 2016, WORLD NEUROSURG, V90, P511, DOI 10.1016/j.wneu.2016.03.040
   Yu YL, 2018, ACTA RADIOL, V59, P980, DOI 10.1177/0284185117738562
   Zanini MA, 2011, ARQ NEURO-PSIQUIAT, V69, P670, DOI 10.1590/S0004-282X2011000500018
   Zhang WH, 2015, J HUAZHONG U SCI-MED, V35, P742, DOI 10.1007/s11596-015-1500-8
NR 51
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E177
EP E190
DI 10.1016/j.wneu.2019.05.092
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900023
PM 31121376
DA 2020-05-12
ER

PT J
AU Handa, K
   Ozawa, H
   Aizawa, T
   Hashimoto, K
   Kanno, H
   Tateda, S
   Toi, E
AF Handa, Kyoichi
   Ozawa, Hiroshi
   Aizawa, Toshimi
   Hashimoto, Ko
   Kanno, Haruo
   Tateda, Satoshi
   Toi, Eiji
TI Surgical Management of Giant Sacral Schwannoma: A Case Series and
   Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Giant schwannoma; Pelvis; Sacrum; Schwannoma
ID INVASIVE SPINAL SCHWANNOMA; CLINICAL-FEATURES; RESECTION
AB OBJECTIVE: Giant sacral schwannomas are rare and difficult to treat. Unexpected neurologic deficits after surgery and tumor recurrence should be considered when surgery is performed. We attempt to remove the tumors via piecemeal total or subtotal excision, leaving parts of the capsule adjacent to nerves to preserve the nerves. This study aimed to present the cases of giant sacral schwannoma at our institutions as well as review the relevant literature and to discuss surgical management.
   METHODS: This study included 11 patients (5 male and 6 female, mean age 53 years) with giant sacral schwannoma who were treated surgically. The clinical features, surgical details, and outcomes were investigated retrospectively.
   RESULTS: The tumors were intraosseous type in 4 cases, dumb-bell type in 3 cases, and retroperitoneal type in 4 cases. The surgeries were performed by a combined anterior and posterior approach in 4 cases, a posterior approach in 4 cases, and an anterior approach in 3 cases. The tumors were removed via piecemeal total or subtotal excision in 7 cases, partial excision in 3 cases, and enucleation in 1 case. After surgery, symptoms improved in all cases. The tumor recurred in 2 patients after partial excision. No patients receiving piecemeal total or subtotal excision showed recurrence. One patient developed motor weakness after piecemeal subtotal excision, but the symptoms resolved.
   CONCLUSIONS: Adopting an appropriate surgical approach based on the location of the tumor is important. Piecemeal total or subtotal excision, with parts of the capsule adjacent to nerves left behind may help achieve a good outcome, avoiding a postoperative neurologic deficit.
C1 [Handa, Kyoichi; Aizawa, Toshimi; Hashimoto, Ko; Kanno, Haruo; Toi, Eiji] Tohoku Univ, Dept Orthopaed Surg, Grad Sch Med, Sendai, Miyagi, Japan.
   [Ozawa, Hiroshi; Tateda, Satoshi] Tohoku Med & Pharmaceut Univ, Dept Orthopaed Surg, Fac Med, Sendai, Miyagi, Japan.
RP Handa, K (reprint author), Tohoku Univ, Dept Orthopaed Surg, Grad Sch Med, Sendai, Miyagi, Japan.
EM khanda@med.thoku.ac.jp
RI Kanno, Haruo/AAA-2187-2020
OI Kanno, Haruo/0000-0003-1985-2257
CR ABERNATHEY CD, 1986, J NEUROSURG, V65, P286, DOI 10.3171/jns.1986.65.3.0286
   Arrotegui I., 2018, J NERV SYST, V1, P7
   Cagli S, 2012, J NEURO-ONCOL, V110, P105, DOI 10.1007/s11060-012-0941-1
   Chandhanayingyong Chandhanarat, 2008, Sarcoma, V2008, P845132, DOI 10.1155/2008/845132
   Change EM, 2001, AM J SURG PATHOL, V25, P13
   Chen KW, 2013, ONCOL LETT, V6, P251, DOI 10.3892/ol.2013.1328
   Dominguez J, 1997, ACTA NEUROCHIR, V139, P954, DOI 10.1007/BF01411305
   Fukuda K, 2006, CLIN ORTHOP SURG, V41, P1309
   Hosaka Seiji, 2010, Gan To Kagaku Ryoho, V37, P2319
   Inoue S, 1996, ORTHOP TRAUMATOL, V45, P86
   Kanamori M, 2013, ASIAN SPINE J, V7, P227, DOI 10.4184/asj.2013.7.3.227
   Kawano K, 1994, CLIN ORTHOP SURG, V29, P99
   Khan UA, 2018, WORLD NEUROSURG, V115, P65, DOI 10.1016/j.wneu.2018.03.203
   Lin CL, 2016, EUR SPINE J, V25, P4103, DOI 10.1007/s00586-016-4782-z
   Matityahu A, 2013, CLIN ORTHOP RELAT R, V471, P2906, DOI 10.1007/s11999-013-3119-z
   Nishikawa R, 2009, J JPN SURG ASS, P912
   Ozturk C, 2009, ACTA ORTHOP BELG, V75, P705
   Pan WB, 2017, ONCOTARGET, V8, P38061, DOI 10.18632/oncotarget.16968
   Park SC, 2009, J KOREAN NEUROSURG S, V46, P403, DOI 10.3340/jkns.2009.46.4.403
   Paulo D, 2018, WORLD NEUROSURG, V114, P13, DOI 10.1016/j.wneu.2018.02.146
   Pongsthorn C, 2010, UPSALA J MED SCI, V115, P146, DOI 10.3109/03009730903359674
   Shi James, 2016, Eur J Orthop Surg Traumatol, V26, P877
   Sridhar K, 2001, J NEUROSURG, V94, P210, DOI 10.3171/spi.2001.94.2.0210
   Togral G, 2014, NEUROSCIENCES, V19, P224
   TURK PS, 1992, CANCER-AM CANCER SOC, V70, P2650, DOI 10.1002/1097-0142(19921201)70:11<2650::AID-CNCR2820701114>3.0.CO;2-1
   Uchihara Y, 2015, ORTHOP SURG, V66, P1069
   Xu H, 2015, INT J CLIN EXP PATHO, V8, P15363
   Yu NH, 2012, NEUROSURGERY, V71, P58, DOI 10.1227/NEU.0b013e31824f4f96
NR 28
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E216
EP E223
DI 10.1016/j.wneu.2019.05.113
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900027
PM 31125780
DA 2020-05-12
ER

PT J
AU Hao, ZL
   Lei, CY
   Liu, JF
   Wang, DR
   Wu, B
   Liu, M
AF Hao, Zilong
   Lei, Chunyan
   Liu, Junfeng
   Wang, Deren
   Wu, Bo
   Liu, Ming
TI Sex-Specific Differences in Clinical Characteristics and Outcomes Among
   Patients with Vascular Abnormality-Related Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracerebral hemorrhage; Prognosis; Sex differences; Vascular
   abnormality
ID STROKE TREATMENT; RISK-FACTORS; CHINA; MORTALITY; FEMALE; CARE
AB BACKGROUND: Results are conflicting as to whether sex has an impact on the outcome of intracerebral hemorrhage (ICH), especially when etiologies differ. In this study, we investigated whether sex differences exist in patients with vascular abnormality-related ICH.
   METHODS: Patients (age >= 18 years) diagnosed with ICH within 7 days of symptom onset were admitted consecutively between January 2012 and February 2014 from 50 hospitals across mainland China. Vascular abnormality related to ICH included aneurysm, arteriovenous malformation, moyamoya disease, and cavernous malformation. The outcomes were death and death/disability at 3 months. Disability was defined as modified Rankin Scale score >2. Multivariable logistic regression was used to estimate the association between sex and outcome.
   RESULTS: Women accounted for 41.9% (170) of the 406 patients, and they tended to be older than the men (women: 43.5 +/- 19.3 years; men: 40.0 +/- 17.7 years; P = 0.056). The proportions of ICH-related vascular abnormalities were as follows: aneurysm, 32% (130/406); arteriovenous malformation, 50.3% (204/406); moyamoya disease, 11.3% (46/406); and cavernous malformation, 6.4% (26/406). After we adjusted for age, National Institute of Health Stroke Scale, Glasgow Coma Scale score, location of hemorrhage, and surgery, female sex remained an independent predictor of death/disability at 3 months (odd ratio 2.49, 95% confidence interval 1.31-4.75), but not for death alone (odd ratio 1.45, 95% confidence interval 0.58-3.61).
   CONCLUSIONS: In our study, female sex was an independent risk factor for poor outcomes in patients with vascular abnormality-related ICH. The factors contributing to this sex difference should be investigated in the future.
C1 [Hao, Zilong; Liu, Junfeng; Wang, Deren; Wu, Bo; Liu, Ming] Sichuan Univ, West China Hosp, Ctr Cerebrovasc Dis, Dept Neurol, Chengdu, Sichuan, Peoples R China.
   [Lei, Chunyan] Kunming Med Univ, Dept Neurol, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China.
RP Liu, M (reprint author), Sichuan Univ, West China Hosp, Ctr Cerebrovasc Dis, Dept Neurol, Chengdu, Sichuan, Peoples R China.
EM wyplmh@hotmail.com
OI Wang, Deren/0000-0002-2388-3585
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81601012]; Key Research and Development Programme,
   Science & Technology Department of Sichuan Province [2017SZ0007];
   Science and Technology Program of Sichuan Province [2016JY0151];
   National Key Technology R&D Program for the 12th Five-year Plan of
   Peoples Republic of ChinaNational Key Technology R&D Program
   [2011BAI08B05]; West China Hospital, Sichuan UniversitySichuan
   University [ZYGD18009]
FX This work was supported by the National Natural Science Foundation of
   China (81601012), Key Research and Development Programme, Science &
   Technology Department of Sichuan Province (Grant No. 2017SZ0007),
   Science and Technology Program of Sichuan Province (No. 2016JY0151), the
   National Key Technology R&D Program for the 12th Five-year Plan of
   Peoples Republic of China (2011BAI08B05), and 1$ 3$ 5 project for
   disciplines of excellence, West China Hospital, Sichuan University
   (ZYGD18009).
CR [Anonymous], 1989, STROKE, V20, P1407
   Appelros P, 2010, ACTA NEUROL SCAND, V121, P359, DOI 10.1111/j.1600-0404.2009.01258.x
   BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828
   Bushnell C, 2018, LANCET NEUROL, V17, P641, DOI 10.1016/S1474-4422(18)30201-1
   Chen ZH, 2017, NEUROEPIDEMIOLOGY, V48, P95, DOI 10.1159/000477494
   Chen ZM, 2015, LANCET, V386, P1447, DOI 10.1016/S0140-6736(15)00340-2
   Cordonnier C, 2017, NAT REV NEUROL, V13, P521, DOI 10.1038/nrneurol.2017.95
   de Ridder I, 2017, INT J STROKE, V12, P416, DOI 10.1177/1747493016677981
   Demel SL, 2018, STROKE, V49, P518, DOI 10.1161/STROKEAHA.117.018415
   Di Carlo A, 2003, STROKE, V34, P1114, DOI 10.1161/01.STR.0000068410.07397.D7
   Flaherty ML, 2008, NEUROLOGY, V71, P1084, DOI 10.1212/01.wnl.0000326895.58992.27
   Gall S, 2018, STROKE, V49, P531, DOI 10.1161/STROKEAHA.117.018417
   Ganti L, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/219097
   Glader EL, 2003, STROKE, V34, P1970, DOI 10.1161/01.STR.0000083534.81284.C5
   Gokhale S, 2015, STROKE, V46, P886, DOI 10.1161/STROKEAHA.114.007682
   Guha R, 2017, NEUROLOGY, V89, P349, DOI 10.1212/WNL.0000000000004143
   Hsieh JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152945
   James ML, 2017, NEUROLOGY, V89, P1011, DOI 10.1212/WNL.0000000000004255
   Labovitz DL, 2005, NEUROLOGY, V65, P518, DOI 10.1212/01.wnl.0000172915.71933.00
   Lovelock CE, 2007, LANCET NEUROL, V6, P487, DOI 10.1016/S1474-4422(07)70107-2
   Marini S, 2017, J NEUROL SCI, V379, P112, DOI 10.1016/j.jns.2017.05.057
   Marti-Fabregas J, 2018, J STROKE CEREBROVASC, V27, P2375, DOI 10.1016/j.jstrokecerebrovasdis.2018.04.026
   Meretoja A, 2012, STROKE, V43, P2592, DOI 10.1161/STROKEAHA.112.661603
   Murthy SB, 2017, NEUROLOGY, V88, P1882, DOI 10.1212/WNL.0000000000003935
   Phan HT, 2018, NEUROLOGY, V90, pE1945, DOI 10.1212/WNL.0000000000005602
   Phan HT, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.003436
   Poorthuis MHF, 2017, JAMA NEUROL, V74, P75, DOI 10.1001/jamaneurol.2016.3482
   Roquer J, 2016, NEUROLOGY, V87, P257, DOI 10.1212/WNL.0000000000002792
   Spani CB, 2018, FRONT NEUROENDOCRIN, V50, P52, DOI 10.1016/j.yfrne.2018.03.006
   Beijnum J, 2009, BRAIN, V132, P537, DOI 10.1093/brain/awn318
   Wei JW, 2010, STROKE, V41, P1877, DOI 10.1161/STROKEAHA.110.586909
   Willers C, 2018, BIOL SEX DIFFER, V9, DOI 10.1186/s13293-018-0170-1
   Wilterdink JL, 2001, STROKE, V32, P2836, DOI 10.1161/hs1201.099384
   Xing YH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00383-6
   Zhou JS, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0172-5
NR 35
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E669
EP E676
DI 10.1016/j.wneu.2019.05.243
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900085
PM 31181362
DA 2020-05-12
ER

PT J
AU He, HY
   Li, WS
   Cai, MQ
   Luo, L
   Li, MT
   Ling, C
   Huang, TC
   Yang, HS
   Guo, Y
AF He, Haiyong
   Li, Wensheng
   Cai, Meiqin
   Luo, Lun
   Li, Manting
   Ling, Cong
   Huang, Tengchao
   Yang, Huasheng
   Guo, Ying
TI Outcomes After Pterional and Supraorbital Eyebrow Approach for
   Cranio-Orbital Lesions Communicated via the Supraorbital Fissure-A
   Retrospective Comparison
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cranio-orbital lesions; Microsurgery; Pterional approach; Supraorbital
   eyebrow approach
ID RADIATION-THERAPY; TUMORS; MENINGIOMAS; MANAGEMENT; SURGERY
AB OBJECTIVE: The pterional approach (PA) has been used to remove cranio-orbital lesions that have communicated via the supraorbital fissure (SOF). The supraorbital eyebrow approach (SEA) has become increasingly popular as a minimally invasive approach. However, few reports have examined the SEA for cranio-orbital lesions. We assessed the relative advantages, disadvantages, and selection criteria for these 2 approaches.
   METHODS: The data from all consecutive patients who had undergone removal of a cranio-orbital lesion that communicated via the SOF using the PA or SEA were analyzed.
   RESULTS: Of the 25 patients, 13 had undergone surgical resection using the SEA and 12 had undergone resection using the PA. The SEA provided better cosmetic satisfaction, resulted in a shorter surgical time, and required a shorter incision (P < 0.05). Proptosis had improved significantly in all the patients. No significant differences were found in the total resection rates, visual outcomes, recovery of ptosis, or other new surgically related complications between the 2 groups (P > 0.05). All the patients were followed up for an average of 21.9 months. One patient in each group had developed recurrence or progression that required radiotherapy. The disease of the other patients with subtotal resection was stable or atrophic.
   CONCLUSION: The SEA provided better cosmetic satisfaction, resulted in a shorter surgical time, and required a shorter incision. The SEA might be a more minimally invasive option for lesions communicating via the SOF without obvious hyperostosis. The PA might be more reasonable for lesions with obvious hyperostosis and more extensive lesions in the cavernous sinus.
C1 [He, Haiyong; Li, Wensheng; Cai, Meiqin; Luo, Lun; Li, Manting; Ling, Cong; Huang, Tengchao; Guo, Ying] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Dept Neurosurg, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
   [Yang, Huasheng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Dept Eye Tumor & Orbital Dis, Guangzhou, Guangdong, Peoples R China.
RP Guo, Y (reprint author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Dept Neurosurg, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
EM neuro3sums@126.com
FU Natural Science Foundation of GuangdongNational Natural Science
   Foundation of Guangdong Province [2018B0303110014]; Science and
   Technology Program of Guangzhou [201604020080]; Science and Technology
   Project of Guangdong Province [2015A020212016, 2016A020214007]
FX The present study was supported by the Natural Science Foundation of
   Guangdong (grant 2018B0303110014), Science and Technology Program of
   Guangzhou (grant 201604020080), and Science and Technology Project of
   Guangdong Province (grants 2015A020212016 and 2016A020214007).
CR Adawi MM, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.058
   Boari N, 2013, BRIT J NEUROSURG, V27, P84, DOI 10.3109/02688697.2012.709557
   Ducasse A, 2016, J FR OPHTALMOL, V39, P387, DOI 10.1016/j.jfo.2015.11.009
   Finger PT, 2009, SURV OPHTHALMOL, V54, P545, DOI 10.1016/j.survophthal.2009.06.004
   Freeman JL, 2017, WORLD NEUROSURG, V99, P369, DOI 10.1016/j.wneu.2016.12.063
   He HY, 2018, WORLD NEUROSURG, V114, pE631, DOI 10.1016/j.wneu.2018.03.043
   Honavar SG, 2017, ASIA-PAC J OPHTHALMO, V6, P153, DOI 10.22608/APO.201736
   Honig S, 2010, NEUROL RES, V32, P314, DOI 10.1179/016164109X12464612122614
   Jian TM, 2015, J CRANIOFAC SURG, V26, P441, DOI 10.1097/SCS.0000000000001346
   Jo KI, 2012, J NEUROSURG, V117, P102, DOI 10.3171/2012.7.GKS12780
   Liu Y, 2012, INT J OPHTHALMOL-CHI, V5, P212, DOI 10.3980/j.issn.2222-3959.2012.02.19
   Margalit Nevo, 2007, Neurosurg Focus, V23, pE11, DOI 10.3171/foc.2007.23.5.12
   Mariniello G, 2013, CLIN NEUROL NEUROSUR, V115, P1615, DOI 10.1016/j.clineuro.2013.02.012
   Marwaha G, 2013, DEV OPHTHALMOL, V52, P94, DOI 10.1159/000351084
   Montano N, 2018, WORLD NEUROSURG, V119, pE449, DOI 10.1016/j.wneu.2018.07.181
   Moscote-Salazar Luis Rafael, 2012, Bol Asoc Med P R, V104, P32
   Poloschek CM, 2011, OPHTHALMOLOGE, V108, P510, DOI 10.1007/s00347-010-2190-z
   Shimizu S, 2015, J NEUROL SURG PART B, V76, P459, DOI 10.1055/s-0035-1554903
   Singh D, 2012, EYE, V26, P448, DOI 10.1038/eye.2011.308
   Talacchi A, 2014, NEUROSURG REV, V37, P301, DOI 10.1007/s10143-014-0517-y
   Terrier LM, 2018, WORLD NEUROSURG, V112, pE145, DOI 10.1016/j.wneu.2017.12.182
   Yannick N, 2012, ACTA OPHTHALMOL, V90, pe663, DOI 10.1111/j.1755-3768.2012.02419.x
NR 22
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E279
EP E285
DI 10.1016/j.wneu.2019.05.128
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900034
PM 31128311
DA 2020-05-12
ER

PT J
AU Heiferman, DM
   Jack, MM
   Johnson, KD
   Katsevman, GA
   Prabhu, VC
   Germanwala, AV
   Serrone, JC
AF Heiferman, Daniel M.
   Jack, Megan M.
   Johnson, Kendrick D.
   Katsevman, Gennadiy A.
   Prabhu, Vikram C.
   Germanwala, Anand, V
   Serrone, Joseph C.
TI Mercury vs. Water: An Analysis of Multi-Institutional Survey Data
   Assessing Intracranial Pressure Unit of Measure Awareness
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial pressure; Measures; Neurological surgery
ID MANAGEMENT
AB BACKGROUND: Intracranial pressure (ICP) reporting impacts neurosurgical care. Millimeters of mercury (mmHg) and centimeters of water (cmH(2)O) are both used to report ICP in clinical practice and the literature. In this study, we investigated ICP unit of measure awareness in the neurosurgical community.
   METHODS: A survey was conducted at four US academic neurosurgery departments asking the following questions: What is your threshold for a concerning ICP? How many minutes is that ICP sustained for you to be concerned? What unit are you implying when you state that ICP? What unit of measure is an ICP reported on the monitor when transduced? When setting an external ventricular drain Becker bag level, what unit of measure do you set it to? Do you ever manually check an ICP based on a column of cerebrospinal fluid? How many cmH(2)O is 20 mmHg?
   RESULTS: An ICP of 20 and sustained for five minutes were the two most common answers. Some 71% of residents and 34% of attendings reported using cmH(2)O as the unit of measure; 18% of residents and 24% of attendings implied different units when discussing ICP than the unit they thought was transduced; and 53% of residents and 34% of attendings did not know the transduced ICP unit of measure reported in their intensive care unit.
   CONCLUSIONS: Variability and discrepancies regarding the ICP unit of measure exist in academic neurosurgery departments. Clinicians should familiarize themselves with their hospital's practices. Institutions and all of medicine may consider standardizing the ICP unit of measure, using mmHg as a universal nomenclature.
C1 [Heiferman, Daniel M.; Prabhu, Vikram C.; Germanwala, Anand, V; Serrone, Joseph C.] Loyola Univ, Med Ctr, Dept Neurol Surg, Stritch Sch Med, 2160 S 1st Ave, Maywood, IL 60153 USA.
   [Jack, Megan M.] Univ Kansas, Med Ctr, Dept Neurol Surg, Kansas City, KS 66103 USA.
   [Johnson, Kendrick D.] Univ Illinois, Coll Med Peoria, Dept Neurol Surg, Peoria, IL USA.
   [Katsevman, Gennadiy A.] West Virginia Univ, Dept Neurol Surg, Morgantown, WV 26506 USA.
RP Heiferman, DM (reprint author), Loyola Univ, Med Ctr, Dept Neurol Surg, Stritch Sch Med, 2160 S 1st Ave, Maywood, IL 60153 USA.
EM daniek@heiferman.com
CR Benvenga S, 2004, LANCET, V363, P1368, DOI 10.1016/S0140-6736(04)16049-2
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Fried HI, 2016, NEUROCRIT CARE, V24, P61, DOI 10.1007/s12028-015-0224-8
   Klopfenstein JD, 2004, J NEUROSURG, V100, P225, DOI 10.3171/jns.2004.100.2.0225
   Lloyd R., 1999, METRIC MISHAP CAUSED
   LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1
   MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523
   Monro A, 1783, OBSERVATIONS STRUCTU
   NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650
   Robba C, 2018, INTENS CARE MED, V44, P1284, DOI 10.1007/s00134-018-5305-7
   Yin HS, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0357
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E657
EP E662
DI 10.1016/j.wneu.2019.05.238
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900083
PM 31281108
DA 2020-05-12
ER

PT J
AU Hejrati, N
   Spieler, D
   Samuel, R
   Regli, L
   Weyerbrock, A
   Surbeck, W
AF Hejrati, Nader
   Spieler, Derek
   Samuel, Robin
   Regli, Luca
   Weyerbrock, Astrid
   Surbeck, Werner
TI Conscious Experience and Psychological Consequences of Awake Craniotomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Awake craniotomy; Brain tumor; Depression; Fear; Pain perception;
   Psychology; Stress
ID QUALITY-OF-LIFE; PATIENT EXPERIENCE; TUMOR SURGERY; SATISFACTION;
   GLIOMA; PAIN; GLIOBLASTOMA; VALIDATION; TOLERANCE; RESECTION
AB BACKGROUND: Experiencing cranial surgery under awake conditions may expose patients to considerable psychological strain.
   METHODS: This study aimed to investigate the occurrence and course of psychological sequelae following awake craniotomy (AC) for brain tumors in a series of 20 patients using a broad, validated psychological assessment preoperatively, intraoperatively, postoperatively and a standardized follow-up of 3 months. In addition, the association of the preoperative psychological condition (including, but not limited to, anxiety and fear) with peri-operative pain perception and interference was assessed.
   RESULTS: AC did not induce any shift in the median levels of anxiety, depression, and stress symptoms already present prior to the procedure. Furthermore, anxiety and depression were all moderately to strongly associated over time (all P < 0.05). Stress symptoms also correlated positively over all times of measurement. Stress 3 days after surgery was strongly associated with stress 3 months after surgery (P < 0.001), whereas the correlation between preoperative and immediate postoperative stress showed a statistical trend (P = 0.07). Preoperative fear was not related to intraoperative pain, but to pain and its interference with daily activity on the third postoperative day (P < 0.001 and P < 0.01, respectively).
   CONCLUSIONS: Postoperative psychological symptoms clearly correlated with their corresponding preoperative symptoms. Thus, mental health was not negatively affected by the AC experience in our series. Intraoperative fear and pain were not related to the preoperative psychological condition. However, preoperative fear and anxiety were positively related with pain and its interference with daily activity in the immediate postoperative period.
C1 [Hejrati, Nader; Weyerbrock, Astrid] Cantonal Hosp St Gallen, Dept Neurosurg, St Gallen, Switzerland.
   [Hejrati, Nader] Univ Hosp Basel, Dept Neurosurg, Basel, Switzerland.
   [Spieler, Derek] Albert Ludwigs Univ Freiburg, Univ Med Ctr Freiburg, Dept Psychosomat Med & Psychotherapy, Freiburg, Germany.
   [Samuel, Robin] Univ Luxembourg, Res Unit INSIDE, Esch Sur Alzette, Luxembourg.
   [Regli, Luca] Univ Hosp Zurich, Dept Neurosurg, Zurich, Switzerland.
   [Surbeck, Werner] Univ Zurich, Dept Psychiat Psychotherapy & Psychosomat, Psychiat Hosp, Zurich, Switzerland.
RP Surbeck, W (reprint author), Univ Zurich, Dept Psychiat Psychotherapy & Psychosomat, Psychiat Hosp, Zurich, Switzerland.
EM werner.surbeck@puk.zh.ch
RI Weyerbrock, Astrid/AAI-1731-2020
OI Weyerbrock, Astrid/0000-0001-9060-4462; Hejrati,
   Nader/0000-0001-8583-9849; Spieler, Derek/0000-0003-0977-753X
CR Beez T, 2013, ACTA NEUROCHIR, V155, P1301, DOI 10.1007/s00701-013-1759-0
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   Brown T, 2013, J NEUROSURG ANESTH, V25, P240, DOI 10.1097/ANA.0b013e318290c230
   Campanella F, 2017, WORLD NEUROSURG, V103, P799, DOI 10.1016/j.wneu.2017.04.006
   Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
   Danks RA, 1998, NEUROSURGERY, V42, P28, DOI 10.1097/00006123-199801000-00006
   De Benedictis A, 2010, NEUROSURGERY, V66, P1074, DOI 10.1227/01.NEU.0000369514.74284.78
   Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0
   Fletcher KJ, 2012, BRIT J HEALTH PSYCH, V17, P828, DOI 10.1111/j.2044-8287.2012.02079.x
   Goebel S, 2011, PSYCHO-ONCOLOGY, V20, P623, DOI 10.1002/pon.1958
   Goebel S, 2010, NEUROSURGERY, V67, P594, DOI 10.1227/01.NEU.0000374870.46963.BB
   Grafe K, 2004, DIAGNOSTICA, V50, P171, DOI 10.1026/0012-1924.50.4.171
   Grossman R, 2013, ANN SURG ONCOL, V20, P1722, DOI 10.1245/s10434-012-2748-x
   Joswig H, 2016, WORLD NEUROSURG, V90, P588, DOI 10.1016/j.wneu.2016.02.051
   Khu KJ, 2010, J NEUROSURG, V112, P1056, DOI 10.3171/2009.6.JNS09716
   Kiebert GM, 1998, EUR J CANCER, V34, P1902, DOI 10.1016/S0959-8049(98)00268-8
   KREMER E, 1981, PAIN, V10, P241, DOI 10.1016/0304-3959(81)90199-8
   Liu R, 2009, NEURO-ONCOLOGY, V11, P59, DOI 10.1215/15228517-2008-063
   Manchella S, 2011, BRIT J NEUROSURG, V25, P391, DOI 10.3109/02688697.2011.568640
   Manninen PH, 2006, ANESTH ANALG, V102, P237, DOI 10.1213/01.ANE.0000181287.86811.5C
   Milian M, 2014, ACTA NEUROCHIR, V156, P1063, DOI 10.1007/s00701-014-2038-4
   Milian M, 2013, J NEUROSURG, V118, P1288, DOI 10.3171/2013.2.JNS121254
   Osoba D, 2000, J CLIN ONCOL, V18, P1481, DOI 10.1200/JCO.2000.18.7.1481
   Palese A, 2008, CANCER NURS, V31, P166, DOI 10.1097/01.NCC.0000305699.97625.dc
   Potters JW, 2015, CURR OPIN ANESTHESIO, V28, P511, DOI 10.1097/ACO.0000000000000231
   Radbruch L, 1999, J PAIN SYMPTOM MANAG, V18, P180, DOI 10.1016/S0885-3924(99)00064-0
   Sanai N, 2008, NEUROSURGERY, V62, P753, DOI 10.1227/01.neu.0000318159.21731.cf
   Santini B, 2012, J NEUROSURG ANESTH, V24, P209, DOI 10.1097/ANA.0b013e3182464aec
   Surbeck W, 2015, ACTA NEUROCHIR, V157, P77, DOI 10.1007/s00701-014-2249-8
   Taphoorn MJB, 2005, LANCET ONCOL, V6, P937, DOI 10.1016/S1470-2045(05)70432-0
   Wahab SS, 2011, BRIT J NEUROSURG, V25, P606, DOI 10.3109/02688697.2011.568642
   Whittle IR, 2005, ACTA NEUROCHIR, V147, P275, DOI 10.1007/s00701-004-0445-7
   Wrede KH, 2011, CLIN NEUROL NEUROSUR, V113, P880, DOI 10.1016/j.clineuro.2011.06.010
   Zabora J, 2001, PSYCHO-ONCOL, V10, P19, DOI 10.1002/1099-1611(200101/02)10:1<19::AID-PON501>3.3.CO;2-Y
NR 34
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E381
EP E386
DI 10.1016/j.wneu.2019.05.156
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900048
PM 31136840
DA 2020-05-12
ER

PT J
AU Hong, JY
   Choi, SW
   Kim, GD
   Kim, H
   Shin, BJ
   Kim, EH
   Lee, JC
   Park, JS
   Jang, HD
AF Hong, Jae-Young
   Choi, Sung-Woo
   Kim, Gi Deok
   Kim, HyunKwon
   Shin, Byung-Joon
   Kim, Eung-Ha
   Lee, Jae Chul
   Park, Jin-Sung
   Jang, Hae-Dong
TI Reliability Analyses of Radiographic Measures of Vertebral Body Height
   Loss in Thoracolumbar Burst Fractures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Burst fracture; Compression ratio; Measurement; Reliability; Vertebral
   body height loss
ID POSTERIOR INSTRUMENTATION; CORONAL CURVATURE; SHORT SEGMENT; MANAGEMENT;
   SCOLIOSIS; INJURY; CLASSIFICATION; INTRAOBSERVER; INTEROBSERVER;
   PARAMETERS
AB OBJECTIVE: In thoracolumbar (TL) burst fractures, vertebral body height loss (VBHL) indicates the degree of instability and constitutes one of the decision criteria for surgical treatment. However, the relative reliability and variability of different measurement techniques for VBHL are unknown. We compared the reliability of different methods used to assess VBHL.
   METHODS: A total of 144 patients with TL burst fractures were included, and lateral radiographs were taken twice at an interval of 2 weeks, which were examined by 3 observers. The measurement methods used included the anterior/posterior vertebral body height compression ratio (APCR), anterior height compression percentage (AHCP), and anterior/posterior vertebral body height compression ratio percentage. To compare the accuracy of measurements according to vertebral degeneration, subjects were divided into 2 groups based on the median age of 50 years.
   RESULTS: In intraobserver comparisons, the APCR method showed a higher inter-and intraclass correlation coefficient (ICC) (>0.714) compared with the other methods. In interobserver comparisons, the ICC of the APCR (>0.793) was excellent. In intraobserver comparisons of the aged >50-years group, only the APCR method showed an excellent ICC (>0.753), whereas the AHCP method showed a fair to good ICC, and the anterior/posterior vertebral body height compression ratio percentage method had the lowest ICC. In interobserver comparisons of the aged >50-years group, the APCR and AHCP methods showed excellent ICCs. In the aged <= 50-years group, all 3 methods showed similar fair to good ICC values.
   CONCLUSIONS: Based on comparative reliability analyses, we recommend the APCR method as the first-line technique and the AHCP as an alternative technique for measuring VBHL in TL burst fractures.
C1 [Hong, Jae-Young; Park, Jin-Sung] Univ Korea Hosp, Dept Orthoped, Gyeonggi Do, South Korea.
   [Choi, Sung-Woo; Shin, Byung-Joon; Lee, Jae Chul] Soonchunhyang Univ, Dept Orthopaed Surg, Seoul Hosp, Seoul, South Korea.
   [Kim, Gi Deok; Kim, HyunKwon; Kim, Eung-Ha; Jang, Hae-Dong] Soonchunhyang Univ, Dept Orthopaed Surg, Bucheon Hosp, Gyeonggi Do, South Korea.
RP Jang, HD (reprint author), Soonchunhyang Univ, Dept Orthopaed Surg, Bucheon Hosp, Gyeonggi Do, South Korea.
EM khaki00@schmc.ac.kr
OI Jang, Hae-Dong/0000-0002-8783-3122
FU Soonchunhyang University Research Fund
FX This work was supported by the Soonchunhyang University Research Fund.
CR Aligizakis A, 2002, Acta Orthop Belg, V68, P279
   Aly TA, 2017, ASIAN SPINE J, V11, P150, DOI 10.4184/asj.2017.11.1.150
   ATLAS SW, 1986, AM J ROENTGENOL, V147, P575, DOI 10.2214/ajr.147.3.575
   Azhari S, 2016, ASIAN SPINE J, V10, P136, DOI 10.4184/asj.2016.10.1.136
   CANTOR JB, 1993, SPINE, V18, P971, DOI 10.1097/00007632-199306150-00004
   Chadha M, 1998, INJURY, V29, P737, DOI 10.1016/S0020-1383(98)00173-9
   DEWALD RL, 1984, CLIN ORTHOP RELAT R, P150
   Dunn G, 1992, Stat Methods Med Res, V1, P123, DOI 10.1177/096228029200100202
   DUNN HK, 1986, ORTHOP CLIN N AM, V17, P113
   FARCY JPC, 1990, SPINE, V15, P958, DOI 10.1097/00007632-199009000-00022
   GERTZBEIN SD, 1992, SPINE, V17, P528, DOI 10.1097/00007632-199205000-00010
   Hiyama A, 2015, INJURY, V46, P392, DOI 10.1016/j.injury.2014.10.047
   Hong JY, 2010, EUR SPINE J, V19, P1551, DOI 10.1007/s00586-010-1422-x
   Hong JY, 2015, SPINE, V40, pE701, DOI 10.1097/BRS.0000000000000875
   Hong JY, 2013, SPINE, V38, pE1684, DOI 10.1097/BRS.0b013e3182a18486
   Hong JY, 2013, SPINE J, V13, P421, DOI 10.1016/j.spinee.2012.11.051
   Hwang JH, 2012, SPINE, V37, pE1273, DOI 10.1097/BRS.0b013e318265a829
   JACOBS RR, 1984, CLIN ORTHOP RELAT R, P22
   Joaquim AF, 2014, J NEUROSURG-SPINE, V20, P562, DOI 10.3171/2014.2.SPINE121114
   Keynan O, 2006, SPINE, V31, pE156, DOI 10.1097/01.brs.0000201261.94907.0d
   KROMPINGER WJ, 1986, ORTHOP CLIN N AM, V17, P161
   Kuklo TR, 2001, SPINE, V26, P61, DOI 10.1097/00007632-200101010-00012
   MCAFEE PC, 1982, SPINE, V7, P365, DOI 10.1097/00007632-198207000-00007
   MCAFEE PC, 1983, J BONE JOINT SURG AM, V65, P461, DOI 10.2106/00004623-198365040-00006
   Mehta JS, 2004, SPINE, V29, P564, DOI 10.1097/01.BRS.0000113873.07484.5D
   Mikles MR, 2004, J AM ACAD ORTHOP SUR, V12, P424, DOI 10.5435/00124635-200411000-00007
   MUMFORD J, 1993, SPINE, V18, P955, DOI 10.1097/00007632-199306150-00003
   Pneumaticos SG, 2016, EUR SPINE J, V25, P1123, DOI 10.1007/s00586-015-3889-y
   Sadiqi S, 2017, EUR SPINE J, V26, P1483, DOI 10.1007/s00586-016-4716-9
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   Srinivasalu S, 2008, ASIAN SPINE J, V2, P90, DOI 10.4184/asj.2008.2.2.90
   Vu TT, 2015, ASIAN SPINE J, V9, P427, DOI 10.4184/asj.2015.9.3.427
   Verheyden AP, 2011, UNFALLCHIRURG, V114, P9, DOI 10.1007/s00113-010-1934-1
   WILLEN J, 1990, J SPINAL DISORD, V3, P39
   손광현, 2010, [Journal of Korean Society of Spine Surgery, 대한척추외과학회지], V17, P120
NR 35
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E191
EP E198
DI 10.1016/j.wneu.2019.05.094
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900024
PM 31121370
DA 2020-05-12
ER

PT J
AU Horisawa, S
   Fukui, A
   Tanaka, Y
   Wendong, L
   Yamahata, H
   Kawamata, T
   Taira, T
AF Horisawa, Shiro
   Fukui, Atsushi
   Tanaka, Yukiko
   Wendong, Lew
   Yamahata, Hayato
   Kawamata, Takakazu
   Taira, Takaomi
TI Pallidothalamic Tractotomy (Forel's Field H1-tomy) for Dystonia:
   Preliminary Results
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dystonia; Forel's field; Pallidothalamic tract
ID GLOBUS-PALLIDUS INTERNUS; STEREOTACTIC TREATMENT; BILATERAL PALLIDOTOMY;
   STIMULATION; CAMPOTOMY
AB OBJECTIVES: The pallidothalamic tract connects the globus pallidus internus with the ventroanterior and ventrolateral parts of the thalamus. Lesioning or stimulation of the pallidothalamic tract has ameliorating effects on dyskinesia and dystonia in patients with Parkinson disease. However, the effect of the procedure on dystonia due to other etiologies has not been reported.
   METHODS: We retrospectively analyzed patients with dystonia who underwent unilateral pallidothalamic tractotomy between July 2017 and October 2018 at Tokyo Women's Medical University Hospital. The Burke-Fahn-Marsden Dystonia Rating Scale-Movement Scale was used to evaluate the severity of dystonia at three time points (before surgery, 3 months postoperatively, and the last available follow-up). Adverse events were also evaluated.
   RESULTS: Eleven patients underwent unilateral pallidothalamic tractotomy, including 5 with generalized dystonia, 4 with segmental dystonia, and 2 with focal (cervical) dystonia. All patients had undergone unilateral pallidotomy before contralateral pallidothalamic tractotomy. The mean interval between the previous surgery (pallidotomy) and pallidothalamic tractotomy was 9.5 +/- 3.1 months. The mean follow-up period was 11.5 +/- 4.2 months. The Burke-Fahn-Marsden Dystonia Rating Scale-Movement Scale scores at 3 months after pallidothalamic tractotomy (5.8 +/- 8.4) and at the last available follow-up (5.6 +/- 8.3, P < 0.001) were significantly improved compared with that before pallidothalamic tractotomy (21.8 +/- 16.3). The most common adverse event was reduced voice volume (6 patients), which was mild and did not interfere with the patient's daily activities.
   CONCLUSIONS: This study suggests that pallidothalamic tractotomy can be an alternative treatment target for dystonia. A larger and longer prospective study is needed to elucidate the safety and efficacy of pallidothalamic tractotomy for dystonia.
C1 [Horisawa, Shiro; Fukui, Atsushi; Tanaka, Yukiko; Wendong, Lew; Yamahata, Hayato; Kawamata, Takakazu; Taira, Takaomi] Tokyo Womens Med Univ, Neurol Inst, Dept Neurosurg, Tokyo, Japan.
RP Horisawa, S (reprint author), Tokyo Womens Med Univ, Neurol Inst, Dept Neurosurg, Tokyo, Japan.
EM neurosurgery21@yahoo.co.jp
OI horisawa, shiro/0000-0002-3016-3244
CR Alterman Ron L, 2004, Neurosurg Focus, V17, pE6
   Aufenberg Christoph, 2005, Thalamus & Related Systems, V3, P121, DOI 10.1017/S147292880700012X
   Cersosimo MG, 2008, CLIN NEUROL NEUROSUR, V110, P145, DOI 10.1016/j.clineuro.2007.10.003
   Danet L, 2015, NEUROLOGY, V85, P2107, DOI 10.1212/WNL.0000000000002226
   HASSLER R, 1970, CONFIN NEUROL, V32, P135
   Horisawa S, 2018, EUR J NEUROL, V25, pE108, DOI 10.1111/ene.13706
   Horisawa S, 2019, J NEUROSURG, V131, P839, DOI 10.3171/2018.5.JNS1840
   Horisawa S, 2019, WORLD NEUROSURG, V121, P193, DOI 10.1016/j.wneu.2018.10.055
   Horisawa S, 2016, WORLD NEUROSURG, V89, DOI 10.1016/j.wneu.2016.01.011
   Huebl J, 2015, PARKINSONISM RELAT D, V21, P800, DOI 10.1016/j.parkreldis.2015.04.023
   Kohara Kotaro, 2017, No Shinkei Geka, V45, P971, DOI 10.11477/mf.1436203631
   LAITINEN LV, 1994, STEREOT FUNCT NEUROS, V62, P41, DOI 10.1159/000098596
   Lozano AM, 1997, MOVEMENT DISORD, V12, P865, DOI 10.1002/mds.870120606
   Magara A, 2014, J THER ULTRASOUND, V2, DOI 10.1186/2050-5736-2-11
   Minkin K, 2017, ACTA NEUROCHIR, V159, P1359, DOI 10.1007/s00701-017-3178-0
   Morel A., 2007, STEREOTACTIC ATLAS H
   MUNDINGE.F, 1972, CONFIN NEUROL, V34, P41
   Neudorfer C, 2018, BRAIN STRUCT FUNCT, V223, P17, DOI 10.1007/s00429-017-1570-4
   Ondo WG, 1998, MOVEMENT DISORD, V13, P693, DOI 10.1002/mds.870130415
   Schrader C, 2011, NEUROLOGY, V77, P483, DOI 10.1212/WNL.0b013e318227b19e
   SPIEGEL EA, 1963, J NEUROSURG, V20, P871, DOI 10.3171/jns.1963.20.10.0871
   Vidailhet M, 2013, HAND CLINIC, V111, P197, DOI [10.1016/B978-0-444-53497-2.00014-0, 10.1016/B978-0-444-52891-9.00019-1]
   Voges J, 2002, J NEUROSURG, V96, P269, DOI 10.3171/jns.2002.96.2.0269
   Zauber SE, 2009, J NEUROSURG, V110, P229, DOI 10.3171/2008.6.17621
   Zhang JY, 2006, EXP NEUROL, V199, P446, DOI 10.1016/j.expneurol.2006.01.006
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E851
EP E856
DI 10.1016/j.wneu.2019.06.055
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900107
PM 31207377
DA 2020-05-12
ER

PT J
AU Huang, CM
   Hong, YF
   Xing, SH
   Xu, K
   Xu, CK
   Zhang, WJ
   Li, H
   Zhang, PF
   Cai, CW
AF Huang, Chu-ming
   Hong, Yi-fan
   Xing, Shi-hui
   Xu, Ke
   Xu, Chu-kai
   Zhang, Wei-jie
   Li, Hui
   Zhang, Pei-feng
   Cai, Chu-wei
TI Thirty-Day Outcomes of the Enterprise Stent in Treating Hypoperfusion of
   Symptomatic Intracranial Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular treatment; Enterprise; Intracranial arterial stenosis;
   Outcomes; Stent
ID ASSISTED COILING; ANGIOPLASTY; ARTERY; ANEURYSMS; DISEASE
AB OBJECTIVE: To evaluate the 30-day outcomes of using the Enterprise stent to treat patients with hypoperfusion of symptomatic severe intracranial stenosis.
   METHODS: Patients with symptomatic severe intracranial stenosis (70%-99%) who underwent Enterprise stent intervention between August 2014 and November 2018 were retrospectively analyzed. The 30-day primary outcomes included the success rate of stenting and the incidence of complications, including ischemic stroke, cerebral hemorrhage, and death. The 30-day complication rates of patients with different lesion locations and classifications of Mori morphology were compared.
   RESULTS: Sixty-eight patients were treated using 70 Enterprise stents. The success rate was 100%. The 30-day complication rate was 4.4%. The rates of ischemic stroke, cerebral hemorrhage, and death were 1.5%, 2.9%, and 0%, respectively. No significant difference was found in the 30-day complication rate between patients with different lesion locations and classifications of Mori morphology (P > 0.05).
   CONCLUSION: Enterprise stents were relatively safe in treating patients with hypoperfusion of symptomatic severe intracranial stenosis.
C1 [Huang, Chu-ming; Hong, Yi-fan; Xu, Ke; Xu, Chu-kai; Zhang, Wei-jie; Li, Hui; Zhang, Pei-feng; Cai, Chu-wei] Shantou Cent Hosp, Dept Neurosurg, Shantou, Guangdong, Peoples R China.
   [Xing, Shi-hui; Xu, Chu-kai] Sun Yat Sen Univ, Dept Neurol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
RP Cai, CW (reprint author), Shantou Cent Hosp, Dept Neurosurg, Shantou, Guangdong, Peoples R China.
EM caichuwei@126.com
CR Alexander MJ, 2012, J NEUROINTERV SURG, V4, P85, DOI 10.1136/neurintsurg-2012-010269
   Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335
   Chimowitz MI, 2005, NEW ENGL J MED, V352, P1305, DOI 10.1056/NEJMoa043033
   Dercleyn CP, 2007, NEUROIMAG CLIN N AM, V17, P355, DOI 10.1016/j.nic.2007.05.001
   Derdeyn CP, 2013, NEUROSURGERY, V72, P777, DOI 10.1227/NEU.0b013e318286fdc8
   Du ZH, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00852
   Duan GL, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011734
   Feng X, 2018, WORLD NEUROSURG, V109, pE99, DOI 10.1016/j.wneu.2017.09.112
   Feng ZZ, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0443-9
   Gorelick PB, 2008, STROKE, V39, P2396, DOI 10.1161/STROKEAHA.107.505776
   Jiang WJ, 2004, STROKE, V35, P1375, DOI 10.1161/01.STR.0000128018.57526.3a
   Krischek O, 2011, MINIM INVAS NEUROSUR, V54, P21, DOI 10.1055/s-0031-1271681
   Lee KY, 2016, INTERV NEURORADIOL, V22, P187, DOI 10.1177/1591019915609165
   Limbucci N, 2016, J NEUROINTERV SURG, V8, P158, DOI 10.1136/neurintsurg-2014-011483
   Miao ZR, 2015, STROKE, V46, P2822, DOI 10.1161/STROKEAHA.115.010549
   Mori T, 1998, AM J NEURORADIOL, V19, P1525
   SACCO RL, 1995, STROKE, V26, P14, DOI 10.1161/01.STR.26.1.14
   Vajda Z, 2012, NEUROSURGERY, V70, P91, DOI 10.1227/NEU.0b013e31822dff0f
   Wang XF, 2016, TURK NEUROSURG, V26, P69, DOI 10.5137/1019-5149.JTN.13350-14.1
   Weber W, 2007, NEURORADIOLOGY, V49, P555, DOI 10.1007/s00234-007-0232-2
   Yu WG, 2018, STROKE VASC NEUROL, V3, P140, DOI 10.1136/svn-2018-000158
   Zaidat OO, 2015, JAMA-J AM MED ASSOC, V313, P1240, DOI 10.1001/jama.2015.1693
   Zhao Lin-Bo, 2012, Neurointervention, V7, P102, DOI 10.5469/neuroint.2012.7.2.102
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E429
EP E435
DI 10.1016/j.wneu.2019.05.167
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900054
PM 31150855
DA 2020-05-12
ER

PT J
AU Ikedo, T
   Kataoka, H
   Minami, M
   Hayashi, K
   Miyatat, T
   Nagata, M
   Fujikawa, R
   Yokode, M
   Imar, H
   Matsuda, T
   Miyamoto, S
AF Ikedo, Taichi
   Kataoka, Hiroharu
   Minami, Manabu
   Hayashi, Kosuke
   Miyatat, Takeshi
   Nagata, Manabu
   Fujikawa, Risako
   Yokode, Masayuki
   Imar, Hirohiko
   Matsuda, Tetsuya
   Miyamoto, Susumu
TI Sequential Inward Bending of Arterial Bifurcations is Associated with
   Intracranial Aneurysm Formation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Animal model; Inflammation; Intracranial aneurysm; 7T-MRI; Vascular
   morphology
ID NF-KAPPA-B; PULSATILE BLOOD-FLOW; CEREBRAL ANEURYSM; MODEL; ANATOMY;
   STRESS; GENE; AGE
AB OBJECTIVE: To investigate the association between vascular morphology and the development of intracranial aneurysms (IAs), the morphological changes of intracranial arteries after IA induction were examined using a rodent model.
   METHODS: The vascular morphology of the circle of Willis in rats was visualized at 1 week and at 3 months after IA induction using 7-T magnetic resonance imaging. The following 2 angle parameters were defined: the angle between the parent artery and the daughter arteries (PD angle), and the widening of the daughter arteries (DD angle). The correlations of the angle parameters with IA size and with the number of macrophages infiltrated in the IA wall by immunohistochemistry were examined.
   RESULTS: Magnetic resonance imaging showed bending of the arteries over time around the predilection site for IAs. The PD angle increased significantly 1 week after IA induction (P < 0.05) and correlated with IA size (P < 0.01). The DD angle did not increase after 1 week, but increased 3 months after IA induction (P < 0.01). The PD angle 1 week after surgery also correlated with the number of infiltrated macrophages in aneurysmal walls (P = 0.01).
   CONCLUSIONS: Sequential inward bending of arterial bifurcations occurred after IA induction in the rat model. The degree of arterial bending correlated with IA development and inflammation in the IA wall, suggesting that the vascular morphology may be strongly associated with IA development through a proinflammatory mechanism.
C1 [Ikedo, Taichi; Kataoka, Hiroharu; Hayashi, Kosuke; Miyatat, Takeshi; Nagata, Manabu; Miyamoto, Susumu] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto 6068501, Japan.
   [Ikedo, Taichi; Minami, Manabu; Hayashi, Kosuke; Miyatat, Takeshi; Nagata, Manabu; Fujikawa, Risako; Yokode, Masayuki] Kyoto Univ, Grad Sch Med, Dept Clin Innovat Med, Kyoto 6068501, Japan.
   [Imar, Hirohiko; Matsuda, Tetsuya] Kyoto Univ, Grad Sch Informat, Dept Syst Sci, Kyoto, Japan.
RP Kataoka, H (reprint author), Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto 6068501, Japan.
EM kataoka@kuhp.kyoto-u.ac.ja
OI Kataoka, Hiroharu/0000-0001-8507-7557; Matsuda,
   Tetsuya/0000-0002-2339-1521
FU Japan Society for the Promotion of Science JSPS KAKENHIMinistry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan
   Society for the Promotion of ScienceGrants-in-Aid for Scientific
   Research (KAKENHI) [23590361, 26460338, 15K08230, 15H04952]
FX The authors declare that the article content was composed in the absence
   of any commercial or financial relationships that could be construed as
   a potential conflict of interest. This work was supported by grants from
   the Japan Society for the Promotion of Science JSPS KAKENHI grants
   23590361 and 26460338 (to MM), 15K08230 (to MY), and 15H04952 (to HK).
CR Aoki T, 2011, BRIT J PHARMACOL, V163, P1237, DOI 10.1111/j.1476-5381.2011.01358.x
   Aoki T, 2007, CIRCULATION, V116, P2830, DOI 10.1161/CIRCULATIONAHA.107.728303
   Aoki T, 2007, STROKE, V38, P162, DOI 10.1161/01.STR.0000252129.18605.c8
   Aoki T, 2009, LAB INVEST, V89, P730, DOI 10.1038/labinvest.2009.36
   Aoki T, 2009, STROKE, V40, P942, DOI 10.1161/STROKEAHA.108.532556
   Arjmandi-Tash O, 2012, BIOIMPACTS, V2, P195, DOI 10.5681/bi.2012.023
   Baharoglu MI, 2014, STROKE, V45, P2649, DOI 10.1161/STROKEAHA.114.005393
   Bhullar IS, 1998, J BIOL CHEM, V273, P30544, DOI 10.1074/jbc.273.46.30544
   Can A, 2015, NEUROSURGERY, V76, P721, DOI 10.1227/NEU.0000000000000713
   Can A, 2015, NEUROSURGERY, V76, P62, DOI 10.1227/NEU.0000000000000564
   Chen J, 2006, J BIOMECH, V39, P818, DOI 10.1016/j.jbiomech.2005.02.003
   COLLINS T, 1995, FASEB J, V9, P899
   Dolan JM, 2013, AM J PHYSIOL-CELL PH, V305, pC854, DOI 10.1152/ajpcell.00315.2012
   Goebeler M, 2001, BLOOD, V97, P46, DOI 10.1182/blood.V97.1.46
   Ikedo T, 2018, BIOCHEM BIOPH RES CO, V495, P332, DOI 10.1016/j.bbrc.2017.10.133
   Ikedo T, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004777
   Jamous MA, 2007, J NEUROSURG, V107, P405, DOI 10.3171/JNS-07/08/0405
   Kanematsu Y, 2011, STROKE, V42, P173, DOI 10.1161/STROKEAHA.110.590976
   Lehman VT, 2018, J NEUROSURG, V128, P969, DOI 10.3171/2016.12.JNS162262
   Meng H, 2014, AM J NEURORADIOL, V35, P1254, DOI 10.3174/ajnr.A3558
   Nowicki KW, 2014, HYPERTENSION, V64, P1306, DOI 10.1161/HYPERTENSIONAHA.114.03775
   Sadatomo T, 2013, NEUROSURG REV, V36, P437, DOI 10.1007/s10143-013-0450-5
   Song JP, 2017, NEUROSURGERY, V81, P779, DOI 10.1093/neuros/nyx093
   Turjman AS, 2014, CIRCULATION, V129, P373, DOI 10.1161/CIRCULATIONAHA.113.001444
   Vlak MHM, 2011, LANCET NEUROL, V10, P626, DOI 10.1016/S1474-4422(11)70109-0
   Yokoi T, 2014, J NEUROSURG, V120, P1193, DOI 10.3171/2014.1.JNS13818
   Zhang XJ, 2018, STROKE, V49, P341, DOI 10.1161/STROKEAHA.117.019701
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E361
EP E366
DI 10.1016/j.wneu.2019.05.153
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900045
PM 31176059
DA 2020-05-12
ER

PT J
AU Iudo, M
   Oya, S
   Shojima, M
   Inokuchi, K
   Yahata, T
   Sugiyama, S
   Matsui, T
AF Iudo, Masahiro
   Oya, Soichi
   Shojima, Masaaki
   Inokuchi, Koichi
   Yahata, Tadashi
   Sugiyama, Satoru
   Matsui, Tom
TI Prevention of Thromboembolic Infarction After Surgery for Traumatic
   Cervical Fracture with Vertebral Artery Occlusion by Preoperative
   Endovascular Coil Embolization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical trauma; Coil embolization; Endovascular surgery; Traumatic
   vertebral artery injury; Vertebral artery occlusion
ID BLUNT CEREBROVASCULAR INJURIES; 10-YEAR RETROSPECTIVE ANALYSIS;
   THROMBOSIS
AB BACKGROUND: Vertebral artery injuries (VAIs) caused by cervical trauma include irregularities with narrowing of the arterial wall, dissection, pseudoaneurysm formation, occlusion, and transection. Although recent guidelines have recommended anticoagulant or antiplatelet therapy to prevent subsequent stroke in patients with traumatic VAIs, regardless of the type of vascular injury, the clinical role of endovascular surgery in the treatment of traumatic VAIs remains to be elucidated.
   METHODS: We retrospectively evaluated the treatment outcomes of 23 patients with cervical fracture and vertebral artery occlusion (VAO) who had required cervical surgery in the acute stage.
   RESULTS: No patient received antiplatelet or anticoagulant therapy, because the VAs had already become occluded. After cervical surgery, 5 of the 23 patients developed radiologically confirmed thromboembolic stroke after cervical surgery. None of these 5 patients with postoperative infarction had undergone preoperative VA embolization. Univariate analysis revealed that only the implementation of preoperative VA embolization was associated with the prevention of postoperative infarction (P = 0.004). Factors such as age, reduction, level of VAO, and diabetes mellitus did not correlate with increased risk.
   CONCLUSIONS: The clinical role of endovascular surgery for traumatic VAI has not been previously established; however, a more specific selection of patients according to the VAI type might be necessary. Our data have indicated that preoperative embolization of the occluded VA significantly reduces the risk of postoperative infarction in a specific cohort of patients with traumatic VAI (i.e., patients with post-traumatic VAO who require cervical surgery).
C1 [Iudo, Masahiro; Oya, Soichi; Shojima, Masaaki; Matsui, Tom] Saitama Med Univ, Saitama Med Ctr, Dept Neurosurg, Saitama, Japan.
   [Inokuchi, Koichi; Yahata, Tadashi; Sugiyama, Satoru] Saitama Med Univ, Saitama Med Ctr, Dept Emergency & Crit Care Med, Saitama, Japan.
RP Oya, S (reprint author), Saitama Med Univ, Saitama Med Ctr, Dept Neurosurg, Saitama, Japan.
EM sooya-tky@umin.ac.jp
CR Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007
   Brommeland T, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-018-0559-1
   Burlew CC, 2014, J AM COLL SURGEONS, V218, P1012, DOI 10.1016/j.jamcollsurg.2014.01.042
   Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111
   Cothren CC, 2005, ARCH SURG-CHICAGO, V140, P480, DOI 10.1001/archsurg.140.5.480
   deSouza RM, 2011, EUR SPINE J, V20, P1405, DOI 10.1007/s00586-011-1862-y
   Fassett DR, 2008, J SPINAL DISORD TECH, V21, P252, DOI 10.1097/BSD.0b013e3180cab162
   GAMBEE MJ, 1986, PARAPLEGIA, V24, P350, DOI 10.1038/sc.1986.52
   Jang D, 2014, J KOREAN NEUROSURG S, V56, P141, DOI 10.3340/jkns.2014.56.2.141
   Lebl DR, 2013, SPINE, V38, P1352, DOI 10.1097/BRS.0b013e318294bacb
   Lee YJ, 2007, J TRAUMA, V62, P886, DOI 10.1097/01.ta.0000209398.07973.60
   Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015
   Price RF, 1998, AM J NEURORADIOL, V19, P1677
   Scott WW, 2015, J NEUROSURG, V122, P610, DOI 10.3171/2014.10.JNS14875
   Scott WW, 2014, J NEUROSURG, V121, P450, DOI 10.3171/2014.4.JNS132235
   Shafafy Roozbeh, 2017, J Spine Surg, V3, P217, DOI 10.21037/jss.2017.05.10
   Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146
   Tumialan LM, 2012, J NEUROSURG-SPINE, V16, P492, DOI 10.3171/2012.1.SPINE11967
   Vishteh A G, 1999, J Neurosurg Sci, V43, P195
   Wahl WL, 2002, J TRAUMA, V52, P896, DOI 10.1097/00005373-200205000-00012
   Wang H, 2008, J NEUROS-PEDIATR, V1, P415, DOI 10.3171/PED/2008/1/5/415
NR 21
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E838
EP E844
DI 10.1016/j.wneu.2019.06.046
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900105
PM 31207373
DA 2020-05-12
ER

PT J
AU Jeon, JP
   Heo, Y
   Kang, SH
   Yang, JS
   Choi, HJ
   Cho, YJ
AF Jeon, Jin Pyeong
   Heo, Yunsuk
   Kang, Suk-Hyung
   Yang, Jin Seo
   Choi, Hyuk Jai
   Cho, Yong-Jun
TI Retrospective Chronologic Computed Tomography Analysis of Bone Flap
   Fusion and Resorption After Craniotomy and Autologous Cryopreserved
   Cranioplasty
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone flap fixation gap; Bone resorption; Cranioplasty; Craniotomy;
   Cryopreserved bone
ID CRANIECTOMY
AB BACKGROUND: In open brain surgery, fixation of the bone flap is the final procedure. The bone flaps then fuse naturally. The objective of this study was to investigate the chronological process of bone fusion after craniotomy and autologous cranioplasty.
   METHODS: Retrospective data were collected from patients who underwent craniotomy or cranioplasty after August 2004 and had at least 1 computed tomography (CT) scan at 3 months postsurgery. The patients were divided into a craniotomy group and a cranioplasty group. Head CT scans were analyzed to evaluate bone fusion and resorption.
   RESULTS: Records from 978 patients who underwent craniotomy or cranioplasty between September 2004 and November 2015 were reviewed; 369 patients were eligible for the final analysis (craniotomy, n = 276; cranioplasty, n = 93). The mean cryopreservation period for the bone flap in the cranioplasty group was 49.3 days. The mean patient age was 51.4 +/- 18.1 years in the craniotomy group and 51.6 +/- 17.1 years in the cranioplasty group. Head CT scans showed bone fusion rates of 76.6% in the craniotomy group and 53.3% in the cranioplasty group at 6 months postsurgery (P = 0.015) and 78.6% and 78.1%, respectively, at 1 year post-surgery (P = 0.951). There was also a significant difference in the bone flap resorption rate between the 2 groups.
   CONCLUSIONS: Bone flap fusion rates after craniotomy and cranioplasty were significantly different before 12 months, but not significantly different thereafter. Bone resorption occurred more frequently in the cranioplasty group over time.
C1 [Jeon, Jin Pyeong; Heo, Yunsuk; Kang, Suk-Hyung; Yang, Jin Seo; Choi, Hyuk Jai; Cho, Yong-Jun] Hallym Univ, Chuncheon Sacred Heart Hosp, Dept Neurosurg, Hallym Univ Med Ctr,Coll Med, Chuncheo Si, Gangwon Do, South Korea.
RP Kang, SH (reprint author), Hallym Univ, Chuncheon Sacred Heart Hosp, Dept Neurosurg, Hallym Univ Med Ctr,Coll Med, Chuncheo Si, Gangwon Do, South Korea.
EM nscharimsa@hanmail.net
FU Korean National IT Industry Promotion Agency [R20190315-004075]; Rural
   Development Administration (BioGreen21 Program)Rural Development
   Administration (RDA) [PJ01121401]
FX This research was supported by the Korean National IT Industry Promotion
   Agency (R20190315-004075) and the Rural Development Administration
   (BioGreen21 Program; PJ01121401). The authors declare that the article
   content was composed in the absence of any commercial or financial
   relationships that could be construed as a potential conflict of
   interest.
CR ABBOTT KH, 1953, J NEUROSURG, V10, P380, DOI 10.3171/jns.1953.10.4.0380
   Bhaskar IP, 2011, J CLIN NEUROSCI, V18, P1690, DOI 10.1016/j.jocn.2011.02.046
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Chibbaro S, 2011, MINIM INVAS NEUROSUR, V54, P282, DOI 10.1055/s-0031-1297246
   Cho TG, 2017, J KOREAN NEUROSURG S, V60, P397, DOI 10.3340/jkns.2017.0101.004
   Cho Yong Jun, 2017, Korean J Neurotrauma, V13, P9, DOI 10.13004/kjnt.2017.13.1.9
   Erdogan E, 2003, NEUROL INDIA, V51, P479
   GREENBERG IM, 1987, NEUROSURGERY, V20, P950, DOI 10.1227/00006123-198706000-00022
   Hayward RD, 1999, BRIT J NEUROSURG, V13, P490, DOI 10.1080/02688699943312
   Honeybul S, 2017, J NEUROSURG, V126, P81, DOI 10.3171/2015.12.JNS152004
   Hwang G, 2009, KOREAN J CEREBROVASC, V11, P49
   Hwang KH, 1998, J KOREAN NEUROSURG S, V27, P159
   Im SH, 2012, J KOREAN NEUROSURG S, V52, P396, DOI 10.3340/jkns.2012.52.4.396
   Kim SP, 2014, J KOREAN NEUROSURG S, V56, P410, DOI 10.3340/jkns.2014.56.5.410
   Lee BS, 2012, KOREAN J NEUROTRAUMA, V8, P21
   Lee KY, 1977, J KOREAN NEUROSURG S, V6, P483
   Lee S. H., 2014, J NEUROTRAUM, V10, P10, DOI [1410.13004/kjnt.2014.10.1.1027169026, DOI 10.13004/KJNT.2014.10.1.10]
   Lemee JM, 2013, NEUROCHIRURGIE, V59, P60, DOI 10.1016/j.neuchi.2012.10.138
   Lethaus B, 2014, J CRANIO MAXILL SURG, V42, P1948, DOI 10.1016/j.jcms.2014.08.006
   Mirhadi S, 2013, TRAUMA, V15, P140, DOI 10.1177/1460408613486571
   Park SP, 2017, J KOREAN NEUROSURG S, V60, P749, DOI 10.3340/jkns.2017.0203.002
   Pilitsis Julie G, 2002, Neurosurg Focus, V13, pe1
   Son S, 2009, J KOREAN NEUROTRAUMA, V5, P118
NR 23
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E900
EP E906
DI 10.1016/j.wneu.2019.06.088
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900112
PM 31229749
DA 2020-05-12
ER

PT J
AU Jiang, C
   Luan, DH
   Wang, C
   Liu, QL
   Han, J
   Li, G
AF Jiang, Chao
   Luan, Deheng
   Wang, Chen
   Liu, Qinglin
   Han, Jie
   Li, Gang
TI Risk and Prognostic Factors for Rupture of Intracranial Aneurysms During
   Endovascular Embolization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular embolization; Intracranial aneurysm; Intraoperative
   aneurysm rupture; Risk factors
ID INTRAPROCEDURAL RUPTURE; COIL EMBOLIZATION; DETACHABLE COILS; OUTCOMES;
   RERUPTURE
AB OBJECTIVE: Intraoperative aneurysm rupture (IPR) always results in a poor prognosis for the patient. However, the risk factors of IPR are unclear. In this article, the risk factors are explored, a nomogram model for predicting IPR is established, and the prognostic factors for patients with IPR are analyzed.
   METHODS: A total of 549 patients with aneurysm, which were embolized from September 2011 to September 2015, were enrolled for analysis. Univariate and multivariate logistic regression were performed to explore the risk factors for IPR, and a nomogram was established. A nonparametric Mann-Whitney U test was performed to analyze prognostic factors for patients with IPR.
   RESULTS: Twenty-one patients (4.4%) experienced IPR. In univariate analysis, Hunt-Hess grade (P = 0.002), time from hospitalization to treatment (P = 0.08) and subarachnoid hemorrhage (SAH) to treatment (P = 0.08), aneurysm neck (P = 0.08), assistive technique (P = 0.03), and intraoperative cerebral vasospasm (P < 0.001) were significantly associated with IPR. In multivariate analysis, Hunt-Hess grade (odds ratio [OR], 8.177; 95% confidence interval [CI], 1.714-39.012; P = 0.008), aneurysm neck (OR, 5.629; 95% CI, 1.149-27.575; P = 0.033), assistive technique (OR, 1.393; 95% CI, 0.961-2.018; P = 0.080), and intraoperative cerebral vasospasm (OR, 4.280; 95% CI, 1.081-16.947; P = 0.038) were independent risk factors for IPR. Hydrocephalus (P = 0.069), history of SAH (P = 0.10), >= 2 SAH (P = 0.051), location of aneurysm (P = 0.09), and number of aneurysms (P = 0.025) were associated with the bad outcome.
   CONCLUSIONS: Hunt-Hess grading, aneurysm neck, intraoperative assistive technology, and vasospasm were independent risk factors for IPR. Hydrocephalus requiring surgical intervention, times of rupture, location of aneurysm, and the number of aneurysms were relevant to the prognosis of patients.
C1 [Jiang, Chao; Li, Gang] Shandong Univ, Dept Neurosurg, Qilu Hosp, Jinan, Shandong, Peoples R China.
   [Jiang, Chao; Luan, Deheng; Wang, Chen; Han, Jie] Shandong Univ, Dept Otorhinolaryngol & Head & Neck Surg, Prov Hosp, Jinan, Shandong, Peoples R China.
   [Liu, Qinglin] Capital Med Univ, Beijing Tiantan Hosp, Beijing Neurosurg Inst, Beijing, Peoples R China.
   [Liu, Qinglin] Capital Med Univ, Beijing Tiantan Hosp, Dept Intervent Neuroradiol, Beijing, Peoples R China.
RP Li, G (reprint author), Shandong Univ, Dept Neurosurg, Qilu Hosp, Jinan, Shandong, Peoples R China.
EM ligangqiluhospital@126.com
CR Baltsavias GS, 2000, NEUROSURGERY, V47, P1320, DOI 10.1097/00006123-200012000-00010
   Bekelis K, 2014, J NEUROINTERV SURG, V6, P556, DOI 10.1136/neurintsurg-2013-010884
   Brisman JL, 2008, NEUROSURGERY, V62, P1525, DOI [10.1227/01.NEU.0000185631.20246.1A, 10.1227/01.neu.0000333816.79777.e0]
   Diaz O, 2016, HAND CLINIC, V136, P1303, DOI 10.1016/B978-0-444-53486-6.00067-3
   Elijovich L, 2008, STROKE, V39, P1501, DOI 10.1161/STROKEAHA.107.504670
   Kawabata S, 2018, J NEUROINTERV SURG, V10, P362, DOI 10.1136/neurintsurg-2017-013156
   Li MH, 2006, NEURORADIOLOGY, V48, P907, DOI 10.1007/s00234-006-0147-3
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Nguyen TN, 2008, J NEUROSURG, V108, P1088, DOI 10.3171/JNS/2008/108/6/1088
   Renowden SA, 2009, CLIN NEUROL NEUROSUR, V111, P179, DOI 10.1016/j.clineuro.2008.09.026
   Sluzewski M, 2001, J NEUROSURG, V94, P238, DOI 10.3171/jns.2001.94.2.0238
   Stapleton CJ, 2015, J NEUROSURG, V122, P128, DOI 10.3171/2014.9.JNS14616
   Thien A, 2017, WORLD NEUROSURG, V97, P326, DOI 10.1016/j.wneu.2016.09.118
   van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6
   Wang zhongcheng, 2004, NEUROSURGERY FINE, P837
   White AC, 2017, J CLIN NEUROSCI, V44, P53, DOI 10.1016/j.jocn.2017.06.033
   Willinsky RA, 2009, AM J NEURORADIOL, V30, P1035, DOI 10.3174/ajnr.A1488
NR 17
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E641
EP E649
DI 10.1016/j.wneu.2019.05.233
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900081
PM 31158537
DA 2020-05-12
ER

PT J
AU Jorge, A
   Fish, EJ
   Dixon, CE
   Hamilton, KD
   Balzer, J
   Thirumala, P
AF Jorge, Ahmed
   Fish, Erika J.
   Dixon, C. Edward
   Hamilton, Kojo D.
   Balzer, Jeffrey
   Thirumala, Parthasarathy
TI The Effect of Prophylactic Hypothermia on Neurophysiological and
   Functional Measures in the Setting of Iatrogenic Spinal Cord Impact
   Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hypothermia; Somatosensory evoked potentials; Spinal cord injury
ID SYSTEMIC HYPOTHERMIA; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA;
   THERAPEUTIC HYPOTHERMIA; ISCHEMIC-INJURY; BRAIN; PROTECTION; DAMAGE;
   OUTCOMES; STROKE
AB BACKGROUND: Iatrogenic spinal cord injury (iSCI) during spinal corrective surgery can result in devastating complications, such as paraplegia or paraparesis. Perioperatively, iSCI often occurs as a direct injury during spinal cord instrumentation placement. Currently, treatment of iSCI remains limited to posttraumatic hypothermia, which has demonstrated some value in recent clinical trials. Here we report the outcomes of preinjury hypothermia initiated preprocedurally and maintained for a considerable time after iSCI.
   METHODS: Twenty-six female SpragueeDawley rats were assigned at random to either a normothermic group (36 degrees C) or a hypothermic group (32 degrees C) and then underwent a laminectomy procedure at the T8 level. Each group was further divided at random to receive a 200-kdyn force contusive spinal cord injury or a sham impact. Hypothermic rats were then rewarmed after 2 hours of hypothermic treatment. Behavioral scores, temperature profiles, weights, and somatosensory evoked potentials were obtained at baseline and at specified time points after the procedure.
   RESULTS: The median survival was 42 days for the iSCI hypothermic group and 11 days for the iSCI normothermic group (hazard ratio, 3.82; 95% confidence interval, 1.52-9.57). The probability of survival was significantly higher in the iSCI hypothermic group compared with the iSCI normothermic group (chi(2) = 4.18; P = 0.040). The hypothermic group exhibited a higher Basso, Beattie and Bresnahan (BBB) locomotor rating scale score (17 vs. 14; P < 0.01), lower normalized latencies (1.06 +/- 0.16 seconds vs. 1.34 +/- 0.17 seconds; P = 0.04), and higher peak-to-peak amplitudes (0.32 +/- 0.10 mV vs. 0.12 +/- 0.09 mV; P = 0.005).
   CONCLUSIONS: The use of prophylactic hypothermia before iSCI was significantly associated with an increased survival rate, higher BBB scores, and improved neurophysiological measures.
C1 [Jorge, Ahmed; Fish, Erika J.; Dixon, C. Edward; Hamilton, Kojo D.; Balzer, Jeffrey; Thirumala, Parthasarathy] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA.
RP Jorge, A (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA.
EM jorgea@upnc.edu
OI Jorge, Ahmed/0000-0003-3484-6197
CR Ahmad FU, 2014, WORLD NEUROSURG, V82, P207, DOI 10.1016/j.wneu.2013.01.008
   Alkabie S, 2016, WORLD NEUROSURG, V86, P432, DOI 10.1016/j.wneu.2015.09.079
   BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1
   Batchelor PE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071317
   Batchelor PE, 2010, J NEUROTRAUM, V27, P1357, DOI 10.1089/neu.2010.1360
   Bazley FA, 2014, THER HYPOTHERMIA TEM, V4, P115, DOI 10.1089/ther.2014.0002
   Benz-Woerner J, 2012, RESUSCITATION, V83, P338, DOI 10.1016/j.resuscitation.2011.10.026
   Berger C, 2007, EXP NEUROL, V204, P131, DOI 10.1016/j.expneurol.2006.10.002
   Cappuccino A, 2010, SPINE, V35, pE57, DOI 10.1097/BRS.0b013e3181b9dc28
   CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13
   Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690
   Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8
   Dididze M, 2013, SPINAL CORD, V51, P395, DOI 10.1038/sc.2012.161
   Dietrich WD, 2011, NEUROTHERAPEUTICS, V8, P229, DOI 10.1007/s13311-011-0035-3
   Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015
   Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806
   Groysman LI, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.4.FOCUS1154
   Hansebout RR, 2014, J NEUROSURG-SPINE, V20, P550, DOI 10.3171/2014.2.SPINE13318
   Hurlbert RJ, 2013, NEUROSURGERY, V72, P93, DOI 10.1227/NEU.0b013e31827765c6
   Inoue S, 2013, J THORAC CARDIOV SUR, V146, P696, DOI 10.1016/j.jtcvs.2012.11.040
   Jorge A, 2019, J CLIN NEUROPHYSIOL, V36, P155, DOI 10.1097/WNP.0000000000000563
   Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303
   Kwon BK, 2011, J NEUROTRAUM, V28, P1545, DOI 10.1089/neu.2009.1149
   Levi AD, 2010, NEUROSURGERY, V66, P670, DOI 10.1227/01.NEU.0000367557.77973.5F
   Lilla N, 2018, WORLD NEUROSURG, V109, pE88, DOI 10.1016/j.wneu.2017.09.109
   Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803
   Maybhate A, 2012, CRIT CARE MED, V40, P573, DOI 10.1097/CCM.0b013e318232d97e
   OToole JE, 2013, HYPOTHERMIA HUMAN SP
   Saito T, 2013, J VASC SURG, V57, P173, DOI 10.1016/j.jvs.2012.05.101
   Samanci MY, 2019, WORLD NEUROSURG, V121, pE481, DOI 10.1016/j.wneu.2018.09.142
   Shiozaki T, 2003, J NEUROSURG, V99, P47, DOI 10.3171/jns.2003.99.1.0047
   Strauch JT, 2004, EUR J CARDIO-THORAC, V25, P708, DOI 10.1016/j.ejcts.2004.01.007
   Thirumala P, 2016, J CLIN NEUROSCI, V25, P122, DOI 10.1016/j.jocn.2015.10.010
   Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272
   Yao Z, 2018, WORLD NEUROSURG, V111, P404, DOI 10.1016/j.wneu.2018.01.020
   Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E607
EP E613
DI 10.1016/j.wneu.2019.05.229
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900077
PM 31158549
DA 2020-05-12
ER

PT J
AU Jung, JM
   Hyun, SJ
   Kim, KJ
   Jahng, TA
   Kim, HJ
   Choi, Y
AF Jung, Jong-Myung
   Hyun, Seung-Jae
   Kim, Ki-Jeong
   Jahng, Tae-Ahn
   Kim, Hyun-Jib
   Choi, Yunhee
TI Anatomic Trajectory Screw Fixation at Upper Instrumented Vertebra Is a
   Substantial Risk Factor for Proximal Junctional Kyphosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult spinal deformity; Proximal junction failure; Proximal junction
   kyphosis; Screw trajectory; Upper instrumented vertebra
ID ADULT SPINAL DEFORMITY; LUMBAR PEDICLE SCREWS; SURGICAL-TREATMENT;
   SAGITTAL BALANCE; THORACIC SPINE; TECHNICAL NOTE; SURGERY; SCOLIOSIS;
   FUSION; COMPLICATIONS
AB BACKGROUND: This study aimed to investigate the risk of proximal junction kyphosis (PJK) and proximal junction failure (PJF) associated with screw trajectory (straightforward vs. mixed vs. anatomic) at upper instrumented vertebra (UIV).
   METHODS: A single-center, single-surgeon consecutive series of adult patients who underwent lumbar fusion for circle minus 4 levels (the UIV of the thoracolumbar spine, T9-L2, and the lower instrumented vertebra at the sacrum or pelvis) was retrospectively reviewed. Patients were divided into 3 groups according to UIV screw trajectory: group S, 2 straightforward screws; group M, 1 straightforward screw and 1 anatomic trajectory screw; and group A, 2 anatomic trajectory screws.
   RESULTS: A total of 83 patients were included in this study, including 51 in group S, 16 in group M, and 16 in group A. The incidence of PJK in group S (12 patients, 23.5%), group M (7 patients, 43.8%), and group A (9 patients, 56.3%) significantly increased in sequence by group (P = 0.044). Anatomic trajectory screw fixation increased the risk for PJF requiring revision surgery compared with straightforward screw fixation (3 patients [18.8%] vs. 1 patient [2.0%]; P = 0.040). Multivariable analysis identified that anatomic trajectory screw fixation was a significant risk factor for PJK (P = 0.008; adjusted odds ratio = 7.591; 95% confidence interval, 1.69-34.093).
   CONCLUSION: Anatomic trajectory screw fixation at the UIV is a substantial risk factor for PJK and PJF. To reduce PJK and PJF, straightforward screw fixation at the UIV is recommended in adult spinal deformity correction surgery.
C1 [Jung, Jong-Myung; Hyun, Seung-Jae; Kim, Ki-Jeong; Jahng, Tae-Ahn; Kim, Hyun-Jib] Seoul Natl Univ, Bundang Hosp, Dept Neurosurg, Spine Ctr,Coll Med, Seongnam, South Korea.
   [Choi, Yunhee] Seoul Natl Univ, Seoul Natl Univ Hosp, Med Res Collaborating Ctr, Div Med Stat,Coll Med, Seoul, South Korea.
RP Hyun, SJ (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Neurosurg, Spine Ctr,Coll Med, Seongnam, South Korea.
EM hyunsj@snu.ac.kr
CR Arlet V, 2013, EUR SPINE J, V22, pS276, DOI 10.1007/s00586-013-2676-x
   Bae J, 2018, NEUROSPINE, V15, P18, DOI 10.14245/ns.1836022.011
   Barber JW, 1998, J SPINAL DISORD, V11, P215
   Bridwell KH, 2013, NEUROSURGERY, V72, P899, DOI 10.1227/NEU.0b013e31828bacd8
   Bridwell KH, 2009, SPINE, V34, P2171, DOI 10.1097/BRS.0b013e3181a8fdc8
   Cho SK, 2014, EUR SPINE J, V23, P2726, DOI 10.1007/s00586-014-3531-4
   Crawford NR, 2009, J NEUROSURG-SPINE, V10, P486, DOI 10.3171/2009.1.SPINE08274
   Glattes RC, 2005, SPINE, V30, P1643, DOI 10.1097/01.brs.0000169451.76359.49
   HALVORSON TL, 1994, SPINE, V19, P2415, DOI 10.1097/00007632-199411000-00008
   Han S, 2017, SPINE J, V17, P962, DOI 10.1016/j.spinee.2017.02.005
   Hart R, 2013, SPINE, V38, pE1223, DOI 10.1097/BRS.0b013e31829fedde
   Hostin R, 2013, SPINE, V38, P1008, DOI 10.1097/BRS.0b013e318271319c
   Hyun Seung-Jae, 2017, Korean J Spine, V14, P126, DOI 10.14245/kjs.2017.14.4.126
   Hyun SJ, 2016, SPINE J, V16, P1095, DOI 10.1016/j.spinee.2016.05.008
   Hyun Seung-Jae, 2013, World J Clin Cases, V1, P242, DOI 10.12998/wjcc.v1.i8.242
   Hyun SJ, 2012, J KOREAN NEUROSURG S, V51, P66, DOI 10.3340/jkns.2012.51.1.66
   Hyun SJ, 2010, J KOREAN NEUROSURG S, V47, P95, DOI 10.3340/jkns.2010.47.2.95
   Inceoglu S, 2011, J NEUROSURG-SPINE, V14, P670, DOI 10.3171/2010.11.SPINE09886
   Kilincer C, 2007, J CLIN NEUROSCI, V14, P1186, DOI 10.1016/j.jocn.2006.10.008
   Kim HJ, 2014, SPINE, V39, pE576, DOI 10.1097/BRS.0000000000000246
   Kim HJ, 2013, SPINE, V38, P896, DOI 10.1097/BRS.0b013e3182815b42
   Kim HJ, 2012, SPINE, V37, pS144, DOI 10.1097/BRS.0b013e31826d611b
   Kim YJ, 2004, SPINE, V29, P333, DOI 10.1097/01.BRS.0000109983.12113.9B
   Kim YJ, 2008, SPINE, V33, P2179, DOI 10.1097/BRS.0b013e31817c0428
   Kim YJ, 2006, SPINE, V31, P2359, DOI 10.1097/01.brs.0000238969.59928.73
   Kim YJ, 2016, J KOREAN NEUROSURG S, V59, P327, DOI 10.3340/jkns.2016.59.4.327
   Lee CH, 2014, ASIAN SPINE J, V8, P237, DOI 10.4184/asj.2014.8.3.237
   Lehman RA, 2003, SPINE, V28, P2058, DOI 10.1097/01.BRS.0000087743.57439.4F
   Makhni MC, 2018, J KOREAN NEUROSURG S, V61, P167, DOI 10.3340/jkns.2017.0404.013
   Maruo K, 2013, SPINE, V38, pE1469, DOI 10.1097/BRS.0b013e3182a51d43
   Newcomb AGUS, 2017, COMPUT METHOD BIOMEC, V20, P182, DOI 10.1080/10255842.2016.1209187
   Ohrt-Nissen S, 2018, NEUROSPINE, V15, P123, DOI 10.14245/ns.1836050.025
   Park JH, 2015, J KOREAN NEUROSURG S, V58, P578, DOI 10.3340/jkns.2015.58.6.578
   Park YS, 2017, J NEUROSURG-SPINE, V26, P638, DOI 10.3171/2016.10.SPINE16535
   Santoni BG, 2009, SPINE J, V9, P366, DOI 10.1016/j.spinee.2008.07.008
   Sanyal A, 2012, J BIOMECH, V45, P2513, DOI 10.1016/j.jbiomech.2012.07.023
   Schwab F, 2005, SPINE, V30, P1082, DOI 10.1097/01.brs.0000160842.43482.cd
   Schwab FJ, 2008, SPINE, V33, P2243, DOI 10.1097/BRS.0b013e31817d1d4e
   Sterba W, 2007, CLIN BIOMECH, V22, P385, DOI 10.1016/j.clinbiomech.2006.11.007
NR 39
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E522
EP E529
DI 10.1016/j.wneu.2019.05.198
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900066
PM 31152888
DA 2020-05-12
ER

PT J
AU Kabbasch, C
   Goertz, L
   Siebert, E
   Herzberg, M
   Borggrefe, J
   Krischek, B
   Dorn, F
   Liebig, T
AF Kabbasch, Christoph
   Goertz, Lukas
   Siebert, Eberhard
   Herzberg, Moriz
   Borggrefe, Jan
   Krischek, Boris
   Dorn, Franziska
   Liebig, Thomas
TI Treatment of Recurrent and Residual Aneurysms with the Woven EndoBridge
   Device: Analysis of 11 Patients and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; Clipping; Coiling; Recurrence; WEB; Woven EndoBridge
ID UNRUPTURED INTRACRANIAL ANEURYSMS; COILED CEREBRAL ANEURYSMS;
   ENDOVASCULAR TREATMENT; EMBOLIZATION DEVICE; WEB DEVICE; SAFETY;
   EFFICACY; COMPLEX; SERIES
AB OBJECTIVE: The Woven EndoBridge (WEB) device is an innovative tool for endovascular treatment of wide-necked bifurcation aneurysms. Numerous studies of primary aneurysm treatment with the WEB device have been reported. We analyzed the safety and efficacy of WEB embolization for recurrent and residual aneurysms.
   METHODS: We performed a retrospective observational study of consecutive patients with initially endovascularly or surgically treated aneurysms and an aneurysm recurrence or remnant retreated with the WEB device at 3 German high-volume neurovascular centers from May 2011 to February 2018. The technical success, complications, and angiographic outcomes were evaluated.
   RESULTS: Eleven patients (median age, 65 years; 5 women) with 11 aneurysms (median size, 6.8 mm) were identified. The aneurysms were located at the anterior communicating artery in 4, basilar tip in 4, internal carotid artery in 1, middle cerebral artery in 1, and posterior communicating artery in 1 patient. Three aneurysms had been previously clipped and 8 had undergone endovascular therapy. WEB embolization was feasible in 10 patients. Ancillary devices were used for 4 aneurysms. Perforation occurred in 1 aneurysm, which resolved without sequelae. Of the 9 patients available for angiographic follow-up (median follow-up, 6 months), complete and nearcomplete aneurysm occlusion was achieved in 3 (33%) and 7 patients (78%), respectively. Three patients underwent repeat treatment (33%).
   CONCLUSIONS: The results of the present study have indicated that WEB embolization of previously treated aneurysms is reasonably safe. However, careful aneurysm selection could be necessary to achieve adequate midterm occlusion rates.
C1 [Kabbasch, Christoph; Borggrefe, Jan] Univ Hosp Cologne, Dept Neuroradiol, Cologne, Germany.
   [Goertz, Lukas; Krischek, Boris] Univ Cologne, Fac Med, Ctr Neurosurg, Cologne, Germany.
   [Goertz, Lukas; Krischek, Boris] Univ Cologne, Univ Hosp, Cologne, Germany.
   [Siebert, Eberhard] Univ Hosp Berlin Charite, Dept Neuroradiol, Berlin, Germany.
   [Herzberg, Moriz; Dorn, Franziska; Liebig, Thomas] Univ Hosp Munich LMU, Dept Neuroradiol, Munich, Germany.
RP Goertz, L (reprint author), Univ Cologne, Fac Med, Ctr Neurosurg, Cologne, Germany.; Goertz, L (reprint author), Univ Cologne, Univ Hosp, Cologne, Germany.
EM lukas.goertz@uk-koeln.de
RI Dorn, Franziska/AAA-7754-2020; Borggrefe, Jan/N-6549-2018
OI Dorn, Franziska/0000-0001-9093-8307; Borggrefe, Jan/0000-0003-2908-7560;
   Kabbasch, Christoph/0000-0003-3712-2258
CR Anil G, 2016, AM J NEURORADIOL, V37, P892, DOI 10.3174/ajnr.A4604
   Caroff J, 2016, AM J NEURORADIOL, V37, P279, DOI 10.3174/ajnr.A4540
   Chalouhi N, 2014, J NEUROINTERV SURG, V6, P19, DOI 10.1136/neurintsurg-2012-010612
   Cho YD, 2012, NEUROSURGERY, V71, P253, DOI 10.1227/NEU.0b013e3182647a97
   Clajus C, 2017, J NEUROINTERV SURG, V9, P411, DOI 10.1136/neurintsurg-2016-012276
   Daou B, 2016, J NEUROSURG, V125, P1337, DOI 10.3171/2015.10.JNS151544
   Ding YH, 2011, AM J NEURORADIOL, V32, P607, DOI 10.3174/ajnr.A2399
   Dorfer C, 2012, NEUROSURGERY, V70, P537, DOI 10.1227/NEU.0b013e3182350da5
   Gawlitza M, 2018, J NEUROINTERV SURG, V10, P629, DOI 10.1136/neurintsurg-2017-013287
   Goertz L, 2019, WORLD NEUROSURG, V125, pE1196, DOI 10.1016/j.wneu.2019.01.279
   Goertz Lukas, 2019, Clin Neuroradiol, DOI 10.1007/s00062-019-00762-8
   Goertz L, 2018, ACTA NEUROCHIR, V160, P2169, DOI 10.1007/s00701-018-3675-9
   Goertz L, 2018, WORLD NEUROSURG, V120, pE1163, DOI 10.1016/j.wneu.2018.09.026
   Goertz L, 2019, J NEUROINTERV SURG, V11, P290, DOI 10.1136/neurintsurg-2018-014166
   Herbreteau D, 2016, AM J NEURORADIOL, V37, P2280, DOI 10.3174/ajnr.A4918
   Kabbasch C, 2016, J NEUROINTERV SURG, V8, P1235, DOI 10.1136/neurintsurg-2015-012126
   Kabbasch C, 2019, WORLD NEUROSURG, V126, pE937, DOI 10.1016/j.wneu.2019.03.016
   Kabbasch C, 2019, J NEUROINTERV SURG, V11, P812, DOI 10.1136/neurintsurg-2018-014555
   Kabbasch C, 2019, J NEUROINTERV SURG, V11, P503, DOI 10.1136/neurintsurg-2018-014361
   Kabbasch C, 2019, J NEUROINTERV SURG, V11, P390, DOI 10.1136/neurintsurg-2018-014230
   Kallmes DF, 2017, J NEUROSURG, V127, P775, DOI 10.3171/2016.8.JNS16467
   Kraus B, 2019, J NEUROINTERV SURG, V11, P68, DOI 10.1136/neurintsurg-2018-013963
   Kuhn AL, 2017, J NEUROINTERV SURG, V9, P1208, DOI 10.1136/neurintsurg-2016-012772
   Li YD, 2010, J NEUROL NEUROSUR PS, V81, P74, DOI 10.1136/jnnp.2009.171967
   Liebig T, 2015, AM J NEURORADIOL, V36, P1721, DOI 10.3174/ajnr.A4347
   Lubicz B, 2013, AM J NEURORADIOL, V34, P1209, DOI 10.3174/ajnr.A3387
   Lv XL, 2018, WORLD NEUROSURG, V110, P20, DOI 10.1016/j.wneu.2017.10.113
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Petr O, 2018, WORLD NEUROSURG, V114, pE137, DOI 10.1016/j.wneu.2018.02.103
   Pierot L, 2015, AM J NEURORADIOL, V36, P2314, DOI 10.3174/ajnr.A4445
   Pierot L, 2018, J NEUROINTERV SURG, V10, P553, DOI 10.1136/neurintsurg-2017-013448
   Piotin M, 2007, RADIOLOGY, V243, P500, DOI 10.1148/radiol.2431060006
   Popielski J, 2018, AM J NEURORADIOL, V39, P111, DOI 10.3174/ajnr.A5413
   Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9
   Rezek I, 2014, AM J NEURORADIOL, V35, P124, DOI 10.3174/ajnr.A3623
   Ringer AJ, 2009, NEUROSURGERY, V65, P311, DOI 10.1227/01.NEU.0000349922.05350.96
   Sindou R, 1998, ACTA NEUROCHIR, V140, P1153, DOI 10.1007/s007010050230
   Soeda A, 2003, AM J NEURORADIOL, V24, P127
   Tahtinen OI, 2013, NEURORADIOLOGY, V55, P1221, DOI 10.1007/s00234-013-1234-x
   Thornton J, 2000, NEUROSURGERY, V46, P1294, DOI 10.1097/00006123-200006000-00003
   van Rooij SBT, 2019, INTERV NEURORADIOL, V25, P21, DOI 10.1177/1591019918798806
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E677
EP E685
DI 10.1016/j.wneu.2019.05.248
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900086
PM 31181365
DA 2020-05-12
ER

PT J
AU Kakusa, BW
   Xu, LW
   Vaca, SD
   Nalwanga, J
   Kiryabwire, J
   Ssenyonjo, H
   Mukasa, J
   Muhumuza, M
   Haglund, MM
   Grant, GA
AF Kakusa, Bina W.
   Xu, Linda W.
   Vaca, Silvia D.
   Nalwanga, Juliet
   Kiryabwire, Joel
   Ssenyonjo, Hussein
   Mukasa, John
   Muhumuza, Michael
   Haglund, Michael M.
   Grant, Gerald A.
TI Central Nervous System Tumors in Uganda: Outcomes of Surgical Treatment
   and Complications Assessed Through Telephone Survey
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Long-term follow-up; Low- and middle-income countries;
   Mulago; Neurosurgery; Phone interview
ID PRIMARY BRAIN-TUMORS; UNITED-STATES; NEUROSURGERY; SITUATION; NIGERIA;
   KAMPALA; CANCER
AB BACKGROUND: Uganda has one of the largest unmet neurosurgical needs in the world, but has seen major improvements in neurosurgery-largely centered at Mulago National Referral Hospital (MNRH). This study implements the first long-term follow-up and outcomes analysis of central nervous system tumor patients in Uganda.
   METHODS: Inpatient data were collected using a prospective database of patients presenting to the MNRH neurosurgical ward between 2014 and 2015. Follow-up health care status was assessed in the patient's language using phone surveys. Analysis was performed to identify which factors were associated with patient outcomes.
   RESULTS: The MNRH neurosurgical ward saw 112 patients with central nervous system tumors (adult N = 87, female: 70%, median age: 37 years). Meningiomas (21%) comprised the most common tumor diagnosis. In-hospital mortality (18%), 30-day mortality (22%), and 1-year mortality (35%) were high. Thirty percent of patients underwent tumor resection in-patient and had greater median overall survival (66.5 months vs. 5.1 months for nonsurgical patients, P = 0.025). For those with known pathologic diagnoses, patients with glioblastomas had decreased median overall survival (0.83 months vs. 59 months for meningiomas, P = 0.02). Phone interviews yielded an 85% response rate. Of the survivors at the time of follow-up, 55% reported a subjective return to normalcy, and 75% received follow-up care for their tumor with most returning to MNRH.
   CONCLUSIONS: We show evidence for improved overall survival with surgical care at MNRH. In addition, phone interviews as a method of measuring health outcomes provided an effective means of follow-up, showing that most patients do seek follow-up care.
C1 [Kakusa, Bina W.; Xu, Linda W.; Vaca, Silvia D.; Grant, Gerald A.] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA.
   [Kakusa, Bina W.; Xu, Linda W.; Vaca, Silvia D.; Grant, Gerald A.] Stanford Ctr Global Hlth Innovat, Palo Alto, CA 94305 USA.
   [Xu, Linda W.] Allegheny Hlth Network, Dept Neurosurg, Pittsburgh, PA USA.
   [Haglund, Michael M.] Duke Univ, Dept Neurosurg, Div Global Neurosurg & Neurol, Durham, NC USA.
   [Nalwanga, Juliet; Kiryabwire, Joel; Ssenyonjo, Hussein; Mukasa, John; Muhumuza, Michael] Mulago Natl Referral Hosp, Dept Neurosurg, Kampala, Uganda.
RP Grant, GA (reprint author), Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA.; Grant, GA (reprint author), Stanford Ctr Global Hlth Innovat, Palo Alto, CA 94305 USA.
EM ggrant2@stanford.edu
OI Kakusa, Bina/0000-0003-0907-2505
FU Stanford School of Medicine Medical Scholars Fellowship Grant; Stanford
   Society of Physician Scholars Grant; Stanford School of Medicine,
   Stanford, California
FX This study was supported by the Stanford School of Medicine Medical
   Scholars Fellowship Grant and the Stanford Society of Physician Scholars
   Grant, Stanford School of Medicine, Stanford, California.
CR Abdelgadir J, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.7.FOCUS18270
   Albright AL, 2016, J NEUROSURG-PEDIATR, V18, P127, DOI 10.3171/2015.8.PEDS15403
   Central Intelligence Agency USA, 2017, WORLD FACTB UG
   de Robles P, 2015, NEURO-ONCOLOGY, V17, P776, DOI 10.1093/neuonc/nou283
   El Khamlichi A, 2001, NEUROSURGERY, V48, P1344, DOI 10.1097/00006123-200106000-00034
   Emejulu JKC, 2008, NIGER J CLIN PRACT, V11, P291
   Eyenga Victor-Claude, 2008, Sante, V18, P39, DOI 10.1684/san.2008.0096
   Fuller AT, 2016, WORLD NEUROSURG, V95, P309, DOI 10.1016/j.wneu.2016.07.090
   Haglund MM, 2017, NEUROSURGERY, V80, P656, DOI 10.1093/neuros/nyw159
   Haglund MM, 2011, WORLD J SURG, V35, P1175, DOI 10.1007/s00268-011-1080-0
   Hatef J, 2014, WORLD NEUROSURG, V82, P258, DOI 10.1016/j.wneu.2014.06.040
   Igun G O, 2001, East Afr Med J, V78, P148
   Jiang T, 2011, CHINESE MED J-PEKING, V124, P2578, DOI 10.3760/cma.j.issn.0366-6999.2011.17.003
   Kuo BJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182285
   Ministry of Health Uganda, 2017, HOSP DAT
   Momin EN, 2012, ARCH SURG-CHICAGO, V147, P1017, DOI 10.1001/archsurg.2012.1459
   Ngulde SI, 2015, CUREUS, V7, DOI 10.7759/cureus.372
   Odebode TO, 2006, J CLIN NEUROSCI, V13, P649, DOI 10.1016/j.jocn.2005.07.023
   Ogun Gabriel Olabiyi, 2016, Pan Afr Med J, V24, P34, DOI 10.11604/pamj.2016.24.34.9344
   Ostrom QT, 2015, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou327
   Park KB, 2016, WORLD NEUROSURG, V88, P32, DOI 10.1016/j.wneu.2015.12.048
   Parkin DM, 2010, INT J CANCER, V126, P1187, DOI 10.1002/ijc.24838
   Porter KR, 2010, NEURO-ONCOLOGY, V12, P520, DOI 10.1093/neuonc/nop066
   Sarfo FS, 2017, J NEUROL SCI, V380, P196, DOI 10.1016/j.jns.2017.07.037
   Soyemi SS, 2015, PAN AFR MED J, V20, P1, DOI 10.11604/pamj.2015.20.24.4935
   Stagno V, 2014, CHILD NERV SYST, V30, P137, DOI 10.1007/s00381-013-2297-z
   Turner CD, 2009, J CHILD NEUROL, V24, P1455, DOI 10.1177/0883073809341709
   Uche EO, 2013, CHILD NERV SYST, V29, P1131, DOI 10.1007/s00381-013-2105-9
   Upadhyayula PS, 2018, J NEUROSCI RURAL PRA, V9, P123, DOI 10.4103/jnrp.jnrp_273_17
   Vaca SD, 2019, J NEUROSURG-PEDIATR, V23, P125, DOI 10.3171/2018.7.PEDS17601
   Wabinga HR, 2014, INT J CANCER, V135, P432, DOI 10.1002/ijc.28661
   Wanyoike P K, 2004, East Afr Med J, V81, P258
   World Health Organization Switzerland, 2017, CANC FACT SHEET
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E866
EP E880
DI 10.1016/j.wneu.2019.06.060
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900109
PM 31303566
DA 2020-05-12
ER

PT J
AU Karhadet, AV
   Senders, JT
   Martin, E
   Muskens, IS
   Zaidi, HA
   Broekman, MLD
   Smith, TR
AF Karhadet, Aditya, V
   Senders, Joeky T.
   Martin, Enrico
   Muskens, Ivo S.
   Zaidi, Hasan A.
   Broekman, Marike L. D.
   Smith, Timothy R.
TI Trends in High-Impact Neurosurgical Randomized Controlled Trials
   Published in General Medical Journals: A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Evidence-based care; High impact; Medical management; Neurosurgery;
   Operative management; Randomized controlled trials
ID DEEP-BRAIN-STIMULATION; SUCCESSFUL CAROTID-ENDARTERECTOMY; INITIAL
   CONSERVATIVE TREATMENT; LUMBAR DISC HERNIATION; INTRAVENOUS T-PA;
   LOW-BACK-PAIN; ENDOVASCULAR TREATMENT; EARLY SURGERY; DECOMPRESSIVE
   CRANIECTOMY; INTRACEREBRAL HEMATOMAS
AB BACKGROUND: The neurosurgery literature lacks a comprehensive report of neurosurgical randomized controlled trials (RCTs) published in general medical journals. RCTs published in these journals have high visibility and impact on decision-making by general medical practitioners and health care policymakers.
   METHODS: A systematic review of neurosurgical RCTs in the New England Journal of Medicine, The Lancet, Journal of the American Medical Association, The BMJ, and Annals of Internal Medicine was completed.
   RESULTS: There were 78 neurosurgical RCTs published in the selected high-impact journals from 2000 to 2017. The most common study topics were neurovascular (n=39, 50%) and spine (n=24, 30.8%). Of these RCTs, 44 (56.4%) compared operative with nonoperative management. For studies published before 2017, the mean number of citations was 899. Approximately half of the studies showed superiority of operative management over nonoperative management in the intent to treat primary outcome of interest (n=24, 54.5%). However, stratified by subsubspecialty, 7 (87.5%) of the functional RCTs, 9 (50%) of the neurovascular RCTs, 1 (50%) of the trauma RCTs, and 7 (43.8%) of the spinal RCTs demonstrated superiority of operative management over nonoperative management. Additionally, there were large subspecialty differences in study characteristics, such as rate of double blinding, proportion of patient enrollment from patients screened, and proportion of crossover from nonsurgical to surgical arm.
   CONCLUSIONS: Neurosurgical RCTs in general medical journals have large subspecialty differences in characteristics such as crossovers from nonsurgical to surgical treatment arms and the proportion of studies demonstrating benefit of operative intervention over nonoperative management.
C1 [Karhadet, Aditya, V; Senders, Joeky T.; Zaidi, Hasan A.; Smith, Timothy R.] Harvard Med Sch, Computat Neurosci Outcomes Ctr, Dept Neurosurg, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Karhadet, Aditya, V; Senders, Joeky T.; Broekman, Marike L. D.] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands.
   [Martin, Enrico; Muskens, Ivo S.; Broekman, Marike L. D.] Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands.
   [Muskens, Ivo S.] Univ Southern Calif, Ctr Genet Epidemiol, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA.
   [Martin, Enrico] Univ Med Ctr Utrecht, Dept Plast & Reconstruct Surg, Utrecht, Netherlands.
RP Karhadet, AV (reprint author), Harvard Med Sch, Computat Neurosci Outcomes Ctr, Dept Neurosurg, Brigham & Womens Hosp, Boston, MA 02115 USA.; Karhadet, AV (reprint author), Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands.
EM aditya.v.karhadet@gmail.com
CR Albrecht J, 2005, J CLIN EPIDEMIOL, V58, P1227, DOI 10.1016/j.jclinepi.2005.04.003
   Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Broderick JP, 2013, NEW ENGL J MED, V368, P893, DOI 10.1056/NEJMoa1214300
   Buchbinder R, 2009, NEW ENGL J MED, V361, P557, DOI 10.1056/NEJMoa0900429
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Ciccone A, 2013, NEW ENGL J MED, V368, P904, DOI 10.1056/NEJMoa1213701
   Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507
   Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077
   Delitto A, 2015, ANN INTERN MED, V162, P465, DOI 10.7326/M14-1420
   Derdeyn CP, 2014, LANCET, V383, P333, DOI 10.1016/S0140-6736(13)62038-3
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   Dwivedi R, 2017, NEW ENGL J MED, V377, P1639, DOI 10.1056/NEJMoa1615335
   Elias WJ, 2016, NEW ENGL J MED, V375, P730, DOI 10.1056/NEJMoa1600159
   Engel J, 2012, JAMA-J AM MED ASSOC, V307, P922, DOI 10.1001/jama.2012.220
   Fairbank J, 2005, BRIT MED J, V330, P1233, DOI 10.1136/bmj.38441.620417.8F
   Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002
   GARFIELD E, 1986, ANN INTERN MED, V105, P313, DOI 10.7326/0003-4819-105-2-313
   Geurts JWM, 2003, LANCET, V361, P21, DOI 10.1016/S0140-6736(03)12115-0
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032
   Haines SJ, 2003, NEUROSURGERY, V52, P36, DOI 10.1097/00006123-200301000-00004
   Halliday A, 2004, LANCET, V363, P1491
   Halliday A, 2010, LANCET, V376, P1074, DOI 10.1016/S0140-6736(10)61197-X
   Hellum C, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2786
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   INGELFINGER FJ, 1977, NEW ENGL J MED, V296, P1258, DOI 10.1056/NEJM197706022962204
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Juch JNS, 2017, JAMA-J AM MED ASSOC, V318, P68, DOI 10.1001/jama.2017.7918
   Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367
   Kallmes DF, 2009, NEW ENGL J MED, V361, P569, DOI 10.1056/NEJMoa0900563
   Kidwell CS, 2013, NEW ENGL J MED, V368, P914, DOI 10.1056/NEJMoa1212793
   Klazen CAH, 2010, LANCET, V376, P1085, DOI 10.1016/S0140-6736(10)60954-3
   Kupsch A, 2006, NEW ENGL J MED, V355, P1978, DOI 10.1056/NEJMoa063618
   Martin E, 2019, ACTA NEUROCHIR, V161, P627, DOI 10.1007/s00701-019-03849-w
   Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1
   Mendelow AD, 2005, LANCET, V365, P387
   Mohr JP, 2014, LANCET, V383, P614, DOI 10.1016/S0140-6736(13)62302-8
   Nwachukwu BU, 2017, ORTHOPEDICS, V40, pE405, DOI 10.3928/01477447-20170223-04
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1
   Peul WC, 2008, BRIT MED J, V336, P1355, DOI 10.1136/bmj.a143
   Peul WC, 2007, NEW ENGL J MED, V356, P2245, DOI 10.1056/NEJMoa064039
   Porter ME, 2009, NEW ENGL J MED, V361, P109, DOI 10.1056/NEJMp0904131
   Powers WJ, 2011, JAMA-J AM MED ASSOC, V306, P1983, DOI 10.1001/jama.2011.1610
   Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Strasak AM, 2007, AM STAT, V61, P47, DOI 10.1198/000313007X170242
   Swensen SJ, 2010, NEW ENGL J MED, V362, DOI 10.1056/NEJMp0911199
   van den Berg LA, 2017, NEW ENGL J MED, V376, P1341, DOI 10.1056/NEJMoa1612136
   van den Hout WB, 2008, BMJ-BRIT MED J, V336, P1351, DOI 10.1136/bmj.39583.709074.BE
   Van Spall HGC, 2007, JAMA-J AM MED ASSOC, V297, P1233, DOI 10.1001/jama.297.11.1233
   Wardlaw D, 2009, LANCET, V373, P1016, DOI 10.1016/S0140-6736(09)60010-6
   Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929
   Weinstein JN, 2008, NEW ENGL J MED, V358, P794, DOI 10.1056/NEJMoa0707136
   Weinstein JN, 2007, NEW ENGL J MED, V356, P2257, DOI 10.1056/NEJMoa070302
   Weinstein JN, 2006, JAMA-J AM MED ASSOC, V296, P2441, DOI 10.1001/jama.296.20.2441
   Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501
   Yarascavitch BA, 2012, NEUROSURGERY, V71, P1131, DOI 10.1227/NEU.0b013e318271bc99
   Zaidat OO, 2015, JAMA-J AM MED ASSOC, V313, P1240, DOI 10.1001/jama.2015.1693
NR 59
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E158
EP E170
DI 10.1016/j.wneu.2019.05.083
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900021
PM 31108256
DA 2020-05-12
ER

PT J
AU Katano, H
   Nishikawa, Y
   Yamada, H
   Shibata, T
   Miyachi, S
   Mase, M
AF Katano, Hiroyuki
   Nishikawa, Yusuke
   Yamada, Hiroshi
   Shibata, Teishiki
   Miyachi, Shigenori
   Mase, Mitsuhito
TI Association of Superficial Temporal Artery Dilatation with Headache
   After Revascularization in Adult Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Headache; Moyamoya disease; rCBF; Revascularization; STA-MCA
   anastomosis; Superficial temporal artery
ID CEREBRAL-BLOOD-FLOW
AB BACKGROUND: The underlying mechanisms of headache in adult moyamoya disease (MMD) are not clear. The aim of this study is to clarify the factors that are associated with headache in adult patients with MMD after superficial temporal artery (STA)-middle cerebral artery (MCA) anastomosis.
   METHODS: We retrospectively analyzed the cases of 68 adult patients with MMD: 30 with surgery and 38 without surgery. Each STA-MCA anastomosis was performed by the standard technique. Magnetic resonance angiography (MRA) and single photon emission computed tomography were performed perioperatively. We stratified the intensity and frequency of the patients' headaches into 4 ranks. Pre-and postoperative STA diameters were retrospectively measured on digital subtraction angiography (DSA) and/or MRA.
   RESULTS: In the surgery group, preoperative regional cerebral blood flow (rCBF) laterality and a postoperative rCBF increase >20% showed no significant difference between the patients with and without headache with a univariate analysis. The postoperative STA diameters of the distal branch (DSA) and main trunk (DSA/MRA) in the patients with headache were significantly larger than those of the patients without headache. The rate of postoperative increase of the STA diameters of the distal branch/main trunk was also significantly higher in the patients with headache than those without headache. A multivariate analysis showed that the standard regression coefficient beta for sex, a >20% increase of postoperative rCBF, and the increase rate of the STA diameter of the distal branch shown by DSA was 0.37, 0.54, and 0.56, respectively.
   CONCLUSIONS: The results of our analyses revealed that aside from ischemia, the postoperative increase rate of the STA may be a candidate reason for headache, especially in adult patients with MMD.
C1 [Katano, Hiroyuki; Nishikawa, Yusuke; Yamada, Hiroshi; Shibata, Teishiki; Mase, Mitsuhito] Nagoya City Univ, Dept Neurosurg, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Katano, Hiroyuki] Nagoya City Univ, Dept Med Informat & Integrat Med, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Miyachi, Shigenori] Nagoya City Univ Hosp, Dept Cent Radiol, Nagoya, Aichi, Japan.
RP Katano, H (reprint author), Nagoya City Univ, Dept Neurosurg, Grad Sch Med Sci, Nagoya, Aichi, Japan.; Katano, H (reprint author), Nagoya City Univ, Dept Med Informat & Integrat Med, Grad Sch Med Sci, Nagoya, Aichi, Japan.
EM katano@med.nagoya-cu.ac.jp
CR Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658
   Iida H, 2010, J NUCL MED, V51, P1624, DOI 10.2967/jnumed.110.078352
   Katano H, 2019, J NEUROL SURG, P1
   Katano H, 2012, ACTA NEUROCHIR, V154, P2139, DOI 10.1007/s00701-012-1498-7
   Kawabori M, 2013, WORLD NEUROSURG, V80, P612, DOI 10.1016/j.wneu.2012.08.005
   Kawaguchi T, 1996, J NEUROSURG, V84, P468, DOI 10.3171/jns.1996.84.3.0468
   Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193
   Kraemer M, 2017, CEPHALALGIA, V37, P496, DOI 10.1177/0333102416643516
   Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0
   MATSUSHIMA Y, 1990, BRAIN DEV-JPN, V12, P784, DOI 10.1016/S0387-7604(12)80007-6
   MINOSHIMA S, 1992, J NUCL MED, V33, P1579
   Ogura T, 2009, ANN NUCL MED, V23, P33, DOI 10.1007/s12149-008-0203-7
   Okada Y, 2012, J NEUROSURG, V116, P672, DOI 10.3171/2011.11.JNS11944
   Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, 2012, Neurol Med Chir (Tokyo), V52, P245
   Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622
   Seol HJ, 2005, J NEUROSURG, V103, P439, DOI 10.3171/ped.2005.103.5.0439
   Sewell RA, 2009, J HEADACHE PAIN, V10, P65, DOI 10.1007/s10194-008-0081-3
   Siddiqui M R, 2010, BMJ Case Rep, V2010, DOI 10.1136/bcr.02.2010.2764
   Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x
   SPETZLER R, 1976, J NEUROSURG, V45, P508, DOI 10.3171/jns.1976.45.5.0508
   Takeuchi R, 2003, NEUROL MED-CHIR, V43, P153, DOI 10.2176/nmc.43.153
   Takeuchi Ryo, 2006, Radiat Med, V24, P538, DOI 10.1007/s11604-006-0054-x
   Torigai T, 2013, J STROKE CEREBROVASC, V22, P197, DOI 10.1016/j.jstrokecerebrovasdis.2011.07.015
   Zach V, 2010, J HEADACHE PAIN, V11, P79, DOI 10.1007/s10194-009-0181-8
NR 24
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E594
EP E606
DI 10.1016/j.wneu.2019.05.228
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900076
PM 31158538
DA 2020-05-12
ER

PT J
AU Kawauchi, D
   Higuchi, Y
   Ikegami, S
   Adachi, A
   Ozaki, K
   Suda, I
   Kobayashi, E
   Iwadate, Y
AF Kawauchi, Daisuke
   Higuchi, Yoshinori
   Ikegami, Shiro
   Adachi, Akihiko
   Ozaki, Ko
   Suda, Izumi
   Kobayashi, Eiichi
   Iwadate, Yasuo
TI Unilateral Occipital Transtentorial Approach with Multimodal Assistance
   for Resection of Large Supracerebellar Hemangioblastomas: Preliminary
   Experience of 2 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic procedure; Occipital transtentorial approach; Preoperative
   embolization; Supracerebellar hemangioblastoma
ID SOLID HEMANGIOBLASTOMAS; OUTCOMES; FEATURES; LESIONS
AB BACKGROUND: The surgical resection of large supracerebellar hemangioblastomas (SHBs) is exceptionally challengingdueto their vascularityanddeepanatomiclocationand is associated with a high risk of postoperative complications and mortality. Access to the posterior incisural space can be achieved by either an infratentorial supracerebellar approach or occipital transtentorial approach (OTA). However, the optimalsurgical strategyhasnotyetbeenestablished. Here, we report 2 cases of large SHBs that were successfully and safely resected via a unilateral OTAwith multimodal assistance.
   CASE DESCRIPTION: Two patients presented to our hospital with ataxia due to large, solid SHBs. After preoperative embolization, gross total resection of the SHBswas achieved via an OTA. Furthermore, endoscopic assistance was used to resect the remnant portion of the tumor in the second patient. Both patients experienced transient ataxia but were discharged from the hospital without serious complications.
   CONCLUSIONS: The combination of an OTA with preoperative embolization and endoscopic assistance may reduce the intraoperative risk and contribute to improved outcome in patients with such clinically challenging tumors.
C1 [Kawauchi, Daisuke; Higuchi, Yoshinori; Ikegami, Shiro; Adachi, Akihiko; Ozaki, Ko; Suda, Izumi; Kobayashi, Eiichi; Iwadate, Yasuo] Chiba Univ, Dept Neurol Surg, Grad Sch Med, Chiba, Japan.
RP Kawauchi, D (reprint author), Chiba Univ, Dept Neurol Surg, Grad Sch Med, Chiba, Japan.
EM daisukee@gmil.com
OI Kawauchi, Daisuke/0000-0002-7679-173X; Higuchi,
   Yoshinori/0000-0001-5689-3416
CR Ampie L, 2016, CLIN NEUROL NEUROSUR, V150, P143, DOI 10.1016/j.clineuro.2016.09.008
   Borg A, 2013, NEUROSURGERY, V73, P244, DOI 10.1227/NEU.0000000000000187
   Cardenas RJ, 2011, J CLIN NEUROSCI, V18, P128, DOI 10.1016/j.jocn.2010.04.053
   Cheng J, 2017, WORLD NEUROSURG, V103, P248, DOI 10.1016/j.wneu.2017.03.144
   Chi JH, 2006, NEUROSURGERY, V59, P41, DOI 10.1227/01.NEU.0000219880.66309.85
   Fukuda M, 2014, WORLD NEUROSURG, V82, P815, DOI 10.1016/j.wneu.2014.06.018
   Hong CS, 2016, J NEUROSURG, V124, P799, DOI 10.3171/2015.1.JNS141113
   Isolan GR, 2007, NEUROSURGERY, V61, P423, DOI 10.1227/01.NEU.0000255516.12085.BB
   Kassam AB, 2009, J NEUROSURG, V110, P116, DOI 10.3171/2008.7.JNS08226
   Kawashima M, 2002, NEUROSURGERY, V51, P1208, DOI 10.1097/00006123-200211000-00017
   KrUger MT, 2014, J T MED EPIDEMIOL, V2, P1016
   Kuharic M, 2018, WORLD NEUROSURG, V110, pE1049, DOI 10.1016/j.wneu.2017.11.173
   Kurokawa Y, 1999, SURG NEUROL, V51, P421, DOI 10.1016/S0090-3019(98)00123-2
   Matsuo S, 2016, J NEUROSURG, V126, P1
   Murai Y, 2006, NEUROL MED-CHIR, V46, P143, DOI 10.2176/nmc.46.143
   Nakajima N, 2017, WORLD NEUROSURG, V105, P591, DOI 10.1016/j.wneu.2017.06.047
   NEUMANN HPH, 1989, J NEUROSURG, V70, P24, DOI 10.3171/jns.1989.70.1.0024
   Perneczky A, 1998, NEUROSURGERY, V42, P219, DOI 10.1097/00006123-199802000-00001
   Rabadan Alejandra T, 2016, J Med Case Rep, V10, P183, DOI 10.1186/s13256-016-0962-z
   Rachinger J, 2009, NEUROSURG REV, V32, P37, DOI 10.1007/s10143-008-0166-0
   Rhoton AL, 2000, NEUROSURGERY, V47, pS131, DOI 10.1097/00006123-200009001-00015
   Sakamoto N, 2012, NEUROL MED-CHIR, V52, P878, DOI 10.2176/nmc.52.878
   SATO O, 1981, ACTA NEUROCHIR, V59, P195, DOI 10.1007/BF01406349
   Shah AH, 2013, J NEUROSURG, V119, P364, DOI 10.3171/2013.3.JNS121328
   Slater A, 2003, AM J NEURORADIOL, V24, P1570
   Staudt MD, 2018, J CLIN NEUROSCI, V53, P224, DOI 10.1016/j.jocn.2018.04.027
   Wan JQ, 2011, J CLIN NEUROSCI, V18, P39, DOI 10.1016/j.jocn.2010.07.099
   Xie T, 2013, NEUROL MED-CHIR, V53, P735, DOI 10.2176/nmc.cr2011-0016
NR 28
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E733
EP E740
DI 10.1016/j.wneu.2019.06.001
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900092
PM 31285176
DA 2020-05-12
ER

PT J
AU Keiner, D
   Kuhn, JP
   Huber, A
   Oertel, J
AF Keiner, Doerthe
   Kuehn, Jan Philipp
   Huber, Alexandra
   Oertel, Joachim
TI Antiapoptotic Effect of Granulocyte-Colony Stimulating Factor After
   Peripheral Nerve Trauma
SO WORLD NEUROSURGERY
LA English
DT Article
DE G-CSF; Nerve regeneration; Peripheral nerve lesion; Traumatic nerve
   injury; Waterjet dissection
ID NEONATAL HYPOXIA-ISCHEMIA; FOCAL CEREBRAL-ISCHEMIA; PROGRAMMED
   CELL-DEATH; FACTOR G-CSF; WATERJET DISSECTION; FUNCTIONAL RECOVERY;
   MOTONEURON DEATH; IN-VIVO; BCL-2; REGENERATION
AB BACKGROUND: Granulocyte-colony stimulating factor (G-CSF) has been observed to have direct protective effects on neurons after stroke in experimental models and in humans. In the present study, the antiapoptotic effects of G-CSF on spinal alpha-motoneurons after inducement of peripheral sciatic nerve lesions were evaluated in a rat model.
   METHODS: Of 48 rats, 24 were treated with G-CSF and 24 were treated with glucose 5% solution (control group). The spinal cord of 6 rats in each group were removed at days 1, 4, 7, and 14. The alpha-motoneurons of spinal cord section L4-L6 were counted and investigated for the expression of choline acetyltransferase (ChAT), G-CSF receptor (G-CSFR), and Bcl-2 and Bax proteins. Additionally, alpha-motoneuron fluorescence double staining was performed for ChAT/Bcl-2, ChAT/Bax, and ChAT/G-CSFR.
   RESULTS: Without G-CSF treatment, the number of ChAT-positive alpha-motoneurons on the lesion side was significantly decreased (P < 0.001). The number of alpha-motoneurons with Bcl-2 and G-CSFR positivity on the lesion side was significantly decreased (P < 0.05). In contrast, the number of alpha-motoneurons with Bax positivity was significantly greater (P < 0.05). After G-CSF treatment, the differences in the number of alpha-motoneurons on the 2 sides were not statistically significant. Fluorescence double staining of alpha-motoneurons was positive for ChAT/Bcl-2, ChAT/Bax, and ChAT/G-CSFR.
   CONCLUSION: The results indicated that G-CSF has neuroprotective properties in spinal alpha-motoneurons and contributes to antiapoptotic effects after peripheral nerve lesions. The relevance of G-CSF, its precise mode of action, and the effect of these findings in clinical situations remains to be elucidated and require examination in further studies.
C1 [Keiner, Doerthe; Kuehn, Jan Philipp; Oertel, Joachim] Saarland Univ, Dept Neurosurg, Med Ctr, Homburg, Germany.
   [Huber, Alexandra] Univ Kaiserslautern, Dept Human Biol & Genet, Kaiserslautern, Germany.
RP Oertel, J (reprint author), Saarland Univ, Dept Neurosurg, Med Ctr, Homburg, Germany.
EM oertelj@freenet.de
RI Keiner, Doerthe/AAK-1195-2020
OI Keiner, Doerthe/0000-0003-2975-7704
FU executive committee of Saarland University [T603180005]; Erbe Company
FX The study was financially supported by the nonprofit research committee
   and the executive committee of Saarland University (grant T603180005).
   Joachim Oertel is a consultant to Karl Storz Company and has received
   grants from Erbe Company. The company was not involved in the
   experimental setup, work, or analysis of the present study, and the
   authors declare they have no personal or institutional financial
   interest in the drugs, materials, or devices described.
CR Alrashdan MS, 2011, ACTA NEUROCHIR, V153, P2021, DOI 10.1007/s00701-011-1054-x
   Belkas JS, 2005, BIOMATERIALS, V26, P1741, DOI 10.1016/j.biomaterials.2004.05.031
   Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027
   Chen WF, 2008, NEUROSCIENCE, V153, P31, DOI 10.1016/j.neuroscience.2008.01.062
   DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5
   DEMETRI GD, 1991, BLOOD, V78, P2791
   Devesa P, 2012, MUSCLE NERVE, V45, P385, DOI 10.1002/mus.22303
   Diederich K, 2012, STROKE, V43, P185, DOI 10.1161/STROKEAHA.111.622159
   Diederich K, 2009, J NEUROSCI, V29, P11572, DOI 10.1523/JNEUROSCI.0453-09.2009
   Galonek HL, 2006, NAT CELL BIOL, V8, P1317, DOI 10.1038/ncb1206-1317
   GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528
   Gibson CL, 2005, J CEREBR BLOOD F MET, V25, P431, DOI 10.1038/sj.jcbfm.9600033
   Haastert-Talini K, 2011, J NEUROTRAUM, V28, P661, DOI 10.1089/neu.2010.1637
   Henriques A, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-25
   Huang HY, 2007, NEUROBIOL AGING, V28, P1258, DOI 10.1016/j.neurobiolaging.2006.05.037
   Imaizumi K, 2004, J NEUROSCI, V24, P3721, DOI 10.1523/JNEUROSCI.5101-03.2004
   Keiner D, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f743bb
   Kemp SWP, 2011, EXP NEUROL, V229, P460, DOI 10.1016/j.expneurol.2011.03.017
   Lee ST, 2005, BRAIN RES, V1058, P120, DOI 10.1016/j.brainres.2005.07.076
   Li L, 2015, EXP NEUROL, V263, P141, DOI 10.1016/j.expneurol.2014.10.004
   Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2
   Liu GY, 2013, BIOMED REP, V1, P861, DOI 10.3892/br.2013.153
   LOWRIE MB, 1994, DEV NEUROSCI-BASEL, V16, P279, DOI 10.1159/000112120
   MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6
   McGrath AM, 2012, NEUROSCI LETT, V516, P171, DOI 10.1016/j.neulet.2012.03.041
   Meuer K, 2006, J NEUROCHEM, V97, P675, DOI 10.1111/j.1471-4159.2006.03727.x
   Mierzejewska-Krzyzowska B, 2014, ANAT HISTOL EMBRYOL, V43, P182, DOI 10.1111/ahe.12060
   Nishio Y, 2007, J NEUROPATH EXP NEUR, V66, P724, DOI 10.1097/nen.0b013e3181257176
   Oertel J, 2004, J NEUROSURG, V100, P498, DOI 10.3171/jns.2004.100.3.0498
   Oertel J, 2003, EUR J SURG ONCOL, V29, P407, DOI 10.1053/ejso.2002.1428
   Oertel J, 2003, NEUROSURGERY, V52, P153, DOI 10.1097/00006123-200301000-00020
   Oertel Joachim, 2005, Neurosurgery, V56, P142, DOI 10.1227/01.NEU.0000144316.87764.13
   Pan HC, 2009, BIOCHEM BIOPH RES CO, V382, P177, DOI 10.1016/j.bbrc.2009.03.003
   Paxinos G, 1986, RAT NERVOUS SYSTEM, V2
   Piek J, 2002, J NEUROSURG, V96, P690, DOI 10.3171/jns.2002.96.4.0690
   Pitzer C, 2010, J NEUROCHEM, V113, P930, DOI 10.1111/j.1471-4159.2010.06659.x
   Pitzer C, 2008, BRAIN, V131, P3335, DOI 10.1093/brain/awn243
   POLLIN MM, 1991, DEVELOPMENT, V112, P83
   Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17
   Schabitz WR, 2007, TRENDS PHARMACOL SCI, V28, P157, DOI 10.1016/j.tips.2007.02.007
   Schabitz WR, 2006, STROKE, V37, P1654, DOI 10.1161/01.STR.0000227299.62106.0e
   Schneider A, 2005, CELL CYCLE, V4, P1753, DOI 10.4161/cc.4.12.2213
   Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559
   SHERIDAN WP, 1989, LANCET, V2, P891
   Solaroglu I, 2006, NEUROSCIENCE, V143, P965, DOI 10.1016/j.neuroscience.2006.09.014
   Strecker JK, 2010, EXP NEUROL, V222, P108, DOI 10.1016/j.expneurol.2009.12.012
   Tanaka M, 2006, J NEUROPATH EXP NEUR, V65, P816, DOI 10.1097/01.jnen.0000232025.84238.e1
   Tiraihi T, 2003, INT J NEUROSCI, V113, P1163, DOI 10.1080/00207450390212311
   Tsai KJ, 2007, J EXP MED, V204, P1273, DOI 10.1084/jem.20062481
   Tschan C, 2009, J NEUROSURG, V110, P656, DOI 10.3171/2008.5.17561
   Tschan CA, 2010, NEUROSURGERY, V67, DOI 10.1227/NEU.0b013e3181f9b0c8
   VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x
   WU YG, 1995, NEUROSCI LETT, V194, P109, DOI 10.1016/0304-3940(95)11741-E
   Yata K, 2007, BRAIN RES, V1145, P227, DOI 10.1016/j.brainres.2007.01.144
   ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533
NR 55
TC 0
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E6
EP E15
DI 10.1016/j.wneu.2019.04.059
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900003
PM 30981793
DA 2020-05-12
ER

PT J
AU Khalid, SI
   Adogwa, O
   Ni, A
   Cheng, J
   Bagley, C
AF Khalid, Syed, I
   Adogwa, Owoicho
   Ni, Amelia
   Cheng, Joseph
   Bagley, Carlos
TI A Comparison of 30-Day Hospital Readmission and Complication Rates After
   Outpatient Versus Inpatient 1 and 2 Level Anterior Cervical Discectomy
   and Fusion Surgery: An Analysis of a Medicare Patient Sample
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACDF; Geriatric; Inpatient; Medicare; Outcomes; Outpatient; Readmission
ID SHORT-TERM COMPLICATIONS; SPINE SURGERY; ELDERLY-PATIENTS; SAFETY
AB BACKGROUND: Same-day surgery has been demonstrated to be a safe and cost-effective alternative to traditional inpatient surgery. Several studies have demonstrated no differences in the postoperative complication profile or 30-day hospital readmission rates with outpatient versus inpatient anterior cervical discectomy and fusion (ACDF). However, none of these studies compared the outcomes in elderly patients (aged >65 years) undergoing ACDF. Whether the results from previous studies can be applied to this subgroup pf patients remains unknown. The aim of the present study was to compare the 30-day hospital readmission rates for Medicare patients (aged >65 years) undergoing outpatient versus inpatient ACDF.
   METHODS: We performed a retrospective analysis of a Medicare database, including data from 17,421 patients. Of the 17,421 patients, 16,386 had undergone inpatient ACDF and 1035, outpatient ACDF. Age, sex, comorbidities, postoperative complications, readmission rates, and overall financial costs were compared between the 2 cohorts.
   RESULTS: In a Medicare sample (aged >65 years), inpatient ACDF was associated with a greater incidence of postoperative complications compared with outpatient ACDF. Outpatient surgery was associated with significantly lower rates of postoperative complications (urinary tract infection, surgical site infection, deep vein thrombosis, pulmonary embolism, and myocardial infarction) and significantly lower treatment costs (P <= 0.001). All-cause 30-day hospital readmission rates were also greater for inpatients (10.1% vs. 4%; P = 0.17).
   CONCLUSION: The results from the present study suggest that outpatient ACDF appears to be safe and effective with low complication and readmission rates in a Medicare patient sample.
C1 [Khalid, Syed, I; Adogwa, Owoicho; Ni, Amelia] Rush Univ, Dept Neurosurg, Med Ctr, Chicago, IL 60612 USA.
   [Khalid, Syed, I] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, N Chicago, IL USA.
   [Cheng, Joseph] Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45267 USA.
   [Bagley, Carlos] Univ Texas Southwestern Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75390 USA.
RP Adogwa, O (reprint author), Rush Univ, Dept Neurosurg, Med Ctr, Chicago, IL 60612 USA.
EM owoicho.adogwa@gmail.com
OI Khalid, Syed/0000-0003-4710-1688
CR Adamson T, 2016, J NEUROSURG-SPINE, V24, P878, DOI 10.3171/2015.8.SPINE14284
   Arshi A, 2018, SPINE J, V18, P1180, DOI 10.1016/j.spinee.2017.11.012
   Awan AS, 2019, J UROL SURG, V6, P1, DOI 10.4274/jus.galenos.2018.2032
   Baird EO, 2014, GLOB SPINE J, V4, P143, DOI 10.1055/s-0034-1376917
   Ban DX, 2016, EUR J MED RES, V21, DOI 10.1186/s40001-016-0229-6
   Bernstein DN, 2017, WORLD NEUROSURG, V103, P859, DOI 10.1016/j.wneu.2017.04.109
   Erickson Mark, 2007, Am J Orthop (Belle Mead NJ), V36, P429
   Fu MC, 2017, SPINE, V42, P1044, DOI 10.1097/BRS.0000000000001988
   Garringer SM, 2010, J SPINAL DISORD TECH, V23, P439, DOI 10.1097/BSD.0b013e3181bd0419
   Khalid SI, 2019, WORLD NEUROSURG, V126, pE1475, DOI 10.1016/j.wneu.2019.03.124
   Khanna R, 2018, CLIN SPINE SURG, V31, P43, DOI 10.1097/BSD.0000000000000499
   Lied B, 2013, ACTA NEUROL SCAND, V127, P31, DOI 10.1111/j.1600-0404.2012.01674.x
   Liu JT, 2009, BMC SURG, V9, DOI 10.1186/1471-2482-9-3
   Marawar S, 2010, SPINE, V35, P1454, DOI 10.1097/BRS.0b013e3181bef3cb
   Martin CT, 2014, J BONE JOINT SURG AM, V96A, P1288, DOI 10.2106/JBJS.M.00767
   McClelland S, 2017, INT J SPINE SURG, V11, DOI 10.14444/4011
   McClelland S, 2016, J CLIN NEUROSCI, V34, P166, DOI 10.1016/j.jocn.2016.06.012
   McGirt MJ, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.9.FOCUS15335
   Mullins J, 2018, J NEUROSURG-SPINE, V28, P630, DOI [10.3171/2017.10.SPINE17938, 10.1080/08952841.2018.1529474]
   Purger DA, 2018, NEUROSURGERY, V82, P454, DOI 10.1093/neuros/nyx215
   Saleh A, 2017, SPINE J, V17, P1106, DOI 10.1016/j.spinee.2017.03.019
   Sheperd CS, 2012, INT SURG, V97, P86, DOI 10.9738/CC35.1
   Silvers HR, 1996, J SPINAL DISORD, V9, P287
   Stieber Jonathan R, 2005, Spine J, V5, P503
   Tally WC, 2013, INT J SPINE SURG, V7, DOI 10.1016/j.ijsp.2013.06.001
   Trahan J, 2011, WORLD NEUROSURG, V75, P145, DOI 10.1016/j.wneu.2010.09.015
   Villavicencio AT, 2007, SPINE J, V7, P148, DOI 10.1016/j.spinee.2006.04.009
   Walid MS, 2010, J CLIN NEUROSCI, V17, P1497, DOI 10.1016/j.jocn.2010.03.037
   Wohns Richard, 2010, Surg Neurol Int, V1, P77, DOI 10.4103/2152-7806.73803
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E233
EP E239
DI 10.1016/j.wneu.2019.05.120
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900029
PM 31128307
DA 2020-05-12
ER

PT J
AU Khatibi, K
   Nour, M
   Tateshima, S
   Jahan, R
   Duckwiler, G
   Saver, J
   Szeder, V
AF Khatibi, Kasra
   Nour, May
   Tateshima, Satoshi
   Jahan, Reza
   Duckwiler, Gary
   Saver, Jefferey
   Szeder, Viktor
TI Posterior Circulation Thrombectomy-pc-ASPECT Score Applied to
   Preintervention Magnetic Resonance Imaging Can Accurately Predict
   Functional Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute stroke therapy; Intervention; Ischemic stroke; MRI; Posterior
   circulation; Prognosis
ID BASILAR ARTERY-OCCLUSION; STROKE; ONSET; MRI
AB BACKGROUND: There are currently no imaging criteria to identify patients who would benefit from endovascular recanalization of posterior circulation strokes. Applying the Posterior Circulation Alberta Stroke Program Early Computed Tomography Score (pc-ASPECTS) to magnetic resonance imaging (MRI) has been demonstrated to be an accurate predictor of functional outcome. Here, we aimed to evaluate the accuracy of the pc-ASPECTS with preintervention MRI as a predictor of functional outcome in a cohort undergoing endovascular recanalization.
   METHODS: This is a 15-year retrospective study of patients undergoing endovascular recanalization of posterior circulation with baseline MRI or computed tomography. We analyzed baseline imaging, clinical data, and type and timing of intervention to the functional outcome at 90 days. Using MRI pc-ASPECTS, we evaluated interrater reliability and accuracy in predicting functional outcome and compared them to the use of single-anatomic location for this function.
   RESULTS: Door-to-recanalization time in the MRI cohort was significantly longer (median: 8.7 vs. 2.7 hours, P = 0.03); however, functional outcome was not different. Within the MRI cohort, pc-ASPECTS and National Institutes of Health Stroke Scale were the only factors that were significantly different between the groups with good and bad functional outcome (P < 0.001). The area under the receiver operating characteristic curve for the pc-ASPECTS and good functional outcome was 0.96, with the optimal threshold of >= 8 resulting in positive predictive value of 90% and negative predictive value of 100%.
   CONCLUSIONS: Despite longer time to intervention with MRI as the initial imaging modality in posterior circulation strokes, it does not negatively affect the functional outcome. Pc-ASPECTS is an easy to use and accurate prognostic tool for the real-time evaluation of preintervention MRI in this population.
C1 [Khatibi, Kasra] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA.
   [Nour, May; Tateshima, Satoshi; Jahan, Reza; Duckwiler, Gary; Szeder, Viktor] Univ Calif Los Angeles, Dept Radiol, Los Angeles, CA USA.
   [Saver, Jefferey] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
RP Khatibi, K (reprint author), Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA.
EM kasra.khatibi@gmail.com
OI Saver, Jeffrey/0000-0001-9141-2251
CR Cho TH, 2009, AM J NEURORADIOL, V30, P194, DOI 10.3174/ajnr.A1278
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Linfante I, 2001, ARCH NEUROL-CHICAGO, V58, P621, DOI 10.1001/archneur.58.4.621
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Mordasini P, 2013, AM J NEURORADIOL, V34, P159, DOI 10.3174/ajnr.A3168
   Mourand I, 2016, AM J NEURORADIOL, V37, P88, DOI 10.3174/ajnr.A4574
   Nagel S, 2012, INT J STROKE, V7, P282, DOI 10.1111/j.1747-4949.2011.00705.x
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Puetz V, 2009, AM J NEURORADIOL, V30, P1877, DOI 10.3174/ajnr.A1723
   Puetz V, 2008, STROKE, V39, P2485, DOI 10.1161/STROKEAHA.107.511162
   Puetz V, 2011, STROKE, V42, P3454, DOI 10.1161/STROKEAHA.111.622175
   Renard D, 2008, CEREBROVASC DIS, V25, P511, DOI 10.1159/000131668
   Schonewille WJ, 2009, LANCET NEUROL, V8, P724, DOI 10.1016/S1474-4422(09)70173-5
   Singer OC, 2015, ANN NEUROL, V77, P415, DOI 10.1002/ana.24336
   Tei H, 2010, J NEUROL, V257, P767, DOI 10.1007/s00415-009-5406-x
   Thomalla G, 2011, LANCET NEUROL, V10, P978, DOI 10.1016/S1474-4422(11)70192-2
   Wouters A, 2016, STROKE, V47, P1018, DOI 10.1161/STROKEAHA.115.012010
NR 17
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E566
EP E571
DI 10.1016/j.wneu.2019.05.217
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900072
PM 31158539
DA 2020-05-12
ER

PT J
AU Khattar, NK
   Fortuny, EM
   Wessell, AP
   John, KD
   Bak, E
   Adams, SW
   Meyer, KS
   Schirmer, CM
   Simard, JM
   Neimat, JS
   Ding, D
   James, RF
AF Khattar, Nicolas K.
   Fortuny, Enzo M.
   Wessell, Aaron P.
   John, Kevin D.
   Bak, Esther
   Adams, Shawn W.
   Meyer, Kimberly S.
   Schirmer, Clemens M.
   Simard, J. Marc
   Neimat, Joseph S.
   Ding, Dale
   James, Robert F.
TI Minimally Invasive Surgery for Spontaneous Cerebellar Hemorrhage: A
   Multicenter Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apollo; Artemis; Cerebellum; Endoscopy; Intracranial hemorrhages;
   Minimally invasive; Stroke
ID INTRACEREBRAL HEMORRHAGE; APOLLO SYSTEM; EVACUATION; MANAGEMENT; SAFETY
AB BACKGROUND: Spontaneous intracranial hemorrhage (ICH) of the cerebellum can be life threatening because of mass effect on the brainstem and fourth ventricle. Suboccipital craniectomy is currently the treatment of choice for cerebellar ICH evacuation. Minimally invasive surgery (MIS) is currently being investigated for the treatment of supratentorial ICH. However, its utility for cerebellar ICH is unknown. The aim of this multicenter, retrospective cohort study is to evaluate the outcomes of MIS for cerebellar ICH.
   METHODS: We retrospectively reviewed the records of all patients with cerebellar ICH who underwent MIS using either the Apollo or Artemis Neuro Evacuation Device (Penumbra Inc., Alameda, California, USA) at 3 institutions from May 2015 to July 2018. Data from each contributing center were deidentified and pooled for analysis.
   RESULTS: The study cohort comprised 6 patients with a median age of 62.5 years. The median pre- and postoperative Glasgow Coma Scale scores were 10.5 and 15, respectively. The median degree of hematoma evacuation was 97.5% (range, 79%-100%). There were no procedural complications, but 1 patient required subsequent craniectomy (retreatment rate 17%). The median discharge modified Rankin scale score was 4, including 3 patients who improved to functional independence at follow-up durations of 3 months. Two patients died from medical complications (mortality rate 33%).
   CONCLUSIONS: MIS could represent a reasonable alternative to conventional surgery for the treatment of appropriately selected patients with cerebellar ICH. However, further studies are needed to clarify the perioperative and long-term risk to benefit profiles of this technique.
C1 [Khattar, Nicolas K.; Fortuny, Enzo M.; John, Kevin D.; Bak, Esther; Adams, Shawn W.; Meyer, Kimberly S.; Neimat, Joseph S.; Ding, Dale; James, Robert F.] Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA.
   [Wessell, Aaron P.; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA.
   [Schirmer, Clemens M.] Geisinger Hlth, Dept Neurosurg & Neurosci Inst, Wilkes Barre, PA USA.
RP James, RF (reprint author), Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA.
EM robert.james@louisville.edu
RI Adams, Shawn/AAK-3854-2020; Ding, Dale/AAN-3583-2020; Khattar,
   Nicolas/H-5058-2016
OI Khattar, Nicolas/0000-0002-5077-9804; Schirmer,
   Clemens/0000-0003-1743-8781
CR An SJ, 2017, J STROKE, V19, P3, DOI 10.5853/jos.2016.00864
   Cai Q, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008435
   Deininger MH, 2008, MINIM INVAS NEUROSUR, V51, P57, DOI 10.1055/s-2007-1004561
   Eroglu U, 2018, WORLD NEUROSURG, V114, pE60, DOI 10.1016/j.wneu.2018.02.056
   Fiorella D, 2016, STROKE, V47, P1399, DOI 10.1161/STROKEAHA.115.011415
   Fiorella D, 2015, J NEUROINTERV SURG, V7, P752, DOI 10.1136/neurintsurg-2014-011358
   Fiorella D, 2015, J NEUROINTERV SURG, V7, P569, DOI 10.1136/neurintsurg-2014-011293
   Hanley DF, 2016, LANCET NEUROL, V15, P1226, DOI 10.1016/S1474-4422(16)30234-4
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Kellner CP, 2019, WORLD NEUROSURG, V122, pE1, DOI 10.1016/j.wneu.2018.07.145
   Kellner CP, 2018, J NEUROINTERV SURG, V10, P771, DOI 10.1136/neurintsurg-2017-013719
   KOBAYASHI S, 1994, NEUROSURGERY, V34, P246, DOI 10.1227/00006123-199402000-00006
   Labib MA, 2017, NEUROSURGERY, V80, P515, DOI 10.1227/NEU.0000000000001316
   Manoel ALD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1432-0
   Pong V, 2012, CEREBELLUM, V11, P939, DOI 10.1007/s12311-012-0371-9
   Przybylowski CJ, 2015, J CLIN NEUROSCI, V22, P1727, DOI 10.1016/j.jocn.2015.05.015
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907
   Rennert RC, 2016, NEURAL REGEN RES, V11, P228, DOI 10.4103/1673-5374.177747
   Spiotta AM, 2015, OPER NEUROSURG, V11, P243, DOI 10.1227/NEU.0000000000000698
   Xia ZW, 2018, WORLD NEUROSURG, V115, P266, DOI 10.1016/j.wneu.2018.04.181
NR 21
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E35
EP E39
DI 10.1016/j.wneu.2019.04.164
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900006
PM 31042595
DA 2020-05-12
ER

PT J
AU Kim, GU
   Yang, JH
   Chang, DG
   Suk, SI
   Suh, SW
   Song, KS
   Nam, KY
   Oh, IS
   Park, HY
   Kim, SI
   Kim, YH
   Ha, KY
AF Kim, Gang-Un
   Yang, Jae Hyuk
   Chang, Dong-Gune
   Suk, Se-Il
   Suh, Seung-Woo
   Song, Kwang-Sup
   Nam, Ki-You
   Oh, In-Soo
   Park, Hyung-You
   Kim, Sang-Il
   Kim, Young-Hoon
   Ha, Kee-Yong
TI Effect of Direct Vertebral Rotation in Single Thoracic Adolescent
   Idiopathic Scoliosis: Better 3-Dimensional Deformity Correction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adding-on; Adolescent idiopathic scoliosis; Fusion level; Pedicle screw
   instrumentation; Selective thoracic fusion; Thoracic scoliosis
ID PEDICLE SCREW FIXATION; DISTAL FUSION LEVEL; LENKE 1A CURVES; ADDING-ON
   PHENOMENON; LUMBAR CURVE; SURGICAL-CORRECTION; SELECTION;
   INSTRUMENTATION; DEROTATION; DECOMPENSATION
AB OBJECTIVE: To analyze the effects of direct vertebral rotation (DVR) on radiologic outcomes in the treatment of thoracic adolescent idiopathic scoliosis after selective thoracic fusion with pedicle screw instrumentation.
   METHODS: Adolescent idiopathic scoliosis patients with single thoracic curves (n = 110) treated by selective thoracic fusion with a minimum of 2 years of follow-up were retrospectively analyzed. The patients were separated into 2 groups: non-DVR (n = 63) and DVR (n = 47).
   RESULTS: There was a significant difference in fused segments between the non-DVR and DVR groups (P < 0.001). There was also a significant difference in main thoracic curve postoperatively (P = 0.001) and at the last follow-up (P = 0.006) between the non-DVR and DVR groups. However, there was no significant difference in proximal thoracic and lumbar curves postoperatively (proximal thoracic curve: P = 0.186; lumbar curve: P = 0.155) and at the last follow-up (proximal thoracic curve: P = 0.250; lumbar curve: P = 0.060) between the 2 groups. Significant improvements in the lowest instrumented vertebra tilt and disc angle were noted but then slight deteriorations in such were observed during the follow-up period in the non-DVR group. The prevalence of unsatisfactory results was 20.6% (13 of 63) in the non-DVR group and 19.1% (9 of 47) in the DVR group, with no significant difference (P = 0.522).
   CONCLUSIONS: For correcting single thoracic adolescent idiopathic scoliosis by selective thoracic fusion with pedicle screw instrumentation, the addition of DVR to the surgical procedure showed comparable radiologic outcomes compared with non-DVR procedures.
C1 [Kim, Gang-Un; Chang, Dong-Gune; Suk, Se-Il; Nam, Ki-You] Inje Univ, Coll Med, Sanggye Paik Hosp, Dept Orthoped Surg, Seoul, South Korea.
   [Yang, Jae Hyuk; Suh, Seung-Woo] Korea Univ, Coll Med, Guro Hosp, Dept Orthoped Surg, Seoul, South Korea.
   [Song, Kwang-Sup] Chung Ang Univ, Coll Med, Chung Ang Univ Hosp, Dept Orthoped Surg, Seoul, South Korea.
   [Oh, In-Soo] Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Orthoped Surg, Incheon, South Korea.
   [Park, Hyung-You; Kim, Sang-Il; Kim, Young-Hoon; Ha, Kee-Yong] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Orthoped Surg, Seoul, South Korea.
RP Chang, DG (reprint author), Inje Univ, Coll Med, Sanggye Paik Hosp, Dept Orthoped Surg, Seoul, South Korea.
EM spine@paik.ac.kr
RI Song, Kwang-Sup/AAC-3891-2020
OI Chang, Dong-Gune/0000-0001-6731-1063; Park,
   Hyung-Youl/0000-0002-0084-8867
FU Inje University
FX The authors declare that the article content was composed in the absence
   of any commercial or financial relationships that could be construed as
   a potential conflict of interest. This research was supported by the
   2018 Inje University Research Grant.
CR BRIDWELL KH, 1991, SPINE, V16, P769, DOI 10.1097/00007632-199107000-00015
   Cao K, 2014, SPINE, V39, pE253, DOI 10.1097/BRS.0000000000000126
   Chang DG, 2017, SPINE, V42, pE890, DOI 10.1097/BRS.0000000000001998
   Chang DG, 2014, SPINE, V39, pE1359, DOI 10.1097/BRS.0000000000000578
   Cho RH, 2012, SPINE, V37, P1384, DOI 10.1097/BRS.0b013e31824bac7a
   Crawford CH, 2013, SPINE, V38, P1380, DOI 10.1097/BRS.0b013e3182987360
   Dobbs MB, 2004, SPINE, V29, P277, DOI 10.1097/01.BRS.0000106488.51299.75
   Edwards CC, 2004, SPINE, V29, P536, DOI 10.1097/01.BRS.0000109992.22248.77
   Erdemir C, 2015, SPINE J, V15, P2378, DOI 10.1016/j.spinee.2015.07.004
   Huang ZF, 2016, CLIN SPINE SURG, V29, pE157, DOI 10.1097/BSD.0000000000000123
   Jansen RC, 2007, EUR SPINE J, V16, P1335, DOI 10.1007/s00586-007-0320-3
   Kato S, 2017, J PEDIATR ORTHOPED, V37, pE543, DOI 10.1097/BPO.0000000000000776
   Kim SS, 2014, ASIAN SPINE J, V8, P804, DOI 10.4184/asj.2014.8.6.804
   KING HA, 1983, J BONE JOINT SURG AM, V65, P1302, DOI 10.2106/00004623-198365090-00012
   Kuklo TR, 2005, SPINE, V30, P444, DOI 10.1097/01.brs.0000153702.99342.9c
   Lee CS, 2016, EUR SPINE J, V25, P3256, DOI 10.1007/s00586-015-4373-4
   Lee SM, 2004, SPINE, V29, P343, DOI 10.1097/01.BRS.0000109991.88149.19
   LENKE LG, 1992, SPINE, V17, pS274
   Lenke LG, 2001, J BONE JOINT SURG AM, V83A, P1169, DOI 10.2106/00004623-200108000-00006
   Marawar SV, 2019, SPINE DEFORM, V7, P11
   Margulies J Y, 1998, Eur Spine J, V7, P88, DOI 10.1007/s005860050036
   Mladenov KV, 2011, EUR SPINE J, V20, P1114, DOI 10.1007/s00586-011-1740-7
   NASH CL, 1969, J BONE JOINT SURG AM, VA 51, P223, DOI 10.2106/00004623-196951020-00002
   Okada E, 2015, SPINE, V40, P25, DOI 10.1097/BRS.0000000000000652
   Parisini P, 2009, EUR SPINE J, V18, pS82, DOI 10.1007/s00586-009-0990-0
   RICHARDS BS, 1992, SPINE, V17, pS282
   Ries Z, 2015, SPINE, V40, P926, DOI 10.1097/BRS.0000000000000861
   Sarlak AY, 2011, SPINE, V36, P1592, DOI 10.1097/BRS.0b013e3181f54f7f
   Schulz J, 2014, SPINE, V39, pE1368, DOI 10.1097/BRS.0000000000000580
   Suk SI, 2012, EUR SPINE J, V21, P13, DOI 10.1007/s00586-011-1986-0
   Suk SI, 2011, CLIN ORTHOP SURG, V3, P89, DOI 10.4055/cios.2011.3.2.89
   SUK SI, 1995, SPINE, V20, P1399, DOI 10.1097/00007632-199506000-00012
   Suk SI, 2005, SPINE, V30, P1602, DOI 10.1097/01.brs.0000169452.50705.61
   Suk SI, 2003, SPINE, V28, P484, DOI 10.1097/00007632-200303010-00014
   Suk SI, 2000, SPINE, V25, P2342, DOI 10.1097/00007632-200009150-00012
   Takahashi J, 2011, SPINE, V36, P1131, DOI 10.1097/BRS.0b013e3182053d19
   Urbanski W, 2017, ARCH ORTHOP TRAUM SU, V137, P879, DOI 10.1007/s00402-017-2700-4
   Wang Y, 2011, SPINE, V36, P1113, DOI 10.1097/BRS.0b013e3181f51e95
   Watanabe K, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-99
   Yang CW, 2016, SPINE, V41, P698, DOI 10.1097/BRS.0000000000001303
NR 40
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E401
EP E408
DI 10.1016/j.wneu.2019.05.164
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900051
PM 31150860
DA 2020-05-12
ER

PT J
AU Kim, JE
   Choi, DJ
   Kim, MC
   Park, EJ
AF Kim, Ju-Eun
   Choi, Dae-Jung
   Kim, Moon-Chan
   Park, Eugene J.
TI Risk Factors of Postoperative Spinal Epidural Hematoma After Biportal
   Endoscopic Spinal Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biportal endoscopic spinal surgery; Lumbar spinal stenosis;
   Postoperative spinal hematoma
ID TECHNICAL NOTE; DECOMPRESSION; STENOSIS; DRAINAGE; MRI
AB BACKGROUND: Although postoperative spinal epidural hematoma is a rare complication, it can cause severe neurologic complications. Studies regarding biportal endoscopic spinal surgery, a type of minimally invasive spinal surgery technique, have been recently reported. The purpose of our study is to report the incidence and risk factors of postoperative hematoma after biportal endoscopic spinal surgery.
   METHODS: The subjects included 310 patients that underwent biportal endoscopic spinal surgery from 2015 to 2017. Magnetic resonance imaging (MRI) was performed in all patients before surgery, and also after surgery to identify epidural hematoma. Using electronic medical records, perioperative factors such as age, sex, operation name, operation level, water infusion pump usage, thrombin-containing hemostatic agent, and anticoagulant medication were statistically analyzed in the aspect of postoperative hematoma.
   RESULTS: The overall occurrence rate of postoperative hematoma was 23.6% (n = 94). A total of 304 levels (76.4%) were without hematoma according to the postoperative MRI among the total 398 levels. Six patients underwent revision surgery of hematoma evacuation. Female sex, old age (>70 years), preoperative anticoagulation medication, and usage of intraoperative water infusion pump were significantly correlated to the occurrence of postoperative hematoma.
   CONCLUSIONS: Although symptomatic postoperative hematoma was extremely rare at 1.9%, radiologic hematoma confirmed by postoperative MRI was higher at 23.6%. The perioperative risk factors of postoperative hematoma after biportal endoscopic spinal surgery include female sex, older age (>70 years), preoperative anticoagulation medication, usage of intraoperative water infusion pump, and surgery requiring more bone work (laminectomy or interbody fusion).
C1 [Kim, Ju-Eun; Choi, Dae-Jung; Kim, Moon-Chan] Himnaera Hosp, Dept Orthoped Surg, Busan, South Korea.
   [Park, Eugene J.] Chungnam Natl Univ Hosp, Sch Med, Dept Orthoped Surg, Daejeon, South Korea.
RP Park, EJ (reprint author), Chungnam Natl Univ Hosp, Sch Med, Dept Orthoped Surg, Daejeon, South Korea.
EM cnuhos55@hotmail.com
CR Ahn JS, 2018, J NEUROSURG-SPINE, V28, P492, DOI 10.3171/2017.8.SPINE17771
   Amiri AR, 2013, SPINE J, V13, P134, DOI 10.1016/j.spinee.2012.10.028
   Anno M, 2019, SPINE, V44, P420, DOI 10.1097/BRS.0000000000002838
   Aono H, 2011, J NEUROSURG-SPINE, V15, P202, DOI 10.3171/2011.3.SPINE10716
   Awad JN, 2005, J BONE JOINT SURG BR, V87B, P1248, DOI 10.1302/0301-620X.87B9.16518
   Babar S, 2002, CLIN RADIOL, V57, P969, DOI 10.1053/crad.2002.1071
   Choi CM, 2016, ACTA NEUROCHIR, V158, P459, DOI 10.1007/s00701-015-2670-7
   Eum JH, 2016, J NEUROSURG-SPINE, V24, P602, DOI 10.3171/2015.7.SPINE15304
   FOO D, 1981, SURG NEUROL, V15, P389, DOI 10.1016/0090-3019(81)90178-6
   Ikuta K, 2006, J NEUROSURG-SPINE, V5, P404, DOI 10.3171/spi.2006.5.5.404
   Jackson R, 1869, LANCET, V2, P5
   Kanayama M, 2010, CLIN ORTHOP RELAT R, V468, P2690, DOI 10.1007/s11999-010-1235-6
   Kebaish Khaled M, 2004, Neurosurg Focus, V16, pe1
   Kim JE, 2018, CLIN ORTHOP SURG, V10, P328, DOI 10.4055/cios.2018.10.3.328
   Kim JE, 2018, J ORTHOP, V15, P366, DOI 10.1016/j.jor.2018.01.039
   Kotil K, 2016, ASIAN SPINE J, V10, P1072, DOI 10.4184/asj.2016.10.6.1072
   Kou J, 2002, SPINE, V27, P1670, DOI 10.1097/00007632-200208010-00016
   LAWTON MT, 1995, J NEUROSURG, V83, P1, DOI 10.3171/jns.1995.83.1.0001
   Shin HK, 2017, CLIN ORTHOP SURG, V9, P184, DOI 10.4055/cios.2017.9.2.184
   Sokolowski MJ, 2008, SPINE, V33, P108, DOI 10.1097/BRS.0b013e31815e39af
   Yi S, 2006, YONSEI MED J, V47, P326, DOI 10.3349/ymj.2006.47.3.326
NR 21
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E324
EP E329
DI 10.1016/j.wneu.2019.05.141
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900040
PM 31158548
DA 2020-05-12
ER

PT J
AU Ko, CC
   Tu, TH
   Chen, YT
   Wu, JC
   Huang, WC
   Cheng, H
AF Ko, Chin-Chu
   Tu, Tsung-Hsi
   Chen, Ya-Tzu
   Wu, Jau-Ching
   Huang, Wen-Cheng
   Cheng, Henrich
TI Monkey Recovery from Spinal Cord Hemisection: Nerve Repair Strategies
   for Rhesus Macaques
SO WORLD NEUROSURGERY
LA English
DT Article
DE Macaque; Monkey; Nerve repair; Nonhuman primate; Spinal cord injury
ID FIBROBLAST-GROWTH-FACTOR; MOTOR EVOKED-POTENTIALS; FUNCTIONAL RECOVERY;
   PARAPLEGIC RATS; INJURY; ROOT; TRANSECTION; GRAFTS; REGENERATION
AB OBJECTIVE: Repair of spinal cord injury (SCI) using peripheral nerve graft (PNG) and acidic fibroblast growth factor (aFGF) has shown promising results in rats and a few human patients, but not in nonhuman primates. The aim of this study was to verify the effective use of PNG and aFGF for repairing incomplete SCI in nonhuman primates.
   METHODS: Six adult rhesus macaques received spinal cord hemisection at T8 level and were grouped into repair and control groups (n = 3 in each). Animals in the repair group underwent nerve repair with autologous PNG plus aFGF immediately after lesioning. The control group received exactly the same operation for lesioning but no treatment. Postoperative behavioral evaluations, electrophysiologic tests (including motor and somatosensory evoked potentials), and magnetic resonance imaging were performed and compared between the 2 groups as well as histologic examination of the spinal cord cephalic to, at, and caudal to the lesion site after sacrifice.
   RESULTS: Animals in the repair group had better motor function in the lower limbs at every observed time point and demonstrated more improvement on electrophysiologic examinations than the control group. The repair group had smaller areas of myelomalacia on magnetic resonance imaging around the lesion compared with the control group, suggesting diminished inflammatory responses with the repair strategy.
   CONCLUSIONS: PNG plus aFGF for SCI in nonhuman primates yielded improvements in clinical behavior, electrophysiologic tests, and magnetic resonance imaging. This study suggests that the repair strategy is feasible and effective for nonhuman primate SCI. Further investigations are warranted to corroborate its effectiveness for clinical application.
C1 [Ko, Chin-Chu] Jhong Jheng Spine & Orthoped Hosp, Kaohsiung, Taiwan.
   [Ko, Chin-Chu; Chen, Ya-Tzu; Wu, Jau-Ching; Cheng, Henrich] Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan.
   [Ko, Chin-Chu; Tu, Tsung-Hsi; Chen, Ya-Tzu; Wu, Jau-Ching; Huang, Wen-Cheng; Cheng, Henrich] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Ko, Chin-Chu; Tu, Tsung-Hsi; Chen, Ya-Tzu; Wu, Jau-Ching; Huang, Wen-Cheng; Cheng, Henrich] Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei, Taiwan.
   [Tu, Tsung-Hsi] Natl Yang Ming Univ, Taiwan Int Grad Program Mol Med, Taipei, Taiwan.
   [Tu, Tsung-Hsi] Acad Sinica, Taipei, Taiwan.
RP Wu, JC (reprint author), Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan.; Wu, JC (reprint author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.; Wu, JC (reprint author), Taipei Vet Gen Hosp, Neurol Inst, Dept Neurosurg, Taipei, Taiwan.
EM jauching@gmail.com
FU National Science CouncilNational Science Council of Taiwan
   [NSC96-3111-B-010-002, NSC99-2628-B-010-009-MY3]
FX This work was supported by the National Science Council (Grant No.
   NSC96-3111-B-010-002 and Grant No. NSC99-2628-B-010-009-MY3).
CR AGUAYO AJ, 1981, J EXP BIOL, V95, P231
   Bou-Haidar P, 2009, J MED IMAG RADIAT ON, V53, P152, DOI 10.1111/j.1754-9485.2009.02067.x
   BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0
   Cheng H, 2004, SPINE, V29, pE284, DOI 10.1097/01.BRS.0000131217.61390.2C
   Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510
   Cloud BA, 2012, J NEUROSCI METH, V211, P179, DOI 10.1016/j.jneumeth.2012.08.024
   Dhall SS, 2018, NEUROSURGERY, V82, P870, DOI 10.1093/neuros/nyx320
   FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5
   Fehlings MG, 2008, J NEUROSURG-SPINE, V8, P205, DOI 10.3171/SPI/2008/8/3/205
   Fehlings MG, 2017, GLOB SPINE J, V7, p231S, DOI 10.1177/2192568217701910
   Fehlings MG, 2011, J NEUROSURG-SPINE, V15, P213, DOI 10.3171/2011.3.SPINE11129
   GLASSMAN SD, 1993, SPINE, V18, P1083, DOI 10.1097/00007632-199306150-00020
   Guest JD, 1997, EXP NEUROL, V148, P502, DOI 10.1006/exnr.1997.6693
   Huang MC, 2003, EXP NEUROL, V180, P101, DOI 10.1016/S0014-4886(02)00026-2
   Kaas JH, 2008, EXP NEUROL, V209, P407, DOI 10.1016/j.expneurol.2007.06.014
   Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3
   KULKARNI MV, 1987, RADIOLOGY, V164, P837, DOI 10.1148/radiology.164.3.3615885
   Lee YS, 2004, J NEUROPATH EXP NEUR, V63, P233, DOI 10.1093/jnen/63.3.223-a
   Lee YS, 2002, J NEUROTRAUM, V19, P1203, DOI 10.1089/08977150260338001
   Lin YL, 2014, LIFE SCI, V109, P44, DOI 10.1016/j.lfs.2014.06.001
   Lin YL, 2011, RESTOR NEUROL NEUROS, V29, P265, DOI 10.3233/RNN-2011-0597
   Ma ZW, 2016, EXP NEUROL, V279, P261, DOI 10.1016/j.expneurol.2016.02.008
   McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986
   Nashmi R, 1997, J NEUROTRAUM, V14, P151, DOI 10.1089/neu.1997.14.151
   Nielsen JB, 2007, EUR J NEUROSCI, V25, P805, DOI 10.1111/j.1460-9568.2007.05326.x
   Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106
   Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8
   Redondo-Castro E, 2016, J NEUROTRAUM, V33, P907, DOI 10.1089/neu.2015.4140
   Tsai MC, 2008, MOL CELL PROTEOMICS, V7, P1668, DOI 10.1074/mcp.M800076-MCP200
   Wu JC, 2008, J NEUROSURG-SPINE, V8, P208, DOI 10.3171/SPI/2008/8/3/208
   Wu JC, 2011, J NEUROSURG-SPINE, V15, P216, DOI 10.3171/2011.4.SPINE10404
   Wu JC, 2009, J NEUROSURG, V110, P775, DOI 10.3171/2008.8.JNS08328
   Wu W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178803
   Ye JC, 2016, SCI REP-UK, V6, DOI 10.1038/srep33243
NR 34
TC 0
Z9 0
U1 3
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E343
EP E351
DI 10.1016/j.wneu.2019.05.145
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900043
PM 31132502
DA 2020-05-12
ER

PT J
AU Koze, Y
   Aydin, N
   Aydin, MD
   Koza, EA
   Bayram, E
   Atalay, C
   Altas, E
   Kursad, H
   Kabalar, ME
AF Koze, Yavuzer
   Aydin, Nazan
   Aydin, Mehmet Dumlu
   Koza, Enise Armagan
   Bayram, Ednan
   Atalay, Canan
   Altas, Ender
   Kursad, Husnu
   Kabalar, Mehmet Esref
TI Neurogenic Stress Cardiomyopathy Following Subarachnoid Hemorrhage Is
   Associated with Vagal Complex Degeneration: First Experimental Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neurogenic stunned myocardium; Stunned heart and vagal complex
   degeneration; Takotsubo cardiomyopathy
ID TAKOTSUBO CARDIOMYOPATHY; STUNNED MYOCARDIUM; HEART; ATRIAL; NERVE;
   STIMULATION; GANGLION; DENSITY
AB BACKGROUND: Neurogenic stunned myocardium (NSM) is a devastating complication of subarachnoid hemorrhage (SAH). The most widely accepted mechanism in the pathogenesis of NSM and takotsubo cardiomyopathy is catecholamine-mediated direct myocardial injury. The aim of this study is to examine if there is any effect of sympathetic overactivity of the stellate ganglions on myocardial tissues, secondary to vagal complex degeneration in SAH-induced NSM.
   MATERIALS AND METHODS: This study was conducted on 25 New Zealand female rabbits. After the examination, all animals were assigned into 3 groups randomly: a control group (n = 5), a sham group (n = 5), and a study group (n = 15) that was subjected to experimental SAH with double injection of blood into the cisterna magna. After 7 animals exhibited NSM, all animals were killed. Their brains, vagal complexes, stellate ganglions, and hearts were extracted and examined by histopathologic methods. Degenerated nodose ganglion neurons and stellate ganglion neuron densities were compared with degenerated myocardial tissue/normal myocardial tissue ratios, and the results were analyzed with the Mann-Whitney U test.
   RESULTS: Three rabbits in the study group died immediately after the second injection of blood. NSM developed in 7 animals after 1 to 5 days, which was diagnosed with transthoracic echocardiography. Interestingly, the animals that developed NSM had more stellate ganglia neurons and more degenerated neuron densities of nodose ganglia (P < 0.001).
   CONCLUSIONS: NSM and takotsubo cardiomyopathy may be induced by vagal complex degeneration and sympathetic overactivity, which originated from more neurons, including stellate ganglia and more degenerated neuron densities of nodose ganglia.
C1 [Koze, Yavuzer; Bayram, Ednan] Ataturk Univ, Med Fac, Dept Cardiol, Erzurum, Turkey.
   [Aydin, Mehmet Dumlu] Ataturk Univ, Med Fac, Dept Neurosurg, Erzurum, Turkey.
   [Atalay, Canan; Kursad, Husnu] Ataturk Univ, Med Fac, Dept Anesthesiol, Erzurum, Turkey.
   [Koza, Enise Armagan] Erzurum Educ & Res Hosp, Dept Anesthesiol, Erzurum, Turkey.
   [Kabalar, Mehmet Esref] Erzurum Educ & Res Hosp, Dept Pathol, Erzurum, Turkey.
   [Altas, Ender] Palandoken State Hosp, Clin Cardiol, Erzurum, Turkey.
   [Aydin, Nazan] Bakirkoy Mental Dis Educ & Res Hosp, Dept Psychiat, Istanbul, Turkey.
RP Aydin, MD (reprint author), Ataturk Univ, Med Fac, Dept Neurosurg, Erzurum, Turkey.
EM nmda11@hotmail.com
CR Ancona F, 2016, EUR HEART J, V37, P2830, DOI 10.1093/eurheartj/ehw035
   Aoki Y, 2016, INT J CARDIOL, V203, P236, DOI 10.1016/j.ijcard.2015.10.121
   ARDELL JL, 1991, AM J PHYSIOL, V260, pH713
   Brack KE, 2013, HEART FAIL REV, V18, P389, DOI 10.1007/s10741-012-9314-2
   CECHETTO DF, 1987, J COMP NEUROL, V262, P27, DOI 10.1002/cne.902620104
   Cerqueira MD, 2002, CIRCULATION, V105, P539, DOI 10.1161/hc0402.102975
   Cheung RTF, 2000, ARCH NEUROL-CHICAGO, V57, P1685, DOI 10.1001/archneur.57.12.1685
   Conlon K, 1996, EXP PHYSIOL, V81, P547, DOI 10.1113/expphysiol.1996.sp003957
   Coote JH, 2013, J PHYSIOL-LONDON, V591, P4073, DOI 10.1113/jphysiol.2013.257758
   Mejia-Renteria HD, 2016, WORLD J CARDIOL, V8, P413, DOI 10.4330/wjc.v8.i7.413
   Delfiner MS, 2017, CARDIOVASC PATHOL, V26, P21, DOI 10.1016/j.carpath.2016.10.003
   Donaldson JW, 2001, SURG NEUROL, V55, P12, DOI 10.1016/S0090-3019(00)00296-2
   Finsterer J, 2014, J NEUROL SCI, V345, P8, DOI 10.1016/j.jns.2014.07.003
   Gatti PJ, 1997, J AUTONOM NERV SYST, V66, P138, DOI 10.1016/S0165-1838(97)00071-4
   Guglin Maya, 2011, Congest Heart Fail, V17, P127, DOI 10.1111/j.1751-7133.2011.00210.x
   HENDRIKX M, 1993, CARDIOVASC RES, V27, P980, DOI 10.1093/cvr/27.6.980
   HIGGINS CB, 1973, PHARMACOL REV, V25, P119
   JACOB WA, 1972, J MOL CELL CARDIOL, V4, P287, DOI 10.1016/0022-2828(72)90076-4
   Jones JFX, 1998, J PHYSIOL-LONDON, V507, P869, DOI 10.1111/j.1469-7793.1998.869bs.x
   Kayaci S, 2011, AUTON NEUROSCI-BASIC, V165, P163, DOI 10.1016/j.autneu.2011.06.008
   Kerro A, 2017, J CRIT CARE, V38, P27, DOI 10.1016/j.jcrc.2016.10.010
   Liu LL, 1997, AM J PHYSIOL-HEART C, V273, pH805
   Mashaly Hazem Antar, 2008, Cleve Clin J Med, V75 Suppl 2, pS26
   MELVILLE KI, 1963, AM J CARDIOL, V12, P781, DOI 10.1016/0002-9149(63)90281-9
   NEILDWYER G, 1978, BRIT MED J, V2, P990, DOI 10.1136/bmj.2.6143.990
   OPPENHEIMER SM, 1990, BRAIN RES, V533, P66, DOI 10.1016/0006-8993(90)91796-J
   Ozdemir NG, 2017, TURK NEUROSURG, V27, P874, DOI 10.5137/1019-5149.JTN.17206-16.2
   RAAB W, 1961, AM J CARDIOL, V8, P203, DOI 10.1016/0002-9149(61)90207-7
   Samuels MA, 2007, CIRCULATION, V116, P77, DOI 10.1161/CIRCULATIONAHA.106.678995
   SARNOFF SJ, 1960, CIRC RES, V8, P1108, DOI 10.1161/01.RES.8.5.1108
   Takato T, 2010, J CARDIOL, V56, P85, DOI 10.1016/j.jjcc.2010.03.002
   Tsai FC, 2002, J HEART LUNG TRANSPL, V21, P623, DOI 10.1016/S1053-2498(01)00425-9
   Uchida Y, 2010, CLIN CARDIOL, V33, P371, DOI 10.1002/clc.20777
   Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046
   Yolas C, 2014, J NEUROL SCI, V336, P220, DOI 10.1016/j.jns.2013.10.047
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E741
EP E748
DI 10.1016/j.wneu.2019.06.005
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900093
PM 31201944
DA 2020-05-12
ER

PT J
AU Kushel, Y
   Danilov, G
   Tekoev, A
   Cheldiev, B
   Strunina, Y
AF Kushel, Yury
   Danilov, Gleb
   Tekoev, Asian
   Cheldiev, Batraz
   Strunina, Yulia
TI A Single-Center Retrospective Descriptive Cohort Study of 211 Pediatric
   Patients: Cerebrospinal Fluid Leakage After Fourth Ventricle Tumor
   Resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid leakage; Children; Craniotomy; Dural sealant;
   Posterior fossa; Pseudomeningocele
ID CONSECUTIVE CRANIOTOMIES; INTRACRANIAL TUMORS; CHILDREN; SURGERY;
   RECONSTRUCTION; COMPLICATIONS; EFFICACY; GRAFT
AB BACKGROUND: Cerebrospinal fluid (CSF) leak remains a significant complication of posterior fossa tumor surgery. The goal of this study was to evaluate the wound CSF leakage rate in pediatric patients who underwent fourth ventricle tumor resection in a single-site setting and to explore the association of CSF leakage with the length of stay in the intensive care unit (ICU) and with dural sealant application.
   METHODS: Two hundred and eleven patients who underwent fourth ventricle tumor surgery between 2008 and 2016 were included in this study. Patient data were evaluated retrospectively.
   RESULTS: Postoperative wound CSF leakage was observed in 6 patients (2.8%). One hundred and seventy-six patients (83.4%) stayed in the ICU for <= 1 day, and CSF leakage developed in 4 of these patients (2.3%). Thirty-five patients (16.6%) stayed in the ICU for >1 day, and CSF leakage was observed in 2 of these patients (5.7%). The observed difference was not statistically significant (P = 0.260). There were no statistically significant differences in the CSF leakage rates in groups with and without dural sealing before (n = 2 [3%] and n [4 = 2.8%], respectively; P = 0.99) and after (n = 2 [3.0%] and n = 4 [6.0%], respectively; P = 0.68) application of the propensity score matching algorithm.
   CONCLUSIONS: The low CSF leakage rate (2.8%) identified in this study was associated with a certain algorithm of patient management. There was no strong evidence that the CSF leakage rate was associated with the length of stay in the ICU or with dural sealant application.
C1 [Kushel, Yury; Tekoev, Asian; Cheldiev, Batraz] Burdenko Neurosurg Inst, Neurosurg Dept 2, Moscow, Russia.
   [Danilov, Gleb] Burdenko Neurosurg Inst, Adm, Moscow, Russia.
   [Strunina, Yulia] Burdenko Neurosurg Inst, Lab Biomed Informat, Moscow, Russia.
RP Kushel, Y (reprint author), Burdenko Neurosurg Inst, Neurosurg Dept 2, Moscow, Russia.
EM kuszel@yandex.ru
RI Kushel, Yury/AAB-1592-2020
OI Kushel, Yury/0000-0001-7136-0693; Cheldiev, Batraz/0000-0002-6326-9504
FU Takeda Pharmaceuticals LLC, Moscow, Russia
FX Medical writing support was funded by Takeda Pharmaceuticals LLC,
   Moscow, Russia.
CR Albright A, 2015, PRINCIPLES PRACTICE
   Di Vitantonio Hambra, 2016, Surg Neurol Int, V7, pS463, DOI 10.4103/2152-7806.185777
   George B, 2017, NEUROSURGERY, V80, P847, DOI 10.1093/neuros/nyx024
   Gnanalingham KK, 2002, J NEUROSURG, V97, P821, DOI 10.3171/jns.2002.97.4.0821
   Green AL, 2015, BRIT J NEUROSURG, V29, P11, DOI 10.3109/02688697.2014.948808
   Grotenhuis JA, 2005, SURG NEUROL, V64, P490, DOI 10.1016/j.surneu.2005.03.041
   Heymanns V, 2016, CLINICS PRACT, V6, P42, DOI 10.4081/cp.2016.824
   Hosainey SAM, 2014, J NEUROSURG-PEDIATR, V14, P604, DOI 10.3171/2014.8.PEDS13585
   Houdemont SP, 2011, CHILD NERV SYST, V27, P933, DOI 10.1007/s00381-010-1373-x
   Hutter G, 2014, J NEUROSURG, V121, P735, DOI 10.3171/2014.6.JNS131917
   Kshettry VR, 2016, J KOREAN NEUROSURG S, V59, P52, DOI 10.3340/jkns.2016.59.1.52
   Lassen B, 2012, NEUROSURGERY, V70, P936, DOI 10.1227/NEU.0b013e31823bcc61
   Mehta AI, 2012, J SPINAL DISORD TECH, V25, P205, DOI 10.1097/BSD.0b013e318215953f
   Piek J, 2012, J NEUROL SURG PART A, V73, P25, DOI 10.1055/s-0032-1304501
   Steinbok P, 2007, CHILD NERV SYST, V23, P171, DOI 10.1007/s00381-006-0234-0
   Taha ANM, 2011, WORLD NEUROSURG, V75, P692, DOI 10.1016/j.wneu.2011.01.023
NR 16
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E171
EP E176
DI 10.1016/j.wneu.2019.05.091
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900022
PM 31121374
DA 2020-05-12
ER

PT J
AU Lee, HS
   Park, W
   Kim, YH
   Park, JC
   Ahn, J
   Kim, JH
AF Lee, Heui Seung
   Park, Wonhyoung
   Kim, Young-Hoon
   Park, Jung Cheol
   Ahn, Jaesung
   Kim, Jeong Hoon
TI Follow-Up and Treatment of Patients with Coexisting Brain Tumor and
   Intracranial Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Astrocytoma; Brain tumor; Intracranial aneurysm; Meningioma;
   Oligodentroglial tumor; Subarachnoid hemorrhage
ID SURGICAL-TREATMENT; ASSOCIATION; HEMORRHAGE; SURVIVAL; GLIOMAS; RUPTURE
AB OBJECTIVE: The association of primary brain tumors with coexisting unruptured intracranial aneurysms (UIAs) has been debated, and treatment strategies have not yet been established. We evaluated the flow association between brain tumors and coexisting UIAs and the outcomes of patients with brain tumor who did not receive treatment of coexisting UIAs.
   METHODS: The medical records of patients with coexisting UIAs and brain tumors who had undergone surgical tumor resection were retrospectively analyzed to evaluate the incidence of UIAs according to tumor type, association of arterial feeder vessels and coexisting UIAs, and the occurrence of subarachnoid hemorrhage during the follow-up period for patients who had not receive treatment for the UIAs.
   RESULTS: Of the 55 patients, 21 (38.9%) had undergone treatment of UIAs and 33 (61.1%) had received regular follow-up examinations without UIA treatment. Two patients (6.1%) developed subarachnoid hemorrhage. Of the 33 patients with astrocytic or oligodendroglial tumors who had not undergone treatment of UIAs, 2 had experienced an interval increase. Flow-related UIAs were found to be significantly more common in patients with astrocytic or oligodendroglial tumors than in those with tumors of other histological types (P [0.01).
   CONCLUSIONS: The incidence of UIAs among patients with primary brain tumors appears to be greater than that in the general population. An interval increase in aneurysm size and aneurysmal rupture was observed in 2 patients with astrocytic or oligodendroglial tumors. We would recommend perioperative treatment of flow-related UIAs in patients with astrocytic or oligodendroglial tumors and noninvasive evaluations such as magnetic resonance angiography if coexisting UIAs remain untreated.
C1 [Lee, Heui Seung; Park, Wonhyoung; Kim, Young-Hoon; Park, Jung Cheol; Ahn, Jaesung; Kim, Jeong Hoon] Univ Ulsan, Asan Med Ctr, Dept Neurosurg, Coll Med, Seoul, South Korea.
RP Kim, JH (reprint author), Univ Ulsan, Asan Med Ctr, Dept Neurosurg, Coll Med, Seoul, South Korea.
EM jhkim1@amc.seoul.kr
OI Kim, Young-Hoon/0000-0002-8852-6503; Park, Jung
   Cheol/0000-0001-6677-455X
CR Argyriou AA, 2009, CRIT REV ONCOL HEMAT, V69, P199, DOI 10.1016/j.critrevonc.2008.05.005
   Diamandis P, 2018, NEUROL CLIN, V36, P439, DOI 10.1016/j.ncl.2018.04.003
   Duffau H, 2012, Adv Tech Stand Neurosurg, V38, P3, DOI 10.1007/978-3-7091-0676-1_1
   Ene CI, 2016, WORLD NEUROSURG, V89, DOI 10.1016/j.wneu.2016.01.068
   Fischer BR, 2009, CLIN NEUROL NEUROSUR, V111, P647, DOI 10.1016/j.clineuro.2009.05.016
   Fischer I, 2005, BRAIN PATHOL, V15, P297
   Johnson DR, 2013, CANCER-AM CANCER SOC, V119, P3489, DOI 10.1002/cncr.28259
   Kim M, 2016, KOREAN J RADIOL, V17, P598, DOI 10.3348/kjr.2016.17.5.598
   Kim YH, 2015, J NEUROSURG, V123, P357, DOI 10.3171/2014.10.JNS14710
   Lee EJ, 2012, J NEUROSURG, V117, P53, DOI 10.3171/2012.3.JNS111221
   Matsukawa H, 2018, J NEUROSURG, V129, P490, DOI 10.3171/2017.3.JNS162984
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Nanney AD, 2014, WORLD NEUROSURG, V81, P511, DOI 10.1016/j.wneu.2013.10.044
   Nguyen HS, 2015, INT MED CASE REP J, V8, P295, DOI 10.2147/IMCRJ.S93271
   Niu XD, 2018, WORLD NEUROSURG, V111, pE592, DOI 10.1016/j.wneu.2017.12.126
   Oh MC, 2012, J NEUROSURG, V116, P942, DOI 10.3171/2011.12.JNS11875
   PIA HW, 1973, ACTA NEUROCHIR, V27, P189
   TAYLOR PE, 1961, NEUROLOGY, V11, P225, DOI 10.1212/WNL.11.3.225
   Wang GX, 2018, WORLD NEUROSURG, V110, pE333, DOI 10.1016/j.wneu.2017.10.174
   Yamada H, 1989, Neurol Med Chir (Tokyo), V29, P846, DOI 10.2176/nmc.29.846
   Zhong ZH, 2013, NEUROSURG REV, V36, P645, DOI 10.1007/s10143-013-0477-7
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E73
EP E80
DI 10.1016/j.wneu.2019.05.023
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900011
PM 31082556
DA 2020-05-12
ER

PT J
AU Lee, S
   Park, SK
   Lee, JA
   Joo, BE
   Park, K
AF Lee, Seunghoon
   Park, Sang-Ku
   Lee, Jeong-A
   Joo, Byung-Euk
   Park, Kwan
TI Missed Culprits in Failed Microvascular Decompression Surgery for
   Hemifacial Spasm and Clinical Outcomes of Redo Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cisternal segment; Failure; Hemifacial spasm; Microvascular
   decompression; Revision; Vein
ID VASCULAR COMPRESSION; NEUROVASCULAR COMPRESSION; FACIAL-NERVE;
   REOPERATION; PERSISTENT; EXPERIENCE; LESSONS
AB OBJECTIVE: To identify causes of recurrent hemifacial spasm (HFS) after initial microvascular decompression (MVD) and to assess the feasibility of redo MVD.
   METHODS: The study included 21 patients who underwent redo MVD over the last 2 decades. Their medical charts were retrospectively reviewed for preoperative medical history, previous and redo MVD intraoperative findings, and previous and redo MVD postoperative outcomes.
   RESULTS: Redo MVDs were the second operation in 20 patients and the third operation in 1 patient. The median interval between previous and redo MVD was 46.3 months (range, 14.4-188.2 months). Compression of offending vessels such as a vein or perforating artery located medial to or at the cisternal segment of the facial nerve was found to be a possible cause of previous MVD failure. MVD failure resulted from neglect of offending vessels in 10 patients, insufficient decompression in 7 patients, and untouched neurovascular compression sites in 4 patients. Spasm-free rates after redo MVD were 80.5% at 1 year and 90.5% in the last year of follow-up (median, 15.8 months; range, 3.6-152.0 months). Permanent hearing loss and facial palsy were each observed in 2 patients (9.5%). In addition, 1 patient each experienced cerebellar infarction and vocal cord palsy.
   CONCLUSIONS: Redo MVD remains a feasible treatment option for patients with HFS who failed to benefit from previous MVD, but it is associated with an increased risk of cranial nerve and vascular injuries.
C1 [Lee, Seunghoon; Lee, Jeong-A; Park, Kwan] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Neurosurg, Seoul, South Korea.
   [Park, Sang-Ku] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Neurol, Seoul, South Korea.
   [Joo, Byung-Euk] Myongji Hosp, Dept Neurol, Myongji, Gyeonggi Do, South Korea.
RP Park, K (reprint author), Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Neurosurg, Seoul, South Korea.
EM kwanpark@skku.edu
OI Park, Sang-Ku/0000-0002-0546-9014
CR BARKER FG, 1995, J NEUROSURG, V82, P201, DOI 10.3171/jns.1995.82.2.0201
   Bigder MG, 2016, J NEUROSURG, V124, P90, DOI 10.3171/2015.1.JNS142714
   Campos-Benitez M, 2008, J NEUROSURG, V109, P416, DOI 10.3171/JNS/2008/109/9/0416
   Chang WS, 2012, ACTA NEUROCHIR, V154, P1613, DOI 10.1007/s00701-012-1424-z
   Chang WS, 2010, ACTA NEUROCHIR, V152, P2105, DOI 10.1007/s00701-010-0826-z
   Deep NL, 2017, LARYNGOSCOPE, V127, P715, DOI 10.1002/lary.26126
   Dou NN, 2016, STEREOT FUNCT NEUROS, V94, P154, DOI 10.1159/000446192
   Engh JA, 2005, J NEUROL NEUROSUR PS, V76, P1574, DOI 10.1136/jnnp.2004.056861
   Hatayama T, 2015, NEUROL MED-CHIR, V55, P663, DOI 10.2176/nmc.ra.2014-0386
   Inoue H, 2016, NEUROL MED-CHIR, V56, P77, DOI 10.2176/nmc.cr.2015-0227
   Jiang CR, 2017, ACTA NEUROCHIR, V159, P259, DOI 10.1007/s00701-016-3006-y
   Jo KW, 2013, NEUROSURG REV, V36, P297, DOI 10.1007/s10143-012-0420-3
   Lee MH, 2016, NEUROSURG REV, V39, P151, DOI 10.1007/s10143-015-0666-7
   Lee S, 2018, CLIN NEUROPHYSIOL, V129, P1490, DOI 10.1016/j.clinph.2018.03.006
   Li ST, 2010, ACTA NEUROCHIR, V152, P2113, DOI 10.1007/s00701-010-0837-9
   Liu MX, 2018, WORLD NEUROSURG, V110, pE897, DOI 10.1016/j.wneu.2017.11.118
   Lv MY, 2017, BRIT J NEUROSURG, V31, P322, DOI 10.1080/02688697.2017.1297368
   McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001
   Miller LE, 2012, BRIT J NEUROSURG, V26, P438, DOI 10.3109/02688697.2011.641613
   NAGAHIRO S, 1991, J NEUROSURG, V75, P388, DOI 10.3171/jns.1991.75.3.0388
   Park YS, 2006, NEUROSURGERY, V58, P1162, DOI 10.1227/01.NEU.0000215954.97948.B3
   Ryu H, 1998, J NEUROSURG, V88, P605, DOI 10.3171/jns.1998.88.3.0605
   Sindou MP, 2005, ACTA NEUROCHIR, V147, P1019, DOI 10.1007/s00701-005-0583-6
   Wang XH, 2013, NEUROSURG REV, V36, P637, DOI 10.1007/s10143-013-0480-z
   Wang XH, 2013, NEUROL RES, V35, P389, DOI 10.1179/1743132812Y.0000000153
   Xu XL, 2018, WORLD NEUROSURG, V110, pE989, DOI 10.1016/j.wneu.2017.11.144
   Zhao H, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.127
   Zhong J, 2010, ACTA NEUROCHIR, V152, P2119, DOI 10.1007/s00701-010-0794-3
NR 28
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E627
EP E633
DI 10.1016/j.wneu.2019.05.231
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900079
PM 31158550
DA 2020-05-12
ER

PT J
AU Li, ZC
   Wu, WC
   Chen, RM
   Chen, XW
   Lin, JH
AF Li, Zhechen
   Wu, Wence
   Chen, Ruomiao
   Chen, Xuanwei
   Lin, Jianhua
TI Perioperative Management of Spinal Tuberculosis in Patients with
   End-Stage Renal Disease: A Preliminary Report on A Patient Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE End-stage renal disease; Morbidity; Mortality; Spinal tuberculosis;
   Surgery
ID CHRONIC KIDNEY-DISEASE; DIALYSIS PATIENTS; MORTALITY; SURGERY
AB OBJECTIVE: To present a preliminary experience of perioperative management for patients with spinal tuberculosis (STB) and end-stage renal disease (ESRD) and discuss strategic factors that should be considered.
   METHODS: A retrospective study of 6 patients with STB and ESRD who underwent spine surgeries in our hospital from January 2010 to May 2017 was carried out. Medical records were reviewed for clinical manifestations, laboratory examinations, radiologic findings, perioperative management, clinical outcomes, and complications.
   RESULTS: Except for 1 patient who died of cardiac arrest 5 days after surgery, this case series was followed with a mean follow-up period of 17.0 months (range, 9-23). There were no patients reporting major side effects related to an adjusted antituberculosis chemotherapy regimen. Post-operatively, surgical incision healed primarily, whereas delirium and pneumonia were noted in 2 patients. At final follow-ups, solid bony fusion was achieved in 4 patients, whereas fusion was indefinite in the patient who underwent surgery at L3/4 level. Visual analogue scale score improved from preoperative 5.2 +/- 0.37 to 2.6 +/- 0.55 at the final follow-ups.
   CONCLUSIONS: Perioperative management of patients with STB and ESRD is a complicated issue, with multiple factors to be considered. Spinal surgery can achieve acceptable outcomes in these patients if meticulous management is performed.
C1 [Li, Zhechen; Chen, Xuanwei; Lin, Jianhua] Fujian Med Univ, Affiliated Hosp 1, Dept Spine Surg, Fuzhou, Fujian, Peoples R China.
   [Chen, Ruomiao] Fujian Med Univ, Affiliated Hosp 1, Dept Plast Surg, Fuzhou, Fujian, Peoples R China.
   [Wu, Wence] Fujian Med Univ, Affiliated Hosp 1, Clin Med Sch 1, Fuzhou, Fujian, Peoples R China.
RP Chen, XW (reprint author), Fujian Med Univ, Affiliated Hosp 1, Dept Spine Surg, Fuzhou, Fujian, Peoples R China.
EM spine2018@sina.com
FU Startup Fund for scientific research, Fujian Medical University
   [2018QH1072]
FX This study was supported by a grant from Startup Fund for scientific
   research, Fujian Medical University (2018QH1072).
CR Alavi S M, 2010, J Infect Public Health, V3, P196, DOI 10.1016/j.jiph.2010.09.005
   Bains RS, 2017, J CLIN NEUROSCI, V43, P208, DOI 10.1016/j.jocn.2017.05.014
   BINDI P, 1990, NEPHRON, V55, P104, DOI 10.1159/000185935
   BoachieAdjei O, 1996, ORTHOP CLIN N AM, V27, P95
   Cengiz K, 1996, NEPHRON, V73, P421
   Chen LH, 2010, EUR SPINE J, V19, P2223, DOI 10.1007/s00586-010-1501-z
   Ramos RD, 2016, WORLD NEUROSURG, V95, P480, DOI 10.1016/j.wneu.2016.06.096
   De Nicola L, 2016, NEPHROL DIAL TRANSPL, V31, P331, DOI 10.1093/ndt/gfv427
   Dobler CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029563
   Han IH, 2009, SPINE, V34, P1990, DOI 10.1097/BRS.0b013e3181abbdff
   Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X
   Launay-Vacher V, 2005, CLIN PHARMACOKINET, V44, P221, DOI 10.2165/00003088-200544030-00001
   London GM, 2000, NEPHRON, V84, P111, DOI 10.1159/000045557
   McLain RF, 2004, CLEV CLIN J MED, V71, P537, DOI 10.3949/ccjm.71.7.537
   Milburn H, 2010, THORAX, V65, P559, DOI 10.1136/thx.2009.133173
   PINSON CW, 1986, AM J SURG, V151, P567, DOI 10.1016/0002-9610(86)90548-9
   Romanowski K, 2016, KIDNEY INT, V90, P34, DOI 10.1016/j.kint.2016.01.034
   Zha Y, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030208
NR 18
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E452
EP E457
DI 10.1016/j.wneu.2019.05.182
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900057
PM 31150864
DA 2020-05-12
ER

PT J
AU Lin, GX
   Rui, G
   Sharma, S
   Kotheeranurak, V
   Suen, TK
   Kim, JS
AF Lin, Guang-Xun
   Rui, Gang
   Sharma, Sager
   Kotheeranurak, Vit
   Suen, Tsz-King
   Kim, Jin-Sung
TI Does the Neck Pain, Function, or Range of Motion Differ After Anterior
   Cervical Fusion, Cervical Disc Replacement, and Posterior Cervical
   Foraminotomy?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical discectomy and fusion; Cervical disc replacement;
   Posterior cervical foraminotomy; Radiculopathy; Range of motion
ID DISKECTOMY; OUTCOMES; ARTHROPLASTY; EXPERIENCE; MINIMUM; RATES
AB OBJECTIVE: To evaluate clinical and radiologic results as well as biomechanical changes after anterior cervical discectomy and fusion (ACDF), cervical disc replacement (CDR), and posterior cervical foraminotomy (PCF) and/or discectomy in individuals with unilateral single-level cervical radiculopathy.
   METHODS: A total of 97 patients received surgical treatment for unilateral intolerable radiculopathy between February 2012 and August 2017. Clinical outcomes included Neck Disability Index (NDI), visual analogue scale (VAS) for neck and arm pain, and modified Odom's criteria. Range of motion (ROM) of the whole cervical (C-ROM), operated segment (S-ROM), and upper and lower adjacent segment (U-ROM and L-ROM) were measured.
   RESULTS: A total of 55 ACDFs, 21 CDRs, and 21 PCFs were performed. Clinical improvement in NDI and VAS scores were significant after surgery; however, there was no statistical significance among groups. Satisfaction rate (based on Odom's criteria) of PCF (76.2%) was inferior to that of ACDF (90.9%) and CDR (90.5%) without statistical difference. S-ROM, U-ROM, and L-ROM were slightly better in the CDR and PCF groups, without statistical significance. C-ROM significantly increased in CDR group (P = 0.04) and slightly increased in PCF group (P = 0.27). In the ACDF group, C-ROM decreased (P = 0.21) and on the contrary, the U-ROM and L-ROM increased (P > 0.05).
   CONCLUSIONS: ACDF, CDR, and PCF resulted in pain relief and improvement in neck function for patients with unilateral radiculopathy. Comparatively, ACDF provides the lowest reoperation rate. CDR is effective in ameliorating cervical ROMs. PCF has a greater probability of reoperation; however, ROM after surgery is better than with ACDF.
C1 [Lin, Guang-Xun; Sharma, Sager; Kim, Jin-Sung] Catholic Univ Korea, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
   [Lin, Guang-Xun; Rui, Gang] Xiamen Univ, Affiliated Hosp 1, Dept Orthoped, Xiamen, Fujian, Peoples R China.
   [Kotheeranurak, Vit] Queen Savang Vadhana Mem Hosp, Spine Unit, Dept Orthopaed, Sriracha, Chonburi, Thailand.
   [Suen, Tsz-King] Kowloon West Cluster Hosp Author, Caritas Med Ctr, Dept Orthopaed & Traumatol, Hong Kong, Peoples R China.
RP Kim, JS (reprint author), Catholic Univ Korea, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea.
EM mdlukekim.@gmail.com
RI Kim, Jin-Sung/Y-2904-2019; Sharma, Sagar/AAG-5911-2020
OI Kim, Jin-Sung/0000-0001-5086-0875; Sharma, Sagar/0000-0002-2559-6010
FU China Scholarship Council (CSC)China Scholarship Council [[2016]3100]
FX Guang-Xun Lin thanks the China Scholarship Council (CSC; No.
   [2016]3100).
CR Bydon M, 2014, J NEUROSURG-SPINE, V21, P727, DOI 10.3171/2014.7.SPINE131110
   Cho Tack Geun, 2014, Korean J Spine, V11, P1, DOI 10.14245/kjs.2014.11.1.1
   Cody JP, 2014, J CLIN NEUROSCI, V21, P1901, DOI 10.1016/j.jocn.2014.05.008
   Dunn C, 2018, J NEUROSURG-SPINE, V29, P358, DOI 10.3171/2018.2.SPINE171003
   Gutman G, 2018, SPINE, V43, pE365, DOI 10.1097/BRS.0000000000002324
   Jagannathan J, 2009, J NEUROSURG-SPINE, V10, P347, DOI 10.3171/2008.12.SPINE08576
   Junaid Mnhammad, 2014, J Ayub Med Coll Abbottabad, V26, P444
   Kang MS, 2014, J SPINAL DISORD TECH, V27, P271, DOI 10.1097/BSD.0b013e3182a35707
   Kim CH, 2015, EUR SPINE J, V24, P3005, DOI 10.1007/s00586-015-4198-1
   Kim KT, 2017, J KOREAN NEUROSURG S, V60, P30, DOI 10.3340/jkns.2015.0506.004
   Leven D, 2017, CURR REV MUSCULOSKE, V10, P160, DOI 10.1007/s12178-017-9398-3
   Lubelski D, 2015, SPINE J, V15, P1277, DOI 10.1016/j.spinee.2015.02.026
   Quintana LM, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.09.044
   Ren CP, 2014, EUR SPINE J, V23, P1115, DOI 10.1007/s00586-014-3220-3
   Roh Sung Woo, 2017, Korean Journal of Neurotrauma, V14, P124
   Ruetten S, 2008, SPINE, V33, P940, DOI 10.1097/BRS.0b013e31816c8b67
   Schroeder GD, 2016, CLIN SPINE SURG, V29, P186, DOI 10.1097/BSD.0000000000000383
   Selvanathan SK, 2015, ACTA NEUROCHIR, V157, P1595, DOI 10.1007/s00701-015-2491-8
   Skeppholm M, 2015, SPINE J, V15, P1284, DOI 10.1016/j.spinee.2015.02.039
   Wang TY, 2015, SPINE J, V15, P971, DOI 10.1016/j.spinee.2013.05.042
   WATTERS WC, 1994, SPINE, V19, P2343, DOI 10.1097/00007632-199410150-00016
   Yue WM, 2005, SPINE, V30, P2138, DOI 10.1097/01.brs.0000180479.63092.17
NR 22
TC 2
Z9 2
U1 5
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E485
EP E493
DI 10.1016/j.wneu.2019.05.188
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900062
PM 31150858
DA 2020-05-12
ER

PT J
AU Liu, N
   Lu, T
   Wang, YB
   Sun, ZW
   Li, JL
   He, XJ
AF Liu, Ning
   Lu, Teng
   Wang, Yibin
   Sun, Zhongwei
   Li, Jialiang
   He, Xijing
TI Effects of New Cage Profiles on the Improvement in Biomechanical
   Performance of Multilevel Anterior Cervical Corpectomy and Fusion: A
   Finite Element Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cage design; Cage subsidence; Cervical; Corpectomy; Diskectomy; Finite
   element; Fusion
ID TITANIUM MESH CAGE; END-PLATE STRENGTH; SPONDYLOTIC MYELOPATHY;
   SINGLE-LEVEL; DISKECTOMY; SPINE; RECONSTRUCTION; SUBSIDENCE; FIXATION;
   AUGMENTATION
AB BACKGROUND: For multilevel cervical fusion, anterior corpectomy and fusion (ACCF) induces more implant-related complications than anterior diskectomy and fusion (ACDF), which implies that the biomechanical stability of ACCF may be insufficient. The aim of this study was to assess whether the optimization of the cage profiles could improve the biomechanical performance of multilevel ACCF.
   METHODS: Three finite element models were constructed and compared, including 3-level ACDF, 2-level ACCF using a conventional cage for reconstruction, and 2-level ACCF using a new cage for reconstruction. The ends of the new cage possessed additional end rings and emulated the end plate geometries. The ranges of motion (ROMs) of the surgical segments and the stress peaks in the end plate, fixation system, and screw-bone interface were compared.
   RESULTS: Compared with preoperative status, ACDF and ACCF reduced the segmental ROMs by 96.1%-98.2%. The end plate stress peaks were the highest in ACCF using the conventional cage (10.1-18.6 MPa), followed by ACCF using the new cage (7.7-14.3 MPa) and ACDF (5.3-9.1 MPa). ACDF induced the highest stress peaks in the fixation system and screw-bone interface (32.5-39.3 MPa and 12.1-12.7 MPa, respectively), followed by ACCF using the conventional cage (20.4-31.7 MPa and 10.3-13.6 MPa, respectively) and ACCF using the new cage (18.6-25.7 MPa and 9.7-12.6 MPa, respectively).
   CONCLUSIONS: The application of the new cage decreased the risks of cage subsidence and instrument-related complications in multilevel ACCF. Under the condition where cage subsidence was prevented, ACCF was superior to ACDF in terms of construct stability and avoiding instrument-related complications.
C1 [Liu, Ning; Lu, Teng; Wang, Yibin; Li, Jialiang; He, Xijing] Xi An Jiao Tong Univ, Dept Orthoped, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China.
   [Liu, Ning] Hanzhong Cent Hosp, Dept Spine Surg, Hanzhong, Shaanxi, Peoples R China.
   [Lu, Teng] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.
   [Sun, Zhongwei] ISFab Inc, Dept Res & Dev, Boston, MA USA.
RP He, XJ (reprint author), Xi An Jiao Tong Univ, Dept Orthoped, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China.
EM he_xijing@126.com
OI Li, Jialiang/0000-0002-5218-9285
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571209]
FX This work was supported by the National Natural Science Foundation of
   China (81571209).
CR Bilbao G, 2010, ACTA NEUROCHIR, V152, P1155, DOI 10.1007/s00701-010-0660-3
   Burkhardt JK, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.3.FOCUS1396
   Chen WM, 2018, CLIN BIOMECH, V59, P19, DOI 10.1016/j.clinbiomech.2018.08.005
   Chen Y, 2008, J SPINAL DISORD TECH, V21, P489, DOI 10.1097/BSD.0b013e318158de22
   Colman MW, 2016, SPINE, V41, pE519, DOI 10.1097/BRS.0000000000001312
   Daubs MD, 2005, SPINE, V30, P1402, DOI 10.1097/01.brs.0000166526.78058.3c
   Feng H, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006296
   Feng H, 2017, SPINE J, V17, P269, DOI 10.1016/j.spinee.2016.09.019
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   Gao R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034811
   Guo LX, 2019, MED BIOL ENG COMPUT, V57, P89, DOI 10.1007/s11517-018-1838-8
   Guo QF, 2011, EUR SPINE J, V20, P1539, DOI 10.1007/s00586-011-1735-4
   Han YC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087191
   Hartmann S, 2016, ACTA NEUROCHIR, V158, P1859, DOI 10.1007/s00701-016-2908-z
   Jiang SD, 2012, ARCH ORTHOP TRAUM SU, V132, P155, DOI 10.1007/s00402-011-1402-6
   Kallemeyn N, 2010, MED ENG PHYS, V32, P482, DOI 10.1016/j.medengphy.2010.03.001
   Lau D, 2015, J NEUROSURG-SPINE, V23, P280, DOI 10.3171/2014.12.SPINE14545
   Li ZH, 2018, EUR SPINE J, V27, P2772, DOI 10.1007/s00586-018-5755-1
   Li ZH, 2017, CLIN SPINE SURG, V30, pE540, DOI 10.1097/BSD.0000000000000212
   Lin QS, 2012, EUR SPINE J, V21, P474, DOI 10.1007/s00586-011-1961-9
   Liu JM, 2015, ARCH ORTHOP TRAUM SU, V135, P149, DOI 10.1007/s00402-014-2123-4
   Lou JG, 2016, CLIN NEUROL NEUROSUR, V142, P132, DOI 10.1016/j.clineuro.2016.01.027
   Lowe TG, 2004, SPINE, V29, P2389, DOI 10.1097/01.brs.0000143623.18098.e5
   Lu T, 2017, MED SCI MONITOR, V23, P3105, DOI 10.12659/MSM.901993
   Lu T, 2017, MED SCI MONITOR, V23, P2863, DOI 10.12659/MSM.905466
   Mummaneni PV, 2009, J NEUROSURG-SPINE, V11, P130, DOI 10.3171/2009.3.SPINE08728
   Nayak AN, 2014, SPINE J, V14, P3002, DOI 10.1016/j.spinee.2014.06.011
   Oh MC, 2009, SPINE, V34, P692, DOI 10.1097/BRS.0b013e318199690a
   Oliver JD, 2018, SPINE, V43, pE413, DOI 10.1097/BRS.0000000000002441
   Ordway NR, 2007, EUR SPINE J, V16, P2104, DOI 10.1007/s00586-007-0482-z
   Ordway NR, 2012, J ORTHOP RES, V30, P587, DOI 10.1002/jor.21566
   Ouyang PR, 2019, MED SCI MONITOR, V25, P1489, DOI 10.12659/MSM.913630
   Panjabi MM, 2001, SPINE, V26, P2692, DOI 10.1097/00007632-200112150-00012
   Peterson JM, 2018, SPINE, V43, pE1069, DOI 10.1097/BRS.0000000000002644
   Pitzen T, 2004, EUR SPINE J, V13, P235, DOI 10.1007/s00586-003-0648-2
   Ruangchainikom M, 2014, SPINE, V39, P932, DOI 10.1097/BRS.0000000000000330
   Schmitz B, 2004, ACTA RADIOL, V45, P53, DOI 10.1080/02841850410000755
   Song KJ, 2011, CLIN ORTHOP SURG, V3, P9, DOI 10.4055/cios.2011.3.1.9
   Song KJ, 2014, ASIAN SPINE J, V8, P531, DOI 10.4184/asj.2014.8.4.531
   Song KJ, 2009, SPINE, V34, P2886, DOI 10.1097/BRS.0b013e3181b64f2c
   Takase H, 2018, WORLD NEUROSURG, V120, pE1107, DOI 10.1016/j.wneu.2018.08.240
   Toledano M, 2013, NEUROL CLIN, V31, P287, DOI 10.1016/j.ncl.2012.09.003
   Tsitsopoulos PP, 2017, ORTHOP SURG, V9, P290, DOI 10.1111/os.12339
   Wang JC, 2003, SPINE, V28, P1016, DOI 10.1097/00007632-200305150-00011
   Wang JC, 2000, SPINE, V25, P41, DOI 10.1097/00007632-200001010-00009
   Wang JC, 2003, SPINE, V28, P1021
   Wei LX, 2019, WORLD NEUROSURG, V126, pE842, DOI 10.1016/j.wneu.2019.02.182
   Wheeldon JA, 2008, ANN BIOMED ENG, V36, P1458, DOI 10.1007/s10439-008-9534-8
   Wu JX, 2015, INT J CLIN EXP MED, V8, P7405
   Wu TK, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-019-2425-3
   Xiao SW, 2015, EUR SPINE J, V24, P31, DOI 10.1007/s00586-014-3607-1
   Yu FB, 2013, EUR SPINE J, V22, P2891, DOI 10.1007/s00586-013-2976-1
   Zhang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096265
   Zhao LJ, 2018, CLIN BIOMECH, V60, P76, DOI 10.1016/j.clinbiomech.2018.09.008
NR 54
TC 1
Z9 1
U1 8
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E87
EP E96
DI 10.1016/j.wneu.2019.05.037
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900013
PM 31150848
DA 2020-05-12
ER

PT J
AU Liu, P
   Xiao, Q
   Zhou, B
   Dai, ZH
   Kang, YJ
AF Liu, Ping
   Xiao, Qing
   Zhou, Bing
   Dai, Zhehao
   Kang, Yijun
TI Prognostic Significance of Programmed Death Ligand 1 Expression and
   Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Axial; Immune microenvironment; Osteosarcoma; PD-1/PD-L1 axis;
   Prognostic marker; Tumor-infiltrating lymphocytes
ID PD-L1 EXPRESSION; BREAST-CANCER; CD8+TIL DENSITY; SURVIVAL;
   MICROENVIRONMENT; RECURRENCE; CARCINOMA; SPINE; TILS
AB OBJECTIVE: To characterize the intratumoral immune microenvironment and evaluate its clinical implications in patients with primary axial osteosarcoma.
   METHODS: Immunohistochemistry was used to interpret tumor programmed death ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) profile of cluster of differentiation 8 (CD8), PD-L1, and programmed death 1 (PD-1) within 69 tumor specimens.
   RESULTS: Overall, all tumor specimens presented lymphocytic infiltrates, with PD-L1+ TILs being the most common subset (mean, 215.1 per slide mm(2)). Positive tumor PD-L1 expression was presented in 43.5% of tumors. Moderate to strong relationships were detected among TILs subsets and tumor PD-L1 expression. In addition, the density of PD-L1+ TILs was significantly correlated with favorable clinicopathologic features, including earlier Enneking stage. The positivity of tumor PD-L1 expression was associated with the tumor site and pathologic grade (P = 0.021 and 0.037, respectively). In univariate survival analysis, the high density of PD-L1+ TILs or CD8+ TILs was significantly correlated with both prolonged event-free survival and overall survival (OS), whereas the high infiltration of PD-1+ TILs was significantly associated with reduced OS, as was the positive tumor PD-L1 expression. Furthermore, multivariate analysis showed that CD8+ TILs and PD-L1+ TILs remained their significance for both event-free survival (P = 0.012 and 0.004, respectively) and OS (P = 0.033 and 0.002, respectively). However, both PD-1+ TILs and tumor PD-L1 expression failed to reach significance for OS.
   CONCLUSIONS: Our results suggested that the immune microenvironment is of clinically relevant significance in patients with axial osteosarcoma. Specifically, we identified both PD-L1+ TILs and CD8+ TILs as independent favorable prognostic markers.
C1 [Liu, Ping; Zhou, Bing; Dai, Zhehao; Kang, Yijun] Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.
   [Xiao, Qing] Cent S Univ, Dept Pathol, Xiangya Hosp, Changsha, Hunan, Peoples R China.
RP Kang, YJ (reprint author), Cent S Univ, Xiangya Hosp 2, Dept Spine Surg, Changsha, Hunan, Peoples R China.
EM kangyijun@csu.edu.cn
CR Anitei MG, 2014, CLIN CANCER RES, V20, P1891, DOI 10.1158/1078-0432.CCR-13-2830
   Bai YH, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0662-z
   Baras AS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1134412
   Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862
   Cai JJ, 2019, J CANCER RES CLIN, V145, P1377, DOI 10.1007/s00432-019-02879-2
   Cao JF, 2017, ONCOTARGET, V8, P54722, DOI 10.18632/oncotarget.18039
   Champiat S, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27817
   Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003
   Cimino-Mathews A, 2016, HUM PATHOL, V47, P52, DOI 10.1016/j.humpath.2015.09.003
   de la Cruz-Merino L, 2017, INT REV CEL MOL BIO, V331, P1, DOI 10.1016/bs.ircmb.2016.09.008
   Dekutoski MB, 2016, J NEUROSURG-SPINE, V25, P59, DOI 10.3171/2015.11.SPINE15870
   Duchman KR, 2015, CANCER EPIDEMIOL, V39, P593, DOI 10.1016/j.canep.2015.05.001
   Finn OJ, 2012, ANN ONCOL, V23, P6, DOI 10.1093/annonc/mds256
   Fritzsching B, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.990800
   Fuchs B, 2009, CLIN ORTHOP RELAT R, V467, P510, DOI 10.1007/s11999-008-0495-x
   Hendry S, 2017, ADV ANAT PATHOL, V24, P311, DOI 10.1097/PAP.0000000000000161
   Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002
   Heymann MF, 2019, CELL IMMUNOL, V343, DOI 10.1016/j.cellimm.2017.10.011
   Hou YJ, 2018, CLIN BREAST CANCER, V18, pE237, DOI 10.1016/j.clbc.2017.11.001
   Huang X, 2018, J CANCER, V9, P2525, DOI 10.7150/jca.25011
   Hung GY, 2015, ANN SURG ONCOL, V22, P1080, DOI 10.1245/s10434-014-4154-z
   Janeway KA, 2012, CANCER-AM CANCER SOC, V118, P4597, DOI 10.1002/cncr.27414
   Joo MW, 2015, ANN SURG ONCOL, V22, P3557, DOI 10.1245/s10434-015-4414-6
   Kager L, 2017, FUTURE ONCOL, V13, P357, DOI 10.2217/fon-2016-0261
   Kim JY, 2017, PATHOLOGY, V49, P589, DOI 10.1016/j.pathol.2017.06.003
   Koh J, 2017, ONCOTARGET, V8, P26356, DOI 10.18632/oncotarget.15465
   Koirala P, 2016, SCI REP-UK, V6, DOI 10.1038/srep30093
   Kumar R, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0658-1
   Kurozumi S, 2017, MED MOL MORPHOL, V50, P185, DOI 10.1007/s00795-017-0170-y
   Liao YF, 2017, ONCOTARGET, V8, P30276, DOI 10.18632/oncotarget.16326
   Lim JBT, 2013, ACTA ORTHOP BELG, V79, P457
   Lin L, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1344-3
   Lin ZY, 2019, J CANCER, V10, P211, DOI 10.7150/jca.26444
   Lussier DM, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0067-z
   Lussier DM, 2015, J IMMUNOTHER, V38, P96, DOI 10.1097/CJI.0000000000000065
   Mandarano M, 2019, VIRCHOWS ARCH, V474, P159, DOI 10.1007/s00428-018-2483-1
   McLemore LE, 2018, APPL IMMUNOHISTO M M, V26, P611, DOI 10.1097/PAI.0000000000000485
   Meng Y, 2018, J CANCER, V9, P2938, DOI 10.7150/jca.22532
   Morihiro T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41177-2
   Najafi M, 2019, J CELL PHYSIOL, V234, P7983, DOI 10.1002/jcp.27553
   Ock CY, 2016, CLIN CANCER RES, V22, P2261, DOI 10.1158/1078-0432.CCR-15-2834
   Ohtaki Y, 2018, AM J TRANSL RES, V10, P3243
   Palmerini E, 2017, ONCOTARGET, V8, P111836, DOI 10.18632/oncotarget.22912
   Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111
   Robbins PF, 2017, CANCER J, V23, P138, DOI 10.1097/PPO.0000000000000267
   Romano E, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0059-z
   Scognamiglio G, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050790
   Shen JK, 2014, CANCER IMMUNOL RES, V2, P690, DOI 10.1158/2326-6066.CIR-13-0224
   Sobral-Leite M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1509820
   Stockmann C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00069
   Stovgaard ES, 2018, ACTA ONCOL, V57, P74, DOI 10.1080/0284186X.2017.1400180
   Sundara YT, 2017, CANCER IMMUNOL IMMUN, V66, P119, DOI 10.1007/s00262-016-1925-3
   Taube JM, 2018, MODERN PATHOL, V31, P214, DOI 10.1038/modpathol.2017.156
   Teng FF, 2015, TRANSL RES, V166, P721, DOI 10.1016/j.trsl.2015.06.019
   Thompson ED, 2017, GUT, V66, P794, DOI 10.1136/gutjnl-2015-310839
   Tokito T, 2016, EUR J CANCER, V55, P7, DOI 10.1016/j.ejca.2015.11.020
   van Erp AEM, 2017, ONCOTARGET, V8, P71371, DOI 10.18632/oncotarget.19071
   Wang D, 2019, CANCER RES, V79, P7, DOI 10.1158/0008-5472.CAN-18-1086
   Wang W, 2017, PATHOL RES PRACT, V213, P119, DOI 10.1016/j.prp.2016.11.009
   Wang Z, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00353
   Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177
   Zhang SY, 2019, ONCOL LETT, V17, P1062, DOI 10.3892/ol.2018.9682
   Zheng WJ, 2015, APMIS, V123, P102, DOI 10.1111/apm.12311
   Zou MX, 2019, NEUROSURGERY, V84, pE318, DOI 10.1093/neuros/nyy274
   Zou MX, 2018, CANCER IMMUNOL IMMUN, V67, P209, DOI 10.1007/s00262-017-2080-1
NR 65
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E240
EP E254
DI 10.1016/j.wneu.2019.05.121
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900030
PM 31128313
DA 2020-05-12
ER

PT J
AU Liu, QL
   Qi, CJ
   Zhang, YP
   Deng, L
   Li, G
   Su, WD
AF Liu, Qinglin
   Qi, Changjing
   Zhang, Yupeng
   Deng, Lin
   Li, Gang
   Su, Wandong
TI Low-Profile Visualized Intraluminal Support Stent-Only Technique for
   Intracranial Aneurysms-A Report of 12 Cases with Midterm Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Follow-up; Intracranial aneurysm; Stent-only technique
ID BASILAR ARTERY DISSECTION; SUBARACHNOID HEMORRHAGE; ENDOVASCULAR
   TREATMENT; INTRAVASCULAR STENT; FUSIFORM ANEURYSM; NATURAL-HISTORY;
   EPIDEMIOLOGY; NEUROFORM; PLACEMENT; MANAGEMENT
AB OBJECTIVE: To evaluate the safety and efficacy of stent-only technique with Low-profile Visualized Intraluminal Support (LVIS) for uncoilable intracranial aneurysms.
   METHODS: Twelve uncoilable aneurysms in 12 patients were treated with the stent-only technique in our department from January 1, 2016, to December 31, 2017. The characteristics of the aneurysms and the patients were analyzed. The midterm follow-up results of these patients also were analyzed.
   RESULTS: Twelve patients (7 male and 5 female) were enrolled in the series. The 12 aneurysms included 6 vertebralebasilar artery aneurysms, 3 internal carotid artery aneurysms (2 blood blister-Llike aneurysms and 1 posterior communicating artery aneurysm), 1 posterior cerebral artery dissecting, 1 anterior cerebral artery dissecting of the third segment, and 1 pseudoaneurysm at the first segment of the anterior cerebral artery. Seven aneurysms were? ruptured, whereas 5 remained unruptured. A total of 24 LVIS stents were deployed. Three aneurysms were covered by 3 overlapped stents, 6 aneurysms were covered by 2 stents, and the other 3 aneurysms were covered by 1 stent. All procedures were successful without any perioperative complications. Imaging follow-up between 3 and 10 months after operation was available in all 12 patients, with complete obliteration in 10 aneurysms, improvement in 1, and parent artery occlusion in 1.
   CONCLUSIONS: LVIS stent-only technique is safe and efficacious for uncoilable aneurysms, even for ruptured ones.
C1 [Liu, Qinglin; Zhang, Yupeng] Beijing Neurosurg Inst, Neurointervet Ctr, Beijing, Peoples R China.
   [Liu, Qinglin; Zhang, Yupeng] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
   [Qi, Changjing] Shandong Univ, Qilu Hosp, Nursing Dept, Jinan, Shandong, Peoples R China.
   [Liu, Qinglin; Deng, Lin; Li, Gang; Su, Wandong] Shandong Univ, Qilu Hosp, Neurosurg Dept, Jinan, Shandong, Peoples R China.
RP Su, WD (reprint author), Shandong Univ, Qilu Hosp, Neurosurg Dept, Jinan, Shandong, Peoples R China.
EM suwandong@sina.com
FU National Natural Science Foundation of Shandong Province of China
   [2017CXGC1203, 2017G006012, 2013GGE27006]; TaiShan Scholars of Shandong
   Province of China [ts201511093]
FX This work was supported by grants from the National Natural Science
   Foundation of Shandong Province of China (No. 2017CXGC1203, 2017G006012,
   2013GGE27006) and TaiShan Scholars of Shandong Province of China (No.
   ts201511093).
CR Aziz-Sultan A, 2008, J NEUROSURG, V108, P1101, DOI 10.3171/JNS/2008/108/6/1101
   Benndorf G, 2001, AM J NEURORADIOL, V22, P1844
   Bogason ET, 2014, NEUROSURGERY, V74, P227, DOI 10.1227/NEU.0000000000000240
   Brassel F, 2001, EUR RADIOL, V11, P1250, DOI 10.1007/s003300000697
   Brown RD, 2014, LANCET NEUROL, V13, P393, DOI 10.1016/S1474-4422(14)70015-8
   Cekirge HS, 2011, AM J NEURORADIOL, V32, P1262, DOI 10.3174/ajnr.A2475
   Durst CR, 2014, CLIN RADIOL, V69, pE471, DOI 10.1016/j.crad.2014.07.015
   Fiorella D, 2006, NEUROSURGERY, V59, P291, DOI 10.1227/01.NEU.0000223650.11954.6C
   Fiorella D, 2006, NEUROSURGERY, V59, P34, DOI 10.1227/01.NEU.0000219853.56553.71
   Geyik S, 2013, AM J NEURORADIOL, V34, P2157, DOI 10.3174/ajnr.A3574
   Grant RA, 2014, NEUROL RES, V36, P351, DOI 10.1179/1743132814Y.0000000321
   Helyar V, 2009, INTERV NEURORADIOL, V15, P87, DOI 10.1177/159101990901500114
   Higashida RT, 1997, J NEUROSURG, V87, P944, DOI 10.3171/jns.1997.87.6.0944
   Ingall T, 2000, STROKE, V31, P1054, DOI 10.1161/01.STR.31.5.1054
   Lawton MT, 2017, NEW ENGL J MED, V377, P257, DOI 10.1056/NEJMcp1605827
   Li L, 2016, INTERV NEURORADIOL, V22, P260, DOI 10.1177/1591019915622162
   Macdonald RL, 2017, LANCET, V389, P655, DOI 10.1016/S0140-6736(16)30668-7
   Malek AM, 1999, NEUROSURGERY, V45, P919, DOI 10.1097/00006123-199910000-00042
   Meng H, 2006, AM J NEURORADIOL, V27, P1861
   Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8
   Rohde S, 2010, NEURORADIOLOGY, V52, P231, DOI 10.1007/s00234-009-0603-y
   Su W, 2018, NEUROL RES, V40, P445, DOI 10.1080/01616412.2018.1457608
   Teng MMH, 2008, INTERV NEURORADIOL, V14, P75, DOI 10.1177/15910199080140S213
   Wang CC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180079
   Zhang XX, 2016, INTERV NEURORADIOL, V22, P659, DOI 10.1177/1591019916656584
NR 25
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E40
EP E47
DI 10.1016/j.wneu.2019.04.174
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900007
PM 31042597
DA 2020-05-12
ER

PT J
AU Longo, M
   Gelfand, Y
   Ramos, RD
   Echt, M
   Kinon, MD
   Yanamadala, V
   Yassari, R
AF Longo, Michael
   Gelfand, Yaroslav
   Ramos, Rafael De la Garza
   Echt, Murray
   Kinon, Merritt D.
   Yanamadala, Vijay
   Yassari, Reza
TI Perioperative Complications and Mortality Following Anterior Odontoid
   Screw Fixation in Elderly Patients: A National Database Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior screw fixation; Morbidity; Mortality; Odontoid fracture
ID FRACTURES; MANAGEMENT; EPIDEMIOLOGY; SURGERY; SPINE; RISK
AB OBJECTIVE: To identify predictors of short-term mortality and complications after anterior odontoid screw fixation.
   METHODS: This was a retrospective analysis of a national database. The American College of Surgeons National Quality Improvement Database was queried using Current Procedural Terminology codes to identify patients aged >= 60 years who underwent surgery for anterior fixation of odontoid fracture admitted from 2007 to 2016. Univariate analysis and subsequent multivariate analysis were used to analyze risk factors for postoperative complications and 30-day postoperative mortality. Complications were defined as surgical-site infection, wound breakdown, pneumonia, venous thromboembolism, stroke, myocardial infarction, sepsis, renal progressive renal insufficiency/acute kidney injury, or cardiac arrest.
   RESULTS: A total of 198 patients were identified. Mean age was 77.7 (+/- 8.7) years and 60.6% were female. Overall mortality rate was 7.6%, and the complication rate was 9.1%. In multivariate analysis, dependent functional status (0.012; odds ratio [OR] 5.2; 95% confidence interval [CI] 1.42-18.72) and preoperative systemic inflammatory response syndrome (P = 0.011; OR 6.2; 95% CI 1.52-25.79) predicted mortality. Emergency case status (P = 0.033; OR 3.4; 95% CI 1.10-10.70) predicted perioperative complications. Age was not significantly associated with either complications or mortality in multivariate analysis.
   CONCLUSIONS: Functional dependence and preoperative systemic inflammatory response syndrome predict mortality following odontoid screw placement. Although age often is considered a limiting factor in pursuing surgical intervention in patients with odontoid fracture, age did not independently increase odds of either complications or perioperative mortality in this analysis. Further studies are needed to explore these findings.
C1 [Longo, Michael; Gelfand, Yaroslav; Ramos, Rafael De la Garza; Echt, Murray; Kinon, Merritt D.; Yanamadala, Vijay; Yassari, Reza] Montefiore Med Ctr, Albert Einstein Coll Med, Spine Res Grp, Bronx, NY 10467 USA.
   [Gelfand, Yaroslav; Ramos, Rafael De la Garza; Echt, Murray; Kinon, Merritt D.; Yanamadala, Vijay; Yassari, Reza] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol Surg, Bronx, NY 10467 USA.
RP Yassari, R (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Spine Res Grp, Bronx, NY 10467 USA.; Yassari, R (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Neurol Surg, Bronx, NY 10467 USA.
EM ryassari@montefiore.org
OI Echt, Murray/0000-0002-4504-4918
CR Alluri RK, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.10.49
   ANDERSON LD, 1974, J BONE JOINT SURG AM, VA 56, P1663, DOI 10.2106/00004623-197456080-00017
   [Anonymous], 2016, USER GUIDE 2015 ACS
   [Anonymous], 2014, USER GUIDE 2014 ACS
   BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452
   Cacciola F, 2016, CERVICAL SPINE MINIM, P207
   Campbell-Furtick M, 2016, AM J SURG, V212, P781, DOI 10.1016/j.amjsurg.2015.12.018
   Carr D, 1996, AM AGING POPULATION
   Chao A, 2013, ASIAN J SURG, V36, P99, DOI 10.1016/j.asjsur.2013.01.001
   Chapman J, 2013, SPINE, V38, P1098, DOI 10.1097/BRS.0b013e318286f0cf
   Charles YP, 2019, ARCH ORTHOP TRAUM SU, V139, P43, DOI 10.1007/s00402-018-3050-6
   Chiba K, 1993, Eur Spine J, V2, P76, DOI 10.1007/BF00302707
   Cutler HS, 2018, GLOB SPINE J, V8, P47, DOI 10.1177/2192568217698132
   Dailey AT, 2010, J NEUROSURG-SPINE, V12, P1, DOI 10.3171/2009.7.SPINE08589
   Fagin AM, 2010, J TRAUMA, V68, P583, DOI 10.1097/TA.0b013e3181b23608
   Harolds JA, 2016, CLIN NUCL MED, V41, P933, DOI 10.1097/RLU.0000000000001388
   Iyer S, 2018, NEUROSURGERY, V82, P419, DOI 10.1093/neuros/nyx546
   Joaquim AF, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14781
   Joestl J, 2016, BONE JOINT J, V98B, P1222, DOI [10.1302/0301-620X.98B9.35216, 10.1302/0301-620X.98139.35216]
   Patel A, 2015, BRIT J NEUROSURG, V29, P249, DOI 10.3109/02688697.2014.958055
   Patterson JT, 2017, CLIN SPINE SURG, V30, pE1033, DOI 10.1097/BSD.0000000000000494
   RYAN MD, 1992, INJURY, V23, P38, DOI 10.1016/0020-1383(92)90123-A
   Smith JS, 2013, SPINE, V38, P2240, DOI 10.1097/BRS.0000000000000009
   Vasudevan K, 2014, CLIN NEUROL NEUROSUR, V126, P185, DOI 10.1016/j.clineuro.2014.09.006
   Walters BC, 2013, NEUROSURGERY, V60, P82, DOI 10.1227/01.neu.0000430319.32247.7f
   White AP, 2010, SPINE, V35, pS146, DOI 10.1097/BRS.0b013e3181d830a4
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E776
EP E781
DI 10.1016/j.wneu.2019.06.022
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900098
PM 31289000
DA 2020-05-12
ER

PT J
AU Lu, T
   Lu, Y
AF Lu, Teng
   Lu, Yi
TI Comparison of Biomechanical Performance Among Posterolateral Fusion and
   Transforaminal, Extreme, and Oblique Lumbar Interbody Fusion: A Finite
   Element Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biomechanical test; Extreme lumbar interbody fusion; Finite element
   analysis; Oblique lumbar interbody fusion; Posterolateral fusion;
   Transforaminal lumbar interbody fusion
ID END-PLATE STRENGTH; ADJACENT SEGMENTS; NATIONAL TRENDS; TLIF;
   SPONDYLOLISTHESIS; OUTCOMES; CAGES; FIXATION; SPINE; PLIF
AB OBJECTIVE: We compared the biomechanical differences among posterolateral fusion (PLF) and transforaminal, extreme, and oblique lumbar interbody fusion (TLIF, XLIF, and OLIF, respectively) procedures.
   METHODS: An intact finite element (FE) model of the L3-L5 lumbar spine was constructed. The PLF, TLIF with a banana-shaped cage, TLIF with a straight cage, XLIF, and OLIF procedures were simulated at the L4-L5 level. The range of motion (ROM) and stress peaks in the cortical endplate, cancellous bone, and posterior instrument were compared among the 5 constructs.
   RESULTS: The PLF construct had much greater ROM than did the other constructs (0.44 degrees-1.05 degrees vs. 0.28 degrees-0.72 degrees). The TLIF with a straight cage induced the greatest stress peaks in the endplate and cancellous bone (24.94-60.03 MPa and 0.72-1.96 MPa, respectively), followed by the TLIF with a banana-shaped cage (23.73-44.8 MPa and 0.6-1.36 MPa, respectively). The OLIF construct (16.76-32.41 MPa and 0.54-1.07 MPa, respectively) and XLIF construct (17.01-35.34 MPa and 0.56-1.12 MPa, respectively) induced much lower stress peaks in the endplate and cancellous bone. In the PLF construct, the stress peaks in the posterior instrument ranged from 244.6 to 377.4 MPa, significantly greater than those in the other constructs (123.9-237.4 MPa).
   CONCLUSION: The PLF had less stability than the other 3 fusion procedures owing to the greater ROM and stress peaks in the posterior instrument. The OLIF and XLIF induced fewer stress peaks in the cortical endplate and cancellous bone than did the TLIF procedure, which was beneficial for subsidence resistance and disc height and segmental angle maintenance.
C1 [Lu, Teng; Lu, Yi] Harvard Med Sch, Dept Neurosurg, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Lu, Teng] Xi An Jiao Tong Univ, Dept Orthoped, Sch Med, Xian, Shaanxi, Peoples R China.
RP Lu, Y (reprint author), Harvard Med Sch, Dept Neurosurg, Brigham & Womens Hosp, Boston, MA 02115 USA.
EM yilu1945@gmail.com
CR Ambati DV, 2015, SPINE J, V15, P1812, DOI 10.1016/j.spinee.2014.06.015
   Bhangoo SS, 2017, NEUROSURGERY, V81, pE11, DOI 10.1093/neuros/nyx061
   Chatham LS, 2017, J BIOMECH ENG-T ASME, V139, DOI 10.1115/1.4036312
   Cho WJ, 2008, CLIN BIOMECH, V23, P979, DOI 10.1016/j.clinbiomech.2008.02.008
   Choi WS, 2018, NEUROSURGERY, V82, P289, DOI 10.1093/neuros/nyx212
   Cole CD, 2009, CURR REV MUSCULOSKE, V2, P118, DOI 10.1007/s12178-009-9053-8
   Hackenberg L, 2005, EUR SPINE J, V14, P551, DOI 10.1007/s00586-004-0830-1
   Isaacs RE, 2016, SPINE, V41, pS133, DOI 10.1097/BRS.0000000000001472
   Kepler CK, 2014, SPINE, V39, P1584, DOI 10.1097/BRS.0000000000000486
   Kiapour A, 2012, SPINE, V37, pE581, DOI 10.1097/BRS.0b013e3182463775
   Kim HJ, 2014, YONSEI MED J, V55, P1386, DOI 10.3349/ymj.2014.55.5.1386
   Kim JT, 2015, EUR SPINE J, V24, P2588, DOI 10.1007/s00586-015-3899-9
   Kono Y, 2018, ASIAN SPINE J, V12, P356, DOI 10.4184/asj.2018.12.2.356
   Kuraishi S, 2016, ASIAN SPINE J, V10, P143, DOI 10.4184/asj.2016.10.1.143
   Lee KH, 2012, EUR SPINE J, V21, P2265, DOI 10.1007/s00586-012-2281-4
   Levin JM, 2018, SPINE J, V18, P1088, DOI 10.1016/j.spinee.2018.01.028
   Lin GX, 2018, WORLD NEUROSURG, V119, pE898, DOI 10.1016/j.wneu.2018.08.003
   Lowe TG, 2004, SPINE, V29, P2389, DOI 10.1097/01.brs.0000143623.18098.e5
   Lowe TG, 2002, CLIN ORTHOP RELAT R, P64
   Lowe TG, 2002, J SPINAL DISORD TECH, V15, P31, DOI 10.1097/00024720-200202000-00005
   Macki M, 2015, CLIN NEUROL NEUROSUR, V138, P117, DOI 10.1016/j.clineuro.2015.08.014
   Makanji H, 2018, EUR SPINE J, V27, P1868, DOI 10.1007/s00586-018-5544-x
   Mehta VA, 2011, NEUROL RES, V33, P38, DOI 10.1179/016164110X12681290831289
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Ordway NR, 2007, EUR SPINE J, V16, P2104, DOI 10.1007/s00586-007-0482-z
   Orita S, 2017, OPER TECH ORTHOP, V27, P223, DOI 10.1053/j.oto.2017.09.004
   Oxland TR, 2000, EUR SPINE J, V9, pS95, DOI 10.1007/PL00010028
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Palepu V, 2019, J BIOMECH ENG-T ASME, V141, DOI 10.1115/1.4042181
   Peck JH, 2018, J BIOMECH, V78, P87, DOI 10.1016/j.jbiomech.2018.07.022
   Polikeit A, 2003, EUR SPINE J, V12, P556, DOI 10.1007/s00586-003-0556-5
   Rajaee SS, 2012, SPINE, V37, P67, DOI 10.1097/BRS.0b013e31820cccfb
   Ruberte LM, 2009, J BIOMECH, V42, P341, DOI 10.1016/j.jbiomech.2008.11.024
   Sharabi M, 2018, BIOMECHANICS OF THE SPINE: BASIC CONCEPTS, SPINAL DISORDERS AND TREATMENTS, P105, DOI 10.1016/B978-0-12-812851-0.00007-0
   Shim CS, 2008, SPINE, V33, pE820, DOI 10.1097/BRS.0b013e3181894fb1
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Suda K, 2006, J SPINAL DISORD TECH, V19, P541, DOI 10.1097/01.bsd.0000211226.97178.b9
   Sudo H, 2006, J NEUROSURG-SPINE, V5, P150, DOI 10.3171/spi.2006.5.2.150
   Teng I, 2017, J CLIN NEUROSCI, V44, P11, DOI 10.1016/j.jocn.2017.06.013
   Thirukumaran CP, 2016, SPINE, V41, P490, DOI 10.1097/BRS.0000000000001238
   Xu DS, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.03.24
   Zhang ZJ, 2018, COMPUT BIOL MED, V95, P167, DOI 10.1016/j.compbiomed.2018.02.016
   Zhao X, 2018, WORLD NEUROSURG, V114, pE114, DOI 10.1016/j.wneu.2018.02.073
   Zhong ZC, 2013, COMPUT METHOD BIOMEC, V16, P943, DOI 10.1080/10255842.2011.645226
NR 44
TC 0
Z9 0
U1 9
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E890
EP E899
DI 10.1016/j.wneu.2019.06.074
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900111
PM 31226452
DA 2020-05-12
ER

PT J
AU Maldonado, AA
   Spinner, RJ
   Carter, JM
   Stone, JJ
   Howe, BM
AF Maldonado, Andres A.
   Spinner, Robert J.
   Carter, Jodi M.
   Stone, Jonathan J.
   Howe, B. Matthew
TI Clinical and Magnetic Resonance Imaging Longitudinal Follow-up of
   Neuromuscular Choristomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Choristoma; Magnetic resonance imaging; Neuromuscular choristoma
ID BENIGN TRITON TUMOR; SCIATIC-NERVE; HAMARTOMA; PLEXUS
AB INTRODUCTION: The natural history of growth and radiologic progression of neuromuscular choristomas (NMCs) remain unknown. The purpose of this study was to describe the radiologic growth pattern of NMCs and to determine how the pattern of growth relates to clinical progression.
   METHODS: A retrospective review was performed for patients with a confirmed diagnosis of NMC and at least 2 years of radiologic (magnetic resonance imaging [MRI]) follow-up. Medical records, including physical examinations and radiologic studies, were reviewed in detail. The NMC length and transverse dimensions were compared between serial MRI examinations.
   RESULTS: Eleven patients with a mean radiologic follow-up time of 5.6 years (range 2-19 years) were identified. Motor deficits occurred in 10 patients (90%), sensory deficits in 5 patients (45%), and neuropathic pain in 4 (36%) patients. Eight patients (73%) presented with manifestations of limb undergrowth, 2 (18%) with congenital hip dysplasia, and 1 with a cavus foot deformity. Progression of motor and sensory deficits was observed in 5 (45%) and 1 (9%) patients, respectively. The maximal length and height of the NMC was significantly (P < 0.05) longer (initial 218 +/- 118 mm vs. follow-up 270 +/- 135 mm) and larger (20 +/- 10 mm vs. 24 +/- 14 mm) on the follow-up scan. MRI demonstrated abnormalities that were in continuity along the longitudinal extent of the NMC.
   CONCLUSIONS: According to this small but relatively long-term follow-up cohort, the growth pattern of this lesion is slow but progressive. We found a longitudinal continuity pattern of growth in all MRI scans, often spanning a great distance.
C1 [Maldonado, Andres A.; Spinner, Robert J.; Stone, Jonathan J.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Carter, Jodi M.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
   [Howe, B. Matthew] Mayo Clin, Dept Radiol, Rochester, MN USA.
   [Maldonado, Andres A.] Goethe Univ Frankfurt Main, Acad Hosp, BG Trauma Ctr Frankfurt Main, Dept Plast Hand & Reconstruct Surg, Frankfurt, Germany.
RP Spinner, RJ (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM spinner.robert@mayo.edu
OI Maldonado, Andres A./0000-0002-3703-5667
CR AWASTHI D, 1991, J NEUROSURG, V75, P795, DOI 10.3171/jns.1991.75.5.0795
   Bassett GS, 1997, J BONE JOINT SURG AM, V79A, P1398, DOI 10.2106/00004623-199709000-00016
   BOMAN F, 1991, ANN PATHOL, V11, P36
   BONNEAU R, 1983, AM J SURG PATHOL, V7, P521, DOI 10.1097/00000478-198309000-00002
   Boyaci S, 2011, NEUROSURGERY, V68, pE551, DOI 10.1227/NEU.0b013e31820397e9
   Castro DE, 2005, AM J NEURORADIOL, V26, P967
   Hebert-Blouin MN, 2013, J NEUROSURG, V119, P252, DOI 10.3171/2013.3.JNS13444
   Hebert-Blouin MN, 2012, J NEUROSURG, V116, P399, DOI 10.3171/2011.6.JNS102171
   Kumar R, 2014, ACTA NEUROCHIR, V156, P1041, DOI 10.1007/s00701-014-2061-5
   Maher CO, 2002, J NEUROSURG, V96, P1123, DOI 10.3171/jns.2002.96.6.1123
   MARKEL SF, 1982, CANCER, V49, P140, DOI 10.1002/1097-0142(19820101)49:1<140::AID-CNCR2820490127>3.0.CO;2-5
   MITCHELL A, 1995, AM J CLIN PATHOL, V103, P460
   Niederhauser BD, 2013, SKELETAL RADIOL, V42, P567, DOI 10.1007/s00256-012-1546-7
   Nikolaou G, 2012, ORL J OTO-RHINO-LARY, V74, P246, DOI 10.1159/000342793
   O'Brien TG, 2016, MUSCLE NERVE, V54, P797, DOI 10.1002/mus.25177
   Park JE, 2019, CLIN IMAG, V55, P18, DOI 10.1016/j.clinimag.2019.01.003
   Thakrar R, 2014, PEDIATR DEVEL PATHOL, V17, P400, DOI 10.2350/14-04-1459-CR.1
   Tiffee JC, 1998, ARCH OTOLARYNGOL, V124, P212, DOI 10.1001/archotol.124.2.212
   VanDorpe J, 1997, AM J SURG PATHOL, V21, P1090, DOI 10.1097/00000478-199709000-00014
   Wilson TJ, 2018, NEUROSURGERY, V132, P2265
NR 20
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E761
EP E766
DI 10.1016/j.wneu.2019.06.018
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900096
PM 31203072
DA 2020-05-12
ER

PT J
AU Man, WT
   Wang, GH
AF Man, Weitao
   Wang, Guihuai
TI Incidence, Outcomes and Predictors of Primary Central Nervous System
   Melanoma: A SEER-Based Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Central nervous system; Incidence; Primary melanoma; SEER; Survival
ID PRIMARY LEPTOMENINGEAL MELANOMA; SPINAL MALIGNANT-MELANOMA; SURVIVAL;
   CNS
AB INTRODUCTION: Primary central nervous system (pCNS) melanoma is an extremely rare malignant tumor. We explored the incidence, outcomes, and predictors of pCNS melanoma.
   METHODS: We queried the Surveillance, Epidemiology, and End Results database to identify all patients diagnosed with pCNS melanoma during 1973-2015. Overall survival (OS) was obtained by using the Kaplan-Meier curves. Log-rank test was used to compare survival across groups of age, sex, race, tumor location, size, surgical resection, radiotherapy, chemotherapy and year of diagnosis. Cox regression was used for univariate and multivariate analysis of survival.
   RESULTS: A total of 84 pCNS melanomas were identified with a 5-year OS of 37.7%. The overall age-adjusted incidence rate was 0.52 per 10,000,000 person-years. Age <= 19 years (vs. age 20-59 years, hazard ratio [HR] = 2.37, 95% confidence interval [CI]: 1.11-5.07, P = 0.03) and intracranial location (vs. intraspinal, HR = 1.98, 95% CI: 1.04-3.77, P = 0.04) were associated with decreased survival rate. Gross total resection surgery (vs. partial resection, HR = 0.31, 95% CI: 0.15-0.66, P = 0.002) was associated with improved survival rate. There was no significant association between other demographic characteristics, tumor size, therapy methods, year of diagnosis, and OS.
   CONCLUSIONS: The overall age-adjusted incidence rate of pCNS melanoma is 0.52 per 10,000,000 person-years. Age <= 19 years and intracranial tumor location are independent risk factors of low survival rate, whereas gross total resection is associated with better survival rate.
C1 [Man, Weitao; Wang, Guihuai] Tsinghua Univ, Sch Clin Med, Beijing, Peoples R China.
   [Man, Weitao; Wang, Guihuai] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Neurosurg, Beijing, Peoples R China.
RP Wang, GH (reprint author), Tsinghua Univ, Sch Clin Med, Beijing, Peoples R China.; Wang, GH (reprint author), Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Neurosurg, Beijing, Peoples R China.
EM guihuai_wang@163.com
OI Wang, Guihuai/0000-0002-9254-5088
CR Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044
   ALLCUTT D, 1993, NEUROSURGERY, V32, P721, DOI 10.1227/00006123-199305000-00004
   Arai N, 2018, WORLD NEUROSURG, V117, P386, DOI 10.1016/j.wneu.2018.06.138
   Arantes M, 2011, CLIN NEUROL NEUROSUR, V113, P59, DOI 10.1016/j.clineuro.2010.08.003
   Barron J, 2007, CAN J NEUROL SCI, V34, P251, DOI 10.1017/S0317167100006156
   Biswas A, 2015, TURK NEUROSURG, V25, P201, DOI 10.5137/1019-5149.JTN.6568-12.1
   Byun DJ, 2017, NAT REV ENDOCRINOL, V13, P195, DOI 10.1038/nrendo.2016.205
   CAMPBELL AN, 1984, CANCER, V53, P974, DOI 10.1002/1097-0142(19840215)53:4<974::AID-CNCR2820530426>3.0.CO;2-C
   Crasto SG, 2001, SURG NEUROL, V55, P163, DOI 10.1016/S0090-3019(01)00348-2
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Freudenstein D, 2004, ZBL NEUROCHIR, V65, P146, DOI 10.1055/s-2004-816266
   Gibney GT, 2012, MELANOMA RES, V22, P177, DOI 10.1097/CMR.0b013e328352dbef
   HELSETH A, 1989, ACTA ONCOL, V28, P103, DOI 10.3109/02841868909111189
   Hung PC, 2019, PEDIATR NEONATOL, V60, P589, DOI 10.1016/j.pedneo.2018.10.003
   Jeong Dong Hwan, 2013, Brain Tumor Res Treat, V1, P116, DOI 10.14791/btrt.2013.1.2.116
   Kim MS, 2010, J KOREAN NEUROSURG S, V48, P157, DOI 10.3340/jkns.2010.48.2.157
   Li YP, 2014, ONCOL LETT, V8, P339, DOI 10.3892/ol.2014.2099
   Liubinas SV, 2010, J CLIN NEUROSCI, V17, P1227, DOI 10.1016/j.jocn.2010.01.017
   Lopez-Castilla JD, 2001, PEDIATR NEUROL, V24, P390, DOI 10.1016/S0887-8994(01)00261-2
   Makin GWJ, 1999, CANCER, V86, P878
   Mohammadpour A, 2019, J CELL PHYSIOL, V234, P3307, DOI 10.1002/jcp.27286
   Mort RL, 2015, DEVELOPMENT, V142, P1387, DOI 10.1242/dev.123729
   Nishihara M, 2009, NEUROL MED-CHIR, V49, P546, DOI 10.2176/nmc.49.546
   Pedersen M, 2013, CANCER DISCOV, V3, P458, DOI 10.1158/2159-8290.CD-12-0464
   Rodriguez-Cerdeira C, 2017, MEDIAT INFLAMM, V2017
   Suranagi Vijayalaxmi V, 2015, Asian J Neurosurg, V10, P39, DOI 10.4103/1793-5482.151508
   Tang K, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005805
   Wendel C, 2018, J NEUROL SURG PART A, V79, P344, DOI 10.1055/s-0038-1639504
   Wu L, 2017, J NEURO-ONCOL, V135, P513, DOI 10.1007/s11060-017-2593-7
   Wuerdeman Marc, 2018, Radiol Case Rep, V13, P424, DOI 10.1016/j.radcr.2018.01.009
   Zhang MZ, 2018, WORLD NEUROSURG, V114, P408, DOI 10.1016/j.wneu.2018.03.169
NR 31
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E782
EP E790
DI 10.1016/j.wneu.2019.06.030
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900099
PM 31203063
DA 2020-05-12
ER

PT J
AU Manfiotto, M
   Beccaria, K
   Rolland, A
   Paternoster, G
   Plas, B
   Boetto, S
   Vinchon, M
   Mottolese, C
   Beuriat, PA
   Szathmari, A
   Di Rocco, F
   Scavarda, D
   Seigneuret, SE
   Wrobleski, SI
   Klein, O
   Joud, A
   Gimbert, E
   Jecko, V
   Vignes, JR
   Roujeau, T
   Dupont, A
   Zerah, M
   Lonjon, M
AF Manfiotto, Marie
   Beccaria, Kevin
   Rolland, Alice
   Paternoster, Giovanna
   Plas, Benjamin
   Boetto, Sergio
   Vinchon, Mathieu
   Mottolese, Carmine
   Beuriat, Pierre-Aurelien
   Szathmari, Alexandru
   Di Rocco, Federico
   Scavarda, Didier
   Seigneuret, Eric S.
   Wrobleski, Isabelle S.
   Klein, Olivier
   Joud, Antony
   Gimbert, Edouard
   Jecko, Vincent
   Vignes, Jean Rodolphe
   Roujeau, Thomas
   Dupont, Audrey
   Zerah, Michel
   Lonjon, Michel
TI Decompressive Craniectomy in Children with Severe Traumatic Brain
   Injury: A Multicenter Retrospective Study and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain injuries; Child; Decompressive craniectomy; Traumatic
ID GLASGOW COMA SCALE; REFRACTORY INTRACRANIAL HYPERTENSION; SINGLE-CENTER
   EXPERIENCE; PEDIATRIC-PATIENTS; OUTCOME SCALE; PREDICTORS
AB BACKGROUND: Severe traumatic brain injury (TBI) is the most common cause of disability in children. Refractory increased intracranial pressure can be a therapeutic challenge. Decompressive craniectomy can be proposed when medical management is insufficient, but its place is not clearly defined in guidelines. The aim of this study was to identify prognostic factors in children with TBI.
   METHODS: We performed a retrospective, multicenter study to analyze long-term outcomes of 150 children with severe TBI treated by decompressive craniectomy and to identify prognostic factors.
   RESULTS: A satisfactory neurologic evolution (represented by a King's Outcome Scale for Childhood Head Injury score >3) was observed in 62% of children with a mean follow-up of 3.5 years. Mortality rate was 17%. Prognostic factors associated with outcome were age, initial Glasgow Coma Scale score, presence of mydriasis, neuromonitoring values (maximal intracranial pressure >30 mm Hg), and radiologic findings (Rotterdam score >= 4).
   CONCLUSIONS: This study in a large population confirms that children with severe TBI treated by decompressive craniectomy can achieve a good neurologic outcome. Further studies are needed to clarify the use of this surgery in the management of children with severe TBI.
C1 [Manfiotto, Marie; Lonjon, Michel] CHU Nice, Serv Neurochirurg, Nice, France.
   [Beccaria, Kevin; Paternoster, Giovanna; Zerah, Michel] Hop Necker Enfants Malad, Serv Neurochirurg Pediat, Paris, France.
   [Rolland, Alice; Roujeau, Thomas] CHU Montpellier, Serv Neurochirurg, Montpellier, France.
   [Plas, Benjamin; Boetto, Sergio] CHU Toulouse, Serv Neurochirurg, Toulouse, France.
   [Vinchon, Mathieu] CHU Lille, Serv Neurochirurg, Lille, France.
   [Mottolese, Carmine; Beuriat, Pierre-Aurelien; Szathmari, Alexandru; Di Rocco, Federico] Hop Femme Mere Enfant, Serv Neurochirurg Pediat, Lyon, France.
   [Scavarda, Didier] Hop La Timone, Serv Neurochirurg Pediat, Marseille, France.
   [Seigneuret, Eric S.; Wrobleski, Isabelle S.] CHU Grenoble, Serv Neurochirurg Pediat, Grenoble, France.
   [Klein, Olivier; Joud, Antony] CHU Nancy, Serv Neurochirurg Pediat, Nancy, France.
   [Gimbert, Edouard; Jecko, Vincent; Vignes, Jean Rodolphe] CHU Bordeaux, Serv Neurochirurg Pediat, Bordeaux, France.
   [Dupont, Audrey] Hop Lenval, Serv Reanimat Pediat, Nice, France.
RP Manfiotto, M (reprint author), CHU Nice, Serv Neurochirurg, Nice, France.
EM marie.manfiotto@hotmail.com
OI Di Rocco, Federico/0000-0003-2145-5533
CR Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310
   Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728
   ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010
   Appelboom G, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.8.FOCUS11177
   Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161
   Beuriat PA, 2015, J NEUROSURG SCI, V59, P405
   BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170
   Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001
   Calvert S, 2008, DEV MED CHILD NEUROL, V50, P426, DOI 10.1111/j.1469-8749.2008.02061.x
   Cambra FJ, 2010, AN PEDIATR, V73, P12, DOI 10.1016/j.anpedi.2010.02.011
   Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120
   Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3
   Guresir E, 2012, NEUROSURGERY, V70, P881, DOI 10.1227/NEU.0b013e318237a6a6
   Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x
   Hieu PD, 1996, CHILD NERV SYST, V12, P270
   Jacob AT, 2011, PEDIATR NEUROSURG, V47, P81, DOI 10.1159/000329624
   Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268
   Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0
   Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337
   Khan SA, 2014, CHILD NERV SYST, V30, P277, DOI 10.1007/s00381-013-2225-2
   Liesemer K, 2014, PEDIATR CRIT CARE ME, V15, P554, DOI 10.1097/PCC.0000000000000150
   Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668
   Mhanna MJ, 2015, J NEUROSURG-PEDIATR, V16, P508, DOI 10.3171/2014.10.PEDS14117
   Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876
   Oluigbo CO, 2012, J NEUROSURG-PEDIATR, V9, P125, DOI 10.3171/2011.11.PEDS09449
   Polin RS, 2003, CRIT CARE, V7, P409, DOI 10.1186/cc2370
   Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355
   Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361
   Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010
   Simma B, 2002, INTENS CARE MED, V28, P1000, DOI 10.1007/s00134-002-1333-3
   Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502
   Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410
   Thomale UW, 2010, CHILD NERV SYST, V26, P1563, DOI 10.1007/s00381-010-1103-4
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E56
EP E62
DI 10.1016/j.wneu.2019.04.215
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900009
PM 31054345
DA 2020-05-12
ER

PT J
AU Mao, G
   Gigliotti, MJ
   Tomycz, N
   Altman, DT
   Philp, FH
AF Mao, Gordon
   Gigliotti, Michael J.
   Tomycz, Nestor
   Altman, Daniel T.
   Philp, Frances Hite
TI Clinical Outcomes After Spine Surgery for Traumatic Injury in the
   Octogenarian Population
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Fusion; Mortality; Octogenarian; Outcomes; Spine; Trauma
ID AGED 80 YEARS; ELDERLY-PATIENTS; CORD-INJURY; COMPLICATIONS; MORTALITY;
   FRACTURES; PREDICTORS; SURVIVAL; STENOSIS; OLDER
AB OBJECTIVE: To review the surgical outcomes of the octogenarian population at a single institution after spinal traumatic injury.
   METHODS: Patients with both radiographic and clinical evidence of acute traumatic spine injury were reviewed using an institutional trauma survey to determine patient demographics and outcome data in a population of patients aged 80 years and older.
   RESULTS: Thirty-nine patients aged 80 years and older underwent surgical intervention for acute spinal trauma. There were 25 cases of cervical spine and 14 cases of thoracolumbar spine surgical intervention. Falls were the number one cause of acute spinal injury (31/39, 71%). Major respiratory disorders were the most common postoperative adverse event (12/39, 31%). Five patients experienced superficial wound dehiscence, fascial dehiscence, superficial infection, or delayed wound erosion. Patients were either discharged to home (10.5%), inpatient rehabilitation, (38.5%), skilled nursing facilities (17.9%), or long-term care facilities (17.9%). The postoperative mortality was 10.3%.
   CONCLUSIONS: Although the octogenarian population has increased risk for postoperative events after acute spinal injuries, surgical intervention may be worthwhile in the elderly population. Although direct surgical complication rates are not higher, medical risks are significantly higher after surgery.
C1 [Mao, Gordon; Gigliotti, Michael J.; Tomycz, Nestor] Allegheny Hlth Network, Dept Neurosurg, Pittsburgh, PA 15212 USA.
   [Altman, Daniel T.] Allegheny Hlth Network, Dept Orthoped Surg, Pittsburgh, PA USA.
   [Philp, Frances Hite] Allegheny Hlth Network, Dept Surg, Pittsburgh, PA USA.
RP Mao, G (reprint author), Allegheny Hlth Network, Dept Neurosurg, Pittsburgh, PA 15212 USA.
EM Godon.Mao@ahn.org
CR Amin S, 2014, J BONE MINER RES, V29, P581, DOI 10.1002/jbmr.2072
   Balabaud L, 2014, EUR J ORTHOP SURG TR, V25, P205
   Bromage DI, 2016, J AM HEART ASSOC, V5, P1
   Camurcu Y, 2017, J ARTHROPLASTY, V32, P3038, DOI 10.1016/j.arth.2017.04.042
   Fassett DR, 2007, J NEUROSURG-SPINE, V7, P277, DOI 10.3171/SPI-07/09/277
   Geiger F, 2007, ARCH ORTHOP TRAUM SU, V127, P959, DOI 10.1007/s00402-007-0423-7
   Gerhardt J, 2018, WORLD NEUROSURG, V112, pE555, DOI 10.1016/j.wneu.2018.01.082
   Graver Adam, 2015, HSS J, V11, P223, DOI 10.1007/s11420-015-9435-y
   Hwabejire JO, 2014, JAMA SURG, V149, P1054, DOI 10.1001/jamasurg.2014.473
   Imajo Y, 2017, J ORTHOP SCI, V22, P10, DOI 10.1016/j.jos.2016.08.014
   Imajo Y, 2015, J ORTHOP SCI, V20, P38, DOI 10.1007/s00776-014-0656-6
   Kobayashi K, 2017, GLOB SPINE J, V7, P636, DOI 10.1177/2192568217716144
   Liao JC, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1239-9
   Marbacher S, 2016, SPINE, V41, P893, DOI 10.1097/BRS.0000000000001364
   Nanjo Y, 2013, ARCH ORTHOP TRAUM SU, V133, P1243, DOI 10.1007/s00402-013-1808-4
   O'Connor PJ, 2005, ARCH PHYS MED REHAB, V86, P37, DOI 10.1016/j.apmr.2004.03.018
   Puvanesarajah V, 2017, SPINE, V42, pE509, DOI 10.1097/BRS.0000000000001876
   Raffo CS, 2006, SPINE, V31, P99, DOI 10.1097/01.brs.0000192678.25586.e5
   Rajpal S, 2018, ACTA NEUROCHIR, V160, P171, DOI 10.1007/s00701-017-3384-9
   Roche JJW, 2005, BMJ-BRIT MED J, V331, P1374, DOI 10.1136/bmj.38643.663843.55
   ROGERS MA, 1990, J APPL PHYSIOL, V68, P2195
   Saleh A, 2017, SPINE J, V17, P1106, DOI 10.1016/j.spinee.2017.03.019
   Scarano KA, 2018, GERIATR ORTHOP SURG, V9, DOI 10.1177/2151459318758106
   Sieber Frederick E, 2011, Anesthesiol Clin, V29, P83, DOI 10.1016/j.anclin.2010.11.011
   Smith HE, 2008, J SPINAL DISORD TECH, V21, P535, DOI 10.1097/BSD.0b013e318163570b
   Torpilliesi T, 2012, J AM MED DIR ASSOC, V13, pe1
   Wilson JR, 2012, J NEUROSURG-SPINE, V17, P11, DOI 10.3171/2012.4.AOSPINE1245
NR 27
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E97
EP E103
DI 10.1016/j.wneu.2019.05.048
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900014
PM 31100527
DA 2020-05-12
ER

PT J
AU Mao, JN
   Zhu, Q
   Ma, Y
   Lan, Q
   Cheng, Y
   Liu, GD
AF Mao, Jinning
   Zhu, Qing
   Ma, Ying
   Lan, Qing
   Cheng, Yuan
   Liu, Guodong
TI Fenestration of Lamina Terminalis During Anterior Circulation Aneurysm
   Clipping on Occurrence of Shunt-Dependent Hydrocephalus After Aneurysmal
   Subarachnoid Hemorrhage: Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Hydrocephalus; Lamina terminalis fenestration; Meta-analysis
ID RUPTURED INTRACRANIAL ANEURYSMS; MICROSURGICAL FENESTRATION;
   ORBITOPTERIONAL APPROACH; MEMBRANE
AB BACKGROUND: Shunt-dependent hydrocephalus (SDH) is a common complication after aneurysmal subarachnoid hemorrhage and affects its outcome significantly. Whether fenestration of the lamina terminalis (FLT) during anterior circulation aneurysm clipping for aneurysmal subarachnoid hemorrhage can decrease the occurrence of SDH is still controversial.
   METHODS: Ovid and PubMed databases were retrieved by the following key words: "hydrocephalus," "subarachnoid hemorrhage," "aneurysm," "fenestration," and "lamina terminalis." The Cochran-Mantel-Haenszel test was used to compare overall incidence of SDH.
   RESULTS: The literatures were searched, and 15 were included involving 2839 patients. The overall incidence of SDH in fenestrated cohort was 11.4%, compared with 15.3% in the nonfenestrated cohort (P = 0.008). The relative risk of SDH in fenestrated cohort was 0.67 (95% confidence interval 0.50-0.90).
   CONCLUSIONS: This meta-analysis suggests that FLT during anterior circulation aneurysm clipping reduces the incidence of SDH. However, a well-designed, randomized controlled trial is necessary to prove the efficacy of FLT to reduce SDH.
C1 [Mao, Jinning] Chongqing Med Univ, Dept Cardiol, Affiliated Hosp 2, Chongqing, Peoples R China.
   [Zhu, Qing; Lan, Qing] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Peoples R China.
   [Ma, Ying; Cheng, Yuan; Liu, Guodong] Chongqing Med Univ, Affiliated Hosp 2, Dept Neurosurg, Chongqing, Peoples R China.
RP Liu, GD (reprint author), Chongqing Med Univ, Affiliated Hosp 2, Dept Neurosurg, Chongqing, Peoples R China.
EM lgd28@suda.edu.cn
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [81401500]; Science Foundation of Jiangsu Province
   [BK20140298]; Natural Science Research Oroject of University in Jiangsu
   Province [14KJD320003]; High-level Medical Reserved Personnel Training
   Project of Chongqing
FX This study was supported by National Nature Science Foundation of China
   (81401500), Science Foundation of Jiangsu Province (BK20140298), and
   Natural Science Research Oroject of University in Jiangsu Province
   (14KJD320003), High-level Medical Reserved Personnel Training Project of
   Chongqing.
CR Akyuz M, 2006, ACTA NEUROCHIR, V148, P725, DOI 10.1007/s00701-006-0738-0
   Andaluz N, 2004, NEUROSURGERY, V55, P1050, DOI 10.1227/01.NEU.0000140837.63105.78
   Andaluz N, 2003, NEUROSURGERY, V52, P1140, DOI 10.1227/01.NEU.0000057834.83222.9F
   Bae In-Seok, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P78, DOI 10.7461/jcen.2014.16.2.78
   Chohan MO, 2013, J NEUROSURG, V119, P629, DOI 10.3171/2013.5.JNS13251
   Dehdashti AR, 2004, J NEUROSURG, V101, P402, DOI 10.3171/jns.2004.101.3.0402
   Demirgil BT, 2003, MINIM INVAS NEUROSUR, V46, P344, DOI 10.1055/s-2003-812500
   Germanwala AV, 2010, NEUROSURG CLIN N AM, V21, P263, DOI 10.1016/j.nec.2009.10.013
   Gonzalez LF, 2004, NEUROSURGERY, V54, P1031, DOI 10.1227/01.NEU.0000117124.32806.37
   Hatefi M, 2015, J CLIN DIAGN RES, V9, DOI 10.7860/JCDR/2015/13603.6264
   Kim JM, 2006, J KOREAN MED SCI, V21, P113, DOI 10.3346/jkms.2006.21.1.113
   Komotar RJ, 2008, NEUROSURGERY, V62, P123, DOI 10.1227/01.NEU.0000311069.48862.C8
   Komotar RJ, 2002, NEUROSURGERY, V51, P1403, DOI 10.1097/00006123-200212000-00010
   Lu JJ, 2012, J CLIN NEUROSCI, V19, P669, DOI 10.1016/j.jocn.2011.06.032
   Nam KH, 2010, J KOREAN NEUROSURG S, V48, P313, DOI 10.3340/jkns.2010.48.4.313
   O'Kelly CJ, 2009, J NEUROSURG, V111, P1029, DOI 10.3171/2008.9.JNS08881
   Schmieder K, 1999, ZBL NEUROCHIR, V60, P133
   SINDOU M, 1994, ACTA NEUROCHIR, V127, P15, DOI 10.1007/BF01808539
   Tao CY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005727
   Tomasello F, 1999, NEUROSURGERY, V45, P827, DOI 10.1097/00006123-199910000-00018
   Winkler EA, 2018, J NEUROSURG, V129, P1166, DOI 10.3171/2017.5.JNS163271
   Xie ZY, 2017, WORLD NEUROSURG, V106, P844, DOI 10.1016/j.wneu.2017.06.119
   Yonekawa Y, 1998, NEUROL MED-CHIR, V38, P45, DOI 10.2176/nmc.38.suppl_45
NR 23
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E1
EP E5
DI 10.1016/j.wneu.2019.01.270
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900002
PM 30780038
DA 2020-05-12
ER

PT J
AU Marek, T
   Mahan, MA
   Carter, JM
   Amrami, KK
   Atkinson, JLD
   Spinner, RJ
AF Marek, Tomas
   Mahan, Mark A.
   Carter, Jodi M.
   Amrami, Kimberly K.
   Atkinson, John L. D.
   Spinner, Robert J.
TI Can Lipomatosis of the Nerve Occur or Extend Intradurally?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fibrolipomatous hamartoma; Intradural; Lipomatosis of nerve; Spinal
   nerves
ID FIBROLIPOMATOUS HAMARTOMA; NEURAL FIBROLIPOMA
AB BACKGROUND: Diverse adipose lesions can affect peripheral nerves, including an intrinsic disorder known as lipomatosis of nerve (LN). This condition leads to massive nerve enlargement and has often been associated with nerve territory overgrowth. Although LN has been well documented as a peripheral lesion, it is uncertain whether LN can occur or extend intradurally.
   METHODS: In the present 2-part study, we searched our institutional database and the world literature to identify any case of LN occurring or extending intradurally. Strict pathognomonic imaging and histopathologic features of LN were required to be present.
   RESULTS: We did not identify any case of LN that had occurred or extended intradurally in our institution. Specifically, in our database, we found no case of intradural LN, and an evaluation of the imaging studies of proximal examples of LN did not show any extension proximal to the spinal foramen. Our literature search identified 208 reports of potential interest, of which only 3 had reported on spinal LN. Although 2 of the 3 cases showed some similarities to LN, none had demonstrated features diagnostic for LN and none had demonstrated nerve territory overgrowth. A review of 16 cases of LN in proximal locations summarized in a recently reported systematic review did not reveal any cases with LN proximal to the foramen or in an intradural location.
   CONCLUSION: A review of our institutional cases and reported cases did not show any example of LN extending or occurring intradurally. It appears that LN is a benign tumor-like nerve lesion that is without a central location, unlike more well-known tumors such as schwannomas.
C1 [Marek, Tomas; Atkinson, John L. D.; Spinner, Robert J.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55904 USA.
   [Carter, Jodi M.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
   [Amrami, Kimberly K.] Mayo Clin, Dept Radiol, Rochester, MN USA.
   [Mahan, Mark A.] Univ Utah, Dept Neurol Surg, Salt Lake City, UT USA.
   [Marek, Tomas] Charles Univ Prague, Fac Med 1, Prague, Czech Republic.
RP Spinner, RJ (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55904 USA.
EM spinner.robert@mayo.edu
RI Marek, Tomas/T-4236-2018
OI Marek, Tomas/0000-0003-3588-9236
CR Blackburn PR, MOD PATHOL
   Chen KY, 2019, WORLD NEUROSURG, V121, P156, DOI 10.1016/j.wneu.2018.09.156
   de Poorter JJ, 2015, EUR SPINE J, V24, pS485, DOI 10.1007/s00586-014-3506-5
   Friedmann DR, 2015, OTOLARYNG CLIN N AM, V48, P461, DOI 10.1016/j.otc.2015.02.006
   LEE M, 1995, J NEUROSURG, V82, P394, DOI 10.3171/jns.1995.82.3.0394
   Lee YK, 1998, J KOREAN NEUROSURG S, V27, P1455, DOI [10.3340/jkns.2008.44.6.392, DOI 10.3340/JKNS.2008.44.6.392]
   Mahan MA, 2014, SKELETAL RADIOL, V43, P963, DOI 10.1007/s00256-014-1871-0
   Mahan MA, 2014, J NEUROSURG, V120, P1118, DOI 10.3171/2013.12.JNS13174
   Mahan MA, 2014, WORLD NEUROSURG, V82, P492, DOI 10.1016/j.wneu.2013.09.005
   Mahan MA, 2013, J NEUROSURG, V119, P934, DOI 10.3171/2013.7.JNS13537
   Mahan MA, 2013, J NEUROSURG-SPINE, V19, P392, DOI 10.3171/2012.11.SPINE12909
   Mahan MA, 2013, ACTA NEUROCHIR, V155, P1131, DOI 10.1007/s00701-013-1707-z
   Marek T, 2020, J NEUROSURG, V132, P1286, DOI 10.3171/2018.12.JNS183050
   Marek T, 2018, ACTA NEUROCHIR, V160, P2209, DOI 10.1007/s00701-018-3677-7
   Marek T, 2019, CLIN ANAT, V32, P166, DOI 10.1002/ca.23279
   Marek T, 2018, CLIN ANAT, V31, P1210, DOI 10.1002/ca.23190
   Marom EM, 1999, SKELETAL RADIOL, V28, P260, DOI 10.1007/s002560050512
   Missori P, 2012, J NEUROSURG-SPINE, V17, P449, DOI 10.3171/2012.8.SPINE11971
   Morota N, 2017, J NEUROSURG-PEDIATR, V19, P428, DOI 10.3171/2016.10.PEDS16247
   Nardone R, 2008, MUSCLE NERVE, V38, P1046, DOI 10.1002/mus.21002
   Netto AB, 2012, J NEUROSCI RURAL PRA, V3, P89, DOI 10.4103/0976-3147.91972
   Nodelman LO, 2016, J FOOT ANKLE SURG, V55, P1063, DOI 10.1053/j.jfas.2015.12.012
   Parihar A, 2014, MALAY J PATHOL, V36, P59
   Pomares G, 2017, HAND SURG REHABIL, V36, P58, DOI 10.1016/j.hansur.2016.05.007
   Prasad NK, 2017, J NEUROSURG, V126, P933, DOI 10.3171/2016.2.JNS151051
   Prasad NK, 2017, NEUROSURGERY, V80, P226, DOI 10.1093/neuros/nyw028
   Reina MA, 2009, ACTA ANAESTH BELG, V60, P7
   Rios JJ, 2013, HUM MOL GENET, V22, P444, DOI 10.1093/hmg/dds440
   SAUER JM, 1985, SKELETAL RADIOL, V13, P276, DOI 10.1007/BF00355349
   SILVERMAN TA, 1985, AM J SURG PATHOL, V9, P7, DOI 10.1097/00000478-198501000-00004
   Spinner RJ, 2012, J NEUROSURG, V116, P418, DOI 10.3171/2011.8.JNS101292
   SUNDERLAND S, 1945, BRAIN, V68, P118, DOI 10.1093/brain/68.2.118
   Tokyol Cigdem, 2015, Asian J Neurosurg, V10, P341, DOI 10.4103/1793-5482.162727
   Wehrli L, 2018, PLAST RECONSTR SURG, V142, P148, DOI 10.1097/PRS.0000000000004455
   Yildiz H, 2006, NEURORADIOLOGY, V48, P1, DOI 10.1007/s00234-005-0001-z
NR 35
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E555
EP E560
DI 10.1016/j.wneu.2019.05.213
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900070
PM 31154102
DA 2020-05-12
ER

PT J
AU Matsumoto, Y
   Ichikawa, T
   Kurozumi, K
   Otani, Y
   Date, I
AF Matsumoto, Yuji
   Ichikawa, Tomotsugu
   Kurozumi, Kazuhiko
   Otani, Yoshihiro
   Date, Isao
TI Clinicopathological and Genetic Features of Supratentorial Cortical
   Ependymomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE C11orf95-RELA fusion; Cortical; Ependymoma; L1CAM
ID CENTRAL-NERVOUS-SYSTEM; C11ORF95-RELA FUSIONS; HEMISPHERIC EPENDYMOMAS;
   ANAPLASTIC EPENDYMOMA; CASE SERIES; GRADE-II; BRAIN; RECURRENT;
   SURVIVAL; TUMORS
AB OBJECTIVE: Supratentorial cortical ependymomas (CEs) are rare. These lesions, selectively occurring in the superficial cortex, have not been fully characterized. We analyzed the clinicopathological and genetic features of CEs.
   METHODS: Eight patients with CEs from our institution and 84 other reported CE cases were included in the present study. We retrospectively reviewed their clinical characteristics, imaging findings, treatment methods, pathological features, molecular status, and clinical outcomes.
   RESULTS: The median age at diagnosis of our 8 patients was 7.5 years. The mean tumor diameter was 70 mm. All the tumors had a cystic appearance, and calcification was observed in 6. Gross total resection was achieved in 6 patients and subtotal resection in 2 patients. Of the 8 tumors, 7 were World Health Organization grade III and 1 was World Health Organization grade II. Six tumors were immunopositive for L1 cell adhesion molecule (L1CAM). We investigated the presence of C11orf95-RELA fusion in 5 patients, all of whom exhibited it. Postoperative radiotherapy was performed for all patients with grade III tumors, except for children aged <3 years. Although 4 patients developed recurrence, all were alive throughout the follow-up period. Compared with previously reported CEs, our patients were younger and had larger tumors; however, the clinical outcomes did not differ significantly.
   CONCLUSIONS: Although most CEs in our group were immunopositive for L1CAM and showed C11orf95-RELA fusion, which have been associated with a poor prognosis in supratentorial ependymomas, all our patients had good outcomes. Gross total resection and adjuvant radiotherapy contributed to the relatively favorable prognosis of CEs compared with other supratentorial ependymomas.
C1 [Matsumoto, Yuji; Ichikawa, Tomotsugu; Kurozumi, Kazuhiko; Otani, Yoshihiro; Date, Isao] Okayama Univ, Grad Sch Med, Dept Neurol Surg, Okayama, Japan.
   [Ichikawa, Tomotsugu] Kagawa Prefectural Cent Hosp, Dept Neurosurg, Takamatsu, Kagawa, Japan.
   [Otani, Yoshihiro] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurosurg, Houston, TX 77030 USA.
RP Ichikawa, T (reprint author), Okayama Univ, Grad Sch Med, Dept Neurol Surg, Okayama, Japan.; Ichikawa, T (reprint author), Kagawa Prefectural Cent Hosp, Dept Neurosurg, Takamatsu, Kagawa, Japan.
EM tomoichi@cc.okayama-u.ac.jp
OI Otani, Yoshihiro/0000-0002-1615-5125; Kurozumi,
   Kazuhiko/0000-0002-6942-9919
CR Beniwal M, 2018, J NEUROSCI RURAL PRA, V9, P264, DOI 10.4103/jnrp.jnrp_31_18
   Bijwe Sanjay, 2015, Asian J Neurosurg, V10, P162, DOI 10.4103/1793-5482.152111
   Bouffet E, 2012, INT J RADIAT ONCOL, V83, P1541, DOI 10.1016/j.ijrobp.2011.10.039
   Davis MJ, 2011, J NEURO-ONCOL, V104, P599, DOI 10.1007/s11060-010-0525-x
   Elsharkawy AE, 2013, CASE REP ONCOL MED, DOI 10.1155/2013/354873
   Fujimoto K, 1999, NEUROL SURG TOKYO, V27, P843
   Fukuoka K, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0630-1
   Ghani ARI, 2008, SINGAP MED J, V49, pE192
   Gilbert MR, 2010, CURR NEUROL NEUROSCI, V10, P240, DOI 10.1007/s11910-010-0109-3
   Grajkowska W, 2009, FOLIA NEUROPATHOL, V47, P354
   Hamano E, 2010, NEUROL MED-CHIR, V50, P150, DOI 10.2176/nmc.50.150
   Hiniker A, 2013, CLIN NEUROPATHOL, V32, P318, DOI 10.5414/NP300593
   Hollon T, 2016, J NEUROSURG, V125, P410, DOI 10.3171/2015.7.JNS151187
   Iqbal MS, 2013, CLIN ONCOL-UK, V25, P726, DOI 10.1016/j.clon.2013.07.009
   Jakacki RI, 2016, J NEURO-ONCOL, V129, P131, DOI 10.1007/s11060-016-2155-4
   Kharosekar Hrushikesh, 2018, Asian J Neurosurg, V13, P144, DOI 10.4103/1793-5482.181133
   Khatri D, 2019, J CLIN NEUROSCI, V60, P49, DOI 10.1016/j.jocn.2018.10.036
   Khatua S, 2017, EUR J CANCER, V70, P34, DOI 10.1016/j.ejca.2016.10.013
   Kiefel H, 2011, TRENDS MOL MED, V17, P178, DOI 10.1016/j.molmed.2010.11.005
   Koshy M, 2011, J NEURO-ONCOL, V105, P583, DOI 10.1007/s11060-011-0624-3
   Lee SK, 2011, J KOREAN NEUROSURG S, V50, P244, DOI 10.3340/jkns.2011.50.3.244
   Lehman NL, 2003, PEDIATR NEUROSURG, V39, P50, DOI 10.1159/000070881
   Lehman NL, 2008, J NEUROPATH EXP NEUR, V67, P900, DOI 10.1097/NEN.0b013e31818521cd
   Liu ZG, 2014, NEUROPATHOLOGY, V34, P243, DOI 10.1111/neup.12087
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Malgulwar PB, 2018, J NEURO-ONCOL, V138, P29, DOI 10.1007/s11060-018-2767-y
   Mangalore Sandhya, 2015, Asian J Neurosurg, V10, P276, DOI 10.4103/1793-5482.162702
   Mansur DB, 2005, INT J RADIAT ONCOL, V61, P387, DOI 10.1016/j.ijrobp.2004.06.002
   McGuire CS, 2009, J NEUROSURG, V110, P725, DOI 10.3171/2008.9.JNS08117
   Merchant TE, 2008, INT J RADIAT ONCOL, V71, P87, DOI 10.1016/j.ijrobp.2007.09.037
   Merchant TE, 2009, LANCET ONCOL, V10, P258, DOI 10.1016/S1470-2045(08)70342-5
   Metellus P, 2007, BRAIN, V130, P1338, DOI 10.1093/brain/awm046
   Miyazawa T, 2007, BRAIN TUMOR PATHOL, V24, P35, DOI 10.1007/s10014-007-0215-3
   Mohaghegh Mohammad Reza, 2015, Adv Biomed Res, V4, P72, DOI 10.4103/2277-9175.153896
   MOHER D, 2009, PLOS MED, V339, DOI DOI 10.1136/BMJ.B2535
   Nakamizo S, 2012, J CLIN NEUROSCI, V19, P1453, DOI 10.1016/j.jocn.2011.09.039
   Ng David W K, 2012, Surg Neurol Int, V3, P107, DOI 10.4103/2152-7806.101001
   Niazi TN, 2009, J NEURO-ONCOL, V91, P323, DOI 10.1007/s11060-008-9717-z
   Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI 10.1093/neuonc/now207
   Pajtler KW, 2015, CANCER CELL, V27, P728, DOI 10.1016/j.ccell.2015.04.002
   Parker M, 2014, NATURE, V506, P451, DOI 10.1038/nature13109
   Pejavar S, 2012, J NEURO-ONCOL, V106, P367, DOI 10.1007/s11060-011-0671-9
   Pietsch T, 2014, ACTA NEUROPATHOL, V127, P609, DOI 10.1007/s00401-014-1264-4
   Reni M, 2004, CANCER, V100, P1221, DOI 10.1002/cncr.20074
   Rigante L, 2013, ACTA NEUROL BELG, V113, P523, DOI 10.1007/s13760-012-0157-3
   Rogers L, 2005, J NEUROSURG, V102, P629, DOI 10.3171/jns.2005.102.4.0629
   Romero FR, 2012, CASE REP ONCOL MED, DOI 10.1155/2012/541431
   Roncaroli Federico, 2005, Neurosurgery, V57, pE192, DOI 10.1227/01.NEU.0000164171.29292.D6
   Ruda R, 2018, NEURO-ONCOLOGY, V20, P445, DOI 10.1093/neuonc/nox166
   Saito T, 1999, NEUROL SURG TOKYO, V27, P1139
   Sato Y, 2000, NEUROPATHOLOGY, V20, P315, DOI 10.1046/j.1440-1789.2000.00355.x
   Takeshima H, 2002, NEUROL MED-CHIR, V42, P166, DOI 10.2176/nmc.42.166
   Tensaouti F, 2017, RADIOTHER ONCOL, V122, P362, DOI 10.1016/j.radonc.2016.12.025
   Van Gompel JJ, 2011, J NEUROSURG, V114, P1187, DOI 10.3171/2010.12.JNS10846
   Vera-Bolanos E, 2015, NEURO-ONCOLOGY, V17, P440, DOI 10.1093/neuonc/nou162
   Wang MM, 2018, WORLD NEUROSURG, V112, pE772, DOI 10.1016/j.wneu.2018.01.153
   Yadav YR, 2009, NEUROL INDIA, V57, P213, DOI 10.4103/0028-3886.51301
   Yamasaki K, 2015, J KOREAN NEUROSURG S, V57, P487, DOI 10.3340/jkns.2015.57.6.487
   Yurt A, 2010, CLIN MED RES, V8, P25, DOI 10.3121/cmr.2010.877
   Zhang J, 2014, CLIN NEUROL NEUROSUR, V124, P142, DOI 10.1016/j.clineuro.2014.06.016
NR 60
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E417
EP E428
DI 10.1016/j.wneu.2019.05.166
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900053
PM 31150846
DA 2020-05-12
ER

PT J
AU Nakanishi, T
   Mitra, B
   Ackland, H
   O'Reilly, G
   Cameron, P
AF Nakanishi, Taizo
   Mitra, Biswadev
   Ackland, Helen
   O'Reilly, Gerard
   Cameron, Peter
TI Time in Collars and Collar-Related Complications in Older Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical collars; Cervical spine immobilization; Collar-related
   complications; Collar-related pressure ulcers; Hospital-acquired
   pneumonia; Older patients; Ventilator-associated pneumonia
ID VENTILATOR-ASSOCIATED PNEUMONIA; CERVICAL-SPINE INJURIES; RISK-FACTORS;
   PRESSURE ULCERS; TRAUMA PATIENTS; INTERFACE PRESSURE; ELDERLY-PATIENTS;
   IMMOBILIZATION; GUIDELINES; EPIDEMIOLOGY
AB BACKGROUND: Cervical spine immobilization, including cervical collars, has been recommended in most trauma guidelines. However, cervical spine immobilization can be associated with harm, and an increasing body of evidence has demonstrated associated complications. We hypothesized that older trauma patients placed in cervical collars for >24 hours were at greater risk of developing collar-related complications compared with those placed in cervical collars for <= 24 hours.
   METHODS: We conducted a retrospective cohort study of injured patients without a fracture of the cervical vertebrae, aged >= 65 years, who had been placed in a cervical collar during the period from January 1, 2015 to December 31, 2015. The primary outcome was the composite of the in-hospital development of nosocomial pneumonia and collar-related pressure ulcers.
   RESULTS: A total of 1154 patients had been treated with cervical collars during the study period, and 61 (5.1%) had developed collar-related complications. Male sex, a lower initial Glasgow Coma Scale score, a history of congestive heart failure, a history of chronic obstructive pulmonary disease or asthma, operative management, and longer hospital and intensive care unit lengths of stay demonstrated a univariable association with collar-related complications (P < 0.10), in addition to a duration in the collar for >24 hours. An independent association was found between collar duration >24 hours and the outcome of interest (adjusted odds ratio, 2.50; 95% confidence interval, 1.16-5.39; P = 0.02).
   CONCLUSIONS: Among older patients without a cervical vertebral fracture, duration of cervical collar use for >24 hours was associated with the development of collar-related complications. We recommend attention to early collar clearance for older trauma patients.
C1 [Nakanishi, Taizo] Univ Fukui Hosp, Dept Emergency Med, Fukui, Japan.
   [Mitra, Biswadev; Ackland, Helen; O'Reilly, Gerard; Cameron, Peter] Alfred Hosp, Emergency & Trauma Ctr, Melbourne, Vic, Australia.
   [Mitra, Biswadev; Ackland, Helen; O'Reilly, Gerard; Cameron, Peter] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic, Australia.
   [Mitra, Biswadev; Ackland, Helen; O'Reilly, Gerard; Cameron, Peter] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic, Australia.
RP Nakanishi, T (reprint author), Univ Fukui Hosp, Dept Emergency Med, Fukui, Japan.
EM taizo81@gmail.com
RI Mitra, Biswadev/AAC-3724-2019
CR Ackland HM, 2007, SPINE, V32, P423, DOI 10.1097/01.brs.0000255096.52871.4e
   Ambulance Victoria, 2019, CLIN PRACT GUID AMB
   ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224
   BAUER D, 1988, ANN EMERG MED, V17, P915, DOI 10.1016/S0196-0644(88)80671-1
   Baumgarten M, 2006, J GERONTOL A-BIOL, V61, P749, DOI 10.1093/gerona/61.7.749
   Benger J, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-44
   Bergeron E, 2003, J TRAUMA, V54, P478, DOI 10.1097/01.TA.0000037095.83469.4C
   Blecher GE, 2008, INJURY, V39, P586, DOI 10.1016/j.injury.2007.10.021
   Bridges EJ, 2003, MIL MED, V168, P280
   Cameron PA, 2014, BRIT J ANAESTH, V113, P226, DOI 10.1093/bja/aeu231
   Chendrasekhar A, 1998, AM SURGEON, V64, P604
   Como JJ, 2009, J TRAUMA, V67, P651, DOI 10.1097/TA.0b013e3181ae583b
   Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002
   Denver D, 2015, J EMERG MED, V49, P294, DOI 10.1016/j.jemermed.2015.03.005
   Edsberg LE, 2016, J WOUND OSTOMY CONT, V43, P585, DOI 10.1097/WON.0000000000000281
   EMORI TG, 1991, AM J INFECT CONTROL, V19, P19, DOI 10.1016/0196-6553(91)90157-8
   Frankel H, 2007, AM SURGEON, V73, P1215
   Ham HW, 2014, J TRAUMA NURS, V21, P94, DOI 10.1097/JTN.0000000000000046
   Harris MB, 2010, J BONE JOINT SURG AM, V92A, P567, DOI 10.2106/JBJS.I.00003
   Healey CD, 2017, J TRAUMA ACUTE CARE, V83, P119, DOI 10.1097/TA.0000000000001497
   HEATH KJ, 1994, ANAESTHESIA, V49, P843, DOI 10.1111/j.1365-2044.1994.tb04254.x
   Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203
   Hosmer D.W., 2013, APPL LOGISTIC REGRES
   Houghton DJ, 1996, BRIT J NEUROSURG, V10, P501, DOI 10.1080/02688699647168
   Jacobson TM, 2008, J NURS CARE QUAL, V23, P283, DOI 10.1097/01.NCQ.0000324595.29956.90
   Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353
   Kwan I, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002803
   Majercik S, 2005, J TRAUMA, V59, P350, DOI 10.1097/01.ta.0000174671.07664.7c
   Malik SA, 2008, EUR SPINE J, V17, P585, DOI 10.1007/s00586-008-0603-3
   Margolis DJ, 2003, AGE AGEING, V32, P259, DOI 10.1093/ageing/32.3.259
   Mobbs RJ, 2002, ANZ J SURG, V72, P389, DOI 10.1046/j.1445-2197.2002.02462.x
   MOCK C, 2004, GUIDELINES ESSENTIAL
   Morris CGT, 2003, ANAESTHESIA, V58, P1051, DOI 10.1046/j.1365-2044.2003.03519.x
   National Institute for Health and Care Excellence, 2016, SPIN INJ ASS IN MAN
   Newgard CD, 2010, ACAD EMERG MED, V17, P142, DOI 10.1111/j.1553-2712.2009.00647.x
   Norton L., 2010, SPINAL CORD INJURY A
   Patel PJ, 2002, SEMIN RESP CRIT CARE, V23, P415, DOI 10.1055/s-2002-35712
   PODOLSKY S, 1983, J TRAUMA, V23, P461, DOI 10.1097/00005373-198306000-00003
   Powers Jan, 2006, J Trauma Nurs, V13, P198
   Purvis TA, 2017, AM J EMERG MED, V35, P860, DOI 10.1016/j.ajem.2017.01.045
   Restrepo MI, 2010, INFECT CONT HOSP EP, V31, P509, DOI 10.1086/651669
   Stambolis V, 2003, DYSPHAGIA, V18, P39, DOI 10.1007/s00455-002-0083-2
   Stiell IG, 2001, JAMA-J AM MED ASSOC, V286, P1841, DOI 10.1001/jama.286.15.1841
   Sundstrom T, 2014, J NEUROTRAUM, V31, P531, DOI 10.1089/neu.2013.3094
   Terpenning MS, 2001, J AM GERIATR SOC, V49, P557, DOI 10.1046/j.1532-5415.2001.49113.x
   Tescher AN, 2007, J TRAUMA, V63, P1120, DOI 10.1097/TA.0b013e3180487d0f
   The State Trauma Committee, 2017, VICT STAT TRAUM SYST
   Thompson DA, 2006, ANN SURG, V243, P547, DOI 10.1097/01.sla.0000207097.38963.3b
   TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523
   Wyndaele M, 2006, SPINAL CORD, V44, P523, DOI 10.1038/sj.sc.3101893
NR 50
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E478
EP E484
DI 10.1016/j.wneu.2019.05.187
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900061
PM 31150857
DA 2020-05-12
ER

PT J
AU Naraoka, M
   Fumoto, T
   Li, YC
   Katagai, T
   Ohkuma, H
AF Naraoka, Masato
   Fumoto, Toshio
   Li, Yuchen
   Katagai, Takeshi
   Ohkuma, Hiroki
TI The Role of Intracranial Pressure and Subarachnoid Blood Clots in Early
   Brain Injury After Experimental Subarachnoid Hemorrhage in Rats
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apoptosis; Brain edema; Early brain injury; Intracranial pressure;
   Subarachnoid hemorrhage
ID DELAYED CEREBRAL-ISCHEMIA; POSSIBLE INVOLVEMENT; APOPTOSIS; FLOW;
   INFLAMMATION; INHIBITION; MODEL; ACTIVATION; VASOSPASM; NECROSIS
AB OBJECTIVE: Early brain injury after subarachnoid hemorrhage (SAH), which is considered a main factor leading to poor outcome, is believed to be caused by the increase of intracranial pressure (ICP) and/or the presence of subarachnoid blood clots (SBC) itself. The purpose of this study was to examine whether ICP or SBC is more important to neurologic deficit in the presence of apoptosis or edema.
   METHODS: A total of 50 rats were allocated to 3 groups: an endovascular perforation SAH model (the SAH group), a cisterna magna saline injection model (the saline injection group), and a cisterna magna sham injection model (the sham injection group). Statistical analysis of correlations among the ICP, the grade of clot volume, neuronal apoptosis, brain water content (brain edema), and neurologic deficit was performed.
   RESULTS: In the SAH group, each of increased ICP and clot volume was correlated with neuronal apoptosis and brain edema. In the saline injection group, increased ICP was associated with apoptosis, but it did not correlate with brain edema. Neuronal apoptosis (r = 0.75; P < 0.01) and brain edema (r = 0.89; P < 0.01) correlated independently with neurologic deficit in the SAH group.
   CONCLUSIONS: The present study suggests that neuronal apoptosis is caused mainly by increased ICP, whereas brain edema is induced by SBC, and increased ICP could aggravate it in the presence of SBC. Brain edema could affect neurologic deficit, but apoptosis alone may be less influential. Not only ICP but also SBC seem important for brain damage in the acute stage of SAH.
C1 [Naraoka, Masato; Fumoto, Toshio; Li, Yuchen; Katagai, Takeshi; Ohkuma, Hiroki] Hirosaki Univ, Sch Med & Hosp, Dept Neurosurg, Hirosaki, Aomori, Japan.
RP Naraoka, M (reprint author), Hirosaki Univ, Sch Med & Hosp, Dept Neurosurg, Hirosaki, Aomori, Japan.
EM nessun@hirosaki-u.ac.jp
OI Naraoka, Masato/0000-0001-6490-527X
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP16K19993]
FX This work was supported by JSPS KAKENHI grant number JP16K19993.
CR Al-Mufti F, 2017, WORLD NEUROSURG, V107, P148, DOI [10.1016/J.WNEU.2017.07.114, 10.1016/j.wneu.2017.07.114]
   Ansar S, 2009, J NEUROSURG, V111, P978, DOI 10.3171/2007.3.16738
   Barry CM, 2011, BRAIN RES, V1389, P143, DOI 10.1016/j.brainres.2011.02.082
   BEDERSON JB, 1995, STROKE, V26, P1086, DOI 10.1161/01.STR.26.6.1086
   Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283
   Caner B, 2012, J NEUROCHEM, V123, P12, DOI 10.1111/j.1471-4159.2012.07939.x
   Chang CZ, 2016, WORLD NEUROSURG, V86, P349, DOI 10.1016/j.wneu.2015.08.071
   Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F
   Dai YX, 2015, ANN CLIN LAB SCI, V45, P615
   Dai YX, 2014, NEUROCHEM RES, V39, P1603, DOI 10.1007/s11064-014-1355-6
   Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658
   ECKER A, 1951, J NEUROSURG, V8, P660, DOI 10.3171/jns.1951.8.6.0660
   Fan LF, 2017, FREE RADICAL BIO MED, V112, P336, DOI 10.1016/j.freeradbiomed.2017.08.003
   Friedrich B, 2012, J CEREBR BLOOD F MET, V32, P447, DOI 10.1038/jcbfm.2011.154
   Friedrich V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080101
   Fujii M, 2013, TRANSL STROKE RES, V4, P432, DOI 10.1007/s12975-013-0257-2
   Gao C, 2008, AUTON NEUROSCI-BASIC, V141, P22, DOI 10.1016/j.autneu.2008.04.007
   GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627
   Hartings JA, 2017, BRAIN, V140, P2673, DOI 10.1093/brain/awx214
   Heuer GG, 2004, J NEUROSURG, V101, P408, DOI 10.3171/jns.2004.101.3.0408
   Hockel K, 2012, STROKE, V43, P227, DOI 10.1161/STROKEAHA.111.626168
   Hollig A, 2015, PLOS ONE, V10, P1
   Hu HM, 2018, NEUROSCI BULL, V34, P951, DOI 10.1007/s12264-018-0232-8
   King JT, 1997, NEUROIMAG CLIN N AM, V7, P659
   Lilla N, 2018, WORLD NEUROSURG, V116, pE57, DOI 10.1016/j.wneu.2018.03.205
   Liu X, 2016, CELL MOL BIOL, V62, P38, DOI 10.14715/cmb/2016.62.11.7
   Lv T, 2017, NEUROCHEM RES, V42, P1044, DOI 10.1007/s11064-016-2138-z
   Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942
   Maddahi A, 2011, J CEREBR BLOOD F MET, V31, P144, DOI 10.1038/jcbfm.2010.62
   Nair P, 2014, METHOD ENZYMOL, V544, P99, DOI 10.1016/B978-0-12-417158-9.00005-4
   OHKUMA H, 1993, STROKE, V24, P1541, DOI 10.1161/01.STR.24.10.1541
   Park S, 2004, STROKE, V35, P2412, DOI 10.1161/01.STR.0000141162.29864.e9
   Pluta RM, 2009, NEUROL RES, V31, P151, DOI 10.1179/174313209X393564
   Prunell GF, 2005, J NEUROSURG, V102, P1046, DOI 10.3171/jns.2005.102.6.1046
   Rozpedek W, 2016, CURR MOL MED, V16, P533, DOI 10.2174/1566524016666160523143937
   Schwartz AY, 2000, J NEUROSCI METH, V96, P161, DOI 10.1016/S0165-0270(00)00156-4
   Sehba FA, 2012, PROG NEUROBIOL, V97, P14, DOI 10.1016/j.pneurobio.2012.02.003
   Sherchan P, 2011, J NEUROTRAUM, V28, P2503, DOI 10.1089/neu.2011.1864
   SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58
   Sugawara T, 2008, J NEUROSCI METH, V167, P327, DOI 10.1016/j.jneumeth.2007.08.004
   SUZUKI S, 1990, Neurologia Medico-Chirurgica, V30, P309, DOI 10.2176/nmc.30.309
   Thal SC, 2009, J NEUROSURG, V111, P988, DOI 10.3171/2009.3.JNS08412
   Topkoru B, 2017, CURR DRUG TARGETS, V18, P1424, DOI 10.2174/1389450117666160905112923
   Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275
   Wang CX, 2015, BRAIN RES, V1594, P245, DOI 10.1016/j.brainres.2014.10.014
   Wang Y, 2009, EUR J NEUROSCI, V30, P2258, DOI 10.1111/j.1460-9568.2009.07025.x
   Wang Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00500-5
NR 47
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E63
EP E72
DI 10.1016/j.wneu.2019.05.009
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900010
PM 31100532
DA 2020-05-12
ER

PT J
AU Netuka, D
   Masopust, V
   Fundova, P
   Astl, J
   Skoloudik, D
   Majovsky, M
   Benes, V
AF Netuka, David
   Masopust, Vaclav
   Fundova, Petra
   Astl, Jaromir
   Skoloudik, David
   Majovsky, Martin
   Benes, Vladimir
TI Olfactory Results of Endoscopic Endonasal Surgery for Pituitary Adenoma:
   A Prospective Study of 143 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic endonasal approach; Olfaction; Olfactory function; Pituitary
   adenoma; Transsphenoidal surgery
ID QUALITY-OF-LIFE; SEPTAL FLAP RECONSTRUCTION; DIRECT TRANSNASAL APPROACH;
   TRANSSPHENOIDAL APPROACH; ODOR IDENTIFICATION; OUTCOMES; PRESERVATION;
   DISCRIMINATION; TUMORS
AB BACKGROUND: Clinical examination, including preand postoperative assessment of olfaction function, should be included in evaluating surgical outcomes in patients with pituitary adenomas. Most of the studies are lacking assessment of olfactory function.
   METHODS: A prospective study of 143 patients who underwent surgical resection of pituitary adenomas from January 2014 to December 2017 was performed. Data on clinical presentation, pre-and postoperative neurologic, endocrinologic, and ophthalmologic examinations, complications, and follow-up outpatient examinations were recorded. Olfactory function was assessed using the Sniffin' Sticks odor identification test preoperatively, postoperatively (3 months), and 1 year after surgery.
   RESULTS: Normosmia was present preoperatively in 93.7% of patients, postoperatively in 95.8% of patients, and in 95.1% 1 year postsurgery. Hyposmia was present preoperatively in 4.2% of patients, postoperatively in 2.1% of patients, and in 1.4% 1 year after surgery. Anosmia was present preoperatively in 2.1% of patients, postoperatively in 2.1% of patients, and in 3.5% 1 year after surgery. In patients with preoperative normosmia, postoperative hyposmia and anosmia were present in 1.5% of patients. There were no differences according to age, sex, size, or type of pituitary adenoma.
   CONCLUSIONS: Assessment of olfactory function should be included in the analysis of pituitary adenoma surgery results. This prospective study showed low risk of olfaction deterioration if an endoscopic endonasal approach is used without any mucosal flaps for skull base reconstruction. Further studies that include objective olfaction assessment are warranted.
C1 [Netuka, David; Masopust, Vaclav; Majovsky, Martin; Benes, Vladimir] Charles Univ Prague, Dept Neurosurg & Neurooncol, Fac Med 1, Prague, Czech Republic.
   [Netuka, David; Masopust, Vaclav; Fundova, Petra; Astl, Jaromir; Majovsky, Martin; Benes, Vladimir] Mil Univ Hosp, Prague, Czech Republic.
   [Fundova, Petra; Astl, Jaromir] Charles Univ Prague, Dept Otorhinolaryngol & Maxillofacial Surg, Fac Med 3, Prague, Czech Republic.
   [Skoloudik, David] Palacky Univ Olomouc, Fac Hlth Sci, Ctr Sci & Res, Olomouc, Czech Republic.
RP Netuka, D (reprint author), Charles Univ Prague, Dept Neurosurg & Neurooncol, Fac Med 1, Prague, Czech Republic.; Netuka, D (reprint author), Mil Univ Hosp, Prague, Czech Republic.
EM netuka.david@gmail.com
RI Majovsky, Martin/AAC-6748-2020
OI Majovsky, Martin/0000-0001-7725-5181
FU Czech Health Research Council [AZV 15-32791A, 15-31379A]
FX The study was supported by Czech Health Research Council grants AZV
   15-32791A and 15-31379A.
CR Actor B, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.7.FOCUS10162
   Alobid I, 2013, NEUROSURGERY, V72, P540, DOI 10.1227/NEU.0b013e318282a535
   Chaaban MR, 2015, AM J RHINOL ALLERGY, V29, P365, DOI 10.2500/ajra.2015.29.4206
   Croy I, 2014, CHEM SENSES, V39, P185, DOI 10.1093/chemse/bjt072
   Eordogh M, 2017, LARYNSCOPE INVESTIG, V2, P281, DOI 10.1002/lio2.82
   GRIFFITH HB, 1987, J NEUROSURG, V66, P140, DOI 10.3171/jns.1987.66.1.0140
   Hart CK, 2010, OTOLARYNG HEAD NECK, V142, P95, DOI 10.1016/j.otohns.2009.09.032
   Harvey RJ, 2015, J NEUROL SURG PART B, V76, P464, DOI 10.1055/s-0035-1554905
   Hong SD, 2016, WORLD NEUROSURG, V87, P162, DOI 10.1016/j.wneu.2015.12.050
   Hong SD, 2015, AM J RHINOL ALLERGY, V29, P221, DOI 10.2500/ajra.2015.29.4165
   Hong SD, 2014, AM J RHINOL ALLERGY, V28, P517, DOI 10.2500/ajra.2014.28.4109
   Hummel T, 2007, EUR ARCH OTO-RHINO-L, V264, P237, DOI 10.1007/s00405-006-0173-0
   Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39
   Ikeda K, 1999, AM J RHINOL, V13, P45, DOI 10.2500/105065899781389957
   Kahilogullari G, 2013, LARYNGOSCOPE, V123, P2112, DOI 10.1002/lary.24037
   Kim BY, 2014, LARYNGOSCOPE, V124, P2470, DOI 10.1002/lary.24674
   Kim DH, 2017, J CRANIOFAC SURG, V28, P959, DOI 10.1097/SCS.0000000000003423
   Kim DH, 2017, J CRANIOFAC SURG, V28, P1005, DOI 10.1097/SCS.0000000000003580
   Kim SW, 2013, LARYNGOSCOPE, V123, P1602, DOI 10.1002/lary.24107
   Kobal G., 1996, Rhinology (Utrecht), V34, P222
   Koren I, 1999, LARYNGOSCOPE, V109, P1838, DOI 10.1097/00005537-199911000-00022
   Little AS, 2015, J NEUROSURG, V122, P1458, DOI 10.3171/2014.10.JNS141624
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Majovsky M, 2019, NEUROSURG REV, V42, P395, DOI 10.1007/s10143-018-1034-1
   Rotenberg BW, 2011, LARYNGOSCOPE, V121, P1611, DOI 10.1002/lary.21890
   Sowerby LJ, 2013, INT FORUM ALLERGY RH, V3, P217, DOI 10.1002/alr.21103
   Soyka MB, 2017, AM J RHINOL ALLERGY, V31, P334, DOI 10.2500/ajra.2017.31.4463
   Starke RM, 2013, J CLIN ENDOCR METAB, V98, P3190, DOI 10.1210/jc.2013-1036
   Tam S, 2013, INT FORUM ALLERGY RH, V3, P62, DOI 10.1002/alr.21069
   Tan LKS, 1995, BRIT J NEUROSURG, V9, P739, DOI 10.1080/02688699550040693
   Thompson CF, 2015, OTOLARYNG CLIN N AM, V48, P795, DOI 10.1016/j.otc.2015.05.007
   Upadhyay S, 2017, LARYNGOSCOPE, V127, P1970, DOI 10.1002/lary.26546
   Wang SS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000465
   Youssef AS, 2016, ACTA NEUROCHIR, V158, P1965, DOI 10.1007/s00701-016-2922-1
NR 34
TC 1
Z9 1
U1 8
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E907
EP E914
DI 10.1016/j.wneu.2019.05.061
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900113
PM 31103759
DA 2020-05-12
ER

PT J
AU Petrowskit, K
   Ritzka, D
   Frohner, P
   Leimert, M
AF Petrowskit, Katja
   Ritzka, Desiree
   Frohner, Patrick
   Leimert, Mario
TI Psychosocial Stress Reactivity as Predictor of Operative Outcome in
   Lumbar Disc Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic stress; Cortisol; Lumbar disc operations; TSST
ID POSTOPERATIVE ANXIETY; PREOPERATIVE ANXIETY; RISK-FACTORS; PAIN;
   CORTISOL; RECOVERY; RESPONSES; SATISFACTION; ADJUSTMENT; DEPRESSION
AB BACKGROUND: A large proportion of the population suffers from chronic back pain. For optimal treatment, the question arises which patients would benefit from conservative therapy and for whom lumbar disc surgery is most appropriate. It seems reasonable to analyze the impact of paraclinical parameters on the operation outcome to identify patients who would benefit less from surgery or need special pre-/postoperative medical care.
   MATERIALS AND METHODS: From March 2012 to July 2014, 32 patients were treated via microscopically supported interlaminar fenestration and discectomy at the Department of Neurosurgery, University Hospital Carl Gustav Carus Dresden. One day before the operation, a cortisol survey was made during the stress response of the Trier Social Stress Test. At the same time, a survey of relevant questionnaires was conducted by which the postoperative symptom experience was made operational and comparable with the evaluation of the same information thirty days afterwards.
   RESULTS: It could be shown that there is a connection between cortisol reactivity and the pain burden following operations. Patients with a greater cortisol reaction under stress exposition partially experienced more intense postoperative pain than the patients with a lower cortisol reaction. However, this relationship could only be explained by single significant results, whereas further calculations could not produce any significance.
   CONCLUSIONS: Cortisol reactivity seems to be associated with pain development. The inconsistent findings in empiricism as well as in this investigation are indicative of a complex association of postoperative pain and cortisol reactivity, which needs to be examined further.
C1 [Petrowskit, Katja; Ritzka, Desiree; Frohner, Patrick] Univ Med Mainz, Clin & Policlin Psychosomat Med & Psychotherapy, Med Psychol & Med Sociol, Mainz, Germany.
   [Petrowskit, Katja] Tech Univ Dresden, Univ Hosp Carl Gustav Carus Dresden, Dept Psychotherapy & Psychosomat Med, Dresden, Germany.
   [Ritzka, Desiree] Univ Witten Herdecke, Dept Psychol & Psychotherapy, Witten, Germany.
   [Leimert, Mario] Interdisciplinary Spine Ctr, Asklepios Orthoped Clin Hohwald, Hohwald, Germany.
RP Petrowskit, K (reprint author), Univ Med Mainz, Clin & Policlin Psychosomat Med & Psychotherapy, Med Psychol & Med Sociol, Mainz, Germany.; Petrowskit, K (reprint author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus Dresden, Dept Psychotherapy & Psychosomat Med, Dresden, Germany.
EM Kpetrows@uni-mainz.de
CR Aghamohammadi Kalkhoran M, 2007, ANN GEN PSYCHIATR, V6, P17, DOI DOI 10.1186/1744-859X-6-17
   ANDERSON EA, 1987, J CONSULT CLIN PSYCH, V55, P513, DOI 10.1037/0022-006X.55.4.513
   Bauknecht M, 2009, GEK BANDSCHEIBEN REP
   Berchtold R, 2006, CHIRURGIE
   BLUMER D, 1982, J NERV MENT DIS, V170, P425, DOI 10.1097/00005053-198207000-00010
   Bornstein SR, 2008, TRENDS ENDOCRIN MET, V19, P175, DOI 10.1016/j.tem.2008.01.009
   Caumo W, 2002, ACTA ANAESTH SCAND, V46, P1265, DOI 10.1034/j.1399-6576.2002.461015.x
   Caumo W, 2001, ACTA ANAESTH SCAND, V45, P298, DOI 10.1034/j.1399-6576.2001.045003298.x
   CHIKANZA IC, 1992, ARTHRITIS RHEUM, V35, P1281, DOI 10.1002/art.1780351107
   DAVIS RA, 1994, J NEUROSURG, V80, P415, DOI 10.3171/jns.1994.80.3.0415
   deGroot KI, 1997, PAIN, V69, P19, DOI 10.1016/S0304-3959(96)03228-9
   DOMZAL T, 1983, PAIN, V17, P67, DOI 10.1016/0304-3959(83)90128-8
   DVORAK J, 1988, SPINE, V13, P1418, DOI 10.1097/00007632-198812000-00015
   Elizur Y, 1999, J BEHAV MED, V22, P157, DOI 10.1023/A:1018735516080
   Erhardt A, 2006, NEUROPSYCHOPHARMACOL, V31, P2515, DOI 10.1038/sj.npp.1301168
   FAGER CA, 1994, SURG NEUROL, V42, P282, DOI 10.1016/0090-3019(94)90393-X
   FRANCE RD, 1985, PAIN, V21, P49, DOI 10.1016/0304-3959(85)90076-4
   Geiss A, 2005, PAIN, V114, P104, DOI 10.1016/j.pain.2004.12.007
   Grafton KV, 2005, CLIN J PAIN, V21, P73, DOI 10.1097/00002508-200501000-00009
   GRAVER V, 1995, J PSYCHOSOM RES, V39, P465, DOI 10.1016/0022-3999(94)00148-X
   GRIEP EN, 1993, J RHEUMATOL, V20, P469
   Hayes M, 1921, PSYCHOL BULL, V18, P98, DOI DOI 10.1037/H0064147
   Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9
   JELICIC M, 1991, PSYCHOL REP, V68, P849, DOI 10.2466/PR0.68.3.849-850
   Johansson AC, 2008, EUR J PAIN, V12, P633, DOI 10.1016/j.ejpain.2007.10.009
   Karanci AN, 2003, J PSYCHOSOM RES, V55, P363, DOI 10.1016/S0022-3999(02)00631-1
   KIRSCHBAUM C, 1993, NEUROPSYCHOBIOLOGY, V28, P76, DOI 10.1159/000119004
   Kopp M, 2003, J PSYCHOSOM RES, V55, P371, DOI 10.1016/S0022-3999(03)00012-6
   KROHNE HW, 2003, Z GESUNDHEITSPSYCHOL, V11, P132, DOI DOI 10.1026//0943-8149.11.4.132
   Kudielka B.M., 2007, SOCIAL NEUROSCIENCE, P56, DOI DOI 10.1007/978-1-4614-6852-3
   Kulik JA, 1996, J PERS SOC PSYCHOL, V71, P967, DOI 10.1037/0022-3514.71.5.967
   KULIK JA, 1989, HEALTH PSYCHOL, V8, P221, DOI 10.1037/0278-6133.8.2.221
   Lemon Jim, 2007, Psychol Health Med, V12, P163, DOI 10.1080/13548500500448478
   MARTELLI MF, 1987, J CONSULT CLIN PSYCH, V55, P201, DOI 10.1037/0022-006X.55.2.201
   McEachern M, 1992, Can Oper Room Nurs J, V10, P7
   MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8
   Mitchell M, 2003, J CLIN NURS, V12, P806
   Ozalp G, 2003, ACTA ANAESTH SCAND, V47, P26, DOI 10.1034/j.1399-6576.2003.470105.x
   Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7
   Pruessner JC, 1999, PSYCHOSOM MED, V61, P197, DOI 10.1097/00006842-199903000-00012
   Rosenberger PH, 2006, J AM ACAD ORTHOP SUR, V14, P397, DOI 10.5435/00124635-200607000-00002
   Rudolph DL, 1998, J SPORT SCI, V16, P121, DOI 10.1080/026404198366830
   Sjoling M, 2003, PATIENT EDUC COUNS, V51, P169, DOI 10.1016/S0738-3991(02)00191-X
   SPANGFORT EV, 1972, ACTA ORTHOP SCAND, P1
   Spiess M., 2010, UMGANG FEHLENDEN WER, DOI [10.1007/978-3-531-92038-2_6, DOI 10.1007/978-3-531-92038-2_6]
   STEIN C, 1988, PAIN, V32, P251, DOI 10.1016/0304-3959(88)90074-7
   van Tulder M, 2002, ACTA ORTHOP SCAND, V73, P20
   WALFISH S, 2006, PHARM TECHNOLOGY, V30, P1
   Weinryb RM, 1997, PSYCHOSOM MED, V59, P626, DOI 10.1097/00006842-199711000-00012
   Wittchen H.U., 1997, SKID STRUKTURIERTES
   Young EA, 2004, ARCH GEN PSYCHIAT, V61, P394, DOI 10.1001/archpsyc.61.4.394
   Young EA, 2004, BIOL PSYCHIAT, V55, P621, DOI 10.1016/j.biopsych.2003.09.009
NR 52
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E436
EP E443
DI 10.1016/j.wneu.2019.05.180
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900055
PM 31150852
DA 2020-05-12
ER

PT J
AU Phillips, HW
   Chen, JS
   Wilson, B
   Udawatta, M
   Prashant, G
   Nagasawa, D
   Yang, I
AF Phillips, H. Westley
   Chen, Jia-Shu
   Wilson, Bayard
   Udawatta, Methma
   Prashant, Giyarpuram
   Nagasawa, Daniel
   Yang, Isaac
TI Social Media Use for Professional Purposes in the Neurosurgical
   Community: A Multi-Institutional Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neurosurgery; Outreach; Social media
AB BACKGROUND: Since the debut of Facebook in 2004, social media (SoMe) has garnered increased popularity and usage worldwide. Given its appeal and visibility, many industries have used SoMe to promote products for professional purposes. Specialized sites have subsequently been created to connect users in similar disciplines. Although SoMe sites have amassed over 1-billion followers, SoMe usage in the neurosurgical community has not yet been well described.
   METHODS: We present an online survey administered to neurosurgery faculty, fellows, and residents in 102 U.S. accredited programs to gauge usage and perception of SoMe for professional purposes.
   RESULTS: Of all surveys distributed, 241 neurosurgeons responded with an attending, resident, to fellow breakdown of 137, 96, and 8, respectively. A total of 55.97% of respondents were under the age of 34, 2% were over the age of 75, and 81% of respondents identified as men. An overwhelming majority cited conferences (83%) and in-person meetings as their preferred method of networking. However, 70% state they use SoMe for professional purposes with Doximity and LinkdIn listed as the most popular (49% and 48%, respectively) platforms. Lack of time and perceived value, in addition to privacy concerns, were noted to be the main factors for those refraining from SoMe use.
   CONCLUSIONS: As SoMe becomes increasingly popular and its use expands, the majority of neurosurgeon respondents are also using SoMe for professional purposes. Although lack of time, lack of perceived value, and privacy concerns were hindrances to usage, other factors like age do not seem to correlate with SoMe adoption for professional aims.
C1 [Phillips, H. Westley; Chen, Jia-Shu; Wilson, Bayard; Udawatta, Methma; Prashant, Giyarpuram; Nagasawa, Daniel; Yang, Isaac] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Los Angeles Biomed Res Inst, Los Angeles, CA 90095 USA.
   [Yang, Isaac] Univ Calif Los Angeles, Harbor UCLA Med Ctr, Los Angeles, CA 90095 USA.
   [Udawatta, Methma; Yang, Isaac] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Yang, I (reprint author), Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Los Angeles Biomed Res Inst, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, Harbor UCLA Med Ctr, Los Angeles, CA 90095 USA.; Yang, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
EM iyang@mednet.ucla.edu
OI Udawatta, Methma/0000-0002-5225-7006
FU National Institutes of Health/National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R25 NS079198]; David Geffen
   Medical Scholarship; UCLA Visionary Ball Fund Grant; Eli and Edythe
   Broad Center of Regenerative Medicine and Stem Cell Research UCLA
   Scholars in Translational Medicine Program Award, Jason Dessel Memorial
   Seed Grant; UCLA Honberger Endowment Brain Tumor Research Seed Grant;
   Stryker Research Award; Stop Cancer (US) Research Career Development
   Award
FX H. Westley Phillips is funded by National Institutes of Health/National
   Cancer Institute grant R25 NS079198. Methma Udawatta is supported by the
   David Geffen Medical Scholarship. Isaac Yang is supported by the UCLA
   Visionary Ball Fund Grant, Eli and Edythe Broad Center of Regenerative
   Medicine and Stem Cell Research UCLA Scholars in Translational Medicine
   Program Award, Jason Dessel Memorial Seed Grant, UCLA Honberger
   Endowment Brain Tumor Research Seed Grant, Stryker Research Award, and
   Stop Cancer (US) Research Career Development Award.
CR Alotaibi NM, 2016, WORLD NEUROSURG, V93, P449, DOI 10.1016/j.wneu.2016.06.134
   Alotaibi NM, 2016, WORLD NEUROSURG, V90, P574, DOI 10.1016/j.wneu.2016.01.087
   Alotaibi NM, 2016, WORLD NEUROSURG, V88, P619, DOI 10.1016/j.wneu.2015.11.011
   Byker T, 2019, CONTRACEPTION, V100, P116, DOI 10.1016/j.contraception.2019.04.001
   Camp SM, 2012, AESTHET SURG J, V32, P349, DOI 10.1177/1090820X12439862
   Campbell L, 2016, BMC MED INFORM DECIS, V16, DOI 10.1186/s12911-016-0327-y
   Canty MJ, 2019, CHILD NERV SYST, V35, P2179, DOI 10.1007/s00381-019-04197-x
   Curry E, 2014, ORTHOP REV, V6, P107, DOI 10.4081/or.2014.5483
   Jain SH, 2009, NEW ENGL J MED, V361, P649, DOI 10.1056/NEJMp0901277
   Lau AYS, 2012, HEALTH INF MANAG J, V41, P30, DOI 10.1177/183335831204100204
   Leow JJ, 2012, SURGERY, V151, P767, DOI 10.1016/j.surg.2011.12.024
   Luc JGY, 2018, AM J SURG, V215, P752, DOI 10.1016/j.amjsurg.2018.02.011
   Mata-Gomez J, 2018, NEUROCIRUGIA, V29, P109, DOI [10.1016/j.neucir.2018.01.001, 10.1016/j.neucie.2018.01.001]
   Taggart T, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4387
   Wagner JP, 2018, J SURG EDUC, V75, P804, DOI 10.1016/j.jsurg.2017.09.008
   Wozney L, 2019, INTERNET INTERV, V17, DOI 10.1016/j.invent.2019.100246
NR 16
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E367
EP E374
DI 10.1016/j.wneu.2019.05.154
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900046
PM 31132504
DA 2020-05-12
ER

PT J
AU Picart, T
   Barritault, M
   Simon, E
   Robinson, P
   Barrey, C
   Meyronet, D
   Mertens, P
AF Picart, Thiebaud
   Barritault, Marc
   Simon, Emile
   Robinson, Philip
   Barrey, Cedric
   Meyronet, David
   Mertens, Patrick
TI Anatomical and Histological Analysis of a Complex Structure Too Long
   Considered a Simple Ligament: The Filum Terminale
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Ependymoma; Filum terminale; Histology; Spine; Tethered cord
   syndrome
ID SPINAL-CORD; DURAL SAC; LEVEL; PARAGANGLIOMA
AB BACKGROUND: The intradural filum terminale (iFT) connects the conus medullaris (CM) with the dural sac (DS), and the extradural filum terminale (eFT) connects the DS to the coccyx. The aim of the present study was to update the description of the FT and integrate these data in a physiological and pathological context.
   METHODS: Anatomical measurements and histological investigations were performed on 10 human cadavers.
   RESULTS: The mean length of the iFT and eFT was 167.13 and 87.59 mm, respectively. The mean cranial diameter of the iFT was 1.84 mm. It was >2 mm in 2 specimens. The mean half and caudal diameter of the iFT was 0.71 and 0.74 mm, respectively. The cranial diameter of the eFT correlated with the caudal diameter of the eFT (rho = 0.94; P = 0.02). The level of the CMeiFT junction correlated significantly with the iFT length (rho = -0.67; P = 0.03). The mobilization of the iFT was not transmitted to the extradural elements and vice versa. The iFT contained axons and ependymal cells, which were dense in the first third and then randomly arranged caudally in islets. This could explain why ependymomas can occur all along the iFT. Ganglion cells were abundant around the junction with the DS. The eFT contained smooth muscle cells, adipocytes, and axons. A mechanoreceptor was identified in 1 specimen.
   CONCLUSIONS: Consistently with their common embryological origin, a real anatomical and histological continuum is present between the CM and FT. The FT should, therefore, no longer be considered a simple ligament but, rather, a complex fibrocellular structure.
C1 [Picart, Thiebaud; Simon, Emile; Barrey, Cedric; Mertens, Patrick] Hosp Civils Lyon, Dept Neurosurg, Hop Neurol Pierre Wertheimer, Bron, France.
   [Barritault, Marc] Hosp Civils Lyon, Grp Hosp Est, Dept Mol Biol, Bron, France.
   [Meyronet, David] Hosp Civils Lyon, Grp Hosp Est, Dept Neuropathol, Bron, France.
   [Barritault, Marc; Meyronet, David; Mertens, Patrick] Claude Bernard Univ Lyon 1, Fac Med Lyon Est, Lyon, France.
   [Simon, Emile; Mertens, Patrick] Claude Bernard Univ Lyon 1, Lab Anat, Fac Med Lyon Est, Lyon, France.
   [Robinson, Philip] Hosp Civils Lyon, Direct Rech Clin & Innovat, Lyon, France.
RP Picart, T (reprint author), Hosp Civils Lyon, Dept Neurosurg, Hop Neurol Pierre Wertheimer, Bron, France.
EM thiebaud.picart@chu-lyon.fr
RI BARREY, Cedric Y/B-9873-2011
CR Benet A, 2014, J NEUROSURG, V120, P1229, DOI 10.3171/2014.1.JNS131857
   Choi D, 1996, SURG RADIOL ANAT, V18, P133, DOI 10.1007/BF01795233
   Choudhary K K, 2002, Indian J Pathol Microbiol, V45, P363
   Chrenek R, 2017, J COMP NEUROL, V525, P661, DOI 10.1002/cne.24094
   De Vloo P, 2016, WORLD NEUROSURG, V90, P565, DOI 10.1016/j.wneu.2015.12.103
   Filippidis AS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.3.FOCUS1085
   Fontes RBV, 2006, NEUROSURGERY, V58, P978, DOI 10.1227/01.NEU.0000210224.54816.40
   GAMBLE HJ, 1971, J ANAT, V110, P173
   George TM, 2003, PEDIATR NEUROSURG, V39, P227, DOI 10.1159/000072866
   Gomes FC, 2002, NEUROSURGERY, V51, P725, DOI 10.1227/01.NEU.0000023605.47661.EA
   Hansasuta A, 1999, PEDIATR NEUROSURG, V30, P176, DOI 10.1159/000028790
   Harmeier JW, 1933, ARCH NEURO PSYCHIATR, V29, P308, DOI 10.1001/archneurpsyc.1933.02240080098008
   Hertzler DA, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.3.FOCUS1079
   Jang HS, 2016, PEDIATR NEUROSURG, V51, P9, DOI 10.1159/000439284
   Liu FY, 2011, CHILD NERV SYST, V27, P2141, DOI 10.1007/s00381-011-1414-0
   Macdonald A, 1999, CLIN ANAT, V12, P149, DOI 10.1002/(SICI)1098-2353(1999)12:3<149::AID-CA1>3.3.CO;2-O
   McCotter RE, 1916, ANAT REC, V10, P559, DOI 10.1002/ar.1090100902
   MOORE G E, 1948, Minn Med, V31, P1073
   Nasr AY, 2018, FOLIA MORPHOL, V77, P609, DOI 10.5603/FM.a2018.0041
   Needles JH, 1935, ANAT REC, V63, P417, DOI 10.1002/ar.1090630409
   Okudera Y, 2014, J NEUROSURG-SPINE, V21, P270, DOI 10.3171/2014.4.SPINE121002
   Pang D, 2013, CHILD NERV SYST, V29, P1459, DOI 10.1007/s00381-013-2189-2
   PEARSON AA, 1971, AM J ANAT, V131, P463, DOI 10.1002/aja.1001310406
   Pinto FC, 2002, NEUROSURGERY, V51, P729
   Pytel P, 2005, HUM PATHOL, V36, P444, DOI 10.1016/j.humpath.2005.01.024
   Reimann AF, 1944, ANAT REC, V88, P127, DOI 10.1002/ar.1090880108
   Saker E, 2016, CUREUS, V8, DOI 10.7759/cureus.927
   Selcuki M, 2003, CHILD NERV SYST, V19, P3, DOI 10.1007/s00381-002-0665-1
   Shankar GM, 2010, J NEUROSURG-SPINE, V12, P709, DOI 10.3171/2009.12.SPINE09482
   Streeter GL, 1919, AM J ANAT, V25
   TANI S, 1987, J NEUROSURG, V66, P116, DOI 10.3171/jns.1987.66.1.0116
   Tani S, 1991, No To Shinkei, V43, P1121
   Tehli O, 2011, PEDIATR NEUROSURG, V47, P412, DOI 10.1159/000338981
   Thomson A, 1894, J Anat Physiol, V29, P35
   TROTTER M, 1947, Curr Res Anesth Analg, V26, P192
   Tubbs RS, 2005, J NEUROSURG-SPINE, V3, P149, DOI 10.3171/spi.2005.3.2.0149
   Yamada Shokei, 2007, Neurosurg Focus, V23, pE6
NR 37
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD SEP
PY 2019
VL 129
BP E464
EP E471
DI 10.1016/j.wneu.2019.05.184
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA IR7GC
UT WOS:000481607900059
PM 31150849
DA 2020-05-12
ER

EF